{ "metadata": { "source": "OpenAlex API", "query_date": "2025-12-14T19:49:32.803272", "keywords": [ "GLP-1 receptor agonist", "Semaglutide", "Liraglutide", "Dulaglutide", "Exenatide" ], "date_range": "2005-2025", "count": 1000 }, "works": [ { "id": "https://openalex.org/W2002757015", "doi": "https://doi.org/10.1038/nrendo.2012.140", "title": "GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus", "abstract": null, "publication_date": "2012-09-04", "publication_year": 2012, "type": "review", "cited_by_count": 1237, "authors": [ { "id": "https://openalex.org/A5002832666", "display_name": "Juris J. Meier" } ] }, { "id": "https://openalex.org/W3093042356", "doi": "https://doi.org/10.1016/j.molmet.2020.101102", "title": "GLP-1 receptor agonists in the treatment of type 2 diabetes \u2013 state-of-the-art", "abstract": null, "publication_date": "2020-10-14", "publication_year": 2020, "type": "review", "cited_by_count": 1286, "authors": [ { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5091130352", "display_name": "Daniel R. Quast" }, { "id": "https://openalex.org/A5089465404", "display_name": "Jakob Wefers" }, { "id": "https://openalex.org/A5002832666", "display_name": "Juris J. Meier" } ] }, { "id": "https://openalex.org/W2425644022", "doi": "https://doi.org/10.1056/nejmoa1603827", "title": "Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes", "abstract": { "In": [ 0 ], "the": [ 1, 4, 7, 40 ], "time-to-event": [ 2 ], "analysis,": [ 3 ], "rate": [ 5 ], "of": [ 6, 10, 43 ], "first": [ 8 ], "occurrence": [ 9 ], "death": [ 11 ], "from": [ 12 ], "cardiovascular": [ 13 ], "causes,": [ 14 ], "nonfatal": [ 15, 19 ], "myocardial": [ 16 ], "infarction,": [ 17 ], "or": [ 18 ], "stroke": [ 20 ], "among": [ 21 ], "patients": [ 22 ], "with": [ 23, 30, 33 ], "type": [ 24 ], "2": [ 25 ], "diabetes": [ 26 ], "mellitus": [ 27 ], "was": [ 28 ], "lower": [ 29 ], "liraglutide": [ 31 ], "than": [ 32 ], "placebo.": [ 34 ], "(Funded": [ 35 ], "by": [ 36 ], "Novo": [ 37 ], "Nordisk": [ 38 ], "and": [ 39 ], "National": [ 41 ], "Institutes": [ 42 ], "Health;": [ 44 ], "LEADER": [ 45 ], "ClinicalTrials.gov": [ 46 ], "number,": [ 47 ], "NCT01179048.).": [ 48 ] }, "publication_date": "2016-06-13", "publication_year": 2016, "type": "article", "cited_by_count": 6755, "authors": [ { "id": "https://openalex.org/A5110355842", "display_name": "Steven P. Marso" }, { "id": "https://openalex.org/A5028469549", "display_name": "Gilbert H. Daniels" }, { "id": "https://openalex.org/A5029446878", "display_name": "Kirstine Brown\u2010Frandsen" }, { "id": "https://openalex.org/A5089441654", "display_name": "Peter Lommer Kristensen" }, { "id": "https://openalex.org/A5043842967", "display_name": "Johannes F.E. Mann" }, { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5040589473", "display_name": "Steven E. Nissen" }, { "id": "https://openalex.org/A5023436129", "display_name": "Stuart Pocock" }, { "id": "https://openalex.org/A5072011562", "display_name": "Neil R Poulter" }, { "id": "https://openalex.org/A5112384354", "display_name": "Lasse Steen Ravn" }, { "id": "https://openalex.org/A5019811162", "display_name": "William M. Steinberg" }, { "id": "https://openalex.org/A5074675845", "display_name": "Mette Stockner" }, { "id": "https://openalex.org/A5090437675", "display_name": "Bernard Zinman" }, { "id": "https://openalex.org/A5113817930", "display_name": "Richard M. Bergenstal" }, { "id": "https://openalex.org/A5040182038", "display_name": "John B. Buse" } ] }, { "id": "https://openalex.org/W2519510391", "doi": "https://doi.org/10.1056/nejmoa1607141", "title": "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes", "abstract": { "In": [ 0 ], "patients": [ 1, 27 ], "with": [ 2 ], "type": [ 3 ], "2": [ 4 ], "diabetes": [ 5 ], "who": [ 6 ], "were": [ 7 ], "at": [ 8 ], "high": [ 9 ], "cardiovascular": [ 10, 15 ], "risk,": [ 11 ], "the": [ 12, 39 ], "rate": [ 13 ], "of": [ 14, 41 ], "death,": [ 16 ], "nonfatal": [ 17, 21 ], "myocardial": [ 18 ], "infarction,": [ 19 ], "or": [ 20 ], "stroke": [ 22 ], "was": [ 23 ], "significantly": [ 24 ], "lower": [ 25 ], "among": [ 26, 31 ], "receiving": [ 28, 33 ], "semaglutide": [ 29 ], "than": [ 30 ], "those": [ 32 ], "placebo,": [ 34 ], "an": [ 35 ], "outcome": [ 36 ], "that": [ 37 ], "confirmed": [ 38 ], "noninferiority": [ 40 ], "semaglutide.": [ 42 ], "(Funded": [ 43 ], "by": [ 44 ], "Novo": [ 45 ], "Nordisk;": [ 46 ], "SUSTAIN-6": [ 47 ], "ClinicalTrials.gov": [ 48 ], "number,": [ 49 ], "NCT01720446": [ 50 ], ".).": [ 51 ] }, "publication_date": "2016-09-16", "publication_year": 2016, "type": "letter", "cited_by_count": 5946, "authors": [ { "id": "https://openalex.org/A5110355842", "display_name": "Steven P. Marso" }, { "id": "https://openalex.org/A5080463002", "display_name": "Stephen C. Bain" }, { "id": "https://openalex.org/A5003186286", "display_name": "Agostino Consoli" }, { "id": "https://openalex.org/A5046305526", "display_name": "Freddy G. Eliaschewitz" }, { "id": "https://openalex.org/A5088506788", "display_name": "Esteban J\u00f3dar" }, { "id": "https://openalex.org/A5080414941", "display_name": "Lawrence A. Leiter" }, { "id": "https://openalex.org/A5001655356", "display_name": "Ildiko Lingvay" }, { "id": "https://openalex.org/A5045489578", "display_name": "Julio Rosenstock" }, { "id": "https://openalex.org/A5056074989", "display_name": "Jochen Seufert" }, { "id": "https://openalex.org/A5011320591", "display_name": "Mark Warren" }, { "id": "https://openalex.org/A5032297044", "display_name": "Vincent Woo" }, { "id": "https://openalex.org/A5103513094", "display_name": "Oluf H. Hansen" }, { "id": "https://openalex.org/A5015716676", "display_name": "Anders G. Holst" }, { "id": "https://openalex.org/A5027935267", "display_name": "Jonas Pettersson" }, { "id": "https://openalex.org/A5004120950", "display_name": "Tina Vilsb\u00f8ll" } ] }, { "id": "https://openalex.org/W2924479779", "doi": "https://doi.org/10.3389/fendo.2019.00155", "title": "The Discovery and Development of Liraglutide and Semaglutide", "abstract": { "The": [ 0, 38 ], "discovery": [ 1, 54 ], "of": [ 2, 40, 57, 98, 111, 217, 224, 241, 257, 268, 285, 289, 307, 334 ], "glucagon-like": [ 3 ], "peptide-1": [ 4 ], "(GLP-1),": [ 5 ], "an": [ 6, 207, 226, 251, 308 ], "incretin": [ 7 ], "hormone": [ 8 ], "with": [ 9, 33, 115, 177, 193, 231, 236, 316 ], "important": [ 10 ], "effects": [ 11, 136 ], "on": [ 12 ], "glycemic": [ 13, 169, 292 ], "control": [ 14, 170 ], "and": [ 15, 26, 42, 55, 74, 78, 87, 90, 96, 113, 119, 151, 157, 171, 179, 183, 247, 274, 301, 346 ], "body": [ 16, 172, 294 ], "weight": [ 17, 173, 204 ], "regulation,": [ 18 ], "led": [ 19, 213, 264 ], "to": [ 20, 22, 82, 103, 123, 162, 209, 214, 265, 282, 321, 326 ], "efforts": [ 21 ], "extend": [ 23 ], "its": [ 24, 248 ], "half-life": [ 25 ], "make": [ 27 ], "it": [ 28 ], "therapeutically": [ 29 ], "effective": [ 30 ], "in": [ 31, 71, 143, 154, 168, 191, 250, 287, 291, 319, 331, 344 ], "people": [ 32 ], "type": [ 34 ], "2": [ 35 ], "diabetes": [ 36 ], "(T2D).": [ 37 ], "development": [ 39, 56, 267, 306 ], "short-": [ 41 ], "then": [ 43 ], "long-acting": [ 44, 59, 270 ], "GLP-1": [ 45, 60, 129, 271 ], "receptor": [ 46, 130 ], "agonists": [ 47 ], "(GLP-1RAs)": [ 48 ], "followed.": [ 49 ], "Our": [ 50 ], "article": [ 51 ], "charts": [ 52 ], "the": [ 53, 58, 68, 76, 108, 144, 155, 165, 196, 215, 222, 239, 255, 266, 283, 305, 332 ], "analogs": [ 61 ], "liraglutide": [ 62, 73, 112, 178, 182, 218, 273, 328 ], "and,": [ 63 ], "subsequently,": [ 64 ], "semaglutide.": [ 65, 180, 232 ], "We": [ 66 ], "examine": [ 67 ], "chemistry": [ 69 ], "employed": [ 70 ], "designing": [ 72 ], "semaglutide,": [ 75, 114, 275 ], "human": [ 77 ], "non-human": [ 79 ], "studies": [ 80 ], "used": [ 81, 106, 330 ], "investigate": [ 83 ], "their": [ 84, 135 ], "cellular": [ 85 ], "targets": [ 86 ], "pharmacological": [ 88 ], "effects,": [ 89 ], "ongoing": [ 91, 234 ], "investigations": [ 92, 235 ], "into": [ 93 ], "new": [ 94 ], "applications": [ 95 ], "formulations": [ 97 ], "these": [ 99 ], "drugs.": [ 100 ], "Reversible": [ 101 ], "binding": [ 102, 126 ], "albumin": [ 104, 125 ], "was": [ 105 ], "for": [ 107, 164, 221, 254, 311, 342 ], "systemic": [ 109 ], "protraction": [ 110 ], "optimal": [ 116 ], "fatty": [ 117, 243 ], "acid": [ 118 ], "linker": [ 120 ], "combinations": [ 121 ], "identified": [ 122 ], "maximize": [ 124 ], "while": [ 127, 336 ], "maintaining": [ 128 ], "(GLP-1R)": [ 131 ], "potency.": [ 132 ], "GLP-1RAs": [ 133 ], "mediate": [ 134 ], "via": [ 137 ], "this": [ 138 ], "receptor,": [ 139 ], "which": [ 140 ], "is": [ 141, 199, 329, 338 ], "expressed": [ 142 ], "pancreas,": [ 145 ], "gastrointestinal": [ 146 ], "tract,": [ 147 ], "heart,": [ 148 ], "lungs,": [ 149 ], "kidneys,": [ 150 ], "brain.": [ 152 ], "GLP-1Rs": [ 153 ], "pancreas": [ 156 ], "brain": [ 158 ], "have": [ 159, 277 ], "been": [ 160 ], "shown": [ 161 ], "account": [ 163 ], "respective": [ 166 ], "improvements": [ 167, 290 ], "that": [ 174, 276 ], "are": [ 175 ], "evident": [ 176 ], "Both": [ 181 ], "semaglutide": [ 184, 237, 312, 337 ], "also": [ 185 ], "positively": [ 186 ], "affect": [ 187 ], "cardiovascular": [ 188 ], "(CV)": [ 189 ], "outcomes": [ 190 ], "individuals": [ 192, 315 ], "T2D,": [ 194, 327 ], "although": [ 195 ], "precise": [ 197 ], "mechanism": [ 198 ], "still": [ 200 ], "being": [ 201 ], "explored.": [ 202 ], "Significant": [ 203 ], "loss,": [ 205 ], "through": [ 206 ], "effect": [ 208 ], "reduce": [ 210 ], "energy": [ 211 ], "intake,": [ 212 ], "approval": [ 216 ], "(3.0": [ 219 ], "mg)": [ 220 ], "treatment": [ 223, 240, 256, 322, 333 ], "obesity,": [ 225, 335 ], "indication": [ 227 ], "currently": [ 228, 339 ], "under": [ 229, 340 ], "investigation": [ 230, 341 ], "Other": [ 233 ], "include": [ 238 ], "non-alcoholic": [ 242 ], "liver": [ 244 ], "disease": [ 245 ], "(NASH)": [ 246 ], "use": [ 249, 343 ], "oral": [ 252, 309 ], "formulation": [ 253, 310 ], "T2D.": [ 258 ], "In": [ 259, 324 ], "summary,": [ 260 ], "rational": [ 261 ], "design": [ 262 ], "has": [ 263 ], "two": [ 269 ], "analogs,": [ 272 ], "made": [ 278 ], "a": [ 279 ], "vast": [ 280 ], "contribution": [ 281 ], "management": [ 284 ], "T2D": [ 286 ], "terms": [ 288 ], "control,": [ 293 ], "weight,": [ 295 ], "blood": [ 296 ], "pressure,": [ 297 ], "lipids,": [ 298 ], "beta-cell": [ 299 ], "function,": [ 300 ], "CV": [ 302 ], "outcomes.": [ 303 ], "Furthermore,": [ 304 ], "may": [ 313 ], "provide": [ 314 ], "additional": [ 317 ], "benefits": [ 318 ], "relation": [ 320 ], "adherence.": [ 323 ], "addition": [ 325 ], "obesity": [ 345 ], "NASH.": [ 347 ] }, "publication_date": "2019-04-12", "publication_year": 2019, "type": "review", "cited_by_count": 793, "authors": [ { "id": "https://openalex.org/A5088627727", "display_name": "Lotte Bjerre Knudsen" }, { "id": "https://openalex.org/A5034154367", "display_name": "Jesper Lau" } ] }, { "id": "https://openalex.org/W2014156217", "doi": "https://doi.org/10.1172/jci75276", "title": "The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss", "abstract": { "Liraglutide": [ 0 ], "is": [ 1, 25 ], "a": [ 2 ], "glucagon-like": [ 3 ], "peptide-1": [ 4 ], "(GLP-1)": [ 5 ], "analog": [ 6 ], "marketed": [ 7 ], "for": [ 8, 117 ], "the": [ 9, 42, 55, 71, 88, 91, 94, 103, 112, 121, 133, 184 ], "treatment": [ 10 ], "of": [ 11, 66, 81, 90, 151 ], "type": [ 12 ], "2": [ 13 ], "diabetes.": [ 14 ], "Besides": [ 15 ], "lowering": [ 16 ], "blood": [ 17 ], "glucose,": [ 18 ], "liraglutide": [ 19, 30, 38, 48, 84, 99, 118, 124, 135 ], "also": [ 20 ], "reduces": [ 21 ], "body": [ 22, 59 ], "weight.": [ 23 ], "It": [ 24 ], "not": [ 26, 50, 127 ], "fully": [ 27 ], "understood": [ 28 ], "how": [ 29 ], "induces": [ 31 ], "weight": [ 32, 60, 193 ], "loss": [ 33 ], "or": [ 34 ], "to": [ 35 ], "what": [ 36 ], "degree": [ 37 ], "acts": [ 39 ], "directly": [ 40, 158 ], "in": [ 41, 54, 62, 70, 85, 93, 111, 120, 129, 138, 166 ], "brain.": [ 43 ], "Here,": [ 44 ], "we": [ 45 ], "determined": [ 46 ], "that": [ 47, 156, 183 ], "does": [ 49 ], "activate": [ 51 ], "GLP-1-producing": [ 52 ], "neurons": [ 53, 101, 139, 161, 167, 189 ], "hindbrain,": [ 56 ], "and": [ 57, 76, 107, 143, 145, 162, 172 ], "liraglutide-dependent": [ 58 ], "reduction": [ 61 ], "rats": [ 63 ], "was": [ 64, 115, 126, 136 ], "independent": [ 65 ], "GLP-1": [ 67, 157 ], "receptors": [ 68 ], "(GLP-1Rs)": [ 69 ], "vagus": [ 72 ], "nerve,": [ 73 ], "area": [ 74 ], "postrema,": [ 75 ], "paraventricular": [ 77 ], "nucleus.": [ 78 ], "Peripheral": [ 79 ], "injection": [ 80 ], "fluorescently": [ 82 ], "labeled": [ 83, 98 ], "mice": [ 86 ], "revealed": [ 87, 155 ], "presence": [ 89 ], "drug": [ 92 ], "circumventricular": [ 95 ], "organs.": [ 96 ], "Moreover,": [ 97 ], "bound": [ 100 ], "within": [ 102 ], "arcuate": [ 104 ], "nucleus": [ 105 ], "(ARC)": [ 106 ], "other": [ 108 ], "discrete": [ 109 ], "sites": [ 110 ], "hypothalamus.": [ 113 ], "GLP-1R": [ 114, 185 ], "necessary": [ 116 ], "uptake": [ 119 ], "brain,": [ 122 ], "as": [ 123 ], "binding": [ 125 ], "seen": [ 128 ], "Glp1r(-/-)": [ 130 ], "mice.": [ 131 ], "In": [ 132 ], "ARC,": [ 134 ], "internalized": [ 137 ], "expressing": [ 140, 168 ], "proopiomelanocortin": [ 141 ], "(POMC)": [ 142 ], "cocaine-": [ 144 ], "amphetamine-regulated": [ 146 ], "transcript": [ 147 ], "(CART).": [ 148 ], "Electrophysiological": [ 149 ], "measurements": [ 150 ], "murine": [ 152 ], "brain": [ 153 ], "slices": [ 154 ], "stimulates": [ 159 ], "POMC/CART": [ 160 ], "indirectly": [ 163 ], "inhibits": [ 164 ], "neurotransmission": [ 165 ], "neuropeptide": [ 169 ], "Y": [ 170 ], "(NPY)": [ 171 ], "agouti-related": [ 173 ], "peptide": [ 174 ], "(AgRP)": [ 175 ], "via": [ 176 ], "GABA-dependent": [ 177 ], "signaling.": [ 178 ], "Collectively,": [ 179 ], "our": [ 180 ], "findings": [ 181 ], "indicate": [ 182 ], "on": [ 186 ], "POMC/CART-expressing": [ 187 ], "ARC": [ 188 ], "likely": [ 190 ], "mediates": [ 191 ], "liraglutide-induced": [ 192 ], "loss.": [ 194 ] }, "publication_date": "2014-09-08", "publication_year": 2014, "type": "article", "cited_by_count": 859, "authors": [ { "id": "https://openalex.org/A5013985442", "display_name": "Anna Secher" }, { "id": "https://openalex.org/A5075602116", "display_name": "Jacob Jelsing" }, { "id": "https://openalex.org/A5023310194", "display_name": "Arian F. Baquero" }, { "id": "https://openalex.org/A5067103368", "display_name": "Jacob Hecksher\u2010S\u00f8rensen" }, { "id": "https://openalex.org/A5076549817", "display_name": "Michael A. Cowley" }, { "id": "https://openalex.org/A5014405609", "display_name": "Louise S. Dalb\u00f8ge" }, { "id": "https://openalex.org/A5110313943", "display_name": "Gitte Hansen" }, { "id": "https://openalex.org/A5047336215", "display_name": "Kevin L. Grove" }, { "id": "https://openalex.org/A5084425804", "display_name": "Charles Pyke" }, { "id": "https://openalex.org/A5064830959", "display_name": "Kirsten Raun" }, { "id": "https://openalex.org/A5110299291", "display_name": "Lauge Sch\u00e4ffer" }, { "id": "https://openalex.org/A5016148396", "display_name": "Mads Tang\u2010Christensen" }, { "id": "https://openalex.org/A5069877461", "display_name": "Saurabh Verma" }, { "id": "https://openalex.org/A5062065720", "display_name": "Brent M. Witgen" }, { "id": "https://openalex.org/A5088582143", "display_name": "Niels Vrang" }, { "id": "https://openalex.org/A5088627727", "display_name": "Lotte Bjerre Knudsen" } ] }, { "id": "https://openalex.org/W2159205789", "doi": "https://doi.org/10.1016/s0140-6736(06)69705-5", "title": "The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes", "abstract": null, "publication_date": "2006-11-01", "publication_year": 2006, "type": "review", "cited_by_count": 3794, "authors": [ { "id": "https://openalex.org/A5057472647", "display_name": "Daniel J. Drucker" }, { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" } ] }, { "id": "https://openalex.org/W3127371223", "doi": "https://doi.org/10.1056/nejmoa2032183", "title": "Once-Weekly Semaglutide in Adults with Overweight or Obesity", "abstract": { "In": [ 0 ], "participants": [ 1 ], "with": [ 2, 17 ], "overweight": [ 3 ], "or": [ 4 ], "obesity,": [ 5 ], "2.4": [ 6 ], "mg": [ 7 ], "of": [ 8 ], "semaglutide": [ 9 ], "once": [ 10 ], "weekly": [ 11 ], "plus": [ 12 ], "lifestyle": [ 13 ], "intervention": [ 14 ], "was": [ 15 ], "associated": [ 16 ], "sustained,": [ 18 ], "clinically": [ 19 ], "relevant": [ 20 ], "reduction": [ 21 ], "in": [ 22 ], "body": [ 23 ], "weight.": [ 24 ], "(Funded": [ 25 ], "by": [ 26 ], "Novo": [ 27 ], "Nordisk;": [ 28 ], "STEP": [ 29 ], "1": [ 30 ], "ClinicalTrials.gov": [ 31 ], "number,": [ 32 ], "NCT03548935).": [ 33 ] }, "publication_date": "2021-02-10", "publication_year": 2021, "type": "article", "cited_by_count": 3574, "authors": [ { "id": "https://openalex.org/A5047195042", "display_name": "John Wilding" }, { "id": "https://openalex.org/A5085481226", "display_name": "Rachel L. Batterham" }, { "id": "https://openalex.org/A5011187014", "display_name": "Salvatore Calanna" }, { "id": "https://openalex.org/A5084593004", "display_name": "Melanie J. Davies" }, { "id": "https://openalex.org/A5111609726", "display_name": "Luc F. Van Gaal" }, { "id": "https://openalex.org/A5001655356", "display_name": "Ildiko Lingvay" }, { "id": "https://openalex.org/A5021130189", "display_name": "Barbara McGowan" }, { "id": "https://openalex.org/A5045489578", "display_name": "Julio Rosenstock" }, { "id": "https://openalex.org/A5008356540", "display_name": "Marie Thi Dao Tran" }, { "id": "https://openalex.org/A5026596594", "display_name": "Thomas A. Wadden" }, { "id": "https://openalex.org/A5027441223", "display_name": "Sean Wharton" }, { "id": "https://openalex.org/A5079640536", "display_name": "Koutaro Yokote" }, { "id": "https://openalex.org/A5091255293", "display_name": "Niels Zeuthen" }, { "id": "https://openalex.org/A5062192624", "display_name": "Robert F. Kushner" } ] }, { "id": "https://openalex.org/W917052595", "doi": "https://doi.org/10.1900/rds.2014.11.202", "title": "Adverse Effects of GLP-1 Receptor Agonists", "abstract": { "Glucagon-like": [ 0 ], "peptide-1": [ 1 ], "(GLP-1)": [ 2 ], "receptor": [ 3, 73, 93, 106, 184, 219, 235, 270, 287, 316 ], "agonists": [ 4, 74, 94, 107, 185, 220, 236, 271, 288 ], "are": [ 5, 186, 289 ], "a": [ 6, 88, 240 ], "class": [ 7, 35 ], "of": [ 8, 31, 36, 52, 65, 71, 98, 104, 124, 138, 152, 160, 182, 211, 229, 255, 268, 304, 312 ], "injective": [ 9 ], "anti-diabetic": [ 10 ], "drugs": [ 11, 37, 54 ], "that": [ 12, 109, 217, 300 ], "improve": [ 13 ], "glycemic": [ 14 ], "control": [ 15 ], "and": [ 16, 57, 63, 79, 95, 172, 200, 279 ], "many": [ 17 ], "other": [ 18, 143 ], "atherosclerosis-related": [ 19 ], "parameters": [ 20 ], "in": [ 21, 209, 272, 277 ], "patients": [ 22, 230 ], "with": [ 23, 41, 75, 117, 157, 179, 231, 297 ], "type": [ 24 ], "2": [ 25 ], "diabetes": [ 26 ], "(T2D).": [ 27 ], "However,": [ 28, 82 ], "the": [ 29, 50, 96, 122, 136, 142, 150, 158, 180, 212, 226, 262, 295, 302, 305, 313 ], "use": [ 30, 151, 181 ], "this": [ 32, 256 ], "relatively": [ 33 ], "new": [ 34 ], "may": [ 38, 129 ], "be": [ 39, 132 ], "associated": [ 40, 178 ], "certain": [ 42, 283 ], "adverse": [ 43, 100, 193, 266, 308 ], "effects.": [ 44, 101, 252 ], "Concerns": [ 45 ], "have": [ 46, 130, 148, 221, 239 ], "been": [ 47 ], "expressed": [ 48 ], "regarding": [ 49, 265 ], "effects": [ 51, 194, 204, 224, 309 ], "these": [ 53, 99, 153, 203 ], "on": [ 55, 225 ], "pancreatic": [ 56, 77 ], "thyroid": [ 58, 80 ], "tissue,": [ 59 ], "since": [ 60 ], "animal": [ 61 ], "studies": [ 62 ], "analyses": [ 64 ], "drug": [ 66 ], "databases": [ 67 ], "indicate": [ 68 ], "an": [ 69 ], "association": [ 70 ], "GLP-1": [ 72, 92, 105, 183, 218, 234, 269, 286, 315 ], "pancreatitis,": [ 76 ], "cancer,": [ 78 ], "cancer.": [ 81 ], "several": [ 83, 145 ], "meta-analyses": [ 84 ], "failed": [ 85 ], "to": [ 86, 131, 134, 169, 238, 259 ], "confirm": [ 87 ], "cause-effect": [ 89 ], "relation": [ 90 ], "between": [ 91, 285 ], "development": [ 97 ], "One": [ 102 ], "benefit": [ 103 ], "is": [ 108, 258 ], "they": [ 110 ], "do": [ 111, 205 ], "not": [ 112, 206 ], "cause": [ 113 ], "hypoglycemia": [ 114 ], "when": [ 115 ], "combined": [ 116 ], "metformin": [ 118 ], "or": [ 119, 127 ], "thiazolidinediones,": [ 120 ], "but": [ 121, 202, 244 ], "dose": [ 123 ], "concomitant": [ 125 ], "sulphonylurea": [ 126 ], "insulin": [ 128 ], "decreased": [ 133 ], "reduce": [ 135 ], "risk": [ 137, 228 ], "hypoglycemic": [ 139 ], "episodes.": [ 140 ], "On": [ 141 ], "hand,": [ 144 ], "case": [ 146 ], "reports": [ 147 ], "linked": [ 149 ], "drugs,": [ 154 ], "mainly": [ 155, 189 ], "exenatide,": [ 156 ], "occurrence": [ 159 ], "acute": [ 161 ], "kidney": [ 162 ], "injury,": [ 163 ], "primarily": [ 164 ], "through": [ 165 ], "hemodynamic": [ 166 ], "derangement": [ 167 ], "due": [ 168 ], "nausea,": [ 170 ], "vomiting,": [ 171 ], "diarrhea.": [ 173 ], "The": [ 174, 253, 291 ], "most": [ 175, 306 ], "common": [ 176, 192, 307 ], "symptoms": [ 177 ], "gastrointestinal": [ 187 ], "symptoms,": [ 188 ], "nausea.": [ 190 ], "Other": [ 191 ], "include": [ 195 ], "injection": [ 196 ], "site": [ 197 ], "reactions,": [ 198 ], "headache,": [ 199 ], "nasopharyngitis,": [ 201 ], "usually": [ 207 ], "result": [ 208 ], "discontinuation": [ 210 ], "drug.": [ 213 ], "Current": [ 214 ], "evidence": [ 215 ], "shows": [ 216 ], "no": [ 222 ], "negative": [ 223 ], "cardiovascular": [ 227, 251 ], "T2D.": [ 232 ], "Thus,": [ 233 ], "appear": [ 237 ], "favorable": [ 241 ], "safety": [ 242 ], "profile,": [ 243 ], "ongoing": [ 245 ], "trials": [ 246 ], "will": [ 247 ], "further": [ 248 ], "assess": [ 249 ], "their": [ 250 ], "aim": [ 254 ], "review": [ 257, 292 ], "analyze": [ 260 ], "critically": [ 261 ], "available": [ 263 ], "data": [ 264, 299 ], "events": [ 267 ], "different": [ 273 ], "anatomic": [ 274 ], "systems": [ 275 ], "published": [ 276 ], "Pubmed": [ 278 ], "Scopus.": [ 280 ], "Whenever": [ 281 ], "possible,": [ 282 ], "differences": [ 284 ], "described.": [ 290 ], "also": [ 293 ], "provides": [ 294 ], "reader": [ 296 ], "structured": [ 298 ], "compare": [ 301 ], "rates": [ 303 ], "for": [ 310 ], "each": [ 311 ], "various": [ 314 ], "agonists.": [ 317 ] }, "publication_date": "2014-01-01", "publication_year": 2014, "type": "review", "cited_by_count": 450, "authors": [ { "id": "https://openalex.org/A5032218366", "display_name": "Theodosios D. Filippatos" }, { "id": "https://openalex.org/A5010773920", "display_name": "Thalia Panagiotopoulou" }, { "id": "https://openalex.org/A5056379080", "display_name": "Moses Elisaf" } ] }, { "id": "https://openalex.org/W3173421961", "doi": "https://doi.org/10.1016/s0140-6736(21)00536-5", "title": "SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications", "abstract": null, "publication_date": "2021-06-30", "publication_year": 2021, "type": "review", "cited_by_count": 479, "authors": [ { "id": "https://openalex.org/A5067624521", "display_name": "Emily Brown" }, { "id": "https://openalex.org/A5031624913", "display_name": "Hiddo J.L. Heerspink" }, { "id": "https://openalex.org/A5076265710", "display_name": "Daniel J. Cuthbertson" }, { "id": "https://openalex.org/A5047195042", "display_name": "John Wilding" } ] }, { "id": "https://openalex.org/W2894993577", "doi": "https://doi.org/10.2337/dci18-0033", "title": "Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)", "abstract": { "The": [ 0 ], "American": [ 1 ], "Diabetes": [ 2, 12 ], "Association": [ 3, 7 ], "and": [ 4, 25, 54, 58, 71, 117 ], "the": [ 5, 9, 18, 28, 40, 136 ], "European": [ 6 ], "for": [ 8, 81 ], "Study": [ 10 ], "of": [ 11, 30, 39 ], "convened": [ 13 ], "a": [ 14, 87, 94 ], "panel": [ 15 ], "to": [ 16, 78 ], "update": [ 17 ], "prior": [ 19 ], "position": [ 20 ], "statements,": [ 21 ], "published": [ 22 ], "in": [ 23, 34 ], "2012": [ 24 ], "2015,": [ 26 ], "on": [ 27, 51 ], "management": [ 29, 53 ], "type": [ 31 ], "2": [ 32, 90 ], "diabetes": [ 33, 55 ], "adults.": [ 35 ], "A": [ 36 ], "systematic": [ 37 ], "evaluation": [ 38 ], "literature": [ 41 ], "since": [ 42 ], "2014": [ 43 ], "informed": [ 44 ], "new": [ 45 ], "recommendations.": [ 46 ], "These": [ 47 ], "include": [ 48 ], "additional": [ 49 ], "focus": [ 50 ], "lifestyle": [ 52 ], "self-management": [ 56 ], "education": [ 57 ], "support.": [ 59 ], "For": [ 60, 107 ], "those": [ 61 ], "with": [ 62, 83, 101, 109, 124 ], "obesity,": [ 63 ], "efforts": [ 64 ], "targeting": [ 65 ], "weight": [ 66 ], "loss,": [ 67 ], "including": [ 68 ], "lifestyle,": [ 69 ], "medication,": [ 70 ], "surgical": [ 72 ], "interventions,": [ 73 ], "are": [ 74, 132 ], "recommended.": [ 75, 106, 128 ], "With": [ 76 ], "regards": [ 77 ], "medication": [ 79 ], "management,": [ 80 ], "patients": [ 82, 108 ], "clinical": [ 84, 114 ], "cardiovascular": [ 85, 103, 119 ], "disease,": [ 86, 120 ], "sodium\u2013glucose": [ 88 ], "cotransporter": [ 89 ], "(SGLT2)": [ 91 ], "inhibitor": [ 92, 123 ], "or": [ 93, 113 ], "glucagon-like": [ 95 ], "peptide": [ 96 ], "1": [ 97 ], "(GLP-1)": [ 98 ], "receptor": [ 99, 130 ], "agonist": [ 100 ], "proven": [ 102, 125 ], "benefit": [ 104, 126 ], "is": [ 105, 127 ], "chronic": [ 110 ], "kidney": [ 111 ], "disease": [ 112 ], "heart": [ 115 ], "failure": [ 116 ], "atherosclerotic": [ 118 ], "an": [ 121 ], "SGLT2": [ 122 ], "GLP-1": [ 129 ], "agonists": [ 131 ], "generally": [ 133 ], "recommended": [ 134 ], "as": [ 135 ], "first": [ 137 ], "injectable": [ 138 ], "medication.": [ 139 ] }, "publication_date": "2018-10-05", "publication_year": 2018, "type": "article", "cited_by_count": 3378, "authors": [ { "id": "https://openalex.org/A5084593004", "display_name": "Melanie J. Davies" }, { "id": "https://openalex.org/A5071074041", "display_name": "David A. D\u2019Alessio" }, { "id": "https://openalex.org/A5031033644", "display_name": "Judith Fradkin" }, { "id": "https://openalex.org/A5037438314", "display_name": "Walter N. Kernan" }, { "id": "https://openalex.org/A5053469409", "display_name": "Chantal Mathieu" }, { "id": "https://openalex.org/A5053488036", "display_name": "Geltrude Mingrone" }, { "id": "https://openalex.org/A5085592050", "display_name": "Peter Rossing" }, { "id": "https://openalex.org/A5018882870", "display_name": "\u0391\u03c0\u03cc\u03c3\u03c4\u03bf\u03bb\u03bf\u03c2 \u03a4\u03c3\u03ac\u03c0\u03b1\u03c2" }, { "id": "https://openalex.org/A5076997901", "display_name": "Deborah J. Wexler" }, { "id": "https://openalex.org/A5040182038", "display_name": "John B. Buse" } ] }, { "id": "https://openalex.org/W952614140", "doi": "https://doi.org/10.7573/dic.212283", "title": "A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond", "abstract": { "The": [ 0, 134 ], "prevalence": [ 1 ], "of": [ 2, 13, 26, 43, 67, 131, 177 ], "type": [ 3, 19, 202 ], "2": [ 4, 20, 203 ], "diabetes": [ 5, 21 ], "is": [ 6, 73, 119 ], "increasing": [ 7, 86, 92, 184 ], "at": [ 8 ], "an": [ 9, 163 ], "astounding": [ 10 ], "rate.": [ 11 ], "Many": [ 12 ], "the": [ 14, 41, 65, 68, 76, 107 ], "agents": [ 15, 198 ], "used": [ 16 ], "to": [ 17, 40, 80, 168, 213 ], "treat": [ 18 ], "have": [ 22 ], "undesirable": [ 23 ], "adverse": [ 24, 137 ], "effects": [ 25, 53, 66, 84, 138 ], "hypoglycemia": [ 27 ], "and": [ 28, 60, 94, 113, 128, 146, 151, 155, 165, 183 ], "weight": [ 29, 181 ], "gain.": [ 30 ], "Glucagon-like": [ 31 ], "peptide-1": [ 32 ], "(GLP-1)": [ 33 ], "receptor": [ 34, 104, 160 ], "agonists": [ 35, 105, 161 ], "represent": [ 36 ], "a": [ 37 ], "unique": [ 38 ], "approach": [ 39 ], "treatment": [ 42 ], "diabetes,": [ 44, 204 ], "with": [ 45, 140, 173, 201 ], "benefits": [ 46, 176 ], "extending": [ 47 ], "outside": [ 48 ], "glucose": [ 49, 171 ], "control,": [ 50, 172 ], "including": [ 51 ], "positive": [ 52 ], "on": [ 54, 209 ], "weight,": [ 55 ], "blood": [ 56, 170 ], "pressure,": [ 57 ], "cholesterol": [ 58 ], "levels,": [ 59 ], "beta-cell": [ 61, 179 ], "function.": [ 62 ], "They": [ 63 ], "mimic": [ 64 ], "incretin": [ 69 ], "hormone": [ 70 ], "GLP-1,": [ 71 ], "which": [ 72 ], "released": [ 74 ], "from": [ 75 ], "intestine": [ 77 ], "in": [ 78, 106, 121 ], "response": [ 79 ], "food": [ 81 ], "intake.": [ 82 ], "Their": [ 83 ], "include": [ 85, 143, 153 ], "insulin": [ 87, 185 ], "secretion,": [ 88 ], "decreasing": [ 89 ], "glucagon": [ 90 ], "release,": [ 91 ], "satiety,": [ 93 ], "slowing": [ 95 ], "gastric": [ 96 ], "emptying.": [ 97 ], "There": [ 98, 123 ], "are": [ 99, 124, 162, 196, 206 ], "currently": [ 100 ], "four": [ 101 ], "approved": [ 102 ], "GLP-1": [ 103, 141, 159 ], "United": [ 108 ], "States:": [ 109 ], "exenatide,": [ 110 ], "liraglutide,": [ 111 ], "albiglutide,": [ 112 ], "dulaglutide.": [ 114 ], "A": [ 115 ], "fifth": [ 116 ], "agent,": [ 117 ], "lixisenatide,": [ 118 ], "available": [ 120 ], "Europe.": [ 122 ], "important": [ 125 ], "pharmacodynamic,": [ 126 ], "pharmacokinetic,": [ 127 ], "clinical": [ 129 ], "differences": [ 130 ], "each": [ 132 ], "agent.": [ 133 ], "most": [ 135 ], "common": [ 136 ], "seen": [ 139 ], "therapy": [ 142 ], "nausea,": [ 144 ], "vomiting,": [ 145 ], "injection-site": [ 147 ], "reactions.": [ 148 ], "Other": [ 149 ], "warnings": [ 150 ], "precautions": [ 152 ], "pancreatitis": [ 154 ], "thyroid": [ 156 ], "cell": [ 157 ], "carcinomas.": [ 158 ], "innovative": [ 164 ], "effective": [ 166, 197 ], "option": [ 167 ], "improve": [ 169, 191 ], "other": [ 174 ], "potential": [ 175 ], "preserving": [ 178 ], "function,": [ 180 ], "loss,": [ 182 ], "sensitivity.": [ 186 ], "Once-weekly": [ 187 ], "formulations": [ 188 ], "may": [ 189 ], "also": [ 190 ], "patient": [ 192 ], "adherence.": [ 193 ], "Overall,": [ 194 ], "these": [ 195 ], "for": [ 199 ], "patients": [ 200 ], "who": [ 205 ], "either": [ 207 ], "uncontrolled": [ 208 ], "metformin": [ 210 ], "or": [ 211 ], "intolerant": [ 212 ], "metformin.": [ 214 ] }, "publication_date": "2015-07-08", "publication_year": 2015, "type": "review", "cited_by_count": 337, "authors": [ { "id": "https://openalex.org/A5031092578", "display_name": "Lalita Prasad-Reddy" }, { "id": "https://openalex.org/A5022179243", "display_name": "Diana Isaacs" } ] }, { "id": "https://openalex.org/W4206445899", "doi": "https://doi.org/10.1056/nejmoa1901118", "title": "Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes", "abstract": { "Establishing": [ 0 ], "cardiovascular": [ 1 ], "safety": [ 2 ], "of": [ 3, 20 ], "new": [ 4 ], "therapies": [ 5 ], "for": [ 6, 16, 30 ], "type": [ 7 ], "2": [ 8 ], "diabetes": [ 9 ], "is": [ 10 ], "important.": [ 11 ], "Safety": [ 12 ], "data": [ 13 ], "are": [ 14, 28 ], "available": [ 15 ], "the": [ 17, 21 ], "subcutaneous": [ 18 ], "form": [ 19 ], "glucagon-like": [ 22 ], "peptide-1": [ 23 ], "receptor": [ 24 ], "agonist": [ 25 ], "semaglutide": [ 26 ], "but": [ 27 ], "needed": [ 29 ], "oral": [ 31 ], "semaglutide.": [ 32 ] }, "publication_date": "2019-06-11", "publication_year": 2019, "type": "article", "cited_by_count": 1708, "authors": [ { "id": "https://openalex.org/A5044527590", "display_name": "Mansoor Husain" }, { "id": "https://openalex.org/A5013839934", "display_name": "Andreas L. Birkenfeld" }, { "id": "https://openalex.org/A5026337749", "display_name": "Morten Donsmark" }, { "id": "https://openalex.org/A5007315645", "display_name": "Kathleen Dungan" }, { "id": "https://openalex.org/A5046305526", "display_name": "Freddy G. Eliaschewitz" }, { "id": "https://openalex.org/A5047248546", "display_name": "Denise Reis Franco" }, { "id": "https://openalex.org/A5055974284", "display_name": "Ole Kleist Jeppesen" }, { "id": "https://openalex.org/A5001655356", "display_name": "Ildiko Lingvay" }, { "id": "https://openalex.org/A5080475619", "display_name": "Ofri Mosenzon" }, { "id": "https://openalex.org/A5040913971", "display_name": "Sue D. Pedersen" }, { "id": "https://openalex.org/A5011314920", "display_name": "Cees J. Tack" }, { "id": "https://openalex.org/A5017671388", "display_name": "Mette S. Thomsen" }, { "id": "https://openalex.org/A5004120950", "display_name": "Tina Vilsb\u00f8ll" }, { "id": "https://openalex.org/A5011320591", "display_name": "Mark Warren" }, { "id": "https://openalex.org/A5080463002", "display_name": "Stephen C. Bain" } ] }, { "id": "https://openalex.org/W3045729180", "doi": "https://doi.org/10.1172/jci.insight.140532", "title": "Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist", "abstract": { "Tirzepatide": [ 0 ], "(LY3298176)": [ 1 ], "is": [ 2 ], "a": [ 3, 40, 58, 88, 141 ], "dual": [ 4 ], "GIP": [ 5, 97, 120, 123, 166, 181 ], "and": [ 6, 22, 52 ], "GLP-1": [ 7, 42, 101, 130, 146, 190 ], "receptor": [ 8, 43, 77, 98, 124, 131, 147 ], "agonist": [ 9 ], "under": [ 10 ], "development": [ 11 ], "for": [ 12, 63, 72, 78, 95, 195 ], "the": [ 13, 49, 83, 96, 100, 116, 122, 129, 159, 171, 189, 196 ], "treatment": [ 14 ], "of": [ 15, 55, 75, 82, 91, 93, 107, 118, 174, 199 ], "type": [ 16 ], "2": [ 17 ], "diabetes": [ 18 ], "mellitus": [ 19 ], "(T2DM),": [ 20 ], "obesity,": [ 21 ], "nonalcoholic": [ 23 ], "steatohepatitis.": [ 24 ], "Early": [ 25 ], "phase": [ 26 ], "trials": [ 27 ], "in": [ 28, 153 ], "T2DM": [ 29 ], "indicate": [ 30 ], "that": [ 31, 48, 113, 170 ], "tirzepatide": [ 32, 56, 94, 114, 175 ], "improves": [ 33 ], "clinical": [ 34 ], "outcomes": [ 35 ], "beyond": [ 36 ], "those": [ 37 ], "achieved": [ 38 ], "by": [ 39 ], "selective": [ 41 ], "agonist.": [ 44 ], "Therefore,": [ 45 ], "we": [ 46, 69 ], "hypothesized": [ 47 ], "integrated": [ 50 ], "potency": [ 51 ], "signaling": [ 53, 110, 186 ], "properties": [ 54, 187 ], "provide": [ 57 ], "unique": [ 59 ], "pharmacological": [ 60 ], "profile": [ 61 ], "tailored": [ 62 ], "improving": [ 64 ], "broad": [ 65 ], "metabolic": [ 66 ], "control.": [ 67 ], "Here,": [ 68 ], "establish": [ 70 ], "methodology": [ 71 ], "calculating": [ 73 ], "occupancy": [ 74 ], "each": [ 76 ], "clinically": [ 79 ], "efficacious": [ 80 ], "doses": [ 81 ], "drug.": [ 84 ], "This": [ 85 ], "analysis": [ 86 ], "reveals": [ 87 ], "greater": [ 89 ], "degree": [ 90 ], "engagement": [ 92 ], "than": [ 99 ], "receptor,": [ 102, 182, 191 ], "corroborating": [ 103 ], "an": [ 104 ], "imbalanced": [ 105 ], "mechanism": [ 106 ], "action.": [ 108 ], "Pharmacologically,": [ 109 ], "studies": [ 111 ], "demonstrate": [ 112 ], "mimics": [ 115 ], "actions": [ 117 ], "native": [ 119 ], "at": [ 121, 128, 188 ], "but": [ 125, 164 ], "shows": [ 126 ], "bias": [ 127 ], "to": [ 132, 144, 162 ], "favor": [ 133 ], "cAMP": [ 134 ], "generation": [ 135 ], "over": [ 136 ], "\u03b2-arrestin": [ 137 ], "recruitment,": [ 138 ], "coincident": [ 139 ], "with": [ 140, 150, 184 ], "weaker": [ 142 ], "ability": [ 143 ], "drive": [ 145 ], "internalization": [ 148 ], "compared": [ 149 ], "GLP-1.": [ 151 ], "Experiments": [ 152 ], "primary": [ 154 ], "islets": [ 155 ], "reveal": [ 156 ], "\u03b2-arrestin1": [ 157 ], "limits": [ 158 ], "insulin": [ 160, 177 ], "response": [ 161 ], "GLP-1,": [ 163 ], "not": [ 165 ], "or": [ 167 ], "tirzepatide,": [ 168 ], "suggesting": [ 169 ], "biased": [ 172 ], "agonism": [ 173 ], "enhances": [ 176 ], "secretion.": [ 178 ], "Imbalance": [ 179 ], "toward": [ 180 ], "combined": [ 183 ], "distinct": [ 185 ], "together": [ 192 ], "may": [ 193 ], "account": [ 194 ], "promising": [ 197 ], "efficacy": [ 198 ], "this": [ 200 ], "investigational": [ 201 ], "agent.": [ 202 ] }, "publication_date": "2020-07-30", "publication_year": 2020, "type": "article", "cited_by_count": 417, "authors": [ { "id": "https://openalex.org/A5083011492", "display_name": "Francis S. Willard" }, { "id": "https://openalex.org/A5002113534", "display_name": "Jonathan D. Douros" }, { "id": "https://openalex.org/A5052462859", "display_name": "M Gabe" }, { "id": "https://openalex.org/A5010458910", "display_name": "Aaron D. Showalter" }, { "id": "https://openalex.org/A5071637884", "display_name": "David B. Wainscott" }, { "id": "https://openalex.org/A5110012088", "display_name": "Todd M. Suter" }, { "id": "https://openalex.org/A5022558489", "display_name": "Megan E. Capozzi" }, { "id": "https://openalex.org/A5055786721", "display_name": "Wijnand J. C. van der Velden" }, { "id": "https://openalex.org/A5040920805", "display_name": "Cynthia Stutsman" }, { "id": "https://openalex.org/A5109508256", "display_name": "Guemalli R. Cardona" }, { "id": "https://openalex.org/A5031510744", "display_name": "Shweta Urva" }, { "id": "https://openalex.org/A5052059067", "display_name": "Paul J. Emmerson" }, { "id": "https://openalex.org/A5085434984", "display_name": "Jens J. Holst" }, { "id": "https://openalex.org/A5071074041", "display_name": "David A. D\u2019Alessio" }, { "id": "https://openalex.org/A5011350446", "display_name": "Matthew P. Coghlan" }, { "id": "https://openalex.org/A5035872776", "display_name": "Mette M. Rosenkilde" }, { "id": "https://openalex.org/A5103123633", "display_name": "Jonathan E. Campbell" }, { "id": "https://openalex.org/A5068951024", "display_name": "Kyle W. Sloop" } ] }, { "id": "https://openalex.org/W807162506", "doi": "https://doi.org/10.1056/nejmoa1411892", "title": "A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management", "abstract": { "In": [ 0 ], "this": [ 1 ], "study,": [ 2 ], "3.0": [ 3 ], "mg": [ 4 ], "of": [ 5 ], "liraglutide,": [ 6 ], "as": [ 7 ], "an": [ 8 ], "adjunct": [ 9 ], "to": [ 10 ], "diet": [ 11 ], "and": [ 12, 20, 30 ], "exercise,": [ 13 ], "was": [ 14 ], "associated": [ 15 ], "with": [ 16 ], "reduced": [ 17 ], "body": [ 18 ], "weight": [ 19 ], "improved": [ 21 ], "metabolic": [ 22 ], "control.": [ 23 ], "(Funded": [ 24 ], "by": [ 25 ], "Novo": [ 26 ], "Nordisk;": [ 27 ], "SCALE": [ 28 ], "Obesity": [ 29 ], "Prediabetes": [ 31 ], "NN8022-1839": [ 32 ], "ClinicalTrials.gov": [ 33 ], "number,": [ 34 ], "NCT01272219.).": [ 35 ] }, "publication_date": "2015-07-01", "publication_year": 2015, "type": "article", "cited_by_count": 2348, "authors": [ { "id": "https://openalex.org/A5025844791", "display_name": "F. Xavier Pi\u2010Sunyer" }, { "id": "https://openalex.org/A5048067129", "display_name": "Arne Astrup" }, { "id": "https://openalex.org/A5077479009", "display_name": "Ken Fujioka" }, { "id": "https://openalex.org/A5080400693", "display_name": "Frank L. Greenway" }, { "id": "https://openalex.org/A5014511991", "display_name": "Alfredo Halpern" }, { "id": "https://openalex.org/A5043484813", "display_name": "Michel Krempf" }, { "id": "https://openalex.org/A5044479380", "display_name": "David C.W. Lau" }, { "id": "https://openalex.org/A5010753663", "display_name": "Carel W. le Roux" }, { "id": "https://openalex.org/A5114256392", "display_name": "Rafael Violante Ort\u00edz" }, { "id": "https://openalex.org/A5111479294", "display_name": "Christine B. Jensen" }, { "id": "https://openalex.org/A5047195042", "display_name": "John Wilding" } ] }, { "id": "https://openalex.org/W2045849794", "doi": "https://doi.org/10.1016/j.beem.2009.03.008", "title": "Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) \u2013 preclinical and clinical results", "abstract": null, "publication_date": "2009-08-01", "publication_year": 2009, "type": "review", "cited_by_count": 127, "authors": [ { "id": "https://openalex.org/A5062239390", "display_name": "Sten Madsbad" } ] }, { "id": "https://openalex.org/W4381716537", "doi": "https://doi.org/10.1056/nejmoa2302392", "title": "Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity", "abstract": { "Daily": [ 0 ], "oral": [ 1 ], "orforglipron,": [ 2 ], "a": [ 3 ], "nonpeptide": [ 4 ], "GLP-1": [ 5, 24 ], "receptor": [ 6, 25 ], "agonist,": [ 7 ], "was": [ 8 ], "associated": [ 9 ], "with": [ 10, 16, 22 ], "weight": [ 11 ], "reduction.": [ 12 ], "Adverse": [ 13 ], "events": [ 14 ], "reported": [ 15 ], "orforglipron": [ 17 ], "were": [ 18 ], "similar": [ 19 ], "to": [ 20 ], "those": [ 21 ], "injectable": [ 23 ], "agonists.": [ 26 ], "(Funded": [ 27 ], "by": [ 28 ], "Eli": [ 29 ], "Lilly;": [ 30 ], "GZGI": [ 31 ], "ClinicalTrials.gov": [ 32 ], "number,": [ 33 ], "NCT05051579.).": [ 34 ] }, "publication_date": "2023-06-23", "publication_year": 2023, "type": "article", "cited_by_count": 339, "authors": [ { "id": "https://openalex.org/A5027441223", "display_name": "Sean Wharton" }, { "id": "https://openalex.org/A5004471830", "display_name": "Thomas Blevins" }, { "id": "https://openalex.org/A5108774960", "display_name": "Lisa Connery" }, { "id": "https://openalex.org/A5045489578", "display_name": "Julio Rosenstock" }, { "id": "https://openalex.org/A5017710279", "display_name": "Sohini Raha" }, { "id": "https://openalex.org/A5013944614", "display_name": "Rong Liu" }, { "id": "https://openalex.org/A5055547863", "display_name": "Xiaosu Ma" }, { "id": "https://openalex.org/A5057140892", "display_name": "Kieren J. Mather" }, { "id": "https://openalex.org/A5040811419", "display_name": "Axel Haupt" }, { "id": "https://openalex.org/A5081732583", "display_name": "Deborah A. Robins" }, { "id": "https://openalex.org/A5090850437", "display_name": "Edward Pratt" }, { "id": "https://openalex.org/A5085855526", "display_name": "Christof Kazda" }, { "id": "https://openalex.org/A5077985126", "display_name": "\u041c\u0430\u043d\u0438\u0433\u0435 \u041a\u043e\u043d\u0438\u0433" } ] }, { "id": "https://openalex.org/W4388592674", "doi": "https://doi.org/10.1056/nejmoa2307563", "title": "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes", "abstract": { "In": [ 0 ], "patients": [ 1 ], "with": [ 2 ], "preexisting": [ 3 ], "cardiovascular": [ 4, 33 ], "disease": [ 5 ], "and": [ 6 ], "overweight": [ 7 ], "or": [ 8, 38 ], "obesity": [ 9 ], "but": [ 10 ], "without": [ 11 ], "diabetes,": [ 12 ], "weekly": [ 13 ], "subcutaneous": [ 14 ], "semaglutide": [ 15 ], "at": [ 16, 41 ], "a": [ 17, 42 ], "dose": [ 18 ], "of": [ 19, 30, 45 ], "2.4": [ 20 ], "mg": [ 21 ], "was": [ 22 ], "superior": [ 23 ], "to": [ 24 ], "placebo": [ 25 ], "in": [ 26 ], "reducing": [ 27 ], "the": [ 28 ], "incidence": [ 29 ], "death": [ 31 ], "from": [ 32 ], "causes,": [ 34 ], "nonfatal": [ 35, 39 ], "myocardial": [ 36 ], "infarction,": [ 37 ], "stroke": [ 40 ], "mean": [ 43 ], "follow-up": [ 44 ], "39.8": [ 46 ], "months.": [ 47 ], "(Funded": [ 48 ], "by": [ 49 ], "Novo": [ 50 ], "Nordisk;": [ 51 ], "SELECT": [ 52 ], "ClinicalTrials.gov": [ 53 ], "number,": [ 54 ], "NCT03574597.).": [ 55 ] }, "publication_date": "2023-11-11", "publication_year": 2023, "type": "article", "cited_by_count": 1860, "authors": [ { "id": "https://openalex.org/A5001994412", "display_name": "A. Michael Lincoff" }, { "id": "https://openalex.org/A5102890913", "display_name": "Kirstine Brown\u2010Frandsen" }, { "id": "https://openalex.org/A5005414020", "display_name": "Helen M. Colhoun" }, { "id": "https://openalex.org/A5039316946", "display_name": "John Deanfield" }, { "id": "https://openalex.org/A5090993994", "display_name": "Scott S. Emerson" }, { "id": "https://openalex.org/A5065344789", "display_name": "Sille Esbjerg" }, { "id": "https://openalex.org/A5074751094", "display_name": "S\u00f8ren Hardt\u2010Lindberg" }, { "id": "https://openalex.org/A5004099465", "display_name": "G. Kees Hovingh" }, { "id": "https://openalex.org/A5066700951", "display_name": "Steven E. Kahn" }, { "id": "https://openalex.org/A5112726774", "display_name": "Robert F. Kushner" }, { "id": "https://openalex.org/A5001655356", "display_name": "Ildiko Lingvay" }, { "id": "https://openalex.org/A5064155603", "display_name": "Tu\u011f\u00e7e Kalayc\u0131 Oral" }, { "id": "https://openalex.org/A5091639613", "display_name": "Marie Mide Michelsen" }, { "id": "https://openalex.org/A5051351787", "display_name": "Jorge Plutzky" }, { "id": "https://openalex.org/A5113629685", "display_name": "Christoffer W. Torn\u00f8e" }, { "id": "https://openalex.org/A5088283488", "display_name": "Donna H. Ryan" } ] }, { "id": "https://openalex.org/W2104252114", "doi": "https://doi.org/10.2337/dc13-2760", "title": "Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)", "abstract": { "OBJECTIVE": [ 0 ], "To": [ 1 ], "compare": [ 2 ], "the": [ 3, 104 ], "efficacy": [ 4 ], "and": [ 5, 16, 82, 140, 166, 170, 190, 196, 204, 240, 248, 261, 267 ], "safety": [ 6, 268 ], "of": [ 7, 30, 181 ], "dulaglutide,": [ 8 ], "a": [ 9 ], "once-weekly": [ 10, 252 ], "GLP-1": [ 11 ], "receptor": [ 12 ], "agonist,": [ 13 ], "with": [ 14, 78, 186, 194, 263 ], "placebo": [ 15, 35, 70, 156, 195, 260 ], "exenatide": [ 17, 66, 167, 197, 262 ], "in": [ 18, 36, 212, 219 ], "type": [ 19 ], "2": [ 20 ], "diabetic": [ 21 ], "patients.": [ 22 ], "The": [ 23, 229 ], "primary": [ 24, 105 ], "objective": [ 25 ], "was": [ 26, 89, 108, 210 ], "to": [ 27, 59, 103, 155, 246 ], "determine": [ 28 ], "superiority": [ 29 ], "dulaglutide": [ 31, 60, 63, 117, 128, 151, 187, 215, 236, 253 ], "1.5": [ 32, 61, 118, 188, 216 ], "mg": [ 33, 189, 192, 217 ], "versus": [ 34, 259 ], "HbA1c": [ 37, 88, 99, 184 ], "change": [ 38, 100 ], "at": [ 39, 157, 168 ], "26": [ 40, 54, 73, 158, 169, 203 ], "weeks.": [ 41 ], "RESEARCH": [ 42 ], "DESIGN": [ 43 ], "AND": [ 44 ], "METHODS": [ 45 ], "This": [ 46 ], "52-week,": [ 47 ], "multicenter,": [ 48 ], "parallel-arm": [ 49 ], "study": [ 50 ], "(primary": [ 51 ], "end": [ 52, 106 ], "point:": [ 53 ], "weeks)": [ 55 ], "randomized": [ 56 ], "patients": [ 57, 182, 213, 225 ], "(2:2:2:1)": [ 58 ], "mg,": [ 62, 65, 119, 130 ], "0.75": [ 64, 129, 191 ], "10": [ 67 ], "\u03bcg,": [ 68 ], "or": [ 69 ], "(placebo-controlled": [ 71 ], "period:": [ 72 ], "weeks).": [ 74 ], "Patients": [ 75 ], "were": [ 76, 153, 237, 243 ], "treated": [ 77 ], "metformin": [ 79 ], "(1,500\u20133,000": [ 80 ], "mg)": [ 81 ], "pioglitazone": [ 83 ], "(30\u201345": [ 84 ], "mg).": [ 85 ], "Mean": [ 86 ], "baseline": [ 87, 102 ], "8.1%": [ 90 ], "(65": [ 91 ], "mmol/mol).": [ 92 ], "RESULTS": [ 93 ], "Least": [ 94 ], "squares": [ 95 ], "mean": [ 96 ], "\u00b1": [ 97, 110, 113, 121, 124, 132, 135, 142, 145 ], "SE": [ 98 ], "from": [ 101 ], "point": [ 107 ], "\u22121.51": [ 109 ], "0.06%": [ 111, 122, 133 ], "(\u221216.5": [ 112 ], "0.7": [ 114, 125, 136 ], "mmol/mol)": [ 115, 126, 137, 147 ], "for": [ 116, 127, 138, 148, 235 ], "\u22121.30": [ 120 ], "(\u221214.2": [ 123 ], "\u22120.99": [ 131 ], "(\u221210.8": [ 134 ], "exenatide,": [ 139 ], "\u22120.46": [ 141 ], "0.08%": [ 143 ], "(\u22125.0": [ 144 ], "0.9": [ 146 ], "placebo.": [ 149 ], "Both": [ 150, 251 ], "doses": [ 152, 254 ], "superior": [ 154, 256 ], "weeks": [ 159, 172 ], "(both": [ 160, 173 ], "adjusted": [ 161, 174 ], "one-sided": [ 162, 175 ], "P": [ 163, 176, 199 ], "&lt;": [ 164, 177, 200 ], "0.001)": [ 165 ], "52": [ 171, 205 ], "0.001).": [ 178, 201 ], "Greater": [ 179 ], "percentages": [ 180 ], "reached": [ 183 ], "targets": [ 185 ], "than": [ 193, 218 ], "(all": [ 198 ], "At": [ 202 ], "weeks,": [ 206 ], "total": [ 207 ], "hypoglycemia": [ 208 ], "incidence": [ 209 ], "lower": [ 211 ], "receiving": [ 214, 221 ], "those": [ 220 ], "exenatide;": [ 222 ], "no": [ 223 ], "dulaglutide-treated": [ 224 ], "reported": [ 226 ], "severe": [ 227 ], "hypoglycemia.": [ 228 ], "most": [ 230 ], "common": [ 231 ], "gastrointestinal": [ 232 ], "adverse": [ 233 ], "events": [ 234 ], "nausea,": [ 238 ], "vomiting,": [ 239 ], "diarrhea.": [ 241 ], "Events": [ 242 ], "mostly": [ 244 ], "mild": [ 245 ], "moderate": [ 247 ], "transient.": [ 249 ], "CONCLUSIONS": [ 250 ], "demonstrated": [ 255 ], "glycemic": [ 257 ], "control": [ 258 ], "an": [ 264 ], "acceptable": [ 265 ], "tolerability": [ 266 ], "profile.": [ 269 ] }, "publication_date": "2014-05-31", "publication_year": 2014, "type": "article", "cited_by_count": 363, "authors": [ { "id": "https://openalex.org/A5040652845", "display_name": "Carol Wysham" }, { "id": "https://openalex.org/A5004471830", "display_name": "Thomas Blevins" }, { "id": "https://openalex.org/A5107277367", "display_name": "Richard F. Arakaki" }, { "id": "https://openalex.org/A5044848582", "display_name": "Gildred Colon" }, { "id": "https://openalex.org/A5088779019", "display_name": "Pedro Garc\u00eda" }, { "id": "https://openalex.org/A5057242778", "display_name": "Charles Atisso" }, { "id": "https://openalex.org/A5022892748", "display_name": "Debra Kuhstoss" }, { "id": "https://openalex.org/A5055443598", "display_name": "Mark Lakshmanan" } ] }, { "id": "https://openalex.org/W3194466821", "doi": "https://doi.org/10.3389/fendo.2021.721135", "title": "GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects", "abstract": { "Glucagon": [ 0 ], "like": [ 1 ], "peptide-1": [ 2 ], "(GLP-1)": [ 3 ], "is": [ 4, 53 ], "an": [ 5 ], "incretin": [ 6 ], "secretory": [ 7 ], "molecule.": [ 8 ], "GLP-1": [ 9 ], "receptor": [ 10 ], "agonists": [ 11 ], "(GLP-1RAs)": [ 12 ], "are": [ 13 ], "widely": [ 14, 54 ], "used": [ 15 ], "in": [ 16, 119, 136 ], "the": [ 17, 110, 126, 137 ], "treatment": [ 18 ], "of": [ 19, 34, 39, 132, 134 ], "type": [ 20 ], "2": [ 21 ], "diabetes": [ 22 ], "(T2DM)": [ 23 ], "due": [ 24 ], "to": [ 25, 109 ], "their": [ 26, 144 ], "attributes": [ 27 ], "such": [ 28, 66 ], "as": [ 29, 67 ], "body": [ 30 ], "weight": [ 31 ], "loss,": [ 32 ], "protection": [ 33 ], "islet": [ 35, 40 ], "\u03b2": [ 36, 41 ], "cells,": [ 37 ], "promotion": [ 38 ], "cell": [ 42 ], "proliferation": [ 43 ], "and": [ 44, 58, 61, 85, 96, 114, 117, 129, 140, 143, 149 ], "minimal": [ 45 ], "side": [ 46 ], "effects.": [ 47 ], "Studies": [ 48 ], "have": [ 49, 91 ], "found": [ 50 ], "that": [ 51 ], "GLP-1R": [ 52 ], "distributed": [ 55 ], "on": [ 56 ], "pancreatic": [ 57 ], "other": [ 59, 150 ], "tissues": [ 60 ], "has": [ 62, 106 ], "multiple": [ 63 ], "biological": [ 64 ], "effects,": [ 65, 99 ], "reducing": [ 68, 86 ], "neuroinflammation,": [ 69 ], "promoting": [ 70 ], "nerve": [ 71 ], "growth,": [ 72 ], "improving": [ 73 ], "heart": [ 74 ], "function,": [ 75 ], "suppressing": [ 76 ], "appetite,": [ 77 ], "delaying": [ 78 ], "gastric": [ 79 ], "emptying,": [ 80 ], "regulating": [ 81 ], "blood": [ 82 ], "lipid": [ 83 ], "metabolism": [ 84 ], "fat": [ 87 ], "deposition.": [ 88 ], "Moreover,": [ 89 ], "GLP-1RAs": [ 90, 113, 135 ], "neuroprotective,": [ 92 ], "anti-infectious,": [ 93 ], "cardiovascular": [ 94 ], "protective,": [ 95 ], "metabolic": [ 97 ], "regulatory": [ 98 ], "exhibiting": [ 100 ], "good": [ 101 ], "application": [ 102 ], "prospects.": [ 103 ], "Growing": [ 104 ], "attention": [ 105 ], "been": [ 107 ], "paid": [ 108 ], "relationship": [ 111 ], "between": [ 112 ], "tumorigenesis,": [ 115 ], "development": [ 116 ], "prognosis": [ 118 ], "patient": [ 120 ], "with": [ 121, 146 ], "T2DM.": [ 122 ], "Here,": [ 123 ], "we": [ 124 ], "reviewed": [ 125 ], "therapeutic": [ 127 ], "effects": [ 128 ], "possible": [ 130 ], "mechanisms": [ 131 ], "action": [ 133 ], "nervous,": [ 138 ], "cardiovascular,": [ 139 ], "endocrine": [ 141 ], "systems": [ 142 ], "correlation": [ 145 ], "metabolism,": [ 147 ], "tumours": [ 148 ], "diseases.": [ 151 ] }, "publication_date": "2021-08-23", "publication_year": 2021, "type": "review", "cited_by_count": 344, "authors": [ { "id": "https://openalex.org/A5101616052", "display_name": "Xin Zhao" }, { "id": "https://openalex.org/A5016791056", "display_name": "Minghe Wang" }, { "id": "https://openalex.org/A5035037261", "display_name": "Zhitong Wen" }, { "id": "https://openalex.org/A5076270839", "display_name": "Zhihong Lu" }, { "id": "https://openalex.org/A5070550289", "display_name": "Lijuan Cui" }, { "id": "https://openalex.org/A5020773915", "display_name": "Chao Fu" }, { "id": "https://openalex.org/A5110974077", "display_name": "Huan Xue" }, { "id": "https://openalex.org/A5100357490", "display_name": "Yunfeng Liu" }, { "id": "https://openalex.org/A5100388266", "display_name": "Yi Zhang" } ] }, { "id": "https://openalex.org/W2754041380", "doi": "https://doi.org/10.1056/nejmoa1612917", "title": "Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes", "abstract": { "Among": [ 0 ], "patients": [ 1, 24 ], "with": [ 2, 6 ], "type": [ 3 ], "2": [ 4 ], "diabetes": [ 5 ], "or": [ 7 ], "without": [ 8 ], "previous": [ 9 ], "cardiovascular": [ 10, 17 ], "disease,": [ 11 ], "the": [ 12 ], "incidence": [ 13 ], "of": [ 14 ], "major": [ 15 ], "adverse": [ 16 ], "events": [ 18 ], "did": [ 19 ], "not": [ 20 ], "differ": [ 21 ], "significantly": [ 22 ], "between": [ 23 ], "who": [ 25, 30 ], "received": [ 26, 31 ], "exenatide": [ 27 ], "and": [ 28 ], "those": [ 29 ], "placebo.": [ 32 ], "(Funded": [ 33 ], "by": [ 34 ], "Amylin": [ 35 ], "Pharmaceuticals;": [ 36 ], "EXSCEL": [ 37 ], "ClinicalTrials.gov": [ 38 ], "number,": [ 39 ], "NCT01144338": [ 40 ], ".).": [ 41 ] }, "publication_date": "2017-09-14", "publication_year": 2017, "type": "article", "cited_by_count": 2001, "authors": [ { "id": "https://openalex.org/A5049740900", "display_name": "Rury R. Holman" }, { "id": "https://openalex.org/A5108816669", "display_name": "M. Angelyn Bethel" }, { "id": "https://openalex.org/A5068642565", "display_name": "Robert J. Mentz" }, { "id": "https://openalex.org/A5089472493", "display_name": "Vivian P. Thompson" }, { "id": "https://openalex.org/A5107918445", "display_name": "Yuliya Lokhnygina" }, { "id": "https://openalex.org/A5040182038", "display_name": "John B. Buse" }, { "id": "https://openalex.org/A5091832416", "display_name": "Juliana C.N. Chan" }, { "id": "https://openalex.org/A5109681058", "display_name": "Jasmine Choi" }, { "id": "https://openalex.org/A5083714915", "display_name": "Stephanie M. Gustavson" }, { "id": "https://openalex.org/A5108458439", "display_name": "Nayyar Iqbal" }, { "id": "https://openalex.org/A5088186128", "display_name": "Aldo P. Maggioni" }, { "id": "https://openalex.org/A5110355842", "display_name": "Steven P. Marso" }, { "id": "https://openalex.org/A5112827962", "display_name": "Peter \u00d6hman" }, { "id": "https://openalex.org/A5088989269", "display_name": "Neha J. Pagidipati" }, { "id": "https://openalex.org/A5072011562", "display_name": "Neil R Poulter" }, { "id": "https://openalex.org/A5105304025", "display_name": "Ambady Ramachandran" }, { "id": "https://openalex.org/A5090437675", "display_name": "Bernard Zinman" }, { "id": "https://openalex.org/A5012849300", "display_name": "Adrian F. Hernandez" } ] }, { "id": "https://openalex.org/W3120821309", "doi": "https://doi.org/10.1136/bmj.m4573", "title": "Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials", "abstract": { "Abstract": [ 0 ], "Objective": [ 1 ], "To": [ 2 ], "evaluate": [ 3 ], "sodium-glucose": [ 4 ], "cotransporter-2": [ 5 ], "(SGLT-2)": [ 6 ], "inhibitors": [ 7, 51, 196, 233, 256, 264, 287, 307, 349, 382 ], "and": [ 8, 23, 33, 90, 106, 113, 161, 167, 197, 218, 246, 288, 344, 383, 389, 397 ], "glucagon-like": [ 9 ], "peptide-1": [ 10 ], "(GLP-1)": [ 11 ], "receptor": [ 12, 54, 199, 244, 248, 272, 290, 310, 385 ], "agonists": [ 13, 55, 200, 249, 273, 291, 311, 386 ], "in": [ 14, 65, 351, 357, 395, 417 ], "patients": [ 15, 129, 135, 185, 335, 359, 376 ], "with": [ 16, 56, 67, 71, 377, 392, 409 ], "type": [ 17, 68, 378 ], "2": [ 18, 69, 379 ], "diabetes": [ 19, 70, 203 ], "at": [ 20, 136 ], "varying": [ 21 ], "cardiovascular": [ 22, 141, 149, 213, 343, 388 ], "renal": [ 24, 345, 390 ], "risk.": [ 25 ], "Design": [ 26 ], "Network": [ 27 ], "meta-analysis.": [ 28 ], "Data": [ 29 ], "sources": [ 30 ], "Medline,": [ 31 ], "Embase,": [ 32 ], "Cochrane": [ 34 ], "CENTRAL": [ 35 ], "up": [ 36, 73 ], "to": [ 37, 116, 191, 201, 236, 259, 338, 353 ], "11": [ 38 ], "August": [ 39 ], "2020.": [ 40 ], "Eligibility": [ 41 ], "criteria": [ 42 ], "for": [ 43, 86, 131, 134, 238, 302, 371, 412 ], "selecting": [ 44 ], "studies": [ 45 ], "Randomised": [ 46 ], "controlled": [ 47 ], "trials": [ 48, 181 ], "comparing": [ 49 ], "SGLT-2": [ 50, 195, 232, 255, 263, 286, 306, 348, 381 ], "or": [ 52, 60, 77, 147, 297, 308, 320 ], "GLP-1": [ 53, 198, 243, 247, 271, 289, 309, 384 ], "placebo,": [ 57 ], "standard": [ 58 ], "care,": [ 59 ], "other": [ 61 ], "glucose": [ 62 ], "lowering": [ 63 ], "treatment": [ 64, 126 ], "adults": [ 66 ], "follow": [ 72 ], "of": [ 74, 93, 109, 125, 175, 194, 207, 305, 324, 329, 342, 407 ], "24": [ 75 ], "weeks": [ 76 ], "longer.": [ 78 ], "Studies": [ 79 ], "were": [ 80, 226 ], "screened": [ 81 ], "independently": [ 82 ], "by": [ 83, 403, 424 ], "two": [ 84, 230 ], "reviewers": [ 85 ], "eligibility,": [ 87 ], "extracted": [ 88 ], "data,": [ 89 ], "assessed": [ 91 ], "risk": [ 92, 139, 142, 145, 150, 153, 157, 164, 341, 405 ], "bias.": [ 94 ], "Main": [ 95 ], "outcome": [ 96 ], "measures": [ 97 ], "Frequentist": [ 98 ], "random": [ 99 ], "effects": [ 100, 124 ], "network": [ 101 ], "meta-analysis": [ 102 ], "was": [ 103, 300 ], "carried": [ 104 ], "out": [ 105 ], "GRADE": [ 107 ], "(grading": [ 108 ], "recommendations": [ 110 ], "assessment,": [ 111 ], "development,": [ 112 ], "evaluation)": [ 114 ], "used": [ 115 ], "assess": [ 117 ], "evidence": [ 118, 283, 299 ], "certainty.": [ 119 ], "Results": [ 120, 179 ], "included": [ 121 ], "estimated": [ 122 ], "absolute": [ 123, 327 ], "per": [ 127 ], "1000": [ 128, 358 ], "treated": [ 130 ], "five": [ 132, 361 ], "years": [ 133 ], "very": [ 137, 162, 339 ], "low": [ 138, 144, 337 ], "(no": [ 140 ], "factors),": [ 143, 151 ], "(three": [ 146 ], "more": [ 148, 241, 253 ], "moderate": [ 152 ], "(cardiovascular": [ 154, 165 ], "disease),": [ 155, 160 ], "high": [ 156, 163, 340 ], "(chronic": [ 158 ], "kidney": [ 159, 168, 219 ], "disease": [ 166 ], "disease).": [ 169 ], "A": [ 170 ], "guideline": [ 171 ], "panel": [ 172 ], "provided": [ 173 ], "oversight": [ 174 ], "the": [ 176, 192, 229, 303, 418 ], "systematic": [ 177, 426 ], "review.": [ 178, 427 ], "764": [ 180 ], "including": [ 182 ], "421": [ 183 ], "346": [ 184 ], "proved": [ 186 ], "eligible.": [ 187 ], "All": [ 188 ], "results": [ 189 ], "refer": [ 190 ], "addition": [ 193 ], "existing": [ 202 ], "treatment.": [ 204 ], "Both": [ 205 ], "classes": [ 206 ], "drugs": [ 208, 331 ], "lowered": [ 209 ], "all": [ 210, 372 ], "cause": [ 211, 275 ], "mortality,": [ 212, 214 ], "non-fatal": [ 215, 251 ], "myocardial": [ 216 ], "infarction,": [ 217 ], "failure": [ 220, 240 ], "(high": [ 221, 268 ], "certainty": [ 222, 282 ], "evidence).": [ 223 ], "Notable": [ 224 ], "differences": [ 225, 394 ], "found": [ 227, 301 ], "between": [ 228 ], "agents:": [ 231 ], "reduced": [ 234, 250, 387 ], "admission": [ 235 ], "hospital": [ 237 ], "heart": [ 239 ], "than": [ 242, 254 ], "agonists,": [ 245 ], "stroke": [ 252 ], "(which": [ 257 ], "appeared": [ 258 ], "have": [ 260 ], "no": [ 261, 298 ], "effect).": [ 262 ], "caused": [ 265 ], "genital": [ 266 ], "infection": [ 267 ], "certainty),": [ 269 ], "whereas": [ 270 ], "might": [ 274, 292 ], "severe": [ 276 ], "gastrointestinal": [ 277 ], "events": [ 278 ], "(low": [ 279 ], "certainty).": [ 280 ], "Low": [ 281 ], "suggested": [ 284 ], "that": [ 285 ], "lower": [ 293 ], "body": [ 294 ], "weight.": [ 295 ], "Little": [ 296 ], "effect": [ 304 ], "on": [ 312 ], "limb": [ 313 ], "amputation,": [ 314 ], "blindness,": [ 315 ], "eye": [ 316 ], "disease,": [ 317 ], "neuropathic": [ 318 ], "pain,": [ 319 ], "health": [ 321 ], "related": [ 322 ], "quality": [ 323 ], "life.": [ 325 ], "The": [ 326 ], "benefits": [ 328, 396, 400 ], "these": [ 330 ], "vary": [ 332 ], "substantially": [ 333 ], "across": [ 334 ], "from": [ 336 ], "outcomes": [ 346 ], "(eg,": [ 347 ], "resulted": [ 350 ], "3": [ 352 ], "40": [ 354 ], "fewer": [ 355 ], "deaths": [ 356 ], "over": [ 360 ], "years;": [ 362 ], "see": [ 363 ], "interactive": [ 364 ], "decision": [ 365 ], "support": [ 366 ], "tool": [ 367 ], "(": [ 368 ], "https://magicevidence.org/match-it/200820dist/#!/": [ 369 ], ")": [ 370 ], "outcomes.": [ 373 ], "Conclusions": [ 374 ], "In": [ 375 ], "diabetes,": [ 380 ], "outcomes,": [ 391 ], "some": [ 393 ], "harms.": [ 398 ], "Absolute": [ 399 ], "are": [ 401 ], "determined": [ 402 ], "individual": [ 404 ], "profiles": [ 406 ], "patients,": [ 408 ], "clear": [ 410 ], "implications": [ 411 ], "clinical": [ 413 ], "practice,": [ 414 ], "as": [ 415 ], "reflected": [ 416 ], "BMJ": [ 419 ], "Rapid": [ 420 ], "Recommendations": [ 421 ], "directly": [ 422 ], "informed": [ 423 ], "this": [ 425 ], "Systematic": [ 428 ], "review": [ 429 ], "registration": [ 430 ], "PROSPERO": [ 431 ], "CRD42019153180.": [ 432 ] }, "publication_date": "2021-01-13", "publication_year": 2021, "type": "review", "cited_by_count": 627, "authors": [ { "id": "https://openalex.org/A5018429053", "display_name": "Suetonia C. Palmer" }, { "id": "https://openalex.org/A5076228132", "display_name": "Britta Tendal" }, { "id": "https://openalex.org/A5067205817", "display_name": "Reem A. Mustafa" }, { "id": "https://openalex.org/A5017952355", "display_name": "Per Olav Vandvik" }, { "id": "https://openalex.org/A5091607881", "display_name": "Sheyu Li" }, { "id": "https://openalex.org/A5100602713", "display_name": "Qiukui Hao" }, { "id": "https://openalex.org/A5021328880", "display_name": "David J. Tunnicliffe" }, { "id": "https://openalex.org/A5003005836", "display_name": "Marinella Ruospo" }, { "id": "https://openalex.org/A5078001075", "display_name": "Patrizia Natale" }, { "id": "https://openalex.org/A5112280958", "display_name": "Valeria Saglimbene" }, { "id": "https://openalex.org/A5010127891", "display_name": "Antonio Nicolucci" }, { "id": "https://openalex.org/A5043394711", "display_name": "David W. Johnson" }, { "id": "https://openalex.org/A5034928512", "display_name": "Marcello Tonelli" }, { "id": "https://openalex.org/A5039243906", "display_name": "Maria Chiara Rossi" }, { "id": "https://openalex.org/A5075474387", "display_name": "Sunil V. Badve" }, { "id": "https://openalex.org/A5041410197", "display_name": "Yeoungjee Cho" }, { "id": "https://openalex.org/A5067579671", "display_name": "Annie\u2010Claire Nadeau\u2010Fredette" }, { "id": "https://openalex.org/A5102089116", "display_name": "Michael Burke" }, { "id": "https://openalex.org/A5050847750", "display_name": "Labib Imran Faruque" }, { "id": "https://openalex.org/A5058741495", "display_name": "Anita Lloyd" }, { "id": "https://openalex.org/A5055943471", "display_name": "Nasreen Ahmad" }, { "id": "https://openalex.org/A5023649089", "display_name": "Yuanchen Liu" }, { "id": "https://openalex.org/A5090796410", "display_name": "Sophanny Tiv" }, { "id": "https://openalex.org/A5076332515", "display_name": "Tanya Millard" }, { "id": "https://openalex.org/A5061621876", "display_name": "Lucia Gagliardi" }, { "id": "https://openalex.org/A5082567963", "display_name": "Nithin Kolanu" }, { "id": "https://openalex.org/A5001668895", "display_name": "Rahul Barmanray" }, { "id": "https://openalex.org/A5088660104", "display_name": "Rita McMorrow" }, { "id": "https://openalex.org/A5053524885", "display_name": "Ana Karina Raygoza Cortez" }, { "id": "https://openalex.org/A5004710720", "display_name": "Heath White" }, { "id": "https://openalex.org/A5101763855", "display_name": "Xiangyang Chen" }, { "id": "https://openalex.org/A5065715690", "display_name": "Xu Zhou" }, { "id": "https://openalex.org/A5057012556", "display_name": "Jiali Liu" }, { "id": "https://openalex.org/A5013151323", "display_name": "Andrea Flores Rodr\u00edguez" }, { "id": "https://openalex.org/A5073054763", "display_name": "Alejandro D\u00edaz Gonz\u00e1lez-Colmenero" }, { "id": "https://openalex.org/A5004682528", "display_name": "Yang Wang" }, { "id": "https://openalex.org/A5100435324", "display_name": "Ling Li" }, { "id": "https://openalex.org/A5060250386", "display_name": "Surya Sutanto" }, { "id": "https://openalex.org/A5071977401", "display_name": "Ricardo C\u00e9sar Sol\u00eds" }, { "id": "https://openalex.org/A5013381390", "display_name": "Fernando D\u00edaz Gonz\u00e1lez-Colmenero" }, { "id": "https://openalex.org/A5035283542", "display_name": "Ren\u00e9 Rodr\u00edguez\u2010Guti\u00e9rrez" }, { "id": "https://openalex.org/A5013696488", "display_name": "Michael Walsh" }, { "id": "https://openalex.org/A5031717153", "display_name": "Gordon Guyatt" }, { "id": "https://openalex.org/A5080193257", "display_name": "Giovanni FM Strippoli" } ] }, { "id": "https://openalex.org/W3134100899", "doi": "https://doi.org/10.1177/2042018821997320", "title": "GLP-1 receptor agonists: an updated review of head-to-head clinical studies", "abstract": { "Glucagon-like": [ 0 ], "peptide-1": [ 1 ], "receptor": [ 2 ], "agonists": [ 3 ], "(GLP-1": [ 4 ], "RA)": [ 5 ], "are": [ 6, 149 ], "attractive": [ 7 ], "options": [ 8, 152 ], "for": [ 9, 51 ], "the": [ 10, 44, 54, 60, 75, 114 ], "treatment": [ 11 ], "of": [ 12, 29, 88, 118, 125, 133, 161, 163, 173 ], "type": [ 13 ], "2": [ 14 ], "diabetes": [ 15 ], "(T2D)": [ 16 ], "because": [ 17 ], "they": [ 18 ], "effectively": [ 19 ], "lower": [ 20 ], "A1C": [ 21, 166 ], "and": [ 22, 57, 62, 68, 83, 104, 116, 167 ], "weight": [ 23, 168 ], "while": [ 24 ], "having": [ 25 ], "a": [ 26, 86 ], "low": [ 27 ], "risk": [ 28 ], "hypoglycemia.": [ 30 ], "Some": [ 31 ], "also": [ 32 ], "have": [ 33, 142 ], "documented": [ 34 ], "cardiovascular": [ 35 ], "benefit.": [ 36 ], "The": [ 37, 123, 136 ], "GLP-1": [ 38, 119, 137, 146 ], "RA": [ 39, 120, 138, 147 ], "class": [ 40 ], "has": [ 41 ], "grown": [ 42 ], "in": [ 43, 53, 159 ], "last": [ 45 ], "decade,": [ 46 ], "with": [ 47 ], "several": [ 48 ], "agents": [ 49, 73, 148 ], "available": [ 50 ], "use": [ 52 ], "United": [ 55 ], "States": [ 56 ], "Europe.": [ 58 ], "Since": [ 59 ], "efficacy": [ 61, 117 ], "tolerability,": [ 63 ], "dosing": [ 64 ], "frequency,": [ 65 ], "administration": [ 66 ], "requirements,": [ 67 ], "cost": [ 69 ], "may": [ 70, 79 ], "vary": [ 71 ], "between": [ 72 ], "within": [ 74 ], "class,": [ 76 ], "each": [ 77 ], "agent": [ 78 ], "offer": [ 80 ], "unique": [ 81 ], "advantages": [ 82 ], "disadvantages.": [ 84 ], "Through": [ 85 ], "review": [ 87, 127 ], "phase": [ 89 ], "III": [ 90 ], "clinical": [ 91, 140 ], "trials": [ 92, 109 ], "studying": [ 93 ], "dulaglutide,": [ 94 ], "exenatide": [ 95, 98 ], "twice": [ 96 ], "daily,": [ 97 ], "once": [ 99 ], "weekly,": [ 100 ], "liraglutide,": [ 101 ], "lixisenatide,": [ 102 ], "semaglutide,": [ 103, 106 ], "oral": [ 105 ], "14": [ 107 ], "head-to-head": [ 108, 139 ], "were": [ 110 ], "identified": [ 111 ], "that": [ 112, 144 ], "evaluated": [ 113 ], "safety": [ 115 ], "active": [ 121 ], "comparators.": [ 122 ], "purpose": [ 124 ], "this": [ 126 ], "is": [ 128 ], "to": [ 129 ], "provide": [ 130 ], "an": [ 131 ], "analysis": [ 132 ], "these": [ 134 ], "trials.": [ 135 ], "studies": [ 141 ], "demonstrated": [ 143 ], "all": [ 145 ], "effective": [ 150 ], "therapeutic": [ 151 ], "at": [ 153 ], "reducing": [ 154 ], "A1C.": [ 155 ], "However,": [ 156 ], "differences": [ 157 ], "exist": [ 158 ], "terms": [ 160 ], "magnitude": [ 162 ], "effect": [ 164 ], "on": [ 165 ], "as": [ 169, 171 ], "well": [ 170 ], "frequency": [ 172 ], "adverse": [ 174 ], "effects.": [ 175 ] }, "publication_date": "2021-01-01", "publication_year": 2021, "type": "review", "cited_by_count": 252, "authors": [ { "id": "https://openalex.org/A5054620018", "display_name": "Jennifer Trujillo" }, { "id": "https://openalex.org/A5016624558", "display_name": "Wesley Nuffer" }, { "id": "https://openalex.org/A5057993696", "display_name": "Brooke A. Smith" } ] }, { "id": "https://openalex.org/W2162140339", "doi": "https://doi.org/10.1021/acs.jmedchem.5b00726", "title": "Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide", "abstract": { "Liraglutide": [ 0 ], "is": [ 1, 16, 110, 161 ], "an": [ 2, 150 ], "acylated": [ 3 ], "glucagon-like": [ 4 ], "peptide-1": [ 5 ], "(GLP-1)": [ 6 ], "analogue": [ 7, 40 ], "that": [ 8 ], "binds": [ 9 ], "to": [ 10, 34, 60, 66, 104, 128, 158 ], "serum": [ 11 ], "albumin": [ 12, 43, 69, 132 ], "in": [ 13, 77, 142, 163 ], "vivo": [ 14 ], "and": [ 15, 45, 56, 71, 76, 82, 109, 147 ], "approved": [ 17 ], "for": [ 18 ], "once-daily": [ 19 ], "treatment": [ 20 ], "of": [ 21, 29, 84, 118, 152 ], "diabetes": [ 22 ], "as": [ 23, 25, 91 ], "well": [ 24 ], "obesity.": [ 26 ], "The": [ 27, 52, 115, 136 ], "aim": [ 28 ], "the": [ 30, 57, 63, 85, 92, 131 ], "present": [ 31 ], "studies": [ 32 ], "was": [ 33, 89, 124, 134, 139 ], "design": [ 35 ], "a": [ 36, 79 ], "once": [ 37, 94 ], "weekly": [ 38, 95 ], "GLP-1": [ 39, 61, 72, 86, 106 ], "by": [ 41 ], "increasing": [ 42 ], "affinity": [ 44, 70, 117, 133 ], "secure": [ 46, 67 ], "full": [ 47 ], "stability": [ 48 ], "against": [ 49 ], "metabolic": [ 50 ], "degradation.": [ 51 ], "fatty": [ 53 ], "acid": [ 54, 101 ], "moiety": [ 55 ], "linking": [ 58 ], "chemistry": [ 59 ], "were": [ 62 ], "key": [ 64 ], "features": [ 65 ], "high": [ 68 ], "receptor": [ 73 ], "(GLP-1R)": [ 74 ], "potency": [ 75 ], "obtaining": [ 78 ], "prolonged": [ 80 ], "exposure": [ 81 ], "action": [ 83 ], "analogue.": [ 87 ], "Semaglutide": [ 88, 97, 160 ], "selected": [ 90 ], "optimal": [ 93 ], "candidate.": [ 96 ], "has": [ 98, 149 ], "two": [ 99 ], "amino": [ 100 ], "substitutions": [ 102 ], "compared": [ 103, 127 ], "human": [ 105 ], "(Aib(8),": [ 107 ], "Arg(34))": [ 108 ], "derivatized": [ 111 ], "at": [ 112 ], "lysine": [ 113 ], "26.": [ 114 ], "GLP-1R": [ 116 ], "semaglutide": [ 119, 148 ], "(0.38": [ 120 ], "\u00b1": [ 121 ], "0.06": [ 122 ], "nM)": [ 123 ], "three-fold": [ 125 ], "decreased": [ 126 ], "liraglutide,": [ 129 ], "whereas": [ 130 ], "increased.": [ 135 ], "plasma": [ 137 ], "half-life": [ 138 ], "46.1": [ 140 ], "h": [ 141, 154 ], "mini-pigs": [ 143 ], "following": [ 144 ], "i.v.": [ 145 ], "administration,": [ 146 ], "MRT": [ 151 ], "63.6": [ 153 ], "after": [ 155 ], "s.c.": [ 156 ], "dosing": [ 157 ], "mini-pigs.": [ 159 ], "currently": [ 162 ], "phase": [ 164 ], "3": [ 165 ], "clinical": [ 166 ], "testing.": [ 167 ] }, "publication_date": "2015-08-26", "publication_year": 2015, "type": "article", "cited_by_count": 923, "authors": [ { "id": "https://openalex.org/A5034154367", "display_name": "Jesper Lau" }, { "id": "https://openalex.org/A5049135697", "display_name": "Paw Bloch" }, { "id": "https://openalex.org/A5110299291", "display_name": "Lauge Sch\u00e4ffer" }, { "id": "https://openalex.org/A5059409495", "display_name": "Ingrid Pettersson" }, { "id": "https://openalex.org/A5075530589", "display_name": "Jane C. Spetzler" }, { "id": "https://openalex.org/A5084182308", "display_name": "Jacob Kofoed" }, { "id": "https://openalex.org/A5078869291", "display_name": "Kjeld Madsen" }, { "id": "https://openalex.org/A5088627727", "display_name": "Lotte Bjerre Knudsen" }, { "id": "https://openalex.org/A5109109068", "display_name": "J. H. McGuire" }, { "id": "https://openalex.org/A5047967902", "display_name": "Dorte B. Steensgaard" }, { "id": "https://openalex.org/A5032325095", "display_name": "Holger M. Strauss" }, { "id": "https://openalex.org/A5111519891", "display_name": "Dorte X. Gram" }, { "id": "https://openalex.org/A5111794237", "display_name": "Sanne M\u00f8ller Knudsen" }, { "id": "https://openalex.org/A5025644697", "display_name": "F. S. Nielsen" }, { "id": "https://openalex.org/A5054540522", "display_name": "Peter Thygesen" }, { "id": "https://openalex.org/A5000218659", "display_name": "Steffen Reedtz\u2010Runge" }, { "id": "https://openalex.org/A5102775505", "display_name": "Thomas Kruse" } ] }, { "id": "https://openalex.org/W3102426258", "doi": "https://doi.org/10.1056/nejmoa2028395", "title": "A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis", "abstract": { "This": [ 0 ], "phase": [ 1 ], "2": [ 2 ], "trial": [ 3, 28 ], "involving": [ 4 ], "patients": [ 5, 20, 40 ], "with": [ 6, 11, 21, 41 ], "NASH": [ 7, 22 ], "showed": [ 8 ], "that": [ 9 ], "treatment": [ 10 ], "semaglutide": [ 12 ], "resulted": [ 13 ], "in": [ 14, 36, 44 ], "a": [ 15, 32 ], "significantly": [ 16 ], "higher": [ 17 ], "percentage": [ 18, 38 ], "of": [ 19, 39 ], "resolution": [ 23 ], "than": [ 24 ], "placebo.": [ 25 ], "However,": [ 26 ], "the": [ 27, 37 ], "did": [ 29 ], "not": [ 30 ], "show": [ 31 ], "significant": [ 33 ], "between-group": [ 34 ], "difference": [ 35 ], "an": [ 42 ], "improvement": [ 43 ], "fibrosis": [ 45 ], "stage.": [ 46 ], "(Funded": [ 47 ], "by": [ 48 ], "Novo": [ 49 ], "Nordisk;": [ 50 ], "ClinicalTrials.gov": [ 51 ], "number,": [ 52 ], "NCT02970942.).": [ 53 ] }, "publication_date": "2020-11-13", "publication_year": 2020, "type": "article", "cited_by_count": 1648, "authors": [ { "id": "https://openalex.org/A5044832887", "display_name": "Philip N. Newsome" }, { "id": "https://openalex.org/A5108666776", "display_name": "Kristine Buchholtz" }, { "id": "https://openalex.org/A5086957117", "display_name": "Kenneth Cusi" }, { "id": "https://openalex.org/A5113321224", "display_name": "Martin Linder" }, { "id": "https://openalex.org/A5017078328", "display_name": "Takeshi Okanoue" }, { "id": "https://openalex.org/A5072395263", "display_name": "Vlad Ratziu" }, { "id": "https://openalex.org/A5070639714", "display_name": "Arun J. Sanyal" }, { "id": "https://openalex.org/A5109649640", "display_name": "Anne\u2010Sophie Sejling" }, { "id": "https://openalex.org/A5091625375", "display_name": "Stephen A. Harrison" } ] }, { "id": "https://openalex.org/W2774157762", "doi": "https://doi.org/10.2337/dc17-0417", "title": "Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial", "abstract": { "OBJECTIVE": [ 0 ], "To": [ 1 ], "compare": [ 2 ], "the": [ 3, 234 ], "efficacy": [ 4 ], "and": [ 5, 94, 124, 140, 225 ], "safety": [ 6, 178, 238 ], "of": [ 7, 232 ], "once-weekly": [ 8 ], "semaglutide": [ 9, 54, 93, 139, 161, 208, 244 ], "1.0": [ 10, 55, 212 ], "mg": [ 11, 19, 56, 61, 213, 220 ], "s.c.": [ 12, 20 ], "with": [ 13, 23, 42, 92, 98, 138, 143, 160, 202, 207, 251 ], "exenatide": [ 14, 58, 99, 105, 144, 171, 193, 203, 217 ], "extended": [ 15 ], "release": [ 16 ], "(ER)": [ 17 ], "2.0": [ 18, 60, 219 ], "in": [ 21, 73, 187, 192, 221 ], "subjects": [ 22, 41, 158, 189, 195, 250 ], "type": [ 24, 43, 252 ], "2": [ 25, 44, 253 ], "diabetes.": [ 26 ], "RESEARCH": [ 27 ], "DESIGN": [ 28 ], "AND": [ 29 ], "METHODS": [ 30 ], "In": [ 31 ], "this": [ 32 ], "phase": [ 33 ], "3a,": [ 34 ], "open-label,": [ 35 ], "parallel-group,": [ 36 ], "randomized": [ 37, 51 ], "controlled": [ 38, 258 ], "trial,": [ 39 ], "813": [ 40 ], "diabetes": [ 45, 254 ], "taking": [ 46, 170 ], "oral": [ 47, 260 ], "antidiabetic": [ 48, 261 ], "drugs": [ 49, 235 ], "were": [ 50, 184, 199 ], "(1:1)": [ 52 ], "to": [ 53, 216 ], "or": [ 57 ], "ER": [ 59, 100, 106, 145, 172, 204, 218 ], "for": [ 62, 122, 249 ], "56": [ 63, 230 ], "weeks.": [ 64 ], "The": [ 65 ], "primary": [ 66 ], "end": [ 67 ], "point": [ 68 ], "was": [ 69, 86, 133, 214 ], "change": [ 70 ], "from": [ 71 ], "baseline": [ 72 ], "HbA1c": [ 74, 80, 164 ], "at": [ 75, 84, 131 ], "week": [ 76 ], "56.": [ 77 ], "RESULTS": [ 78 ], "Mean": [ 79, 126 ], "(8.3%": [ 81 ], "[67.7": [ 82 ], "mmol/mol]": [ 83 ], "baseline)": [ 85, 132 ], "reduced": [ 87, 134 ], "by": [ 88, 135 ], "1.5%": [ 89 ], "(16.8": [ 90 ], "mmol/mol)": [ 91, 97, 167 ], "0.9%": [ 95 ], "(10.0": [ 96 ], "(estimated": [ 101 ], "treatment": [ 102, 245 ], "difference": [ 103 ], "vs.": [ 104 ], "[ETD]": [ 107 ], "\u20130.62%": [ 108 ], "[95%": [ 109, 149 ], "CI": [ 110, 116, 150 ], "\u20130.80,": [ 111 ], "\u20130.44]": [ 112 ], "[\u20136.78": [ 113 ], "mmol/mol": [ 114 ], "(95%": [ 115 ], "\u20138.70,": [ 117 ], "\u20134.86)];": [ 118 ], "P": [ 119, 153 ], "&lt;": [ 120, 154 ], "0.0001": [ 121 ], "noninferiority": [ 123 ], "superiority).": [ 125 ], "body": [ 127, 227 ], "weight": [ 128, 228 ], "(95.8": [ 129 ], "kg": [ 130, 137, 142, 148 ], "5.6": [ 136 ], "1.9": [ 141 ], "(ETD": [ 146 ], "\u20133.78": [ 147 ], "\u20134.58,": [ 151 ], "\u20132.98];": [ 152 ], "0.0001).": [ 155 ], "Significantly": [ 156 ], "more": [ 157, 185, 200 ], "treated": [ 159 ], "(67%)": [ 162 ], "achieved": [ 163 ], "&lt;7.0%": [ 165 ], "(&lt;53": [ 166 ], "versus": [ 168 ], "those": [ 169 ], "(40%).": [ 173 ], "Both": [ 174 ], "treatments": [ 175 ], "had": [ 176, 236 ], "similar": [ 177 ], "profiles,": [ 179 ], "but": [ 180 ], "gastrointestinal": [ 181 ], "adverse": [ 182 ], "events": [ 183 ], "common": [ 186 ], "semaglutide-treated": [ 188 ], "(41.8%)": [ 190 ], "than": [ 191, 206 ], "ER\u2013treated": [ 194 ], "(33.3%);": [ 196 ], "injection-site": [ 197 ], "reactions": [ 198 ], "frequent": [ 201 ], "(22.0%)": [ 205 ], "(1.2%).": [ 209 ], "CONCLUSIONS": [ 210 ], "Semaglutide": [ 211 ], "superior": [ 215 ], "improving": [ 222 ], "glycemic": [ 223 ], "control": [ 224 ], "reducing": [ 226 ], "after": [ 229 ], "weeks": [ 231 ], "treatment;": [ 233 ], "comparable": [ 237 ], "profiles.": [ 239 ], "These": [ 240 ], "results": [ 241 ], "indicate": [ 242 ], "that": [ 243 ], "is": [ 246 ], "highly": [ 247 ], "effective": [ 248 ], "who": [ 255 ], "are": [ 256 ], "inadequately": [ 257 ], "on": [ 259 ], "drugs.": [ 262 ] }, "publication_date": "2017-12-15", "publication_year": 2017, "type": "article", "cited_by_count": 528, "authors": [ { "id": "https://openalex.org/A5082525611", "display_name": "Andrew Ahmann" }, { "id": "https://openalex.org/A5073949429", "display_name": "Matthew Capehorn" }, { "id": "https://openalex.org/A5022459640", "display_name": "G. Charpentier" }, { "id": "https://openalex.org/A5069364785", "display_name": "Francesco Dotta" }, { "id": "https://openalex.org/A5042438941", "display_name": "Elena Henkel" }, { "id": "https://openalex.org/A5001655356", "display_name": "Ildiko Lingvay" }, { "id": "https://openalex.org/A5015716676", "display_name": "Anders G. Holst" }, { "id": "https://openalex.org/A5024546399", "display_name": "Miriam Annett" }, { "id": "https://openalex.org/A5005405894", "display_name": "Vanita R. Aroda" } ] }, { "id": "https://openalex.org/W2097771449", "doi": "https://doi.org/10.1177/2042018814559725", "title": "GLP-1 receptor agonists: a review of head-to-head clinical studies", "abstract": { "Glucagon-like": [ 0 ], "peptide-1": [ 1 ], "receptor": [ 2 ], "agonists": [ 3 ], "(GLP-1": [ 4 ], "RA)": [ 5 ], "are": [ 6, 143 ], "attractive": [ 7 ], "options": [ 8, 146 ], "for": [ 9, 45, 91 ], "the": [ 10, 38, 48, 58, 73, 108 ], "treatment": [ 11 ], "of": [ 12, 29, 86, 112, 119, 127, 155, 157, 169 ], "type": [ 13 ], "2": [ 14 ], "diabetes": [ 15 ], "(T2D)": [ 16 ], "because": [ 17 ], "they": [ 18 ], "effectively": [ 19 ], "lower": [ 20 ], "A1C": [ 21, 160 ], "and": [ 22, 50, 52, 60, 66, 81, 101, 110, 161, 167 ], "weight": [ 23, 162 ], "while": [ 24 ], "having": [ 25 ], "a": [ 26, 84 ], "low": [ 27 ], "risk": [ 28 ], "hypoglycemia.": [ 30 ], "The": [ 31, 117, 130 ], "GLP-1": [ 32, 113, 131, 140 ], "RA": [ 33, 114, 132, 141 ], "class": [ 34 ], "has": [ 35 ], "grown": [ 36 ], "in": [ 37, 47, 55, 153 ], "last": [ 39 ], "decade": [ 40 ], "with": [ 41 ], "several": [ 42, 53 ], "agents": [ 43, 71, 142 ], "available": [ 44 ], "use": [ 46 ], "US": [ 49 ], "Europe": [ 51 ], "more": [ 54 ], "development.": [ 56 ], "Since": [ 57 ], "efficacy": [ 59, 111 ], "tolerability,": [ 61 ], "dosing": [ 62 ], "frequency,": [ 63 ], "administration": [ 64 ], "requirements,": [ 65 ], "cost": [ 67 ], "may": [ 68, 77 ], "vary": [ 69 ], "between": [ 70 ], "within": [ 72 ], "class,": [ 74 ], "each": [ 75 ], "agent": [ 76 ], "offer": [ 78 ], "unique": [ 79 ], "advantages": [ 80 ], "disadvantages.": [ 82 ], "Through": [ 83 ], "review": [ 85, 121 ], "phase": [ 87 ], "III": [ 88 ], "clinical": [ 89, 134 ], "programs": [ 90 ], "exenatide": [ 92, 95 ], "twice": [ 93 ], "daily,": [ 94 ], "once": [ 96 ], "weekly,": [ 97 ], "liraglutide,": [ 98 ], "albiglutide,": [ 99 ], "lixisenatide,": [ 100 ], "dulaglutide,": [ 102 ], "eight": [ 103 ], "head-to-head": [ 104, 133 ], "trials": [ 105 ], "have": [ 106, 136 ], "evaluated": [ 107 ], "safety": [ 109 ], "active": [ 115 ], "comparators.": [ 116 ], "purpose": [ 118 ], "this": [ 120 ], "is": [ 122 ], "to": [ 123 ], "provide": [ 124 ], "an": [ 125 ], "analysis": [ 126 ], "these": [ 128 ], "trials.": [ 129 ], "studies": [ 135 ], "demonstrated": [ 137 ], "that": [ 138 ], "all": [ 139 ], "effective": [ 144 ], "therapeutic": [ 145 ], "at": [ 147 ], "reducing": [ 148 ], "A1C.": [ 149 ], "However,": [ 150 ], "differences": [ 151 ], "exist": [ 152 ], "terms": [ 154 ], "magnitude": [ 156 ], "effect": [ 158 ], "on": [ 159 ], "as": [ 163, 165 ], "well": [ 164 ], "frequency": [ 166 ], "severity": [ 168 ], "adverse": [ 170 ], "effects.": [ 171 ] }, "publication_date": "2014-11-25", "publication_year": 2014, "type": "review", "cited_by_count": 272, "authors": [ { "id": "https://openalex.org/A5054620018", "display_name": "Jennifer Trujillo" }, { "id": "https://openalex.org/A5016624558", "display_name": "Wesley Nuffer" }, { "id": "https://openalex.org/A5109955262", "display_name": "Samuel L. Ellis" } ] }, { "id": "https://openalex.org/W3012225375", "doi": "https://doi.org/10.1210/jendso/bvz042", "title": "Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity", "abstract": { "Abstract": [ 0 ], "Background": [ 1 ], "and": [ 2, 21, 25, 79, 87, 101, 138, 144, 147, 160, 175, 202, 231, 251 ], "Aims": [ 3 ], "Epicardial": [ 4, 53, 166, 212 ], "adipose": [ 5, 54, 167, 213 ], "tissue": [ 6, 55, 168, 214 ], "(EAT),": [ 7 ], "the": [ 8, 13, 35, 72, 123, 150, 162, 195, 224 ], "visceral": [ 9 ], "fat": [ 10 ], "depot": [ 11 ], "of": [ 12, 37, 74, 125, 227, 239 ], "heart,": [ 14 ], "is": [ 15, 64 ], "a": [ 16, 91, 145, 186, 248 ], "modifiable": [ 17 ], "cardio-metbolic": [ 18 ], "risk": [ 19 ], "factor": [ 20 ], "therapeutic": [ 22 ], "target.": [ 23 ], "Semaglutide": [ 24 ], "dulaglutide,": [ 26, 115 ], "glucagon-like": [ 27 ], "peptide-1": [ 28 ], "(GLP-1)": [ 29 ], "receptor": [ 30, 44, 61, 76, 242 ], "agonists,": [ 31 ], "are": [ 32, 84 ], "indicated": [ 33 ], "for": [ 34, 185 ], "treatment": [ 36 ], "type": [ 38 ], "2": [ 39 ], "diabetes": [ 40 ], "mellitus": [ 41 ], "(T2DM).": [ 42 ], "GLP-1": [ 43, 57, 60, 75, 241 ], "agonists": [ 45, 77, 243 ], "have": [ 46 ], "recently": [ 47 ], "shown": [ 48 ], "to": [ 49, 66, 108, 117, 129 ], "reduce": [ 50 ], "cardiovascular": [ 51 ], "risk.": [ 52 ], "expresses": [ 56 ], "receptors": [ 58 ], "(GLP-1Rs).": [ 59 ], "agonist": [ 62 ], "liraglutide": [ 63 ], "known": [ 65 ], "significantly": [ 67, 170, 218 ], "decrease": [ 68 ], "EAT": [ 69, 82, 154, 192, 255 ], "thickness.": [ 70, 256 ], "However,": [ 71 ], "effects": [ 73 ], "semaglutide": [ 78, 174, 228, 244 ], "dulaglutide": [ 80, 176, 232, 246 ], "on": [ 81, 142 ], "thickness": [ 83, 155, 169, 215 ], "unknown.": [ 85 ], "Materials": [ 86 ], "Methods": [ 88 ], "We": [ 89 ], "performed": [ 90 ], "12-week,": [ 92 ], "controlled,": [ 93 ], "parallel": [ 94 ], "study": [ 95 ], "in": [ 96, 127, 172, 194, 205, 254 ], "80": [ 97 ], "subjects": [ 98, 135 ], "with": [ 99, 136, 223 ], "T2DM": [ 100, 137 ], "obesity.": [ 102 ], "Patients": [ 103 ], "received": [ 104 ], "either": [ 105, 240 ], "semaglutide,": [ 106 ], "up": [ 107, 116 ], "1": [ 109 ], "mg": [ 110, 119 ], "subcutaneous": [ 111 ], "(sc)": [ 112 ], "weekly,": [ 113, 121 ], "or": [ 114, 245 ], "1.5": [ 118 ], "sc": [ 120 ], "as": [ 122, 149 ], "standard": [ 124 ], "care": [ 126 ], "addition": [ 128 ], "their": [ 130 ], "usual": [ 131 ], "medication": [ 132 ], "regimen.": [ 133 ], "Twenty": [ 134 ], "obesity": [ 139 ], "were": [ 140 ], "started": [ 141 ], "metformin": [ 143, 196 ], "diet": [ 146 ], "served": [ 148 ], "control": [ 151 ], "group.": [ 152, 197 ], "Ultrasound-measured": [ 153 ], "was": [ 156, 190, 217 ], "measured": [ 157 ], "at": [ 158, 161 ], "baseline": [ 159 ], "12-week": [ 163 ], "follow-up.": [ 164 ], "Results": [ 165 ], "decreased": [ 171 ], "both": [ 173 ], "groups": [ 177, 207 ], "(P": [ 178, 220 ], "&lt;": [ 179, 221 ], "0.001)": [ 180 ], "after": [ 181 ], "12": [ 182 ], "weeks,": [ 183 ], "accounting": [ 184 ], "20%": [ 187 ], "reduction.": [ 188 ], "There": [ 189 ], "no": [ 191 ], "reduction": [ 193, 216, 253 ], "Body": [ 198 ], "mass": [ 199 ], "index": [ 200 ], "(BMI)": [ 201 ], "HbA1c": [ 203 ], "improved": [ 204 ], "all": [ 206 ], "without": [ 208 ], "reaching": [ 209 ], "statistical": [ 210 ], "significance.": [ 211 ], "greater": [ 219 ], "0.01)": [ 222 ], "higher": [ 225 ], "doses": [ 226 ], "(1": [ 229 ], "mg)": [ 230 ], "(1.5": [ 233 ], "mg),": [ 234 ], "respectively.": [ 235 ], "Conclusion": [ 236 ], "Weekly": [ 237 ], "administration": [ 238 ], "causes": [ 247 ], "rapid,": [ 249 ], "substantial,": [ 250 ], "dose-dependent": [ 252 ] }, "publication_date": "2020-03-13", "publication_year": 2020, "type": "article", "cited_by_count": 143, "authors": [ { "id": "https://openalex.org/A5007644539", "display_name": "Gianluca Iacobellis" }, { "id": "https://openalex.org/A5023230394", "display_name": "Alexandra C. Villasante Fricke" } ] }, { "id": "https://openalex.org/W3026155818", "doi": "https://doi.org/10.1210/clinem/dgaa285", "title": "Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists", "abstract": { "Abstract": [ 0 ], "Context": [ 1 ], "Obesity": [ 2 ], "is": [ 3, 31, 41, 68 ], "responsible": [ 4, 73 ], "for": [ 5, 74, 104 ], "an": [ 6, 132 ], "increased": [ 7 ], "risk": [ 8 ], "of": [ 9, 20, 23, 43, 47, 63, 77, 92, 131, 160, 207 ], "sub-fecundity": [ 10 ], "and": [ 11, 25, 49, 79, 120, 125, 141, 178, 186, 199 ], "infertility.": [ 12 ], "Obese": [ 13 ], "women": [ 14, 51, 82, 106, 175 ], "show": [ 15 ], "poorer": [ 16, 34 ], "reproductive": [ 17 ], "outcomes": [ 18 ], "regardless": [ 19 ], "the": [ 21, 44, 64, 71, 75, 89, 114, 129, 146, 158, 216 ], "mode": [ 22 ], "conception,": [ 24 ], "higher": [ 26 ], "body": [ 27 ], "mass": [ 28 ], "index": [ 29 ], "(BMI)": [ 30 ], "associated": [ 32 ], "with": [ 33, 52, 83, 85, 107, 154, 169, 176, 189 ], "fertility": [ 35, 119 ], "prognosis.": [ 36 ], "Polycystic": [ 37 ], "ovary": [ 38 ], "syndrome": [ 39 ], "(PCOS)": [ 40 ], "one": [ 42 ], "leading": [ 45 ], "causes": [ 46 ], "infertility,": [ 48 ], "many": [ 50 ], "PCOS": [ 53, 80, 142, 221 ], "are": [ 54 ], "also": [ 55 ], "overweight": [ 56 ], "or": [ 57, 155, 166 ], "obese.": [ 58 ], "Evidence": [ 59, 109 ], "Acquisition": [ 60 ], "The": [ 61, 203 ], "aim": [ 62 ], "present": [ 65 ], "narrative": [ 66 ], "review": [ 67 ], "to": [ 69, 193, 214, 220 ], "describe": [ 70 ], "mechanisms": [ 72 ], "development": [ 76 ], "infertility": [ 78 ], "in": [ 81, 149, 167, 174, 195 ], "obesity/overweight,": [ 84 ], "a": [ 86, 101, 211 ], "focus": [ 87 ], "on": [ 88, 145 ], "emerging": [ 90 ], "role": [ 91 ], "glucagon-like": [ 93 ], "peptide-1": [ 94 ], "(GLP-1)": [ 95 ], "receptor": [ 96 ], "agonists": [ 97 ], "(GLP-1": [ 98 ], "RAs)": [ 99 ], "as": [ 100 ], "therapeutic": [ 102 ], "option": [ 103 ], "obese": [ 105 ], "PCOS.": [ 108, 179 ], "synthesis": [ 110 ], "Weight": [ 111 ], "reduction": [ 112 ], "represents": [ 113 ], "most": [ 115 ], "significant": [ 116, 183 ], "factor": [ 117 ], "affecting": [ 118 ], "pregnancy": [ 121 ], "outcomes.": [ 122 ], "Current": [ 123 ], "experimental": [ 124 ], "clinical": [ 126 ], "evidence": [ 127 ], "suggests": [ 128 ], "presence": [ 130 ], "underlying": [ 133 ], "pathophysiological": [ 134 ], "link": [ 135 ], "between": [ 136 ], "obesity,": [ 137, 153 ], "GLP-1": [ 138, 161, 208 ], "kinetic": [ 139 ], "alterations,": [ 140 ], "pathogenesis.": [ 143 ], "Based": [ 144 ], "positive": [ 147 ], "results": [ 148, 191 ], "patients": [ 150 ], "affected": [ 151 ], "by": [ 152 ], "without": [ 156 ], "diabetes,": [ 157 ], "administration": [ 159 ], "RA": [ 162, 209 ], "(mainly": [ 163 ], "liraglutide)": [ 164 ], "alone": [ 165 ], "combination": [ 168 ], "metformin": [ 170 ], "has": [ 171 ], "been": [ 172 ], "investigated": [ 173 ], "obesity": [ 177 ], "Several": [ 180 ], "studies": [ 181 ], "demonstrated": [ 182 ], "weight": [ 184, 204 ], "loss": [ 185, 205 ], "testosterone": [ 187 ], "reduction,": [ 188 ], "mixed": [ 190 ], "relative": [ 192 ], "improvements": [ 194 ], "insulin": [ 196 ], "resistance": [ 197 ], "parameters": [ 198 ], "menstrual": [ 200 ], "patterns.": [ 201 ], "Conclusions": [ 202 ], "effects": [ 206 ], "offer": [ 210 ], "unique": [ 212 ], "opportunity": [ 213 ], "expand": [ 215 ], "treatment": [ 217 ], "options": [ 218 ], "available": [ 219 ], "patients.": [ 222 ] }, "publication_date": "2020-05-22", "publication_year": 2020, "type": "review", "cited_by_count": 298, "authors": [ { "id": "https://openalex.org/A5054108843", "display_name": "Hellas Cena" }, { "id": "https://openalex.org/A5071641712", "display_name": "Luca Chiovato" }, { "id": "https://openalex.org/A5070824746", "display_name": "Rossella E. Nappi" } ] }, { "id": "https://openalex.org/W2968073288", "doi": "https://doi.org/10.1016/s2213-8587(19)30249-9", "title": "Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials", "abstract": null, "publication_date": "2019-08-14", "publication_year": 2019, "type": "review", "cited_by_count": 1475, "authors": [ { "id": "https://openalex.org/A5012666230", "display_name": "S\u00f8ren Lund Kristensen" }, { "id": "https://openalex.org/A5061885256", "display_name": "Rasmus R\u00f8rth" }, { "id": "https://openalex.org/A5018432247", "display_name": "Pardeep S. Jhund" }, { "id": "https://openalex.org/A5007964446", "display_name": "Kieran F. Docherty" }, { "id": "https://openalex.org/A5078498803", "display_name": "Naveed Sattar" }, { "id": "https://openalex.org/A5039985378", "display_name": "David Preiss" }, { "id": "https://openalex.org/A5033436516", "display_name": "Lars K\u00f8ber" }, { "id": "https://openalex.org/A5009535057", "display_name": "Mark C. Petrie" }, { "id": "https://openalex.org/A5027213857", "display_name": "John J.V. McMurray" } ] }, { "id": "https://openalex.org/W3177122952", "doi": "https://doi.org/10.1056/nejmoa2107519", "title": "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes", "abstract": { "In": [ 0 ], "patients": [ 1 ], "with": [ 2, 13 ], "type": [ 3 ], "2": [ 4 ], "diabetes,": [ 5 ], "tirzepatide": [ 6 ], "was": [ 7 ], "noninferior": [ 8 ], "and": [ 9 ], "superior": [ 10 ], "to": [ 11, 15, 26 ], "semaglutide": [ 12 ], "respect": [ 14 ], "the": [ 16, 20 ], "mean": [ 17 ], "change": [ 18 ], "in": [ 19 ], "glycated": [ 21 ], "hemoglobin": [ 22 ], "level": [ 23 ], "from": [ 24 ], "baseline": [ 25 ], "40": [ 27 ], "weeks.": [ 28 ], "(Funded": [ 29 ], "by": [ 30 ], "Eli": [ 31 ], "Lilly;": [ 32 ], "SURPASS-2": [ 33 ], "ClinicalTrials.gov": [ 34 ], "number,": [ 35 ], "NCT03987919.).": [ 36 ] }, "publication_date": "2021-06-25", "publication_year": 2021, "type": "article", "cited_by_count": 1528, "authors": [ { "id": "https://openalex.org/A5086072427", "display_name": "Juan P. Fr\u00edas" }, { "id": "https://openalex.org/A5084593004", "display_name": "Melanie J. Davies" }, { "id": "https://openalex.org/A5045489578", "display_name": "Julio Rosenstock" }, { "id": "https://openalex.org/A5057457335", "display_name": "Federico C. P\u00e9rez Manghi" }, { "id": "https://openalex.org/A5072715491", "display_name": "Laura Fern\u00e1ndez Land\u00f3" }, { "id": "https://openalex.org/A5040651874", "display_name": "Brandon K. Bergman" }, { "id": "https://openalex.org/A5109831307", "display_name": "Bing Liu" }, { "id": "https://openalex.org/A5058864022", "display_name": "Xuewei Cui" }, { "id": "https://openalex.org/A5111127692", "display_name": "Katelyn Brown" } ] }, { "id": "https://openalex.org/W1965072462", "doi": "https://doi.org/10.1210/en.2011-0174", "title": "Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4", "abstract": { "The": [ 0, 16 ], "long-acting": [ 1 ], "glucagon-like": [ 2 ], "peptide-1": [ 3 ], "receptor": [ 4 ], "(GLP-1R)": [ 5 ], "agonists,": [ 6 ], "exendin-4": [ 7, 46, 91, 178, 235 ], "and": [ 8, 13, 47, 90, 98, 153, 166, 177, 187, 216, 221, 236 ], "liraglutide,": [ 9 ], "suppress": [ 10 ], "food": [ 11, 39, 155, 180, 207 ], "intake": [ 12, 40, 83, 156, 181, 208, 229 ], "body": [ 14 ], "weight.": [ 15 ], "mediating": [ 17 ], "site(s)": [ 18 ], "of": [ 19, 29, 45, 74, 126, 131, 140, 151, 172, 199, 234, 242 ], "action": [ 20 ], "for": [ 21, 190, 192, 205 ], "the": [ 22, 75, 82, 113, 134, 138, 148, 173, 200 ], "anorectic": [ 23, 149 ], "effects": [ 24, 150 ], "produced": [ 25 ], "by": [ 26, 52, 85, 240 ], "peripheral": [ 27, 53, 127, 232 ], "administration": [ 28, 233 ], "these": [ 30, 105 ], "GLP-1R": [ 31, 54, 63, 76, 114, 128, 141, 201, 243, 253 ], "agonists": [ 32, 202 ], "are": [ 33 ], "not": [ 34 ], "known.": [ 35 ], "Experiments": [ 36 ], "addressed": [ 37 ], "whether": [ 38 ], "suppression": [ 41, 84, 230 ], "after": [ 42, 169, 219, 225, 231 ], "ip": [ 43, 86, 170 ], "delivery": [ 44, 69, 171 ], "liraglutide": [ 48, 87, 152, 176, 220, 237 ], "is": [ 49, 238 ], "mediated": [ 50, 239 ], "exclusively": [ 51 ], "or": [ 55 ], "also": [ 56 ], "involves": [ 57 ], "direct": [ 58, 251 ], "central": [ 59 ], "nervous": [ 60 ], "system": [ 61 ], "(CNS)": [ 62 ], "activation.": [ 64, 254 ], "Results": [ 65 ], "showed": [ 66 ], "that": [ 67, 104 ], "CNS": [ 68, 252 ], "[third": [ 70 ], "intracerebroventricular": [ 71 ], "(3rd": [ 72 ], "ICV)]": [ 73 ], "antagonist": [ 77, 115 ], "exendin-(9\u201339)": [ 78, 132 ], "(100": [ 79 ], "\u03bcg),": [ 80, 93 ], "attenuated": [ 81 ], "(10": [ 88 ], "\u03bcg)": [ 89 ], "(3": [ 92 ], "particularly": [ 94 ], "at": [ 95, 182, 213, 222 ], "6": [ 96, 185, 214 ], "h": [ 97, 189, 215, 218, 224 ], "24": [ 99, 188, 217, 223 ], "h.": [ 100 ], "Control": [ 101 ], "experiments": [ 102 ], "show": [ 103 ], "findings": [ 106 ], "appear": [ 107 ], "to": [ 108, 133, 147 ], "be": [ 109 ], "based": [ 110 ], "neither": [ 111 ], "on": [ 112, 124, 143, 245 ], "acting": [ 116 ], "as": [ 117, 248, 250 ], "a": [ 118 ], "nonspecific": [ 119 ], "competing": [ 120 ], "orexigenic": [ 121 ], "signal": [ 122 ], "nor": [ 123 ], "blockade": [ 125 ], "via": [ 129 ], "efflux": [ 130 ], "periphery.": [ 135 ], "To": [ 136 ], "assess": [ 137 ], "contribution": [ 139 ], "expressed": [ 142, 244 ], "subdiaphragmatic": [ 144, 163, 193 ], "vagal": [ 145, 164, 194, 246 ], "afferents": [ 146, 247 ], "exendin-4,": [ 154 ], "was": [ 157, 211 ], "compared": [ 158 ], "in": [ 159 ], "rats": [ 160, 196 ], "with": [ 161 ], "complete": [ 162 ], "deafferentation": [ 165, 195 ], "surgical": [ 167 ], "controls": [ 168 ], "agonists.": [ 174 ], "Both": [ 175 ], "suppressed": [ 179 ], "3": [ 183 ], "h,": [ 184, 186 ], "controls;": [ 191 ], "higher": [ 197 ], "doses": [ 198 ], "were": [ 203 ], "needed": [ 204 ], "significant": [ 206 ], "suppression,": [ 209 ], "which": [ 210 ], "observed": [ 212 ], "exendin-4.": [ 226 ], "Conclusion:": [ 227 ], "Food": [ 228 ], "activation": [ 241 ], "well": [ 249 ] }, "publication_date": "2011-06-21", "publication_year": 2011, "type": "article", "cited_by_count": 330, "authors": [ { "id": "https://openalex.org/A5012443533", "display_name": "Scott E. Kanoski" }, { "id": "https://openalex.org/A5015531927", "display_name": "Samantha M. Fortin" }, { "id": "https://openalex.org/A5103379486", "display_name": "Myrtha Arnold" }, { "id": "https://openalex.org/A5016431924", "display_name": "Harvey J. Grill" }, { "id": "https://openalex.org/A5065258001", "display_name": "Matthew R. Hayes" } ] }, { "id": "https://openalex.org/W3195404919", "doi": "https://doi.org/10.1016/s2213-8587(21)00203-5", "title": "Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials", "abstract": null, "publication_date": "2021-08-20", "publication_year": 2021, "type": "review", "cited_by_count": 1304, "authors": [ { "id": "https://openalex.org/A5078498803", "display_name": "Naveed Sattar" }, { "id": "https://openalex.org/A5061857615", "display_name": "Matthew M.Y. Lee" }, { "id": "https://openalex.org/A5012666230", "display_name": "S\u00f8ren Lund Kristensen" }, { "id": "https://openalex.org/A5001064258", "display_name": "Kelley R. Branch" }, { "id": "https://openalex.org/A5019711625", "display_name": "Stefano Del Prato" }, { "id": "https://openalex.org/A5023004151", "display_name": "Nardev S. Khurmi" }, { "id": "https://openalex.org/A5067422552", "display_name": "Carolyn S.P. Lam" }, { "id": "https://openalex.org/A5067237537", "display_name": "Renato D. L\u00f3pes" }, { "id": "https://openalex.org/A5027213857", "display_name": "John J.V. McMurray" }, { "id": "https://openalex.org/A5059098934", "display_name": "Richard E. Pratley" }, { "id": "https://openalex.org/A5045489578", "display_name": "Julio Rosenstock" }, { "id": "https://openalex.org/A5024577116", "display_name": "Hertzel C. Gerstein" } ] }, { "id": "https://openalex.org/W2752707491", "doi": "https://doi.org/10.1056/nejmoa1616011", "title": "Liraglutide and Renal Outcomes in Type 2 Diabetes", "abstract": { "This": [ 0 ], "prespecified": [ 1 ], "secondary": [ 2 ], "analysis": [ 3 ], "shows": [ 4 ], "that,": [ 5 ], "when": [ 6 ], "added": [ 7 ], "to": [ 8 ], "usual": [ 9 ], "care,": [ 10 ], "liraglutide": [ 11 ], "resulted": [ 12 ], "in": [ 13 ], "lower": [ 14 ], "rates": [ 15 ], "of": [ 16, 21, 35 ], "the": [ 17, 32 ], "development": [ 18 ], "and": [ 19, 31 ], "progression": [ 20 ], "diabetic": [ 22 ], "kidney": [ 23 ], "disease": [ 24 ], "than": [ 25 ], "placebo.": [ 26 ], "(Funded": [ 27 ], "by": [ 28 ], "Novo": [ 29 ], "Nordisk": [ 30 ], "National": [ 33 ], "Institutes": [ 34 ], "Health;": [ 36 ], "LEADER": [ 37 ], "ClinicalTrials.gov": [ 38 ], "number,": [ 39 ], "NCT01179048": [ 40 ], ".).": [ 41 ] }, "publication_date": "2017-08-30", "publication_year": 2017, "type": "article", "cited_by_count": 1155, "authors": [ { "id": "https://openalex.org/A5043842967", "display_name": "Johannes F.E. Mann" }, { "id": "https://openalex.org/A5006684229", "display_name": "David D. \u00d8rsted" }, { "id": "https://openalex.org/A5029446878", "display_name": "Kirstine Brown\u2010Frandsen" }, { "id": "https://openalex.org/A5110355842", "display_name": "Steven P. Marso" }, { "id": "https://openalex.org/A5072011562", "display_name": "Neil R Poulter" }, { "id": "https://openalex.org/A5110231477", "display_name": "S\u00f8ren Rasmussen" }, { "id": "https://openalex.org/A5017628699", "display_name": "Karen Torn\u00f8e" }, { "id": "https://openalex.org/A5090437675", "display_name": "Bernard Zinman" }, { "id": "https://openalex.org/A5040182038", "display_name": "John B. Buse" } ] }, { "id": "https://openalex.org/W2592545469", "doi": "https://doi.org/10.2337/ds16-0026", "title": "Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes", "abstract": { "The": [ 0, 31, 62 ], "incretin": [ 1, 41 ], "system": [ 2 ], "has": [ 3 ], "become": [ 4 ], "an": [ 5 ], "important": [ 6 ], "target": [ 7 ], "in": [ 8, 15, 45, 68, 144 ], "the": [ 9, 40, 69, 73, 91, 130 ], "treatment": [ 10, 74, 147 ], "of": [ 11, 24, 37, 58, 75, 127 ], "type": [ 12, 49, 76 ], "2": [ 13, 50, 77 ], "diabetes": [ 14, 51, 78 ], "recent": [ 16 ], "years,": [ 17 ], "and": [ 18, 85, 90, 97, 116, 129, 140 ], "glucagon-like": [ 19 ], "peptide": [ 20 ], "1": [ 21 ], "(GLP-1)": [ 22 ], "is": [ 23, 43 ], "particular": [ 25 ], "interest": [ 26 ], "for": [ 27, 72 ], "its": [ 28 ], "glucose-lowering": [ 29 ], "effects.": [ 30 ], "physiological": [ 32 ], "response": [ 33 ], "to": [ 34, 104 ], "oral": [ 35 ], "ingestion": [ 36 ], "nutrients,": [ 38 ], "involving": [ 39 ], "system,": [ 42 ], "reduced": [ 44 ], "some": [ 46 ], "patients": [ 47 ], "with": [ 48, 123 ], "but": [ 52 ], "may": [ 53 ], "be": [ 54 ], "augmented": [ 55 ], "by": [ 56 ], "administration": [ 57 ], "GLP-1": [ 59, 63, 118 ], "receptor": [ 60, 64, 119 ], "agonists.": [ 61 ], "agonists": [ 65, 120 ], "currently": [ 66 ], "approved": [ 67 ], "United": [ 70 ], "States": [ 71 ], "include": [ 79 ], "exenatide": [ 80, 94 ], "(administered": [ 81, 87 ], "twice": [ 82 ], "daily),": [ 83, 89 ], "liraglutide": [ 84 ], "lixisenatide": [ 86 ], "once": [ 88 ], "once-weekly": [ 92 ], "agents": [ 93, 100 ], "extended-release,": [ 95 ], "albiglutide,": [ 96 ], "dulaglutide.": [ 98 ], "These": [ 99 ], "have": [ 101 ], "been": [ 102 ], "shown": [ 103 ], "reduce": [ 105 ], "A1C": [ 106 ], "(by": [ 107, 111 ], "\u223c0.8\u20131.6%),": [ 108 ], "body": [ 109 ], "weight": [ 110 ], "\u223c1\u20133": [ 112 ], "kg),": [ 113 ], "blood": [ 114 ], "pressure,": [ 115 ], "lipids.": [ 117 ], "are": [ 121, 135 ], "associated": [ 122 ], "a": [ 124 ], "low": [ 125 ], "risk": [ 126 ], "hypoglycemia,": [ 128 ], "most": [ 131 ], "common": [ 132 ], "adverse": [ 133 ], "effects": [ 134 ], "gastrointestinal.": [ 136 ], "Proper": [ 137 ], "patient": [ 138 ], "selection": [ 139 ], "education": [ 141 ], "can": [ 142 ], "assist": [ 143 ], "achieving": [ 145 ], "positive": [ 146 ], "outcomes.": [ 148 ] }, "publication_date": "2017-08-01", "publication_year": 2017, "type": "article", "cited_by_count": 367, "authors": [ { "id": "https://openalex.org/A5110272769", "display_name": "Deborah Hinnen" } ] }, { "id": "https://openalex.org/W1984740259", "doi": "https://doi.org/10.2337/diacare.28.5.1092", "title": "Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes", "abstract": { "OBJECTIVE\u2014This": [ 0 ], "study": [ 1, 38 ], "evaluates": [ 2 ], "the": [ 3, 6, 54 ], "ability": [ 4 ], "of": [ 5, 67, 74, 81, 210, 242 ], "incretin": [ 7 ], "mimetic": [ 8 ], "exenatide": [ 9, 87 ], "(exendin-4)": [ 10 ], "to": [ 11, 22, 145, 207, 212, 251 ], "improve": [ 12 ], "glycemic": [ 13, 24, 253 ], "control": [ 14, 25, 254 ], "in": [ 15, 202, 244 ], "patients": [ 16, 52, 245 ], "with": [ 17, 26, 45, 65, 222, 234, 246, 255 ], "type": [ 18, 247 ], "2": [ 19, 248 ], "diabetes": [ 20, 249 ], "failing": [ 21, 250 ], "achieve": [ 23, 252 ], "maximally": [ 27 ], "effective": [ 28 ], "metformin": [ 29, 114 ], "doses.": [ 30 ], "RESEARCH": [ 31 ], "DESIGN": [ 32 ], "AND": [ 33 ], "METHODS\u2014A": [ 34 ], "triple-blind,": [ 35 ], "placebo-controlled,": [ 36 ], "30-week": [ 37 ], "at": [ 39 ], "82": [ 40 ], "U.S.": [ 41 ], "sites": [ 42 ], "was": [ 43, 60, 215, 227 ], "performed": [ 44 ], "336": [ 46 ], "randomized": [ 47 ], "patients.": [ 48 ], "In": [ 49 ], "all,": [ 50 ], "272": [ 51 ], "completed": [ 53 ], "study.": [ 55 ], "The": [ 56, 195 ], "intent-to-treat": [ 57 ], "population": [ 58 ], "baseline": [ 59, 122 ], "53": [ 61 ], "\u00b1": [ 62, 69, 76, 123, 130, 135, 141, 179, 185 ], "10": [ 63, 100 ], "years": [ 64 ], "BMI": [ 66 ], "34.2": [ 68 ], "5.9": [ 70 ], "kg/m2": [ 71 ], "and": [ 72, 139, 160, 204, 217, 231, 238 ], "HbA1c": [ 73, 119, 164, 233 ], "8.2": [ 75 ], "1.1%.": [ 77 ], "After": [ 78 ], "4": [ 79, 94 ], "weeks": [ 80, 95 ], "placebo,": [ 82 ], "subjects": [ 83, 112, 172 ], "self-administered": [ 84 ], "5": [ 85, 98 ], "\u03bcg": [ 86, 101 ], "or": [ 88, 99, 103 ], "placebo": [ 89, 104 ], "subcutaneously": [ 90, 105 ], "twice": [ 91, 106 ], "daily": [ 92, 107 ], "for": [ 93, 108, 125 ], "followed": [ 96 ], "by": [ 97 ], "exenatide,": [ 102 ], "26": [ 109 ], "weeks.": [ 110 ], "All": [ 111 ], "continued": [ 113 ], "therapy.": [ 115 ], "RESULTS\u2014At": [ 116 ], "week": [ 117 ], "30,": [ 118 ], "changes": [ 120 ], "from": [ 121 ], "SE": [ 124 ], "each": [ 126 ], "group": [ 127 ], "were": [ 128, 200 ], "\u22120.78": [ 129 ], "0.10%": [ 131, 142 ], "(10": [ 132, 155 ], "\u03bcg),": [ 133, 138, 156, 159 ], "\u22120.40": [ 134 ], "0.11%": [ 136 ], "(5": [ 137, 158 ], "+0.08": [ 140 ], "(placebo;": [ 143 ], "intent": [ 144 ], "treat;": [ 146 ], "adjusted": [ 147 ], "P": [ 148, 190 ], "&lt;": [ 149, 167, 191 ], "0.002).": [ 150 ], "Of": [ 151 ], "evaluable": [ 152 ], "subjects,": [ 153 ], "46%": [ 154 ], "32%": [ 157 ], "13%": [ 161 ], "(placebo)": [ 162 ], "achieved": [ 163 ], "\u22647%": [ 165 ], "(P": [ 166 ], "0.01": [ 168 ], "vs.": [ 169, 193 ], "placebo).": [ 170, 194 ], "Exenatide-treated": [ 171 ], "displayed": [ 173 ], "progressive": [ 174 ], "dose-dependent": [ 175 ], "weight": [ 176, 236 ], "loss": [ 177 ], "(\u22122.8": [ 178 ], "0.5": [ 180 ], "kg": [ 181, 187 ], "[10": [ 182 ], "\u03bcg],": [ 183 ], "\u22121.6": [ 184 ], "0.4": [ 186 ], "[5": [ 188 ], "\u03bcg];": [ 189 ], "0.001": [ 192 ], "most": [ 196 ], "frequent": [ 197 ], "adverse": [ 198 ], "events": [ 199 ], "gastrointestinal": [ 201 ], "nature": [ 203 ], "generally": [ 205, 228 ], "mild": [ 206, 211 ], "moderate.": [ 208 ], "Incidence": [ 209 ], "moderate": [ 213 ], "hypoglycemia": [ 214, 243 ], "low": [ 216 ], "similar": [ 218 ], "across": [ 219 ], "treatment": [ 220 ], "arms,": [ 221 ], "no": [ 223, 235, 239 ], "severe": [ 224 ], "hypoglycemia.": [ 225 ], "CONCLUSIONS\u2014Exenatide": [ 226 ], "well": [ 229 ], "tolerated": [ 230 ], "reduced": [ 232 ], "gain": [ 237 ], "increased": [ 240 ], "incidence": [ 241 ], "metformin.": [ 256 ] }, "publication_date": "2005-05-01", "publication_year": 2005, "type": "article", "cited_by_count": 1541, "authors": [ { "id": "https://openalex.org/A5073917506", "display_name": "Ralph A. DeFronzo" }, { "id": "https://openalex.org/A5081205041", "display_name": "Robert E. Ratner" }, { "id": "https://openalex.org/A5111694431", "display_name": "Jenny Han" }, { "id": "https://openalex.org/A5084708084", "display_name": "Dennis Dong Hwan Kim" }, { "id": "https://openalex.org/A5083503351", "display_name": "Mark Fineman" }, { "id": "https://openalex.org/A5110941359", "display_name": "Alain Baron" } ] }, { "id": "https://openalex.org/W3110873848", "doi": "https://doi.org/10.1007/s13300-020-00981-0", "title": "The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type\u00a02 Diabetes: The SURPASS Clinical Trials", "abstract": null, "publication_date": "2020-12-15", "publication_year": 2020, "type": "review", "cited_by_count": 243, "authors": [ { "id": "https://openalex.org/A5031828883", "display_name": "Thinzar Min" }, { "id": "https://openalex.org/A5080463002", "display_name": "Stephen C. Bain" } ] }, { "id": "https://openalex.org/W344771105", "doi": "https://doi.org/10.3233/jad-143090", "title": "The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer\u2019s Disease", "abstract": { "Abstract": [ 0 ], "Recent": [ 1 ], "studies": [ 2 ], "indicate": [ 3 ], "that": [ 4 ], "glucagon-like": [ 5 ], "peptide": [ 6 ], "1": [ 7 ], "(GLP-1)": [ 8 ], "receptor": [ 9, 46 ], "agonists,": [ 10 ], "currently": [ 11 ], "used": [ 12, 97 ], "in": [ 13, 25, 49, 116, 155, 171, 191, 199, 214 ], "the": [ 14, 36, 43, 141, 188 ], "management": [ 15 ], "of": [ 16, 30, 42, 58, 134, 143, 149, 203, 208 ], "type": [ 17 ], "2": [ 18 ], "diabetes,": [ 19 ], "exhibit": [ 20 ], "neurotrophic": [ 21 ], "and": [ 22, 39, 112, 152, 164, 210 ], "neuroprotective": [ 23, 40 ], "effects": [ 24, 41 ], "amyloid-\u03b2": [ 26, 135 ], "(A\u03b2)": [ 27 ], "toxicity": [ 28 ], "models": [ 29 ], "Alzheimer\u2019s": [ 31 ], "disease": [ 32 ], "(AD).": [ 33 ], "We": [ 34 ], "investigated": [ 35 ], "potential": [ 37 ], "pro-cognitive": [ 38 ], "once-daily": [ 44 ], "GLP-1": [ 45 ], "agonist": [ 47 ], "liraglutide": [ 48, 71, 183 ], "senescence-accelerated": [ 50 ], "mouse": [ 51, 201 ], "prone": [ 52 ], "8": [ 53 ], "(SAMP8)": [ 54 ], "mice,": [ 55, 173 ], "a": [ 56, 200 ], "model": [ 57, 202 ], "age-related": [ 59 ], "sporadic": [ 60, 216 ], "AD": [ 61, 157 ], "not": [ 62 ], "dominated": [ 63 ], "by": [ 64 ], "amyloid": [ 65, 150 ], "plaques.": [ 66 ], "Six-month-old": [ 67 ], "SAMP8": [ 68, 94, 107, 128, 172, 179 ], "mice": [ 69, 95, 108, 129 ], "received": [ 70 ], "(100": [ 72 ], "or": [ 73, 77, 137, 185 ], "500": [ 74 ], "\u03bcg/kg/day,": [ 75 ], "s.c.)": [ 76 ], "vehicle": [ 78 ], "once": [ 79 ], "daily": [ 80 ], "for": [ 81, 101 ], "4": [ 82 ], "months.": [ 83 ], "Vehicle-dosed": [ 84, 105 ], "age-matched": [ 85, 177 ], "50%": [ 86 ], "back-crossed": [ 87 ], "as": [ 88, 90, 98, 120, 174 ], "well": [ 89 ], "untreated": [ 91 ], "young": [ 92 ], "(4-month-old)": [ 93 ], "were": [ 96 ], "control": [ 99, 124 ], "groups": [ 100 ], "normal": [ 102 ], "memory": [ 103, 113, 162, 192 ], "function.": [ 104 ], "10-month-old": [ 106, 127 ], "showed": [ 109 ], "significant": [ 110 ], "learning": [ 111 ], "retention": [ 114, 163 ], "deficits": [ 115, 145 ], "an": [ 117 ], "active-avoidance": [ 118 ], "T-maze,": [ 119 ], "compared": [ 121, 175 ], "to": [ 122, 147, 176 ], "both": [ 123 ], "groups.": [ 125 ], "Also,": [ 126 ], "displayed": [ 130 ], "no": [ 131 ], "immunohistological": [ 132 ], "signatures": [ 133 ], "plaques": [ 136, 151 ], "hyperphosphorylated": [ 138 ], "tau,": [ 139 ], "indicating": [ 140 ], "onset": [ 142 ], "cognitive": [ 144 ], "prior": [ 146 ], "deposition": [ 148 ], "neurofibrillary": [ 153 ], "tangles": [ 154 ], "this": [ 156 ], "model.": [ 158 ], "Liraglutide": [ 159 ], "significantly": [ 160 ], "increased": [ 161 ], "total": [ 165 ], "hippocampal": [ 166, 196 ], "CA1": [ 167 ], "pyramidal": [ 168 ], "neuron": [ 169 ], "numbers": [ 170 ], "vehicle-dosed": [ 178 ], "mice.": [ 180 ], "In": [ 181 ], "conclusion,": [ 182 ], "delayed": [ 184 ], "partially": [ 186 ], "halted": [ 187 ], "progressive": [ 189 ], "decline": [ 190 ], "function": [ 193 ], "associated": [ 194 ], "with": [ 195, 206 ], "neuronal": [ 197 ], "loss": [ 198 ], "pathological": [ 204 ], "aging": [ 205 ], "characteristics": [ 207 ], "neurobehavioral": [ 209 ], "neuropathological": [ 211 ], "impairments": [ 212 ], "observed": [ 213 ], "early-stage": [ 215 ], "AD.": [ 217 ] }, "publication_date": "2015-06-26", "publication_year": 2015, "type": "article", "cited_by_count": 167, "authors": [ { "id": "https://openalex.org/A5001683046", "display_name": "Henrik H. Hansen" }, { "id": "https://openalex.org/A5047010404", "display_name": "Katrine Fabricius" }, { "id": "https://openalex.org/A5005450058", "display_name": "Pernille Barkholt" }, { "id": "https://openalex.org/A5013741811", "display_name": "Michael L. Niehoff" }, { "id": "https://openalex.org/A5102748794", "display_name": "John E. Morley" }, { "id": "https://openalex.org/A5075602116", "display_name": "Jacob Jelsing" }, { "id": "https://openalex.org/A5084425804", "display_name": "Charles Pyke" }, { "id": "https://openalex.org/A5088627727", "display_name": "Lotte Bjerre Knudsen" }, { "id": "https://openalex.org/A5037000230", "display_name": "Susan A. Farr" }, { "id": "https://openalex.org/A5088582143", "display_name": "Niels Vrang" } ] }, { "id": "https://openalex.org/W3138431202", "doi": "https://doi.org/10.1001/jama.2021.3224", "title": "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity", "abstract": { "Importance": [ 0 ], "The": [ 1, 176 ], "effect": [ 2 ], "of": [ 3, 98, 114, 128, 133, 152, 236, 353, 368 ], "continuing": [ 4 ], "vs": [ 5, 284, 341, 359 ], "withdrawing": [ 6 ], "treatment": [ 7, 33, 366, 401 ], "with": [ 8, 22, 34, 39, 47, 52, 60, 94, 104, 286, 337, 361, 371, 383, 393, 402, 405 ], "semaglutide,": [ 9, 36, 271, 395 ], "a": [ 10, 57, 232, 389 ], "glucagon-like": [ 11 ], "peptide": [ 12 ], "1": [ 13 ], "receptor": [ 14 ], "agonist,": [ 15 ], "on": [ 16 ], "weight": [ 17, 44, 185, 234, 274, 412 ], "loss": [ 18, 235, 413 ], "maintenance": [ 19, 45, 134, 144 ], "in": [ 20, 50, 83, 92, 169, 183, 198, 351, 410 ], "people": [ 21 ], "overweight": [ 23, 53, 384 ], "or": [ 24, 54, 159, 385 ], "obesity": [ 25, 55, 386 ], "is": [ 26 ], "unknown.": [ 27 ], "Objective": [ 28 ], "To": [ 29 ], "compare": [ 30 ], "continued": [ 31, 153, 270, 338, 356, 372, 411 ], "once-weekly": [ 32, 118 ], "subcutaneous": [ 35, 61, 119, 154, 339, 357, 394 ], "2.4": [ 37, 65, 396 ], "mg,": [ 38 ], "switch": [ 40, 288 ], "to": [ 41, 64, 89, 149, 161, 189, 279, 289, 296, 310, 322, 407 ], "placebo": [ 42, 162, 290, 342, 376, 408 ], "for": [ 43 ], "(both": [ 46 ], "lifestyle": [ 48, 167 ], "intervention)": [ 49 ], "adults": [ 51, 93, 382 ], "after": [ 56 ], "20-week": [ 58, 228, 390 ], "run-in": [ 59, 229, 391 ], "semaglutide": [ 62, 120, 143, 155, 340, 358, 373, 403 ], "titrated": [ 63 ], "mg": [ 66, 397 ], "weekly.": [ 67 ], "Design,": [ 68 ], "Setting,": [ 69 ], "and": [ 70, 108, 174, 204, 238, 264, 326, 375, 379 ], "Participants": [ 71 ], "Randomized,": [ 72 ], "double-blind,": [ 73 ], "68-week": [ 74 ], "phase": [ 75 ], "3a": [ 76 ], "withdrawal": [ 77 ], "study": [ 78, 223 ], "conducted": [ 79 ], "at": [ 80, 99 ], "73": [ 81 ], "sites": [ 82 ], "10": [ 84 ], "countries": [ 85 ], "from": [ 86, 186, 276 ], "June": [ 87 ], "2018": [ 88 ], "March": [ 90 ], "2020": [ 91 ], "body": [ 95, 184, 251, 273 ], "mass": [ 96 ], "index": [ 97 ], "least": [ 100 ], "30": [ 101 ], "(or": [ 102 ], "\u226527": [ 103 ], "\u22651": [ 105 ], "weight-related": [ 106 ], "comorbidity)": [ 107 ], "without": [ 109 ], "diabetes.": [ 110 ], "Interventions": [ 111 ], "A": [ 112 ], "total": [ 113 ], "902": [ 115 ], "participants": [ 116, 137, 224, 259, 354 ], "received": [ 117 ], "during": [ 121 ], "run-in.": [ 122 ], "After": [ 123 ], "20": [ 124, 188, 278 ], "weeks": [ 125, 127, 132, 151 ], "(16": [ 126 ], "dose": [ 129, 145 ], "escalation;": [ 130 ], "4": [ 131 ], "dose),": [ 135 ], "803": [ 136, 222 ], "(89.0%)": [ 138 ], "who": [ 139, 225, 355, 387 ], "reached": [ 140 ], "the": [ 141, 209, 227, 262, 287, 415 ], "2.4-mg/wk": [ 142 ], "were": [ 146, 196, 239, 349 ], "randomized": [ 147, 240 ], "(2:1)": [ 148 ], "48": [ 150, 417 ], "(n": [ 156, 163 ], "=": [ 157, 164 ], "535)": [ 158 ], "switched": [ 160 ], "268),": [ 165 ], "plus": [ 166 ], "intervention": [ 168 ], "both": [ 170 ], "groups.": [ 171 ], "Main": [ 172 ], "Outcomes": [ 173 ], "Measures": [ 175 ], "primary": [ 177 ], "end": [ 178, 194 ], "point": [ 179 ], "was": [ 180, 282 ], "percent": [ 181 ], "change": [ 182, 275 ], "week": [ 187, 190, 277, 280 ], "68;": [ 191 ], "confirmatory": [ 192 ], "secondary": [ 193 ], "points": [ 195 ], "changes": [ 197 ], "waist": [ 199 ], "circumference,": [ 200 ], "systolic": [ 201, 313 ], "blood": [ 202, 314 ], "pressure,": [ 203 ], "physical": [ 205, 328 ], "functioning": [ 206, 329 ], "(assessed": [ 207 ], "using": [ 208 ], "Short": [ 210 ], "Form": [ 211 ], "36": [ 212 ], "Version": [ 213, 218 ], "2": [ 214 ], "Health": [ 215 ], "Survey,": [ 216 ], "Acute": [ 217 ], "[SF-36]).": [ 219 ], "Results": [ 220 ], "Among": [ 221, 381 ], "completed": [ 226, 261, 267, 388 ], "period": [ 230, 392 ], "(with": [ 231 ], "mean": [ 233, 250, 272 ], "10.6%)": [ 237 ], "(mean": [ 241 ], "age,": [ 242 ], "46": [ 243 ], "[SD,": [ 244, 255 ], "12]": [ 245 ], "years;": [ 246 ], "634": [ 247 ], "[79%]": [ 248 ], "women;": [ 249 ], "weight,": [ 252 ], "107.2": [ 253 ], "kg": [ 254 ], "22.7": [ 256 ], "kg]),": [ 257 ], "787": [ 258 ], "(98.0%)": [ 260 ], "trial": [ 263 ], "741": [ 265 ], "(92.3%)": [ 266 ], "treatment.": [ 268 ], "With": [ 269 ], "68": [ 281 ], "\u22127.9%": [ 283 ], "+6.9%": [ 285 ], "(difference,": [ 291 ], "\u221214.8": [ 292 ], "[95%": [ 293, 307, 319, 332 ], "CI,": [ 294, 308, 320, 333 ], "\u221216.0": [ 295 ], "\u221213.5]": [ 297 ], "percentage": [ 298 ], "points;": [ 299 ], "P": [ 300, 344 ], "&amp;lt;": [ 301, 345 ], ".001).": [ 302, 346 ], "Waist": [ 303 ], "circumference": [ 304 ], "(\u22129.7": [ 305 ], "cm": [ 306 ], "\u221210.9": [ 309 ], "\u22128.5": [ 311 ], "cm]),": [ 312 ], "pressure": [ 315 ], "(\u22123.9": [ 316 ], "mm": [ 317, 324 ], "Hg": [ 318 ], "\u22125.8": [ 321 ], "\u22122.0": [ 323 ], "Hg]),": [ 325 ], "SF-36": [ 327 ], "score": [ 330 ], "(2.5": [ 331 ], "1.6-3.3])": [ 334 ], "also": [ 335 ], "improved": [ 336 ], "(all": [ 343 ], "Gastrointestinal": [ 347 ], "events": [ 348, 370 ], "reported": [ 350 ], "41.9%": [ 352 ], "26.1%": [ 360 ], "placebo;": [ 362 ], "similar": [ 363 ], "proportions": [ 364 ], "discontinued": [ 365 ], "because": [ 367 ], "adverse": [ 369 ], "(2.4%)": [ 374 ], "(2.2%).": [ 377 ], "Conclusions": [ 378 ], "Relevance": [ 380 ], "once": [ 398 ], "weekly,": [ 399 ], "maintaining": [ 400 ], "compared": [ 404 ], "switching": [ 406 ], "resulted": [ 409 ], "over": [ 414 ], "following": [ 416 ], "weeks.": [ 418 ], "Trial": [ 419 ], "Registration": [ 420 ], "ClinicalTrials.gov": [ 421 ], "Identifier:": [ 422 ], "NCT03548987": [ 423 ] }, "publication_date": "2021-03-23", "publication_year": 2021, "type": "article", "cited_by_count": 993, "authors": [ { "id": "https://openalex.org/A5060266336", "display_name": "Domenica Rubino" }, { "id": "https://openalex.org/A5053615730", "display_name": "Niclas Abrahamsson" }, { "id": "https://openalex.org/A5084593004", "display_name": "Melanie J. Davies" }, { "id": "https://openalex.org/A5039497762", "display_name": "Dan Hesse" }, { "id": "https://openalex.org/A5080400693", "display_name": "Frank L. Greenway" }, { "id": "https://openalex.org/A5078072521", "display_name": "Camilla Jensen" }, { "id": "https://openalex.org/A5001655356", "display_name": "Ildiko Lingvay" }, { "id": "https://openalex.org/A5080475619", "display_name": "Ofri Mosenzon" }, { "id": "https://openalex.org/A5045489578", "display_name": "Julio Rosenstock" }, { "id": "https://openalex.org/A5074462156", "display_name": "Miguel A. Rubio" }, { "id": "https://openalex.org/A5047494174", "display_name": "Gottfried Rudofsky" }, { "id": "https://openalex.org/A5109382569", "display_name": "Sayeh Tadayon" }, { "id": "https://openalex.org/A5026596594", "display_name": "Thomas A. Wadden" }, { "id": "https://openalex.org/A5009921349", "display_name": "Dror Dicker" }, { "id": "https://openalex.org/A5008183225", "display_name": "M. Friberg" }, { "id": "https://openalex.org/A5050303522", "display_name": "Anders Sj\u00f6din" }, { "id": "https://openalex.org/A5009921349", "display_name": "Dror Dicker" }, { "id": "https://openalex.org/A5103960057", "display_name": "Gabriella Segal" }, { "id": "https://openalex.org/A5080475619", "display_name": "Ofri Mosenzon" }, { "id": "https://openalex.org/A5039981818", "display_name": "Muhammad Sabbah" }, { "id": "https://openalex.org/A5080831092", "display_name": "Yael Sofer" }, { "id": "https://openalex.org/A5097134396", "display_name": "Victor Vishlitzky" }, { "id": "https://openalex.org/A5034348972", "display_name": "Eelco W. Meesters" }, { "id": "https://openalex.org/A5112619679", "display_name": "Mirelle Serlie" }, { "id": "https://openalex.org/A5088451409", "display_name": "Arianne van Bon" }, { "id": "https://openalex.org/A5105979449", "display_name": "Helena Cardoso" }, { "id": "https://openalex.org/A5025107493", "display_name": "Paula Freitas" }, { "id": "https://openalex.org/A5020297807", "display_name": "Pedro Carneiro de Melo" }, { "id": "https://openalex.org/A5101559235", "display_name": "Margarida Monteiro" }, { "id": "https://openalex.org/A5031304031", "display_name": "Mariana P. Monteiro" }, { "id": "https://openalex.org/A5072336972", "display_name": "D\u00edrcea Rodrigues" }, { "id": "https://openalex.org/A5042696644", "display_name": "Aysha Badat" }, { "id": "https://openalex.org/A5057336874", "display_name": "P Joshi" }, { "id": "https://openalex.org/A5037563846", "display_name": "Gulam Latiff" }, { "id": "https://openalex.org/A5008158999", "display_name": "Essack Mitha" }, { "id": "https://openalex.org/A5112619680", "display_name": "Hans H. Snyman" }, { "id": "https://openalex.org/A5046802233", "display_name": "Elane van Nieuwenhuizen" }, { "id": "https://openalex.org/A5083731854", "display_name": "Olga Gonz\u00e1lez Albarr\u00e1n" }, { "id": "https://openalex.org/A5059425869", "display_name": "Assumpta Caix\u00e0s" }, { "id": "https://openalex.org/A5103960058", "display_name": "Carmen de al Cuesta" }, { "id": "https://openalex.org/A5084216788", "display_name": "Pedro Pablo Garc\u00eda\u2010Luna" }, { "id": "https://openalex.org/A5051089128", "display_name": "Crist\u00f3bal Morales" }, { "id": "https://openalex.org/A5039297952", "display_name": "Pedro Mezquita Raya" }, { "id": "https://openalex.org/A5074462156", "display_name": "Miguel A. Rubio" }, { "id": "https://openalex.org/A5053615730", "display_name": "Niclas Abrahamsson" }, { "id": "https://openalex.org/A5016185012", "display_name": "Johan Hoffstedt" }, { "id": "https://openalex.org/A5069243907", "display_name": "Fredrik von Wowern" }, { "id": "https://openalex.org/A5000442895", "display_name": "Erik Uddman" }, { "id": "https://openalex.org/A5003897050", "display_name": "Birgit Bach-Kliegel" }, { "id": "https://openalex.org/A5014771501", "display_name": "Felix Beuschlein" }, { "id": "https://openalex.org/A5067406711", "display_name": "Stefan Bilz" }, { "id": "https://openalex.org/A5107771860", "display_name": "Alain Golay" }, { "id": "https://openalex.org/A5047494174", "display_name": "Gottfried Rudofsky" }, { "id": "https://openalex.org/A5015564601", "display_name": "Christopher Strey" }, { "id": "https://openalex.org/A5065826467", "display_name": "G. D. Fadieienko" }, { "id": "https://openalex.org/A5045048508", "display_name": "\u041d. \u0412. \u041a\u043e\u0441\u0435\u0439" }, { "id": "https://openalex.org/A5077691474", "display_name": "\u0422. \u0424 \u0422\u0430\u0442\u0430\u0440\u0447\u0443\u043a" }, { "id": "https://openalex.org/A5054862170", "display_name": "V. I. Velychko" }, { "id": "https://openalex.org/A5103960059", "display_name": "Olesya Zinych" }, { "id": "https://openalex.org/A5113643367", "display_name": "Stephen Aronoff" }, { "id": "https://openalex.org/A5053191013", "display_name": "Harold Bays" }, { "id": "https://openalex.org/A5068219751", "display_name": "Andrew Brockmyre" }, { "id": "https://openalex.org/A5112104128", "display_name": "Robert S. Call" }, { "id": "https://openalex.org/A5034756567", "display_name": "Charles H. Crump" }, { "id": "https://openalex.org/A5077027153", "display_name": "Cyrus Desouza" }, { "id": "https://openalex.org/A5057250312", "display_name": "Valerie Espinosa" }, { "id": "https://openalex.org/A5065636691", "display_name": "Almena Free" }, { "id": "https://openalex.org/A5059130634", "display_name": "Winston H. Gandy" }, { "id": "https://openalex.org/A5020066648", "display_name": "S Geller" }, { "id": "https://openalex.org/A5004283619", "display_name": "Gregory Gottschlich" }, { "id": "https://openalex.org/A5080400693", "display_name": "Frank L. Greenway" }, { "id": "https://openalex.org/A5001668011", "display_name": "Laurie J. Han-Conrad" }, { "id": "https://openalex.org/A5016580496", "display_name": "Wayne L. Harper" }, { "id": "https://openalex.org/A5102789903", "display_name": "Lee Herman" }, { "id": "https://openalex.org/A5086166789", "display_name": "Mitzie Hewitt" }, { "id": "https://openalex.org/A5072786933", "display_name": "Priscilla Hollander" }, { "id": "https://openalex.org/A5031900071", "display_name": "S. Kaster" }, { "id": "https://openalex.org/A5065712252", "display_name": "Anastasios Manessis" }, { "id": "https://openalex.org/A5110751520", "display_name": "Frederick A. Martin" }, { "id": "https://openalex.org/A5112619681", "display_name": "Robert E. McNeill" }, { "id": "https://openalex.org/A5109425508", "display_name": "Alexander V. Murray" }, { "id": "https://openalex.org/A5019150153", "display_name": "Paul Norwood" }, { "id": "https://openalex.org/A5112619682", "display_name": "John C.H. Reed" }, { "id": "https://openalex.org/A5045489578", "display_name": "Julio Rosenstock" }, { "id": "https://openalex.org/A5060266336", "display_name": "Domenica Rubino" }, { "id": "https://openalex.org/A5021117774", "display_name": "Martin Schear" }, { "id": "https://openalex.org/A5011320591", "display_name": "Mark Warren" } ] }, { "id": "https://openalex.org/W2168245033", "doi": "https://doi.org/10.2337/db14-0263", "title": "SIRT1 Mediates the Effect of GLP-1 Receptor Agonist Exenatide on Ameliorating Hepatic Steatosis", "abstract": { "GLP-1": [ 0, 56, 180 ], "and": [ 1, 16, 80, 90, 114, 124, 203 ], "incretin": [ 2 ], "mimetics,": [ 3 ], "such": [ 4 ], "as": [ 5, 34, 185 ], "exenatide,": [ 6 ], "have": [ 7 ], "been": [ 8, 32 ], "shown": [ 9 ], "to": [ 10 ], "attenuate": [ 11 ], "hepatocyte": [ 12 ], "steatosis": [ 13 ], "in": [ 14, 17, 38, 71, 92, 99, 104, 128, 142, 196 ], "vivo": [ 15 ], "vitro,": [ 18 ], "but": [ 19 ], "the": [ 20, 52, 55, 93, 100, 109, 129, 170, 179 ], "specific": [ 21 ], "underlying": [ 22 ], "mechanism": [ 23 ], "is": [ 24 ], "unclear.": [ 25 ], "SIRT1,": [ 26 ], "an": [ 27 ], "NAD+-dependent": [ 28 ], "protein": [ 29, 110 ], "deacetylase,": [ 30 ], "has": [ 31 ], "considered": [ 33 ], "a": [ 35, 77, 186, 207 ], "crucial": [ 36 ], "regulator": [ 37 ], "hepatic": [ 39, 63, 176 ], "lipid": [ 40, 88, 149 ], "homeostasis": [ 41 ], "by": [ 42, 152, 160 ], "accumulated": [ 43 ], "studies.": [ 44 ], "Here,": [ 45 ], "we": [ 46, 85 ], "speculate": [ 47 ], "that": [ 48, 87, 167 ], "SIRT1": [ 49, 113, 157, 161, 168, 204 ], "might": [ 50 ], "mediate": [ 51 ], "effect": [ 53, 171 ], "of": [ 54, 68, 112, 137, 172, 210 ], "receptor": [ 57, 181 ], "agonist": [ 58, 182 ], "exenatide": [ 59, 69, 133, 173 ], "(exendin-4)": [ 60 ], "on": [ 61, 174 ], "ameliorating": [ 62, 175 ], "steatosis.": [ 64 ], "After": [ 65 ], "8": [ 66 ], "weeks": [ 67 ], "treatment": [ 70 ], "male": [ 72 ], "SIRT1+/\u2212": [ 73, 105, 143 ], "mice": [ 74 ], "challenged": [ 75 ], "with": [ 76, 201 ], "high-fat": [ 78 ], "diet": [ 79 ], "their": [ 81 ], "wild-type": [ 82 ], "(WT)": [ 83 ], "littermates,": [ 84 ], "found": [ 86 ], "deposition": [ 89, 150 ], "inflammation": [ 91 ], "liver,": [ 94 ], "which": [ 95 ], "were": [ 96, 140 ], "improved": [ 97 ], "dramatically": [ 98 ], "WT": [ 101, 130 ], "group,": [ 102 ], "diminished": [ 103 ], "mice.": [ 106, 144 ], "In": [ 107, 145 ], "addition,": [ 108 ], "expression": [ 111 ], "phosphorylated": [ 115 ], "AMPK": [ 116 ], "was": [ 117, 126, 154, 158 ], "upregulated,": [ 118 ], "whereas": [ 119 ], "lipogenic-related": [ 120 ], "protein,": [ 121 ], "including": [ 122 ], "SREBP-1c": [ 123 ], "PNPLA3,": [ 125 ], "downregulated": [ 127 ], "group": [ 131 ], "after": [ 132 ], "treatment.": [ 134 ], "However,": [ 135 ], "none": [ 136 ], "these": [ 138 ], "changes": [ 139 ], "observed": [ 141 ], "HepG2": [ 146 ], "cells,": [ 147 ], "exendin-4\u2013reversed": [ 148 ], "induced": [ 151 ], "palmitate": [ 153 ], "hampered": [ 155 ], "when": [ 156 ], "silenced": [ 159 ], "RNA": [ 162 ], "interference.": [ 163 ], "Our": [ 164 ], "data": [ 165 ], "demonstrate": [ 166 ], "mediates": [ 169 ], "steatosis,": [ 177 ], "suggesting": [ 178 ], "could": [ 183, 205 ], "serve": [ 184 ], "potential": [ 187 ], "drug": [ 188 ], "for": [ 189 ], "nonalcoholic": [ 190 ], "fatty": [ 191 ], "liver": [ 192 ], "disease": [ 193 ], "(NAFLD),": [ 194 ], "especially": [ 195 ], "type": [ 197 ], "2": [ 198 ], "diabetes": [ 199 ], "combined": [ 200 ], "NAFLD,": [ 202 ], "be": [ 206 ], "therapeutic": [ 208 ], "target": [ 209 ], "NAFLD.": [ 211 ] }, "publication_date": "2014-06-20", "publication_year": 2014, "type": "article", "cited_by_count": 111, "authors": [ { "id": "https://openalex.org/A5001571073", "display_name": "Fen Xu" }, { "id": "https://openalex.org/A5101518285", "display_name": "Zhuo Li" }, { "id": "https://openalex.org/A5101887807", "display_name": "Xiaobin Zheng" }, { "id": "https://openalex.org/A5100434449", "display_name": "Hongxia Liu" }, { "id": "https://openalex.org/A5023641721", "display_name": "Hua Liang" }, { "id": "https://openalex.org/A5103254578", "display_name": "Haixia Xu" }, { "id": "https://openalex.org/A5061044616", "display_name": "Zonglan Chen" }, { "id": "https://openalex.org/A5035495468", "display_name": "Kejing Zeng" }, { "id": "https://openalex.org/A5012775407", "display_name": "Jianping Weng" } ] }, { "id": "https://openalex.org/W4386154055", "doi": "https://doi.org/10.1056/nejmoa2306963", "title": "Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity", "abstract": { "In": [ 0 ], "patients": [ 1 ], "with": [ 2, 5, 12 ], "heart": [ 3 ], "failure": [ 4 ], "preserved": [ 6 ], "ejection": [ 7 ], "fraction": [ 8 ], "and": [ 9, 22, 30 ], "obesity,": [ 10 ], "treatment": [ 11 ], "semaglutide": [ 13 ], "(2.4": [ 14 ], "mg)": [ 15 ], "led": [ 16 ], "to": [ 17 ], "larger": [ 18 ], "reductions": [ 19 ], "in": [ 20, 27 ], "symptoms": [ 21 ], "physical": [ 23 ], "limitations,": [ 24 ], "greater": [ 25, 31 ], "improvements": [ 26 ], "exercise": [ 28 ], "function,": [ 29 ], "weight": [ 32 ], "loss": [ 33 ], "than": [ 34 ], "placebo.": [ 35 ], "(Funded": [ 36 ], "by": [ 37 ], "Novo": [ 38 ], "Nordisk;": [ 39 ], "STEP-HFpEF": [ 40 ], "ClinicalTrials.gov": [ 41 ], "number,": [ 42 ], "NCT04788511.).": [ 43 ] }, "publication_date": "2023-08-25", "publication_year": 2023, "type": "article", "cited_by_count": 1090, "authors": [ { "id": "https://openalex.org/A5052533254", "display_name": "Mikhail Kosiborod" }, { "id": "https://openalex.org/A5016659797", "display_name": "Steen Z. Abildstr\u00f8m" }, { "id": "https://openalex.org/A5030461468", "display_name": "Barry A. Borlaug" }, { "id": "https://openalex.org/A5022314919", "display_name": "Javed Butler" }, { "id": "https://openalex.org/A5110231477", "display_name": "S\u00f8ren Rasmussen" }, { "id": "https://openalex.org/A5084593004", "display_name": "Melanie J. Davies" }, { "id": "https://openalex.org/A5004099465", "display_name": "G. Kees Hovingh" }, { "id": "https://openalex.org/A5054890754", "display_name": "Dalane W. Kitzman" }, { "id": "https://openalex.org/A5108481559", "display_name": "Marie L.S. Lindegaard" }, { "id": "https://openalex.org/A5111525200", "display_name": "Dani\u00e9l V. M\u00f8ller" }, { "id": "https://openalex.org/A5005215114", "display_name": "Sanjiv J. Shah" }, { "id": "https://openalex.org/A5048183455", "display_name": "Marianne Bach Treppendahl" }, { "id": "https://openalex.org/A5080334509", "display_name": "Subodh Verma" }, { "id": "https://openalex.org/A5046452701", "display_name": "Walter P. Abhayaratna" }, { "id": "https://openalex.org/A5075620293", "display_name": "Fozia Ahmed" }, { "id": "https://openalex.org/A5075949562", "display_name": "Vijay Chopra" }, { "id": "https://openalex.org/A5006527198", "display_name": "Justin A. Ezekowitz" }, { "id": "https://openalex.org/A5027994405", "display_name": "Michael Fu" }, { "id": "https://openalex.org/A5044544721", "display_name": "Hiroshi Ito" }, { "id": "https://openalex.org/A5078615816", "display_name": "Ma\u0142gorzata Lelonek" }, { "id": "https://openalex.org/A5069131955", "display_name": "Vojt\u011bch Melenovsk\u00fd" }, { "id": "https://openalex.org/A5086692319", "display_name": "B\u00e9la Merkely" }, { "id": "https://openalex.org/A5039483633", "display_name": "Julio N\u00fa\u00f1ez" }, { "id": "https://openalex.org/A5079453333", "display_name": "Eduardo Perna" }, { "id": "https://openalex.org/A5090618779", "display_name": "Morten Schou" }, { "id": "https://openalex.org/A5060241741", "display_name": "Michele Senni" }, { "id": "https://openalex.org/A5048642882", "display_name": "Kavita Sharma" }, { "id": "https://openalex.org/A5105820804", "display_name": "Peter van der Meer" }, { "id": "https://openalex.org/A5009903680", "display_name": "Dirk von Lewinski" }, { "id": "https://openalex.org/A5039523683", "display_name": "Dennis Wolf" }, { "id": "https://openalex.org/A5009535057", "display_name": "Mark C. Petrie" } ] }, { "id": "https://openalex.org/W1970250630", "doi": "https://doi.org/10.1016/j.neuropharm.2011.12.022", "title": "The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide", "abstract": null, "publication_date": "2011-12-30", "publication_year": 2011, "type": "article", "cited_by_count": 262, "authors": [ { "id": "https://openalex.org/A5012443533", "display_name": "Scott E. Kanoski" }, { "id": "https://openalex.org/A5019177348", "display_name": "Laura E. Rupprecht" }, { "id": "https://openalex.org/A5015531927", "display_name": "Samantha M. Fortin" }, { "id": "https://openalex.org/A5079833063", "display_name": "Bart C. De Jonghe" }, { "id": "https://openalex.org/A5065258001", "display_name": "Matthew R. Hayes" } ] }, { "id": "https://openalex.org/W2901979245", "doi": "https://doi.org/10.1016/j.jacbts.2018.09.004", "title": "The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in\u00a0ApoE\u2212/\u2212 and LDLr\u2212/\u2212 Mice by\u00a0a\u00a0Mechanism That Includes Inflammatory Pathways", "abstract": { "The": [ 0, 17 ], "glucagon-like": [ 1 ], "peptide-1": [ 2 ], "receptor": [ 3 ], "agonists": [ 4 ], "(GLP-1RAs)": [ 5 ], "liraglutide": [ 6 ], "and": [ 7, 46, 59, 96 ], "semaglutide": [ 8, 101 ], "reduce": [ 9 ], "cardiovascular": [ 10 ], "risk": [ 11 ], "in": [ 12, 41, 74 ], "type": [ 13 ], "2": [ 14 ], "diabetes": [ 15 ], "patients.": [ 16 ], "mode": [ 18 ], "of": [ 19, 33, 57, 72, 80 ], "action": [ 20 ], "is": [ 21 ], "suggested": [ 22 ], "to": [ 23, 66, 77 ], "occur": [ 24 ], "through": [ 25, 112 ], "modified": [ 26 ], "atherosclerotic": [ 27 ], "progression.": [ 28 ], "In": [ 29, 62 ], "this": [ 30 ], "study,": [ 31 ], "both": [ 32 ], "the": [ 34, 78 ], "compounds": [ 35 ], "significantly": [ 36, 102 ], "attenuated": [ 37 ], "plaque": [ 38, 97 ], "lesion": [ 39 ], "development": [ 40 ], "apolipoprotein": [ 42 ], "E-deficient": [ 43 ], "(ApoE-/-)": [ 44 ], "mice": [ 45 ], "low-density": [ 47 ], "lipoprotein": [ 48 ], "receptor-deficient": [ 49 ], "(LDLr-/-)": [ 50 ], "mice.": [ 51 ], "This": [ 52 ], "attenuation": [ 53 ], "was": [ 54 ], "partly": [ 55 ], "independent": [ 56 ], "weight": [ 58 ], "cholesterol": [ 60, 88 ], "lowering.": [ 61 ], "aortic": [ 63 ], "tissue,": [ 64 ], "exposure": [ 65 ], "a": [ 67 ], "Western": [ 68 ], "diet": [ 69 ], "alters": [ 70 ], "expression": [ 71 ], "genes": [ 73 ], "pathways": [ 75 ], "relevant": [ 76 ], "pathogenesis": [ 79 ], "atherosclerosis,": [ 81 ], "including": [ 82 ], "leukocyte": [ 83, 85 ], "recruitment,": [ 84 ], "rolling,": [ 86 ], "adhesion/extravasation,": [ 87 ], "metabolism,": [ 89 ], "lipid-mediated": [ 90 ], "signaling,": [ 91 ], "extracellular": [ 92 ], "matrix": [ 93 ], "protein": [ 94 ], "turnover,": [ 95 ], "hemorrhage.": [ 98 ], "Treatment": [ 99 ], "with": [ 100 ], "reversed": [ 103 ], "these": [ 104 ], "changes.": [ 105 ], "These": [ 106 ], "data": [ 107 ], "suggest": [ 108 ], "GLP-1RAs": [ 109 ], "affect": [ 110 ], "atherosclerosis": [ 111 ], "an": [ 113 ], "anti-inflammatory": [ 114 ], "mechanism.": [ 115 ] }, "publication_date": "2018-11-21", "publication_year": 2018, "type": "article", "cited_by_count": 414, "authors": [ { "id": "https://openalex.org/A5088177635", "display_name": "G\u00fcnaj Rakipovski" }, { "id": "https://openalex.org/A5043387635", "display_name": "Bidda Rolin" }, { "id": "https://openalex.org/A5087674673", "display_name": "Jane N\u00f8hr" }, { "id": "https://openalex.org/A5055523029", "display_name": "Ib Vestergaard Klewe" }, { "id": "https://openalex.org/A5015151949", "display_name": "Klaus Stensgaard Frederiksen" }, { "id": "https://openalex.org/A5083460732", "display_name": "Robert Augustin" }, { "id": "https://openalex.org/A5067103368", "display_name": "Jacob Hecksher\u2010S\u00f8rensen" }, { "id": "https://openalex.org/A5086471334", "display_name": "Camilla Ingvorsen" }, { "id": "https://openalex.org/A5048226541", "display_name": "Joseph Polex-Wolf" }, { "id": "https://openalex.org/A5088627727", "display_name": "Lotte Bjerre Knudsen" } ] }, { "id": "https://openalex.org/W4311927977", "doi": "https://doi.org/10.1161/circulationaha.122.059595", "title": "GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes", "abstract": { "Patients": [ 0 ], "with": [ 1, 28, 73, 101, 111, 187 ], "type": [ 2, 74, 112, 244 ], "2": [ 3, 75, 113, 245 ], "diabetes": [ 4, 78, 246 ], "are": [ 5 ], "at": [ 6 ], "high": [ 7 ], "risk": [ 8, 107, 223 ], "for": [ 9, 60, 69, 119 ], "development": [ 10 ], "of": [ 11, 48, 71, 116, 133, 196, 206, 221, 243 ], "cardiovascular": [ 12, 21, 25, 51, 55, 106, 172, 190, 198, 222 ], "disease,": [ 13 ], "including": [ 14, 92 ], "myocardial": [ 15 ], "infarction,": [ 16 ], "stroke,": [ 17 ], "heart": [ 18, 61 ], "failure,": [ 19 ], "and": [ 20, 36, 45, 53, 79, 82, 147, 165, 178, 218, 229 ], "death.": [ 22 ], "Multiple": [ 23 ], "large": [ 24 ], "outcome": [ 26, 173 ], "trials": [ 27, 174 ], "novel": [ 29 ], "glucose-lowering": [ 30, 129 ], "agents,": [ 31 ], "namely": [ 32 ], "SGLT2i": [ 33, 97 ], "(SGLT2": [ 34 ], "inhibitors)": [ 35 ], "GLP-1": [ 37, 99, 123, 135, 160, 227 ], "RA": [ 38, 124, 161 ], "(GLP-1": [ 39 ], "receptor": [ 40, 136 ], "agonists),": [ 41 ], "have": [ 42, 85 ], "demonstrated": [ 43, 175 ], "robust": [ 44, 177 ], "significant": [ 46 ], "reductions": [ 47 ], "major": [ 49 ], "adverse": [ 50 ], "events": [ 52 ], "additional": [ 54, 120 ], "outcomes,": [ 56 ], "such": [ 57 ], "as": [ 58, 128 ], "hospitalizations": [ 59 ], "failure.": [ 62 ], "This": [ 63, 213 ], "evidence": [ 64, 195, 220 ], "has": [ 65 ], "changed": [ 66 ], "the": [ 67, 117, 134, 193, 204, 216, 241, 248 ], "landscape": [ 68 ], "treatment": [ 70, 242 ], "patients": [ 72, 186, 207 ], "diabetes.": [ 76 ], "Both": [ 77 ], "cardiology": [ 80, 249 ], "guidelines": [ 81 ], "professional": [ 83 ], "societies": [ 84 ], "responded": [ 86 ], "to": [ 87, 95, 104, 141, 167 ], "this": [ 88 ], "paradigm": [ 89 ], "shift": [ 90 ], "by": [ 91, 137, 226 ], "strong": [ 93 ], "recommendations": [ 94 ], "use": [ 96 ], "and/or": [ 98 ], "RA,": [ 100, 228 ], "evidence-based": [ 102 ], "benefits": [ 103 ], "reduce": [ 105 ], "in": [ 108, 144, 150, 157, 181, 185, 240, 247 ], "high-risk": [ 109 ], "individuals": [ 110 ], "diabetes,": [ 114 ], "independent": [ 115 ], "need": [ 118 ], "glucose": [ 121, 146, 152 ], "control.": [ 122 ], "were": [ 125 ], "initially": [ 126 ], "developed": [ 127 ], "drugs": [ 130, 210, 236 ], "because": [ 131 ], "activation": [ 132 ], "these": [ 138, 202, 209, 235 ], "agents": [ 139 ], "leads": [ 140 ], "a": [ 142, 176 ], "reduction": [ 143, 180, 224 ], "blood": [ 145 ], "an": [ 148 ], "improvement": [ 149 ], "postprandial": [ 151 ], "metabolism.": [ 153 ], "By": [ 154 ], "stimulating": [ 155 ], "GLP-1R": [ 156 ], "hypothalamic": [ 158 ], "neurons,": [ 159 ], "additionally": [ 162 ], "induce": [ 163 ], "satiety": [ 164 ], "lead": [ 166 ], "weight": [ 168 ], "loss.": [ 169 ], "Data": [ 170 ], "from": [ 171, 201 ], "consistent": [ 179, 194 ], "atherothrombotic": [ 182 ], "events,": [ 183 ], "particularly": [ 184 ], "established": [ 188 ], "atherosclerotic": [ 189, 197 ], "disease.": [ 191 ], "Despite": [ 192 ], "disease": [ 199 ], "benefit": [ 200 ], "trials,": [ 203 ], "number": [ 205 ], "receiving": [ 208 ], "remains": [ 211 ], "low.": [ 212 ], "overview": [ 214 ], "summarizes": [ 215 ], "experimental": [ 217 ], "clinical": [ 219 ], "offered": [ 225 ], "provides": [ 230 ], "practical": [ 231 ], "information": [ 232 ], "on": [ 233 ], "how": [ 234 ], "should": [ 237 ], "be": [ 238 ], "implemented": [ 239 ], "community.": [ 250 ] }, "publication_date": "2022-12-12", "publication_year": 2022, "type": "review", "cited_by_count": 364, "authors": [ { "id": "https://openalex.org/A5019976194", "display_name": "Nikolaus Marx" }, { "id": "https://openalex.org/A5044527590", "display_name": "Mansoor Husain" }, { "id": "https://openalex.org/A5078666970", "display_name": "Michael Lehrke" }, { "id": "https://openalex.org/A5080334509", "display_name": "Subodh Verma" }, { "id": "https://openalex.org/A5078498803", "display_name": "Naveed Sattar" } ] }, { "id": "https://openalex.org/W2071835038", "doi": "https://doi.org/10.2337/dc08-1355", "title": "Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes", "abstract": { "OBJECTIVE\u2014The": [ 0 ], "efficacy": [ 1 ], "and": [ 2, 42, 110, 142, 144, 150, 217, 242 ], "safety": [ 3 ], "of": [ 4, 18, 93, 133, 153, 181, 208, 222, 246, 256 ], "adding": [ 5 ], "liraglutide": [ 6, 54, 121, 149, 162, 185, 234 ], "(a": [ 7 ], "glucagon-like": [ 8 ], "peptide-1": [ 9 ], "receptor": [ 10 ], "agonist)": [ 11 ], "to": [ 12, 22, 52, 63, 66, 189 ], "metformin": [ 13, 23, 79 ], "were": [ 14, 48, 74, 116 ], "compared": [ 15, 166, 248 ], "with": [ 16, 28, 78, 130, 167, 184, 191, 197, 229, 249 ], "addition": [ 17 ], "placebo": [ 19, 125, 192, 216 ], "or": [ 20, 58, 65, 101 ], "glimepiride": [ 21, 67, 143, 172, 198, 218 ], "in": [ 24, 75, 119, 160, 170, 214 ], "subjects": [ 25, 47, 84, 211, 228 ], "previously": [ 26 ], "treated": [ 27 ], "oral": [ 29 ], "antidiabetes": [ 30 ], "(OAD)": [ 31 ], "therapy.": [ 32 ], "RESEARCH": [ 33 ], "DESIGN": [ 34 ], "AND": [ 35 ], "METHODS\u2014In": [ 36 ], "this": [ 37 ], "26-week,": [ 38 ], "double-blind,": [ 39 ], "double-dummy,": [ 40 ], "placebo-": [ 41 ], "active-controlled,": [ 43 ], "parallel-group": [ 44 ], "trial,": [ 45 ], "1,091": [ 46 ], "randomly": [ 49 ], "assigned": [ 50 ], "(2:2:2:1:2)": [ 51 ], "once-daily": [ 53, 233 ], "(either": [ 55 ], "0.6,": [ 56 ], "1.2,": [ 57 ], "1.8": [ 59, 136 ], "mg/day": [ 60 ], "injected": [ 61 ], "subcutaneously),": [ 62 ], "placebo,": [ 64 ], "(4": [ 68 ], "mg": [ 69, 137, 140, 148 ], "once": [ 70 ], "daily).": [ 71, 82 ], "All": [ 72 ], "treatments": [ 73 ], "combination": [ 76, 105 ], "therapy": [ 77, 106, 255 ], "(1g": [ 80 ], "twice": [ 81 ], "Enrolled": [ 83 ], "(aged": [ 85 ], "25\u201379": [ 86 ], "years)": [ 87 ], "had": [ 88, 253 ], "type": [ 89, 230 ], "2": [ 90, 231 ], "diabetes,": [ 91, 232 ], "A1C": [ 92 ], "7\u201311%": [ 94 ], "(previous": [ 95, 103 ], "OAD": [ 96, 104 ], "monotherapy": [ 97 ], "for": [ 98, 107, 135, 146, 155 ], "\u22653": [ 99, 108 ], "months)": [ 100 ], "7\u201310%": [ 102 ], "months),": [ 109 ], "BMI": [ 111 ], "\u226440": [ 112 ], "kg/m2.": [ 113 ], "RESULTS\u2014A1C": [ 114 ], "values": [ 115 ], "significantly": [ 117 ], "reduced": [ 118, 239 ], "all": [ 120, 161 ], "groups": [ 122, 163 ], "versus": [ 123, 212 ], "the": [ 124, 171, 209, 215, 244 ], "group": [ 126, 173 ], "(P": [ 127 ], "&lt;": [ 128, 177, 201 ], "0.0001)": [ 129 ], "mean": [ 131 ], "decreases": [ 132 ], "1.0%": [ 134 ], "liraglutide,": [ 138, 141 ], "1.2": [ 139 ], "0.7%": [ 145 ], "0.6": [ 147 ], "an": [ 151, 168 ], "increase": [ 152, 169 ], "0.1%": [ 154 ], "placebo.": [ 156 ], "Body": [ 157 ], "weight": [ 158 ], "decreased": [ 159 ], "(1.8\u20132.8": [ 164 ], "kg)": [ 165 ], "(1.0": [ 174 ], "kg;": [ 175 ], "P": [ 176, 200 ], "0.0001).": [ 178 ], "The": [ 179, 220 ], "incidence": [ 180, 221 ], "minor": [ 182 ], "hypoglycemia": [ 183, 247 ], "(\u223c3%)": [ 186 ], "was": [ 187, 204 ], "comparable": [ 188 ], "that": [ 190, 196 ], "but": [ 193 ], "less": [ 194 ], "than": [ 195 ], "(17%;": [ 199 ], "0.001).": [ 202 ], "Nausea": [ 203 ], "reported": [ 205 ], "by": [ 206 ], "11\u201319%": [ 207 ], "liraglutide-treated": [ 210 ], "3\u20134%": [ 213 ], "groups.": [ 219 ], "nausea": [ 223 ], "declined": [ 224 ], "over": [ 225 ], "time.": [ 226 ], "CONCLUSIONS\u2014In": [ 227 ], "induced": [ 235 ], "similar": [ 236 ], "glycemic": [ 237 ], "control,": [ 238 ], "body": [ 240 ], "weight,": [ 241 ], "lowered": [ 243 ], "occurrence": [ 245 ], "glimepiride,": [ 250 ], "when": [ 251 ], "both": [ 252 ], "background": [ 254 ], "metformin.": [ 257 ] }, "publication_date": "2008-10-17", "publication_year": 2008, "type": "article", "cited_by_count": 1104, "authors": [ { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5054017533", "display_name": "Anders Frid" }, { "id": "https://openalex.org/A5088641715", "display_name": "Kjeld Hermansen" }, { "id": "https://openalex.org/A5077452584", "display_name": "Nalini S. Shah" }, { "id": "https://openalex.org/A5064505204", "display_name": "Tsvetalina Tankova" }, { "id": "https://openalex.org/A5001170166", "display_name": "Ismail Mitha" }, { "id": "https://openalex.org/A5017200089", "display_name": "Milan Zdravkovi\u0107" }, { "id": "https://openalex.org/A5078549507", "display_name": "Maria D\u00fcring" }, { "id": "https://openalex.org/A5011127007", "display_name": "David R. Matthews" } ] }, { "id": "https://openalex.org/W3108676144", "doi": "https://doi.org/10.1210/clinem/dgaa863", "title": "Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes", "abstract": { "Abstract": [ 0 ], "Context": [ 1 ], "Novel": [ 2 ], "dual": [ 3, 270 ], "glucose-dependent": [ 4 ], "insulinotropic": [ 5 ], "polypeptide": [ 6 ], "(GIP)": [ 7 ], "and": [ 8, 21, 45, 62, 88, 92, 112, 116, 126, 134, 140, 147, 157, 170, 180, 217, 231, 240, 250 ], "glucagon-like": [ 9 ], "peptide-1": [ 10 ], "(GLP-1)": [ 11 ], "receptor": [ 12, 271 ], "agonist": [ 13 ], "(RA)": [ 14 ], "tirzepatide": [ 15, 113, 132, 158, 190, 238, 262 ], "demonstrated": [ 16 ], "substantially": [ 17 ], "greater": [ 18, 255 ], "glucose": [ 19, 34 ], "control": [ 20, 35 ], "weight": [ 22 ], "loss": [ 23 ], "(WL)": [ 24 ], "compared": [ 25, 119, 137, 167 ], "with": [ 26, 65, 110, 120, 131, 138, 168, 209, 237 ], "selective": [ 27 ], "GLP-1RA": [ 28 ], "dulaglutide.": [ 29, 171, 258 ], "Objective": [ 30 ], "Explore": [ 31 ], "mechanisms": [ 32, 275 ], "of": [ 33, 42, 85, 173, 189, 233, 248, 261, 276 ], "by": [ 36, 184 ], "tirzepatide.": [ 37 ], "Design": [ 38 ], "Post": [ 39 ], "hoc": [ 40 ], "analyses": [ 41 ], "fasting": [ 43, 152 ], "biomarkers": [ 44, 84 ], "multiple": [ 46, 205 ], "linear": [ 47, 206 ], "regression": [ 48, 207 ], "analysis.": [ 49 ], "Setting": [ 50 ], "Forty-seven": [ 51 ], "sites": [ 52 ], "in": [ 53, 198, 235 ], "4": [ 54 ], "countries.": [ 55 ], "Patients": [ 56 ], "or": [ 57, 186 ], "other": [ 58 ], "Participants": [ 59 ], "Three": [ 60 ], "hundred": [ 61 ], "sixteen": [ 63 ], "subjects": [ 64 ], "type": [ 66 ], "2": [ 67 ], "diabetes.": [ 68 ], "Interventions": [ 69 ], "Tirzepatide": [ 70, 145, 245 ], "(1,": [ 71 ], "5,": [ 72, 114 ], "10,": [ 73, 115 ], "15": [ 74, 117, 135, 148, 241 ], "mg),": [ 75, 78 ], "dulaglutide": [ 76, 111, 141 ], "(1.5": [ 77 ], "placebo.": [ 79 ], "Main": [ 80 ], "Outcome": [ 81 ], "Measures": [ 82 ], "Analyze": [ 83 ], "beta-cell": [ 86, 251 ], "function": [ 87, 252 ], "insulin": [ 89, 153, 175 ], "resistance": [ 90 ], "(IR)": [ 91 ], "evaluate": [ 93 ], "WL": [ 94, 223 ], "contributions": [ 95 ], "to": [ 96, 203, 253, 267 ], "IR": [ 97, 199 ], "improvements": [ 98, 197 ], "at": [ 99 ], "26": [ 100 ], "weeks.": [ 101 ], "Results": [ 102 ], "Homeostatic": [ 103 ], "model": [ 104 ], "assessment": [ 105 ], "(HOMA)": [ 106 ], "2-B": [ 107 ], "significantly": [ 108, 129, 150, 161, 182, 224 ], "increased": [ 109, 183 ], "mg": [ 118, 136, 149, 160 ], "placebo": [ 121, 139, 169 ], "(P": [ 122, 142, 154, 164, 191, 225 ], "\u2264": [ 123, 143, 155, 226 ], ".02).": [ 124 ], "Proinsulin/insulin": [ 125 ], "proinsulin/C-peptide": [ 127 ], "ratios": [ 128 ], "decreased": [ 130, 151, 162 ], "10": [ 133, 146, 159, 239 ], ".007).": [ 144 ], ".033)": [ 156 ], "HOMA2-IR": [ 163, 236 ], "=": [ 165 ], ".004)": [ 166 ], "Markers": [ 172 ], "improved": [ 174, 246 ], "sensitivity": [ 176 ], "(IS)": [ 177 ], "adiponectin,": [ 178 ], "IGFBP-1,": [ 179 ], "IGFBP-2": [ 181 ], "1": [ 185 ], "more": [ 187 ], "doses": [ 188 ], "&lt;": [ 192 ], ".05).": [ 193 ], "To": [ 194 ], "determine": [ 195 ], "whether": [ 196 ], "were": [ 200, 263 ], "directly": [ 201 ], "attributable": [ 202, 266 ], "WL,": [ 204, 268 ], "analysis": [ 208 ], "potential": [ 210 ], "confounding": [ 211 ], "variables": [ 212 ], "age,": [ 213 ], "sex,": [ 214 ], "metformin,": [ 215 ], "triglycerides,": [ 216 ], "glycated": [ 218 ], "hemoglobin": [ 219 ], "A1c": [ 220 ], "was": [ 221 ], "conducted.": [ 222 ], ".028)": [ 227 ], "explained": [ 228 ], "only": [ 229, 264 ], "13%": [ 230 ], "21%": [ 232 ], "improvement": [ 234 ], "mg,": [ 242 ], "respectively.": [ 243 ], "Conclusions": [ 244 ], "markers": [ 247 ], "IS": [ 249, 259 ], "a": [ 254 ], "extent": [ 256 ], "than": [ 257 ], "effects": [ 260 ], "partly": [ 265 ], "suggesting": [ 269 ], "agonism": [ 272 ], "confers": [ 273 ], "distinct": [ 274 ], "glycemic": [ 277 ], "control.": [ 278 ] }, "publication_date": "2020-11-24", "publication_year": 2020, "type": "article", "cited_by_count": 277, "authors": [ { "id": "https://openalex.org/A5013110210", "display_name": "Melissa K. Thomas" }, { "id": "https://openalex.org/A5061113397", "display_name": "Amir Nikooienejad" }, { "id": "https://openalex.org/A5091446537", "display_name": "Ross Bray" }, { "id": "https://openalex.org/A5058864022", "display_name": "Xuewei Cui" }, { "id": "https://openalex.org/A5003206993", "display_name": "Jonathan M. Wilson" }, { "id": "https://openalex.org/A5072130761", "display_name": "Kevin L. Duffin" }, { "id": "https://openalex.org/A5024563374", "display_name": "Zvonko Mili\u010devi\u0107" }, { "id": "https://openalex.org/A5040811419", "display_name": "Axel Haupt" }, { "id": "https://openalex.org/A5081732583", "display_name": "Deborah A. Robins" } ] }, { "id": "https://openalex.org/W2979558564", "doi": "https://doi.org/10.1530/eje-19-0566", "title": "MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?", "abstract": { "GLP-1,": [ 0 ], "a": [ 1, 17, 44, 99 ], "peptide": [ 2 ], "hormone": [ 3 ], "secreted": [ 4 ], "from": [ 5 ], "the": [ 6, 107, 139, 172, 197, 200, 226 ], "gut,": [ 7 ], "stimulating": [ 8 ], "insulin": [ 9 ], "and": [ 10, 30, 80, 90, 97, 138, 169, 183, 192, 218, 224 ], "suppressing": [ 11 ], "glucagon": [ 12 ], "secretion": [ 13 ], "was": [ 14, 26, 66 ], "identified": [ 15 ], "as": [ 16, 43, 106 ], "parent": [ 18 ], "compound": [ 19 ], "for": [ 20, 135 ], "novel": [ 21 ], "treatments": [ 22 ], "of": [ 23, 74, 114, 160, 199, 214, 225, 228 ], "diabetes,": [ 24 ], "but": [ 25 ], "degraded": [ 27 ], "(dipeptidyl": [ 28 ], "peptidase-4)": [ 29 ], "eliminated": [ 31 ], "(mainly": [ 32 ], "by": [ 33 ], "kidneys)": [ 34 ], "too": [ 35 ], "fast": [ 36 ], "(half-life": [ 37 ], "1\u20132": [ 38 ], "min)": [ 39 ], "to": [ 40, 53, 87, 174, 203 ], "be": [ 41 ], "useful": [ 42 ], "therapeutic": [ 45 ], "agent.": [ 46 ], "GLP-1": [ 47, 119, 229 ], "receptor": [ 48, 120, 230 ], "agonist": [ 49, 231 ], "has": [ 50 ], "been": [ 51, 95, 146 ], "used": [ 52 ], "treat": [ 54 ], "patients": [ 55, 237 ], "with": [ 56, 71, 81, 85, 240 ], "type": [ 57 ], "2": [ 58 ], "diabetes": [ 59, 110 ], "since": [ 60 ], "2007,": [ 61 ], "when": [ 62 ], "exenatide": [ 63, 126 ], "(twice": [ 64 ], "daily)": [ 65 ], "approved": [ 67 ], "in": [ 68, 98, 148, 156, 188, 236 ], "2007.": [ 69 ], "Compounds": [ 70 ], "longer": [ 72 ], "duration": [ 73 ], "action": [ 75 ], "(once": [ 76 ], "daily,": [ 77 ], "once": [ 78 ], "weekly)": [ 79 ], "increasingly": [ 82 ], "better": [ 83 ], "efficacy": [ 84 ], "respect": [ 86 ], "glycaemic": [ 88 ], "control": [ 89 ], "body": [ 91, 216 ], "weight": [ 92, 217 ], "reduction": [ 93 ], "have": [ 94, 145 ], "developed,": [ 96 ], "recent": [ 100 ], "ADA/EASD": [ 101 ], "consensus": [ 102 ], "statement,": [ 103 ], "were": [ 104 ], "recommended": [ 105 ], "first": [ 108, 140, 175 ], "injectable": [ 109 ], "therapy": [ 111 ], "after": [ 112 ], "failure": [ 113 ], "oral": [ 115, 141, 143 ], "glucose-lowering": [ 116, 211 ], "medications.": [ 117 ], "Most": [ 118 ], "agonists": [ 121 ], "(lixisenatide": [ 122 ], "q.d.,": [ 123, 125 ], "liraglutide": [ 124 ], "q.w.,": [ 127, 129, 131, 133 ], "dulaglutide": [ 128, 170 ], "albiglutide": [ 130 ], "semaglutide": [ 132 ], "all": [ 134 ], "s.c.": [ 136 ], "injection,": [ 137 ], "preparation,": [ 142 ], "semaglutide)": [ 144 ], "examined": [ 147 ], "cardiovascular": [ 149, 178, 185, 191, 221, 234, 244 ], "outcomes": [ 150, 235 ], "studies.": [ 151 ], "Beyond": [ 152 ], "proving": [ 153 ], "their": [ 154 ], "safety": [ 155 ], "vulnerable": [ 157 ], "patients,": [ 158 ], "most": [ 159 ], "whom": [ 161 ], "had": [ 162 ], "pre-existing": [ 163, 243 ], "heart": [ 164, 250 ], "disease,": [ 165 ], "liraglutide,": [ 166 ], "semaglutide,": [ 167 ], "albiglutide,": [ 168 ], "reduced": [ 171, 190 ], "time": [ 173 ], "major": [ 176 ], "adverse": [ 177 ], "events": [ 179 ], "(non-fatal": [ 180 ], "myocardial": [ 181 ], "infarction": [ 182 ], "stroke,": [ 184 ], "death).": [ 186 ], "Liraglutide,": [ 187 ], "addition,": [ 189 ], "all-cause": [ 193 ], "mortality.": [ 194 ], "It": [ 195 ], "is": [ 196 ], "purpose": [ 198 ], "present": [ 201 ], "review": [ 202 ], "describe": [ 204 ], "clinically": [ 205 ], "important": [ 206 ], "differences,": [ 207 ], "regarding": [ 208 ], "pharmacokinetic": [ 209 ], "behaviour,": [ 210 ], "potency,": [ 212 ], "effectiveness": [ 213 ], "reducing": [ 215 ], "controlling": [ 219 ], "other": [ 220 ], "risk": [ 222 ], "factors,": [ 223 ], "influence": [ 227 ], "treatment": [ 232 ], "on": [ 233 ], "either": [ 238 ], "presenting": [ 239 ], "or": [ 241, 248 ], "without": [ 242 ], "disease": [ 245 ], "(atherosclerotic,": [ 246 ], "ischemic": [ 247 ], "congestive": [ 249 ], "failure).": [ 251 ] }, "publication_date": "2019-10-10", "publication_year": 2019, "type": "review", "cited_by_count": 222, "authors": [ { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5002832666", "display_name": "Juris J. Meier" } ] }, { "id": "https://openalex.org/W4308701204", "doi": "https://doi.org/10.2337/dc22-1148", "title": "GLP-1 Receptor Agonists and the Risk of Thyroid Cancer", "abstract": { "OBJECTIVE": [ 0 ], "To": [ 1 ], "determine": [ 2 ], "whether": [ 3 ], "use": [ 4, 32, 97, 102, 142, 239 ], "of": [ 5, 18, 33, 101, 129, 137, 143, 169, 188, 199, 230, 240, 248 ], "glucagon-like": [ 6 ], "peptide": [ 7 ], "1": [ 8, 109 ], "(GLP-1)": [ 9 ], "receptor": [ 10 ], "agonists": [ 11 ], "(RA)": [ 12 ], "is": [ 13 ], "associated": [ 14, 195 ], "with": [ 15, 31, 44, 49, 118, 131, 148, 153, 173, 183, 196, 238 ], "increased": [ 16, 197, 228 ], "risk": [ 17, 198, 229 ], "thyroid": [ 19, 63, 138, 174, 201, 213, 232, 236 ], "cancer.": [ 20 ], "RESEARCH": [ 21 ], "DESIGN": [ 22 ], "AND": [ 23 ], "METHODS": [ 24 ], "A": [ 25, 167 ], "nested": [ 26 ], "case-control": [ 27 ], "analysis": [ 28 ], "was": [ 29, 82, 146, 194 ], "performed": [ 30 ], "the": [ 34, 60, 85, 132, 179, 223 ], "French": [ 35 ], "national": [ 36 ], "health": [ 37 ], "care": [ 38 ], "insurance": [ 39 ], "system": [ 40 ], "(SNDS)": [ 41 ], "database.": [ 42 ], "Individuals": [ 43 ], "type": [ 45 ], "2": [ 46 ], "diabetes": [ 47, 130 ], "treated": [ 48 ], "second-line": [ 50 ], "antidiabetes": [ 51, 160 ], "drugs": [ 52 ], "between": [ 53, 74 ], "2006": [ 54 ], "and": [ 55, 71, 76, 93, 98, 127, 162, 181, 211, 234 ], "2018": [ 56 ], "were": [ 57, 65, 116, 176 ], "included": [ 58, 177 ], "in": [ 59, 178, 243 ], "cohort.": [ 61 ], "All": [ 62 ], "cancers": [ 64, 175 ], "identified": [ 66 ], "through": [ 67 ], "hospital": [ 68 ], "discharge": [ 69 ], "diagnoses": [ 70 ], "medical": [ 72 ], "procedures": [ 73 ], "2014": [ 75 ], "2018.": [ 77 ], "Exposure": [ 78 ], "to": [ 79, 110, 120, 141 ], "GLP-1": [ 80, 144, 189, 241 ], "RA": [ 81, 145, 190 ], "measured": [ 83 ], "within": [ 84 ], "6": [ 86 ], "years": [ 87, 193, 247 ], "preceding": [ 88 ], "a": [ 89, 149 ], "6-month": [ 90 ], "lag-time": [ 91 ], "period": [ 92 ], "considered": [ 94 ], "as": [ 95 ], "current": [ 96, 224 ], "cumulative": [ 99 ], "duration": [ 100 ], "based": [ 103 ], "on": [ 104, 124 ], "defined": [ 105 ], "daily": [ 106 ], "dose": [ 107 ], "(\u22641,": [ 108 ], "3,": [ 111 ], "&gt;3": [ 112 ], "years).": [ 113 ], "Case": [ 114 ], "subjects": [ 115, 123, 172 ], "matched": [ 117, 182 ], "up": [ 119 ], "20": [ 121 ], "control": [ 122, 185 ], "age,": [ 125 ], "sex,": [ 126 ], "length": [ 128 ], "risk-set": [ 133 ], "sampling": [ 134 ], "procedure.": [ 135 ], "Risk": [ 136 ], "cancer": [ 139, 202, 214, 233, 237 ], "related": [ 140 ], "estimated": [ 147 ], "conditional": [ 150 ], "logistic": [ 151 ], "regression": [ 152 ], "adjustment": [ 154 ], "for": [ 155, 191 ], "goiter,": [ 156 ], "hypothyroidism,": [ 157 ], "hyperthyroidism,": [ 158 ], "other": [ 159 ], "drugs,": [ 161 ], "social": [ 163 ], "deprivation": [ 164 ], "index.": [ 165 ], "RESULTS": [ 166 ], "total": [ 168 ], "2,562": [ 170 ], "case": [ 171 ], "study": [ 180, 225 ], "45,184": [ 184 ], "subjects.": [ 186 ], "Use": [ 187 ], "1\u20133": [ 192, 246 ], "all": [ 200, 231 ], "(adjusted": [ 203, 215 ], "hazard": [ 204 ], "ratio": [ 205 ], "[HR]": [ 206 ], "1.58,": [ 207 ], "95%": [ 208, 218 ], "CI": [ 209, 219 ], "1.27\u20131.95)": [ 210 ], "medullary": [ 212, 235 ], "HR": [ 216 ], "1.78,": [ 217 ], "1.04\u20133.05).": [ 220 ], "CONCLUSIONS": [ 221 ], "In": [ 222 ], "we": [ 226 ], "found": [ 227 ], "RA,": [ 242 ], "particular": [ 244 ], "after": [ 245 ], "treatment.": [ 249 ] }, "publication_date": "2022-11-10", "publication_year": 2022, "type": "article", "cited_by_count": 247, "authors": [ { "id": "https://openalex.org/A5032424009", "display_name": "Julien Bezin" }, { "id": "https://openalex.org/A5067471884", "display_name": "Amandine Gouverneur" }, { "id": "https://openalex.org/A5057998719", "display_name": "Marine P\u00e9nichon" }, { "id": "https://openalex.org/A5108010061", "display_name": "Cl\u00e9ment Mathieu" }, { "id": "https://openalex.org/A5026955224", "display_name": "R. Garrel" }, { "id": "https://openalex.org/A5106419581", "display_name": "Dominique Hillaire\u2010Buys" }, { "id": "https://openalex.org/A5010670616", "display_name": "Alexandre Pariente" }, { "id": "https://openalex.org/A5056419976", "display_name": "Jean\u2010Luc Faillie" } ] }, { "id": "https://openalex.org/W2138077952", "doi": "https://doi.org/10.1016/s0140-6736(08)61206-4", "title": "Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study", "abstract": null, "publication_date": "2008-09-08", "publication_year": 2008, "type": "article", "cited_by_count": 1053, "authors": [ { "id": "https://openalex.org/A5057472647", "display_name": "Daniel J. Drucker" }, { "id": "https://openalex.org/A5040182038", "display_name": "John B. Buse" }, { "id": "https://openalex.org/A5110734241", "display_name": "Kristin Taylor" }, { "id": "https://openalex.org/A5013350892", "display_name": "David M. Kendall" }, { "id": "https://openalex.org/A5062021087", "display_name": "Michael Trautmann" }, { "id": "https://openalex.org/A5074705033", "display_name": "Dongliang Zhuang" }, { "id": "https://openalex.org/A5082524181", "display_name": "Lisa A. Porter" } ] }, { "id": "https://openalex.org/W4311708850", "doi": "https://doi.org/10.3389/fendo.2022.1043789", "title": "Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database", "abstract": { "Objective": [ 0 ], "Glucagon-like": [ 1 ], "peptide-1": [ 2 ], "receptor": [ 3 ], "agonists": [ 4 ], "(GLP-1": [ 5 ], "RAs)": [ 6 ], "have": [ 7 ], "significantly": [ 8, 290 ], "improved": [ 9 ], "clinical": [ 10 ], "effects": [ 11 ], "on": [ 12, 54 ], "glycemic": [ 13 ], "control.": [ 14 ], "However,": [ 15 ], "real-world": [ 16, 55 ], "data": [ 17 ], "concerning": [ 18 ], "the": [ 19, 64, 77, 94, 97, 126, 130, 186, 206, 237, 267, 278, 296, 310, 323, 342 ], "difference": [ 20 ], "in": [ 21, 185 ], "gastrointestinal": [ 22, 40, 70, 103, 115, 150, 257, 272, 293, 347 ], "adverse": [ 23, 71, 122 ], "events": [ 24, 183 ], "(AEs)": [ 25 ], "among": [ 26, 42 ], "different": [ 27, 43 ], "GLP-1": [ 28, 45, 67, 101, 142, 287, 338, 345 ], "RAs": [ 29, 46, 68, 143, 339 ], "are": [ 30 ], "still": [ 31 ], "lacking.": [ 32 ], "Our": [ 33, 330 ], "study": [ 34, 331 ], "aimed": [ 35 ], "to": [ 36, 62, 162, 260, 301, 340 ], "characterize": [ 37 ], "and": [ 38, 51, 69, 89, 96, 125, 175, 228, 249, 295, 304, 318 ], "compare": [ 39 ], "AEs": [ 41, 104, 258, 273 ], "marketed": [ 44 ], "(exenatide,": [ 47 ], "liraglutide,": [ 48, 302 ], "dulaglutide,": [ 49, 303 ], "lixisenatide,": [ 50 ], "semaglutide)": [ 52 ], "based": [ 53 ], "data.": [ 56 ], "Methods": [ 57 ], "Disproportionality": [ 58 ], "analysis": [ 59 ], "was": [ 60, 133, 201, 298 ], "used": [ 61 ], "evaluate": [ 63 ], "association": [ 65, 297 ], "between": [ 66, 86 ], "events.": [ 72 ], "Data": [ 73 ], "were": [ 74, 105, 117, 144, 159, 289 ], "extracted": [ 75 ], "from": [ 76 ], "US": [ 78 ], "FDA": [ 79 ], "Adverse": [ 80, 182 ], "Event": [ 81 ], "Reporting": [ 82 ], "System": [ 83 ], "(FAERS)": [ 84 ], "database": [ 85 ], "January": [ 87 ], "2018": [ 88 ], "September": [ 90 ], "2022.": [ 91 ], "Clinical": [ 92 ], "characteristics,": [ 93 ], "time-to-onset,": [ 95 ], "severe": [ 98, 269, 282 ], "proportion": [ 99 ], "of": [ 100, 111, 114, 120, 129, 149, 209, 240, 271, 284, 313, 326, 344 ], "RAs-associated": [ 102 ], "further": [ 106, 160, 299 ], "analyzed.": [ 107 ], "Results": [ 108 ], "A": [ 109 ], "total": [ 110 ], "21,281": [ 112 ], "reports": [ 113 ], "toxicity": [ 116 ], "analyzed": [ 118 ], "out": [ 119 ], "81,752": [ 121 ], "event": [ 123 ], "reports,": [ 124 ], "median": [ 127 ], "age": [ 128 ], "included": [ 131, 188 ], "patients": [ 132 ], "62": [ 134 ], "(interquartile": [ 135 ], "range": [ 136 ], "[IQR]": [ 137 ], "54\u201370)": [ 138 ], "years": [ 139 ], "old.": [ 140 ], "Overall": [ 141 ], "associated": [ 145, 291 ], "with": [ 146, 280, 292 ], "increased": [ 147 ], "risk": [ 148, 208, 239, 312, 325 ], "system": [ 151 ], "disorders": [ 152 ], "(ROR,": [ 153, 164, 170, 177, 211, 217, 223, 230, 244, 251 ], "1.46;": [ 154 ], "95%": [ 155, 166, 172, 179, 213, 219, 225, 232, 246, 253 ], "CI,": [ 156, 167, 173, 180, 214, 220, 226, 233, 247, 254 ], "1.44\u20131.49),": [ 157 ], "which": [ 158 ], "attributed": [ 161, 300 ], "liraglutide": [ 163, 235, 321 ], "2.39;": [ 165 ], "2.28\u20132.51),": [ 168 ], "dulaglutide": [ 169, 276 ], "1.39;": [ 171 ], "1.36-1.42),": [ 174 ], "semaglutide": [ 176, 204, 308 ], "3.00;": [ 178 ], "2.89\u20133.11).": [ 181 ], "uncovered": [ 184 ], "labels": [ 187 ], "gastroesophageal": [ 189 ], "reflux": [ 190 ], "disease,": [ 191 ], "gastritis,": [ 192 ], "bezoar,": [ 193 ], "breath": [ 194 ], "odor,": [ 195 ], "intra-abdominal": [ 196 ], "hematoma,": [ 197 ], "etc.": [ 198 ], "Furthermore,": [ 199 ], "it": [ 200 ], "observed": [ 202 ], "that": [ 203 ], "had": [ 205, 236, 266, 277, 309, 322 ], "greatest": [ 207, 238, 311, 324 ], "nausea": [ 210 ], "7.41;": [ 212 ], "7.10\u20137.74),": [ 215 ], "diarrhea": [ 216 ], "3.55;": [ 218 ], "3.35\u20133.77),": [ 221 ], "vomiting": [ 222 ], "6.67;": [ 224 ], "6.32\u20137.05),": [ 227 ], "constipation": [ 229 ], "6.17;": [ 231 ], "5.72\u20136.66);": [ 234 ], "abdominal": [ 241, 328 ], "pain": [ 242 ], "upper": [ 243, 327 ], "4.63;": [ 245 ], "4.12\u20135.21)": [ 248 ], "pancreatitis": [ 250 ], "32.67;": [ 252 ], "29.44\u201336.25).": [ 255 ], "Most": [ 256 ], "tended": [ 259 ], "occur": [ 261 ], "within": [ 262 ], "one": [ 263 ], "month.": [ 264 ], "Liraglutide": [ 265 ], "highest": [ 268 ], "rate": [ 270, 283 ], "(23.31%),": [ 274 ], "while": [ 275, 320 ], "lowest,": [ 279 ], "a": [ 281 ], "12.29%.": [ 285 ], "Conclusion": [ 286 ], "RA": [ 288 ], "AEs,": [ 294 ], "semaglutide.": [ 305 ], "In": [ 306 ], "addition,": [ 307 ], "nausea,": [ 314 ], "diarrhea,": [ 315 ], "vomiting,": [ 316 ], "constipation,": [ 317 ], "pancreatitis,": [ 319 ], "pain.": [ 329 ], "provided": [ 332 ], "valuable": [ 333 ], "evidence": [ 334 ], "for": [ 335 ], "selecting": [ 336 ], "appropriate": [ 337 ], "avoid": [ 341 ], "occurrence": [ 343 ], "RA-induced": [ 346 ], "AEs.": [ 348 ] }, "publication_date": "2022-12-07", "publication_year": 2022, "type": "article", "cited_by_count": 180, "authors": [ { "id": "https://openalex.org/A5102709026", "display_name": "Lulu Liu" }, { "id": "https://openalex.org/A5100416027", "display_name": "Jia Chen" }, { "id": "https://openalex.org/A5100436126", "display_name": "Lei Wang" }, { "id": "https://openalex.org/A5108049551", "display_name": "Chen Chen" }, { "id": "https://openalex.org/A5100379172", "display_name": "Li Chen" } ] }, { "id": "https://openalex.org/W2162934281", "doi": "https://doi.org/10.2337/diacare.28.5.1083", "title": "Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea", "abstract": { "OBJECTIVE\u2014This": [ 0 ], "study": [ 1, 34 ], "evaluated": [ 2 ], "the": [ 3, 152, 210 ], "effects": [ 4 ], "of": [ 5, 94, 109, 143, 217, 260 ], "exenatide,": [ 6 ], "a": [ 7 ], "novel": [ 8 ], "incretin": [ 9 ], "mimetic,": [ 10 ], "in": [ 11, 37, 244, 266 ], "hyperglycemic": [ 12 ], "patients": [ 13, 245 ], "with": [ 14, 23, 233, 236, 246, 256, 271 ], "type": [ 15, 247 ], "2": [ 16, 248 ], "diabetes": [ 17, 249 ], "unable": [ 18, 250 ], "to": [ 19, 58, 85, 99, 160, 251 ], "achieve": [ 20, 161, 252 ], "glycemic": [ 21, 254, 267 ], "control": [ 22, 255, 268 ], "metformin-sulfonylurea": [ 24, 262 ], "combination": [ 25 ], "therapy.": [ 26, 263 ], "RESEARCH": [ 27 ], "DESIGN": [ 28 ], "AND": [ 29 ], "METHODS\u2014A": [ 30 ], "30-week,": [ 31 ], "double-blind,": [ 32 ], "placebo-controlled": [ 33 ], "was": [ 35, 209, 220, 269, 276 ], "performed": [ 36 ], "733": [ 38 ], "subjects": [ 39, 156, 166 ], "(aged": [ 40 ], "55": [ 41 ], "\u00b1": [ 42, 47, 52, 55, 120, 125, 131, 187, 196 ], "10": [ 43, 86 ], "years,": [ 44 ], "BMI": [ 45 ], "33.6": [ 46 ], "5.7": [ 48 ], "kg/m2,": [ 49 ], "A1C": [ 50, 113, 162, 243 ], "8.5": [ 51 ], "1.0%;": [ 53 ], "means": [ 54 ], "SD)": [ 56 ], "randomized": [ 57, 98 ], "5": [ 59, 78 ], "\u03bcg": [ 60, 79, 87 ], "subcutaneous": [ 61 ], "exenatide": [ 62, 180, 193 ], "b.i.d.": [ 63, 80, 88 ], "(arms": [ 64 ], "A": [ 65, 75 ], "and": [ 66, 81, 96, 129, 147, 173, 227, 230, 275 ], "B)": [ 67 ], "or": [ 68, 104, 206 ], "placebo": [ 69 ], "for": [ 70 ], "4": [ 71 ], "weeks.": [ 72 ], "Thereafter,": [ 73 ], "arm": [ 74, 82 ], "remained": [ 76 ], "at": [ 77 ], "B": [ 83 ], "escalated": [ 84 ], "Subjects": [ 89 ], "continued": [ 90 ], "taking": [ 91 ], "their": [ 92 ], "dose": [ 93 ], "metformin": [ 95 ], "were": [ 97, 118, 157 ], "either": [ 100 ], "maximally": [ 101, 257 ], "effective": [ 102, 258 ], "(MAX)": [ 103 ], "minimum": [ 105 ], "recommended": [ 106 ], "(MIN)": [ 107 ], "doses": [ 108, 259 ], "sulfonylurea.": [ 110 ], "RESULTS\u2014Week": [ 111 ], "30": [ 112 ], "changes": [ 114 ], "from": [ 115, 190 ], "baseline": [ 116, 191 ], "(\u00b1SE)": [ 117 ], "\u22120.8": [ 119 ], "0.1%": [ 121, 126, 132 ], "(10": [ 122, 145, 222 ], "\u03bcg),": [ 123, 128, 223, 226 ], "\u22120.6": [ 124 ], "(5": [ 127, 149, 225 ], "+0.2": [ 130 ], "(placebo;": [ 133 ], "adjusted": [ 134 ], "P": [ 135, 176, 200 ], "&lt;": [ 136, 177 ], "0.0001": [ 137 ], "vs.": [ 138, 203 ], "placebo),": [ 139 ], "yielding": [ 140 ], "placebo-adjusted": [ 141 ], "reductions": [ 142 ], "\u22121.0%": [ 144 ], "\u03bcg)": [ 146 ], "\u22120.8%": [ 148 ], "\u03bcg).": [ 150 ], "In": [ 151 ], "evaluable": [ 153 ], "population,": [ 154 ], "exenatide-treated": [ 155 ], "more": [ 158 ], "likely": [ 159 ], "\u22647%": [ 163 ], "than": [ 164, 235 ], "placebo-treated": [ 165 ], "(34%": [ 167 ], "[10": [ 168 ], "\u03bcg],": [ 169, 172 ], "27%": [ 170 ], "[5": [ 171 ], "9%": [ 174 ], "[placebo];": [ 175 ], "0.0001).": [ 178 ], "Both": [ 179 ], "arms": [ 181 ], "demonstrated": [ 182 ], "significant": [ 183 ], "weight": [ 184, 273 ], "loss": [ 185 ], "(\u22121.6": [ 186 ], "0.2": [ 188, 197 ], "kg": [ 189, 198 ], "each": [ 192 ], "arm,": [ 194 ], "\u22120.9": [ 195 ], "placebo;": [ 199 ], "\u2264": [ 201 ], "0.01": [ 202 ], "placebo).": [ 204 ], "Mild": [ 205 ], "moderate": [ 207 ], "nausea": [ 208 ], "most": [ 211 ], "frequent": [ 212 ], "adverse": [ 213 ], "event.": [ 214 ], "The": [ 215 ], "incidence": [ 216 ], "mild/moderate": [ 218 ], "hypoglycemia": [ 219 ], "28%": [ 221 ], "19%": [ 224 ], "13%": [ 228 ], "(placebo)": [ 229 ], "appeared": [ 231 ], "lower": [ 232 ], "MIN": [ 234 ], "MAX": [ 237 ], "sulfonylurea": [ 238 ], "treatment.": [ 239 ], "CONCLUSIONS\u2014Exenatide": [ 240 ], "significantly": [ 241 ], "reduced": [ 242 ], "adequate": [ 253 ], "combined": [ 261 ], "This": [ 264 ], "improvement": [ 265 ], "associated": [ 270 ], "no": [ 272 ], "gain": [ 274 ], "generally": [ 277 ], "well": [ 278 ], "tolerated.": [ 279 ] }, "publication_date": "2005-05-01", "publication_year": 2005, "type": "article", "cited_by_count": 1169, "authors": [ { "id": "https://openalex.org/A5013350892", "display_name": "David M. Kendall" }, { "id": "https://openalex.org/A5087844534", "display_name": "Matthew C. Riddle" }, { "id": "https://openalex.org/A5045489578", "display_name": "Julio Rosenstock" }, { "id": "https://openalex.org/A5074705033", "display_name": "Dongliang Zhuang" }, { "id": "https://openalex.org/A5084708084", "display_name": "Dennis Dong Hwan Kim" }, { "id": "https://openalex.org/A5083503351", "display_name": "Mark Fineman" }, { "id": "https://openalex.org/A5110941359", "display_name": "Alain Baron" } ] }, { "id": "https://openalex.org/W2973758715", "doi": "https://doi.org/10.1016/j.diabet.2019.101117", "title": "Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1\u20133 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)", "abstract": null, "publication_date": "2019-09-17", "publication_year": 2019, "type": "article", "cited_by_count": 364, "authors": [ { "id": "https://openalex.org/A5073949429", "display_name": "Matthew Capehorn" }, { "id": "https://openalex.org/A5009303872", "display_name": "Andrei\u2010Mircea Catarig" }, { "id": "https://openalex.org/A5070066086", "display_name": "Julie Kj\u00e6rulff Furberg" }, { "id": "https://openalex.org/A5002770606", "display_name": "Andrej Jane\u017e" }, { "id": "https://openalex.org/A5058668146", "display_name": "Hermione Price" }, { "id": "https://openalex.org/A5109430061", "display_name": "S Tadayon" }, { "id": "https://openalex.org/A5003323204", "display_name": "Bruno Verg\u00e8s" }, { "id": "https://openalex.org/A5088350286", "display_name": "Michel Marre" } ] }, { "id": "https://openalex.org/W4398781461", "doi": "https://doi.org/10.1056/nejmoa2403347", "title": "Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes", "abstract": { "Semaglutide": [ 0 ], "reduced": [ 1 ], "the": [ 2 ], "risk": [ 3 ], "of": [ 4 ], "clinically": [ 5 ], "important": [ 6 ], "kidney": [ 7, 22 ], "outcomes": [ 8 ], "and": [ 9, 20 ], "death": [ 10 ], "from": [ 11 ], "cardiovascular": [ 12 ], "causes": [ 13 ], "in": [ 14 ], "patients": [ 15 ], "with": [ 16 ], "type": [ 17 ], "2": [ 18 ], "diabetes": [ 19 ], "chronic": [ 21 ], "disease.": [ 23 ], "(Funded": [ 24 ], "by": [ 25 ], "Novo": [ 26 ], "Nordisk;": [ 27 ], "FLOW": [ 28 ], "ClinicalTrials.gov": [ 29 ], "number,": [ 30 ], "NCT03819153.).": [ 31 ] }, "publication_date": "2024-05-24", "publication_year": 2024, "type": "article", "cited_by_count": 1020, "authors": [ { "id": "https://openalex.org/A5108135795", "display_name": "Vlado Perkovic" }, { "id": "https://openalex.org/A5046793050", "display_name": "Katherine R. Tuttle" }, { "id": "https://openalex.org/A5085592050", "display_name": "Peter Rossing" }, { "id": "https://openalex.org/A5039432822", "display_name": "Kenneth W. Mahaffey" }, { "id": "https://openalex.org/A5043842967", "display_name": "Johannes F.E. Mann" }, { "id": "https://openalex.org/A5012514694", "display_name": "George L. Bakris" }, { "id": "https://openalex.org/A5112384687", "display_name": "Florian M.M. Baeres" }, { "id": "https://openalex.org/A5113682378", "display_name": "Thomas Idorn" }, { "id": "https://openalex.org/A5070579413", "display_name": "Heidrun Bosch\u2010Traberg" }, { "id": "https://openalex.org/A5068233206", "display_name": "Nanna L. Lausvig" }, { "id": "https://openalex.org/A5110875486", "display_name": "Richard Pratley" } ] }, { "id": "https://openalex.org/W2109677274", "doi": "https://doi.org/10.1136/bmjopen-2012-001986", "title": "Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis", "abstract": { "Objectives": [ 0 ], "To": [ 1 ], "synthesise": [ 2 ], "current": [ 3 ], "evidence": [ 4 ], "for": [ 5, 57, 110, 117 ], "the": [ 6, 82, 223 ], "effects": [ 7 ], "of": [ 8, 22, 70 ], "exenatide": [ 9, 113, 118 ], "and": [ 10, 17, 64, 96, 112, 134, 144, 166, 212, 218 ], "liraglutide": [ 11, 111 ], "on": [ 12 ], "heart": [ 13, 60, 83, 210, 226 ], "rate,": [ 14, 61 ], "blood": [ 15, 62, 125, 151, 219 ], "pressure": [ 16, 63, 126, 152 ], "body": [ 18, 65, 216 ], "weight.": [ 19 ], "Design": [ 20 ], "Meta-analysis": [ 21 ], "available": [ 23 ], "data": [ 24 ], "from": [ 25 ], "randomised": [ 26 ], "controlled": [ 27 ], "trials": [ 28, 75 ], "comparing": [ 29 ], "Glucagon-like": [ 30 ], "peptide-1": [ 31 ], "(GLP-1)": [ 32 ], "analogues": [ 33, 202 ], "with": [ 34, 45, 205 ], "placebo,": [ 35 ], "active": [ 36, 103, 145, 174, 187 ], "antidiabetic": [ 37 ], "drug": [ 38 ], "therapy": [ 39 ], "or": [ 40 ], "lifestyle": [ 41 ], "intervention.": [ 42 ], "Participants": [ 43 ], "Patients": [ 44 ], "type": [ 46 ], "2": [ 47 ], "diabetes.": [ 48 ], "Outcome": [ 49 ], "measures": [ 50 ], "Weighted": [ 51 ], "mean": [ 52 ], "differences": [ 53 ], "between": [ 54 ], "trial": [ 55 ], "arms": [ 56 ], "changes": [ 58 ], "in": [ 59, 149, 209, 215, 225 ], "weight,": [ 66 ], "after": [ 67 ], "a": [ 68, 206 ], "minimum": [ 69 ], "12-week": [ 71 ], "follow-up.": [ 72 ], "Results": [ 73 ], "32": [ 74 ], "were": [ 76 ], "included.": [ 77 ], "Overall,": [ 78 ], "GLP-1": [ 79, 121, 201 ], "agonists": [ 80, 122 ], "increased": [ 81 ], "rate": [ 84, 211, 227 ], "by": [ 85, 127, 179, 190 ], "1.86": [ 86 ], "beats/min": [ 87 ], "(bpm)": [ 88 ], "(95%": [ 89 ], "CI": [ 90 ], "0.85": [ 91 ], "to": [ 92, 100, 132, 139, 142, 154, 162, 171, 183, 186, 195, 198 ], "2.87)": [ 93 ], "versus": [ 94, 102 ], "placebo": [ 95, 143, 165 ], "1.90": [ 97 ], "bpm": [ 98 ], "(1.30": [ 99 ], "2.50)": [ 101 ], "control.": [ 104 ], "This": [ 105 ], "effect": [ 106 ], "was": [ 107 ], "more": [ 108 ], "evident": [ 109 ], "long-acting": [ 114 ], "release": [ 115 ], "than": [ 116 ], "twice": [ 119 ], "daily.": [ 120 ], "decreased": [ 123, 178 ], "systolic": [ 124 ], "\u22121.79": [ 128 ], "mm": [ 129, 136, 159, 168 ], "Hg": [ 130, 137, 160, 169 ], "(\u22122.94": [ 131 ], "\u22120.64)": [ 133 ], "\u22122.39": [ 135 ], "(\u22123.35": [ 138 ], "\u22121.42)": [ 140 ], "compared": [ 141, 185, 197 ], "control,": [ 146, 188 ], "respectively.": [ 147 ], "Reduction": [ 148 ], "diastolic": [ 150 ], "failed": [ 153 ], "reach": [ 155 ], "statistical": [ 156 ], "significance": [ 157 ], "(\u22120.54": [ 158 ], "(\u22121.15": [ 161 ], "0.07)": [ 163 ], "vs": [ 164, 173 ], "\u22120.50": [ 167 ], "(\u22121.24": [ 170 ], "0.24)": [ 172 ], "control).": [ 175 ], "Body": [ 176 ], "weight": [ 177, 217 ], "\u22123.31": [ 180 ], "kg": [ 181, 193 ], "(\u22124.05": [ 182 ], "\u22122.57)": [ 184 ], "but": [ 189 ], "only": [ 191 ], "\u22121.22": [ 192 ], "(\u22121.51": [ 194 ], "\u22120.93)": [ 196 ], "placebo.": [ 199 ], "Conclusions": [ 200 ], "are": [ 203 ], "associated": [ 204 ], "small": [ 207 ], "increase": [ 208 ], "modest": [ 213 ], "reductions": [ 214 ], "pressure.": [ 220 ], "Mechanisms": [ 221 ], "underlying": [ 222 ], "rise": [ 224 ], "require": [ 228 ], "further": [ 229 ], "investigation.": [ 230 ] }, "publication_date": "2013-01-01", "publication_year": 2013, "type": "article", "cited_by_count": 288, "authors": [ { "id": "https://openalex.org/A5023209402", "display_name": "Louise Robinson" }, { "id": "https://openalex.org/A5030848728", "display_name": "Tim Holt" }, { "id": "https://openalex.org/A5052174968", "display_name": "Karen Rees" }, { "id": "https://openalex.org/A5050049384", "display_name": "Harpal Randeva" }, { "id": "https://openalex.org/A5112029257", "display_name": "Joseph Paul O\u2019Hare" } ] }, { "id": "https://openalex.org/W2563047690", "doi": "https://doi.org/10.1111/dom.12849", "title": "Efficacy and safety of glucagon\u2010like peptide\u20101 receptor agonists in type 2 diabetes: A systematic review and mixed\u2010treatment comparison analysis", "abstract": { "Aims": [ 0 ], "To": [ 1 ], "compare": [ 2 ], "efficacy": [ 3 ], "and": [ 4, 21, 39, 50, 56, 67, 108, 120, 130, 146, 155, 170, 174, 184, 190, 194, 221, 227, 231, 236, 272, 274, 299, 334, 342, 347, 375 ], "safety": [ 5, 68 ], "of": [ 6, 80, 225, 270, 280, 303, 367 ], "glucagon\u2010like": [ 7 ], "peptide\u20101": [ 8 ], "receptor": [ 9 ], "agonists": [ 10 ], "(": [ 11, 105, 112 ], "GLP\u20101RAs": [ 12, 101, 216, 244, 292 ], ")": [ 13, 107, 114 ], "in": [ 14, 256, 285, 354 ], "people": [ 15 ], "with": [ 16, 58, 98, 159, 166, 210, 213, 247, 308, 320, 329, 372 ], "type": [ 17 ], "2": [ 18 ], "diabetes.": [ 19 ], "Materials": [ 20 ], "methods": [ 22 ], "We": [ 23 ], "electronically": [ 24 ], "searched,": [ 25 ], "up": [ 26 ], "to": [ 27, 128, 339 ], "J": [ 28 ], "une": [ 29 ], "3,": [ 30 ], "2016,": [ 31 ], "published": [ 32, 91 ], "randomized": [ 33 ], "clinical": [ 34 ], "trials": [ 35, 82 ], "lasting": [ 36 ], "between": [ 37, 356 ], "24": [ 38 ], "32": [ 40 ], "weeks": [ 41 ], "that": [ 42, 290 ], "compared": [ 43, 209, 246, 307, 319, 328 ], "a": [ 44, 73, 383 ], "GLP\u20101RA": [ 45, 62, 384 ], "(albiglutide,": [ 46, 150 ], "dulaglutide,": [ 47, 151, 332 ], "twice\u2010daily": [ 48, 160, 340 ], "exenatide": [ 49, 145, 192, 276, 336, 341, 362 ], "once\u2010weekly": [ 51, 152, 191, 275, 335, 361 ], "exenatide,": [ 52, 153, 161 ], "liraglutide,": [ 53 ], "lixisenatide,": [ 54 ], "semaglutide": [ 55, 94 ], "taspoglutide)": [ 57, 156 ], "placebo": [ 59 ], "or": [ 60, 148, 262, 323 ], "another": [ 61 ], ".": [ 63, 385 ], "Data": [ 64 ], "on": [ 65 ], "cardiometabolic": [ 66 ], "outcomes": [ 69 ], "were": [ 70, 95, 139, 202, 208, 245, 254, 312, 318, 327, 337, 351 ], "analysed": [ 71 ], "using": [ 72 ], "mixed\u2010treatment": [ 74 ], "comparison": [ 75 ], "meta\u2010analysis.": [ 76 ], "Results": [ 77 ], "A": [ 78 ], "total": [ 79 ], "34": [ 81 ], "(14": [ 83 ], "464": [ 84 ], "participants)": [ 85 ], "met": [ 86 ], "the": [ 87, 167, 223, 267, 277, 286, 301, 364 ], "inclusion": [ 88 ], "criteria;": [ 89 ], "no": [ 90, 140, 250, 313, 352 ], "data": [ 92 ], "for": [ 93, 126, 136 ], "available.": [ 96 ], "Compared": [ 97, 158, 212 ], "placebo,": [ 99, 214 ], "all": [ 100, 215, 232, 243, 291 ], "reduced": [ 102, 219, 238 ], "glycated": [ 103 ], "haemoglobin": [ 104 ], "HbA1c": [ 106, 169, 346 ], "fasting": [ 109 ], "plasma": [ 110 ], "glucose": [ 111 ], "FPG": [ 113, 171, 348 ], "levels": [ 115 ], "(reductions": [ 116 ], "ranged": [ 117 ], "from": [ 118 ], "\u22120.55%": [ 119 ], "\u22120.73": [ 121 ], "mmol/": [ 122, 132, 176, 186, 196 ], "L": [ 123, 133, 177, 187, 197 ], ",": [ 124, 134, 178, 188, 198 ], "respectively,": [ 125, 135 ], "lixisenatide": [ 127, 343 ], "\u22121.21%": [ 129 ], "\u22121.97": [ 131 ], "dulaglutide).": [ 137 ], "There": [ 138, 350 ], "differences": [ 141, 253, 314, 353 ], "within": [ 142 ], "short\u2010acting": [ 143, 316 ], "(twice\u2010daily": [ 144 ], "lixisenatide)": [ 147 ], "long\u2010acting": [ 149, 325 ], "liraglutide": [ 154, 182, 333 ], "groups.": [ 157 ], "dulaglutide": [ 162, 235 ], "treatment": [ 163 ], "was": [ 164 ], "associated": [ 165 ], "greatest": [ 168 ], "reduction": [ 172, 261 ], "(0.51%": [ 173 ], "1.04": [ 175 ], "respectively),": [ 179 ], "followed": [ 180 ], "by": [ 181 ], "(0.45%": [ 183 ], "0.93": [ 185 ], "respectively)": [ 189 ], "(0.38%": [ 193 ], "0.85": [ 195 ], "respectively);": [ 199 ], "similar": [ 200 ], "reductions": [ 201 ], "found": [ 203 ], "when": [ 204, 315, 324, 381 ], "these": [ 205, 357 ], "3": [ 206, 358 ], "agents": [ 207, 233, 317, 326 ], "lixisenatide.": [ 211 ], "except": [ 217, 234 ], "albiglutide": [ 218 ], "weight": [ 220, 257, 298 ], "increased": [ 222 ], "risk": [ 224, 269, 279, 302, 366 ], "hypoglycaemia": [ 226, 263, 355 ], "gastrointestinal": [ 228, 305 ], "side": [ 229 ], "effects,": [ 230 ], "taspoglutide": [ 237 ], "systolic": [ 239 ], "blood": [ 240, 259 ], "pressure.": [ 241 ], "When": [ 242 ], "each": [ 248, 321, 330 ], "other,": [ 249, 331 ], "clinically": [ 251 ], "meaningful": [ 252 ], "observed": [ 255 ], "loss,": [ 258 ], "pressure": [ 260 ], "risk.": [ 264 ], "Albiglutide": [ 265 ], "had": [ 266, 363 ], "lowest": [ 268, 278, 365 ], "nausea": [ 271 ], "diarrhoea": [ 273 ], "vomiting.": [ 281, 368 ], "Conclusions": [ 282 ], "The": [ 283 ], "RCTs": [ 284 ], "present": [ 287 ], "analysis": [ 288 ], "show": [ 289 ], "improve": [ 293 ], "glycaemic": [ 294 ], "control,": [ 295 ], "reduce": [ 296 ], "body": [ 297 ], "increase": [ 300 ], "adverse": [ 304 ], "symptoms": [ 306 ], "placebo.": [ 309 ], "Although": [ 310 ], "there": [ 311 ], "other": [ 322 ], "superior": [ 338 ], "at": [ 344 ], "lowering": [ 345 ], "levels.": [ 349 ], "agents,": [ 359 ], "whilst": [ 360 ], "These": [ 369 ], "results,": [ 370 ], "along": [ 371 ], "patient's": [ 373 ], "preferences": [ 374 ], "individualized": [ 376 ], "targets,": [ 377 ], "should": [ 378 ], "be": [ 379 ], "considered": [ 380 ], "selecting": [ 382 ] }, "publication_date": "2016-12-17", "publication_year": 2016, "type": "review", "cited_by_count": 388, "authors": [ { "id": "https://openalex.org/A5042443875", "display_name": "Zin Zin Htike" }, { "id": "https://openalex.org/A5081356520", "display_name": "Francesco Zaccardi" }, { "id": "https://openalex.org/A5017193412", "display_name": "Dimitris Papamargaritis" }, { "id": "https://openalex.org/A5068804442", "display_name": "David R. Webb" }, { "id": "https://openalex.org/A5083222970", "display_name": "Kamlesh Khunti" }, { "id": "https://openalex.org/A5084593004", "display_name": "Melanie J. Davies" } ] }, { "id": "https://openalex.org/W2496216273", "doi": "https://doi.org/10.1186/s12967-016-0985-7", "title": "The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism", "abstract": null, "publication_date": "2016-07-30", "publication_year": 2016, "type": "article", "cited_by_count": 100, "authors": [ { "id": "https://openalex.org/A5044887229", "display_name": "Francesco Andreozzi" }, { "id": "https://openalex.org/A5010906352", "display_name": "Gregory Alexander Raciti" }, { "id": "https://openalex.org/A5066298134", "display_name": "Cecilia Nigro" }, { "id": "https://openalex.org/A5081126527", "display_name": "Gaia Chiara Mannino" }, { "id": "https://openalex.org/A5006291591", "display_name": "Teresa Procopio" }, { "id": "https://openalex.org/A5081259193", "display_name": "Alberto M. Davalli" }, { "id": "https://openalex.org/A5028448449", "display_name": "Francesco B\u00e8guinot" }, { "id": "https://openalex.org/A5084623347", "display_name": "Giorgio Sesti" }, { "id": "https://openalex.org/A5103240716", "display_name": "Claudia Miele" }, { "id": "https://openalex.org/A5053802958", "display_name": "Franco Folli" } ] }, { "id": "https://openalex.org/W1541796658", "doi": "https://doi.org/10.1900/rds.2008.5.73", "title": "Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors", "abstract": { "Until": [ 0 ], "recently,": [ 1 ], "the": [ 2, 16, 37, 43, 85, 105, 142, 233, 240 ], "pathogenesis": [ 3 ], "of": [ 4, 15, 39, 62, 88, 107, 144, 147, 226, 242 ], "type": [ 5 ], "2": [ 6, 174 ], "diabetes": [ 7 ], "mellitus": [ 8 ], "(T2DM)": [ 9 ], "has": [ 10, 116, 155 ], "been": [ 11, 117 ], "conceptualized": [ 12 ], "in": [ 13, 19, 31, 58, 66, 205, 209 ], "terms": [ 14 ], "predominant": [ 17 ], "defects": [ 18 ], "insulin": [ 20, 23 ], "secretion": [ 21 ], "and": [ 22, 51, 110, 122, 141, 158, 183, 202, 211, 228, 246 ], "action.": [ 24 ], "It": [ 25 ], "is": [ 26, 56, 128, 165 ], "now": [ 27 ], "recognized": [ 28 ], "that": [ 29, 101, 153, 231 ], "abnormalities": [ 30 ], "other": [ 32 ], "hormones": [ 33 ], "also": [ 34, 159 ], "contribute": [ 35 ], "to": [ 36, 83, 119, 181 ], "development": [ 38, 143 ], "hyperglycemia.": [ 40 ], "For": [ 41 ], "example,": [ 42 ], "incretin": [ 44, 234 ], "effect,": [ 45 ], "mediated": [ 46 ], "by": [ 47, 103, 130, 179, 185 ], "glucagon-like": [ 48 ], "peptide-1": [ 49 ], "(GLP-1)": [ 50 ], "glucose-dependent": [ 52 ], "insulinotropic": [ 53 ], "peptide": [ 54 ], "(GIP),": [ 55 ], "attenuated": [ 57 ], "T2DM.": [ 59 ], "Intravenous": [ 60 ], "administration": [ 61 ], "GLP-1": [ 63, 89, 91, 109, 113, 170, 243 ], "ameliorates": [ 64 ], "hyperglycemia": [ 65 ], "patients": [ 67 ], "with": [ 68, 189, 215, 236 ], "T2DM,": [ 69 ], "but": [ 70 ], "an": [ 71, 224 ], "extremely": [ 72 ], "short": [ 73, 133 ], "half-life": [ 74 ], "limits": [ 75 ], "its": [ 76, 131 ], "utility": [ 77 ], "as": [ 78, 200 ], "a": [ 79, 148, 167, 237 ], "therapeutic": [ 80 ], "agent.": [ 81 ], "Strategies": [ 82 ], "leverage": [ 84 ], "beneficial": [ 86 ], "effects": [ 87, 194 ], "include": [ 90 ], "receptor": [ 92, 244 ], "agonists": [ 93, 245 ], "or": [ 94, 96 ], "analogs": [ 95 ], "dipeptidyl": [ 97 ], "peptidase-4": [ 98 ], "(DPP-4)": [ 99 ], "inhibitors-agents": [ 100 ], "act": [ 102 ], "slowing": [ 104 ], "inactivation": [ 106 ], "endogenous": [ 108 ], "GIP.": [ 111 ], "The": [ 112 ], "agonist": [ 114 ], "exenatide": [ 115, 127, 150 ], "shown": [ 118 ], "improve": [ 120 ], "HbA1c": [ 121, 178 ], "decrease": [ 123 ], "body": [ 124 ], "weight.": [ 125 ], "However,": [ 126 ], "limited": [ 129 ], "relatively": [ 132 ], "pharmacologic": [ 134 ], "half-life,": [ 135 ], "various": [ 136 ], "gastrointestinal": [ 137 ], "(GI)": [ 138 ], "side": [ 139, 193, 218 ], "effects,": [ 140 ], "antibodies.": [ 145 ], "Studies": [ 146 ], "long-acting": [ 149 ], "formulation": [ 151 ], "suggest": [ 152 ], "it": [ 154 ], "improved": [ 156 ], "efficacy": [ 157 ], "promotes": [ 160 ], "weight": [ 161, 184, 213 ], "loss.": [ 162 ], "Another": [ 163 ], "prospect": [ 164 ], "liraglutide,": [ 166 ], "once-daily": [ 168 ], "human": [ 169 ], "analog.": [ 171 ], "In": [ 172 ], "phase": [ 173 ], "studies,": [ 175 ], "liraglutide": [ 176 ], "lowered": [ 177 ], "up": [ 180 ], "1.7%": [ 182 ], "approximately": [ 186 ], "3": [ 187 ], "kg,": [ 188 ], "apparently": [ 190 ], "fewer": [ 191 ], "GI": [ 192, 217 ], "than": [ 195 ], "exenatide.": [ 196 ], "DPP-4": [ 197, 247 ], "inhibitors": [ 198 ], "such": [ 199 ], "sitagliptin": [ 201 ], "vildagliptin": [ 203 ], "result": [ 204 ], "clinically": [ 206 ], "significant": [ 207 ], "reductions": [ 208 ], "HbA1c,": [ 210 ], "are": [ 212 ], "neutral": [ 214 ], "few": [ 216 ], "effects.": [ 219 ], "This": [ 220 ], "review": [ 221 ], "will": [ 222 ], "provide": [ 223 ], "overview": [ 225 ], "current": [ 227 ], "emerging": [ 229 ], "agents": [ 230 ], "augment": [ 232 ], "system": [ 235 ], "focus": [ 238 ], "on": [ 239 ], "role": [ 241 ], "inhibitors.": [ 248 ] }, "publication_date": "2008-01-01", "publication_year": 2008, "type": "article", "cited_by_count": 111, "authors": [ { "id": "https://openalex.org/A5059098934", "display_name": "Richard E. Pratley" }, { "id": "https://openalex.org/A5035502539", "display_name": "Matthew P. Gilbert" } ] }, { "id": "https://openalex.org/W3013242926", "doi": "https://doi.org/10.1172/jci.insight.133429", "title": "Semaglutide lowers body weight in rodents via distributed neural pathways", "abstract": { "Semaglutide,": [ 0 ], "a": [ 1 ], "glucagon-like": [ 2 ], "peptide": [ 3 ], "1": [ 4 ], "(GLP-1)": [ 5 ], "analog,": [ 6 ], "induces": [ 7 ], "weight": [ 8, 25, 51, 172 ], "loss,": [ 9 ], "lowers": [ 10, 170 ], "glucose": [ 11 ], "levels,": [ 12 ], "and": [ 13, 49, 64, 82, 106, 128, 160, 180, 183, 196 ], "reduces": [ 14 ], "cardiovascular": [ 15 ], "risk": [ 16 ], "in": [ 17, 33, 95, 141, 163, 192 ], "patients": [ 18 ], "with": [ 19, 75, 176 ], "diabetes.": [ 20 ], "Mechanistic": [ 21 ], "preclinical": [ 22 ], "studies": [ 23 ], "suggest": [ 24, 168 ], "loss": [ 26, 52 ], "is": [ 27 ], "mediated": [ 28 ], "through": [ 29, 78 ], "GLP-1": [ 30 ], "receptors": [ 31 ], "(GLP-1Rs)": [ 32 ], "the": [ 34, 60, 70, 76, 79, 88, 115, 142, 164, 186 ], "brain.": [ 35 ], "The": [ 36 ], "findings": [ 37 ], "presented": [ 38 ], "here": [ 39 ], "show": [ 40 ], "that": [ 41, 132 ], "semaglutide": [ 42, 122, 169 ], "modulated": [ 43 ], "food": [ 44, 47, 193 ], "preference,": [ 45 ], "reduced": [ 46 ], "intake,": [ 48, 194 ], "caused": [ 50 ], "without": [ 53, 109 ], "decreasing": [ 54 ], "energy": [ 55, 197 ], "expenditure.": [ 56, 198 ], "Semaglutide": [ 57, 90 ], "directly": [ 58, 102, 182 ], "accessed": [ 59 ], "brainstem,": [ 61 ], "septal": [ 62 ], "nucleus,": [ 63 ], "hypothalamus": [ 65 ], "but": [ 66 ], "did": [ 67 ], "not": [ 68 ], "cross": [ 69 ], "blood-brain": [ 71 ], "barrier;": [ 72 ], "it": [ 73 ], "interacted": [ 74 ], "brain": [ 77, 97, 129, 150 ], "circumventricular": [ 80 ], "organs": [ 81 ], "several": [ 83 ], "select": [ 84 ], "sites": [ 85 ], "adjacent": [ 86 ], "to": [ 87 ], "ventricles.": [ 89 ], "induced": [ 91 ], "central": [ 92 ], "c-Fos": [ 93, 124 ], "activation": [ 94, 133 ], "10": [ 96 ], "areas,": [ 98 ], "including": [ 99 ], "hindbrain": [ 100 ], "areas": [ 101, 108, 151 ], "targeted": [ 103 ], "by": [ 104, 139, 173, 181 ], "semaglutide,": [ 105 ], "secondary": [ 107 ], "direct": [ 110, 174 ], "GLP-1R": [ 111, 126, 178 ], "interaction,": [ 112 ], "such": [ 113 ], "as": [ 114 ], "lateral": [ 116, 143 ], "parabrachial": [ 117, 144 ], "nucleus.": [ 118, 145 ], "Automated": [ 119 ], "analysis": [ 120, 147 ], "of": [ 121, 148, 157, 188 ], "access,": [ 123 ], "activity,": [ 125 ], "distribution,": [ 127 ], "connectivity": [ 130 ], "revealed": [ 131 ], "may": [ 134 ], "involve": [ 135 ], "meal": [ 136 ], "termination": [ 137 ], "controlled": [ 138 ], "neurons": [ 140 ], "Transcriptomic": [ 146 ], "microdissected": [ 149 ], "from": [ 152 ], "semaglutide-treated": [ 153 ], "rats": [ 154 ], "showed": [ 155 ], "upregulation": [ 156 ], "prolactin-releasing": [ 158 ], "hormone": [ 159 ], "tyrosine": [ 161 ], "hydroxylase": [ 162 ], "area": [ 165 ], "postrema.": [ 166 ], "We": [ 167 ], "body": [ 171 ], "interaction": [ 175 ], "diverse": [ 177 ], "populations": [ 179 ], "indirectly": [ 184 ], "affecting": [ 185 ], "activity": [ 187 ], "neural": [ 189 ], "pathways": [ 190 ], "involved": [ 191 ], "reward,": [ 195 ] }, "publication_date": "2020-03-25", "publication_year": 2020, "type": "article", "cited_by_count": 573, "authors": [ { "id": "https://openalex.org/A5028859185", "display_name": "Sanaz Gabery" }, { "id": "https://openalex.org/A5006733321", "display_name": "Casper G. Salinas" }, { "id": "https://openalex.org/A5088587889", "display_name": "Sarah Juel Paulsen" }, { "id": "https://openalex.org/A5074025492", "display_name": "Jonas Ahnfelt\u2010R\u00f8nne" }, { "id": "https://openalex.org/A5050465677", "display_name": "Tomas Alanentalo" }, { "id": "https://openalex.org/A5023310194", "display_name": "Arian F. Baquero" }, { "id": "https://openalex.org/A5078356634", "display_name": "Stephen T. Buckley" }, { "id": "https://openalex.org/A5065798444", "display_name": "Erzs\u00e9bet Farkas" }, { "id": "https://openalex.org/A5001902256", "display_name": "Csaba Fekete" }, { "id": "https://openalex.org/A5015151949", "display_name": "Klaus Stensgaard Frederiksen" }, { "id": "https://openalex.org/A5010563977", "display_name": "Hans Christian Cederberg Helms" }, { "id": "https://openalex.org/A5110949287", "display_name": "Jacob Jeppesen" }, { "id": "https://openalex.org/A5068775038", "display_name": "Linu M. John" }, { "id": "https://openalex.org/A5084425804", "display_name": "Charles Pyke" }, { "id": "https://openalex.org/A5087674673", "display_name": "Jane N\u00f8hr" }, { "id": "https://openalex.org/A5055643415", "display_name": "Tess Tsai-Hsiu Lu" }, { "id": "https://openalex.org/A5048226541", "display_name": "Joseph Polex-Wolf" }, { "id": "https://openalex.org/A5083058332", "display_name": "Vincent Pr\u00e9vot" }, { "id": "https://openalex.org/A5064830959", "display_name": "Kirsten Raun" }, { "id": "https://openalex.org/A5088597413", "display_name": "Lotte Simonsen" }, { "id": "https://openalex.org/A5067444073", "display_name": "Gao Sun" }, { "id": "https://openalex.org/A5063303067", "display_name": "Anett Szilv\u00e1sy\u2010Szab\u00f3" }, { "id": "https://openalex.org/A5014801050", "display_name": "Hanni Willenbrock" }, { "id": "https://openalex.org/A5013985442", "display_name": "Anna Secher" }, { "id": "https://openalex.org/A5088627727", "display_name": "Lotte Bjerre Knudsen" } ] }, { "id": "https://openalex.org/W2028272916", "doi": "https://doi.org/10.7326/0003-4819-143-8-200510180-00006", "title": "Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes", "abstract": { "Exenatide": [ 0, 25 ], "and": [ 1, 31 ], "insulin": [ 2, 41 ], "glargine": [ 3 ], "achieved": [ 4 ], "similar": [ 5 ], "improvements": [ 6 ], "in": [ 7, 11 ], "overall": [ 8 ], "glycemic": [ 9 ], "control": [ 10 ], "patients": [ 12 ], "with": [ 13, 21, 28 ], "type": [ 14 ], "2": [ 15 ], "diabetes": [ 16 ], "that": [ 17 ], "was": [ 18, 26 ], "suboptimally": [ 19 ], "controlled": [ 20 ], "oral": [ 22 ], "combination": [ 23 ], "therapy.": [ 24 ], "associated": [ 27 ], "weight": [ 29 ], "reduction": [ 30 ], "had": [ 32 ], "a": [ 33 ], "higher": [ 34 ], "incidence": [ 35 ], "of": [ 36 ], "gastrointestinal": [ 37 ], "adverse": [ 38 ], "effects": [ 39 ], "than": [ 40 ], "glargine.": [ 42 ] }, "publication_date": "2005-10-18", "publication_year": 2005, "type": "article", "cited_by_count": 794, "authors": [ { "id": "https://openalex.org/A5113467761", "display_name": "Robert J. Heine" }, { "id": "https://openalex.org/A5111609726", "display_name": "Luc F. Van Gaal" }, { "id": "https://openalex.org/A5071736666", "display_name": "Don Johns" }, { "id": "https://openalex.org/A5110563793", "display_name": "Michael J. Mihm" }, { "id": "https://openalex.org/A5048529356", "display_name": "Mario Widel" }, { "id": "https://openalex.org/A5109961740", "display_name": "Robert G. Brodows" } ] }, { "id": "https://openalex.org/W2142400535", "doi": "https://doi.org/10.2337/dc10-1393", "title": "Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies", "abstract": { "OBJECTIVE": [ 0 ], "To": [ 1 ], "test": [ 2 ], "the": [ 3, 10, 40, 60, 76, 83 ], "hypothesis": [ 4 ], "that": [ 5 ], "exenatide": [ 6, 91, 151, 166 ], "twice": [ 7, 152 ], "daily": [ 8 ], "reduces": [ 9 ], "relative": [ 11 ], "incidence": [ 12 ], "of": [ 13, 39, 43, 64, 141, 209, 235 ], "cardiovascular": [ 14 ], "disease": [ 15 ], "(CVD)": [ 16 ], "events": [ 17, 98, 237 ], "among": [ 18 ], "patients": [ 19, 143, 156, 185, 196 ], "with": [ 20, 25, 56, 133, 144, 150, 159, 231, 242 ], "type": [ 21, 145 ], "2": [ 22, 146 ], "diabetes": [ 23, 147 ], "compared": [ 24, 125 ], "other": [ 26, 160, 180, 243 ], "glucose-lowering": [ 27, 161, 244 ], "agent(s).": [ 28 ], "RESEARCH": [ 29 ], "DESIGN": [ 30 ], "AND": [ 31 ], "METHODS": [ 32 ], "A": [ 33, 139 ], "retrospective": [ 34 ], "database": [ 35, 42 ], "analysis": [ 36, 132 ], "was": [ 37, 92, 229 ], "performed": [ 38 ], "LifeLink": [ 41 ], "medical": [ 44 ], "and": [ 45, 88, 121, 124, 154, 206, 217, 238 ], "pharmaceutical": [ 46 ], "insurance": [ 47 ], "claims": [ 48 ], "for": [ 49, 117 ], "June": [ 50 ], "2005": [ 51 ], "through": [ 52 ], "March": [ 53 ], "2009.": [ 54 ], "Patients": [ 55, 163 ], "no": [ 57 ], "history": [ 58 ], "in": [ 59, 119 ], "preceding": [ 61 ], "9": [ 62 ], "months": [ 63 ], "myocardial": [ 65 ], "infarction,": [ 66, 100 ], "ischemic": [ 67, 101, 173 ], "stroke,": [ 68, 102 ], "or": [ 69, 78, 94, 103 ], "coronary": [ 70, 104 ], "revascularization": [ 71, 105 ], "procedure": [ 72 ], "were": [ 73, 107, 115, 148, 157, 167, 186 ], "assigned": [ 74 ], "to": [ 75, 136, 170, 189 ], "exenatide-initiated": [ 77 ], "non\u2013exenatide-initiated": [ 79 ], "cohorts": [ 80 ], "based": [ 81 ], "on": [ 82 ], "first": [ 84 ], "new": [ 85 ], "prescription": [ 86 ], "filled": [ 87 ], "reassigned": [ 89 ], "if": [ 90 ], "prescribed": [ 93 ], "discontinued.": [ 95 ], "Incident": [ 96 ], "CVD": [ 97, 192, 236 ], "(myocardial": [ 99 ], "procedure)": [ 106 ], "identified": [ 108 ], "by": [ 109 ], "ICD-9-CM": [ 110 ], "diagnosis": [ 111 ], "codes.": [ 112 ], "Patient": [ 113 ], "outcomes": [ 114 ], "adjusted": [ 116 ], "differences": [ 118 ], "clinical": [ 120 ], "demographic": [ 122 ], "characteristics": [ 123 ], "using": [ 126 ], "propensity": [ 127 ], "score\u2013weighted": [ 128 ], "discrete": [ 129 ], "time": [ 130 ], "survival": [ 131 ], "time-varying": [ 134 ], "exposure": [ 135 ], "exenatide.": [ 137 ], "RESULTS": [ 138 ], "total": [ 140 ], "39,275": [ 142 ], "treated": [ 149, 158 ], "daily,": [ 153 ], "381,218": [ 155 ], "therapies.": [ 162, 245 ], "who": [ 164 ], "initiated": [ 165 ], "more": [ 168 ], "likely": [ 169, 188 ], "have": [ 171, 190 ], "prior": [ 172 ], "heart": [ 174 ], "disease,": [ 175 ], "obesity,": [ 176 ], "hyperlipidemia,": [ 177 ], "hypertension,": [ 178 ], "and/or": [ 179 ], "comorbidities": [ 181 ], "at": [ 182 ], "baseline.": [ 183 ], "Exenatide-treated": [ 184 ], "less": [ 187 ], "a": [ 191, 232 ], "event": [ 193 ], "than": [ 194, 240 ], "non\u2013exenatide-treated": [ 195 ], "(hazard": [ 197 ], "ratio": [ 198 ], "0.81;": [ 199 ], "95%": [ 200 ], "CI": [ 201 ], "0.68\u20130.95;": [ 202 ], "P": [ 203, 214, 222 ], "=": [ 204, 215 ], "0.01)": [ 205 ], "lower": [ 207, 233 ], "rates": [ 208 ], "CVD-related": [ 210 ], "hospitalization": [ 211, 219 ], "(0.88;": [ 212 ], "0.79\u20130.98;": [ 213 ], "0.02)": [ 216 ], "all-cause": [ 218 ], "(0.94;": [ 220 ], "0.91\u20130.97;": [ 221 ], "&lt;": [ 223 ], "0.001).": [ 224 ], "CONCLUSIONS": [ 225 ], "Exenatide": [ 226 ], "twice-daily": [ 227 ], "treatment": [ 228, 241 ], "associated": [ 230 ], "risk": [ 234 ], "hospitalizations": [ 239 ] }, "publication_date": "2010-10-07", "publication_year": 2010, "type": "article", "cited_by_count": 250, "authors": [ { "id": "https://openalex.org/A5108098563", "display_name": "Jennie H. Best" }, { "id": "https://openalex.org/A5058778822", "display_name": "Byron J. Hoogwerf" }, { "id": "https://openalex.org/A5057706291", "display_name": "William H. Herman" }, { "id": "https://openalex.org/A5110001759", "display_name": "Elise M. Pelletier" }, { "id": "https://openalex.org/A5113070248", "display_name": "Daniel B. Smith" }, { "id": "https://openalex.org/A5073093450", "display_name": "Mad\u00e9 Wenten" }, { "id": "https://openalex.org/A5037162928", "display_name": "Mohamed Hussein" } ] }, { "id": "https://openalex.org/W2414005931", "doi": "https://doi.org/10.1002/dmrr.2810", "title": "Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program", "abstract": { "Summary": [ 0 ], "Dulaglutide": [ 1, 108 ], "(DU)": [ 2 ], "is": [ 3, 48, 216 ], "a": [ 4, 89 ], "once": [ 5, 69 ], "weekly": [ 6, 70, 118 ], "glucagon\u2010like": [ 7 ], "peptide\u20101": [ 8 ], "receptor": [ 9, 159 ], "agonist": [ 10 ], "(GLP\u20101": [ 11 ], "RA)": [ 12 ], "approved": [ 13 ], "for": [ 14, 220 ], "the": [ 15, 39, 54, 60, 66, 77, 133, 152 ], "treatment": [ 16, 161, 219 ], "of": [ 17, 28, 44, 65, 92, 100, 126, 138, 171, 177, 201 ], "type": [ 18 ], "2": [ 19 ], "diabetes": [ 20 ], "mellitus": [ 21 ], "(T2DM).": [ 22 ], "Glycaemic": [ 23 ], "efficacy": [ 24 ], "and": [ 25, 86, 104, 129, 145, 147, 174, 197, 222, 227 ], "safety": [ 26, 228 ], "characteristics": [ 27 ], "dulaglutide": [ 29, 71, 119, 163, 202, 215 ], "have": [ 30 ], "been": [ 31 ], "assessed": [ 32 ], "in": [ 33, 38, 63, 115, 124, 136, 151 ], "six": [ 34, 55, 67 ], "Phase": [ 35 ], "3": [ 36 ], "studies": [ 37, 141 ], "AWARD": [ 40, 57, 140 ], "program.": [ 41 ], "The": [ 42, 186, 199 ], "objective": [ 43 ], "this": [ 45 ], "review": [ 46 ], "article": [ 47 ], "to": [ 49, 76, 113, 132, 149, 156 ], "summarize": [ 50 ], "these": [ 51, 127 ], "results": [ 52 ], "from": [ 53 ], "completed": [ 56 ], "studies.": [ 58 ], "At": [ 59 ], "primary": [ 61 ], "endpoint,": [ 62 ], "five": [ 64, 125, 139 ], "studies,": [ 68 ], "1.5": [ 72, 109 ], "mg": [ 73, 110, 121 ], "was": [ 74, 111, 122, 164, 206 ], "superior": [ 75 ], "active": [ 78, 134 ], "comparator": [ 79, 135 ], "[exenatide,": [ 80 ], "insulin": [ 81 ], "glargine": [ 82, 150 ], "(two": [ 83 ], "studies),": [ 84 ], "metformin,": [ 85, 144 ], "sitagliptin],": [ 87 ], "with": [ 88, 162, 166, 183, 208 ], "greater": [ 90 ], "proportion": [ 91 ], "patients": [ 93 ], "reaching": [ 94 ], "glycated": [ 95 ], "hemoglobin": [ 96 ], "A1c": [ 97 ], "(HbA1c)": [ 98 ], "targets": [ 99 ], "<7.0%": [ 101 ], "(53.0": [ 102 ], "mmol/mol)": [ 103 ], "\u22646.5%": [ 105 ], "(47.5": [ 106 ], "mmol/mol).": [ 107 ], "non\u2010inferior": [ 112 ], "liraglutide": [ 114 ], "AWARD\u20106.": [ 116 ], "Once": [ 117 ], "0.75": [ 120 ], "evaluated": [ 123 ], "trials": [ 128 ], "demonstrated": [ 130 ], "superiority": [ 131 ], "four": [ 137 ], "(exenatide,": [ 142 ], "glargine,": [ 143 ], "sitagliptin),": [ 146 ], "non\u2010inferiority": [ 148 ], "AWARD\u20102": [ 153 ], "study.": [ 154 ], "Similar": [ 155 ], "other": [ 157 ], "GLP\u20101": [ 158 ], "agonists,": [ 160 ], "associated": [ 165 ], "weight": [ 167, 172 ], "loss": [ 168 ], "or": [ 169, 182 ], "attenuation": [ 170 ], "gain": [ 173 ], "low": [ 175 ], "rates": [ 176 ], "hypoglycaemia": [ 178 ], "when": [ 179 ], "used": [ 180 ], "alone": [ 181 ], "non\u2010insulin\u2010secretagogue": [ 184 ], "therapy.": [ 185 ], "most": [ 187 ], "frequently": [ 188 ], "reported": [ 189 ], "adverse": [ 190 ], "events": [ 191 ], "were": [ 192 ], "gastrointestinal,": [ 193 ], "including": [ 194 ], "nausea,": [ 195 ], "vomiting,": [ 196 ], "diarrhea.": [ 198 ], "incidence": [ 200 ], "antidrug": [ 203 ], "antibody": [ 204 ], "formation": [ 205 ], "1\u20132.8%": [ 207 ], "rare": [ 209 ], "injection": [ 210 ], "site": [ 211 ], "reactions.": [ 212 ], "In": [ 213 ], "conclusion,": [ 214 ], "an": [ 217, 224 ], "effective": [ 218 ], "T2DM": [ 221 ], "has": [ 223 ], "acceptable": [ 225 ], "tolerability": [ 226 ], "profile.": [ 229 ], "Copyright": [ 230 ], "\u00a9": [ 231 ], "2016": [ 232 ], "John": [ 233 ], "Wiley": [ 234 ], "&": [ 235 ], "Sons,": [ 236 ], "Ltd.": [ 237 ] }, "publication_date": "2016-04-22", "publication_year": 2016, "type": "review", "cited_by_count": 148, "authors": [ { "id": "https://openalex.org/A5073354239", "display_name": "Johan Jendle" }, { "id": "https://openalex.org/A5034509828", "display_name": "George Grunberger" }, { "id": "https://openalex.org/A5004471830", "display_name": "Thomas Blevins" }, { "id": "https://openalex.org/A5064872622", "display_name": "Francesco Giorgino" }, { "id": "https://openalex.org/A5047600098", "display_name": "Ryan T. Hietpas" }, { "id": "https://openalex.org/A5051731762", "display_name": "Fady T. Botros" } ] }, { "id": "https://openalex.org/W4281763444", "doi": "https://doi.org/10.1007/s11095-022-03302-1", "title": "Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review", "abstract": null, "publication_date": "2022-06-01", "publication_year": 2022, "type": "review", "cited_by_count": 95, "authors": [ { "id": "https://openalex.org/A5061471517", "display_name": "Manoj K. Mahapatra" }, { "id": "https://openalex.org/A5079133716", "display_name": "Muthukumar Karuppasamy" }, { "id": "https://openalex.org/A5112880815", "display_name": "Biswa Mohan Sahoo" } ] }, { "id": "https://openalex.org/W2170606300", "doi": "https://doi.org/10.1016/s0140-6736(09)60659-0", "title": "Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)", "abstract": null, "publication_date": "2009-06-09", "publication_year": 2009, "type": "article", "cited_by_count": 1465, "authors": [ { "id": "https://openalex.org/A5040182038", "display_name": "John B. Buse" }, { "id": "https://openalex.org/A5045489578", "display_name": "Julio Rosenstock" }, { "id": "https://openalex.org/A5084623347", "display_name": "Giorgio Sesti" }, { "id": "https://openalex.org/A5111040183", "display_name": "Wolfgang E. Schmidt" }, { "id": "https://openalex.org/A5031060251", "display_name": "Eduard Montanya" }, { "id": "https://openalex.org/A5111550916", "display_name": "Jason Brett" }, { "id": "https://openalex.org/A5113524401", "display_name": "Marcin Zychma" }, { "id": "https://openalex.org/A5070289715", "display_name": "Lawrence Blonde" } ] }, { "id": "https://openalex.org/W2196507910", "doi": "https://doi.org/10.2337/db15-0443", "title": "Topical Administration of GLP-1 Receptor Agonists Prevents Retinal Neurodegeneration in Experimental Diabetes", "abstract": { "Retinal": [ 0 ], "neurodegeneration": [ 1, 118 ], "is": [ 2, 29 ], "an": [ 3, 139 ], "early": [ 4, 202 ], "event": [ 5 ], "in": [ 6, 21, 54, 77, 95, 175, 197 ], "the": [ 7, 22, 27, 34, 37, 46, 63, 84, 96, 198, 201 ], "pathogenesis": [ 8 ], "of": [ 9, 36, 50, 67, 74, 93, 111, 135, 141, 155, 200, 204 ], "diabetic": [ 10 ], "retinopathy": [ 11 ], "(DR).": [ 12 ], "Since": [ 13 ], "glucagon-like": [ 14 ], "peptide": [ 15 ], "1": [ 16 ], "(GLP-1)": [ 17 ], "exerts": [ 18 ], "neuroprotective": [ 19, 65, 86, 150, 168 ], "effects": [ 20, 66 ], "central": [ 23 ], "nervous": [ 24 ], "system": [ 25 ], "and": [ 26, 48, 56, 69, 80, 99, 123, 138, 158, 164 ], "retina": [ 28, 98 ], "ontogenically": [ 30 ], "a": [ 31, 112, 132, 148, 194 ], "brain-derived": [ 32 ], "tissue,": [ 33 ], "aims": [ 35 ], "current": [ 38 ], "study": [ 39 ], "were": [ 40 ], "as": [ 41 ], "follows:": [ 42 ], "1)": [ 43 ], "to": [ 44, 61, 82, 131 ], "examine": [ 45, 83 ], "expression": [ 47, 92 ], "content": [ 49 ], "GLP-1": [ 51, 157 ], "receptor": [ 52 ], "(GLP-1R)": [ 53 ], "human": [ 55, 97 ], "db/db": [ 57, 78, 102 ], "mice": [ 58 ], "retinas;": [ 59 ], "2)": [ 60 ], "determine": [ 62 ], "retinal": [ 64, 117, 187 ], "systemic": [ 68, 109 ], "topical": [ 70, 153 ], "administration": [ 71, 110, 154 ], "(eye": [ 72 ], "drops)": [ 73 ], "GLP-1R": [ 75, 94, 113, 160, 183 ], "agonists": [ 76, 161 ], "mice;": [ 79 ], "3)": [ 81 ], "underlying": [ 85 ], "mechanisms.": [ 87 ], "We": [ 88, 145 ], "have": [ 89, 106, 146 ], "found": [ 90, 147 ], "abundant": [ 91 ], "retinas": [ 100 ], "from": [ 101 ], "mice.": [ 103 ], "Moreover,": [ 104 ], "we": [ 105 ], "demonstrated": [ 107 ], "that": [ 108, 182 ], "agonist": [ 114 ], "(liraglutide)": [ 115 ], "prevents": [ 116, 186 ], "(glial": [ 119 ], "activation,": [ 120 ], "neural": [ 121 ], "apoptosis,": [ 122 ], "electroretinographical": [ 124 ], "abnormalities).": [ 125 ], "This": [ 126 ], "effect": [ 127, 151 ], "can": [ 128 ], "be": [ 129 ], "attributed": [ 130 ], "significant": [ 133 ], "reduction": [ 134, 174 ], "extracellular": [ 136 ], "glutamate": [ 137 ], "increase": [ 140 ], "prosurvival": [ 142 ], "signaling": [ 143 ], "pathways.": [ 144 ], "similar": [ 149 ], "using": [ 152 ], "native": [ 156 ], "several": [ 159 ], "(liraglutide,": [ 162 ], "lixisenatide,": [ 163 ], "exenatide).": [ 165 ], "Notably,": [ 166 ], "this": [ 167 ], "action": [ 169 ], "was": [ 170 ], "observed": [ 171 ], "without": [ 172 ], "any": [ 173 ], "blood": [ 176 ], "glucose": [ 177 ], "levels.": [ 178 ], "These": [ 179 ], "results": [ 180, 190 ], "suggest": [ 181 ], "activation": [ 184 ], "itself": [ 185 ], "neurodegeneration.": [ 188 ], "Our": [ 189 ], "should": [ 191 ], "open": [ 192 ], "up": [ 193 ], "new": [ 195 ], "approach": [ 196 ], "treatment": [ 199 ], "stages": [ 203 ], "DR.": [ 205 ] }, "publication_date": "2015-09-17", "publication_year": 2015, "type": "article", "cited_by_count": 230, "authors": [ { "id": "https://openalex.org/A5017014718", "display_name": "Cristina Hern\u00e1ndez" }, { "id": "https://openalex.org/A5022750465", "display_name": "Patricia Bogdanov" }, { "id": "https://openalex.org/A5089400617", "display_name": "L\u00eddia Corraliza" }, { "id": "https://openalex.org/A5060798915", "display_name": "Marta Garc\u00eda\u2010Ram\u00edrez" }, { "id": "https://openalex.org/A5061471316", "display_name": "Cristina Sol\u00e0-Adell" }, { "id": "https://openalex.org/A5065582084", "display_name": "Jos\u00e9 Antonio Arranz" }, { "id": "https://openalex.org/A5032364391", "display_name": "Ana I. Arroba" }, { "id": "https://openalex.org/A5022850312", "display_name": "\u00c1ngela M. Valverde" }, { "id": "https://openalex.org/A5091908088", "display_name": "Rafael Sim\u00f3" } ] }, { "id": "https://openalex.org/W1863540633", "doi": "https://doi.org/10.1080/00325481.2015.1090295", "title": "User\u2019s guide to mechanism of action and clinical use of GLP-1 receptor agonists", "abstract": { "Glucagon-like": [ 0 ], "peptide-1": [ 1 ], "(GLP-1)": [ 2 ], "receptor": [ 3, 73 ], "agonists": [ 4 ], "(GLP-1RAs)": [ 5 ], "are": [ 6, 61, 116, 153, 156, 166 ], "injectable": [ 7 ], "glucose-lowering": [ 8 ], "medications": [ 9 ], "approved": [ 10, 63 ], "for": [ 11, 123 ], "the": [ 12, 34, 65, 103, 130, 133, 162, 189, 205 ], "treatment": [ 13 ], "of": [ 14, 36, 71, 78, 183 ], "adult": [ 15 ], "patients": [ 16, 39, 213 ], "with": [ 17, 40, 161, 173, 193, 214 ], "type": [ 18 ], "2": [ 19 ], "diabetes": [ 20 ], "mellitus": [ 21 ], "(T2DM).": [ 22 ], "This": [ 23 ], "article": [ 24 ], "provides": [ 25 ], "practical": [ 26 ], "information": [ 27 ], "to": [ 28, 86, 107, 144, 211 ], "guide": [ 29 ], "primary": [ 30, 206 ], "care": [ 31, 207 ], "physicians": [ 32 ], "on": [ 33, 126 ], "use": [ 35, 210 ], "GLP-1RAs": [ 37, 60, 82, 165, 199 ], "in": [ 38, 64, 102, 129, 171 ], "T2DM.": [ 41 ], "Two": [ 42 ], "short-acting": [ 43 ], "(once-": [ 44 ], "or": [ 45, 177 ], "twice-daily": [ 46 ], "administration;": [ 47, 55 ], "exenatide": [ 48 ], "and": [ 49, 51, 58, 91, 111, 132, 139, 158, 195 ], "liraglutide)": [ 50 ], "three": [ 52 ], "long-acting": [ 53, 163 ], "(weekly": [ 54 ], "albiglutide,": [ 56 ], "dulaglutide": [ 57 ], "exenatide)": [ 59 ], "currently": [ 62 ], "US.": [ 66 ], "These": [ 67, 95 ], "drugs": [ 68 ], "provide": [ 69 ], "levels": [ 70 ], "GLP-1": [ 72, 100, 127 ], "agonism": [ 74 ], "many": [ 75 ], "times": [ 76 ], "that": [ 77, 115, 204 ], "endogenous": [ 79 ], "GLP-1.": [ 80 ], "The": [ 81, 148 ], "have": [ 83 ], "been": [ 84 ], "shown": [ 85 ], "significantly": [ 87 ], "improve": [ 88 ], "glycemic": [ 89 ], "parameters": [ 90 ], "reduce": [ 92 ], "body": [ 93 ], "weight.": [ 94 ], "agents": [ 96 ], "work": [ 97 ], "by": [ 98 ], "activating": [ 99 ], "receptors": [ 101, 128 ], "pancreas,": [ 104 ], "which": [ 105, 155 ], "leads": [ 106 ], "enhanced": [ 108 ], "insulin": [ 109, 194 ], "release": [ 110 ], "reduced": [ 112, 137 ], "glucagon": [ 113 ], "release-responses": [ 114 ], "both": [ 117 ], "glucose-dependent-with": [ 118 ], "a": [ 119, 181, 201 ], "consequent": [ 120 ], "low": [ 121 ], "risk": [ 122 ], "hypoglycemia.": [ 124 ], "Effects": [ 125 ], "CNS": [ 131 ], "gastrointestinal": [ 134 ], "tract": [ 135 ], "cause": [ 136 ], "appetite": [ 138 ], "delayed": [ 140 ], "glucose": [ 141, 185 ], "absorption": [ 142 ], "due": [ 143 ], "slower": [ 145 ], "gastric": [ 146 ], "emptying.": [ 147 ], "most": [ 149 ], "common": [ 150, 160 ], "adverse": [ 151 ], "effects": [ 152 ], "gastrointestinal,": [ 154 ], "transient": [ 157 ], "less": [ 159 ], "drugs.": [ 164 ], "recommended": [ 167 ], "as": [ 168 ], "second-line": [ 169 ], "therapy": [ 170 ], "combination": [ 172 ], "metformin,": [ 174 ], "sulfonylureas,": [ 175 ], "thiazolidinediones": [ 176 ], "basal": [ 178 ], "insulin,": [ 179 ], "providing": [ 180 ], "means": [ 182 ], "enhancing": [ 184 ], "control": [ 186 ], "while": [ 187 ], "offsetting": [ 188 ], "weight": [ 190 ], "gain": [ 191 ], "associated": [ 192 ], "some": [ 196 ], "oral": [ 197 ], "agents.": [ 198 ], "represent": [ 200 ], "useful": [ 202 ], "tool": [ 203 ], "physician": [ 208 ], "can": [ 209 ], "help": [ 212 ], "T2DM": [ 215 ], "achieve": [ 216 ], "their": [ 217 ], "therapeutic": [ 218 ], "goals.": [ 219 ] }, "publication_date": "2015-09-15", "publication_year": 2015, "type": "review", "cited_by_count": 108, "authors": [ { "id": "https://openalex.org/A5072046850", "display_name": "Charles F. Shaefer" }, { "id": "https://openalex.org/A5026925969", "display_name": "Pamela Kushner" }, { "id": "https://openalex.org/A5053430741", "display_name": "Richard Aguilar" } ] }, { "id": "https://openalex.org/W4253996779", "doi": "https://doi.org/10.2337/dci19-0066", "title": "2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)", "abstract": { "The": [ 0 ], "American": [ 1 ], "Diabetes": [ 2, 12 ], "Association": [ 3, 7 ], "and": [ 4, 120, 132, 148, 190 ], "the": [ 5, 9, 40, 112, 184 ], "European": [ 6 ], "for": [ 8, 68 ], "Study": [ 10 ], "of": [ 11, 21, 84, 114, 117, 186 ], "have": [ 13 ], "briefly": [ 14 ], "updated": [ 15 ], "their": [ 16 ], "2018": [ 17 ], "recommendations": [ 18 ], "on": [ 19, 24 ], "management": [ 20 ], "hyperglycemia,": [ 22 ], "based": [ 23 ], "important": [ 25 ], "research": [ 26 ], "findings": [ 27 ], "from": [ 28 ], "large": [ 29 ], "cardiovascular": [ 30, 64, 72, 107, 191 ], "outcomes": [ 31 ], "trials": [ 32 ], "published": [ 33 ], "in": [ 34, 99, 126, 154 ], "2019.": [ 35 ], "Important": [ 36 ], "changes": [ 37 ], "include:": [ 38 ], "1)": [ 39 ], "decision": [ 41 ], "to": [ 42, 60, 144, 167, 182 ], "treat": [ 43 ], "high-risk": [ 44 ], "individuals": [ 45 ], "with": [ 46, 101, 111, 128, 137, 140, 156, 160 ], "a": [ 47 ], "glucagon-like": [ 48 ], "peptide": [ 49 ], "1": [ 50 ], "(GLP-1)": [ 51 ], "receptor": [ 52, 93 ], "agonist": [ 53 ], "or": [ 54, 74, 87, 173 ], "sodium\u2013glucose": [ 55 ], "cotransporter": [ 56 ], "2": [ 57, 103, 130, 158 ], "(SGLT2)": [ 58 ], "inhibitor": [ 59 ], "reduce": [ 61, 145 ], "major": [ 62 ], "adverse": [ 63 ], "events": [ 65 ], "(MACE),": [ 66 ], "hospitalization": [ 67 ], "heart": [ 69, 133, 138 ], "failure": [ 70, 139 ], "(hHF),": [ 71 ], "death,": [ 73, 150 ], "chronic": [ 75 ], "kidney": [ 76 ], "disease": [ 77, 108 ], "(CKD)": [ 78 ], "progression": [ 79, 185 ], "should": [ 80 ], "be": [ 81, 97 ], "considered": [ 82, 98 ], "independently": [ 83 ], "baseline": [ 85 ], "HbA1c": [ 86, 89 ], "individualized": [ 88 ], "target;": [ 90 ], "2)": [ 91 ], "GLP-1": [ 92 ], "agonists": [ 94 ], "can": [ 95 ], "also": [ 96 ], "patients": [ 100, 127, 155 ], "type": [ 102, 129, 157 ], "diabetes": [ 104, 131, 159 ], "without": [ 105 ], "established": [ 106 ], "(CVD)": [ 109 ], "but": [ 110 ], "presence": [ 113 ], "specific": [ 115 ], "indicators": [ 116 ], "high": [ 118 ], "risk;": [ 119 ], "3)": [ 121 ], "SGLT2": [ 122 ], "inhibitors": [ 123 ], "are": [ 124 ], "recommended": [ 125 ], "failure,": [ 134 ], "particularly": [ 135, 179 ], "those": [ 136 ], "reduced": [ 141 ], "ejection": [ 142 ], "fraction,": [ 143 ], "hHF,": [ 146, 188 ], "MACE,": [ 147, 189 ], "CVD": [ 149 ], "as": [ 151, 153 ], "well": [ 152 ], "CKD": [ 161 ], "(estimated": [ 162 ], "glomerular": [ 163 ], "filtration": [ 164 ], "rate": [ 165 ], "30": [ 166 ], "\u226460": [ 168 ], "mL": [ 169 ], "min\u20131": [ 170 ], "[1.73": [ 171 ], "m]\u20132": [ 172 ], "urinary": [ 174 ], "albumin-to-creatinine": [ 175 ], "ratio": [ 176 ], "&gt;30": [ 177 ], "mg/g,": [ 178 ], "&gt;300": [ 180 ], "mg/g)": [ 181 ], "prevent": [ 183 ], "CKD,": [ 187 ], "death.": [ 192 ] }, "publication_date": "2019-12-19", "publication_year": 2019, "type": "article", "cited_by_count": 1135, "authors": [ { "id": "https://openalex.org/A5040182038", "display_name": "John B. Buse" }, { "id": "https://openalex.org/A5076997901", "display_name": "Deborah J. Wexler" }, { "id": "https://openalex.org/A5018882870", "display_name": "\u0391\u03c0\u03cc\u03c3\u03c4\u03bf\u03bb\u03bf\u03c2 \u03a4\u03c3\u03ac\u03c0\u03b1\u03c2" }, { "id": "https://openalex.org/A5085592050", "display_name": "Peter Rossing" }, { "id": "https://openalex.org/A5053488036", "display_name": "Geltrude Mingrone" }, { "id": "https://openalex.org/A5053469409", "display_name": "Chantal Mathieu" }, { "id": "https://openalex.org/A5071074041", "display_name": "David A. D\u2019Alessio" }, { "id": "https://openalex.org/A5084593004", "display_name": "Melanie J. Davies" } ] }, { "id": "https://openalex.org/W2030270894", "doi": "https://doi.org/10.1523/jneurosci.0529-11.2011", "title": "The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease", "abstract": { "Type": [ 0 ], "2": [ 1 ], "diabetes": [ 2, 44 ], "is": [ 3 ], "a": [ 4, 242 ], "risk": [ 5 ], "factor": [ 6 ], "for": [ 7, 94, 246 ], "Alzheimer's": [ 8, 235, 247 ], "disease,": [ 9, 236 ], "most": [ 10 ], "likely": [ 11 ], "linked": [ 12 ], "to": [ 13, 50, 82, 211 ], "an": [ 14, 70, 88 ], "impairment": [ 15 ], "of": [ 16, 65, 132, 160, 184 ], "insulin": [ 17, 29 ], "signaling": [ 18 ], "in": [ 19, 54, 57, 69, 87, 105, 119, 135, 140, 147, 179, 187, 193, 220, 234 ], "the": [ 20, 41, 63, 84, 136, 148, 188, 221 ], "brain.": [ 21 ], "The": [ 22, 168 ], "incretin": [ 23 ], "hormone": [ 24 ], "glucagon-like": [ 25 ], "peptide-1": [ 26 ], "(GLP-1)": [ 27 ], "facilitates": [ 28 ], "signaling,": [ 30 ], "and": [ 31, 56, 108, 122, 126, 130, 150 ], "novel": [ 32, 243 ], "long-lasting": [ 33 ], "GLP-1": [ 34, 46, 239 ], "analogs,": [ 35 ], "such": [ 36 ], "as": [ 37, 43, 171 ], "liraglutide,": [ 38 ], "are": [ 39 ], "on": [ 40, 203 ], "market": [ 42 ], "therapeutics.": [ 45 ], "has": [ 47 ], "been": [ 48 ], "shown": [ 49, 81 ], "have": [ 51 ], "neuroprotective": [ 52 ], "properties": [ 53 ], "vitro": [ 55 ], "vivo": [ 58 ], ".": [ 59 ], "Here": [ 60 ], "we": [ 61 ], "tested": [ 62 ], "effects": [ 64 ], "peripherally": [ 66 ], "injected": [ 67, 93 ], "liraglutide": [ 68, 115, 228 ], "Alzheimer": [ 71 ], "mouse": [ 72 ], "model,": [ 73 ], "APP": [ 74 ], "swe": [ 75 ], "/PS1": [ 76 ], "\u0394E9": [ 77 ], "(APP/PS1).": [ 78 ], "Liraglutide": [ 79, 91, 198 ], "was": [ 80, 92, 177, 209, 218 ], "cross": [ 83 ], "blood\u2013brain": [ 85 ], "barrier": [ 86 ], "acute": [ 89 ], "study.": [ 90 ], "8": [ 95 ], "weeks": [ 96 ], "at": [ 97 ], "25": [ 98 ], "nmol/kg": [ 99 ], "body": [ 100 ], "weight": [ 101 ], "i.p.": [ 102 ], "once": [ 103 ], "daily": [ 104 ], "7-month-old": [ 106 ], "APP/PS1": [ 107, 113, 181, 194 ], "wild-type": [ 109, 212 ], "littermate": [ 110, 204 ], "controls.": [ 111 ], "In": [ 112 ], "mice,": [ 114, 206 ], "prevented": [ 116, 127 ], "memory": [ 117 ], "impairments": [ 118 ], "object": [ 120 ], "recognition": [ 121 ], "water": [ 123 ], "maze": [ 124 ], "tasks,": [ 125 ], "synapse": [ 128 ], "loss": [ 129 ], "deterioration": [ 131 ], "synaptic": [ 133, 216 ], "plasticity": [ 134, 217 ], "hippocampus,": [ 137 ], "commonly": [ 138 ], "observed": [ 139 ], "this": [ 141 ], "model.": [ 142 ], "Overall": [ 143 ], "\u03b2-amyloid": [ 144 ], "plaque": [ 145, 152 ], "count": [ 146 ], "cortex": [ 149 ], "dense-core": [ 151 ], "numbers": [ 153, 176 ], "were": [ 154, 164, 191 ], "reduced": [ 155, 165 ], "by": [ 156, 166, 173 ], "40\u201350%,": [ 157 ], "while": [ 158 ], "levels": [ 159 ], "soluble": [ 161 ], "amyloid": [ 162 ], "oligomers": [ 163 ], "25%.": [ 167 ], "inflammation": [ 169 ], "response": [ 170 ], "measured": [ 172 ], "activated": [ 174 ], "microglia": [ 175 ], "halved": [ 178 ], "liraglutide-treated": [ 180 ], "mice.": [ 182 ], "Numbers": [ 183 ], "young": [ 185 ], "neurons": [ 186 ], "dentate": [ 189 ], "gyrus": [ 190 ], "increased": [ 192 ], "mice": [ 195 ], "with": [ 196 ], "treatment.": [ 197 ], "treatment": [ 199, 244 ], "had": [ 200 ], "little": [ 201 ], "effect": [ 202 ], "control": [ 205 ], "whose": [ 207 ], "behavior": [ 208 ], "comparable": [ 210 ], "saline": [ 213 ], "controls;": [ 214 ], "however,": [ 215 ], "enhanced": [ 219 ], "drug": [ 222 ], "group.": [ 223 ], "Our": [ 224 ], "results": [ 225 ], "show": [ 226 ], "that": [ 227, 238 ], "prevents": [ 229 ], "key": [ 230 ], "neurodegenerative": [ 231 ], "developments": [ 232 ], "found": [ 233 ], "suggesting": [ 237 ], "analogs": [ 240 ], "represent": [ 241 ], "strategy": [ 245 ], "disease.": [ 248 ] }, "publication_date": "2011-04-27", "publication_year": 2011, "type": "article", "cited_by_count": 660, "authors": [ { "id": "https://openalex.org/A5004424324", "display_name": "Paula L. McClean" }, { "id": "https://openalex.org/A5066857047", "display_name": "Vadivel Parthsarathy" }, { "id": "https://openalex.org/A5091517952", "display_name": "\u00c9milie Faivre" }, { "id": "https://openalex.org/A5082707086", "display_name": "Christian H\u00f6lscher" } ] }, { "id": "https://openalex.org/W3015345942", "doi": "https://doi.org/10.2337/dc19-1892", "title": "Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes", "abstract": { "OBJECTIVE": [ 0 ], "To": [ 1 ], "determine": [ 2 ], "the": [ 3 ], "effect": [ 4 ], "of": [ 5, 10, 21 ], "tirzepatide,": [ 6 ], "a": [ 7, 81 ], "dual": [ 8 ], "agonist": [ 9 ], "glucose-dependent": [ 11 ], "insulinotropic": [ 12 ], "polypeptide": [ 13 ], "and": [ 14, 25, 76, 110, 132, 136, 169 ], "glucagon-like": [ 15 ], "peptide": [ 16 ], "1": [ 17 ], "receptors,": [ 18 ], "on": [ 19 ], "biomarkers": [ 20, 168 ], "nonalcoholic": [ 22 ], "steatohepatitis": [ 23 ], "(NASH)": [ 24 ], "fibrosis": [ 26 ], "in": [ 27, 64, 80, 93, 172 ], "patients": [ 28, 173 ], "with": [ 29, 40, 121, 126, 137, 149, 152, 174 ], "type": [ 30 ], "2": [ 31 ], "diabetes": [ 32 ], "mellitus": [ 33 ], "(T2DM).": [ 34 ], "RESEARCH": [ 35 ], "DESIGN": [ 36 ], "AND": [ 37 ], "METHODS": [ 38 ], "Patients": [ 39 ], "T2DM": [ 41 ], "received": [ 42 ], "either": [ 43 ], "once": [ 44 ], "weekly": [ 45 ], "tirzepatide": [ 46, 101, 122, 150, 163 ], "(1,": [ 47 ], "5,": [ 48, 106 ], "10,": [ 49, 107 ], "or": [ 50, 56 ], "15": [ 51, 108, 113, 142, 155 ], "mg),": [ 52, 55, 103, 109 ], "dulaglutide": [ 53, 138 ], "(1.5": [ 54 ], "placebo": [ 57, 127, 153 ], "for": [ 58, 128, 139 ], "26": [ 59, 118 ], "weeks.": [ 60, 119 ], "Changes": [ 61 ], "from": [ 62, 91, 147 ], "baseline": [ 63, 92, 148 ], "alanine": [ 65 ], "aminotransferase": [ 66, 69 ], "(ALT),": [ 67 ], "aspartate": [ 68 ], "(AST),": [ 70 ], "keratin-18": [ 71 ], "(K-18),": [ 72 ], "procollagen": [ 73 ], "III": [ 74 ], "(Pro-C3),": [ 75 ], "adiponectin": [ 77, 171 ], "were": [ 78, 115, 123 ], "analyzed": [ 79 ], "modified": [ 82 ], "intention-to-treat": [ 83 ], "population.": [ 84 ], "RESULTS": [ 85 ], "Significant": [ 86 ], "(P": [ 87 ], "&lt;": [ 88 ], "0.05)": [ 89 ], "reductions": [ 90 ], "ALT": [ 94, 140 ], "(all": [ 95, 98 ], "groups),": [ 96 ], "AST": [ 97 ], "groups": [ 99 ], "except": [ 100 ], "10": [ 102 ], "K-18": [ 104, 129 ], "(tirzepatide": [ 105, 112 ], "Pro-C3": [ 111, 133 ], "mg)": [ 114, 131, 135 ], "observed": [ 116 ], "at": [ 117 ], "Decreases": [ 120 ], "significant": [ 124 ], "compared": [ 125, 151 ], "(10": [ 130 ], "(15": [ 134 ], "(10,": [ 141, 154 ], "mg).": [ 143, 156 ], "Adiponectin": [ 144 ], "significantly": [ 145, 165 ], "increased": [ 146, 170 ], "CONCLUSIONS": [ 157 ], "In": [ 158 ], "post": [ 159 ], "hoc": [ 160 ], "analyses,": [ 161 ], "higher": [ 162 ], "doses": [ 164 ], "decreased": [ 166 ], "NASH-related": [ 167 ], "T2DM.": [ 175 ] }, "publication_date": "2020-04-14", "publication_year": 2020, "type": "article", "cited_by_count": 312, "authors": [ { "id": "https://openalex.org/A5057894973", "display_name": "Mark L. Hartman" }, { "id": "https://openalex.org/A5070639714", "display_name": "Arun J. Sanyal" }, { "id": "https://openalex.org/A5052059601", "display_name": "Rohit Loomba" }, { "id": "https://openalex.org/A5087372555", "display_name": "Jonathan M. Wilson" }, { "id": "https://openalex.org/A5061113397", "display_name": "Amir Nikooienejad" }, { "id": "https://openalex.org/A5091446537", "display_name": "Ross Bray" }, { "id": "https://openalex.org/A5030157221", "display_name": "Chrisanthi A. Karanikas" }, { "id": "https://openalex.org/A5072130761", "display_name": "Kevin L. Duffin" }, { "id": "https://openalex.org/A5081732583", "display_name": "Deborah A. Robins" }, { "id": "https://openalex.org/A5040811419", "display_name": "Axel Haupt" } ] }, { "id": "https://openalex.org/W2160001758", "doi": "https://doi.org/10.2337/dc08-2124", "title": "Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)", "abstract": { "OBJECTIVE": [ 0 ], "To": [ 1 ], "determine": [ 2 ], "the": [ 3, 97, 226 ], "efficacy": [ 4 ], "and": [ 5, 18, 56, 85, 111, 115, 128, 133, 136, 139, 147, 166, 173, 199, 204, 208, 215, 222, 259, 267 ], "safety": [ 6 ], "of": [ 7, 219 ], "liraglutide": [ 8, 40, 46, 98, 114, 156, 169, 207, 231 ], "(a": [ 9 ], "glucagon-like": [ 10 ], "peptide-1": [ 11 ], "receptor": [ 12 ], "agonist)": [ 13 ], "when": [ 14 ], "added": [ 15 ], "to": [ 16, 38 ], "metformin": [ 17, 51, 266 ], "rosiglitazone": [ 19, 57 ], "in": [ 20, 48, 96, 213, 225, 282 ], "type": [ 21, 64, 276 ], "2": [ 22, 65, 277 ], "diabetes.": [ 23 ], "RESEARCH": [ 24 ], "DESIGN": [ 25 ], "AND": [ 26 ], "METHODS": [ 27 ], "This": [ 28 ], "26-week,": [ 29 ], "double-blind,": [ 30 ], "placebo-controlled,": [ 31 ], "parallel-group": [ 32 ], "trial": [ 33 ], "randomized": [ 34 ], "533": [ 35 ], "subjects": [ 36 ], "(1:1:1)": [ 37 ], "once-daily": [ 39 ], "(1.2": [ 41 ], "or": [ 42, 45, 77 ], "1.8": [ 43, 112, 134, 167, 205 ], "mg)": [ 44 ], "placebo": [ 47, 101, 187 ], "combination": [ 49, 81, 273 ], "with": [ 50, 164, 183, 186, 202, 230, 239, 253, 265 ], "(1": [ 52 ], "g": [ 53 ], "twice": [ 54, 60 ], "daily)": [ 55 ], "(4": [ 58 ], "mg": [ 59, 113, 135, 168, 206 ], "daily).": [ 61 ], "Subjects": [ 62 ], "had": [ 63 ], "diabetes,": [ 66, 278 ], "A1C": [ 67, 91 ], "7\u201311%": [ 68 ], "(previous": [ 69, 79 ], "oral": [ 70 ], "antidiabetes": [ 71 ], "drug": [ 72 ], "[OAD]": [ 73 ], "monotherapy": [ 74 ], "\u22653": [ 75, 83 ], "months)": [ 76 ], "7\u201310%": [ 78 ], "OAD": [ 80 ], "therapy": [ 82, 274 ], "months),": [ 84 ], "BMI": [ 86 ], "\u226445": [ 87 ], "kg/m2.": [ 88 ], "RESULTS": [ 89 ], "Mean": [ 90 ], "values": [ 92 ], "decreased": [ 93, 124, 143, 195 ], "significantly": [ 94 ], "more": [ 95, 237, 251 ], "groups": [ 99, 157 ], "versus": [ 100, 232 ], "(mean": [ 102 ], "\u00b1": [ 103, 106, 117, 171, 175, 189 ], "SE": [ 104 ], "\u22121.5": [ 105 ], "0.1%": [ 107, 118 ], "for": [ 108, 119, 131, 154, 275 ], "both": [ 109 ], "1.2": [ 110, 132, 165, 203 ], "\u22120.5": [ 116 ], "placebo).": [ 120, 159 ], "Fasting": [ 121 ], "plasma": [ 122 ], "glucose": [ 123, 142 ], "by": [ 125, 144, 196 ], "40,": [ 126 ], "44,": [ 127 ], "8": [ 129 ], "mg/dl": [ 130 ], "placebo,": [ 137, 209 ], "respectively,": [ 138 ], "90-min": [ 140 ], "postprandial": [ 141 ], "47,": [ 145 ], "49,": [ 146 ], "14": [ 148 ], "mg/dl,": [ 149 ], "respectively": [ 150 ], "(P": [ 151, 179 ], "&lt;": [ 152, 180 ], "0.001": [ 153 ], "all": [ 155 ], "vs.": [ 158 ], "Dose-dependent": [ 160 ], "weight": [ 161, 184 ], "loss": [ 162 ], "occurred": [ 163, 229, 236, 257 ], "(1.0": [ 170 ], "0.3": [ 172, 176, 190 ], "2.0": [ 174 ], "kg,": [ 177 ], "respectively)": [ 178 ], "0.0001)": [ 181 ], "compared": [ 182 ], "gain": [ 185 ], "(0.6": [ 188 ], "kg).": [ 191 ], "Systolic": [ 192 ], "blood": [ 193 ], "pressure": [ 194 ], "6.7,": [ 197 ], "5.6,": [ 198 ], "1.1": [ 200 ], "mmHg": [ 201 ], "respectively.": [ 210 ], "Significant": [ 211 ], "increases": [ 212 ], "C-peptide": [ 214 ], "homeostasis": [ 216 ], "model": [ 217 ], "assessment": [ 218 ], "\u03b2-cell": [ 220 ], "function": [ 221 ], "significant": [ 223, 280 ], "decreases": [ 224 ], "proinsulin-to-insulin": [ 227 ], "ratio": [ 228 ], "placebo.": [ 233 ], "Minor": [ 234 ], "hypoglycemia": [ 235 ], "frequently": [ 238 ], "liraglutide,": [ 240, 254 ], "but": [ 241, 255 ], "there": [ 242 ], "was": [ 243 ], "no": [ 244 ], "major": [ 245 ], "hypoglycemia.": [ 246 ], "Gastrointestinal": [ 247 ], "adverse": [ 248 ], "events": [ 249 ], "were": [ 250, 260 ], "common": [ 252 ], "most": [ 256 ], "early": [ 258 ], "transient.": [ 261 ], "CONCLUSIONS": [ 262 ], "Liraglutide": [ 263 ], "combined": [ 264 ], "a": [ 268, 271 ], "thiazolidinedione": [ 269 ], "is": [ 270 ], "well-tolerated": [ 272 ], "providing": [ 279 ], "improvements": [ 281 ], "glycemic": [ 283 ], "control.": [ 284 ] }, "publication_date": "2009-03-16", "publication_year": 2009, "type": "article", "cited_by_count": 831, "authors": [ { "id": "https://openalex.org/A5090437675", "display_name": "Bernard Zinman" }, { "id": "https://openalex.org/A5012926020", "display_name": "John Gerich" }, { "id": "https://openalex.org/A5040182038", "display_name": "John B. Buse" }, { "id": "https://openalex.org/A5103371371", "display_name": "Andrew Lewin" }, { "id": "https://openalex.org/A5064307950", "display_name": "Sherwyn Schwartz" }, { "id": "https://openalex.org/A5015275535", "display_name": "Philip Raskin" }, { "id": "https://openalex.org/A5023487929", "display_name": "Paula M. Hale" }, { "id": "https://openalex.org/A5103492502", "display_name": "Milan Zdravkovic" }, { "id": "https://openalex.org/A5070289715", "display_name": "Lawrence Blonde" } ] }, { "id": "https://openalex.org/W2951522032", "doi": "https://doi.org/10.2337/dc19-0749", "title": "PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes", "abstract": { "OBJECTIVE": [ 0 ], "This": [ 1, 75 ], "trial": [ 2, 48, 57, 61, 85, 189, 228 ], "compared": [ 3 ], "the": [ 4, 9, 149, 254 ], "efficacy": [ 5 ], "and": [ 6, 33, 55, 102, 159, 185, 198, 207, 220, 241, 271, 287, 295 ], "safety": [ 7, 306 ], "of": [ 8, 47 ], "first": [ 10 ], "oral": [ 11, 18, 109, 166, 260, 269, 282 ], "glucagon-like": [ 12 ], "peptide": [ 13 ], "1": [ 14 ], "(GLP-1)": [ 15 ], "receptor": [ 16, 312 ], "agonist,": [ 17 ], "semaglutide,": [ 19 ], "as": [ 20 ], "monotherapy": [ 21, 284 ], "with": [ 22, 26, 94, 100, 259, 268, 273, 278, 304, 309 ], "placebo": [ 23 ], "in": [ 24, 67, 87, 90, 130, 144, 266, 291 ], "patients": [ 25, 151, 277 ], "type": [ 27, 95, 279 ], "2": [ 28, 96, 280 ], "diabetes": [ 29, 97 ], "managed": [ 30 ], "by": [ 31 ], "diet": [ 32, 101 ], "exercise": [ 34, 103 ], "alone.": [ 35 ], "Two": [ 36 ], "estimands": [ 37 ], "addressed": [ 38 ], "two": [ 39 ], "efficacy-related": [ 40 ], "questions:": [ 41 ], "a": [ 42, 56, 77, 305 ], "treatment": [ 43, 171, 176 ], "policy": [ 44, 177 ], "estimand": [ 45, 59 ], "(regardless": [ 46 ], "product": [ 49, 58, 62, 190, 263 ], "discontinuation": [ 50 ], "or": [ 51, 117 ], "rescue": [ 52, 64 ], "medication": [ 53, 65 ], "use)": [ 54, 66 ], "(on": [ 60 ], "without": [ 63 ], "all": [ 68 ], "randomized": [ 69, 105, 152 ], "patients.": [ 70 ], "RESEARCH": [ 71 ], "DESIGN": [ 72 ], "AND": [ 73 ], "METHODS": [ 74 ], "was": [ 76, 123, 137 ], "26-week,": [ 78 ], "phase": [ 79 ], "3a,": [ 80 ], "randomized,": [ 81 ], "double-blind,": [ 82 ], "placebo-controlled,": [ 83 ], "parallel-group": [ 84 ], "conducted": [ 86 ], "93": [ 88 ], "sites": [ 89 ], "nine": [ 91 ], "countries.": [ 92 ], "Adults": [ 93 ], "insufficiently": [ 98 ], "controlled": [ 99 ], "were": [ 104, 253 ], "(1:1:1:1)": [ 106 ], "to": [ 107, 127, 141 ], "once-daily": [ 108 ], "semaglutide": [ 110, 167, 270, 283 ], "3": [ 111 ], "mg,": [ 112, 114, 116, 224, 237, 245 ], "7": [ 113 ], "14": [ 115 ], "placebo.": [ 118, 274 ], "The": [ 119, 132 ], "primary": [ 120 ], "end": [ 121, 135 ], "point": [ 122, 136 ], "change": [ 124, 138 ], "from": [ 125, 139 ], "baseline": [ 126, 140, 161 ], "week": [ 128, 142, 174 ], "26": [ 129, 143 ], "HbA1c.": [ 131 ], "confirmatory": [ 133 ], "secondary": [ 134 ], "body": [ 145, 208, 296 ], "weight.": [ 146 ], "RESULTS": [ 147 ], "In": [ 148, 276 ], "703": [ 150 ], "(mean": [ 153 ], "age": [ 154 ], "55": [ 155 ], "years,": [ 156 ], "50.8%": [ 157 ], "male,": [ 158 ], "mean": [ 160 ], "HbA1c": [ 162, 169, 292 ], "8.0%": [ 163 ], "[64": [ 164 ], "mmol/mol]),": [ 165 ], "reduced": [ 168 ], "(placebo-adjusted": [ 170 ], "differences": [ 172 ], "at": [ 173 ], "26:": [ 175 ], "estimand,": [ 178, 191 ], "\u22120.6%": [ 179 ], "[3": [ 180, 193, 214, 232 ], "mg],": [ 181, 184, 194, 197, 215, 219, 233 ], "\u22120.9%": [ 182 ], "[7": [ 183, 196, 218, 236 ], "\u22121.1%": [ 186 ], "[14": [ 187, 200, 223, 244 ], "mg];": [ 188, 201 ], "\u22120.7%": [ 192 ], "\u22121.2%": [ 195 ], "\u22121.4%": [ 199 ], "P": [ 202, 225, 238, 246 ], "&lt;": [ 203, 226, 247 ], "0.001": [ 204 ], "for": [ 205 ], "all)": [ 206 ], "weight": [ 209, 297 ], "(treatment": [ 210 ], "policy,": [ 211 ], "\u22120.1": [ 212 ], "kg": [ 213, 217, 222, 231, 235, 243 ], "\u22120.9": [ 216 ], "\u22122.3": [ 221 ], "0.001];": [ 227 ], "product,": [ 229 ], "\u22120.2": [ 230 ], "\u22121.0": [ 234 ], "=": [ 239 ], "0.01],": [ 240 ], "\u22122.6": [ 242 ], "0.001]).": [ 248 ], "Mild-to-moderate": [ 249 ], "transient": [ 250 ], "gastrointestinal": [ 251 ], "events": [ 252, 258 ], "most": [ 255 ], "common": [ 256 ], "adverse": [ 257 ], "semaglutide.": [ 261 ], "Trial": [ 262 ], "discontinuations": [ 264 ], "occurred": [ 265 ], "2.3\u20137.4%": [ 267 ], "2.2%": [ 272 ], "CONCLUSIONS": [ 275 ], "diabetes,": [ 281 ], "demonstrated": [ 285 ], "superior": [ 286 ], "clinically": [ 288 ], "relevant": [ 289 ], "improvements": [ 290 ], "(all": [ 293 ], "doses)": [ 294 ], "loss": [ 298 ], "(14": [ 299 ], "mg": [ 300 ], "dose)": [ 301 ], "versus": [ 302 ], "placebo,": [ 303 ], "profile": [ 307 ], "consistent": [ 308 ], "other": [ 310 ], "GLP-1": [ 311 ], "agonists.": [ 313 ] }, "publication_date": "2019-06-11", "publication_year": 2019, "type": "article", "cited_by_count": 414, "authors": [ { "id": "https://openalex.org/A5005405894", "display_name": "Vanita R. Aroda" }, { "id": "https://openalex.org/A5045489578", "display_name": "Julio Rosenstock" }, { "id": "https://openalex.org/A5088387334", "display_name": "Yasuo Terauchi" }, { "id": "https://openalex.org/A5086580698", "display_name": "Y\u00fcksel Altunta\u015f" }, { "id": "https://openalex.org/A5103854967", "display_name": "Nebojsa M. Lalic" }, { "id": "https://openalex.org/A5046428704", "display_name": "Enrique C. Morales Villegas" }, { "id": "https://openalex.org/A5055974284", "display_name": "Ole Kleist Jeppesen" }, { "id": "https://openalex.org/A5036497949", "display_name": "Erik Christiansen" }, { "id": "https://openalex.org/A5112539846", "display_name": "CHRISTIN L. HERTZ" }, { "id": "https://openalex.org/A5023584418", "display_name": "Martin Haluz\u0131\u0301k" }, { "id": "https://openalex.org/A5112446154", "display_name": "Krim Belkacem" }, { "id": "https://openalex.org/A5080544796", "display_name": "Nabil Chiali" }, { "id": "https://openalex.org/A5098433777", "display_name": "Samia Bourezane" }, { "id": "https://openalex.org/A5034215235", "display_name": "R. Guermaz" }, { "id": "https://openalex.org/A5109112738", "display_name": "P Popivanov" }, { "id": "https://openalex.org/A5049976190", "display_name": "Ivaylo Lefterov" }, { "id": "https://openalex.org/A5064505204", "display_name": "Tsvetalina Tankova" }, { "id": "https://openalex.org/A5087097726", "display_name": "I Penchev" }, { "id": "https://openalex.org/A5098130005", "display_name": "Martina Ko\u0161kov\u00e1" }, { "id": "https://openalex.org/A5112139538", "display_name": "Miroslava Hudcova" }, { "id": "https://openalex.org/A5109169257", "display_name": "A. Vesel\u00e1" }, { "id": "https://openalex.org/A5098104344", "display_name": "Anna Rancova" }, { "id": "https://openalex.org/A5023584418", "display_name": "Martin Haluz\u0131\u0301k" }, { "id": "https://openalex.org/A5068421637", "display_name": "Arihiro Kiyosue" }, { "id": "https://openalex.org/A5020583276", "display_name": "Osamu Matsuoka" }, { "id": "https://openalex.org/A5105592918", "display_name": "Satoshi Inoue" }, { "id": "https://openalex.org/A5088387334", "display_name": "Yasuo Terauchi" }, { "id": "https://openalex.org/A5007583907", "display_name": "Yasushi Fukushima" }, { "id": "https://openalex.org/A5084908775", "display_name": "Yumiko Ide" }, { "id": "https://openalex.org/A5113835756", "display_name": "R. Ortiz" }, { "id": "https://openalex.org/A5112446155", "display_name": "Enrique Villegas" }, { "id": "https://openalex.org/A5083611299", "display_name": "Albina Golovach" }, { "id": "https://openalex.org/A5027455418", "display_name": "Diana Alpenidze" }, { "id": "https://openalex.org/A5018118772", "display_name": "Elena Frolova" }, { "id": "https://openalex.org/A5104026855", "display_name": "Elena Zhdanova" }, { "id": "https://openalex.org/A5058259461", "display_name": "Ludmila Ruyatkina" }, { "id": "https://openalex.org/A5070385243", "display_name": "\u041e. \u0411. \u0415\u0440\u0448\u043e\u0432\u0430" }, { "id": "https://openalex.org/A5010120589", "display_name": "\u042e. \u0413. \u0421\u0430\u043c\u043e\u0439\u043b\u043e\u0432\u0430" }, { "id": "https://openalex.org/A5049708484", "display_name": "S. T. Zyangirova" }, { "id": "https://openalex.org/A5088531614", "display_name": "Katarina Lali\u0107" }, { "id": "https://openalex.org/A5000893155", "display_name": "Neboj\u0161a Lali\u0107" }, { "id": "https://openalex.org/A5046911517", "display_name": "Teodora Belji\u0107 \u017divkovi\u0107" }, { "id": "https://openalex.org/A5075472863", "display_name": "Hayriye Esra Atao\u011flu" }, { "id": "https://openalex.org/A5011972215", "display_name": "Okan Bak\u0131ner" }, { "id": "https://openalex.org/A5068955624", "display_name": "A. D. Dayan" }, { "id": "https://openalex.org/A5101919371", "display_name": "Mehmet Sarg\u0131n" }, { "id": "https://openalex.org/A5066457365", "display_name": "Meral Mert" }, { "id": "https://openalex.org/A5008163527", "display_name": "Mine Ada\u015f" }, { "id": "https://openalex.org/A5019315656", "display_name": "\u00d6m\u00fcr Tabak" }, { "id": "https://openalex.org/A5086580698", "display_name": "Y\u00fcksel Altunta\u015f" }, { "id": "https://openalex.org/A5109425508", "display_name": "Alexander V. Murray" }, { "id": "https://openalex.org/A5059777426", "display_name": "Ali Iranmanesh" }, { "id": "https://openalex.org/A5079147062", "display_name": "Aron Schlau" }, { "id": "https://openalex.org/A5033552004", "display_name": "Bram Wieskopf" }, { "id": "https://openalex.org/A5033229659", "display_name": "Brian D. Snyder" }, { "id": "https://openalex.org/A5027130773", "display_name": "Carl J. Griffin" }, { "id": "https://openalex.org/A5052604055", "display_name": "Charles Fogarty" }, { "id": "https://openalex.org/A5075397209", "display_name": "Charles Lovell" }, { "id": "https://openalex.org/A5023839322", "display_name": "Nils Holger Petersen" }, { "id": "https://openalex.org/A5055650452", "display_name": "David Fitzpatrick" }, { "id": "https://openalex.org/A5110062545", "display_name": "David Grant" }, { "id": "https://openalex.org/A5086077960", "display_name": "David C. Klonoff" }, { "id": "https://openalex.org/A5112201748", "display_name": "Dwayne Williams" }, { "id": "https://openalex.org/A5072114600", "display_name": "Eddie Armas" }, { "id": "https://openalex.org/A5082136707", "display_name": "Eileen Palace" }, { "id": "https://openalex.org/A5112146338", "display_name": "Gary Ruoff" }, { "id": "https://openalex.org/A5110125474", "display_name": "Gilbert Martinez" }, { "id": "https://openalex.org/A5010682647", "display_name": "Gilberto Perez" }, { "id": "https://openalex.org/A5053191013", "display_name": "Harold Bays" }, { "id": "https://openalex.org/A5084505649", "display_name": "Horia Tatu" }, { "id": "https://openalex.org/A5108264153", "display_name": "James Maynard" }, { "id": "https://openalex.org/A5104112199", "display_name": "Jeanne-Elyse Cedeno" }, { "id": "https://openalex.org/A5005405894", "display_name": "Vanita R. Aroda" }, { "id": "https://openalex.org/A5037529101", "display_name": "Jean Park" }, { "id": "https://openalex.org/A5060840226", "display_name": "Jennefer Sutton" }, { "id": "https://openalex.org/A5013096249", "display_name": "Joe Pouzar" }, { "id": "https://openalex.org/A5042804015", "display_name": "John Bertsch" }, { "id": "https://openalex.org/A5071128993", "display_name": "Jonathan Condit" }, { "id": "https://openalex.org/A5098346898", "display_name": "Jorge Serje" }, { "id": "https://openalex.org/A5010816838", "display_name": "Josel Cabaccan" }, { "id": "https://openalex.org/A5043837364", "display_name": "Joseph Risser" }, { "id": "https://openalex.org/A5086072427", "display_name": "Juan P. Fr\u00edas" }, { "id": "https://openalex.org/A5045489578", "display_name": "Julio Rosenstock" }, { "id": "https://openalex.org/A5113977358", "display_name": "Kanagaratnam Sivalingam" }, { "id": "https://openalex.org/A5112446156", "display_name": "Kelli Maw" }, { "id": "https://openalex.org/A5059966967", "display_name": "Lenita Hanson" }, { "id": "https://openalex.org/A5087749895", "display_name": "Liana K. Billings" }, { "id": "https://openalex.org/A5108774960", "display_name": "Lisa Connery" }, { "id": "https://openalex.org/A5108774663", "display_name": "Mario Juarez" }, { "id": "https://openalex.org/A5060303776", "display_name": "Michael Lillestol" }, { "id": "https://openalex.org/A5109031653", "display_name": "Neil Fraser" }, { "id": "https://openalex.org/A5073543671", "display_name": "Paul Beckett" }, { "id": "https://openalex.org/A5042406838", "display_name": "Ralph Wade" }, { "id": "https://openalex.org/A5059005025", "display_name": "Raul Gaona" }, { "id": "https://openalex.org/A5065370427", "display_name": "Richard F. W. Jackson" }, { "id": "https://openalex.org/A5050631819", "display_name": "Robert DeLuca" }, { "id": "https://openalex.org/A5082914721", "display_name": "Sady Alpizar" }, { "id": "https://openalex.org/A5069608211", "display_name": "Sharon J. Herring" }, { "id": "https://openalex.org/A5035076634", "display_name": "Stanley Stringam" }, { "id": "https://openalex.org/A5028221586", "display_name": "Steven M. Bauer" } ] }, { "id": "https://openalex.org/W4304080455", "doi": "https://doi.org/10.1038/s41591-022-02026-4", "title": "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial", "abstract": { "Abstract": [ 0 ], "The": [ 1, 39, 145 ], "STEP": [ 2 ], "5": [ 3, 74 ], "trial": [ 4, 105 ], "assessed": [ 5, 61 ], "the": [ 6, 43, 104, 107, 159, 194, 199 ], "efficacy": [ 7 ], "and": [ 8, 49, 117, 139 ], "safety": [ 9, 109 ], "of": [ 10, 25, 51, 54, 67, 101, 126, 133, 141, 179 ], "once-weekly": [ 11 ], "subcutaneous": [ 12 ], "semaglutide": [ 13, 87, 160, 195, 227, 248 ], "2.4": [ 14, 88 ], "mg": [ 15, 89 ], "versus": [ 16, 166, 212, 232, 259 ], "placebo": [ 17, 95, 169, 200, 230 ], "(both": [ 18 ], "plus": [ 19 ], "behavioral": [ 20 ], "intervention)": [ 21 ], "for": [ 22, 174 ], "long-term": [ 23 ], "treatment": [ 24, 68, 177, 249 ], "adults": [ 26, 237 ], "with": [ 27, 31, 121, 168, 226, 229, 238 ], "obesity,": [ 28, 247 ], "or": [ 29, 70, 94, 246 ], "overweight": [ 30, 239 ], "at": [ 32, 56, 208, 241 ], "least": [ 33, 242 ], "one": [ 34, 243 ], "weight-related": [ 35, 244 ], "comorbidity,": [ 36 ], "without": [ 37 ], "diabetes.": [ 38 ], "co-primary": [ 40 ], "endpoints": [ 41 ], "were": [ 42, 83, 113, 222 ], "percentage": [ 44 ], "change": [ 45, 147 ], "in": [ 46, 148, 158, 193, 198, 236 ], "body": [ 47, 130, 149 ], "weight": [ 48, 52, 140, 150, 203, 254 ], "achievement": [ 50 ], "loss": [ 53, 204, 255 ], "\u22655%": [ 55, 205 ], "week": [ 57, 154, 209 ], "104.": [ 58 ], "Efficacy": [ 59 ], "was": [ 60, 156 ], "among": [ 62 ], "all": [ 63 ], "randomized": [ 64 ], "participants": [ 65, 82, 112, 192 ], "regardless": [ 66 ], "discontinuation": [ 69 ], "rescue": [ 71 ], "intervention.": [ 72 ], "From": [ 73 ], "October": [ 75 ], "2018": [ 76 ], "to": [ 77, 86, 153, 186, 251 ], "1": [ 78 ], "February": [ 79 ], "2019,": [ 80 ], "304": [ 81 ], "randomly": [ 84 ], "assigned": [ 85 ], "(": [ 90, 96, 162, 170 ], "n": [ 91, 97, 163, 171 ], "=": [ 92, 98, 164, 172 ], "152)": [ 93, 165 ], "152),": [ 99, 173 ], "92.8%": [ 100 ], "whom": [ 102 ], "completed": [ 103 ], "(attended": [ 106 ], "end-of-trial": [ 108 ], "visit).": [ 110 ], "Most": [ 111 ], "female": [ 114 ], "(236": [ 115 ], "(77.6%))": [ 116 ], "white": [ 118 ], "(283": [ 119 ], "(93.1%)),": [ 120 ], "a": [ 122 ], "mean": [ 123, 146 ], "(s.d.)": [ 124 ], "age": [ 125 ], "47.3": [ 127 ], "(11.0)": [ 128 ], "years,": [ 129 ], "mass": [ 131 ], "index": [ 132 ], "38.5": [ 134 ], "(6.9)": [ 135 ], "kg": [ 136 ], "m": [ 137 ], "\u20132": [ 138 ], "106.0": [ 142 ], "(22.0)": [ 143 ], "kg.": [ 144 ], "from": [ 151, 206 ], "baseline": [ 152, 207 ], "104": [ 155, 210, 257 ], "\u221215.2%": [ 157 ], "group": [ 161, 196, 201 ], "\u22122.6%": [ 167 ], "an": [ 175 ], "estimated": [ 176 ], "difference": [ 178 ], "\u221212.6": [ 180 ], "%-points": [ 181 ], "(95%": [ 182 ], "confidence": [ 183 ], "interval,": [ 184 ], "\u221215.3": [ 185 ], "\u22129.8;": [ 187 ], "P": [ 188, 214 ], "<": [ 189, 215 ], "0.0001).": [ 190, 216 ], "More": [ 191 ], "than": [ 197, 228 ], "achieved": [ 202 ], "(77.1%": [ 211 ], "34.4%;": [ 213 ], "Gastrointestinal": [ 217 ], "adverse": [ 218 ], "events,": [ 219 ], "mostly": [ 220 ], "mild-to-moderate,": [ 221 ], "reported": [ 223 ], "more": [ 224 ], "often": [ 225 ], "(82.2%": [ 231 ], "53.9%).": [ 233 ], "In": [ 234 ], "summary,": [ 235 ], "(with": [ 240 ], "comorbidity)": [ 245 ], "led": [ 250 ], "substantial,": [ 252 ], "sustained": [ 253 ], "over": [ 256 ], "weeks": [ 258 ], "placebo.": [ 260 ], "NCT03693430": [ 261 ] }, "publication_date": "2022-10-01", "publication_year": 2022, "type": "article", "cited_by_count": 625, "authors": [ { "id": "https://openalex.org/A5038221659", "display_name": "W. Timothy Garvey" }, { "id": "https://openalex.org/A5085481226", "display_name": "Rachel L. Batterham" }, { "id": "https://openalex.org/A5049042396", "display_name": "Meena Bhatta" }, { "id": "https://openalex.org/A5052679600", "display_name": "Silvio Buscemi" }, { "id": "https://openalex.org/A5003160509", "display_name": "Louise Christensen" }, { "id": "https://openalex.org/A5086072427", "display_name": "Juan P. Fr\u00edas" }, { "id": "https://openalex.org/A5088506788", "display_name": "Esteban J\u00f3dar" }, { "id": "https://openalex.org/A5081590711", "display_name": "Kristian Kandler" }, { "id": "https://openalex.org/A5020292142", "display_name": "Georgia Rigas" }, { "id": "https://openalex.org/A5026596594", "display_name": "Thomas A. Wadden" }, { "id": "https://openalex.org/A5027441223", "display_name": "Sean Wharton" } ] }, { "id": "https://openalex.org/W1526784932", "doi": "https://doi.org/10.1111/j.1755-5922.2010.00256.x", "title": "The Cardiovascular Effects of GLP\u20101 Receptor Agonists", "abstract": { "SUMMARY": [ 0 ], "Glucagon\u2010like": [ 1 ], "peptide\u20101": [ 2 ], "receptor": [ 3 ], "(GLP\u20101R)": [ 4 ], "agonists": [ 5, 48, 88, 157, 181, 204, 230 ], "have": [ 6, 31, 115 ], "been": [ 7, 33, 116 ], "shown": [ 8 ], "to": [ 9, 43, 64, 205, 226, 235 ], "regulate": [ 10 ], "blood": [ 11, 40, 159 ], "glucose": [ 12 ], "concentrations": [ 13 ], "by": [ 14 ], "mechanisms": [ 15 ], "including": [ 16 ], "enhanced": [ 17, 27 ], "insulin": [ 18 ], "synthesis/secretion,": [ 19 ], "suppressed": [ 20 ], "glucagon": [ 21 ], "secretion,": [ 22 ], "slowed": [ 23 ], "gastric": [ 24 ], "emptying,": [ 25 ], "and": [ 26, 39, 66, 69, 108, 127, 168, 191, 215 ], "satiety.": [ 28 ], "GLP\u20101": [ 29, 122 ], "receptors": [ 30 ], "also": [ 32, 177 ], "identified": [ 34 ], "in": [ 35, 111, 118, 124 ], "the": [ 36, 44, 77, 86, 199 ], "heart,": [ 37 ], "kidneys,": [ 38 ], "vessels,": [ 41 ], "leading": [ 42 ], "hypothesis": [ 45 ], "that": [ 46, 95, 154, 169, 179 ], "GLP\u20101R": [ 47, 81, 87, 96, 156, 180, 203, 229 ], "may": [ 49 ], "affect": [ 50 ], "cardiovascular": [ 51, 54, 78 ], "function": [ 52, 110 ], "or": [ 53, 91, 149, 151, 240 ], "disease": [ 55 ], "(CVD).": [ 56 ], "The": [ 57 ], "aim": [ 58 ], "of": [ 59, 72, 80, 136, 140, 165, 184, 201, 209 ], "this": [ 60 ], "literature": [ 61 ], "review": [ 62 ], "was": [ 63 ], "assemble": [ 65 ], "assess": [ 67 ], "preclinical": [ 68 ], "clinical": [ 70 ], "data": [ 71, 176, 225 ], "potential": [ 73 ], "medical": [ 74 ], "importance": [ 75 ], "regarding": [ 76 ], "effects": [ 79, 200 ], "agonists.": [ 82 ], "Preclinical": [ 83 ], "studies": [ 84, 120, 139, 196, 221 ], "with": [ 85, 129, 142, 147, 217, 241 ], "GLP\u20101,": [ 89 ], "exenatide,": [ 90 ], "liraglutide": [ 92, 170 ], "provided": [ 93 ], "evidence": [ 94 ], "stimulation": [ 97 ], "favorably": [ 98 ], "affects": [ 99 ], "endothelial": [ 100 ], "function,": [ 101 ], "sodium": [ 102 ], "excretion,": [ 103 ], "recovery": [ 104 ], "from": [ 105 ], "ischemic": [ 106 ], "injury,": [ 107 ], "myocardial": [ 109 ], "animals.": [ 112 ], "Similar": [ 113 ], "observations": [ 114 ], "made": [ 117 ], "exploratory": [ 119 ], "on": [ 121 ], "infusion": [ 123 ], "normal": [ 125 ], "subjects": [ 126 ], "patients": [ 128, 141, 206, 216, 236 ], "type": [ 130, 143 ], "2": [ 131, 144 ], "diabetes.": [ 132 ], "Post": [ 133 ], "hoc": [ 134 ], "analyses": [ 135 ], "phase": [ 137 ], "III": [ 138 ], "diabetes": [ 145 ], "treated": [ 146 ], "exenatide(bid": [ 148 ], "qw)": [ 150 ], "liraglutide(qd)": [ 152 ], "showed": [ 153 ], "these": [ 155 ], "reduced": [ 158, 182 ], "pressure,": [ 160 ], "an": [ 161 ], "effect": [ 162 ], "largely": [ 163 ], "independent": [ 164 ], "weight": [ 166 ], "loss,": [ 167 ], "slightly": [ 171 ], "increased": [ 172 ], "heart": [ 173, 218 ], "rate.": [ 174 ], "Preliminary": [ 175 ], "indicated": [ 178 ], "markers": [ 183 ], "CVD": [ 185 ], "risk": [ 186, 208, 238 ], "such": [ 187 ], "as": [ 188 ], "C\u2010reactive": [ 189 ], "protein": [ 190 ], "plasminogen": [ 192 ], "activator": [ 193 ], "inhibitor\u20101.": [ 194 ], "Ongoing": [ 195 ], "are": [ 197 ], "examining": [ 198 ], "administering": [ 202 ], "at": [ 207, 237 ], "CVD,": [ 210 ], "postangioplasty": [ 211 ], "patients,": [ 212, 214 ], "post\u2010CABG": [ 213 ], "failure.": [ 219 ], "Additional": [ 220 ], "should": [ 222 ], "provide": [ 223, 231 ], "meaningful": [ 224 ], "determine": [ 227 ], "whether": [ 228 ], "unique": [ 232 ], "treatment": [ 233 ], "benefits": [ 234 ], "for": [ 239 ], "established": [ 242 ], "CVD.": [ 243 ] }, "publication_date": "2010-12-19", "publication_year": 2010, "type": "review", "cited_by_count": 133, "authors": [ { "id": "https://openalex.org/A5016623368", "display_name": "Theodore Okerson" }, { "id": "https://openalex.org/A5083786375", "display_name": "Robert \u0106hilton" } ] }, { "id": "https://openalex.org/W2940562424", "doi": "https://doi.org/10.1016/j.rbmo.2019.04.017", "title": "GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis", "abstract": null, "publication_date": "2019-04-25", "publication_year": 2019, "type": "review", "cited_by_count": 140, "authors": [ { "id": "https://openalex.org/A5017841122", "display_name": "Yi Han" }, { "id": "https://openalex.org/A5100425082", "display_name": "Yingjie Li" }, { "id": "https://openalex.org/A5044734672", "display_name": "Bing He" } ] }, { "id": "https://openalex.org/W2790574529", "doi": "https://doi.org/10.1111/dom.13162", "title": "A review of GLP\u20101 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials", "abstract": { "Aims": [ 0 ], "To": [ 1 ], "review": [ 2, 37 ], "the": [ 3, 14, 111, 118, 125 ], "evolution": [ 4 ], "and": [ 5, 26, 32, 49, 65, 75, 92, 132, 152, 159 ], "advancement": [ 6 ], "of": [ 7, 16, 38, 51, 60, 84, 106, 114, 120, 145 ], "GLP\u20101": [ 8, 53, 68, 115, 127 ], "receptor": [ 9 ], "agonist": [ 10 ], "(GLP\u20101RA)": [ 11 ], "therapy,": [ 12 ], "through": [ 13, 148 ], "lens": [ 15 ], "randomised": [ 17 ], "controlled": [ 18 ], "trials,": [ 19 ], "from": [ 20 ], "differentiating": [ 21 ], "characteristics,": [ 22 ], "efficacy,": [ 23, 47 ], "safety,": [ 24, 48 ], "tolerability,": [ 25 ], "cardiovascular": [ 27, 96 ], "outcomes,": [ 28 ], "to": [ 29, 77, 87, 140, 157 ], "evidence": [ 30, 93, 146 ], "gaps": [ 31 ], "next": [ 33 ], "steps.": [ 34 ], "Methods": [ 35 ], "Clinical": [ 36 ], "published": [ 39 ], "phase": [ 40 ], "3": [ 41 ], "or": [ 42 ], "later": [ 43 ], "RCT": [ 44 ], "data": [ 45 ], "studying": [ 46 ], "outcomes": [ 50, 97 ], "approved": [ 52 ], "RA": [ 54 ], "therapies.": [ 55 ], "Results": [ 56 ], "Through": [ 57 ], "a": [ 58, 104 ], "wealth": [ 59 ], "studies,": [ 61, 67, 154 ], "including": [ 62 ], "both": [ 63, 150 ], "placebo\u2010controlled": [ 64 ], "active\u2010controlled": [ 66 ], "RAs": [ 69, 116 ], "have": [ 70, 109 ], "demonstrated": [ 71 ], "high": [ 72 ], "glycemic": [ 73 ], "efficacy": [ 74 ], "ability": [ 76 ], "facilitate": [ 78 ], "weight": [ 79 ], "loss,": [ 80 ], "with": [ 81 ], "minimal": [ 82 ], "risk": [ 83 ], "hypoglycemia,": [ 85 ], "potential": [ 86 ], "restore": [ 88 ], "beta": [ 89 ], "cell": [ 90 ], "function,": [ 91 ], "for": [ 94, 137 ], "improved": [ 95 ], "in": [ 98, 117, 129, 164 ], "those": [ 99 ], "at": [ 100 ], "risk.": [ 101 ], "Conclusions": [ 102 ], "Over": [ 103 ], "decade": [ 105 ], "clinical": [ 107, 133, 141 ], "studies": [ 108 ], "established": [ 110 ], "unique": [ 112 ], "contributions": [ 113 ], "treatment": [ 119 ], "diabetes.": [ 121 ], "Individual": [ 122 ], "differences": [ 123 ], "between": [ 124 ], "different": [ 126 ], "RAs,": [ 128 ], "delivery,": [ 130 ], "pharmacokinetic": [ 131 ], "effects,": [ 134 ], "exist,": [ 135 ], "allowing": [ 136 ], "tailored": [ 138 ], "approaches": [ 139 ], "care.": [ 142, 166 ], "The": [ 143 ], "strength": [ 144 ], "generated": [ 147 ], "RCTs,": [ 149 ], "short\u2010term": [ 151 ], "long\u2010term": [ 153 ], "will": [ 155 ], "continue": [ 156 ], "evolve": [ 158 ], "inform": [ 160 ], "our": [ 161 ], "current": [ 162 ], "paradigms": [ 163 ], "diabetes": [ 165 ] }, "publication_date": "2018-01-24", "publication_year": 2018, "type": "review", "cited_by_count": 247, "authors": [ { "id": "https://openalex.org/A5005405894", "display_name": "Vanita R. Aroda" } ] }, { "id": "https://openalex.org/W4205651374", "doi": "https://doi.org/10.1001/jama.2021.23619", "title": "Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes", "abstract": { "ClinicalTrials.gov": [ 0 ], "Identifier:": [ 1 ], "NCT04074161.": [ 2 ] }, "publication_date": "2022-01-11", "publication_year": 2022, "type": "article", "cited_by_count": 745, "authors": [ { "id": "https://openalex.org/A2488271461", "display_name": "Domenica M Rubino" }, { "id": "https://openalex.org/A390485263", "display_name": "Frank L Greenway" }, { "id": "https://openalex.org/A2005920384", "display_name": "Usman Khalid" }, { "id": "https://openalex.org/A4208053130", "display_name": "Patrick M. O\u2019Neil" }, { "id": "https://openalex.org/A1348679775", "display_name": "JULIO ROSENSTOCK" }, { "id": "https://openalex.org/A306656311", "display_name": "Rasmus S\u00f8rrig" }, { "id": "https://openalex.org/A2297614858", "display_name": "Thomas A. Wadden" }, { "id": "https://openalex.org/A2079297014", "display_name": "Alicja Wizert" }, { "id": "https://openalex.org/A2247335857", "display_name": "W Timothy Garvey" }, { "id": null, "display_name": "STEP 8 Investigators" }, { "id": "https://openalex.org/A4208053135", "display_name": "Carlos Arauz-Pacheco" }, { "id": "https://openalex.org/A2070581405", "display_name": "Kevin Cannon" }, { "id": "https://openalex.org/A2548027018", "display_name": "H. Jackson Downey" }, { "id": "https://openalex.org/A4208053138", "display_name": "David Fitz-Patrick" }, { "id": "https://openalex.org/A1975546430", "display_name": "Jeffrey Geohas" }, { "id": "https://openalex.org/A2765487754", "display_name": "Gregg Gerety" }, { "id": "https://openalex.org/A1911603113", "display_name": "John Gilbert" }, { "id": "https://openalex.org/A1939813269", "display_name": "Priscilla Hollander" }, { "id": "https://openalex.org/A2135868136", "display_name": "Eric Klein" }, { "id": "https://openalex.org/A4208053143", "display_name": "Karen Laufer" }, { "id": "https://openalex.org/A4208053144", "display_name": "Philip O Donnell" }, { "id": "https://openalex.org/A2494017831", "display_name": "Paul Rosenblit" }, { "id": "https://openalex.org/A2130240681", "display_name": "Phillip Toth" } ] }, { "id": "https://openalex.org/W2895135221", "doi": "https://doi.org/10.1016/j.molmet.2018.09.009", "title": "LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept", "abstract": null, "publication_date": "2018-10-03", "publication_year": 2018, "type": "article", "cited_by_count": 728, "authors": [ { "id": "https://openalex.org/A5054260296", "display_name": "Tamer Co\u015fkun" }, { "id": "https://openalex.org/A5068951024", "display_name": "Kyle W. Sloop" }, { "id": "https://openalex.org/A5030999700", "display_name": "Corina Loghin" }, { "id": "https://openalex.org/A5067913727", "display_name": "Jorge Alsina\u2010Fernandez" }, { "id": "https://openalex.org/A5031510744", "display_name": "Shweta Urva" }, { "id": "https://openalex.org/A5090291879", "display_name": "Krister Bokvist" }, { "id": "https://openalex.org/A5058864022", "display_name": "Xuewei Cui" }, { "id": "https://openalex.org/A5046834158", "display_name": "Daniel A. Briere" }, { "id": "https://openalex.org/A5065870082", "display_name": "Over Cabrera" }, { "id": "https://openalex.org/A5040082320", "display_name": "William C. Roell" }, { "id": "https://openalex.org/A5078428155", "display_name": "Uma Kuchibhotla" }, { "id": "https://openalex.org/A5001702290", "display_name": "Julie S. Moyers" }, { "id": "https://openalex.org/A5023603655", "display_name": "Charles Benson" }, { "id": "https://openalex.org/A5064772594", "display_name": "Ruth E. Gimeno" }, { "id": "https://openalex.org/A5071074041", "display_name": "David A. D\u2019Alessio" }, { "id": "https://openalex.org/A5040811419", "display_name": "Axel Haupt" } ] }, { "id": "https://openalex.org/W4200101053", "doi": "https://doi.org/10.1161/circulationaha.121.055459", "title": "Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER", "abstract": { "Background:": [ 0 ], "We": [ 1 ], "assessed": [ 2, 60 ], "the": [ 3, 103, 139, 281 ], "effect": [ 4 ], "of": [ 5, 54, 66, 215, 283 ], "once-weekly": [ 6 ], "semaglutide": [ 7, 143, 156, 205 ], "and": [ 8, 22, 32, 45, 49, 73, 82, 97, 159, 169, 178, 202, 208, 218, 233, 250, 261 ], "once-daily": [ 9 ], "liraglutide": [ 10 ], "on": [ 11 ], "kidney": [ 12, 339 ], "outcomes": [ 13 ], "in": [ 14, 38, 51, 130, 187, 334 ], "type": [ 15, 323 ], "2": [ 16, 42, 112, 153, 173, 197, 279, 324 ], "diabetes.": [ 17 ], "Methods:": [ 18 ], "Pooled": [ 19 ], "(n=12": [ 20 ], "637)": [ 21 ], "by-trial": [ 23, 131 ], "data": [ 24, 132 ], "from": [ 25, 84, 109, 292 ], "SUSTAIN": [ 26, 95 ], "6": [ 27, 96 ], "(Trial": [ 28 ], "to": [ 29, 75, 111, 275, 306 ], "Evaluate": [ 30 ], "Cardiovascular": [ 31, 55 ], "Other": [ 33 ], "Long-Term": [ 34 ], "Outcomes": [ 35 ], "With": [ 36, 40, 155 ], "Semaglutide": [ 37 ], "Subjects": [ 39 ], "Type": [ 41 ], "Diabetes;": [ 43 ], "n=3297)": [ 44 ], "LEADER": [ 46 ], "(Liraglutide": [ 47 ], "Effect": [ 48 ], "Action": [ 50 ], "Diabetes:": [ 52 ], "Evaluation": [ 53 ], "Outcome": [ 56 ], "Results;": [ 57 ], "n=9340)": [ 58 ], "were": [ 59, 91, 127, 246 ], "for": [ 61, 94, 100, 137, 204, 248, 286, 295, 308 ], "albuminuria": [ 62, 108 ], "change,": [ 63, 72 ], "annual": [ 64 ], "slope": [ 65, 162 ], "estimated": [ 67 ], "glomerular": [ 68 ], "filtration": [ 69 ], "rate": [ 70 ], "(eGFR)": [ 71 ], "time": [ 74 ], "persistent": [ 76, 216, 284 ], "eGFR": [ 77, 161, 191, 220, 252, 273 ], "reduction": [ 78, 285, 297, 310 ], "(30%,": [ 79 ], "40%,": [ 80 ], "50%,": [ 81 ], "57%)": [ 83 ], "baseline.": [ 85 ], "Results:": [ 86 ], "The": [ 87 ], "median": [ 88 ], "follow-up": [ 89 ], "durations": [ 90 ], "2.1": [ 92 ], "years": [ 93, 99, 113 ], "3.8": [ 98 ], "LEADER.": [ 101 ], "In": [ 102, 269, 320 ], "pooled": [ 104 ], "analysis,": [ 105 ], "semaglutide/liraglutide": [ 106, 326 ], "lowered": [ 107, 213 ], "baseline": [ 110, 190, 272 ], "after": [ 114 ], "randomization": [ 115 ], "by": [ 116, 167 ], "24%": [ 117 ], "versus": [ 118, 182, 193, 222 ], "placebo": [ 119, 223 ], "(95%": [ 120, 298, 311 ], "CI,": [ 121, 148, 229, 237, 257, 265, 299, 312 ], "20%\u201327%;": [ 122 ], "P": [ 123, 135, 150, 176, 179, 199, 231, 239, 259, 267, 301, 303, 314, 316 ], "<0.001).": [ 124 ], "Significant": [ 125 ], "reductions": [ 126, 221, 253 ], "also": [ 128 ], "observed": [ 129, 247 ], "analyses": [ 133 ], "(": [ 134, 175, 198 ], "<0.001": [ 136 ], "all),": [ 138 ], "largest": [ 140 ], "being": [ 141 ], "with": [ 142, 189, 271, 322, 336 ], "1.0": [ 144, 157, 206 ], "mg": [ 145, 158, 207 ], "(33%": [ 146 ], "[95%": [ 147, 228, 236, 256, 264 ], "24%\u201340%];": [ 149 ], "<0.001)": [ 151 ], "at": [ 152 ], "years.": [ 154 ], "liraglutide,": [ 160, 209 ], "decline": [ 163 ], "was": [ 164, 289 ], "significantly": [ 165, 212 ], "slowed": [ 166 ], "0.87": [ 168 ], "0.26": [ 170 ], "mL/min/1.73": [ 171, 195, 277 ], "m": [ 172, 196, 278 ], "/y": [ 174 ], "<0.0001": [ 177 ], "<0.001),": [ 180 ], "respectively,": [ 181 ], "placebo.": [ 183 ], "Effects": [ 184 ], "appeared": [ 185, 331 ], "larger": [ 186 ], "patients": [ 188, 270, 321, 335 ], "<60": [ 192, 276 ], "\u226560": [ 194 ], "interaction": [ 200, 304, 317 ], "=0.06": [ 201 ], "0.008": [ 203 ], "respectively).": [ 210, 241 ], "Semaglutide/liraglutide": [ 211 ], "risk": [ 214 ], "40%": [ 217 ], "50%": [ 219 ], "(hazard": [ 224 ], "ratio": [ 225 ], "[HR],": [ 226 ], "0.86": [ 227 ], "0.75\u20130.99];": [ 230 ], "=0.039": [ 232 ], "HR,": [ 234, 262 ], "0.80": [ 235 ], "0.66\u20130.97];": [ 238 ], "=0.023,": [ 240 ], "Similar,": [ 242 ], "nonsignificant,": [ 243 ], "directional": [ 244 ], "results": [ 245 ], "30%": [ 249, 296 ], "57%": [ 251, 309 ], "(HR,": [ 254 ], "0.92": [ 255 ], "0.84\u20131.02];": [ 258 ], "=0.10": [ 260 ], "0.89": [ 263 ], "0.69\u20131.13];": [ 266 ], "=0.34).": [ 268 ], "30": [ 274 ], ",": [ 280 ], "likelihood": [ 282 ], "all": [ 287 ], "thresholds": [ 288 ], "increased,": [ 290 ], "ranging": [ 291 ], "HR": [ 293 ], "0.71": [ 294 ], "0.59\u20130.85;": [ 300 ], "=0.0003,": [ 302 ], "=0.017)": [ 305 ], "0.54": [ 307 ], "0.36\u20130.81;": [ 313 ], "=0.003,": [ 315 ], "=0.035).": [ 318 ], "Conclusions:": [ 319 ], "diabetes,": [ 325 ], "offered": [ 327 ], "kidney-protective": [ 328 ], "effects,": [ 329 ], "which": [ 330 ], "more": [ 332 ], "pronounced": [ 333 ], "preexisting": [ 337 ], "chronic": [ 338 ], "disease.": [ 340 ] }, "publication_date": "2021-12-14", "publication_year": 2021, "type": "article", "cited_by_count": 214, "authors": [ { "id": "https://openalex.org/A5072182652", "display_name": "Ahmed M. Shaman" }, { "id": "https://openalex.org/A5080463002", "display_name": "Stephen C. Bain" }, { "id": "https://openalex.org/A5012514694", "display_name": "George L. Bakris" }, { "id": "https://openalex.org/A5040182038", "display_name": "John B. Buse" }, { "id": "https://openalex.org/A5113682378", "display_name": "Thomas Idorn" }, { "id": "https://openalex.org/A5039432822", "display_name": "Kenneth W. Mahaffey" }, { "id": "https://openalex.org/A5043842967", "display_name": "Johannes F.E. Mann" }, { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5110231477", "display_name": "S\u00f8ren Rasmussen" }, { "id": "https://openalex.org/A5085592050", "display_name": "Peter Rossing" }, { "id": "https://openalex.org/A5052608802", "display_name": "Benjamin Ole Wolthers" }, { "id": "https://openalex.org/A5090437675", "display_name": "Bernard Zinman" }, { "id": "https://openalex.org/A5027520502", "display_name": "Vlado Perkovic" } ] }, { "id": "https://openalex.org/W2948612418", "doi": "https://doi.org/10.1016/s0140-6736(19)31149-3", "title": "Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial", "abstract": null, "publication_date": "2019-06-09", "publication_year": 2019, "type": "article", "cited_by_count": 2683, "authors": [ { "id": "https://openalex.org/A5024577116", "display_name": "Hertzel C. Gerstein" }, { "id": "https://openalex.org/A5005414020", "display_name": "Helen M. Colhoun" }, { "id": "https://openalex.org/A5102952426", "display_name": "Gilles R. Dagenais" }, { "id": "https://openalex.org/A5013408607", "display_name": "Rafael D\u00edaz" }, { "id": "https://openalex.org/A5055443598", "display_name": "Mark Lakshmanan" }, { "id": "https://openalex.org/A5082084514", "display_name": "Prem Pais" }, { "id": "https://openalex.org/A5080292021", "display_name": "Jeffrey L. Probstfield" }, { "id": "https://openalex.org/A5102750154", "display_name": "Jeffrey S. Riesmeyer" }, { "id": "https://openalex.org/A5087844534", "display_name": "Matthew C. Riddle" }, { "id": "https://openalex.org/A5041670111", "display_name": "Lars Ryd\u00e9n" }, { "id": "https://openalex.org/A5057705555", "display_name": "Denis Xavier" }, { "id": "https://openalex.org/A5057242778", "display_name": "Charles Atisso" }, { "id": "https://openalex.org/A5072590707", "display_name": "Leanne Dyal" }, { "id": "https://openalex.org/A5052672899", "display_name": "Stephanie Hall" }, { "id": "https://openalex.org/A5045898172", "display_name": "Rao Ps" }, { "id": "https://openalex.org/A5102309441", "display_name": "G.C. Wong" }, { "id": "https://openalex.org/A5078888395", "display_name": "\u00c1lvaro Avezum" }, { "id": "https://openalex.org/A5056252103", "display_name": "Jan Basile" }, { "id": "https://openalex.org/A5103570650", "display_name": "Namsik Chung" }, { "id": "https://openalex.org/A5084120269", "display_name": "Ignacio Conget" }, { "id": "https://openalex.org/A5006628692", "display_name": "William C. Cushman" }, { "id": "https://openalex.org/A5030909625", "display_name": "Edward Franek" }, { "id": "https://openalex.org/A5078130962", "display_name": "Nicolae H\u00e2ncu" }, { "id": "https://openalex.org/A5052329017", "display_name": "M Hanefeld" }, { "id": "https://openalex.org/A5103401989", "display_name": "Shaun Holt" }, { "id": "https://openalex.org/A5107857922", "display_name": "Petr Jansk\u00fd" }, { "id": "https://openalex.org/A5041291525", "display_name": "M\u00e1ty\u00e1s Keltai" }, { "id": "https://openalex.org/A5005906845", "display_name": "Fernando La\u0146as" }, { "id": "https://openalex.org/A5080414941", "display_name": "Lawrence A. Leiter" }, { "id": "https://openalex.org/A5026568725", "display_name": "Patricio L\u00f3pez\u2010Jaramillo" }, { "id": "https://openalex.org/A5000849073", "display_name": "Ernesto Mu\u00f1oz" }, { "id": "https://openalex.org/A5082643599", "display_name": "Valdis P\u012br\u0101gs" }, { "id": "https://openalex.org/A5042971997", "display_name": "Nana Pogosova" }, { "id": "https://openalex.org/A5038086852", "display_name": "Peter Raubenheimer" }, { "id": "https://openalex.org/A5024475260", "display_name": "Jonathan E. Shaw" }, { "id": "https://openalex.org/A5031812511", "display_name": "Wayne Huey\u2010Herng Sheu" }, { "id": "https://openalex.org/A5043108571", "display_name": "Theodora Temelkova\u2010Kurktschiev" }, { "id": "https://openalex.org/A5113870455", "display_name": "Mercedes Abella" }, { "id": "https://openalex.org/A5097469081", "display_name": "Andrea Alebuena" }, { "id": "https://openalex.org/A5112441120", "display_name": "Sandra Almagro" }, { "id": "https://openalex.org/A5108683294", "display_name": "Eduardo Amoroso" }, { "id": "https://openalex.org/A5097469083", "display_name": "Paula Anadon" }, { "id": "https://openalex.org/A5110617217", "display_name": "Elizabeth Andreu" }, { "id": "https://openalex.org/A5112440989", "display_name": "Guillermo Aristimu\u00f1o" }, { "id": "https://openalex.org/A5097469086", "display_name": "Maria Arzadun" }, { "id": "https://openalex.org/A5065249383", "display_name": "Mar\u00eda Antonietta Barbieri" }, { "id": "https://openalex.org/A5065622117", "display_name": "Ra\u00fal Barcudi" }, { "id": "https://openalex.org/A5061109527", "display_name": "Ines Bartolacci" }, { "id": "https://openalex.org/A5097469087", "display_name": "Gabriel Bolobanich" }, { "id": "https://openalex.org/A5048608077", "display_name": "Anselmo P. Bordonava" }, { "id": "https://openalex.org/A5112441128", "display_name": "Miguel Bustamante Labarta" }, { "id": "https://openalex.org/A5109425628", "display_name": "B. Bustos" }, { "id": "https://openalex.org/A5073504040", "display_name": "Alberto Caccavo" }, { "id": "https://openalex.org/A5000839611", "display_name": "Alejandra Camino" }, { "id": "https://openalex.org/A5049277864", "display_name": "Mar\u00eda del Roc\u00edo Cantero" }, { "id": "https://openalex.org/A5107561439", "display_name": "Maria Carignano" }, { "id": "https://openalex.org/A5112579844", "display_name": "Luis R Cartasegna" }, { "id": "https://openalex.org/A5008435640", "display_name": "Marcela Cipullo" }, { "id": "https://openalex.org/A5037145579", "display_name": "V\u00edctor Commendatore" }, { "id": "https://openalex.org/A5097520881", "display_name": "Victoria Conosciuto" }, { "id": "https://openalex.org/A5088329952", "display_name": "Osvaldo Costamagna" }, { "id": "https://openalex.org/A5048300573", "display_name": "Claudia A. Crespo" }, { "id": "https://openalex.org/A5013896156", "display_name": "Jos\u00e9 Cuello-Navarro" }, { "id": "https://openalex.org/A5110475263", "display_name": "Carlos Alberto Cuneo" }, { "id": "https://openalex.org/A5095860955", "display_name": "Sandra Cusimano" }, { "id": "https://openalex.org/A5006392094", "display_name": "Sofia Dean" }, { "id": "https://openalex.org/A5051257159", "display_name": "Claudio Fabi\u00e1n Dituro" }, { "id": "https://openalex.org/A5072197792", "display_name": "Andrea Dom\u00ednguez" }, { "id": "https://openalex.org/A5103852092", "display_name": "Miguel Farah" }, { "id": "https://openalex.org/A5074810713", "display_name": "Alberto Oca\u00f1a" }, { "id": "https://openalex.org/A5082929744", "display_name": "Florencia Fernandez" }, { "id": "https://openalex.org/A5082727500", "display_name": "Adriana Cristina Ferrari" }, { "id": "https://openalex.org/A5097495183", "display_name": "Patricia Flammia" }, { "id": "https://openalex.org/A5024597866", "display_name": "Jos\u00e9 Antonio Fuentealba" }, { "id": "https://openalex.org/A5029907585", "display_name": "Karina Beatriz Gallardo" }, { "id": "https://openalex.org/A5103737215", "display_name": "C. Perez Garcia" }, { "id": "https://openalex.org/A5109606492", "display_name": "Ruben Garcia Duran" }, { "id": "https://openalex.org/A5061291087", "display_name": "Marcelo Garrido" }, { "id": "https://openalex.org/A5038082296", "display_name": "Rodolfo Gav\u00edcola" }, { "id": "https://openalex.org/A5097625543", "display_name": "Claudio Gerbaudo" }, { "id": "https://openalex.org/A5110617115", "display_name": "Graciela Gilli" }, { "id": "https://openalex.org/A5071213182", "display_name": "Ana Paula Giotto" }, { "id": "https://openalex.org/A5040928846", "display_name": "Pedro Godoy Bolz\u00e1n" }, { "id": "https://openalex.org/A5022884921", "display_name": "Oscar G\u00f3mez Vilamaj\u00f3" }, { "id": "https://openalex.org/A5001262620", "display_name": "Fernando Guerlloy" }, { "id": "https://openalex.org/A5009907112", "display_name": "Cristian Guridi" }, { "id": "https://openalex.org/A5112441136", "display_name": "Narcisa Gutierrez Garrido" }, { "id": "https://openalex.org/A5109046786", "display_name": "Eduardo Hasbani" }, { "id": "https://openalex.org/A5048243688", "display_name": "Sonia Hermida" }, { "id": "https://openalex.org/A5026717712", "display_name": "Miguel Hominal" }, { "id": "https://openalex.org/A5113970781", "display_name": "Adrian D. Hrabar" }, { "id": "https://openalex.org/A5034761943", "display_name": "Adri\u00e1n Ingaramo" }, { "id": "https://openalex.org/A5097469157", "display_name": "Alejandra Izzicupo" }, { "id": "https://openalex.org/A5110617223", "display_name": "Mario Krynski" }, { "id": "https://openalex.org/A5081483031", "display_name": "Mariana Lagrutta" }, { "id": "https://openalex.org/A5076352092", "display_name": "Paulina Virginia Lanchiotti" }, { "id": "https://openalex.org/A5097495196", "display_name": "Maria Langhe" }, { "id": "https://openalex.org/A5110617120", "display_name": "Veronica Leonard" }, { "id": "https://openalex.org/A5016775080", "display_name": "Javier Llanos" }, { "id": "https://openalex.org/A5073184612", "display_name": "Ricardo L\u00f3pez Santi" } ] }, { "id": "https://openalex.org/W4308053954", "doi": "https://doi.org/10.1056/nejmoa2208601", "title": "Once-Weekly Semaglutide in Adolescents with Obesity", "abstract": { "Among": [ 0 ], "adolescents": [ 1 ], "with": [ 2, 6 ], "obesity,": [ 3 ], "once-weekly": [ 4 ], "treatment": [ 5 ], "a": [ 7, 17 ], "2.4-mg": [ 8 ], "dose": [ 9 ], "of": [ 10 ], "semaglutide": [ 11 ], "plus": [ 12 ], "lifestyle": [ 13, 23 ], "intervention": [ 14, 24 ], "resulted": [ 15 ], "in": [ 16, 20 ], "greater": [ 18 ], "reduction": [ 19 ], "BMI": [ 21 ], "than": [ 22 ], "alone.": [ 25 ], "(Funded": [ 26 ], "by": [ 27 ], "Novo": [ 28 ], "Nordisk;": [ 29 ], "STEP": [ 30 ], "TEENS": [ 31 ], "ClinicalTrials.gov": [ 32 ], "number,": [ 33 ], "NCT04102189.).": [ 34 ] }, "publication_date": "2022-11-02", "publication_year": 2022, "type": "article", "cited_by_count": 496, "authors": [ { "id": "https://openalex.org/A5087302320", "display_name": "Daniel Weghuber" }, { "id": "https://openalex.org/A5026203609", "display_name": "Timothy Barrett" }, { "id": "https://openalex.org/A5083846346", "display_name": "Margarita Barrientos\u2010P\u00e9rez" }, { "id": "https://openalex.org/A5077703023", "display_name": "Inge Gies" }, { "id": "https://openalex.org/A5039497762", "display_name": "Dan Hesse" }, { "id": "https://openalex.org/A5055974284", "display_name": "Ole Kleist Jeppesen" }, { "id": "https://openalex.org/A5012739284", "display_name": "Aaron S. Kelly" }, { "id": "https://openalex.org/A5045940638", "display_name": "Lucy D. Mastrandrea" }, { "id": "https://openalex.org/A5016311849", "display_name": "Rasmus S\u00f8rrig" }, { "id": "https://openalex.org/A5044519340", "display_name": "Silva Arslanian" } ] }, { "id": "https://openalex.org/W2004409542", "doi": "https://doi.org/10.1210/en.2009-1272", "title": "Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation", "abstract": { "Liraglutide": [ 0 ], "is": [ 1 ], "a": [ 2, 30, 66 ], "glucagon-like": [ 3 ], "peptide-1": [ 4 ], "(GLP-1)": [ 5 ], "analog": [ 6 ], "developed": [ 7 ], "for": [ 8, 34, 128 ], "type": [ 9 ], "2": [ 10, 129 ], "diabetes.": [ 11 ], "Long-term": [ 12 ], "liraglutide": [ 13, 104, 127 ], "exposure": [ 14, 110 ], "in": [ 15, 37, 62, 69, 82, 98, 118, 123, 145, 169, 175, 187 ], "rodents": [ 16 ], "was": [ 17, 42, 142 ], "associated": [ 18 ], "with": [ 19, 150 ], "thyroid": [ 20, 83, 190 ], "C-cell": [ 21, 60, 116 ], "hyperplasia": [ 22, 61, 117 ], "and": [ 23, 58, 85, 140, 173, 193 ], "tumors.": [ 24 ], "Here,": [ 25 ], "we": [ 26 ], "report": [ 27 ], "data": [ 28 ], "supporting": [ 29 ], "GLP-1": [ 31, 40, 47, 79, 86, 170, 184 ], "receptor-mediated": [ 32 ], "mechanism": [ 33 ], "these": [ 35 ], "changes": [ 36 ], "rodents.": [ 38 ], "The": [ 39 ], "receptor": [ 41, 48, 80, 87, 171, 185 ], "localized": [ 43 ], "to": [ 44, 65, 115, 126 ], "rodent": [ 45 ], "C-cells.": [ 46 ], "agonists": [ 49, 88 ], "stimulated": [ 50 ], "calcitonin": [ 51, 55, 96, 121, 151 ], "release,": [ 52 ], "up-regulation": [ 53 ], "of": [ 54, 103, 136, 148, 160, 182 ], "gene": [ 56 ], "expression,": [ 57 ], "subsequently": [ 59 ], "rats": [ 63 ], "and,": [ 64 ], "lesser": [ 67 ], "extent,": [ 68 ], "mice.": [ 70 ], "In": [ 71 ], "contrast,": [ 72 ], "humans": [ 73 ], "and/or": [ 74 ], "cynomolgus": [ 75 ], "monkeys": [ 76 ], "had": [ 77 ], "low": [ 78 ], "expression": [ 81, 172 ], "C-cells,": [ 84 ], "did": [ 89, 112 ], "not": [ 90, 113 ], "activate": [ 91 ], "adenylate": [ 92 ], "cyclase": [ 93 ], "or": [ 94 ], "generate": [ 95 ], "release": [ 97 ], "primates.": [ 99 ], "Moreover,": [ 100 ], "20": [ 101, 161 ], "months": [ 102 ], "treatment": [ 105 ], "(at": [ 106 ], "&gt;60": [ 107 ], "times": [ 108 ], "human": [ 109, 189 ], "levels)": [ 111 ], "lead": [ 114 ], "monkeys.": [ 119 ], "Mean": [ 120 ], "levels": [ 122, 152 ], "patients": [ 124, 149 ], "exposed": [ 125 ], "yr": [ 130 ], "remained": [ 131 ], "at": [ 132 ], "the": [ 133, 137, 146, 155, 176, 179, 188 ], "lower": [ 134 ], "end": [ 135 ], "normal": [ 138 ], "range,": [ 139 ], "there": [ 141 ], "no": [ 143 ], "difference": [ 144 ], "proportion": [ 147 ], "increasing": [ 153 ], "above": [ 154 ], "clinically": [ 156 ], "relevant": [ 157 ], "cutoff": [ 158 ], "level": [ 159 ], "pg/ml.": [ 162 ], "Our": [ 163 ], "findings": [ 164 ], "delineate": [ 165 ], "important": [ 166 ], "species-specific": [ 167 ], "differences": [ 168 ], "action": [ 174 ], "thyroid.": [ 177 ], "Nevertheless,": [ 178 ], "long-term": [ 180 ], "consequences": [ 181 ], "sustained": [ 183 ], "activation": [ 186 ], "remain": [ 191 ], "unknown": [ 192 ], "merit": [ 194 ], "further": [ 195 ], "investigation.": [ 196 ] }, "publication_date": "2010-03-04", "publication_year": 2010, "type": "article", "cited_by_count": 609, "authors": [ { "id": "https://openalex.org/A5088627727", "display_name": "Lotte Bjerre Knudsen" }, { "id": "https://openalex.org/A5073611205", "display_name": "Lars Wichmann Madsen" }, { "id": "https://openalex.org/A5103529626", "display_name": "S\u00f8ren Andersen" }, { "id": "https://openalex.org/A5062115269", "display_name": "Kasper Almholt" }, { "id": "https://openalex.org/A5034904352", "display_name": "Anne Sietske de Boer" }, { "id": "https://openalex.org/A5057472647", "display_name": "Daniel J. Drucker" }, { "id": "https://openalex.org/A5103583268", "display_name": "C. F. Gotfredsen" }, { "id": "https://openalex.org/A5048911478", "display_name": "Frederikke Lihme Egerod" }, { "id": "https://openalex.org/A5018185847", "display_name": "Anne Charlotte Hegelund" }, { "id": "https://openalex.org/A5113669973", "display_name": "Helene Jacobsen" }, { "id": "https://openalex.org/A5077790996", "display_name": "S\u00f8ren Dyring Jacobsen" }, { "id": "https://openalex.org/A5104132238", "display_name": "Alan C. Moses" }, { "id": "https://openalex.org/A5112354527", "display_name": "Anne-Marie M\u00f8lck" }, { "id": "https://openalex.org/A5063312041", "display_name": "Henriette Svarre Nielsen" }, { "id": "https://openalex.org/A5083781927", "display_name": "Jette Nowak" }, { "id": "https://openalex.org/A5044989809", "display_name": "Helene Solberg" }, { "id": "https://openalex.org/A5110001248", "display_name": "Tu D. L. Thi" }, { "id": "https://openalex.org/A5103492502", "display_name": "Milan Zdravkovic" } ] }, { "id": "https://openalex.org/W2030546890", "doi": "https://doi.org/10.2337/dc13-2759", "title": "Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)", "abstract": { "OBJECTIVE": [ 0 ], "Compare": [ 1 ], "the": [ 2, 222 ], "efficacy": [ 3 ], "and": [ 4, 29, 71, 77, 130, 141, 154, 173, 180, 208, 219, 232, 239 ], "safety": [ 5 ], "of": [ 6, 92 ], "monotherapy": [ 7, 244 ], "with": [ 8, 18, 75, 177, 184, 197, 204, 210, 247 ], "dulaglutide,": [ 9 ], "a": [ 10 ], "once-weekly": [ 11 ], "GLP-1": [ 12 ], "receptor": [ 13 ], "agonist,": [ 14 ], "to": [ 15, 52, 146 ], "metformin-treated": [ 16 ], "patients": [ 17, 51, 246 ], "type": [ 19, 250 ], "2": [ 20, 251 ], "diabetes.": [ 21, 252 ], "The": [ 22 ], "primary": [ 23 ], "objective": [ 24 ], "compared": [ 25, 183 ], "dulaglutide": [ 26, 54, 57, 110, 120, 178, 205, 211, 231 ], "1.5": [ 27, 55, 111, 140, 179, 206 ], "mg": [ 28, 143, 182, 207 ], "metformin": [ 30, 147, 185 ], "on": [ 31 ], "change": [ 32 ], "from": [ 33, 100 ], "baseline": [ 34, 101 ], "glycosylated": [ 35 ], "hemoglobin": [ 36 ], "A1c": [ 37 ], "(HbA1c)": [ 38 ], "at": [ 39, 90 ], "26": [ 40, 97 ], "weeks.": [ 41 ], "RESEARCH": [ 42 ], "DESIGN": [ 43 ], "AND": [ 44 ], "METHODS": [ 45 ], "This": [ 46 ], "52-week": [ 47 ], "double-blind": [ 48 ], "study": [ 49 ], "randomized": [ 50 ], "subcutaneous": [ 53 ], "mg,": [ 56, 59, 112, 122 ], "0.75": [ 58, 121, 142, 181, 212 ], "or": [ 60, 80 ], "metformin.": [ 61, 233 ], "Patients": [ 62 ], "(N": [ 63 ], "=": [ 64 ], "807)": [ 65 ], "had": [ 66 ], "HbA1c": [ 67, 102, 168 ], "\u22656.5%": [ 68 ], "(\u226548": [ 69 ], "mmol/mol)": [ 70, 74, 153, 157, 172, 176 ], "\u22649.5%": [ 72 ], "(\u226480": [ 73 ], "diet": [ 76 ], "exercise": [ 78 ], "alone": [ 79 ], "low-dose": [ 81 ], "oral": [ 82 ], "antihyperglycemic": [ 83 ], "medication": [ 84 ], "(OAM)": [ 85 ], "monotherapy;": [ 86 ], "OAMs": [ 87 ], "were": [ 88, 144, 221, 228 ], "discontinued": [ 89 ], "beginning": [ 91 ], "lead-in": [ 93 ], "period.": [ 94 ], "RESULTS": [ 95 ], "At": [ 96 ], "weeks,": [ 98, 216 ], "changes": [ 99 ], "(least": [ 103 ], "squares": [ 104 ], "[LS]": [ 105 ], "mean": [ 106, 149 ], "\u00b1": [ 107, 114, 117, 124, 127, 133, 136 ], "SE)": [ 108 ], "were:": [ 109 ], "\u22120.78": [ 113 ], "0.06%": [ 115, 125, 134 ], "(\u22128.5": [ 116 ], "0.70": [ 118, 128, 137 ], "mmol/mol);": [ 119, 129 ], "\u22120.71": [ 123 ], "(\u22127.8": [ 126 ], "metformin,": [ 131, 198 ], "\u22120.56": [ 132 ], "(\u22126.1": [ 135 ], "mmol/mol).": [ 138 ], "Dulaglutide": [ 139, 235 ], "superior": [ 145 ], "(LS": [ 148 ], "difference):": [ 150 ], "\u22120.22%": [ 151 ], "(\u22122.4": [ 152 ], "\u22120.15%": [ 155 ], "(\u22121.6": [ 156 ], "(one-sided": [ 158 ], "P": [ 159 ], "&lt;": [ 160, 187 ], "0.025,": [ 161 ], "both": [ 162 ], "comparisons),": [ 163 ], "respectively.": [ 164 ], "Greater": [ 165 ], "percentages": [ 166 ], "reached": [ 167 ], "targets": [ 169 ], "&lt;7.0%": [ 170 ], "(&lt;53": [ 171 ], "\u22646.5%": [ 174 ], "(\u226448": [ 175 ], "(P": [ 186 ], "0.05,": [ 188 ], "all": [ 189 ], "comparisons).": [ 190 ], "No": [ 191 ], "severe": [ 192 ], "hypoglycemia": [ 193 ], "was": [ 194, 202 ], "reported.": [ 195 ], "Compared": [ 196 ], "decrease": [ 199 ], "in": [ 200, 245 ], "weight": [ 201 ], "similar": [ 203, 229 ], "smaller": [ 209 ], "mg.": [ 213 ], "Over": [ 214 ], "52": [ 215 ], "nausea,": [ 217 ], "diarrhea,": [ 218 ], "vomiting": [ 220 ], "most": [ 223 ], "common": [ 224 ], "adverse": [ 225 ], "events;": [ 226 ], "incidences": [ 227 ], "between": [ 230 ], "CONCLUSIONS": [ 234 ], "improves": [ 236 ], "glycemic": [ 237 ], "control": [ 238 ], "is": [ 240 ], "well": [ 241 ], "tolerated": [ 242 ], "as": [ 243 ], "early": [ 248 ], "stage": [ 249 ] }, "publication_date": "2014-05-20", "publication_year": 2014, "type": "article", "cited_by_count": 317, "authors": [ { "id": "https://openalex.org/A5061058170", "display_name": "Guillermo E. Umpierrez" }, { "id": "https://openalex.org/A5037602130", "display_name": "Santiago Tof\u00e9" }, { "id": "https://openalex.org/A5042706567", "display_name": "Federico P\u00e9rez Manghi" }, { "id": "https://openalex.org/A5037842574", "display_name": "Linda Shurzinske" }, { "id": "https://openalex.org/A5089497324", "display_name": "V. Pechtner" } ] }, { "id": "https://openalex.org/W4316664733", "doi": "https://doi.org/10.3390/ijms24021703", "title": "GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives", "abstract": { "To": [ 0 ], "date,": [ 1 ], "non-alcoholic": [ 2 ], "fatty": [ 3, 63 ], "liver": [ 4, 11, 64 ], "disease": [ 5 ], "(NAFLD)": [ 6 ], "is": [ 7, 92 ], "the": [ 8, 36, 79, 95, 100, 106 ], "most": [ 9 ], "frequent": [ 10 ], "disease,": [ 12 ], "affecting": [ 13 ], "up": [ 14 ], "to": [ 15, 93, 111 ], "70%": [ 16 ], "of": [ 17, 39, 62, 81, 89, 102, 108 ], "patients": [ 18, 68 ], "with": [ 19, 69 ], "diabetes.": [ 20 ], "Currently,": [ 21 ], "there": [ 22 ], "are": [ 23 ], "no": [ 24 ], "specific": [ 25 ], "drugs": [ 26 ], "available": [ 27, 98 ], "for": [ 28, 78 ], "its": [ 29 ], "treatment.": [ 30 ], "Beyond": [ 31 ], "their": [ 32 ], "anti-hyperglycemic": [ 33 ], "effect": [ 34 ], "and": [ 35, 41, 56, 59, 65, 85, 110 ], "surprising": [ 37 ], "role": [ 38, 101 ], "cardio-": [ 40 ], "nephroprotection,": [ 42 ], "GLP-1": [ 43, 72, 103 ], "receptor": [ 44 ], "agonists": [ 45 ], "(GLP-1": [ 46 ], "RAs)": [ 47 ], "have": [ 48 ], "shown": [ 49 ], "a": [ 50, 76 ], "significant": [ 51 ], "impact": [ 52 ], "on": [ 53, 99 ], "body": [ 54 ], "weight": [ 55 ], "clinical,": [ 57 ], "biochemical": [ 58 ], "histological": [ 60 ], "markers": [ 61 ], "fibrosis": [ 66 ], "in": [ 67, 105 ], "NAFLD.": [ 70, 86 ], "Therefore,": [ 71 ], "RAs": [ 73, 104 ], "could": [ 74 ], "be": [ 75 ], "weapon": [ 77 ], "treatment": [ 80, 107 ], "both": [ 82 ], "diabetes": [ 83 ], "mellitus": [ 84 ], "The": [ 87 ], "aim": [ 88 ], "this": [ 90 ], "review": [ 91 ], "summarize": [ 94 ], "evidence": [ 96 ], "currently": [ 97 ], "NAFLD": [ 109 ], "hypothesize": [ 112 ], "potential": [ 113 ], "future": [ 114 ], "scenarios.": [ 115 ] }, "publication_date": "2023-01-15", "publication_year": 2023, "type": "review", "cited_by_count": 200, "authors": [ { "id": "https://openalex.org/A5079719360", "display_name": "Riccardo Nevola" }, { "id": "https://openalex.org/A5015992391", "display_name": "Raffaella Epifani" }, { "id": "https://openalex.org/A5050272476", "display_name": "Simona Imbriani" }, { "id": "https://openalex.org/A5012968088", "display_name": "Giovanni Tortorella" }, { "id": "https://openalex.org/A5058942695", "display_name": "Concetta Aprea" }, { "id": "https://openalex.org/A5031221374", "display_name": "Raffaele Galiero" }, { "id": "https://openalex.org/A5007407416", "display_name": "Luca Rinaldi" }, { "id": "https://openalex.org/A5035487463", "display_name": "Raffaele Marfella" }, { "id": "https://openalex.org/A5055583365", "display_name": "Ferdinando Carlo Sasso" } ] }, { "id": "https://openalex.org/W2081283952", "doi": "https://doi.org/10.1177/1479164111404257", "title": "A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model", "abstract": { "The": [ 0 ], "glucagon": [ 1 ], "like": [ 2 ], "peptide-1": [ 3 ], "receptor": [ 4 ], "(GLP-1R)": [ 5 ], "agonist": [ 6, 181 ], "liraglutide": [ 7, 59, 138 ], "attenuates": [ 8 ], "induction": [ 9 ], "of": [ 10, 53, 58, 73, 93, 101, 122 ], "plasminogen": [ 11 ], "activator": [ 12 ], "inhibitor": [ 13 ], "type-1": [ 14 ], "(PAI-1)": [ 15 ], "and": [ 16, 30, 63, 86, 95, 104, 125, 154, 185 ], "vascular": [ 17, 24, 44, 81, 102 ], "adhesion": [ 18, 157 ], "molecule": [ 19 ], "(VAM)": [ 20 ], "expression": [ 21, 160 ], "in": [ 22, 28, 42, 55, 66, 69, 109, 134, 137, 161, 175 ], "human": [ 23, 80 ], "endothelial": [ 25, 35, 82, 135, 149 ], "cells": [ 26 ], "(hVECs)": [ 27 ], "vitro": [ 29, 56, 76, 116 ], "may": [ 31 ], "afford": [ 32 ], "protection": [ 33 ], "against": [ 34, 183 ], "cell": [ 36, 83 ], "dysfunction": [ 37 ], "(ECD),": [ 38 ], "an": [ 39, 164 ], "early": [ 40 ], "abnormality": [ 41 ], "diabetic": [ 43 ], "disease.": [ 45 ], "Our": [ 46 ], "study": [ 47 ], "aimed": [ 48 ], "to": [ 49 ], "establish": [ 50 ], "the": [ 51, 54, 61, 79, 110, 169, 179 ], "dependence": [ 52 ], "effects": [ 57, 68 ], "on": [ 60, 168 ], "GLP-1R": [ 62, 142, 180 ], "characterise": [ 64 ], "its": [ 65 ], "vivo": [ 67, 99, 129, 176 ], "a": [ 70, 141, 187 ], "mouse": [ 71, 113 ], "model": [ 72 ], "ECD.": [ 74 ], "In": [ 75, 98, 115, 128 ], "studies": [ 77, 100, 117, 130, 173 ], "utilised": [ 78 ], "line": [ 84 ], "C11-STH": [ 85 ], "enzyme-linked": [ 87 ], "immunosorbent": [ 88 ], "assays": [ 89 ], "(ELISA)": [ 90 ], "for": [ 91, 192 ], "determination": [ 92 ], "PAI-1": [ 94, 124 ], "VAM": [ 96, 126 ], "expression.": [ 97, 127 ], "reactivity": [ 103 ], "immunohistochemical": [ 105 ], "analysis": [ 106 ], "were": [ 107 ], "performed": [ 108 ], "ApoE": [ 111 ], "-/-": [ 112 ], "model.": [ 114 ], "demonstrated": [ 118, 131 ], "GLP-1R-dependent": [ 119 ], "liraglutide-mediated": [ 120 ], "inhibition": [ 121 ], "stimulated": [ 123 ], "significant": [ 132 ], "improvement": [ 133 ], "function": [ 136 ], "treated": [ 139 ], "mice,": [ 140 ], "dependent": [ 143, 167 ], "effect.": [ 144 ], "Liraglutide": [ 145 ], "treatment": [ 146 ], "also": [ 147 ], "increased": [ 148 ], "nitric": [ 150 ], "oxide": [ 151 ], "synthase": [ 152 ], "(eNOS)": [ 153 ], "reduced": [ 155 ], "intercellular": [ 156 ], "molecule-1": [ 158 ], "(ICAM-1)": [ 159 ], "aortic": [ 162 ], "endothelium,": [ 163 ], "effect": [ 165 ], "again": [ 166 ], "GLP-1R.": [ 170 ], "Together": [ 171 ], "these": [ 172, 193 ], "identify": [ 174 ], "protection,": [ 177 ], "by": [ 178 ], "liraglutide,": [ 182 ], "ECD": [ 184 ], "provide": [ 186 ], "potential": [ 188 ], "molecular": [ 189 ], "mechanism": [ 190 ], "responsible": [ 191 ], "effects.": [ 194 ] }, "publication_date": "2011-04-01", "publication_year": 2011, "type": "article", "cited_by_count": 187, "authors": [ { "id": "https://openalex.org/A5010359995", "display_name": "Tracey A. Gaspari" }, { "id": "https://openalex.org/A5108140331", "display_name": "Hongbin Liu" }, { "id": "https://openalex.org/A5054531748", "display_name": "Iresha Welungoda" }, { "id": "https://openalex.org/A5102189643", "display_name": "Yunshan Hu" }, { "id": "https://openalex.org/A5070440854", "display_name": "Robert E. Widdop" }, { "id": "https://openalex.org/A5088627727", "display_name": "Lotte Bjerre Knudsen" }, { "id": "https://openalex.org/A5103403579", "display_name": "Richard W Simpson" }, { "id": "https://openalex.org/A5045994438", "display_name": "Anthony E. Dear" } ] }, { "id": "https://openalex.org/W2904088434", "doi": "https://doi.org/10.1111/dom.13603", "title": "Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12\u2010month follow\u2010up in a real\u2010world setting in the United States", "abstract": { "Aims": [ 0 ], "To": [ 1 ], "evaluate": [ 2 ], "adherence,": [ 3 ], "persistence,": [ 4 ], "glycaemic": [ 5 ], "control": [ 6 ], "and": [ 7, 23, 38, 65, 91, 119, 153, 183, 222, 253, 263, 282, 297 ], "costs": [ 8, 245 ], "at": [ 9 ], "12\u2010month": [ 10 ], "follow\u2010up": [ 11 ], "for": [ 12, 43, 109, 267, 270, 291, 299, 318 ], "patients": [ 13, 32, 140, 168, 292, 319 ], "initiating": [ 14, 130, 145 ], "dulaglutide": [ 15, 113, 120, 131, 171, 187, 202, 252, 268, 300 ], "versus": [ 16, 114, 121, 173, 188 ], "liraglutide": [ 17, 45, 115, 146, 177, 213, 255, 303 ], "or": [ 18, 46, 304 ], "exenatide": [ 19, 47, 122, 154, 192, 232, 271, 305 ], "once": [ 20, 48, 123, 155, 272, 306 ], "weekly.": [ 21 ], "Materials": [ 22 ], "methods": [ 24 ], "The": [ 25, 104, 201, 242 ], "present": [ 26 ], "retrospective": [ 27 ], "observational": [ 28 ], "claims": [ 29 ], "study": [ 30 ], "included": [ 31 ], "with": [ 33, 89, 142, 293, 302, 320 ], "type": [ 34 ], "2": [ 35 ], "diabetes": [ 36 ], "(T2D)": [ 37 ], "\u2265": [ 39 ], "1": [ 40 ], "pharmacy": [ 41 ], "claim": [ 42 ], "dulaglutide,": [ 44 ], "weekly": [ 49, 124, 156, 273, 307 ], "from": [ 50, 77 ], "the": [ 51, 101, 110, 143, 170, 176, 186, 191, 212, 231, 251, 254 ], "HealthCore": [ 52 ], "Integrated": [ 53 ], "Research": [ 54 ], "Database.": [ 55 ], "Adherence": [ 56, 281 ], "was": [ 57, 67, 84, 133 ], "defined": [ 58 ], "as": [ 59 ], "proportion": [ 60, 137 ], "of": [ 61, 73, 138, 167 ], "days": [ 62 ], "covered": [ 63 ], "\u226580%,": [ 64 ], "persistence": [ 66, 283, 298 ], "measured": [ 68 ], "by": [ 69 ], "time": [ 70 ], "to": [ 71, 99 ], "discontinuation": [ 72 ], "index": [ 74 ], "therapy.": [ 75 ], "Change": [ 76 ], "baseline": [ 78, 105 ], "in": [ 79, 86, 169, 175, 185, 190, 209, 228, 287 ], "glycated": [ 80 ], "haemoglobin": [ 81 ], "(HbA1c)": [ 82 ], "concentration": [ 83 ], "assessed": [ 85 ], "a": [ 87, 134, 205, 223 ], "subset": [ 88 ], "pre\u2010": [ 90 ], "post\u2010index": [ 92 ], "HbA1c": [ 93, 210, 229 ], "results.": [ 94 ], "Propensity": [ 95 ], "scores": [ 96 ], "were": [ 97, 107, 199, 246, 264 ], "used": [ 98 ], "match": [ 100 ], "cohorts.": [ 102 ], "Results": [ 103 ], "characteristics": [ 106 ], "balanced": [ 108 ], "matched": [ 111 ], "cohorts,": [ 112 ], "(n": [ 116, 125 ], "=": [ 117, 126, 220, 240, 261, 278 ], "2471)": [ 118 ], "1891).": [ 127 ], "Among": [ 128 ], "those": [ 129 ], "there": [ 132 ], "significantly": [ 135, 206, 248, 265 ], "higher": [ 136, 266 ], "adherent": [ 139 ], "compared": [ 141, 301 ], "groups": [ 144 ], "(51.2%": [ 147 ], "vs.": [ 148, 158, 216, 236, 258, 275 ], "38.2%;": [ 149 ], "P": [ 150, 160, 180, 196, 219, 239, 260, 277 ], "<": [ 151, 161, 181, 197 ], "0.001)": [ 152, 198 ], "(50.7%": [ 157 ], "31.9%;": [ 159 ], "0.001).": [ 162 ], "At": [ 163 ], "12": [ 164 ], "months,": [ 165 ], "55%": [ 166 ], "group": [ 172, 178, 194, 203, 214, 234, 256 ], "43.8%": [ 174 ], "(": [ 179, 195 ], "0.001),": [ 182 ], "54.9%": [ 184 ], "34.4%": [ 189 ], "once\u2010weekly": [ 193, 233 ], "persistent.": [ 200 ], "had": [ 204 ], "greater": [ 207 ], "reduction": [ 208, 227 ], "than": [ 211, 230, 269 ], "(\u221234.24": [ 215 ], "\u221231.94": [ 217, 237 ], "mmol/mol;": [ 218, 238 ], "0.032),": [ 221 ], "greater,": [ 224 ], "but": [ 225 ], "nonsignificant,": [ 226 ], "(\u221234.46": [ 235 ], "0.056).": [ 241 ], "diabetes\u2010related": [ 243 ], "total": [ 244 ], "not": [ 247 ], "different": [ 249 ], "between": [ 250 ], "($16,174": [ 257 ], "$16,694;": [ 259 ], "0.184),": [ 262 ], "($15,768": [ 274 ], "$14,615;": [ 276 ], "0.005).": [ 279 ], "Conclusions": [ 280 ], "are": [ 284, 308 ], "important": [ 285 ], "considerations": [ 286 ], "patient\u2010centric": [ 288 ], "treatment": [ 289, 317 ], "selection": [ 290 ], "T2D.": [ 294, 321 ], "Higher": [ 295 ], "adherence": [ 296 ], "relevant": [ 309 ], "criteria": [ 310 ], "when": [ 311 ], "choosing": [ 312 ], "glucagon\u2010like": [ 313 ], "peptide\u20101": [ 314 ], "receptor": [ 315 ], "agonist": [ 316 ] }, "publication_date": "2018-12-05", "publication_year": 2018, "type": "article", "cited_by_count": 87, "authors": [ { "id": "https://openalex.org/A5011388259", "display_name": "Reema Mody" }, { "id": "https://openalex.org/A5101782148", "display_name": "Qing Huang" }, { "id": "https://openalex.org/A5109226707", "display_name": "Maria Yu" }, { "id": "https://openalex.org/A5102011203", "display_name": "Ruizhi Zhao" }, { "id": "https://openalex.org/A5086878406", "display_name": "Hiren Patel" }, { "id": "https://openalex.org/A5090788600", "display_name": "Michael Grabner" }, { "id": "https://openalex.org/A5072715491", "display_name": "Laura Fern\u00e1ndez Land\u00f3" } ] }, { "id": "https://openalex.org/W3177393241", "doi": "https://doi.org/10.1016/s0140-6736(21)01324-6", "title": "Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial", "abstract": null, "publication_date": "2021-06-27", "publication_year": 2021, "type": "article", "cited_by_count": 848, "authors": [ { "id": "https://openalex.org/A5045489578", "display_name": "Julio Rosenstock" }, { "id": "https://openalex.org/A5040652845", "display_name": "Carol Wysham" }, { "id": "https://openalex.org/A5086072427", "display_name": "Juan P. Fr\u00edas" }, { "id": "https://openalex.org/A5101474154", "display_name": "Shizuka Kaneko" }, { "id": "https://openalex.org/A5031509690", "display_name": "Clare J. Lee" }, { "id": "https://openalex.org/A5072715491", "display_name": "Laura Fern\u00e1ndez Land\u00f3" }, { "id": "https://openalex.org/A5112368424", "display_name": "Huzhang Mao" }, { "id": "https://openalex.org/A5058864022", "display_name": "Xuewei Cui" }, { "id": "https://openalex.org/A5030157221", "display_name": "Chrisanthi A. Karanikas" }, { "id": "https://openalex.org/A5057128422", "display_name": "Vivian T. Thieu" } ] }, { "id": "https://openalex.org/W1976503602", "doi": "https://doi.org/10.2337/dc09-0366", "title": "Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes", "abstract": { "OBJECTIVE": [ 0 ], "To": [ 1 ], "evaluate": [ 2 ], "the": [ 3, 220 ], "efficacy,": [ 4 ], "safety,": [ 5 ], "and": [ 6, 34, 165, 171, 180, 223, 238, 251 ], "tolerability": [ 7, 252 ], "of": [ 8, 11, 128, 203, 226 ], "incremental": [ 9 ], "doses": [ 10, 195, 225 ], "albiglutide,": [ 12 ], "a": [ 13, 248 ], "long-acting": [ 14 ], "glucagon-like": [ 15 ], "peptide-1": [ 16 ], "receptor": [ 17 ], "agonist,": [ 18 ], "administered": [ 19 ], "with": [ 20, 26, 32, 55, 191, 196, 247 ], "three": [ 21, 193 ], "dosing": [ 22 ], "schedules": [ 23 ], "in": [ 24, 106, 139, 207, 242 ], "patients": [ 25 ], "type": [ 27, 51, 243 ], "2": [ 28, 52, 163, 244 ], "diabetes": [ 29, 63 ], "inadequately": [ 30 ], "controlled": [ 31 ], "diet": [ 33 ], "exercise": [ 35 ], "or": [ 36, 75, 80, 86, 89, 92, 95, 228 ], "metformin": [ 37, 107 ], "monotherapy.": [ 38 ], "RESEARCH": [ 39 ], "DESIGN": [ 40 ], "AND": [ 41 ], "METHODS": [ 42 ], "In": [ 43 ], "this": [ 44 ], "randomized": [ 45 ], "multicenter": [ 46 ], "double-blind": [ 47 ], "parallel-group": [ 48 ], "study,": [ 49 ], "356": [ 50 ], "diabetic": [ 53, 245 ], "subjects": [ 54, 108, 208 ], "similar": [ 56 ], "mean": [ 57 ], "baseline": [ 58, 126, 153 ], "characteristics": [ 59 ], "(age": [ 60 ], "54": [ 61 ], "years,": [ 62, 66 ], "duration": [ 64 ], "4.9": [ 65 ], "BMI": [ 67 ], "32.1": [ 68 ], "kg/m2,": [ 69 ], "A1C": [ 70, 127, 140, 148 ], "8.0%)": [ 71 ], "received": [ 72 ], "subcutaneous": [ 73 ], "placebo": [ 74, 132, 175 ], "albiglutide": [ 76, 129, 145, 155, 194, 210, 227, 232 ], "(weekly": [ 77 ], "[4,": [ 78 ], "15,": [ 79 ], "30": [ 81, 156, 211 ], "mg],": [ 82, 88 ], "biweekly": [ 83, 161, 222 ], "[15,": [ 84 ], "30,": [ 85 ], "50": [ 87, 159 ], "monthly": [ 90, 168, 224 ], "[50": [ 91 ], "100": [ 93, 166 ], "mg])": [ 94 ], "exenatide": [ 96, 181 ], "twice": [ 97 ], "daily": [ 98 ], "as": [ 99 ], "an": [ 100, 115 ], "open-label": [ 101 ], "active": [ 102 ], "reference": [ 103 ], "(per": [ 104 ], "labeling": [ 105 ], "only)": [ 109 ], "over": [ 110 ], "16": [ 111 ], "weeks": [ 112 ], "followed": [ 113 ], "by": [ 114, 154 ], "11-week": [ 116 ], "washout": [ 117 ], "period.": [ 118 ], "The": [ 119, 201 ], "main": [ 120 ], "outcome": [ 121 ], "measure": [ 122 ], "was": [ 123, 149, 189, 214 ], "change": [ 124 ], "from": [ 125, 152 ], "groups": [ 130 ], "versus": [ 131, 174 ], "at": [ 133 ], "week": [ 134 ], "16.": [ 135 ], "RESULTS": [ 136 ], "Dose-dependent": [ 137 ], "reductions": [ 138 ], "were": [ 141 ], "observed": [ 142, 190, 218 ], "within": [ 143 ], "all": [ 144 ], "schedules.": [ 146 ], "Mean": [ 147 ], "similarly": [ 150 ], "reduced": [ 151 ], "mg": [ 157, 160, 167, 212 ], "weekly,": [ 158 ], "(every": [ 162 ], "weeks),": [ 164 ], "(\u22120.87,": [ 169 ], "\u22120.79,": [ 170 ], "\u22120.87%,": [ 172 ], "respectively)": [ 173 ], "(\u22120.17%,": [ 176 ], "P": [ 177 ], "&lt;": [ 178 ], "0.004)": [ 179 ], "(\u22120.54%).": [ 182 ], "Weight": [ 183 ], "loss": [ 184, 241 ], "(\u22121.1": [ 185 ], "to": [ 186 ], "\u22121.7": [ 187 ], "kg)": [ 188 ], "these": [ 192 ], "no": [ 197 ], "significant": [ 198 ], "between-group": [ 199 ], "effects.": [ 200 ], "incidence": [ 202 ], "gastrointestinal": [ 204 ], "adverse": [ 205 ], "events": [ 206 ], "receiving": [ 209 ], "weekly": [ 213 ], "less": [ 215 ], "than": [ 216 ], "that": [ 217 ], "for": [ 219 ], "highest": [ 221 ], "exenatide.": [ 229 ], "CONCLUSIONS": [ 230 ], "Weekly": [ 231 ], "administration": [ 233 ], "significantly": [ 234 ], "improved": [ 235 ], "glycemic": [ 236 ], "control": [ 237 ], "elicited": [ 239 ], "weight": [ 240 ], "patients,": [ 246 ], "favorable": [ 249 ], "safety": [ 250 ], "profile.": [ 253 ] }, "publication_date": "2009-07-10", "publication_year": 2009, "type": "article", "cited_by_count": 230, "authors": [ { "id": "https://openalex.org/A5045489578", "display_name": "Julio Rosenstock" }, { "id": "https://openalex.org/A5029406825", "display_name": "Jane E.B. Reusch" }, { "id": "https://openalex.org/A5108384973", "display_name": "Mark Bush" }, { "id": "https://openalex.org/A5110475866", "display_name": "Fred Yang" }, { "id": "https://openalex.org/A5113581999", "display_name": "Murray Stewart" } ] }, { "id": "https://openalex.org/W4391309422", "doi": "https://doi.org/10.1136/bmj-2023-076410", "title": "Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis", "abstract": { "Abstract": [ 0 ], "Objective": [ 1 ], "To": [ 2 ], "evaluate": [ 3 ], "the": [ 4, 143, 162, 181, 205, 236, 269, 325, 329, 360 ], "comparative": [ 5 ], "efficacy": [ 6 ], "and": [ 7, 20, 32, 48, 76, 103, 114, 128, 155, 190, 203, 280, 301, 342 ], "safety": [ 8, 304, 368 ], "of": [ 9, 39, 44, 89, 165, 188, 252, 271, 294 ], "glucagon-like": [ 10 ], "peptide-1": [ 11 ], "receptor": [ 12 ], "agonists": [ 13 ], "(GLP-1RAs)": [ 14 ], "on": [ 15 ], "glycaemic": [ 16, 211, 335 ], "control,": [ 17 ], "body": [ 18 ], "weight,": [ 19 ], "lipid": [ 21 ], "profile": [ 22 ], "in": [ 23, 134, 235, 267, 316 ], "adults": [ 24, 67, 318 ], "with": [ 25, 68, 79, 85, 95, 145, 226, 232, 319, 324, 357, 373 ], "type": [ 26, 69, 227, 320, 354 ], "2": [ 27, 70, 228, 321, 355 ], "diabetes.": [ 28, 229, 322 ], "Design": [ 29 ], "Systematic": [ 30, 381 ], "review": [ 31, 382 ], "network": [ 33, 136 ], "meta-analysis.": [ 34 ], "Data": [ 35 ], "sources": [ 36 ], "PubMed,": [ 37 ], "Web": [ 38 ], "Science,": [ 40 ], "Cochrane": [ 41 ], "Central": [ 42 ], "Register": [ 43 ], "Controlled": [ 45 ], "Trials": [ 46, 94 ], "(CENTRAL),": [ 47 ], "Embase": [ 49 ], "from": [ 50 ], "database": [ 51 ], "inception": [ 52 ], "to": [ 53, 142, 177, 198, 217, 221, 248, 260, 278, 286 ], "19": [ 54 ], "August": [ 55 ], "2023.": [ 56 ], "Eligibility": [ 57 ], "criteria": [ 58 ], "for": [ 59, 210, 224, 308, 334, 353, 362, 370 ], "selecting": [ 60 ], "studies": [ 61, 100, 116 ], "Eligible": [ 62 ], "randomised": [ 63 ], "controlled": [ 64 ], "trials": [ 65, 123 ], "enrolled": [ 66 ], "diabetes": [ 71 ], "who": [ 72 ], "received": [ 73 ], "GLP-1RA": [ 74, 83, 102, 126, 208, 332 ], "treatments": [ 75 ], "compared": [ 77 ], "effects": [ 78 ], "placebo": [ 80, 109 ], "or": [ 81 ], "any": [ 82 ], "drug,": [ 84 ], "a": [ 86, 96, 108 ], "follow-up": [ 87 ], "duration": [ 88 ], "at": [ 90 ], "least": [ 91 ], "12": [ 92 ], "weeks.": [ 93 ], "crossover": [ 97 ], "design,": [ 98 ], "non-inferiority": [ 99 ], "comparing": [ 101 ], "other": [ 104 ], "drug": [ 105, 209, 333 ], "classes": [ 106 ], "without": [ 107 ], "group,": [ 110 ], "using": [ 111 ], "withdrawn": [ 112 ], "drugs,": [ 113 ], "non-English": [ 115 ], "were": [ 117, 132, 215 ], "deemed": [ 118 ], "ineligible.": [ 119 ], "Results": [ 120 ], "76": [ 121 ], "eligible": [ 122 ], "involving": [ 124 ], "15": [ 125, 148 ], "drugs": [ 127 ], "39": [ 129 ], "246": [ 130 ], "participants": [ 131 ], "included": [ 133 ], "this": [ 135, 289 ], "meta-analysis;": [ 137 ], "all": [ 138 ], "subsequent": [ 139 ], "estimates": [ 140 ], "refer": [ 141 ], "comparison": [ 144 ], "placebo.": [ 146 ], "All": [ 147 ], "GLP-1RAs": [ 149, 214, 313, 347 ], "effectively": [ 150 ], "lowered": [ 151 ], "haemoglobin": [ 152, 166, 339 ], "A": [ 153, 167, 340 ], "1c": [ 154, 168, 341 ], "fasting": [ 156, 191, 343 ], "plasma": [ 157, 192, 344 ], "glucose": [ 158, 193, 345 ], "concentrations.": [ 159, 346 ], "Tirzepatide": [ 160 ], "induced": [ 161, 298 ], "largest": [ 163 ], "reduction": [ 164 ], "concentrations": [ 169, 194 ], "(mean": [ 170, 240 ], "difference": [ 171, 241 ], "\u22122.10%": [ 172 ], "(95%": [ 173, 244 ], "confidence": [ 174, 187, 245, 251 ], "interval": [ 175, 246 ], "\u22122.47%": [ 176 ], "\u22121.74%),": [ 178 ], "surface": [ 179 ], "under": [ 180 ], "cumulative": [ 182 ], "ranking": [ 183 ], "curve": [ 184 ], "94.2%;": [ 185 ], "high": [ 186, 201, 250, 262, 309, 374 ], "evidence),": [ 189, 253 ], "(\u22123.12": [ 195 ], "mmol/L": [ 196, 276, 284 ], "(\u22123.59": [ 197 ], "\u22122.66),": [ 199 ], "97.2%;": [ 200 ], "confidence),": [ 202 ], "proved": [ 204 ], "most": [ 206, 330 ], "effective": [ 207, 266, 331 ], "control.": [ 212 ], "Furthermore,": [ 213 ], "shown": [ 216 ], "have": [ 218 ], "strong": [ 219 ], "benefits": [ 220 ], "weight": [ 222, 238, 351, 363 ], "management": [ 223, 352 ], "patients": [ 225 ], "CagriSema": [ 230, 358 ], "(semaglutide": [ 231 ], "cagrilintide)": [ 233 ], "resulted": [ 234 ], "highest": [ 237 ], "loss": [ 239 ], "\u221214.03": [ 242 ], "kg": [ 243, 258 ], "\u221217.05": [ 247 ], "\u221211.00);": [ 249 ], "followed": [ 254 ], "by": [ 255, 299, 337 ], "tirzepatide": [ 256, 327 ], "(\u22128.47": [ 257 ], "(\u22129.68": [ 259 ], "\u22127.26);": [ 261 ], "confidence).": [ 263 ], "Semaglutide": [ 264 ], "was": [ 265, 328 ], "lowering": [ 268 ], "concentration": [ 270 ], "low": [ 272 ], "density": [ 273 ], "lipoprotein": [ 274 ], "(\u22120.16": [ 275 ], "(\u22120.30": [ 277 ], "\u22120.02))": [ 279 ], "total": [ 281 ], "cholesterol": [ 282 ], "(\u22120.48": [ 283 ], "(\u22120.84": [ 285 ], "\u22120.11)).": [ 287 ], "Moreover,": [ 288 ], "study": [ 290 ], "also": [ 291, 348 ], "raises": [ 292 ], "awareness": [ 293 ], "gastrointestinal": [ 295, 378 ], "adverse": [ 296, 379 ], "events": [ 297 ], "GLP-1RAs,": [ 300, 371 ], "concerns": [ 302, 369 ], "about": [ 303 ], "are": [ 305, 314 ], "especially": [ 306, 372 ], "warranted": [ 307 ], "dose": [ 310, 375 ], "administration.": [ 311 ], "Conclusions": [ 312 ], "efficacious": [ 315 ], "treating": [ 317 ], "Compared": [ 323 ], "placebo,": [ 326 ], "control": [ 336 ], "reducing": [ 338 ], "significantly": [ 349 ], "improved": [ 350 ], "diabetes,": [ 356 ], "performing": [ 359 ], "best": [ 361 ], "loss.": [ 364 ], "The": [ 365 ], "results": [ 366 ], "prompt": [ 367 ], "administration,": [ 376 ], "regarding": [ 377 ], "events.": [ 380 ], "registration": [ 383 ], "PROSPERO": [ 384 ], "CRD42022342845.": [ 385 ] }, "publication_date": "2024-01-29", "publication_year": 2024, "type": "review", "cited_by_count": 332, "authors": [ { "id": "https://openalex.org/A5014434675", "display_name": "Haiqiang Yao" }, { "id": "https://openalex.org/A5100336625", "display_name": "Anqi Zhang" }, { "id": "https://openalex.org/A5017563110", "display_name": "Delong Li" }, { "id": "https://openalex.org/A5037069397", "display_name": "Yuqi Wu" }, { "id": "https://openalex.org/A5075669369", "display_name": "Chong\u2010Zhi Wang" }, { "id": "https://openalex.org/A5082562345", "display_name": "Jin\u2010Yi Wan" }, { "id": "https://openalex.org/A5020423570", "display_name": "Chun\u2010Su Yuan" } ] }, { "id": "https://openalex.org/W2804938814", "doi": "https://doi.org/10.1016/j.bbadis.2018.05.012", "title": "GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms", "abstract": null, "publication_date": "2018-05-17", "publication_year": 2018, "type": "review", "cited_by_count": 139, "authors": [ { "id": "https://openalex.org/A5049796469", "display_name": "Manfredi Rizzo" }, { "id": "https://openalex.org/A5002357548", "display_name": "Dragana Nikoli\u0107" }, { "id": "https://openalex.org/A5049777035", "display_name": "Angelo Maria Patti" }, { "id": "https://openalex.org/A5090177131", "display_name": "Carlo Mannina" }, { "id": "https://openalex.org/A5082733849", "display_name": "Giuseppe Montalto" }, { "id": "https://openalex.org/A5027352817", "display_name": "Brooke S. McAdams" }, { "id": "https://openalex.org/A5008776901", "display_name": "Ali A. Rizvi" }, { "id": "https://openalex.org/A5070855397", "display_name": "Francesco Cosentino" } ] }, { "id": "https://openalex.org/W2032322539", "doi": "https://doi.org/10.1016/j.cmet.2006.01.004", "title": "The biology of incretin hormones", "abstract": null, "publication_date": "2006-03-01", "publication_year": 2006, "type": "review", "cited_by_count": 2102, "authors": [ { "id": "https://openalex.org/A5057472647", "display_name": "Daniel J. Drucker" } ] }, { "id": "https://openalex.org/W2032254224", "doi": "https://doi.org/10.1331/japha.2009.09078", "title": "Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors", "abstract": null, "publication_date": "2009-09-01", "publication_year": 2009, "type": "review", "cited_by_count": 141, "authors": [ { "id": "https://openalex.org/A5082350484", "display_name": "Joshua J. Neumiller" } ] }, { "id": "https://openalex.org/W2130583827", "doi": "https://doi.org/10.2337/db14-0976", "title": "Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans", "abstract": { "GLP-1": [ 0 ], "receptor": [ 1 ], "(GLP-1R)": [ 2 ], "agonists": [ 3 ], "may": [ 4 ], "improve": [ 5 ], "endothelial": [ 6, 116, 149, 160, 188 ], "function": [ 7 ], "(EF)": [ 8 ], "via": [ 9, 198 ], "metabolic": [ 10 ], "improvement": [ 11 ], "and": [ 12, 33, 59, 61, 63, 68, 72, 89, 115, 129, 136, 145, 151, 155, 183, 186, 200 ], "direct": [ 13 ], "vascular": [ 14 ], "action.": [ 15 ], "The": [ 16 ], "current": [ 17 ], "study": [ 18 ], "determined": [ 19 ], "the": [ 20, 34, 96 ], "effect": [ 21 ], "of": [ 22, 101, 124 ], "GLP-1R": [ 23, 37, 97, 102, 199 ], "agonist": [ 24, 103 ], "exenatide": [ 25, 53, 119, 132, 175 ], "on": [ 26, 109 ], "postprandial": [ 27, 121, 177 ], "EF": [ 28, 86, 122, 178 ], "in": [ 29, 126, 148, 162, 179, 190 ], "type": [ 30, 48, 82 ], "2": [ 31, 49, 83 ], "diabetes": [ 32, 50, 84, 182 ], "mechanisms": [ 35 ], "underlying": [ 36 ], "agonist\u2013mediated": [ 38 ], "vasodilation.": [ 39 ], "Two": [ 40 ], "crossover": [ 41 ], "studies": [ 42 ], "were": [ 43, 70, 105, 168, 195 ], "conducted:": [ 44 ], "36": [ 45 ], "participants": [ 46, 74 ], "with": [ 47, 75, 93, 170, 181 ], "received": [ 51 ], "subcutaneous": [ 52, 111 ], "or": [ 54, 80, 94, 158 ], "placebo": [ 55 ], "for": [ 56 ], "11": [ 57 ], "days": [ 58 ], "EF,": [ 60, 135 ], "glucose": [ 62, 77, 128 ], "lipid": [ 64 ], "responses": [ 65 ], "to": [ 66 ], "breakfast": [ 67 ], "lunch": [ 69 ], "determined;": [ 71 ], "32": [ 73 ], "impaired": [ 76 ], "tolerance": [ 78 ], "(IGT)": [ 79 ], "diet-controlled": [ 81 ], "had": [ 85 ], "measured": [ 87 ], "before": [ 88 ], "after": [ 90 ], "intravenous": [ 91 ], "exenatide,": [ 92 ], "without": [ 95 ], "antagonist": [ 98 ], "exendin-9.": [ 99 ], "Mechanisms": [ 100 ], "action": [ 104 ], "studied": [ 106 ], "ex": [ 107, 164 ], "vivo": [ 108 ], "human": [ 110, 191 ], "adipose": [ 112 ], "tissue": [ 113 ], "arterioles": [ 114, 163 ], "cells.": [ 117 ], "Subcutaneous": [ 118 ], "increased": [ 120, 133 ], "independent": [ 123 ], "reductions": [ 125 ], "plasma": [ 127 ], "triglycerides.": [ 130 ], "Intravenous": [ 131 ], "fasting": [ 134 ], "exendin-9": [ 137 ], "abolished": [ 138 ], "this": [ 139 ], "effect.": [ 140 ], "Exenatide": [ 141 ], "elicited": [ 142 ], "eNOS": [ 143 ], "activation": [ 144 ], "NO": [ 146 ], "production": [ 147 ], "cells,": [ 150 ], "induced": [ 152 ], "dose-dependent": [ 153 ], "vasorelaxation": [ 154 ], "reduced": [ 156, 169 ], "high-glucose": [ 157, 185 ], "lipid-induced": [ 159, 187 ], "dysfunction": [ 161, 189 ], "vivo.": [ 165 ], "These": [ 166, 193 ], "effects": [ 167, 194 ], "AMPK": [ 171, 201 ], "inhibition.": [ 172 ], "In": [ 173 ], "conclusion,": [ 174 ], "augmented": [ 176 ], "subjects": [ 180 ], "prevented": [ 184 ], "arterioles.": [ 192 ], "largely": [ 196 ], "direct,": [ 197 ], "activation.": [ 202 ] }, "publication_date": "2015-02-26", "publication_year": 2015, "type": "article", "cited_by_count": 157, "authors": [ { "id": "https://openalex.org/A5109148559", "display_name": "Juraj Ko\u0161ka" }, { "id": "https://openalex.org/A5090083723", "display_name": "Michelle Sands" }, { "id": "https://openalex.org/A5079304323", "display_name": "Camelia Burciu" }, { "id": "https://openalex.org/A5108709076", "display_name": "Karen D\u2019Souza" }, { "id": "https://openalex.org/A5024312270", "display_name": "Kalyani Raravikar" }, { "id": "https://openalex.org/A5103642205", "display_name": "James Liu" }, { "id": "https://openalex.org/A5076508749", "display_name": "Seth Truran" }, { "id": "https://openalex.org/A5054321132", "display_name": "Daniel Franco" }, { "id": "https://openalex.org/A5034236019", "display_name": "Eric A. Schwartz" }, { "id": "https://openalex.org/A5003255105", "display_name": "Dawn C. Schwenke" }, { "id": "https://openalex.org/A5071074041", "display_name": "David A. D\u2019Alessio" }, { "id": "https://openalex.org/A5081140590", "display_name": "Raymond Q. Migrino" }, { "id": "https://openalex.org/A5007571294", "display_name": "Peter D. Reaven" } ] }, { "id": "https://openalex.org/W2118762421", "doi": "https://doi.org/10.2337/dc09-2260", "title": "Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents", "abstract": { "OBJECTIVE": [ 0 ], "To": [ 1 ], "evaluate": [ 2 ], "efficacy": [ 3 ], "and": [ 4, 39, 52, 66, 96, 110, 137, 150, 163, 168 ], "safety": [ 5 ], "of": [ 6, 15, 18, 56, 72, 147 ], "switching": [ 7 ], "from": [ 8, 76, 91, 156 ], "twice-daily": [ 9, 79 ], "exenatide": [ 10, 80, 92, 157 ], "to": [ 11, 28, 81, 93, 158 ], "once-daily": [ 12, 84 ], "liraglutide": [ 13, 20, 44, 85, 94, 159 ], "or": [ 14, 86, 122 ], "40": [ 16 ], "weeks": [ 17 ], "continuous": [ 19 ], "therapy.": [ 21 ], "RESEARCH": [ 22 ], "DESIGN": [ 23 ], "AND": [ 24 ], "METHODS": [ 25 ], "When": [ 26 ], "added": [ 27 ], "oral": [ 29 ], "antidiabetes": [ 30 ], "drugs": [ 31 ], "in": [ 32, 41, 132 ], "a": [ 33 ], "26-week": [ 34 ], "randomized": [ 35 ], "trial": [ 36 ], "(Liraglutide": [ 37 ], "Effect": [ 38 ], "Action": [ 40 ], "Diabetes": [ 42 ], "[LEAD]-6),": [ 43 ], "more": [ 45 ], "effectively": [ 46 ], "improved": [ 47 ], "A1C,": [ 48 ], "fasting": [ 49, 101 ], "plasma": [ 50, 102 ], "glucose,": [ 51 ], "the": [ 53 ], "homeostasis": [ 54 ], "model": [ 55 ], "\u03b2-cell": [ 57 ], "function": [ 58 ], "(HOMA-B)": [ 59 ], "than": [ 60 ], "exenatide,": [ 61 ], "with": [ 62, 116, 144 ], "less": [ 63 ], "persistent": [ 64 ], "nausea": [ 65, 123 ], "hypoglycemia.": [ 67 ], "In": [ 68 ], "this": [ 69 ], "14-week": [ 70 ], "extension": [ 71 ], "LEAD-6,": [ 73 ], "patients": [ 74, 126 ], "switched": [ 75 ], "10": [ 77 ], "\u03bcg": [ 78 ], "1.8": [ 82 ], "mg": [ 83 ], "continued": [ 87 ], "liraglutide.": [ 88 ], "RESULTS": [ 89 ], "Switching": [ 90 ], "further": [ 95, 129 ], "significantly": [ 97 ], "reduced": [ 98 ], "A1C": [ 99 ], "(0.32%),": [ 100 ], "glucose": [ 103 ], "(0.9": [ 104, 108 ], "mmol/l),": [ 105 ], "body": [ 106, 133 ], "weight": [ 107, 134 ], "kg),": [ 109 ], "systolic": [ 111, 138 ], "blood": [ 112, 139 ], "pressure": [ 113, 140 ], "(3.8": [ 114 ], "mmHg)": [ 115, 142 ], "minimal": [ 117 ], "minor": [ 118, 148 ], "hypoglycemia": [ 119, 149 ], "(1.30": [ 120 ], "episodes/patient-year)": [ 121 ], "(3.2%).": [ 124 ], "Among": [ 125 ], "continuing": [ 127 ], "liraglutide,": [ 128 ], "significant": [ 130 ], "decreases": [ 131 ], "(0.4": [ 135 ], "kg)": [ 136 ], "(2.2": [ 141 ], "occurred": [ 143 ], "0.74": [ 145 ], "episodes/patient-year": [ 146 ], "1.5%": [ 151 ], "experiencing": [ 152 ], "nausea.": [ 153 ], "CONCLUSIONS": [ 154 ], "Conversion": [ 155 ], "is": [ 160 ], "well": [ 161 ], "tolerated": [ 162 ], "provides": [ 164 ], "additional": [ 165 ], "glycemic": [ 166 ], "control": [ 167 ], "cardiometabolic": [ 169 ], "benefits.": [ 170 ] }, "publication_date": "2010-03-23", "publication_year": 2010, "type": "article", "cited_by_count": 175, "authors": [ { "id": "https://openalex.org/A5040182038", "display_name": "John B. Buse" }, { "id": "https://openalex.org/A5084623347", "display_name": "Giorgio Sesti" }, { "id": "https://openalex.org/A5111040183", "display_name": "Wolfgang E. Schmidt" }, { "id": "https://openalex.org/A5031060251", "display_name": "Eduard Montanya" }, { "id": "https://openalex.org/A5103469037", "display_name": "Cheng\u2010Tao Chang" }, { "id": "https://openalex.org/A5101865568", "display_name": "Yizhen Xu" }, { "id": "https://openalex.org/A5070289715", "display_name": "Lawrence Blonde" }, { "id": "https://openalex.org/A5045489578", "display_name": "Julio Rosenstock" } ] }, { "id": "https://openalex.org/W2974621372", "doi": "https://doi.org/10.2337/dc19-0883", "title": "Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial", "abstract": { "OBJECTIVE": [ 0 ], "Efficacy": [ 1 ], "and": [ 2, 13, 74, 94, 117, 201, 281 ], "safety": [ 3, 300 ], "of": [ 4, 87, 302 ], "the": [ 5, 14, 113, 121, 125, 177, 298 ], "glucagon-like": [ 6 ], "peptide": [ 7 ], "1": [ 8 ], "(GLP-1)": [ 9 ], "analog": [ 10 ], "oral": [ 11, 43, 114, 171, 223, 249 ], "semaglutide": [ 12, 44, 115, 128, 172, 224, 253, 293 ], "sodium\u2013glucose": [ 15 ], "cotransporter": [ 16 ], "2": [ 17, 26, 272 ], "inhibitor": [ 18 ], "empagliflozin": [ 19, 51, 122, 135, 229, 257 ], "were": [ 20, 36, 64, 245, 287 ], "compared": [ 21 ], "in": [ 22, 57, 71, 103, 112, 120, 132, 167, 258, 268 ], "patients": [ 23, 111, 269 ], "with": [ 24, 42, 248, 270 ], "type": [ 25, 271 ], "diabetes": [ 27, 273 ], "uncontrolled": [ 28, 274 ], "on": [ 29, 275 ], "metformin.": [ 30, 276 ], "RESEARCH": [ 31 ], "DESIGN": [ 32 ], "AND": [ 33 ], "METHODS": [ 34 ], "Patients": [ 35 ], "randomized": [ 37, 105 ], "to": [ 38, 68, 256 ], "once-daily": [ 39 ], "open-label": [ 40 ], "treatment": [ 41, 84, 149, 165 ], "14": [ 45 ], "mg": [ 46, 53 ], "(n": [ 47, 54 ], "=": [ 48, 55, 240 ], "412)": [ 49 ], "or": [ 50, 91 ], "25": [ 52 ], "410)": [ 56 ], "a": [ 58 ], "52-week": [ 59 ], "trial.": [ 60, 126 ], "Key": [ 61 ], "end": [ 62 ], "points": [ 63 ], "change": [ 65 ], "from": [ 66 ], "baseline": [ 67 ], "week": [ 69, 137, 174, 203, 218, 231, 278 ], "26": [ 70, 138, 175, 219, 266 ], "HbA1c": [ 72, 133, 168, 260, 280 ], "(primary)": [ 73 ], "body": [ 75, 263, 282 ], "weight": [ 76, 212, 264, 283 ], "(confirmatory": [ 77 ], "secondary).": [ 78 ], "Two": [ 79 ], "estimands": [ 80, 207 ], "addressed": [ 81 ], "efficacy-related": [ 82 ], "questions:": [ 83 ], "policy": [ 85, 140 ], "(regardless": [ 86 ], "trial": [ 88, 95, 98, 178 ], "product": [ 89, 96, 99, 179, 234, 285 ], "discontinuation": [ 90 ], "rescue": [ 92, 101 ], "medication)": [ 93, 102 ], "(on": [ 97 ], "without": [ 100 ], "all": [ 104 ], "patients.": [ 106 ], "RESULTS": [ 107 ], "Four": [ 108 ], "hundred": [ 109 ], "(97.1%)": [ 110 ], "group": [ 116, 123 ], "387": [ 118 ], "(94.4%)": [ 119 ], "completed": [ 124 ], "Oral": [ 127, 252, 292 ], "provided": [ 129 ], "superior": [ 130, 255 ], "reductions": [ 131 ], "versus": [ 134, 290 ], "at": [ 136, 173, 202, 217, 230, 265 ], "(treatment": [ 139, 220 ], "\u20131.3%": [ 141 ], "vs.": [ 142, 145, 182, 185, 236 ], "\u20130.9%": [ 143, 183 ], "[\u201314": [ 144 ], "\u20139": [ 146, 186 ], "mmol/mol],": [ 147, 187 ], "estimated": [ 148 ], "difference": [ 150, 166 ], "[ETD]": [ 151 ], "\u20130.4%": [ 152 ], "[95%": [ 153, 190 ], "CI": [ 154, 191 ], "\u20130.6,": [ 155 ], "\u20130.3]": [ 156 ], "[\u20135": [ 157 ], "mmol/mol": [ 158, 195 ], "(\u20136,": [ 159 ], "\u20133)];": [ 160 ], "P": [ 161, 198, 239 ], "&lt;": [ 162, 199, 209 ], "0.0001).": [ 163, 210 ], "The": [ 164 ], "significantly": [ 169, 226, 288 ], "favored": [ 170 ], "for": [ 176, 205 ], "estimand": [ 180 ], "(\u20131.4%": [ 181 ], "[\u201315": [ 184 ], "ETD": [ 188 ], "\u20130.5%": [ 189 ], "\u20130.7,": [ 192 ], "\u20130.4]": [ 193 ], "[\u20136": [ 194 ], "(\u20137,": [ 196 ], "\u20135)];": [ 197 ], "0.0001)": [ 200 ], "52": [ 204, 232 ], "both": [ 206 ], "(P": [ 208 ], "Superior": [ 211 ], "loss": [ 213 ], "was": [ 214, 225, 254, 294 ], "not": [ 215, 262 ], "confirmed": [ 216 ], "policy),": [ 221 ], "but": [ 222, 261 ], "better": [ 227 ], "than": [ 228 ], "(trial": [ 233, 284 ], "\u22124.7": [ 235 ], "\u22123.8": [ 237 ], "kg;": [ 238 ], "0.0114).": [ 241 ], "Gastrointestinal": [ 242 ], "adverse": [ 243 ], "events": [ 244 ], "more": [ 246 ], "common": [ 247 ], "semaglutide.": [ 250 ], "CONCLUSIONS": [ 251 ], "reducing": [ 259 ], "weeks": [ 267 ], "At": [ 277 ], "52,": [ 279 ], "estimand)": [ 286 ], "reduced": [ 289 ], "empagliflozin.": [ 291 ], "well": [ 295 ], "tolerated": [ 296 ], "within": [ 297 ], "established": [ 299 ], "profile": [ 301 ], "GLP-1": [ 303 ], "receptor": [ 304 ], "agonists.": [ 305 ] }, "publication_date": "2019-09-17", "publication_year": 2019, "type": "article", "cited_by_count": 400, "authors": [ { "id": "https://openalex.org/A5020174004", "display_name": "Helena W. Rodbard" }, { "id": "https://openalex.org/A5045489578", "display_name": "Julio Rosenstock" }, { "id": "https://openalex.org/A5064782627", "display_name": "Lu\u00eds Henrique Santos Canani" }, { "id": "https://openalex.org/A5058016758", "display_name": "Chaicharn Deerochanawong" }, { "id": "https://openalex.org/A5057777286", "display_name": "Janusz Gumprecht" }, { "id": "https://openalex.org/A5016152313", "display_name": "S\u00f8ren Lindberg" }, { "id": "https://openalex.org/A5001655356", "display_name": "Ildiko Lingvay" }, { "id": "https://openalex.org/A5085014745", "display_name": "ANETTE L. S\u00d8NDERGAARD" }, { "id": "https://openalex.org/A5048183455", "display_name": "Marianne Bach Treppendahl" }, { "id": "https://openalex.org/A5031060251", "display_name": "Eduard Montanya" }, { "id": "https://openalex.org/A5036493477", "display_name": "Pablo Jord\u00e3o Alc\u00e2ntara Cruz" }, { "id": "https://openalex.org/A5022890768", "display_name": "Luis De Loredo" }, { "id": "https://openalex.org/A5056851414", "display_name": "Cecilia Luquez" }, { "id": "https://openalex.org/A5096901637", "display_name": "Maria Alejandra Moisello" }, { "id": "https://openalex.org/A5103027167", "display_name": "Gustavo Akerman Augusto" }, { "id": "https://openalex.org/A5113454311", "display_name": "Marise Lazaretti Castro" }, { "id": "https://openalex.org/A5064782627", "display_name": "Lu\u00eds Henrique Santos Canani" }, { "id": "https://openalex.org/A5098391008", "display_name": "Branko Akrap" }, { "id": "https://openalex.org/A5080243862", "display_name": "Tomislav Bulum" }, { "id": "https://openalex.org/A5085605928", "display_name": "Dario Raheli\u0107" }, { "id": "https://openalex.org/A5098306979", "display_name": "Ivana Sunic-Grcic" }, { "id": "https://openalex.org/A5017746662", "display_name": "Srecko Tusek" }, { "id": "https://openalex.org/A5015986876", "display_name": "Iakovos Avramidis" }, { "id": "https://openalex.org/A5113435233", "display_name": "Marian Benroubi" }, { "id": "https://openalex.org/A5034510351", "display_name": "Triantafyllos Didangelos" }, { "id": "https://openalex.org/A5059311070", "display_name": "Gerasimos Karousos" }, { "id": "https://openalex.org/A5081653997", "display_name": "Emmanouil Pagkalos" }, { "id": "https://openalex.org/A5112297547", "display_name": "Christos Sampanis" }, { "id": "https://openalex.org/A5082784015", "display_name": "Maria Somali" }, { "id": "https://openalex.org/A5077797891", "display_name": "Zsolt Dombor\u00f3czki" }, { "id": "https://openalex.org/A5070666608", "display_name": "P\u00e9ter Faludi" }, { "id": "https://openalex.org/A5026012526", "display_name": "Zsolt Ga\u00e1l" }, { "id": "https://openalex.org/A5098648558", "display_name": "Piroska Kis-Gombos" }, { "id": "https://openalex.org/A5055222340", "display_name": "Gy\u0151z\u0151 Kocsis" }, { "id": "https://openalex.org/A5109043811", "display_name": "Zolt\u00e1n M\u00e1rton" }, { "id": "https://openalex.org/A5055971647", "display_name": "Zsolt Sud\u00e1r" }, { "id": "https://openalex.org/A5052679600", "display_name": "Silvio Buscemi" }, { "id": "https://openalex.org/A5023676153", "display_name": "Alberto Di Carlo" }, { "id": "https://openalex.org/A5069364785", "display_name": "Francesco Dotta" }, { "id": "https://openalex.org/A5048808735", "display_name": "Alessandra Gambineri" }, { "id": "https://openalex.org/A5040626995", "display_name": "Davide Lauro" }, { "id": "https://openalex.org/A5083451515", "display_name": "Marianna Maranghi" }, { "id": "https://openalex.org/A5062464920", "display_name": "Ma\u0142gorzata Arciszewska" }, { "id": "https://openalex.org/A5057777286", "display_name": "Janusz Gumprecht" }, { "id": "https://openalex.org/A5109436345", "display_name": "Krystyna Matuszewska" }, { "id": "https://openalex.org/A5020616006", "display_name": "Ewa Skokowska" }, { "id": "https://openalex.org/A5049354254", "display_name": "Teresa Stasinska" }, { "id": "https://openalex.org/A5066257563", "display_name": "Svetlana Feofanova" }, { "id": "https://openalex.org/A5007526392", "display_name": "\u0415. \u041e. \u0424\u0438\u043b\u0438\u043f\u043f\u043e\u0432\u0430" }, { "id": "https://openalex.org/A5043877274", "display_name": "G. R. Galstyan" }, { "id": "https://openalex.org/A5072627594", "display_name": "Leyla Gaysina" }, { "id": "https://openalex.org/A5112353431", "display_name": "\u041c. \u0410. \u041a\u0443\u043d\u0438\u0446\u044b\u043d\u0430" }, { "id": "https://openalex.org/A5108130610", "display_name": "Lyudmila Suplotova" }, { "id": "https://openalex.org/A5045813766", "display_name": "Slobodan Anti\u0107" }, { "id": "https://openalex.org/A5020546385", "display_name": "Aleksandar Djuki\u0107" }, { "id": "https://openalex.org/A5102911574", "display_name": "Milena Mitrovi\u0107" }, { "id": "https://openalex.org/A5069673029", "display_name": "Milica Pe\u0161i\u0107" }, { "id": "https://openalex.org/A5108508358", "display_name": "Edita Stoki\u0107" }, { "id": "https://openalex.org/A5088506788", "display_name": "Esteban J\u00f3dar" }, { "id": "https://openalex.org/A5101061580", "display_name": "Encarna Mart\u00ednez" }, { "id": "https://openalex.org/A5039297952", "display_name": "Pedro Mezquita Raya" }, { "id": "https://openalex.org/A5031060251", "display_name": "Eduard Montanya" }, { "id": "https://openalex.org/A5051089128", "display_name": "Crist\u00f3bal Morales" }, { "id": "https://openalex.org/A5050823405", "display_name": "Merc\u00e8 P\u00e9rez Vera" }, { "id": "https://openalex.org/A5112303326", "display_name": "Margarita Fern\u00e1ndez" }, { "id": "https://openalex.org/A5056115281", "display_name": "Patricia San Jos\u00e9" }, { "id": "https://openalex.org/A5064165080", "display_name": "Manel Terns Riera" }, { "id": "https://openalex.org/A5077286181", "display_name": "Apussanee Boonyavarakul" }, { "id": "https://openalex.org/A5058016758", "display_name": "Chaicharn Deerochanawong" }, { "id": "https://openalex.org/A5015937048", "display_name": "Apiradee Sriwijitkamol" }, { "id": "https://openalex.org/A5081851739", "display_name": "Dilawar Ajani" }, { "id": "https://openalex.org/A5072114600", "display_name": "Eddie Armas" }, { "id": "https://openalex.org/A5065356177", "display_name": "Kim Barbel-Johnson" }, { "id": "https://openalex.org/A5092911968", "display_name": "Darlene Bartilucci" }, { "id": "https://openalex.org/A5043484664", "display_name": "Gholamreza Bonabi" }, { "id": "https://openalex.org/A5103165011", "display_name": "Robert S. Busch" }, { "id": "https://openalex.org/A5028867550", "display_name": "David Butuk" }, { "id": "https://openalex.org/A5083412123", "display_name": "Kevin D. Cannon" }, { "id": "https://openalex.org/A5112469283", "display_name": "Craig Chase" }, { "id": "https://openalex.org/A5005982472", "display_name": "Louis Chaykin" }, { "id": "https://openalex.org/A5085369763", "display_name": "Vasundhara Cheekati" }, { "id": "https://openalex.org/A5110385838", "display_name": "Thomas R. A. Davis" }, { "id": "https://openalex.org/A5040939919", "display_name": "Belkis Delgado" }, { "id": "https://openalex.org/A5058938529", "display_name": "Neil Farris" }, { "id": "https://openalex.org/A5080265363", "display_name": "Mark Graves" }, { "id": "https://openalex.org/A5110638357", "display_name": "Chi Ha" }, { "id": "https://openalex.org/A5103868085", "display_name": "Linda Harper" }, { "id": "https://openalex.org/A5069608211", "display_name": "Sharon J. Herring" }, { "id": "https://openalex.org/A5086166789", "display_name": "Mitzie Hewitt" }, { "id": "https://openalex.org/A5018627458", "display_name": "Daniel S. Hsia" }, { "id": "https://openalex.org/A5103378250", "display_name": "Richard A. Jackson" }, { "id": "https://openalex.org/A5015410022", "display_name": "Michael Jardula" }, { "id": "https://openalex.org/A5108374131", "display_name": "Mark Joyce" }, { "id": "https://openalex.org/A5108774663", "display_name": "Mario Juarez" }, { "id": "https://openalex.org/A5102330516", "display_name": "Anoop Kapoor" }, { "id": "https://openalex.org/A5051341808", "display_name": "Dennis G. Karounos" }, { "id": "https://openalex.org/A5072568098", "display_name": "David Kayne" }, { "id": "https://openalex.org/A5112945912", "display_name": "Audrey Lacour" }, { "id": "https://openalex.org/A5034084520", "display_name": "Gilbert Ledesma" }, { "id": "https://openalex.org/A5001655356", "display_name": "Ildiko Lingvay" } ] }, { "id": "https://openalex.org/W2794447083", "doi": "https://doi.org/10.1002/14651858.cd012990.pub2", "title": "GLP-1 receptor agonists for Parkinson's disease", "abstract": { "Low-": [ 0 ], "or": [ 1 ], "very": [ 2 ], "low-certainty": [ 3 ], "evidence": [ 4 ], "suggests": [ 5 ], "that": [ 6, 37 ], "exenatide": [ 7, 38, 55 ], "may": [ 8, 24, 39 ], "improve": [ 9 ], "motor": [ 10, 19 ], "impairment": [ 11, 20 ], "for": [ 12, 26, 56 ], "people": [ 13 ], "with": [ 14 ], "PD.": [ 15 ], "The": [ 16, 52 ], "difference": [ 17 ], "in": [ 18 ], "observed": [ 21 ], "between": [ 22 ], "groups": [ 23 ], "persist": [ 25 ], "some": [ 27 ], "time": [ 28 ], "following": [ 29 ], "cessation": [ 30 ], "of": [ 31, 54 ], "exenatide.": [ 32 ], "This": [ 33 ], "raises": [ 34 ], "the": [ 35 ], "possibility": [ 36 ], "have": [ 40 ], "a": [ 41 ], "disease-modifying": [ 42 ], "effect.": [ 43 ], "SAEs": [ 44 ], "were": [ 45 ], "unlikely": [ 46 ], "to": [ 47, 50 ], "be": [ 48 ], "related": [ 49 ], "treatment.": [ 51 ], "effectiveness": [ 53 ], "improving": [ 57 ], "HRQoL,": [ 58 ], "non-motor": [ 59 ], "outcomes,": [ 60 ], "ADLs,": [ 61 ], "and": [ 62 ], "psychological": [ 63 ], "outcomes": [ 64 ], "is": [ 65 ], "unclear.": [ 66 ], "Ongoing": [ 67 ], "studies": [ 68 ], "are": [ 69 ], "assessing": [ 70 ], "other": [ 71 ], "GLP-1": [ 72 ], "receptor": [ 73 ], "agonists.": [ 74 ] }, "publication_date": "2020-07-23", "publication_year": 2020, "type": "review", "cited_by_count": 60, "authors": [ { "id": "https://openalex.org/A5105457591", "display_name": "Caroline Mulvaney" }, { "id": "https://openalex.org/A5077191137", "display_name": "Gon\u00e7alo S. Duarte" }, { "id": "https://openalex.org/A5087057901", "display_name": "Joel Handley" }, { "id": "https://openalex.org/A5102974478", "display_name": "David Evans" }, { "id": "https://openalex.org/A5010005544", "display_name": "Suresh Menon" }, { "id": "https://openalex.org/A5021732872", "display_name": "Richard Wyse" }, { "id": "https://openalex.org/A5029502706", "display_name": "Hedley Emsley" } ] }, { "id": "https://openalex.org/W2741958922", "doi": "https://doi.org/10.1016/j.cmet.2017.07.011", "title": "The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes", "abstract": null, "publication_date": "2017-08-01", "publication_year": 2017, "type": "article", "cited_by_count": 313, "authors": [ { "id": "https://openalex.org/A5086072427", "display_name": "Juan P. Fr\u00edas" }, { "id": "https://openalex.org/A5061691275", "display_name": "Edward J. Bastyr" }, { "id": "https://openalex.org/A5068506691", "display_name": "Louis Vignati" }, { "id": "https://openalex.org/A5109987976", "display_name": "Matthias H. Tsch\u00f6p" }, { "id": "https://openalex.org/A5020001100", "display_name": "Christophe Schmitt" }, { "id": "https://openalex.org/A5042726003", "display_name": "K Owen" }, { "id": "https://openalex.org/A5086458689", "display_name": "Rune Haubo Bojesen Christensen" }, { "id": "https://openalex.org/A5071517746", "display_name": "Richard D. DiMarchi" } ] }, { "id": "https://openalex.org/W2094250264", "doi": "https://doi.org/10.2337/dc12-0709", "title": "The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes", "abstract": { "OBJECTIVE": [ 0 ], "Taspoglutide": [ 1, 148 ], "is": [ 2 ], "a": [ 3, 44 ], "long-acting": [ 4 ], "glucagon-like": [ 5 ], "peptide": [ 6 ], "1": [ 7 ], "receptor": [ 8 ], "agonist": [ 9 ], "developed": [ 10, 198 ], "for": [ 11 ], "treatment": [ 12 ], "of": [ 13, 21, 97, 235, 255 ], "type": [ 14, 38 ], "2": [ 15, 39 ], "diabetes.": [ 16 ], "The": [ 17, 78 ], "efficacy": [ 18 ], "and": [ 19, 179, 193, 205, 207, 212, 216, 259 ], "safety": [ 20 ], "once-weekly": [ 22 ], "taspoglutide": [ 23, 50, 57, 98, 121, 138, 157, 172, 191, 239 ], "was": [ 24, 82, 93, 168 ], "compared": [ 25 ], "with": [ 26, 35, 171, 190, 222, 227, 247, 252 ], "twice-daily": [ 27, 245 ], "exenatide.": [ 28, 147 ], "RESEARCH": [ 29 ], "DESIGN": [ 30 ], "AND": [ 31 ], "METHODS": [ 32 ], "Overweight": [ 33 ], "adults": [ 34 ], "inadequately": [ 36 ], "controlled": [ 37 ], "diabetes": [ 40 ], "on": [ 41 ], "metformin": [ 42 ], "\u00b1": [ 43 ], "thiazolidinedione": [ 45 ], "were": [ 46, 182, 219, 225, 231 ], "randomized": [ 47 ], "to": [ 48, 116, 129 ], "subcutaneous": [ 49 ], "10": [ 51, 66, 106, 153, 173, 192 ], "mg": [ 52, 59, 174, 195 ], "weekly": [ 53, 60 ], "(n": [ 54, 61, 70 ], "=": [ 55, 62, 71 ], "399),": [ 56 ], "20": [ 58, 122, 158, 194 ], "398),": [ 63 ], "or": [ 64 ], "exenatide": [ 65, 104, 164, 197, 246 ], "\u00b5g": [ 67 ], "twice": [ 68 ], "daily": [ 69 ], "392)": [ 72 ], "in": [ 73, 84, 202, 209, 233 ], "an": [ 74 ], "open-label,": [ 75 ], "multicenter": [ 76 ], "trial.": [ 77 ], "primary": [ 79 ], "end": [ 80 ], "point": [ 81 ], "change": [ 83 ], "HbA1c": [ 85, 92, 100, 178 ], "after": [ 86, 184 ], "24": [ 87 ], "weeks.": [ 88, 186 ], "RESULTS": [ 89 ], "Mean": [ 90 ], "baseline": [ 91 ], "8.1%.": [ 94 ], "Both": [ 95, 137 ], "doses": [ 96, 139 ], "reduced": [ 99, 140, 149 ], "significantly": [ 101, 144 ], "more": [ 102, 145, 220 ], "than": [ 103, 146, 170, 196, 244 ], "(taspoglutide": [ 105, 152 ], "mg:": [ 107, 123 ], "\u20131.24%": [ 108 ], "[SE": [ 109 ], "0.09],": [ 110 ], "difference": [ 111, 126 ], "\u20130.26,": [ 112 ], "95%": [ 113 ], "CI": [ 114 ], "\u20130.37": [ 115 ], "\u20130.15,": [ 117 ], "P": [ 118, 131 ], "&lt;": [ 119, 132, 176 ], "0.0001;": [ 120, 133 ], "\u20131.31%": [ 124 ], "[0.08],": [ 125 ], "\u20130.33,": [ 127 ], "\u20130.44": [ 128 ], "\u20130.22,": [ 130 ], "exenatide:": [ 134 ], "\u20130.98%": [ 135 ], "[0.08]).": [ 136 ], "fasting": [ 141 ], "plasma": [ 142 ], "glucose": [ 143 ], "body": [ 150 ], "weight": [ 151, 180, 249 ], "mg,": [ 154, 159 ], "\u20131.6": [ 155 ], "kg;": [ 156 ], "\u20132.3": [ 160 ], "kg)": [ 161 ], "as": [ 162 ], "did": [ 163 ], "(\u20132.3": [ 165 ], "kg),": [ 166 ], "which": [ 167 ], "greater": [ 169, 226, 241 ], "(P": [ 175 ], "0.05).": [ 177 ], "effects": [ 181 ], "maintained": [ 183 ], "52": [ 185 ], "More": [ 187 ], "adverse": [ 188 ], "events": [ 189 ], "over": [ 199 ], "time": [ 200 ], "(nausea": [ 201 ], "53,": [ 203 ], "59,": [ 204 ], "35%": [ 206 ], "vomiting": [ 208 ], "33,": [ 210 ], "37,": [ 211 ], "16%,": [ 213 ], "respectively).": [ 214 ], "Allergic": [ 215 ], "injection-site": [ 217, 257 ], "reactions": [ 218 ], "common": [ 221 ], "taspoglutide.": [ 223, 228 ], "Discontinuations": [ 224 ], "Antitaspoglutide": [ 229 ], "antibodies": [ 230 ], "detected": [ 232 ], "49%": [ 234 ], "patients.": [ 236 ], "CONCLUSIONS": [ 237 ], "Once-weekly": [ 238 ], "demonstrated": [ 240 ], "glycemic": [ 242 ], "control": [ 243 ], "comparable": [ 248 ], "loss,": [ 250 ], "but": [ 251 ], "unacceptable": [ 253 ], "levels": [ 254 ], "nausea/vomiting,": [ 256 ], "reactions,": [ 258 ], "systemic": [ 260 ], "allergic": [ 261 ], "reactions.": [ 262 ] }, "publication_date": "2012-11-09", "publication_year": 2012, "type": "article", "cited_by_count": 111, "authors": [ { "id": "https://openalex.org/A5045489578", "display_name": "Julio Rosenstock" }, { "id": "https://openalex.org/A5028793097", "display_name": "Bogdan Balas" }, { "id": "https://openalex.org/A5025169113", "display_name": "B Charbonnel" }, { "id": "https://openalex.org/A5057323309", "display_name": "Geremia B. Bolli" }, { "id": "https://openalex.org/A5063044383", "display_name": "Mark Boldrin" }, { "id": "https://openalex.org/A5081205041", "display_name": "Robert E. Ratner" }, { "id": "https://openalex.org/A5027294690", "display_name": "R. Balena" } ] }, { "id": "https://openalex.org/W2075514437", "doi": "https://doi.org/10.1002/hep.21006", "title": "Exendin\u20104, a glucagon\u2010like protein\u20101 (GLP\u20101) receptor agonist, reverses hepatic steatosis in ob/ob mice\u2020", "abstract": { "Nonalcoholic": [ 0 ], "fatty": [ 1, 192, 203 ], "liver": [ 2, 229 ], "disease": [ 3 ], "(NAFLD)": [ 4 ], "represents": [ 5 ], "a": [ 6, 19, 109, 153, 171, 231 ], "burgeoning": [ 7 ], "problem": [ 8 ], "in": [ 9, 48, 111, 127, 136, 161, 170, 174, 181, 215, 228 ], "hepatology,": [ 10 ], "and": [ 11, 80, 93, 102, 121, 188 ], "is": [ 12, 18 ], "associated": [ 13, 190, 201 ], "with": [ 14, 59, 104, 164, 191, 202 ], "insulin": [ 15, 30, 134, 220 ], "resistance.": [ 16 ], "Exendin-4": [ 17, 43, 60, 117, 128, 132, 208 ], "peptide": [ 20, 25 ], "agonist": [ 21 ], "of": [ 22, 34, 42, 74, 148, 155, 184 ], "the": [ 23, 112, 142, 195 ], "glucagon-like": [ 24 ], "(GLP)": [ 26 ], "receptor": [ 27 ], "that": [ 28, 225 ], "promotes": [ 29 ], "secretion.": [ 31 ], "The": [ 32, 146 ], "aim": [ 33 ], "this": [ 35 ], "study": [ 36 ], "was": [ 37, 70, 85, 124, 158, 197 ], "to": [ 38, 210 ], "determine": [ 39 ], "whether": [ 40 ], "administration": [ 41 ], "would": [ 44 ], "reverse": [ 45, 212 ], "hepatic": [ 46, 122, 213 ], "steatosis": [ 47, 123, 214 ], "ob/ob": [ 49, 130, 137, 216 ], "mice.": [ 50, 131 ], "Ob/ob": [ 51, 106 ], "mice,": [ 52, 138 ], "or": [ 53, 63 ], "their": [ 54 ], "lean": [ 55 ], "littermates,": [ 56 ], "were": [ 57, 100 ], "treated": [ 58, 103, 129 ], "[10": [ 61 ], "microg/kg": [ 62 ], "20": [ 64 ], "microg/kg]": [ 65 ], "for": [ 66, 72, 87, 95, 199 ], "60": [ 67 ], "days.": [ 68 ], "Serum": [ 69, 119 ], "collected": [ 71 ], "measurement": [ 73, 147 ], "insulin,": [ 75 ], "adiponectin,": [ 76 ], "fasting": [ 77 ], "glucose,": [ 78 ], "lipids,": [ 79 ], "aminotransferase": [ 81 ], "concentrations.": [ 82 ], "Liver": [ 83 ], "tissue": [ 84 ], "procured": [ 86 ], "histological": [ 88 ], "examination,": [ 89 ], "real-time": [ 90 ], "RT-PCR": [ 91 ], "analysis": [ 92 ], "assay": [ 94 ], "oxidative": [ 96, 156 ], "stress.": [ 97 ], "Rat": [ 98 ], "hepatocytes": [ 99, 168 ], "isolated": [ 101 ], "GLP-1.": [ 105 ], "mice": [ 107, 163, 217 ], "sustained": [ 108 ], "reduction": [ 110, 180 ], "net": [ 113 ], "weight": [ 114 ], "gained": [ 115 ], "during": [ 116 ], "treatment.": [ 118 ], "glucose": [ 120 ], "significantly": [ 125, 159 ], "reduced": [ 126, 160 ], "improved": [ 133 ], "sensitivity": [ 135 ], "as": [ 139, 152, 177, 179 ], "calculated": [ 140 ], "by": [ 141, 218 ], "homeostasis": [ 143 ], "model": [ 144 ], "assessment.": [ 145 ], "thiobarbituric": [ 149 ], "reactive": [ 150 ], "substances": [ 151 ], "marker": [ 154 ], "stress": [ 157 ], "ob/ob-treated": [ 162 ], "Exendin-4.": [ 165 ], "Finally,": [ 166 ], "GLP-1-treated": [ 167 ], "resulted": [ 169 ], "significant": [ 172 ], "increase": [ 173 ], "cAMP": [ 175 ], "production": [ 176 ], "well": [ 178 ], "mRNA": [ 182 ], "expression": [ 183 ], "stearoyl-CoA": [ 185 ], "desaturase": [ 186 ], "1": [ 187 ], "genes": [ 189, 200 ], "acid": [ 193, 204 ], "synthesis;": [ 194 ], "converse": [ 196 ], "true": [ 198 ], "oxidation.": [ 205 ], "In": [ 206 ], "conclusion,": [ 207 ], "appears": [ 209 ], "effectively": [ 211 ], "improving": [ 219 ], "sensitivity.": [ 221 ], "Our": [ 222 ], "data": [ 223 ], "suggest": [ 224 ], "GLP-1": [ 226 ], "proteins": [ 227 ], "have": [ 230 ], "novel": [ 232 ], "direct": [ 233 ], "effect": [ 234 ], "on": [ 235 ], "hepatocyte": [ 236 ], "fat": [ 237 ], "metabolism.": [ 238 ] }, "publication_date": "2005-12-22", "publication_year": 2005, "type": "article", "cited_by_count": 539, "authors": [ { "id": "https://openalex.org/A5088767282", "display_name": "Xiaokun Ding" }, { "id": "https://openalex.org/A5059496981", "display_name": "Neeraj K. Saxena" }, { "id": "https://openalex.org/A5102153436", "display_name": "Songbai Lin" }, { "id": "https://openalex.org/A5111821475", "display_name": "Narita Gupta" }, { "id": "https://openalex.org/A5035375857", "display_name": "Frank A. Anania" } ] }, { "id": "https://openalex.org/W2809045056", "doi": "https://doi.org/10.1007/s40262-018-0668-z", "title": "Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist", "abstract": null, "publication_date": "2018-06-18", "publication_year": 2018, "type": "review", "cited_by_count": 90, "authors": [ { "id": "https://openalex.org/A5012567680", "display_name": "Sylvie Hall" }, { "id": "https://openalex.org/A5022179243", "display_name": "Diana Isaacs" }, { "id": "https://openalex.org/A5029137344", "display_name": "Jennifer N. Clements" } ] }, { "id": "https://openalex.org/W3013213902", "doi": "https://doi.org/10.1056/nejmoa1916038", "title": "A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity", "abstract": { "In": [ 0 ], "adolescents": [ 1 ], "with": [ 2 ], "obesity,": [ 3 ], "the": [ 4, 20 ], "use": [ 5 ], "of": [ 6 ], "liraglutide": [ 7 ], "(3.0": [ 8 ], "mg)": [ 9 ], "plus": [ 10, 26 ], "lifestyle": [ 11, 27 ], "therapy": [ 12 ], "led": [ 13 ], "to": [ 14 ], "a": [ 15 ], "significantly": [ 16 ], "greater": [ 17 ], "reduction": [ 18 ], "in": [ 19 ], "BMI": [ 21 ], "standard-deviation": [ 22 ], "score": [ 23 ], "than": [ 24 ], "placebo": [ 25 ], "therapy.": [ 28 ], "(Funded": [ 29 ], "by": [ 30 ], "Novo": [ 31 ], "Nordisk;": [ 32 ], "NN8022-4180": [ 33 ], "ClinicalTrials.gov": [ 34 ], "number,": [ 35 ], "NCT02918279.).": [ 36 ] }, "publication_date": "2020-03-31", "publication_year": 2020, "type": "article", "cited_by_count": 585, "authors": [ { "id": "https://openalex.org/A5012739284", "display_name": "Aaron S. Kelly" }, { "id": "https://openalex.org/A5035576643", "display_name": "Pernille Auerbach" }, { "id": "https://openalex.org/A5083846346", "display_name": "Margarita Barrientos\u2010P\u00e9rez" }, { "id": "https://openalex.org/A5077703023", "display_name": "Inge Gies" }, { "id": "https://openalex.org/A5023487929", "display_name": "Paula M. Hale" }, { "id": "https://openalex.org/A5059419357", "display_name": "Claude Marcus" }, { "id": "https://openalex.org/A5045940638", "display_name": "Lucy D. Mastrandrea" }, { "id": "https://openalex.org/A5028185678", "display_name": "Nandana Prabhu" }, { "id": "https://openalex.org/A5044519340", "display_name": "Silva Arslanian" } ] }, { "id": "https://openalex.org/W4283165920", "doi": "https://doi.org/10.1016/j.phrs.2022.106320", "title": "The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists", "abstract": null, "publication_date": "2022-06-20", "publication_year": 2022, "type": "review", "cited_by_count": 270, "authors": [ { "id": "https://openalex.org/A5048432334", "display_name": "Giulia Bendotti" }, { "id": "https://openalex.org/A5036331320", "display_name": "Laura Montefusco" }, { "id": "https://openalex.org/A5016910221", "display_name": "Maria Elena Lunati" }, { "id": "https://openalex.org/A5001694345", "display_name": "Vera Usuelli" }, { "id": "https://openalex.org/A5054756814", "display_name": "Ida Pastore" }, { "id": "https://openalex.org/A5034349860", "display_name": "Elisa Lazzaroni" }, { "id": "https://openalex.org/A5025504684", "display_name": "Emma Assi" }, { "id": "https://openalex.org/A5050108132", "display_name": "Andy Joe Seelam" }, { "id": "https://openalex.org/A5112258409", "display_name": "Basset El Essawy" }, { "id": "https://openalex.org/A5054173969", "display_name": "Jun Young Jang" }, { "id": "https://openalex.org/A5087468685", "display_name": "Cristian Loretelli" }, { "id": "https://openalex.org/A5015681797", "display_name": "Francesca D\u2019Addio" }, { "id": "https://openalex.org/A5025347212", "display_name": "Cesare Berra" }, { "id": "https://openalex.org/A5007087886", "display_name": "Moufida Ben Nasr" }, { "id": "https://openalex.org/A5068743420", "display_name": "Gianvincenzo Zuccotti" }, { "id": "https://openalex.org/A5028314110", "display_name": "Paolo Fiorina" } ] }, { "id": "https://openalex.org/W2889521172", "doi": "https://doi.org/10.1002/dmrr.3070", "title": "Glucagon\u2010like peptide\u20101 receptor agonists in type 2 diabetes treatment: are they all the same?", "abstract": { "Summary": [ 0 ], "Glucagon\u2010like": [ 1 ], "peptide\u20101": [ 2 ], "(GLP\u20101)": [ 3 ], "receptor": [ 4 ], "agonists": [ 5 ], "(RAs)": [ 6 ], "are": [ 7, 31 ], "an": [ 8, 92 ], "important": [ 9, 93 ], "class": [ 10, 30 ], "of": [ 11, 45, 56, 97, 108, 204, 209 ], "drugs": [ 12, 53 ], "with": [ 13, 22 ], "a": [ 14 ], "well\u2010established": [ 15 ], "efficacy": [ 16, 134 ], "and": [ 17, 66, 72, 106, 125, 135, 148, 150, 159, 174, 186, 194, 202, 224, 234, 244, 251 ], "safety": [ 18, 136 ], "profile": [ 19 ], "in": [ 20, 28, 39, 54, 190, 216 ], "patients": [ 21 ], "type": [ 23 ], "2": [ 24 ], "diabetes": [ 25 ], "mellitus.": [ 26 ], "Agents": [ 27 ], "this": [ 29, 98 ], "derived": [ 32 ], "from": [ 33 ], "either": [ 34 ], "exendin\u20104": [ 35 ], "(a": [ 36 ], "compound": [ 37 ], "present": [ 38 ], "Gila": [ 40 ], "monster": [ 41 ], "venom)": [ 42 ], "or": [ 43 ], "modifications": [ 44 ], "human": [ 46 ], "GLP\u20101": [ 47, 109, 127, 161, 211 ], "active": [ 48 ], "fragment.": [ 49 ], "Differences": [ 50 ], "among": [ 51 ], "these": [ 52 ], "duration": [ 55 ], "action": [ 57 ], "(ie,": [ 58, 144, 152 ], "short\u2010acting": [ 59, 124, 143, 165 ], "vs": [ 60 ], "long\u2010acting),": [ 61 ], "effects": [ 62 ], "on": [ 63, 118, 131 ], "glycaemic": [ 64 ], "control": [ 65 ], "weight": [ 67 ], "loss,": [ 68 ], "immunogenicity,": [ 69 ], "tolerability": [ 70, 222 ], "profiles,": [ 71, 223 ], "administration": [ 73, 228 ], "routes": [ 74 ], "offer": [ 75 ], "physicians": [ 76 ], "several": [ 77 ], "options": [ 78 ], "when": [ 79 ], "selecting": [ 80 ], "the": [ 81, 103, 119, 122, 191, 240 ], "most": [ 82 ], "appropriate": [ 83 ], "agent": [ 84 ], "for": [ 85, 113, 232, 237 ], "individual": [ 86, 133 ], "patients.": [ 87 ], "Patient": [ 88 ], "preference": [ 89 ], "is": [ 90, 100, 163 ], "also": [ 91 ], "consideration.": [ 94 ], "The": [ 95, 138 ], "aim": [ 96 ], "review": [ 99 ], "to": [ 101 ], "discuss": [ 102 ], "differences": [ 104 ], "between": [ 105, 142 ], "similarities": [ 107 ], "RAs": [ 110, 128, 162, 212 ], "currently": [ 111 ], "approved": [ 112 ], "clinical": [ 114 ], "use,": [ 115 ], "focusing": [ 116 ], "particularly": [ 117 ], "properties": [ 120 ], "characterising": [ 121 ], "single": [ 123 ], "long\u2010acting": [ 126, 151, 175, 210, 241 ], "rather": [ 129 ], "than": [ 130 ], "their": [ 132 ], "profiles.": [ 137 ], "primary": [ 139 ], "pharmacodynamic": [ 140 ], "difference": [ 141 ], "exenatide": [ 145, 155, 242 ], "twice": [ 146 ], "daily": [ 147, 231 ], "lixisenatide)": [ 149 ], "albiglutide,": [ 153, 238 ], "dulaglutide,": [ 154, 239 ], "once": [ 156, 235 ], "weekly,": [ 157 ], "liraglutide,": [ 158 ], "semaglutide)": [ 160 ], "that": [ 164 ], "agents": [ 166, 176 ], "primarily": [ 167 ], "delay": [ 168 ], "gastric": [ 169 ], "emptying": [ 170 ], "(lowering": [ 171 ], "postprandial": [ 172, 195, 199 ], "glucose)": [ 173 ], "affect": [ 177 ], "both": [ 178 ], "fasting": [ 179, 192 ], "glucose": [ 180, 196 ], "(via": [ 181, 197 ], "enhanced": [ 182, 198 ], "glucose\u2010dependent": [ 183 ], "insulin": [ 184, 200 ], "secretion": [ 185, 189, 201 ], "reduced": [ 187 ], "glucagon": [ 188, 205 ], "state)": [ 193 ], "inhibition": [ 203 ], "secretion).": [ 206 ], "Other": [ 207 ], "advantages": [ 208 ], "include": [ 213 ], "smaller": [ 214 ], "fluctuations": [ 215 ], "plasma": [ 217 ], "drug": [ 218 ], "concentrations,": [ 219 ], "improved": [ 220 ], "gastrointestinal": [ 221 ], "simpler,": [ 225 ], "more": [ 226 ], "convenient": [ 227 ], "schedules": [ 229 ], "(once": [ 230 ], "liraglutide": [ 233 ], "weekly": [ 236 ], "formulation,": [ 243 ], "semaglutide),": [ 245 ], "which": [ 246 ], "might": [ 247 ], "improve": [ 248 ], "treatment": [ 249 ], "adherence": [ 250 ], "persistence.": [ 252 ] }, "publication_date": "2018-08-30", "publication_year": 2018, "type": "review", "cited_by_count": 208, "authors": [ { "id": "https://openalex.org/A5060140104", "display_name": "R. Gentilella" }, { "id": "https://openalex.org/A5089497324", "display_name": "V. Pechtner" }, { "id": "https://openalex.org/A5005241900", "display_name": "Antonella Corcos" }, { "id": "https://openalex.org/A5003186286", "display_name": "Agostino Consoli" } ] }, { "id": "https://openalex.org/W2586129535", "doi": "https://doi.org/10.1111/dom.12902", "title": "Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon\u2010like peptide\u20101 receptor agonists: H igher adherence and persistence with dulaglutide compared with once\u2010weekly exenatide and liraglutide", "abstract": { "Aims": [ 0 ], "To": [ 1 ], "compare": [ 2, 41 ], "adherence": [ 3, 121 ], "(proportion": [ 4 ], "of": [ 5, 152, 232, 279 ], "days": [ 6, 186 ], "covered": [ 7 ], "[": [ 8 ], "PDC": [ 9, 155 ], "]),": [ 10 ], "persistence,": [ 11 ], "and": [ 12, 47, 65, 71, 100, 107, 109, 142, 174, 217, 251, 271 ], "treatment": [ 13, 188, 237 ], "patterns": [ 14, 111 ], "among": [ 15 ], "patients": [ 16, 153, 192, 197, 233 ], "with": [ 17, 53, 102, 164, 203, 239, 277 ], "type": [ 18 ], "2": [ 19 ], "diabetes": [ 20 ], "mellitus": [ 21 ], "(": [ 22, 31 ], "T2DM": [ 23, 54 ], ")": [ 24 ], "newly": [ 25, 55 ], "initiating": [ 26, 56 ], "glucagon\u2010like": [ 27 ], "peptide\u20101": [ 28 ], "receptor": [ 29 ], "agonists": [ 30 ], "GLP\u20101RAs": [ 32 ], ").": [ 33 ], "More": [ 34 ], "specifically,": [ 35 ], "the": [ 36, 103, 115, 123, 199, 206, 286 ], "main": [ 37 ], "objectives": [ 38 ], "were": [ 39, 75, 112, 268 ], "to": [ 40, 93, 99 ], "dulaglutide": [ 42, 48, 130, 162, 200, 235 ], "vs": [ 43, 49, 137, 145, 169, 177, 211, 222, 246, 256 ], "exenatide": [ 44, 59, 62, 133, 165, 207, 242, 280 ], "once": [ 45, 60, 134, 166, 243, 281 ], "weekly": [ 46, 135, 167, 244, 282 ], "liraglutide.": [ 50 ], "Methods": [ 51 ], "Patients": [ 52 ], "dulaglutide,": [ 57 ], "albiglutide,": [ 58 ], "weekly,": [ 61 ], "twice": [ 63 ], "daily": [ 64 ], "liraglutide": [ 66, 143, 175, 218, 254, 284 ], "between": [ 67 ], "N": [ 68 ], "ovember": [ 69 ], "2014": [ 70 ], "A": [ 72, 228 ], "pril": [ 73 ], "2015": [ 74 ], "hierarchically": [ 76 ], "selected": [ 77 ], "from": [ 78 ], "T": [ 79 ], "ruven": [ 80 ], "H": [ 81 ], "ealth's": [ 82 ], "MarketScan": [ 83 ], "R": [ 84 ], "esearch": [ 85 ], "D": [ 86 ], "atabases.": [ 87 ], "Propensity": [ 88 ], "score": [ 89 ], "matching": [ 90 ], "was": [ 91, 126, 158, 193 ], "used": [ 92 ], "account": [ 94 ], "for": [ 95, 122, 129, 132, 161, 189, 196 ], "selection": [ 96 ], "bias.": [ 97 ], "Adherence": [ 98 ], "persistence": [ 101 ], "index": [ 104 ], "GLP\u20101RA": [ 105 ], ",": [ 106 ], "switching": [ 108 ], "augmentation": [ 110 ], "assessed": [ 113 ], "during": [ 114, 285 ], "6\u2010month": [ 116, 287 ], "post\u2010index": [ 117 ], "period.": [ 118, 289 ], "Results": [ 119 ], "Mean": [ 120 ], "matched": [ 124, 191 ], "cohorts": [ 125, 219 ], "significantly": [ 127, 159, 194, 229, 265 ], "higher": [ 128, 160, 195, 266 ], "than": [ 131 ], "(0.72": [ 136 ], "0.61;": [ 138 ], "P": [ 139, 147, 171, 179, 214, 225, 248, 258 ], "<": [ 140, 148, 172, 180, 215, 226, 249, 259 ], ".0001)": [ 141, 173, 216, 250 ], "(0.71": [ 144 ], "0.67;": [ 146 ], ".0001).": [ 149, 181, 227, 260 ], "The": [ 150, 182 ], "percentage": [ 151 ], "achieving": [ 154 ], "\u2265": [ 156 ], "0.80": [ 157 ], "compared": [ 163, 202, 238, 276 ], "(54.2%": [ 168 ], "37.9%;": [ 170 ], "(53.5%": [ 176 ], "44.3%;": [ 178 ], "mean": [ 183 ], "(standard": [ 184 ], "deviation)": [ 185 ], "on": [ 187, 234, 241, 253 ], "all": [ 190 ], "in": [ 198, 205 ], "cohort": [ 201 ], "those": [ 204, 240, 252 ], "once\u2010weekly": [ 208 ], "(148.4": [ 209 ], "[55.4]": [ 210 ], "123.6": [ 212 ], "[61.6];": [ 213 ], "(146.0": [ 220 ], "[56.9]": [ 221 ], "137.4": [ 223 ], "[60.1];": [ 224 ], "lower": [ 230, 273 ], "proportion": [ 231 ], "discontinued": [ 236 ], "(26.2%": [ 245 ], "48.4%;": [ 247 ], "(28.0%": [ 255 ], "35.6%;": [ 257 ], "Conclusions": [ 261 ], "Dulaglutide": [ 262 ], "initiators": [ 263, 278 ], "had": [ 264, 272 ], "adherence,": [ 267 ], "more": [ 269 ], "persistent,": [ 270 ], "discontinuation": [ 274 ], "rates": [ 275 ], "or": [ 283 ], "follow\u2010up": [ 288 ] }, "publication_date": "2017-02-09", "publication_year": 2017, "type": "article", "cited_by_count": 106, "authors": [ { "id": "https://openalex.org/A5027604315", "display_name": "Carlos Alatorre" }, { "id": "https://openalex.org/A5072715491", "display_name": "Laura Fern\u00e1ndez Land\u00f3" }, { "id": "https://openalex.org/A5109226707", "display_name": "Maria Yu" }, { "id": "https://openalex.org/A5111127692", "display_name": "Katelyn Brown" }, { "id": "https://openalex.org/A5101935262", "display_name": "Leslie Montejano" }, { "id": "https://openalex.org/A5077652159", "display_name": "Paul Juneau" }, { "id": "https://openalex.org/A5011388259", "display_name": "Reema Mody" }, { "id": "https://openalex.org/A5091374453", "display_name": "Ralph Swindle" } ] }, { "id": "https://openalex.org/W2196942236", "doi": "https://doi.org/10.1111/dom.12596", "title": "Review of head\u2010to\u2010head comparisons of glucagon\u2010like peptide\u20101 receptor agonists", "abstract": { "Currently,": [ 0 ], "six": [ 1 ], "glucagon\u2010like": [ 2 ], "peptide\u20101": [ 3 ], "receptor": [ 4, 24 ], "agonists": [ 5 ], "(": [ 6, 68, 103 ], "GLP\u20101RAs": [ 7, 91, 131, 189, 254 ], ")": [ 8, 105 ], "are": [ 9 ], "approved": [ 10 ], "for": [ 11, 240 ], "treating": [ 12 ], "type": [ 13 ], "2": [ 14 ], "diabetes.": [ 15 ], "These": [ 16 ], "fall": [ 17 ], "into": [ 18 ], "two": [ 19 ], "classes": [ 20 ], "based": [ 21, 243 ], "on": [ 22, 139, 244 ], "their": [ 23 ], "activation:": [ 25 ], "short\u2010acting": [ 26, 130 ], "exenatide": [ 27, 39, 114, 169, 177, 203, 209, 215 ], "twice": [ 28, 170, 210 ], "daily": [ 29, 171, 211 ], "and": [ 30, 34, 45, 76, 86, 116, 118, 126, 181, 196, 206, 212, 217, 230, 247, 255 ], "lixisenatide": [ 31 ], "once": [ 32, 37, 40, 43, 47, 59, 178, 204 ], "daily;": [ 33 ], "longer\u2010acting": [ 35, 145, 149 ], "liraglutide": [ 36, 108, 125, 229 ], "daily,": [ 38 ], "weekly,": [ 41, 60, 179 ], "albiglutide": [ 42, 180, 207, 218 ], "weekly": [ 44, 205 ], "dulaglutide": [ 46 ], "weekly.": [ 48 ], "The": [ 49, 183 ], "phase": [ 50, 72, 79 ], "III": [ 51, 73 ], "trial": [ 52 ], "of": [ 53, 64, 88, 225, 252 ], "a": [ 54 ], "seventh": [ 55 ], "GLP\u20101RA": [ 56, 232 ], ",": [ 57 ], "taspoglutide": [ 58 ], "was": [ 61, 160 ], "stopped": [ 62 ], "because": [ 63 ], "unacceptable": [ 65 ], "adverse": [ 66 ], "events": [ 67 ], "AEs": [ 69, 187 ], ").": [ 70 ], "Nine": [ 71 ], "head\u2010to\u2010head": [ 74 ], "trials": [ 75, 94 ], "one": [ 77 ], "large": [ 78 ], "II": [ 80 ], "study": [ 81 ], "have": [ 82, 136 ], "compared": [ 83 ], "the": [ 84, 129, 144, 148, 155 ], "efficacy": [ 85 ], "safety": [ 87 ], "these": [ 89 ], "seven": [ 90 ], ".": [ 92 ], "All": [ 93 ], "were": [ 95, 190 ], "associated": [ 96, 161, 221 ], "with": [ 97, 162, 168, 176, 188, 202, 222 ], "notable": [ 98 ], "reductions": [ 99, 120, 164 ], "in": [ 100, 234 ], "glycated": [ 101 ], "haemoglobin": [ 102 ], "HbA1c": [ 104, 119 ], "levels,": [ 106 ], "although": [ 107 ], "led": [ 109 ], "to": [ 110, 166 ], "greater": [ 111, 137, 173 ], "decreases": [ 112 ], "than": [ 113, 143, 174, 208, 228 ], "formulations": [ 115, 216 ], "albiglutide,": [ 117 ], "did": [ 121 ], "not": [ 122 ], "differ": [ 123 ], "between": [ 124 ], "dulaglutide.": [ 127, 182, 231 ], "As": [ 128 ], "delay": [ 132 ], "gastric": [ 133 ], "emptying,": [ 134 ], "they": [ 135 ], "effects": [ 138 ], "postprandial": [ 140 ], "glucose": [ 141, 153 ], "levels": [ 142 ], "agents,": [ 146 ], "whereas": [ 147 ], "compounds": [ 150 ], "reduced": [ 151 ], "plasma": [ 152 ], "throughout": [ 154 ], "24\u2010h": [ 156 ], "period": [ 157 ], "studied.": [ 158 ], "Liraglutide": [ 159 ], "weight": [ 163 ], "similar": [ 165 ], "those": [ 167, 175 ], "but": [ 172 ], "most": [ 184 ], "frequently": [ 185 ], "observed": [ 186 ], "gastrointestinal": [ 191 ], "disorders,": [ 192 ], "particularly": [ 193 ], "nausea,": [ 194 ], "vomiting": [ 195 ], "diarrhoea.": [ 197 ], "Nauseaoccurred": [ 198 ], "less": [ 199 ], "frequently,": [ 200 ], "however,": [ 201 ], "liraglutide.": [ 213 ], "Both": [ 214 ], "may": [ 219, 258 ], "be": [ 220, 238 ], "higher": [ 223 ], "incidences": [ 224 ], "injection\u2010site": [ 226 ], "reactions": [ 227 ], "use": [ 233 ], "clinical": [ 235, 245 ], "practice": [ 236 ], "should": [ 237 ], "customized": [ 239 ], "individual": [ 241 ], "patients,": [ 242 ], "profile": [ 246 ], "patient": [ 248 ], "preference.": [ 249 ], "Ongoing": [ 250 ], "assessments": [ 251 ], "novel": [ 253 ], "delivery": [ 256 ], "methods": [ 257 ], "further": [ 259 ], "expand": [ 260 ], "future": [ 261 ], "treatment": [ 262 ], "options.": [ 263 ] }, "publication_date": "2015-10-29", "publication_year": 2015, "type": "review", "cited_by_count": 280, "authors": [ { "id": "https://openalex.org/A5062239390", "display_name": "Sten Madsbad" } ] }, { "id": "https://openalex.org/W3176713229", "doi": "https://doi.org/10.3389/fendo.2021.645617", "title": "Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation", "abstract": { "Despite": [ 0 ], "the": [ 1, 10, 45, 72, 115, 147, 233, 248, 262 ], "benefits": [ 2, 234 ], "of": [ 3, 12, 60, 85, 210, 219, 226, 229, 235, 247 ], "early": [ 4, 89 ], "and": [ 5, 40, 55, 64, 75, 94, 108, 166, 199, 201, 221, 243, 265 ], "effective": [ 6, 35, 238 ], "glycemic": [ 7 ], "control": [ 8 ], "in": [ 9, 26, 37, 51, 71, 82, 240 ], "management": [ 11 ], "type": [ 13 ], "2": [ 14 ], "diabetes": [ 15 ], "(T2D),": [ 16 ], "achieving": [ 17 ], "glycated": [ 18 ], "hemoglobin": [ 19 ], "(HbA": [ 20 ], "1c": [ 21, 39, 125, 157 ], ")": [ 22 ], "targets": [ 23 ], "is": [ 24, 44, 49 ], "challenging": [ 25 ], "some": [ 27 ], "patients.": [ 28 ], "Glucagon-like": [ 29 ], "peptide-1": [ 30 ], "receptor": [ 31 ], "agonists": [ 32 ], "(GLP-1RAs)": [ 33 ], "provide": [ 34 ], "reductions": [ 36 ], "HbA": [ 38, 124, 156 ], "body": [ 41, 181, 194 ], "weight.": [ 42 ], "Semaglutide": [ 43, 231 ], "only": [ 46 ], "GLP-1RA": [ 47, 239 ], "that": [ 48 ], "available": [ 50 ], "both": [ 52, 222, 241 ], "an": [ 53, 216, 256 ], "injectable": [ 54, 242 ], "oral": [ 56, 66, 105, 151, 191, 244 ], "formulation.": [ 57 ], "The": [ 58 ], "efficacy": [ 59 ], "once-weekly": [ 61, 118 ], "subcutaneous": [ 62, 119, 178 ], "semaglutide": [ 63, 67, 120, 152, 179, 192, 211 ], "once-daily": [ 65, 150 ], "has": [ 68, 212 ], "been": [ 69, 213 ], "investigated": [ 70 ], "global": [ 73 ], "SUSTAIN": [ 74, 116 ], "PIONEER": [ 76, 148 ], "phase": [ 77 ], "III": [ 78 ], "clinical": [ 79, 86 ], "trial": [ 80 ], "programs": [ 81 ], "a": [ 83, 168, 203, 236 ], "range": [ 84 ], "settings,": [ 87 ], "including": [ 88 ], "T2D": [ 90, 99 ], "managed": [ 91 ], "with": [ 92, 112, 215 ], "diet": [ 93 ], "exercise": [ 95 ], "only,": [ 96 ], "more": [ 97, 134, 161, 184, 196 ], "established": [ 98 ], "uncontrolled": [ 100 ], "on": [ 101, 255 ], "one": [ 102 ], "to": [ 103, 167, 202, 259 ], "three": [ 104 ], "antidiabetic": [ 106 ], "drugs,": [ 107 ], "advanced": [ 109 ], "disease": [ 110 ], "treated": [ 111 ], "insulin.": [ 113 ], "Across": [ 114, 146 ], "program,": [ 117, 149 ], "1.0": [ 121 ], "mg": [ 122, 154 ], "reduced": [ 123, 155, 180, 193 ], "by": [ 126, 158 ], "1.5\u20131.8%": [ 127 ], "after": [ 128, 173 ], "30\u201356": [ 129 ], "weeks,": [ 130 ], "which": [ 131 ], "was": [ 132 ], "significantly": [ 133, 160, 183 ], "than": [ 135, 162, 185, 197 ], "sitagliptin,": [ 136 ], "liraglutide,": [ 137, 200 ], "exenatide": [ 138 ], "extended": [ 139 ], "release,": [ 140 ], "dulaglutide,": [ 141 ], "canagliflozin,": [ 142 ], "or": [ 143, 164 ], "insulin": [ 144 ], "glargine.": [ 145 ], "14": [ 153 ], "1.0\u20131.4%,": [ 159 ], "sitagliptin": [ 163, 198 ], "empagliflozin,": [ 165 ], "similar": [ 169, 204 ], "extent": [ 170, 205 ], "as": [ 171, 206 ], "liraglutide": [ 172 ], "26": [ 174 ], "weeks.": [ 175 ], "In": [ 176 ], "addition,": [ 177 ], "weight": [ 182, 195 ], "all": [ 186 ], "active": [ 187 ], "comparators": [ 188 ], "tested,": [ 189 ], "while": [ 190 ], "empagliflozin.": [ 207 ], "Neither": [ 208 ], "formulation": [ 209, 251 ], "associated": [ 214 ], "increased": [ 217 ], "risk": [ 218 ], "hypoglycemia": [ 220 ], "improve": [ 223 ], "various": [ 224 ], "measures": [ 225 ], "health-related": [ 227 ], "quality": [ 228 ], "life.": [ 230 ], "offers": [ 232 ], "highly": [ 237 ], "formulations.": [ 245 ], "Selection": [ 246 ], "most": [ 249 ], "appropriate": [ 250 ], "can": [ 252 ], "be": [ 253 ], "made": [ 254 ], "individual": [ 257 ], "basis": [ 258 ], "best": [ 260 ], "suit": [ 261 ], "patient\u2019s": [ 263 ], "preferences": [ 264 ], "needs.": [ 266 ] }, "publication_date": "2021-06-25", "publication_year": 2021, "type": "review", "cited_by_count": 120, "authors": [ { "id": "https://openalex.org/A5002832666", "display_name": "Juris J. Meier" } ] }, { "id": "https://openalex.org/W2118805427", "doi": "https://doi.org/10.1111/j.1463-1326.2011.01357.x", "title": "An overview of once\u2010weekly glucagon\u2010like peptide\u20101 receptor agonists\u2014available efficacy and safety data and perspectives for the future", "abstract": { "Incretin\u2010based": [ 0 ], "therapies,": [ 1 ], "such": [ 2 ], "as": [ 3 ], "the": [ 4, 27, 52, 58, 61, 78, 101, 111, 119, 149, 161, 197, 224, 258 ], "injectable": [ 5 ], "glucagon\u2010like": [ 6 ], "peptide\u20101": [ 7 ], "(GLP\u20101)": [ 8 ], "receptor": [ 9, 29, 42, 64, 104, 122, 200, 252 ], "agonists": [ 10, 30, 43, 105, 163, 201, 226 ], "and": [ 11, 55, 72, 74, 84, 94, 138, 151, 202, 211, 227, 237 ], "orally": [ 12 ], "administered": [ 13, 34 ], "dipeptidyl": [ 14 ], "peptidase\u20104": [ 15 ], "(DPP\u20104)": [ 16 ], "inhibitors,": [ 17 ], "have": [ 18 ], "recently": [ 19 ], "been": [ 20, 184, 218 ], "introduced": [ 21 ], "into": [ 22 ], "clinical": [ 23 ], "practice.": [ 24 ], "At": [ 25 ], "present,": [ 26 ], "GLP\u20101": [ 28, 41, 63, 103, 121, 199, 251 ], "need": [ 31 ], "to": [ 32, 77, 134, 173, 271 ], "be": [ 33, 174, 269 ], "once": [ 35, 67, 179 ], "or": [ 36 ], "twice": [ 37 ], "daily.": [ 38 ], "Several": [ 39 ], "once\u2010weekly": [ 40, 62, 102, 120, 162, 225, 250 ], "are": [ 44, 203, 254 ], "in": [ 45, 90, 126, 129, 143, 186 ], "phase": [ 46 ], "3": [ 47 ], "development.": [ 48 ], "This": [ 49 ], "review": [ 50 ], "examines": [ 51 ], "efficacy,": [ 53 ], "safety": [ 54 ], "perspective": [ 56 ], "for": [ 57, 169, 257 ], "future": [ 59 ], "of": [ 60, 234, 260 ], "agonists:": [ 65 ], "exenatide": [ 66, 82, 108, 166, 178, 209 ], "weekly,": [ 68, 180 ], "taspoglutide,": [ 69 ], "albiglutide,": [ 70 ], "LY2189265": [ 71 ], "CJC\u20101134\u2010PC,": [ 73 ], "compared": [ 75, 106, 133, 164 ], "them": [ 76 ], "currently": [ 79 ], "available": [ 80 ], "agonists,": [ 81 ], "BID": [ 83, 210 ], "liraglutide": [ 85 ], "QD.": [ 86 ], "A": [ 87 ], "greater": [ 88, 132 ], "reduction": [ 89, 125, 142 ], "haemoglobin": [ 91 ], "A1c": [ 92 ], "(HbA1c)": [ 93 ], "fasting": [ 95 ], "plasma": [ 96 ], "glucose": [ 97, 235 ], "was": [ 98, 116, 128 ], "found": [ 99, 219 ], "with": [ 100, 107, 118, 160, 165, 177, 190, 208 ], "BID,": [ 109, 167 ], "while": [ 110, 181 ], "effect": [ 112, 238 ], "on": [ 113, 239 ], "postprandial": [ 114 ], "hyperglycaemia": [ 115 ], "modest": [ 117 ], "agonist.": [ 123 ], "The": [ 124, 141, 154, 230, 249 ], "HbA1c": [ 127 ], "most": [ 130, 175 ], "studies": [ 131 ], "oral": [ 135 ], "antidiabetic": [ 136 ], "drugs": [ 137 ], "insulin": [ 139 ], "glargine.": [ 140 ], "weight": [ 144, 240 ], "did": [ 145 ], "not": [ 146, 268 ], "differ": [ 147, 195 ], "between": [ 148, 223 ], "short\u2010": [ 150 ], "long\u2010acting": [ 152, 198 ], "agonists.": [ 153 ], "gastrointestinal": [ 155 ], "side": [ 156 ], "effects": [ 157 ], "were": [ 158 ], "less": [ 159 ], "except": [ 168 ], "taspoglutide.": [ 170, 191 ], "Antibodies": [ 171 ], "seem": [ 172 ], "frequent": [ 176 ], "hypersensitivity": [ 182 ], "has": [ 183, 217 ], "described": [ 185 ], "few": [ 187 ], "patients": [ 188 ], "treated": [ 189 ], "Injection": [ 192 ], "site": [ 193 ], "reactions": [ 194 ], "among": [ 196 ], "observed": [ 204 ], "more": [ 205 ], "frequently": [ 206 ], "than": [ 207 ], "liraglutide.": [ 212, 274 ], "In": [ 213 ], "humans,": [ 214 ], "no": [ 215 ], "signal": [ 216 ], "indicating": [ 220 ], "an": [ 221 ], "association": [ 222 ], "C\u2010cell": [ 228 ], "cancer.": [ 229 ], "cardiovascular": [ 231 ], "safety,": [ 232 ], "durability": [ 233 ], "control": [ 236 ], "will": [ 241 ], "emerge": [ 242 ], "from": [ 243 ], "several": [ 244 ], "ongoing": [ 245 ], "major": [ 246 ], "long\u2010term": [ 247 ], "trials.": [ 248 ], "analogues": [ 253 ], "promising": [ 255 ], "candidates": [ 256 ], "treatment": [ 259 ], "type": [ 261 ], "2": [ 262 ], "diabetes,": [ 263 ], "although": [ 264 ], "their": [ 265 ], "efficacy": [ 266 ], "may": [ 267 ], "superior": [ 270 ], "once\u2010daily": [ 272 ], "analogue": [ 273 ] }, "publication_date": "2011-01-05", "publication_year": 2011, "type": "review", "cited_by_count": 198, "authors": [ { "id": "https://openalex.org/A5062239390", "display_name": "Sten Madsbad" }, { "id": "https://openalex.org/A5051507182", "display_name": "Urd Kielgast" }, { "id": "https://openalex.org/A5029761654", "display_name": "Meena Asmar" }, { "id": "https://openalex.org/A5054335526", "display_name": "Carolyn F. Deacon" }, { "id": "https://openalex.org/A5038081896", "display_name": "Signe S. Torekov" }, { "id": "https://openalex.org/A5085434984", "display_name": "Jens J. Holst" } ] }, { "id": "https://openalex.org/W2051298109", "doi": "https://doi.org/10.1093/eurheartj/ehr309", "title": "Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction", "abstract": { "In": [ 0 ], "patients": [ 1 ], "with": [ 2 ], "STEMI": [ 3 ], "undergoing": [ 4 ], "pPCI,": [ 5 ], "administration": [ 6 ], "of": [ 7, 12 ], "exenatide": [ 8 ], "at": [ 9 ], "the": [ 10 ], "time": [ 11 ], "reperfusion": [ 13 ], "increases": [ 14 ], "myocardial": [ 15 ], "salvage.": [ 16 ] }, "publication_date": "2011-09-14", "publication_year": 2011, "type": "article", "cited_by_count": 535, "authors": [ { "id": "https://openalex.org/A5112380754", "display_name": "Jacob L\u00f8nborg" }, { "id": "https://openalex.org/A5007735550", "display_name": "Niels Vejlstrup" }, { "id": "https://openalex.org/A5059617202", "display_name": "Henning Kelb\u00e6k" }, { "id": "https://openalex.org/A5004368211", "display_name": "Hans Erik B\u00f8tker" }, { "id": "https://openalex.org/A5078536482", "display_name": "Won Yong Kim" }, { "id": "https://openalex.org/A5089123500", "display_name": "Anders Bruun Mathiasen" }, { "id": "https://openalex.org/A5073393275", "display_name": "Erik J\u00f8rgensen" }, { "id": "https://openalex.org/A5037020231", "display_name": "Steffen Helqvist" }, { "id": "https://openalex.org/A5085232519", "display_name": "Kari Saunam\u00e4ki" }, { "id": "https://openalex.org/A5108534869", "display_name": "Peter Clemmensen" }, { "id": "https://openalex.org/A5014707937", "display_name": "Lene Holmvang" }, { "id": "https://openalex.org/A5080877318", "display_name": "Leif Thuesen" }, { "id": "https://openalex.org/A5110193493", "display_name": "Lars Romer Krusell" }, { "id": "https://openalex.org/A5080676555", "display_name": "Jan Skov Jensen" }, { "id": "https://openalex.org/A5033436516", "display_name": "Lars K\u00f8ber" }, { "id": "https://openalex.org/A5054169231", "display_name": "Marek Treiman" }, { "id": "https://openalex.org/A5085434984", "display_name": "Jens J. Holst" }, { "id": "https://openalex.org/A5055011899", "display_name": "Thomas Engstr\u00f8m" } ] }, { "id": "https://openalex.org/W2220065337", "doi": "https://doi.org/10.1016/j.brainres.2015.12.052", "title": "The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy", "abstract": null, "publication_date": "2015-12-31", "publication_year": 2015, "type": "article", "cited_by_count": 88, "authors": [ { "id": "https://openalex.org/A5001683046", "display_name": "Henrik H. Hansen" }, { "id": "https://openalex.org/A5005450058", "display_name": "Pernille Barkholt" }, { "id": "https://openalex.org/A5047010404", "display_name": "Katrine Fabricius" }, { "id": "https://openalex.org/A5075602116", "display_name": "Jacob Jelsing" }, { "id": "https://openalex.org/A5054385268", "display_name": "Dick Terwel" }, { "id": "https://openalex.org/A5084425804", "display_name": "Charles Pyke" }, { "id": "https://openalex.org/A5088627727", "display_name": "Lotte Bjerre Knudsen" }, { "id": "https://openalex.org/A5088582143", "display_name": "Niels Vrang" } ] }, { "id": "https://openalex.org/W2904780076", "doi": "https://doi.org/10.1016/j.hjc.2018.11.008", "title": "GLP-1 receptor agonists and cardiovascular outcome trials: An update", "abstract": { "Major": [ 0 ], "cardiovascular": [ 1 ], "(CV)": [ 2 ], "outcome": [ 3, 133 ], "trials": [ 4, 134 ], "with": [ 5, 24, 135, 139 ], "glucagon-like": [ 6 ], "peptide-1": [ 7 ], "receptor": [ 8 ], "agonists": [ 9, 16 ], "(GLP-1": [ 10 ], "RAs)": [ 11 ], "are": [ 12, 109 ], "currently": [ 13 ], "available.": [ 14 ], "These": [ 15 ], "have": [ 17, 81 ], "proven": [ 18 ], "their": [ 19, 46 ], "CV": [ 20, 52, 132, 152 ], "safety,": [ 21 ], "in": [ 22, 50, 56, 62 ], "harmony": [ 23 ], "the": [ 25, 51, 72, 86, 114, 124, 127, 140, 144, 151 ], "US": [ 26 ], "Food": [ 27 ], "and": [ 28, 68, 74, 79, 96, 143 ], "Drug": [ 29 ], "Administration": [ 30 ], "(FDA)": [ 31 ], "recommendation": [ 32 ], "for": [ 33 ], "antidiabetic": [ 34 ], "drugs.": [ 35 ], "The": [ 36 ], "potential": [ 37, 141 ], "cardioprotective": [ 38 ], "effect": [ 39 ], "of": [ 40, 88, 116, 126, 147 ], "incretin-based": [ 41 ], "therapies": [ 42 ], "is": [ 43, 105 ], "attributed": [ 44 ], "to": [ 45, 84 ], "multiple": [ 47 ], "non-glycaemic": [ 48 ], "actions": [ 49, 146 ], "system,": [ 53 ], "including": [ 54 ], "changes": [ 55 ], "insulin": [ 57 ], "resistance,": [ 58 ], "weight": [ 59 ], "loss,": [ 60 ], "reduction": [ 61 ], "blood": [ 63 ], "pressure,": [ 64 ], "improved": [ 65 ], "lipid": [ 66 ], "profile": [ 67 ], "direct": [ 69 ], "effects": [ 70 ], "on": [ 71, 150 ], "heart": [ 73 ], "vascular": [ 75 ], "endothelium.": [ 76 ], "Liraglutide,": [ 77 ], "semaglutide": [ 78 ], "albiglutide": [ 80 ], "been": [ 82 ], "demonstrated": [ 83 ], "reduce": [ 85 ], "risk": [ 87 ], "major": [ 89 ], "adverse": [ 90 ], "cardiac": [ 91 ], "events": [ 92 ], "(MACE),": [ 93 ], "whereas": [ 94 ], "lixisenatide": [ 95 ], "extended-release": [ 97 ], "exenatide": [ 98 ], "had": [ 99 ], "a": [ 100 ], "neutral": [ 101 ], "effect.": [ 102 ], "Thus,": [ 103 ], "it": [ 104 ], "conceivable": [ 106 ], "that": [ 107 ], "there": [ 108 ], "different": [ 110 ], "drug-specific": [ 111 ], "properties": [ 112 ], "across": [ 113 ], "class": [ 115 ], "GLP-1": [ 117, 136 ], "RAs.": [ 118 ], "In": [ 119 ], "this": [ 120 ], "review,": [ 121 ], "we": [ 122 ], "discuss": [ 123 ], "results": [ 125 ], "five": [ 128 ], "recently": [ 129 ], "published": [ 130 ], "randomised": [ 131 ], "RAs,": [ 137 ], "along": [ 138 ], "differences": [ 142 ], "pleiotropic": [ 145 ], "these": [ 148 ], "agents": [ 149 ], "system.": [ 153 ] }, "publication_date": "2018-12-06", "publication_year": 2018, "type": "review", "cited_by_count": 103, "authors": [ { "id": "https://openalex.org/A5017305680", "display_name": "E. Andrikou" }, { "id": "https://openalex.org/A5107877457", "display_name": "Costas Tsioufis" }, { "id": "https://openalex.org/A5033954889", "display_name": "Ioannis Andrikou" }, { "id": "https://openalex.org/A5023579524", "display_name": "Ioannis Leontsinis" }, { "id": "https://openalex.org/A5110406210", "display_name": "Dimitrios Tousoulis" }, { "id": "https://openalex.org/A5064490540", "display_name": "\u039d\u03b9\u03ba\u03cc\u03bb\u03b1\u03bf\u03c2 \u03a0\u03b1\u03c0\u03ac\u03bd\u03b1\u03c2" } ] }, { "id": "https://openalex.org/W3172134520", "doi": "https://doi.org/10.7150/ijbs.59965", "title": "GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential", "abstract": { "Type": [ 0 ], "2": [ 1 ], "diabetes": [ 2 ], "mellitus": [ 3 ], "(T2DM)": [ 4 ], "is": [ 5, 129 ], "closely": [ 6 ], "associated": [ 7 ], "with": [ 8, 23, 82 ], "cardiovascular": [ 9, 77, 90, 101, 133, 183 ], "diseases": [ 10 ], "(CVD),": [ 11 ], "including": [ 12 ], "atherosclerosis,": [ 13 ], "hypertension": [ 14 ], "and": [ 15, 57, 70, 111, 125, 144, 161, 185, 197, 200, 214 ], "heart": [ 16 ], "failure.": [ 17 ], "Some": [ 18 ], "anti-diabetic": [ 19 ], "medications": [ 20 ], "are": [ 21 ], "linked": [ 22 ], "an": [ 24 ], "increased": [ 25 ], "risk": [ 26 ], "of": [ 27, 37, 42, 103, 117, 123, 189, 191, 209, 212, 217 ], "weight": [ 28, 68 ], "gain": [ 29, 69 ], "or": [ 30, 83 ], "hypoglycemia": [ 31 ], "which": [ 32, 96, 118 ], "may": [ 33, 169 ], "reduce": [ 34, 58 ], "the": [ 35, 38, 99, 151, 162, 177, 182, 210, 215 ], "efficacy": [ 36 ], "intended": [ 39 ], "anti-hyperglycemic": [ 40 ], "effects": [ 41, 65, 79, 158, 184 ], "these": [ 43, 104, 203 ], "therapies.": [ 44 ], "The": [ 45 ], "recently": [ 46 ], "developed": [ 47 ], "receptor": [ 48 ], "agonists": [ 49 ], "for": [ 50 ], "glucagon-like": [ 51 ], "peptide-1": [ 52 ], "(GLP-1RAs),": [ 53 ], "stimulate": [ 54 ], "insulin": [ 55 ], "secretion": [ 56 ], "glycated": [ 59 ], "hemoglobin": [ 60 ], "levels": [ 61, 110 ], "without": [ 62, 84 ], "having": [ 63 ], "side": [ 64 ], "such": [ 66, 136 ], "as": [ 67, 137 ], "hypoglycemia.": [ 71 ], "In": [ 72, 176 ], "addition,": [ 73 ], "GLP1-RAs": [ 74, 106 ], "demonstrate": [ 75 ], "numerous": [ 76 ], "protective": [ 78, 152 ], "in": [ 80, 131, 193 ], "subjects": [ 81 ], "diabetes.": [ 85 ], "There": [ 86 ], "have": [ 87, 97, 148, 205 ], "been": [ 88 ], "several": [ 89 ], "outcomes": [ 91 ], "trials": [ 92 ], "(CVOTs)": [ 93 ], "involving": [ 94 ], "GLP-1RAs,": [ 95 ], "supported": [ 98 ], "overall": [ 100 ], "benefits": [ 102 ], "drugs.": [ 105 ], "lower": [ 107, 112 ], "plasma": [ 108 ], "lipid": [ 109 ], "blood": [ 113 ], "pressure": [ 114 ], "(BP),": [ 115 ], "both": [ 116 ], "contribute": [ 119, 170 ], "to": [ 120, 171 ], "a": [ 121 ], "reduction": [ 122 ], "atherosclerosis": [ 124 ], "reduced": [ 126 ], "CVD.": [ 127, 218 ], "GLP-1R": [ 128, 174 ], "expressed": [ 130 ], "multiple": [ 132 ], "cell": [ 134 ], "types": [ 135 ], "monocyte/macrophages,": [ 138 ], "smooth": [ 139, 166 ], "muscle": [ 140, 167 ], "cells,": [ 141, 143, 199 ], "endothelial": [ 142, 155 ], "cardiomyocytes.": [ 145 ], "Recent": [ 146 ], "studies": [ 147 ], "indicated": [ 149 ], "that": [ 150 ], "properties": [ 153 ], "against": [ 154 ], "dysfunction,": [ 156 ], "anti-inflammatory": [ 157 ], "on": [ 159, 165 ], "macrophages": [ 160 ], "anti-proliferative": [ 163 ], "action": [ 164, 190 ], "cells": [ 168 ], "atheroprotection": [ 172 ], "through": [ 173 ], "signaling.": [ 175 ], "present": [ 178 ], "review,": [ 179 ], "we": [ 180 ], "describe": [ 181 ], "underlying": [ 186 ], "molecular": [ 187 ], "mechanisms": [ 188 ], "GLP-1RAs": [ 192 ], "CVOTs,": [ 194 ], "animal": [ 195 ], "models": [ 196 ], "cultured": [ 198 ], "address": [ 201 ], "how": [ 202 ], "findings": [ 204 ], "transformed": [ 206 ], "our": [ 207 ], "understanding": [ 208 ], "pharmacotherapy": [ 211 ], "T2DM": [ 213 ], "prevention": [ 216 ] }, "publication_date": "2021-01-01", "publication_year": 2021, "type": "review", "cited_by_count": 225, "authors": [ { "id": "https://openalex.org/A5037554979", "display_name": "Xiaoxuan Ma" }, { "id": "https://openalex.org/A5032835568", "display_name": "Zhenghong Liu" }, { "id": "https://openalex.org/A5021955716", "display_name": "Iqra Ilyas" }, { "id": "https://openalex.org/A5075494494", "display_name": "Peter J. Little" }, { "id": "https://openalex.org/A5090763521", "display_name": "Danielle Kamato" }, { "id": "https://openalex.org/A5055433124", "display_name": "Amirhossein Sahebka" }, { "id": "https://openalex.org/A5059767899", "display_name": "Zhengfang Chen" }, { "id": "https://openalex.org/A5058784085", "display_name": "Sihui Luo" }, { "id": "https://openalex.org/A5091284598", "display_name": "Xueying Zheng" }, { "id": "https://openalex.org/A5012775407", "display_name": "Jianping Weng" }, { "id": "https://openalex.org/A5032138738", "display_name": "Suowen Xu" } ] }, { "id": "https://openalex.org/W2795534327", "doi": "https://doi.org/10.1155/2018/4020492", "title": "GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes", "abstract": { "Diabetes": [ 0 ], "mellitus": [ 1 ], "is": [ 2, 9, 185 ], "a": [ 3, 41, 155 ], "chronic": [ 4 ], "disease": [ 5, 15 ], "prevalence": [ 6 ], "of": [ 7, 22, 30, 37, 70, 86, 146, 182 ], "which": [ 8, 150 ], "high": [ 10 ], "and": [ 11, 33, 110, 133, 152, 199 ], "continually": [ 12 ], "growing.": [ 13 ], "Cardiovascular": [ 14 ], "continues": [ 16 ], "to": [ 17, 63, 74, 168, 186 ], "be": [ 18, 40, 64, 75, 163, 169 ], "the": [ 19, 34, 49, 52, 114, 147, 172, 203 ], "leading": [ 20 ], "cause": [ 21 ], "death": [ 23 ], "in": [ 24, 68, 138, 177, 193 ], "patients": [ 25 ], "with": [ 26, 128, 142 ], "T2DM.": [ 27 ], "The": [ 28, 180 ], "prevention": [ 29 ], "cardiovascular": [ 31, 35, 88, 123, 139, 156, 194, 208 ], "complications": [ 32 ], "safety": [ 36 ], "treatments": [ 38 ], "should": [ 39 ], "primary": [ 42 ], "objective": [ 43 ], "when": [ 44 ], "selecting": [ 45 ], "treatment.": [ 46 ], "Among": [ 47 ], "all": [ 48 ], "drugs": [ 50 ], "available,": [ 51 ], "compounds": [ 53 ], "known": [ 54 ], "as": [ 55, 92 ], "glucagon-like": [ 56 ], "peptide-1": [ 57 ], "receptor": [ 58 ], "agonists": [ 59 ], "(GLP-1": [ 60 ], "RAs)": [ 61 ], "appear": [ 62 ], "not": [ 65, 80, 191 ], "just": [ 66 ], "innocuous": [ 67 ], "terms": [ 69 ], "CVD": [ 71 ], "but": [ 72, 100, 201 ], "indeed": [ 73 ], "beneficial.": [ 76 ], "GLP-1": [ 77, 129, 188 ], "RA": [ 78, 189 ], "actions": [ 79, 190 ], "only": [ 81, 192 ], "translate": [ 82 ], "on": [ 83, 105, 206 ], "an": [ 84 ], "improvement": [ 85 ], "well-known": [ 87 ], "risk": [ 89, 195 ], "factors": [ 90, 196 ], "such": [ 91 ], "glycaemic": [ 93 ], "control,": [ 94 ], "dyslipidaemia,": [ 95 ], "weight,": [ 96, 198 ], "or": [ 97 ], "arterial": [ 98 ], "hypertension": [ 99 ], "also": [ 101, 202 ], "might": [ 102 ], "show": [ 103 ], "benefits": [ 104, 167 ], "endothelial": [ 106 ], "function,": [ 107 ], "coronary": [ 108 ], "ischaemia,": [ 109 ], "heart": [ 111 ], "failure.": [ 112 ], "On": [ 113 ], "other": [ 115 ], "hand,": [ 116 ], "recent": [ 117 ], "clinical": [ 118, 178 ], "trials": [ 119 ], "aimed": [ 120 ], "at": [ 121 ], "studying": [ 122 ], "episodes": [ 124 ], "have": [ 125, 135 ], "been": [ 126 ], "conducted": [ 127 ], "RAs.": [ 130 ], "Only": [ 131 ], "liraglutide": [ 132, 151 ], "semaglutide": [ 134, 153 ], "shown": [ 136 ], "superiority": [ 137 ], "benefit": [ 140, 157 ], "compared": [ 141 ], "placebo.": [ 143 ], "Although": [ 144 ], "many": [ 145 ], "mechanisms": [ 148 ], "by": [ 149 ], "produce": [ 154 ], "are": [ 158 ], "still": [ 159 ], "unknown": [ 160 ], "it": [ 161 ], "would": [ 162 ], "desirable": [ 164 ], "for": [ 165 ], "these": [ 166 ], "incorporated": [ 170 ], "into": [ 171 ], "therapeutic": [ 173 ], "algorithms": [ 174 ], "routinely": [ 175 ], "used": [ 176 ], "practice.": [ 179 ], "purpose": [ 181 ], "this": [ 183 ], "review": [ 184 ], "explore": [ 187 ], "(glucose,": [ 197 ], "hypertension)": [ 200 ], "possible": [ 204 ], "effects": [ 205 ], "established": [ 207 ], "disease.": [ 209 ] }, "publication_date": "2018-04-02", "publication_year": 2018, "type": "review", "cited_by_count": 132, "authors": [ { "id": "https://openalex.org/A5058301928", "display_name": "Mar\u00eda Isabel Del Olmo-Garc\u00eda" }, { "id": "https://openalex.org/A5081762662", "display_name": "Juan Francisco Merino-Torres" } ] }, { "id": "https://openalex.org/W3182424616", "doi": "https://doi.org/10.3389/fendo.2021.645563", "title": "Safety of Semaglutide", "abstract": { "The": [ 0 ], "glucagon-like": [ 1 ], "peptide-1": [ 2 ], "receptor": [ 3 ], "agonist": [ 4 ], "(GLP-1RA)": [ 5 ], "semaglutide": [ 6, 88, 116, 163, 171, 201, 275 ], "is": [ 7, 202 ], "the": [ 8, 18, 45, 55, 84, 104, 109, 181, 196, 259, 268 ], "most": [ 9 ], "recently": [ 10 ], "approved": [ 11 ], "agent": [ 12 ], "of": [ 13, 74, 111, 183, 206, 227, 241, 265 ], "this": [ 14, 221 ], "drug": [ 15 ], "class,": [ 16 ], "and": [ 17, 26, 35, 78, 89, 96, 126, 142, 144, 147, 175, 179, 195, 214, 262, 267 ], "only": [ 19 ], "GLP-1RA": [ 20 ], "currently": [ 21 ], "available": [ 22 ], "as": [ 23 ], "both": [ 24, 66 ], "subcutaneous": [ 25, 67 ], "oral": [ 27, 79 ], "formulation.": [ 28 ], "While": [ 29 ], "GLP-1RAs": [ 30, 208 ], "effectively": [ 31 ], "improve": [ 32 ], "glycemic": [ 33 ], "control": [ 34 ], "cause": [ 36 ], "weight": [ 37 ], "loss,": [ 38 ], "potential": [ 39, 152 ], "safety": [ 40, 124, 189, 198 ], "concerns": [ 41, 50 ], "have": [ 42, 51, 191 ], "arisen": [ 43, 192 ], "over": [ 44 ], "years.": [ 46 ], "For": [ 47 ], "semaglutide,": [ 48, 251, 266 ], "such": [ 49 ], "been": [ 52 ], "addressed": [ 53 ], "in": [ 54, 72, 93 ], "extensive": [ 56 ], "phase": [ 57 ], "3": [ 58 ], "registration": [ 59 ], "trials": [ 60, 64, 95 ], "including": [ 61, 98 ], "cardiovascular": [ 62, 133, 263 ], "outcome": [ 63 ], "for": [ 65, 83, 162, 200, 212, 239, 271, 282 ], "(SUSTAIN:": [ 68 ], "Semaglutide": [ 69 ], "Unabated": [ 70 ], "Sustainability": [ 71 ], "Treatment": [ 73 ], "Type": [ 75 ], "2": [ 76, 286 ], "Diabetes)": [ 77 ], "(PIONEER:": [ 80 ], "Peptide": [ 81 ], "InnOvatioN": [ 82 ], "Early": [ 85 ], "diabEtes": [ 86 ], "tReatment)": [ 87 ], "are": [ 90, 160 ], "being": [ 91 ], "studied": [ 92 ], "further": [ 94 ], "registries,": [ 97 ], "real": [ 99 ], "world": [ 100 ], "data": [ 101 ], "studies.": [ 102 ], "In": [ 103 ], "current": [ 105 ], "review": [ 106 ], "we": [ 107, 150, 156 ], "discuss": [ 108, 157 ], "occurrence": [ 110 ], "adverse": [ 112, 273 ], "events": [ 113 ], "associated": [ 114 ], "with": [ 115, 250, 256, 284 ], "focusing": [ 117 ], "on": [ 118 ], "hypoglycemia,": [ 119 ], "gastrointestinal": [ 120, 177 ], "side": [ 121 ], "effects,": [ 122 ], "pancreatic": [ 123, 127, 213 ], "(pancreatitis": [ 125 ], "cancer),": [ 128 ], "thyroid": [ 129, 215 ], "cancer,": [ 130 ], "gallbladder": [ 131 ], "events,": [ 132, 274 ], "aspects,": [ 134 ], "acute": [ 135 ], "kidney": [ 136 ], "injury,": [ 137 ], "diabetic": [ 138 ], "retinopathy": [ 139 ], "(DRP)": [ 140 ], "complications": [ 141 ], "injection-site": [ 143 ], "allergic": [ 145 ], "reactions": [ 146 ], "where": [ 148, 209 ], "available,": [ 149 ], "highlight": [ 151 ], "underlying": [ 153 ], "mechanisms.": [ 154 ], "Furthermore,": [ 155 ], "whether": [ 158 ], "effects": [ 159 ], "specific": [ 161 ], "or": [ 164 ], "a": [ 165 ], "class": [ 166 ], "effect.": [ 167 ], "We": [ 168 ], "conclude": [ 169 ], "that": [ 170, 205 ], "induces": [ 172 ], "mostly": [ 173 ], "mild-to-moderate": [ 174 ], "transient": [ 176 ], "disturbances": [ 178 ], "increases": [ 180 ], "risk": [ 182, 238, 270 ], "biliary": [ 184 ], "disease": [ 185 ], "(cholelithiasis).": [ 186 ], "No": [ 187 ], "unexpected": [ 188 ], "issues": [ 190 ], "to": [ 193, 204, 224, 231 ], "date,": [ 194 ], "established": [ 197 ], "profile": [ 199, 281 ], "similar": [ 203 ], "other": [ 207 ], "definitive": [ 210 ], "conclusions": [ 211 ], "cancer": [ 216 ], "cannot": [ 217 ], "be": [ 218, 245 ], "drawn": [ 219 ], "at": [ 220, 237 ], "point": [ 222 ], "due": [ 223 ], "low": [ 225, 269 ], "incidence": [ 226 ], "these": [ 228 ], "conditions.": [ 229 ], "Due": [ 230 ], "its": [ 232 ], "potent": [ 233 ], "glucose-lowering": [ 234 ], "effect,": [ 235 ], "patients": [ 236 ], "deterioration": [ 240 ], "existing": [ 242 ], "DRP": [ 243 ], "should": [ 244 ], "carefully": [ 246 ], "monitored": [ 247 ], "if": [ 248, 253 ], "treated": [ 249, 255 ], "particularly": [ 252 ], "also": [ 254 ], "insulin.": [ 257 ], "Given": [ 258 ], "beneficial": [ 260 ], "metabolic": [ 261 ], "actions": [ 264 ], "severe": [ 272 ], "has": [ 276 ], "an": [ 277 ], "overall": [ 278 ], "favorable": [ 279 ], "risk/benefit": [ 280 ], "patient": [ 283 ], "type": [ 285 ], "diabetes.": [ 287 ] }, "publication_date": "2021-07-07", "publication_year": 2021, "type": "review", "cited_by_count": 237, "authors": [ { "id": "https://openalex.org/A5091895526", "display_name": "Mark M. Smits" }, { "id": "https://openalex.org/A5067127165", "display_name": "Dani\u00ebl H. van Raalte" } ] }, { "id": "https://openalex.org/W2106036385", "doi": "https://doi.org/10.1152/physrev.00034.2006", "title": "The Physiology of Glucagon-like Peptide 1", "abstract": { "Glucagon-like": [ 0 ], "peptide": [ 1, 8 ], "1": [ 2 ], "(GLP-1)": [ 3 ], "is": [ 4, 25, 56, 73, 120 ], "a": [ 5, 210 ], "30-amino": [ 6 ], "acid": [ 7 ], "hormone": [ 9, 88, 129, 140 ], "produced": [ 10 ], "in": [ 11, 27, 39, 43, 58, 106 ], "the": [ 12, 22, 40, 44, 50, 64, 80, 87, 91, 94, 97, 107, 110, 113, 127, 135, 138, 145, 152, 201, 232, 245 ], "intestinal": [ 13 ], "epithelial": [ 14 ], "endocrine": [ 15, 132 ], "L-cells": [ 16 ], "by": [ 17, 79 ], "differential": [ 18 ], "processing": [ 19, 52 ], "of": [ 20, 35, 99, 117, 126, 137, 159, 200, 213, 219, 234, 240, 247 ], "proglucagon,": [ 21 ], "gene": [ 23, 37 ], "which": [ 24 ], "expressed": [ 26 ], "these": [ 28, 220 ], "cells.": [ 29 ], "The": [ 30, 156 ], "current": [ 31 ], "knowledge": [ 32 ], "regarding": [ 33 ], "regulation": [ 34 ], "proglucagon": [ 36 ], "expression": [ 38 ], "gut": [ 41 ], "and": [ 42, 46, 63, 66, 77, 109, 141, 149, 173, 190, 192, 198, 215, 249 ], "brain": [ 45 ], "mechanisms": [ 47, 68 ], "responsible": [ 48, 254 ], "for": [ 49, 131, 231, 255 ], "posttranslational": [ 51 ], "are": [ 53, 70, 101, 161, 227 ], "reviewed.": [ 54 ], "GLP-1": [ 55, 72, 100, 114, 160, 205, 222, 224, 241 ], "released": [ 57 ], "response": [ 59 ], "to": [ 60, 122, 162, 167, 174, 180, 208, 244 ], "meal": [ 61 ], "intake,": [ 62 ], "stimuli": [ 65 ], "molecular": [ 67 ], "involved": [ 69 ], "discussed.": [ 71 ], "extremely": [ 74 ], "rapidly": [ 75 ], "metabolized": [ 76 ], "inactivated": [ 78 ], "enzyme": [ 81 ], "dipeptidyl": [ 82 ], "peptidase": [ 83 ], "IV": [ 84 ], "even": [ 85 ], "before": [ 86 ], "has": [ 89 ], "left": [ 90 ], "gut,": [ 92 ], "raising": [ 93 ], "possibility": [ 95 ], "that": [ 96 ], "actions": [ 98, 158 ], "transmitted": [ 102 ], "via": [ 103 ], "sensory": [ 104 ], "neurons": [ 105 ], "intestine": [ 108 ], "liver": [ 111 ], "expressing": [ 112 ], "receptor.": [ 115 ], "Because": [ 116, 218 ], "this,": [ 118 ], "it": [ 119 ], "important": [ 121 ], "distinguish": [ 123 ], "between": [ 124 ], "measurements": [ 125 ], "intact": [ 128, 139 ], "(responsible": [ 130 ], "actions)": [ 133 ], "or": [ 134, 223 ], "sum": [ 136 ], "its": [ 142 ], "metabolites,": [ 143 ], "reflecting": [ 144 ], "total": [ 146 ], "L-cell": [ 147 ], "secretion": [ 148, 165, 191, 239, 251 ], "therefore": [ 150 ], "also": [ 151, 186, 206 ], "possible": [ 153 ], "neural": [ 154 ], "actions.": [ 155 ], "main": [ 157 ], "stimulate": [ 163 ], "insulin": [ 164 ], "(i.e.,": [ 166 ], "act": [ 168 ], "as": [ 169, 195 ], "an": [ 170, 196 ], "incretin": [ 171 ], "hormone)": [ 172 ], "inhibit": [ 175 ], "glucagon": [ 176 ], "secretion,": [ 177 ], "thereby": [ 178 ], "contributing": [ 179 ], "limit": [ 181 ], "postprandial": [ 182, 256 ], "glucose": [ 183 ], "excursions.": [ 184 ], "It": [ 185 ], "inhibits": [ 187 ], "gastrointestinal": [ 188 ], "motility": [ 189 ], "thus": [ 193 ], "acts": [ 194 ], "enterogastrone": [ 197 ], "part": [ 199 ], "\u201cileal": [ 202 ], "brake\u201d": [ 203 ], "mechanism.": [ 204 ], "appears": [ 207 ], "be": [ 209, 253 ], "physiological": [ 211 ], "regulator": [ 212 ], "appetite": [ 214 ], "food": [ 216 ], "intake.": [ 217 ], "actions,": [ 221 ], "receptor": [ 225 ], "agonists": [ 226 ], "currently": [ 228 ], "being": [ 229 ], "evaluated": [ 230 ], "therapy": [ 233 ], "type": [ 235 ], "2": [ 236 ], "diabetes.": [ 237 ], "Decreased": [ 238 ], "may": [ 242, 252 ], "contribute": [ 243 ], "development": [ 246 ], "obesity,": [ 248 ], "exaggerated": [ 250 ], "reactive": [ 257 ], "hypoglycemia.": [ 258 ] }, "publication_date": "2007-10-01", "publication_year": 2007, "type": "review", "cited_by_count": 3107, "authors": [ { "id": "https://openalex.org/A5085434984", "display_name": "Jens J. Holst" } ] }, { "id": "https://openalex.org/W4292466554", "doi": "https://doi.org/10.3389/fphar.2022.901559", "title": "Effects of GLP-1 Receptor Agonists on Biological Behavior of Colorectal Cancer Cells by Regulating PI3K/AKT/mTOR Signaling Pathway", "abstract": { "Colorectal": [ 0 ], "cancer": [ 1 ], "(CRC)": [ 2 ], "has": [ 3, 104 ], "become": [ 4 ], "one": [ 5 ], "of": [ 6, 23, 30, 40, 50, 63, 72, 98, 111, 138, 168 ], "the": [ 7, 21, 31, 38, 48, 54, 60, 66, 70, 91, 109, 125, 131, 141, 166, 184, 199 ], "top": [ 8 ], "ten": [ 9 ], "malignant": [ 10 ], "tumors": [ 11 ], "with": [ 12, 95, 130 ], "a": [ 13, 24, 178 ], "high": [ 14 ], "incidence": [ 15 ], "rate": [ 16 ], "and": [ 17, 53, 81, 128, 145, 152, 163, 165, 171, 192, 194 ], "mortality.": [ 18 ], "Due": [ 19 ], "to": [ 20, 77, 117 ], "lack": [ 22 ], "good": [ 25 ], "CRC": [ 26, 32, 51, 119, 146, 185 ], "screening": [ 27 ], "program,": [ 28 ], "most": [ 29 ], "patients": [ 33, 64 ], "are": [ 34, 154 ], "being": [ 35 ], "transferred": [ 36 ], "at": [ 37, 124 ], "time": [ 39 ], "treatment.": [ 41 ], "The": [ 42, 136, 173 ], "conventional": [ 43 ], "treatment": [ 44, 94, 110 ], "cannot": [ 45 ], "effectively": [ 46 ], "improve": [ 47 ], "prognosis": [ 49 ], "patients,": [ 52 ], "target": [ 55 ], "drugs": [ 56 ], "can": [ 57 ], "significantly": [ 58 ], "prolong": [ 59 ], "overall": [ 61 ], "survival": [ 62 ], "in": [ 65, 122 ], "advanced": [ 67 ], "stage.": [ 68 ], "However,": [ 69 ], "use": [ 71 ], "single": [ 73, 99 ], "drug": [ 74, 79, 88, 101 ], "may": [ 75 ], "lead": [ 76 ], "acquired": [ 78 ], "resistance": [ 80 ], "various": [ 82 ], "serious": [ 83 ], "complications.": [ 84 ], "Therefore,": [ 85, 113 ], "combined": [ 86 ], "targeted": [ 87, 100 ], "therapy": [ 89 ], "is": [ 90 ], "main": [ 92 ], "alternative": [ 93 ], "poor": [ 96 ], "effect": [ 97 ], "therapy,": [ 102 ], "which": [ 103 ], "important": [ 105 ], "research": [ 106 ], "significance": [ 107 ], "for": [ 108 ], "CRC.": [ 112 ], "this": [ 114 ], "study": [ 115 ], "intends": [ 116 ], "culture": [ 118 ], "cell": [ 120, 126, 147, 158, 186, 189 ], "lines": [ 121 ], "vitro": [ 123 ], "level": [ 127 ], "intervene": [ 129 ], "GLP-1": [ 132, 179 ], "receptor": [ 133, 180 ], "agonist": [ 134 ], "liraglutide.": [ 135 ], "effects": [ 137 ], "liraglutide": [ 139 ], "on": [ 140 ], "PI3K/Akt/mTOR": [ 142, 200 ], "signal": [ 143, 201 ], "pathway": [ 144 ], "proliferation,": [ 148, 159, 190 ], "cycle,": [ 149, 160, 187 ], "migration,": [ 150, 161, 191 ], "invasion,": [ 151, 162 ], "apoptosis": [ 153, 164, 196 ], "explored": [ 155 ], "by": [ 156, 197 ], "detecting": [ 157 ], "expression": [ 167 ], "related": [ 169 ], "mRNA": [ 170 ], "protein.": [ 172 ], "results": [ 174 ], "showed": [ 175 ], "that": [ 176 ], "liraglutide,": [ 177 ], "agonist,": [ 181 ], "could": [ 182 ], "block": [ 183 ], "reduce": [ 188 ], "invasion": [ 193 ], "promote": [ 195 ], "inhibiting": [ 198 ], "pathway.": [ 202 ] }, "publication_date": "2022-08-10", "publication_year": 2022, "type": "article", "cited_by_count": 116, "authors": [ { "id": "https://openalex.org/A5001676122", "display_name": "Guoxiang Tong" }, { "id": "https://openalex.org/A5102291228", "display_name": "Tianhao Peng" }, { "id": "https://openalex.org/A5100762743", "display_name": "Ya Chen" }, { "id": "https://openalex.org/A5107304184", "display_name": "Lijuan Sha" }, { "id": "https://openalex.org/A5017525200", "display_name": "Huikang Dai" }, { "id": "https://openalex.org/A5059626717", "display_name": "Yidong Xiang" }, { "id": "https://openalex.org/A5084750949", "display_name": "Zhi-Qi Zou" }, { "id": "https://openalex.org/A5059160925", "display_name": "Heli He" }, { "id": "https://openalex.org/A5100608374", "display_name": "Sha Wang" } ] }, { "id": "https://openalex.org/W2098459806", "doi": "https://doi.org/10.1016/s0140-6736(08)61246-5", "title": "Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial", "abstract": null, "publication_date": "2008-09-25", "publication_year": 2008, "type": "article", "cited_by_count": 1036, "authors": [ { "id": "https://openalex.org/A5111831506", "display_name": "Alan J. Garber" }, { "id": "https://openalex.org/A5045462483", "display_name": "Robert R. Henry" }, { "id": "https://openalex.org/A5081205041", "display_name": "Robert E. Ratner" }, { "id": "https://openalex.org/A5049691512", "display_name": "Pedro Alberto Garc\u00eda-Hern\u00e1ndez" }, { "id": "https://openalex.org/A5068362917", "display_name": "Hiromi Rodriguez-Pattzi" }, { "id": "https://openalex.org/A5080770579", "display_name": "Israel Olvera-Alvarez" }, { "id": "https://openalex.org/A5023487929", "display_name": "Paula M. Hale" }, { "id": "https://openalex.org/A5103492502", "display_name": "Milan Zdravkovic" }, { "id": "https://openalex.org/A5005036709", "display_name": "Bruce W. Bode" } ] }, { "id": "https://openalex.org/W2007910256", "doi": "https://doi.org/10.1002/dmrr.1202", "title": "The safety and tolerability of GLP\u20101 receptor agonists in the treatment of type 2 diabetes: a review", "abstract": { "Abstract": [ 0 ], "Although": [ 1 ], "several": [ 2 ], "classes": [ 3 ], "of": [ 4, 43, 50, 76, 91, 112, 131, 154, 198, 216, 224 ], "pharmacotherapy": [ 5 ], "are": [ 6 ], "available": [ 7 ], "for": [ 8, 114, 170, 228 ], "type": [ 9 ], "2": [ 10 ], "diabetes,": [ 11 ], "glycaemic": [ 12 ], "control": [ 13 ], "is": [ 14, 84, 190, 207, 232 ], "often": [ 15 ], "hampered": [ 16 ], "by": [ 17, 80 ], "medication\u2010related": [ 18 ], "adverse": [ 19 ], "effects": [ 20, 42, 163 ], "and": [ 21, 67, 106, 138, 159, 162, 180, 226, 230 ], "contraindications": [ 22 ], "such": [ 23 ], "as": [ 24 ], "renal": [ 25, 117 ], "impairment.": [ 26, 118 ], "Glucagon\u2010like": [ 27 ], "peptide\u20101": [ 28 ], "(GLP\u20101)": [ 29 ], "receptor": [ 30, 62, 82, 100, 125, 218, 244 ], "agonists": [ 31, 63, 83, 101, 126, 219 ], "provide": [ 32 ], "a": [ 33, 88, 168 ], "new": [ 34 ], "pharmacotherapeutic": [ 35 ], "option": [ 36 ], "based": [ 37 ], "on": [ 38, 142, 164, 174 ], "the": [ 39, 44, 110, 129, 195, 212, 222 ], "multiple": [ 40 ], "glucose\u2010lowering": [ 41 ], "human": [ 45 ], "hormone": [ 46 ], "GLP\u20101.": [ 47 ], "This": [ 48 ], "mechanism": [ 49 ], "action": [ 51 ], "not": [ 52, 186 ], "only": [ 53 ], "provides": [ 54 ], "therapeutic": [ 55, 136 ], "efficacy": [ 56, 137 ], "but": [ 57, 149 ], "also": [ 58 ], "suggests": [ 59 ], "that": [ 60, 94, 133, 188 ], "GLP\u20101": [ 61, 81, 99, 124, 199, 217, 243 ], "have": [ 64 ], "distinct": [ 65 ], "safety": [ 66, 144 ], "tolerability": [ 68, 235 ], "concerns": [ 69 ], "compared": [ 70 ], "with": [ 71, 96, 116, 120, 204, 242 ], "other": [ 72, 121 ], "diabetes": [ 73 ], "therapies.": [ 74 ], "Stimulation": [ 75 ], "pancreatic": [ 77, 181 ], "insulin": [ 78 ], "secretion": [ 79 ], "glucose": [ 85 ], "dependent,": [ 86 ], "conferring": [ 87 ], "lesser": [ 89 ], "risk": [ 90, 165, 223 ], "hypoglycaemia": [ 92 ], "than": [ 93 ], "seen": [ 95 ], "sulfonylureas.": [ 97 ], "Individual": [ 98 ], "differ": [ 102 ], "in": [ 103, 178, 183, 201, 220 ], "their": [ 104 ], "metabolism": [ 105 ], "excretion": [ 107 ], "profiles,": [ 108 ], "affecting": [ 109 ], "choice": [ 111 ], "agent": [ 113 ], "patients": [ 115 ], "As": [ 119 ], "protein\u2010based": [ 122 ], "therapies,": [ 123 ], "may": [ 127, 134 ], "induce": [ 128 ], "formation": [ 130 ], "antibodies": [ 132 ], "attenuate": [ 135 ], "affect": [ 139 ], "safety.": [ 140 ], "Conclusions": [ 141 ], "cardiovascular": [ 143 ], "must": [ 145 ], "await": [ 146 ], "outcomes": [ 147 ], "studies,": [ 148 ], "at": [ 150 ], "present": [ 151 ], "no": [ 152 ], "signal": [ 153 ], "harm": [ 155 ], "has": [ 156 ], "been": [ 157 ], "reported,": [ 158 ], "preclinical": [ 160 ], "data": [ 161, 173 ], "markers": [ 166 ], "suggest": [ 167, 187 ], "potential": [ 169 ], "benefit.": [ 171 ], "Current": [ 172 ], "thyroid": [ 175 ], "medullary": [ 176 ], "cancer": [ 177 ], "humans": [ 179 ], "malignancy": [ 182 ], "rodents": [ 184 ], "do": [ 185 ], "there": [ 189 ], "any": [ 191 ], "reason": [ 192 ], "to": [ 193, 210 ], "restrict": [ 194 ], "clinical": [ 196 ], "use": [ 197 ], "analogues": [ 200 ], "most": [ 202 ], "people": [ 203 ], "diabetes.": [ 205 ], "It": [ 206 ], "currently": [ 208 ], "difficult": [ 209 ], "ascertain": [ 211 ], "possible": [ 213 ], "contributory": [ 214 ], "role": [ 215 ], "increasing": [ 221 ], "pancreatitis,": [ 225 ], "vigilance": [ 227 ], "signs": [ 229 ], "symptoms": [ 231 ], "prudent.": [ 233 ], "Primary": [ 234 ], "issues": [ 236 ], "include": [ 237 ], "transient": [ 238 ], "gastrointestinal": [ 239 ], "symptoms,": [ 240 ], "common": [ 241 ], "agonists,": [ 245 ], "which": [ 246 ], "can": [ 247 ], "be": [ 248 ], "reduced": [ 249 ], "through": [ 250 ], "dose": [ 251 ], "titration.": [ 252 ], "Copyright": [ 253 ], "\u00a9": [ 254 ], "2011": [ 255 ], "John": [ 256 ], "Wiley": [ 257 ], "&": [ 258 ], "Sons,": [ 259 ], "Ltd.": [ 260 ] }, "publication_date": "2011-04-12", "publication_year": 2011, "type": "review", "cited_by_count": 106, "authors": [ { "id": "https://openalex.org/A5005405894", "display_name": "Vanita R. Aroda" }, { "id": "https://openalex.org/A5081205041", "display_name": "Robert E. Ratner" } ] }, { "id": "https://openalex.org/W2947335986", "doi": "https://doi.org/10.3390/medicina55060233", "title": "GLP-1 Receptor Agonists and Kidney Protection", "abstract": { "Type": [ 0 ], "2": [ 1 ], "diabetes": [ 2 ], "mellitus": [ 3 ], "(T2DM)": [ 4 ], "is": [ 5, 17 ], "the": [ 6, 27, 83, 89, 104, 160, 172 ], "leading": [ 7 ], "cause": [ 8 ], "of": [ 9, 26, 41, 74, 85, 91, 115, 123, 159, 174 ], "chronic": [ 10 ], "kidney": [ 11, 62, 181 ], "disease": [ 12, 63 ], "(CKD).": [ 13 ], "Diabetic": [ 14 ], "nephropathy": [ 15 ], "(DN)": [ 16 ], "determined": [ 18 ], "by": [ 19 ], "specific": [ 20 ], "pathological": [ 21 ], "structural": [ 22 ], "and": [ 23, 33, 39, 87, 109, 118, 180, 183, 186 ], "functional": [ 24 ], "alterations": [ 25 ], "kidneys": [ 28, 105 ], "in": [ 29, 93, 149 ], "patients": [ 30 ], "with": [ 31, 153 ], "diabetes,": [ 32 ], "its": [ 34 ], "clinical": [ 35, 136, 151 ], "manifestations": [ 36 ], "are": [ 37, 55, 70 ], "albuminuria": [ 38 ], "decline": [ 40, 90 ], "glomerular": [ 42 ], "filtration": [ 43 ], "rate": [ 44 ], "(GFR).": [ 45 ], "Apart": [ 46 ], "from": [ 47, 131 ], "renin\u2013angiotensin\u2013aldosterone": [ 48 ], "system": [ 49 ], "(RAAS)": [ 50 ], "inhibitors,": [ 51 ], "no": [ 52 ], "other": [ 53 ], "drugs": [ 54, 76, 97, 145, 192 ], "currently": [ 56 ], "available": [ 57 ], "as": [ 58 ], "therapy": [ 59 ], "for": [ 60 ], "diabetic": [ 61, 94 ], "(DKD).": [ 64 ], "Glucagon-like": [ 65 ], "peptide-1": [ 66 ], "receptor": [ 67 ], "(GLP-1R)": [ 68 ], "agonists": [ 69, 125, 176 ], "a": [ 71 ], "new": [ 72 ], "class": [ 73 ], "anti-hyperglycemic": [ 75 ], "which": [ 77, 190 ], "have": [ 78 ], "been": [ 79 ], "demonstrated": [ 80 ], "to": [ 81, 129, 139, 156 ], "prevent": [ 82 ], "onset": [ 84 ], "macroalbuminuria": [ 86 ], "reduce": [ 88 ], "GFR": [ 92 ], "patients.": [ 95 ], "These": [ 96, 144 ], "may": [ 98, 193 ], "exert": [ 99 ], "their": [ 100, 141 ], "beneficial": [ 101 ], "actions": [ 102, 161, 173 ], "on": [ 103, 162, 171, 177 ], "through": [ 106, 189 ], "blood": [ 107, 110 ], "glucose-": [ 108 ], "pressure": [ 111 ], "(BP)-lowering": [ 112 ], "effects,": [ 113 ], "reduction": [ 114 ], "insulin": [ 116 ], "levels": [ 117 ], "weight": [ 119 ], "loss.": [ 120 ], "Clinical": [ 121 ], "benefits": [ 122 ], "GLP-1R": [ 124, 175 ], "were": [ 126 ], "acknowledged": [ 127 ], "due": [ 128 ], "data": [ 130 ], "large": [ 132 ], "randomized": [ 133 ], "phase": [ 134 ], "III": [ 135 ], "trials": [ 137 ], "conducted": [ 138 ], "assess": [ 140 ], "cardiovascular(CV)": [ 142 ], "safety.": [ 143 ], "improved": [ 146 ], "renal": [ 147, 195 ], "biomarkers": [ 148 ], "placebo-controlled": [ 150 ], "studies,": [ 152 ], "effects": [ 154 ], "supposed": [ 155 ], "be": [ 157 ], "independent": [ 158 ], "glycemic": [ 163 ], "control.": [ 164 ], "In": [ 165 ], "this": [ 166 ], "review,": [ 167 ], "we": [ 168 ], "will": [ 169 ], "focus": [ 170 ], "glucose": [ 178 ], "metabolism": [ 179 ], "physiology,": [ 182 ], "evaluate": [ 184 ], "direct": [ 185 ], "indirect": [ 187 ], "mechanisms": [ 188 ], "these": [ 191 ], "confer": [ 194 ], "protection.": [ 196 ] }, "publication_date": "2019-05-31", "publication_year": 2019, "type": "review", "cited_by_count": 155, "authors": [ { "id": "https://openalex.org/A5024055728", "display_name": "Eulalia Greco" }, { "id": "https://openalex.org/A5042676043", "display_name": "Giuseppina Russo" }, { "id": "https://openalex.org/A5048420209", "display_name": "Annalisa Giandalia" }, { "id": "https://openalex.org/A5050050288", "display_name": "Francesca Viazzi" }, { "id": "https://openalex.org/A5081154400", "display_name": "Roberto Pontremoli" }, { "id": "https://openalex.org/A5057527058", "display_name": "Salvatore De Cosmo" } ] }, { "id": "https://openalex.org/W1994320162", "doi": "https://doi.org/10.1038/ijo.2011.158", "title": "Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide", "abstract": null, "publication_date": "2011-08-16", "publication_year": 2011, "type": "article", "cited_by_count": 728, "authors": [ { "id": "https://openalex.org/A5048067129", "display_name": "Arne Astrup" }, { "id": "https://openalex.org/A5082931469", "display_name": "Raffaele Carraro" }, { "id": "https://openalex.org/A5018535962", "display_name": "Nick Finer" }, { "id": "https://openalex.org/A5111708851", "display_name": "A E Harper" }, { "id": "https://openalex.org/A5107896266", "display_name": "Marie Kune\u0161ov\u00e1" }, { "id": "https://openalex.org/A5112474664", "display_name": "MEJ Lean" }, { "id": "https://openalex.org/A5048168425", "display_name": "Leo Niskanen" }, { "id": "https://openalex.org/A5109227325", "display_name": "Maria Rasmussen" }, { "id": "https://openalex.org/A5020700497", "display_name": "A Rissanen" }, { "id": "https://openalex.org/A5059778565", "display_name": "Stephan R\u00f6ssner" }, { "id": "https://openalex.org/A5025549582", "display_name": "Markku J. Savolainen" }, { "id": "https://openalex.org/A5109345483", "display_name": "L. Van Gaal" } ] }, { "id": "https://openalex.org/W3163431844", "doi": "https://doi.org/10.1136/bmj.n1091", "title": "SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline", "abstract": { "Abstract": [ 0 ], "Clinical": [ 1, 49 ], "question": [ 2 ], "What": [ 3 ], "are": [ 4, 71 ], "the": [ 5, 112, 256, 351, 359, 392, 400, 428, 432, 435, 446, 474, 490, 495, 513 ], "benefits": [ 6, 98, 283 ], "and": [ 7, 15, 44, 67, 93, 167, 185, 192, 200, 219, 244, 254, 272, 284, 290, 298, 303, 326, 398, 422, 441, 443, 453, 470, 506, 523, 536 ], "harms": [ 8, 285 ], "of": [ 9, 53, 100, 114, 282, 300, 335, 379, 410, 437, 448, 508 ], "sodium-glucose": [ 10 ], "cotransporter": [ 11 ], "2": [ 12, 37, 55, 125, 488 ], "(SGLT-2)": [ 13 ], "inhibitors": [ 14, 66, 116, 144, 166, 184, 199, 227, 289, 465 ], "glucagon-like": [ 16 ], "peptide": [ 17 ], "1": [ 18 ], "(GLP-1)": [ 19 ], "receptor": [ 20, 69, 119, 147, 172, 187, 206, 231, 292 ], "agonists": [ 21, 70, 120, 293 ], "when": [ 22 ], "added": [ 23 ], "to": [ 24, 212, 311, 354, 390, 477, 498 ], "usual": [ 25 ], "care": [ 26 ], "(lifestyle": [ 27 ], "interventions": [ 28 ], "and/or": [ 29 ], "other": [ 30, 451, 484 ], "diabetes": [ 31, 38, 56, 126 ], "drugs)": [ 32 ], "in": [ 33, 74, 121, 330, 350, 358, 387, 466 ], "adults": [ 34, 122, 485 ], "with": [ 35, 76, 123, 468, 486 ], "type": [ 36, 54, 124, 487 ], "at": [ 39 ], "different": [ 40, 318, 331 ], "risk": [ 41, 132, 154, 216, 343, 353, 375, 385, 438, 458, 520, 528 ], "for": [ 42, 63, 163, 181, 196, 203, 217, 224, 251, 323, 362, 439, 456, 463, 521 ], "cardiovascular": [ 43, 90, 131, 153, 522 ], "kidney": [ 45, 95, 305, 308, 524 ], "outcomes?": [ 46 ], "Current": [ 47 ], "practice": [ 48 ], "decisions": [ 50 ], "about": [ 51 ], "treatment": [ 52, 509, 543 ], "have": [ 57 ], "been": [ 58 ], "led": [ 59 ], "by": [ 60, 404, 434 ], "glycaemic": [ 61 ], "control": [ 62 ], "decades.": [ 64 ], "SGLT-2": [ 65, 115, 143, 165, 183, 198, 226, 288, 464 ], "GLP-1": [ 68, 118, 146, 171, 186, 205, 230, 291 ], "traditionally": [ 72 ], "used": [ 73 ], "people": [ 75 ], "elevated": [ 77 ], "glucose": [ 78 ], "level": [ 79 ], "after": [ 80 ], "metformin": [ 81 ], "treatment.": [ 82 ], "This": [ 83 ], "has": [ 84 ], "changed": [ 85 ], "through": [ 86 ], "trials": [ 87, 277 ], "demonstrating": [ 88 ], "atherosclerotic": [ 89 ], "disease": [ 91, 96, 306 ], "(CVD)": [ 92 ], "chronic": [ 94 ], "(CKD)": [ 97 ], "independent": [ 99 ], "medications\u2019": [ 101 ], "glucose-lowering": [ 102 ], "potential.": [ 103 ], "Recommendations": [ 104 ], "The": [ 105, 259, 266, 460 ], "guideline": [ 106, 235, 424, 514 ], "panel": [ 107, 240, 260, 425, 475, 496 ], "issued": [ 108 ], "risk-stratified": [ 109, 393 ], "recommendations": [ 110, 248, 401, 433, 492 ], "concerning": [ 111 ], "use": [ 113 ], "or": [ 117, 129, 137, 145, 159, 177, 307 ], "\u2022": [ 127, 149, 174, 189, 208 ], "Three": [ 128 ], "fewer": [ 130, 348, 356 ], "factors": [ 133, 155 ], "without": [ 134, 156 ], "established": [ 135, 157 ], "CVD": [ 136, 158, 176, 191, 218, 440, 469 ], "CKD:": [ 138, 160, 178, 193 ], "Weak": [ 139, 161, 179, 222 ], "recommendation": [ 140, 162, 180, 195, 202, 223, 429, 462 ], "against": [ 141, 169 ], "starting": [ 142, 164, 170, 182, 197, 204, 225 ], "agonists.": [ 148, 173, 188, 207, 232 ], "More": [ 150 ], "than": [ 151, 229 ], "three": [ 152 ], "weak": [ 168, 201, 491 ], "Established": [ 175, 190 ], "Strong": [ 194 ], "For": [ 209, 482 ], "those": [ 210 ], "committed": [ 211 ], "further": [ 213 ], "reducing": [ 214 ], "their": [ 215, 517 ], "CKD": [ 220, 442, 471 ], "outcomes:": [ 221 ], "rather": [ 228 ], "How": [ 233 ], "this": [ 234 ], "was": [ 236 ], "created": [ 237, 246 ], "An": [ 238 ], "international": [ 239 ], "including": [ 241, 545 ], "patients,": [ 242 ], "clinicians,": [ 243 ], "methodologists": [ 245 ], "these": [ 247 ], "following": [ 249 ], "standards": [ 250 ], "trustworthy": [ 252 ], "guidelines": [ 253 ], "using": [ 255, 512, 526 ], "GRADE": [ 257 ], "approach.": [ 258 ], "applied": [ 261 ], "an": [ 262 ], "individual": [ 263, 342, 519 ], "patient": [ 264, 414 ], "perspective.": [ 265 ], "evidence": [ 267, 388, 405, 534 ], "A": [ 268, 369 ], "linked": [ 269 ], "systematic": [ 270, 408 ], "review": [ 271, 371, 409 ], "network": [ 273 ], "meta-analysis": [ 274 ], "(764": [ 275 ], "randomised": [ 276 ], "included": [ 278 ], "421": [ 279 ], "346": [ 280 ], "participants)": [ 281 ], "found": [ 286 ], "that": [ 287 ], "generally": [ 294 ], "reduce": [ 295 ], "overall": [ 296 ], "death,": [ 297 ], "incidence": [ 299 ], "myocardial": [ 301 ], "infarctions,": [ 302 ], "end-stage": [ 304 ], "failure": [ 309 ], "(moderate": [ 310 ], "high": [ 312 ], "certainty": [ 313 ], "evidence).": [ 314 ], "These": [ 315 ], "medications": [ 316 ], "exert": [ 317 ], "effects": [ 319, 334 ], "on": [ 320, 340 ], "stroke,": [ 321 ], "hospitalisations": [ 322 ], "heart": [ 324 ], "failure,": [ 325 ], "key": [ 327 ], "adverse": [ 328 ], "events": [ 329 ], "subgroups.": [ 332 ], "Absolute": [ 333 ], "benefit": [ 336 ], "varied": [ 337 ], "widely": [ 338 ], "based": [ 339 ], "patients\u2019": [ 341, 396 ], "(for": [ 344 ], "example,": [ 345 ], "from": [ 346, 406 ], "five": [ 347, 367 ], "deaths": [ 349, 357 ], "lowest": [ 352 ], "48": [ 355 ], "highest": [ 360 ], "risk,": [ 361 ], "1000": [ 363 ], "patients": [ 364, 467 ], "treated": [ 365 ], "over": [ 366 ], "years).": [ 368 ], "prognosis": [ 370 ], "identified": [ 372 ], "14": [ 373 ], "eligible": [ 374 ], "prediction": [ 376 ], "models,": [ 377 ], "one": [ 378 ], "which": [ 380 ], "(RECODe)": [ 381 ], "informed": [ 382, 542 ], "most": [ 383 ], "baseline": [ 384 ], "estimates": [ 386 ], "summaries": [ 389, 535 ], "underpin": [ 391 ], "recommendations.": [ 394 ], "Concerning": [ 395 ], "values": [ 397 ], "preferences,": [ 399 ], "were": [ 402 ], "supported": [ 403 ], "a": [ 407, 413, 418, 423, 479, 500 ], "published": [ 411 ], "literature,": [ 412 ], "focus": [ 415 ], "group": [ 416 ], "study,": [ 417 ], "practical": [ 419, 454 ], "issues": [ 420, 455 ], "summary,": [ 421 ], "survey.": [ 426 ], "Understanding": [ 427 ], "We": [ 430 ], "stratified": [ 431 ], "levels": [ 436 ], "systematically": [ 444 ], "considered": [ 445, 476, 497 ], "balance": [ 447, 502 ], "benefits,": [ 449, 504 ], "harms,": [ 450, 505 ], "considerations,": [ 452 ], "each": [ 457 ], "group.": [ 459 ], "strong": [ 461 ], "reflects": [ 472 ], "what": [ 473, 494 ], "be": [ 478, 499 ], "clear": [ 480 ], "benefit.": [ 481 ], "all": [ 483 ], "diabetes,": [ 489 ], "reflect": [ 493 ], "finer": [ 501 ], "between": [ 503 ], "burdens": [ 507 ], "options.": [ 510 ], "Clinicians": [ 511 ], "can": [ 515 ], "identify": [ 516 ], "patient\u2019s": [ 518 ], "outcomes": [ 525 ], "credible": [ 527 ], "calculators": [ 529 ], "such": [ 530 ], "as": [ 531 ], "RECODe.": [ 532 ], "Interactive": [ 533 ], "decision": [ 537, 547 ], "aids": [ 538 ], "may": [ 539 ], "support": [ 540 ], "well": [ 541 ], "choices,": [ 544 ], "shared": [ 546 ], "making.": [ 548 ] }, "publication_date": "2021-05-11", "publication_year": 2021, "type": "review", "cited_by_count": 111, "authors": [ { "id": "https://openalex.org/A5091607881", "display_name": "Sheyu Li" }, { "id": "https://openalex.org/A5017952355", "display_name": "Per Olav Vandvik" }, { "id": "https://openalex.org/A5108797836", "display_name": "Lyubov Lytvyn" }, { "id": "https://openalex.org/A5031717153", "display_name": "Gordon Guyatt" }, { "id": "https://openalex.org/A5018429053", "display_name": "Suetonia C. Palmer" }, { "id": "https://openalex.org/A5035283542", "display_name": "Ren\u00e9 Rodr\u00edguez\u2010Guti\u00e9rrez" }, { "id": "https://openalex.org/A5064459641", "display_name": "Farid Foroutan" }, { "id": "https://openalex.org/A5010837310", "display_name": "Thomas Agoritsas" }, { "id": "https://openalex.org/A5072226388", "display_name": "Reed Siemieniuk" }, { "id": "https://openalex.org/A5013696488", "display_name": "Michael Walsh" }, { "id": "https://openalex.org/A5003739848", "display_name": "Lawrie Frere" }, { "id": "https://openalex.org/A5021328880", "display_name": "David J. Tunnicliffe" }, { "id": "https://openalex.org/A5028969645", "display_name": "Evi Nagler" }, { "id": "https://openalex.org/A5028887083", "display_name": "Veena Manja" }, { "id": "https://openalex.org/A5069421607", "display_name": "Bj\u00f8rn Olav \u00c5svold" }, { "id": "https://openalex.org/A5036931186", "display_name": "Vivekanand Jha" }, { "id": "https://openalex.org/A5025403646", "display_name": "Mieke Vermandere" }, { "id": "https://openalex.org/A5028737784", "display_name": "Karim Gariani" }, { "id": "https://openalex.org/A5017047667", "display_name": "Qian Zhao" }, { "id": "https://openalex.org/A5100644439", "display_name": "Yan Ren" }, { "id": "https://openalex.org/A5081581107", "display_name": "Emma Jane Cartwright" }, { "id": "https://openalex.org/A5018643885", "display_name": "Patrick O. Gee" }, { "id": "https://openalex.org/A5080699844", "display_name": "Alan Wickes" }, { "id": "https://openalex.org/A5052341063", "display_name": "Linda Ferns" }, { "id": "https://openalex.org/A5073412298", "display_name": "Robin Wright" }, { "id": "https://openalex.org/A5100435324", "display_name": "Ling Li" }, { "id": "https://openalex.org/A5100602713", "display_name": "Qiukui Hao" }, { "id": "https://openalex.org/A5067205817", "display_name": "Reem A. Mustafa" } ] }, { "id": "https://openalex.org/W1969856989", "doi": "https://doi.org/10.1111/j.1463-1326.2012.01557.x", "title": "Liraglutide: short\u2010lived effect on gastric emptying\u2014long lasting effects on body weight", "abstract": { "Aim:": [ 0 ], "Previous": [ 1 ], "studies": [ 2 ], "with": [ 3, 57, 84, 149 ], "the": [ 4, 14, 47, 70, 78, 101, 124, 139, 163, 179, 226, 232 ], "novel": [ 5 ], "once": [ 6 ], "daily": [ 7 ], "glucagon\u2010like": [ 8 ], "peptide\u20101": [ 9 ], "(GLP\u20101)": [ 10 ], "analogue": [ 11 ], "liraglutide": [ 12, 83 ], "and": [ 13, 23, 34, 36, 49, 65, 82, 116, 228 ], "GLP\u20101": [ 15, 55, 182, 209 ], "receptor": [ 16, 210 ], "agonist": [ 17 ], "exenatide": [ 18, 81 ], "have": [ 19 ], "revealed": [ 20 ], "profound": [ 21, 158 ], "insulinotrophic": [ 22 ], "antidiabetic": [ 24 ], "effects,": [ 25 ], "but": [ 26, 190 ], "also": [ 27 ], "potent": [ 28 ], "effects": [ 29, 51, 88, 170, 207 ], "on": [ 30, 61, 171, 196 ], "gastric": [ 31 ], "emptying": [ 32 ], "(GE)": [ 33 ], "long\u2010term": [ 35 ], "lasting": [ 37 ], "reductions": [ 38, 136 ], "in": [ 39, 111, 137, 160, 184, 225 ], "body": [ 40, 66, 117, 172, 205 ], "weight.": [ 41, 67, 173 ], "In": [ 42, 151 ], "this": [ 43, 192 ], "study,": [ 44 ], "we": [ 45 ], "examined": [ 46 ], "acute": [ 48, 86, 102, 135 ], "chronic": [ 50 ], "of": [ 52, 72, 75, 80, 147, 208, 222 ], "two": [ 53 ], "different": [ 54, 58 ], "analogues": [ 56 ], "pharmacokinetic": [ 59 ], "profiles": [ 60 ], "GE,": [ 62, 138, 230 ], "food": [ 63, 114 ], "intake": [ 64, 115 ], "Methods:": [ 68 ], "On": [ 69, 121 ], "basis": [ 71 ], "a": [ 73, 95, 157 ], "series": [ 74 ], "dose\u2010finding": [ 76 ], "studies,": [ 77 ], "doses": [ 79 ], "similar": [ 85, 169 ], "anorectic": [ 87 ], "were": [ 89, 105 ], "identified.": [ 90 ], "GE": [ 91, 125, 161 ], "was": [ 92, 119, 127, 141 ], "assessed": [ 93 ], "using": [ 94 ], "standard": [ 96 ], "acetaminophen": [ 97 ], "release": [ 98 ], "assay.": [ 99 ], "After": [ 100 ], "test,": [ 103 ], "rats": [ 104, 154, 185 ], "dosed": [ 106 ], "bi\u2010daily": [ 107 ], "for": [ 108, 235 ], "14": [ 109, 145 ], "days": [ 110, 146 ], "which": [ 112 ], "period": [ 113 ], "weight": [ 118, 237 ], "monitored.": [ 120 ], "day": [ 122 ], "14,": [ 123 ], "rate": [ 126 ], "reassessed.": [ 128 ], "Results:": [ 129 ], "While": [ 130 ], "both": [ 131 ], "compounds": [ 132, 167 ], "exerted": [ 133, 168 ], "robust": [ 134 ], "effect": [ 140, 193 ], "markedly": [ 142 ], "diminished": [ 143 ], "following": [ 144 ], "dosing": [ 148 ], "liraglutide.": [ 150, 203 ], "contrast,": [ 152 ], "exenatide\u2010treated": [ 153 ], "still": [ 155 ], "displayed": [ 156 ], "reduction": [ 159 ], "at": [ 162 ], "14\u2010day": [ 164 ], "time\u2010point.": [ 165 ], "Both": [ 166 ], "Conclusion:": [ 174 ], "The": [ 175, 204 ], "data": [ 176, 218 ], "suggest": [ 177 ], "that": [ 178, 191, 220 ], "\u2018gastric": [ 180 ], "inhibitory\u2019": [ 181 ], "receptors": [ 183 ], "are": [ 186, 212 ], "subject": [ 187, 214 ], "to": [ 188, 215 ], "desensitization/tachyphylaxis": [ 189 ], "is": [ 194, 231 ], "dependent": [ 195 ], "full": [ 197 ], "24\u2010h": [ 198 ], "exposure": [ 199 ], "as": [ 200 ], "obtained": [ 201 ], "by": [ 202 ], "weight\u2010lowering": [ 206 ], "stimulation": [ 211 ], "not": [ 213, 229 ], "desensitization.": [ 216 ], "These": [ 217 ], "indicate": [ 219 ], "regulation": [ 221 ], "appetite": [ 223 ], "signals": [ 224 ], "brain,": [ 227 ], "main": [ 233 ], "mechanism": [ 234 ], "liraglutide\u2010induced": [ 236 ], "loss.": [ 238 ] }, "publication_date": "2012-01-06", "publication_year": 2012, "type": "article", "cited_by_count": 174, "authors": [ { "id": "https://openalex.org/A5075602116", "display_name": "Jacob Jelsing" }, { "id": "https://openalex.org/A5088582143", "display_name": "Niels Vrang" }, { "id": "https://openalex.org/A5110313943", "display_name": "Gitte Hansen" }, { "id": "https://openalex.org/A5064830959", "display_name": "Kirsten Raun" }, { "id": "https://openalex.org/A5016148396", "display_name": "Mads Tang\u2010Christensen" }, { "id": "https://openalex.org/A5088627727", "display_name": "Lotte Bjerre Knudsen" } ] }, { "id": "https://openalex.org/W3126030429", "doi": "https://doi.org/10.3390/metabo11020073", "title": "Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials", "abstract": { "To": [ 0 ], "assess": [ 1 ], "the": [ 2, 137 ], "efficacy": [ 3 ], "of": [ 4, 13, 29, 67, 128, 140, 172, 176 ], "glucagon-like": [ 5 ], "peptide-1": [ 6 ], "receptor": [ 7 ], "agonists": [ 8 ], "(GLP-1": [ 9 ], "RAs)": [ 10 ], "for": [ 11, 125, 187, 207 ], "treatment": [ 12, 121, 194, 205 ], "nonalcoholic": [ 14 ], "fatty": [ 15 ], "liver": [ 16, 102, 141, 162, 177 ], "disease": [ 17 ], "(NAFLD)": [ 18 ], "or": [ 19, 49, 60, 88, 98, 108, 118, 209 ], "steatohepatitis": [ 20 ], "(NASH),": [ 21 ], "we": [ 22 ], "performed": [ 23 ], "a": [ 24, 65, 126, 203 ], "systematic": [ 25 ], "review": [ 26 ], "and": [ 27, 160, 189, 200 ], "meta-analysis": [ 28 ], "randomized": [ 30 ], "controlled": [ 31 ], "trials": [ 32 ], "(RCTs).": [ 33 ], "Three": [ 34 ], "large": [ 35 ], "electronic": [ 36 ], "databases": [ 37 ], "were": [ 38 ], "systematically": [ 39 ], "searched": [ 40 ], "(up": [ 41 ], "to": [ 42, 46, 94, 116, 158 ], "15": [ 43 ], "December": [ 44 ], "2020)": [ 45 ], "identify": [ 47 ], "placebo-controlled": [ 48, 59 ], "active-controlled": [ 50, 61 ], "RCTs": [ 51, 63 ], "using": [ 52 ], "different": [ 53 ], "GLP-1": [ 54, 123, 196 ], "RAs.": [ 55 ], "We": [ 56 ], "included": [ 57 ], "eleven": [ 58 ], "phase-2": [ 62 ], "(involving": [ 64 ], "total": [ 66 ], "936": [ 68 ], "middle-aged": [ 69 ], "individuals)": [ 70 ], "that": [ 71, 211 ], "used": [ 72 ], "liraglutide": [ 73, 188, 199 ], "(n": [ 74, 79, 84, 90, 104, 111 ], "=": [ 75, 80, 85, 91, 105, 112 ], "6": [ 76 ], "RCTs),": [ 77, 82 ], "exenatide": [ 78 ], "3": [ 81 ], "dulaglutide": [ 83 ], "1": [ 86, 92 ], "RCT)": [ 87, 93 ], "semaglutide": [ 89, 190 ], "specifically": [ 95 ], "treat": [ 96 ], "NAFLD": [ 97, 208 ], "NASH,": [ 99 ], "detected": [ 100 ], "by": [ 101 ], "biopsy": [ 103 ], "2": [ 106 ], "RCTs)": [ 107 ], "imaging": [ 109 ], "techniques": [ 110, 147 ], "9": [ 113 ], "RCTs).": [ 114 ], "Compared": [ 115 ], "placebo": [ 117 ], "reference": [ 119 ], "therapy,": [ 120 ], "with": [ 122, 133, 168, 195 ], "RAs": [ 124, 197 ], "median": [ 127 ], "26": [ 129 ], "weeks": [ 130 ], "was": [ 131 ], "associated": [ 132 ], "significant": [ 134 ], "reductions": [ 135 ], "in": [ 136 ], "absolute": [ 138 ], "percentage": [ 139 ], "fat": [ 142 ], "content": [ 143 ], "on": [ 144 ], "magnetic": [ 145 ], "resonance-based": [ 146 ], "(pooled": [ 148, 179 ], "weighted": [ 149 ], "mean": [ 150 ], "difference:": [ 151 ], "\u22123.92%,": [ 152 ], "95%": [ 153, 184 ], "confidence": [ 154 ], "intervals": [ 155 ], "(CI)": [ 156 ], "\u22126.27%": [ 157 ], "\u22121.56%)": [ 159 ], "serum": [ 161 ], "enzyme": [ 163 ], "levels,": [ 164 ], "as": [ 165, 167 ], "well": [ 166 ], "greater": [ 169 ], "histological": [ 170 ], "resolution": [ 171 ], "NASH": [ 173, 210 ], "without": [ 174 ], "worsening": [ 175 ], "fibrosis": [ 178 ], "random-effects": [ 180 ], "odds": [ 181 ], "ratio": [ 182 ], "4.06,": [ 183 ], "CI": [ 185 ], "2.52\u20136.55;": [ 186 ], "only).": [ 191 ], "In": [ 192 ], "conclusion,": [ 193 ], "(mostly": [ 198 ], "semaglutide)": [ 201 ], "is": [ 202 ], "promising": [ 204 ], "option": [ 206 ], "warrants": [ 212 ], "further": [ 213 ], "investigation.": [ 214 ] }, "publication_date": "2021-01-27", "publication_year": 2021, "type": "review", "cited_by_count": 263, "authors": [ { "id": "https://openalex.org/A5036950034", "display_name": "Alessandro Mantovani" }, { "id": "https://openalex.org/A5033545058", "display_name": "Graziana Petracca" }, { "id": "https://openalex.org/A5049532567", "display_name": "Giorgia Beatrice" }, { "id": "https://openalex.org/A5000867151", "display_name": "Alessandro Csermely" }, { "id": "https://openalex.org/A5083867437", "display_name": "Amedeo Lonardo" }, { "id": "https://openalex.org/A5071075382", "display_name": "Giovanni Targher" } ] }, { "id": "https://openalex.org/W4285014503", "doi": "https://doi.org/10.3389/fendo.2022.927859", "title": "Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials", "abstract": { "The": [ 0 ], "association": [ 1, 111 ], "between": [ 2, 25 ], "glucagon-like": [ 3 ], "peptide-1": [ 4 ], "(GLP-1)": [ 5 ], "receptor": [ 6, 30, 106, 127, 199, 213 ], "agonists": [ 7, 31, 128, 200, 214 ], "and": [ 8, 32, 54, 84, 169, 178, 188, 230 ], "the": [ 9, 23, 26, 33, 46, 97, 134, 195, 220, 235 ], "risk": [ 10, 81, 115, 221 ], "of": [ 11, 14, 28, 35, 38, 50, 56, 91, 116, 136, 186, 197, 222, 238 ], "various": [ 12 ], "kinds": [ 13, 37 ], "thyroid": [ 15, 39, 118, 137, 162, 203, 223, 228 ], "disorders": [ 16, 119, 204 ], "remains": [ 17 ], "uncertain.": [ 18 ], "We": [ 19, 41, 72 ], "aimed": [ 20 ], "to": [ 21, 61, 65, 79, 194, 234, 244 ], "evaluate": [ 22 ], "relationship": [ 24 ], "use": [ 27, 108 ], "GLP-1": [ 29, 105, 126, 198, 212 ], "occurrence": [ 34, 135 ], "6": [ 36 ], "disorders.": [ 40 ], "searched": [ 42 ], "PubMed": [ 43 ], "(MEDLINE),": [ 44 ], "EMBASE,": [ 45 ], "Cochrane": [ 47 ], "Central": [ 48 ], "Register": [ 49 ], "Controlled": [ 51 ], "Trials": [ 52 ], "(CENTRAL)": [ 53 ], "Web": [ 55 ], "Science": [ 57 ], "from": [ 58 ], "database": [ 59 ], "inception": [ 60 ], "31": [ 62 ], "October": [ 63 ], "2021": [ 64 ], "identify": [ 66 ], "eligible": [ 67 ], "randomized": [ 68 ], "controlled": [ 69 ], "trials": [ 70, 93 ], "(RCTs).": [ 71 ], "performed": [ 73 ], "meta-analysis": [ 74 ], "using": [ 75 ], "a": [ 76 ], "random-effects": [ 77 ], "model": [ 78 ], "calculate": [ 80 ], "ratios": [ 82 ], "(RRs)": [ 83 ], "95%": [ 85, 122, 141, 147, 153, 159, 166, 173 ], "confidence": [ 86 ], "intervals": [ 87 ], "(CIs).": [ 88 ], "A": [ 89 ], "total": [ 90 ], "45": [ 92 ], "were": [ 94, 191 ], "included": [ 95 ], "in": [ 96 ], "meta-analysis.": [ 98 ], "Compared": [ 99 ], "with": [ 100, 112 ], "placebo": [ 101 ], "or": [ 102, 218 ], "other": [ 103 ], "interventions,": [ 104 ], "agonists\u2019": [ 107 ], "showed": [ 109, 181 ], "an": [ 110, 113 ], "increased": [ 114 ], "overall": [ 117, 202 ], "(RR": [ 120, 139, 145, 151, 157, 164, 171 ], "1.28,": [ 121 ], "CI": [ 123, 142, 148, 154, 160, 167, 174 ], "1.03-1.60).": [ 124 ], "However,": [ 125, 232 ], "had": [ 129 ], "no": [ 130 ], "significant": [ 131 ], "effects": [ 132 ], "on": [ 133, 201 ], "cancer": [ 138 ], "1.30,": [ 140 ], "0.86-1.97),": [ 143 ], "hyperthyroidism": [ 144 ], "1.19,": [ 146 ], "0.61-2.35),": [ 149 ], "hypothyroidism": [ 150 ], "1.22,": [ 152 ], "0.80-1.87),": [ 155 ], "thyroiditis": [ 156 ], "1.83,": [ 158 ], "0.51-6.57),": [ 161 ], "mass": [ 163, 229 ], "1.17,": [ 165, 172 ], "0.43-3.20),": [ 168 ], "goiter": [ 170 ], "0.74-1.86).": [ 175 ], "Subgroup": [ 176 ], "analyses": [ 177, 180 ], "meta-regression": [ 179 ], "that": [ 182 ], "underlying": [ 183 ], "diseases,": [ 184, 240 ], "type": [ 185 ], "control,": [ 187 ], "trial": [ 189 ], "durations": [ 190 ], "not": [ 192, 216 ], "related": [ 193 ], "effect": [ 196 ], "(all": [ 205 ], "P": [ 206 ], "subgroup": [ 207 ], "&gt;": [ 208 ], "0.05).": [ 209 ], "In": [ 210 ], "conclusion,": [ 211 ], "did": [ 215 ], "increase": [ 217 ], "decrease": [ 219 ], "cancer,": [ 224 ], "hyperthyroidism,": [ 225 ], "hypothyroidism,": [ 226 ], "thyroiditis,": [ 227 ], "goiter.": [ 231 ], "due": [ 233 ], "low": [ 236 ], "incidence": [ 237 ], "these": [ 239, 241 ], "findings": [ 242 ], "need": [ 243 ], "be": [ 245 ], "examined": [ 246 ], "further.": [ 247 ], "Systematic": [ 248 ], "Review": [ 249 ], "Registration": [ 250 ], "PROSPERO": [ 251 ], "https://www.crd.york.ac.uk/prospero/": [ 252 ], ",": [ 253 ], "identifier:": [ 254 ], "CRD42021289121.": [ 255 ] }, "publication_date": "2022-07-11", "publication_year": 2022, "type": "review", "cited_by_count": 93, "authors": [ { "id": "https://openalex.org/A5084307808", "display_name": "Weiting Hu" }, { "id": "https://openalex.org/A5085236392", "display_name": "Rui Song" }, { "id": "https://openalex.org/A5101847496", "display_name": "Rui Cheng" }, { "id": "https://openalex.org/A5100650423", "display_name": "Caihong Liu" }, { "id": "https://openalex.org/A5068595169", "display_name": "Rui Guo" }, { "id": "https://openalex.org/A5101624212", "display_name": "Wei Tang" }, { "id": "https://openalex.org/A5100436712", "display_name": "Jie Zhang" }, { "id": "https://openalex.org/A5101617998", "display_name": "Qian Zhao" }, { "id": "https://openalex.org/A5100358661", "display_name": "Xing Li" }, { "id": "https://openalex.org/A5119272186", "display_name": "Jing Liu" } ] }, { "id": "https://openalex.org/W2015788437", "doi": "https://doi.org/10.1038/ijo.2013.120", "title": "Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study", "abstract": null, "publication_date": "2013-07-01", "publication_year": 2013, "type": "article", "cited_by_count": 784, "authors": [ { "id": "https://openalex.org/A5026596594", "display_name": "Thomas A. Wadden" }, { "id": "https://openalex.org/A5048198396", "display_name": "Priscilla Hollander" }, { "id": "https://openalex.org/A5021042114", "display_name": "Samuel Klein" }, { "id": "https://openalex.org/A5068362253", "display_name": "Kevin D. Niswender" }, { "id": "https://openalex.org/A5069140407", "display_name": "V. Woo" }, { "id": "https://openalex.org/A5023487929", "display_name": "Paula M. Hale" }, { "id": "https://openalex.org/A5051043505", "display_name": "Louis J. Aronne" } ] }, { "id": "https://openalex.org/W2606536757", "doi": "https://doi.org/10.1016/s1262-3636(17)30068-x", "title": "GLP-1 receptor agonists and heart failure in diabetes", "abstract": null, "publication_date": "2017-04-01", "publication_year": 2017, "type": "review", "cited_by_count": 64, "authors": [ { "id": "https://openalex.org/A5039563874", "display_name": "Andr\u00e9 Scheen" } ] }, { "id": "https://openalex.org/W2895666357", "doi": "https://doi.org/10.1016/s0140-6736(18)32260-8", "title": "Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial", "abstract": null, "publication_date": "2018-10-04", "publication_year": 2018, "type": "article", "cited_by_count": 737, "authors": [ { "id": "https://openalex.org/A5086072427", "display_name": "Juan P. Fr\u00edas" }, { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5051676894", "display_name": "Joanna Van" }, { "id": "https://openalex.org/A5000970130", "display_name": "Mark E Kutner" }, { "id": "https://openalex.org/A5058864022", "display_name": "Xuewei Cui" }, { "id": "https://openalex.org/A5023603655", "display_name": "Charles Benson" }, { "id": "https://openalex.org/A5031510744", "display_name": "Shweta Urva" }, { "id": "https://openalex.org/A5064772594", "display_name": "Ruth E. Gimeno" }, { "id": "https://openalex.org/A5024563374", "display_name": "Zvonko Mili\u010devi\u0107" }, { "id": "https://openalex.org/A5081732583", "display_name": "Deborah A. Robins" }, { "id": "https://openalex.org/A5040811419", "display_name": "Axel Haupt" } ] }, { "id": "https://openalex.org/W2982670142", "doi": "https://doi.org/10.1038/s41598-019-52295-2", "title": "GLP-1 receptor agonist liraglutide has a neuroprotective effect on an aged rat model of Wolfram syndrome", "abstract": null, "publication_date": "2019-10-31", "publication_year": 2019, "type": "article", "cited_by_count": 52, "authors": [ { "id": "https://openalex.org/A5028452806", "display_name": "Kadri Seppa" }, { "id": "https://openalex.org/A5004852760", "display_name": "Maarja Toots" }, { "id": "https://openalex.org/A5029241731", "display_name": "Riin Reimets" }, { "id": "https://openalex.org/A5075013832", "display_name": "Toomas Jagom\u00e4e" }, { "id": "https://openalex.org/A5066483057", "display_name": "Tuuliki Koppel" }, { "id": "https://openalex.org/A5088704266", "display_name": "Maia Pallase" }, { "id": "https://openalex.org/A5090818471", "display_name": "Stine Hasselholt" }, { "id": "https://openalex.org/A5043894573", "display_name": "Maiken Krogsbaek" }, { "id": "https://openalex.org/A5033337407", "display_name": "Jens Randel Nyengaard" }, { "id": "https://openalex.org/A5048622515", "display_name": "Eero Vasar" }, { "id": "https://openalex.org/A5089896099", "display_name": "Anton Terasmaa" }, { "id": "https://openalex.org/A5072489475", "display_name": "Mario Plaas" } ] }, { "id": "https://openalex.org/W4224218205", "doi": "https://doi.org/10.1111/dom.14725", "title": "Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension", "abstract": { "Abstract": [ 0 ], "Aim": [ 1 ], "To": [ 2 ], "explore": [ 3 ], "changes": [ 4, 253 ], "in": [ 5, 15, 112, 120, 134, 191, 254, 272 ], "body": [ 6, 32 ], "weight": [ 7, 152, 249, 273 ], "and": [ 8, 22, 115, 118, 124, 160, 170, 177, 198, 240, 263, 274 ], "cardiometabolic": [ 9, 255 ], "risk": [ 10 ], "factors": [ 11 ], "after": [ 12, 232 ], "treatment": [ 13, 167, 266 ], "withdrawal": [ 14, 233 ], "the": [ 16, 116, 121, 127, 135, 259 ], "STEP": [ 17, 24 ], "1": [ 18, 25, 46 ], "trial": [ 19 ], "extension.": [ 20 ], "Materials": [ 21 ], "Methods": [ 23 ], "(NCT03548935)": [ 26 ], "randomized": [ 27 ], "1961": [ 28 ], "adults": [ 29 ], "with": [ 30, 44, 126, 158, 164, 218, 251 ], "a": [ 31, 88, 91 ], "mass": [ 33 ], "index": [ 34 ], "\u2265": [ 35, 40, 45 ], "30": [ 36 ], "kg/m": [ 37, 42 ], "2": [ 38, 43 ], "(or": [ 39 ], "27": [ 41 ], "weight\u2010related": [ 47 ], "co\u2010morbidity)": [ 48 ], "without": [ 49 ], "diabetes": [ 50 ], "to": [ 51, 71, 148, 206, 215, 269 ], "68": [ 52, 99, 217 ], "weeks": [ 53, 62, 100 ], "of": [ 54, 63, 94, 101, 183, 194, 234, 246, 261 ], "once\u2010weekly": [ 55, 235 ], "subcutaneous": [ 56, 236 ], "semaglutide": [ 57, 159, 169, 219, 237 ], "2.4": [ 58, 238 ], "mg": [ 59, 239 ], "(including": [ 60, 78 ], "16": [ 61 ], "dose": [ 64 ], "escalation)": [ 65 ], "or": [ 66 ], "placebo,": [ 67 ], "as": [ 68 ], "an": [ 69 ], "adjunct": [ 70 ], "lifestyle": [ 72, 79, 241 ], "intervention.": [ 73 ], "At": [ 74 ], "week": [ 75, 146, 149, 188, 204, 207, 213, 216, 224 ], "68,": [ 76, 150 ], "treatments": [ 77 ], "intervention)": [ 80 ], "were": [ 81, 137 ], "discontinued.": [ 82 ], "An": [ 83 ], "off\u2010treatment": [ 84 ], "extension": [ 85, 136 ], "assessed": [ 86 ], "for": [ 87, 226 ], "further": [ 89 ], "year": [ 90, 231 ], "representative": [ 92 ], "subset": [ 93, 104 ], "participants": [ 95, 108, 172, 243 ], "who": [ 96 ], "had": [ 97 ], "completed": [ 98 ], "treatment.": [ 102 ], "This": [ 103 ], "comprised": [ 105 ], "all": [ 106 ], "eligible": [ 107 ], "from": [ 109, 203, 212 ], "any": [ 110 ], "site": [ 111 ], "Canada,": [ 113 ], "Germany": [ 114 ], "UK,": [ 117 ], "sites": [ 119 ], "United": [ 122 ], "States": [ 123 ], "Japan": [ 125 ], "highest": [ 128 ], "main": [ 129 ], "phase": [ 130 ], "recruitment.": [ 131 ], "All": [ 132 ], "analyses": [ 133, 141 ], "exploratory.": [ 138 ], "Results": [ 139 ], "Extension": [ 140 ], "included": [ 142 ], "327": [ 143 ], "participants.": [ 144 ], "From": [ 145 ], "0": [ 147, 205, 214 ], "mean": [ 151 ], "loss": [ 153 ], "was": [ 154 ], "17.3%": [ 155 ], "(SD:": [ 156, 162, 175, 179, 196, 200 ], "9.3%)": [ 157 ], "2.0%": [ 161 ], "6.1%)": [ 163 ], "placebo.": [ 165 ], "Following": [ 166 ], "withdrawal,": [ 168 ], "placebo": [ 171 ], "regained": [ 173, 244 ], "11.6": [ 174 ], "7.7)": [ 176 ], "1.9": [ 178 ], "4.8)": [ 180 ], "percentage": [ 181 ], "points": [ 182 ], "lost": [ 184 ], "weight,": [ 185 ], "respectively,": [ 186, 202 ], "by": [ 187 ], "120,": [ 189 ], "resulting": [ 190 ], "net": [ 192 ], "losses": [ 193 ], "5.6%": [ 195 ], "8.9%)": [ 197 ], "0.1%": [ 199 ], "5.8%),": [ 201 ], "120.": [ 208 ], "Cardiometabolic": [ 209 ], "improvements": [ 210, 271 ], "seen": [ 211 ], "reverted": [ 220 ], "towards": [ 221 ], "baseline": [ 222 ], "at": [ 223 ], "120": [ 225 ], "most": [ 227 ], "variables.": [ 228, 256 ], "Conclusions": [ 229 ], "One": [ 230 ], "intervention,": [ 242 ], "two\u2010thirds": [ 245 ], "their": [ 247 ], "prior": [ 248 ], "loss,": [ 250 ], "similar": [ 252 ], "Findings": [ 257 ], "confirm": [ 258 ], "chronicity": [ 260 ], "obesity": [ 262 ], "suggest": [ 264 ], "ongoing": [ 265 ], "is": [ 267 ], "required": [ 268 ], "maintain": [ 270 ], "health.": [ 275 ] }, "publication_date": "2022-04-19", "publication_year": 2022, "type": "article", "cited_by_count": 696, "authors": [ { "id": "https://openalex.org/A5047195042", "display_name": "John Wilding" }, { "id": "https://openalex.org/A5085481226", "display_name": "Rachel L. Batterham" }, { "id": "https://openalex.org/A5084593004", "display_name": "Melanie J. Davies" }, { "id": "https://openalex.org/A5111609726", "display_name": "Luc F. Van Gaal" }, { "id": "https://openalex.org/A5081590711", "display_name": "Kristian Kandler" }, { "id": "https://openalex.org/A5018597063", "display_name": "Katerina Konakli" }, { "id": "https://openalex.org/A5001655356", "display_name": "Ildiko Lingvay" }, { "id": "https://openalex.org/A5021130189", "display_name": "Barbara McGowan" }, { "id": "https://openalex.org/A5064155603", "display_name": "Tu\u011f\u00e7e Kalayc\u0131 Oral" }, { "id": "https://openalex.org/A5045489578", "display_name": "Julio Rosenstock" }, { "id": "https://openalex.org/A5026596594", "display_name": "Thomas A. Wadden" }, { "id": "https://openalex.org/A5027441223", "display_name": "Sean Wharton" }, { "id": "https://openalex.org/A5079640536", "display_name": "Koutaro Yokote" }, { "id": "https://openalex.org/A5062192624", "display_name": "Robert F. Kushner" } ] }, { "id": "https://openalex.org/W2787255324", "doi": "https://doi.org/10.1016/s2213-8587(18)30024-x", "title": "Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial", "abstract": null, "publication_date": "2018-02-01", "publication_year": 2018, "type": "article", "cited_by_count": 691, "authors": [ { "id": "https://openalex.org/A5059098934", "display_name": "Richard E. Pratley" }, { "id": "https://openalex.org/A5005405894", "display_name": "Vanita R. Aroda" }, { "id": "https://openalex.org/A5001655356", "display_name": "Ildiko Lingvay" }, { "id": "https://openalex.org/A5015283109", "display_name": "J L\u00fcdemann" }, { "id": "https://openalex.org/A5037530982", "display_name": "Camilla Andreassen" }, { "id": "https://openalex.org/A5020470965", "display_name": "Andrea Navarria" }, { "id": "https://openalex.org/A5070756199", "display_name": "Adie Viljoen" } ] }, { "id": "https://openalex.org/W2913950552", "doi": "https://doi.org/10.3233/jpd-181503", "title": "Semaglutide is Neuroprotective and Reduces \u03b1-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson\u2019s Disease", "abstract": { "Parkinson's": [ 0 ], "disease": [ 1, 38 ], "(PD)": [ 2 ], "is": [ 3, 13, 30 ], "a": [ 4, 61, 130, 233 ], "progressive": [ 5 ], "neurological": [ 6 ], "motor": [ 7, 146 ], "control": [ 8 ], "disorder.": [ 9 ], "A": [ 10, 238 ], "key": [ 11, 189 ], "feature": [ 12 ], "the": [ 14, 21, 32, 66, 80, 86, 90, 115, 127, 153, 161, 166, 171, 178, 188, 198, 205 ], "loss": [ 15 ], "of": [ 16, 23, 56, 89, 120, 155, 163, 187 ], "midbrain": [ 17 ], "dopaminergic": [ 18, 195 ], "neurons": [ 19, 196 ], "and": [ 20, 104, 142, 176, 183, 202 ], "accumulation": [ 22, 162 ], "aggregated": [ 24 ], "alpha-synuclein": [ 25 ], "(\u03b1-syn).": [ 26 ], "No": [ 27 ], "current": [ 28 ], "treatment": [ 29, 131, 235 ], "on": [ 31, 126 ], "market": [ 33, 128 ], "that": [ 34, 44, 139, 193, 229 ], "slows": [ 35 ], "or": [ 36 ], "halts": [ 37 ], "progression.": [ 39 ], "Previous": [ 40 ], "studies": [ 41 ], "have": [ 42, 50, 84 ], "shown": [ 43, 72 ], "glucagon-like": [ 45 ], "peptide-1": [ 46 ], "(GLP-1)": [ 47 ], "receptor": [ 48, 68 ], "agonists": [ 49 ], "neuroprotective": [ 51, 87 ], "effects": [ 52, 75, 88 ], "in": [ 53, 60, 76, 114, 170, 197, 219, 223, 243 ], "animal": [ 54 ], "models": [ 55 ], "PD.": [ 57, 121, 237 ], "In": [ 58, 79, 148 ], "addition,": [ 59, 149 ], "phase": [ 62 ], "II": [ 63, 134 ], "clinical": [ 64, 239 ], "trial,": [ 65 ], "GLP-1": [ 67, 91, 208 ], "agonist": [ 69 ], "exendin-4": [ 70 ], "has": [ 71 ], "good": [ 73 ], "protective": [ 74 ], "PD": [ 77, 244 ], "patients.": [ 78 ], "present": [ 81 ], "study,": [ 82 ], "we": [ 83 ], "investigated": [ 85 ], "analogues": [ 92 ], "semaglutide": [ 93, 141, 210, 230, 242 ], "(25": [ 94, 106 ], "nmol/kg": [ 95, 107 ], "ip.": [ 96, 108 ], "once": [ 97, 109, 216 ], "every": [ 98 ], "two": [ 99 ], "days": [ 100 ], "for": [ 101, 111, 132, 236 ], "30": [ 102, 112 ], "days)": [ 103, 113 ], "liraglutide": [ 105, 143, 218 ], "daily": [ 110, 217 ], "chronic": [ 116, 167 ], "MPTP": [ 117 ], "mouse": [ 118 ], "model": [ 119 ], "Both": [ 122 ], "drugs": [ 123, 151 ], "are": [ 124 ], "currently": [ 125 ], "as": [ 129 ], "Type": [ 133 ], "diabetes.": [ 135 ], "Our": [ 136, 226 ], "results": [ 137, 227 ], "show": [ 138 ], "both": [ 140, 150 ], "improved": [ 144 ], "MPTP-induced": [ 145 ], "impairments.": [ 147 ], "rescued": [ 152 ], "decrease": [ 154 ], "tyrosine": [ 156 ], "hydroxylase": [ 157 ], "(TH)": [ 158 ], "levels,": [ 159 ], "reduced": [ 160, 173 ], "\u03b1-syn,": [ 164 ], "alleviated": [ 165 ], "inflammation": [ 168 ], "response": [ 169 ], "brain,": [ 172 ], "lipid": [ 174 ], "peroxidation,": [ 175 ], "inhibited": [ 177 ], "mitochondrial": [ 179 ], "mitophagy": [ 180 ], "signaling": [ 181 ], "pathway,": [ 182 ], "furthermore": [ 184 ], "increased": [ 185 ], "expression": [ 186 ], "growth": [ 190 ], "factor": [ 191 ], "GDNF": [ 192 ], "protects": [ 194 ], "substantia": [ 199 ], "nigra": [ 200 ], "(SN)": [ 201 ], "striatum.": [ 203 ], "Moreover,": [ 204 ], "long-": [ 206 ], "acting": [ 207 ], "analogue": [ 209 ], "was": [ 211 ], "more": [ 212 ], "potent": [ 213 ], "compared": [ 214 ], "with": [ 215 ], "most": [ 220 ], "parameters": [ 221 ], "measured": [ 222 ], "this": [ 224 ], "study.": [ 225 ], "demonstrate": [ 228 ], "may": [ 231 ], "be": [ 232 ], "promising": [ 234 ], "trial": [ 240 ], "testing": [ 241 ], "patients": [ 245 ], "will": [ 246 ], "start": [ 247 ], "shortly.": [ 248 ] }, "publication_date": "2019-02-05", "publication_year": 2019, "type": "article", "cited_by_count": 139, "authors": [ { "id": "https://openalex.org/A5100405781", "display_name": "Ping Zhang" }, { "id": "https://openalex.org/A5100758902", "display_name": "Lingyu Zhang" }, { "id": "https://openalex.org/A5100729355", "display_name": "Lin Li" }, { "id": "https://openalex.org/A5082707086", "display_name": "Christian H\u00f6lscher" } ] }, { "id": "https://openalex.org/W2084948079", "doi": "https://doi.org/10.1053/j.gastro.2007.03.054", "title": "Biology of Incretins: GLP-1 and GIP", "abstract": null, "publication_date": "2007-05-01", "publication_year": 2007, "type": "review", "cited_by_count": 3481, "authors": [ { "id": "https://openalex.org/A5078676914", "display_name": "Laurie L. Baggio" }, { "id": "https://openalex.org/A5057472647", "display_name": "Daniel J. Drucker" } ] }, { "id": "https://openalex.org/W4319808936", "doi": "https://doi.org/10.3389/fendo.2023.1085799", "title": "GLP\u22121 receptor agonists for the treatment of obesity: Role as a promising approach", "abstract": { "Obesity": [ 0 ], "is": [ 1, 11 ], "a": [ 2, 136 ], "complex": [ 3 ], "disease": [ 4 ], "characterized": [ 5 ], "by": [ 6, 13 ], "excessive": [ 7 ], "fat": [ 8 ], "accumulation": [ 9 ], "which": [ 10 ], "caused": [ 12 ], "genetic,": [ 14 ], "environmental": [ 15 ], "and": [ 16, 43, 45, 67, 79, 101, 145, 157, 163 ], "other": [ 17, 158 ], "factors.": [ 18 ], "In": [ 19 ], "recent": [ 20 ], "years,": [ 21 ], "there": [ 22 ], "has": [ 23 ], "been": [ 24 ], "an": [ 25 ], "increase": [ 26 ], "in": [ 27, 106, 151, 174 ], "the": [ 28, 62, 84, 112, 122, 186, 199 ], "morbidity,": [ 29 ], "disability": [ 30 ], "rate,and": [ 31 ], "mortality": [ 32 ], "due": [ 33 ], "to": [ 34, 40, 88 ], "obesity,": [ 35 ], "making": [ 36 ], "it": [ 37 ], "great": [ 38 ], "threat": [ 39 ], "people\u2019s": [ 41 ], "health": [ 42, 48 ], "lives,": [ 44 ], "increasing": [ 46 ], "public": [ 47 ], "care": [ 49 ], "expenses.": [ 50 ], "Evidence": [ 51 ], "from": [ 52, 195 ], "previous": [ 53, 196 ], "studies": [ 54 ], "show": [ 55 ], "that": [ 56, 140, 168, 208, 214 ], "weight": [ 57 ], "loss": [ 58 ], "can": [ 59 ], "significantly": [ 60 ], "reduce": [ 61 ], "risk": [ 63 ], "of": [ 64, 117, 121, 138, 188, 201 ], "obesity-related": [ 65 ], "complications": [ 66 ], "chronic": [ 68 ], "diseases.": [ 69 ], "Diet": [ 70 ], "control,": [ 71 ], "moderate": [ 72 ], "exercise,": [ 73 ], "behavior": [ 74 ], "modification": [ 75 ], "programs,": [ 76 ], "bariatric": [ 77 ], "surgery": [ 78 ], "prescription": [ 80 ], "drug": [ 81 ], "treatment": [ 82, 187 ], "are": [ 83, 135, 148, 171, 182 ], "major": [ 85 ], "interventions": [ 86 ], "used": [ 87, 124 ], "help": [ 89, 216 ], "people": [ 90 ], "lose": [ 91 ], "weight.": [ 92 ], "Among": [ 93 ], "them,": [ 94 ], "anti-obesity": [ 95, 118 ], "drugs": [ 96, 125, 139 ], "have": [ 97, 126, 166 ], "high": [ 98 ], "compliance": [ 99 ], "rates": [ 100 ], "cause": [ 102 ], "noticeable": [ 103 ], "short-term": [ 104 ], "effects": [ 105, 200 ], "reducing": [ 107 ], "obese": [ 108, 189 ], "levels.": [ 109 ], "However,": [ 110 ], "given": [ 111 ], "safety": [ 113 ], "or": [ 114, 176, 219 ], "effectiveness": [ 115 ], "concerns": [ 116 ], "drugs,": [ 119 ], "many": [ 120 ], "currently": [ 123 ], "limited": [ 127 ], "clinical": [ 128, 164, 220 ], "use.": [ 129 ], "Glucagon-like": [ 130 ], "peptide-1": [ 131 ], "receptor": [ 132 ], "(GLP-1R)": [ 133 ], "agonists": [ 134, 170, 181, 203 ], "group": [ 137 ], "targets": [ 141 ], "incretin": [ 142 ], "hormone": [ 143 ], "action,": [ 144 ], "its": [ 146 ], "receptors": [ 147 ], "widely": [ 149 ], "distributed": [ 150 ], "nerves,": [ 152 ], "islets,": [ 153 ], "heart,": [ 154 ], "lung,": [ 155 ], "skin,": [ 156 ], "organs.": [ 159 ], "Several": [ 160 ], "animal": [ 161 ], "experiments": [ 162 ], "trials": [ 165 ], "demonstrated": [ 167 ], "GLP-1R": [ 169, 180, 202, 227 ], "more": [ 172 ], "effective": [ 173 ], "treating": [ 175 ], "preventing": [ 177 ], "obesity.": [ 178, 205 ], "Therefore,": [ 179 ], "promising": [ 183 ], "agents": [ 184 ], "for": [ 185 ], "individuals.": [ 190 ], "This": [ 191 ], "review": [ 192, 210 ], "describes": [ 193 ], "evidence": [ 194 ], "research": [ 197 ], "on": [ 198, 204, 226 ], "We": [ 206 ], "anticipate": [ 207 ], "this": [ 209 ], "will": [ 211, 215 ], "generate": [ 212 ], "data": [ 213 ], "biomedical": [ 217 ], "researchers": [ 218 ], "workers": [ 221 ], "develop": [ 222 ], "obesity": [ 223 ], "treatments": [ 224 ], "based": [ 225 ], "agonists.": [ 228 ] }, "publication_date": "2023-02-01", "publication_year": 2023, "type": "review", "cited_by_count": 187, "authors": [ { "id": "https://openalex.org/A5101692076", "display_name": "Jingyue Wang" }, { "id": "https://openalex.org/A5060746096", "display_name": "Quanwei Wang" }, { "id": "https://openalex.org/A5056067943", "display_name": "Xinyu Yang" }, { "id": "https://openalex.org/A5076807614", "display_name": "Wei Yang" }, { "id": "https://openalex.org/A5030452035", "display_name": "Dong-Rui Li" }, { "id": "https://openalex.org/A5102797094", "display_name": "Jingyu Jin" }, { "id": "https://openalex.org/A5055501200", "display_name": "Hui-Cong Zhang" }, { "id": "https://openalex.org/A5100693716", "display_name": "Xianfeng Zhang" } ] }, { "id": "https://openalex.org/W2344620176", "doi": "https://doi.org/10.1093/ajhp/62.2.173", "title": "Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus", "abstract": { "Administration": [ 0 ], "of": [ 1, 34, 39 ], "preprandial": [ 2 ], "exenatide": [ 3, 10, 24 ], "by": [ 4, 31 ], "s.c.": [ 5 ], "injection": [ 6 ], "resulted": [ 7 ], "in": [ 8 ], "dose-proportional": [ 9 ], "pharmacokinetics": [ 11 ], "and": [ 12, 37 ], "antidiabetic": [ 13 ], "pharmacodynamic": [ 14 ], "activity.": [ 15 ], "At": [ 16 ], "doses": [ 17 ], "ranging": [ 18 ], "from": [ 19 ], "0.02": [ 20 ], "to": [ 21 ], "0.2": [ 22 ], "microg/kg,": [ 23 ], "dose-dependently": [ 25 ], "reduced": [ 26 ], "postprandial": [ 27 ], "plasma": [ 28, 35 ], "glucose": [ 29 ], "excursion": [ 30 ], "insulinotropism,": [ 32 ], "suppression": [ 33 ], "glucagon,": [ 36 ], "slowing": [ 38 ], "gastric": [ 40 ], "emptying.": [ 41 ] }, "publication_date": "2005-01-15", "publication_year": 2005, "type": "article", "cited_by_count": 430, "authors": [ { "id": "https://openalex.org/A5019395960", "display_name": "Orville Kolterman" }, { "id": "https://openalex.org/A5084708084", "display_name": "Dennis Dong Hwan Kim" }, { "id": "https://openalex.org/A5113725447", "display_name": "Larry Z. Shen" }, { "id": "https://openalex.org/A5113780900", "display_name": "James A. Ruggles" }, { "id": "https://openalex.org/A5075068030", "display_name": "Loretta L. Nielsen" }, { "id": "https://openalex.org/A5083503351", "display_name": "Mark Fineman" }, { "id": "https://openalex.org/A5110941359", "display_name": "Alain Baron" } ] }, { "id": "https://openalex.org/W2593691145", "doi": "https://doi.org/10.1111/dom.12932", "title": "Effects of once\u2010weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity", "abstract": { "Aim": [ 0 ], "The": [ 1 ], "aim": [ 2 ], "of": [ 3, 11, 32, 35, 55, 62, 167, 200, 212, 229, 255 ], "this": [ 4, 273 ], "trial": [ 5, 28 ], "was": [ 6, 157, 218 ], "to": [ 7, 42, 86, 191, 237, 271 ], "investigate": [ 8 ], "the": [ 9, 30, 103, 132 ], "mechanism": [ 10 ], "action": [ 12 ], "for": [ 13, 173, 180, 243, 261 ], "body": [ 14, 69, 72, 182, 198, 205, 230 ], "weight": [ 15, 70, 199, 231, 245 ], "loss": [ 16, 228, 246 ], "with": [ 17, 37, 48, 83, 147, 159, 221, 225, 233 ], "semaglutide.": [ 18, 234 ], "Materials": [ 19 ], "and": [ 20, 59, 71, 101, 111, 162, 169, 250, 257 ], "methods": [ 21 ], "This": [ 22 ], "randomised,": [ 23 ], "double\u2010blind,": [ 24 ], "placebo\u2010controlled,": [ 25 ], "two\u2010period": [ 26 ], "crossover": [ 27 ], "investigated": [ 29 ], "effects": [ 31 ], "12": [ 33, 210 ], "weeks": [ 34, 211 ], "treatment": [ 36 ], "once\u2010weekly": [ 38 ], "subcutaneous": [ 39 ], "semaglutide,": [ 40, 81 ], "dose\u2010escalated": [ 41 ], "1.0": [ 43 ], "mg,": [ 44 ], "in": [ 45, 118, 122, 196 ], "30": [ 46 ], "subjects": [ 47 ], "obesity.": [ 49 ], "Ad": [ 50 ], "libitum": [ 51, 90, 129, 215 ], "energy": [ 52, 91, 124, 216, 239 ], "intake,": [ 53, 240 ], "ratings": [ 54, 153 ], "appetite,": [ 56 ], "thirst,": [ 57 ], "nausea": [ 58, 152 ], "well\u2010being,": [ 60 ], "control": [ 61, 166, 254 ], "eating,": [ 63 ], "food": [ 64, 163, 251 ], "preference,": [ 65 ], "resting": [ 66 ], "metabolic": [ 67, 177 ], "rate,": [ 68, 178 ], "composition": [ 73 ], "were": [ 74, 145, 154 ], "assessed.": [ 75 ], "Results": [ 76 ], "After": [ 77, 209 ], "a": [ 78, 87, 119, 170, 192, 226 ], "standardised": [ 79 ], "breakfast,": [ 80 ], "compared": [ 82 ], "placebo,": [ 84, 150 ], "led": [ 85, 190 ], "lower": [ 88, 171, 220, 258 ], "ad": [ 89, 128, 214 ], "intake": [ 92, 125, 217 ], "during": [ 93, 102 ], "lunch": [ 94 ], "(\u22121255": [ 95 ], "kJ": [ 96, 135 ], ";": [ 97, 136 ], "P": [ 98, 108, 114, 137 ], "<": [ 99, 138 ], ".0001)": [ 100 ], "subsequent": [ 104 ], "evening": [ 105 ], "meal": [ 106 ], "(": [ 107, 113 ], "=": [ 109, 115 ], ".0401)": [ 110 ], "snacks": [ 112 ], ".0034),": [ 116 ], "resulting": [ 117 ], "24%": [ 120 ], "reduction": [ 121, 193 ], "total": [ 123 ], "across": [ 126 ], "all": [ 127 ], "meals": [ 130 ], "throughout": [ 131 ], "day": [ 133 ], "(\u22123036": [ 134 ], ".0001).": [ 139 ], "Fasting": [ 140 ], "overall": [ 141 ], "appetite": [ 142, 249 ], "suppression": [ 143 ], "scores": [ 144 ], "improved": [ 146 ], "semaglutide": [ 148, 222 ], "vs": [ 149, 223 ], "while": [ 151 ], "similar.": [ 155 ], "Semaglutide": [ 156, 189 ], "associated": [ 158 ], "less": [ 160, 248 ], "hunger": [ 161 ], "cravings,": [ 164, 252 ], "better": [ 165, 253 ], "eating": [ 168, 256 ], "preference": [ 172, 260 ], "high\u2010fat": [ 174 ], "foods.": [ 175, 264 ], "Resting": [ 176 ], "adjusted": [ 179 ], "lean": [ 181 ], "mass,": [ 183 ], "did": [ 184 ], "not": [ 185 ], "differ": [ 186 ], "between": [ 187 ], "treatments.": [ 188 ], "from": [ 194, 204 ], "baseline": [ 195 ], "mean": [ 197 ], "5.0": [ 201 ], "kg,": [ 202 ], "predominantly": [ 203 ], "fat": [ 206 ], "mass.": [ 207 ], "Conclusion": [ 208 ], "treatment,": [ 213 ], "substantially": [ 219 ], "placebo": [ 224 ], "corresponding": [ 227 ], "observed": [ 232 ], "In": [ 235 ], "addition": [ 236 ], "reduced": [ 238 ], "likely": [ 241 ], "mechanisms": [ 242 ], "semaglutide\u2010induced": [ 244 ], "included": [ 247 ], "relative": [ 259 ], "fatty,": [ 262 ], "energy\u2010dense": [ 263 ], "Video": [ 265, 269 ], "Abstract": [ 266, 270 ], "A": [ 267 ], "free": [ 268 ], "accompany": [ 272 ], "article": [ 274 ], "is": [ 275 ], "available": [ 276 ], "at:": [ 277 ], "https://player.vimeo.com/video/218478638": [ 278 ], ".": [ 279 ] }, "publication_date": "2017-03-07", "publication_year": 2017, "type": "article", "cited_by_count": 549, "authors": [ { "id": "https://openalex.org/A5039586613", "display_name": "John E. Blundell" }, { "id": "https://openalex.org/A5013981637", "display_name": "Graham Finlayson" }, { "id": "https://openalex.org/A5112278544", "display_name": "Mads Axelsen" }, { "id": "https://openalex.org/A5019076349", "display_name": "Anne Flint" }, { "id": "https://openalex.org/A5008159825", "display_name": "Catherine Gibbons" }, { "id": "https://openalex.org/A5103723237", "display_name": "Trine Kvist" }, { "id": "https://openalex.org/A5085348099", "display_name": "Julie Hjerpsted" } ] }, { "id": "https://openalex.org/W2095774646", "doi": "https://doi.org/10.1016/j.regpep.2010.05.008", "title": "Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes", "abstract": null, "publication_date": "2010-06-03", "publication_year": 2010, "type": "review", "cited_by_count": 168, "authors": [ { "id": "https://openalex.org/A5077344547", "display_name": "Werner Ulrich" }, { "id": "https://openalex.org/A5085658741", "display_name": "Guido Haschke" }, { "id": "https://openalex.org/A5060556419", "display_name": "Andreas W. Herling" }, { "id": "https://openalex.org/A5029787700", "display_name": "Werner Kramer" } ] }, { "id": "https://openalex.org/W1985482823", "doi": "https://doi.org/10.2174/157488412800958686", "title": "GLP-1 Agonists Exenatide and Liraglutide: A Review About Their Safety and Efficacy", "abstract": { "Recently": [ 0 ], "incretin-based": [ 1 ], "therapies": [ 2 ], "have": [ 3, 44, 177 ], "been": [ 4 ], "developed": [ 5 ], "in": [ 6, 76, 103, 125, 138, 251, 264, 266 ], "the": [ 7, 14, 24, 50, 89, 132, 139, 225, 228, 279, 286 ], "clinical": [ 8, 111 ], "practice,": [ 9 ], "this": [ 10 ], "class": [ 11 ], "includes": [ 12 ], "both": [ 13, 75, 122 ], "dipeptidyl": [ 15 ], "peptidase-4": [ 16 ], "(DPP-4)": [ 17 ], "inhibitors": [ 18 ], "(sitagliptin,": [ 19 ], "vildagliptin,": [ 20 ], "saxagliptin,": [ 21 ], "linagliptin),": [ 22 ], "and": [ 23, 37, 42, 47, 70, 85, 97, 113, 120, 124, 159, 171, 183, 227, 270, 285 ], "glucagon-like": [ 25 ], "peptide-": [ 26 ], "1": [ 27 ], "(GLP-1)": [ 28 ], "receptor": [ 29, 117, 147, 243, 258 ], "agonists": [ 30, 118, 148, 244, 259 ], "[exenatide,": [ 31 ], "exenatide": [ 32, 41, 119 ], "long": [ 33 ], "acting": [ 34 ], "release": [ 35 ], "(LAR)": [ 36 ], "liraglutide].": [ 38 ], "In": [ 39 ], "particular": [ 40 ], "liraglutide": [ 43 ], "structural": [ 45 ], "similarity": [ 46 ], "bind": [ 48 ], "to": [ 49, 61, 150, 155, 160, 236 ], "GLP-1": [ 51, 81, 116, 146, 242, 257 ], "receptor,": [ 52 ], "displaying": [ 53 ], "a": [ 54, 77, 108, 152, 186, 200, 247, 275 ], "similar": [ 55 ], "broad": [ 56 ], "range": [ 57 ], "of": [ 58, 67, 72, 115, 189, 204, 215, 224, 278, 282 ], "activities": [ 59 ], "relevant": [ 60 ], "improving": [ 62 ], "glycemic": [ 63, 240 ], "control,": [ 64, 241 ], "including": [ 65, 131 ], "stimulation": [ 66 ], "insulin": [ 68 ], "secretion": [ 69, 170 ], "reduction": [ 71 ], "glucagon": [ 73, 169 ], "secretion,": [ 74 ], "glucose-dependent": [ 78 ], "manner.": [ 79 ], "Furthermore,": [ 80 ], "slows": [ 82 ], "gastrointestinal": [ 83, 205 ], "motility": [ 84 ], "increases": [ 86 ], "satiety,": [ 87 ], "reducing": [ 88, 101 ], "food": [ 90 ], "intake;": [ 91 ], "it": [ 92 ], "also": [ 93, 167, 176, 263 ], "promotes": [ 94 ], "\u03b2-cell": [ 95, 181 ], "proliferation": [ 96 ], "probably": [ 98 ], "neogenesis,": [ 99 ], "while": [ 100 ], "apoptosis": [ 102 ], "animal": [ 104 ], "models.": [ 105 ], "We": [ 106, 143 ], "conducted": [ 107 ], "review": [ 109 ], "analyzing": [ 110 ], "efficacy": [ 112 ], "safety": [ 114 ], "liraglutide,": [ 121 ], "alone": [ 123 ], "combination": [ 126 ], "with": [ 127, 196, 207, 268 ], "other": [ 128 ], "anti-diabetic": [ 129 ], "drugs,": [ 130 ], "most": [ 133 ], "important": [ 134 ], "studies": [ 135 ], "about": [ 136 ], "them": [ 137 ], "latest": [ 140 ], "ten": [ 141 ], "years.": [ 142 ], "concluded": [ 144, 231 ], "that": [ 145 ], "appear": [ 149 ], "be": [ 151, 246, 261 ], "good": [ 153 ], "choice": [ 154 ], "decrease": [ 156, 188 ], "HbA1c": [ 157 ], "levels": [ 158 ], "lower": [ 161 ], "postprandial": [ 162 ], "blood": [ 163 ], "glucose": [ 164 ], "levels.": [ 165 ], "They": [ 166, 175, 192 ], "suppress": [ 168 ], "slow": [ 172 ], "gastric": [ 173 ], "motility.": [ 174 ], "positive": [ 178, 287 ], "effects": [ 179 ], "on": [ 180, 289 ], "function": [ 182 ], "they": [ 184 ], "gave": [ 185 ], "significant": [ 187 ], "body": [ 190, 290 ], "weight.": [ 191, 291 ], "are": [ 193 ], "not": [ 194 ], "associated": [ 195 ], "hypoglycemia,": [ 197 ], "but": [ 198 ], "cause": [ 199 ], "relatively": [ 201 ], "high": [ 202 ], "frequency": [ 203 ], "disturbances,": [ 206 ], "some": [ 208 ], "patients": [ 209, 265 ], "experiencing": [ 210 ], "one": [ 211 ], "or": [ 212, 218 ], "more": [ 213 ], "episodes": [ 214 ], "nausea,": [ 216 ], "vomiting,": [ 217 ], "diarrhea.": [ 219 ], "However,": [ 220 ], "after": [ 221 ], "an": [ 222, 238 ], "evaluation": [ 223 ], "advantages": [ 226 ], "disadvantages,": [ 229 ], "we": [ 230 ], "that,": [ 232 ], "once": [ 233 ], "metformin": [ 234, 269 ], "fails": [ 235 ], "reach": [ 237 ], "adequate": [ 239 ], "can": [ 245 ], "valid": [ 248 ], "alternative,": [ 249 ], "especially": [ 250 ], "obese": [ 252 ], "type": [ 253 ], "2": [ 254 ], "diabetic": [ 255 ], "patients.": [ 256 ], "should": [ 260 ], "considered": [ 262 ], "therapy": [ 267 ], "another": [ 271 ], "agent,": [ 272 ], "such": [ 273 ], "as": [ 274 ], "sulfonylurea,": [ 276 ], "because": [ 277 ], "minor": [ 280 ], "risk": [ 281 ], "developing": [ 283 ], "hypoglycemia": [ 284 ], "effect": [ 288 ] }, "publication_date": "2012-06-01", "publication_year": 2012, "type": "review", "cited_by_count": 59, "authors": [ { "id": "https://openalex.org/A5021841408", "display_name": "Giuseppe Derosa" }, { "id": "https://openalex.org/A5011551760", "display_name": "Pamela Maffioli" } ] }, { "id": "https://openalex.org/W2028637607", "doi": "https://doi.org/10.1038/ijo.2013.162", "title": "Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults", "abstract": null, "publication_date": "2013-09-03", "publication_year": 2013, "type": "article", "cited_by_count": 487, "authors": [ { "id": "https://openalex.org/A5112788441", "display_name": "J van Can" }, { "id": "https://openalex.org/A5078986821", "display_name": "Birgitte Sloth" }, { "id": "https://openalex.org/A5045125689", "display_name": "Camilla Bj\u00f8rn Jensen" }, { "id": "https://openalex.org/A5019076349", "display_name": "Anne Flint" }, { "id": "https://openalex.org/A5081222354", "display_name": "Ellen E. Blaak" }, { "id": "https://openalex.org/A5063705490", "display_name": "Wim H. M. Saris" } ] }, { "id": "https://openalex.org/W2070710390", "doi": "https://doi.org/10.1185/030079908x253870", "title": "Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years", "abstract": { "Adjunctive": [ 0 ], "exenatide": [ 1 ], "treatment": [ 2 ], "for": [ 3 ], ">": [ 4 ], "or": [ 5 ], "=": [ 6 ], "3": [ 7 ], "years": [ 8 ], "in": [ 9, 13, 16 ], "T2DM": [ 10 ], "patients": [ 11 ], "resulted": [ 12 ], "sustained": [ 14 ], "improvements": [ 15 ], "glycemic": [ 17 ], "control,": [ 18 ], "cardiovascular": [ 19 ], "risk": [ 20 ], "factors,": [ 21 ], "and": [ 22 ], "hepatic": [ 23 ], "biomarkers,": [ 24 ], "coupled": [ 25 ], "with": [ 26 ], "progressive": [ 27 ], "weight": [ 28 ], "reduction.": [ 29 ] }, "publication_date": "2007-12-03", "publication_year": 2007, "type": "article", "cited_by_count": 696, "authors": [ { "id": "https://openalex.org/A5086077960", "display_name": "David C. Klonoff" }, { "id": "https://openalex.org/A5040182038", "display_name": "John B. Buse" }, { "id": "https://openalex.org/A5075068030", "display_name": "Loretta L. Nielsen" }, { "id": "https://openalex.org/A5103833180", "display_name": "Xuesong Guan" }, { "id": "https://openalex.org/A5029813521", "display_name": "Christopher L. Bowlus" }, { "id": "https://openalex.org/A5111741705", "display_name": "John H. Holcombe" }, { "id": "https://openalex.org/A5087662137", "display_name": "Matthew Wintle" }, { "id": "https://openalex.org/A5062921481", "display_name": "David Maggs" } ] }, { "id": "https://openalex.org/W3005696213", "doi": "https://doi.org/10.1126/scitranslmed.aaw9996", "title": "GLP-1 receptor agonists synergize with DYRK1A inhibitors to potentiate functional human \u03b2 cell regeneration", "abstract": { "GLP-1": [ 0 ], "receptor": [ 1 ], "agonists,": [ 2 ], "widely": [ 3 ], "used": [ 4 ], "to": [ 5, 10 ], "treat": [ 6 ], "diabetes,": [ 7 ], "are": [ 8 ], "converted": [ 9 ], "human": [ 11 ], "\u03b2": [ 12 ], "cell": [ 13 ], "regenerative": [ 14 ], "drugs": [ 15 ], "by": [ 16 ], "adding": [ 17 ], "a": [ 18 ], "DYRK1A": [ 19 ], "inhibitor.": [ 20 ] }, "publication_date": "2020-02-12", "publication_year": 2020, "type": "article", "cited_by_count": 114, "authors": [ { "id": "https://openalex.org/A5031643134", "display_name": "Courtney Ackeifi" }, { "id": "https://openalex.org/A5100718709", "display_name": "Peng Wang" }, { "id": "https://openalex.org/A5029845343", "display_name": "Esra Karak\u00f6se" }, { "id": "https://openalex.org/A5087706383", "display_name": "Jocelyn E. Manning Fox" }, { "id": "https://openalex.org/A5082404594", "display_name": "Bryan J. Gonz\u00e1lez" }, { "id": "https://openalex.org/A5100444850", "display_name": "Hongtao Liu" }, { "id": "https://openalex.org/A5032953014", "display_name": "Jessica Wilson" }, { "id": "https://openalex.org/A5041928463", "display_name": "Ethan Swartz" }, { "id": "https://openalex.org/A5032992689", "display_name": "Cecilia Berrouet" }, { "id": "https://openalex.org/A5043276636", "display_name": "Yansui Li" }, { "id": "https://openalex.org/A5058318565", "display_name": "Kunal Kumar" }, { "id": "https://openalex.org/A5015722444", "display_name": "Patrick E. MacDonald" }, { "id": "https://openalex.org/A5101531243", "display_name": "Roberto S\u00e1nchez" }, { "id": "https://openalex.org/A5079729308", "display_name": "Bernard Thorens" }, { "id": "https://openalex.org/A5008459770", "display_name": "Robert J. DeVita" }, { "id": "https://openalex.org/A5001602213", "display_name": "Dirk Homann" }, { "id": "https://openalex.org/A5086997649", "display_name": "Dieter Egli" }, { "id": "https://openalex.org/A5074154164", "display_name": "Donald K. Scott" }, { "id": "https://openalex.org/A5006140692", "display_name": "Adolfo Garc\u00eda\u2010Oca\u00f1a" }, { "id": "https://openalex.org/A5047201441", "display_name": "Andrew F. Stewart" } ] }, { "id": "https://openalex.org/W4387008365", "doi": "https://doi.org/10.1016/j.ahj.2023.09.007", "title": "Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS\u2010CVOT design and baseline characteristics", "abstract": { "SURPASS-CVOT": [ 0 ], "will": [ 1 ], "provide": [ 2 ], "definitive": [ 3 ], "evidence": [ 4 ], "as": [ 5, 14 ], "to": [ 6 ], "the": [ 7 ], "CV": [ 8, 24 ], "safety": [ 9 ], "and": [ 10 ], "efficacy": [ 11 ], "of": [ 12 ], "tirzepatide": [ 13 ], "compared": [ 15 ], "with": [ 16, 22 ], "dulaglutide,": [ 17 ], "a": [ 18 ], "GLP-1": [ 19 ], "receptor": [ 20 ], "agonist": [ 21 ], "established": [ 23 ], "benefit.": [ 25 ] }, "publication_date": "2023-09-25", "publication_year": 2023, "type": "article", "cited_by_count": 161, "authors": [ { "id": "https://openalex.org/A5055849986", "display_name": "Stephen J. Nicholls" }, { "id": "https://openalex.org/A5010571732", "display_name": "Deepak L. Bhatt" }, { "id": "https://openalex.org/A5040182038", "display_name": "John B. Buse" }, { "id": "https://openalex.org/A5019711625", "display_name": "Stefano Del Prato" }, { "id": "https://openalex.org/A5066700951", "display_name": "Steven E. Kahn" }, { "id": "https://openalex.org/A5001994412", "display_name": "A. Michael Lincoff" }, { "id": "https://openalex.org/A5071945904", "display_name": "Darren K. McGuire" }, { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5040589473", "display_name": "Steven E. Nissen" }, { "id": "https://openalex.org/A5078498803", "display_name": "Naveed Sattar" }, { "id": "https://openalex.org/A5090437675", "display_name": "Bernard Zinman" }, { "id": "https://openalex.org/A5033053622", "display_name": "Sophia Zoungas" }, { "id": "https://openalex.org/A5056252103", "display_name": "Jan Basile" }, { "id": "https://openalex.org/A5073455739", "display_name": "Amy Bartee" }, { "id": "https://openalex.org/A5004434602", "display_name": "Debra L. Miller" }, { "id": "https://openalex.org/A5065805983", "display_name": "Hiroshi Nishiyama" }, { "id": "https://openalex.org/A5026505577", "display_name": "Imre P\u00e1v\u00f3" }, { "id": "https://openalex.org/A5079645471", "display_name": "Govinda J. Weerakkody" }, { "id": "https://openalex.org/A5021136102", "display_name": "Russell J. Wiese" }, { "id": "https://openalex.org/A5071074041", "display_name": "David A. D\u2019Alessio" } ] }, { "id": "https://openalex.org/W2883897596", "doi": "https://doi.org/10.1111/dom.13479", "title": "Impact on HbA1c and body weight of switching from other GLP\u20101 receptor agonists to semaglutide: A model\u2010based approach", "abstract": { "Aims": [ 0 ], "Semaglutide": [ 1 ], "is": [ 2 ], "a": [ 3, 240 ], "glucagon\u2010like": [ 4 ], "peptide\u20101": [ 5 ], "(GLP\u20101)": [ 6 ], "analogue": [ 7 ], "approved": [ 8 ], "for": [ 9, 65, 162, 169 ], "the": [ 10, 56, 62, 83, 92, 118, 128 ], "treatment": [ 11, 20, 103, 112, 238 ], "of": [ 12, 18, 33, 50, 101, 122, 132 ], "type": [ 13 ], "2": [ 14 ], "diabetes.": [ 15 ], "The": [ 16, 138 ], "impact": [ 17 ], "switching": [ 19, 146, 184, 202, 227 ], "from": [ 21, 52, 147, 158, 165, 189, 205 ], "another": [ 22, 148 ], "GLP\u20101": [ 23 ], "receptor": [ 24 ], "agonist": [ 25 ], "(GLP\u20101RA)": [ 26 ], "to": [ 27, 47, 86, 150, 160, 167, 185, 203, 228 ], "semaglutide": [ 28, 57, 111, 151, 173, 186, 204, 229, 237 ], "was": [ 29, 80, 113, 153 ], "investigated": [ 30 ], "by": [ 31, 82, 235 ], "analyses": [ 32 ], "exposure\u2010response": [ 34 ], "models.": [ 35 ], "Methods": [ 36 ], "HbA1c": [ 37, 163, 180, 216 ], "and": [ 38, 78, 124, 152, 164, 217 ], "body": [ 39, 170, 218 ], "weight": [ 40, 171 ], "time\u2010course": [ 41 ], "models": [ 42, 77 ], "were": [ 43, 70, 181 ], "developed,": [ 44 ], "using": [ 45 ], "up": [ 46 ], "30": [ 48 ], "weeks": [ 49, 100 ], "observations": [ 51 ], "four": [ 53 ], "trials": [ 54 ], "in": [ 55, 95, 179, 212, 215, 223 ], "phase": [ 58 ], "3": [ 59 ], "programme.": [ 60 ], "Given": [ 61 ], "recommended": [ 63 ], "dosing": [ 64 ], "each": [ 66 ], "GLP\u20101RA,": [ 67 ], "pharmacokinetic": [ 68, 76 ], "profiles": [ 69 ], "simulated": [ 71, 102, 110 ], "based": [ 72 ], "on": [ 73 ], "published": [ 74 ], "population": [ 75 ], "exposure": [ 79 ], "adjusted": [ 81 ], "relative": [ 84 ], "potencies": [ 85 ], "ensure": [ 87 ], "that": [ 88, 201 ], "model": [ 89 ], "predictions": [ 90 ], "matched": [ 91 ], "effects": [ 93 ], "observed": [ 94, 182 ], "clinical": [ 96 ], "trials.": [ 97 ], "After": [ 98 ], "26": [ 99 ], "with": [ 104, 155, 172 ], "liraglutide,": [ 105, 206 ], "dulaglutide": [ 106, 133, 194, 207 ], "or": [ 107, 134, 193, 208 ], "exenatide": [ 108, 135, 209 ], "extended\u2010release,": [ 109 ], "initiated": [ 114 ], "1": [ 115, 125 ], "day": [ 116 ], "after": [ 117, 127, 145, 183 ], "last": [ 119, 129 ], "once\u2010daily": [ 120 ], "dose": [ 121 ], "liraglutide": [ 123, 190 ], "week": [ 126 ], "once\u2010weekly": [ 130 ], "doses": [ 131 ], "extended\u2010release.": [ 136 ], "Results": [ 137 ], "potency\u2010adjusted": [ 139 ], "total": [ 140 ], "effective": [ 141 ], "GLP\u20101RA": [ 142, 149 ], "concentration": [ 143 ], "increased": [ 144 ], "associated": [ 154 ], "reductions": [ 156, 214 ], "ranging": [ 157 ], "~0.3%": [ 159 ], "~0.8%\u2010points": [ 161 ], "~2%": [ 166 ], "~4%": [ 168 ], "1.0": [ 174 ], "mg.": [ 175, 196 ], "Temporary": [ 176 ], "slight": [ 177, 221 ], "deteriorations": [ 178 ], "0.25": [ 187, 230 ], "mg": [ 188, 192, 231 ], "1.2/1.8": [ 191 ], "1.5": [ 195 ], "Conclusions": [ 197 ], "Exposure\u2010response": [ 198 ], "modelling": [ 199 ], "suggests": [ 200 ], "extended\u2010release": [ 210 ], "results": [ 211 ], "further": [ 213 ], "weight.": [ 219 ], "Initial": [ 220 ], "deterioration": [ 222 ], "outcome": [ 224 ], "values": [ 225 ], "when": [ 226 ], "could": [ 232 ], "be": [ 233 ], "avoided": [ 234 ], "initiating": [ 236 ], "at": [ 239 ], "higher": [ 241 ], "dose.": [ 242 ] }, "publication_date": "2018-07-26", "publication_year": 2018, "type": "article", "cited_by_count": 30, "authors": [ { "id": "https://openalex.org/A5026540782", "display_name": "Rune Viig Overgaard" }, { "id": "https://openalex.org/A5016152313", "display_name": "S\u00f8ren Lindberg" }, { "id": "https://openalex.org/A5039484944", "display_name": "Desir\u00e9e Thielke" } ] }, { "id": "https://openalex.org/W2050826565", "doi": "https://doi.org/10.7326/0003-4819-146-7-200704030-00003", "title": "The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes", "abstract": { "Exenatide": [ 0 ], "therapy": [ 1 ], "improved": [ 2 ], "glycemic": [ 3 ], "control,": [ 4 ], "reduced": [ 5 ], "body": [ 6 ], "weight,": [ 7 ], "and": [ 8 ], "caused": [ 9 ], "gastrointestinal": [ 10 ], "symptoms": [ 11 ], "more": [ 12, 33 ], "than": [ 13 ], "placebo": [ 14 ], "in": [ 15 ], "patients": [ 16 ], "with": [ 17, 25 ], "type": [ 18 ], "2": [ 19 ], "diabetes": [ 20 ], "that": [ 21 ], "was": [ 22 ], "suboptimally": [ 23 ], "controlled": [ 24 ], "TZD": [ 26 ], "therapy.": [ 27 ], "ClinicalTrials.gov": [ 28 ], "registration": [ 29 ], "number:": [ 30 ], "NCT00099320.": [ 31 ], "For": [ 32 ], "information": [ 34 ], "on": [ 35 ], "exenatide": [ 36 ], "click": [ 37 ], "here.": [ 38 ] }, "publication_date": "2007-04-03", "publication_year": 2007, "type": "article", "cited_by_count": 428, "authors": [ { "id": "https://openalex.org/A5090437675", "display_name": "Bernard Zinman" }, { "id": "https://openalex.org/A5058778822", "display_name": "Byron J. Hoogwerf" }, { "id": "https://openalex.org/A5109963796", "display_name": "Santiago Dur\u00e1n Garc\u00eda" }, { "id": "https://openalex.org/A5111928597", "display_name": "Den\u00e1i R. Milton" }, { "id": "https://openalex.org/A5091856313", "display_name": "Joseph M. Giaconia" }, { "id": "https://openalex.org/A5084708084", "display_name": "Dennis Dong Hwan Kim" }, { "id": "https://openalex.org/A5062021087", "display_name": "Michael Trautmann" }, { "id": "https://openalex.org/A5109961740", "display_name": "Robert G. Brodows" } ] }, { "id": "https://openalex.org/W2041468536", "doi": "https://doi.org/10.1371/journal.pone.0050117", "title": "Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists", "abstract": { "Glucagon-like": [ 0 ], "peptide-1": [ 1 ], "receptor": [ 2 ], "agonists": [ 3 ], "(GLP-1": [ 4 ], "RA)": [ 5 ], "are": [ 6, 239 ], "effective": [ 7 ], "for": [ 8 ], "obese": [ 9 ], "patients": [ 10, 35, 55 ], "with": [ 11, 36, 56, 67, 103, 124, 168, 202, 217, 233 ], "type": [ 12 ], "2": [ 13 ], "diabetes": [ 14 ], "mellitus": [ 15 ], "(T2DM)": [ 16 ], "because": [ 17 ], "they": [ 18 ], "concomitantly": [ 19 ], "target": [ 20 ], "obesity": [ 21 ], "and": [ 22, 59, 75, 80, 85, 111, 119, 126, 154, 156, 187 ], "dysglycaemia.": [ 23 ], "Considering": [ 24 ], "the": [ 25, 40, 61 ], "high": [ 26 ], "prevalence": [ 27 ], "of": [ 28, 42, 77, 106, 113, 172, 182, 246 ], "non-alcoholic": [ 29 ], "fatty": [ 30 ], "liver": [ 31, 147, 251 ], "disease": [ 32 ], "(NAFLD)": [ 33 ], "in": [ 34, 52, 65, 69, 192, 199, 204, 219, 231 ], "T2DM,": [ 37 ], "we": [ 38 ], "determined": [ 39 ], "impact": [ 41 ], "6": [ 43, 131 ], "months'": [ 44 ], "GLP-1": [ 45, 133, 247 ], "RA": [ 46, 134, 248 ], "therapy": [ 47 ], "on": [ 48, 249 ], "intrahepatic": [ 49 ], "lipid": [ 50, 252 ], "(IHL)": [ 51 ], "obese,": [ 53 ], "T2DM": [ 54 ], "hepatic": [ 57 ], "steatosis,": [ 58 ], "evaluated": [ 60 ], "inter-relationship": [ 62 ], "between": [ 63 ], "changes": [ 64 ], "IHL": [ 66, 105, 143, 193, 200, 228 ], "those": [ 68 ], "glycosylated": [ 70 ], "haemoglobin": [ 71 ], "(HbA(1)c),": [ 72 ], "body": [ 73, 160, 221 ], "weight,": [ 74, 222 ], "volume": [ 76 ], "abdominal": [ 78 ], "visceral": [ 79 ], "subcutaneous": [ 81 ], "adipose": [ 82 ], "tissue": [ 83 ], "(VAT": [ 84 ], "SAT).": [ 86 ], "We": [ 87 ], "prospectively": [ 88 ], "studied": [ 89 ], "25": [ 90 ], "(12": [ 91 ], "male)": [ 92 ], "patients,": [ 93 ], "age": [ 94 ], "50\u00b110": [ 95 ], "years,": [ 96 ], "BMI": [ 97 ], "38.4\u00b15.6": [ 98 ], "kg/m(2)": [ 99 ], "(mean": [ 100 ], "\u00b1": [ 101 ], "SD)": [ 102 ], "baseline": [ 104 ], "28.2%": [ 107 ], "(16.5": [ 108 ], "to": [ 109, 116, 241 ], "43.1%)": [ 110 ], "HbA(1)c": [ 112, 205 ], "9.6%": [ 114 ], "(7.9": [ 115 ], "10.7%)": [ 117 ], "(median": [ 118 ], "interquartile": [ 120 ], "range).": [ 121 ], "Patients": [ 122 ], "treated": [ 123 ], "metformin": [ 125 ], "sulphonylureas/DPP-IV": [ 127 ], "inhibitors": [ 128 ], "were": [ 129 ], "given": [ 130 ], "months": [ 132 ], "(exenatide,": [ 135 ], "n": [ 136, 140 ], "=": [ 137, 141, 207, 210 ], "19;": [ 138 ], "liraglutide,": [ 139 ], "6).": [ 142 ], "was": [ 144, 166, 213 ], "quantified": [ 145 ], "by": [ 146, 158 ], "proton": [ 148 ], "magnetic": [ 149, 161 ], "resonance": [ 150, 162 ], "spectroscopy": [ 151 ], "((1)H": [ 152 ], "MRS)": [ 153 ], "VAT": [ 155, 223 ], "SAT": [ 157 ], "whole": [ 159 ], "imaging": [ 163 ], "(MRI).": [ 164 ], "Treatment": [ 165 ], "associated": [ 167 ], "mean": [ 169, 179 ], "weight": [ 170 ], "loss": [ 171 ], "5.0": [ 173 ], "kg": [ 174 ], "(95%": [ 175 ], "CI": [ 176 ], "3.5,6.5": [ 177 ], "kg),": [ 178 ], "HbA(1c)": [ 180 ], "reduction": [ 181, 191, 198, 229 ], "1\u00b76%": [ 183 ], "(17": [ 184 ], "mmol/mol)": [ 185 ], "(0\u00b78,2\u00b74%)": [ 186 ], "a": [ 188 ], "42%": [ 189 ], "relative": [ 190, 197 ], "(-59.3,": [ 194 ], "-16.5%).": [ 195 ], "The": [ 196, 226 ], "correlated": [ 201, 216 ], "that": [ 203, 218 ], "(\u03c1": [ 206 ], "0.49;": [ 208 ], "p": [ 209 ], "0.01)": [ 211 ], "but": [ 212 ], "not": [ 214 ], "significantly": [ 215 ], "total": [ 220 ], "or": [ 224 ], "SAT.": [ 225 ], "greatest": [ 227 ], "occurred": [ 230 ], "individuals": [ 232 ], "highest": [ 234 ], "pre-treatment": [ 235 ], "levels.": [ 236 ], "Mechanistic": [ 237 ], "studies": [ 238 ], "needed": [ 240 ], "determine": [ 242 ], "potential": [ 243 ], "direct": [ 244 ], "effects": [ 245 ], "human": [ 250 ], "metabolism.": [ 253 ] }, "publication_date": "2012-12-06", "publication_year": 2012, "type": "article", "cited_by_count": 219, "authors": [ { "id": "https://openalex.org/A5076265710", "display_name": "Daniel J. Cuthbertson" }, { "id": "https://openalex.org/A5037640971", "display_name": "Andrew J. Irwin" }, { "id": "https://openalex.org/A5110205301", "display_name": "Chris J. Gardner" }, { "id": "https://openalex.org/A5065750682", "display_name": "Christina Daousi" }, { "id": "https://openalex.org/A5025806334", "display_name": "Tej Purewal" }, { "id": "https://openalex.org/A5109901924", "display_name": "Niall Furlong" }, { "id": "https://openalex.org/A5109075606", "display_name": "Niru Goenka" }, { "id": "https://openalex.org/A5067497811", "display_name": "E. Louise Thomas" }, { "id": "https://openalex.org/A5008640508", "display_name": "Valerie L. Adams" }, { "id": "https://openalex.org/A5013788703", "display_name": "Sudeep Pushpakom" }, { "id": "https://openalex.org/A5006847944", "display_name": "Munir Pirmohamed" }, { "id": "https://openalex.org/A5082908640", "display_name": "Graham J. Kemp" } ] }, { "id": "https://openalex.org/W1973442218", "doi": "https://doi.org/10.1111/dom.12085", "title": "Blood pressure\u2010lowering effects of GLP \u20101 receptor agonists exenatide and liraglutide: a meta\u2010analysis of clinical trials", "abstract": { "Aims": [ 0 ], "Aside": [ 1 ], "from": [ 2, 75 ], "lowering": [ 3 ], "blood": [ 4, 32, 69, 173, 225 ], "glucose,": [ 5 ], "glucagon\u2010like": [ 6 ], "peptide\u20101": [ 7 ], "receptor": [ 8 ], "agonists": [ 9 ], "(": [ 10, 54, 62, 71, 175, 201, 227 ], "GLP": [ 11, 37, 149, 167, 378, 409 ], "\u20101": [ 12, 38, 150, 168, 379, 410 ], "RAs": [ 13, 39, 380, 411 ], ")": [ 14, 56, 64, 73, 177, 203, 229 ], "attract": [ 15 ], "much": [ 16 ], "attention": [ 17 ], "because": [ 18 ], "of": [ 19, 25, 35, 100, 106, 129, 140, 189, 204, 240, 259, 308, 317, 349, 359 ], "their": [ 20 ], "cardioprotective": [ 21 ], "effects.": [ 22 ], "The": [ 23, 115, 166 ], "aim": [ 24 ], "this": [ 26, 164, 274 ], "study": [ 27, 131 ], "was": [ 28, 230 ], "to": [ 29, 49, 104, 111, 206, 213, 242, 261, 319, 326, 361, 368, 390 ], "assess": [ 30 ], "the": [ 31, 36, 80, 98, 124, 127, 130, 148, 158, 221, 249, 268, 279, 291, 333, 377 ], "pressure\u2010lowering": [ 33 ], "effects": [ 34, 99 ], "exenatide": [ 40, 101, 170, 381 ], "and": [ 41, 96, 102, 126, 154, 183, 191, 196, 211, 252, 302, 310, 314, 324, 343, 351, 355, 366, 382, 386, 402, 420 ], "liraglutide": [ 42, 103, 287, 295, 336, 383 ], "compared": [ 43, 97, 179, 247, 266, 299, 340, 393 ], "with": [ 44, 94, 180, 186, 197, 236, 248, 255, 267, 282, 300, 305, 341, 346, 376, 394, 406 ], "other": [ 45, 107, 396 ], "common": [ 46, 108 ], "drugs": [ 47, 109, 398 ], "used": [ 48, 110 ], "treat": [ 50, 112 ], "type": [ 51 ], "2": [ 52 ], "diabetes": [ 53 ], "T2DM": [ 55, 95, 113, 407 ], "based": [ 57 ], "on": [ 58 ], "randomized": [ 59 ], "controlled": [ 60 ], "trials": [ 61 ], "RCTs": [ 63, 87, 116, 142 ], "including": [ 65, 399 ], "data": [ 66, 119 ], "describing": [ 67, 120 ], "complete": [ 68 ], "pressure": [ 70, 174, 226 ], "BP": [ 72, 121 ], "changes": [ 74, 122, 272 ], "baseline.": [ 76 ], "Methods": [ 77 ], "We": [ 78 ], "searched": [ 79 ], "major": [ 81 ], "databases": [ 82 ], "for": [ 83, 134, 404, 417 ], "published": [ 84 ], "or": [ 85, 284 ], "unpublished": [ 86 ], "that": [ 88, 117, 143 ], "had": [ 89 ], "been": [ 90 ], "performed": [ 91 ], "in": [ 92, 147, 157, 163, 220, 273, 278 ], "patients": [ 93, 146, 405, 419 ], "those": [ 105 ], ".": [ 114, 408 ], "included": [ 118, 162 ], "between": [ 123 ], "baseline": [ 125 ], "end": [ 128 ], "were": [ 132, 161, 276 ], "selected": [ 133 ], "further": [ 135 ], "analysis.": [ 136 ], "Results": [ 137 ], "A": [ 138 ], "total": [ 139 ], "16": [ 141 ], "enrolled": [ 144 ], "3443": [ 145 ], "RA": [ 151, 169 ], "treatment": [ 152, 296, 345 ], "group": [ 153, 160 ], "2417": [ 155 ], "subjects": [ 156 ], "control": [ 159 ], "meta\u2010analysis.": [ 165 ], "reduced": [ 171, 231, 297, 338, 384 ], "systolic": [ 172 ], "SBP": [ 176, 271, 298, 339, 385 ], "when": [ 178 ], "both": [ 181 ], "placebo": [ 182, 250, 301, 342, 403 ], "insulin": [ 184 ], "glargine,": [ 185 ], "mean": [ 187, 306, 347 ], "differences": [ 188, 307, 348 ], "\u22125.24": [ 190 ], "\u22123.46": [ 192 ], "mmHg": [ 193, 234, 254, 312, 353, 392 ], ",": [ 194, 235, 313, 354 ], "respectively,": [ 195 ], "95%": [ 198, 238, 257, 315, 357 ], "confidence": [ 199 ], "intervals": [ 200 ], "CI": [ 202, 239, 258, 358 ], "\u22126.88": [ 205 ], "\u22123.59,": [ 207 ], "p": [ 208, 215, 244, 263, 321, 328, 363, 370 ], "<": [ 209, 216, 245, 264, 322, 364, 371 ], "0.00001": [ 210, 246, 265, 323 ], "\u22123.63": [ 212 ], "\u22123.29,": [ 214 ], "0.00001,": [ 217, 365, 372 ], "respectively.": [ 218, 331, 373 ], "Meanwhile,": [ 219 ], "exenatide\u2010treated": [ 222 ], "group,": [ 223, 251, 294, 335 ], "diastolic": [ 224 ], "DBP": [ 228, 387 ], "by": [ 232, 388 ], "\u22125.91": [ 233 ], "a": [ 237, 256, 356 ], "\u22127.53": [ 241 ], "\u22124.28,": [ 243 ], "\u22120.99": [ 253 ], "\u22121.12": [ 260 ], "\u22120.87,": [ 262 ], "sitagliptin": [ 269 ], "group.": [ 270 ], "meta\u2010analysis": [ 275 ], "assessed": [ 277 ], "groups": [ 280 ], "treated": [ 281 ], "1.2": [ 283, 292 ], "1.8": [ 285 ], "mg": [ 286 ], "per": [ 288 ], "day.": [ 289 ], "In": [ 290, 332 ], "mg\u2010treated": [ 293 ], "glimepiride": [ 303, 344, 401 ], "treatment,": [ 304 ], "\u22125.60": [ 309 ], "\u22122.38": [ 311 ], "CIs": [ 316 ], "\u22125.84": [ 318 ], "\u22125.36,": [ 320 ], "\u22124.75": [ 325 ], "\u22120.01,": [ 327 ], "=": [ 329 ], "0.05,": [ 330 ], "1.8\u2010mg\u2010treated": [ 334 ], "also": [ 337 ], "\u22124.49": [ 350 ], "\u22122.62": [ 352 ], "\u22124.73": [ 360 ], "\u22124.26,": [ 362 ], "\u22122.91": [ 367 ], "\u22122.33,": [ 369 ], "Conclusion": [ 374 ], "Treatment": [ 375 ], "1": [ 389 ], "5": [ 391 ], "some": [ 395 ], "anti\u2010diabetic": [ 397 ], "insulin,": [ 400 ], "may": [ 412 ], "offer": [ 413 ], "an": [ 414 ], "alternative": [ 415 ], "therapy": [ 416 ], "these": [ 418 ], "will": [ 421 ], "help": [ 422 ], "provide": [ 423 ], "extra": [ 424 ], "cardiovascular": [ 425 ], "benefits.": [ 426 ] }, "publication_date": "2013-02-22", "publication_year": 2013, "type": "review", "cited_by_count": 215, "authors": [ { "id": "https://openalex.org/A5100372391", "display_name": "Bin Wang" }, { "id": "https://openalex.org/A5077862629", "display_name": "Jixin Zhong" }, { "id": "https://openalex.org/A5002888467", "display_name": "Hui Lin" }, { "id": "https://openalex.org/A5102015631", "display_name": "Zhigang Zhao" }, { "id": "https://openalex.org/A5010985917", "display_name": "Zhencheng Yan" }, { "id": "https://openalex.org/A5075945214", "display_name": "Hongbo He" }, { "id": "https://openalex.org/A5108196965", "display_name": "Yinxing Ni" }, { "id": "https://openalex.org/A5036445049", "display_name": "D. Liu" }, { "id": "https://openalex.org/A5087745821", "display_name": "Zhiming Zhu" } ] }, { "id": "https://openalex.org/W2159859567", "doi": "https://doi.org/10.1210/10.1210/er.2006-0038", "title": "\u03b2-Cell Failure in Diabetes and Preservation by Clinical Treatment", "abstract": { "There": [ 0, 249 ], "is": [ 1, 48, 138, 162, 333, 382, 403, 495, 513 ], "a": [ 2, 31, 132 ], "progressive": [ 3, 57 ], "deterioration": [ 4 ], "in": [ 5, 10, 33, 229, 244, 268, 424, 428, 451, 482, 489, 509 ], "\u03b2-cell": [ 6, 34, 46, 60, 75, 79, 100, 127, 142, 188, 197, 237, 332, 405, 414, 420, 436, 475, 491 ], "function": [ 7, 19, 61, 76 ], "and": [ 8, 30, 62, 70, 77, 173, 176, 199, 297, 310, 362, 376, 394, 411, 427, 432, 471, 478, 505, 511 ], "mass": [ 9, 35, 47, 63, 80, 101 ], "type": [ 11, 122, 159 ], "2": [ 12, 123 ], "diabetics.": [ 13 ], "It": [ 14 ], "was": [ 15, 20, 39 ], "found": [ 16 ], "that": [ 17, 517 ], "islet": [ 18, 71, 201, 409 ], "about": [ 21, 37 ], "50%": [ 22 ], "of": [ 23, 28, 36, 45, 59, 89, 98, 119, 141, 147, 160, 165, 184, 206, 255, 285, 290, 294, 299, 339, 343, 366, 374, 384, 391, 396, 408, 413, 419, 440, 443, 480, 502 ], "normal": [ 24 ], "at": [ 25, 41, 86 ], "the": [ 26, 90, 93, 108, 139, 163, 170, 265, 279, 282, 303, 316, 330, 340, 441, 444, 499 ], "time": [ 27 ], "diagnosis,": [ 29 ], "reduction": [ 32, 44 ], "60%": [ 38 ], "shown": [ 40 ], "necropsy.": [ 42 ], "The": [ 43, 53, 190, 208, 219, 371, 400, 438 ], "attributable": [ 49 ], "to": [ 50, 82, 110, 131, 270, 273, 335, 368, 497 ], "accelerated": [ 51 ], "apoptosis.": [ 52 ], "major": [ 54, 305 ], "factors": [ 55 ], "for": [ 56, 96, 327 ], "loss": [ 58 ], "are": [ 64, 222, 242, 250, 262 ], "glucotoxicity,": [ 65 ], "lipotoxicity,": [ 66 ], "proinflammatory": [ 67 ], "cytokines,": [ 68 ], "leptin,": [ 69 ], "cell": [ 72, 202 ], "amyloid.": [ 73 ], "Impaired": [ 74 ], "possibly": [ 78 ], "appear": [ 81 ], "be": [ 83, 325 ], "reversible,": [ 84 ], "particularly": [ 85 ], "early": [ 87 ], "stages": [ 88 ], "disease": [ 91 ], "where": [ 92 ], "limiting": [ 94 ], "threshold": [ 95 ], "reversibility": [ 97 ], "decreased": [ 99 ], "has": [ 102 ], "probably": [ 103 ], "not": [ 104, 454 ], "been": [ 105 ], "passed.": [ 106 ], "Among": [ 107 ], "interventions": [ 109 ], "preserve": [ 111 ], "or": [ 112, 319, 322 ], "\u201crejuvenate\u201d": [ 113 ], "\u03b2-cells,": [ 114 ], "short-term": [ 115 ], "intensive": [ 116 ], "insulin": [ 117, 193, 217, 276, 386, 392, 397 ], "therapy": [ 118 ], "newly": [ 120 ], "diagnosed": [ 121 ], "diabetes": [ 124, 256, 426 ], "will": [ 125 ], "improve": [ 126, 192 ], "function,": [ 128 ], "usually": [ 129 ], "leading": [ 130 ], "temporary": [ 133 ], "remission": [ 134 ], "time.": [ 135, 248 ], "Another": [ 136 ], "intervention": [ 137, 161 ], "induction": [ 140, 407 ], "\u201crest\u201d": [ 143 ], "by": [ 144, 215, 345, 364, 389, 456, 460 ], "selective": [ 145 ], "activation": [ 146, 228 ], "ATP-sensitive": [ 148 ], "K+": [ 149 ], "(KATP)": [ 150 ], "channels,": [ 151 ], "using": [ 152 ], "drugs": [ 153, 519 ], "such": [ 154, 168 ], "as": [ 155, 169, 422 ], "diazoxide.": [ 156 ], "A": [ 157 ], "third": [ 158 ], "use": [ 164 ], "antiapoptotic": [ 166 ], "drugs,": [ 167 ], "thiazolidinediones": [ 171 ], "(TZDs),": [ 172 ], "incretin": [ 174, 350, 503 ], "mimetics": [ 175, 321, 504 ], "enhancers,": [ 177 ], "which": [ 178, 261 ], "have": [ 179, 210, 521 ], "demonstrated": [ 180 ], "significant": [ 181 ], "clinical": [ 182, 515 ], "evidence": [ 183, 516 ], "effects": [ 185, 212, 221, 241, 501, 523 ], "on": [ 186, 213, 253, 380, 507, 524 ], "human": [ 187 ], "function.": [ 189, 238, 437, 492 ], "TZDs": [ 191, 209, 233 ], "secretory": [ 194 ], "capacity,": [ 195 ], "decrease": [ 196 ], "apoptosis,": [ 198, 415 ], "reduce": [ 200 ], "amyloid": [ 203 ], "with": [ 204, 232, 247, 257 ], "maintenance": [ 205, 284 ], "neogenesis.": [ 207 ], "indirect": [ 211 ], "\u03b2-cells": [ 214, 381, 508 ], "being": [ 216 ], "sensitizers.": [ 218 ], "direct": [ 220 ], "via": [ 223 ], "peroxisome": [ 224 ], "proliferator-activated": [ 225 ], "receptor": [ 226, 355, 378 ], "\u03b3": [ 227 ], "pancreatic": [ 230 ], "islets,": [ 231 ], "consistently": [ 234 ], "improving": [ 235 ], "basal": [ 236 ], "These": [ 239 ], "beneficial": [ 240 ], "sustained": [ 243 ], "some": [ 245 ], "individuals": [ 246 ], "several": [ 251, 349 ], "trials": [ 252 ], "prevention": [ 254 ], "TZDs.": [ 258 ], "Incretin": [ 259 ], "hormones,": [ 260 ], "released": [ 263 ], "from": [ 264, 278 ], "gastrointestinal": [ 266 ], "tract": [ 267 ], "response": [ 269 ], "nutrient": [ 271 ], "ingestion": [ 272 ], "enhance": [ 274 ], "glucose-dependent": [ 275, 311, 385 ], "secretion": [ 277 ], "pancreas,": [ 280 ], "aid": [ 281 ], "overall": [ 283 ], "glucose": [ 286 ], "homeostasis": [ 287 ], "through": [ 288 ], "slowing": [ 289 ], "gastric": [ 291 ], "emptying,": [ 292 ], "inhibition": [ 293, 412, 439, 479 ], "glucagon": [ 295 ], "secretion,": [ 296 ], "control": [ 298 ], "body": [ 300 ], "weight.": [ 301 ], "From": [ 302 ], "two": [ 304 ], "incretins,": [ 306 ], "glucagon-like": [ 307 ], "peptide-1": [ 308 ], "(GLP-1)": [ 309 ], "insulinotropic": [ 312 ], "polypeptide": [ 313 ], "(GIP),": [ 314 ], "only": [ 315, 455 ], "first": [ 317 ], "one": [ 318 ], "its": [ 320 ], "enhancers": [ 323, 506 ], "can": [ 324 ], "used": [ 326 ], "treatment": [ 328 ], "because": [ 329 ], "diabetic": [ 331 ], "resistant": [ 334 ], "GIP": [ 336 ], "action.": [ 337 ], "Because": [ 338 ], "rapid": [ 341 ], "inactivation": [ 342 ], "GLP-1": [ 344, 354, 367, 375, 377, 449, 457 ], "dipeptidyl": [ 346 ], "peptidase": [ 347 ], "(DPP)-IV,": [ 348 ], "analogs": [ 351 ], "were": [ 352 ], "developed:": [ 353 ], "agonists": [ 356, 379 ], "(incretin": [ 357 ], "mimetics)": [ 358 ], "exenatide": [ 359 ], "(synthetic": [ 360 ], "exendin-4)": [ 361 ], "liraglutide,": [ 363 ], "conjugation": [ 365 ], "circulating": [ 369 ], "albumin.": [ 370 ], "acute": [ 372 ], "effect": [ 373 ], "stimulation": [ 383, 395 ], "release,": [ 387 ], "followed": [ 388 ], "enhancement": [ 390 ], "biosynthesis": [ 393 ], "gene": [ 398 ], "transcription.": [ 399 ], "chronic": [ 401 ], "action": [ 402, 450 ], "stimulating": [ 404 ], "proliferation,": [ 406, 476 ], "neogenesis,": [ 410, 477 ], "thus": [ 416 ], "promoting": [ 417 ], "expansion": [ 418 ], "mass,": [ 421 ], "observed": [ 423 ], "rodent": [ 425 ], "cultured": [ 429 ], "\u03b2-cells.": [ 430, 525 ], "Exenatide": [ 431 ], "liraglutide": [ 433 ], "enhanced": [ 434 ], "postprandial": [ 435, 490 ], "activity": [ 442 ], "DPP-IV": [ 445, 468 ], "enzyme": [ 446 ], "enhances": [ 447 ], "endogenous": [ 448 ], "vivo,": [ 452 ], "mediated": [ 453 ], "but": [ 458 ], "also": [ 459, 473 ], "other": [ 461 ], "mediators.": [ 462 ], "In": [ 463 ], "preclinical": [ 464 ], "studies,": [ 465 ], "oral": [ 466 ], "active": [ 467 ], "inhibitors": [ 469 ], "(sitagliptin": [ 470 ], "vildagliptin)": [ 472 ], "promoted": [ 474 ], "apoptosis": [ 481 ], "rodents.": [ 483 ], "Meal": [ 484 ], "tolerance": [ 485 ], "tests": [ 486 ], "showed": [ 487 ], "improvement": [ 488 ], "Obviously,": [ 493 ], "it": [ 494 ], "difficult": [ 496 ], "estimate": [ 498 ], "protective": [ 500, 522 ], "humans,": [ 510 ], "there": [ 512 ], "no": [ 514 ], "these": [ 518 ], "really": [ 520 ] }, "publication_date": "2007-03-12", "publication_year": 2007, "type": "review", "cited_by_count": 701, "authors": [ { "id": "https://openalex.org/A5079582404", "display_name": "B L Wajchenberg" } ] }, { "id": "https://openalex.org/W4294805044", "doi": "https://doi.org/10.1172/jci.insight.159863", "title": "Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial", "abstract": { "BackgroundAlcohol": [ 0 ], "use": [ 1 ], "disorder": [ 2, 9 ], "(AUD)": [ 3 ], "is": [ 4, 19, 52 ], "a": [ 5, 54, 189, 210, 229 ], "chronic,": [ 6 ], "relapsing": [ 7 ], "brain": [ 8, 107, 151 ], "that": [ 10, 118, 177 ], "accounts": [ 11 ], "for": [ 12, 27, 75, 153 ], "5%": [ 13 ], "of": [ 14, 91, 110, 127, 191, 209, 224, 247, 253 ], "deaths": [ 15 ], "annually,": [ 16 ], "and": [ 17, 42, 102, 145, 156, 184, 272, 278, 281 ], "there": [ 18 ], "an": [ 20 ], "urgent": [ 21 ], "need": [ 22 ], "to": [ 23, 65, 80 ], "develop": [ 24 ], "new": [ 25, 218 ], "targets": [ 26 ], "therapeutic": [ 28 ], "intervention.": [ 29 ], "The": [ 30, 84 ], "glucagon-like": [ 31 ], "peptide-1": [ 32 ], "(GLP-1)": [ 33 ], "receptor": [ 34, 212, 226 ], "agonist": [ 35, 213 ], "exenatide": [ 36, 67, 120, 167, 178 ], "reduces": [ 37 ], "alcohol": [ 38, 138, 186 ], "consumption": [ 39 ], "in": [ 40, 48, 78, 89, 141, 165, 188, 214, 233 ], "rodents": [ 41 ], "nonhuman": [ 43 ], "primates,": [ 44 ], "but": [ 45 ], "its": [ 46 ], "efficacy": [ 47 ], "patients": [ 49, 62, 112, 193, 216 ], "with": [ 50, 132, 170 ], "AUD": [ 51, 61, 215 ], "unknown.MethodsIn": [ 53 ], "randomized,": [ 55 ], "double-blinded,": [ 56 ], "placebo-controlled": [ 57 ], "clinical": [ 58 ], "trial,": [ 59 ], "treatment-seeking": [ 60 ], "were": [ 63, 113, 200 ], "assigned": [ 64 ], "receive": [ 66 ], "(2": [ 68 ], "mg": [ 69 ], "subcutaneously)": [ 70 ], "or": [ 71 ], "placebo": [ 72, 172 ], "once": [ 73 ], "weekly": [ 74 ], "26": [ 76 ], "weeks,": [ 77 ], "addition": [ 79 ], "standard": [ 81 ], "cognitive-behavioral": [ 82 ], "therapy.": [ 83 ], "primary": [ 85 ], "outcome": [ 86 ], "was": [ 87, 163 ], "reduction": [ 88 ], "number": [ 90, 126 ], "heavy": [ 92, 128, 181 ], "drinking": [ 93, 129, 182 ], "days.": [ 94 ], "A": [ 95 ], "subgroup": [ 96, 190 ], "also": [ 97 ], "completed": [ 98 ], "functional": [ 99 ], "MRI": [ 100 ], "(fMRI)": [ 101 ], "single-photon": [ 103 ], "emission": [ 104 ], "CT": [ 105 ], "(SPECT)": [ 106 ], "scans.ResultsA": [ 108 ], "total": [ 109, 185 ], "127": [ 111 ], "enrolled.": [ 114 ], "Our": [ 115 ], "data": [ 116 ], "revealed": [ 117, 176 ], "although": [ 119 ], "did": [ 121 ], "not": [ 122 ], "significantly": [ 123, 135, 179 ], "reduce": [ 124 ], "the": [ 125, 142, 166, 171, 207, 222 ], "days": [ 130, 183 ], "compared": [ 131, 169 ], "placebo,": [ 133 ], "it": [ 134 ], "attenuated": [ 136 ], "fMRI": [ 137 ], "cue": [ 139 ], "reactivity": [ 140 ], "ventral": [ 143 ], "striatum": [ 144 ], "septal": [ 146 ], "area,": [ 147 ], "which": [ 148 ], "are": [ 149 ], "crucial": [ 150 ], "areas": [ 152 ], "drug": [ 154 ], "reward": [ 155 ], "addiction.": [ 157 ], "In": [ 158 ], "addition,": [ 159 ], "dopamine": [ 160 ], "transporter": [ 161 ], "availability": [ 162 ], "lower": [ 164 ], "group": [ 168 ], "group.": [ 173 ], "Exploratory": [ 174 ], "analyses": [ 175 ], "reduced": [ 180 ], "intake": [ 187 ], "obese": [ 192 ], "(BMI": [ 194 ], ">": [ 195 ], "30": [ 196 ], "kg/m2).": [ 197 ], "Adverse": [ 198 ], "events": [ 199 ], "mainly": [ 201 ], "gastrointestinal.ConclusionThis": [ 202 ], "randomized": [ 203 ], "controlled": [ 204 ], "trial": [ 205 ], "on": [ 206, 221 ], "effects": [ 208, 223 ], "GLP-1": [ 211, 225 ], "provides": [ 217 ], "important": [ 219 ], "knowledge": [ 220 ], "agonists": [ 227 ], "as": [ 228 ], "novel": [ 230 ], "treatment": [ 231 ], "target": [ 232 ], "addiction.Trial": [ 234 ], "registrationEudraCT:": [ 235 ], "2016-003343-11.": [ 236 ], "ClinicalTrials.gov": [ 237 ], "(NCT03232112).FundingNovavi": [ 238 ], "Foundation;": [ 239, 257, 260, 262, 264, 268, 270, 275, 280 ], "Research": [ 240, 249 ], "Foundation,": [ 241, 250 ], "Mental": [ 242 ], "Health": [ 243 ], "Services,": [ 244 ], "Capital": [ 245, 251 ], "Region": [ 246, 252 ], "Denmark;": [ 248, 254 ], "Ivan": [ 255 ], "Nielsen": [ 256 ], "A.P.": [ 258 ], "Moeller": [ 259 ], "Augustinus": [ 261 ], "Woerzner": [ 263 ], "Grosserer": [ 265 ], "L.F.": [ 266 ], "Foghts": [ 267 ], "Hartmann": [ 269 ], "Aase": [ 271 ], "Ejnar": [ 273 ], "Danielsen": [ 274 ], "P.A.": [ 276 ], "Messerschmidt": [ 277 ], "Wife": [ 279 ], "Lundbeck": [ 282 ], "Foundation.": [ 283 ] }, "publication_date": "2022-09-06", "publication_year": 2022, "type": "article", "cited_by_count": 167, "authors": [ { "id": "https://openalex.org/A5091141863", "display_name": "Mette Kruse Klausen" }, { "id": "https://openalex.org/A5006234017", "display_name": "Mathias E. Jensen" }, { "id": "https://openalex.org/A5030055611", "display_name": "Marco M\u00f8ller" }, { "id": "https://openalex.org/A5042733593", "display_name": "Nina Le Dous" }, { "id": "https://openalex.org/A5101184672", "display_name": "Anne-Marie \u00d8stergaard Jensen" }, { "id": "https://openalex.org/A5097423674", "display_name": "Victoria Alberte Zeeman" }, { "id": "https://openalex.org/A5089727435", "display_name": "Claas-Frederik Johannsen" }, { "id": "https://openalex.org/A5089900411", "display_name": "Alycia Lee" }, { "id": "https://openalex.org/A5112006491", "display_name": "Gerda Thomsen" }, { "id": "https://openalex.org/A5083106393", "display_name": "Julian Macoveanu" }, { "id": "https://openalex.org/A5021085020", "display_name": "Patrick M. Fisher" }, { "id": "https://openalex.org/A5084927745", "display_name": "Matthew P. Gillum" }, { "id": "https://openalex.org/A5069431123", "display_name": "Niklas Rye J\u00f8rgensen" }, { "id": "https://openalex.org/A5088491140", "display_name": "M Bergmann" }, { "id": "https://openalex.org/A5005766981", "display_name": "Henrik E. Poulsen" }, { "id": "https://openalex.org/A5086459548", "display_name": "Ulrik Becker" }, { "id": "https://openalex.org/A5085434984", "display_name": "Jens J. Holst" }, { "id": "https://openalex.org/A5073935438", "display_name": "Helene Benveniste" }, { "id": "https://openalex.org/A5002969658", "display_name": "Nora D. Volkow" }, { "id": "https://openalex.org/A5010414376", "display_name": "Sabine Vollst\u00e4dt\u2010Klein" }, { "id": "https://openalex.org/A5044746918", "display_name": "Kamilla Woznica Miskowiak" }, { "id": "https://openalex.org/A5065962810", "display_name": "Claus Thorn Ekstr\u00f8m" }, { "id": "https://openalex.org/A5015895924", "display_name": "Gitte M. Knudsen" }, { "id": "https://openalex.org/A5004120950", "display_name": "Tina Vilsb\u00f8ll" }, { "id": "https://openalex.org/A5001609083", "display_name": "Anders Fink\u2010Jensen" } ] }, { "id": "https://openalex.org/W2938775788", "doi": "https://doi.org/10.1002/iub.2046", "title": "The GLP\u20101 receptor agonist liraglutide protects against oxidized LDL\u2010induced endothelial inflammation and dysfunction via KLF2", "abstract": { "Abstract": [ 0 ], "Cardiovascular": [ 1 ], "complications": [ 2 ], "are": [ 3, 39 ], "the": [ 4, 8, 82, 107, 112, 144, 155, 187, 240, 253 ], "major": [ 5 ], "causes": [ 6 ], "of": [ 7, 22, 42, 62, 70, 85, 106, 121, 136, 146, 157, 172, 195, 211, 223, 239, 259 ], "mortality": [ 9 ], "and": [ 10, 31, 134, 178, 200, 206, 230, 251 ], "morbidities": [ 11 ], "in": [ 12, 92, 248, 256, 262 ], "diabetic": [ 13, 16 ], "patients.": [ 14, 264 ], "The": [ 15 ], "patients": [ 17 ], "have": [ 18, 54, 58 ], "an": [ 19 ], "increased": [ 20 ], "risk": [ 21 ], "developing": [ 23 ], "atherosclerosis,": [ 24 ], "which": [ 25 ], "could": [ 26 ], "lead": [ 27 ], "to": [ 28, 46, 57, 214 ], "heart": [ 29 ], "attack": [ 30 ], "stroke.": [ 32 ], "Glucagon\u2010like": [ 33 ], "peptide": [ 34 ], "1": [ 35 ], "(GLP\u20101)": [ 36 ], "receptor": [ 37, 52, 75 ], "agonists": [ 38, 53 ], "a": [ 40, 245 ], "class": [ 41 ], "potent": [ 43 ], "anti\u2010glycemic": [ 44 ], "agents": [ 45 ], "treat": [ 47 ], "diabetes.": [ 48 ], "Recently,": [ 49 ], "several": [ 50 ], "GLP\u20101": [ 51, 74 ], "been": [ 55 ], "found": [ 56 ], "cardiovascular": [ 59 ], "benefit": [ 60 ], "independent": [ 61 ], "their": [ 63 ], "glucose": [ 64 ], "lowing": [ 65 ], "ability.": [ 66 ], "Liraglutide": [ 67, 86, 100, 115, 147, 158, 166, 190, 218, 243 ], "is": [ 68, 162, 244 ], "one": [ 69 ], "clinically": [ 71 ], "approved": [ 72 ], "effective": [ 73 ], "agonists.": [ 76 ], "In": [ 77, 111 ], "this": [ 78 ], "study,": [ 79 ], "we": [ 80 ], "explored": [ 81 ], "molecular": [ 83 ], "mechanism": [ 84 ], "against": [ 87 ], "oxidized": [ 88 ], "low\u2010density": [ 89 ], "lipoprotein": [ 90 ], "(ox\u2010LDL)": [ 91 ], "cultured": [ 93 ], "endothelial": [ 94, 160, 173, 182, 215, 224, 249 ], "cells.": [ 95, 216 ], "Our": [ 96 ], "data": [ 97 ], "show": [ 98 ], "that": [ 99, 154, 242 ], "treatment": [ 101 ], "ameliorates": [ 102, 179 ], "ox\u2010LDL": [ 103, 118, 169, 180, 192, 208, 220 ], "caused": [ 104, 170 ], "reduction": [ 105, 120, 171, 222 ], "transcriptional": [ 108 ], "factor": [ 109 ], "KLF2.": [ 110 ], "same": [ 113 ], "experiment,": [ 114 ], "also": [ 116, 167 ], "rescues": [ 117 ], "induced": [ 119, 181, 193, 209 ], "mitogen\u2010activated": [ 122 ], "protein": [ 123, 176 ], "kinase": [ 124, 126, 130 ], "(MAPK)": [ 125 ], "extracellular": [ 127 ], "signal": [ 128 ], "regulated": [ 129 ], "5": [ 131 ], "(ERK5)": [ 132 ], "phosphorylation,": [ 133 ], "blockage": [ 135 ], "ERK5": [ 137 ], "activity": [ 138 ], "by": [ 139 ], "its": [ 140 ], "inhibitor": [ 141 ], "XMD8\u201092": [ 142 ], "abolishes": [ 143 ], "protection": [ 145 ], "on": [ 148, 159, 164 ], "KLF2": [ 149, 161 ], "expression.": [ 150 ], "These": [ 151 ], "facts": [ 152 ], "suggest": [ 153 ], "action": [ 156 ], "dependent": [ 163 ], "ERK5.": [ 165 ], "recovers": [ 168 ], "tight": [ 174 ], "junctions": [ 175 ], "Occludin": [ 177 ], "monolayer": [ 183 ], "permeability": [ 184 ], "increase.": [ 185 ], "On": [ 186 ], "other": [ 188 ], "hand,": [ 189 ], "inhibits": [ 191 ], "expression": [ 194, 229 ], "vascular": [ 196, 201, 260 ], "adhesion": [ 197, 203, 213 ], "molecules": [ 198 ], "(E\u2010selectin": [ 199 ], "cell": [ 202 ], "molecule": [ 204 ], "1),": [ 205 ], "prevents": [ 207 ], "attachment": [ 210 ], "monocytes": [ 212 ], "Moreover,": [ 217 ], "mitigates": [ 219 ], "triggered": [ 221 ], "nitric": [ 225 ], "oxide": [ 226 ], "synthase": [ 227 ], "(eNOS)": [ 228 ], "NO": [ 231 ], "release.": [ 232 ], "Collectively,": [ 233 ], "our": [ 234 ], "study": [ 235 ], "provides": [ 236 ], "multiple": [ 237 ], "facets": [ 238 ], "mechanisms": [ 241 ], "protective": [ 246 ], "agent": [ 247 ], "cells": [ 250 ], "has": [ 252 ], "potential": [ 254 ], "implication": [ 255 ], "therapeutic": [ 257 ], "usage": [ 258 ], "complication": [ 261 ], "diabetes": [ 263 ], "\u00a9": [ 265 ], "2019": [ 266, 270 ], "IUBMB": [ 267 ], "Life,": [ 268 ], "71(9):1347\u20131354,": [ 269 ] }, "publication_date": "2019-04-10", "publication_year": 2019, "type": "article", "cited_by_count": 55, "authors": [ { "id": "https://openalex.org/A5110051043", "display_name": "Yue Wen" }, { "id": "https://openalex.org/A5100421246", "display_name": "Yi Li" }, { "id": "https://openalex.org/A5090927539", "display_name": "Dengke Ou" }, { "id": "https://openalex.org/A5101665543", "display_name": "Qing Yang" } ] }, { "id": "https://openalex.org/W2150913805", "doi": "https://doi.org/10.2337/db08-1193", "title": "GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice", "abstract": { "OBJECTIVE": [ 0 ], "Glucagon-like": [ 1 ], "peptide-1": [ 2 ], "receptor": [ 3 ], "(GLP-1R)": [ 4 ], "agonists": [ 5 ], "are": [ 6 ], "used": [ 7 ], "to": [ 8, 244 ], "treat": [ 9 ], "type": [ 10 ], "2": [ 11 ], "diabetes,": [ 12 ], "and": [ 13, 27, 50, 58, 108, 121, 141, 155, 172, 200, 211, 239, 247 ], "transient": [ 14 ], "GLP-1": [ 15 ], "administration": [ 16 ], "improved": [ 17, 122, 245 ], "cardiac": [ 18, 96, 123 ], "function": [ 19 ], "in": [ 20, 56, 91, 146, 181, 218, 220, 224, 236, 252 ], "humans": [ 21 ], "after": [ 22, 196, 250 ], "acute": [ 23 ], "myocardial": [ 24, 38 ], "infarction": [ 25 ], "(MI)": [ 26 ], "percutaneous": [ 28 ], "revascularization.": [ 29 ], "However,": [ 30 ], "the": [ 31, 48, 63, 139, 147, 213, 237 ], "consequences": [ 32 ], "of": [ 33, 52, 85, 99, 103, 143, 159, 165, 190, 198, 215 ], "GLP-1R": [ 34, 64, 231 ], "activation": [ 35, 217, 232 ], "before": [ 36 ], "ischemic": [ 37 ], "injury": [ 39 ], "remain": [ 40 ], "unclear.": [ 41 ], "RESEARCH": [ 42 ], "DESIGN": [ 43 ], "AND": [ 44 ], "METHODS": [ 45 ], "We": [ 46 ], "assessed": [ 47 ], "pathophysiology": [ 49 ], "outcome": [ 51 ], "coronary": [ 53 ], "artery": [ 54 ], "occlusion": [ 55 ], "normal": [ 57, 238 ], "diabetic": [ 59, 182, 240 ], "mice": [ 60, 70, 183 ], "pretreated": [ 61 ], "with": [ 62, 78, 184 ], "agonist": [ 65 ], "liraglutide.": [ 66 ], "RESULTS": [ 67 ], "Male": [ 68 ], "C57BL/6": [ 69 ], "were": [ 71, 163 ], "treated": [ 72 ], "twice": [ 73 ], "daily": [ 74 ], "for": [ 75 ], "7": [ 76 ], "days": [ 77, 195 ], "liraglutide": [ 79, 160, 169, 191, 206 ], "or": [ 80 ], "saline": [ 81 ], "followed": [ 82 ], "by": [ 83 ], "induction": [ 84 ], "MI.": [ 86, 186 ], "Survival": [ 87 ], "was": [ 88 ], "significantly": [ 89 ], "higher": [ 90 ], "liraglutide-treated": [ 92 ], "mice.": [ 93 ], "Liraglutide": [ 94, 136 ], "reduced": [ 95, 212 ], "rupture": [ 97 ], "(12": [ 98 ], "60": [ 100 ], "versus": [ 101, 114, 128 ], "46": [ 102 ], "60;": [ 104 ], "P": [ 105, 118, 133 ], "=": [ 106, 119, 134 ], "0.0001)": [ 107 ], "infarct": [ 109 ], "size": [ 110 ], "(21": [ 111 ], "\u00b1": [ 112, 116, 126, 130 ], "2%": [ 113 ], "29": [ 115 ], "3%,": [ 117 ], "0.02)": [ 120 ], "output": [ 124 ], "(12.4": [ 125 ], "0.6": [ 127, 131 ], "9.7": [ 129 ], "ml/min;": [ 132 ], "0.002).": [ 135 ], "also": [ 137 ], "modulated": [ 138 ], "expression": [ 140 ], "activity": [ 142 ], "cardioprotective": [ 144, 188 ], "genes": [ 145 ], "mouse": [ 148, 241 ], "heart,": [ 149, 242 ], "including": [ 150 ], "Akt,": [ 151 ], "GSK3\u03b2,": [ 152 ], "PPAR\u03b2-\u03b4,": [ 153 ], "Nrf-2,": [ 154 ], "HO-1.": [ 156 ], "The": [ 157, 187 ], "effects": [ 158, 189 ], "on": [ 161 ], "survival": [ 162, 173, 249 ], "independent": [ 164 ], "weight": [ 166 ], "loss.": [ 167 ], "Moreover,": [ 168 ], "conferred": [ 170 ], "cardioprotection": [ 171 ], "advantages": [ 174 ], "over": [ 175 ], "metformin,": [ 176 ], "despite": [ 177 ], "equivalent": [ 178 ], "glycemic": [ 179 ], "control,": [ 180 ], "experimental": [ 185 ], "remained": [ 192 ], "detectable": [ 193 ], "4": [ 194 ], "cessation": [ 197 ], "therapy": [ 199 ], "may": [ 201 ], "be": [ 202 ], "partly": [ 203 ], "direct,": [ 204 ], "because": [ 205 ], "increased": [ 207 ], "cyclic": [ 208 ], "AMP": [ 209 ], "formation": [ 210 ], "extent": [ 214 ], "caspase-3": [ 216 ], "cardiomyocytes": [ 219 ], "a": [ 221 ], "GLP-1R\u2013dependent": [ 222 ], "manner": [ 223 ], "vitro.": [ 225 ], "CONCLUSIONS": [ 226 ], "These": [ 227 ], "findings": [ 228 ], "demonstrate": [ 229 ], "that": [ 230 ], "engages": [ 233 ], "prosurvival": [ 234 ], "pathways": [ 235 ], "leading": [ 243 ], "outcomes": [ 246 ], "enhanced": [ 248 ], "MI": [ 251 ], "vivo.": [ 253 ] }, "publication_date": "2009-01-16", "publication_year": 2009, "type": "article", "cited_by_count": 559, "authors": [ { "id": "https://openalex.org/A5073316080", "display_name": "M. Hossein Noyan-Ashraf" }, { "id": "https://openalex.org/A5112632938", "display_name": "M. Abdul Momen" }, { "id": "https://openalex.org/A5020171481", "display_name": "Kiwon Ban" }, { "id": "https://openalex.org/A5111965234", "display_name": "Al-Muktafi Sadi" }, { "id": "https://openalex.org/A5100725421", "display_name": "Yuqing Zhou" }, { "id": "https://openalex.org/A5072188619", "display_name": "Ali Riazi" }, { "id": "https://openalex.org/A5078676914", "display_name": "Laurie L. Baggio" }, { "id": "https://openalex.org/A5004947747", "display_name": "R. Mark Henkelman" }, { "id": "https://openalex.org/A5044527590", "display_name": "Mansoor Husain" }, { "id": "https://openalex.org/A5057472647", "display_name": "Daniel J. Drucker" } ] }, { "id": "https://openalex.org/W2092434810", "doi": "https://doi.org/10.1177/1479164112441526", "title": "GLP-1 receptor agonists: A clinical perspective on cardiovascular effects", "abstract": { "The": [ 0 ], "active": [ 1 ], "incretin": [ 2 ], "hormone": [ 3 ], "glucagon-like": [ 4 ], "peptide-1(7-36)amide": [ 5 ], "(GLP-1)": [ 6 ], "is": [ 7 ], "a": [ 8, 69 ], "30-amino": [ 9 ], "acid": [ 10 ], "peptide": [ 11 ], "that": [ 12 ], "exerts": [ 13 ], "glucoregulatory": [ 14 ], "and": [ 15, 60, 67, 87, 106 ], "insulinotropic": [ 16 ], "actions": [ 17 ], "by": [ 18 ], "functioning": [ 19 ], "as": [ 20, 80, 90, 92, 100 ], "an": [ 21 ], "agonist": [ 22 ], "for": [ 23, 51 ], "the": [ 24, 42, 46, 52 ], "GLP-1": [ 25, 34, 47 ], "receptor": [ 26 ], "(GLP-1R).": [ 27 ], "In": [ 28 ], "addition": [ 29 ], "to": [ 30 ], "its": [ 31 ], "anti-diabetic": [ 32 ], "effects,": [ 33 ], "has": [ 35 ], "demonstrated": [ 36 ], "cardioprotective": [ 37 ], "actions.": [ 38 ], "Here": [ 39 ], "we": [ 40, 109 ], "review": [ 41, 111 ], "cardiovascular": [ 43, 76, 97 ], "effects": [ 44, 74 ], "of": [ 45, 54, 72 ], "analogues": [ 48 ], "currently": [ 49 ], "approved": [ 50 ], "treatment": [ 53 ], "type": [ 55 ], "2": [ 56 ], "diabetes,": [ 57 ], "namely": [ 58 ], "exenatide": [ 59 ], "liraglutide.": [ 61 ], "We": [ 62 ], "discuss": [ 63 ], "their": [ 64, 73, 93 ], "anti-hyperglycaemic": [ 65 ], "efficacy,": [ 66 ], "offer": [ 68 ], "clinical": [ 70, 116 ], "perspective": [ 71 ], "on": [ 75, 96 ], "risk": [ 77 ], "factors": [ 78 ], "such": [ 79, 99 ], "body": [ 81 ], "weight,": [ 82 ], "blood": [ 83 ], "pressure,": [ 84 ], "heart": [ 85, 102 ], "rate": [ 86 ], "lipid": [ 88 ], "profiles,": [ 89 ], "well": [ 91 ], "potential": [ 94 ], "consequences": [ 95 ], "events,": [ 98 ], "arrhythmias,": [ 101 ], "failure,": [ 103 ], "myocardial": [ 104 ], "infarction": [ 105 ], "death.": [ 107 ], "Lastly,": [ 108 ], "briefly": [ 110 ], "additional": [ 112 ], "GLP-1R": [ 113 ], "agonists": [ 114 ], "in": [ 115 ], "development.": [ 117 ] }, "publication_date": "2012-04-01", "publication_year": 2012, "type": "review", "cited_by_count": 102, "authors": [ { "id": "https://openalex.org/A5068601841", "display_name": "Dhanwantee Mundil" }, { "id": "https://openalex.org/A5113185431", "display_name": "Alison Cameron-Vendrig" }, { "id": "https://openalex.org/A5044527590", "display_name": "Mansoor Husain" } ] }, { "id": "https://openalex.org/W2914947684", "doi": "https://doi.org/10.1093/ndt/gfy407", "title": "SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA", "abstract": { "Abstract": [ 0 ], "Chronic": [ 1 ], "kidney": [ 2 ], "disease": [ 3 ], "(CKD)": [ 4 ], "in": [ 5, 93, 134, 143, 165, 172 ], "patients": [ 6, 22, 135, 176 ], "with": [ 7, 99, 136, 177 ], "diabetes": [ 8 ], "mellitus": [ 9 ], "(DM)": [ 10 ], "is": [ 11 ], "a": [ 12, 102 ], "major": [ 13 ], "problem": [ 14 ], "of": [ 15, 20, 25, 45, 53, 104, 131, 154, 175 ], "public": [ 16 ], "health.": [ 17 ], "Currently,": [ 18 ], "many": [ 19 ], "these": [ 21, 68, 166 ], "experience": [ 23 ], "progression": [ 24, 130 ], "cardiovascular": [ 26, 79, 122 ], "and": [ 27, 58, 80, 87, 114, 124, 151, 157, 168, 179 ], "renal": [ 28, 54, 81, 132 ], "disease,": [ 29, 133 ], "even": [ 30 ], "when": [ 31 ], "receiving": [ 32 ], "optimal": [ 33 ], "treatment.": [ 34 ], "In": [ 35 ], "previous": [ 36, 97 ], "years,": [ 37 ], "several": [ 38 ], "new": [ 39 ], "drug": [ 40 ], "classes": [ 41, 69 ], "for": [ 42, 77 ], "the": [ 43, 78, 145, 149, 161, 173 ], "treatment": [ 44, 174 ], "type": [ 46, 137 ], "2": [ 47, 138 ], "DM": [ 48 ], "have": [ 49, 73 ], "emerged,": [ 50 ], "including": [ 51 ], "inhibitors": [ 52, 113, 156 ], "sodium\u2013glucose": [ 55 ], "co-transporter-2": [ 56 ], "(SGLT-2)": [ 57 ], "glucagon-like": [ 59 ], "peptide-1": [ 60 ], "(GLP-1)": [ 61 ], "receptor": [ 62, 116 ], "agonists.": [ 63 ], "Apart": [ 64 ], "from": [ 65 ], "reducing": [ 66 ], "glycaemia,": [ 67 ], "were": [ 70 ], "reported": [ 71 ], "to": [ 72, 95, 120 ], "other": [ 74 ], "beneficial": [ 75 ], "effects": [ 76, 153 ], "systems,": [ 82 ], "such": [ 83 ], "as": [ 84, 127, 129 ], "weight": [ 85 ], "loss": [ 86 ], "blood": [ 88 ], "pressure": [ 89 ], "reduction.": [ 90 ], "Most": [ 91 ], "importantly,": [ 92 ], "contrast": [ 94 ], "all": [ 96 ], "studies": [ 98 ], "anti-diabetic": [ 100 ], "agents,": [ 101 ], "series": [ 103 ], "recent": [ 105 ], "randomized,": [ 106 ], "placebo-controlled": [ 107 ], "outcome": [ 108 ], "trials": [ 109 ], "showed": [ 110 ], "that": [ 111 ], "SGLT-2": [ 112, 155 ], "GLP-1": [ 115, 158 ], "agonists": [ 117 ], "are": [ 118 ], "able": [ 119 ], "reduce": [ 121 ], "events": [ 123 ], "all-cause": [ 125 ], "mortality,": [ 126 ], "well": [ 128 ], "DM.": [ 139, 180 ], "This": [ 140 ], "document": [ 141 ], "presents": [ 142 ], "detail": [ 144 ], "available": [ 146 ], "evidence": [ 147 ], "on": [ 148 ], "cardioprotective": [ 150 ], "nephroprotective": [ 152 ], "analogues,": [ 159 ], "analyses": [ 160 ], "potential": [ 162 ], "mechanisms": [ 163 ], "involved": [ 164 ], "actions": [ 167 ], "discusses": [ 169 ], "their": [ 170 ], "place": [ 171 ], "CKD": [ 178 ] }, "publication_date": "2019-01-25", "publication_year": 2019, "type": "article", "cited_by_count": 192, "authors": [ { "id": "https://openalex.org/A5028159985", "display_name": "Pantelis Sarafidis" }, { "id": "https://openalex.org/A5049930083", "display_name": "Charles J. Ferro" }, { "id": "https://openalex.org/A5036894659", "display_name": "Enrique Morales" }, { "id": "https://openalex.org/A5063245254", "display_name": "Alberto Ort\u00edz" }, { "id": "https://openalex.org/A5085600917", "display_name": "Jolanta Ma\u0142yszko" }, { "id": "https://openalex.org/A5073678061", "display_name": "Radovan Hojs" }, { "id": "https://openalex.org/A5044110321", "display_name": "Khaled Khazim" }, { "id": "https://openalex.org/A5004723925", "display_name": "Robert Ekart" }, { "id": "https://openalex.org/A5003985028", "display_name": "Jos\u00e9 Manuel Valdivielso" }, { "id": "https://openalex.org/A5005480103", "display_name": "Denis Fouque" }, { "id": "https://openalex.org/A5041217068", "display_name": "G\u00e9rard M. London" }, { "id": "https://openalex.org/A5071660720", "display_name": "Ziad A. Massy" }, { "id": "https://openalex.org/A5044774486", "display_name": "P. Ruggenenti" }, { "id": "https://openalex.org/A5074561062", "display_name": "Esteban Porrini" }, { "id": "https://openalex.org/A5044605455", "display_name": "Andrzej Wi\u0119cek" }, { "id": "https://openalex.org/A5054081924", "display_name": "Carmine Zoccali" }, { "id": "https://openalex.org/A5027465947", "display_name": "Francesca Mallamaci" }, { "id": "https://openalex.org/A5059227599", "display_name": "Mads Hornum" } ] }, { "id": "https://openalex.org/W2163387116", "doi": "https://doi.org/10.2337/db13-1087", "title": "The Human GLP-1 Analogs Liraglutide and Semaglutide: Absence of Histopathological Effects on the Pancreas in Nonhuman Primates", "abstract": { "Increased": [ 0 ], "pancreas": [ 1, 31, 59, 97, 150, 159, 178 ], "mass": [ 2, 109, 136 ], "and": [ 3, 33, 118, 130, 137, 152 ], "glucagon-positive": [ 4 ], "adenomas": [ 5 ], "have": [ 6 ], "been": [ 7 ], "suggested": [ 8 ], "to": [ 9 ], "be": [ 10 ], "a": [ 11, 49, 54 ], "risk": [ 12 ], "associated": [ 13, 179 ], "with": [ 14, 39, 52, 113, 180 ], "sitagliptin": [ 15 ], "or": [ 16, 78, 162, 182 ], "exenatide": [ 17 ], "therapy": [ 18 ], "in": [ 19, 35, 57, 63, 73, 88, 105, 110, 149, 157, 168, 176 ], "humans.": [ 20 ], "Novo": [ 21 ], "Nordisk": [ 22 ], "has": [ 23 ], "conducted": [ 24 ], "extensive": [ 25 ], "toxicology": [ 26 ], "studies,": [ 27 ], "including": [ 28 ], "data": [ 29 ], "on": [ 30 ], "weight": [ 32, 60, 151 ], "histology,": [ 34 ], "Cynomolgus": [ 36 ], "monkeys": [ 37, 65 ], "dosed": [ 38 ], "two": [ 40, 184 ], "different": [ 41, 186 ], "human": [ 42 ], "glucagon-like": [ 43 ], "peptide-1": [ 44 ], "(GLP-1)": [ 45 ], "receptor": [ 46, 188 ], "agonists.": [ 47, 189 ], "In": [ 48 ], "52-week": [ 50, 100 ], "study": [ 51, 101 ], "liraglutide,": [ 53 ], "dose-related": [ 55, 68 ], "increase": [ 56, 69, 104, 148 ], "absolute": [ 58 ], "was": [ 61, 70, 128 ], "observed": [ 62, 87 ], "female": [ 64 ], "only.": [ 66 ], "Such": [ 67 ], "not": [ 71 ], "found": [ 72 ], "studies": [ 74 ], "of": [ 75, 90, 95, 116, 124 ], "4,": [ 76 ], "13,": [ 77 ], "87": [ 79 ], "weeks\u2019": [ 80, 164 ], "duration.": [ 81 ], "No": [ 82 ], "treatment-related": [ 83, 154 ], "histopathological": [ 84, 155, 174 ], "abnormalities": [ 85 ], "were": [ 86, 140 ], "any": [ 89 ], "the": [ 91, 96, 99, 106, 125, 158, 177 ], "studies.": [ 92 ], "Quantitative": [ 93 ], "histology": [ 94 ], "from": [ 98 ], "showed": [ 102, 146, 172 ], "an": [ 103 ], "exocrine": [ 107, 119, 126 ], "cell": [ 108, 135 ], "liraglutide-dosed": [ 111 ], "animals,": [ 112 ], "normal": [ 114 ], "composition": [ 115 ], "endocrine": [ 117 ], "cellular": [ 120 ], "compartments.": [ 121 ], "Proliferation": [ 122 ], "rate": [ 123 ], "tissue": [ 127 ], "low": [ 129 ], "comparable": [ 131 ], "between": [ 132 ], "groups.": [ 133 ], "Endocrine": [ 134 ], "proliferation": [ 138 ], "rates": [ 139 ], "unaltered": [ 141 ], "by": [ 142 ], "liraglutide": [ 143, 181 ], "treatment.": [ 144 ], "Semaglutide": [ 145 ], "no": [ 147, 153, 173 ], "findings": [ 156 ], "after": [ 160 ], "13": [ 161 ], "52": [ 163 ], "dosing.": [ 165 ], "Overall,": [ 166 ], "results": [ 167 ], "138": [ 169 ], "nonhuman": [ 170 ], "primates": [ 171 ], "changes": [ 175 ], "semaglutide,": [ 183 ], "structurally": [ 185 ], "GLP-1": [ 187 ] }, "publication_date": "2014-03-08", "publication_year": 2014, "type": "article", "cited_by_count": 57, "authors": [ { "id": "https://openalex.org/A5103583268", "display_name": "C. F. Gotfredsen" }, { "id": "https://openalex.org/A5111572681", "display_name": "Anne\u2010Marie M\u00f8lck" }, { "id": "https://openalex.org/A5051655702", "display_name": "Inger Thorup" }, { "id": "https://openalex.org/A5090786732", "display_name": "Niels C. Berg Nyborg" }, { "id": "https://openalex.org/A5047550631", "display_name": "Zaki Salanti" }, { "id": "https://openalex.org/A5088627727", "display_name": "Lotte Bjerre Knudsen" }, { "id": "https://openalex.org/A5103409929", "display_name": "Marianne O. Larsen" } ] }, { "id": "https://openalex.org/W2117764934", "doi": "https://doi.org/10.2337/dc15-0165", "title": "A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes", "abstract": { "OBJECTIVE": [ 0 ], "To": [ 1 ], "investigate": [ 2 ], "the": [ 3, 110, 199 ], "dose-response": [ 4 ], "relationship": [ 5 ], "of": [ 6, 15, 48, 112, 145, 151, 188, 219, 224, 256, 273 ], "semaglutide": [ 7, 49, 159, 200, 232, 271 ], "versus": [ 8 ], "placebo": [ 9 ], "and": [ 10, 104, 126, 155, 170, 181, 191, 209, 221, 237, 275 ], "open-label": [ 11, 74 ], "liraglutide": [ 12, 75, 168 ], "in": [ 13, 18, 90, 100, 239 ], "terms": [ 14 ], "glycemic": [ 16 ], "control": [ 17 ], "patients": [ 19, 146, 240 ], "with": [ 20, 58, 158, 167, 198, 241, 278 ], "type": [ 21, 242 ], "2": [ 22, 35, 243 ], "diabetes.": [ 23, 244 ], "RESEARCH": [ 24 ], "DESIGN": [ 25 ], "AND": [ 26 ], "METHODS": [ 27 ], "This": [ 28 ], "was": [ 29, 88 ], "a": [ 30, 45, 279 ], "12-week,": [ 31 ], "randomized,": [ 32 ], "double-blind": [ 33 ], "phase": [ 34, 286 ], "trial.": [ 36 ], "Patients": [ 37 ], "(n": [ 38 ], "=": [ 39 ], "415)": [ 40 ], "were": [ 41, 163, 204, 215, 251, 262, 283 ], "randomized": [ 42 ], "to": [ 43, 65, 119, 124, 131, 143, 194, 206 ], "receive": [ 44 ], "subcutaneous": [ 46 ], "injection": [ 47, 225 ], "once": [ 50, 76 ], "weekly": [ 51, 270 ], "without": [ 52 ], "dose": [ 53, 59, 212, 265, 281 ], "escalation": [ 54, 60, 282 ], "(0.1\u20130.8": [ 55 ], "mg)": [ 56 ], "or": [ 57, 67, 79, 82, 248 ], "(E)": [ 61 ], "(0.4": [ 62 ], "mg": [ 63, 69, 135, 161, 172, 277 ], "steps": [ 64 ], "0.8": [ 66 ], "1.6": [ 68, 160 ], "E": [ 70, 162 ], "over": [ 71 ], "1\u20132": [ 72 ], "weeks),": [ 73 ], "daily": [ 77 ], "(1.2": [ 78 ], "1.8": [ 80, 171 ], "mg),": [ 81 ], "placebo.": [ 83 ], "The": [ 84, 186 ], "primary": [ 85 ], "end": [ 86, 96 ], "point": [ 87 ], "change": [ 89, 99 ], "HbA1c": [ 91, 113, 149, 153, 235 ], "level": [ 92, 111, 150, 154, 236 ], "from": [ 93, 114 ], "baseline.": [ 94 ], "Secondary": [ 95 ], "points": [ 97 ], "included": [ 98 ], "body": [ 101, 127 ], "weight,": [ 102 ], "safety,": [ 103 ], "tolerability.": [ 105 ], "RESULTS": [ 106 ], "Semaglutide": [ 107 ], "dose-dependently": [ 108, 233 ], "reduced": [ 109, 234 ], "baseline": [ 115 ], "(8.1": [ 116 ], "\u00b1": [ 117 ], "0.8%)": [ 118 ], "week": [ 120 ], "12": [ 121, 230 ], "by": [ 122, 129, 211, 264 ], "up": [ 123, 130 ], "\u22121.7%,": [ 125 ], "weight": [ 128, 156, 238 ], "\u22124.8": [ 132 ], "kg": [ 133 ], "(1.6": [ 134 ], "E,": [ 136 ], "P": [ 137 ], "&lt;": [ 138 ], "0.001": [ 139 ], "vs.": [ 140 ], "placebo).": [ 141 ], "Up": [ 142 ], "81%": [ 144 ], "achieved": [ 147 ], "an": [ 148 ], "&lt;7%.": [ 152 ], "reductions": [ 157 ], "greater": [ 164 ], "than": [ 165 ], "those": [ 166 ], "1.2": [ 169 ], "(based": [ 173 ], "on": [ 174 ], "unadjusted": [ 175 ], "CIs),": [ 176 ], "but": [ 177 ], "adverse": [ 178 ], "events": [ 179, 203 ], "(AEs)": [ 180 ], "withdrawals": [ 182 ], "occurred": [ 183 ], "more": [ 184 ], "frequently.": [ 185 ], "incidence": [ 187 ], "nausea,": [ 189 ], "vomiting,": [ 190 ], "withdrawal": [ 192 ], "due": [ 193 ], "gastrointestinal": [ 195, 253 ], "AEs": [ 196, 254 ], "increased": [ 197 ], "dose;": [ 201 ], "most": [ 202 ], "mild": [ 205 ], "moderate,": [ 207 ], "transient,": [ 208 ], "ameliorated": [ 210 ], "escalation.": [ 213, 266 ], "There": [ 214 ], "no": [ 216 ], "major": [ 217 ], "episodes": [ 218 ], "hypoglycemia": [ 220 ], "few": [ 222 ], "cases": [ 223 ], "site": [ 226 ], "reactions.": [ 227 ], "CONCLUSIONS": [ 228 ], "After": [ 229 ], "weeks,": [ 231 ], "No": [ 245 ], "unexpected": [ 246 ], "safety": [ 247 ], "tolerability": [ 249 ], "concerns": [ 250 ], "identified;": [ 252 ], "typical": [ 255 ], "glucagon-like": [ 257 ], "peptide": [ 258 ], "1": [ 259 ], "receptor": [ 260 ], "agonists": [ 261 ], "mitigated": [ 263 ], "On": [ 267 ], "this": [ 268 ], "basis,": [ 269 ], "doses": [ 272 ], "0.5": [ 274 ], "1.0": [ 276 ], "4-week": [ 280 ], "selected": [ 284 ], "for": [ 285 ], "3.": [ 287 ] }, "publication_date": "2015-09-10", "publication_year": 2015, "type": "article", "cited_by_count": 216, "authors": [ { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5077595764", "display_name": "John R. Petrie" }, { "id": "https://openalex.org/A5084623347", "display_name": "Giorgio Sesti" }, { "id": "https://openalex.org/A5059685674", "display_name": "Edoardo Mannucci" }, { "id": "https://openalex.org/A5004454263", "display_name": "J.P. Courr\u00e8ges" }, { "id": "https://openalex.org/A5108481559", "display_name": "Marie L.S. Lindegaard" }, { "id": "https://openalex.org/A5111479294", "display_name": "Christine B. Jensen" }, { "id": "https://openalex.org/A5064495299", "display_name": "Stephen L. Atkin" } ] }, { "id": "https://openalex.org/W2576609254", "doi": "https://doi.org/10.1186/s13098-017-0204-6", "title": "Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?", "abstract": { "Several": [ 0 ], "GLP-1": [ 1, 25, 33, 52, 97, 124 ], "receptor": [ 2, 26, 34, 53 ], "agonists": [ 3, 27, 35, 54, 98, 125 ], "are": [ 4, 21, 45 ], "currently": [ 5 ], "available": [ 6, 88 ], "for": [ 7 ], "treatment": [ 8, 73 ], "of": [ 9, 77, 94 ], "type": [ 10 ], "2": [ 11 ], "diabetic": [ 12 ], "patients.": [ 13 ], "Based": [ 14 ], "on": [ 15, 68, 90 ], "their": [ 16, 101, 127 ], "pharmacokinetic/pharmacodynamic": [ 17 ], "profile,": [ 18 ], "these": [ 19 ], "drugs": [ 20 ], "classified": [ 22, 47 ], "as": [ 23, 48, 71, 129 ], "short-acting": [ 24 ], "(exenatide": [ 28 ], "and": [ 29, 39, 74, 99 ], "lixisenatide)": [ 30 ], "or": [ 31, 50, 65, 79, 131 ], "long-acting": [ 32 ], "(exenatide-LAR,": [ 36 ], "liraglutide,": [ 37 ], "albiglutide,": [ 38 ], "dulaglutide).": [ 40 ], "In": [ 41, 82 ], "clinical": [ 42 ], "practice,": [ 43 ], "they": [ 44 ], "also": [ 46, 116 ], "basal": [ 49, 130 ], "prandial": [ 51 ], "to": [ 55, 105, 110 ], "differentiate": [ 56 ], "between": [ 57, 121 ], "patients": [ 58 ], "who": [ 59 ], "would": [ 60 ], "benefit": [ 61 ], "more": [ 62 ], "from": [ 63 ], "one": [ 64 ], "another": [ 66 ], "based": [ 67 ], "characteristics": [ 69, 93 ], "such": [ 70 ], "previous": [ 72 ], "the": [ 75, 83, 91, 95, 106, 119, 122 ], "predominance": [ 76 ], "fasting": [ 78 ], "postprandial": [ 80 ], "hyperglycemia.": [ 81 ], "present": [ 84 ], "article": [ 85, 115 ], "we": [ 86 ], "examine": [ 87 ], "data": [ 89 ], "pharmacokinetic": [ 92 ], "various": [ 96 ], "compare": [ 100 ], "effects": [ 102 ], "with": [ 103 ], "respect": [ 104 ], "main": [ 107 ], "parameters": [ 108 ], "used": [ 109 ], "evaluate": [ 111 ], "glycemic": [ 112 ], "control.": [ 113 ], "The": [ 114 ], "analyzes": [ 117 ], "whether": [ 118 ], "differences": [ 120 ], "different": [ 123 ], "justify": [ 126 ], "classification": [ 128 ], "prandial.": [ 132 ] }, "publication_date": "2017-01-18", "publication_year": 2017, "type": "review", "cited_by_count": 28, "authors": [ { "id": "https://openalex.org/A5075479255", "display_name": "Inka Mi\u00f1ambres" }, { "id": "https://openalex.org/A5006014238", "display_name": "Antonio P\u00e9rez" } ] }, { "id": "https://openalex.org/W2061549173", "doi": "https://doi.org/10.1111/j.1463-1326.2009.01075.x", "title": "The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1\u20135 studies", "abstract": { "Liraglutide": [ 0, 159 ], "is": [ 1 ], "a": [ 2, 10, 23, 74, 163 ], "new": [ 3 ], "glucagon\u2010like": [ 4 ], "peptide\u20101": [ 5 ], "(GLP\u20101)": [ 6 ], "receptor": [ 7 ], "agonist": [ 8 ], "and": [ 9, 31, 40, 54, 101, 168 ], "true": [ 11 ], "GLP\u20101": [ 12 ], "analogue.": [ 13 ], "After": [ 14 ], "successful": [ 15 ], "phase": [ 16, 26 ], "2": [ 17, 47 ], "studies,": [ 18 ], "liraglutide": [ 19, 69, 76, 108, 115, 146 ], "was": [ 20, 116, 128, 160, 169, 185 ], "assessed": [ 21 ], "in": [ 22, 33, 55, 80, 83, 95, 121, 137, 153 ], "series": [ 24 ], "of": [ 25, 45, 139, 166, 175, 183 ], "3": [ 27 ], "trials": [ 28 ], "[(Liraglutide": [ 29 ], "Effect": [ 30 ], "Action": [ 32 ], "Diabetes": [ 34 ], "(LEAD)]": [ 35 ], "designed": [ 36 ], "to": [ 37 ], "demonstrate": [ 38 ], "efficacy": [ 39 ], "safety": [ 41 ], "across": [ 42, 148 ], "the": [ 43, 113, 124, 180 ], "continuum": [ 44 ], "type": [ 46 ], "diabetes": [ 48 ], "antihyperglycaemic": [ 49 ], "care,": [ 50 ], "both": [ 51 ], "as": [ 52 ], "monotherapy": [ 53 ], "combination": [ 56 ], "with": [ 57, 70, 85, 89, 107, 110, 118, 134, 145, 162 ], "commonly": [ 58 ], "used": [ 59 ], "oral": [ 60 ], "antidiabetic": [ 61 ], "drugs": [ 62 ], "(OADs).": [ 63 ], "The": [ 64, 173 ], "LEAD": [ 65 ], "programme": [ 66 ], "also": [ 67 ], "compared": [ 68 ], "other": [ 71 ], "OADs.": [ 72 ], "As": [ 73 ], "monotherapy,": [ 75 ], "demonstrated": [ 77 ], "significant": [ 78 ], "improvements": [ 79 ], "glycaemic": [ 81 ], "control": [ 82 ], "comparison": [ 84 ], "glimepiride.": [ 86 ], "When": [ 87 ], "combined": [ 88 ], "one": [ 90 ], "or": [ 91 ], "two": [ 92 ], "OADs,": [ 93 ], "reductions": [ 94, 152 ], "haemoglobin": [ 96 ], "A1c,": [ 97 ], "fasting": [ 98 ], "plasma": [ 99 ], "glucose": [ 100, 103 ], "postprandial": [ 102 ], "were": [ 104, 142, 157, 178 ], "generally": [ 105, 170 ], "greater": [ 106, 130 ], "than": [ 109, 131 ], "comparators.": [ 111, 135 ], "Throughout": [ 112 ], "trials,": [ 114 ], "associated": [ 117, 161 ], "weight": [ 119 ], "reduction;": [ 120 ], "most": [ 122, 181 ], "instances,": [ 123 ], "reduction": [ 125 ], "from": [ 126 ], "baseline": [ 127 ], "significantly": [ 129 ], "that": [ 132 ], "seen": [ 133 ], "Improvements": [ 136 ], "assessments": [ 138 ], "beta\u2010cell": [ 140 ], "function": [ 141 ], "consistently": [ 143 ], "shown": [ 144 ], "treatment": [ 147 ], "all": [ 149 ], "trials.": [ 150 ], "Furthermore,": [ 151 ], "systolic": [ 154 ], "blood": [ 155 ], "pressure": [ 156 ], "reported.": [ 158 ], "low": [ 164 ], "risk": [ 165 ], "hypoglycaemia": [ 167 ], "well": [ 171 ], "tolerated.": [ 172 ], "majority": [ 174 ], "adverse": [ 176 ], "effects": [ 177 ], "gastrointestinal,": [ 179 ], "frequent": [ 182 ], "which": [ 184 ], "nausea.": [ 186 ] }, "publication_date": "2009-10-29", "publication_year": 2009, "type": "review", "cited_by_count": 227, "authors": [ { "id": "https://openalex.org/A5070289715", "display_name": "Lawrence Blonde" }, { "id": "https://openalex.org/A5082184915", "display_name": "David Russell\u2010Jones" } ] }, { "id": "https://openalex.org/W4221065885", "doi": "https://doi.org/10.23876/j.krcp.22.001", "title": "GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions", "abstract": { "With": [ 0 ], "the": [ 1, 11, 87, 133 ], "emergence": [ 2 ], "of": [ 3, 6, 76, 114, 121, 127, 135 ], "various": [ 4 ], "classes": [ 5 ], "blood": [ 7, 61, 105, 108 ], "glucose-lowering": [ 8, 62 ], "agents,": [ 9 ], "choosing": [ 10 ], "appropriate": [ 12 ], "drug": [ 13 ], "for": [ 14, 36, 100, 152 ], "each": [ 15 ], "patient": [ 16 ], "is": [ 17 ], "emphasized": [ 18 ], "in": [ 19, 64, 89 ], "diabetes": [ 20, 69 ], "management.": [ 21 ], "Among": [ 22 ], "incretin-based": [ 23 ], "drugs,": [ 24 ], "glucagon-like": [ 25 ], "peptide": [ 26 ], "1": [ 27 ], "(GLP-1)": [ 28 ], "receptor": [ 29, 51, 78, 144 ], "agonists": [ 30, 52, 79, 145 ], "are": [ 31, 123 ], "a": [ 32 ], "promising": [ 33 ], "therapeutic": [ 34 ], "option": [ 35 ], "patients": [ 37, 65, 153 ], "with": [ 38, 66, 154 ], "diabetic": [ 39 ], "kidney": [ 40 ], "disease": [ 41 ], "(DKD).": [ 42 ], "Several": [ 43 ], "cardiovascular": [ 44 ], "outcome": [ 45 ], "trials": [ 46 ], "have": [ 47, 53 ], "demonstrated": [ 48 ], "that": [ 49, 95, 142 ], "GLP-1": [ 50, 77, 128, 143 ], "beneficial": [ 54 ], "effects": [ 55, 63, 75 ], "on": [ 56, 86 ], "cardiorenal": [ 57 ], "outcomes": [ 58 ], "beyond": [ 59 ], "their": [ 60, 83, 92 ], "type": [ 67 ], "2": [ 68 ], "mellitus": [ 70 ], "(T2DM).": [ 71 ], "The": [ 72 ], "renal": [ 73 ], "protective": [ 74 ], "likely": [ 80 ], "result": [ 81 ], "from": [ 82, 132 ], "direct": [ 84 ], "actions": [ 85, 94 ], "kidney,": [ 88 ], "addition": [ 90 ], "to": [ 91 ], "indirect": [ 93 ], "improve": [ 96 ], "conventional": [ 97 ], "risk": [ 98 ], "factors": [ 99 ], "DKD,": [ 101 ], "such": [ 102 ], "as": [ 103 ], "reducing": [ 104 ], "glucose": [ 106 ], "levels,": [ 107 ], "pressure,": [ 109 ], "and": [ 110, 117, 119, 137 ], "body": [ 111 ], "weight.": [ 112 ], "Inhibition": [ 113 ], "oxidative": [ 115 ], "stress": [ 116 ], "inflammation": [ 118 ], "induction": [ 120 ], "natriuresis": [ 122 ], "major": [ 124 ], "renoprotective": [ 125 ], "mechanisms": [ 126 ], "analogues.": [ 129 ], "Early": [ 130 ], "evidence": [ 131 ], "development": [ 134 ], "dual": [ 136 ], "triple": [ 138 ], "combination": [ 139 ], "agents": [ 140 ], "suggests": [ 141 ], "will": [ 146 ], "probably": [ 147 ], "become": [ 148 ], "popular": [ 149 ], "treatment": [ 150 ], "options": [ 151 ], "T2DM.": [ 155 ] }, "publication_date": "2022-03-25", "publication_year": 2022, "type": "article", "cited_by_count": 69, "authors": [ { "id": "https://openalex.org/A5014349996", "display_name": "Ji Hee Yu" }, { "id": "https://openalex.org/A5100382174", "display_name": "So Young Park" }, { "id": "https://openalex.org/A5043690102", "display_name": "Da Young Lee" }, { "id": "https://openalex.org/A5055753007", "display_name": "Nan Hee Kim" }, { "id": "https://openalex.org/A5050772654", "display_name": "Ji A Seo" } ] }, { "id": "https://openalex.org/W3200446817", "doi": "https://doi.org/10.1186/s12933-021-01366-8", "title": "GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs", "abstract": { "Abstract": [ 0 ], "Background": [ 1 ], "A": [ 2 ], "meta-analysis": [ 3, 47 ], "is": [ 4 ], "presented": [ 5 ], "of": [ 6, 48, 105, 120, 204 ], "cardiovascular": [ 7, 79, 85, 110, 121 ], "outcome": [ 8, 156 ], "trials": [ 9 ], "(CVOTs)": [ 10 ], "comparing": [ 11 ], "glucagon-like": [ 12 ], "peptide-1": [ 13 ], "receptor": [ 14 ], "agonists": [ 15 ], "(GLP-1RA)": [ 16 ], "versus": [ 17 ], "placebo": [ 18 ], "on": [ 19, 183, 200 ], "cardiorenal": [ 20 ], "outcomes": [ 21 ], "in": [ 22, 168 ], "patients": [ 23, 75, 106 ], "with": [ 24, 77, 99, 107 ], "type": [ 25 ], "2": [ 26 ], "diabetes": [ 27 ], "mellitus": [ 28 ], "(T2DM).": [ 29 ], "Methods": [ 30 ], "We": [ 31, 44, 67 ], "did": [ 32, 45 ], "an": [ 33 ], "electronic": [ 34 ], "search": [ 35 ], "up": [ 36 ], "to": [ 37, 56 ], "June": [ 38 ], "30,": [ 39 ], "2021,": [ 40 ], "for": [ 41, 136, 189 ], "eligible": [ 42 ], "trials.": [ 43 ], "a": [ 46, 53, 100, 166 ], "available": [ 49 ], "trial": [ 50 ], "data": [ 51, 69 ], "using": [ 52 ], "random-effects": [ 54 ], "model": [ 55 ], "calculate": [ 57 ], "overall": [ 58 ], "hazard": [ 59 ], "ratios": [ 60 ], "(HRs)": [ 61 ], "and": [ 62, 73, 108, 151, 185, 192 ], "95%": [ 63, 93 ], "CI": [ 64, 94 ], "(confidence": [ 65 ], "intervals).": [ 66 ], "included": [ 68 ], "from": [ 70 ], "8": [ 71 ], "CVOTs": [ 72 ], "60,080": [ 74 ], "(72.4%": [ 76 ], "established": [ 78 ], "disease).": [ 80 ], "Results": [ 81 ], "GLP-1RA": [ 82, 115, 179 ], "reduced": [ 83, 117 ], "major": [ 84 ], "events": [ 86 ], "(MACE)": [ 87 ], "by": [ 88, 123, 130, 139, 146, 157, 165 ], "14%": [ 89 ], "(HR": [ 90, 171 ], "=": [ 91, 97, 113, 126, 133, 142, 149, 160, 172 ], "0.86,": [ 92 ], "0.79\u20130.94,": [ 95 ], "P": [ 96, 175 ], "0.006)": [ 98 ], "non-significant": [ 101 ], "heterogeneity": [ 102 ], "between": [ 103 ], "subgroups": [ 104 ], "without": [ 109 ], "disease": [ 111 ], "(P": [ 112, 125, 132, 141, 148, 159 ], "0.127).": [ 114 ], "also": [ 116, 186, 196 ], "the": [ 118, 152, 202 ], "risk": [ 119 ], "death": [ 122 ], "13%": [ 124 ], "0.016),": [ 127 ], "nonfatal": [ 128 ], "stroke": [ 129 ], "16%": [ 131 ], "0.007),": [ 134 ], "hospitalization": [ 135, 188 ], "heart": [ 137, 190 ], "failure": [ 138, 191 ], "10%": [ 140 ], "0.023),": [ 143 ], "all-cause": [ 144, 193 ], "mortality": [ 145 ], "12%": [ 147 ], "0.012),": [ 150, 161 ], "broad": [ 153 ], "composite": [ 154 ], "kidney": [ 155 ], "17%": [ 158 ], "which": [ 162 ], "was": [ 163 ], "driven": [ 164 ], "reduction": [ 167 ], "macroalbuminuria": [ 169 ], "only": [ 170 ], "0.74,": [ 173 ], "0.67\u20130.82,": [ 174 ], "<": [ 176 ], "0.001).": [ 177 ], "Conclusions": [ 178 ], "have": [ 180, 197 ], "moderate": [ 181 ], "benefits": [ 182, 199 ], "MACE,": [ 184 ], "reduce": [ 187 ], "mortality;": [ 194 ], "they": [ 195 ], "robust": [ 198 ], "reducing": [ 201 ], "incidence": [ 203 ], "macroalbuminuria.": [ 205 ] }, "publication_date": "2021-09-15", "publication_year": 2021, "type": "review", "cited_by_count": 237, "authors": [ { "id": "https://openalex.org/A5056173815", "display_name": "Dario Giugliano" }, { "id": "https://openalex.org/A5039806023", "display_name": "Lorenzo Scappaticcio" }, { "id": "https://openalex.org/A5005827466", "display_name": "Miriam Longo" }, { "id": "https://openalex.org/A5054748643", "display_name": "Paola Caruso" }, { "id": "https://openalex.org/A5043443418", "display_name": "Maria Ida Maiorino" }, { "id": "https://openalex.org/A5025735798", "display_name": "Giuseppe Bellastella" }, { "id": "https://openalex.org/A5044764461", "display_name": "Antonio Ceriello" }, { "id": "https://openalex.org/A5048229494", "display_name": "Paolo Chiodini" }, { "id": "https://openalex.org/A5052044111", "display_name": "Katherine Esposito" } ] }, { "id": "https://openalex.org/W2058514432", "doi": "https://doi.org/10.1111/j.1463-1326.2012.01603.x", "title": "Glycaemic efficacy of glucagon\u2010like peptide\u20101 receptor agonists and dipeptidyl peptidase\u20104 inhibitors as add\u2010on therapy to metformin in subjects with type 2 diabetes\u2014a review and meta analysis", "abstract": { "Aims:": [ 0 ], "During": [ 1 ], "recent": [ 2 ], "years,": [ 3 ], "two": [ 4, 190, 268 ], "strategies": [ 5, 374 ], "of": [ 6, 26, 59, 94, 104, 114, 136, 309, 364, 384, 414 ], "incretin\u2010based": [ 7, 83, 116, 166 ], "therapy": [ 8, 35, 42, 84, 117, 167, 319 ], "[glucagon\u2010like": [ 9 ], "peptide\u20101": [ 10 ], "(GLP\u20101)": [ 11 ], "receptor": [ 12, 142, 151, 184, 272, 315, 348, 393 ], "agonism": [ 13 ], "and": [ 14, 69, 204, 220, 274, 288, 311, 333, 351, 358, 418 ], "dipeptidyl": [ 15 ], "peptidase\u20104": [ 16 ], "(DPP\u20104)": [ 17 ], "inhibition]": [ 18 ], "have": [ 19, 50 ], "entered": [ 20 ], "the": [ 21, 112, 188, 267, 280, 362, 365, 370, 390, 400 ], "market": [ 22 ], "for": [ 23, 33, 132 ], "pharmacological": [ 24 ], "management": [ 25 ], "type": [ 27, 46, 129, 330 ], "2": [ 28, 47, 130, 331 ], "diabetes.": [ 29 ], "A": [ 30, 102 ], "main": [ 31 ], "indication": [ 32 ], "this": [ 34, 60 ], "is": [ 36, 338, 367 ], "as": [ 37, 74, 76, 85, 118 ], "add\u2010on": [ 38, 86, 119 ], "to": [ 39, 63, 87, 120, 325, 376, 421 ], "on\u2010going": [ 40 ], "metformin": [ 41, 55, 121, 326 ], "in": [ 43, 66, 71, 79, 108, 126, 173, 178, 222, 236, 245, 266, 279, 327, 343 ], "subjects": [ 44 ], "with": [ 45, 54, 82, 128, 181, 187, 270, 282, 313, 329, 345, 355, 379, 410 ], "diabetes": [ 48, 131 ], "who": [ 49 ], "insufficient": [ 51 ], "glycaemic": [ 52, 67 ], "control": [ 53, 68 ], "alone.": [ 56 ], "The": [ 57, 171 ], "aim": [ 58 ], "study": [ 61, 106, 179, 209, 237 ], "was": [ 62, 175, 212, 260, 275 ], "compare": [ 64 ], "improvements": [ 65 ], "changes": [ 70 ], "body": [ 72, 258, 397 ], "weight,": [ 73 ], "well": [ 75 ], "adverse": [ 77, 385 ], "events,": [ 78, 386 ], "comparable": [ 80 ], "studies": [ 81, 110, 159 ], "metformin.": [ 88 ], "Methods:": [ 89 ], "Studies": [ 90 ], "having": [ 91 ], "a": [ 92, 139, 213, 263, 339, 380, 411, 419 ], "duration": [ 93 ], "16\u201330": [ 95, 133, 335 ], "weeks": [ 96, 336 ], "were": [ 97, 198, 291, 303 ], "identified": [ 98 ], "from": [ 99, 306 ], "PubMed.": [ 100 ], "Results:": [ 101 ], "total": [ 103 ], "27": [ 105 ], "groups": [ 107, 180, 191, 238, 269, 281 ], "21": [ 109 ], "fulfilled": [ 111 ], "criteria": [ 113 ], "examining": [ 115 ], "at": [ 122 ], "clinically": [ 123 ], "recommended": [ 124 ], "doses": [ 125 ], "patients": [ 127, 328 ], "weeks;": [ 134 ], "7": [ 135, 146 ], "these": [ 137 ], "used": [ 138, 147 ], "short\u2010acting": [ 140 ], "GLP\u20101": [ 141, 150, 183, 271, 314, 347, 392 ], "agonist": [ 143 ], "(exenatide": [ 144 ], "BID),": [ 145 ], "longer": [ 148 ], "acting": [ 149 ], "agonists": [ 152, 185, 273, 349, 394 ], "(liraglutide": [ 153, 350 ], "or": [ 154, 241, 250 ], "exenatide": [ 155, 202, 242, 248, 352, 356 ], "LAR),": [ 156 ], "whereas": [ 157, 196 ], "14": [ 158 ], "examined": [ 160 ], "DPP\u20104": [ 161, 205, 251, 283, 359, 401 ], "inhibitors.": [ 162, 206, 284 ], "In": [ 163 ], "all": [ 164, 208 ], "studies,": [ 165 ], "reduced": [ 168, 261 ], "HbA1c": [ 169, 174, 219, 223, 344 ], "concentrations.": [ 170 ], "reduction": [ 172, 342 ], "significantly": [ 176, 234, 277 ], "greater": [ 177, 412 ], "long\u2010acting": [ 182, 346 ], "than": [ 186, 244, 354 ], "other": [ 189 ], "(both": [ 192, 253 ], "p": [ 193, 227, 254 ], "<": [ 194, 228, 255 ], "0.001),": [ 195 ], "there": [ 197, 211, 337 ], "no": [ 199 ], "differences": [ 200 ], "between": [ 201, 217 ], "BID": [ 203, 249, 357 ], "Across": [ 207 ], "groups,": [ 210 ], "negative": [ 214 ], "linear": [ 215 ], "correlation": [ 216 ], "baseline": [ 218, 371 ], "change": [ 221 ], "(r": [ 224 ], "=": [ 225 ], "\u22120.70;": [ 226 ], "0.001).": [ 229, 256 ], "Fasting": [ 230 ], "glucose": [ 231 ], "also": [ 232, 395, 408 ], "fell": [ 233 ], "more": [ 235, 340 ], "given": [ 239, 247 ], "liraglutide": [ 240 ], "LAR": [ 243 ], "those": [ 246 ], "inhibitors": [ 252, 402 ], "Furthermore,": [ 257 ], "weight": [ 259, 398, 404 ], "by": [ 262 ], "similar": [ 264 ], "extent": [ 265 ], "not": [ 276, 292, 297 ], "altered": [ 278 ], "Lipids,": [ 285 ], "blood": [ 286 ], "pressure": [ 287 ], "heart": [ 289, 423 ], "rate": [ 290 ], "reported": [ 293 ], "consistently,": [ 294 ], "which": [ 295 ], "did": [ 296 ], "allow": [ 298 ], "general": [ 299 ], "conclusions.": [ 300 ], "Adverse": [ 301 ], "events": [ 302 ], "rare,": [ 304 ], "apart": [ 305 ], "increased": [ 307 ], "incidence": [ 308, 413 ], "nausea": [ 310 ], "vomiting": [ 312 ], "agonists.": [ 316 ], "Conclusion:": [ 317 ], "Incretin\u2010based": [ 318 ], "efficiently": [ 320 ], "improves": [ 321 ], "glycaemia": [ 322 ], "when": [ 323 ], "added": [ 324 ], "diabetes,": [ 332 ], "within": [ 334 ], "pronounced": [ 341 ], "LAR)": [ 353 ], "inhibitors,": [ 360 ], "although": [ 361 ], "magnitude": [ 363 ], "effect": [ 366 ], "dependent": [ 368 ], "on": [ 369 ], "values.": [ 372 ], "Both": [ 373 ], "appear": [ 375 ], "be": [ 377 ], "associated": [ 378, 409 ], "very": [ 381 ], "low": [ 382 ], "risk": [ 383 ], "including": [ 387 ], "hypoglycaemia.": [ 388 ], "Finally,": [ 389 ], "injectable": [ 391 ], "reduce": [ 396 ], "(whereas": [ 399 ], "are": [ 403, 407 ], "neutral)": [ 405 ], "but": [ 406 ], "gastrointestinal": [ 415 ], "side": [ 416 ], "effects": [ 417 ], "tendency": [ 420 ], "increase": [ 422 ], "rate.": [ 424 ] }, "publication_date": "2012-04-03", "publication_year": 2012, "type": "review", "cited_by_count": 188, "authors": [ { "id": "https://openalex.org/A5054335526", "display_name": "Carolyn F. Deacon" }, { "id": "https://openalex.org/A5059685674", "display_name": "Edoardo Mannucci" }, { "id": "https://openalex.org/A5027109387", "display_name": "Bo \u00c5hr\u00e9n" } ] }, { "id": "https://openalex.org/W3210916260", "doi": "https://doi.org/10.1136/jim-2021-001952", "title": "Wegovy (Semaglutide): A New Weight Loss Drug for Chronic Weight Management", "abstract": { "Obesity": [ 0 ], "is": [ 1, 11, 29 ], "a": [ 2, 46 ], "growing": [ 3 ], "epidemic": [ 4 ], "within": [ 5 ], "the": [ 6, 77, 82, 119, 144, 168, 177 ], "USA.": [ 7 ], "Because": [ 8 ], "weight": [ 9, 61, 78, 204, 218 ], "gain": [ 10 ], "associated": [ 12 ], "with": [ 13, 65, 107, 136, 154, 197 ], "an": [ 14 ], "increased": [ 15 ], "risk": [ 16 ], "of": [ 17, 48, 89, 121, 146, 172, 214 ], "developing": [ 18, 33 ], "life-threatening": [ 19 ], "comorbidities,": [ 20 ], "such": [ 21 ], "as": [ 22 ], "hypertension": [ 23 ], "or": [ 24, 66, 191 ], "type": [ 25, 68, 137 ], "2": [ 26, 69, 91, 138 ], "diabetes,": [ 27 ], "there": [ 28 ], "great": [ 30 ], "interest": [ 31 ], "in": [ 32, 55, 63, 87, 105, 203 ], "non-invasive": [ 34 ], "pharmacotherapeutics": [ 35 ], "to": [ 36, 208 ], "help": [ 37 ], "combat": [ 38 ], "obesity.": [ 39, 155 ], "Glucagon-like": [ 40 ], "peptide-1": [ 41 ], "(GLP-1)": [ 42 ], "receptor": [ 43 ], "agonists": [ 44 ], "are": [ 45 ], "class": [ 47 ], "antidiabetic": [ 49, 201 ], "medications": [ 50, 202 ], "that": [ 51, 188 ], "have": [ 52 ], "shown": [ 53 ], "promise": [ 54 ], "encouraging": [ 56 ], "glycemic": [ 57 ], "control": [ 58 ], "and": [ 59, 75, 100, 114, 126, 158, 176, 199, 210 ], "promoting": [ 60 ], "loss": [ 62, 79 ], "patients": [ 64, 153 ], "without": [ 67 ], "diabetes.": [ 70, 139 ], "This": [ 71 ], "literature": [ 72 ], "review": [ 73 ], "summarizes": [ 74 ], "discusses": [ 76 ], "results": [ 80 ], "from": [ 81 ], "SUSTAIN": [ 83, 113 ], "(Semaglutide": [ 84, 102 ], "Unabated": [ 85 ], "Sustainability": [ 86 ], "Treatment": [ 88, 103 ], "Type": [ 90 ], "Diabetes),": [ 92 ], "PIONEER": [ 93, 115 ], "(Peptide": [ 94 ], "Innovation": [ 95 ], "for": [ 96, 180, 217 ], "Early": [ 97 ], "Diabetes": [ 98 ], "Treatment),": [ 99 ], "STEP": [ 101, 141 ], "Effect": [ 104 ], "People": [ 106 ], "Obesity)": [ 108 ], "clinical": [ 109, 116, 185 ], "trial": [ 110, 142 ], "programs.": [ 111 ], "The": [ 112, 140 ], "trials": [ 117, 186 ], "studied": [ 118 ], "use": [ 120 ], "1.0": [ 122 ], "mg,": [ 123, 148 ], "once-weekly,": [ 124, 149 ], "subcutaneous": [ 125, 150 ], "oral": [ 127 ], "semaglutide": [ 128, 151, 189 ], "(a": [ 129 ], "new": [ 130 ], "GLP-1": [ 131 ], "homolog),": [ 132 ], "respectively,": [ 133 ], "on": [ 134, 152 ], "participants": [ 135 ], "examined": [ 143 ], "effects": [ 145 ], "2.4": [ 147 ], "Trial": [ 156 ], "data": [ 157 ], "other": [ 159, 200 ], "pertinent": [ 160 ], "articles": [ 161 ], "were": [ 162 ], "obtained": [ 163 ], "via": [ 164 ], "database": [ 165 ], "search": [ 166 ], "through": [ 167 ], "US": [ 169 ], "National": [ 170, 178 ], "Library": [ 171 ], "Medicine": [ 173 ], "Clinical": [ 174 ], "Trials": [ 175 ], "Center": [ 179 ], "Biotechnology": [ 181 ], "Information.": [ 182 ], "All": [ 183 ], "three": [ 184 ], "demonstrated": [ 187 ], "(injected": [ 190 ], "oral)": [ 192 ], "has": [ 193 ], "superior": [ 194 ], "efficacy": [ 195 ], "compared": [ 196 ], "placebo": [ 198 ], "reduction,": [ 205 ], "which": [ 206 ], "led": [ 207 ], "Food": [ 209 ], "Drug": [ 211 ], "Administration": [ 212 ], "approval": [ 213 ], "Wegovy": [ 215 ], "(semaglutide)": [ 216 ], "loss.": [ 219 ] }, "publication_date": "2021-10-27", "publication_year": 2021, "type": "review", "cited_by_count": 200, "authors": [ { "id": "https://openalex.org/A5013895532", "display_name": "Gurdeep Singh" }, { "id": "https://openalex.org/A5050763877", "display_name": "Matthew Krauthamer" }, { "id": "https://openalex.org/A5001692594", "display_name": "Meghan Bjalme-Evans" } ] }, { "id": "https://openalex.org/W2018940614", "doi": "https://doi.org/10.2337/db14-0849", "title": "GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans", "abstract": { "Gut-derived": [ 0 ], "hormones,": [ 1 ], "such": [ 2 ], "as": [ 3 ], "GLP-1,": [ 4 ], "have": [ 5 ], "been": [ 6 ], "proposed": [ 7 ], "to": [ 8, 11, 14, 37, 113, 134 ], "relay": [ 9 ], "information": [ 10 ], "the": [ 12, 23, 88, 95, 188 ], "brain": [ 13, 61, 111, 132, 141, 154 ], "regulate": [ 15 ], "appetite.": [ 16 ], "GLP-1": [ 17, 52, 96, 104, 176, 192, 198 ], "receptor": [ 18, 53, 97, 105, 177, 199 ], "agonists,": [ 19 ], "currently": [ 20 ], "used": [ 21 ], "for": [ 22 ], "treatment": [ 24 ], "of": [ 25, 91, 94 ], "type": [ 26 ], "2": [ 27 ], "diabetes": [ 28 ], "(T2DM),": [ 29 ], "improve": [ 30 ], "glycemic": [ 31 ], "control": [ 32 ], "and": [ 33, 42, 59, 66, 69, 124, 139, 144, 152, 159, 166, 196 ], "stimulate": [ 34 ], "satiety,": [ 35 ], "leading": [ 36 ], "decreases": [ 38 ], "in": [ 39, 77, 137, 156 ], "food": [ 40, 48, 114, 135, 150, 194 ], "intake": [ 41, 49, 151, 195 ], "body": [ 43 ], "weight.": [ 44 ], "We": [ 45 ], "hypothesized": [ 46 ], "that": [ 47 ], "reduction": [ 50 ], "after": [ 51 ], "activation": [ 54 ], "is": [ 55 ], "mediated": [ 56 ], "through": [ 57 ], "appetite-": [ 58, 138 ], "reward-related": [ 60, 140 ], "areas.": [ 62 ], "Obese": [ 63, 121 ], "T2DM": [ 64, 122, 157 ], "patients": [ 65, 123, 158 ], "normoglycemic": [ 67, 125 ], "obese": [ 68, 126, 160 ], "lean": [ 70, 128 ], "individuals": [ 71 ], "(n": [ 72 ], "=": [ 73 ], "48)": [ 74 ], "were": [ 75, 171 ], "studied": [ 76 ], "a": [ 78, 117 ], "randomized,": [ 79 ], "crossover,": [ 80 ], "placebo-controlled": [ 81 ], "trial.": [ 82 ], "Using": [ 83 ], "functional": [ 84 ], "MRI,": [ 85 ], "we": [ 86 ], "determined": [ 87 ], "acute": [ 89 ], "effects": [ 90, 170 ], "intravenous": [ 92 ], "administration": [ 93 ], "agonist": [ 98 ], "exenatide,": [ 99 ], "with": [ 100 ], "or": [ 101 ], "without": [ 102 ], "prior": [ 103, 175 ], "blockade": [ 106, 178 ], "using": [ 107, 179 ], "exendin": [ 108, 180 ], "9-39,": [ 109 ], "on": [ 110 ], "responses": [ 112, 133, 155 ], "pictures": [ 115, 136 ], "during": [ 116 ], "somatostatin": [ 118 ], "pancreatic-pituitary": [ 119 ], "clamp.": [ 120 ], "versus": [ 127, 147 ], "subjects": [ 129, 161 ], "showed": [ 130 ], "increased": [ 131 ], "regions": [ 142 ], "(insula": [ 143 ], "amygdala).": [ 145 ], "Exenatide": [ 146 ], "placebo": [ 148 ], "decreased": [ 149 ], "food-related": [ 153 ], "(in": [ 162 ], "insula,": [ 163 ], "amygdala,": [ 164 ], "putamen,": [ 165 ], "orbitofrontal": [ 167 ], "cortex).": [ 168 ], "These": [ 169 ], "largely": [ 172 ], "blocked": [ 173 ], "by": [ 174, 190 ], "9-39.": [ 181 ], "Our": [ 182 ], "findings": [ 183 ], "provide": [ 184 ], "novel": [ 185 ], "insights": [ 186 ], "into": [ 187 ], "mechanisms": [ 189 ], "which": [ 191 ], "regulates": [ 193 ], "how": [ 197 ], "agonists": [ 200 ], "cause": [ 201 ], "weight": [ 202 ], "loss.": [ 203 ] }, "publication_date": "2014-07-29", "publication_year": 2014, "type": "article", "cited_by_count": 372, "authors": [ { "id": "https://openalex.org/A5030383711", "display_name": "Liselotte van Bloemendaal" }, { "id": "https://openalex.org/A5035147756", "display_name": "Richard G. IJzerman" }, { "id": "https://openalex.org/A5045375576", "display_name": "Jennifer S. ten Kulve" }, { "id": "https://openalex.org/A5064378373", "display_name": "Frederik Barkhof" }, { "id": "https://openalex.org/A5051170290", "display_name": "Robert J. Konrad" }, { "id": "https://openalex.org/A5103608675", "display_name": "Madeleine L. Drent" }, { "id": "https://openalex.org/A5030054670", "display_name": "Dick J. Veltman" }, { "id": "https://openalex.org/A5109335776", "display_name": "Micha\u00ebla Diamant" } ] }, { "id": "https://openalex.org/W2017810555", "doi": "https://doi.org/10.1530/joe-13-0414", "title": "Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS", "abstract": { "The": [ 0 ], "delivery": [ 1 ], "of": [ 2, 14, 42, 84, 89, 103, 109, 116, 124, 131 ], "nutrients": [ 3 ], "to": [ 4, 57, 135 ], "the": [ 5, 12, 19, 40, 82, 97, 106, 113 ], "gastrointestinal": [ 6 ], "tract": [ 7 ], "after": [ 8 ], "food": [ 9, 60, 142 ], "ingestion": [ 10 ], "activates": [ 11 ], "secretion": [ 13 ], "several": [ 15, 87 ], "gut-derived": [ 16 ], "mediators,": [ 17 ], "including": [ 18 ], "incretin": [ 20 ], "hormone": [ 21 ], "glucagon-like": [ 22 ], "peptide": [ 23 ], "1": [ 24 ], "(GLP-1).": [ 25 ], "GLP-1": [ 26, 104, 132 ], "receptor": [ 27 ], "agonists": [ 28 ], "(GLP-1RA),": [ 29 ], "such": [ 30 ], "as": [ 31 ], "exenatide": [ 32 ], "and": [ 33, 53, 62, 68, 86, 112, 144 ], "liraglutide,": [ 34 ], "are": [ 35 ], "currently": [ 36 ], "employed": [ 37 ], "successfully": [ 38 ], "in": [ 39, 59, 81, 105, 137, 141 ], "treatment": [ 41 ], "patients": [ 43 ], "with": [ 44 ], "type": [ 45 ], "2": [ 46 ], "diabetes": [ 47 ], "mellitus.": [ 48 ], "GLP-1RA": [ 49, 73 ], "improve": [ 50 ], "glycaemic": [ 51 ], "control": [ 52 ], "stimulate": [ 54 ], "satiety,": [ 55 ], "leading": [ 56, 134 ], "reductions": [ 58, 140 ], "intake": [ 61, 143 ], "body": [ 63 ], "weight.": [ 64 ], "Besides": [ 65 ], "gastric": [ 66 ], "distension": [ 67 ], "peripheral": [ 69 ], "vagal": [ 70 ], "nerve": [ 71 ], "activation,": [ 72 ], "induce": [ 74 ], "satiety": [ 75 ], "by": [ 76 ], "influencing": [ 77 ], "brain": [ 78 ], "regions": [ 79 ], "involved": [ 80 ], "regulation": [ 83, 108 ], "feeding,": [ 85 ], "routes": [ 88, 115 ], "action": [ 90, 117 ], "have": [ 91 ], "been": [ 92 ], "proposed.": [ 93 ], "This": [ 94 ], "review": [ 95 ], "summarises": [ 96 ], "evidence": [ 98 ], "for": [ 99 ], "a": [ 100 ], "physiological": [ 101 ], "role": [ 102 ], "central": [ 107 ], "feeding": [ 110 ], "behaviour": [ 111 ], "different": [ 114 ], "involved.": [ 118 ], "Also,": [ 119 ], "we": [ 120 ], "provide": [ 121 ], "an": [ 122 ], "overview": [ 123 ], "presently": [ 125 ], "available": [ 126 ], "data": [ 127 ], "on": [ 128 ], "pharmacological": [ 129 ], "stimulation": [ 130 ], "pathways": [ 133 ], "alterations": [ 136 ], "CNS": [ 138 ], "activity,": [ 139 ], "weight": [ 145 ], "loss.": [ 146 ] }, "publication_date": "2013-12-09", "publication_year": 2013, "type": "review", "cited_by_count": 290, "authors": [ { "id": "https://openalex.org/A5030383711", "display_name": "Liselotte van Bloemendaal" }, { "id": "https://openalex.org/A5045375576", "display_name": "Jennifer S. ten Kulve" }, { "id": "https://openalex.org/A5082108008", "display_name": "Susanne E. la Fleur" }, { "id": "https://openalex.org/A5035147756", "display_name": "Richard G. IJzerman" }, { "id": "https://openalex.org/A5109591880", "display_name": "M. Diamant" } ] }, { "id": "https://openalex.org/W4205983920", "doi": "https://doi.org/10.1007/s11154-021-09699-1", "title": "Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes", "abstract": null, "publication_date": "2022-01-07", "publication_year": 2022, "type": "article", "cited_by_count": 119, "authors": [ { "id": "https://openalex.org/A2186087229", "display_name": "Manoj Kumar Mahapatra" }, { "id": "https://openalex.org/A2581908243", "display_name": "Muthukumar Karuppasamy" }, { "id": "https://openalex.org/A2187153442", "display_name": "Biswa Mohan Sahoo" }, { "id": "https://openalex.org/A2186087229", "display_name": "Manoj Kumar Mahapatra" }, { "id": "https://openalex.org/A2581908243", "display_name": "Muthukumar Karuppasamy" }, { "id": "https://openalex.org/A2187153442", "display_name": "Biswa Mohan Sahoo" } ] }, { "id": "https://openalex.org/W2097575918", "doi": "https://doi.org/10.1177/1479164113481817", "title": "The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE\u2212/\u2212 mouse model", "abstract": { "Liraglutide,": [ 0 ], "a": [ 1, 12, 24, 80, 106, 164 ], "once-daily": [ 2 ], "glucagon-like": [ 3 ], "peptide-1": [ 4 ], "receptor": [ 5 ], "(GLP-1R)": [ 6 ], "agonist,": [ 7 ], "has": [ 8 ], "been": [ 9 ], "approved": [ 10 ], "as": [ 11 ], "new": [ 13 ], "treatment": [ 14, 70, 93 ], "for": [ 15, 167 ], "type": [ 16 ], "2": [ 17 ], "diabetes": [ 18 ], "and": [ 19, 35, 64, 100, 172 ], "is": [ 20 ], "the": [ 21, 30, 43, 56, 85, 170 ], "subject": [ 22 ], "of": [ 23, 47, 51, 73, 96, 113, 117, 147, 174 ], "clinical": [ 25 ], "trial": [ 26 ], "programme": [ 27 ], "to": [ 28, 41 ], "evaluate": [ 29 ], "effects": [ 31 ], "on": [ 32, 49, 115 ], "cardiovascular": [ 33, 184 ], "disease": [ 34, 54, 78, 122, 177 ], "safety.": [ 36 ], "The": [ 37 ], "current": [ 38 ], "study": [ 39 ], "aimed": [ 40 ], "determine": [ 42 ], "in": [ 44, 55, 79, 84, 105, 134, 152, 169 ], "vivo": [ 45 ], "effect": [ 46, 112 ], "liraglutide": [ 48, 92, 114, 168 ], "progression": [ 50, 72, 95, 116 ], "atherosclerotic": [ 52, 77, 97, 121, 142, 175 ], "vascular": [ 53, 176 ], "apolipoprotein": [ 57 ], "E-deficient": [ 58 ], "(ApoE": [ 59 ], "\u2212/\u2212": [ 60, 87, 136 ], ")": [ 61 ], "mouse": [ 62, 88 ], "model": [ 63 ], "identify": [ 65 ], "underlying": [ 66 ], "mechanisms": [ 67 ], "responsible.": [ 68 ], "Liraglutide": [ 69 ], "inhibited": [ 71, 94 ], "early": [ 74, 139 ], "onset,": [ 75, 119, 140 ], "low-burden": [ 76, 141 ], "partially": [ 81, 107 ], "GLP-1R-dependent": [ 82, 108 ], "manner": [ 83 ], "ApoE": [ 86, 135 ], "model.": [ 89 ], "In": [ 90, 125 ], "addition,": [ 91, 126 ], "plaque": [ 98, 102 ], "formation": [ 99 ], "enhanced": [ 101 ], "stability,": [ 103 ], "again": [ 104 ], "manner.": [ 109 ], "No": [ 110 ], "significant": [ 111, 128, 145 ], "late": [ 118 ], "high-burden": [ 120 ], "was": [ 123, 132, 150 ], "observed.": [ 124 ], "no": [ 127 ], "endothelial": [ 129 ], "cell": [ 130 ], "dysfunction": [ 131 ], "identified": [ 133 ], "mice": [ 137, 154 ], "with": [ 138, 179 ], "disease,": [ 143 ], "although": [ 144 ], "prevention": [ 146, 171 ], "weight": [ 148 ], "gain": [ 149 ], "observed": [ 151 ], "liraglutide-treated": [ 153 ], "using": [ 155 ], "this": [ 156 ], "dietary": [ 157 ], "protocol.": [ 158 ], "Taken": [ 159 ], "together,": [ 160 ], "these": [ 161 ], "results": [ 162 ], "suggest": [ 163 ], "potential": [ 165 ], "role": [ 166 ], "stabilisation": [ 173 ], "together": [ 178 ], "possible": [ 180 ], "protection": [ 181 ], "against": [ 182 ], "major": [ 183 ], "events.": [ 185 ] }, "publication_date": "2013-05-14", "publication_year": 2013, "type": "article", "cited_by_count": 136, "authors": [ { "id": "https://openalex.org/A5010359995", "display_name": "Tracey A. Gaspari" }, { "id": "https://openalex.org/A5054531748", "display_name": "Iresha Welungoda" }, { "id": "https://openalex.org/A5070440854", "display_name": "Robert E. Widdop" }, { "id": "https://openalex.org/A5103403579", "display_name": "Richard W Simpson" }, { "id": "https://openalex.org/A5045994438", "display_name": "Anthony E. Dear" } ] }, { "id": "https://openalex.org/W2038245016", "doi": "https://doi.org/10.1517/13543784.2012.638282", "title": "Novel GLP-1 receptor agonists for diabetes", "abstract": { "GLP-1": [ 0 ], "receptor": [ 1 ], "agonists": [ 2 ], "result": [ 3 ], "in": [ 4, 9 ], "clinically": [ 5 ], "meaningful": [ 6 ], "weight": [ 7 ], "loss": [ 8 ], "addition": [ 10 ], "to": [ 11 ], "their": [ 12 ], "beneficial": [ 13 ], "effects": [ 14 ], "on": [ 15 ], "glucose": [ 16 ], "homeostasis.": [ 17 ], "These": [ 18 ], "agents": [ 19 ], "provide": [ 20 ], "substantial": [ 21 ], "clinical": [ 22 ], "benefits": [ 23 ], "for": [ 24, 42 ], "patients": [ 25, 43 ], "compared": [ 26 ], "with": [ 27, 44 ], "sulfonylureas": [ 28 ], "or": [ 29 ], "DPP-4": [ 30 ], "inhibitors": [ 31 ], "and": [ 32 ], "will,": [ 33 ], "therefore,": [ 34 ], "become": [ 35 ], "one": [ 36 ], "of": [ 37 ], "the": [ 38 ], "major": [ 39 ], "therapeutic": [ 40 ], "choices": [ 41 ], "T2DM.": [ 45 ] }, "publication_date": "2011-11-24", "publication_year": 2011, "type": "review", "cited_by_count": 66, "authors": [ { "id": "https://openalex.org/A5111831506", "display_name": "Alan J. Garber" } ] }, { "id": "https://openalex.org/W188703145", "doi": "https://doi.org/10.2165/11592810-000000000-00000", "title": "Glucagon-like Peptide\u20131 Analogues for Type 2 Diabetes Mellitus", "abstract": null, "publication_date": "2011-09-01", "publication_year": 2011, "type": "review", "cited_by_count": 141, "authors": [ { "id": "https://openalex.org/A5105783630", "display_name": "Baptist Gallwitz" } ] }, { "id": "https://openalex.org/W2055611619", "doi": "https://doi.org/10.1210/jc.2011-1508", "title": "Exenatide Exerts a Potent Antiinflammatory Effect", "abstract": { "Exenatide": [ 0 ], "exerts": [ 1 ], "a": [ 2, 16 ], "rapid": [ 3 ], "antiinflammatory": [ 4 ], "effect": [ 5, 22 ], "at": [ 6 ], "the": [ 7 ], "cellular": [ 8 ], "and": [ 9 ], "molecular": [ 10 ], "level.": [ 11 ], "This": [ 12, 21 ], "may": [ 13 ], "contribute": [ 14 ], "to": [ 15 ], "potentially": [ 17 ], "beneficial": [ 18 ], "antiatherogenic": [ 19 ], "effect.": [ 20 ], "was": [ 23 ], "independent": [ 24 ], "of": [ 25 ], "weight": [ 26 ], "loss.": [ 27 ] }, "publication_date": "2011-10-20", "publication_year": 2011, "type": "article", "cited_by_count": 260, "authors": [ { "id": "https://openalex.org/A5113664206", "display_name": "Ajay Chaudhuri" }, { "id": "https://openalex.org/A5079289558", "display_name": "Husam Ghanim" }, { "id": "https://openalex.org/A5067479908", "display_name": "Mehul Vora" }, { "id": "https://openalex.org/A5110967596", "display_name": "Chang Ling Sia" }, { "id": "https://openalex.org/A5011951702", "display_name": "Kelly Korzeniewski" }, { "id": "https://openalex.org/A5021182210", "display_name": "Sandeep Dhindsa" }, { "id": "https://openalex.org/A5069086977", "display_name": "Antoine Makdissi" }, { "id": "https://openalex.org/A5032877471", "display_name": "Paresh Dandona" } ] }, { "id": "https://openalex.org/W2118710260", "doi": "https://doi.org/10.1210/jc.2010-2318", "title": "GLP-1 and Calcitonin Concentration in Humans: Lack of Evidence of Calcitonin Release from Sequential Screening in over 5000 Subjects with Type 2 Diabetes or Nondiabetic Obese Subjects Treated with the Human GLP-1 Analog, Liraglutide", "abstract": { "Background:": [ 0 ], "Serum": [ 1 ], "calcitonin": [ 2 ], "(CT)": [ 3 ], "is": [ 4 ], "a": [ 5, 51, 122, 188, 257 ], "well-accepted": [ 6 ], "marker": [ 7 ], "of": [ 8, 54, 65, 77, 124, 145, 181, 192, 224, 251, 259 ], "C-cell": [ 9, 34 ], "proliferation,": [ 10 ], "particularly": [ 11 ], "in": [ 12, 23, 44, 94, 121, 126, 148, 198, 232, 240 ], "medullary": [ 13, 47, 55 ], "thyroid": [ 14, 48, 56 ], "carcinoma.": [ 15 ], "Chronic": [ 16 ], "glucagon-like": [ 17 ], "peptide-1": [ 18 ], "(GLP-1)": [ 19 ], "receptor": [ 20, 67, 91, 226, 253 ], "agonist": [ 21, 92, 254 ], "administration": [ 22 ], "rodents": [ 24, 241 ], "has": [ 25 ], "been": [ 26 ], "associated": [ 27 ], "with": [ 28, 96 ], "increased": [ 29, 186 ], "serum": [ 30, 71, 83, 107, 229 ], "CT": [ 31, 43, 72, 84, 108, 138, 184, 230 ], "levels": [ 32, 185, 231 ], "and": [ 33, 58, 152, 178, 209, 234 ], "tumor": [ 35 ], "formation.": [ 36 ], "There": [ 37, 201 ], "are": [ 38, 256 ], "no": [ 39, 59, 116, 166, 203, 210 ], "longitudinal": [ 40 ], "studies": [ 41, 61 ], "measuring": [ 42 ], "humans": [ 45, 233 ], "without": [ 46 ], "carcinoma": [ 49, 57 ], "or": [ 50, 101, 132, 206 ], "family": [ 52 ], "history": [ 53 ], "published": [ 60 ], "on": [ 62, 69, 228 ], "the": [ 63, 78, 89, 142, 156, 248 ], "effect": [ 64, 223 ], "GLP-1": [ 66, 90, 225, 252 ], "agonists": [ 68 ], "human": [ 70 ], "concentrations.": [ 73 ], "Aim:": [ 74 ], "The": [ 75 ], "aim": [ 76 ], "study": [ 79 ], "was": [ 80, 202 ], "to": [ 81, 88, 245 ], "determine": [ 82 ], "response": [ 85 ], "over": [ 86, 127 ], "time": [ 87 ], "liraglutide": [ 93, 131 ], "subjects": [ 95, 129, 182 ], "type": [ 97 ], "2": [ 98, 119, 159 ], "diabetes": [ 99 ], "mellitus": [ 100 ], "nondiabetic": [ 102 ], "obese": [ 103 ], "subjects.": [ 104 ], "Methods:": [ 105 ], "Unstimulated": [ 106 ], "concentrations": [ 109, 139 ], "were": [ 110, 140, 165, 195 ], "measured": [ 111 ], "at": [ 112, 141 ], "3-month": [ 113 ], "intervals": [ 114 ], "for": [ 115, 176 ], "more": [ 117 ], "than": [ 118, 168 ], "yr": [ 120 ], "series": [ 123 ], "trials": [ 125 ], "5000": [ 128 ], "receiving": [ 130 ], "control": [ 133 ], "therapy.": [ 134 ], "Results:": [ 135 ], "Basal": [ 136 ], "mean": [ 137, 163 ], "low": [ 143, 154, 197 ], "end": [ 144 ], "normal": [ 146, 174 ], "range": [ 147 ], "all": [ 149, 199 ], "treatment": [ 150, 214, 255 ], "groups": [ 151 ], "remained": [ 153 ], "throughout": [ 155 ], "trials.": [ 157 ], "At": [ 158 ], "yr,": [ 160 ], "estimated": [ 161 ], "geometric": [ 162 ], "values": [ 164 ], "greater": [ 167 ], "1.0": [ 169 ], "ng/liter,": [ 170 ], "well": [ 171 ], "below": [ 172 ], "upper": [ 173 ], "ranges": [ 175 ], "males": [ 177 ], "females.": [ 179 ], "Proportions": [ 180 ], "whose": [ 183 ], "above": [ 187 ], "clinically": [ 189 ], "relevant": [ 190 ], "cutoff": [ 191 ], "20": [ 193 ], "ng/liter": [ 194 ], "very": [ 196 ], "groups.": [ 200, 215 ], "consistent": [ 204, 211 ], "dose": [ 205 ], "time-dependent": [ 207 ], "relationship": [ 208 ], "difference": [ 212 ], "between": [ 213 ], "Conclusions:": [ 216 ], "These": [ 217 ], "data": [ 218 ], "do": [ 219 ], "not": [ 220, 243 ], "support": [ 221 ], "an": [ 222 ], "activation": [ 227 ], "suggest": [ 235 ], "that": [ 236 ], "findings": [ 237 ], "previously": [ 238 ], "reported": [ 239 ], "may": [ 242 ], "apply": [ 244 ], "humans.": [ 246 ], "However,": [ 247 ], "long-term": [ 249 ], "consequences": [ 250 ], "subject": [ 258 ], "further": [ 260 ], "studies.": [ 261 ] }, "publication_date": "2011-01-05", "publication_year": 2011, "type": "article", "cited_by_count": 187, "authors": [ { "id": "https://openalex.org/A5039528393", "display_name": "L\u00e1szl\u00f3 Heged\u00fcs" }, { "id": "https://openalex.org/A5104132238", "display_name": "Alan C. Moses" }, { "id": "https://openalex.org/A5017200089", "display_name": "Milan Zdravkovi\u0107" }, { "id": "https://openalex.org/A5078992047", "display_name": "Tu Le Thi" }, { "id": "https://openalex.org/A5028469549", "display_name": "Gilbert H. Daniels" } ] }, { "id": "https://openalex.org/W2104818363", "doi": "https://doi.org/10.1016/j.jacc.2008.10.033", "title": "Exenatide Reduces Infarct Size and Improves Cardiac Function in a Porcine Model of Ischemia and Reperfusion Injury", "abstract": null, "publication_date": "2009-02-01", "publication_year": 2009, "type": "article", "cited_by_count": 462, "authors": [ { "id": "https://openalex.org/A5087781390", "display_name": "Leo Timmers" }, { "id": "https://openalex.org/A5001146356", "display_name": "Jos\u00e8 P.S. Henriques" }, { "id": "https://openalex.org/A5065971022", "display_name": "Dominique P.V. de Kleijn" }, { "id": "https://openalex.org/A5027649851", "display_name": "J. Hans DeVries" }, { "id": "https://openalex.org/A5023268881", "display_name": "Hans Kemperman" }, { "id": "https://openalex.org/A5074091229", "display_name": "Paul Steendijk" }, { "id": "https://openalex.org/A5109116374", "display_name": "Cees W.J. Verlaan" }, { "id": "https://openalex.org/A5080804656", "display_name": "Marjolein Kerver" }, { "id": "https://openalex.org/A5006701743", "display_name": "Jan J. Piek" }, { "id": "https://openalex.org/A5081338491", "display_name": "Pieter A. Doevendans" }, { "id": "https://openalex.org/A5038272951", "display_name": "Gerard Pasterkamp" }, { "id": "https://openalex.org/A5067234996", "display_name": "Imo E. Hoefer" } ] }, { "id": "https://openalex.org/W3208624876", "doi": "https://doi.org/10.3389/fendo.2021.738848", "title": "Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System", "abstract": { "Sodium-glucose": [ 0 ], "cotransporters": [ 1 ], "inhibitors": [ 2 ], "(SGLT2-i)": [ 3 ], "and": [ 4, 51, 75, 101, 134, 139, 176, 187, 230 ], "GLP-1": [ 5 ], "receptor": [ 6 ], "agonists": [ 7 ], "(GLP1-RA)": [ 8 ], "are": [ 9, 13, 144, 242 ], "glucose-lowering": [ 10 ], "drugs": [ 11 ], "that": [ 12, 85, 115 ], "proved": [ 14 ], "to": [ 15, 36, 66, 131, 150, 217, 233, 244 ], "reduce": [ 16 ], "the": [ 17, 30, 71, 94, 151, 159, 170 ], "cardiovascular": [ 18 ], "(CV)": [ 19 ], "risk": [ 20 ], "in": [ 21, 93, 106, 126, 147, 221 ], "type": [ 22 ], "2": [ 23 ], "diabetes": [ 24 ], "mellitus": [ 25 ], "(T2DM).": [ 26 ], "In": [ 27, 155, 226 ], "this": [ 28, 212, 246 ], "process,": [ 29 ], "renin-angiotensin-aldosterone": [ 31 ], "system": [ 32 ], "(RAAS)": [ 33 ], "is": [ 34, 79, 198 ], "assumed": [ 35 ], "play": [ 37 ], "a": [ 38 ], "role.": [ 39 ], "The": [ 40, 137 ], "inhibition": [ 41 ], "of": [ 42, 49, 97, 142, 161, 172 ], "SGLT2": [ 43 ], "improves": [ 44 ], "hyperglycemia": [ 45 ], "hampering": [ 46 ], "urinary": [ 47 ], "reabsorption": [ 48 ], "glucose": [ 50 ], "inducing": [ 52 ], "glycosuria.": [ 53 ], "This": [ 54 ], "\u201chybrid\u201d": [ 55 ], "diuretic": [ 56, 133 ], "effect,": [ 57 ], "which": [ 58, 197 ], "couples": [ 59 ], "natriuresis": [ 60, 192 ], "with": [ 61, 128, 153, 224 ], "osmotic": [ 62 ], "diuresis,": [ 63 ], "potentially": [ 64 ], "leads": [ 65 ], "systemic": [ 67, 76 ], "RAAS": [ 68, 77 ], "activation.": [ 69 ], "However,": [ 70 ], "association": [ 72 ], "between": [ 73 ], "SGLT2-i": [ 74, 86, 116, 229 ], "activation": [ 78 ], "not": [ 80, 215 ], "straightforward.": [ 81 ], "Available": [ 82 ], "data": [ 83 ], "indicate": [ 84 ], "cause": [ 87 ], "plasma": [ 88 ], "renin": [ 89 ], "activity": [ 90 ], "(PRA)": [ 91 ], "increase": [ 92 ], "early": [ 95 ], "phase": [ 96 ], "treatment,": [ 98 ], "while": [ 99 ], "PRA": [ 100 ], "aldosterone": [ 102 ], "levels": [ 103 ], "remain": [ 104 ], "unchanged": [ 105 ], "chronic": [ 107 ], "treated": [ 108, 223 ], "patients.": [ 109 ], "Furthermore,": [ 110, 189 ], "emerging": [ 111 ], "studies": [ 112, 241 ], "provide": [ 113 ], "evidence": [ 114 ], "might": [ 117 ], "have": [ 118, 234 ], "an": [ 119 ], "interfering": [ 120 ], "effect": [ 121, 213 ], "on": [ 122, 180, 237 ], "aldosterone/renin": [ 123 ], "ratio": [ 124 ], "(ARR)": [ 125 ], "patients": [ 127, 222 ], "T2DM,": [ 129 ], "due": [ 130 ], "their": [ 132 ], "sympathoinhibition": [ 135 ], "effects.": [ 136 ], "cardio-": [ 138 ], "reno-protective": [ 140 ], "effects": [ 141, 236 ], "GLP-1-RA": [ 143 ], "at": [ 145 ], "least": [ 146 ], "part": [ 148 ], "related": [ 149 ], "interaction": [ 152 ], "RAAS.": [ 154 ], "particular,": [ 156 ], "GLP1-RA": [ 157, 190, 231 ], "counteract": [ 158 ], "action": [ 160, 179 ], "angiotensin": [ 162 ], "II": [ 163 ], "(ANG": [ 164 ], "II)": [ 165 ], "inhibiting": [ 166, 193 ], "its": [ 167, 173, 178 ], "synthesis,": [ 168 ], "increasing": [ 169 ], "inactivation": [ 171 ], "circulating": [ 174, 209 ], "form": [ 175 ], "contrasting": [ 177 ], "target": [ 181 ], "tissue": [ 182 ], "like": [ 183 ], "glomerular": [ 184 ], "endothelial": [ 185 ], "cells": [ 186 ], "cardiomyocytes.": [ 188 ], "stimulate": [ 191 ], "Na+/H+": [ 194 ], "exchanger": [ 195 ], "NHE-3,": [ 196 ], "conversely": [ 199 ], "activated": [ 200 ], "by": [ 201 ], "ANG": [ 202 ], "II.": [ 203 ], "Moreover,": [ 204 ], "GLP1": [ 205 ], "infusion": [ 206 ], "acutely": [ 207 ], "reduces": [ 208 ], "aldosterone,": [ 210 ], "but": [ 211 ], "does": [ 214 ], "seem": [ 216, 232 ], "be": [ 218 ], "chronically": [ 219 ], "maintained": [ 220 ], "GLP1-RA.": [ 225 ], "conclusion,": [ 227 ], "both": [ 228 ], "several": [ 235 ], "RAAS,": [ 238 ], "though": [ 239 ], "additional": [ 240 ], "needed": [ 243 ], "clarify": [ 245 ], "relationship.": [ 247 ] }, "publication_date": "2021-10-21", "publication_year": 2021, "type": "review", "cited_by_count": 112, "authors": [ { "id": "https://openalex.org/A5053031594", "display_name": "Soraya Puglisi" }, { "id": "https://openalex.org/A5070667739", "display_name": "Alessandro Rossini" }, { "id": "https://openalex.org/A5083951598", "display_name": "Roberta Poli" }, { "id": "https://openalex.org/A5059929465", "display_name": "Francesca Dughera" }, { "id": "https://openalex.org/A5110243596", "display_name": "Anna Pia" }, { "id": "https://openalex.org/A5003946700", "display_name": "Massimo Terzolo" }, { "id": "https://openalex.org/A5037744319", "display_name": "Giuseppe Reimondo" } ] }, { "id": "https://openalex.org/W3042751537", "doi": "https://doi.org/10.1016/j.ahj.2020.07.008", "title": "Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design", "abstract": { "Cardiovascular": [ 0 ], "disease": [ 1 ], "(CVD)": [ 2 ], "is": [ 3, 19, 114, 149, 163, 192 ], "a": [ 4, 20, 120, 126, 150, 213 ], "major": [ 5, 21, 175, 202 ], "cause": [ 6 ], "of": [ 7, 36, 128, 171 ], "morbidity": [ 8 ], "and": [ 9, 33, 104, 140, 184 ], "mortality.": [ 10 ], "Although": [ 11 ], "it": [ 12 ], "has": [ 13, 52, 70, 218 ], "been": [ 14, 44, 53, 71 ], "widely": [ 15 ], "appreciated": [ 16 ], "that": [ 17, 27, 79 ], "obesity": [ 18, 123, 187 ], "risk": [ 22, 42, 50, 227 ], "factor": [ 23 ], "for": [ 24, 58, 122, 173, 207, 221 ], "CVD,": [ 25 ], "treatments": [ 26 ], "produce": [ 28 ], "effective,": [ 29 ], "durable": [ 30 ], "weight": [ 31, 37, 82 ], "loss": [ 32, 83 ], "the": [ 34, 193, 219 ], "impact": [ 35 ], "reduction": [ 38, 51, 206, 228 ], "in": [ 39, 48, 100, 115, 142, 179, 201, 211 ], "reducing": [ 40 ], "cardiovascular": [ 41, 87, 98, 177, 195, 204 ], "have": [ 43, 85, 106 ], "elusive.": [ 45 ], "Instead,": [ 46 ], "progress": [ 47 ], "CVD": [ 49, 183, 226 ], "achieved": [ 54 ], "through": [ 55 ], "medications": [ 56 ], "indicated": [ 57 ], "controlling": [ 59 ], "lipids,": [ 60 ], "hyperglycemia,": [ 61 ], "blood": [ 62 ], "pressure,": [ 63 ], "heart": [ 64 ], "failure,": [ 65 ], "inflammation,": [ 66 ], "and/or": [ 67 ], "thrombosis.": [ 68 ], "Obesity": [ 69, 147 ], "implicated": [ 72 ], "as": [ 73, 119 ], "promoting": [ 74 ], "all": [ 75 ], "these": [ 76 ], "issues,": [ 77 ], "suggesting": [ 78 ], "sustained,": [ 80 ], "effective": [ 81 ], "may": [ 84, 105 ], "independent": [ 86 ], "benefit.": [ 88 ], "GLP-1": [ 89, 111 ], "receptor": [ 90 ], "agonists": [ 91 ], "(RAs)": [ 92 ], "reduce": [ 93 ], "weight,": [ 94 ], "improve": [ 95 ], "glycemia,": [ 96 ], "decrease": [ 97 ], "events": [ 99, 178, 205 ], "those": [ 101 ], "with": [ 102, 144, 181 ], "diabetes,": [ 103 ], "additional": [ 107 ], "cardioprotective": [ 108 ], "effects.": [ 109 ], "The": [ 110 ], "RA": [ 112 ], "semaglutide": [ 113, 157 ], "phase": [ 116 ], "3": [ 117 ], "studies": [ 118 ], "medication": [ 121, 210 ], "treatment": [ 124 ], "at": [ 125 ], "dose": [ 127 ], "2.4": [ 129, 158 ], "mg": [ 130, 159 ], "subcutaneously": [ 131, 160 ], "(s.c.)": [ 132 ], "once": [ 133, 161 ], "weekly.": [ 134 ], "Semaglutide": [ 135 ], "Effects": [ 136 ], "on": [ 137 ], "Heart": [ 138 ], "Disease": [ 139 ], "Stroke": [ 141 ], "Patients": [ 143 ], "Overweight": [ 145 ], "or": [ 146, 186 ], "(SELECT)": [ 148 ], "randomized,": [ 151 ], "double-blind,": [ 152 ], "parallel-group": [ 153 ], "trial": [ 154, 197 ], "testing": [ 155 ], "if": [ 156 ], "weekly": [ 162 ], "superior": [ 164 ], "to": [ 165, 169, 198, 225 ], "placebo": [ 166 ], "when": [ 167 ], "added": [ 168 ], "standard": [ 170 ], "care": [ 172 ], "preventing": [ 174 ], "adverse": [ 176, 203 ], "patients": [ 180 ], "established": [ 182 ], "overweight": [ 185 ], "but": [ 188 ], "without": [ 189 ], "diabetes.": [ 190 ], "SELECT": [ 191, 217 ], "first": [ 194 ], "outcomes": [ 196 ], "evaluate": [ 199 ], "superiority": [ 200 ], "an": [ 208 ], "antiobesity": [ 209 ], "such": [ 212 ], "population.": [ 214 ], "As": [ 215 ], "such,": [ 216 ], "potential": [ 220 ], "advancing": [ 222 ], "new": [ 223 ], "approaches": [ 224 ], "while": [ 229 ], "targeting": [ 230 ], "obesity.": [ 231 ] }, "publication_date": "2020-07-17", "publication_year": 2020, "type": "article", "cited_by_count": 223, "authors": [ { "id": "https://openalex.org/A5088283488", "display_name": "Donna H. Ryan" }, { "id": "https://openalex.org/A5001655356", "display_name": "Ildiko Lingvay" }, { "id": "https://openalex.org/A5005414020", "display_name": "Helen M. Colhoun" }, { "id": "https://openalex.org/A5039316946", "display_name": "John Deanfield" }, { "id": "https://openalex.org/A5090993994", "display_name": "Scott S. Emerson" }, { "id": "https://openalex.org/A5066700951", "display_name": "Steven E. Kahn" }, { "id": "https://openalex.org/A5062192624", "display_name": "Robert F. Kushner" }, { "id": "https://openalex.org/A5113902966", "display_name": "Steve Marso" }, { "id": "https://openalex.org/A5051351787", "display_name": "Jorge Plutzky" }, { "id": "https://openalex.org/A5102890913", "display_name": "Kirstine Brown\u2010Frandsen" }, { "id": "https://openalex.org/A5042177250", "display_name": "Marianne O. L. Gronning" }, { "id": "https://openalex.org/A5004099465", "display_name": "G. Kees Hovingh" }, { "id": "https://openalex.org/A5015716676", "display_name": "Anders G. Holst" }, { "id": "https://openalex.org/A5101467428", "display_name": "Henrik Ravn" }, { "id": "https://openalex.org/A5001994412", "display_name": "A. Michael Lincoff" } ] }, { "id": "https://openalex.org/W2164416879", "doi": "https://doi.org/10.2337/dc06-2375", "title": "Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes", "abstract": { "OBJECTIVE\u2014In": [ 0 ], "patients": [ 1 ], "with": [ 2, 58, 67, 128, 132, 160, 187, 192, 228, 247, 266 ], "type": [ 3, 59, 272 ], "2": [ 4, 40, 60, 273 ], "diabetes,": [ 5 ], "exenatide": [ 6, 24, 42, 108, 156, 210, 248 ], "reduces": [ 7 ], "A1C,": [ 8 ], "postprandial": [ 9, 204 ], "and": [ 10, 13, 72, 96, 121, 147, 153, 179, 232, 263 ], "fasting": [ 11, 84 ], "glucose,": [ 12 ], "weight.": [ 14 ], "In": [ 15 ], "this": [ 16, 36 ], "study": [ 17 ], "we": [ 18 ], "investigated": [ 19 ], "the": [ 20, 233, 239, 252, 257 ], "effects": [ 21 ], "of": [ 22, 141, 149, 162, 259 ], "continuous": [ 23 ], "administration": [ 25 ], "from": [ 26, 251 ], "a": [ 27, 267 ], "long-acting": [ 28 ], "release": [ 29 ], "(LAR)": [ 30 ], "formulation.": [ 31 ], "RESEARCH": [ 32 ], "DESIGN": [ 33 ], "AND": [ 34 ], "METHODS\u2014In": [ 35 ], "randomized,": [ 37 ], "placebo-controlled": [ 38 ], "phase": [ 39 ], "study,": [ 41 ], "LAR": [ 43, 109, 134, 194, 201, 211, 231, 249, 255 ], "(0.8": [ 44, 119, 177 ], "or": [ 45 ], "2.0": [ 46, 154, 208 ], "mg)": [ 47, 120, 178, 185 ], "was": [ 48, 143, 170, 226, 238 ], "administered": [ 49 ], "subcutaneously": [ 50 ], "once": [ 51 ], "weekly": [ 52 ], "for": [ 53, 138, 198, 271 ], "15": [ 54 ], "weeks": [ 55 ], "to": [ 56, 105 ], "subjects": [ 57, 150, 163, 245 ], "diabetes": [ 61, 97 ], "(n": [ 62 ], "=": [ 63 ], "45)": [ 64 ], "suboptimally": [ 65 ], "controlled": [ 66 ], "metformin": [ 68 ], "(60%)": [ 69 ], "and/or": [ 70 ], "diet": [ 71 ], "exercise": [ 73 ], "(40%):": [ 74 ], "40%": [ 75 ], "female,": [ 76 ], "A1C": [ 77, 114, 140 ], "(mean": [ 78 ], "\u00b1": [ 79, 82, 88, 93, 100, 112, 117, 123, 130, 174, 181, 189, 217 ], "SD)": [ 80 ], "8.5": [ 81 ], "1.2%,": [ 83 ], "plasma": [ 85, 168 ], "glucose": [ 86, 169 ], "9.9": [ 87 ], "2.3": [ 89 ], "mmol/l,": [ 90 ], "weight": [ 91, 214, 225, 264 ], "106": [ 92 ], "20": [ 94 ], "kg,": [ 95 ], "duration": [ 98 ], "5": [ 99 ], "4": [ 101 ], "years.": [ 102 ], "RESULTS\u2014From": [ 103 ], "baseline": [ 104 ], "week": [ 106 ], "15,": [ 107 ], "reduced": [ 110, 171, 202 ], "mean": [ 111 ], "SE": [ 113 ], "by": [ 115, 145, 172 ], "\u22121.4": [ 116 ], "0.3%": [ 118, 124, 131 ], "\u22121.7": [ 122 ], "(2.0": [ 125, 184 ], "mg),": [ 126 ], "compared": [ 127, 159, 186 ], "+0.4": [ 129 ], "placebo": [ 133, 165, 193, 230 ], "(P": [ 135, 195, 220 ], "&lt;": [ 136, 196, 221 ], "0.0001": [ 137 ], "both).": [ 139, 199 ], "\u22647%": [ 142 ], "achieved": [ 144 ], "36": [ 146 ], "86%": [ 148 ], "receiving": [ 151, 164, 207 ], "0.8": [ 152 ], "mg": [ 155, 209 ], "LAR,": [ 157 ], "respectively,": [ 158 ], "0%": [ 161 ], "LAR.": [ 166 ], "Fasting": [ 167 ], "\u22122.4": [ 173 ], "0.9": [ 175 ], "mmol/l": [ 176, 183, 191 ], "\u22122.2": [ 180 ], "0.5": [ 182 ], "+1.0": [ 188 ], "0.7": [ 190 ], "0.001": [ 197 ], "Exenatide": [ 200 ], "self-monitored": [ 203 ], "hyperglycemia.": [ 205 ], "Subjects": [ 206 ], "had": [ 212 ], "body": [ 213, 224 ], "reductions": [ 215 ], "(\u22123.8": [ 216 ], "1.4": [ 218 ], "kg)": [ 219 ], "0.05),": [ 222 ], "whereas": [ 223 ], "unchanged": [ 227 ], "both": [ 229 ], "0.8-mg": [ 234 ], "dose.": [ 235 ], "Mild": [ 236 ], "nausea": [ 237 ], "most": [ 240 ], "frequent": [ 241 ], "adverse": [ 242 ], "event.": [ 243 ], "No": [ 244 ], "treated": [ 246 ], "withdrew": [ 250 ], "study.": [ 253 ], "CONCLUSIONS\u2014Exenatide": [ 254 ], "offers": [ 256 ], "potential": [ 258 ], "24-h": [ 260 ], "glycemic": [ 261 ], "control": [ 262 ], "reduction": [ 265 ], "novel": [ 268 ], "once-weekly": [ 269 ], "treatment": [ 270 ], "diabetes.": [ 274 ] }, "publication_date": "2007-05-25", "publication_year": 2007, "type": "article", "cited_by_count": 443, "authors": [ { "id": "https://openalex.org/A5007758632", "display_name": "Dennis Kim" }, { "id": "https://openalex.org/A5018272606", "display_name": "Leigh MacConell" }, { "id": "https://openalex.org/A5074705033", "display_name": "Dongliang Zhuang" }, { "id": "https://openalex.org/A5079794570", "display_name": "Prajakti A. Kothare" }, { "id": "https://openalex.org/A5062021087", "display_name": "Michael Trautmann" }, { "id": "https://openalex.org/A5083503351", "display_name": "Mark Fineman" }, { "id": "https://openalex.org/A5110734241", "display_name": "Kristin Taylor" } ] }, { "id": "https://openalex.org/W2824830902", "doi": "https://doi.org/10.1016/j.npep.2018.07.003", "title": "Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model", "abstract": null, "publication_date": "2018-07-11", "publication_year": 2018, "type": "article", "cited_by_count": 128, "authors": [ { "id": "https://openalex.org/A5100405781", "display_name": "Ping Zhang" }, { "id": "https://openalex.org/A5100758902", "display_name": "Lingyu Zhang" }, { "id": "https://openalex.org/A5100412926", "display_name": "Lin Li" }, { "id": "https://openalex.org/A5082707086", "display_name": "Christian H\u00f6lscher" } ] }, { "id": "https://openalex.org/W2038193252", "doi": "https://doi.org/10.1007/s11011-014-9591-7", "title": "GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats", "abstract": null, "publication_date": "2014-07-14", "publication_year": 2014, "type": "article", "cited_by_count": 62, "authors": [ { "id": "https://openalex.org/A5100867710", "display_name": "Ajaykumar N. Sharma" }, { "id": "https://openalex.org/A5029256093", "display_name": "Sagar S. Ligade" }, { "id": "https://openalex.org/A5003320777", "display_name": "Jay N. Sharma" }, { "id": "https://openalex.org/A5036475364", "display_name": "Praveen Shukla" }, { "id": "https://openalex.org/A5011146585", "display_name": "Khalid M. Elased" }, { "id": "https://openalex.org/A5058930507", "display_name": "James B. Lucot" } ] }, { "id": "https://openalex.org/W4401230453", "doi": "https://doi.org/10.1016/s2468-1253(24)00188-2", "title": "Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions", "abstract": null, "publication_date": "2024-08-01", "publication_year": 2024, "type": "review", "cited_by_count": 67, "authors": [ { "id": "https://openalex.org/A5072607848", "display_name": "Ryan J. Jalleh" }, { "id": "https://openalex.org/A5056037142", "display_name": "Christopher K. Rayner" }, { "id": "https://openalex.org/A5078839162", "display_name": "Trygve Hausken" }, { "id": "https://openalex.org/A5048913465", "display_name": "Karen L. Jones" }, { "id": "https://openalex.org/A5001729912", "display_name": "Michael Camilleri" }, { "id": "https://openalex.org/A5069463167", "display_name": "Michael Horowitz" } ] }, { "id": "https://openalex.org/W4389553854", "doi": "https://doi.org/10.1001/jamainternmed.2023.6663", "title": "Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy", "abstract": { "Importance": [ 0 ], "Increasing": [ 1 ], "use": [ 2, 32 ], "of": [ 3, 33, 45, 112, 142, 210, 314, 323, 333, 349 ], "second-line": [ 4, 34, 176, 315, 359 ], "noninsulin": [ 5, 35, 177, 316 ], "antidiabetic": [ 6 ], "medication": [ 7 ], "(ADM)": [ 8 ], "in": [ 9, 19, 50, 167, 190, 204, 214, 223, 329 ], "pregnant": [ 10 ], "individuals": [ 11 ], "with": [ 12, 42, 84, 229, 272 ], "type": [ 13 ], "2": [ 14, 128 ], "diabetes": [ 15 ], "(T2D)": [ 16 ], "may": [ 17 ], "result": [ 18 ], "fetal": [ 20 ], "exposure,": [ 21 ], "but": [ 22 ], "their": [ 23, 89 ], "teratogenic": [ 24 ], "risk": [ 25, 44, 348, 353 ], "is": [ 26, 40, 318, 367 ], "unknown.": [ 27 ], "Objective": [ 28 ], "To": [ 29 ], "evaluate": [ 30 ], "periconceptional": [ 31 ], "ADMs": [ 36, 178, 317 ], "and": [ 37, 55, 74, 88, 125, 147, 152, 170, 184, 194, 197, 235, 265, 291, 306, 311, 325, 369 ], "whether": [ 38 ], "it": [ 39 ], "associated": [ 41 ], "increased": [ 43, 198, 347 ], "major": [ 46 ], "congenital": [ 47 ], "malformations": [ 48 ], "(MCMs)": [ 49 ], "the": [ 51, 69, 75, 191, 200, 205, 224, 352 ], "infant.": [ 52 ], "Design,": [ 53 ], "Setting,": [ 54 ], "Participants": [ 56 ], "This": [ 57 ], "observational": [ 58 ], "population-based": [ 59 ], "cohort": [ 60, 169 ], "study": [ 61, 201 ], "used": [ 62 ], "data": [ 63, 378 ], "from": [ 64, 135, 364 ], "4": [ 65, 116 ], "Nordic": [ 66 ], "countries": [ 67, 181 ], "(2009-2020),": [ 68 ], "US": [ 70 ], "MarketScan": [ 71 ], "Database": [ 72 ], "(2012-2021),": [ 73 ], "Israeli": [ 76 ], "Maccabi": [ 77 ], "Health": [ 78 ], "Services": [ 79 ], "database": [ 80 ], "(2009-2020).": [ 81 ], "Pregnant": [ 82 ], "women": [ 83, 228 ], "T2D": [ 85, 230, 324, 357 ], "were": [ 86, 92, 157, 278, 339 ], "identified": [ 87 ], "live-born": [ 90 ], "infants": [ 91, 216, 225, 237, 297 ], "followed": [ 93 ], "until": [ 94 ], "up": [ 95 ], "to": [ 96, 140, 175, 227, 239, 299 ], "1": [ 97, 107, 121 ], "year": [ 98 ], "after": [ 99 ], "birth.": [ 100 ], "Exposure": [ 101 ], "Periconceptional": [ 102, 173 ], "exposure": [ 103, 174 ], "was": [ 104, 212, 241 ], "defined": [ 105 ], "as": [ 106, 377 ], "or": [ 108, 131 ], "more": [ 109, 374 ], "prescription": [ 110 ], "fill": [ 111 ], "sulfonylureas,": [ 113, 300 ], "dipeptidyl": [ 114 ], "peptidase": [ 115 ], "(DPP-4)": [ 117 ], "inhibitors,": [ 118, 130, 247, 260, 302, 308 ], "glucagon-like": [ 119 ], "peptide": [ 120 ], "(GLP-1)": [ 122 ], "receptor": [ 123, 253, 304 ], "agonists,": [ 124, 254, 305 ], "sodium-glucose": [ 126 ], "cotransporter": [ 127 ], "(SGLT2)": [ 129 ], "insulin": [ 132 ], "(active": [ 133 ], "comparator)": [ 134 ], "90": [ 136 ], "days": [ 137 ], "before": [ 138 ], "pregnancy": [ 139 ], "end": [ 141 ], "first": [ 143 ], "trimester.": [ 144 ], "Main": [ 145 ], "Outcomes": [ 146 ], "Measures": [ 148 ], "Relative": [ 149 ], "risks": [ 150 ], "(RRs)": [ 151 ], "95%": [ 153 ], "CIs": [ 154 ], "for": [ 155, 164, 276, 296, 321 ], "MCMs": [ 156, 211, 277, 350 ], "estimated": [ 158 ], "using": [ 159 ], "log-binomial": [ 160 ], "regression": [ 161 ], "models,": [ 162 ], "adjusting": [ 163 ], "key": [ 165 ], "confounders": [ 166 ], "each": [ 168 ], "meta-analyzed.": [ 171 ], "Results": [ 172 ], "differed": [ 179 ], "between": [ 180 ], "(32,": [ 182 ], "295,": [ 183 ], "73": [ 185 ], "per": [ 186 ], "100": [ 187 ], "000": [ 188 ], "pregnancies": [ 189 ], "Nordics,": [ 192 ], "US,": [ 193 ], "Israel,": [ 195 ], "respectively),": [ 196 ], "over": [ 199 ], "period,": [ 202 ], "especially": [ 203 ], "US.": [ 206 ], "The": [ 207 ], "standardized": [ 208 ], "prevalence": [ 209 ], "3.7%": [ 213 ], "all": [ 215 ], "(n": [ 217, 231, 243, 249, 256, 262, 268 ], "=": [ 218, 232, 244, 250, 257, 263, 269 ], "3": [ 219 ], "514": [ 220 ], "865),": [ 221 ], "5.3%": [ 222 ], "born": [ 226 ], "51": [ 233 ], "826),": [ 234 ], "among": [ 236 ], "exposed": [ 238, 298, 334 ], "sulfonylureas": [ 240 ], "9.7%": [ 242 ], "1362);": [ 245 ], "DPP-4": [ 246, 301 ], "6.1%": [ 248 ], "687);": [ 251 ], "GLP-1": [ 252, 303 ], "8.3%": [ 255 ], "938);": [ 258 ], "SGLT2": [ 259, 307 ], "7.0%": [ 261 ], "335);": [ 264 ], "insulin,": [ 266, 273 ], "7.8%": [ 267 ], "5078).": [ 270 ], "Compared": [ 271 ], "adjusted": [ 274 ], "RRs": [ 275 ], "1.18": [ 279 ], "(95%": [ 280, 284, 288, 293 ], "CI,": [ 281, 285, 289, 294 ], "0.94-1.48),": [ 282 ], "0.83": [ 283 ], "0.64-1.06),": [ 286 ], "0.95": [ 287 ], "0.72-1.26),": [ 290 ], "0.98": [ 292 ], "0.65-1.46)": [ 295 ], "respectively.": [ 309 ], "Conclusions": [ 310 ], "Relevance": [ 312 ], "Use": [ 313 ], "rapidly": [ 319 ], "increasing": [ 320, 331 ], "treatment": [ 322 ], "other": [ 326, 365 ], "indications,": [ 327 ], "resulting": [ 328 ], "an": [ 330 ], "number": [ 332 ], "pregnancies.": [ 335 ], "Although": [ 336, 361 ], "some": [ 337 ], "estimates": [ 338, 376 ], "imprecise,": [ 340 ], "results": [ 341 ], "did": [ 342 ], "not": [ 343 ], "indicate": [ 344 ], "a": [ 345 ], "large": [ 346 ], "above": [ 351 ], "conferred": [ 354 ], "by": [ 355 ], "maternal": [ 356 ], "requiring": [ 358 ], "treatment.": [ 360 ], "reassuring,": [ 362 ], "confirmation": [ 363 ], "studies": [ 366 ], "needed,": [ 368 ], "continuous": [ 370 ], "monitoring": [ 371 ], "will": [ 372 ], "provide": [ 373 ], "precise": [ 375 ], "accumulate.": [ 379 ] }, "publication_date": "2023-12-11", "publication_year": 2023, "type": "article", "cited_by_count": 103, "authors": [ { "id": "https://openalex.org/A5078909355", "display_name": "Carolyn E. Cesta" }, { "id": "https://openalex.org/A5091526885", "display_name": "Ran S. Rotem" }, { "id": "https://openalex.org/A5034554999", "display_name": "Brian T. Bateman" }, { "id": "https://openalex.org/A5110497360", "display_name": "Gabriel Chodick" }, { "id": "https://openalex.org/A5061744288", "display_name": "Jacqueline M. Cohen" }, { "id": "https://openalex.org/A5044865490", "display_name": "Kari Furu" }, { "id": "https://openalex.org/A5044713639", "display_name": "Mika Gissler" }, { "id": "https://openalex.org/A5024775911", "display_name": "Krista F. Huybrechts" }, { "id": "https://openalex.org/A5009346714", "display_name": "Lars J. Kjerpeseth" }, { "id": "https://openalex.org/A5071210488", "display_name": "Maarit K. Leinonen" }, { "id": "https://openalex.org/A5063723476", "display_name": "Laura Pazzagli" }, { "id": "https://openalex.org/A5086208075", "display_name": "Helga Zo\u00ebga" }, { "id": "https://openalex.org/A5030601213", "display_name": "Ellen W. Seely" }, { "id": "https://openalex.org/A5044474781", "display_name": "Elisabetta Patorno" }, { "id": "https://openalex.org/A5006217491", "display_name": "Sonia Hern\u00e1ndez\u2013D\u0131\u0301az" } ] }, { "id": "https://openalex.org/W4315490546", "doi": "https://doi.org/10.1016/j.ando.2022.12.423", "title": "Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes", "abstract": null, "publication_date": "2023-01-10", "publication_year": 2023, "type": "review", "cited_by_count": 51, "authors": [ { "id": "https://openalex.org/A5039563874", "display_name": "Andr\u00e9 Scheen" } ] }, { "id": "https://openalex.org/W2519618698", "doi": "https://doi.org/10.1038/srep33251", "title": "Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment", "abstract": { "Abstract": [ 0 ], "The": [ 1, 14, 69 ], "mechanisms": [ 2 ], "underlying": [ 3 ], "the": [ 4, 21, 28, 31, 79, 83, 89, 136, 146, 181, 184 ], "weight-loss": [ 5 ], "effect": [ 6 ], "of": [ 7, 23, 30, 53, 56, 82, 92, 138, 148, 183 ], "GLP-1": [ 8, 175 ], "receptor": [ 9, 176 ], "agonists": [ 10 ], "need": [ 11 ], "further": [ 12 ], "elucidation.": [ 13 ], "present": [ 15 ], "study": [ 16 ], "was": [ 17, 58, 140, 194 ], "performed": [ 18 ], "to": [ 19, 103, 188 ], "explore": [ 20 ], "effects": [ 22 ], "liraglutide": [ 24, 41, 139, 178 ], "and": [ 25, 50, 119 ], "saxagliptin": [ 26, 39 ], "on": [ 27 ], "composition": [ 29, 182 ], "gut": [ 32, 84, 185 ], "microbiota.": [ 33 ], "Mice": [ 34 ], "were": [ 35, 48 ], "randomly": [ 36 ], "treated": [ 37 ], "with": [ 38, 116, 133, 145, 196 ], "or": [ 40 ], "for": [ 42 ], "eight": [ 43 ], "weeks.": [ 44 ], "Their": [ 45 ], "metabolic": [ 46 ], "profiles": [ 47 ], "assessed,": [ 49 ], "454": [ 51 ], "pyrosequencing": [ 52, 70 ], "16s": [ 54 ], "rRNA": [ 55 ], "faeces": [ 57 ], "performed.": [ 59 ], "Liraglutide": [ 60 ], "induced": [ 61 ], "a": [ 62, 189 ], "smaller": [ 63 ], "body": [ 64, 117, 134 ], "weight": [ 65 ], "gain": [ 66 ], "in": [ 67, 101, 112, 129, 157, 167 ], "mice.": [ 68 ], "showed": [ 71 ], "that": [ 72, 174, 193 ], "liraglutide,": [ 73 ], "but": [ 74 ], "not": [ 75 ], "saxagliptin,": [ 76 ], "substantially": [ 77 ], "changed": [ 78 ], "overall": [ 80 ], "structure": [ 81 ], "microbiota": [ 85 ], "as": [ 86, 88 ], "well": [ 87 ], "relative": [ 90 ], "abundance": [ 91, 147 ], "weight-relevant": [ 93, 149 ], "phylotypes.": [ 94 ], "Subsequent": [ 95 ], "ridge": [ 96 ], "regression": [ 97 ], "analyses": [ 98 ], "indicated": [ 99 ], "that,": [ 100 ], "addition": [ 102 ], "food": [ 104 ], "intake": [ 105 ], "(\u03b2": [ 106, 123, 151 ], "=": [ 107, 110, 124, 127, 152, 155, 162, 165 ], "\u22120.182,": [ 108 ], "p": [ 109, 126, 154, 164 ], "0.043": [ 111 ], "phylotypes": [ 113, 130, 150 ], "inversely": [ 114, 158 ], "correlated": [ 115, 132, 159, 169 ], "weight)": [ 118 ], "blood": [ 120 ], "glucose": [ 121 ], "level": [ 122 ], "\u22120.240,": [ 125 ], "0.039": [ 128 ], "positively": [ 131, 168 ], "weight),": [ 135 ], "administration": [ 137 ], "another": [ 141 ], "independent": [ 142 ], "factor": [ 143 ], "associated": [ 144 ], "0.389,": [ 153 ], "6.24e-5": [ 156 ], "ones;": [ 160 ], "\u03b2": [ 161 ], "\u22120.508,": [ 163 ], "2.25e-5": [ 166 ], "ones).": [ 170 ], "These": [ 171 ], "results": [ 172 ], "evidenced": [ 173 ], "agonist": [ 177 ], "could": [ 179 ], "modulate": [ 180 ], "microbiota,": [ 186 ], "leading": [ 187 ], "more": [ 190 ], "lean-related": [ 191 ], "profile": [ 192 ], "consistent": [ 195 ], "its": [ 197 ], "weight-losing": [ 198 ], "effect.": [ 199 ] }, "publication_date": "2016-09-16", "publication_year": 2016, "type": "article", "cited_by_count": 149, "authors": [ { "id": "https://openalex.org/A5100403121", "display_name": "Lin Wang" }, { "id": "https://openalex.org/A5017535182", "display_name": "Peicheng Li" }, { "id": "https://openalex.org/A5019684293", "display_name": "Zhaosheng Tang" }, { "id": "https://openalex.org/A5103144710", "display_name": "Xinfeng Yan" }, { "id": "https://openalex.org/A5100650895", "display_name": "Bo Feng" } ] }, { "id": "https://openalex.org/W2307508267", "doi": "https://doi.org/10.1038/ijo.2016.52", "title": "Effect of liraglutide 3.0\u2009mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial", "abstract": { "As": [ 0 ], "an": [ 1 ], "adjunct": [ 2 ], "to": [ 3 ], "diet": [ 4 ], "and": [ 5, 14, 26, 32 ], "exercise,": [ 6 ], "liraglutide": [ 7 ], "3.0": [ 8 ], "mg": [ 9 ], "was": [ 10 ], "generally": [ 11 ], "well": [ 12 ], "tolerated": [ 13 ], "produced": [ 15 ], "significantly": [ 16 ], "greater": [ 17 ], "reductions": [ 18 ], "than": [ 19 ], "placebo": [ 20 ], "in": [ 21, 28 ], "AHI,": [ 22 ], "body": [ 23 ], "weight,": [ 24 ], "SBP": [ 25 ], "HbA1c": [ 27 ], "participants": [ 29 ], "with": [ 30 ], "obesity": [ 31 ], "moderate/severe": [ 33 ], "OSA.": [ 34 ], "The": [ 35 ], "results": [ 36 ], "confirm": [ 37 ], "that": [ 38 ], "weight": [ 39 ], "loss": [ 40 ], "improves": [ 41 ], "OSA-related": [ 42 ], "parameters.": [ 43 ] }, "publication_date": "2016-03-23", "publication_year": 2016, "type": "article", "cited_by_count": 464, "authors": [ { "id": "https://openalex.org/A5008844555", "display_name": "Adam Blackman" }, { "id": "https://openalex.org/A5053620348", "display_name": "Gary D. Foster" }, { "id": "https://openalex.org/A5060017251", "display_name": "Gary Zammit" }, { "id": "https://openalex.org/A5082868877", "display_name": "Russell Rosenberg" }, { "id": "https://openalex.org/A5051043505", "display_name": "Louis J. Aronne" }, { "id": "https://openalex.org/A5026596594", "display_name": "Thomas A. Wadden" }, { "id": "https://openalex.org/A5110454964", "display_name": "Birgitte Claudius" }, { "id": "https://openalex.org/A5078072521", "display_name": "Camilla Jensen" }, { "id": "https://openalex.org/A5073040042", "display_name": "Emmanuel Mignot" } ] }, { "id": "https://openalex.org/W2108122035", "doi": "https://doi.org/10.2337/dc11-1935", "title": "Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy", "abstract": { "OBJECTIVE": [ 0 ], "To": [ 1 ], "assess": [ 2 ], "efficacy": [ 3 ], "and": [ 4, 52, 66, 139, 148, 165, 225, 260, 263 ], "safety": [ 5 ], "of": [ 6, 21, 33, 160, 223, 227 ], "lixisenatide": [ 7, 40, 59, 103, 130, 186, 224, 244 ], "monotherapy": [ 8, 245 ], "in": [ 9, 110, 178, 184, 192, 199, 221, 257, 266 ], "type": [ 10, 267 ], "2": [ 11, 64, 268 ], "diabetes.": [ 12, 269 ], "RESEARCH": [ 13 ], "DESIGN": [ 14 ], "AND": [ 15 ], "METHODS": [ 16 ], "Randomized,": [ 17 ], "double-blind,": [ 18 ], "12-week": [ 19 ], "study": [ 20 ], "361": [ 22 ], "patients": [ 23, 131 ], "not": [ 24 ], "on": [ 25 ], "glucose-lowering": [ 26 ], "therapy": [ 27 ], "(HbA1c": [ 28 ], "7\u201310%)": [ 29 ], "allocated": [ 30 ], "to": [ 31, 98, 156 ], "one": [ 32 ], "four": [ 34 ], "once-daily": [ 35 ], "subcutaneous": [ 36 ], "dose": [ 37, 240 ], "increase": [ 38 ], "regimens:": [ 39 ], "2-step": [ 41, 74 ], "(10": [ 42, 61 ], "\u03bcg": [ 43, 48, 62 ], "for": [ 44, 49, 63, 88, 120, 123, 237 ], "1": [ 45, 50 ], "week,": [ 46, 51 ], "15": [ 47 ], "then": [ 53, 67 ], "20": [ 54, 68 ], "\u03bcg;": [ 55, 69 ], "n": [ 56, 70 ], "=": [ 57, 71, 76, 82 ], "120),": [ 58 ], "1-step": [ 60, 80 ], "weeks": [ 65 ], "119),": [ 72 ], "placebo": [ 73, 79, 146, 216, 228 ], "(n": [ 75, 81 ], "61),": [ 77 ], "or": [ 78 ], "61)": [ 83 ], "(placebo": [ 84 ], "groups": [ 85, 112, 187 ], "were": [ 86, 197, 207 ], "combined": [ 87 ], "analyses).": [ 89 ], "Primary": [ 90 ], "end": [ 91 ], "point": [ 92 ], "was": [ 93, 182, 209, 235, 261 ], "HbA1c": [ 94, 106, 133 ], "change": [ 95, 116 ], "from": [ 96 ], "baseline": [ 97, 108 ], "week": [ 99 ], "12.": [ 100 ], "RESULTS": [ 101 ], "Once-daily": [ 102, 243 ], "significantly": [ 104, 246 ], "improved": [ 105, 247 ], "(mean": [ 107 ], "8.0%)": [ 109 ], "both": [ 111, 185 ], "(least": [ 113 ], "squares": [ 114 ], "mean": [ 115 ], "vs.": [ 117 ], "placebo:": [ 118 ], "\u22120.54%": [ 119 ], "2-step,": [ 121, 136, 142 ], "\u22120.66%": [ 122 ], "1-step;": [ 124 ], "P": [ 125, 151 ], "&lt;": [ 126, 152 ], "0.0001).": [ 127 ], "Significantly": [ 128 ], "more": [ 129 ], "achieved": [ 132 ], "&lt;7.0%": [ 134 ], "(52.2%": [ 135 ], "46.5%": [ 137 ], "1-step)": [ 138, 144 ], "\u22646.5%": [ 140 ], "(31.9%": [ 141 ], "25.4%": [ 143 ], "versus": [ 145, 188 ], "(26.8%": [ 147 ], "12.5%,": [ 149 ], "respectively;": [ 150 ], "0.01).": [ 153 ], "Lixisenatide": [ 154 ], "led": [ 155 ], "marked": [ 157 ], "significant": [ 158, 176 ], "improvements": [ 159 ], "2-h": [ 161 ], "postprandial": [ 162, 253 ], "glucose": [ 163, 167, 181, 258 ], "levels": [ 164 ], "blood": [ 166 ], "excursions": [ 168 ], "measured": [ 169 ], "during": [ 170 ], "a": [ 171, 251 ], "standardized": [ 172 ], "breakfast": [ 173 ], "test.": [ 174 ], "A": [ 175 ], "decrease": [ 177 ], "fasting": [ 179 ], "plasma": [ 180 ], "observed": [ 183, 198 ], "placebo.": [ 189 ], "Mean": [ 190 ], "decreases": [ 191 ], "body": [ 193 ], "weight": [ 194 ], "(\u223c2": [ 195 ], "kg)": [ 196 ], "all": [ 200 ], "groups.": [ 201 ], "The": [ 202 ], "most": [ 203, 211 ], "common": [ 204 ], "adverse": [ 205 ], "events": [ 206 ], "gastrointestinal\u2014nausea": [ 208 ], "the": [ 210, 238 ], "frequent": [ 212 ], "(lixisenatide": [ 213 ], "23%": [ 214 ], "overall,": [ 215 ], "4.1%).": [ 217 ], "Symptomatic": [ 218 ], "hypoglycemia": [ 219 ], "occurred": [ 220 ], "1.7%": [ 222 ], "1.6%": [ 226 ], "patients,": [ 229 ], "with": [ 230, 250 ], "no": [ 231 ], "severe": [ 232 ], "episodes.": [ 233 ], "Safety/tolerability": [ 234 ], "similar": [ 236 ], "two": [ 239 ], "regimens.": [ 241 ], "CONCLUSIONS": [ 242 ], "glycemic": [ 248 ], "control": [ 249 ], "pronounced": [ 252 ], "effect": [ 254 ], "(75%": [ 255 ], "reduction": [ 256 ], "excursion)": [ 259 ], "safe": [ 262 ], "well": [ 264 ], "tolerated": [ 265 ] }, "publication_date": "2012-03-20", "publication_year": 2012, "type": "article", "cited_by_count": 217, "authors": [ { "id": "https://openalex.org/A5034671525", "display_name": "Vivian Fonseca" }, { "id": "https://openalex.org/A5086863208", "display_name": "Ricardo Alvarado-Ruiz" }, { "id": "https://openalex.org/A5012472100", "display_name": "D. Raccah" }, { "id": "https://openalex.org/A5111927290", "display_name": "Gabor Boka" }, { "id": "https://openalex.org/A5074845584", "display_name": "P. Miossec" }, { "id": "https://openalex.org/A5114012252", "display_name": "John E. Gerich" } ] }, { "id": "https://openalex.org/W2158778171", "doi": "https://doi.org/10.1186/1475-2840-10-22", "title": "Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes", "abstract": { "Abstract": [ 0 ], "It": [ 1 ], "is": [ 2 ], "important": [ 3 ], "for": [ 4, 8, 35, 93 ], "patients": [ 5, 39, 114, 246, 262 ], "that": [ 6, 159, 243, 245 ], "treatments": [ 7 ], "diabetes": [ 9, 43, 105 ], "not": [ 10, 44, 165, 181 ], "increase": [ 11, 166 ], "cardiovascular": [ 12, 274 ], "(CV)": [ 13 ], "risk.": [ 14 ], "The": [ 15, 141, 224 ], "objective": [ 16 ], "of": [ 17, 27, 62, 104, 117, 194, 208, 214, 226, 233, 238 ], "this": [ 18, 169 ], "analysis": [ 19, 237 ], "was": [ 20, 54, 171 ], "to": [ 21, 56, 183, 200, 255 ], "examine": [ 22 ], "retrospectively": [ 23, 190 ], "the": [ 24, 58, 152, 178, 205, 211 ], "CV": [ 25, 63, 126, 167, 185, 209, 258 ], "safety": [ 26, 275 ], "exenatide": [ 28, 66, 160, 249 ], "BID,": [ 29 ], "a": [ 30, 69, 192, 219, 234, 239, 257 ], "GLP-1": [ 31, 270 ], "receptor": [ 32, 271 ], "agonist": [ 33 ], "approved": [ 34 ], "treating": [ 36 ], "hyperglycemia": [ 37 ], "in": [ 38 ], "with": [ 40, 47, 65, 75, 115, 231, 248, 264 ], "type": [ 41 ], "2": [ 42, 100 ], "adequately": [ 45 ], "controlled": [ 46 ], "diet": [ 48 ], "and": [ 49, 102, 138, 218 ], "exercise.": [ 50 ], "Individual": [ 51 ], "participant": [ 52 ], "data": [ 53 ], "pooled": [ 55, 70 ], "assess": [ 57, 184 ], "relative": [ 59 ], "risk": [ 60 ], "(RR)": [ 61 ], "events": [ 64, 127, 187 ], "BID": [ 67 ], "versus": [ 68 ], "comparator": [ 71, 222 ], "(PC)": [ 72 ], "group": [ 73 ], "treated": [ 74, 247, 263 ], "either": [ 76 ], "placebo": [ 77 ], "or": [ 78 ], "insulin": [ 79 ], "from": [ 80, 87, 191 ], "12": [ 81 ], "controlled,": [ 82 ], "randomized,": [ 83 ], "clinical": [ 84 ], "trials": [ 85, 179, 215 ], "ranging": [ 86 ], "12-52": [ 88 ], "weeks.": [ 89 ], "Mean": [ 90 ], "baseline": [ 91 ], "values": [ 92 ], "HbA": [ 94 ], "1c": [ 95 ], "(8.33-8.38%),": [ 96 ], "BMI": [ 97 ], "(31.3-31.5": [ 98 ], "kg/m": [ 99 ], "),": [ 101 ], "duration": [ 103, 213 ], "(8": [ 106 ], "y)": [ 107 ], "were": [ 108, 180, 188, 252, 261 ], "similar": [ 109 ], "between": [ 110 ], "groups.": [ 111 ], "Trials": [ 112 ], "included": [ 113, 129, 204 ], "histories": [ 116 ], "microvascular": [ 118 ], "and/or": [ 119 ], "macrovascular": [ 120 ], "disease.": [ 121 ], "Customized": [ 122 ], "primary": [ 123 ], "major": [ 124 ], "adverse": [ 125 ], "(MACE)": [ 128 ], "stroke,": [ 130 ], "myocardial": [ 131 ], "infarction,": [ 132 ], "cardiac": [ 133 ], "mortality,": [ 134 ], "acute": [ 135 ], "coronary": [ 136 ], "syndrome,": [ 137 ], "revascularization": [ 139 ], "procedures.": [ 140 ], "Primary": [ 142 ], "MACE": [ 143 ], "RR": [ 144 ], "(0.7;": [ 145 ], "95%": [ 146 ], "CI": [ 147 ], "0.38,": [ 148 ], "1.31),": [ 149 ], "calculated": [ 150 ], "by": [ 151, 156, 197 ], "Mantel-Haenszel": [ 153 ], "method": [ 154 ], "(stratified": [ 155 ], "study),": [ 157 ], "suggested": [ 158 ], "use": [ 161 ], "(vs.": [ 162 ], "PC)": [ 163 ], "did": [ 164 ], "risk;": [ 168 ], "result": [ 170 ], "consistent": [ 172, 230 ], "across": [ 173 ], "multiple": [ 174 ], "analytic": [ 175 ], "methods.": [ 176 ], "Because": [ 177 ], "designed": [ 182 ], "outcomes,": [ 186 ], "identified": [ 189 ], "list": [ 193 ], "preferred": [ 195 ], "terms": [ 196 ], "physicians": [ 198 ], "blinded": [ 199 ], "treatment.": [ 201 ], "Other": [ 202 ], "limitations": [ 203 ], "low": [ 206 ], "number": [ 207 ], "events,": [ 210 ], "short": [ 212 ], "(\u22641": [ 216 ], "y),": [ 217 ], "single": [ 220 ], "active": [ 221 ], "(insulin).": [ 223 ], "results": [ 225 ], "these": [ 227 ], "analyses": [ 228 ], "are": [ 229 ], "those": [ 232 ], "recent": [ 235 ], "retrospective": [ 236 ], "large": [ 240 ], "insurance": [ 241 ], "database": [ 242 ], "found": [ 244 ], "twice": [ 250 ], "daily": [ 251 ], "less": [ 253 ], "likely": [ 254 ], "have": [ 256 ], "event": [ 259 ], "than": [ 260 ], "other": [ 265 ], "glucose-lowering": [ 266 ], "therapies.": [ 267 ], "Keywords": [ 268 ], ":": [ 269 ], "agonist,": [ 272 ], "diabetes,": [ 273 ] }, "publication_date": "2011-03-16", "publication_year": 2011, "type": "review", "cited_by_count": 152, "authors": [ { "id": "https://openalex.org/A5081205041", "display_name": "Robert E. Ratner" }, { "id": "https://openalex.org/A5111694431", "display_name": "Jenny Han" }, { "id": "https://openalex.org/A5036735551", "display_name": "Dawn Nicewarner" }, { "id": "https://openalex.org/A5000166921", "display_name": "Irina Yushmanova" }, { "id": "https://openalex.org/A5058778822", "display_name": "Byron J. Hoogwerf" }, { "id": "https://openalex.org/A5113725447", "display_name": "Larry Z. Shen" } ] }, { "id": "https://openalex.org/W2518652627", "doi": "https://doi.org/10.2337/dc16-1371", "title": "Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial", "abstract": { "OBJECTIVE": [ 0 ], "To": [ 1 ], "investigate": [ 2 ], "effects": [ 3 ], "of": [ 4, 26, 127, 283 ], "dipeptidyl": [ 5 ], "peptidase-4": [ 6 ], "inhibitor": [ 7 ], "(DPP-4I)": [ 8 ], "sitagliptin": [ 9, 90, 182, 243, 255 ], "or": [ 10, 96, 194, 256, 270 ], "glucagon-like": [ 11 ], "peptide": [ 12 ], "1": [ 13 ], "(GLP-1)": [ 14 ], "receptor": [ 15 ], "agonist": [ 16 ], "liraglutide": [ 17, 93, 195, 257 ], "treatment": [ 18, 253 ], "on": [ 19 ], "renal": [ 20, 27, 105, 135, 224, 262, 273 ], "hemodynamics,": [ 21 ], "tubular": [ 22, 268 ], "functions,": [ 23 ], "and": [ 24, 103, 113, 124, 131, 134, 143, 154, 163, 167, 227, 246, 280 ], "markers": [ 25, 137, 275 ], "damage": [ 28, 136, 225, 274 ], "in": [ 29, 267, 272 ], "overweight": [ 30 ], "patients": [ 31, 53 ], "with": [ 32, 54, 206, 254 ], "type": [ 33, 55 ], "2": [ 34, 56, 162 ], "diabetes": [ 35, 57 ], "without": [ 36 ], "chronic": [ 37 ], "kidney": [ 38, 144 ], "disease": [ 39 ], "(CKD).": [ 40 ], "RESEARCH": [ 41 ], "DESIGN": [ 42 ], "AND": [ 43 ], "METHODS": [ 44 ], "In": [ 45 ], "this": [ 46 ], "12-week,": [ 47 ], "randomized,": [ 48 ], "double-blind": [ 49 ], "trial,": [ 50 ], "55": [ 51 ], "insulin-na\u00efve": [ 52 ], "(mean": [ 58 ], "\u00b1": [ 59, 63, 68, 76 ], "SEM:": [ 60 ], "age": [ 61 ], "63": [ 62 ], "7": [ 64 ], "years,": [ 65 ], "BMI": [ 66 ], "31.8": [ 67 ], "4.1": [ 69 ], "kg/m2,": [ 70 ], "glomerular": [ 71, 212 ], "filtration": [ 72 ], "rate": [ 73 ], "[GFR]": [ 74 ], "83": [ 75 ], "16": [ 77 ], "mL/min/1.73": [ 78, 184, 197 ], "m2;": [ 79 ], "median": [ 80 ], "[interquartile": [ 81 ], "range]:": [ 82 ], "albumin-to-creatinine": [ 83 ], "ratio": [ 84 ], "(ACR)": [ 85 ], "1.09": [ 86 ], "mg/mmol": [ 87 ], "[0.47\u20133.31])": [ 88 ], "received": [ 89 ], "(100": [ 91 ], "mg/day),": [ 92, 95 ], "(1.8": [ 94 ], "matching": [ 97 ], "placebos.": [ 98 ], "GFR": [ 99, 166, 177 ], "(primary": [ 100 ], "end": [ 101 ], "point)": [ 102 ], "effective": [ 104 ], "plasma": [ 106 ], "flow": [ 107 ], "(ERPF)": [ 108 ], "were": [ 109, 121, 148, 158, 171, 276 ], "determined": [ 110 ], "by": [ 111, 181 ], "inulin": [ 112 ], "para-aminohippuric": [ 114 ], "acid": [ 115 ], "clearance,": [ 116 ], "respectively.": [ 117 ], "Intrarenal": [ 118 ], "hemodynamic": [ 119, 222 ], "variables": [ 120 ], "estimated.": [ 122 ], "Absolute": [ 123 ], "fractional": [ 125, 168 ], "excretions": [ 126, 170 ], "sodium": [ 128 ], "(FENa),": [ 129 ], "potassium,": [ 130 ], "urea": [ 132 ], "(FEU)": [ 133 ], "(ACR,": [ 138 ], "neutrophil": [ 139 ], "gelatinase\u2013associated": [ 140 ], "lipocalin": [ 141 ], "[NGAL],": [ 142 ], "injury": [ 145 ], "molecule-1": [ 146 ], "[KIM-1])": [ 147 ], "measured.": [ 149 ], "Plasma": [ 150 ], "renin": [ 151 ], "concentration": [ 152 ], "(PRC)": [ 153 ], "glycated": [ 155 ], "hemoglobin": [ 156 ], "(HbA1c)": [ 157 ], "assessed.": [ 159 ], "At": [ 160, 174 ], "weeks": [ 161 ], "6,": [ 164 ], "estimated": [ 165, 211 ], "electrolyte": [ 169 ], "determined.": [ 172 ], "RESULTS": [ 173 ], "week": [ 175, 241 ], "12,": [ 176 ], "was": [ 178 ], "not": [ 179, 230, 259 ], "affected": [ 180 ], "(\u22126": [ 183 ], "m2": [ 185, 198 ], "[95%": [ 186 ], "CI": [ 187 ], "\u221214": [ 188 ], "to": [ 189, 200 ], "3],": [ 190 ], "P": [ 191, 202, 216 ], "=": [ 192, 203, 217, 249 ], "0.17)": [ 193 ], "(+3": [ 196 ], "[\u22125": [ 199 ], "11],": [ 201 ], "0.46),": [ 204 ], "compared": [ 205 ], "placebo.": [ 207 ], "Sitagliptin": [ 208 ], "modestly": [ 209 ], "reduced": [ 210, 237 ], "hydraulic": [ 213 ], "pressure": [ 214 ], "(PGLO;": [ 215 ], "0.043).": [ 218 ], "ERPF,": [ 219 ], "other": [ 220 ], "intrarenal": [ 221 ], "variables,": [ 223 ], "markers,": [ 226 ], "PRC": [ 228 ], "did": [ 229 ], "change": [ 231 ], "for": [ 232 ], "both": [ 233 ], "treatments.": [ 234 ], "Both": [ 235 ], "agents": [ 236 ], "HbA1c.": [ 238 ], "Only": [ 239 ], "at": [ 240 ], "2,": [ 242 ], "increased": [ 244 ], "FENa": [ 245 ], "FEU": [ 247 ], "(P": [ 248 ], "0.005).": [ 250 ], "CONCLUSIONS": [ 251 ], "Twelve-week": [ 252 ], "does": [ 258 ], "affect": [ 260 ], "measured": [ 261 ], "hemodynamics.": [ 263 ], "No": [ 264 ], "sustained": [ 265 ], "changes": [ 266 ], "functions": [ 269 ], "alteration": [ 271 ], "observed.": [ 277 ], "The": [ 278 ], "validity": [ 279 ], "clinical": [ 281 ], "relevance": [ 282 ], "the": [ 284 ], "slight": [ 285 ], "sitagliptin-induced": [ 286 ], "PGLO": [ 287 ], "reduction": [ 288 ], "remains": [ 289 ], "speculative.": [ 290 ] }, "publication_date": "2016-09-01", "publication_year": 2016, "type": "article", "cited_by_count": 110, "authors": [ { "id": "https://openalex.org/A5067721247", "display_name": "Lennart Tonneijck" }, { "id": "https://openalex.org/A5091895526", "display_name": "Mark M. Smits" }, { "id": "https://openalex.org/A5084278641", "display_name": "Marcel H.A. Muskiet" }, { "id": "https://openalex.org/A5016447558", "display_name": "Trynke Hoekstra" }, { "id": "https://openalex.org/A5028760009", "display_name": "Mark H.H. Kramer" }, { "id": "https://openalex.org/A5046295598", "display_name": "A.H. Jan Danser" }, { "id": "https://openalex.org/A5102711067", "display_name": "Piet M. ter Wee" }, { "id": "https://openalex.org/A5109335776", "display_name": "Micha\u00ebla Diamant" }, { "id": "https://openalex.org/A5113916096", "display_name": "Jaap A. Joles" }, { "id": "https://openalex.org/A5067127165", "display_name": "Dani\u00ebl H. van Raalte" } ] }, { "id": "https://openalex.org/W3143601195", "doi": "https://doi.org/10.1007/s13300-021-01053-7", "title": "Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type\u00a02 Diabetes in a US Real-World Setting", "abstract": null, "publication_date": "2021-04-10", "publication_year": 2021, "type": "article", "cited_by_count": 56, "authors": [ { "id": "https://openalex.org/A5008390651", "display_name": "Chioma Uzoigwe" }, { "id": "https://openalex.org/A5112215480", "display_name": "Yuanjie Liang" }, { "id": "https://openalex.org/A5089705418", "display_name": "Sarah Whitmire" }, { "id": "https://openalex.org/A5013281261", "display_name": "Yurek Paprocki" } ] }, { "id": "https://openalex.org/W3023544430", "doi": "https://doi.org/10.1007/s40620-020-00738-9", "title": "Nephroprotective effects of GLP-1 receptor agonists: where do we stand?", "abstract": null, "publication_date": "2020-04-30", "publication_year": 2020, "type": "review", "cited_by_count": 48, "authors": [ { "id": "https://openalex.org/A5056375762", "display_name": "Charlotte M. Mosterd" }, { "id": "https://openalex.org/A5036425382", "display_name": "Petter Bjornstad" }, { "id": "https://openalex.org/A5067127165", "display_name": "Dani\u00ebl H. van Raalte" } ] }, { "id": "https://openalex.org/W2786440693", "doi": "https://doi.org/10.1016/j.peptides.2017.11.017", "title": "GLP-1 receptor agonists show neuroprotective effects in animal models of diabetes", "abstract": null, "publication_date": "2018-02-01", "publication_year": 2018, "type": "review", "cited_by_count": 73, "authors": [ { "id": "https://openalex.org/A5013136657", "display_name": "Victor A. Gault" }, { "id": "https://openalex.org/A5082707086", "display_name": "Christian H\u00f6lscher" } ] }, { "id": "https://openalex.org/W1798757189", "doi": "https://doi.org/10.1001/jama.2015.9676", "title": "Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes", "abstract": { "clinicaltrials.gov": [ 0 ], "Identifier:NCT01272232.": [ 1 ] }, "publication_date": "2015-08-18", "publication_year": 2015, "type": "article", "cited_by_count": 1050, "authors": [ { "id": "https://openalex.org/A5084593004", "display_name": "Melanie J. Davies" }, { "id": "https://openalex.org/A5034096266", "display_name": "Richard M. Bergenstal" }, { "id": "https://openalex.org/A5005036709", "display_name": "Bruce W. Bode" }, { "id": "https://openalex.org/A5062192624", "display_name": "Robert F. Kushner" }, { "id": "https://openalex.org/A5103371371", "display_name": "Andrew Lewin" }, { "id": "https://openalex.org/A5041637994", "display_name": "Trine Vang Skj\u00f8th" }, { "id": "https://openalex.org/A5028274777", "display_name": "Arne Haahr Andreasen" }, { "id": "https://openalex.org/A5111479294", "display_name": "Christine B. Jensen" }, { "id": "https://openalex.org/A5073917506", "display_name": "Ralph A. DeFronzo" } ] }, { "id": "https://openalex.org/W3114726363", "doi": "https://doi.org/10.1007/s13300-020-00984-x", "title": "Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type\u00a02 Diabetes Mellitus: The Retrospective REALISE-DM Study", "abstract": null, "publication_date": "2020-12-26", "publication_year": 2020, "type": "article", "cited_by_count": 43, "authors": [ { "id": "https://openalex.org/A5087185790", "display_name": "Akshay Jain" }, { "id": "https://openalex.org/A5056574916", "display_name": "Steve Kanters" }, { "id": "https://openalex.org/A5000585816", "display_name": "Reena Khurana" }, { "id": "https://openalex.org/A5005492791", "display_name": "Jagoda Kissock" }, { "id": "https://openalex.org/A5080151883", "display_name": "Naomi Severin" }, { "id": "https://openalex.org/A5091074610", "display_name": "Sara Stafford" } ] }, { "id": "https://openalex.org/W3138099017", "doi": "https://doi.org/10.1111/bph.15462", "title": "Glucagon\u2010like peptide\u20101 (GLP\u20101) receptor agonists and their cardiovascular benefits\u2014The role of the GLP\u20101 receptor", "abstract": { "Cardiovascular": [ 0 ], "outcome": [ 1, 75 ], "trials": [ 2, 76 ], "revealed": [ 3 ], "cardiovascular": [ 4, 63, 74, 89, 130, 143 ], "benefits": [ 5 ], "for": [ 6, 115, 141 ], "type": [ 7 ], "2": [ 8 ], "diabetes": [ 9 ], "mellitus": [ 10 ], "patients": [ 11 ], "when": [ 12 ], "treated": [ 13 ], "with": [ 14 ], "long\u2010acting": [ 15 ], "glucagon\u2010like": [ 16 ], "peptide\u20101": [ 17 ], "(GLP\u20101)": [ 18 ], "receptor": [ 19, 55, 60, 79, 101, 134, 161 ], "agonists.": [ 20 ], "In": [ 21 ], "the": [ 22, 30, 50, 58, 62, 105, 128, 168 ], "last": [ 23 ], "decade,": [ 24 ], "major": [ 25 ], "advances": [ 26 ], "were": [ 27 ], "made": [ 28 ], "characterising": [ 29 ], "physiological": [ 31 ], "effects": [ 32, 51, 120 ], "of": [ 33, 52, 77, 122, 132, 155 ], "GLP\u20101": [ 34, 53, 59, 78, 99, 116, 123, 133 ], "and": [ 35, 46, 54, 57, 81, 85, 100, 110, 112 ], "its": [ 36 ], "action": [ 37 ], "on": [ 38, 61, 98, 104, 159 ], "numerous": [ 39 ], "targets": [ 40 ], "including": [ 41 ], "brain,": [ 42 ], "liver,": [ 43 ], "kidney,": [ 44 ], "heart": [ 45 ], "blood": [ 47 ], "vessels.": [ 48 ], "However,": [ 49 ], "agonists,": [ 56 ], "system": [ 64 ], "have": [ 65 ], "not": [ 66 ], "been": [ 67 ], "fully": [ 68 ], "elucidated.": [ 69 ], "We": [ 70, 94, 125 ], "compare": [ 71 ], "results": [ 72 ], "from": [ 73 ], "agonists": [ 80, 135 ], "review": [ 82 ], "pleiotropic": [ 83 ], "clinical": [ 84 ], "preclinical": [ 86 ], "data": [ 87 ], "concerning": [ 88 ], "protection": [ 90 ], "beyond": [ 91 ], "glycaemic": [ 92 ], "control.": [ 93 ], "address": [ 95 ], "current": [ 96 ], "knowledge": [ 97 ], "agonist": [ 102 ], "actions": [ 103 ], "heart,": [ 106 ], "vasculature,": [ 107 ], "inflammatory": [ 108 ], "cells": [ 109 ], "platelets,": [ 111 ], "discuss": [ 113 ], "evidence": [ 114 ], "receptor\u2010dependent": [ 117 ], "versus": [ 118 ], "independent": [ 119 ], "secondary": [ 121 ], "metabolites.": [ 124 ], "conclude": [ 126 ], "that": [ 127 ], "favourable": [ 129 ], "profile": [ 131 ], "might": [ 136 ], "expand": [ 137 ], "their": [ 138 ], "therapeutic": [ 139 ], "use": [ 140 ], "treating": [ 142 ], "disease": [ 144 ], "even": [ 145 ], "in": [ 146, 171 ], "non\u2010diabetic": [ 147 ], "populations.": [ 148 ], "LINKED": [ 149 ], "ARTICLES": [ 150 ], "This": [ 151 ], "article": [ 152 ], "is": [ 153 ], "part": [ 154 ], "a": [ 156 ], "themed": [ 157 ], "issue": [ 158 ], "GLP1": [ 160 ], "ligands": [ 162 ], "(BJP": [ 163 ], "75th": [ 164 ], "Anniversary).": [ 165 ], "To": [ 166 ], "view": [ 167 ], "other": [ 169 ], "articles": [ 170 ], "this": [ 172 ], "section": [ 173 ], "visit": [ 174 ], "http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.4/issuetoc": [ 175 ] }, "publication_date": "2021-03-25", "publication_year": 2021, "type": "review", "cited_by_count": 79, "authors": [ { "id": "https://openalex.org/A5068831026", "display_name": "Johanna Helmst\u00e4dter" }, { "id": "https://openalex.org/A5055650937", "display_name": "Karin Keppeler" }, { "id": "https://openalex.org/A5072269331", "display_name": "Leonie K\u00fcster" }, { "id": "https://openalex.org/A5113521673", "display_name": "Thomas M\u00fcnzel" }, { "id": "https://openalex.org/A5039361810", "display_name": "Andreas Daiber" }, { "id": "https://openalex.org/A5066963864", "display_name": "Sebastian Steven" } ] }, { "id": "https://openalex.org/W2152984355", "doi": "https://doi.org/10.1016/s0140-6736(12)61267-7", "title": "Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study", "abstract": null, "publication_date": "2012-11-06", "publication_year": 2012, "type": "article", "cited_by_count": 553, "authors": [ { "id": "https://openalex.org/A5040182038", "display_name": "John B. Buse" }, { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5044778195", "display_name": "Thomas F\u00f6rst" }, { "id": "https://openalex.org/A5110125460", "display_name": "Wayne H.-H. Sheu" }, { "id": "https://openalex.org/A5042251550", "display_name": "Sylvia Shenouda" }, { "id": "https://openalex.org/A5084630296", "display_name": "Cory R. Heilmann" }, { "id": "https://openalex.org/A5058778822", "display_name": "Byron J. Hoogwerf" }, { "id": "https://openalex.org/A5022638250", "display_name": "Aijun Gao" }, { "id": "https://openalex.org/A5012995950", "display_name": "Marilyn K. Boardman" }, { "id": "https://openalex.org/A5083503351", "display_name": "Mark Fineman" }, { "id": "https://openalex.org/A5082524181", "display_name": "Lisa A. Porter" }, { "id": "https://openalex.org/A5048027389", "display_name": "Guntram Schernthaner" } ] }, { "id": "https://openalex.org/W3140265053", "doi": "https://doi.org/10.3389/fendo.2021.645566", "title": "Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6", "abstract": { "To": [ 0 ], "exclude": [ 1 ], "an": [ 2 ], "excess": [ 3 ], "risk": [ 4, 39, 225, 236 ], "of": [ 5, 17, 44, 92, 112, 226, 287 ], "cardiovascular": [ 6 ], "(CV)": [ 7 ], "events,": [ 8 ], "CV": [ 9, 35, 38, 42, 104, 139, 160, 189, 227, 247, 256, 285 ], "outcomes": [ 10, 161, 208 ], "trials": [ 11 ], "(CVOTs)": [ 12 ], "have": [ 13, 209, 249 ], "assessed": [ 14 ], "the": [ 15, 56, 61, 71, 93, 124, 133, 177, 224, 246, 281 ], "effects": [ 16, 241 ], "new": [ 18, 72 ], "glucose-lowering": [ 19 ], "therapies,": [ 20 ], "including": [ 21 ], "glucagon-like": [ 22 ], "peptide-1": [ 23 ], "receptor": [ 24 ], "agonists": [ 25 ], "(GLP-1RAs),": [ 26 ], "in": [ 27, 55, 67, 149, 212, 229, 245 ], "patients": [ 28 ], "with": [ 29, 106, 110, 162, 180, 193, 202 ], "type": [ 30 ], "2": [ 31 ], "diabetes": [ 32 ], "and": [ 33, 66, 79, 117, 130, 140, 172, 195, 205, 220, 239 ], "established": [ 34 ], "disease": [ 36 ], "or": [ 37 ], "factors.": [ 40 ], "The": [ 41, 152, 259 ], "safety": [ 43 ], "semaglutide": [ 45, 107, 148, 164 ], "vs.": [ 46, 108, 165, 185 ], "placebo,": [ 47, 109 ], "when": [ 48 ], "added": [ 49 ], "to": [ 50, 84, 222, 252, 263, 268, 272, 279 ], "standard": [ 51 ], "care,": [ 52 ], "was": [ 53, 135, 191, 200 ], "evaluated": [ 54 ], "SUSTAIN": [ 57, 77, 122, 170 ], "6": [ 58, 69, 78, 171, 174 ], "trial": [ 59 ], "for": [ 60, 70, 128, 187, 255, 284 ], "formulation": [ 62 ], "administered": [ 63 ], "once-weekly": [ 64 ], "subcutaneously": [ 65 ], "PIONEER": [ 68, 80, 150, 173 ], "once-daily": [ 73 ], "oral": [ 74, 147, 163 ], "formulation.": [ 75 ], "In": [ 76, 121 ], "6,": [ 81, 123 ], "both": [ 82 ], "powered": [ 83 ], "demonstrate": [ 85 ], "noninferiority": [ 86, 129, 184 ], "(upper": [ 87 ], "95%": [ 88 ], "confidence": [ 89 ], "interval": [ 90 ], "[CI]": [ 91 ], "hazard": [ 94 ], "ratio": [ 95 ], "[HR]": [ 96 ], "&lt;1.8),": [ 97 ], "there": [ 98 ], "were": [ 99, 126, 143 ], "fewer": [ 100 ], "first": [ 101 ], "major": [ 102, 188 ], "adverse": [ 103 ], "events": [ 105, 190, 228 ], "HRs": [ 111 ], "0.74": [ 113 ], "(95%": [ 114 ], "CI": [ 115 ], "0.58\u20130.95)": [ 116 ], "0.79": [ 118 ], "(0.57\u20131.11),": [ 119 ], "respectively.": [ 120 ], "results": [ 125 ], "significant": [ 127 ], "superiority,": [ 131 ], "although": [ 132 ], "latter": [ 134 ], "not": [ 136 ], "prespecified.": [ 137 ], "Surprisingly,": [ 138 ], "all-cause": [ 141 ], "mortality": [ 142 ], "significantly": [ 144 ], "reduced": [ 145 ], "by": [ 146 ], "6.": [ 151 ], "ongoing": [ 153 ], "SOUL": [ 154 ], "CVOT": [ 155 ], "will": [ 156 ], "further": [ 157 ], "inform": [ 158 ], "about": [ 159 ], "placebo": [ 166, 186 ], "(NCT03914326).": [ 167 ], "Findings": [ 168 ], "from": [ 169 ], "fall": [ 175 ], "within": [ 176 ], "spectrum": [ 178 ], "reported": [ 179 ], "other": [ 181 ], "GLP-1RA": [ 182 ], "CVOTs:": [ 183 ], "seen": [ 192 ], "lixisenatide": [ 194 ], "exenatide": [ 196 ], "extended-release,": [ 197 ], "while": [ 198 ], "superiority": [ 199 ], "demonstrated": [ 201 ], "liraglutide,": [ 203, 218 ], "albiglutide,": [ 204 ], "dulaglutide.": [ 206 ], "Beneficial": [ 207 ], "been": [ 210, 250 ], "recognized": [ 211 ], "international": [ 213 ], "guidelines,": [ 214 ], "which": [ 215 ], "recommend": [ 216 ], "subcutaneous": [ 217 ], "semaglutide,": [ 219 ], "dulaglutide": [ 221 ], "reduce": [ 223 ], "high-risk": [ 230 ], "patients.": [ 231 ], "Both": [ 232 ], "indirect": [ 233 ], "mechanisms": [ 234, 283 ], "via": [ 235, 242 ], "factor": [ 237 ], "modification": [ 238 ], "direct": [ 240 ], "GLP-1": [ 243 ], "receptors": [ 244 ], "system": [ 248 ], "proposed": [ 251 ], "be": [ 253, 264, 269 ], "responsible": [ 254 ], "event": [ 257 ], "reductions.": [ 258 ], "exact": [ 260 ], "mechanism(s)": [ 261 ], "remains": [ 262 ], "characterized,": [ 265 ], "but": [ 266 ], "appears": [ 267 ], "mainly": [ 270 ], "linked": [ 271 ], "anti-atherosclerotic": [ 273 ], "effects.": [ 274 ], "Further": [ 275 ], "research": [ 276 ], "is": [ 277 ], "needed": [ 278 ], "elucidate": [ 280 ], "relevant": [ 282 ], "benefits": [ 286 ], "GLP-1RAs.": [ 288 ] }, "publication_date": "2021-03-29", "publication_year": 2021, "type": "review", "cited_by_count": 106, "authors": [ { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5091130352", "display_name": "Daniel R. Quast" } ] }, { "id": "https://openalex.org/W2462710388", "doi": "https://doi.org/10.2147/dmso.s99732", "title": "Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany", "abstract": { "Adherence": [ 0 ], "to": [ 1, 11 ], "treatment": [ 2 ], "with": [ 3, 13, 22 ], "exenatide": [ 4 ], "once": [ 5, 15 ], "weekly": [ 6 ], "was": [ 7 ], "significantly": [ 8 ], "increased": [ 9 ], "compared": [ 10 ], "that": [ 12 ], "liraglutide": [ 14 ], "daily": [ 16 ], "over": [ 17 ], "6": [ 18 ], "months": [ 19 ], "in": [ 20 ], "patients": [ 21 ], "type": [ 23 ], "2": [ 24 ], "diabetes.": [ 25 ] }, "publication_date": "2016-06-01", "publication_year": 2016, "type": "article", "cited_by_count": 89, "authors": [ { "id": "https://openalex.org/A5053278199", "display_name": "Karel Kostev" }, { "id": "https://openalex.org/A5055776171", "display_name": "Mario Ouwens" }, { "id": "https://openalex.org/A5035420893", "display_name": "Susan Grandy" }, { "id": "https://openalex.org/A5062793550", "display_name": "Kristina Johnsson" }, { "id": "https://openalex.org/A5108631605", "display_name": "Qing Qiao" } ] }, { "id": "https://openalex.org/W2092287139", "doi": "https://doi.org/10.1016/j.clinthera.2012.04.013", "title": "Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review", "abstract": null, "publication_date": "2012-05-18", "publication_year": 2012, "type": "review", "cited_by_count": 247, "authors": [ { "id": "https://openalex.org/A5005405894", "display_name": "Vanita R. Aroda" }, { "id": "https://openalex.org/A5045462483", "display_name": "Robert R. Henry" }, { "id": "https://openalex.org/A5111694431", "display_name": "Jenny Han" }, { "id": "https://openalex.org/A5037345577", "display_name": "Wenying Huang" }, { "id": "https://openalex.org/A5010846329", "display_name": "Mary Beth DeYoung" }, { "id": "https://openalex.org/A5069521580", "display_name": "Tamara Darsow" }, { "id": "https://openalex.org/A5058778822", "display_name": "Byron J. Hoogwerf" } ] }, { "id": "https://openalex.org/W3083723931", "doi": "https://doi.org/10.1016/j.cbi.2020.109252", "title": "GLP-1 receptor agonist liraglutide protects cardiomyocytes from IL-1\u03b2-induced metabolic disturbance and mitochondrial dysfunction", "abstract": null, "publication_date": "2020-09-06", "publication_year": 2020, "type": "article", "cited_by_count": 57, "authors": [ { "id": "https://openalex.org/A5100461222", "display_name": "Lili Zhang" }, { "id": "https://openalex.org/A5070222550", "display_name": "Jiali Tian" }, { "id": "https://openalex.org/A5053711769", "display_name": "Sujuan Diao" }, { "id": "https://openalex.org/A5100350872", "display_name": "Guowei Zhang" }, { "id": "https://openalex.org/A5112642672", "display_name": "Mochao Xiao" }, { "id": "https://openalex.org/A5027315631", "display_name": "Dong Chang" } ] }, { "id": "https://openalex.org/W2166969890", "doi": "https://doi.org/10.1210/en.2011-1864", "title": "GLP-1 Receptor Agonists and the Thyroid: C-Cell Effects in Mice Are Mediated via the GLP-1 Receptor and not Associated with RET Activation", "abstract": { "Liraglutide": [ 0, 127 ], "and": [ 1, 48, 81, 178 ], "exenatide": [ 2 ], "are": [ 3, 42, 60, 156 ], "glucagon-like": [ 4 ], "peptide": [ 5 ], "receptor": [ 6 ], "(GLP-1R)": [ 7 ], "agonists": [ 8, 72, 162 ], "used": [ 9 ], "in": [ 10, 32, 78, 82, 88, 98, 111, 125, 175 ], "the": [ 11, 23, 56, 83, 112, 140 ], "treatment": [ 12 ], "of": [ 13, 25, 67, 85, 139, 160, 172 ], "type": [ 14 ], "2": [ 15 ], "diabetes.": [ 16 ], "Both": [ 17 ], "molecules": [ 18 ], "have": [ 19 ], "been": [ 20, 37 ], "associated": [ 21, 74 ], "with": [ 22, 75, 158 ], "development": [ 24 ], "thyroid": [ 26 ], "C-cell": [ 27, 49, 58, 86, 103 ], "tumors": [ 28, 41 ], "after": [ 29 ], "lifetime": [ 30 ], "exposure": [ 31, 69 ], "rodents.": [ 33 ], "Previously,": [ 34 ], "it": [ 35 ], "has": [ 36 ], "reported": [ 38 ], "that": [ 39, 55, 144 ], "these": [ 40 ], "preceded": [ 43 ], "by": [ 44, 108 ], "increased": [ 45, 146 ], "plasma": [ 46, 79 ], "calcitonin": [ 47, 80 ], "hyperplasia.": [ 50 ], "We": [ 51, 116 ], "can": [ 52 ], "now": [ 53 ], "document": [ 54 ], "murine": [ 57 ], "effects": [ 59, 94, 159 ], "mediated": [ 61, 168 ], "via": [ 62, 169 ], "GLP-1R.": [ 63 ], "Thus,": [ 64 ], "13": [ 65 ], "wk": [ 66 ], "continuous": [ 68 ], "to": [ 70, 121, 129, 134 ], "GLP-1R": [ 71, 99, 161 ], "was": [ 73, 131 ], "marked": [ 76 ], "increases": [ 77 ], "incidence": [ 84 ], "hyperplasia": [ 87 ], "wild-type": [ 89 ], "mice.": [ 90, 101 ], "In": [ 91 ], "contrast,": [ 92 ], "similar": [ 93 ], "were": [ 95 ], "not": [ 96, 132, 150 ], "seen": [ 97 ], "knockout": [ 100 ], "Human": [ 102 ], "cancer": [ 104 ], "is": [ 105 ], "often": [ 106 ], "caused": [ 107 ], "activating": [ 109 ], "mutations": [ 110 ], "rearranged-during-transfection": [ 113 ], "(RET)": [ 114 ], "protooncogene.": [ 115 ], "developed": [ 117 ], "an": [ 118 ], "immunohistochemical": [ 119 ], "method": [ 120 ], "assess": [ 122 ], "RET": [ 123 ], "activation": [ 124, 174 ], "tissues.": [ 126 ], "dosing": [ 128 ], "mice": [ 130 ], "found": [ 133 ], "activate": [ 135 ], "RET.": [ 136 ], "Further": [ 137 ], "evaluation": [ 138 ], "signaling": [ 141 ], "pathways": [ 142 ], "demonstrated": [ 143 ], "liraglutide": [ 145 ], "ribosomal": [ 147 ], "S6,": [ 148 ], "but": [ 149 ], "MAPK": [ 151 ], "kinase,": [ 152 ], "phosphorylation.": [ 153 ], "These": [ 154 ], "observations": [ 155 ], "consistent": [ 157 ], "on": [ 163 ], "rodent": [ 164 ], "C": [ 165 ], "cells": [ 166 ], "being": [ 167 ], "mammalian": [ 170 ], "target": [ 171 ], "rapamycin": [ 173 ], "a": [ 176 ], "RET-": [ 177 ], "MAPK-independent": [ 179 ], "manner.": [ 180 ] }, "publication_date": "2012-01-10", "publication_year": 2012, "type": "article", "cited_by_count": 130, "authors": [ { "id": "https://openalex.org/A5073611205", "display_name": "Lars Wichmann Madsen" }, { "id": "https://openalex.org/A5067136142", "display_name": "Jeffrey A. Knauf" }, { "id": "https://openalex.org/A5103583268", "display_name": "C. F. Gotfredsen" }, { "id": "https://openalex.org/A5086492184", "display_name": "Andrew Pilling" }, { "id": "https://openalex.org/A5089555429", "display_name": "Ingrid Sj\u00f6gren" }, { "id": "https://openalex.org/A5103529626", "display_name": "S\u00f8ren Andersen" }, { "id": "https://openalex.org/A5053613116", "display_name": "Lene Frost Andersen" }, { "id": "https://openalex.org/A5034904352", "display_name": "Anne Sietske de Boer" }, { "id": "https://openalex.org/A5109189567", "display_name": "Katia Manova" }, { "id": "https://openalex.org/A5081351546", "display_name": "Af\u015far Barlas" }, { "id": "https://openalex.org/A5041721023", "display_name": "Sushil Vundavalli" }, { "id": "https://openalex.org/A5090786732", "display_name": "Niels C. Berg Nyborg" }, { "id": "https://openalex.org/A5088627727", "display_name": "Lotte Bjerre Knudsen" }, { "id": "https://openalex.org/A5066000201", "display_name": "Anne Marie Moelck" }, { "id": "https://openalex.org/A5080716045", "display_name": "James A. Fagin" } ] }, { "id": "https://openalex.org/W2153002428", "doi": "https://doi.org/10.1155/2012/381713", "title": "Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective", "abstract": { "In": [ 0 ], "recent": [ 1 ], "years": [ 2 ], "the": [ 3, 25, 29, 70, 86, 97, 125, 130, 181 ], "incretin": [ 4, 21, 31, 101, 131, 146, 182 ], "therapies": [ 5, 22, 102, 132 ], "have": [ 6, 103 ], "provided": [ 7 ], "a": [ 8, 113, 170 ], "new": [ 9 ], "treatment": [ 10 ], "option": [ 11 ], "for": [ 12 ], "patients": [ 13 ], "with": [ 14, 112 ], "type": [ 15 ], "2": [ 16 ], "diabetes": [ 17 ], "mellitus": [ 18 ], "(T2DM).": [ 19 ], "The": [ 20 ], "focus": [ 23 ], "on": [ 24, 65, 124 ], "increasing": [ 26 ], "levels": [ 27 ], "of": [ 28, 72, 88, 96, 115, 165 ], "two": [ 30 ], "hormones,": [ 32 ], "glucagon-like": [ 33 ], "peptide": [ 34 ], "1": [ 35 ], "(GLP-1)": [ 36 ], "and": [ 37, 50, 58, 83, 91, 106, 109, 134, 140, 150, 158, 162, 167, 186 ], "glucose-dependent": [ 38 ], "insulinotropic": [ 39 ], "polypeptide": [ 40 ], "(GIP).": [ 41 ], "This": [ 42, 121 ], "results": [ 43 ], "in": [ 44, 119 ], "increased": [ 45 ], "glucose": [ 46 ], "dependent": [ 47 ], "insulin": [ 48, 73 ], "synthesis": [ 49 ], "release.": [ 51 ], "GLP-1": [ 52, 66, 90 ], "receptor": [ 53 ], "agonists": [ 54 ], "such": [ 55, 80, 155, 190 ], "as": [ 56, 81, 156, 191 ], "liraglutide": [ 57 ], "exenatide": [ 59 ], "exert": [ 60 ], "an": [ 61 ], "intrinsic": [ 62 ], "biological": [ 63 ], "effect": [ 64 ], "receptors": [ 67 ], "directly": [ 68 ], "stimulating": [ 69 ], "release": [ 71 ], "from": [ 74 ], "pancreatic": [ 75 ], "beta": [ 76 ], "cells.": [ 77 ], "DPP-4": [ 78, 98 ], "inhibitors": [ 79 ], "sitagliptin": [ 82 ], "linagliptin": [ 84 ], "prevent": [ 85 ], "inactivation": [ 87 ], "endogenous": [ 89 ], "GIP": [ 92 ], "through": [ 93 ], "competitive": [ 94 ], "inhibition": [ 95 ], "enzyme.": [ 99 ], "Both": [ 100 ], "good": [ 104 ], "safety": [ 105, 161 ], "tolerability": [ 107 ], "profiles": [ 108 ], "interact": [ 110 ], "minimally": [ 111 ], "number": [ 114 ], "medications": [ 116 ], "commonly": [ 117 ], "prescribed": [ 118 ], "T2DM.": [ 120 ], "paper": [ 122 ], "focuses": [ 123 ], "pharmacological": [ 126 ], "basis": [ 127 ], "by": [ 128 ], "which": [ 129 ], "function": [ 133 ], "how": [ 135 ], "this": [ 136 ], "knowledge": [ 137 ], "can": [ 138 ], "inform": [ 139 ], "benefit": [ 141, 185 ], "clinical": [ 142 ], "decisions.": [ 143 ], "Each": [ 144 ], "individual": [ 145 ], "agent": [ 147, 183 ], "has": [ 148, 174 ], "benefits": [ 149 ], "pitfalls": [ 151 ], "relating": [ 152 ], "to": [ 153, 177, 184 ], "aspects": [ 154 ], "glycaemic": [ 157 ], "nonglycaemic": [ 159 ], "efficacy,": [ 160 ], "tolerability,": [ 163 ], "ease": [ 164 ], "administration,": [ 166 ], "cost.": [ 168 ], "Overall,": [ 169 ], "personalized": [ 171 ], "medicine": [ 172 ], "approach": [ 173 ], "been": [ 175 ], "found": [ 176 ], "be": [ 178 ], "favourable,": [ 179 ], "tailoring": [ 180 ], "suit": [ 187 ], "patient's": [ 188 ], "needs": [ 189 ], "renal": [ 192 ], "impairment": [ 193, 197 ], "(RI)": [ 194 ], "or": [ 195 ], "hepatic": [ 196 ], "(HI).": [ 198 ] }, "publication_date": "2012-01-01", "publication_year": 2012, "type": "article", "cited_by_count": 59, "authors": [ { "id": "https://openalex.org/A5052968162", "display_name": "Dominique Brown" }, { "id": "https://openalex.org/A5053232051", "display_name": "Marc Evans" } ] }, { "id": "https://openalex.org/W4406602151", "doi": "https://doi.org/10.1038/s41591-024-03412-w", "title": "Mapping the effectiveness and risks of GLP-1 receptor agonists", "abstract": null, "publication_date": "2025-01-20", "publication_year": 2025, "type": "article", "cited_by_count": 153, "authors": [ { "id": "https://openalex.org/A5044152940", "display_name": "Yan Xie" }, { "id": "https://openalex.org/A5049487652", "display_name": "Taeyoung Choi" }, { "id": "https://openalex.org/A5047490642", "display_name": "Ziyad Al\u2010Aly" } ] }, { "id": "https://openalex.org/W2164535707", "doi": "https://doi.org/10.2337/dc10-0482", "title": "Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin", "abstract": { "OBJECTIVE": [ 0 ], "Cases": [ 1 ], "of": [ 2, 19, 32, 43, 69, 88, 118, 143, 171, 188, 197, 206 ], "acute": [ 3, 33, 70, 89, 119, 144, 172, 193 ], "pancreatitis": [ 4, 71, 90, 120, 145, 173 ], "have": [ 5 ], "been": [ 6 ], "reported": [ 7 ], "in": [ 8, 91, 124, 130, 148, 174 ], "association": [ 9, 184 ], "with": [ 10 ], "exenatide,": [ 11, 79 ], "sitagliptin,": [ 12, 80 ], "and": [ 13, 47, 74, 77, 81, 101, 108, 157, 192 ], "type": [ 14 ], "2": [ 15 ], "diabetes": [ 16, 83 ], "without": [ 17 ], "use": [ 18, 187 ], "these": [ 20 ], "medications.": [ 21 ], "It": [ 22 ], "remains": [ 23 ], "unknown": [ 24 ], "whether": [ 25 ], "exenatide": [ 26, 99, 150, 189 ], "or": [ 27, 190 ], "sitagliptin": [ 28, 102, 158, 191 ], "increase": [ 29 ], "the": [ 30, 67, 92, 125, 131, 149, 186, 204 ], "risk": [ 31, 68, 117 ], "pancreatitis.": [ 34, 194 ], "RESEARCH": [ 35 ], "DESIGN": [ 36 ], "AND": [ 37 ], "METHODS": [ 38 ], "A": [ 39 ], "retrospective": [ 40 ], "cohort": [ 41 ], "study": [ 42, 167 ], "a": [ 44 ], "large": [ 45 ], "medical": [ 46 ], "pharmacy": [ 48 ], "claims": [ 49 ], "database": [ 50 ], "was": [ 51, 104, 121, 146 ], "performed.": [ 52 ], "Data": [ 53 ], "for": [ 54 ], "786,656": [ 55 ], "patients": [ 56, 178 ], "were": [ 57, 63 ], "analyzed.": [ 58 ], "Cox": [ 59 ], "proportional": [ 60 ], "hazard": [ 61, 136 ], "models": [ 62 ], "built": [ 64 ], "to": [ 65 ], "compare": [ 66 ], "between": [ 72, 78, 185 ], "diabetic": [ 73, 96, 127, 152, 160, 175 ], "nondiabetic": [ 75, 93, 132, 177 ], "subjects": [ 76 ], "control": [ 82, 94, 97, 133, 153, 161 ], "medication": [ 84 ], "use.": [ 85 ], "RESULTS": [ 86 ], "Incidence": [ 87 ], "group,": [ 95, 98, 100 ], "group": [ 103, 134, 154, 162 ], "1.9,": [ 105 ], "5.6,": [ 106 ], "5.7,": [ 107 ], "5.6": [ 109 ], "cases": [ 110 ], "per": [ 111 ], "1,000": [ 112 ], "patient": [ 113 ], "years,": [ 114 ], "respectively.": [ 115 ], "The": [ 116, 195 ], "significantly": [ 122 ], "higher": [ 123 ], "combined": [ 126 ], "groups": [ 128 ], "than": [ 129 ], "(adjusted": [ 135 ], "ratio": [ 137 ], "2.1": [ 138 ], "[95%": [ 139 ], "CI": [ 140 ], "1.7\u20132.5]).": [ 141 ], "Risk": [ 142 ], "similar": [ 147 ], "versus": [ 151, 159, 176 ], "(0.9": [ 155 ], "[0.6\u20131.5])": [ 156 ], "(1.0": [ 163 ], "[0.7\u20131.3]).": [ 164 ], "CONCLUSIONS": [ 165 ], "Our": [ 166 ], "demonstrated": [ 168 ], "increased": [ 169, 208 ], "incidence": [ 170 ], "but": [ 179 ], "did": [ 180 ], "not": [ 181 ], "find": [ 182 ], "an": [ 183, 207 ], "limitations": [ 196 ], "this": [ 198 ], "observational": [ 199 ], "claims-based": [ 200 ], "analysis": [ 201 ], "cannot": [ 202 ], "exclude": [ 203 ], "possibility": [ 205 ], "risk.": [ 209 ] }, "publication_date": "2010-08-03", "publication_year": 2010, "type": "article", "cited_by_count": 320, "authors": [ { "id": "https://openalex.org/A5014116477", "display_name": "Rajesh Garg" }, { "id": "https://openalex.org/A5055644612", "display_name": "William Chen" }, { "id": "https://openalex.org/A5112524758", "display_name": "Merri Pendergrass" } ] }, { "id": "https://openalex.org/W2803540340", "doi": "https://doi.org/10.1111/dom.13361", "title": "Semaglutide for type 2 diabetes mellitus: A systematic review and meta\u2010analysis", "abstract": { "Aims": [ 0 ], "To": [ 1 ], "assess": [ 2 ], "the": [ 3, 195 ], "efficacy": [ 4, 127 ], "and": [ 5, 24, 31, 68, 76, 85, 108, 118, 138, 165, 187, 194, 222, 240 ], "safety": [ 6 ], "of": [ 7, 70, 82, 184, 190, 233 ], "semaglutide,": [ 8 ], "a": [ 9, 144, 212 ], "recently": [ 10 ], "approved": [ 11 ], "glucagon\u2010like": [ 12 ], "peptide": [ 13 ], "1": [ 14, 97, 109, 163 ], "receptor": [ 15 ], "agonist": [ 16 ], "(GLP\u20101": [ 17 ], "RA)": [ 18 ], "for": [ 19, 35, 161, 198, 238 ], "type": [ 20 ], "2": [ 21 ], "diabetes.": [ 22 ], "Materials": [ 23 ], "methods": [ 25 ], "We": [ 26, 94, 169 ], "searched": [ 27 ], "major": [ 28 ], "electronic": [ 29 ], "databases": [ 30 ], "grey": [ 32 ], "literature": [ 33 ], "sources": [ 34 ], "randomized": [ 36 ], "controlled": [ 37 ], "trials": [ 38 ], "comparing": [ 39 ], "semaglutide": [ 40, 91, 106, 162 ], "with": [ 41, 89, 99, 103, 176, 202, 230 ], "placebo": [ 42, 153, 203 ], "or": [ 43 ], "other": [ 44, 130 ], "antidiabetic": [ 45, 131 ], "agents.": [ 46 ], "Primary": [ 47 ], "outcome": [ 48 ], "was": [ 49, 204 ], "change": [ 50, 58 ], "from": [ 51, 59 ], "baseline": [ 52, 60 ], "in": [ 53, 61, 245 ], "HbA1c.": [ 54 ], "Secondary": [ 55 ], "endpoints": [ 56 ], "included": [ 57 ], "body": [ 62, 148, 220 ], "weight,": [ 63 ], "blood": [ 64, 167, 224 ], "pressure,": [ 65 ], "heart": [ 66 ], "rate": [ 67 ], "incidence": [ 69, 183, 232 ], "hypoglycaemia,": [ 71 ], "gastrointestinal": [ 72, 234 ], "adverse": [ 73, 235 ], "effects,": [ 74 ], "pancreatitis": [ 75, 191, 239 ], "diabetic": [ 77, 199 ], "retinopathy.": [ 78 ], "Results": [ 79, 237 ], "A": [ 80 ], "total": [ 81 ], "6": [ 83 ], "placebo\u2010controlled": [ 84 ], "7": [ 86 ], "active\u2010controlled": [ 87 ], "studies": [ 88 ], "subcutaneous": [ 90, 105 ], "were": [ 92, 192 ], "included.": [ 93 ], "identified": [ 95 ], "only": [ 96 ], "trial": [ 98 ], "oral": [ 100 ], "semaglutide.": [ 101 ], "Compared": [ 102 ], "placebo,": [ 104 ], "0.5": [ 107 ], "mg": [ 110 ], "reduced": [ 111 ], "HbA1c": [ 112 ], "by": [ 113 ], "1.01%": [ 114 ], "(95%": [ 115, 206 ], "CI,": [ 116, 207 ], "0.56\u20101.47)": [ 117 ], "1.38%": [ 119 ], "(1.05\u20101.70),": [ 120 ], "respectively.": [ 121 ], "Both": [ 122 ], "doses": [ 123 ], "demonstrated": [ 124 ], "superior": [ 125 ], "glycaemic": [ 126 ], "compared": [ 128, 201 ], "to": [ 129, 159 ], "agents,": [ 132 ], "including": [ 133 ], "sitagliptin,": [ 134 ], "exenatide,": [ 135 ], "liraglutide,": [ 136 ], "dulaglutide": [ 137 ], "insulin": [ 139 ], "glargine.": [ 140 ], "Semaglutide": [ 141, 210 ], "also": [ 142 ], "had": [ 143 ], "beneficial": [ 145 ], "effect": [ 146 ], "on": [ 147 ], "weight": [ 149, 221 ], "(mean": [ 150 ], "difference": [ 151 ], "vs": [ 152 ], "\u22124.11": [ 154 ], "kg,": [ 155 ], "95%": [ 156 ], "CI": [ 157 ], "\u22124.85": [ 158 ], "\u22123.37": [ 160 ], "mg)": [ 164 ], "systolic": [ 166, 223 ], "pressure.": [ 168, 225 ], "did": [ 170 ], "not": [ 171 ], "observe": [ 172 ], "increased": [ 173, 182, 231 ], "hypoglycaemia": [ 174 ], "rates": [ 175 ], "semaglutide;": [ 177 ], "nevertheless,": [ 178 ], "we": [ 179 ], "noted": [ 180 ], "an": [ 181 ], "nausea,": [ 185 ], "vomiting": [ 186 ], "diarrhoea.": [ 188 ], "Cases": [ 189 ], "infrequent": [ 193 ], "odds": [ 196 ], "ratio": [ 197 ], "retinopathy": [ 200, 241 ], "1.32": [ 205 ], "0.98\u20101.77).": [ 208 ], "Conclusions": [ 209 ], "is": [ 211, 228 ], "potent": [ 213 ], "once\u2010weekly": [ 214 ], "GLP\u20101": [ 215 ], "RA,": [ 216 ], "significantly": [ 217 ], "reducing": [ 218 ], "HbA1c,": [ 219 ], "However,": [ 226 ], "it": [ 227 ], "associated": [ 229 ], "events.": [ 236 ], "require": [ 242 ], "further": [ 243 ], "assessment": [ 244 ], "post\u2010approval": [ 246 ], "pharmacovigilance": [ 247 ], "studies.": [ 248 ] }, "publication_date": "2018-05-13", "publication_year": 2018, "type": "review", "cited_by_count": 140, "authors": [ { "id": "https://openalex.org/A5071123372", "display_name": "P Andr\u00e9adis" }, { "id": "https://openalex.org/A5084182369", "display_name": "Thomas Karagiannis" }, { "id": "https://openalex.org/A5082971097", "display_name": "Konstantinos Malandris" }, { "id": "https://openalex.org/A5026527950", "display_name": "Ioannis Avgerinos" }, { "id": "https://openalex.org/A5010856150", "display_name": "Aris Liakos" }, { "id": "https://openalex.org/A5070546163", "display_name": "Apostolos Manolopoulos" }, { "id": "https://openalex.org/A5051305906", "display_name": "Eleni Bekiari" }, { "id": "https://openalex.org/A5101473066", "display_name": "David Matthews" }, { "id": "https://openalex.org/A5018882870", "display_name": "\u0391\u03c0\u03cc\u03c3\u03c4\u03bf\u03bb\u03bf\u03c2 \u03a4\u03c3\u03ac\u03c0\u03b1\u03c2" } ] }, { "id": "https://openalex.org/W2168014297", "doi": "https://doi.org/10.1517/14656566.7.8.1055", "title": "Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus", "abstract": { "Exenatide": [ 0, 24 ], "is": [ 1, 25 ], "a": [ 2 ], "glucagon-like": [ 3 ], "peptide": [ 4 ], "1": [ 5 ], "receptor": [ 6 ], "agonist,": [ 7 ], "which": [ 8 ], "has": [ 9 ], "recently": [ 10 ], "received": [ 11 ], "FDA": [ 12 ], "approval": [ 13 ], "in": [ 14, 33, 68, 79, 94 ], "the": [ 15, 18, 84, 95 ], "US": [ 16 ], "for": [ 17 ], "treatment": [ 19, 96 ], "of": [ 20, 44, 48, 54, 65, 76, 86, 97 ], "Type": [ 21, 98 ], "2": [ 22, 99 ], "diabetes.": [ 23, 100 ], "an": [ 26 ], "incretin": [ 27 ], "mimetic": [ 28 ], "that": [ 29, 62 ], "improves": [ 30 ], "glycaemic": [ 31 ], "control": [ 32 ], "patients": [ 34 ], "with": [ 35 ], "diabetes": [ 36 ], "through": [ 37 ], "acute": [ 38 ], "mechanisms,": [ 39 ], "such": [ 40 ], "as": [ 41, 57, 59, 89, 91 ], "glucose-dependent": [ 42 ], "stimulation": [ 43 ], "insulin": [ 45 ], "secretion,": [ 46 ], "suppression": [ 47 ], "inappropriate": [ 49 ], "glucagon": [ 50 ], "secretion": [ 51 ], "and": [ 52, 71, 74 ], "slowing": [ 53 ], "gastric": [ 55 ], "emptying,": [ 56 ], "well": [ 58, 90 ], "chronic": [ 60 ], "mechanisms": [ 61, 85 ], "include": [ 63 ], "enhancement": [ 64 ], "beta-cell": [ 66 ], "mass": [ 67 ], "rodent": [ 69 ], "studies": [ 70 ], "weight": [ 72 ], "loss": [ 73 ], "inhibition": [ 75 ], "food": [ 77 ], "intake": [ 78 ], "humans.": [ 80 ], "This": [ 81 ], "article": [ 82 ], "reviews": [ 83 ], "exenatide": [ 87 ], "action,": [ 88 ], "its": [ 92 ], "efficacy": [ 93 ] }, "publication_date": "2006-05-24", "publication_year": 2006, "type": "review", "cited_by_count": 63, "authors": [ { "id": "https://openalex.org/A5068625093", "display_name": "Mariele Briones" }, { "id": "https://openalex.org/A5072087217", "display_name": "Mandeep Bajaj" } ] }, { "id": "https://openalex.org/W4393255879", "doi": "https://doi.org/10.1056/nejmoa2313917", "title": "Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes", "abstract": { "Among": [ 0 ], "patients": [ 1 ], "with": [ 2, 6 ], "obesity-related": [ 3 ], "heart": [ 4, 20 ], "failure": [ 5 ], "preserved": [ 7 ], "ejection": [ 8 ], "fraction": [ 9 ], "and": [ 10, 23, 26 ], "type": [ 11 ], "2": [ 12 ], "diabetes,": [ 13 ], "semaglutide": [ 14 ], "led": [ 15 ], "to": [ 16 ], "larger": [ 17 ], "reductions": [ 18 ], "in": [ 19 ], "failure-related": [ 21 ], "symptoms": [ 22 ], "physical": [ 24 ], "limitations": [ 25 ], "greater": [ 27 ], "weight": [ 28 ], "loss": [ 29 ], "than": [ 30 ], "placebo": [ 31 ], "at": [ 32 ], "1": [ 33 ], "year.": [ 34 ], "(Funded": [ 35 ], "by": [ 36 ], "Novo": [ 37 ], "Nordisk;": [ 38 ], "STEP-HFpEF": [ 39 ], "DM": [ 40 ], "ClinicalTrials.gov": [ 41 ], "number,": [ 42 ], "NCT04916470.).": [ 43 ] }, "publication_date": "2024-03-28", "publication_year": 2024, "type": "article", "cited_by_count": 441, "authors": [ { "id": "https://openalex.org/A5052533254", "display_name": "Mikhail Kosiborod" }, { "id": "https://openalex.org/A5009535057", "display_name": "Mark C. Petrie" }, { "id": "https://openalex.org/A5030461468", "display_name": "Barry A. Borlaug" }, { "id": "https://openalex.org/A5022314919", "display_name": "Javed Butler" }, { "id": "https://openalex.org/A5084593004", "display_name": "Melanie J. Davies" }, { "id": "https://openalex.org/A5004099465", "display_name": "G. Kees Hovingh" }, { "id": "https://openalex.org/A5054890754", "display_name": "Dalane W. Kitzman" }, { "id": "https://openalex.org/A5111525200", "display_name": "Dani\u00e9l V. M\u00f8ller" }, { "id": "https://openalex.org/A5048183455", "display_name": "Marianne Bach Treppendahl" }, { "id": "https://openalex.org/A5080334509", "display_name": "Subodh Verma" }, { "id": "https://openalex.org/A5002690212", "display_name": "Thomas Jensen" }, { "id": "https://openalex.org/A5094266570", "display_name": "Karoline Liisberg" }, { "id": "https://openalex.org/A5108481559", "display_name": "Marie L.S. Lindegaard" }, { "id": "https://openalex.org/A5046452701", "display_name": "Walter P. Abhayaratna" }, { "id": "https://openalex.org/A5075620293", "display_name": "Fozia Ahmed" }, { "id": "https://openalex.org/A5025463635", "display_name": "Tuvia Ben\u2010Gal" }, { "id": "https://openalex.org/A5075949562", "display_name": "Vijay Chopra" }, { "id": "https://openalex.org/A5006527198", "display_name": "Justin A. Ezekowitz" }, { "id": "https://openalex.org/A5027994405", "display_name": "Michael Fu" }, { "id": "https://openalex.org/A5044544721", "display_name": "Hiroshi Ito" }, { "id": "https://openalex.org/A5078615816", "display_name": "Ma\u0142gorzata Lelonek" }, { "id": "https://openalex.org/A5069131955", "display_name": "Vojt\u011bch Melenovsk\u00fd" }, { "id": "https://openalex.org/A5086692319", "display_name": "B\u00e9la Merkely" }, { "id": "https://openalex.org/A5039483633", "display_name": "Julio N\u00fa\u00f1ez" }, { "id": "https://openalex.org/A5079453333", "display_name": "Eduardo Perna" }, { "id": "https://openalex.org/A5032789207", "display_name": "Morten Schou" }, { "id": "https://openalex.org/A5060241741", "display_name": "Michele Senni" }, { "id": "https://openalex.org/A5048642882", "display_name": "Kavita Sharma" }, { "id": "https://openalex.org/A5105820804", "display_name": "Peter van der Meer" }, { "id": "https://openalex.org/A5009903680", "display_name": "Dirk von Lewinski" }, { "id": "https://openalex.org/A5039523683", "display_name": "Dennis Wolf" }, { "id": "https://openalex.org/A5005215114", "display_name": "Sanjiv J. Shah" } ] }, { "id": "https://openalex.org/W4391170552", "doi": "https://doi.org/10.1007/s11096-023-01694-7", "title": "Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database", "abstract": null, "publication_date": "2024-01-24", "publication_year": 2024, "type": "article", "cited_by_count": 63, "authors": [ { "id": "https://openalex.org/A5070990016", "display_name": "Mansour Tobaiqy" }, { "id": "https://openalex.org/A5034747079", "display_name": "Hajer Elkout" } ] }, { "id": "https://openalex.org/W2152969995", "doi": "https://doi.org/10.1530/eje-09-0101", "title": "Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials", "abstract": { "Objective": [ 0 ], "The": [ 1 ], "role": [ 2 ], "of": [ 3, 12, 79, 83, 115, 130, 136, 143, 194, 209 ], "glucagon-like": [ 4 ], "peptide-1": [ 5 ], "(GLP-1)": [ 6 ], "receptor": [ 7, 53, 93, 109, 145, 148, 161, 179 ], "agonists": [ 8, 54, 94, 110, 162, 180 ], "in": [ 9, 25, 46, 105, 117, 165, 212 ], "the": [ 10, 106, 141, 190, 195 ], "treatment": [ 11 ], "type": [ 13, 47 ], "2": [ 14, 48 ], "diabetes": [ 15 ], "is": [ 16, 133, 200 ], "debated;": [ 17 ], "many": [ 18 ], "recent": [ 19 ], "trials,": [ 20 ], "which": [ 21, 84, 150, 199 ], "were": [ 22, 62 ], "not": [ 23 ], "included": [ 24, 104 ], "previous": [ 26 ], "meta-analyses,": [ 27 ], "could": [ 28 ], "add": [ 29 ], "relevant": [ 30 ], "information.": [ 31 ], "Design": [ 32 ], "and": [ 33, 56, 70, 75, 88, 95, 103, 168, 192 ], "methods": [ 34 ], "All": [ 35 ], "available": [ 36 ], "randomized": [ 37 ], "controlled": [ 38 ], "trials": [ 39 ], "(RCTs),": [ 40 ], "either": [ 41 ], "published": [ 42 ], "or": [ 43, 98 ], "unpublished,": [ 44 ], "performed": [ 45 ], "diabetic": [ 49 ], "patients": [ 50, 90, 172 ], "with": [ 51, 58, 119, 126, 140, 156, 207 ], "GLP-1": [ 52, 92, 108, 144, 147, 160, 178 ], "(exenatide": [ 55 ], "liraglutide),": [ 57 ], "a": [ 59, 112, 127 ], "duration>12": [ 60 ], "weeks": [ 61 ], "meta-analysed": [ 63 ], "for": [ 64, 202 ], "HbA1c,": [ 65 ], "body": [ 66 ], "mass": [ 67 ], "index,": [ 68 ], "hypoglycaemia": [ 69 ], "other": [ 71 ], "adverse": [ 72 ], "events.": [ 73 ], "Results": [ 74 ], "conclusions": [ 76 ], "A": [ 77 ], "total": [ 78 ], "21": [ 80 ], "RCTs": [ 81 ], "(six": [ 82 ], "unpublished),": [ 85 ], "enrolling": [ 86 ], "5429": [ 87 ], "3053": [ 89 ], "(with": [ 91 ], "active": [ 96 ], "comparator": [ 97 ], "placebo": [ 99, 120 ], "respectively),": [ 100 ], "was": [ 101 ], "retrieved": [ 102 ], "analysis.": [ 107 ], "determine": [ 111 ], "significant": [ 113 ], "improvement": [ 114 ], "HbA1c": [ 116, 167 ], "comparison": [ 118 ], "(\u22121.0": [ 121 ], "(\u22121.1,": [ 122 ], "\u22120.8),": [ 123 ], "P": [ 124 ], "<0.001),": [ 125 ], "low": [ 128 ], "risk": [ 129, 139 ], "hypoglycaemia.": [ 131 ], "There": [ 132 ], "no": [ 134 ], "evidence": [ 135 ], "increased": [ 137 ], "cardiovascular": [ 138 ], "use": [ 142 ], "agonists.": [ 146 ], "agonists,": [ 149 ], "induce": [ 151 ], "weight": [ 152 ], "loss,": [ 153 ], "are": [ 154, 163, 181, 205 ], "associated": [ 155 ], "gastrointestinal": [ 157 ], "side": [ 158 ], "effects.": [ 159 ], "effective": [ 164, 183 ], "reducing": [ 166 ], "postprandial": [ 169 ], "glucose.": [ 170 ], "In": [ 171 ], "failing": [ 173 ], "to": [ 174 ], "sulphonylureas": [ 175 ], "and/or": [ 176 ], "metformin,": [ 177 ], "similarly": [ 182 ], "as": [ 184 ], "insulin.": [ 185 ], "Available": [ 186 ], "data": [ 187 ], "suggest": [ 188 ], "that": [ 189 ], "efficacy": [ 191 ], "tolerability": [ 193 ], "novel": [ 196 ], "agent,": [ 197 ], "liraglutide,": [ 198 ], "adequate": [ 201 ], "once-a-day": [ 203 ], "administration,": [ 204 ], "comparable": [ 206 ], "those": [ 208 ], "exenatide": [ 210 ], "bis": [ 211 ], "die.": [ 213 ] }, "publication_date": "2009-03-25", "publication_year": 2009, "type": "review", "cited_by_count": 142, "authors": [ { "id": "https://openalex.org/A5059413618", "display_name": "Matteo Monami" }, { "id": "https://openalex.org/A5068485330", "display_name": "Niccol\u00f2 Marchionni" }, { "id": "https://openalex.org/A5059685674", "display_name": "Edoardo Mannucci" } ] }, { "id": "https://openalex.org/W4280579438", "doi": "https://doi.org/10.1007/s00125-022-05715-4", "title": "Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis", "abstract": null, "publication_date": "2022-05-17", "publication_year": 2022, "type": "review", "cited_by_count": 233, "authors": [ { "id": "https://openalex.org/A5084182369", "display_name": "Thomas Karagiannis" }, { "id": "https://openalex.org/A5026527950", "display_name": "Ioannis Avgerinos" }, { "id": "https://openalex.org/A5010856150", "display_name": "Aris Liakos" }, { "id": "https://openalex.org/A5019711625", "display_name": "Stefano Del Prato" }, { "id": "https://openalex.org/A5011127007", "display_name": "David R. Matthews" }, { "id": "https://openalex.org/A5018882870", "display_name": "\u0391\u03c0\u03cc\u03c3\u03c4\u03bf\u03bb\u03bf\u03c2 \u03a4\u03c3\u03ac\u03c0\u03b1\u03c2" }, { "id": "https://openalex.org/A5051305906", "display_name": "Eleni Bekiari" } ] }, { "id": "https://openalex.org/W3005269555", "doi": "https://doi.org/10.2337/dc19-1943", "title": "Trends in Clinical Characteristics and Prescribing Preferences for SGLT2 Inhibitors and GLP-1 Receptor Agonists, 2013\u20132018", "abstract": { "OBJECTIVE": [ 0 ], "There": [ 1 ], "is": [ 2 ], "a": [ 3, 59, 111, 190 ], "paucity": [ 4 ], "of": [ 5, 15, 48, 61, 93, 113, 133, 184 ], "data": [ 6, 37 ], "evaluating": [ 7 ], "recent": [ 8 ], "changes": [ 9, 168 ], "in": [ 10, 90, 140, 163, 169 ], "clinical": [ 11 ], "and": [ 12, 23, 50, 122, 172 ], "prescriber": [ 13 ], "characteristics": [ 14 ], "patients": [ 16, 94, 134 ], "initiating": [ 17 ], "sodium\u2013glucose": [ 18 ], "cotransporter": [ 19 ], "2": [ 20 ], "inhibitors": [ 21 ], "(SGLT2i)": [ 22 ], "glucagon-like": [ 24 ], "peptide": [ 25 ], "1": [ 26 ], "receptor": [ 27 ], "agonists": [ 28 ], "(GLP-1RA).": [ 29 ], "RESEARCH": [ 30 ], "DESIGN": [ 31 ], "AND": [ 32 ], "METHODS": [ 33 ], "U.S.-based": [ 34 ], "administrative": [ 35 ], "claims": [ 36 ], "(July": [ 38 ], "2013": [ 39 ], "to": [ 40, 45, 189 ], "June": [ 41 ], "2018)": [ 42 ], "were": [ 43, 150 ], "used": [ 44 ], "identify": [ 46 ], "initiators": [ 47, 142 ], "SGLT2i": [ 49, 86 ], "GLP-1RA.": [ 51 ], "RESULTS": [ 52 ], "Over": [ 53 ], "5": [ 54 ], "years,": [ 55 ], "empagliflozin": [ 56, 166 ], "initiation": [ 57, 73, 109, 124 ], "(as": [ 58, 110 ], "proportion": [ 60, 92, 112, 132 ], "SGLT2i)": [ 62 ], "increased": [ 63, 125, 137 ], "by": [ 64, 75, 117, 126 ], "57.1%": [ 65 ], "(P": [ 66, 77, 105, 119, 128 ], "&lt;": [ 67, 78, 106, 120, 129, 146 ], "0.001": [ 68 ], "for": [ 69, 165, 175, 192 ], "trend),": [ 70 ], "while": [ 71, 174 ], "canagliflozin": [ 72 ], "declined": [ 74, 116 ], "75.1%": [ 76 ], "0.001).": [ 79, 107, 147 ], "Empagliflozin": [ 80 ], "was": [ 81 ], "the": [ 82, 91, 131, 138 ], "only": [ 83 ], "agent": [ 84 ], "within": [ 85 ], "with": [ 87, 95, 135 ], "an": [ 88 ], "increase": [ 89 ], "myocardial": [ 96 ], "infarction,": [ 97 ], "stroke,": [ 98 ], "or": [ 99, 152, 182 ], "heart": [ 100 ], "failure": [ 101 ], "(collectively": [ 102 ], "called": [ 103 ], "CVD-HF)": [ 104 ], "Liraglutide": [ 108 ], "total": [ 114 ], "GLP-1RA)": [ 115 ], "32.1%": [ 118 ], "0.001),": [ 121 ], "dulaglutide": [ 123, 193 ], "34.1%": [ 127 ], "0.001);": [ 130 ], "CVD-HF": [ 136 ], "most": [ 139 ], "liraglutide": [ 141 ], "(5.1%": [ 143 ], "increase;": [ 144 ], "P": [ 145 ], "Most": [ 148 ], "prescribers": [ 149 ], "internists": [ 151 ], "endocrinologists;": [ 153 ], "cardiologist": [ 154 ], "prescribing": [ 155 ], "remained": [ 156 ], "low": [ 157 ], "(&lt;1%).": [ 158 ], "CONCLUSIONS": [ 159 ], "For": [ 160 ], "SGLT2i,": [ 161 ], "shifts": [ 162 ], "preference": [ 164, 191 ], "followed": [ 167 ], "drug": [ 170 ], "labels": [ 171 ], "guidelines,": [ 173 ], "GLP-1RA,": [ 176 ], "other": [ 177 ], "factors": [ 178 ], "such": [ 179 ], "as": [ 180 ], "price": [ 181 ], "ease": [ 183 ], "administration": [ 185 ], "may": [ 186 ], "have": [ 187 ], "led": [ 188 ], "over": [ 194 ], "liraglutide.": [ 195 ] }, "publication_date": "2020-02-10", "publication_year": 2020, "type": "article", "cited_by_count": 95, "authors": [ { "id": "https://openalex.org/A5101652561", "display_name": "Chintan V. Dave" }, { "id": "https://openalex.org/A5004416630", "display_name": "Sebastian Schneewei\u00df" }, { "id": "https://openalex.org/A5076997901", "display_name": "Deborah J. Wexler" }, { "id": "https://openalex.org/A5105786687", "display_name": "Gregory Brill" }, { "id": "https://openalex.org/A5044474781", "display_name": "Elisabetta Patorno" } ] }, { "id": "https://openalex.org/W1999325368", "doi": "https://doi.org/10.2147/dddt.s58459", "title": "Liraglutide and obesity: a review of the data so far", "abstract": { "The": [ 0, 36, 103 ], "prevalence": [ 1 ], "of": [ 2, 13, 39, 48, 88 ], "obesity": [ 3, 20, 40, 123 ], "worldwide": [ 4, 37 ], "has": [ 5, 60, 83 ], "nearly": [ 6 ], "doubled": [ 7 ], "since": [ 8 ], "1980": [ 9 ], "with": [ 10, 149 ], "current": [ 11 ], "estimates": [ 12 ], "2.1": [ 14 ], "billion": [ 15 ], "in": [ 16, 128, 134 ], "2013.": [ 17 ], "Overweight": [ 18 ], "and": [ 19, 33, 41, 118, 126, 136, 155, 164 ], "lead": [ 21 ], "to": [ 22, 62, 131 ], "numerous": [ 23 ], "adverse": [ 24 ], "conditions": [ 25 ], "including": [ 26 ], "type": [ 27 ], "2": [ 28 ], "diabetes,": [ 29 ], "cardiovascular": [ 30 ], "disease,": [ 31 ], "stroke,": [ 32 ], "certain": [ 34 ], "cancers.": [ 35 ], "spread": [ 38 ], "associated": [ 42 ], "comorbidities": [ 43 ], "not": [ 44 ], "only": [ 45 ], "threatens": [ 46 ], "quality": [ 47 ], "life": [ 49 ], "but": [ 50 ], "also": [ 51 ], "presents": [ 52, 143 ], "a": [ 53, 64, 75, 150 ], "significant": [ 54 ], "economic": [ 55 ], "burden.": [ 56 ], "While": [ 57 ], "bariatric": [ 58 ], "surgery": [ 59 ], "proven": [ 61 ], "be": [ 63, 132 ], "viable": [ 65 ], "treatment": [ 66, 124 ], "option": [ 67, 125 ], "for": [ 68, 77, 146 ], "the": [ 69, 89, 115, 144 ], "morbidly": [ 70 ], "obese,": [ 71 ], "there": [ 72 ], "is": [ 73 ], "clearly": [ 74 ], "need": [ 76 ], "less": [ 78 ], "invasive": [ 79 ], "alternatives.": [ 80 ], "Recent": [ 81 ], "research": [ 82 ], "suggested": [ 84 ], "that": [ 85 ], "long-acting": [ 86 ], "analogs": [ 87 ], "gut": [ 90 ], "hormone,": [ 91 ], "glucagon-like": [ 92 ], "peptide": [ 93 ], "1": [ 94 ], "(GLP-1),": [ 95 ], "may": [ 96 ], "have": [ 97 ], "potential": [ 98 ], "as": [ 99, 121 ], "an": [ 100, 122 ], "antiobesity": [ 101 ], "treatment.": [ 102 ], "GLP-1": [ 104 ], "receptor": [ 105 ], "agonist,": [ 106 ], "liraglutide": [ 107 ], "(trade": [ 108 ], "name": [ 109 ], "Saxenda),": [ 110 ], "was": [ 111 ], "recently": [ 112 ], "approved": [ 113 ], "by": [ 114 ], "US": [ 116 ], "Food": [ 117 ], "Drug": [ 119 ], "Administration": [ 120 ], "shown": [ 127 ], "clinical": [ 129 ], "trials": [ 130 ], "effective": [ 133 ], "reducing": [ 135 ], "sustaining": [ 137 ], "body": [ 138, 165 ], "weight": [ 139 ], "loss.": [ 140 ], "This": [ 141 ], "review": [ 142 ], "basis": [ 145 ], "GLP-1-based": [ 147 ], "therapies": [ 148 ], "specific": [ 151 ], "focus": [ 152 ], "on": [ 153, 161 ], "animal": [ 154 ], "human": [ 156 ], "studies": [ 157 ], "examining": [ 158 ], "liraglutide's": [ 159 ], "effects": [ 160 ], "food": [ 162 ], "intake": [ 163 ], "weight.": [ 166 ] }, "publication_date": "2015-03-01", "publication_year": 2015, "type": "review", "cited_by_count": 138, "authors": [ { "id": "https://openalex.org/A5111524825", "display_name": "Ellen E. Ladenheim" } ] }, { "id": "https://openalex.org/W2127732641", "doi": "https://doi.org/10.2337/dc13-3007", "title": "Glucose-Lowering Effects and Low Risk of Hypoglycemia in Patients With Maturity-Onset Diabetes of the Young When Treated With a GLP-1 Receptor Agonist: A Double-Blind, Randomized, Crossover Trial", "abstract": { "OBJECTIVE": [ 0 ], "The": [ 1, 279 ], "most": [ 2 ], "common": [ 3 ], "form": [ 4 ], "of": [ 5, 8, 29, 89, 140, 245, 262, 289, 293 ], "maturity-onset": [ 6 ], "diabetes": [ 7, 52 ], "the": [ 9, 138, 161, 197, 287 ], "young": [ 10 ], "(MODY),": [ 11 ], "hepatocyte": [ 12 ], "nuclear": [ 13 ], "factor": [ 14 ], "1\u03b1": [ 15 ], "(HNF1A": [ 16 ], "diabetes:": [ 17 ], "MODY3)": [ 18 ], "is": [ 19 ], "often": [ 20 ], "treated": [ 21 ], "with": [ 22, 34, 41, 50, 91, 181, 201, 219, 235, 264, 276, 284 ], "sulfonylureas": [ 23 ], "that": [ 24 ], "confer": [ 25 ], "a": [ 26, 92, 101, 111, 121, 144, 152, 290 ], "high": [ 27 ], "risk": [ 28, 292 ], "hypoglycemia.": [ 30, 296 ], "We": [ 31 ], "evaluated": [ 32 ], "treatment": [ 33, 90, 142, 162, 253, 263 ], "GLP-1": [ 35 ], "receptor": [ 36 ], "agonists": [ 37 ], "(GLP-1RAs)": [ 38 ], "in": [ 39, 107, 110, 120, 274 ], "patients": [ 40, 49, 275 ], "HNF1A": [ 42, 51, 277 ], "diabetes.": [ 43, 278 ], "RESEARCH": [ 44 ], "DESIGN": [ 45 ], "AND": [ 46 ], "METHODS": [ 47 ], "Sixteen": [ 48 ], "(8": [ 53 ], "women;": [ 54 ], "mean": [ 55 ], "age": [ 56 ], "39": [ 57 ], "years": [ 58 ], "[range": [ 59 ], "23\u201367": [ 60 ], "years];": [ 61 ], "BMI": [ 62 ], "24.9": [ 63 ], "\u00b1": [ 64, 68, 75, 80, 83, 165, 174, 205, 213, 222 ], "0.5": [ 65, 166 ], "kg/m2": [ 66 ], "[mean": [ 67 ], "SEM];": [ 69 ], "fasting": [ 70 ], "plasma": [ 71, 190 ], "glucose": [ 72, 191, 272 ], "[FPG]": [ 73 ], "9.9": [ 74 ], "0.9": [ 76 ], "mmol/L;": [ 77, 226 ], "HbA1c": [ 78 ], "6.4": [ 79 ], "0.2%": [ 81 ], "[47": [ 82 ], "3": [ 84 ], "mmol/mol])": [ 85 ], "received": [ 86 ], "6": [ 87 ], "weeks": [ 88, 261 ], "GLP-1RA": [ 93 ], "(liraglutide)": [ 94 ], "and": [ 95, 104, 136, 172, 210, 254, 270 ], "placebo": [ 96, 105 ], "(tablets),": [ 97 ], "as": [ 98, 100 ], "well": [ 99 ], "sulfonylurea": [ 102 ], "(glimepiride)": [ 103 ], "(injections),": [ 106 ], "randomized": [ 108 ], "order,": [ 109 ], "double-blind,": [ 112 ], "crossover": [ 113 ], "trial.": [ 114 ], "Glimepiride": [ 115 ], "was": [ 116, 125, 149, 282 ], "up-titrated": [ 117, 126 ], "once": [ 118, 127, 132 ], "weekly": [ 119, 128 ], "treat-to-target": [ 122 ], "manner;": [ 123 ], "liraglutide": [ 124, 168, 211, 257, 267 ], "to": [ 129 ], "1.8": [ 130 ], "mg": [ 131 ], "daily.": [ 133 ], "At": [ 134 ], "baseline": [ 135, 220 ], "at": [ 137, 286 ], "end": [ 139 ], "each": [ 141 ], "period": [ 143 ], "standardized": [ 145 ], "liquid": [ 146 ], "meal": [ 147 ], "test": [ 148 ], "performed,": [ 150 ], "including": [ 151 ], "30-min": [ 153 ], "light": [ 154 ], "bicycle": [ 155 ], "test.": [ 156 ], "RESULTS": [ 157 ], "FPG": [ 158, 269 ], "decreased": [ 159 ], "during": [ 160, 251, 256 ], "periods": [ 163 ], "(\u22121.6": [ 164 ], "mmol/L": [ 167, 176 ], "[P": [ 169, 178 ], "=": [ 170, 179, 187, 232, 241 ], "0.012]": [ 171 ], "\u22122.8": [ 173 ], "0.7": [ 175 ], "glimepiride": [ 177, 203, 252, 265, 285 ], "0.003]),": [ 180 ], "no": [ 182, 236 ], "difference": [ 183, 237 ], "between": [ 184, 238 ], "treatments": [ 185, 239 ], "(P": [ 186, 240 ], "0.624).": [ 188 ], "Postprandial": [ 189 ], "(PG)": [ 192 ], "responses": [ 193 ], "(total": [ 194 ], "area": [ 195 ], "under": [ 196 ], "curve)": [ 198 ], "were": [ 199 ], "lower": [ 200 ], "both": [ 202 ], "(2,136": [ 204 ], "292": [ 206 ], "min": [ 207, 215, 224 ], "\u00d7": [ 208, 216, 225 ], "mmol/L)": [ 209, 217, 249 ], "(2,624": [ 212 ], "340": [ 214 ], "compared": [ 218 ], "(3,127": [ 221 ], "291": [ 223 ], "P": [ 227, 231 ], "&lt;": [ 228 ], "0.001,": [ 229 ], "glimepiride;": [ 230 ], "0.017,": [ 233 ], "liraglutide),": [ 234 ], "0.121).": [ 242 ], "Eighteen": [ 243 ], "episodes": [ 244 ], "hypoglycemia": [ 246 ], "(PG": [ 247 ], "\u22643.9": [ 248 ], "occurred": [ 250 ], "one": [ 255 ], "treatment.": [ 258 ], "CONCLUSIONS": [ 259 ], "Six": [ 260 ], "or": [ 266 ], "lowered": [ 268 ], "postprandial": [ 271 ], "excursions": [ 273 ], "glucose-lowering": [ 280 ], "effect": [ 281 ], "greater": [ 283 ], "expense": [ 288 ], "higher": [ 291 ], "exclusively": [ 294 ], "mild": [ 295 ] }, "publication_date": "2014-06-12", "publication_year": 2014, "type": "article", "cited_by_count": 125, "authors": [ { "id": "https://openalex.org/A5038410410", "display_name": "Signe Harring \u00d8stoft" }, { "id": "https://openalex.org/A5035045477", "display_name": "Jonatan I. Bagger" }, { "id": "https://openalex.org/A5100704087", "display_name": "Torben Hansen" }, { "id": "https://openalex.org/A5066665434", "display_name": "Oluf Pedersen" }, { "id": "https://openalex.org/A5072362865", "display_name": "Jens Faber" }, { "id": "https://openalex.org/A5085434984", "display_name": "Jens J. Holst" }, { "id": "https://openalex.org/A5079352451", "display_name": "Filip K. Knop" }, { "id": "https://openalex.org/A5004120950", "display_name": "Tina Vilsb\u00f8ll" } ] }, { "id": "https://openalex.org/W2969705410", "doi": "https://doi.org/10.1089/dia.2019.0185", "title": "Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist", "abstract": { "Glucagon-like": [ 0 ], "peptide": [ 1 ], "1": [ 2 ], "receptor": [ 3 ], "agonists": [ 4 ], "(GLP-1": [ 5 ], "RAs)": [ 6 ], "are": [ 7 ], "highly": [ 8 ], "effective": [ 9 ], "at": [ 10 ], "lowering": [ 11, 123 ], "hemoglobin": [ 12 ], "A1c": [ 13 ], "(HbA1c)": [ 14 ], "and": [ 15, 29, 70, 84, 124 ], "facilitating": [ 16 ], "weight": [ 17, 125 ], "loss.": [ 18, 126 ], "Four": [ 19 ], "agents": [ 20, 40 ], "in": [ 21, 81, 106 ], "the": [ 22, 60, 67, 82, 89, 107, 114, 128, 149, 152 ], "GLP-1": [ 23, 63, 117 ], "RA": [ 24, 64 ], "class,": [ 25 ], "albiglutide,": [ 26 ], "liraglutide,": [ 27 ], "dulaglutide,": [ 28 ], "semaglutide,": [ 30, 140 ], "also": [ 31 ], "have": [ 32 ], "cardioprotective": [ 33 ], "effects.": [ 34 ], "However,": [ 35 ], "subcutaneous": [ 36 ], "administration": [ 37 ], "of": [ 38, 51, 79, 102, 151 ], "these": [ 39, 141 ], "remains": [ 41 ], "a": [ 42 ], "major": [ 43 ], "reason": [ 44 ], "for": [ 45 ], "their": [ 46 ], "underutilization.": [ 47 ], "A": [ 48 ], "new": [ 49 ], "coformulation": [ 50 ], "semaglutide": [ 52, 80, 93, 103 ], "with": [ 53, 119, 138 ], "sodium": [ 54 ], "N-[8-(2-hydroxybenzoyl)": [ 55 ], "amino": [ 56 ], "caprylate": [ 57 ], "(SNAC)": [ 58 ], "is": [ 59 ], "first": [ 61 ], "oral": [ 62, 100, 139 ], "reviewed": [ 65 ], "by": [ 66 ], "U.S.": [ 68 ], "Food": [ 69 ], "Drug": [ 71 ], "Administration": [ 72 ], "(FDA).": [ 73 ], "The": [ 74, 99 ], "SNAC": [ 75 ], "technology": [ 76 ], "prevents": [ 77 ], "destruction": [ 78 ], "stomach": [ 83 ], "facilitates": [ 85 ], "transcellular": [ 86 ], "absorption": [ 87 ], "through": [ 88 ], "gastric": [ 90 ], "membrane": [ 91 ], "enabling": [ 92 ], "to": [ 94, 113, 121 ], "reach": [ 95 ], "systemic": [ 96 ], "circulation": [ 97 ], "intact.": [ 98 ], "formulation": [ 101 ], "was": [ 104 ], "studied": [ 105 ], "PIONEER": [ 108, 129 ], "trials,": [ 109 ], "demonstrating": [ 110 ], "similar": [ 111 ], "efficacy": [ 112 ], "presently": [ 115 ], "available": [ 116 ], "RAs": [ 118 ], "regard": [ 120 ], "HbA1c": [ 122 ], "Although": [ 127 ], "6": [ 130 ], "trial": [ 131 ], "suggests": [ 132 ], "positive": [ 133 ], "effects": [ 134 ], "on": [ 135 ], "cardiovascular": [ 136 ], "mortality": [ 137 ], "benefits": [ 142 ], "may": [ 143 ], "not": [ 144 ], "fully": [ 145 ], "be": [ 146 ], "appreciated": [ 147 ], "until": [ 148 ], "completion": [ 150 ], "SOUL": [ 153 ], "trial.": [ 154 ] }, "publication_date": "2019-08-22", "publication_year": 2019, "type": "review", "cited_by_count": 145, "authors": [ { "id": "https://openalex.org/A5014755813", "display_name": "John D. Bucheit" }, { "id": "https://openalex.org/A5020833178", "display_name": "Lauren G. Pamulapati" }, { "id": "https://openalex.org/A5101453068", "display_name": "Nicole Carter" }, { "id": "https://openalex.org/A5069324357", "display_name": "Kevin J. Malloy" }, { "id": "https://openalex.org/A5017348274", "display_name": "Dave L. Dixon" }, { "id": "https://openalex.org/A5028628945", "display_name": "Evan M. Sisson" } ] }, { "id": "https://openalex.org/W1854533075", "doi": "https://doi.org/10.1111/j.1464-5491.2010.03020.x", "title": "Dose\u2010dependent effects of the once\u2010daily GLP\u20101 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double\u2010blind, placebo\u2010controlled trial", "abstract": { "Diabet.": [ 0 ], "Med.": [ 1 ], "27,": [ 2 ], "1024\u20131032": [ 3 ], "(2010)": [ 4 ], "Abstract": [ 5 ], "Aims": [ 6 ], "To": [ 7 ], "evaluate": [ 8 ], "the": [ 9, 99, 275, 288 ], "dose\u2013response": [ 10 ], "relationship": [ 11 ], "of": [ 12, 36, 71, 112, 182, 272, 290 ], "lixisenatide": [ 13, 69, 190, 222, 273 ], "(AVE0010),": [ 14 ], "a": [ 15, 110, 267 ], "glucagon\u2010like": [ 16 ], "peptide\u20101": [ 17 ], "(GLP\u20101)": [ 18 ], "receptor": [ 19, 283 ], "agonist,": [ 20 ], "in": [ 21, 90, 98, 180, 243, 287 ], "metformin\u2010treated": [ 22 ], "patients": [ 23, 38, 183, 246 ], "with": [ 24, 39, 67, 160, 221, 226, 247, 262, 266 ], "Type": [ 25, 40, 248, 291 ], "2": [ 26, 41, 249, 292 ], "diabetes.": [ 27 ], "Methods": [ 28 ], "Randomized,": [ 29 ], "double\u2010blind,": [ 30 ], "placebo\u2010controlled,": [ 31 ], "parallel\u2010group,": [ 32 ], "13": [ 33, 96 ], "week": [ 34 ], "study": [ 35, 176 ], "542": [ 37 ], "diabetes": [ 42, 250, 293 ], "inadequately": [ 43 ], "controlled": [ 44 ], "[glycated": [ 45 ], "haemoglobin": [ 46 ], "(HbA": [ 47 ], "1c": [ 48, 92, 108, 170 ], ")": [ 49 ], "\u2265": [ 50 ], "7.0": [ 51 ], "and": [ 52, 57, 123, 131, 136, 141, 145, 150, 186, 206, 259 ], "<": [ 53, 58, 164, 171, 197 ], "9.0%": [ 54 ], "(\u2265": [ 55, 63 ], "53": [ 56 ], "75": [ 59 ], "mmol/mol)]": [ 60 ], "on": [ 61, 139, 153, 251 ], "metformin": [ 62 ], "1000": [ 64 ], "mg/day)": [ 65 ], "treated": [ 66 ], "subcutaneous": [ 68 ], "doses": [ 70, 126 ], "5,": [ 72, 120 ], "10,": [ 73, 121 ], "20": [ 74, 122, 185, 268 ], "or": [ 75, 80, 83 ], "30": [ 76, 124, 187 ], "\u03bcg": [ 77, 125, 188, 269 ], "once": [ 78 ], "daily": [ 79, 82 ], "twice": [ 81 ], "placebo.": [ 84, 227 ], "The": [ 85, 228 ], "primary": [ 86 ], "end\u2010point": [ 87 ], "was": [ 88, 178, 233 ], "change": [ 89 ], "HbA": [ 91, 107, 169 ], "from": [ 93, 109, 216 ], "baseline": [ 94, 111 ], "to": [ 95, 218, 294 ], "weeks": [ 97 ], "intent\u2010to\u2010treat": [ 100 ], "population.": [ 101 ], "Results": [ 102 ], "Lixisenatide": [ 103, 238 ], "significantly": [ 104, 239 ], "improved": [ 105, 240 ], "mean": [ 106, 117 ], "7.55%": [ 113 ], "(59.0": [ 114 ], "mmol/mol);": [ 115 ], "respective": [ 116 ], "reductions": [ 118 ], "for": [ 119, 203, 257 ], "were": [ 127, 201, 255 ], "0.47,": [ 128 ], "0.50,": [ 129 ], "0.69": [ 130 ], "0.76%": [ 132 ], "(5.1,": [ 133 ], "5.5,": [ 134 ], "7.5": [ 135 ], "8.3": [ 137 ], "mmol/mol),": [ 138 ], "once\u2010daily": [ 140, 189, 270, 281 ], "0.65,": [ 142 ], "0.78,": [ 143 ], "0.75": [ 144 ], "0.87%": [ 146 ], "(7.1,": [ 147 ], "8.5,": [ 148 ], "8.2": [ 149 ], "9.5": [ 151 ], "mmol/mol)": [ 152, 159, 174 ], "twice\u2010daily": [ 154, 260 ], "administrations": [ 155 ], "vs.": [ 156, 166, 191, 223 ], "0.18%": [ 157 ], "(2.0": [ 158 ], "placebo": [ 161, 194 ], "(all": [ 162 ], "P": [ 163, 196 ], "0.01": [ 165 ], "placebo).": [ 167 ], "Target": [ 168 ], "7.0%": [ 172 ], "(53": [ 173 ], "at": [ 175 ], "end": [ 177 ], "achieved": [ 179 ], "68%": [ 181 ], "receiving": [ 184, 193 ], "32%": [ 192 ], "(": [ 195 ], "0.0001).": [ 198 ], "Dose\u2010dependent": [ 199 ], "improvements": [ 200 ], "observed": [ 202 ], "fasting,": [ 204 ], "postprandial": [ 205 ], "average": [ 207 ], "self\u2010monitored": [ 208 ], "seven\u2010point": [ 209 ], "blood": [ 210 ], "glucose": [ 211 ], "levels.": [ 212 ], "Weight": [ 213 ], "changes": [ 214 ], "ranged": [ 215 ], "\u22122.0": [ 217 ], "\u22123.9": [ 219 ], "kg": [ 220, 225 ], "\u22121.9": [ 224 ], "most": [ 229 ], "frequent": [ 230 ], "adverse": [ 231 ], "event": [ 232 ], "mild\u2010to\u2010moderate": [ 234 ], "nausea": [ 235 ], ".": [ 236 ], "Conclusions": [ 237 ], "glycaemic": [ 241 ], "control": [ 242 ], "mildly": [ 244 ], "hyperglycaemic": [ 245 ], "metformin.": [ 252 ], "Dose\u2013response": [ 253 ], "relationships": [ 254 ], "seen": [ 256 ], "once\u2010": [ 258 ], "regimens,": [ 261 ], "similar": [ 263 ], "efficacy": [ 264 ], "levels,": [ 265 ], "dose": [ 271 ], "demonstrating": [ 274 ], "best": [ 276 ], "efficacy\u2010to\u2010tolerability": [ 277 ], "ratio.": [ 278 ], "This": [ 279 ], "new,": [ 280 ], "GLP\u20101": [ 282 ], "agonist": [ 284 ], "shows": [ 285 ], "promise": [ 286 ], "management": [ 289 ], "be": [ 295 ], "defined": [ 296 ], "further": [ 297 ], "by": [ 298 ], "ongoing": [ 299 ], "long\u2010term": [ 300 ], "studies.": [ 301 ] }, "publication_date": "2010-05-01", "publication_year": 2010, "type": "article", "cited_by_count": 153, "authors": [ { "id": "https://openalex.org/A5081205041", "display_name": "Robert E. Ratner" }, { "id": "https://openalex.org/A5045489578", "display_name": "Julio Rosenstock" }, { "id": "https://openalex.org/A5112960670", "display_name": "G. Boka" } ] }, { "id": "https://openalex.org/W2138290933", "doi": "https://doi.org/10.1111/j.1464-5491.2009.02666.x", "title": "Liraglutide, a once\u2010daily human GLP\u20101 analogue, added to a sulphonylurea over 26\u00a0weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type\u00a02 diabetes (LEAD\u20101 SU)", "abstract": { "Abstract": [ 0 ], "Aim": [ 1 ], "To": [ 2 ], "compare": [ 3 ], "the": [ 4 ], "effects": [ 5 ], "of": [ 6 ], "combining": [ 7 ], "liraglutide": [ 8, 165, 211, 251 ], "(0.6,": [ 9 ], "1.2": [ 10, 166, 212, 259 ], "or": [ 11, 14, 22, 103, 126, 171, 190, 213, 236, 266 ], "1.8": [ 12, 104, 172, 214, 252 ], "mg/day)": [ 13, 31 ], "rosiglitazone": [ 15, 127, 237, 277 ], "4": [ 16 ], "mg/day": [ 17 ], "(all": [ 18 ], "n": [ 19, 25 ], "\u2265": [ 20 ], "228)": [ 21 ], "placebo": [ 23, 119, 227, 267 ], "(": [ 24 ], "=": [ 26 ], "114)": [ 27 ], "with": [ 28, 118, 154, 164, 178, 210, 226, 250, 276 ], "glimepiride": [ 29, 311 ], "(2\u20134": [ 30 ], "on": [ 32, 80 ], "glycaemic": [ 33, 318 ], "control,": [ 34 ], "body": [ 35, 248 ], "weight": [ 36, 57, 249, 322 ], "and": [ 37, 62, 303, 315, 320 ], "safety": [ 38 ], "in": [ 39, 74, 93, 109, 202, 247 ], "Type": [ 40 ], "2": [ 41 ], "diabetes.": [ 42 ], "Methods": [ 43 ], "In": [ 44 ], "total,": [ 45 ], "1041": [ 46 ], "adults": [ 47 ], "(mean": [ 48 ], "\u00b1": [ 49, 54, 59, 69 ], "sd": [ 50 ], "),": [ 51 ], "age": [ 52 ], "56": [ 53 ], "10": [ 55 ], "years,": [ 56 ], "82": [ 58 ], "17": [ 60 ], "kg": [ 61 ], "glycated": [ 63 ], "haemoglobin": [ 64 ], "(HbA": [ 65 ], "1c": [ 66, 111 ], ")": [ 67 ], "8.4": [ 68 ], "1.0%": [ 70 ], "at": [ 71, 161 ], "116": [ 72 ], "sites": [ 73 ], "21": [ 75 ], "countries": [ 76 ], "were": [ 77, 208, 273, 292 ], "stratified": [ 78 ], "based": [ 79 ], "previous": [ 81 ], "oral": [ 82 ], "glucose\u2010lowering": [ 83 ], "mono": [ 84 ], ":": [ 85, 89 ], "combination": [ 86 ], "therapies": [ 87 ], "(30": [ 88 ], "70%)": [ 90 ], "to": [ 91, 136, 217, 310 ], "participate": [ 92 ], "a": [ 94, 155, 179 ], "five\u2010arm,": [ 95 ], "26\u2010week,": [ 96 ], "double\u2010dummy,": [ 97 ], "randomized": [ 98 ], "study.": [ 99 ], "Results": [ 100 ], "Liraglutide": [ 101, 138, 308 ], "(1.2": [ 102 ], "mg)": [ 105 ], "produced": [ 106 ], "greater": [ 107, 209 ], "reductions": [ 108 ], "HbA": [ 110 ], "from": [ 112, 159, 206 ], "baseline,": [ 113 ], "(\u22121.1%,": [ 114 ], "baseline": [ 115, 124, 132, 145, 160, 187, 198, 207, 233, 243, 256, 263, 270, 283 ], "8.5%)": [ 116 ], "compared": [ 117, 177, 225 ], "(+0.2%,": [ 120 ], "P": [ 121, 129, 184, 195, 230, 240, 280 ], "<": [ 122, 130, 185, 196, 231, 241, 281 ], "0.0001,": [ 123, 131, 186, 232, 282 ], "8.4%)": [ 125, 133 ], "(\u22120.4%,": [ 128 ], "when": [ 134 ], "added": [ 135, 309 ], "glimepiride.": [ 137 ], "0.6": [ 139 ], "mg": [ 140, 167, 173, 215, 253, 260 ], "was": [ 141, 312 ], "less": [ 142, 274 ], "effective": [ 143 ], "(\u22120.6%,": [ 144 ], "8.4%).": [ 146 ], "Fasting": [ 147 ], "plasma": [ 148, 204 ], "glucose": [ 149, 205 ], "decreased": [ 150 ], "by": [ 151 ], "week": [ 152, 162 ], "2,": [ 153 ], "1.6": [ 156 ], "mmol/l": [ 157, 181, 192, 219, 222 ], "decrease": [ 158, 193 ], "26": [ 163 ], "(baseline": [ 168, 174, 220 ], "9.8": [ 169 ], "mmol/l)": [ 170, 176, 189, 235 ], "9.7": [ 175 ], "0.9": [ 180 ], "increase": [ 182 ], "(placebo,": [ 183 ], "9.5": [ 188 ], "1.0": [ 191 ], "(rosiglitazone,": [ 194 ], "0.006,": [ 197 ], "9.9": [ 199 ], "mmol/l).": [ 200, 245 ], "Decreases": [ 201 ], "postprandial": [ 203 ], "[\u22122.5": [ 216 ], "\u22122.7": [ 218 ], "12.9": [ 221 ], "for": [ 223, 289 ], "both)]": [ 224 ], "(\u22120.4": [ 228 ], "mmol/l,": [ 229, 239 ], "12.7": [ 234 ], "(\u22121.8": [ 238 ], "0.05,": [ 242 ], "13.0": [ 244 ], "Changes": [ 246 ], "(\u22120.2": [ 254 ], "kg,": [ 255, 262, 269, 279 ], "83.0": [ 257 ], "kg),": [ 258 ], "(+0.3": [ 261 ], "80.0": [ 264 ], "kg)": [ 265, 272 ], "(\u22120.1": [ 268 ], "81.9": [ 271 ], "than": [ 275 ], "(+2.1": [ 278 ], "80.6": [ 284 ], "kg).": [ 285 ], "Main": [ 286 ], "adverse": [ 287 ], "events": [ 288 ], "all": [ 290 ], "treatments": [ 291 ], "minor": [ 293 ], "hypoglycaemia": [ 294 ], "(<": [ 295, 298, 301, 305 ], "10%),": [ 296 ], "nausea": [ 297 ], "11%),": [ 299 ], "vomiting": [ 300 ], "5%)": [ 302 ], "diarrhoea": [ 304 ], "8%).": [ 306 ], "Conclusions": [ 307 ], "well": [ 313 ], "tolerated": [ 314 ], "provided": [ 316 ], "improved": [ 317 ], "control": [ 319 ], "favourable": [ 321 ], "profile.": [ 323 ] }, "publication_date": "2009-01-14", "publication_year": 2009, "type": "article", "cited_by_count": 804, "authors": [ { "id": "https://openalex.org/A5088350286", "display_name": "Michel Marre" }, { "id": "https://openalex.org/A5021564821", "display_name": "J. Shaw" }, { "id": "https://openalex.org/A5054303361", "display_name": "Michael Br\u00e4ndle" }, { "id": "https://openalex.org/A5108202861", "display_name": "Wan Mohamed Wan Bebakar" }, { "id": "https://openalex.org/A5107854830", "display_name": "Nor Azmi Kamaruddin" }, { "id": "https://openalex.org/A5075280104", "display_name": "Jorma Strand" }, { "id": "https://openalex.org/A5059007137", "display_name": "Marija Zdravkovi\u0107" }, { "id": "https://openalex.org/A5110001248", "display_name": "Tu D. L. Thi" }, { "id": "https://openalex.org/A5080414613", "display_name": "Stephen Colagiuri" } ] }, { "id": "https://openalex.org/W4229012762", "doi": "https://doi.org/10.1055/a-1844-1176", "title": "The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis", "abstract": { "Abstract": [ 0 ], "Aim": [ 1 ], "To": [ 2 ], "determine": [ 3 ], "the": [ 4, 54, 69, 92, 103, 143, 153, 189 ], "antiobesity": [ 5, 146, 209, 233 ], "effect": [ 6, 147, 210, 234 ], "and": [ 7, 18, 45, 68, 80, 115, 129, 160, 175, 179, 224, 235, 242 ], "safety": [ 8 ], "of": [ 9, 64, 71, 86, 105, 150, 155, 192, 199, 220 ], "glucagon-like": [ 10 ], "peptide-1": [ 11 ], "receptor": [ 12 ], "agonist": [ 13 ], "(GLP-1RA)": [ 14 ], "including": [ 15, 112 ], "liraglutide,": [ 16, 113 ], "exenatide": [ 17, 114 ], "semaglutide": [ 19, 116, 141, 187 ], "treatment": [ 20, 104 ], "in": [ 21, 91, 148, 213, 218 ], "overweight/obese": [ 22, 106, 214 ], "patients": [ 23, 107, 215 ], "without": [ 24, 108, 216 ], "diabetes.": [ 25 ], "The": [ 26, 38, 62, 99, 136, 181 ], "random-effect": [ 27 ], "model": [ 28 ], "was": [ 29 ], "used": [ 30, 51 ], "to": [ 31, 52 ], "pool": [ 32 ], "data": [ 33 ], "extracted": [ 34 ], "from": [ 35 ], "included": [ 36, 96 ], "literatures.": [ 37 ], "weighted": [ 39 ], "mean": [ 40 ], "difference": [ 41 ], "(WMD),": [ 42 ], "odds": [ 43 ], "ratio": [ 44 ], "95%": [ 46, 125, 132 ], "confidence": [ 47 ], "interval": [ 48 ], "(CI)": [ 49 ], "were": [ 50, 73, 89 ], "present": [ 53, 93 ], "meta-analysis": [ 55, 202 ], "results": [ 56, 72, 100 ], "(PROSPERO": [ 57 ], "registration": [ 58 ], "number:": [ 59 ], "CRD": [ 60 ], "42020173199).": [ 61 ], "sources": [ 63 ], "intertrial": [ 65 ], "heterogeneity,": [ 66 ], "bias": [ 67 ], "robustness": [ 70 ], "evaluated": [ 74 ], "by": [ 75 ], "subgroup": [ 76, 137, 182 ], "analysis,": [ 77, 82 ], "sensitivity": [ 78 ], "analysis": [ 79, 94, 138, 183 ], "regression": [ 81 ], "respectively.": [ 83 ], "A": [ 84 ], "total": [ 85 ], "24": [ 87 ], "RCTs": [ 88 ], "recruited": [ 90 ], "which": [ 95, 229 ], "5867": [ 97 ], "patients.": [ 98 ], "showed": [ 101, 139 ], "that": [ 102, 140, 186, 204 ], "diabetes": [ 109, 217 ], "with": [ 110 ], "GLP-1RAs": [ 111, 165 ], "significantly": [ 117 ], "achieved": [ 118 ], "greater": [ 119 ], "weight": [ 120, 151 ], "loss": [ 121 ], "than": [ 122, 177, 211, 240 ], "placebo": [ 123, 178 ], "[WMD=\u20135.39,": [ 124 ], "CI": [ 126, 133 ], "(\u20136.82,": [ 127 ], "\u20133.96)]": [ 128 ], "metformin": [ 130 ], "[WMD=\u20135.46,": [ 131 ], "(\u20135.87,": [ 134 ], "\u20135.05)].": [ 135 ], "displayed": [ 142, 188 ], "most": [ 144 ], "obvious": [ 145, 232 ], "terms": [ 149, 219 ], "loss,": [ 152 ], "reduction": [ 154 ], "body": [ 156, 221 ], "mass": [ 157 ], "index": [ 158 ], "(BMI)": [ 159 ], "waist": [ 161 ], "circumference": [ 162 ], "(WC).": [ 163 ], "However,": [ 164 ], "treatments": [ 166 ], "had": [ 167, 206, 230 ], "more": [ 168, 231 ], "gastrointestinal": [ 169, 193 ], "adverse": [ 170, 194, 238 ], "events": [ 171, 195, 239 ], "(such": [ 172 ], "as": [ 173 ], "nausea": [ 174 ], "vomiting)": [ 176 ], "Met.": [ 180 ], "also": [ 184 ], "represented": [ 185 ], "lowest": [ 190 ], "risk": [ 191 ], "among": [ 196 ], "three": [ 197 ], "kinds": [ 198 ], "GLP-1RAs.": [ 200 ], "Our": [ 201 ], "demonstrated": [ 203 ], "GLP-1RA": [ 205 ], "a": [ 207 ], "superior": [ 208 ], "placebo/Met": [ 212 ], "weight,": [ 222 ], "BMI,": [ 223 ], "WC,": [ 225 ], "especially": [ 226 ], "for": [ 227 ], "semaglutide,": [ 228 ], "lower": [ 236 ], "GI": [ 237 ], "liraglutide": [ 241 ], "exenatide.": [ 243 ] }, "publication_date": "2022-05-05", "publication_year": 2022, "type": "review", "cited_by_count": 53, "authors": [ { "id": "https://openalex.org/A5008845556", "display_name": "Xiaonan Guo" }, { "id": "https://openalex.org/A5101846294", "display_name": "Zhibo Zhou" }, { "id": "https://openalex.org/A5041595146", "display_name": "Xiaorui Lyu" }, { "id": "https://openalex.org/A5021972817", "display_name": "Hanyuan Xu" }, { "id": "https://openalex.org/A5054551633", "display_name": "Huijuan Zhu" }, { "id": "https://openalex.org/A5085187324", "display_name": "Hui Pan" }, { "id": "https://openalex.org/A5100737549", "display_name": "Linjie Wang" }, { "id": "https://openalex.org/A5042656907", "display_name": "Hongbo Yang" }, { "id": "https://openalex.org/A5068009587", "display_name": "Fengying Gong" } ] }, { "id": "https://openalex.org/W2885588864", "doi": "https://doi.org/10.1016/s0140-6736(18)31773-2", "title": "Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial", "abstract": null, "publication_date": "2018-08-01", "publication_year": 2018, "type": "article", "cited_by_count": 729, "authors": [ { "id": "https://openalex.org/A5085642856", "display_name": "Patrick M. O\u2019Neil" }, { "id": "https://openalex.org/A5013839934", "display_name": "Andreas L. Birkenfeld" }, { "id": "https://openalex.org/A5021130189", "display_name": "Barbara McGowan" }, { "id": "https://openalex.org/A5080475619", "display_name": "Ofri Mosenzon" }, { "id": "https://openalex.org/A5040913971", "display_name": "Sue D. Pedersen" }, { "id": "https://openalex.org/A5027441223", "display_name": "Sean Wharton" }, { "id": "https://openalex.org/A5102729119", "display_name": "Charlotte Giwercman Carson" }, { "id": "https://openalex.org/A5009688853", "display_name": "Cecilie H. Jepsen" }, { "id": "https://openalex.org/A5076666367", "display_name": "Maria Kabisch" }, { "id": "https://openalex.org/A5047195042", "display_name": "John Wilding" } ] }, { "id": "https://openalex.org/W3158123746", "doi": "https://doi.org/10.1056/nejmoa2028198", "title": "Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined", "abstract": { "A": [ 0 ], "strategy": [ 1 ], "combining": [ 2 ], "exercise": [ 3 ], "and": [ 4, 23 ], "liraglutide": [ 5 ], "therapy": [ 6 ], "improved": [ 7 ], "healthy": [ 8 ], "weight": [ 9 ], "loss": [ 10 ], "maintenance": [ 11 ], "more": [ 12 ], "than": [ 13 ], "either": [ 14 ], "treatment": [ 15 ], "alone.": [ 16 ], "(Funded": [ 17 ], "by": [ 18 ], "the": [ 19 ], "Novo": [ 20 ], "Nordisk": [ 21 ], "Foundation": [ 22 ], "others;": [ 24 ], "EudraCT": [ 25 ], "number,": [ 26, 29 ], "2015-005585-32;": [ 27 ], "ClinicalTrials.gov": [ 28 ], "NCT04122716.).": [ 30 ] }, "publication_date": "2021-05-05", "publication_year": 2021, "type": "article", "cited_by_count": 392, "authors": [ { "id": "https://openalex.org/A5007991615", "display_name": "J. Lundgren" }, { "id": "https://openalex.org/A5089416119", "display_name": "Charlotte Janus" }, { "id": "https://openalex.org/A5078868922", "display_name": "Simon Birk Kj\u00e6r Jensen" }, { "id": "https://openalex.org/A5043941957", "display_name": "Christian R. Juhl" }, { "id": "https://openalex.org/A5045178005", "display_name": "Lisa Olsen" }, { "id": "https://openalex.org/A5108492751", "display_name": "Rasmus M. Christensen" }, { "id": "https://openalex.org/A5051265599", "display_name": "Maria S. Svane" }, { "id": "https://openalex.org/A5082280266", "display_name": "Thomas Bandholm" }, { "id": "https://openalex.org/A5040861246", "display_name": "Kirstine N. Bojsen\u2010M\u00f8ller" }, { "id": "https://openalex.org/A5101591653", "display_name": "Martin B\u00e6k Blond" }, { "id": "https://openalex.org/A5058323484", "display_name": "Jens\u2010Erik Beck Jensen" }, { "id": "https://openalex.org/A5066604050", "display_name": "Bente Stallknecht" }, { "id": "https://openalex.org/A5085434984", "display_name": "Jens J. Holst" }, { "id": "https://openalex.org/A5062239390", "display_name": "Sten Madsbad" }, { "id": "https://openalex.org/A5038081896", "display_name": "Signe S. Torekov" } ] }, { "id": "https://openalex.org/W1493207176", "doi": "https://doi.org/10.2337/dc15-0258", "title": "Markers of \u03b2-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes", "abstract": { "OBJECTIVE": [ 0 ], "To": [ 1 ], "assess": [ 2 ], "whether": [ 3 ], "clinical": [ 4, 74 ], "characteristics": [ 5 ], "and": [ 6, 45, 60, 80, 102, 109, 135, 204, 228 ], "simple": [ 7 ], "biomarkers": [ 8, 233 ], "of": [ 9, 55, 123, 214, 237 ], "\u03b2-cell": [ 10, 78, 216 ], "failure": [ 11, 79 ], "are": [ 12, 218 ], "associated": [ 13, 76, 119, 207, 219 ], "with": [ 14, 28, 41, 77, 89, 104, 120, 148, 208, 220 ], "individual": [ 15 ], "variation": [ 16 ], "in": [ 17, 26, 91, 201, 240 ], "glycemic": [ 18, 81, 114, 162, 222 ], "response": [ 19, 62, 82, 115, 163, 223 ], "to": [ 20, 63, 116, 164, 224 ], "GLP-1": [ 21 ], "receptor": [ 22 ], "agonist": [ 23 ], "(GLP-1RA)": [ 24 ], "therapy": [ 25, 52, 64, 166, 239 ], "patients": [ 27 ], "type": [ 29, 42 ], "2": [ 30, 43 ], "diabetes.": [ 31, 242 ], "RESEARCH": [ 32 ], "DESIGN": [ 33 ], "AND": [ 34 ], "METHODS": [ 35 ], "We": [ 36, 68 ], "prospectively": [ 37 ], "studied": [ 38 ], "620": [ 39 ], "participants": [ 40, 203 ], "diabetes": [ 44, 58 ], "HbA1c": [ 46, 85, 108, 169 ], "\u226558": [ 47 ], "mmol/mol": [ 48, 174, 189 ], "(7.5%)": [ 49 ], "commencing": [ 50 ], "GLP-1RA": [ 51, 165, 225, 238 ], "as": [ 53, 95 ], "part": [ 54 ], "their": [ 56 ], "usual": [ 57 ], "care": [ 59 ], "assessed": [ 61, 69 ], "over": [ 65 ], "6": [ 66 ], "months.": [ 67 ], "the": [ 70, 235 ], "association": [ 71 ], "between": [ 72 ], "baseline": [ 73, 107 ], "measurements": [ 75 ], "(primary": [ 83 ], "outcome": [ 84, 98 ], "change": [ 86, 90, 170, 185 ], "0\u20136": [ 87 ], "months)": [ 88, 94 ], "weight": [ 92, 209 ], "(0\u20136": [ 93 ], "a": [ 96 ], "secondary": [ 97 ], "using": [ 99 ], "linear": [ 100 ], "regression": [ 101 ], "ANOVA": [ 103 ], "adjustment": [ 105 ], "for": [ 106, 145, 234 ], "cotreatment": [ 110 ], "change.": [ 111, 210 ], "RESULTS": [ 112 ], "Reduced": [ 113 ], "GLP-1RAs": [ 117 ], "was": [ 118 ], "longer": [ 121 ], "duration": [ 122 ], "diabetes,": [ 124 ], "insulin": [ 125, 153 ], "cotreatment,": [ 126 ], "lower": [ 127, 130 ], "fasting": [ 128 ], "C-peptide,": [ 129 ], "postmeal": [ 131 ], "urine": [ 132 ], "C-peptide\u2013to\u2013creatinine": [ 133 ], "ratio,": [ 134 ], "positive": [ 136, 149 ], "GAD": [ 137 ], "or": [ 138, 151 ], "IA2": [ 139 ], "islet": [ 140, 229 ], "autoantibodies": [ 141, 150, 230 ], "(P": [ 142 ], "\u2264": [ 143 ], "0.01": [ 144 ], "all).": [ 146 ], "Participants": [ 147 ], "severe": [ 152 ], "deficiency": [ 154 ], "(fasting": [ 155 ], "C-peptide": [ 156, 181, 227 ], "\u22640.25": [ 157 ], "nmol/L)": [ 158 ], "had": [ 159 ], "markedly": [ 160 ], "reduced": [ 161, 221 ], "(autoantibodies,": [ 167 ], "mean": [ 168, 184 ], "\u22125.2": [ 171 ], "vs.": [ 172, 176, 187, 191 ], "\u221215.2": [ 173 ], "[\u22120.5": [ 175 ], "\u22121.4%],": [ 177, 192 ], "P": [ 178, 193 ], "=": [ 179, 194 ], "0.005;": [ 180 ], "&lt;0.25": [ 182 ], "nmol/L,": [ 183 ], "\u22122.1": [ 186 ], "\u221215.3": [ 188 ], "[\u22120.2": [ 190 ], "0.002).": [ 195 ], "These": [ 196 ], "markers": [ 197, 213 ], "were": [ 198, 205 ], "predominantly": [ 199 ], "present": [ 200 ], "insulin-treated": [ 202, 241 ], "not": [ 206 ], "CONCLUSIONS": [ 211 ], "Clinical": [ 212 ], "low": [ 215 ], "function": [ 217 ], "therapy.": [ 226 ], "represent": [ 231 ], "potential": [ 232 ], "stratification": [ 236 ] }, "publication_date": "2015-08-04", "publication_year": 2015, "type": "article", "cited_by_count": 165, "authors": [ { "id": "https://openalex.org/A5036287780", "display_name": "Angus G. Jones" }, { "id": "https://openalex.org/A5103163871", "display_name": "Timothy J. McDonald" }, { "id": "https://openalex.org/A5073846514", "display_name": "Beverley M. Shields" }, { "id": "https://openalex.org/A5001829491", "display_name": "Anita Hill" }, { "id": "https://openalex.org/A5067817683", "display_name": "Christopher Hyde" }, { "id": "https://openalex.org/A5055929158", "display_name": "Bridget Knight" }, { "id": "https://openalex.org/A5060736941", "display_name": "Andrew T. Hattersley" } ] }, { "id": "https://openalex.org/W2791728731", "doi": "https://doi.org/10.1111/dom.13129", "title": "Incretin hormones: Their role in health and disease", "abstract": { "Incretin": [ 0 ], "hormones": [ 1, 30, 319 ], "are": [ 2, 6, 26, 45, 123, 181, 327 ], "gut": [ 3, 202 ], "peptides": [ 4 ], "that": [ 5, 134, 297, 343 ], "secreted": [ 7 ], "after": [ 8, 261 ], "nutrient": [ 9 ], "intake": [ 10 ], "and": [ 11, 37, 98, 118, 144, 162, 186, 256, 269, 283, 307, 334, 338 ], "stimulate": [ 12 ], "insulin": [ 13, 56 ], "secretion": [ 14, 199, 226 ], "together": [ 15 ], "with": [ 16, 69, 127, 313 ], "hyperglycaemia.": [ 17 ], "GIP": [ 18, 92, 268 ], "(glucose\u2010dependent": [ 19 ], "insulinotropic": [ 20, 117 ], "polypeptide)": [ 21 ], "und": [ 22 ], "GLP\u20101": [ 23, 105, 122, 138, 198, 228, 298 ], "(glucagon\u2010like": [ 24 ], "peptide\u20101)": [ 25 ], "the": [ 27, 32, 48, 84, 94, 100, 108, 116, 132, 194, 201, 217, 237, 284, 288, 330 ], "known": [ 28 ], "incretin": [ 29, 49, 74, 109, 274, 318 ], "from": [ 31, 200 ], "upper": [ 33 ], "(GIP,": [ 34 ], "K": [ 35 ], "cells)": [ 36, 41, 243 ], "lower": [ 38, 234 ], "(GLP\u20101,": [ 39 ], "L": [ 40, 242 ], "gut.": [ 42 ], "Together,": [ 43 ], "they": [ 44, 326, 339 ], "responsible": [ 46 ], "for": [ 47 ], "effect:": [ 50 ], "a": [ 51, 87, 152, 182, 214 ], "two\u2010": [ 52 ], "to": [ 53, 59, 63, 131, 190, 204, 233, 347 ], "three\u2010fold": [ 54 ], "higher": [ 55 ], "secretory": [ 57 ], "response": [ 58 ], "oral": [ 60 ], "as": [ 61, 273, 302 ], "compared": [ 62 ], "intravenous": [ 64 ], "glucose": [ 65, 143 ], "administration.": [ 66 ], "In": [ 67 ], "subjects": [ 68, 126 ], "type": [ 70, 128, 314, 335 ], "2": [ 71, 129, 315, 336 ], "diabetes,": [ 72, 337 ], "this": [ 73, 210 ], "effect": [ 75, 110 ], "is": [ 76, 83 ], "diminished": [ 77 ], "or": [ 78, 167 ], "no": [ 79 ], "longer": [ 80 ], "present.": [ 81 ], "This": [ 82 ], "consequence": [ 85 ], "of": [ 86, 91, 99, 104, 121, 137, 155, 164, 219, 227, 236, 332 ], "substantially": [ 88 ], "reduced": [ 89 ], "effectiveness": [ 90 ], "on": [ 93, 175, 294 ], "diabetic": [ 95 ], "endocrine": [ 96 ], "pancreas,": [ 97 ], "negligible": [ 101 ], "physiological": [ 102, 349 ], "role": [ 103, 215, 323 ], "in": [ 106, 112, 125, 170, 184, 193, 207, 216, 241, 258, 279, 310, 329 ], "mediating": [ 107 ], "even": [ 111, 212 ], "healthy": [ 113 ], "subjects.": [ 114 ], "However,": [ 115 ], "glucagonostatic": [ 119 ], "effects": [ 120, 174, 278 ], "preserved": [ 124 ], "diabetes": [ 130 ], "degree": [ 133 ], "pharmacological": [ 135 ], "stimulation": [ 136 ], "receptors": [ 139 ], "significantly": [ 140 ], "reduces": [ 141 ], "plasma": [ 142 ], "improves": [ 145 ], "glycaemic": [ 146, 259 ], "control.": [ 147 ], "Thus,": [ 148, 317 ], "it": [ 149 ], "has": [ 150, 172 ], "become": [ 151 ], "parent": [ 153 ], "compound": [ 154 ], "incretin\u2010based": [ 156 ], "glucose\u2010lowering": [ 157 ], "medications": [ 158 ], "(GLP\u20101": [ 159 ], "receptor": [ 160, 299 ], "agonists": [ 161, 300 ], "inhibitors": [ 163 ], "dipeptidyl": [ 165 ], "peptidase\u20104": [ 166 ], "DPP\u20104).": [ 168 ], "GLP\u20101,": [ 169, 270 ], "addition,": [ 171 ], "multiple": [ 173 ], "various": [ 176 ], "organ": [ 177 ], "systems.": [ 178 ], "Most": [ 179 ], "relevant": [ 180 ], "reduction": [ 183 ], "appetite": [ 185 ], "food": [ 187 ], "intake,": [ 188 ], "leading": [ 189 ], "weight": [ 191, 254 ], "loss": [ 192, 255 ], "long": [ 195 ], "term.": [ 196 ], "Since": [ 197 ], "seems": [ 203 ], "be": [ 205, 245, 345 ], "impaired": [ 206 ], "obese": [ 208 ], "subjects,": [ 209 ], "may": [ 211, 244 ], "indicate": [ 213 ], "pathophysiology": [ 218, 331 ], "obesity.": [ 220 ], "Along": [ 221 ], "these": [ 222 ], "lines,": [ 223 ], "an": [ 224, 321 ], "increased": [ 225 ], "induced": [ 229 ], "by": [ 230 ], "delivering": [ 231 ], "nutrients": [ 232 ], "parts": [ 235 ], "small": [ 238 ], "intestines": [ 239 ], "(rich": [ 240 ], "one": [ 246 ], "factor": [ 247 ], "(among": [ 248 ], "others": [ 249 ], "like": [ 250 ], "peptide": [ 251 ], "YY)": [ 252 ], "explaining": [ 253 ], "improvements": [ 257 ], "control": [ 260 ], "bariatric": [ 262 ], "surgery": [ 263 ], "(e.g.,": [ 264 ], "Roux\u2010en\u2010Y": [ 265 ], "gastric": [ 266 ], "bypass).": [ 267 ], "originally": [ 271 ], "characterized": [ 272 ], "hormones,": [ 275 ], "have": [ 276, 290, 320, 340 ], "additional": [ 277 ], "adipose": [ 280 ], "cells,": [ 281 ], "bone,": [ 282 ], "cardiovascular": [ 285, 305 ], "system.": [ 286 ], "Especially,": [ 287 ], "latter": [ 289 ], "received": [ 291 ], "attention": [ 292 ], "based": [ 293 ], "recent": [ 295 ], "findings": [ 296 ], "such": [ 301 ], "liraglutide": [ 303 ], "reduce": [ 304 ], "events": [ 306 ], "prolong": [ 308 ], "life": [ 309 ], "high\u2010risk": [ 311 ], "patients": [ 312 ], "diabetes.": [ 316 ], "important": [ 322 ], "physiologically,": [ 324 ], "namely": [ 325 ], "involved": [ 328 ], "obesity": [ 333 ], "therapeutic": [ 341 ], "potential": [ 342 ], "can": [ 344 ], "traced": [ 346 ], "well\u2010characterized": [ 348 ], "effects.": [ 350 ] }, "publication_date": "2018-01-24", "publication_year": 2018, "type": "review", "cited_by_count": 777, "authors": [ { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5002832666", "display_name": "Juris J. Meier" } ] }, { "id": "https://openalex.org/W2948622224", "doi": "https://doi.org/10.1016/s0140-6736(19)31271-1", "title": "Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial", "abstract": null, "publication_date": "2019-06-08", "publication_year": 2019, "type": "article", "cited_by_count": 537, "authors": [ { "id": "https://openalex.org/A5059098934", "display_name": "Richard E. Pratley" }, { "id": "https://openalex.org/A5068563768", "display_name": "Aslam Amod" }, { "id": "https://openalex.org/A5078003599", "display_name": "S\u00f8ren T. Hoff" }, { "id": "https://openalex.org/A5040548657", "display_name": "Takashi Kadowaki" }, { "id": "https://openalex.org/A5001655356", "display_name": "Ildiko Lingvay" }, { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5004964619", "display_name": "Karen Boje Pedersen" }, { "id": "https://openalex.org/A5087297771", "display_name": "Trine Saugstrup" }, { "id": "https://openalex.org/A5002832666", "display_name": "Juris J. Meier" } ] }, { "id": "https://openalex.org/W1932004110", "doi": "https://doi.org/10.1111/adb.12295", "title": "The glucagon\u2010like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents", "abstract": { "Abstract": [ 0 ], "The": [ 1, 65 ], "incretin": [ 2 ], "hormone,": [ 3 ], "glucagon\u2010like": [ 4 ], "peptide": [ 5 ], "1": [ 6 ], "(GLP\u20101),": [ 7 ], "regulates": [ 8 ], "gastric": [ 9 ], "emptying,": [ 10 ], "glucose\u2010dependent": [ 11 ], "stimulation": [ 12 ], "of": [ 13, 27, 68, 76, 92, 105, 127, 144, 158, 179 ], "insulin": [ 14 ], "secretion": [ 15 ], "and": [ 16, 19, 44, 47, 62, 117, 134 ], "glucagon": [ 17 ], "release,": [ 18 ], "GLP\u20101": [ 20, 31, 48, 78, 171 ], "analogs": [ 21 ], "are": [ 22, 33 ], "therefore": [ 23 ], "approved": [ 24 ], "for": [ 25, 177 ], "treatment": [ 26, 100, 143, 178 ], "type": [ 28 ], "II": [ 29 ], "diabetes.": [ 30 ], "receptors": [ 32 ], "expressed": [ 34 ], "in": [ 35, 86, 96, 121, 138, 149, 160, 182 ], "reward\u2010related": [ 36 ], "areas": [ 37 ], "such": [ 38 ], "as": [ 39, 57, 59, 152, 154 ], "the": [ 40, 74, 77, 102, 108, 130 ], "ventral": [ 41 ], "tegmental": [ 42 ], "area": [ 43 ], "nucleus": [ 45 ], "accumbens,": [ 46 ], "was": [ 49 ], "recently": [ 50 ], "shown": [ 51 ], "to": [ 52, 72 ], "regulate": [ 53 ], "several": [ 54, 83 ], "alcohol\u2010mediated": [ 55 ], "behaviors": [ 56, 85 ], "well": [ 58, 153 ], "amphetamine\u2010induced,": [ 60 ], "cocaine\u2010induced": [ 61 ], "nicotine\u2010induced": [ 63 ], "reward.": [ 64 ], "present": [ 66 ], "series": [ 67 ], "experiments": [ 69 ], "were": [ 70 ], "undertaken": [ 71 ], "investigate": [ 73 ], "effect": [ 75, 133 ], "receptor": [ 79, 172 ], "agonist,": [ 80 ], "liraglutide,": [ 81 ], "on": [ 82, 107 ], "alcohol\u2010related": [ 84 ], "rats": [ 87, 151 ], "that": [ 88, 170 ], "model": [ 89 ], "different": [ 90 ], "aspects": [ 91 ], "alcohol": [ 93, 106, 131, 136, 147, 159, 180 ], "use": [ 94 ], "disorder": [ 95 ], "humans.": [ 97, 183 ], "Acute": [ 98 ], "liraglutide": [ 99, 128, 145 ], "suppressed": [ 101 ], "well\u2010documented": [ 103 ], "effects": [ 104 ], "mesolimbic": [ 109 ], "dopamine": [ 110, 115 ], "system,": [ 111 ], "namely": [ 112 ], "alcohol\u2010induced": [ 113 ], "accumbal": [ 114 ], "release": [ 116 ], "conditioned": [ 118 ], "place": [ 119 ], "preference": [ 120 ], "mice.": [ 122 ], "In": [ 123 ], "addition,": [ 124 ], "acute": [ 125 ], "administration": [ 126 ], "prevented": [ 129 ], "deprivation": [ 132 ], "reduced": [ 135, 155 ], "intake": [ 137, 148 ], "outbred": [ 139, 150 ], "rats,": [ 140 ], "while": [ 141 ], "repeated": [ 142 ], "decreased": [ 146 ], "operant": [ 156 ], "self\u2010administration": [ 157 ], "selectively": [ 161 ], "bred": [ 162 ], "Sardinian": [ 163 ], "alcohol\u2010preferring": [ 164 ], "rats.": [ 165 ], "Collectively,": [ 166 ], "these": [ 167 ], "data": [ 168 ], "suggest": [ 169 ], "agonists": [ 173 ], "could": [ 174 ], "be": [ 175 ], "tested": [ 176 ], "dependence": [ 181 ] }, "publication_date": "2015-08-25", "publication_year": 2015, "type": "article", "cited_by_count": 120, "authors": [ { "id": "https://openalex.org/A5050691569", "display_name": "Daniel Vall\u00f6f" }, { "id": "https://openalex.org/A5064150026", "display_name": "Paola Maccioni" }, { "id": "https://openalex.org/A5015502998", "display_name": "Giancarlo Colombo" }, { "id": "https://openalex.org/A5039110635", "display_name": "Minja Mandrapa" }, { "id": "https://openalex.org/A5075640358", "display_name": "Julia Winsa J\u00f6rnulf" }, { "id": "https://openalex.org/A5065224153", "display_name": "Emil Egecioglu" }, { "id": "https://openalex.org/A5111952789", "display_name": "J\u00f6rgen A. Engel" }, { "id": "https://openalex.org/A5011345299", "display_name": "Elisabet Jerlhag" } ] }, { "id": "https://openalex.org/W2785139619", "doi": "https://doi.org/10.1111/dom.13172", "title": "Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy", "abstract": { "Aims": [ 0 ], "To": [ 1 ], "evaluate": [ 2 ], "diabetic": [ 3 ], "retinopathy": [ 4 ], "(DR)": [ 5 ], "data": [ 6, 67, 83 ], "from": [ 7, 68 ], "across": [ 8, 69, 140 ], "the": [ 9, 23, 34, 58, 70, 80, 114, 117, 141, 152, 165, 173, 208, 219, 231 ], "SUSTAIN": [ 10, 18, 42, 71, 81, 142, 159, 223 ], "clinical": [ 11, 19 ], "trial": [ 12, 20 ], "programme.": [ 13 ], "Materials": [ 14 ], "and": [ 15, 25, 75, 94, 146, 167, 185, 191, 210 ], "methods": [ 16 ], "The": [ 17, 149 ], "programme": [ 21 ], "evaluated": [ 22 ], "efficacy": [ 24 ], "safety": [ 26 ], "of": [ 27, 36, 60, 79, 116, 119, 129, 151, 169, 177, 200, 212, 234 ], "semaglutide,": [ 28 ], "a": [ 29, 44, 54, 95, 110, 203 ], "glucagon\u2010like": [ 30 ], "peptide\u20101": [ 31 ], "analogue,": [ 32 ], "for": [ 33, 245 ], "treatment": [ 35, 178 ], "type": [ 37 ], "2": [ 38 ], "diabetes": [ 39 ], "(T2D).": [ 40 ], "In": [ 41 ], "6,": [ 43 ], "2\u2010year,": [ 45 ], "pre\u2010approval": [ 46 ], "cardiovascular": [ 47 ], "outcomes": [ 48 ], "trial,": [ 49 ], "semaglutide": [ 50, 155 ], "was": [ 51, 133 ], "associated": [ 52, 206 ], "with": [ 53, 98, 154, 195, 207, 217, 227, 238 ], "significant": [ 55 ], "increase": [ 56 ], "in": [ 57, 101, 121, 136, 158, 179, 214, 222 ], "risk": [ 59, 128 ], "DR": [ 61, 66, 137, 184, 201, 235 ], "complications": [ 62 ], "(DRC)": [ 63 ], "vs": [ 64, 156 ], "placebo.": [ 65 ], "trials": [ 72 ], "were": [ 73, 84, 193 ], "evaluated,": [ 74 ], "post": [ 76 ], "hoc": [ 77 ], "analyses": [ 78, 89 ], "6": [ 82, 160, 224 ], "conducted.": [ 85 ], "These": [ 86 ], "included": [ 87 ], "subgroup": [ 88 ], "to": [ 90, 112, 144, 164 ], "identify": [ 91 ], "at\u2010risk": [ 92 ], "patients": [ 93, 180 ], "mediation": [ 96 ], "analysis": [ 97 ], "initial": [ 99 ], "change": [ 100 ], "glycated": [ 102 ], "haemoglobin": [ 103 ], "(HbA1c;": [ 104 ], "percentage\u2010points": [ 105 ], "at": [ 106, 189 ], "week": [ 107 ], "16)": [ 108 ], "as": [ 109, 123 ], "covariate,": [ 111 ], "examine": [ 113 ], "role": [ 115 ], "magnitude": [ 118, 166, 211 ], "reduction": [ 120, 171 ], "HbA1c": [ 122, 170 ], "an": [ 124 ], "intermediate": [ 125 ], "factor": [ 126 ], "affecting": [ 127 ], "DRC.": [ 130 ], "Results": [ 131 ], "There": [ 132 ], "no": [ 134 ], "imbalance": [ 135 ], "adverse": [ 138 ], "events": [ 139 ], "1": [ 143 ], "5": [ 145 ], "Japanese": [ 147 ], "trials.": [ 148 ], "majority": [ 150 ], "effect": [ 153 ], "placebo": [ 157 ], "may": [ 161, 242 ], "be": [ 162, 243 ], "attributed": [ 163 ], "rapidity": [ 168, 209 ], "during": [ 172 ], "first": [ 174 ], "16": [ 175 ], "weeks": [ 176 ], "who": [ 181, 192 ], "had": [ 182 ], "pre\u2010existing": [ 183 ], "poor": [ 186 ], "glycaemic": [ 187, 215 ], "control": [ 188, 216 ], "baseline,": [ 190 ], "treated": [ 194 ], "insulin.": [ 196, 239 ], "Conclusions": [ 197 ], "Early": [ 198 ], "worsening": [ 199, 233 ], "is": [ 202, 236 ], "known": [ 204 ], "phenomenon": [ 205 ], "improvement": [ 213 ], "insulin;": [ 218 ], "DRC": [ 220 ], "findings": [ 221 ], "are": [ 225 ], "consistent": [ 226 ], "this.": [ 228 ], "Guidance": [ 229 ], "regarding": [ 230 ], "early": [ 232 ], "recommended": [ 237 ], "Similar": [ 240 ], "recommendations": [ 241 ], "appropriate": [ 244 ], "semaglutide.": [ 246 ] }, "publication_date": "2017-11-27", "publication_year": 2017, "type": "article", "cited_by_count": 253, "authors": [ { "id": "https://openalex.org/A5004120950", "display_name": "Tina Vilsb\u00f8ll" }, { "id": "https://openalex.org/A5080463002", "display_name": "Stephen C. Bain" }, { "id": "https://openalex.org/A5080414941", "display_name": "Lawrence A. Leiter" }, { "id": "https://openalex.org/A5001655356", "display_name": "Ildiko Lingvay" }, { "id": "https://openalex.org/A5101473066", "display_name": "David Matthews" }, { "id": "https://openalex.org/A5091908088", "display_name": "Rafael Sim\u00f3" }, { "id": "https://openalex.org/A5078426191", "display_name": "Ida Car\u00f8e Helmark" }, { "id": "https://openalex.org/A5007924361", "display_name": "Nelun Wijayasinghe" }, { "id": "https://openalex.org/A5034221126", "display_name": "Michael Larsen" } ] }, { "id": "https://openalex.org/W4237332786", "doi": "https://doi.org/10.1007/s00125-019-05039-w", "title": "2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)", "abstract": null, "publication_date": "2019-12-19", "publication_year": 2019, "type": "article", "cited_by_count": 491, "authors": [ { "id": "https://openalex.org/A5040182038", "display_name": "John B. Buse" }, { "id": "https://openalex.org/A5076997901", "display_name": "Deborah J. Wexler" }, { "id": "https://openalex.org/A5018882870", "display_name": "\u0391\u03c0\u03cc\u03c3\u03c4\u03bf\u03bb\u03bf\u03c2 \u03a4\u03c3\u03ac\u03c0\u03b1\u03c2" }, { "id": "https://openalex.org/A5085592050", "display_name": "Peter Rossing" }, { "id": "https://openalex.org/A5053488036", "display_name": "Geltrude Mingrone" }, { "id": "https://openalex.org/A5053469409", "display_name": "Chantal Mathieu" }, { "id": "https://openalex.org/A5071074041", "display_name": "David A. D\u2019Alessio" }, { "id": "https://openalex.org/A5084593004", "display_name": "Melanie J. Davies" } ] }, { "id": "https://openalex.org/W2978840913", "doi": "https://doi.org/10.1016/j.molmet.2019.09.010", "title": "Glucagon-like peptide 1 (GLP-1)", "abstract": { "BACKGROUND:": [ 0 ], "The": [ 1, 160 ], "glucagon-like": [ 2 ], "peptide-1": [ 3 ], "(GLP-1)": [ 4 ], "is": [ 5 ], "a": [ 6, 111, 140, 144 ], "multifaceted": [ 7, 116 ], "hormone": [ 8, 142, 168 ], "with": [ 9, 143 ], "broad": [ 10 ], "pharmacological": [ 11 ], "potential.": [ 12 ], "Among": [ 13 ], "the": [ 14, 21, 85, 99, 115, 173 ], "numerous": [ 15, 161 ], "metabolic": [ 16, 147 ], "effects": [ 17, 163 ], "of": [ 18, 24, 28, 32, 36, 42, 87, 101, 118, 146, 164, 175 ], "GLP-1": [ 19, 46, 76, 119, 136, 165 ], "are": [ 20, 79, 94 ], "glucose-dependent": [ 22 ], "stimulation": [ 23 ], "insulin": [ 25 ], "secretion,": [ 26 ], "decrease": [ 27 ], "gastric": [ 29 ], "emptying,": [ 30 ], "inhibition": [ 31 ], "food": [ 33 ], "intake,": [ 34 ], "increase": [ 35 ], "natriuresis": [ 37 ], "and": [ 38, 40, 50, 55, 57, 62, 66, 73, 90, 120, 123, 181 ], "diuresis,": [ 39 ], "modulation": [ 41 ], "rodent": [ 43 ], "\u03b2-cell": [ 44 ], "proliferation.": [ 45 ], "also": [ 47 ], "has": [ 48, 58, 137 ], "cardio-": [ 49 ], "neuroprotective": [ 51 ], "effects,": [ 52 ], "decreases": [ 53 ], "inflammation": [ 54 ], "apoptosis,": [ 56 ], "implications": [ 59, 127 ], "for": [ 60, 70, 84, 98, 172 ], "learning": [ 61 ], "memory,": [ 63 ], "reward": [ 64 ], "behavior,": [ 65 ], "palatability.": [ 67 ], "Biochemically": [ 68 ], "modified": [ 69 ], "enhanced": [ 71 ], "potency": [ 72 ], "sustained": [ 74 ], "action,": [ 75 ], "receptor": [ 77 ], "agonists": [ 78 ], "successfully": [ 80 ], "in": [ 81, 95 ], "clinical": [ 82, 96 ], "use": [ 83 ], "treatment": [ 86, 100 ], "type-2": [ 88 ], "diabetes,": [ 89, 180 ], "several": [ 91 ], "GLP-1-based": [ 92 ], "pharmacotherapies": [ 93, 176 ], "evaluation": [ 97 ], "obesity.": [ 102 ], "SCOPE": [ 103 ], "OF": [ 104 ], "REVIEW:": [ 105 ], "In": [ 106 ], "this": [ 107, 167 ], "review,": [ 108 ], "we": [ 109 ], "provide": [ 110 ], "detailed": [ 112 ], "overview": [ 113 ], "on": [ 114, 128 ], "nature": [ 117 ], "its": [ 121, 125, 134, 153 ], "pharmacology": [ 122 ], "discuss": [ 124 ], "therapeutic": [ 126 ], "various": [ 129 ], "diseases.": [ 130 ], "MAJOR": [ 131 ], "CONCLUSIONS:": [ 132 ], "Since": [ 133 ], "discovery,": [ 135 ], "emerged": [ 138 ], "as": [ 139, 156 ], "pleiotropic": [ 141 ], "myriad": [ 145 ], "functions": [ 148 ], "that": [ 149 ], "go": [ 150 ], "well": [ 151 ], "beyond": [ 152 ], "classical": [ 154 ], "identification": [ 155 ], "an": [ 157, 169 ], "incretin": [ 158 ], "hormone.": [ 159 ], "beneficial": [ 162 ], "render": [ 166 ], "interesting": [ 170 ], "candidate": [ 171 ], "development": [ 174 ], "to": [ 177 ], "treat": [ 178 ], "obesity,": [ 179 ], "neurodegenerative": [ 182 ], "disorders.": [ 183 ] }, "publication_date": "2019-09-30", "publication_year": 2019, "type": "review", "cited_by_count": 1549, "authors": [ { "id": "https://openalex.org/A5055064257", "display_name": "Timo D. M\u00fcller" }, { "id": "https://openalex.org/A5050283762", "display_name": "Brian Finan" }, { "id": "https://openalex.org/A5011196462", "display_name": "Stephen R. Bloom" }, { "id": "https://openalex.org/A5071074041", "display_name": "David A. D\u2019Alessio" }, { "id": "https://openalex.org/A5057472647", "display_name": "Daniel J. Drucker" }, { "id": "https://openalex.org/A5064124957", "display_name": "Peter R. Flatt" }, { "id": "https://openalex.org/A5062462205", "display_name": "Andreas Fritsche" }, { "id": "https://openalex.org/A5002740985", "display_name": "Fiona M. Gribble" }, { "id": "https://openalex.org/A5016431924", "display_name": "Harvey J. Grill" }, { "id": "https://openalex.org/A5034913449", "display_name": "Joel F. Habener" }, { "id": "https://openalex.org/A5085434984", "display_name": "Jens J. Holst" }, { "id": "https://openalex.org/A5102776375", "display_name": "Wolfgang Langhans" }, { "id": "https://openalex.org/A5002832666", "display_name": "Juris J. Meier" }, { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5005758541", "display_name": "Diego P\u00e9rez\u2013Tilve" }, { "id": "https://openalex.org/A5040533601", "display_name": "Alessandro Pocai" }, { "id": "https://openalex.org/A5020444111", "display_name": "Frank Reimann" }, { "id": "https://openalex.org/A5045342696", "display_name": "Darleen A. Sandoval" }, { "id": "https://openalex.org/A5021396103", "display_name": "Thue W. Schwartz" }, { "id": "https://openalex.org/A5065488328", "display_name": "Randy J. Seeley" }, { "id": "https://openalex.org/A5065738138", "display_name": "Kerstin Stemmer" }, { "id": "https://openalex.org/A5016148396", "display_name": "Mads Tang\u2010Christensen" }, { "id": "https://openalex.org/A5072321501", "display_name": "Stephen C. Woods" }, { "id": "https://openalex.org/A5071517746", "display_name": "Richard D. DiMarchi" }, { "id": "https://openalex.org/A5110054612", "display_name": "M. Tsch\u00f6p" } ] }, { "id": "https://openalex.org/W2126862523", "doi": "https://doi.org/10.2337/dc14-0785", "title": "Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)", "abstract": { "OBJECTIVE": [ 0 ], "Insulin": [ 1 ], "degludec/liraglutide": [ 2 ], "(IDegLira)": [ 3 ], "is": [ 4 ], "a": [ 5, 43 ], "novel": [ 6 ], "combination": [ 7 ], "of": [ 8, 19, 23, 125, 144, 217, 237, 246, 252, 262, 268 ], "insulin": [ 9, 58, 241 ], "degludec": [ 10 ], "(IDeg)": [ 11 ], "and": [ 12, 30, 61, 88, 107, 158, 215, 248, 260, 264 ], "liraglutide.": [ 13 ], "This": [ 14 ], "trial": [ 15 ], "investigated": [ 16 ], "the": [ 17, 20, 250, 258, 265, 269 ], "contribution": [ 18, 267 ], "liraglutide": [ 21, 270 ], "component": [ 22 ], "IDegLira": [ 24, 72, 157, 186, 205, 230, 263 ], "versus": [ 25 ], "IDeg": [ 26, 76, 102, 138, 164, 227, 238 ], "alone": [ 27, 140 ], "on": [ 28, 56 ], "efficacy": [ 29, 259 ], "safety": [ 31, 261 ], "in": [ 32, 118, 221 ], "patients": [ 33, 47, 127 ], "with": [ 34, 48, 63, 79, 156, 163, 185, 194, 249 ], "type": [ 35, 49 ], "2": [ 36, 50 ], "diabetes.": [ 37 ], "RESEARCH": [ 38 ], "DESIGN": [ 39 ], "AND": [ 40 ], "METHODS": [ 41 ], "In": [ 42 ], "26-week,": [ 44 ], "double-blind": [ 45 ], "trial,": [ 46 ], "diabetes": [ 51 ], "(A1C": [ 52 ], "7.5\u201310.0%": [ 53 ], "[58\u201386": [ 54 ], "mmol/mol])": [ 55 ], "basal": [ 57 ], "(20\u201340": [ 59 ], "units)": [ 60 ], "metformin": [ 62, 74, 78 ], "or": [ 64, 75, 141 ], "without": [ 65, 243 ], "sulfonylurea/glinides": [ 66 ], "were": [ 67, 94, 128, 213 ], "randomized": [ 68, 129 ], "(1:1)": [ 69 ], "to": [ 70, 99, 235 ], "once-daily": [ 71 ], "+": [ 73, 77 ], "titration": [ 80 ], "aiming": [ 81 ], "for": [ 82, 110, 204, 208 ], "fasting": [ 83 ], "plasma": [ 84 ], "glucose": [ 85 ], "between": [ 86 ], "4": [ 87 ], "5": [ 89 ], "mmol/L.": [ 90 ], "Maximum": [ 91 ], "allowed": [ 92 ], "doses": [ 93, 242 ], "50": [ 95, 100, 108 ], "dose": [ 96 ], "steps": [ 97 ], "(equal": [ 98 ], "units": [ 101, 109 ], "plus": [ 103 ], "1.8": [ 104 ], "mg": [ 105 ], "liraglutide)": [ 106 ], "IDeg.": [ 111 ], "The": [ 112 ], "primary": [ 113 ], "end": [ 114 ], "point": [ 115 ], "was": [ 116, 146, 187, 201, 219 ], "change": [ 117, 193 ], "A1C": [ 119, 131, 150 ], "from": [ 120 ], "baseline.": [ 121 ], "RESULTS": [ 122 ], "A": [ 123 ], "total": [ 124 ], "413": [ 126 ], "(mean": [ 130 ], "8.8%": [ 132 ], "[73": [ 133 ], "mmol/mol];": [ 134 ], "BMI": [ 135 ], "33.7": [ 136 ], "kg/m2).": [ 137 ], "dose,": [ 139 ], "as": [ 142 ], "part": [ 143 ], "IDegLira,": [ 145 ], "equivalent": [ 147, 240 ], "(45": [ 148 ], "units).": [ 149 ], "decreased": [ 151 ], "by": [ 152, 159 ], "1.9%": [ 153 ], "(21": [ 154 ], "mmol/mol)": [ 155, 162 ], "0.9%": [ 160 ], "(10": [ 161 ], "(estimated": [ 165 ], "treatment": [ 166 ], "difference": [ 167 ], "\u22121.1%": [ 168 ], "[95%": [ 169, 175 ], "CI": [ 170, 176 ], "\u22121.3,": [ 171 ], "\u22120.8],": [ 172 ], "\u221212": [ 173 ], "mmol/mol": [ 174 ], "\u221214,": [ 177 ], "\u22129;": [ 178 ], "P": [ 179, 196 ], "&lt;": [ 180, 197 ], "0.0001).": [ 181 ], "Mean": [ 182 ], "weight": [ 183, 192, 253 ], "reduction": [ 184 ], "2.7": [ 188 ], "kg": [ 189 ], "vs.": [ 190, 206, 226 ], "no": [ 191 ], "IDeg,": [ 195 ], "0.0001.": [ 198 ], "Hypoglycemia": [ 199 ], "incidence": [ 200, 216 ], "comparable": [ 202 ], "(24%": [ 203 ], "25%": [ 207 ], "IDeg).": [ 209 ], "Overall": [ 210 ], "adverse": [ 211 ], "events": [ 212 ], "similar,": [ 214 ], "nausea": [ 218 ], "low": [ 220 ], "both": [ 222 ], "groups": [ 223 ], "(IDegLira": [ 224 ], "6.5%": [ 225 ], "3.5%).": [ 228 ], "CONCLUSIONS": [ 229 ], "achieved": [ 231 ], "glycemic": [ 232 ], "control": [ 233 ], "superior": [ 234 ], "that": [ 236 ], "at": [ 239 ], "higher": [ 244 ], "risk": [ 245 ], "hypoglycemia": [ 247 ], "benefit": [ 251 ], "loss.": [ 254 ], "These": [ 255 ], "findings": [ 256 ], "establish": [ 257 ], "distinct": [ 266 ], "component.": [ 271 ] }, "publication_date": "2014-08-12", "publication_year": 2014, "type": "article", "cited_by_count": 246, "authors": [ { "id": "https://openalex.org/A5040182038", "display_name": "John B. Buse" }, { "id": "https://openalex.org/A5004120950", "display_name": "Tina Vilsb\u00f8ll" }, { "id": "https://openalex.org/A5041493587", "display_name": "Jerry Thurman" }, { "id": "https://openalex.org/A5004471830", "display_name": "Thomas Blevins" }, { "id": "https://openalex.org/A5011930122", "display_name": "Irene H. Langbakke" }, { "id": "https://openalex.org/A5111476943", "display_name": "Susanne Gammelgaard B\u00f8ttcher" }, { "id": "https://openalex.org/A5020174004", "display_name": "Helena W. Rodbard" } ] }, { "id": "https://openalex.org/W3014018229", "doi": "https://doi.org/10.3390/jcm9040947", "title": "GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists", "abstract": { "Type": [ 0 ], "2": [ 1 ], "diabetes": [ 2 ], "mellitus": [ 3 ], "(T2DM)": [ 4 ], "represents": [ 5 ], "the": [ 6, 37, 44, 49, 121, 139, 145, 175 ], "main": [ 7 ], "cause": [ 8, 27 ], "of": [ 9, 28, 40, 65, 91, 104, 130, 136, 141, 147, 177 ], "chronic": [ 10 ], "kidney": [ 11, 21, 165, 182 ], "disease": [ 12, 17, 22 ], "(CKD)": [ 13 ], "and": [ 14, 19, 30, 57, 84, 89, 111, 143, 163 ], "end-stage": [ 15 ], "renal": [ 16, 52, 112 ], "(ESKD),": [ 18 ], "diabetic": [ 20, 153 ], "(DKD)": [ 23 ], "is": [ 24, 60 ], "a": [ 25, 101 ], "major": [ 26 ], "morbidity": [ 29 ], "mortality": [ 31 ], "in": [ 32, 36, 114, 127, 152, 159, 184 ], "diabetes.": [ 33 ], "Despite": [ 34 ], "advances": [ 35 ], "nephroprotective": [ 38 ], "treatment": [ 39 ], "T2DM,": [ 41 ], "DKD": [ 42, 66, 131 ], "remains": [ 43 ], "most": [ 45 ], "common": [ 46 ], "complication,": [ 47 ], "driving": [ 48 ], "need": [ 50 ], "for": [ 51, 123 ], "replacement": [ 53 ], "therapies": [ 54 ], "(RRT)": [ 55 ], "worldwide,": [ 56 ], "its": [ 58 ], "incidence": [ 59 ], "increasing.": [ 61 ], "Until": [ 62 ], "recently,": [ 63 ], "prevention": [ 64 ], "progression": [ 67 ], "was": [ 68 ], "based": [ 69 ], "around": [ 70 ], "strict": [ 71 ], "blood": [ 72 ], "pressure": [ 73 ], "(BP)": [ 74 ], "control,": [ 75 ], "using": [ 76 ], "renin\u2013angiotensin": [ 77 ], "system": [ 78 ], "blockers": [ 79 ], "that": [ 80 ], "simultaneously": [ 81 ], "reduce": [ 82 ], "BP": [ 83 ], "proteinuria,": [ 85 ], "adequate": [ 86, 124 ], "glycemic": [ 87, 125 ], "control": [ 88, 90, 126 ], "cardiovascular": [ 92, 110, 162 ], "risk": [ 93, 135 ], "factors.": [ 94 ], "Glucagon-like": [ 95 ], "peptide-1": [ 96 ], "receptor": [ 97 ], "agonists": [ 98 ], "(GLP-1RA)": [ 99 ], "are": [ 100, 171 ], "new": [ 102 ], "class": [ 103 ], "anti-hyperglycemic": [ 105 ], "drugs": [ 106 ], "shown": [ 107 ], "to": [ 108, 173 ], "improve": [ 109 ], "events": [ 113 ], "DKD.": [ 115, 185 ], "In": [ 116 ], "this": [ 117 ], "regard,": [ 118 ], "GLP-1RA": [ 119, 178 ], "offer": [ 120 ], "potential": [ 122 ], "multiple": [ 128 ], "stages": [ 129 ], "without": [ 132 ], "an": [ 133 ], "increased": [ 134 ], "hypoglycemia,": [ 137 ], "preventing": [ 138 ], "onset": [ 140 ], "macroalbuminuria": [ 142 ], "slowing": [ 144 ], "decline": [ 146 ], "glomerular": [ 148 ], "filtration": [ 149 ], "rate": [ 150 ], "(GFR)": [ 151 ], "patients,": [ 154 ], "also": [ 155 ], "bringing": [ 156 ], "additional": [ 157 ], "benefit": [ 158 ], "weight": [ 160 ], "reduction,": [ 161 ], "other": [ 164 ], "outcomes.": [ 166 ], "Results": [ 167 ], "from": [ 168 ], "ongoing": [ 169 ], "trials": [ 170 ], "pending": [ 172 ], "assess": [ 174 ], "impact": [ 176 ], "treatments": [ 179 ], "on": [ 180 ], "primary": [ 181 ], "endpoints": [ 183 ] }, "publication_date": "2020-03-30", "publication_year": 2020, "type": "review", "cited_by_count": 135, "authors": [ { "id": "https://openalex.org/A5046692355", "display_name": "Jos\u00e9 Luis G\u00f3rriz" }, { "id": "https://openalex.org/A5071593060", "display_name": "Mar\u00eda Jos\u00e9 Soler" }, { "id": "https://openalex.org/A5055273250", "display_name": "Juan F. Navarro\u2010Gonz\u00e1lez" }, { "id": "https://openalex.org/A5032570786", "display_name": "Clara Garc\u00eda-Carro" }, { "id": "https://openalex.org/A5047440765", "display_name": "Mar\u00eda Jes\u00fas Puchades" }, { "id": "https://openalex.org/A5090919713", "display_name": "Luis D\u2019Marco" }, { "id": "https://openalex.org/A5022061520", "display_name": "Alberto Mart\u00ednez Castelao" }, { "id": "https://openalex.org/A5054160581", "display_name": "Beatriz Fern\u00e1ndez\u2010Fern\u00e1ndez" }, { "id": "https://openalex.org/A5063245254", "display_name": "Alberto Ort\u00edz" }, { "id": "https://openalex.org/A5068166159", "display_name": "C. G\u00f3rriz-Zambrano" }, { "id": "https://openalex.org/A5112841619", "display_name": "Jorge Navarro-P\u00e9rez" }, { "id": "https://openalex.org/A5076277987", "display_name": "Juan Jos\u00e9 Gorgojo Mart\u00ednez" } ] }, { "id": "https://openalex.org/W4385648883", "doi": "https://doi.org/10.1016/j.jhep.2023.07.033", "title": "Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver", "abstract": { "The": [ 0 ], "principle": [ 1 ], "pathological": [ 2 ], "drivers": [ 3 ], "of": [ 4, 33, 40, 90, 126, 161, 208, 210 ], "metabolic": [ 5 ], "dysfunction-associated": [ 6 ], "steatohepatitis": [ 7 ], "(MASH)": [ 8 ], "are": [ 9, 129, 186 ], "obesity": [ 10 ], "and": [ 11, 35, 52, 56, 96, 120, 151, 163, 172, 240 ], "associated": [ 12 ], "insulin": [ 13, 94, 118 ], "resistance,": [ 14 ], "rendering": [ 15 ], "them": [ 16 ], "key": [ 17 ], "therapeutic": [ 18 ], "targets.": [ 19 ], "As": [ 20 ], "glucagon-like": [ 21 ], "peptide": [ 22, 78 ], "1": [ 23 ], "receptor": [ 24 ], "agonists": [ 25, 74, 80, 194, 213 ], "(GLP-1RAs)": [ 26 ], "have": [ 27, 59, 81, 102, 225, 229 ], "been": [ 28, 82, 226 ], "licensed": [ 29 ], "for": [ 30 ], "the": [ 31, 41, 133, 144, 158, 181, 200, 204 ], "treatment": [ 32 ], "diabetes": [ 34 ], "obesity,": [ 36 ], "they": [ 37, 110 ], "were": [ 38 ], "one": [ 39 ], "first": [ 42 ], "drug": [ 43 ], "types": [ 44 ], "to": [ 45, 63, 140, 166, 174, 228 ], "be": [ 46, 141 ], "evaluated": [ 47 ], "in": [ 48, 61, 84, 92, 116, 136, 169, 199 ], "patients": [ 49 ], "with": [ 50, 72, 88, 195 ], "MASH,": [ 51 ], "successful": [ 53 ], "phase": [ 54, 64 ], "IIa": [ 55 ], "IIb": [ 57 ], "studies": [ 58 ], "resulted": [ 60 ], "progression": [ 62 ], "III": [ 65 ], "clinical": [ 66 ], "trials.": [ 67 ], "Alongside": [ 68 ], "GLP-1RAs,": [ 69 ], "newer": [ 70 ], "combinations": [ 71, 219 ], "glucagon": [ 73, 162 ], "and/or": [ 75 ], "glucose-dependent": [ 76 ], "insulinotropic": [ 77 ], "(GIP)": [ 79 ], "explored": [ 83 ], "related": [ 85 ], "patient": [ 86 ], "groups,": [ 87 ], "evidence": [ 89 ], "improvements": [ 91, 115 ], "weight,": [ 93, 117, 217 ], "resistance": [ 95, 119 ], "non-invasive": [ 97 ], "liver": [ 98 ], "parameters.": [ 99 ], "Whether": [ 100 ], "GLP-1RAs": [ 101 ], "direct,": [ 103 ], "independent": [ 104 ], "effects": [ 105 ], "on": [ 106, 112, 216, 222, 234 ], "MASH": [ 107 ], "or": [ 108, 178 ], "whether": [ 109, 175 ], "impact": [ 111 ], "pathophysiology": [ 113 ], "through": [ 114 ], "glycaemic": [ 121 ], "control": [ 122 ], "remains": [ 123 ], "a": [ 124, 230 ], "matter": [ 125 ], "debate.": [ 127 ], "Combinations": [ 128 ], "being": [ 130 ], "explored,": [ 131 ], "although": [ 132 ], "potential": [ 134, 148 ], "improvement": [ 135 ], "efficacy": [ 137 ], "will": [ 138 ], "need": [ 139 ], "weighed": [ 142 ], "against": [ 143 ], "cumulative": [ 145 ], "side-effect": [ 146 ], "burden,": [ 147 ], "drug-drug": [ 149 ], "interactions": [ 150 ], "costs.": [ 152 ], "There": [ 153 ], "is": [ 154, 180, 214 ], "also": [ 155, 187 ], "uncertainty": [ 156 ], "regarding": [ 157 ], "optimal": [ 159, 182 ], "ratio": [ 160 ], "GIP": [ 164, 176 ], "agonism": [ 165, 168, 177 ], "GLP-1": [ 167 ], "combination": [ 170 ], "agents,": [ 171 ], "as": [ 173 ], "antagonism": [ 179 ], "approach.": [ 183 ], "Finally,": [ 184 ], "there": [ 185 ], "multiple": [ 188 ], "hypothetical": [ 189 ], "permutations": [ 190 ], "combining": [ 191 ], "gut": [ 192, 211 ], "hormone": [ 193, 212 ], "other": [ 196 ], "emerging": [ 197 ], "assets": [ 198 ], "field.": [ 201 ], "Given": [ 202 ], "that": [ 203 ], "likely": [ 205 ], "dominant": [ 206 ], "mode": [ 207 ], "action": [ 209 ], "upstream": [ 215 ], "initial": [ 218 ], "might": [ 220 ], "focus": [ 221 ], "agents": [ 223 ], "which": [ 224, 236 ], "shown": [ 227 ], "more": [ 231 ], "direct": [ 232 ], "effect": [ 233 ], "fibrosis,": [ 235 ], "would": [ 237 ], "include": [ 238 ], "FGF21": [ 239 ], "pan-PPAR": [ 241 ], "agonists.": [ 242 ] }, "publication_date": "2023-08-08", "publication_year": 2023, "type": "review", "cited_by_count": 127, "authors": [ { "id": "https://openalex.org/A5044832887", "display_name": "Philip N. Newsome" }, { "id": "https://openalex.org/A5091070939", "display_name": "Phil Ambery" } ] }, { "id": "https://openalex.org/W2914029654", "doi": "https://doi.org/10.1111/obr.12839", "title": "Semaglutide as a promising antiobesity drug", "abstract": { "Summary": [ 0 ], "Semaglutide": [ 1, 72 ], "is": [ 2 ], "a": [ 3, 11, 81, 150 ], "glucagon\u2010like": [ 4 ], "peptide\u20101": [ 5 ], "receptor": [ 6 ], "agonist": [ 7 ], "(GLP\u20101": [ 8 ], "RA)": [ 9 ], "with": [ 10, 62, 70, 98, 109 ], "long": [ 12 ], "elimination": [ 13 ], "half\u2010life,": [ 14 ], "allowing": [ 15 ], "subcutaneous": [ 16 ], "(sc)": [ 17 ], "administration": [ 18 ], "once": [ 19, 93, 102, 145 ], "per": [ 20 ], "week.": [ 21 ], "Both": [ 22 ], "the": [ 23, 29, 41, 63, 124, 128, 142 ], "European": [ 24 ], "Medicines": [ 25 ], "Agency": [ 26 ], "(EMA)": [ 27 ], "and": [ 28, 31, 101, 130, 135 ], "Food": [ 30 ], "Drug": [ 32 ], "Administration": [ 33 ], "(FDA)": [ 34 ], "recently": [ 35, 74 ], "approved": [ 36 ], "once\u2010weekly": [ 37, 54, 65 ], "sc": [ 38, 55, 95, 147 ], "semaglutide": [ 39, 56, 96, 148 ], "for": [ 40, 132 ], "treatment": [ 42 ], "of": [ 43, 53, 92, 116, 126, 144 ], "type": [ 44 ], "2": [ 45 ], "diabetes": [ 46 ], "mellitus": [ 47 ], "(T2DM).": [ 48 ], "The": [ 49, 114 ], "weight": [ 50, 89, 118 ], "loss": [ 51, 90, 119 ], "efficacy": [ 52, 91 ], "appears": [ 57 ], "to": [ 58 ], "be": [ 59 ], "superior": [ 60, 88 ], "compared": [ 61, 97 ], "other": [ 64 ], "GLP\u20101": [ 66 ], "RAs": [ 67 ], "in": [ 68, 80, 107, 120 ], "patients": [ 69, 108 ], "T2DM.": [ 71, 113 ], "was": [ 73 ], "evaluated": [ 75 ], "as": [ 76, 149 ], "an": [ 77 ], "antiobesity": [ 78, 133, 152 ], "drug": [ 79 ], "phase": [ 82 ], "II": [ 83 ], "dose\u2010finding": [ 84 ], "trial,": [ 85 ], "which": [ 86 ], "demonstrated": [ 87 ], "daily": [ 94, 103, 146 ], "both": [ 99, 127 ], "placebo": [ 100 ], "3.0": [ 104 ], "mg": [ 105 ], "liraglutide": [ 106 ], "obesity": [ 110 ], "but": [ 111 ], "without": [ 112 ], "magnitude": [ 115 ], "semaglutide\u2010induced": [ 117 ], "this": [ 121 ], "study": [ 122 ], "exceeded": [ 123 ], "criteria": [ 125 ], "EMA": [ 129 ], "FDA": [ 131 ], "drugs,": [ 134 ], "there": [ 136 ], "were": [ 137 ], "no": [ 138 ], "safety": [ 139 ], "concerns,": [ 140 ], "indicating": [ 141 ], "eligibility": [ 143 ], "future": [ 151 ], "drug.": [ 153 ] }, "publication_date": "2019-02-15", "publication_year": 2019, "type": "review", "cited_by_count": 148, "authors": [ { "id": "https://openalex.org/A5036522041", "display_name": "Georgios A. Christou" }, { "id": "https://openalex.org/A5058321397", "display_name": "Niki Katsiki" }, { "id": "https://openalex.org/A5039586613", "display_name": "John E. Blundell" }, { "id": "https://openalex.org/A5016527523", "display_name": "Gema Fr\u00fchbeck" }, { "id": "https://openalex.org/A5015613158", "display_name": "Dimitrios N. Kiortsis" } ] }, { "id": "https://openalex.org/W2158351892", "doi": "https://doi.org/10.1177/0192623312472402", "title": "On-target Effects of GLP-1 Receptor Agonists on Thyroid C-cells in Rats and Mice", "abstract": { "Glucagon-like": [ 0 ], "peptide-1": [ 1 ], "is": [ 2, 33, 59 ], "an": [ 3, 182 ], "incretin": [ 4 ], "hormone": [ 5 ], "from": [ 6, 66 ], "the": [ 7, 53, 67, 107 ], "gastrointestinal": [ 8 ], "tract,": [ 9 ], "which": [ 10 ], "enhances": [ 11 ], "insulin": [ 12 ], "secretion,": [ 13 ], "slows": [ 14 ], "gastric": [ 15 ], "emptying,": [ 16 ], "and": [ 17, 58, 88, 92, 96, 164, 167 ], "reduces": [ 18 ], "food": [ 19 ], "intake.": [ 20 ], "GLP-1": [ 21, 32, 55, 78, 110, 117, 140, 175 ], "receptor": [ 22, 79 ], "agonists": [ 23, 80, 111, 118, 176 ], "are": [ 24, 48, 103, 150 ], "being": [ 25 ], "developed": [ 26 ], "for": [ 27, 73 ], "Type": [ 28 ], "2": [ 29 ], "diabetes": [ 30 ], "mellitus.": [ 31 ], "rapidly": [ 34 ], "degraded": [ 35 ], "by": [ 36 ], "serum": [ 37, 46 ], "dipeptidyl": [ 38 ], "peptidase": [ 39 ], "IV,": [ 40 ], "so": [ 41 ], "analogues": [ 42 ], "with": [ 43, 174 ], "a": [ 44, 60, 178 ], "prolonged": [ 45 ], "half-life": [ 47 ], "used": [ 49 ], "clinically.": [ 50 ], "Exenatide": [ 51 ], "was": [ 52, 71 ], "first": [ 54 ], "agonist": [ 56 ], "approved": [ 57, 72 ], "synthetic": [ 61 ], "version": [ 62 ], "of": [ 63, 98, 109, 116, 161, 169, 181 ], "exendin-4": [ 64 ], "derived": [ 65 ], "Gila": [ 68 ], "monster.": [ 69 ], "Liraglutide": [ 70 ], "clinical": [ 74 ], "use": [ 75 ], "in": [ 76, 94, 128, 156, 171 ], "2010.": [ 77 ], "have": [ 81, 124, 142, 189 ], "been": [ 82, 126, 143 ], "shown": [ 83 ], "to": [ 84, 106, 191 ], "increase": [ 85 ], "calcitonin": [ 86 ], "secretion": [ 87 ], "stimulate": [ 89 ], "C-cell": [ 90, 120, 135 ], "hyperplasia": [ 91 ], "neoplasia": [ 93, 123, 168 ], "rats": [ 95 ], "mice": [ 97 ], "both": [ 99 ], "sexes.": [ 100 ], "Rat": [ 101 ], "C-cells": [ 102, 160, 170 ], "more": [ 104 ], "sensitive": [ 105 ], "effects": [ 108, 115, 136 ], "than": [ 112 ], "mice.": [ 113 ], "The": [ 114, 133 ], "on": [ 119, 145, 159 ], "proliferation": [ 121 ], "or": [ 122, 131, 154 ], "not": [ 125, 152, 188 ], "documented": [ 127 ], "nonhuman": [ 129, 162 ], "primates": [ 130, 163 ], "humans.": [ 132, 165, 192 ], "proliferative": [ 134 ], "may": [ 137, 187 ], "be": [ 138 ], "rodent-specific.": [ 139 ], "receptors": [ 141 ], "demonstrated": [ 144 ], "normal": [ 146 ], "rodent": [ 147 ], "C-cells,": [ 148 ], "but": [ 149 ], "either": [ 151 ], "present": [ 153 ], "occur": [ 155 ], "low": [ 157 ], "numbers": [ 158 ], "Hyperplasia": [ 166 ], "rodents": [ 172 ], "treated": [ 173 ], "represent": [ 177 ], "unique": [ 179 ], "example": [ 180 ], "on-target": [ 183 ], "species-specific": [ 184 ], "effect": [ 185 ], "that": [ 186 ], "relevance": [ 190 ] }, "publication_date": "2013-02-01", "publication_year": 2013, "type": "article", "cited_by_count": 50, "authors": [ { "id": "https://openalex.org/A5035821309", "display_name": "Thomas J. Rosol" } ] }, { "id": "https://openalex.org/W4402190714", "doi": "https://doi.org/10.1001/jamainternmed.2024.4369", "title": "GLP-1 Receptor Agonist Use and Risk of Suicide Death", "abstract": { "Importance": [ 0 ], "Concerns": [ 1 ], "have": [ 2 ], "been": [ 3 ], "raised": [ 4 ], "regarding": [ 5 ], "a": [ 6, 100, 164, 173, 202 ], "link": [ 7 ], "between": [ 8, 28, 305 ], "use": [ 9, 29, 306 ], "of": [ 10, 19, 30, 37, 97, 121, 129, 138, 206, 216, 227, 249, 307, 315, 338, 349 ], "glucagon-like": [ 11 ], "peptide-1": [ 12 ], "(GLP-1)": [ 13 ], "receptor": [ 14, 32, 76, 102, 175, 186, 218, 309, 329 ], "agonists": [ 15, 33, 77, 219, 310 ], "and": [ 16, 21, 34, 46, 59, 109, 132, 135, 141, 161, 177, 197, 220, 270, 273, 284, 288, 311, 322, 334 ], "increased": [ 17, 313 ], "risk": [ 18, 36, 314, 347 ], "suicidality": [ 20 ], "self-harm.": [ 22 ], "Objective": [ 23 ], "To": [ 24 ], "assess": [ 25 ], "the": [ 26, 35, 79, 119, 127, 136, 158, 189, 274, 335, 339 ], "association": [ 27, 304 ], "GLP-1": [ 31, 75, 101, 174, 185, 217, 308, 328 ], "suicide": [ 38, 115, 130, 211, 222, 268, 316 ], "death": [ 39, 116, 122, 131, 269, 326 ], "in": [ 40, 118, 157, 163 ], "routine": [ 41 ], "clinical": [ 42 ], "practice.": [ 43 ], "Design,": [ 44 ], "Setting,": [ 45 ], "Participants": [ 47 ], "This": [ 48, 290 ], "active-comparator": [ 49 ], "new-user": [ 50 ], "cohort": [ 51, 291 ], "study": [ 52 ], "used": [ 53 ], "nationwide": [ 54 ], "register": [ 55 ], "data": [ 56 ], "from": [ 57, 61, 90 ], "Sweden": [ 58 ], "Denmark": [ 60 ], "2013": [ 62 ], "to": [ 63, 67, 92, 254 ], "2021.": [ 64 ], "Adults": [ 65 ], "18": [ 66 ], "84": [ 68 ], "years": [ 69 ], "old": [ 70 ], "who": [ 71 ], "initiated": [ 72, 172, 180 ], "treatment": [ 73, 98 ], "with": [ 74, 99, 151, 245, 296, 344 ], "or": [ 78, 104, 319 ], "comparator": [ 80 ], "sodium-glucose": [ 81 ], "cotransporter-2": [ 82 ], "(SGLT2)": [ 83 ], "inhibitors": [ 84 ], "were": [ 85, 88, 126, 154, 199, 232 ], "included.": [ 86 ], "Data": [ 87 ], "analyzed": [ 89 ], "March": [ 91 ], "June": [ 93 ], "2024.": [ 94 ], "Exposure": [ 95 ], "Initiation": [ 96 ], "agonist": [ 103, 176, 187, 330 ], "SGLT2": [ 105, 182, 228 ], "inhibitor.": [ 106 ], "Main": [ 107 ], "Outcomes": [ 108 ], "Measures": [ 110 ], "The": [ 111, 260 ], "primary": [ 112 ], "outcome": [ 113 ], "was": [ 114, 193, 262, 276, 332, 342 ], "recorded": [ 117 ], "cause": [ 120 ], "registers.": [ 123 ], "Secondary": [ 124 ], "outcomes": [ 125 ], "composite": [ 128, 137 ], "nonfatal": [ 133, 271 ], "self-harm": [ 134 ], "incident": [ 139, 282, 320 ], "depression": [ 140, 283, 321 ], "anxiety-related": [ 142, 285, 323 ], "disorders.": [ 143, 286, 324 ], "Using": [ 144 ], "propensity": [ 145 ], "score": [ 146 ], "weighting,": [ 147 ], "hazard": [ 148 ], "ratios": [ 149 ], "(HRs)": [ 150 ], "95%": [ 152, 242 ], "CIs": [ 153 ], "calculated": [ 155 ], "separately": [ 156 ], "2": [ 159, 298 ], "countries": [ 160 ], "pooled": [ 162 ], "meta-analysis.": [ 165 ], "Results": [ 166 ], "In": [ 167 ], "total,": [ 168 ], "124": [ 169 ], "517": [ 170 ], "adults": [ 171 ], "174": [ 178 ], "036": [ 179 ], "an": [ 181, 246, 303, 312, 345 ], "inhibitor;": [ 183 ], "among": [ 184, 214, 225, 327 ], "users,": [ 188 ], "mean": [ 190, 203 ], "(SD)": [ 191, 204 ], "age": [ 192 ], "60": [ 194 ], "(13)": [ 195 ], "years,": [ 196, 209 ], "45%": [ 198 ], "women.": [ 200 ], "During": [ 201 ], "follow-up": [ 205 ], "2.5": [ 207 ], "(1.7)": [ 208 ], "77": [ 210 ], "deaths": [ 212, 223 ], "occurred": [ 213, 224 ], "users": [ 215, 226, 331 ], "71": [ 221 ], "inhibitors:": [ 229 ], "weighted": [ 230 ], "incidences": [ 231 ], "0.23": [ 233 ], "vs": [ 234 ], "0.18": [ 235 ], "events": [ 236, 256, 354 ], "per": [ 237, 257, 355 ], "1000": [ 238, 258, 356 ], "person-years": [ 239 ], "(HR,": [ 240 ], "1.25;": [ 241 ], "CI,": [ 243, 252, 265, 279 ], "0.83-1.88),": [ 244 ], "absolute": [ 247, 346 ], "difference": [ 248 ], "0.05": [ 250 ], "(95%": [ 251, 264, 278 ], "\u22120.03": [ 253 ], "0.16)": [ 255 ], "person-years.": [ 259, 357 ], "HR": [ 261, 275 ], "0.83": [ 263 ], "0.70-0.97)": [ 266 ], "for": [ 267, 281 ], "self-harm,": [ 272, 318 ], "1.01": [ 277 ], "0.97-1.06)": [ 280 ], "Conclusions": [ 287 ], "Relevance": [ 289 ], "study,": [ 292 ], "including": [ 293 ], "mostly": [ 294 ], "patients": [ 295 ], "type": [ 297 ], "diabetes,": [ 299 ], "does": [ 300 ], "not": [ 301 ], "show": [ 302 ], "death,": [ 317 ], "Suicide": [ 325 ], "rare,": [ 333 ], "upper": [ 336 ], "limit": [ 337 ], "confidence": [ 340 ], "interval": [ 341 ], "compatible": [ 343 ], "increase": [ 348 ], "no": [ 350 ], "more": [ 351 ], "than": [ 352 ], "0.16": [ 353 ] }, "publication_date": "2024-09-03", "publication_year": 2024, "type": "letter", "cited_by_count": 53, "authors": [ { "id": "https://openalex.org/A5052794043", "display_name": "Peter Ueda" }, { "id": "https://openalex.org/A5107701736", "display_name": "Jonas S\u00f6derling" }, { "id": "https://openalex.org/A5026440130", "display_name": "Viktor Wintzell" }, { "id": "https://openalex.org/A5046772961", "display_name": "Henrik Svanstr\u00f6m" }, { "id": "https://openalex.org/A5063723476", "display_name": "Laura Pazzagli" }, { "id": "https://openalex.org/A5061198575", "display_name": "Bj\u00f6rn Eliasson" }, { "id": "https://openalex.org/A5001189522", "display_name": "Mads Melbye" }, { "id": "https://openalex.org/A5022804650", "display_name": "Anders Hviid" }, { "id": "https://openalex.org/A5072660677", "display_name": "Bj\u00f6rn Pasternak" } ] }, { "id": "https://openalex.org/W2020562212", "doi": "https://doi.org/10.3949/ccjm.76.s5.05", "title": "Advances in therapy for type 2 diabetes: GLP\u20131 receptor agonists and DPP\u20134 inhibitors", "abstract": { "Type": [ 0 ], "2": [ 1 ], "diabetes": [ 2 ], "mellitus": [ 3 ], "(T2DM)": [ 4 ], "is": [ 5, 13, 23 ], "intrinsically": [ 6 ], "connected": [ 7 ], "to": [ 8, 30, 66 ], "overweight": [ 9 ], "and": [ 10, 22, 47, 57, 79, 97 ], "obesity.": [ 11 ], "It": [ 12 ], "a": [ 14 ], "complex": [ 15 ], "metabolic": [ 16 ], "disorder": [ 17 ], "that": [ 18 ], "predisposes": [ 19 ], "patients": [ 20 ], "to,": [ 21 ], "associated": [ 24, 36 ], "with,": [ 25 ], "cardiovascular": [ 26 ], "disease.": [ 27 ], "In": [ 28 ], "addition": [ 29 ], "the": [ 31, 41, 45, 48, 67 ], "triumvirate": [ 32 ], "of": [ 33, 40, 69 ], "core": [ 34 ], "defects": [ 35 ], "with": [ 37 ], "T2DM": [ 38 ], "(involvement": [ 39 ], "pancreatic": [ 42, 98 ], "beta": [ 43 ], "cell,": [ 44 ], "muscle,": [ 46 ], "liver),": [ 49 ], "other": [ 50 ], "mechanisms": [ 51 ], "including": [ 52 ], "hyperglucagonemia,": [ 53 ], "accelerated": [ 54 ], "gastric": [ 55 ], "emptying,": [ 56 ], "incretin": [ 58 ], "deficiency/resistance": [ 59 ], "are": [ 60 ], "also": [ 61 ], "involved.": [ 62 ], "This": [ 63 ], "has": [ 64 ], "led": [ 65 ], "development": [ 68 ], "incretinbased": [ 70 ], "therapies,": [ 71 ], "such": [ 72 ], "as": [ 73 ], "glucagon-like": [ 74 ], "peptide-1": [ 75 ], "(GLP-1)": [ 76 ], "receptor": [ 77 ], "agonists": [ 78 ], "dipeptidyl": [ 80 ], "peptidase-4": [ 81 ], "(DPP-4)": [ 82 ], "inhibitors.": [ 83 ], "These": [ 84 ], "newer": [ 85 ], "therapies": [ 86 ], "have": [ 87 ], "beneficial": [ 88 ], "effects": [ 89 ], "on": [ 90 ], "glycosylated": [ 91 ], "hemoglobin": [ 92 ], "A1c": [ 93 ], "(HbA1c)": [ 94 ], "levels,": [ 95 ], "weight,": [ 96 ], "beta-cell": [ 99 ], "function.": [ 100 ] }, "publication_date": "2009-12-01", "publication_year": 2009, "type": "review", "cited_by_count": 76, "authors": [ { "id": "https://openalex.org/A5111703004", "display_name": "Laurence Kennedy" }, { "id": "https://openalex.org/A5112058416", "display_name": "Jaime A. Davidson" } ] }, { "id": "https://openalex.org/W4379379336", "doi": "https://doi.org/10.1016/j.jpsychires.2023.05.041", "title": "Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review", "abstract": null, "publication_date": "2023-06-05", "publication_year": 2023, "type": "review", "cited_by_count": 56, "authors": [ { "id": "https://openalex.org/A5102965726", "display_name": "Daniel Cooper" }, { "id": "https://openalex.org/A5045499717", "display_name": "Ranuk Ramachandra" }, { "id": "https://openalex.org/A5074782402", "display_name": "Felicia Ceban" }, { "id": "https://openalex.org/A5080826593", "display_name": "Joshua D. Di Vincenzo" }, { "id": "https://openalex.org/A5072363222", "display_name": "Taeho Greg Rhee" }, { "id": "https://openalex.org/A5032613018", "display_name": "Rodrigo B. Mansur" }, { "id": "https://openalex.org/A5072332368", "display_name": "Kayla M. Teopiz" }, { "id": "https://openalex.org/A5019608736", "display_name": "Hartej Gill" }, { "id": "https://openalex.org/A5062759333", "display_name": "Roger Ho" }, { "id": "https://openalex.org/A5021387325", "display_name": "Bing Cao" }, { "id": "https://openalex.org/A5007416915", "display_name": "Leanna M.W. Lui" }, { "id": "https://openalex.org/A5076186053", "display_name": "Muhammad Youshay Jawad" }, { "id": "https://openalex.org/A5114055214", "display_name": "Juliet Arsenault" }, { "id": "https://openalex.org/A5034847365", "display_name": "Gia Han Le" }, { "id": "https://openalex.org/A5092088002", "display_name": "Diluk Ramachandra" }, { "id": "https://openalex.org/A5087184510", "display_name": "Ziji Guo" }, { "id": "https://openalex.org/A5068850044", "display_name": "Roger S. McIntyre" } ] }, { "id": "https://openalex.org/W2969411997", "doi": "https://doi.org/10.1007/s13300-019-00680-5", "title": "Cardiorenal Protection: Potential of SGLT2Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2Diabetes", "abstract": { "Recent": [ 0 ], "large": [ 1 ], "clinical": [ 2, 99, 136 ], "trials": [ 3, 131 ], "on": [ 4, 32 ], "sodium-glucose": [ 5 ], "cotransporter": [ 6 ], "2": [ 7, 49 ], "(SGLT2)": [ 8 ], "inhibitors": [ 9, 140 ], "and": [ 10, 41, 64, 83, 98, 132, 141, 162, 170 ], "glucagon-like": [ 11 ], "peptide-1": [ 12 ], "(GLP-1)": [ 13 ], "receptor": [ 14, 118, 143 ], "agonists,": [ 15 ], "with": [ 16, 47, 60, 96, 103, 109, 168 ], "the": [ 17, 61, 65, 73, 78, 84, 88, 125, 134, 156 ], "aim": [ 18 ], "of": [ 19, 38, 43, 90, 127, 138, 150, 158 ], "verifying": [ 20 ], "cardiovascular": [ 21, 34, 100, 129, 160 ], "safety,": [ 22 ], "have": [ 23, 28 ], "revealed": [ 24 ], "that": [ 25, 94 ], "these": [ 26, 151 ], "medications": [ 27 ], "a": [ 29 ], "preventative": [ 30 ], "advantage": [ 31, 137 ], "adverse": [ 33, 159 ], "outcomes,": [ 35 ], "including": [ 36 ], "worsening": [ 37 ], "heart": [ 39 ], "failure": [ 40 ], "deterioration": [ 42 ], "nephropathy,": [ 44 ], "in": [ 45, 166 ], "patients": [ 46, 95, 167 ], "type": [ 48 ], "diabetes": [ 50 ], "(T2D).": [ 51 ], "These": [ 52 ], "observed": [ 53 ], "benefits": [ 54 ], "do": [ 55 ], "not": [ 56 ], "seem": [ 57 ], "to": [ 58 ], "correlate": [ 59 ], "glucose-lowering": [ 62, 152 ], "effect,": [ 63 ], "underlying": [ 66 ], "mechanism": [ 67 ], "is": [ 68 ], "being": [ 69 ], "intensively": [ 70 ], "investigated.": [ 71 ], "Given": [ 72 ], "results": [ 74, 126 ], "from": [ 75 ], "recent": [ 76, 128 ], "studies,": [ 77 ], "American": [ 79 ], "Diabetes": [ 80, 91 ], "Association": [ 81, 86 ], "(ADA)": [ 82 ], "European": [ 85 ], "for": [ 87, 154 ], "Study": [ 89 ], "(EASD)": [ 92 ], "recommend": [ 93 ], "T2D": [ 97, 169 ], "disease": [ 101 ], "(CVD)": [ 102 ], "inadequate": [ 104 ], "glucose": [ 105 ], "control": [ 106 ], "despite": [ 107 ], "treatment": [ 108 ], "metformin": [ 110 ], "should": [ 111 ], "receive": [ 112 ], "an": [ 113 ], "SGLT2": [ 114, 139 ], "inhibitor": [ 115 ], "or": [ 116 ], "GLP-1": [ 117, 142 ], "agonist.": [ 119 ], "In": [ 120 ], "this": [ 121 ], "review": [ 122 ], "we": [ 123 ], "summarize": [ 124 ], "outcome": [ 130 ], "discuss": [ 133 ], "potential": [ 135 ], "agonists.": [ 144 ], "We": [ 145 ], "also": [ 146 ], "present": [ 147 ], "practical": [ 148 ], "implications": [ 149 ], "agents": [ 153 ], "reducing": [ 155 ], "risk": [ 157 ], "events": [ 161 ], "progressive": [ 163 ], "renal": [ 164 ], "comorbidity": [ 165 ], "CVD.": [ 171 ] }, "publication_date": "2019-08-22", "publication_year": 2019, "type": "review", "cited_by_count": 67, "authors": [ { "id": "https://openalex.org/A5034942182", "display_name": "Taichi Nagahisa" }, { "id": "https://openalex.org/A5013836607", "display_name": "Yoshifumi Saisho" } ] }, { "id": "https://openalex.org/W2129934471", "doi": "https://doi.org/10.2337/dc09-1914", "title": "DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks", "abstract": { "OBJECTIVE": [ 0 ], "In": [ 1, 98, 198 ], "the": [ 2, 22, 32, 59, 108, 172 ], "Diabetes": [ 3 ], "Therapy": [ 4 ], "Utilization:": [ 5 ], "Researching": [ 6 ], "Changes": [ 7 ], "in": [ 8, 49, 66, 223, 242, 261 ], "A1C,": [ 9, 121 ], "Weight": [ 10 ], "and": [ 11, 24, 61, 80, 133, 176, 187, 195, 208, 227, 245, 263 ], "Other": [ 12 ], "Factors": [ 13 ], "Through": [ 14 ], "Intervention": [ 15 ], "with": [ 16, 31, 46, 52, 265 ], "Exenatide": [ 17, 237 ], "Once": [ 18 ], "Weekly": [ 19 ], "(DURATION-1)": [ 20 ], "study,": [ 21 ], "safety": [ 23, 60 ], "efficacy": [ 25, 62 ], "of": [ 26, 29, 63, 189, 251 ], "30": [ 27, 92 ], "weeks": [ 28, 76, 78, 147, 250 ], "treatment": [ 30, 71, 200 ], "glucagon-like": [ 33 ], "peptide-1": [ 34 ], "receptor": [ 35 ], "agonist": [ 36 ], "exenatide": [ 37, 47, 64, 86, 89, 140, 160, 163, 256 ], "once": [ 38 ], "weekly": [ 39 ], "(exenatide": [ 40 ], "QW;": [ 41 ], "2": [ 42, 54 ], "mg)": [ 43 ], "was": [ 44, 203, 211, 228, 234 ], "compared": [ 45 ], "BID": [ 48, 87, 161 ], "295": [ 50 ], "patients": [ 51, 68, 82, 106, 191 ], "type": [ 53 ], "diabetes.": [ 55 ], "We": [ 56 ], "now": [ 57 ], "report": [ 58 ], "QW": [ 65, 90, 141, 164, 238, 257 ], "1)": [ 67 ], "who": [ 69, 83 ], "continued": [ 70 ], "for": [ 72 ], "an": [ 73 ], "additional": [ 74 ], "22": [ 75 ], "(52": [ 77 ], "total)": [ 79 ], "2)": [ 81 ], "switched": [ 84 ], "from": [ 85, 159 ], "to": [ 88, 155, 162, 255 ], "after": [ 91, 216 ], "weeks.": [ 93, 218 ], "RESEARCH": [ 94 ], "DESIGN": [ 95 ], "AND": [ 96 ], "METHODS": [ 97 ], "this": [ 99, 224 ], "randomized,": [ 100 ], "multicenter,": [ 101 ], "comparator-controlled,": [ 102 ], "open-label": [ 103 ], "trial,": [ 104 ], "258": [ 105 ], "entered": [ 107 ], "22-week": [ 109 ], "open-ended": [ 110 ], "assessment": [ 111, 225 ], "phase": [ 112 ], "(n": [ 113 ], "=": [ 114, 118 ], "128": [ 115 ], "QW-only;": [ 116 ], "n": [ 117 ], "130": [ 119 ], "BID\u2192QW).": [ 120 ], "fasting": [ 122, 130 ], "plasma": [ 123 ], "glucose": [ 124 ], "(FPG),": [ 125 ], "body": [ 126, 209, 246 ], "weight,": [ 127 ], "blood": [ 128 ], "pressure,": [ 129 ], "lipids,": [ 131 ], "safety,": [ 132 ], "tolerability": [ 134 ], "were": [ 135 ], "assessed.": [ 136 ], "RESULTS": [ 137 ], "Patients": [ 138, 157, 253 ], "continuing": [ 139 ], "maintained": [ 142 ], "A1C": [ 143, 167, 174, 178, 193, 262 ], "improvements": [ 144, 241, 260 ], "through": [ 145, 248 ], "52": [ 146, 217, 249 ], "(least": [ 148 ], "squares": [ 149 ], "mean": [ 150, 177 ], "\u22122.0%": [ 151 ], "[95%": [ 152 ], "CI": [ 153 ], "\u22122.1": [ 154 ], "\u22121.8%]).": [ 156 ], "switching": [ 158, 254 ], "achieved": [ 165, 192 ], "further": [ 166, 259 ], "improvements;": [ 168 ], "both": [ 169, 199 ], "groups": [ 170 ], "exhibited": [ 171 ], "same": [ 173 ], "reduction": [ 175 ], "(6.6%)": [ 179 ], "at": [ 180 ], "week": [ 181, 184 ], "52.": [ 182 ], "At": [ 183 ], "52,": [ 185 ], "71": [ 186 ], "54%": [ 188 ], "all": [ 190 ], "&lt;7.0%": [ 194 ], "\u22646.5%,": [ 196 ], "respectively.": [ 197 ], "arms,": [ 201 ], "FPG": [ 202 ], "reduced": [ 204, 212 ], "by": [ 205, 213 ], "&gt;40": [ 206 ], "mg/dl,": [ 207 ], "weight": [ 210, 247, 267 ], "&gt;4": [ 214 ], "kg": [ 215 ], "Nausea": [ 219 ], "occurred": [ 220 ], "less": [ 221 ], "frequently": [ 222 ], "period": [ 226 ], "predominantly": [ 229 ], "mild.": [ 230 ], "No": [ 231 ], "major": [ 232 ], "hypoglycemia": [ 233 ], "observed.": [ 235 ], "CONCLUSION": [ 236 ], "elicited": [ 239 ], "sustained": [ 240, 266 ], "glycemic": [ 243 ], "control": [ 244 ], "treatment.": [ 252 ], "experienced": [ 258 ], "FPG,": [ 264 ], "loss.": [ 268 ] }, "publication_date": "2010-03-09", "publication_year": 2010, "type": "article", "cited_by_count": 346, "authors": [ { "id": "https://openalex.org/A5040182038", "display_name": "John B. Buse" }, { "id": "https://openalex.org/A5057472647", "display_name": "Daniel J. Drucker" }, { "id": "https://openalex.org/A5110734241", "display_name": "Kristin Taylor" }, { "id": "https://openalex.org/A5079701705", "display_name": "Terri Kim" }, { "id": "https://openalex.org/A5102775095", "display_name": "Brandon Walsh" }, { "id": "https://openalex.org/A5100721089", "display_name": "Hao Hu" }, { "id": "https://openalex.org/A5112080455", "display_name": "Ken Wilhelm" }, { "id": "https://openalex.org/A5062021087", "display_name": "Michael Trautmann" }, { "id": "https://openalex.org/A5113725447", "display_name": "Larry Z. Shen" }, { "id": "https://openalex.org/A5103540035", "display_name": "Lisa E. Porter" } ] }, { "id": "https://openalex.org/W2555053373", "doi": "https://doi.org/10.1002/osp4.84", "title": "Liraglutide for weight management: a critical review of the evidence", "abstract": { "Summary": [ 0 ], "Objective": [ 1 ], "To": [ 2 ], "review": [ 3 ], "the": [ 4, 24, 48, 57, 121, 168, 230 ], "efficacy,": [ 5 ], "safety,": [ 6 ], "and": [ 7, 39, 44, 52, 78, 102, 116, 202, 211, 247 ], "clinical": [ 8, 18, 41, 190 ], "applicability": [ 9, 163 ], "of": [ 10, 23, 66, 96, 164, 233 ], "liraglutide": [ 11, 67, 81, 131 ], "for": [ 12, 68, 167, 204 ], "weight": [ 13, 69, 90, 104, 128, 176, 213 ], "management": [ 14, 70 ], "from": [ 15 ], "phase": [ 16 ], "III": [ 17 ], "trials.": [ 19 ], "Methods": [ 20 ], "A": [ 21 ], "search": [ 22, 32 ], "English": [ 25 ], "language": [ 26 ], "literature": [ 27 ], "was": [ 28, 151 ], "performed": [ 29 ], "using": [ 30 ], "PubMed": [ 31 ], "terms:": [ 33 ], "\u201cliraglutide\u201d,": [ 34 ], "\u201cglucagon\u2010like": [ 35 ], "peptide\u20101": [ 36 ], "receptor": [ 37 ], "agonist\u201d,": [ 38 ], "\u201crandomized": [ 40 ], "trial\u201d.": [ 42 ], "Articles": [ 43 ], "bibliographies": [ 45 ], "relevant": [ 46 ], "to": [ 47, 56, 75, 87, 154, 188, 209, 223, 241 ], "subject": [ 49 ], "were": [ 50, 59, 71, 114 ], "reviewed": [ 51 ], "additional": [ 53 ], "references": [ 54 ], "known": [ 55 ], "authors": [ 58 ], "included.": [ 60 ], "Results": [ 61 ], "Five": [ 62 ], "randomized,": [ 63 ], "placebo\u2010controlled": [ 64 ], "trials": [ 65 ], "identified.": [ 72 ], "In": [ 73 ], "addition": [ 74 ], "recommended": [ 76 ], "diet": [ 77 ], "physical": [ 79 ], "activity,": [ 80 ], "consistently": [ 82 ], "resulted": [ 83 ], "in": [ 84, 120, 158, 172, 215 ], "a": [ 85, 93, 159, 173, 193 ], "4": [ 86 ], "6": [ 88 ], "kg": [ 89 ], "loss,": [ 91 ], "with": [ 92, 107, 130, 137, 146, 217 ], "greater": [ 94, 133 ], "proportion": [ 95 ], "patients": [ 97, 216 ], "achieving": [ 98 ], "at": [ 99, 179 ], "least": [ 100 ], "5": [ 101 ], "10%": [ 103 ], "loss": [ 105, 129, 177, 214 ], "compared": [ 106 ], "placebo.": [ 108 ], "The": [ 109 ], "most": [ 110 ], "common": [ 111 ], "adverse": [ 112 ], "effects": [ 113 ], "gastrointestinal": [ 115, 197 ], "primarily": [ 117 ], "occurred": [ 118 ], "early": [ 119 ], "treatment": [ 122 ], "course.": [ 123 ], "Comparative": [ 124 ], "data": [ 125 ], "suggest": [ 126 ], "that": [ 127, 135, 144 ], "is": [ 132, 183, 221 ], "than": [ 134 ], "seen": [ 136, 145 ], "orlistat": [ 138 ], "or": [ 139 ], "lorcaserin,": [ 140 ], "but": [ 141, 227 ], "slightly": [ 142 ], "less": [ 143 ], "phentermine/topiramate.": [ 147 ], "Liraglutide": [ 148, 207 ], "1.8": [ 149 ], "mg": [ 150, 170 ], "recently": [ 152 ], "shown": [ 153 ], "have": [ 155 ], "cardiovascular": [ 156, 181 ], "benefit": [ 157, 232 ], "large": [ 160 ], "outcomes": [ 161 ], "trial;": [ 162 ], "these": [ 165 ], "results": [ 166 ], "3.0": [ 169 ], "formulation": [ 171 ], "more": [ 174 ], "diverse": [ 175 ], "population": [ 178 ], "high": [ 180, 200 ], "risk": [ 182 ], "not": [ 184 ], "currently": [ 185 ], "known.": [ 186 ], "Barriers": [ 187 ], "real\u2010world": [ 189 ], "use": [ 191 ], "as": [ 192 ], "first\u2010line": [ 194 ], "agent": [ 195 ], "include": [ 196 ], "side": [ 198 ], "effects,": [ 199 ], "cost,": [ 201 ], "need": [ 203 ], "injection.": [ 205 ], "Conclusions": [ 206 ], "helps": [ 208 ], "induce": [ 210 ], "sustain": [ 212 ], "obesity.": [ 218 ], "Its": [ 219 ], "efficacy": [ 220, 246 ], "comparable": [ 222 ], "other": [ 224 ], "available": [ 225 ], "agents": [ 226 ], "it": [ 228 ], "offers": [ 229 ], "unique": [ 231 ], "improved": [ 234 ], "glycemic": [ 235 ], "control.": [ 236 ], "Additional": [ 237 ], "studies": [ 238 ], "are": [ 239 ], "needed": [ 240 ], "determine": [ 242 ], "its": [ 243 ], "long": [ 244 ], "term": [ 245 ], "safety": [ 248 ], "profile.": [ 249 ] }, "publication_date": "2016-11-10", "publication_year": 2016, "type": "review", "cited_by_count": 277, "authors": [ { "id": "https://openalex.org/A5077706163", "display_name": "Anurag Mehta" }, { "id": "https://openalex.org/A5110355842", "display_name": "Steven P. Marso" }, { "id": "https://openalex.org/A5069986121", "display_name": "Ian J. Neeland" } ] }, { "id": "https://openalex.org/W2766836053", "doi": "https://doi.org/10.1001/jama.2017.14752", "title": "Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes", "abstract": { "clinicaltrials.gov": [ 0 ], "Identifier:": [ 1 ], "NCT01923181.": [ 2 ] }, "publication_date": "2017-10-17", "publication_year": 2017, "type": "article", "cited_by_count": 433, "authors": [ { "id": "https://openalex.org/A5084593004", "display_name": "Melanie J. Davies" }, { "id": "https://openalex.org/A5023877066", "display_name": "Thomas R. Pieber" }, { "id": "https://openalex.org/A5047558107", "display_name": "Marie\u2010Louise Hartoft\u2010Nielsen" }, { "id": "https://openalex.org/A5103336595", "display_name": "OLUF K. H\u00d8JBJERG HANSEN" }, { "id": "https://openalex.org/A5076877188", "display_name": "Serge Jabbour" }, { "id": "https://openalex.org/A5045489578", "display_name": "Julio Rosenstock" } ] }, { "id": "https://openalex.org/W2129377335", "doi": "https://doi.org/10.1007/s00125-006-0510-2", "title": "A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study", "abstract": null, "publication_date": "2006-12-07", "publication_year": 2006, "type": "article", "cited_by_count": 439, "authors": [ { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5013132040", "display_name": "Santiago Dur\u00e1n" }, { "id": "https://openalex.org/A5035998759", "display_name": "D. Kim" }, { "id": "https://openalex.org/A5071736666", "display_name": "Don Johns" }, { "id": "https://openalex.org/A5024896088", "display_name": "Justin Northrup" }, { "id": "https://openalex.org/A5111922692", "display_name": "Andreas Festa" }, { "id": "https://openalex.org/A5109961740", "display_name": "Robert G. Brodows" }, { "id": "https://openalex.org/A5062021087", "display_name": "Michael Trautmann" } ] }, { "id": "https://openalex.org/W2982236336", "doi": "https://doi.org/10.1111/dom.13902", "title": "Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER)", "abstract": { "Abstract": [ 0 ], "Aim": [ 1 ], "When": [ 2 ], "selecting": [ 3 ], "treatments": [ 4 ], "for": [ 5, 45, 67, 79, 107, 251 ], "type": [ 6, 80, 212 ], "2": [ 7, 81, 213 ], "diabetes": [ 8, 214 ], "(T2D),": [ 9 ], "it": [ 10 ], "is": [ 11 ], "important": [ 12 ], "to": [ 13, 38, 86, 155, 177, 190, 220, 235 ], "consider": [ 14 ], "not": [ 15 ], "only": [ 16 ], "efficacy": [ 17 ], "and": [ 18, 52, 69, 97, 169 ], "safety,": [ 19 ], "but": [ 20 ], "also": [ 21 ], "other": [ 22 ], "treatment": [ 23 ], "attributes": [ 24 ], "that": [ 25 ], "have": [ 26, 156 ], "an": [ 27, 58, 102 ], "impact": [ 28 ], "on": [ 29 ], "patient": [ 30, 65 ], "preference.": [ 31 ], "The": [ 32, 54 ], "objective": [ 33 ], "of": [ 34, 94, 159 ], "this": [ 35 ], "study": [ 36, 56, 63 ], "was": [ 37, 57, 110 ], "examine": [ 39 ], "preference": [ 40, 66 ], "between": [ 41 ], "injection": [ 42, 71, 95, 103, 218, 223, 252 ], "devices": [ 43, 72, 253 ], "used": [ 44 ], "two": [ 46 ], "weekly": [ 47 ], "GLP\u20101": [ 48 ], "receptor": [ 49 ], "agonists.": [ 50 ], "Materials": [ 51 ], "Methods": [ 53 ], "PREFER": [ 55 ], "open\u2010label,": [ 59 ], "multicentre,": [ 60 ], "randomized,": [ 61 ], "crossover": [ 62 ], "assessing": [ 64 ], "dulaglutide": [ 68, 137, 153, 180, 193, 217 ], "semaglutide": [ 70, 141, 185, 200, 222 ], "among": [ 73 ], "injection\u2010na\u00efve": [ 74 ], "patients": [ 75, 226 ], "receiving": [ 76 ], "oral": [ 77 ], "medication": [ 78 ], "diabetes.": [ 82 ], "After": [ 83, 167 ], "being": [ 84 ], "trained": [ 85 ], "use": [ 87, 160, 178, 191, 236 ], "each": [ 88, 108 ], "device,": [ 89, 229 ], "participants": [ 90, 120, 128, 134, 150, 174, 189 ], "performed": [ 91 ], "all": [ 92 ], "steps": [ 93 ], "preparation": [ 96 ], "administered": [ 98 ], "mock": [ 99 ], "injections": [ 100 ], "into": [ 101 ], "pad.": [ 104 ], "Time\u2010to\u2010train": [ 105 ], "(TTT)": [ 106 ], "device": [ 109, 138, 142, 154, 181, 186, 194, 201, 219 ], "assessed": [ 111 ], "in": [ 112, 129, 242, 257 ], "a": [ 113, 228, 247 ], "subset.": [ 114 ], "Results": [ 115 ], "There": [ 116 ], "were": [ 117, 175 ], "310": [ 118 ], "evaluable": [ 119 ], "(48.4%": [ 121 ], "female;": [ 122 ], "mean": [ 123 ], "age,": [ 124 ], "60.0": [ 125 ], "years;": [ 126 ], "78": [ 127 ], "the": [ 130, 136, 140, 152, 171, 179, 184, 192, 199, 216, 221, 237 ], "TTT": [ 131 ], "subgroup).": [ 132 ], "More": [ 133, 149 ], "preferred": [ 135, 215 ], "than": [ 139, 183, 198 ], "(84.2%": [ 143 ], "vs.": [ 144, 162, 203 ], "12.3%;": [ 145 ], "P": [ 146, 164, 206 ], "<": [ 147, 165, 207 ], "0.0001).": [ 148, 166, 208 ], "perceived": [ 151 ], "greater": [ 157 ], "ease": [ 158 ], "(86.8%": [ 161 ], "6.8%;": [ 163 ], "preparing": [ 168 ], "using": [ 170 ], "devices,": [ 172 ], "more": [ 173, 233 ], "willing": [ 176, 234 ], "(93.5%)": [ 182 ], "(45.8%).": [ 187 ], "Training": [ 188 ], "required": [ 195 ], "less": [ 196 ], "time": [ 197, 250 ], "(3.38": [ 202 ], "8.14": [ 204 ], "minutes;": [ 205 ], "Conclusions": [ 209 ], "Participants": [ 210 ], "with": [ 211 ], "device.": [ 224 ], "If": [ 225 ], "prefer": [ 227 ], "they": [ 230 ], "may": [ 231, 254 ], "be": [ 232, 255 ], "medication,": [ 238 ], "which": [ 239 ], "could": [ 240 ], "result": [ 241 ], "better": [ 243 ], "health": [ 244 ], "outcomes.": [ 245 ], "Furthermore,": [ 246 ], "shorter": [ 248 ], "training": [ 249 ], "helpful": [ 256 ], "busy": [ 258 ], "clinical": [ 259 ], "practice": [ 260 ], "settings.": [ 261 ] }, "publication_date": "2019-10-24", "publication_year": 2019, "type": "article", "cited_by_count": 41, "authors": [ { "id": "https://openalex.org/A5051703711", "display_name": "Louis S. Matza" }, { "id": "https://openalex.org/A5039006946", "display_name": "Kristina S. Boye" }, { "id": "https://openalex.org/A5000247720", "display_name": "Katie D. Stewart" }, { "id": "https://openalex.org/A5062880958", "display_name": "Karin S. Coyne" }, { "id": "https://openalex.org/A5000479492", "display_name": "Paula Wullenweber" }, { "id": "https://openalex.org/A5068121215", "display_name": "Katelyn Cutts" }, { "id": "https://openalex.org/A5111937124", "display_name": "Jessica Jordan" }, { "id": "https://openalex.org/A5115594555", "display_name": "Qianqian Wang" }, { "id": "https://openalex.org/A5109226707", "display_name": "Maria Yu" }, { "id": "https://openalex.org/A5060624698", "display_name": "Brooke M. Currie" }, { "id": "https://openalex.org/A5058300563", "display_name": "Karen G. Malley" }, { "id": "https://openalex.org/A5053370609", "display_name": "KJ Ishak" }, { "id": "https://openalex.org/A5047600098", "display_name": "Ryan T. Hietpas" }, { "id": "https://openalex.org/A5048081580", "display_name": "Luis\u2010Emilio Garc\u00eda\u2010P\u00e9rez" } ] }, { "id": "https://openalex.org/W4384067410", "doi": "https://doi.org/10.3390/ph16070994", "title": "Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration\u2019s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset", "abstract": { "Recent": [ 0 ], "media": [ 1 ], "reports": [ 2, 82 ], "commented": [ 3 ], "about": [ 4 ], "a": [ 5, 18, 34, 76, 105, 154 ], "possible": [ 6 ], "issue": [ 7 ], "of": [ 8, 11, 79, 107, 142, 173, 189, 201, 231 ], "the": [ 9, 54, 63, 90, 96, 111, 135, 138, 143, 176, 187, 194, 198, 210, 228 ], "misuse": [ 10 ], "antidiabetics": [ 12 ], "related": [ 13, 31, 86 ], "to": [ 14, 32, 41, 116, 218, 225 ], "molecules": [ 15, 113 ], "promoted": [ 16 ], "as": [ 17 ], "weight-loss": [ 19 ], "treatment": [ 20 ], "in": [ 21, 39, 203 ], "non-obese": [ 22 ], "people.": [ 23 ], "We": [ 24 ], "evaluated": [ 25 ], "here": [ 26 ], "available": [ 27 ], "pharmacovigilance": [ 28, 87 ], "misuse/abuse": [ 29, 199 ], "signals": [ 30 ], "semaglutide,": [ 33 ], "glucagon-like": [ 35 ], "peptide-1": [ 36 ], "(GLP-1)": [ 37 ], "analogue,": [ 38 ], "comparison": [ 40, 204 ], "other": [ 42, 206 ], "GLP-1": [ 43 ], "receptor": [ 44 ], "agonists": [ 45 ], "(albiglutide,": [ 46 ], "dulaglutide,": [ 47 ], "exenatide,": [ 48 ], "liraglutide,": [ 49 ], "lixisenatide,": [ 50 ], "and": [ 51, 53, 65, 84, 95, 125, 156, 165, 209 ], "tirzepatide)": [ 52 ], "phentermine\u2013topiramate": [ 55, 177, 211 ], "combination.": [ 56, 212 ], "To": [ 57, 186 ], "acheieve": [ 58 ], "that": [ 59 ], "aim,": [ 60 ], "we": [ 61 ], "analyzed": [ 62 ], "Food": [ 64 ], "Drug": [ 66 ], "Administration\u2019s": [ 67 ], "FDA": [ 68 ], "Adverse": [ 69 ], "Events": [ 70 ], "Reporting": [ 71 ], "System": [ 72 ], "(FAERS)": [ 73 ], "dataset,": [ 74 ], "performing": [ 75 ], "descriptive": [ 77 ], "analysis": [ 78 ], "adverse": [ 80 ], "event": [ 81 ], "(AERs)": [ 83 ], "calculating": [ 85 ], "measures,": [ 88 ], "including": [ 89 ], "reporting": [ 91, 98 ], "odds": [ 92 ], "ratio": [ 93, 99 ], "(ROR)": [ 94 ], "proportional": [ 97 ], "(PRR).": [ 100 ], "During": [ 101 ], "January": [ 102 ], "2018\u2013December": [ 103 ], "2022,": [ 104 ], "total": [ 106 ], "31,542": [ 108 ], "AERs": [ 109, 144 ], "involving": [ 110 ], "selected": [ 112 ], "were": [ 114, 161, 179 ], "submitted": [ 115 ], "FAERS;": [ 117 ], "most": [ 118 ], "involved": [ 119 ], "dulaglutide": [ 120 ], "(n": [ 121, 127 ], "=": [ 122, 128 ], "11,858;": [ 123 ], "37.6%)": [ 124 ], "semaglutide": [ 126, 133, 174, 202 ], "8249;": [ 129 ], "26.1%).": [ 130 ], "In": [ 131 ], "comparing": [ 132 ], "vs.": [ 134, 175 ], "remaining": [ 136 ], "molecules,": [ 137 ], "respective": [ 139 ], "PRR": [ 140 ], "values": [ 141 ], "\u2018drug": [ 145, 147 ], "abuse\u2019,": [ 146 ], "withdrawal": [ 148 ], "syndrome\u2019,": [ 149 ], "\u2018prescription": [ 150 ], "drug": [ 151 ], "used": [ 152 ], "without": [ 153 ], "prescription\u2019,": [ 155 ], "\u2018intentional": [ 157 ], "product": [ 158 ], "use": [ 159 ], "issue\u2019": [ 160 ], "4.05,": [ 162, 163 ], "3.60,": [ 164 ], "1.80": [ 166 ], "(all": [ 167 ], "<": [ 168 ], "0.01).": [ 169 ], "The": [ 170, 213 ], "same": [ 171 ], "comparisons": [ 172 ], "combination": [ 178 ], "not": [ 180 ], "associated": [ 181 ], "with": [ 182, 205 ], "any": [ 183 ], "significant": [ 184 ], "differences.": [ 185 ], "best": [ 188 ], "our": [ 190 ], "knowledge,": [ 191 ], "this": [ 192 ], "is": [ 193 ], "first": [ 195 ], "study": [ 196 ], "documenting": [ 197 ], "potential": [ 200 ], "GLP1": [ 207 ], "analogues": [ 208 ], "current": [ 214 ], "findings": [ 215 ], "will": [ 216 ], "need": [ 217 ], "be": [ 219 ], "confirmed": [ 220 ], "by": [ 221 ], "further": [ 222 ], "empirical": [ 223 ], "investigations": [ 224 ], "fully": [ 226 ], "understand": [ 227 ], "safety": [ 229 ], "profile": [ 230 ], "those": [ 232 ], "molecules.": [ 233 ] }, "publication_date": "2023-07-11", "publication_year": 2023, "type": "article", "cited_by_count": 52, "authors": [ { "id": "https://openalex.org/A5041705984", "display_name": "Stefania Chiappini" }, { "id": "https://openalex.org/A5035097834", "display_name": "Rachel Vickers\u2010Smith" }, { "id": "https://openalex.org/A5013578015", "display_name": "Daniel R. Harris" }, { "id": "https://openalex.org/A5104754386", "display_name": "Guy Pelletier" }, { "id": "https://openalex.org/A5058372793", "display_name": "John Corkery" }, { "id": "https://openalex.org/A5080313345", "display_name": "Amira Guirguis" }, { "id": "https://openalex.org/A5070312407", "display_name": "Giovanni Martinotti" }, { "id": "https://openalex.org/A5024277256", "display_name": "Stefano L. Sensi" }, { "id": "https://openalex.org/A5078706372", "display_name": "Fabrizio Schifano" } ] }, { "id": "https://openalex.org/W2972655539", "doi": "https://doi.org/10.2174/1567205016666190913155950", "title": "A Pilot Study of Exenatide Actions in Alzheimer\u2019s Disease", "abstract": { "Background:": [ 0 ], "Strong": [ 1 ], "preclinical": [ 2 ], "evidence": [ 3, 170 ], "suggests": [ 4 ], "that": [ 5, 171, 218 ], "exenatide,": [ 6 ], "a": [ 7, 154 ], "glucagon-like": [ 8 ], "peptide-1": [ 9 ], "(GLP-": [ 10 ], "1)": [ 11 ], "receptor": [ 12 ], "agonist": [ 13 ], "used": [ 14 ], "for": [ 15, 52, 90, 131, 153, 179 ], "treating": [ 16 ], "type": [ 17 ], "2": [ 18 ], "diabetes,": [ 19 ], "is": [ 20, 220 ], "neuroprotective": [ 21 ], "and": [ 22, 44, 48, 55, 96, 105, 111, 114, 133, 139, 146, 196, 225, 230 ], "disease-modifying": [ 23 ], "in": [ 24, 58, 143, 158, 183, 186, 213, 222, 229, 238 ], "Alzheimer\u2019s": [ 25 ], "Disease": [ 26 ], "(AD).": [ 27 ], "Objective:": [ 28 ], "We": [ 29 ], "performed": [ 30 ], "an": [ 31, 99, 176 ], "18-month": [ 32 ], "double-blind": [ 33 ], "randomized": [ 34 ], "placebo-controlled": [ 35 ], "Phase": [ 36 ], "II": [ 37 ], "clinical": [ 38, 132, 184, 223 ], "trial": [ 39 ], "to": [ 40, 79, 109, 129, 193 ], "assess": [ 41 ], "the": [ 42, 75, 84, 205, 216 ], "safety": [ 43 ], "tolerability": [ 45 ], "of": [ 46, 103, 156, 164, 207, 215, 231 ], "exenatide": [ 47, 219 ], "explore": [ 49 ], "treatment": [ 50, 122 ], "responses": [ 51, 182 ], "clinical,": [ 53 ], "cognitive,": [ 54 ], "biomarker": [ 56, 181 ], "outcomes": [ 57, 87, 209, 237 ], "early": [ 59, 81, 194 ], "AD.": [ 60, 187, 239 ], "Method:": [ 61 ], "Eighteen": [ 62 ], "participants": [ 63 ], "with": [ 64 ], "high": [ 65 ], "probability": [ 66 ], "AD": [ 67 ], "based": [ 68 ], "on": [ 69 ], "cerebrospinal": [ 70 ], "fluid": [ 71 ], "(CSF)": [ 72 ], "biomarkers": [ 73, 142 ], "completed": [ 74 ], "entire": [ 76 ], "study": [ 77, 189 ], "prior": [ 78 ], "its": [ 80 ], "termination": [ 82, 195 ], "by": [ 83 ], "sponsor;": [ 85 ], "partial": [ 86 ], "were": [ 88 ], "available": [ 89 ], "twentyone.": [ 91 ], "Results:": [ 92 ], "Exenatide": [ 93, 121 ], "was": [ 94, 190 ], "safe": [ 95 ], "well-tolerated,": [ 97 ], "showing": [ 98 ], "expectedly": [ 100 ], "higher": [ 101 ], "incidence": [ 102 ], "nausea": [ 104 ], "decreased": [ 106 ], "appetite": [ 107 ], "compared": [ 108, 128 ], "placebo": [ 110, 130 ], "decreasing": [ 112 ], "glucose": [ 113 ], "GLP-1": [ 115 ], "during": [ 116 ], "Oral": [ 117 ], "Glucose": [ 118 ], "Tolerance": [ 119 ], "Tests.": [ 120 ], "produced": [ 123 ], "no": [ 124, 211 ], "differences": [ 125 ], "or": [ 126, 141 ], "trends": [ 127, 212 ], "cognitive": [ 134, 236 ], "measures,": [ 135 ], "MRI": [ 136 ], "cortical": [ 137 ], "thickness": [ 138 ], "volume,": [ 140 ], "CSF,": [ 144 ], "plasma,": [ 145 ], "plasma": [ 147, 172 ], "neuronal": [ 148, 173 ], "extracellular": [ 149 ], "vesicles": [ 150 ], "(EV)": [ 151 ], "except": [ 152 ], "reduction": [ 155 ], "A\u03b242": [ 157, 167, 228 ], "EVs.": [ 159 ], "Conclusion:": [ 160 ], "The": [ 161, 188 ], "positive": [ 162 ], "finding": [ 163 ], "lower": [ 165 ], "EV": [ 166, 227 ], "supports": [ 168 ], "emerging": [ 169 ], "EVs": [ 174 ], "provide": [ 175 ], "effective": [ 177 ], "platform": [ 178 ], "demonstrating": [ 180 ], "trials": [ 185 ], "underpowered": [ 191 ], "due": [ 192 ], "therefore": [ 197 ], "we": [ 198 ], "cannot": [ 199 ], "draw": [ 200 ], "any": [ 201 ], "firm": [ 202 ], "conclusions.": [ 203 ], "However,": [ 204 ], "analysis": [ 206 ], "secondary": [ 208 ], "shows": [ 210 ], "support": [ 214 ], "hypothesis": [ 217 ], "diseasemodifying": [ 221 ], "AD,": [ 224 ], "lowering": [ 226 ], "itself": [ 232 ], "may": [ 233 ], "not": [ 234 ], "improve": [ 235 ] }, "publication_date": "2019-09-13", "publication_year": 2019, "type": "article", "cited_by_count": 129, "authors": [ { "id": "https://openalex.org/A5019721067", "display_name": "Roger J. Mullins" }, { "id": "https://openalex.org/A5013330262", "display_name": "Maja Mustapi\u0107" }, { "id": "https://openalex.org/A5058369658", "display_name": "Chee W. Chia" }, { "id": "https://openalex.org/A5037684812", "display_name": "Olga D. Carlson" }, { "id": "https://openalex.org/A5005797736", "display_name": "Seema Gulyani" }, { "id": "https://openalex.org/A5090912288", "display_name": "Joyce Tran" }, { "id": "https://openalex.org/A5100669061", "display_name": "Yazhou Li" }, { "id": "https://openalex.org/A5083040475", "display_name": "Mark P. Mattson" }, { "id": "https://openalex.org/A5003112344", "display_name": "Susan M. Resnick" }, { "id": "https://openalex.org/A5000777749", "display_name": "Josephine M. Egan" }, { "id": "https://openalex.org/A5056649584", "display_name": "Nigel H. Greig" }, { "id": "https://openalex.org/A5063213339", "display_name": "Dimitrios Kapogiannis" } ] }, { "id": "https://openalex.org/W2144960258", "doi": "https://doi.org/10.1111/aji.12420", "title": "GLP\u20101 Receptor Agonist Exenatide Attenuates the Detrimental Effects of Obesity on Inflammatory Profile in Testis and Sperm Quality in Mice", "abstract": { "Problem": [ 0 ], "Male": [ 1 ], "obesity": [ 2, 113 ], "has": [ 3 ], "been": [ 4 ], "linked": [ 5 ], "to": [ 6, 11, 48, 115, 144 ], "subfecundity.": [ 7 ], "This": [ 8 ], "study": [ 9, 32 ], "is": [ 10 ], "investigate": [ 12 ], "the": [ 13, 62, 75, 81, 100, 107, 116, 129 ], "effects": [ 14 ], "of": [ 15, 31, 36, 65, 77, 90, 102, 109, 118, 124 ], "GLP\u20101": [ 16 ], "receptor": [ 17 ], "(GLP\u20101R)": [ 18 ], "agonist": [ 19 ], "exenatide": [ 20, 52, 136 ], "on": [ 21, 44 ], "sperm": [ 22, 78, 119, 151 ], "quality": [ 23, 60, 76, 108, 120 ], "in": [ 24, 95, 126 ], "high\u2010fat": [ 25 ], "diet": [ 26, 38 ], "(HFD)\u2010induced": [ 27 ], "obese": [ 28, 145 ], "mice.": [ 29 ], "Method": [ 30 ], "After": [ 33 ], "12": [ 34 ], "weeks": [ 35 ], "chow": [ 37 ], "(CD)": [ 39 ], "or": [ 40, 51 ], "HFD": [ 41, 45 ], "challenge,": [ 42 ], "mice": [ 43 ], "were": [ 46, 67 ], "allocated": [ 47 ], "either": [ 49 ], "saline": [ 50 ], "(24": [ 53 ], "nmol/kg/day)": [ 54 ], "interventions": [ 55 ], "for": [ 56 ], "8": [ 57 ], "weeks.": [ 58 ], "Sperm": [ 59 ], "and": [ 61, 79, 93, 105, 121, 128, 146 ], "inflammatory": [ 63, 82 ], "profile": [ 64, 83 ], "testis": [ 66, 125 ], "compared": [ 68 ], "among": [ 69 ], "three": [ 70 ], "groups.": [ 71 ], "Results": [ 72 ], "Obesity": [ 73 ], "reduced": [ 74, 99 ], "changed": [ 80 ], "characterized": [ 84 ], "by": [ 85, 135, 149 ], "increased": [ 86, 122 ], "mRNA": [ 87 ], "expression": [ 88, 101 ], "levels": [ 89 ], "TNF\u2010\u03b1,": [ 91 ], "MCP\u20101,": [ 92 ], "F4/80": [ 94 ], "testis.": [ 96 ], "Exenatide": [ 97, 138 ], "intervention": [ 98 ], "pro\u2010inflammatory": [ 103 ], "cytokines": [ 104 ], "improved": [ 106 ], "sperm.": [ 110 ], "Conclusion": [ 111 ], "HFD\u2010induced": [ 112 ], "leads": [ 114 ], "impairment": [ 117 ], "inflammation": [ 123 ], "mice,": [ 127 ], "abnormal": [ 130 ], "physiology": [ 131 ], "can": [ 132 ], "be": [ 133 ], "attenuated": [ 134 ], "treatment.": [ 137 ], "treatment": [ 139 ], "may": [ 140 ], "bring": [ 141 ], "additional": [ 142 ], "profits": [ 143 ], "diabetes": [ 147 ], "men": [ 148 ], "improving": [ 150 ], "function.": [ 152 ] }, "publication_date": "2015-08-19", "publication_year": 2015, "type": "article", "cited_by_count": 69, "authors": [ { "id": "https://openalex.org/A5002966261", "display_name": "Erhong Zhang" }, { "id": "https://openalex.org/A5001571073", "display_name": "Fen Xu" }, { "id": "https://openalex.org/A5023641721", "display_name": "Hua Liang" }, { "id": "https://openalex.org/A5066741898", "display_name": "Jinhua Yan" }, { "id": "https://openalex.org/A5103254578", "display_name": "Haixia Xu" }, { "id": "https://openalex.org/A5101518285", "display_name": "Zhuo Li" }, { "id": "https://openalex.org/A5100662372", "display_name": "Xingqiao Wen" }, { "id": "https://openalex.org/A5012775407", "display_name": "Jianping Weng" } ] }, { "id": "https://openalex.org/W2580189755", "doi": "https://doi.org/10.1002/oby.21718", "title": "Liraglutide causes large and rapid epicardial fat reduction", "abstract": { "Objective": [ 0 ], "Epicardial": [ 1 ], "adipose": [ 2 ], "tissue": [ 3 ], "(EAT),": [ 4 ], "the": [ 5, 10, 31, 58, 139, 182, 191 ], "visceral": [ 6 ], "fat": [ 7 ], "depot": [ 8 ], "of": [ 9, 25, 33, 167 ], "heart,": [ 11 ], "is": [ 12, 28, 53 ], "a": [ 13, 60, 163, 200 ], "modifiable": [ 14 ], "cardiovascular": [ 15, 45 ], "risk": [ 16 ], "factor": [ 17 ], "and": [ 18, 82, 131, 134, 152, 165, 171, 186, 202 ], "emerging": [ 19 ], "therapeutic": [ 20 ], "target.": [ 21 ], "Liraglutide,": [ 22 ], "an": [ 23 ], "analog": [ 24 ], "glucagon\u2010like": [ 26 ], "peptide\u20101,": [ 27 ], "indicated": [ 29 ], "for": [ 30, 162 ], "treatment": [ 32 ], "type": [ 34, 70 ], "2": [ 35, 71, 81, 147 ], "diabetes": [ 36 ], "mellitus.": [ 37 ], "Liraglutide": [ 38, 198, 206 ], "has": [ 39 ], "recently": [ 40 ], "been": [ 41 ], "shown": [ 42 ], "to": [ 43, 94, 99, 110, 115, 148 ], "reduce": [ 44, 51 ], "risk.": [ 46 ], "Nevertheless,": [ 47 ], "whether": [ 48 ], "liraglutide": [ 49, 97, 140, 192 ], "could": [ 50 ], "EAT": [ 52, 125, 142, 179, 204 ], "unknown.": [ 54 ], "Methods": [ 55 ], "To": [ 56 ], "test": [ 57 ], "hypothesis,": [ 59 ], "6\u2010month": [ 61, 135 ], "randomized,": [ 62 ], "open\u2010label,": [ 63 ], "controlled": [ 64 ], "study": [ 65 ], "was": [ 66, 127, 177 ], "performed": [ 67 ], "in": [ 68, 91, 181, 190 ], "95": [ 69 ], "diabetic": [ 72 ], "subjects": [ 73 ], "with": [ 74 ], "body": [ 75 ], "mass": [ 76 ], "index": [ 77 ], "(BMI)": [ 78 ], "\u226527": [ 79 ], "kg/m": [ 80 ], "hemoglobinA1c": [ 83, 187 ], "\u22648%": [ 84 ], "on": [ 85, 112 ], "metformin": [ 86, 113, 183 ], "monotherapy.": [ 87 ], "Individuals": [ 88 ], "were": [ 89 ], "randomized": [ 90 ], "two": [ 92 ], "groups": [ 93 ], "receive": [ 95 ], "additional": [ 96 ], "up": [ 98, 114 ], "1.8": [ 100 ], "mg": [ 101, 117 ], "s.c.": [ 102 ], "once": [ 103 ], "daily": [ 104, 119 ], "(": [ 105, 120, 157 ], "n": [ 106, 121 ], "=": [ 107, 122 ], "54)": [ 108 ], "or": [ 109 ], "remain": [ 111 ], "1,000": [ 116 ], "twice": [ 118 ], "41).": [ 123 ], "Ultrasound\u2010measured": [ 124 ], "thickness": [ 126 ], "measured": [ 128 ], "at": [ 129, 132, 169 ], "baseline": [ 130 ], "3\u2010": [ 133 ], "follow\u2010ups.": [ 136 ], "Results": [ 137 ], "In": [ 138 ], "group,": [ 141 ], "decreased": [ 143 ], "from": [ 144 ], "9.6": [ 145 ], "\u00b1": [ 146, 150, 154 ], "6.8": [ 149 ], "1.5": [ 151, 155 ], "6.2": [ 153 ], "mm": [ 156 ], "P": [ 158 ], "<": [ 159 ], "0.001),": [ 160 ], "accounting": [ 161 ], "\u221229%": [ 164 ], "\u221236%": [ 166 ], "reduction": [ 168, 180 ], "3": [ 170 ], "6": [ 172, 195 ], "months,": [ 173 ], "respectively,": [ 174 ], "whereas": [ 175 ], "there": [ 176 ], "no": [ 178 ], "group;": [ 184 ], "BMI": [ 185 ], "improved": [ 188 ], "only": [ 189 ], "group": [ 193 ], "after": [ 194 ], "months.": [ 196 ], "Conclusions": [ 197 ], "causes": [ 199 ], "substantial": [ 201 ], "rapid": [ 203 ], "reduction.": [ 205 ], "cardiometabolic": [ 207 ], "effects": [ 208 ], "may": [ 209 ], "be": [ 210 ], "EAT\u2010mediated.": [ 211 ] }, "publication_date": "2017-01-26", "publication_year": 2017, "type": "article", "cited_by_count": 228, "authors": [ { "id": "https://openalex.org/A5007644539", "display_name": "Gianluca Iacobellis" }, { "id": "https://openalex.org/A5110750862", "display_name": "Mahshid Mohseni" }, { "id": "https://openalex.org/A5011980037", "display_name": "Suzy D.C. Bianco" }, { "id": "https://openalex.org/A5065524664", "display_name": "Pritisheel K. Banga" } ] }, { "id": "https://openalex.org/W2992144798", "doi": "https://doi.org/10.1136/postgradmedj-2019-137186", "title": "An overview of GLP-1 agonists and recent cardiovascular outcomes trials", "abstract": { "Abstract": [ 0 ], "Glucagon-like": [ 1 ], "peptide": [ 2 ], "1": [ 3 ], "receptor": [ 4 ], "agonists": [ 5 ], "(GLP-1": [ 6 ], "RAs)": [ 7 ], "are": [ 8 ], "emerging": [ 9 ], "as": [ 10 ], "an": [ 11 ], "important": [ 12 ], "therapy": [ 13 ], "to": [ 14, 29, 105 ], "consider": [ 15 ], "for": [ 16, 41, 71 ], "patients": [ 17 ], "with": [ 18, 74 ], "type": [ 19 ], "2": [ 20 ], "diabetes": [ 21 ], "(T2D)": [ 22 ], "given": [ 23 ], "this": [ 24 ], "class": [ 25 ], "of": [ 26, 78, 90 ], "treatment\u2019s": [ 27 ], "ability": [ 28 ], "reduce": [ 30 ], "glycated": [ 31 ], "haemoglobin": [ 32 ], "and": [ 33, 38, 64, 107, 114 ], "their": [ 34 ], "associated": [ 35 ], "weight": [ 36 ], "loss": [ 37 ], "low": [ 39 ], "risk": [ 40 ], "hypoglycaemia.": [ 42 ], "Additionally,": [ 43 ], "seven": [ 44, 102 ], "cardiovascular": [ 45, 72 ], "outcomes": [ 46 ], "trials": [ 47 ], "(CVOTs)": [ 48 ], "have": [ 49, 68, 83 ], "been": [ 50 ], "performed": [ 51 ], "in": [ 52 ], "the": [ 53, 101, 109 ], "past": [ 54 ], "4": [ 55 ], "years": [ 56 ], "using": [ 57 ], "lixisenatide,": [ 58 ], "liraglutide,": [ 59 ], "semaglutide,": [ 60 ], "exenatide,": [ 61 ], "albiglutide,": [ 62 ], "dulaglutide": [ 63 ], "oral": [ 65 ], "semaglutide.": [ 66 ], "All": [ 67 ], "found": [ 69 ], "non-inferiority": [ 70 ], "outcomes,": [ 73 ], "many": [ 75 ], "finding": [ 76 ], "superiority": [ 77 ], "these": [ 79 ], "drugs.": [ 80 ], "These": [ 81 ], "findings": [ 82 ], "transformed": [ 84 ], "our": [ 85 ], "guidelines": [ 86, 113 ], "on": [ 87, 111 ], "pharmacological": [ 88 ], "treatment": [ 89 ], "T2D.": [ 91 ], "This": [ 92 ], "review": [ 93, 100 ], "article": [ 94 ], "will": [ 95 ], "discuss": [ 96, 108 ], "GLP-1": [ 97 ], "RA": [ 98 ], "therapy,": [ 99 ], "CVOTs": [ 103 ], "reported": [ 104 ], "date": [ 106 ], "implications": [ 110 ], "current": [ 112 ], "therapies": [ 115 ], "going": [ 116 ], "forward.": [ 117 ] }, "publication_date": "2019-12-04", "publication_year": 2019, "type": "review", "cited_by_count": 185, "authors": [ { "id": "https://openalex.org/A5028713837", "display_name": "Kelsey H. Sheahan" }, { "id": "https://openalex.org/A5018390203", "display_name": "Elizabeth A. Wahlberg" }, { "id": "https://openalex.org/A5035502539", "display_name": "Matthew P. Gilbert" } ] }, { "id": "https://openalex.org/W2070771474", "doi": "https://doi.org/10.1038/ijo.2012.208", "title": "Incretin hormones and the satiation signal", "abstract": { "Recent": [ 0 ], "research": [ 1 ], "has": [ 2 ], "indicated": [ 3, 36 ], "that": [ 4, 37, 56 ], "appetite-regulating": [ 5 ], "hormones": [ 6 ], "from": [ 7 ], "the": [ 8, 70 ], "gut": [ 9 ], "may": [ 10, 44, 92 ], "have": [ 11, 34, 53 ], "therapeutic": [ 12 ], "potential.": [ 13 ], "The": [ 14 ], "incretin": [ 15 ], "hormone,": [ 16 ], "glucagon-like": [ 17 ], "peptide-1": [ 18 ], "(GLP-1),": [ 19 ], "appears": [ 20 ], "to": [ 21, 42 ], "be": [ 22, 45 ], "involved": [ 23 ], "in": [ 24, 47, 74, 84 ], "both": [ 25 ], "peripheral": [ 26 ], "and": [ 27, 40, 64 ], "central": [ 28 ], "pathways": [ 29 ], "mediating": [ 30 ], "satiation.": [ 31 ], "Several": [ 32 ], "studies": [ 33 ], "also": [ 35, 80 ], "GLP-1": [ 38, 58, 90 ], "levels": [ 39 ], "responses": [ 41 ], "meals": [ 43 ], "altered": [ 46 ], "obese": [ 48 ], "subjects.": [ 49 ], "Clinical": [ 50 ], "trial": [ 51 ], "results": [ 52 ], "shown": [ 54 ], "further": [ 55 ], "two": [ 57 ], "receptor": [ 59 ], "agonists": [ 60 ], "(GLP-1": [ 61 ], "RAs),": [ 62 ], "exenatide": [ 63 ], "liraglutide,": [ 65 ], "which": [ 66 ], "are": [ 67 ], "approved": [ 68 ], "for": [ 69, 97 ], "treatment": [ 71, 99 ], "of": [ 72, 100 ], "hyperglycemia": [ 73 ], "patients": [ 75 ], "with": [ 76 ], "type": [ 77 ], "2": [ 78 ], "diabetes,": [ 79 ], "produce": [ 81 ], "weight": [ 82 ], "loss": [ 83 ], "overweight": [ 85 ], "subjects": [ 86 ], "without": [ 87 ], "diabetes.": [ 88 ], "Thus,": [ 89 ], "RAs": [ 91 ], "provide": [ 93 ], "a": [ 94 ], "new": [ 95 ], "option": [ 96 ], "pharmacological": [ 98 ], "obesity.": [ 101 ] }, "publication_date": "2013-01-08", "publication_year": 2013, "type": "review", "cited_by_count": 182, "authors": [ { "id": "https://openalex.org/A5085434984", "display_name": "Jens J. Holst" } ] }, { "id": "https://openalex.org/W2103684966", "doi": "https://doi.org/10.1111/j.1742-1241.2010.02465.x", "title": "The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes", "abstract": { "Established": [ 0 ], "therapies": [ 1, 75 ], "for": [ 2, 43, 138, 187 ], "type-2": [ 3, 198 ], "diabetes": [ 4, 199 ], "effectively": [ 5 ], "reduce": [ 6 ], "blood": [ 7, 112 ], "glucose,": [ 8 ], "but": [ 9, 129, 167 ], "are": [ 10, 33, 72, 115, 127, 146 ], "often": [ 11 ], "associated": [ 12, 117, 147 ], "with": [ 13, 47, 118, 140, 148 ], "adverse": [ 14, 195 ], "effects": [ 15, 196 ], "that": [ 16 ], "pose": [ 17 ], "risks": [ 18 ], "to": [ 19, 25, 81, 134, 163 ], "patient's": [ 20 ], "health": [ 21 ], "or": [ 22, 50 ], "diminish": [ 23 ], "adherence": [ 24 ], "treatment.": [ 26 ], "Weight": [ 27 ], "gain,": [ 28 ], "hypoglycaemia": [ 29 ], "and": [ 30, 36, 70, 89, 94, 114, 131, 172, 183 ], "gastrointestinal": [ 31 ], "symptoms": [ 32, 126 ], "commonly": [ 34 ], "reported": [ 35 ], "some": [ 37, 191 ], "agents": [ 38, 159 ], "may": [ 39 ], "not": [ 40 ], "be": [ 41, 135 ], "safe": [ 42 ], "use": [ 44 ], "in": [ 45, 107 ], "patients": [ 46 ], "renal": [ 48 ], "impairment": [ 49 ], "elevated": [ 51, 111 ], "cardiovascular": [ 52 ], "risk.": [ 53 ], "New": [ 54 ], "treatments": [ 55 ], "based": [ 56 ], "on": [ 57, 170 ], "the": [ 58, 61, 108, 161, 168, 193 ], "action": [ 59 ], "of": [ 60, 87, 110, 123, 192, 197 ], "endogenous": [ 62 ], "human": [ 63 ], "hormone": [ 64 ], "glucagon-like": [ 65 ], "peptide-1": [ 66 ], "(GLP-1),": [ 67 ], "including": [ 68 ], "exenatide": [ 69 ], "liraglutide,": [ 71 ], "available.": [ 73 ], "These": [ 74 ], "provide": [ 76 ], "a": [ 77, 119, 181 ], "novel": [ 78 ], "pharmacological": [ 79 ], "approach": [ 80 ], "glycaemic": [ 82 ], "control": [ 83 ], "via": [ 84 ], "multiple": [ 85 ], "mechanisms": [ 86 ], "action,": [ 88 ], "accordingly": [ 90 ], "exhibit": [ 91 ], "different": [ 92 ], "safety": [ 93, 173 ], "tolerability": [ 95 ], "profiles": [ 96 ], "than": [ 97, 152 ], "conventional": [ 98 ], "treatments.": [ 99 ], "GLP-1": [ 100, 143, 176 ], "receptor": [ 101, 144, 177 ], "agonists": [ 102, 145, 178 ], "stimulate": [ 103 ], "insulin": [ 104 ], "release": [ 105 ], "only": [ 106 ], "presence": [ 109 ], "glucose": [ 113 ], "therefore": [ 116 ], "fairly": [ 120 ], "low": [ 121 ], "risk": [ 122 ], "hypoglycaemia.": [ 124 ], "Gastrointestinal": [ 125 ], "common": [ 128, 194 ], "transient,": [ 130 ], "there": [ 132 ], "appears": [ 133 ], "little": [ 136 ], "potential": [ 137, 162 ], "interaction": [ 139 ], "other": [ 141 ], "drugs.": [ 142 ], "weight": [ 149, 153 ], "loss": [ 150 ], "rather": [ 151 ], "gain.": [ 154 ], "As": [ 155 ], "protein-based": [ 156 ], "therapies,": [ 157 ], "these": [ 158 ], "have": [ 160 ], "induce": [ 164 ], "antibody": [ 165 ], "formation,": [ 166 ], "impact": [ 169 ], "efficacy": [ 171 ], "is": [ 174 ], "minor.": [ 175 ], "thus": [ 179 ], "offer": [ 180 ], "new": [ 182 ], "potentially": [ 184 ], "useful": [ 185 ], "option": [ 186 ], "clinicians": [ 188 ], "concerned": [ 189 ], "about": [ 190 ], "therapies.": [ 200 ] }, "publication_date": "2010-08-16", "publication_year": 2010, "type": "review", "cited_by_count": 39, "authors": [ { "id": "https://openalex.org/A5082184915", "display_name": "David Russell\u2010Jones" } ] }, { "id": "https://openalex.org/W2942388295", "doi": "https://doi.org/10.1056/nejmoa1903822", "title": "Liraglutide in Children and Adolescents with Type 2 Diabetes", "abstract": { "In": [ 0 ], "children": [ 1 ], "and": [ 2 ], "adolescents": [ 3 ], "with": [ 4, 22 ], "type": [ 5 ], "2": [ 6 ], "diabetes,": [ 7 ], "liraglutide,": [ 8 ], "at": [ 9, 39 ], "a": [ 10 ], "dose": [ 11 ], "of": [ 12, 42, 46 ], "up": [ 13 ], "to": [ 14, 20 ], "1.8": [ 15 ], "mg": [ 16 ], "per": [ 17 ], "day": [ 18 ], "(added": [ 19 ], "metformin,": [ 21 ], "or": [ 23 ], "without": [ 24 ], "basal": [ 25 ], "insulin),": [ 26 ], "was": [ 27 ], "efficacious": [ 28 ], "in": [ 29 ], "improving": [ 30 ], "glycemic": [ 31 ], "control": [ 32 ], "over": [ 33 ], "52": [ 34 ], "weeks.": [ 35 ], "This": [ 36 ], "efficacy": [ 37 ], "came": [ 38 ], "the": [ 40 ], "cost": [ 41 ], "an": [ 43 ], "increased": [ 44 ], "frequency": [ 45 ], "gastrointestinal": [ 47 ], "adverse": [ 48 ], "events.": [ 49 ], "(Funded": [ 50 ], "by": [ 51 ], "Novo": [ 52 ], "Nordisk;": [ 53 ], "Ellipse": [ 54 ], "ClinicalTrials.gov": [ 55 ], "number,": [ 56 ], "NCT01541215.).": [ 57 ] }, "publication_date": "2019-04-28", "publication_year": 2019, "type": "article", "cited_by_count": 322, "authors": [ { "id": "https://openalex.org/A5002265183", "display_name": "William V. Tamborlane" }, { "id": "https://openalex.org/A5083846346", "display_name": "Margarita Barrientos\u2010P\u00e9rez" }, { "id": "https://openalex.org/A5069958367", "display_name": "Udi Fainberg" }, { "id": "https://openalex.org/A5086676591", "display_name": "Helle Frimer\u2010Larsen" }, { "id": "https://openalex.org/A5108487846", "display_name": "Mona Hafez" }, { "id": "https://openalex.org/A5023487929", "display_name": "Paula M. Hale" }, { "id": "https://openalex.org/A5001023285", "display_name": "Muhammad Yazid Jalaludin" }, { "id": "https://openalex.org/A5009095653", "display_name": "\u041c. \u0410. \u041a\u043e\u0432\u0430\u0440\u0435\u043d\u043a\u043e" }, { "id": "https://openalex.org/A5031541043", "display_name": "Ingrid Libman" }, { "id": "https://openalex.org/A5018028030", "display_name": "Jane Lynch" }, { "id": "https://openalex.org/A5046761553", "display_name": "Paturi Rao" }, { "id": "https://openalex.org/A5042407874", "display_name": "Naim Shehadeh" }, { "id": "https://openalex.org/A5074886036", "display_name": "Serap Turan" }, { "id": "https://openalex.org/A5087302320", "display_name": "Daniel Weghuber" }, { "id": "https://openalex.org/A5026203609", "display_name": "Timothy Barrett" } ] }, { "id": "https://openalex.org/W4310711873", "doi": "https://doi.org/10.2147/clep.s391819", "title": "Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review", "abstract": { "This": [ 0 ], "meta-analysis": [ 1 ], "indicates": [ 2 ], "that": [ 3 ], "all": [ 4 ], "GLP-1RAs": [ 5 ], "were": [ 6, 60 ], "more": [ 7 ], "efficacious": [ 8 ], "than": [ 9, 54 ], "placebo": [ 10 ], "in": [ 11, 25 ], "people": [ 12 ], "with": [ 13 ], "obesity": [ 14 ], "or": [ 15 ], "overweight": [ 16 ], "on": [ 17 ], "efficacy.": [ 18 ], "Semaglutide": [ 19 ], "2.4mg": [ 20 ], "has": [ 21 ], "an": [ 22 ], "absolute": [ 23 ], "advantage": [ 24 ], "weight": [ 26 ], "loss": [ 27 ], "and": [ 28, 42 ], "decreased": [ 29 ], "HbA1c,": [ 30 ], "but": [ 31 ], "the": [ 32, 40, 62 ], "incidence": [ 33 ], "of": [ 34 ], "total": [ 35 ], "adverse": [ 36, 58 ], "events": [ 37, 59 ], "is": [ 38 ], "also": [ 39 ], "highest": [ 41 ], "can": [ 43 ], "cause": [ 44 ], "hypoglycemia.": [ 45 ], "In": [ 46 ], "addition,": [ 47 ], "although": [ 48 ], "liraglutide": [ 49 ], "3.0mg": [ 50 ], "was": [ 51 ], "less": [ 52 ], "effective": [ 53 ], "semaglutide": [ 55 ], "2.4mg,": [ 56 ], "serious": [ 57 ], "still": [ 61 ], "most": [ 63 ], "elevated.": [ 64 ] }, "publication_date": "2022-12-01", "publication_year": 2022, "type": "review", "cited_by_count": 75, "authors": [ { "id": "https://openalex.org/A5000090719", "display_name": "Zeyu Xie" }, { "id": "https://openalex.org/A5035597236", "display_name": "Sensen Yang" }, { "id": "https://openalex.org/A5047239410", "display_name": "Weishang Deng" }, { "id": "https://openalex.org/A5101956579", "display_name": "Jinjian Li" }, { "id": "https://openalex.org/A5067358412", "display_name": "Jisheng Chen" } ] }, { "id": "https://openalex.org/W2148798434", "doi": "https://doi.org/10.2337/dc08-1797", "title": "One-Year Treatment With Exenatide Improves \u03b2-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients", "abstract": { "OBJECTIVE": [ 0 ], "Traditional": [ 1 ], "blood": [ 2 ], "glucose\u2013lowering": [ 3 ], "agents": [ 4 ], "do": [ 5 ], "not": [ 6 ], "sustain": [ 7 ], "adequate": [ 8 ], "glycemic": [ 9, 54, 111, 241 ], "control": [ 10, 242 ], "in": [ 11, 25, 120, 186 ], "most": [ 12 ], "type": [ 13, 67 ], "2": [ 14, 68 ], "diabetic": [ 15 ], "patients.": [ 16 ], "Preclinical": [ 17 ], "studies": [ 18 ], "with": [ 19, 37, 66, 142, 170, 225 ], "exenatide": [ 20, 38, 74, 139, 147, 208, 233 ], "have": [ 21 ], "suggested": [ 22 ], "sustained": [ 23 ], "improvements": [ 24 ], "\u03b2-cell": [ 26, 52, 217, 238 ], "function.": [ 27 ], "We": [ 28 ], "investigated": [ 29 ], "the": [ 30, 255 ], "effects": [ 31, 109, 257 ], "of": [ 32, 35, 51, 206, 222, 231, 258 ], "52": [ 33 ], "weeks": [ 34, 203 ], "treatment": [ 36, 140, 223, 250 ], "or": [ 39, 78, 209 ], "insulin": [ 40, 79, 143, 149, 171, 210, 227, 235 ], "glargine": [ 41, 80, 144, 150, 172, 211, 236 ], "followed": [ 42 ], "by": [ 43 ], "an": [ 44, 89 ], "off-drug": [ 45, 103, 192 ], "period": [ 46 ], "on": [ 47, 110 ], "hyperglycemic": [ 48, 91 ], "clamp\u2013derived": [ 49 ], "measures": [ 50, 181 ], "function,": [ 53 ], "control,": [ 55, 112 ], "and": [ 56, 99, 115, 123, 148, 157, 195, 234, 240 ], "body": [ 57, 113, 167, 196 ], "weight.": [ 58 ], "RESEARCH": [ 59 ], "DESIGN": [ 60 ], "AND": [ 61 ], "METHODS": [ 62 ], "Sixty-nine": [ 63 ], "metformin-treated": [ 64 ], "patients": [ 65 ], "diabetes": [ 69 ], "were": [ 70 ], "randomly": [ 71 ], "assigned": [ 72 ], "to": [ 73, 183, 199, 244, 253 ], "(n": [ 75, 81 ], "=": [ 76, 82, 163 ], "36)": [ 77 ], "33).": [ 83 ], "\u03b2-Cell": [ 84, 179 ], "function": [ 85, 180, 218, 239 ], "was": [ 86, 127 ], "measured": [ 87 ], "during": [ 88, 219 ], "arginine-stimulated": [ 90, 124 ], "clamp": [ 92 ], "at": [ 93, 96 ], "week": [ 94, 97 ], "0,": [ 95 ], "52,": [ 98 ], "after": [ 100, 136, 189, 204 ], "a": [ 101, 137, 190 ], "4-week": [ 102, 191 ], "period.": [ 104, 193 ], "Additional": [ 105 ], "end": [ 106 ], "points": [ 107 ], "included": [ 108 ], "weight,": [ 114 ], "safety.": [ 116 ], "RESULTS": [ 117 ], "Treatment-induced": [ 118 ], "change": [ 119 ], "combined": [ 121 ], "glucose-": [ 122 ], "C-peptide": [ 125 ], "secretion": [ 126 ], "2.46-fold": [ 128 ], "(95%": [ 129 ], "CI": [ 130 ], "2.09\u20132.90,": [ 131 ], "P": [ 132, 176 ], "&lt;": [ 133, 177 ], "0.0001)": [ 134 ], "greater": [ 135 ], "52-week": [ 138 ], "compared": [ 141, 169, 224 ], "treatment.": [ 145 ], "Both": [ 146 ], "reduced": [ 151, 166 ], "A1C": [ 152, 194 ], "similarly:": [ 153 ], "\u22120.8": [ 154 ], "\u00b1": [ 155, 159 ], "0.1": [ 156 ], "\u22120.7": [ 158 ], "0.2%,": [ 160 ], "respectively": [ 161 ], "(P": [ 162 ], "0.55).": [ 164 ], "Exenatide": [ 165, 214 ], "weight": [ 168, 197 ], "(difference": [ 173 ], "\u22124.6": [ 174 ], "kg,": [ 175 ], "0.0001).": [ 178 ], "returned": [ 182, 243 ], "pretreatment": [ 184, 200, 245 ], "values": [ 185, 201 ], "both": [ 187, 232 ], "groups": [ 188 ], "rose": [ 198 ], "12": [ 202 ], "discontinuation": [ 205 ], "either": [ 207, 259 ], "therapy.": [ 212, 260 ], "CONCLUSIONS": [ 213 ], "significantly": [ 215 ], "improves": [ 216 ], "1": [ 220 ], "year": [ 221 ], "titrated": [ 226 ], "glargine.": [ 228 ], "After": [ 229 ], "cessation": [ 230 ], "therapy,": [ 237 ], "values,": [ 246 ], "suggesting": [ 247 ], "that": [ 248 ], "ongoing": [ 249 ], "is": [ 251 ], "necessary": [ 252 ], "maintain": [ 254 ], "beneficial": [ 256 ] }, "publication_date": "2009-02-05", "publication_year": 2009, "type": "article", "cited_by_count": 382, "authors": [ { "id": "https://openalex.org/A5110611896", "display_name": "Mathijs C. Bunck" }, { "id": "https://openalex.org/A5109335776", "display_name": "Micha\u00ebla Diamant" }, { "id": "https://openalex.org/A5059226156", "display_name": "A. H. Corner" }, { "id": "https://openalex.org/A5061198575", "display_name": "Bj\u00f6rn Eliasson" }, { "id": "https://openalex.org/A5004842224", "display_name": "Jaret Malloy" }, { "id": "https://openalex.org/A5112350413", "display_name": "Rimma M. Shaginian" }, { "id": "https://openalex.org/A5031987801", "display_name": "Wei Deng" }, { "id": "https://openalex.org/A5013350892", "display_name": "David M. Kendall" }, { "id": "https://openalex.org/A5057557099", "display_name": "Marja\u2010Riitta Taskinen" }, { "id": "https://openalex.org/A5028599620", "display_name": "Ulf Smith" }, { "id": "https://openalex.org/A5028953583", "display_name": "Hannele Yki\u2010J\u00e4rvinen" }, { "id": "https://openalex.org/A5113467761", "display_name": "Robert J. Heine" } ] }, { "id": "https://openalex.org/W3161120012", "doi": "https://doi.org/10.1080/17512433.2021.1933433", "title": "Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome", "abstract": { "Introduction:": [ 0 ], "Glucagon-like": [ 1 ], "peptide-1": [ 2 ], "receptor": [ 3 ], "agonists": [ 4 ], "(GLP-1": [ 5 ], "RA)": [ 6 ], "offer": [ 7 ], "a": [ 8 ], "unique": [ 9 ], "opportunity": [ 10 ], "to": [ 11, 113 ], "simultaneously": [ 12 ], "address": [ 13 ], "various": [ 14 ], "comorbid": [ 15 ], "associated": [ 16 ], "conditions": [ 17 ], "and": [ 18, 41, 58, 64, 89 ], "phenotypic": [ 19 ], "presentations": [ 20 ], "of": [ 21, 97 ], "polycystic": [ 22 ], "ovary": [ 23 ], "syndrome": [ 24 ], "(PCOS)": [ 25 ], "as": [ 26 ], "these": [ 27 ], "agents": [ 28 ], "improve": [ 29, 42 ], "insulin": [ 30 ], "sensitivity,": [ 31 ], "reduce": [ 32 ], "cardiovascular": [ 33 ], "disease": [ 34 ], "(CVD)": [ 35 ], "risk,": [ 36 ], "result": [ 37 ], "in": [ 38, 67, 82, 103 ], "weight": [ 39 ], "loss,": [ 40 ], "nonalcoholic": [ 43 ], "fatty": [ 44 ], "liver": [ 45 ], "disease.Areas": [ 46 ], "covered:": [ 47 ], "The": [ 48 ], "authors": [ 49 ], "describe": [ 50 ], "trials": [ 51 ], "conducted": [ 52 ], "during": [ 53 ], "the": [ 54, 72, 95 ], "last": [ 55 ], "5": [ 56 ], "years": [ 57 ], "provide": [ 59 ], "an": [ 60 ], "update": [ 61 ], "on": [ 62, 78 ], "exenatide": [ 63 ], "liraglutide": [ 65, 90 ], "use": [ 66 ], "PCOS": [ 68, 83, 98, 121 ], "women.": [ 69 ], "Information": [ 70 ], "from": [ 71 ], "studies": [ 73 ], "investigating": [ 74 ], "GLP-1": [ 75, 114 ], "RAs": [ 76, 115 ], "effects": [ 77 ], "reducing": [ 79 ], "CVD": [ 80, 131 ], "risk": [ 81, 135 ], "is": [ 84 ], "also": [ 85 ], "presented.Expert": [ 86 ], "opinion:": [ 87 ], "Exenatide": [ 88 ], "are": [ 91, 124, 138 ], "good": [ 92 ], "options": [ 93 ], "for": [ 94, 120, 141 ], "treatment": [ 96, 118, 140 ], "when": [ 99, 116 ], "used": [ 100 ], "alone": [ 101 ], "or": [ 102, 126, 132 ], "combination": [ 104 ], "with": [ 105 ], "metformin.": [ 106 ], "Especially": [ 107 ], "strong": [ 108 ], "consideration": [ 109 ], "should": [ 110 ], "be": [ 111 ], "given": [ 112 ], "developing": [ 117 ], "strategies": [ 119 ], "women": [ 122 ], "who": [ 123 ], "overweight": [ 125 ], "obese,": [ 127 ], "glucose": [ 128 ], "intolerant,": [ 129 ], "have": [ 130 ], "its": [ 133 ], "attendant": [ 134 ], "factors,": [ 136 ], "and/or": [ 137 ], "seeking": [ 139 ], "infertility.": [ 142 ] }, "publication_date": "2021-05-20", "publication_year": 2021, "type": "review", "cited_by_count": 66, "authors": [ { "id": "https://openalex.org/A5002752144", "display_name": "Maka Siamashvili" }, { "id": "https://openalex.org/A5080379883", "display_name": "Stephen N. Davis" } ] }, { "id": "https://openalex.org/W2093738306", "doi": "https://doi.org/10.1111/j.1463-1326.2006.00602.x", "title": "Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes", "abstract": { "Aim:": [ 0 ], "Exenatide,": [ 1 ], "an": [ 2, 35 ], "incretin": [ 3 ], "mimetic": [ 4 ], "for": [ 5, 80, 197 ], "the": [ 6, 25, 66, 198 ], "adjunct": [ 7 ], "treatment": [ 8, 102, 255 ], "of": [ 9, 27, 59, 75, 83, 100, 158, 213, 252 ], "type": [ 10 ], "2": [ 11, 125 ], "diabetes": [ 12 ], "(DM2),": [ 13 ], "reduced": [ 14, 171 ], "A1C": [ 15, 127, 136, 161, 207, 270 ], "and": [ 16, 32, 70, 208, 217, 245, 271 ], "weight": [ 17, 33, 113, 173, 209 ], "in": [ 18, 38, 65, 72, 85, 135, 206, 231, 256, 266, 269, 274, 280 ], "30\u2010week": [ 19, 67 ], "placebo\u2010controlled": [ 20, 68 ], "trials.": [ 21 ], "This": [ 22, 55 ], "analysis": [ 23, 57 ], "examined": [ 24 ], "effects": [ 26 ], "exenatide": [ 28, 64, 84, 101, 170, 254 ], "on": [ 29 ], "glycaemic": [ 30, 46 ], "control": [ 31, 47 ], "over": [ 34 ], "82\u2010week": [ 36, 224 ], "period": [ 37 ], "patients": [ 39, 61, 159, 257 ], "with": [ 40, 48, 156, 183, 204, 258, 261 ], "DM2": [ 41, 259 ], "unable": [ 42 ], "to": [ 43, 139, 150 ], "achieve": [ 44 ], "adequate": [ 45 ], "sulphonylurea": [ 49 ], "(SU)": [ 50 ], "and/or": [ 51, 91, 263 ], "metformin": [ 52 ], "(MET).": [ 53 ], "Methods:": [ 54 ], "interim": [ 56 ], "is": [ 58 ], "314": [ 60 ], "who": [ 62 ], "received": [ 63 ], "trials": [ 69 ], "subsequently": [ 71 ], "52": [ 73 ], "weeks": [ 74, 82, 99, 251 ], "open\u2010label": [ 76 ], "uncontrolled": [ 77 ], "extension": [ 78 ], "studies": [ 79 ], "82": [ 81, 98, 152, 188, 212, 250 ], "total.": [ 86 ], "Patients": [ 87, 96 ], "continued": [ 88 ], "their": [ 89 ], "SU": [ 90, 262 ], "MET": [ 92, 264 ], "regimens": [ 93 ], "throughout.": [ 94 ], "Results:": [ 95 ], "completed": [ 97 ], "[n": [ 103 ], "=": [ 104, 202 ], "314,": [ 105 ], "63%": [ 106 ], "M,": [ 107 ], "age": [ 108 ], "56": [ 109 ], "\u00b1": [ 110, 115, 122, 129, 132, 143, 146, 154, 180, 190, 215, 219 ], "10": [ 111 ], "years,": [ 112 ], "99": [ 114 ], "21": [ 116 ], "kg,": [ 117 ], "body": [ 118, 172 ], "mass": [ 119 ], "index": [ 120 ], "34": [ 121 ], "6": [ 123 ], "kg/m": [ 124 ], ",": [ 126 ], "8.3": [ 128 ], "1.0%": [ 130 ], "(mean": [ 131, 145 ], "SD)].": [ 133 ], "Reduction": [ 134 ], "from": [ 137, 177 ], "baseline": [ 138, 178 ], "week": [ 140, 151, 165, 168, 187, 211 ], "30": [ 141 ], "[\u22120.9": [ 142 ], "0.1%": [ 144, 216 ], "SE)]": [ 147 ], "was": [ 148 ], "sustained": [ 149, 267 ], "(\u22121.1": [ 153 ], "0.1%),": [ 155 ], "48%": [ 157 ], "achieving": [ 160 ], "\u2264": [ 162 ], "7%": [ 163 ], "at": [ 164, 186, 210 ], "82.": [ 166 ], "At": [ 167 ], "30,": [ 169 ], "(a": [ 174 ], "secondary": [ 175 ], "endpoint)": [ 176 ], "(\u22122.1": [ 179 ], "0.2": [ 181, 220 ], "kg),": [ 182 ], "progressive": [ 184, 272 ], "reduction": [ 185, 268, 273 ], "(\u22124.4": [ 189 ], "0.3": [ 191 ], "kg).": [ 192 ], "Similar": [ 193 ], "results": [ 194 ], "were": [ 195, 241 ], "observed": [ 196 ], "intent\u2010to\u2010treat": [ 199 ], "population": [ 200 ], "(n": [ 201 ], "551),": [ 203 ], "reductions": [ 205 ], "\u22120.8": [ 214 ], "\u22123.5": [ 218 ], "kg": [ 221 ], "respectively.": [ 222 ], "The": [ 223, 236 ], "completer": [ 225 ], "cohort": [ 226 ], "showed": [ 227 ], "statistically": [ 228 ], "significant": [ 229 ], "improvement": [ 230, 279 ], "some": [ 232, 281 ], "cardiovascular": [ 233, 282 ], "risk": [ 234, 283 ], "factors.": [ 235, 284 ], "most": [ 237 ], "frequent": [ 238 ], "adverse": [ 239 ], "events": [ 240 ], "generally": [ 242 ], "mild\u2010to\u2010moderate": [ 243 ], "nausea": [ 244 ], "hypoglycaemia.": [ 246 ], "Conclusion:": [ 247 ], "In": [ 248 ], "summary,": [ 249 ], "adjunctive": [ 253 ], "treated": [ 260 ], "resulted": [ 265 ], "weight,": [ 275 ], "as": [ 276, 278 ], "well": [ 277 ] }, "publication_date": "2006-04-18", "publication_year": 2006, "type": "article", "cited_by_count": 417, "authors": [ { "id": "https://openalex.org/A5070289715", "display_name": "Lawrence Blonde" }, { "id": "https://openalex.org/A5047160563", "display_name": "E. Klein" }, { "id": "https://openalex.org/A5089249621", "display_name": "J. Han" }, { "id": "https://openalex.org/A5008311039", "display_name": "B. Zhang" }, { "id": "https://openalex.org/A5003605219", "display_name": "Susanna Mac" }, { "id": "https://openalex.org/A5108497778", "display_name": "Terri Poon" }, { "id": "https://openalex.org/A5110734241", "display_name": "Kristin Taylor" }, { "id": "https://openalex.org/A5062021087", "display_name": "Michael Trautmann" }, { "id": "https://openalex.org/A5055583882", "display_name": "D. D. Kim" }, { "id": "https://openalex.org/A5013350892", "display_name": "David M. Kendall" } ] }, { "id": "https://openalex.org/W3204012661", "doi": "https://doi.org/10.3390/ijms221910822", "title": "Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists", "abstract": { "The": [ 0, 182 ], "incidence": [ 1 ], "of": [ 2, 18, 23, 27, 38, 46, 52, 96, 107, 110, 126, 145, 198 ], "type": [ 3 ], "2": [ 4 ], "diabetes": [ 5, 202 ], "(T2D)": [ 6 ], "has": [ 7 ], "been": [ 8 ], "increasing": [ 9 ], "worldwide,": [ 10 ], "and": [ 11, 36, 59, 114, 129, 134, 141, 176, 189, 203 ], "diabetic": [ 12 ], "kidney": [ 13, 167 ], "disease": [ 14 ], "(DKD)": [ 15 ], "remains": [ 16 ], "one": [ 17 ], "the": [ 19, 34, 92, 105, 124, 157, 180 ], "leading": [ 20 ], "long-term": [ 21 ], "complications": [ 22 ], "T2D.": [ 24 ], "Several": [ 25 ], "lines": [ 26 ], "evidence": [ 28 ], "indicate": [ 29 ], "that": [ 30 ], "glucose-lowering": [ 31 ], "agents": [ 32, 111 ], "prevent": [ 33 ], "onset": [ 35 ], "progression": [ 37 ], "DKD": [ 39, 146, 164 ], "in": [ 40, 49, 71, 123, 137, 139, 142, 147, 163, 165, 173, 201 ], "its": [ 41 ], "early": [ 42 ], "stages": [ 43, 51 ], "but": [ 44 ], "are": [ 45 ], "limited": [ 47 ], "efficacy": [ 48 ], "later": [ 50 ], "DKD.": [ 53 ], "However,": [ 54 ], "sodium-glucose": [ 55 ], "cotransporter-2": [ 56 ], "inhibitors": [ 57 ], "(SGLT2i)": [ 58 ], "glucagon-like": [ 60 ], "peptide-1": [ 61 ], "receptor": [ 62 ], "(GLP-1R)": [ 63 ], "agonists": [ 64, 131 ], "were": [ 65 ], "shown": [ 66 ], "to": [ 67, 91, 103, 120, 193 ], "exert": [ 68 ], "nephroprotective": [ 69 ], "effects": [ 70, 86 ], "patients": [ 72 ], "with": [ 73, 112 ], "established": [ 74 ], "DKD,": [ 75 ], "i.e.,": [ 76 ], "those": [ 77 ], "who": [ 78 ], "had": [ 79 ], "a": [ 80, 195 ], "reduced": [ 81 ], "glomerular": [ 82 ], "filtration": [ 83 ], "rate.": [ 84 ], "These": [ 85 ], "cannot": [ 87 ], "be": [ 88 ], "solely": [ 89 ], "attributed": [ 90 ], "improved": [ 93 ], "metabolic": [ 94 ], "control": [ 95 ], "diabetes.": [ 97, 127 ], "In": [ 98, 150 ], "our": [ 99 ], "review,": [ 100 ], "we": [ 101, 152 ], "attempted": [ 102 ], "discuss": [ 104 ], "interactions": [ 106 ], "both": [ 108, 185 ], "groups": [ 109 ], "inflammation": [ 113, 133, 188 ], "oxidative": [ 115, 135, 190 ], "stress\u2014the": [ 116 ], "key": [ 117 ], "pathways": [ 118 ], "contributing": [ 119 ], "organ": [ 121, 199 ], "damage": [ 122 ], "course": [ 125 ], "SGLT2i": [ 128 ], "GLP-1R": [ 130 ], "attenuate": [ 132 ], "stress": [ 136, 191 ], "experimental": [ 138 ], "vitro": [ 140 ], "vivo": [ 143 ], "models": [ 144, 169 ], "several": [ 148 ], "ways.": [ 149 ], "addition,": [ 151 ], "have": [ 153, 194 ], "described": [ 154 ], "experiments": [ 155 ], "showing": [ 156 ], "same": [ 158 ], "protective": [ 159 ], "mechanisms": [ 160 ], "as": [ 161, 170, 172 ], "found": [ 162 ], "non-diabetic": [ 166 ], "injury": [ 168 ], "well": [ 171 ], "some": [ 174 ], "tissues": [ 175 ], "organs": [ 177 ], "other": [ 178, 204 ], "than": [ 179 ], "kidney.": [ 181 ], "interaction": [ 183 ], "between": [ 184 ], "drug": [ 186 ], "groups,": [ 187 ], "appears": [ 192 ], "universal": [ 196 ], "mechanism": [ 197 ], "protection": [ 200 ], "diseases.": [ 205 ] }, "publication_date": "2021-10-06", "publication_year": 2021, "type": "review", "cited_by_count": 167, "authors": [ { "id": "https://openalex.org/A5020679087", "display_name": "Agata Winiarska" }, { "id": "https://openalex.org/A5078110407", "display_name": "Monika Knysak" }, { "id": "https://openalex.org/A5056947531", "display_name": "Katarzyna Nabrdalik" }, { "id": "https://openalex.org/A5057777286", "display_name": "Janusz Gumprecht" }, { "id": "https://openalex.org/A5045551258", "display_name": "Tomasz Stomp\u00f3r" } ] }, { "id": "https://openalex.org/W3184607597", "doi": "https://doi.org/10.1111/bph.15638", "title": "Brain GLP\u20101 and the regulation of food intake: GLP\u20101 action in the brain and its implications for GLP\u20101 receptor agonists in obesity treatment", "abstract": { "This": [ 0, 53, 77 ], "review": [ 1, 54 ], "considers": [ 2 ], "the": [ 3, 8, 23, 40, 57, 60, 66, 94 ], "similarities": [ 4 ], "and": [ 5, 14, 28, 38 ], "differences": [ 6 ], "between": [ 7 ], "physiological": [ 9 ], "systems": [ 10, 37 ], "regulated": [ 11 ], "by": [ 12 ], "gut\u2010derived": [ 13 ], "neuronally": [ 15 ], "produced": [ 16 ], "glucagon\u2010like": [ 17 ], "peptide": [ 18 ], "1": [ 19 ], "(GLP\u20101).": [ 20 ], "It": [ 21 ], "addresses": [ 22 ], "questions": [ 24, 64 ], "of": [ 25, 45, 59, 68, 81 ], "whether": [ 26, 39 ], "peripheral": [ 27 ], "central": [ 29 ], "GLP\u20101": [ 30, 42, 69 ], "sources": [ 31 ], "constitute": [ 32 ], "separate,": [ 33 ], "linked": [ 34 ], "or": [ 35, 48 ], "redundant": [ 36 ], "brain": [ 41 ], "system": [ 43 ], "consists": [ 44 ], "disparate": [ 46 ], "sections": [ 47 ], "is": [ 49, 79 ], "a": [ 50, 82 ], "homogenous": [ 51 ], "entity.": [ 52 ], "also": [ 55 ], "explores": [ 56 ], "implications": [ 58 ], "answers": [ 61 ], "to": [ 62 ], "these": [ 63 ], "for": [ 65 ], "use": [ 67 ], "receptor": [ 70, 87 ], "agonists": [ 71 ], "as": [ 72 ], "anti\u2010obesity": [ 73 ], "drugs.": [ 74 ], "LINKED": [ 75 ], "ARTICLES": [ 76 ], "article": [ 78 ], "part": [ 80 ], "themed": [ 83 ], "issue": [ 84 ], "on": [ 85 ], "GLP1": [ 86 ], "ligands": [ 88 ], "(BJP": [ 89 ], "75th": [ 90 ], "Anniversary).": [ 91 ], "To": [ 92 ], "view": [ 93 ], "other": [ 95 ], "articles": [ 96 ], "in": [ 97 ], "this": [ 98 ], "section": [ 99 ], "visit": [ 100 ], "http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.4/issuetoc": [ 101 ] }, "publication_date": "2021-07-29", "publication_year": 2021, "type": "review", "cited_by_count": 124, "authors": [ { "id": "https://openalex.org/A5103240189", "display_name": "Stefan Trapp" }, { "id": "https://openalex.org/A5035201872", "display_name": "Daniel I. Brierley" } ] }, { "id": "https://openalex.org/W2034769818", "doi": "https://doi.org/10.1016/j.diabet.2013.09.004", "title": "Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus", "abstract": null, "publication_date": "2013-10-22", "publication_year": 2013, "type": "review", "cited_by_count": 72, "authors": [ { "id": "https://openalex.org/A5078134786", "display_name": "David R. Owens" }, { "id": "https://openalex.org/A5089792254", "display_name": "L. Monnier" }, { "id": "https://openalex.org/A5057323309", "display_name": "Geremia B. Bolli" } ] }, { "id": "https://openalex.org/W4391303884", "doi": "https://doi.org/10.1016/j.bja.2024.01.001", "title": "Perioperative management of long-acting glucagon-like peptide-1 (GLP-1) receptor agonists: concerns for delayed gastric emptying and pulmonary aspiration", "abstract": null, "publication_date": "2024-01-29", "publication_year": 2024, "type": "editorial", "cited_by_count": 74, "authors": [ { "id": "https://openalex.org/A5006395482", "display_name": "Mark L. van Zuylen" }, { "id": "https://openalex.org/A5046947444", "display_name": "Sarah E. Siegelaar" }, { "id": "https://openalex.org/A5078516494", "display_name": "Mark P. Plummer" }, { "id": "https://openalex.org/A5076380234", "display_name": "Adam M. Deane" }, { "id": "https://openalex.org/A5028341906", "display_name": "Jeroen Hermanides" }, { "id": "https://openalex.org/A5029121343", "display_name": "Abraham H. Hulst" } ] }, { "id": "https://openalex.org/W4307373867", "doi": "https://doi.org/10.3389/fphar.2022.925377", "title": "GLP-1 receptor agonist-associated tumor adverse events: A real-world study from 2004 to 2021 based on FAERS", "abstract": { "Background:": [ 0 ], "GLP-1": [ 1 ], "receptor": [ 2 ], "agonists": [ 3 ], "(GLP-1RA)": [ 4 ], "have": [ 5 ], "demonstrated": [ 6 ], "cardiovascular": [ 7 ], "benefits,": [ 8 ], "but": [ 9 ], "the": [ 10, 43, 54, 67, 74, 81, 93, 100, 110, 124, 161, 181, 199, 250, 271 ], "relationship": [ 11, 101 ], "between": [ 12, 102, 206 ], "GLP-1RA": [ 13, 46, 103, 159, 167, 197, 207, 242, 302 ], "and": [ 14, 47, 104, 151, 184, 208, 219, 230, 234 ], "tumors": [ 15, 140, 194 ], "is": [ 16, 38 ], "controversial.": [ 17 ], "Recently,": [ 18 ], "clinical": [ 19 ], "trials": [ 20 ], "reported": [ 21 ], "higher": [ 22 ], "rates": [ 23 ], "of": [ 24, 34, 45, 50, 71, 78, 107, 112, 137, 193, 241, 268, 274 ], "malignancy": [ 25 ], "with": [ 26, 145, 158, 196, 243, 303 ], "semaglutide": [ 27 ], "than": [ 28 ], "control": [ 29 ], "group.": [ 30 ], "As": [ 31 ], "real-world": [ 32, 262 ], "evidence": [ 33, 263 ], "GLP-1RA-associated": [ 35, 114, 139 ], "tumor": [ 36, 115, 176 ], "risk": [ 37 ], "very": [ 39 ], "limited,": [ 40 ], "we": [ 41 ], "explored": [ 42 ], "association": [ 44 ], "all": [ 48, 105, 175 ], "types": [ 49, 106, 192 ], "neoplasms": [ 51, 226, 233 ], "by": [ 52, 92 ], "mining": [ 53 ], "FDA": [ 55 ], "Adverse": [ 56 ], "Event": [ 57 ], "Reporting": [ 58 ], "System": [ 59 ], "(FAERS)": [ 60 ], "database.": [ 61 ], "Methods:": [ 62 ], "The": [ 63, 239 ], "FAERS": [ 64, 125 ], "data": [ 65 ], "from": [ 66, 117 ], "first": [ 68 ], "quarter": [ 69, 76 ], "(Q1)": [ 70 ], "2004": [ 72, 119 ], "to": [ 73, 85, 98, 120, 130, 292 ], "second": [ 75 ], "(Q2)": [ 77 ], "2020": [ 79 ], "in": [ 80, 123, 174, 190, 254 ], "AERSMine": [ 82 ], "were": [ 83, 128, 141, 165, 204 ], "extracted": [ 84 ], "conduct": [ 86 ], "disproportionality": [ 87 ], "analysis,": [ 88 ], "which": [ 89 ], "was": [ 90, 186 ], "used": [ 91 ], "proportional": [ 94 ], "reporting": [ 95, 252 ], "ratio": [ 96 ], "(PRR)": [ 97 ], "assess": [ 99 ], "neoplasms.": [ 108 ], "Then,": [ 109 ], "details": [ 111 ], "disproportionate": [ 113, 172 ], "cases": [ 116, 144, 157, 177 ], "Q1": [ 118 ], "Q2": [ 121 ], "2021": [ 122 ], "Public": [ 126 ], "Dashboard": [ 127 ], "collected": [ 129 ], "analyze": [ 131 ], "demographic": [ 132 ], "characteristics.": [ 133 ], "Results:": [ 134 ], "A": [ 135 ], "total": [ 136 ], "8718": [ 138 ], "reported.": [ 142 ], "Excluding": [ 143 ], "pre-existing": [ 146 ], "tumors,": [ 147, 210 ], "other": [ 148, 152 ], "glucose-lowering": [ 149 ], "drugs,": [ 150 ], "GLP-1RA-related": [ 153 ], "adverse": [ 154, 284, 298 ], "events,": [ 155 ], "diabetes": [ 156 ], "as": [ 160 ], "main": [ 162 ], "suspected": [ 163 ], "drug": [ 164 ], "selected.": [ 166 ], "did": [ 168 ], "not": [ 169 ], "cause": [ 170 ], "a": [ 171 ], "increase": [ 173, 189 ], "(PRR": [ 178, 217, 223, 228, 237 ], "0.83)": [ 179 ], "at": [ 180, 198 ], "SOC": [ 182 ], "level,": [ 183 ], "there": [ 185 ], "also": [ 187, 289 ], "no": [ 188 ], "most": [ 191 ], "associated": [ 195 ], "HLGT/HLT": [ 200 ], "levels.": [ 201 ], "Significant": [ 202 ], "signals": [ 203 ], "detected": [ 205 ], "certain": [ 209 ], "including": [ 211 ], "thyroid": [ 212, 215, 221 ], "cancers": [ 213 ], "[medullary": [ 214 ], "cancer": [ 216, 222 ], "27.43)": [ 218 ], "papillary": [ 220 ], "8.68)],": [ 224 ], "pancreatic": [ 225 ], "malignant": [ 227 ], "9.86),": [ 229 ], "islet": [ 231 ], "cell": [ 232 ], "APUDoma": [ 235 ], "NEC": [ 236 ], "2.86).": [ 238 ], "combination": [ 240 ], "dipeptidyl-peptidase": [ 244 ], "IV": [ 245 ], "inhibitors": [ 246 ], "(DPP4i)": [ 247 ], "perhaps": [ 248 ], "caused": [ 249 ], "increased": [ 251 ], "rate": [ 253 ], "some": [ 255 ], "tumors.": [ 256 ], "Conclusion:": [ 257 ], "Our": [ 258, 286 ], "study": [ 259 ], "provided": [ 260 ], "new": [ 261 ], "for": [ 264 ], "oncology": [ 265 ], "safety": [ 266 ], "information": [ 267 ], "GLP-1RA.": [ 269 ], "Given": [ 270 ], "wide": [ 272 ], "use": [ 273 ], "GLP-1RA,": [ 275 ], "clinicians": [ 276, 291 ], "should": [ 277 ], "be": [ 278 ], "well": [ 279 ], "informed": [ 280 ], "about": [ 281, 295 ], "important": [ 282 ], "potential": [ 283, 296 ], "events.": [ 285 ], "pharmacovigilance": [ 287 ], "analysis": [ 288 ], "prompted": [ 290 ], "raise": [ 293 ], "concerns": [ 294 ], "tumor-related": [ 297 ], "effects": [ 299 ], "when": [ 300 ], "combining": [ 301 ], "DPP4i.": [ 304 ] }, "publication_date": "2022-10-25", "publication_year": 2022, "type": "article", "cited_by_count": 95, "authors": [ { "id": "https://openalex.org/A5101511884", "display_name": "Zheng Yang" }, { "id": "https://openalex.org/A5084478744", "display_name": "Yuhuan Lv" }, { "id": "https://openalex.org/A5101502554", "display_name": "Yu Meng" }, { "id": "https://openalex.org/A5114626833", "display_name": "Mei Mei" }, { "id": "https://openalex.org/A5043349572", "display_name": "Linyu Xiang" }, { "id": "https://openalex.org/A5001680863", "display_name": "Subei Zhao" }, { "id": "https://openalex.org/A5091705726", "display_name": "Li Rong" } ] }, { "id": "https://openalex.org/W2130979632", "doi": "https://doi.org/10.2147/dmsott.s6816", "title": "Emerging role of GLP-1 receptor agonists in the treatment of obesity", "abstract": { "The": [ 0 ], "prevalence": [ 1 ], "of": [ 2, 22, 36, 43, 48, 80, 83, 89, 122, 134, 141, 154 ], "obesity": [ 3, 142 ], "has": [ 4, 73, 127 ], "increased": [ 5, 76 ], "dramatically": [ 6 ], "in": [ 7, 11, 86, 101, 131, 143 ], "recent": [ 8, 70 ], "decades,": [ 9 ], "both": [ 10 ], "the": [ 12, 19, 41, 46, 81, 87, 120, 132, 139, 149 ], "US": [ 13 ], "and": [ 14, 25, 45, 67, 78, 110, 115, 152, 156 ], "worldwide.": [ 15 ], "Pharmacotherapy": [ 16 ], "can": [ 17, 26 ], "augment": [ 18 ], "weight-reducing": [ 20 ], "effects": [ 21 ], "lifestyle": [ 23 ], "modification": [ 24 ], "facilitate": [ 27 ], "long-term": [ 28 ], "weight": [ 29, 50 ], "maintenance.": [ 30 ], "However,": [ 31 ], "there": [ 32, 72 ], "is": [ 33, 53 ], "a": [ 34 ], "paucity": [ 35 ], "pharmacologic": [ 37 ], "agents": [ 38, 160 ], "approved": [ 39, 118 ], "for": [ 40, 119, 138, 161 ], "treatment": [ 42, 121, 140 ], "obesity,": [ 44 ], "use": [ 47, 133 ], "existing": [ 49 ], "loss": [ 51 ], "medications": [ 52 ], "frequently": [ 54 ], "limited": [ 55, 62 ], "by": [ 56, 64 ], "contraindications,": [ 57 ], "drug": [ 58 ], "interactions,": [ 59 ], "adverse": [ 60 ], "effects,": [ 61 ], "coverage": [ 63 ], "third-party": [ 65 ], "payers,": [ 66 ], "cost.": [ 68 ], "In": [ 69 ], "years,": [ 71 ], "been": [ 74, 113, 129 ], "an": [ 75, 98 ], "understanding": [ 77 ], "appreciation": [ 79 ], "role": [ 82, 100 ], "gastrointestinal": [ 84 ], "hormones": [ 85 ], "control": [ 88 ], "body": [ 90 ], "weight.": [ 91 ], "One": [ 92 ], "such": [ 93, 107 ], "hormone,": [ 94 ], "GLP-1,": [ 95 ], "also": [ 96, 128 ], "plays": [ 97 ], "important": [ 99 ], "glucose": [ 102 ], "homeostasis.": [ 103 ], "GLP-1": [ 104, 135 ], "receptor": [ 105, 136 ], "agonists,": [ 106 ], "as": [ 108, 158 ], "exenatide": [ 109, 155 ], "liraglutide,": [ 111 ], "have": [ 112 ], "developed": [ 114 ], "are": [ 116 ], "already": [ 117 ], "type": [ 123 ], "2": [ 124 ], "diabetes.": [ 125 ], "There": [ 126 ], "interest": [ 130 ], "agonists": [ 137 ], "nondiabetic": [ 144 ], "patients.": [ 145 ], "This": [ 146 ], "review": [ 147 ], "explores": [ 148 ], "potential": [ 150 ], "utility": [ 151 ], "limitations": [ 153 ], "liraglutide": [ 157 ], "therapeutic": [ 159 ], "obesity.": [ 162 ] }, "publication_date": "2010-07-01", "publication_year": 2010, "type": "article", "cited_by_count": 25, "authors": [ { "id": "https://openalex.org/A5089150497", "display_name": "Lisa A. Neff" } ] }, { "id": "https://openalex.org/W2079252875", "doi": "https://doi.org/10.2337/dc13-2575", "title": "Use of GLP-1 Receptor Agonists in Prader-Willi Syndrome: Report of Six Cases", "abstract": { "A": [ 0 ], "high": [ 1 ], "incidence": [ 2 ], "of": [ 3, 82, 98 ], "glucose": [ 4, 11 ], "metabolism": [ 5 ], "alterations": [ 6 ], "(impaired": [ 7 ], "fasting": [ 8 ], "glucose,": [ 9 ], "impaired": [ 10 ], "tolerance,": [ 12 ], "and": [ 13, 29, 41, 58, 61, 94 ], "type": [ 14, 51, 124 ], "2": [ 15, 52, 125 ], "diabetes)": [ 16 ], "has": [ 17 ], "been": [ 18, 66 ], "observed": [ 19 ], "in": [ 20, 30, 69, 88 ], "Prader-Willi": [ 21 ], "syndrome": [ 22 ], "(PWS)": [ 23 ], "(7\u201340%),": [ 24 ], "particularly": [ 25 ], "after": [ 26 ], "pubertal": [ 27 ], "age": [ 28 ], "obese": [ 31 ], "subjects": [ 32 ], "(1).": [ 33 ], "Glucagon-like": [ 34 ], "peptide": [ 35 ], "1": [ 36 ], "(GLP-1)": [ 37 ], "receptor": [ 38 ], "agonist": [ 39 ], "(exenatide)": [ 40 ], "analog": [ 42 ], "(liraglutide)": [ 43 ], "are": [ 44 ], "the": [ 45, 77, 80 ], "new": [ 46 ], "drugs": [ 47 ], "recently": [ 48 ], "introduced": [ 49 ], "for": [ 50, 76 ], "diabetes": [ 53 ], "that": [ 54 ], "simultaneously": [ 55 ], "reduce": [ 56 ], "appetite": [ 57 ], "body": [ 59 ], "weight,": [ 60 ], "their": [ 62 ], "beneficial": [ 63 ], "effects": [ 64, 81 ], "have": [ 65 ], "reported": [ 67 ], "only": [ 68 ], "few": [ 70 ], "cases": [ 71 ], "with": [ 72, 119 ], "PWS": [ 73, 103 ], "(2\u20135).\n\nWe": [ 74 ], "report,": [ 75 ], "first": [ 78 ], "time,": [ 79 ], "long-term": [ 83 ], "liraglutide": [ 84 ], "or": [ 85 ], "exenatide": [ 86 ], "treatment": [ 87 ], "six": [ 89 ], "genetically": [ 90 ], "confirmed": [ 91 ], "(3": [ 92, 105 ], "deletion": [ 93 ], "3": [ 95 ], "uniparental": [ 96 ], "disomy": [ 97 ], "chromosome": [ 99 ], "15)": [ 100 ], "(UPD)": [ 101 ], "adult": [ 102 ], "patients": [ 104, 128 ], "males,": [ 106 ], "aged": [ 107 ], "20.7\u201337.7": [ 108 ], "years;": [ 109 ], "all": [ 110 ], "but": [ 111 ], "one": [ 112 ], "obese,": [ 113 ], "BMI": [ 114 ], "28\u201357.2": [ 115 ], "kg/m2)": [ 116 ], "never": [ 117 ], "treated": [ 118, 130 ], "growth": [ 120 ], "hormone,": [ 121 ], "affected": [ 122 ], "by": [ 123 ], "diabetes.": [ 126 ], "All": [ 127 ], "were": [ 129 ], "at": [ 131 ], "least": [ 132 ], "\u2026": [ 133 ] }, "publication_date": "2014-03-08", "publication_year": 2014, "type": "article", "cited_by_count": 40, "authors": [ { "id": "https://openalex.org/A5051509801", "display_name": "Danilo Fintini" }, { "id": "https://openalex.org/A5041905851", "display_name": "Graziano Grugni" }, { "id": "https://openalex.org/A5102171001", "display_name": "Claudia Brufani" }, { "id": "https://openalex.org/A5074975004", "display_name": "Sarah Bocchini" }, { "id": "https://openalex.org/A5031667283", "display_name": "Marco Cappa" }, { "id": "https://openalex.org/A5025954822", "display_name": "Antonino Crin\u00f2" } ] }, { "id": "https://openalex.org/W3049003652", "doi": "https://doi.org/10.1056/nejmc1615712", "title": "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes", "abstract": { "To": [ 0 ], "the": [ 1, 5, 8, 48, 67, 84, 92, 102, 106, 109, 119, 124, 130, 140, 145, 154, 167, 170, 180, 183, 226, 232, 237, 248 ], "Editor:": [ 2 ], "In": [ 3 ], "reporting": [ 4 ], "results": [ 6, 61 ], "of": [ 7, 36, 75, 86, 94, 111, 132, 151, 172, 185, 206, 229, 251 ], "Trial": [ 9 ], "to": [ 10, 211 ], "Evaluate": [ 11 ], "Cardiovascular": [ 12, 76 ], "and": [ 13, 70, 127, 192, 239, 253 ], "Other": [ 14 ], "Longterm": [ 15 ], "Outcomes": [ 16 ], "with": [ 17, 21, 41, 64, 203 ], "Semaglutide": [ 18 ], "in": [ 19, 66, 72, 118, 123, 139, 144, 153, 157, 164, 169, 182, 194, 215, 219, 231, 236 ], "Subjects": [ 20 ], "Type": [ 22 ], "2": [ 23, 43, 81 ], "Diabetes": [ 24 ], "(SUSTAIN-6),": [ 25 ], "Marso": [ 26 ], "et": [ 27 ], "al.": [ 28 ], "(Nov.10": [ 29 ], "issue)": [ 30 ], "1": [ 31, 51 ], "describe": [ 32 ], "a": [ 33 ], "lower": [ 34 ], "rate": [ 35 ], "cardiovascular": [ 37, 188 ], "events": [ 38, 201 ], "among": [ 39, 56 ], "patients": [ 40, 57 ], "type": [ 42 ], "diabetes": [ 44 ], "mellitus": [ 45 ], "who": [ 46, 58 ], "received": [ 47, 59 ], "glucagon-like": [ 49 ], "peptide": [ 50 ], "(GLP-1)": [ 52 ], "analogue": [ 53 ], "semaglutide": [ 54, 146, 240 ], "than": [ 55, 122, 143, 235 ], "placebo.Their": [ 60 ], "are": [ 62 ], "consistent": [ 63 ], "those": [ 65 ], "Liraglutide": [ 68 ], "Effect": [ 69 ], "Action": [ 71 ], "Diabetes:": [ 73 ], "Evaluation": [ 74 ], "Outcome": [ 77 ], "Results": [ 78 ], "(LEADER)": [ 79 ], "trial,": [ 80, 108 ], "which": [ 82 ], "assessed": [ 83 ], "effects": [ 85, 250 ], "another": [ 87 ], "GLP-1": [ 88 ], "analogue,": [ 89 ], "liraglutide.In": [ 90 ], "SUSTAIN-6,": [ 91, 129 ], "use": [ 93, 110, 131, 150, 205, 228 ], "insulin": [ 95, 112, 133, 152, 207, 230 ], "at": [ 96, 162 ], "trial": [ 97 ], "entry": [ 98 ], "was": [ 99, 113, 134 ], "similar": [ 100 ], "between": [ 101 ], "two": [ 103, 115, 159, 196, 216 ], "groups.However,": [ 104 ], "during": [ 105, 128, 242 ], "LEADER": [ 107 ], "approximately": [ 114, 135 ], "times": [ 116, 137 ], "higher": [ 117, 138 ], "placebo": [ 120, 141, 155, 233 ], "group": [ 121, 142 ], "liraglutide": [ 125, 238, 252 ], "group,": [ 126 ], "three": [ 136 ], "group.The": [ 147 ], "significantly": [ 148 ], "greater": [ 149, 227 ], "groups": [ 156, 234, 241 ], "these": [ 158, 195, 200, 243 ], "trials": [ 160, 244 ], "may,": [ 161 ], "least": [ 163 ], "part,": [ 165 ], "explain": [ 166 ], "increase": [ 168, 181 ], "risk": [ 171 ], "death": [ 173 ], "from": [ 174, 209 ], "any": [ 175 ], "cause": [ 176 ], "as": [ 177, 179, 213 ], "well": [ 178 ], "risks": [ 184 ], "heart": [ 186 ], "failure,": [ 187, 191 ], "events,": [ 189 ], "renal": [ 190 ], "hypoglycemia": [ 193 ], "groups.Hazard": [ 197 ], "ratios": [ 198 ], "for": [ 199 ], "associated": [ 202 ], "increased": [ 204 ], "range": [ 208 ], "1.23": [ 210 ], "4.57,": [ 212 ], "shown": [ 214 ], "cohort": [ 217 ], "studies": [ 218 ], "primary": [ 220 ], "care.": [ 221 ], "3,4Thus,": [ 222 ], "we": [ 223 ], "wonder": [ 224 ], "whether": [ 225 ], "may": [ 245 ], "have": [ 246 ], "amplified": [ 247 ], "beneficial": [ 249 ], "semaglutide.": [ 254 ] }, "publication_date": "2017-03-01", "publication_year": 2017, "type": "letter", "cited_by_count": 140, "authors": [ { "id": "https://openalex.org/A5110355842", "display_name": "Steven P. Marso" }, { "id": "https://openalex.org/A5015716676", "display_name": "Anders G. Holst" }, { "id": "https://openalex.org/A5004120950", "display_name": "Tina Vilsb\u00f8ll" } ] }, { "id": "https://openalex.org/W2152835319", "doi": "https://doi.org/10.1016/s0140-6736(09)61375-1", "title": "Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study", "abstract": null, "publication_date": "2009-10-24", "publication_year": 2009, "type": "article", "cited_by_count": 1132, "authors": [ { "id": "https://openalex.org/A5048067129", "display_name": "Arne Astrup" }, { "id": "https://openalex.org/A5059778565", "display_name": "Stephan R\u00f6ssner" }, { "id": "https://openalex.org/A5109054975", "display_name": "Luc Van Gaal" }, { "id": "https://openalex.org/A5104085781", "display_name": "Aila Rissanen" }, { "id": "https://openalex.org/A5048168425", "display_name": "Leo Niskanen" }, { "id": "https://openalex.org/A5039770600", "display_name": "M Al Hakim" }, { "id": "https://openalex.org/A5028471911", "display_name": "Jesper Madsen" }, { "id": "https://openalex.org/A5109247811", "display_name": "Mads Frederik Rasmussen" }, { "id": "https://openalex.org/A5103548273", "display_name": "Michael EJ Lean" } ] }, { "id": "https://openalex.org/W2215535790", "doi": "https://doi.org/10.1016/s0140-6736(15)00803-x", "title": "Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study", "abstract": null, "publication_date": "2015-11-20", "publication_year": 2015, "type": "article", "cited_by_count": 1980, "authors": [ { "id": "https://openalex.org/A5029173327", "display_name": "Matthew J. Armstrong" }, { "id": "https://openalex.org/A5074685337", "display_name": "Piers Gaunt" }, { "id": "https://openalex.org/A5084012349", "display_name": "Guruprasad P. Aithal" }, { "id": "https://openalex.org/A5066381179", "display_name": "Darren Barton" }, { "id": "https://openalex.org/A5064807470", "display_name": "Diana Hull" }, { "id": "https://openalex.org/A5044325739", "display_name": "Richard Parker" }, { "id": "https://openalex.org/A5043977432", "display_name": "Jonathan Hazlehurst" }, { "id": "https://openalex.org/A5109060739", "display_name": "Kathy Guo" }, { "id": "https://openalex.org/A5011626527", "display_name": "George Abouda" }, { "id": "https://openalex.org/A5017964659", "display_name": "Mark Aldersley" }, { "id": "https://openalex.org/A5023057149", "display_name": "Deborah Stocken" }, { "id": "https://openalex.org/A5107850059", "display_name": "Stephen Gough" }, { "id": "https://openalex.org/A5083236737", "display_name": "Jeremy Tomlinson" }, { "id": "https://openalex.org/A5054982837", "display_name": "Rachel M. Brown" }, { "id": "https://openalex.org/A5068853056", "display_name": "Stefan G. H\u00fcbscher" }, { "id": "https://openalex.org/A5044832887", "display_name": "Philip N. Newsome" } ] }, { "id": "https://openalex.org/W2587682809", "doi": "https://doi.org/10.1080/17512433.2017.1292125", "title": "GLP-1 receptor agonists in the treatment of polycystic ovary syndrome", "abstract": { "Polycystic": [ 0 ], "ovarian": [ 1 ], "syndrome": [ 2 ], "(PCOS)": [ 3 ], "affects": [ 4 ], "many": [ 5 ], "women": [ 6, 102 ], "of": [ 7, 30, 62, 90, 97, 174, 176, 181 ], "child-bearing": [ 8 ], "age": [ 9 ], "and": [ 10, 16, 40, 108, 133, 184, 190 ], "is": [ 11, 23 ], "characterized": [ 12 ], "by": [ 13 ], "hyperandrogenism,": [ 14 ], "ovulatory": [ 15 ], "metabolic": [ 17 ], "dysfunction.": [ 18 ], "A": [ 19, 123 ], "primary": [ 20 ], "treatment": [ 21, 96 ], "goal": [ 22 ], "weight": [ 24, 27, 100, 113 ], "reduction.": [ 25 ], "The": [ 26, 87 ], "loss": [ 28 ], "effects": [ 29 ], "glucagon-like": [ 31, 63 ], "peptide-1": [ 32, 64 ], "receptor": [ 33, 65 ], "agonists": [ 34 ], "(GLP-1RA),": [ 35 ], "previously": [ 36 ], "demonstrated": [ 37 ], "in": [ 38, 68, 94, 101, 112, 119 ], "diabetic": [ 39 ], "obese": [ 41 ], "non-diabetic": [ 42 ], "patients,": [ 43 ], "offer": [ 44 ], "a": [ 45 ], "unique": [ 46 ], "opportunity": [ 47 ], "to": [ 48, 54, 82, 165 ], "expand": [ 49 ], "the": [ 50, 95, 158, 169, 177, 179, 185 ], "medical": [ 51 ], "options": [ 52 ], "available": [ 53, 88 ], "PCOS": [ 55, 69, 104 ], "patients.": [ 56 ], "Areas": [ 57 ], "covered:": [ 58 ], "Available": [ 59 ], "clinical": [ 60 ], "trials": [ 61 ], "agonist": [ 66 ], "therapy": [ 67, 93 ], "were": [ 70, 153 ], "reviewed.": [ 71 ], "Literature": [ 72 ], "was": [ 73 ], "searched": [ 74 ], "from": [ 75 ], "PubMed": [ 76 ], "using": [ 77 ], "appropriate": [ 78 ], "search": [ 79 ], "terms": [ 80 ], "up": [ 81 ], "November": [ 83 ], "2016.": [ 84 ], "Expert": [ 85 ], "commentary:": [ 86 ], "studies": [ 89, 125 ], "GLP-1": [ 91 ], "RA": [ 92 ], "excess": [ 98 ], "body": [ 99 ], "with": [ 103, 121, 144, 155 ], "demonstrate": [ 105 ], "that": [ 106, 127 ], "exenatide": [ 107 ], "liraglutide": [ 109, 145 ], "are": [ 110, 149 ], "effective": [ 111 ], "reduction": [ 114 ], "either": [ 115 ], "as": [ 116 ], "monotherapy": [ 117 ], "or": [ 118 ], "combination": [ 120 ], "metformin.": [ 122 ], "few": [ 124 ], "showed": [ 126 ], "androgens": [ 128 ], "may": [ 129, 136, 141, 167 ], "be": [ 130, 137, 142, 168 ], "modestly": [ 131 ], "decreased": [ 132 ], "menstrual": [ 134 ], "frequency": [ 135 ], "increased.": [ 138 ], "Eating": [ 139 ], "behavior": [ 140 ], "improved": [ 143 ], "therapy.": [ 146 ], "Glucose": [ 147 ], "parameters": [ 148 ], "generally": [ 150 ], "improved.": [ 151 ], "GLP-1RAs": [ 152 ], "well-tolerated,": [ 154 ], "nausea": [ 156 ], "being": [ 157 ], "most": [ 159 ], "significant": [ 160 ], "adverse": [ 161 ], "side": [ 162 ], "effect.": [ 163 ], "Barriers": [ 164 ], "utilization": [ 166 ], "short": [ 170 ], "duration": [ 171 ], "studies,": [ 172 ], "lack": [ 173 ], "familiarity": [ 175 ], "medication,": [ 178 ], "route": [ 180 ], "administration": [ 182 ], "(injection)": [ 183 ], "variable": [ 186 ], "outcomes": [ 187 ], "on": [ 188 ], "ovulation": [ 189 ], "hyperandrogenism.": [ 191 ] }, "publication_date": "2017-02-07", "publication_year": 2017, "type": "review", "cited_by_count": 66, "authors": [ { "id": "https://openalex.org/A5044739438", "display_name": "Elizabeth M. Lamos" }, { "id": "https://openalex.org/A5012245518", "display_name": "Rana Malek" }, { "id": "https://openalex.org/A5080379883", "display_name": "Stephen N. Davis" } ] }, { "id": "https://openalex.org/W2078090288", "doi": "https://doi.org/10.1111/j.1463-1326.2009.01154.x", "title": "Exenatide compared with long\u2010acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long\u2010Acting insulin (HEELA) study", "abstract": { "Aim": [ 0 ], ":": [ 1, 44, 102, 257 ], "The": [ 2, 103, 149 ], "Helping": [ 3 ], "Evaluate": [ 4 ], "Exenatide": [ 5, 186 ], "in": [ 6, 137, 144, 196, 251, 263 ], "overweight": [ 7, 266 ], "patients": [ 8, 126, 152, 269 ], "with": [ 9, 12, 33, 40, 54, 160, 239, 248, 260, 270, 283, 288 ], "diabetes": [ 10, 61, 278 ], "compared": [ 11, 39, 287 ], "Long\u2010Acting": [ 13 ], "insulin": [ 14, 41, 84, 146, 175, 184, 188, 289 ], "(HEELA)": [ 15 ], "study": [ 16, 104 ], "was": [ 17, 134 ], "designed": [ 18 ], "to": [ 19, 74, 88 ], "examine": [ 20 ], "whether": [ 21 ], "the": [ 22, 138, 145, 154, 168, 174 ], "glucagon\u2010like": [ 23 ], "peptide\u20101": [ 24 ], "(GLP\u20101)": [ 25 ], "receptor": [ 26 ], "agonist,": [ 27 ], "exenatide,": [ 28 ], "could": [ 29 ], "improve": [ 30 ], "HbA1c": [ 31, 133, 158, 197 ], "(\u22647.4%)": [ 32 ], "minimal": [ 34, 284 ], "weight": [ 35, 161, 219, 285 ], "gain": [ 36, 162, 286 ], "(\u22641": [ 37 ], "kg)": [ 38 ], "glargine.": [ 42, 290 ], "Methods": [ 43 ], "Patients": [ 45 ], "[body": [ 46 ], "mass": [ 47 ], "index": [ 48 ], "(BMI)": [ 49 ], ">27": [ 50 ], "kg/m": [ 51, 120 ], "2": [ 52, 60, 121, 277 ], "]": [ 53 ], "elevated": [ 55, 272 ], "cardiovascular": [ 56, 273 ], "risk": [ 57, 274 ], "and": [ 58, 115, 123, 141, 171, 187, 206, 267, 275 ], "type": [ 59, 276 ], "inadequately": [ 62 ], "controlled": [ 63 ], "on": [ 64, 217 ], "two": [ 65, 129 ], "or": [ 66, 83, 253 ], "three": [ 67 ], "oral": [ 68 ], "antidiabetes": [ 69 ], "drugs": [ 70 ], "(OADs)": [ 71 ], "were": [ 72, 127, 165, 234 ], "randomized": [ 73 ], "add\u2010on": [ 75 ], "exenatide": [ 76, 139, 169, 182, 240, 261 ], "5\u201310": [ 77 ], "\u03bcg": [ 78 ], "b.i.d.": [ 79 ], "(n": [ 80 ], "=": [ 81, 96, 211 ], "118)": [ 82 ], "glargine": [ 85, 147, 176, 189 ], "o.d.": [ 86 ], "(titrated": [ 87 ], "target": [ 89 ], "fasting": [ 90 ], "plasma": [ 91 ], "glucose": [ 92 ], "\u22645.6": [ 93 ], "mmol/l;": [ 94 ], "n": [ 95 ], "117)": [ 97 ], "for": [ 98, 167, 173, 181 ], "26": [ 99, 231 ], "weeks.": [ 100, 232 ], "Results": [ 101 ], "population": [ 105 ], "had": [ 106, 214 ], "baseline": [ 107, 132 ], "mean": [ 108, 202 ], "(s.d.)": [ 109 ], "age": [ 110 ], "of": [ 111, 117, 125, 151, 157, 245 ], "56.5": [ 112 ], "(9.1)": [ 113 ], "years": [ 114 ], "BMI": [ 116 ], "34.1": [ 118 ], "(5.3)": [ 119 ], ",": [ 122 ], "58.5%": [ 124 ], "taking": [ 128 ], "OADs.": [ 130 ], "Mean": [ 131 ], "8.65": [ 135 ], "(0.68)%": [ 136 ], "group": [ 140, 170, 177 ], "8.48": [ 142 ], "(0.66)%": [ 143 ], "group.": [ 148 ], "proportions": [ 150 ], "achieving": [ 153, 279 ], "composite": [ 155 ], "endpoint": [ 156 ], "\u22647.4%": [ 159 ], "\u22641": [ 163 ], "kg": [ 164, 225 ], "53.4%": [ 166 ], "19.8%": [ 172 ], "(p": [ 178 ], "<": [ 179, 228 ], "0.001": [ 180 ], "vs.": [ 183, 222 ], "glargine).": [ 185 ], "did": [ 190 ], "not": [ 191 ], "demonstrate": [ 192 ], "a": [ 193, 242 ], "significant": [ 194 ], "difference": [ 195 ], "improvements": [ 198 ], "[least": [ 199 ], "square": [ 200 ], "(LS)": [ 201 ], "[s.e.m.]:": [ 203 ], "\u22121.25": [ 204 ], "[0.09]%": [ 205, 208 ], "\u22121.26": [ 207 ], "respectively;": [ 209 ], "p": [ 210, 227 ], "0.924],": [ 212 ], "but": [ 213, 241 ], "divergent": [ 215 ], "effects": [ 216 ], "body": [ 218 ], "(\u22122.73": [ 220 ], "[0.31]": [ 221, 224 ], "+2.98": [ 223 ], "respectively,": [ 226 ], "0.001)": [ 229 ], "after": [ 230 ], "There": [ 233 ], "more": [ 235, 265 ], "treatment\u2010related": [ 236 ], "adverse": [ 237 ], "events": [ 238 ], "lower": [ 243 ], "incidence": [ 244 ], "nocturnal": [ 246 ], "hypoglycaemia,": [ 247 ], "no": [ 249 ], "differences": [ 250 ], "overall": [ 252 ], "severe": [ 254 ], "hypoglycaemia.": [ 255 ], "Conclusions": [ 256 ], "Additional": [ 258 ], "treatment": [ 259 ], "resulted": [ 262 ], "significantly": [ 264 ], "obese": [ 268 ], "an": [ 271 ], "better": [ 280 ], "glycaemic": [ 281 ], "control": [ 282 ] }, "publication_date": "2009-09-22", "publication_year": 2009, "type": "article", "cited_by_count": 147, "authors": [ { "id": "https://openalex.org/A5084593004", "display_name": "Melanie J. Davies" }, { "id": "https://openalex.org/A5067259082", "display_name": "Richard Donnelly" }, { "id": "https://openalex.org/A5023295361", "display_name": "Anthony Barnett" }, { "id": "https://openalex.org/A5038261825", "display_name": "Stephen C. Jones" }, { "id": "https://openalex.org/A5029763402", "display_name": "Claudia Nicolay" }, { "id": "https://openalex.org/A5061673207", "display_name": "Aoife Kilcoyne" } ] }, { "id": "https://openalex.org/W2162001095", "doi": "https://doi.org/10.1210/jc.2010-2822", "title": "Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials", "abstract": { "Liraglutide": [ 0 ], "was": [ 1 ], "less": [ 2 ], "immunogenic": [ 3 ], "than": [ 4 ], "exenatide;": [ 5 ], "the": [ 6 ], "frequency": [ 7 ], "and": [ 8, 15 ], "levels": [ 9 ], "of": [ 10 ], "anti-liraglutide": [ 11 ], "antibodies": [ 12 ], "were": [ 13 ], "low": [ 14 ], "did": [ 16 ], "not": [ 17 ], "impact": [ 18 ], "glycemic": [ 19 ], "efficacy": [ 20 ], "or": [ 21 ], "safety.": [ 22 ] }, "publication_date": "2011-03-30", "publication_year": 2011, "type": "article", "cited_by_count": 146, "authors": [ { "id": "https://openalex.org/A5040182038", "display_name": "John B. Buse" }, { "id": "https://openalex.org/A5111831506", "display_name": "Alan J. Garber" }, { "id": "https://openalex.org/A5045489578", "display_name": "Julio Rosenstock" }, { "id": "https://openalex.org/A5111040183", "display_name": "Wolfgang E. Schmidt" }, { "id": "https://openalex.org/A5111550916", "display_name": "Jason Brett" }, { "id": "https://openalex.org/A5006541022", "display_name": "Nicoline Videb\u00e6k" }, { "id": "https://openalex.org/A5085434984", "display_name": "Jens J. Holst" }, { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" } ] }, { "id": "https://openalex.org/W3163402894", "doi": "https://doi.org/10.1111/dom.14443", "title": "Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis", "abstract": { "Abstract": [ 0 ], "Aims": [ 1 ], "To": [ 2 ], "investigate": [ 3 ], "whether": [ 4 ], "effects": [ 5, 86, 168, 204 ], "on": [ 6, 83 ], "chronic": [ 7 ], "kidney": [ 8, 18, 85, 167, 245, 262 ], "disease": [ 9 ], "risk": [ 10 ], "factors": [ 11 ], "could": [ 12 ], "explain": [ 13 ], "the": [ 14, 42, 58, 69, 84, 113, 184, 198, 206 ], "apparent": [ 15 ], "reduction": [ 16 ], "in": [ 17, 37, 51, 57, 133, 171, 197, 205, 214 ], "outcomes": [ 19 ], "(composite": [ 20 ], "of": [ 21, 24, 72, 87, 166, 169, 247 ], "macroalbuminuria,": [ 22 ], "doubling": [ 23 ], "serum": [ 25 ], "creatinine,": [ 26 ], "renal": [ 27, 31 ], "replacement": [ 28 ], "therapy,": [ 29 ], "or": [ 30, 178, 270 ], "death),": [ 32 ], "primarily": [ 33 ], "driven": [ 34, 266 ], "by": [ 35, 112, 210, 267, 272 ], "changes": [ 36 ], "albuminuria,": [ 38 ], "after": [ 39 ], "treatment": [ 40 ], "with": [ 41, 53, 119, 216, 225, 251 ], "glucagon\u2010like": [ 43 ], "peptide\u20101": [ 44 ], "receptor": [ 45 ], "agonists": [ 46 ], "(GLP\u20101RAs)": [ 47 ], "liraglutide": [ 48, 248 ], "and": [ 49, 60, 65, 80, 96, 99, 126, 148, 153, 161, 173, 200, 239, 249 ], "semaglutide": [ 50 ], "patients": [ 52, 215 ], "type": [ 54 ], "2": [ 55, 130, 221, 230 ], "diabetes": [ 56 ], "LEADER": [ 59, 172 ], "SUSTAIN": [ 61, 174 ], "6": [ 62 ], "trials.": [ 63 ], "Materials": [ 64 ], "Methods": [ 66 ], "We": [ 67, 136 ], "evaluated": [ 68 ], "mediation": [ 70, 108, 180 ], "effect": [ 71, 109 ], "glycated": [ 73 ], "haemoglobin": [ 74 ], "(HbA1c),": [ 75 ], "systolic": [ 76, 154, 240 ], "blood": [ 77, 101 ], "pressure": [ 78 ], "(BP),": [ 79 ], "body": [ 81, 189 ], "weight": [ 82, 190 ], "GLP\u20101RAs.": [ 88 ], "Diastolic": [ 89 ], "BP,": [ 90 ], "haemoglobin,": [ 91 ], "heart": [ 92 ], "rate,": [ 93 ], "low\u2010density": [ 94 ], "lipoprotein": [ 95 ], "total": [ 97 ], "cholesterol,": [ 98 ], "white": [ 100 ], "cell": [ 102 ], "count": [ 103 ], "were": [ 104, 131 ], "also": [ 105 ], "investigated.": [ 106 ], "The": [ 107 ], "was": [ 110, 181, 212 ], "estimated": [ 111, 120 ], "novel": [ 114 ], "Vansteelandt": [ 115 ], "statistical": [ 116 ], "method.": [ 117 ], "Subgroups": [ 118 ], "glomerular": [ 121 ], "filtration": [ 122 ], "rate": [ 123 ], "(eGFR)": [ 124 ], "<60": [ 125, 227 ], "\u226560": [ 127, 218 ], "mL/min/1.73": [ 128, 219, 228 ], "m": [ 129, 220, 229 ], "examined": [ 132 ], "LEADER.": [ 134 ], "Results": [ 135 ], "observed": [ 137, 182 ], "that": [ 138, 237 ], "HbA1c": [ 139, 211, 238 ], "mediated": [ 140, 191 ], "25%": [ 141 ], "(95%": [ 142, 150, 157, 163, 193 ], "confidence": [ 143 ], "interval": [ 144 ], "[CI]": [ 145 ], "\u22127.1;": [ 146 ], "67.3)": [ 147 ], "26%": [ 149 ], "CI": [ 151, 158, 164, 194 ], "noncalculable),": [ 152 ], "BP": [ 155, 241 ], "9%": [ 156, 192 ], "2.8;": [ 159 ], "22.7)": [ 160 ], "22%": [ 162 ], "noncalculable)": [ 165 ], "GLP\u20101RAs": [ 170 ], "6,": [ 175 ], "respectively.": [ 176 ], "Small": [ 177 ], "no": [ 179, 259 ], "for": [ 183, 187 ], "other": [ 185, 253, 268 ], "parameters;": [ 186 ], "example,": [ 188 ], "\u22127.9;": [ 195 ], "35.5)": [ 196 ], "former": [ 199 ], "did": [ 201 ], "not": [ 202 ], "mediate": [ 203, 244 ], "latter": [ 207 ], "study.": [ 208 ], "Mediation": [ 209 ], "greater": [ 213 ], "eGFR": [ 217, 226 ], "(57%)": [ 222 ], "versus": [ 223 ], "those": [ 224 ], "(no": [ 231 ], "mediation).": [ 232 ], "Conclusions": [ 233 ], "Our": [ 234 ], "results": [ 235 ], "suggest": [ 236 ], "may": [ 242, 264 ], "moderately": [ 243 ], "benefits": [ 246, 263 ], "semaglutide,": [ 250 ], "all": [ 252 ], "variables": [ 254 ], "having": [ 255 ], "a": [ 256 ], "small": [ 257 ], "to": [ 258 ], "effect.": [ 260 ], "Potential": [ 261 ], "be": [ 265 ], "mediators": [ 269 ], "potentially": [ 271 ], "direct": [ 273 ], "mechanisms.": [ 274 ] }, "publication_date": "2021-05-19", "publication_year": 2021, "type": "article", "cited_by_count": 95, "authors": [ { "id": "https://openalex.org/A5043842967", "display_name": "Johannes F.E. Mann" }, { "id": "https://openalex.org/A5040182038", "display_name": "John B. Buse" }, { "id": "https://openalex.org/A5113682378", "display_name": "Thomas Idorn" }, { "id": "https://openalex.org/A5080414941", "display_name": "Lawrence A. Leiter" }, { "id": "https://openalex.org/A5103974030", "display_name": "Richard E. Pratley" }, { "id": "https://openalex.org/A5110231477", "display_name": "S\u00f8ren Rasmussen" }, { "id": "https://openalex.org/A5004120950", "display_name": "Tina Vilsb\u00f8ll" }, { "id": "https://openalex.org/A5052608802", "display_name": "Benjamin Ole Wolthers" }, { "id": "https://openalex.org/A5027520502", "display_name": "Vlado Perkovic" } ] }, { "id": "https://openalex.org/W1906367066", "doi": "https://doi.org/10.1111/dom.12534", "title": "Once\u2010weekly glucagon\u2010like peptide\u20101 receptor agonist dulaglutide is non\u2010inferior to once\u2010daily liraglutide and superior to placebo in J apanese patients with type 2 diabetes: a 26\u2010week randomized phase III study", "abstract": { "Aims": [ 0 ], "To": [ 1 ], "examine": [ 2 ], "the": [ 3, 94, 117, 187 ], "efficacy": [ 4 ], "and": [ 5, 16, 64, 75, 84, 131, 178, 189, 247, 264 ], "safety": [ 6 ], "of": [ 7, 96 ], "once\u2010weekly": [ 8, 125, 239 ], "dulaglutide": [ 9, 83, 97, 126, 145, 155, 188, 240 ], "monotherapy": [ 10 ], "(0.75": [ 11, 241 ], "mg)": [ 12, 20, 242, 253 ], "compared": [ 13 ], "with": [ 14, 25, 52, 225, 235 ], "placebo": [ 15, 85, 99, 130, 147, 246 ], "once\u2010daily": [ 17, 134, 250 ], "liraglutide": [ 18, 135, 157, 190, 251 ], "(0.9": [ 19, 252 ], "in": [ 21, 104, 256 ], "J": [ 22, 49, 232 ], "apanese": [ 23, 50, 233 ], "patients": [ 24, 51, 207, 234 ], "type": [ 26, 53, 236 ], "2": [ 27, 54, 195, 218, 237 ], "diabetes.": [ 28 ], "Methods": [ 29 ], "This": [ 30 ], "was": [ 31, 127, 184, 243, 262 ], "a": [ 32 ], "phase": [ 33 ], "III": [ 34 ], ",": [ 35 ], "52\u2010week": [ 36 ], "(26\u2010week": [ 37 ], "primary": [ 38, 91 ], "endpoint),": [ 39 ], "randomized,": [ 40 ], "double\u2010blind,": [ 41 ], "placebo\u2010controlled,": [ 42 ], "open\u2010label": [ 43 ], "comparator": [ 44 ], "(liraglutide)": [ 45 ], "trial": [ 46 ], "comparing": [ 47 ], "492": [ 48 ], "diabetes": [ 55 ], "(dulaglutide,": [ 56 ], "n": [ 57, 61, 66, 193, 198, 211, 216, 221 ], "=": [ 58, 62, 67, 194, 199, 203, 212, 217, 222 ], "281;": [ 59 ], "liraglutide,": [ 60, 197, 215 ], "141;": [ 63 ], "placebo,": [ 65, 220 ], "70)": [ 68 ], "who": [ 69 ], "were": [ 70, 77, 114, 171 ], "aged": [ 71 ], "\u226520": [ 72 ], "years.": [ 73 ], "Patients": [ 74 ], "investigators": [ 76 ], "blinded": [ 78 ], "to": [ 79, 129, 133, 153, 163, 245, 249 ], "treatment": [ 80 ], "assignment": [ 81 ], "for": [ 82, 88, 136, 254 ], "but": [ 86 ], "not": [ 87 ], "liraglutide.": [ 89 ], "The": [ 90, 165 ], "objective": [ 92 ], "evaluated": [ 93 ], "superiority": [ 95 ], "versus": [ 98 ], "on": [ 100, 116 ], "change": [ 101, 138 ], "from": [ 102, 139 ], "baseline": [ 103, 140 ], "glycated": [ 105 ], "haemoglobin": [ 106 ], "(": [ 107 ], "HbA1c": [ 108, 137, 257 ], ")": [ 109 ], "at": [ 110, 258 ], "26": [ 111, 123, 259 ], "weeks.": [ 112, 260 ], "Analyses": [ 113 ], "performed": [ 115 ], "full": [ 118 ], "analysis": [ 119 ], "set.": [ 120 ], "Results": [ 121 ], "At": [ 122 ], "weeks,": [ 124 ], "superior": [ 128, 244 ], "non\u2010inferior": [ 132, 248 ], "[least": [ 141 ], "squares": [ 142 ], "mean": [ 143 ], "difference:": [ 144 ], "vs": [ 146, 156 ], "\u22121.57%": [ 148 ], "(95%": [ 149, 159 ], "confidence": [ 150, 160 ], "interval": [ 151, 161 ], "\u22121.79": [ 152 ], "\u22121.35);": [ 154 ], "\u22120.10%": [ 158 ], "\u22120.27": [ 162 ], "0.07)].": [ 164 ], "most": [ 166 ], "frequently": [ 167 ], "reported": [ 168 ], "adverse": [ 169 ], "events": [ 170 ], "nasopharyngitis,": [ 172 ], "constipation,": [ 173 ], "diarrhoea,": [ 174 ], "nausea,": [ 175 ], "abdominal": [ 176 ], "distension": [ 177 ], "decreased": [ 179, 182 ], "appetite;": [ 180 ], "only": [ 181 ], "appetite": [ 183 ], "different": [ 185 ], "between": [ 186 ], "groups": [ 191 ], "[dulaglutide,": [ 192, 210 ], "(0.7%);": [ 196 ], "8": [ 200 ], "(5.8%);": [ 201 ], "p": [ 202 ], "0.003].": [ 204 ], "Nine": [ 205 ], "(1.8%)": [ 206 ], "experienced": [ 208 ], "hypoglycaemia": [ 209 ], "6": [ 213 ], "(2.1%);": [ 214 ], "(1.5%);": [ 219 ], "1": [ 223 ], "(1.4%)],": [ 224 ], "no": [ 226 ], "event": [ 227 ], "being": [ 228 ], "severe.": [ 229 ], "Conclusions": [ 230 ], "In": [ 231 ], "diabetes,": [ 238 ], "reduction": [ 255 ], "Dulaglutide": [ 261 ], "safe": [ 263 ], "well": [ 265 ], "tolerated.": [ 266 ] }, "publication_date": "2015-07-14", "publication_year": 2015, "type": "article", "cited_by_count": 90, "authors": [ { "id": "https://openalex.org/A5108287618", "display_name": "Jun\u2010ichiro Miyagawa" }, { "id": "https://openalex.org/A5065240624", "display_name": "Masato Odawara" }, { "id": "https://openalex.org/A5046506553", "display_name": "Toshinari Takamura" }, { "id": "https://openalex.org/A5058832963", "display_name": "Noriyuki Iwamoto" }, { "id": "https://openalex.org/A5113205488", "display_name": "Y. Takita" }, { "id": "https://openalex.org/A5082595973", "display_name": "Takeshi Imaoka" } ] }, { "id": "https://openalex.org/W1974411409", "doi": "https://doi.org/10.1007/s12020-014-0179-0", "title": "Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature", "abstract": null, "publication_date": "2014-02-07", "publication_year": 2014, "type": "review", "cited_by_count": 82, "authors": [ { "id": "https://openalex.org/A5038036766", "display_name": "Carlo Giorda" }, { "id": "https://openalex.org/A5071855267", "display_name": "Elisa Nada" }, { "id": "https://openalex.org/A5061061768", "display_name": "Barbara Tartaglino" } ] }, { "id": "https://openalex.org/W1695457816", "doi": "https://doi.org/10.1007/s13300-015-0127-x", "title": "Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists", "abstract": { "Glucagon-like": [ 0 ], "peptide-1": [ 1 ], "(GLP-1)": [ 2 ], "receptor": [ 3 ], "agonists": [ 4 ], "(GLP-1": [ 5 ], "RAs)": [ 6 ], "are": [ 7, 42 ], "useful": [ 8, 112 ], "tools": [ 9 ], "for": [ 10, 28, 48, 77, 121 ], "treating": [ 11 ], "type": [ 12 ], "2": [ 13 ], "diabetes": [ 14 ], "mellitus.": [ 15 ], "In": [ 16 ], "their": [ 17, 62 ], "recent": [ 18 ], "position": [ 19 ], "statement,": [ 20 ], "the": [ 21, 29, 117 ], "American": [ 22 ], "Diabetes": [ 23, 32 ], "Association": [ 24, 27 ], "and": [ 25, 69, 86, 98, 106, 110 ], "European": [ 26 ], "Study": [ 30 ], "of": [ 31, 64, 67, 73, 104 ], "recommend": [ 33 ], "GLP1-RAs": [ 34, 58, 93 ], "as": [ 35 ], "add-on": [ 36 ], "to": [ 37, 52, 114 ], "metformin": [ 38 ], "when": [ 39 ], "therapeutic": [ 40 ], "goals": [ 41 ], "not": [ 43 ], "achieved": [ 44 ], "with": [ 45 ], "monotherapy,": [ 46 ], "particularly": [ 47 ], "patients": [ 49 ], "who": [ 50 ], "wish": [ 51 ], "avoid": [ 53 ], "weight": [ 54 ], "gain": [ 55 ], "or": [ 56 ], "hypoglycemia.": [ 57 ], "differ": [ 59 ], "substantially": [ 60 ], "in": [ 61 ], "duration": [ 63 ], "action,": [ 65 ], "frequency": [ 66 ], "administration": [ 68 ], "clinical": [ 70, 78 ], "profile.": [ 71 ], "Members": [ 72 ], "this": [ 74 ], "class": [ 75 ], "approved": [ 76 ], "use": [ 79 ], "include": [ 80 ], "exenatide": [ 81, 83 ], "twice-daily,": [ 82 ], "once-weekly,": [ 84 ], "liraglutide": [ 85 ], "lixisenatide": [ 87 ], "once-daily.": [ 88 ], "Recently,": [ 89 ], "two": [ 90 ], "new": [ 91 ], "once-weekly": [ 92 ], "have": [ 94 ], "been": [ 95 ], "approved:": [ 96 ], "dulaglutide": [ 97 ], "albiglutide.": [ 99 ], "This": [ 100 ], "article": [ 101 ], "summarizes": [ 102 ], "properties": [ 103 ], "short-": [ 105 ], "long-acting": [ 107 ], "GLP-1": [ 108 ], "analogs,": [ 109 ], "provides": [ 111 ], "information": [ 113 ], "help": [ 115 ], "choose": [ 116 ], "most": [ 118 ], "appropriate": [ 119 ], "compound": [ 120 ], "individual": [ 122 ], "patients.": [ 123 ] }, "publication_date": "2015-08-13", "publication_year": 2015, "type": "article", "cited_by_count": 91, "authors": [ { "id": "https://openalex.org/A5058865684", "display_name": "Annachiara Uccellatore" }, { "id": "https://openalex.org/A5049715149", "display_name": "Stefano Genovese" }, { "id": "https://openalex.org/A5014780759", "display_name": "Ilaria Dicembrini" }, { "id": "https://openalex.org/A5059685674", "display_name": "Edoardo Mannucci" }, { "id": "https://openalex.org/A5044764461", "display_name": "Antonio Ceriello" } ] }, { "id": "https://openalex.org/W3159005948", "doi": "https://doi.org/10.1007/s40265-021-01499-w", "title": "A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes", "abstract": { "Oral": [ 0, 57 ], "semaglutide": [ 1, 34, 58, 116, 147, 205 ], "(Rybelsus\u00ae)": [ 2 ], "is": [ 3, 18, 59, 206 ], "a": [ 4, 29, 76, 152 ], "glucagon-like": [ 5 ], "peptide-1": [ 6 ], "(GLP-1)": [ 7 ], "receptor": [ 8 ], "agonist": [ 9 ], "(GLP-1RA)": [ 10 ], "with": [ 11, 35, 114, 139, 151, 156, 175 ], "94%": [ 12 ], "homology": [ 13 ], "to": [ 14, 83, 191, 194, 208, 211, 222, 241 ], "human": [ 15 ], "GLP-1.": [ 16 ], "It": [ 17 ], "the": [ 19, 32, 36, 45, 51, 55, 110, 157, 168, 181, 200, 219, 229, 236 ], "first": [ 20 ], "GLP-1RA": [ 21, 158, 220 ], "developed": [ 22 ], "for": [ 23, 61, 85 ], "oral": [ 24, 115, 146, 204, 225 ], "administration,": [ 25 ], "and": [ 26, 91, 126, 167, 177, 196, 246 ], "it": [ 27 ], "comprises": [ 28 ], "co-formulation": [ 30 ], "of": [ 31, 47, 54, 163, 203, 213, 218, 231 ], "peptide": [ 33, 48 ], "absorption": [ 37, 49 ], "enhancer": [ 38 ], "sodium": [ 39 ], "N-(8-[2-hydroxybenzoyl]": [ 40 ], "amino)": [ 41 ], "caprylate,": [ 42 ], "which": [ 43 ], "overcomes": [ 44 ], "challenges": [ 46 ], "in": [ 50, 118, 123, 128, 137, 235 ], "acidic": [ 52 ], "conditions": [ 53 ], "stomach.": [ 56 ], "indicated": [ 60 ], "use": [ 62, 230 ], "as": [ 63, 75, 134 ], "an": [ 64, 100, 224 ], "add-on": [ 65 ], "combination": [ 66, 138 ], "therapy": [ 67 ], "(with": [ 68 ], "other": [ 69, 140 ], "glucose-lowering": [ 70, 141 ], "agents,": [ 71 ], "including": [ 72, 106 ], "insulin)": [ 73 ], "or": [ 74, 136 ], "monotherapy": [ 77, 135 ], "(in": [ 78 ], "patients": [ 79, 107, 245 ], "who": [ 80 ], "are": [ 81 ], "intolerant": [ 82 ], "metformin)": [ 84 ], "type": [ 86 ], "2": [ 87 ], "diabetes": [ 88, 237 ], "when": [ 89, 132 ], "diet": [ 90 ], "exercise": [ 92 ], "do": [ 93 ], "not": [ 94 ], "provide": [ 95 ], "adequate": [ 96 ], "glycemic": [ 97, 120 ], "control.": [ 98 ], "In": [ 99 ], "extensive": [ 101 ], "phase": [ 102 ], "III": [ 103 ], "clinical": [ 104 ], "program": [ 105 ], "from": [ 108, 244 ], "across": [ 109 ], "disease": [ 111 ], "spectrum,": [ 112 ], "treatment": [ 113, 238 ], "resulted": [ 117 ], "effective": [ 119 ], "control,": [ 121 ], "reductions": [ 122 ], "body": [ 124 ], "weight,": [ 125 ], "decreases": [ 127 ], "systolic": [ 129 ], "blood": [ 130 ], "pressure": [ 131 ], "used": [ 133 ], "therapies.": [ 142 ], "Studies": [ 143 ], "showed": [ 144 ], "that": [ 145, 199, 212 ], "was": [ 148, 165, 189 ], "well": [ 149 ], "tolerated,": [ 150 ], "safety": [ 153, 188 ], "profile": [ 154, 202 ], "consistent": [ 155 ], "drug": [ 159 ], "class.": [ 160 ], "The": [ 161, 216 ], "risk": [ 162 ], "hypoglycemia": [ 164 ], "low,": [ 166 ], "most": [ 169, 182 ], "common": [ 170 ], "adverse": [ 171 ], "events": [ 172 ], "were": [ 173 ], "gastrointestinal,": [ 174 ], "nausea": [ 176 ], "diarrhea": [ 178 ], "generally": [ 179 ], "being": [ 180 ], "frequently": [ 183 ], "reported": [ 184 ], "manifestations.": [ 185 ], "Cardiovascular": [ 186 ], "(CV)": [ 187 ], "shown": [ 190 ], "be": [ 192, 209 ], "noninferior": [ 193 ], "placebo": [ 195 ], "observations": [ 197 ], "suggest": [ 198 ], "CV": [ 201 ], "likely": [ 207 ], "similar": [ 210 ], "subcutaneous": [ 214 ], "semaglutide.": [ 215 ], "evolution": [ 217 ], "class": [ 221 ], "include": [ 223 ], "agent": [ 226 ], "could": [ 227 ], "facilitate": [ 228 ], "these": [ 232 ], "agents": [ 233 ], "earlier": [ 234 ], "cascade": [ 239 ], "owing": [ 240 ], "wider": [ 242 ], "acceptance": [ 243 ], "healthcare": [ 247 ], "professionals.": [ 248 ] }, "publication_date": "2021-05-08", "publication_year": 2021, "type": "review", "cited_by_count": 97, "authors": [ { "id": "https://openalex.org/A5079170139", "display_name": "Andreas Andersen" }, { "id": "https://openalex.org/A5079352451", "display_name": "Filip K. Knop" }, { "id": "https://openalex.org/A5004120950", "display_name": "Tina Vilsb\u00f8ll" } ] }, { "id": "https://openalex.org/W4378349085", "doi": "https://doi.org/10.1007/s11154-023-09807-3", "title": "Effects of GLP-1 receptor agonists on neurological complications of diabetes", "abstract": { "Abstract": [ 0 ], "Emerging": [ 1 ], "evidence": [ 2, 39 ], "suggests": [ 3 ], "that": [ 4, 155 ], "treatment": [ 5, 17 ], "with": [ 6, 147 ], "glucagon-like": [ 7 ], "peptide-1": [ 8 ], "receptor": [ 9 ], "agonists": [ 10 ], "(GLP-1": [ 11 ], "RAs)": [ 12 ], "could": [ 13 ], "be": [ 14, 158 ], "an": [ 15 ], "interesting": [ 16 ], "strategy": [ 18 ], "to": [ 19, 36, 117, 157 ], "reduce": [ 20, 118, 125 ], "neurological": [ 21, 47, 165 ], "complications": [ 22, 48, 166 ], "such": [ 23 ], "as": [ 24 ], "stroke,": [ 25, 71 ], "cognitive": [ 26, 72, 94 ], "impairment,": [ 27, 73 ], "and": [ 28, 57, 74, 96, 103, 112, 131 ], "peripheral": [ 29, 75, 99, 142 ], "neuropathy.": [ 30, 76, 100 ], "We": [ 31, 59, 77 ], "performed": [ 32 ], "a": [ 33, 79 ], "systematic": [ 34 ], "review": [ 35 ], "examine": [ 37 ], "the": [ 38, 41, 65, 119, 161 ], "concerning": [ 40 ], "effects": [ 42 ], "of": [ 43, 49, 67, 81, 121, 163, 167 ], "GLP-1": [ 44, 68, 148, 150 ], "RAs": [ 45, 69, 151 ], "on": [ 46, 70, 140 ], "diabetes.": [ 50, 168 ], "The": [ 51 ], "databases": [ 52 ], "used": [ 53 ], "were": [ 54, 114 ], "Pubmed,": [ 55 ], "Scopus": [ 56 ], "Cochrane.": [ 58 ], "selected": [ 60 ], "clinical": [ 61 ], "trials": [ 62 ], "which": [ 63 ], "analysed": [ 64 ], "effect": [ 66, 139 ], "found": [ 78 ], "total": [ 80 ], "19": [ 82 ], "studies:": [ 83 ], "8": [ 84 ], "studies": [ 85, 171 ], "include": [ 86, 98 ], "stroke": [ 87, 106 ], "or": [ 88 ], "major": [ 89, 126 ], "cardiovascular": [ 90, 127 ], "events,": [ 91 ], "7": [ 92 ], "involve": [ 93 ], "impairment": [ 95 ], "4": [ 97 ], "Semaglutide": [ 101 ], "subcutaneous": [ 102 ], "dulaglutide": [ 104, 130 ], "reduced": [ 105 ], "cases.": [ 107 ], "Liraglutide,": [ 108 ], "albiglutide,": [ 109 ], "oral": [ 110 ], "semaglutide": [ 111 ], "efpeglenatide,": [ 113 ], "not": [ 115 ], "shown": [ 116 ], "number": [ 120 ], "strokes": [ 122 ], "but": [ 123, 136 ], "did": [ 124 ], "events.": [ 128 ], "Exenatide,": [ 129 ], "liraglutide": [ 132 ], "improved": [ 133 ], "general": [ 134 ], "cognition": [ 135 ], "no": [ 137 ], "significant": [ 138 ], "diabetic": [ 141 ], "neuropathy": [ 143 ], "has": [ 144 ], "been": [ 145 ], "reported": [ 146 ], "RAs.": [ 149 ], "are": [ 152, 172 ], "promising": [ 153 ], "drugs": [ 154 ], "seem": [ 156 ], "useful": [ 159 ], "in": [ 160 ], "reduction": [ 162 ], "some": [ 164 ], "However,": [ 169 ], "more": [ 170 ], "needed.": [ 173 ] }, "publication_date": "2023-05-26", "publication_year": 2023, "type": "review", "cited_by_count": 27, "authors": [ { "id": "https://openalex.org/A5040444633", "display_name": "Natalia Garc\u00eda\u2010Casares" }, { "id": "https://openalex.org/A5044475673", "display_name": "Guillermo Gonz\u00e1lez-Gonz\u00e1lez" }, { "id": "https://openalex.org/A5003892447", "display_name": "Carlos de la Cruz Cosme" }, { "id": "https://openalex.org/A5053297606", "display_name": "Francisco J Garz\u00f3n-Maldonado" }, { "id": "https://openalex.org/A5092022789", "display_name": "Carmen de Rojas-Leal" }, { "id": "https://openalex.org/A5101488564", "display_name": "M.J. Ariza" }, { "id": "https://openalex.org/A5020373627", "display_name": "Manuel Narv\u00e1ez" }, { "id": "https://openalex.org/A5013881020", "display_name": "Miguel \u00c1ngel Barbancho" }, { "id": "https://openalex.org/A5007499817", "display_name": "Juan Antonio Garc\u00eda-Arn\u00e9s" }, { "id": "https://openalex.org/A5061677162", "display_name": "Francisco J. Tinahones" } ] }, { "id": "https://openalex.org/W2115692972", "doi": "https://doi.org/10.1186/s12933-014-0142-7", "title": "Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists", "abstract": { "Patients": [ 0, 46 ], "with": [ 1, 16, 32, 47, 78, 90, 103, 106, 188 ], "type": [ 2, 111, 189 ], "2": [ 3, 112, 190 ], "diabetes": [ 4, 48, 68, 113 ], "have": [ 5, 70, 136 ], "a": [ 6, 36, 73, 79, 92, 129, 137 ], "several-fold": [ 7 ], "increased": [ 8, 38 ], "risk": [ 9, 58, 81, 109 ], "of": [ 10, 27, 40, 121, 132, 177, 186 ], "developing": [ 11 ], "cardiovascular": [ 12, 52, 97, 122, 175 ], "disease": [ 13, 53 ], "when": [ 14 ], "compared": [ 15 ], "nondiabetic": [ 17 ], "controls.": [ 18 ], "Myocardial": [ 19 ], "infarction": [ 20 ], "and": [ 21, 143, 162 ], "stroke": [ 22 ], "are": [ 23, 49 ], "responsible": [ 24 ], "for": [ 25, 51, 183 ], "75%": [ 26 ], "all": [ 28 ], "death": [ 29, 41 ], "in": [ 30, 65, 85, 95, 101, 150 ], "patients": [ 31, 66, 187 ], "diabetes,": [ 33 ], "who": [ 34, 69 ], "present": [ 35 ], "2-4\u00d7": [ 37 ], "incidence": [ 39 ], "from": [ 42 ], "coronary": [ 43 ], "artery": [ 44 ], "disease.": [ 45 ], "considered": [ 50, 116 ], "secondary": [ 54 ], "prevention": [ 55 ], "because": [ 56 ], "their": [ 57 ], "level": [ 59 ], "is": [ 60, 168 ], "similar": [ 61 ], "to": [ 62, 170 ], "that": [ 63, 135 ], "reported": [ 64 ], "without": [ 67 ], "already": [ 71 ], "suffered": [ 72 ], "myocardial": [ 74 ], "infarction.": [ 75 ], "More": [ 76 ], "recently,": [ 77 ], "better": [ 80 ], "factors": [ 82 ], "control,": [ 83 ], "mainly": [ 84 ], "intensive": [ 86 ], "LDL": [ 87 ], "cholesterol": [ 88 ], "targets": [ 89 ], "statins,": [ 91 ], "significant": [ 93 ], "decrease": [ 94 ], "acute": [ 96 ], "events": [ 98 ], "was": [ 99 ], "observed": [ 100 ], "population": [ 102 ], "diabetes.": [ 104, 191 ], "Together": [ 105 ], "other": [ 107 ], "major": [ 108 ], "factors,": [ 110 ], "must": [ 114 ], "be": [ 115 ], "as": [ 117 ], "an": [ 118, 147 ], "important": [ 119 ], "cause": [ 120 ], "disease.Glucagon": [ 123 ], "like": [ 124 ], "peptide-1": [ 125, 179 ], "receptor": [ 126, 180 ], "agonists": [ 127, 181 ], "represent": [ 128 ], "novel": [ 130 ], "class": [ 131 ], "anti-hyperglycemic": [ 133 ], "agents": [ 134 ], "cardiac-friendly": [ 138 ], "profile,": [ 139 ], "preserve": [ 140 ], "neuronal": [ 141, 145 ], "cells": [ 142 ], "inhibit": [ 144 ], "degeneration,": [ 146 ], "anti-inflammatory": [ 148 ], "effect": [ 149 ], "liver": [ 151 ], "protecting": [ 152 ], "it": [ 153 ], "against": [ 154 ], "steatosis,": [ 155 ], "increase": [ 156, 163 ], "insulin": [ 157 ], "sensitivity,": [ 158 ], "promote": [ 159 ], "weight": [ 160 ], "loss,": [ 161 ], "satiety": [ 164 ], "or": [ 165 ], "anorexia.This": [ 166 ], "review": [ 167 ], "intended": [ 169 ], "rationally": [ 171 ], "compile": [ 172 ], "the": [ 173, 184 ], "multifactorial": [ 174 ], "effects": [ 176 ], "glucagon-like": [ 178 ], "available": [ 182 ], "treatment": [ 185 ] }, "publication_date": "2014-10-22", "publication_year": 2014, "type": "review", "cited_by_count": 132, "authors": [ { "id": "https://openalex.org/A5060570498", "display_name": "Francisco Saraiva" }, { "id": "https://openalex.org/A5086183706", "display_name": "Andrei C. Sp\u00f3sito" } ] }, { "id": "https://openalex.org/W2115047538", "doi": "https://doi.org/10.14814/phy2.12610", "title": "Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study", "abstract": { "Obesity": [ 0 ], "is": [ 1, 24, 207 ], "associated": [ 2, 25, 189, 208 ], "with": [ 3, 26, 72, 170, 190, 209 ], "differences": [ 4 ], "in": [ 5, 69, 140, 181, 212, 221 ], "satiety,": [ 6 ], "gastric": [ 7, 10, 153 ], "emptying": [ 8, 154 ], "(GE),": [ 9 ], "volume,": [ 11 ], "and": [ 12, 38, 50, 66, 97, 122, 156, 215 ], "psychological": [ 13 ], "traits.": [ 14 ], "Exenatide,": [ 15 ], "a": [ 16 ], "short-acting": [ 17, 200 ], "glucagon-like": [ 18 ], "peptide": [ 19 ], "1": [ 20 ], "(GLP-1)": [ 21 ], "receptor": [ 22, 202 ], "agonist,": [ 23, 203 ], "variable": [ 27 ], "weight": [ 28, 67, 111, 168, 191, 219 ], "loss.": [ 29 ], "We": [ 30 ], "compared": [ 31, 107 ], "the": [ 32, 143, 182, 199, 210, 216 ], "effects": [ 33 ], "of": [ 34, 48, 76, 85, 134, 167, 198 ], "exenatide,": [ 35, 204 ], "5": [ 36 ], "\u03bcg,": [ 37 ], "placebo": [ 39, 129 ], "SQ,": [ 40 ], "twice": [ 41 ], "daily": [ 42 ], "for": [ 43, 120, 128 ], "30": [ 44 ], "days": [ 45 ], "on": [ 46, 205 ], "GE": [ 47, 75, 84, 206 ], "solids": [ 49, 77, 86 ], "liquids": [ 51 ], "(scintigraphy),": [ 52 ], "satiety": [ 53 ], "(ad": [ 54 ], "libitum": [ 55 ], "buffet": [ 56, 102 ], "meal),": [ 57 ], "satiation": [ 58 ], "(nutrient": [ 59 ], "drink": [ 60 ], "test,": [ 61 ], "maximum": [ 62 ], "tolerated": [ 63 ], "volume": [ 64 ], "[MTV]),": [ 65 ], "loss": [ 68, 112, 220 ], "20": [ 70 ], "participants": [ 71 ], "documented": [ 73, 138 ], "accelerated": [ 74 ], "(T1/2": [ 78, 87 ], "<": [ 79, 95 ], "90": [ 80 ], "min).": [ 81 ], "Exenatide": [ 82 ], "delayed": [ 83 ], "[\u0394]": [ 88 ], "86": [ 89 ], "min": [ 90 ], "relative": [ 91 ], "to": [ 92, 108, 118, 126, 223 ], "placebo,": [ 93 ], "P": [ 94, 161, 178 ], "0.001)": [ 96 ], "reduced": [ 98 ], "calorie": [ 99 ], "intake": [ 100 ], "at": [ 101 ], "meal": [ 103 ], "([\u0394]": [ 104 ], "129": [ 105 ], "kcal": [ 106 ], "placebo).": [ 109 ], "Median": [ 110 ], "was": [ 113, 148, 173, 188 ], "-0.95": [ 114 ], "kg": [ 115, 124 ], "(IQR": [ 116 ], "-0.7": [ 117 ], "-2.1)": [ 119, 127 ], "exenatide": [ 121, 135, 144, 224 ], "-0.55": [ 123 ], "(0.3": [ 125 ], "(P": [ 130, 193 ], "=": [ 131, 159, 162, 176, 179, 194 ], "0.23);": [ 132 ], "80%": [ 133 ], "group": [ 136 ], "had": [ 137 ], "reduction": [ 139 ], "weight.": [ 141 ], "In": [ 142 ], "treatment": [ 145 ], "group,": [ 146 ], "there": [ 147 ], "an": [ 149 ], "inverse": [ 150 ], "correlation": [ 151 ], "between": [ 152 ], "T1/2": [ 155 ], "MTV": [ 157, 172, 187 ], "(R": [ 158 ], "-0.548,": [ 160 ], "0.089).": [ 163 ], "The": [ 164, 196 ], "univariate": [ 165 ], "association": [ 166 ], "change": [ 169, 192, 211 ], "posttreatment": [ 171, 186 ], "borderline": [ 174 ], "(Rs": [ 175 ], "0.43,": [ 177 ], "0.06);": [ 180 ], "multiple": [ 183 ], "regression": [ 184 ], "model,": [ 185 ], "0.047).": [ 195 ], "effect": [ 197 ], "GLP-1": [ 201 ], "food": [ 213 ], "intake,": [ 214 ], "latter": [ 217 ], "impacts": [ 218 ], "response": [ 222 ], "treatment.": [ 225 ] }, "publication_date": "2015-11-01", "publication_year": 2015, "type": "article", "cited_by_count": 73, "authors": [ { "id": "https://openalex.org/A5060455870", "display_name": "Andr\u00e9s Acosta" }, { "id": "https://openalex.org/A5001729912", "display_name": "Michael Camilleri" }, { "id": "https://openalex.org/A5016581938", "display_name": "Duane D. Burton" }, { "id": "https://openalex.org/A5109065517", "display_name": "Jessica O\u2019Neill" }, { "id": "https://openalex.org/A5091240380", "display_name": "Deborah J. Eckert" }, { "id": "https://openalex.org/A5107828987", "display_name": "Paula Carlson" }, { "id": "https://openalex.org/A5055945168", "display_name": "Alan R. Zinsmeister" } ] }, { "id": "https://openalex.org/W4362458746", "doi": "https://doi.org/10.1002/oby.23736", "title": "Effectiveness of semaglutide versus liraglutide for treating post\u2010metabolic and bariatric surgery weight recurrence", "abstract": { "Abstract": [ 0 ], "Objective": [ 1 ], "The": [ 2, 69, 90, 145 ], "aim": [ 3 ], "of": [ 4, 12, 29, 81, 180, 225, 231 ], "this": [ 5 ], "study": [ 6 ], "was": [ 7, 67, 73, 94, 99, 130 ], "to": [ 8, 209 ], "compare": [ 9 ], "the": [ 10, 135, 171, 229 ], "effectiveness": [ 11 ], "semaglutide": [ 13, 38, 86, 136, 172, 181, 204 ], "versus": [ 14, 132, 174 ], "liraglutide": [ 15, 47, 138, 175, 215 ], "for": [ 16, 154, 163, 219 ], "treating": [ 17, 220 ], "post\u2010metabolic": [ 18 ], "and": [ 19, 107, 117, 137, 158, 193 ], "bariatric": [ 20 ], "surgery": [ 21 ], "(MBS)": [ 22 ], "weight": [ 23, 34, 76, 125, 156, 165, 211, 222, 232 ], "recurrence.": [ 24, 233 ], "Methods": [ 25 ], "A": [ 26 ], "retrospective": [ 27 ], "analysis": [ 28 ], "207": [ 30 ], "adults": [ 31 ], "with": [ 32, 37, 83, 214 ], "post\u2010MBS": [ 33, 221 ], "recurrence": [ 35 ], "treated": [ 36 ], "1.0": [ 39, 205 ], "mg": [ 40, 49, 206, 217 ], "weekly": [ 41, 207 ], "(": [ 42, 51, 141 ], "n": [ 43, 52 ], "=": [ 44, 53 ], "115)": [ 45 ], "or": [ 46, 87, 228 ], "3.0": [ 48, 216 ], "daily": [ 50, 218 ], "92)": [ 54 ], "at": [ 55, 78, 127 ], "an": [ 56 ], "academic": [ 57 ], "center": [ 58 ], "from": [ 59 ], "January": [ 60 ], "1,": [ 61, 65 ], "2015,": [ 62 ], "through": [ 63 ], "April": [ 64 ], "2021,": [ 66 ], "conducted.": [ 68 ], "primary": [ 70 ], "end": [ 71 ], "point": [ 72 ], "percentage": [ 74 ], "body": [ 75 ], "change": [ 77, 126 ], "12": [ 79, 128, 168 ], "months": [ 80, 129, 169 ], "treatment": [ 82, 201 ], "regimens": [ 84, 202 ], "containing": [ 85 ], "liraglutide.": [ 88 ], "Results": [ 89 ], "mean": [ 91, 97, 124 ], "sample": [ 92 ], "age": [ 93 ], "55.2": [ 95 ], "years;": [ 96 ], "BMI": [ 98 ], "40.4": [ 100 ], "kg/m": [ 101 ], "2": [ 102 ], ";": [ 103 ], "89.9%": [ 104 ], "were": [ 105, 149 ], "female;": [ 106 ], "50%": [ 108 ], "completed": [ 109, 113, 119 ], "sleeve": [ 110 ], "gastrectomy,": [ 111 ], "29%": [ 112 ], "Roux\u2010en\u2010Y": [ 114 ], "gastric": [ 115, 121 ], "bypass,": [ 116 ], "21%": [ 118 ], "adjustable": [ 120 ], "banding.": [ 122 ], "Least\u2010squares": [ 123 ], "\u221212.92%": [ 131 ], "\u22128.77%": [ 133 ], "in": [ 134, 170 ], "groups,": [ 139 ], "respectively": [ 140 ], "p": [ 142 ], "<": [ 143 ], "0.001).": [ 144 ], "adjusted": [ 146 ], "odds": [ 147 ], "ratios": [ 148 ], "2.34": [ 150 ], "(95%": [ 151, 160 ], "CI:": [ 152, 161 ], "1.28\u20104.29)": [ 153 ], "\u226510%": [ 155 ], "loss": [ 157, 166, 212 ], "2.55": [ 159 ], "1.22\u20105.36)": [ 162 ], "\u226515%": [ 164 ], "over": [ 167 ], "group": [ 173 ], "group,": [ 176 ], "respectively.": [ 177 ], "Weight\u2010loss": [ 178 ], "efficacy": [ 179 ], "(vs.": [ 182 ], "liraglutide)": [ 183 ], "did": [ 184 ], "not": [ 185 ], "differ": [ 186 ], "by": [ 187 ], "subgroups": [ 188 ], "explored,": [ 189 ], "including": [ 190, 203 ], "age,": [ 191 ], "sex,": [ 192 ], "MBS": [ 194 ], "procedure.": [ 195 ], "Conclusions": [ 196 ], "These": [ 197 ], "results": [ 198 ], "show": [ 199 ], "that": [ 200 ], "lead": [ 208 ], "superior": [ 210 ], "compared": [ 213 ], "recurrence,": [ 223 ], "regardless": [ 224 ], "procedure": [ 226 ], "type": [ 227 ], "magnitude": [ 230 ] }, "publication_date": "2023-03-30", "publication_year": 2023, "type": "article", "cited_by_count": 66, "authors": [ { "id": "https://openalex.org/A5056753377", "display_name": "Natia Murvelashvili" }, { "id": "https://openalex.org/A5000246334", "display_name": "Luyu Xie" }, { "id": "https://openalex.org/A5019457502", "display_name": "Jeffrey N. Schellinger" }, { "id": "https://openalex.org/A5069337998", "display_name": "M. Sunil Mathew" }, { "id": "https://openalex.org/A5067387245", "display_name": "Elisa Morales" }, { "id": "https://openalex.org/A5001655356", "display_name": "Ildiko Lingvay" }, { "id": "https://openalex.org/A5000111197", "display_name": "Sarah Messiah" }, { "id": "https://openalex.org/A5055828494", "display_name": "Jaime P. Almandoz" } ] }, { "id": "https://openalex.org/W2058922633", "doi": "https://doi.org/10.1056/nejmp1001578", "title": "Weighing Risks and Benefits of Liraglutide \u2014 The FDA's Review of a New Antidiabetic Therapy", "abstract": { "On": [ 0 ], "January": [ 1 ], "25,": [ 2 ], "the": [ 3, 29 ], "FDA": [ 4 ], "approved": [ 5 ], "liraglutide,": [ 6 ], "a": [ 7 ], "glucagon-like-peptide-1": [ 8 ], "receptor": [ 9 ], "agonist": [ 10 ], "that": [ 11 ], "can": [ 12 ], "improve": [ 13 ], "glycemic": [ 14 ], "control": [ 15 ], "in": [ 16 ], "adults": [ 17 ], "with": [ 18, 37 ], "type": [ 19 ], "2": [ 20 ], "diabetes.": [ 21 ], "Drs.": [ 22 ], "Mary": [ 23 ], "Parks": [ 24 ], "and": [ 25, 31 ], "Curtis": [ 26 ], "Rosebraugh": [ 27 ], "discuss": [ 28 ], "benefits": [ 30 ], "potentially": [ 32 ], "serious": [ 33 ], "safety": [ 34 ], "concerns": [ 35 ], "associated": [ 36 ], "this": [ 38 ], "new": [ 39 ], "therapy.": [ 40 ] }, "publication_date": "2010-02-18", "publication_year": 2010, "type": "review", "cited_by_count": 266, "authors": [ { "id": "https://openalex.org/A5000357211", "display_name": "Mary Parks" }, { "id": "https://openalex.org/A5005198440", "display_name": "Curtis J. Rosebraugh" } ] }, { "id": "https://openalex.org/W2149852822", "doi": "https://doi.org/10.1177/1060028014564180", "title": "Dulaglutide", "abstract": { "Objective:": [ 0 ], "To": [ 1 ], "review": [ 2 ], "the": [ 3, 10, 19, 43, 67, 192, 200 ], "pharmacology,": [ 4, 68 ], "pharmacokinetics,": [ 5, 69 ], "safety,": [ 6, 70 ], "and": [ 7, 47, 58, 83, 89, 99, 125, 132, 148, 166, 187, 224, 233 ], "efficacy": [ 8, 72 ], "of": [ 9, 21, 73, 104 ], "glucagon-like": [ 11 ], "peptide-1": [ 12 ], "receptor": [ 13 ], "agonist": [ 14 ], "(GLP-1": [ 15 ], "RA),": [ 16 ], "dulaglutide,": [ 17 ], "in": [ 18, 92, 126, 154, 181, 199 ], "treatment": [ 20 ], "type": [ 22 ], "2": [ 23, 105 ], "diabetes": [ 24 ], "mellitus": [ 25 ], "(T2D).": [ 26 ], "Data": [ 27, 59, 75 ], "Sources:": [ 28 ], "A": [ 29 ], "PubMed": [ 30 ], "search": [ 31, 44 ], "was": [ 32 ], "completed": [ 33 ], "to": [ 34, 39, 52, 112, 157, 164, 173, 217, 222, 231 ], "identify": [ 35, 53 ], "publications": [ 36 ], "from": [ 37 ], "1947": [ 38 ], "October": [ 40 ], "2014": [ 41 ], "using": [ 42 ], "terms": [ 45 ], "dulaglutide": [ 46 ], "LY2189265.": [ 48 ], "References": [ 49 ], "were": [ 50, 62, 184 ], "reviewed": [ 51 ], "additional": [ 54 ], "resources.": [ 55 ], "Study": [ 56 ], "Selection": [ 57 ], "Extraction:": [ 60 ], "Articles": [ 61 ], "included": [ 63 ], "if": [ 64 ], "they": [ 65 ], "evaluated": [ 66 ], "or": [ 71 ], "dulaglutide.": [ 74 ], "Synthesis:": [ 76 ], "Dulaglutide": [ 77, 102, 119, 159, 190 ], "reduces": [ 78 ], "both": [ 79 ], "glycosylated": [ 80 ], "hemoglobin": [ 81 ], "(A1C)": [ 82 ], "weight": [ 84, 169, 219 ], "by": [ 85, 162, 170 ], "stimulating": [ 86 ], "insulin": [ 87, 133, 145 ], "secretion": [ 88 ], "suppressing": [ 90 ], "glucagon": [ 91 ], "a": [ 93, 115 ], "glucose-dependent": [ 94 ], "manner,": [ 95 ], "delaying": [ 96 ], "gastric": [ 97 ], "emptying,": [ 98 ], "promoting": [ 100 ], "satiety.": [ 101 ], "consists": [ 103 ], "GLP-1": [ 106, 194 ], "analogues": [ 107 ], "that": [ 108 ], "have": [ 109 ], "been": [ 110, 121 ], "modified": [ 111 ], "make": [ 113 ], "it": [ 114, 167, 209 ], "long-acting,": [ 116 ], "once-weekly": [ 117 ], "agent.": [ 118 ], "has": [ 120, 136, 225 ], "studied": [ 122 ], "as": [ 123 ], "monotherapy": [ 124 ], "combination": [ 127 ], "with": [ 128, 142 ], "metformin,": [ 129, 144 ], "glimepiride,": [ 130 ], "pioglitazone,": [ 131 ], "lispro.": [ 134 ], "It": [ 135, 151, 203 ], "demonstrated": [ 137, 152 ], "superior": [ 138 ], "A1C": [ 139, 155, 161, 214 ], "reduction": [ 140, 156, 220 ], "compared": [ 141 ], "placebo,": [ 143 ], "glargine,": [ 146 ], "sitagliptin,": [ 147 ], "twice-daily": [ 149 ], "exenatide.": [ 150 ], "noninferiority": [ 153 ], "liraglutide.": [ 158, 234 ], "changed": [ 160, 168 ], "\u22120.78%": [ 163 ], "\u22121.51%,": [ 165 ], "\u22120.35": [ 171 ], "kg": [ 172 ], "\u22123.03": [ 174 ], "kg.": [ 175 ], "The": [ 176 ], "most": [ 177 ], "common": [ 178 ], "adverse": [ 179, 227 ], "effects": [ 180 ], "clinical": [ 182 ], "studies": [ 183 ], "nausea,": [ 185 ], "vomiting,": [ 186 ], "diarrhea.": [ 188 ], "Conclusions:": [ 189 ], "is": [ 191, 204, 210 ], "fifth": [ 193 ], "RA": [ 195 ], "approved": [ 196 ], "for": [ 197 ], "T2D": [ 198 ], "United": [ 201 ], "States.": [ 202 ], "an": [ 205, 226 ], "attractive": [ 206 ], "option": [ 207 ], "because": [ 208 ], "dosed": [ 211 ], "once-weekly,": [ 212 ], "provides": [ 213 ], "lowering": [ 215 ], "similar": [ 216, 221, 230 ], "liraglutide,": [ 218 ], "exenatide,": [ 223 ], "effect": [ 228 ], "profile": [ 229 ], "exenatide": [ 232 ] }, "publication_date": "2015-01-06", "publication_year": 2015, "type": "review", "cited_by_count": 46, "authors": [ { "id": "https://openalex.org/A5103214803", "display_name": "Angela Thompson" }, { "id": "https://openalex.org/A5054620018", "display_name": "Jennifer Trujillo" } ] }, { "id": "https://openalex.org/W4385330768", "doi": "https://doi.org/10.1001/jama.2023.13872", "title": "Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists", "abstract": { "Importance": [ 0 ], "Glucagon-like": [ 1 ], "peptide": [ 2 ], "1": [ 3, 237 ], "(GLP-1)": [ 4 ], "receptor": [ 5, 45, 82, 160, 209, 278, 300 ], "agonists": [ 6, 46, 83, 161, 210, 279, 301 ], "were": [ 7, 211 ], "first": [ 8 ], "approved": [ 9, 84 ], "for": [ 10, 20, 98, 255 ], "the": [ 11, 49, 117, 124, 130, 140, 149, 157, 164, 170, 213, 303 ], "treatment": [ 12 ], "of": [ 13, 42, 57, 123, 132, 148, 174, 184, 203, 227, 247, 298 ], "type": [ 14 ], "2": [ 15, 228 ], "diabetes": [ 16 ], "in": [ 17, 26, 163 ], "2005.": [ 18 ], "Demand": [ 19 ], "these": [ 21 ], "drugs": [ 22 ], "has": [ 23, 272 ], "increased": [ 24 ], "rapidly": [ 25 ], "recent": [ 27 ], "years,": [ 28 ], "as": [ 29, 139 ], "indications": [ 30 ], "have": [ 31, 47 ], "expanded,": [ 32 ], "but": [ 33 ], "they": [ 34 ], "remain": [ 35 ], "expensive.": [ 36 ], "Objective": [ 37 ], "To": [ 38 ], "analyze": [ 39 ], "how": [ 40 ], "manufacturers": [ 41, 167 ], "brand-name": [ 43 ], "GLP-1": [ 44, 81, 159, 208, 277, 299 ], "used": [ 48, 78, 104 ], "patent": [ 50, 151, 222 ], "and": [ 51, 66, 89, 93, 193, 236, 258, 261, 285, 288 ], "regulatory": [ 52, 153, 229, 262, 289 ], "systems": [ 53 ], "to": [ 54, 79, 87, 90, 105, 280, 293, 302 ], "extend": [ 55 ], "periods": [ 56 ], "market": [ 58 ], "exclusivity.": [ 59, 154 ], "Evidence": [ 60 ], "Review": [ 61 ], "The": [ 62, 126, 243 ], "annual": [ 63 ], "US": [ 64 ], "Food": [ 65 ], "Drug": [ 67, 71 ], "Administration\u2019s": [ 68 ], "(FDA)": [ 69 ], "Approved": [ 70 ], "Products": [ 72 ], "With": [ 73 ], "Therapeutic": [ 74 ], "Equivalence": [ 75 ], "Evaluations": [ 76 ], "was": [ 77, 103, 114, 129, 264 ], "identify": [ 80 ], "from": [ 85, 135, 143 ], "2005": [ 86 ], "2021": [ 88 ], "record": [ 91 ], "patents": [ 92, 176, 186, 205, 260, 275 ], "nonpatent": [ 94 ], "statutory": [ 95 ], "exclusivities": [ 96, 230 ], "listed": [ 97, 168, 206 ], "each": [ 99, 113 ], "product.": [ 100, 125 ], "Google": [ 101 ], "Patents": [ 102 ], "extract": [ 106 ], "additional": [ 107 ], "data": [ 108 ], "on": [ 109, 116, 207, 212, 276 ], "patents,": [ 110 ], "including": [ 111, 181 ], "whether": [ 112 ], "obtained": [ 115, 233 ], "delivery": [ 118, 214 ], "device": [ 119 ], "or": [ 120, 152 ], "another": [ 121 ], "aspect": [ 122 ], "primary": [ 127 ], "outcome": [ 128 ], "duration": [ 131, 246 ], "expected": [ 133, 248 ], "protection": [ 134, 223, 249 ], "generic": [ 136, 270, 296 ], "competition,": [ 137 ], "defined": [ 138 ], "time": [ 141 ], "elapsed": [ 142 ], "FDA": [ 144, 171, 191, 199, 251, 282 ], "approval": [ 145, 192, 235 ], "until": [ 146 ], "expiration": [ 147 ], "last-to-expire": [ 150 ], "Findings": [ 155 ], "On": [ 156 ], "10": [ 158 ], "included": [ 162 ], "cohort,": [ 165 ], "drug": [ 166 ], "with": [ 169, 224 ], "a": [ 172, 182, 225 ], "median": [ 173, 183, 226, 244 ], "19.5": [ 175 ], "(IQR,": [ 177, 187, 195, 231, 238, 267 ], "9.0-25.8)": [ 178 ], "per": [ 179 ], "product,": [ 180 ], "17": [ 185 ], "8.3-22.8)": [ 188 ], "filed": [ 189, 197 ], "before": [ 190 ], "1.5": [ 194 ], "0-2.8)": [ 196 ], "after": [ 198, 241, 250 ], "approval.": [ 200, 242, 283 ], "Fifty-four": [ 201 ], "percent": [ 202 ], "all": [ 204 ], "devices": [ 215 ], "rather": [ 216 ], "than": [ 217 ], "active": [ 218 ], "ingredients.": [ 219 ], "Manufacturers": [ 220 ], "augmented": [ 221 ], "0-3)": [ 232 ], "at": [ 234 ], "0.3-4.3)": [ 239 ], "added": [ 240 ], "total": [ 245 ], "approval,": [ 252 ], "when": [ 253 ], "accounting": [ 254 ], "both": [ 256 ], "preapproval": [ 257 ], "postapproval": [ 259 ], "exclusivities,": [ 263 ], "18.3": [ 265 ], "years": [ 266 ], "16.0-19.4).": [ 268 ], "No": [ 269 ], "firm": [ 271 ], "successfully": [ 273 ], "challenged": [ 274 ], "gain": [ 281 ], "Conclusions": [ 284 ], "Relevance": [ 286 ], "Patent": [ 287 ], "reform": [ 290 ], "is": [ 291 ], "needed": [ 292 ], "ensure": [ 294 ], "timely": [ 295 ], "entry": [ 297 ], "market.": [ 304 ] }, "publication_date": "2023-07-28", "publication_year": 2023, "type": "article", "cited_by_count": 42, "authors": [ { "id": "https://openalex.org/A5048397557", "display_name": "Rasha Alhiary" }, { "id": "https://openalex.org/A5074257304", "display_name": "Aaron S. Kesselheim" }, { "id": "https://openalex.org/A5056110570", "display_name": "Sarah Gabriele" }, { "id": "https://openalex.org/A5089495059", "display_name": "Reed F. Beall" }, { "id": "https://openalex.org/A5035419359", "display_name": "S. Sean Tu" }, { "id": "https://openalex.org/A5048211823", "display_name": "William B. Feldman" } ] }, { "id": "https://openalex.org/W2039296612", "doi": "https://doi.org/10.1210/jc.2005-1093", "title": "Exenatide Augments First- and Second-Phase Insulin Secretion in Response to Intravenous Glucose in Subjects with Type 2 Diabetes", "abstract": { "Short-term": [ 0 ], "exposure": [ 1 ], "to": [ 2, 12 ], "exenatide": [ 3 ], "can": [ 4 ], "restore": [ 5 ], "the": [ 6, 23 ], "insulin": [ 7, 34, 39 ], "secretory": [ 8 ], "pattern": [ 9 ], "in": [ 10, 15, 18, 22, 41 ], "response": [ 11 ], "acute": [ 13 ], "rises": [ 14 ], "glucose": [ 16 ], "concentrations": [ 17 ], "DM2": [ 19, 42 ], "patients": [ 20, 43 ], "who,": [ 21 ], "absence": [ 24 ], "of": [ 25, 33, 37 ], "exenatide,": [ 26 ], "do": [ 27 ], "not": [ 28 ], "display": [ 29 ], "a": [ 30 ], "first": [ 31 ], "phase": [ 32 ], "secretion.": [ 35 ], "Loss": [ 36 ], "first-phase": [ 38 ], "secretion": [ 40 ], "may": [ 44 ], "be": [ 45 ], "restored": [ 46 ], "by": [ 47 ], "treatment": [ 48 ], "with": [ 49 ], "exenatide.": [ 50 ] }, "publication_date": "2005-11-01", "publication_year": 2005, "type": "article", "cited_by_count": 298, "authors": [ { "id": "https://openalex.org/A5043006137", "display_name": "Frauke Fehse" }, { "id": "https://openalex.org/A5062021087", "display_name": "Michael Trautmann" }, { "id": "https://openalex.org/A5085434984", "display_name": "Jens J. Holst" }, { "id": "https://openalex.org/A5013319510", "display_name": "Amy E. Halseth" }, { "id": "https://openalex.org/A5050194946", "display_name": "Nuwan D. Nanayakkara" }, { "id": "https://openalex.org/A5075068030", "display_name": "Loretta L. Nielsen" }, { "id": "https://openalex.org/A5083503351", "display_name": "Mark Fineman" }, { "id": "https://openalex.org/A5084708084", "display_name": "Dennis Dong Hwan Kim" }, { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" } ] }, { "id": "https://openalex.org/W2105812875", "doi": "https://doi.org/10.1007/s11892-010-0102-x", "title": "Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide?", "abstract": null, "publication_date": "2010-03-01", "publication_year": 2010, "type": "review", "cited_by_count": 46, "authors": [ { "id": "https://openalex.org/A5051382562", "display_name": "Mikkel Christensen" }, { "id": "https://openalex.org/A5079352451", "display_name": "Filip K. Knop" } ] }, { "id": "https://openalex.org/W4321850189", "doi": "https://doi.org/10.1186/s12933-023-01765-z", "title": "Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial", "abstract": null, "publication_date": "2023-02-25", "publication_year": 2023, "type": "article", "cited_by_count": 125, "authors": [ { "id": "https://openalex.org/A5007796517", "display_name": "Rasmus Michael Sandsdal" }, { "id": "https://openalex.org/A5043941957", "display_name": "Christian R. Juhl" }, { "id": "https://openalex.org/A5078868922", "display_name": "Simon Birk Kj\u00e6r Jensen" }, { "id": "https://openalex.org/A5007991615", "display_name": "J. Lundgren" }, { "id": "https://openalex.org/A5089416119", "display_name": "Charlotte Janus" }, { "id": "https://openalex.org/A5101591653", "display_name": "Martin B\u00e6k Blond" }, { "id": "https://openalex.org/A5085031473", "display_name": "Mads Rosenkilde" }, { "id": "https://openalex.org/A5064519269", "display_name": "Adrian F. Bogh" }, { "id": "https://openalex.org/A5011413745", "display_name": "Lasse Gliemann" }, { "id": "https://openalex.org/A5058323484", "display_name": "Jens\u2010Erik Beck Jensen" }, { "id": "https://openalex.org/A5007720638", "display_name": "Charalambos Antoniades" }, { "id": "https://openalex.org/A5066604050", "display_name": "Bente Stallknecht" }, { "id": "https://openalex.org/A5085434984", "display_name": "Jens J. Holst" }, { "id": "https://openalex.org/A5062239390", "display_name": "Sten Madsbad" }, { "id": "https://openalex.org/A5038081896", "display_name": "Signe S. Torekov" } ] }, { "id": "https://openalex.org/W4400956092", "doi": "https://doi.org/10.3389/fendo.2024.1431292", "title": "Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists", "abstract": { "Glucose-dependent": [ 0 ], "insulinotropic": [ 1 ], "polypeptide": [ 2 ], "(GIP)": [ 3 ], "and": [ 4, 17, 25, 29, 71, 96, 100, 117, 121, 134, 138, 166, 175, 193, 212 ], "glucagon-like": [ 5 ], "peptide-1": [ 6 ], "(GLP-1)": [ 7 ], "are": [ 8, 200 ], "two": [ 9, 108 ], "incretins": [ 10, 109 ], "that": [ 11 ], "bind": [ 12 ], "to": [ 13, 111, 146 ], "their": [ 14, 54 ], "respective": [ 15 ], "receptors": [ 16 ], "activate": [ 18 ], "the": [ 19, 41, 98, 123, 152, 172, 182, 208 ], "downstream": [ 20 ], "signaling": [ 21 ], "in": [ 22, 33, 40, 50, 59, 128, 151, 163, 181 ], "various": [ 23 ], "tissues": [ 24 ], "organs.": [ 26 ], "Both": [ 27 ], "GIP": [ 28, 64, 79 ], "GLP-1": [ 30, 72, 84, 137 ], "play": [ 31 ], "roles": [ 32 ], "regulating": [ 34 ], "food": [ 35 ], "intake": [ 36 ], "by": [ 37 ], "stimulating": [ 38 ], "neurons": [ 39 ], "brain\u2019s": [ 42 ], "satiety": [ 43 ], "center.": [ 44 ], "They": [ 45 ], "also": [ 46 ], "stimulate": [ 47 ], "insulin": [ 48 ], "secretion": [ 49, 101 ], "pancreatic": [ 51, 60 ], "\u03b2-cells,": [ 52 ], "but": [ 53 ], "effects": [ 55, 150 ], "on": [ 56, 203 ], "glucagon": [ 57 ], "production": [ 58, 99 ], "\u03b1-cells": [ 61 ], "differ,": [ 62 ], "with": [ 63, 130, 158, 190 ], "having": [ 65 ], "a": [ 66 ], "glucagonotropic": [ 67 ], "effect": [ 68, 75 ], "during": [ 69, 76 ], "hypoglycemia": [ 70 ], "exhibiting": [ 73 ], "glucagonostatic": [ 74 ], "hyperglycemia.": [ 77 ], "Additionally,": [ 78 ], "directly": [ 80 ], "stimulates": [ 81 ], "lipogenesis,": [ 82 ], "while": [ 83 ], "indirectly": [ 85 ], "promotes": [ 86 ], "lipolysis,": [ 87 ], "collectively": [ 88 ], "maintaining": [ 89 ], "healthy": [ 90 ], "adipocytes,": [ 91 ], "reducing": [ 92, 122 ], "ectopic": [ 93 ], "fat": [ 94 ], "distribution,": [ 95 ], "increasing": [ 97 ], "of": [ 102, 125, 154, 168, 184, 187, 210 ], "adiponectin": [ 103 ], "from": [ 104 ], "adipocytes.": [ 105 ], "Together,": [ 106 ], "these": [ 107, 148 ], "contribute": [ 110 ], "metabolic": [ 112, 211 ], "homeostasis,": [ 113 ], "preventing": [ 114 ], "both": [ 115 ], "hyperglycemia": [ 116 ], "hypoglycemia,": [ 118 ], "mitigating": [ 119 ], "dyslipidemia,": [ 120 ], "risk": [ 124 ], "cardiovascular": [ 126, 169, 213 ], "diseases": [ 127 ], "individuals": [ 129 ], "type": [ 131, 155 ], "2": [ 132, 156 ], "diabetes": [ 133 ], "obesity.": [ 135 ], "Several": [ 136 ], "dual": [ 139 ], "GIP/GLP-1": [ 140 ], "receptor": [ 141 ], "agonists": [ 142 ], "have": [ 143 ], "been": [ 144 ], "developed": [ 145 ], "harness": [ 147 ], "pharmacological": [ 149 ], "treatment": [ 153, 198 ], "diabetes,": [ 157 ], "some": [ 159 ], "demonstrating": [ 160 ], "robust": [ 161 ], "effectiveness": [ 162 ], "weight": [ 164 ], "management": [ 165, 209 ], "prevention": [ 167 ], "diseases.": [ 170, 214 ], "Elucidating": [ 171 ], "underlying": [ 173 ], "cellular": [ 174 ], "molecular": [ 176 ], "mechanisms": [ 177 ], "could": [ 178 ], "potentially": [ 179 ], "usher": [ 180 ], "development": [ 183 ], "new": [ 185 ], "generations": [ 186 ], "incretin": [ 188 ], "mimetics": [ 189 ], "enhanced": [ 191 ], "efficacy": [ 192 ], "fewer": [ 194 ], "adverse": [ 195 ], "effects.": [ 196 ], "The": [ 197 ], "guidelines": [ 199 ], "evolving": [ 201 ], "based": [ 202 ], "clinical": [ 204 ], "trial": [ 205 ], "outcomes,": [ 206 ], "shaping": [ 207 ] }, "publication_date": "2024-07-24", "publication_year": 2024, "type": "review", "cited_by_count": 94, "authors": [ { "id": "https://openalex.org/A5077960280", "display_name": "Qiyuan Keith Liu" } ] }, { "id": "https://openalex.org/W1984845045", "doi": "https://doi.org/10.1016/j.regpep.2008.07.003", "title": "Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes", "abstract": null, "publication_date": "2008-07-17", "publication_year": 2008, "type": "article", "cited_by_count": 255, "authors": [ { "id": "https://openalex.org/A5064098013", "display_name": "Helle Linnebjerg" }, { "id": "https://openalex.org/A5100716431", "display_name": "Soomin Park" }, { "id": "https://openalex.org/A5079794570", "display_name": "Prajakti A. Kothare" }, { "id": "https://openalex.org/A5062021087", "display_name": "Michael Trautmann" }, { "id": "https://openalex.org/A5058443646", "display_name": "Kenneth Mace" }, { "id": "https://openalex.org/A5083503351", "display_name": "Mark Fineman" }, { "id": "https://openalex.org/A5111695883", "display_name": "Ian R. Wilding" }, { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5069463167", "display_name": "Michael Horowitz" } ] }, { "id": "https://openalex.org/W2899627734", "doi": "https://doi.org/10.3389/fendo.2018.00649", "title": "Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD", "abstract": { "Along": [ 0 ], "the": [ 1, 4, 15, 19, 26, 38, 44, 80, 119, 174, 179, 190, 197, 207 ], "obesity": [ 2 ], "pandemic,": [ 3 ], "prevalence": [ 5 ], "of": [ 6, 18, 40, 82, 121, 176, 182, 199, 209 ], "non-alcoholic": [ 7 ], "fatty": [ 8 ], "liver": [ 9, 28, 107 ], "disease": [ 10, 29 ], "(NAFLD),": [ 11 ], "often": [ 12 ], "regarded": [ 13 ], "as": [ 14, 131, 133 ], "hepatic": [ 16 ], "manifestation": [ 17 ], "metabolic": [ 20 ], "syndrome,": [ 21 ], "increases": [ 22 ], "worldwide": [ 23 ], "representing": [ 24 ], "now": [ 25 ], "prevalent": [ 27 ], "in": [ 30, 151, 173, 206 ], "western": [ 31 ], "countries.": [ 32 ], "No": [ 33 ], "pharmacotherapy": [ 34 ], "is": [ 35, 47, 115, 149 ], "approved": [ 36, 78 ], "for": [ 37, 79, 118 ], "treatment": [ 39, 46, 81, 120, 164, 208 ], "NAFLD": [ 41, 122, 163 ], "and,": [ 42 ], "currently,": [ 43 ], "cornerstone": [ 45 ], "lifestyle": [ 48 ], "modifications": [ 49 ], "focusing": [ 50 ], "on": [ 51 ], "bodyweight": [ 52 ], "loss,": [ 53 ], "notoriously": [ 54 ], "difficult": [ 55, 61 ], "to": [ 56, 62, 105, 124, 136, 189 ], "obtain": [ 57 ], "and": [ 58, 86, 97, 109, 127, 140, 184, 194, 202 ], "even": [ 59 ], "more": [ 60 ], "maintain.": [ 63 ], "Thus,": [ 64 ], "novel": [ 65 ], "therapeutic": [ 66 ], "approaches": [ 67 ], "are": [ 68, 77 ], "highly": [ 69 ], "demanded.": [ 70 ], "Glucagon-like": [ 71 ], "peptide-1": [ 72 ], "(GLP-1)": [ 73 ], "receptor": [ 74, 113, 147, 157, 204 ], "agonists": [ 75 ], "(GLP-1RAs)": [ 76 ], "type": [ 83 ], "2": [ 84 ], "diabetes": [ 85 ], "obesity.": [ 87 ], "They": [ 88 ], "exert": [ 89 ], "their": [ 90 ], "body": [ 91 ], "weight-lowering": [ 92 ], "effect": [ 93 ], "by": [ 94 ], "reducing": [ 95 ], "satiety": [ 96 ], "food": [ 98, 128 ], "intake.": [ 99 ], "GLP-1RAs": [ 100, 193, 201 ], "have": [ 101 ], "also": [ 102 ], "been": [ 103 ], "shown": [ 104 ], "reduce": [ 106 ], "inflammation": [ 108 ], "fibrosis.": [ 110 ], "Furthermore,": [ 111 ], "glucagon": [ 112, 146, 156 ], "agonism": [ 114, 158 ], "being": [ 116 ], "investigated": [ 117 ], "due": [ 123 ], "its": [ 125, 134 ], "appetite": [ 126 ], "intake-reducing": [ 129 ], "effects,": [ 130 ], "well": [ 132 ], "ability": [ 135 ], "increase": [ 137 ], "lipid": [ 138 ], "oxidation": [ 139 ], "thermogenesis.": [ 141 ], "Recent": [ 142 ], "studies": [ 143 ], "suggest": [ 144 ], "that": [ 145, 154 ], "signaling": [ 148 ], "disrupted": [ 150 ], "NAFLD,": [ 152, 177 ], "indicating": [ 153 ], "supra-physiological": [ 155 ], "might": [ 159 ], "represent": [ 160 ], "a": [ 161 ], "new": [ 162 ], "target.": [ 165 ], "The": [ 166 ], "present": [ 167 ], "review": [ 168 ], "provides": [ 169 ], "(1)": [ 170 ], "an": [ 171, 187 ], "overview": [ 172 ], "pathophysiology": [ 175 ], "including": [ 178 ], "potential": [ 180, 198 ], "involvement": [ 181 ], "GLP-1": [ 183 ], "glucagon,": [ 185 ], "(2)": [ 186 ], "introduction": [ 188 ], "currently": [ 191 ], "available": [ 192 ], "(3)": [ 195 ], "outlines": [ 196 ], "emerging": [ 200 ], "GLP-1/glucagon": [ 203 ], "co-agonists": [ 205 ], "NAFLD.": [ 210 ] }, "publication_date": "2018-11-06", "publication_year": 2018, "type": "review", "cited_by_count": 84, "authors": [ { "id": "https://openalex.org/A5042009011", "display_name": "Marta Seghieri" }, { "id": "https://openalex.org/A5048013842", "display_name": "Alexander S. Christensen" }, { "id": "https://openalex.org/A5079170139", "display_name": "Andreas Andersen" }, { "id": "https://openalex.org/A5045879499", "display_name": "Anna Solini" }, { "id": "https://openalex.org/A5079352451", "display_name": "Filip K. Knop" }, { "id": "https://openalex.org/A5004120950", "display_name": "Tina Vilsb\u00f8ll" } ] }, { "id": "https://openalex.org/W2571824959", "doi": "https://doi.org/10.1080/14740338.2017.1281246", "title": "Cardiovascular safety and benefits of GLP-1 receptor agonists", "abstract": { "Glucagon-like": [ 0 ], "peptide-1": [ 1 ], "(GLP-1)": [ 2 ], "receptor": [ 3 ], "agonists": [ 4 ], "(GLP-1RAs)": [ 5 ], "constitute": [ 6 ], "a": [ 7, 40, 124, 144 ], "class": [ 8 ], "of": [ 9, 14, 43, 91, 96, 110, 131, 139, 183, 206, 213, 222, 232, 245 ], "drugs": [ 10 ], "for": [ 11, 192, 203 ], "the": [ 12, 29, 47, 97, 140, 165, 204, 207, 211, 225, 230 ], "treatment": [ 13, 173, 212 ], "type": [ 15, 59, 82, 101, 177, 216, 238 ], "2": [ 16, 60, 83, 102, 178, 217, 239 ], "diabetes,": [ 17 ], "and": [ 18, 39, 62, 69, 155, 159, 168, 180, 188, 194, 219, 229 ], "currently,": [ 19 ], "six": [ 20 ], "different": [ 21 ], "GLP-1RAs": [ 22, 30, 99, 142, 209, 233 ], "are": [ 23, 185 ], "approved.": [ 24 ], "Besides": [ 25 ], "improving": [ 26 ], "glycemic": [ 27 ], "control,": [ 28 ], "have": [ 31, 71 ], "other": [ 32 ], "beneficial": [ 33 ], "effects": [ 34, 150 ], "such": [ 35 ], "as": [ 36 ], "weight": [ 37 ], "loss": [ 38 ], "low": [ 41 ], "risk": [ 42, 80, 90, 109, 153, 182, 221, 244 ], "hypoglycemia.": [ 44 ], "Treatment": [ 45 ], "with": [ 46, 58, 86, 105, 143, 171, 176, 215, 242 ], "GLP-1RA": [ 48, 172 ], "lixisenatide": [ 49 ], "has": [ 50 ], "been": [ 51, 72 ], "shown": [ 52, 73 ], "to": [ 53, 74, 135, 234 ], "be": [ 54, 201 ], "safe": [ 55 ], "in": [ 56, 81, 100, 174, 210, 237 ], "patients": [ 57, 85, 104, 175, 214, 241 ], "diabetes": [ 61, 84, 103, 179, 218, 240 ], "recent": [ 63 ], "acute": [ 64 ], "coronary": [ 65 ], "syndrome.": [ 66 ], "Furthermore,": [ 67 ], "liraglutide": [ 68, 193 ], "semaglutide": [ 70 ], "reduce": [ 75 ], "cardiovascular": [ 76 ], "(CV)": [ 77 ], "disease": [ 78 ], "(CVD)": [ 79 ], "established": [ 87, 106 ], "and/or": [ 88, 107 ], "high": [ 89, 108, 181, 220 ], "CVD.": [ 92, 223 ], "The": [ 93, 129 ], "CV": [ 94, 116, 152, 157, 166, 227 ], "safety": [ 95, 158, 228 ], "remaining": [ 98 ], "CVD": [ 111, 184, 236, 246 ], "remains": [ 112 ], "uncertain,": [ 113 ], "but": [ 114 ], "ongoing": [ 115, 198 ], "outcome": [ 117 ], "trials": [ 118 ], "(CVOTs)": [ 119 ], "will": [ 120, 200 ], "elucidate": [ 121 ], "this": [ 122, 132 ], "within": [ 123 ], "few": [ 125 ], "years.": [ 126 ], "Areas": [ 127 ], "covered:": [ 128 ], "aim": [ 130 ], "review": [ 133 ], "is": [ 134 ], "provide": [ 136 ], "an": [ 137 ], "overview": [ 138 ], "existing": [ 141 ], "particular": [ 145 ], "focus": [ 146 ], "on": [ 147, 151, 164 ], "their": [ 148, 156 ], "clinical": [ 149 ], "factors": [ 154 ], "benefits.": [ 160 ], "Expert": [ 161 ], "opinion:": [ 162 ], "Data": [ 163, 196 ], "risks": [ 167 ], "benefits": [ 169 ], "associated": [ 170 ], "emerging": [ 186 ], "-": [ 187 ], "look": [ 189 ], "promising": [ 190 ], "(especially": [ 191 ], "semaglutide).": [ 195 ], "from": [ 197 ], "CVOTs": [ 199 ], "crucial": [ 202 ], "positioning": [ 205 ], "individual": [ 208 ], "However,": [ 224 ], "long-term": [ 226 ], "potential": [ 231 ], "prevent": [ 235 ], "less": [ 243 ], "(e.g.": [ 247 ], "newly": [ 248 ], "diagnosed": [ 249 ], "patients)": [ 250 ], "remain": [ 251 ], "uncertain.": [ 252 ] }, "publication_date": "2017-01-19", "publication_year": 2017, "type": "article", "cited_by_count": 34, "authors": [ { "id": "https://openalex.org/A5011619068", "display_name": "Niels B. Dalsgaard" }, { "id": "https://openalex.org/A5024869586", "display_name": "Andreas Br\u00f8nden" }, { "id": "https://openalex.org/A5004120950", "display_name": "Tina Vilsb\u00f8ll" }, { "id": "https://openalex.org/A5079352451", "display_name": "Filip K. Knop" } ] }, { "id": "https://openalex.org/W2174832318", "doi": "https://doi.org/10.1007/s40262-015-0343-6", "title": "Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics", "abstract": null, "publication_date": "2015-11-23", "publication_year": 2015, "type": "review", "cited_by_count": 200, "authors": [ { "id": "https://openalex.org/A5112171221", "display_name": "Lisbeth V. Jacobsen" }, { "id": "https://openalex.org/A5019076349", "display_name": "Anne Flint" }, { "id": "https://openalex.org/A5082276988", "display_name": "Annette Olsen" }, { "id": "https://openalex.org/A5109417363", "display_name": "Steen H. Ingwersen" } ] }, { "id": "https://openalex.org/W4308952350", "doi": "https://doi.org/10.1016/j.phrs.2022.106550", "title": "Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment", "abstract": null, "publication_date": "2022-11-11", "publication_year": 2022, "type": "review", "cited_by_count": 196, "authors": [ { "id": "https://openalex.org/A5017288216", "display_name": "Katherine O. Kopp" }, { "id": "https://openalex.org/A5012561586", "display_name": "Elliot J. Glotfelty" }, { "id": "https://openalex.org/A5100669061", "display_name": "Yazhou Li" }, { "id": "https://openalex.org/A5056649584", "display_name": "Nigel H. Greig" } ] }, { "id": "https://openalex.org/W2542456927", "doi": "https://doi.org/10.1002/ejhf.657", "title": "Effect of liraglutide, a glucagon\u2010like peptide\u20101 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)\u2014a multicentre, double\u2010blind, randomised, placebo\u2010controlled trial", "abstract": { "Aims": [ 0 ], "To": [ 1 ], "determine": [ 2 ], "the": [ 3, 6, 89, 92, 109, 112, 159, 213, 231 ], "effect": [ 4 ], "of": [ 5, 215, 233, 238 ], "glucagon\u2010like": [ 7 ], "peptide\u20101": [ 8 ], "analogue": [ 9 ], "liraglutide": [ 10, 71, 90, 110, 131, 152, 190, 216, 234 ], "on": [ 11, 64, 230 ], "left": [ 12, 45, 171, 225 ], "ventricular": [ 13, 46, 172, 226 ], "function": [ 14, 174 ], "in": [ 15, 88, 103, 146, 158, 178, 196, 217, 235 ], "chronic": [ 16, 180, 220 ], "heart": [ 17, 66, 181, 197, 221, 239 ], "failure": [ 18, 67, 182, 222, 240 ], "patients": [ 19, 149, 157, 183, 218, 241 ], "with": [ 20, 43, 130, 151, 154, 176, 184, 189, 193, 210, 219 ], "and": [ 21, 27, 63, 91, 111, 185, 199, 205, 223 ], "without": [ 22, 186 ], "type": [ 23 ], "2": [ 24 ], "diabetes.": [ 25, 187 ], "Methods": [ 26 ], "results": [ 28 ], "LIVE": [ 29 ], "was": [ 30, 70, 84, 120, 191 ], "an": [ 31, 194 ], "investigator\u2010initiated,": [ 32 ], "randomised,": [ 33 ], "double\u2010blinded,": [ 34 ], "placebo\u2010controlled": [ 35 ], "multicentre": [ 36 ], "trial.": [ 37 ], "Patients": [ 38, 59 ], "(": [ 39, 49, 162 ], "n": [ 40 ], "=": [ 41, 125, 164 ], "241)": [ 42 ], "reduced": [ 44, 224 ], "ejection": [ 47 ], "fraction": [ 48 ], "LVEF": [ 50, 83, 104 ], "\u226445%)": [ 51 ], "were": [ 52, 60, 144 ], "recruited": [ 53 ], "(February": [ 54 ], "2012": [ 55 ], "to": [ 56, 212 ], "August": [ 57 ], "2015).": [ 58 ], "clinically": [ 61 ], "stable": [ 62, 179 ], "optimal": [ 65 ], "treatment.": [ 68 ], "Intervention": [ 69 ], "1.8": [ 72 ], "mg": [ 73 ], "once": [ 74 ], "daily": [ 75 ], "or": [ 76 ], "matching": [ 77 ], "placebo": [ 78, 93, 113, 160, 177 ], "for": [ 79 ], "24": [ 80 ], "weeks.": [ 81 ], "The": [ 82 ], "similar": [ 85 ], "at": [ 86 ], "baseline": [ 87 ], "group": [ 94, 161 ], "(33.7": [ 95 ], "\u00b1": [ 96, 100 ], "7.6%": [ 97 ], "vs.": [ 98 ], "35.4": [ 99 ], "9.4%).": [ 101 ], "Change": [ 102 ], "did": [ 105, 168 ], "not": [ 106, 169 ], "differ": [ 107 ], "between": [ 108 ], "group;": [ 114 ], "mean": [ 115 ], "difference": [ 116 ], "(95%": [ 117 ], "confidence": [ 118 ], "interval)": [ 119 ], "\u22120.8%": [ 121 ], "(\u22122.1,": [ 122 ], "0.5;": [ 123 ], "P": [ 124, 138, 163 ], "0.24).": [ 126 ], "Heart": [ 127 ], "rate": [ 128, 198 ], "increased": [ 129 ], "[mean": [ 132 ], "difference:": [ 133 ], "7": [ 134 ], "b.p.m.": [ 135 ], "(5,": [ 136 ], "9),": [ 137 ], "<": [ 139 ], "0.0001].": [ 140 ], "Serious": [ 141 ], "cardiac": [ 142, 202 ], "events": [ 143 ], "seen": [ 145 ], "12": [ 147 ], "(10%)": [ 148 ], "treated": [ 150 ], "compared": [ 153, 175 ], "3": [ 155 ], "(3%)": [ 156 ], "0.04).": [ 165 ], "Conclusion": [ 166 ], "Liraglutide": [ 167 ], "affect": [ 170 ], "systolic": [ 173 ], "Treatment": [ 188 ], "associated": [ 192 ], "increase": [ 195 ], "more": [ 200 ], "serious": [ 201 ], "adverse": [ 203 ], "events,": [ 204 ], "this": [ 206 ], "raises": [ 207 ], "some": [ 208 ], "concern": [ 209 ], "respect": [ 211 ], "use": [ 214 ], "function.": [ 227 ], "More": [ 228 ], "data": [ 229 ], "safety": [ 232 ], "different": [ 236 ], "subgroups": [ 237 ], "are": [ 242 ], "needed.": [ 243 ] }, "publication_date": "2016-10-28", "publication_year": 2016, "type": "article", "cited_by_count": 497, "authors": [ { "id": "https://openalex.org/A5070545719", "display_name": "Anders Jorsal" }, { "id": "https://openalex.org/A5053899216", "display_name": "Caroline Kistorp" }, { "id": "https://openalex.org/A5049290759", "display_name": "Pernille Holmager" }, { "id": "https://openalex.org/A5010064968", "display_name": "Rasmus Stilling Tougaard" }, { "id": "https://openalex.org/A5066472039", "display_name": "Roni Nielsen" }, { "id": "https://openalex.org/A5070171928", "display_name": "Anja H\u00e4nselmann" }, { "id": "https://openalex.org/A5105359338", "display_name": "Brian Nilsson" }, { "id": "https://openalex.org/A5100668347", "display_name": "Jacob Eifer M\u00f8ller" }, { "id": "https://openalex.org/A5015935565", "display_name": "Jakob Hjort" }, { "id": "https://openalex.org/A5009690083", "display_name": "Jon Rasmussen" }, { "id": "https://openalex.org/A5059839635", "display_name": "Trine Well\u00f8v Boesgaard" }, { "id": "https://openalex.org/A5032789207", "display_name": "Morten Schou" }, { "id": "https://openalex.org/A5022050813", "display_name": "Lars Videb\u00e6k" }, { "id": "https://openalex.org/A5009799168", "display_name": "Finn Gustafsson" }, { "id": "https://openalex.org/A5041201756", "display_name": "Allan Flyvbjerg" }, { "id": "https://openalex.org/A5025152450", "display_name": "Henrik Wiggers" }, { "id": "https://openalex.org/A5070884818", "display_name": "Lise Tarnow" } ] }, { "id": "https://openalex.org/W4323981273", "doi": "https://doi.org/10.1093/brain/awad003", "title": "The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial", "abstract": { "Abstract": [ 0 ], "Therapeutics": [ 1 ], "to": [ 2, 17, 41, 187, 189, 202 ], "reduce": [ 3 ], "intracranial": [ 4, 19, 52, 56, 59, 64, 75, 95, 135, 146, 196, 213 ], "pressure": [ 5, 20, 53, 60, 65, 78, 96, 136, 147 ], "are": [ 6 ], "an": [ 7 ], "unmet": [ 8 ], "need.": [ 9 ], "Preclinical": [ 10 ], "data": [ 11, 184 ], "have": [ 12 ], "demonstrated": [ 13 ], "a": [ 14, 36, 47, 108, 190 ], "novel": [ 15 ], "strategy": [ 16 ], "lower": [ 18 ], "using": [ 21 ], "glucagon-like": [ 22 ], "peptide-1": [ 23 ], "(GLP-1)": [ 24 ], "receptor": [ 25, 49, 205 ], "signalling.": [ 26 ], "Here,": [ 27 ], "we": [ 28 ], "translate": [ 29 ], "these": [ 30 ], "findings": [ 31 ], "into": [ 32 ], "patients": [ 33 ], "by": [ 34, 211 ], "conducting": [ 35 ], "randomized,": [ 37 ], "placebo-controlled,": [ 38 ], "double-blind": [ 39 ], "trial": [ 40, 68, 193 ], "assess": [ 42 ], "the": [ 43, 115, 121, 200 ], "effect": [ 44 ], "of": [ 45 ], "exenatide,": [ 46 ], "GLP-1": [ 48, 204 ], "agonist,": [ 50 ], "on": [ 51 ], "in": [ 54, 194, 207 ], "idiopathic": [ 55, 74, 195 ], "hypertension.": [ 57 ], "Telemetric": [ 58 ], "catheters": [ 61 ], "enabled": [ 62 ], "long-term": [ 63 ], "monitoring.": [ 66 ], "The": [ 67, 89 ], "enrolled": [ 69 ], "adult": [ 70 ], "women": [ 71, 117 ], "with": [ 72 ], "active": [ 73 ], "hypertension": [ 76, 197 ], "(intracranial": [ 77 ], "&gt;25": [ 79 ], "cmCSF": [ 80, 154, 163, 173 ], "and": [ 81, 102, 105, 143, 167, 198 ], "papilloedema)": [ 82 ], "who": [ 83 ], "receive": [ 84 ], "subcutaneous": [ 85 ], "exenatide": [ 86 ], "or": [ 87 ], "placebo.": [ 88 ], "three": [ 90 ], "primary": [ 91 ], "outcome": [ 92 ], "measures": [ 93 ], "were": [ 94, 181 ], "at": [ 97, 110, 148 ], "2.5": [ 98, 149 ], "h,": [ 99 ], "24": [ 100, 158 ], "h": [ 101, 150, 159 ], "12": [ 103, 168 ], "weeks": [ 104, 169 ], "alpha": [ 106 ], "set": [ 107 ], "priori": [ 109 ], "less": [ 111 ], "than": [ 112 ], "0.1.": [ 113 ], "Among": [ 114 ], "16": [ 116 ], "recruited,": [ 118 ], "15": [ 119 ], "completed": [ 120 ], "study": [ 122 ], "(mean": [ 123 ], "age": [ 124 ], "28": [ 125 ], "\u00b1": [ 126, 132, 138, 152, 161, 171 ], "9,": [ 127 ], "body": [ 128 ], "mass": [ 129 ], "index": [ 130 ], "38.1": [ 131 ], "6.2": [ 133 ], "kg/m2,": [ 134 ], "30.6": [ 137 ], "5.1": [ 139 ], "cmCSF).": [ 140 ], "Exenatide": [ 141 ], "significantly": [ 142 ], "meaningfully": [ 144 ], "lowered": [ 145 ], "\u22125.7": [ 151 ], "2.9": [ 153, 162 ], "(P": [ 155, 164, 174 ], "=": [ 156, 165, 175 ], "0.048);": [ 157 ], "\u22126.4": [ 160 ], "0.030);": [ 166 ], "\u22125.6": [ 170 ], "3.0": [ 172 ], "0.058).": [ 176 ], "No": [ 177 ], "serious": [ 178 ], "safety": [ 179 ], "signals": [ 180 ], "noted.": [ 182 ], "These": [ 183 ], "provide": [ 185 ], "confidence": [ 186 ], "proceed": [ 188 ], "phase": [ 191 ], "3": [ 192 ], "highlight": [ 199 ], "potential": [ 201 ], "utilize": [ 203 ], "agonist": [ 206 ], "other": [ 208 ], "conditions": [ 209 ], "characterized": [ 210 ], "raised": [ 212 ], "pressure.": [ 214 ] }, "publication_date": "2023-03-13", "publication_year": 2023, "type": "article", "cited_by_count": 111, "authors": [ { "id": "https://openalex.org/A5089294491", "display_name": "James Mitchell" }, { "id": "https://openalex.org/A5072997413", "display_name": "Hannah Lyons" }, { "id": "https://openalex.org/A5038928990", "display_name": "Jessica Walker" }, { "id": "https://openalex.org/A5009672224", "display_name": "Andreas Yiangou" }, { "id": "https://openalex.org/A5075744602", "display_name": "Olivia Grech" }, { "id": "https://openalex.org/A5043293131", "display_name": "Zerin Alimajstorovic" }, { "id": "https://openalex.org/A5056649584", "display_name": "Nigel H. Greig" }, { "id": "https://openalex.org/A5100669061", "display_name": "Yazhou Li" }, { "id": "https://openalex.org/A5026984500", "display_name": "Georgios Tsermoulas" }, { "id": "https://openalex.org/A5019472985", "display_name": "Kristian Brock" }, { "id": "https://openalex.org/A5063268602", "display_name": "Susan P. Mollan" }, { "id": "https://openalex.org/A5073278152", "display_name": "Alexandra J. Sinclair" } ] }, { "id": "https://openalex.org/W2315065708", "doi": "https://doi.org/10.1007/s00125-016-3938-z", "title": "Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial", "abstract": null, "publication_date": "2016-04-01", "publication_year": 2016, "type": "article", "cited_by_count": 119, "authors": [ { "id": "https://openalex.org/A5067721247", "display_name": "Lennart Tonneijck" }, { "id": "https://openalex.org/A5091895526", "display_name": "Mark M. Smits" }, { "id": "https://openalex.org/A5084278641", "display_name": "Marcel H.A. Muskiet" }, { "id": "https://openalex.org/A5016447558", "display_name": "Trynke Hoekstra" }, { "id": "https://openalex.org/A5028760009", "display_name": "Mark H.H. Kramer" }, { "id": "https://openalex.org/A5046295598", "display_name": "A.H. Jan Danser" }, { "id": "https://openalex.org/A5109335776", "display_name": "Micha\u00ebla Diamant" }, { "id": "https://openalex.org/A5062438369", "display_name": "Jaap A. Joles" }, { "id": "https://openalex.org/A5067127165", "display_name": "Dani\u00ebl H. van Raalte" } ] }, { "id": "https://openalex.org/W3200615296", "doi": "https://doi.org/10.1155/2021/3361309", "title": "Effects of GLP\u20101 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52\u2010Week Clinical Study", "abstract": { "Introduction": [ 0 ], ".": [ 1, 43, 104, 292, 336 ], "Hypoglycemic": [ 2 ], "drugs": [ 3 ], "affect": [ 4 ], "the": [ 5, 9, 25, 64, 108, 115, 164, 167, 170, 175, 179, 182, 191, 200, 203, 219, 224, 228, 242, 245, 248, 255, 259, 272, 275, 280, 295, 307, 315 ], "bone": [ 6, 36, 318 ], "quality": [ 7 ], "and": [ 8, 33, 84, 95, 144, 209, 233, 251, 258 ], "risk": [ 10 ], "of": [ 11, 27, 50, 169, 181, 193, 205, 230, 247, 277, 301, 306, 317 ], "fractures": [ 12 ], "in": [ 13, 40, 114, 199, 218, 223, 254, 279 ], "patients": [ 14, 52, 326 ], "with": [ 15, 53, 106, 241, 271, 294, 327, 333 ], "type": [ 16 ], "2": [ 17 ], "diabetes": [ 18 ], "mellitus": [ 19 ], "(T2DM).": [ 20 ], "We": [ 21 ], "aimed": [ 22 ], "to": [ 23 ], "investigate": [ 24 ], "effects": [ 26 ], "glucagon\u2010like": [ 28 ], "peptide\u20101": [ 29 ], "receptor": [ 30 ], "agonists": [ 31 ], "(GLP\u20101RAs)": [ 32 ], "insulin": [ 34, 77, 145, 225, 260, 281 ], "on": [ 35 ], "mineral": [ 37 ], "density": [ 38 ], "(BMD)": [ 39 ], "T2DM.": [ 41, 328 ], "Methods": [ 42 ], "In": [ 44, 163, 174 ], "this": [ 45 ], "single\u2010blinded": [ 46 ], "study,": [ 47 ], "a": [ 48 ], "total": [ 49, 171, 210, 252 ], "65": [ 51 ], "T2DM": [ 54 ], "were": [ 55, 93, 263 ], "randomly": [ 56 ], "assigned": [ 57 ], "into": [ 58 ], "four": [ 59 ], "groups": [ 60, 160 ], "for": [ 61, 325 ], "52": [ 62 ], "weeks:": [ 63 ], "exenatide": [ 65, 116, 165, 256, 273 ], "group": [ 66, 72, 79, 257, 262, 283 ], "(": [ 67, 73, 80, 86, 186, 214, 236, 266, 287 ], "n": [ 68, 74, 81, 87 ], "=": [ 69, 75, 82, 88, 128, 188, 289 ], "19),": [ 70, 76 ], "dulaglutide": [ 71, 130, 176 ], "glargine": [ 78, 146, 226, 261, 282 ], "10),": [ 83 ], "placebo": [ 85, 201, 220, 243 ], "17).": [ 89 ], "General": [ 90 ], "clinical": [ 91 ], "data": [ 92 ], "collected,": [ 94 ], "BMD": [ 96, 168, 180, 204, 229, 246, 276, 302 ], "was": [ 97, 195, 284 ], "measured": [ 98 ], "by": [ 99 ], "dual\u2010energy": [ 100 ], "X\u2010ray": [ 101 ], "absorptiometry.": [ 102 ], "Results": [ 103 ], "Compared": [ 105, 240, 293 ], "baseline,": [ 107 ], "glycosylated": [ 109 ], "hemoglobin": [ 110 ], "(HbA1c)": [ 111 ], "decreased": [ 112, 185, 212 ], "significantly": [ 113, 213, 265 ], "(8.11": [ 117 ], "\u00b1": [ 118, 123, 132, 137, 148, 153 ], "0.24": [ 119, 149 ], "%": [ 120, 125, 134, 139, 150, 155 ], "vs.": [ 121, 135, 151 ], "7.40": [ 122 ], "0.16": [ 124 ], ",": [ 126, 140, 156 ], "P": [ 127, 141, 157, 187, 215, 237, 267, 288 ], "0.007),": [ 129 ], "(8.77": [ 131 ], "0.37": [ 133 ], "7.06": [ 136 ], "0.28": [ 138 ], "<": [ 142, 158, 216, 238, 268 ], "0.001),": [ 143 ], "(8.57": [ 147 ], "7.23": [ 152 ], "0.25": [ 154 ], "0.001)": [ 159 ], "after": [ 161, 309 ], "treatment.": [ 162 ], "group,": [ 166, 177, 221, 227, 244, 274 ], "hip": [ 172, 211, 253 ], "increased.": [ 173 ], "only": [ 178 ], "femoral": [ 183, 207, 249 ], "neck": [ 184, 250 ], "0.027),": [ 189 ], "but": [ 190 ], "magnitude": [ 192 ], "decrease": [ 194 ], "less": [ 196 ], "than": [ 197 ], "that": [ 198 ], "group;": [ 202 ], "L1\u2010L4,": [ 206 ], "neck,": [ 208 ], "0.05)": [ 217 ], "while": [ 222 ], "L2,": [ 231 ], "L4,": [ 232 ], "L1\u20104": [ 234 ], "increased": [ 235, 264, 286 ], "0.05).": [ 239 ], "0.05);": [ 269 ], "compared": [ 270 ], "L4": [ 278 ], "also": [ 285 ], "0.001).": [ 290 ], "Conclusions": [ 291 ], "placebo,": [ 296 ], "GLP\u20101RAs": [ 297, 321 ], "demonstrated": [ 298 ], "an": [ 299 ], "increase": [ 300 ], "at": [ 303 ], "multiple": [ 304 ], "sites": [ 305 ], "body": [ 308 ], "treatment,": [ 310 ], "which": [ 311 ], "may": [ 312 ], "not": [ 313 ], "exacerbate": [ 314 ], "consequences": [ 316 ], "fragility.": [ 319 ], "Therefore,": [ 320 ], "might": [ 322 ], "be": [ 323 ], "considered": [ 324 ], "This": [ 329 ], "trial": [ 330 ], "is": [ 331 ], "registered": [ 332 ], "ClinicalTrials.gov": [ 334 ], "NCT01648582": [ 335 ] }, "publication_date": "2021-01-01", "publication_year": 2021, "type": "article", "cited_by_count": 65, "authors": [ { "id": "https://openalex.org/A5102832964", "display_name": "Tingting Cai" }, { "id": "https://openalex.org/A5100678639", "display_name": "Huiqin Li" }, { "id": "https://openalex.org/A5103229061", "display_name": "Lanlan Jiang" }, { "id": "https://openalex.org/A5109539024", "display_name": "Huiying Wang" }, { "id": "https://openalex.org/A5101854195", "display_name": "Meng-hui Luo" }, { "id": "https://openalex.org/A5101901750", "display_name": "Xiaofei Su" }, { "id": "https://openalex.org/A5070820936", "display_name": "Jianhua Ma" } ] }, { "id": "https://openalex.org/W2001097346", "doi": "https://doi.org/10.1111/j.1365-2125.2007.02890.x", "title": "Effect of renal impairment on the pharmacokinetics of exenatide", "abstract": { "What": [ 0, 42 ], "is": [ 1, 14, 63 ], "already": [ 2 ], "known": [ 3, 25 ], "about": [ 4 ], "this": [ 5, 43 ], "subject": [ 6 ], "\u2022": [ 7, 21, 46, 60 ], "Nonclinical": [ 8 ], "studies": [ 9, 171 ], "have": [ 10, 277 ], "shown": [ 11 ], "that": [ 12 ], "exenatide": [ 13, 62, 87, 183, 268, 315 ], "primarily": [ 15 ], "cleared": [ 16 ], "by": [ 17, 37, 113 ], "the": [ 18, 29, 78, 180, 249, 284, 331 ], "renal": [ 19, 39, 73, 92, 114, 154, 224 ], "system.": [ 20 ], "It": [ 22 ], "was": [ 23, 101, 244 ], "not": [ 24, 64, 256 ], "to": [ 26, 50, 178, 262, 306, 313, 316 ], "what": [ 27 ], "degree": [ 28 ], "clinical": [ 30 ], "pharmacokinetics": [ 31, 79 ], "and": [ 32, 82, 186, 197, 204, 230, 236, 251, 264, 295, 325, 337 ], "tolerability": [ 33, 83, 282, 294, 324 ], "would": [ 34, 310 ], "be": [ 35, 311 ], "affected": [ 36 ], "increasing": [ 38 ], "impairment": [ 40, 93 ], "(RI).": [ 41, 94 ], "study": [ 44 ], "adds": [ 45 ], "Patients": [ 47 ], "with": [ 48, 68, 91, 108, 167, 174, 222, 259, 274, 304 ], "mild": [ 49, 132, 193, 226, 250, 305 ], "moderate": [ 51, 142, 195, 228, 252, 307 ], "RI": [ 52, 70, 133, 143, 196, 229, 253, 343 ], "adequately": [ 53 ], "tolerate": [ 54 ], "current": [ 55 ], "therapeutic": [ 56, 287, 334 ], "doses": [ 57, 335 ], "of": [ 58, 84, 121, 182, 267 ], "exenatide.": [ 59 ], "However,": [ 61, 322 ], "recommended": [ 65 ], "in": [ 66, 89, 104, 172, 220, 248, 257, 302, 328, 341 ], "patients": [ 67, 90, 173, 273, 303, 318 ], "severe": [ 69, 342 ], "or": [ 71, 98, 152, 344 ], "end\u2010stage": [ 72, 153 ], "disease.": [ 74 ], "Aims": [ 75 ], "To": [ 76 ], "evaluate": [ 77 ], "(PK),": [ 80 ], "safety": [ 81 ], "a": [ 85, 278 ], "single": [ 86 ], "dose": [ 88 ], "Methods": [ 95 ], "Exenatide": [ 96, 243 ], "(5": [ 97, 289, 336 ], "10": [ 99, 338 ], "\u00b5g)": [ 100, 339 ], "injected": [ 102 ], "subcutaneously": [ 103 ], "31": [ 105 ], "subjects": [ 106, 221, 258 ], "(one": [ 107 ], "Type": [ 109, 175 ], "2": [ 110, 176 ], "diabetes)": [ 111 ], "stratified": [ 112 ], "function": [ 115 ], "[Cockcroft\u2013Gault": [ 116 ], "creatinine": [ 117 ], "clearance": [ 118, 184 ], "(CrCL),": [ 119 ], "number": [ 120 ], "subjects]:": [ 122 ], "normal": [ 123, 223 ], "(>80": [ 124 ], "ml": [ 125, 135, 145 ], "min": [ 126, 136, 146 ], "\u22121": [ 127, 137, 147, 240 ], ",": [ 128, 138, 148, 241 ], "n": [ 129, 139, 149, 160 ], "=": [ 130, 140, 150, 161 ], "8),": [ 131, 141 ], "(51\u201380": [ 134 ], "(31\u201350": [ 144 ], "7)": [ 151 ], "disease": [ 155 ], "(ESRD)": [ 156 ], "requiring": [ 157 ], "haemodialysis": [ 158 ], "(": [ 159 ], "8).": [ 162 ], "PK": [ 163, 296, 329 ], "data": [ 164, 210 ], "were": [ 165, 200, 232, 298 ], "combined": [ 166 ], "four": [ 168 ], "previous": [ 169 ], "single\u2010dose": [ 170 ], "diabetes": [ 177 ], "explore": [ 179 ], "relationship": [ 181 ], "(CLp/F)": [ 185 ], "CrCL.": [ 187 ], "Results": [ 188 ], "Mean": [ 189 ], "half\u2010life": [ 190 ], "for": [ 191, 218, 280 ], "healthy,": [ 192 ], "RI,": [ 194, 227, 308 ], "ESRD": [ 198, 231, 260, 275 ], "groups": [ 199 ], "1.5,": [ 201 ], "2.1,": [ 202 ], "3.2": [ 203 ], "6.0": [ 205 ], "h,": [ 206 ], "respectively.": [ 207, 242 ], "After": [ 208 ], "combining": [ 209 ], "from": [ 211 ], "multiple": [ 212 ], "studies,": [ 213 ], "least": [ 214 ], "squares": [ 215 ], "geometric": [ 216 ], "means": [ 217 ], "CLp/F": [ 219 ], "function,": [ 225 ], "8.14,": [ 233 ], "5.19,": [ 234 ], "7.11": [ 235 ], "1.3": [ 237 ], "l": [ 238 ], "h": [ 239 ], "generally": [ 245 ], "well": [ 246 ], "tolerated": [ 247 ], "groups,": [ 254 ], "but": [ 255 ], "due": [ 261 ], "nausea": [ 263 ], "vomiting.": [ 265 ], "Simulations": [ 266 ], "plasma": [ 269 ], "concentrations": [ 270 ], "also": [ 271 ], "suggest": [ 272 ], "should": [ 276 ], "propensity": [ 279 ], "poor": [ 281, 323 ], "at": [ 283 ], "lowest": [ 285 ], "available": [ 286, 333 ], "dosage": [ 288, 320 ], "\u00b5g": [ 290 ], "q.d.).": [ 291 ], "Conclusions": [ 292 ], "Since": [ 293 ], "changes": [ 297, 327 ], "considered": [ 299 ], "clinically": [ 300 ], "acceptable": [ 301 ], "it": [ 309 ], "appropriate": [ 312 ], "administer": [ 314 ], "these": [ 317 ], "without": [ 319 ], "adjustment.": [ 321 ], "significant": [ 326 ], "make": [ 330 ], "currently": [ 332 ], "unsuitable": [ 340 ], "ESRD.": [ 345 ] }, "publication_date": "2007-04-10", "publication_year": 2007, "type": "article", "cited_by_count": 198, "authors": [ { "id": "https://openalex.org/A5064098013", "display_name": "Helle Linnebjerg" }, { "id": "https://openalex.org/A5079794570", "display_name": "Prajakti A. Kothare" }, { "id": "https://openalex.org/A5100716431", "display_name": "Soomin Park" }, { "id": "https://openalex.org/A5058443646", "display_name": "Kenneth Mace" }, { "id": "https://openalex.org/A5014388321", "display_name": "Shobha Reddy" }, { "id": "https://openalex.org/A5103400317", "display_name": "Malcolm I. Mitchell" }, { "id": "https://openalex.org/A5033324762", "display_name": "R. Lins" } ] }, { "id": "https://openalex.org/W2107037013", "doi": "https://doi.org/10.2337/dc09-1203", "title": "Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes", "abstract": { "OBJECTIVE": [ 0 ], "To": [ 1 ], "assess": [ 2 ], "the": [ 3 ], "effects": [ 4 ], "of": [ 5, 139 ], "exenatide": [ 6, 63, 140 ], "on": [ 7 ], "body": [ 8 ], "weight": [ 9, 45, 106, 156 ], "and": [ 10, 137, 141, 153, 169 ], "glucose": [ 11, 21, 27, 163 ], "tolerance": [ 12, 22, 164 ], "in": [ 13, 104, 135, 155, 158, 165 ], "nondiabetic": [ 14, 159 ], "obese": [ 15 ], "subjects": [ 16, 34, 81, 166 ], "with": [ 17, 73, 94, 161, 167 ], "normal": [ 18 ], "or": [ 19, 24, 56, 67, 129 ], "impaired": [ 20, 25 ], "(IGT)": [ 23 ], "fasting": [ 26 ], "(IFG).": [ 28 ], "RESEARCH": [ 29 ], "DESIGN": [ 30 ], "AND": [ 31 ], "METHODS": [ 32 ], "Obese": [ 33 ], "(n": [ 35, 64, 69 ], "=": [ 36, 65, 70 ], "152;": [ 37 ], "age": [ 38 ], "46": [ 39 ], "\u00b1": [ 40, 47, 52, 84, 91, 110 ], "12": [ 41 ], "years,": [ 42 ], "female": [ 43 ], "82%,": [ 44 ], "108.6": [ 46 ], "23.0": [ 48 ], "kg,": [ 49 ], "BMI": [ 50 ], "39.6": [ 51 ], "7.0": [ 53 ], "kg/m2,": [ 54 ], "IGT": [ 55, 128, 168 ], "IFG": [ 57, 130 ], "25%)": [ 58 ], "were": [ 59 ], "randomized": [ 60 ], "to": [ 61 ], "receive": [ 62 ], "73)": [ 66 ], "placebo": [ 68, 95, 142 ], "79),": [ 71 ], "along": [ 72 ], "lifestyle": [ 74, 148 ], "intervention,": [ 75 ], "for": [ 76 ], "24": [ 77 ], "weeks.": [ 78 ], "RESULTS": [ 79 ], "Exenatide-treated": [ 80 ], "lost": [ 82 ], "5.1": [ 83 ], "0.5": [ 85, 92 ], "kg": [ 86, 93 ], "from": [ 87 ], "baseline": [ 88 ], "versus": [ 89 ], "1.6": [ 90 ], "(exenatide": [ 96 ], "\u2212": [ 97 ], "placebo,": [ 98, 125 ], "P": [ 99 ], "&lt;": [ 100, 113 ], "0.001).": [ 101, 114 ], "Placebo-subtracted": [ 102 ], "difference": [ 103 ], "percent": [ 105 ], "reduction": [ 107 ], "was": [ 108 ], "\u22123.3": [ 109 ], "0.5%": [ 111 ], "(P": [ 112 ], "Both": [ 115 ], "groups": [ 116 ], "reduced": [ 117 ], "their": [ 118 ], "daily": [ 119 ], "calorie": [ 120 ], "intake": [ 121, 152 ], "(exenatide,": [ 122 ], "\u2212449": [ 123 ], "cal;": [ 124 ], "\u2212387": [ 126 ], "cal).": [ 127 ], "normalized": [ 131 ], "at": [ 132 ], "end": [ 133 ], "point": [ 134 ], "77": [ 136 ], "56%": [ 138 ], "subjects,": [ 143 ], "respectively.": [ 144 ], "CONCLUSIONS": [ 145 ], "Exenatide": [ 146 ], "plus": [ 147 ], "modification": [ 149 ], "decreased": [ 150 ], "caloric": [ 151 ], "resulted": [ 154 ], "loss": [ 157 ], "obesity": [ 160 ], "improved": [ 162 ], "IFG.": [ 170 ] }, "publication_date": "2010-03-23", "publication_year": 2010, "type": "article", "cited_by_count": 224, "authors": [ { "id": "https://openalex.org/A5045489578", "display_name": "Julio Rosenstock" }, { "id": "https://openalex.org/A5069113394", "display_name": "Leslie J. Klaff" }, { "id": "https://openalex.org/A5064307950", "display_name": "Sherwyn Schwartz" }, { "id": "https://openalex.org/A5024896088", "display_name": "Justin Northrup" }, { "id": "https://openalex.org/A5111741705", "display_name": "John H. Holcombe" }, { "id": "https://openalex.org/A5110468882", "display_name": "Kenneth Wilhelm" }, { "id": "https://openalex.org/A5062021087", "display_name": "Michael Trautmann" } ] }, { "id": "https://openalex.org/W2159198773", "doi": "https://doi.org/10.1185/03007990802418851", "title": "Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study", "abstract": { "Although": [ 0 ], "this": [ 1 ], "study": [ 2 ], "was": [ 3 ], "limited": [ 4 ], "by": [ 5 ], "a": [ 6, 18, 29 ], "2-week": [ 7 ], "duration": [ 8 ], "of": [ 9, 64 ], "exposure,": [ 10 ], "these": [ 11 ], "data": [ 12 ], "demonstrate": [ 13 ], "that,": [ 14 ], "exenatide": [ 15, 49 ], "had:": [ 16 ], "(i)": [ 17 ], "greater": [ 19 ], "effect": [ 20, 32 ], "than": [ 21 ], "sitagliptin": [ 22 ], "to": [ 23, 33, 47 ], "lower": [ 24 ], "postprandial": [ 25, 39 ], "glucose": [ 26 ], "and": [ 27, 37, 53, 69 ], "(ii)": [ 28 ], "more": [ 30 ], "potent": [ 31 ], "increase": [ 34 ], "insulin": [ 35 ], "secretion": [ 36, 41 ], "reduce": [ 38 ], "glucagon": [ 40 ], "in": [ 42 ], "T2D": [ 43 ], "patients.": [ 44 ], "In": [ 45 ], "contrast": [ 46 ], "sitagliptin,": [ 48 ], "slowed": [ 50 ], "gastric": [ 51 ], "emptying": [ 52 ], "reduced": [ 54 ], "caloric": [ 55 ], "intake.": [ 56 ], "These": [ 57 ], "key": [ 58 ], "findings": [ 59 ], "differentiate": [ 60 ], "the": [ 61, 65 ], "therapeutic": [ 62 ], "actions": [ 63 ], "two": [ 66 ], "incretin-based": [ 67 ], "approaches,": [ 68 ], "may": [ 70 ], "have": [ 71 ], "meaningful": [ 72 ], "clinical": [ 73 ], "implications.": [ 74 ] }, "publication_date": "2008-09-10", "publication_year": 2008, "type": "article", "cited_by_count": 373, "authors": [ { "id": "https://openalex.org/A5091912602", "display_name": "Ralph A. DeFronzo" }, { "id": "https://openalex.org/A5013022794", "display_name": "Ted Okerson" }, { "id": "https://openalex.org/A5108978199", "display_name": "Prabhakar Viswanathan" }, { "id": "https://openalex.org/A5103833180", "display_name": "Xuesong Guan" }, { "id": "https://openalex.org/A5111741705", "display_name": "John H. Holcombe" }, { "id": "https://openalex.org/A5018272606", "display_name": "Leigh MacConell" } ] }, { "id": "https://openalex.org/W4385840652", "doi": "https://doi.org/10.2147/dmso.s425642", "title": "GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway", "abstract": { "Liraglutide": [ 0 ], "and": [ 1 ], "semaglutide": [ 2 ], "protects": [ 3 ], "skeletal": [ 4 ], "muscle": [ 5, 8 ], "against": [ 6 ], "obesity-induced": [ 7 ], "atrophy": [ 9 ], "via": [ 10 ], "the": [ 11 ], "SIRT1": [ 12 ], "pathway.": [ 13 ] }, "publication_date": "2023-08-01", "publication_year": 2023, "type": "article", "cited_by_count": 64, "authors": [ { "id": "https://openalex.org/A5100638992", "display_name": "Jie Xiang" }, { "id": "https://openalex.org/A5072788491", "display_name": "Liyan Qin" }, { "id": "https://openalex.org/A5006633429", "display_name": "Jinling Zhong" }, { "id": "https://openalex.org/A5101606814", "display_name": "Xia Ning" }, { "id": "https://openalex.org/A5102000016", "display_name": "Yuzhen Liang" } ] }, { "id": "https://openalex.org/W2801715295", "doi": "https://doi.org/10.1210/jc.2018-00070", "title": "Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial", "abstract": { "Semaglutide,": [ 0 ], "added": [ 1 ], "to": [ 2 ], "basal": [ 3 ], "insulin,": [ 4 ], "significantly": [ 5 ], "reduced": [ 6 ], "HbA1c": [ 7 ], "and": [ 8 ], "body": [ 9 ], "weight": [ 10 ], "in": [ 11 ], "patients": [ 12 ], "with": [ 13 ], "uncontrolled": [ 14 ], "T2D": [ 15 ], "vs": [ 16 ], "placebo.": [ 17 ] }, "publication_date": "2018-04-23", "publication_year": 2018, "type": "article", "cited_by_count": 347, "authors": [ { "id": "https://openalex.org/A5020174004", "display_name": "Helena W. Rodbard" }, { "id": "https://openalex.org/A5001655356", "display_name": "Ildiko Lingvay" }, { "id": "https://openalex.org/A5113013213", "display_name": "John H. Reed" }, { "id": "https://openalex.org/A5109361288", "display_name": "Raymond de la Rosa" }, { "id": "https://openalex.org/A5075717817", "display_name": "Ludger Rose" }, { "id": "https://openalex.org/A5081546904", "display_name": "Danny Sugimoto" }, { "id": "https://openalex.org/A5067248419", "display_name": "Eiichi Araki" }, { "id": "https://openalex.org/A5021990560", "display_name": "Pei-Ling Chu" }, { "id": "https://openalex.org/A5007924361", "display_name": "Nelun Wijayasinghe" }, { "id": "https://openalex.org/A5019150153", "display_name": "Paul Norwood" } ] }, { "id": "https://openalex.org/W2807279220", "doi": "https://doi.org/10.1016/j.jcjd.2018.05.008", "title": "Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes", "abstract": null, "publication_date": "2018-06-05", "publication_year": 2018, "type": "review", "cited_by_count": 85, "authors": [ { "id": "https://openalex.org/A5071214023", "display_name": "Ronald Goldenberg" }, { "id": "https://openalex.org/A5044805383", "display_name": "Oren Steen" } ] }, { "id": "https://openalex.org/W2629223022", "doi": "https://doi.org/10.1016/j.diabet.2017.05.009", "title": "Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy", "abstract": { "Liraglutide": [ 0 ], "causes": [ 1 ], "delayed": [ 2 ], "gastric": [ 3 ], "emptying": [ 4 ], "and": [ 5, 8 ], "inhibits": [ 6 ], "duodenal": [ 7 ], "small": [ 9 ], "intestine": [ 10 ], "motility.": [ 11 ], "However,": [ 12 ], "these": [ 13 ], "GI": [ 14 ], "movement-inhibiting": [ 15 ], "effects": [ 16 ], "may": [ 17 ], "be": [ 18 ], "decreased": [ 19 ], "or": [ 20 ], "absent": [ 21 ], "in": [ 22 ], "patients": [ 23 ], "with": [ 24 ], "DN-associated": [ 25 ], "dysautonomia.": [ 26 ] }, "publication_date": "2017-06-23", "publication_year": 2017, "type": "article", "cited_by_count": 105, "authors": [ { "id": "https://openalex.org/A5084456792", "display_name": "Yuki Nakatani" }, { "id": "https://openalex.org/A5018752670", "display_name": "Mitsunori Maeda" }, { "id": "https://openalex.org/A5081590770", "display_name": "Mihoko Matsumura" }, { "id": "https://openalex.org/A5049293626", "display_name": "Riha Shimizu" }, { "id": "https://openalex.org/A5030509095", "display_name": "Nobuyuki Banba" }, { "id": "https://openalex.org/A5002804119", "display_name": "Yoshimasa Aso" }, { "id": "https://openalex.org/A5038398017", "display_name": "Takanori Yasu" }, { "id": "https://openalex.org/A5028119693", "display_name": "Hisato Harasawa" } ] }, { "id": "https://openalex.org/W2536045672", "doi": "https://doi.org/10.1530/eje-16-0507", "title": "Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial", "abstract": { "Objective": [ 0 ], "To": [ 1 ], "examine": [ 2 ], "mechanisms": [ 3 ], "underlying": [ 4 ], "resting": [ 5 ], "heart": [ 6, 139 ], "rate": [ 7, 140 ], "(RHR)": [ 8 ], "increments": [ 9 ], "of": [ 10 ], "GLP-1": [ 11, 74, 100, 251 ], "receptor": [ 12, 75, 101, 252 ], "agonists": [ 13 ], "in": [ 14, 255, 265 ], "type": [ 15, 33, 256 ], "2": [ 16, 34, 50, 257 ], "diabetes": [ 17, 35, 258 ], "patients.": [ 18 ], "Design": [ 19 ], "Acute": [ 20 ], "and": [ 21, 66, 119, 142, 169, 171, 189, 199, 222, 235, 249, 268 ], "12-week": [ 22, 250 ], "randomised,": [ 23 ], "placebo-controlled,": [ 24 ], "double-blind,": [ 25 ], "single-centre,": [ 26 ], "parallel-group": [ 27 ], "trial.": [ 28 ], "Methods": [ 29 ], "In": [ 30, 69, 274 ], "total,": [ 31 ], "57": [ 32 ], "patients": [ 36, 93, 259 ], "(mean": [ 37, 159 ], "\u00b1": [ 38, 42, 47, 54, 160, 163, 211, 219 ], "s.d.": [ 39 ], "age:": [ 40 ], "62.8": [ 41 ], "6.9": [ 43 ], "years;": [ 44 ], "BMI:": [ 45 ], "31.8": [ 46 ], "4.1": [ 48 ], "kg/m": [ 49 ], ";": [ 51 ], "HbA1c:": [ 52 ], "7.3": [ 53 ], "0.6%),": [ 55 ], "treated": [ 56 ], "with": [ 57, 179, 206, 247, 276 ], "metformin": [ 58 ], "and/or": [ 59 ], "sulfonylureas,": [ 60 ], "were": [ 61, 94, 123, 202 ], "included": [ 62 ], "between": [ 63 ], "July": [ 64 ], "2013": [ 65 ], "August": [ 67 ], "2015.": [ 68 ], "the": [ 70, 73, 99 ], "acute": [ 71, 248 ], "study,": [ 72 ], "agonist": [ 76, 102, 253 ], "exenatide": [ 77 ], "(": [ 78, 104, 111, 193 ], "n": [ 79, 86, 105, 112 ], "=": [ 80, 87, 106, 113 ], "29)": [ 81 ], "or": [ 82, 108 ], "placebo": [ 83, 110 ], "(saline": [ 84 ], "0.9%;": [ 85 ], "28)": [ 88 ], "was": [ 89, 150 ], "infused": [ 90 ], "intravenously.": [ 91 ], "Subsequently,": [ 92 ], "again": [ 95 ], "randomised": [ 96 ], "to": [ 97 ], "receive": [ 98 ], "liraglutide": [ 103, 207 ], "19)": [ 107 ], "matching": [ 109 ], "17)": [ 114 ], "for": [ 115 ], "12": [ 116 ], "weeks.": [ 117 ], "RHR": [ 118, 158, 209, 245 ], "blood": [ 120 ], "pressure": [ 121 ], "(BP)": [ 122 ], "measured": [ 124 ], "by": [ 125, 130, 138, 145, 263 ], "oscillometric": [ 126 ], "technique,": [ 127 ], "systemic": [ 128 ], "haemodynamics": [ 129 ], "finger": [ 131 ], "photoplethysmography,": [ 132 ], "sympathetic": [ 133 ], "nervous": [ 134 ], "system": [ 135 ], "(SNS)": [ 136 ], "activity": [ 137, 198, 237 ], "variability": [ 141 ], "arterial": [ 143, 190, 233 ], "stiffness": [ 144, 191, 234 ], "applanation": [ 146 ], "tonometry.": [ 147 ], "This": [ 148 ], "trial": [ 149 ], "registered": [ 151 ], "at": [ 152 ], "ClinicalTrials.gov": [ 153 ], "(Nbib1744236).": [ 154 ], "Results": [ 155 ], "Exenatide-infusion": [ 156 ], "increased": [ 157, 183, 208 ], "s.e.m.": [ 161 ], "+7.5": [ 162 ], "0.9": [ 164 ], "BPM,": [ 165 ], "P": [ 166, 175, 194, 226, 241 ], "<": [ 167, 176, 195, 227 ], "0.001),": [ 168 ], "systolic": [ 170, 216 ], "diastolic": [ 172 ], "BP": [ 173, 217 ], "(both": [ 174 ], "0.05),": [ 177 ], "compared": [ 178 ], "placebo.": [ 180 ], "Vascular": [ 181 ], "resistance": [ 182 ], "during": [ 184 ], "exenatide-infusion,": [ 185 ], "whereas": [ 186 ], "stroke": [ 187, 223 ], "volume": [ 188, 224 ], "decreased": [ 192 ], "0.05).": [ 196, 243 ], "SNS": [ 197, 236, 266 ], "cardiac": [ 200 ], "output": [ 201 ], "unaffected.": [ 203 ], "Twelve-week": [ 204 ], "treatment": [ 205, 254 ], "(+6.6": [ 210 ], "2.1": [ 212 ], "BPM),": [ 213 ], "while": [ 214 ], "reducing": [ 215 ], "(\u221212.6": [ 218 ], "4.7": [ 220 ], "mmHg)": [ 221 ], "(all": [ 225, 240 ], "0.01).": [ 228 ], "Cardiac": [ 229 ], "output,": [ 230 ], "vascular": [ 231 ], "resistance,": [ 232 ], "remained": [ 238 ], "unchanged": [ 239 ], ">": [ 242 ], "Conclusions": [ 244 ], "acceleration": [ 246 ], "is": [ 260 ], "not": [ 261 ], "explained": [ 262 ], "changes": [ 264 ], "activity,": [ 267 ], "our": [ 269 ], "data": [ 270 ], "argue": [ 271 ], "against": [ 272 ], "vasodilation.": [ 273 ], "line": [ 275 ], "pre-clinical": [ 277 ], "data,": [ 278 ], "direct": [ 279 ], "sino-atrial": [ 280 ], "stimulation": [ 281 ], "may": [ 282 ], "be": [ 283 ], "involved.": [ 284 ] }, "publication_date": "2016-10-25", "publication_year": 2016, "type": "article", "cited_by_count": 49, "authors": [ { "id": "https://openalex.org/A5091895526", "display_name": "Mark M. Smits" }, { "id": "https://openalex.org/A5067721247", "display_name": "Lennart Tonneijck" }, { "id": "https://openalex.org/A5084278641", "display_name": "Marcel H.A. Muskiet" }, { "id": "https://openalex.org/A5016447558", "display_name": "Trynke Hoekstra" }, { "id": "https://openalex.org/A5028760009", "display_name": "Mark H.H. Kramer" }, { "id": "https://openalex.org/A5109335776", "display_name": "Micha\u00ebla Diamant" }, { "id": "https://openalex.org/A5067127165", "display_name": "Dani\u00ebl H. van Raalte" } ] }, { "id": "https://openalex.org/W4245650535", "doi": "https://doi.org/10.1038/nrd3148", "title": "Liraglutide", "abstract": null, "publication_date": "2010-04-01", "publication_year": 2010, "type": "review", "cited_by_count": 166, "authors": [ { "id": "https://openalex.org/A5057472647", "display_name": "Daniel J. Drucker" }, { "id": "https://openalex.org/A5088507935", "display_name": "Argyris Dritselis" }, { "id": "https://openalex.org/A5019823418", "display_name": "Peter Kirkpatrick" } ] }, { "id": "https://openalex.org/W2140536043", "doi": "https://doi.org/10.1111/j.1365-2125.2009.03536.x", "title": "Effect of renal impairment on the pharmacokinetics of the GLP\u20101 analogue liraglutide", "abstract": { "WHAT": [ 0, 54 ], "IS": [ 1 ], "ALREADY": [ 2 ], "KNOWN": [ 3 ], "ABOUT": [ 4 ], "THIS": [ 5, 55 ], "SUBJECT": [ 6 ], "\u2022": [ 7, 30, 58, 70 ], "Patients": [ 8 ], "with": [ 9, 46, 82, 90, 110, 171, 225, 254, 284, 304, 319, 339 ], "Type": [ 10, 83, 320 ], "2": [ 11, 84, 321 ], "diabetes": [ 12, 85, 322 ], "are": [ 13 ], "likely": [ 14 ], "to": [ 15, 18, 64, 77, 266, 281, 312 ], "have": [ 16 ], "or": [ 17 ], "develop": [ 19 ], "renal": [ 20, 47, 87, 114, 129, 135, 173, 227, 231, 276, 305, 324, 345 ], "impairment,": [ 21 ], "which": [ 22 ], "affects": [ 23 ], "the": [ 24, 34, 66, 99, 176, 180, 183, 218, 242, 251, 255, 262 ], "pharmacokinetics": [ 25, 166, 243 ], "of": [ 26, 33, 68, 98, 113, 119, 122, 128, 142, 179, 221, 237, 244, 275, 288, 300, 315, 331 ], "some": [ 27 ], "antidiabetic": [ 28 ], "treatments.": [ 29 ], "Whether": [ 31 ], "dosing": [ 32 ], "once\u2010daily": [ 35, 100 ], "human": [ 36, 101 ], "glucagon\u2010like": [ 37, 102 ], "peptide\u20101": [ 38, 103 ], "analogue": [ 39, 104 ], "liraglutide": [ 40, 105, 154, 184, 301, 340 ], "should": [ 41, 326 ], "be": [ 42, 78, 267, 282 ], "modified": [ 43 ], "in": [ 44, 80, 108, 165, 261, 302, 341 ], "patients": [ 45, 81, 109, 303, 318, 342 ], "impairment": [ 48, 88, 130, 232, 277, 325 ], "has": [ 49 ], "not": [ 50, 62, 188, 279, 310 ], "previously": [ 51 ], "been": [ 52 ], "studied.": [ 53 ], "STUDY": [ 56 ], "ADDS": [ 57 ], "Renal": [ 59, 307 ], "dysfunction": [ 60, 308 ], "was": [ 61, 167, 264, 309 ], "found": [ 63, 311 ], "increase": [ 65, 313 ], "exposure": [ 67, 314 ], "liraglutide.": [ 69, 91, 245, 332 ], "Hence,": [ 71 ], "no": [ 72, 234, 295 ], "dose": [ 73, 96, 141 ], "adjustment": [ 74, 97 ], "is": [ 75, 106 ], "expected": [ 76, 247 ], "required": [ 79, 107 ], "and": [ 86, 131, 147, 204, 229, 257, 317, 323 ], "treated": [ 89 ], "AIMS": [ 92 ], "To": [ 93 ], "investigate": [ 94 ], "whether": [ 95 ], "varying": [ 111, 126 ], "stages": [ 112 ], "impairment.": [ 115, 306 ], "METHODS": [ 116 ], "A": [ 117 ], "cohort": [ 118 ], "30": [ 120 ], "subjects,": [ 121 ], "whom": [ 123 ], "24": [ 124 ], "had": [ 125, 133 ], "degrees": [ 127 ], "six": [ 132 ], "normal": [ 134, 226 ], "function,": [ 136 ], "were": [ 137 ], "given": [ 138 ], "a": [ 139 ], "single": [ 140 ], "liraglutide,": [ 143, 316 ], "0.75": [ 144 ], "mg": [ 145 ], "subcutaneously,": [ 146 ], "completed": [ 148 ], "serial": [ 149 ], "blood": [ 150 ], "sampling": [ 151 ], "for": [ 152, 156, 163, 223 ], "plasma": [ 153 ], "measurements": [ 155 ], "pharmacokinetic": [ 157 ], "estimation.": [ 158 ], "RESULTS": [ 159 ], "No": [ 160 ], "clear": [ 161 ], "trend": [ 162 ], "change": [ 164 ], "evident": [ 168 ], "across": [ 169 ], "groups": [ 170 ], "increasing": [ 172 ], "dysfunction.": [ 174 ], "While": [ 175 ], "between\u2010group": [ 177 ], "comparisons": [ 178 ], "area": [ 181 ], "under": [ 182 ], "concentration\u2013curve": [ 185 ], "(AUC)": [ 186 ], "did": [ 187, 278 ], "demonstrate": [ 189 ], "equivalence": [ 190 ], "[estimated": [ 191 ], "ratio": [ 192, 249 ], "AUC": [ 193, 205, 248 ], "severe": [ 194 ], "/AUC": [ 195, 211 ], "healthy": [ 196, 212 ], "0.73,": [ 197 ], "90%": [ 198, 214 ], "confidence": [ 199 ], "interval": [ 200 ], "(CI)": [ 201 ], "0.57,": [ 202 ], "0.94;": [ 203 ], "(continuous": [ 206 ], "ambulatory": [ 207 ], "peritoneal": [ 208 ], "dialysis)": [ 209 ], "CAPD": [ 210 ], "0.74,": [ 213 ], "CI": [ 215, 270 ], "0.56,": [ 216 ], "0.97],": [ 217 ], "regression": [ 219 ], "analysis": [ 220 ], "log(AUC)": [ 222 ], "subjects": [ 224, 253 ], "function": [ 228 ], "mild\u2010to\u2010severe": [ 230 ], "showed": [ 233 ], "significant": [ 235 ], "effect": [ 236 ], "decreasing": [ 238 ], "creatinine": [ 239, 259 ], "clearance": [ 240, 260 ], "on": [ 241 ], "The": [ 246 ], "between": [ 250 ], "two": [ 252 ], "lowest": [ 256 ], "highest": [ 258 ], "study": [ 263, 293 ], "estimated": [ 265 ], "0.88": [ 268 ], "(95%": [ 269 ], "0.58,": [ 271 ], "1.34)": [ 272 ], "(NS).": [ 273 ], "Degree": [ 274 ], "appear": [ 280 ], "associated": [ 283 ], "an": [ 285 ], "increased": [ 286 ], "risk": [ 287 ], "adverse": [ 289 ], "events.": [ 290 ], "CONCLUSIONS": [ 291 ], "This": [ 292 ], "indicated": [ 294 ], "safety": [ 296 ], "concerns": [ 297 ], "regarding": [ 298 ], "use": [ 299, 327 ], "standard": [ 328 ], "treatment": [ 329 ], "regimens": [ 330 ], "There": [ 333 ], "is,": [ 334 ], "however,": [ 335 ], "currently": [ 336 ], "limited": [ 337 ], "experience": [ 338 ], "beyond": [ 343 ], "mild\u2010stage": [ 344 ], "disease.": [ 346 ] }, "publication_date": "2009-09-01", "publication_year": 2009, "type": "article", "cited_by_count": 213, "authors": [ { "id": "https://openalex.org/A5112171221", "display_name": "Lisbeth V. Jacobsen" }, { "id": "https://openalex.org/A5041014919", "display_name": "Charlotte Hindsberger" }, { "id": "https://openalex.org/A5108417421", "display_name": "Richard A. Robson" }, { "id": "https://openalex.org/A5017200089", "display_name": "Milan Zdravkovi\u0107" } ] }, { "id": "https://openalex.org/W4386274913", "doi": "https://doi.org/10.1016/j.diabet.2023.101470", "title": "GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes", "abstract": { "Glucagon-like": [ 0 ], "peptide": [ 1 ], "1": [ 2 ], "(GLP-1)": [ 3 ], "is": [ 4 ], "a": [ 5, 19, 28, 31, 182, 198 ], "hormone": [ 6 ], "of": [ 7, 36, 44, 52, 63, 73, 98, 138, 144 ], "the": [ 8, 61, 71, 96, 118, 132, 136, 233 ], "incretin": [ 9 ], "family,": [ 10 ], "secreted": [ 11 ], "in": [ 12, 21, 60, 159, 218, 232 ], "response": [ 13 ], "to": [ 14, 70, 81, 90, 108, 116, 155, 180, 185, 204 ], "nutrient": [ 15 ], "ingestion,": [ 16 ], "and": [ 17, 30, 40, 47, 50, 75, 104, 125, 130, 220, 228 ], "plays": [ 18 ], "role": [ 20 ], "metabolic": [ 22 ], "homeostasis.": [ 23 ], "GLP-1": [ 24, 127, 139, 193, 212 ], "receptor": [ 25, 194, 213 ], "agonist": [ 26 ], "has": [ 27, 67 ], "peripheral": [ 29 ], "central": [ 32, 128 ], "action,": [ 33 ], "including": [ 34 ], "stimulation": [ 35 ], "glucose-dependent": [ 37 ], "insulin": [ 38, 41, 109 ], "secretion": [ 39, 46 ], "biosynthesis,": [ 42 ], "inhibition": [ 43, 51 ], "glucagon": [ 45 ], "gastric": [ 48 ], "emptying,": [ 49 ], "food": [ 53 ], "intake.": [ 54 ], "Through": [ 55 ], "their": [ 56, 58, 83 ], "mechanism,": [ 57 ], "use": [ 59 ], "treatment": [ 62 ], "type": [ 64, 122, 147 ], "2": [ 65, 87, 123, 148 ], "diabetes": [ 66, 88, 124, 149 ], "been": [ 68 ], "extended": [ 69 ], "management": [ 72 ], "obesity,": [ 74 ], "numerous": [ 76 ], "trials": [ 77, 216 ], "are": [ 78, 209, 217 ], "being": [ 79, 178 ], "conducted": [ 80 ], "assess": [ 82 ], "cardiovascular": [ 84 ], "effect.": [ 85 ], "Type": [ 86 ], "appears": [ 89 ], "share": [ 91 ], "common": [ 92 ], "pathophysiological": [ 93 ], "mechanisms": [ 94 ], "with": [ 95, 146, 211 ], "development": [ 97 ], "cognitive": [ 99, 142, 186 ], "disorders,": [ 100 ], "such": [ 101 ], "as": [ 102 ], "Alzheimer's": [ 103, 226 ], "Parkinson's": [ 105, 229 ], "disease,": [ 106 ], "related": [ 107 ], "resistance.": [ 110 ], "In": [ 111 ], "this": [ 112 ], "review,": [ 113 ], "we": [ 114 ], "aim": [ 115 ], "examine": [ 117 ], "pathological": [ 119 ], "features": [ 120 ], "between": [ 121 ], "dementia,": [ 126 ], "effects,": [ 129 ], "analyze": [ 131 ], "relevant": [ 133 ], "literature": [ 134 ], "about": [ 135 ], "effect": [ 137 ], "analogs": [ 140 ], "on": [ 141, 171 ], "function": [ 143 ], "patients": [ 145, 208, 231 ], "but": [ 150, 176 ], "also": [ 151 ], "without.": [ 152 ], "Results": [ 153 ], "tends": [ 154 ], "show": [ 156 ], "an": [ 157 ], "improvement": [ 158 ], "some": [ 160 ], "brain": [ 161 ], "markers": [ 162 ], "(e.g.": [ 163 ], "hippocampal": [ 164, 169 ], "connections,": [ 165 ], "cerebral": [ 166 ], "glucose": [ 167 ], "metabolism,": [ 168 ], "activation": [ 170 ], "functional": [ 172 ], "magnetic": [ 173 ], "resonance": [ 174 ], "imaging),": [ 175 ], "without": [ 177 ], "able": [ 179 ], "demonstrate": [ 181 ], "strong": [ 183 ], "correlation": [ 184 ], "scores.": [ 187 ], "Some": [ 188 ], "epidemiological": [ 189 ], "studies": [ 190 ], "suggest": [ 191 ], "that": [ 192 ], "agonists": [ 195 ], "may": [ 196, 221 ], "offer": [ 197 ], "protective": [ 199 ], "effect,": [ 200 ], "by": [ 201 ], "delaying": [ 202 ], "progression": [ 203 ], "dementia": [ 205 ], "when": [ 206 ], "diabetic": [ 207 ], "treated": [ 210 ], "agonists.": [ 214 ], "Ongoing": [ 215 ], "progress": [ 219 ], "provide": [ 222 ], "disease-modifying": [ 223 ], "care": [ 224 ], "for": [ 225 ], "disease": [ 227, 230 ], "future.": [ 234 ] }, "publication_date": "2023-08-30", "publication_year": 2023, "type": "review", "cited_by_count": 61, "authors": [ { "id": "https://openalex.org/A5061154237", "display_name": "M. Monney" }, { "id": "https://openalex.org/A5056462107", "display_name": "Fran\u00e7ois R. Jornayvaz" }, { "id": "https://openalex.org/A5028737784", "display_name": "Karim Gariani" } ] }, { "id": "https://openalex.org/W2984187781", "doi": "https://doi.org/10.1007/s10557-019-06915-8", "title": "Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues\u2014Liraglutide and Semaglutide", "abstract": null, "publication_date": "2019-11-13", "publication_year": 2019, "type": "article", "cited_by_count": 58, "authors": [ { "id": "https://openalex.org/A5004522478", "display_name": "Marina Basalay" }, { "id": "https://openalex.org/A5010243430", "display_name": "Sean M. Davidson" }, { "id": "https://openalex.org/A5090808868", "display_name": "Derek M. Yellon" } ] }, { "id": "https://openalex.org/W3011600512", "doi": "https://doi.org/10.1016/j.cjca.2020.02.098", "title": "The GLP-1 Receptor Agonist Liraglutide Increases Myocardial Glucose Oxidation Rates via Indirect Mechanisms and Mitigates Experimental Diabetic Cardiomyopathy", "abstract": null, "publication_date": "2020-03-08", "publication_year": 2020, "type": "article", "cited_by_count": 68, "authors": [ { "id": "https://openalex.org/A5059889861", "display_name": "Malak Almutairi" }, { "id": "https://openalex.org/A5101971702", "display_name": "Keshav Gopal" }, { "id": "https://openalex.org/A5066035797", "display_name": "Amanda A. Greenwell" }, { "id": "https://openalex.org/A5108676053", "display_name": "Adrian Young" }, { "id": "https://openalex.org/A5003190574", "display_name": "Robert M. Gill" }, { "id": "https://openalex.org/A5037034855", "display_name": "Hanin Aburasayn" }, { "id": "https://openalex.org/A5003760407", "display_name": "Rami Al Batran" }, { "id": "https://openalex.org/A5059222562", "display_name": "Jadin J. Chahade" }, { "id": "https://openalex.org/A5031525733", "display_name": "Manoj Gandhi" }, { "id": "https://openalex.org/A5046567898", "display_name": "Farah Eaton" }, { "id": "https://openalex.org/A5061668188", "display_name": "Ryan J. Mailloux" }, { "id": "https://openalex.org/A5024507895", "display_name": "John R. Ussher" } ] }, { "id": "https://openalex.org/W2746874591", "doi": "https://doi.org/10.1161/circulationaha.117.028136", "title": "Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors", "abstract": { "Potentiation": [ 0 ], "of": [ 1, 15, 20, 30, 38, 54, 82, 94, 139, 167, 176, 192, 209, 216, 254, 266, 281, 308, 319, 330, 341 ], "glucagon-like": [ 2 ], "peptide-1": [ 3 ], "(GLP-1)": [ 4 ], "action": [ 5 ], "through": [ 6, 88 ], "selective": [ 7 ], "GLP-1": [ 8 ], "receptor": [ 9 ], "(GLP-1R)": [ 10 ], "agonism": [ 11 ], "or": [ 12 ], "by": [ 13, 18, 35, 52 ], "prevention": [ 14, 338 ], "enzymatic": [ 16 ], "degradation": [ 17 ], "inhibition": [ 19 ], "dipeptidyl": [ 21 ], "peptidase-4": [ 22 ], "(DPP-4)": [ 23 ], "promotes": [ 24 ], "glycemic": [ 25 ], "reduction": [ 26, 53, 116 ], "for": [ 27, 305, 336 ], "the": [ 28, 126, 165, 168, 183, 251, 264, 306, 317, 320, 325, 337 ], "treatment": [ 29, 307, 340 ], "type": [ 31, 102, 309 ], "2": [ 32, 103, 222, 310 ], "diabetes": [ 33, 104, 311 ], "mellitus": [ 34, 105 ], "glucose-dependent": [ 36 ], "control": [ 37 ], "insulin": [ 39 ], "and": [ 40, 57, 62, 73, 85, 106, 134, 144, 152, 182, 225, 229, 257, 291, 300, 314, 328, 339 ], "glucagon": [ 41 ], "secretion.": [ 42 ], "GLP-1R": [ 43, 71, 127, 170, 255, 298 ], "agonists": [ 44, 72, 128, 256, 299 ], "also": [ 45 ], "decelerate": [ 46 ], "gastric": [ 47 ], "emptying,": [ 48 ], "reduce": [ 49 ], "body": [ 50 ], "weight": [ 51 ], "food": [ 55 ], "intake": [ 56 ], "lower": [ 58 ], "circulating": [ 59 ], "lipoproteins,": [ 60 ], "inflammation,": [ 61 ], "systolic": [ 63 ], "blood": [ 64 ], "pressure.": [ 65 ], "Preclinical": [ 66 ], "studies": [ 67, 271 ], "demonstrate": [ 68 ], "that": [ 69, 239, 323 ], "both": [ 70 ], "DPP-4": [ 74, 184, 258 ], "inhibitors": [ 75, 185 ], "exhibit": [ 76 ], "cardioprotective": [ 77 ], "actions": [ 78, 253 ], "in": [ 79, 98, 117, 136, 178, 196, 201, 218, 275, 287 ], "animal": [ 80 ], "models": [ 81 ], "myocardial": [ 83 ], "ischemia": [ 84 ], "ventricular": [ 86 ], "dysfunction": [ 87 ], "incompletely": [ 89 ], "characterized": [ 90 ], "mechanisms.": [ 91 ], "The": [ 92 ], "results": [ 93 ], "cardiovascular": [ 95, 108, 113, 123, 161, 246, 252, 326, 342 ], "outcome": [ 96, 162 ], "trials": [ 97, 163 ], "human": [ 99 ], "subjects": [ 100 ], "with": [ 101, 125, 156, 260 ], "increased": [ 107, 243 ], "risk": [ 109 ], "have": [ 110, 333 ], "demonstrated": [ 111 ], "a": [ 112, 261 ], "benefit": [ 114, 327 ], "(significant": [ 115 ], "time": [ 118 ], "to": [ 119, 149, 272 ], "first": [ 120 ], "major": [ 121 ], "adverse": [ 122 ], "event)": [ 124 ], "liraglutide": [ 129 ], "(LEADER": [ 130 ], "trial": [ 131, 147, 174, 189, 207 ], "[Liraglutide": [ 132 ], "Effect": [ 133 ], "Action": [ 135 ], "Diabetes:": [ 137 ], "Evaluation": [ 138 ], "Cardiovascular": [ 140, 151, 210, 234 ], "Ourcome": [ 141 ], "Results],": [ 142 ], "\u221213%)": [ 143 ], "semaglutide": [ 145 ], "(SUSTAIN-6": [ 146 ], "[Trial": [ 148, 232 ], "Evaluate": [ 150 ], "Other": [ 153 ], "Long-term": [ 154 ], "Outcomes": [ 155, 194, 211, 235 ], "Semaglutide],": [ 157 ], "\u221224%).": [ 158 ], "In": [ 159 ], "contrast,": [ 160 ], "examining": [ 164 ], "safety": [ 166, 329 ], "shorter-acting": [ 169 ], "agonist": [ 171 ], "lixisenatide": [ 172 ], "(ELIXA": [ 173 ], "[Evaluation": [ 175 ], "Lixisenatide": [ 177 ], "Acute": [ 179, 226 ], "Coronary": [ 180, 227 ], "Syndrom])": [ 181 ], "saxagliptin": [ 186 ], "(SAVOR-TIMI": [ 187 ], "53": [ 188 ], "[Saxagliptin": [ 190 ], "Assessment": [ 191 ], "Vascular": [ 193 ], "Recorded": [ 195 ], "Patients": [ 197, 219 ], "With": [ 198, 212, 220, 236 ], "Diabetes": [ 199, 223 ], "Mellitus-Thrombolysis": [ 200 ], "Myocardial": [ 202 ], "Infarction": [ 203 ], "53]),": [ 204 ], "alogliptin": [ 205 ], "(EXAMINE": [ 206 ], "[Examination": [ 208 ], "Alogliptin": [ 213 ], "Versus": [ 214 ], "Standard": [ 215 ], "Care": [ 217 ], "Type": [ 221 ], "Mellitus": [ 224 ], "Syndrome]),": [ 228 ], "sitagliptin": [ 230 ], "(TECOS": [ 231 ], "Evaluating": [ 233 ], "Sitagliptin])": [ 237 ], "found": [ 238 ], "these": [ 240, 331 ], "agents": [ 241, 332 ], "neither": [ 242 ], "nor": [ 244 ], "decreased": [ 245 ], "events.": [ 247 ], "Here": [ 248 ], "we": [ 249 ], "review": [ 250 ], "inhibitors,": [ 259 ], "focus": [ 262 ], "on": [ 263 ], "translation": [ 265 ], "mechanisms": [ 267, 322 ], "derived": [ 268 ], "from": [ 269 ], "preclinical": [ 270 ], "complementary": [ 273 ], "findings": [ 274 ], "clinical": [ 276, 292 ], "studies.": [ 277, 293 ], "We": [ 278 ], "highlight": [ 279 ], "areas": [ 280 ], "uncertainty": [ 282 ], "requiring": [ 283 ], "more": [ 284, 296 ], "careful": [ 285 ], "scrutiny": [ 286 ], "ongoing": [ 288 ], "basic": [ 289 ], "science": [ 290 ], "As": [ 294 ], "newer": [ 295 ], "potent": [ 297 ], "coagonists": [ 301 ], "are": [ 302 ], "being": [ 303 ], "developed": [ 304 ], "mellitus,": [ 312 ], "obesity,": [ 313 ], "nonalcoholic": [ 315 ], "steatohepatitis,": [ 316 ], "delineation": [ 318 ], "potential": [ 321 ], "underlie": [ 324 ], "immediate": [ 334 ], "relevance": [ 335 ], "disease.": [ 343 ] }, "publication_date": "2017-08-28", "publication_year": 2017, "type": "review", "cited_by_count": 546, "authors": [ { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5002832666", "display_name": "Juris J. Meier" }, { "id": "https://openalex.org/A5083542202", "display_name": "Matthew A. Cavender" }, { "id": "https://openalex.org/A5070441611", "display_name": "Mirna Abd El Aziz" }, { "id": "https://openalex.org/A5057472647", "display_name": "Daniel J. Drucker" } ] }, { "id": "https://openalex.org/W2068393876", "doi": "https://doi.org/10.1007/s00125-011-2297-z", "title": "Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology", "abstract": null, "publication_date": "2011-09-03", "publication_year": 2011, "type": "letter", "cited_by_count": 60, "authors": [ { "id": "https://openalex.org/A5057472647", "display_name": "Daniel J. Drucker" }, { "id": "https://openalex.org/A5026133486", "display_name": "Cheryl F. Rosen" } ] }, { "id": "https://openalex.org/W4404319582", "doi": "https://doi.org/10.1001/jamapsychiatry.2024.3599", "title": "Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder", "abstract": { "Importance": [ 0 ], "Preliminary": [ 1 ], "studies": [ 2 ], "suggest": [ 3 ], "that": [ 4, 361 ], "glucagon-like": [ 5 ], "peptide-1": [ 6 ], "receptor": [ 7 ], "(GLP-1)": [ 8 ], "agonists,": [ 9 ], "used": [ 10 ], "to": [ 11, 31, 73, 100, 354, 384 ], "treat": [ 12 ], "type": [ 13 ], "2": [ 14, 336 ], "diabetes": [ 15 ], "and": [ 16, 55, 91, 125, 137, 163, 180, 238, 265, 291, 327, 333, 342, 368, 378 ], "obesity,": [ 17 ], "may": [ 18, 370 ], "decrease": [ 19 ], "alcohol": [ 20, 32 ], "consumption.": [ 21 ], "Objective": [ 22 ], "To": [ 23 ], "test": [ 24 ], "whether": [ 25 ], "the": [ 26, 39, 50, 126, 219, 245, 338, 374 ], "risk": [ 27, 221, 248, 279, 304, 350, 357 ], "of": [ 28, 41, 47, 83, 107, 115, 122, 191, 205, 240, 262, 269, 305, 340, 351, 362, 376 ], "hospitalization": [ 29, 144, 352 ], "due": [ 30, 353 ], "use": [ 33, 40, 114, 157, 239, 298, 339 ], "disorder": [ 34, 158 ], "(AUD)": [ 35 ], "is": [ 36 ], "decreased": [ 37, 278, 303, 349 ], "during": [ 38 ], "GLP-1": [ 42, 117, 123 ], "agonists": [ 43, 118 ], "compared": [ 44 ], "with": [ 45, 120, 131, 173, 186, 218, 244, 275, 302, 311, 331, 346 ], "periods": [ 46 ], "nonuse": [ 48, 121 ], "for": [ 49, 133 ], "same": [ 51 ], "individual.": [ 52 ], "Design,": [ 53 ], "Setting,": [ 54 ], "Participants": [ 56, 94 ], "This": [ 57, 356 ], "cohort": [ 58, 78, 168 ], "study": [ 59, 63 ], "was": [ 60, 79, 113, 129, 142, 199, 216, 273, 358 ], "an": [ 61 ], "observational": [ 62 ], "conducted": [ 64 ], "nationwide": [ 65 ], "in": [ 66, 146, 373 ], "Sweden": [ 67 ], "using": [ 68 ], "data": [ 69 ], "from": [ 70, 81 ], "January": [ 71 ], "2006": [ 72 ], "December": [ 74 ], "2023.": [ 75 ], "The": [ 76, 110, 139, 167 ], "population-based": [ 77 ], "identified": [ 80 ], "registers": [ 82 ], "inpatient": [ 84 ], "care,": [ 85, 88 ], "specialized": [ 86 ], "outpatient": [ 87 ], "sickness": [ 89 ], "absence,": [ 90 ], "disability": [ 92 ], "pension.": [ 93 ], "were": [ 95, 154, 178, 184, 299, 344 ], "all": [ 96 ], "residents": [ 97 ], "aged": [ 98 ], "16": [ 99 ], "64": [ 101 ], "years": [ 102 ], "who": [ 103 ], "had": [ 104 ], "a": [ 105, 147, 187, 276, 347 ], "diagnosis": [ 106 ], "AUD.": [ 108, 134, 355 ], "Exposures": [ 109 ], "primary": [ 111, 140 ], "exposure": [ 112, 128 ], "individual": [ 116 ], "(compared": [ 119 ], "agonists),": [ 124 ], "secondary": [ 127 ], "medications": [ 130 ], "indication": [ 132 ], "Main": [ 135 ], "Outcomes": [ 136 ], "Measures": [ 138 ], "outcome": [ 141 ], "AUD": [ 143, 211, 264, 271, 332, 365 ], "analyzed": [ 145 ], "Cox": [ 148 ], "regression": [ 149 ], "within-individual": [ 150 ], "model.": [ 151 ], "Secondary": [ 152 ], "outcomes": [ 153 ], "any": [ 155, 231, 255, 270 ], "substance": [ 156 ], "(SUD)\u2013related": [ 159 ], "hospitalization,": [ 160, 162 ], "somatic": [ 161, 306 ], "suicide": [ 164, 312 ], "attempt.": [ 165 ], "Results": [ 166 ], "included": [ 169 ], "227": [ 170 ], "866": [ 171 ], "individuals": [ 172, 208 ], "AUD;": [ 174 ], "144": [ 175 ], "714": [ 176 ], "(63.5%)": [ 177 ], "male": [ 179 ], "83": [ 181 ], "154": [ 182 ], "(36.5%)": [ 183 ], "female,": [ 185 ], "mean": [ 188 ], "(SD)": [ 189 ], "age": [ 190 ], "40.0": [ 192 ], "(15.7)": [ 193 ], "years.": [ 194, 202 ], "Median": [ 195 ], "(IQR)": [ 196 ], "follow-up": [ 197 ], "time": [ 198 ], "8.8": [ 200 ], "(4.0-13.3)": [ 201 ], "A": [ 203 ], "total": [ 204 ], "133": [ 206 ], "210": [ 207 ], "(58.5%)": [ 209 ], "experienced": [ 210 ], "hospitalization.": [ 212, 267 ], "Semaglutide": [ 213, 285, 367 ], "(4321": [ 214 ], "users)": [ 215, 243 ], "associated": [ 217, 274, 301, 310, 345 ], "lowest": [ 220, 247 ], "(AUD:": [ 222, 249 ], "adjusted": [ 223 ], "hazard": [ 224 ], "ratio": [ 225 ], "[aHR],": [ 226 ], "0.64;": [ 227 ], "95%": [ 228, 235, 252, 259, 282, 288, 295, 317, 323 ], "CI,": [ 229, 236, 253, 260, 283, 289, 296, 318, 324 ], "0.50-0.83;": [ 230 ], "SUD:": [ 232, 256 ], "aHR,": [ 233, 250, 257, 315, 321 ], "0.68;": [ 234 ], "0.54-0.85)": [ 237 ], "liraglutide": [ 241, 292, 343, 369 ], "(2509": [ 242 ], "second": [ 246 ], "0.72;": [ 251 ], "0.57-0.92;": [ 254 ], "0.78;": [ 258, 287 ], "0.64-0.97)": [ 261 ], "both": [ 263 ], "SUD": [ 266 ], "Use": [ 268 ], "medication": [ 272 ], "modestly": [ 277 ], "(aHR,": [ 280, 286, 293 ], "0.98;": [ 281 ], "0.96-1.00).": [ 284 ], "0.68-0.90)": [ 290 ], "0.79;": [ 294 ], "0.69-0.91)": [ 297 ], "also": [ 300 ], "hospitalizations": [ 307 ], "but": [ 308 ], "not": [ 309 ], "attempts": [ 313 ], "(semaglutide:": [ 314 ], "0.55;": [ 316 ], "0.23-1.30;": [ 319 ], "liraglutide:": [ 320 ], "1.08;": [ 322 ], "0.55-2.15).": [ 325 ], "Conclusions": [ 326 ], "Relevance": [ 328 ], "Among": [ 329 ], "patients": [ 330 ], "comorbid": [ 334 ], "obesity/type": [ 335 ], "diabetes,": [ 337 ], "semaglutide": [ 341 ], "substantially": [ 348 ], "lower": [ 359 ], "than": [ 360 ], "officially": [ 363 ], "approved": [ 364 ], "medications.": [ 366 ], "be": [ 371 ], "effective": [ 372 ], "treatment": [ 375 ], "AUD,": [ 377 ], "clinical": [ 379 ], "trials": [ 380 ], "are": [ 381 ], "urgently": [ 382 ], "needed": [ 383 ], "confirm": [ 385 ], "these": [ 386 ], "findings.": [ 387 ] }, "publication_date": "2024-11-13", "publication_year": 2024, "type": "article", "cited_by_count": 60, "authors": [ { "id": "https://openalex.org/A5091611612", "display_name": "Markku L\u00e4hteenvuo" }, { "id": "https://openalex.org/A5072366449", "display_name": "Jari Tiihonen" }, { "id": "https://openalex.org/A5024622219", "display_name": "Anssi Solismaa" }, { "id": "https://openalex.org/A5077285311", "display_name": "Antti O. Tanskanen" }, { "id": "https://openalex.org/A5047541131", "display_name": "Ellenor Mittendorfer\u2010Rutz" }, { "id": "https://openalex.org/A5063615584", "display_name": "Heidi Taipale" } ] }, { "id": "https://openalex.org/W4385566892", "doi": "https://doi.org/10.1055/a-2148-6321", "title": "Implications of Ozempic and Other GLP-1 Receptor Agonists for Facial Plastic Surgeons", "abstract": { "Abstract": [ 0 ], "Obesity": [ 1 ], "is": [ 2 ], "a": [ 3, 106 ], "growing": [ 4 ], "global": [ 5 ], "health": [ 6 ], "concern.": [ 7 ], "Glucagon-like": [ 8 ], "peptide-1": [ 9 ], "(GLP-1)": [ 10 ], "receptor": [ 11, 22, 33, 142, 165 ], "agonists,": [ 12, 34 ], "such": [ 13 ], "as": [ 14, 18 ], "Ozempic,": [ 15 ], "have": [ 16 ], "emerged": [ 17 ], "potential": [ 19, 95 ], "treatments.": [ 20 ], "GLP-1": [ 21, 32, 141, 164 ], "agonists": [ 23, 143, 166 ], "regulate": [ 24 ], "appetite": [ 25 ], "and": [ 26, 37, 53, 71, 79, 86, 100, 123, 134, 181 ], "can": [ 27, 59 ], "promote": [ 28 ], "weight": [ 29, 48, 52, 116 ], "loss.": [ 30, 117 ], "Some": [ 31 ], "though": [ 35 ], "Food": [ 36 ], "Drug": [ 38 ], "Administration": [ 39 ], "(FDA)-approved": [ 40 ], "for": [ 41, 47, 128 ], "diabetes,": [ 42 ], "are": [ 43, 81, 126 ], "also": [ 44 ], "used": [ 45 ], "off-label": [ 46 ], "loss": [ 49, 55 ], "alone.": [ 50 ], "Rapid": [ 51 ], "fat": [ 54, 80 ], "with": [ 56, 114 ], "these": [ 57, 158 ], "medications": [ 58 ], "lead": [ 60 ], "to": [ 61, 135, 148, 152 ], "what": [ 62 ], "has": [ 63 ], "been": [ 64 ], "called": [ 65 ], "\u201cOzempic": [ 66 ], "Face\u201d": [ 67 ], "on": [ 68, 97, 157, 178 ], "social": [ 69 ], "media": [ 70 ], "in": [ 72, 84, 108 ], "the": [ 73, 94, 98, 101, 110, 161, 176 ], "lay": [ 74 ], "press,": [ 75 ], "where": [ 76 ], "facial": [ 77, 111, 132, 168, 179 ], "volume": [ 78, 133 ], "depleted,": [ 82 ], "resulting": [ 83 ], "wrinkles": [ 85 ], "sagging": [ 87 ], "skin.": [ 88, 138 ], "Prescribers": [ 89 ], "rarely": [ 90 ], "counsel": [ 91 ], "patients": [ 92 ], "about": [ 93 ], "impact": [ 96, 177 ], "face,": [ 99 ], "plastic": [ 102, 169 ], "surgery": [ 103 ], "community": [ 104 ], "faces": [ 105 ], "challenge": [ 107 ], "managing": [ 109 ], "changes": [ 112 ], "associated": [ 113 ], "rapid": [ 115 ], "Dermal": [ 118 ], "fillers,": [ 119 ], "skin": [ 120 ], "tightening": [ 121 ], "techniques,": [ 122 ], "surgical": [ 124 ], "interventions": [ 125 ], "useful": [ 127 ], "both": [ 129, 175 ], "restoration": [ 130 ], "of": [ 131, 140, 163, 174 ], "manage": [ 136 ], "excess": [ 137 ], "Discontinuation": [ 139 ], "should": [ 144 ], "be": [ 145, 172 ], "considered": [ 146 ], "prior": [ 147 ], "general": [ 149 ], "anesthesia": [ 150 ], "due": [ 151 ], "delayed": [ 153 ], "gastric": [ 154 ], "emptying": [ 155 ], "while": [ 156 ], "medications.": [ 159 ], "As": [ 160 ], "popularity": [ 162 ], "grows,": [ 167 ], "surgeons": [ 170 ], "must": [ 171 ], "aware": [ 173 ], "appearance": [ 180 ], "perioperative": [ 182 ], "considerations.": [ 183 ] }, "publication_date": "2023-08-04", "publication_year": 2023, "type": "article", "cited_by_count": 41, "authors": [ { "id": "https://openalex.org/A5064202322", "display_name": "Clinton D. Humphrey" }, { "id": "https://openalex.org/A5061135639", "display_name": "Anna Lawrence" } ] }, { "id": "https://openalex.org/W2059858692", "doi": "https://doi.org/10.1016/j.ejphar.2009.11.022", "title": "Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline", "abstract": null, "publication_date": "2009-11-16", "publication_year": 2009, "type": "article", "cited_by_count": 36, "authors": [ { "id": "https://openalex.org/A5001545372", "display_name": "Nigel Irwin" }, { "id": "https://openalex.org/A5064124957", "display_name": "Peter R. Flatt" }, { "id": "https://openalex.org/A5021190735", "display_name": "Steven Patterson" }, { "id": "https://openalex.org/A5001457345", "display_name": "Brian D. Green" } ] }, { "id": "https://openalex.org/W2756558030", "doi": "https://doi.org/10.1111/dom.13120", "title": "Semaglutide improves postprandial glucose and lipid metabolism, and delays first\u2010hour gastric emptying in subjects with obesity", "abstract": { "Aim": [ 0 ], "To": [ 1 ], "investigate": [ 2 ], "the": [ 3, 120, 164, 186, 247, 262 ], "effects": [ 4 ], "of": [ 5, 83, 259 ], "semaglutide": [ 6, 114, 157, 169, 215, 252 ], "on": [ 7, 16 ], "fasting": [ 8, 81, 230 ], "and": [ 9, 12, 15, 20, 53, 59, 68, 85, 87, 151, 207, 222, 231, 234 ], "postprandial": [ 10, 152, 188, 208, 232 ], "glucose": [ 11, 52, 84, 109, 132, 189, 233, 260 ], "lipid": [ 13, 54, 153, 235 ], "responses,": [ 14 ], "gastric": [ 17, 161, 195, 238 ], "emptying.": [ 18 ], "Materials": [ 19 ], "methods": [ 21 ], "This": [ 22 ], "was": [ 23, 166, 200, 240 ], "a": [ 24, 256 ], "randomized,": [ 25 ], "double\u2010blind,": [ 26 ], "placebo\u2010controlled,": [ 27 ], "2\u2010period,": [ 28 ], "crossover": [ 29 ], "trial.": [ 30 ], "Subjects": [ 31 ], "with": [ 32, 113, 156, 168, 214, 244, 251 ], "obesity": [ 33 ], "(N": [ 34 ], "=": [ 35, 220, 224 ], "30)": [ 36 ], "received": [ 37 ], "once\u2010weekly": [ 38 ], "subcutaneous": [ 39 ], "semaglutide,": [ 40 ], "dose\u2010escalated": [ 41 ], "to": [ 42, 123, 185, 242, 255 ], "1.0": [ 43 ], "mg,": [ 44 ], "or": [ 45 ], "placebo.": [ 46, 159 ], "After": [ 47 ], "each": [ 48 ], "12\u2010week": [ 49 ], "treatment": [ 50, 78, 93, 130, 176 ], "period,": [ 51 ], "metabolism": [ 55, 110, 154 ], "were": [ 56, 73, 211 ], "assessed": [ 57 ], "before": [ 58 ], "after": [ 60, 163 ], "standardized": [ 61 ], "meals.": [ 62 ], "Gastric": [ 63 ], "emptying": [ 64, 162, 196, 239 ], "(paracetamol": [ 65 ], "absorption": [ 66 ], "test)": [ 67 ], "peptide": [ 69 ], "YY": [ 70 ], "(PYY)": [ 71 ], "response": [ 72 ], "also": [ 74 ], "assessed.": [ 75 ], "Results": [ 76 ], "Semaglutide": [ 77, 228 ], "significantly": [ 79, 111, 212 ], "lowered": [ 80 ], "concentrations": [ 82 ], "glucagon,": [ 86 ], "increased": [ 88 ], "insulin": [ 89, 138 ], "vs": [ 90, 115, 158, 170, 216 ], "placebo": [ 91, 116, 171, 217 ], "(estimated": [ 92 ], "ratio:": [ 94, 177 ], "0.95": [ 95 ], "[95%": [ 96 ], "confidence": [ 97 ], "interval:": [ 98 ], "0.91,": [ 99 ], "0.98];": [ 100, 103 ], "0.86": [ 101 ], "[0.75,": [ 102 ], "1.45": [ 104 ], "[1.20,": [ 105 ], "1.75],": [ 106 ], "respectively).": [ 107, 226 ], "Postprandial": [ 108 ], "improved": [ 112, 155, 229 ], "(incremental": [ 117 ], "area": [ 118 ], "under": [ 119 ], "curve": [ 121 ], "0": [ 122 ], "5": [ 124 ], "hours": [ 125 ], "[iAUC": [ 126 ], "0\u20105h": [ 127, 198 ], "];": [ 128 ], "estimated": [ 129, 175 ], "difference:": [ 131 ], "\u22121.34": [ 133 ], "mmol": [ 134 ], "h/L": [ 135, 141, 147 ], "[\u22122.42,": [ 136 ], "\u22120.27];": [ 137 ], "\u2212921": [ 139 ], "pmol": [ 140 ], "[\u22121461,": [ 142 ], "\u2212381];": [ 143 ], "C\u2010peptide": [ 144 ], "\u22121.42": [ 145 ], "nmol": [ 146 ], "[\u22122.33,": [ 148 ], "\u22120.51]).": [ 149 ], "Fasting": [ 150, 206 ], "First\u2010hour": [ 160 ], "meal": [ 165 ], "delayed": [ 167 ], "(AUC": [ 172, 197 ], "0\u20101h": [ 173 ], ";": [ 174 ], "0.73": [ 178 ], "[0.61,": [ 179 ], "0.87]);": [ 180 ], "this": [ 181 ], "may": [ 182, 253 ], "have": [ 183 ], "contributed": [ 184 ], "lower": [ 187, 213 ], "increase": [ 190 ], "in": [ 191 ], "semaglutide\u2010treated": [ 192 ], "subjects.": [ 193 ], "Overall": [ 194, 237 ], ")": [ 199 ], "not": [ 201 ], "statistically": [ 202 ], "different": [ 203 ], "between": [ 204 ], "treatments.": [ 205 ], "PYY": [ 209 ], "responses": [ 210 ], "(": [ 218 ], "P": [ 219, 223 ], ".0397": [ 221 ], ".0097,": [ 225 ], "Conclusion": [ 227 ], "metabolism.": [ 236 ], "similar": [ 241 ], "that": [ 243 ], "placebo;": [ 245 ], "however,": [ 246 ], "observed": [ 248 ], "first\u2010hour": [ 249 ], "delay": [ 250 ], "contribute": [ 254 ], "slower": [ 257 ], "entry": [ 258 ], "into": [ 261 ], "circulation.": [ 263 ] }, "publication_date": "2017-09-23", "publication_year": 2017, "type": "article", "cited_by_count": 201, "authors": [ { "id": "https://openalex.org/A5085348099", "display_name": "Julie Hjerpsted" }, { "id": "https://openalex.org/A5019076349", "display_name": "Anne Flint" }, { "id": "https://openalex.org/A5022373908", "display_name": "Ashley Brooks" }, { "id": "https://openalex.org/A5112278544", "display_name": "Mads Axelsen" }, { "id": "https://openalex.org/A5103723237", "display_name": "Trine Kvist" }, { "id": "https://openalex.org/A5039586613", "display_name": "John E. Blundell" } ] }, { "id": "https://openalex.org/W2058954571", "doi": "https://doi.org/10.1016/j.ando.2012.06.002", "title": "GLP-1 receptor agonists or DPP-4 inhibitors: How to guide the clinician?", "abstract": null, "publication_date": "2013-04-06", "publication_year": 2013, "type": "review", "cited_by_count": 25, "authors": [ { "id": "https://openalex.org/A5039563874", "display_name": "Andr\u00e9 Scheen" } ] }, { "id": "https://openalex.org/W2898542079", "doi": "https://doi.org/10.1111/dom.13564", "title": "Evaluation of the long\u2010term cost\u2010effectiveness of once\u2010weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK", "abstract": { "Aims": [ 0 ], "Glucagon\u2010like": [ 1 ], "peptide\u20101": [ 2 ], "(GLP\u20101)": [ 3 ], "receptor": [ 4, 52 ], "agonists": [ 5 ], "are": [ 6, 26, 233 ], "appealing": [ 7 ], "as": [ 8, 19 ], "glucose\u2010lowering": [ 9 ], "therapy": [ 10 ], "for": [ 11, 224 ], "individuals": [ 12, 226 ], "with": [ 13, 28, 137, 152, 163, 170, 178, 214, 216, 230, 238 ], "type": [ 14 ], "2": [ 15 ], "diabetes": [ 16 ], "mellitus": [ 17 ], "(T2DM)": [ 18 ], "they": [ 20 ], "also": [ 21 ], "reduce": [ 22, 247 ], "body": [ 23 ], "weight": [ 24 ], "and": [ 25, 42, 73, 94, 113, 118, 132, 145, 175, 209, 246 ], "associated": [ 27, 136 ], "low": [ 29 ], "rates": [ 30, 97 ], "of": [ 31, 39, 120, 143, 167, 197 ], "hypoglycaemia.": [ 32 ], "This": [ 33 ], "analysis": [ 34 ], "assessed": [ 35 ], "the": [ 36, 62, 80, 101, 179, 228 ], "long\u2010term": [ 37 ], "cost\u2010effectiveness": [ 38 ], "semaglutide": [ 40, 130, 172, 181, 199, 219 ], "0.5": [ 41, 131, 173 ], "1": [ 43, 133, 182 ], "mg": [ 44, 48, 134, 174, 206 ], "vs": [ 45, 203 ], "dulaglutide": [ 46, 153, 204 ], "1.5": [ 47, 154, 205 ], "(two": [ 49 ], "once\u2010weekly": [ 50, 171, 180, 198, 218 ], "GLP\u20101": [ 51 ], "agonists)": [ 53 ], "from": [ 54, 100, 125, 185 ], "a": [ 55, 108, 221 ], "UK": [ 56, 229 ], "healthcare": [ 57, 69, 109 ], "payer": [ 58, 110 ], "perspective,": [ 59 ], "based": [ 60 ], "on": [ 61 ], "head\u2010to\u2010head": [ 63 ], "SUSTAIN": [ 64, 103 ], "7": [ 65, 104 ], "trial,": [ 66 ], "to": [ 67, 107, 190, 241 ], "inform": [ 68 ], "decision": [ 70 ], "making.": [ 71 ], "Materials": [ 72 ], "Methods": [ 74 ], "Long\u2010term": [ 75 ], "outcomes": [ 76, 208, 245 ], "were": [ 77, 98, 111, 123, 135, 158, 200 ], "projected": [ 78, 240 ], "using": [ 79 ], "IQVIA": [ 81 ], "CORE": [ 82 ], "Diabetes": [ 83 ], "Model": [ 84 ], "(version": [ 85 ], "9.0).": [ 86 ], "Baseline": [ 87 ], "cohort": [ 88 ], "characteristics,": [ 89 ], "changes": [ 90 ], "in": [ 91, 139, 227 ], "physiological": [ 92 ], "parameters": [ 93 ], "adverse": [ 95 ], "event": [ 96 ], "derived": [ 99 ], "40\u2010week": [ 102 ], "trial.": [ 105 ], "Costs": [ 106 ], "assessed,": [ 112 ], "these": [ 114 ], "captured": [ 115 ], "pharmacy": [ 116 ], "costs": [ 117, 119 ], "complications.": [ 121 ], "Utilities": [ 122 ], "taken": [ 124 ], "published": [ 126 ], "sources.": [ 127 ], "Results": [ 128 ], "Once\u2010weekly": [ 129 ], "improvements": [ 138 ], "quality\u2010adjusted": [ 140, 147 ], "life": [ 141, 148 ], "expectancy": [ 142 ], "0.04": [ 144 ], "0.10": [ 146 ], "years,": [ 149 ], "respectively,": [ 150 ], "compared": [ 151 ], "mg.": [ 155 ], "Clinical": [ 156 ], "benefits": [ 157 ], "achieved": [ 159 ], "at": [ 160 ], "reduced": [ 161 ], "costs,": [ 162 ], "lifetime": [ 164 ], "cost": [ 165 ], "savings": [ 166 ], "GBP": [ 168, 176 ], "35": [ 169 ], "106": [ 177 ], "mg,": [ 183 ], "resulting": [ 184 ], "fewer": [ 186 ], "diabetes\u2010related": [ 187 ], "complications": [ 188 ], "due": [ 189 ], "better": [ 191 ], "glycaemic": [ 192, 236 ], "control.": [ 193 ], "Therefore,": [ 194 ], "both": [ 195, 242 ], "doses": [ 196 ], "considered": [ 201 ], "dominant": [ 202 ], "(improving": [ 207 ], "reducing": [ 210 ], "costs).": [ 211 ], "Conclusions": [ 212 ], "Compared": [ 213 ], "treatment": [ 215 ], "dulaglutide,": [ 217 ], "represents": [ 220 ], "cost\u2010effective": [ 222 ], "option": [ 223 ], "treating": [ 225 ], "T2DM": [ 231 ], "who": [ 232 ], "not": [ 234 ], "achieving": [ 235 ], "control": [ 237 ], "metformin,": [ 239 ], "improve": [ 243 ], "clinical": [ 244 ], "costs.": [ 248 ] }, "publication_date": "2018-10-26", "publication_year": 2018, "type": "article", "cited_by_count": 43, "authors": [ { "id": "https://openalex.org/A5070756199", "display_name": "Adie Viljoen" }, { "id": "https://openalex.org/A5027220489", "display_name": "C. S. Hoxer" }, { "id": "https://openalex.org/A5051180257", "display_name": "Pierre Johansen" }, { "id": "https://openalex.org/A5029230724", "display_name": "Samuel J. P. Malkin" }, { "id": "https://openalex.org/A5072605000", "display_name": "Barnaby Hunt" }, { "id": "https://openalex.org/A5080463002", "display_name": "Stephen C. Bain" } ] }, { "id": "https://openalex.org/W2989987822", "doi": "https://doi.org/10.1177/1060028019889064", "title": "Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus", "abstract": { "Objective:The": [ 0 ], "purpose": [ 1 ], "of": [ 2, 14, 20, 126, 190, 257 ], "this": [ 3 ], "article": [ 4 ], "is": [ 5 ], "to": [ 6, 104, 131, 140, 166, 169, 185, 188, 202, 236 ], "review": [ 7, 73 ], "the": [ 8, 18, 70, 95, 124, 255 ], "pharmacological": [ 9, 252 ], "characteristics": [ 10 ], "and": [ 11, 37, 53, 59, 108, 119, 133, 151, 153, 158, 196, 205, 231, 234, 246, 250 ], "clinical": [ 12, 76 ], "evidence": [ 13 ], "oral": [ 15, 100 ], "semaglutide": [ 16, 101, 115, 136, 162, 209, 243 ], "for": [ 17, 123, 171, 219, 254 ], "treatment": [ 19, 125, 227, 256 ], "type": [ 21, 54 ], "2": [ 22, 55 ], "diabetes": [ 23 ], "mellitus": [ 24 ], "(T2DM).": [ 25 ], "Data": [ 26, 60, 112 ], "Sources:": [ 27 ], "A": [ 28, 146 ], "MEDLINE/PubMed": [ 29 ], "search": [ 30 ], "was": [ 31 ], "conducted": [ 32 ], "between": [ 33, 149, 156 ], "January": [ 34 ], "1,": [ 35 ], "2005,": [ 36 ], "September": [ 38 ], "30,": [ 39 ], "2019.": [ 40 ], "Search": [ 41 ], "terms": [ 42 ], "included": [ 43, 68, 88 ], "semaglutide,": [ 44 ], "glucagon-like": [ 45, 192 ], "peptide": [ 46 ], "1": [ 47 ], "receptor": [ 48, 51, 194 ], "agonist,": [ 49, 52 ], "GLP-1": [ 50 ], "diabetes.": [ 56 ], "Study": [ 57 ], "Selection": [ 58 ], "Extraction": [ 61 ], "Quantification:": [ 62 ], "The": [ 63 ], "following": [ 64 ], "study": [ 65, 80 ], "designs": [ 66 ], "were": [ 67, 84, 87, 92 ], "in": [ 69, 94, 110, 142, 199 ], "analysis:": [ 71 ], "systematic": [ 72 ], "and/or": [ 74 ], "meta-analyses,": [ 75 ], "trial,": [ 77 ], "or": [ 78, 98, 215 ], "observational": [ 79 ], "design.": [ 81 ], "Narrative": [ 82 ], "reviews": [ 83 ], "excluded.": [ 85 ], "Articles": [ 86 ], "only": [ 89 ], "if": [ 90 ], "they": [ 91 ], "published": [ 93 ], "English": [ 96 ], "language": [ 97 ], "evaluated": [ 99 ], "with": [ 102, 221 ], "regard": [ 103 ], "pharmacology,": [ 105 ], "pharmacokinetics,": [ 106 ], "safety,": [ 107 ], "efficacy": [ 109 ], "humans.": [ 111 ], "Synthesis:": [ 113 ], "Oral": [ 114, 135, 161, 208, 242 ], "has": [ 116, 137, 163 ], "been": [ 117, 138, 164 ], "Food": [ 118 ], "Drug": [ 120 ], "Administration": [ 121 ], "approved": [ 122 ], "T2DM": [ 127, 222 ], "as": [ 128, 213, 248 ], "an": [ 129, 143, 238 ], "adjunct": [ 130 ], "diet": [ 132 ], "exercise.": [ 134 ], "shown": [ 139, 165 ], "result": [ 141 ], "absolute": [ 144 ], "hemoglobin": [ 145 ], "1C": [ 147 ], "reduction": [ 148 ], "\u22120.5%": [ 150 ], "\u22121.5%": [ 152 ], "weight": [ 154 ], "reductions": [ 155 ], "\u22121": [ 157 ], "\u22124.7": [ 159 ], "kg.": [ 160 ], "be": [ 167, 186, 211 ], "noninferior": [ 168 ], "placebo": [ 170 ], "cardiovascular": [ 172 ], "(CV)": [ 173 ], "safety": [ 174 ], "although": [ 175 ], "additional": [ 176 ], "CV": [ 177 ], "outcomes": [ 178 ], "trials": [ 179 ], "are": [ 180, 197, 224, 232 ], "ongoing.": [ 181 ], "Adverse": [ 182 ], "effects": [ 183 ], "appear": [ 184 ], "similar": [ 187 ], "those": [ 189 ], "other": [ 191 ], "peptide-1": [ 193 ], "agonists": [ 195 ], "gastrointestinal": [ 198 ], "nature.": [ 200 ], "Relevance": [ 201 ], "Patient": [ 203 ], "Care": [ 204 ], "Clinical": [ 206 ], "Practice:": [ 207 ], "may": [ 210 ], "appropriate": [ 212 ], "second-": [ 214 ], "third-line": [ 216 ], "add-on": [ 217, 251 ], "therapy": [ 218, 253 ], "patients": [ 220 ], "who": [ 223 ], "not": [ 225 ], "meeting": [ 226 ], "goals": [ 228 ], "on": [ 229 ], "metformin": [ 230 ], "overweight": [ 233 ], "reluctant": [ 235 ], "use": [ 237 ], "injectable": [ 239 ], "drug.": [ 240 ], "Conclusions:": [ 241 ], "appears": [ 244 ], "safe": [ 245 ], "effective": [ 247 ], "monotherapy": [ 249 ], "T2DM.": [ 258 ] }, "publication_date": "2019-11-19", "publication_year": 2019, "type": "review", "cited_by_count": 35, "authors": [ { "id": "https://openalex.org/A5059786545", "display_name": "Kevin Cowart" } ] }, { "id": "https://openalex.org/W1934495549", "doi": "https://doi.org/10.1210/jc.2015-1176", "title": "GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women", "abstract": { "Treatment": [ 0 ], "with": [ 1 ], "a": [ 2, 20, 27 ], "long-acting": [ 3 ], "GLP-1": [ 4 ], "RA": [ 5 ], "increased": [ 6 ], "bone": [ 7, 13 ], "formation": [ 8 ], "by": [ 9 ], "16%": [ 10 ], "and": [ 11 ], "prevented": [ 12 ], "loss": [ 14, 17 ], "after": [ 15 ], "weight": [ 16 ], "obtained": [ 18 ], "through": [ 19 ], "low-calorie": [ 21 ], "diet,": [ 22 ], "supporting": [ 23 ], "its": [ 24 ], "role": [ 25 ], "as": [ 26 ], "safe": [ 28 ], "weight-lowering": [ 29 ], "agent.": [ 30 ] }, "publication_date": "2015-06-04", "publication_year": 2015, "type": "article", "cited_by_count": 173, "authors": [ { "id": "https://openalex.org/A5109903929", "display_name": "Eva W. Iepsen" }, { "id": "https://openalex.org/A5007991615", "display_name": "J. Lundgren" }, { "id": "https://openalex.org/A5047145712", "display_name": "Bolette Hartmann" }, { "id": "https://openalex.org/A5066665434", "display_name": "Oluf Pedersen" }, { "id": "https://openalex.org/A5100704087", "display_name": "Torben Hansen" }, { "id": "https://openalex.org/A5069431123", "display_name": "Niklas Rye J\u00f8rgensen" }, { "id": "https://openalex.org/A5058323484", "display_name": "Jens\u2010Erik Beck Jensen" }, { "id": "https://openalex.org/A5085434984", "display_name": "Jens J. Holst" }, { "id": "https://openalex.org/A5062239390", "display_name": "Sten Madsbad" }, { "id": "https://openalex.org/A5038081896", "display_name": "Signe S. Torekov" } ] }, { "id": "https://openalex.org/W2090054860", "doi": "https://doi.org/10.2337/dc13-2761", "title": "Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)", "abstract": { "OBJECTIVE": [ 0 ], "To": [ 1 ], "compare": [ 2, 34 ], "the": [ 3 ], "efficacy": [ 4 ], "and": [ 5, 37, 147, 162, 200, 230, 236, 255 ], "safety": [ 6, 256 ], "of": [ 7, 10, 179 ], "two": [ 8 ], "doses": [ 9, 167, 241 ], "once-weekly": [ 11 ], "dulaglutide,": [ 12 ], "a": [ 13 ], "glucagon-like": [ 14 ], "peptide": [ 15 ], "1": [ 16 ], "receptor": [ 17 ], "agonist,": [ 18 ], "to": [ 19, 33, 88, 103, 124, 170, 187 ], "sitagliptin": [ 20, 44, 95, 171, 210, 247 ], "in": [ 21, 45, 49, 227 ], "uncontrolled,": [ 22 ], "metformin-treated": [ 23 ], "patients": [ 24, 68 ], "with": [ 25, 112, 192, 209, 251 ], "type": [ 26 ], "2": [ 27 ], "diabetes.": [ 28 ], "The": [ 29, 106, 120, 220 ], "primary": [ 30, 114 ], "objective": [ 31 ], "was": [ 32 ], "(for": [ 35 ], "noninferiority": [ 36 ], "then": [ 38 ], "superiority)": [ 39 ], "dulaglutide": [ 40, 89, 92, 156, 159, 166, 193, 201, 228, 240 ], "1.5": [ 41, 90, 157, 194 ], "mg": [ 42, 195, 203 ], "versus": [ 43, 246 ], "change": [ 46 ], "from": [ 47 ], "baseline": [ 48, 73 ], "glycosylated": [ 50 ], "hemoglobin": [ 51 ], "A1c": [ 52 ], "(HbA1c)": [ 53 ], "at": [ 54, 248 ], "52": [ 55, 125, 188, 249 ], "weeks.": [ 56 ], "RESEARCH": [ 57 ], "DESIGN": [ 58 ], "AND": [ 59 ], "METHODS": [ 60 ], "This": [ 61 ], "multicenter,": [ 62 ], "adaptive,": [ 63 ], "double-blind,": [ 64 ], "parallel-arm": [ 65 ], "study": [ 66 ], "randomized": [ 67 ], "(N": [ 69 ], "=": [ 70 ], "1,098;": [ 71 ], "mean": [ 72, 121, 130 ], "age": [ 74 ], "54": [ 75 ], "years;": [ 76 ], "HbA1c": [ 77, 122 ], "8.1%": [ 78 ], "[65": [ 79 ], "mmol/mol];": [ 80 ], "weight": [ 81, 185 ], "86.4": [ 82 ], "kg;": [ 83 ], "diabetes": [ 84 ], "duration": [ 85 ], "7": [ 86 ], "years)": [ 87 ], "mg,": [ 91, 94, 97, 158, 161 ], "0.75": [ 93, 160, 202 ], "100": [ 96 ], "or": [ 98 ], "placebo": [ 99 ], "(placebo-controlled": [ 100 ], "period": [ 101, 108 ], "up": [ 102 ], "26": [ 104 ], "weeks).": [ 105 ], "treatment": [ 107 ], "lasted": [ 109 ], "104": [ 110 ], "weeks,": [ 111 ], "52-week": [ 113 ], "end": [ 115 ], "point": [ 116 ], "data": [ 117 ], "presented.": [ 118 ], "RESULTS": [ 119 ], "changes": [ 123, 186 ], "weeks": [ 126, 189, 250 ], "were": [ 127, 168, 182, 190, 233 ], "(least": [ 128 ], "squares": [ 129 ], "\u00b1": [ 131, 134, 137, 141, 144, 149, 152, 197, 205, 212 ], "SE):": [ 132 ], "\u22121.10": [ 133 ], "0.06%": [ 135, 142, 150 ], "(\u221212.0": [ 136 ], "0.7": [ 138, 145, 153 ], "mmol/mol),": [ 139, 146 ], "\u22120.87": [ 140 ], "(9.5": [ 143 ], "\u22120.39": [ 148 ], "(4.3": [ 151 ], "mmol/mol)": [ 154 ], "for": [ 155 ], "sitagliptin,": [ 163 ], "respectively.": [ 164 ], "Both": [ 165, 239 ], "superior": [ 169, 243 ], "(P": [ 172, 215 ], "&lt;": [ 173, 216 ], "0.001,": [ 174, 217 ], "both": [ 175, 218 ], "comparisons).": [ 176, 219 ], "No": [ 177 ], "events": [ 178, 226 ], "severe": [ 180 ], "hypoglycemia": [ 181 ], "reported.": [ 183 ], "Mean": [ 184 ], "greater": [ 191 ], "(\u22123.03": [ 196 ], "0.22": [ 198, 213 ], "kg)": [ 199, 207, 214 ], "(\u22122.60": [ 204 ], "0.23": [ 206 ], "compared": [ 208 ], "(\u22121.53": [ 211 ], "most": [ 221 ], "common": [ 222 ], "gastrointestinal": [ 223 ], "treatment-emergent": [ 224 ], "adverse": [ 225 ], "1.5-": [ 229 ], "0.75-mg": [ 231 ], "arms": [ 232 ], "nausea,": [ 234 ], "diarrhea,": [ 235 ], "vomiting.": [ 237 ], "CONCLUSIONS": [ 238 ], "demonstrated": [ 242 ], "glycemic": [ 244 ], "control": [ 245 ], "an": [ 252 ], "acceptable": [ 253 ], "tolerability": [ 254 ], "profile.": [ 257 ] }, "publication_date": "2014-04-18", "publication_year": 2014, "type": "article", "cited_by_count": 269, "authors": [ { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5080916339", "display_name": "Ruth S. Weinstock" }, { "id": "https://openalex.org/A5061058170", "display_name": "Guillermo E. Umpierrez" }, { "id": "https://openalex.org/A5064287355", "display_name": "Bruno Guerci" }, { "id": "https://openalex.org/A5010436601", "display_name": "Zachary Skrivanek" }, { "id": "https://openalex.org/A5024563374", "display_name": "Zvonko Mili\u010devi\u0107" } ] }, { "id": "https://openalex.org/W2122945478", "doi": "https://doi.org/10.1161/atvbaha.115.305447", "title": "GLP-1 Receptor Agonist Exenatide Increases Capillary Perfusion Independent of Nitric Oxide in Healthy Overweight Men", "abstract": { "Objective\u2014": [ 0 ], "The": [ 1 ], "insulinotropic": [ 2 ], "gut\u2013derived": [ 3 ], "hormone": [ 4 ], "glucagon-like": [ 5 ], "peptide-1": [ 6 ], "(GLP-1)": [ 7 ], "increases": [ 8, 211 ], "capillary": [ 9, 39, 54, 122, 134, 187, 212 ], "perfusion": [ 10, 188, 213, 230 ], "via": [ 11, 214 ], "a": [ 12, 97 ], "nitric": [ 13, 62, 104, 215 ], "oxide\u2013dependent": [ 14 ], "mechanism": [ 15 ], "in": [ 16, 64, 218 ], "rodents.": [ 17 ], "This": [ 18 ], "improves": [ 19 ], "skeletal": [ 20 ], "muscle": [ 21 ], "glucose": [ 22 ], "use": [ 23 ], "and": [ 24, 67, 96, 101, 117, 119, 132, 138, 183 ], "cardiac": [ 25 ], "function.": [ 26 ], "In": [ 27 ], "humans,": [ 28 ], "the": [ 29, 47, 50, 59, 102, 155, 169 ], "effect": [ 30 ], "of": [ 31, 49, 61, 91, 99, 157, 172, 203, 225 ], "clinically": [ 32 ], "used": [ 33 ], "GLP-1": [ 34 ], "receptor": [ 35 ], "agonists": [ 36 ], "(GLP-1RAs)": [ 37 ], "on": [ 38, 53, 228 ], "density": [ 40, 55, 135 ], "is": [ 41 ], "unknown.": [ 42 ], "We": [ 43, 69 ], "aimed": [ 44 ], "to": [ 45 ], "assess": [ 46 ], "effects": [ 48, 156 ], "GLP-1RA": [ 51, 227 ], "exenatide": [ 52, 100, 129, 199, 209 ], "as": [ 56, 58 ], "well": [ 57 ], "involvement": [ 60 ], "oxide": [ 63 ], "humans.": [ 65 ], "Approach": [ 66 ], "Results\u2014": [ 68 ], "included": [ 70 ], "10": [ 71 ], "healthy": [ 72, 219 ], "overweight": [ 73, 220 ], "men": [ 74 ], "(age,": [ 75 ], "20\u201327": [ 76 ], "years;": [ 77 ], "body": [ 78 ], "mass": [ 79 ], "index,": [ 80 ], "26\u201331": [ 81 ], "kg/m": [ 82 ], "2": [ 83 ], ").": [ 84 ], "Measurements": [ 85 ], "were": [ 86, 124, 196, 205 ], "performed": [ 87 ], "during": [ 88, 198 ], "intravenous": [ 89 ], "infusion": [ 90, 151, 210 ], "placebo": [ 92 ], "(saline": [ 93 ], "0.9%),": [ 94 ], "exenatide,": [ 95 ], "combination": [ 98 ], "nonselective": [ 103 ], "oxide\u2013synthase": [ 105 ], "inhibitor": [ 106 ], "l": [ 107, 145 ], "-": [ 108, 146 ], "N": [ 109, 147 ], "G": [ 110, 148 ], "-monomethyl": [ 111, 149 ], "arginine.": [ 112 ], "Capillary": [ 113 ], "videomicroscopy": [ 114 ], "was": [ 115, 160, 181 ], "performed,": [ 116 ], "baseline": [ 118, 131 ], "postocclusive": [ 120 ], "(peak)": [ 121 ], "densities": [ 123 ], "counted.": [ 125 ], "Compared": [ 126 ], "with": [ 127, 186, 233 ], "placebo,": [ 128 ], "increased": [ 130 ], "peak": [ 133 ], "by": [ 136 ], "20.1%": [ 137 ], "8.3%,": [ 139 ], "respectively": [ 140 ], "(both": [ 141 ], "P": [ 142, 178, 192 ], "=0.016).": [ 143 ], "Concomitant": [ 144 ], "arginine": [ 150 ], "did": [ 152 ], "not": [ 153 ], "alter": [ 154 ], "exenatide.": [ 158 ], "Vasomotion": [ 159 ], "assessed": [ 161 ], "using": [ 162 ], "laser": [ 163 ], "Doppler": [ 164 ], "fluxmetry.": [ 165 ], "Exenatide": [ 166 ], "nonsignificantly": [ 167 ], "reduced": [ 168, 197 ], "neurogenic": [ 170 ], "domain": [ 171 ], "vasomotion": [ 173 ], "measurements": [ 174 ], "(": [ 175, 189 ], "R": [ 176, 190 ], "=\u22125.6%;": [ 177 ], "=0.092),": [ 179 ], "which": [ 180 ], "strongly": [ 182 ], "inversely": [ 184 ], "associated": [ 185 ], "=\u22120.928;": [ 191 ], "=0.036).": [ 193 ], "Glucose": [ 194 ], "levels": [ 195, 202 ], "infusion,": [ 200 ], "whereas": [ 201 ], "insulin": [ 204 ], "unchanged.": [ 206 ], "Conclusions\u2014": [ 207 ], "Acute": [ 208 ], "oxide\u2013independent": [ 216 ], "pathways": [ 217 ], "men,": [ 221 ], "suggesting": [ 222 ], "direct": [ 223 ], "actions": [ 224 ], "this": [ 226 ], "microvascular": [ 229 ], "or": [ 231 ], "interaction": [ 232 ], "vasoactive": [ 234 ], "factors.": [ 235 ] }, "publication_date": "2015-04-24", "publication_year": 2015, "type": "article", "cited_by_count": 36, "authors": [ { "id": "https://openalex.org/A5091895526", "display_name": "Mark M. Smits" }, { "id": "https://openalex.org/A5084278641", "display_name": "Marcel H.A. Muskiet" }, { "id": "https://openalex.org/A5067721247", "display_name": "Lennart Tonneijck" }, { "id": "https://openalex.org/A5028760009", "display_name": "Mark H.H. Kramer" }, { "id": "https://openalex.org/A5109335776", "display_name": "Micha\u00ebla Diamant" }, { "id": "https://openalex.org/A5067127165", "display_name": "Dani\u00ebl H. van Raalte" }, { "id": "https://openalex.org/A5075327554", "display_name": "Erik H. Sern\u00e9" } ] }, { "id": "https://openalex.org/W2020657853", "doi": "https://doi.org/10.1177/8755122514539462", "title": "Systemic Allergic Reaction to the GLP-1 Receptor Agonist Exenatide", "abstract": { "Objective:": [ 0 ], "To": [ 1 ], "report": [ 2, 39 ], "a": [ 3, 41, 100, 251 ], "case": [ 4 ], "of": [ 5, 27, 31, 153, 211, 227, 241 ], "systemic": [ 6, 245 ], "hypersensitivity": [ 7, 246 ], "to": [ 8, 20, 60, 69, 76, 86, 158, 184, 202 ], "the": [ 9, 25, 54, 104, 135, 146, 185, 199, 221, 225 ], "glucagon-like": [ 10 ], "peptide-1": [ 11 ], "(GLP-1)": [ 12 ], "receptor": [ 13, 229, 243 ], "agonist": [ 14, 49 ], "exenatide": [ 15, 63, 111, 203 ], "used": [ 16 ], "in": [ 17, 253 ], "diabetes": [ 18 ], "care": [ 19 ], "provide": [ 21 ], "significant": [ 22 ], "information": [ 23 ], "within": [ 24 ], "context": [ 26 ], "postmarketing": [ 28 ], "safety": [ 29 ], "surveillance": [ 30 ], "this": [ 32 ], "new": [ 33 ], "drug": [ 34 ], "class.": [ 35 ], "Case": [ 36 ], "Summary:": [ 37 ], "We": [ 38 ], "on": [ 40, 58, 108 ], "52-year-old": [ 42 ], "male": [ 43 ], "with": [ 44, 84, 234 ], "insufficiently": [ 45 ], "controlled": [ 46 ], "diabetes.": [ 47 ], "GLP-1": [ 48, 228, 242 ], "treatment": [ 50, 116 ], "was": [ 51, 56, 93, 106, 177, 187, 205, 214 ], "indicated": [ 52 ], "and": [ 53, 123, 140, 144, 151, 160, 169, 220 ], "patient": [ 55, 105 ], "started": [ 57, 107 ], "5": [ 59 ], "10": [ 61 ], "\u00b5g": [ 62 ], "(Byetta)": [ 64 ], "twice": [ 65, 121 ], "daily,": [ 66 ], "which": [ 67, 156 ], "had": [ 68 ], "be": [ 70, 248 ], "stopped": [ 71 ], "after": [ 72, 99, 134, 145 ], "1": [ 73 ], "month": [ 74 ], "due": [ 75 ], "intolerable": [ 77 ], "nausea.": [ 78 ], "One": [ 79 ], "year": [ 80 ], "later,": [ 81 ], "an": [ 82 ], "attempt": [ 83 ], "0.6": [ 85 ], "1.8": [ 87 ], "mg": [ 88, 110, 120, 128 ], "liraglutide": [ 89 ], "(Victoza)": [ 90 ], "once": [ 91, 113, 129 ], "daily": [ 92, 122 ], "well": [ 94 ], "tolerated": [ 95 ], "but": [ 96 ], "lacked": [ 97 ], "efficacy": [ 98 ], "few": [ 101, 132 ], "months.": [ 102 ], "Finally,": [ 103 ], "2": [ 109 ], "(Bydureon)": [ 112, 204 ], "weekly.": [ 114 ], "Concomitant": [ 115 ], "included": [ 117 ], "metformine": [ 118 ], "1000": [ 119 ], "candesartan/hydrochlorothiazide": [ 124 ], "(Blopress": [ 125 ], "Plus)": [ 126 ], "16/12.5": [ 127 ], "daily.": [ 130 ], "A": [ 131 ], "hours": [ 133 ], "second": [ 136 ], "injection,": [ 137 ], "local": [ 138 ], "urticaria": [ 139 ], "disseminated": [ 141 ], "pruritus": [ 142 ], "evolved": [ 143 ], "third": [ 147 ], "injection": [ 148 ], "pruritus,": [ 149 ], "urticaria,": [ 150 ], "shortness": [ 152 ], "breath": [ 154 ], "developed,": [ 155 ], "resolved": [ 157 ], "antihistamines": [ 159 ], "corticosteroids.": [ 161 ], "Intradermal": [ 162 ], "tests": [ 163, 219 ], "were": [ 164 ], "positive": [ 165, 217 ], "for": [ 166, 190 ], "Byetta": [ 167 ], "(1:1000)": [ 168 ], "Bydureon": [ 170 ], "(1:100)": [ 171 ], "(both": [ 172 ], "exenatide),": [ 173 ], "while": [ 174 ], "Victoza": [ 175 ], "(liraglutide)": [ 176 ], "negative": [ 178 ], "(1:10).": [ 179 ], "Specific": [ 180 ], "immunoglobulin": [ 181 ], "E": [ 182 ], "(IgE)": [ 183 ], "drugs": [ 186 ], "not": [ 188 ], "available": [ 189 ], "testing.": [ 191 ], "Discussion:": [ 192 ], "An": [ 193 ], "objective": [ 194 ], "causality": [ 195 ], "assessment": [ 196 ], "revealed": [ 197 ], "that": [ 198, 224 ], "adverse": [ 200 ], "effect": [ 201 ], "probable": [ 206 ], "(Naranjo": [ 207 ], "probability": [ 208 ], "scale:": [ 209 ], "score": [ 210 ], "8).": [ 212 ], "Consistency": [ 213 ], "established": [ 215 ], "through": [ 216 ], "skin": [ 218 ], "biological": [ 222 ], "explanation": [ 223 ], "administration": [ 226 ], "agonists": [ 230 ], "has": [ 231 ], "been": [ 232 ], "associated": [ 233 ], "antibody": [ 235 ], "formation.": [ 236 ], "Conclusion:": [ 237 ], "Considering": [ 238 ], "emerging": [ 239 ], "use": [ 240 ], "agonists,": [ 244 ], "should": [ 247 ], "recognized": [ 249 ], "as": [ 250 ], "risk": [ 252 ], "clinical": [ 254 ], "practice.": [ 255 ] }, "publication_date": "2014-06-19", "publication_year": 2014, "type": "article", "cited_by_count": 15, "authors": [ { "id": "https://openalex.org/A5072179317", "display_name": "Esther Helen Steveling" }, { "id": "https://openalex.org/A5023967301", "display_name": "Bettina Winzeler" }, { "id": "https://openalex.org/A5002183309", "display_name": "Andreas J. Bircher" } ] }, { "id": "https://openalex.org/W4401715897", "doi": "https://doi.org/10.1001/jamanetworkopen.2024.23385", "title": "Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality", "abstract": { "Importance": [ 0 ], "Glucagon-like": [ 1 ], "peptide-1": [ 2 ], "receptor": [ 3 ], "agonists": [ 4 ], "(GLP-1": [ 5 ], "RAs)": [ 6 ], "have": [ 7 ], "gained": [ 8 ], "use": [ 9, 158, 263 ], "primarily": [ 10 ], "due": [ 11 ], "to": [ 12, 78, 87, 96 ], "their": [ 13 ], "weight-reduction": [ 14 ], "effects,": [ 15 ], "although": [ 16 ], "a": [ 17, 335 ], "regulatory": [ 18 ], "review": [ 19 ], "was": [ 20, 174, 239 ], "undertaken": [ 21 ], "for": [ 22, 31, 242 ], "potential": [ 23, 29 ], "suicidality": [ 24 ], "concern.": [ 25 ], "Objectives": [ 26 ], "To": [ 27 ], "evaluate": [ 28 ], "signals": [ 30 ], "suicidal": [ 32, 136, 220, 244, 339 ], "and": [ 33, 45, 49, 113, 119, 137, 143, 161, 163, 167, 183, 188, 206, 229, 234, 276, 313, 326 ], "self-injurious": [ 34, 138, 222 ], "adverse": [ 35 ], "drug": [ 36 ], "reactions": [ 37 ], "(ADRs)": [ 38 ], "associated": [ 39, 140 ], "with": [ 40, 101, 125, 141, 146, 156, 232, 261, 290 ], "the": [ 41, 54, 58, 83, 120, 177, 181, 331 ], "GLP-1": [ 42 ], "RAs": [ 43 ], "semaglutide": [ 44, 79, 102, 142, 233 ], "liraglutide.": [ 46 ], "Design,": [ 47 ], "Setting,": [ 48 ], "Participants": [ 50, 68 ], "Disproportionality": [ 51 ], "analysis": [ 52 ], "through": [ 53 ], "case-control": [ 55 ], "design": [ 56 ], "using": [ 57, 164, 330 ], "World": [ 59 ], "Health": [ 60 ], "Organization": [ 61 ], "(WHO)": [ 62 ], "global": [ 63 ], "database": [ 64, 84, 333 ], "of": [ 65, 106, 132, 135, 159, 180, 194, 219, 264, 337 ], "suspected": [ 66 ], "ADRs.": [ 67 ], "were": [ 69, 92, 128, 152, 185, 224 ], "clinical": [ 70 ], "patients": [ 71, 155, 204, 216, 260 ], "worldwide": [ 72 ], "experiencing": [ 73 ], "an": [ 74 ], "ADR": [ 75 ], "suspectedly": [ 76 ], "attributable": [ 77 ], "or": [ 80, 103, 108 ], "liraglutide": [ 81, 104, 144 ], "in": [ 82, 259 ], "from": [ 85, 94 ], "inception": [ 86 ], "August": [ 88, 230 ], "30,": [ 89 ], "2023.": [ 90, 98 ], "Data": [ 91 ], "analyzed": [ 93 ], "September": [ 95 ], "December": [ 97 ], "Exposure": [ 99 ], "Treatment": [ 100 ], "regardless": [ 105 ], "indication": [ 107 ], "treatment": [ 109 ], "duration.": [ 110 ], "Main": [ 111 ], "Outcomes": [ 112 ], "Measures": [ 114 ], "Reporting": [ 115 ], "odds": [ 116 ], "ratio": [ 117 ], "(ROR)": [ 118 ], "bayesian": [ 121 ], "information": [ 122 ], "component": [ 123 ], "(IC)": [ 124 ], "95%": [ 126, 248, 253, 268, 273, 280, 285, 294, 299, 305, 310, 317, 322 ], "CIs": [ 127 ], "calculated": [ 129 ], "as": [ 130, 169 ], "measures": [ 131 ], "disproportionate": [ 133 ], "reporting": [ 134 ], "ADRs": [ 139, 223 ], "compared": [ 145, 289 ], "all": [ 147 ], "other": [ 148 ], "medications.": [ 149 ], "Sensitivity": [ 150 ], "analyses": [ 151 ], "conducted": [ 153 ], "including": [ 154 ], "coreported": [ 157, 262 ], "antidepressants": [ 160, 265 ], "benzodiazepines": [ 162, 277 ], "dapagliflozin,": [ 165 ], "metformin,": [ 166 ], "orlistat": [ 168, 314 ], "comparators.": [ 170 ], "A": [ 171, 192 ], "disproportionality": [ 172, 238 ], "signal": [ 173, 336 ], "considered": [ 175 ], "when": [ 176, 288 ], "lower": [ 178 ], "limits": [ 179 ], "ROR": [ 182 ], "IC": [ 184 ], "above": [ 186 ], "1": [ 187 ], "0,": [ 189 ], "respectively.": [ 190, 236 ], "Results": [ 191 ], "total": [ 193 ], "107": [ 195 ], "(median": [ 196, 208 ], "[IQR]": [ 197, 209 ], "age": [ 198, 210 ], "48": [ 199 ], "[40-56]": [ 200 ], "years;": [ 201, 213 ], "59": [ 202 ], "female": [ 203, 215 ], "[55%])": [ 205 ], "162": [ 207 ], "47": [ 211 ], "[38-60]": [ 212 ], "100": [ 214 ], "[61%])": [ 217 ], "cases": [ 218 ], "and/or": [ 221 ], "reported": [ 225 ], "between": [ 226 ], "November": [ 227 ], "2000": [ 228 ], "2023": [ 231 ], "liraglutide,": [ 235 ], "Significant": [ 237 ], "detected": [ 240 ], "only": [ 241 ], "semaglutide-associated": [ 243, 338 ], "ideation": [ 245 ], "(ROR,": [ 246, 266, 278, 292, 303, 315 ], "1.45;": [ 247 ], "CI,": [ 249, 254, 269, 274, 281, 286, 295, 300, 306, 311, 318, 323 ], "1.18-1.77;": [ 250 ], "IC,": [ 251, 271, 283, 297, 308, 320 ], "0.53;": [ 252 ], "0.19-0.78),": [ 255 ], "which": [ 256, 341 ], "remained": [ 257 ], "significant": [ 258 ], "4.45;": [ 267 ], "2.52-7.86;": [ 270 ], "1.96;": [ 272 ], "0.98-2.63)": [ 275 ], "4.07;": [ 279 ], "1.69-9.82;": [ 282 ], "1.67;": [ 284 ], "0.11-2.65),": [ 287 ], "dapagliflozin": [ 291 ], "5.56;": [ 293 ], "3.23-9.60;": [ 296 ], "0.70;": [ 298, 321 ], "0.36-0.95),": [ 301 ], "metformin": [ 302 ], "3.86;": [ 304 ], "2.91-5.12;": [ 307 ], "1.20;": [ 309 ], "0.94-1.53)": [ 312 ], "4.24;": [ 316 ], "2.69-6.69;": [ 319 ], "0.36-0.95).": [ 324 ], "Conclusions": [ 325 ], "Relevance": [ 327 ], "This": [ 328 ], "study": [ 329 ], "WHO": [ 332 ], "found": [ 334 ], "ideation,": [ 340 ], "warrants": [ 342 ], "urgent": [ 343 ], "clarification.": [ 344 ] }, "publication_date": "2024-08-20", "publication_year": 2024, "type": "article", "cited_by_count": 60, "authors": [ { "id": "https://openalex.org/A5071320525", "display_name": "Georgios Schoretsanitis" }, { "id": "https://openalex.org/A5038573071", "display_name": "Stefan Weiler" }, { "id": "https://openalex.org/A5039199295", "display_name": "Corrado Barbui" }, { "id": "https://openalex.org/A5069397170", "display_name": "Emanuel Raschi" }, { "id": "https://openalex.org/A5037977828", "display_name": "Chiara Gastaldon" } ] }, { "id": "https://openalex.org/W2893883775", "doi": "https://doi.org/10.1016/j.biopha.2018.08.088", "title": "Recent updates on GLP-1 agonists: Current advancements & challenges", "abstract": { "Glucagon-like": [ 0 ], "peptide": [ 1 ], "(GLP)-1": [ 2 ], "is": [ 3 ], "an": [ 4 ], "incretin": [ 5 ], "hormone": [ 6 ], "exhibiting": [ 7 ], "several": [ 8 ], "pharmacological": [ 9 ], "actions": [ 10, 34 ], "such": [ 11, 101 ], "as": [ 12, 102, 156 ], "neuroprotection,": [ 13 ], "increased": [ 14 ], "cognitive": [ 15 ], "function,": [ 16 ], "cardio-protection,": [ 17 ], "decreased": [ 18 ], "hypertension,": [ 19 ], "suppression": [ 20 ], "of": [ 21, 42, 83, 94, 136, 140, 169 ], "acid": [ 22 ], "secretion,": [ 23 ], "increase": [ 24 ], "in": [ 25, 52, 98, 121, 162 ], "lyposis,": [ 26 ], "and": [ 27, 38, 48, 71, 114, 127, 134, 171 ], "protection": [ 28 ], "from": [ 29 ], "inflammation.": [ 30 ], "The": [ 31 ], "most": [ 32 ], "potent": [ 33 ], "are": [ 35 ], "glucose-dependent": [ 36 ], "insulinotropic": [ 37 ], "glucagonostatic": [ 39 ], "actions,": [ 40, 65 ], "stimulation": [ 41 ], "\u03b2-cell": [ 43 ], "proliferation,": [ 44 ], "enhanced": [ 45 ], "insulin": [ 46 ], "secretion": [ 47 ], "reduced": [ 49 ], "weight": [ 50, 172 ], "gain": [ 51 ], "patients": [ 53 ], "with": [ 54 ], "type-2": [ 55, 152 ], "diabetes": [ 56, 153 ], "pertaining": [ 57 ], "to": [ 58, 150, 158 ], "blood": [ 59 ], "glucose": [ 60 ], "control.": [ 61 ], "Despite": [ 62 ], "all": [ 63 ], "these": [ 64 ], "its": [ 66 ], "short": [ 67 ], "half-life": [ 68 ], "(around": [ 69 ], "2\u223cmin)": [ 70 ], "degradation": [ 72 ], "by": [ 73 ], "a": [ 74 ], "dipeptidyl": [ 75 ], "peptidase-4": [ 76 ], "enzyme": [ 77 ], "(DPP-4)": [ 78 ], "limits": [ 79 ], "the": [ 80, 123, 166 ], "therapeutic": [ 81 ], "utility": [ 82 ], "GLP1.": [ 84 ], "In": [ 85 ], "this": [ 86 ], "review,": [ 87 ], "we": [ 88, 117 ], "have": [ 89, 118, 146 ], "discussed": [ 90, 120 ], "DPP": [ 91, 137 ], "IV-resistant": [ 92, 138 ], "analogs": [ 93, 139 ], "GLP-1": [ 95, 143 ], "currently": [ 96, 159 ], "present": [ 97 ], "clinical": [ 99 ], "trials": [ 100 ], "Exenatide,": [ 103 ], "Liraglutide,": [ 104 ], "Semaglutide,": [ 105 ], "Efpeglenatide,": [ 106 ], "Exenatide": [ 107 ], "ER,": [ 108 ], "Ittca": [ 109 ], "650": [ 110 ], "(Intarcia),": [ 111 ], "Dulaglutide,": [ 112 ], "Albiglutide,": [ 113 ], "Lixisenatide.": [ 115 ], "Moreover,": [ 116 ], "also": [ 119 ], "detail": [ 122 ], "pharmacology,": [ 124 ], "signaling": [ 125 ], "mechanisms,": [ 126 ], "pharmacokinetic": [ 128 ], "properties": [ 129 ], "(Cmax,": [ 130 ], "Tmax,": [ 131 ], "T1/2,": [ 132 ], "Vd,": [ 133 ], "Bioavailability)": [ 135 ], "(GLP-1).": [ 141 ], "Interestingly,": [ 142 ], "agonist": [ 144 ], "drugs": [ 145, 161 ], "shown": [ 147 ], "better": [ 148 ], "potential": [ 149 ], "treat": [ 151 ], "mellitus": [ 154 ], "(T2DM)": [ 155 ], "compared": [ 157 ], "used": [ 160 ], "clinics": [ 163 ], "without": [ 164 ], "causing": [ 165 ], "side": [ 167 ], "effects": [ 168 ], "hypoglycemia": [ 170 ], "gain.": [ 173 ] }, "publication_date": "2018-09-26", "publication_year": 2018, "type": "review", "cited_by_count": 238, "authors": [ { "id": "https://openalex.org/A5082191286", "display_name": "Dilip Kumar Sharma" }, { "id": "https://openalex.org/A5002181874", "display_name": "Suril Verma" }, { "id": "https://openalex.org/A5026061187", "display_name": "Shivani Vaidya" }, { "id": "https://openalex.org/A5082544781", "display_name": "Kiran Kalia" }, { "id": "https://openalex.org/A5074901729", "display_name": "Vinod Tiwari" } ] }, { "id": "https://openalex.org/W2160442093", "doi": "https://doi.org/10.1517/14656566.2012.692777", "title": "A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes", "abstract": { "Liraglutide": [ 0 ], "seems": [ 1 ], "to": [ 2, 47, 49 ], "be": [ 3 ], "the": [ 4 ], "most": [ 5 ], "effective": [ 6 ], "GLP-1": [ 7 ], "receptor": [ 8 ], "agonist": [ 9 ], "in": [ 10, 59 ], "terms": [ 11, 60 ], "of": [ 12, 61 ], "HbA(1c)": [ 13 ], "reduction": [ 14 ], "and": [ 15, 38, 67 ], "weight": [ 16 ], "loss.": [ 17 ], "Exenatide": [ 18, 32 ], "BID": [ 19, 37 ], "may": [ 20, 55 ], "offer": [ 21 ], "an": [ 22 ], "advantage": [ 23 ], "where": [ 24 ], "postprandial": [ 25 ], "glucose": [ 26 ], "control": [ 27 ], "is": [ 28, 39 ], "a": [ 29, 40 ], "primary": [ 30 ], "concern.": [ 31 ], "ER": [ 33 ], "generally": [ 34 ], "outperforms": [ 35 ], "exenatide": [ 36 ], "good": [ 41 ], "option": [ 42 ], "for": [ 43 ], "patients": [ 44 ], "who": [ 45 ], "struggle": [ 46 ], "adhere": [ 48 ], "more": [ 50 ], "frequent": [ 51 ], "regimens.": [ 52 ], "The": [ 53 ], "future": [ 54 ], "hold": [ 56 ], "interesting": [ 57 ], "developments": [ 58 ], "reduced": [ 62 ], "dosing": [ 63 ], "frequency,": [ 64 ], "oral": [ 65 ], "formulations": [ 66 ], "alternative": [ 68 ], "therapeutic": [ 69 ], "uses.": [ 70 ] }, "publication_date": "2012-06-23", "publication_year": 2012, "type": "review", "cited_by_count": 27, "authors": [ { "id": "https://openalex.org/A5031060251", "display_name": "Eduard Montanya" } ] }, { "id": "https://openalex.org/W2996732450", "doi": "https://doi.org/10.1038/s41598-019-55524-w", "title": "Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis", "abstract": null, "publication_date": "2019-12-18", "publication_year": 2019, "type": "review", "cited_by_count": 74, "authors": [ { "id": "https://openalex.org/A5030971082", "display_name": "Marco Castellana" }, { "id": "https://openalex.org/A5010465088", "display_name": "Angelo Cignarelli" }, { "id": "https://openalex.org/A5023487340", "display_name": "Francesco Brescia" }, { "id": "https://openalex.org/A5089737683", "display_name": "Sebastio Perrini" }, { "id": "https://openalex.org/A5021200845", "display_name": "Annalisa Natalicchio" }, { "id": "https://openalex.org/A5038077594", "display_name": "Luigi Laviola" }, { "id": "https://openalex.org/A5064872622", "display_name": "Francesco Giorgino" } ] }, { "id": "https://openalex.org/W3081124857", "doi": "https://doi.org/10.1080/00325481.2020.1798099", "title": "GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date", "abstract": { "Glucagon-like": [ 0 ], "peptide-1": [ 1 ], "(GLP-1)": [ 2 ], "is": [ 3, 48, 268 ], "a": [ 4, 12, 49, 56, 86, 181, 232, 257, 269 ], "hormone": [ 5 ], "of": [ 6, 14, 20, 24, 29, 58, 136, 213, 216, 238, 264, 281, 294, 308 ], "the": [ 7, 27, 66, 79, 134, 235, 262, 289, 295, 303 ], "incretin": [ 8 ], "system": [ 9 ], "responsible": [ 10 ], "for": [ 11, 68, 81, 113, 259, 276 ], "variety": [ 13 ], "glucoregulatory": [ 15 ], "effects,": [ 16, 163 ], "including": [ 17, 187 ], "glucose-dependent": [ 18 ], "secretion": [ 19 ], "insulin": [ 21, 227 ], "and": [ 22, 71, 77, 92, 115, 126, 171, 200, 241, 291 ], "inhibition": [ 23 ], "glucagon": [ 25 ], "release,": [ 26 ], "effects": [ 28 ], "which": [ 30, 164, 301 ], "are": [ 31, 161, 244 ], "impaired": [ 32 ], "in": [ 33, 52, 74, 142, 184, 188, 248, 310 ], "people": [ 34 ], "with": [ 35, 54, 95, 144, 159, 278, 283 ], "type": [ 36 ], "2": [ 37 ], "diabetes": [ 38 ], "(T2D).": [ 39 ], "Targeting": [ 40 ], "this": [ 41 ], "deficiency": [ 42 ], "using": [ 43 ], "GLP-1": [ 44 ], "receptor": [ 45 ], "agonists": [ 46 ], "(GLP-1RAs)": [ 47 ], "well-established": [ 50 ], "approach": [ 51, 271 ], "T2D,": [ 53 ], "over": [ 55, 173 ], "decade": [ 57 ], "clinical": [ 59, 311 ], "experience": [ 60 ], "now": [ 61 ], "accrued.": [ 62 ], "This": [ 63 ], "article": [ 64 ], "reviews": [ 65 ], "evidence": [ 67 ], "subcutaneous": [ 69, 96 ], "GLP-1RAs": [ 70, 97, 128, 160, 179, 215, 309 ], "their": [ 72 ], "role": [ 73 ], "T2D": [ 75, 175 ], "treatment,": [ 76 ], "explores": [ 78 ], "rationale": [ 80 ], "an": [ 82, 109, 265, 284 ], "oral": [ 83, 260, 266, 297, 299 ], "GLP-1RA": [ 84, 267 ], "from": [ 85 ], "primary": [ 87 ], "care": [ 88 ], "perspective.": [ 89 ], "Clinical": [ 90 ], "trials": [ 91, 121 ], "real-world": [ 93 ], "studies": [ 94 ], "indicate": [ 98 ], "that": [ 99 ], "these": [ 100 ], "agents": [ 101 ], "have": [ 102, 122, 129 ], "good": [ 103 ], "glycated": [ 104 ], "hemoglobin": [ 105 ], "(HbA1": [ 106 ], "c)-lowering": [ 107 ], "efficacy,": [ 108 ], "inherently": [ 110 ], "low": [ 111 ], "potential": [ 112, 304 ], "hypoglycemia,": [ 114 ], "reduce": [ 116, 133 ], "body": [ 117 ], "weight.": [ 118 ], "Cardiovascular": [ 119 ], "outcomes": [ 120 ], "established": [ 123, 145, 208 ], "cardiovascular": [ 124, 139, 146, 151, 210 ], "safety,": [ 125 ], "three": [ 127 ], "been": [ 130 ], "proven": [ 131, 217 ], "to": [ 132, 166, 250, 272, 305 ], "risk": [ 135, 206 ], "major": [ 137 ], "adverse": [ 138, 156 ], "events": [ 140, 157 ], "(MACE)": [ 141 ], "patients": [ 143, 255, 277 ], "disease": [ 147, 211 ], "or": [ 148 ], "at": [ 149, 204 ], "high": [ 150, 205 ], "risk.": [ 152 ], "The": [ 153 ], "most": [ 154 ], "common": [ 155 ], "associated": [ 158 ], "gastrointestinal": [ 162 ], "tend": [ 165 ], "occur": [ 167 ], "soon": [ 168 ], "after": [ 169, 197 ], "initiation": [ 170 ], "decline": [ 172 ], "time.": [ 174 ], "treatment": [ 176, 274 ], "guidelines": [ 177 ], "recommend": [ 178 ], "as": [ 180 ], "therapeutic": [ 182 ], "option": [ 183 ], "various": [ 185 ], "settings,": [ 186 ], "those": [ 189 ], "patients:": [ 190 ], "i)": [ 191 ], "not": [ 192, 220, 229 ], "achieving": [ 193, 221 ], "HbA1": [ 194, 222 ], "c": [ 195, 223 ], "targets": [ 196, 224 ], "first-line": [ 198 ], "metformin": [ 199 ], "lifestyle": [ 201 ], "modifications;": [ 202 ], "ii)": [ 203 ], "of/with": [ 207 ], "atherosclerotic": [ 209 ], "(regardless": [ 212 ], "HbA1c;": [ 214 ], "benefit);": [ 218 ], "iii)": [ 219 ], "on": [ 225 ], "basal": [ 226 ], "if": [ 228 ], "already": [ 230 ], "receiving": [ 231 ], "GLP-1RA.": [ 233 ], "Despite": [ 234 ], "known": [ 236 ], "benefits": [ 237 ], "GLP-1RAs,": [ 239 ], "adherence": [ 240 ], "persistence": [ 242 ], "rates": [ 243 ], "suboptimal,": [ 245 ], "potentially": [ 246 ], "due": [ 247 ], "part": [ 249 ], "injection-related": [ 251 ], "concerns.": [ 252 ], "With": [ 253 ], "some": [ 254 ], "having": [ 256 ], "preference": [ 258 ], "medications,": [ 261 ], "development": [ 263, 290 ], "logical": [ 270 ], "improving": [ 273 ], "options": [ 275 ], "T2D.": [ 279 ], "Co-formulation": [ 280 ], "semaglutide": [ 282 ], "absorption": [ 285 ], "enhancer": [ 286 ], "has": [ 287, 302 ], "enabled": [ 288 ], "recent": [ 292 ], "approval": [ 293 ], "first": [ 296 ], "GLP-1RA,": [ 298 ], "semaglutide,": [ 300 ], "expand": [ 306 ], "use": [ 307 ], "practice.": [ 312 ] }, "publication_date": "2020-08-20", "publication_year": 2020, "type": "review", "cited_by_count": 67, "authors": [ { "id": "https://openalex.org/A5062486589", "display_name": "Stephen Brunton" }, { "id": "https://openalex.org/A5040652845", "display_name": "Carol Wysham" } ] }, { "id": "https://openalex.org/W3003534791", "doi": "https://doi.org/10.1080/13696998.2020.1722678", "title": "Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis", "abstract": { "Aims:": [ 0 ], "The": [ 1, 48 ], "efficacy": [ 2 ], "and": [ 3, 34, 85, 105, 142, 179, 195, 269, 273, 291 ], "safety": [ 4 ], "of": [ 5, 22, 58, 92, 103, 108, 125, 139, 172, 190, 206, 238, 249, 277, 288 ], "oral": [ 6, 17, 59, 180, 224 ], "semaglutide,": [ 7 ], "the": [ 8, 20, 29, 54, 93, 114, 123, 128, 169, 187, 204, 236, 295 ], "first": [ 9 ], "glucagon-like": [ 10 ], "peptide-1": [ 11 ], "(GLP-1)": [ 12 ], "receptor": [ 13, 46, 149 ], "agonist": [ 14 ], "developed": [ 15 ], "for": [ 16, 19, 137, 145, 235, 252 ], "administration": [ 18 ], "treatment": [ 21, 116, 129, 152, 170 ], "type": [ 23, 281 ], "2": [ 24, 71, 282 ], "diabetes,": [ 25 ], "was": [ 26, 110, 208 ], "evaluated": [ 27 ], "in": [ 28, 90, 156, 275, 294 ], "PIONEER": [ 30 ], "clinical": [ 31 ], "trial": [ 32 ], "program,": [ 33 ], "a": [ 35 ], "recently": [ 36 ], "published": [ 37 ], "network": [ 38 ], "meta-analysis": [ 39 ], "allowed": [ 40 ], "comparison": [ 41 ], "with": [ 42, 119, 131, 134, 186, 210, 246, 280 ], "further": [ 43 ], "injectable": [ 44 ], "GLP-1": [ 45, 148 ], "agonists.": [ 47, 150 ], "present": [ 49 ], "study": [ 50 ], "aimed": [ 51 ], "to": [ 52, 261, 284 ], "assess": [ 53 ], "short-term": [ 55 ], "cost-": [ 56 ], "effectiveness": [ 57 ], "semaglutide": [ 60, 87, 176, 181, 212, 225, 256 ], "14": [ 61, 182, 226, 257 ], "mg": [ 62, 178, 183, 214, 227, 258 ], "versus": [ 63, 264 ], "subcutaneous": [ 64 ], "once-weekly": [ 65, 69, 86, 175, 211 ], "dulaglutide": [ 66 ], "1.5": [ 67 ], "mg,": [ 68, 72, 80, 89 ], "exenatide": [ 70, 74, 266 ], "twice-daily": [ 73 ], "10": [ 75 ], "\u00b5g,": [ 76, 84 ], "once-daily": [ 77, 81 ], "liraglutide": [ 78 ], "1.8": [ 79 ], "lixisenatide": [ 82, 274 ], "20": [ 83 ], "1": [ 88, 177, 213 ], "terms": [ 91, 276 ], "cost": [ 94, 205, 248 ], "per": [ 95, 198, 218, 231 ], "patient": [ 96, 199, 219, 232 ], "achieving": [ 97, 127, 200, 220, 233 ], "glycated": [ 98 ], "hemoglobin": [ 99 ], "(HbA1c)": [ 100 ], "targets": [ 101, 138, 287 ], "(cost": [ 102 ], "control).Materials": [ 104 ], "methods:": [ 106 ], "Cost": [ 107 ], "control": [ 109, 207, 250, 286 ], "calculated": [ 111, 136 ], "by": [ 112, 122, 223 ], "dividing": [ 113 ], "annual": [ 115 ], "costs": [ 117, 153, 189 ], "associated": [ 118, 185, 245 ], "an": [ 120, 132 ], "intervention": [ 121 ], "proportion": [ 124 ], "patients": [ 126 ], "target": [ 130, 171, 234, 237 ], "intervention,": [ 133 ], "outcomes": [ 135 ], "HbA1c": [ 140, 143, 173, 239, 289, 292 ], "\u22646.5%": [ 141, 290 ], "<7.0%": [ 144, 293 ], "all": [ 146 ], "included": [ 147 ], "Annual": [ 151 ], "were": [ 154, 184, 244 ], "accounted": [ 155 ], "2019": [ 157, 164 ], "United": [ 158 ], "States": [ 159 ], "dollars": [ 160 ], "(USD),": [ 161 ], "based": [ 162 ], "on": [ 163 ], "wholesale": [ 165 ], "acquisition": [ 166 ], "cost.Results:": [ 167 ], "For": [ 168 ], "\u22646.5%,": [ 174 ], "lowest": [ 188, 209 ], "control,": [ 191 ], "at": [ 192, 215, 228 ], "USD": [ 193, 196, 216, 229 ], "15,430": [ 194 ], "17,383": [ 197 ], "target,": [ 201, 221 ], "respectively.": [ 202 ], "Similarly,": [ 203 ], "12,627": [ 217 ], "followed": [ 222 ], "13,493": [ 230 ], "<7.0%.": [ 240 ], "All": [ 241 ], "other": [ 242 ], "interventions": [ 243 ], "higher": [ 247 ], "values": [ 251 ], "both": [ 253 ], "targets.Conclusions:": [ 254 ], "Oral": [ 255 ], "is": [ 259 ], "likely": [ 260 ], "be": [ 262 ], "cost-effective": [ 263 ], "dulaglutide,": [ 265 ], "(once": [ 267 ], "weekly": [ 268 ], "twice": [ 270 ], "daily),": [ 271 ], "liraglutide,": [ 272 ], "bringing": [ 278 ], "people": [ 279 ], "diabetes": [ 283 ], "glycemic": [ 285 ], "US.": [ 296 ] }, "publication_date": "2020-01-28", "publication_year": 2020, "type": "article", "cited_by_count": 33, "authors": [ { "id": "https://openalex.org/A5107897442", "display_name": "B.B. Hansen" }, { "id": "https://openalex.org/A5001771184", "display_name": "Solomon Nuhoho" }, { "id": "https://openalex.org/A5021916965", "display_name": "Sarah Ali" }, { "id": "https://openalex.org/A5034860372", "display_name": "Tam Dang\u2010Tan" }, { "id": "https://openalex.org/A5037654589", "display_name": "William J. Valentine" }, { "id": "https://openalex.org/A5029230724", "display_name": "Samuel J. P. Malkin" }, { "id": "https://openalex.org/A5072605000", "display_name": "Barnaby Hunt" } ] }, { "id": "https://openalex.org/W2105554519", "doi": "https://doi.org/10.1586/eem.13.20", "title": "Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature", "abstract": { "With": [ 0 ], "the": [ 1, 19, 52, 56, 92, 108 ], "rapidly": [ 2 ], "rising": [ 3 ], "incidence": [ 4, 104 ], "of": [ 5, 13, 51, 55, 96, 105, 110, 142, 146 ], "Type": [ 6 ], "2": [ 7 ], "diabetes": [ 8 ], "and": [ 9, 33, 39, 46, 66, 88, 148 ], "an": [ 10 ], "increasing": [ 11 ], "variety": [ 12 ], "medications": [ 14 ], "available": [ 15 ], "for": [ 16, 22, 68 ], "treatment,": [ 17 ], "choosing": [ 18 ], "ideal": [ 20 ], "regimen": [ 21 ], "patients": [ 23, 130 ], "can": [ 24 ], "be": [ 25, 118 ], "challenging.": [ 26 ], "Longer-acting": [ 27 ], "glucagon-like": [ 28 ], "peptide-1": [ 29 ], "(GLP-1)": [ 30 ], "receptor": [ 31, 58, 135 ], "agonists": [ 32, 136 ], "devices": [ 34 ], "have": [ 35, 74, 137 ], "been": [ 36, 75 ], "recently": [ 37 ], "developed": [ 38 ], "include": [ 40, 61 ], "once-weekly": [ 41 ], "exenatide,": [ 42 ], "dulaglutide,": [ 43 ], "albiglutide,": [ 44 ], "semaglutide": [ 45 ], "miniosmotic": [ 47 ], "pump": [ 48 ], "ITCA650.": [ 49 ], "Some": [ 50 ], "attractive": [ 53 ], "qualities": [ 54 ], "GLP-1": [ 57, 134 ], "agonist": [ 59 ], "class": [ 60 ], "its": [ 62 ], "association": [ 63 ], "with": [ 64, 91, 132 ], "weightloss": [ 65 ], "potential": [ 67 ], "cardiovascular": [ 69 ], "benefits.": [ 70 ], "The": [ 71 ], "longer-acting": [ 72, 133 ], "forms": [ 73 ], "shown": [ 76 ], "in": [ 77, 86, 101, 107 ], "several": [ 78 ], "studies": [ 79 ], "to": [ 80, 120, 128 ], "produce": [ 81 ], "equal": [ 82 ], "or": [ 83 ], "greater": [ 84 ], "reduction": [ 85 ], "A1c": [ 87, 149 ], "weight": [ 89, 147 ], "compared": [ 90 ], "standard": [ 93 ], "twice-daily": [ 94 ], "formulation": [ 95 ], "exenatide.": [ 97 ], "They": [ 98 ], "also": [ 99 ], "result": [ 100 ], "lower": [ 102 ], "reported": [ 103 ], "nausea,": [ 106 ], "setting": [ 109 ], "a": [ 111 ], "less": [ 112 ], "frequent": [ 113 ], "injection": [ 114 ], "schedule": [ 115 ], "that": [ 116 ], "would": [ 117 ], "desirable": [ 119 ], "many": [ 121 ], "diabetic": [ 122 ], "patients.": [ 123 ], "There": [ 124 ], "are": [ 125, 144 ], "emerging": [ 126 ], "data": [ 127 ], "suggest": [ 129 ], "treated": [ 131 ], "improved": [ 138 ], "cardiac": [ 139 ], "parameters,": [ 140 ], "some": [ 141 ], "which": [ 143 ], "independent": [ 145 ], "reductions.": [ 150 ] }, "publication_date": "2013-04-29", "publication_year": 2013, "type": "review", "cited_by_count": 23, "authors": [ { "id": "https://openalex.org/A5036424601", "display_name": "Courtney Tibble" }, { "id": "https://openalex.org/A5049271325", "display_name": "Tricia Santos Cavaiola" }, { "id": "https://openalex.org/A5045462483", "display_name": "Robert R. Henry" } ] }, { "id": "https://openalex.org/W2395478387", "doi": "https://doi.org/10.1016/j.brainres.2016.05.038", "title": "Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease", "abstract": null, "publication_date": "2016-05-25", "publication_year": 2016, "type": "article", "cited_by_count": 39, "authors": [ { "id": "https://openalex.org/A5001683046", "display_name": "Henrik H. Hansen" }, { "id": "https://openalex.org/A5047010404", "display_name": "Katrine Fabricius" }, { "id": "https://openalex.org/A5005450058", "display_name": "Pernille Barkholt" }, { "id": "https://openalex.org/A5066252280", "display_name": "Jens D. Mikkelsen" }, { "id": "https://openalex.org/A5075602116", "display_name": "Jacob Jelsing" }, { "id": "https://openalex.org/A5084425804", "display_name": "Charles Pyke" }, { "id": "https://openalex.org/A5088627727", "display_name": "Lotte Bjerre Knudsen" }, { "id": "https://openalex.org/A5088582143", "display_name": "Niels Vrang" } ] }, { "id": "https://openalex.org/W3028216699", "doi": "https://doi.org/10.1002/oby.22794", "title": "Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5", "abstract": { "Objective": [ 0 ], "The": [ 1, 25, 161, 180 ], "obesity": [ 2, 32, 53, 190 ], "epidemic": [ 3 ], "is": [ 4, 112 ], "a": [ 5, 126, 141, 151, 177 ], "public": [ 6 ], "health": [ 7 ], "concern,": [ 8 ], "warranting": [ 9 ], "further": [ 10 ], "research": [ 11 ], "into": [ 12 ], "pharmacological": [ 13 ], "treatments": [ 14 ], "for": [ 15 ], "weight": [ 16, 45 ], "management": [ 17 ], "(WM)": [ 18 ], "as": [ 19 ], "an": [ 20 ], "adjunct": [ 21 ], "to": [ 22, 36, 89, 116, 131, 146, 157 ], "lifestyle": [ 23 ], "interventions.": [ 24 ], "Semaglutide": [ 26 ], "Treatment": [ 27 ], "Effect": [ 28 ], "in": [ 29, 50, 66, 103, 120, 176, 187 ], "People": [ 30 ], "with": [ 31, 52, 72, 189, 191 ], "(STEP)": [ 33 ], "program": [ 34, 163 ], "aims": [ 35 ], "investigate": [ 37 ], "the": [ 38, 108, 165 ], "effect": [ 39 ], "of": [ 40, 118, 129, 144, 155, 169 ], "semaglutide": [ 41, 91, 170 ], "versus": [ 42, 97 ], "placebo": [ 43 ], "on": [ 44, 185, 198 ], "loss,": [ 46 ], "safety,": [ 47 ], "and": [ 48, 79, 139, 150, 167, 192, 197 ], "tolerability": [ 49 ], "adults": [ 51 ], "or": [ 54 ], "overweight.": [ 55 ], "Methods": [ 56 ], "Across": [ 57 ], "five": [ 58 ], "phase": [ 59 ], "3": [ 60 ], "trials": [ 61, 181 ], "(NCT03548935,": [ 62 ], "WM;": [ 63, 78 ], "NCT03552757,": [ 64 ], "WM": [ 65, 71, 186 ], "type": [ 67, 194 ], "2": [ 68, 149, 195 ], "diabetes;": [ 69 ], "NCT03611582,": [ 70 ], "intensive": [ 73 ], "behavioral": [ 74 ], "therapy;": [ 75 ], "NCT03548987,": [ 76 ], "sustained": [ 77 ], "NCT03693430,": [ 80 ], "long\u2010term": [ 81, 199 ], "WM),": [ 82 ], "~5,000": [ 83 ], "participants": [ 84 ], "are": [ 85, 134 ], "being": [ 86 ], "randomly": [ 87 ], "assigned": [ 88 ], "receive": [ 90 ], "2.4": [ 92, 171 ], "mg": [ 93, 172 ], "once": [ 94, 174 ], "weekly": [ 95, 175 ], "subcutaneously": [ 96, 173 ], "placebo.": [ 98 ], "Results": [ 99, 123 ], "will": [ 100, 182 ], "be": [ 101 ], "available": [ 102 ], "2020/2021.": [ 104 ], "For": [ 105 ], "all": [ 106 ], "trials,": [ 107 ], "primary": [ 109 ], "end": [ 110, 117 ], "point": [ 111 ], "change": [ 113 ], "from": [ 114 ], "baseline": [ 115 ], "treatment": [ 119 ], "body": [ 121 ], "weight.": [ 122 ], "Participants": [ 124 ], "have": [ 125, 140 ], "mean": [ 127, 142, 152 ], "age": [ 128 ], "46.2": [ 130 ], "55.3": [ 132 ], "years,": [ 133 ], "mostly": [ 135 ], "female": [ 136 ], "(mean:": [ 137 ], "74.1%\u201081.0%),": [ 138 ], "BMI": [ 143 ], "35.7": [ 145 ], "38.5": [ 147 ], "kg/m": [ 148 ], "waist": [ 153 ], "circumference": [ 154 ], "113.0": [ 156 ], "115.7": [ 158 ], "cm.": [ 159 ], "Conclusions": [ 160 ], "STEP": [ 162 ], "evaluates": [ 164 ], "efficacy": [ 166 ], "safety": [ 168 ], "broad": [ 178 ], "population.": [ 179 ], "provide": [ 183 ], "insights": [ 184 ], "people": [ 188 ], "without": [ 193 ], "diabetes": [ 196 ], "follow\u2010up.": [ 200 ], "image": [ 201 ] }, "publication_date": "2020-05-22", "publication_year": 2020, "type": "article", "cited_by_count": 253, "authors": [ { "id": "https://openalex.org/A5062192624", "display_name": "Robert F. Kushner" }, { "id": "https://openalex.org/A5011187014", "display_name": "Salvatore Calanna" }, { "id": "https://openalex.org/A5084593004", "display_name": "Melanie J. Davies" }, { "id": "https://openalex.org/A5009921349", "display_name": "Dror Dicker" }, { "id": "https://openalex.org/A5038221659", "display_name": "W. Timothy Garvey" }, { "id": "https://openalex.org/A5075289235", "display_name": "Bryan Goldman" }, { "id": "https://openalex.org/A5001655356", "display_name": "Ildiko Lingvay" }, { "id": "https://openalex.org/A5017671388", "display_name": "Mette S. Thomsen" }, { "id": "https://openalex.org/A5026596594", "display_name": "Thomas A. Wadden" }, { "id": "https://openalex.org/A5027441223", "display_name": "Sean Wharton" }, { "id": "https://openalex.org/A5047195042", "display_name": "John Wilding" }, { "id": "https://openalex.org/A5060266336", "display_name": "Domenica Rubino" } ] }, { "id": "https://openalex.org/W3037096516", "doi": "https://doi.org/10.3389/fphar.2020.00967", "title": "GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms", "abstract": { "Diabetic": [ 0 ], "Kidney": [ 1 ], "Disease": [ 2 ], "(DKD)": [ 3 ], "is": [ 4 ], "the": [ 5, 26, 109, 142, 146, 150, 153 ], "leading": [ 6 ], "cause": [ 7 ], "of": [ 8, 28, 37, 51, 113, 145, 155 ], "end": [ 9 ], "stage": [ 10 ], "renal": [ 11, 72, 85 ], "disease": [ 12 ], "(ESRD)": [ 13 ], "worldwide.": [ 14 ], "Glucagon-like": [ 15 ], "peptide": [ 16 ], "1": [ 17 ], "receptor": [ 18 ], "agonists": [ 19 ], "(GLP-1RAs)": [ 20 ], "are": [ 21, 56, 93 ], "now": [ 22 ], "widely": [ 23 ], "used": [ 24 ], "in": [ 25, 88, 107, 157 ], "treatment": [ 27 ], "patients": [ 29, 89 ], "with": [ 30, 90 ], "type": [ 31 ], "2": [ 32 ], "diabetes": [ 33 ], "(T2D).": [ 34 ], "A": [ 35 ], "series": [ 36 ], "clinical": [ 38, 75, 147 ], "and": [ 39, 61, 111, 124, 149 ], "experimental": [ 40 ], "studies": [ 41 ], "demonstrated": [ 42, 78 ], "that": [ 43, 79, 102 ], "GLP-1RAs": [ 44, 66, 80, 103, 116, 156 ], "have": [ 45, 67, 77, 81, 117 ], "beneficial": [ 46, 82 ], "effects": [ 47, 83, 154 ], "on": [ 48, 84 ], "DKD,": [ 49 ], "independent": [ 50 ], "their": [ 52, 125 ], "glucose-lowering": [ 53 ], "abilities,": [ 54 ], "which": [ 55 ], "mediated": [ 57 ], "by": [ 58 ], "natriuresis,": [ 59 ], "anti-inflammatory": [ 60 ], "anti-oxidative": [ 62 ], "stress": [ 63 ], "properties.": [ 64 ], "Furthermore,": [ 65 ], "been": [ 68, 119 ], "shown": [ 69, 120 ], "to": [ 70, 121, 127, 130, 133 ], "suppress": [ 71 ], "fibrosis.": [ 73 ], "Recent": [ 74 ], "trials": [ 76 ], "outcomes,": [ 86 ], "especially": [ 87 ], "T2D": [ 91 ], "who": [ 92 ], "at": [ 94 ], "high": [ 95 ], "risk": [ 96 ], "for": [ 97 ], "CVD.": [ 98 ], "These": [ 99 ], "findings": [ 100 ], "suggest": [ 101 ], "hold": [ 104 ], "great": [ 105 ], "promise": [ 106 ], "preventing": [ 108 ], "onset": [ 110 ], "progression": [ 112, 129 ], "DKD.": [ 114, 158 ], "However,": [ 115 ], "only": [ 118 ], "reduce": [ 122, 128 ], "albuminuria,": [ 123 ], "ability": [ 126 ], "ESRD": [ 131 ], "remains": [ 132 ], "be": [ 134 ], "elucidated.": [ 135 ], "In": [ 136 ], "this": [ 137 ], "review": [ 138 ], "article,": [ 139 ], "we": [ 140 ], "highlight": [ 141 ], "current": [ 143 ], "understanding": [ 144 ], "efficacy": [ 148 ], "mechanisms": [ 151 ], "underlying": [ 152 ] }, "publication_date": "2020-06-30", "publication_year": 2020, "type": "review", "cited_by_count": 106, "authors": [ { "id": "https://openalex.org/A5089533893", "display_name": "Daiji Kawanami" }, { "id": "https://openalex.org/A5068575679", "display_name": "Yuichi Takashi" } ] }, { "id": "https://openalex.org/W2574032118", "doi": "https://doi.org/10.1186/s12933-016-0490-6", "title": "Differential effects of glucagon-like peptide-1 receptor agonists on heart rate", "abstract": null, "publication_date": "2017-01-13", "publication_year": 2017, "type": "review", "cited_by_count": 146, "authors": [ { "id": "https://openalex.org/A5073494000", "display_name": "M. Lorenz" }, { "id": "https://openalex.org/A5050726657", "display_name": "Francesca Lawson" }, { "id": "https://openalex.org/A5078134786", "display_name": "David R. Owens" }, { "id": "https://openalex.org/A5012472100", "display_name": "D. Raccah" }, { "id": "https://openalex.org/A5009161997", "display_name": "Christine Roy-Duval" }, { "id": "https://openalex.org/A5041388816", "display_name": "Anne Lehmann" }, { "id": "https://openalex.org/A5008946836", "display_name": "Riccardo Perfetti" }, { "id": "https://openalex.org/A5070289715", "display_name": "Lawrence Blonde" } ] }, { "id": "https://openalex.org/W3129305070", "doi": "https://doi.org/10.1001/jama.2021.1831", "title": "Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity", "abstract": { "ClinicalTrials.gov": [ 0 ], "Identifier:": [ 1 ], "NCT03611582.": [ 2 ] }, "publication_date": "2021-02-24", "publication_year": 2021, "type": "article", "cited_by_count": 844, "authors": [ { "id": "https://openalex.org/A5026596594", "display_name": "Thomas A. Wadden" }, { "id": "https://openalex.org/A5054058644", "display_name": "Timothy S. Bailey" }, { "id": "https://openalex.org/A5087749895", "display_name": "Liana K. Billings" }, { "id": "https://openalex.org/A5084593004", "display_name": "Melanie J. Davies" }, { "id": "https://openalex.org/A5086072427", "display_name": "Juan P. Fr\u00edas" }, { "id": "https://openalex.org/A5072583224", "display_name": "Anna Koroleva" }, { "id": "https://openalex.org/A5001655356", "display_name": "Ildiko Lingvay" }, { "id": "https://openalex.org/A5085642856", "display_name": "Patrick M. O\u2019Neil" }, { "id": "https://openalex.org/A5060266336", "display_name": "Domenica Rubino" }, { "id": "https://openalex.org/A5029901911", "display_name": "Dorthe Skovgaard" }, { "id": "https://openalex.org/A5091625167", "display_name": "Signe Olrik Rytter Wallenstein" }, { "id": "https://openalex.org/A5038221659", "display_name": "W. Timothy Garvey" } ] }, { "id": "https://openalex.org/W4297489959", "doi": "https://doi.org/10.1002/cbf.3751", "title": "Semaglutide (GLP\u20101 receptor agonist) stimulates browning on subcutaneous fat adipocytes and mitigates inflammation and endoplasmic reticulum stress in visceral fat adipocytes of obese mice", "abstract": { "Abstract": [ 0 ], "Semaglutide": [ 1, 136, 177, 219 ], "(GLP\u20101": [ 2 ], "agonist)": [ 3 ], "was": [ 4 ], "approved": [ 5 ], "for": [ 6, 46, 59, 225 ], "treating": [ 7 ], "obesity.": [ 8 ], "Although": [ 9 ], "the": [ 10, 19, 105, 226 ], "effects": [ 11, 248 ], "on": [ 12, 253 ], "weight": [ 13, 250, 284 ], "loss": [ 14 ], "and": [ 15, 49, 67, 70, 73, 80, 94, 115, 133, 155, 158, 169, 180, 193, 213, 239, 256, 263, 267, 279 ], "metabolism": [ 16 ], "are": [ 17, 25 ], "known,": [ 18 ], "responses": [ 20 ], "of": [ 21, 144, 258 ], "adipocytes": [ 22, 257 ], "to": [ 23 ], "semaglutide": [ 24, 103, 244, 271 ], "yet": [ 26 ], "limited.": [ 27 ], "C57BL/6": [ 28 ], "male": [ 29 ], "mice": [ 30 ], "(": [ 31, 55 ], "n": [ 32, 56 ], "=": [ 33, 57 ], "20/group)": [ 34 ], "were": [ 35, 88, 172 ], "fed": [ 36 ], "a": [ 37, 42 ], "control": [ 38 ], "diet": [ 39, 45, 66, 72 ], "(C)": [ 40 ], "or": [ 41 ], "high\u2010fat": [ 43 ], "(HF)": [ 44 ], "16": [ 47, 237 ], "weeks": [ 48 ], "then": [ 50 ], "separated": [ 51 ], "into": [ 52 ], "four": [ 53, 62 ], "groups": [ 54 ], "10/group)": [ 58 ], "an": [ 60 ], "additional": [ 61 ], "weeks:": [ 63 ], "C,": [ 64 ], "C": [ 65 ], "semaglutide,": [ 68 ], "HF,": [ 69 ], "HF": [ 71 ], "semaglutide.": [ 74, 176 ], "Epididymal": [ 75 ], "white": [ 76, 82 ], "adipose": [ 77, 83 ], "tissue": [ 78, 84 ], "(eWAT)": [ 79 ], "subcutaneous": [ 81 ], "(sWAT)": [ 85 ], "fat": [ 86, 106, 254 ], "pads": [ 87, 255 ], "studied": [ 89 ], "with": [ 90 ], "biochemistry,": [ 91 ], "immunohistochemistry/fluorescence,": [ 92 ], "stereology,": [ 93 ], "reverse": [ 95 ], "transcription\u2010quantitative": [ 96 ], "polymerase": [ 97 ], "chain": [ 98 ], "reaction.": [ 99 ], "In": [ 100, 242 ], "obese": [ 101, 165, 187, 259 ], "mice,": [ 102, 260 ], "reduced": [ 104, 174, 264 ], "pad": [ 107 ], "masses": [ 108 ], "(eWAT,": [ 109 ], "\u221255%;": [ 110 ], "sWAT,": [ 111 ], "\u221240%),": [ 112 ], "plasmatic": [ 113 ], "cytokines,": [ 114 ], "proinflammatory": [ 116 ], "gene": [ 117, 161, 223 ], "expressions:": [ 118 ], "tumor": [ 119 ], "necrosis": [ 120 ], "factor\u2010alpha": [ 121 ], "(\u221260%);": [ 122 ], "interleukin": [ 123 ], "(IL)\u20106": [ 124 ], "(\u221255%);": [ 125 ], "IL\u20101": [ 126 ], "beta": [ 127 ], "(\u221240%);": [ 128 ], "monocyte": [ 129 ], "chemoattractant": [ 130 ], "protein\u20101": [ 131 ], "(\u221290%);": [ 132 ], "leptin": [ 134 ], "(\u221280%).": [ 135 ], "also": [ 137, 220 ], "lessened": [ 138 ], "endoplasmic": [ 139 ], "reticulum": [ 140 ], "(ER)": [ 141 ], "stress": [ 142 ], "genes": [ 143 ], "activating": [ 145 ], "transcription": [ 146, 215 ], "factor\u20104": [ 147 ], "(\u221285%),": [ 148 ], "CCAAT": [ 149 ], "enhancer\u2010binding": [ 150 ], "protein": [ 151, 153, 182, 200 ], "homologous": [ 152 ], "(\u221255%),": [ 154 ], "growth": [ 156 ], "arrest": [ 157 ], "DNA": [ 159 ], "damage\u2010inducible": [ 160 ], "45": [ 162 ], "(\u221245%).": [ 163 ], "The": [ 164 ], "mice's": [ 166 ], "adipocyte": [ 167, 265, 273 ], "hypertrophy": [ 168 ], "macrophage": [ 170 ], "infiltration": [ 171 ], "equally": [ 173 ], "by": [ 175 ], "enhanced": [ 178 ], "multiloculation": [ 179 ], "uncoupled": [ 181 ], "1": [ 183, 211 ], "(UCP1)": [ 184 ], "labeling": [ 185 ], "in": [ 186 ], "mice:": [ 188 ], "peroxisome": [ 189, 203 ], "proliferator\u2010activated": [ 190, 204 ], "receptor\u2010alpha": [ 191, 205 ], "(+560%)": [ 192 ], "gamma": [ 194 ], "(+150%),": [ 195 ], "fibronectin": [ 196 ], "type": [ 197 ], "III": [ 198 ], "domain\u2010containing": [ 199 ], "5": [ 201 ], "(+215%),": [ 202 ], "coactivator": [ 206 ], "(+110%),": [ 207 ], "nuclear": [ 208 ], "respiratory": [ 209 ], "factor": [ 210, 216 ], "(+260%),": [ 212 ], "mitochondrial": [ 214, 277 ], "A": [ 217 ], "(+120%).": [ 218 ], "increased": [ 221 ], "thermogenetic": [ 222 ], "expressions": [ 224, 282 ], "browning": [ 227 ], "phenotype": [ 228 ], "maintenance:": [ 229 ], "beta\u20103": [ 230 ], "adrenergic": [ 231 ], "receptor": [ 232 ], "(+520%),": [ 233 ], "PR": [ 234 ], "domain": [ 235 ], "containing": [ 236 ], "(+90%),": [ 238 ], "Ucp1": [ 240 ], "(+110%).": [ 241 ], "conclusion,": [ 243 ], "showed": [ 245 ], "significant": [ 246 ], "beneficial": [ 247 ], "beyond": [ 249 ], "loss,": [ 251 ], "directly": [ 252 ], "remarkably": [ 261 ], "anti\u2010inflammatory,": [ 262 ], "size": [ 266 ], "ER": [ 268 ], "stress.": [ 269 ], "Besides,": [ 270 ], "activated": [ 272 ], "browning,": [ 274 ], "improving": [ 275 ], "UCP1,": [ 276 ], "biogenesis,": [ 278 ], "thermogenic": [ 280 ], "marker": [ 281 ], "help": [ 283 ], "loss.": [ 285 ] }, "publication_date": "2022-09-28", "publication_year": 2022, "type": "article", "cited_by_count": 72, "authors": [ { "id": "https://openalex.org/A5070189317", "display_name": "Fabiane Ferreira Martins" }, { "id": "https://openalex.org/A5024493537", "display_name": "Thatiany de Souza Marinho" }, { "id": "https://openalex.org/A5001973676", "display_name": "Luiz E.M. Cardoso" }, { "id": "https://openalex.org/A5018388994", "display_name": "Sandra Barbosa\u2010da\u2010Silva" }, { "id": "https://openalex.org/A5048659788", "display_name": "Vanessa Souza\u2010Mello" }, { "id": "https://openalex.org/A5084203631", "display_name": "M\u00e1rcia Barbosa \u00c1guila" }, { "id": "https://openalex.org/A5072346695", "display_name": "Carlos Alberto Mandarim\u2010de\u2010Lacerda" } ] }, { "id": "https://openalex.org/W906438903", "doi": "https://doi.org/10.2337/dc14-1625", "title": "Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)", "abstract": { "OBJECTIVE": [ 0 ], "This": [ 1 ], "study": [ 2 ], "compared": [ 3, 268 ], "the": [ 4, 48, 104 ], "efficacy": [ 5 ], "and": [ 6, 28, 131, 158, 185, 214, 242, 244, 248, 257, 280, 291 ], "safety": [ 7 ], "of": [ 8, 26, 41, 149, 166, 238, 287, 295 ], "once-weekly": [ 9 ], "dulaglutide,": [ 10 ], "a": [ 11, 159, 284, 292 ], "glucagon-like": [ 12 ], "peptide-1": [ 13 ], "receptor": [ 14 ], "agonist,": [ 15 ], "with": [ 16, 22, 32, 141, 181, 188, 212, 216, 223, 253, 261, 269, 283 ], "daily": [ 17, 270 ], "insulin": [ 18, 271 ], "glargine,": [ 19, 140 ], "both": [ 20 ], "combined": [ 21 ], "maximally": [ 23 ], "tolerated": [ 24 ], "doses": [ 25 ], "metformin": [ 27 ], "glimepiride": [ 29 ], "in": [ 30, 47, 230 ], "patients": [ 31, 66, 193 ], "type": [ 33 ], "2": [ 34 ], "diabetes.": [ 35 ], "The": [ 36, 79, 93 ], "primary": [ 37, 105 ], "objective": [ 38 ], "was": [ 39, 85, 108, 227 ], "noninferiority": [ 40, 187 ], "dulaglutide": [ 42, 70, 73, 117, 128, 182, 189, 195, 213, 254, 265 ], "1.5": [ 43, 71, 118, 183, 196, 255, 266 ], "mg": [ 44, 184, 197, 256, 259 ], "to": [ 45, 69, 103 ], "glargine": [ 46, 205, 272 ], "HbA1c": [ 49, 84, 99, 199, 278 ], "change": [ 50, 100 ], "from": [ 51, 101, 171 ], "baseline": [ 52, 80, 102 ], "at": [ 53 ], "52": [ 54 ], "weeks.": [ 55 ], "RESEARCH": [ 56 ], "DESIGN": [ 57 ], "AND": [ 58 ], "METHODS": [ 59 ], "In": [ 60 ], "this": [ 61 ], "78-week,": [ 62 ], "open-label": [ 63 ], "study,": [ 64 ], "810": [ 65 ], "were": [ 67, 179, 221, 233, 250 ], "randomized": [ 68 ], "mg,": [ 72, 75, 119, 130, 267 ], "0.75": [ 74, 129, 190, 258 ], "or": [ 76 ], "glargine.": [ 77, 217, 262 ], "RESULTS": [ 78 ], "mean": [ 81, 96, 145 ], "\u00b1": [ 82, 87, 90, 97, 110, 113, 121, 124, 133, 136, 146, 151, 155, 164, 168 ], "SD": [ 83, 147 ], "8.1": [ 86 ], "1.0%": [ 88 ], "(65.5": [ 89 ], "10.8": [ 91 ], "mmol/mol).": [ 92 ], "least": [ 94 ], "squares": [ 95 ], "SE": [ 98 ], "end": [ 106, 143 ], "point": [ 107, 144 ], "\u22121.08": [ 109 ], "0.06%": [ 111, 122, 134 ], "(\u221211.8": [ 112 ], "0.7": [ 114, 125, 137 ], "mmol/mol)": [ 115, 126, 138, 203 ], "for": [ 116, 127, 139, 177, 186, 235 ], "\u22120.76": [ 120 ], "(\u22128.3": [ 123 ], "\u22120.63": [ 132 ], "(\u22126.9": [ 135 ], "an": [ 142 ], "dose": [ 148 ], "29": [ 150 ], "26": [ 152 ], "units": [ 153 ], "(0.33": [ 154 ], "0.24": [ 156 ], "units/kg),": [ 157 ], "fasting": [ 160 ], "plasma": [ 161, 173 ], "glucose": [ 162 ], "(mean": [ 163 ], "SD)": [ 165 ], "118": [ 167 ], "23": [ 169 ], "mg/dL": [ 170 ], "self-monitored": [ 172 ], "glucose.": [ 174 ], "Statistical": [ 175 ], "criteria": [ 176 ], "superiority": [ 178 ], "met": [ 180 ], "mg.": [ 191 ], "More": [ 192 ], "on": [ 194 ], "achieved": [ 198 ], "targets": [ 200 ], "&lt;7.0%": [ 201 ], "(53": [ 202 ], "versus": [ 204 ], "(P": [ 206 ], "&lt;": [ 207 ], "0.001).": [ 208 ], "Body": [ 209 ], "weight": [ 210, 281 ], "decreased": [ 211 ], "increased": [ 215 ], "Total": [ 218 ], "hypoglycemia": [ 219, 226 ], "rates": [ 220 ], "lower": [ 222, 293 ], "dulaglutide;": [ 224 ], "severe": [ 225 ], "minimal.": [ 228 ], "Increases": [ 229 ], "pancreatic": [ 231 ], "enzymes": [ 232 ], "observed": [ 234 ], "dulaglutide.": [ 236 ], "Incidence": [ 237 ], "nausea": [ 239 ], "(15.4,": [ 240 ], "7.7,": [ 241 ], "1.5%)": [ 243 ], "diarrhea": [ 245 ], "(10.6,": [ 246 ], "9.2,": [ 247 ], "5.7%)": [ 249 ], "more": [ 251 ], "common": [ 252 ], "than": [ 260 ], "CONCLUSIONS": [ 263 ], "Once-weekly": [ 264 ], "without": [ 273 ], "forced": [ 274 ], "titration,": [ 275 ], "demonstrated": [ 276 ], "greater": [ 277 ], "reduction": [ 279 ], "loss,": [ 282 ], "higher": [ 285 ], "incidence": [ 286 ], "gastrointestinal": [ 288 ], "adverse": [ 289 ], "events": [ 290 ], "risk": [ 294 ], "hypoglycemia.": [ 296 ] }, "publication_date": "2015-06-18", "publication_year": 2015, "type": "article", "cited_by_count": 244, "authors": [ { "id": "https://openalex.org/A5064872622", "display_name": "Francesco Giorgino" }, { "id": "https://openalex.org/A5113435233", "display_name": "Marian Benroubi" }, { "id": "https://openalex.org/A5101146711", "display_name": "Jui\u2010Hung Sun" }, { "id": "https://openalex.org/A5113170261", "display_name": "Alan G. Zimmermann" }, { "id": "https://openalex.org/A5089497324", "display_name": "V. Pechtner" } ] }, { "id": "https://openalex.org/W4313260808", "doi": "https://doi.org/10.3390/jcm12010145", "title": "Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus", "abstract": { "Glucagon-like": [ 0 ], "peptide-1": [ 1 ], "receptor": [ 2 ], "agonists": [ 3 ], "(GLP-1": [ 4 ], "RAs)": [ 5 ], "are": [ 6, 93, 115, 144 ], "indicated": [ 7 ], "in": [ 8, 18, 132 ], "type": [ 9 ], "2": [ 10 ], "diabetes": [ 11, 75 ], "and": [ 12, 21, 45, 50, 74, 102, 124, 135, 142, 170 ], "obesity": [ 13, 154 ], "for": [ 14 ], "their": [ 15, 43, 164 ], "high": [ 16 ], "efficacy": [ 17 ], "controlling": [ 19 ], "glycaemia": [ 20 ], "inducing": [ 22 ], "body": [ 23 ], "weight": [ 24, 171 ], "loss,": [ 25 ], "respectively.": [ 26 ], "Patients": [ 27 ], "may": [ 28, 148 ], "develop": [ 29, 109 ], "gastrointestinal": [ 30 ], "adverse": [ 31 ], "events": [ 32 ], "(GI": [ 33 ], "AEs),": [ 34 ], "namely": [ 35 ], "nausea,": [ 36, 121 ], "vomiting,": [ 37, 122 ], "diarrhoea": [ 38, 123 ], "and/or": [ 39, 153 ], "constipation.": [ 40 ], "To": [ 41 ], "minimize": [ 42 ], "severity": [ 44 ], "duration,": [ 46 ], "healthcare": [ 47 ], "providers": [ 48 ], "(HCPs)": [ 49 ], "patients": [ 51 ], "must": [ 52 ], "be": [ 53 ], "aware": [ 54 ], "of": [ 55 ], "appropriate": [ 56 ], "measures": [ 57 ], "to": [ 58, 82, 97, 104, 119, 138 ], "follow": [ 59 ], "while": [ 60 ], "undergoing": [ 61 ], "treatment.": [ 62 ], "An": [ 63 ], "expert": [ 64 ], "panel": [ 65 ], "comprising": [ 66 ], "endocrinologists,": [ 67 ], "nephrologists,": [ 68 ], "primary": [ 69 ], "care": [ 70 ], "physicians,": [ 71 ], "cardiologists,": [ 72 ], "internists": [ 73 ], "nurse": [ 76 ], "educators": [ 77 ], "convened": [ 78 ], "across": [ 79 ], "virtual": [ 80 ], "meetings": [ 81 ], "reach": [ 83, 98 ], "a": [ 84 ], "consensus": [ 85 ], "regarding": [ 86 ], "these": [ 87 ], "compelling": [ 88 ], "recommendations.": [ 89 ], "Firstly,": [ 90 ], "specific": [ 91, 113 ], "guidelines": [ 92 ], "provided": [ 94 ], "about": [ 95, 117 ], "how": [ 96, 103, 118 ], "the": [ 99 ], "maintenance": [ 100 ], "dose": [ 101 ], "proceed": [ 105 ], "if": [ 106 ], "GI": [ 107 ], "AEs": [ 108 ], "during": [ 110 ], "dose-escalation.": [ 111 ], "Secondly,": [ 112 ], "directions": [ 114 ], "set": [ 116 ], "avoid/minimize": [ 120 ], "constipation": [ 125 ], "symptoms.": [ 126 ], "Clinical": [ 127 ], "scenarios": [ 128 ], "representing": [ 129 ], "common": [ 130 ], "situations": [ 131 ], "daily": [ 133 ], "practice,": [ 134 ], "infographics": [ 136 ], "useful": [ 137 ], "guide": [ 139 ], "both": [ 140 ], "HCPs": [ 141 ], "patients,": [ 143 ], "included.": [ 145 ], "These": [ 146 ], "recommendations": [ 147 ], "prevent": [ 149 ], "people": [ 150 ], "with": [ 151 ], "T2D": [ 152 ], "from": [ 155, 157, 163 ], "withdrawing": [ 156 ], "GLP-1": [ 158 ], "RAs": [ 159 ], "treatment,": [ 160 ], "thus": [ 161 ], "benefitting": [ 162 ], "superior": [ 165 ], "effect": [ 166 ], "on": [ 167 ], "glycaemic": [ 168 ], "control": [ 169 ], "loss.": [ 172 ] }, "publication_date": "2022-12-24", "publication_year": 2022, "type": "article", "cited_by_count": 207, "authors": [ { "id": "https://openalex.org/A5076277987", "display_name": "Juan Jos\u00e9 Gorgojo Mart\u00ednez" }, { "id": "https://openalex.org/A5013519134", "display_name": "Pedro Mezquita\u2010Raya" }, { "id": "https://openalex.org/A5014623904", "display_name": "Juana Carretero\u2010G\u00f3mez" }, { "id": "https://openalex.org/A5103948854", "display_name": "Almudena Castro" }, { "id": "https://openalex.org/A5082726087", "display_name": "Ana Mar\u00eda Cebri\u00e1n Cuenca" }, { "id": "https://openalex.org/A5110549540", "display_name": "Alejandra de Torres-S\u00e1nchez" }, { "id": "https://openalex.org/A5065536532", "display_name": "Mar\u00eda Dolores Garc\u00eda-de-Lucas" }, { "id": "https://openalex.org/A5039483633", "display_name": "Julio N\u00fa\u00f1ez" }, { "id": "https://openalex.org/A5080168252", "display_name": "Juan Carlos Obaya" }, { "id": "https://openalex.org/A5071593060", "display_name": "Mar\u00eda Jos\u00e9 Soler" }, { "id": "https://openalex.org/A5046692355", "display_name": "Jos\u00e9 Luis G\u00f3rriz" }, { "id": "https://openalex.org/A5074462156", "display_name": "Miguel A. Rubio" } ] }, { "id": "https://openalex.org/W4391831812", "doi": "https://doi.org/10.1186/s12916-024-03274-6", "title": "Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database", "abstract": null, "publication_date": "2024-02-14", "publication_year": 2024, "type": "article", "cited_by_count": 59, "authors": [ { "id": "https://openalex.org/A5101787839", "display_name": "Jianxing Zhou" }, { "id": "https://openalex.org/A5060263032", "display_name": "You Zheng" }, { "id": "https://openalex.org/A5062481777", "display_name": "Baohua Xu" }, { "id": "https://openalex.org/A5113119429", "display_name": "Songjun Long" }, { "id": "https://openalex.org/A5108901272", "display_name": "Li-e Zhu" }, { "id": "https://openalex.org/A5100731403", "display_name": "Yunhui Liu" }, { "id": "https://openalex.org/A5068111727", "display_name": "Chengliang Li" }, { "id": "https://openalex.org/A5100376952", "display_name": "Yifan Zhang" }, { "id": "https://openalex.org/A5024465638", "display_name": "Maobai Liu" }, { "id": "https://openalex.org/A5015521265", "display_name": "Xuemei Wu" } ] }, { "id": "https://openalex.org/W1518543897", "doi": "https://doi.org/10.1111/j.1464-5491.2011.03301.x", "title": "DURATION\u20102: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once\u2010weekly exenatide", "abstract": { "Diabet.": [ 0 ], "Med.": [ 1 ], "28,": [ 2 ], "705\u2013714": [ 3 ], "(2011)": [ 4 ], "Abstract": [ 5 ], "Aims": [ 6 ], "In": [ 7 ], "the": [ 8, 16, 27, 64, 97, 124, 253 ], "initial": [ 9 ], "26\u2010week,": [ 10, 58 ], "double\u2010blind,": [ 11 ], "double\u2010dummy": [ 12 ], "assessment": [ 13, 61, 260 ], "period": [ 14, 62, 261 ], "of": [ 15, 52, 68 ], "DURATION\u20102": [ 17 ], "trial": [ 18 ], "in": [ 19, 38, 151, 183, 249, 258 ], "patients": [ 20, 92, 99, 128, 135, 171 ], "with": [ 21, 47, 227, 299 ], "Type": [ 22 ], "2": [ 23 ], "diabetes": [ 24 ], "on": [ 25 ], "metformin,": [ 26 ], "once\u2010weekly": [ 28, 36, 72, 140, 178, 209, 236, 269, 274, 286 ], "glucagon\u2010like": [ 29 ], "peptide": [ 30 ], "1": [ 31 ], "(GLP\u20101)": [ 32 ], "receptor": [ 33 ], "agonist": [ 34 ], "exenatide": [ 35, 71, 82, 94, 139, 177, 208, 263, 268, 273, 287 ], "resulted": [ 37 ], "greater": [ 39 ], "HbA": [ 40, 102, 152, 184, 211 ], "1c": [ 41, 103, 153, 185, 212 ], "improvement": [ 42 ], "and": [ 43, 66, 74, 90, 164, 196, 213, 241 ], "weight": [ 44, 116, 165, 197, 229, 300 ], "reduction": [ 45, 230 ], "compared": [ 46 ], "maximum": [ 48 ], "approved": [ 49 ], "daily": [ 50, 289 ], "doses": [ 51 ], "sitagliptin": [ 53, 78, 175, 266, 290 ], "or": [ 54, 79, 247, 291, 295 ], "pioglitazone.": [ 55 ], "This": [ 56 ], "subsequent,": [ 57 ], "open\u2010label,": [ 59 ], "uncontrolled": [ 60 ], "evaluated": [ 63 ], "safety": [ 65 ], "efficacy": [ 67 ], "(i)": [ 69 ], "continued": [ 70, 122 ], "treatment": [ 73 ], "(ii)": [ 75 ], "switching": [ 76 ], "from": [ 77, 174, 205, 288 ], "pioglitazone": [ 80, 206, 271, 292 ], "to": [ 81, 176, 207, 285 ], "once\u2010weekly.": [ 83, 95 ], "Methods": [ 84 ], "Randomised": [ 85 ], "oral": [ 86 ], "medications": [ 87 ], "were": [ 88, 244 ], "discontinued": [ 89 ], "all": [ 91 ], "received": [ 93, 137 ], "Of": [ 96 ], "364": [ 98 ], "[original": [ 100 ], "baseline": [ 101 ], "8.5": [ 104 ], "\u00b1": [ 105, 113, 118, 148, 155, 161, 167, 187, 193, 199, 221, 224, 232 ], "1.1%": [ 106 ], "(70": [ 107 ], "mmol/mol),": [ 108 ], "fasting": [ 109, 157, 189, 214 ], "plasma": [ 110, 158, 190, 215 ], "glucose": [ 111, 159, 191, 216 ], "9.0": [ 112 ], "2.5": [ 114 ], "mmol/l,": [ 115 ], "88": [ 117 ], "20": [ 119 ], "kg)": [ 120 ], "who": [ 121, 136, 172, 203, 283 ], "into": [ 123 ], "open\u2010label": [ 125 ], "period,": [ 126 ], "319": [ 127 ], "(88%)": [ 129 ], "completed": [ 130 ], "52": [ 131 ], "weeks.": [ 132 ], "Results": [ 133 ], "Evaluable": [ 134, 170 ], "only": [ 138 ], "demonstrated": [ 141, 179 ], "significant": [ 142, 180, 228 ], "52\u2010week": [ 143 ], "improvements": [ 144, 182, 217 ], "(least": [ 145 ], "square": [ 146 ], "mean": [ 147 ], "se": [ 149 ], ")": [ 150 ], "(\u22121.6": [ 154 ], "0.1%),": [ 156, 188 ], "(\u22121.8": [ 160, 166 ], "0.3": [ 162, 200, 225, 233 ], "mmol/l)": [ 163, 195 ], "0.5": [ 168 ], "kg).": [ 169, 201, 234 ], "switched": [ 173, 204, 284 ], "incremental": [ 181 ], "(\u22120.3": [ 186 ], "(\u22120.7": [ 192 ], "0.2": [ 194 ], "(\u22121.1": [ 198 ], "Patients": [ 202, 282 ], "maintained": [ 210 ], "(week": [ 218 ], "52:": [ 219 ], "\u22121.6": [ 220 ], "0.1%,": [ 222 ], "\u22121.7": [ 223 ], "mmol/l),": [ 226 ], "(\u22123.0": [ 231 ], "Exenatide": [ 235 ], "was": [ 237, 252, 279 ], "generally": [ 238 ], "well": [ 239 ], "tolerated": [ 240 ], "adverse": [ 242, 256 ], "events": [ 243 ], "predominantly": [ 245 ], "mild": [ 246 ], "moderate": [ 248 ], "intensity.": [ 250 ], "Nausea": [ 251 ], "most": [ 254 ], "frequent": [ 255 ], "event": [ 257 ], "this": [ 259 ], "(intent\u2010to\u2010treat:": [ 262 ], "once\u2010weekly\u2010only": [ 264 ], "5%;": [ 265 ], "\u2192": [ 267, 272 ], "11%;": [ 270 ], "10%).": [ 275 ], "No": [ 276 ], "major": [ 277 ], "hypoglycaemia": [ 278 ], "observed.": [ 280 ], "Conclusions": [ 281 ], "had": [ 293 ], "improved": [ 294 ], "sustained": [ 296 ], "glycaemic": [ 297 ], "control,": [ 298 ], "loss.": [ 301 ] }, "publication_date": "2011-03-22", "publication_year": 2011, "type": "article", "cited_by_count": 117, "authors": [ { "id": "https://openalex.org/A5040652845", "display_name": "Carol Wysham" }, { "id": "https://openalex.org/A5034096266", "display_name": "Richard M. Bergenstal" }, { "id": "https://openalex.org/A5004842224", "display_name": "Jaret Malloy" }, { "id": "https://openalex.org/A5101819344", "display_name": "Ping Yan" }, { "id": "https://openalex.org/A5102775095", "display_name": "Brandon Walsh" }, { "id": "https://openalex.org/A5112515114", "display_name": "James Malone" }, { "id": "https://openalex.org/A5069680011", "display_name": "Kathryn Taylor" } ] }, { "id": "https://openalex.org/W2807118415", "doi": "https://doi.org/10.1089/dia.2018.0103", "title": "The Clinical Impact of GLP-1 Receptor Agonists in Type 2 Diabetes: Focus on the Long-Acting Analogs", "abstract": { "GLP-1": [ 0, 62, 95, 109, 126, 155 ], "receptor": [ 1 ], "agonists": [ 2 ], "(GLP-1": [ 3 ], "RAs),": [ 4 ], "introduced": [ 5 ], "for": [ 6, 104, 180, 195 ], "clinical": [ 7 ], "use": [ 8, 174 ], "in": [ 9, 14, 57, 85, 147 ], "2005,": [ 10 ], "have": [ 11, 52, 77 ], "excellent": [ 12 ], "potency": [ 13 ], "reducing": [ 15, 37 ], "HbA1c": [ 16, 150 ], "and": [ 17, 39, 48, 135, 152, 199, 202 ], "mean": [ 18 ], "glucose,": [ 19, 23 ], "improving": [ 20, 137 ], "fasting": [ 21 ], "plasma": [ 22 ], "inducing": [ 24 ], "weight": [ 25, 31, 153 ], "loss": [ 26 ], "or": [ 27, 89 ], "protecting": [ 28 ], "against": [ 29 ], "the": [ 30, 144, 173 ], "gain": [ 32 ], "associated": [ 33, 65 ], "with": [ 34, 66, 87, 98, 160 ], "insulin": [ 35, 88, 90, 101 ], "therapy,": [ 36 ], "appetite,": [ 38 ], "delaying": [ 40 ], "gastric": [ 41 ], "emptying.": [ 42 ], "Two": [ 43, 92 ], "of": [ 44, 81, 94, 149, 163, 175, 183, 192, 197, 204 ], "these": [ 45 ], "medications,": [ 46 ], "liraglutide": [ 47 ], "semaglutide,": [ 49, 193 ], "appear": [ 50 ], "to": [ 51, 72, 142 ], "cardioprotective": [ 53, 205 ], "effects": [ 54, 69 ], "as": [ 55 ], "reflected": [ 56 ], "cardiovascular": [ 58 ], "outcomes": [ 59 ], "studies.": [ 60 ], "The": [ 61, 107 ], "RAs": [ 63, 96, 127, 156 ], "are": [ 64, 102, 118, 128, 171 ], "gastrointestinal": [ 67 ], "side": [ 68 ], "that": [ 70 ], "tend": [ 71 ], "diminish": [ 73 ], "over": [ 74 ], "time.": [ 75 ], "They": [ 76 ], "very": [ 78 ], "low": [ 79 ], "risk": [ 80 ], "hypoglycemia": [ 82 ], "unless": [ 83 ], "used": [ 84 ], "conjunction": [ 86 ], "secretagogues.": [ 91 ], "coformulations": [ 93 ], "together": [ 97 ], "long-acting": [ 99, 125 ], "basal": [ 100 ], "available": [ 103, 124 ], "daily": [ 105 ], "use.": [ 106 ], "original": [ 108 ], "RA,": [ 110 ], "exenatide,": [ 111 ], "requires": [ 112 ], "twice-daily": [ 113 ], "injections;": [ 114 ], "two": [ 115 ], "short-acting": [ 116 ], "analogs": [ 117 ], "given": [ 119 ], "once": [ 120, 130 ], "daily.": [ 121 ], "Three": [ 122 ], "currently": [ 123 ], "injected": [ 129 ], "weekly,": [ 131 ], "providing": [ 132 ], "greater": [ 133 ], "convenience": [ 134 ], "potentially": [ 136 ], "patient": [ 138 ], "adherence.": [ 139 ], "Semaglutide": [ 140 ], "appears": [ 141 ], "be": [ 143, 158 ], "most": [ 145 ], "effective": [ 146 ], "terms": [ 148 ], "reduction": [ 151 ], "loss.": [ 154 ], "can": [ 157 ], "combined": [ 159 ], "all": [ 161 ], "classes": [ 162 ], "antihyperglycemic": [ 164 ], "agents": [ 165 ], "except": [ 166 ], "DPP-4": [ 167 ], "inhibitors.": [ 168 ], "Current": [ 169 ], "studies": [ 170 ], "exploring": [ 172 ], "an": [ 176, 189 ], "implantable": [ 177 ], "osmotic": [ 178 ], "pump": [ 179 ], "long-term": [ 181 ], "administration": [ 182 ], "a": [ 184 ], "rapid": [ 185 ], "acting": [ 186 ], "analog": [ 187 ], "(exenatide),": [ 188 ], "oral": [ 190 ], "preparation": [ 191 ], "benefits": [ 194 ], "management": [ 196 ], "obesity": [ 198 ], "nonalcoholic": [ 200 ], "steatohepatitis,": [ 201 ], "mechanisms": [ 203 ], "effects.": [ 206 ] }, "publication_date": "2018-06-01", "publication_year": 2018, "type": "article", "cited_by_count": 26, "authors": [ { "id": "https://openalex.org/A5020174004", "display_name": "Helena W. Rodbard" } ] }, { "id": "https://openalex.org/W2123319002", "doi": "https://doi.org/10.1172/jci68295", "title": "Exenatide and the treatment of patients with Parkinson\u2019s disease", "abstract": { "Cure": [ 0 ], "Parkinson's": [ 1 ], "Trust.": [ 2 ] }, "publication_date": "2013-05-20", "publication_year": 2013, "type": "article", "cited_by_count": 480, "authors": [ { "id": "https://openalex.org/A5030193280", "display_name": "Ic\u00edar Avil\u00e9s-Olmos" }, { "id": "https://openalex.org/A5067401921", "display_name": "John Dickson" }, { "id": "https://openalex.org/A5000414294", "display_name": "Zinovia Kefalopoulou" }, { "id": "https://openalex.org/A5003960100", "display_name": "Atbin Djamshidian" }, { "id": "https://openalex.org/A5110225490", "display_name": "Peter J. Ell" }, { "id": "https://openalex.org/A5112005008", "display_name": "Therese A. S\u00f6derlund" }, { "id": "https://openalex.org/A5017380295", "display_name": "Peter S. Whitton" }, { "id": "https://openalex.org/A5021732872", "display_name": "Richard Wyse" }, { "id": "https://openalex.org/A5108758328", "display_name": "Tom Isaacs" }, { "id": "https://openalex.org/A5063335320", "display_name": "Andrew J. Lees" }, { "id": "https://openalex.org/A5040249146", "display_name": "Patricia Limousin" }, { "id": "https://openalex.org/A5031389008", "display_name": "Thomas Foltynie" } ] }, { "id": "https://openalex.org/W2208246363", "doi": "https://doi.org/10.1016/j.clinthera.2015.11.017", "title": "Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation", "abstract": null, "publication_date": "2015-12-17", "publication_year": 2015, "type": "article", "cited_by_count": 28, "authors": [ { "id": "https://openalex.org/A5109226707", "display_name": "Maria Yu" }, { "id": "https://openalex.org/A5101493193", "display_name": "Jin Xie" }, { "id": "https://openalex.org/A5072715491", "display_name": "Laura Fern\u00e1ndez Land\u00f3" }, { "id": "https://openalex.org/A5023835677", "display_name": "Samaneh Kabul" }, { "id": "https://openalex.org/A5091374453", "display_name": "Ralph Swindle" } ] }, { "id": "https://openalex.org/W3198007080", "doi": "https://doi.org/10.1172/jci151800", "title": "A randomized controlled trial of the GLP-1 receptor agonist dulaglutide in primary polydipsia", "abstract": { "BackgroundPrimary": [ 0 ], "polydipsia,": [ 1 ], "characterized": [ 2 ], "by": [ 3, 155, 164, 206 ], "excessive": [ 4 ], "fluid": [ 5, 59, 117, 162, 253 ], "intake,": [ 6 ], "carries": [ 7 ], "the": [ 8, 94, 97, 120, 293, 300, 309 ], "risk": [ 9 ], "of": [ 10, 48, 134, 199, 284, 296, 316 ], "water": [ 11 ], "intoxication": [ 12 ], "and": [ 13, 26, 43, 88, 137, 145, 233, 248, 255, 263, 282, 299 ], "hyponatremia,": [ 14 ], "but": [ 15, 241 ], "treatment": [ 16, 86, 99, 268 ], "options": [ 17 ], "are": [ 18 ], "scarce.": [ 19 ], "Glucagon-like": [ 20 ], "peptide": [ 21 ], "1": [ 22 ], "(GLP-1)": [ 23 ], "reduces": [ 24 ], "appetite": [ 25 ], "food": [ 27 ], "intake.": [ 28 ], "In": [ 29, 131 ], "experimental": [ 30 ], "models,": [ 31 ], "GLP-1": [ 32, 55 ], "has": [ 33 ], "also": [ 34 ], "been": [ 35 ], "shown": [ 36 ], "to": [ 37, 52, 110, 150, 183, 195, 220 ], "play": [ 38 ], "a": [ 39, 132, 196, 267 ], "role": [ 40 ], "in": [ 41, 61, 84, 93, 148, 218, 258, 288, 312 ], "thirst": [ 42, 143, 256 ], "drinking": [ 44 ], "behavior.": [ 45 ], "The": [ 46, 112 ], "aim": [ 47 ], "this": [ 49, 66 ], "trial": [ 50 ], "was": [ 51, 115, 204, 223, 244 ], "investigate": [ 53 ], "whether": [ 54 ], "receptor": [ 56, 250 ], "agonists": [ 57, 251 ], "reduce": [ 58, 252 ], "intake": [ 60, 118, 163, 254 ], "patients": [ 62, 74, 101, 136, 226, 236, 259 ], "with": [ 63, 75, 107, 227, 260 ], "primary": [ 64, 76, 113, 228, 261 ], "polydipsia.MethodsIn": [ 65 ], "randomized,": [ 67 ], "double-blind,": [ 68 ], "placebo-controlled,": [ 69 ], "3-week": [ 70 ], "crossover": [ 71 ], "trial,": [ 72 ], "34": [ 73 ], "polydipsia": [ 77, 229, 262 ], "received": [ 78 ], "weekly": [ 79 ], "dulaglutide": [ 80, 159, 191, 238 ], "(1.5": [ 81 ], "mg,": [ 82 ], "Trulicity)": [ 83 ], "one": [ 85 ], "segment": [ 87 ], "placebo": [ 89, 182 ], "(0.9%": [ 90 ], "sodium": [ 91 ], "chloride)": [ 92 ], "other.": [ 95 ], "During": [ 96 ], "last": [ 98 ], "week,": [ 100 ], "attended": [ 102 ], "an": [ 103, 138 ], "8-hour": [ 104 ], "evaluation": [ 105, 121 ], "visit": [ 106 ], "free": [ 108 ], "access": [ 109 ], "water.": [ 111 ], "endpoint": [ 114 ], "total": [ 116 ], "during": [ 119 ], "visits.": [ 122 ], "Treatment": [ 123 ], "effects": [ 124 ], "were": [ 125, 153 ], "estimated": [ 126 ], "using": [ 127 ], "linear": [ 128 ], "mixed-effects": [ 129 ], "models.": [ 130 ], "subset": [ 133 ], "15": [ 135, 140 ], "additional": [ 139 ], "matched": [ 141 ], "controls,": [ 142, 232 ], "perception": [ 144, 217, 257 ], "neuronal": [ 146 ], "activity": [ 147, 243 ], "response": [ 149, 219 ], "beverage": [ 151, 221 ], "pictures": [ 152, 222 ], "assessed": [ 154 ], "functional": [ 156, 242 ], "MRI.RESULTsPatients": [ 157 ], "on": [ 158, 181, 190, 237 ], "reduced": [ 160, 205 ], "their": [ 161 ], "490": [ 165 ], "mL": [ 166, 176, 185, 208 ], "(95%": [ 167, 177, 186, 209 ], "CI:": [ 168, 178, 187, 210 ], "-780,": [ 169 ], "-199;": [ 170 ], "P": [ 171, 213 ], "=": [ 172, 214 ], "0.002),": [ 173 ], "from": [ 174, 292, 308 ], "2950": [ 175 ], "2435,": [ 179 ], "3465)": [ 180 ], "2460": [ 184 ], "1946,": [ 188 ], "2475)": [ 189 ], "(model": [ 192 ], "estimates),": [ 193 ], "corresponding": [ 194 ], "relative": [ 197 ], "reduction": [ 198 ], "17%.": [ 200 ], "Twenty-four-hour": [ 201 ], "urinary": [ 202 ], "output": [ 203 ], "-943": [ 207 ], "-1473,": [ 211 ], "-413;": [ 212 ], "0.001).": [ 215 ], "Thirst": [ 216 ], "higher": [ 224 ], "for": [ 225, 231, 235, 270 ], "than": [ 230 ], "lower": [ 234 ], "versus": [ 239 ], "placebo,": [ 240 ], "similar": [ 245 ], "among": [ 246 ], "groups": [ 247 ], "treatments.CONCLUSIONSGLP-1": [ 249 ], "could": [ 264 ], "therefore": [ 265 ], "be": [ 266 ], "option": [ 269 ], "these": [ 271 ], "patients.Trial": [ 272 ], "registrationClinicaltrials.gov": [ 273 ], "NCT02770885.FundingSwiss": [ 274 ], "National": [ 275 ], "Science": [ 276 ], "Foundation": [ 277 ], "(grant": [ 278 ], "32473B_162608);": [ 279 ], "University": [ 280, 283, 315 ], "Hospital": [ 281 ], "Basel;": [ 285 ], "Young": [ 286 ], "Talents": [ 287 ], "Clinical": [ 289 ], "Research": [ 290 ], "grant": [ 291 ], "Swiss": [ 294 ], "Academy": [ 295 ], "Medical": [ 297 ], "Sciences": [ 298 ], "Gottfried": [ 301 ], "&": [ 302 ], "Julia": [ 303 ], "Bangerter-Rhyner": [ 304 ], "Foundation;": [ 305 ], "Top-up": [ 306 ], "Grant": [ 307 ], "PhD": [ 310 ], "Programme": [ 311 ], "Health": [ 313 ], "Sciences,": [ 314 ], "Basel.": [ 317 ] }, "publication_date": "2021-09-02", "publication_year": 2021, "type": "article", "cited_by_count": 24, "authors": [ { "id": "https://openalex.org/A5023967301", "display_name": "Bettina Winzeler" }, { "id": "https://openalex.org/A5045826714", "display_name": "Clara Odilia Sailer" }, { "id": "https://openalex.org/A5050624927", "display_name": "David Coynel" }, { "id": "https://openalex.org/A5082616506", "display_name": "Davide Zanchi" }, { "id": "https://openalex.org/A5057598527", "display_name": "D. Vogt" }, { "id": "https://openalex.org/A5067434539", "display_name": "Sandrine Urwyler" }, { "id": "https://openalex.org/A5016702558", "display_name": "Julie Refardt" }, { "id": "https://openalex.org/A5075635162", "display_name": "Mirjam Christ\u2010Crain" } ] }, { "id": "https://openalex.org/W2604171241", "doi": "https://doi.org/10.1016/j.atherosclerosis.2017.04.001", "title": "Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice", "abstract": null, "publication_date": "2017-04-07", "publication_year": 2017, "type": "article", "cited_by_count": 100, "authors": [ { "id": "https://openalex.org/A5066098744", "display_name": "Teruo Jojima" }, { "id": "https://openalex.org/A5113761807", "display_name": "Kohsuke Uchida" }, { "id": "https://openalex.org/A5070910498", "display_name": "Kazumi Akimoto" }, { "id": "https://openalex.org/A5008322865", "display_name": "Takanori Tomotsune" }, { "id": "https://openalex.org/A5111846982", "display_name": "Kazunori Yanagi" }, { "id": "https://openalex.org/A5038865449", "display_name": "Toshie Iijima" }, { "id": "https://openalex.org/A5100650773", "display_name": "Kunihiro Suzuki" }, { "id": "https://openalex.org/A5045166593", "display_name": "Kikuo Kasai" }, { "id": "https://openalex.org/A5002804119", "display_name": "Yoshimasa Aso" } ] }, { "id": "https://openalex.org/W3213283278", "doi": "https://doi.org/10.1080/00325481.2021.2002616", "title": "Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice", "abstract": { "Glucagon-like": [ 0 ], "peptide-1": [ 1 ], "receptor": [ 2 ], "agonists": [ 3 ], "(GLP-1RAs)": [ 4 ], "are": [ 5, 19, 33 ], "well": [ 6, 34 ], "established": [ 7 ], "in": [ 8, 26 ], "clinical": [ 9, 64 ], "practice": [ 10 ], "for": [ 11, 23, 50 ], "the": [ 12, 37 ], "treatment": [ 13 ], "of": [ 14, 42 ], "type": [ 15 ], "2": [ 16 ], "diabetes,": [ 17 ], "and": [ 18, 21, 45, 61 ], "approved": [ 20 ], "recommended": [ 22 ], "weight": [ 24 ], "management": [ 25 ], "overweight": [ 27 ], "or": [ 28 ], "obesity.": [ 29 ], "Gastrointestinal": [ 30 ], "side": [ 31, 74 ], "effects": [ 32, 41, 75 ], "known": [ 35 ], "as": [ 36 ], "most": [ 38 ], "common": [ 39 ], "adverse": [ 40 ], "these": [ 43, 73 ], "agents": [ 44 ], "represent": [ 46 ], "a": [ 47, 77 ], "potential": [ 48 ], "barrier": [ 49 ], "use,": [ 51 ], "particularly": [ 52 ], "at": [ 53 ], "higher": [ 54 ], "doses.": [ 55 ], "Drawing": [ 56 ], "on": [ 57 ], "both": [ 58 ], "published": [ 59 ], "evidence": [ 60 ], "our": [ 62 ], "collective": [ 63 ], "experience,": [ 65 ], "we": [ 66 ], "aim": [ 67 ], "to": [ 68, 79 ], "guide": [ 69 ], "practitioners": [ 70 ], "through": [ 71 ], "managing": [ 72 ], "with": [ 76, 83 ], "view": [ 78 ], "optimizing": [ 80 ], "therapeutic": [ 81 ], "outcomes": [ 82 ], "GLP-1RAs.": [ 84 ] }, "publication_date": "2021-11-15", "publication_year": 2021, "type": "article", "cited_by_count": 162, "authors": [ { "id": "https://openalex.org/A5027441223", "display_name": "Sean Wharton" }, { "id": "https://openalex.org/A5084593004", "display_name": "Melanie J. Davies" }, { "id": "https://openalex.org/A5009921349", "display_name": "Dror Dicker" }, { "id": "https://openalex.org/A5001655356", "display_name": "Ildiko Lingvay" }, { "id": "https://openalex.org/A5080475619", "display_name": "Ofri Mosenzon" }, { "id": "https://openalex.org/A5060266336", "display_name": "Domenica Rubino" }, { "id": "https://openalex.org/A5040913971", "display_name": "Sue D. Pedersen" } ] }, { "id": "https://openalex.org/W2947155305", "doi": "https://doi.org/10.1002/dmrr.3191", "title": "The use of GLP\u20101 receptor agonists in hospitalised patients: An untapped potential", "abstract": { "Summary": [ 0 ], "In": [ 1 ], "the": [ 2, 61, 69, 82, 92, 100, 107, 116, 124, 184 ], "outpatient": [ 3 ], "setting,": [ 4 ], "glucagon\u2010like": [ 5 ], "peptide\u20101": [ 6 ], "(GLP\u20101)": [ 7 ], "receptor": [ 8, 31 ], "agonists": [ 9, 32 ], "have": [ 10, 218, 234 ], "proved": [ 11 ], "to": [ 12, 35, 90, 236 ], "be": [ 13, 66, 237 ], "highly": [ 14 ], "efficacious": [ 15 ], "drugs": [ 16 ], "that": [ 17, 196 ], "provide": [ 18 ], "glycaemic": [ 19, 45 ], "control": [ 20 ], "with": [ 21, 51, 106, 202 ], "a": [ 22, 57, 73, 78 ], "low": [ 23 ], "risk": [ 24, 211 ], "of": [ 25, 72, 81, 94, 109, 186, 204, 212 ], "hypoglycaemia.": [ 26, 213 ], "These": [ 27 ], "characteristics": [ 28 ], "make": [ 29 ], "GLP\u20101": [ 30, 54, 110, 200 ], "attractive": [ 33 ], "agents": [ 34 ], "treat": [ 36 ], "dysglycaemia": [ 37 ], "in": [ 38, 68, 84, 112, 183, 221 ], "perioperative": [ 39, 194 ], "or": [ 40, 230 ], "high\u2010dependency": [ 41 ], "hospital": [ 42 ], "settings,": [ 43 ], "where": [ 44 ], "variability": [ 46 ], "and": [ 47, 63, 99, 102, 119, 193, 209, 215 ], "hyperglycaemia": [ 48 ], "are": [ 49 ], "associated": [ 50 ], "poor": [ 52 ], "prognosis.": [ 53 ], "also": [ 55 ], "has": [ 56 ], "direct": [ 58 ], "action": [ 59 ], "on": [ 60 ], "myocardium": [ 62 ], "vasculature\u2014which": [ 64 ], "may": [ 65 ], "advantageous": [ 67 ], "immediate": [ 70 ], "aftermath": [ 71 ], "vascular": [ 74, 228 ], "insult.": [ 75 ], "This": [ 76 ], "is": [ 77 ], "narrative": [ 79 ], "review": [ 80 ], "work": [ 83 ], "this": [ 85 ], "area.": [ 86 ], "The": [ 87 ], "aim": [ 88 ], "was": [ 89 ], "determine": [ 91 ], "populations": [ 93 ], "hospitalised": [ 95 ], "patients": [ 96 ], "being": [ 97 ], "evaluated": [ 98 ], "clinical": [ 101, 241 ], "mechanistic": [ 103 ], "end\u2010points": [ 104 ], "tested,": [ 105 ], "institution": [ 108 ], "therapy": [ 111 ], "hospital.": [ 113 ], "We": [ 114 ], "searched": [ 115 ], "PubMed,": [ 117 ], "Embase,": [ 118 ], "Google": [ 120 ], "scholar": [ 121 ], "databases,": [ 122 ], "combining": [ 123 ], "term": [ 125 ], "\u201cglucagon\u2010like": [ 126 ], "peptide": [ 127 ], "1\u201d": [ 128 ], "OR": [ 129, 131, 133, 135, 137, 139, 141, 145, 147, 149, 151, 153, 156, 158, 161, 165, 167, 170, 173, 175 ], "\u201cGLP\u20101\u201d": [ 130 ], "\u201cincretin\u201d": [ 132 ], "\u201cliraglutide\u201d": [ 134 ], "\u201cexenatide\u201d": [ 136 ], "\u201clixisenatide\u201d": [ 138 ], "\u201cdulaglutide\u201d": [ 140 ], "\u201calbiglutide\u201d": [ 142 ], "AND": [ 143 ], "\u201cinpatient\u201d": [ 144 ], "\u201chospital\u201d": [ 146 ], "\u201cperioperative\u201d": [ 148 ], "\u201cpostoperative\u201d": [ 150 ], "\u201csurgery\u201d": [ 152 ], "\u201cmyocardial": [ 154 ], "infarction\u201d": [ 155 ], "\u201cstroke\u201d": [ 157 ], "\u201ccerebrovascular": [ 159 ], "disease\u201d": [ 160 ], "\u201ctransient": [ 162 ], "ischaemic": [ 163 ], "attack\u201d": [ 164 ], "\u201cICU\u201d": [ 166 ], "\u201ccritical": [ 168, 171 ], "care\u201d": [ 169 ], "illness\u201d": [ 172 ], "\u201cCCU\u201d": [ 174 ], "\u201ccoronary": [ 176 ], "care": [ 177, 195 ], "unit.\u201d": [ 178 ], "Pilot": [ 179 ], "studies": [ 180, 217 ], "were": [ 181 ], "reported": [ 182, 219 ], "fields": [ 185 ], "acute": [ 187 ], "stroke,": [ 188 ], "cardiac": [ 189 ], "resuscitation,": [ 190 ], "coronary": [ 191 ], "care,": [ 192 ], "showed": [ 197 ], "advantages": [ 198 ], "for": [ 199 ], "therapy,": [ 201 ], "normalisation": [ 203 ], "glucose,": [ 205 ], "lower": [ 206, 210 ], "glucose": [ 207 ], "variability,": [ 208 ], "Animal": [ 214 ], "human": [ 216 ], "improvements": [ 220 ], "myocardial": [ 222 ], "performance": [ 223 ], "when": [ 224 ], "given": [ 225 ], "acutely": [ 226 ], "after": [ 227 ], "insult": [ 229 ], "surgery,": [ 231 ], "but": [ 232 ], "these": [ 233 ], "yet": [ 235 ], "translated": [ 238 ], "into": [ 239 ], "randomised": [ 240 ], "trials.": [ 242 ] }, "publication_date": "2019-05-29", "publication_year": 2019, "type": "review", "cited_by_count": 24, "authors": [ { "id": "https://openalex.org/A5010855712", "display_name": "\u041e\u043c\u0430\u0440 \u041c\u0443\u0441\u0442\u0430\u0444\u0430" }, { "id": "https://openalex.org/A5081689241", "display_name": "Martin Whyte" } ] }, { "id": "https://openalex.org/W2160474387", "doi": "https://doi.org/10.1152/ajpendo.00182.2012", "title": "The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis", "abstract": { "A": [ 0, 122 ], "possible": [ 1 ], "association": [ 2 ], "between": [ 3 ], "glucagon-like": [ 4 ], "peptide-1": [ 5 ], "(GLP-1)": [ 6 ], "analogs": [ 7 ], "and": [ 8, 21, 38, 46, 52, 85, 91, 95, 100, 107, 115, 120, 126, 133, 162, 171, 202, 224, 239, 258, 262, 279 ], "incidences": [ 9 ], "of": [ 10, 33, 36, 49, 104, 193, 214, 256 ], "pancreatitis": [ 11 ], "has": [ 12 ], "been": [ 13 ], "suggested": [ 14 ], "based": [ 15 ], "on": [ 16, 40, 218, 271 ], "clinical": [ 17, 276 ], "studies.": [ 18 ], "In": [ 19 ], "male": [ 20, 125, 238 ], "female": [ 22, 53, 127, 240 ], "diabetic": [ 23, 25, 237 ], "Zucker": [ 24 ], "fatty": [ 26 ], "(ZDF)": [ 27 ], "rats,": [ 28, 129, 242 ], "we": [ 29 ], "investigated": [ 30 ], "the": [ 31, 105, 108, 207, 272 ], "effects": [ 32, 192, 213 ], "continuous": [ 34 ], "administration": [ 35 ], "liraglutide": [ 37, 62, 114, 161, 215, 263 ], "exenatide": [ 39, 74, 116, 217, 261 ], "biochemical": [ 41, 252 ], "[lipase,": [ 42 ], "pancreatic": [ 43 ], "amylase": [ 44 ], "(P-amylase)]": [ 45 ], "histopathological": [ 47, 94, 186, 254 ], "markers": [ 48, 255 ], "pancreatitis.": [ 50 ], "Male": [ 51 ], "ZDF": [ 54, 128, 241 ], "rats": [ 55 ], "were": [ 56, 89, 136, 155, 174, 178, 197 ], "dosed": [ 57 ], "for": [ 58 ], "13": [ 59 ], "wk": [ 60 ], "with": [ 61, 138, 160 ], "(0.4": [ 63 ], "or": [ 64, 73, 166, 216, 222, 228, 253 ], "1.0": [ 65 ], "mg\u00b7kg": [ 66, 76 ], "\u22121": [ 67, 69, 77, 79 ], "\u00b7day": [ 68, 78 ], "sc": [ 70 ], "once": [ 71 ], "daily)": [ 72 ], "(0.25": [ 75 ], "sc,": [ 80 ], "Alzet": [ 81 ], "osmotic": [ 82 ], "minipumps).": [ 83 ], "P-amylase": [ 84, 153, 172 ], "lipase": [ 86, 148, 170 ], "plasma": [ 87 ], "activity": [ 88, 154, 173 ], "measured,": [ 90 ], "an": [ 92 ], "extended": [ 93 ], "stereological": [ 96, 209 ], "(specific": [ 97 ], "cell": [ 98, 226 ], "mass": [ 99, 132, 227 ], "proliferation": [ 101, 134 ], "rate)": [ 102 ], "evaluation": [ 103 ], "exocrine": [ 106, 223, 273 ], "endocrine": [ 109 ], "pancreas": [ 110, 220 ], "was": [ 111 ], "performed.": [ 112 ], "Expectedly,": [ 113 ], "lowered": [ 117, 179 ], "blood": [ 118, 141 ], "glucose": [ 119, 142 ], "Hb": [ 121 ], "1c": [ 123 ], "in": [ 124, 152, 157, 169, 200, 204, 235, 286 ], "whereas": [ 130, 259 ], "\u03b2-cell": [ 131, 265 ], "rate": [ 135 ], "increased": [ 137 ], "greatly": [ 139 ], "improved": [ 140 ], "control.": [ 143 ], "Whereas": [ 144 ], "neither": [ 145 ], "analog": [ 146 ], "affected": [ 147 ], "activity,": [ 149 ], "small": [ 150 ], "increases": [ 151, 168 ], "observed": [ 156 ], "animals": [ 158 ], "treated": [ 159 ], "exenatide.": [ 163 ], "However,": [ 164, 275 ], "concurrent": [ 165 ], "permanent": [ 167 ], "never": [ 175 ], "observed.": [ 176 ], "Triglycerides": [ 177 ], "by": [ 180 ], "both": [ 181, 260 ], "GLP-1": [ 182, 246 ], "analogs.": [ 183 ], "The": [ 184, 195, 230 ], "qualitative": [ 185 ], "findings": [ 187, 196 ], "did": [ 188 ], "not": [ 189, 250 ], "reveal": [ 190 ], "adverse": [ 191 ], "liraglutide.": [ 194 ], "mainly": [ 198 ], "minimal": [ 199 ], "severity": [ 201 ], "focal": [ 203 ], "distribution.": [ 205 ], "Similarly,": [ 206 ], "quantitative": [ 208 ], "analyses": [ 210 ], "revealed": [ 211 ], "no": [ 212, 269 ], "overall": [ 219 ], "weight": [ 221 ], "duct": [ 225 ], "proliferation.": [ 229 ], "present": [ 231 ], "study": [ 232 ], "demonstrates": [ 233 ], "that,": [ 234 ], "overtly": [ 236 ], "prolonged": [ 243 ], "exposure": [ 244 ], "to": [ 245, 291 ], "receptor": [ 247 ], "agonists": [ 248 ], "does": [ 249 ], "affect": [ 251 ], "pancreatitis,": [ 257 ], "increase": [ 264 ], "mass,": [ 266 ], "they": [ 267 ], "have": [ 268 ], "effect": [ 270 ], "pancreas.": [ 274 ], "outcome": [ 277 ], "studies": [ 278, 280, 285 ], "using": [ 281 ], "primate": [ 282 ], "tissues": [ 283 ], "and/or": [ 284 ], "nonhuman": [ 287 ], "primates": [ 288 ], "are": [ 289 ], "needed": [ 290 ], "further": [ 292 ], "assess": [ 293 ], "human": [ 294 ], "risk.": [ 295 ] }, "publication_date": "2012-05-16", "publication_year": 2012, "type": "article", "cited_by_count": 90, "authors": [ { "id": "https://openalex.org/A5088582143", "display_name": "Niels Vrang" }, { "id": "https://openalex.org/A5075602116", "display_name": "Jacob Jelsing" }, { "id": "https://openalex.org/A5088597413", "display_name": "Lotte Simonsen" }, { "id": "https://openalex.org/A5041608440", "display_name": "Andres Eskj\u00e6r Jensen" }, { "id": "https://openalex.org/A5051655702", "display_name": "Inger Thorup" }, { "id": "https://openalex.org/A5030736840", "display_name": "Henrik S\u00f8eborg" }, { "id": "https://openalex.org/A5088627727", "display_name": "Lotte Bjerre Knudsen" } ] }, { "id": "https://openalex.org/W3109063372", "doi": "https://doi.org/10.1111/dom.14280", "title": "The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity", "abstract": { "Abstract": [ 0 ], "Aim": [ 1 ], "To": [ 2 ], "investigate": [ 3 ], "the": [ 4, 88, 229 ], "effects": [ 5 ], "of": [ 6, 68, 200, 232, 248, 267 ], "once\u2010weekly": [ 7, 40, 239 ], "subcutaneous": [ 8 ], "(s.c.)": [ 9 ], "semaglutide": [ 10, 42, 116, 162, 207, 220, 241 ], "2.4": [ 11, 45, 117, 242 ], "mg": [ 12, 118, 243 ], "on": [ 13, 139 ], "gastric": [ 14, 269 ], "emptying,": [ 15 ], "appetite,": [ 16, 245 ], "and": [ 17, 25, 66, 75, 179, 183, 186, 202, 221, 250, 258 ], "energy": [ 18, 76, 156, 256 ], "intake": [ 19, 77, 157, 257 ], "in": [ 20, 33 ], "adults": [ 21, 35, 236 ], "with": [ 22, 36, 115, 161, 190, 206, 219, 223, 228, 237 ], "obesity.": [ 23 ], "Materials": [ 24 ], "Methods": [ 26 ], "A": [ 27 ], "double\u2010blind,": [ 28 ], "parallel\u2010group": [ 29 ], "trial": [ 30 ], "was": [ 31, 54, 78, 107, 137, 158, 215, 226, 264 ], "conducted": [ 32 ], "72": [ 34 ], "obesity,": [ 37, 238 ], "randomized": [ 38 ], "to": [ 39, 44, 95, 149 ], "s.c.": [ 41, 240 ], "(dose\u2010escalated": [ 43 ], "mg)": [ 46 ], "or": [ 47, 147 ], "placebo": [ 48, 120, 164, 191, 209 ], "for": [ 49, 92, 127 ], "20": [ 50, 123, 129 ], "weeks.": [ 51 ], "Gastric": [ 52 ], "emptying": [ 53, 270 ], "assessed": [ 55, 274 ], "using": [ 56 ], "paracetamol": [ 57, 93, 145, 152, 277 ], "absorption": [ 58 ], "following": [ 59 ], "a": [ 60, 99 ], "standardized": [ 61, 100 ], "breakfast.": [ 62 ], "Participant\u2010reported": [ 63 ], "appetite": [ 64 ], "ratings": [ 65 ], "Control": [ 67 ], "Eating": [ 69 ], "Questionnaire": [ 70 ], "(CoEQ)": [ 71 ], "responses": [ 72 ], "were": [ 73 ], "assessed,": [ 74 ], "measured": [ 79 ], "during": [ 80 ], "ad": [ 81, 254 ], "libitum": [ 82, 155, 255 ], "lunch.": [ 83 ], "Results": [ 84 ], "The": [ 85, 195 ], "area": [ 86 ], "under": [ 87 ], "concentration\u2013time": [ 89 ], "curve": [ 90 ], "(AUC)": [ 91 ], "0": [ 94 ], "5": [ 96 ], "hours": [ 97 ], "after": [ 98 ], "meal": [ 101 ], "(AUC": [ 102 ], "0\u20135h,para": [ 103 ], ";": [ 104 ], "primary": [ 105 ], "endpoint)": [ 106 ], "increased": [ 108, 184 ], "by": [ 109, 217 ], "8%": [ 110 ], "(": [ 111, 210 ], "P": [ 112, 132, 174, 193, 211 ], "=": [ 113, 133 ], "0.005)": [ 114 ], "versus": [ 119, 163, 166, 208, 261 ], "at": [ 121, 271 ], "week": [ 122, 128, 272 ], "(non\u2010significant": [ 124 ], "when": [ 125, 188 ], "corrected": [ 126 ], "body": [ 130, 259 ], "weight;": [ 131 ], "0.12).": [ 134 ], "No": [ 135 ], "effect": [ 136 ], "seen": [ 138 ], "AUC": [ 140 ], "0\u20131h,para": [ 141 ], ",": [ 142 ], "maximum": [ 143, 150 ], "observed": [ 144, 151 ], "concentration,": [ 146 ], "time": [ 148 ], "concentration.": [ 153 ], "Ad": [ 154 ], "35%": [ 159 ], "lower": [ 160 ], "(1736": [ 165 ], "2676": [ 167 ], "kJ;": [ 168, 173 ], "estimated": [ 169 ], "treatment": [ 170 ], "difference": [ 171 ], "\u2212940": [ 172 ], "<0.0001).": [ 175 ], "Semaglutide": [ 176 ], "reduced": [ 177, 216, 251 ], "hunger": [ 178 ], "prospective": [ 180 ], "food": [ 181, 204, 252 ], "consumption,": [ 182 ], "fullness": [ 185 ], "satiety": [ 187 ], "compared": [ 189 ], "(all": [ 192 ], "<0.02).": [ 194 ], "CoEQ": [ 196 ], "indicated": [ 197 ], "better": [ 198 ], "control": [ 199, 247 ], "eating": [ 201 ], "fewer/weaker": [ 203 ], "cravings": [ 205 ], "<0.05).": [ 212 ], "Body": [ 213 ], "weight": [ 214, 260 ], "9.9%": [ 218 ], "0.4%": [ 222 ], "placebo.": [ 224, 262 ], "Safety": [ 225 ], "consistent": [ 227 ], "known": [ 230 ], "profile": [ 231 ], "semaglutide.": [ 233 ], "Conclusions": [ 234 ], "In": [ 235 ], "suppressed": [ 244 ], "improved": [ 246 ], "eating,": [ 249 ], "cravings,": [ 253 ], "There": [ 263 ], "no": [ 265 ], "evidence": [ 266 ], "delayed": [ 268 ], "20,": [ 273 ], "indirectly": [ 275 ], "via": [ 276 ], "absorption.": [ 278 ] }, "publication_date": "2020-12-02", "publication_year": 2020, "type": "article", "cited_by_count": 315, "authors": [ { "id": "https://openalex.org/A5025369867", "display_name": "Martin Friedrichsen" }, { "id": "https://openalex.org/A5036974871", "display_name": "Astrid Breitschaft" }, { "id": "https://openalex.org/A5109382569", "display_name": "Sayeh Tadayon" }, { "id": "https://openalex.org/A5065915042", "display_name": "Alicja Wizert" }, { "id": "https://openalex.org/A5029901911", "display_name": "Dorthe Skovgaard" } ] }, { "id": "https://openalex.org/W72281339", "doi": null, "title": "Liraglutide: a review of the first once-daily GLP-1 receptor agonist.", "abstract": { "Liraglutide": [ 0, 51, 107 ], "is": [ 1, 99, 158 ], "an": [ 2, 197 ], "analog": [ 3 ], "with": [ 4, 39, 46, 68, 91, 101, 112, 154, 179, 243 ], "97%": [ 5 ], "homology": [ 6 ], "to": [ 7, 80, 116, 186 ], "human": [ 8 ], "glucagon-like": [ 9 ], "peptide": [ 10 ], "(GLP-1)": [ 11 ], "and": [ 12, 29, 36, 53, 82, 119, 123, 162, 168, 192, 213, 222, 231, 238, 261 ], "acts": [ 13 ], "as": [ 14 ], "a": [ 15, 102, 163 ], "GLP-1": [ 16, 133, 229, 248 ], "receptor": [ 17, 134 ], "agonist.": [ 18 ], "Several": [ 19, 128 ], "large,": [ 20 ], "randomized,": [ 21 ], "multicenter": [ 22 ], "phase": [ 23 ], "3": [ 24 ], "trials": [ 25 ], "evaluated": [ 26 ], "the": [ 27, 150, 206, 214 ], "efficacy": [ 28, 221 ], "safety": [ 30 ], "of": [ 31, 95, 105, 126, 205, 209, 217, 225, 254 ], "liraglutide": [ 32, 98, 157, 194 ], "by": [ 33 ], "comparing": [ 34 ], "monotherapy": [ 35 ], "combination": [ 37, 67 ], "therapy": [ 38 ], "other": [ 40, 69, 93 ], "antidiabetic": [ 41, 70, 96 ], "medications": [ 42 ], "in": [ 43, 55, 66, 85, 227, 266 ], "adult": [ 44 ], "patients": [ 45, 84, 178 ], "type": [ 47, 180 ], "2": [ 48, 181 ], "diabetes.": [ 49 ], "The": [ 50, 201, 245 ], "Effect": [ 52 ], "Action": [ 54 ], "Diabetes": [ 56 ], "(LEAD)": [ 57 ], "program": [ 58 ], "demonstrated": [ 59, 131 ], "that": [ 60, 132, 257 ], "liraglutide,": [ 61 ], "when": [ 62 ], "used": [ 63 ], "alone": [ 64 ], "or": [ 65 ], "medications,": [ 71 ], "effectively": [ 72 ], "controls": [ 73 ], "hyperglycemia": [ 74 ], "(glycosylated": [ 75 ], "hemoglobin": [ 76 ], "[A1C]": [ 77 ], "reductions": [ 78 ], "up": [ 79 ], "1.6%)": [ 81 ], "assists": [ 83 ], "meeting": [ 86 ], "established": [ 87 ], "glycemic": [ 88, 188 ], "targets.": [ 89 ], "Compared": [ 90 ], "certain": [ 92 ], "classes": [ 94 ], "agents,": [ 97 ], "associated": [ 100, 111 ], "lower": [ 103 ], "risk": [ 104, 224 ], "hypoglycemia.": [ 106 ], "has": [ 108 ], "also": [ 109 ], "been": [ 110 ], "weight": [ 113, 259 ], "loss": [ 114, 260 ], "(1.8": [ 115 ], "3.4": [ 117 ], "kg)": [ 118 ], "improved": [ 120 ], "patient": [ 121 ], "satisfaction": [ 122 ], "health-related": [ 124 ], "quality": [ 125 ], "life.": [ 127 ], "studies": [ 129 ], "have": [ 130, 184 ], "agonists": [ 135, 230, 249 ], "may": [ 136, 143, 195 ], "improve": [ 137 ], "pancreatic": [ 138 ], "beta": [ 139 ], "cell": [ 140 ], "function,": [ 141 ], "which": [ 142 ], "delay": [ 144 ], "disease": [ 145 ], "progression": [ 146 ], "if": [ 147 ], "maintained": [ 148 ], "over": [ 149, 236, 250 ], "long": [ 151 ], "term.": [ 152 ], "As": [ 153 ], "any": [ 155 ], "drug,": [ 156 ], "not": [ 159 ], "without": [ 160 ], "risk,": [ 161 ], "patient's": [ 164 ], "complete": [ 165 ], "clinical": [ 166 ], "status": [ 167 ], "benefit-to-risk": [ 169 ], "profile": [ 170 ], "should": [ 171 ], "be": [ 172, 196 ], "considered": [ 173 ], "before": [ 174 ], "prescribing": [ 175 ], "treatment.": [ 176 ], "For": [ 177 ], "diabetes": [ 182 ], "who": [ 183 ], "failed": [ 185 ], "achieve": [ 187 ], "control": [ 189 ], "through": [ 190 ], "diet": [ 191 ], "exercise,": [ 193 ], "important": [ 198 ], "treatment": [ 199, 242 ], "option.": [ 200 ], "current": [ 202 ], "consensus": [ 203 ], "statement": [ 204 ], "American": [ 207, 215 ], "Association": [ 208 ], "Clinical": [ 210 ], "Endocrinologists": [ 211 ], "(AACE)": [ 212 ], "College": [ 216 ], "Endocrinology": [ 218 ], "(ACE)": [ 219 ], "cites": [ 220 ], "low": [ 223 ], "hypoglycemia": [ 226 ], "preferring": [ 228 ], "dipeptidyl": [ 232 ], "peptidase-4": [ 233 ], "(DPP-4)": [ 234 ], "inhibitors": [ 235, 252 ], "sulfonylureas": [ 237 ], "glinides,": [ 239 ], "after": [ 240 ], "initial": [ 241 ], "metformin.": [ 244 ], "guidelines": [ 246 ], "prefer": [ 247 ], "DPP-4": [ 251 ], "because": [ 253 ], "their": [ 255, 262 ], "actions": [ 256 ], "promote": [ 258 ], "somewhat": [ 263 ], "greater": [ 264 ], "effectiveness": [ 265 ], "reducing": [ 267 ], "postprandial": [ 268 ], "glucose": [ 269 ], "excursions.": [ 270 ] }, "publication_date": "2011-03-01", "publication_year": 2011, "type": "review", "cited_by_count": 21, "authors": [ { "id": "https://openalex.org/A5005036709", "display_name": "Bruce W. Bode" } ] }, { "id": "https://openalex.org/W2277023506", "doi": "https://doi.org/10.4103/2230-8210.176351", "title": "Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future", "abstract": { "Glucagon-like": [ 0 ], "peptide-1": [ 1 ], "(GLP-1)-based": [ 2 ], "therapy": [ 3 ], "improves": [ 4 ], "glycaemic": [ 5 ], "control": [ 6 ], "through": [ 7 ], "multiple": [ 8 ], "mechanisms,": [ 9 ], "with": [ 10 ], "a": [ 11, 51, 106 ], "low": [ 12 ], "risk": [ 13 ], "of": [ 14, 20, 33, 48, 53, 69, 109, 121, 200 ], "hypoglycaemia": [ 15 ], "and": [ 16, 27, 103, 111, 128, 152, 162, 167, 174, 186 ], "the": [ 17, 31, 38, 46, 67, 71, 89, 93, 115, 138, 142, 193 ], "additional": [ 18 ], "benefit": [ 19 ], "clinically": [ 21 ], "relevant": [ 22 ], "weight": [ 23 ], "loss.": [ 24 ], "Since": [ 25 ], "Starling": [ 26 ], "Bayliss": [ 28 ], "first": [ 29 ], "proposed": [ 30 ], "existence": [ 32 ], "intestinal": [ 34 ], "secretions": [ 35 ], "that": [ 36, 158 ], "stimulate": [ 37 ], "pancreas,": [ 39 ], "tremendous": [ 40 ], "progress": [ 41 ], "has": [ 42 ], "been": [ 43 ], "made": [ 44 ], "in": [ 45, 114, 119 ], "area": [ 47 ], "incretins.": [ 49 ], "As": [ 50 ], "number": [ 52 ], "GLP-1": [ 54, 116, 169 ], "receptor": [ 55 ], "agonists": [ 56 ], "(GLP-1": [ 57 ], "RAs)": [ 58 ], "continue": [ 59 ], "to": [ 60, 75 ], "become": [ 61 ], "available,": [ 62 ], "physicians": [ 63 ], "will": [ 64 ], "soon": [ 65 ], "face": [ 66 ], "challenge": [ 68 ], "selecting": [ 70 ], "right": [ 72 ], "option": [ 73 ], "customized": [ 74 ], "their": [ 76, 122 ], "patient's": [ 77 ], "needs.": [ 78 ], "The": [ 79 ], "following": [ 80 ], "discussion,": [ 81 ], "derived": [ 82 ], "from": [ 83 ], "an": [ 84 ], "extensive": [ 85 ], "literature": [ 86, 133 ], "search": [ 87, 134 ], "using": [ 88, 137 ], "PubMed": [ 90, 139 ], "database,": [ 91, 140 ], "applying": [ 92, 141 ], "terms": [ 94, 120, 143 ], "incretin,": [ 95, 144 ], "GLP-1,": [ 96, 145 ], "exenatide,": [ 97, 146 ], "liraglutide,": [ 98, 147 ], "albiglutide,": [ 99, 148 ], "dulaglutide,": [ 100, 149 ], "lixisenatide,": [ 101, 150 ], "semaglutide,": [ 102, 151 ], "taspoglutide,": [ 104 ], "provides": [ 105 ], "comprehensive": [ 107 ], "review": [ 108 ], "existing": [ 110 ], "upcoming": [ 112 ], "molecules": [ 113 ], "RA": [ 117 ], "class": [ 118 ], "structure,": [ 123 ], "pharmacological": [ 124 ], "profiles,": [ 125 ], "efficacy,": [ 126 ], "safety,": [ 127, 189 ], "convenience.": [ 129 ], "Search": [ 130 ], "Methodology:": [ 131 ], "A": [ 132 ], "was": [ 135 ], "conducted": [ 136, 181 ], "taspoglutide.": [ 153 ], "Relevant": [ 154 ], "articles": [ 155 ], "were": [ 156, 180 ], "those": [ 157 ], "discussed": [ 159 ], "structural,": [ 160 ], "pharmacokinetic": [ 161 ], "pharmacodynamic": [ 163 ], "differences,": [ 164 ], "classification,": [ 165 ], "long-acting": [ 166 ], "short-acting": [ 168 ], "RAs,": [ 170 ], "phase": [ 171 ], "3": [ 172 ], "trials,": [ 173 ], "expert": [ 175 ], "opinions.": [ 176 ], "Additional": [ 177 ], "targeted": [ 178 ], "searches": [ 179 ], "on": [ 182, 188, 204 ], "diabetes": [ 183 ], "treatment": [ 184 ], "guidelines": [ 185 ], "reviews": [ 187 ], "as": [ 190, 192 ], "well": [ 191 ], "American": [ 194 ], "Diabetes": [ 195, 201 ], "Association/European": [ 196 ], "Society": [ 197 ], "for": [ 198 ], "Study": [ 199 ], "(ADA/EASD)": [ 202 ], "statement": [ 203 ], "pancreatic": [ 205 ], "safety.": [ 206 ] }, "publication_date": "2016-01-01", "publication_year": 2016, "type": "review", "cited_by_count": 69, "authors": [ { "id": "https://openalex.org/A5109398958", "display_name": "Omolara Adetunji" }, { "id": "https://openalex.org/A5112255433", "display_name": "Sanjay Kalra" }, { "id": "https://openalex.org/A5107862158", "display_name": "ManashP Baruah" }, { "id": "https://openalex.org/A5041017184", "display_name": "Rakesh Sahay" }, { "id": "https://openalex.org/A5111903836", "display_name": "AmbikaGopalakrishnan Unnikrishnan" }, { "id": "https://openalex.org/A5016321357", "display_name": "Shweta Uppal" } ] }, { "id": "https://openalex.org/W3118921917", "doi": "https://doi.org/10.1016/j.xkme.2020.10.008", "title": "Acute Kidney Injury Associated With Semaglutide", "abstract": null, "publication_date": "2021-01-10", "publication_year": 2021, "type": "article", "cited_by_count": 41, "authors": [ { "id": "https://openalex.org/A5016393319", "display_name": "David J. Leehey" }, { "id": "https://openalex.org/A5112456440", "display_name": "Mohamed A. Rahman" }, { "id": "https://openalex.org/A5037987993", "display_name": "Ewa Borys" }, { "id": "https://openalex.org/A5090125195", "display_name": "Maria M. Picken" }, { "id": "https://openalex.org/A5046303192", "display_name": "Christina E. Clise" } ] }, { "id": "https://openalex.org/W4389739323", "doi": "https://doi.org/10.1007/s00125-023-06053-9", "title": "Dose\u2013response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial", "abstract": null, "publication_date": "2023-12-14", "publication_year": 2023, "type": "article", "cited_by_count": 85, "authors": [ { "id": "https://openalex.org/A5073471236", "display_name": "Matthias Bl\u00fcher" }, { "id": "https://openalex.org/A5045489578", "display_name": "Julio Rosenstock" }, { "id": "https://openalex.org/A5016967386", "display_name": "Josef Hoefler" }, { "id": "https://openalex.org/A5002819063", "display_name": "Raymond C. Manuel" }, { "id": "https://openalex.org/A5036652363", "display_name": "Anita M. Hennige" } ] }, { "id": "https://openalex.org/W4280635291", "doi": "https://doi.org/10.1186/s12902-022-01036-0", "title": "Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials", "abstract": { "Abstract": [ 0 ], "Background": [ 1 ], "The": [ 2, 24, 84, 134 ], "cardiovascular": [ 3, 35, 78, 100, 105, 147, 218, 238 ], "effects": [ 4 ], "of": [ 5, 17, 26, 34, 37, 73, 87, 130, 144, 215, 232 ], "glucagon-like": [ 6 ], "peptide-1": [ 7 ], "(GLP-1)": [ 8 ], "receptor": [ 9, 46, 75, 139, 177, 208 ], "agonists": [ 10, 47, 76, 140, 178 ], "are": [ 11 ], "still": [ 12 ], "controversial": [ 13 ], "in": [ 14, 48, 80, 229, 235 ], "the": [ 15, 32, 71, 89, 99, 142, 172, 183, 191, 213, 227, 230 ], "treatment": [ 16, 231 ], "type": [ 18 ], "2": [ 19 ], "diabetes": [ 20 ], "mellitus": [ 21 ], "(T2DM)": [ 22 ], "patients.": [ 23, 50, 133 ], "purpose": [ 25 ], "this": [ 27 ], "study": [ 28 ], "was": [ 29 ], "to": [ 30, 57, 66 ], "evaluate": [ 31 ], "risk": [ 33, 143, 214 ], "events": [ 36, 79 ], "GLP-1": [ 38, 74, 94, 138, 176, 207 ], "(albiglutide,": [ 39 ], "exenatide,": [ 40 ], "liraglutide,": [ 41 ], "semaglutide,": [ 42 ], "lixisenatide": [ 43 ], "and": [ 44, 53, 98, 112, 157, 220 ], "dulaglutide)": [ 45 ], "T2DM": [ 49, 85, 132, 233 ], "Methods": [ 51 ], "PubMed": [ 52 ], "Embase": [ 54 ], "were": [ 55 ], "searched": [ 56 ], "find": [ 58 ], "relevant": [ 59 ], "randomized": [ 60, 123 ], "controlled": [ 61 ], "trials": [ 62, 91, 125, 236 ], "(RCTs)": [ 63 ], "from": [ 64, 104, 146, 217 ], "inception": [ 65 ], "June": [ 67 ], "2019": [ 68 ], "that": [ 69, 126, 137, 206 ], "evaluated": [ 70 ], "effect": [ 72 ], "on": [ 77 ], "patients": [ 81, 86, 234 ], "with": [ 82, 171, 190, 226, 237 ], "T2DM.": [ 83 ], "all": [ 88 ], "eligible": [ 90 ], "received": [ 92 ], "either": [ 93 ], "therapy": [ 95, 210 ], "or": [ 96, 108, 114, 159, 185, 222 ], "placebo,": [ 97 ], "outcomes": [ 101 ], "included": [ 102, 119, 127 ], "death": [ 103, 145, 216 ], "causes,": [ 106 ], "fatal": [ 107, 113, 158, 184, 221 ], "non-fatal": [ 109, 115, 160, 186, 223 ], "myocardial": [ 110, 187 ], "infarction": [ 111, 188 ], "stroke.": [ 116 ], "Results": [ 117 ], "We": [ 118, 204 ], "6": [ 120 ], "multinational": [ 121 ], "double-blind": [ 122 ], "placebo-control": [ 124 ], "a": [ 128 ], "total": [ 129 ], "52821": [ 131 ], "results": [ 135 ], "indicated": [ 136 ], "reduced": [ 141 ], "causes": [ 148, 219 ], "(RR:": [ 149, 162, 193 ], "0.90;": [ 150 ], "95%": [ 151, 164, 195 ], "CI:": [ 152, 165, 196 ], "0.83\u20130.97;": [ 153 ], "P": [ 154, 167, 200 ], "=": [ 155, 168, 201 ], "0.004)": [ 156 ], "stroke": [ 161, 224 ], "0.85;": [ 163 ], "0.77\u20130.94;": [ 166 ], "0.001)": [ 169 ], "compared": [ 170, 189, 225 ], "placebo": [ 173, 192, 228 ], "controls.": [ 174 ], "But": [ 175 ], "did": [ 179 ], "not": [ 180 ], "significantly": [ 181 ], "alter": [ 182 ], "0.91;": [ 194 ], "0.82": [ 197 ], "\u2013": [ 198 ], "1.01;": [ 199 ], "0.06).": [ 202 ], "Conclusion": [ 203 ], "concluded": [ 205 ], "agonist": [ 209 ], "could": [ 211 ], "reduce": [ 212 ], "outcomes.": [ 239 ] }, "publication_date": "2022-05-12", "publication_year": 2022, "type": "review", "cited_by_count": 28, "authors": [ { "id": "https://openalex.org/A5101675970", "display_name": "Jing Qin" }, { "id": "https://openalex.org/A5077369858", "display_name": "Li Song" } ] }, { "id": "https://openalex.org/W2514658869", "doi": "https://doi.org/10.2337/dc16-0691", "title": "Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial", "abstract": { "OBJECTIVE": [ 0 ], "To": [ 1 ], "investigate": [ 2 ], "whether": [ 3 ], "liraglutide": [ 4, 45, 76, 90, 98, 106, 120, 132, 140, 148, 162, 170, 179, 188, 203, 210, 218, 226, 239 ], "added": [ 5, 53, 253 ], "to": [ 6, 39, 54, 254 ], "treat-to-target": [ 7, 32 ], "insulin": [ 8, 14, 255, 261 ], "improves": [ 9 ], "glycemic": [ 10 ], "control": [ 11 ], "and": [ 12, 16, 72, 78, 122, 232, 263, 286 ], "reduces": [ 13 ], "requirements": [ 15 ], "body": [ 17, 155, 264 ], "weight": [ 18, 156, 265 ], "in": [ 19, 160, 201, 266, 294 ], "subjects": [ 20, 274 ], "with": [ 21, 82, 165, 234, 275, 288 ], "type": [ 22, 276 ], "1": [ 23, 277 ], "diabetes.": [ 24 ], "RESEARCH": [ 25 ], "DESIGN": [ 26 ], "AND": [ 27 ], "METHODS": [ 28 ], "A": [ 29 ], "52-week,": [ 30 ], "double-blind,": [ 31 ], "trial": [ 33 ], "involving": [ 34 ], "1,398": [ 35 ], "adults": [ 36 ], "randomized": [ 37 ], "3:1": [ 38 ], "receive": [ 40 ], "once-daily": [ 41 ], "subcutaneous": [ 42 ], "injections": [ 43 ], "of": [ 44, 68, 119, 197, 273, 283 ], "(1.8,": [ 46 ], "1.2,": [ 47 ], "or": [ 48, 51 ], "0.6": [ 49, 104, 146, 186, 224 ], "mg)": [ 50 ], "placebo": [ 52, 83, 126, 166 ], "insulin.": [ 55 ], "RESULTS": [ 56 ], "HbA1c": [ 57, 258 ], "level": [ 58 ], "was": [ 59, 157, 270 ], "reduced": [ 60, 115, 159, 257 ], "0.34\u20130.54%": [ 61 ], "(3.7\u20135.9": [ 62 ], "mmol/mol)": [ 63 ], "from": [ 64 ], "a": [ 65, 267 ], "mean": [ 66 ], "baseline": [ 67 ], "8.2%": [ 69 ], "(66": [ 70 ], "mmol/mol),": [ 71 ], "significantly": [ 73, 158, 237 ], "more": [ 74 ], "for": [ 75, 238 ], "1.8": [ 77, 88, 121, 130, 208, 240 ], "1.2": [ 79, 96, 123, 138, 177, 216 ], "mg": [ 80, 89, 97, 105, 124, 131, 139, 147, 169, 178, 187, 209, 217, 225, 241 ], "compared": [ 81, 164 ], "(estimated": [ 84, 127, 205 ], "treatment": [ 85, 128 ], "differences": [ 86 ], "[ETDs]:": [ 87 ], "\u22120.20%": [ 91 ], "[95%": [ 92, 100, 108, 134, 142, 150, 173, 182, 191, 212, 220, 228, 247 ], "CI": [ 93, 101, 109, 135, 143, 151, 174, 183, 192, 213, 221, 229, 248 ], "\u22120.32;": [ 94 ], "\u22120.07];": [ 95 ], "\u22120.15%": [ 99 ], "\u22120.27;": [ 102 ], "\u22120.03];": [ 103 ], "\u22120.09%": [ 107 ], "\u22120.21;": [ 110 ], "0.03]).": [ 111 ], "Insulin": [ 112 ], "doses": [ 113 ], "were": [ 114 ], "by": [ 116, 280 ], "the": [ 117 ], "addition": [ 118 ], "versus": [ 125 ], "ratios:": [ 129, 207 ], "0.92": [ 133 ], "0.88;": [ 136 ], "0.96];": [ 137 ], "0.95": [ 141 ], "0.91;": [ 144 ], "0.99];": [ 145 ], "1.00": [ 149 ], "0.96;": [ 152 ], "1.04]).": [ 153 ], "Mean": [ 154 ], "all": [ 161, 202 ], "groups": [ 163, 204 ], "ETDs": [ 167 ], "(1.8": [ 168 ], "\u22124.9": [ 171 ], "kg": [ 172, 181, 190 ], "\u22125.7;": [ 175 ], "\u22124.2];": [ 176 ], "\u22123.6": [ 180 ], "\u22124.3;": [ 184 ], "\u22122.8];": [ 185 ], "\u22122.2": [ 189 ], "\u22122.9;": [ 193 ], "\u22121.5]).": [ 194 ], "The": [ 195 ], "rate": [ 196, 206, 244 ], "symptomatic": [ 198, 284 ], "hypoglycemia": [ 199, 285 ], "increased": [ 200, 236, 281 ], "1.31": [ 211 ], "1.07;": [ 214 ], "1.59];": [ 215 ], "1.27": [ 219 ], "1.03;": [ 222 ], "1.55];": [ 223 ], "1.17": [ 227 ], "0.97;": [ 230 ], "1.43]),": [ 231 ], "hyperglycemia": [ 233, 287 ], "ketosis": [ 235 ], "only": [ 242 ], "(event": [ 243 ], "ratio": [ 245 ], "2.22": [ 246 ], "1.13;": [ 249 ], "4.34]).": [ 250 ], "CONCLUSIONS": [ 251 ], "Liraglutide": [ 252 ], "therapy": [ 256 ], "levels,": [ 259 ], "total": [ 260 ], "dose,": [ 262 ], "population": [ 268 ], "that": [ 269 ], "generally": [ 271 ], "representative": [ 272 ], "diabetes,": [ 278 ], "accompanied": [ 279 ], "rates": [ 282 ], "ketosis,": [ 289 ], "thereby": [ 290 ], "limiting": [ 291 ], "clinical": [ 292 ], "use": [ 293 ], "this": [ 295 ], "group.": [ 296 ] }, "publication_date": "2016-08-09", "publication_year": 2016, "type": "article", "cited_by_count": 287, "authors": [ { "id": "https://openalex.org/A5053469409", "display_name": "Chantal Mathieu" }, { "id": "https://openalex.org/A5090437675", "display_name": "Bernard Zinman" }, { "id": "https://openalex.org/A5086573291", "display_name": "Joanna Udd\u00e9n" }, { "id": "https://openalex.org/A5032297044", "display_name": "Vincent Woo" }, { "id": "https://openalex.org/A5046649014", "display_name": "Peter G. Colman" }, { "id": "https://openalex.org/A5036497949", "display_name": "Erik Christiansen" }, { "id": "https://openalex.org/A5113321224", "display_name": "Martin Linder" }, { "id": "https://openalex.org/A5005036709", "display_name": "Bruce W. Bode" } ] }, { "id": "https://openalex.org/W2060170946", "doi": "https://doi.org/10.1016/j.neuropharm.2013.08.005", "title": "Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease", "abstract": null, "publication_date": "2013-08-22", "publication_year": 2013, "type": "article", "cited_by_count": 319, "authors": [ { "id": "https://openalex.org/A5004424324", "display_name": "Paula L. McClean" }, { "id": "https://openalex.org/A5082707086", "display_name": "Christian H\u00f6lscher" } ] }, { "id": "https://openalex.org/W2288966387", "doi": "https://doi.org/10.1007/s00125-016-3896-5", "title": "GLP-1 receptor agonist promotes brown remodelling in mouse white adipose tissue through SIRT1", "abstract": null, "publication_date": "2016-02-28", "publication_year": 2016, "type": "article", "cited_by_count": 138, "authors": [ { "id": "https://openalex.org/A5001571073", "display_name": "Fen Xu" }, { "id": "https://openalex.org/A5100914386", "display_name": "Beisi Lin" }, { "id": "https://openalex.org/A5071498928", "display_name": "Xiaobin Zheng" }, { "id": "https://openalex.org/A5061044616", "display_name": "Zonglan Chen" }, { "id": "https://openalex.org/A5108726379", "display_name": "Huanyi Cao" }, { "id": "https://openalex.org/A5087013751", "display_name": "Haixia Xu" }, { "id": "https://openalex.org/A5023641721", "display_name": "Hua Liang" }, { "id": "https://openalex.org/A5012775407", "display_name": "Jianping Weng" } ] }, { "id": "https://openalex.org/W2964603908", "doi": "https://doi.org/10.1016/j.tem.2019.07.004", "title": "Heterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials", "abstract": null, "publication_date": "2019-08-07", "publication_year": 2019, "type": "review", "cited_by_count": 57, "authors": [ { "id": "https://openalex.org/A5103115613", "display_name": "Irene Caruso" }, { "id": "https://openalex.org/A5010465088", "display_name": "Angelo Cignarelli" }, { "id": "https://openalex.org/A5064872622", "display_name": "Francesco Giorgino" } ] }, { "id": "https://openalex.org/W2594728560", "doi": "https://doi.org/10.2337/dc16-0984", "title": "Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide", "abstract": { "OBJECTIVE": [ 0 ], "To": [ 1 ], "assess": [ 2 ], "the": [ 3, 114, 211, 242, 251 ], "risk": [ 4 ], "of": [ 5, 32, 97, 103, 117, 185, 205, 233 ], "acute": [ 6, 234 ], "pancreatitis": [ 7, 142, 186, 235 ], "during": [ 8, 250 ], "treatment": [ 9 ], "with": [ 10, 35, 194, 216, 226, 244, 246 ], "glucagon-like": [ 11 ], "peptide": [ 12 ], "1": [ 13 ], "receptor": [ 14 ], "agonist": [ 15 ], "dulaglutide,": [ 16 ], "placebo,": [ 17, 245 ], "and": [ 18, 75, 106, 207 ], "active": [ 19, 49 ], "comparators": [ 20 ], "across": [ 21 ], "phase": [ 22 ], "2/3": [ 23 ], "dulaglutide": [ 24, 72, 168 ], "trials.": [ 25 ], "RESEARCH": [ 26 ], "DESIGN": [ 27 ], "AND": [ 28 ], "METHODS": [ 29 ], "A": [ 30 ], "total": [ 31 ], "6,005": [ 33 ], "patients": [ 34, 69, 126, 149, 192, 238 ], "type": [ 36 ], "2": [ 37 ], "diabetes": [ 38 ], "participated": [ 39 ], "(dulaglutide": [ 40, 129, 150 ], "group": [ 41, 51, 63, 130, 135, 169, 174, 179 ], "N": [ 42, 59, 64 ], "=": [ 43, 60, 65, 132, 139, 152, 156, 160 ], "4,006": [ 44 ], "[dose": [ 45 ], "range": [ 46, 213 ], "0.1\u20133.0": [ 47 ], "mg];": [ 48 ], "comparator": [ 50, 134 ], "[metformin,": [ 52 ], "sitagliptin,": [ 53 ], "exenatide": [ 54, 195 ], "twice": [ 55, 196 ], "daily,": [ 56, 197 ], "insulin": [ 57 ], "glargine]": [ 58 ], "1,541;": [ 61 ], "placebo": [ 62, 137, 154, 173 ], "703;": [ 66 ], "245": [ 67 ], "placebo-treated": [ 68 ], "subsequently": [ 70 ], "received": [ 71 ], "or": [ 73, 99, 199 ], "sitagliptin": [ 74, 158, 178 ], "were": [ 76, 90, 165, 187, 214, 223 ], "also": [ 77 ], "included": [ 78 ], "in": [ 79, 110, 147, 191, 202, 236 ], "these": [ 80 ], "groups)": [ 81 ], "for": [ 82 ], "up": [ 83 ], "to": [ 84, 241 ], "104": [ 85 ], "weeks.": [ 86 ], "The": [ 87, 229 ], "following": [ 88 ], "events": [ 89, 95, 123, 184 ], "adjudicated:": [ 91 ], "investigator-reported": [ 92 ], "pancreatitis,": [ 93 ], "adverse": [ 94 ], "(AEs)": [ 96 ], "severe": [ 98 ], "serious": [ 100 ], "abdominal": [ 101 ], "pain": [ 102 ], "unknown": [ 104 ], "etiology,": [ 105 ], "confirmed": [ 107, 144, 188 ], "asymptomatic": [ 108 ], "increases": [ 109 ], "pancreatic": [ 111, 208 ], "enzymes": [ 112 ], "\u22653\u00d7": [ 113 ], "upper": [ 115 ], "limit": [ 116 ], "normal": [ 118, 212 ], "range.": [ 119 ], "RESULTS": [ 120 ], "Overall,": [ 121 ], "203": [ 122 ], "from": [ 124 ], "151": [ 125 ], "underwent": [ 127 ], "adjudication": [ 128, 146, 190 ], "n": [ 131, 138, 151, 155, 159 ], "108;": [ 133 ], "including": [ 136 ], "43).": [ 140 ], "Acute": [ 141 ], "was": [ 143, 239 ], "by": [ 145, 189 ], "seven": [ 148 ], "3,": [ 153 ], "1,": [ 157 ], "3).": [ 161 ], "Exposure-adjusted": [ 162 ], "incidence": [ 163, 231 ], "rates": [ 164, 243 ], "as": [ 166 ], "follows:": [ 167 ], "0.85": [ 170 ], "patients/1,000": [ 171, 176, 181 ], "patient-years,": [ 172, 177 ], "3.52": [ 175 ], "4.71": [ 180 ], "patient-years.": [ 182 ], "No": [ 183 ], "treated": [ 193 ], "metformin,": [ 198 ], "glargine.": [ 200, 220 ], "Increases": [ 201 ], "median": [ 203 ], "values": [ 204 ], "lipase": [ 206 ], "amylase": [ 209 ], "within": [ 210 ], "observed": [ 215 ], "all": [ 217 ], "treatments": [ 218 ], "except": [ 219 ], "These": [ 221 ], "changes": [ 222 ], "not": [ 224 ], "associated": [ 225 ], "AEs.": [ 227 ], "CONCLUSIONS": [ 228 ], "exposure-adjusted": [ 230 ], "rate": [ 232 ], "dulaglutide-treated": [ 237 ], "similar": [ 240 ], "few": [ 247 ], "reported": [ 248 ], "cases": [ 249 ], "entire": [ 252 ], "program.": [ 253 ] }, "publication_date": "2017-03-10", "publication_year": 2017, "type": "article", "cited_by_count": 30, "authors": [ { "id": "https://openalex.org/A5103130370", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5022343141", "display_name": "Jean\u2010Louis Frossard" }, { "id": "https://openalex.org/A5055447015", "display_name": "Jamie S. Barkin" }, { "id": "https://openalex.org/A5070070101", "display_name": "Greg Anglin" }, { "id": "https://openalex.org/A5031296616", "display_name": "Ingrid E. Hensley" }, { "id": "https://openalex.org/A5045969194", "display_name": "Kristine D. Harper" }, { "id": "https://openalex.org/A5024563374", "display_name": "Zvonko Mili\u010devi\u0107" } ] }, { "id": "https://openalex.org/W2137562839", "doi": "https://doi.org/10.2337/dc14-0001", "title": "Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro", "abstract": { "OBJECTIVE": [ 0 ], "GLP-1": [ 1 ], "receptor": [ 2 ], "agonists": [ 3 ], "may": [ 4 ], "provide": [ 5 ], "an": [ 6, 33 ], "alternative": [ 7 ], "to": [ 8, 35, 66, 76, 96, 158, 196, 203 ], "prandial": [ 9, 29, 83 ], "insulin": [ 10, 14, 30, 38, 47, 255 ], "for": [ 11, 209, 252 ], "advancing": [ 12, 253 ], "basal": [ 13, 46, 254 ], "therapy.": [ 15 ], "Harmony": [ 16 ], "6": [ 17 ], "was": [ 18, 94, 105, 115 ], "a": [ 19, 59, 245 ], "randomized,": [ 20 ], "open-label,": [ 21 ], "active-controlled": [ 22 ], "trial": [ 23 ], "testing": [ 24 ], "once-weekly": [ 25 ], "albiglutide": [ 26, 143, 175, 210, 243 ], "vs.": [ 27, 184, 217, 224, 228, 232, 239 ], "thrice-daily": [ 28, 82, 250 ], "lispro": [ 31, 84, 104, 179, 212, 251 ], "as": [ 32 ], "add-on": [ 34 ], "titrated": [ 36, 95 ], "once-daily": [ 37 ], "glargine.": [ 39 ], "RESEARCH": [ 40 ], "DESIGN": [ 41 ], "AND": [ 42 ], "METHODS": [ 43 ], "Patients": [ 44 ], "taking": [ 45 ], "(with": [ 48 ], "or": [ 49, 81 ], "without": [ 50 ], "oral": [ 51 ], "agents)": [ 52 ], "with": [ 53, 142, 150, 174, 178, 263 ], "HbA1c": [ 54, 120, 131, 261 ], "7\u201310.5%": [ 55 ], "(53\u201391": [ 56 ], "mmol/mol)": [ 57, 141, 149 ], "entered": [ 58 ], "glargine": [ 60, 191, 256 ], "standardization": [ 61 ], "period,": [ 62 ], "followed": [ 63 ], "by": [ 64, 135 ], "randomization": [ 65 ], "albiglutide,": [ 67 ], "30": [ 68 ], "mg": [ 69 ], "weekly": [ 70 ], "(n": [ 71, 85 ], "=": [ 72, 86 ], "282),": [ 73 ], "subsequently": [ 74 ], "uptitrated": [ 75 ], "50": [ 77 ], "mg,": [ 78 ], "if": [ 79 ], "necessary,": [ 80 ], "281)": [ 87 ], "while": [ 88 ], "continuing": [ 89 ], "metformin": [ 90 ], "and/or": [ 91 ], "pioglitazone.": [ 92 ], "Glargine": [ 93 ], "fasting": [ 97 ], "plasma": [ 98 ], "glucose": [ 99, 109 ], "of": [ 100 ], "&lt;5.6": [ 101 ], "mmol/L,": [ 102 ], "and": [ 103, 144, 200, 234, 266 ], "adjusted": [ 106 ], "based": [ 107 ], "on": [ 108 ], "monitoring.": [ 110 ], "The": [ 111, 189 ], "primary": [ 112 ], "end": [ 113, 168 ], "point": [ 114, 169 ], "the": [ 116, 119, 166 ], "difference": [ 117 ], "in": [ 118, 259 ], "change": [ 121 ], "from": [ 122, 133, 194, 201 ], "baseline": [ 123, 134 ], "at": [ 124 ], "week": [ 125, 129 ], "26.": [ 126 ], "RESULTS": [ 127 ], "At": [ 128 ], "26,": [ 130 ], "decreased": [ 132, 173 ], "\u22120.82": [ 136 ], "\u00b1": [ 137, 146, 181, 186 ], "SE": [ 138 ], "0.06%": [ 139, 147 ], "(9.0": [ 140 ], "\u22120.66": [ 145 ], "(7.2": [ 148 ], "lispro;": [ 151 ], "treatment": [ 152 ], "difference,": [ 153 ], "\u22120.16%": [ 154 ], "(95%": [ 155 ], "CI": [ 156 ], "\u22120.32": [ 157 ], "0.00;": [ 159 ], "1.8": [ 160 ], "mmol/mol;": [ 161 ], "P": [ 162 ], "&lt;": [ 163 ], "0.0001),": [ 164 ], "meeting": [ 165 ], "noninferiority": [ 167 ], "(margin,": [ 170 ], "0.4%).": [ 171 ], "Weight": [ 172 ], "but": [ 176 ], "increased": [ 177, 193 ], "(\u22120.73": [ 180 ], "0.19": [ 182, 187 ], "kg": [ 183 ], "+0.81": [ 185 ], "kg).": [ 188 ], "mean": [ 190 ], "dose": [ 192 ], "47": [ 195 ], "53": [ 197 ], "IU": [ 198, 205 ], "(albiglutide)": [ 199 ], "44": [ 202 ], "51": [ 204 ], "(lispro).": [ 206 ], "Adverse": [ 207 ], "events": [ 208 ], "versus": [ 211 ], "included": [ 213 ], "severe": [ 214 ], "hypoglycemia": [ 215, 222, 268 ], "(0": [ 216 ], "2": [ 218 ], "events),": [ 219 ], "documented": [ 220 ], "symptomatic": [ 221 ], "(15.8%": [ 223 ], "29.9%),": [ 225 ], "nausea": [ 226 ], "(11.2%": [ 227 ], "1.4%),": [ 229, 233 ], "vomiting": [ 230 ], "(6.7%": [ 231 ], "injection": [ 235 ], "site": [ 236 ], "reactions": [ 237 ], "(9.5%": [ 238 ], "5.3%).": [ 240 ], "CONCLUSIONS": [ 241 ], "Weekly": [ 242 ], "is": [ 244 ], "simpler": [ 246 ], "therapeutic": [ 247 ], "option": [ 248 ], "than": [ 249 ], "therapy,": [ 257 ], "resulting": [ 258 ], "comparable": [ 260 ], "reduction": [ 262 ], "weight": [ 264 ], "loss": [ 265 ], "lower": [ 267 ], "risk.": [ 269 ] }, "publication_date": "2014-06-05", "publication_year": 2014, "type": "article", "cited_by_count": 200, "authors": [ { "id": "https://openalex.org/A5045489578", "display_name": "Julio Rosenstock" }, { "id": "https://openalex.org/A5034671525", "display_name": "Vivian Fonseca" }, { "id": "https://openalex.org/A5102728954", "display_name": "Jorge Luiz Gross" }, { "id": "https://openalex.org/A5081205041", "display_name": "Robert E. Ratner" }, { "id": "https://openalex.org/A5027109387", "display_name": "Bo \u00c5hr\u00e9n" }, { "id": "https://openalex.org/A5110447350", "display_name": "Francis C. C. Chow" }, { "id": "https://openalex.org/A5110475866", "display_name": "Fred Yang" }, { "id": "https://openalex.org/A5080323311", "display_name": "Diane Miller" }, { "id": "https://openalex.org/A5102938468", "display_name": "Susan Johnson" }, { "id": "https://openalex.org/A5113581999", "display_name": "Murray Stewart" }, { "id": "https://openalex.org/A5080414941", "display_name": "Lawrence A. Leiter" } ] }, { "id": "https://openalex.org/W2913778098", "doi": "https://doi.org/10.3389/fendo.2019.00051", "title": "The GLP-1 Receptor Agonist Exenatide Ameliorates Bone Composition and Tissue Material Properties in High Fat Fed Diabetic Mice", "abstract": { "Type": [ 0 ], "2": [ 1 ], "diabetes": [ 2, 54, 87 ], "mellitus": [ 3 ], "(T2DM)": [ 4 ], "has": [ 5, 35 ], "recently": [ 6 ], "been": [ 7, 37 ], "recognized": [ 8 ], "as": [ 9, 124, 180, 182 ], "a": [ 10, 103 ], "significant": [ 11 ], "risk": [ 12 ], "factor": [ 13 ], "for": [ 14, 82, 108 ], "bone": [ 15, 20, 30, 67, 153, 168, 186, 198, 214, 239 ], "fragility.": [ 16 ], "Careful": [ 17 ], "investigations": [ 18 ], "of": [ 19, 29, 42, 50, 91, 105, 167, 191, 209, 234, 236, 245, 251 ], "mechanical": [ 21, 68, 127, 169, 199 ], "properties": [ 22, 69, 128, 170, 200 ], "in": [ 23, 197, 238, 248, 254 ], "human": [ 24 ], "studies": [ 25 ], "suggested": [ 26 ], "possible": [ 27 ], "alterations": [ 28, 166 ], "composition,": [ 31 ], "although": [ 32 ], "this": [ 33, 43 ], "axis": [ 34 ], "poorly": [ 36 ], "investigated.": [ 38 ], "The": [ 39 ], "main": [ 40 ], "aim": [ 41 ], "study": [ 44 ], "was": [ 45, 95, 129, 147, 155 ], "to": [ 46, 78, 85, 89, 194 ], "evaluate": [ 47 ], "the": [ 48, 58, 92, 132, 140, 173, 202, 232, 243, 249 ], "impact": [ 49 ], "high": [ 51, 79, 113 ], "fat": [ 52, 80, 114 ], "diet-induced": [ 53 ], "and": [ 55, 70, 112, 138, 152, 175, 184, 204, 213, 241 ], "therapy": [ 56 ], "using": [ 57 ], "clinically": [ 59 ], "approved": [ 60 ], "GLP-1": [ 61, 246 ], "receptor": [ 62 ], "agonist,": [ 63 ], "exenatide,": [ 64, 192 ], "on": [ 65, 231 ], "tissue": [ 66, 141, 176, 205 ], "compositional": [ 71, 215 ], "parameters.": [ 72 ], "Male": [ 73 ], "mice": [ 74, 118, 163 ], "had": [ 75 ], "free": [ 76 ], "access": [ 77 ], "diet": [ 81, 115 ], "16": [ 83 ], "weeks": [ 84 ], "induce": [ 86 ], "prior": [ 88 ], "commencement": [ 90 ], "study.": [ 93 ], "Exenatide": [ 94 ], "administered": [ 96 ], "twice": [ 97 ], "daily": [ 98 ], "by": [ 99, 135, 143, 149, 157, 207 ], "i.p.": [ 100 ], "injection": [ 101 ], "at": [ 102, 131, 139, 171, 201 ], "dose": [ 104 ], "25": [ 106 ], "nmol/kg": [ 107 ], "52": [ 109 ], "days.": [ 110 ], "Normal": [ 111 ], "fed": [ 116 ], "(HFD)": [ 117 ], "injected": [ 119 ], "with": [ 120 ], "saline": [ 121 ], "were": [ 122, 188 ], "used": [ 123 ], "controls.": [ 125 ], "Bone": [ 126, 145 ], "assessed": [ 130 ], "organ": [ 133, 174, 203 ], "level": [ 134, 142 ], "3-point": [ 136 ], "bending": [ 137 ], "nanoindentation.": [ 144 ], "microarchitecture": [ 146, 212 ], "investigated": [ 148 ], "microcomputed": [ 150 ], "tomography": [ 151 ], "composition": [ 154 ], "evaluated": [ 156 ], "Fourier": [ 158 ], "transform": [ 159 ], "infrared": [ 160 ], "imaging.": [ 161 ], "HFD": [ 162 ], "exhibited": [ 164 ], "profound": [ 165 ], "both": [ 172, 210 ], "level.": [ 177 ], "Collagen": [ 178 ], "maturity": [ 179 ], "well": [ 181 ], "trabecular": [ 183 ], "cortical": [ 185, 211 ], "microarchitectures": [ 187 ], "abnormal.": [ 189 ], "Administration": [ 190 ], "led": [ 193 ], "clear": [ 195 ], "ameliorations": [ 196 ], "levels": [ 206 ], "modifications": [ 208 ], "parameters": [ 216 ], "(collagen": [ 217 ], "maturity,": [ 218 ], "mineral": [ 219 ], "crystallinity,": [ 220 ], "carbonate/phosphate": [ 221 ], "ratio,": [ 222 ], "acid": [ 223 ], "phosphate": [ 224 ], "content).": [ 225 ], "These": [ 226 ], "results": [ 227 ], "bring": [ 228 ], "new": [ 229 ], "light": [ 230 ], "mode": [ 233 ], "action": [ 235 ], "exenatide": [ 237 ], "physiology": [ 240 ], "demonstrate": [ 242 ], "value": [ 244 ], "mimetics": [ 247 ], "treatment": [ 250 ], "fragility": [ 252 ], "fractures": [ 253 ], "diabetes.": [ 255 ] }, "publication_date": "2019-02-12", "publication_year": 2019, "type": "article", "cited_by_count": 33, "authors": [ { "id": "https://openalex.org/A5030540225", "display_name": "Sity Aishah Mansur" }, { "id": "https://openalex.org/A5043303299", "display_name": "A. Mieczkowska" }, { "id": "https://openalex.org/A5064124957", "display_name": "Peter R. Flatt" }, { "id": "https://openalex.org/A5015664452", "display_name": "Daniel Chappard" }, { "id": "https://openalex.org/A5001545372", "display_name": "Nigel Irwin" }, { "id": "https://openalex.org/A5049469702", "display_name": "Guillaume Mabilleau" } ] }, { "id": "https://openalex.org/W2103525547", "doi": "https://doi.org/10.2337/dc06-2593", "title": "Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes", "abstract": { "iraglutide": [ 0 ], "is": [ 1 ], "a": [ 2 ], "long-acting": [ 3 ], "human": [ 4 ], "glucagon-like": [ 5 ], "peptide-1": [ 6 ], "(GLP-1)": [ 7 ], "analog": [ 8 ], "(1-4),": [ 9 ], "and": [ 10, 19, 48, 51, 56, 100, 129, 146, 150 ], "the": [ 11, 78, 80, 90, 160, 164, 177 ], "current": [ 12 ], "study": [ 13, 84, 95 ], "was": [ 14, 63, 70, 74, 82, 85, 96, 157 ], "undertaken": [ 15 ], "to": [ 16 ], "evaluate": [ 17 ], "efficacy": [ 18, 114 ], "safety": [ 20 ], "after": [ 21 ], "14": [ 22 ], "weeks'": [ 23 ], "treatment": [ 24 ], "with": [ 25, 29, 44, 89 ], "liraglutide": [ 26, 106 ], "in": [ 27, 87, 159, 163, 176 ], "patients": [ 28, 40 ], "type": [ 30, 45 ], "2": [ 31, 46, 169 ], "diabetes.": [ 32 ], "RESEARCH": [ 33 ], "DESIGN": [ 34 ], "AND": [ 35 ], "METHODS": [ 36 ], "-Main": [ 37 ], "inclusion": [ 38 ], "criteriawere": [ 39 ], "aged": [ 41 ], "\u054618": [ 42 ], "years": [ 43 ], "diabetes": [ 47 ], "A1C": [ 49 ], "\u05467.5": [ 50 ], "\u054510.0%": [ 52 ], "(diet)": [ 53 ], "or": [ 54, 109, 155, 179 ], "\u05467.0": [ 55 ], "\u05459.5%": [ 57 ], "(mono-oral": [ 58 ], "antidiabetes": [ 59 ], "drug);": [ 60 ], "previous": [ 61 ], "therapy": [ 62 ], "discontinued.Fasting": [ 64 ], "plasma": [ 65, 126 ], "glucose": [ 66, 127 ], "(FPG)": [ 67 ], "at": [ 68 ], "randomization": [ 69 ], "7-13": [ 71 ], "mmol/l.If": [ 72 ], "FPG": [ 73 ], "\u03fe15": [ 75 ], "mmol/l": [ 76 ], "during": [ 77 ], "study,": [ 79 ], "patient": [ 81 ], "withdrawn.The": [ 83 ], "conducted": [ 86 ], "accordance": [ 88 ], "Declaration": [ 91 ], "of": [ 92, 105 ], "Helsinki": [ 93 ], "(5).The": [ 94 ], "double-blind,": [ 97 ], "randomized": [ 98 ], "(1:1:1:1),": [ 99 ], "placebo-controlled": [ 101 ], "using": [ 102 ], "three": [ 103 ], "doses": [ 104 ], "(0.65,": [ 107 ], "1.25,": [ 108 ], "1.90": [ 110 ], "mg).The": [ 111 ], "following": [ 112 ], "main": [ 113 ], "parameters": [ 115, 132, 152 ], "were": [ 116, 153 ], "assessed:": [ 117 ], "A1C,": [ 118 ], "insulin,": [ 119 ], "proinsulin,": [ 120 ], "glucagon,": [ 121 ], "fructosamine,": [ 122 ], "lipids,": [ 123 ], "homemeasured": [ 124 ], "seven-point": [ 125 ], "profiles,": [ 128 ], "body": [ 130 ], "weight.Safety": [ 131 ], "(adverse": [ 133 ], "events,": [ 134 ], "hypoglycemic": [ 135 ], "episodes,": [ 136 ], "clinical": [ 137 ], "laboratory": [ 138 ], "parameters,": [ 139 ], "antibodies": [ 140 ], "against": [ 141 ], "liraglutide,": [ 142 ], "vital": [ 143 ], "signs,": [ 144 ], "electrocardiogram,": [ 145 ], "thyroid": [ 147 ], "(including": [ 148 ], "ultrasonography)": [ 149 ], "parathyroid": [ 151 ], "assessed.Liraglutide": [ 154 ], "placebo": [ 156 ], "administered": [ 158 ], "evening": [ 161 ], "(as": [ 162 ], "most": [ 165 ], "recently": [ 166 ], "completed": [ 167 ], "phase": [ 168 ], "study)": [ 170 ], "(6)": [ 171 ], "as": [ 172 ], "once-daily": [ 173 ], "subcutaneous": [ 174 ], "injections": [ 175 ], "abdomen": [ 178 ], "thigh.": [ 180 ] }, "publication_date": "2007-05-25", "publication_year": 2007, "type": "article", "cited_by_count": 466, "authors": [ { "id": "https://openalex.org/A5004120950", "display_name": "Tina Vilsb\u00f8ll" }, { "id": "https://openalex.org/A5103492502", "display_name": "Milan Zdravkovic" }, { "id": "https://openalex.org/A5087556486", "display_name": "T Le-Thi" }, { "id": "https://openalex.org/A5018061859", "display_name": "Thure Krarup" }, { "id": "https://openalex.org/A5103589587", "display_name": "Ole Schmitz" }, { "id": "https://openalex.org/A5004454263", "display_name": "J.P. Courr\u00e8ges" }, { "id": "https://openalex.org/A5003532820", "display_name": "Rob H.A. Verhoeven" }, { "id": "https://openalex.org/A5052370565", "display_name": "Ingrid Bug\u00e1\u0148ov\u00e1" }, { "id": "https://openalex.org/A5062239390", "display_name": "Sten Madsbad" } ] }, { "id": "https://openalex.org/W4409963211", "doi": "https://doi.org/10.1056/nejmoa2413258", "title": "Phase 3 Trial of Semaglutide in Metabolic Dysfunction\u2013Associated Steatohepatitis", "abstract": { "In": [ 0 ], "patients": [ 1 ], "with": [ 2 ], "MASH": [ 3 ], "and": [ 4 ], "moderate": [ 5 ], "or": [ 6 ], "advanced": [ 7 ], "liver": [ 8, 19 ], "fibrosis,": [ 9 ], "once-weekly": [ 10 ], "semaglutide": [ 11 ], "at": [ 12 ], "a": [ 13 ], "dose": [ 14 ], "of": [ 15 ], "2.4": [ 16 ], "mg": [ 17 ], "improved": [ 18 ], "histologic": [ 20 ], "results.": [ 21 ], "(Funded": [ 22 ], "by": [ 23 ], "Novo": [ 24 ], "Nordisk;": [ 25 ], "ClinicalTrials.gov": [ 26 ], "number,": [ 27 ], "NCT04822181.).": [ 28 ] }, "publication_date": "2025-05-01", "publication_year": 2025, "type": "article", "cited_by_count": 250, "authors": [ { "id": "https://openalex.org/A5072398062", "display_name": "Danny Issa" }, { "id": "https://openalex.org/A5044832887", "display_name": "Philip N. Newsome" }, { "id": "https://openalex.org/A5088732240", "display_name": "Iris Kliers" }, { "id": "https://openalex.org/A5104323167", "display_name": "Laura \u00d8stergaard" }, { "id": "https://openalex.org/A5064848842", "display_name": "Michelle T. Long" }, { "id": "https://openalex.org/A5101498640", "display_name": "Mette Skalsh\u00f8i Kj\u00e6r" }, { "id": "https://openalex.org/A5117231459", "display_name": "Anna M.G. Cali" }, { "id": "https://openalex.org/A5039389628", "display_name": "Elisabetta Bugianesi" }, { "id": "https://openalex.org/A5109691034", "display_name": "Mary E. Rinella" }, { "id": "https://openalex.org/A5022032933", "display_name": "Michael Roden" }, { "id": "https://openalex.org/A5018682188", "display_name": "Vlad Ratziu" } ] }, { "id": "https://openalex.org/W1910083626", "doi": "https://doi.org/10.1016/j.diabres.2015.07.015", "title": "Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis", "abstract": null, "publication_date": "2015-08-13", "publication_year": 2015, "type": "review", "cited_by_count": 280, "authors": [ { "id": "https://openalex.org/A5005170922", "display_name": "Feng Sun" }, { "id": "https://openalex.org/A5103434941", "display_name": "Shanshan Wu" }, { "id": "https://openalex.org/A5102854981", "display_name": "Shuxia Guo" }, { "id": "https://openalex.org/A5013202820", "display_name": "Kai Yu" }, { "id": "https://openalex.org/A5018869790", "display_name": "Zhirong Yang" }, { "id": "https://openalex.org/A5082217568", "display_name": "Lishi Li" }, { "id": "https://openalex.org/A5100368706", "display_name": "Yuan Zhang" }, { "id": "https://openalex.org/A5057346352", "display_name": "Xiaochi Quan" }, { "id": "https://openalex.org/A5036949656", "display_name": "Linong Ji" }, { "id": "https://openalex.org/A5070369468", "display_name": "Siyan Zhan" } ] }, { "id": "https://openalex.org/W2007330805", "doi": "https://doi.org/10.1155/2012/230624", "title": "Impact of GLP-1 Receptor Agonists on Major Gastrointestinal Disorders for Type 2 Diabetes Mellitus: A Mixed Treatment Comparison Meta-Analysis", "abstract": { "Aim": [ 0 ], ".": [ 1, 36, 93, 179 ], "We": [ 2 ], "aimed": [ 3 ], "to": [ 4, 108, 137, 204 ], "integrate": [ 5 ], "evidence": [ 6 ], "from": [ 7 ], "all": [ 8, 88 ], "randomized": [ 9 ], "controlled": [ 10 ], "trials": [ 11 ], "(RCTs)": [ 12 ], "and": [ 13, 43, 58, 65, 76, 82, 105, 110, 120, 139, 172, 202 ], "assess": [ 14 ], "the": [ 15, 69, 100 ], "impact": [ 16 ], "of": [ 17, 20, 41, 62, 87, 102, 162, 170, 195 ], "different": [ 18, 39 ], "doses": [ 19, 40 ], "exenatide": [ 21, 42, 127, 171 ], "or": [ 22, 47 ], "liraglutide": [ 23, 44, 152, 173 ], "on": [ 24, 174 ], "major": [ 25 ], "gastrointestinal": [ 26 ], "adverse": [ 27 ], "events": [ 28 ], "(GIAEs)": [ 29 ], "in": [ 30, 192 ], "type": [ 31 ], "2": [ 32 ], "diabetes": [ 33 ], "(T2DM).": [ 34 ], "Methods": [ 35 ], "RCTs": [ 37, 67, 89 ], "evaluating": [ 38 ], "against": [ 45 ], "placebo": [ 46, 109 ], "an": [ 48 ], "active": [ 49 ], "comparator": [ 50 ], "with": [ 51, 126, 143 ], "treatment": [ 52, 84, 196, 206 ], "duration": [ 53 ], "\u22654": [ 54 ], "weeks": [ 55 ], "were": [ 56, 90 ], "searched": [ 57 ], "reviewed.": [ 59 ], "A": [ 60, 167 ], "total": [ 61 ], "35,": [ 63 ], "32": [ 64 ], "28": [ 66 ], "met": [ 68 ], "selection": [ 70 ], "criteria": [ 71 ], "evaluated": [ 72 ], "for": [ 73 ], "nausea,": [ 74, 103 ], "vomiting,": [ 75 ], "diarrhea,": [ 77 ], "respectively.": [ 78 ], "Pairwise": [ 79 ], "random-effects": [ 80 ], "meta-analyses": [ 81 ], "mixed": [ 83 ], "comparisons": [ 85 ], "(MTC)": [ 86 ], "performed.": [ 91 ], "Results": [ 92 ], "All": [ 94 ], "GLP-1": [ 95 ], "dose": [ 96 ], "groups": [ 97 ], "significantly": [ 98 ], "increased": [ 99 ], "probability": [ 101, 150 ], "vomiting": [ 104, 140 ], "diarrhea": [ 106, 163 ], "relative": [ 107 ], "conventional": [ 111 ], "treatment.": [ 112 ], "MTC": [ 113, 181 ], "meta-analysis": [ 114, 182 ], "showed": [ 115 ], "that": [ 116, 124, 151, 184 ], "there": [ 117 ], "was": [ 118, 134, 147, 176 ], "99.2%": [ 119 ], "85.0%": [ 121 ], "probability,": [ 122 ], "respectively,": [ 123 ], "people": [ 125 ], "10": [ 128 ], "\u03bc": [ 129 ], "g": [ 130 ], "twice": [ 131 ], "daily": [ 132, 156 ], "(EX10BID)": [ 133 ], "more": [ 135 ], "vulnerable": [ 136 ], "nausea": [ 138 ], "than": [ 141, 164 ], "those": [ 142 ], "other": [ 144, 165 ], "treatments.": [ 145 ], "There": [ 146 ], "a": [ 148, 159 ], "78.90%": [ 149 ], "1.2": [ 153 ], "mg": [ 154 ], "once": [ 155 ], "(LIR1.2)": [ 157 ], "has": [ 158 ], "higher": [ 160 ], "risk": [ 161 ], "groups.": [ 166 ], "dose-dependent": [ 168 ], "relationship": [ 169 ], "GIAEs": [ 175, 191 ], "observed.": [ 177 ], "Conclusions": [ 178 ], "Our": [ 180 ], "suggests": [ 183 ], "patients": [ 185 ], "should": [ 186 ], "be": [ 187 ], "warned": [ 188 ], "about": [ 189 ], "these": [ 190 ], "early": [ 193 ], "stage": [ 194 ], "by": [ 197, 200 ], "GLP-1s,": [ 198 ], "especially": [ 199 ], "EX10BID": [ 201 ], "LIR1.2,": [ 203 ], "promote": [ 205 ], "compliance.": [ 207 ] }, "publication_date": "2012-01-01", "publication_year": 2012, "type": "review", "cited_by_count": 53, "authors": [ { "id": "https://openalex.org/A5005170922", "display_name": "Feng Sun" }, { "id": "https://openalex.org/A5013202820", "display_name": "Kai Yu" }, { "id": "https://openalex.org/A5018869790", "display_name": "Zhirong Yang" }, { "id": "https://openalex.org/A5103434941", "display_name": "Shanshan Wu" }, { "id": "https://openalex.org/A5100368706", "display_name": "Yuan Zhang" }, { "id": "https://openalex.org/A5101279976", "display_name": "Luwen Shi" }, { "id": "https://openalex.org/A5036949656", "display_name": "Linong Ji" }, { "id": "https://openalex.org/A5070369468", "display_name": "Siyan Zhan" } ] }, { "id": "https://openalex.org/W2090360729", "doi": "https://doi.org/10.1007/s00125-010-2028-x", "title": "Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes", "abstract": null, "publication_date": "2011-01-20", "publication_year": 2011, "type": "article", "cited_by_count": 373, "authors": [ { "id": "https://openalex.org/A5048108194", "display_name": "Ryo Kodera" }, { "id": "https://openalex.org/A5080291594", "display_name": "Kenichi Shikata" }, { "id": "https://openalex.org/A5017327531", "display_name": "Hitomi Kataoka" }, { "id": "https://openalex.org/A5111982534", "display_name": "T. Takatsuka" }, { "id": "https://openalex.org/A5057153302", "display_name": "Satoshi Miyamoto" }, { "id": "https://openalex.org/A5047185170", "display_name": "Motofumi Sasaki" }, { "id": "https://openalex.org/A5090295718", "display_name": "Nobuo Kajitani" }, { "id": "https://openalex.org/A5110100123", "display_name": "Soichi Nishishita" }, { "id": "https://openalex.org/A5043060860", "display_name": "Kei Sarai" }, { "id": "https://openalex.org/A5045191798", "display_name": "Daisho Hirota" }, { "id": "https://openalex.org/A5033338291", "display_name": "Chikage Sato" }, { "id": "https://openalex.org/A5103268123", "display_name": "Daisuke Ogawa" }, { "id": "https://openalex.org/A5101668258", "display_name": "Hirofumi Makino" } ] }, { "id": "https://openalex.org/W2998275298", "doi": "https://doi.org/10.1111/dom.13955", "title": "Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk", "abstract": { "Abstract": [ 0 ], "Aim": [ 1 ], "To": [ 2 ], "investigate": [ 3 ], "the": [ 4, 33, 94, 112, 136, 196, 201 ], "effects": [ 5, 229 ], "of": [ 6, 44, 52, 118, 184, 205, 240 ], "semaglutide": [ 7, 119, 206, 226, 241 ], "versus": [ 8, 120, 207, 232 ], "comparators": [ 9, 208, 233 ], "on": [ 10, 122, 138, 186, 209, 230, 242 ], "major": [ 11 ], "adverse": [ 12 ], "cardiovascular": [ 13, 16 ], "events": [ 14 ], "(MACE:": [ 15 ], "[CV]": [ 17 ], "death,": [ 18 ], "nonfatal": [ 19, 24, 139 ], "myocardial": [ 20 ], "infarction": [ 21 ], "[MI]": [ 22 ], "and": [ 23, 26, 37, 60, 68, 76, 89, 96, 108, 220 ], "stroke)": [ 25 ], "hospitalization": [ 27, 150 ], "for": [ 28, 116, 149, 151, 161, 169, 182, 192, 203 ], "heart": [ 29 ], "failure": [ 30 ], "(HF)": [ 31 ], "in": [ 32, 73, 93, 165, 246 ], "SUSTAIN": [ 34, 58, 95, 106, 219 ], "(subcutaneous": [ 35 ], "semaglutide)": [ 36, 40 ], "PIONEER": [ 38, 61, 97, 109, 221 ], "(oral": [ 39 ], "trials": [ 41, 100 ], "across": [ 42, 234 ], "subgroups": [ 43 ], "varying": [ 45, 235 ], "CV": [ 46, 79, 236 ], "risk.": [ 47, 237 ], "Methods": [ 48 ], "Post": [ 49 ], "hoc": [ 50 ], "analyses": [ 51 ], "individual": [ 53 ], "patient\u2010level": [ 54 ], "data": [ 55 ], "combined": [ 56, 197 ], "from": [ 57 ], "6": [ 59, 62, 107, 110 ], "were": [ 63, 71, 101, 163, 189 ], "performed": [ 64 ], "to": [ 65 ], "assess": [ 66 ], "MACE": [ 67, 70, 92, 124, 162, 210, 231, 243 ], "HF.": [ 69, 91, 250 ], "analysed": [ 72 ], "subjects": [ 74, 247 ], "with": [ 75, 171, 248 ], "without:": [ 77 ], "established": [ 78 ], "disease": [ 80 ], "and/or": [ 81 ], "chronic": [ 82 ], "kidney": [ 83 ], "disease;": [ 84 ], "prior": [ 85, 90, 172, 249 ], "MI": [ 86 ], "or": [ 87 ], "stroke;": [ 88 ], "glycaemic": [ 98, 198 ], "efficacy": [ 99, 199 ], "also": [ 102 ], "assessed.": [ 103 ], "Results": [ 104 ], "In": [ 105, 195, 218 ], "combined,": [ 111, 222 ], "hazard": [ 113 ], "ratio": [ 114 ], "(HR)": [ 115 ], "effect": [ 117, 137, 188, 204, 239 ], "placebo": [ 121 ], "overall": [ 123 ], "was": [ 125, 132, 153, 211, 244 ], "0.76": [ 126 ], "(95%": [ 127, 155, 213 ], "CI": [ 128, 144, 156, 177, 214 ], "0.62,": [ 129 ], "0.92),": [ 130 ], "which": [ 131 ], "mainly": [ 133 ], "driven": [ 134 ], "by": [ 135 ], "stroke": [ 140 ], "(HR": [ 141, 174 ], "0.65": [ 142 ], "[95%": [ 143, 176 ], "0.43,": [ 145 ], "0.97]).": [ 146 ], "The": [ 147, 159 ], "HR": [ 148, 202 ], "HF": [ 152, 173, 193 ], "1.03": [ 154 ], "0.75,": [ 157 ], "1.40).": [ 158 ], "HRs": [ 160 ], "<1.0": [ 164 ], "all": [ 166 ], "subgroups,": [ 167 ], "except": [ 168, 191 ], "those": [ 170 ], "1.06": [ 175 ], "0.72,": [ 178 ], "1.57]);": [ 179 ], "P": [ 180 ], "\u2010values": [ 181 ], "interaction": [ 183 ], "subgroup": [ 185 ], "treatment": [ 187 ], ">0.05,": [ 190 ], "(0.046).": [ 194 ], "trials,": [ 200 ], "0.85": [ 212 ], "0.55,": [ 215 ], "1.33).": [ 216 ], "Conclusions": [ 217 ], "glucagon\u2010like": [ 223 ], "peptide\u20101": [ 224 ], "analogue": [ 225 ], "showed": [ 227 ], "consistent": [ 228 ], "No": [ 238 ], "observed": [ 245 ] }, "publication_date": "2020-01-06", "publication_year": 2020, "type": "article", "cited_by_count": 184, "authors": [ { "id": "https://openalex.org/A5044527590", "display_name": "Mansoor Husain" }, { "id": "https://openalex.org/A5080463002", "display_name": "Stephen C. Bain" }, { "id": "https://openalex.org/A5055974284", "display_name": "Ole Kleist Jeppesen" }, { "id": "https://openalex.org/A5001655356", "display_name": "Ildiko Lingvay" }, { "id": "https://openalex.org/A5016311849", "display_name": "Rasmus S\u00f8rrig" }, { "id": "https://openalex.org/A5048183455", "display_name": "Marianne Bach Treppendahl" }, { "id": "https://openalex.org/A5004120950", "display_name": "Tina Vilsb\u00f8ll" } ] }, { "id": "https://openalex.org/W1981183973", "doi": "https://doi.org/10.1016/j.clinthera.2008.08.006", "title": "Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug\u2014naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study", "abstract": null, "publication_date": "2008-08-01", "publication_year": 2008, "type": "article", "cited_by_count": 348, "authors": [ { "id": "https://openalex.org/A5068157430", "display_name": "T. Moretto" }, { "id": "https://openalex.org/A5001694053", "display_name": "Donald K. Milton" }, { "id": "https://openalex.org/A5109090811", "display_name": "Terry Ridge" }, { "id": "https://openalex.org/A5018272606", "display_name": "Leigh MacConell" }, { "id": "https://openalex.org/A5013022794", "display_name": "Ted Okerson" }, { "id": "https://openalex.org/A5063856648", "display_name": "Anne M. Wolka" }, { "id": "https://openalex.org/A5109961740", "display_name": "Robert G. Brodows" } ] }, { "id": "https://openalex.org/W4306681944", "doi": "https://doi.org/10.1111/dom.14863", "title": "Semaglutide for the treatment of overweight and obesity: A review", "abstract": { "Abstract": [ 0 ], "Obesity": [ 1 ], "is": [ 2, 39, 55 ], "a": [ 3, 12, 25 ], "chronic,": [ 4 ], "relapsing": [ 5 ], "disease": [ 6 ], "associated": [ 7, 83 ], "with": [ 8, 49, 68, 84, 92, 112, 118, 128, 138, 144, 155, 168, 174, 203, 241 ], "multiple": [ 9 ], "complications": [ 10 ], "and": [ 11, 16, 77, 120, 159, 192, 197 ], "substantial": [ 13 ], "morbidity,": [ 14 ], "mortality": [ 15 ], "health": [ 17 ], "care": [ 18 ], "burden.": [ 19 ], "Pharmacological": [ 20 ], "treatments": [ 21 ], "for": [ 22, 235, 239 ], "obesity": [ 23, 50, 95 ], "provide": [ 24 ], "valuable": [ 26 ], "adjunct": [ 27 ], "to": [ 28, 41, 102, 148, 178 ], "lifestyle": [ 29 ], "intervention,": [ 30 ], "which": [ 31 ], "often": [ 32 ], "achieves": [ 33 ], "only": [ 34 ], "limited": [ 35 ], "weight": [ 36, 86, 110, 124, 134, 164, 225 ], "loss": [ 37, 111, 125, 135, 165, 226 ], "that": [ 38 ], "difficult": [ 40 ], "maintain.": [ 42 ], "The": [ 43, 207, 222 ], "Semaglutide": [ 44 ], "Treatment": [ 45 ], "Effect": [ 46 ], "in": [ 47, 66, 90, 182, 228 ], "People": [ 48 ], "(STEP)": [ 51 ], "clinical": [ 52 ], "trial": [ 53 ], "programme": [ 54 ], "evaluating": [ 56 ], "once\u2010weekly": [ 57 ], "subcutaneous": [ 58 ], "semaglutide": [ 59, 79, 113, 139, 169, 204, 211 ], "2.4": [ 60, 80, 114, 140, 170, 205, 212 ], "mg": [ 61, 81, 115, 141, 171, 213 ], "(a": [ 62 ], "glucagon\u2010like": [ 63 ], "peptide\u20101": [ 64 ], "analogue)": [ 65 ], "people": [ 67 ], "overweight": [ 69, 93, 156 ], "or": [ 70, 94, 157 ], "obesity.": [ 71 ], "Across": [ 72 ], "STEP": [ 73, 131, 152, 230 ], "1,": [ 74 ], "3,": [ 75 ], "4": [ 76 ], "8,": [ 78 ], "was": [ 82, 136, 166, 214 ], "mean": [ 85, 133, 163 ], "losses": [ 87 ], "of": [ 88, 106, 199, 210, 224 ], "14.9%\u201017.4%": [ 89 ], "individuals": [ 91, 240 ], "without": [ 96 ], "type": [ 97, 160 ], "2": [ 98, 153, 161 ], "diabetes": [ 99 ], "from": [ 100, 146, 176 ], "baseline": [ 101, 147, 177 ], "week": [ 103, 149, 179 ], "68;": [ 104 ], "69%\u201079%": [ 105 ], "participants": [ 107 ], "achieved": [ 108, 122 ], "\u226510%": [ 109 ], "(vs.": [ 116, 126 ], "12%\u201027%": [ 117 ], "placebo)": [ 119 ], "51%\u201064%": [ 121 ], "\u226515%": [ 123 ], "5%\u201013%": [ 127 ], "placebo).": [ 129 ], "In": [ 130, 151 ], "5,": [ 132 ], "\u221215.2%": [ 137 ], "versus": [ 142, 172 ], "\u22122.6%": [ 143 ], "placebo": [ 145, 175 ], "104.": [ 150 ], "(individuals": [ 154 ], "obesity,": [ 158 ], "diabetes),": [ 162 ], "\u22129.6%": [ 167 ], "\u22123.4%": [ 173 ], "68.": [ 180 ], "Improvements": [ 181 ], "cardiometabolic": [ 183 ], "risk": [ 184 ], "factors,": [ 185 ], "including": [ 186 ], "high": [ 187 ], "blood": [ 188 ], "pressure,": [ 189 ], "atherogenic": [ 190 ], "lipids": [ 191 ], "benefits": [ 193 ], "on": [ 194 ], "physical": [ 195 ], "function": [ 196 ], "quality": [ 198 ], "life": [ 200 ], "were": [ 201 ], "seen": [ 202 ], "mg.": [ 206 ], "safety": [ 208 ], "profile": [ 209 ], "consistent": [ 215 ], "across": [ 216 ], "trials,": [ 217 ], "primarily": [ 218 ], "gastrointestinal": [ 219 ], "adverse": [ 220 ], "events.": [ 221 ], "magnitude": [ 223 ], "reported": [ 227 ], "the": [ 229, 233 ], "trials": [ 231 ], "offers": [ 232 ], "potential": [ 234 ], "clinically": [ 236 ], "relevant": [ 237 ], "improvement": [ 238 ], "obesity\u2010related": [ 242 ], "diseases.": [ 243 ] }, "publication_date": "2022-10-18", "publication_year": 2022, "type": "review", "cited_by_count": 180, "authors": [ { "id": "https://openalex.org/A5071807773", "display_name": "Natasha C. Bergmann" }, { "id": "https://openalex.org/A5084593004", "display_name": "Melanie J. Davies" }, { "id": "https://openalex.org/A5001655356", "display_name": "Ildiko Lingvay" }, { "id": "https://openalex.org/A5079352451", "display_name": "Filip K. Knop" } ] }, { "id": "https://openalex.org/W4385263964", "doi": "https://doi.org/10.1186/s13098-023-01118-6", "title": "The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials", "abstract": { "Abstract": [ 0, 287 ], "Aim": [ 1 ], "We": [ 2 ], "aimed": [ 3 ], "to": [ 4, 50, 82, 236, 256 ], "assess": [ 5 ], "the": [ 6, 9, 17, 45, 48, 172, 192, 205, 250, 257, 263, 270, 275 ], "association": [ 7 ], "between": [ 8, 259 ], "use": [ 10 ], "of": [ 11, 19, 47, 78, 92, 174, 194, 207, 240, 265, 272, 280 ], "Glucagon-like": [ 12 ], "peptide-1": [ 13 ], "receptor": [ 14, 196 ], "agonists": [ 15, 197 ], "and": [ 16, 39, 60, 157, 169, 180, 186, 218, 247, 262, 268, 277 ], "risk": [ 18, 91, 173, 206, 239, 264 ], "12": [ 20 ], "respiratory": [ 21, 93, 175, 200, 242, 266, 281 ], "diseases": [ 22, 176, 267 ], "in": [ 23, 274 ], "patients": [ 24, 84 ], "with": [ 25, 85, 103, 191 ], "type": [ 26 ], "2": [ 27 ], "diabetes,": [ 28 ], "obesity,": [ 29 ], "or": [ 30 ], "overweight.": [ 31 ], "Method": [ 32 ], "The": [ 33 ], "PubMed": [ 34 ], "(MEDLINE),": [ 35 ], "EMBASE,": [ 36 ], "Cochrane": [ 37 ], "Library,": [ 38 ], "ClinicalTrials.gov": [ 40 ], "databases": [ 41 ], "were": [ 42, 56, 70, 188, 234 ], "searched": [ 43 ], "from": [ 44, 64 ], "establishment": [ 46 ], "database": [ 49 ], "December": [ 51 ], "24,": [ 52 ], "2022.": [ 53 ], "Dichotomous": [ 54 ], "outcomes": [ 55 ], "analyzed": [ 57 ], "using": [ 58 ], "RR": [ 59 ], "95%": [ 61, 97, 107, 116, 125, 142, 151, 161, 212, 222 ], "CI": [ 62, 98, 108, 117, 126, 134, 143, 152, 162, 213, 223 ], "calculated": [ 63 ], "fixed-effects": [ 65 ], "models.": [ 66 ], "Results": [ 67 ], "Twenty-eight": [ 68 ], "RCTs": [ 69 ], "ultimately": [ 71 ], "included": [ 72 ], "for": [ 73 ], "analysis,": [ 74 ], "involving": [ 75 ], "a": [ 76, 88, 237 ], "total": [ 77 ], "77,485": [ 79 ], "participants.": [ 80 ], "Compared": [ 81 ], "controls,": [ 83 ], "GLP-1RAs": [ 86, 233, 273 ], "have": [ 87 ], "14%": [ 89, 179 ], "lower": [ 90, 238 ], "disease": [ 94 ], "(RR": [ 95, 105, 114, 123, 132, 140, 149, 159, 210, 220 ], "0.86,": [ 96, 221 ], "0.81\u20130.93": [ 99 ], "p": [ 100, 110, 119, 128, 136, 145, 154, 164, 215, 225 ], "<": [ 101 ], "0.0001),": [ 102 ], "Semaglutid": [ 104 ], "0.82,": [ 106, 124 ], "0.68\u20130.97,": [ 109 ], "=": [ 111, 120, 129, 137, 146, 155, 165, 216, 226 ], "0.02),": [ 112, 130 ], "Liraglutide": [ 113, 168 ], "0.86.": [ 115 ], "0.75\u20130.98,": [ 118 ], "0.03),": [ 121 ], "Dulaglutide": [ 122, 170 ], "0.70\u20130.96,": [ 127 ], "Albiglutide": [ 131 ], "0.93,95%": [ 133 ], "0.79\u20131.10,": [ 135 ], "0.40),": [ 138 ], "Exenatide": [ 139 ], "0.93,": [ 141 ], "0.74\u20131.18,": [ 144 ], "0.55),": [ 147 ], "Lixisenatide": [ 148 ], "0.83,": [ 150 ], "0.62\u20131.12,": [ 153 ], "0.22),": [ 156 ], "Efpeglenatide": [ 158 ], "0.76,": [ 160 ], "0.46\u20131.24,": [ 163 ], "0.27).": [ 166 ], "Semaglutide,": [ 167 ], "reduce": [ 171 ], "by": [ 177 ], "18%,": [ 178, 181 ], "respectively.Trial": [ 182 ], "duration,": [ 183 ], "control": [ 184 ], "type,": [ 185 ], "indication": [ 187 ], "not": [ 189 ], "associated": [ 190 ], "impact": [ 193 ], "GLP-1": [ 195, 260 ], "on": [ 198 ], "overall": [ 199, 241 ], "disease.": [ 201 ], "Among": [ 202 ], "secondary": [ 203, 278 ], "outcomes,": [ 204 ], "Pulmonary": [ 208, 245 ], "edema": [ 209, 246 ], "0.66,": [ 211 ], "0.44\u20130.98,": [ 214 ], "0.04),": [ 217 ], "Bronchitis": [ 219 ], "0.74\u20131.00,": [ 224 ], "0.04)": [ 227 ], "was": [ 228 ], "reduced.": [ 229 ], "Conclusion": [ 230 ], "In": [ 231, 249 ], "conclusion,": [ 232 ], "linked": [ 235 ], "diseases,": [ 243 ], "especially": [ 244 ], "Bronchitis.": [ 248 ], "future,": [ 251 ], "physicians": [ 252 ], "should": [ 253 ], "pay": [ 254 ], "attention": [ 255 ], "relationship": [ 258 ], "RA": [ 261 ], "evaluate": [ 269 ], "efficacy": [ 271 ], "primary": [ 276 ], "prevention": [ 279 ], "diseases.": [ 282 ], "Trial": [ 283 ], "registration": [ 284 ], "CRD42023396138.": [ 285 ], "Graphical": [ 286 ] }, "publication_date": "2023-07-26", "publication_year": 2023, "type": "article", "cited_by_count": 30, "authors": [ { "id": "https://openalex.org/A5113375613", "display_name": "Meixin Yu" }, { "id": "https://openalex.org/A5065798206", "display_name": "Ruxin Wang" }, { "id": "https://openalex.org/A5100943096", "display_name": "Ling Pei" }, { "id": "https://openalex.org/A5100782557", "display_name": "Xiaofang Zhang" }, { "id": "https://openalex.org/A5079887758", "display_name": "Jinjing Wei" }, { "id": "https://openalex.org/A5100991962", "display_name": "Yun Wen" }, { "id": "https://openalex.org/A5101083368", "display_name": "Han Liu" }, { "id": "https://openalex.org/A5079905135", "display_name": "Haowen Ye" }, { "id": "https://openalex.org/A5047441471", "display_name": "Jinghao Wang" }, { "id": "https://openalex.org/A5100443572", "display_name": "Lihong Wang" } ] }, { "id": "https://openalex.org/W2136579005", "doi": "https://doi.org/10.2337/db13-1169", "title": "Exendin-4, a GLP-1 Receptor Agonist, Attenuates Prostate Cancer Growth", "abstract": { "Recently,": [ 0 ], "pleiotropic": [ 1 ], "benefits": [ 2 ], "of": [ 3, 16, 20, 31, 38, 73, 85, 98, 113, 132, 173, 185, 203 ], "incretin": [ 4, 40 ], "therapy": [ 5 ], "beyond": [ 6 ], "glycemic": [ 7 ], "control": [ 8 ], "have": [ 9 ], "been": [ 10 ], "reported.": [ 11 ], "Although": [ 12, 137 ], "cancer": [ 13, 55, 88, 168, 198 ], "is": [ 14 ], "one": [ 15 ], "the": [ 17, 28, 36, 39, 83, 86, 110, 129, 182, 201 ], "main": [ 18 ], "causes": [ 19 ], "death": [ 21 ], "in": [ 22, 77, 115, 159, 165 ], "diabetic": [ 23 ], "patients,": [ 24 ], "few": [ 25 ], "reports": [ 26 ], "describe": [ 27 ], "anticancer": [ 29 ], "effects": [ 30 ], "incretin.": [ 32 ], "Here,": [ 33 ], "we": [ 34 ], "examined": [ 35 ], "effect": [ 37, 102, 131, 141 ], "drug": [ 41 ], "exendin": [ 42 ], "(Ex)-4,": [ 43 ], "a": [ 44, 71, 118 ], "GLP-1": [ 45 ], "receptor": [ 46, 145 ], "(GLP-1R)": [ 47 ], "agonist,": [ 48 ], "on": [ 49, 104, 134, 142 ], "prostate": [ 50, 54, 74, 87, 167, 197 ], "cancer.": [ 51, 75 ], "In": [ 52, 76, 107 ], "human": [ 53 ], "tissue": [ 56 ], "obtained": [ 57 ], "from": [ 58 ], "patients": [ 59 ], "after": [ 60 ], "they": [ 61 ], "had": [ 62, 139 ], "undergone": [ 63 ], "radical": [ 64 ], "prostatectomy,": [ 65 ], "GLP-1R": [ 66, 105, 114, 119, 122 ], "expression": [ 67, 112, 184 ], "colocalized": [ 68 ], "with": [ 69, 109, 124 ], "P504S,": [ 70, 186 ], "marker": [ 72 ], "vitro": [ 78 ], "experiments,": [ 79 ], "Ex-4": [ 80, 133, 138, 163, 195 ], "significantly": [ 81, 180 ], "decreased": [ 82, 150 ], "proliferation": [ 84 ], "cell": [ 89, 135 ], "lines": [ 90 ], "LNCap,": [ 91 ], "PC3,": [ 92 ], "and": [ 93, 179, 188 ], "DU145,": [ 94 ], "but": [ 95 ], "not": [ 96 ], "that": [ 97, 194 ], "ALVA-41.": [ 99 ], "This": [ 100 ], "antiproliferative": [ 101 ], "depended": [ 103 ], "expression.": [ 106 ], "accordance": [ 108 ], "abundant": [ 111 ], "LNCap": [ 116, 160, 174 ], "cells,": [ 117 ], "antagonist": [ 120 ], "or": [ 121, 147 ], "knockdown": [ 123 ], "small": [ 125 ], "interfering": [ 126 ], "RNA": [ 127 ], "abolished": [ 128 ], "inhibitory": [ 130 ], "proliferation.": [ 136 ], "no": [ 140 ], "either": [ 143 ], "androgen": [ 144 ], "activation": [ 146 ], "apoptosis,": [ 148 ], "it": [ 149 ], "extracellular": [ 151 ], "signal\u2013regulated": [ 152 ], "kinase": [ 153, 156 ], "(ERK)-mitogen-activated": [ 154 ], "protein": [ 155 ], "(MAPK)": [ 157 ], "phosphorylation": [ 158 ], "cells.": [ 161 ], "Importantly,": [ 162 ], "attenuated": [ 164 ], "vivo": [ 166 ], "growth": [ 169, 199 ], "induced": [ 170 ], "by": [ 171 ], "transplantation": [ 172 ], "cells": [ 175 ], "into": [ 176 ], "athymic": [ 177 ], "mice": [ 178 ], "reduced": [ 181 ], "tumor": [ 183 ], "Ki67,": [ 187 ], "phosphorylated": [ 189 ], "ERK-MAPK.": [ 190 ], "These": [ 191 ], "data": [ 192 ], "suggest": [ 193 ], "attenuates": [ 196 ], "through": [ 200 ], "inhibition": [ 202 ], "ERK-MAPK": [ 204 ], "activation.": [ 205 ] }, "publication_date": "2014-05-31", "publication_year": 2014, "type": "article", "cited_by_count": 127, "authors": [ { "id": "https://openalex.org/A5073875461", "display_name": "Takashi Nomiyama" }, { "id": "https://openalex.org/A5110408547", "display_name": "Takako Kawanami" }, { "id": "https://openalex.org/A5049868799", "display_name": "Shinichiro Irie" }, { "id": "https://openalex.org/A5112311013", "display_name": "Yuriko Hamaguchi" }, { "id": "https://openalex.org/A5037112854", "display_name": "Yuichi Terawaki" }, { "id": "https://openalex.org/A5025195368", "display_name": "Kunitaka Murase" }, { "id": "https://openalex.org/A5108284069", "display_name": "Yoko Tsutsumi" }, { "id": "https://openalex.org/A5036392763", "display_name": "Ryoko Nagaishi" }, { "id": "https://openalex.org/A5009221410", "display_name": "Makito Tanabe" }, { "id": "https://openalex.org/A5055206062", "display_name": "Hidetaka Morinaga" }, { "id": "https://openalex.org/A5019219010", "display_name": "Tomoko Tanaka" }, { "id": "https://openalex.org/A5110238233", "display_name": "Makio Mizoguchi" }, { "id": "https://openalex.org/A5021016213", "display_name": "Kazuki Nabeshima" }, { "id": "https://openalex.org/A5039425264", "display_name": "Masatoshi Tanaka" }, { "id": "https://openalex.org/A5020123456", "display_name": "Toshihiko Yanase" } ] }, { "id": "https://openalex.org/W3186079597", "doi": "https://doi.org/10.1021/acs.oprd.1c00021", "title": "Copper(II) Lysinate and Pseudoproline Assistance in the Convergent Synthesis of the GLP-1 Receptor Agonists Liraglutide and Semaglutide", "abstract": { "A": [ 0 ], "growing": [ 1 ], "interest": [ 2 ], "in": [ 3, 23, 60 ], "peptides": [ 4, 28, 82, 124 ], "as": [ 5 ], "active": [ 6 ], "pharmaceutical": [ 7 ], "ingredients": [ 8 ], "(APIs)": [ 9 ], "requires": [ 10 ], "the": [ 11, 24, 40, 54, 61, 71, 92, 114 ], "development": [ 12 ], "of": [ 13, 26, 44, 57, 66, 73, 94, 117 ], "efficient": [ 14 ], "strategies": [ 15 ], "for": [ 16, 33, 91, 113 ], "their": [ 17 ], "preparation.": [ 18 ], "This": [ 19 ], "is": [ 20 ], "particularly": [ 21, 111 ], "challenging": [ 22 ], "case": [ 25 ], "long": [ 27 ], "with": [ 29, 83, 125 ], "a": [ 30, 67, 100, 126 ], "strong": [ 31 ], "tendency": [ 32 ], "aggregation": [ 34, 77 ], "and": [ 35, 50, 78, 86, 108, 120, 122 ], "folding.": [ 36 ], "Here,": [ 37 ], "we": [ 38, 98 ], "describe": [ 39 ], "pseudoproline-assisted": [ 41 ], "convergent": [ 42 ], "synthesis": [ 43, 93 ], "GLP-1": [ 45 ], "receptor": [ 46 ], "agonist": [ 47 ], "lipopeptides": [ 48 ], "liraglutide": [ 49, 119 ], "semaglutide,": [ 51 ], "which": [ 52 ], "involves": [ 53, 104 ], "stepwise": [ 55 ], "condensation": [ 56 ], "three": [ 58 ], "fragments": [ 59 ], "solid": [ 62 ], "phase.": [ 63 ], "The": [ 64 ], "insertion": [ 65 ], "pseudoproline": [ 68 ], "residue": [ 69 ], "at": [ 70 ], "site": [ 72 ], "fragment": [ 74 ], "coupling": [ 75 ], "prevents": [ 76 ], "allows": [ 79 ], "obtaining": [ 80 ], "these": [ 81 ], "excellent": [ 84 ], "purity": [ 85 ], "high": [ 87 ], "yield.": [ 88 ], "In": [ 89 ], "addition,": [ 90 ], "lipidated": [ 95 ], "side": [ 96 ], "chains,": [ 97 ], "developed": [ 99 ], "novel": [ 101 ], "approach": [ 102 ], "that": [ 103 ], "copper(II)": [ 105 ], "lysinate": [ 106 ], "intermediates": [ 107 ], "can": [ 109 ], "be": [ 110 ], "suitable": [ 112 ], "industrial": [ 115 ], "preparation": [ 116 ], "both": [ 118 ], "semaglutide": [ 121 ], "other": [ 123 ], "similar": [ 127 ], "branched": [ 128 ], "structure.": [ 129 ] }, "publication_date": "2021-06-24", "publication_year": 2021, "type": "article", "cited_by_count": 14, "authors": [ { "id": "https://openalex.org/A5028983279", "display_name": "Ivan Guryanov" }, { "id": "https://openalex.org/A5006193615", "display_name": "Andrea Orlandin" }, { "id": "https://openalex.org/A5016633232", "display_name": "Ivan de Paola" }, { "id": "https://openalex.org/A5002231139", "display_name": "Angelo Viola" }, { "id": "https://openalex.org/A5047638923", "display_name": "Barbara Biondi" }, { "id": "https://openalex.org/A5041156464", "display_name": "Denis Badocco" }, { "id": "https://openalex.org/A5040500402", "display_name": "Fernando Formaggio" }, { "id": "https://openalex.org/A5020293697", "display_name": "Ant\u00f4nio Ricci" }, { "id": "https://openalex.org/A5045385809", "display_name": "Walter Cabri" } ] }, { "id": "https://openalex.org/W2788810904", "doi": "https://doi.org/10.1016/j.peptides.2017.12.009", "title": "Newer GLP-1 receptor agonists and obesity-diabetes", "abstract": null, "publication_date": "2018-02-01", "publication_year": 2018, "type": "review", "cited_by_count": 93, "authors": [ { "id": "https://openalex.org/A5067624521", "display_name": "Emily Brown" }, { "id": "https://openalex.org/A5076265710", "display_name": "Daniel J. Cuthbertson" }, { "id": "https://openalex.org/A5047195042", "display_name": "John Wilding" } ] }, { "id": "https://openalex.org/W4289277896", "doi": "https://doi.org/10.3949/ccjm.89a.21110", "title": "The role of GLP-1 receptor agonists in managing type 2 diabetes", "abstract": { "Glucagon-like": [ 0 ], "peptide-1": [ 1 ], "(GLP-1)": [ 2 ], "receptor": [ 3 ], "agonists": [ 4 ], "improve": [ 5 ], "glycemic": [ 6 ], "control": [ 7 ], "in": [ 8, 41 ], "patients": [ 9, 42 ], "with": [ 10, 43, 45 ], "type": [ 11 ], "2": [ 12 ], "diabetes": [ 13 ], "mellitus,": [ 14 ], "have": [ 15, 32 ], "cardioprotective": [ 16 ], "and": [ 17, 20, 46 ], "renoprotective": [ 18 ], "effects,": [ 19 ], "do": [ 21 ], "not": [ 22, 66 ], "cause": [ 23 ], "weight": [ 24, 39 ], "gain": [ 25 ], "or": [ 26 ], "significant": [ 27 ], "hypoglycemia.": [ 28 ], "In": [ 29 ], "fact,": [ 30 ], "they": [ 31 ], "been": [ 33 ], "found": [ 34 ], "to": [ 35, 55, 57, 68 ], "be": [ 36 ], "effective": [ 37 ], "for": [ 38 ], "loss": [ 40 ], "obesity": [ 44 ], "without": [ 47 ], "diabetes.": [ 48 ], "They": [ 49 ], "are": [ 50 ], "now": [ 51 ], "the": [ 52, 58, 70 ], "preferred": [ 53 ], "drugs": [ 54 ], "add": [ 56 ], "regimen": [ 59 ], "when": [ 60 ], "oral": [ 61 ], "metformin": [ 62 ], "by": [ 63 ], "itself": [ 64 ], "is": [ 65 ], "enough": [ 67 ], "meet": [ 69 ], "patient's": [ 71 ], "hemoglobin": [ 72 ], "A1c": [ 73 ], "goal.": [ 74 ] }, "publication_date": "2022-08-01", "publication_year": 2022, "type": "article", "cited_by_count": 37, "authors": [ { "id": "https://openalex.org/A5059303499", "display_name": "Noura Nachawi" }, { "id": "https://openalex.org/A5076079979", "display_name": "Pratibha PR Rao" }, { "id": "https://openalex.org/A5000942332", "display_name": "Vinni Makin" } ] }, { "id": "https://openalex.org/W2038335142", "doi": "https://doi.org/10.1111/j.1463-1326.2009.01073.x", "title": "The effects of glucagon\u2010like peptide\u20101 on the beta cell", "abstract": { "Type": [ 0 ], "2": [ 1, 29, 78, 127, 213 ], "diabetes": [ 2 ], "is": [ 3, 34, 39, 59 ], "a": [ 4 ], "progressive": [ 5 ], "disease": [ 6 ], "characterized": [ 7 ], "by": [ 8, 62, 131 ], "insulin": [ 9, 44, 139, 152 ], "resistance": [ 10 ], "and": [ 11, 92, 97, 136, 143, 150, 154, 170, 183 ], "impaired": [ 12 ], "beta\u2010cell": [ 13, 19, 121, 159, 175, 178, 181, 185 ], "function.": [ 14 ], "Treatments": [ 15 ], "that": [ 16, 38, 105, 167 ], "prevent": [ 17 ], "further": [ 18 ], "decline": [ 20 ], "are": [ 21, 99, 145, 155, 189 ], "therefore": [ 22 ], "essential": [ 23 ], "for": [ 24, 73, 208 ], "the": [ 25, 68, 74, 111, 209 ], "management": [ 26 ], "of": [ 27, 71, 76, 83, 101, 114, 198, 211 ], "type": [ 28, 77, 126, 212 ], "diabetes.": [ 30, 79, 214 ], "Glucagon\u2010like": [ 31 ], "peptide\u20101": [ 32 ], "(GLP\u20101)": [ 33 ], "an": [ 35 ], "incretin": [ 36 ], "hormone": [ 37 ], "known": [ 40 ], "to": [ 41, 49, 109, 147, 157, 161, 191 ], "stimulate": [ 42, 177 ], "glucose\u2010dependent": [ 43 ], "secretion.": [ 45 ], "Furthermore,": [ 46 ], "GLP\u20101": [ 47, 58, 72, 93, 102 ], "appears": [ 48 ], "have": [ 50, 86, 106, 118, 165, 204 ], "multiple": [ 51 ], "positive": [ 52 ], "effects": [ 53 ], "on": [ 54 ], "beta": [ 55 ], "cells.": [ 56 ], "However,": [ 57 ], "rapidly": [ 60 ], "degraded": [ 61 ], "dipeptidyl": [ 63 ], "peptidase\u20104": [ 64 ], "(DPP\u20104),": [ 65 ], "which": [ 66 ], "limits": [ 67 ], "clinical": [ 69, 206 ], "relevance": [ 70 ], "treatment": [ 75, 172, 210 ], "Two": [ 80 ], "main": [ 81 ], "classes": [ 82 ], "GLP\u20101\u2010based": [ 84 ], "therapies": [ 85 ], "now": [ 87 ], "been": [ 88, 107 ], "developed:": [ 89 ], "DPP\u20104": [ 90 ], "inhibitors": [ 91 ], "receptor": [ 94, 103 ], "agonists.": [ 95 ], "Liraglutide": [ 96 ], "exenatide": [ 98, 144, 171 ], "examples": [ 100 ], "agonists": [ 104 ], "developed": [ 108 ], "mimic": [ 110 ], "insulinotropic": [ 112 ], "characteristics": [ 113 ], "endogenous": [ 115 ], "GLP\u20101.": [ 116 ], "Both": [ 117 ], "demonstrated": [ 119 ], "improved": [ 120 ], "function": [ 122 ], "in": [ 123, 195, 201 ], "patients": [ 124 ], "with": [ 125 ], "diabetes,": [ 128 ], "as": [ 129 ], "assessed": [ 130 ], "homoeostasis": [ 132 ], "model": [ 133 ], "assessment\u2010B": [ 134 ], "analysis": [ 135 ], "proinsulin": [ 137 ], ":": [ 138 ], "ratio.": [ 140 ], "Additionally,": [ 141 ], "liraglutide": [ 142, 169 ], "able": [ 146, 156 ], "enhance": [ 148 ], "first\u2010": [ 149 ], "second\u2010phase": [ 151 ], "secretion": [ 153 ], "restore": [ 158 ], "sensitivity": [ 160 ], "glucose.": [ 162 ], "Preclinical": [ 163 ], "studies": [ 164, 188 ], "shown": [ 166 ], "both": [ 168 ], "can": [ 173 ], "increase": [ 174, 180 ], "mass,": [ 176 ], "proliferation,": [ 179 ], "neogenesis": [ 182 ], "inhibit": [ 184 ], "apoptosis.": [ 186 ], "Clinical": [ 187 ], "needed": [ 190 ], "confirm": [ 192 ], "these": [ 193, 199 ], "findings": [ 194 ], "humans.": [ 196 ], "Replication": [ 197 ], "data": [ 200 ], "humans": [ 202 ], "could": [ 203 ], "important": [ 205 ], "implications": [ 207 ] }, "publication_date": "2009-10-29", "publication_year": 2009, "type": "review", "cited_by_count": 117, "authors": [ { "id": "https://openalex.org/A5004120950", "display_name": "Tina Vilsb\u00f8ll" } ] }, { "id": "https://openalex.org/W2332387004", "doi": "https://doi.org/10.1017/neu.2014.36", "title": "GLP-1 receptor agonists have a sustained stimulatory effect on corticosterone release after chronic treatment", "abstract": { "Objective": [ 0 ], "Glucagon-like": [ 1 ], "peptide": [ 2 ], "1": [ 3 ], "(GLP-1)": [ 4 ], "receptor": [ 5, 30, 43, 168 ], "agonists": [ 6, 31, 44, 169 ], "are": [ 7 ], "a": [ 8, 94, 124, 197 ], "new": [ 9 ], "group": [ 10 ], "of": [ 11, 38, 81, 97, 102, 165, 187, 199, 228, 240 ], "antidiabetic": [ 12 ], "medications": [ 13 ], "quickly": [ 14 ], "gaining": [ 15 ], "popularity.": [ 16 ], "We": [ 17 ], "aimed": [ 18 ], "to": [ 19 ], "examine": [ 20 ], "behavioural": [ 21, 48 ], "and": [ 22, 71 ], "neuroendocrine": [ 23 ], "changes": [ 24 ], "following": [ 25 ], "chronic": [ 26, 39, 82, 139, 162 ], "treatment": [ 27, 40, 84, 103, 140, 221, 229 ], "with": [ 28, 41, 104, 141, 189 ], "GLP-1": [ 29, 42, 167, 241 ], "in": [ 32, 52, 60, 65, 75, 88, 123, 133, 136, 149, 158, 173, 176, 184, 212 ], "animal": [ 33 ], "models.": [ 34 ], "Methods": [ 35 ], "The": [ 36, 77, 210 ], "effects": [ 37 ], "were": [ 45 ], "determined": [ 46 ], "on": [ 47, 72, 146 ], "parameters": [ 49 ], "[anxiety": [ 50 ], "level": [ 51, 122 ], "the": [ 53, 57, 66, 120, 134, 156, 166, 185 ], "light\u2013dark": [ 54, 125 ], "compartment": [ 55, 126 ], "test,": [ 56 ], "motor": [ 58 ], "activity": [ 59, 62 ], "automated": [ 61 ], "cages,": [ 63 ], "immobility": [ 64 ], "forced": [ 67 ], "swimming": [ 68, 190 ], "test": [ 69, 127 ], "(FST)]": [ 70 ], "corticosterone": [ 73, 174, 200, 213 ], "release": [ 74, 201, 214 ], "mice.": [ 76, 137 ], "possible": [ 78 ], "antidepressant": [ 79 ], "effect": [ 80, 132, 145, 239 ], "liraglutide": [ 83, 112, 142, 220 ], "was": [ 85, 194 ], "also": [ 86 ], "studied": [ 87 ], "Flinders": [ 89 ], "Sensitive": [ 90 ], "Line": [ 91 ], "(FSL)": [ 92 ], "rats,": [ 93 ], "genetic": [ 95 ], "model": [ 96 ], "depression.": [ 98 ], "Results": [ 99 ], "Two": [ 100 ], "weeks": [ 101, 204, 227 ], "exenatide": [ 105, 193, 218 ], "(10": [ 106 ], "\u00b5g": [ 107 ], "/kg": [ 108 ], "twice": [ 109 ], "daily)": [ 110, 116 ], "or": [ 111, 219 ], "(1200": [ 113 ], "\u00b5g/kg": [ 114 ], "once": [ 115 ], "did": [ 117 ], "not": [ 118, 223, 234 ], "affect": [ 119 ], "anxiety": [ 121 ], "nor": [ 128 ], "induce": [ 129 ], "an": [ 130 ], "antidepressant-like": [ 131 ], "FST": [ 135 ], "Moreover,": [ 138 ], "had": [ 143 ], "no": [ 144 ], "depression-related": [ 147 ], "behaviour": [ 148 ], "FSL": [ 150 ], "rats.": [ 151 ], "Interestingly,": [ 152 ], "hypolocomotion": [ 153 ], "induced": [ 154, 170 ], "by": [ 155 ], "drugs": [ 157 ], "mice": [ 159, 177 ], "disappeared": [ 160 ], "after": [ 161, 202, 206, 216, 225 ], "dosing.": [ 163 ], "Both": [ 164 ], "robust": [ 171 ], "increases": [ 172, 211 ], "levels": [ 175 ], "under": [ 178 ], "basal": [ 179 ], "conditions": [ 180 ], "as": [ 181, 183, 195, 205 ], "well": [ 182 ], "case": [ 186 ], "combination": [ 188 ], "stress.": [ 191 ], "Remarkably,": [ 192 ], "potent": [ 196 ], "stimulator": [ 198 ], "2": [ 203, 226 ], "acute": [ 207, 217 ], "administration.": [ 208 ], "Conclusions": [ 209 ], "seen": [ 215 ], "do": [ 222 ], "abate": [ 224 ], "demonstrating": [ 230 ], "that": [ 231 ], "tolerance": [ 232 ], "does": [ 233 ], "develop": [ 235 ], "towards": [ 236 ], "this": [ 237 ], "particular": [ 238 ], "agonists.": [ 242 ] }, "publication_date": "2014-12-03", "publication_year": 2014, "type": "article", "cited_by_count": 26, "authors": [ { "id": "https://openalex.org/A5028669651", "display_name": "Maarja Krass" }, { "id": "https://openalex.org/A5072840966", "display_name": "Annika Volke" }, { "id": "https://openalex.org/A5089242399", "display_name": "Kertu R\u00fcnkorg" }, { "id": "https://openalex.org/A5012173155", "display_name": "Gregers Wegener" }, { "id": "https://openalex.org/A5026488520", "display_name": "Sten Lund" }, { "id": "https://openalex.org/A5090018331", "display_name": "Anders Abildgaard" }, { "id": "https://openalex.org/A5048622515", "display_name": "Eero Vasar" }, { "id": "https://openalex.org/A5033444495", "display_name": "Vallo Volke" } ] }, { "id": "https://openalex.org/W2046686669", "doi": "https://doi.org/10.1517/14740338.2012.675326", "title": "Anti-obesity drugs: a review about their effects and their safety", "abstract": { "Orlistat": [ 0 ], "is": [ 1, 27 ], "a": [ 2 ], "good": [ 3 ], "choice": [ 4 ], "for": [ 5, 104 ], "the": [ 6, 56 ], "treatment": [ 7 ], "of": [ 8, 11 ], "obesity,": [ 9 ], "because": [ 10 ], "its": [ 12, 18 ], "safety": [ 13 ], "on": [ 14, 21, 119 ], "cardiovascular": [ 15 ], "events": [ 16 ], "and": [ 17, 63, 94, 112, 126 ], "positive": [ 19 ], "effects": [ 20 ], "diabetic": [ 22, 44 ], "control,": [ 23, 69 ], "even": [ 24 ], "if": [ 25 ], "it": [ 26 ], "not": [ 28 ], "as": [ 29, 31, 86 ], "effective": [ 30 ], "rimonabant": [ 32 ], "or": [ 33 ], "sibutramine": [ 34 ], "in": [ 35, 43, 83, 109 ], "reducing": [ 36, 74 ], "body": [ 37, 75 ], "weight.": [ 38, 76 ], "Regarding": [ 39 ], "emerging": [ 40 ], "anti-obesity": [ 41 ], "therapies": [ 42 ], "people,": [ 45 ], "we": [ 46 ], "currently": [ 47, 82 ], "have": [ 48, 51 ], "drugs": [ 49, 80 ], "that": [ 50 ], "already": [ 52 ], "been": [ 53 ], "marketed": [ 54 ], "including": [ 55 ], "glucagon-like": [ 57 ], "peptide-1": [ 58 ], "(GLP-1)": [ 59 ], "receptor": [ 60 ], "agonists": [ 61 ], "exenatide": [ 62 ], "liraglutide;": [ 64 ], "other": [ 65, 79 ], "than": [ 66 ], "improving": [ 67 ], "glycemic": [ 68 ], "they": [ 70 ], "also": [ 71 ], "suppress": [ 72 ], "appetite": [ 73 ], "Moreover,": [ 77 ], "some": [ 78 ], "are": [ 81, 106 ], "study": [ 84 ], "such": [ 85 ], "tesofensine,": [ 87 ], "phentermine": [ 88 ], "+": [ 89, 92, 96 ], "topiramate,": [ 90 ], "bupropion": [ 91, 95 ], "naltrexone": [ 93 ], "zonisamide.": [ 97 ], "Furthermore,": [ 98 ], "several": [ 99 ], "additional": [ 100 ], "gut": [ 101 ], "hormone-based": [ 102 ], "treatments": [ 103 ], "obesity": [ 105 ], "under": [ 107 ], "investigation": [ 108 ], "Phase": [ 110 ], "II": [ 111 ], "III": [ 113 ], "clinical": [ 114 ], "trials,": [ 115 ], "with": [ 116 ], "particular": [ 117 ], "focus": [ 118 ], "ghrelin,": [ 120 ], "peptide": [ 121 ], "YY,": [ 122 ], "pancreatic": [ 123 ], "polypeptide,": [ 124 ], "amylin": [ 125 ], "oxyntomodulin.": [ 127 ] }, "publication_date": "2012-03-23", "publication_year": 2012, "type": "review", "cited_by_count": 182, "authors": [ { "id": "https://openalex.org/A5021841408", "display_name": "Giuseppe Derosa" }, { "id": "https://openalex.org/A5011551760", "display_name": "Pamela Maffioli" } ] }, { "id": "https://openalex.org/W1999843320", "doi": "https://doi.org/10.1038/ajh.2009.245", "title": "Effects of Exenatide on Systolic Blood Pressure in Subjects With Type 2 Diabetes", "abstract": { "These": [ 0 ], "results": [ 1 ], "support": [ 2 ], "the": [ 3 ], "need": [ 4 ], "for": [ 5 ], "a": [ 6 ], "prospective,": [ 7 ], "randomized,": [ 8 ], "controlled": [ 9 ], "study": [ 10 ], "of": [ 11 ], "BP": [ 12 ], "changes": [ 13 ], "during": [ 14 ], "exenatide": [ 15 ], "treatment": [ 16 ], "in": [ 17 ], "patients": [ 18 ], "with": [ 19 ], "hypertension": [ 20 ], "and": [ 21 ], "type": [ 22 ], "2": [ 23 ], "diabetes.": [ 24 ] }, "publication_date": "2009-12-17", "publication_year": 2009, "type": "article", "cited_by_count": 187, "authors": [ { "id": "https://openalex.org/A5013022794", "display_name": "Ted Okerson" }, { "id": "https://openalex.org/A5054580767", "display_name": "Peijing Yan" }, { "id": "https://openalex.org/A5049307365", "display_name": "Anthony H. Stonehouse" }, { "id": "https://openalex.org/A5109961740", "display_name": "Robert G. Brodows" } ] }, { "id": "https://openalex.org/W2054981500", "doi": "https://doi.org/10.1016/s0140-6736(14)60976-4", "title": "Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial", "abstract": null, "publication_date": "2014-07-10", "publication_year": 2014, "type": "article", "cited_by_count": 472, "authors": [ { "id": "https://openalex.org/A5007315645", "display_name": "Kathleen Dungan" }, { "id": "https://openalex.org/A5037602130", "display_name": "Santiago Tof\u00e9" }, { "id": "https://openalex.org/A5044778195", "display_name": "Thomas F\u00f6rst" }, { "id": "https://openalex.org/A5031965655", "display_name": "Jos\u00e9 Gerardo Gonz\u00e1lez\u2010Gonz\u00e1lez" }, { "id": "https://openalex.org/A5057242778", "display_name": "Charles Atisso" }, { "id": "https://openalex.org/A5044182566", "display_name": "Whitney Sealls" }, { "id": "https://openalex.org/A5020495499", "display_name": "Jessie L. Fahrbach" } ] }, { "id": "https://openalex.org/W2465813776", "doi": "https://doi.org/10.1371/journal.pone.0158205", "title": "Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on \u03b2-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer\u2019s Disease", "abstract": { "One": [ 0 ], "of": [ 1, 6, 13, 35, 53, 57, 60, 68, 83, 93, 107, 124, 128, 222, 244 ], "the": [ 2, 33, 81, 116, 168, 197 ], "major": [ 3 ], "histopathological": [ 4 ], "hallmarks": [ 5, 243 ], "Alzheimer's": [ 7, 108 ], "disease": [ 8, 109 ], "(AD)": [ 9 ], "is": [ 10 ], "cerebral": [ 11, 179, 214 ], "deposits": [ 12 ], "extracellular": [ 14 ], "\u03b2-amyloid": [ 15 ], "peptides.": [ 16 ], "Preclinical": [ 17 ], "studies": [ 18 ], "have": [ 19, 44 ], "pointed": [ 20 ], "to": [ 21, 47, 79, 187, 231 ], "glucagon-like": [ 22 ], "peptide": [ 23 ], "1": [ 24 ], "(GLP-1)": [ 25 ], "receptors": [ 26 ], "as": [ 27 ], "a": [ 28, 55 ], "potential": [ 29, 84 ], "novel": [ 30 ], "target": [ 31 ], "in": [ 32, 54, 100, 135, 200, 217, 235 ], "treatment": [ 34, 96, 192, 209, 234 ], "AD.": [ 36, 61, 245 ], "GLP-1": [ 37 ], "receptor": [ 38 ], "agonists,": [ 39 ], "including": [ 40 ], "exendin-4": [ 41 ], "and": [ 42, 50, 73, 86, 119, 202, 224 ], "liraglutide,": [ 43 ], "been": [ 45 ], "shown": [ 46 ], "promote": [ 48 ], "plaque-lowering": [ 49 ], "mnemonic": [ 51 ], "effects": [ 52, 92 ], "number": [ 56 ], "experimental": [ 58 ], "models": [ 59, 64, 106, 221, 239 ], "Transgenic": [ 62 ], "mouse": [ 63, 105, 220, 238 ], "carrying": [ 65, 110 ], "genetic": [ 66 ], "mutations": [ 67 ], "amyloid": [ 69 ], "protein": [ 70 ], "precursor": [ 71 ], "(APP)": [ 72 ], "presenilin-1": [ 74 ], "(PS1)": [ 75 ], "are": [ 76 ], "commonly": [ 77 ], "used": [ 78 ], "assess": [ 80 ], "pharmacodynamics": [ 82 ], "amyloidosis-lowering": [ 85 ], "pro-cognitive": [ 87 ], "compounds.": [ 88 ], "In": [ 89, 159, 205 ], "this": [ 90 ], "study,": [ 91 ], "long-term": [ 94, 207, 232 ], "liraglutide": [ 95, 191, 208, 233 ], "were": [ 97 ], "therefore": [ 98 ], "determined": [ 99 ], "two": [ 101, 218 ], "double": [ 102 ], "APP/PS1": [ 103, 113 ], "transgenic": [ 104, 189, 219, 237 ], "different": [ 111 ], "clinical": [ 112 ], "mutations,": [ 114 ], "i.e.": [ 115 ], "'London'": [ 117 ], "(hAPPLon/PS1A246E)": [ 118 ], "'Swedish'": [ 120 ], "mutation": [ 121 ], "variant": [ 122 ], "(hAPPSwe/PS1\u0394E9)": [ 123 ], "APP,": [ 125 ], "with": [ 126 ], "co-expression": [ 127 ], "distinct": [ 129, 241 ], "PS1": [ 130 ], "variants.": [ 131 ], "Liraglutide": [ 132 ], "was": [ 133, 165 ], "administered": [ 134 ], "5": [ 136, 154 ], "month-old": [ 137, 150 ], "hAPPLon/PS1A246E": [ 138, 183, 201 ], "mice": [ 139, 152, 175 ], "for": [ 140, 153 ], "3": [ 141 ], "months": [ 142, 155 ], "(100": [ 143 ], "or": [ 144, 148 ], "500": [ 145 ], "ng/kg/day,": [ 146, 157 ], "s.c.),": [ 147 ], "7": [ 149 ], "hAPPSwe/PS1\u0394E9": [ 151, 174, 203 ], "(500": [ 156 ], "s.c.).": [ 158 ], "both": [ 160 ], "models,": [ 161 ], "regional": [ 162 ], "plaque": [ 163, 180, 198, 215 ], "load": [ 164, 181, 216 ], "quantified": [ 166 ], "throughout": [ 167 ], "brain": [ 169 ], "using": [ 170 ], "stereological": [ 171 ], "methods.": [ 172 ], "Vehicle-dosed": [ 173 ], "exhibited": [ 176, 210 ], "considerably": [ 177 ], "higher": [ 178 ], "than": [ 182 ], "control": [ 184 ], "mice.": [ 185, 204 ], "Compared": [ 186 ], "vehicle-dosed": [ 188 ], "controls,": [ 190 ], "had": [ 193 ], "no": [ 194, 211 ], "effect": [ 195, 212 ], "on": [ 196, 213 ], "levels": [ 199 ], "conclusion,": [ 206 ], "low-": [ 223 ], "high-grade": [ 225 ], "amyloidosis,": [ 226 ], "which": [ 227 ], "suggests": [ 228 ], "differential": [ 229 ], "sensitivity": [ 230 ], "various": [ 236 ], "mimicking": [ 240 ], "pathological": [ 242 ] }, "publication_date": "2016-07-15", "publication_year": 2016, "type": "article", "cited_by_count": 49, "authors": [ { "id": "https://openalex.org/A5001683046", "display_name": "Henrik H. Hansen" }, { "id": "https://openalex.org/A5047010404", "display_name": "Katrine Fabricius" }, { "id": "https://openalex.org/A5005450058", "display_name": "Pernille Barkholt" }, { "id": "https://openalex.org/A5019226907", "display_name": "Pernille Kongsbak-Wismann" }, { "id": "https://openalex.org/A5081826616", "display_name": "Chantal Schlumberger" }, { "id": "https://openalex.org/A5075602116", "display_name": "Jacob Jelsing" }, { "id": "https://openalex.org/A5054385268", "display_name": "Dick Terwel" }, { "id": "https://openalex.org/A5043991469", "display_name": "Annelies Termont" }, { "id": "https://openalex.org/A5084425804", "display_name": "Charles Pyke" }, { "id": "https://openalex.org/A5088627727", "display_name": "Lotte Bjerre Knudsen" }, { "id": "https://openalex.org/A5088582143", "display_name": "Niels Vrang" } ] }, { "id": "https://openalex.org/W4200213833", "doi": "https://doi.org/10.1016/j.tcm.2021.12.008", "title": "Semaglutide for the treatment of obesity", "abstract": null, "publication_date": "2021-12-21", "publication_year": 2021, "type": "review", "cited_by_count": 149, "authors": [ { "id": "https://openalex.org/A5021408335", "display_name": "Ariana M. Chao" }, { "id": "https://openalex.org/A5001055593", "display_name": "Jena Shaw Tronieri" }, { "id": "https://openalex.org/A5044175873", "display_name": "Anastassia Amaro" }, { "id": "https://openalex.org/A5026596594", "display_name": "Thomas A. Wadden" } ] }, { "id": "https://openalex.org/W2999154349", "doi": "https://doi.org/10.1111/dom.13964", "title": "Comparison of the glucagon\u2010like\u2010peptide\u20101 receptor agonists dulaglutide and liraglutide for the management of diabetes in solid organ transplant: A retrospective study", "abstract": { "Abstract": [ 0 ], "Glucagon\u2010like": [ 1 ], "peptide\u20101": [ 2 ], "receptor": [ 3 ], "agonists": [ 4 ], "(GLP\u20101RAs)": [ 5 ], "are": [ 6, 21 ], "gaining": [ 7 ], "popularity": [ 8 ], "in": [ 9, 14, 32, 49, 76, 92, 121, 143, 149, 168, 176 ], "the": [ 10, 26, 42, 118, 122, 156, 179 ], "management": [ 11 ], "of": [ 12, 46, 79, 158, 181 ], "diabetes": [ 13, 53 ], "solid": [ 15 ], "organ": [ 16 ], "transplant": [ 17 ], "(SOT)": [ 18 ], "recipients.": [ 19 ], "There": [ 20, 60, 71, 138 ], "no": [ 22 ], "studies": [ 23 ], "available": [ 24 ], "comparing": [ 25 ], "two": [ 27, 123 ], "GLP\u20101RAs": [ 28 ], "dulaglutide": [ 29, 67, 86, 100, 133 ], "and": [ 30, 44, 57, 63, 68, 82, 97, 101, 104, 111, 134, 145, 172 ], "liraglutide": [ 31, 107 ], "SOT.": [ 33 ], "We": [ 34 ], "performed": [ 35 ], "a": [ 36, 73, 140, 146 ], "retrospective": [ 37 ], "chart": [ 38 ], "review": [ 39 ], "to": [ 40, 89 ], "assess": [ 41 ], "safety": [ 43 ], "effectiveness": [ 45 ], "these": [ 47 ], "agents": [ 48 ], "adult": [ 50 ], "SOT": [ 51 ], "with": [ 52, 85, 99, 106, 132, 136, 161, 184 ], "at": [ 54, 108, 155, 178 ], "6,": [ 55, 109 ], "12": [ 56, 110 ], "24": [ 58, 112, 159, 182 ], "months.": [ 59 ], "were": [ 61 ], "63": [ 62 ], "25": [ 64 ], "recipients": [ 65 ], "on": [ 66 ], "liraglutide,": [ 69 ], "respectively.": [ 70, 114 ], "was": [ 72, 94, 130, 139, 165 ], "sustained": [ 74 ], "reduction": [ 75, 116, 127, 142 ], "primary": [ 77 ], "endpoints": [ 78 ], "weight,": [ 80 ], "BMI": [ 81, 115 ], "insulin": [ 83, 129 ], "requirement": [ 84 ], "when": [ 87 ], "compared": [ 88 ], "liraglutide.": [ 90, 137, 185 ], "Decrease": [ 91 ], "weight": [ 93 ], "2%,": [ 95 ], "4%": [ 96 ], "5.2%": [ 98 ], "0.09%,": [ 102 ], "0.87%": [ 103 ], "0.89%": [ 105 ], "months": [ 113, 160, 183 ], "followed": [ 117 ], "same": [ 119 ], "trend": [ 120 ], "groups.": [ 124 ], "The": [ 125 ], "percentage": [ 126 ], "for": [ 128 ], "26%": [ 131 ], "3.6%": [ 135 ], "10%": [ 141 ], "creatinine": [ 144, 169 ], "15%": [ 147 ], "increase": [ 148, 167 ], "estimated": [ 150 ], "glomerular": [ 151 ], "filtration": [ 152 ], "rate": [ 153 ], "(eGFR)": [ 154 ], "end": [ 157, 180 ], "dulaglutide.": [ 162 ], "However,": [ 163 ], "there": [ 164 ], "an": [ 166, 173 ], "by": [ 170 ], "7%": [ 171 ], "8%": [ 174 ], "decrease": [ 175 ], "eGFR": [ 177 ] }, "publication_date": "2020-01-14", "publication_year": 2020, "type": "article", "cited_by_count": 57, "authors": [ { "id": "https://openalex.org/A5007150294", "display_name": "Priyamvada Singh" }, { "id": "https://openalex.org/A5051582654", "display_name": "Maryam Taufeeq" }, { "id": "https://openalex.org/A5030252271", "display_name": "Todd E. Pesavento" }, { "id": "https://openalex.org/A5083495718", "display_name": "Kenneth Washburn" }, { "id": "https://openalex.org/A5103332009", "display_name": "Debbie Walsh" }, { "id": "https://openalex.org/A5103245794", "display_name": "Shumei Meng" } ] }, { "id": "https://openalex.org/W2979241049", "doi": "https://doi.org/10.1136/bmjdrc-2019-000705", "title": "Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands", "abstract": { "Objective": [ 0 ], "Choosing": [ 1 ], "therapies": [ 2 ], "for": [ 3, 82, 228, 254, 277 ], "type": [ 4, 281 ], "2": [ 5, 282 ], "diabetes": [ 6 ], "that": [ 7, 147 ], "are": [ 8 ], "both": [ 9, 255 ], "effective": [ 10 ], "and": [ 11, 52, 70, 87, 102, 119, 128, 132, 169, 196, 223, 233, 269, 274, 284 ], "cost-effective": [ 12, 264 ], "is": [ 13, 263 ], "vital": [ 14 ], "as": [ 15 ], "healthcare": [ 16, 290 ], "systems": [ 17 ], "worldwide": [ 18 ], "aim": [ 19 ], "to": [ 20, 79 ], "maximize": [ 21 ], "health": [ 22 ], "of": [ 23, 32, 135, 140, 144, 189, 221, 257, 280, 289 ], "the": [ 24, 30, 66, 116, 133, 278, 293 ], "population.": [ 25 ], "The": [ 26, 72, 124 ], "present": [ 27 ], "analysis": [ 28, 125 ], "assessed": [ 29 ], "cost-effectiveness": [ 31, 215 ], "once-weekly": [ 33, 57, 83, 94, 103, 148, 229, 258 ], "semaglutide": [ 34, 84, 95, 104, 149, 177, 230, 262 ], "(a": [ 35 ], "novel": [ 36 ], "glucagon-like": [ 37 ], "peptide-1": [ 38 ], "(GLP-1)": [ 39 ], "receptor": [ 40, 59 ], "agonist)": [ 41 ], "versus": [ 42, 53, 90, 98, 107, 165, 172, 192, 199, 209, 243, 265, 271 ], "insulin": [ 43, 91, 166, 193, 210, 266 ], "glargine": [ 44, 92, 167, 194, 211, 267 ], "U100": [ 45, 168, 195 ], "(the": [ 46 ], "most": [ 47 ], "commonly": [ 48 ], "used": [ 49, 78 ], "basal": [ 50 ], "insulin)": [ 51 ], "dulaglutide": [ 54, 99, 108, 173, 200, 244, 272 ], "(an": [ 55 ], "alternative": [ 56 ], "GLP-1": [ 58 ], "agonist),": [ 60 ], "from": [ 61, 115, 217, 250 ], "a": [ 62, 218, 247, 251, 286 ], "societal": [ 63, 219, 252 ], "perspective": [ 64, 220, 253 ], "in": [ 65, 185, 292 ], "Netherlands.": [ 67, 294 ], "Research": [ 68 ], "design": [ 69 ], "methods": [ 71 ], "IQVIA": [ 73 ], "CORE": [ 74 ], "Diabetes": [ 75 ], "Model": [ 76 ], "was": [ 77, 152, 180 ], "project": [ 80 ], "outcomes": [ 81, 145 ], "0.5": [ 85, 96, 150, 231 ], "mg": [ 86, 89, 97, 106, 151, 179, 232, 276 ], "1": [ 88, 105, 178, 234 ], "U100,": [ 93, 212, 268 ], "0.75": [ 100, 174, 273 ], "mg,": [ 101, 235 ], "1.5": [ 109, 201, 275 ], "mg.": [ 110, 175, 202 ], "Clinical": [ 111 ], "data": [ 112 ], "were": [ 113 ], "taken": [ 114 ], "SUSTAIN": [ 117, 120 ], "4": [ 118 ], "7": [ 121 ], "clinical": [ 122 ], "trials.": [ 123 ], "captured": [ 126 ], "direct": [ 127 ], "indirect": [ 129 ], "costs,": [ 130 ], "mortality,": [ 131 ], "impact": [ 134 ], "diabetes-related": [ 136 ], "complications": [ 137 ], "on": [ 138 ], "quality": [ 139 ], "life.": [ 141 ], "Results": [ 142 ], "Projections": [ 143 ], "suggested": [ 146 ], "associated": [ 153, 181 ], "with": [ 154, 182, 213 ], "improved": [ 155 ], "quality-adjusted": [ 156, 161, 186 ], "life": [ 157, 162, 187 ], "expectancy": [ 158, 188 ], "by": [ 159 ], "0.19": [ 160 ], "years": [ 163 ], "(QALYs)": [ 164 ], "0.07": [ 170 ], "QALYs": [ 171, 191, 198 ], "Once-weekly": [ 176, 261 ], "mean": [ 183 ], "increases": [ 184 ], "0.27": [ 190 ], "0.13": [ 197 ], "Improvements": [ 203, 242 ], "came": [ 204, 245 ], "at": [ 205, 246 ], "an": [ 206 ], "increased": [ 207 ], "cost": [ 208, 249 ], "incremental": [ 214 ], "ratios": [ 216 ], "\u20ac4988": [ 222 ], "\u20ac495": [ 224 ], "per": [ 225 ], "QALY": [ 226 ], "gained": [ 227 ], "respectively,": [ 236 ], "falling": [ 237 ], "below": [ 238 ], "Netherlands-specific": [ 239 ], "willingness-to-pay": [ 240 ], "thresholds.": [ 241 ], "reduced": [ 248 ], "doses": [ 256 ], "semaglutide.": [ 259 ], "Conclusions": [ 260 ], "dominant": [ 270 ], "treatment": [ 279 ], "diabetes,": [ 283 ], "represents": [ 285 ], "good": [ 287 ], "use": [ 288 ], "resources": [ 291 ] }, "publication_date": "2019-10-01", "publication_year": 2019, "type": "article", "cited_by_count": 40, "authors": [ { "id": "https://openalex.org/A5072605000", "display_name": "Barnaby Hunt" }, { "id": "https://openalex.org/A5029230724", "display_name": "Samuel J. P. Malkin" }, { "id": "https://openalex.org/A5023821485", "display_name": "Robert Gerald Jan Moes" }, { "id": "https://openalex.org/A5001789783", "display_name": "Eline L. Huisman" }, { "id": "https://openalex.org/A5047071721", "display_name": "T. Vandebrouck" }, { "id": "https://openalex.org/A5060728967", "display_name": "Bruce H. R. Wolffenbuttel" } ] }, { "id": "https://openalex.org/W2559748650", "doi": "https://doi.org/10.1007/s13300-016-0218-3", "title": "The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial", "abstract": { "Novo": [ 0 ], "Nordisk.": [ 1 ] }, "publication_date": "2016-12-10", "publication_year": 2016, "type": "article", "cited_by_count": 129, "authors": [ { "id": "https://openalex.org/A5002865126", "display_name": "Sultan Linjawi" }, { "id": "https://openalex.org/A5005036709", "display_name": "Bruce W. Bode" }, { "id": "https://openalex.org/A5005982472", "display_name": "Louis Chaykin" }, { "id": "https://openalex.org/A5004454263", "display_name": "J.P. Courr\u00e8ges" }, { "id": "https://openalex.org/A5037652425", "display_name": "Yehuda Handelsman" }, { "id": "https://openalex.org/A5019909242", "display_name": "Lucine Lehmann" }, { "id": "https://openalex.org/A5010721799", "display_name": "Abhishek Mishra" }, { "id": "https://openalex.org/A5103403579", "display_name": "Richard W Simpson" } ] }, { "id": "https://openalex.org/W3044996075", "doi": "https://doi.org/10.1016/j.trsl.2020.07.008", "title": "The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet", "abstract": { "Nonalcoholic": [ 0 ], "fatty": [ 1 ], "liver": [ 2, 160 ], "disease": [ 3, 18 ], "(NAFLD)": [ 4 ], "is": [ 5, 33 ], "the": [ 6, 54, 76, 87, 94, 97, 102, 111, 117, 142, 159, 166, 194, 201, 213 ], "most": [ 7 ], "common": [ 8 ], "hepatic": [ 9, 28, 114, 178, 244, 252 ], "disorder": [ 10 ], "related": [ 11 ], "to": [ 12, 109 ], "type": [ 13 ], "2": [ 14 ], "diabetes": [ 15 ], "(T2D).": [ 16 ], "The": [ 17 ], "can": [ 19 ], "evolve": [ 20 ], "toward": [ 21 ], "nonalcoholic": [ 22 ], "steatohepatitis": [ 23 ], "(NASH),": [ 24 ], "a": [ 25, 207, 216 ], "state": [ 26 ], "of": [ 27, 78, 84, 89, 116, 123, 144, 161, 168, 183, 189, 196, 206, 228, 236, 247 ], "inflammation": [ 29, 179, 233 ], "and": [ 30, 69, 170, 187, 220, 230, 234, 250 ], "fibrosis.": [ 31, 190 ], "There": [ 32 ], "presently": [ 34 ], "no": [ 35 ], "drug": [ 36 ], "that": [ 37 ], "effectively": [ 38 ], "improves": [ 39 ], "and/or": [ 40 ], "prevents": [ 41, 226 ], "NAFLD/NASH/fibrosis.": [ 42 ], "GLP-1": [ 43 ], "receptor": [ 44 ], "agonists": [ 45 ], "(GLP-1Ra)": [ 46 ], "are": [ 47 ], "effective": [ 48 ], "in": [ 49, 75, 137, 158, 238 ], "treating": [ 50 ], "T2D.": [ 51 ], "As": [ 52 ], "with": [ 53 ], "endogenous": [ 55 ], "gut": [ 56, 197 ], "incretins,": [ 57 ], "GLP-1Ra": [ 58, 65, 85, 118 ], "potentiate": [ 59 ], "glucose-induced": [ 60 ], "insulin": [ 61 ], "secretion.": [ 62 ], "In": [ 63, 96, 173, 223 ], "addition,": [ 64, 174 ], "limit": [ 66 ], "food": [ 67 ], "intake": [ 68 ], "weight": [ 70, 248 ], "gain,": [ 71 ], "additional": [ 72 ], "beneficial": [ 73, 243 ], "properties": [ 74 ], "context": [ 77 ], "obesity/insulin-resistance.": [ 79 ], "Nevertheless,": [ 80 ], "these": [ 81 ], "pleiotropic": [ 82 ], "effects": [ 83 ], "complicate": [ 86 ], "elucidation": [ 88 ], "their": [ 90 ], "direct": [ 91, 113 ], "action": [ 92 ], "on": [ 93 ], "liver.": [ 95 ], "present": [ 98 ], "study,": [ 99 ], "we": [ 100 ], "used": [ 101 ], "classical": [ 103 ], "methionine-choline": [ 104 ], "deficient": [ 105 ], "(MCD)": [ 106 ], "dietary": [ 107 ], "model": [ 108, 146 ], "investigate": [ 110 ], "potential": [ 112 ], "actions": [ 115, 245 ], "liraglutide.": [ 119 ], "A": [ 120 ], "4-week": [ 121 ], "infusion": [ 122 ], "liraglutide": [ 124, 175, 225 ], "(570": [ 125 ], "\u00b5g/kg/day)": [ 126 ], "did": [ 127, 153 ], "not": [ 128, 154 ], "impact": [ 129 ], "body": [ 130 ], "weight,": [ 131 ], "fat": [ 132 ], "accretion": [ 133 ], "or": [ 134 ], "glycemic": [ 135 ], "control": [ 136 ], "MCD-diet": [ 138 ], "fed": [ 139 ], "mice,": [ 140 ], "confirming": [ 141 ], "suitability": [ 143 ], "this": [ 145 ], "for": [ 147 ], "avoiding": [ 148 ], "confounding": [ 149 ], "factors.": [ 150 ], "Liraglutide": [ 151, 191 ], "treatment": [ 152, 176 ], "prevent": [ 155 ], "lipid": [ 156 ], "deposition": [ 157 ], "MCD-fed": [ 162 ], "mice": [ 163, 240 ], "but": [ 164 ], "limited": [ 165 ], "accumulation": [ 167, 182, 227 ], "C16": [ 169, 229 ], "C24-ceramide/sphingomyelin": [ 171 ], "species.": [ 172 ], "alleviated": [ 177 ], "(in": [ 180 ], "particular": [ 181 ], "M1": [ 184 ], "pro-inflammatory": [ 185 ], "macrophages)": [ 186 ], "initiation": [ 188, 235 ], "also": [ 192 ], "influenced": [ 193 ], "composition": [ 195 ], "microbiota": [ 198 ], "induced": [ 199 ], "by": [ 200 ], "MCD-diet.": [ 202 ], "This": [ 203 ], "included": [ 204 ], "recovery": [ 205 ], "normal": [ 208 ], "Bacteroides": [ 209 ], "proportion": [ 210 ], "and,": [ 211 ], "among": [ 212 ], "Erysipelotrichaceae": [ 214 ], "family,": [ 215 ], "shift": [ 217 ], "between": [ 218 ], "Allobaculum": [ 219 ], "Turicibacter": [ 221 ], "genera.": [ 222 ], "conclusion,": [ 224 ], "C24-ceramides/sphingomyelins": [ 231 ], "species,": [ 232 ], "fibrosis": [ 237 ], "MCD-diet-fed": [ 239 ], "liver,": [ 241 ], "suggesting": [ 242 ], "independent": [ 246 ], "loss": [ 249 ], "global": [ 251 ], "steatosis.": [ 253 ] }, "publication_date": "2020-07-22", "publication_year": 2020, "type": "article", "cited_by_count": 113, "authors": [ { "id": "https://openalex.org/A5024094411", "display_name": "Emmanuel Somm" }, { "id": "https://openalex.org/A5056944490", "display_name": "Sophie A. Montandon" }, { "id": "https://openalex.org/A5051778445", "display_name": "Ursula Loizides\u2010Mangold" }, { "id": "https://openalex.org/A5045080230", "display_name": "Nadia Ga\u00efa" }, { "id": "https://openalex.org/A5059773554", "display_name": "Vladimir Lazarevi\u0107" }, { "id": "https://openalex.org/A5091883258", "display_name": "Claudio De Vito" }, { "id": "https://openalex.org/A5082184014", "display_name": "Elodie Perroud" }, { "id": "https://openalex.org/A5056954886", "display_name": "Marie\u2010Luce Bochaton\u2010Piallat" }, { "id": "https://openalex.org/A5040291166", "display_name": "Charna Dibner" }, { "id": "https://openalex.org/A5088214706", "display_name": "Jacques Schrenzel" }, { "id": "https://openalex.org/A5056462107", "display_name": "Fran\u00e7ois R. Jornayvaz" } ] }, { "id": "https://openalex.org/W3131216226", "doi": "https://doi.org/10.1016/j.drugalcdep.2021.108614", "title": "Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder", "abstract": null, "publication_date": "2021-02-16", "publication_year": 2021, "type": "article", "cited_by_count": 50, "authors": [ { "id": "https://openalex.org/A5008253709", "display_name": "Gustavo A. Angarita" }, { "id": "https://openalex.org/A5084609706", "display_name": "David Matuskey" }, { "id": "https://openalex.org/A5056238262", "display_name": "Brian Pittman" }, { "id": "https://openalex.org/A5035261695", "display_name": "Jessica Costeines" }, { "id": "https://openalex.org/A5067499997", "display_name": "Marc N. Potenza" }, { "id": "https://openalex.org/A5016003520", "display_name": "Ania M. Jastreboff" }, { "id": "https://openalex.org/A5056521587", "display_name": "Heath D. Schmidt" }, { "id": "https://openalex.org/A5029861832", "display_name": "Robert T. Malison" } ] }, { "id": "https://openalex.org/W4381803348", "doi": "https://doi.org/10.1016/j.jhep.2023.05.013", "title": "A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease", "abstract": { "Currently,": [ 0 ], "there": [ 1 ], "are": [ 2 ], "no": [ 3 ], "approved": [ 4 ], "therapies": [ 5 ], "for": [ 6, 113 ], "non-alcoholic": [ 7, 72 ], "steatohepatitis": [ 8 ], "(NASH).": [ 9 ], "The": [ 10 ], "weight": [ 11, 41 ], "loss": [ 12 ], "associated": [ 13 ], "with": [ 14, 29, 71, 76, 96 ], "glucagon-like": [ 15 ], "peptide-1": [ 16 ], "(GLP-1)": [ 17 ], "receptor": [ 18, 44, 79, 99 ], "agonists": [ 19 ], "has": [ 20 ], "been": [ 21 ], "shown": [ 22 ], "to": [ 23, 33, 56, 86, 94 ], "decrease": [ 24 ], "hepatic": [ 25 ], "inflammation": [ 26 ], "in": [ 27, 91 ], "patients": [ 28, 70 ], "NASH.": [ 30, 114 ], "In": [ 31 ], "addition": [ 32 ], "reducing": [ 34 ], "liver": [ 35, 54, 74 ], "fat": [ 36 ], "content": [ 37 ], "(LFC)": [ 38 ], "indirectly": [ 39 ], "through": [ 40 ], "loss,": [ 42 ], "glucagon": [ 43 ], "agonism": [ 45 ], "may": [ 46, 108 ], "also": [ 47 ], "reduce": [ 48, 62 ], "LFC": [ 49, 92 ], "by": [ 50 ], "acting": [ 51 ], "on": [ 52 ], "the": [ 53, 77, 97 ], "directly": [ 55 ], "stimulate": [ 57 ], "fatty": [ 58, 73 ], "acid": [ 59 ], "oxidation": [ 60 ], "and": [ 61 ], "lipogenesis.": [ 63 ], "This": [ 64 ], "study": [ 65 ], "demonstrated": [ 66 ], "that": [ 67, 106 ], "treatment": [ 68, 95, 112 ], "of": [ 69 ], "disease": [ 75 ], "GLP-1/glucagon": [ 78 ], "co-agonist": [ 80 ], "efinopegdutide": [ 81, 107 ], "(10": [ 82 ], "mg": [ 83, 103 ], "weekly)": [ 84 ], "led": [ 85 ], "a": [ 87 ], "significantly": [ 88 ], "greater": [ 89 ], "reduction": [ 90 ], "compared": [ 93 ], "GLP-1": [ 98 ], "agonist": [ 100 ], "semaglutide": [ 101 ], "(1": [ 102 ], "weekly),": [ 104 ], "suggesting": [ 105 ], "be": [ 109 ], "an": [ 110 ], "effective": [ 111 ] }, "publication_date": "2023-06-23", "publication_year": 2023, "type": "article", "cited_by_count": 153, "authors": [ { "id": "https://openalex.org/A5037480677", "display_name": "Manuel Romero\u2010G\u00f3mez" }, { "id": "https://openalex.org/A5075322332", "display_name": "Eric Lawitz" }, { "id": "https://openalex.org/A5064493392", "display_name": "R. Ravi Shankar" }, { "id": "https://openalex.org/A5103590025", "display_name": "Eirum Chaudhri" }, { "id": "https://openalex.org/A5100454162", "display_name": "Jie Liu" }, { "id": "https://openalex.org/A5104521823", "display_name": "Raymond L. H. Lam" }, { "id": "https://openalex.org/A5027357772", "display_name": "Keith D. Kaufman" }, { "id": "https://openalex.org/A5031476174", "display_name": "Samuel S. Engel" }, { "id": "https://openalex.org/A5092248506", "display_name": "Santiago Oscar Bruzone" }, { "id": "https://openalex.org/A5114107668", "display_name": "Maria Jimena Coronel" }, { "id": "https://openalex.org/A5011452410", "display_name": "Fernando Gruz" }, { "id": "https://openalex.org/A5027817080", "display_name": "Ignacio MacKinnon" }, { "id": "https://openalex.org/A5011865871", "display_name": "Jacob George" }, { "id": "https://openalex.org/A5012594152", "display_name": "Kate Muller" }, { "id": "https://openalex.org/A5042678528", "display_name": "Samuel S. Lee" }, { "id": "https://openalex.org/A5034921512", "display_name": "Cyrielle Caussy" }, { "id": "https://openalex.org/A5007995895", "display_name": "Jean\u2010Michel Petit" }, { "id": "https://openalex.org/A5000898451", "display_name": "Ziv Ben Ari" }, { "id": "https://openalex.org/A5101442165", "display_name": "Marius Braun" }, { "id": "https://openalex.org/A5029114407", "display_name": "Helena Katchman" }, { "id": "https://openalex.org/A5010874906", "display_name": "Yoav Lurie" }, { "id": "https://openalex.org/A5031572282", "display_name": "Ella Veitsman" }, { "id": "https://openalex.org/A5109557248", "display_name": "Eli Zuckerman" }, { "id": "https://openalex.org/A5061042436", "display_name": "Alessio Aghemo" }, { "id": "https://openalex.org/A5047687063", "display_name": "Stefania Basili" }, { "id": "https://openalex.org/A5024750114", "display_name": "Anna Ludovica Fracanzani" }, { "id": "https://openalex.org/A5047570187", "display_name": "Antonello Pietrangelo" }, { "id": "https://openalex.org/A5081373303", "display_name": "David Sacerdoti" }, { "id": "https://openalex.org/A5060705026", "display_name": "J. Arce" }, { "id": "https://openalex.org/A5091190806", "display_name": "A. Cetina" }, { "id": "https://openalex.org/A5033059979", "display_name": "Norberto C. Ch\u00e1vez\u2010Tapia" }, { "id": "https://openalex.org/A5108769126", "display_name": "Eira Cerda Reyes" }, { "id": "https://openalex.org/A5078928816", "display_name": "Lourdes Lol-be Pinzon Te" }, { "id": "https://openalex.org/A5001549960", "display_name": "John Baker" }, { "id": "https://openalex.org/A5050074764", "display_name": "Jeffrey Ngu" }, { "id": "https://openalex.org/A5108786570", "display_name": "David Orr" }, { "id": "https://openalex.org/A5055297251", "display_name": "Ewa Janczewska" }, { "id": "https://openalex.org/A5077896934", "display_name": "Pawe\u0142 Matusik" }, { "id": "https://openalex.org/A5092248505", "display_name": "Maciej Murawski Stanislaw Sadurski" }, { "id": "https://openalex.org/A5110997242", "display_name": "Anna Valerievna Akinina" }, { "id": "https://openalex.org/A5027455418", "display_name": "Diana Alpenidze" }, { "id": "https://openalex.org/A5030437694", "display_name": "Pavel Bogomolov" }, { "id": "https://openalex.org/A5104134014", "display_name": "Polina Yurievna Ermakova" }, { "id": "https://openalex.org/A5083611299", "display_name": "Albina Golovach" }, { "id": "https://openalex.org/A5057447649", "display_name": "Sang Gyune Kim" }, { "id": "https://openalex.org/A5025329995", "display_name": "Jin Woo Lee" }, { "id": "https://openalex.org/A5111499517", "display_name": "Yong Han Paik" }, { "id": "https://openalex.org/A5100397347", "display_name": "Jun Yong Park" }, { "id": "https://openalex.org/A5072368981", "display_name": "Jong Eun Yeon" }, { "id": "https://openalex.org/A5106571813", "display_name": "Victor Vargas Blasco" }, { "id": "https://openalex.org/A5061677162", "display_name": "Francisco J. Tinahones" }, { "id": "https://openalex.org/A5037927976", "display_name": "Jos\u00e9 Lu\u00eds Calleja" }, { "id": "https://openalex.org/A5080176940", "display_name": "Esther Molina" }, { "id": "https://openalex.org/A5037480677", "display_name": "Manuel Romero\u2010G\u00f3mez" }, { "id": "https://openalex.org/A5090245512", "display_name": "Pin\u2010Nan Cheng" }, { "id": "https://openalex.org/A5090025048", "display_name": "Wen\u2010Juei Jeng" }, { "id": "https://openalex.org/A5072593323", "display_name": "Chun\u2013Jen Liu" }, { "id": "https://openalex.org/A5027003965", "display_name": "Filiz Aky\u00fcz" }, { "id": "https://openalex.org/A5088061880", "display_name": "Hatice Balaban" }, { "id": "https://openalex.org/A5007546876", "display_name": "Metin Ba\u015farano\u011flu" }, { "id": "https://openalex.org/A5042404232", "display_name": "Tevfik Demir" }, { "id": "https://openalex.org/A5030413648", "display_name": "Ramazan \u0130dilman" }, { "id": "https://openalex.org/A5091706005", "display_name": "Tarkan Karakan" }, { "id": "https://openalex.org/A5005978466", "display_name": "Olga Gyrina" }, { "id": "https://openalex.org/A5102527043", "display_name": "\u041e. \u0412. \u041a\u043e\u043b\u0435\u0441\u043d\u0438\u043a\u043e\u0432\u0430" }, { "id": "https://openalex.org/A5082448516", "display_name": "S. M. Pyvovar" }, { "id": "https://openalex.org/A5112394155", "display_name": "Oleksandr Oliinyk" }, { "id": "https://openalex.org/A5088733913", "display_name": "I. Skrypnyk" }, { "id": "https://openalex.org/A5004749982", "display_name": "Isaac Bassan" }, { "id": "https://openalex.org/A5109534340", "display_name": "William Bowman" }, { "id": "https://openalex.org/A5024000693", "display_name": "Douglas Denham" }, { "id": "https://openalex.org/A5087324362", "display_name": "Reem Ghalib" }, { "id": "https://openalex.org/A5075322332", "display_name": "Eric Lawitz" }, { "id": "https://openalex.org/A5030205518", "display_name": "Kathryn Jean Lucas" }, { "id": "https://openalex.org/A5038440873", "display_name": "Rizwana Mohseni" }, { "id": "https://openalex.org/A5104134015", "display_name": "William Eduardo Sanchez" }, { "id": "https://openalex.org/A5021954687", "display_name": "John M. Vierling" } ] }, { "id": "https://openalex.org/W2938583963", "doi": "https://doi.org/10.1111/obr.12841", "title": "Weight loss variability with SGLT2 inhibitors and GLP\u20101 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities", "abstract": { "Summary": [ 0 ], "We": [ 1 ], "are": [ 2, 48 ], "facing": [ 3 ], "a": [ 4, 109, 126 ], "global": [ 5 ], "epidemic": [ 6 ], "of": [ 7, 18, 113, 132, 141, 181 ], "obesity": [ 8, 19 ], "and": [ 9, 20, 28, 31, 84, 95, 105, 122, 184, 189, 201 ], "type": [ 10, 21 ], "2": [ 11, 22, 81, 115 ], "diabetes.": [ 12 ], "Weight": [ 13 ], "loss,": [ 14 ], "in": [ 15, 32, 65, 129, 161, 187 ], "the": [ 16, 75, 130, 133, 139, 142 ], "context": [ 17 ], "diabetes,": [ 23 ], "may": [ 24, 43, 70, 195 ], "improve": [ 25 ], "glycaemic": [ 26, 96 ], "control": [ 27, 180 ], "weight\u2010related": [ 29 ], "comorbidities,": [ 30 ], "some": [ 33, 154 ], "cases,": [ 34 ], "induce": [ 35 ], "diabetes": [ 36 ], "remission.": [ 37 ], "Although": [ 38 ], "lifestyle\u2010based": [ 39 ], "weight": [ 40, 63, 72, 93, 111, 134, 144, 158, 176 ], "loss": [ 41, 64, 94, 112, 135, 145 ], "strategies": [ 42 ], "be": [ 44, 196 ], "initially": [ 45 ], "successful,": [ 46 ], "most": [ 47 ], "not": [ 49 ], "effective": [ 50 ], "long\u2010term.": [ 51 ], "There": [ 52 ], "is": [ 53, 146, 177 ], "an": [ 54 ], "increasing": [ 55 ], "need": [ 56 ], "to": [ 57, 61, 116, 163 ], "consider": [ 58, 191 ], "pharmacological": [ 59, 165 ], "approaches": [ 60 ], "assist": [ 62 ], "diabetes\u2010obesity.": [ 66 ], "Older": [ 67 ], "glucose\u2010lowering": [ 68 ], "agents": [ 69 ], "cause": [ 71, 108 ], "gain,": [ 73 ], "whereas": [ 74 ], "newer": [ 76 ], "drug": [ 77 ], "classes,": [ 78 ], "sodium\u2010glucose": [ 79 ], "co\u2010transporter": [ 80 ], "inhibitors": [ 82 ], "(SGLT2i)": [ 83 ], "glucagon\u2010like": [ 85 ], "peptide": [ 86 ], "receptor": [ 87 ], "agonists": [ 88 ], "(GLP\u20101": [ 89, 136 ], "RAs),": [ 90 ], "concomitantly": [ 91 ], "target": [ 92 ], "control.": [ 97 ], "Clinical": [ 98 ], "trial": [ 99 ], "data": [ 100 ], "suggest": [ 101 ], "that": [ 102 ], "both": [ 103 ], "SGLT2i": [ 104, 200 ], "GLP1": [ 106, 202 ], "RAs": [ 107 ], "mean": [ 110 ], "approximately": [ 114 ], "3": [ 117 ], "kg": [ 118 ], "but": [ 119 ], "real\u2010world": [ 120 ], "evidence": [ 121 ], "clinical": [ 123 ], "experience": [ 124 ], "suggests": [ 125 ], "significant": [ 127 ], "heterogeneity": [ 128 ], "magnitude": [ 131, 140 ], "RAs)": [ 137 ], "or": [ 138 ], "actual": [ 143 ], "significantly": [ 147 ], "less": [ 148 ], "than": [ 149, 159 ], "anticipated": [ 150 ], "(SGLT2i).": [ 151 ], "Why": [ 152 ], "do": [ 153 ], "individuals": [ 155 ], "lose": [ 156 ], "more": [ 157 ], "others": [ 160 ], "response": [ 162 ], "these": [ 164, 193 ], "treatments?": [ 166 ], "This": [ 167 ], "review": [ 168 ], "will": [ 169 ], "first": [ 170 ], "explore": [ 171 ], "mechanisms": [ 172, 194 ], "by": [ 173 ], "which": [ 174 ], "body": [ 175 ], "regulated": [ 178 ], "through": [ 179 ], "energy": [ 182 ], "balance": [ 183 ], "its": [ 185 ], "dysregulation": [ 186 ], "obesity,": [ 188 ], "then": [ 190 ], "how": [ 192 ], "modulated": [ 197 ], "therapeutically": [ 198 ], "with": [ 199 ], "RAs.": [ 203 ] }, "publication_date": "2019-04-10", "publication_year": 2019, "type": "review", "cited_by_count": 203, "authors": [ { "id": "https://openalex.org/A5067624521", "display_name": "Emily Brown" }, { "id": "https://openalex.org/A5047195042", "display_name": "John Wilding" }, { "id": "https://openalex.org/A5027919996", "display_name": "Thomas M. Barber" }, { "id": "https://openalex.org/A5021599391", "display_name": "Uazman Alam" }, { "id": "https://openalex.org/A5076265710", "display_name": "Daniel J. Cuthbertson" } ] }, { "id": "https://openalex.org/W1970638723", "doi": "https://doi.org/10.1185/03007990902820519", "title": "Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide", "abstract": { "These": [ 0, 22 ], "data": [ 1, 28 ], "do": [ 2 ], "not": [ 3 ], "provide": [ 4 ], "evidence": [ 5 ], "for": [ 6 ], "an": [ 7, 31 ], "association": [ 8 ], "of": [ 9, 14 ], "acute": [ 10 ], "pancreatitis": [ 11 ], "among": [ 12 ], "initiators": [ 13 ], "exenatide": [ 15 ], "or": [ 16 ], "sitagliptin": [ 17 ], "compared": [ 18 ], "to": [ 19 ], "met/gly": [ 20 ], "initiators.": [ 21 ], "results": [ 23 ], "are": [ 24 ], "limited": [ 25 ], "by": [ 26 ], "the": [ 27 ], "available": [ 29 ], "in": [ 30 ], "administrative,": [ 32 ], "healthcare": [ 33 ], "database.": [ 34 ] }, "publication_date": "2009-03-12", "publication_year": 2009, "type": "article", "cited_by_count": 328, "authors": [ { "id": "https://openalex.org/A5055406653", "display_name": "David D. Dore" }, { "id": "https://openalex.org/A5002078534", "display_name": "John D. Seeger" }, { "id": "https://openalex.org/A5045255444", "display_name": "K. Arnold Chan" } ] }, { "id": "https://openalex.org/W2944628830", "doi": "https://doi.org/10.1016/j.bbr.2019.111932", "title": "Exenatide alleviates mitochondrial dysfunction and cognitive impairment in the 5\u00d7FAD mouse model of Alzheimer\u2019s disease", "abstract": null, "publication_date": "2019-05-10", "publication_year": 2019, "type": "article", "cited_by_count": 70, "authors": [ { "id": "https://openalex.org/A5112713747", "display_name": "Jingjing An" }, { "id": "https://openalex.org/A5115597722", "display_name": "Yu Zhou" }, { "id": "https://openalex.org/A5081106870", "display_name": "Mengjun Zhang" }, { "id": "https://openalex.org/A5107872259", "display_name": "Yunzhen Xie" }, { "id": "https://openalex.org/A5003455152", "display_name": "Sujie Ke" }, { "id": "https://openalex.org/A5100644187", "display_name": "Libin Liu" }, { "id": "https://openalex.org/A5067409432", "display_name": "Xiaodong Pan" }, { "id": "https://openalex.org/A5035117508", "display_name": "Chen Zhou" } ] }, { "id": "https://openalex.org/W4407010133", "doi": "https://doi.org/10.1001/jamanetworkopen.2024.57349", "title": "Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity", "abstract": { "Importance": [ 0 ], "Adherence": [ 1 ], "to": [ 2, 128, 131, 139, 477, 483 ], "glucagon-like": [ 3 ], "peptide-1": [ 4 ], "receptor": [ 5 ], "agonists": [ 6 ], "(GLP-1": [ 7 ], "RAs)": [ 8 ], "is": [ 9 ], "important": [ 10 ], "for": [ 11, 126, 135, 202, 242, 284, 300, 381, 421, 432 ], "their": [ 12 ], "effectiveness.": [ 13 ], "Discontinuation": [ 14 ], "and": [ 15, 27, 32, 46, 76, 99, 134, 156, 162, 179, 185, 205, 290, 306, 370, 427, 439, 468, 475 ], "reinitiation": [ 16, 34, 186, 378, 415, 470 ], "patterns": [ 17 ], "are": [ 18 ], "not": [ 19 ], "well": [ 20 ], "understood.": [ 21 ], "Objective": [ 22 ], "To": [ 23 ], "describe": [ 24 ], "rates": [ 25, 327, 467 ], "of": [ 26, 35, 86, 117, 148, 159, 172, 216, 282, 298, 328, 344, 404, 414, 416 ], "factors": [ 28 ], "associated": [ 29, 273, 324, 339, 410 ], "with": [ 30, 40, 56, 63, 80, 183, 204, 253, 255, 274, 286, 325, 340, 392, 394, 411, 423, 447 ], "discontinuation": [ 31, 133, 184, 238, 283, 299, 345, 373, 407, 466 ], "subsequent": [ 33 ], "GLP-1": [ 36, 66, 164, 452 ], "RAs": [ 37 ], "among": [ 38 ], "adults": [ 39, 55, 219 ], "overweight": [ 41, 57, 448 ], "or": [ 42, 58, 70, 88, 332, 449 ], "obesity.": [ 43, 487 ], "Design,": [ 44 ], "Setting,": [ 45 ], "Participants": [ 47 ], "In": [ 48, 212, 441 ], "this": [ 49, 213, 442 ], "retrospective": [ 50 ], "cohort": [ 51, 214, 443 ], "study,": [ 52, 444 ], "125": [ 53, 217 ], "474": [ 54, 218 ], "obesity": [ 59, 450 ], "newly": [ 60 ], "initiated": [ 61 ], "treatment": [ 62 ], "a": [ 64, 81, 115, 275, 291, 341, 372 ], "dual-labeled": [ 65 ], "RA": [ 67, 165, 453 ], "(liraglutide,": [ 68 ], "semaglutide,": [ 69 ], "tirzepatide)": [ 71 ], "between": [ 72 ], "January": [ 73 ], "1,": [ 74 ], "2018,": [ 75 ], "December": [ 77 ], "31,": [ 78 ], "2023,": [ 79 ], "baseline": [ 82, 271 ], "body": [ 83 ], "mass": [ 84 ], "index": [ 85 ], "27": [ 87 ], "more,": [ 89 ], "an": [ 90 ], "available": [ 91 ], "weight": [ 92, 177, 264, 269, 374 ], "measurement": [ 93, 375 ], "within": [ 94, 455 ], "60": [ 95 ], "days": [ 96 ], "before": [ 97, 105 ], "initiation,": [ 98 ], "regular": [ 100 ], "care": [ 101, 120 ], "in": [ 102, 268, 473, 486 ], "the": [ 103, 481 ], "year": [ 104 ], "initiation": [ 106 ], "were": [ 107, 123, 144, 166, 188, 199, 322, 338 ], "identified": [ 108 ], "using": [ 109, 190 ], "electronic": [ 110 ], "health": [ 111, 119, 175 ], "record": [ 112 ], "data": [ 113 ], "from": [ 114, 168, 270, 406 ], "collective": [ 116 ], "US": [ 118 ], "systems.": [ 121 ], "Patients": [ 122, 143 ], "followed": [ 124 ], "up": [ 125, 127 ], "2": [ 129, 136, 150, 209, 235, 246, 257, 288, 304, 310, 348, 357, 385, 396, 425, 436, 462 ], "years": [ 130, 138 ], "assess": [ 132, 140 ], "additional": [ 137 ], "reinitiation.": [ 141 ], "Exposure": [ 142 ], "stratified": [ 145 ], "by": [ 146 ], "presence": [ 147 ], "type": [ 149, 208, 234, 245, 256, 287, 303, 347, 356, 384, 395, 424, 435, 461 ], "diabetes": [ 151, 247, 258, 289, 311, 386, 397, 426, 463 ], "at": [ 152 ], "baseline.": [ 153 ], "Main": [ 154 ], "Outcomes": [ 155 ], "Measures": [ 157 ], "Proportions": [ 158 ], "patients": [ 160, 203, 206, 243, 285, 301, 367, 422, 433, 446 ], "discontinuing": [ 161 ], "reinitiating": [ 163 ], "estimated": [ 167 ], "Kaplan-Meier": [ 169 ], "models.": [ 170, 196 ], "Associations": [ 171 ], "sociodemographic": [ 173 ], "characteristics,": [ 174 ], "factors,": [ 176 ], "changes,": [ 178 ], "gastrointestinal": [ 180, 335 ], "adverse": [ 181, 336 ], "events": [ 182, 337 ], "outcomes": [ 187 ], "modeled": [ 189 ], "time-varying": [ 191 ], "Cox": [ 192 ], "proportional": [ 193 ], "hazards": [ 194, 413 ], "regression": [ 195 ], "All": [ 197 ], "analyses": [ 198 ], "conducted": [ 200 ], "separately": [ 201 ], "without": [ 207, 244, 302, 355, 383, 434, 460 ], "diabetes.": [ 210, 236, 437 ], "Results": [ 211 ], "study": [ 215 ], "(mean": [ 220 ], "[SD]": [ 221 ], "age,": [ 222 ], "54.4": [ 223 ], "[13.1]": [ 224 ], "years;": [ 225 ], "82": [ 226 ], "063": [ 227 ], "women": [ 228 ], "[65.4%]),": [ 229 ], "76": [ 230 ], "524": [ 231 ], "(61.0%)": [ 232 ], "had": [ 233, 371, 464 ], "One-year": [ 237 ], "was": [ 239, 272, 379, 408 ], "significantly": [ 240, 323, 409 ], "higher": [ 241, 307, 342, 465 ], "(64.8%": [ 248 ], "[95%": [ 249, 260, 277, 293, 319, 352, 361, 388, 399 ], "CI,": [ 250, 261, 278, 294, 320, 353, 362, 389, 400, 419, 430 ], "64.4%-65.2%])": [ 251 ], "compared": [ 252, 391 ], "those": [ 254, 382, 393, 459 ], "(46.5%": [ 259 ], "46.2%-46.9%]).": [ 262 ], "Higher": [ 263 ], "loss": [ 265 ], "(1%": [ 266 ], "reduction": [ 267 ], "3.1%": [ 276 ], "2.9%-3.2%]": [ 279 ], "lower": [ 280, 296, 326, 380, 469 ], "hazard": [ 281, 297, 315, 343 ], "3.3%": [ 292 ], "3.2%-3.5%]": [ 295 ], "diabetes)": [ 305 ], "income": [ 308 ], "(type": [ 309 ], "only;": [ 312 ], "&amp;gt;$80": [ 313 ], "000:": [ 314 ], "ratio": [ 316 ], "[HR],": [ 317 ], "0.72": [ 318 ], "0.69-0.76])": [ 321 ], "discontinuation,": [ 329 ], "while": [ 330 ], "moderate": [ 331 ], "severe": [ 333 ], "incident": [ 334 ], "(with": [ 346 ], "diabetes:": [ 349, 358 ], "HR,": [ 350, 359 ], "1.38": [ 351 ], "1.31-1.45];": [ 354 ], "1.19": [ 360 ], "1.12-1.27]).": [ 363 ], "Of": [ 364 ], "41": [ 365 ], "792": [ 366 ], "who": [ 368 ], "discontinued": [ 369, 451 ], "available,": [ 376 ], "1-year": [ 377 ], "(36.3%": [ 387 ], "35.6%-37.0%])": [ 390 ], "(47.3%": [ 398 ], "46.6%-48.0%]).": [ 401 ], "Weight": [ 402 ], "regain": [ 403 ], "1%": [ 405 ], "increased": [ 412 ], "2.3%": [ 417 ], "(95%": [ 418, 429 ], "1.9%-2.8%)": [ 420 ], "2.8%": [ 428 ], "2.4%-3.2%)": [ 431 ], "Conclusions": [ 438 ], "Relevance": [ 440 ], "most": [ 445 ], "therapy": [ 454 ], "1": [ 456 ], "year,": [ 457 ], "but": [ 458 ], "rates.": [ 471 ], "Inequities": [ 472 ], "access": [ 474 ], "adherence": [ 476 ], "effective": [ 478 ], "treatments": [ 479 ], "have": [ 480 ], "potential": [ 482 ], "exacerbate": [ 484 ], "disparities": [ 485 ] }, "publication_date": "2025-01-31", "publication_year": 2025, "type": "article", "cited_by_count": 107, "authors": [ { "id": "https://openalex.org/A5046818234", "display_name": "Patricia J. Rodriguez" }, { "id": "https://openalex.org/A5082141622", "display_name": "Vincent Zhang" }, { "id": "https://openalex.org/A5082052835", "display_name": "Samuel Gratzl" }, { "id": "https://openalex.org/A5040232424", "display_name": "Duy Do" }, { "id": "https://openalex.org/A5016459438", "display_name": "Brianna M Goodwin Cartwright" }, { "id": "https://openalex.org/A5045037086", "display_name": "Charlotte Baker" }, { "id": "https://openalex.org/A5080450969", "display_name": "Ty J. Gluckman" }, { "id": "https://openalex.org/A5058087088", "display_name": "Nicholas L Stucky" }, { "id": "https://openalex.org/A5012567636", "display_name": "Ezekiel Emanuel" } ] }, { "id": "https://openalex.org/W4306155811", "doi": "https://doi.org/10.3389/fendo.2022.1004044", "title": "Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity", "abstract": { "Incretin-based": [ 0 ], "therapies": [ 1 ], "with": [ 2 ], "glucagon-like": [ 3 ], "peptide-1": [ 4 ], "receptor": [ 5 ], "agonists": [ 6, 26, 65 ], "(GLP-1RA)": [ 7 ], "are": [ 8 ], "already": [ 9 ], "established": [ 10 ], "in": [ 11, 75, 83, 102, 123, 130, 153, 167, 194 ], "the": [ 12, 30, 39, 84, 91, 112, 117, 124, 141, 178, 184, 195 ], "treatment": [ 13, 85, 113, 196 ], "of": [ 14, 21, 77, 86, 114, 197, 203 ], "type": [ 15 ], "2": [ 16 ], "diabetes": [ 17 ], "(T2D).": [ 18 ], "The": [ 19, 105 ], "development": [ 20 ], "novel": [ 22 ], "dual-": [ 23 ], "or": [ 24, 80 ], "triple-receptor": [ 25, 64 ], "that": [ 27 ], "bind": [ 28 ], "to": [ 29, 38, 50, 149, 163 ], "receptors": [ 31, 40, 69 ], "not": [ 32 ], "only": [ 33 ], "for": [ 34, 41, 55, 94, 111, 126, 192 ], "GLP-1": [ 35 ], "but": [ 36 ], "also": [ 37 ], "glucose-dependent": [ 42 ], "insulinotropic": [ 43 ], "polypeptide": [ 44 ], "(GIP)": [ 45 ], "and/or": [ 46 ], "glucagon": [ 47 ], "is": [ 48 ], "intended": [ 49 ], "address": [ 51 ], "different": [ 52, 68 ], "metabolic": [ 53 ], "pathways": [ 54, 72 ], "carbohydrate,": [ 56 ], "lipid,": [ 57 ], "and": [ 58, 63, 70, 88, 119, 133, 156, 159, 183, 187, 199 ], "protein": [ 59 ], "metabolism": [ 60 ], "simultaneously.": [ 61 ], "Dual-": [ 62 ], "acting": [ 66 ], "via": [ 67 ], "postreceptor": [ 71 ], "seem": [ 73 ], "attractive": [ 74 ], "view": [ 76 ], "potentially": [ 78, 200 ], "additive": [ 79 ], "synergistic": [ 81 ], "effects": [ 82, 166 ], "T2D": [ 87, 115 ], "obesity.": [ 89 ], "Recently,": [ 90 ], "first": [ 92 ], "approval": [ 93 ], "a": [ 95, 137 ], "dual-receptor": [ 96 ], "agonist": [ 97, 107 ], "marks": [ 98 ], "an": [ 99 ], "important": [ 100 ], "step": [ 101 ], "this": [ 103 ], "development.": [ 104 ], "GIP/GLP-1-receptor": [ 106 ], "tirzepatide": [ 108, 193 ], "was": [ 109 ], "approved": [ 110 ], "by": [ 116 ], "Food": [ 118 ], "Drug": [ 120 ], "Administration": [ 121 ], "(FDA)": [ 122 ], "USA": [ 125 ], "once-weekly": [ 127 ], "subcutaneous": [ 128 ], "injections": [ 129 ], "May": [ 131 ], "2022": [ 132 ], "has": [ 134, 160 ], "just": [ 135 ], "received": [ 136 ], "positive": [ 138 ], "opinion": [ 139 ], "from": [ 140 ], "European": [ 142 ], "Medicines": [ 143 ], "Agency": [ 144 ], "(EMA).": [ 145 ], "Tirzepatide": [ 146 ], "dose-dependently": [ 147 ], "leads": [ 148 ], "clinically": [ 150 ], "significant": [ 151 ], "reductions": [ 152 ], "glycemic": [ 154 ], "parameters": [ 155, 170 ], "body": [ 157 ], "weight": [ 158 ], "been": [ 161 ], "shown": [ 162 ], "have": [ 164 ], "stronger": [ 165 ], "reducing": [ 168 ], "these": [ 169 ], "than": [ 171 ], "standard": [ 172 ], "antidiabetic": [ 173 ], "therapy.": [ 174 ], "This": [ 175 ], "article": [ 176 ], "summarizes": [ 177 ], "current": [ 179 ], "clinical": [ 180 ], "study": [ 181 ], "program": [ 182 ], "respective": [ 185 ], "outcomes": [ 186 ], "highlights": [ 188 ], "further": [ 189 ], "potential": [ 190 ], "indications": [ 191 ], "obesity": [ 198 ], "other": [ 201 ], "comorbidities": [ 202 ], "T2D.": [ 204 ] }, "publication_date": "2022-10-13", "publication_year": 2022, "type": "review", "cited_by_count": 62, "authors": [ { "id": "https://openalex.org/A5031742996", "display_name": "Baptist Gallwitz" } ] }, { "id": "https://openalex.org/W1969181381", "doi": "https://doi.org/10.1111/j.1463-1326.2010.01330.x", "title": "Liraglutide \u2013 overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes", "abstract": { "Type": [ 0 ], "2": [ 1 ], "diabetes": [ 2, 14, 50 ], "is": [ 3, 119 ], "characterized": [ 4 ], "by": [ 5 ], "a": [ 6, 42, 89, 125 ], "progressive": [ 7 ], "decline": [ 8 ], "in": [ 9, 137 ], "glycaemic": [ 10, 22, 104 ], "control.": [ 11 ], "Many": [ 12 ], "standard": [ 13 ], "treatments,": [ 15 ], "however,": [ 16 ], "fail": [ 17 ], "to": [ 18, 45, 79, 102 ], "achieve": [ 19 ], "or": [ 20 ], "maintain": [ 21 ], "control,": [ 23 ], "and": [ 24, 34, 66, 68, 74, 84, 114, 140 ], "are": [ 25, 41, 57 ], "often": [ 26 ], "associated": [ 27 ], "with": [ 28, 106, 124 ], "an": [ 29 ], "increased": [ 30 ], "risk": [ 31, 127 ], "of": [ 32, 49, 54, 87, 128 ], "hypoglycaemia": [ 33 ], "weight": [ 35 ], "gain.": [ 36 ], "Recently": [ 37 ], "developed": [ 38 ], "incretin\u2010based": [ 39, 55 ], "therapies": [ 40, 56 ], "promising": [ 43 ], "addition": [ 44 ], "the": [ 46, 81, 141 ], "current": [ 47 ], "armamentarium": [ 48 ], "treatments.": [ 51 ], "Two": [ 52 ], "types": [ 53 ], "currently": [ 58 ], "available:": [ 59 ], "glucagon\u2010like": [ 60 ], "peptide": [ 61 ], "(GLP)\u20101": [ 62 ], "receptor": [ 63 ], "agonists": [ 64 ], "(liraglutide": [ 65 ], "exenatide)": [ 67 ], "dipeptidyl": [ 69 ], "peptidase\u20104": [ 70 ], "inhibitors": [ 71 ], "(sitaglipin,": [ 72 ], "vildagliptin": [ 73 ], "saxagliptin).": [ 75 ], "This": [ 76 ], "review": [ 77 ], "aims": [ 78 ], "summarize": [ 80 ], "key": [ 82 ], "efficacy": [ 83 ], "safety": [ 85 ], "data": [ 86 ], "liraglutide,": [ 88 ], "once\u2010daily": [ 90 ], "human": [ 91 ], "GLP\u20101": [ 92 ], "analogue.": [ 93 ], "Extensive": [ 94 ], "phase": [ 95 ], "III": [ 96 ], "clinical": [ 97 ], "trials": [ 98 ], "have": [ 99 ], "shown": [ 100 ], "liraglutide": [ 101 ], "improve": [ 103 ], "control": [ 105 ], "additional": [ 107 ], "benefits": [ 108 ], "on": [ 109 ], "body": [ 110 ], "weight,": [ 111 ], "blood": [ 112 ], "pressure": [ 113 ], "\u03b2": [ 115 ], "\u2010cell": [ 116 ], "function.": [ 117 ], "Liraglutide": [ 118, 130 ], "also": [ 120 ], "generally": [ 121 ], "well": [ 122 ], "tolerated": [ 123 ], "low": [ 126 ], "hypoglycaemia.": [ 129 ], "has": [ 131 ], "recently": [ 132 ], "been": [ 133 ], "approved": [ 134 ], "for": [ 135 ], "marketing": [ 136 ], "Europe,": [ 138 ], "Japan": [ 139 ], "USA.": [ 142 ] }, "publication_date": "2010-11-18", "publication_year": 2010, "type": "review", "cited_by_count": 66, "authors": [ { "id": "https://openalex.org/A5084593004", "display_name": "Melanie J. Davies" }, { "id": "https://openalex.org/A5069551723", "display_name": "Ram Kela" }, { "id": "https://openalex.org/A5083222970", "display_name": "Kamlesh Khunti" } ] }, { "id": "https://openalex.org/W2108365604", "doi": "https://doi.org/10.2337/db14-0302", "title": "GLP-1 Agonism Stimulates Brown Adipose Tissue Thermogenesis and Browning Through Hypothalamic AMPK", "abstract": { "GLP-1": [ 0, 18 ], "receptor": [ 1 ], "(GLP-1R)": [ 2 ], "is": [ 3, 71, 87 ], "widely": [ 4 ], "located": [ 5, 72 ], "throughout": [ 6 ], "the": [ 7, 10, 15, 29, 74, 80, 104, 117, 147, 152, 160, 165 ], "brain,": [ 8 ], "but": [ 9 ], "precise": [ 11 ], "molecular": [ 12 ], "mechanisms": [ 13, 190 ], "mediating": [ 14 ], "actions": [ 16, 70 ], "of": [ 17, 44, 63, 82, 107, 119, 162 ], "and": [ 19, 59, 79, 95, 141, 187 ], "its": [ 20 ], "long-acting": [ 21, 169 ], "analogs": [ 22 ], "on": [ 23 ], "adipose": [ 24, 55 ], "tissue": [ 25, 56 ], "as": [ 26, 28 ], "well": [ 27 ], "brain": [ 30 ], "areas": [ 31, 156 ], "responsible": [ 32 ], "for": [ 33, 133 ], "these": [ 34, 69, 189 ], "interactions": [ 35 ], "remain": [ 36 ], "largely": [ 37 ], "unknown.": [ 38 ], "We": [ 39 ], "found": [ 40 ], "that": [ 41, 154, 168, 188 ], "central": [ 42, 92, 105 ], "injection": [ 43, 106 ], "a": [ 45, 123 ], "clinically": [ 46, 193 ], "used": [ 47 ], "GLP-1R": [ 48, 137, 163, 170 ], "agonist,": [ 49 ], "liraglutide,": [ 50 ], "in": [ 51, 73, 84, 109 ], "mice": [ 52 ], "stimulates": [ 53 ], "brown": [ 54 ], "(BAT)": [ 57 ], "thermogenesis": [ 58, 94 ], "adipocyte": [ 60, 96 ], "browning": [ 61 ], "independent": [ 62 ], "nutrient": [ 64 ], "intake.": [ 65, 121 ], "The": [ 66, 98 ], "mechanism": [ 67 ], "controlling": [ 68 ], "hypothalamic": [ 75, 111, 185 ], "ventromedial": [ 76 ], "nucleus": [ 77 ], "(VMH),": [ 78 ], "activation": [ 81 ], "AMPK": [ 83 ], "this": [ 85 ], "area": [ 86 ], "sufficient": [ 88 ], "to": [ 89 ], "blunt": [ 90 ], "both": [ 91, 139 ], "liraglutide-induced": [ 93 ], "browning.": [ 97 ], "decreased": [ 99 ], "body": [ 100, 173 ], "weight": [ 101, 174 ], "caused": [ 102 ], "by": [ 103, 116, 175 ], "liraglutide": [ 108, 142 ], "other": [ 110 ], "sites": [ 112, 186 ], "was": [ 113 ], "sufficiently": [ 114 ], "explained": [ 115 ], "suppression": [ 118 ], "food": [ 120, 178 ], "In": [ 122 ], "longitudinal": [ 124 ], "study": [ 125 ], "involving": [ 126 ], "obese": [ 127 ], "type": [ 128 ], "2": [ 129 ], "diabetic": [ 130 ], "patients": [ 131 ], "treated": [ 132 ], "1": [ 134 ], "year": [ 135 ], "with": [ 136 ], "agonists,": [ 138, 164 ], "exenatide": [ 140 ], "increased": [ 143 ], "energy": [ 144, 181 ], "expenditure.": [ 145 ], "Although": [ 146 ], "results": [ 148 ], "do": [ 149 ], "not": [ 150 ], "exclude": [ 151 ], "possibility": [ 153 ], "extrahypothalamic": [ 155 ], "are": [ 157 ], "also": [ 158 ], "modulating": [ 159 ], "effects": [ 161 ], "data": [ 166 ], "indicate": [ 167 ], "agonists": [ 171 ], "influence": [ 172 ], "regulating": [ 176 ], "either": [ 177 ], "intake": [ 179 ], "or": [ 180 ], "expenditure": [ 182 ], "through": [ 183 ], "various": [ 184 ], "might": [ 191 ], "be": [ 192 ], "relevant.": [ 194 ] }, "publication_date": "2014-06-11", "publication_year": 2014, "type": "article", "cited_by_count": 547, "authors": [ { "id": "https://openalex.org/A5074391983", "display_name": "Daniel Beiroa" }, { "id": "https://openalex.org/A5053054124", "display_name": "M\u00f3nica Imbern\u00f3n" }, { "id": "https://openalex.org/A5012898265", "display_name": "Rosal\u0131\u0301a Gallego" }, { "id": "https://openalex.org/A5007802576", "display_name": "Ana Senra" }, { "id": "https://openalex.org/A5081724547", "display_name": "Daniel Herranz" }, { "id": "https://openalex.org/A5003437583", "display_name": "Francesc Villarroya" }, { "id": "https://openalex.org/A5061302501", "display_name": "Manuel Serrano" }, { "id": "https://openalex.org/A5043267458", "display_name": "Johan Fern\u00f8" }, { "id": "https://openalex.org/A5049387270", "display_name": "Javier Salvador" }, { "id": "https://openalex.org/A5065818509", "display_name": "Javier Escalada" }, { "id": "https://openalex.org/A5044168126", "display_name": "Carlos Di\u00e9guez" }, { "id": "https://openalex.org/A5100657656", "display_name": "Miguel L\u00f3pez" }, { "id": "https://openalex.org/A5016527523", "display_name": "Gema Fr\u00fchbeck" }, { "id": "https://openalex.org/A5020982137", "display_name": "Rub\u00e9n Nogueiras" } ] }, { "id": "https://openalex.org/W2607254478", "doi": "https://doi.org/10.1016/s1262-3636(17)30067-8", "title": "After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists?", "abstract": null, "publication_date": "2017-04-01", "publication_year": 2017, "type": "review", "cited_by_count": 40, "authors": [ { "id": "https://openalex.org/A5003323204", "display_name": "Bruno Verg\u00e8s" }, { "id": "https://openalex.org/A5025169113", "display_name": "B Charbonnel" } ] }, { "id": "https://openalex.org/W2142097676", "doi": "https://doi.org/10.2337/db09-1694", "title": "Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4", "abstract": { "OBJECTIVE": [ 0 ], "Exogenous": [ 1 ], "administration": [ 2 ], "of": [ 3, 34, 42, 46, 53, 66, 83, 99, 111, 132, 157, 166, 178, 182, 209, 242 ], "glucagon-like": [ 4 ], "peptide-1": [ 5 ], "(GLP-1)": [ 6 ], "or": [ 7, 74, 87, 195 ], "GLP-1": [ 8, 43, 216 ], "receptor": [ 9, 217 ], "agonists": [ 10, 218 ], "such": [ 11 ], "as": [ 12 ], "an": [ 13 ], "exendin-4": [ 14, 84, 112, 124, 161, 205 ], "has": [ 15 ], "direct": [ 16 ], "beneficial": [ 17 ], "effects": [ 18, 25, 41, 110 ], "on": [ 19, 26, 44, 48 ], "the": [ 20, 40, 49, 54, 97, 106, 130, 142, 149, 207, 223, 228, 240 ], "cardiovascular": [ 21 ], "system.": [ 22 ], "However,": [ 23 ], "their": [ 24 ], "atherosclerogenesis": [ 27 ], "have": [ 28 ], "not": [ 29 ], "been": [ 30 ], "elucidated.": [ 31 ], "The": [ 32, 109 ], "aim": [ 33 ], "this": [ 35, 235 ], "study": [ 36 ], "was": [ 37, 187 ], "to": [ 38, 96, 148, 239 ], "investigate": [ 39 ], "accumulation": [ 45, 221 ], "monocytes/macrophages": [ 47 ], "vascular": [ 50 ], "wall,": [ 51 ], "one": [ 52 ], "earliest": [ 55 ], "steps": [ 56 ], "in": [ 57, 85, 115, 129, 222, 231 ], "atherosclerogenesis.": [ 58, 153 ], "RESEARCH": [ 59 ], "DESIGN": [ 60 ], "AND": [ 61 ], "METHODS": [ 62 ], "After": [ 63 ], "continuous": [ 64 ], "infusion": [ 65 ], "low": [ 67 ], "(300": [ 68 ], "pmol": [ 69 ], "\u00b7": [ 70, 72, 78, 80 ], "kg\u22121": [ 71, 79 ], "day\u22121)": [ 73, 81 ], "high": [ 75 ], "(24": [ 76 ], "nmol": [ 77 ], "dose": [ 82 ], "C57BL/6": [ 86, 133 ], "apolipoprotein": [ 88 ], "E\u2013deficient": [ 89 ], "mice": [ 90, 134 ], "(apoE\u2212/\u2212),": [ 91 ], "we": [ 92 ], "evaluated": [ 93 ], "monocyte": [ 94, 146, 171 ], "adhesion": [ 95, 128, 147 ], "endothelia": [ 98 ], "thoracic": [ 100 ], "aorta": [ 101 ], "and": [ 102, 118, 151, 170, 174, 233 ], "arteriosclerotic": [ 103 ], "lesions": [ 104 ], "around": [ 105 ], "aortic": [ 107 ], "valve.": [ 108 ], "were": [ 113 ], "investigated": [ 114 ], "mouse": [ 116, 158 ], "macrophages": [ 117, 159 ], "human": [ 119, 203 ], "monocytes.": [ 120 ], "RESULTS": [ 121 ], "Treatment": [ 122 ], "with": [ 123, 160 ], "significantly": [ 125 ], "inhibited": [ 126 ], "monocytic": [ 127 ], "aortas": [ 131 ], "without": [ 135 ], "affecting": [ 136 ], "metabolic": [ 137 ], "parameters.": [ 138 ], "In": [ 139, 154, 202 ], "apoE\u2212/\u2212": [ 140 ], "mice,": [ 141 ], "same": [ 143 ], "treatment": [ 144, 156 ], "reduced": [ 145, 206, 219 ], "endothelium": [ 150 ], "suppressed": [ 152, 162, 175 ], "vitro": [ 155 ], "lipopolysaccharide-induced": [ 163 ], "mRNA": [ 164 ], "expression": [ 165, 208 ], "tumor": [ 167 ], "necrosis": [ 168 ], "factor-\u03b1": [ 169 ], "chemoattractant": [ 172 ], "protein-1,": [ 173 ], "nuclear": [ 176, 183 ], "translocation": [ 177 ], "p65,": [ 179 ], "a": [ 180, 192, 197 ], "component": [ 181 ], "factor-\u03baB.": [ 184 ], "This": [ 185 ], "effect": [ 186, 236 ], "reversed": [ 188 ], "by": [ 189, 226, 245 ], "either": [ 190 ], "MDL-12330A,": [ 191 ], "cAMP": [ 193 ], "inhibitor": [ 194 ], "PKI14-22,": [ 196 ], "protein": [ 198 ], "kinase": [ 199 ], "A\u2013specific": [ 200 ], "inhibitor.": [ 201 ], "monocytes,": [ 204 ], "CD11b.": [ 210 ], "CONCLUSIONS": [ 211 ], "Our": [ 212 ], "data": [ 213 ], "suggested": [ 214 ], "that": [ 215, 234 ], "monocyte/macrophage": [ 220 ], "arterial": [ 224 ], "wall": [ 225 ], "inhibiting": [ 227 ], "inflammatory": [ 229 ], "response": [ 230 ], "macrophages,": [ 232 ], "may": [ 237 ], "contribute": [ 238 ], "attenuation": [ 241 ], "atherosclerotic": [ 243 ], "lesion": [ 244 ], "exendin-4.": [ 246 ] }, "publication_date": "2010-01-12", "publication_year": 2010, "type": "article", "cited_by_count": 514, "authors": [ { "id": "https://openalex.org/A5110386030", "display_name": "Masayuki Arakawa" }, { "id": "https://openalex.org/A5070216766", "display_name": "Tomoya Mita" }, { "id": "https://openalex.org/A5074285902", "display_name": "Kosuke Azuma" }, { "id": "https://openalex.org/A5063296671", "display_name": "Chie Ebato" }, { "id": "https://openalex.org/A5103807166", "display_name": "Hiromasa Goto" }, { "id": "https://openalex.org/A5073875461", "display_name": "Takashi Nomiyama" }, { "id": "https://openalex.org/A5027831207", "display_name": "Yoshio Fujitani" }, { "id": "https://openalex.org/A5109490627", "display_name": "Takahisa Hirose" }, { "id": "https://openalex.org/A5032317621", "display_name": "Ryuzo Kawamori" }, { "id": "https://openalex.org/A5043895658", "display_name": "Hirotaka Watada" } ] }, { "id": "https://openalex.org/W4292242922", "doi": "https://doi.org/10.1016/j.cmet.2022.07.013", "title": "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept", "abstract": null, "publication_date": "2022-08-18", "publication_year": 2022, "type": "article", "cited_by_count": 229, "authors": [ { "id": "https://openalex.org/A5054260296", "display_name": "Tamer Co\u015fkun" }, { "id": "https://openalex.org/A5031510744", "display_name": "Shweta Urva" }, { "id": "https://openalex.org/A5040082320", "display_name": "William C. Roell" }, { "id": "https://openalex.org/A5079894417", "display_name": "Hongchang Qu" }, { "id": "https://openalex.org/A5030999700", "display_name": "Corina Loghin" }, { "id": "https://openalex.org/A5001702290", "display_name": "Julie S. Moyers" }, { "id": "https://openalex.org/A5075599028", "display_name": "Libbey S. O\u2019Farrell" }, { "id": "https://openalex.org/A5046834158", "display_name": "Daniel A. Briere" }, { "id": "https://openalex.org/A5068951024", "display_name": "Kyle W. Sloop" }, { "id": "https://openalex.org/A5013110210", "display_name": "Melissa K. Thomas" }, { "id": "https://openalex.org/A5059515011", "display_name": "Valentina Pirro" }, { "id": "https://openalex.org/A5071637884", "display_name": "David B. Wainscott" }, { "id": "https://openalex.org/A5083011492", "display_name": "Francis S. Willard" }, { "id": "https://openalex.org/A5103699142", "display_name": "Matthew Abernathy" }, { "id": "https://openalex.org/A5050841742", "display_name": "LaRonda L. Morford" }, { "id": "https://openalex.org/A5076543480", "display_name": "Yu Du" }, { "id": "https://openalex.org/A5023603655", "display_name": "Charles Benson" }, { "id": "https://openalex.org/A5064772594", "display_name": "Ruth E. Gimeno" }, { "id": "https://openalex.org/A5040811419", "display_name": "Axel Haupt" }, { "id": "https://openalex.org/A5024563374", "display_name": "Zvonko Mili\u010devi\u0107" } ] }, { "id": "https://openalex.org/W2161155577", "doi": "https://doi.org/10.1371/journal.pone.0126003", "title": "Liraglutide Improves Pancreatic Beta Cell Mass and Function in Alloxan-Induced Diabetic Mice", "abstract": { "Glucagon-like": [ 0 ], "peptide-1": [ 1 ], "(GLP-1)": [ 2 ], "receptor": [ 3, 32 ], "agonists": [ 4, 33 ], "potentiate": [ 5 ], "glucose-induced": [ 6 ], "insulin": [ 7, 93, 105 ], "secretion.": [ 8, 94 ], "In": [ 9, 208 ], "addition,": [ 10 ], "they": [ 11 ], "have": [ 12 ], "been": [ 13 ], "reported": [ 14 ], "to": [ 15, 36, 107, 154, 173 ], "increase": [ 16, 175 ], "pancreatic": [ 17, 61, 122, 135, 185 ], "beta": [ 18, 51, 62, 82, 123, 136, 140, 152, 156, 177, 217 ], "cell": [ 19, 52, 63, 83, 178, 218 ], "mass": [ 20, 84, 120, 219 ], "in": [ 21, 81, 116, 127, 176, 184, 198, 222 ], "diabetic": [ 22, 68, 190, 224 ], "rodents.": [ 23 ], "However,": [ 24, 146 ], "the": [ 25, 42, 45, 147, 174, 193 ], "precise": [ 26 ], "mode": [ 27 ], "of": [ 28, 30, 44, 121, 134, 150, 171, 188, 196 ], "action": [ 29 ], "GLP-1": [ 31, 47 ], "still": [ 34 ], "needs": [ 35 ], "be": [ 37 ], "elucidated.": [ 38 ], "Here": [ 39 ], "we": [ 40 ], "clarify": [ 41 ], "effects": [ 43, 195 ], "human": [ 46 ], "analog": [ 48 ], "liraglutide": [ 49, 99, 114, 164, 197, 211 ], "on": [ 50 ], "fate": [ 53 ], "and": [ 54, 66, 92, 104, 138, 162, 220 ], "function": [ 55, 221 ], "by": [ 56, 215 ], "using": [ 57 ], "an": [ 58 ], "inducible": [ 59 ], "Cre/loxP-based": [ 60 ], "tracing": [ 64 ], "system": [ 65 ], "alloxan-induced": [ 67, 189, 223 ], "mice.": [ 69, 191, 225 ], "Liraglutide": [ 70, 130, 180 ], "was": [ 71, 158 ], "subcutaneously": [ 72 ], "administered": [ 73 ], "once": [ 74 ], "daily": [ 75 ], "for": [ 76 ], "30": [ 77 ], "days.": [ 78 ], "The": [ 79 ], "changes": [ 80 ], "were": [ 85, 201 ], "examined": [ 86 ], "as": [ 87, 89 ], "well": [ 88 ], "glucose": [ 90, 102, 109 ], "tolerance": [ 91, 103 ], "We": [ 95 ], "found": [ 96 ], "that": [ 97, 126 ], "chronic": [ 98, 210 ], "treatment": [ 100, 112, 212 ], "improved": [ 101 ], "response": [ 106 ], "oral": [ 108 ], "load.": [ 110 ], "Thirty-day": [ 111 ], "with": [ 113 ], "resulted": [ 115 ], "a": [ 117 ], "2-fold": [ 118 ], "higher": [ 119 ], "cells": [ 124, 137, 141, 144, 153, 157, 187 ], "than": [ 125 ], "vehicle": [ 128 ], "group.": [ 129 ], "increased": [ 131 ], "proliferation": [ 132 ], "rate": [ 133 ], "prevented": [ 139 ], "from": [ 142 ], "apoptotic": [ 143 ], "death.": [ 145 ], "relative": [ 148 ], "abundance": [ 149 ], "YFP-labeled": [ 151 ], "total": [ 155 ], "no": [ 159, 167 ], "different": [ 160 ], "before": [ 161 ], "after": [ 163, 205 ], "treatment,": [ 165 ], "suggesting": [ 166 ], "or": [ 168 ], "little": [ 169 ], "contribution": [ 170 ], "neogenesis": [ 172 ], "mass.": [ 179 ], "reduced": [ 181 ], "oxidative": [ 182 ], "stress": [ 183 ], "islet": [ 186 ], "Furthermore,": [ 192 ], "beneficial": [ 194 ], "these": [ 199 ], "mice": [ 200 ], "maintained": [ 202 ], "two": [ 203 ], "weeks": [ 204 ], "drug": [ 206 ], "withdrawal.": [ 207 ], "conclusion,": [ 209 ], "improves": [ 213 ], "hyperglycemia": [ 214 ], "ameliorating": [ 216 ] }, "publication_date": "2015-05-04", "publication_year": 2015, "type": "article", "cited_by_count": 65, "authors": [ { "id": "https://openalex.org/A5110266194", "display_name": "Kanako Tamura" }, { "id": "https://openalex.org/A5102990852", "display_name": "Kohtaro Minami" }, { "id": "https://openalex.org/A5083115944", "display_name": "Maya Kudo" }, { "id": "https://openalex.org/A5076331397", "display_name": "Keisuke Iemoto" }, { "id": "https://openalex.org/A5064131880", "display_name": "Harumi Takahashi" }, { "id": "https://openalex.org/A5046353080", "display_name": "Susumu Seino" } ] }, { "id": "https://openalex.org/W4220949041", "doi": "https://doi.org/10.1111/dom.14700", "title": "Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease", "abstract": { "Abstract": [ 0 ], "Aim": [ 1 ], "To": [ 2 ], "evaluate": [ 3 ], "the": [ 4, 83 ], "cardiovascular": [ 5 ], "(CV)": [ 6 ], "efficacy": [ 7, 226 ], "of": [ 8, 67, 85, 115, 139, 228 ], "liraglutide": [ 9, 34, 179, 218 ], "and": [ 10, 19, 25, 28, 37, 50, 57, 96, 160, 180, 219 ], "semaglutide": [ 11, 38, 220 ], "in": [ 12, 46, 94, 99, 147, 191 ], "patients": [ 13, 47, 93, 148, 192 ], "with": [ 14, 48, 107, 149, 193, 223 ], "type": [ 15 ], "2": [ 16 ], "diabetes": [ 17 ], "(T2D)": [ 18 ], "peripheral": [ 20 ], "artery": [ 21 ], "disease": [ 22 ], "(PAD).": [ 23 ], "Materials": [ 24 ], "Methods": [ 26 ], "LEADER": [ 27, 95 ], "SUSTAIN": [ 29, 100, 130 ], "6": [ 30, 101 ], "trials": [ 31 ], "investigated": [ 32 ], "subcutaneous": [ 33 ], "(\u22641.8": [ 35 ], "mg/day)": [ 36 ], "(0.5": [ 39 ], "or": [ 40, 73 ], "1.0": [ 41 ], "mg/week),": [ 42 ], "respectively,": [ 43 ], "versus": [ 44, 117, 205 ], "placebo": [ 45 ], "T2D": [ 49 ], "high": [ 51 ], "CV": [ 52, 68, 78, 225 ], "risk": [ 53, 114, 185 ], "(median": [ 54 ], "follow\u2010up:": [ 55 ], "3.8": [ 56 ], "2.1": [ 58 ], "years,": [ 59 ], "respectively).": [ 60 ], "The": [ 61, 137 ], "primary": [ 62 ], "outcome": [ 63 ], "was": [ 64 ], "a": [ 65 ], "composite": [ 66 ], "death,": [ 69 ], "non\u2010fatal": [ 70, 74 ], "myocardial": [ 71 ], "infarction": [ 72 ], "stroke": [ 75 ], "(major": [ 76 ], "adverse": [ 77 ], "event": [ 79 ], "[MACE])": [ 80 ], "according": [ 81 ], "to": [ 82 ], "presence": [ 84 ], "PAD": [ 86, 103, 108, 150, 194, 229 ], "at": [ 87, 104, 110 ], "baseline.": [ 88, 105 ], "Results": [ 89 ], "Overall,": [ 90 ], "1184/9340": [ 91 ], "(12.7%)": [ 92 ], "460/3297": [ 97 ], "(14.0%)": [ 98 ], "had": [ 102 ], "Patients": [ 106 ], "were": [ 109, 144, 189 ], "an": [ 111 ], "~35%": [ 112 ], "increased": [ 113 ], "MACE": [ 116, 143, 188, 222 ], "those": [ 118 ], "without": [ 119, 161, 206 ], "(LEADER:": [ 120 ], "hazard": [ 121 ], "ratio": [ 122 ], "[HR]": [ 123 ], "1.36,": [ 124 ], "95%": [ 125, 134, 154, 165, 171, 197, 202, 208, 213 ], "confidence": [ 126 ], "interval": [ 127 ], "[CI]": [ 128 ], "1.17\u20101.58;": [ 129 ], "6:": [ 131 ], "HR": [ 132, 152, 163, 169 ], "1.33,": [ 133 ], "CI": [ 135, 155, 166, 172, 198, 203, 209, 214 ], "0.94\u20101.83).": [ 136 ], "effects": [ 138 ], "both": [ 140 ], "therapies": [ 141 ], "on": [ 142 ], "consistently": [ 145 ], "beneficial": [ 146 ], "(liraglutide:": [ 151, 162, 195 ], "0.77,": [ 153, 170 ], "0.58\u20101.01;": [ 156, 173 ], "semaglutide:": [ 157, 168, 200, 211 ], "0.61,": [ 158 ], "0.33\u20101.13)": [ 159 ], "0.89,": [ 164 ], "0.79\u20101.00;": [ 167 ], "P": [ 174 ], "interaction": [ 175 ], "=": [ 176 ], ".34": [ 177 ], "for": [ 178, 182, 187 ], ".49": [ 181 ], "semaglutide).": [ 183 ], "Absolute": [ 184 ], "reductions": [ 186 ], "higher": [ 190 ], "4.13%\u2010point,": [ 196 ], "\u22120.15\u20108.42;": [ 199 ], "4.63%\u2010point,": [ 201 ], "\u22120.58\u20109.84)": [ 204 ], "(liraglutide:1.42%\u2010point,": [ 207 ], "\u22120.03\u20102.87;": [ 210 ], "1.90%\u2010point,": [ 212 ], "0.00\u20103.80).": [ 215 ], "Conclusion": [ 216 ], "Both": [ 217 ], "reduce": [ 221 ], "consistent": [ 224 ], "regardless": [ 227 ], "status.": [ 230 ] }, "publication_date": "2022-03-25", "publication_year": 2022, "type": "article", "cited_by_count": 47, "authors": [ { "id": "https://openalex.org/A5080334509", "display_name": "Subodh Verma" }, { "id": "https://openalex.org/A5102839331", "display_name": "Mohammed Al\u2010Omran" }, { "id": "https://openalex.org/A5080414941", "display_name": "Lawrence A. Leiter" }, { "id": "https://openalex.org/A5041840962", "display_name": "C. David Mazer" }, { "id": "https://openalex.org/A5110231477", "display_name": "S\u00f8ren Rasmussen" }, { "id": "https://openalex.org/A5085775549", "display_name": "Hans A. Saevereid" }, { "id": "https://openalex.org/A5078101576", "display_name": "Maria Sejersten Ripa" }, { "id": "https://openalex.org/A5090903599", "display_name": "Marc P. Bonaca" } ] }, { "id": "https://openalex.org/W2099903872", "doi": "https://doi.org/10.2337/dc09-2062", "title": "Weight Loss, Glycemic Control, and Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort Database", "abstract": { "OBJECTIVE": [ 0 ], "Weight": [ 1, 200, 224 ], "loss": [ 2, 28, 75, 180, 201 ], "in": [ 3, 81, 86, 143, 184, 194, 207, 210, 219, 250, 256, 259 ], "patients": [ 4, 87, 134, 147, 159, 167, 260 ], "with": [ 5, 26, 88, 94, 188, 204, 216, 226, 232, 261 ], "type": [ 6, 89, 262 ], "2": [ 7, 90, 263 ], "diabetes": [ 8, 91 ], "can": [ 9 ], "improve": [ 10, 17 ], "glycemic": [ 11, 77 ], "control,": [ 12 ], "lower": [ 13 ], "blood": [ 14, 82, 112, 115, 195 ], "pressure,": [ 15, 116 ], "and": [ 16, 29, 76, 79, 84, 100, 118, 121, 132, 165, 181, 186, 191 ], "dyslipidemia.": [ 18 ], "Glucagon-like": [ 19 ], "peptide": [ 20 ], "(GLP-1)": [ 21 ], "receptor": [ 22, 213, 228 ], "agonists": [ 23, 229 ], "are": [ 24, 244 ], "associated": [ 25, 203, 231 ], "weight": [ 27, 74, 179 ], "have": [ 30 ], "potentially": [ 31 ], "beneficial": [ 32 ], "effects": [ 33, 47 ], "on": [ 34 ], "cardiovascular": [ 35, 239, 257 ], "risk": [ 36, 240 ], "biomarkers;": [ 37 ], "however,": [ 38 ], "there": [ 39 ], "is": [ 40 ], "limited": [ 41 ], "information": [ 42 ], "to": [ 43, 69, 246 ], "indicate": [ 44 ], "whether": [ 45, 248 ], "these": [ 46 ], "remain": [ 48 ], "outside": [ 49 ], "of": [ 50, 129, 153 ], "clinical": [ 51 ], "trials.": [ 52 ], "RESEARCH": [ 53 ], "DESIGN": [ 54 ], "AND": [ 55 ], "METHODS": [ 56 ], "Medical": [ 57 ], "records": [ 58 ], "from": [ 59 ], "the": [ 60, 71, 105, 144, 211, 220 ], "General": [ 61 ], "Electric": [ 62 ], "Centricity": [ 63 ], "research": [ 64 ], "database": [ 65 ], "were": [ 66, 124, 141 ], "analyzed": [ 67 ], "retrospectively": [ 68 ], "evaluate": [ 70 ], "relationship": [ 72 ], "between": [ 73, 178 ], "control": [ 78 ], "changes": [ 80 ], "pressure": [ 83, 196 ], "lipids": [ 85 ], "initiating": [ 92 ], "therapy": [ 93 ], "exenatide,": [ 95, 136 ], "sitagliptin,": [ 96, 137 ], "or": [ 97, 138 ], "insulin.": [ 98 ], "Baseline": [ 99 ], "follow-up": [ 101 ], "(90\u2013365": [ 102 ], "days": [ 103 ], "after": [ 104 ], "index": [ 106 ], "date)": [ 107 ], "for": [ 108, 197 ], "weight,": [ 109 ], "A1C,": [ 110 ], "fasting": [ 111 ], "glucose": [ 113 ], "(FBG),": [ 114 ], "triglycerides,": [ 117 ], "LDL,": [ 119 ], "HDL,": [ 120 ], "total": [ 122, 128 ], "cholesterol": [ 123 ], "assessed.": [ 125 ], "RESULTS": [ 126 ], "A": [ 127 ], "6,280,": [ 130 ], "5,861,": [ 131 ], "32,398": [ 133 ], "receiving": [ 135 ], "insulin,": [ 139 ], "respectively,": [ 140 ], "included": [ 142 ], "analysis.": [ 145 ], "Exenatide-treated": [ 146 ], "lost": [ 148, 160 ], "a": [ 149, 175, 182, 192, 233, 236, 254 ], "mean": [ 150 ], "\u00b1": [ 151, 155, 162, 170 ], "SD": [ 152 ], "3.0": [ 154 ], "7.33": [ 156 ], "kg,": [ 157, 164 ], "sitagliptin-treated": [ 158 ], "1.1": [ 161 ], "5.39": [ 163 ], "insulin-treated": [ 166 ], "gained": [ 168 ], "0.6": [ 169 ], "9.49": [ 171 ], "kg.": [ 172 ], "There": [ 173 ], "was": [ 174, 202, 230 ], "significant": [ 176 ], "association": [ 177, 218 ], "reduction": [ 183, 193, 225, 255 ], "A1C": [ 185 ], "FBG": [ 187 ], "exenatide": [ 189 ], "only": [ 190 ], "all": [ 198 ], "therapies.": [ 199 ], "some": [ 205 ], "improvements": [ 206 ], "lipids,": [ 208 ], "primarily": [ 209 ], "GLP-1": [ 212, 227 ], "agonist": [ 214 ], "group,": [ 215 ], "little": [ 217 ], "insulin": [ 221 ], "group.": [ 222 ], "CONCLUSIONS": [ 223 ], "shift": [ 234 ], "toward": [ 235 ], "more": [ 237 ], "favorable": [ 238 ], "profile.": [ 241 ], "Outcome": [ 242 ], "trials": [ 243 ], "needed": [ 245 ], "determine": [ 247 ], "improvement": [ 249 ], "biomarkers": [ 251 ], "translates": [ 252 ], "into": [ 253 ], "events": [ 258 ], "diabetes.": [ 264 ] }, "publication_date": "2010-05-11", "publication_year": 2010, "type": "article", "cited_by_count": 152, "authors": [ { "id": "https://openalex.org/A5069336249", "display_name": "Edward S. Horton" }, { "id": "https://openalex.org/A5108155995", "display_name": "Cheryl Silberman" }, { "id": "https://openalex.org/A5000219240", "display_name": "Keith L. Davis" }, { "id": "https://openalex.org/A5046249009", "display_name": "Rachele Berria" } ] }, { "id": "https://openalex.org/W4311850409", "doi": "https://doi.org/10.3389/fimmu.2022.997578", "title": "GLP-1 receptor agonist as a modulator of innate immunity", "abstract": { "Glucagon-like": [ 0 ], "peptide-1": [ 1, 48 ], "(GLP-1)": [ 2 ], "is": [ 3, 106 ], "a": [ 4, 73, 114 ], "30-amino": [ 5 ], "acid": [ 6 ], "hormone": [ 7 ], "secreted": [ 8 ], "by": [ 9, 27, 60 ], "L": [ 10 ], "cells": [ 11 ], "in": [ 12, 23, 51, 90, 95, 113, 133 ], "the": [ 13, 46, 52, 56, 96, 120, 125 ], "distal": [ 14 ], "ileum,": [ 15 ], "colon,": [ 16 ], "and": [ 17, 39, 65, 67, 83, 92, 130, 135 ], "pancreatic": [ 18, 61 ], "\u03b1": [ 19 ], "cells,": [ 20 ], "which": [ 21 ], "participates": [ 22 ], "blood": [ 24 ], "sugar": [ 25 ], "regulation": [ 26 ], "promoting": [ 28, 63 ], "insulin": [ 29, 59 ], "release,": [ 30 ], "reducing": [ 31, 40 ], "glucagon": [ 32 ], "levels,": [ 33 ], "delaying": [ 34 ], "gastric": [ 35 ], "emptying,": [ 36 ], "increasing": [ 37 ], "satiety,": [ 38 ], "appetite.": [ 41 ], "GLP-1": [ 42, 82, 105, 129 ], "specifically": [ 43 ], "binds": [ 44 ], "to": [ 45, 108 ], "glucagon-like": [ 47 ], "receptor": [ 49 ], "(GLP-1R)": [ 50 ], "body,": [ 53 ], "directly": [ 54 ], "stimulating": [ 55 ], "secretion": [ 57 ], "of": [ 58, 81, 98, 116, 128 ], "\u03b2-cells,": [ 62 ], "proliferation": [ 64 ], "differentiation,": [ 66 ], "inhibiting": [ 68 ], "cell": [ 69 ], "apoptosis,": [ 70 ], "thereby": [ 71 ], "exerting": [ 72 ], "glycemic": [ 74, 78 ], "lowering": [ 75 ], "effect.": [ 76 ], "The": [ 77 ], "regulating": [ 79 ], "effect": [ 80 ], "its": [ 84, 131 ], "analogues": [ 85, 132 ], "has": [ 86 ], "been": [ 87 ], "well": [ 88 ], "studied": [ 89 ], "human": [ 91 ], "murine": [ 93 ], "models": [ 94 ], "circumstance": [ 97 ], "many": [ 99 ], "diseases.": [ 100, 118 ], "Recent": [ 101 ], "studies": [ 102 ], "found": [ 103 ], "that": [ 104 ], "able": [ 107 ], "modulate": [ 109 ], "innate": [ 110 ], "immune": [ 111 ], "response": [ 112 ], "number": [ 115 ], "inflammatory": [ 117 ], "In": [ 119 ], "present": [ 121 ], "review,": [ 122 ], "we": [ 123 ], "summarize": [ 124 ], "research": [ 126 ], "progression": [ 127 ], "immunomodulation": [ 134 ], "related": [ 136 ], "signal": [ 137 ], "pathways.": [ 138 ] }, "publication_date": "2022-12-08", "publication_year": 2022, "type": "review", "cited_by_count": 66, "authors": [ { "id": "https://openalex.org/A5100450228", "display_name": "Jun Chen" }, { "id": "https://openalex.org/A5026871706", "display_name": "Aihua Mei" }, { "id": "https://openalex.org/A5102987469", "display_name": "Yingying Wei" }, { "id": "https://openalex.org/A5100341692", "display_name": "Chunlei Li" }, { "id": "https://openalex.org/A5012714430", "display_name": "Hang Qian" }, { "id": "https://openalex.org/A5055758787", "display_name": "Xinwen Min" }, { "id": "https://openalex.org/A5101626561", "display_name": "Handong Yang" }, { "id": "https://openalex.org/A5046840576", "display_name": "Lingli Dong" }, { "id": "https://openalex.org/A5083282950", "display_name": "Xiaoquan Rao" }, { "id": "https://openalex.org/A5077862629", "display_name": "Jixin Zhong" } ] }, { "id": "https://openalex.org/W2107680428", "doi": "https://doi.org/10.3111/13696998.2010.529377", "title": "A comparison of preferences for two GLP-1 products \u2013 liraglutide and exenatide \u2013 for the treatment of type 2 diabetes", "abstract": { "Based": [ 0 ], "on": [ 1, 14 ], "the": [ 2 ], "four": [ 3 ], "attributes": [ 4 ], "presented,": [ 5 ], "patients": [ 6 ], "prefer": [ 7 ], "liraglutide": [ 8 ], "over": [ 9 ], "exenatide.": [ 10 ], "Preference": [ 11 ], "is": [ 12 ], "based": [ 13 ], "superior": [ 15 ], "efficacy": [ 16 ], "and": [ 17, 24 ], "less": [ 18, 22 ], "nausea": [ 19 ], "more": [ 20 ], "than": [ 21 ], "hypoglycemia": [ 23 ], "once-daily": [ 25 ], "dosing.": [ 26 ] }, "publication_date": "2010-11-01", "publication_year": 2010, "type": "article", "cited_by_count": 60, "authors": [ { "id": "https://openalex.org/A5017303016", "display_name": "Michael R. Polster" }, { "id": "https://openalex.org/A5075598801", "display_name": "Elaine Zanutto" }, { "id": "https://openalex.org/A5089629082", "display_name": "Susan McDonald" }, { "id": "https://openalex.org/A5111948661", "display_name": "Christopher S. Conner" }, { "id": "https://openalex.org/A5109998971", "display_name": "Mette Hammer" } ] }, { "id": "https://openalex.org/W2158762809", "doi": "https://doi.org/10.2337/dcs13-2004", "title": "Do GLP-1\u2013Based Therapies Increase Cancer Risk?", "abstract": { "Cases": [ 0 ], "of": [ 1, 11, 78, 92, 127, 177, 199, 251 ], "pancreatitis": [ 2, 257, 270, 286 ], "have": [ 3, 110, 236, 243 ], "been": [ 4, 30, 244 ], "described": [ 5 ], "in": [ 6, 49, 59, 71, 118, 135, 155, 175 ], "connection": [ 7 ], "with": [ 8, 36, 157, 162, 280 ], "the": [ 9, 26, 33, 50, 66, 76, 90, 125, 128, 133, 139, 148, 180, 187, 197, 247, 272 ], "use": [ 10 ], "exenatide": [ 12, 163, 239 ], "(1),": [ 13 ], "liraglutide": [ 14 ], "(2)": [ 15 ], "and": [ 16, 48, 63, 80, 89, 95, 137, 152, 164, 212, 225, 233, 240, 258 ], "other": [ 17, 194 ], "glucagon-like": [ 18 ], "peptide": [ 19 ], "(GLP)-1": [ 20 ], "receptor": [ 21, 35, 68, 206 ], "agonists.": [ 22 ], "From": [ 23 ], "these": [ 24, 102 ], "findings,": [ 25, 103 ], "following": [ 27 ], "hypothesis": [ 28, 140, 181 ], "has": [ 29, 39 ], "generated:": [ 31 ], "stimulating": [ 32, 65 ], "GLP-1": [ 34, 67, 205 ], "respective": [ 37 ], "agonists": [ 38, 207 ], "a": [ 40, 111 ], "potential": [ 41, 112 ], "to": [ 42, 113, 131 ], "cause": [ 43, 114, 256, 263 ], "pancreatitis,": [ 44, 47 ], "perhaps": [ 45 ], "chronic": [ 46, 269, 285 ], "long": [ 51 ], "term,": [ 52 ], "potentially": [ 53 ], "even": [ 54 ], "pancreatic": [ 55, 151, 264, 275 ], "cancer": [ 56, 145 ], "(3\u20135).": [ 57 ], "Furthermore,": [ 58 ], "rodents": [ 60 ], "like": [ 61 ], "mice": [ 62 ], "rats,": [ 64 ], "raises": [ 69 ], "cAMP": [ 70 ], "thyroid": [ 72, 116, 153 ], "C": [ 73 ], "cells,": [ 74 ], "initiates": [ 75 ], "release": [ 77 ], "calcitonin,": [ 79 ], "upon": [ 81 ], "longer-term": [ 82 ], "exposure,": [ 83 ], "is": [ 84, 124, 289 ], "accompanied": [ 85 ], "by": [ 86 ], "C-cell": [ 87, 93 ], "proliferation": [ 88 ], "formation": [ 91 ], "adenomas": [ 94 ], "(medullary": [ 96 ], "thyroid)": [ 97 ], "carcinomas": [ 98, 154 ], "(6).": [ 99 ], "Based": [ 100 ], "on": [ 101 ], "it": [ 104 ], "was": [ 105 ], "hypothesized": [ 106 ], "that": [ 107, 141, 182 ], "GLP-1\u2013derived": [ 108 ], "medications": [ 109, 184 ], "medullary": [ 115 ], "carcinoma": [ 117, 265, 276 ], "humans": [ 119 ], "as": [ 120, 209, 220 ], "well": [ 121 ], "(3,7).": [ 122 ], "It": [ 123 ], "purpose": [ 126, 198 ], "current": [ 129 ], "review": [ 130 ], "discuss": [ 132 ], "evidence": [ 134 ], "favor": [ 136, 176 ], "against": [ 138 ], "GLP-1\u2013based": [ 142, 202 ], "therapies": [ 143, 203 ], "increase": [ 144, 186 ], "risk,": [ 146 ], "specifically": [ 147, 237 ], "risk": [ 149, 188, 273 ], "for": [ 150, 189, 246, 274 ], "patients": [ 156 ], "type": [ 158 ], "2": [ 159 ], "diabetes": [ 160 ], "treated": [ 161 ], "sitagliptin.\n\nIn": [ 165 ], "principle,": [ 166 ], "there": [ 167 ], "could": [ 168 ], "be": [ 169 ], "weak": [ 170 ], "or": [ 171, 178, 193, 214 ], "strong": [ 172 ], "evidence,": [ 173 ], "either": [ 174 ], "against,": [ 179 ], "incretin-based": [ 183 ], "can": [ 185, 255, 262 ], "pancreatic,": [ 190 ], "(medullary)": [ 191 ], "thyroid,": [ 192 ], "carcinomas.": [ 195 ], "For": [ 196 ], "this": [ 200 ], "review,": [ 201 ], "are": [ 204, 266 ], "such": [ 208, 219 ], "exenatide,": [ 210 ], "liraglutide,": [ 211 ], "others": [ 213 ], "dipeptidyl": [ 215 ], "peptidase-4": [ 216 ], "(DPP-4)": [ 217 ], "inhibitors": [ 218 ], "sitagliptin,": [ 221, 241 ], "vildagliptin,": [ 222 ], "saxagliptin,": [ 223 ], "alogliptin,": [ 224 ], "linagliptin": [ 226 ], "(8).": [ 227 ], "However,": [ 228 ], "almost": [ 229 ], "all": [ 230 ], "available": [ 231, 245 ], "data": [ 232 ], "quoted": [ 234 ], "studies": [ 235 ], "examined": [ 238 ], "which": [ 242 ], "longest": [ 248 ], "time.\n\nThe": [ 249 ], "questions": [ 250 ], "whether": [ 252, 259 ], "certain": [ 253, 260 ], "drugs": [ 254, 261 ], "interrelated,": [ 267 ], "since": [ 268 ], "increases": [ 271 ], "approximately": [ 277 ], "26-fold": [ 278 ], "compared": [ 279 ], "subjects": [ 281 ], "not": [ 282 ], "suffering": [ 283 ], "from": [ 284 ], "(9).": [ 287 ], "There": [ 288 ], "an": [ 290 ], "etiological": [ 291 ], "sequence": [ 292 ], "leading": [ 293 ], "\u2026": [ 294 ] }, "publication_date": "2013-07-17", "publication_year": 2013, "type": "review", "cited_by_count": 137, "authors": [ { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5107860130", "display_name": "Nele Friedrich" } ] }, { "id": "https://openalex.org/W3087290101", "doi": "https://doi.org/10.1111/dom.14195", "title": "Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise : 6\u2010month follow\u2010up from US real\u2010world data", "abstract": { "Abstract": [ 0 ], "Aim": [ 1 ], "To": [ 2 ], "compare": [ 3 ], "6\u2010month": [ 4, 76, 226 ], "adherence,": [ 5 ], "persistence": [ 6 ], "and": [ 7, 22, 36, 79, 85, 137, 145, 151, 158, 238 ], "treatment": [ 8 ], "patterns": [ 9 ], "among": [ 10 ], "patients": [ 11, 114, 232, 246 ], "initiating": [ 12, 233, 247 ], "once\u2010weekly": [ 13 ], "glucagon\u2010like": [ 14 ], "peptide\u20101": [ 15 ], "receptor": [ 16 ], "agonists": [ 17 ], "(GLP\u20101RAs),": [ 18 ], "dulaglutide": [ 19, 23, 167, 191, 234 ], "versus": [ 20, 24 ], "semaglutide,": [ 21 ], "exenatide": [ 25, 52, 100, 179, 212, 251 ], "BCise,": [ 26 ], "using": [ 27, 117, 128 ], "claims": [ 28 ], "from": [ 29 ], "the": [ 30, 55, 75, 146 ], "HealthCore": [ 31 ], "Integrated": [ 32 ], "Research": [ 33 ], "Database.": [ 34 ], "Materials": [ 35 ], "methods": [ 37 ], "Patients": [ 38 ], "aged": [ 39 ], "\u226518": [ 40 ], "years,": [ 41, 153 ], "with": [ 42, 155, 240 ], "type": [ 43 ], "2": [ 44 ], "diabetes,": [ 45 ], "\u22651": [ 46 ], "claim": [ 47, 71 ], "for": [ 48, 72 ], "dulaglutide,": [ 49 ], "semaglutide": [ 50, 95, 172, 200, 249 ], "or": [ 51, 99, 178, 211, 250 ], "BCise": [ 53, 101, 180, 213 ], "during": [ 54 ], "index": [ 56 ], "period": [ 57 ], "February": [ 58 ], "2018": [ 59, 62 ], "to": [ 60, 94, 124, 196, 237, 244 ], "December": [ 61 ], "(index": [ 63 ], "date": [ 64 ], "=": [ 65 ], "earliest": [ 66 ], "GLP\u20101RA": [ 67 ], "fill": [ 68 ], "date),": [ 69 ], "no": [ 70 ], "GLP\u20101RAs": [ 73 ], "in": [ 74, 142 ], "pre\u2010index": [ 77 ], "period,": [ 78 ], "continuous": [ 80 ], "enrolment": [ 81 ], "6": [ 82, 163 ], "months": [ 83 ], "pre\u2010": [ 84 ], "post\u2010index": [ 86 ], "were": [ 87, 91, 115, 140, 169, 193, 235 ], "included.": [ 88 ], "Dulaglutide": [ 89 ], "users": [ 90, 96, 102, 168, 181, 192, 214 ], "propensity\u2010matched": [ 92 ], "1:1": [ 93 ], "(3852": [ 97 ], "pairs)": [ 98 ], "(1879": [ 103 ], "pairs).": [ 104 ], "The": [ 105 ], "proportions": [ 106 ], "of": [ 107, 110, 231 ], "adherent": [ 108, 170, 236 ], "(proportion": [ 109 ], "days": [ 111, 123 ], "covered": [ 112 ], "\u226580%)": [ 113 ], "compared": [ 116, 243 ], "chi\u2010squared": [ 118 ], "tests.": [ 119 ], "Persistence,": [ 120 ], "measured": [ 121 ], "as": [ 122 ], "discontinuation,": [ 125 ], "was": [ 126, 149 ], "analysed": [ 127 ], "a": [ 129, 228 ], "Cox": [ 130, 187 ], "regression": [ 131, 188 ], "model.": [ 132 ], "Results": [ 133 ], "Matched": [ 134 ], "cohorts": [ 135 ], "(dulaglutide:semaglutide": [ 136 ], "dulagutide:exenatide": [ 138 ], "BCise)": [ 139 ], "balanced": [ 141 ], "baseline": [ 143 ], "characteristics": [ 144 ], "mean": [ 147 ], "age": [ 148 ], "54": [ 150 ], "55": [ 152 ], "respectively,": [ 154 ], "approximately": [ 156 ], "51%": [ 157 ], "49%": [ 159 ], "women,": [ 160 ], "respectively.": [ 161 ], "At": [ 162, 225 ], "months,": [ 164 ], "significantly": [ 165 ], "more": [ 166 ], "than": [ 171, 199 ], "(59.7%": [ 173 ], "vs.": [ 174, 183 ], "42.7%;": [ 175 ], "P": [ 176, 185, 221 ], "<0.0001)": [ 177 ], "(58.1%": [ 182 ], "40.3%;": [ 184 ], "<0.0001).": [ 186 ], "showed": [ 189 ], "that": [ 190 ], "less": [ 194 ], "likely": [ 195 ], "discontinue": [ 197 ], "therapy": [ 198 ], "(hazard": [ 201 ], "ratio": [ 202 ], "[HR]": [ 203 ], "0.71,": [ 204 ], "95%": [ 205, 217 ], "confidence": [ 206 ], "interval": [ 207 ], "[CI]": [ 208 ], "0.66,": [ 209 ], "0.76)": [ 210 ], "(HR": [ 215 ], "0.59,": [ 216 ], "CI": [ 218 ], "0.53,": [ 219 ], "0.65;": [ 220 ], "<0.0001,": [ 222 ], "both).": [ 223 ], "Conclusion": [ 224 ], "follow\u2010up,": [ 227 ], "higher": [ 229 ], "proportion": [ 230 ], "persistent": [ 239 ], "their": [ 241 ], "treatment,": [ 242 ], "matched": [ 245 ], "either": [ 248 ], "BCise.": [ 252 ] }, "publication_date": "2020-09-18", "publication_year": 2020, "type": "article", "cited_by_count": 28, "authors": [ { "id": "https://openalex.org/A5011388259", "display_name": "Reema Mody" }, { "id": "https://openalex.org/A5109226707", "display_name": "Maria Yu" }, { "id": "https://openalex.org/A5035354854", "display_name": "Bal Nepal" }, { "id": "https://openalex.org/A5077985126", "display_name": "\u041c\u0430\u043d\u0438\u0433\u0435 \u041a\u043e\u043d\u0438\u0433" }, { "id": "https://openalex.org/A5090788600", "display_name": "Michael Grabner" } ] }, { "id": "https://openalex.org/W2605549377", "doi": "https://doi.org/10.1016/s1262-3636(17)30070-8", "title": "GLP-1 receptor agonists in NAFLD", "abstract": null, "publication_date": "2017-04-01", "publication_year": 2017, "type": "review", "cited_by_count": 67, "authors": [ { "id": "https://openalex.org/A5081003569", "display_name": "J. Petit" }, { "id": "https://openalex.org/A5003323204", "display_name": "Bruno Verg\u00e8s" } ] }, { "id": "https://openalex.org/W4396850943", "doi": "https://doi.org/10.1038/s41591-024-02996-7", "title": "Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial", "abstract": null, "publication_date": "2024-05-13", "publication_year": 2024, "type": "article", "cited_by_count": 200, "authors": [ { "id": "https://openalex.org/A5088283488", "display_name": "Donna H. Ryan" }, { "id": "https://openalex.org/A5001655356", "display_name": "Ildiko Lingvay" }, { "id": "https://openalex.org/A5039316946", "display_name": "John Deanfield" }, { "id": "https://openalex.org/A5066700951", "display_name": "Steven E. Kahn" }, { "id": "https://openalex.org/A5038572693", "display_name": "Eric Barros" }, { "id": "https://openalex.org/A5082147810", "display_name": "Bartolom\u00e9 Burguera" }, { "id": "https://openalex.org/A5005414020", "display_name": "Helen M. Colhoun" }, { "id": "https://openalex.org/A5063472322", "display_name": "C\u00edntia Cercato" }, { "id": "https://openalex.org/A5009921349", "display_name": "Dror Dicker" }, { "id": "https://openalex.org/A5050261888", "display_name": "Deborah B. Horn" }, { "id": "https://openalex.org/A5004099465", "display_name": "G. Kees Hovingh" }, { "id": "https://openalex.org/A5055974284", "display_name": "Ole Kleist Jeppesen" }, { "id": "https://openalex.org/A5082358327", "display_name": "Alexander Kokkinos" }, { "id": "https://openalex.org/A5001994412", "display_name": "A. Michael Lincoff" }, { "id": "https://openalex.org/A5031235277", "display_name": "Sebastian M. Meyh\u00f6fer" }, { "id": "https://openalex.org/A5064155603", "display_name": "Tu\u011f\u00e7e Kalayc\u0131 Oral" }, { "id": "https://openalex.org/A5051351787", "display_name": "Jorge Plutzky" }, { "id": "https://openalex.org/A5069071532", "display_name": "Andr\u00e9 P. van Beek" }, { "id": "https://openalex.org/A5047195042", "display_name": "John Wilding" }, { "id": "https://openalex.org/A5062192624", "display_name": "Robert F. Kushner" } ] }, { "id": "https://openalex.org/W2017044017", "doi": "https://doi.org/10.1016/j.amjmed.2009.03.015", "title": "Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical Use", "abstract": null, "publication_date": "2009-05-21", "publication_year": 2009, "type": "review", "cited_by_count": 171, "authors": [ { "id": "https://openalex.org/A5013350892", "display_name": "David M. Kendall" }, { "id": "https://openalex.org/A5101709468", "display_name": "Robert Cuddihy" }, { "id": "https://openalex.org/A5113817930", "display_name": "Richard M. Bergenstal" } ] }, { "id": "https://openalex.org/W4386035099", "doi": "https://doi.org/10.1016/j.jagp.2023.08.010", "title": "The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis", "abstract": { "Adults": [ 0 ], "treated": [ 1, 16 ], "with": [ 2, 17 ], "GLP-1RAs": [ 3, 24 ], "showed": [ 4 ], "significant": [ 5 ], "reductions": [ 6 ], "in": [ 7, 34 ], "the": [ 8 ], "depression": [ 9 ], "rating": [ 10 ], "scale": [ 11 ], "scores": [ 12 ], "compared": [ 13 ], "to": [ 14 ], "those": [ 15 ], "control": [ 18 ], "substances.": [ 19 ], "Our": [ 20 ], "findings": [ 21 ], "suggest": [ 22 ], "that": [ 23 ], "may": [ 25 ], "be": [ 26 ], "a": [ 27 ], "potential": [ 28 ], "treatment": [ 29 ], "for": [ 30 ], "alleviating": [ 31 ], "depressive": [ 32 ], "symptoms": [ 33 ], "humans.": [ 35 ] }, "publication_date": "2023-08-21", "publication_year": 2023, "type": "review", "cited_by_count": 116, "authors": [ { "id": "https://openalex.org/A5033560291", "display_name": "Xinda Chen" }, { "id": "https://openalex.org/A5104260857", "display_name": "Peiyi Zhao" }, { "id": "https://openalex.org/A5100627296", "display_name": "Weihao Wang" }, { "id": "https://openalex.org/A5012578672", "display_name": "Lixin Guo" }, { "id": "https://openalex.org/A5100778410", "display_name": "Qi Pan" } ] }, { "id": "https://openalex.org/W169333368", "doi": "https://doi.org/10.4239/wjd.v4.i5.190", "title": "Effects of glucagon-like peptide-1 receptor agonists on renal function", "abstract": { "Glucagon-like": [ 0 ], "peptide-1": [ 1 ], "(GLP-1)": [ 2 ], "receptor": [ 3, 38, 63, 148, 173 ], "agonists": [ 4, 64, 149, 174 ], "result": [ 5 ], "in": [ 6, 9, 21, 70, 100, 133, 153 ], "greater": [ 7 ], "improvements": [ 8 ], "glycemic": [ 10 ], "control": [ 11 ], "than": [ 12 ], "placebo": [ 13 ], "and": [ 14, 76, 95, 177 ], "promote": [ 15 ], "weight": [ 16 ], "loss": [ 17 ], "with": [ 18, 23, 42, 72, 80, 102, 125, 135, 156 ], "minimal": [ 19 ], "hypoglycemia": [ 20 ], "patients": [ 22, 101, 134 ], "type": [ 24 ], "2": [ 25 ], "diabetes": [ 26 ], "mellitus.": [ 27 ], "A": [ 28 ], "number": [ 29 ], "of": [ 30, 36, 45, 61, 163 ], "case": [ 31 ], "reports": [ 32 ], "show": [ 33 ], "an": [ 34 ], "association": [ 35, 79 ], "GLP-1": [ 37, 62, 147, 172 ], "agonists,": [ 39 ], "mainly": [ 40 ], "exenatide,": [ 41 ], "the": [ 43, 55, 59, 86 ], "development": [ 44 ], "acute": [ 46, 81 ], "kidney": [ 47, 82 ], "injury.": [ 48, 83 ], "The": [ 49 ], "present": [ 50, 54 ], "review": [ 51 ], "aims": [ 52 ], "to": [ 53, 160, 186 ], "available": [ 56 ], "data": [ 57, 132 ], "regarding": [ 58 ], "effects": [ 60, 181 ], "on": [ 65, 85 ], "renal": [ 66, 74, 93, 104, 109, 116, 136 ], "function,": [ 67 ], "their": [ 68, 77, 164 ], "use": [ 69 ], "subjects": [ 71 ], "chronic": [ 73 ], "failure": [ 75 ], "possible": [ 78 ], "Based": [ 84 ], "current": [ 87 ], "evidence,": [ 88 ], "exenatide": [ 89 ], "is": [ 90, 112, 141, 169 ], "eliminated": [ 91, 114 ], "by": [ 92, 115 ], "mechanisms": [ 94, 157 ], "should": [ 96, 122 ], "not": [ 97, 113 ], "be": [ 98, 123, 161 ], "given": [ 99 ], "severe": [ 103 ], "impairment": [ 105 ], "or": [ 106, 117, 137, 188 ], "end": [ 107 ], "stage": [ 108 ], "disease.": [ 110 ], "Liraglutide": [ 111 ], "hepatic": [ 118, 138 ], "mechanisms,": [ 119 ], "but": [ 120 ], "it": [ 121 ], "used": [ 124 ], "caution": [ 126 ], "since": [ 127 ], "there": [ 128, 168 ], "are": [ 129 ], "only": [ 130 ], "limited": [ 131 ], "impairment.": [ 139 ], "There": [ 140 ], "evidence": [ 142, 170 ], "from": [ 143 ], "animal": [ 144 ], "studies": [ 145 ], "that": [ 146, 158, 171 ], "exert": [ 150 ], "protective": [ 151 ], "role": [ 152 ], "diabetic": [ 154, 191 ], "nephropathy": [ 155 ], "seem": [ 159 ], "independent": [ 162 ], "glucose-lowering": [ 165 ], "effect.": [ 166 ], "Additionally,": [ 167 ], "influence": [ 175 ], "water": [ 176 ], "electrolyte": [ 178 ], "balance.": [ 179 ], "These": [ 180 ], "may": [ 182 ], "represent": [ 183 ], "new": [ 184 ], "ways": [ 185 ], "improve": [ 187 ], "even": [ 189 ], "prevent": [ 190 ], "nephropathy.": [ 192 ] }, "publication_date": "2013-01-01", "publication_year": 2013, "type": "review", "cited_by_count": 91, "authors": [ { "id": "https://openalex.org/A5032218366", "display_name": "Theodosios D. Filippatos" }, { "id": "https://openalex.org/A5056379080", "display_name": "Moses Elisaf" } ] }, { "id": "https://openalex.org/W2088164570", "doi": "https://doi.org/10.3810/pgm.2014.10.2821", "title": "Safety and Efficacy of Dulaglutide, a Once Weekly GLP-1 Receptor Agonist, for the Management of Type 2 Diabetes", "abstract": { "A": [ 0 ], "literature": [ 1 ], "search": [ 2 ], "was": [ 3 ], "performed": [ 4 ], "using": [ 5 ], "PubMed": [ 6 ], "and": [ 7, 12, 25, 70, 79, 106 ], "MEDSCAPE": [ 8 ], "to": [ 9, 15, 60, 64, 68, 71, 77, 91 ], "retrieve": [ 10 ], "abstracts": [ 11 ], "articles": [ 13, 37 ], "pertinent": [ 14 ], "topics": [ 16 ], "discussed": [ 17 ], "in": [ 18, 47, 86 ], "this": [ 19 ], "review.": [ 20 ], "Original": [ 21 ], "research": [ 22 ], "articles,": [ 23 ], "reviews,": [ 24 ], "clinical": [ 26 ], "trial": [ 27 ], "manuscripts": [ 28 ], "were": [ 29, 38 ], "identified": [ 30 ], "based": [ 31 ], "on": [ 32, 109 ], "relevance.": [ 33 ], "Only": [ 34 ], "English": [ 35 ], "language": [ 36 ], "considered.": [ 39 ], "Results": [ 40 ], "In": [ 41 ], "3": [ 42, 44 ], "phase": [ 43 ], "registration": [ 45 ], "trials": [ 46, 88 ], "patients": [ 48 ], "with": [ 49 ], "T2D,": [ 50 ], "once-weekly": [ 51, 112 ], "dulaglutide": [ 52, 85, 113 ], "demonstrated": [ 53 ], "superior": [ 54 ], "efficacy": [ 55 ], "at": [ 56 ], "the": [ 57, 122 ], "primary": [ 58 ], "endpoint": [ 59 ], "metformin": [ 61, 78 ], "as": [ 62, 66, 75 ], "monotherapy,": [ 63 ], "sitagliptin": [ 65 ], "add-on": [ 67, 76 ], "metformin,": [ 69 ], "exenatide": [ 72 ], "twice": [ 73 ], "daily": [ 74 ], "pioglitazone.": [ 80 ], "The": [ 81 ], "safety": [ 82 ], "profile": [ 83 ], "of": [ 84, 124 ], "these": [ 87, 110 ], "is": [ 89 ], "similar": [ 90 ], "currently": [ 92 ], "available": [ 93 ], "glucagon-like": [ 94 ], "peptide-1": [ 95 ], "receptor": [ 96 ], "agonists,": [ 97 ], "characterized": [ 98 ], "predominantly": [ 99 ], "by": [ 100 ], "gastrointestinal": [ 101 ], "symptoms": [ 102 ], "(ie,": [ 103 ], "nausea,": [ 104 ], "vomiting,": [ 105 ], "diarrhea).": [ 107 ], "Based": [ 108 ], "results,": [ 111 ], "should": [ 114 ], "be": [ 115 ], "a": [ 116 ], "relevant": [ 117 ], "additional": [ 118 ], "treatment": [ 119 ], "option": [ 120 ], "for": [ 121 ], "management": [ 123 ], "T2D.": [ 125 ] }, "publication_date": "2014-10-01", "publication_year": 2014, "type": "review", "cited_by_count": 28, "authors": [ { "id": "https://openalex.org/A5064627053", "display_name": "Louis Kuritzky" }, { "id": "https://openalex.org/A5061058170", "display_name": "Guillermo E. Umpierrez" }, { "id": "https://openalex.org/A5109200868", "display_name": "J.M. Eko\u00e9" }, { "id": "https://openalex.org/A5045697253", "display_name": "Leonardo Mancillas\u2010Adame" }, { "id": "https://openalex.org/A5072715491", "display_name": "Laura Fern\u00e1ndez Land\u00f3" } ] }, { "id": "https://openalex.org/W3187492301", "doi": "https://doi.org/10.2337/db21-0459", "title": "GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist\u2013Induced Nausea and Emesis in Preclinical Models", "abstract": { "Glucagon-like": [ 0 ], "peptide": [ 1 ], "1": [ 2 ], "receptor": [ 3, 51 ], "(GLP-1R)": [ 4 ], "agonists": [ 5 ], "decrease": [ 6 ], "body": [ 7, 69, 93 ], "weight": [ 8, 70, 94 ], "and": [ 9, 15, 19, 33, 42, 56, 72, 79, 92, 99, 118, 125, 147, 155, 160 ], "improve": [ 10 ], "glycemic": [ 11 ], "control": [ 12 ], "in": [ 13, 134, 152 ], "obesity": [ 14, 154 ], "diabetes.": [ 16 ], "Patient": [ 17 ], "compliance": [ 18 ], "maximal": [ 20 ], "efficacy": [ 21, 151 ], "of": [ 22, 84, 101, 113, 123, 132, 145 ], "GLP-1": [ 23 ], "therapeutics": [ 24 ], "are": [ 25, 87 ], "limited": [ 26 ], "by": [ 27, 61, 96, 157 ], "adverse": [ 28 ], "side": [ 29 ], "effects,": [ 30 ], "including": [ 31 ], "nausea": [ 32, 159 ], "emesis.": [ 34 ], "In": [ 35 ], "three": [ 36 ], "different": [ 37 ], "species": [ 38 ], "(i.e.,": [ 39 ], "mice,": [ 40 ], "rats,": [ 41 ], "musk": [ 43 ], "shrews),": [ 44 ], "we": [ 45, 108 ], "show": [ 46 ], "that": [ 47, 141 ], "glucose-dependent": [ 48 ], "insulinotropic": [ 49 ], "polypeptide": [ 50 ], "(GIPR)": [ 52 ], "signaling": [ 53 ], "blocks": [ 54 ], "emesis": [ 55 ], "attenuates": [ 57 ], "illness": [ 58 ], "behaviors": [ 59 ], "elicited": [ 60 ], "GLP-1R": [ 62, 97, 119, 146 ], "activation,": [ 63 ], "while": [ 64 ], "maintaining": [ 65 ], "reduced": [ 66 ], "food": [ 67, 90 ], "intake,": [ 68 ], "loss,": [ 71 ], "improved": [ 73 ], "glucose": [ 74 ], "tolerance.": [ 75 ], "The": [ 76 ], "area": [ 77 ], "postrema": [ 78 ], "nucleus": [ 80 ], "tractus": [ 81 ], "solitarius": [ 82 ], "(AP/NTS)": [ 83 ], "the": [ 85, 110, 129 ], "hindbrain": [ 86 ], "required": [ 88 ], "for": [ 89 ], "intake": [ 91 ], "suppression": [ 95 ], "ligands": [ 98 ], "processing": [ 100 ], "emetic": [ 102 ], "stimuli.": [ 103 ], "Using": [ 104 ], "single-nuclei": [ 105 ], "RNA": [ 106 ], "sequencing,": [ 107 ], "identified": [ 109 ], "cellular": [ 111 ], "phenotypes": [ 112 ], "AP/NTS": [ 114 ], "cells": [ 115 ], "expressing": [ 116 ], "GIPR": [ 117, 133, 148 ], "on": [ 120 ], "distinct": [ 121 ], "populations": [ 122 ], "inhibitory": [ 124 ], "excitatory": [ 126 ], "neurons,": [ 127 ], "with": [ 128 ], "greatest": [ 130 ], "expression": [ 131 ], "\u03b3-aminobutyric": [ 135 ], "acid-ergic": [ 136 ], "neurons.": [ 137 ], "This": [ 138 ], "work": [ 139 ], "suggests": [ 140 ], "combinatorial": [ 142 ], "pharmaceutical": [ 143 ], "targeting": [ 144 ], "will": [ 149 ], "increase": [ 150 ], "treating": [ 153 ], "diabetes": [ 156 ], "reducing": [ 158 ], "vomiting.": [ 161 ] }, "publication_date": "2021-08-11", "publication_year": 2021, "type": "article", "cited_by_count": 151, "authors": [ { "id": "https://openalex.org/A5032144545", "display_name": "Tito Borner" }, { "id": "https://openalex.org/A5045854601", "display_name": "Caroline E. Geisler" }, { "id": "https://openalex.org/A5015531927", "display_name": "Samantha M. Fortin" }, { "id": "https://openalex.org/A5083089869", "display_name": "Richard Cosgrove" }, { "id": "https://openalex.org/A5067913727", "display_name": "Jorge Alsina\u2010Fernandez" }, { "id": "https://openalex.org/A5031449244", "display_name": "Mridula Dogra" }, { "id": "https://openalex.org/A5020206341", "display_name": "Sarah A. Doebley" }, { "id": "https://openalex.org/A5077812592", "display_name": "Marcos J. Sanchez-Navarro" }, { "id": "https://openalex.org/A5031894849", "display_name": "Rosa M. Leon" }, { "id": "https://openalex.org/A5015305915", "display_name": "Jane Gaisinsky" }, { "id": "https://openalex.org/A5024235694", "display_name": "Arianna White" }, { "id": "https://openalex.org/A5073404653", "display_name": "Ankur Bamezai" }, { "id": "https://openalex.org/A5037557890", "display_name": "Misgana Y. Ghidewon" }, { "id": "https://openalex.org/A5016431924", "display_name": "Harvey J. Grill" }, { "id": "https://openalex.org/A5027913658", "display_name": "Richard C. Crist" }, { "id": "https://openalex.org/A5006965852", "display_name": "Benjamin C. Reiner" }, { "id": "https://openalex.org/A5066901728", "display_name": "Minrong Ai" }, { "id": "https://openalex.org/A5061640534", "display_name": "Ricardo J. Samms" }, { "id": "https://openalex.org/A5079833063", "display_name": "Bart C. De Jonghe" }, { "id": "https://openalex.org/A5065258001", "display_name": "Matthew R. Hayes" } ] }, { "id": "https://openalex.org/W4399753996", "doi": "https://doi.org/10.1007/s00213-024-06637-2", "title": "Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys", "abstract": null, "publication_date": "2024-06-17", "publication_year": 2024, "type": "article", "cited_by_count": 30, "authors": [ { "id": "https://openalex.org/A5001609083", "display_name": "Anders Fink\u2010Jensen" }, { "id": "https://openalex.org/A5013639019", "display_name": "Gitta W\u00f6rtwein" }, { "id": "https://openalex.org/A5091141863", "display_name": "Mette Kruse Klausen" }, { "id": "https://openalex.org/A5085434984", "display_name": "Jens J. Holst" }, { "id": "https://openalex.org/A5047145712", "display_name": "Bolette Hartmann" }, { "id": "https://openalex.org/A5031395961", "display_name": "Morgane Thomsen" }, { "id": "https://openalex.org/A5024917674", "display_name": "Maurice Ptito" }, { "id": "https://openalex.org/A5036304998", "display_name": "Amy Beierschmitt" }, { "id": "https://openalex.org/A5075617067", "display_name": "Roberta M. Palmour" } ] }, { "id": "https://openalex.org/W2133648480", "doi": "https://doi.org/10.2337/dc12-2709", "title": "Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin", "abstract": { "OBJECTIVE": [ 0 ], "To": [ 1 ], "compare": [ 2 ], "efficacy": [ 3 ], "and": [ 4, 119, 140, 158, 166, 178, 187, 199, 259 ], "safety": [ 5 ], "of": [ 6, 71, 134, 170, 183, 257 ], "lixisenatide": [ 7, 38, 72, 109, 165, 177, 197, 206, 233 ], "once": [ 8, 41, 85, 234 ], "daily": [ 9, 13, 42, 51, 86, 235 ], "versus": [ 10, 73, 92, 110 ], "exenatide": [ 11, 47, 74, 93, 201, 265 ], "twice": [ 12, 50, 94, 266 ], "in": [ 14, 55, 75, 89, 142, 195, 236, 247 ], "type": [ 15, 237 ], "2": [ 16, 238 ], "diabetes": [ 17, 28, 239 ], "inadequately": [ 18, 29, 240 ], "controlled": [ 19, 30, 241 ], "with": [ 20, 27, 33, 164, 219, 242, 249, 264 ], "metformin.": [ 21 ], "RESEARCH": [ 22 ], "DESIGN": [ 23 ], "AND": [ 24 ], "METHODS": [ 25 ], "Adults": [ 26 ], "(HbA1c": [ 31, 138 ], "7\u201310%)": [ 32 ], "metformin": [ 34, 243 ], "were": [ 35, 146 ], "randomized": [ 36 ], "to": [ 37, 80, 106, 115, 155, 161, 192 ], "20": [ 39 ], "\u03bcg": [ 40, 49 ], "(n": [ 43, 52 ], "=": [ 44, 53 ], "318)": [ 45 ], "or": [ 46 ], "10": [ 48 ], "316)": [ 54 ], "a": [ 56, 68, 128 ], "24-week": [ 57 ], "(main": [ 58 ], "period),": [ 59 ], "open-label,": [ 60 ], "parallel-group,": [ 61 ], "multicenter": [ 62 ], "study.": [ 63 ], "The": [ 64, 96 ], "primary": [ 65 ], "objective": [ 66 ], "was": [ 67, 101, 122, 174, 181 ], "noninferiority": [ 69, 88, 130 ], "assessment": [ 70 ], "HbA1c": [ 76, 90 ], "change": [ 77, 100 ], "from": [ 78, 159 ], "baseline": [ 79 ], "week": [ 81 ], "24.": [ 82 ], "RESULTS": [ 83 ], "Lixisenatide": [ 84 ], "demonstrated": [ 87, 244 ], "reduction": [ 91 ], "daily.": [ 95, 267 ], "least": [ 97 ], "squares": [ 98 ], "mean": [ 99, 252 ], "\u22120.79%": [ 102 ], "(mean": [ 103, 112 ], "decrease": [ 104, 113 ], "7.97": [ 105 ], "7.17%)": [ 107 ], "for": [ 108, 117, 176 ], "\u22120.96%": [ 111 ], "7.96": [ 114 ], "7.01%)": [ 116 ], "exenatide,": [ 118, 167, 179 ], "treatment": [ 120 ], "difference": [ 121 ], "0.17%": [ 123 ], "(95%": [ 124 ], "CI,": [ 125 ], "0.033\u20130.297),": [ 126 ], "meeting": [ 127 ], "predefined": [ 129 ], "upper": [ 131 ], "CI": [ 132 ], "margin": [ 133 ], "0.4%.": [ 135 ], "Responder": [ 136 ], "rate": [ 137 ], "&lt;7.0%)": [ 139 ], "improvements": [ 141, 246 ], "fasting": [ 143 ], "plasma": [ 144 ], "glucose": [ 145 ], "comparable.": [ 147 ], "Both": [ 148 ], "agents": [ 149 ], "induced": [ 150 ], "weight": [ 151, 253 ], "loss": [ 152 ], "(from": [ 153 ], "94.5": [ 154 ], "91.7": [ 156 ], "kg": [ 157, 163 ], "96.7": [ 160 ], "92.9": [ 162 ], "respectively).": [ 168, 189 ], "Incidence": [ 169 ], "adverse": [ 171 ], "events": [ 172, 222 ], "(AEs)": [ 173 ], "similar": [ 175 ], "as": [ 180 ], "incidence": [ 182, 256 ], "serious": [ 184 ], "AEs": [ 185, 193 ], "(2.8": [ 186 ], "2.2%,": [ 188 ], "Discontinuations": [ 190 ], "attributable": [ 191 ], "occurred": [ 194 ], "33": [ 196 ], "(10.4%)": [ 198 ], "41": [ 200 ], "(13.0%)": [ 202 ], "patients.": [ 203 ], "In": [ 204 ], "the": [ 205 ], "group,": [ 207 ], "fewer": [ 208, 220 ], "participants": [ 209 ], "experienced": [ 210 ], "symptomatic": [ 211 ], "hypoglycemia": [ 212 ], "(2.5": [ 213 ], "vs.": [ 214, 226 ], "7.9%;": [ 215 ], "P": [ 216, 228 ], "&lt;": [ 217, 229 ], "0.05),": [ 218 ], "gastrointestinal": [ 221, 261 ], "(especially": [ 223 ], "nausea;": [ 224 ], "24.5": [ 225 ], "35.1%;": [ 227 ], "0.05).": [ 230 ], "CONCLUSIONS": [ 231 ], "Add-on": [ 232 ], "noninferior": [ 245 ], "HbA1c,": [ 248 ], "slightly": [ 250 ], "lower": [ 251, 255 ], "loss,": [ 254 ], "hypoglycemia,": [ 258 ], "better": [ 260 ], "tolerability": [ 262 ], "compared": [ 263 ] }, "publication_date": "2013-05-23", "publication_year": 2013, "type": "article", "cited_by_count": 244, "authors": [ { "id": "https://openalex.org/A5045489578", "display_name": "Julio Rosenstock" }, { "id": "https://openalex.org/A5012472100", "display_name": "D. Raccah" }, { "id": "https://openalex.org/A5004335707", "display_name": "L\u00e1szl\u00f3 Kor\u00e1nyi" }, { "id": "https://openalex.org/A5004934159", "display_name": "Laura Maffei" }, { "id": "https://openalex.org/A5111927290", "display_name": "Gabor Boka" }, { "id": "https://openalex.org/A5074845584", "display_name": "P. Miossec" }, { "id": "https://openalex.org/A5114012252", "display_name": "John E. Gerich" } ] }, { "id": "https://openalex.org/W4253101646", "doi": "https://doi.org/10.1038/nrd1828", "title": "Exenatide", "abstract": null, "publication_date": "2005-09-01", "publication_year": 2005, "type": "review", "cited_by_count": 115, "authors": [ { "id": "https://openalex.org/A5049298087", "display_name": "Mayer B. Davidson" }, { "id": "https://openalex.org/A5108427508", "display_name": "Guy Bate" }, { "id": "https://openalex.org/A5019823418", "display_name": "Peter Kirkpatrick" } ] }, { "id": "https://openalex.org/W2884645397", "doi": "https://doi.org/10.2337/dc17-2381", "title": "A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin", "abstract": { "OBJECTIVE": [ 0 ], "To": [ 1 ], "investigate": [ 2 ], "the": [ 3, 172 ], "efficacy": [ 4 ], "and": [ 5, 15, 44, 48, 77, 136, 180, 185 ], "safety": [ 6 ], "of": [ 7, 66, 153, 187, 215 ], "once-daily": [ 8, 13, 59 ], "semaglutide": [ 9, 127, 155, 179, 192 ], "in": [ 10, 17, 64, 98, 122, 151, 183, 200, 203 ], "comparison": [ 11 ], "with": [ 12, 19, 35, 39, 46, 50, 85, 126, 137, 158, 178, 206, 211 ], "liraglutide": [ 14, 78, 138, 207 ], "placebo": [ 16, 63, 160, 209 ], "patients": [ 18, 33, 110 ], "type": [ 20, 36 ], "2": [ 21, 37 ], "diabetes.": [ 22 ], "RESEARCH": [ 23 ], "DESIGN": [ 24 ], "AND": [ 25 ], "METHODS": [ 26 ], "This": [ 27 ], "26-week,": [ 28 ], "multicenter,": [ 29 ], "double-blind": [ 30 ], "trial": [ 31, 114 ], "involved": [ 32 ], "diagnosed": [ 34 ], "diabetes": [ 38 ], "HbA1c": [ 40, 99, 123, 204 ], "7.0\u201310.0%": [ 41 ], "(53\u201386": [ 42 ], "mmol/mol)": [ 43 ], "treated": [ 45 ], "diet": [ 47 ], "exercise": [ 49 ], "or": [ 51, 62, 74, 82, 208 ], "without": [ 52 ], "metformin.": [ 53 ], "Patients": [ 54 ], "were": [ 55, 111, 171 ], "randomized": [ 56, 109 ], "2:2:1": [ 57 ], "to": [ 58, 102, 113, 132, 143, 196 ], "semaglutide,": [ 60 ], "liraglutide,": [ 61, 181 ], "one": [ 65 ], "four": [ 67 ], "volume-matched": [ 68, 90, 154 ], "doses": [ 69, 194 ], "(semaglutide": [ 70 ], "0.05,": [ 71 ], "0.1,": [ 72 ], "0.2,": [ 73 ], "0.3": [ 75, 197 ], "mg": [ 76 ], "0.3,": [ 79 ], "0.6,": [ 80 ], "1.2,": [ 81 ], "1.8": [ 83 ], "mg,": [ 84 ], "both": [ 86 ], "compared": [ 87, 205 ], "within": [ 88 ], "each": [ 89 ], "dose": [ 91 ], "group).": [ 92 ], "Primary": [ 93 ], "end": [ 94 ], "point": [ 95 ], "was": [ 96, 124, 161 ], "change": [ 97, 121 ], "from": [ 100, 128, 139 ], "baseline": [ 101 ], "week": [ 103, 117 ], "26.": [ 104 ], "RESULTS": [ 105 ], "In": [ 106 ], "total,": [ 107 ], "705": [ 108 ], "exposed": [ 112 ], "products.": [ 115 ], "At": [ 116 ], "26,": [ 118 ], "a": [ 119, 212 ], "dose-dependent": [ 120 ], "observed": [ 125 ], "\u22121.1%": [ 129 ], "(0.05": [ 130 ], "mg)": [ 131, 135, 142, 146 ], "\u22121.9%": [ 133 ], "(0.3": [ 134, 141 ], "\u22120.5%": [ 140 ], "\u22121.3%": [ 144 ], "(1.8": [ 145 ], "(all": [ 147 ], "P": [ 148 ], "&lt;": [ 149, 164 ], "0.001": [ 150 ], "favor": [ 152 ], "dose).": [ 156 ], "Change": [ 157 ], "pooled": [ 159 ], "\u22120.02%": [ 162 ], "(P": [ 163 ], "0.0001": [ 165 ], "vs.": [ 166 ], "semaglutide).": [ 167 ], "Gastrointestinal": [ 168 ], "(GI)": [ 169 ], "disorders": [ 170 ], "most": [ 173 ], "common": [ 174 ], "adverse": [ 175 ], "events": [ 176 ], "(AEs)": [ 177 ], "occurring": [ 182 ], "32.8\u201354.0%": [ 184 ], "21.9\u201341.5%": [ 186 ], "patients,": [ 188 ], "respectively.": [ 189 ], "CONCLUSIONS": [ 190 ], "Once-daily": [ 191 ], "at": [ 193 ], "up": [ 195 ], "mg/day": [ 198 ], "resulted": [ 199 ], "greater": [ 201 ], "reductions": [ 202 ], "but": [ 210 ], "higher": [ 213 ], "frequency": [ 214 ], "GI": [ 216 ], "AEs.": [ 217 ] }, "publication_date": "2018-07-19", "publication_year": 2018, "type": "article", "cited_by_count": 75, "authors": [ { "id": "https://openalex.org/A5001655356", "display_name": "Ildiko Lingvay" }, { "id": "https://openalex.org/A5077027153", "display_name": "Cyrus Desouza" }, { "id": "https://openalex.org/A5088531614", "display_name": "Katarina Lali\u0107" }, { "id": "https://openalex.org/A5075717817", "display_name": "Ludger Rose" }, { "id": "https://openalex.org/A5109185807", "display_name": "Thomas K. Hansen" }, { "id": "https://openalex.org/A5007252132", "display_name": "Jeppe Zacho" }, { "id": "https://openalex.org/A5023877066", "display_name": "Thomas R. Pieber" } ] }, { "id": "https://openalex.org/W4393184731", "doi": "https://doi.org/10.1097/01.jaa.0001007388.97793.41", "title": "GLP-1 receptor agonists", "abstract": { "ABSTRACT": [ 0 ], "Type": [ 1 ], "2": [ 2 ], "diabetes": [ 3 ], "mellitus": [ 4 ], "(T2DM)": [ 5 ], "is": [ 6, 20, 39, 100, 118 ], "a": [ 7, 121 ], "chronic": [ 8 ], "medical": [ 9 ], "condition": [ 10 ], "affecting": [ 11 ], "millions": [ 12 ], "of": [ 13, 18, 31, 37, 85 ], "individuals": [ 14 ], "worldwide.": [ 15 ], "The": [ 16, 35 ], "burden": [ 17 ], "disease": [ 19, 174 ], "significant,": [ 21 ], "as": [ 22, 58, 120, 143, 145 ], "demonstrated": [ 23 ], "by": [ 24 ], "high": [ 25 ], "morbidity": [ 26 ], "and": [ 27, 29, 69, 92, 114, 141, 150, 169 ], "mortality": [ 28 ], "billions": [ 30 ], "healthcare": [ 32 ], "dollars": [ 33 ], "spent.": [ 34 ], "pathophysiology": [ 36 ], "T2DM": [ 38, 162 ], "complex,": [ 40 ], "with": [ 41, 161 ], "eight": [ 42 ], "primary": [ 43 ], "deficits.": [ 44 ], "In": [ 45, 124 ], "recent": [ 46 ], "years,": [ 47 ], "an": [ 48, 104 ], "increased": [ 49 ], "focus": [ 50 ], "has": [ 51 ], "been": [ 52, 133 ], "placed": [ 53 ], "on": [ 54 ], "incretin": [ 55 ], "hormones,": [ 56 ], "such": [ 57 ], "glucagon-like": [ 59 ], "peptide-1": [ 60 ], "(GLP-1)": [ 61 ], "for": [ 62, 82 ], "its": [ 63 ], "glucose-lowering": [ 64 ], "benefits.": [ 65 ], "Several": [ 66 ], "FDA-approved": [ 67 ], "short-acting": [ 68 ], "long-acting": [ 70 ], "GLP-1": [ 71, 115, 130 ], "receptor": [ 72 ], "agonists": [ 73 ], "(GLP-1": [ 74 ], "RAs)": [ 75 ], "are": [ 76, 88 ], "available": [ 77, 102, 119 ], "in": [ 78, 103, 158 ], "the": [ 79, 83 ], "United": [ 80 ], "States": [ 81 ], "treatment": [ 84 ], "T2DM.": [ 86 ], "These": [ 87, 153 ], "liraglutide,": [ 89 ], "exenatide,": [ 90 ], "dulaglutide,": [ 91 ], "semaglutide,": [ 93 ], "all": [ 94 ], "administered": [ 95 ], "via": [ 96 ], "subcutaneous": [ 97, 122 ], "injection.": [ 98 ], "Semaglutide": [ 99 ], "also": [ 101 ], "oral": [ 105 ], "formulation.": [ 106 ], "A": [ 107 ], "newer": [ 108 ], "dual": [ 109 ], "glucose-dependent": [ 110 ], "insulinotropic": [ 111 ], "peptide": [ 112 ], "(GIP)": [ 113 ], "RA,": [ 116 ], "tirzepatide,": [ 117 ], "injectable.": [ 123 ], "addition": [ 125 ], "to": [ 126, 135, 146, 164, 171 ], "improving": [ 127 ], "glycemic": [ 128 ], "control,": [ 129 ], "RAs": [ 131 ], "have": [ 132 ], "shown": [ 134 ], "lower": [ 136 ], "total": [ 137 ], "body": [ 138 ], "weight,": [ 139 ], "BP,": [ 140 ], "cholesterol": [ 142 ], "well": [ 144 ], "improve": [ 147 ], "renal": [ 148 ], "function": [ 149 ], "beta-cell": [ 151 ], "proliferation.": [ 152 ], "agents": [ 154 ], "should": [ 155 ], "be": [ 156 ], "considered": [ 157 ], "every": [ 159 ], "patient": [ 160 ], "due": [ 163 ], "their": [ 165 ], "substantial": [ 166 ], "clinical": [ 167 ], "benefits": [ 168 ], "potential": [ 170 ], "help": [ 172 ], "reduce": [ 173 ], "burden.": [ 175 ] }, "publication_date": "2024-03-26", "publication_year": 2024, "type": "review", "cited_by_count": 13, "authors": [ { "id": "https://openalex.org/A5112359413", "display_name": "L. G. Clark" } ] }, { "id": "https://openalex.org/W2049798496", "doi": "https://doi.org/10.2147/tcrm.s7313", "title": "Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide", "abstract": { "Failure": [ 0 ], "of": [ 1, 3, 20, 32, 34, 70, 93, 109, 124, 165, 174, 219 ], "secretion": [ 2 ], "the": [ 4, 29, 65, 185 ], "incretin": [ 5 ], "hormone": [ 6 ], "glucagon-like": [ 7 ], "peptide-1": [ 8 ], "(GLP-1)": [ 9 ], "plays": [ 10 ], "a": [ 11, 51, 178 ], "prominent": [ 12 ], "role": [ 13 ], "in": [ 14, 54, 67, 105, 121, 148, 184 ], "type": [ 15 ], "2": [ 16, 42 ], "diabetes,": [ 17 ], "and": [ 18, 48, 113, 157, 177, 209, 223 ], "restoration": [ 19 ], "GLP-1": [ 21, 35, 44, 100 ], "action": [ 22, 33 ], "is": [ 23, 146 ], "an": [ 24 ], "important": [ 25 ], "therapeutic": [ 26, 40 ], "objective.": [ 27 ], "Although": [ 28 ], "short": [ 30 ], "duration": [ 31 ], "renders": [ 36 ], "it": [ 37, 168 ], "unsuited": [ 38 ], "to": [ 39, 72, 79, 96, 205 ], "use,": [ 41 ], "long-acting": [ 43 ], "receptor": [ 45, 101 ], "agonists,": [ 46 ], "exenatide": [ 47 ], "liraglutide,": [ 49 ], "represent": [ 50 ], "significant": [ 52, 97 ], "advance": [ 53 ], "treatment.": [ 55 ], "In": [ 56 ], "controlled": [ 57 ], "trials,": [ 58 ], "both": [ 59 ], "produce": [ 60, 134 ], "short-term": [ 61, 213 ], "glucose-lowering": [ 62, 180 ], "effects,": [ 63 ], "with": [ 64, 82, 150 ], "reduction": [ 66 ], "hemoglobin": [ 68 ], "A(1c)": [ 69 ], "up": [ 71 ], "1.3%.": [ 73 ], "These": [ 74 ], "responses": [ 75 ], "are": [ 76, 160, 203 ], "often": [ 77 ], "superior": [ 78, 179 ], "those": [ 80 ], "observed": [ 81, 183 ], "additional": [ 83 ], "oral": [ 84 ], "agents.": [ 85 ], "However,": [ 86, 154 ], "unlike": [ 87 ], "sulfonylureas,": [ 88 ], "thiazolidinediones,": [ 89 ], "or": [ 90 ], "insulin,": [ 91 ], "all": [ 92 ], "which": [ 94 ], "lead": [ 95 ], "weight": [ 98, 107 ], "gain,": [ 99 ], "agonists": [ 102 ], "uniquely": [ 103 ], "result": [ 104 ], "long-term": [ 106, 207, 217 ], "loss": [ 108 ], "around": [ 110 ], "5": [ 111 ], "kg,": [ 112 ], "higher": [ 114 ], "doses": [ 115 ], "may": [ 116 ], "enhance": [ 117 ], "this": [ 118, 145 ], "further.": [ 119 ], "Reduction": [ 120 ], "blood": [ 122 ], "pressure": [ 123 ], "2-7": [ 125 ], "mm": [ 126 ], "Hg": [ 127 ], "also": [ 128 ], "has": [ 129 ], "been": [ 130 ], "observed.": [ 131 ], "Both": [ 132 ], "drugs": [ 133 ], "transient": [ 135 ], "mild": [ 136, 141 ], "gastrointestinal": [ 137 ], "side": [ 138 ], "effects;": [ 139 ], "although": [ 140 ], "hypoglycemia": [ 142, 156 ], "can": [ 143 ], "occur,": [ 144 ], "usually": [ 147 ], "combination": [ 149 ], "other": [ 151, 224 ], "hypoglycemic": [ 152 ], "therapies.": [ 153 ], "serious": [ 155 ], "acute": [ 158 ], "pancreatitis": [ 159 ], "rare.": [ 161 ], "The": [ 162 ], "once-daily": [ 163 ], "dosage": [ 164, 173 ], "liraglutide": [ 166, 198 ], "makes": [ 167 ], "more": [ 169 ], "convenient": [ 170 ], "than": [ 171 ], "twice-daily": [ 172 ], "prandial": [ 175 ], "exenatide,": [ 176 ], "effect": [ 181 ], "was": [ 182 ], "only": [ 186 ], "head-to-head": [ 187 ], "comparison": [ 188 ], "reported": [ 189 ], "so": [ 190 ], "far.": [ 191 ], "Besides": [ 192 ], "cost,": [ 193 ], "these": [ 194 ], "considerations": [ 195 ], "currently": [ 196 ], "favor": [ 197 ], "over": [ 199 ], "exenatide.": [ 200 ], "Further": [ 201 ], "studies": [ 202 ], "needed": [ 204 ], "confirm": [ 206 ], "safety,": [ 208 ], "most": [ 210 ], "importantly,": [ 211 ], "that": [ 212 ], "benefits": [ 214 ], "translate": [ 215 ], "into": [ 216 ], "reductions": [ 218 ], "diabetes-related": [ 220 ], "cardiovascular": [ 221 ], "events": [ 222 ], "complications.": [ 225 ] }, "publication_date": "2010-08-01", "publication_year": 2010, "type": "article", "cited_by_count": 30, "authors": [ { "id": "https://openalex.org/A5071097357", "display_name": "Jonathan Pinkney" } ] }, { "id": "https://openalex.org/W2913246107", "doi": "https://doi.org/10.1016/s2213-8587(18)30351-6", "title": "GLP-1 receptor agonists and cardiovascular disease: drug-specific or class effects?", "abstract": null, "publication_date": "2019-01-27", "publication_year": 2019, "type": "letter", "cited_by_count": 25, "authors": [ { "id": "https://openalex.org/A5052436747", "display_name": "Elric Zweck" }, { "id": "https://openalex.org/A5022032933", "display_name": "Michael Roden" } ] }, { "id": "https://openalex.org/W2157869836", "doi": "https://doi.org/10.2337/dc09-2361", "title": "Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition", "abstract": { "OBJECTIVE": [ 0 ], "To": [ 1 ], "study": [ 2 ], "the": [ 3, 113, 135 ], "effect": [ 4 ], "of": [ 5, 112, 137, 140 ], "exenatide": [ 6, 31, 61, 87 ], "on": [ 7 ], "body": [ 8, 49, 67, 73, 117, 121, 130 ], "composition": [ 9, 41 ], "and": [ 10, 35, 53, 71, 74, 82, 93, 120, 133 ], "circulating": [ 11, 138 ], "cardiovascular": [ 12, 54, 141 ], "risk": [ 13 ], "biomarkers.": [ 14 ], "RESEARCH": [ 15 ], "DESIGN": [ 16 ], "AND": [ 17 ], "METHODS": [ 18 ], "Metformin-treated": [ 19 ], "patients": [ 20 ], "with": [ 21, 60, 148 ], "type": [ 22 ], "2": [ 23 ], "diabetes": [ 24 ], "(N": [ 25 ], "=": [ 26 ], "69)": [ 27 ], "were": [ 28, 56, 109, 146 ], "randomized": [ 29 ], "to": [ 30 ], "or": [ 32 ], "insulin": [ 33, 149 ], "glargine": [ 34, 101, 150 ], "treated": [ 36 ], "for": [ 37, 62, 126, 154 ], "1": [ 38, 63, 127 ], "year.": [ 39 ], "Body": [ 40 ], "was": [ 42 ], "evaluated": [ 43 ], "by": [ 44, 78, 91, 98, 105 ], "dual-energy": [ 45 ], "X-ray": [ 46 ], "absorptiometry.": [ 47 ], "Additionally,": [ 48 ], "weight,": [ 50, 68 ], "waist": [ 51, 69 ], "circumference,": [ 52, 70 ], "biomarkers": [ 55, 139 ], "measured.": [ 57 ], "RESULTS": [ 58 ], "Treatment": [ 59 ], "year": [ 64, 128 ], "significantly": [ 65, 102 ], "reduced": [ 66, 94, 103, 129, 155 ], "total": [ 72, 89, 116 ], "trunkal": [ 75 ], "fat": [ 76, 118, 131 ], "mass": [ 77, 119, 132 ], "6,": [ 79 ], "5,": [ 80 ], "11,": [ 81 ], "13%,": [ 83 ], "respectively.": [ 84 ], "In": [ 85 ], "addition,": [ 86 ], "increased": [ 88 ], "adiponectin": [ 90 ], "12%": [ 92 ], "high-sensitivity": [ 95 ], "C-reactive": [ 96 ], "protein": [ 97 ], "61%.": [ 99 ], "Insulin": [ 100 ], "endothelin-1": [ 104, 156 ], "7%.": [ 106 ], "These": [ 107 ], "changes": [ 108, 145 ], "statistically": [ 110 ], "independent": [ 111 ], "change": [ 114 ], "in": [ 115 ], "weight.": [ 122 ], "CONCLUSIONS": [ 123 ], "Exenatide": [ 124 ], "treatment": [ 125 ], "improved": [ 134 ], "profile": [ 136 ], "risk.": [ 142 ], "No": [ 143 ], "significant": [ 144 ], "seen": [ 147 ], "except": [ 151 ], "a": [ 152 ], "trend": [ 153 ], "levels.": [ 157 ] }, "publication_date": "2010-04-27", "publication_year": 2010, "type": "article", "cited_by_count": 152, "authors": [ { "id": "https://openalex.org/A5110611896", "display_name": "Mathijs C. Bunck" }, { "id": "https://openalex.org/A5109335776", "display_name": "Micha\u00ebla Diamant" }, { "id": "https://openalex.org/A5061198575", "display_name": "Bj\u00f6rn Eliasson" }, { "id": "https://openalex.org/A5059226156", "display_name": "A. H. Corner" }, { "id": "https://openalex.org/A5112350413", "display_name": "Rimma M. Shaginian" }, { "id": "https://openalex.org/A5113467761", "display_name": "Robert J. Heine" }, { "id": "https://openalex.org/A5057557099", "display_name": "Marja\u2010Riitta Taskinen" }, { "id": "https://openalex.org/A5028953583", "display_name": "Hannele Yki\u2010J\u00e4rvinen" }, { "id": "https://openalex.org/A5028599620", "display_name": "Ulf Smith" } ] }, { "id": "https://openalex.org/W2169818177", "doi": "https://doi.org/10.1007/s13300-010-0013-5", "title": "Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications", "abstract": { "Because": [ 0 ], "GLP-1": [ 1, 30, 48 ], "receptor": [ 2, 49 ], "agonists": [ 3, 31, 50 ], "work": [ 4 ], "in": [ 5, 58, 79 ], "a": [ 6, 17 ], "glucose-dependent": [ 7 ], "manner,": [ 8 ], "they": [ 9 ], "are": [ 10 ], "likely": [ 11 ], "to": [ 12, 35, 51, 71 ], "reduce": [ 13 ], "hyperglycemia": [ 14 ], "safely,": [ 15 ], "without": [ 16, 39 ], "marked": [ 18 ], "fluctuation": [ 19 ], "toward": [ 20 ], "hypoglycemia.": [ 21, 44 ], "In": [ 22 ], "the": [ 23, 59, 69, 75 ], "process": [ 24 ], "of": [ 25, 47, 61, 74 ], "acutely": [ 26 ], "restoring": [ 27 ], "\u03b2-cell": [ 28 ], "function,": [ 29 ], "may": [ 32, 67 ], "allow": [ 33 ], "patients": [ 34, 80 ], "achieve": [ 36 ], "HbA(1c)": [ 37 ], "<7%": [ 38 ], "experiencing": [ 40 ], "weight": [ 41, 62, 65 ], "gain": [ 42 ], "or": [ 43, 64 ], "The": [ 45 ], "ability": [ 46 ], "improve": [ 52 ], "blood": [ 53 ], "pressure": [ 54 ], "and": [ 55 ], "postprandial": [ 56 ], "lipidemia": [ 57 ], "context": [ 60 ], "neutrality": [ 63 ], "loss": [ 66 ], "have": [ 68 ], "potential": [ 70 ], "ameliorate": [ 72 ], "some": [ 73 ], "cardiovascular": [ 76 ], "risks": [ 77 ], "observed": [ 78 ], "with": [ 81 ], "T2DM.": [ 82 ] }, "publication_date": "2011-01-18", "publication_year": 2011, "type": "article", "cited_by_count": 35, "authors": [ { "id": "https://openalex.org/A5044386273", "display_name": "Jeffrey Unger" }, { "id": "https://openalex.org/A5031856386", "display_name": "Christopher G. Parkin" } ] }, { "id": "https://openalex.org/W1985110387", "doi": "https://doi.org/10.2165/00003495-200767060-00008", "title": "Exenatide", "abstract": null, "publication_date": "2007-01-01", "publication_year": 2007, "type": "review", "cited_by_count": 100, "authors": [ { "id": "https://openalex.org/A5109084979", "display_name": "Risto S Cvetkovi" }, { "id": "https://openalex.org/A5065257894", "display_name": "Greg L. Plosker" } ] }, { "id": "https://openalex.org/W3014953461", "doi": "https://doi.org/10.1111/dom.14054", "title": "Efficacy, safety and cardiovascular outcomes of once\u2010daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme", "abstract": { "Abstract": [ 0 ], "Glucagon\u2010like": [ 1 ], "peptide\u20101": [ 2 ], "receptor": [ 3 ], "agonists": [ 4 ], "(GLP\u20101RAs)": [ 5 ], "are": [ 6 ], "recommended": [ 7 ], "for": [ 8, 28, 42, 224, 251 ], "glycaemic": [ 9, 252 ], "management": [ 10 ], "in": [ 11, 55, 73, 117, 200, 227, 274 ], "patients": [ 12, 56, 118, 228 ], "with": [ 13, 57, 119, 202, 209, 229 ], "type": [ 14 ], "2": [ 15 ], "diabetes": [ 16 ], "(T2D).": [ 17 ], "Oral": [ 18, 161, 195 ], "semaglutide,": [ 19 ], "the": [ 20, 33, 36, 111, 147, 175, 189, 203, 214, 239, 275 ], "first": [ 21 ], "oral": [ 22, 53, 115, 133, 225, 244, 259 ], "GLP\u20101RA,": [ 23 ], "has": [ 24 ], "recently": [ 25 ], "been": [ 26 ], "approved": [ 27 ], "clinical": [ 29, 47 ], "use,": [ 30 ], "based": [ 31 ], "on": [ 32 ], "results": [ 34, 237 ], "of": [ 35, 59, 114, 127, 149, 207, 238, 254, 258, 270, 277 ], "randomized,": [ 37 ], "Phase": [ 38 ], "3a": [ 39 ], "Peptide": [ 40 ], "InnOvatioN": [ 41 ], "Early": [ 43 ], "diabEtes": [ 44 ], "tReatment": [ 45 ], "(PIONEER)": [ 46 ], "trials.": [ 48 ], "The": [ 49, 236, 256 ], "PIONEER": [ 50, 240 ], "programme": [ 51, 241 ], "tested": [ 52, 99 ], "semaglutide": [ 54, 116, 134, 162, 196, 226, 245, 260 ], "T2D": [ 58, 120, 278 ], "duration": [ 60 ], "ranging": [ 61 ], "from": [ 62, 67, 174 ], "3.5": [ 63 ], "to": [ 64, 70, 80, 130, 263 ], "15": [ 65 ], "years,": [ 66 ], "monotherapy": [ 68 ], "through": [ 69 ], "insulin": [ 71 ], "add\u2010on,": [ 72 ], "global": [ 74 ], "populations": [ 75 ], "and": [ 76, 87, 95, 103, 136, 143, 151, 169, 180, 193, 248, 267 ], "two": [ 77 ], "trials": [ 78 ], "dedicated": [ 79 ], "Japanese": [ 81 ], "patients.": [ 82 ], "Outcomes": [ 83 ], "(glycated": [ 84 ], "haemoglobin": [ 85 ], "[HbA1c]": [ 86 ], "body": [ 88, 144 ], "weight": [ 89, 145 ], "reduction,": [ 90 ], "plus": [ 91 ], "other": [ 92, 153 ], "relevant": [ 93 ], "efficacy": [ 94, 166 ], "safety": [ 96, 113, 205, 221 ], "endpoints)": [ 97 ], "were": [ 98 ], "against": [ 100 ], "both": [ 101 ], "placebo": [ 102, 168 ], "active": [ 104 ], "standard\u2010of\u2010care": [ 105 ], "medications.": [ 106 ], "A": [ 107 ], "separate": [ 108 ], "trial": [ 109 ], "evaluated": [ 110 ], "cardiovascular": [ 112, 123, 230, 234 ], "at": [ 121 ], "high": [ 122, 233 ], "risk.": [ 124, 235 ], "Over": [ 125 ], "periods": [ 126 ], "treatment": [ 128, 265, 273 ], "up": [ 129 ], "78": [ 131 ], "weeks,": [ 132 ], "7": [ 135 ], "14": [ 137 ], "mg": [ 138 ], "once": [ 139 ], "daily": [ 140 ], "reduced": [ 141 ], "HbA1c": [ 142 ], "across": [ 146 ], "spectrum": [ 148 ], "T2D,": [ 150 ], "improved": [ 152 ], "diabetes\u2010related": [ 154 ], "endpoints,": [ 155 ], "such": [ 156 ], "as": [ 157, 186, 188 ], "fasting": [ 158 ], "plasma": [ 159 ], "glucose.": [ 160 ], "provided": [ 163 ], "significantly": [ 164 ], "better": [ 165 ], "than": [ 167 ], "commonly": [ 170 ], "used": [ 171 ], "glucose\u2010lowering": [ 172 ], "medications": [ 173 ], "dipeptidyl": [ 176 ], "peptidase\u20104": [ 177 ], "inhibitor": [ 178, 183 ], "(sitagliptin)": [ 179 ], "sodium\u2010glucose": [ 181 ], "co\u2010transporter\u20102": [ 182 ], "(empagliflozin)": [ 184 ], "classes,": [ 185 ], "well": [ 187, 198, 249 ], "subcutaneous": [ 190 ], "GLP\u20101RAs": [ 191 ], "liraglutide": [ 192 ], "dulaglutide.": [ 194 ], "was": [ 197, 222 ], "tolerated": [ 199, 250 ], "line": [ 201 ], "known": [ 204 ], "profile": [ 206 ], "GLP\u20101RAs,": [ 208 ], "transient": [ 210 ], "gastrointestinal": [ 211 ], "events": [ 212 ], "being": [ 213 ], "most": [ 215 ], "common": [ 216 ], "side": [ 217 ], "effects": [ 218 ], "reported.": [ 219 ], "Cardiovascular": [ 220 ], "demonstrated": [ 223 ], "disease": [ 231 ], "or": [ 232 ], "suggest": [ 242 ], "that": [ 243 ], "is": [ 246 ], "efficacious": [ 247 ], "control": [ 253 ], "T2D.": [ 255 ], "availability": [ 257 ], "may": [ 261 ], "help": [ 262 ], "broaden": [ 264 ], "choice": [ 266 ], "facilitate": [ 268 ], "adoption": [ 269 ], "earlier": [ 271 ], "GLP\u20101RA": [ 272 ], "paradigm": [ 276 ], "management.": [ 279 ] }, "publication_date": "2020-04-08", "publication_year": 2020, "type": "review", "cited_by_count": 120, "authors": [ { "id": "https://openalex.org/A5021569298", "display_name": "Tina K. Thethi" }, { "id": "https://openalex.org/A5059098934", "display_name": "Richard E. Pratley" }, { "id": "https://openalex.org/A5002832666", "display_name": "Juris J. Meier" } ] }, { "id": "https://openalex.org/W3216821013", "doi": "https://doi.org/10.1186/s12933-021-01412-5", "title": "The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect", "abstract": { "Abstract": [ 0 ], "Incretin": [ 1 ], "hormones": [ 2 ], "are": [ 3, 22, 278 ], "peptides": [ 4 ], "released": [ 5 ], "in": [ 6, 9, 16, 64, 80, 90, 230 ], "the": [ 7, 12, 54, 60, 70, 74, 91, 134, 137, 150, 162, 195, 215, 231, 241, 263, 272 ], "intestine": [ 8 ], "response": [ 10, 76 ], "to": [ 11, 118, 172, 197, 234, 252, 261 ], "presence": [ 13 ], "of": [ 14, 49, 56, 68, 139, 152, 243, 266 ], "nutrients": [ 15 ], "its": [ 17, 124 ], "lumen.": [ 18 ], "The": [ 19 ], "main": [ 20, 61 ], "incretins": [ 21 ], "glucagon-like": [ 23 ], "peptide-1": [ 24 ], "(GLP-1)": [ 25 ], "and": [ 26, 42, 123, 166, 210, 219, 269, 283 ], "glucose-dependent": [ 27 ], "insulinotropic": [ 28 ], "polypeptide": [ 29 ], "(GIP).": [ 30 ], "GLP-1": [ 31, 167 ], "stimulates": [ 32 ], "insulin": [ 33, 75, 206 ], "secretion,": [ 34 ], "inhibits": [ 35 ], "glucagon": [ 36 ], "secretion": [ 37, 79 ], "at": [ 38 ], "pancreatic": [ 39 ], "\u03b1": [ 40 ], "cells": [ 41 ], "has": [ 43, 94, 105, 113, 194 ], "also": [ 44, 148 ], "extrapancreatic": [ 45 ], "influences": [ 46 ], "as": [ 47, 181, 202, 204 ], "slowing": [ 48 ], "gastric": [ 50 ], "emptying": [ 51 ], "which": [ 52 ], "increases": [ 53 ], "feeling": [ 55 ], "satiety.": [ 57 ], "GIP": [ 58, 78, 93, 119, 141, 165 ], "is": [ 59, 86, 187, 249, 258 ], "incretin": [ 62, 71 ], "hormone": [ 63 ], "healthy": [ 65 ], "people,": [ 66 ], "causative": [ 67 ], "most": [ 69 ], "effects,": [ 72 ], "but": [ 73 ], "after": [ 77 ], "type": [ 81 ], "2": [ 82 ], "diabetes": [ 83 ], "mellitus": [ 84 ], "(T2DM)": [ 85 ], "strongly": [ 87 ], "reduced.": [ 88 ], "Therefore,": [ 89 ], "past": [ 92 ], "been": [ 95, 106, 114 ], "considered": [ 96 ], "an": [ 97 ], "unappealing": [ 98 ], "therapeutic": [ 99, 286 ], "target": [ 100 ], "for": [ 101, 136, 145, 149, 240 ], "T2DM.": [ 102 ], "This": [ 103, 131 ], "conception": [ 104 ], "changing": [ 107 ], "during": [ 108 ], "recent": [ 109 ], "years,": [ 110 ], "since": [ 111, 256 ], "it": [ 112, 186, 248, 257 ], "reported": [ 115 ], "that": [ 116, 193, 225 ], "resistance": [ 117 ], "can": [ 120 ], "be": [ 121, 173, 228, 235, 253 ], "reversed": [ 122 ], "effectiveness": [ 125 ], "restored": [ 126 ], "by": [ 127 ], "improving": [ 128 ], "glycemic": [ 129 ], "control.": [ 130 ], "fact": [ 132 ], "paved": [ 133 ], "way": [ 135 ], "development": [ 138 ], "a": [ 140, 154, 176, 182, 188, 236, 281 ], "receptor": [ 142, 157, 168, 223 ], "agonist-based": [ 143 ], "therapy": [ 144 ], "T2DM,": [ 146 ], "looking": [ 147 ], "possibility": [ 151 ], "finding": [ 153 ], "combined": [ 155 ], "GLP-1/GIP": [ 156, 222 ], "agonist.": [ 158 ], "In": [ 159 ], "this": [ 160 ], "framework,": [ 161 ], "novel": [ 163, 282 ], "dual": [ 164, 221 ], "agonist": [ 169 ], "tirzepatide": [ 170 ], "seems": [ 171 ], "not": [ 174 ], "just": [ 175 ], "new": [ 177 ], "antidiabetic": [ 178 ], "medication.": [ 179 ], "Administered": [ 180 ], "subcutaneous": [ 183 ], "weekly": [ 184 ], "injection,": [ 185 ], "manifold": [ 189 ], "single": [ 190 ], "pharmacological": [ 191 ], "agent": [ 192 ], "ability": [ 196 ], "significantly": [ 198 ], "lower": [ 199 ], "glucose": [ 200 ], "levels,": [ 201 ], "well": [ 203 ], "improve": [ 205 ], "sensitivity,": [ 207 ], "reduce": [ 208 ], "weight": [ 209 ], "amend": [ 211 ], "dyslipidemia": [ 212 ], "favorably": [ 213 ], "modifying": [ 214 ], "lipid": [ 216 ], "profile.": [ 217 ], "Tirzepatide": [ 218 ], "additional": [ 220 ], "agonists": [ 224 ], "could": [ 226 ], "eventually": [ 227 ], "developed": [ 229 ], "future": [ 232 ], "seem": [ 233 ], "promising": [ 237 ], "furthest": [ 238 ], "advance": [ 239 ], "management": [ 242 ], "several": [ 244 ], "cardiometabolic": [ 245 ], "settings.": [ 246 ], "Obviously,": [ 247 ], "too": [ 250 ], "early": [ 251 ], "overly": [ 254 ], "hopeful": [ 255 ], "still": [ 259 ], "necessary": [ 260 ], "determine": [ 262 ], "long-term": [ 264 ], "effects": [ 265 ], "these": [ 267 ], "compounds": [ 268 ], "properly": [ 270 ], "verify": [ 271 ], "potential": [ 273 ], "cardiovascular": [ 274 ], "benefits.": [ 275 ], "Anyway,": [ 276 ], "we": [ 277 ], "currently": [ 279 ], "facing": [ 280 ], "very": [ 284 ], "appealing": [ 285 ], "option.": [ 287 ] }, "publication_date": "2021-11-24", "publication_year": 2021, "type": "article", "cited_by_count": 92, "authors": [ { "id": "https://openalex.org/A5066402379", "display_name": "Enrique Z. Fisman" }, { "id": "https://openalex.org/A5046330272", "display_name": "Alexander Tenenbaum" } ] }, { "id": "https://openalex.org/W4400430779", "doi": "https://doi.org/10.3389/fphar.2024.1416985", "title": "Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events", "abstract": { "Aims:": [ 0 ], "Glucagon-like": [ 1 ], "peptide-1": [ 2 ], "receptor": [ 3 ], "agonists": [ 4 ], "(GLP-1": [ 5 ], "RAs)": [ 6 ], "are": [ 7, 314 ], "employed": [ 8, 119, 135 ], "extensively": [ 9 ], "in": [ 10, 38, 141 ], "the": [ 11, 47, 59, 76, 88, 94, 142, 236, 279, 288, 347 ], "management": [ 12 ], "of": [ 13, 24, 53, 90, 97, 129, 144, 199, 271, 349 ], "type": [ 14 ], "2": [ 15 ], "diabetes": [ 16 ], "and": [ 17, 30, 34, 49, 61, 112, 131, 169, 184, 194, 260, 278, 287, 296, 312, 319, 329 ], "obesity.": [ 18 ], "However,": [ 19 ], "there": [ 20 ], "is": [ 21 ], "a": [ 22 ], "paucity": [ 23 ], "real-world": [ 25 ], "data": [ 26, 72 ], "on": [ 27 ], "their": [ 28 ], "safety": [ 29, 51 ], "tolerability": [ 31 ], "for": [ 32, 83, 147, 151, 155, 159, 163, 167, 172, 244, 291, 293, 346 ], "metabolic": [ 33, 48, 318 ], "nutritional": [ 35, 50, 320 ], "adverse": [ 36 ], "events": [ 37 ], "large": [ 39 ], "sample": [ 40 ], "populations.": [ 41 ], "This": [ 42 ], "study": [ 43, 307 ], "aimed": [ 44 ], "to": [ 45, 120, 136, 241, 268, 317, 332 ], "analyse": [ 46 ], "signatures": [ 52 ], "different": [ 54, 275 ], "GLP-1": [ 55, 85, 281, 324, 341 ], "RAs": [ 56, 282, 342 ], "by": [ 57 ], "exploring": [ 58 ], "Food": [ 60 ], "Drug": [ 62 ], "Administration": [ 63 ], "(FDA)": [ 64 ], "Adverse": [ 65, 78 ], "Event": [ 66, 79 ], "Reporting": [ 67, 80 ], "System": [ 68, 81 ], "(FAERS).": [ 69 ], "Methods:": [ 70 ], "AEs": [ 71, 321 ], "were": [ 73, 118, 190, 203 ], "extracted": [ 74 ], "from": [ 75, 87 ], "FDA": [ 77 ], "database": [ 82 ], "each": [ 84 ], "RA": [ 86 ], "time": [ 89, 267 ], "its": [ 91 ], "launch": [ 92 ], "until": [ 93 ], "second": [ 95 ], "quarter": [ 96 ], "2023.": [ 98 ], "The": [ 99, 197, 266 ], "reported": [ 100 ], "odds": [ 101 ], "ratio": [ 102, 106 ], "(ROR),": [ 103 ], "proportional": [ 104 ], "reporting": [ 105 ], "(PRR),": [ 107 ], "Empirical": [ 108 ], "Bayesian": [ 109, 113 ], "Geometric": [ 110 ], "Mean": [ 111 ], "Confidence": [ 114 ], "Propagation": [ 115 ], "Neural": [ 116 ], "Network": [ 117 ], "identify": [ 121 ], "AE": [ 122, 138, 200, 239, 272 ], "signals.": [ 123 ], "Results:": [ 124 ], "A": [ 125 ], "system": [ 126 ], "organ": [ 127 ], "class": [ 128 ], "metabolism": [ 130, 193 ], "nutrition": [ 132, 195 ], "disorders": [ 133 ], "was": [ 134, 235, 273 ], "filter": [ 137 ], "reports,": [ 139 ], "resulting": [ 140 ], "identification": [ 143 ], "10,450": [ 145 ], "reports": [ 146, 150, 154, 158, 162, 166, 171 ], "exenatide,": [ 148, 310 ], "2,860": [ 149 ], "liraglutide,": [ 152, 294, 311 ], "240": [ 153 ], "albiglutide,": [ 156 ], "4,847": [ 157 ], "dulaglutide,": [ 160, 295, 327 ], "2,905": [ 161 ], "semaglutide,": [ 164, 328 ], "1,089": [ 165 ], "tirzepatide,": [ 168 ], "13": [ 170 ], "lixisenatide.": [ 173 ], "Semaglutide": [ 174 ], "(ROR,": [ 175, 180, 186 ], "3.34;": [ 176 ], "95%CI,": [ 177, 182, 188 ], "3.22),": [ 178 ], "liraglutide": [ 179, 222, 245 ], "2.78;": [ 181 ], "2.69),": [ 183 ], "exenatide": [ 185, 218, 277 ], "2.15;": [ 187 ], "2.11)": [ 189 ], "associated": [ 191 ], "with": [ 192 ], "disorders.": [ 196, 351 ], "number": [ 198 ], "signals": [ 201 ], "detected": [ 202 ], "as": [ 204 ], "follows:": [ 205 ], "albiglutide": [ 206 ], "(n": [ 207, 211, 215, 219, 223, 227, 231, 246, 251, 256, 262 ], "=": [ 208, 212, 216, 220, 224, 228, 232, 247, 252, 257, 263 ], "1),": [ 209 ], "lixisenatide": [ 210 ], "2),": [ 213 ], "tirzepatide": [ 214, 261 ], "11),": [ 217 ], "12),": [ 221 ], "16),": [ 225 ], "semaglutide": [ 226, 255, 297, 313 ], "20),": [ 229 ], "dulaglutide": [ 230, 250 ], "22).": [ 233 ], "Dehydration": [ 234 ], "most": [ 237 ], "frequent": [ 238 ], "contributing": [ 240 ], "serious": [ 242 ], "outcomes": [ 243 ], "318,": [ 248 ], "23.93%),": [ 249 ], "434,": [ 253 ], "20.90%),": [ 254 ], "370,": [ 258 ], "25.10%)": [ 259 ], "70,": [ 264 ], "32.86%).": [ 265 ], "onset": [ 269 ], "(TTO)": [ 270 ], "statistically": [ 274 ], "between": [ 276 ], "other": [ 280, 323 ], "(": [ 283 ], "p": [ 284 ], "&lt;": [ 285 ], "0.001),": [ 286 ], "Weibull": [ 289 ], "parameters": [ 290 ], "dehydration": [ 292 ], "analyses": [ 298 ], "all": [ 299 ], "showed": [ 300 ], "an": [ 301 ], "early": [ 302 ], "failure-type": [ 303 ], "profile.": [ 304 ], "Conclusion:": [ 305 ], "Our": [ 306 ], "suggests": [ 308 ], "that": [ 309 ], "more": [ 315 ], "susceptible": [ 316 ], "than": [ 322 ], "RAs.": [ 325 ], "Liraglutide,": [ 326 ], "tirzepaptide\u2019s": [ 330 ], "potential": [ 331, 345 ], "induce": [ 333 ], "dehydration,": [ 334 ], "necessitates": [ 335 ], "special": [ 336 ], "attention.": [ 337 ], "Despite": [ 338 ], "certain": [ 339 ], "deficiencies,": [ 340 ], "have": [ 343 ], "considerable": [ 344 ], "treatment": [ 348 ], "eating": [ 350 ] }, "publication_date": "2024-07-08", "publication_year": 2024, "type": "article", "cited_by_count": 17, "authors": [ { "id": "https://openalex.org/A5100779346", "display_name": "Long He" }, { "id": "https://openalex.org/A5101571454", "display_name": "Qiuyu Li" }, { "id": "https://openalex.org/A5101999024", "display_name": "Yongfeng Yang" }, { "id": "https://openalex.org/A5100328382", "display_name": "Jiahao Li" }, { "id": "https://openalex.org/A5007279056", "display_name": "Wei Luo" }, { "id": "https://openalex.org/A5103012547", "display_name": "Yilan Huang" }, { "id": "https://openalex.org/A5100529610", "display_name": "Xiaoyan Zhong" } ] }, { "id": "https://openalex.org/W1983581861", "doi": "https://doi.org/10.1038/oby.2011.152", "title": "Effects of Combined Exenatide and Pioglitazone Therapy on Hepatic Fat Content in Type 2 Diabetes", "abstract": { "We": [ 0, 276 ], "examined": [ 1 ], "the": [ 2, 109, 234, 263, 301 ], "effects": [ 3 ], "of": [ 4, 236, 303 ], "combined": [ 5, 77, 271, 279 ], "pioglitazone": [ 6, 66, 80, 162, 194, 231, 272, 284, 304 ], "(peroxisome": [ 7 ], "proliferator\u2010activated": [ 8 ], "receptor\u2010\u03b3": [ 9 ], "(PPAR\u2010\u03b3)": [ 10 ], "agonist)": [ 11, 16 ], "and": [ 12, 22, 83, 102, 132, 184, 195, 211, 226, 252, 273, 285 ], "exenatide": [ 13, 84, 196, 274, 286 ], "(GLP\u20101": [ 14 ], "receptor": [ 15 ], "therapy": [ 17, 78, 197, 232, 287, 305 ], "on": [ 18, 57 ], "hepatic": [ 19, 99, 217, 295 ], "fat": [ 20, 100, 153, 218, 296 ], "content": [ 21, 101, 297 ], "plasma": [ 23, 103, 116, 143, 206, 227 ], "adiponectin": [ 24, 104, 144, 207 ], "levels": [ 25, 105 ], "in": [ 26, 205, 216, 240, 265, 280, 294 ], "patients": [ 27, 35, 281 ], "with": [ 28, 64, 79, 200, 282, 290 ], "type": [ 29 ], "2": [ 30 ], "diabetes": [ 31 ], "(T2DM).": [ 32 ], "Twenty\u2010one": [ 33 ], "T2DM": [ 34 ], "(age": [ 36 ], "=": [ 37, 43, 53, 74, 95, 136, 190, 209, 244, 307 ], "52": [ 38 ], "\u00b1": [ 39, 45, 55, 165, 169, 220, 224 ], "3": [ 40 ], "years,": [ 41 ], "BMI": [ 42 ], "32.0": [ 44 ], "1.5,": [ 46 ], "hemoglobin": [ 47 ], "A": [ 48 ], "1c": [ 49, 51, 134 ], "(HbA": [ 50 ], ")": [ 52 ], "8.2": [ 54 ], "0.4%)": [ 56 ], "diet": [ 58 ], "and/or": [ 59 ], "metformin": [ 60 ], "received": [ 61 ], "additional": [ 62 ], "treatment": [ 63, 111, 163 ], "either": [ 65 ], "45": [ 67 ], "mg/day": [ 68 ], "for": [ 69, 90 ], "12": [ 70, 91 ], "months": [ 71, 92 ], "(": [ 72, 93, 119, 128, 148, 180 ], "n": [ 73, 94 ], "10)": [ 75 ], "or": [ 76 ], "(45": [ 81 ], "mg/day)": [ 82 ], "(10": [ 85 ], "\u00b5g": [ 86 ], "subcutaneously": [ 87 ], "twice": [ 88 ], "daily)": [ 89 ], "11).": [ 96 ], "At": [ 97 ], "baseline,": [ 98 ], "were": [ 106, 256 ], "similar": [ 107 ], "between": [ 108 ], "two": [ 110 ], "groups.": [ 112 ], "Pioglitazone": [ 113 ], "reduced": [ 114, 160 ], "fasting": [ 115, 123 ], "glucose": [ 117 ], "(FPG)": [ 118 ], "P": [ 120, 129, 138, 149, 171, 181, 311 ], "<": [ 121, 130, 139, 150, 172, 182, 312 ], "0.05),": [ 122, 131 ], "free": [ 124 ], "fatty": [ 125 ], "acid": [ 126 ], "(FFA)": [ 127 ], "HbA": [ 133 ], "(\u0394": [ 135, 189, 208, 243, 306 ], "1.0%,": [ 137 ], "0.01),": [ 140 ], "while": [ 141 ], "increasing": [ 142 ], "concentration": [ 145, 176 ], "by": [ 146, 178, 259 ], "86%": [ 147 ], "0.05).": [ 151, 173, 313 ], "Hepatic": [ 152, 247 ], "(magnetic": [ 154 ], "resonance": [ 155 ], "spectroscopy": [ 156 ], "(MRS))": [ 157 ], "was": [ 158, 198, 267 ], "significantly": [ 159, 188, 202, 213, 257, 268 ], "following": [ 161, 270 ], "(11.0": [ 164 ], "3.1": [ 166 ], "to": [ 167, 222, 300 ], "6.5": [ 168 ], "1.9%,": [ 170 ], "Plasma": [ 174 ], "triglyceride": [ 175, 228 ], "decreased": [ 177, 258 ], "14%": [ 179 ], "0.05)": [ 183 ], "body": [ 185, 241 ], "weight": [ 186, 242 ], "increased": [ 187 ], "3.7": [ 191 ], "kg).": [ 192, 246 ], "Combined": [ 193 ], "associated": [ 199, 289 ], "a": [ 201, 212, 237, 291 ], "greater": [ 203, 214, 269, 292 ], "increase": [ 204 ], "193%)": [ 210 ], "decrease": [ 215 ], "(12.1": [ 219 ], "1.7": [ 221 ], "4.7": [ 223 ], "1.3%)": [ 225 ], "(38%)": [ 229 ], "vs.": [ 230, 309 ], "despite": [ 233 ], "lack": [ 235 ], "significant": [ 238 ], "change": [ 239 ], "0.2": [ 245 ], "injury": [ 248 ], "biomarkers": [ 249 ], "aspartate": [ 250 ], "aminotransferase": [ 251, 254 ], "alanine": [ 253 ], "(ALT)": [ 255 ], "both": [ 260 ], "treatments;": [ 261 ], "however,": [ 262 ], "reduction": [ 264, 293 ], "ALT": [ 266 ], "therapy.": [ 275 ], "conclude": [ 277 ], "that": [ 278 ], "T2DM,": [ 283 ], "is": [ 288 ], "as": [ 298 ], "compared": [ 299 ], "addition": [ 302 ], "61%": [ 308 ], "41%,": [ 310 ] }, "publication_date": "2011-06-09", "publication_year": 2011, "type": "article", "cited_by_count": 119, "authors": [ { "id": "https://openalex.org/A5029470140", "display_name": "Padma Sathyanarayana" }, { "id": "https://openalex.org/A5057652642", "display_name": "Medhavi Jogi" }, { "id": "https://openalex.org/A5081250834", "display_name": "Raja Muthupillai" }, { "id": "https://openalex.org/A5004146948", "display_name": "Ramkumar Krishnamurthy" }, { "id": "https://openalex.org/A5007146249", "display_name": "Susan L. Samson" }, { "id": "https://openalex.org/A5072087217", "display_name": "Mandeep Bajaj" } ] }, { "id": "https://openalex.org/W3119307884", "doi": "https://doi.org/10.2337/dc20-1473", "title": "Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)", "abstract": { "OBJECTIVE": [ 0 ], "To": [ 1 ], "compare": [ 2 ], "efficacy": [ 3, 82, 94, 159, 188 ], "and": [ 4, 12, 93, 109, 122, 266, 306 ], "safety": [ 5, 312 ], "of": [ 6, 10, 55, 87 ], "dulaglutide": [ 7, 38, 56, 129, 290 ], "at": [ 8, 68, 220 ], "doses": [ 9 ], "3.0": [ 11, 41, 57, 176, 294 ], "4.5": [ 13, 44, 60, 130, 210, 263, 274, 297 ], "mg": [ 14, 17, 45, 58, 61, 64, 131, 139, 177, 182, 211, 216, 292, 295, 298 ], "versus": [ 15 ], "1.5": [ 16, 39, 63, 138, 181, 215, 291 ], "in": [ 18, 65, 76, 100, 111, 304 ], "patients": [ 19, 114, 279 ], "with": [ 20, 26, 137, 280, 309 ], "type": [ 21, 281 ], "2": [ 22, 282 ], "diabetes": [ 23, 283 ], "inadequately": [ 24, 284 ], "controlled": [ 25, 285 ], "metformin.": [ 27 ], "RESEARCH": [ 28 ], "DESIGN": [ 29 ], "AND": [ 30 ], "METHODS": [ 31 ], "Patients": [ 32 ], "were": [ 33 ], "randomly": [ 34, 102, 112 ], "assigned": [ 35, 103, 113 ], "to": [ 36, 180, 214, 293 ], "once-weekly": [ 37 ], "mg,": [ 40, 42, 258, 261, 264, 269, 272, 275 ], "or": [ 43, 90, 296 ], "for": [ 46, 183, 217, 223 ], "52": [ 47 ], "weeks.": [ 48, 70 ], "The": [ 49 ], "primary": [ 50 ], "objective": [ 51 ], "was": [ 52, 118, 178, 212 ], "determining": [ 53 ], "superiority": [ 54, 72 ], "and/or": [ 59 ], "over": [ 62 ], "HbA1c": [ 66, 108, 134, 305 ], "reduction": [ 67 ], "36": [ 69, 127, 221, 253 ], "Secondary": [ 71 ], "objectives": [ 73 ], "included": [ 74, 255 ], "change": [ 75 ], "body": [ 77, 307 ], "weight.": [ 78 ], "Two": [ 79 ], "estimands": [ 80, 225 ], "addressed": [ 81 ], "objectives:": [ 83 ], "treatment": [ 84, 88, 96, 150 ], "regimen": [ 85 ], "(regardless": [ 86 ], "discontinuation": [ 89 ], "rescue": [ 91, 98 ], "medication)": [ 92, 99 ], "(on": [ 95 ], "without": [ 97 ], "all": [ 101 ], "patients.": [ 104 ], "RESULTS": [ 105 ], "Mean": [ 106 ], "baseline": [ 107 ], "BMI": [ 110 ], "(N": [ 115 ], "=": [ 116, 195, 207 ], "1,842)": [ 117 ], "8.6%": [ 119 ], "(70": [ 120 ], "mmol/mol)": [ 121 ], "34.2": [ 123 ], "kg/m2,": [ 124 ], "respectively.": [ 125 ], "At": [ 126 ], "weeks,": [ 128 ], "provided": [ 132, 299 ], "superior": [ 133, 179, 213 ], "reductions": [ 135, 303 ], "compared": [ 136 ], "(treatment-regimen": [ 140 ], "estimand:": [ 141, 160 ], "\u22121.77": [ 142 ], "vs.": [ 143, 146, 162, 165, 229, 240 ], "\u22121.54%": [ 144 ], "[\u221219.4": [ 145 ], "\u221216.8": [ 147 ], "mmol/mol],": [ 148, 167 ], "estimated": [ 149 ], "difference": [ 151 ], "[ETD]": [ 152 ], "\u22120.24%": [ 153 ], "(\u22122.6": [ 154 ], "mmol/mol),": [ 155, 171 ], "P": [ 156, 172, 194, 206, 235, 246 ], "&lt;": [ 157, 173, 236, 247 ], "0.001;": [ 158, 237 ], "\u22121.87": [ 161 ], "\u22121.53%": [ 163 ], "[\u221220.4": [ 164 ], "\u221216.7": [ 166 ], "ETD": [ 168, 232, 243 ], "\u22120.34%": [ 169 ], "(\u22123.7": [ 170 ], "0.001).": [ 174, 248 ], "Dulaglutide": [ 175, 209 ], "reducing": [ 184 ], "HbA1c,": [ 185 ], "using": [ 186 ], "the": [ 187, 199 ], "estimand": [ 189, 201 ], "(ETD": [ 190, 202 ], "\u22120.17%": [ 191 ], "[\u22121.9": [ 192 ], "mmol/mol];": [ 193, 205 ], "0.003)": [ 196 ], "but": [ 197 ], "not": [ 198 ], "treatment-regimen": [ 200 ], "\u22120.10%": [ 203 ], "[\u22121.1": [ 204 ], "0.096).": [ 208 ], "weight": [ 218, 308 ], "loss": [ 219 ], "weeks": [ 222, 254 ], "both": [ 224 ], "(treatment": [ 226 ], "regimen:": [ 227 ], "\u22124.6": [ 228 ], "\u22123.0": [ 230 ], "kg,": [ 231, 234, 242, 245 ], "\u22121.6": [ 233, 244 ], "efficacy:": [ 238 ], "\u22124.7": [ 239 ], "\u22123.1": [ 241 ], "Common": [ 249 ], "adverse": [ 250 ], "events": [ 251 ], "through": [ 252 ], "nausea": [ 256 ], "(1.5": [ 257, 268 ], "13.4%;": [ 259 ], "3": [ 260, 271 ], "15.6%;": [ 262 ], "16.4%)": [ 265 ], "vomiting": [ 267 ], "5.6%;": [ 270 ], "8.3%;": [ 273 ], "9.3%).": [ 276 ], "CONCLUSIONS": [ 277 ], "In": [ 278 ], "by": [ 286 ], "metformin,": [ 287 ], "escalation": [ 288 ], "from": [ 289 ], "clinically": [ 300 ], "relevant,": [ 301 ], "dose-related": [ 302 ], "a": [ 310 ], "similar": [ 311 ], "profile.": [ 313 ] }, "publication_date": "2021-01-04", "publication_year": 2021, "type": "article", "cited_by_count": 167, "authors": [ { "id": "https://openalex.org/A5086072427", "display_name": "Juan P. Fr\u00edas" }, { "id": "https://openalex.org/A5054048049", "display_name": "Enzo Bonora" }, { "id": "https://openalex.org/A5112598273", "display_name": "Luis Nev\u00e1rez Ruiz" }, { "id": "https://openalex.org/A5003331531", "display_name": "Ying G. Li" }, { "id": "https://openalex.org/A5046165783", "display_name": "Zhuoxin Yu" }, { "id": "https://openalex.org/A5024563374", "display_name": "Zvonko Mili\u010devi\u0107" }, { "id": "https://openalex.org/A5012989716", "display_name": "Raleigh Malik" }, { "id": "https://openalex.org/A5065924611", "display_name": "M. Angelyn Bethel" }, { "id": "https://openalex.org/A5014043242", "display_name": "David A. Cox" } ] }, { "id": "https://openalex.org/W1987270716", "doi": "https://doi.org/10.1016/j.diabres.2013.12.041", "title": "The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy", "abstract": null, "publication_date": "2014-01-06", "publication_year": 2014, "type": "article", "cited_by_count": 45, "authors": [ { "id": "https://openalex.org/A5052879144", "display_name": "Lakshminarayanan Varadhan" }, { "id": "https://openalex.org/A5042173664", "display_name": "Tracy Humphreys" }, { "id": "https://openalex.org/A5010103732", "display_name": "Adrian B Walker" }, { "id": "https://openalex.org/A5002098240", "display_name": "George Varughese" } ] }, { "id": "https://openalex.org/W2276028032", "doi": "https://doi.org/10.1007/s13300-016-0155-1", "title": "A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus", "abstract": null, "publication_date": "2016-02-17", "publication_year": 2016, "type": "review", "cited_by_count": 42, "authors": [ { "id": "https://openalex.org/A5046919539", "display_name": "Sheena Kayaniyil" }, { "id": "https://openalex.org/A5082817242", "display_name": "Greta Lozano\u2010Ortega" }, { "id": "https://openalex.org/A5071811427", "display_name": "Heather A. Bennett" }, { "id": "https://openalex.org/A5062793550", "display_name": "Kristina Johnsson" }, { "id": "https://openalex.org/A5044449612", "display_name": "Alka Shaunik" }, { "id": "https://openalex.org/A5035420893", "display_name": "Susan Grandy" }, { "id": "https://openalex.org/A5074693806", "display_name": "Bernt Kartman" } ] }, { "id": "https://openalex.org/W3118786201", "doi": "https://doi.org/10.1038/s42255-021-00344-4", "title": "Central and peripheral GLP-1 systems independently suppress eating", "abstract": null, "publication_date": "2021-02-15", "publication_year": 2021, "type": "article", "cited_by_count": 232, "authors": [ { "id": "https://openalex.org/A5035201872", "display_name": "Daniel I. Brierley" }, { "id": "https://openalex.org/A5059205572", "display_name": "Marie K. Holt" }, { "id": "https://openalex.org/A5018985683", "display_name": "Arashdeep Singh" }, { "id": "https://openalex.org/A5042861247", "display_name": "Alan de Araujo" }, { "id": "https://openalex.org/A5020342052", "display_name": "Molly McDougle" }, { "id": "https://openalex.org/A5060799429", "display_name": "Macarena Vergara" }, { "id": "https://openalex.org/A5069016635", "display_name": "Majd H. Afaghani" }, { "id": "https://openalex.org/A5110301835", "display_name": "Shin Jae Lee" }, { "id": "https://openalex.org/A5002827970", "display_name": "Karen A. Scott" }, { "id": "https://openalex.org/A5051674943", "display_name": "Calyn B. Maske" }, { "id": "https://openalex.org/A5102776375", "display_name": "Wolfgang Langhans" }, { "id": "https://openalex.org/A5043580237", "display_name": "Eric G. Krause" }, { "id": "https://openalex.org/A5036979170", "display_name": "Annette D. de Kloet" }, { "id": "https://openalex.org/A5002740985", "display_name": "Fiona M. Gribble" }, { "id": "https://openalex.org/A5020444111", "display_name": "Frank Reimann" }, { "id": "https://openalex.org/A5040598688", "display_name": "Linda Rinaman" }, { "id": "https://openalex.org/A5002779994", "display_name": "Guillaume de Lartigue" }, { "id": "https://openalex.org/A5103240189", "display_name": "Stefan Trapp" } ] }, { "id": "https://openalex.org/W3093879544", "doi": "https://doi.org/10.1038/s41598-020-74912-1", "title": "GLP-1 receptor agonist ameliorates experimental lung fibrosis", "abstract": null, "publication_date": "2020-10-22", "publication_year": 2020, "type": "article", "cited_by_count": 47, "authors": [ { "id": "https://openalex.org/A5037462792", "display_name": "Juan Fandi\u00f1o" }, { "id": "https://openalex.org/A5087816743", "display_name": "Laura Toba" }, { "id": "https://openalex.org/A5090051162", "display_name": "Lucas C. Gonz\u00e1lez-Mat\u00edas" }, { "id": "https://openalex.org/A5057841370", "display_name": "Yolanda Diz-Chaves" }, { "id": "https://openalex.org/A5074609207", "display_name": "Federico Mallo" } ] }, { "id": "https://openalex.org/W2809697129", "doi": "https://doi.org/10.1038/s41598-018-28496-6", "title": "Integrated Brain Atlas for Unbiased Mapping of Nervous System Effects Following Liraglutide Treatment", "abstract": null, "publication_date": "2018-07-03", "publication_year": 2018, "type": "article", "cited_by_count": 90, "authors": [ { "id": "https://openalex.org/A5112481533", "display_name": "Casper Bo Gravesen Salinas" }, { "id": "https://openalex.org/A5055643415", "display_name": "Tess Tsai-Hsiu Lu" }, { "id": "https://openalex.org/A5028859185", "display_name": "Sanaz Gabery" }, { "id": "https://openalex.org/A5064006763", "display_name": "Kasper Marstal" }, { "id": "https://openalex.org/A5050465677", "display_name": "Tomas Alanentalo" }, { "id": "https://openalex.org/A5044811565", "display_name": "Aaron J. Mercer" }, { "id": "https://openalex.org/A5109058258", "display_name": "Anda Cornea" }, { "id": "https://openalex.org/A5027390018", "display_name": "Knut Conradsen" }, { "id": "https://openalex.org/A5067103368", "display_name": "Jacob Hecksher\u2010S\u00f8rensen" }, { "id": "https://openalex.org/A5031953389", "display_name": "Anders Bjorholm Dahl" }, { "id": "https://openalex.org/A5088627727", "display_name": "Lotte Bjerre Knudsen" }, { "id": "https://openalex.org/A5013985442", "display_name": "Anna Secher" } ] }, { "id": "https://openalex.org/W2048532245", "doi": "https://doi.org/10.1007/s40265-014-0320-7", "title": "Dulaglutide: First Global Approval", "abstract": null, "publication_date": "2014-11-01", "publication_year": 2014, "type": "review", "cited_by_count": 50, "authors": [ { "id": "https://openalex.org/A5110106420", "display_name": "Mark Sanford" } ] }, { "id": "https://openalex.org/W4296360201", "doi": "https://doi.org/10.3390/medicines9090047", "title": "The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study", "abstract": { "Background": [ 0 ], "and": [ 1, 15, 22, 37, 44, 50, 75, 96, 108, 111, 120, 144, 151, 155 ], "Objectives:": [ 2 ], "This": [ 3 ], "study": [ 4 ], "aimed": [ 5 ], "to": [ 6 ], "investigate": [ 7 ], "the": [ 8, 81, 89, 91, 97, 100, 113, 133, 156, 159, 172, 181 ], "changes": [ 9 ], "in": [ 10, 18, 183 ], "obesity": [ 11, 21 ], "severity,": [ 12 ], "glucose": [ 13, 101, 107 ], "metabolism,": [ 14 ], "body": [ 16, 45, 59, 92, 177 ], "composition": [ 17, 46 ], "patients": [ 19 ], "with": [ 20, 28 ], "type": [ 23, 185 ], "2": [ 24, 186 ], "diabetes": [ 25 ], "mellitus": [ 26 ], "treated": [ 27 ], "glucagon-like": [ 29 ], "peptide": [ 30 ], "1": [ 31 ], "receptor": [ 32 ], "agonist": [ 33 ], "(GLP1-RA)": [ 34 ], "semaglutide.": [ 35 ], "Materials": [ 36 ], "Methods:": [ 38 ], "Body": [ 39 ], "weight": [ 40, 63 ], "(BW),": [ 41 ], "metabolic": [ 42, 102 ], "parameters,": [ 43 ], "were": [ 47, 78, 162 ], "examined": [ 48 ], "before": [ 49 ], "3": [ 51, 136 ], "months": [ 52 ], "after": [ 53, 122, 135 ], "semaglutide": [ 54, 123, 128, 165, 174 ], "administration.": [ 55 ], "The": [ 56 ], "mass": [ 57, 66, 93 ], "of": [ 58, 67, 99, 115, 158 ], "fat": [ 60, 62 ], "(FM),": [ 61 ], "percentage": [ 64, 73 ], "(%FM),": [ 65 ], "skeletal": [ 68, 71 ], "muscle": [ 69, 140, 147 ], "(MM),": [ 70 ], "MM": [ 72, 182 ], "(%MM),": [ 74 ], "limb": [ 76, 139 ], "muscles": [ 77, 161 ], "measured": [ 79 ], "using": [ 80 ], "bioelectrical": [ 82 ], "impedance": [ 83 ], "method.": [ 84 ], "Results:": [ 85 ], "Semaglutide": [ 86 ], "dramatically": [ 87 ], "reduced": [ 88 ], "weight,": [ 90 ], "index": [ 94 ], "(BMI),": [ 95 ], "levels": [ 98 ], "markers,": [ 103 ], "including": [ 104 ], "fasting": [ 105 ], "blood": [ 106 ], "hemoglobin": [ 109 ], "A1c,": [ 110 ], "accelerated": [ 112 ], "loss": [ 114 ], "excess": [ 116 ], "BW.": [ 117 ], "FM,": [ 118 ], "MM,": [ 119 ], "%FM": [ 121 ], "treatment": [ 124 ], "also": [ 125 ], "decreased.": [ 126 ], "Conversely,": [ 127 ], "had": [ 129 ], "no": [ 130 ], "effect": [ 131 ], "on": [ 132 ], "%MM": [ 134 ], "months.": [ 137 ], "In": [ 138 ], "analyses,": [ 141 ], "right": [ 142 ], "upper": [ 143, 150 ], "lower": [ 145, 152 ], "leg": [ 146, 153 ], "percentages,": [ 148 ], "left": [ 149 ], "muscles,": [ 154 ], "ratios": [ 157 ], "lower/upper": [ 160 ], "maintained": [ 163 ], "by": [ 164 ], "treatment.": [ 166 ], "Conclusions:": [ 167 ], "These": [ 168 ], "results": [ 169 ], "suggest": [ 170 ], "that": [ 171 ], "GLP1-RA": [ 173 ], "effectively": [ 175 ], "reduces": [ 176 ], "adiposity": [ 178 ], "while": [ 179 ], "maintaining": [ 180 ], "obese": [ 184 ], "diabetic": [ 187 ], "patients.": [ 188 ] }, "publication_date": "2022-09-16", "publication_year": 2022, "type": "article", "cited_by_count": 41, "authors": [ { "id": "https://openalex.org/A5056982712", "display_name": "Yoshinori Ozeki" }, { "id": "https://openalex.org/A5034593993", "display_name": "Takayuki Masaki" }, { "id": "https://openalex.org/A5072944169", "display_name": "Akari Kamata" }, { "id": "https://openalex.org/A5030419896", "display_name": "Shotaro Miyamoto" }, { "id": "https://openalex.org/A5005572945", "display_name": "Yuichi Yoshida" }, { "id": "https://openalex.org/A5044706467", "display_name": "Mitsuhiro Okamoto" }, { "id": "https://openalex.org/A5036019539", "display_name": "Koro Gotoh" }, { "id": "https://openalex.org/A5084913194", "display_name": "Hirotaka Shibata" } ] }, { "id": "https://openalex.org/W4281778950", "doi": "https://doi.org/10.1056/nejmoa2204601", "title": "Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes", "abstract": { "Treatment": [ 0 ], "with": [ 1, 26, 34 ], "dulaglutide": [ 2 ], "at": [ 3 ], "a": [ 4 ], "once-weekly": [ 5 ], "dose": [ 6 ], "of": [ 7 ], "0.75": [ 8 ], "mg": [ 9, 12 ], "or": [ 10, 35, 38 ], "1.5": [ 11 ], "was": [ 13 ], "superior": [ 14 ], "to": [ 15 ], "placebo": [ 16 ], "in": [ 17 ], "improving": [ 18 ], "glycemic": [ 19 ], "control": [ 20 ], "through": [ 21 ], "26": [ 22 ], "weeks": [ 23 ], "among": [ 24 ], "youths": [ 25 ], "type": [ 27 ], "2": [ 28 ], "diabetes": [ 29 ], "who": [ 30 ], "were": [ 31 ], "being": [ 32 ], "treated": [ 33 ], "without": [ 36, 41 ], "metformin": [ 37 ], "basal": [ 39 ], "insulin,": [ 40 ], "an": [ 42 ], "effect": [ 43 ], "on": [ 44 ], "BMI.": [ 45 ], "(Funded": [ 46 ], "by": [ 47 ], "Eli": [ 48 ], "Lilly;": [ 49 ], "AWARD-PEDS": [ 50 ], "ClinicalTrials.gov": [ 51 ], "number,": [ 52 ], "NCT02963766.).": [ 53 ] }, "publication_date": "2022-06-04", "publication_year": 2022, "type": "article", "cited_by_count": 120, "authors": [ { "id": "https://openalex.org/A5044519340", "display_name": "Silva Arslanian" }, { "id": "https://openalex.org/A5108246913", "display_name": "Tamara S. Hannon" }, { "id": "https://openalex.org/A5007232966", "display_name": "Philip Zeitler" }, { "id": "https://openalex.org/A5008619893", "display_name": "Lily C. Chao" }, { "id": "https://openalex.org/A5045597872", "display_name": "Claudia Boucher\u2010Berry" }, { "id": "https://openalex.org/A5083846346", "display_name": "Margarita Barrientos\u2010P\u00e9rez" }, { "id": "https://openalex.org/A5083886733", "display_name": "\u00c9lise Bismuth" }, { "id": "https://openalex.org/A5054516816", "display_name": "S\u00e9rgio Atala Dib" }, { "id": "https://openalex.org/A5037056978", "display_name": "Jang Ik Cho" }, { "id": "https://openalex.org/A5014043242", "display_name": "David A. Cox" } ] }, { "id": "https://openalex.org/W2100788723", "doi": "https://doi.org/10.1155/2014/304032", "title": "Study of Postprandial Lipaemia in Type 2 Diabetes Mellitus: Exenatide versus Liraglutide", "abstract": { "Therapeutic": [ 0 ], "approaches": [ 1 ], "based": [ 2 ], "on": [ 3, 63, 91 ], "the": [ 4, 7, 16, 29, 79, 135, 170 ], "actions": [ 5 ], "of": [ 6, 18, 31, 73, 81, 146, 190 ], "incretin": [ 8 ], "hormone": [ 9 ], "GLP-1": [ 10, 32, 46 ], "have": [ 11, 66 ], "been": [ 12, 25, 68 ], "widely": [ 13 ], "established": [ 14 ], "in": [ 15, 33, 37, 94, 111, 134, 165 ], "management": [ 17 ], "T2DM.": [ 19, 98, 115 ], "Nevertheless,": [ 20 ], "much": [ 21 ], "less": [ 22 ], "research": [ 23 ], "has": [ 24 ], "aimed": [ 26 ], "at": [ 27, 141 ], "elucidating": [ 28 ], "role": [ 30 ], "lipid": [ 34 ], "metabolism": [ 35 ], "and": [ 36, 42, 126, 148, 157, 173 ], "particular": [ 38 ], "postprandial": [ 39, 64, 92, 167 ], "dyslipidemia.": [ 40 ], "Exenatide": [ 41, 156 ], "liraglutide": [ 43, 85, 122, 158 ], "are": [ 44, 50, 193 ], "two": [ 45, 89 ], "receptor": [ 47 ], "agonists": [ 48 ], "which": [ 49, 180, 185 ], "currently": [ 51 ], "available": [ 52 ], "as": [ 53 ], "subcutaneously": [ 54 ], "administered": [ 55 ], "treatment": [ 56, 82, 125, 152 ], "for": [ 57, 88 ], "T2DM": [ 58 ], "but": [ 59 ], "their": [ 60 ], "chronic": [ 61 ], "effects": [ 62 ], "lipaemia": [ 65, 93, 168 ], "not": [ 67 ], "well": [ 69 ], "investigated.": [ 70 ], "The": [ 71, 178 ], "aim": [ 72 ], "this": [ 74, 183 ], "study": [ 75, 100 ], "is": [ 76 ], "to": [ 77, 119, 161, 182, 187, 195 ], "examine": [ 78 ], "effect": [ 80 ], "with": [ 83, 97, 114 ], "either": [ 84, 121 ], "or": [ 86, 123 ], "exenatide": [ 87, 124 ], "weeks": [ 90 ], "obese": [ 95 ], "subjects": [ 96, 113 ], "This": [ 99 ], "was": [ 101 ], "a": [ 102, 128, 150, 175 ], "single-center,": [ 103 ], "two-armed,": [ 104 ], "randomized,": [ 105 ], "controlled": [ 106 ], "2-week": [ 107 ], "prospective": [ 108 ], "intervention": [ 109 ], "trial": [ 110 ], "20": [ 112 ], "Patients": [ 116 ], "were": [ 117 ], "randomized": [ 118 ], "receive": [ 120 ], "underwent": [ 127 ], "standardized": [ 129 ], "meal": [ 130 ], "tolerance": [ 131 ], "test": [ 132 ], "early": [ 133 ], "morning": [ 136 ], "after": [ 137, 149, 169, 174 ], "10": [ 138 ], "h": [ 139 ], "fast": [ 140 ], "baseline": [ 142 ], "(visit": [ 143, 154 ], "1,": [ 144 ], "beginning": [ 145 ], "treatment)": [ 147 ], "two-week": [ 151, 176 ], "period": [ 153 ], "2).": [ 155 ], "both": [ 159 ], "appear": [ 160 ], "be": [ 162, 188, 196 ], "equally": [ 163 ], "effective": [ 164 ], "lowering": [ 166 ], "first": [ 171 ], "administration": [ 172 ], "treatment.": [ 177 ], "mechanisms": [ 179 ], "lead": [ 181 ], "phenomenon,": [ 184 ], "seem": [ 186 ], "independent": [ 189 ], "gastric": [ 191 ], "emptying,": [ 192 ], "yet": [ 194 ], "studied.": [ 197 ] }, "publication_date": "2014-01-01", "publication_year": 2014, "type": "article", "cited_by_count": 24, "authors": [ { "id": "https://openalex.org/A5017187884", "display_name": "Maria Voukali" }, { "id": "https://openalex.org/A5089224778", "display_name": "Irene Kastrinelli" }, { "id": "https://openalex.org/A5091502201", "display_name": "Sapfo Stragalinou" }, { "id": "https://openalex.org/A5042966114", "display_name": "Dimitra Tasiopoulou" }, { "id": "https://openalex.org/A5111548409", "display_name": "Pinelopi Paraskevopoulou" }, { "id": "https://openalex.org/A5009593791", "display_name": "Nicholas Katsilambros" }, { "id": "https://openalex.org/A5090963153", "display_name": "Alexandros Kokkinos" }, { "id": "https://openalex.org/A5014280857", "display_name": "Nikola\u03bfs Tentolouris" }, { "id": "https://openalex.org/A5103210154", "display_name": "Ioannis Ioannidis" } ] }, { "id": "https://openalex.org/W2003589032", "doi": "https://doi.org/10.1016/j.bmcl.2013.05.022", "title": "Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity", "abstract": { "The": [ 0, 106 ], "dramatic": [ 1 ], "rise": [ 2 ], "of": [ 3, 52, 64, 71, 96, 109, 115 ], "the": [ 4, 37, 40, 49, 65, 93, 113, 122 ], "twin": [ 5 ], "epidemics,": [ 6 ], "type": [ 7 ], "2": [ 8 ], "diabetes": [ 9 ], "and": [ 10, 17, 81 ], "obesity": [ 11 ], "is": [ 12, 26 ], "associated": [ 13, 56 ], "with": [ 14, 32, 57, 121 ], "increased": [ 15, 125 ], "mortality": [ 16 ], "morbidity": [ 18 ], "worldwide.": [ 19 ], "Based": [ 20 ], "on": [ 21 ], "this": [ 22 ], "global": [ 23 ], "development": [ 24 ], "there": [ 25 ], "clinical": [ 27, 89 ], "need": [ 28 ], "for": [ 29, 124 ], "anti-diabetic": [ 30 ], "therapies": [ 31 ], "accompanied": [ 33 ], "weight": [ 34, 60 ], "reduction.": [ 35, 61 ], "From": [ 36 ], "approved": [ 38 ], "therapies,": [ 39 ], "injectable": [ 41 ], "glucagon-like": [ 42 ], "peptide-1": [ 43 ], "receptor": [ 44 ], "agonists": [ 45 ], "(GLP-1": [ 46 ], "RAs)": [ 47 ], "are": [ 48, 55, 69, 86 ], "only": [ 50 ], "class": [ 51 ], "agents": [ 53 ], "which": [ 54 ], "a": [ 58, 77 ], "modest": [ 59 ], "Physiological": [ 62 ], "effects": [ 63 ], "gastro-intestinal": [ 66, 119 ], "hormone": [ 67 ], "GLP-1": [ 68, 97, 116, 130 ], "improvement": [ 70 ], "glycemic": [ 72 ], "control": [ 73 ], "as": [ 74, 76 ], "well": [ 75 ], "reduction": [ 78 ], "in": [ 79 ], "appetite": [ 80 ], "food": [ 82 ], "intake.": [ 83 ], "Different": [ 84 ], "approaches": [ 85 ], "currently": [ 87 ], "under": [ 88 ], "evaluation": [ 90 ], "to": [ 91, 100, 103, 129 ], "optimize": [ 92 ], "therapeutic": [ 94, 126 ], "potential": [ 95, 123 ], "RAs": [ 98 ], "directed": [ 99 ], "once-weekly": [ 101 ], "up": [ 102 ], "once-monthly": [ 104 ], "administration.": [ 105 ], "next": [ 107 ], "generation": [ 108 ], "peptidic": [ 110 ], "co-agonists": [ 111 ], "comprises": [ 112 ], "activity": [ 114 ], "plus": [ 117 ], "additional": [ 118 ], "hormones": [ 120 ], "benefits": [ 127 ], "compared": [ 128 ], "RAs.": [ 131 ] }, "publication_date": "2013-05-16", "publication_year": 2013, "type": "review", "cited_by_count": 118, "authors": [ { "id": "https://openalex.org/A5073494000", "display_name": "M. Lorenz" }, { "id": "https://openalex.org/A5042208848", "display_name": "Andreas Evers" }, { "id": "https://openalex.org/A5109959153", "display_name": "Michael Wagner" } ] }, { "id": "https://openalex.org/W2148850438", "doi": "https://doi.org/10.1161/atvbaha.113.301586", "title": "Cardioprotective Effects of Exenatide in Patients With ST-Segment\u2013Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention", "abstract": { "Objective\u2014": [ 0 ], "Experimental": [ 1 ], "evidence": [ 2 ], "suggests": [ 3 ], "that": [ 4 ], "exenatide,": [ 5 ], "a": [ 6, 206 ], "glucagon-like": [ 7 ], "peptide": [ 8 ], "1": [ 9, 102 ], "receptor": [ 10 ], "analogue,": [ 11 ], "has": [ 12 ], "significant": [ 13, 220 ], "cardiovascular": [ 14 ], "protective": [ 15 ], "effects": [ 16, 222 ], "in": [ 17, 39, 56, 63, 162, 183 ], "various": [ 18 ], "conditions.": [ 19 ], "We": [ 20 ], "examined": [ 21 ], "whether": [ 22 ], "routine": [ 23 ], "use": [ 24 ], "of": [ 25, 30, 85, 153, 177, 210, 223, 247, 252 ], "exenatide": [ 26, 72, 129, 164, 185, 203, 224, 236 ], "at": [ 27, 101, 113, 117 ], "the": [ 28, 64, 83, 163, 174, 184, 190, 202 ], "time": [ 29 ], "primary": [ 31, 124, 147, 239 ], "percutaneous": [ 32, 125, 148, 240 ], "coronary": [ 33, 126, 149, 241 ], "intervention": [ 34, 242 ], "would": [ 35 ], "reduce": [ 36 ], "infarct": [ 37, 248 ], "size": [ 38, 78, 249 ], "patients": [ 40, 49, 168, 230 ], "with": [ 41, 50, 136, 170, 189, 215, 231, 238, 245 ], "ST-segment\u2013elevation": [ 42, 51, 232 ], "myocardial": [ 43, 52, 57, 233 ], "infarction.": [ 44, 105 ], "Approach": [ 45 ], "and": [ 46, 54, 66, 88, 94, 107, 116, 120, 130, 143, 156, 250 ], "Results\u2014": [ 47 ], "Fifty-eight": [ 48 ], "infarction": [ 53, 58 ], "thrombolysis": [ 55 ], "flow": [ 59 ], "0": [ 60 ], "were": [ 61, 159, 226 ], "enrolled": [ 62 ], "study": [ 65 ], "randomly": [ 67 ], "assigned": [ 68 ], "to": [ 69, 138 ], "receive": [ 70 ], "either": [ 71 ], "or": [ 73 ], "placebo": [ 74 ], "(saline)": [ 75 ], "subcutaneously.": [ 76 ], "Infarct": [ 77 ], "was": [ 79, 111, 180, 243 ], "assessed": [ 80 ], "by": [ 81, 95 ], "measuring": [ 82 ], "release": [ 84 ], "creatine": [ 86, 154 ], "kinase-MB": [ 87, 155 ], "troponin": [ 89, 157 ], "I": [ 90, 158 ], "during": [ 91 ], "72": [ 92 ], "hours": [ 93 ], "performing": [ 96 ], "cardiac": [ 97, 171 ], "magnetic": [ 98, 172 ], "resonance": [ 99 ], "imaging": [ 100 ], "month": [ 103 ], "after": [ 104, 123 ], "Routine": [ 106 ], "speckle": [ 108 ], "tracking": [ 109 ], "echocardiography": [ 110 ], "performed": [ 112 ], "initial": [ 114 ], "presentation": [ 115 ], "3": [ 118 ], "days": [ 119 ], "6": [ 121, 200 ], "months": [ 122 ], "intervention.": [ 127, 150 ], "The": [ 128, 151 ], "control": [ 131, 191 ], "groups": [ 132 ], "had": [ 133 ], "similar": [ 134 ], "results": [ 135 ], "respect": [ 137 ], "ischemia": [ 139 ], "time,": [ 140 ], "demographic": [ 141 ], "characteristics,": [ 142 ], "ejection": [ 144 ], "fraction": [ 145 ], "before": [ 146 ], "releases": [ 152 ], "significantly": [ 160, 181, 207 ], "reduced": [ 161, 182 ], "group.": [ 165 ], "In": [ 166, 229 ], "58": [ 167 ], "evaluated": [ 169 ], "resonance,": [ 173 ], "absolute": [ 175 ], "mass": [ 176 ], "delayed": [ 178 ], "hyperenhancement": [ 179 ], "group": [ 186, 192, 204 ], "as": [ 187 ], "compared": [ 188 ], "(12.8\u00b111.7": [ 193 ], "versus": [ 194 ], "26.4\u00b111.6": [ 195 ], "g;": [ 196 ], "P": [ 197 ], "<0.01).": [ 198 ], "At": [ 199 ], "months,": [ 201 ], "showed": [ 205 ], "lower": [ 208 ], "value": [ 209 ], "E": [ 211, 213 ], "/": [ 212 ], "\u2032": [ 214 ], "improved": [ 216 ], "strain": [ 217 ], "parameters.": [ 218 ], "No": [ 219 ], "adverse": [ 221 ], "administration": [ 225 ], "detected.": [ 227 ], "Conclusions\u2014": [ 228 ], "infarction,": [ 234 ], "adjunctive": [ 235 ], "therapy": [ 237 ], "associated": [ 244 ], "reduction": [ 246 ], "improvement": [ 251 ], "subclinical": [ 253 ], "left": [ 254 ], "ventricular": [ 255 ], "function.": [ 256 ] }, "publication_date": "2013-07-19", "publication_year": 2013, "type": "article", "cited_by_count": 216, "authors": [ { "id": "https://openalex.org/A5073706004", "display_name": "Jong Shin Woo" }, { "id": "https://openalex.org/A5038699850", "display_name": "Weon Kim" }, { "id": "https://openalex.org/A5015855535", "display_name": "Sang Jin Ha" }, { "id": "https://openalex.org/A5055814473", "display_name": "Jin\u2010Bae Kim" }, { "id": "https://openalex.org/A5089285629", "display_name": "Soo\u2013Joong Kim" }, { "id": "https://openalex.org/A5103265754", "display_name": "Woo-Shik Kim" }, { "id": "https://openalex.org/A5103080787", "display_name": "Hyun Ju Seon" }, { "id": "https://openalex.org/A5109945656", "display_name": "Kwon Sam Kim" } ] }, { "id": "https://openalex.org/W2795005430", "doi": "https://doi.org/10.1371/journal.pone.0193473", "title": "GLP-1 receptor agonist ameliorates obesity-induced chronic kidney injury via restoring renal metabolism homeostasis", "abstract": { "Increasing": [ 0 ], "evidence": [ 1 ], "indicates": [ 2 ], "that": [ 3, 111, 149, 176 ], "obesity": [ 4, 31 ], "is": [ 5, 32, 193 ], "highly": [ 6 ], "associated": [ 7 ], "with": [ 8 ], "chronic": [ 9 ], "kidney": [ 10, 21, 28, 51, 142, 180 ], "disease": [ 11 ], "(CKD).": [ 12 ], "GLP-1": [ 13 ], "receptor": [ 14 ], "(GLP-1R)": [ 15 ], "agonist": [ 16, 192 ], "has": [ 17 ], "shown": [ 18 ], "benefits": [ 19 ], "on": [ 20, 27, 50 ], "diseases,": [ 22 ], "but": [ 23 ], "its": [ 24 ], "direct": [ 25 ], "role": [ 26, 46 ], "metabolism": [ 29, 66 ], "in": [ 30, 105, 140, 170 ], "still": [ 33 ], "not": [ 34 ], "clear.": [ 35 ], "This": [ 36, 173 ], "study": [ 37, 174 ], "aims": [ 38 ], "to": [ 39 ], "investigate": [ 40 ], "the": [ 41, 141 ], "protection": [ 42 ], "and": [ 43, 62, 65, 73, 86, 95, 123, 125, 135, 158, 161 ], "metabolic": [ 44, 80 ], "modulation": [ 45 ], "of": [ 47, 52, 143 ], "liraglutide": [ 48 ], "(Lira)": [ 49 ], "obesity.": [ 53 ], "Rats": [ 54 ], "were": [ 55, 68 ], "induced": [ 56 ], "obese": [ 57 ], "by": [ 58, 70, 155 ], "high-fat": [ 59 ], "diet": [ 60 ], "(HFD),": [ 61 ], "renal": [ 63, 93, 115, 152, 164, 188 ], "function": [ 64, 96, 166 ], "changes": [ 67 ], "evaluated": [ 69 ], "metabolomic,": [ 71 ], "biological": [ 72 ], "histological": [ 74, 94 ], "methods.": [ 75 ], "HFD": [ 76, 106, 144, 171 ], "rats": [ 77 ], "exhibited": [ 78 ], "systemic": [ 79 ], "disorders": [ 81 ], "such": [ 82, 129 ], "as": [ 83, 90, 92, 130 ], "obesity,": [ 84 ], "hyperlipidemia": [ 85 ], "impaired": [ 87 ], "glucose": [ 88 ], "tolerance,": [ 89 ], "well": [ 91 ], "damages,": [ 97 ], "while": [ 98 ], "Lira": [ 99, 112, 150, 177 ], "significantly": [ 100 ], "ameliorated": [ 101 ], "these": [ 102 ], "adverse": [ 103 ], "effects": [ 104 ], "rats.": [ 107, 145, 172 ], "Metabolomic": [ 108 ], "data": [ 109 ], "showed": [ 110 ], "directly": [ 113, 186 ], "reduced": [ 114 ], "lipids": [ 116 ], "including": [ 117 ], "fatty": [ 118 ], "acid": [ 119 ], "residues,": [ 120 ], "cholesterol,": [ 121 ], "phospholipids": [ 122 ], "triglycerides,": [ 124 ], "improved": [ 126 ], "mitochondria": [ 127, 165 ], "metabolites": [ 128 ], "succinate,": [ 131 ], "citrate,": [ 132 ], "taurine,": [ 133 ], "fumarate": [ 134 ], "nicotinamide": [ 136 ], "adenine": [ 137 ], "dinucleotide": [ 138 ], "(NAD+)": [ 139 ], "Furthermore,": [ 146 ], "we": [ 147 ], "revealed": [ 148 ], "inhibited": [ 151 ], "lipid": [ 153 ], "accumulation": [ 154 ], "coordinating": [ 156 ], "lipogenic": [ 157 ], "lipolytic": [ 159 ], "signals,": [ 160 ], "partly": [ 162, 184 ], "rescued": [ 163 ], "via": [ 167, 185 ], "Sirt1/AMPK/PGC1\u03b1": [ 168 ], "pathways": [ 169 ], "suggested": [ 175 ], "alleviated": [ 178 ], "HFD-induced": [ 179 ], "injury": [ 181 ], "at": [ 182 ], "least": [ 183 ], "restoring": [ 187 ], "metabolism,": [ 189 ], "thus": [ 190 ], "GLP-1R": [ 191 ], "a": [ 194 ], "promising": [ 195 ], "therapy": [ 196 ], "for": [ 197 ], "obesity-associated": [ 198 ], "CKD.": [ 199 ] }, "publication_date": "2018-03-28", "publication_year": 2018, "type": "article", "cited_by_count": 94, "authors": [ { "id": "https://openalex.org/A5103060286", "display_name": "Chengshi Wang" }, { "id": "https://openalex.org/A5100435314", "display_name": "Ling Li" }, { "id": "https://openalex.org/A5101973444", "display_name": "Shuyun Liu" }, { "id": "https://openalex.org/A5080056355", "display_name": "Guangneng Liao" }, { "id": "https://openalex.org/A5100373019", "display_name": "Lan Li" }, { "id": "https://openalex.org/A5045305757", "display_name": "Younan Chen" }, { "id": "https://openalex.org/A5100513371", "display_name": "Jingqiu Cheng" }, { "id": "https://openalex.org/A5041756956", "display_name": "Yanrong Lu" }, { "id": "https://openalex.org/A5100746222", "display_name": "Jingping Liu" } ] }, { "id": "https://openalex.org/W2059228484", "doi": "https://doi.org/10.1517/17460441.2013.741580", "title": "Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1", "abstract": { "GLP-1": [ 0 ], "receptor": [ 1 ], "agonists": [ 2 ], "represent": [ 3 ], "a": [ 4, 18 ], "new": [ 5 ], "paradigm": [ 6 ], "for": [ 7, 58, 108 ], "the": [ 8, 39, 56, 62, 66, 109 ], "treatment": [ 9, 110 ], "of": [ 10, 29, 41, 69, 111 ], "patients": [ 11 ], "with": [ 12, 27, 72 ], "T2DM.": [ 13, 42, 116 ], "By": [ 14 ], "leveraging": [ 15 ], "incretin": [ 16 ], "physiology,": [ 17 ], "natural": [ 19 ], "regulatory": [ 20 ], "system": [ 21, 64 ], "that": [ 22 ], "coordinates": [ 23 ], "oral": [ 24 ], "nutrient": [ 25 ], "intake": [ 26 ], "mechanisms": [ 28 ], "metabolic": [ 30 ], "control,": [ 31 ], "these": [ 32 ], "agents": [ 33 ], "address": [ 34 ], "multiple": [ 35 ], "core": [ 36 ], "defects": [ 37 ], "in": [ 38, 50 ], "pathophysiology": [ 40 ], "Studies": [ 43 ], "have": [ 44 ], "identified": [ 45 ], "unique": [ 46 ], "benefits": [ 47 ], "including": [ 48 ], "improvements": [ 49 ], "glycemic": [ 51 ], "control": [ 52 ], "and": [ 53, 55, 93 ], "weight,": [ 54 ], "potential": [ 57 ], "beneficial": [ 59 ], "effects": [ 60 ], "on": [ 61 ], "cardiometabolic": [ 63 ], "without": [ 65 ], "increased": [ 67 ], "risk": [ 68 ], "hypoglycemia": [ 70 ], "associated": [ 71 ], "insulin": [ 73 ], "therapy.": [ 74 ], "Peptide": [ 75 ], "hormone": [ 76 ], "therapeutics": [ 77 ], "can": [ 78, 104 ], "offer": [ 79 ], "significant": [ 80 ], "advantages": [ 81 ], "over": [ 82 ], "small": [ 83 ], "molecule": [ 84 ], "drug": [ 85 ], "targets": [ 86 ], "when": [ 87 ], "it": [ 88 ], "comes": [ 89 ], "to": [ 90 ], "specificity,": [ 91 ], "potency,": [ 92 ], "more": [ 94 ], "predictable": [ 95 ], "side": [ 96 ], "effects.": [ 97 ], "As": [ 98 ], "exemplified": [ 99 ], "by": [ 100 ], "exenatide,": [ 101 ], "injectable": [ 102 ], "peptides": [ 103 ], "be": [ 105 ], "important": [ 106 ], "drugs": [ 107 ], "chronic": [ 112 ], "diseases,": [ 113 ], "such": [ 114 ], "as": [ 115 ] }, "publication_date": "2012-12-12", "publication_year": 2012, "type": "review", "cited_by_count": 97, "authors": [ { "id": "https://openalex.org/A5077809872", "display_name": "David G. Parkes" }, { "id": "https://openalex.org/A5058443646", "display_name": "Kenneth Mace" }, { "id": "https://openalex.org/A5062021087", "display_name": "Michael Trautmann" } ] }, { "id": "https://openalex.org/W2756066122", "doi": "https://doi.org/10.1016/j.neuropharm.2017.09.023", "title": "Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease", "abstract": null, "publication_date": "2017-09-19", "publication_year": 2017, "type": "review", "cited_by_count": 91, "authors": [ { "id": "https://openalex.org/A5043990676", "display_name": "Dilan Athauda" }, { "id": "https://openalex.org/A5031389008", "display_name": "Thomas Foltynie" } ] }, { "id": "https://openalex.org/W3114565741", "doi": "https://doi.org/10.2337/dc20-1815", "title": "HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression", "abstract": { "BACKGROUND": [ 0 ], "Long-term": [ 1 ], "glycemic": [ 2, 279 ], "control": [ 3, 14, 280 ], "reduces": [ 4 ], "retinopathy": [ 5, 29, 43, 73, 113, 141, 200, 216, 247, 262, 282 ], "risk,": [ 6 ], "but": [ 7, 24, 156, 273 ], "transient": [ 8 ], "worsening": [ 9 ], "can": [ 10 ], "occur": [ 11 ], "with": [ 12, 122, 192, 234, 245, 261, 266 ], "glucose": [ 13 ], "intensification.": [ 15 ], "Glucagon-like": [ 16 ], "peptide": [ 17 ], "1": [ 18, 177 ], "receptor": [ 19 ], "agonists": [ 20 ], "(GLP-1RA)": [ 21 ], "lower": [ 22 ], "glucose,": [ 23 ], "the": [ 25, 48, 83, 147, 202, 235, 274 ], "long-term": [ 26, 38, 275 ], "impact": [ 27, 276 ], "on": [ 28, 281 ], "is": [ 30, 231 ], "unknown.": [ 31 ], "GLP-1RA": [ 32, 60, 69, 110, 252 ], "cardiovascular": [ 33, 270 ], "outcome": [ 34 ], "trials": [ 35 ], "(CVOTs)": [ 36 ], "provide": [ 37 ], "follow-up,": [ 39, 207 ], "allowing": [ 40 ], "examination": [ 41 ], "of": [ 42, 228, 237, 256, 277 ], "outcomes.": [ 44, 74 ], "PURPOSE": [ 45 ], "To": [ 46 ], "examine": [ 47 ], "associations": [ 49 ], "between": [ 50, 109, 125, 140 ], "retinopathy,": [ 51 ], "HbA1c,": [ 52, 89 ], "systolic": [ 53 ], "blood": [ 54 ], "pressure": [ 55 ], "(SBP),": [ 56 ], "and": [ 57, 91, 112, 142, 176, 205, 218, 223, 268 ], "weight": [ 58, 92 ], "in": [ 59, 187, 220, 249, 264, 285 ], "CVOTs.": [ 61, 253 ], "DATA": [ 62, 87, 101 ], "SOURCES": [ 63 ], "Systematic": [ 64 ], "review": [ 65 ], "identified": [ 66 ], "six": [ 67 ], "placebo-controlled": [ 68 ], "CVOTs": [ 70, 210 ], "reporting": [ 71 ], "prespecified": [ 72 ], "STUDY": [ 75 ], "SELECTION": [ 76 ], "Published": [ 77 ], "trial": [ 78 ], "reports": [ 79 ], "were": [ 80, 99, 211 ], "used": [ 81 ], "as": [ 82 ], "primary": [ 84 ], "data": [ 85, 93 ], "sources.": [ 86 ], "EXTRACTION": [ 88 ], "SBP,": [ 90 ], "throughout": [ 94 ], "follow-up": [ 95, 149, 227 ], "by": [ 96 ], "treatment": [ 97, 111 ], "group": [ 98 ], "extracted.": [ 100 ], "SYNTHESIS": [ 102 ], "Random-effects": [ 103 ], "model": [ 104 ], "meta-analysis": [ 105 ], "showed": [ 106, 137, 167 ], "no": [ 107, 157 ], "association": [ 108, 139 ], "(odds": [ 114 ], "ratio": [ 115 ], "[OR]": [ 116 ], "1.10;": [ 117 ], "95%": [ 118 ], "CI": [ 119 ], "0.93,": [ 120 ], "1.30),": [ 121 ], "high": [ 123 ], "heterogeneity": [ 124 ], "studies": [ 126 ], "(I2": [ 127 ], "=": [ 128, 133, 151, 154, 174, 180 ], "52.2%;": [ 129 ], "Q": [ 130 ], "statistic": [ 131 ], "P": [ 132, 153 ], "0.063).": [ 134 ], "Univariate": [ 135 ], "meta-regression": [ 136, 250 ], "an": [ 138 ], "average": [ 143 ], "HbA1c": [ 144, 166, 188, 240, 257 ], "reduction": [ 145, 189, 241, 258 ], "during": [ 146 ], "overall": [ 148, 206 ], "(slope": [ 150 ], "0.77,": [ 152 ], "0.007),": [ 155 ], "relationship": [ 158, 169 ], "for": [ 159, 165, 199, 251 ], "SBP": [ 160 ], "or": [ 161, 195 ], "weight.": [ 162 ], "Sensitivity": [ 163 ], "analyses": [ 164 ], "a": [ 168 ], "at": [ 170, 201 ], "3": [ 171 ], "months": [ 172 ], "(P": [ 173, 179 ], "0.006)": [ 175 ], "year": [ 178 ], "0.002).": [ 181 ], "A": [ 182 ], "0.1%": [ 183 ], "(1.09": [ 184 ], "mmol/mol)": [ 185 ], "increase": [ 186 ], "was": [ 190, 242, 259, 283 ], "associated": [ 191, 244 ], "6%,": [ 193 ], "14%,": [ 194 ], "8%": [ 196 ], "increased": [ 197, 246 ], "Ln(OR)": [ 198 ], "3-month,": [ 203 ], "1-year,": [ 204 ], "respectively.": [ 208 ], "LIMITATIONS": [ 209 ], "not": [ 212 ], "powered": [ 213 ], "to": [ 214 ], "assess": [ 215 ], "outcomes": [ 217 ], "differed": [ 219 ], "retinopathy-related": [ 221 ], "criteria": [ 222 ], "methodology.": [ 224 ], "The": [ 225, 254 ], "median": [ 226 ], "3.4": [ 229 ], "years": [ 230 ], "short": [ 232 ], "compared": [ 233 ], "onset": [ 236 ], "retinopathy.": [ 238 ], "CONCLUSIONS": [ 239 ], "significantly": [ 243 ], "risk": [ 248, 263, 271 ], "magnitude": [ 255 ], "correlated": [ 260 ], "people": [ 265 ], "diabetes": [ 267 ], "additional": [ 269 ], "factors,": [ 272 ], "improved": [ 278 ], "unmeasured": [ 284 ], "these": [ 286 ], "studies.": [ 287 ], "Retinopathy": [ 288 ], "status": [ 289 ], "should": [ 290 ], "be": [ 291 ], "assessed": [ 292 ], "when": [ 293 ], "intensifying": [ 294 ], "glucose-lowering": [ 295 ], "therapy.": [ 296 ] }, "publication_date": "2020-12-14", "publication_year": 2020, "type": "review", "cited_by_count": 123, "authors": [ { "id": "https://openalex.org/A5065924611", "display_name": "M. Angelyn Bethel" }, { "id": "https://openalex.org/A5013408607", "display_name": "Rafael D\u00edaz" }, { "id": "https://openalex.org/A5038764606", "display_name": "Noelia Castellana" }, { "id": "https://openalex.org/A5101620096", "display_name": "Indranil Bhattacharya" }, { "id": "https://openalex.org/A5024577116", "display_name": "Hertzel C. Gerstein" }, { "id": "https://openalex.org/A5055443598", "display_name": "Mark Lakshmanan" } ] }, { "id": "https://openalex.org/W3165273770", "doi": "https://doi.org/10.1016/j.metabol.2021.154799", "title": "Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists", "abstract": null, "publication_date": "2021-05-23", "publication_year": 2021, "type": "review", "cited_by_count": 65, "authors": [ { "id": "https://openalex.org/A5018275689", "display_name": "Francesco Prattichizzo" }, { "id": "https://openalex.org/A5056961111", "display_name": "Paola de Candia" }, { "id": "https://openalex.org/A5044764461", "display_name": "Antonio Ceriello" } ] }, { "id": "https://openalex.org/W4254638778", "doi": "https://doi.org/10.2147/dmso.s6816", "title": "Emerging role of GLP-1 receptor agonists in the treatment of obesity", "abstract": { "Abstract:": [ 0 ], "The": [ 1 ], "prevalence": [ 2 ], "of": [ 3, 23, 37, 44, 49, 81, 84, 90, 123, 135, 142, 155 ], "obesity": [ 4, 143 ], "has": [ 5, 74, 128 ], "increased": [ 6, 77 ], "dramatically": [ 7 ], "in": [ 8, 12, 87, 102, 132, 144 ], "recent": [ 9, 71 ], "decades,": [ 10 ], "both": [ 11 ], "the": [ 13, 20, 42, 47, 82, 88, 121, 133, 140, 150 ], "US": [ 14 ], "and": [ 15, 26, 46, 68, 79, 111, 116, 153, 157 ], "worldwide.": [ 16 ], "Pharmacotherapy": [ 17 ], "can": [ 18, 27 ], "augment": [ 19 ], "weight-reducing": [ 21 ], "effects": [ 22 ], "lifestyle": [ 24 ], "modification": [ 25 ], "facilitate": [ 28 ], "long-term": [ 29 ], "weight": [ 30, 51 ], "maintenance.": [ 31 ], "However,": [ 32 ], "there": [ 33, 73 ], "is": [ 34, 54 ], "a": [ 35 ], "paucity": [ 36 ], "pharmacologic": [ 38 ], "agents": [ 39, 161 ], "approved": [ 40, 119 ], "for": [ 41, 120, 139, 162 ], "treatment": [ 43, 122, 141 ], "obesity,": [ 45, 165 ], "use": [ 48, 134 ], "existing": [ 50 ], "loss": [ 52 ], "medications": [ 53 ], "frequently": [ 55 ], "limited": [ 56, 63 ], "by": [ 57, 65 ], "contraindications,": [ 58 ], "drug": [ 59 ], "interactions,": [ 60 ], "adverse": [ 61 ], "effects,": [ 62 ], "coverage": [ 64 ], "third-party": [ 66 ], "payers,": [ 67 ], "cost.": [ 69 ], "In": [ 70 ], "years,": [ 72 ], "been": [ 75, 114, 130 ], "an": [ 76, 99 ], "understanding": [ 78 ], "appreciation": [ 80 ], "role": [ 83, 101 ], "gastrointestinal": [ 85 ], "hormones": [ 86 ], "control": [ 89 ], "body": [ 91 ], "weight.": [ 92 ], "One": [ 93 ], "such": [ 94, 108 ], "hormone,": [ 95 ], "GLP-1,": [ 96, 166 ], "also": [ 97, 129 ], "plays": [ 98 ], "important": [ 100 ], "glucose": [ 103 ], "homeostasis.": [ 104 ], "GLP-1": [ 105, 136 ], "receptor": [ 106, 137 ], "agonists,": [ 107 ], "as": [ 109, 159 ], "exenatide": [ 110, 156 ], "liraglutide,": [ 112 ], "have": [ 113 ], "developed": [ 115 ], "are": [ 117 ], "already": [ 118 ], "type": [ 124 ], "2": [ 125 ], "diabetes.": [ 126 ], "There": [ 127 ], "interest": [ 131 ], "agonists": [ 138 ], "nondiabetic": [ 145 ], "patients.": [ 146 ], "This": [ 147 ], "review": [ 148 ], "explores": [ 149 ], "potential": [ 151 ], "utility": [ 152 ], "limitations": [ 154 ], "liraglutide": [ 158, 168 ], "therapeutic": [ 160 ], "obesity.": [ 163 ], "Keywords:": [ 164 ], "exenatide,": [ 167 ] }, "publication_date": "2010-07-01", "publication_year": 2010, "type": "article", "cited_by_count": 16, "authors": [ { "id": "https://openalex.org/A5010312288", "display_name": "Lisa M. Neff" } ] }, { "id": "https://openalex.org/W4379053744", "doi": "https://doi.org/10.3892/etm.2023.12054", "title": "Therapeutic management of atypical antipsychotic\u2011related metabolic dysfunctions using GLP\u20111 receptor agonists: A systematic review", "abstract": { "Metabolic": [ 0 ], "disorders": [ 1, 19, 118 ], "(MDs)": [ 2 ], "like": [ 3 ], "obesity,": [ 4 ], "dyslipidemia,": [ 5 ], "and": [ 6, 56, 77, 119, 126, 138, 145, 150, 155, 159, 183, 187, 223, 234, 250, 314, 346 ], "type": [ 7 ], "2": [ 8 ], "diabetes": [ 9 ], "are": [ 10, 82, 247, 319 ], "more": [ 11 ], "frequently": [ 12 ], "observed": [ 13 ], "in": [ 14, 28, 44, 61, 114, 189, 218, 262, 290, 328, 349 ], "patients": [ 15, 115, 263, 350 ], "diagnosed": [ 16 ], "with": [ 17, 22, 41, 116 ], "psychiatric": [ 18, 63, 117 ], "undergoing": [ 20 ], "treatment": [ 21, 283 ], "antipsychotics,": [ 23, 268 ], "particularly": [ 24 ], "atypical": [ 25, 267 ], "agents,": [ 26 ], "than": [ 27 ], "the": [ 29, 62, 91, 94, 104, 143, 168, 178, 190, 203, 226, 272, 276, 282, 291, 324 ], "general": [ 30 ], "population.": [ 31, 221 ], "The": [ 32, 164, 181, 285 ], "second": [ 33 ], "generation": [ 34 ], "of": [ 35, 59, 75, 79, 93, 103, 167, 185, 192, 199, 240, 271, 278, 305, 326 ], "antidiabetics": [ 36 ], "(SGAD)": [ 37 ], "has": [ 38 ], "been": [ 39 ], "associated": [ 40 ], "cardiovascular": [ 42, 70 ], "benefits": [ 43 ], "large": [ 45, 165 ], "clinical": [ 46, 127, 149, 160, 317 ], "trials": [ 47, 318 ], "which": [ 48 ], "represent": [ 49 ], "an": [ 50 ], "important": [ 51, 336 ], "advantage": [ 52 ], "over": [ 53 ], "first-generation": [ 54 ], "agents": [ 55, 110, 257 ], "might": [ 57 ], "be": [ 58, 112, 253 ], "interest": [ 60 ], "population": [ 64 ], "where": [ 65 ], "multiple": [ 66 ], "risk": [ 67 ], "factors": [ 68 ], "for": [ 69, 132, 215 ], "disease": [ 71 ], "(e.g.,": [ 72 ], "smoking,": [ 73 ], "lack": [ 74, 78 ], "exercise,": [ 76 ], "healthy": [ 80 ], "diet)": [ 81 ], "common": [ 83 ], "occurrences.": [ 84 ], "Therefore,": [ 85, 237 ], "this": [ 86, 219 ], "systematic": [ 87 ], "review": [ 88 ], "focused": [ 89 ], "on": [ 90, 177, 230, 334 ], "evaluation": [ 92 ], "glucagon-like": [ 95 ], "peptide-1": [ 96 ], "receptor": [ 97 ], "agonists": [ 98 ], "(GLP1-RAs),": [ 99 ], "as": [ 100, 255, 340 ], "a": [ 101, 213 ], "representative": [ 102 ], "SGAD,": [ 105 ], "to": [ 106, 211, 258, 322 ], "determine": [ 107 ], "whether": [ 108 ], "these": [ 109, 246, 265 ], "may": [ 111, 252 ], "recommended": [ 113, 254 ], "MDs.": [ 120 ], "For": [ 121 ], "analysis,": [ 122 ], "three": [ 123, 315 ], "electronic": [ 124 ], "databases": [ 125 ], "trial": [ 128 ], "registers": [ 129 ], "were": [ 130, 157, 162, 173, 195, 208 ], "explored": [ 131 ], "papers": [ 133 ], "published": [ 134 ], "between": [ 135 ], "January": [ 136 ], "2000": [ 137 ], "November": [ 139 ], "2022.": [ 140 ], "After": [ 141 ], "applying": [ 142 ], "inclusion": [ 144 ], "exclusion": [ 146 ], "criteria,": [ 147 ], "20": [ 148 ], "preclinical": [ 151 ], "trials,": [ 152 ], "therapeutic": [ 153 ], "guidelines,": [ 154 ], "meta-analyses": [ 156 ], "reviewed,": [ 158 ], "recommendations": [ 161 ], "formulated.": [ 163 ], "majority": [ 166 ], "reviewed": [ 169, 273 ], "data": [ 170, 274 ], "(nine": [ 171 ], "papers)": [ 172 ], "graded": [ 174 ], "'moderate'": [ 175 ], "based": [ 176 ], "GRADE": [ 179 ], "criteria.": [ 180 ], "efficacy": [ 182, 277 ], "tolerability": [ 184 ], "liraglutide": [ 186 ], "exenatide": [ 188, 251 ], "management": [ 191 ], "antipsychotic-induced": [ 193 ], "MDs": [ 194 ], "supported": [ 196, 275 ], "by": [ 197 ], "evidence": [ 198 ], "average": [ 200 ], "quality,": [ 201 ], "while": [ 202 ], "results": [ 204 ], "regarding": [ 205 ], "other": [ 206, 335 ], "GLP-1RAs": [ 207, 279, 327 ], "not": [ 209 ], "sufficient": [ 210 ], "formulate": [ 212 ], "recommendation": [ 214 ], "their": [ 216 ], "administration": [ 217 ], "specific": [ 220 ], "Clozapine": [ 222 ], "olanzapine": [ 224 ], "had": [ 225 ], "most": [ 227, 270 ], "negative": [ 228 ], "consequences": [ 229 ], "body": [ 231, 330 ], "weight,": [ 232, 331 ], "glycemic,": [ 233 ], "lipid": [ 235, 347 ], "metabolism.": [ 236 ], "careful": [ 238 ], "monitoring": [ 239, 304 ], "metabolic": [ 241, 306, 337 ], "parameters": [ 242, 307 ], "is": [ 243, 308, 312 ], "required": [ 244 ], "when": [ 245 ], "prescribed.": [ 248 ], "Liraglutide": [ 249 ], "augmentative": [ 256 ], "metformin": [ 259 ], "therapy,": [ 260 ], "especially": [ 261 ], "receiving": [ 264, 351 ], "two": [ 266, 286 ], "but": [ 269, 332 ], "only": [ 280 ], "during": [ 281 ], "administration.": [ 284 ], "follow-up": [ 287 ], "studies": [ 288 ], "retrieved": [ 289 ], "literature": [ 292 ], "reported": [ 293 ], "modest": [ 294 ], "effects": [ 295, 325 ], "after": [ 296, 299 ], "GLP-1RA": [ 297 ], "discontinuation": [ 298 ], "1": [ 300 ], "year;": [ 301 ], "therefore,": [ 302 ], "long-term": [ 303 ], "required.": [ 309 ], "More": [ 310 ], "research": [ 311 ], "needed,": [ 313 ], "randomized": [ 316 ], "already": [ 320 ], "ongoing,": [ 321 ], "evaluate": [ 323 ], "decreasing": [ 329 ], "also": [ 333 ], "variables,": [ 338 ], "such": [ 339 ], "HbA1c": [ 341 ], "status,": [ 342 ], "fasting": [ 343 ], "glucose": [ 344 ], "levels,": [ 345 ], "levels": [ 348 ], "antipsychotic": [ 352 ], "treatment.": [ 353 ] }, "publication_date": "2023-06-01", "publication_year": 2023, "type": "review", "cited_by_count": 49, "authors": [ { "id": "https://openalex.org/A5024728304", "display_name": "O. Vasiliu" } ] }, { "id": "https://openalex.org/W3008898784", "doi": "https://doi.org/10.1016/j.metabol.2020.154190", "title": "Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies", "abstract": null, "publication_date": "2020-02-25", "publication_year": 2020, "type": "review", "cited_by_count": 29, "authors": [ { "id": "https://openalex.org/A5087917482", "display_name": "Mario Luca Morieri" }, { "id": "https://openalex.org/A5030061168", "display_name": "Mauro Rigato" }, { "id": "https://openalex.org/A5030115381", "display_name": "Vera Frison" }, { "id": "https://openalex.org/A5001802237", "display_name": "Natalino Simioni" }, { "id": "https://openalex.org/A5108102259", "display_name": "M. Dambrosio" }, { "id": "https://openalex.org/A5025537921", "display_name": "Federica Tadiotto" }, { "id": "https://openalex.org/A5108390487", "display_name": "Agostino Paccagnella" }, { "id": "https://openalex.org/A5013454962", "display_name": "Annunziata Lapolla" }, { "id": "https://openalex.org/A5029164653", "display_name": "Angelo Avogaro" }, { "id": "https://openalex.org/A5027393457", "display_name": "Gian Paolo Fadini" } ] }, { "id": "https://openalex.org/W897329354", "doi": "https://doi.org/10.1371/journal.pone.0132744", "title": "Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetes.", "abstract": { "Recently,": [ 0 ], "a": [ 1, 169, 193, 214 ], "number": [ 2 ], "of": [ 3, 34, 65, 148, 158, 176, 233, 240 ], "studies": [ 4 ], "have": [ 5 ], "demonstrated": [ 6 ], "the": [ 7, 19, 32, 35, 60, 93, 135, 145, 173, 182, 208, 231, 236 ], "potential": [ 8 ], "beneficial": [ 9 ], "role": [ 10 ], "for": [ 11, 96 ], "novel": [ 12 ], "anti-diabetic": [ 13, 209 ], "GLP-1": [ 14 ], "receptor": [ 15, 199 ], "agonists": [ 16 ], "(GLP-1RAs)": [ 17 ], "in": [ 18, 22, 44, 134, 137, 144, 155, 172, 196, 219 ], "skeleton": [ 20 ], "metabolism": [ 21 ], "diabetic": [ 23 ], "rodents": [ 24 ], "and": [ 25, 42, 62, 109, 126, 130, 160, 181, 188 ], "patients.": [ 26 ], "In": [ 27, 202 ], "this": [ 28 ], "study,": [ 29 ], "we": [ 30 ], "evaluated": [ 31 ], "impacts": [ 33 ], "synthetic": [ 36 ], "GLP-1RA": [ 37 ], "Liraglutide": [ 38, 113, 121, 211, 234 ], "on": [ 39, 59, 235 ], "bone": [ 40, 66, 215 ], "mass": [ 41 ], "quality": [ 43 ], "osteoporotic": [ 45, 221 ], "rats": [ 46, 84, 150 ], "induced": [ 47 ], "by": [ 48, 118 ], "ovariectomy": [ 49 ], "(OVX)": [ 50 ], "but": [ 51, 192 ], "without": [ 52 ], "diabetes,": [ 53 ], "as": [ 54, 56 ], "well": [ 55 ], "its": [ 57 ], "effect": [ 58, 217, 226 ], "adipogenic": [ 61 ], "osteoblastogenic": [ 63 ], "differentiation": [ 64 ], "marrow": [ 67 ], "stromal": [ 68 ], "cells": [ 69 ], "(BMSCs).": [ 70 ], "Three": [ 71 ], "months": [ 72 ], "after": [ 73 ], "sham": [ 74 ], "surgery": [ 75 ], "or": [ 76 ], "bilateral": [ 77 ], "OVX,": [ 78 ], "eighteen": [ 79 ], "5-month": [ 80 ], "old": [ 81 ], "female": [ 82 ], "Wistar": [ 83 ], "were": [ 85, 142 ], "randomly": [ 86 ], "divided": [ 87 ], "into": [ 88 ], "three": [ 89 ], "groups": [ 90 ], "to": [ 91, 230 ], "receive": [ 92 ], "following": [ 94 ], "treatments": [ 95 ], "2": [ 97 ], "months:": [ 98 ], "(1)": [ 99 ], "Sham": [ 100 ], "+": [ 101, 106, 112 ], "normal": [ 102, 107 ], "saline;": [ 103, 108 ], "(2)": [ 104 ], "OVX": [ 105, 111, 138, 149, 222 ], "(3)": [ 110 ], "(0.6": [ 114 ], "mg/day).": [ 115 ], "As": [ 116 ], "revealed": [ 117 ], "micro-CT": [ 119 ], "analysis,": [ 120 ], "improved": [ 122 ], "trabecular": [ 123, 132 ], "volume,": [ 124 ], "thickness": [ 125 ], "number,": [ 127 ], "increased": [ 128 ], "BMD,": [ 129 ], "reduced": [ 131 ], "spacing": [ 133 ], "femurs": [ 136 ], "rats;": [ 139 ], "similar": [ 140 ], "results": [ 141, 205 ], "observed": [ 143 ], "lumbar": [ 146 ], "vertebrae": [ 147 ], "treated": [ 151 ], "with": [ 152, 163 ], "Liraglutide.": [ 153 ], "Following": [ 154 ], "vitro": [ 156 ], "treatment": [ 157 ], "rat": [ 159 ], "human": [ 161 ], "BMSCs": [ 162 ], "10": [ 164 ], "nM": [ 165 ], "Liraglutide,": [ 166 ], "there": [ 167 ], "was": [ 168 ], "significant": [ 170, 194 ], "increase": [ 171 ], "mRNA": [ 174 ], "expression": [ 175 ], "osteoblast-specific": [ 177 ], "transcriptional": [ 178 ], "factor": [ 179 ], "Runx2": [ 180 ], "osteoblast": [ 183 ], "markers": [ 184 ], "alkaline": [ 185 ], "phosphatase": [ 186 ], "(ALP)": [ 187 ], "collagen": [ 189 ], "\u03b11": [ 190 ], "(Col-1),": [ 191 ], "decrease": [ 195 ], "peroxisome": [ 197 ], "proliferator-activated": [ 198 ], "\u03b3": [ 200 ], "(PPAR\u03b3).": [ 201 ], "conclusion,": [ 203 ], "our": [ 204 ], "indicate": [ 206 ], "that": [ 207 ], "drug": [ 210 ], "can": [ 212 ], "exert": [ 213 ], "protective": [ 216, 225 ], "even": [ 218 ], "non-diabetic": [ 220 ], "rats.": [ 223 ], "This": [ 224 ], "is": [ 227 ], "likely": [ 228 ], "attributable": [ 229 ], "impact": [ 232 ], "lineage": [ 237 ], "fate": [ 238 ], "determination": [ 239 ], "BMSCs.": [ 241 ] }, "publication_date": "2015-07-15", "publication_year": 2015, "type": "article", "cited_by_count": 97, "authors": [ { "id": "https://openalex.org/A5029071585", "display_name": "Nan L\u00fc" }, { "id": "https://openalex.org/A5100700659", "display_name": "Hanxiao Sun" }, { "id": "https://openalex.org/A5045694141", "display_name": "Jingjia Yu" }, { "id": "https://openalex.org/A5100411579", "display_name": "Xiaojing Wang" }, { "id": "https://openalex.org/A5100417626", "display_name": "Dongmei Liu" }, { "id": "https://openalex.org/A5101406167", "display_name": "Lin Zhao" }, { "id": "https://openalex.org/A5100677376", "display_name": "Li\u2010hao Sun" }, { "id": "https://openalex.org/A5027391530", "display_name": "Hongyan Zhao" }, { "id": "https://openalex.org/A5050055469", "display_name": "Bei Tao" }, { "id": "https://openalex.org/A5100724024", "display_name": "Jianmin Liu" } ] }, { "id": "https://openalex.org/W4400001604", "doi": "https://doi.org/10.1001/jamanetworkopen.2024.16775", "title": "Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment", "abstract": { "Importance": [ 0 ], "A": [ 1 ], "major": [ 2 ], "concern": [ 3 ], "with": [ 4, 52, 100, 119, 235, 322, 365 ], "weight": [ 5, 19, 28, 45, 267, 433, 455 ], "loss": [ 6, 20, 46, 434 ], "is": [ 7 ], "concomitant": [ 8 ], "bone": [ 9, 25, 33, 179, 438 ], "loss.": [ 10, 29, 456 ], "Exercise": [ 11 ], "and": [ 12, 41, 60, 78, 86, 107, 170, 188, 224, 254, 303, 346, 395, 415, 426 ], "glucagon-like": [ 13 ], "peptide-1": [ 14 ], "receptor": [ 15 ], "agonists": [ 16 ], "(GLP-1RAs)": [ 17 ], "represent": [ 18 ], "strategies": [ 21 ], "that": [ 22 ], "may": [ 23 ], "protect": [ 24 ], "mass": [ 26, 103 ], "despite": [ 27, 453 ], "Objective": [ 30 ], "To": [ 31 ], "investigate": [ 32 ], "health": [ 34 ], "at": [ 35, 81, 183, 326, 375, 445 ], "clinically": [ 36, 446 ], "relevant": [ 37, 447 ], "sites": [ 38, 448 ], "(hip,": [ 39 ], "spine,": [ 40, 187 ], "forearm)": [ 42 ], "after": [ 43 ], "diet-induced": [ 44 ], "followed": [ 47 ], "by": [ 48, 202 ], "a": [ 49, 65, 70, 146 ], "1-year": [ 50 ], "intervention": [ 51 ], "exercise,": [ 53 ], "liraglutide,": [ 54 ], "or": [ 55, 166 ], "both": [ 56 ], "combined.": [ 57 ], "Design,": [ 58 ], "Setting,": [ 59 ], "Participants": [ 61 ], "This": [ 62 ], "study": [ 63, 271 ], "was": [ 64, 112, 175, 272, 319, 429 ], "predefined": [ 66 ], "secondary": [ 67 ], "analysis": [ 68, 111, 121 ], "of": [ 69, 84, 105, 140, 157, 199, 424 ], "randomized": [ 71, 137, 419 ], "clinical": [ 72, 420 ], "trial": [ 73 ], "conducted": [ 74, 113 ], "between": [ 75 ], "August": [ 76 ], "2016": [ 77 ], "November": [ 79 ], "2019": [ 80 ], "the": [ 82, 158, 164, 184, 193, 197, 207, 239, 245, 251, 258, 270, 280, 290, 300, 311, 315, 323, 327, 366, 372, 376, 422, 430 ], "University": [ 83 ], "Copenhagen": [ 85 ], "Hvidovre": [ 87 ], "Hospital": [ 88 ], "in": [ 89, 122, 177, 206, 238, 244, 250, 257, 266, 279, 289, 299, 310 ], "Denmark.": [ 90 ], "Eligible": [ 91 ], "participants": [ 92, 135, 214, 237, 243, 249, 256 ], "included": [ 93 ], "adults": [ 94 ], "aged": [ 95 ], "18": [ 96 ], "to": [ 97, 116, 138, 148, 196, 338, 356, 387, 406 ], "65": [ 98 ], "years": [ 99 ], "obesity": [ 101 ], "(body": [ 102 ], "index": [ 104 ], "32-43)": [ 106 ], "without": [ 108 ], "diabetes.": [ 109 ], "Data": [ 110 ], "from": [ 114, 191 ], "March": [ 115 ], "April": [ 117 ], "2023,": [ 118 ], "additional": [ 120 ], "February": [ 123 ], "2024": [ 124 ], "during": [ 125, 269 ], "revision.": [ 126 ], "Interventions": [ 127 ], "After": [ 128 ], "an": [ 129 ], "8-week": [ 130 ], "low-calorie": [ 131, 194 ], "diet": [ 132, 195 ], "(800": [ 133 ], "kcal/day),": [ 134 ], "were": [ 136, 233 ], "1": [ 139 ], "4": [ 141 ], "groups": [ 142 ], "for": [ 143, 371 ], "52": [ 144 ], "weeks:": [ 145 ], "moderate-": [ 147 ], "vigorous-intensity": [ 149 ], "exercise": [ 150, 240, 291, 367, 425, 451 ], "program": [ 151 ], "(exercise": [ 152 ], "alone),": [ 153, 163 ], "3.0": [ 154 ], "mg": [ 155 ], "daily": [ 156 ], "GLP-1": [ 159 ], "RA": [ 160 ], "liraglutide": [ 161, 246, 301, 373 ], "(liraglutide": [ 162 ], "combination,": [ 165 ], "placebo.": [ 167 ], "Main": [ 168 ], "Outcomes": [ 169 ], "Measures": [ 171 ], "The": [ 172, 261 ], "primary": [ 173 ], "outcome": [ 174 ], "change": [ 176, 265 ], "site-specific": [ 178 ], "mineral": [ 180 ], "density": [ 181 ], "(BMD)": [ 182 ], "hip,": [ 185 ], "lumbar": [ 186, 347 ], "distal": [ 189 ], "forearm": [ 190 ], "before": [ 192 ], "end": [ 198 ], "treatment,": [ 200 ], "measured": [ 201 ], "dual-energy": [ 203 ], "x-ray": [ 204 ], "absorptiometry": [ 205 ], "intention-to-treat": [ 208 ], "population.": [ 209 ], "Results": [ 210 ], "In": [ 211, 314, 417 ], "total,": [ 212 ], "195": [ 213 ], "(mean": [ 215, 329, 378, 397 ], "[SD]": [ 216, 229 ], "age,": [ 217 ], "42.84": [ 218 ], "[11.87]": [ 219 ], "years;": [ 220 ], "124": [ 221 ], "female": [ 222 ], "[64%]": [ 223 ], "71": [ 225 ], "male": [ 226 ], "[36%];": [ 227 ], "mean": [ 228, 264 ], "BMI,": [ 230 ], "37.00": [ 231 ], "[2.92])": [ 232 ], "randomized,": [ 234 ], "48": [ 236 ], "group,": [ 241, 247, 253, 282, 292, 302, 317, 368 ], "49": [ 242, 248, 255 ], "combination": [ 252, 312, 316, 423 ], "placebo": [ 259, 281, 324 ], "group.": [ 260, 313 ], "total": [ 262 ], "estimated": [ 263 ], "losses": [ 268 ], "7.03": [ 273 ], "kg": [ 274, 284, 294, 305 ], "(95%": [ 275, 285, 295, 306 ], "CI,": [ 276, 286, 296, 307, 336, 354, 385, 404 ], "4.25-9.80": [ 277 ], "kg)": [ 278, 288, 298, 309 ], "11.19": [ 283 ], "8.40-13.99": [ 287 ], "13.74": [ 293 ], "11.04-16.44": [ 297 ], "16.88": [ 304 ], "14.23-19.54": [ 308 ], "BMD": [ 318, 369, 444 ], "unchanged": [ 320 ], "compared": [ 321 ], "group": [ 325, 374 ], "hip": [ 328, 377 ], "change,": [ 330, 379, 398 ], "\u22120.006": [ 331 ], "g/cm": [ 332, 340, 350, 358, 381, 389, 400, 408 ], "2": [ 333, 341, 351, 359, 382, 390, 401, 409 ], ";": [ 334, 342, 352, 360, 383, 391, 402, 410 ], "95%": [ 335, 353, 384, 403 ], "\u22120.017": [ 337 ], "0.004": [ 339 ], "P": [ 343, 361, 392, 411 ], "=": [ 344, 362, 393, 412 ], ".24)": [ 345 ], "spine": [ 348, 396 ], "(\u22120.010": [ 349 ], "\u22120.025": [ 355 ], "0.005": [ 357 ], ".20).": [ 363 ], "Compared": [ 364 ], "decreased": [ 370 ], "\u22120.013": [ 380 ], "\u22120.024": [ 386 ], "\u22120.001": [ 388, 407 ], ".03)": [ 394 ], "\u22120.016": [ 399 ], "\u22120.032": [ 405 ], ".04).": [ 413 ], "Conclusions": [ 414 ], "Relevance": [ 416 ], "this": [ 418 ], "trial,": [ 421 ], "GLP-1RA": [ 427 ], "(liraglutide)": [ 428 ], "most": [ 431 ], "effective": [ 432 ], "strategy": [ 435 ], "while": [ 436 ], "preserving": [ 437 ], "health.": [ 439 ], "Liraglutide": [ 440 ], "treatment": [ 441 ], "alone": [ 442, 452 ], "reduced": [ 443 ], "more": [ 449 ], "than": [ 450 ], "similar": [ 454 ], "Trial": [ 457 ], "Registration": [ 458 ], "EudraCT:": [ 459 ], "2015-005585-32": [ 460 ] }, "publication_date": "2024-06-25", "publication_year": 2024, "type": "article", "cited_by_count": 70, "authors": [ { "id": "https://openalex.org/A5078868922", "display_name": "Simon Birk Kj\u00e6r Jensen" }, { "id": "https://openalex.org/A5028948652", "display_name": "Victor S\u00f8rensen" }, { "id": "https://openalex.org/A5007796517", "display_name": "Rasmus Michael Sandsdal" }, { "id": "https://openalex.org/A5006884016", "display_name": "Eva Winning Lehmann" }, { "id": "https://openalex.org/A5007991615", "display_name": "J. Lundgren" }, { "id": "https://openalex.org/A5043941957", "display_name": "Christian R. Juhl" }, { "id": "https://openalex.org/A5089416119", "display_name": "Charlotte Janus" }, { "id": "https://openalex.org/A5027535987", "display_name": "Tummas Ternhamar" }, { "id": "https://openalex.org/A5066604050", "display_name": "Bente Stallknecht" }, { "id": "https://openalex.org/A5085434984", "display_name": "Jens J. Holst" }, { "id": "https://openalex.org/A5069431123", "display_name": "Niklas Rye J\u00f8rgensen" }, { "id": "https://openalex.org/A5058323484", "display_name": "Jens\u2010Erik Beck Jensen" }, { "id": "https://openalex.org/A5062239390", "display_name": "Sten Madsbad" }, { "id": "https://openalex.org/A5038081896", "display_name": "Signe S. Torekov" } ] }, { "id": "https://openalex.org/W4387357834", "doi": "https://doi.org/10.1001/jama.2023.19574", "title": "Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss", "abstract": { "This": [ 0 ], "database": [ 1 ], "study": [ 2 ], "examines": [ 3 ], "the": [ 4 ], "association": [ 5 ], "between": [ 6 ], "glucagon-like": [ 7 ], "peptide": [ 8 ], "1": [ 9 ], "agonists": [ 10 ], "(eg,": [ 11 ], "semaglutide,": [ 12 ], "liraglutide)": [ 13 ], "used": [ 14 ], "for": [ 15 ], "weight": [ 16 ], "loss": [ 17 ], "and": [ 18 ], "reports": [ 19 ], "of": [ 20 ], "gastrointestinal": [ 21 ], "adverse": [ 22 ], "events.": [ 23 ] }, "publication_date": "2023-10-05", "publication_year": 2023, "type": "article", "cited_by_count": 339, "authors": [ { "id": "https://openalex.org/A5089950788", "display_name": "Mohit Sodhi" }, { "id": "https://openalex.org/A5009306106", "display_name": "Ramin Rezaeianzadeh" }, { "id": "https://openalex.org/A5041831769", "display_name": "Abbas Kezouh" }, { "id": "https://openalex.org/A5028615443", "display_name": "Mahyar Etminan" } ] }, { "id": "https://openalex.org/W1976838333", "doi": "https://doi.org/10.1016/j.diabres.2012.09.008", "title": "A meta-analysis of serious adverse events reported with exenatide and liraglutide: Acute pancreatitis and cancer", "abstract": null, "publication_date": "2012-09-23", "publication_year": 2012, "type": "review", "cited_by_count": 176, "authors": [ { "id": "https://openalex.org/A5067324565", "display_name": "Carlos Alves" }, { "id": "https://openalex.org/A5052010496", "display_name": "Francisco Batel Marques" }, { "id": "https://openalex.org/A5103372170", "display_name": "Ana Filipa Macedo" } ] }, { "id": "https://openalex.org/W4319795041", "doi": "https://doi.org/10.3390/molecules28031369", "title": "Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update", "abstract": { "Angiotensin": [ 0 ], "II": [ 1 ], "(Ang": [ 2 ], "II),": [ 3 ], "a": [ 4, 141 ], "peptide": [ 5 ], "hormone": [ 6 ], "generated": [ 7 ], "as": [ 8, 25, 40 ], "part": [ 9 ], "of": [ 10, 20, 46, 63, 72, 107, 112, 148 ], "the": [ 11, 18, 47, 61, 87, 101, 105, 110, 134, 146 ], "renin\u2013angiotensin": [ 12 ], "system,": [ 13 ], "has": [ 14, 54 ], "been": [ 15, 55 ], "implicated": [ 16 ], "in": [ 17, 60 ], "pathophysiology": [ 19 ], "many": [ 21 ], "cardiovascular": [ 22, 64, 88, 149 ], "diseases": [ 23 ], "such": [ 24 ], "peripheral": [ 26 ], "artery": [ 27, 33 ], "disease,": [ 28 ], "heart": [ 29, 125 ], "failure,": [ 30 ], "hypertension,": [ 31, 118 ], "coronary": [ 32 ], "disease": [ 34 ], "and": [ 35, 53, 83, 95, 124 ], "other": [ 36 ], "conditions.": [ 37 ], "Liraglutide,": [ 38 ], "known": [ 39 ], "an": [ 41, 85 ], "incretin": [ 42 ], "mimetic,": [ 43 ], "is": [ 44, 75 ], "one": [ 45 ], "glucagon-like": [ 48 ], "peptide-1": [ 49 ], "(GLP-1)": [ 50 ], "receptor": [ 51 ], "agonists,": [ 52 ], "proven": [ 56 ], "to": [ 57, 76, 139 ], "be": [ 58, 140 ], "effective": [ 59 ], "treatment": [ 62 ], "disorders": [ 65 ], "beyond": [ 66 ], "adequate": [ 67 ], "glycemic": [ 68 ], "control.": [ 69 ], "The": [ 70 ], "objective": [ 71 ], "this": [ 73 ], "review": [ 74 ], "compile": [ 77 ], "our": [ 78 ], "recent": [ 79 ], "experimental": [ 80 ], "outcomes-based": [ 81 ], "studies,": [ 82 ], "provide": [ 84 ], "overview": [ 86 ], "protection": [ 89 ], "from": [ 90 ], "liraglutide": [ 91, 128, 137 ], "against": [ 92 ], "Ang": [ 93 ], "II-": [ 94 ], "pressure": [ 96 ], "overload-mediated": [ 97 ], "deleterious": [ 98 ], "effects": [ 99 ], "on": [ 100 ], "heart.": [ 102 ], "In": [ 103 ], "particular,": [ 104 ], "mechanisms": [ 106 ], "action": [ 108 ], "underlying": [ 109 ], "inhibition": [ 111 ], "oxidative": [ 113 ], "stress,": [ 114 ], "vascular": [ 115 ], "endothelial": [ 116 ], "dysfunction,": [ 117 ], "cardiac": [ 119 ], "fibrosis,": [ 120 ], "left": [ 121 ], "ventricular": [ 122 ], "hypertrophy": [ 123 ], "failure": [ 126 ], "with": [ 127 ], "are": [ 129 ], "addressed.": [ 130 ], "Thus,": [ 131 ], "we": [ 132 ], "support": [ 133 ], "notion": [ 135 ], "that": [ 136 ], "continues": [ 138 ], "useful": [ 142 ], "add-on": [ 143 ], "therapy": [ 144 ], "for": [ 145 ], "management": [ 147 ], "diseases.": [ 150 ] }, "publication_date": "2023-02-01", "publication_year": 2023, "type": "review", "cited_by_count": 17, "authors": [ { "id": "https://openalex.org/A5068264151", "display_name": "Collin Vandemark" }, { "id": "https://openalex.org/A5079326712", "display_name": "Jimmy Nguyen" }, { "id": "https://openalex.org/A5010668713", "display_name": "Zhi\u2010Qing Zhao" } ] }, { "id": "https://openalex.org/W2003463625", "doi": "https://doi.org/10.1210/en.2014-1722", "title": "Chronic Toxicity and Carcinogenicity Studies of the Long-Acting GLP-1 Receptor Agonist Dulaglutide in Rodents", "abstract": { "The": [ 0 ], "tumorigenic": [ 1 ], "potential": [ 2 ], "of": [ 3, 142, 183, 207, 219, 244 ], "dulaglutide": [ 4, 22, 60, 149, 184, 213 ], "was": [ 5, 111, 133, 145 ], "evaluated": [ 6 ], "in": [ 7, 116, 147, 156, 197, 210, 233 ], "rats": [ 8, 178 ], "and": [ 9, 36, 83, 99, 121, 174 ], "transgenic": [ 10, 125 ], "mice.": [ 11 ], "Rats": [ 12 ], "were": [ 13, 54, 72, 85, 102 ], "injected": [ 14 ], "sc": [ 15, 56, 181 ], "twice": [ 16, 57 ], "weekly": [ 17, 58 ], "for": [ 18, 67 ], "93": [ 19 ], "weeks": [ 20, 243 ], "with": [ 21, 59, 114, 204 ], "0,": [ 23, 32, 61 ], "0.05,": [ 24 ], "0.5,": [ 25, 33, 119 ], "1.5,": [ 26, 120 ], "or": [ 27, 64, 91, 131, 186, 223, 225 ], "5": [ 28, 97, 106, 122, 187 ], "mg/kg": [ 29, 66, 90 ], "corresponding": [ 30 ], "to": [ 31, 74, 160, 170 ], "7,": [ 34 ], "20,": [ 35 ], "58": [ 37 ], "times,": [ 38 ], "respectively,": [ 39 ], "the": [ 40, 50, 75, 205, 217, 240, 245 ], "maximum": [ 41 ], "recommended": [ 42 ], "human": [ 43 ], "dose": [ 44 ], "based": [ 45 ], "on": [ 46 ], "plasma": [ 47, 175, 227 ], "area": [ 48 ], "under": [ 49 ], "curve.": [ 51 ], "Transgenic": [ 52 ], "mice": [ 53 ], "dosed": [ 55 ], "0.3,": [ 62 ], "1,": [ 63 ], "3": [ 65 ], "26": [ 68 ], "weeks.": [ 69 ], "Dulaglutide": [ 70, 189 ], "effects": [ 71 ], "limited": [ 73 ], "thyroid": [ 76 ], "C-cells.": [ 77 ], "In": [ 78, 124, 165 ], "rats,": [ 79 ], "diffuse": [ 80, 220, 231 ], "C-cell": [ 81, 100, 109, 129, 172, 192, 198, 211, 221, 234 ], "hyperplasia": [ 82, 110, 130, 222 ], "adenomas": [ 84 ], "statistically": [ 86 ], "increased": [ 87, 104, 190 ], "at": [ 88, 96, 105, 135 ], "0.5": [ 89 ], "greater": [ 92 ], "(P": [ 93 ], "\u2264": [ 94 ], ".01": [ 95 ], "mg/kg),": [ 98 ], "carcinomas": [ 101 ], "numerically": [ 103 ], "mg/kg.": [ 107, 123, 188 ], "Focal": [ 108 ], "higher": [ 112 ], "compared": [ 113 ], "controls": [ 115 ], "females": [ 117 ], "given": [ 118 ], "mice,": [ 126, 157 ], "no": [ 127 ], "dulaglutide-related": [ 128 ], "neoplasia": [ 132 ], "observed": [ 134, 146 ], "any": [ 136 ], "dose;": [ 137 ], "however,": [ 138, 194 ], "minimal": [ 139 ], "cytoplasmic": [ 140 ], "hypertrophy": [ 141 ], "C": [ 143 ], "cells": [ 144 ], "all": [ 148 ], "groups.": [ 150 ], "Systemic": [ 151 ], "exposures": [ 152 ], "decreased": [ 153 ], "over": [ 154 ], "time": [ 155 ], "possibly": [ 158 ], "due": [ 159 ], "an": [ 161 ], "antidrug": [ 162 ], "antibody": [ 163 ], "response.": [ 164 ], "a": [ 166 ], "52-week": [ 167 ], "study": [ 168 ], "designed": [ 169 ], "quantitate": [ 171 ], "mass": [ 173, 199, 235 ], "calcitonin": [ 176 ], "responses,": [ 177 ], "received": [ 179 ], "twice-weekly": [ 180 ], "injections": [ 182 ], "0": [ 185 ], "focal": [ 191 ], "hyperplasia;": [ 193 ], "quantitative": [ 195 ], "increases": [ 196, 232 ], "did": [ 200, 214, 236 ], "not": [ 201, 215, 237 ], "occur.": [ 202 ], "Consistent": [ 203 ], "lack": [ 206 ], "morphometric": [ 208 ], "changes": [ 209 ], "mass,": [ 212 ], "affect": [ 216 ], "incidence": [ 218 ], "basal": [ 224 ], "calcium-stimulated": [ 226 ], "calcitonin,": [ 228 ], "suggesting": [ 229 ], "that": [ 230 ], "occur": [ 238 ], "during": [ 239 ], "initial": [ 241 ], "52": [ 242 ], "rat": [ 246 ], "carcinogenicity": [ 247 ], "study.": [ 248 ] }, "publication_date": "2015-04-10", "publication_year": 2015, "type": "article", "cited_by_count": 30, "authors": [ { "id": "https://openalex.org/A5047433195", "display_name": "Richard A. Byrd" }, { "id": "https://openalex.org/A5001483460", "display_name": "Steven D. Sorden" }, { "id": "https://openalex.org/A5085333979", "display_name": "Thomas E. Ryan" }, { "id": "https://openalex.org/A5108537539", "display_name": "Thomas P. Pienkowski" }, { "id": "https://openalex.org/A5061187623", "display_name": "Richard C. Larock" }, { "id": "https://openalex.org/A5085599921", "display_name": "Ricardo V. Quander" }, { "id": "https://openalex.org/A5083306709", "display_name": "John A. Wijsman" }, { "id": "https://openalex.org/A5031695615", "display_name": "Holly W. Smith" }, { "id": "https://openalex.org/A5002096833", "display_name": "Jamie L. Blackbourne" }, { "id": "https://openalex.org/A5035821309", "display_name": "Thomas J. Rosol" }, { "id": "https://openalex.org/A5035076639", "display_name": "Gerald G. Long" }, { "id": "https://openalex.org/A5105937279", "display_name": "Jennifer A. Martin" }, { "id": "https://openalex.org/A5042601716", "display_name": "John L. Vahle" } ] }, { "id": "https://openalex.org/W4394952614", "doi": "https://doi.org/10.1001/jama.2024.1017", "title": "Could GLP-1 Receptor Agonists Like Semaglutide Treat Addiction, Alzheimer Disease, and Other Conditions?", "abstract": { "This": [ 0 ], "Medical": [ 1 ], "News": [ 2 ], "story": [ 3 ], "examines": [ 4 ], "other": [ 5 ], "potential": [ 6 ], "uses": [ 7 ], "of": [ 8 ], "GLP-1": [ 9 ], "receptor": [ 10 ], "agonists,": [ 11 ], "the": [ 12 ], "popular": [ 13 ], "type": [ 14 ], "2": [ 15 ], "diabetes": [ 16 ], "and": [ 17 ], "weight-loss": [ 18 ], "drugs.": [ 19 ] }, "publication_date": "2024-04-19", "publication_year": 2024, "type": "article", "cited_by_count": 26, "authors": [ { "id": "https://openalex.org/A5109451552", "display_name": "Rita Rubin" } ] }, { "id": "https://openalex.org/W3214549833", "doi": "https://doi.org/10.1038/s41598-021-01750-0", "title": "Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease", "abstract": null, "publication_date": "2021-11-18", "publication_year": 2021, "type": "article", "cited_by_count": 63, "authors": [ { "id": "https://openalex.org/A5088002321", "display_name": "Sergei Pechenov" }, { "id": "https://openalex.org/A5001301767", "display_name": "Jefferson D. Revell" }, { "id": "https://openalex.org/A5021197756", "display_name": "Sarah Will" }, { "id": "https://openalex.org/A5082104372", "display_name": "Jacqueline Naylor" }, { "id": "https://openalex.org/A5016538830", "display_name": "Puneet Tyagi" }, { "id": "https://openalex.org/A5009574193", "display_name": "Chandresh Patel" }, { "id": "https://openalex.org/A5100886716", "display_name": "Lihuan Liang" }, { "id": "https://openalex.org/A5065354481", "display_name": "Leo Tseng" }, { "id": "https://openalex.org/A5103755605", "display_name": "Yue Huang" }, { "id": "https://openalex.org/A5040578796", "display_name": "Anton I. Rosenbaum" }, { "id": "https://openalex.org/A5030794461", "display_name": "Kemal Balic" }, { "id": "https://openalex.org/A5086944869", "display_name": "Anish Konkar" }, { "id": "https://openalex.org/A5084966112", "display_name": "Joseph Grimsby" }, { "id": "https://openalex.org/A5051578715", "display_name": "J. Anand Subramony" } ] }, { "id": "https://openalex.org/W3119986206", "doi": "https://doi.org/10.1186/s12902-020-00678-2", "title": "The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile", "abstract": null, "publication_date": "2021-01-07", "publication_year": 2021, "type": "article", "cited_by_count": 27, "authors": [ { "id": "https://openalex.org/A5077488254", "display_name": "Anna Thors\u00f8 Larsen" }, { "id": "https://openalex.org/A5053038687", "display_name": "Sofie Gydesen" }, { "id": "https://openalex.org/A5066080561", "display_name": "Nina Sonne" }, { "id": "https://openalex.org/A5063475809", "display_name": "M.A. Karsdal" }, { "id": "https://openalex.org/A5082542112", "display_name": "Kim Henriksen" } ] }, { "id": "https://openalex.org/W2768885511", "doi": "https://doi.org/10.12659/msm.906603", "title": "Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Liraglutide Alters Bone Marrow Exosome-Mediated miRNA Signal Pathways in Ovariectomized Rats with Type 2 Diabetes", "abstract": { "BACKGROUND": [ 0 ], "Compared": [ 1 ], "with": [ 2, 13, 41, 152 ], "normal": [ 3 ], "postmenopausal": [ 4, 11 ], "women,": [ 5 ], "estrogen": [ 6 ], "deficiency": [ 7 ], "and": [ 8, 74, 102, 119, 158, 167, 177, 192, 222 ], "hyperglycemia": [ 9 ], "in": [ 10, 53, 69, 184, 236 ], "women": [ 12 ], "type": [ 14 ], "2": [ 15 ], "diabetes": [ 16 ], "(T2DM)": [ 17 ], "lead": [ 18, 180 ], "to": [ 19, 35, 63, 124, 135, 154, 181, 189, 220 ], "more": [ 20 ], "severe": [ 21 ], "bone": [ 22, 37, 71, 76, 89, 204, 238 ], "property": [ 23 ], "degradation.": [ 24 ], "Liraglutide,": [ 25 ], "a": [ 26, 234 ], "glucagon-like": [ 27 ], "peptide-1": [ 28 ], "(GLP-1)": [ 29 ], "receptor": [ 30 ], "agonist,": [ 31 ], "has": [ 32 ], "been": [ 33 ], "reported": [ 34 ], "improve": [ 36 ], "condition": [ 38, 166 ], "among": [ 39 ], "people": [ 40 ], "T2DM": [ 42, 100, 105, 165, 176, 221 ], "but": [ 43 ], "the": [ 44, 65, 75, 126, 200, 210, 237 ], "precise": [ 45 ], "mechanisms": [ 46, 78 ], "remain": [ 47 ], "unclear.": [ 48 ], "Exosomes": [ 49 ], "work": [ 50 ], "as": [ 51 ], "mediators": [ 52 ], "cell-to-cell": [ 54 ], "communication,": [ 55 ], "delivering": [ 56 ], "functional": [ 57, 214 ], "miRNAs": [ 58, 92, 131, 149, 186 ], "between": [ 59 ], "cells.": [ 60 ], "We": [ 61, 84 ], "aimed": [ 62 ], "explore": [ 64 ], "role": [ 66 ], "of": [ 67, 79, 88, 213, 241 ], "exosomes": [ 68, 218 ], "T2DM-related": [ 70 ], "metabolic": [ 72 ], "disorders": [ 73 ], "protective": [ 77, 239 ], "liraglutide.": [ 80, 242 ], "MATERIAL": [ 81 ], "AND": [ 82 ], "METHODS": [ 83 ], "made": [ 85 ], "comparative": [ 86 ], "analyses": [ 87 ], "marrow-derived": [ 90, 147 ], "exosomal": [ 91, 148, 185 ], "from": [ 93 ], "ovariectomized": [ 94 ], "(OVX)": [ 95 ], "control": [ 96 ], "rats,": [ 97, 101 ], "OVX": [ 98, 103 ], "+": [ 99, 104, 106 ], "liraglutide-treated": [ 107 ], "rats.": [ 108 ], "miRNA": [ 109, 155, 161, 215 ], "profiles": [ 110 ], "were": [ 111, 122, 132, 150 ], "generated": [ 112 ], "using": [ 113 ], "high-throughput": [ 114 ], "sequencing.": [ 115 ], "Target": [ 116 ], "gene": [ 117 ], "prediction": [ 118 ], "pathway": [ 120, 128, 197, 230 ], "analysis": [ 121 ], "performed": [ 123 ], "investigate": [ 125 ], "signal": [ 127 ], "alterations.": [ 129 ], "Three": [ 130 ], "randomly": [ 133 ], "chosen": [ 134 ], "validate": [ 136 ], "their": [ 137 ], "absolute": [ 138 ], "expression": [ 139, 159 ], "levels": [ 140 ], "by": [ 141 ], "real-time": [ 142 ], "quantitative": [ 143 ], "PCR.": [ 144 ], "RESULTS": [ 145 ], "Bone": [ 146, 225 ], "different": [ 151 ], "respect": [ 153 ], "numbers,": [ 156 ], "species,": [ 157 ], "levels.": [ 160 ], "spectra": [ 162 ], "varied": [ 163 ], "under": [ 164 ], "after": [ 168 ], "liraglutide": [ 169, 178, 223 ], "treatment.": [ 170, 224 ], "By": [ 171 ], "bioinformatics": [ 172 ], "analysis,": [ 173 ], "we": [ 174 ], "found": [ 175 ], "administration": [ 179 ], "significant": [ 182 ], "changes": [ 183 ], "which": [ 187 ], "targeted": [ 188 ], "insulin": [ 190 ], "secretion": [ 191 ], "insulin-signaling": [ 193 ], "pathway.": [ 194 ], "Wnt": [ 195, 228 ], "signaling": [ 196, 229 ], "alteration": [ 198, 231 ], "was": [ 199 ], "critical": [ 201 ], "point": [ 202 ], "regarding": [ 203 ], "metabolism.": [ 205 ], "CONCLUSIONS": [ 206 ], "Our": [ 207 ], "findings": [ 208 ], "show": [ 209 ], "selective": [ 211 ], "packaging": [ 212 ], "cargoes": [ 216 ], "into": [ 217 ], "due": [ 219 ], "marrow": [ 226 ], "exosome-mediated": [ 227 ], "may": [ 232 ], "play": [ 233 ], "part": [ 235 ], "effect": [ 240 ] }, "publication_date": "2017-11-14", "publication_year": 2017, "type": "article", "cited_by_count": 35, "authors": [ { "id": "https://openalex.org/A5100364769", "display_name": "Jin Li" }, { "id": "https://openalex.org/A5076236759", "display_name": "Ling-Zhi Fu" }, { "id": "https://openalex.org/A5100396514", "display_name": "Lu Liu" }, { "id": "https://openalex.org/A5110700487", "display_name": "Fen Xie" }, { "id": "https://openalex.org/A5101970117", "display_name": "Ru-Chun Dai" } ] }, { "id": "https://openalex.org/W4205591291", "doi": "https://doi.org/10.2147/dmso.s348025", "title": "Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study", "abstract": { "GLP-1RAs": [ 0 ], "produce": [ 1 ], "a": [ 2 ], "spectrum": [ 3 ], "of": [ 4, 7, 12, 22, 30 ], "distinct": [ 5 ], "classes": [ 6 ], "GADRs.": [ 8 ], "The": [ 9 ], "individual": [ 10 ], "properties": [ 11 ], "GADRs": [ 13 ], "between": [ 14 ], "semaglutide": [ 15 ], "and": [ 16 ], "liraglutide": [ 17 ], "might": [ 18 ], "enable": [ 19 ], "incretin-based": [ 20 ], "treatment": [ 21 ], "obesity": [ 23 ], "to": [ 24, 27 ], "be": [ 25 ], "\"tailored\"": [ 26 ], "the": [ 28 ], "needs": [ 29 ], "each": [ 31 ], "patient.": [ 32 ] }, "publication_date": "2022-01-01", "publication_year": 2022, "type": "article", "cited_by_count": 35, "authors": [ { "id": "https://openalex.org/A2105593998", "display_name": "Yu Zhou" }, { "id": "https://openalex.org/A2098200930", "display_name": "Mingyu Chen" }, { "id": "https://openalex.org/A2061579747", "display_name": "Libin Liu" }, { "id": "https://openalex.org/A2106825763", "display_name": "Zhou Chen" }, { "id": "https://openalex.org/A2105593998", "display_name": "Yu Zhou" }, { "id": "https://openalex.org/A2098200930", "display_name": "Mingyu Chen" }, { "id": "https://openalex.org/A2061579747", "display_name": "Libin Liu" }, { "id": "https://openalex.org/A2106825763", "display_name": "Zhou Chen" } ] }, { "id": "https://openalex.org/W2059678666", "doi": "https://doi.org/10.1111/dom.12007", "title": "A network meta\u2010analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo", "abstract": { "Abstract": [ 0 ], "Aims": [ 1 ], "The": [ 2, 212 ], "glucagon\u2010like": [ 3 ], "peptide\u20101": [ 4 ], "receptor": [ 5 ], "agonists": [ 6 ], "(": [ 7, 15, 22, 110 ], "GLP": [ 8, 264 ], "\u20101": [ 9, 265 ], "RAs": [ 10, 266 ], ")": [ 11, 17, 24 ], "exenatide": [ 12, 107 ], "once": [ 13, 20 ], "weekly": [ 14 ], "ExQW": [ 16, 41, 55, 97, 159, 187, 256 ], "and": [ 18, 137, 172, 192, 203, 222, 240, 257 ], "liraglutide": [ 19, 43, 57, 99, 169, 181, 189, 219, 259 ], "daily": [ 21, 109 ], "QD": [ 23, 44, 58, 100 ], "are": [ 25 ], "indicated": [ 26 ], "to": [ 27, 80, 132, 156, 166, 178, 201, 209 ], "improve": [ 28 ], "glycaemic": [ 29, 38, 72, 269 ], "control": [ 30, 39 ], "in": [ 31, 123, 129, 146, 216, 252 ], "patients": [ 32, 120 ], "with": [ 33, 40, 56 ], "type": [ 34 ], "2": [ 35 ], "diabetes.": [ 36 ], "Although": [ 37 ], "versus": [ 42, 148, 188 ], "1.8": [ 45, 103, 182, 193, 223 ], "mg": [ 46, 60, 191, 194, 221, 224 ], "has": [ 47 ], "been": [ 48 ], "directly": [ 49 ], "compared,": [ 50 ], "no": [ 51 ], "studies": [ 52, 116 ], "have": [ 53, 267 ], "compared": [ 54, 96 ], "1.2": [ 59, 170, 190, 220 ], "or": [ 61, 113, 134 ], "determined": [ 62 ], "the": [ 63, 124 ], "probable": [ 64 ], "relative": [ 65, 131 ], "efficacies": [ 66 ], "of": [ 67, 92 ], "various": [ 68 ], "injectable": [ 69 ], "therapies": [ 70 ], "for": [ 71, 158, 168, 180, 186, 236 ], "control;": [ 73 ], "therefore,": [ 74 ], "a": [ 75 ], "network": [ 76, 125, 245 ], "meta\u2010analysis": [ 77, 246 ], "was": [ 78, 225 ], "performed": [ 79 ], "address": [ 81 ], "these": [ 82, 263 ], "questions.": [ 83 ], "Methods": [ 84 ], "A": [ 85 ], "systematic": [ 86 ], "review": [ 87 ], "identified": [ 88 ], "randomized": [ 89 ], "controlled": [ 90 ], "trials": [ 91 ], "\u226524": [ 93 ], "weeks": [ 94 ], "that": [ 95, 262 ], ",": [ 98, 160 ], "(1.2": [ 101 ], "mg,": [ 102, 171 ], "mg),": [ 104 ], "insulin": [ 105 ], "glargine,": [ 106 ], "twice": [ 108 ], "ExBID": [ 111 ], "),": [ 112 ], "placebo.": [ 114 ], "Twenty\u2010two": [ 115 ], "evaluating": [ 117 ], "11": [ 118 ], "049": [ 119 ], "were": [ 121, 140, 150, 195, 232 ], "included": [ 122 ], "meta\u2010analysis.": [ 126 ], "Mean": [ 127 ], "differences": [ 128, 145, 185, 251 ], "HbA1c": [ 130, 147, 184, 217, 253 ], "placebo": [ 133, 149 ], "each": [ 135 ], "other": [ 136 ], "probability": [ 138 ], "rankings": [ 139 ], "estimated.": [ 141 ], "Results": [ 142, 231 ], "Estimated": [ 143 ], "mean": [ 144, 214 ], "\u22121.15%": [ 151 ], "(95%": [ 152, 162, 174, 197, 205, 227 ], "CrI": [ 153, 163, 175, 198, 206, 228 ], ":": [ 154, 164, 176, 199, 207, 229 ], "\u22121.31": [ 155 ], "\u22121.00)": [ 157 ], "\u22121.01%": [ 161 ], "\u22121.18": [ 165 ], "\u22120.85)": [ 167 ], "\u22121.18%": [ 173 ], "\u22121.32": [ 177 ], "\u22121.04)": [ 179 ], "mg.": [ 183 ], "\u22120.14%": [ 196 ], "\u22120.34": [ 200 ], "0.06)": [ 202 ], "0.03%": [ 204 ], "\u22120.14": [ 208 ], "0.18),": [ 210 ], "respectively.": [ 211 ], "estimated": [ 213 ], "difference": [ 215 ], "between": [ 218, 255 ], "0.17%": [ 226 ], "0.02\u20130.30).": [ 230 ], "consistent": [ 233 ], "when": [ 234 ], "adjusted": [ 235 ], "background": [ 237 ], "antihyperglycaemic": [ 238 ], "medications": [ 239 ], "diabetes": [ 241 ], "duration.": [ 242 ], "Conclusions": [ 243 ], "This": [ 244 ], "did": [ 247 ], "not": [ 248 ], "identify": [ 249 ], "meaningful": [ 250 ], "lowering": [ 254 ], "both": [ 258 ], "doses,": [ 260 ], "suggesting": [ 261 ], "similar": [ 268 ], "effects.": [ 270 ] }, "publication_date": "2012-09-07", "publication_year": 2012, "type": "review", "cited_by_count": 80, "authors": [ { "id": "https://openalex.org/A5039505685", "display_name": "David A. Scott" }, { "id": "https://openalex.org/A5039006946", "display_name": "Kristina S. Boye" }, { "id": "https://openalex.org/A5001088637", "display_name": "L. Timlin" }, { "id": "https://openalex.org/A5010724494", "display_name": "James F. Clark" }, { "id": "https://openalex.org/A5108098563", "display_name": "Jennie H. Best" } ] }, { "id": "https://openalex.org/W4281788945", "doi": "https://doi.org/10.2337/dc21-2275", "title": "Once-Weekly Exenatide in Youth With Type 2 Diabetes", "abstract": { "OBJECTIVE": [ 0 ], "Approved": [ 1 ], "treatments": [ 2 ], "for": [ 3, 48, 145, 150 ], "type": [ 4, 54, 227 ], "2": [ 5, 55, 75, 228 ], "diabetes": [ 6, 56, 229 ], "in": [ 7, 87, 140, 209, 216 ], "pediatric": [ 8 ], "patients": [ 9 ], "include": [ 10 ], "metformin,": [ 11 ], "liraglutide,": [ 12 ], "and": [ 13, 33, 41, 102, 123, 148, 197, 212, 219, 243 ], "insulin.": [ 14 ], "However,": [ 15 ], "approximately": [ 16 ], "one-half": [ 17 ], "of": [ 18, 43, 46, 51, 105, 114 ], "the": [ 19, 39, 49, 103, 135, 146, 151, 217 ], "youth": [ 20, 52, 225 ], "fail": [ 21 ], "metformin": [ 22 ], "monotherapy": [ 23 ], "within": [ 24 ], "1": [ 25 ], "year,": [ 26 ], "insulin": [ 27 ], "therapy": [ 28 ], "is": [ 29 ], "associated": [ 30 ], "with": [ 31, 53, 226, 232 ], "challenges,": [ 32 ], "liraglutide": [ 34 ], "requires": [ 35 ], "daily": [ 36 ], "injections.": [ 37 ], "Consequently,": [ 38 ], "efficacy": [ 40, 82, 96 ], "safety": [ 42 ], "once-weekly": [ 44, 73, 235 ], "injections": [ 45 ], "exenatide": [ 47, 74, 147, 175, 218, 236 ], "treatment": [ 50, 127 ], "was": [ 57, 85, 109, 143, 244 ], "evaluated.": [ 58 ], "RESEARCH": [ 59 ], "DESIGN": [ 60 ], "AND": [ 61 ], "METHODS": [ 62 ], "Participants": [ 63 ], "(aged": [ 64 ], "10": [ 65 ], "to": [ 66, 72, 92, 171 ], "&lt;18": [ 67 ], "years)": [ 68 ], "were": [ 69, 99, 117, 176 ], "randomized": [ 70, 118 ], "(5:2)": [ 71 ], "mg": [ 76 ], "or": [ 77 ], "placebo,": [ 78, 121, 130 ], "respectively.": [ 79, 222 ], "The": [ 80 ], "primary": [ 81 ], "end": [ 83, 97 ], "point": [ 84 ], "change": [ 86, 139 ], "glycated": [ 88, 141, 238 ], "hemoglobin": [ 89, 142, 239 ], "from": [ 90, 169 ], "baseline": [ 91, 170 ], "week": [ 93 ], "24.": [ 94 ], "Secondary": [ 95 ], "points": [ 98 ], "also": [ 100 ], "evaluated,": [ 101 ], "frequency": [ 104 ], "adverse": [ 106 ], "events": [ 107 ], "(AEs)": [ 108 ], "assessed.": [ 110 ], "RESULTS": [ 111 ], "A": [ 112 ], "total": [ 113 ], "83": [ 115 ], "participants": [ 116, 215 ], "(exenatide,": [ 119, 128 ], "59;": [ 120 ], "24)": [ 122 ], "72": [ 124 ], "completed": [ 125 ], "24-week": [ 126 ], "49;": [ 129 ], "23).": [ 131 ], "At": [ 132 ], "24": [ 133, 172, 241 ], "weeks,": [ 134 ], "least": [ 136, 165 ], "squares": [ 137, 166 ], "mean": [ 138, 167 ], "\u22120.36%": [ 144 ], "+0.49%": [ 149 ], "placebo": [ 152, 220 ], "groups": [ 153 ], "(between-group": [ 154 ], "difference,": [ 155 ], "\u22120.85%;": [ 156 ], "95%": [ 157 ], "CI": [ 158 ], "\u22121.51,": [ 159 ], "\u22120.19;": [ 160 ], "P": [ 161, 184, 194, 204 ], "=": [ 162, 185, 195, 205 ], "0.012).": [ 163 ], "Nonsignificant": [ 164 ], "differences": [ 168 ], "weeks": [ 173, 242 ], "favoring": [ 174 ], "observed:": [ 177 ], "fasting": [ 178 ], "glucose": [ 179 ], "\u221221.6": [ 180 ], "mg/dL": [ 181 ], "(\u221249.0,": [ 182 ], "5.7;": [ 183 ], "0.119),": [ 186 ], "systolic": [ 187 ], "blood": [ 188 ], "pressure": [ 189 ], "\u22122.8": [ 190 ], "mmHg": [ 191 ], "(\u22128.0,": [ 192 ], "2.4;": [ 193 ], "0.284),": [ 196 ], "body": [ 198 ], "weight": [ 199 ], "\u22121.22": [ 200 ], "kg": [ 201 ], "(\u22123.59,": [ 202 ], "1.15;": [ 203 ], "0.307).": [ 206 ], "AEs": [ 207 ], "occurred": [ 208 ], "36": [ 210 ], "(61.0%)": [ 211 ], "17": [ 213 ], "(73.9%)": [ 214 ], "groups,": [ 221 ], "CONCLUSIONS": [ 223 ], "In": [ 224 ], "suboptimally": [ 230 ], "controlled": [ 231 ], "current": [ 233 ], "treatments,": [ 234 ], "reduced": [ 237 ], "at": [ 240 ], "well": [ 245 ], "tolerated.": [ 246 ] }, "publication_date": "2022-06-09", "publication_year": 2022, "type": "article", "cited_by_count": 79, "authors": [ { "id": "https://openalex.org/A5002265183", "display_name": "William V. Tamborlane" }, { "id": "https://openalex.org/A5059786724", "display_name": "Raafat Bishai" }, { "id": "https://openalex.org/A5068374034", "display_name": "David H. Geller" }, { "id": "https://openalex.org/A5042407874", "display_name": "Naim Shehadeh" }, { "id": "https://openalex.org/A5064393241", "display_name": "Dalia Al\u2010Abdulrazzaq" }, { "id": "https://openalex.org/A5014789793", "display_name": "Evelina M\u00e1nica Vazquez" }, { "id": "https://openalex.org/A5000555147", "display_name": "Eva Karoly" }, { "id": "https://openalex.org/A5046234384", "display_name": "T\u00fcnde Troja" }, { "id": "https://openalex.org/A5008694066", "display_name": "Orlando Doehring" }, { "id": "https://openalex.org/A5039648499", "display_name": "Debra Carter" }, { "id": "https://openalex.org/A5017595887", "display_name": "John T. Monyak" }, { "id": "https://openalex.org/A5041913215", "display_name": "C. David Sj\u00f6str\u00f6m" } ] }, { "id": "https://openalex.org/W2725053346", "doi": "https://doi.org/10.1080/00325481.2017.1342509", "title": "Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes", "abstract": { "Among": [ 0 ], "persons": [ 1 ], "with": [ 2, 32, 78, 94, 203, 237, 265 ], "type": [ 3 ], "2": [ 4, 114 ], "diabetes": [ 5 ], "(t2d),": [ 6 ], "the": [ 7, 20, 86, 160, 166, 188, 248, 257 ], "development": [ 8 ], "of": [ 9, 38, 64, 75, 85, 159, 168, 192, 251 ], "glucose": [ 10, 112 ], "intolerance": [ 11 ], "involves": [ 12 ], "dysfunction": [ 13 ], "in": [ 14, 103, 120, 165, 187, 199, 227 ], "several": [ 15 ], "organs": [ 16, 161 ], "and": [ 17, 29, 43, 48, 67, 110, 135, 139, 162, 170, 176, 184, 195, 232, 255, 268 ], "tissues,": [ 18 ], "including": [ 19, 40 ], "muscle,": [ 21 ], "liver,": [ 22 ], "pancreas,": [ 23 ], "kidney,": [ 24 ], "gastrointestinal": [ 25 ], "tract,": [ 26 ], "adipose": [ 27 ], "tissue,": [ 28 ], "brain.": [ 30 ], "individuals": [ 31 ], "t2d": [ 33, 204 ], "typically": [ 34 ], "have": [ 35, 117, 124 ], "a": [ 36, 57, 193, 266 ], "number": [ 37 ], "comorbidities,": [ 39 ], "hypertension,": [ 41 ], "hyperlipidemia,": [ 42 ], "being": [ 44 ], "overweight": [ 45 ], "or": [ 46, 155 ], "obese,": [ 47 ], "are,": [ 49 ], "consequently,": [ 50 ], "at": [ 51 ], "high": [ 52 ], "cardiovascular": [ 53, 132, 141 ], "risk.": [ 54 ], "guidelines": [ 55 ], "recommend": [ 56 ], "comprehensive": [ 58 ], "care": [ 59 ], "strategy": [ 60 ], "that": [ 61, 81 ], "includes": [ 62 ], "treatment": [ 63, 216 ], "diabetes-related": [ 65 ], "complications": [ 66 ], "comorbidities": [ 68 ], "beyond": [ 69 ], "those": [ 70 ], "related": [ 71 ], "to": [ 72, 123, 181, 214 ], "hyperglycemia.": [ 73 ], "use": [ 74, 102 ], "glucose-lowering": [ 76 ], "therapies": [ 77 ], "complementary": [ 79, 183, 249 ], "activities": [ 80 ], "address": [ 82 ], "multiple": [ 83 ], "facets": [ 84 ], "disease": [ 87 ], "may": [ 88 ], "improve": [ 89 ], "long-term": [ 90 ], "outcomes": [ 91 ], "for": [ 92, 101, 218 ], "patients": [ 93, 202, 238, 261 ], "t2d.": [ 95 ], "two": [ 96 ], "recent": [ 97 ], "drug": [ 98, 152, 242, 253 ], "classes": [ 99, 153, 254 ], "developed": [ 100 ], "t2d,": [ 104, 169 ], "glucagon-like": [ 105 ], "peptide-1": [ 106 ], "receptor": [ 107 ], "agonists": [ 108 ], "(glp-1ras)": [ 109 ], "sodium": [ 111 ], "cotransporter": [ 113 ], "(sglt2)": [ 115 ], "inhibitors,": [ 116 ], "been": [ 118 ], "shown": [ 119 ], "clinical": [ 121, 190 ], "trials": [ 122 ], "beneficial": [ 125, 172 ], "effects": [ 126, 173 ], "on": [ 127, 174 ], "glycemic": [ 128 ], "control,": [ 129 ], "body": [ 130, 230 ], "weight,": [ 131, 231 ], "risk": [ 133 ], "factors,": [ 134 ], "(for": [ 136 ], "liraglutide,": [ 137 ], "semaglutide,": [ 138 ], "empagliflozin)": [ 140 ], "outcomes,": [ 142 ], "while": [ 143 ], "having": [ 144 ], "an": [ 145, 196, 269 ], "acceptable": [ 146 ], "safety": [ 147 ], "profile.": [ 148 ], "between": [ 149 ], "them,": [ 150 ], "these": [ 151, 252 ], "directly": [ 154 ], "indirectly": [ 156 ], "affect": [ 157 ], "many": [ 158 ], "tissues": [ 163 ], "involved": [ 164 ], "pathogenesis": [ 167 ], "their": [ 171, 215 ], "glycemic-": [ 175 ], "cardiovascular-related": [ 177 ], "parameters": [ 178 ], "are": [ 179 ], "likely": [ 180 ], "be": [ 182 ], "potentially": [ 185 ], "additive.": [ 186 ], "largest": [ 189 ], "trial": [ 191 ], "glp-1ra": [ 194, 267 ], "sglt2": [ 197, 270 ], "inhibitor": [ 198 ], "combination": [ 200 ], "(duration-8),": [ 201 ], "(n": [ 205 ], "=": [ 206 ], "685)": [ 207 ], "who": [ 208, 239 ], "received": [ 209, 240 ], "exenatide": [ 210 ], "plus": [ 211 ], "dapagliflozin": [ 212 ], "added": [ 213 ], "regimen": [ 217 ], "28": [ 219 ], "weeks": [ 220 ], "had": [ 221 ], "significantly": [ 222 ], "greater": [ 223 ], "reductions": [ 224 ], "from": [ 225 ], "baseline": [ 226 ], "glycated": [ 228 ], "hemoglobin,": [ 229 ], "systolic": [ 233 ], "blood": [ 234 ], "pressure": [ 235 ], "compared": [ 236 ], "either": [ 241 ], "as": [ 243 ], "monotherapy.": [ 244 ], "this": [ 245 ], "review": [ 246 ], "summarizes": [ 247 ], "aspects": [ 250 ], "presents": [ 256 ], "available": [ 258 ], "data": [ 259 ], "among": [ 260 ], "receiving": [ 262 ], "dual": [ 263 ], "therapy": [ 264 ], "inhibitor.": [ 271 ] }, "publication_date": "2017-06-28", "publication_year": 2017, "type": "article", "cited_by_count": 57, "authors": [ { "id": "https://openalex.org/A5103165011", "display_name": "Robert S. Busch" }, { "id": "https://openalex.org/A5038468673", "display_name": "Michael P. Kane" } ] }, { "id": "https://openalex.org/W4296286895", "doi": "https://doi.org/10.1001/jamanetworkopen.2022.31982", "title": "Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity", "abstract": { "Importance": [ 0 ], "No": [ 1 ], "retrospective": [ 2 ], "cohort": [ 3, 54, 407 ], "study": [ 4, 28, 217, 408 ], "has": [ 5 ], "assessed": [ 6 ], "the": [ 7, 68, 161, 170, 197, 236, 274, 303 ], "effectiveness": [ 8 ], "of": [ 9, 70, 89, 96, 105, 124, 163, 172, 177, 199, 266, 293, 318, 327, 336, 346, 405, 416, 435 ], "semaglutide": [ 10, 34, 71, 112, 144, 417 ], "at": [ 11, 36, 57, 238, 244, 310, 363, 380, 393 ], "doses": [ 12, 37, 415 ], "used": [ 13, 38 ], "in": [ 14, 39, 235, 427 ], "randomized": [ 15, 40, 428 ], "clinical": [ 16, 41, 429 ], "trials": [ 17, 42 ], "to": [ 18, 91, 149, 260, 287, 424, 439 ], "treat": [ 19 ], "obesity": [ 20, 77 ], "(ie,": [ 21 ], "1.7": [ 22 ], "and": [ 23, 51, 82, 131, 154, 187, 193, 196, 212, 241, 273, 340, 365, 387, 401, 413 ], "2.4": [ 24 ], "mg).": [ 25 ], "Objective": [ 26 ], "To": [ 27 ], "weight": [ 29, 62, 164, 175, 200, 250, 264, 277, 291, 316, 325, 334, 344, 361, 421, 442 ], "loss": [ 30, 176, 201, 251, 265, 278, 292, 317, 326, 335, 345, 362, 422, 443 ], "outcomes": [ 31 ], "associated": [ 32, 419 ], "with": [ 33, 45, 74, 86, 99, 121, 132, 204, 351, 369, 420, 432 ], "treatment": [ 35 ], "for": [ 43, 61, 72, 115, 147, 202 ], "patients": [ 44, 98, 173, 203, 220, 243, 305 ], "overweight": [ 46, 75 ], "or": [ 47, 76, 107, 118, 142, 179, 182, 185, 189, 205, 320, 329, 338, 348 ], "obesity.": [ 48 ], "Design,": [ 49 ], "Setting,": [ 50 ], "Participants": [ 52 ], "This": [ 53 ], "study,": [ 55 ], "conducted": [ 56 ], "a": [ 58, 87, 100, 122, 261, 288, 356 ], "referral": [ 59 ], "center": [ 60 ], "management,": [ 63 ], "retrospectively": [ 64 ], "collected": [ 65 ], "data": [ 66 ], "on": [ 67 ], "use": [ 69 ], "adults": [ 73 ], "between": [ 78 ], "January": [ 79 ], "1,": [ 80 ], "2021,": [ 81 ], "March": [ 83 ], "15,": [ 84 ], "2022,": [ 85 ], "follow-up": [ 88, 436 ], "up": [ 90, 309 ], "6": [ 92, 150, 194, 213, 245, 280, 311, 366, 394 ], "months.": [ 93, 151, 214, 246 ], "A": [ 94 ], "total": [ 95 ], "408": [ 97 ], "body": [ 101 ], "mass": [ 102 ], "index": [ 103 ], "(BMI)": [ 104 ], "27": [ 106 ], "more": [ 108, 190 ], "were": [ 109, 137, 169, 307, 418 ], "prescribed": [ 110 ], "weekly": [ 111, 411 ], "subcutaneous": [ 113, 145 ], "injections": [ 114, 146 ], "3": [ 116, 148, 192, 211, 239, 253, 364, 381 ], "months": [ 117, 195, 240, 254, 281, 367, 382, 395 ], "more.": [ 119, 349 ], "Patients": [ 120, 350 ], "history": [ 123 ], "bariatric": [ 125 ], "procedures,": [ 126 ], "taking": [ 127 ], "other": [ 128 ], "antiobesity": [ 129 ], "medications,": [ 130 ], "an": [ 133 ], "active": [ 134 ], "malignant": [ 135 ], "neoplasm": [ 136 ], "excluded.": [ 138 ], "Exposures": [ 139 ], "Weekly": [ 140 ], "1.7-mg": [ 141, 412 ], "2.4-mg": [ 143, 414 ], "Main": [ 152 ], "Outcomes": [ 153 ], "Measures": [ 155 ], "The": [ 156, 216, 247, 403 ], "primary": [ 157 ], "end": [ 158, 167 ], "point": [ 159 ], "was": [ 160, 255, 282 ], "percentage": [ 162, 198, 360 ], "loss.": [ 165 ], "Secondary": [ 166 ], "points": [ 168 ], "proportion": [ 171 ], "achieving": [ 174 ], "5%": [ 178, 319 ], "more,": [ 180, 183, 186, 321, 330, 339 ], "10%": [ 181, 328 ], "15%": [ 184, 337 ], "20%": [ 188, 347 ], "after": [ 191, 210, 252, 279 ], "without": [ 206, 371 ], "type": [ 207, 352, 372 ], "2": [ 208, 353, 373 ], "diabetes": [ 209, 354 ], "Results": [ 215 ], "included": [ 218 ], "175": [ 219 ], "(132": [ 221 ], "women": [ 222 ], "[75.4%];": [ 223 ], "mean": [ 224, 230, 248, 262, 275, 289, 358 ], "[SD]": [ 225, 231 ], "age,": [ 226 ], "49.3": [ 227 ], "[12.5]": [ 228 ], "years;": [ 229 ], "BMI,": [ 232 ], "41.3": [ 233 ], "[9.1])": [ 234 ], "analysis": [ 237 ], "102": [ 242, 304 ], "(SD)": [ 249, 263, 276, 290, 359 ], "6.7": [ 256 ], "(4.4)": [ 257 ], "kg,": [ 258, 285 ], "equivalent": [ 259, 286 ], "5.9%": [ 267 ], "(3.7%)": [ 268, 379 ], "(": [ 269, 296, 383, 396 ], "P": [ 270, 297, 384, 397 ], "&lt;": [ 271, 298 ], ".001),": [ 272 ], "12.3": [ 283 ], "(6.6)": [ 284 ], "10.9%": [ 294 ], "(5.8%)": [ 295 ], ".001": [ 299 ], "from": [ 300 ], "baseline).": [ 301 ], "Of": [ 302 ], "who": [ 306 ], "followed": [ 308 ], "months,": [ 312 ], "89": [ 313 ], "(87.3%)": [ 314 ], "achieved": [ 315, 324, 333, 343 ], "56": [ 322 ], "(54.9%)": [ 323 ], "24": [ 331 ], "(23.5%)": [ 332 ], "8": [ 341 ], "(7.8%)": [ 342 ], "had": [ 355 ], "lower": [ 357 ], "compared": [ 368 ], "those": [ 370 ], "diabetes:": [ 374 ], "3.9%": [ 375 ], "(3.1%)": [ 376 ], "vs": [ 377, 390 ], "6.3%": [ 378 ], "=": [ 385, 398 ], ".001)": [ 386 ], "7.2%": [ 388 ], "(6.3%)": [ 389 ], "11.8%": [ 391 ], "(5.3%)": [ 392 ], ".005).": [ 399 ], "Conclusions": [ 400 ], "Relevance": [ 402 ], "results": [ 404 ], "this": [ 406 ], "suggest": [ 409 ], "that": [ 410, 425 ], "similar": [ 423 ], "seen": [ 426 ], "trials.": [ 430 ], "Studies": [ 431 ], "longer": [ 433 ], "periods": [ 434 ], "are": [ 437 ], "needed": [ 438 ], "evaluate": [ 440 ], "prolonged": [ 441 ], "outcomes.": [ 444 ] }, "publication_date": "2022-09-19", "publication_year": 2022, "type": "article", "cited_by_count": 185, "authors": [ { "id": "https://openalex.org/A5023098051", "display_name": "Wissam Ghusn" }, { "id": "https://openalex.org/A5012040437", "display_name": "Alan De la Rosa" }, { "id": "https://openalex.org/A5049943356", "display_name": "Daniel Sacoto" }, { "id": "https://openalex.org/A5089247154", "display_name": "Lizeth Cifuentes" }, { "id": "https://openalex.org/A5034433339", "display_name": "Alejandro Campos" }, { "id": "https://openalex.org/A5085639403", "display_name": "Fauzi Feris" }, { "id": "https://openalex.org/A5067763694", "display_name": "Maria D. Hurtado" }, { "id": "https://openalex.org/A5060455870", "display_name": "Andr\u00e9s Acosta" } ] }, { "id": "https://openalex.org/W4288034125", "doi": "https://doi.org/10.1002/oby.23481", "title": "Effects of liraglutide on gastrointestinal functions and weight in obesity: A randomized clinical and pharmacogenomic trial", "abstract": { "Abstract": [ 0 ], "Objective": [ 1 ], "This": [ 2 ], "study": [ 3, 48 ], "aimed": [ 4 ], "to": [ 5, 30, 59, 115, 132 ], "determine": [ 6 ], "the": [ 7 ], "effects": [ 8, 43, 246 ], "of": [ 9, 33, 44, 56, 74, 97, 183 ], "a": [ 10, 50 ], "long\u2010acting": [ 11 ], "glucagon\u2010like": [ 12 ], "peptide\u20101": [ 13 ], "(GLP\u20101)": [ 14 ], "receptor": [ 15 ], "agonist,": [ 16 ], "liraglutide,": [ 17, 57, 184 ], "and": [ 18, 26, 29, 39, 80, 86, 105, 123, 140, 147, 156, 201, 230, 236, 240 ], "placebo": [ 19, 106 ], "subcutaneously": [ 20, 62 ], "over": [ 21 ], "16": [ 22, 124, 141, 163, 181 ], "weeks": [ 23, 125, 142, 182 ], "on": [ 24, 174 ], "weight": [ 25, 119, 172, 212, 222 ], "gastric": [ 27, 72, 77, 150 ], "functions": [ 28 ], "evaluate": [ 31 ], "associations": [ 32 ], "single\u2010nucleotide": [ 34 ], "polymorphisms": [ 35 ], "in": [ 36, 64, 91, 226, 238, 247 ], "GLP1R": [ 37, 185, 239 ], "(rs6923761)": [ 38 ], "TCF7L2": [ 40, 202, 241 ], "(rs7903146)": [ 41 ], "with": [ 42, 69, 171, 192, 209, 224, 244 ], "liraglutide.": [ 45 ], "Methods": [ 46 ], "The": [ 47 ], "conducted": [ 49 ], "randomized,": [ 51 ], "parallel\u2010group,": [ 52 ], "placebo\u2010controlled,": [ 53 ], "16\u2010week": [ 54 ], "trial": [ 55 ], "escalated": [ 58 ], "3": [ 60, 219 ], "mg": [ 61 ], "daily": [ 63 ], "136": [ 65 ], "otherwise": [ 66 ], "healthy": [ 67 ], "adults": [ 68 ], "obesity.": [ 70, 248 ], "Weight,": [ 71 ], "emptying": [ 73 ], "solids": [ 75 ], "(GES),": [ 76 ], "volumes,": [ 78 ], "satiation,": [ 79 ], "body": [ 81, 195, 211 ], "composition": [ 82 ], "measured": [ 83 ], "at": [ 84, 121, 138, 162 ], "baseline": [ 85 ], "after": [ 87 ], "treatment": [ 88, 93 ], "were": [ 89 ], "compared": [ 90 ], "two": [ 92 ], "groups": [ 94, 111 ], "using": [ 95 ], "analysis": [ 96 ], "covariance.": [ 98 ], "Results": [ 99 ], "Liraglutide": [ 100 ], "(": [ 101, 107, 152, 158, 197, 213 ], "n": [ 102, 108 ], "=": [ 103, 109, 154, 199, 215 ], "59)": [ 104 ], "65)": [ 110 ], "completed": [ 112 ], "treatment.": [ 113 ], "Relative": [ 114 ], "placebo,": [ 116 ], "liraglutide": [ 117, 175, 245 ], "increased": [ 118, 148 ], "loss": [ 120, 173, 223 ], "5": [ 122, 139 ], "(both": [ 126, 143, 176 ], "p": [ 127, 144, 153, 159, 177, 198, 214 ], "<": [ 128, 145, 160, 178 ], "0.05),": [ 129 ], "slowed": [ 130 ], "time": [ 131 ], "half": [ 133 ], "GES": [ 134, 165, 227, 235 ], "(T": [ 135 ], "1/2": [ 136, 167, 229 ], ")": [ 137 ], "0.001),": [ 146 ], "fasting": [ 149 ], "volume": [ 151 ], "0.01)": [ 155, 161 ], "satiation": [ 157 ], "weeks.": [ 164 ], "T": [ 166, 228 ], "was": [ 168, 190, 207 ], "positively": [ 169 ], "correlated": [ 170 ], "0.001).": [ 179 ], "After": [ 180 ], "rs6923761": [ 186 ], "(AG/AA": [ 187 ], "vs.": [ 188, 205 ], "GG)": [ 189 ], "associated": [ 191, 208, 243 ], "reduced": [ 193 ], "percent": [ 194 ], "fat": [ 196 ], "0.062),": [ 200 ], "rs7903146": [ 203 ], "(CC": [ 204 ], "CT/TT)": [ 206 ], "lower": [ 210 ], "0.015).": [ 216 ], "Conclusions": [ 217 ], "Liraglutide,": [ 218 ], "mg,": [ 220 ], "induces": [ 221 ], "delay": [ 225 ], "reduces": [ 231 ], "calorie": [ 232 ], "intake.": [ 233 ], "Slowing": [ 234 ], "variations": [ 237 ], "are": [ 242 ] }, "publication_date": "2022-07-27", "publication_year": 2022, "type": "article", "cited_by_count": 105, "authors": [ { "id": "https://openalex.org/A5046327975", "display_name": "Daniel B. Maselli" }, { "id": "https://openalex.org/A5077795610", "display_name": "Jessica Atieh" }, { "id": "https://openalex.org/A5047821084", "display_name": "Matthew M. Clark" }, { "id": "https://openalex.org/A5091240380", "display_name": "Deborah J. Eckert" }, { "id": "https://openalex.org/A5049918508", "display_name": "Ann Taylor" }, { "id": "https://openalex.org/A5107828987", "display_name": "Paula Carlson" }, { "id": "https://openalex.org/A5016581938", "display_name": "Duane D. Burton" }, { "id": "https://openalex.org/A5040287595", "display_name": "Irene Busciglio" }, { "id": "https://openalex.org/A5044847415", "display_name": "William S. Harmsen" }, { "id": "https://openalex.org/A5034412938", "display_name": "Adrian Vella" }, { "id": "https://openalex.org/A5060455870", "display_name": "Andr\u00e9s Acosta" }, { "id": "https://openalex.org/A5001729912", "display_name": "Michael Camilleri" } ] }, { "id": "https://openalex.org/W4210669371", "doi": "https://doi.org/10.1007/s11883-022-00982-3", "title": "The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia", "abstract": null, "publication_date": "2022-01-01", "publication_year": 2022, "type": "review", "cited_by_count": 18, "authors": [ { "id": "https://openalex.org/A5025245063", "display_name": "Peter Novodvorsk\u00fd" }, { "id": "https://openalex.org/A5023584418", "display_name": "Martin Haluz\u0131\u0301k" } ] }, { "id": "https://openalex.org/W4362693001", "doi": "https://doi.org/10.1136/bmj-2022-074068", "title": "Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials", "abstract": { "Abstract": [ 0 ], "Objective": [ 1 ], "To": [ 2 ], "compare": [ 3 ], "the": [ 4, 123, 154, 221, 335, 366, 409, 413, 441 ], "benefits": [ 5, 222, 373, 411 ], "and": [ 6, 24, 45, 53, 110, 130, 175, 226, 243, 257, 262, 289, 293, 319, 355, 380, 395, 418, 426, 429, 436 ], "harms": [ 7, 300 ], "of": [ 8, 72, 85, 94, 106, 118, 126, 223, 297, 374, 415, 446 ], "drug": [ 9, 98, 147, 305 ], "treatments": [ 10 ], "for": [ 11, 63, 240, 254, 393, 443, 458 ], "adults": [ 12, 75 ], "with": [ 13, 76, 101, 139, 156, 197, 201, 310, 317, 329, 385, 412, 460 ], "type": [ 14, 77, 386, 461 ], "2": [ 15, 78, 387, 462 ], "diabetes,": [ 16, 388 ], "adding": [ 17, 432 ], "non-steroidal": [ 18, 189 ], "mineralocorticoid": [ 19, 190 ], "receptor": [ 20, 35, 177, 191, 228, 268, 287, 321, 378, 420 ], "antagonists": [ 21 ], "(including": [ 22 ], "finerenone)": [ 23 ], "tirzepatide": [ 25, 294, 318 ], "(a": [ 26 ], "dual": [ 27 ], "glucose": [ 28, 160 ], "dependent": [ 29 ], "insulinotropic": [ 30 ], "polypeptide": [ 31 ], "(GIP)/glucagon-like": [ 32 ], "peptide-1": [ 33 ], "(GLP-1)": [ 34 ], "agonist)": [ 36 ], "to": [ 37, 57, 153, 171, 181, 210, 238, 252, 277, 304, 325, 327, 449 ], "previously": [ 38 ], "existing": [ 39 ], "treatment": [ 40, 99 ], "options.": [ 41 ], "Design": [ 42 ], "Systematic": [ 43, 464 ], "review": [ 44, 465 ], "network": [ 46, 403 ], "meta-analysis.": [ 47 ], "Data": [ 48 ], "sources": [ 49 ], "Ovid": [ 50 ], "Medline,": [ 51 ], "Embase,": [ 52 ], "Cochrane": [ 54 ], "Central": [ 55 ], "up": [ 56 ], "14": [ 58 ], "October": [ 59 ], "2022.": [ 60 ], "Eligibility": [ 61 ], "criteria": [ 62 ], "selecting": [ 64 ], "studies": [ 65, 113 ], "Eligible": [ 66, 80 ], "randomised": [ 67, 107 ], "controlled": [ 68, 108 ], "trials": [ 69, 81, 138 ], "compared": [ 70 ], "drugs": [ 71, 215, 279 ], "interest": [ 73 ], "in": [ 74, 199, 230, 280, 334, 338, 365, 369, 383, 422, 454 ], "diabetes.": [ 79, 463 ], "had": [ 82 ], "a": [ 83 ], "follow-up": [ 84 ], "24": [ 86 ], "weeks": [ 87 ], "or": [ 88 ], "longer.": [ 89 ], "Trials": [ 90 ], "systematically": [ 91 ], "comparing": [ 92 ], "combinations": [ 93 ], "more": [ 95 ], "than": [ 96 ], "one": [ 97 ], "class": [ 100, 306 ], "no": [ 102 ], "drug,": [ 103 ], "subgroup": [ 104 ], "analyses": [ 105 ], "trials,": [ 109 ], "non-English": [ 111 ], "language": [ 112 ], "were": [ 114, 301 ], "deemed": [ 115 ], "ineligible.": [ 116 ], "Certainty": [ 117 ], "evidence": [ 119 ], "was": [ 120 ], "assessed": [ 121 ], "following": [ 122 ], "GRADE": [ 124 ], "(grading": [ 125 ], "recommendations,": [ 127 ], "assessment,": [ 128 ], "development": [ 129 ], "evaluation)": [ 131 ], "approach.": [ 132 ], "Results": [ 133 ], "The": [ 134, 218 ], "analysis": [ 135 ], "identified": [ 136 ], "816": [ 137 ], "471": [ 140 ], "038": [ 141 ], "patients,": [ 142 ], "together": [ 143 ], "evaluating": [ 144 ], "13": [ 145 ], "different": [ 146 ], "classes;": [ 148 ], "all": [ 149, 186 ], "subsequent": [ 150 ], "estimates": [ 151 ], "refer": [ 152 ], "comparison": [ 155 ], "standard": [ 157 ], "treatments.": [ 158 ], "Sodium": [ 159 ], "cotransporter-2": [ 161 ], "(SGLT-2)": [ 162 ], "inhibitors": [ 163, 225, 274, 292, 417 ], "(odds": [ 164 ], "ratio": [ 165 ], "0.88,": [ 166 ], "95%": [ 167 ], "confidence": [ 168 ], "interval": [ 169 ], "0.83": [ 170 ], "0.94;": [ 172 ], "high": [ 173, 183 ], "certainty)": [ 174, 184, 354, 362 ], "GLP-1": [ 176, 227, 267, 286, 320, 377, 419 ], "agonists": [ 178, 229, 269, 288, 421 ], "(0.88,": [ 179 ], "0.82": [ 180 ], "0.93;": [ 182 ], "reduce": [ 185, 206, 270 ], "cause": [ 187 ], "death;": [ 188 ], "antagonists,": [ 192 ], "so": [ 193 ], "far": [ 194 ], "tested": [ 195 ], "only": [ 196 ], "finerenone": [ 198, 381, 435 ], "patients": [ 200 ], "chronic": [ 202 ], "kidney": [ 203, 246, 260, 284, 396, 427 ], "disease,": [ 204, 261 ], "probably": [ 205, 249, 290, 332, 363 ], "mortality": [ 207 ], "(0.89,": [ 208 ], "0.79": [ 209 ], "1.00;": [ 211 ], "moderate": [ 212, 345, 353, 361 ], "certainty);": [ 213 ], "other": [ 214, 278 ], "may": [ 216 ], "not.": [ 217 ], "study": [ 219 ], "confirmed": [ 220 ], "SGLT-2": [ 224, 273, 291, 311, 375, 416 ], "reducing": [ 231, 281, 423 ], "cardiovascular": [ 232, 264, 394, 425 ], "death,": [ 233 ], "non-fatal": [ 234, 271 ], "myocardial": [ 235 ], "infarction,": [ 236 ], "admission": [ 237, 326 ], "hospital": [ 239, 253, 328 ], "heart": [ 241, 255 ], "failure,": [ 242 ], "end": [ 244, 258, 282 ], "stage": [ 245, 259, 283 ], "disease.": [ 247, 285 ], "Finerenone": [ 248 ], "reduces": [ 250 ], "admissions": [ 251 ], "failure": [ 256 ], "possibly": [ 263 ], "death.": [ 265 ], "Only": [ 266 ], "stroke;": [ 272 ], "are": [ 275 ], "superior": [ 276 ], "improve": [ 295 ], "quality": [ 296 ], "life.": [ 298 ], "Reported": [ 299 ], "largely": [ 302 ], "specific": [ 303 ], "(eg,": [ 307 ], "genital": [ 308 ], "infections": [ 309 ], "inhibitors,": [ 312, 376 ], "severe": [ 313 ], "gastrointestinal": [ 314 ], "adverse": [ 315, 424 ], "events": [ 316 ], "agonists,": [ 322, 379 ], "hyperkalaemia": [ 323 ], "leading": [ 324 ], "finerenone).": [ 330 ], "Tirzepatide": [ 331 ], "results": [ 333 ], "largest": [ 336, 367 ], "reduction": [ 337 ], "body": [ 339, 370 ], "weight": [ 340 ], "(mean": [ 341, 349, 357 ], "difference": [ 342, 350, 358 ], "\u22128.57": [ 343 ], "kg;": [ 344, 352, 360 ], "certainty).": [ 346 ], "Basal": [ 347 ], "insulin": [ 348 ], "2.15": [ 351 ], "thiazolidinediones": [ 356 ], "2.81": [ 359 ], "result": [ 364 ], "increases": [ 368 ], "weight.": [ 371 ], "Absolute": [ 372 ], "vary": [ 382 ], "people": [ 384, 459 ], "depending": [ 389 ], "on": [ 390, 434 ], "baseline": [ 391 ], "risks": [ 392 ], "outcomes": [ 397, 428 ], "(": [ 398 ], "https://matchit.magicevidence.org/230125dist-diabetes": [ 399 ], ").": [ 400 ], "Conclusions": [ 401 ], "This": [ 402 ], "meta-analysis": [ 404 ], "extends": [ 405 ], "knowledge": [ 406 ], "beyond": [ 407 ], "confirming": [ 408 ], "substantial": [ 410 ], "use": [ 414 ], "death": [ 430 ], "by": [ 431 ], "information": [ 433 ], "tirzepatide.": [ 437 ], "These": [ 438 ], "findings": [ 439 ], "highlight": [ 440 ], "need": [ 442 ], "continuous": [ 444 ], "assessment": [ 445 ], "scientific": [ 447 ], "progress": [ 448 ], "introduce": [ 450 ], "cutting": [ 451 ], "edge": [ 452 ], "updates": [ 453 ], "clinical": [ 455 ], "practice": [ 456 ], "guidelines": [ 457 ], "registration": [ 466 ], "PROSPERO": [ 467 ], "CRD42022325948.": [ 468 ] }, "publication_date": "2023-04-06", "publication_year": 2023, "type": "review", "cited_by_count": 235, "authors": [ { "id": "https://openalex.org/A5066253638", "display_name": "Qingyang Shi" }, { "id": "https://openalex.org/A5112664062", "display_name": "Kailei Nong" }, { "id": "https://openalex.org/A5017952355", "display_name": "Per Olav Vandvik" }, { "id": "https://openalex.org/A5031717153", "display_name": "Gordon Guyatt" }, { "id": "https://openalex.org/A5011161870", "display_name": "Oliver Schnell" }, { "id": "https://openalex.org/A5041670111", "display_name": "Lars Ryd\u00e9n" }, { "id": "https://openalex.org/A5019976194", "display_name": "Nikolaus Marx" }, { "id": "https://openalex.org/A5003676386", "display_name": "Frank C. Brosius" }, { "id": "https://openalex.org/A5067205817", "display_name": "Reem A. Mustafa" }, { "id": "https://openalex.org/A5020341898", "display_name": "Arnav Agarwal" }, { "id": "https://openalex.org/A5103274540", "display_name": "Xinyu Zou" }, { "id": "https://openalex.org/A5012796677", "display_name": "Yunhe Mao" }, { "id": "https://openalex.org/A5053661448", "display_name": "Aminreza Asadollahifar" }, { "id": "https://openalex.org/A5046108974", "display_name": "Saifur Rahman Chowdhury" }, { "id": "https://openalex.org/A5051222058", "display_name": "Chunjuan Zhai" }, { "id": "https://openalex.org/A5024405133", "display_name": "Sana Gupta" }, { "id": "https://openalex.org/A5044717022", "display_name": "Ya Gao" }, { "id": "https://openalex.org/A5060968792", "display_name": "Jo\u00e3o Pedro Lima" }, { "id": "https://openalex.org/A5021636747", "display_name": "Kenji Numata" }, { "id": "https://openalex.org/A5101679769", "display_name": "Zhi Qiao" }, { "id": "https://openalex.org/A5036040772", "display_name": "Qinlin Fan" }, { "id": "https://openalex.org/A5056284145", "display_name": "Qinbo Yang" }, { "id": "https://openalex.org/A5109498000", "display_name": "Yinghui Jin" }, { "id": "https://openalex.org/A5109378556", "display_name": "Long Ge" }, { "id": "https://openalex.org/A5032897384", "display_name": "Qiuyu Yang" }, { "id": "https://openalex.org/A5004309272", "display_name": "Hongfei Zhu" }, { "id": "https://openalex.org/A5101956701", "display_name": "Fan Yang" }, { "id": "https://openalex.org/A5100457749", "display_name": "Zhe Chen" }, { "id": "https://openalex.org/A5112202066", "display_name": "Xi L\u00fc" }, { "id": "https://openalex.org/A5104179639", "display_name": "Siyu He" }, { "id": "https://openalex.org/A5101763855", "display_name": "Xiangyang Chen" }, { "id": "https://openalex.org/A5056267812", "display_name": "Xiafei Lyu" }, { "id": "https://openalex.org/A5063763726", "display_name": "Xingxing An" }, { "id": "https://openalex.org/A5043818935", "display_name": "Yaolong Chen" }, { "id": "https://openalex.org/A5100602713", "display_name": "Qiukui Hao" }, { "id": "https://openalex.org/A5090174827", "display_name": "Eberhard Standl" }, { "id": "https://openalex.org/A5072226388", "display_name": "Reed Siemieniuk" }, { "id": "https://openalex.org/A5010837310", "display_name": "Thomas Agoritsas" }, { "id": "https://openalex.org/A5085639572", "display_name": "Haoming Tian" }, { "id": "https://openalex.org/A5091607881", "display_name": "Sheyu Li" } ] }, { "id": "https://openalex.org/W4403912607", "doi": "https://doi.org/10.1056/nejmoa2403664", "title": "Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis", "abstract": { "Among": [ 0 ], "participants": [ 1 ], "with": [ 2, 7, 11 ], "obesity": [ 3 ], "and": [ 4, 23 ], "knee": [ 5, 27 ], "osteoarthritis": [ 6, 28 ], "moderate-to-severe": [ 8 ], "pain,": [ 9 ], "treatment": [ 10 ], "once-weekly": [ 12 ], "injectable": [ 13 ], "semaglutide": [ 14 ], "resulted": [ 15 ], "in": [ 16, 20 ], "significantly": [ 17 ], "greater": [ 18 ], "reductions": [ 19 ], "body": [ 21 ], "weight": [ 22 ], "pain": [ 24 ], "related": [ 25 ], "to": [ 26 ], "than": [ 29 ], "placebo.": [ 30 ], "(Funded": [ 31 ], "by": [ 32 ], "Novo": [ 33 ], "Nordisk;": [ 34 ], "STEP": [ 35 ], "9": [ 36 ], "ClinicalTrials.gov": [ 37 ], "number,": [ 38 ], "NCT05064735.).": [ 39 ] }, "publication_date": "2024-10-30", "publication_year": 2024, "type": "article", "cited_by_count": 193, "authors": [ { "id": "https://openalex.org/A5015244702", "display_name": "Henning Bliddal" }, { "id": "https://openalex.org/A5053191013", "display_name": "Harold Bays" }, { "id": "https://openalex.org/A5012626312", "display_name": "S\u00e9bastien Czernichow" }, { "id": "https://openalex.org/A5086573291", "display_name": "Joanna Udd\u00e9n" }, { "id": "https://openalex.org/A5079047032", "display_name": "J\u00f8ran Hjelmes\u00e6th" }, { "id": "https://openalex.org/A5034995274", "display_name": "Thomas Morville" }, { "id": "https://openalex.org/A5072583224", "display_name": "Anna Koroleva" }, { "id": "https://openalex.org/A5102967092", "display_name": "Jesper Skov Neergaard" }, { "id": "https://openalex.org/A5049433095", "display_name": "Purificaci\u00f3n S\u00e1nchez-S\u00e1nchez" }, { "id": "https://openalex.org/A5027441223", "display_name": "Sean Wharton" }, { "id": "https://openalex.org/A5065915042", "display_name": "Alicja Wizert" }, { "id": "https://openalex.org/A5023940584", "display_name": "Lars Erik Kristensen" } ] }, { "id": "https://openalex.org/W4402066452", "doi": "https://doi.org/10.1161/circulationaha.124.071689", "title": "Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis", "abstract": { "BACKGROUND:": [ 0 ], "GLP-1": [ 1, 36, 67, 205, 354 ], "(glucagon-like": [ 2 ], "peptide-1)": [ 3 ], "receptor": [ 4, 37, 68, 206, 355 ], "agonists": [ 5, 38, 69, 207, 356 ], "and": [ 6, 15, 29, 43, 51, 119, 145, 163, 231, 243, 272, 292, 318, 324, 338, 350 ], "SGLT2": [ 7, 45, 82, 96, 201, 234, 264, 312, 332, 361 ], "(sodium-glucose": [ 8 ], "cotransporter": [ 9 ], "2)": [ 10 ], "inhibitors": [ 11, 235 ], "both": [ 12 ], "improve": [ 13 ], "cardiovascular": [ 14, 105, 110, 117, 214, 349 ], "kidney": [ 16, 137, 143, 284, 351 ], "outcomes": [ 17, 41, 106, 125 ], "in": [ 18, 70, 132, 150, 228 ], "people": [ 19, 343 ], "with": [ 20, 42, 84, 188, 195, 225, 344 ], "type": [ 21, 71, 196, 345 ], "2": [ 22, 72, 197, 301, 346 ], "diabetes.": [ 23 ], "We": [ 24, 48, 90, 184 ], "conducted": [ 25 ], "a": [ 26, 127 ], "systematic": [ 27 ], "review": [ 28 ], "meta-analysis": [ 30, 170 ], "to": [ 31, 311 ], "assess": [ 32 ], "the": [ 33, 174, 209, 282, 348 ], "effects": [ 34, 77, 93, 227, 323 ], "of": [ 35, 66, 81, 129, 148, 178, 190, 211, 263, 331, 353, 360 ], "on": [ 39, 173, 254, 281 ], "clinical": [ 40 ], "without": [ 44 ], "inhibitors.": [ 46 ], "METHODS:": [ 47 ], "searched": [ 49 ], "MEDLINE": [ 50 ], "Embase": [ 52 ], "databases": [ 53 ], "from": [ 54 ], "inception": [ 55 ], "until": [ 56 ], "July": [ 57 ], "12,": [ 58 ], "2024,": [ 59 ], "for": [ 60, 121, 256 ], "randomized,": [ 61 ], "double-blind,": [ 62 ], "placebo-controlled": [ 63 ], "outcome": [ 64, 285 ], "trials": [ 65, 187 ], "diabetes": [ 73, 198 ], "that": [ 74 ], "reported": [ 75 ], "treatment": [ 76, 92 ], "by": [ 78, 87, 94, 142, 216 ], "baseline": [ 79, 95, 237 ], "use": [ 80, 98, 266, 314, 334 ], "inhibitors,": [ 83 ], "findings": [ 85 ], "supplemented": [ 86 ], "unpublished": [ 88 ], "data.": [ 89 ], "estimated": [ 91, 133, 151, 293 ], "inhibitor": [ 97, 202, 265, 313, 333, 362 ], "using": [ 99 ], "inverse": [ 100 ], "variance-weighted": [ 101 ], "meta-analysis.": [ 102 ], "The": [ 103, 252 ], "main": [ 104 ], "were": [ 107, 166, 327 ], "major": [ 108, 212 ], "adverse": [ 109, 161, 213, 322 ], "events": [ 111, 162, 215 ], "(nonfatal": [ 112 ], "myocardial": [ 113 ], "infarction,": [ 114 ], "stroke,": [ 115 ], "or": [ 116, 139 ], "death)": [ 118 ], "hospitalization": [ 120, 255 ], "heart": [ 122, 257 ], "failure.": [ 123 ], "Kidney": [ 124 ], "included": [ 126 ], "composite": [ 128, 283 ], "\u226550%": [ 130 ], "reduction": [ 131 ], "glomerular": [ 134, 152, 156, 294 ], "filtration": [ 135, 153, 157, 295 ], "rate,": [ 136 ], "failure": [ 138, 258 ], "death": [ 140 ], "caused": [ 141 ], "failure,": [ 144 ], "annualized": [ 146 ], "rate": [ 147, 154, 158, 296 ], "decline": [ 149 ], "(estimated": [ 155 ], "slope).": [ 159 ], "Serious": [ 160, 321 ], "severe": [ 164, 325 ], "hypoglycemia": [ 165, 326 ], "also": [ 167, 306, 328 ], "evaluated.": [ 168 ], "This": [ 169 ], "was": [ 171, 259 ], "registered": [ 172 ], "International": [ 175 ], "Prospective": [ 176 ], "Register": [ 177 ], "Systematic": [ 179 ], "Reviews": [ 180 ], "(PROSPERO;": [ 181 ], "CRD42024565765).": [ 182 ], "RESULTS:": [ 183 ], "identified": [ 185 ], "3": [ 186 ], "1743": [ 189 ], "17": [ 191 ], "072": [ 192 ], "(10.2%)": [ 193 ], "participants": [ 194 ], "receiving": [ 199, 230, 233 ], "an": [ 200 ], "at": [ 203, 236 ], "baseline.": [ 204 ], "reduced": [ 208 ], "risk": [ 210 ], "21%": [ 217 ], "(hazard": [ 218 ], "ratio": [ 219 ], "[HR],": [ 220 ], "0.79": [ 221, 245, 288 ], "[95%": [ 222, 240, 246, 269, 275, 289, 303 ], "CI,": [ 223, 241, 247, 270, 276, 290, 304 ], "0.71\u20130.87]),": [ 224 ], "consistent": [ 226, 261, 358 ], "those": [ 229 ], "not": [ 232, 308 ], "(HR,": [ 238, 267 ], "0.77": [ 239 ], "0.54\u20131.09]": [ 242 ], "HR,": [ 244, 273 ], "0.71\u20130.87],": [ 248 ], "respectively;": [ 249 ], "P": [ 250, 278, 316, 336 ], "-heterogeneity=0.78).": [ 251 ], "effect": [ 253 ], "similarly": [ 260 ], "regardless": [ 262, 330, 359 ], "0.58": [ 268 ], "0.36\u20130.93]": [ 271 ], "0.73": [ 274 ], "0.63\u20130.85];": [ 277 ], "-heterogeneity=0.26).": [ 279 ], "Effects": [ 280 ], "(risk": [ 286 ], "ratio,": [ 287 ], "0.66\u20130.95])": [ 291 ], "slope": [ 297 ], "(0.78": [ 298 ], "mL/min/1.73": [ 299 ], "m": [ 300 ], "/y": [ 302 ], "0.57\u20130.98])": [ 305 ], "did": [ 307 ], "vary": [ 309 ], "according": [ 310 ], "(": [ 315, 335 ], "-heterogeneity=0.53": [ 317 ], "0.94,": [ 319 ], "respectively).": [ 320, 340 ], "similar": [ 329 ], "-heterogeneity=0.29": [ 337 ], "0.50,": [ 339 ], "CONCLUSIONS:": [ 341 ], "In": [ 342 ], "diabetes,": [ 347 ], "benefits": [ 352 ], "are": [ 357 ], "use.": [ 363 ] }, "publication_date": "2024-08-30", "publication_year": 2024, "type": "review", "cited_by_count": 66, "authors": [ { "id": "https://openalex.org/A5015488634", "display_name": "Brendon L. Neuen" }, { "id": "https://openalex.org/A5017801776", "display_name": "Robert A. Fletcher" }, { "id": "https://openalex.org/A5001365729", "display_name": "Lauren Heath" }, { "id": "https://openalex.org/A5055901858", "display_name": "Adam Perkovic" }, { "id": "https://openalex.org/A5061881316", "display_name": "Muthiah Vaduganathan" }, { "id": "https://openalex.org/A5075474387", "display_name": "Sunil V. Badve" }, { "id": "https://openalex.org/A5046793050", "display_name": "Katherine R. Tuttle" }, { "id": "https://openalex.org/A5059098934", "display_name": "Richard E. Pratley" }, { "id": "https://openalex.org/A5024577116", "display_name": "Hertzel C. Gerstein" }, { "id": "https://openalex.org/A5027520502", "display_name": "Vlado Perkovic" }, { "id": "https://openalex.org/A5031624913", "display_name": "Hiddo J.L. Heerspink" } ] }, { "id": "https://openalex.org/W4285589154", "doi": "https://doi.org/10.1007/s11154-022-09735-8", "title": "A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes", "abstract": null, "publication_date": "2022-07-15", "publication_year": 2022, "type": "review", "cited_by_count": 71, "authors": [ { "id": "https://openalex.org/A5005405894", "display_name": "Vanita R. Aroda" }, { "id": "https://openalex.org/A5070289715", "display_name": "Lawrence Blonde" }, { "id": "https://openalex.org/A5059098934", "display_name": "Richard E. Pratley" } ] }, { "id": "https://openalex.org/W2903342525", "doi": "https://doi.org/10.1080/14656566.2018.1552258", "title": "Oral semaglutide for the treatment of type 2 diabetes", "abstract": { "Glucagon-like": [ 0 ], "peptide-1": [ 1 ], "(GLP-1)": [ 2 ], "receptor": [ 3, 43 ], "agonists": [ 4 ], "are": [ 5, 57 ], "highly": [ 6 ], "potent": [ 7 ], "antihyperglycemic": [ 8 ], "drugs": [ 9, 144 ], "that": [ 10, 145 ], "impose": [ 11 ], "low": [ 12 ], "risk": [ 13 ], "of": [ 14, 27, 54, 74, 81, 109, 118, 138, 141, 169 ], "hypoglycemia": [ 15 ], "and": [ 16, 51, 59, 92, 99, 104, 107, 128, 157, 167 ], "also": [ 17 ], "result": [ 18 ], "in": [ 19, 45, 88, 95, 113, 126, 172 ], "body": [ 20, 93 ], "weight": [ 21, 94 ], "reduction.": [ 22 ], "Currently,": [ 23 ], "all": [ 24 ], "approved": [ 25 ], "members": [ 26, 117 ], "the": [ 28, 55, 72, 119, 136, 165 ], "class": [ 29 ], "require": [ 30 ], "administration": [ 31 ], "by": [ 32 ], "injection.": [ 33 ], "Areas": [ 34 ], "covered:": [ 35 ], "This": [ 36 ], "manuscript": [ 37 ], "reviews": [ 38 ], "oral": [ 39, 83, 110, 143, 151, 170 ], "semaglutide-an": [ 40 ], "experimental": [ 41 ], "GLP-1": [ 42 ], "agonist": [ 44 ], "phase-3": [ 46 ], "clinical": [ 47, 52, 78 ], "development.": [ 48 ], "Available": [ 49 ], "pharmacological": [ 50 ], "data": [ 53 ], "drug": [ 56 ], "reviewed,": [ 58 ], "important": [ 60 ], "end-points": [ 61 ], "described.": [ 62 ], "Expert": [ 63 ], "opinion:": [ 64 ], "Oral": [ 65 ], "peptide": [ 66 ], "delivery": [ 67 ], "has": [ 68, 85 ], "become": [ 69 ], "possible": [ 70 ], "with": [ 71, 97, 115 ], "discovery": [ 73 ], "absorption": [ 75, 130 ], "enhancers.": [ 76 ], "The": [ 77 ], "development": [ 79 ], "program": [ 80 ], "once-daily": [ 82 ], "semaglutide": [ 84, 111, 171 ], "shown": [ 86 ], "superiority": [ 87 ], "reducing": [ 89 ], "glycosylated": [ 90 ], "hemoglobin": [ 91 ], "comparison": [ 96 ], "placebo": [ 98 ], "active": [ 100 ], "comparators": [ 101 ], "(sitagliptin,": [ 102 ], "liraglutide,": [ 103 ], "empagliflozin).": [ 105 ], "Safety": [ 106 ], "tolerability": [ 108 ], "is": [ 112 ], "line": [ 114 ], "injectable": [ 116 ], "class.": [ 120 ], "Delayed": [ 121 ], "gastric": [ 122 ], "emptying,": [ 123 ], "local": [ 124 ], "increase": [ 125 ], "pH,": [ 127 ], "enhanced": [ 129 ], "do": [ 131 ], "not": [ 132 ], "seem": [ 133 ], "to": [ 134 ], "affect": [ 135 ], "exposure": [ 137 ], "a": [ 139 ], "number": [ 140 ], "other": [ 142 ], "have": [ 146 ], "been": [ 147 ], "tested": [ 148 ], "(metformin,": [ 149 ], "digoxin,": [ 150 ], "contraceptive": [ 152 ], "ethinylestradiol/levonorgestrel,": [ 153 ], "lisinopril,": [ 154 ], "warfarin,": [ 155 ], "furosemide": [ 156 ], "rosuvastatin).": [ 158 ], "Clinical": [ 159 ], "questions": [ 160 ], "for": [ 161 ], "further": [ 162 ], "investigation": [ 163 ], "include": [ 164 ], "effectiveness": [ 166 ], "safety": [ 168 ], "cardiovascular": [ 173 ], "indications.": [ 174 ] }, "publication_date": "2018-11-30", "publication_year": 2018, "type": "review", "cited_by_count": 39, "authors": [ { "id": "https://openalex.org/A5030521441", "display_name": "Maka S. Hedrington" }, { "id": "https://openalex.org/A5080379883", "display_name": "Stephen N. Davis" } ] }, { "id": "https://openalex.org/W2054088567", "doi": "https://doi.org/10.1002/jcph.443", "title": "Semaglutide, a once\u2010weekly human GLP\u20101 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel", "abstract": { "Abstract": [ 0 ], "The": [ 1, 102 ], "effect": [ 2 ], "of": [ 3, 22, 78, 88, 210, 232 ], "semaglutide,": [ 4 ], "a": [ 5, 23 ], "once\u2010weekly": [ 6, 169 ], "human": [ 7 ], "glucagon\u2010like": [ 8 ], "peptide\u20101": [ 9 ], "(GLP\u20101)": [ 10 ], "analog": [ 11 ], "in": [ 12, 150, 188, 192 ], "development": [ 13 ], "for": [ 14, 48, 85, 107, 117, 128, 143 ], "type": [ 15 ], "2": [ 16 ], "diabetes": [ 17 ], "(T2D),": [ 18 ], "on": [ 19, 36 ], "the": [ 20, 86, 111, 171, 207, 230 ], "bioavailability": [ 21, 231 ], "combined": [ 24 ], "oral": [ 25, 79 ], "contraceptive": [ 26, 214 ], "was": [ 27, 81, 97, 105, 125, 139 ], "investigated.": [ 28 ], "Postmenopausal": [ 29 ], "women": [ 30 ], "with": [ 31, 168 ], "T2D": [ 32 ], "(n": [ 33 ], "=": [ 34 ], "43)": [ 35 ], "diet/exercise": [ 37 ], "\u00b1": [ 38, 148, 154, 159 ], "metformin": [ 39 ], "received": [ 40 ], "ethinylestradiol": [ 41, 108, 233 ], "(0.03": [ 42 ], "mg)/levonorgestrel": [ 43 ], "(0.15": [ 44 ], "mg)": [ 45, 57 ], "once": [ 46, 61 ], "daily": [ 47 ], "8": [ 49 ], "days": [ 50 ], "before": [ 51 ], "(semaglutide\u2010free)": [ 52 ], "and": [ 53, 94, 156, 174, 195, 234 ], "during": [ 54, 91, 212, 224 ], "(steady\u2010state": [ 55 ], "1.0": [ 56, 73 ], "semaglutide": [ 58, 92, 118, 131, 172 ], "treatment": [ 59 ], "(subcutaneous": [ 60 ], "weekly;": [ 62 ], "dose": [ 63, 173 ], "escalation:": [ 64 ], "0.25": [ 65 ], "mg": [ 66, 70, 74 ], "4": [ 67, 71 ], "weeks;": [ 68, 72 ], "0.5": [ 69 ], "5": [ 75 ], "weeks).": [ 76 ], "Bioequivalence": [ 77 ], "contraceptives": [ 80 ], "established": [ 82 ], "if": [ 83 ], "90%CI": [ 84 ], "ratio": [ 87 ], "pharmacokinetic": [ 89 ], "parameters": [ 90 ], "steady\u2010state": [ 93, 132 ], "semaglutide\u2010free": [ 95, 134 ], "periods": [ 96 ], "within": [ 98, 140 ], "prespecified": [ 99 ], "limits": [ 100 ], "(0.80\u20131.25).": [ 101 ], "bioequivalence": [ 103, 141 ], "criterion": [ 104, 142 ], "met": [ 106 ], "area": [ 109 ], "under": [ 110 ], "curve": [ 112 ], "(AUC": [ 113 ], "0\u201324": [ 114, 123 ], "h": [ 115, 124 ], ")": [ 116 ], "steady\u2010state/semaglutide\u2010free;": [ 119 ], "1.11": [ 120 ], "(1.06\u20131.15).": [ 121 ], "AUC": [ 122 ], "20%": [ 126 ], "higher": [ 127 ], "levonorgestrel": [ 129 ], "at": [ 130 ], "vs.": [ 133 ], "(1.20": [ 135 ], "[1.15\u20131.26]).": [ 136 ], "C": [ 137 ], "max": [ 138 ], "both": [ 144 ], "contraceptives.": [ 145 ], "Reductions": [ 146 ], "(mean": [ 147 ], "SD)": [ 149 ], "HbA": [ 151 ], "1c": [ 152 ], "(\u20131.1": [ 153 ], "0.6%)": [ 155 ], "weight": [ 157 ], "(\u20134.3": [ 158 ], "3.1": [ 160 ], "kg)": [ 161 ], "were": [ 162, 166, 177, 184, 197, 217 ], "observed.": [ 163, 198 ], "Semaglutide": [ 164, 226 ], "pharmacokinetics": [ 165 ], "compatible": [ 167 ], "dosing;": [ 170 ], "dose\u2010escalation": [ 175 ], "regimen": [ 176 ], "well": [ 178 ], "tolerated.": [ 179 ], "Adverse": [ 180 ], "events,": [ 181, 221 ], "mainly": [ 182 ], "gastrointestinal,": [ 183 ], "mild": [ 185 ], "to": [ 186 ], "moderate": [ 187 ], "severity.": [ 189 ], "Asymptomatic": [ 190 ], "increases": [ 191 ], "mean": [ 193 ], "amylase": [ 194 ], "lipase": [ 196 ], "Three": [ 199 ], "subjects": [ 200 ], "had": [ 201 ], "elevated": [ 202 ], "alanine": [ 203 ], "aminotransferase": [ 204 ], "levels": [ 205 ], "\u22653x": [ 206 ], "upper": [ 208 ], "limit": [ 209 ], "normal": [ 211 ], "semaglutide/oral": [ 213 ], "coadministration,": [ 215 ], "which": [ 216 ], "reported": [ 218 ], "as": [ 219 ], "adverse": [ 220 ], "but": [ 222 ], "resolved": [ 223 ], "follow\u2010up.": [ 225 ], "did": [ 227 ], "not": [ 228 ], "reduce": [ 229 ], "levonorgestrel.": [ 235 ] }, "publication_date": "2014-12-09", "publication_year": 2014, "type": "article", "cited_by_count": 151, "authors": [ { "id": "https://openalex.org/A5068619321", "display_name": "Christoph Kapitza" }, { "id": "https://openalex.org/A5054068635", "display_name": "Leszek Nosek" }, { "id": "https://openalex.org/A5019447119", "display_name": "Lene Jensen" }, { "id": "https://openalex.org/A5017679173", "display_name": "Helle B\u00f8ggild Hartvig" }, { "id": "https://openalex.org/A5111479294", "display_name": "Christine B. Jensen" }, { "id": "https://openalex.org/A5019076349", "display_name": "Anne Flint" } ] }, { "id": "https://openalex.org/W2125563242", "doi": "https://doi.org/10.1016/j.diabet.2011.11.004", "title": "Improvement of psoriasis during exenatide treatment in a patient with diabetes", "abstract": null, "publication_date": "2012-01-09", "publication_year": 2012, "type": "article", "cited_by_count": 48, "authors": [ { "id": "https://openalex.org/A5030821450", "display_name": "Martin Buysschaert" }, { "id": "https://openalex.org/A5053175997", "display_name": "Dominique Tennstedt" }, { "id": "https://openalex.org/A5070435011", "display_name": "Vanessa Preumont" } ] }, { "id": "https://openalex.org/W2087787276", "doi": "https://doi.org/10.1016/j.neuropharm.2014.07.015", "title": "Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease", "abstract": null, "publication_date": "2014-08-08", "publication_year": 2014, "type": "article", "cited_by_count": 162, "authors": [ { "id": "https://openalex.org/A5004424324", "display_name": "Paula L. McClean" }, { "id": "https://openalex.org/A5082707086", "display_name": "Christian H\u00f6lscher" } ] }, { "id": "https://openalex.org/W2793413710", "doi": "https://doi.org/10.1002/path.5056", "title": "The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non\u2010human primate model of Alzheimer's disease", "abstract": { "Abstract": [ 0 ], "Alzheimer's": [ 1 ], "disease": [ 2 ], "(AD)": [ 3 ], "is": [ 4, 63 ], "a": [ 5, 43 ], "devastating": [ 6 ], "neurological": [ 7 ], "disorder": [ 8 ], "that": [ 9, 70, 82, 111, 203 ], "still": [ 10 ], "lacks": [ 11 ], "an": [ 12, 19, 64 ], "effective": [ 13 ], "treatment,": [ 14 ], "and": [ 15, 32, 91, 93, 144, 166, 175, 184, 201, 215, 242 ], "this": [ 16 ], "has": [ 17 ], "stimulated": [ 18 ], "intense": [ 20 ], "pursuit": [ 21 ], "of": [ 22, 41, 51, 58, 67, 75, 87, 114, 120, 126, 133, 141, 154, 188, 197, 225, 236, 239 ], "disease\u2010modifying": [ 23 ], "therapeutics.": [ 24 ], "Given": [ 25 ], "the": [ 26, 39, 72, 85, 112, 121, 129, 179, 185 ], "increasingly": [ 27 ], "recognized": [ 28 ], "link": [ 29 ], "between": [ 30 ], "AD": [ 31, 68 ], "defective": [ 33 ], "brain": [ 34, 88, 147, 171, 212 ], "insulin": [ 35, 77, 89, 142, 163, 213 ], "signaling,": [ 36 ], "we": [ 37, 80, 109 ], "investigated": [ 38 ], "actions": [ 40, 74 ], "liraglutide,": [ 42, 200 ], "glucagon\u2010like": [ 44 ], "peptide\u20101": [ 45 ], "(GLP\u20101)": [ 46 ], "analog": [ 47 ], "marketed": [ 48 ], "for": [ 49 ], "treatment": [ 50, 153 ], "type": [ 52 ], "2": [ 53 ], "diabetes,": [ 54 ], "in": [ 55, 103, 146, 169, 191, 217 ], "experimental": [ 56 ], "models": [ 57 ], "AD.": [ 59, 192, 218 ], "Insulin": [ 60 ], "receptor": [ 61, 205 ], "pathology": [ 62, 168 ], "important": [ 65 ], "feature": [ 66 ], "brains": [ 69 ], "impairs": [ 71 ], "neuroprotective": [ 73 ], "central": [ 76 ], "signaling.": [ 78 ], "Here,": [ 79 ], "show": [ 81 ], "liraglutide": [ 83, 117, 157 ], "prevented": [ 84 ], "loss": [ 86, 140 ], "receptors": [ 90, 143, 214 ], "synapses,": [ 92 ], "reversed": [ 94 ], "memory": [ 95, 189 ], "impairment": [ 96, 190 ], "induced": [ 97 ], "by": [ 98, 116, 199, 228 ], "AD\u2010linked": [ 99 ], "amyloid\u2010\u03b2": [ 100 ], "oligomers": [ 101 ], "(A\u03b2Os)": [ 102 ], "mice.": [ 104 ], "Using": [ 105 ], "hippocampal": [ 106 ], "neuronal": [ 107 ], "cultures,": [ 108 ], "determined": [ 110 ], "mechanism": [ 113 ], "neuroprotection": [ 115, 198 ], "involves": [ 118 ], "activation": [ 119, 206 ], "PKA": [ 122 ], "signaling": [ 123 ], "pathway.": [ 124 ], "Infusion": [ 125 ], "A\u03b2Os": [ 127 ], "into": [ 128 ], "lateral": [ 130 ], "cerebral": [ 131 ], "ventricle": [ 132 ], "non\u2010human": [ 134 ], "primates": [ 135 ], "(NHPs)": [ 136 ], "led": [ 137 ], "to": [ 138, 150, 210 ], "marked": [ 139 ], "synapses": [ 145, 216 ], "regions": [ 148 ], "related": [ 149 ], "memory.": [ 151 ], "Systemic": [ 152 ], "NHPs": [ 155 ], "with": [ 156 ], "provided": [ 158 ], "partial": [ 159 ], "protection,": [ 160 ], "decreasing": [ 161 ], "AD\u2010related": [ 162 ], "receptor,": [ 164 ], "synaptic,": [ 165 ], "tau": [ 167 ], "specific": [ 170 ], "regions.": [ 172 ], "Synapse": [ 173 ], "damage": [ 174 ], "elimination": [ 176 ], "are": [ 177 ], "amongst": [ 178 ], "earliest": [ 180 ], "known": [ 181 ], "pathological": [ 182 ], "changes": [ 183 ], "best": [ 186 ], "correlates": [ 187 ], "The": [ 193, 221, 223 ], "results": [ 194 ], "illuminate": [ 195 ], "mechanisms": [ 196 ], "indicate": [ 202 ], "GLP\u20101": [ 204 ], "may": [ 207 ], "be": [ 208 ], "harnessed": [ 209 ], "protect": [ 211 ], "\u00a9": [ 219 ], "2018": [ 220 ], "Authors.": [ 222 ], "Journal": [ 224 ], "Pathology": [ 226 ], "published": [ 227 ], "John": [ 229 ], "Wiley": [ 230 ], "&": [ 231 ], "Sons": [ 232 ], "Ltd": [ 233 ], "on": [ 234 ], "behalf": [ 235 ], "Pathological": [ 237 ], "Society": [ 238 ], "Great": [ 240 ], "Britain": [ 241 ], "Ireland.": [ 243 ] }, "publication_date": "2018-02-12", "publication_year": 2018, "type": "article", "cited_by_count": 227, "authors": [ { "id": "https://openalex.org/A5072794782", "display_name": "Andr\u00e9 F. Batista" }, { "id": "https://openalex.org/A5014150791", "display_name": "Let\u00edcia Forny\u2010Germano" }, { "id": "https://openalex.org/A5002641462", "display_name": "Julia R. Clarke" }, { "id": "https://openalex.org/A5059730132", "display_name": "Natalia M. Lyra e Silva" }, { "id": "https://openalex.org/A5042868082", "display_name": "Jordano Brito\u2010Moreira" }, { "id": "https://openalex.org/A5086470213", "display_name": "Susan E. Boehnke" }, { "id": "https://openalex.org/A5022782313", "display_name": "Andrew Winterborn" }, { "id": "https://openalex.org/A5067317854", "display_name": "Brian C. Coe" }, { "id": "https://openalex.org/A5085248060", "display_name": "Ann Lablans" }, { "id": "https://openalex.org/A5039644033", "display_name": "Juliana F.S. Vital" }, { "id": "https://openalex.org/A5063458381", "display_name": "Suelen Adriani Marques" }, { "id": "https://openalex.org/A5112354306", "display_name": "Ana MB Martinez" }, { "id": "https://openalex.org/A5077533094", "display_name": "Matthias Gralle" }, { "id": "https://openalex.org/A5082707086", "display_name": "Christian H\u00f6lscher" }, { "id": "https://openalex.org/A5054687151", "display_name": "William L. Klein" }, { "id": "https://openalex.org/A5090026310", "display_name": "Jean\u2010Christophe Houzel" }, { "id": "https://openalex.org/A5070851422", "display_name": "S\u00e9rgio T. Ferreira" }, { "id": "https://openalex.org/A5060071876", "display_name": "Douglas P. Munoz" }, { "id": "https://openalex.org/A5032823810", "display_name": "Fernanda G. De Felice" } ] }, { "id": "https://openalex.org/W2093375074", "doi": "https://doi.org/10.1507/endocrj.ej14-0147", "title": "Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study", "abstract": { "The": [ 0, 76, 205 ], "aim": [ 1 ], "of": [ 2, 11, 54, 219, 223 ], "this": [ 3, 40 ], "study": [ 4, 189 ], "was": [ 5, 79, 155 ], "to": [ 6, 179, 188 ], "evaluate": [ 7 ], "the": [ 8, 169 ], "dose-dependent": [ 9, 103, 207 ], "effect": [ 10 ], "dulaglutide,": [ 12 ], "a": [ 13, 96 ], "glucagon-like": [ 14 ], "peptide-1": [ 15 ], "receptor": [ 16 ], "agonist,": [ 17 ], "on": [ 18 ], "glycaemic": [ 19 ], "control": [ 20 ], "in": [ 21, 83, 105, 134, 164, 209, 228 ], "Japanese": [ 22 ], "patients": [ 23, 47, 176, 193 ], "with": [ 24, 32, 149, 167 ], "type": [ 25, 224 ], "2": [ 26, 225 ], "diabetes": [ 27, 226 ], "mellitus": [ 28, 227 ], "who": [ 29 ], "were": [ 30, 93, 107, 146, 161 ], "treated": [ 31 ], "diet/exercise": [ 33 ], "or": [ 34, 57, 68 ], "oral": [ 35 ], "antidiabetic": [ 36 ], "drug": [ 37 ], "monotherapy.": [ 38 ], "In": [ 39 ], "randomised,": [ 41 ], "double-blind,": [ 42 ], "placebo-controlled,": [ 43 ], "parallel-group,": [ 44 ], "12-week": [ 45 ], "study,": [ 46 ], "received": [ 48 ], "once": [ 49 ], "weekly": [ 50 ], "subcutaneous": [ 51 ], "dulaglutide": [ 52, 150, 220 ], "doses": [ 53 ], "0.25,": [ 55, 61 ], "0.5,": [ 56, 63 ], "0.75": [ 58 ], "mg": [ 59 ], "(DU": [ 60, 194 ], "DU": [ 62, 65, 118, 122, 127, 197 ], "and": [ 64, 73, 126, 140, 183, 196, 211 ], "0.75,": [ 66 ], "respectively)": [ 67 ], "placebo": [ 69, 114, 152 ], "(n=36,": [ 70 ], "37,": [ 71, 74 ], "35,": [ 72 ], "respectively).": [ 75 ], "primary": [ 77 ], "measure": [ 78 ], "change": [ 80 ], "from": [ 81 ], "baseline": [ 82 ], "glycated": [ 84 ], "haemoglobin": [ 85 ], "(HbA1c;": [ 86 ], "%)": [ 87 ], "at": [ 88 ], "12": [ 89 ], "weeks.": [ 90 ], "Continuous": [ 91 ], "variables": [ 92 ], "analysed": [ 94 ], "using": [ 95 ], "mixed-effects": [ 97 ], "model": [ 98 ], "for": [ 99, 221 ], "repeated": [ 100 ], "measures.": [ 101 ], "Significant": [ 102, 132 ], "reductions": [ 104 ], "HbA1c": [ 106, 210 ], "observed": [ 108, 148, 206 ], "(least": [ 109 ], "squares": [ 110 ], "mean": [ 111 ], "difference": [ 112 ], "versus": [ 113, 151 ], "[95%": [ 115 ], "confidence": [ 116 ], "interval]):": [ 117 ], "0.25=-0.72%": [ 119 ], "(-0.95,": [ 120 ], "-0.48),": [ 121 ], "0.5=-0.97%": [ 123 ], "(-1.20,": [ 124 ], "-0.73),": [ 125 ], "0.75=-1.17%": [ 128 ], "(-1.41,": [ 129 ], "-0.93);": [ 130 ], "p<0.001.": [ 131 ], "improvements": [ 133 ], "plasma": [ 135 ], "glucose": [ 136 ], "(PG),": [ 137 ], "both": [ 138 ], "fasting": [ 139 ], "average": [ 141 ], "7-point": [ 142 ], "self-monitored": [ 143 ], "blood": [ 144 ], "glucose,": [ 145 ], "also": [ 147 ], "(p<0.001).": [ 153 ], "Dulaglutide": [ 154 ], "well-tolerated.": [ 156 ], "Gastrointestinal": [ 157 ], "adverse": [ 158 ], "events": [ 159 ], "(AEs)": [ 160 ], "more": [ 162 ], "common": [ 163 ], "dulaglutide-treated": [ 165, 175 ], "patients,": [ 166 ], "nausea": [ 168 ], "most": [ 170 ], "frequent": [ 171 ], "(8": [ 172 ], "[5.5%]).": [ 173 ], "Few": [ 174 ], "discontinued": [ 177 ], "due": [ 178 ], "AEs": [ 180, 186 ], "(4": [ 181 ], "[3.7%]),": [ 182 ], "no": [ 184 ], "serious": [ 185 ], "related": [ 187 ], "medication": [ 190 ], "occurred.": [ 191 ], "Three": [ 192 ], "0.5=1": [ 195 ], "0.75=2)": [ 198 ], "reported": [ 199 ], "asymptomatic": [ 200 ], "hypoglycaemia": [ 201 ], "(PG": [ 202 ], "\u226470": [ 203 ], "mg/dL).": [ 204 ], "reduction": [ 208 ], "acceptable": [ 212 ], "safety": [ 213 ], "profile": [ 214 ], "support": [ 215 ], "further": [ 216 ], "clinical": [ 217 ], "development": [ 218 ], "treatment": [ 222 ], "Japan.": [ 229 ] }, "publication_date": "2014-01-01", "publication_year": 2014, "type": "article", "cited_by_count": 49, "authors": [ { "id": "https://openalex.org/A5088387334", "display_name": "Yasuo Terauchi" }, { "id": "https://openalex.org/A5069840291", "display_name": "Yoichi Satoi" }, { "id": "https://openalex.org/A5018046892", "display_name": "Masakazu Takeuchi" }, { "id": "https://openalex.org/A5082595973", "display_name": "Takeshi Imaoka" } ] }, { "id": "https://openalex.org/W2061691264", "doi": "https://doi.org/10.1089/dia.2009.0141", "title": "Exenatide Versus Glibenclamide in Patients with Diabetes", "abstract": { "Both": [ 0 ], "exenatide": [ 1, 13 ], "and": [ 2, 19, 29 ], "glibenclamide": [ 3 ], "gave": [ 4, 14 ], "a": [ 5, 24 ], "similar": [ 6 ], "improvement": [ 7 ], "of": [ 8, 16, 26, 30 ], "glycemic": [ 9 ], "control,": [ 10 ], "but": [ 11 ], "only": [ 12 ], "improvements": [ 15 ], "insulin": [ 17 ], "resistance": [ 18 ], "beta-cell": [ 20 ], "function,": [ 21 ], "giving": [ 22 ], "also": [ 23 ], "decrease": [ 25 ], "body": [ 27 ], "weight": [ 28 ], "inflammatory": [ 31 ], "state.": [ 32 ] }, "publication_date": "2010-02-12", "publication_year": 2010, "type": "article", "cited_by_count": 122, "authors": [ { "id": "https://openalex.org/A5021841408", "display_name": "Giuseppe Derosa" }, { "id": "https://openalex.org/A5011551760", "display_name": "Pamela Maffioli" }, { "id": "https://openalex.org/A5113650018", "display_name": "Sibilla Salvadeo" }, { "id": "https://openalex.org/A5049126629", "display_name": "Ilaria Ferrari" }, { "id": "https://openalex.org/A5113523458", "display_name": "P. D. Ragonesi" }, { "id": "https://openalex.org/A5035687365", "display_name": "Fabrizio Querci" }, { "id": "https://openalex.org/A5018253704", "display_name": "Ivano Franzetti" }, { "id": "https://openalex.org/A5021449932", "display_name": "G. Gadaleta" }, { "id": "https://openalex.org/A5111714931", "display_name": "Leonardina Ciccarelli" }, { "id": "https://openalex.org/A5111617213", "display_name": "Mario N. Piccinni" }, { "id": "https://openalex.org/A5049217502", "display_name": "Angela D\u2019Angelo" }, { "id": "https://openalex.org/A5068440626", "display_name": "Arrigo F.G. Cicero" } ] }, { "id": "https://openalex.org/W2995024744", "doi": "https://doi.org/10.1007/s13300-019-00736-6", "title": "Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme", "abstract": null, "publication_date": "2019-12-12", "publication_year": 2019, "type": "article", "cited_by_count": 49, "authors": [ { "id": "https://openalex.org/A5080463002", "display_name": "Stephen C. Bain" }, { "id": "https://openalex.org/A5107600118", "display_name": "Brian Bekker Hansen" }, { "id": "https://openalex.org/A5029230724", "display_name": "Samuel J. P. Malkin" }, { "id": "https://openalex.org/A5001771184", "display_name": "Solomon Nuhoho" }, { "id": "https://openalex.org/A5037654589", "display_name": "William J. Valentine" }, { "id": "https://openalex.org/A5064518045", "display_name": "Barrie Chubb" }, { "id": "https://openalex.org/A5072605000", "display_name": "Barnaby Hunt" }, { "id": "https://openalex.org/A5073949429", "display_name": "Matthew Capehorn" } ] }, { "id": "https://openalex.org/W2094195067", "doi": "https://doi.org/10.1111/j.1463-1326.2011.01376.x", "title": "A cohort study of acute pancreatitis in relation to exenatide use", "abstract": { "Aim:": [ 0 ], "Reports": [ 1 ], "of": [ 2, 63, 72, 84, 89, 110, 139, 164, 219, 259 ], "acute": [ 3, 17, 85, 165, 260 ], "pancreatitis": [ 4, 18, 53, 86, 166 ], "associated": [ 5, 254 ], "with": [ 6, 56, 255 ], "exenatide": [ 7, 20, 41, 111, 140, 169, 188 ], "treatment": [ 8 ], "prompted": [ 9 ], "this": [ 10 ], "study": [ 11, 30 ], "to": [ 12, 23, 113, 179 ], "estimate": [ 13 ], "the": [ 14, 82, 168, 183, 240 ], "association": [ 15, 243 ], "between": [ 16, 46 ], "and": [ 19, 49, 59, 76, 102, 150, 171, 204, 227 ], "use": [ 21, 104, 203, 223, 231, 242, 251 ], "relative": [ 22, 112 ], "other": [ 24, 43, 114, 174, 180 ], "antihyperglycaemic": [ 25, 44, 115, 175, 181 ], "drugs.": [ 26 ], "Methods:": [ 27 ], "This": [ 28 ], "cohort": [ 29, 170 ], "included": [ 31 ], "patients": [ 32 ], "without": [ 33 ], "claims": [ 34, 147 ], "for": [ 35, 118, 130, 148, 187, 194, 201, 209, 221, 229 ], "prior": [ 36 ], "pancreatic": [ 37 ], "disease": [ 38 ], "who": [ 39 ], "initiated": [ 40 ], "or": [ 42 ], "drugs": [ 45, 153 ], "June": [ 47 ], "2005": [ 48 ], "December": [ 50 ], "2007.": [ 51 ], "Acute": [ 52 ], "was": [ 54, 189, 252 ], "identified": [ 55 ], "diagnosis": [ 57 ], "codes": [ 58 ], "confirmed": [ 60, 162 ], "through": [ 61 ], "review": [ 62 ], "blinded": [ 64 ], "medical": [ 65, 135 ], "records.": [ 66, 136 ], "Poisson": [ 67 ], "regression": [ 68 ], "models": [ 69 ], "provided": [ 70, 126 ], "estimates": [ 71, 128 ], "rate": [ 73, 83 ], "ratios": [ 74 ], "(RRs)": [ 75 ], "95%": [ 77, 246 ], "confidence": [ 78 ], "intervals": [ 79 ], "(CIs)": [ 80 ], "comparing": [ 81 ], "during": [ 87 ], "periods": [ 88 ], "current": [ 90, 108, 195, 222 ], "(days": [ 91 ], "supplied": [ 92 ], "+": [ 93, 99 ], "31": [ 94, 100 ], "days),": [ 95 ], "recent": [ 96, 202, 230 ], "(current": [ 97 ], "definition": [ 98 ], "days)": [ 101 ], "past": [ 103, 210, 241 ], "(\u226532": [ 105 ], "days": [ 106 ], "beyond": [ 107 ], "definition)": [ 109 ], "drugs,": [ 116, 182 ], "adjusted": [ 117, 129 ], "propensity": [ 119, 184 ], "scores.": [ 120 ], "A": [ 121 ], "prespecified": [ 122 ], "nested": [ 123 ], "case\u2013control": [ 124, 213 ], "analysis": [ 125, 214 ], "RR": [ 127, 186, 218, 238 ], "patient": [ 131 ], "characteristics": [ 132 ], "abstracted": [ 133 ], "from": [ 134 ], "Results:": [ 137 ], "Initiators": [ 138 ], "(N": [ 141, 156 ], "=": [ 142, 157 ], "25719)": [ 143 ], "had": [ 144 ], "more": [ 145 ], "baseline": [ 146 ], "obesity": [ 149 ], "concomitant": [ 151 ], "diabetes": [ 152 ], "than": [ 154 ], "comparators": [ 155 ], "234536).": [ 158 ], "There": [ 159 ], "were": [ 160 ], "40": [ 161 ], "cases": [ 163 ], "in": [ 167, 216, 239 ], "254": [ 172 ], "among": [ 173 ], "drug": [ 176 ], "initiators.": [ 177 ], "Compared": [ 178 ], "score\u2010adjusted": [ 185 ], "0.5": [ 190 ], "(95%": [ 191, 198, 206, 224, 232 ], "CI": [ 192, 199, 207, 225, 233, 247 ], "0.2\u20130.9)": [ 193 ], "use,": [ 196 ], "1.1": [ 197 ], "0.4\u20133.2)": [ 200 ], "2.8": [ 205 ], "1.6\u20134.7)": [ 208 ], "use.": [ 211 ], "The": [ 212 ], "resulted": [ 215 ], "a": [ 217 ], "0.2": [ 220 ], "0.0\u20131.4)": [ 226 ], "0.1": [ 228 ], "0.0\u20131.3),": [ 234 ], "but": [ 235 ], "an": [ 236, 256 ], "attenuated": [ 237 ], "(RR": [ 244 ], "1.1;": [ 245 ], "0.1\u201311.0).": [ 248 ], "Conclusions:": [ 249 ], "Exenatide": [ 250 ], "not": [ 253 ], "increased": [ 257 ], "risk": [ 258 ], "pancreatitis.": [ 261 ] }, "publication_date": "2011-02-14", "publication_year": 2011, "type": "article", "cited_by_count": 145, "authors": [ { "id": "https://openalex.org/A5055406653", "display_name": "David D. Dore" }, { "id": "https://openalex.org/A5085931384", "display_name": "Gary Bloomgren" }, { "id": "https://openalex.org/A5073093450", "display_name": "Mad\u00e9 Wenten" }, { "id": "https://openalex.org/A5059198864", "display_name": "Clorinda Hoffman" }, { "id": "https://openalex.org/A5076651983", "display_name": "C. Robin Clifford" }, { "id": "https://openalex.org/A5113843236", "display_name": "Shoana Quinn" }, { "id": "https://openalex.org/A5060099393", "display_name": "Daniel Braun" }, { "id": "https://openalex.org/A5059791517", "display_name": "Rebecca Noel" }, { "id": "https://openalex.org/A5002078534", "display_name": "John D. Seeger" } ] }, { "id": "https://openalex.org/W2896061464", "doi": "https://doi.org/10.1002/hep.30320", "title": "Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease", "abstract": { "To": [ 0 ], "investigate": [ 1 ], "the": [ 2, 52, 200, 216 ], "effect": [ 3 ], "of": [ 4 ], "antidiabetic": [ 5 ], "agents": [ 6 ], "on": [ 7 ], "nonalcoholic": [ 8 ], "fatty": [ 9 ], "liver": [ 10 ], "disease": [ 11 ], "(NAFLD)": [ 12 ], "in": [ 13, 44, 54, 78, 185, 199, 215, 225, 266, 272 ], "patients": [ 14, 22, 273 ], "with": [ 15, 23, 112, 193, 234, 250, 274 ], "type": [ 16 ], "2": [ 17 ], "diabetes": [ 18 ], "mellitus": [ 19 ], "(T2DM),": [ 20 ], "75": [ 21 ], "T2DM": [ 24, 275 ], "and": [ 25, 85, 92, 108, 147, 218, 228, 246, 254, 264, 276 ], "NAFLD": [ 26 ], "under": [ 27 ], "inadequate": [ 28 ], "glycemic": [ 29, 270 ], "control": [ 30, 271 ], "by": [ 31, 65 ], "metformin": [ 32 ], "were": [ 33, 231 ], "randomized": [ 34 ], "(1:1:1)": [ 35 ], "to": [ 36, 60, 97, 117, 127, 138, 152, 162, 173, 206, 268 ], "receive": [ 37 ], "add\u2010on": [ 38 ], "liraglutide,": [ 39 ], "sitagliptin,": [ 40, 255 ], "or": [ 41, 188 ], "insulin": [ 42, 194, 219, 237, 258 ], "glargine": [ 43, 220, 238 ], "this": [ 45 ], "26\u2010week": [ 46 ], "trial.": [ 47 ], "The": [ 48 ], "primary": [ 49 ], "endpoint": [ 50 ], "was": [ 51, 191 ], "change": [ 53, 184 ], "intrahepatic": [ 55 ], "lipid": [ 56 ], "(IHL)": [ 57 ], "from": [ 58, 95, 103, 223 ], "baseline": [ 59, 96, 224 ], "week": [ 61, 98 ], "26": [ 62 ], "as": [ 63 ], "quantified": [ 64 ], "magnetic": [ 66 ], "resonance": [ 67 ], "imaging\u2013estimated": [ 68 ], "proton": [ 69 ], "density": [ 70 ], "fat": [ 71 ], "fraction": [ 72 ], "(MRI\u2010PDFF).": [ 73 ], "Secondary": [ 74 ], "endpoints": [ 75 ], "included": [ 76 ], "changes": [ 77 ], "abdominal": [ 79 ], "adiposity": [ 80 ], "(subcutaneous": [ 81 ], "adipose": [ 82, 87 ], "tissue": [ 83, 88 ], "[SAT]": [ 84 ], "visceral": [ 86 ], "[VAT]),": [ 89 ], "glycated": [ 90 ], "hemoglobin,": [ 91 ], "body": [ 93, 189, 229, 261 ], "weight": [ 94, 109, 190, 230 ], "26.": [ 99 ], "We": [ 100 ], "analysed": [ 101 ], "data": [ 102 ], "intent\u2010to\u2010treat": [ 104 ], "population.": [ 105 ], "MRI\u2010PDFF,": [ 106, 186, 226 ], "VAT,": [ 107, 187, 227 ], "decreased": [ 110, 197 ], "significantly": [ 111, 198, 232, 243 ], "liraglutide": [ 113, 201, 235, 245, 253 ], "(15.4%": [ 114 ], "\u00b1": [ 115, 119, 125, 129, 135, 140, 150, 154, 160, 164, 170, 175, 204, 208 ], "5.6%": [ 116, 151 ], "12.5%": [ 118 ], "6.4%,": [ 120 ], "P": [ 121, 131, 143, 156, 166, 178, 210 ], "<": [ 122 ], "0.001;": [ 123, 158 ], "171.4": [ 124 ], "27.8": [ 126 ], "150.5": [ 128 ], "30.8,": [ 130 ], "=": [ 132, 144, 157, 167, 179, 211 ], "0.003;": [ 133 ], "86.6": [ 134 ], "12.9": [ 136 ], "kg": [ 137, 172 ], "82.9": [ 139 ], "11.1": [ 141 ], "kg,": [ 142, 177 ], "0.005,": [ 145, 180 ], "respectively)": [ 146 ], "sitagliptin": [ 148, 217 ], "(15.5%": [ 149 ], "11.7%": [ 153 ], "5.0%,": [ 155 ], "153.4": [ 159 ], "31.5": [ 161 ], "139.8": [ 163 ], "27.3,": [ 165 ], "0.027;": [ 168 ], "88.2": [ 169 ], "13.6": [ 171 ], "86.5": [ 174 ], "13.2": [ 176 ], "respectively).": [ 181 ], "No": [ 182 ], "significant": [ 183 ], "observed": [ 192 ], "glargine.": [ 195 ], "SAT": [ 196 ], "group": [ 202 ], "(239.9": [ 203 ], "69.0": [ 205 ], "211.3": [ 207 ], "76.1;": [ 209 ], "0.020)": [ 212 ], "but": [ 213, 239, 256 ], "not": [ 214, 241, 257 ], "groups.": [ 221 ], "Changes": [ 222 ], "greater": [ 233 ], "than": [ 236 ], "did": [ 240 ], "differ": [ 242 ], "between": [ 244 ], "sitagliptin.": [ 247 ], "Conclusion:": [ 248 ], "Combined": [ 249 ], "metformin,": [ 251 ], "both": [ 252 ], "glargine,": [ 259 ], "reduced": [ 260 ], "weight,": [ 262 ], "IHL,": [ 263 ], "VAT": [ 265 ], "addition": [ 267 ], "improving": [ 269 ], "NAFLD.": [ 277 ] }, "publication_date": "2018-10-20", "publication_year": 2018, "type": "article", "cited_by_count": 233, "authors": [ { "id": "https://openalex.org/A5066741898", "display_name": "Jinhua Yan" }, { "id": "https://openalex.org/A5100628586", "display_name": "Bin Yao" }, { "id": "https://openalex.org/A5101596080", "display_name": "Hongyu Kuang" }, { "id": "https://openalex.org/A5033357444", "display_name": "Xubin Yang" }, { "id": "https://openalex.org/A5100626764", "display_name": "Qin Huang" }, { "id": "https://openalex.org/A5006301048", "display_name": "Tianpei Hong" }, { "id": "https://openalex.org/A5043691548", "display_name": "Yushu Li" }, { "id": "https://openalex.org/A5101883889", "display_name": "Jingtao Dou" }, { "id": "https://openalex.org/A5083581289", "display_name": "Wenying Yang" }, { "id": "https://openalex.org/A5077624156", "display_name": "Guijun Qin" }, { "id": "https://openalex.org/A5068853641", "display_name": "Huijuan Yuan" }, { "id": "https://openalex.org/A5043994794", "display_name": "Xinhua Xiao" }, { "id": "https://openalex.org/A5058784085", "display_name": "Sihui Luo" }, { "id": "https://openalex.org/A5055675142", "display_name": "Zhongyan Shan" }, { "id": "https://openalex.org/A5031803193", "display_name": "Hongrong Deng" }, { "id": "https://openalex.org/A5005546864", "display_name": "Ying Tan" }, { "id": "https://openalex.org/A5001571073", "display_name": "Fen Xu" }, { "id": "https://openalex.org/A5061894086", "display_name": "Wen Xu" }, { "id": "https://openalex.org/A5081066035", "display_name": "Longyi Zeng" }, { "id": "https://openalex.org/A5110483066", "display_name": "Zhuang Kang" }, { "id": "https://openalex.org/A5012775407", "display_name": "Jianping Weng" } ] }, { "id": "https://openalex.org/W4376643286", "doi": "https://doi.org/10.1172/jci.insight.170671", "title": "The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission", "abstract": { "Growing": [ 0 ], "evidence": [ 1 ], "indicates": [ 2 ], "that": [ 3 ], "the": [ 4, 12, 24, 34, 57, 72, 123, 168 ], "glucagon-like": [ 5 ], "peptide-1": [ 6 ], "(GLP-1)": [ 7 ], "system": [ 8 ], "is": [ 9 ], "involved": [ 10 ], "in": [ 11, 48, 64, 82, 115, 137, 143, 163 ], "neurobiology": [ 13 ], "of": [ 14, 26, 36, 45, 59, 74, 92, 125, 191 ], "addictive": [ 15 ], "behaviors,": [ 16 ], "and": [ 17, 66, 78, 84, 104, 133, 145, 179, 181 ], "GLP-1": [ 18, 40, 169 ], "analogues": [ 19 ], "may": [ 20 ], "be": [ 21 ], "used": [ 22, 54 ], "for": [ 23, 188, 198 ], "treatment": [ 25 ], "alcohol": [ 27, 46, 80, 113, 135, 173 ], "use": [ 28, 47 ], "disorder": [ 29 ], "(AUD).": [ 30 ], "Here,": [ 31 ], "we": [ 32 ], "examined": [ 33 ], "effects": [ 35, 58, 73, 91 ], "semaglutide,": [ 37 ], "a": [ 38, 117, 194 ], "long-acting": [ 39 ], "analogue,": [ 41 ], "on": [ 42, 61, 76, 94, 122, 160 ], "biobehavioral": [ 43 ], "correlates": [ 44 ], "rodents.": [ 49 ], "A": [ 50 ], "drinking-in-the-dark": [ 51 ], "procedure": [ 52 ], "was": [ 53, 120 ], "to": [ 55 ], "test": [ 56 ], "semaglutide": [ 60, 75, 93, 171, 192 ], "binge-like": [ 62, 77, 112, 132 ], "drinking": [ 63, 81, 114, 136, 177 ], "male": [ 65, 83 ], "female": [ 67, 85 ], "mice.": [ 68 ], "We": [ 69 ], "also": [ 70, 130 ], "tested": [ 71 ], "dependence-induced": [ 79, 134 ], "rats,": [ 86, 150 ], "as": [ 87, 89, 193 ], "well": [ 88 ], "acute": [ 90 ], "spontaneous": [ 95 ], "inhibitory": [ 96 ], "postsynaptic": [ 97 ], "currents": [ 98 ], "(sIPSCs)": [ 99 ], "from": [ 100, 148 ], "central": [ 101, 183 ], "amygdala": [ 102 ], "(CeA)": [ 103 ], "infralimbic": [ 105 ], "cortex": [ 106 ], "(ILC)": [ 107 ], "neurons.": [ 108 ], "Semaglutide": [ 109, 129, 139 ], "dose-dependently": [ 110 ], "reduced": [ 111, 131 ], "mice;": [ 116 ], "similar": [ 118 ], "effect": [ 119, 159 ], "observed": [ 121 ], "intake": [ 124, 174 ], "other": [ 126 ], "caloric/noncaloric": [ 127 ], "solutions.": [ 128 ], "rats.": [ 138, 165 ], "increased": [ 140 ], "sIPSC": [ 141 ], "frequency": [ 142 ], "CeA": [ 144 ], "ILC": [ 146 ], "neurons": [ 147 ], "alcohol-naive": [ 149 ], "suggesting": [ 151 ], "enhanced": [ 152 ], "GABA": [ 153, 161, 184 ], "release,": [ 154 ], "but": [ 155 ], "had": [ 156 ], "no": [ 157 ], "overall": [ 158 ], "transmission": [ 162 ], "alcohol-dependent": [ 164 ], "In": [ 166 ], "conclusion,": [ 167 ], "analogue": [ 170 ], "decreased": [ 172 ], "across": [ 175 ], "different": [ 176 ], "models": [ 178 ], "species": [ 180 ], "modulated": [ 182 ], "neurotransmission,": [ 185 ], "providing": [ 186 ], "support": [ 187 ], "clinical": [ 189 ], "testing": [ 190 ], "potentially": [ 195 ], "novel": [ 196 ], "pharmacotherapy": [ 197 ], "AUD.": [ 199 ] }, "publication_date": "2023-05-16", "publication_year": 2023, "type": "article", "cited_by_count": 149, "authors": [ { "id": "https://openalex.org/A5051573714", "display_name": "Vicky Chuong" }, { "id": "https://openalex.org/A5087628785", "display_name": "Mehdi Farokhnia" }, { "id": "https://openalex.org/A5004795848", "display_name": "Sophia Khom" }, { "id": "https://openalex.org/A5091220197", "display_name": "Claire Pince" }, { "id": "https://openalex.org/A5071453077", "display_name": "Sophie K. Elvig" }, { "id": "https://openalex.org/A5009134770", "display_name": "Roman Vlkolinsk\u00fd" }, { "id": "https://openalex.org/A5016621517", "display_name": "Renata C.N. Marchette" }, { "id": "https://openalex.org/A5075246876", "display_name": "George F. Koob" }, { "id": "https://openalex.org/A5060479945", "display_name": "Marisa Roberto" }, { "id": "https://openalex.org/A5085936446", "display_name": "Leandro F. Vendruscolo" }, { "id": "https://openalex.org/A5038660835", "display_name": "Lorenzo Leggio" } ] }, { "id": "https://openalex.org/W2085458648", "doi": "https://doi.org/10.1155/2012/672658", "title": "Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis", "abstract": { "Glucagon-Like": [ 0 ], "Peptide-1": [ 1 ], "receptor": [ 2, 63 ], "agonists": [ 3, 64 ], "(GLP-1RAs),": [ 4 ], "approved": [ 5 ], "as": [ 6, 166 ], "glucose-lowering": [ 7 ], "drugs": [ 8 ], "for": [ 9, 32 ], "the": [ 10, 115, 158 ], "treatment": [ 11 ], "of": [ 12, 56, 102, 107, 130, 157, 160, 173 ], "type": [ 13 ], "2": [ 14, 112, 122 ], "diabetes,": [ 15 ], "have": [ 16 ], "also": [ 17 ], "been": [ 18 ], "shown": [ 19 ], "to": [ 20, 49, 154, 180, 186 ], "reduce": [ 21 ], "body": [ 22, 84, 163 ], "weight.": [ 23 ], "An": [ 24 ], "extensive": [ 25 ], "Medline,": [ 26 ], "Cochrane": [ 27 ], "database,": [ 28 ], "and": [ 29, 37, 75, 88, 178 ], "Embase": [ 30 ], "search": [ 31 ], "\u201cexenatide,\u201d": [ 33 ], "\u201cliraglutide,\u201d": [ 34 ], "\u201calbiglutide,\u201d": [ 35 ], "\u201csemaglutide,\u201d": [ 36 ], "\u201clixisenatide\u201d": [ 38 ], "was": [ 39 ], "performed,": [ 40 ], "collecting": [ 41 ], "all": [ 42 ], "randomized": [ 43 ], "clinical": [ 44, 143 ], "trials": [ 45, 79 ], "on": [ 46, 83, 162, 175 ], "humans": [ 47 ], "up": [ 48 ], "December": [ 50 ], "15,": [ 51 ], "2011,": [ 52 ], "with": [ 53, 65, 80, 96 ], "a": [ 54, 100, 127, 142 ], "duration": [ 55 ], "at": [ 57, 86, 104, 118, 133 ], "least": [ 58 ], "24": [ 59 ], "weeks,": [ 60 ], "comparing": [ 61 ], "GLP-1": [ 62 ], "either": [ 66 ], "placebo": [ 67 ], "or": [ 68 ], "active": [ 69 ], "drugs.": [ 70 ], "Twenty": [ 71 ], "two": [ 72 ], "(7,859": [ 73 ], "patients)": [ 74, 78 ], "7": [ 76 ], "(2,416": [ 77 ], "available": [ 81 ], "results": [ 82 ], "weight": [ 85, 128, 187 ], "6": [ 87, 105, 134 ], "12": [ 89 ], "months,": [ 90 ], "respectively,": [ 91 ], "were": [ 92 ], "included.": [ 93 ], "When": [ 94 ], "compared": [ 95 ], "placebo,": [ 97 ], "GLP-1RAs": [ 98 ], "determine": [ 99 ], "reduction": [ 101, 129 ], "BMI": [ 103, 117 ], "months": [ 106 ], "\u22121.0": [ 108 ], "[\u22121.3;": [ 109 ], "\u22120.6]": [ 110 ], "kg/m": [ 111, 121 ], ".": [ 113 ], "Considering": [ 114 ], "average": [ 116 ], "baseline": [ 119 ], "(32.4": [ 120 ], ")": [ 123 ], "these": [ 124 ], "data": [ 125 ], "means": [ 126 ], "about": [ 131 ], "3%": [ 132 ], "months.": [ 135 ], "This": [ 136 ], "result": [ 137 ], "could": [ 138, 147 ], "seem": [ 139 ], "modest": [ 140 ], "from": [ 141 ], "standpoint;": [ 144 ], "however,": [ 145 ], "it": [ 146 ], "be": [ 148 ], "affected": [ 149 ], "by": [ 150 ], "many": [ 151 ], "factors": [ 152 ], "contributing": [ 153 ], "an": [ 155 ], "underestimation": [ 156 ], "effect": [ 159 ], "GLP-1RA": [ 161, 174 ], "weight,": [ 164 ], "such": [ 165 ], "non": [ 167 ], "adequate": [ 168 ], "doses,": [ 169 ], "inclusion": [ 170 ], "criteria,": [ 171 ], "efficacy": [ 172 ], "reducing": [ 176 ], "glycosuria,": [ 177 ], "association": [ 179 ], "non-pharmacological": [ 181 ], "interventions": [ 182 ], "not": [ 183 ], "specifically": [ 184 ], "aimed": [ 185 ], "reduction.": [ 188 ] }, "publication_date": "2012-01-01", "publication_year": 2012, "type": "review", "cited_by_count": 98, "authors": [ { "id": "https://openalex.org/A5059413618", "display_name": "Matteo Monami" }, { "id": "https://openalex.org/A5014780759", "display_name": "Ilaria Dicembrini" }, { "id": "https://openalex.org/A5068485330", "display_name": "Niccol\u00f2 Marchionni" }, { "id": "https://openalex.org/A5068223964", "display_name": "Carlo Maria Rotella" }, { "id": "https://openalex.org/A5059685674", "display_name": "Edoardo Mannucci" } ] }, { "id": "https://openalex.org/W2530347223", "doi": "https://doi.org/10.1210/jc.2016-2775", "title": "Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes. The Lira-NAFLD study", "abstract": { "Six": [ 0 ], "months": [ 1 ], "of": [ 2 ], "treatment": [ 3 ], "with": [ 4, 13 ], "liraglutide": [ 5 ], "1.2": [ 6 ], "mg/d": [ 7 ], "significantly": [ 8, 41 ], "reduced": [ 9 ], "LFC": [ 10, 39 ], "in": [ 11, 38 ], "patients": [ 12 ], "inadequately": [ 14 ], "controlled": [ 15 ], "type": [ 16 ], "2": [ 17 ], "diabetes": [ 18 ], "and": [ 19 ], "this": [ 20, 36 ], "effect": [ 21 ], "was": [ 22 ], "mainly": [ 23 ], "driven": [ 24 ], "by": [ 25 ], "body": [ 26 ], "weight": [ 27 ], "reduction.": [ 28 ], "Further": [ 29 ], "studies": [ 30 ], "are": [ 31 ], "needed": [ 32 ], "to": [ 33 ], "confirm": [ 34 ], "that": [ 35 ], "reduction": [ 37 ], "may": [ 40 ], "reduce": [ 42 ], "fibrosis": [ 43 ], "progression.": [ 44 ] }, "publication_date": "2016-10-12", "publication_year": 2016, "type": "article", "cited_by_count": 224, "authors": [ { "id": "https://openalex.org/A5007995895", "display_name": "Jean\u2010Michel Petit" }, { "id": "https://openalex.org/A5026651154", "display_name": "Jean\u2013Pierre Cercueil" }, { "id": "https://openalex.org/A5030985674", "display_name": "Romaric Loffroy" }, { "id": "https://openalex.org/A5063608373", "display_name": "Damien Denimal" }, { "id": "https://openalex.org/A5091480628", "display_name": "Benjamin Bouillet" }, { "id": "https://openalex.org/A5035540039", "display_name": "C. Fourmont" }, { "id": "https://openalex.org/A5006488764", "display_name": "Olivier Chevallier" }, { "id": "https://openalex.org/A5073486115", "display_name": "Laurence Duvillard" }, { "id": "https://openalex.org/A5108114159", "display_name": "Bruno Verg\u00e8s" } ] }, { "id": "https://openalex.org/W2963422972", "doi": "https://doi.org/10.1016/s2352-4642(19)30236-6", "title": "FDA approval of GLP-1 receptor agonist (liraglutide) for use in children", "abstract": null, "publication_date": "2019-07-22", "publication_year": 2019, "type": "article", "cited_by_count": 34, "authors": [ { "id": "https://openalex.org/A5048155776", "display_name": "Fida Bacha" } ] }, { "id": "https://openalex.org/W2913876135", "doi": "https://doi.org/10.1016/j.bbrc.2019.01.103", "title": "Dulaglutide ameliorates STZ induced AD-like impairment of learning and memory ability by modulating hyperphosphorylation of tau and NFs through GSK3\u03b2", "abstract": null, "publication_date": "2019-02-14", "publication_year": 2019, "type": "article", "cited_by_count": 80, "authors": [ { "id": "https://openalex.org/A5101531129", "display_name": "Mei Zhou" }, { "id": "https://openalex.org/A5100607345", "display_name": "Shuyi Chen" }, { "id": "https://openalex.org/A5100416315", "display_name": "Peng Peng" }, { "id": "https://openalex.org/A5059151720", "display_name": "Zhongya Gu" }, { "id": "https://openalex.org/A5044964184", "display_name": "Jing Yu" }, { "id": "https://openalex.org/A5101892824", "display_name": "Gang Zhao" }, { "id": "https://openalex.org/A5112432315", "display_name": "Yanqiu Deng" } ] }, { "id": "https://openalex.org/W2045188930", "doi": "https://doi.org/10.1111/dom.12076", "title": "Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin", "abstract": { "ABSTRACT": [ 0 ], "Aim": [ 1 ], "Assess": [ 2 ], "the": [ 3 ], "pharmacodynamics": [ 4 ], "of": [ 5, 123, 217 ], "lixisenatide": [ 6, 41, 198, 223, 239 ], "once": [ 7 ], "daily": [ 8, 237 ], "(": [ 9, 32, 82, 247 ], "QD": [ 10, 14, 42, 55 ], ")": [ 11, 84, 249 ], "versus": [ 12, 225, 255 ], "liraglutide": [ 13, 54, 103, 159, 226 ], "in": [ 15, 78, 106, 126, 152, 171, 189, 245, 262 ], "type": [ 16 ], "2": [ 17 ], "diabetes": [ 18 ], "insufficiently": [ 19 ], "controlled": [ 20 ], "on": [ 21 ], "metformin.": [ 22 ], "Methods": [ 23 ], "In": [ 24 ], "this": [ 25 ], "28\u2010day,": [ 26 ], "randomized,": [ 27 ], "open\u2010label,": [ 28 ], "parallel\u2010group,": [ 29 ], "multicentre": [ 30 ], "study": [ 31 ], "NCT01175473": [ 33 ], "),": [ 34 ], "patients": [ 35, 142 ], "(mean": [ 36 ], "HbA1c": [ 37, 187 ], "7.3%)": [ 38 ], "received": [ 39 ], "subcutaneous": [ 40 ], "(10": [ 43 ], "\u00b5g": [ 44 ], "weeks": [ 45 ], "1\u20132,": [ 46 ], "then": [ 47, 64 ], "20": [ 48 ], "\u00b5g;": [ 49 ], "n": [ 50, 67 ], "=": [ 51, 68, 121 ], "77)": [ 52 ], "or": [ 53, 232 ], "(0.6": [ 56 ], "mg": [ 57, 61 ], "week": [ 58, 62 ], "1,": [ 59 ], "1.2": [ 60 ], "2,": [ 63 ], "1.8": [ 65 ], "mg;": [ 66 ], "71)": [ 69 ], "30": [ 70 ], "min": [ 71 ], "before": [ 72 ], "breakfast.": [ 73 ], "Primary": [ 74 ], "endpoint": [ 75 ], "was": [ 76, 130, 220 ], "change": [ 77, 105 ], "postprandial": [ 79, 172, 263 ], "plasma": [ 80, 154 ], "glucose": [ 81, 155 ], "PPG": [ 83, 99, 128, 145, 246 ], "exposure": [ 85 ], "from": [ 86 ], "baseline": [ 87 ], "to": [ 88, 195, 201 ], "day": [ 89 ], "28": [ 90 ], "during": [ 91, 250 ], "a": [ 92, 241, 251 ], "breakfast": [ 93 ], "test": [ 94, 253 ], "meal.": [ 95 ], "Results": [ 96 ], "Lixisenatide": [ 97, 167, 258 ], "reduced": [ 98 ], "significantly": [ 100, 242 ], "more": [ 101 ], "than": [ 102, 277 ], "[mean": [ 104 ], "AUC": [ 107, 248 ], "0": [ 108 ], ":30\u20134:30h": [ 109 ], ":": [ 110 ], "\u221212.6": [ 111 ], "vs.": [ 112, 133, 149, 161, 199, 211 ], "\u22124.0": [ 113 ], "h\u00b7mmol/L,": [ 114 ], "respectively;": [ 115 ], "p": [ 116, 164 ], "<": [ 117, 138, 165, 175, 179, 184 ], "0.0001": [ 118 ], "(0:30": [ 119 ], "h": [ 120 ], "start": [ 122 ], "meal)].": [ 124 ], "Change": [ 125 ], "maximum": [ 127 ], "excursion": [ 129 ], "\u22123.9": [ 131 ], "mmol/l": [ 132, 147 ], "\u22121.4": [ 134 ], "mmol/l,": [ 135, 163 ], "respectively": [ 136 ], "(p": [ 137, 174, 178, 183 ], "0.0001).": [ 139, 166, 185 ], "More": [ 140 ], "lixisenatide\u2010treated": [ 141 ], "achieved": [ 143 ], "2\u2010h": [ 144 ], "<7.8": [ 146 ], "(69%": [ 148 ], "29%).": [ 150 ], "Changes": [ 151 ], "fasting": [ 153 ], "were": [ 156 ], "greater": [ 157, 169, 243 ], "with": [ 158, 197, 203, 222, 228, 269 ], "(\u22120.3": [ 160 ], "\u22121.3": [ 162 ], "provided": [ 168, 240, 259 ], "decreases": [ 170, 261 ], "glucagon": [ 173 ], "0.05),": [ 176 ], "insulin": [ 177 ], "0.0001)": [ 180 ], "and": [ 181, 271, 273 ], "C\u2010peptide": [ 182, 265 ], "Mean": [ 186 ], "decreased": [ 188 ], "both": [ 190 ], "treatment": [ 191 ], "groups": [ 192 ], "(from": [ 193 ], "7.2%": [ 194 ], "6.9%": [ 196, 202 ], "7.4%": [ 200 ], "liraglutide)": [ 204, 270 ], "as": [ 205 ], "did": [ 206 ], "body": [ 207 ], "weight": [ 208 ], "(\u22121.6": [ 209 ], "kg": [ 210 ], "\u22122.4": [ 212 ], "kg,": [ 213 ], "respectively).": [ 214 ], "Overall": [ 215 ], "incidence": [ 216 ], "adverse": [ 218 ], "events": [ 219, 231 ], "lower": [ 221 ], "(55%)": [ 224 ], "(65%),": [ 227 ], "no": [ 229 ], "serious": [ 230 ], "hypoglycaemia": [ 233 ], "reported.": [ 234 ], "Conclusions": [ 235 ], "Once": [ 236 ], "prebreakfast": [ 238, 256 ], "reduction": [ 244 ], "morning": [ 252 ], "meal": [ 254 ], "liraglutide.": [ 257, 278 ], "significant": [ 260 ], "insulin,": [ 264 ], "(vs.": [ 266 ], "an": [ 267 ], "increase": [ 268 ], "glucagon,": [ 272 ], "better": [ 274 ], "gastrointestinal": [ 275 ], "tolerability": [ 276 ] }, "publication_date": "2013-01-31", "publication_year": 2013, "type": "article", "cited_by_count": 188, "authors": [ { "id": "https://openalex.org/A5068619321", "display_name": "Christoph Kapitza" }, { "id": "https://openalex.org/A5044778195", "display_name": "Thomas F\u00f6rst" }, { "id": "https://openalex.org/A5112477463", "display_name": "Hans Veit Coester" }, { "id": "https://openalex.org/A5044299629", "display_name": "Franck Poitiers" }, { "id": "https://openalex.org/A5083638044", "display_name": "Peter Ruus" }, { "id": "https://openalex.org/A5072715151", "display_name": "Agn\u00e8s Hincelin-M\u00e9ry" } ] }, { "id": "https://openalex.org/W2053104308", "doi": "https://doi.org/10.1111/j.1601-5215.2012.00648.x", "title": "Acute administration of GLP-1 receptor agonists induces hypolocomotion but not anxiety in mice", "abstract": { "Krass": [ 0 ], "M,": [ 1 ], "R\u00fcnkorg": [ 2 ], "K,": [ 3 ], "Vasar": [ 4 ], "E,": [ 5 ], "Volke": [ 6 ], "V.": [ 7 ], "Acute": [ 8 ], "administration": [ 9 ], "of": [ 10, 25, 36, 44, 54, 155, 160 ], "GLP-1": [ 11, 148 ], "receptor": [ 12, 58, 149 ], "agonists": [ 13, 59, 150 ], "induces": [ 14 ], "hypolocomotion": [ 15 ], "but": [ 16 ], "not": [ 17 ], "anxiety": [ 18, 63, 124 ], "in": [ 19, 48, 65, 73, 102, 163 ], "mice.": [ 20, 49, 164 ], "Objective": [ 21 ], ":": [ 22, 51, 86, 140 ], "The": [ 23, 52 ], "aim": [ 24 ], "this": [ 26 ], "study": [ 27 ], "was": [ 28, 83, 120 ], "to": [ 29, 100 ], "compare": [ 30 ], "the": [ 31, 66, 70, 79, 96, 110, 144 ], "behavioural": [ 32, 115 ], "and": [ 33, 46, 77, 91, 116, 135, 158 ], "hormonal": [ 34, 117 ], "effects": [ 35, 53 ], "systemic": [ 37 ], "(subcutaneous)": [ 38 ], "treatment": [ 39 ], "with": [ 40 ], "glucaemically": [ 41, 107 ], "equipotent": [ 42, 108 ], "doses": [ 43, 109 ], "exenatide": [ 45, 88 ], "liraglutide": [ 47, 92 ], "Methods": [ 50 ], "glucagon-like": [ 55 ], "peptide-1": [ 56 ], "(GLP-1)": [ 57 ], "were": [ 60 ], "determined": [ 61 ], "on": [ 62, 123 ], "level": [ 64, 125 ], "light\u2013dark": [ 67 ], "compartment": [ 68 ], "test,": [ 69 ], "motor": [ 71, 133, 156 ], "activity": [ 72, 75, 134, 157 ], "automated": [ 74 ], "cages": [ 76 ], "finally": [ 78 ], "forced": [ 80 ], "swimming": [ 81 ], "test": [ 82 ], "performed.": [ 84 ], "Results": [ 85 ], "Both": [ 87 ], "(1\u201320": [ 89 ], "\u00b5g/kg)": [ 90, 94 ], "(200\u20131200": [ 93 ], "decreased": [ 95 ], "glucose": [ 97 ], "levels": [ 98 ], "up": [ 99 ], "30%": [ 101 ], "freely": [ 103 ], "fed": [ 104 ], "animals.": [ 105 ], "In": [ 106 ], "drugs": [ 111, 131 ], "induced": [ 112 ], "very": [ 113, 152 ], "similar": [ 114, 153 ], "effects:": [ 118 ], "there": [ 119 ], "no": [ 121 ], "change": [ 122 ], "or": [ 126 ], "immobility": [ 127 ], "time,": [ 128 ], "however,": [ 129 ], "both": [ 130 ], "suppressed": [ 132 ], "increased": [ 136 ], "corticosterone": [ 137, 161 ], "levels.": [ 138 ], "Conclusion": [ 139 ], "We": [ 141 ], "conclude": [ 142 ], "that": [ 143 ], "two": [ 145 ], "clinically": [ 146 ], "approved": [ 147 ], "induce": [ 151 ], "suppression": [ 154 ], "stimulation": [ 159 ], "release": [ 162 ] }, "publication_date": "2012-01-11", "publication_year": 2012, "type": "article", "cited_by_count": 18, "authors": [ { "id": "https://openalex.org/A5028669651", "display_name": "Maarja Krass" }, { "id": "https://openalex.org/A5089242399", "display_name": "Kertu R\u00fcnkorg" }, { "id": "https://openalex.org/A5048622515", "display_name": "Eero Vasar" }, { "id": "https://openalex.org/A5033444495", "display_name": "Vallo Volke" } ] }, { "id": "https://openalex.org/W2927797006", "doi": "https://doi.org/10.1016/j.physbeh.2019.03.029", "title": "The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: A systematic review", "abstract": null, "publication_date": "2019-04-01", "publication_year": 2019, "type": "review", "cited_by_count": 40, "authors": [ { "id": "https://openalex.org/A5047396778", "display_name": "Amanda Brunchmann" }, { "id": "https://openalex.org/A5031395961", "display_name": "Morgane Thomsen" }, { "id": "https://openalex.org/A5001609083", "display_name": "Anders Fink\u2010Jensen" } ] }, { "id": "https://openalex.org/W2311442718", "doi": "https://doi.org/10.1185/03007995.2016.1147025", "title": "Physician perceptions of GLP-1 receptor agonists in the UK", "abstract": { "Objectives": [ 0 ], "Glucagon-like": [ 1 ], "peptide-1": [ 2 ], "(GLP-1)": [ 3 ], "receptor": [ 4, 39, 79, 117, 194, 209, 297 ], "agonists": [ 5, 40, 80, 210 ], "have": [ 6, 24, 231 ], "been": [ 7, 26 ], "used": [ 8 ], "to": [ 9, 34, 90, 164, 190, 234, 245, 266, 281 ], "treat": [ 10, 44 ], "type": [ 11, 47, 214 ], "2": [ 12, 48, 215 ], "diabetes": [ 13, 49, 60, 216 ], "for": [ 14, 113, 211, 240 ], "almost": [ 15, 221 ], "a": [ 16, 68, 115, 192, 222, 238 ], "decade,": [ 17 ], "and": [ 18, 105, 140, 176, 279 ], "new": [ 19 ], "treatments": [ 20 ], "in": [ 21, 50, 70, 217, 285 ], "this": [ 22, 31, 155, 282 ], "class": [ 23, 156 ], "recently": [ 25, 294 ], "introduced.": [ 27 ], "The": [ 28 ], "purpose": [ 29 ], "of": [ 30, 37, 56, 103, 178, 199, 207, 213, 224, 243, 248, 256, 291 ], "study": [ 32 ], "was": [ 33 ], "examine": [ 35 ], "perceptions": [ 36, 290 ], "GLP-1": [ 38, 78, 116, 193, 208, 296 ], "among": [ 41 ], "physicians": [ 42, 58, 75 ], "who": [ 43 ], "patients": [ 45, 91, 107 ], "with": [ 46, 99, 121, 136, 197 ], "the": [ 51, 204, 218, 254, 257, 276, 292 ], "UK.": [ 52, 219 ], "Methods": [ 53 ], "A": [ 54 ], "total": [ 55, 82 ], "670": [ 57 ], "(226": [ 59 ], "specialists;": [ 61, 85 ], "444": [ 62 ], "general": [ 63 ], "practice": [ 64 ], "[GP]": [ 65 ], "physicians)": [ 66, 104 ], "completed": [ 67 ], "survey": [ 69, 262, 283 ], "2014.": [ 71 ], "Results": [ 72, 202 ], "Almost": [ 73, 181 ], "all": [ 74, 182 ], "had": [ 76, 187 ], "prescribed": [ 77 ], "(95.4%": [ 81 ], "sample;": [ 83 ], "99.1%": [ 84 ], "93.5%": [ 86 ], "GP),": [ 87 ], "most": [ 88, 110, 149, 293 ], "frequently": [ 89 ], "whose": [ 92 ], "glucose": [ 93 ], "levels": [ 94 ], "are": [ 95 ], "not": [ 96, 134, 158, 230, 288 ], "adequately": [ 97 ], "controlled": [ 98 ], "oral": [ 100, 144 ], "medications": [ 101, 145 ], "(85.9%": [ 102 ], "obese/overweight": [ 106 ], "(83.7%).": [ 108 ], "Physicians'": [ 109 ], "common": [ 111 ], "reasons": [ 112 ], "prescribing": [ 114, 154 ], "agonist": [ 118 ], "were:": [ 119, 157 ], "associated": [ 120, 135 ], "weight": [ 122, 137 ], "loss": [ 123 ], "(65.8%),": [ 124 ], "good": [ 125 ], "efficacy": [ 126, 142 ], "(55.7%),": [ 127 ], "less": [ 128 ], "hypoglycemia": [ 129 ], "risk": [ 130, 177 ], "than": [ 131, 143, 274 ], "insulin": [ 132 ], "(55.2%),": [ 133 ], "gain": [ 138 ], "(34.5%),": [ 139 ], "better": [ 141 ], "(32.7%).": [ 146 ], "Factors": [ 147 ], "that": [ 148, 227, 253 ], "commonly": [ 150 ], "cause": [ 151 ], "hesitation": [ 152 ], "when": [ 153 ], "considered": [ 159 ], "first": [ 160 ], "line": [ 161 ], "therapy": [ 162 ], "according": [ 163 ], "guidelines": [ 165 ], "(56.9%),": [ 166 ], "injectable": [ 167 ], "administration": [ 168 ], "(44.6%),": [ 169 ], "cost": [ 170 ], "(36.7%),": [ 171 ], "gastrointestinal": [ 172 ], "side": [ 173 ], "effects": [ 174 ], "(33.4%),": [ 175 ], "pancreatitis": [ 179 ], "(26.7%).": [ 180 ], "specialists": [ 183 ], "(99.1%)": [ 184 ], "believed": [ 185 ], "they": [ 186, 228 ], "sufficient": [ 188 ], "knowledge": [ 189, 233 ], "prescribe": [ 191, 235 ], "agonist,": [ 195 ], "compared": [ 196 ], "76.1%": [ 198 ], "GPs.": [ 200 ], "Conclusions": [ 201 ], "highlight": [ 203 ], "widespread": [ 205 ], "use": [ 206 ], "treatment": [ 212 ], "However,": [ 220 ], "quarter": [ 223 ], "GPs": [ 225 ], "reported": [ 226 ], "do": [ 229, 287 ], "enough": [ 232 ], "GLP-1s,": [ 236 ], "suggesting": [ 237 ], "need": [ 239 ], "increased": [ 241 ], "dissemination": [ 242 ], "information": [ 244 ], "targeted": [ 246 ], "groups": [ 247 ], "physicians.": [ 249 ], "Study": [ 250 ], "limitations": [ 251 ], "were": [ 252 ], "generalizability": [ 255 ], "clinician": [ 258 ], "sample": [ 259 ], "is": [ 260 ], "unknown;": [ 261 ], "questions": [ 263 ], "required": [ 264 ], "clinicians": [ 265 ], "select": [ 267 ], "answers": [ 268 ], "from": [ 269 ], "multiple": [ 270 ], "response": [ 271 ], "options": [ 272 ], "rather": [ 273 ], "generating": [ 275 ], "responses": [ 277, 280 ], "themselves;": [ 278 ], "conducted": [ 284 ], "2014": [ 286 ], "reflect": [ 289 ], "introduced": [ 295 ], "agonists.": [ 298 ] }, "publication_date": "2016-01-25", "publication_year": 2016, "type": "article", "cited_by_count": 25, "authors": [ { "id": "https://openalex.org/A5051703711", "display_name": "Louis S. Matza" }, { "id": "https://openalex.org/A5103857669", "display_name": "Sarah E. Curtis" }, { "id": "https://openalex.org/A5111937124", "display_name": "Jessica Jordan" }, { "id": "https://openalex.org/A5109398958", "display_name": "Omolara Adetunji" }, { "id": "https://openalex.org/A5111702291", "display_name": "Sherry Martin" }, { "id": "https://openalex.org/A5039006946", "display_name": "Kristina S. Boye" } ] }, { "id": "https://openalex.org/W3011482816", "doi": "https://doi.org/10.1016/j.tem.2020.02.006", "title": "How May GIP Enhance the Therapeutic Efficacy of GLP-1?", "abstract": { "Glucagon-like": [ 0 ], "peptide-1": [ 1 ], "(GLP-1)": [ 2 ], "receptor": [ 3, 117 ], "agonists": [ 4 ], "improve": [ 5, 75 ], "glucose": [ 6, 78 ], "homeostasis,": [ 7 ], "reduce": [ 8 ], "bodyweight,": [ 9 ], "and": [ 10, 28, 77, 102, 126 ], "over": [ 11 ], "time": [ 12 ], "benefit": [ 13 ], "cardiovascular": [ 14 ], "health": [ 15 ], "in": [ 16, 97, 105, 111 ], "type": [ 17 ], "2": [ 18 ], "diabetes": [ 19 ], "mellitus": [ 20 ], "(T2DM).": [ 21 ], "However,": [ 22 ], "dose-related": [ 23 ], "gastrointestinal": [ 24 ], "effects": [ 25 ], "limit": [ 26 ], "efficacy,": [ 27 ], "therefore": [ 29 ], "agents": [ 30 ], "possessing": [ 31 ], "GLP-1": [ 32, 50 ], "pharmacology": [ 33 ], "that": [ 34, 114 ], "can": [ 35 ], "also": [ 36 ], "target": [ 37 ], "alternative": [ 38 ], "pathways": [ 39 ], "may": [ 40 ], "expand": [ 41 ], "the": [ 42, 53, 61, 65, 86, 93, 106 ], "therapeutic": [ 43, 62 ], "index.": [ 44 ], "One": [ 45 ], "approach": [ 46 ], "is": [ 47, 80 ], "to": [ 48, 74 ], "engineer": [ 49 ], "activity": [ 51 ], "into": [ 52 ], "sequence": [ 54 ], "of": [ 55, 64, 68, 89, 95, 108 ], "glucose-dependent": [ 56 ], "insulinotropic": [ 57 ], "polypeptide": [ 58 ], "(GIP).": [ 59 ], "Although": [ 60 ], "implications": [ 63 ], "lipogenic": [ 66 ], "actions": [ 67 ], "GIP": [ 69, 96 ], "are": [ 70 ], "debated,": [ 71 ], "its": [ 72 ], "ability": [ 73 ], "lipid": [ 76, 127 ], "metabolism": [ 79 ], "especially": [ 81 ], "evident": [ 82 ], "when": [ 83 ], "paired": [ 84 ], "with": [ 85 ], "anorexigenic": [ 87 ], "mechanism": [ 88 ], "GLP-1.": [ 90 ], "We": [ 91 ], "review": [ 92 ], "complexity": [ 94 ], "regulating": [ 98 ], "adipose": [ 99 ], "tissue": [ 100 ], "function": [ 101 ], "energy": [ 103 ], "balance": [ 104 ], "context": [ 107 ], "recent": [ 109 ], "findings": [ 110 ], "T2DM": [ 112 ], "showing": [ 113 ], "dual": [ 115 ], "GIP/GLP-1": [ 116 ], "agonist": [ 118 ], "therapy": [ 119 ], "produces": [ 120 ], "profound": [ 121 ], "weight": [ 122 ], "loss,": [ 123 ], "glycemic": [ 124 ], "control,": [ 125 ], "lowering.": [ 128 ] }, "publication_date": "2020-03-16", "publication_year": 2020, "type": "review", "cited_by_count": 347, "authors": [ { "id": "https://openalex.org/A5061640534", "display_name": "Ricardo J. Samms" }, { "id": "https://openalex.org/A5011350446", "display_name": "Matthew P. Coghlan" }, { "id": "https://openalex.org/A5068951024", "display_name": "Kyle W. Sloop" } ] }, { "id": "https://openalex.org/W4393950379", "doi": "https://doi.org/10.3390/ijms25073812", "title": "GLP-1 Receptor Agonists: A New Treatment in Parkinson\u2019s Disease", "abstract": { "Parkinson\u2019s": [ 0 ], "disease": [ 1 ], "(PD)": [ 2 ], "is": [ 3, 145 ], "one": [ 4 ], "of": [ 5, 93, 106, 139, 152, 160 ], "the": [ 6, 31, 81, 91, 94, 107, 150, 157 ], "most": [ 7, 105 ], "common": [ 8 ], "neurodegenerative": [ 9, 16 ], "diseases.": [ 10 ], "Recent": [ 11 ], "data": [ 12, 112 ], "highlight": [ 13 ], "similarities": [ 14 ], "between": [ 15, 30 ], "diseases,": [ 17 ], "including": [ 18 ], "PD": [ 19, 52, 78, 164 ], "and": [ 20, 63, 71, 77, 116, 133, 136 ], "type": [ 21 ], "2": [ 22 ], "diabetes": [ 23 ], "mellitus": [ 24 ], "(T2DM),": [ 25 ], "suggesting": [ 26 ], "a": [ 27 ], "crucial": [ 28 ], "interplay": [ 29 ], "gut\u2013brain": [ 32 ], "axis.": [ 33 ], "Glucagon-like": [ 34 ], "peptide-1": [ 35 ], "receptor": [ 36 ], "(GLP-1R)": [ 37 ], "agonists,": [ 38 ], "known": [ 39 ], "for": [ 40, 66, 97, 163 ], "their": [ 41 ], "use": [ 42 ], "in": [ 43, 80, 101 ], "T2DM": [ 44 ], "treatment,": [ 45 ], "are": [ 46 ], "currently": [ 47 ], "extensively": [ 48 ], "studied": [ 49 ], "as": [ 50 ], "novel": [ 51 ], "modifying": [ 53 ], "agents.": [ 54 ], "For": [ 55 ], "this": [ 56 ], "narrative": [ 57 ], "review": [ 58, 69 ], "article,": [ 59 ], "we": [ 60 ], "searched": [ 61 ], "PubMed": [ 62 ], "Scopus": [ 64 ], "databases": [ 65 ], "peer-reviewed": [ 67 ], "research,": [ 68 ], "articles": [ 70, 96, 100 ], "clinical": [ 72, 143 ], "trials": [ 73 ], "regarding": [ 74 ], "GLP-1R": [ 75 ], "agonists": [ 76, 122, 155 ], "published": [ 79 ], "English": [ 82 ], "language": [ 83 ], "with": [ 84 ], "no": [ 85 ], "time": [ 86 ], "restrictions.": [ 87 ], "We": [ 88 ], "also": [ 89, 146 ], "screened": [ 90 ], "references": [ 92 ], "selected": [ 95 ], "possible": [ 98 ], "additional": [ 99 ], "order": [ 102 ], "to": [ 103, 156 ], "include": [ 104 ], "key": [ 108 ], "recent": [ 109 ], "evidence.": [ 110 ], "Many": [ 111 ], "on": [ 113 ], "animal": [ 114 ], "models": [ 115 ], "preclinical": [ 117 ], "studies": [ 118, 144 ], "show": [ 119 ], "that": [ 120 ], "GLP1-R": [ 121, 154 ], "can": [ 123 ], "restore": [ 124 ], "dopamine": [ 125 ], "levels,": [ 126 ], "inhibit": [ 127 ], "dopaminergic": [ 128 ], "loss,": [ 129 ], "attenuate": [ 130 ], "neuronal": [ 131 ], "degeneration": [ 132 ], "alleviate": [ 134 ], "motor": [ 135 ], "non-motor": [ 137 ], "features": [ 138 ], "PD.": [ 140 ], "Evidence": [ 141 ], "from": [ 142 ], "very": [ 147 ], "promising,": [ 148 ], "enhancing": [ 149 ], "possibility": [ 151 ], "adding": [ 153 ], "current": [ 158 ], "armamentarium": [ 159 ], "drugs": [ 161 ], "available": [ 162 ], "treatment.": [ 165 ] }, "publication_date": "2024-03-29", "publication_year": 2024, "type": "article", "cited_by_count": 59, "authors": [ { "id": "https://openalex.org/A5050900261", "display_name": "Kallirhoe Kalinderi" }, { "id": "https://openalex.org/A5036292767", "display_name": "Vasileios Papaliagkas" }, { "id": "https://openalex.org/A5058116150", "display_name": "Liana Fidani" } ] }, { "id": "https://openalex.org/W4398783915", "doi": "https://doi.org/10.1001/jamanetworkopen.2024.13172", "title": "GLP-1 Receptor Agonist Discontinuation Among Patients With Obesity and/or Type 2 Diabetes", "abstract": { "This": [ 0 ], "cohort": [ 1 ], "study": [ 2 ], "examines": [ 3 ], "the": [ 4 ], "prevalence": [ 5 ], "of": [ 6 ], "and": [ 7 ], "factors": [ 8 ], "associated": [ 9 ], "with": [ 10 ], "glucagon-like": [ 11 ], "peptide": [ 12 ], "1": [ 13 ], "agonist": [ 14 ], "discontinuation": [ 15 ], "among": [ 16 ], "new": [ 17 ], "users.": [ 18 ] }, "publication_date": "2024-05-24", "publication_year": 2024, "type": "article", "cited_by_count": 108, "authors": [ { "id": "https://openalex.org/A5023034294", "display_name": "Duy Ngoc" }, { "id": "https://openalex.org/A5047570678", "display_name": "Tiffany Lee" }, { "id": "https://openalex.org/A5058342645", "display_name": "Samuel K. Peasah" }, { "id": "https://openalex.org/A5012227398", "display_name": "Chester B. Good" }, { "id": "https://openalex.org/A5098815376", "display_name": "Angela Inneh" }, { "id": "https://openalex.org/A5113227853", "display_name": "Urvashi Patel" } ] }, { "id": "https://openalex.org/W4387903893", "doi": "https://doi.org/10.3390/brainsci13111503", "title": "GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach", "abstract": { "The": [ 0, 188 ], "emergence": [ 1 ], "of": [ 2, 17, 49, 55, 67, 84, 102, 120, 156, 182, 185, 190, 203, 240, 261 ], "glucagon-like": [ 3 ], "peptide-1": [ 4 ], "receptor": [ 5 ], "agonists": [ 6 ], "(GLP-1": [ 7 ], "RAs;": [ 8 ], "semaglutide": [ 9, 57 ], "and": [ 10, 22, 36, 70, 93, 114, 144, 179, 213, 224, 235, 248, 264, 270 ], "others)": [ 11 ], "now": [ 12 ], "promises": [ 13 ], "effective,": [ 14 ], "non-invasive": [ 15 ], "treatment": [ 16 ], "obesity": [ 18 ], "for": [ 19 ], "individuals": [ 20 ], "with": [ 21, 53, 74, 99, 163 ], "without": [ 23 ], "diabetes.": [ 24 ], "Social": [ 25 ], "media": [ 26 ], "platforms\u2019": [ 27 ], "users": [ 28 ], "started": [ 29 ], "promoting": [ 30 ], "semaglutide/Ozempic": [ 31 ], "as": [ 32, 90, 198, 219 ], "a": [ 33, 103, 165, 172, 183, 195, 227 ], "weight-loss": [ 34 ], "treatment,": [ 35 ], "the": [ 37, 50, 75, 81, 100, 154, 201, 208, 258 ], "associated": [ 38, 52, 162 ], "increase": [ 39 ], "in": [ 40, 95, 148, 169, 174, 177 ], "demand": [ 41 ], "has": [ 42 ], "contributed": [ 43 ], "to": [ 44, 79, 127, 255 ], "an": [ 45 ], "ongoing": [ 46 ], "worldwide": [ 47 ], "shortage": [ 48 ], "drug": [ 51 ], "levels": [ 54 ], "non-prescribed": [ 56 ], "intake.": [ 58 ], "Furthermore,": [ 59 ], "recent": [ 60 ], "reports": [ 61 ], "emphasized": [ 62 ], "some": [ 63, 170 ], "GLP-1": [ 64, 85, 157, 215 ], "RA-associated": [ 65 ], "risks": [ 66 ], "triggering": [ 68 ], "depression": [ 69, 140, 234 ], "suicidal": [ 71 ], "thoughts.": [ 72 ], "Consistent": [ 73 ], "above,": [ 76 ], "we": [ 77 ], "aimed": [ 78 ], "assess": [ 80 ], "possible": [ 82, 242 ], "impact": [ 83, 267 ], "RAs": [ 86, 216 ], "on": [ 87, 268 ], "mental": [ 88, 145, 222 ], "health": [ 89, 146 ], "being": [ 91 ], "perceived": [ 92, 218 ], "discussed": [ 94 ], "popular": [ 96 ], "open": [ 97 ], "platforms": [ 98 ], "help": [ 101 ], "mixed-methods": [ 104 ], "approach.": [ 105 ], "Reddit": [ 106 ], "posts": [ 107 ], "yielded": [ 108 ], "12,136": [ 109 ], "comments,": [ 110 ], "YouTube": [ 111 ], "videos": [ 112, 116 ], "14,515,": [ 113 ], "TikTok": [ 115 ], "17,059,": [ 117 ], "respectively.": [ 118 ], "Out": [ 119 ], "these": [ 121, 192, 262 ], "posts/entries,": [ 122 ], "most": [ 123 ], "represented": [ 124 ], "matches": [ 125 ], "related": [ 126 ], "sleep-related": [ 128 ], "issues,": [ 129 ], "including": [ 130 ], "insomnia": [ 131 ], "(n": [ 132, 137, 141, 150 ], "=": [ 133, 138, 142, 151 ], "620": [ 134 ], "matches);": [ 135 ], "anxiety": [ 136 ], "353);": [ 139 ], "204);": [ 143 ], "issues": [ 147 ], "general": [ 149 ], "165).": [ 152 ], "After": [ 153 ], "initiation": [ 155 ], "RAs,": [ 158 ], "losing": [ 159 ], "weight": [ 160 ], "was": [ 161 ], "either": [ 164 ], "marked": [ 166 ], "improvement": [ 167 ], "or,": [ 168 ], "cases,": [ 171 ], "deterioration,": [ 173 ], "mood;": [ 175 ], "increase/decrease": [ 176 ], "anxiety/insomnia;": [ 178 ], "better": [ 180, 256 ], "control": [ 181 ], "range": [ 184 ], "addictive": [ 186 ], "behaviors.": [ 187, 225 ], "challenges": [ 189 ], "accessing": [ 191 ], "medications": [ 193, 236 ], "were": [ 194 ], "hot": [ 196 ], "topic": [ 197 ], "well.": [ 199 ], "To": [ 200 ], "best": [ 202 ], "our": [ 204 ], "knowledge,": [ 205 ], "this": [ 206 ], "is": [ 207, 237, 253 ], "first": [ 209 ], "study": [ 210 ], "documenting": [ 211 ], "if": [ 212 ], "how": [ 214 ], "are": [ 217 ], "affecting": [ 220 ], "mood,": [ 221 ], "health,": [ 223 ], "Establishing": [ 226 ], "clear": [ 228 ], "cause-and-effect": [ 229 ], "link": [ 230 ], "between": [ 231 ], "metabolic": [ 232 ], "diseases,": [ 233 ], "difficult": [ 238 ], "because": [ 239 ], "their": [ 241, 265 ], "reciprocal": [ 243 ], "relationship,": [ 244 ], "shared": [ 245 ], "underlying": [ 246 ], "mechanisms": [ 247 ], "individual": [ 249 ], "differences.": [ 250 ], "Further": [ 251 ], "research": [ 252 ], "needed": [ 254 ], "understand": [ 257 ], "safety": [ 259 ], "profile": [ 260 ], "molecules": [ 263 ], "putative": [ 266 ], "behavioral": [ 269 ], "non-behavioral": [ 271 ], "addictions.": [ 272 ] }, "publication_date": "2023-10-24", "publication_year": 2023, "type": "article", "cited_by_count": 78, "authors": [ { "id": "https://openalex.org/A5069522381", "display_name": "Davide Arillotta" }, { "id": "https://openalex.org/A5047386031", "display_name": "Giuseppe Floresta" }, { "id": "https://openalex.org/A5080313345", "display_name": "Amira Guirguis" }, { "id": "https://openalex.org/A5058372793", "display_name": "John Corkery" }, { "id": "https://openalex.org/A5086740240", "display_name": "Valeria Catalani" }, { "id": "https://openalex.org/A5070312407", "display_name": "Giovanni Martinotti" }, { "id": "https://openalex.org/A5024277256", "display_name": "Stefano L. Sensi" }, { "id": "https://openalex.org/A5078706372", "display_name": "Fabrizio Schifano" } ] }, { "id": "https://openalex.org/W4317213523", "doi": "https://doi.org/10.1093/ndt/gfad009", "title": "The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease", "abstract": { "ABSTRACT": [ 0 ], "Background": [ 1 ], "Chronic": [ 2 ], "kidney": [ 3, 74, 146, 157, 168, 246 ], "disease": [ 4 ], "(CKD)": [ 5 ], "is": [ 6, 84, 142, 255 ], "a": [ 7, 62, 69, 85, 179 ], "common": [ 8 ], "complication": [ 9 ], "of": [ 10, 36, 67, 155, 183, 192, 198, 204, 213, 243 ], "type": [ 11 ], "2": [ 12 ], "diabetes": [ 13, 196 ], "(T2D).": [ 14 ], "Glucagon-like": [ 15 ], "peptide-1": [ 16 ], "receptor": [ 17 ], "agonists": [ 18 ], "(GLP-1RAs)": [ 19 ], "improve": [ 20 ], "glycaemic": [ 21 ], "control": [ 22 ], "and": [ 23, 31, 56, 80, 104, 116, 210, 252, 254 ], "lower": [ 24 ], "body": [ 25 ], "weight": [ 26 ], "in": [ 27, 40, 76, 163, 248, 260 ], "people": [ 28 ], "with": [ 29, 42, 78, 94, 131, 250 ], "T2D,": [ 30, 95, 253 ], "some": [ 32 ], "reduce": [ 33 ], "the": [ 34, 54, 65, 241 ], "risk": [ 35, 233 ], "cardiovascular": [ 37 ], "(CV)": [ 38 ], "events": [ 39 ], "those": [ 41 ], "high": [ 43, 232 ], "CV": [ 44, 170 ], "risk.": [ 45 ], "GLP-1RAs": [ 46 ], "might": [ 47 ], "also": [ 48 ], "have": [ 49 ], "kidney-protective": [ 50 ], "effects.": [ 51 ], "We": [ 52 ], "report": [ 53 ], "design": [ 55 ], "baseline": [ 57, 180 ], "data": [ 58 ], "for": [ 59, 234 ], "FLOW": [ 60, 83, 238 ], "(NCT03819153),": [ 61 ], "trial": [ 63 ], "investigating": [ 64 ], "effects": [ 66 ], "semaglutide,": [ 68 ], "once-weekly": [ 70 ], "(OW)": [ 71 ], "GLP-1RA,": [ 72 ], "on": [ 73, 245 ], "outcomes": [ 75, 247 ], "participants": [ 77, 174, 249 ], "CKD": [ 79, 235, 251 ], "T2D.": [ 81 ], "Methods": [ 82 ], "randomised,": [ 86 ], "double-blind,": [ 87 ], "parallel-group,": [ 88 ], "multinational,": [ 89 ], "phase": [ 90 ], "3b": [ 91 ], "trial.": [ 92 ], "Participants": [ 93 ], "estimated": [ 96 ], "glomerular": [ 97 ], "filtration": [ 98 ], "rate": [ 99 ], "(eGFR)": [ 100 ], "\u226550\u2012\u226475": [ 101 ], "ml/min/1.73": [ 102, 114, 151, 206 ], "m2": [ 103, 115, 152, 207 ], "urine": [ 105 ], "albumin:creatinine": [ 106 ], "ratio": [ 107 ], "(UACR)": [ 108 ], "&gt;300\u2012&lt;5000": [ 109 ], "mg/g": [ 110, 119, 215 ], "or": [ 111, 128, 153, 165, 169 ], "eGFR": [ 112, 149, 164, 203 ], "\u226525\u2012&lt;50": [ 113 ], "UACR": [ 117, 212 ], "&gt;100\u2012&lt;5000": [ 118 ], "were": [ 120, 229 ], "randomised": [ 121 ], "1:1": [ 122 ], "to": [ 123, 144, 220, 257 ], "OW": [ 124 ], "semaglutide": [ 125, 244 ], "1.0": [ 126 ], "mg": [ 127 ], "matched": [ 129 ], "placebo,": [ 130 ], "renin\u2013angiotensin\u2013aldosterone": [ 132 ], "system": [ 133 ], "blockade": [ 134 ], "(unless": [ 135 ], "not": [ 136 ], "tolerated/contraindicated).": [ 137 ], "The": [ 138 ], "composite": [ 139 ], "primary": [ 140 ], "endpoint": [ 141 ], "time": [ 143 ], "first": [ 145 ], "failure": [ 147 ], "(persistent": [ 148 ], "&lt;15": [ 150 ], "initiation": [ 154 ], "chronic": [ 156 ], "replacement": [ 158 ], "therapy),": [ 159 ], "persistent": [ 160 ], "\u226550%": [ 161 ], "reduction": [ 162 ], "death": [ 166 ], "from": [ 167 ], "causes.": [ 171 ], "Results": [ 172 ], "Enrolled": [ 173 ], "(N": [ 175 ], "=": [ 176 ], "3534)": [ 177 ], "had": [ 178 ], "mean": [ 181 ], "age": [ 182 ], "66.6": [ 184 ], "years": [ 185, 200 ], "[standard": [ 186 ], "deviation": [ 187 ], "(SD)": [ 188 ], "9.0],": [ 189 ], "haemoglobin": [ 190 ], "A1c": [ 191 ], "7.8%": [ 193 ], "(SD": [ 194, 201, 208 ], "1.3),": [ 195 ], "duration": [ 197 ], "17.4": [ 199 ], "9.3),": [ 202 ], "47.0": [ 205 ], "15.2)": [ 209 ], "median": [ 211 ], "568": [ 214 ], "(range": [ 216 ], "2\u201211": [ 217 ], "852).": [ 218 ], "According": [ 219 ], "Kidney": [ 221 ], "Disease:": [ 222 ], "Improving": [ 223 ], "Global": [ 224 ], "Outcomes": [ 225 ], "guidelines": [ 226 ], "categorisation,": [ 227 ], "68.2%": [ 228 ], "at": [ 230 ], "very": [ 231 ], "progression.": [ 236 ], "Conclusion": [ 237 ], "will": [ 239 ], "evaluate": [ 240 ], "effect": [ 242 ], "expected": [ 256 ], "be": [ 258 ], "completed": [ 259 ], "late": [ 261 ], "2024.": [ 262 ] }, "publication_date": "2023-01-18", "publication_year": 2023, "type": "article", "cited_by_count": 214, "authors": [ { "id": "https://openalex.org/A5085592050", "display_name": "Peter Rossing" }, { "id": "https://openalex.org/A5112384687", "display_name": "Florian M.M. Baeres" }, { "id": "https://openalex.org/A5012514694", "display_name": "George L. Bakris" }, { "id": "https://openalex.org/A5070579413", "display_name": "Heidrun Bosch\u2010Traberg" }, { "id": "https://openalex.org/A5054860387", "display_name": "Mette Gislum" }, { "id": "https://openalex.org/A5108267083", "display_name": "Stephen Gough" }, { "id": "https://openalex.org/A5113682378", "display_name": "Thomas Idorn" }, { "id": "https://openalex.org/A5108350451", "display_name": "Jack Lawson" }, { "id": "https://openalex.org/A5039432822", "display_name": "Kenneth W. Mahaffey" }, { "id": "https://openalex.org/A5043842967", "display_name": "Johannes F.E. Mann" }, { "id": "https://openalex.org/A5049115466", "display_name": "Henriette Mersebach" }, { "id": "https://openalex.org/A5027520502", "display_name": "Vlado Perkovic" }, { "id": "https://openalex.org/A5046793050", "display_name": "Katherine R. Tuttle" }, { "id": "https://openalex.org/A5110875486", "display_name": "Richard Pratley" } ] }, { "id": "https://openalex.org/W2007217090", "doi": "https://doi.org/10.2174/157339910791658853", "title": "Impact of GLP-1 and GLP-1 Receptor Agonists on Cardiovascular Risk Factors in Type 2 Diabetes", "abstract": { "Type": [ 0 ], "2": [ 1 ], "diabetes": [ 2, 13, 113, 200 ], "(T2D)": [ 3 ], "is": [ 4 ], "associated": [ 5, 25 ], "with": [ 6, 26, 176 ], "increased": [ 7 ], "cardiovascular": [ 8, 30, 100, 144, 191, 208 ], "disease": [ 9, 209 ], "and": [ 10, 22, 55, 78, 110, 117, 127, 143, 156, 163, 170, 210 ], "mortality.": [ 11 ], "Most": [ 12 ], "treatments": [ 14 ], "have": [ 15, 119, 186 ], "not": [ 16, 195 ], "proven": [ 17 ], "to": [ 18, 108, 111, 121, 128, 167, 213 ], "reduce": [ 19, 129 ], "this": [ 20 ], "risk": [ 21, 31, 101, 145, 192 ], "may": [ 23 ], "be": [ 24, 214 ], "worsening": [ 27 ], "of": [ 28, 45, 73, 154 ], "specific": [ 29 ], "factors.": [ 32 ], "GLP-1": [ 33, 155 ], "receptor": [ 34 ], "agonists": [ 35, 68, 93, 185 ], "(GLP-1R": [ 36 ], "agonists)": [ 37 ], "are": [ 38, 65 ], "new": [ 39, 204 ], "incretin-based": [ 40 ], "therapies": [ 41 ], "for": [ 42, 70 ], "the": [ 43, 71, 140, 160, 164 ], "treatment": [ 44, 72 ], "T2D.": [ 46 ], "They": [ 47 ], "improve": [ 48 ], "glucose": [ 49 ], "control": [ 50 ], "by": [ 51, 84, 197 ], "stimulating": [ 52 ], "insulin": [ 53 ], "secretion": [ 54 ], "suppressing": [ 56 ], "glucagon": [ 57 ], "release,": [ 58 ], "both": [ 59, 82 ], "in": [ 60, 99, 159, 174, 216 ], "a": [ 61, 96, 136, 151, 187 ], "glucose-dependent": [ 62 ], "manner.": [ 63 ], "There": [ 64 ], "two": [ 66 ], "GLP-1R": [ 67, 92, 184 ], "approved": [ 69 ], "T2D:": [ 74 ], "once": [ 75 ], "daily": [ 76, 80 ], "liraglutide": [ 77, 116 ], "twice": [ 79 ], "exenatide,": [ 81 ], "administered": [ 83 ], "sc": [ 85 ], "injection.": [ 86 ], "Based": [ 87 ], "on": [ 88, 139, 190 ], "recent": [ 89, 148 ], "clinical": [ 90 ], "trials,": [ 91 ], "suggest": [ 94 ], "having": [ 95 ], "protective": [ 97 ], "role": [ 98 ], "factors": [ 102, 193 ], "besides": [ 103 ], "improving": [ 104 ], "glycemic": [ 105 ], "control,": [ 106 ], "compared": [ 107 ], "placebo": [ 109 ], "standard": [ 112, 199 ], "therapies.": [ 114, 201 ], "Both": [ 115 ], "exenatide": [ 118 ], "demonstrated": [ 120, 215 ], "induce": [ 122 ], "clinically": [ 123 ], "significant": [ 124 ], "weight": [ 125 ], "loss": [ 126 ], "systolic": [ 130 ], "blood": [ 131 ], "pressure.": [ 132 ], "Liraglutide": [ 133 ], "also": [ 134 ], "has": [ 135 ], "positive": [ 137, 188 ], "effect": [ 138, 153 ], "lipid": [ 141 ], "profile": [ 142 ], "biomakers.": [ 146 ], "Furthermore,": [ 147 ], "data": [ 149 ], "shows": [ 150 ], "direct": [ 152 ], "its": [ 157 ], "metabolites": [ 158 ], "vascular": [ 161 ], "endothelium": [ 162 ], "myocardium,": [ 165 ], "leading": [ 166 ], "vasodilator": [ 168 ], "effects": [ 169 ], "improved": [ 171 ], "cardiac": [ 172 ], "function": [ 173 ], "humans": [ 175 ], "acute": [ 177 ], "myocardial": [ 178 ], "infarction": [ 179 ], "or": [ 180 ], "congestive": [ 181 ], "heart": [ 182 ], "failure.": [ 183 ], "impact": [ 189 ], "otherwise": [ 194 ], "addressed": [ 196 ], "most": [ 198 ], "Whether": [ 202 ], "these": [ 203 ], "compounds": [ 205 ], "actually": [ 206 ], "decrease": [ 207 ], "mortality": [ 211 ], "remains": [ 212 ], "outcome": [ 217 ], "studies.": [ 218 ] }, "publication_date": "2010-07-01", "publication_year": 2010, "type": "review", "cited_by_count": 27, "authors": [ { "id": "https://openalex.org/A5049261756", "display_name": "Danilo Verge" }, { "id": "https://openalex.org/A5006437121", "display_name": "Ximena L\u00f3pez" } ] }, { "id": "https://openalex.org/W3176758271", "doi": "https://doi.org/10.1016/s2213-8587(21)00113-3", "title": "Treatment of type 2 diabetes: challenges, hopes, and anticipated successes", "abstract": null, "publication_date": "2021-06-25", "publication_year": 2021, "type": "review", "cited_by_count": 258, "authors": [ { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5089465404", "display_name": "Jakob Wefers" }, { "id": "https://openalex.org/A5002832666", "display_name": "Juris J. Meier" } ] }, { "id": "https://openalex.org/W3041477129", "doi": "https://doi.org/10.2337/dc20-0720", "title": "Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes", "abstract": { "OBJECTIVE": [ 0 ], "Short-acting": [ 1 ], "glucagon-like": [ 2 ], "peptide": [ 3 ], "1": [ 4 ], "receptor": [ 5 ], "agonists": [ 6 ], "(GLP-1": [ 7 ], "RAs)": [ 8 ], "decelerate": [ 9 ], "gastric": [ 10, 18, 39, 98, 106, 240 ], "emptying": [ 11, 19, 40, 99, 117, 241 ], "more": [ 12, 236 ], "than": [ 13, 244 ], "long-acting": [ 14, 50 ], "GLP-1": [ 15, 52, 197, 230, 267 ], "RAs.": [ 16, 53, 198, 231, 268 ], "Delayed": [ 17 ], "is": [ 20 ], "a": [ 21, 70, 235 ], "risk": [ 22 ], "factor": [ 23 ], "for": [ 24, 165, 194 ], "gastroesophageal": [ 25, 177 ], "reflux": [ 26, 33, 84, 153, 178, 255 ], "disease.": [ 27 ], "We": [ 28 ], "aimed": [ 29 ], "to": [ 30, 69, 262 ], "measure": [ 31 ], "esophageal": [ 32, 208, 212, 254 ], "and": [ 34, 41, 49, 105, 134, 167, 210 ], "function": [ 35, 214 ], "as": [ 36, 38 ], "well": [ 37 ], "acid": [ 42, 102, 107, 259 ], "secretion": [ 43, 108, 260 ], "during": [ 44, 86 ], "treatment": [ 45, 72 ], "with": [ 46, 63, 73, 129, 140, 191, 228 ], "short-acting": [ 47 ], "(lixisenatide)": [ 48 ], "(liraglutide)": [ 51 ], "RESEARCH": [ 54 ], "DESIGN": [ 55 ], "AND": [ 56 ], "METHODS": [ 57 ], "A": [ 58 ], "total": [ 59 ], "of": [ 60, 83, 152, 176, 207 ], "57": [ 61 ], "subjects": [ 62 ], "type": [ 64 ], "2": [ 65 ], "diabetes": [ 66 ], "were": [ 67, 113, 215 ], "randomized": [ 68 ], "10-week": [ 71 ], "lixisenatide": [ 74, 130, 166, 247 ], "or": [ 75, 173, 256 ], "liraglutide.": [ 76, 245 ], "Changes": [ 77 ], "from": [ 78, 202 ], "baseline": [ 79, 203 ], "in": [ 80, 90, 149, 204 ], "the": [ 81, 91, 150, 174, 195, 229 ], "number": [ 82, 151 ], "episodes": [ 85, 154 ], "24-h": [ 87 ], "pH": [ 88 ], "registration": [ 89 ], "lower": [ 92, 94, 211 ], "esophagus,": [ 93 ], "esophagus": [ 95 ], "sphincter": [ 96, 213 ], "pressure,": [ 97 ], "(13C-sodium": [ 100 ], "octanoate": [ 101 ], "breath": [ 103, 111 ], "test),": [ 104 ], "(13C-calcium": [ 109 ], "carbonate": [ 110 ], "test)": [ 112 ], "analyzed.": [ 114 ], "RESULTS": [ 115 ], "Gastric": [ 116, 217, 258 ], "half-time": [ 118 ], "was": [ 119, 146 ], "delayed": [ 120 ], "by": [ 121, 135, 221, 266 ], "52": [ 122 ], "min": [ 123, 137 ], "(\u0394": [ 124 ], "95%": [ 125 ], "CI": [ 126 ], "16,": [ 127 ], "88)": [ 128 ], "(P": [ 131, 142, 225 ], "=": [ 132, 143, 171, 189, 226 ], "0.0065)": [ 133 ], "25": [ 136 ], "(3,": [ 138 ], "46)": [ 139 ], "liraglutide": [ 141, 249 ], "0.025).": [ 144 ], "There": [ 145 ], "no": [ 147 ], "difference": [ 148 ], "(mean": [ 155 ], "\u00b1": [ 156, 159, 163, 182, 186 ], "SEM": [ 157 ], "33.7": [ 158 ], "4.1": [ 160 ], "vs.": [ 161, 184 ], "40.1": [ 162 ], "5.3": [ 164 ], "liraglutide,": [ 168 ], "respectively,": [ 169 ], "P": [ 170, 188 ], "0.17)": [ 172 ], "extent": [ 175 ], "(DeMeester": [ 179 ], "score)": [ 180 ], "(35.1": [ 181 ], "6.7": [ 183 ], "39.7": [ 185 ], "7.5,": [ 187 ], "0.61),": [ 190 ], "similar": [ 192 ], "results": [ 193 ], "individual": [ 196 ], "No": [ 199 ], "significant": [ 200, 251 ], "changes": [ 201 ], "other": [ 205 ], "parameters": [ 206 ], "motility": [ 209 ], "observed.": [ 216 ], "acidity": [ 218 ], "decreased": [ 219 ], "significantly": [ 220 ], "\u221220.7%": [ 222 ], "(\u221240.6,": [ 223 ], "\u22120.8)": [ 224 ], "0.042)": [ 227 ], "CONCLUSIONS": [ 232 ], "Lixisenatide": [ 233 ], "exerted": [ 234 ], "pronounced": [ 237 ], "influence": [ 238 ], "on": [ 239, 253 ], "after": [ 242 ], "breakfast": [ 243 ], "Neither": [ 246 ], "nor": [ 248 ], "had": [ 250 ], "effects": [ 252 ], "motility.": [ 257 ], "appears": [ 261 ], "be": [ 263 ], "slightly": [ 264 ], "reduced": [ 265 ] }, "publication_date": "2020-07-09", "publication_year": 2020, "type": "article", "cited_by_count": 50, "authors": [ { "id": "https://openalex.org/A5091130352", "display_name": "Daniel R. Quast" }, { "id": "https://openalex.org/A5023745586", "display_name": "Nina Schenker" }, { "id": "https://openalex.org/A5111907741", "display_name": "Bj\u00f6rn A. Menge" }, { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5068619321", "display_name": "Christoph Kapitza" }, { "id": "https://openalex.org/A5002832666", "display_name": "Juris J. Meier" } ] }, { "id": "https://openalex.org/W2030872041", "doi": "https://doi.org/10.1371/journal.pone.0012734", "title": "Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist", "abstract": { "GLP-1": [ 0, 9, 31, 38, 188, 197 ], "has": [ 1, 152 ], "a": [ 2, 29, 75, 111, 138, 195 ], "variety": [ 3 ], "of": [ 4, 15, 37, 158, 171 ], "anti-diabetic": [ 5 ], "effects.": [ 6 ], "However,": [ 7 ], "native": [ 8, 187 ], "is": [ 10 ], "not": [ 11 ], "suitable": [ 12 ], "for": [ 13, 113 ], "therapy": [ 14 ], "diabetes": [ 16, 172, 178 ], "due": [ 17 ], "to": [ 18, 55, 164 ], "its": [ 19 ], "short": [ 20 ], "half-life": [ 21 ], "(t1/2<2": [ 22 ], "min).": [ 23 ], "To": [ 24 ], "circumvent": [ 25 ], "this,": [ 26 ], "we": [ 27 ], "developed": [ 28 ], "long-lasting": [ 30, 153, 183 ], "receptor": [ 32, 45, 198 ], "agonist": [ 33 ], "by": [ 34, 71 ], "the": [ 35, 56, 101, 156, 169, 182 ], "fusion": [ 36, 150 ], "with": [ 39, 97 ], "human": [ 40 ], "IgG2": [ 41 ], "Fc": [ 42 ], "(GLP-1/hIgG2).": [ 43 ], "ELISA-based": [ 44 ], "binding": [ 46, 53 ], "assay": [ 47 ], "demonstrated": [ 48 ], "that": [ 49, 81, 96, 124, 148 ], "GLP-1/hIgG2": [ 50, 67, 102, 125, 149, 161, 185 ], "had": [ 51 ], "high": [ 52 ], "affinity": [ 54 ], "GLP-1R": [ 57 ], "in": [ 58, 74, 92, 107, 121, 167, 173, 179 ], "INS-1": [ 59, 72, 88 ], "cells": [ 60, 73 ], "(Kd": [ 61 ], "=": [ 62 ], "13.90\u00b11.52": [ 63 ], "nM).": [ 64 ], "Upon": [ 65 ], "binding,": [ 66 ], "was": [ 68, 162 ], "rapidly": [ 69 ], "internalized": [ 70 ], "dynamin-dependent": [ 76 ], "manner.": [ 77 ], "Insulin": [ 78 ], "RIA": [ 79 ], "showed": [ 80, 95, 123 ], "GLP-1/IgG2": [ 82 ], "dose-dependently": [ 83 ], "stimulated": [ 84 ], "insulin": [ 85 ], "secretion": [ 86 ], "from": [ 87 ], "cells.": [ 89 ], "Pharmacokinetic": [ 90 ], "studies": [ 91 ], "CD1": [ 93 ], "mice": [ 94, 122, 134 ], "intraperitoneal": [ 98 ], "injection": [ 99 ], "(i.p.),": [ 100 ], "peaked": [ 103 ], "at": [ 104 ], "30": [ 105 ], "minutes": [ 106 ], "circulation": [ 108 ], "and": [ 109, 190 ], "maintained": [ 110 ], "plateau": [ 112 ], ">168": [ 114 ], "h.": [ 115 ], "Intraperitoneal": [ 116 ], "glucose": [ 117, 128, 145, 159 ], "tolerance": [ 118 ], "test": [ 119 ], "(IPGTT)": [ 120 ], "significantly": [ 126, 143 ], "decreased": [ 127 ], "excursion.": [ 129 ], "Furthermore,": [ 130 ], "IPGTT": [ 131 ], "performed": [ 132 ], "on": [ 133, 155 ], "one": [ 135 ], "week": [ 136 ], "after": [ 137 ], "single": [ 139 ], "drug-injection": [ 140 ], "also": [ 141 ], "displayed": [ 142 ], "reduced": [ 144 ], "excursion,": [ 146 ], "indicating": [ 147 ], "protein": [ 151 ], "effects": [ 154 ], "modulation": [ 157 ], "homeostasis.": [ 160 ], "found": [ 163 ], "be": [ 165 ], "effective": [ 166 ], "reducing": [ 168 ], "incidence": [ 170 ], "multiple-low-dose": [ 174 ], "streptozotocin-induced": [ 175 ], "type": [ 176 ], "1": [ 177 ], "mice.": [ 180 ], "Together,": [ 181 ], "bioactive": [ 184 ], "retains": [ 186 ], "activities": [ 189 ], "thus": [ 191 ], "may": [ 192 ], "serve": [ 193 ], "as": [ 194 ], "potent": [ 196 ], "agonist.": [ 199 ] }, "publication_date": "2010-09-15", "publication_year": 2010, "type": "article", "cited_by_count": 45, "authors": [ { "id": "https://openalex.org/A5100432301", "display_name": "Qinghua Wang" }, { "id": "https://openalex.org/A5100682687", "display_name": "Kui Chen" }, { "id": "https://openalex.org/A5100448594", "display_name": "Rui Liu" }, { "id": "https://openalex.org/A5101687692", "display_name": "Fang Zhao" }, { "id": "https://openalex.org/A5103011210", "display_name": "Sandeep Gupta" }, { "id": "https://openalex.org/A5072127164", "display_name": "Nina Zhang" }, { "id": "https://openalex.org/A5032149753", "display_name": "G\u00e9rald J. Prud\u2019homme" } ] }, { "id": "https://openalex.org/W2886532433", "doi": "https://doi.org/10.1152/ajprenal.00211.2018", "title": "GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side", "abstract": { "Diabetic": [ 0 ], "kidney": [ 1, 21, 25, 97 ], "disease": [ 2, 22, 26 ], "(DKD),": [ 3 ], "one": [ 4 ], "of": [ 5, 13, 19, 31, 49, 58, 67, 96 ], "the": [ 6, 16, 29 ], "most": [ 7 ], "common": [ 8 ], "and": [ 9, 23, 70, 76, 91 ], "severe": [ 10 ], "microvascular": [ 11 ], "complications": [ 12 ], "diabetes,": [ 14 ], "is": [ 15 ], "leading": [ 17 ], "cause": [ 18 ], "chronic": [ 20 ], "end-stage": [ 24 ], "worldwide.": [ 27 ], "Since": [ 28 ], "development": [ 30 ], "renin-angiotensin": [ 32 ], "system": [ 33 ], "inhibition": [ 34 ], "nearly": [ 35 ], "three": [ 36 ], "decades": [ 37 ], "ago,": [ 38 ], "no": [ 39 ], "new": [ 40 ], "therapeutic": [ 41 ], "agents": [ 42 ], "have": [ 43, 62 ], "received": [ 44 ], "regulatory": [ 45 ], "approval": [ 46 ], "for": [ 47, 65, 94 ], "treatment": [ 48 ], "DKD.": [ 50 ], "Glucagon-like": [ 51 ], "peptide-1": [ 52 ], "(GLP-1)": [ 53 ], "receptor": [ 54 ], "agonists,": [ 55 ], "a": [ 56 ], "class": [ 57 ], "newer": [ 59 ], "antihyperglycemic": [ 60 ], "agents,": [ 61 ], "shown": [ 63 ], "promise": [ 64 ], "prevention": [ 66 ], "DKD": [ 68 ], "onset": [ 69 ], "progression.": [ 71 ], "This": [ 72 ], "perspective": [ 73 ], "summarizes": [ 74 ], "clinical": [ 75 ], "experimental": [ 77 ], "observations": [ 78 ], "to": [ 79 ], "give": [ 80 ], "insight": [ 81 ], "into": [ 82 ], "biological": [ 83 ], "mechanisms": [ 84 ], "beyond": [ 85 ], "glycemic": [ 86 ], "control,": [ 87 ], "such": [ 88 ], "as": [ 89 ], "natriuresis": [ 90 ], "anti-inflammatory": [ 92 ], "actions,": [ 93 ], "preservation": [ 95 ], "function": [ 98 ], "in": [ 99 ], "patients": [ 100 ], "with": [ 101 ], "diabetes.": [ 102 ] }, "publication_date": "2018-08-15", "publication_year": 2018, "type": "review", "cited_by_count": 37, "authors": [ { "id": "https://openalex.org/A5067167930", "display_name": "Brad P. Dieter" }, { "id": "https://openalex.org/A5005596615", "display_name": "Radica Z. Alicic" }, { "id": "https://openalex.org/A5046793050", "display_name": "Katherine R. Tuttle" } ] }, { "id": "https://openalex.org/W2022271042", "doi": "https://doi.org/10.1111/j.1463-1326.2009.01158.x", "title": "Weight loss with liraglutide, a once\u2010daily human glucagon\u2010like peptide\u20101 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue", "abstract": { "Aim": [ 0 ], ":": [ 1, 31, 130, 222 ], "The": [ 2 ], "effect": [ 3 ], "on": [ 4 ], "body": [ 5, 57, 111 ], "composition": [ 6 ], "of": [ 7, 38 ], "liraglutide,": [ 8 ], "a": [ 9 ], "once\u2010daily": [ 10 ], "human": [ 11 ], "glucagon\u2010like": [ 12 ], "peptide\u20101": [ 13 ], "analogue,": [ 14 ], "as": [ 15 ], "monotherapy": [ 16, 210 ], "or": [ 17, 81, 85, 102, 225 ], "added": [ 18, 226 ], "to": [ 19, 77, 98, 227 ], "metformin": [ 20, 92 ], "was": [ 21, 140 ], "examined": [ 22 ], "in": [ 23, 44, 95, 106, 162, 202, 238 ], "patients": [ 24, 239 ], "with": [ 25, 52, 91, 134, 167, 178, 185, 191, 208, 216, 240 ], "type": [ 26 ], "2": [ 27, 63, 67 ], "diabetes": [ 28 ], "(T2D).": [ 29 ], "Methods": [ 30 ], "These": [ 32 ], "were": [ 33, 72, 75, 118, 127, 158, 172, 211 ], "randomized,": [ 34 ], "double\u2010blind,": [ 35 ], "parallel\u2010group": [ 36 ], "trials": [ 37 ], "26": [ 39 ], "[Liraglutide": [ 40 ], "Effect": [ 41 ], "and": [ 42, 47, 69, 97, 115, 124, 137, 153, 205, 233 ], "Action": [ 43 ], "Diabetes\u20102": [ 45 ], "(LEAD\u20102)]": [ 46 ], "52": [ 48 ], "weeks": [ 49 ], "(LEAD\u20103).": [ 50 ], "Patients": [ 51, 74 ], "T2D,": [ 53 ], "aged": [ 54 ], "18\u201380": [ 55 ], "years,": [ 56 ], "mass": [ 58, 204, 232 ], "index": [ 59 ], "(BMI)": [ 60 ], "\u226440": [ 61 ], "kg/m": [ 62, 66 ], "(LEAD\u20102),": [ 64 ], "\u226445": [ 65 ], "(LEAD\u20103)": [ 68 ], "HbA1c": [ 70 ], "7.0\u201311.0%": [ 71 ], "included.": [ 73 ], "randomized": [ 76 ], "liraglutide": [ 78, 99, 135, 168, 192, 209 ], "1.8,": [ 79, 100 ], "1.2": [ 80, 101, 136 ], "0.6": [ 82, 169 ], "mg/day,": [ 83, 88 ], "placebo": [ 84 ], "glimepiride": [ 86, 103, 179, 217, 237 ], "4": [ 87 ], "all": [ 89, 163 ], "combined": [ 90 ], "1.5\u20132": [ 93 ], "g/day": [ 94 ], "LEAD\u20102": [ 96 ], "8": [ 104 ], "mg/day": [ 105 ], "LEAD\u20103.": [ 107 ], "LEAD\u20102/3:": [ 108 ], "total": [ 109 ], "lean": [ 110 ], "tissue,": [ 112 ], "fat": [ 113, 116, 132, 203, 206, 231, 234 ], "tissue": [ 114, 122, 156 ], "percentage": [ 117, 133, 207, 235 ], "measured.": [ 119 ], "LEAD\u20102:": [ 120, 131 ], "adipose": [ 121, 155 ], "area": [ 123 ], "hepatic": [ 125, 198 ], "steatosis": [ 126 ], "assessed.": [ 128 ], "Results": [ 129 ], "1.8": [ 138, 193 ], "mg/metformin": [ 139, 194 ], "significantly": [ 141, 173, 212, 229 ], "reduced": [ 142, 159, 197, 230 ], "vs.": [ 143, 150, 175, 214, 236 ], "glimepiride/metformin": [ 144 ], "(p": [ 145, 180, 218 ], "<": [ 146, 181, 219 ], "0.05)": [ 147, 182 ], "but": [ 148, 183 ], "not": [ 149, 184 ], "placebo.": [ 151, 186 ], "Visceral": [ 152 ], "subcutaneous": [ 154 ], "areas": [ 157 ], "from": [ 160 ], "baseline": [ 161 ], "liraglutide/metformin": [ 164 ], "arms.": [ 165 ], "Except": [ 166 ], "mg/metformin,": [ 170 ], "reductions": [ 171, 201 ], "different": [ 174, 213 ], "changes": [ 176 ], "seen": [ 177 ], "Liver\u2010to\u2010spleen": [ 187 ], "attenuation": [ 188 ], "ratio": [ 189 ], "increased": [ 190 ], "possibly": [ 195 ], "indicating": [ 196 ], "steatosis.": [ 199 ], "LEAD\u20103:": [ 200 ], "increases": [ 215 ], "0.01).": [ 220 ], "Conclusion": [ 221 ], "Liraglutide": [ 223 ], "(monotherapy": [ 224 ], "metformin)": [ 228 ], "T2D.": [ 241 ] }, "publication_date": "2009-09-22", "publication_year": 2009, "type": "article", "cited_by_count": 294, "authors": [ { "id": "https://openalex.org/A5073354239", "display_name": "Johan Jendle" }, { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5011127007", "display_name": "David R. Matthews" }, { "id": "https://openalex.org/A5054017533", "display_name": "Anders Frid" }, { "id": "https://openalex.org/A5088641715", "display_name": "Kjeld Hermansen" }, { "id": "https://openalex.org/A5078549507", "display_name": "Maria D\u00fcring" }, { "id": "https://openalex.org/A5059007137", "display_name": "Marija Zdravkovi\u0107" }, { "id": "https://openalex.org/A5046704389", "display_name": "Boyd J. Strauss" }, { "id": "https://openalex.org/A5111569181", "display_name": "A. J. Garber" } ] }, { "id": "https://openalex.org/W4390544908", "doi": "https://doi.org/10.1038/s41591-023-02669-x", "title": "Inequalities in the provision of GLP-1 receptor agonists for the treatment of obesity", "abstract": null, "publication_date": "2024-01-01", "publication_year": 2024, "type": "article", "cited_by_count": 29, "authors": [ { "id": "https://openalex.org/A5054871611", "display_name": "Stephanie Waldrop" }, { "id": "https://openalex.org/A5087500698", "display_name": "Veronica R. Johnson" }, { "id": "https://openalex.org/A5015963587", "display_name": "Fatima Cody Stanford" } ] }, { "id": "https://openalex.org/W2211791999", "doi": "https://doi.org/10.1007/s13300-015-0149-4", "title": "Non-Persistence and Non-Adherence of Patients with Type 2 Diabetes Mellitus in Therapy with GLP-1 Receptor Agonists: A Retrospective Analysis", "abstract": { "NP": [ 0 ], "and": [ 1, 12, 32 ], "NA": [ 2 ], "to": [ 3, 15, 19, 25 ], "treatment": [ 4, 21, 27 ], "with": [ 5 ], "GLP-1": [ 6 ], "receptor": [ 7 ], "agonists": [ 8 ], "in": [ 9, 28 ], "both": [ 10, 29 ], "UK": [ 11, 31 ], "Germany": [ 13 ], "appear": [ 14 ], "be": [ 16 ], "similar.": [ 17 ], "Persistence": [ 18 ], "OD": [ 20 ], "is": [ 22 ], "higher": [ 23 ], "than": [ 24 ], "BID": [ 26 ], "the": [ 30 ], "Germany.": [ 33 ] }, "publication_date": "2015-12-22", "publication_year": 2015, "type": "article", "cited_by_count": 38, "authors": [ { "id": "https://openalex.org/A5059506644", "display_name": "Thomas Wilke" }, { "id": "https://openalex.org/A5101541634", "display_name": "S. Mueller" }, { "id": "https://openalex.org/A5038236778", "display_name": "A. Groth" }, { "id": "https://openalex.org/A5102170968", "display_name": "Bjoern Berg" }, { "id": "https://openalex.org/A5064659899", "display_name": "Andreas Fuchs" }, { "id": "https://openalex.org/A5081383670", "display_name": "Mirko Sikirica" }, { "id": "https://openalex.org/A5108564409", "display_name": "John Logie" }, { "id": "https://openalex.org/A5026383766", "display_name": "Alan Martin" }, { "id": "https://openalex.org/A5086048816", "display_name": "Ulf Maywald" } ] }, { "id": "https://openalex.org/W1755903692", "doi": "https://doi.org/10.1111/j.1742-1241.2010.02499.x", "title": "Liraglutide: the therapeutic promise from animal models", "abstract": { "The": [ 0 ], "therapeutic": [ 1 ], "promise": [ 2 ], "of": [ 3, 23, 71 ], "liraglutide": [ 4, 62 ], "is": [ 5 ], "evident": [ 6 ], "from": [ 7 ], "preclinical": [ 8 ], "data.": [ 9 ], "Liraglutide": [ 10 ], "showed": [ 11, 63 ], "the": [ 12, 21, 64, 68, 76 ], "potential": [ 13, 65 ], "to": [ 14, 34, 66 ], "provide": [ 15 ], "good": [ 16 ], "glycaemic": [ 17, 80 ], "control": [ 18, 81 ], "without": [ 19 ], "increasing": [ 20 ], "risk": [ 22 ], "hypoglycaemia": [ 24 ], "and,": [ 25 ], "as": [ 26 ], "with": [ 27, 58, 84 ], "exenatide,": [ 28 ], "but": [ 29, 100 ], "not": [ 30 ], "dipeptidyl": [ 31 ], "peptidase-4": [ 32 ], "inhibitors,": [ 33 ], "mediate": [ 35 ], "weight": [ 36, 89, 111 ], "loss.": [ 37, 112 ], "Although": [ 38 ], "these": [ 39 ], "benefits": [ 40 ], "have": [ 41 ], "subsequently": [ 42 ], "been": [ 43 ], "studied": [ 44, 51 ], "clinically,": [ 45 ], "beta-cell": [ 46, 72 ], "mass": [ 47 ], "can": [ 48 ], "be": [ 49 ], "directly": [ 50 ], "only": [ 52 ], "in": [ 53, 79, 82 ], "animal": [ 54 ], "models.": [ 55 ], "In": [ 56 ], "common": [ 57 ], "other": [ 59 ], "incretin-based": [ 60 ], "therapies,": [ 61 ], "modulate": [ 67 ], "progressive": [ 69 ], "loss": [ 70 ], "function": [ 73 ], "that": [ 74 ], "drives": [ 75 ], "continuing": [ 77 ], "deterioration": [ 78 ], "patients": [ 83 ], "type": [ 85 ], "2": [ 86 ], "diabetes.": [ 87 ], "Body": [ 88 ], "was": [ 90 ], "lowered": [ 91, 97 ], "by": [ 92 ], "a": [ 93 ], "mechanism": [ 94 ], "involving": [ 95 ], "mainly": [ 96 ], "energy": [ 98, 108 ], "intake,": [ 99 ], "also": [ 101 ], "potentially": [ 102 ], "altered": [ 103 ], "food": [ 104 ], "preference": [ 105 ], "and": [ 106 ], "maintained": [ 107 ], "expenditure": [ 109 ], "despite": [ 110 ] }, "publication_date": "2010-09-23", "publication_year": 2010, "type": "review", "cited_by_count": 94, "authors": [ { "id": "https://openalex.org/A5088627727", "display_name": "Lotte Bjerre Knudsen" } ] }, { "id": "https://openalex.org/W4309614066", "doi": "https://doi.org/10.3389/fendo.2022.1033479", "title": "The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer\u2019s disease", "abstract": { "Since": [ 0 ], "type": [ 1 ], "2": [ 2 ], "diabetes": [ 3 ], "mellitus": [ 4 ], "(T2DM)": [ 5 ], "is": [ 6 ], "a": [ 7, 80 ], "risk": [ 8 ], "factor": [ 9 ], "for": [ 10, 83 ], "Alzheimer\u2019s": [ 11 ], "disease": [ 12 ], "(AD)": [ 13 ], "and": [ 14, 53, 63, 71, 109 ], "both": [ 15 ], "have": [ 16, 28, 54, 60 ], "the": [ 17, 34, 84, 103, 107 ], "same": [ 18 ], "pathogenesis": [ 19 ], "(e.g.,": [ 20 ], "insulin": [ 21 ], "resistance),": [ 22 ], "drugs": [ 23 ], "used": [ 24 ], "to": [ 25, 32, 91, 101 ], "treat": [ 26 ], "T2DM": [ 27 ], "been": [ 29 ], "gradually": [ 30 ], "found": [ 31 ], "reduce": [ 33 ], "progression": [ 35 ], "of": [ 36, 86, 111 ], "AD": [ 37, 39, 75 ], "in": [ 38, 74, 114 ], "models.": [ 40 ], "Of": [ 41 ], "these": [ 42 ], "drugs,": [ 43 ], "glucagon-like": [ 44 ], "peptide": [ 45 ], "1": [ 46 ], "receptor": [ 47 ], "(GLP-1R)": [ 48 ], "agonists": [ 49, 59, 113 ], "are": [ 50 ], "more": [ 51 ], "effective": [ 52 ], "fewer": [ 55 ], "side": [ 56 ], "effects.": [ 57 ], "GLP-1R": [ 58, 112 ], "reducing": [ 61 ], "neuroinflammation": [ 62 ], "oxidative": [ 64 ], "stress,": [ 65 ], "neurotrophic": [ 66 ], "effects,": [ 67 ], "decreasing": [ 68 ], "A\u03b2": [ 69 ], "deposition": [ 70 ], "tau": [ 72 ], "hyperphosphorylation": [ 73 ], "models,": [ 76 ], "which": [ 77 ], "may": [ 78 ], "be": [ 79, 92 ], "potential": [ 81 ], "drug": [ 82 ], "treatment": [ 85 ], "AD.": [ 87, 115 ], "However,": [ 88 ], "this": [ 89 ], "needs": [ 90 ], "verified": [ 93 ], "by": [ 94 ], "further": [ 95 ], "clinical": [ 96 ], "trials.": [ 97 ], "This": [ 98 ], "study": [ 99 ], "aims": [ 100 ], "summarize": [ 102 ], "current": [ 104 ], "information": [ 105 ], "on": [ 106 ], "mechanisms": [ 108 ], "effects": [ 110 ] }, "publication_date": "2022-11-17", "publication_year": 2022, "type": "review", "cited_by_count": 87, "authors": [ { "id": "https://openalex.org/A5100963137", "display_name": "Haiyang Du" }, { "id": "https://openalex.org/A5013293043", "display_name": "Xiaoyu Meng" }, { "id": "https://openalex.org/A5033079800", "display_name": "Yao Yu" }, { "id": "https://openalex.org/A5100416696", "display_name": "Jun Xu" } ] }, { "id": "https://openalex.org/W1980022623", "doi": "https://doi.org/10.1161/circinterventions.112.968388", "title": "Exenatide Reduces Final Infarct Size in Patients With ST-Segment\u2013Elevation Myocardial Infarction and Short-Duration of Ischemia", "abstract": { "Background\u2014": [ 0 ], "Exenatide": [ 1 ], "has": [ 2 ], "been": [ 3 ], "demonstrated": [ 4 ], "to": [ 5, 11, 32, 40, 50, 69, 97, 149, 229 ], "be": [ 6, 286 ], "cardioprotective": [ 7, 272 ], "as": [ 8, 44, 208 ], "an": [ 9 ], "adjunct": [ 10 ], "primary": [ 12 ], "percutaneous": [ 13 ], "coronary": [ 14 ], "intervention": [ 15, 83 ], "in": [ 16, 38, 130, 204, 238, 260, 264, 274, 288 ], "patients": [ 17, 93, 118, 193, 265, 275 ], "with": [ 18, 57, 119, 127, 194, 256, 266, 276 ], "ST-segment\u2013elevation": [ 19 ], "myocardial": [ 20, 107, 169 ], "infarction": [ 21 ], "(STEMI).": [ 22 ], "The": [ 23, 92 ], "aim": [ 24 ], "of": [ 25, 36, 157, 176, 240 ], "the": [ 26, 34, 90, 158, 173, 177, 185, 192 ], "post": [ 27, 249 ], "hoc": [ 28, 250 ], "analysis": [ 29, 166 ], "study": [ 30 ], "was": [ 31, 78, 202, 219, 254, 280 ], "evaluate": [ 33 ], "effect": [ 35, 273 ], "exenatide": [ 37, 71, 128, 178, 252 ], "relation": [ 39 ], "system": [ 41, 99, 121, 195, 223, 268, 278 ], "delay,": [ 42, 269 ], "defined": [ 43 ], "time": [ 45 ], "from": [ 46 ], "first": [ 47, 51 ], "medical": [ 48 ], "contact": [ 49 ], "balloon.": [ 52 ], "Methods": [ 53 ], "and": [ 54, 59, 84, 106, 235 ], "Results\u2014": [ 55 ], "Patients": [ 56 ], "STEMI": [ 58 ], "Thrombolysis": [ 60 ], "In": [ 61, 163, 191, 247 ], "Myocardial": [ 62 ], "Infarction": [ 63 ], "flow": [ 64 ], "0/1": [ 65 ], "were": [ 66, 94, 111 ], "randomly": [ 67 ], "assigned": [ 68 ], "intravenous": [ 70 ], "or": [ 72, 213, 227 ], "placebo": [ 73, 186 ], "continuous": [ 74 ], "infusion.": [ 75 ], "Study": [ 76 ], "treatment": [ 77, 126, 236, 253 ], "commenced": [ 79 ], "15": [ 80 ], "minutes": [ 81, 124, 198 ], "before": [ 82 ], "maintained": [ 85 ], "for": [ 86, 168, 184 ], "6": [ 87 ], "hours": [ 88 ], "after": [ 89 ], "procedure.": [ 91 ], "stratified": [ 95 ], "according": [ 96 ], "median": [ 98, 230 ], "delay": [ 100, 122, 196, 224, 279 ], "(132": [ 101 ], "minutes).": [ 102 ], "Final": [ 103 ], "infarct": [ 104, 133, 205, 241, 262 ], "size": [ 105, 134, 206, 242, 263 ], "area": [ 108, 170 ], "at": [ 109, 171 ], "risk": [ 110, 172 ], "measured": [ 112 ], "by": [ 113 ], "cardiovascular": [ 114 ], "magnetic": [ 115 ], "resonance.": [ 116 ], "Among": [ 117 ], "a": [ 120, 131, 164, 257 ], "\u2264132": [ 123 ], "(n=74),": [ 125 ], "resulted": [ 129 ], "smaller": [ 132 ], "(9": [ 135 ], "grams": [ 136, 143, 209 ], "[interquartile": [ 137 ], "range": [ 138 ], "(IQR),": [ 139 ], "4\u201313]": [ 140 ], "versus": [ 141, 153, 231 ], "13": [ 142 ], "[IQR,": [ 144, 151, 155 ], "8\u201324],": [ 145 ], "P": [ 146, 161, 189, 211, 216, 244 ], "=0.008,": [ 147 ], "corresponding": [ 148 ], "8%": [ 150 ], "4\u201312]": [ 152 ], "11%": [ 154 ], "7\u201317]": [ 156 ], "left": [ 159 ], "ventricle,": [ 160 ], "=0.015).": [ 162 ], "regression": [ 165 ], "adjusting": [ 167 ], "data": [ 174 ], "points": [ 175 ], "group": [ 179, 187 ], "lay": [ 180 ], "significantly": [ 181 ], "lower": [ 182 ], "than": [ 183, 226, 233 ], "(": [ 188, 210, 215, 243 ], "=0.006).": [ 190 ], ">132": [ 197 ], "(n=74)": [ 199 ], "no": [ 200, 271 ], "difference": [ 201 ], "observed": [ 203 ], "expressed": [ 207 ], "=0.49)": [ 212 ], "percentage": [ 214 ], "=0.46).": [ 217 ], "There": [ 218 ], "significant": [ 220 ], "interaction": [ 221 ], "between": [ 222 ], "(less": [ 225 ], "equal": [ 228 ], "greater": [ 232 ], "median)": [ 234 ], "allocation": [ 237 ], "terms": [ 239 ], "=0.018).": [ 245 ], "Conclusions\u2014": [ 246 ], "this": [ 248, 283 ], "analysis,": [ 251 ], "associated": [ 255 ], "30%": [ 258 ], "decrease": [ 259 ], "final": [ 261 ], "short": [ 267 ], "whereas": [ 270 ], "long": [ 277 ], "seen.": [ 281 ], "However,": [ 282 ], "finding": [ 284 ], "must": [ 285 ], "confirmed": [ 287 ], "larger": [ 289 ], "studies.": [ 290 ], "Clinical": [ 291 ], "Trial": [ 292 ], "Registration\u2014": [ 293 ], "URL:": [ 294 ], "http://www.clinicaltrials.gov": [ 295 ], ".": [ 296 ], "Unique": [ 297 ], "identifier:": [ 298 ], "NCT00835848.": [ 299 ] }, "publication_date": "2012-04-01", "publication_year": 2012, "type": "article", "cited_by_count": 204, "authors": [ { "id": "https://openalex.org/A5112380754", "display_name": "Jacob L\u00f8nborg" }, { "id": "https://openalex.org/A5059617202", "display_name": "Henning Kelb\u00e6k" }, { "id": "https://openalex.org/A5007735550", "display_name": "Niels Vejlstrup" }, { "id": "https://openalex.org/A5004368211", "display_name": "Hans Erik B\u00f8tker" }, { "id": "https://openalex.org/A5078536482", "display_name": "Won Yong Kim" }, { "id": "https://openalex.org/A5014707937", "display_name": "Lene Holmvang" }, { "id": "https://openalex.org/A5073393275", "display_name": "Erik J\u00f8rgensen" }, { "id": "https://openalex.org/A5037020231", "display_name": "Steffen Helqvist" }, { "id": "https://openalex.org/A5085232519", "display_name": "Kari Saunam\u00e4ki" }, { "id": "https://openalex.org/A5005919344", "display_name": "Christian Juhl Terkelsen" }, { "id": "https://openalex.org/A5004532405", "display_name": "Mikkel Malby Schoos" }, { "id": "https://openalex.org/A5033436516", "display_name": "Lars K\u00f8ber" }, { "id": "https://openalex.org/A5108534869", "display_name": "Peter Clemmensen" }, { "id": "https://openalex.org/A5054169231", "display_name": "Marek Treiman" }, { "id": "https://openalex.org/A5055011899", "display_name": "Thomas Engstr\u00f8m" } ] }, { "id": "https://openalex.org/W2050324334", "doi": "https://doi.org/10.1016/j.diabres.2011.01.004", "title": "GLP-1 receptor agonists today", "abstract": null, "publication_date": "2011-07-24", "publication_year": 2011, "type": "review", "cited_by_count": 20, "authors": [ { "id": "https://openalex.org/A5088350286", "display_name": "Michel Marre" }, { "id": "https://openalex.org/A5006947224", "display_name": "A. Penfornis" } ] }, { "id": "https://openalex.org/W2027276740", "doi": "https://doi.org/10.1155/2011/215764", "title": "Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events: A Meta-Analysis of Randomized Clinical Trials", "abstract": { "Objective": [ 0 ], ".": [ 1, 44, 100, 151 ], "Data": [ 2 ], "from": [ 3 ], "randomized": [ 4, 53, 156 ], "clinical": [ 5 ], "trials": [ 6, 54, 95, 157, 174 ], "with": [ 7, 64, 78, 96 ], "metabolic": [ 8 ], "outcomes": [ 9 ], "can": [ 10 ], "be": [ 11 ], "used": [ 12 ], "to": [ 13, 33, 177 ], "address": [ 14 ], "concerns": [ 15 ], "about": [ 16 ], "potential": [ 17 ], "issues": [ 18 ], "of": [ 19, 37, 55, 102, 155, 164, 181 ], "cardiovascular": [ 20, 35, 87, 169 ], "safety": [ 21, 36 ], "for": [ 22, 25, 52, 85, 113, 128, 135 ], "newer": [ 23 ], "drugs": [ 24 ], "type": [ 26, 71 ], "2": [ 27, 72 ], "diabetes.": [ 28 ], "This": [ 29 ], "meta-analysis": [ 30 ], "was": [ 31, 83, 118 ], "designed": [ 32, 172 ], "assess": [ 34 ], "GLP-1": [ 38, 56, 115, 165 ], "receptor": [ 39, 57, 116, 166 ], "agonists.": [ 40 ], "Design": [ 41 ], "and": [ 42, 47, 124, 130, 137, 145 ], "Methods": [ 43 ], "MEDLINE,": [ 45 ], "Embase,": [ 46 ], "Cochrane": [ 48 ], "databases": [ 49 ], "were": [ 50, 141 ], "searched": [ 51 ], "agonists": [ 58, 117, 167 ], "(versus": [ 59 ], "placebo": [ 60 ], "or": [ 61 ], "other": [ 62 ], "comparators)": [ 63 ], "a": [ 65, 182 ], "duration": [ 66 ], "\u226512": [ 67 ], "weeks,": [ 68 ], "performed": [ 69 ], "in": [ 70 ], "diabetic": [ 73 ], "patients.": [ 74 ], "Mantel-Haenszel": [ 75 ], "odds": [ 76 ], "ratio": [ 77 ], "95%": [ 79 ], "confidence": [ 80 ], "interval": [ 81 ], "(MH-OR)": [ 82 ], "calculated": [ 84 ], "major": [ 86 ], "events": [ 88 ], "(MACE),": [ 89 ], "on": [ 90, 168 ], "an": [ 91 ], "intention-to-treat": [ 92 ], "basis,": [ 93 ], "excluding": [ 94 ], "zero": [ 97 ], "events.": [ 98, 170 ], "Results": [ 99 ], "Out": [ 101 ], "36": [ 103 ], "trials,": [ 104 ], "20": [ 105 ], "reported": [ 106 ], "at": [ 107 ], "least": [ 108 ], "one": [ 109 ], "MACE.": [ 110 ], "The": [ 111 ], "MH-OR": [ 112 ], "all": [ 114 ], "0.74": [ 119 ], "(0.50\u20131.08),P=.12(0.85": [ 121 ], "(0.50\u20131.45),P=.55,": [ 123 ], "0.69": [ 125 ], "(0.40\u20131.22),P=.20,": [ 127 ], "exenatide": [ 129 ], "liraglutide,": [ 131 ], "resp.).": [ 132 ], "Corresponding": [ 133 ], "figures": [ 134 ], "placebo-controlled": [ 136 ], "active": [ 138 ], "comparator": [ 139 ], "studies": [ 140 ], "0.46": [ 142 ], "(0.25\u20130.83),P=.009,": [ 144 ], "1.05": [ 146 ], "(0.63\u20131.76),P=.84,": [ 148 ], "respectively.": [ 149 ], "Conclusions": [ 150 ], "To": [ 152 ], "date,": [ 153 ], "results": [ 154 ], "do": [ 158 ], "not": [ 159 ], "suggest": [ 160 ], "any": [ 161 ], "detrimental": [ 162 ], "effect": [ 163 ], "Specifically": [ 171 ], "longer-term": [ 173 ], "are": [ 175 ], "needed": [ 176 ], "verify": [ 178 ], "the": [ 179 ], "possibility": [ 180 ], "beneficial": [ 183 ], "effect.": [ 184 ] }, "publication_date": "2011-01-01", "publication_year": 2011, "type": "review", "cited_by_count": 112, "authors": [ { "id": "https://openalex.org/A5059413618", "display_name": "Matteo Monami" }, { "id": "https://openalex.org/A5069544902", "display_name": "Francesco Cremasco" }, { "id": "https://openalex.org/A5002099366", "display_name": "Caterina Lamanna" }, { "id": "https://openalex.org/A5061641001", "display_name": "Claudia Colombi" }, { "id": "https://openalex.org/A5086703556", "display_name": "Carla Maria Desideri" }, { "id": "https://openalex.org/A5028972691", "display_name": "Iacopo Iacomelli" }, { "id": "https://openalex.org/A5068485330", "display_name": "Niccol\u00f2 Marchionni" }, { "id": "https://openalex.org/A5059685674", "display_name": "Edoardo Mannucci" } ] }, { "id": "https://openalex.org/W4404685978", "doi": "https://doi.org/10.1016/s2213-8587(24)00271-7", "title": "Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials", "abstract": null, "publication_date": "2024-11-25", "publication_year": 2024, "type": "review", "cited_by_count": 137, "authors": [ { "id": "https://openalex.org/A5075474387", "display_name": "Sunil V. Badve" }, { "id": "https://openalex.org/A5022709099", "display_name": "Anika Bilal" }, { "id": "https://openalex.org/A5061857615", "display_name": "Matthew M.Y. Lee" }, { "id": "https://openalex.org/A5078498803", "display_name": "Naveed Sattar" }, { "id": "https://openalex.org/A5024577116", "display_name": "Hertzel C. Gerstein" }, { "id": "https://openalex.org/A5016322021", "display_name": "Christian T. Ruff" }, { "id": "https://openalex.org/A5027213857", "display_name": "John J.V. McMurray" }, { "id": "https://openalex.org/A5085592050", "display_name": "Peter Rossing" }, { "id": "https://openalex.org/A5059110151", "display_name": "George Bakris" }, { "id": "https://openalex.org/A5039432822", "display_name": "Kenneth W. Mahaffey" }, { "id": "https://openalex.org/A5043842967", "display_name": "Johannes F.E. Mann" }, { "id": "https://openalex.org/A5005414020", "display_name": "Helen M. Colhoun" }, { "id": "https://openalex.org/A5046793050", "display_name": "Katherine R. Tuttle" }, { "id": "https://openalex.org/A5059098934", "display_name": "Richard E. Pratley" }, { "id": "https://openalex.org/A5108135795", "display_name": "Vlado Perkovic" } ] }, { "id": "https://openalex.org/W3097926417", "doi": "https://doi.org/10.1136/bmjdrc-2020-001706", "title": "Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events", "abstract": { "Introduction": [ 0 ], "Gastrointestinal": [ 1 ], "(GI)": [ 2 ], "adverse": [ 3 ], "events": [ 4 ], "(AEs)": [ 5 ], "are": [ 6, 127 ], "the": [ 7, 39, 49, 204, 282 ], "most": [ 8, 129 ], "common": [ 9 ], "AEs": [ 10, 28, 113, 126 ], "with": [ 11, 52, 101, 285 ], "glucagon-like": [ 12 ], "peptide-1": [ 13 ], "receptor": [ 14 ], "agonists": [ 15 ], "(GLP-1RAs).": [ 16 ], "Weight": [ 17 ], "loss": [ 18 ], "(WL)": [ 19 ], "is": [ 20, 106 ], "slightly": [ 21 ], "greater": [ 22, 50, 99 ], "in": [ 23, 70, 173, 207 ], "people": [ 24 ], "who": [ 25, 31, 161 ], "experience": [ 26 ], "GI": [ 27, 112, 125, 168, 193 ], "than": [ 29 ], "those": [ 30, 160 ], "do": [ 32 ], "not.": [ 33 ], "A": [ 34, 182 ], "previous": [ 35 ], "mediation": [ 36, 183 ], "analysis": [ 37, 93, 184 ], "of": [ 38, 46, 91, 136, 215, 226, 238, 252, 271 ], "SUSTAIN": [ 40, 71, 79, 84, 261 ], "1\u20135": [ 41 ], "trials": [ 42, 156 ], "indicated": [ 43 ], "minor": [ 44 ], "contribution": [ 45 ], "nausea/vomiting": [ 47, 109, 164, 266 ], "to": [ 48, 95, 121, 134, 199, 281 ], "WL": [ 51, 100, 186, 208, 284 ], "once-weekly": [ 53 ], "semaglutide": [ 54, 102, 286 ], "versus": [ 55, 67, 103, 287 ], "comparators.": [ 56 ], "Semaglutide": [ 57 ], "demonstrated": [ 58 ], "superior": [ 59, 283 ], "glycated": [ 60 ], "hemoglobin": [ 61 ], "and": [ 62, 83, 110, 131, 152, 180, 233, 247, 264 ], "body": [ 63 ], "weight": [ 64 ], "(BW)": [ 65 ], "reductions": [ 66 ], "other": [ 68, 104, 111, 167 ], "GLP-1RAs": [ 69, 105 ], "3": [ 72 ], "(versus": [ 73, 81 ], "exenatide": [ 74 ], "extended": [ 75 ], "release": [ 76 ], "2.0": [ 77 ], "mg),": [ 78 ], "7": [ 80, 263 ], "dulaglutide)": [ 82 ], "10": [ 85 ], "(liraglutide": [ 86 ], "1.2": [ 87 ], "mg).": [ 88 ], "The": [ 89 ], "objective": [ 90 ], "this": [ 92 ], "was": [ 94, 175 ], "assess": [ 96 ], "if": [ 97 ], "significantly": [ 98 ], "mediated": [ 107 ], "by": [ 108, 192, 267 ], "(diarrhea,": [ 114 ], "constipation,": [ 115 ], "dyspepsia)": [ 116 ], "during": [ 117 ], "dose": [ 118, 272 ], "escalation": [ 119 ], "(baseline": [ 120 ], "week": [ 122, 139, 200, 268 ], "12,": [ 123 ], "when": [ 124 ], "generally": [ 128 ], "prevalent)": [ 130 ], "from": [ 132, 171 ], "baseline": [ 133, 172, 198 ], "end": [ 135 ], "treatment": [ 137, 276 ], "(EOT:": [ 138 ], "56": [ 140 ], "(SUSTAIN": [ 141, 144, 148, 220, 245, 257 ], "3),": [ 142 ], "40": [ 143 ], "7)": [ 145, 246 ], "or": [ 146, 165, 189, 202, 212, 223, 235, 249, 274 ], "30": [ 147 ], "10)).": [ 149 ], "Research": [ 150 ], "design": [ 151 ], "methods": [ 153 ], "Subjects": [ 154 ], "within": [ 155, 177 ], "were": [ 157 ], "subdivided": [ 158 ], "into": [ 159, 187 ], "reported": [ 162 ], "(yes/no)": [ 163 ], "any": [ 166 ], "AE.": [ 169 ], "Change": [ 170 ], "BW": [ 174 ], "assessed": [ 176 ], "each": [ 178 ], "trial": [ 179 ], "subgroup.": [ 181 ], "separated": [ 185 ], "direct": [ 188 ], "indirect": [ 190 ], "(mediated": [ 191 ], "AEs)": [ 194 ], "effects.": [ 195 ], "Results": [ 196 ], "From": [ 197 ], "12": [ 201, 269 ], "EOT,": [ 203 ], "nausea/vomiting-mediated": [ 205 ], "difference": [ 206 ], "was,": [ 209 ], "respectively:": [ 210 ], "0.05": [ 211, 248 ], "0.09": [ 213, 250 ], "kg": [ 214, 217, 225, 228, 237, 240, 251, 254 ], "3.78": [ 216 ], "at": [ 218, 229, 241, 255, 290 ], "EOT": [ 219, 230, 242, 256 ], "3);": [ 221 ], "0.06": [ 222 ], "0.03": [ 224 ], "2.26": [ 227 ], "(low-dose": [ 231 ], "comparison)": [ 232, 244 ], "0.08": [ 234 ], "0.04": [ 236 ], "3.55": [ 239 ], "(high-dose": [ 243 ], "3.82": [ 253 ], "10).": [ 258 ], "Conclusions": [ 259 ], "In": [ 260 ], "3,": [ 262 ], "10,": [ 265 ], "(end": [ 270 ], "escalation)": [ 273 ], "throughout": [ 275 ], "contributed": [ 277 ], "minimally": [ 278 ], "(<0.1": [ 279 ], "kg)": [ 280 ], "GLP-1RA": [ 288 ], "comparators": [ 289 ], "EOT.": [ 291 ] }, "publication_date": "2020-10-01", "publication_year": 2020, "type": "article", "cited_by_count": 73, "authors": [ { "id": "https://openalex.org/A5001655356", "display_name": "Ildiko Lingvay" }, { "id": "https://openalex.org/A5109185807", "display_name": "Thomas K. Hansen" }, { "id": "https://openalex.org/A5034071515", "display_name": "Stanislava Macura" }, { "id": "https://openalex.org/A5088350286", "display_name": "Michel Marre" }, { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5109361288", "display_name": "Raymond de la Rosa" }, { "id": "https://openalex.org/A5032297044", "display_name": "Vincent Woo" }, { "id": "https://openalex.org/A5102201296", "display_name": "Emre Y\u0131ld\u0131r\u0131m" }, { "id": "https://openalex.org/A5047195042", "display_name": "John Wilding" } ] }, { "id": "https://openalex.org/W4390616108", "doi": "https://doi.org/10.1038/s41591-023-02672-2", "title": "Association of semaglutide with risk of suicidal ideation in a real-world cohort", "abstract": null, "publication_date": "2024-01-01", "publication_year": 2024, "type": "article", "cited_by_count": 172, "authors": [ { "id": "https://openalex.org/A5100702491", "display_name": "William Wang" }, { "id": "https://openalex.org/A5002969658", "display_name": "Nora D. Volkow" }, { "id": "https://openalex.org/A5037635525", "display_name": "Nathan A. Berger" }, { "id": "https://openalex.org/A5021719854", "display_name": "Pamela B. Davis" }, { "id": "https://openalex.org/A5075366571", "display_name": "David C. Kaelber" }, { "id": "https://openalex.org/A5050134236", "display_name": "Rong Xu" } ] }, { "id": "https://openalex.org/W1978470174", "doi": "https://doi.org/10.1007/s11892-013-0404-x", "title": "Rationale Use of GLP-1 Receptor Agonists in Patients with Type 1 Diabetes", "abstract": null, "publication_date": "2013-08-16", "publication_year": 2013, "type": "review", "cited_by_count": 29, "authors": [ { "id": "https://openalex.org/A5019608933", "display_name": "Jeff Unger" } ] }, { "id": "https://openalex.org/W4402513654", "doi": "https://doi.org/10.1001/jamanetworkopen.2024.33326", "title": "One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice", "abstract": { "Importance": [ 0 ], "Limited": [ 1 ], "data": [ 2 ], "are": [ 3 ], "available": [ 4 ], "on": [ 5, 397 ], "long-term": [ 6, 411 ], "weight": [ 7, 27, 42, 84, 136, 140, 190, 353, 371 ], "loss": [ 8, 28 ], "achieved": [ 9, 29 ], "with": [ 10, 30, 41, 76, 101, 198, 203, 229, 248, 258, 347, 369, 378 ], "semaglutide": [ 11, 34, 102, 123, 171, 184, 199, 273 ], "or": [ 12, 19, 35, 46, 103, 124, 129, 144, 309, 351 ], "liraglutide": [ 13, 36, 104, 125, 175, 179, 204, 275 ], "for": [ 14, 127, 172, 176, 180, 185, 211, 220, 401 ], "type": [ 15 ], "2": [ 16 ], "diabetes": [ 17 ], "(T2D)": [ 18 ], "obesity": [ 20, 221, 284 ], "in": [ 21, 69, 85, 91 ], "clinical": [ 22 ], "practice.": [ 23 ], "Objective": [ 24 ], "To": [ 25 ], "document": [ 26 ], "injectable": [ 31 ], "forms": [ 32, 121 ], "of": [ 33, 44, 94, 122, 142, 152, 237, 327, 366, 403 ], "and": [ 37, 53, 71, 109, 133, 138, 182, 226, 255, 337, 359, 390, 406 ], "identify": [ 38 ], "factors": [ 39 ], "associated": [ 40, 346, 377 ], "reduction": [ 43, 141, 354, 372 ], "10%": [ 45, 143, 350 ], "greater": [ 47, 145, 352 ], "at": [ 48, 95, 146, 192, 242, 355, 373, 409 ], "1": [ 49, 147, 193, 243, 374 ], "year.": [ 50, 148 ], "Design,": [ 51 ], "Setting,": [ 52 ], "Participants": [ 54, 73 ], "This": [ 55 ], "retrospective": [ 56, 363 ], "cohort": [ 57, 364 ], "study": [ 58, 365 ], "used": [ 59 ], "electronic": [ 60 ], "health": [ 61, 67 ], "records": [ 62 ], "from": [ 63 ], "a": [ 64, 77, 214, 234, 286, 349 ], "large,": [ 65 ], "integrated": [ 66 ], "system": [ 68 ], "Ohio": [ 70 ], "Florida.": [ 72 ], "included": [ 74 ], "adults": [ 75 ], "body": [ 78 ], "mass": [ 79 ], "index": [ 80 ], "(calculated": [ 81 ], "as": [ 82, 213, 285 ], "the": [ 83, 89, 270, 317, 328, 379, 399 ], "kilograms": [ 86 ], "divided": [ 87 ], "by": [ 88 ], "height": [ 90 ], "meters": [ 92 ], "squared)": [ 93 ], "least": [ 96 ], "30.0": [ 97 ], "who": [ 98 ], "initiated": [ 99 ], "treatment": [ 100, 215, 287, 385 ], "between": [ 105 ], "July": [ 106, 116 ], "1,": [ 107 ], "2015,": [ 108 ], "June": [ 110 ], "30,": [ 111 ], "2022.": [ 112 ], "Follow-up": [ 113 ], "was": [ 114, 195, 376 ], "completed": [ 115 ], "28,": [ 117 ], "2023.": [ 118 ], "Exposure": [ 119 ], "Injectable": [ 120 ], "approved": [ 126 ], "T2D": [ 128, 212, 290 ], "obesity.": [ 130, 186 ], "Main": [ 131 ], "Outcomes": [ 132 ], "Measures": [ 134 ], "Percentage": [ 135 ], "change": [ 137, 191 ], "categorical": [ 139 ], "Results": [ 149 ], "A": [ 150 ], "total": [ 151 ], "3389": [ 153, 367 ], "patients": [ 154, 169, 368 ], "(mean": [ 155 ], "[SD]": [ 156 ], "age,": [ 157 ], "50.4": [ 158 ], "[12.2]": [ 159 ], "years;": [ 160 ], "1835": [ 161 ], "[54.7%]": [ 162 ], "female)": [ 163 ], "were": [ 164, 345 ], "identified.": [ 165 ], "Of": [ 166 ], "these,": [ 167 ], "1341": [ 168 ], "received": [ 170 ], "T2D;": [ 173, 177 ], "1444,": [ 174 ], "227,": [ 178 ], "obesity;": [ 181 ], "377,": [ 183 ], "Mean": [ 187 ], "(SD)": [ 188 ], "percentage": [ 189 ], "year": [ 194, 244, 319, 356, 375 ], "\u22125.1%": [ 196 ], "(7.8%)": [ 197 ], "vs": [ 200, 217, 245, 274, 289, 299, 330 ], "\u22122.2%": [ 201 ], "(6.4%)": [ 202 ], "(": [ 205, 222, 265 ], "P": [ 206, 223, 266 ], "&amp;lt;": [ 207, 224, 267 ], ".001);": [ 208, 225 ], "\u22123.2%": [ 209 ], "(6.8%)": [ 210 ], "indication": [ 216, 288 ], "\u22125.9%": [ 218 ], "(9.0%)": [ 219 ], "\u22125.5%": [ 227 ], "(7.5%)": [ 228 ], "persistent": [ 230, 296, 387, 412 ], "medication": [ 231, 252, 262, 297, 301, 313, 329, 388, 404 ], "coverage": [ 232, 253, 263, 298, 302, 314 ], "(ie,": [ 233 ], "cumulative": [ 235 ], "gap": [ 236 ], "less": [ 238 ], "than": [ 239, 260 ], "90": [ 240, 249, 261, 300, 310 ], "days)": [ 241 ], "\u22122.8%": [ 246 ], "(7.0%)": [ 247 ], "to": [ 250, 311 ], "275": [ 251, 312 ], "days": [ 254, 264, 303, 315 ], "\u22121.8%": [ 256 ], "(6.7%)": [ 257 ], "fewer": [ 259 ], ".001).": [ 268 ], "In": [ 269, 361 ], "multivariable": [ 271 ], "model,": [ 272 ], "(adjusted": [ 276 ], "odds": [ 277 ], "ratio": [ 278 ], "[AOR],": [ 279 ], "2.19": [ 280 ], "[95%": [ 281, 293, 306, 322, 334, 342 ], "CI,": [ 282, 294, 307, 323, 335, 343 ], "1.77-2.72]),": [ 283 ], "(AOR,": [ 291, 304, 320, 332, 340 ], "2.46": [ 292 ], "1.83-3.30]),": [ 295 ], "3.36": [ 305 ], "2.52-4.54])": [ 308 ], "within": [ 316 ], "first": [ 318 ], "1.50": [ 321 ], "1.10-2.06]),": [ 324 ], "high": [ 325 ], "dosage": [ 326 ], "low": [ 331 ], "1.58": [ 333 ], "1.11-2.25]),": [ 336 ], "female": [ 338 ], "sex": [ 339 ], "1.57": [ 341 ], "1.27-1.94])": [ 344 ], "achieving": [ 348 ], "1.": [ 357 ], "Conclusions": [ 358 ], "Relevance": [ 360 ], "this": [ 362 ], "obesity,": [ 370 ], "medication\u2019s": [ 380 ], "active": [ 381 ], "agent,": [ 382 ], "its": [ 383 ], "dosage,": [ 384 ], "indication,": [ 386 ], "coverage,": [ 389 ], "patient": [ 391 ], "sex.": [ 392 ], "Future": [ 393 ], "research": [ 394 ], "should": [ 395 ], "focus": [ 396 ], "identifying": [ 398 ], "reasons": [ 400 ], "discontinuation": [ 402 ], "use": [ 405 ], "interventions": [ 407 ], "aimed": [ 408 ], "improving": [ 410 ], "coverage.": [ 413 ] }, "publication_date": "2024-09-13", "publication_year": 2024, "type": "article", "cited_by_count": 40, "authors": [ { "id": "https://openalex.org/A5083102303", "display_name": "Hamlet Gasoyan" }, { "id": "https://openalex.org/A5044461828", "display_name": "Elizabeth R. Pfoh" }, { "id": "https://openalex.org/A5086216056", "display_name": "Rebecca Schulte" }, { "id": "https://openalex.org/A5030444507", "display_name": "Phuc Le" }, { "id": "https://openalex.org/A5048871234", "display_name": "W. Scott Butsch" }, { "id": "https://openalex.org/A5007153736", "display_name": "Michael B. Rothberg" } ] }, { "id": "https://openalex.org/W2744843428", "doi": "https://doi.org/10.1016/s0140-6736(17)31585-4", "title": "Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial", "abstract": null, "publication_date": "2017-08-03", "publication_year": 2017, "type": "article", "cited_by_count": 774, "authors": [ { "id": "https://openalex.org/A5043990676", "display_name": "Dilan Athauda" }, { "id": "https://openalex.org/A5066036690", "display_name": "Kate Maclagan" }, { "id": "https://openalex.org/A5002212651", "display_name": "Simon S. Skene" }, { "id": "https://openalex.org/A5008167560", "display_name": "Martha Bajwa-Joseph" }, { "id": "https://openalex.org/A5108669055", "display_name": "Dawn Letchford" }, { "id": "https://openalex.org/A5067573670", "display_name": "Kashfia Chowdhury" }, { "id": "https://openalex.org/A5084619759", "display_name": "Steve Hibbert" }, { "id": "https://openalex.org/A5038450078", "display_name": "Natalia Budnik" }, { "id": "https://openalex.org/A5028435449", "display_name": "Luca Zampedri" }, { "id": "https://openalex.org/A5067401921", "display_name": "John Dickson" }, { "id": "https://openalex.org/A5100669061", "display_name": "Yazhou Li" }, { "id": "https://openalex.org/A5030193280", "display_name": "Ic\u00edar Avil\u00e9s-Olmos" }, { "id": "https://openalex.org/A5011838243", "display_name": "Thomas T. Warner" }, { "id": "https://openalex.org/A5040249146", "display_name": "Patricia Limousin" }, { "id": "https://openalex.org/A5063335320", "display_name": "Andrew J. Lees" }, { "id": "https://openalex.org/A5056649584", "display_name": "Nigel H. Greig" }, { "id": "https://openalex.org/A5070415897", "display_name": "Susan Tebbs" }, { "id": "https://openalex.org/A5031389008", "display_name": "Thomas Foltynie" } ] }, { "id": "https://openalex.org/W4323255451", "doi": "https://doi.org/10.1111/jdi.14000", "title": "Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial", "abstract": { "ABSTRACT": [ 0 ], "Introduction": [ 1 ], "Few": [ 2 ], "studies": [ 3 ], "have": [ 4 ], "examined": [ 5 ], "the": [ 6, 23, 39, 93, 101, 126, 134, 139, 157, 173, 192, 211, 220 ], "effects": [ 7, 24, 43 ], "of": [ 8, 25, 41, 122, 200 ], "glucagon\u2010like": [ 9 ], "peptide\u20101": [ 10 ], "receptor": [ 11 ], "agonist": [ 12 ], "switching,": [ 13 ], "particularly": [ 14 ], "in": [ 15, 44, 75, 100, 133, 138, 156, 172, 188, 210, 219 ], "Japanese": [ 16 ], "patients.": [ 17 ], "Therefore,": [ 18 ], "we": [ 19 ], "aimed": [ 20 ], "to": [ 21, 29, 82, 92, 107, 228, 239, 254 ], "investigate": [ 22 ], "switching": [ 26, 253 ], "from": [ 27, 79, 105, 236 ], "liraglutide": [ 28, 66, 238 ], "semaglutide": [ 30, 94, 135, 158, 212, 221, 241 ], "or": [ 31, 68, 95 ], "dulaglutide": [ 32, 96, 140, 174, 214, 256 ], "on": [ 33 ], "blood": [ 34 ], "glucose,": [ 35 ], "body": [ 36, 189, 249 ], "weight,": [ 37 ], "and": [ 38, 48, 111, 208, 213, 231, 248 ], "occurrence": [ 40 ], "adverse": [ 42, 204 ], "clinical": [ 45 ], "practice.": [ 46 ], "Materials": [ 47 ], "Methods": [ 49 ], "This": [ 50 ], "was": [ 51, 130, 170, 206 ], "an": [ 52 ], "open\u2010label,": [ 53 ], "prospective,": [ 54 ], "randomized,": [ 55 ], "parallel\u2010group": [ 56 ], "controlled": [ 57 ], "trial.": [ 58 ], "Patients": [ 59 ], "with": [ 60, 65, 252 ], "type": [ 61 ], "2": [ 62 ], "diabetes": [ 63 ], "treated": [ 64 ], "(0.6": [ 67 ], "0.9": [ 69 ], "mg)": [ 70 ], "at": [ 71 ], "Yokosuka": [ 72 ], "Kyosai": [ 73 ], "Hospital": [ 74 ], "Japan": [ 76 ], "were": [ 77, 113, 120 ], "recruited": [ 78 ], "September": [ 80 ], "2020": [ 81 ], "March": [ 83 ], "2022": [ 84 ], "and,": [ 85 ], "after": [ 86 ], "obtaining": [ 87 ], "informed": [ 88 ], "consent,": [ 89 ], "randomly": [ 90 ], "assigned": [ 91 ], "group": [ 97, 136, 141, 159, 175, 222 ], "(1:1).": [ 98 ], "Changes": [ 99 ], "glycated": [ 102 ], "hemoglobin": [ 103 ], "level": [ 104 ], "baseline": [ 106 ], "weeks": [ 108 ], "8,": [ 109 ], "16,": [ 110 ], "26": [ 112 ], "evaluated": [ 114 ], "post\u2010treatment.": [ 115 ], "Results": [ 116 ], "Initially,": [ 117 ], "32": [ 118 ], "participants": [ 119, 201 ], "enrolled,": [ 121 ], "whom": [ 123 ], "30": [ 124 ], "completed": [ 125 ], "study.": [ 127 ], "Glycemic": [ 128 ], "control": [ 129, 247 ], "significantly": [ 131, 154, 244 ], "better": [ 132 ], "than": [ 137 ], "(\u22120.42": [ 142 ], "\u00b1": [ 143, 147, 161, 177 ], "0.49%": [ 144 ], "vs": [ 145 ], "\u22120.00": [ 146 ], "0.34%,": [ 148 ], "P": [ 149, 164, 180, 195 ], "=": [ 150, 165, 181, 196 ], "0.0120).": [ 151 ], "Body": [ 152 ], "weight": [ 153, 190, 232, 250 ], "decreased": [ 155 ], "(\u22122.6": [ 160 ], "3.6": [ 162 ], "kg,": [ 163, 179 ], "0.0153),": [ 166 ], "whereas": [ 167 ], "no": [ 168 ], "change": [ 169 ], "observed": [ 171 ], "(\u22120.1": [ 176 ], "2.7": [ 178 ], "0.8432).": [ 182 ], "We": [ 183 ], "found": [ 184 ], "a": [ 185 ], "significant": [ 186 ], "difference": [ 187 ], "between": [ 191 ], "groups": [ 193 ], "(": [ 194 ], "0.0469).": [ 197 ], "The": [ 198 ], "proportion": [ 199 ], "who": [ 202 ], "reported": [ 203 ], "events": [ 205 ], "75.0%": [ 207 ], "18.8%": [ 209 ], "groups,": [ 215 ], "respectively.": [ 216 ], "One": [ 217 ], "patient": [ 218 ], "had": [ 223 ], "difficulty": [ 224 ], "continuing": [ 225 ], "treatment": [ 226 ], "due": [ 227 ], "severe": [ 229 ], "vomiting": [ 230 ], "loss.": [ 233 ], "Conclusions": [ 234 ], "Switching": [ 235 ], "once\u2010daily": [ 237 ], "once\u2010weekly": [ 240, 255 ], "0.5": [ 242 ], "mg": [ 243 ], "improved": [ 245 ], "glycemic": [ 246 ], "compared": [ 251 ], "0.75": [ 257 ], "mg.": [ 258 ] }, "publication_date": "2023-03-05", "publication_year": 2023, "type": "article", "cited_by_count": 15, "authors": [ { "id": "https://openalex.org/A5022724001", "display_name": "Takahiro Iijima" }, { "id": "https://openalex.org/A5103098869", "display_name": "Makoto Shibuya" }, { "id": "https://openalex.org/A5060715738", "display_name": "Yuzuru Ito" }, { "id": "https://openalex.org/A5088387334", "display_name": "Yasuo Terauchi" } ] }, { "id": "https://openalex.org/W3086646659", "doi": "https://doi.org/10.1111/jcpt.13225", "title": "Safety and tolerability of once\u2010weekly GLP\u20101 receptor agonists in type 2 diabetes", "abstract": { "This": [ 0 ], "review": [ 1 ], "puts": [ 2 ], "the": [ 3, 8, 34, 50 ], "latest": [ 4 ], "clinical": [ 5 ], "data": [ 6 ], "from": [ 7, 17 ], "marketed": [ 9 ], "QW": [ 10, 36 ], "GLP-1": [ 11, 37 ], "RAs": [ 12, 38 ], "into": [ 13 ], "context": [ 14 ], "with": [ 15 ], "results": [ 16 ], "older": [ 18 ], "Phase": [ 19 ], "3": [ 20 ], "trials,": [ 21 ], "to": [ 22, 27 ], "enable": [ 23 ], "pharmacists": [ 24 ], "and": [ 25 ], "HCPs": [ 26 ], "make": [ 28 ], "informed": [ 29 ], "treatment": [ 30, 52 ], "decisions.": [ 31 ], "Each": [ 32 ], "of": [ 33 ], "three": [ 35 ], "has": [ 39 ], "their": [ 40 ], "own": [ 41 ], "safety": [ 42 ], "profile,": [ 43 ], "which": [ 44 ], "should": [ 45 ], "be": [ 46 ], "considered": [ 47 ], "when": [ 48 ], "choosing": [ 49 ], "optimal": [ 51 ], "for": [ 53 ], "patients.": [ 54 ] }, "publication_date": "2020-09-01", "publication_year": 2020, "type": "review", "cited_by_count": 105, "authors": [ { "id": "https://openalex.org/A5054620018", "display_name": "Jennifer Trujillo" } ] }, { "id": "https://openalex.org/W2795981708", "doi": "https://doi.org/10.1007/s40262-018-0649-2", "title": "Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment", "abstract": null, "publication_date": "2018-04-06", "publication_year": 2018, "type": "article", "cited_by_count": 111, "authors": [ { "id": "https://openalex.org/A5048052863", "display_name": "Charlotte Granhall" }, { "id": "https://openalex.org/A5023510885", "display_name": "Flemming L. S\u00f8ndergaard" }, { "id": "https://openalex.org/A5017671388", "display_name": "Mette S. Thomsen" }, { "id": "https://openalex.org/A5073012388", "display_name": "Thomas W. Anderson" } ] }, { "id": "https://openalex.org/W2029214914", "doi": "https://doi.org/10.2337/diacare.29.02.06.dc05-2043", "title": "Exenatide (Exendin-4)\u2013Induced Pancreatitis", "abstract": { "Exenatide": [ 0 ], "is": [ 1, 16, 22 ], "a": [ 2 ], "39\u2013amino": [ 3 ], "acid": [ 4 ], "peptide": [ 5, 31 ], "approved": [ 6 ], "for": [ 7, 98, 112 ], "the": [ 8, 27, 81 ], "adjunctive": [ 9 ], "treatment": [ 10 ], "of": [ 11, 29, 35, 46, 51, 56, 66, 93 ], "type": [ 12, 90 ], "2": [ 13, 91 ], "diabetes.": [ 14 ], "It": [ 15 ], "an": [ 17 ], "incretin": [ 18 ], "mimetic": [ 19 ], "agent": [ 20 ], "that": [ 21 ], "consistent": [ 23 ], "in": [ 24 ], "activity": [ 25 ], "with": [ 26, 73, 89 ], "actions": [ 28 ], "glucagon-like": [ 30 ], "1.": [ 32 ], "Proposed": [ 33 ], "mechanisms": [ 34 ], "action": [ 36 ], "include": [ 37 ], "enhanced": [ 38 ], "glucose-dependent": [ 39 ], "insulin": [ 40, 48 ], "secretion": [ 41 ], "from": [ 42 ], "pancreatic": [ 43 ], "\u03b2-cells,": [ 44 ], "restoration": [ 45 ], "first-phase": [ 47 ], "response,": [ 49 ], "suppression": [ 50 ], "glucagon": [ 52 ], "secretion,": [ 53 ], "and": [ 54, 77, 105, 121 ], "delay": [ 55 ], "gastric": [ 57 ], "emptying.": [ 58 ], "Kendall": [ 59 ], "et": [ 60 ], "al.": [ 61 ], "(1)": [ 62 ], "found": [ 63 ], "no": [ 64 ], "evidence": [ 65 ], "cardiovascular,": [ 67 ], "pulmonary,": [ 68 ], "hepatic,": [ 69 ], "or": [ 70 ], "renal": [ 71 ], "toxicities": [ 72 ], "exenatide.": [ 74 ], "Nausea": [ 75 ], "(39\u201348%)": [ 76 ], "hypoglycemia": [ 78 ], "(19\u201327%)": [ 79 ], "were": [ 80 ], "most": [ 82 ], "common": [ 83 ], "side": [ 84 ], "effects": [ 85 ], "reported.\n\nA": [ 86 ], "69-year-old": [ 87 ], "man": [ 88 ], "diabetes": [ 92 ], "15": [ 94 ], "years\u2019": [ 95 ], "duration": [ 96 ], "presented": [ 97 ], "follow-up.": [ 99 ], "He": [ 100 ], "had": [ 101 ], "known": [ 102 ], "diabetic": [ 103 ], "neuropathy": [ 104 ], "retinopathy.": [ 106 ], "His": [ 107 ], "medical": [ 108 ], "history": [ 109 ], "was": [ 110 ], "remarkable": [ 111 ], "coronary": [ 113 ], "artery": [ 114 ], "disease,": [ 115, 118 ], "gastroesophageal": [ 116 ], "reflux": [ 117 ], "rheumatoid": [ 119 ], "arthritis,": [ 120 ], "\u2026": [ 122 ] }, "publication_date": "2006-02-01", "publication_year": 2006, "type": "letter", "cited_by_count": 143, "authors": [ { "id": "https://openalex.org/A5111696175", "display_name": "Paul S. Denker" }, { "id": "https://openalex.org/A5066088179", "display_name": "Paul E. Dimarco" } ] }, { "id": "https://openalex.org/W2306319461", "doi": "https://doi.org/10.1155/2016/3094642", "title": "Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control", "abstract": { "Glucagon-like": [ 0 ], "peptide-1": [ 1 ], "(GLP-1)": [ 2 ], "is": [ 3, 59 ], "an": [ 4 ], "incretin": [ 5 ], "hormone": [ 6 ], "mainly": [ 7 ], "secreted": [ 8 ], "from": [ 9, 29 ], "intestinal": [ 10 ], "L": [ 11 ], "cells": [ 12 ], "in": [ 13, 88, 123, 126 ], "response": [ 14 ], "to": [ 15, 75 ], "nutrient": [ 16 ], "ingestion.": [ 17 ], "GLP-1": [ 18, 50, 61 ], "has": [ 19 ], "beneficial": [ 20 ], "effects": [ 21, 87 ], "for": [ 22, 67 ], "glucose": [ 23, 43 ], "homeostasis": [ 24 ], "by": [ 25 ], "stimulating": [ 26, 42 ], "insulin": [ 27 ], "secretion": [ 28 ], "pancreatic": [ 30 ], "beta-cells,": [ 31 ], "delaying": [ 32 ], "gastric": [ 33 ], "emptying,": [ 34 ], "decreasing": [ 35 ], "plasma": [ 36 ], "glucagon,": [ 37 ], "reducing": [ 38 ], "food": [ 39 ], "intake,": [ 40 ], "and": [ 41, 53, 95, 106, 125, 129 ], "disposal.": [ 44 ], "Therefore,": [ 45 ], "GLP-1-based": [ 46, 82, 115 ], "therapies": [ 47, 83, 116 ], "such": [ 48 ], "as": [ 49 ], "receptor": [ 51 ], "agonists": [ 52 ], "inhibitors": [ 54 ], "of": [ 55, 69, 114, 133 ], "dipeptidyl": [ 56 ], "peptidase-4,": [ 57 ], "which": [ 58 ], "a": [ 60 ], "inactivating": [ 62 ], "enzyme,": [ 63 ], "have": [ 64 ], "been": [ 65 ], "developed": [ 66 ], "treatment": [ 68 ], "type": [ 70, 93 ], "2": [ 71, 96 ], "diabetes.": [ 72 ], "In": [ 73 ], "addition": [ 74 ], "glucose-lowering": [ 76 ], "effects,": [ 77 ], "emerging": [ 78 ], "data": [ 79 ], "suggests": [ 80 ], "that": [ 81 ], "also": [ 84 ], "show": [ 85 ], "anti-inflammatory": [ 86, 112, 134 ], "chronic": [ 89, 121 ], "inflammatory": [ 90 ], "diseases": [ 91, 118 ], "including": [ 92 ], "1": [ 94 ], "diabetes,": [ 97 ], "atherosclerosis,": [ 98 ], "neurodegenerative": [ 99 ], "disorders,": [ 100 ], "nonalcoholic": [ 101 ], "steatohepatitis,": [ 102 ], "diabetic": [ 103 ], "nephropathy,": [ 104 ], "asthma,": [ 105 ], "psoriasis.": [ 107 ], "This": [ 108 ], "review": [ 109 ], "outlines": [ 110 ], "the": [ 111 ], "actions": [ 113 ], "on": [ 117 ], "associated": [ 119 ], "with": [ 120 ], "inflammation": [ 122 ], "vivo": [ 124 ], "vitro": [ 127 ], ",": [ 128 ], "their": [ 130 ], "molecular": [ 131 ], "mechanisms": [ 132 ], "action.": [ 135 ] }, "publication_date": "2016-01-01", "publication_year": 2016, "type": "review", "cited_by_count": 446, "authors": [ { "id": "https://openalex.org/A5108055112", "display_name": "Young-Sun Lee" }, { "id": "https://openalex.org/A5083258493", "display_name": "Hee\u2010Sook Jun" } ] }, { "id": "https://openalex.org/W2033185429", "doi": "https://doi.org/10.1111/j.1463-1326.2012.01673.x", "title": "Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme", "abstract": { "Abstract": [ 0 ], "Aim": [ 1 ], "We": [ 2 ], "investigated": [ 3 ], "the": [ 4, 39, 122, 182 ], "relationship": [ 5 ], "between": [ 6 ], "weight": [ 7, 68, 74, 97, 102, 119, 147, 173, 178, 195, 223, 232, 242 ], "change": [ 8, 69, 75, 98, 103, 105 ], "and": [ 9, 48, 53, 58, 71, 86, 99, 128, 141, 154, 206, 251 ], "related": [ 10 ], "factors": [ 11 ], "in": [ 12, 38, 66, 106, 193, 244, 254, 261 ], "subjects": [ 13, 65, 116, 214, 240, 259 ], "with": [ 14, 23, 104, 151, 158, 170, 175 ], "type": [ 15 ], "2": [ 16 ], "diabetes": [ 17, 27 ], "mellitus": [ 18 ], "(": [ 19, 83, 88, 93, 109 ], "T2DM": [ 20, 41, 239 ], ")": [ 21, 85, 90, 95 ], "treated": [ 22 ], "liraglutide": [ 24, 40, 51, 125, 130, 152 ], "versus": [ 25 ], "comparator": [ 26, 57 ], "therapies.": [ 28 ], "Methods": [ 29 ], "Twenty\u2010six\u2010week": [ 30 ], "data": [ 31 ], "from": [ 32, 76 ], "seven": [ 33 ], "phase": [ 34 ], "3,": [ 35 ], "randomized": [ 36 ], "trials": [ 37, 123 ], "development": [ 42 ], "programme": [ 43 ], "were": [ 44, 204 ], "analysed": [ 45 ], "by": [ 46 ], "trial": [ 47 ], "treatment": [ 49 ], "group:": [ 50 ], "(1.2": [ 52 ], "1.8": [ 54, 126, 155 ], "mg),": [ 55 ], "active": [ 56, 159, 262 ], "placebo.": [ 59 ], "Outcome": [ 60 ], "measures": [ 61 ], "included": [ 62 ], "proportions": [ 63 ], "of": [ 64, 79, 101, 115, 237 ], "various": [ 67 ], "categories": [ 70, 197 ], "their": [ 72 ], "percentage": [ 73 ], "baseline;": [ 77 ], "impact": [ 78 ], "body": [ 80 ], "mass": [ 81 ], "index": [ 82 ], "BMI": [ 84, 167 ], "gastrointestinal": [ 87 ], "GI": [ 89, 184 ], "adverse": [ 91 ], "events": [ 92 ], "AEs": [ 94, 185 ], "on": [ 96 ], "correlation": [ 100, 209 ], "glycosylated": [ 107 ], "haemoglobin": [ 108 ], "HbA1c": [ 110, 188, 217, 228 ], ").": [ 111 ], "Results": [ 112 ], "A": [ 113 ], "number": [ 114 ], "experienced": [ 117, 215, 241 ], ">5%": [ 118 ], "loss": [ 120, 148, 174, 179, 196, 243, 248 ], "during": [ 121 ], "(24.4%": [ 124 ], "mg": [ 127, 156 ], "17.7%": [ 129, 133 ], "1.2": [ 131, 153 ], "mg;": [ 132 ], "exenatide,": [ 134 ], "10.0%": [ 135 ], "sitagliptin,": [ 136 ], "3.6\u22127.0%": [ 137 ], "sulphonylurea,": [ 138 ], "2.6%": [ 139, 142 ], "thiazolidinedione": [ 140 ], "glargine;": [ 143 ], "9.9%": [ 144 ], "placebo).": [ 145 ], "More": [ 146 ], "was": [ 149, 168, 190, 249 ], "seen": [ 150 ], "than": [ 157, 260 ], "comparators": [ 160 ], "except": [ 161 ], "exenatide.": [ 162 ], "Across": [ 163 ], "trials,": [ 164 ], "higher": [ 165, 194 ], "initial": [ 166 ], "associated": [ 169 ], "slightly": [ 171, 181, 191 ], "greater": [ 172, 250 ], "liraglutide.": [ 176 ], "Mean": [ 177 ], "increased": [ 180 ], "longer": [ 183 ], "persisted.": [ 186 ], "Although": [ 187 ], "reduction": [ 189, 218 ], "larger": [ 192 ], "across": [ 198 ], "treatments": [ 199 ], "(including": [ 200 ], "placebo),": [ 201 ], "sample": [ 202 ], "sizes": [ 203 ], "small": [ 205 ], "no": [ 207 ], "clear": [ 208 ], "could": [ 210 ], "be": [ 211 ], "determined.": [ 212 ], "Liraglutide\u2010treated": [ 213 ], "additional": [ 216 ], "beyond": [ 219 ], "that": [ 220 ], "which": [ 221 ], "appeared": [ 222 ], "induced;": [ 224 ], "thus,": [ 225 ], "not": [ 226 ], "all": [ 227 ], "\u2010lowering": [ 229 ], "effect": [ 230 ], "appears": [ 231 ], "mediated.": [ 233 ], "Conclusions": [ 234 ], "The": [ 235 ], "majority": [ 236 ], "liraglutide\u2010treated": [ 238 ], "this": [ 245 ], "analysis.": [ 246 ], "Weight": [ 247 ], "occurred": [ 252 ], "more": [ 253 ], "glucagon\u2010like": [ 255 ], "peptide\u20101": [ 256 ], "receptor": [ 257 ], "agonist\u2010treated": [ 258 ], "comparator\u2010treated": [ 263 ], "subjects.": [ 264 ] }, "publication_date": "2012-08-03", "publication_year": 2012, "type": "article", "cited_by_count": 98, "authors": [ { "id": "https://openalex.org/A5068362253", "display_name": "Kevin D. Niswender" }, { "id": "https://openalex.org/A5108098922", "display_name": "Xavier Pi\u2010Sunyer" }, { "id": "https://openalex.org/A5040182038", "display_name": "John B. Buse" }, { "id": "https://openalex.org/A5061856428", "display_name": "Klaus H. Jensen" }, { "id": "https://openalex.org/A5059248628", "display_name": "Anders Toft" }, { "id": "https://openalex.org/A5082184915", "display_name": "David Russell\u2010Jones" }, { "id": "https://openalex.org/A5090437675", "display_name": "Bernard Zinman" } ] }, { "id": "https://openalex.org/W4210666004", "doi": "https://doi.org/10.2337/dc21-1113", "title": "Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes", "abstract": { "OBJECTIVE": [ 0 ], "To": [ 1 ], "assess": [ 2 ], "associations": [ 3 ], "between": [ 4 ], "current": [ 5 ], "use": [ 6 ], "of": [ 7, 145, 227 ], "sodium\u2013glucose": [ 8 ], "cotransporter": [ 9 ], "2": [ 10, 40, 55, 131, 149 ], "inhibitors": [ 11 ], "(SGLT2is),": [ 12 ], "glucagon-like": [ 13 ], "peptide": [ 14 ], "1": [ 15 ], "receptor": [ 16 ], "agonists": [ 17 ], "(GLP-1RAs),": [ 18 ], "and": [ 19, 22, 28, 32, 59, 70, 80, 102, 120, 133, 151, 169, 188, 209, 217, 229, 231, 245 ], "their": [ 20, 246 ], "combination": [ 21, 163, 192, 211, 219 ], "risk": [ 23 ], "for": [ 24, 100, 172, 198, 233, 238 ], "major": [ 25 ], "adverse": [ 26 ], "cardiac": [ 27 ], "cerebrovascular": [ 29 ], "events": [ 30 ], "(MACCE)": [ 31 ], "heart": [ 33 ], "failure": [ 34 ], "(HF)": [ 35 ], "in": [ 36, 57, 224 ], "people": [ 37, 128 ], "with": [ 38, 53, 76, 90, 129, 147, 161, 175, 182, 189 ], "type": [ 39, 54, 130, 148 ], "diabetes.": [ 41 ], "RESEARCH": [ 42 ], "DESIGN": [ 43 ], "AND": [ 44 ], "METHODS": [ 45 ], "In": [ 46, 142 ], "three": [ 47 ], "nested": [ 48 ], "case-control": [ 49 ], "studies": [ 50 ], "involving": [ 51 ], "patients": [ 52, 105 ], "diabetes": [ 56, 132, 150 ], "England": [ 58 ], "Wales": [ 60 ], "(primary": [ 61 ], "care": [ 62 ], "data": [ 63, 197, 236 ], "from": [ 64 ], "the": [ 65, 165, 190 ], "Clinical": [ 66 ], "Practice": [ 67 ], "Research": [ 68 ], "Datalink": [ 69 ], "Secure": [ 71 ], "Anonymised": [ 72 ], "Information": [ 73 ], "Linkage": [ 74 ], "Databank": [ 75 ], "linkage": [ 77 ], "to": [ 78, 92 ], "hospital": [ 79 ], "mortality": [ 81 ], "records),": [ 82 ], "we": [ 83 ], "matched": [ 84 ], "each": [ 85 ], "patient": [ 86 ], "experiencing": [ 87 ], "an": [ 88, 157 ], "event": [ 89 ], "up": [ 91 ], "20": [ 93 ], "control": [ 94 ], "subjects.": [ 95 ], "Adjusted": [ 96 ], "odds": [ 97 ], "ratios": [ 98 ], "(ORs)": [ 99 ], "MACCE": [ 101, 173, 228 ], "HF": [ 103, 158, 199, 230 ], "among": [ 104 ], "receiving": [ 106 ], "SGLT2i": [ 107, 176, 201, 216 ], "or": [ 108 ], "GLP-1RA": [ 109, 183, 205, 232 ], "regimens": [ 110, 177, 184, 220 ], "versus": [ 111 ], "other": [ 112, 162 ], "combinations": [ 113 ], "were": [ 114, 200 ], "estimated": [ 115 ], "using": [ 116, 122, 242 ], "conditional": [ 117 ], "logistic": [ 118 ], "regression": [ 119 ], "pooled": [ 121, 167 ], "random-effects": [ 123 ], "meta-analysis.": [ 124 ], "RESULTS": [ 125 ], "Among": [ 126 ], "336,334": [ 127 ], "without": [ 134, 152 ], "cardiovascular": [ 135 ], "disease,": [ 136 ], "18,531": [ 137 ], "(5.5%)": [ 138 ], "experienced": [ 139, 156 ], "a": [ 140, 143 ], "MACCE.": [ 141 ], "cohort": [ 144 ], "411,206": [ 146 ], "HF,": [ 153 ], "17,451": [ 154 ], "(4.2%)": [ 155 ], "event.": [ 159 ], "Compared": [ 160 ], "regimens,": [ 164 ], "adjusted": [ 166 ], "OR": [ 168 ], "95%": [ 170 ], "CI": [ 171 ], "associated": [ 174 ], "was": [ 178 ], "0.82": [ 179, 206 ], "(0.73,": [ 180 ], "0.92),": [ 181 ], "0.93": [ 185 ], "(0.81,": [ 186 ], "1.06),": [ 187 ], "SGLT2i/GLP-1RA": [ 191, 210, 218 ], "0.70": [ 193 ], "(0.50,": [ 194 ], "0.98).": [ 195 ], "Corresponding": [ 196 ], "0.49": [ 202 ], "(0.42,": [ 203 ], "0.58),": [ 204 ], "(0.71,": [ 207 ], "0.95),": [ 208 ], "0.43": [ 212 ], "(0.28,": [ 213 ], "0.64).": [ 214 ], "CONCLUSIONS": [ 215 ], "may": [ 221 ], "be": [ 222 ], "beneficial": [ 223 ], "primary": [ 225, 239 ], "prevention": [ 226, 240 ], "HF.": [ 234 ], "These": [ 235 ], "call": [ 237 ], "trials": [ 241 ], "these": [ 243 ], "agents": [ 244 ], "combination.": [ 247 ] }, "publication_date": "2022-01-31", "publication_year": 2022, "type": "review", "cited_by_count": 132, "authors": [ { "id": "https://openalex.org/A5034330450", "display_name": "Alison K. Wright" }, { "id": "https://openalex.org/A5023710291", "display_name": "Matthew Carr" }, { "id": "https://openalex.org/A5057258772", "display_name": "Evangelos Kontopantelis" }, { "id": "https://openalex.org/A5084909252", "display_name": "Lalantha Leelarathna" }, { "id": "https://openalex.org/A5027935204", "display_name": "Hood Thabit" }, { "id": "https://openalex.org/A5053708270", "display_name": "Richard Emsley" }, { "id": "https://openalex.org/A5011177296", "display_name": "Iain Buchan" }, { "id": "https://openalex.org/A5057514332", "display_name": "Mamas A. Mamas" }, { "id": "https://openalex.org/A5016347038", "display_name": "Tjeerd van Staa" }, { "id": "https://openalex.org/A5078498803", "display_name": "Naveed Sattar" }, { "id": "https://openalex.org/A5005808294", "display_name": "Darren M. Ashcroft" }, { "id": "https://openalex.org/A5044466332", "display_name": "Martin K. Rutter" } ] }, { "id": "https://openalex.org/W4317867152", "doi": "https://doi.org/10.1080/00325481.2022.2147326", "title": "Efficacy and safety of semaglutide for weight management: evidence from the STEP program", "abstract": { "Obesity": [ 0 ], "is": [ 1, 7, 67 ], "a": [ 2, 8, 74, 236 ], "global": [ 3 ], "health": [ 4, 17 ], "challenge.": [ 5 ], "It": [ 6 ], "multifactorial,": [ 9 ], "complex,": [ 10 ], "and": [ 11, 19, 50, 56, 81, 105, 111, 117, 123, 163, 216, 230, 261, 276 ], "progressive": [ 12 ], "disease": [ 13 ], "associated": [ 14 ], "with": [ 15, 133, 145, 167, 196, 221, 228, 235, 240 ], "various": [ 16 ], "complications": [ 18 ], "increased": [ 20 ], "mortality.": [ 21 ], "Lifestyle": [ 22 ], "modifications": [ 23 ], "are": [ 24, 40, 119 ], "central": [ 25 ], "to": [ 26, 33, 45, 48, 151 ], "weight": [ 27, 37, 54, 129, 160, 192, 218 ], "management": [ 28, 130, 193 ], "but": [ 29 ], "may": [ 30 ], "be": [ 31 ], "insufficient": [ 32 ], "maintain": [ 34 ], "clinically": [ 35, 52, 278 ], "meaningful": [ 36, 53 ], "loss.": [ 38 ], "Pharmacotherapies": [ 39 ], "recommended": [ 41 ], "as": [ 42 ], "an": [ 43, 68 ], "adjunct": [ 44 ], "lifestyle": [ 46 ], "interventions": [ 47 ], "induce": [ 49 ], "sustain": [ 51 ], "loss": [ 55 ], "reduce": [ 57 ], "the": [ 58, 94, 153, 172, 175, 178, 182, 205, 271 ], "risk": [ 59, 225 ], "of": [ 60, 76, 96, 155, 174, 177 ], "comorbidities": [ 61 ], "in": [ 62, 131, 143, 165, 194, 200, 223, 249, 259 ], "appropriate": [ 63 ], "patients.": [ 64 ], "Glucagon-like": [ 65 ], "peptide-1": [ 66, 86 ], "incretin": [ 69 ], "metabolic": [ 70 ], "hormone": [ 71 ], "responsible": [ 72 ], "for": [ 73, 93, 127, 190, 281 ], "range": [ 75 ], "physiological": [ 77 ], "effects,": [ 78 ], "including": [ 79, 102 ], "glucose": [ 80 ], "appetite": [ 82 ], "regulation.": [ 83 ], "Several": [ 84 ], "glucagon-like": [ 85 ], "receptor": [ 87 ], "agonists": [ 88 ], "(GLP-1RAs)": [ 89 ], "have": [ 90 ], "been": [ 91 ], "approved": [ 92, 184 ], "treatment": [ 95, 266 ], "type": [ 97 ], "2": [ 98 ], "diabetes": [ 99 ], "since": [ 100 ], "2005": [ 101 ], "exenatide": [ 103 ], "(short-": [ 104 ], "extended-release),": [ 106 ], "lixisenatide,": [ 107 ], "liraglutide,": [ 108 ], "dulaglutide,": [ 109 ], "albiglutide,": [ 110 ], "semaglutide.": [ 112 ], "Of": [ 113 ], "these,": [ 114 ], "semaglutide": [ 115, 156, 187, 209 ], "(subcutaneous)": [ 116 ], "liraglutide": [ 118 ], "currently": [ 120 ], "US": [ 121 ], "Food": [ 122 ], "Drug": [ 124 ], "Administration": [ 125 ], "(FDA)-approved": [ 126 ], "chronic": [ 128, 191 ], "patients": [ 132 ], "or": [ 134, 169, 198 ], "without": [ 135, 264 ], "diabetes.": [ 136 ], "The": [ 137, 243 ], "phase": [ 138 ], "3": [ 139 ], "Semaglutide": [ 140 ], "Treatment": [ 141 ], "Effect": [ 142 ], "People": [ 144 ], "obesity": [ 146, 199 ], "(STEP)": [ 147 ], "program": [ 148, 206 ], "was": [ 149, 231 ], "designed": [ 150 ], "investigate": [ 152 ], "effect": [ 154 ], "versus": [ 157 ], "placebo": [ 158 ], "on": [ 159 ], "loss,": [ 161, 219 ], "safety,": [ 162 ], "tolerability": [ 164 ], "adults": [ 166 ], "overweight": [ 168, 197 ], "obesity.": [ 170 ], "Following": [ 171 ], "submission": [ 173 ], "results": [ 176 ], "STEP": [ 179, 250, 274 ], "1-4": [ 180 ], "trials,": [ 181 ], "FDA": [ 183 ], "once-weekly": [ 185 ], "subcutaneous": [ 186 ], "2.4": [ 188 ], "mg": [ 189, 211 ], "people": [ 195 ], "April": [ 201 ], "2021.": [ 202 ], "Data": [ 203 ], "from": [ 204, 273 ], "demonstrated": [ 207 ], "that": [ 208 ], "(2.4": [ 210 ], "once": [ 212 ], "weekly)": [ 213 ], "achieved": [ 214 ], "significant": [ 215 ], "sustained": [ 217 ], "together": [ 220 ], "improvements": [ 222 ], "cardiometabolic": [ 224 ], "factors": [ 226 ], "compared": [ 227 ], "placebo,": [ 229 ], "generally": [ 232 ], "well": [ 233 ], "tolerated,": [ 234 ], "safety": [ 237 ], "profile": [ 238 ], "consistent": [ 239 ], "other": [ 241 ], "GLP-1RAs.": [ 242 ], "most": [ 244 ], "common": [ 245 ], "adverse": [ 246 ], "events": [ 247 ], "reported": [ 248 ], "1-5": [ 251, 275 ], "were": [ 252, 256 ], "gastrointestinal": [ 253 ], "events,": [ 254 ], "which": [ 255 ], "transient,": [ 257 ], "mild-to-moderate": [ 258 ], "severity,": [ 260 ], "typically": [ 262 ], "resolved": [ 263 ], "permanent": [ 265 ], "discontinuation.": [ 267 ], "This": [ 268 ], "article": [ 269 ], "reviews": [ 270 ], "data": [ 272 ], "highlights": [ 277 ], "relevant": [ 279 ], "findings": [ 280 ], "primary": [ 282 ], "care": [ 283 ], "providers.": [ 284 ] }, "publication_date": "2022-04-14", "publication_year": 2022, "type": "review", "cited_by_count": 54, "authors": [ { "id": "https://openalex.org/A5044175873", "display_name": "Anastassia Amaro" }, { "id": "https://openalex.org/A5081546904", "display_name": "Danny Sugimoto" }, { "id": "https://openalex.org/A5027441223", "display_name": "Sean Wharton" } ] }, { "id": "https://openalex.org/W2494601841", "doi": "https://doi.org/10.2337/dc16-0690", "title": "Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial", "abstract": { "OBJECTIVE": [ 0 ], "To": [ 1 ], "investigate": [ 2 ], "the": [ 3 ], "efficacy": [ 4 ], "and": [ 5, 41, 102, 108, 122, 154, 195, 208 ], "safety": [ 6 ], "of": [ 7, 54, 126, 138, 155, 179, 202 ], "liraglutide": [ 8, 38, 69, 131, 149, 162, 186, 205, 213 ], "added": [ 9, 46, 187 ], "to": [ 10, 47, 188 ], "capped": [ 11, 50, 189 ], "insulin": [ 12, 120, 190, 196 ], "doses": [ 13 ], "in": [ 14, 118, 124 ], "subjects": [ 15, 32, 180 ], "with": [ 16, 68, 130, 148, 157, 161, 181, 199, 210 ], "type": [ 17, 183 ], "1": [ 18, 184 ], "diabetes.": [ 19 ], "RESEARCH": [ 20 ], "DESIGN": [ 21 ], "AND": [ 22 ], "METHODS": [ 23 ], "A": [ 24 ], "26-week,": [ 25 ], "placebo-controlled,": [ 26 ], "double-blind,": [ 27 ], "parallel-group": [ 28 ], "trial": [ 29 ], "enrolling": [ 30 ], "835": [ 31 ], "randomized": [ 33 ], "3:1": [ 34 ], "receiving": [ 35 ], "once-daily": [ 36 ], "subcutaneous": [ 37 ], "(1.8,": [ 39 ], "1.2,": [ 40, 107 ], "0.6": [ 42, 85, 109 ], "mg)": [ 43 ], "or": [ 44 ], "placebo": [ 45, 71, 113, 153, 166 ], "an": [ 48 ], "individually": [ 49 ], "total": [ 51 ], "daily": [ 52, 119 ], "dose": [ 53, 121 ], "insulin.": [ 55 ], "RESULTS": [ 56 ], "Mean": [ 57 ], "baseline": [ 58 ], "glycated": [ 59 ], "hemoglobin": [ 60 ], "(HbA1c)": [ 61 ], "(8.1%": [ 62 ], "[65.0": [ 63 ], "mmol/mol])": [ 64 ], "was": [ 65 ], "significantly": [ 66, 95 ], "decreased": [ 67 ], "versus": [ 70, 112, 132 ], "at": [ 72 ], "week": [ 73 ], "26": [ 74 ], "(1.8": [ 75 ], "mg:": [ 76, 81, 86 ], "\u20130.33%": [ 77 ], "[3.6": [ 78 ], "mmol/mol];": [ 79, 84, 89 ], "1.2": [ 80, 150, 206 ], "\u20130.22%": [ 82 ], "[2.4": [ 83 ], "\u20130.23%": [ 87 ], "[2.5": [ 88 ], "placebo:": [ 90 ], "0.01%": [ 91 ], "[0.1": [ 92 ], "mmol/mol]).": [ 93 ], "Liraglutide": [ 94 ], "reduced": [ 96, 191 ], "mean": [ 97 ], "body": [ 98, 193 ], "weight": [ 99 ], "(\u20135.1,": [ 100 ], "\u20134.0,": [ 101 ], "\u20132.5": [ 103 ], "kg": [ 104 ], "for": [ 105, 204, 212 ], "1.8,": [ 106 ], "mg,": [ 110 ], "respectively)": [ 111 ], "(\u20130.2": [ 114 ], "kg).": [ 115 ], "Significant": [ 116 ], "reductions": [ 117 ], "increases": [ 123 ], "quality": [ 125 ], "life": [ 127 ], "were": [ 128, 135 ], "seen": [ 129 ], "placebo.": [ 133 ], "There": [ 134 ], "higher": [ 136, 200 ], "rates": [ 137, 201 ], "symptomatic": [ 139 ], "hypoglycemia": [ 140, 203 ], "(21.3": [ 141 ], "vs.": [ 142, 152, 165, 168 ], "16.6": [ 143 ], "events/patient/year;": [ 144, 170 ], "P": [ 145, 171 ], "=": [ 146, 172 ], "0.03)": [ 147 ], "mg": [ 151, 164, 207 ], "hyperglycemia": [ 156, 209 ], "ketosis": [ 158, 211 ], "&gt;1.5": [ 159 ], "mmol/L": [ 160 ], "1.8": [ 163, 214 ], "(0.5": [ 167 ], "0.1": [ 169 ], "0.01).": [ 173 ], "CONCLUSIONS": [ 174 ], "In": [ 175 ], "a": [ 176 ], "broad": [ 177 ], "population": [ 178 ], "long-standing": [ 182 ], "diabetes,": [ 185 ], "HbA1c,": [ 192 ], "weight,": [ 194 ], "requirements": [ 197 ], "but": [ 198 ], "mg.": [ 215 ] }, "publication_date": "2016-08-04", "publication_year": 2016, "type": "article", "cited_by_count": 218, "authors": [ { "id": "https://openalex.org/A5027109387", "display_name": "Bo \u00c5hr\u00e9n" }, { "id": "https://openalex.org/A5029280234", "display_name": "Irl B. Hirsch" }, { "id": "https://openalex.org/A5023877066", "display_name": "Thomas R. Pieber" }, { "id": "https://openalex.org/A5053469409", "display_name": "Chantal Mathieu" }, { "id": "https://openalex.org/A5056057120", "display_name": "Fernando G\u00f3mez\u2010Peralta" }, { "id": "https://openalex.org/A5053849098", "display_name": "Troels Krarup Hansen" }, { "id": "https://openalex.org/A5059447899", "display_name": "Areti Philotheou" }, { "id": "https://openalex.org/A5076526695", "display_name": "Stephen Birch" }, { "id": "https://openalex.org/A5036497949", "display_name": "Erik Christiansen" }, { "id": "https://openalex.org/A5002690212", "display_name": "Thomas Jensen" }, { "id": "https://openalex.org/A5040182038", "display_name": "John B. Buse" } ] }, { "id": "https://openalex.org/W2398993912", "doi": "https://doi.org/10.1002/biof.1295", "title": "Antiobesity efficacy of GLP\u20101 receptor agonist liraglutide is associated with peripheral tissue\u2010specific modulation of lipid metabolic regulators", "abstract": { "Abstract": [ 0 ], "To": [ 1 ], "investigate": [ 2 ], "the": [ 3, 26, 30, 36, 41, 90, 109, 156, 197, 212, 223, 231, 237 ], "role": [ 4 ], "of": [ 5, 29, 35, 43, 75, 92, 112, 159, 171, 193, 199, 209, 233, 239 ], "glucagon\u2010like\u2010peptide\u20101": [ 6 ], "receptor": [ 7 ], "(GLP\u20101R)": [ 8 ], "in": [ 9, 47, 53, 79, 85, 98, 115, 136, 144, 175, 187 ], "peripheral": [ 10, 27, 224 ], "lipid": [ 11, 48, 93, 161, 182, 194, 227 ], "metabolism.": [ 12 ], "Both": [ 13 ], "lean": [ 14, 105 ], "and": [ 15, 32, 51, 57, 72, 77, 89, 101, 129, 138, 147, 181, 211, 241 ], "high\u2010fat": [ 16 ], "diet": [ 17, 100 ], "(HFD)\u2010induced": [ 18 ], "obesity": [ 19 ], "(DIO)": [ 20 ], "rats": [ 21, 201 ], "were": [ 22, 96 ], "used": [ 23 ], "to": [ 24, 149, 220 ], "compare": [ 25 ], "effects": [ 28 ], "subcutaneous": [ 31 ], "repeated": [ 33 ], "administration": [ 34 ], "GLP\u20101R": [ 37 ], "agonist": [ 38 ], "liraglutide": [ 39, 66, 107, 164, 204 ], "on": [ 40 ], "expression": [ 42, 91, 111, 170, 208 ], "key": [ 44 ], "regulators": [ 45, 95 ], "involved": [ 46, 114, 174 ], "metabolism,": [ 49 ], "\u03b2\u2010oxidation": [ 50, 127, 179 ], "thermogenesis": [ 52, 130 ], "liver,": [ 54, 188 ], "abdominal": [ 55 ], "muscle,": [ 56, 139 ], "epididymal": [ 58 ], "white": [ 59 ], "adipose": [ 60 ], "tissue": [ 61 ], "(eWAT).": [ 62 ], "We": [ 63 ], "observed": [ 64 ], "that": [ 65, 229 ], "reduced": [ 67 ], "caloric": [ 68 ], "intake,": [ 69 ], "body": [ 70 ], "weight,": [ 71 ], "plasma": [ 73 ], "levels": [ 74 ], "triglycerides": [ 76 ], "VLDL": [ 78 ], "a": [ 80, 99, 168, 191, 206 ], "diet\u2010independent": [ 81 ], "manner.": [ 82, 103 ], "However,": [ 83 ], "changes": [ 84 ], "liver": [ 86, 160 ], "fat": [ 87 ], "content": [ 88, 162 ], "metabolism": [ 94, 228 ], "produced": [ 97 ], "tissue\u2010dependent": [ 102 ], "In": [ 104 ], "rats,": [ 106, 155 ], "increased": [ 108 ], "gene/protein": [ 110 ], "elements": [ 113, 173 ], "lipogenesis": [ 116, 176 ], "(": [ 117, 131, 184 ], "ChREBP": [ 118 ], ",": [ 119, 133 ], "Acaca": [ 120 ], "/ACC,": [ 121 ], "Fasn": [ 122 ], "/FAS,": [ 123 ], "Scd1": [ 124 ], "/SCD1,": [ 125 ], "PPAR\u03b1/\u03b3),": [ 126 ], "(CPT1b),": [ 128 ], "Cox4i1": [ 132 ], "Ucp1": [ 134 ], "/UCP1)": [ 135 ], "eWAT": [ 137 ], "which": [ 140, 189 ], "suggest": [ 141, 190 ], "an": [ 142 ], "increase": [ 143 ], "fatty\u2010acid": [ 145 ], "flux": [ 146 ], "utilization": [ 148 ], "activate": [ 150 ], "energy": [ 151 ], "expenditure.": [ 152 ], "Regarding": [ 153 ], "DIO": [ 154, 200 ], "specific": [ 157 ], "reduction": [ 158 ], "by": [ 163 ], "was": [ 165 ], "associated": [ 166 ], "with": [ 167, 203 ], "decreased": [ 169, 207 ], "main": [ 172 ], "(phospho\u2010ACC),": [ 177 ], "peroxisomal": [ 178 ], "(ACOX1),": [ 180 ], "flux/storage": [ 183 ], "Ppar\u03b3": [ 185 ], "/PPAR\u03b3)": [ 186 ], "recovery": [ 192 ], "homeostasis.": [ 195 ], "Interestingly,": [ 196 ], "muscle": [ 198 ], "treated": [ 202 ], "showed": [ 205 ], "PPAR\u03b3": [ 210 ], "thermogenic": [ 213 ], "factor": [ 214 ], "UCP1.": [ 215 ], "These": [ 216 ], "results": [ 217 ], "help": [ 218 ], "us": [ 219 ], "better": [ 221 ], "understand": [ 222 ], "mechanisms": [ 225 ], "regulating": [ 226 ], "underlay": [ 230 ], "effectiveness": [ 232 ], "GLP\u20101": [ 234 ], "analogues": [ 235 ], "for": [ 236 ], "treatment": [ 238 ], "diabetes": [ 240 ], "obesity.": [ 242 ], "\u00a9": [ 243 ], "2016": [ 244, 247 ], "BioFactors,": [ 245 ], "42(6):600\u2013611,": [ 246 ] }, "publication_date": "2016-05-23", "publication_year": 2016, "type": "article", "cited_by_count": 41, "authors": [ { "id": "https://openalex.org/A5086353415", "display_name": "Juan Decara" }, { "id": "https://openalex.org/A5036671707", "display_name": "Sergio Arrabal" }, { "id": "https://openalex.org/A5074391983", "display_name": "Daniel Beiroa" }, { "id": "https://openalex.org/A5072058120", "display_name": "Patricia Rivera" }, { "id": "https://openalex.org/A5044127247", "display_name": "Antonio Vargas" }, { "id": "https://openalex.org/A5013915946", "display_name": "Antonia Serrano" }, { "id": "https://openalex.org/A5089785370", "display_name": "Francisco Javier Pav\u00f3n" }, { "id": "https://openalex.org/A5110721391", "display_name": "Joan Ballesteros" }, { "id": "https://openalex.org/A5044168126", "display_name": "Carlos Di\u00e9guez" }, { "id": "https://openalex.org/A5020982137", "display_name": "Rub\u00e9n Nogueiras" }, { "id": "https://openalex.org/A5014291973", "display_name": "Fern\u00e1ndo Rodr\u00edguez de Fonseca" }, { "id": "https://openalex.org/A5015422381", "display_name": "Juan Su\u00e1rez" } ] }, { "id": "https://openalex.org/W3046891294", "doi": "https://doi.org/10.1111/dom.14160", "title": "Effects of glucagon\u2010like peptide\u20101 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials", "abstract": { "Abstract": [ 0 ], "Associations": [ 1 ], "between": [ 2 ], "body": [ 3 ], "mass": [ 4 ], "index": [ 5 ], "(BMI)": [ 6 ], "and": [ 7, 11, 38, 49, 55, 78, 86, 106, 111, 113, 132, 141, 198, 213, 221 ], "the": [ 8, 35, 50 ], "cardiovascular": [ 9 ], "(CV)": [ 10 ], "kidney": [ 12, 114, 199 ], "efficacy": [ 13, 158 ], "of": [ 14, 43, 90, 143, 156, 174, 203 ], "glucagon\u2010like": [ 15 ], "peptide\u20101": [ 16 ], "receptor": [ 17 ], "agonists": [ 18 ], "(GLP\u20101": [ 19 ], "RAs)": [ 20 ], "in": [ 21, 40, 61, 82 ], "patients": [ 22, 83, 97, 144, 220 ], "with": [ 23, 59, 63, 84, 116, 145 ], "type": [ 24 ], "2": [ 25, 65, 109 ], "diabetes": [ 26 ], "(T2D)": [ 27 ], "are": [ 28 ], "uncertain;": [ 29 ], "therefore,": [ 30 ], "data": [ 31, 126 ], "analysed": [ 32 ], "separately": [ 33 ], "from": [ 34, 127, 206 ], "Liraglutide": [ 36 ], "Effect": [ 37 ], "Action": [ 39 ], "Diabetes:": [ 41 ], "Evaluation": [ 42 ], "Cardiovascular": [ 44, 54 ], "Outcome": [ 45 ], "Results": [ 46 ], "(LEADER)": [ 47 ], "trial": [ 48 ], "Trial": [ 51 ], "to": [ 52, 225 ], "Evaluate": [ 53 ], "Other": [ 56 ], "Long\u2010term": [ 57 ], "Outcomes": [ 58 ], "Semaglutide": [ 60 ], "Subjects": [ 62 ], "Type": [ 64 ], "Diabetes": [ 66 ], "(SUSTAIN": [ 67 ], "6)": [ 68 ], "were": [ 69, 98, 121, 138 ], "examined.": [ 70 ], "These": [ 71 ], "international,": [ 72 ], "randomized,": [ 73 ], "placebo\u2010controlled": [ 74 ], "trials": [ 75 ], "investigated": [ 76 ], "liraglutide": [ 77, 212 ], "semaglutide": [ 79, 157, 214 ], "(both": [ 80 ], "subcutaneous)": [ 81 ], "T2D": [ 85 ], "at": [ 87 ], "high": [ 88 ], "risk": [ 89 ], "CV": [ 91, 112, 165, 170, 197 ], "events.": [ 92 ], "In": [ 93, 150 ], "post": [ 94 ], "hoc": [ 95 ], "analyses,": [ 96 ], "categorized": [ 99 ], "by": [ 100, 159 ], "baseline": [ 101, 124, 160, 229 ], "BMI": [ 102, 125, 161, 193 ], "(<25,": [ 103 ], "\u226525\u2010<30,": [ 104 ], "\u226530\u2010<35": [ 105 ], "\u226535": [ 107 ], "kg/m": [ 108 ], "),": [ 110 ], "outcomes": [ 115, 209 ], "GLP\u20101": [ 117, 188 ], "RA": [ 118, 189 ], "versus": [ 119, 190 ], "placebo": [ 120, 191 ], "analysed.": [ 122 ], "All": [ 123 ], "LEADER": [ 128 ], "(n": [ 129, 135 ], "=": [ 130, 136, 178 ], "9331)": [ 131 ], "SUSTAIN": [ 133, 151 ], "6": [ 134 ], "3290)": [ 137 ], "included": [ 139 ], "(91%": [ 140 ], "92%": [ 142 ], "overweight": [ 146 ], "or": [ 147 ], "obesity,": [ 148 ], "respectively).": [ 149 ], "6,": [ 152 ], "nominally": [ 153 ], "significant": [ 154 ], "heterogeneity": [ 155, 185, 205 ], "was": [ 162, 182 ], "observed": [ 163 ], "for": [ 164, 186, 195, 218 ], "death/myocardial": [ 166 ], "infarction/stroke": [ 167 ], "(major": [ 168 ], "adverse": [ 169 ], "events,": [ 171 ], "primary": [ 172 ], "outcome": [ 173 ], "both;": [ 175 ], "P": [ 176 ], "interaction": [ 177 ], ".02);": [ 179 ], "otherwise,": [ 180 ], "there": [ 181 ], "no": [ 183 ], "statistical": [ 184, 204 ], "either": [ 187 ], "across": [ 192 ], "categories": [ 194 ], "key": [ 196 ], "outcomes.": [ 200 ], "The": [ 201 ], "lack": [ 202 ], "these": [ 207 ], "cardiorenal": [ 208 ], "implies": [ 210 ], "that": [ 211 ], "may": [ 215 ], "be": [ 216 ], "beneficial": [ 217 ], "many": [ 219 ], "is": [ 222, 234 ], "probable": [ 223 ], "not": [ 224 ], "depend": [ 226 ], "on": [ 227 ], "their": [ 228 ], "BMI,": [ 230 ], "but": [ 231 ], "further": [ 232 ], "study": [ 233 ], "needed.": [ 235 ] }, "publication_date": "2020-08-03", "publication_year": 2020, "type": "article", "cited_by_count": 77, "authors": [ { "id": "https://openalex.org/A5080334509", "display_name": "Subodh Verma" }, { "id": "https://openalex.org/A5071945904", "display_name": "Darren K. McGuire" }, { "id": "https://openalex.org/A5080463002", "display_name": "Stephen C. Bain" }, { "id": "https://openalex.org/A5010571732", "display_name": "Deepak L. Bhatt" }, { "id": "https://openalex.org/A5080414941", "display_name": "Lawrence A. Leiter" }, { "id": "https://openalex.org/A5041840962", "display_name": "C. David Mazer" }, { "id": "https://openalex.org/A5067480548", "display_name": "Tea Monk Fries" }, { "id": "https://openalex.org/A5059098934", "display_name": "Richard E. Pratley" }, { "id": "https://openalex.org/A5110231477", "display_name": "S\u00f8ren Rasmussen" }, { "id": "https://openalex.org/A5054552742", "display_name": "Hrvoje Vra\u017ei\u0107" }, { "id": "https://openalex.org/A5090437675", "display_name": "Bernard Zinman" }, { "id": "https://openalex.org/A5040182038", "display_name": "John B. Buse" } ] }, { "id": "https://openalex.org/W2049155190", "doi": "https://doi.org/10.1007/s40265-014-0325-2", "title": "Combining a GLP-1 Receptor Agonist and Basal Insulin: Study Evidence and Practical Considerations", "abstract": null, "publication_date": "2014-11-21", "publication_year": 2014, "type": "review", "cited_by_count": 28, "authors": [ { "id": "https://openalex.org/A5087018300", "display_name": "Nicholas W. Carris" }, { "id": "https://openalex.org/A5074308176", "display_name": "James R. Taylor" }, { "id": "https://openalex.org/A5075968422", "display_name": "John G. Gums" } ] }, { "id": "https://openalex.org/W4396217668", "doi": "https://doi.org/10.3389/fnut.2024.1398059", "title": "Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity", "abstract": { "Obesity,": [ 0 ], "a": [ 1 ], "chronic": [ 2 ], "global": [ 3, 30 ], "health": [ 4 ], "problem,": [ 5 ], "is": [ 6 ], "associated": [ 7 ], "with": [ 8 ], "an": [ 9 ], "increase": [ 10 ], "in": [ 11, 75, 84, 115 ], "various": [ 12 ], "comorbidities,": [ 13 ], "such": [ 14, 86 ], "as": [ 15, 58, 87 ], "cardiovascular": [ 16 ], "disease,": [ 17 ], "type": [ 18, 50 ], "2": [ 19, 51 ], "diabetes": [ 20, 52 ], "mellitus,": [ 21 ], "hypertension,": [ 22 ], "and": [ 23, 46, 73, 79, 96, 110 ], "certain": [ 24 ], "types": [ 25 ], "of": [ 26, 32, 63, 71, 82, 112 ], "cancer.": [ 27 ], "The": [ 28 ], "increasing": [ 29 ], "prevalence": [ 31 ], "obesity": [ 33, 116 ], "requires": [ 34 ], "research": [ 35 ], "into": [ 36 ], "new": [ 37 ], "therapeutic": [ 38 ], "strategies.": [ 39 ], "Glucagon-like": [ 40 ], "peptide-1": [ 41 ], "receptor": [ 42 ], "agonists,": [ 43 ], "specifically": [ 44 ], "semaglutide": [ 45, 72 ], "liraglutide,": [ 47 ], "designed": [ 48 ], "for": [ 49, 60 ], "mellitus": [ 53 ], "treatment,": [ 54 ], "have": [ 55 ], "been": [ 56 ], "explored": [ 57 ], "drugs": [ 59, 114 ], "the": [ 61, 68, 108 ], "treatment": [ 62 ], "obesity.": [ 64 ], "This": [ 65 ], "minireview": [ 66 ], "describes": [ 67 ], "molecular": [ 69 ], "mechanisms": [ 70 ], "liraglutide": [ 74 ], "different": [ 76 ], "metabolic": [ 77 ], "pathways,": [ 78 ], "its": [ 80 ], "mechanism": [ 81 ], "action": [ 83 ], "processes": [ 85 ], "appetite": [ 88 ], "regulation,": [ 89 ], "insulin": [ 90 ], "secretion,": [ 91 ], "glucose": [ 92 ], "homeostasis,": [ 93 ], "energy": [ 94 ], "expenditure,": [ 95 ], "lipid": [ 97 ], "metabolism.": [ 98 ], "Finally,": [ 99 ], "several": [ 100 ], "clinical": [ 101 ], "trial": [ 102 ], "outcomes": [ 103 ], "are": [ 104 ], "described": [ 105 ], "to": [ 106 ], "show": [ 107 ], "safety": [ 109 ], "efficacy": [ 111 ], "these": [ 113 ], "management.": [ 117 ] }, "publication_date": "2024-04-29", "publication_year": 2024, "type": "article", "cited_by_count": 38, "authors": [ { "id": "https://openalex.org/A5010580419", "display_name": "Rafael Tamayo\u2010Trujillo" }, { "id": "https://openalex.org/A5079074364", "display_name": "Viviana A. Ruiz\u2010Pozo" }, { "id": "https://openalex.org/A5004104130", "display_name": "Santiago Cadena-Ullauri" }, { "id": "https://openalex.org/A5068857247", "display_name": "Patricia Guevara-Ram\u00ed\u00adrez" }, { "id": "https://openalex.org/A5074567304", "display_name": "Elius Paz\u2010Cruz" }, { "id": "https://openalex.org/A5094358432", "display_name": "Raynier Zambrano-Villacres" }, { "id": "https://openalex.org/A5051753481", "display_name": "Daniel Simancas\u2010Racines" }, { "id": "https://openalex.org/A5073359409", "display_name": "Ana Karina Zambrano" } ] }, { "id": "https://openalex.org/W1959592008", "doi": "https://doi.org/10.1002/phar.1639", "title": "Liraglutide: A New Option for the Treatment of Obesity", "abstract": { "Obesity": [ 0, 28 ], "continues": [ 1 ], "to": [ 2, 9, 122, 162, 213 ], "pose": [ 3 ], "a": [ 4, 41, 58, 85, 126, 156, 248 ], "major": [ 5 ], "public": [ 6 ], "health": [ 7 ], "risk": [ 8 ], "the": [ 10, 15, 32, 96, 120, 132, 142, 159, 260 ], "United": [ 11 ], "States": [ 12 ], "and": [ 13, 124, 145, 197, 211 ], "across": [ 14 ], "world,": [ 16 ], "with": [ 17, 57, 115, 177 ], "an": [ 18, 112 ], "estimated": [ 19 ], "one\u2010third": [ 20 ], "of": [ 21, 34, 48, 60, 98, 134, 158, 193, 219, 262 ], "adult": [ 22 ], "Americans": [ 23 ], "being": [ 24 ], "defined": [ 25 ], "as": [ 26, 111 ], "obese.": [ 27 ], "treatment": [ 29, 97, 133, 261 ], "guidelines": [ 30 ], "recommend": [ 31 ], "use": [ 33 ], "pharmacologic": [ 35, 257 ], "therapy": [ 36, 220 ], "in": [ 37, 55, 95, 151, 171, 215 ], "adults": [ 38 ], "who": [ 39, 66 ], "have": [ 40, 67 ], "body": [ 42 ], "mass": [ 43 ], "index": [ 44 ], "(": [ 45 ], "BMI": [ 46, 59 ], ")": [ 47 ], "30": [ 49 ], "kg/m": [ 50, 62 ], "2": [ 51, 63, 80, 100 ], "or": [ 52, 54, 64, 195, 199 ], "higher": [ 53, 65, 127 ], "patients": [ 56 ], "27": [ 61 ], "at": [ 68 ], "least": [ 69 ], "one": [ 70 ], "weight\u2010related": [ 71 ], "comorbid": [ 72 ], "condition": [ 73 ], "(e.g.,": [ 74 ], "hypertension,": [ 75 ], "dyslipidemia,": [ 76 ], "insulin": [ 77 ], "resistance,": [ 78 ], "type": [ 79, 99 ], "diabetes": [ 81, 101 ], "mellitus).": [ 82 ], "Liraglutide": [ 83, 136, 235, 252 ], "is": [ 84, 221, 232, 236 ], "glucagon\u2010like": [ 86 ], "peptide\u20101": [ 87 ], "receptor": [ 88 ], "agonist": [ 89 ], "that": [ 90, 186 ], "has": [ 91, 107 ], "been": [ 92, 108 ], "successfully": [ 93, 189 ], "used": [ 94 ], "for": [ 102, 131, 148, 226, 239, 250, 259 ], "several": [ 103 ], "years.": [ 104 ], "Weight": [ 105 ], "loss": [ 106, 201 ], "well": [ 109 ], "described": [ 110 ], "additional": [ 113 ], "benefit": [ 114 ], "liraglutide": [ 116, 187 ], "therapy,": [ 117 ], "which": [ 118, 245 ], "prompted": [ 119 ], "manufacturer": [ 121 ], "evaluate": [ 123 ], "develop": [ 125 ], "dose": [ 128 ], "formulation": [ 129 ], "specifically": [ 130, 170 ], "obesity.": [ 135, 173, 263 ], "3": [ 137, 253 ], "mg/day": [ 138, 254 ], "was": [ 139 ], "approved": [ 140 ], "by": [ 141, 242 ], "U.S.": [ 143 ], "Food": [ 144 ], "Drug": [ 146 ], "Administration": [ 147 ], "this": [ 149, 178 ], "indication": [ 150 ], "December": [ 152 ], "2014.": [ 153 ], "We": [ 154 ], "performed": [ 155 ], "search": [ 157 ], "Medline": [ 160 ], "database": [ 161 ], "identify": [ 163 ], "relevant": [ 164 ], "literature": [ 165 ], "focused": [ 166 ], "on": [ 167 ], "liraglutide's": [ 168 ], "role": [ 169 ], "treating": [ 172 ], "Five": [ 174 ], "clinical": [ 175 ], "trials": [ 176 ], "primary": [ 179 ], "end": [ 180 ], "point": [ 181 ], "were": [ 182, 209 ], "identified.": [ 183 ], "Data": [ 184 ], "demonstrated": [ 185 ], "can": [ 188 ], "achieve": [ 190 ], "weight\u2010loss": [ 191 ], "benchmarks": [ 192 ], "5%": [ 194 ], "more": [ 196, 200 ], "10%": [ 198 ], "from": [ 202 ], "baseline.": [ 203 ], "The": [ 204, 217 ], "most": [ 205 ], "common": [ 206 ], "adverse": [ 207 ], "effects": [ 208 ], "gastrointestinal": [ 210 ], "mild": [ 212 ], "moderate": [ 214 ], "intensity.": [ 216 ], "cost": [ 218 ], "high,": [ 222 ], "averaging": [ 223 ], "over": [ 224 ], "$1000/month": [ 225 ], "out\u2010of\u2010pocket": [ 227 ], "expenses": [ 228 ], "if": [ 229 ], "insurance": [ 230 ], "coverage": [ 231 ], "not": [ 233 ], "available.": [ 234 ], "also": [ 237 ], "available": [ 238 ], "delivery": [ 240 ], "only": [ 241 ], "subcutaneous": [ 243 ], "injection,": [ 244 ], "may": [ 246 ], "represent": [ 247 ], "barrier": [ 249 ], "patients.": [ 251 ], "represents": [ 255 ], "another": [ 256 ], "option": [ 258 ] }, "publication_date": "2015-10-01", "publication_year": 2015, "type": "review", "cited_by_count": 143, "authors": [ { "id": "https://openalex.org/A5016624558", "display_name": "Wesley Nuffer" }, { "id": "https://openalex.org/A5054620018", "display_name": "Jennifer Trujillo" } ] }, { "id": "https://openalex.org/W2070260892", "doi": "https://doi.org/10.2337/dc11-0931", "title": "Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes", "abstract": { "OBJECTIVE": [ 0 ], "To": [ 1 ], "investigate": [ 2 ], "the": [ 3, 8, 177, 224 ], "effect": [ 4 ], "of": [ 5, 84, 113, 121, 123, 206, 212, 226 ], "treatment": [ 6, 55, 105, 172, 192 ], "with": [ 7, 79, 90, 103, 163, 174, 186, 195 ], "glucagon-like": [ 9 ], "peptide": [ 10 ], "1": [ 11 ], "receptor": [ 12 ], "agonist": [ 13 ], "exenatide": [ 14, 80, 104, 164, 171, 191 ], "on": [ 15 ], "weight": [ 16, 96, 114, 132, 144, 154, 187, 197, 216 ], "loss": [ 17, 102, 115, 198, 217 ], "and": [ 18, 37, 148, 182, 199 ], "metabolic": [ 19 ], "parameters": [ 20 ], "in": [ 21, 44, 73, 203, 223 ], "obese": [ 22, 30, 207 ], "nondiabetic": [ 23, 208 ], "women.": [ 24, 209 ], "RESEARCH": [ 25 ], "DESIGN": [ 26 ], "AND": [ 27 ], "METHODS": [ 28 ], "Forty-one": [ 29 ], "women": [ 31 ], "(aged": [ 32 ], "48": [ 33 ], "\u00b1": [ 34, 40, 86, 93, 134, 146, 156 ], "11": [ 35 ], "years": [ 36 ], "BMI": [ 38 ], "33.1": [ 39 ], "4.1": [ 41 ], "kg/m2)": [ 42 ], "participated": [ 43 ], "a": [ 45, 59, 91, 204 ], "35-week": [ 46 ], "randomized,": [ 47 ], "double-blind,": [ 48 ], "placebo-controlled,": [ 49 ], "crossover": [ 50 ], "study,": [ 51 ], "including": [ 52 ], "two": [ 53 ], "16-week": [ 54 ], "periods": [ 56 ], "separated": [ 57 ], "by": [ 58 ], "3-week": [ 60 ], "washout": [ 61 ], "period.": [ 62 ], "There": [ 63 ], "was": [ 64, 71, 106, 193, 219 ], "no": [ 65 ], "lifestyle": [ 66 ], "intervention.": [ 67 ], "The": [ 68, 111 ], "primary": [ 69 ], "outcome": [ 70 ], "change": [ 72 ], "body": [ 74, 131, 143 ], "weight.": [ 75 ], "RESULTS": [ 76 ], "Subjects": [ 77, 166 ], "treated": [ 78 ], "lost": [ 81, 129, 141 ], "an": [ 82 ], "average": [ 83 ], "2.49": [ 85 ], "0.66": [ 87 ], "kg": [ 88, 95 ], "compared": [ 89, 173 ], "0.43": [ 92 ], "0.63": [ 94 ], "gain": [ 97 ], "during": [ 98, 170 ], "placebo": [ 99 ], "treatment.": [ 100, 165, 227 ], "Weight": [ 101 ], "noted": [ 107 ], "at": [ 108 ], "2": [ 109 ], "weeks.": [ 110 ], "degree": [ 112 ], "could": [ 116 ], "be": [ 117 ], "stratified.": [ 118 ], "A": [ 119, 210 ], "total": [ 120 ], "30%": [ 122 ], "subjects": [ 124 ], "were": [ 125, 137, 150 ], "high": [ 126 ], "responders": [ 127, 139 ], "who": [ 128, 140, 152 ], "\u22655%": [ 130 ], "(\u22127.96": [ 133 ], "0.52%),": [ 135 ], "39%": [ 136 ], "moderate": [ 138 ], "&lt;5%": [ 142 ], "(\u22122.43": [ 145 ], "0.45%),": [ 147 ], "31%": [ 149 ], "nonresponders": [ 151 ], "gained": [ 153 ], "(1.93": [ 155 ], "0.53%).": [ 157 ], "Waist": [ 158 ], "circumference": [ 159, 202 ], "also": [ 160 ], "decreased": [ 161, 179, 200 ], "significantly": [ 162 ], "experienced": [ 167 ], "more": [ 168 ], "nausea": [ 169 ], "placebo,": [ 175 ], "but": [ 176 ], "severity": [ 178 ], "over": [ 180 ], "time": [ 181 ], "did": [ 183 ], "not": [ 184 ], "correlate": [ 185 ], "loss.": [ 188 ], "CONCLUSIONS": [ 189 ], "Short-term": [ 190 ], "associated": [ 194 ], "modest": [ 196 ], "waist": [ 201 ], "cohort": [ 205 ], "subset": [ 211 ], "individuals": [ 213 ], "demonstrated": [ 214 ], "robust": [ 215 ], "that": [ 218 ], "detected": [ 220 ], "very": [ 221 ], "early": [ 222 ], "course": [ 225 ] }, "publication_date": "2011-11-01", "publication_year": 2011, "type": "article", "cited_by_count": 149, "authors": [ { "id": "https://openalex.org/A5042799696", "display_name": "Jody Dushay" }, { "id": "https://openalex.org/A5052960352", "display_name": "Chong Gao" }, { "id": "https://openalex.org/A5027247902", "display_name": "Gosala Gopalakrishnan" }, { "id": "https://openalex.org/A5032182500", "display_name": "Meghan B. Crawley" }, { "id": "https://openalex.org/A5046830065", "display_name": "Emilie K. Mitten" }, { "id": "https://openalex.org/A5036555241", "display_name": "Elissa H. Wilker" }, { "id": "https://openalex.org/A5047605036", "display_name": "Janet Mullington" }, { "id": "https://openalex.org/A5051918182", "display_name": "Eleftheria Maratos\u2013Flier" } ] }, { "id": "https://openalex.org/W2908397509", "doi": "https://doi.org/10.1016/j.diabet.2018.12.001", "title": "Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1\u20137 trials", "abstract": null, "publication_date": "2019-01-03", "publication_year": 2019, "type": "review", "cited_by_count": 248, "authors": [ { "id": "https://openalex.org/A5005405894", "display_name": "Vanita R. Aroda" }, { "id": "https://openalex.org/A5082525611", "display_name": "Andrew Ahmann" }, { "id": "https://openalex.org/A5004521406", "display_name": "Bertrand Cariou" }, { "id": "https://openalex.org/A5110447350", "display_name": "Francis C. C. Chow" }, { "id": "https://openalex.org/A5084593004", "display_name": "Melanie J. Davies" }, { "id": "https://openalex.org/A5088506788", "display_name": "Esteban J\u00f3dar" }, { "id": "https://openalex.org/A5040703874", "display_name": "Rajendra Mehta" }, { "id": "https://openalex.org/A5032297044", "display_name": "Vincent Woo" }, { "id": "https://openalex.org/A5001655356", "display_name": "Ildiko Lingvay" } ] }, { "id": "https://openalex.org/W1970656852", "doi": "https://doi.org/10.1111/j.1463-1326.2012.01579.x", "title": "Non\u2010glycaemic effects mediated via GLP\u20101 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide", "abstract": { "The": [ 0 ], "glucagon\u2010like": [ 1 ], "peptide\u20101": [ 2 ], "receptor": [ 3 ], "agonists": [ 4 ], "(GLP\u20101": [ 5 ], "RAs)": [ 6 ], "liraglutide": [ 7, 117 ], "and": [ 8, 42, 67, 92, 101, 118, 132, 142, 148 ], "exenatide": [ 9, 119 ], "can": [ 10 ], "improve": [ 11, 107 ], "glycaemic": [ 12 ], "control": [ 13 ], "by": [ 14, 87 ], "stimulating": [ 15 ], "insulin": [ 16 ], "release": [ 17 ], "through": [ 18 ], "pancreatic": [ 19 ], "\u03b2": [ 20, 61, 88 ], "\u2010cells": [ 21 ], "in": [ 22, 60, 129, 159 ], "a": [ 23, 47, 74 ], "glucose\u2010dependent": [ 24 ], "manner.": [ 25 ], "GLP\u20101": [ 26, 35, 55, 127, 153 ], "receptors": [ 27 ], "are": [ 28, 72, 85, 103, 155 ], "not": [ 29 ], "restricted": [ 30 ], "to": [ 31, 54, 77 ], "the": [ 32, 130 ], "pancreas;": [ 33 ], "therefore,": [ 34 ], "RAs": [ 36, 128 ], "cause": [ 37 ], "additional": [ 38, 50 ], "non\u2010glycaemic": [ 39 ], "effects.": [ 40 ], "Preclinical": [ 41 ], "clinical": [ 43, 144, 162 ], "trial": [ 44 ], "data": [ 45 ], "suggest": [ 46 ], "multitude": [ 48 ], "of": [ 49, 73, 152 ], "beneficial": [ 51 ], "effects": [ 52, 71, 147 ], "related": [ 53 ], "RA": [ 56 ], "therapy,": [ 57 ], "including": [ 58 ], "improvements": [ 59 ], "\u2010cell": [ 62, 89 ], "function,": [ 63 ], "systolic": [ 64 ], "blood": [ 65 ], "pressure": [ 66 ], "body": [ 68 ], "weight.": [ 69 ], "These": [ 70, 146 ], "particular": [ 75 ], "advantage": [ 76 ], "patients": [ 78 ], "with": [ 79, 116 ], "type": [ 80 ], "2": [ 81 ], "diabetes,": [ 82 ], "as": [ 83, 99 ], "most": [ 84 ], "affected": [ 86 ], "dysfunction,": [ 90 ], "obesity": [ 91 ], "hypertension.": [ 93 ], "Transient": [ 94 ], "gastrointestinal": [ 95, 108 ], "adverse": [ 96 ], "events,": [ 97 ], "such": [ 98 ], "nausea": [ 100 ], "diarrhoea,": [ 102 ], "also": [ 104 ], "common.": [ 105 ], "To": [ 106 ], "tolerability,": [ 109 ], "an": [ 110 ], "incremental": [ 111 ], "dosing": [ 112 ], "approach": [ 113 ], "is": [ 114 ], "used": [ 115 ], "twice": [ 120 ], "daily.": [ 121 ], "A": [ 122 ], "potential": [ 123 ], "protective": [ 124 ], "role": [ 125 ], "for": [ 126 ], "cardiovascular": [ 131 ], "central": [ 133 ], "nervous": [ 134 ], "systems": [ 135 ], "has": [ 136 ], "been": [ 137 ], "suggested": [ 138 ], "from": [ 139 ], "animal": [ 140 ], "studies": [ 141 ], "short\u2010term": [ 143 ], "trials.": [ 145 ], "other": [ 149 ], "safety": [ 150 ], "aspects": [ 151 ], "therapy": [ 154 ], "currently": [ 156 ], "being": [ 157 ], "investigated": [ 158 ], "ongoing": [ 160 ], "long\u2010term": [ 161 ], "studies.": [ 163 ] }, "publication_date": "2012-03-08", "publication_year": 2012, "type": "review", "cited_by_count": 29, "authors": [ { "id": "https://openalex.org/A5004120950", "display_name": "Tina Vilsb\u00f8ll" }, { "id": "https://openalex.org/A5111569181", "display_name": "A. J. Garber" } ] }, { "id": "https://openalex.org/W3014755863", "doi": "https://doi.org/10.3389/fendo.2020.00178", "title": "GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials", "abstract": { "The": [ 0 ], "incretin": [ 1 ], "hormones": [ 2 ], "glucagon-like": [ 3 ], "peptide-1": [ 4 ], "(GLP-1)": [ 5 ], "and": [ 6, 58, 72, 99, 128, 150, 163, 170, 215, 220, 236, 251, 291, 305, 343 ], "glucose-dependent": [ 7 ], "insulinotropic": [ 8 ], "polypeptide": [ 9 ], "(GIP)": [ 10 ], "are": [ 11, 94, 112, 165, 294, 308, 364 ], "released": [ 12 ], "from": [ 13, 279 ], "enteroendocrine": [ 14 ], "cells": [ 15 ], "in": [ 16, 23, 36, 176, 198, 340, 347 ], "response": [ 17, 55 ], "to": [ 18, 56, 61, 74, 122, 142, 188, 240, 282, 300, 368 ], "the": [ 19, 24, 68, 78, 103, 124, 191, 213, 229, 241, 297, 312, 320, 337, 348 ], "presence": [ 20 ], "of": [ 21, 70, 77, 105, 115, 126, 154, 193, 217, 254, 268, 315, 322, 336 ], "nutrients": [ 22 ], "small": [ 25 ], "intestines.": [ 26 ], "These": [ 27, 223 ], "homones": [ 28 ], "facilitate": [ 29 ], "glucose": [ 30, 38 ], "regulation": [ 31 ], "by": [ 32 ], "stimulating": [ 33 ], "insulin": [ 34, 54 ], "secretion": [ 35 ], "a": [ 37, 87, 131, 151, 249, 265, 283, 360 ], "dependent": [ 39 ], "manner": [ 40 ], "while": [ 41, 181 ], "suppressing": [ 42 ], "glucagon": [ 43 ], "secretion.": [ 44 ], "In": [ 45, 81, 134 ], "patients": [ 46, 278, 316, 334, 352 ], "with": [ 47, 200, 202, 248, 258, 264, 317, 353, 359 ], "type": [ 48 ], "2": [ 49 ], "diabetes": [ 50 ], "(T2DM),": [ 51 ], "an": [ 52 ], "impaired": [ 53 ], "GLP-1": [ 57, 71, 107, 120, 171, 183, 221, 230, 259, 356 ], "GIP": [ 59, 73 ], "contributes": [ 60 ], "hyperglycemia.": [ 62 ], "Dipeptidyl": [ 63 ], "peptidase-4": [ 64 ], "(DPP-4)": [ 65 ], "inhibitors": [ 66, 85, 169, 219, 281, 307, 331 ], "block": [ 67 ], "breakdown": [ 69 ], "increase": [ 75, 102 ], "levels": [ 76 ], "active": [ 79 ], "hormones.": [ 80 ], "clinical": [ 82, 135, 208, 302, 349 ], "trials,": [ 83, 136, 180 ], "DPP-4": [ 84, 127, 168, 218, 242, 280, 306 ], "have": [ 86, 130, 138, 173, 185, 210, 225, 275 ], "modest": [ 88 ], "impact": [ 89 ], "on": [ 90 ], "glycemic": [ 91, 234, 289, 313 ], "control.": [ 92 ], "They": [ 93 ], "generally": [ 95, 226 ], "well-tolerated,": [ 96 ], "weight": [ 97, 148, 237, 292, 344 ], "neutral": [ 98 ], "do": [ 100 ], "not": [ 101 ], "risk": [ 104, 153, 192 ], "hypoglycemia.": [ 106, 155 ], "receptor": [ 108, 357 ], "agonists": [ 109, 358 ], "(GLP-1": [ 110 ], "RA)": [ 111 ], "peptide": [ 113 ], "derivatives": [ 114 ], "either": [ 116 ], "exendin-4": [ 117 ], "or": [ 118 ], "human": [ 119 ], "designed": [ 121 ], "resist": [ 123 ], "activity": [ 125 ], "therefore,": [ 129 ], "prolonged": [ 132 ], "half-life.": [ 133 ], "they": [ 137 ], "demonstrated": [ 139, 174, 227 ], "superior": [ 140, 233 ], "efficacy": [ 141, 214 ], "many": [ 143, 333 ], "oral": [ 144 ], "antihyperglycemic": [ 145 ], "drugs,": [ 146 ], "improved": [ 147, 288 ], "loss": [ 149, 238, 293, 345 ], "low": [ 152, 250 ], "However,": [ 156 ], "GI": [ 157, 269 ], "adverse": [ 158, 195, 270 ], "events,": [ 159 ], "particularly": [ 160 ], "nausea,": [ 161 ], "vomiting,": [ 162 ], "diarrhea": [ 164 ], "seen.": [ 166 ], "Both": [ 167, 244 ], "RAs": [ 172, 184, 260 ], "safety": [ 175, 216 ], "robust": [ 177 ], "cardiovascular": [ 178, 196, 204, 362 ], "outcome": [ 179 ], "several": [ 182 ], "been": [ 186 ], "shown": [ 187 ], "significantly": [ 189 ], "reduce": [ 190 ], "major": [ 194 ], "events": [ 197 ], "persons": [ 199 ], "T2DM": [ 201, 318 ], "pre-existing": [ 203 ], "disease": [ 205 ], "(CVD).": [ 206 ], "Several": [ 207 ], "trials": [ 209 ], "directly": [ 211 ], "compared": [ 212 ], "RAs.": [ 222 ], "studies": [ 224, 274 ], "that": [ 228 ], "RA": [ 231 ], "provided": [ 232 ], "control": [ 235, 290 ], "relative": [ 239 ], "inhibitor.": [ 243 ], "treatments": [ 245 ], "were": [ 246, 261 ], "associated": [ 247, 263 ], "comparable": [ 252 ], "incidence": [ 253, 267 ], "hypoglycemia,": [ 255 ], "but": [ 256 ], "treatment": [ 257 ], "invariably": [ 262 ], "higher": [ 266 ], "events.": [ 271 ], "A": [ 272 ], "few": [ 273 ], "evaluated": [ 276 ], "switching": [ 277 ], "GLP-1RA": [ 284, 304, 324 ], "and,": [ 285 ], "as": [ 286, 366 ], "expected,": [ 287 ], "seen": [ 295 ], "following": [ 296 ], "switch.": [ 298 ], "According": [ 299 ], "current": [ 301 ], "guidelines,": [ 303 ], "both": [ 309 ], "indicated": [ 310, 365 ], "for": [ 311, 332 ], "management": [ 314 ], "across": [ 319 ], "spectrum": [ 321 ], "disease.": [ 323 ], "may": [ 325 ], "be": [ 326 ], "preferred": [ 327 ], "over": [ 328 ], "DPP-": [ 329 ], "4": [ 330 ], "because": [ 335 ], "greater": [ 338 ], "reductions": [ 339 ], "hemoglobin": [ 341 ], "A1c": [ 342 ], "observed": [ 346 ], "trials.": [ 350 ], "Among": [ 351 ], "preexisting": [ 354 ], "CVD,": [ 355 ], "proven": [ 361 ], "benefit": [ 363 ], "add-on": [ 367 ], "metformin": [ 369 ], "therapy.": [ 370 ] }, "publication_date": "2020-04-03", "publication_year": 2020, "type": "review", "cited_by_count": 338, "authors": [ { "id": "https://openalex.org/A5035502539", "display_name": "Matthew P. Gilbert" }, { "id": "https://openalex.org/A5059098934", "display_name": "Richard E. Pratley" } ] }, { "id": "https://openalex.org/W2094706071", "doi": "https://doi.org/10.3390/ijms141121513", "title": "Neuroprotective Effects of Liraglutide for Stroke Model of Rats", "abstract": { "The": [ 0, 113, 141 ], "number": [ 1 ], "of": [ 2, 19, 47, 90, 96, 107, 116, 124, 129, 138, 143, 145, 156, 172, 186 ], "diabetes": [ 3 ], "mellitus": [ 4 ], "(DM)": [ 5 ], "patients": [ 6 ], "is": [ 7, 11, 178 ], "increasing,": [ 8 ], "and": [ 9, 73, 94, 194 ], "stroke": [ 10, 41 ], "deeply": [ 12 ], "associated": [ 13 ], "with": [ 14, 136 ], "DM.": [ 15 ], "Recently,": [ 16 ], "neuroprotective": [ 17, 184 ], "effects": [ 18, 37, 185, 193 ], "glucagon-like": [ 20 ], "peptide-1": [ 21 ], "(GLP-1)": [ 22 ], "are": [ 23 ], "reported.": [ 24 ], "In": [ 25, 175 ], "this": [ 26, 177 ], "study,": [ 27 ], "we": [ 28 ], "explored": [ 29 ], "whether": [ 30 ], "liraglutide,": [ 31 ], "a": [ 32, 39 ], "GLP-1": [ 33 ], "analogue": [ 34 ], "exerts": [ 35 ], "therapeutic": [ 36 ], "on": [ 38, 188 ], "rat": [ 40 ], "model.": [ 42 ], "Wistar": [ 43 ], "rats": [ 44, 78, 118, 131, 158 ], "received": [ 45 ], "occlusion": [ 46 ], "the": [ 48, 105, 160, 165, 179 ], "middle": [ 49 ], "cerebral": [ 50, 189 ], "artery": [ 51 ], "for": [ 52, 81, 88 ], "90": [ 53 ], "min.": [ 54 ], "At": [ 55 ], "one": [ 56 ], "hour": [ 57 ], "after": [ 58 ], "reperfusion,": [ 59 ], "liraglutide": [ 60, 187 ], "or": [ 61 ], "saline": [ 62 ], "was": [ 63, 69, 86, 149 ], "administered": [ 64 ], "intraperitoneally.": [ 65 ], "Modified": [ 66 ], "Bederson\u2019s": [ 67 ], "test": [ 68 ], "performed": [ 70 ], "at": [ 71, 132 ], "1": [ 72 ], "24": [ 74 ], "h": [ 75 ], "and,": [ 76 ], "subsequently,": [ 77 ], "were": [ 79, 101, 119, 133 ], "euthanized": [ 80 ], "histological": [ 82 ], "investigation.": [ 83 ], "Peripheral": [ 84 ], "blood": [ 85, 91 ], "obtained": [ 87 ], "measurement": [ 89 ], "glucose": [ 92 ], "level": [ 93, 106, 142, 155 ], "evaluation": [ 95 ], "oxidative": [ 97 ], "stress.": [ 98 ], "Brain": [ 99 ], "tissues": [ 100 ], "collected": [ 102 ], "to": [ 103, 170, 182 ], "evaluate": [ 104 ], "vascular": [ 108 ], "endothelial": [ 109 ], "growth": [ 110 ], "factor": [ 111 ], "(VEGF).": [ 112 ], "behavioral": [ 114 ], "scores": [ 115 ], "liraglutide-treated": [ 117, 130, 152, 157 ], "significantly": [ 120, 167 ], "better": [ 121 ], "than": [ 122 ], "those": [ 123, 137 ], "control": [ 125, 139, 173 ], "rats.": [ 126, 140, 153, 174 ], "Infarct": [ 127 ], "volumes": [ 128 ], "reduced,": [ 134 ], "compared": [ 135, 169 ], "derivatives": [ 144 ], "reactive": [ 146 ], "oxygen": [ 147 ], "metabolite": [ 148 ], "lower": [ 150 ], "in": [ 151, 159, 164 ], "VEGF": [ 154, 195 ], "cortex,": [ 161 ], "but": [ 162 ], "not": [ 163 ], "striatum": [ 166 ], "increased,": [ 168 ], "that": [ 171 ], "conclusion,": [ 176 ], "first": [ 180 ], "study": [ 181 ], "demonstrate": [ 183 ], "ischemia": [ 190 ], "through": [ 191 ], "anti-oxidative": [ 192 ], "upregulation.": [ 196 ] }, "publication_date": "2013-10-30", "publication_year": 2013, "type": "article", "cited_by_count": 119, "authors": [ { "id": "https://openalex.org/A5023848866", "display_name": "Kenichiro Sato" }, { "id": "https://openalex.org/A5102791680", "display_name": "Masahiro Kameda" }, { "id": "https://openalex.org/A5027946887", "display_name": "Takao Yasuhara" }, { "id": "https://openalex.org/A5021785223", "display_name": "Takashi Agari" }, { "id": "https://openalex.org/A5062548149", "display_name": "Tanefumi Baba" }, { "id": "https://openalex.org/A5100442814", "display_name": "Feifei Wang" }, { "id": "https://openalex.org/A5034755525", "display_name": "Aiko Shinko" }, { "id": "https://openalex.org/A5036940893", "display_name": "Takaaki Wakamori" }, { "id": "https://openalex.org/A5034622699", "display_name": "Atsuhiko Toyoshima" }, { "id": "https://openalex.org/A5052484804", "display_name": "Hayato Takeuchi" }, { "id": "https://openalex.org/A5101111156", "display_name": "Tatsuya Sasaki" }, { "id": "https://openalex.org/A5087607692", "display_name": "Susumu Sasada" }, { "id": "https://openalex.org/A5014256354", "display_name": "Akihiko Kondo" }, { "id": "https://openalex.org/A5035194870", "display_name": "Cesar V. Borlongan" }, { "id": "https://openalex.org/A5077943905", "display_name": "Mitsunori Matsumae" }, { "id": "https://openalex.org/A5004595871", "display_name": "Isao Date" } ] }, { "id": "https://openalex.org/W2132277825", "doi": "https://doi.org/10.2337/diaclin.30.1.3", "title": "Choosing GLP-1 Receptor Agonists or DPP-4 Inhibitors: Weighing the Clinical Trial Evidence", "abstract": { "IN": [ 0 ], "BRIEF": [ 1 ], "Comparative": [ 2 ], "trials": [ 3 ], "show": [ 4 ], "that": [ 5 ], "there": [ 6 ], "are": [ 7, 46, 63 ], "important": [ 8 ], "differences": [ 9 ], "between": [ 10 ], "and": [ 11, 19, 31, 37, 44, 61 ], "among": [ 12 ], "the": [ 13, 38, 51, 66 ], "glucagon-like": [ 14 ], "peptide-1": [ 15 ], "(GLP-1)": [ 16 ], "receptor": [ 17, 54 ], "agonists": [ 18 ], "dipeptidyl": [ 20 ], "peptidase-4": [ 21 ], "(DPP-4)": [ 22 ], "inhibitors": [ 23 ], "with": [ 24, 48, 65 ], "respect": [ 25 ], "to": [ 26 ], "glycemic": [ 27 ], "lowering,": [ 28 ], "weight": [ 29 ], "effects,": [ 30 ], "effects": [ 32 ], "on": [ 33 ], "systolic": [ 34 ], "blood": [ 35 ], "pressure": [ 36 ], "lipid": [ 39 ], "profile.": [ 40 ], "Nausea,": [ 41 ], "diarrhea,": [ 42 ], "headaches,": [ 43 ], "dizziness": [ 45 ], "common": [ 47, 64 ], "both": [ 49 ], "of": [ 50 ], "available": [ 52 ], "GLP-1": [ 53 ], "agonists.": [ 55 ], "Upper": [ 56 ], "respiratory": [ 57 ], "tract": [ 58 ], "infections,": [ 59 ], "nasopharyngitis,": [ 60 ], "headaches": [ 62 ], "DPP-4": [ 67 ], "inhibitors.": [ 68 ], "Ongoing": [ 69 ], "safety": [ 70 ], "evaluations": [ 71 ], "should": [ 72 ], "provide": [ 73 ], "a": [ 74 ], "clear": [ 75 ], "picture": [ 76 ], "regarding": [ 77 ], "long-term": [ 78 ], "safety.": [ 79 ] }, "publication_date": "2012-01-01", "publication_year": 2012, "type": "article", "cited_by_count": 35, "authors": [ { "id": "https://openalex.org/A5000792801", "display_name": "Timothy Reid" } ] }, { "id": "https://openalex.org/W2443300690", "doi": "https://doi.org/10.1038/srep26859", "title": "The Neuroprotection of Liraglutide Against Ischaemia-induced Apoptosis through the Activation of the PI3K/AKT and MAPK Pathways", "abstract": null, "publication_date": "2016-05-31", "publication_year": 2016, "type": "article", "cited_by_count": 172, "authors": [ { "id": "https://openalex.org/A5102012640", "display_name": "Huili Zhu" }, { "id": "https://openalex.org/A5100703882", "display_name": "Yusheng Zhang" }, { "id": "https://openalex.org/A5003362646", "display_name": "Zhongshan Shi" }, { "id": "https://openalex.org/A5003564506", "display_name": "Dan Lu" }, { "id": "https://openalex.org/A5100416451", "display_name": "Tingting Li" }, { "id": "https://openalex.org/A5103268061", "display_name": "Yan Ding" }, { "id": "https://openalex.org/A5102309079", "display_name": "Yiwen Ruan" }, { "id": "https://openalex.org/A5101613294", "display_name": "Chunxue Wang" } ] }, { "id": "https://openalex.org/W2146837981", "doi": "https://doi.org/10.4093/dmj.2012.36.4.262", "title": "GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease", "abstract": { "Non-alcoholic": [ 0 ], "fatty": [ 1, 66 ], "liver": [ 2, 10 ], "disease": [ 3 ], "(NAFLD),": [ 4 ], "one": [ 5 ], "of": [ 6, 17, 83, 88 ], "the": [ 7, 15, 84 ], "most": [ 8 ], "common": [ 9 ], "diseases,": [ 11 ], "is": [ 12, 22, 37 ], "caused": [ 13 ], "by": [ 14, 64 ], "disruption": [ 16 ], "hepatic": [ 18, 73 ], "lipid": [ 19 ], "homeostasis.": [ 20 ], "It": [ 21 ], "associated": [ 23 ], "with": [ 24 ], "insulin": [ 25, 42 ], "resistance": [ 26 ], "as": [ 27 ], "seen": [ 28 ], "in": [ 29, 50, 53, 90 ], "type": [ 30 ], "2": [ 31 ], "diabetes": [ 32 ], "mellitus.": [ 33 ], "Glucagon-like": [ 34 ], "peptide-1": [ 35 ], "(GLP-1)": [ 36 ], "an": [ 38, 81 ], "incretin": [ 39 ], "that": [ 40 ], "increases": [ 41 ], "sensitivity": [ 43 ], "and": [ 44, 52, 71, 86 ], "aids": [ 45 ], "glucose": [ 46, 74 ], "metabolism.": [ 47, 75 ], "In": [ 48, 76 ], "recent": [ 49 ], "vivo": [ 51 ], "vitro": [ 54 ], "studies,": [ 55 ], "GLP-1": [ 56, 89 ], "presents": [ 57 ], "a": [ 58 ], "novel": [ 59 ], "therapeutic": [ 60 ], "approach": [ 61 ], "against": [ 62 ], "NAFLD": [ 63 ], "increasing": [ 65 ], "acid": [ 67 ], "oxidation,": [ 68 ], "decreasing": [ 69 ], "lipogenesis,": [ 70 ], "improving": [ 72 ], "this": [ 77 ], "report,": [ 78 ], "we": [ 79 ], "provide": [ 80 ], "overview": [ 82 ], "role": [ 85 ], "mechanism": [ 87 ], "relieving": [ 91 ], "NAFLD.": [ 92 ] }, "publication_date": "2012-01-01", "publication_year": 2012, "type": "article", "cited_by_count": 83, "authors": [ { "id": "https://openalex.org/A5066159813", "display_name": "Jinmi Lee" }, { "id": "https://openalex.org/A5024596417", "display_name": "Seok Woo Hong" }, { "id": "https://openalex.org/A5024434898", "display_name": "Eun\u2010Jung Rhee" }, { "id": "https://openalex.org/A5100775283", "display_name": "Won\u2010Young Lee" } ] }, { "id": "https://openalex.org/W1978191819", "doi": "https://doi.org/10.1111/j.1463-1326.2011.01523.x", "title": "The role of GLP\u20101 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide", "abstract": { "In": [ 0 ], "people": [ 1 ], "with": [ 2, 40, 131, 151, 207, 219, 240, 276 ], "type": [ 3 ], "2": [ 4, 215, 224, 256 ], "diabetes": [ 5 ], "mellitus": [ 6 ], "(T2DM),": [ 7 ], "the": [ 8, 14, 34, 37, 54, 88, 106, 116, 180, 183, 187, 199 ], "incretin": [ 9, 38 ], "effect": [ 10 ], "is": [ 11 ], "reduced,": [ 12 ], "but": [ 13 ], "recent": [ 15 ], "advent": [ 16 ], "of": [ 17, 29, 33, 36, 56, 76, 108, 161, 182 ], "dipeptidyl": [ 18 ], "peptidase\u20104": [ 19 ], "inhibitors": [ 20 ], "and": [ 21, 66, 97, 119, 138, 154, 163, 176, 186, 217, 231 ], "glucagon\u2010like": [ 22 ], "peptide": [ 23 ], "(GLP)\u20101": [ 24 ], "agonists/analogues": [ 25, 49 ], "has": [ 26, 83, 101 ], "enabled": [ 27 ], "restoration": [ 28 ], "at": [ 30 ], "least": [ 31 ], "some": [ 32, 164 ], "function": [ 35 ], "system,": [ 39 ], "accompanying": [ 41 ], "improvements": [ 42 ], "in": [ 43, 110, 121, 172, 198, 274 ], "glycaemic": [ 44, 238 ], "control.": [ 45 ], "Two": [ 46 ], "GLP\u20101": [ 47, 272 ], "receptor": [ 48 ], "are": [ 50, 226, 232, 258 ], "currently": [ 51 ], "approved": [ 52, 86 ], "for": [ 53, 95, 201, 229, 237, 271 ], "treatment": [ 55 ], "T2DM\u2014exenatide": [ 57 ], "(Byetta\u00ae,": [ 58 ], "Eli": [ 59, 79 ], "Lilly": [ 60, 80 ], "&": [ 61, 81 ], "Co.,": [ 62 ], "Indianapolis,": [ 63 ], "IN,": [ 64 ], "US)": [ 65 ], "liraglutide": [ 67, 109, 130, 152, 190 ], "(Victoza\u00ae,": [ 68 ], "Novo": [ 69 ], "Nordisk,": [ 70 ], "Bagsvaerd,": [ 71 ], "Denmark);": [ 72 ], "a": [ 73, 208, 220, 268 ], "once\u2010weekly": [ 74 ], "formulation": [ 75 ], "exenatide": [ 77, 137 ], "(Bydureon\u00ae,": [ 78 ], "Co.)": [ 82 ], "also": [ 84, 266 ], "been": [ 85 ], "by": [ 87, 158 ], "European": [ 89 ], "Medicines": [ 90 ], "Agency.": [ 91 ], "The": [ 92, 141 ], "National": [ 93 ], "Institute": [ 94 ], "Health": [ 96 ], "Clinical": [ 98 ], "Excellence": [ 99 ], "(NICE)": [ 100 ], "recently": [ 102 ], "published": [ 103 ], "guidance": [ 104 ], "on": [ 105, 113, 179 ], "use": [ 107 ], "T2DM,": [ 111 ], "based": [ 112 ], "evidence": [ 114 ], "from": [ 115, 147 ], "Liraglutide": [ 117 ], "Effect": [ 118 ], "Action": [ 120 ], "Diabetes": [ 122 ], "(LEAD)": [ 123 ], "Phase": [ 124 ], "III": [ 125 ], "trial": [ 126 ], "programme,": [ 127 ], "which": [ 128 ], "compared": [ 129 ], "existing": [ 132 ], "glucose\u2010lowering": [ 133 ], "therapies,": [ 134 ], "such": [ 135 ], "as": [ 136 ], "insulin": [ 139, 230, 263 ], "glargine.": [ 140 ], "LEAD": [ 142, 184 ], "programme": [ 143 ], "reported": [ 144 ], "HbA1c": [ 145 ], "reductions": [ 146 ], "0.8": [ 148 ], "to": [ 149, 234 ], "1.5%": [ 150 ], "(1.2": [ 153 ], "1.8": [ 155 ], "mg),": [ 156 ], "accompanied": [ 157 ], "low": [ 159 ], "rates": [ 160 ], "hypoglycaemia": [ 162 ], "weight": [ 165 ], "loss;": [ 166 ], "side": [ 167 ], "effects": [ 168 ], "were": [ 169 ], "primarily": [ 170 ], "gastrointestinal": [ 171 ], "nature": [ 173 ], "(e.g.": [ 174 ], "nausea": [ 175 ], "diarrhoea).": [ 177 ], "Based": [ 178 ], "findings": [ 181 ], "studies": [ 185 ], "NICE": [ 188, 243 ], "recommendation,": [ 189 ], "now": [ 191 ], "represents": [ 192 ], "an": [ 193 ], "important": [ 194 ], "therapy": [ 195 ], "widely": [ 196 ], "available": [ 197 ], "UK": [ 200 ], "certain": [ 202 ], "patient": [ 203 ], "groups,": [ 204 ], "including": [ 205 ], "those": [ 206 ], "body": [ 209 ], "mass": [ 210 ], "index": [ 211 ], "(BMI)": [ 212 ], "\u226535.0": [ 213 ], "kg/m": [ 214, 223, 255 ], ",": [ 216 ], "patients": [ 218, 249 ], "BMI": [ 221 ], "<35": [ 222, 254 ], "who": [ 225 ], "considered": [ 227 ], "unsuitable": [ 228 ], "failing": [ 233 ], "meet": [ 235 ], "targets": [ 236 ], "control": [ 239 ], "oral": [ 241 ], "agents.": [ 242 ], "guidelines": [ 244 ], "still": [ 245 ], "suggest": [ 246 ], "that": [ 247 ], "most": [ 248 ], "without": [ 250 ], "considerable": [ 251 ], "obesity": [ 252 ], "(BMI": [ 253 ], ")": [ 257 ], "probably": [ 259 ], "best": [ 260 ], "managed": [ 261 ], "using": [ 262 ], "therapy.": [ 264 ], "Evidence": [ 265 ], "suggests": [ 267 ], "future": [ 269 ], "role": [ 270 ], "mimetics": [ 273 ], "combination": [ 275 ], "basal": [ 277 ], "insulin.": [ 278 ] }, "publication_date": "2011-11-03", "publication_year": 2011, "type": "review", "cited_by_count": 52, "authors": [ { "id": "https://openalex.org/A5023295361", "display_name": "Anthony Barnett" } ] }, { "id": "https://openalex.org/W2043900831", "doi": "https://doi.org/10.1210/jc.2010-2081", "title": "DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes", "abstract": { "Continuous": [ 0 ], "glucagon-like": [ 1 ], "peptide-1": [ 2 ], "receptor": [ 3 ], "agonism": [ 4 ], "with": [ 5, 12, 16, 20 ], "ExQW": [ 6 ], "resulted": [ 7 ], "in": [ 8, 18 ], "superior": [ 9 ], "glycemic": [ 10 ], "control,": [ 11 ], "less": [ 13 ], "nausea,": [ 14 ], "compared": [ 15 ], "ExBID": [ 17 ], "patients": [ 19 ], "type": [ 21 ], "2": [ 22 ], "diabetes.": [ 23 ], "Both": [ 24 ], "groups": [ 25 ], "lost": [ 26 ], "weight.": [ 27 ] }, "publication_date": "2011-02-10", "publication_year": 2011, "type": "article", "cited_by_count": 440, "authors": [ { "id": "https://openalex.org/A5004471830", "display_name": "Thomas Blevins" }, { "id": "https://openalex.org/A5111673292", "display_name": "John Pullman" }, { "id": "https://openalex.org/A5004842224", "display_name": "Jaret Malloy" }, { "id": "https://openalex.org/A5101819344", "display_name": "Ping Yan" }, { "id": "https://openalex.org/A5110734241", "display_name": "Kristin Taylor" }, { "id": "https://openalex.org/A5059677593", "display_name": "Christine T. Schulteis" }, { "id": "https://openalex.org/A5062021087", "display_name": "Michael Trautmann" }, { "id": "https://openalex.org/A5082524181", "display_name": "Lisa A. Porter" } ] }, { "id": "https://openalex.org/W1951367122", "doi": "https://doi.org/10.1111/dom.12602", "title": "Once\u2010weekly glucagon\u2010like peptide\u20101 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once\u2010daily liraglutide in J apanese patients with type 2 diabetes: 52\u2009weeks of treatment in a randomized phase III study", "abstract": { "Aims": [ 0 ], "To": [ 1 ], "examine": [ 2 ], "the": [ 3, 166, 173 ], "efficacy": [ 4 ], "and": [ 5, 46, 62, 68, 77, 110, 158, 180, 207, 212, 233 ], "safety": [ 6 ], "of": [ 7, 168, 175 ], "once\u2010weekly": [ 8, 95, 227 ], "dulaglutide": [ 9, 76, 96, 109, 122, 154, 228 ], "0.75": [ 10, 97, 229 ], "mg": [ 11, 18, 98, 230 ], "monotherapy": [ 12 ], "compared": [ 13, 128, 183, 246 ], "with": [ 14, 23, 108, 113, 129, 184, 219, 226, 239, 242, 247 ], "once\u2010daily": [ 15, 248 ], "liraglutide": [ 16, 82, 114, 130, 249 ], "0.9": [ 17, 250 ], "in": [ 19, 191, 235 ], "J": [ 20, 51, 236 ], "apanese": [ 21, 52, 237 ], "patients": [ 22, 53, 88, 106, 111, 216, 238 ], "type": [ 24 ], "2": [ 25 ], "diabetes": [ 26 ], "(": [ 27, 139, 162 ], "T2D": [ 28, 240 ], ")": [ 29, 141, 164 ], "for": [ 30, 75, 81, 105, 115 ], "52": [ 31, 116, 149, 195 ], "weeks.": [ 32, 117, 196 ], "Methods": [ 33 ], "We": [ 34 ], "conducted": [ 35 ], "a": [ 36 ], "phase": [ 37 ], "III": [ 38 ], ",": [ 39, 241 ], "randomized,": [ 40 ], "52\u2010week": [ 41 ], "(26\u2010week": [ 42 ], "primary": [ 43 ], "endpoint),": [ 44 ], "active\u2010": [ 45 ], "placebo\u2010controlled": [ 47 ], "trial": [ 48 ], "comparing": [ 49 ], "492": [ 50 ], "(dulaglutide,": [ 54 ], "n": [ 55, 59, 64 ], "=": [ 56, 60, 65, 145 ], "281;": [ 57 ], "liraglutide,": [ 58 ], "141;": [ 61 ], "placebo,": [ 63 ], "70).": [ 66 ], "Participants": [ 67 ], "investigators": [ 69 ], "were": [ 70, 92, 203 ], "blinded": [ 71 ], "to": [ 72, 90, 94 ], "treatment": [ 73 ], "assignment": [ 74 ], "placebo": [ 78, 91 ], "but": [ 79 ], "not": [ 80 ], "(open\u2010label": [ 83 ], "comparator);": [ 84 ], "after": [ 85 ], "26": [ 86 ], "weeks,": [ 87 ], "randomized": [ 89 ], "switched": [ 93 ], "(open\u2010label).": [ 99 ], "The": [ 100, 197 ], "present": [ 101 ], "paper": [ 102 ], "reports": [ 103 ], "results": [ 104 ], "treated": [ 107, 112 ], "Results": [ 118 ], "At": [ 119, 147 ], "week": [ 120, 148 ], "52,": [ 121 ], "decreased": [ 123, 156 ], "HbA1c": [ 124 ], "significantly": [ 125, 155 ], "from": [ 126 ], "baseline": [ 127 ], "[least": [ 131 ], "squares": [ 132 ], "mean": [ 133, 167, 174 ], "difference:": [ 134 ], "\u22120.20;": [ 135 ], "95%": [ 136 ], "confidence": [ 137 ], "interval": [ 138 ], "CI": [ 140 ], "\u22120.39,": [ 142 ], "\u22120.01;": [ 143 ], "p": [ 144 ], "0.04].": [ 146 ], "(last": [ 150 ], "observation": [ 151 ], "carried": [ 152 ], "forward),": [ 153 ], "pre\u2010": [ 157 ], "post\u2010dinner": [ 159 ], "blood": [ 160 ], "glucose": [ 161 ], "BG": [ 163, 171, 178 ], "levels,": [ 165 ], "seven\u2010point": [ 169 ], "self\u2010monitored": [ 170 ], "profiles,": [ 172 ], "all": [ 176 ], "postprandial": [ 177 ], "levels": [ 179 ], "circadian": [ 181 ], "variation": [ 182 ], "liraglutide.": [ 185 ], "Body": [ 186 ], "weight": [ 187 ], "was": [ 188, 231 ], "generally": [ 189 ], "stable": [ 190 ], "both": [ 192 ], "groups": [ 193 ], "through": [ 194 ], "most": [ 198 ], "frequently": [ 199 ], "reported": [ 200, 217 ], "adverse": [ 201 ], "events": [ 202 ], "nasopharyngitis,": [ 204 ], "constipation,": [ 205 ], "nausea": [ 206 ], "diarrhoea.": [ 208 ], "Eight": [ 209 ], "dulaglutide\u2010treated": [ 210 ], "(2.9%)": [ 211, 215 ], "four": [ 213 ], "liraglutide\u2010treated": [ 214 ], "hypoglycaemia,": [ 218 ], "no": [ 220 ], "event": [ 221 ], "being": [ 222 ], "severe.": [ 223 ], "Conclusions": [ 224 ], "Monotherapy": [ 225 ], "effective": [ 232 ], "safe": [ 234 ], "better": [ 243 ], "glycaemic": [ 244 ], "control": [ 245 ], "mg.": [ 251 ] }, "publication_date": "2015-11-02", "publication_year": 2015, "type": "article", "cited_by_count": 54, "authors": [ { "id": "https://openalex.org/A5065240624", "display_name": "Masato Odawara" }, { "id": "https://openalex.org/A5108287618", "display_name": "Jun\u2010ichiro Miyagawa" }, { "id": "https://openalex.org/A5058832963", "display_name": "Noriyuki Iwamoto" }, { "id": "https://openalex.org/A5113205488", "display_name": "Y. Takita" }, { "id": "https://openalex.org/A5082595973", "display_name": "Takeshi Imaoka" }, { "id": "https://openalex.org/A5046506553", "display_name": "Toshinari Takamura" } ] }, { "id": "https://openalex.org/W4385264826", "doi": "https://doi.org/10.1001/jamasurg.2023.2930", "title": "Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery", "abstract": { "Importance": [ 0 ], "Metabolic": [ 1 ], "surgery": [ 2, 97, 111, 243 ], "leads": [ 3 ], "to": [ 4, 188, 221, 273, 334, 379, 382, 400, 416, 456 ], "weight": [ 5, 17, 47, 53, 105, 270, 325, 413, 443, 504, 510 ], "loss": [ 6, 18, 54, 106, 326, 511 ], "and": [ 7, 34, 55, 64, 78, 112, 128, 147, 154, 182, 200, 206, 253, 260, 297, 302, 364, 371, 392, 486, 491, 512 ], "improved": [ 8 ], "health,": [ 9 ], "but": [ 10 ], "these": [ 11 ], "outcomes": [ 12 ], "are": [ 13 ], "highly": [ 14 ], "variable.": [ 15 ], "Poor": [ 16, 75 ], "is": [ 19 ], "associated": [ 20 ], "with": [ 21, 51, 224, 322, 422, 432, 468, 508 ], "lower": [ 22 ], "circulating": [ 23 ], "levels": [ 24 ], "of": [ 25, 36, 68, 110, 149, 276, 292, 310, 353, 498 ], "glucagon-like": [ 26 ], "peptide-1": [ 27 ], "(GLP-1).": [ 28 ], "Objective": [ 29 ], "To": [ 30 ], "assess": [ 31 ], "the": [ 32, 37, 108, 204, 274, 277, 354, 367, 374, 388, 395, 496 ], "efficacy": [ 33 ], "safety": [ 35, 287 ], "GLP-1": [ 38, 57, 116, 151, 514 ], "receptor": [ 39, 152 ], "agonist,": [ 40 ], "liraglutide,": [ 41, 423, 446, 469, 500 ], "3.0": [ 42, 70, 212, 424, 447, 470, 501 ], "mg,": [ 43, 213, 448, 502 ], "on": [ 44, 233, 282 ], "percentage": [ 45, 268, 411, 441 ], "body": [ 46, 104, 269, 412, 442 ], "reduction": [ 48 ], "in": [ 49, 72, 121, 177, 203, 267, 366, 373, 387, 394, 408, 440, 506 ], "patients": [ 50, 90, 507 ], "poor": [ 52, 324, 509 ], "suboptimal": [ 56, 114, 513 ], "response": [ 58, 117, 327, 515 ], "after": [ 59, 95, 516 ], "metabolic": [ 60, 96, 145, 517 ], "surgery.": [ 61, 518 ], "Design,": [ 62 ], "Setting,": [ 63 ], "Participants": [ 65 ], "The": [ 66, 160, 262, 437 ], "Evaluation": [ 67 ], "Liraglutide": [ 69 ], "mg": [ 71, 425, 471 ], "Patients": [ 73 ], "With": [ 74 ], "Weight": [ 76 ], "Loss": [ 77 ], "a": [ 79, 113, 168, 225, 234, 323 ], "Suboptimal": [ 80 ], "Glucagon-Like": [ 81 ], "Peptide-1": [ 82 ], "Response": [ 83 ], "(BARI-OPTIMISE)": [ 84 ], "randomized": [ 85, 333 ], "placebo-controlled": [ 86 ], "trial": [ 87, 198, 355 ], "recruited": [ 88 ], "adult": [ 89 ], "at": [ 91, 349 ], "least": [ 92, 350 ], "1": [ 93, 136, 351, 372 ], "year": [ 94 ], "who": [ 98 ], "had": [ 99 ], "experienced": [ 100 ], "20%": [ 101 ], "or": [ 102, 144, 216, 249, 330, 341 ], "less": [ 103 ], "from": [ 107, 118, 271, 414 ], "day": [ 109 ], "nutrient-stimulated": [ 115 ], "2": [ 119, 255, 365 ], "hospitals": [ 120 ], "London,": [ 122 ], "United": [ 123 ], "Kingdom,": [ 124 ], "between": [ 125 ], "October": [ 126 ], "2018": [ 127 ], "November": [ 129 ], "2019.": [ 130 ], "Key": [ 131 ], "exclusion": [ 132 ], "criteria": [ 133, 199 ], "were": [ 134, 186, 201, 332, 377, 398, 465, 481 ], "type": [ 135, 244, 254 ], "diabetes;": [ 137 ], "severe": [ 138 ], "concomitant": [ 139 ], "psychiatric,": [ 140 ], "gastrointestinal,": [ 141, 464 ], "cardiac,": [ 142 ], "kidney": [ 143, 296 ], "disease;": [ 146 ], "use": [ 148, 497 ], "insulin,": [ 150 ], "analogues,": [ 153 ], "medication": [ 155 ], "that": [ 156 ], "can": [ 157 ], "affect": [ 158 ], "weight.": [ 159 ], "study": [ 161, 184, 279 ], "period": [ 162, 280 ], "was": [ 163, 175, 265, 288, 419, 451 ], "24": [ 164, 231, 418 ], "weeks": [ 165 ], "followed": [ 166 ], "by": [ 167, 237, 242 ], "4-week": [ 169 ], "follow-up": [ 170, 174 ], "period.": [ 171 ], "Last": [ 172 ], "participant": [ 173 ], "completed": [ 176, 208 ], "June": [ 178 ], "2020.": [ 179 ], "All": [ 180, 346 ], "participants": [ 181, 312, 347, 358, 386 ], "clinical": [ 183 ], "personnel": [ 185 ], "blinded": [ 187 ], "treatment": [ 189, 360 ], "allocation.": [ 190 ], "Of": [ 191 ], "154": [ 192 ], "assessed": [ 193, 289 ], "for": [ 194, 230, 304, 445, 503 ], "eligibility,": [ 195 ], "70": [ 196, 311 ], "met": [ 197 ], "included": [ 202 ], "study,": [ 205 ], "57": [ 207 ], "follow-up.": [ 209, 380 ], "Interventions": [ 210 ], "Liraglutide,": [ 211 ], "once": [ 214 ], "daily": [ 215, 227 ], "placebo": [ 217, 342, 375, 396, 433, 450, 476 ], "as": [ 218 ], "an": [ 219, 283 ], "adjunct": [ 220 ], "lifestyle": [ 222 ], "intervention": [ 223 ], "500-kcal": [ 226 ], "energy": [ 228 ], "deficit": [ 229 ], "weeks,": [ 232 ], "1:1": [ 235 ], "allocation": [ 236 ], "computer-generated": [ 238 ], "randomization": [ 239 ], "sequence,": [ 240 ], "stratified": [ 241 ], "(Roux-en-Y": [ 245 ], "gastric": [ 246 ], "bypass": [ 247 ], "[RYGB]": [ 248 ], "sleeve": [ 250 ], "gastrectomy": [ 251 ], "[SG])": [ 252 ], "diabetes": [ 256 ], "status.": [ 257 ], "Main": [ 258 ], "Outcome": [ 259 ], "Measures": [ 261 ], "primary": [ 263 ], "outcome": [ 264 ], "change": [ 266, 407, 444 ], "baseline": [ 272, 415 ], "end": [ 275 ], "24-week": [ 278 ], "based": [ 281 ], "intention-to-treat": [ 284 ], "analysis.": [ 285 ], "Participant": [ 286 ], "through": [ 290 ], "monitoring": [ 291 ], "biochemical": [ 293 ], "parameters,": [ 294 ], "including": [ 295 ], "liver": [ 298 ], "function,": [ 299 ], "physical": [ 300 ], "examination,": [ 301 ], "assessment": [ 303 ], "adverse": [ 305, 484 ], "events.": [ 306 ], "Results": [ 307 ], "A": [ 308 ], "total": [ 309 ], "(mean": [ 313 ], "[SD]": [ 314 ], "age,": [ 315 ], "47.6": [ 316 ], "[10.7]": [ 317 ], "years;": [ 318 ], "52": [ 319 ], "[74%]": [ 320 ], "female)": [ 321 ], "following": [ 328 ], "RYGB": [ 329 ], "SG": [ 331 ], "receive": [ 335 ], "3.0-mg": [ 336, 368, 389 ], "liraglutide": [ 337, 369, 390 ], "(n": [ 338, 343, 426, 434 ], "=": [ 339, 344, 427, 435 ], "35)": [ 340 ], "35).": [ 345 ], "received": [ 348 ], "dose": [ 352 ], "drug.": [ 356 ], "Eight": [ 357 ], "discontinued": [ 359 ], "(4": [ 361 ], "per": [ 362 ], "group),": [ 363 ], "group": [ 370, 376, 391, 397 ], "lost": [ 378 ], "Due": [ 381 ], "COVID-19": [ 383 ], "restrictions,": [ 384 ], "3": [ 385 ], "7": [ 393 ], "unable": [ 399 ], "attend": [ 401 ], "their": [ 402 ], "final": [ 403 ], "in-person": [ 404 ], "assessment.": [ 405 ], "Estimated": [ 406 ], "mean": [ 409, 438 ], "(SD)": [ 410 ], "week": [ 417 ], "\u22128.82": [ 420 ], "(4.94)": [ 421 ], "31),": [ 428 ], "vs": [ 429, 449 ], "\u22120.54": [ 430 ], "(3.32)": [ 431 ], "26).": [ 436 ], "difference": [ 439 ], "\u22128.03": [ 452 ], "(95%": [ 453 ], "CI,": [ 454 ], "\u221210.39": [ 455 ], "\u22125.66;": [ 457 ], "P": [ 458 ], "&amp;lt;": [ 459 ], ".001).": [ 460 ], "Adverse": [ 461 ], "events,": [ 462 ], "predominantly": [ 463 ], "more": [ 466 ], "frequent": [ 467 ], "(28": [ 472 ], "events": [ 473, 478, 485 ], "[80%]),": [ 474 ], "than": [ 475 ], "(20": [ 477 ], "[57%]).": [ 479 ], "There": [ 480 ], "no": [ 482, 487 ], "serious": [ 483 ], "treatment-related": [ 488 ], "deaths.": [ 489 ], "Conclusion": [ 490 ], "Relevance": [ 492 ], "These": [ 493 ], "findings": [ 494 ], "support": [ 495 ], "adjuvant": [ 499 ], "management": [ 505 ], "Trial": [ 519 ], "Registration": [ 520 ], "ClinicalTrials.gov": [ 521 ], "Identifier:": [ 522 ], "NCT03341429": [ 523 ] }, "publication_date": "2023-07-26", "publication_year": 2023, "type": "article", "cited_by_count": 120, "authors": [ { "id": "https://openalex.org/A5043257639", "display_name": "Jessica Mok" }, { "id": "https://openalex.org/A5012598603", "display_name": "Mariam O. Adeleke" }, { "id": "https://openalex.org/A5070482511", "display_name": "Adrian Brown" }, { "id": "https://openalex.org/A5108749685", "display_name": "Cormac Magee" }, { "id": "https://openalex.org/A5027180543", "display_name": "Chloe Firman" }, { "id": "https://openalex.org/A5047534120", "display_name": "Christwishes Makahamadze" }, { "id": "https://openalex.org/A5031558685", "display_name": "Friedrich C. Jassil" }, { "id": "https://openalex.org/A5071561128", "display_name": "Parastou Marvasti" }, { "id": "https://openalex.org/A5007504985", "display_name": "Alisia Carnemolla" }, { "id": "https://openalex.org/A5083690439", "display_name": "Kalpana Devalia" }, { "id": "https://openalex.org/A5110440784", "display_name": "N. Fakih" }, { "id": "https://openalex.org/A5002215488", "display_name": "Mohamed Elkalaawy" }, { "id": "https://openalex.org/A5101980727", "display_name": "Andrea Pucci" }, { "id": "https://openalex.org/A5058905663", "display_name": "Andrew Jenkinson" }, { "id": "https://openalex.org/A5075424827", "display_name": "Marco Adamo" }, { "id": "https://openalex.org/A5022810365", "display_name": "Rumana Z. Omar" }, { "id": "https://openalex.org/A5085481226", "display_name": "Rachel L. Batterham" }, { "id": "https://openalex.org/A5014205200", "display_name": "Janine Makaronidis" } ] }, { "id": "https://openalex.org/W1509386155", "doi": "https://doi.org/10.1002/dmrr.2580", "title": "GLP\u20101 receptor agonists: effects on the progression of non\u2010alcoholic fatty liver disease", "abstract": { "Summary": [ 0 ], "Non\u2010alcoholic": [ 1 ], "fatty": [ 2 ], "liver": [ 3, 12 ], "disease": [ 4 ], "(NAFLD)": [ 5 ], "is": [ 6, 27, 52, 61 ], "one": [ 7 ], "of": [ 8, 74, 87, 94, 111, 135, 148, 153, 158 ], "the": [ 9, 39, 85, 92, 109, 149, 156 ], "most": [ 10 ], "common": [ 11 ], "diseases,": [ 13 ], "and": [ 14, 49, 137, 151 ], "its": [ 15 ], "incidence": [ 16 ], "has": [ 17 ], "been": [ 18, 99 ], "increasing": [ 19 ], "recently.": [ 20 ], "In": [ 21, 141 ], "addition": [ 22 ], "to": [ 23 ], "hepatic": [ 24 ], "complications,": [ 25 ], "NAFLD": [ 26, 43, 95, 112 ], "also": [ 28, 128 ], "recognized": [ 29 ], "as": [ 30 ], "an": [ 31, 117, 146 ], "independent": [ 32 ], "risk": [ 33 ], "factor": [ 34 ], "for": [ 35, 42, 66 ], "cardiovascular": [ 36 ], "disease.": [ 37 ], "Unfortunately,": [ 38 ], "current": [ 40 ], "therapies": [ 41 ], "display": [ 44 ], "variable": [ 45 ], "efficacy;": [ 46 ], "a": [ 47, 58, 62, 78, 129 ], "novel": [ 48, 79 ], "effective": [ 50 ], "drug": [ 51, 64 ], "urgently": [ 53 ], "needed.": [ 54 ], "Glucagon\u2010like": [ 55 ], "peptide\u20101": [ 56 ], "(GLP\u20101),": [ 57 ], "receptor": [ 59, 89 ], "agonist": [ 60 ], "new": [ 63 ], "approved": [ 65 ], "treating": [ 67 ], "type": [ 68 ], "2": [ 69 ], "diabetes.": [ 70 ], "Recently,": [ 71 ], "these": [ 72 ], "types": [ 73 ], "agents": [ 75 ], "have": [ 76, 96, 104 ], "shown": [ 77 ], "therapeutic": [ 80 ], "effect": [ 81, 119, 131 ], "on": [ 82, 91, 132 ], "NAFLD.": [ 83, 159 ], "However,": [ 84 ], "mechanisms": [ 86, 152 ], "GLP\u20101": [ 88, 107, 154 ], "agonists": [ 90 ], "treatment": [ 93 ], "not": [ 97, 113 ], "yet": [ 98 ], "explained": [ 100 ], "precisely.": [ 101 ], "Recent": [ 102 ], "studies": [ 103 ], "demonstrated": [ 105 ], "that": [ 106, 120 ], "reverses": [ 108 ], "progression": [ 110 ], "only": [ 114 ], "indirectly": [ 115 ], "through": [ 116 ], "incretin": [ 118 ], "improves": [ 121 ], "key": [ 122 ], "parameters": [ 123 ], "involved": [ 124 ], "in": [ 125, 139, 155 ], "NAFLD,": [ 126 ], "but": [ 127 ], "direct": [ 130 ], "lipid": [ 133 ], "metabolism": [ 134 ], "hepatocytes": [ 136 ], "inflammation": [ 138 ], "liver.": [ 140 ], "this": [ 142 ], "review,": [ 143 ], "we": [ 144 ], "provided": [ 145 ], "overview": [ 147 ], "role": [ 150 ], "therapy": [ 157 ], "Copyright": [ 160 ], "\u00a9": [ 161 ], "2014": [ 162 ], "John": [ 163 ], "Wiley": [ 164 ], "&": [ 165 ], "Sons,": [ 166 ], "Ltd.": [ 167 ] }, "publication_date": "2014-07-28", "publication_year": 2014, "type": "review", "cited_by_count": 47, "authors": [ { "id": "https://openalex.org/A5100409716", "display_name": "Jia Liu" }, { "id": "https://openalex.org/A5100451757", "display_name": "Guang Wang" }, { "id": "https://openalex.org/A5063464191", "display_name": "Yumei Jia" }, { "id": "https://openalex.org/A5101874310", "display_name": "Yuan Xu" } ] }, { "id": "https://openalex.org/W1997595732", "doi": "https://doi.org/10.1038/ijo.2013.149", "title": "Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults", "abstract": { "Transient": [ 0 ], "nausea": [ 1, 31 ], "and": [ 2, 20 ], "vomiting": [ 3 ], "on": [ 4, 30 ], "treatment": [ 5 ], "with": [ 6, 12 ], "liraglutide": [ 7 ], "3.0": [ 8 ], "mg": [ 9 ], "was": [ 10 ], "associated": [ 11 ], "greater": [ 13 ], "weight": [ 14 ], "loss,": [ 15 ], "although": [ 16 ], "symptoms": [ 17 ], "appeared": [ 18 ], "tolerable": [ 19 ], "did": [ 21 ], "not": [ 22 ], "attenuate": [ 23 ], "quality-of-life": [ 24 ], "improvements.": [ 25 ], "Improved": [ 26 ], "data": [ 27 ], "collection": [ 28 ], "methods": [ 29 ], "are": [ 32 ], "warranted.": [ 33 ] }, "publication_date": "2013-08-14", "publication_year": 2013, "type": "article", "cited_by_count": 201, "authors": [ { "id": "https://openalex.org/A5012241596", "display_name": "Michael E. J. Lean" }, { "id": "https://openalex.org/A5082931469", "display_name": "Raffaele Carraro" }, { "id": "https://openalex.org/A5018535962", "display_name": "Nick Finer" }, { "id": "https://openalex.org/A5017679173", "display_name": "Helle B\u00f8ggild Hartvig" }, { "id": "https://openalex.org/A5108481559", "display_name": "Marie L.S. Lindegaard" }, { "id": "https://openalex.org/A5059778565", "display_name": "Stephan R\u00f6ssner" }, { "id": "https://openalex.org/A5109345483", "display_name": "L. Van Gaal" }, { "id": "https://openalex.org/A5048067129", "display_name": "Arne Astrup" } ] }, { "id": "https://openalex.org/W3193716349", "doi": "https://doi.org/10.1038/s41598-021-96418-0", "title": "The GLP-1 receptor agonist, liraglutide, fails to slow disease progression in SOD1G93A and TDP-43Q331K transgenic mouse models of ALS", "abstract": null, "publication_date": "2021-08-23", "publication_year": 2021, "type": "article", "cited_by_count": 16, "authors": [ { "id": "https://openalex.org/A5050164696", "display_name": "Amy Keerie" }, { "id": "https://openalex.org/A5036385137", "display_name": "Heledd Brown-Wright" }, { "id": "https://openalex.org/A5038041605", "display_name": "Isaac Kirkland" }, { "id": "https://openalex.org/A5042655438", "display_name": "Andrew J. Grierson" }, { "id": "https://openalex.org/A5040166835", "display_name": "James J. P. Alix" }, { "id": "https://openalex.org/A5082707086", "display_name": "Christian H\u00f6lscher" }, { "id": "https://openalex.org/A5043615781", "display_name": "Richard J. Mead" } ] }, { "id": "https://openalex.org/W1747915135", "doi": "https://doi.org/10.1007/s40259-015-0143-4", "title": "Dulaglutide: A Review in Type 2 Diabetes", "abstract": null, "publication_date": "2015-09-30", "publication_year": 2015, "type": "review", "cited_by_count": 26, "authors": [ { "id": "https://openalex.org/A5059490674", "display_name": "Celeste B. Burness" }, { "id": "https://openalex.org/A5109531112", "display_name": "Lesley J. Scott" } ] }, { "id": "https://openalex.org/W4410277932", "doi": "https://doi.org/10.1056/nejmoa2416394", "title": "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity", "abstract": { "Among": [ 0 ], "participants": [ 1 ], "with": [ 2, 8, 14, 16 ], "obesity": [ 3 ], "but": [ 4 ], "without": [ 5 ], "diabetes,": [ 6 ], "treatment": [ 7, 13 ], "tirzepatide": [ 9 ], "was": [ 10 ], "superior": [ 11 ], "to": [ 12, 18 ], "semaglutide": [ 15 ], "respect": [ 17 ], "reduction": [ 19 ], "in": [ 20 ], "body": [ 21 ], "weight": [ 22 ], "and": [ 23 ], "waist": [ 24 ], "circumference": [ 25 ], "at": [ 26 ], "week": [ 27 ], "72.": [ 28 ], "(Funded": [ 29 ], "by": [ 30 ], "Eli": [ 31 ], "Lilly;": [ 32 ], "SURMOUNT-5": [ 33 ], "ClinicalTrials.gov": [ 34 ], "number,": [ 35 ], "NCT05822830.).": [ 36 ] }, "publication_date": "2025-05-11", "publication_year": 2025, "type": "article", "cited_by_count": 151, "authors": [ { "id": "https://openalex.org/A5051043505", "display_name": "Louis J. Aronne" }, { "id": "https://openalex.org/A5050261888", "display_name": "Deborah B. Horn" }, { "id": "https://openalex.org/A5010753663", "display_name": "Carel W. le Roux" }, { "id": "https://openalex.org/A5103607491", "display_name": "Wayne Ho" }, { "id": "https://openalex.org/A5019317536", "display_name": "Beverly L. Falc\u00f3n" }, { "id": "https://openalex.org/A5046171106", "display_name": "Elisa Gomez Valderas" }, { "id": "https://openalex.org/A5101975424", "display_name": "Swapan Kumar Das" }, { "id": "https://openalex.org/A5031509690", "display_name": "Clare J. Lee" }, { "id": "https://openalex.org/A5111625146", "display_name": "Leonard C. Glass" }, { "id": "https://openalex.org/A5025064589", "display_name": "\u00c7a\u011fr\u0131 \u015eeny\u00fccel" }, { "id": "https://openalex.org/A5080576431", "display_name": "Julia P. Dunn" } ] }, { "id": "https://openalex.org/W3096251629", "doi": "https://doi.org/10.1016/j.celrep.2020.108271", "title": "GLP-1 Receptor Agonist NLY01 Reduces Retinal Inflammation and Neuron Death Secondary to Ocular Hypertension", "abstract": { "Glaucoma": [ 0 ], "is": [ 1, 9, 44, 61 ], "the": [ 2, 12, 30, 83 ], "leading": [ 3 ], "cause": [ 4 ], "of": [ 5, 14, 32, 37, 54, 66, 85, 89, 104, 111, 138 ], "irreversible": [ 6 ], "blindness": [ 7 ], "and": [ 8, 26, 70, 79, 114, 128 ], "characterized": [ 10 ], "by": [ 11, 99, 107, 146 ], "death": [ 13 ], "retinal": [ 15 ], "ganglion": [ 16 ], "cells": [ 17, 97 ], "(RGCs).": [ 18 ], "Recent": [ 19 ], "studies": [ 20 ], "have": [ 21 ], "implicated": [ 22 ], "pro-inflammatory": [ 23 ], "microglia,": [ 24 ], "macrophages,": [ 25 ], "A1": [ 27, 40, 86, 125 ], "astrocytes": [ 28, 41 ], "in": [ 29, 42, 94 ], "pathogenesis": [ 31 ], "neurodegenerative": [ 33 ], "diseases.": [ 34 ], "The": [ 35 ], "role": [ 36 ], "pro-inflammatory,": [ 38 ], "neurotoxic": [ 39 ], "glaucoma": [ 43 ], "just": [ 45 ], "beginning": [ 46 ], "to": [ 47, 63, 81 ], "be": [ 48, 143 ], "explored.": [ 49 ], "Using": [ 50 ], "a": [ 51, 135 ], "mouse": [ 52 ], "model": [ 53 ], "glaucoma,": [ 55 ], "we": [ 56 ], "demonstrate": [ 57 ], "that": [ 58, 141 ], "ocular": [ 59 ], "hypertension": [ 60 ], "sufficient": [ 62, 80 ], "trigger": [ 64 ], "production": [ 65 ], "C1q,": [ 67 ], "interleukin-1\u03b1": [ 68 ], "(IL-1\u03b1),": [ 69 ], "tumor": [ 71 ], "necrosis": [ 72 ], "factor": [ 73 ], "\u03b1": [ 74 ], "(TNF-\u03b1),": [ 75 ], "three": [ 76 ], "cytokines": [ 77, 91 ], "necessary": [ 78 ], "drive": [ 82 ], "formation": [ 84 ], "astrocytes.": [ 87 ], "Upregulation": [ 88 ], "these": [ 90, 132 ], "occurs": [ 92 ], "first": [ 93 ], "CD11b+": [ 95, 100 ], "CD11c+": [ 96 ], "followed": [ 98 ], "CD11c-": [ 101 ], "cells.": [ 102 ], "Ablation": [ 103 ], "this": [ 105 ], "pathway,": [ 106 ], "either": [ 108 ], "genetic": [ 109 ], "deletions": [ 110 ], "C1qa,": [ 112 ], "IL-1\u03b1,": [ 113 ], "TNF-\u03b1,": [ 115 ], "or": [ 116 ], "treatment": [ 117 ], "with": [ 118 ], "glucagon-like": [ 119 ], "peptide-1": [ 120 ], "receptor": [ 121 ], "agonist": [ 122 ], "NLY01,": [ 123 ], "reduces": [ 124 ], "astrocyte": [ 126 ], "transformation": [ 127 ], "RGC": [ 129 ], "death.": [ 130 ], "Together,": [ 131 ], "results": [ 133 ], "highlight": [ 134 ], "neuroinflammatory": [ 136 ], "mechanism": [ 137 ], "glaucomatous": [ 139 ], "neurodegeneration": [ 140 ], "can": [ 142 ], "therapeutically": [ 144 ], "targeted": [ 145 ], "NLY01": [ 147 ], "administration.": [ 148 ] }, "publication_date": "2020-11-01", "publication_year": 2020, "type": "article", "cited_by_count": 118, "authors": [ { "id": "https://openalex.org/A5052282897", "display_name": "Jacob Sterling" }, { "id": "https://openalex.org/A5082685026", "display_name": "Modupe O. Adetunji" }, { "id": "https://openalex.org/A5113153069", "display_name": "Samyuktha Guttha" }, { "id": "https://openalex.org/A5077327903", "display_name": "Albert Bargoud" }, { "id": "https://openalex.org/A5073558140", "display_name": "Katherine E. Uyhazi" }, { "id": "https://openalex.org/A5054684551", "display_name": "Ahmara G. Ross" }, { "id": "https://openalex.org/A5109833665", "display_name": "Joshua L. Dunaief" }, { "id": "https://openalex.org/A5030007290", "display_name": "Qi N. Cui" } ] }, { "id": "https://openalex.org/W2604152120", "doi": "https://doi.org/10.2147/dmso.s116810", "title": "Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials", "abstract": { "This": [ 0 ], "was": [ 1 ], "a": [ 2, 18 ], "comprehensive": [ 3 ], "assessment": [ 4 ], "of": [ 5, 9 ], "the": [ 6, 33 ], "comparative": [ 7 ], "effectiveness": [ 8 ], "GLP-1": [ 10, 15 ], "RAs": [ 11, 16 ], "and": [ 12, 25, 30 ], "A1C": [ 13 ], "outcome.": [ 14 ], "are": [ 17, 32 ], "viable": [ 19 ], "addition": [ 20 ], "to": [ 21 ], "oral": [ 22 ], "antidiabetes": [ 23 ], "therapy,": [ 24 ], "dulaglutide,": [ 26 ], "exenatide": [ 27 ], "once": [ 28 ], "weekly,": [ 29 ], "liraglutide": [ 31 ], "most": [ 34 ], "effective.": [ 35 ] }, "publication_date": "2017-03-01", "publication_year": 2017, "type": "article", "cited_by_count": 27, "authors": [ { "id": "https://openalex.org/A5028132227", "display_name": "Michelle Orme" }, { "id": "https://openalex.org/A5112251630", "display_name": "Hiep Nguyen" }, { "id": "https://openalex.org/A5037732380", "display_name": "Jackie Lu" }, { "id": "https://openalex.org/A5071727722", "display_name": "Susan Thomas" } ] }, { "id": "https://openalex.org/W2519154616", "doi": "https://doi.org/10.1016/s2213-8587(16)30263-7", "title": "GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?", "abstract": null, "publication_date": "2016-09-16", "publication_year": 2016, "type": "letter", "cited_by_count": 21, "authors": [ { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5002832666", "display_name": "Juris J. Meier" } ] }, { "id": "https://openalex.org/W4400281029", "doi": "https://doi.org/10.1001/jamaophthalmol.2024.2296", "title": "Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide", "abstract": { "Importance": [ 0 ], "Anecdotal": [ 1 ], "experience": [ 2 ], "raised": [ 3 ], "the": [ 4, 165, 267, 282, 293, 339, 353, 360, 370 ], "possibility": [ 5 ], "that": [ 6 ], "semaglutide,": [ 7 ], "a": [ 8, 48, 56, 77, 169, 397 ], "glucagon-like": [ 9 ], "peptide": [ 10 ], "1": [ 11, 66 ], "receptor": [ 12 ], "agonist": [ 13 ], "(GLP-1": [ 14 ], "RA)": [ 15 ], "with": [ 16, 22, 103, 119, 123, 164, 269 ], "rapidly": [ 17 ], "increasing": [ 18 ], "use,": [ 19 ], "is": [ 20, 34, 435 ], "associated": [ 21, 118 ], "nonarteritic": [ 23 ], "anterior": [ 24 ], "ischemic": [ 25 ], "optic": [ 26, 94 ], "neuropathy": [ 27 ], "(NAION).": [ 28 ], "Objective": [ 29 ], "To": [ 30 ], "investigate": [ 31 ], "whether": [ 32, 114 ], "there": [ 33 ], "an": [ 35, 421, 430 ], "association": [ 36, 422 ], "between": [ 37, 423 ], "semaglutide": [ 38, 116, 194, 278, 294, 327, 355, 371, 405, 424 ], "and": [ 39, 45, 85, 96, 147, 151, 168, 207, 211, 242, 295, 307, 384, 415, 425 ], "risk": [ 40, 321, 399 ], "of": [ 41, 60, 83, 106, 155, 160, 214, 290, 322, 341, 367, 400 ], "NAION.": [ 42, 107, 215, 426 ], "Design,": [ 43 ], "Setting,": [ 44 ], "Participants": [ 46 ], "In": [ 47, 266, 338 ], "retrospective": [ 49 ], "matched": [ 50 ], "cohort": [ 51, 356 ], "study": [ 52, 434 ], "using": [ 53 ], "data": [ 54, 58 ], "from": [ 55, 69, 183 ], "centralized": [ 57 ], "registry": [ 59 ], "patients": [ 61, 102, 122, 276, 325, 342, 403 ], "evaluated": [ 62 ], "by": [ 63 ], "neuro-ophthalmologists": [ 64 ], "at": [ 65 ], "academic": [ 67 ], "institution": [ 68 ], "December": [ 70, 184 ], "1,": [ 71, 185 ], "2017,": [ 72, 186 ], "through": [ 73, 187 ], "November": [ 74, 188 ], "30,": [ 75, 189 ], "2023,": [ 76 ], "search": [ 78, 98 ], "for": [ 79, 134, 153, 176, 193, 292, 324, 369, 402 ], "International": [ 80 ], "Statistical": [ 81 ], "Classification": [ 82 ], "Diseases": [ 84 ], "Related": [ 86 ], "Health": [ 87 ], "Problems,": [ 88 ], "Tenth": [ 89 ], "Revision": [ 90 ], "code": [ 91 ], "H47.01": [ 92 ], "(ischemic": [ 93 ], "neuropathy)": [ 95 ], "text": [ 97 ], "yielded": [ 99 ], "16": [ 100, 218 ], "827": [ 101, 219 ], "no": [ 104 ], "history": [ 105 ], "Propensity": [ 108 ], "matching": [ 109 ], "was": [ 110, 117, 162, 302, 379, 429 ], "used": [ 111 ], "to": [ 112, 199, 437 ], "assess": [ 113, 438 ], "prescribed": [ 115, 225, 228, 249, 252, 277, 354, 404 ], "NAION": [ 120, 161, 272, 291, 323, 349, 368, 401 ], "in": [ 121, 130, 275, 281, 352, 359 ], "type": [ 124 ], "2": [ 125 ], "diabetes": [ 126 ], "(T2D)": [ 127 ], "or": [ 128, 203, 246, 346 ], "overweight/obesity,": [ 129 ], "each": [ 131 ], "case": [ 132 ], "accounting": [ 133 ], "covarying": [ 135 ], "factors": [ 136 ], "(sex,": [ 137 ], "age,": [ 138, 235, 259 ], "systemic": [ 139 ], "hypertension,": [ 140 ], "T2D,": [ 141, 270 ], "obstructive": [ 142 ], "sleep": [ 143 ], "apnea,": [ 144 ], "obesity,": [ 145 ], "hyperlipidemia,": [ 146 ], "coronary": [ 148 ], "artery": [ 149 ], "disease)": [ 150 ], "contraindications": [ 152 ], "use": [ 154 ], "semaglutide.": [ 156 ], "The": [ 157, 287, 364 ], "cumulative": [ 158, 288, 365 ], "incidence": [ 159, 210, 289, 366 ], "determined": [ 163 ], "Kaplan-Meier": [ 166 ], "method": [ 167 ], "Cox": [ 170, 314, 391 ], "proportional": [ 171, 315, 392 ], "hazards": [ 172, 316, 393 ], "regression": [ 173, 317, 394 ], "model": [ 174, 318, 395 ], "adjusted": [ 175 ], "potential": [ 177 ], "confounding": [ 178 ], "comorbidities.": [ 179 ], "Data": [ 180 ], "were": [ 181, 244, 344 ], "analyzed": [ 182 ], "2023.": [ 190 ], "Exposures": [ 191 ], "Prescriptions": [ 192 ], "vs": [ 195, 279, 357, 372 ], "non\u2013GLP-1": [ 196, 229, 253, 283, 296, 361, 373 ], "RA": [ 197, 230, 254, 284, 297, 362, 374 ], "medications": [ 198 ], "manage": [ 200 ], "either": [ 201 ], "T2D": [ 202, 223 ], "weight.": [ 204 ], "Main": [ 205 ], "Outcomes": [ 206 ], "Measures": [ 208 ], "Cumulative": [ 209 ], "hazard": [ 212 ], "ratio": [ 213, 329 ], "Results": [ 216 ], "Among": [ 217 ], "patients,": [ 220 ], "710": [ 221 ], "had": [ 222 ], "(194": [ 224 ], "semaglutide;": [ 226, 250 ], "516": [ 227 ], "antidiabetic": [ 231 ], "medications;": [ 232, 256 ], "median": [ 233, 257 ], "[IQR]": [ 234, 258 ], "59": [ 236 ], "[49-68]": [ 237 ], "years;": [ 238, 262 ], "369": [ 239 ], "[52%]": [ 240 ], "female)": [ 241 ], "979": [ 243 ], "overweight": [ 245, 345 ], "obese": [ 247 ], "(361": [ 248 ], "618": [ 251 ], "weight-loss": [ 255 ], "47": [ 260 ], "[32-59]": [ 261 ], "708": [ 263 ], "[72%]": [ 264 ], "female).": [ 265 ], "population": [ 268, 340 ], "17": [ 271 ], "events": [ 273, 350 ], "occurred": [ 274, 351 ], "6": [ 280 ], "antidiabetes": [ 285 ], "cohort.": [ 286, 363 ], "cohorts": [ 298, 375 ], "over": [ 299, 376 ], "36": [ 300, 377 ], "months": [ 301, 378 ], "8.9%": [ 303 ], "(95%": [ 304, 309, 381, 386 ], "CI,": [ 305, 310, 333, 382, 387, 409 ], "4.5%-13.1%)": [ 306 ], "1.8%": [ 308 ], "0%-3.5%),": [ 311 ], "respectively.": [ 312, 389 ], "A": [ 313, 390 ], "showed": [ 319, 396 ], "higher": [ 320, 398 ], "receiving": [ 326 ], "(hazard": [ 328 ], "[HR],": [ 330 ], "4.28;": [ 331 ], "95%": [ 332, 408 ], "1.62-11.29);": [ 334 ], "P": [ 335, 411 ], "&amp;lt;": [ 336, 412 ], ".001).": [ 337, 413 ], "who": [ 343 ], "obese,": [ 347 ], "20": [ 348 ], "3": [ 358 ], "6.7%": [ 380 ], "3.6%-9.7%)": [ 383 ], "0.8%": [ 385 ], "0%-1.8%),": [ 388 ], "(HR,": [ 406 ], "7.64;": [ 407 ], "2.21-26.36;": [ 410 ], "Conclusions": [ 414 ], "Relevance": [ 416 ], "This": [ 417 ], "study\u2019s": [ 418 ], "findings": [ 419 ], "suggest": [ 420 ], "As": [ 427 ], "this": [ 428 ], "observational": [ 431 ], "study,": [ 432 ], "future": [ 433 ], "required": [ 436 ], "causality.": [ 439 ] }, "publication_date": "2024-07-03", "publication_year": 2024, "type": "letter", "cited_by_count": 165, "authors": [ { "id": "https://openalex.org/A5109742205", "display_name": "Jimena Tatiana Hathaway" }, { "id": "https://openalex.org/A5016434156", "display_name": "Madhura Shah" }, { "id": "https://openalex.org/A5081150980", "display_name": "David Hathaway" }, { "id": "https://openalex.org/A5028719733", "display_name": "Seyedeh M. Zekavat" }, { "id": "https://openalex.org/A5043918697", "display_name": "Drenushe Krasniqi" }, { "id": "https://openalex.org/A5041865885", "display_name": "John W. Gittinger" }, { "id": "https://openalex.org/A5052260050", "display_name": "Dean M. Cestari" }, { "id": "https://openalex.org/A5052478477", "display_name": "Robert M. Mallery" }, { "id": "https://openalex.org/A5052491762", "display_name": "Bardia Abbasi" }, { "id": "https://openalex.org/A5023290219", "display_name": "Marc A. Bouffard" }, { "id": "https://openalex.org/A5028305623", "display_name": "Bart K. Chwalisz" }, { "id": "https://openalex.org/A5109742206", "display_name": "Tais Estrela" }, { "id": "https://openalex.org/A5108444862", "display_name": "Joseph F. Rizzo" } ] }, { "id": "https://openalex.org/W2605440965", "doi": "https://doi.org/10.1016/s1262-3636(17)30069-1", "title": "The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes", "abstract": null, "publication_date": "2017-04-01", "publication_year": 2017, "type": "review", "cited_by_count": 100, "authors": [ { "id": "https://openalex.org/A5008098216", "display_name": "Merlin C. Thomas" } ] }, { "id": "https://openalex.org/W4285035640", "doi": "https://doi.org/10.1177/20406223221108064", "title": "Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review", "abstract": { "Background": [ 0 ], "&": [ 1 ], "Objective:": [ 2 ], "Although": [ 3 ], "data": [ 4, 124 ], "on": [ 5, 40, 177 ], "the": [ 6, 41, 47, 77, 112, 122, 165, 205, 209 ], "effects": [ 7, 39 ], "of": [ 8, 79, 114, 130, 137, 149, 156, 188, 199, 236 ], "liraglutide": [ 9, 138, 244 ], "and": [ 10, 52, 85, 95, 118, 128, 135, 147, 154, 208, 225, 245, 252 ], "semaglutide": [ 11, 157, 183, 226, 246 ], "in": [ 12, 22, 164, 194 ], "patients": [ 13 ], "with": [ 14, 62, 65, 81, 101, 192, 249 ], "diabetes": [ 15, 26, 60, 106 ], "have": [ 16, 27 ], "been": [ 17, 29 ], "reviewed,": [ 18 ], "their": [ 19, 38 ], "therapeutic": [ 20 ], "outcomes": [ 21, 75, 91 ], "obese/overweight": [ 23, 57, 103, 239 ], "individuals": [ 24 ], "without": [ 25, 59, 105, 241 ], "not": [ 28 ], "summarized.": [ 30 ], "We": [ 31, 45 ], "conducted": [ 32 ], "a": [ 33, 230 ], "systematic": [ 34 ], "review": [ 35 ], "to": [ 36, 218, 229 ], "evaluate": [ 37 ], "latter": [ 42 ], "population.": [ 43 ], "Methods:": [ 44 ], "searched": [ 46 ], "PubMed,": [ 48 ], "EMBASE,": [ 49 ], "Cochrane,": [ 50 ], "CNKI,": [ 51 ], "Wanfang": [ 53 ], "databases.": [ 54 ], "Studies": [ 55 ], "regarding": [ 56 ], "adults": [ 58, 80, 104, 240 ], "treated": [ 61 ], "liraglutide/semaglutide": [ 63 ], "compared": [ 64 ], "other": [ 66 ], "active": [ 67 ], "agents": [ 68, 170 ], "or": [ 69, 173, 179, 182 ], "placebos": [ 70 ], "were": [ 71, 76, 107, 162, 216 ], "accessed.": [ 72 ], "The": [ 73, 89, 197 ], "primary": [ 74 ], "proportions": [ 78 ], "at": [ 82, 115 ], "least": [ 83, 116 ], "5%": [ 84, 117 ], "10%": [ 86, 119 ], "weight": [ 87, 120, 234, 250 ], "reduction.": [ 88 ], "secondary": [ 90 ], "included": [ 92 ], "metabolic": [ 93 ], "indicators": [ 94 ], "adverse": [ 96, 200 ], "events.": [ 97 ], "Results:": [ 98 ], "Eighteen": [ 99 ], "studies": [ 100 ], "10,938": [ 102 ], "included.": [ 108 ], "When": [ 109 ], "stratified": [ 110 ], "by": [ 111, 221 ], "categories": [ 113 ], "loss,": [ 121 ], "pooled": [ 123 ], "showed": [ 125 ], "medians": [ 126, 145 ], "27.7%": [ 127 ], "10.3%": [ 129 ], "control": [ 131, 150, 195, 210 ], "groups": [ 132, 151, 207, 211 ], "versus": [ 133 ], "65.3%": [ 134 ], "30.7%": [ 136 ], "3": [ 139 ], "mg": [ 140, 159 ], "once": [ 141, 160 ], "daily,": [ 142 ], "respectively;": [ 143 ], "whereas": [ 144 ], "47.6%": [ 146 ], "20.4%": [ 148 ], "vs": [ 152, 213 ], "86.6%": [ 153 ], "75.3%": [ 155 ], "2.4": [ 158 ], "weekly": [ 161 ], "found": [ 163 ], "two": [ 166 ], "categories,": [ 167 ], "respectively.": [ 168 ], "Both": [ 169, 243 ], "either": [ 171 ], "improved": [ 172 ], "had": [ 174, 185 ], "no": [ 175 ], "impact": [ 176 ], "lipid": [ 178 ], "glycemia.": [ 180 ], "Liraglutide": [ 181, 224 ], "therapy": [ 184, 227 ], "discontinuation": [ 186 ], "rates": [ 187 ], "2.4%\u201311.4%": [ 189 ], "which": [ 190, 215 ], "overlapped": [ 191 ], "0.7%\u20138.6%": [ 193 ], "groups.": [ 196 ], "frequency": [ 198 ], "events": [ 201 ], "was": [ 202 ], "comparable": [ 203 ], "between": [ 204 ], "treatment": [ 206 ], "(66.5%\u201395.8%": [ 212 ], "46.9%\u201396.1%),": [ 214 ], "mild": [ 217 ], "moderate": [ 219 ], "graded": [ 220 ], "studies.": [ 222 ], "Conclusion:": [ 223 ], "led": [ 228 ], "clinically": [ 231 ], "relevant": [ 232 ], "(\u2a7e5%)": [ 233 ], "loss": [ 235, 251 ], "48.2%\u201388.7%": [ 237 ], "among": [ 238 ], "diabetes.": [ 242 ], "are": [ 247, 253 ], "associated": [ 248 ], "well-tolerated.": [ 254 ] }, "publication_date": "2022-01-01", "publication_year": 2022, "type": "review", "cited_by_count": 40, "authors": [ { "id": "https://openalex.org/A5064871225", "display_name": "You Deng" }, { "id": "https://openalex.org/A5100657865", "display_name": "Andrew Park" }, { "id": "https://openalex.org/A5016290362", "display_name": "Lin Zhu" }, { "id": "https://openalex.org/A5052998000", "display_name": "Wen Xie" }, { "id": "https://openalex.org/A5069582580", "display_name": "Calvin Q. Pan" } ] }, { "id": "https://openalex.org/W4223485211", "doi": "https://doi.org/10.1016/j.clinre.2022.101922", "title": "The mTORC1/AMPK pathway plays a role in the beneficial effects of semaglutide (GLP-1 receptor agonist) on the liver of obese mice", "abstract": null, "publication_date": "2022-04-12", "publication_year": 2022, "type": "article", "cited_by_count": 40, "authors": [ { "id": "https://openalex.org/A5042697708", "display_name": "Pedro H. Reis\u2010Barbosa" }, { "id": "https://openalex.org/A5002457194", "display_name": "Ilitch Aquino Marcondes\u2010de\u2010Castro" }, { "id": "https://openalex.org/A5024493537", "display_name": "Thatiany de Souza Marinho" }, { "id": "https://openalex.org/A5084203631", "display_name": "M\u00e1rcia Barbosa \u00c1guila" }, { "id": "https://openalex.org/A5072346695", "display_name": "Carlos Alberto Mandarim\u2010de\u2010Lacerda" } ] }, { "id": "https://openalex.org/W3188801076", "doi": "https://doi.org/10.1016/j.peptides.2021.170624", "title": "Dulaglutide, a long-acting GLP-1 receptor agonist, can improve hyperandrogenemia and ovarian function in DHEA-induced PCOS rats", "abstract": null, "publication_date": "2021-08-08", "publication_year": 2021, "type": "article", "cited_by_count": 36, "authors": [ { "id": "https://openalex.org/A5034321630", "display_name": "Luming Wu" }, { "id": "https://openalex.org/A5008274125", "display_name": "Yin-Xue Wang" }, { "id": "https://openalex.org/A5056919422", "display_name": "Yue Zhan" }, { "id": "https://openalex.org/A5075213530", "display_name": "A-hui Liu" }, { "id": "https://openalex.org/A5100706395", "display_name": "Yixiang Wang" }, { "id": "https://openalex.org/A5048143422", "display_name": "Haofei Shen" }, { "id": "https://openalex.org/A5100398535", "display_name": "Yifan Wang" }, { "id": "https://openalex.org/A5107845442", "display_name": "Liyan Wang" }, { "id": "https://openalex.org/A5113953601", "display_name": "Zhongbin Tao" }, { "id": "https://openalex.org/A5100748005", "display_name": "Yiqing Wang" } ] }, { "id": "https://openalex.org/W2022207575", "doi": "https://doi.org/10.1007/s12020-014-0373-0", "title": "Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis", "abstract": null, "publication_date": "2014-08-12", "publication_year": 2014, "type": "review", "cited_by_count": 42, "authors": [ { "id": "https://openalex.org/A5005170922", "display_name": "Feng Sun" }, { "id": "https://openalex.org/A5103434941", "display_name": "Shanshan Wu" }, { "id": "https://openalex.org/A5102854981", "display_name": "Shuxia Guo" }, { "id": "https://openalex.org/A5013202820", "display_name": "Kai Yu" }, { "id": "https://openalex.org/A5018869790", "display_name": "Zhirong Yang" }, { "id": "https://openalex.org/A5082217568", "display_name": "Lishi Li" }, { "id": "https://openalex.org/A5100368706", "display_name": "Yuan Zhang" }, { "id": "https://openalex.org/A5036949656", "display_name": "Linong Ji" }, { "id": "https://openalex.org/A5070369468", "display_name": "Siyan Zhan" } ] }, { "id": "https://openalex.org/W2062883844", "doi": "https://doi.org/10.1111/j.1463-1326.2006.00589.x", "title": "Long\u2010term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over\u2010weight metformin\u2010treated patients with type 2 diabetes mellitus", "abstract": { "Aim:": [ 0 ], "The": [ 1, 130, 194 ], "ability": [ 2 ], "of": [ 3, 36, 47, 51, 64, 79, 92, 108, 126, 132, 160, 171, 204, 211 ], "the": [ 4, 86, 90, 93, 221, 225 ], "incretin": [ 5 ], "mimetic": [ 6 ], "exenatide": [ 7, 57, 80, 96, 152, 181, 205 ], "to": [ 8, 28, 55, 265 ], "improve": [ 9 ], "glycaemic": [ 10, 30, 267 ], "control": [ 11, 31, 268 ], "and": [ 12, 142, 146, 201, 224, 249 ], "reduce": [ 13 ], "body": [ 14 ], "weight": [ 15, 157, 170, 254 ], "was": [ 16, 144, 206, 209, 230, 238 ], "assessed": [ 17 ], "over": [ 18, 255 ], "82": [ 19, 77, 124, 143, 177, 192, 202, 256 ], "weeks": [ 20, 78, 125, 140, 203, 257 ], "in": [ 21, 59, 98, 156, 169, 187, 216, 220, 246, 253, 258 ], "patients": [ 22, 53, 73, 133, 259 ], "with": [ 23, 32, 118, 165, 232, 260, 269 ], "type": [ 24, 261 ], "2": [ 25, 262 ], "diabetes": [ 26, 263 ], "failing": [ 27, 264 ], "achieve": [ 29, 266 ], "maximally": [ 33 ], "effective": [ 34 ], "doses": [ 35 ], "metformin.": [ 37, 270 ], "Methods:": [ 38 ], "In": [ 39, 179 ], "this": [ 40 ], "interim": [ 41 ], "82\u2010week": [ 42 ], "analysis,": [ 43 ], "150": [ 44 ], "(total": [ 45 ], "cohort)": [ 46, 75 ], "an": [ 48, 60, 99 ], "eligible": [ 49 ], "population": [ 50 ], "183": [ 52 ], "opted": [ 54 ], "continue": [ 56 ], "treatment": [ 58, 116, 182 ], "uncontrolled": [ 61, 226 ], "open\u2010label": [ 62, 227 ], "extension": [ 63 ], "a": [ 65, 154, 166, 243, 250 ], "30\u2010week": [ 66 ], "double\u2010blind,": [ 67 ], "placebo\u2010controlled": [ 68, 94 ], "trial.": [ 69 ], "Of": [ 70 ], "these,": [ 71 ], "92": [ 72 ], "(completer": [ 74 ], "achieved": [ 76, 135 ], "therapy.": [ 81 ], "Patients": [ 82 ], "continued": [ 83 ], "metformin": [ 84 ], "throughout": [ 85 ], "study.": [ 87 ], "Results:": [ 88 ], "At": [ 89 ], "end": [ 91 ], "trial,": [ 95 ], "resulted": [ 97 ], "haemoglobin": [ 100 ], "A1c": [ 101 ], "(HbA": [ 102 ], "1c": [ 103, 121, 137, 248 ], ")": [ 104 ], "reduction": [ 105, 155, 168, 245, 252 ], "from": [ 106, 158 ], "baseline": [ 107, 159 ], "\u22121.0": [ 109 ], "\u00b1": [ 110, 113, 128, 162, 173 ], "0.1%": [ 111 ], "(mean": [ 112 ], "SE)": [ 114 ], "(exenatide": [ 115 ], "arms),": [ 117 ], "durable": [ 119, 244 ], "HbA": [ 120, 136, 247 ], "reductions": [ 122 ], "after": [ 123, 176, 191, 199, 218 ], "\u22121.3": [ 127 ], "0.1%.": [ 129 ], "percent": [ 131 ], "who": [ 134 ], "\u22647%": [ 138 ], "at": [ 139 ], "30": [ 141, 150, 200 ], "46": [ 145 ], "59%": [ 147 ], "respectively.": [ 148 ], "After": [ 149 ], "weeks,": [ 151 ], "caused": [ 153 ], "\u22123.0": [ 161 ], "0.6": [ 163 ], "kg,": [ 164 ], "progressive": [ 167, 251 ], "\u22125.3": [ 172 ], "0.8": [ 174 ], "kg": [ 175 ], "weeks.": [ 178, 193 ], "addition,": [ 180 ], "produced": [ 183 ], "clinically": [ 184 ], "significant": [ 185 ], "improvements": [ 186 ], "cardiovascular": [ 188 ], "risk": [ 189 ], "factors": [ 190 ], "most": [ 195 ], "frequent": [ 196 ], "adverse": [ 197 ], "event": [ 198 ], "nausea,": [ 207 ], "which": [ 208 ], "generally": [ 210, 239 ], "mild\u2010or\u2010moderate": [ 212 ], "intensity.": [ 213 ], "It": [ 214 ], "decreased": [ 215 ], "incidence": [ 217 ], "initiation": [ 219 ], "controlled": [ 222 ], "trial": [ 223 ], "extension.": [ 228 ], "Hypoglycaemia": [ 229 ], "rare,": [ 231 ], "no": [ 233 ], "severe": [ 234 ], "events.": [ 235 ], "Conclusion:": [ 236 ], "Exenatide": [ 237 ], "well": [ 240 ], "tolerated,": [ 241 ], "producing": [ 242 ] }, "publication_date": "2006-05-08", "publication_year": 2006, "type": "article", "cited_by_count": 220, "authors": [ { "id": "https://openalex.org/A5081205041", "display_name": "Robert E. Ratner" }, { "id": "https://openalex.org/A5062921481", "display_name": "David Maggs" }, { "id": "https://openalex.org/A5075068030", "display_name": "Loretta L. Nielsen" }, { "id": "https://openalex.org/A5049307365", "display_name": "Anthony H. Stonehouse" }, { "id": "https://openalex.org/A5108497778", "display_name": "Terri Poon" }, { "id": "https://openalex.org/A5008311039", "display_name": "B. Zhang" }, { "id": "https://openalex.org/A5008162033", "display_name": "Thomas A. Bicsak" }, { "id": "https://openalex.org/A5109961740", "display_name": "Robert G. Brodows" }, { "id": "https://openalex.org/A5016396904", "display_name": "D. D. Kim" } ] }, { "id": "https://openalex.org/W3005278786", "doi": "https://doi.org/10.1007/s12325-020-01242-z", "title": "A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK", "abstract": { "The": [ 0 ], "present": [ 1 ], "study": [ 2 ], "showed": [ 3 ], "that": [ 4 ], "once-weekly": [ 5 ], "semaglutide": [ 6, 29 ], "offers": [ 7 ], "superior": [ 8 ], "cost": [ 9 ], "of": [ 10, 20 ], "control": [ 11 ], "versus": [ 12 ], "exenatide": [ 13 ], "ER,": [ 14 ], "dulaglutide": [ 15 ], "and": [ 16, 25 ], "liraglutide": [ 17 ], "in": [ 18, 39 ], "terms": [ 19 ], "achieving": [ 21 ], "clinically": [ 22 ], "relevant,": [ 23 ], "single": [ 24 ], "composite": [ 26 ], "endpoints.": [ 27 ], "Once-weekly": [ 28 ], "1": [ 30 ], "mg": [ 31 ], "would": [ 32 ], "therefore": [ 33 ], "represent": [ 34 ], "good": [ 35 ], "value": [ 36 ], "for": [ 37 ], "money": [ 38 ], "the": [ 40 ], "UK": [ 41 ], "setting.": [ 42 ] }, "publication_date": "2020-02-11", "publication_year": 2020, "type": "article", "cited_by_count": 8, "authors": [ { "id": "https://openalex.org/A5051180257", "display_name": "Pierre Johansen" }, { "id": "https://openalex.org/A5036868434", "display_name": "Anna Sandberg" }, { "id": "https://openalex.org/A5073949429", "display_name": "Matthew Capehorn" } ] }, { "id": "https://openalex.org/W2595209157", "doi": "https://doi.org/10.1016/j.ejps.2017.03.020", "title": "Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species", "abstract": { "Semaglutide": [ 0, 167 ], "is": [ 1 ], "a": [ 2, 23 ], "human": [ 3, 36 ], "glucagon-like": [ 4 ], "peptide-1": [ 5 ], "analogue": [ 6 ], "in": [ 7, 34, 46, 54, 60, 65, 70, 106, 136, 139, 143, 162, 195, 204, 210, 216, 218, 225 ], "clinical": [ 8 ], "development": [ 9 ], "for": [ 10, 108, 115, 198 ], "the": [ 11, 102, 118, 159, 174, 181, 201, 232, 235 ], "treatment": [ 12 ], "of": [ 13, 22, 29, 86, 92, 117, 121, 131, 154, 173, 180, 200, 223 ], "type": [ 14 ], "2": [ 15 ], "diabetes.": [ 16 ], "The": [ 17, 81, 220 ], "absorption,": [ 18 ], "metabolism": [ 19, 186 ], "and": [ 20, 38, 50, 57, 67, 73, 79, 84, 91, 110, 124, 141, 146, 165, 177, 185, 206 ], "excretion": [ 21 ], "single": [ 24 ], "0.5mg/450\u03bcCi": [ 25 ], "[16.7MBq]": [ 26 ], "subcutaneous": [ 27 ], "dose": [ 28, 203 ], "[3H]-radiolabelled": [ 30 ], "semaglutide": [ 31, 93, 100, 194, 224 ], "was": [ 32, 52, 63, 101, 125, 134, 168, 187, 213 ], "investigated": [ 33 ], "healthy": [ 35 ], "subjects": [ 37 ], "compared": [ 39 ], "with": [ 40, 156 ], "data": [ 41 ], "from": [ 42, 234 ], "nonclinical": [ 43, 112, 236 ], "studies.": [ 44 ], "Radioactivity": [ 45 ], "blood,": [ 47 ], "plasma,": [ 48, 71 ], "urine": [ 49, 72, 157, 196, 217 ], "faeces": [ 51, 74, 147 ], "determined": [ 53, 64 ], "humans,": [ 55, 137 ], "rats": [ 56, 140 ], "monkeys;": [ 58 ], "radioactivity": [ 59, 133 ], "expired": [ 61 ], "air": [ 62 ], "humans": [ 66, 95, 109, 164, 205, 226 ], "rats.": [ 68 ], "Metabolites": [ 69 ], "were": [ 75, 97, 148 ], "quantified": [ 76 ], "following": [ 77 ], "profiling": [ 78 ], "radiodetection.": [ 80 ], "blood-to-plasma": [ 82 ], "ratio": [ 83 ], "pharmacokinetics": [ 85 ], "both": [ 87, 111, 163 ], "radiolabelled": [ 88 ], "semaglutide-related": [ 89, 122 ], "material": [ 90 ], "(in": [ 94 ], "only)": [ 96 ], "assessed.": [ 98 ], "Intact": [ 99, 193 ], "primary": [ 103, 160 ], "component": [ 104 ], "circulating": [ 105 ], "plasma": [ 107 ], "species,": [ 113 ], "accounting": [ 114 ], "69-83%": [ 116 ], "total": [ 119 ], "amount": [ 120 ], "material,": [ 123 ], "metabolised": [ 126, 169 ], "prior": [ 127 ], "to": [ 128, 150, 190, 228, 231 ], "excretion.": [ 129 ], "Recovery": [ 130 ], "excreted": [ 132 ], "75.1%": [ 135 ], "72.1%": [ 138 ], "58.2%": [ 142 ], "monkeys.": [ 144, 219 ], "Urine": [ 145 ], "shown": [ 149 ], "be": [ 151, 229 ], "important": [ 152 ], "routes": [ 153 ], "excretion,": [ 155 ], "as": [ 158 ], "route": [ 161 ], "animals.": [ 166 ], "through": [ 170 ], "proteolytic": [ 171 ], "cleavage": [ 172 ], "peptide": [ 175 ], "backbone": [ 176 ], "sequential": [ 178 ], "beta-oxidation": [ 179 ], "fatty": [ 182 ], "acid": [ 183 ], "sidechain,": [ 184 ], "not": [ 188, 214 ], "confined": [ 189 ], "specific": [ 191 ], "organs.": [ 192 ], "accounted": [ 197 ], "3.1%": [ 199 ], "administered": [ 202 ], "less": [ 207 ], "than": [ 208 ], "1%": [ 209 ], "rats;": [ 211 ], "it": [ 212 ], "detected": [ 215 ], "metabolite": [ 221 ], "profiles": [ 222, 233 ], "appear": [ 227 ], "similar": [ 230 ], "species": [ 237 ], "investigated.": [ 238 ] }, "publication_date": "2017-03-16", "publication_year": 2017, "type": "article", "cited_by_count": 156, "authors": [ { "id": "https://openalex.org/A5019447119", "display_name": "Lene Jensen" }, { "id": "https://openalex.org/A5012114174", "display_name": "Hans Helleberg" }, { "id": "https://openalex.org/A5020030500", "display_name": "Ad F. Roffel" }, { "id": "https://openalex.org/A5055811263", "display_name": "Jan Jaap van Lier" }, { "id": "https://openalex.org/A5042403500", "display_name": "Inga Bj\u00f8rnsdottir" }, { "id": "https://openalex.org/A5017195842", "display_name": "Palle J. Pedersen" }, { "id": "https://openalex.org/A5110340900", "display_name": "Everton Rowe" }, { "id": "https://openalex.org/A5008923622", "display_name": "Julie Derving Karsb\u00f8l" }, { "id": "https://openalex.org/A5072663611", "display_name": "Mette Lund Pedersen" } ] }, { "id": "https://openalex.org/W3092048046", "doi": "https://doi.org/10.1186/s12933-020-01148-8", "title": "Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis", "abstract": null, "publication_date": "2020-10-09", "publication_year": 2020, "type": "review", "cited_by_count": 35, "authors": [ { "id": "https://openalex.org/A5109436805", "display_name": "Kai-Cheng Chang" }, { "id": "https://openalex.org/A5073945647", "display_name": "Shih\u2010Chieh Shao" }, { "id": "https://openalex.org/A5000139592", "display_name": "Shihchen Kuo" }, { "id": "https://openalex.org/A5112687114", "display_name": "Chen-Yi Yang" }, { "id": "https://openalex.org/A5101073434", "display_name": "Hui-Yu Chen" }, { "id": "https://openalex.org/A5112521512", "display_name": "Yuk-Ying Chan" }, { "id": "https://openalex.org/A5064013873", "display_name": "Huang\u2010Tz Ou" } ] }, { "id": "https://openalex.org/W2125769727", "doi": "https://doi.org/10.1186/s13048-015-0161-3", "title": "Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study", "abstract": null, "publication_date": "2015-06-01", "publication_year": 2015, "type": "article", "cited_by_count": 85, "authors": [ { "id": "https://openalex.org/A5091436678", "display_name": "Mojca Jensterle" }, { "id": "https://openalex.org/A5048550196", "display_name": "Vesna \u0160alamun" }, { "id": "https://openalex.org/A5053086437", "display_name": "Toma\u017e Kocjan" }, { "id": "https://openalex.org/A5027331667", "display_name": "Eda Vrta\u010dnik Bokal" }, { "id": "https://openalex.org/A5002770606", "display_name": "Andrej Jane\u017e" } ] }, { "id": "https://openalex.org/W3033887523", "doi": "https://doi.org/10.1186/s12933-020-01049-w", "title": "Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice", "abstract": null, "publication_date": "2020-06-10", "publication_year": 2020, "type": "article", "cited_by_count": 64, "authors": [ { "id": "https://openalex.org/A5013911767", "display_name": "Enrico Longato" }, { "id": "https://openalex.org/A5077821068", "display_name": "Barbara Di Camillo" }, { "id": "https://openalex.org/A5071251680", "display_name": "Giovanni Sparacino" }, { "id": "https://openalex.org/A5006609733", "display_name": "Lara Tramontan" }, { "id": "https://openalex.org/A5029164653", "display_name": "Angelo Avogaro" }, { "id": "https://openalex.org/A5027393457", "display_name": "Gian Paolo Fadini" } ] }, { "id": "https://openalex.org/W2065372294", "doi": "https://doi.org/10.1186/1471-2202-13-33", "title": "Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis", "abstract": { "Our": [ 0 ], "results": [ 1 ], "suggest": [ 2 ], "that": [ 3 ], "these": [ 4 ], "novel": [ 5 ], "incretin": [ 6 ], "analogues": [ 7 ], "cross": [ 8 ], "the": [ 9, 18 ], "BBB": [ 10 ], "and": [ 11, 15 ], "show": [ 12 ], "physiological": [ 13 ], "activity": [ 14 ], "neurogenesis": [ 16 ], "in": [ 17 ], "brain,": [ 19 ], "which": [ 20 ], "may": [ 21 ], "be": [ 22 ], "of": [ 23, 28 ], "use": [ 24 ], "as": [ 25 ], "a": [ 26 ], "treatment": [ 27 ], "neurodegenerative": [ 29 ], "diseases.": [ 30 ] }, "publication_date": "2012-03-23", "publication_year": 2012, "type": "article", "cited_by_count": 476, "authors": [ { "id": "https://openalex.org/A5048209552", "display_name": "Kerry Hunter" }, { "id": "https://openalex.org/A5082707086", "display_name": "Christian H\u00f6lscher" } ] }, { "id": "https://openalex.org/W1774706564", "doi": "https://doi.org/10.1002/oby.21107", "title": "GLP\u20101 receptor agonists: Nonglycemic clinical effects in weight loss and beyond", "abstract": { "Obective": [ 0 ], "Glucagon\u2010like": [ 1 ], "peptide\u20101": [ 2 ], "(GLP\u20101)": [ 3 ], "receptor": [ 4, 86, 105, 168, 189 ], "agonists": [ 5, 169, 190 ], "are": [ 6, 110, 123 ], "indicated": [ 7 ], "for": [ 8, 59, 184, 191, 198 ], "treatment": [ 9 ], "of": [ 10, 19, 39, 46, 84, 103, 116, 163 ], "type": [ 11 ], "2": [ 12 ], "diabetes": [ 13 ], "since": [ 14 ], "they": [ 15 ], "mimic": [ 16 ], "the": [ 17, 63, 71, 80, 127, 140, 150 ], "actions": [ 18 ], "native": [ 20 ], "GLP\u20101": [ 21, 85, 104, 108, 167, 188 ], "on": [ 22, 65, 73, 100, 130, 149, 157 ], "pancreatic": [ 23 ], "islet": [ 24 ], "cells,": [ 25 ], "stimulating": [ 26 ], "insulin": [ 27 ], "release,": [ 28, 32 ], "while": [ 29 ], "inhibiting": [ 30 ], "glucagon": [ 31 ], "in": [ 33, 62, 70, 113, 118, 186 ], "a": [ 34, 114 ], "glucose\u2010dependent": [ 35 ], "manner.": [ 36 ], "The": [ 37 ], "observation": [ 38 ], "weight": [ 40, 60, 135, 164, 177, 200 ], "loss": [ 41 ], "has": [ 42 ], "led": [ 43 ], "to": [ 44, 94, 126 ], "exploration": [ 45 ], "their": [ 47, 121 ], "potential": [ 48, 81 ], "as": [ 49 ], "antiobesity": [ 50 ], "agents,": [ 51 ], "with": [ 52 ], "liraglutide": [ 53 ], "3.0": [ 54 ], "mg": [ 55 ], "day": [ 56 ], "\u22121": [ 57 ], "approved": [ 58, 197 ], "management": [ 61 ], "US": [ 64 ], "December": [ 66 ], "23,": [ 67, 75 ], "2014,": [ 68 ], "and": [ 69, 97, 120, 153, 156 ], "EU": [ 72 ], "March": [ 74 ], "2015.": [ 76 ], "This": [ 77 ], "review": [ 78 ], "examines": [ 79 ], "nonglycemic": [ 82, 101, 144, 173 ], "effects": [ 83, 102, 122, 129, 133, 148, 175, 181 ], "agonists.": [ 87, 106 ], "Methods": [ 88 ], "A": [ 89 ], "literature": [ 90 ], "search": [ 91 ], "was": [ 92 ], "conducted": [ 93 ], "identify": [ 95 ], "preclinical": [ 96 ], "clinical": [ 98, 174 ], "evidence": [ 99 ], "Results": [ 107 ], "receptors": [ 109 ], "distributed": [ 111 ], "widely": [ 112, 142 ], "number": [ 115 ], "tissues": [ 117 ], "humans,": [ 119 ], "not": [ 124 ], "limited": [ 125 ], "well\u2010recognized": [ 128 ], "glycemia.": [ 131 ], "Nonglycemic": [ 132 ], "include": [ 134 ], "loss,": [ 136 ], "which": [ 137 ], "is": [ 138, 182 ], "perhaps": [ 139 ], "most": [ 141 ], "recognized": [ 143 ], "effect.": [ 145 ], "In": [ 146 ], "addition,": [ 147 ], "cardiovascular,": [ 151 ], "neurologic,": [ 152 ], "renal": [ 154 ], "systems": [ 155 ], "taste": [ 158 ], "perception": [ 159 ], "may": [ 160, 170 ], "occur": [ 161 ], "independently": [ 162 ], "loss.": [ 165, 178 ], "Conclusions": [ 166 ], "provide": [ 171 ], "other": [ 172 ], "besides": [ 176 ], "Understanding": [ 179 ], "these": [ 180 ], "important": [ 183 ], "prescribers": [ 185 ], "using": [ 187 ], "diabetic": [ 192 ], "patients,": [ 193 ], "but": [ 194 ], "also": [ 195 ], "if": [ 196 ], "chronic": [ 199 ], "management.": [ 201 ] }, "publication_date": "2015-05-09", "publication_year": 2015, "type": "review", "cited_by_count": 101, "authors": [ { "id": "https://openalex.org/A5088283488", "display_name": "Donna H. Ryan" }, { "id": "https://openalex.org/A5060455870", "display_name": "Andr\u00e9s Acosta" } ] }, { "id": "https://openalex.org/W2566045659", "doi": "https://doi.org/10.2174/1570161114666161221115324", "title": "Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome", "abstract": { "Polycystic": [ 0 ], "ovary": [ 1 ], "syndrome": [ 2 ], "(PCOS)": [ 3 ], "is": [ 4, 13, 190 ], "the": [ 5, 126, 129, 200 ], "most": [ 6 ], "common": [ 7 ], "endocrine": [ 8 ], "disorder": [ 9 ], "in": [ 10, 66, 72, 86, 100, 107, 125, 148, 161, 206 ], "females": [ 11 ], "and": [ 12, 33, 53, 57, 105, 112, 128, 158, 173, 182, 208 ], "often": [ 14 ], "associated": [ 15 ], "with": [ 16, 88, 146, 179 ], "a": [ 17, 42, 47, 159 ], "number": [ 18 ], "of": [ 19, 102, 136, 185, 203 ], "cardiometabolic": [ 20 ], "disorders": [ 21 ], "such": [ 22 ], "as": [ 23, 121, 142 ], "central": [ 24 ], "obesity,": [ 25 ], "dyslipidaemia,": [ 26 ], "hypertension,": [ 27 ], "insulin": [ 28, 51, 169, 171 ], "resistance,": [ 29 ], "hyperinsulinaemia,": [ 30 ], "glucose": [ 31 ], "intolerance": [ 32 ], "type": [ 34 ], "2": [ 35 ], "diabetes": [ 36, 111 ], "mellitus": [ 37 ], "(T2DM).": [ 38 ], "Glucagon-like": [ 39 ], "peptide-1": [ 40 ], "(GLP-1),": [ 41 ], "gut": [ 43 ], "hormone": [ 44 ], "secreted": [ 45 ], "after": [ 46 ], "meal,": [ 48 ], "enhances": [ 49 ], "glucosestimulated": [ 50 ], "secretion": [ 52 ], "additionally": [ 54 ], "suppresses": [ 55 ], "appetite": [ 56 ], "gastric": [ 58 ], "motility.": [ 59 ], "Most": [ 60 ], "studies": [ 61, 71, 178 ], "found": [ 62 ], "impaired": [ 63 ], "GLP-1": [ 64, 80, 91, 140, 204 ], "kinetics": [ 65 ], "obese": [ 67, 108, 149, 194 ], "individuals,": [ 68 ], "whereas": [ 69 ], "small": [ 70, 134 ], "PCOS": [ 73, 150, 207 ], "reported": [ 74 ], "reduced,": [ 75 ], "normal": [ 76 ], "or": [ 77, 144 ], "even": [ 78 ], "elevated": [ 79 ], "levels.": [ 81 ], "Apart": [ 82 ], "from": [ 83 ], "their": [ 84 ], "efficacy": [ 85 ], "patients": [ 87, 181 ], "T2DM,": [ 89 ], "some": [ 90, 133 ], "receptor": [ 92 ], "agonists": [ 93 ], "(GLP-1": [ 94 ], "RAs)": [ 95 ], "have": [ 96 ], "been": [ 97, 119 ], "successfully": [ 98 ], "tested": [ 99 ], "terms": [ 101 ], "both": [ 103 ], "efficiency": [ 104 ], "safety": [ 106, 211 ], "individuals": [ 109 ], "without": [ 110, 165 ], "liraglutide": [ 113, 186 ], "3": [ 114 ], "mg": [ 115 ], "once": [ 116 ], "daily": [ 117 ], "has": [ 118 ], "approved": [ 120, 192 ], "an": [ 122 ], "antiobesity": [ 123 ], "drug": [ 124, 189 ], "USA": [ 127 ], "European": [ 130 ], "Union.": [ 131 ], "Recently,": [ 132 ], "trials": [ 135 ], "short": [ 137 ], "duration": [ 138 ], "using": [ 139 ], "RAs": [ 141, 205 ], "monotherapy": [ 143 ], "combined": [ 145 ], "metformin": [ 147 ], "women": [ 151 ], "showed": [ 152 ], "positive": [ 153 ], "results": [ 154 ], "regarding": [ 155 ], "weight": [ 156 ], "reduction": [ 157 ], "decrease": [ 160 ], "testosterone": [ 162 ], "levels": [ 163 ], "but": [ 164 ], "significant": [ 166 ], "effects": [ 167 ], "on": [ 168 ], "levels,": [ 170 ], "sensitivity": [ 172 ], "menstrual": [ 174 ], "patterns.": [ 175 ], "Longer": [ 176 ], "term": [ 177 ], "more": [ 180 ], "higher": [ 183 ], "doses": [ 184 ], "(as": [ 187 ], "this": [ 188 ], "already": [ 191 ], "for": [ 193 ], "individuals)": [ 195 ], "are": [ 196 ], "required": [ 197 ], "to": [ 198, 209 ], "determine": [ 199 ], "precise": [ 201 ], "indications": [ 202 ], "evaluate": [ 210 ], "issues.": [ 212 ] }, "publication_date": "2017-04-11", "publication_year": 2017, "type": "review", "cited_by_count": 39, "authors": [ { "id": "https://openalex.org/A5108136810", "display_name": "Themistoklis Tzotzas" }, { "id": "https://openalex.org/A5056052693", "display_name": "Spyridon \u039d. Karras" }, { "id": "https://openalex.org/A5058321397", "display_name": "Niki Katsiki" } ] }, { "id": "https://openalex.org/W2974714926", "doi": "https://doi.org/10.2337/dc19-0898", "title": "Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial", "abstract": { "OBJECTIVE": [ 0 ], "To": [ 1 ], "investigate": [ 2 ], "the": [ 3 ], "efficacy,": [ 4 ], "safety,": [ 5 ], "and": [ 6, 78, 98, 134, 141, 148, 162, 178, 191, 205, 240 ], "tolerability": [ 7 ], "of": [ 8, 91, 220 ], "oral": [ 9, 37, 200, 215 ], "semaglutide": [ 10, 38, 114, 201, 216, 232 ], "added": [ 11, 244 ], "to": [ 12, 36, 56, 72, 117, 228, 235, 245 ], "insulin": [ 13, 29, 246 ], "with": [ 14, 23, 30, 199, 214, 224, 247, 253, 262 ], "or": [ 15, 31, 49, 55, 95, 248 ], "without": [ 16, 32, 106, 249 ], "metformin.": [ 17 ], "RESEARCH": [ 18 ], "DESIGN": [ 19 ], "AND": [ 20 ], "METHODS": [ 21 ], "Patients": [ 22 ], "type": [ 24, 254 ], "2": [ 25, 255 ], "diabetes": [ 26 ], "uncontrolled": [ 27 ], "on": [ 28 ], "metformin": [ 33, 250 ], "were": [ 34, 68, 85, 197 ], "randomized": [ 35, 110 ], "3": [ 39, 171 ], "mg": [ 40, 45, 51 ], "(N": [ 41, 46, 52, 58 ], "=": [ 42, 47, 53, 59, 168 ], "184),": [ 43 ], "7": [ 44, 177 ], "182),": [ 48 ], "14": [ 50, 142, 179 ], "181)": [ 54 ], "placebo": [ 57, 118, 196, 236 ], "184)": [ 60 ], "in": [ 61, 75, 109, 119, 237, 251 ], "a": [ 62 ], "52-week,": [ 63 ], "double-blind": [ 64 ], "trial.": [ 65 ], "End": [ 66 ], "points": [ 67 ], "change": [ 69 ], "from": [ 70 ], "baseline": [ 71 ], "week": [ 73, 182 ], "26": [ 74, 183, 204 ], "HbA1c": [ 76, 121, 190, 239 ], "(primary)": [ 77 ], "body": [ 79, 149, 192, 241 ], "weight": [ 80, 150, 193, 242 ], "(confirmatory": [ 81 ], "secondary).": [ 82 ], "Two": [ 83 ], "estimands": [ 84 ], "defined:": [ 86 ], "treatment": [ 87, 123 ], "policy": [ 88, 185 ], "(effect": [ 89, 101 ], "regardless": [ 90 ], "trial": [ 92, 99, 103 ], "product": [ 93, 100, 104 ], "discontinuation": [ 94 ], "rescue": [ 96, 107 ], "medication)": [ 97, 108 ], "assuming": [ 102 ], "continuation": [ 105 ], "patients.": [ 111 ], "RESULTS": [ 112 ], "Oral": [ 113, 231 ], "was": [ 115, 217, 233, 260 ], "superior": [ 116, 234 ], "reducing": [ 120, 238 ], "(estimated": [ 122 ], "difference": [ 124 ], "[ETD]": [ 125 ], "\u20130.5%": [ 126 ], "[95%": [ 127, 154 ], "CI": [ 128, 155 ], "\u20130.7,": [ 129 ], "\u20130.3],": [ 130 ], "\u20130.9%": [ 131 ], "[\u20131.1,": [ 132 ], "\u20130.7],": [ 133 ], "\u20131.2%": [ 135 ], "[\u20131.4,": [ 136 ], "\u20131.0]": [ 137 ], "for": [ 138, 170, 176 ], "3,": [ 139 ], "7,": [ 140 ], "mg,": [ 143, 172 ], "respectively;": [ 144 ], "P": [ 145, 167, 173 ], "&lt;": [ 146 ], "0.001)": [ 147 ], "(ETD": [ 151 ], "\u22120.9": [ 152 ], "kg": [ 153, 159, 164 ], "\u22121.8,": [ 156 ], "\u22120.0],": [ 157 ], "\u22122.0": [ 158 ], "[\u22123.0,": [ 160 ], "\u22121.0],": [ 161 ], "\u22123.3": [ 163 ], "[\u22124.2,": [ 165 ], "\u22122.3];": [ 166 ], "0.0392": [ 169 ], "\u2264": [ 174 ], "0.0001": [ 175 ], "mg)": [ 180 ], "at": [ 181, 202 ], "(treatment": [ 184 ], "estimand).": [ 186 ], "Significantly": [ 187 ], "greater": [ 188 ], "dose-dependent": [ 189 ], "reductions": [ 194 ], "versus": [ 195 ], "achieved": [ 198 ], "weeks": [ 203 ], "52": [ 206 ], "(both": [ 207 ], "estimands).": [ 208 ], "The": [ 209, 257 ], "most": [ 210 ], "frequent": [ 211 ], "adverse": [ 212 ], "event": [ 213 ], "nausea": [ 218 ], "(11.4\u201323.2%": [ 219 ], "patients": [ 221, 252 ], "vs.": [ 222 ], "7.1%": [ 223 ], "placebo;": [ 225 ], "mostly": [ 226 ], "mild": [ 227 ], "moderate).": [ 229 ], "CONCLUSIONS": [ 230 ], "when": [ 243 ], "diabetes.": [ 256 ], "safety": [ 258 ], "profile": [ 259 ], "consistent": [ 261 ], "other": [ 263 ], "glucagon-like": [ 264 ], "peptide": [ 265 ], "1": [ 266 ], "receptor": [ 267 ], "agonists.": [ 268 ] }, "publication_date": "2019-07-10", "publication_year": 2019, "type": "article", "cited_by_count": 253, "authors": [ { "id": "https://openalex.org/A5090437675", "display_name": "Bernard Zinman" }, { "id": "https://openalex.org/A5005405894", "display_name": "Vanita R. Aroda" }, { "id": "https://openalex.org/A5040182038", "display_name": "John B. Buse" }, { "id": "https://openalex.org/A5004521406", "display_name": "Bertrand Cariou" }, { "id": "https://openalex.org/A5102945405", "display_name": "Stewart B. Harris" }, { "id": "https://openalex.org/A5078003599", "display_name": "S\u00f8ren T. Hoff" }, { "id": "https://openalex.org/A5004964619", "display_name": "Karen Boje Pedersen" }, { "id": "https://openalex.org/A5044044784", "display_name": "Mads Jeppe Tarp-Johansen" }, { "id": "https://openalex.org/A5067248419", "display_name": "Eiichi Araki" }, { "id": "https://openalex.org/A5090437675", "display_name": "Bernard Zinman" }, { "id": "https://openalex.org/A5068025360", "display_name": "Sameh Fikry" }, { "id": "https://openalex.org/A5065730535", "display_name": "Harpreet S. Bajaj" }, { "id": "https://openalex.org/A5025605998", "display_name": "Daniel Landry" }, { "id": "https://openalex.org/A5110638415", "display_name": "David Caplan" }, { "id": "https://openalex.org/A5032297044", "display_name": "Vincent Woo" }, { "id": "https://openalex.org/A5102945405", "display_name": "Stewart B. Harris" }, { "id": "https://openalex.org/A5050716127", "display_name": "Jean-Francois Thuan" }, { "id": "https://openalex.org/A5061673342", "display_name": "Pierre S\u00e9rusclat" }, { "id": "https://openalex.org/A5004521406", "display_name": "Bertrand Cariou" }, { "id": "https://openalex.org/A5047653403", "display_name": "Pierre Gourdy" }, { "id": "https://openalex.org/A5014948473", "display_name": "G. Fradet" }, { "id": "https://openalex.org/A5085985221", "display_name": "Arnaud Monier" }, { "id": "https://openalex.org/A5005612876", "display_name": "Sophie Borot" }, { "id": "https://openalex.org/A5037911835", "display_name": "P. Monguillon" }, { "id": "https://openalex.org/A5077120707", "display_name": "D. Gouet" }, { "id": "https://openalex.org/A5090372980", "display_name": "John Doupis" }, { "id": "https://openalex.org/A5014280857", "display_name": "Nikola\u03bfs Tentolouris" }, { "id": "https://openalex.org/A5083556958", "display_name": "V. Tsimichodimos" }, { "id": "https://openalex.org/A5053814166", "display_name": "Andreas Melidonis" }, { "id": "https://openalex.org/A5051305906", "display_name": "Eleni Bekiari" }, { "id": "https://openalex.org/A5015534459", "display_name": "\u0391lexandra Bargiota" }, { "id": "https://openalex.org/A5101414707", "display_name": "Sanjay Agarwal" }, { "id": "https://openalex.org/A5039062359", "display_name": "Banshi Saboo" }, { "id": "https://openalex.org/A5101850086", "display_name": "Sanjay Chatterjee" }, { "id": "https://openalex.org/A5034363861", "display_name": "Viswanathan Mohan" }, { "id": "https://openalex.org/A5017826099", "display_name": "Shehla Shaikh" }, { "id": "https://openalex.org/A5028363725", "display_name": "Yashdeep Gupta" }, { "id": "https://openalex.org/A5113614996", "display_name": "Arpandev Bhattacharyya" }, { "id": "https://openalex.org/A5021041231", "display_name": "Neeraj Manikath" }, { "id": "https://openalex.org/A5101981284", "display_name": "Sunil Jain" }, { "id": "https://openalex.org/A5021357642", "display_name": "Takashi Sasaki" }, { "id": "https://openalex.org/A5070116155", "display_name": "Takeshi Osonoi" }, { "id": "https://openalex.org/A5054228678", "display_name": "Shuichi Fukuda" }, { "id": "https://openalex.org/A5109316164", "display_name": "Seiki Wada" }, { "id": "https://openalex.org/A5048971859", "display_name": "Arihiro Kiyosue" }, { "id": "https://openalex.org/A5084908775", "display_name": "Yumiko Ide" }, { "id": "https://openalex.org/A5087983151", "display_name": "Yukiko Onishi" }, { "id": "https://openalex.org/A5111499456", "display_name": "Kiyokazu Matoba" }, { "id": "https://openalex.org/A5011620812", "display_name": "Kuninobu Takai" }, { "id": "https://openalex.org/A5068870878", "display_name": "Akira Yamauchi" }, { "id": "https://openalex.org/A5091296972", "display_name": "Satoshi Inoue" }, { "id": "https://openalex.org/A5101474154", "display_name": "Shizuka Kaneko" }, { "id": "https://openalex.org/A5101682541", "display_name": "Hiroki Ikeda" }, { "id": "https://openalex.org/A5102947863", "display_name": "Yasuharu Ohta" }, { "id": "https://openalex.org/A5111797507", "display_name": "Akitaka Hisatomi" }, { "id": "https://openalex.org/A5050744890", "display_name": "Takafumi Senokuchi" }, { "id": "https://openalex.org/A5103007377", "display_name": "Hideaki Jinnouchi" }, { "id": "https://openalex.org/A5060156624", "display_name": "Shuji Nakamura" }, { "id": "https://openalex.org/A5035038428", "display_name": "Jos\u00e9 Roberto Lazcano Soto" }, { "id": "https://openalex.org/A5106668490", "display_name": "Ignacio Rodr\u00edguez Briones" }, { "id": "https://openalex.org/A5074308535", "display_name": "Pawe\u0142 Bogda\u0144ski" }, { "id": "https://openalex.org/A5069528386", "display_name": "Ewa Szyprowska" }, { "id": "https://openalex.org/A5040536329", "display_name": "Anna Modzelewska" }, { "id": "https://openalex.org/A5087478382", "display_name": "Iwona Wozniak" }, { "id": "https://openalex.org/A5049708484", "display_name": "S. T. Zyangirova" }, { "id": "https://openalex.org/A5110936699", "display_name": "M. Sergeeva-Kondrachenko" }, { "id": "https://openalex.org/A5110385838", "display_name": "Thomas R. A. Davis" }, { "id": "https://openalex.org/A5019240653", "display_name": "Stephen P. Thomson" }, { "id": "https://openalex.org/A5086072427", "display_name": "Juan P. Fr\u00edas" }, { "id": "https://openalex.org/A5085073829", "display_name": "Winston Gandy" }, { "id": "https://openalex.org/A5001655356", "display_name": "Ildiko Lingvay" }, { "id": "https://openalex.org/A5041023480", "display_name": "Kevin Pounds" }, { "id": "https://openalex.org/A5017587063", "display_name": "Cynthia Bowman-Stroud" }, { "id": "https://openalex.org/A5082192327", "display_name": "Michael Dempsey" }, { "id": "https://openalex.org/A5018206939", "display_name": "David Huffman" }, { "id": "https://openalex.org/A5011258913", "display_name": "Azazuddin Ahmed" }, { "id": "https://openalex.org/A5109031653", "display_name": "Neil Fraser" }, { "id": "https://openalex.org/A5098306980", "display_name": "Ramon Ortiz-Carrasquillo" }, { "id": "https://openalex.org/A5081820361", "display_name": "D. Eric Bolster" }, { "id": "https://openalex.org/A5056338234", "display_name": "Michael Adams" }, { "id": "https://openalex.org/A5110775156", "display_name": "Matthew A. Hummel" }, { "id": "https://openalex.org/A5065636691", "display_name": "Almena Free" }, { "id": "https://openalex.org/A5072732477", "display_name": "Patricia Houser" }, { "id": "https://openalex.org/A5012858028", "display_name": "Gerald Shockey" }, { "id": "https://openalex.org/A5054042884", "display_name": "Otis Barnum" }, { "id": "https://openalex.org/A5023114248", "display_name": "Kala R. Bhasker" }, { "id": "https://openalex.org/A5064634271", "display_name": "George Mitchell Cornett" }, { "id": "https://openalex.org/A5108598798", "display_name": "Dan Streja" }, { "id": "https://openalex.org/A5076538487", "display_name": "William Kirby" }, { "id": "https://openalex.org/A5098182282", "display_name": "Sean Lynd" }, { "id": "https://openalex.org/A5016666630", "display_name": "Steven Folkerth" }, { "id": "https://openalex.org/A5004966069", "display_name": "Samer Nakhle" }, { "id": "https://openalex.org/A5019150153", "display_name": "Paul Norwood" }, { "id": "https://openalex.org/A5091912961", "display_name": "Rodolfo P\u00e9rez" }, { "id": "https://openalex.org/A5033229659", "display_name": "Brian D. Snyder" }, { "id": "https://openalex.org/A5058938529", "display_name": "Neil Farris" }, { "id": "https://openalex.org/A5109436369", "display_name": "Willian Litchfield" }, { "id": "https://openalex.org/A5087246793", "display_name": "Osama Hamdy" }, { "id": "https://openalex.org/A5037529101", "display_name": "Jean Park" }, { "id": "https://openalex.org/A5005405894", "display_name": "Vanita R. Aroda" } ] }, { "id": "https://openalex.org/W2009288620", "doi": "https://doi.org/10.1111/j.1463-1326.2012.01561.x", "title": "Clinical relevance of anti\u2010exenatide antibodies: safety, efficacy and cross\u2010reactivity with long\u2010term treatment", "abstract": { "Aims:": [ 0 ], "Antibody": [ 1, 101 ], "formation": [ 2 ], "to": [ 3, 43, 104, 128 ], "therapeutic": [ 4 ], "peptides": [ 5 ], "is": [ 6 ], "common.": [ 7 ], "This": [ 8 ], "analysis": [ 9 ], "characterizes": [ 10 ], "the": [ 11, 210, 241, 313 ], "time\u2010course": [ 12 ], "and": [ 13, 18, 23, 36, 50, 77, 95, 163, 174, 181, 187, 197, 232, 283 ], "cross\u2010reactivity": [ 14 ], "of": [ 15, 84, 114, 143, 213, 243, 315 ], "anti\u2010exenatide": [ 16, 138, 251, 308 ], "antibodies": [ 17, 139, 252, 273, 309 ], "potential": [ 19 ], "effects": [ 20 ], "on": [ 21, 270 ], "efficacy": [ 22, 296 ], "safety.": [ 24 ], "Methods:": [ 25 ], "Data": [ 26 ], "from": [ 27, 140 ], "intent\u2010to\u2010treat": [ 28 ], "patients": [ 29, 87, 117, 144, 165, 176, 214, 244 ], "in": [ 30, 161, 171, 195, 209, 240 ], "12": [ 31 ], "controlled": [ 32, 52 ], "(n": [ 33, 39, 53, 65 ], "=": [ 34, 40, 54, 66 ], "2225,12\u201352weeks)": [ 35 ], "5": [ 37 ], "uncontrolled": [ 38, 63 ], "1538,": [ 41 ], "up": [ 42 ], "3": [ 44, 110 ], "years)": [ 45 ], "exenatide": [ 46, 56, 85, 115, 184, 189, 202, 225, 256, 259, 262, 278, 281, 302 ], "twice\u2010daily": [ 47 ], "(BID)": [ 48 ], "trials": [ 49, 60 ], "4": [ 51 ], "653,24\u201330weeks)": [ 55 ], "once": [ 57 ], "weekly": [ 58 ], "(QW)": [ 59 ], "with": [ 61, 149, 216, 227, 246, 255, 293 ], "1": [ 62 ], "period": [ 64 ], "128,52weeks)": [ 67 ], "were": [ 68, 88, 118, 166, 207, 253, 274 ], "analysed.": [ 69 ], "Results:": [ 70 ], "Mean": [ 71 ], "titres": [ 72, 93, 99 ], "peaked": [ 73 ], "early": [ 74 ], "(6\u201322": [ 75 ], "weeks)": [ 76 ], "subsequently": [ 78 ], "declined.": [ 79 ], "At": [ 80 ], "30": [ 81 ], "weeks,": [ 82, 126 ], "36.7%": [ 83 ], "BID": [ 86 ], "antibody\u2010positive;": [ 89 ], "31.7%": [ 90 ], "exhibited": [ 91 ], "low": [ 92 ], "(\u2264125)": [ 94 ], "5.0%": [ 96 ], "had": [ 97, 266 ], "higher": [ 98, 107, 122, 132, 217, 247 ], "(\u2265625).": [ 100 ], "incidence": [ 102 ], "declined": [ 103 ], "16.9%": [ 105 ], "(1.4%": [ 106 ], "titre)": [ 108, 123, 133 ], "at": [ 109, 124, 134 ], "years.": [ 111 ], "Similarly,": [ 112 ], "56.8%": [ 113 ], "QW": [ 116, 226, 263 ], "antibody\u2010positive": [ 119, 162, 175 ], "(45.0%": [ 120 ], "low/11.8%": [ 121 ], "24\u201330": [ 125 ], "declining": [ 127 ], "45.4%": [ 129 ], "positive": [ 130 ], "(9.2%": [ 131 ], "52": [ 135 ], "weeks.": [ 136 ], "Treatment\u2010emergent": [ 137 ], "a": [ 141 ], "subset": [ 142, 212, 242 ], "tested": [ 145 ], "did": [ 146, 310 ], "not": [ 147, 311 ], "cross\u2010react": [ 148 ], "human": [ 150 ], "GLP\u20101": [ 151 ], "or": [ 152 ], "glucagon.": [ 153 ], "Other": [ 154, 304 ], "than": [ 155, 305 ], "injection\u2010site": [ 156, 306 ], "reactions,": [ 157, 307 ], "adverse": [ 158 ], "event": [ 159 ], "rates": [ 160 ], "antibody\u2010negative": [ 164, 173, 231 ], "similar.": [ 167 ], "Efficacy": [ 168 ], "was": [ 169, 199, 222, 291, 298 ], "robust": [ 170 ], "both": [ 172 ], "(mean": [ 177 ], "HbA1c": [ 178, 196 ], "change:": [ 179 ], "\u22121.0": [ 180 ], "\u22120.9%,": [ 182 ], "respectively,": [ 183 ], "BID;": [ 185 ], "\u22121.6%": [ 186 ], "\u22121.3%": [ 188 ], "QW).": [ 190 ], "No": [ 191 ], "correlation": [ 192, 221 ], "between": [ 193, 230 ], "change": [ 194 ], "titre": [ 198, 286, 290 ], "observed": [ 200, 223 ], "for": [ 201, 224, 301 ], "BID,": [ 203, 260, 279 ], "although": [ 204 ], "mean": [ 205, 238 ], "reductions": [ 206 ], "attenuated": [ 208, 237 ], "small": [ 211 ], "(5%)": [ 215 ], "titres.": [ 218, 248 ], "A": [ 219 ], "significant": [ 220, 300 ], "no": [ 228, 267 ], "difference": [ 229 ], "low\u2010titre": [ 233 ], "patients,": [ 234 ], "but": [ 235, 265 ], "an": [ 236 ], "reduction": [ 239 ], "(12%)": [ 245 ], "Conclusions:": [ 249 ], "Low\u2010titre": [ 250 ], "common": [ 254, 276 ], "treatment": [ 257 ], "(32%": [ 258 ], "45%": [ 261 ], "patients),": [ 264 ], "apparent": [ 268 ], "effect": [ 269 ], "efficacy.": [ 271 ], "Higher\u2010titre": [ 272 ], "less": [ 275 ], "(5%": [ 277 ], "12%": [ 280 ], "QW)": [ 282 ], "within": [ 284 ], "that": [ 285, 297 ], "group,": [ 287 ], "increasing": [ 288 ], "antibody": [ 289 ], "associated": [ 292 ], "reduced": [ 294 ], "average": [ 295 ], "statistically": [ 299 ], "QW.": [ 303 ], "impact": [ 312 ], "safety": [ 314 ], "exenatide.": [ 316 ] }, "publication_date": "2012-01-11", "publication_year": 2012, "type": "article", "cited_by_count": 145, "authors": [ { "id": "https://openalex.org/A5083503351", "display_name": "Mark Fineman" }, { "id": "https://openalex.org/A5058443646", "display_name": "Kenneth Mace" }, { "id": "https://openalex.org/A5109591880", "display_name": "M. Diamant" }, { "id": "https://openalex.org/A5069521580", "display_name": "Tamara Darsow" }, { "id": "https://openalex.org/A5043407893", "display_name": "Brenda Cirincione" }, { "id": "https://openalex.org/A5112009440", "display_name": "T. K. Booker Porter" }, { "id": "https://openalex.org/A5083620836", "display_name": "L. A. Kinninger" }, { "id": "https://openalex.org/A5062021087", "display_name": "Michael Trautmann" } ] }, { "id": "https://openalex.org/W4403972995", "doi": "https://doi.org/10.1016/j.intimp.2024.113537", "title": "Neuroprotective effects of GLP-1 receptor agonists in neurodegenerative Disorders: A Large-Scale Propensity-Matched cohort study", "abstract": null, "publication_date": "2024-11-01", "publication_year": 2024, "type": "article", "cited_by_count": 35, "authors": [ { "id": "https://openalex.org/A5072889856", "display_name": "Nabeela Siddeeque" }, { "id": "https://openalex.org/A5081532312", "display_name": "Mohammad H. Hussein" }, { "id": "https://openalex.org/A5002233490", "display_name": "Ahmed Abdelmaksoud" }, { "id": "https://openalex.org/A5090210646", "display_name": "Julia Newton\u2010Bishop" }, { "id": "https://openalex.org/A5009868097", "display_name": "Abdallah S. Attia" }, { "id": "https://openalex.org/A5057888609", "display_name": "Rami M. Elshazli" }, { "id": "https://openalex.org/A5048465962", "display_name": "Manal S. Fawzy" }, { "id": "https://openalex.org/A5061780884", "display_name": "Eman A. Toraih" } ] }, { "id": "https://openalex.org/W1975612744", "doi": "https://doi.org/10.1517/13543780902766802", "title": "Exenatide once weekly for the treatment of type 2 diabetes", "abstract": { "Exenatide": [ 0, 19 ], "is": [ 1, 62, 79, 152 ], "the": [ 2, 11, 82, 88, 94, 141, 158 ], "first": [ 3 ], "glucagon-like": [ 4 ], "peptide-1": [ 5 ], "(GLP-1)": [ 6 ], "receptor": [ 7 ], "agonist": [ 8 ], "approved": [ 9 ], "for": [ 10, 66, 93, 157 ], "treatment": [ 12, 95, 159 ], "of": [ 13, 28, 33, 38, 43, 49, 60, 76, 90, 96, 145, 160 ], "type": [ 14 ], "2": [ 15 ], "diabetes": [ 16, 146 ], "mellitus": [ 17 ], "(T2DM).": [ 18 ], "lowers": [ 20 ], "blood": [ 21 ], "glucose": [ 22 ], "through": [ 23 ], "multiple": [ 24 ], "mechanisms,": [ 25 ], "including": [ 26 ], "enhancement": [ 27 ], "glucose-dependent": [ 29 ], "insulin": [ 30 ], "secretion,": [ 31, 36 ], "suppression": [ 32 ], "excess": [ 34 ], "glucagon": [ 35 ], "reduction": [ 37 ], "food": [ 39 ], "intake": [ 40 ], "and": [ 41, 56, 112, 133, 147 ], "slowing": [ 42 ], "gastric": [ 44 ], "emptying.": [ 45 ], "The": [ 46, 74 ], "current": [ 47, 84 ], "formulation": [ 48, 59 ], "exenatide": [ 50, 61, 91, 101, 125, 138, 150 ], "requires": [ 51 ], "twice-daily": [ 52 ], "dosing": [ 53 ], "(exenatide": [ 54, 72 ], "BID),": [ 55 ], "an": [ 57 ], "extended-release": [ 58 ], "now": [ 63 ], "in": [ 64, 108, 116, 130 ], "development": [ 65, 89, 155 ], "use": [ 67 ], "as": [ 68 ], "a": [ 69, 121, 153 ], "once-weekly": [ 70 ], "injection": [ 71 ], "QW).": [ 73 ], "purpose": [ 75 ], "this": [ 77 ], "report": [ 78 ], "to": [ 80 ], "review": [ 81 ], "most": [ 83 ], "clinical": [ 85, 99, 123 ], "data": [ 86 ], "on": [ 87 ], "QW": [ 92, 102, 126, 151 ], "T2DM.": [ 97, 119, 161 ], "In": [ 98, 120 ], "trials,": [ 100 ], "significantly": [ 103 ], "improved": [ 104 ], "glycemic": [ 105, 131 ], "control,": [ 106 ], "resulted": [ 107 ], "patient": [ 109 ], "weight": [ 110 ], "loss,": [ 111 ], "was": [ 113, 134 ], "well": [ 114 ], "tolerated": [ 115, 136 ], "patients": [ 117 ], "with": [ 118 ], "head-to-head": [ 122 ], "trial,": [ 124 ], "caused": [ 127 ], "greater": [ 128 ], "improvements": [ 129 ], "control": [ 132 ], "better": [ 135 ], "than": [ 137 ], "BID.": [ 139 ], "Given": [ 140 ], "rapidly": [ 142 ], "increasing": [ 143 ], "prevalence": [ 144 ], "obesity": [ 148 ], "worldwide,": [ 149 ], "promising": [ 154 ], "candidate": [ 156 ] }, "publication_date": "2009-02-26", "publication_year": 2009, "type": "review", "cited_by_count": 50, "authors": [ { "id": "https://openalex.org/A5112515114", "display_name": "James Malone" }, { "id": "https://openalex.org/A5062021087", "display_name": "Michael Trautmann" }, { "id": "https://openalex.org/A5112080455", "display_name": "Ken Wilhelm" }, { "id": "https://openalex.org/A5110734241", "display_name": "Kristin Taylor" }, { "id": "https://openalex.org/A5013350892", "display_name": "David M. Kendall" } ] }, { "id": "https://openalex.org/W2948519518", "doi": "https://doi.org/10.1016/s0140-6736(19)31150-x", "title": "Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial", "abstract": null, "publication_date": "2019-06-09", "publication_year": 2019, "type": "article", "cited_by_count": 586, "authors": [ { "id": "https://openalex.org/A5024577116", "display_name": "Hertzel C. Gerstein" }, { "id": "https://openalex.org/A5005414020", "display_name": "Helen M. Colhoun" }, { "id": "https://openalex.org/A5102952426", "display_name": "Gilles R. Dagenais" }, { "id": "https://openalex.org/A5013408607", "display_name": "Rafael D\u00edaz" }, { "id": "https://openalex.org/A5055443598", "display_name": "Mark Lakshmanan" }, { "id": "https://openalex.org/A5082084514", "display_name": "Prem Pais" }, { "id": "https://openalex.org/A5080292021", "display_name": "Jeffrey L. Probstfield" }, { "id": "https://openalex.org/A5051731762", "display_name": "Fady T. Botros" }, { "id": "https://openalex.org/A5087844534", "display_name": "Matthew C. Riddle" }, { "id": "https://openalex.org/A5082101100", "display_name": "Lars Ryd\u00e9n" }, { "id": "https://openalex.org/A5057705555", "display_name": "Denis Xavier" }, { "id": "https://openalex.org/A5057242778", "display_name": "Charles Atisso" }, { "id": "https://openalex.org/A5072590707", "display_name": "Leanne Dyal" }, { "id": "https://openalex.org/A5052672899", "display_name": "Stephanie Hall" }, { "id": "https://openalex.org/A5045898172", "display_name": "Rao Ps" }, { "id": "https://openalex.org/A5102309441", "display_name": "G.C. Wong" }, { "id": "https://openalex.org/A5078888395", "display_name": "\u00c1lvaro Avezum" }, { "id": "https://openalex.org/A5056252103", "display_name": "Jan Basile" }, { "id": "https://openalex.org/A5103570650", "display_name": "Namsik Chung" }, { "id": "https://openalex.org/A5084120269", "display_name": "Ignacio Conget" }, { "id": "https://openalex.org/A5006628692", "display_name": "William C. Cushman" }, { "id": "https://openalex.org/A5030909625", "display_name": "Edward Franek" }, { "id": "https://openalex.org/A5078130962", "display_name": "Nicolae H\u00e2ncu" }, { "id": "https://openalex.org/A5052329017", "display_name": "M Hanefeld" }, { "id": "https://openalex.org/A5103401989", "display_name": "Shaun Holt" }, { "id": "https://openalex.org/A5107857922", "display_name": "Petr Jansk\u00fd" }, { "id": "https://openalex.org/A5041291525", "display_name": "M\u00e1ty\u00e1s Keltai" }, { "id": "https://openalex.org/A5005906845", "display_name": "Fernando La\u0146as" }, { "id": "https://openalex.org/A5080414941", "display_name": "Lawrence A. Leiter" }, { "id": "https://openalex.org/A5026568725", "display_name": "Patricio L\u00f3pez\u2010Jaramillo" }, { "id": "https://openalex.org/A5000849073", "display_name": "Ernesto Mu\u00f1oz" }, { "id": "https://openalex.org/A5082643599", "display_name": "Valdis P\u012br\u0101gs" }, { "id": "https://openalex.org/A5042971997", "display_name": "Nana Pogosova" }, { "id": "https://openalex.org/A5038086852", "display_name": "Peter Raubenheimer" }, { "id": "https://openalex.org/A5024475260", "display_name": "Jonathan E. Shaw" }, { "id": "https://openalex.org/A5031812511", "display_name": "Wayne Huey\u2010Herng Sheu" }, { "id": "https://openalex.org/A5043108571", "display_name": "Theodora Temelkova\u2010Kurktschiev" }, { "id": "https://openalex.org/A5113870455", "display_name": "Mercedes Abella" }, { "id": "https://openalex.org/A5097469081", "display_name": "Andrea Alebuena" }, { "id": "https://openalex.org/A5112441120", "display_name": "Sandra Almagro" }, { "id": "https://openalex.org/A5108683294", "display_name": "Eduardo Amoroso" }, { "id": "https://openalex.org/A5097469083", "display_name": "Paula Anadon" }, { "id": "https://openalex.org/A5110617217", "display_name": "Elizabeth Andreu" }, { "id": "https://openalex.org/A5112440989", "display_name": "Guillermo Aristimu\u00f1o" }, { "id": "https://openalex.org/A5097469086", "display_name": "Maria Arzadun" }, { "id": "https://openalex.org/A5065249383", "display_name": "Mar\u00eda Antonietta Barbieri" }, { "id": "https://openalex.org/A5065622117", "display_name": "Ra\u00fal Barcudi" }, { "id": "https://openalex.org/A5061109527", "display_name": "Ines Bartolacci" }, { "id": "https://openalex.org/A5097469087", "display_name": "Gabriel Bolobanich" }, { "id": "https://openalex.org/A5048608077", "display_name": "Anselmo P. Bordonava" }, { "id": "https://openalex.org/A5112441128", "display_name": "Miguel Bustamante Labarta" }, { "id": "https://openalex.org/A5109425628", "display_name": "B. Bustos" }, { "id": "https://openalex.org/A5073504040", "display_name": "Alberto Caccavo" }, { "id": "https://openalex.org/A5000839611", "display_name": "Alejandra Camino" }, { "id": "https://openalex.org/A5049277864", "display_name": "Mar\u00eda del Roc\u00edo Cantero" }, { "id": "https://openalex.org/A5107561439", "display_name": "Maria Carignano" }, { "id": "https://openalex.org/A5112579844", "display_name": "Luis R Cartasegna" }, { "id": "https://openalex.org/A5008435640", "display_name": "Marcela Cipullo" }, { "id": "https://openalex.org/A5037145579", "display_name": "V\u00edctor Commendatore" }, { "id": "https://openalex.org/A5097520881", "display_name": "Victoria Conosciuto" }, { "id": "https://openalex.org/A5088329952", "display_name": "Osvaldo Costamagna" }, { "id": "https://openalex.org/A5048300573", "display_name": "Claudia A. Crespo" }, { "id": "https://openalex.org/A5013896156", "display_name": "Jos\u00e9 Cuello-Navarro" }, { "id": "https://openalex.org/A5110475263", "display_name": "Carlos Alberto Cuneo" }, { "id": "https://openalex.org/A5095860955", "display_name": "Sandra Cusimano" }, { "id": "https://openalex.org/A5006392094", "display_name": "Sofia Dean" }, { "id": "https://openalex.org/A5051257159", "display_name": "Claudio Fabi\u00e1n Dituro" }, { "id": "https://openalex.org/A5072197792", "display_name": "Andrea Dom\u00ednguez" }, { "id": "https://openalex.org/A5103852092", "display_name": "Miguel Farah" }, { "id": "https://openalex.org/A5074810713", "display_name": "Alberto Oca\u00f1a" }, { "id": "https://openalex.org/A5082929744", "display_name": "Florencia Fernandez" }, { "id": "https://openalex.org/A5082727500", "display_name": "Adriana Cristina Ferrari" }, { "id": "https://openalex.org/A5097495183", "display_name": "Patricia Flammia" }, { "id": "https://openalex.org/A5024597866", "display_name": "Jos\u00e9 Antonio Fuentealba" }, { "id": "https://openalex.org/A5029907585", "display_name": "Karina Beatriz Gallardo" }, { "id": "https://openalex.org/A5103737215", "display_name": "C. Perez Garcia" }, { "id": "https://openalex.org/A5109606492", "display_name": "Ruben Garcia Duran" }, { "id": "https://openalex.org/A5061291087", "display_name": "Marcelo Garrido" }, { "id": "https://openalex.org/A5038082296", "display_name": "Rodolfo Gav\u00edcola" }, { "id": "https://openalex.org/A5097625543", "display_name": "Claudio Gerbaudo" }, { "id": "https://openalex.org/A5110617115", "display_name": "Graciela Gilli" }, { "id": "https://openalex.org/A5071213182", "display_name": "Ana Paula Giotto" }, { "id": "https://openalex.org/A5040928846", "display_name": "Pedro Godoy Bolz\u00e1n" }, { "id": "https://openalex.org/A5022884921", "display_name": "Oscar G\u00f3mez Vilamaj\u00f3" }, { "id": "https://openalex.org/A5001262620", "display_name": "Fernando Guerlloy" }, { "id": "https://openalex.org/A5009907112", "display_name": "Cristian Guridi" }, { "id": "https://openalex.org/A5112441136", "display_name": "Narcisa Gutierrez Garrido" }, { "id": "https://openalex.org/A5109046786", "display_name": "Eduardo Hasbani" }, { "id": "https://openalex.org/A5048243688", "display_name": "Sonia Hermida" }, { "id": "https://openalex.org/A5026717712", "display_name": "Miguel Hominal" }, { "id": "https://openalex.org/A5113970781", "display_name": "Adrian D. Hrabar" }, { "id": "https://openalex.org/A5034761943", "display_name": "Adri\u00e1n Ingaramo" }, { "id": "https://openalex.org/A5097469157", "display_name": "Alejandra Izzicupo" }, { "id": "https://openalex.org/A5110617223", "display_name": "Mario Krynski" }, { "id": "https://openalex.org/A5081483031", "display_name": "Mariana Lagrutta" }, { "id": "https://openalex.org/A5076352092", "display_name": "Paulina Virginia Lanchiotti" }, { "id": "https://openalex.org/A5097495196", "display_name": "Maria Langhe" }, { "id": "https://openalex.org/A5110617120", "display_name": "Veronica Leonard" }, { "id": "https://openalex.org/A5016775080", "display_name": "Javier Llanos" }, { "id": "https://openalex.org/A5073184612", "display_name": "Ricardo L\u00f3pez Santi" } ] }, { "id": "https://openalex.org/W2008026539", "doi": "https://doi.org/10.1371/journal.pone.0097554", "title": "Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Inhibits Endothelial Cell Inflammation through a Calcium and AMPK Dependent Mechanism", "abstract": { "Liraglutide": [ 0, 120 ], "is": [ 1, 73, 93, 235 ], "a": [ 2, 80, 184, 224 ], "glucagon-like": [ 3 ], "peptide-1": [ 4 ], "(GLP-1)": [ 5 ], "mimetic": [ 6 ], "used": [ 7 ], "for": [ 8, 62 ], "the": [ 9, 17, 24, 51, 91, 98, 107, 122, 138, 180, 189, 195, 213 ], "treatment": [ 10, 44 ], "of": [ 11, 19, 27, 53, 90, 100, 109, 137, 179, 191, 197, 207, 216 ], "Type": [ 12 ], "2": [ 13 ], "diabetes.": [ 14 ], "Similar": [ 15 ], "to": [ 16, 67, 125, 151, 161, 237, 240 ], "actions": [ 18, 167 ], "endogenous": [ 20 ], "GLP-1,": [ 21 ], "liraglutide": [ 22, 110, 222 ], "potentiates": [ 23 ], "post-prandial": [ 25 ], "release": [ 26, 31 ], "insulin,": [ 28 ], "inhibits": [ 29 ], "glucagon": [ 30 ], "and": [ 32, 38, 127, 142, 144, 157, 176, 194, 199, 244 ], "increases": [ 33 ], "satiety.": [ 34 ], "Recent": [ 35 ], "epidemiological": [ 36 ], "studies": [ 37 ], "clinical": [ 39 ], "trials": [ 40 ], "have": [ 41 ], "suggested": [ 42 ], "that": [ 43, 74, 221, 233 ], "with": [ 45, 163, 182 ], "GLP-1": [ 46 ], "mimetics": [ 47 ], "may": [ 48 ], "also": [ 49, 231 ], "diminish": [ 50 ], "risk": [ 52 ], "cardiovascular": [ 54, 102 ], "disease": [ 55, 103 ], "in": [ 56, 97, 113, 168, 248 ], "diabetic": [ 57 ], "patients.": [ 58 ], "The": [ 59, 218 ], "mechanism": [ 60 ], "responsible": [ 61 ], "this": [ 63, 234 ], "effect": [ 64, 82, 227 ], "has": [ 65 ], "yet": [ 66 ], "be": [ 68 ], "determined;": [ 69 ], "however,": [ 70 ], "one": [ 71 ], "possibility": [ 72 ], "they": [ 75 ], "might": [ 76 ], "do": [ 77 ], "so": [ 78 ], "by": [ 79, 132, 203 ], "direct": [ 81 ], "on": [ 83, 111, 228 ], "vascular": [ 84 ], "endothelium.": [ 85 ], "Since": [ 86 ], "low": [ 87 ], "grade": [ 88 ], "inflammation": [ 89, 112 ], "endothelium": [ 92 ], "an": [ 94, 208 ], "early": [ 95 ], "event": [ 96 ], "pathogenesis": [ 99 ], "atherosclerotic": [ 101 ], "(ASCVD),": [ 104 ], "we": [ 105 ], "determined": [ 106 ], "effects": [ 108, 215 ], "cultured": [ 114 ], "human": [ 115 ], "aortic": [ 116 ], "endothelial": [ 117, 169 ], "cells": [ 118, 181 ], "(HAECs).": [ 119 ], "reduced": [ 121, 134 ], "inflammatory": [ 123, 166 ], "responses": [ 124 ], "TNF\u03b1": [ 126, 198 ], "LPS": [ 128 ], "stimulation,": [ 129 ], "as": [ 130 ], "evidenced": [ 131 ], "both": [ 133, 188 ], "protein": [ 135 ], "expression": [ 136, 206 ], "adhesion": [ 139, 202 ], "molecules": [ 140, 159 ], "VCAM-1": [ 141 ], "E-Selectin,": [ 143 ], "THP-1": [ 145 ], "monocyte": [ 146, 201 ], "adhesion.": [ 147 ], "This": [ 148 ], "was": [ 149 ], "found": [ 150 ], "result": [ 152 ], "from": [ 153 ], "increased": [ 154 ], "cell": [ 155 ], "Ca2+": [ 156, 162, 243 ], "several": [ 158 ], "sensitive": [ 160 ], "known": [ 164 ], "anti": [ 165 ], "cells,": [ 170 ], "including": [ 171 ], "CaMKK\u03b2,": [ 172 ], "CaMKI,": [ 173 ], "AMPK,": [ 174, 192 ], "eNOS": [ 175 ], "CREB.": [ 177 ], "Treatment": [ 178 ], "STO-609,": [ 183 ], "CaMKK": [ 185 ], "inhibitor,": [ 186 ], "diminished": [ 187 ], "activation": [ 190 ], "CaMKI": [ 193 ], "inhibition": [ 196 ], "LPS-induced": [ 200 ], "liraglutide.": [ 204, 217 ], "Likewise,": [ 205 ], "shRNA": [ 209 ], "against": [ 210 ], "AMPK": [ 211 ], "nullified": [ 212 ], "anti-inflammatory": [ 214, 226 ], "results": [ 219 ], "indicate": [ 220 ], "exerts": [ 223 ], "strong": [ 225 ], "HAECs.": [ 229 ], "They": [ 230 ], "demonstrate": [ 232 ], "due": [ 236 ], "its": [ 238 ], "ability": [ 239 ], "increase": [ 241 ], "intracellular": [ 242 ], "activate": [ 245 ], "CAMKK\u03b2,": [ 246 ], "which": [ 247 ], "turn": [ 249 ], "activates": [ 250 ], "AMPK.": [ 251 ] }, "publication_date": "2014-05-16", "publication_year": 2014, "type": "article", "cited_by_count": 170, "authors": [ { "id": "https://openalex.org/A5040085704", "display_name": "N. Krasner" }, { "id": "https://openalex.org/A5035237276", "display_name": "Yasuo Ido" }, { "id": "https://openalex.org/A5055882378", "display_name": "Neil B. Ruderman" }, { "id": "https://openalex.org/A5089198169", "display_name": "Jos\u00e9 M. Cacicedo" } ] }, { "id": "https://openalex.org/W2617135545", "doi": "https://doi.org/10.1186/s13098-017-0242-0", "title": "The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0\u00a0mg", "abstract": null, "publication_date": "2017-05-31", "publication_year": 2017, "type": "review", "cited_by_count": 52, "authors": [ { "id": "https://openalex.org/A5045341413", "display_name": "M\u00e1rcio C. Mancini" }, { "id": "https://openalex.org/A5065856271", "display_name": "Maria Edna de Melo" } ] }, { "id": "https://openalex.org/W2008132861", "doi": "https://doi.org/10.2165/11585880-000000000-00000", "title": "Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing", "abstract": null, "publication_date": "2010-12-02", "publication_year": 2010, "type": "article", "cited_by_count": 133, "authors": [ { "id": "https://openalex.org/A5083503351", "display_name": "Mark Fineman" }, { "id": "https://openalex.org/A5103063696", "display_name": "Shawn Flanagan" }, { "id": "https://openalex.org/A5110734241", "display_name": "Kristin Taylor" }, { "id": "https://openalex.org/A5051160249", "display_name": "Maria Aisporna" }, { "id": "https://openalex.org/A5113725447", "display_name": "Larry Z. Shen" }, { "id": "https://openalex.org/A5058443646", "display_name": "Kenneth Mace" }, { "id": "https://openalex.org/A5102775095", "display_name": "Brandon Walsh" }, { "id": "https://openalex.org/A5109335776", "display_name": "Micha\u00ebla Diamant" }, { "id": "https://openalex.org/A5043407893", "display_name": "Brenda Cirincione" }, { "id": "https://openalex.org/A5079794570", "display_name": "Prajakti A. Kothare" }, { "id": "https://openalex.org/A5070023750", "display_name": "Wen-I Li" }, { "id": "https://openalex.org/A5018272606", "display_name": "Leigh MacConell" } ] }, { "id": "https://openalex.org/W4250485558", "doi": "https://doi.org/10.1517/14656566.8.15.2593", "title": "Exenatide", "abstract": { "Exenatide": [ 0, 99, 180, 231 ], "is": [ 1, 181, 186, 204 ], "the": [ 2, 15, 25, 88, 138, 163, 187, 247 ], "first": [ 3 ], "in": [ 4, 104, 115, 165, 177, 206, 216 ], "a": [ 5, 33, 85, 174, 199 ], "new": [ 6 ], "class": [ 7 ], "of": [ 8, 24, 27, 35, 41, 45, 49, 87, 95, 128, 140, 202, 219, 224, 249 ], "compounds,": [ 9 ], "which": [ 10, 37 ], "possess": [ 11 ], "similar": [ 12 ], "activity": [ 13 ], "to": [ 14, 80, 113, 136, 239 ], "naturally-occurring": [ 16 ], "hormone": [ 17 ], "glucagon-like": [ 18 ], "peptide-1": [ 19 ], "(GLP-1).": [ 20 ], "It": [ 21 ], "mirrors": [ 22 ], "many": [ 23 ], "effects": [ 26 ], "GLP-1,": [ 28 ], "improving": [ 29 ], "glycaemic": [ 30, 166, 241 ], "control": [ 31, 127, 167, 242 ], "through": [ 32 ], "combination": [ 34, 86, 105 ], "mechanisms,": [ 36 ], "include": [ 38 ], "glucose-dependent": [ 39 ], "stimulation": [ 40 ], "insulin": [ 42, 114 ], "secretion,": [ 43, 47 ], "suppression": [ 44 ], "glucagon": [ 46 ], "slowing": [ 48 ], "gastric": [ 50 ], "emptying": [ 51 ], "and": [ 52, 69, 71, 82, 108, 131, 172, 243, 251 ], "reduced": [ 53, 66, 197 ], "appetite.": [ 54 ], "Phase": [ 55 ], "III": [ 56 ], "clinical": [ 57, 217 ], "trials": [ 58, 149, 218 ], "showed": [ 59 ], "exenatide": [ 60, 155, 203 ], "therapy": [ 61, 225 ], "for": [ 62, 156 ], "30": [ 63, 170 ], "weeks": [ 64, 171 ], "significantly": [ 65, 196 ], "glycated": [ 67 ], "haemoglobin,": [ 68 ], "fasting": [ 70 ], "postprandial": [ 72 ], "plasma": [ 73 ], "glucose": [ 74 ], "compared": [ 75 ], "with": [ 76, 90, 106, 122, 154, 208, 226, 229, 235 ], "baseline": [ 77 ], "when": [ 78, 198 ], "added": [ 79 ], "metformin": [ 81 ], "sulfonylureas": [ 83, 227 ], "or": [ 84, 158, 245 ], "two,": [ 89 ], "an": [ 91, 111 ], "average": [ 92 ], "weight": [ 93, 133, 252 ], "loss": [ 94 ], "approximately": [ 96 ], "2": [ 97, 125, 237 ], "kg.": [ 98 ], "can": [ 100, 194 ], "also": [ 101 ], "be": [ 102, 110, 195 ], "used": [ 103 ], "thiazolidinediones": [ 107 ], "may": [ 109, 232 ], "alternative": [ 112 ], "patients": [ 116, 121, 152, 207, 234 ], "requiring": [ 117 ], "additional": [ 118 ], "therapy.": [ 119 ], "In": [ 120 ], "established": [ 123 ], "Type": [ 124, 236 ], "diabetes,": [ 126 ], "both": [ 129 ], "glycaemia": [ 130 ], "body": [ 132, 178 ], "are": [ 134 ], "important": [ 135 ], "minimise": [ 137 ], "risk": [ 139, 248 ], "future": [ 141 ], "diabetes": [ 142, 238 ], "complications.": [ 143 ], "Open-label": [ 144 ], "extensions": [ 145 ], "from": [ 146 ], "these": [ 147 ], "pivotal": [ 148 ], "demonstrate": [ 150 ], "that": [ 151 ], "treated": [ 153 ], "<": [ 157 ], "=": [ 159 ], "3": [ 160 ], "years": [ 161 ], "sustained": [ 162 ], "reductions": [ 164 ], "achieved": [ 168, 205 ], "at": [ 169 ], "had": [ 173 ], "progressive": [ 175 ], "reduction": [ 176 ], "weight.": [ 179 ], "generally": [ 182 ], "well": [ 183 ], "tolerated;": [ 184 ], "nausea": [ 185 ], "most": [ 188 ], "commonly": [ 189 ], "reported": [ 190 ], "side": [ 191 ], "effect,": [ 192 ], "but": [ 193 ], "target": [ 200 ], "dose": [ 201, 210 ], "gradual": [ 209 ], "titration.": [ 211 ], "Hypoglycaemia": [ 212 ], "has": [ 213 ], "been": [ 214 ], "encountered": [ 215 ], "exenatide,": [ 220 ], "especially": [ 221 ], "on": [ 222 ], "initiation": [ 223 ], "(not": [ 228 ], "metformin).": [ 230 ], "enable": [ 233 ], "improve": [ 240 ], "reduce": [ 244 ], "eliminate": [ 246 ], "hypoglycaemia": [ 250 ], "gain.": [ 253 ] }, "publication_date": "2007-10-01", "publication_year": 2007, "type": "review", "cited_by_count": 75, "authors": [ { "id": "https://openalex.org/A5023295361", "display_name": "Anthony Barnett" } ] }, { "id": "https://openalex.org/W2064437324", "doi": "https://doi.org/10.1016/j.amjmed.2010.11.002", "title": "Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications", "abstract": null, "publication_date": "2010-12-30", "publication_year": 2010, "type": "review", "cited_by_count": 286, "authors": [ { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" } ] }, { "id": "https://openalex.org/W3084893820", "doi": "https://doi.org/10.1111/jcpt.13230", "title": "A review of GLP\u20101 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once\u2010weekly agents", "abstract": { "From": [ 0 ], "the": [ 1, 7, 11, 15, 31, 74 ], "literature,": [ 2 ], "this": [ 3 ], "appears": [ 4 ], "to": [ 5, 55, 87 ], "be": [ 6 ], "first": [ 8 ], "review": [ 9 ], "of": [ 10, 17, 34 ], "evidence": [ 12 ], "base": [ 13 ], "supporting": [ 14 ], "MoA": [ 16, 81 ], "once-weekly": [ 18, 76 ], "GLP-1": [ 19, 43, 77 ], "RAs": [ 20, 44, 78 ], "in": [ 21, 36, 85 ], "T2D": [ 22 ], "aimed": [ 23 ], "at": [ 24 ], "pharmacists,": [ 25 ], "with": [ 26, 52 ], "a": [ 27, 41 ], "particular": [ 28 ], "emphasis": [ 29 ], "on": [ 30 ], "expanding": [ 32 ], "role": [ 33 ], "pharmacists": [ 35, 70 ], "team-based": [ 37 ], "diabetes": [ 38 ], "management.": [ 39 ], "As": [ 40 ], "class,": [ 42 ], "are": [ 45 ], "an": [ 46 ], "effective": [ 47 ], "treatment": [ 48, 90 ], "option": [ 49 ], "for": [ 50, 91 ], "people": [ 51 ], "T2D,": [ 53 ], "shown": [ 54 ], "achieve": [ 56 ], "multi-factorial": [ 57 ], "clinical": [ 58, 83 ], "benefits.": [ 59 ], "The": [ 60 ], "results": [ 61 ], "suggest": [ 62 ], "that": [ 63 ], "when": [ 64 ], "selecting": [ 65 ], "or": [ 66 ], "advising": [ 67 ], "about": [ 68 ], "treatments,": [ 69 ], "should": [ 71 ], "consider": [ 72 ], "how": [ 73 ], "different": [ 75 ], "and": [ 79 ], "their": [ 80 ], "affect": [ 82 ], "outcomes": [ 84 ], "order": [ 86 ], "ensure": [ 88 ], "optimal": [ 89 ], "individuals.": [ 92 ] }, "publication_date": "2020-09-01", "publication_year": 2020, "type": "review", "cited_by_count": 123, "authors": [ { "id": "https://openalex.org/A5090784160", "display_name": "Susan Cornell" } ] }, { "id": "https://openalex.org/W2432501512", "doi": "https://doi.org/10.1001/jama.2016.7602", "title": "Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events", "abstract": { "Among": [ 0 ], "overweight": [ 1 ], "or": [ 2 ], "obese": [ 3 ], "adults,": [ 4 ], "orlistat,": [ 5 ], "lorcaserin,": [ 6 ], "naltrexone-bupropion,": [ 7 ], "phentermine-topiramate,": [ 8 ], "and": [ 9, 28 ], "liraglutide,": [ 10 ], "compared": [ 11 ], "with": [ 12, 17, 32 ], "placebo,": [ 13 ], "were": [ 14, 30 ], "each": [ 15 ], "associated": [ 16, 31 ], "achieving": [ 18, 37 ], "at": [ 19, 24, 38 ], "least": [ 20, 39 ], "5%": [ 21, 40 ], "weight": [ 22, 41 ], "loss": [ 23 ], "52": [ 25 ], "weeks.": [ 26 ], "Phentermine-topiramate": [ 27 ], "liraglutide": [ 29 ], "the": [ 33 ], "highest": [ 34 ], "odds": [ 35 ], "of": [ 36 ], "loss.": [ 42 ] }, "publication_date": "2016-06-14", "publication_year": 2016, "type": "review", "cited_by_count": 806, "authors": [ { "id": "https://openalex.org/A5017974764", "display_name": "Rohan Khera" }, { "id": "https://openalex.org/A5054802858", "display_name": "M. Hassan Murad" }, { "id": "https://openalex.org/A5054798942", "display_name": "Apoorva K. Chandar" }, { "id": "https://openalex.org/A5025171267", "display_name": "Parambir S. Dulai" }, { "id": "https://openalex.org/A5100422396", "display_name": "Zhen Wang" }, { "id": "https://openalex.org/A5073495332", "display_name": "Larry J. Prokop" }, { "id": "https://openalex.org/A5052059601", "display_name": "Rohit Loomba" }, { "id": "https://openalex.org/A5001729912", "display_name": "Michael Camilleri" }, { "id": "https://openalex.org/A5035847062", "display_name": "Siddharth Singh" } ] }, { "id": "https://openalex.org/W2810075315", "doi": "https://doi.org/10.1016/j.diabres.2018.06.008", "title": "Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists", "abstract": null, "publication_date": "2018-06-23", "publication_year": 2018, "type": "review", "cited_by_count": 58, "authors": [ { "id": "https://openalex.org/A5039563874", "display_name": "Andr\u00e9 Scheen" } ] }, { "id": "https://openalex.org/W3080787886", "doi": "https://doi.org/10.1080/00325481.2020.1798127", "title": "Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy", "abstract": { "Injectable": [ 0 ], "therapies": [ 1 ], "such": [ 2, 224 ], "as": [ 3, 270 ], "glucagon-like": [ 4 ], "peptide-1": [ 5 ], "receptor": [ 6 ], "agonists": [ 7 ], "(GLP-1RAs)": [ 8 ], "and": [ 9, 36, 69, 133, 155, 174, 180, 186, 217, 254, 280 ], "insulin": [ 10, 113, 166, 193 ], "are": [ 11 ], "high-efficacy": [ 12 ], "options": [ 13, 295 ], "for": [ 14, 241, 296 ], "people": [ 15 ], "with": [ 16, 54, 84, 105, 109, 116, 128, 144, 151, 184, 199, 238, 244, 284 ], "type": [ 17 ], "2": [ 18 ], "diabetes": [ 19 ], "(T2D)": [ 20 ], "who": [ 21 ], "require": [ 22 ], "treatment": [ 23, 264, 297 ], "intensification.": [ 24 ], "In": [ 25 ], "addition": [ 26 ], "to": [ 27, 42, 165, 213, 228, 256, 272 ], "high": [ 28 ], "glycemic": [ 29 ], "efficacy,": [ 30 ], "GLP-1RAs": [ 31 ], "offer": [ 32 ], "weight": [ 33, 143, 176, 282 ], "loss": [ 34 ], "benefits,": [ 35 ], "some": [ 37 ], "agents": [ 38 ], "have": [ 39 ], "been": [ 40 ], "shown": [ 41 ], "reduce": [ 43 ], "cardiovascular": [ 44 ], "risk.": [ 45 ], "This": [ 46 ], "article": [ 47 ], "summarizes": [ 48 ], "data": [ 49 ], "from": [ 50 ], "two": [ 51 ], "clinical": [ 52 ], "studies": [ 53 ], "the": [ 55, 221, 291 ], "first": [ 56 ], "oral": [ 57, 59, 80, 97, 103, 117, 145, 159, 214, 234, 267, 274 ], "GLP-1RA,": [ 58, 87 ], "semaglutide,": [ 60 ], "in": [ 61, 74, 93, 107, 122, 141, 168, 171, 190, 300 ], "situations": [ 62 ], "where": [ 63 ], "injectable": [ 64, 86, 242 ], "therapy": [ 65, 268 ], "is": [ 66 ], "often": [ 67 ], "considered,": [ 68 ], "provides": [ 70, 276 ], "guidance": [ 71 ], "on": [ 72, 96, 112 ], "use": [ 73 ], "primary": [ 75, 301 ], "care.": [ 76, 302 ], "PIONEER": [ 77, 100 ], "4": [ 78 ], "compared": [ 79, 102, 127, 150, 183 ], "semaglutide": [ 81, 104, 118, 146, 160, 196, 235, 275 ], "14": [ 82, 163 ], "mg": [ 83, 164 ], "an": [ 85 ], "liraglutide": [ 88, 129, 152 ], "1.8": [ 89 ], "mg,": [ 90 ], "or": [ 91, 162, 206, 269 ], "placebo": [ 92, 106 ], "patients": [ 94, 108, 203, 262 ], "uncontrolled": [ 95 ], "glucose-lowering": [ 98, 215 ], "therapies.": [ 99 ], "8": [ 101 ], "T2D": [ 110, 299 ], "already": [ 111 ], "therapy.": [ 114 ], "Treatment": [ 115 ], "gave": [ 119 ], "similar": [ 120 ], "reductions": [ 121, 136, 170 ], "glycated": [ 123 ], "hemoglobin": [ 124 ], "(HbA1": [ 125 ], "c)": [ 126 ], "at": [ 130, 137, 177 ], "26": [ 131, 154, 179 ], "weeks,": [ 132 ], "significantly": [ 134, 148 ], "greater": [ 135, 149 ], "52": [ 138, 156, 181 ], "weeks.": [ 139, 157 ], "Changes": [ 140 ], "body": [ 142, 175, 281 ], "were": [ 147, 252 ], "after": [ 153, 266 ], "Adding": [ 158 ], "7": [ 161 ], "resulted": [ 167 ], "significant": [ 169 ], "HbA1": [ 172 ], "c": [ 173 ], "both": [ 178 ], "weeks": [ 182 ], "placebo,": [ 185 ], "facilitated": [ 187 ], "a": [ 188 ], "decrease": [ 189 ], "total": [ 191 ], "daily": [ 192 ], "dosage.": [ 194 ], "Oral": [ 195 ], "was": [ 197, 236 ], "associated": [ 198 ], "low": [ 200, 285 ], "proportions": [ 201 ], "of": [ 202, 223, 233, 287, 293, 298 ], "experiencing": [ 204 ], "severe": [ 205 ], "blood": [ 207 ], "glucose-confirmed": [ 208 ], "symptomatic": [ 209 ], "hypoglycemia": [ 210 ], "when": [ 211, 226 ], "added": [ 212, 227 ], "therapies,": [ 216 ], "did": [ 218 ], "not": [ 219 ], "increase": [ 220 ], "incidence": [ 222 ], "events": [ 225 ], "insulin.": [ 229 ], "The": [ 230 ], "tolerability": [ 231 ], "profile": [ 232 ], "consistent": [ 237 ], "that": [ 239 ], "seen": [ 240, 248 ], "GLP-1RAs,": [ 243 ], "gastrointestinal": [ 245 ], "side": [ 246 ], "effects": [ 247 ], "most": [ 249, 251 ], "frequently;": [ 250 ], "transient": [ 253 ], "tended": [ 255 ], "occur": [ 257 ], "during": [ 258 ], "dose": [ 259 ], "escalation.": [ 260 ], "For": [ 261 ], "requiring": [ 263 ], "intensification": [ 265 ], "add-on": [ 271 ], "insulin,": [ 273 ], "effective": [ 277 ], "glucose": [ 278 ], "lowering": [ 279 ], "loss,": [ 283 ], "risk": [ 286 ], "hypoglycemia,": [ 288 ], "thus": [ 289 ], "broadening": [ 290 ], "range": [ 292 ], "therapeutic": [ 294 ] }, "publication_date": "2020-08-20", "publication_year": 2020, "type": "review", "cited_by_count": 31, "authors": [ { "id": "https://openalex.org/A5054577746", "display_name": "Eugene E. Wright" }, { "id": "https://openalex.org/A5005405894", "display_name": "Vanita R. Aroda" } ] }, { "id": "https://openalex.org/W1977583243", "doi": "https://doi.org/10.5694/mja12.11856", "title": "The rationale for combining GLP\u20101 receptor agonists with basal insulin", "abstract": { "\u2022": [ 0, 37, 57, 96, 131, 162 ], "Type": [ 1 ], "2": [ 2 ], "diabetes": [ 3 ], "mellitus": [ 4 ], "(T2DM)": [ 5 ], "is": [ 6, 12, 16, 55, 188 ], "progressive;": [ 7 ], "the": [ 8, 14, 17, 49, 125, 139, 145, 199 ], "more": [ 9 ], "intensively": [ 10 ], "it": [ 11, 180 ], "treated,": [ 13 ], "greater": [ 15 ], "risk": [ 18, 126 ], "of": [ 19, 42, 51, 77, 93, 127, 141, 148 ], "hypoglycaemia": [ 20 ], "and": [ 21, 73, 118, 168, 187 ], "weight": [ 22, 117 ], "gain.": [ 23 ], "Achieving": [ 24 ], "treatment": [ 25 ], "intensification": [ 26, 92 ], "while": [ 27 ], "mitigating": [ 28 ], "these": [ 29 ], "risks": [ 30 ], "presents": [ 31 ], "a": [ 32 ], "challenge": [ 33 ], "to": [ 34, 91, 106, 182, 190 ], "patient": [ 35 ], "management.": [ 36 ], "Basal": [ 38 ], "insulins": [ 39 ], "provide": [ 40 ], "control": [ 41, 50 ], "fasting": [ 43 ], "glucose;": [ 44 ], "however,": [ 45 ], "their": [ 46 ], "utility": [ 47 ], "in": [ 48, 81, 185, 198 ], "postprandial": [ 52, 110 ], "glucose": [ 53, 111 ], "excursions": [ 54 ], "limited.": [ 56 ], "Glucagon-like": [ 58 ], "peptide-1": [ 59 ], "(GLP-1)": [ 60 ], "receptor": [ 61, 79, 103, 150 ], "agonists": [ 62, 80, 104, 151 ], "stimulate": [ 63 ], "glucose-medicated": [ 64 ], "insulin": [ 65, 86, 94, 108, 121 ], "secretion,": [ 66, 69 ], "suppress": [ 67 ], "glucagon": [ 68 ], "delay": [ 70 ], "gastric": [ 71 ], "emptying": [ 72 ], "decrease": [ 74, 109, 116 ], "appetite.": [ 75 ], "Use": [ 76 ], "GLP-1": [ 78, 102, 149 ], "combination": [ 82 ], "therapy": [ 83 ], "with": [ 84 ], "basal": [ 85, 107, 120 ], "offers": [ 87 ], "an": [ 88, 192 ], "alternative": [ 89 ], "approach": [ 90 ], "therapy.": [ 95 ], "Prospective": [ 97 ], "interventional": [ 98 ], "trials": [ 99 ], "demonstrate": [ 100 ], "that": [ 101 ], "added": [ 105 ], "levels,": [ 112, 115 ], "lower": [ 113, 119 ], "HbA1c": [ 114 ], "requirements": [ 122 ], "without": [ 123 ], "increasing": [ 124 ], "major": [ 128 ], "hypoglycaemic": [ 129 ], "events.": [ 130 ], "The": [ 132 ], "current": [ 133 ], "clinical": [ 134 ], "data": [ 135, 143 ], "are": [ 136 ], "limited": [ 137 ], "by": [ 138 ], "lack": [ 140 ], "any": [ 142 ], "on": [ 144 ], "long-term": [ 146, 169 ], "effects": [ 147, 167 ], "over": [ 152 ], "additional": [ 153 ], "prandial": [ 154 ], "regimens;": [ 155 ], "they": [ 156 ], "may": [ 157 ], "be": [ 158, 172, 183, 191 ], "beneficial": [ 159 ], "or": [ 160 ], "deleterious.": [ 161 ], "Although": [ 163 ], "cost,": [ 164 ], "gastrointestinal": [ 165 ], "side": [ 166 ], "safety": [ 170 ], "should": [ 171 ], "taken": [ 173 ], "into": [ 174 ], "account": [ 175 ], "when": [ 176 ], "considering": [ 177 ], "this": [ 178 ], "combination,": [ 179 ], "appears": [ 181 ], "growing": [ 184 ], "popularity": [ 186 ], "likely": [ 189 ], "important": [ 193 ], "therapeutic": [ 194 ], "option": [ 195 ], "for": [ 196 ], "T2DM": [ 197 ], "future.": [ 200 ] }, "publication_date": "2013-08-01", "publication_year": 2013, "type": "review", "cited_by_count": 24, "authors": [ { "id": "https://openalex.org/A5084459936", "display_name": "Neale Cohen" }, { "id": "https://openalex.org/A5085701832", "display_name": "Ralph Audehm" }, { "id": "https://openalex.org/A5015696712", "display_name": "Etheresia Pretorius" }, { "id": "https://openalex.org/A5104069625", "display_name": "Joey Kaye" }, { "id": "https://openalex.org/A5079155238", "display_name": "Leon H Chapman" }, { "id": "https://openalex.org/A5080414613", "display_name": "Stephen Colagiuri" } ] }, { "id": "https://openalex.org/W2127509345", "doi": "https://doi.org/10.1177/0091270009354996", "title": "Population Pharmacokinetics of Liraglutide, a Once\u2010Daily Human Glucagon\u2010Like Peptide\u20101 Analog, in Healthy Volunteers and Subjects With Type 2 Diabetes, and Comparison to Twice\u2010Daily Exenatide", "abstract": { "The": [ 0, 26, 104 ], "once\u2010daily": [ 1, 108, 158 ], "human": [ 2 ], "glucagon\u2010like": [ 3 ], "peptide\u20101": [ 4 ], "(GLP\u20101)": [ 5 ], "analog,": [ 6 ], "liraglutide,": [ 7 ], "was": [ 8, 128, 137, 142 ], "recently": [ 9 ], "shown": [ 10 ], "to": [ 11, 32, 43, 62, 72 ], "provide": [ 12 ], "improved": [ 13 ], "glycemic": [ 14 ], "control": [ 15 ], "in": [ 16, 78, 87, 122, 160, 167, 179 ], "subjects": [ 17, 67, 133, 185 ], "with": [ 18, 24, 68, 98, 116, 134, 157, 169, 186 ], "type": [ 19 ], "2": [ 20 ], "diabetes": [ 21 ], "(T2D)": [ 22 ], "compared": [ 23, 115 ], "exenatide.": [ 25, 48, 118, 171 ], "aim": [ 27 ], "of": [ 28, 37, 47, 55, 60, 107, 125 ], "this": [ 29 ], "work": [ 30 ], "is": [ 31 ], "estimate": [ 33 ], "the": [ 34, 44, 123 ], "population": [ 35, 75 ], "pharmacokinetics": [ 36, 90, 181 ], "liraglutide": [ 38, 61, 109, 152, 180 ], "and": [ 39, 57, 66, 101, 132, 162, 184 ], "make": [ 40 ], "a": [ 41, 74, 84, 95 ], "comparison": [ 42, 168 ], "pharmacokinetic": [ 45, 76, 105, 145, 154, 165 ], "profile": [ 46, 106 ], "Pharmacokinetic": [ 49 ], "data": [ 50, 81 ], "from": [ 51, 83 ], "5": [ 52 ], "published": [ 53, 85 ], "studies": [ 54 ], "subcutaneous": [ 56 ], "intravenous": [ 58 ], "administration": [ 59 ], "healthy": [ 63 ], "volunteers": [ 64 ], "(HV)": [ 65 ], "T2D": [ 69, 135 ], "were": [ 70, 91, 177 ], "used": [ 71 ], "develop": [ 73 ], "model": [ 77, 97 ], "NONMEM.": [ 79 ], "Exenatide": [ 80 ], "came": [ 82 ], "study": [ 86 ], "T2D.": [ 88, 187 ], "Liraglutide": [ 89 ], "adequately": [ 92 ], "described": [ 93 ], "using": [ 94 ], "1\u2010compartment": [ 96 ], "sequential": [ 99 ], "zero\u2010": [ 100 ], "first\u2010order": [ 102 ], "absorption.": [ 103 ], "showed": [ 110, 150 ], "considerably": [ 111 ], "smaller": [ 112 ], "peak\u2010to\u2010trough": [ 113 ], "fluctuations": [ 114 ], "twice\u2010daily": [ 117, 170 ], "A": [ 119 ], "small": [ 120 ], "difference": [ 121 ], "estimates": [ 124 ], "absorption": [ 126 ], "parameters": [ 127 ], "found": [ 129, 178 ], "between": [ 130, 182 ], "HV": [ 131, 183 ], "but": [ 136 ], "not": [ 138 ], "clinically": [ 139, 174 ], "relevant.": [ 140 ], "It": [ 141 ], "concluded": [ 143 ], "that": [ 144, 151 ], "profiles": [ 146 ], "estimated": [ 147 ], "by": [ 148 ], "modeling": [ 149 ], "has": [ 153 ], "properties": [ 155 ], "consistent": [ 156 ], "dosing": [ 159 ], "humans": [ 161 ], "provides": [ 163 ], "better": [ 164 ], "coverage": [ 166 ], "Furthermore,": [ 172 ], "no": [ 173 ], "relevant": [ 175 ], "differences": [ 176 ] }, "publication_date": "2010-02-05", "publication_year": 2010, "type": "article", "cited_by_count": 51, "authors": [ { "id": "https://openalex.org/A5102776327", "display_name": "Estelle Watson" }, { "id": "https://openalex.org/A5008224959", "display_name": "Dani\u00ebl M. Jonker" }, { "id": "https://openalex.org/A5112171221", "display_name": "Lisbeth V. Jacobsen" }, { "id": "https://openalex.org/A5109417363", "display_name": "Steen H. Ingwersen" } ] }, { "id": "https://openalex.org/W2027239684", "doi": "https://doi.org/10.1038/ijo.2014.177", "title": "Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss", "abstract": null, "publication_date": "2014-10-07", "publication_year": 2014, "type": "article", "cited_by_count": 107, "authors": [ { "id": "https://openalex.org/A5109903929", "display_name": "Eva W. Iepsen" }, { "id": "https://openalex.org/A5007991615", "display_name": "J. Lundgren" }, { "id": "https://openalex.org/A5020611204", "display_name": "Carsten Dirksen" }, { "id": "https://openalex.org/A5058323484", "display_name": "Jens\u2010Erik Beck Jensen" }, { "id": "https://openalex.org/A5066665434", "display_name": "Oluf Pedersen" }, { "id": "https://openalex.org/A5100704087", "display_name": "Torben Hansen" }, { "id": "https://openalex.org/A5062239390", "display_name": "Sten Madsbad" }, { "id": "https://openalex.org/A5085434984", "display_name": "Jens J. Holst" }, { "id": "https://openalex.org/A5038081896", "display_name": "Signe S. Torekov" } ] }, { "id": "https://openalex.org/W2059897529", "doi": "https://doi.org/10.1007/s40262-014-0198-2", "title": "Pharmacokinetics and Clinical Use of Incretin-Based Therapies in Patients with Chronic Kidney Disease and Type\u00a02 Diabetes", "abstract": null, "publication_date": "2014-10-20", "publication_year": 2014, "type": "review", "cited_by_count": 99, "authors": [ { "id": "https://openalex.org/A5039563874", "display_name": "Andr\u00e9 Scheen" } ] }, { "id": "https://openalex.org/W4400415068", "doi": "https://doi.org/10.1001/jamainternmed.2024.2525", "title": "Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity", "abstract": { "Importance": [ 0 ], "Although": [ 1 ], "tirzepatide": [ 2, 48, 77, 294, 302, 344, 396 ], "and": [ 3, 34, 63, 81, 118, 144, 174, 195, 201, 209, 270, 295, 327, 364, 383 ], "semaglutide": [ 4, 50, 75, 162 ], "were": [ 5, 84, 111, 149, 216, 249, 254, 264, 303, 339, 378 ], "shown": [ 6 ], "to": [ 7, 93, 142, 307, 353, 362, 372, 410 ], "reduce": [ 8 ], "weight": [ 9, 32, 105, 148, 177, 199, 205, 279, 309, 338, 402 ], "in": [ 10, 18, 57, 121, 163, 179, 204, 337, 413 ], "randomized": [ 11 ], "clinical": [ 12, 59 ], "trials,": [ 13 ], "data": [ 14, 91 ], "from": [ 15, 96 ], "head-to-head": [ 16 ], "comparisons": [ 17 ], "populations": [ 19 ], "with": [ 20, 43, 70, 114, 390, 399 ], "overweight": [ 21, 44, 71, 115, 391 ], "or": [ 22, 45, 49, 72, 76, 116, 161, 169, 190, 193, 197, 267, 392 ], "obesity": [ 23, 46, 73, 117 ], "are": [ 24 ], "not": [ 25 ], "yet": [ 26 ], "available.": [ 27 ], "Objective": [ 28 ], "To": [ 29 ], "compare": [ 30 ], "on-treatment": [ 31 ], "loss": [ 33, 310, 403 ], "rates": [ 35 ], "of": [ 36, 99, 187, 213, 265, 375, 388, 395 ], "gastrointestinal": [ 37, 214, 376 ], "adverse": [ 38 ], "events": [ 39 ], "(AEs)": [ 40 ], "among": [ 41 ], "adults": [ 42, 69, 222, 389 ], "receiving": [ 47, 74, 293, 298, 301, 343 ], "labeled": [ 51, 165 ], "for": [ 52, 166, 289, 341 ], "type": [ 53 ], "2": [ 54 ], "diabetes": [ 55 ], "(T2D)": [ 56 ], "a": [ 58, 97, 136, 180 ], "setting.": [ 60 ], "Design,": [ 61 ], "Setting,": [ 62 ], "Participants": [ 64 ], "In": [ 65, 385 ], "this": [ 66, 386 ], "cohort": [ 67 ], "study,": [ 68 ], "between": [ 78, 380 ], "May": [ 79 ], "2022": [ 80 ], "September": [ 82 ], "2023": [ 83 ], "identified": [ 85 ], "using": [ 86 ], "electronic": [ 87 ], "health": [ 88, 101 ], "record": [ 89 ], "(EHR)": [ 90 ], "linked": [ 92 ], "dispensing": [ 94 ], "information": [ 95 ], "collective": [ 98 ], "US": [ 100 ], "care": [ 102, 120 ], "systems.": [ 103 ], "On-treatment": [ 104, 176, 335 ], "outcomes": [ 106 ], "through": [ 107 ], "November": [ 108 ], "3,": [ 109, 157, 207 ], "2023,": [ 110 ], "assessed.": [ 112 ], "Adults": [ 113 ], "regular": [ 119 ], "the": [ 122, 224 ], "year": [ 123 ], "before": [ 124 ], "initiation,": [ 125, 143 ], "no": [ 126 ], "prior": [ 127, 141 ], "glucagon-like": [ 128 ], "peptide": [ 129 ], "1": [ 130 ], "receptor": [ 131, 133 ], "agonist": [ 132, 134 ], "use,": [ 135 ], "prescription": [ 137 ], "within": [ 138 ], "60": [ 139 ], "days": [ 140 ], "an": [ 145 ], "available": [ 146 ], "baseline": [ 147, 278 ], "identified.": [ 150 ], "The": [ 151, 239, 275 ], "analysis": [ 152 ], "was": [ 153, 243, 280, 285, 397 ], "completed": [ 154 ], "on": [ 155, 168 ], "April": [ 156 ], "2024.": [ 158 ], "Exposures": [ 159 ], "Tirzepatide": [ 160 ], "formulations": [ 164 ], "T2D,": [ 167 ], "off": [ 170 ], "label.": [ 171 ], "Main": [ 172 ], "Outcomes": [ 173 ], "Measures": [ 175 ], "change": [ 178, 203 ], "propensity": [ 181, 236 ], "score\u2013matched": [ 182 ], "population,": [ 183 ], "assessed": [ 184 ], "as": [ 185 ], "hazard": [ 186, 312 ], "achieving": [ 188 ], "5%": [ 189 ], "greater,": [ 191, 194 ], "10%": [ 192 ], "15%": [ 196 ], "greater": [ 198, 401 ], "loss,": [ 200 ], "percentage": [ 202 ], "at": [ 206, 345 ], "6,": [ 208 ], "12": [ 210, 247, 365 ], "months.": [ 211 ], "Hazards": [ 212 ], "AEs": [ 215, 377 ], "compared.": [ 217 ], "Results": [ 218 ], "Among": [ 219 ], "41": [ 220 ], "222": [ 221 ], "meeting": [ 223 ], "study": [ 225, 407 ], "criteria": [ 226 ], "(semaglutide,": [ 227 ], "32": [ 228 ], "029;": [ 229 ], "tirzepatide,": [ 230 ], "9193),": [ 231 ], "18": [ 232 ], "386": [ 233 ], "remained": [ 234 ], "after": [ 235 ], "score": [ 237 ], "matching.": [ 238 ], "mean": [ 240, 276 ], "(SD)": [ 241, 277 ], "age": [ 242 ], "52.0": [ 244 ], "(12.9)": [ 245 ], "years,": [ 246 ], "970": [ 248 ], "female": [ 250 ], "(70.5%),": [ 251 ], "14": [ 252 ], "182": [ 253 ], "white": [ 255 ], "(77.1%),": [ 256 ], "2171": [ 257 ], "Black": [ 258 ], "(11.8%),": [ 259 ], "354": [ 260 ], "Asian": [ 261 ], "(1.9%),": [ 262 ], "1679": [ 263 ], "other": [ 266, 414 ], "unknown": [ 268 ], "race,": [ 269 ], "9563": [ 271 ], "(52.0%)": [ 272 ], "had": [ 273 ], "T2D.": [ 274 ], "110": [ 281 ], "(25.8)": [ 282 ], "kg.": [ 283 ], "Follow-up": [ 284 ], "ended": [ 286 ], "by": [ 287 ], "discontinuation": [ 288 ], "5140": [ 290 ], "patients": [ 291, 342 ], "(55.9%)": [ 292 ], "4823": [ 296 ], "(52.5%)": [ 297 ], "semaglutide.": [ 299, 405 ], "Patients": [ 300 ], "significantly": [ 304, 400 ], "more": [ 305 ], "likely": [ 306 ], "achieve": [ 308 ], "(\u22655%;": [ 311 ], "ratio": [ 313 ], "[HR],": [ 314 ], "1.76,": [ 315 ], "95%": [ 316, 323, 331, 350, 359, 369 ], "CI,": [ 317, 324, 332, 360, 370 ], "1.68,": [ 318 ], "1.84;": [ 319 ], "\u226510%;": [ 320 ], "HR,": [ 321, 329 ], "2.54;": [ 322 ], "2.37,": [ 325 ], "2.73;": [ 326 ], "\u226515%;": [ 328 ], "3.24;": [ 330 ], "2.91,": [ 333 ], "3.61).": [ 334 ], "changes": [ 336 ], "larger": [ 340 ], "3": [ 346 ], "months": [ 347, 356, 366 ], "(difference,": [ 348, 357, 367 ], "\u22122.4%;": [ 349 ], "CI": [ 351 ], "\u22122.5%": [ 352 ], "\u22122.2%),": [ 354 ], "6": [ 355 ], "\u22124.3%;": [ 358 ], "\u22124.7%": [ 361 ], "\u22124.0%),": [ 363 ], "\u22126.9%;": [ 368 ], "\u22127.9%": [ 371 ], "\u22125.8%).": [ 373 ], "Rates": [ 374 ], "similar": [ 379 ], "groups.": [ 381 ], "Conclusions": [ 382 ], "Relevance": [ 384 ], "population": [ 387 ], "obesity,": [ 393 ], "use": [ 394 ], "associated": [ 398 ], "than": [ 404 ], "Future": [ 406 ], "is": [ 408 ], "needed": [ 409 ], "understand": [ 411 ], "differences": [ 412 ], "important": [ 415 ], "outcomes.": [ 416 ] }, "publication_date": "2024-07-08", "publication_year": 2024, "type": "article", "cited_by_count": 165, "authors": [ { "id": "https://openalex.org/A5046818234", "display_name": "Patricia J. Rodriguez" }, { "id": "https://openalex.org/A5049865807", "display_name": "Brianna M. Goodwin Cartwright" }, { "id": "https://openalex.org/A5082052835", "display_name": "Samuel Gratzl" }, { "id": "https://openalex.org/A5034294493", "display_name": "Rajdeep Brar" }, { "id": "https://openalex.org/A5045037086", "display_name": "Charlotte Baker" }, { "id": "https://openalex.org/A5080450969", "display_name": "Ty J. Gluckman" }, { "id": "https://openalex.org/A5058087088", "display_name": "Nicholas L Stucky" } ] }, { "id": "https://openalex.org/W2505843168", "doi": "https://doi.org/10.1001/jama.2016.10260", "title": "Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction", "abstract": { "clinicaltrials.gov": [ 0 ], "Identifier:": [ 1 ], "NCT01800968.": [ 2 ] }, "publication_date": "2016-08-02", "publication_year": 2016, "type": "article", "cited_by_count": 615, "authors": [ { "id": "https://openalex.org/A5003776673", "display_name": "Kenneth B. Margulies" }, { "id": "https://openalex.org/A5012849300", "display_name": "Adrian F. Hernandez" }, { "id": "https://openalex.org/A5028644714", "display_name": "Margaret M. Redfield" }, { "id": "https://openalex.org/A5088310205", "display_name": "Michael M. Givertz" }, { "id": "https://openalex.org/A5103819065", "display_name": "Guilherme H. Oliveira" }, { "id": "https://openalex.org/A5102713118", "display_name": "Robert T. Cole" }, { "id": "https://openalex.org/A5076497318", "display_name": "Douglas L. Mann" }, { "id": "https://openalex.org/A5032690649", "display_name": "David J. Whellan" }, { "id": "https://openalex.org/A5060658296", "display_name": "Michael S. Kiernan" }, { "id": "https://openalex.org/A5022076272", "display_name": "G. Michael Felker" }, { "id": "https://openalex.org/A5057943199", "display_name": "Steven E. McNulty" }, { "id": "https://openalex.org/A5071968251", "display_name": "Kevin J. Anstrom" }, { "id": "https://openalex.org/A5002931918", "display_name": "Monica Shah" }, { "id": "https://openalex.org/A5022267024", "display_name": "Eugene Braunwald" }, { "id": "https://openalex.org/A5029333303", "display_name": "Thomas P. Cappola" } ] }, { "id": "https://openalex.org/W4313398673", "doi": "https://doi.org/10.1016/j.intimp.2022.109653", "title": "The GLP-1 receptor agonist exenatide ameliorates neuroinflammation, locomotor activity, and anxiety-like behavior in mice with diet-induced obesity through the modulation of microglial M2 polarization and downregulation of SR-A4", "abstract": null, "publication_date": "2022-12-30", "publication_year": 2022, "type": "article", "cited_by_count": 31, "authors": [ { "id": "https://openalex.org/A5082917185", "display_name": "Ming\u2010Hong Lin" }, { "id": "https://openalex.org/A5023059725", "display_name": "Po-Ching Cheng" }, { "id": "https://openalex.org/A5084240133", "display_name": "Pi\u2010Jung Hsiao" }, { "id": "https://openalex.org/A5059930981", "display_name": "Szu\u2010Chia Chen" }, { "id": "https://openalex.org/A5073269098", "display_name": "Chih\u2010Hsing Hung" }, { "id": "https://openalex.org/A5017298793", "display_name": "Chao\u2010Hung Kuo" }, { "id": "https://openalex.org/A5104110429", "display_name": "Shau\u2010Ku Huang" }, { "id": "https://openalex.org/A5034081035", "display_name": "Hung\u2010Yi Chiou" } ] }, { "id": "https://openalex.org/W2030809658", "doi": "https://doi.org/10.1016/j.atherosclerosis.2011.12.039", "title": "The glucagon-like peptide 1 analog liraglutide reduces TNF-\u03b1-induced oxidative stress and inflammation in endothelial cells", "abstract": null, "publication_date": "2012-01-05", "publication_year": 2012, "type": "article", "cited_by_count": 247, "authors": [ { "id": "https://openalex.org/A5054593686", "display_name": "Aya Shiraki" }, { "id": "https://openalex.org/A5076888051", "display_name": "Jun\u2010ichi Oyama" }, { "id": "https://openalex.org/A5000595844", "display_name": "Hiroshi Komoda" }, { "id": "https://openalex.org/A5007368993", "display_name": "Machiko Asaka" }, { "id": "https://openalex.org/A5018907597", "display_name": "Aiko Komatsu" }, { "id": "https://openalex.org/A5090353170", "display_name": "Masashi Sakuma" }, { "id": "https://openalex.org/A5110892230", "display_name": "Kazuhisa Kodama" }, { "id": "https://openalex.org/A5034123005", "display_name": "Yoshiko Sakamoto" }, { "id": "https://openalex.org/A5032008228", "display_name": "Norihiko Kotooka" }, { "id": "https://openalex.org/A5003043319", "display_name": "Tetsuaki Hirase" }, { "id": "https://openalex.org/A5052966356", "display_name": "Koichi Node" } ] }, { "id": "https://openalex.org/W2055849242", "doi": "https://doi.org/10.3810/pgm.2009.05.1998", "title": "Insights from the Liraglutide Clinical Development Program\u2014the Liraglutide Effect and Action in Diabetes (LEAD) Studies", "abstract": { "Standard": [ 0 ], "therapies": [ 1 ], "for": [ 2 ], "type": [ 3, 120 ], "2": [ 4, 121, 164 ], "diabetes": [ 5, 122 ], "often": [ 6 ], "fail": [ 7 ], "to": [ 8, 44, 126, 169 ], "maintain": [ 9, 127 ], "glycemic": [ 10, 128, 172 ], "control": [ 11, 129, 173 ], "over": [ 12 ], "the": [ 13, 23, 61, 80, 88, 92, 148 ], "long": [ 14 ], "term,": [ 15 ], "in": [ 16, 54, 60, 104, 174, 180 ], "part": [ 17 ], "because": [ 18 ], "they": [ 19 ], "do": [ 20 ], "not": [ 21 ], "target": [ 22 ], "underlying": [ 24 ], "cause.": [ 25 ], "Current": [ 26 ], "treatments": [ 27 ], "may": [ 28 ], "also": [ 29 ], "be": [ 30, 42 ], "associated": [ 31 ], "with": [ 32, 119, 130, 136, 161, 195 ], "weight": [ 33, 179 ], "gain,": [ 34 ], "hypoglycemia,": [ 35 ], "and": [ 36, 40, 64, 102, 132, 150, 157, 189, 191 ], "other": [ 37 ], "adverse": [ 38 ], "effects,": [ 39 ], "can": [ 41 ], "difficult": [ 43 ], "use.": [ 45 ], "Disease": [ 46 ], "progression": [ 47 ], "is": [ 48 ], "accompanied": [ 49 ], "by": [ 50 ], "a": [ 51 ], "progressive": [ 52 ], "decline": [ 53 ], "beta-cell": [ 55, 184 ], "function,": [ 56, 185 ], "which": [ 57 ], "begins": [ 58 ], "early": [ 59 ], "disease": [ 62 ], "course,": [ 63 ], "an": [ 65 ], "impaired": [ 66 ], "incretin": [ 67 ], "response.": [ 68 ], "The": [ 69, 145 ], "recently": [ 70 ], "developed": [ 71 ], "glucagon-like": [ 72 ], "peptide-1": [ 73 ], "(GLP-1)": [ 74 ], "receptor": [ 75, 95 ], "agonists": [ 76 ], "overcome": [ 77 ], "some": [ 78 ], "of": [ 79, 82, 91, 110, 141, 152, 198 ], "limitations": [ 81 ], "conventional": [ 83 ], "treatments.": [ 84 ], "This": [ 85, 108 ], "article": [ 86 ], "summarizes": [ 87 ], "key": [ 89 ], "results": [ 90 ], "new": [ 93 ], "GLP-1": [ 94 ], "agonist": [ 96 ], "(liraglutide)": [ 97 ], "phase": [ 98 ], "3": [ 99 ], "Liraglutide": [ 100 ], "Effect": [ 101 ], "Action": [ 103 ], "Diabetes": [ 105 ], "(LEAD)": [ 106 ], "studies.": [ 107 ], "series": [ 109 ], "6": [ 111 ], "randomized": [ 112 ], "controlled": [ 113 ], "studies": [ 114, 146 ], "involved": [ 115 ], ">": [ 116 ], "4400": [ 117 ], "patients": [ 118 ], "who": [ 123 ], "were": [ 124 ], "unable": [ 125 ], "diet": [ 131 ], "exercise": [ 133 ], "alone": [ 134 ], "or": [ 135, 163 ], "oral": [ 137, 165 ], "treatment,": [ 138 ], "approximately": [ 139 ], "2700": [ 140 ], "whom": [ 142 ], "received": [ 143 ], "liraglutide.": [ 144 ], "demonstrated": [ 147 ], "efficacy": [ 149 ], "safety": [ 151 ], "liraglutide": [ 153, 177 ], "both": [ 154 ], "as": [ 155, 158 ], "monotherapy": [ 156 ], "combination": [ 159 ], "therapy": [ 160 ], "1": [ 162 ], "agents.": [ 166 ], "In": [ 167 ], "addition": [ 168 ], "providing": [ 170 ], "robust": [ 171 ], "these": [ 175 ], "studies,": [ 176 ], "reduced": [ 178 ], "most": [ 181 ], "patients,": [ 182 ], "improved": [ 183 ], "lowered": [ 186 ], "blood": [ 187 ], "pressure": [ 188 ], "triglycerides,": [ 190 ], "was": [ 192 ], "well": [ 193 ], "tolerated": [ 194 ], "minimal": [ 196 ], "risk": [ 197 ], "hypoglycemia.": [ 199 ] }, "publication_date": "2009-05-01", "publication_year": 2009, "type": "review", "cited_by_count": 43, "authors": [ { "id": "https://openalex.org/A5050076657", "display_name": "Janet B. McGill" } ] }, { "id": "https://openalex.org/W2793795908", "doi": "https://doi.org/10.1002/ejhf.1170", "title": "Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology", "abstract": { "The": [ 0, 40 ], "coexistence": [ 1 ], "of": [ 2, 24, 32, 44, 59, 78, 100, 119, 183, 228, 241, 253 ], "type": [ 3 ], "2": [ 4 ], "diabetes": [ 5 ], "mellitus": [ 6 ], "(T2DM)": [ 7 ], "and": [ 8, 26, 36, 54, 71, 137, 144, 188, 208, 248 ], "heart": [ 9 ], "failure": [ 10 ], "(HF),": [ 11 ], "either": [ 12 ], "with": [ 13, 28, 179, 194, 221, 246 ], "reduced": [ 14 ], "(HFrEF)": [ 15 ], "or": [ 16, 225 ], "preserved": [ 17 ], "ejection": [ 18 ], "fraction": [ 19 ], "(HFpEF),": [ 20 ], "is": [ 21, 65, 152 ], "frequent": [ 22 ], "(30\u201340%": [ 23 ], "patients)": [ 25 ], "associated": [ 27, 178 ], "a": [ 29, 55, 172, 180, 213 ], "higher": [ 30, 181 ], "risk": [ 31, 167, 182, 197, 227 ], "HF": [ 33, 45, 69, 95, 103, 113, 125, 151, 169, 184, 217 ], "hospitalization,": [ 34 ], "all\u2010cause": [ 35 ], "cardiovascular": [ 37 ], "(CV)": [ 38 ], "mortality.": [ 39 ], "most": [ 41, 127 ], "important": [ 42 ], "causes": [ 43 ], "in": [ 46, 68, 85, 97, 105, 124, 150, 192, 216, 219, 244, 250 ], "T2DM": [ 47, 60, 64, 122 ], "are": [ 48, 90, 115, 190 ], "coronary": [ 49 ], "artery": [ 50 ], "disease,": [ 51 ], "arterial": [ 52 ], "hypertension": [ 53 ], "direct": [ 56 ], "detrimental": [ 57 ], "effect": [ 58 ], "on": [ 61 ], "the": [ 62, 76, 86, 106, 133, 141, 166, 239, 251 ], "myocardium.": [ 63 ], "often": [ 66 ], "unrecognized": [ 67 ], "patients,": [ 70, 126 ], "vice": [ 72 ], "versa,": [ 73 ], "which": [ 74 ], "emphasizes": [ 75 ], "importance": [ 77 ], "an": [ 79, 236 ], "active": [ 80 ], "search": [ 81 ], "for": [ 82, 168 ], "both": [ 83, 211 ], "disorders": [ 84 ], "clinical": [ 87 ], "practice.": [ 88 ], "There": [ 89 ], "no": [ 91 ], "specific": [ 92 ], "limitations": [ 93 ], "to": [ 94 ], "treatment": [ 96, 104, 123 ], "T2DM.": [ 98, 120, 254 ], "Subanalyses": [ 99 ], "trials": [ 101, 233 ], "addressing": [ 102 ], "general": [ 107 ], "population": [ 108 ], "have": [ 109, 139, 210 ], "shown": [ 110, 212 ], "that": [ 111 ], "all": [ 112 ], "therapies": [ 114, 146 ], "similarly": [ 116 ], "effective": [ 117 ], "regardless": [ 118 ], "Concerning": [ 121 ], "guidelines": [ 128 ], "currently": [ 129 ], "recommend": [ 130 ], "metformin": [ 131 ], "as": [ 132 ], "first\u2010line": [ 134 ], "choice.": [ 135 ], "Sulphonylureas": [ 136 ], "insulin": [ 138 ], "been": [ 140, 177 ], "traditional": [ 142 ], "second\u2010": [ 143 ], "third\u2010line": [ 145 ], "although": [ 147 ], "their": [ 148 ], "safety": [ 149 ], "equivocal.": [ 153 ], "Neither": [ 154 ], "glucagon\u2010like": [ 155 ], "preptide\u20101": [ 156 ], "(GLP\u20101)": [ 157 ], "receptor": [ 158 ], "agonists,": [ 159 ], "nor": [ 160 ], "dipeptidyl": [ 161 ], "peptidase\u20104": [ 162 ], "(DPP4)": [ 163 ], "inhibitors": [ 164, 243 ], "reduce": [ 165 ], "hospitalization.": [ 170, 185 ], "Indeed,": [ 171 ], "DPP4": [ 173 ], "inhibitor,": [ 174 ], "saxagliptin,": [ 175 ], "has": [ 176 ], "Thiazolidinediones": [ 186 ], "(pioglitazone": [ 187 ], "rosiglitazone)": [ 189 ], "contraindicated": [ 191 ], "patients": [ 193, 220, 245 ], "(or": [ 195 ], "at": [ 196, 226 ], "of)": [ 198 ], "HF.": [ 199 ], "In": [ 200 ], "recent": [ 201 ], "trials,": [ 202 ], "sodium\u2013glucose": [ 203 ], "co\u2010transporter\u20102": [ 204 ], "(SGLT2)": [ 205 ], "inhibitors,": [ 206 ], "empagliflozin": [ 207 ], "canagliflozin,": [ 209 ], "significant": [ 214 ], "reduction": [ 215 ], "hospitalization": [ 218 ], "established": [ 222 ], "CV": [ 223, 229 ], "disease": [ 224 ], "disease.": [ 230 ], "Several": [ 231 ], "ongoing": [ 232 ], "should": [ 234 ], "provide": [ 235 ], "insight": [ 237 ], "into": [ 238 ], "effectiveness": [ 240 ], "SGLT2": [ 242 ], "HFrEF": [ 247 ], "HFpEF": [ 249 ], "absence": [ 252 ] }, "publication_date": "2018-03-08", "publication_year": 2018, "type": "review", "cited_by_count": 672, "authors": [ { "id": "https://openalex.org/A5076848838", "display_name": "Petar Seferovi\u0107" }, { "id": "https://openalex.org/A5009535057", "display_name": "Mark C. Petrie" }, { "id": "https://openalex.org/A5023320363", "display_name": "Gerasimos Filippatos" }, { "id": "https://openalex.org/A5103049137", "display_name": "Stefan D. Anker" }, { "id": "https://openalex.org/A5068884647", "display_name": "Giuseppe Rosano" }, { "id": "https://openalex.org/A5016118935", "display_name": "Johann Bauersachs" }, { "id": "https://openalex.org/A5016743789", "display_name": "Walter J. Paulus" }, { "id": "https://openalex.org/A5108014854", "display_name": "Michel Komajda" }, { "id": "https://openalex.org/A5070855397", "display_name": "Francesco Cosentino" }, { "id": "https://openalex.org/A5031658795", "display_name": "Rudolf A. de Boer" }, { "id": "https://openalex.org/A5062238016", "display_name": "Dimitrios Farmakis" }, { "id": "https://openalex.org/A5078822921", "display_name": "Wolfram Doehner" }, { "id": "https://openalex.org/A5045351485", "display_name": "Ekaterini Lambrinou" }, { "id": "https://openalex.org/A5005956916", "display_name": "Yu. M. Lopatin" }, { "id": "https://openalex.org/A5086153061", "display_name": "Massimo Piepoli" }, { "id": "https://openalex.org/A5078018996", "display_name": "Michael J. Theodorakis" }, { "id": "https://openalex.org/A5025152450", "display_name": "Henrik Wiggers" }, { "id": "https://openalex.org/A5106184717", "display_name": "John Lekakis" }, { "id": "https://openalex.org/A5079600079", "display_name": "Alexandre Mebazaa" }, { "id": "https://openalex.org/A5057514332", "display_name": "Mamas A. Mamas" }, { "id": "https://openalex.org/A5089159272", "display_name": "Carsten Tsch\u00f6pe" }, { "id": "https://openalex.org/A5032508279", "display_name": "Arno W. Hoes" }, { "id": "https://openalex.org/A5054973235", "display_name": "Jelena P. Seferovi\u0107" }, { "id": "https://openalex.org/A5047880468", "display_name": "Jennifer Logue" }, { "id": "https://openalex.org/A5028116777", "display_name": "Theresa A. McDonagh" }, { "id": "https://openalex.org/A5035704904", "display_name": "Jillian Riley" }, { "id": "https://openalex.org/A5034363984", "display_name": "Ivan Milinkovi\u0107" }, { "id": "https://openalex.org/A5064845217", "display_name": "Marija Polovina" }, { "id": "https://openalex.org/A5069496306", "display_name": "Dirk J. van Veldhuisen" }, { "id": "https://openalex.org/A5057446742", "display_name": "Mitja Lain\u0161\u010dak" }, { "id": "https://openalex.org/A5088186128", "display_name": "Aldo P. Maggioni" }, { "id": "https://openalex.org/A5013727186", "display_name": "Frank Ruschitzka" }, { "id": "https://openalex.org/A5027213857", "display_name": "John J.V. McMurray" } ] }, { "id": "https://openalex.org/W1966372003", "doi": "https://doi.org/10.1152/ajpendo.00030.2008", "title": "Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes", "abstract": { "We": [ 0, 301 ], "examined": [ 1 ], "the": [ 2, 19, 92, 264 ], "contributions": [ 3 ], "of": [ 4, 21 ], "insulin": [ 5 ], "secretion,": [ 6 ], "glucagon": [ 7, 86, 154, 215 ], "suppression,": [ 8 ], "splanchnic": [ 9, 265 ], "and": [ 10, 14, 68, 81, 114, 140, 171, 211, 247, 276, 314 ], "peripheral": [ 11 ], "glucose": [ 12, 115, 227, 261 ], "metabolism,": [ 13 ], "delayed": [ 15 ], "gastric": [ 16, 106, 317 ], "emptying": [ 17 ], "to": [ 18, 104, 160, 190, 220, 272, 277 ], "attenuation": [ 20 ], "postprandial": [ 22, 307 ], "hyperglycemia": [ 23, 126, 308 ], "during": [ 24 ], "intravenous": [ 25 ], "exenatide": [ 26, 79, 84, 186, 304 ], "administration.": [ 27 ], "Twelve": [ 28 ], "subjects": [ 29 ], "with": [ 30, 60, 91, 147 ], "type": [ 31 ], "2": [ 32, 39, 46 ], "diabetes": [ 33 ], "(3": [ 34 ], "F/9": [ 35 ], "M,": [ 36 ], "44": [ 37 ], "\u00b1": [ 38, 43, 52, 137, 144, 150, 162, 180, 188, 192, 198, 201, 218, 222, 231, 238, 249 ], "yr,": [ 40 ], "BMI": [ 41 ], "34": [ 42 ], "4": [ 44, 163, 232 ], "kg/m": [ 45 ], ",": [ 47 ], "Hb": [ 48 ], "A": [ 49 ], "1c": [ 50 ], "7.5": [ 51 ], "1.5%)": [ 53 ], "participated": [ 54 ], "in": [ 55, 134, 141, 165, 177, 234, 241, 252, 270, 274, 279, 293 ], "three": [ 56 ], "meal-tolerance": [ 57 ], "tests": [ 58 ], "performed": [ 59 ], "double": [ 61 ], "tracer": [ 62 ], "technique": [ 63 ], "(iv": [ 64 ], "[3-": [ 65 ], "3": [ 66 ], "H]glucose": [ 67 ], "oral": [ 69 ], "[1-": [ 70 ], "14": [ 71 ], "C]glucose):": [ 72 ], "1)": [ 73 ], "iv": [ 74, 78, 83 ], "saline": [ 75 ], "(CON),": [ 76 ], "2)": [ 77 ], "(EXE),": [ 80 ], "3)": [ 82 ], "plus": [ 85 ], "(E+G).": [ 87 ], "Acetaminophen": [ 88, 287 ], "was": [ 89, 127, 172, 183, 229, 289 ], "given": [ 90 ], "mixed": [ 93 ], "meal": [ 94 ], "(75": [ 95 ], "g": [ 96, 99, 102, 233, 240, 251 ], "glucose,": [ 97, 109 ], "25": [ 98 ], "fat,": [ 100 ], "20": [ 101 ], "protein)": [ 103 ], "monitor": [ 105 ], "emptying.": [ 107, 318 ], "Plasma": [ 108 ], "insulin,": [ 110 ], "glucagon,": [ 111 ], "acetaminophen": [ 112 ], "concentrations": [ 113 ], "specific": [ 116 ], "activities": [ 117 ], "were": [ 118 ], "measured": [ 119 ], "for": [ 120 ], "6": [ 121, 239 ], "h": [ 122 ], "post": [ 123 ], "meal.": [ 124 ], "Post-meal": [ 125 ], "markedly": [ 128 ], "reduced": [ 129, 290 ], "(": [ 130, 167, 243, 254, 281, 297 ], "P": [ 131, 168, 205, 244, 255, 282, 298 ], "<": [ 132, 169, 206, 245, 256, 283, 299 ], "0.01)": [ 133, 170 ], "EXE": [ 135, 166, 208, 242, 275, 294 ], "(138": [ 136 ], "16": [ 138 ], "mg/dl)": [ 139 ], "E+G": [ 142, 178, 280 ], "(165": [ 143 ], "12)": [ 145 ], "compared": [ 146 ], "CON": [ 148, 176, 235, 271, 296 ], "(206": [ 149 ], "15).": [ 151 ], "Baseline": [ 152 ], "plasma": [ 153 ], "(\u223c90": [ 155 ], "pg/ml)": [ 156 ], "decreased": [ 157 ], "by": [ 158, 185, 214, 291, 309, 315 ], "\u223c20%": [ 159 ], "73": [ 161 ], "pg/ml": [ 164 ], "not": [ 173 ], "different": [ 174 ], "from": [ 175, 268 ], "(81": [ 179 ], "2).": [ 181 ], "EGP": [ 182, 311 ], "suppressed": [ 184 ], "[231": [ 187 ], "9": [ 189 ], "108": [ 191 ], "8": [ 193 ], "mg/min": [ 194, 203, 224 ], "(54%)": [ 195 ], "vs.": [ 196, 209, 236, 258, 285, 295 ], "254": [ 197 ], "29": [ 199 ], "to189": [ 200 ], "27": [ 202 ], "(26%,": [ 204 ], "0.001,": [ 207 ], "CON]": [ 210 ], "partially": [ 212 ], "reversed": [ 213 ], "replacement": [ 216 ], "[247": [ 217 ], "15": [ 219, 248 ], "173": [ 221 ], "18": [ 223 ], "(31%)].": [ 225 ], "Oral": [ 226 ], "appearance": [ 228 ], "39": [ 230 ], "23": [ 237 ], "0.001)": [ 246 ], "5": [ 250 ], "E+G,": [ 253 ], "0.01": [ 257 ], "CON).": [ 259, 286 ], "The": [ 260 ], "retained": [ 262 ], "within": [ 263 ], "bed": [ 266 ], "increased": [ 267 ], "\u223c36g": [ 269 ], "\u223c52g": [ 273 ], "\u223c60g": [ 278 ], "0.001": [ 284 ], "(AUC)": [ 288 ], "\u223c80%": [ 292 ], "0.01).": [ 300 ], "conclude": [ 302 ], "that": [ 303 ], "infusion": [ 305 ], "attenuates": [ 306 ], "decreasing": [ 310 ], "(by": [ 312 ], "\u223c50%)": [ 313 ], "slowing": [ 316 ] }, "publication_date": "2008-03-12", "publication_year": 2008, "type": "article", "cited_by_count": 157, "authors": [ { "id": "https://openalex.org/A5045289586", "display_name": "Antonio Cervera" }, { "id": "https://openalex.org/A5059228126", "display_name": "Estela Wajcberg" }, { "id": "https://openalex.org/A5015937048", "display_name": "Apiradee Sriwijitkamol" }, { "id": "https://openalex.org/A5109993207", "display_name": "M. \u00c1ngeles Guzm\u00e1n Fern\u00e1ndez" }, { "id": "https://openalex.org/A5112127978", "display_name": "Pengou Zuo" }, { "id": "https://openalex.org/A5083775716", "display_name": "Curtis Triplitt" }, { "id": "https://openalex.org/A5034471398", "display_name": "Nicolas Musi" }, { "id": "https://openalex.org/A5091912602", "display_name": "Ralph A. DeFronzo" }, { "id": "https://openalex.org/A5079024626", "display_name": "Eug\u00eanio Cers\u00f3simo" } ] }, { "id": "https://openalex.org/W2225666383", "doi": "https://doi.org/10.1038/srep18904", "title": "Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review", "abstract": { "Abstract": [ 0 ], "A": [ 1 ], "meta-analysis": [ 2, 182 ], "was": [ 3, 59 ], "conducted": [ 4 ], "to": [ 5, 31, 44, 84, 93, 113, 143, 155, 171, 194, 199 ], "assess": [ 6 ], "the": [ 7, 56, 62, 184 ], "clinical": [ 8 ], "efficacy": [ 9 ], "and": [ 10, 26, 55, 69, 124, 133, 145, 158, 196, 202 ], "safety": [ 11 ], "of": [ 12, 98, 176, 186 ], "dulaglutide": [ 13, 43, 71, 135, 187 ], "in": [ 14, 73, 77, 163 ], "patients": [ 15 ], "with": [ 16, 65, 119, 127, 206 ], "type": [ 17 ], "2": [ 18 ], "diabetes": [ 19 ], "mellitus": [ 20 ], "(T2DM).": [ 21 ], "Medline,": [ 22 ], "Embase,": [ 23 ], "Cochrane": [ 24 ], "Library": [ 25 ], "www.": [ 27 ], "clinicaltrials.": [ 28 ], "gov": [ 29 ], "(up": [ 30 ], "February": [ 32 ], "15": [ 33 ], "th": [ 34 ], ",": [ 35 ], "2015)": [ 36 ], "were": [ 37, 49, 53 ], "searched.": [ 38 ], "Randomized": [ 39 ], "controlled": [ 40 ], "trials": [ 41 ], "comparing": [ 42 ], "other": [ 45 ], "drugs": [ 46 ], "for": [ 47, 204 ], "T2DM": [ 48 ], "collected.": [ 50 ], "Twelve": [ 51 ], "RCTs": [ 52 ], "included": [ 54 ], "overall": [ 57 ], "bias": [ 58 ], "low.": [ 60 ], "As": [ 61, 115 ], "monotherapy,": [ 63 ], "compared": [ 64, 126 ], "control": [ 66, 128 ], "(placebo,": [ 67, 129 ], "metformin": [ 68 ], "liraglutide),": [ 70 ], "resulted": [ 72 ], "a": [ 74, 95, 160, 189 ], "significant": [ 75 ], "reduction": [ 76, 162 ], "HbA1c": [ 78, 137 ], "(WMD,": [ 79, 87, 107, 138, 149, 165 ], "\u22120.68%;": [ 80 ], "95%": [ 81, 90, 110, 140, 152, 168 ], "CI,": [ 82, 91, 111, 141, 153, 169 ], "\u22120.95": [ 83 ], "\u22120.40),": [ 85 ], "FPG": [ 86, 164 ], "\u22120.90": [ 88 ], "mmol/L;": [ 89, 167 ], "\u22121.28": [ 92 ], "\u22120.52),": [ 94 ], "similar": [ 96, 161, 174 ], "risk": [ 97 ], "hypoglycemia": [ 99, 177 ], "(7.8%": [ 100 ], "vs.": [ 101, 179 ], "10.6%),": [ 102 ], "less": [ 103 ], "body": [ 104, 146 ], "weight": [ 105, 147 ], "loss": [ 106 ], "0.51": [ 108 ], "kg;": [ 109 ], "0.27": [ 112 ], "0.75).": [ 114 ], "an": [ 116, 173, 192 ], "add-on": [ 117, 193 ], "intervention": [ 118 ], "oral": [ 120 ], "antihyperglycemic": [ 121 ], "medication": [ 122 ], "(OAM)": [ 123 ], "insulin,": [ 125 ], "sitagliptin,": [ 130 ], "exenatide,": [ 131 ], "liraglutide": [ 132 ], "glargine),": [ 134 ], "lowered": [ 136 ], "\u22120.51%;": [ 139 ], "\u22120.68": [ 142 ], "\u22120.35)": [ 144 ], "significantly": [ 148 ], "\u22121.30": [ 150 ], "kg,": [ 151 ], "\u22121.85": [ 154 ], "\u22121.02)": [ 156 ], "notably": [ 157 ], "elicited": [ 159 ], "\u22120.19": [ 166 ], "\u22121.20": [ 170 ], "0.82),": [ 172 ], "incidence": [ 175 ], "(24.5%": [ 178 ], "24.5%).": [ 180 ], "This": [ 181 ], "revealed": [ 183 ], "use": [ 185 ], "as": [ 188 ], "monotherapy": [ 190 ], "or": [ 191 ], "OAM": [ 195 ], "lispro": [ 197 ], "appeared": [ 198 ], "be": [ 200 ], "effective": [ 201 ], "safe": [ 203 ], "adults": [ 205 ], "T2DM.": [ 207 ] }, "publication_date": "2016-01-08", "publication_year": 2016, "type": "review", "cited_by_count": 42, "authors": [ { "id": "https://openalex.org/A5100351779", "display_name": "Lin Zhang" }, { "id": "https://openalex.org/A5100400614", "display_name": "Mei Zhang" }, { "id": "https://openalex.org/A5100326591", "display_name": "Yuwei Zhang" }, { "id": "https://openalex.org/A5002005546", "display_name": "Nanwei Tong" } ] }, { "id": "https://openalex.org/W4324085426", "doi": "https://doi.org/10.3389/fphar.2023.1102792", "title": "Comparative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials", "abstract": { "Background:": [ 0 ], "The": [ 1, 73, 98 ], "relative": [ 2 ], "efficacy": [ 3 ], "of": [ 4, 90 ], "5": [ 5 ], "sodium-glucose": [ 6 ], "cotransporter": [ 7 ], "protein-2": [ 8 ], "(SGLT-2)": [ 9 ], "inhibitors": [ 10, 44, 110 ], "and": [ 11, 58, 70, 94, 111, 179, 203, 210, 233 ], "4": [ 12, 112 ], "glucagon-like": [ 13 ], "peptide-1": [ 14 ], "(GLP-1)": [ 15 ], "receptor": [ 16, 47, 114 ], "agonists": [ 17, 48 ], "for": [ 18 ], "non-alcoholic": [ 19 ], "fatty": [ 20 ], "liver": [ 21, 56, 59, 146 ], "disease": [ 22 ], "(NAFLD)": [ 23 ], "therapy": [ 24 ], "has": [ 25 ], "not": [ 26 ], "been": [ 27 ], "sufficiently": [ 28 ], "investigated.": [ 29 ], "Methods:": [ 30 ], "Randomized": [ 31 ], "controlled": [ 32, 143 ], "trials": [ 33 ], "(RCTs)": [ 34 ], "in": [ 35, 55, 121, 254 ], "which": [ 36 ], "patients": [ 37, 122 ], "with": [ 38, 42, 105, 123, 127, 221 ], "NAFLD": [ 39, 124, 218 ], "were": [ 40, 49, 53, 100 ], "treated": [ 41 ], "SGLT-2": [ 43, 109 ], "or": [ 45 ], "GLP-1": [ 46, 113 ], "included.": [ 50 ], "Primary": [ 51 ], "outcomes": [ 52, 64 ], "improvements": [ 54 ], "enzymes": [ 57 ], "fat": [ 60 ], "parameters,": [ 61 ], "while": [ 62, 183 ], "secondary": [ 63 ], "included": [ 65, 244 ], "anthropometric": [ 66 ], "measures,": [ 67 ], "blood": [ 68, 152, 174, 195, 198 ], "lipids": [ 69 ], "glycemic": [ 71 ], "parameters.": [ 72 ], "frequentist": [ 74 ], "method": [ 75 ], "was": [ 76, 85 ], "used": [ 77 ], "to": [ 78, 236, 250 ], "perform": [ 79 ], "a": [ 80, 214, 238 ], "network": [ 81 ], "meta-analysis.": [ 82 ], "Evidence": [ 83 ], "certainty": [ 84, 119 ], "assessed": [ 86 ], "using": [ 87 ], "the": [ 88, 242 ], "grading": [ 89 ], "recommendations": [ 91 ], "assessment,": [ 92, 182 ], "development,": [ 93 ], "evaluation": [ 95 ], "(GRADE).": [ 96 ], "Results:": [ 97 ], "criteria": [ 99 ], "satisfied": [ 101 ], "by": [ 102 ], "37": [ 103 ], "RCTs": [ 104 ], "9": [ 106 ], "interventions": [ 107 ], "(5": [ 108 ], "agonists).": [ 115 ], "Based": [ 116 ], "on": [ 117, 217, 226 ], "high": [ 118, 227 ], "evidence,": [ 120 ], "(or": [ 125, 219 ], "comorbid": [ 126, 220 ], "type": [ 128, 222 ], "2": [ 129, 223 ], "diabetes),": [ 130 ], "semaglutide": [ 131, 234 ], "could": [ 132, 160, 185 ], "lower": [ 133, 161, 186 ], "alanine": [ 134, 162, 187 ], "aminotransferase": [ 135, 163, 188 ], "as": [ 136, 138, 164, 166, 189, 191 ], "well": [ 137, 165, 190 ], "aspartate": [ 139 ], "aminotransferase,": [ 140 ], "\u03b3-glutamyl": [ 141 ], "transferase,": [ 142 ], "attenuation": [ 144 ], "parameter,": [ 145 ], "stiffness": [ 147 ], "measurement,": [ 148 ], "body": [ 149, 170, 192 ], "weight,": [ 150, 193 ], "systolic": [ 151 ], "pressure,": [ 153 ], "triglycerides,": [ 154 ], "high-density": [ 155 ], "lipoprotein-cholesterol,": [ 156 ], "glycosylated": [ 157, 176, 200 ], "hemoglobin.": [ 158 ], "Liraglutide": [ 159 ], "subcutaneous": [ 167 ], "adipose": [ 168 ], "tissue,": [ 169 ], "mass": [ 171 ], "index,": [ 172 ], "fasting": [ 173, 194 ], "glucose,": [ 175, 196, 199 ], "hemoglobin,": [ 177, 201 ], "glucose": [ 178, 202 ], "homeostasis": [ 180, 204 ], "model": [ 181, 205 ], "dapagliflozin": [ 184, 211 ], "postprandial": [ 197 ], "assessment.": [ 206 ], "Conclusion:": [ 207 ], "Semaglutide,": [ 208 ], "liraglutide,": [ 209 ], "all": [ 212 ], "have": [ 213, 237 ], "certain": [ 215 ], "effect": [ 216 ], "diabetes)": [ 224 ], "based": [ 225 ], "confidence": [ 228, 253 ], "evidence": [ 229 ], "from": [ 230 ], "indirect": [ 231 ], "comparisons,": [ 232 ], "appears": [ 235 ], "therapeutic": [ 239 ], "advantage": [ 240 ], "over": [ 241 ], "other": [ 243 ], "medicines.": [ 245 ], "Head-to-head": [ 246 ], "studies": [ 247 ], "are": [ 248 ], "needed": [ 249 ], "provide": [ 251 ], "more": [ 252 ], "clinical": [ 255 ], "decision-making.": [ 256 ] }, "publication_date": "2023-03-13", "publication_year": 2023, "type": "review", "cited_by_count": 29, "authors": [ { "id": "https://openalex.org/A5110347339", "display_name": "Yunpeng Gu" }, { "id": "https://openalex.org/A5101080325", "display_name": "Lei Sun" }, { "id": "https://openalex.org/A5100441818", "display_name": "Wei Zhang" }, { "id": "https://openalex.org/A5082900596", "display_name": "Tingting Kong" }, { "id": "https://openalex.org/A5070574650", "display_name": "Run Zhou" }, { "id": "https://openalex.org/A5037536977", "display_name": "Yining He" }, { "id": "https://openalex.org/A5077279297", "display_name": "Chaohua Deng" }, { "id": "https://openalex.org/A5103959900", "display_name": "Luping Yang" }, { "id": "https://openalex.org/A5045327860", "display_name": "Jianing Kong" }, { "id": "https://openalex.org/A5100415366", "display_name": "Yutong Chen" }, { "id": "https://openalex.org/A5034139304", "display_name": "Junping Shi" }, { "id": "https://openalex.org/A5090664354", "display_name": "Yanli Hu" } ] }, { "id": "https://openalex.org/W2805436655", "doi": "https://doi.org/10.3389/fphar.2018.00576", "title": "Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "abstract": { "Background:": [ 0 ], "Semaglutide,": [ 1 ], "a": [ 2, 13, 134, 286, 318 ], "newly": [ 3 ], "once-weekly": [ 4 ], "glucagon": [ 5 ], "like": [ 6 ], "peptide-1": [ 7 ], "(GLP-1)": [ 8 ], "receptor": [ 9, 344 ], "agonist,": [ 10 ], "has": [ 11 ], "showed": [ 12 ], "favorable": [ 14 ], "effect": [ 15 ], "on": [ 16, 248 ], "glycaemic": [ 17, 327 ], "control": [ 18, 105, 331 ], "and": [ 19, 37, 60, 65, 77, 98, 110, 245, 282, 310, 328, 349 ], "weight": [ 20, 73, 184, 330 ], "reduction": [ 21, 136 ], "in": [ 22, 41, 133, 137, 312 ], "type": [ 23 ], "2": [ 24 ], "diabetes": [ 25 ], "mellitus": [ 26 ], "(T2DM).": [ 27 ], "This": [ 28 ], "meta-analysis": [ 29 ], "was": [ 30, 47, 93, 308 ], "conducted": [ 31 ], "to": [ 32, 148, 162, 178, 191, 205, 219, 240, 256, 301 ], "evaluate": [ 33 ], "the": [ 34, 58, 78, 122, 225, 266, 275 ], "clinical": [ 35 ], "efficacy": [ 36, 59, 69 ], "safety": [ 38, 61, 79 ], "of": [ 39, 63, 108, 112, 169, 227, 230, 277, 289, 321, 326, 332, 346 ], "semaglutide": [ 40, 64, 131, 271, 333 ], "T2DM.": [ 42 ], "Methods:": [ 43 ], "A": [ 44 ], "comprehensive": [ 45 ], "searching": [ 46 ], "performed": [ 48, 102 ], "for": [ 49, 317 ], "Phase": [ 50 ], "III": [ 51 ], "randomized": [ 52 ], "controlled": [ 53 ], "trials": [ 54 ], "(RCTs)": [ 55 ], "which": [ 56 ], "reported": [ 57 ], "data": [ 62, 70, 80 ], "other": [ 66, 129, 295, 338, 342 ], "therapies.": [ 67 ], "The": [ 68, 261, 324 ], "expressed": [ 71, 81 ], "as": [ 72, 82 ], "mean": [ 74, 141, 167 ], "difference": [ 75 ], "(WMD)": [ 76 ], "risk": [ 83, 276, 288, 320 ], "ratios": [ 84 ], "(RRs)": [ 85 ], "were": [ 86, 101, 263 ], "calculated": [ 87 ], "by": [ 88, 103 ], "employing": [ 89 ], "random-effects": [ 90 ], "model.": [ 91 ], "Heterogeneity": [ 92 ], "assessed": [ 94 ], "through": [ 95 ], "I2": [ 96 ], "test,": [ 97 ], "subgroup": [ 99 ], "analyses": [ 100 ], "different": [ 104 ], "groups,": [ 106 ], "dosage": [ 107 ], "semaglutide,": [ 109 ], "durations": [ 111 ], "follow": [ 113 ], "up.": [ 114 ], "Results:": [ 115 ], "9": [ 116 ], "RCTs": [ 117 ], "including": [ 118, 341 ], "9,773": [ 119 ], "subjects": [ 120 ], "met": [ 121 ], "inclusion": [ 123 ], "criteria.": [ 124 ], "For": [ 125, 269 ], "efficacy,": [ 126 ], "compared": [ 127, 293 ], "with": [ 128, 224, 294, 314 ], "therapies,": [ 130 ], "resulted": [ 132 ], "significant": [ 135 ], "glycosylated": [ 138 ], "hemoglobin": [ 139 ], "(weight": [ 140 ], "difference,": [ 142 ], "WMD:": [ 143 ], "-0.93%,": [ 144 ], "95%": [ 145, 159, 175, 188, 202, 216, 237, 253 ], "CI:": [ 146, 160, 176, 189, 203, 217, 238, 254 ], "-1.24": [ 147 ], "-0.62,": [ 149 ], "P": [ 150, 164, 180, 193, 207, 221, 242, 258, 303 ], "<": [ 151, 165, 181, 194, 208, 222, 259, 304 ], "0.001),": [ 152, 166, 182, 195, 209, 223 ], "fasting": [ 153 ], "plasma": [ 154, 170 ], "glucose": [ 155, 171 ], "(WMD:": [ 156, 172, 185, 199, 213, 234, 251 ], "-1.15": [ 157 ], "mmol/L,": [ 158, 174 ], "-1.67": [ 161 ], "-0.63,": [ 163 ], "self-monitoring": [ 168 ], "-1.19": [ 173 ], "-1.68": [ 177 ], "-0.70,": [ 179 ], "body": [ 183, 196, 329 ], "-3.47": [ 186 ], "kg,": [ 187 ], "-3.96": [ 190 ], "-2.98,": [ 192 ], "mass": [ 197 ], "index": [ 198 ], "-1.25": [ 200 ], "kg/m2,": [ 201 ], "-1.45": [ 204 ], "-1.04,": [ 206 ], "systolic": [ 210 ], "blood": [ 211, 232 ], "pressure": [ 212, 233 ], "-2.55": [ 214 ], "mmHg,": [ 215, 236 ], "-3.22": [ 218 ], "-1.88,": [ 220 ], "exception": [ 226 ], "negative": [ 228 ], "result": [ 229 ], "diastolic": [ 231 ], "-0.29": [ 235 ], "-0.65": [ 239 ], "0.07,": [ 241 ], "=": [ 243 ], "0.113)": [ 244 ], "increased": [ 246 ], "impact": [ 247 ], "pulse": [ 249 ], "rate": [ 250 ], "-2.21,": [ 252 ], "1.54": [ 255 ], "2.88,": [ 257 ], "0.001).": [ 260, 305 ], "results": [ 262 ], "consistent": [ 264 ], "across": [ 265 ], "key": [ 267 ], "subgroups.": [ 268 ], "safety,": [ 270 ], "did": [ 272 ], "not": [ 273 ], "increase": [ 274 ], "any": [ 278 ], "adverse": [ 279 ], "events,": [ 280 ], "hypoglycemia": [ 281 ], "pancreatitis,": [ 283 ], "but": [ 284 ], "induced": [ 285 ], "higher": [ 287 ], "gastrointestinal": [ 290, 322 ], "disorders": [ 291 ], "when": [ 292 ], "therapies": [ 296, 340 ], "(RR:": [ 297 ], "1.98,": [ 298 ], "95%CI:": [ 299 ], "1.49": [ 300 ], "2.62,": [ 302 ], "Conclusion:": [ 306 ], "Semaglutide": [ 307 ], "effective": [ 309, 336 ], "acceptable": [ 311 ], "patients": [ 313 ], "T2DM": [ 315 ], "except": [ 316 ], "high": [ 319 ], "disorders.": [ 323 ], "capacity": [ 325 ], "appeared": [ 334 ], "more": [ 335 ], "than": [ 337 ], "add-on": [ 339 ], "GLP-1": [ 343 ], "agonists": [ 345 ], "exenatide": [ 347 ], "release": [ 348 ], "dulaglutide.": [ 350 ] }, "publication_date": "2018-06-04", "publication_year": 2018, "type": "review", "cited_by_count": 47, "authors": [ { "id": "https://openalex.org/A5027495721", "display_name": "Fang\u2010Hong Shi" }, { "id": "https://openalex.org/A5100348687", "display_name": "Hao Li" }, { "id": "https://openalex.org/A5101538643", "display_name": "Min Cui" }, { "id": "https://openalex.org/A5028653401", "display_name": "Zai-Li Zhang" }, { "id": "https://openalex.org/A5062429074", "display_name": "Zhi\u2010Chun Gu" }, { "id": "https://openalex.org/A5100324637", "display_name": "Xiaoyan Liu" } ] }, { "id": "https://openalex.org/W4224024335", "doi": "https://doi.org/10.3390/ijms23084334", "title": "The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome", "abstract": { "Insulin": [ 0, 51 ], "resistance": [ 1, 52 ], "is": [ 2, 18, 28, 115 ], "documented": [ 3 ], "in": [ 4, 7, 21, 44, 53, 93, 101, 109, 138, 148, 171 ], "clamp": [ 5 ], "studies": [ 6 ], "75%": [ 8 ], "of": [ 9, 25, 32, 48, 56, 98, 105, 145, 195, 202, 206 ], "women": [ 10 ], "with": [ 11, 38, 179 ], "polycystic": [ 12 ], "ovary": [ 13 ], "syndrome": [ 14 ], "(PCOS).": [ 15 ], "Although": [ 16 ], "it": [ 17 ], "not": [ 19, 124 ], "included": [ 20 ], "the": [ 22, 62, 94, 103, 135, 203, 209 ], "diagnostic": [ 23 ], "criteria": [ 24 ], "PCOS,": [ 26, 102 ], "there": [ 27 ], "a": [ 29, 45, 90 ], "crucial": [ 30 ], "role": [ 31, 92, 104 ], "this": [ 33, 54 ], "metabolic": [ 34 ], "impairment,": [ 35 ], "which": [ 36 ], "along": [ 37 ], "hormonal": [ 39 ], "abnormalities,": [ 40 ], "increase": [ 41 ], "each": [ 42 ], "other": [ 43 ], "vicious": [ 46 ], "circle": [ 47 ], "PCOS": [ 49, 197, 207 ], "pathogenesis.": [ 50 ], "group": [ 55 ], "patients": [ 57 ], "results": [ 58 ], "from": [ 59 ], "defects": [ 60 ], "at": [ 61, 208 ], "molecular": [ 63, 210 ], "level,": [ 64 ], "including": [ 65 ], "impaired": [ 66 ], "insulin": [ 67, 139 ], "receptor-related": [ 68 ], "signaling": [ 69 ], "pathways": [ 70 ], "enhanced": [ 71 ], "by": [ 72, 127, 167 ], "obesity": [ 73, 180 ], "and": [ 74, 82, 96, 111, 156 ], "its": [ 75 ], "features:": [ 76 ], "Excess": [ 77 ], "visceral": [ 78 ], "fat,": [ 79 ], "chronic": [ 80 ], "inflammation,": [ 81, 152 ], "reactive": [ 83 ], "oxygen": [ 84 ], "species.": [ 85 ], "While": [ 86 ], "lifestyle": [ 87 ], "intervention": [ 88 ], "has": [ 89 ], "first-line": [ 91 ], "prevention": [ 95 ], "management": [ 97 ], "excess": [ 99, 177 ], "weight": [ 100, 113, 130 ], "anti-obesity": [ 106 ], "pharmacological": [ 107 ], "agents": [ 108 ], "achieving": [ 110 ], "maintaining": [ 112 ], "loss": [ 114 ], "being": [ 116 ], "increasingly": [ 117 ], "recognized.": [ 118 ], "Glucagon-like": [ 119 ], "peptide-1": [ 120 ], "receptor": [ 121 ], "agonists": [ 122 ], "(GLP1-RAs)": [ 123 ], "only": [ 125 ], "act": [ 126 ], "reducing": [ 128, 153 ], "body": [ 129 ], "but": [ 131 ], "also": [ 132, 161 ], "can": [ 133 ], "affect": [ 134 ], "mechanisms": [ 136 ], "involved": [ 137 ], "resistance,": [ 140 ], "like": [ 141 ], "an": [ 142 ], "increasing": [ 143, 168 ], "expression": [ 144 ], "glucose": [ 146 ], "transporters": [ 147 ], "insulin-dependent": [ 149 ], "tissues,": [ 150 ], "decreasing": [ 151, 182 ], "oxidative": [ 154 ], "stress,": [ 155 ], "modulating": [ 157 ], "lipid": [ 158 ], "metabolism.": [ 159 ], "They": [ 160 ], "tend": [ 162 ], "to": [ 163, 175 ], "improve": [ 164 ], "fertility": [ 165 ], "either": [ 166 ], "LH": [ 169, 185 ], "surge": [ 170 ], "hypothalamus-pituitary": [ 172 ], "inhibition": [ 173 ], "due": [ 174 ], "estrogen": [ 176 ], "connected": [ 178 ], "or": [ 181 ], "too": [ 183 ], "high": [ 184 ], "levels": [ 186 ], "accompanying": [ 187 ], "hyperinsulinemia.": [ 188 ], "GLP1-RAs": [ 189 ], "seem": [ 190 ], "promising": [ 191 ], "for": [ 192 ], "effective": [ 193 ], "treatment": [ 194 ], "obese": [ 196 ], "patients,": [ 198 ], "acting": [ 199 ], "on": [ 200 ], "one": [ 201 ], "primary": [ 204 ], "causes": [ 205 ], "level.": [ 211 ] }, "publication_date": "2022-04-14", "publication_year": 2022, "type": "review", "cited_by_count": 109, "authors": [ { "id": "https://openalex.org/A5067181066", "display_name": "Krzysztof Bednarz" }, { "id": "https://openalex.org/A5005973953", "display_name": "Karolina Kowalczyk" }, { "id": "https://openalex.org/A5057085960", "display_name": "Marlena Cwynar" }, { "id": "https://openalex.org/A5087279057", "display_name": "Dominika Czapla" }, { "id": "https://openalex.org/A5072697806", "display_name": "Wiktor Maria Czarkowski" }, { "id": "https://openalex.org/A5037472557", "display_name": "Dominika Kmita" }, { "id": "https://openalex.org/A5039983885", "display_name": "Artur Nowak" }, { "id": "https://openalex.org/A5012854665", "display_name": "Pawe\u0142 Madej" } ] }, { "id": "https://openalex.org/W2084991399", "doi": "https://doi.org/10.1371/journal.pone.0069010", "title": "The Glucagon-Like Peptide 1 Analogue, Exendin-4, Attenuates the Rewarding Properties of Psychostimulant Drugs in Mice", "abstract": { "Glucagon-like": [ 0 ], "peptide": [ 1 ], "1": [ 2 ], "(GLP-1)": [ 3 ], "is": [ 4, 16 ], "an": [ 5 ], "incretine": [ 6 ], "hormone": [ 7 ], "that": [ 8, 36, 54, 64, 103, 176, 195 ], "controls": [ 9 ], "consummatory": [ 10 ], "behavior": [ 11 ], "and": [ 12, 26, 49, 53, 59, 84, 182 ], "glucose": [ 13 ], "homeostasis.": [ 14 ], "It": [ 15 ], "released": [ 17 ], "in": [ 18, 28, 41, 69, 94, 132, 143, 155 ], "response": [ 19 ], "to": [ 20 ], "nutrient": [ 21 ], "ingestion": [ 22 ], "from": [ 23 ], "the": [ 24, 29, 46, 73, 76, 88, 148, 156, 162, 171 ], "intestine": [ 25 ], "production": [ 27 ], "brain": [ 30 ], "has": [ 31 ], "also": [ 32 ], "been": [ 33 ], "identified.": [ 34 ], "Given": [ 35, 175 ], "GLP-1": [ 37, 65, 77, 141, 149, 177 ], "receptors": [ 38, 66, 142 ], "are": [ 39, 67, 184 ], "expressed": [ 40 ], "reward": [ 42, 61, 70 ], "areas,": [ 43 ], "such": [ 44, 179 ], "as": [ 45, 117, 119, 126, 128, 180, 200 ], "nucleus": [ 47 ], "accumbens": [ 48 ], "ventral": [ 50 ], "tegmental": [ 51 ], "area,": [ 52 ], "common": [ 55 ], "mechanisms": [ 56 ], "regulate": [ 57 ], "food": [ 58 ], "drug-induced": [ 60 ], "we": [ 62, 101, 193 ], "hypothesize": [ 63 ], "involved": [ 68, 154 ], "regulation.": [ 71 ], "Herein": [ 72 ], "effect": [ 74, 112 ], "of": [ 75, 87, 99, 158, 165, 189, 202 ], "receptor": [ 78 ], "agonist": [ 79 ], "Exendin-4": [ 80 ], "(Ex4),": [ 81 ], "on": [ 82 ], "amphetamine-": [ 83, 116 ], "cocaine-induced": [ 85, 120 ], "activation": [ 86 ], "mesolimbic": [ 89, 172 ], "dopamine": [ 90, 124, 173 ], "system": [ 91, 151 ], "was": [ 92 ], "investigated": [ 93 ], "mice.": [ 95, 133 ], "In": [ 96 ], "a": [ 97, 108, 138 ], "series": [ 98 ], "experiments": [ 100 ], "show": [ 102 ], "treatment": [ 104, 188 ], "with": [ 105, 110, 170 ], "Ex4,": [ 106 ], "at": [ 107 ], "dose": [ 109 ], "no": [ 111 ], "per": [ 113 ], "se,": [ 114 ], "reduce": [ 115 ], "well": [ 118, 127 ], "locomotor": [ 121 ], "stimulation,": [ 122 ], "accumbal": [ 123 ], "release": [ 125 ], "conditioned": [ 129 ], "place": [ 130 ], "preference": [ 131 ], "Collectively": [ 134 ], "these": [ 135, 196 ], "data": [ 136 ], "propose": [ 137, 194 ], "role": [ 139 ], "for": [ 140, 187 ], "regulating": [ 144 ], "drug": [ 145, 159, 203 ], "reward.": [ 146 ], "Moreover,": [ 147 ], "signaling": [ 150 ], "may": [ 152 ], "be": [ 153, 198 ], "development": [ 157 ], "dependence": [ 160 ], "since": [ 161 ], "rewarding": [ 163 ], "effects": [ 164 ], "addictive": [ 166 ], "drugs": [ 167 ], "involves": [ 168 ], "interferences": [ 169 ], "system.": [ 174 ], "analogues,": [ 178 ], "exenatide": [ 181 ], "liraglutide,": [ 183 ], "clinically": [ 185 ], "available": [ 186 ], "type": [ 190 ], "II": [ 191 ], "diabetes,": [ 192 ], "should": [ 197 ], "elucidated": [ 199 ], "treatments": [ 201 ], "dependence.": [ 204 ] }, "publication_date": "2013-07-16", "publication_year": 2013, "type": "article", "cited_by_count": 151, "authors": [ { "id": "https://openalex.org/A5065224153", "display_name": "Emil Egecioglu" }, { "id": "https://openalex.org/A5111952789", "display_name": "J\u00f6rgen A. Engel" }, { "id": "https://openalex.org/A5011345299", "display_name": "Elisabet Jerlhag" } ] }, { "id": "https://openalex.org/W2884458055", "doi": "https://doi.org/10.1136/bmjopen-2017-019562", "title": "Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence: study protocol of a randomised, double-blinded, placebo-controlled clinical trial", "abstract": { "Introduction": [ 0 ], "Alcohol": [ 1 ], "dependence": [ 2 ], "is": [ 3, 10, 33, 128 ], "a": [ 4, 94, 120, 167, 224 ], "major": [ 5 ], "public": [ 6 ], "health": [ 7 ], "problem.": [ 8 ], "It": [ 9 ], "underdiagnosed": [ 11 ], "and": [ 12, 76, 80, 105, 152, 162, 185, 200, 215, 218 ], "undertreated.": [ 13 ], "Even": [ 14 ], "when": [ 15 ], "treated,": [ 16 ], "more": [ 17 ], "than": [ 18 ], "2/3": [ 19 ], "of": [ 20, 41, 61, 85, 132, 158, 160, 169, 229 ], "patients": [ 21, 195 ], "in": [ 22, 55, 65, 93, 130, 141, 149, 164 ], "abstinence-oriented": [ 23 ], "treatment": [ 24, 40, 108, 228 ], "will": [ 25, 90, 102, 196, 209 ], "relapse": [ 26 ], "within": [ 27 ], "the": [ 28, 59, 86, 204, 220 ], "first": [ 29 ], "year.": [ 30 ], "Thus,": [ 31 ], "there": [ 32 ], "an": [ 34 ], "urgent": [ 35 ], "need": [ 36 ], "for": [ 37, 116 ], "efficacious": [ 38 ], "medical": [ 39, 227 ], "alcohol": [ 42, 53, 143, 170, 230 ], "dependence.": [ 43, 231 ], "Glucagon-like": [ 44 ], "peptide-1": [ 45 ], "(GLP-1)": [ 46 ], "receptor": [ 47, 63 ], "stimulation": [ 48 ], "has": [ 49, 67, 189, 219 ], "proven": [ 50 ], "to": [ 51, 68, 107, 122, 174, 222 ], "reduce": [ 52 ], "consumption": [ 54, 171 ], "preclinical": [ 56 ], "experiments.": [ 57 ], "However,": [ 58 ], "effect": [ 60, 84 ], "GLP-1": [ 62 ], "agonists": [ 64 ], "humans": [ 66 ], "our": [ 69 ], "knowledge,": [ 70 ], "not": [ 71 ], "yet": [ 72 ], "been": [ 73, 190 ], "investigated.": [ 74 ], "Methods": [ 75 ], "analysis": [ 77 ], "Design,": [ 78 ], "participants": [ 79 ], "intervention": [ 81 ], ":": [ 82, 180 ], "The": [ 83, 125, 136, 206 ], "once-weekly": [ 87 ], "GLP-1-receptor-agonist": [ 88 ], "exenatide": [ 89, 113 ], "be": [ 91, 103, 197, 210 ], "investigated": [ 92 ], "double-blinded,": [ 95 ], "placebo-controlled,": [ 96 ], "randomised": [ 97, 106 ], "clinical": [ 98 ], "trial.": [ 99, 205 ], "114": [ 100 ], "outpatients": [ 101 ], "recruited": [ 104 ], "with": [ 109 ], "either": [ 110 ], "placebo": [ 111 ], "or": [ 112 ], "once": [ 114 ], "weekly": [ 115 ], "26": [ 117 ], "weeks": [ 118 ], "as": [ 119, 166 ], "supplement": [ 121 ], "cognitive\u2013behavioural": [ 123 ], "therapy.": [ 124 ], "primary": [ 126 ], "endpoint": [ 127 ], "reduction": [ 129 ], "number": [ 131 ], "\u2018heavy": [ 133 ], "drinking": [ 134 ], "days\u2019.": [ 135 ], "secondary": [ 137 ], "endpoints": [ 138 ], "include": [ 139 ], "changes": [ 140, 148, 163 ], "total": [ 142 ], "consumption,": [ 144, 147 ], "days": [ 145 ], "without": [ 146 ], "brain": [ 150 ], "activity": [ 151 ], "function,": [ 153 ], "smoking": [ 154 ], "status,": [ 155 ], "cognition,": [ 156 ], "measures": [ 157 ], "quality": [ 159 ], "life": [ 161 ], "phosphatidylethanol": [ 165 ], "biomarker": [ 168 ], "from": [ 172 ], "baseline": [ 173 ], "follow-up": [ 175 ], "at": [ 176 ], "week": [ 177 ], "26.": [ 178 ], "Status": [ 179 ], "Currently": [ 181 ], "recruiting": [ 182 ], "patients.": [ 183 ], "Ethics": [ 184 ], "dissemination": [ 186 ], "Ethical": [ 187 ], "approval": [ 188 ], "obtained.": [ 191 ], "Before": [ 192 ], "screening,": [ 193 ], "all": [ 194 ], "provided": [ 198 ], "oral": [ 199 ], "written": [ 201 ], "information": [ 202 ], "about": [ 203 ], "study": [ 207 ], "results": [ 208 ], "disseminated": [ 211 ], "by": [ 212 ], "peer-review": [ 213 ], "publications": [ 214 ], "conference": [ 216 ], "presentations": [ 217 ], "potential": [ 221 ], "reveal": [ 223 ], "completely": [ 225 ], "new": [ 226 ] }, "publication_date": "2018-07-01", "publication_year": 2018, "type": "article", "cited_by_count": 42, "authors": [ { "id": "https://openalex.org/A5007295164", "display_name": "Kerstin K Antonsen" }, { "id": "https://openalex.org/A5091141863", "display_name": "Mette Kruse Klausen" }, { "id": "https://openalex.org/A5047396778", "display_name": "Amanda Brunchmann" }, { "id": "https://openalex.org/A5042733593", "display_name": "Nina Le Dous" }, { "id": "https://openalex.org/A5006234017", "display_name": "Mathias E. Jensen" }, { "id": "https://openalex.org/A5044746918", "display_name": "Kamilla Woznica Miskowiak" }, { "id": "https://openalex.org/A5021085020", "display_name": "Patrick M. Fisher" }, { "id": "https://openalex.org/A5112006491", "display_name": "Gerda Thomsen" }, { "id": "https://openalex.org/A5047801816", "display_name": "Henrik Rindom" }, { "id": "https://openalex.org/A5036650173", "display_name": "Thomas P Fahmy" }, { "id": "https://openalex.org/A5010414376", "display_name": "Sabine Vollst\u00e4dt\u2010Klein" }, { "id": "https://openalex.org/A5073935438", "display_name": "Helene Benveniste" }, { "id": "https://openalex.org/A5002969658", "display_name": "Nora D. Volkow" }, { "id": "https://openalex.org/A5086459548", "display_name": "Ulrik Becker" }, { "id": "https://openalex.org/A5065962810", "display_name": "Claus Thorn Ekstr\u00f8m" }, { "id": "https://openalex.org/A5015895924", "display_name": "Gitte M. Knudsen" }, { "id": "https://openalex.org/A5004120950", "display_name": "Tina Vilsb\u00f8ll" }, { "id": "https://openalex.org/A5001609083", "display_name": "Anders Fink\u2010Jensen" } ] }, { "id": "https://openalex.org/W2070762414", "doi": "https://doi.org/10.1016/s0140-6736(09)60942-9", "title": "GLP-1 receptor agonists for type 2 diabetes", "abstract": null, "publication_date": "2009-06-09", "publication_year": 2009, "type": "letter", "cited_by_count": 28, "authors": [ { "id": "https://openalex.org/A5032977803", "display_name": "Christophe De Block" }, { "id": "https://openalex.org/A5111609726", "display_name": "Luc F. Van Gaal" } ] }, { "id": "https://openalex.org/W3087618888", "doi": "https://doi.org/10.4081/ejh.2020.3160", "title": "\u03b2-catenin mediates the effect of GLP-1 receptor agonist on ameliorating hepatic steatosis induced by high fructose diet", "abstract": { "The": [ 0 ], "hypoglycemic": [ 1 ], "drug": [ 2, 188, 207 ], "GLP-1": [ 3, 38, 47, 57, 83, 162, 180 ], "receptor": [ 4, 48, 58, 84, 163, 181 ], "agonist": [ 5, 59, 85, 164, 182 ], "can": [ 6 ], "ameliorate": [ 7, 166 ], "hepatic": [ 8, 62, 106, 119, 167 ], "steatosis": [ 9, 63, 107, 120, 168 ], "but": [ 10 ], "the": [ 11, 33, 44, 90, 97, 105, 109, 114, 118, 127, 137, 143, 148, 190, 198, 206 ], "mechanism": [ 12 ], "is": [ 13, 32 ], "not": [ 14 ], "clear.": [ 15 ], "Intake": [ 16 ], "of": [ 17, 46, 92, 102, 108, 116, 132, 142, 156, 192 ], "high": [ 18, 66, 73, 123, 171 ], "fructose": [ 19, 74, 124, 172 ], "leads": [ 20 ], "to": [ 21 ], "non-alcoholic": [ 22, 193 ], "fatty": [ 23, 194 ], "liver": [ 24, 195 ], "disease": [ 25 ], "by": [ 26, 65, 122, 170, 173 ], "stimulating": [ 27 ], "lipid": [ 28, 93 ], "synthesis,": [ 29 ], "and": [ 30, 79, 99, 104, 130, 136, 139, 147, 154, 197 ], "\u03b2-catenin": [ 31, 54, 133, 174, 199 ], "key": [ 34, 150 ], "molecule": [ 35 ], "for": [ 36, 76, 87, 189, 205 ], "realizing": [ 37 ], "function": [ 39 ], "in": [ 40, 49 ], "extrahepatic": [ 41 ], "tissues;": [ 42 ], "with": [ 43, 72, 82 ], "discovery": [ 45 ], "liver,": [ 50 ], "we": [ 51 ], "speculate": [ 52 ], "that": [ 53 ], "might": [ 55 ], "mediate": [ 56 ], "on": [ 60 ], "ameliorating": [ 61 ], "induced": [ 64, 121, 169 ], "fructose.": [ 67 ], "Wistar": [ 68 ], "rats": [ 69, 110 ], "were": [ 70, 111, 134, 160 ], "fed": [ 71 ], "diet": [ 75 ], "8": [ 77 ], "weeks": [ 78 ], "then": [ 80 ], "treated": [ 81 ], "exenatide": [ 86 ], "4": [ 88 ], "weeks;": [ 89 ], "changes": [ 91 ], "synthesis": [ 94 ], "pathway": [ 95 ], "factors,": [ 96 ], "expression": [ 98, 131, 141 ], "nuclear": [ 100, 128 ], "translocation": [ 101, 129 ], "\u03b2-catenin,": [ 103 ], "observed.": [ 112 ], "After": [ 113 ], "intervention": [ 115 ], "exenatide,": [ 117 ], "was": [ 125 ], "improved,": [ 126 ], "facilitated,": [ 135 ], "mRNA": [ 138 ], "protein": [ 140 ], "upstream": [ 144 ], "regulator": [ 145 ], "SREBP-1": [ 146 ], "downstream": [ 149 ], "enzymes": [ 151 ], "ACC,": [ 152 ], "FAS": [ 153 ], "SCD-1": [ 155 ], "de": [ 157, 176 ], "novo": [ 158, 177 ], "lipogenesis": [ 159, 178 ], "down-regulated.": [ 161 ], "may": [ 165, 183, 200 ], "regulating": [ 175 ], "pathway.": [ 179 ], "be": [ 184, 201 ], "a": [ 185 ], "potential": [ 186 ], "new": [ 187 ], "treatment": [ 191 ], "disease,": [ 196 ], "an": [ 202 ], "important": [ 203 ], "target": [ 204 ], "therapy.": [ 208 ] }, "publication_date": "2020-09-15", "publication_year": 2020, "type": "article", "cited_by_count": 20, "authors": [ { "id": "https://openalex.org/A5029834763", "display_name": "Zhe Gao" }, { "id": "https://openalex.org/A5054071082", "display_name": "Guangyao Song" }, { "id": "https://openalex.org/A5004042766", "display_name": "Luping Ren" }, { "id": "https://openalex.org/A5050527113", "display_name": "Huijuan Ma" }, { "id": "https://openalex.org/A5013183732", "display_name": "Boqing Ma" }, { "id": "https://openalex.org/A5022962573", "display_name": "Shuchun Chen" } ] }, { "id": "https://openalex.org/W2550818850", "doi": "https://doi.org/10.1080/14740338.2016.1221402", "title": "Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review", "abstract": { "Attaining": [ 0 ], "optimal": [ 1 ], "glycemic": [ 2, 25 ], "targets": [ 3 ], "in": [ 4, 92 ], "patients": [ 5 ], "with": [ 6, 101, 131, 134, 145, 152 ], "type": [ 7 ], "2": [ 8, 93 ], "diabetes": [ 9 ], "is": [ 10 ], "often": [ 11 ], "hard": [ 12 ], "and": [ 13, 37, 123, 155 ], "compromised": [ 14 ], "by": [ 15 ], "the": [ 16, 19, 47, 65, 121, 124, 146 ], "shortcomings": [ 17 ], "of": [ 18, 33, 50, 57, 126, 148 ], "several": [ 20 ], "treatments.": [ 21 ], "Areas": [ 22 ], "covered:": [ 23 ], "When": [ 24 ], "levels": [ 26 ], "are": [ 27 ], "not": [ 28 ], "adequately": [ 29 ], "controlled,": [ 30 ], "an": [ 31, 78, 85 ], "association": [ 32 ], "GLP-1": [ 34, 71, 87, 98, 128 ], "receptor": [ 35, 72, 88, 99, 129 ], "agonists": [ 36, 73, 89, 100, 130 ], "insulin": [ 38, 82, 104, 112 ], "therapy": [ 39 ], "can": [ 40 ], "be": [ 41 ], "adopted.": [ 42 ], "In": [ 43, 68 ], "order": [ 44 ], "to": [ 45, 77, 84, 109 ], "assess": [ 46 ], "benefit/risk": [ 48 ], "profile": [ 49 ], "this": [ 51 ], "combination": [ 52 ], "therapy,": [ 53 ], "a": [ 54, 106 ], "literature": [ 55 ], "search": [ 56 ], "randomized": [ 58 ], "clinical": [ 59 ], "trials": [ 60, 63, 117 ], "was": [ 61 ], "performed.Eighteen": [ 62 ], "matched": [ 64 ], "inclusion": [ 66 ], "criteria.": [ 67 ], "10": [ 69 ], "studies,": [ 70 ], "were": [ 74 ], "added": [ 75, 83 ], "on": [ 76 ], "existing": [ 79, 86 ], "regimen,": [ 80 ], "whereas": [ 81 ], "regimen": [ 90 ], "occurred": [ 91 ], "studies.": [ 94 ], "Six": [ 95 ], "studies": [ 96, 136 ], "compared": [ 97, 144 ], "short": [ 102 ], "acting": [ 103 ], "as": [ 105, 143 ], "treatment": [ 107 ], "strategy": [ 108 ], "intensify": [ 110 ], "basal": [ 111, 132 ], "therapy.": [ 113 ], "Expert": [ 114 ], "opinion:": [ 115 ], "Clinical": [ 116 ], "herein": [ 118 ], "reviewed": [ 119 ], "demonstrated": [ 120 ], "safety": [ 122 ], "efficacy": [ 125 ], "combining": [ 127 ], "insulin,": [ 133, 150 ], "most": [ 135 ], "showing": [ 137 ], "equal": [ 138 ], "or": [ 139 ], "slightly": [ 140 ], "superior": [ 141 ], "efficacy,": [ 142 ], "addition": [ 147 ], "prandial": [ 149 ], "associated": [ 151 ], "weight": [ 153 ], "loss": [ 154 ], "less": [ 156 ], "hypoglycemia.": [ 157 ] }, "publication_date": "2016-11-22", "publication_year": 2016, "type": "review", "cited_by_count": 30, "authors": [ { "id": "https://openalex.org/A5090319341", "display_name": "Daniela Cimmaruta" }, { "id": "https://openalex.org/A5043443418", "display_name": "Maria Ida Maiorino" }, { "id": "https://openalex.org/A5085998598", "display_name": "Cristina Scavone" }, { "id": "https://openalex.org/A5084091332", "display_name": "Liberata Sportiello" }, { "id": "https://openalex.org/A5101446132", "display_name": "Francesca Rossi" }, { "id": "https://openalex.org/A5056173815", "display_name": "Dario Giugliano" }, { "id": "https://openalex.org/A5052044111", "display_name": "Katherine Esposito" }, { "id": "https://openalex.org/A5005557373", "display_name": "Annalisa Capuano" } ] }, { "id": "https://openalex.org/W1992055007", "doi": "https://doi.org/10.1111/dom.12479", "title": "Safety and efficacy of once\u2010weekly dulaglutide versus sitagliptin after 2\u2009years in metformin\u2010treated patients with type 2 diabetes ( AWARD \u20105): a randomized, phase III study", "abstract": { "Aims": [ 0 ], "To": [ 1 ], "compare": [ 2 ], "the": [ 3, 13, 70, 95, 105 ], "once\u2010weekly": [ 4 ], "glucagon\u2010like": [ 5 ], "peptide\u20101": [ 6 ], "(": [ 7, 16, 63 ], "GLP": [ 8 ], "\u20101)": [ 9 ], "receptor": [ 10 ], "dulaglutide": [ 11, 40, 101, 145, 148, 158, 167, 199, 243 ], "with": [ 12, 79, 166, 175, 198, 256 ], "dipeptidyl": [ 14 ], "peptidase\u20104": [ 15 ], "DPP": [ 17 ], "\u20104)": [ 18 ], "inhibitor": [ 19 ], "sitagliptin": [ 20, 46, 103, 179, 205, 252 ], "after": [ 21 ], "104": [ 22, 50, 113, 254 ], "weeks": [ 23, 51, 114 ], "of": [ 24, 76 ], "treatment.": [ 25 ], "Methods": [ 26 ], "This": [ 27 ], "AWARD": [ 28 ], "\u20105": [ 29 ], "study": [ 30 ], "was": [ 31, 69, 164 ], "a": [ 32 ], "multicentre,": [ 33 ], "double\u2010blind": [ 34 ], "trial": [ 35 ], "that": [ 36 ], "randomized": [ 37 ], "participants": [ 38, 78 ], "to": [ 39 ], "(1.5": [ 41 ], "or": [ 42, 45, 52 ], "0.75": [ 43, 149, 176, 202 ], "mg)": [ 44 ], "100": [ 47 ], "mg": [ 48, 150, 169, 177, 203, 245 ], "for": [ 49, 56, 100, 144 ], "placebo": [ 53 ], "(reported": [ 54 ], "separately)": [ 55 ], "26": [ 57 ], "weeks.": [ 58 ], "Change": [ 59 ], "in": [ 60, 110, 247 ], "glycated": [ 61 ], "haemoglobin": [ 62 ], "HbA1c": [ 64, 80, 111 ], ")": [ 65 ], "concentration": [ 66 ], "from": [ 67 ], "baseline": [ 68 ], "primary": [ 71 ], "efficacy": [ 72 ], "measure.": [ 73 ], "A": [ 74 ], "total": [ 75 ], "1098": [ 77 ], "concentrations": [ 81 ], "\u22657.0%": [ 82 ], "(\u226553.0": [ 83 ], "mmol/mol)": [ 84, 88, 135, 143 ], "and": [ 85, 91, 102, 136, 151, 173, 186, 201, 208, 214, 220, 228, 242 ], "\u22649.5%": [ 86 ], "(\u226480.3": [ 87 ], "were": [ 89, 115, 195, 231 ], "randomized,": [ 90 ], "657": [ 92 ], "(59.8%)": [ 93 ], "completed": [ 94 ], "study.": [ 96 ], "We": [ 97 ], "report": [ 98 ], "results": [ 99 ], "at": [ 104, 112, 253 ], "final": [ 106 ], "endpoint.": [ 107 ], "Results": [ 108 ], "Changes": [ 109 ], "(least": [ 116 ], "squares": [ 117 ], "mean": [ 118 ], "\u00b1": [ 119, 123, 126, 130, 133, 138, 141, 181, 184, 188 ], "standard": [ 120 ], "error)": [ 121 ], "\u22120.99": [ 122 ], "0.06%": [ 124, 139 ], "(\u221210.82": [ 125 ], "0.66": [ 127, 142 ], "mmol/mol),": [ 128 ], "\u22120.71": [ 129 ], "0.07%": [ 131 ], "(\u22127.76": [ 132 ], "0.77": [ 134 ], "\u22120.32": [ 137 ], "(\u22123.50": [ 140 ], "1.5": [ 146, 168, 200, 244 ], "mg,": [ 147 ], "sitagliptin,": [ 152 ], "respectively": [ 153 ], "(p": [ 154, 170 ], "<": [ 155, 171 ], "0.001,": [ 156 ], "both": [ 157 ], "doses": [ 159, 237 ], "vs": [ 160, 210, 216, 222 ], "sitagliptin).": [ 161 ], "Weight": [ 162 ], "loss": [ 163 ], "greater": [ 165, 248 ], "0.001)": [ 172 ], "similar": [ 174, 232 ], "versus": [ 178, 204, 251 ], "(2.88": [ 180 ], "0.25,": [ 182 ], "2.39": [ 183 ], "0.26": [ 185 ], "1.75": [ 187 ], "0.25": [ 189 ], "kg,": [ 190 ], "respectively).": [ 191, 224 ], "Gastrointestinal": [ 192 ], "adverse": [ 193 ], "events": [ 194 ], "more": [ 196 ], "common": [ 197 ], "(nausea": [ 206 ], "17": [ 207 ], "15%": [ 209 ], "7%,": [ 211 ], "diarrhoea": [ 212 ], "16": [ 213 ], "12%": [ 215 ], "6%,": [ 217 ], "vomiting": [ 218 ], "14": [ 219 ], "8%": [ 221 ], "4%": [ 223 ], "Pancreatic,": [ 225 ], "thyroid,": [ 226 ], "cardiovascular": [ 227 ], "hypersensitivity": [ 229 ], "safety": [ 230 ], "across": [ 233 ], "groups.": [ 234 ], "Conclusions": [ 235 ], "Dulaglutide": [ 236 ], "provided": [ 238 ], "superior": [ 239 ], "glycaemic": [ 240 ], "control": [ 241 ], "resulted": [ 246 ], "weight": [ 249 ], "reduction": [ 250 ], "weeks,": [ 255 ], "acceptable": [ 257 ], "safety.": [ 258 ] }, "publication_date": "2015-04-23", "publication_year": 2015, "type": "article", "cited_by_count": 139, "authors": [ { "id": "https://openalex.org/A5080916339", "display_name": "Ruth S. Weinstock" }, { "id": "https://openalex.org/A5064287355", "display_name": "Bruno Guerci" }, { "id": "https://openalex.org/A5061058170", "display_name": "Guillermo E. Umpierrez" }, { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5010436601", "display_name": "Zachary Skrivanek" }, { "id": "https://openalex.org/A5024563374", "display_name": "Zvonko Mili\u010devi\u0107" } ] }, { "id": "https://openalex.org/W1976287166", "doi": "https://doi.org/10.1016/j.clinthera.2007.11.006", "title": "Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial", "abstract": null, "publication_date": "2007-11-01", "publication_year": 2007, "type": "article", "cited_by_count": 240, "authors": [ { "id": "https://openalex.org/A5023295361", "display_name": "Anthony Barnett" }, { "id": "https://openalex.org/A5000895745", "display_name": "Jude Burger" }, { "id": "https://openalex.org/A5071736666", "display_name": "Don Johns" }, { "id": "https://openalex.org/A5109961740", "display_name": "Robert G. Brodows" }, { "id": "https://openalex.org/A5013350892", "display_name": "David M. Kendall" }, { "id": "https://openalex.org/A5079857137", "display_name": "Anthony Roberts" }, { "id": "https://openalex.org/A5062021087", "display_name": "Michael Trautmann" } ] }, { "id": "https://openalex.org/W4376619668", "doi": "https://doi.org/10.23736/s2724-6507.20.03219-8", "title": "Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials", "abstract": { "An": [ 0 ], "association": [ 1, 148 ], "between": [ 2 ], "glucagon-like": [ 3 ], "peptide-1": [ 4 ], "receptor": [ 5, 54, 84, 92 ], "agonists": [ 6, 55 ], "(GLP1-RA)": [ 7 ], "and": [ 8, 12, 80, 139, 156 ], "risk": [ 9, 167 ], "of": [ 10, 46, 128, 166 ], "pancreatitis": [ 11, 138, 150, 169 ], "pancreatic": [ 13, 99, 140, 157, 175 ], "cancer": [ 14, 100, 158, 176 ], "has": [ 15 ], "been": [ 16, 31 ], "suggested.": [ 17 ], "Since": [ 18 ], "its": [ 19 ], "first": [ 20 ], "description,": [ 21 ], "several": [ 22 ], "new": [ 23 ], "trials": [ 24, 130 ], "(including": [ 25 ], "three": [ 26 ], "cardiovascular": [ 27 ], "outcome": [ 28 ], "trials)": [ 29 ], "have": [ 30 ], "published,": [ 32 ], "substantially": [ 33 ], "increasing": [ 34 ], "the": [ 35, 41, 47 ], "available": [ 36 ], "data": [ 37, 136, 173 ], "set.": [ 38 ], "This": [ 39 ], "suggests": [ 40 ], "need": [ 42 ], "for": [ 43, 52, 118, 168 ], "an": [ 44, 124 ], "update": [ 45 ], "previous": [ 48 ], "meta-analysis.A": [ 49 ], "Medline": [ 50 ], "search": [ 51 ], "GLP-1": [ 53, 83, 144 ], "(exenatide,": [ 56 ], "liraglutide,": [ 57 ], "lixisenatide,": [ 58 ], "albiglutide,": [ 59 ], "dulaglutide,": [ 60 ], "or": [ 61, 88 ], "semaglutide)": [ 62 ], "was": [ 63, 116, 142, 170 ], "performed,": [ 64 ], "collecting": [ 65 ], "all": [ 66, 119 ], "randomized": [ 67 ], "clinical": [ 68 ], "trials,": [ 69 ], "with": [ 70, 76, 86, 110, 149 ], "duration": [ 71 ], "\u226552": [ 72 ], "weeks,": [ 73 ], "enrolling": [ 74 ], "patients": [ 75 ], "type": [ 77 ], "2": [ 78 ], "diabetes,": [ 79 ], "comparing": [ 81 ], "a": [ 82 ], "agonist": [ 85, 93 ], "placebo": [ 87 ], "any": [ 89, 182 ], "other": [ 90 ], "non-GLP-1": [ 91 ], "drug.": [ 94 ], "The": [ 95 ], "endpoints": [ 96 ], "were": [ 97 ], "pancreatitis,": [ 98 ], "reported": [ 101 ], "as": [ 102 ], "serious": [ 103 ], "adverse": [ 104 ], "events.": [ 105 ], "Mantel-Haenszel": [ 106 ], "Odds": [ 107 ], "Ratio": [ 108 ], "(MH-OR)": [ 109 ], "95%": [ 111 ], "confidence": [ 112 ], "interval": [ 113 ], "(95%": [ 114 ], "CI)": [ 115 ], "calculated": [ 117 ], "outcomes": [ 120 ], "defined": [ 121 ], "above,": [ 122 ], "on": [ 123, 137, 174 ], "intention-to-treat": [ 125 ], "basis.A": [ 126 ], "total": [ 127 ], "43": [ 129 ], "fulfilling": [ 131 ], "inclusion": [ 132 ], "criteria": [ 133 ], "(all": [ 134 ], "reporting": [ 135 ], "cancer)": [ 141 ], "identified.": [ 143 ], "RA": [ 145 ], "showed": [ 146 ], "no": [ 147 ], "(MH-OR": [ 151, 159 ], "1.24": [ 152 ], "[0.94,": [ 153 ], "1.64];": [ 154 ], "P=0.13)": [ 155 ], "1.28": [ 160 ], "[0.87,": [ 161 ], "1.89];": [ 162 ], "P=0.20).No": [ 163 ], "clear": [ 164 ], "evidence": [ 165 ], "observed,": [ 171 ], "whereas": [ 172 ], "are": [ 177 ], "too": [ 178 ], "scarce": [ 179 ], "to": [ 180 ], "draw": [ 181 ], "conclusion.": [ 183 ] }, "publication_date": "2023-05-01", "publication_year": 2023, "type": "article", "cited_by_count": 48, "authors": [ { "id": "https://openalex.org/A5052431647", "display_name": "Besmir Nreu" }, { "id": "https://openalex.org/A5014780759", "display_name": "Ilaria Dicembrini" }, { "id": "https://openalex.org/A5051991791", "display_name": "Federico Tinti" }, { "id": "https://openalex.org/A5059685674", "display_name": "Edoardo Mannucci" }, { "id": "https://openalex.org/A5059413618", "display_name": "Matteo Monami" } ] }, { "id": "https://openalex.org/W3202116011", "doi": "https://doi.org/10.1111/apt.16608", "title": "Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non\u2010alcoholic fatty liver disease assessed by magnetic resonance imaging", "abstract": { "Summary": [ 0 ], "Background": [ 1 ], "Glucagon\u2010like": [ 2 ], "peptide\u20101": [ 3 ], "receptor": [ 4 ], "agonists": [ 5 ], "may": [ 6 ], "be": [ 7 ], "a": [ 8, 183, 255 ], "treatment": [ 9, 125, 158 ], "option": [ 10 ], "in": [ 11, 32, 82, 110, 137, 149, 187, 204, 220, 223, 248 ], "patients": [ 12 ], "with": [ 13, 34, 51, 155, 191, 215, 225, 242, 246 ], "non\u2010alcoholic": [ 14 ], "fatty": [ 15 ], "liver": [ 16, 27, 30, 52, 62, 83, 111, 138, 150, 188, 205, 221, 239, 249 ], "disease": [ 17, 259 ], "(NAFLD).": [ 18 ], "Aims": [ 19 ], "To": [ 20 ], "investigate": [ 21 ], "the": [ 22 ], "effects": [ 23 ], "of": [ 24 ], "semaglutide": [ 25, 96, 118, 156, 192, 232, 236 ], "on": [ 26, 258 ], "stiffness": [ 28, 53, 84, 112, 139, 222 ], "and": [ 29, 61, 119, 172, 179, 197, 209, 233, 251, 261 ], "fat": [ 31, 69, 189 ], "subjects": [ 33, 50, 90, 181, 224 ], "NAFLD": [ 35, 226 ], "using": [ 36 ], "non\u2010invasive": [ 37 ], "magnetic": [ 38, 57 ], "resonance": [ 39, 58 ], "imaging": [ 40 ], "(MRI)": [ 41 ], "methods.": [ 42 ], "Methods": [ 43 ], "This": [ 44 ], "randomised,": [ 45 ], "double\u2010blind,": [ 46 ], "placebo\u2010controlled": [ 47 ], "trial": [ 48 ], "enrolled": [ 49 ], "2.50\u20104.63": [ 54 ], "kPa": [ 55 ], "by": [ 56, 65, 86 ], "elastography": [ 59 ], "(MRE)": [ 60 ], "steatosis": [ 63, 151, 240 ], "\u226510%": [ 64 ], "MRI": [ 66 ], "proton": [ 67 ], "density": [ 68 ], "fraction": [ 70 ], "(MRI\u2010PDFF).": [ 71 ], "The": [ 72, 218 ], "primary": [ 73 ], "endpoint": [ 74 ], "was": [ 75, 113, 227 ], "change": [ 76, 219 ], "from": [ 77, 108 ], "baseline": [ 78, 109 ], "to": [ 79, 93 ], "week": [ 80, 122 ], "48": [ 81, 123, 196 ], "assessed": [ 85 ], "MRE.": [ 87 ], "Results": [ 88 ], "Sixty\u2010seven": [ 89 ], "were": [ 91, 140, 152, 212 ], "randomised": [ 92 ], "once\u2010daily": [ 94 ], "subcutaneous": [ 95 ], "0.4": [ 97 ], "mg": [ 98 ], "(n": [ 99, 104 ], "=": [ 100, 105, 133, 164 ], "34)": [ 101 ], "or": [ 102, 146 ], "placebo": [ 103, 120, 243 ], "33).": [ 106 ], "Change": [ 107 ], "not": [ 114, 141, 228 ], "significantly": [ 115, 153, 229, 237 ], "different": [ 116, 230 ], "between": [ 117, 231 ], "at": [ 121, 143, 193 ], "(estimated": [ 124, 157 ], "ratio": [ 126 ], "0.96": [ 127 ], "(95%": [ 128 ], "CI": [ 129 ], "0.89,": [ 130 ], "1.03;": [ 131 ], "P": [ 132, 163, 169, 176, 200 ], "0.2798);": [ 134 ], "significant": [ 135 ], "differences": [ 136 ], "observed": [ 142, 214 ], "weeks": [ 144, 194 ], "24": [ 145 ], "72.": [ 147 ], "Reductions": [ 148 ], "greater": [ 154 ], "ratios:": [ 159 ], "0.70": [ 160 ], "[0.59,": [ 161 ], "0.84],": [ 162 ], "0.0002;": [ 165 ], "0.47": [ 166 ], "[0.36,": [ 167 ], "0.60],": [ 168 ], "<": [ 170, 177, 201 ], "0.0001;": [ 171 ], "0.50": [ 173 ], "[0.39,": [ 174 ], "0.66],": [ 175 ], "0.0001)": [ 178 ], "more": [ 180 ], "achieved": [ 182 ], "\u2265": [ 184 ], "30%": [ 185 ], "reduction": [ 186 ], "content": [ 190 ], "24,": [ 195 ], "72,": [ 198 ], "(all": [ 199 ], "0.001).": [ 202 ], "Decreases": [ 203 ], "enzymes,": [ 206 ], "body": [ 207 ], "weight": [ 208 ], "HbA": [ 210 ], "1c": [ 211 ], "also": [ 213 ], "semaglutide.": [ 216 ], "Conclusions": [ 217 ], "placebo.": [ 234 ], "However,": [ 235 ], "reduced": [ 238 ], "compared": [ 241 ], "which,": [ 244 ], "together": [ 245 ], "improvements": [ 247 ], "enzymes": [ 250 ], "metabolic": [ 252, 262 ], "parameters,": [ 253 ], "suggests": [ 254 ], "positive": [ 256 ], "impact": [ 257 ], "activity": [ 260 ], "profile.": [ 263 ], "ClinicalTrials.gov": [ 264 ], "identifier:": [ 265 ], "NCT03357380.": [ 266 ] }, "publication_date": "2021-09-27", "publication_year": 2021, "type": "article", "cited_by_count": 179, "authors": [ { "id": "https://openalex.org/A5019076349", "display_name": "Anne Flint" }, { "id": "https://openalex.org/A5067649934", "display_name": "Grit Andersen" }, { "id": "https://openalex.org/A5071795535", "display_name": "Paul Hockings" }, { "id": "https://openalex.org/A5054798676", "display_name": "L. E. B. Johansson" }, { "id": "https://openalex.org/A5113508090", "display_name": "Anni Morsing" }, { "id": "https://openalex.org/A5005490834", "display_name": "Mads Sundby Palle" }, { "id": "https://openalex.org/A5103211760", "display_name": "Thomas J. Vogl" }, { "id": "https://openalex.org/A5052059601", "display_name": "Rohit Loomba" }, { "id": "https://openalex.org/A5048747915", "display_name": "Leona Plum\u2010M\u00f6rschel" } ] }, { "id": "https://openalex.org/W4386203424", "doi": "https://doi.org/10.1038/s41591-023-02526-x", "title": "Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial", "abstract": { "Abstract": [ 0 ], "In": [ 1, 139, 181, 205 ], "the": [ 2, 34, 208, 216 ], "STEP-HFpEF": [ 3 ], "trial,": [ 4 ], "semaglutide": [ 5, 37, 113, 188 ], "improved": [ 6, 119, 189 ], "symptoms,": [ 7, 190 ], "physical": [ 8, 191 ], "limitations": [ 9, 192 ], "and": [ 10, 13, 25, 51, 54, 72, 74, 99, 106, 146, 164, 173, 193, 196, 199 ], "exercise": [ 11, 194 ], "function": [ 12, 195 ], "reduced": [ 14, 197 ], "body": [ 15, 52, 109, 152, 178, 200 ], "weight": [ 16, 110, 153, 179, 201, 219, 226 ], "in": [ 17, 43, 59, 70, 76, 143, 171, 233 ], "patients": [ 18, 234 ], "with": [ 19, 112, 150, 183, 235 ], "obesity": [ 20, 81, 123, 184, 203, 236 ], "phenotype": [ 21, 185, 237 ], "of": [ 22, 36, 186, 210, 218, 238 ], "heart": [ 23 ], "failure": [ 24 ], "preserved": [ 26 ], "ejection": [ 27 ], "fraction": [ 28 ], "(HFpEF).": [ 29 ], "This": [ 30 ], "prespecified": [ 31 ], "analysis": [ 32 ], "examined": [ 33 ], "effects": [ 35, 130 ], "on": [ 38 ], "dual": [ 39 ], "primary": [ 40 ], "endpoints": [ 41, 57 ], "(change": [ 42, 58 ], "Kansas": [ 44 ], "City": [ 45 ], "Cardiomyopathy": [ 46 ], "Questionnaire-Clinical": [ 47 ], "Summary": [ 48 ], "Score": [ 49 ], "(KCCQ-CSS)": [ 50 ], "weight)": [ 53 ], "confirmatory": [ 55 ], "secondary": [ 56 ], "6-minute": [ 60 ], "walk": [ 61 ], "distance": [ 62 ], "(6MWD),": [ 63 ], "hierarchical": [ 64 ], "composite": [ 65 ], "(death,": [ 66 ], "HF": [ 67 ], "events,": [ 68 ], "change": [ 69, 75 ], "KCCQ-CSS": [ 71, 172 ], "6MWD)": [ 73 ], "C-reactive": [ 77 ], "protein": [ 78 ], "(CRP))": [ 79 ], "across": [ 80, 122, 202 ], "classes": [ 82 ], "I\u2013III": [ 83 ], "(body": [ 84 ], "mass": [ 85 ], "index": [ 86 ], "(BMI)": [ 87 ], "30.0\u201334.9": [ 88 ], "kg": [ 89, 95, 101 ], "m": [ 90, 96, 102 ], "\u2212": [ 91, 97, 103 ], "2": [ 92, 98, 104 ], ",": [ 93 ], "35.0\u201339.9": [ 94 ], "\u226540": [ 100 ], ")": [ 105 ], "according": [ 107 ], "to": [ 108, 215 ], "reduction": [ 111, 154 ], "after": [ 114 ], "52": [ 115 ], "weeks.": [ 116 ], "Semaglutide": [ 117 ], "consistently": [ 118 ], "all": [ 120 ], "outcomes": [ 121 ], "categories": [ 124 ], "(": [ 125 ], "P": [ 126 ], "value": [ 127 ], "for": [ 128, 137, 175 ], "treatment": [ 129, 231 ], "\u00d7": [ 131 ], "BMI": [ 132 ], "interactions": [ 133 ], "=": [ 134 ], "not": [ 135 ], "significant": [ 136 ], "all).": [ 138 ], "semaglutide-treated": [ 140, 206 ], "patients,": [ 141, 207 ], "improvements": [ 142, 170 ], "KCCQ-CSS,": [ 144 ], "6MWD": [ 145, 174 ], "CRP": [ 147 ], "were": [ 148 ], "greater": [ 149 ], "larger": [ 151 ], "(for": [ 155 ], "example,": [ 156 ], "6.4-point": [ 157 ], "(95%": [ 158, 166 ], "confidence": [ 159 ], "interval": [ 160 ], "(CI):": [ 161 ], "4.1,": [ 162 ], "8.8)": [ 163 ], "14.4-m": [ 165 ], "CI:": [ 167 ], "5.5,": [ 168 ], "23.3)": [ 169 ], "each": [ 176 ], "10%": [ 177 ], "reduction).": [ 180 ], "participants": [ 182 ], "HFpEF,": [ 187 ], "inflammation": [ 198 ], "categories.": [ 204 ], "magnitude": [ 209 ], "benefit": [ 211 ], "was": [ 212 ], "directly": [ 213 ], "related": [ 214 ], "extent": [ 217 ], "loss.": [ 220 ], "Collectively,": [ 221 ], "these": [ 222 ], "data": [ 223 ], "support": [ 224 ], "semaglutide-mediated": [ 225 ], "loss": [ 227 ], "as": [ 228 ], "a": [ 229 ], "key": [ 230 ], "strategy": [ 232 ], "HFpEF.": [ 239 ], "ClinicalTrials.gov": [ 240 ], "identifier:": [ 241 ], "NCT04788511": [ 242 ], ".": [ 243 ] }, "publication_date": "2023-08-27", "publication_year": 2023, "type": "article", "cited_by_count": 167, "authors": [ { "id": "https://openalex.org/A5030461468", "display_name": "Barry A. Borlaug" }, { "id": "https://openalex.org/A5054890754", "display_name": "Dalane W. Kitzman" }, { "id": "https://openalex.org/A5084593004", "display_name": "Melanie J. Davies" }, { "id": "https://openalex.org/A5110231477", "display_name": "S\u00f8ren Rasmussen" }, { "id": "https://openalex.org/A5038572693", "display_name": "Eric Barros" }, { "id": "https://openalex.org/A5022314919", "display_name": "Javed Butler" }, { "id": "https://openalex.org/A5025504969", "display_name": "Mette Nygaard Einfeldt" }, { "id": "https://openalex.org/A5004099465", "display_name": "G. Kees Hovingh" }, { "id": "https://openalex.org/A5104272220", "display_name": "Dani\u00e9l Vega M\u00f8ller" }, { "id": "https://openalex.org/A5009535057", "display_name": "Mark C. Petrie" }, { "id": "https://openalex.org/A5005215114", "display_name": "Sanjiv J. Shah" }, { "id": "https://openalex.org/A5080334509", "display_name": "Subodh Verma" }, { "id": "https://openalex.org/A5046452701", "display_name": "Walter P. Abhayaratna" }, { "id": "https://openalex.org/A5075620293", "display_name": "Fozia Ahmed" }, { "id": "https://openalex.org/A5075949562", "display_name": "Vijay Chopra" }, { "id": "https://openalex.org/A5006527198", "display_name": "Justin A. Ezekowitz" }, { "id": "https://openalex.org/A5027994405", "display_name": "Michael Fu" }, { "id": "https://openalex.org/A5044544721", "display_name": "Hiroshi Ito" }, { "id": "https://openalex.org/A5078615816", "display_name": "Ma\u0142gorzata Lelonek" }, { "id": "https://openalex.org/A5069131955", "display_name": "Vojt\u011bch Melenovsk\u00fd" }, { "id": "https://openalex.org/A5039483633", "display_name": "Julio N\u00fa\u00f1ez" }, { "id": "https://openalex.org/A5079453333", "display_name": "Eduardo Perna" }, { "id": "https://openalex.org/A5032789207", "display_name": "Morten Schou" }, { "id": "https://openalex.org/A5060241741", "display_name": "Michele Senni" }, { "id": "https://openalex.org/A5105820804", "display_name": "Peter van der Meer" }, { "id": "https://openalex.org/A5009903680", "display_name": "Dirk von Lewinski" }, { "id": "https://openalex.org/A5039523683", "display_name": "Dennis Wolf" }, { "id": "https://openalex.org/A5052533254", "display_name": "Mikhail Kosiborod" } ] }, { "id": "https://openalex.org/W4390484551", "doi": "https://doi.org/10.1176/appi.ajp.20230922", "title": "Psychotropic Drug\u2013Related Weight Gain and Its Treatment", "abstract": { "Psychotropic": [ 0 ], "drug-related": [ 1 ], "weight": [ 2, 86, 92 ], "gain": [ 3, 93 ], "(PDWG)": [ 4 ], "is": [ 5, 10, 83, 94, 114, 126 ], "a": [ 6 ], "common": [ 7 ], "occurrence": [ 8 ], "and": [ 9, 16, 30, 53, 75, 104, 135, 139, 185 ], "highly": [ 11 ], "associated": [ 12, 31, 84 ], "with": [ 13, 18, 24, 67, 85, 116, 161, 181 ], "non-initiation,": [ 14 ], "discontinuation,": [ 15 ], "dissatisfaction": [ 17 ], "psychiatric": [ 19, 40, 112 ], "drugs.": [ 20 ], "Moreover,": [ 21 ], "PDWG": [ 22, 48, 74, 110, 158, 175 ], "intersects": [ 23 ], "the": [ 25, 39, 56, 88, 122, 127, 133 ], "elevated": [ 26 ], "risk": [ 27 ], "for": [ 28, 47, 50, 73, 107, 144, 157, 171, 174 ], "obesity": [ 29, 108 ], "morbidity": [ 32 ], "that": [ 33, 44, 120 ], "has": [ 34 ], "been": [ 35 ], "amply": [ 36 ], "reported": [ 37 ], "in": [ 38, 111, 121, 132 ], "population.": [ 41, 124 ], "Evidence": [ 42 ], "indicates": [ 43 ], "differential": [ 45 ], "liability": [ 46, 72 ], "exists": [ 49 ], "antipsychotics,": [ 51 ], "antidepressants,": [ 52 ], "anticonvulsants.": [ 54 ], "During": [ 55 ], "past": [ 57 ], "two": [ 58 ], "decades,": [ 59 ], "agents": [ 60 ], "within": [ 61 ], "these": [ 62 ], "classes": [ 63 ], "have": [ 64 ], "become": [ 65 ], "available": [ 66 ], "significantly": [ 68, 95 ], "lower": [ 69, 96 ], "or": [ 70 ], "no": [ 71 ], "as": [ 76, 193, 195 ], "such": [ 77 ], "should": [ 78 ], "be": [ 79 ], "prioritized.": [ 80 ], "Although": [ 81 ], "lithium": [ 82 ], "gain,": [ 87 ], "overall": [ 89 ], "extent": [ 90 ], "of": [ 91, 102, 137 ], "than": [ 97 ], "previously": [ 98 ], "estimated.": [ 99 ], "The": [ 100 ], "benefit": [ 101 ], "lifestyle": [ 103 ], "behavioral": [ 105 ], "modification": [ 106 ], "and/or": [ 109 ], "populations": [ 113 ], "established,": [ 115 ], "effectiveness": [ 117 ], "similar": [ 118 ], "to": [ 119 ], "general": [ 123 ], "Metformin": [ 125 ], "most": [ 128 ], "studied": [ 129 ], "pharmacological": [ 130 ], "treatment": [ 131, 136, 173 ], "prevention": [ 134 ], "PDWG,": [ 138 ], "promising": [ 140 ], "data": [ 141, 163 ], "are": [ 142, 159 ], "emerging": [ 143 ], "glucagon-like": [ 145 ], "peptide-1": [ 146 ], "(GLP-1)": [ 147 ], "receptor": [ 148, 167, 183 ], "agonists": [ 149, 184 ], "(e.g.,": [ 150, 164, 191 ], "liraglutide,": [ 151 ], "exenatide,": [ 152 ], "semaglutide).": [ 153 ], "Most": [ 154 ], "pharmacologic": [ 155, 172 ], "antidotes": [ 156 ], "supported": [ 160 ], "low-confidence": [ 162 ], "topiramate,": [ 165 ], "histamine-2": [ 166 ], "antagonists).": [ 168 ], "Future": [ 169 ], "vistas": [ 170 ], "include": [ 176 ], "large,": [ 177 ], "adequately": [ 178 ], "controlled": [ 179 ], "studies": [ 180 ], "GLP-1": [ 182 ], "possibly": [ 186 ], "GLP-1/glucose-dependent": [ 187 ], "insulinotropic": [ 188 ], "polypeptide": [ 189 ], "co-agonists": [ 190 ], "tirzepatide)": [ 192 ], "well": [ 194 ], "specific": [ 196 ], "dietary": [ 197 ], "modifications.": [ 198 ] }, "publication_date": "2024-01-01", "publication_year": 2024, "type": "article", "cited_by_count": 78, "authors": [ { "id": "https://openalex.org/A5068850044", "display_name": "Roger S. McIntyre" }, { "id": "https://openalex.org/A5005858724", "display_name": "Angela T.H. Kwan" }, { "id": "https://openalex.org/A5050740394", "display_name": "Joshua D. Rosenblat" }, { "id": "https://openalex.org/A5072332368", "display_name": "Kayla M. Teopiz" }, { "id": "https://openalex.org/A5032613018", "display_name": "Rodrigo B. Mansur" } ] }, { "id": "https://openalex.org/W2902989158", "doi": "https://doi.org/10.1007/s13300-018-0535-9", "title": "A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes", "abstract": null, "publication_date": "2018-11-30", "publication_year": 2018, "type": "review", "cited_by_count": 74, "authors": [ { "id": "https://openalex.org/A5001555041", "display_name": "Irene Romera" }, { "id": "https://openalex.org/A5082726087", "display_name": "Ana Mar\u00eda Cebri\u00e1n Cuenca" }, { "id": "https://openalex.org/A5035188189", "display_name": "Fernando \u00c1lvarez Guisasola" }, { "id": "https://openalex.org/A5056057120", "display_name": "Fernando G\u00f3mez\u2010Peralta" }, { "id": "https://openalex.org/A5044502073", "display_name": "Jes\u00fas Reviriego" } ] }, { "id": "https://openalex.org/W2091480327", "doi": "https://doi.org/10.1111/ijcp.12361", "title": "GLP\u20101 receptor agonists vs. DPP\u20104 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?", "abstract": { "GLP-1RAs": [ 0 ], "provide": [ 1 ], "superior": [ 2 ], "glycaemic": [ 3 ], "control": [ 4 ], "and": [ 5 ], "weight": [ 6, 25 ], "loss": [ 7 ], "vs.": [ 8 ], "DPP-4": [ 9, 15 ], "inhibitors": [ 10, 16 ], "in": [ 11 ], "patients": [ 12 ], "with": [ 13 ], "T2D.": [ 14 ], "may": [ 17 ], "sometimes": [ 18 ], "be": [ 19, 41 ], "preferred": [ 20 ], "to": [ 21 ], "a": [ 22, 28, 33, 38 ], "GLP-1RA": [ 23, 39 ], "if": [ 24 ], "is": [ 26, 32 ], "not": [ 27 ], "concern,": [ 29 ], "oral": [ 30 ], "administration": [ 31 ], "desirable": [ 34 ], "feature": [ 35 ], "or": [ 36 ], "when": [ 37 ], "cannot": [ 40 ], "tolerated.": [ 42 ] }, "publication_date": "2014-02-06", "publication_year": 2014, "type": "review", "cited_by_count": 118, "authors": [ { "id": "https://openalex.org/A5062486589", "display_name": "Stephen Brunton" } ] }, { "id": "https://openalex.org/W3134470949", "doi": "https://doi.org/10.3390/jcm10050985", "title": "Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes", "abstract": { "Aims": [ 0 ], "and": [ 1, 17, 50, 84, 93, 99, 120, 208, 230, 327, 373, 387, 425 ], "methods:": [ 2 ], "The": [ 3, 241, 307 ], "aim": [ 4 ], "of": [ 5, 19, 79, 127, 141, 153, 166, 201, 232, 244, 288, 296, 336, 346, 389, 410, 423 ], "this": [ 6 ], "monocentric": [ 7 ], "retrospective": [ 8, 385 ], "observational": [ 9 ], "study": [ 10, 44, 65 ], "was": [ 11, 86, 160, 239, 249 ], "to": [ 12, 33, 68, 105, 133, 172, 236, 270, 359, 369, 394, 405 ], "evaluate": [ 13 ], "the": [ 14, 334, 395, 402, 421 ], "18-month": [ 15, 340 ], "safety": [ 16 ], "effectiveness": [ 18 ], "GLP-1": [ 20, 69, 274, 318 ], "receptor": [ 21 ], "agonist": [ 22 ], "(GLP-1": [ 23 ], "RA)": [ 24 ], "dulaglutide": [ 25 ], "(DU)": [ 26 ], "1.5": [ 27 ], "mg/once": [ 28, 61 ], "weekly": [ 29 ], "as": [ 30, 88, 286 ], "an": [ 31 ], "add-on": [ 32 ], "metformin": [ 34 ], "(MET)": [ 35 ], "or": [ 36, 301, 412 ], "MET": [ 37, 411, 413 ], "plus": [ 38, 414 ], "conventional": [ 39, 264 ], "insulin": [ 40, 265, 415 ], "secretagogues": [ 41, 416 ], "in": [ 42, 63, 294, 330, 420 ], "a": [ 43, 64, 89, 138, 161, 190, 198, 221, 317, 342, 384, 408 ], "cohort": [ 45 ], "with": [ 46, 170, 197, 315, 320, 371, 375 ], "excess": [ 47 ], "body": [ 48, 226, 302, 328 ], "weight": [ 49, 192, 303, 329 ], "type": [ 51 ], "2": [ 52 ], "diabetes": [ 53 ], "(T2D).": [ 54 ], "Comparative": [ 55 ], "efficacy": [ 56, 97, 291, 308 ], "versus": [ 57 ], "liraglutide": [ 58 ], "(LIRA)": [ 59 ], "1.2\u20131.8": [ 60 ], "daily": [ 62 ], "sample": [ 66 ], "na\u00efve": [ 67 ], "RAs,": [ 70 ], "frequency": [ 71 ], "matching": [ 72 ], "for": [ 73, 96, 392 ], "age,": [ 74, 258 ], "gender,": [ 75, 256 ], "T2D": [ 76, 122, 260 ], "duration,": [ 77, 261 ], "degree": [ 78 ], "glycemic": [ 80, 325, 352 ], "impairment,": [ 81 ], "cardiovascular": [ 82 ], "comorbidities,": [ 83 ], "medications,": [ 85 ], "addressed": [ 87 ], "secondary": [ 90 ], "aim.": [ 91 ], "Clinical": [ 92 ], "biochemical": [ 94 ], "data": [ 95 ], "outcomes": [ 98, 309 ], "information": [ 100 ], "on": [ 101, 324, 348, 361, 407 ], "drug": [ 102, 233, 247 ], "discontinuation": [ 103, 234, 248 ], "due": [ 104, 132, 235 ], "adverse": [ 106 ], "events": [ 107 ], "(AEs)": [ 108 ], "were": [ 109, 187, 310 ], "collected": [ 110 ], "from": [ 111, 272, 363 ], "digital": [ 112 ], "records.": [ 113 ], "Results:": [ 114 ], "Initial": [ 115 ], "analysis": [ 116 ], "included": [ 117 ], "126": [ 118 ], "overweight": [ 119 ], "obese": [ 121 ], "patients": [ 123, 347 ], "(48.4%": [ 124 ], "females).": [ 125 ], "Out": [ 126 ], "these,": [ 128 ], "13": [ 129 ], "discontinued": [ 130 ], "DU": [ 131, 271, 349, 372, 406 ], "moderate\u2013severe": [ 134 ], "gastrointestinal": [ 135, 237 ], "AEs": [ 136, 238 ], "after": [ 137 ], "mean": [ 139, 163, 199 ], "follow-up": [ 140 ], "6": [ 142, 157, 206 ], "(4": [ 143 ], "standard": [ 144 ], "deviations": [ 145 ], "(SD))": [ 146 ], "months,": [ 147, 158 ], "while": [ 148 ], "65": [ 149 ], "completed": [ 150 ], "18": [ 151, 182, 213 ], "months": [ 152, 183, 207, 214 ], "continuous": [ 154 ], "therapy.": [ 155 ], "At": [ 156, 218 ], "there": [ 159 ], "significant": [ 162 ], "HbA1c": [ 164, 283, 297, 427 ], "reduction": [ 165, 200, 298 ], "\u22120.85%": [ 167 ], "(1.17": [ 168 ], "SD)": [ 169, 204, 211 ], "respect": [ 171 ], "baseline": [ 173, 225, 282, 366 ], "values": [ 174, 284 ], "(p": [ 175, 215, 377 ], "<": [ 176 ], "0.001),": [ 177 ], "which": [ 178 ], "remained": [ 179 ], "stable": [ 180 ], "during": [ 181 ], "follow-up.": [ 184 ], "These": [ 185 ], "results": [ 186 ], "accompanied": [ 188 ], "by": [ 189, 251, 312, 383 ], "moderate": [ 191 ], "loss": [ 193, 304 ], "sustained": [ 194 ], "over": [ 195 ], "time,": [ 196 ], "\u22122.0%": [ 202 ], "(4.3": [ 203 ], "at": [ 205, 212, 339, 365 ], "\u22121.3%": [ 209 ], "(4.8": [ 210 ], "=": [ 216, 378 ], "0.091).": [ 217 ], "univariate": [ 219 ], "analysis,": [ 220 ], "negative": [ 222 ], "correlation": [ 223 ], "between": [ 224 ], "mass": [ 227 ], "index": [ 228 ], "(BMI)": [ 229 ], "risk": [ 231 ], "observed.": [ 240 ], "protective": [ 242 ], "effect": [ 243 ], "obesity": [ 245, 424 ], "against": [ 246 ], "confirmed": [ 250 ], "logistic": [ 252 ], "regression": [ 253 ], "analysis.": [ 254 ], "Neither": [ 255 ], "nor": [ 257, 259, 262, 268 ], "concomitant": [ 263 ], "secretagogue": [ 266 ], "use,": [ 267 ], "switching": [ 269 ], "other": [ 273 ], "RAs": [ 275 ], "influenced": [ 276 ], "its": [ 277 ], "long-term": [ 278 ], "effectiveness.": [ 279 ], "However,": [ 280 ], "higher": [ 281 ], "emerged": [ 285 ], "predictors": [ 287 ], "clinically": [ 289 ], "relevant": [ 290 ], "outcomes,": [ 292 ], "either": [ 293 ], "terms": [ 295 ], "\u2265": [ 299, 305 ], "0.5%": [ 300 ], "5%.": [ 306 ], "corroborated": [ 311 ], "head-to-head": [ 313 ], "comparison": [ 314 ], "LIRA,": [ 316 ], "RA": [ 319 ], "durable": [ 321 ], "beneficial": [ 322, 403 ], "effects": [ 323 ], "control": [ 326 ], "real-world": [ 331 ], "experiences.": [ 332 ], "With": [ 333 ], "advantage": [ 335 ], "once-weekly": [ 337 ], "administration,": [ 338 ], "follow-up,": [ 341 ], "significantly": [ 343 ], "larger": [ 344 ], "fraction": [ 345 ], "therapy": [ 350 ], "reached": [ 351 ], "targets": [ 353 ], "(HbA1c": [ 354 ], "\u2264": [ 355 ], "7.0%)": [ 356 ], "when": [ 357 ], "compared": [ 358 ], "those": [ 360 ], "LIRA:": [ 362 ], "14.8%": [ 364 ], "(both": [ 367 ], "groups)": [ 368 ], "64.8%": [ 370 ], "42.6%": [ 374 ], "LIRA": [ 376, 393 ], "0.033).": [ 379 ], "Conclusions:": [ 380 ], "Although": [ 381 ], "limited": [ 382 ], "design": [ 386 ], "lack": [ 388 ], "constant": [ 390 ], "up-titration": [ 391 ], "highest": [ 396 ], "dose,": [ 397 ], "these": [ 398 ], "findings": [ 399 ], "indicate": [ 400 ], "that": [ 401 ], "responses": [ 404 ], "background": [ 409 ], "are": [ 417 ], "durable,": [ 418 ], "especially": [ 419 ], "presence": [ 422 ], "greater": [ 426 ], "impairment.": [ 428 ] }, "publication_date": "2021-03-02", "publication_year": 2021, "type": "article", "cited_by_count": 34, "authors": [ { "id": "https://openalex.org/A5067161558", "display_name": "Maria Mirabelli" }, { "id": "https://openalex.org/A5053969558", "display_name": "Eusebio Chiefari" }, { "id": "https://openalex.org/A5017890403", "display_name": "Vera Tocci" }, { "id": "https://openalex.org/A5012308079", "display_name": "Patrizia Caroleo" }, { "id": "https://openalex.org/A5065399264", "display_name": "Stefania Giuliano" }, { "id": "https://openalex.org/A5045188156", "display_name": "Emanuela A. Greco" }, { "id": "https://openalex.org/A5006658221", "display_name": "Ra\u00fal M. Luque" }, { "id": "https://openalex.org/A5073936683", "display_name": "Luigi Puccio" }, { "id": "https://openalex.org/A5051882371", "display_name": "Daniela Foti" }, { "id": "https://openalex.org/A5089438091", "display_name": "Ant\u00f4nio Aversa" }, { "id": "https://openalex.org/A5076502823", "display_name": "Antonio Brunetti" } ] }, { "id": "https://openalex.org/W2772389138", "doi": "https://doi.org/10.1111/dom.13167", "title": "Treatment of clozapine\u2010associated obesity and diabetes with exenatide in adults with schizophrenia: A randomized controlled trial ( CODEX )", "abstract": { "Clozapine": [ 0 ], "causes": [ 1 ], "obesity": [ 2 ], "and": [ 3, 22, 92, 137, 151, 162, 192, 200, 208 ], "type": [ 4 ], "2": [ 5, 146 ], "diabetes": [ 6 ], "(T2DM).": [ 7 ], "Glucagon\u2010like": [ 8 ], "peptide\u20101": [ 9 ], "(GLP\u20101)": [ 10 ], "receptor": [ 11 ], "agonists": [ 12 ], "(e.g.": [ 13 ], "exenatide)": [ 14 ], "can": [ 15 ], "counter": [ 16 ], "clozapine\u2010associated": [ 17, 205 ], "GLP\u20101": [ 18 ], "dysregulation": [ 19 ], "in": [ 20, 26, 88, 94, 177, 195, 203 ], "animals,": [ 21 ], "may": [ 23, 183 ], "be": [ 24, 184 ], "beneficial": [ 25 ], "people": [ 27, 102, 197 ], "on": [ 28, 103, 123 ], "clozapine.": [ 29 ], "This": [ 30 ], "randomized,": [ 31 ], "controlled,": [ 32 ], "open\u2010label,": [ 33 ], "pilot": [ 34 ], "trial": [ 35 ], "evaluated": [ 36 ], "weekly": [ 37 ], "exenatide": [ 38, 63, 90, 104, 124 ], "for": [ 39, 67, 189 ], "weight": [ 40, 79, 107, 128, 193 ], "loss": [ 41, 108, 129, 194 ], "among": [ 42 ], "clozapine\u2010treated": [ 43, 196 ], "obese": [ 44 ], "adults": [ 45 ], "with": [ 46, 48, 77, 119, 198 ], "schizophrenia,": [ 47 ], "or": [ 49, 64 ], "without": [ 50 ], "T2DM.": [ 51, 100 ], "A": [ 52 ], "total": [ 53 ], "of": [ 54, 75 ], "28": [ 55, 82 ], "outpatients": [ 56 ], "were": [ 57, 173 ], "randomized": [ 58 ], "to": [ 59 ], "once\u2010weekly": [ 60 ], "extended\u2010release": [ 61 ], "subcutaneous": [ 62 ], "usual": [ 65, 96, 112, 120 ], "care": [ 66, 97, 113 ], "24": [ 68 ], "weeks.": [ 69 ], "The": [ 70 ], "primary": [ 71 ], "outcome": [ 72 ], "was": [ 73 ], "proportion": [ 74 ], "participants": [ 76, 83, 122 ], ">5%": [ 78, 106 ], "loss.": [ 80 ], "All": [ 81 ], "completed": [ 84 ], "the": [ 85, 89, 95 ], "study;": [ 86 ], "3/14": [ 87 ], "group": [ 91, 98 ], "2/14": [ 93 ], "had": [ 99, 125 ], "Six": [ 101 ], "achieved": [ 105 ], "vs": [ 109, 131, 143, 156, 167 ], "one": [ 110 ], "receiving": [ 111 ], "(": [ 114 ], "P": [ 115, 134, 148, 159, 169 ], "=": [ 116, 135, 149, 160, 170 ], ".029).": [ 117 ], "Compared": [ 118 ], "care,": [ 121 ], "greater": [ 126 ], "mean": [ 127 ], "(\u22125.29": [ 130 ], "\u22121.12": [ 132 ], "kg;": [ 133 ], ".015)": [ 136 ], "body": [ 138 ], "mass": [ 139 ], "index": [ 140 ], "reduction": [ 141 ], "(\u22121.78": [ 142 ], "\u22120.39": [ 144 ], "kg/m": [ 145 ], ";": [ 147 ], ".019),": [ 150 ], "reduced": [ 152 ], "fasting": [ 153 ], "glucose": [ 154 ], "(\u22120.34": [ 155 ], "0.39": [ 157 ], "mmol/L;": [ 158 ], ".036)": [ 161 ], "glycated": [ 163 ], "haemoglobin": [ 164 ], "levels": [ 165 ], "(\u22120.21%": [ 166 ], "0.03%;": [ 168 ], ".004).": [ 171 ], "There": [ 172 ], "no": [ 174 ], "significant": [ 175 ], "differences": [ 176 ], "other": [ 178 ], "metabolic": [ 179 ], "syndrome": [ 180 ], "components.": [ 181 ], "Exenatide": [ 182 ], "a": [ 185 ], "promising": [ 186 ], "therapeutic": [ 187 ], "agent": [ 188 ], "glycaemic": [ 190 ], "control": [ 191 ], "obesity,": [ 199 ], "could": [ 201 ], "assist": [ 202 ], "reducing": [ 204 ], "cardio\u2010metabolic": [ 206 ], "morbidity": [ 207 ], "mortality.": [ 209 ] }, "publication_date": "2017-11-30", "publication_year": 2017, "type": "article", "cited_by_count": 79, "authors": [ { "id": "https://openalex.org/A5001271340", "display_name": "Dan Siskind" }, { "id": "https://openalex.org/A5045549568", "display_name": "Anthony Russell" }, { "id": "https://openalex.org/A5112335452", "display_name": "Clare Gamble" }, { "id": "https://openalex.org/A5057259316", "display_name": "Karl Winckel" }, { "id": "https://openalex.org/A5038996649", "display_name": "Karla Mayfield" }, { "id": "https://openalex.org/A5058569306", "display_name": "Samantha Hollingworth" }, { "id": "https://openalex.org/A5048594764", "display_name": "Ingrid J. Hickman" }, { "id": "https://openalex.org/A5003226234", "display_name": "Victor Siskind" }, { "id": "https://openalex.org/A5065763584", "display_name": "Steve Kisely" } ] }, { "id": "https://openalex.org/W1987538170", "doi": "https://doi.org/10.1111/j.1463-1326.2010.01356.x", "title": "Liraglutide, a once\u2010daily human glucagon\u2010like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes", "abstract": { "Aims:": [ 0 ], "Most": [ 1 ], "treatments": [ 2 ], "for": [ 3, 59, 67, 79, 245 ], "type": [ 4 ], "2": [ 5, 28, 112, 213, 246 ], "diabetes": [ 6 ], "fail": [ 7 ], "over": [ 8, 27 ], "time,": [ 9 ], "necessitating": [ 10 ], "combination": [ 11 ], "therapy.": [ 12 ], "We": [ 13 ], "investigated": [ 14 ], "the": [ 15, 49, 68, 80, 155 ], "safety,": [ 16 ], "tolerability": [ 17 ], "and": [ 18, 74, 84, 102, 106, 138, 180, 199, 210, 233, 250, 256 ], "efficacy": [ 19, 75 ], "of": [ 20, 104, 114, 216, 267 ], "liraglutide": [ 21, 37, 40, 125, 141, 167, 183, 202, 230 ], "monotherapy": [ 22, 26, 244 ], "compared": [ 23, 236, 259 ], "with": [ 24, 120, 124, 140, 162, 166, 182, 229, 237, 260 ], "glimepiride": [ 25, 44, 121, 163, 238, 261 ], "years.": [ 29 ], "Methods:": [ 30 ], "Participants": [ 31, 47 ], "were": [ 32, 65, 77, 118, 160, 226 ], "randomized": [ 33 ], "to": [ 34, 72, 133, 149, 175, 191 ], "receive": [ 35 ], "once\u2010daily": [ 36 ], "1.2": [ 38, 126, 168, 231 ], "mg,": [ 39 ], "1.8": [ 41, 142, 184, 234 ], "mg": [ 42, 127, 143, 169, 185, 232, 235 ], "or": [ 43 ], "8": [ 45 ], "mg.": [ 46 ], "completing": [ 48, 111 ], "1\u2010year": [ 50 ], "randomized,": [ 51 ], "double\u2010blind,": [ 52 ], "double\u2010dummy": [ 53 ], "period": [ 54 ], "could": [ 55 ], "continue": [ 56 ], "open\u2010label": [ 57 ], "treatment": [ 58 ], "an": [ 60 ], "additional": [ 61 ], "year.": [ 62 ], "Safety": [ 63 ], "data": [ 64, 76 ], "evaluated": [ 66, 78 ], "full": [ 69, 81 ], "population": [ 70 ], "exposed": [ 71 ], "treatment,": [ 73 ], "intention\u2010to\u2010treat": [ 82 ], "(ITT)": [ 83 ], "2\u2010year": [ 85 ], "completer": [ 86, 200 ], "populations.": [ 87 ], "Outcome": [ 88 ], "measures": [ 89 ], "included": [ 90 ], "change": [ 91 ], "in": [ 92, 206, 253 ], "glycosylated": [ 93 ], "haemoglobin": [ 94 ], "(HbA1c),": [ 95 ], "fasting": [ 96 ], "plasma": [ 97, 220 ], "glucose": [ 98, 221 ], "(FPG),": [ 99 ], "body": [ 100, 257 ], "weight": [ 101, 258 ], "frequency": [ 103 ], "nausea": [ 105 ], "hypoglycaemia.": [ 107, 268 ], "Results:": [ 108 ], "For": [ 109, 196 ], "patients": [ 110 ], "years": [ 113, 247 ], "therapy,": [ 115 ], "HbA1c": [ 116, 158 ], "reductions": [ 117, 159 ], "\u22120.6%": [ 119, 165 ], "versus": [ 122, 164 ], "\u22120.9%": [ 123, 181 ], "(difference:": [ 128, 144, 170, 186 ], "\u22120.37,": [ 129 ], "95%": [ 130, 146, 172, 188 ], "CI:": [ 131, 147, 173, 189 ], "\u22120.71": [ 132 ], "\u22120.02;": [ 134 ], "p": [ 135, 151, 177, 193 ], "=": [ 136, 152, 178 ], "0.0376)": [ 137 ], "\u22121.1%": [ 139 ], "\u22120.55,": [ 145 ], "\u22120.88": [ 148 ], "\u22120.21;": [ 150 ], "0.0016).": [ 153 ], "In": [ 154 ], "ITT": [ 156, 198 ], "population,": [ 157 ], "\u22120.3%": [ 161 ], "\u22120.31,": [ 171 ], "\u22120.54": [ 174 ], "\u22120.08;": [ 176 ], "0.0076)": [ 179 ], "\u22120.60,": [ 187 ], "\u22120.83": [ 190 ], "\u22120.38;": [ 192 ], "<": [ 194, 240 ], "0.0001).": [ 195, 241 ], "both": [ 197 ], "populations,": [ 201 ], "was": [ 203 ], "more": [ 204 ], "effective": [ 205 ], "reducing": [ 207 ], "HbA1c,": [ 208 ], "FPG": [ 209 ], "weight.": [ 211 ], "Over": [ 212 ], "years,": [ 214 ], "rates": [ 215 ], "minor": [ 217 ], "hypoglycaemia": [ 218 ], "[self\u2010treated": [ 219 ], "<3.1": [ 222 ], "mmol/l": [ 223 ], "(<56": [ 224 ], "mg/dl)]": [ 225 ], "significantly": [ 227 ], "lower": [ 228, 265 ], "(p": [ 239 ], "Conclusion:": [ 242 ], "Liraglutide": [ 243 ], "provides": [ 248 ], "significant": [ 249 ], "sustained": [ 251 ], "improvements": [ 252 ], "glycaemic": [ 254 ], "control": [ 255 ], "monotherapy,": [ 262 ], "at": [ 263 ], "a": [ 264 ], "risk": [ 266 ] }, "publication_date": "2010-12-22", "publication_year": 2010, "type": "article", "cited_by_count": 191, "authors": [ { "id": "https://openalex.org/A5111569181", "display_name": "A. J. Garber" }, { "id": "https://openalex.org/A5045462483", "display_name": "Robert R. Henry" }, { "id": "https://openalex.org/A5081205041", "display_name": "Robert E. Ratner" }, { "id": "https://openalex.org/A5023487929", "display_name": "Paula M. Hale" }, { "id": "https://openalex.org/A5039321628", "display_name": "Cheng\u2010Chieh Chang" }, { "id": "https://openalex.org/A5005036709", "display_name": "Bruce W. Bode" } ] }, { "id": "https://openalex.org/W4391485990", "doi": "https://doi.org/10.3390/ph17020199", "title": "Glucagon-like Peptide-1 Receptor Agonists Associated Gastrointestinal Adverse Events: A Cross-Sectional Analysis of the National Institutes of Health All of Us Cohort", "abstract": { "Background:": [ 0 ], "Glucagon-like": [ 1 ], "peptide-1": [ 2 ], "receptor": [ 3 ], "agonists": [ 4 ], "(GLP-1": [ 5 ], "RAs)": [ 6 ], "are": [ 7, 273 ], "commonly": [ 8 ], "used": [ 9 ], "diabetes": [ 10 ], "and": [ 11, 47, 52, 90, 124, 148, 156, 160, 170, 172, 176, 179, 186, 193, 201, 203, 280 ], "obesity": [ 12 ], "medications": [ 13 ], "but": [ 14 ], "have": [ 15 ], "been": [ 16 ], "associated": [ 17, 100 ], "with": [ 18, 72, 101, 238, 249, 284 ], "gastrointestinal": [ 19 ], "(GI)": [ 20 ], "adverse": [ 21, 29, 41, 58, 92, 103, 139, 234 ], "events.": [ 22, 104 ], "However,": [ 23 ], "real-world": [ 24, 67, 231 ], "evidence": [ 25 ], "on": [ 26, 69 ], "comparative": [ 27 ], "GI": [ 28, 40, 57, 91, 102, 138, 151, 219, 233, 243, 268 ], "reaction": [ 30, 59 ], "profiles": [ 31, 245 ], "is": [ 32 ], "limited.": [ 33 ], "Objectives:": [ 34 ], "This": [ 35, 62 ], "study": [ 36, 111 ], "aimed": [ 37 ], "to": [ 38, 190, 275 ], "evaluate": [ 39, 276 ], "events": [ 42, 93, 235 ], "among": [ 43 ], "GLP-1": [ 44, 85, 226, 239, 255, 264, 281 ], "RA": [ 45, 86, 265, 282 ], "users": [ 46, 87 ], "compare": [ 48 ], "semaglutide,": [ 49, 191 ], "dulaglutide,": [ 50 ], "liraglutide,": [ 51 ], "exenatide": [ 53, 180, 250 ], "safety": [ 54, 244, 283 ], "regarding": [ 55 ], "the": [ 56, 75, 110, 135, 182, 225, 277 ], "profile.": [ 60 ], "Methods:": [ 61 ], "retrospective": [ 63 ], "cross-sectional": [ 64 ], "analysis": [ 65 ], "utilized": [ 66 ], "data": [ 68 ], "10,328": [ 70 ], "adults": [ 71 ], "diabetes/obesity": [ 73 ], "in": [ 74, 218, 242 ], "National": [ 76 ], "Institutes": [ 77 ], "of": [ 78, 81, 109, 165, 198, 210 ], "Health": [ 79 ], "All": [ 80 ], "Us": [ 82 ], "cohort.": [ 83 ], "New": [ 84 ], "were": [ 88, 94, 119, 122, 236 ], "identified,": [ 89 ], "examined.": [ 95 ], "Logistic": [ 96 ], "regression": [ 97 ], "determined": [ 98 ], "factors": [ 99 ], "Results:": [ 105 ], "The": [ 106 ], "mean": [ 107 ], "age": [ 108 ], "population": [ 112 ], "was": [ 113, 134 ], "61.4": [ 114 ], "\u00b1": [ 115 ], "12.6": [ 116 ], "years,": [ 117 ], "65.7%": [ 118 ], "female,": [ 120 ], "51.3%": [ 121 ], "White,": [ 123 ], "they": [ 125 ], "had": [ 126, 162, 181, 195, 207 ], "a": [ 127 ], "high": [ 128 ], "comorbidity": [ 129 ], "burden.": [ 130 ], "Abdominal": [ 131 ], "pain": [ 132 ], "(57.6%)": [ 133 ], "most": [ 136 ], "common": [ 137, 237 ], "event,": [ 140 ], "followed": [ 141 ], "by": [ 142 ], "constipation": [ 143 ], "(30.4%),": [ 144 ], "diarrhea": [ 145 ], "(32.7%),": [ 146 ], "nausea": [ 147, 171, 202 ], "vomiting": [ 149, 173 ], "(23.4%),": [ 150 ], "bleeding": [ 152, 220 ], "(15.9%),": [ 153 ], "gastroparesis": [ 154, 211 ], "(5.1%),": [ 155 ], "pancreatitis": [ 157, 184, 222 ], "(3.4%).": [ 158 ], "Dulaglutide": [ 159 ], "liraglutide": [ 161, 194 ], "higher": [ 163, 196, 208 ], "rates": [ 164 ], "abdominal": [ 166, 199 ], "pain,": [ 167, 200 ], "constipation,": [ 168 ], "diarrhea,": [ 169 ], "than": [ 174, 212, 253 ], "semaglutide": [ 175 ], "exenatide.": [ 177 ], "Liraglutide": [ 178 ], "highest": [ 183 ], "(4.0%": [ 185 ], "3.8%,": [ 187 ], "respectively).": [ 188 ], "Compared": [ 189 ], "dulaglutide": [ 192 ], "odds": [ 197, 209 ], "vomiting.": [ 204 ], "They": [ 205 ], "also": [ 206 ], "semaglutide.": [ 213 ], "No": [ 214 ], "significant": [ 215 ], "differences": [ 216 ], "existed": [ 217, 246 ], "or": [ 221 ], "risks": [ 223 ], "between": [ 224, 247 ], "RAs.": [ 227, 240 ], "Conclusions:": [ 228 ], "In": [ 229 ], "this": [ 230 ], "cohort,": [ 232 ], "Differences": [ 241 ], "agents,": [ 248 ], "appearing": [ 251 ], "safer": [ 252 ], "other": [ 254 ], "RAs,": [ 256 ], "except": [ 257 ], "for": [ 258 ], "gastroparesis.": [ 259 ], "These": [ 260 ], "findings": [ 261 ], "can": [ 262 ], "inform": [ 263 ], "selection": [ 266 ], "considering": [ 267 ], "risk": [ 269 ], "factors.": [ 270 ], "Further": [ 271 ], "studies": [ 272 ], "needed": [ 274 ], "causal": [ 278 ], "relationship": [ 279 ], "concomitant": [ 285 ], "medication": [ 286 ], "use.": [ 287 ] }, "publication_date": "2024-02-02", "publication_year": 2024, "type": "article", "cited_by_count": 45, "authors": [ { "id": "https://openalex.org/A5026005763", "display_name": "Wafa Ali Aldhaleei" }, { "id": "https://openalex.org/A5061733966", "display_name": "Tadesse Melaku Abegaz" }, { "id": "https://openalex.org/A5008363918", "display_name": "Akshaya Srikanth Bhagavathula" } ] }, { "id": "https://openalex.org/W1973333544", "doi": "https://doi.org/10.1007/s40265-013-0172-6", "title": "Exenatide Twice Daily: A Review of Its Use in the Management of Patients with Type 2 Diabetes Mellitus", "abstract": null, "publication_date": "2014-01-16", "publication_year": 2014, "type": "review", "cited_by_count": 51, "authors": [ { "id": "https://openalex.org/A5001997464", "display_name": "Paul L. McCormack" } ] }, { "id": "https://openalex.org/W2550011910", "doi": "https://doi.org/10.1111/dom.12824", "title": "Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon\u2010like peptide\u20101 receptor agonists: A systematic analysis of published clinical trials", "abstract": { "Aim": [ 0 ], "GLP": [ 1, 31, 59, 105, 133, 209, 227 ], "\u20101": [ 2, 32, 60, 106, 134, 210, 228 ], "receptor": [ 3 ], "agonists": [ 4 ], "(": [ 5, 27, 126, 136, 148, 155, 168, 174 ], "RAs": [ 6, 33, 61, 107, 135, 211, 229 ], ")": [ 7, 29 ], "may": [ 8, 246 ], "cause": [ 9 ], "nausea,": [ 10, 78 ], "vomiting": [ 11, 79, 147, 173, 260 ], "or": [ 12, 80 ], "diarrhoea.": [ 13, 264 ], "The": [ 14, 49, 118 ], "aim": [ 15 ], "of": [ 16, 24, 43, 75, 98, 120 ], "this": [ 17 ], "study": [ 18 ], "was": [ 19, 52, 122, 144, 153, 163, 183, 194 ], "to": [ 20, 37, 91, 179, 191, 238 ], "assess": [ 21 ], "the": [ 22, 73, 96, 110 ], "risk": [ 23, 119, 197 ], "adverse": [ 25 ], "events": [ 26 ], "AEs": [ 28, 234 ], "with": [ 30, 58, 161, 165, 188, 199, 203, 214, 220, 232, 256, 262 ], "and": [ 34, 41, 47, 54, 71, 85, 89, 102, 130, 140, 172, 186, 201, 206, 217, 240, 245, 259 ], "their": [ 35 ], "relation": [ 36 ], "dose,": [ 38 ], "background": [ 39, 87, 241 ], "medication": [ 40 ], "duration": [ 42 ], "action.": [ 44 ], "Research": [ 45 ], "design": [ 46 ], "methods": [ 48 ], "PubMed": [ 50 ], "database": [ 51 ], "searched": [ 53 ], "32": [ 55 ], "clinical": [ 56 ], "trials": [ 57 ], "(phase": [ 62 ], "3)": [ 63 ], "were": [ 64, 212 ], "selected.": [ 65 ], "We": [ 66 ], "performed": [ 67 ], "a": [ 68, 92, 141, 195, 249 ], "systematic": [ 69 ], "analysis": [ 70 ], "compared": [ 72 ], "proportion": [ 74 ], "patients": [ 76 ], "reporting": [ 77 ], "diarrhoea,": [ 81 ], "for": [ 82, 124, 146 ], "different": [ 83 ], "doses": [ 84 ], "glucose\u2010lowering": [ 86 ], "medications,": [ 88 ], "relative": [ 90, 111 ], "reference": [ 93 ], "compound": [ 94 ], "within": [ 95 ], "subclasses": [ 97 ], "short\u2010": [ 99 ], "(exenatide": [ 100 ], "b.i.d.)": [ 101 ], "long\u2010acting": [ 103, 125 ], "(liraglutide)": [ 104 ], ",": [ 108 ], "calculating": [ 109 ], "risks": [ 112 ], "\u00b1": [ 113 ], "95%": [ 114 ], "confidence": [ 115 ], "intervals.": [ 116 ], "Results": [ 117 ], "nausea": [ 121, 167, 185, 216, 258 ], "dose\u2010dependent": [ 123, 154 ], "P": [ 127, 137, 149, 156, 169, 175 ], "=": [ 128, 138, 150, 157, 170, 176 ], ".0063)": [ 129 ], "across": [ 131 ], "all": [ 132 ], ".0017),": [ 139 ], "similar": [ 142, 196 ], "trend": [ 143 ], "observed": [ 145 ], ".23).": [ 151 ], "Diarrhoea": [ 152 ], ".031).": [ 158 ], "Background": [ 159 ], "treatment": [ 160 ], "metformin": [ 162 ], "associated": [ 164, 198, 213, 231, 255 ], "more": [ 166, 221, 263 ], ".04)": [ 171 ], ".0009).": [ 177 ], "Compared": [ 178, 190 ], "exenatide": [ 180, 204 ], "b.i.d.,": [ 181 ], "there": [ 182, 193 ], "less": [ 184, 202, 215, 257 ], "diarrhoea": [ 187, 222 ], "lixisenatide.": [ 189 ], "liraglutide,": [ 192 ], "dulaglutide,": [ 200 ], "q.w.": [ 205 ], "albiglutide.": [ 207 ], "Long\u2010acting": [ 208, 252 ], "vomiting,": [ 218 ], "but": [ 219, 261 ], "than": [ 223 ], "short\u2010acting": [ 224 ], "agents.": [ 225 ], "Conclusions": [ 226 ], "are": [ 230, 236, 254 ], "gastrointestinal": [ 233 ], "that": [ 235 ], "related": [ 237 ], "dose": [ 239 ], "medications": [ 242 ], "(especially": [ 243 ], "metformin)": [ 244 ], "vary": [ 247 ], "in": [ 248 ], "compound\u2010specific": [ 250 ], "manner.": [ 251 ], "agents": [ 253 ] }, "publication_date": "2016-11-10", "publication_year": 2016, "type": "review", "cited_by_count": 320, "authors": [ { "id": "https://openalex.org/A5022914724", "display_name": "Karolin Bettge" }, { "id": "https://openalex.org/A5055701457", "display_name": "Melanie Kahle" }, { "id": "https://openalex.org/A5057647094", "display_name": "Mirna S. Abd El Aziz" }, { "id": "https://openalex.org/A5002832666", "display_name": "Juris J. Meier" }, { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" } ] }, { "id": "https://openalex.org/W2110333911", "doi": "https://doi.org/10.1016/j.ahj.2013.07.012", "title": "Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial", "abstract": { "LEADER": [ 0, 68 ], "commenced": [ 1 ], "in": [ 2, 8, 19 ], "September": [ 3 ], "2010,": [ 4 ], "and": [ 5, 35, 53 ], "enrollment": [ 6 ], "concluded": [ 7 ], "April": [ 9 ], "2012.": [ 10 ], "There": [ 11, 45 ], "were": [ 12, 33, 46, 57 ], "9,340": [ 13 ], "patients": [ 14, 26, 49, 92 ], "enrolled": [ 15 ], "at": [ 16 ], "410": [ 17 ], "sites": [ 18 ], "32": [ 20 ], "countries.": [ 21 ], "The": [ 22 ], "mean": [ 23, 36 ], "age": [ 24 ], "of": [ 25, 77, 84, 91 ], "was": [ 27, 40 ], "64.3": [ 28 ], "\u00b1": [ 29, 42 ], "7.2": [ 30 ], "years,": [ 31 ], "64.3%": [ 32 ], "men,": [ 34 ], "body": [ 37 ], "mass": [ 38 ], "index": [ 39 ], "32.5": [ 41 ], "6.3": [ 43 ], "kg/m2.": [ 44 ], "7,592": [ 47 ], "(81.3%)": [ 48 ], "with": [ 50, 93 ], "prior": [ 51, 62 ], "CVD": [ 52 ], "1,748": [ 54 ], "(18.7%)": [ 55 ], "who": [ 56 ], "high": [ 58 ], "risk": [ 59 ], "but": [ 60 ], "without": [ 61 ], "CVD.": [ 63 ], "It": [ 64 ], "is": [ 65 ], "expected": [ 66 ], "that": [ 67 ], "will": [ 69 ], "provide": [ 70 ], "conclusive": [ 71 ], "data": [ 72 ], "regarding": [ 73 ], "the": [ 74, 81 ], "cardiovascular": [ 75 ], "safety": [ 76 ], "liraglutide": [ 78 ], "relative": [ 79 ], "to": [ 80 ], "current": [ 82 ], "standard": [ 83 ], "usual": [ 85 ], "care": [ 86 ], "for": [ 87 ], "a": [ 88 ], "global": [ 89 ], "population": [ 90 ], "T2DM.": [ 94 ] }, "publication_date": "2013-10-02", "publication_year": 2013, "type": "article", "cited_by_count": 238, "authors": [ { "id": "https://openalex.org/A5110355842", "display_name": "Steven P. Marso" }, { "id": "https://openalex.org/A5072011562", "display_name": "Neil R Poulter" }, { "id": "https://openalex.org/A5040589473", "display_name": "Steven E. Nissen" }, { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5090437675", "display_name": "Bernard Zinman" }, { "id": "https://openalex.org/A5028469549", "display_name": "Gilbert H. Daniels" }, { "id": "https://openalex.org/A5023436129", "display_name": "Stuart Pocock" }, { "id": "https://openalex.org/A5019811162", "display_name": "William M. Steinberg" }, { "id": "https://openalex.org/A5113817930", "display_name": "Richard M. Bergenstal" }, { "id": "https://openalex.org/A5043842967", "display_name": "Johannes F.E. Mann" }, { "id": "https://openalex.org/A5112384354", "display_name": "Lasse Steen Ravn" }, { "id": "https://openalex.org/A5112869255", "display_name": "Kirstine Brown Frandsen" }, { "id": "https://openalex.org/A5104132238", "display_name": "Alan C. Moses" }, { "id": "https://openalex.org/A5040182038", "display_name": "John B. Buse" } ] }, { "id": "https://openalex.org/W2057793858", "doi": "https://doi.org/10.1016/j.peptides.2012.10.006", "title": "The human glucagon-like peptide-1 analogue liraglutide regulates pancreatic beta-cell proliferation and apoptosis via an AMPK/mTOR/P70S6K signaling pathway", "abstract": null, "publication_date": "2012-10-30", "publication_year": 2012, "type": "article", "cited_by_count": 95, "authors": [ { "id": "https://openalex.org/A5108599915", "display_name": "Xinyu Miao" }, { "id": "https://openalex.org/A5109180382", "display_name": "Zhaoyan Gu" }, { "id": "https://openalex.org/A5100442376", "display_name": "Ping Liu" }, { "id": "https://openalex.org/A5007504600", "display_name": "Yuan Hu" }, { "id": "https://openalex.org/A5100412890", "display_name": "Lin Li" }, { "id": "https://openalex.org/A5101511127", "display_name": "Yanping Gong" }, { "id": "https://openalex.org/A5101679450", "display_name": "Hua Shu" }, { "id": "https://openalex.org/A5100345976", "display_name": "Yu Liu" }, { "id": "https://openalex.org/A5100388495", "display_name": "Chunlin Li" } ] }, { "id": "https://openalex.org/W3008859491", "doi": "https://doi.org/10.2147/dmso.s193693", "title": "<p>Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data</p>", "abstract": { "Glucagon-like": [ 0 ], "peptide-1": [ 1 ], "(GLP-1)": [ 2 ], "receptor": [ 3, 55, 86, 98, 131 ], "agonists": [ 4, 56, 99 ], "have": [ 5, 32 ], "been": [ 6, 122 ], "available": [ 7, 57, 95 ], "as": [ 8 ], "glucose-lowering": [ 9, 77 ], "therapies": [ 10, 78 ], "for": [ 11, 34, 118 ], "people": [ 12 ], "with": [ 13, 79 ], "type": [ 14, 74 ], "2": [ 15, 75 ], "diabetes": [ 16, 76 ], "since": [ 17 ], "2006,": [ 18 ], "when": [ 19 ], "twice-daily": [ 20 ], "exenatide": [ 21 ], "was": [ 22 ], "licenced.": [ 23 ], "Since": [ 24 ], "then,": [ 25 ], "advances": [ 26 ], "in": [ 27, 44, 58 ], "peptide": [ 28 ], "chemistry": [ 29 ], "and": [ 30, 36, 47, 90 ], "delivery": [ 31, 41 ], "allowed": [ 33 ], "once-daily": [ 35 ], "more": [ 37 ], "recently": [ 38 ], "once-weekly": [ 39 ], "(QW)": [ 40 ], "of": [ 42, 93, 113, 125, 127 ], "peptides": [ 43 ], "this": [ 45 ], "class": [ 46 ], "there": [ 48, 120 ], "are": [ 49, 100 ], "currently": [ 50 ], "three": [ 51 ], "QW": [ 52, 96, 129 ], "\"long-acting\"": [ 53 ], "GLP-1": [ 54, 85, 97, 130 ], "clinical": [ 59, 105, 135 ], "practice.": [ 60 ], "This": [ 61 ], "short": [ 62 ], "review": [ 63 ], "describes": [ 64 ], "the": [ 65, 72, 94, 114, 128 ], "therapeutic": [ 66 ], "landscape": [ 67 ], "that": [ 68 ], "is": [ 69, 109 ], "occupied": [ 70 ], "by": [ 71 ], "modern": [ 73 ], "a": [ 80 ], "particular": [ 81 ], "focus": [ 82 ], "on": [ 83, 103 ], "long-acting": [ 84 ], "agonists.": [ 87 ], "The": [ 88 ], "efficacy": [ 89 ], "side-effect": [ 91 ], "profiles": [ 92 ], "discussed,": [ 101 ], "focusing": [ 102 ], "head-to-head": [ 104 ], "trial": [ 106 ], "comparisons.": [ 107 ], "There": [ 108 ], "also": [ 110 ], "an": [ 111, 123 ], "appraisal": [ 112 ], "cardiovascular": [ 115 ], "outcome": [ 116 ], "trials,": [ 117 ], "which": [ 119 ], "has": [ 121 ], "assessment": [ 124 ], "each": [ 126 ], "agonists,": [ 132 ], "leading": [ 133 ], "to": [ 134 ], "conclusions": [ 136 ], "regarding": [ 137 ], "their": [ 138 ], "comparative": [ 139 ], "effectiveness.": [ 140 ] }, "publication_date": "2020-02-01", "publication_year": 2020, "type": "review", "cited_by_count": 22, "authors": [ { "id": "https://openalex.org/A5089449708", "display_name": "Richard Chudleigh" }, { "id": "https://openalex.org/A5061502974", "display_name": "Julia Platts" }, { "id": "https://openalex.org/A5080463002", "display_name": "Stephen C. Bain" } ] }, { "id": "https://openalex.org/W2145185779", "doi": "https://doi.org/10.1152/ajpgi.00274.2011", "title": "Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet", "abstract": { "The": [ 0 ], "aims": [ 1 ], "of": [ 2, 20, 85, 146, 188, 213 ], "this": [ 3 ], "study": [ 4 ], "were": [ 5, 59, 78, 96, 111, 135 ], "designed": [ 6 ], "to": [ 7, 119 ], "determine": [ 8 ], "whether": [ 9, 39 ], "liraglutide,": [ 10 ], "a": [ 11, 21 ], "long-acting": [ 12 ], "glucagon-like": [ 13 ], "peptide,": [ 14 ], "could": [ 15, 43 ], "reverse": [ 16 ], "the": [ 17, 70, 76, 210 ], "adverse": [ 18 ], "effects": [ 19, 212 ], "diet": [ 22, 216 ], "high": [ 23 ], "in": [ 24, 226 ], "fat": [ 25 ], "that": [ 26, 207 ], "also": [ 27 ], "contained": [ 28 ], "trans-fat": [ 29 ], "and": [ 30, 48, 81, 107, 115, 120, 130, 132, 153, 165, 175, 200, 221, 233 ], "high-fructose": [ 31 ], "corn": [ 32 ], "syrup": [ 33 ], "(ALIOS": [ 34 ], "diet).": [ 35 ], "Specifically,": [ 36 ], "we": [ 37 ], "examined": [ 38 ], "treatment": [ 40 ], "with": [ 41 ], "liraglutide": [ 42, 87, 122, 162, 208 ], "reduce": [ 44 ], "hepatic": [ 45, 102, 140 ], "insulin": [ 46, 103, 108, 141, 166, 219 ], "resistance": [ 47, 109, 142 ], "steatosis": [ 49 ], "as": [ 50, 52 ], "well": [ 51 ], "improve": [ 53 ], "cardiac": [ 54, 126, 177 ], "function.": [ 55 ], "Male": [ 56 ], "C57BL/6J": [ 57 ], "mice": [ 58, 77, 183 ], "pair": [ 60 ], "fed": [ 61, 63 ], "or": [ 62, 69, 88 ], "ad": [ 64 ], "libitum": [ 65 ], "either": [ 66, 86 ], "standard": [ 67 ], "chow": [ 68 ], "ALIOS": [ 71, 147, 215 ], "diet.": [ 72, 148 ], "After": [ 73 ], "8": [ 74, 114 ], "wk": [ 75, 117, 145 ], "further": [ 79 ], "subdivided": [ 80 ], "received": [ 82 ], "daily": [ 83 ], "injections": [ 84 ], "saline": [ 89 ], "for": [ 90 ], "4": [ 91 ], "wk.": [ 92 ], "Hyperinsulinemic-euglycemic": [ 93 ], "clamp": [ 94 ], "studies": [ 95, 138 ], "performed": [ 97, 112 ], "after": [ 98, 143 ], "6": [ 99, 144 ], "wk,": [ 100 ], "revealing": [ 101 ], "resistance.": [ 104 ], "Glucose": [ 105 ], "tolerance": [ 106 ], "tests": [ 110 ], "at": [ 113 ], "12": [ 116 ], "prior": [ 118 ], "following": [ 121 ], "treatment.": [ 123 ], "Liver": [ 124 ], "pathology,": [ 125 ], "measurements,": [ 127 ], "blood": [ 128 ], "chemistry,": [ 129 ], "RNA": [ 131 ], "protein": [ 133 ], "analyses": [ 134 ], "performed.": [ 136 ], "Clamp": [ 137 ], "revealed": [ 139 ], "Liraglutide": [ 149, 168 ], "reduced": [ 150, 176 ], "visceral": [ 151 ], "adiposity": [ 152 ], "liver": [ 154, 180, 227 ], "weight": [ 155 ], "(": [ 156, 171 ], "P": [ 157, 172 ], "<": [ 158, 173 ], "0.001).": [ 159 ], "As": [ 160 ], "expected,": [ 161 ], "improved": [ 163, 169 ], "glucose": [ 164 ], "tolerance.": [ 167 ], "hypertension": [ 170 ], "0.05)": [ 174 ], "hypertrophy.": [ 178 ], "Surprisingly,": [ 179 ], "from": [ 181 ], "liraglutide-treated": [ 182 ], "had": [ 184 ], "significantly": [ 185 ], "higher": [ 186 ], "levels": [ 187 ], "fatty": [ 189 ], "acid": [ 190 ], "binding": [ 191 ], "protein,": [ 192 ], "acyl-CoA": [ 193, 198 ], "oxidase": [ 194 ], "II,": [ 195 ], "very": [ 196 ], "long-chain": [ 197 ], "dehydrogenase,": [ 199 ], "microsomal": [ 201 ], "triglyceride": [ 202 ], "transfer": [ 203 ], "protein.": [ 204 ], "We": [ 205 ], "conclude": [ 206 ], "reduces": [ 209 ], "harmful": [ 211 ], "an": [ 214 ], "by": [ 217, 222 ], "improving": [ 218 ], "sensitivity": [ 220 ], "reducing": [ 223 ], "lipid": [ 224 ], "accumulation": [ 225 ], "through": [ 228 ], "multiple": [ 229 ], "mechanisms": [ 230 ], "including,": [ 231 ], "transport,": [ 232 ], "increase": [ 234 ], "\u03b2-oxidation.": [ 235 ] }, "publication_date": "2011-10-28", "publication_year": 2011, "type": "article", "cited_by_count": 194, "authors": [ { "id": "https://openalex.org/A5085828175", "display_name": "Jamie E. Mells" }, { "id": "https://openalex.org/A5101883391", "display_name": "Ping Fu" }, { "id": "https://openalex.org/A5088960523", "display_name": "Shvetank Sharma" }, { "id": "https://openalex.org/A5112804424", "display_name": "Darin E. Olson" }, { "id": "https://openalex.org/A5066316498", "display_name": "Lihong Cheng" }, { "id": "https://openalex.org/A5090861182", "display_name": "Jeffrey A. Handy" }, { "id": "https://openalex.org/A5059496981", "display_name": "Neeraj K. Saxena" }, { "id": "https://openalex.org/A5073595309", "display_name": "Dan C. Sorescu" }, { "id": "https://openalex.org/A5035375857", "display_name": "Frank A. Anania" } ] }, { "id": "https://openalex.org/W3034133160", "doi": "https://doi.org/10.1111/dom.14110", "title": "The novel dual glucose\u2010dependent insulinotropic polypeptide and glucagon\u2010like peptide\u20101 ( GLP \u20101) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long\u2010acting GLP \u20101 receptor agonists", "abstract": { "Abstract": [ 0 ], "The": [ 1 ], "effect": [ 2, 111, 117, 140 ], "of": [ 3, 25, 104, 145, 161, 189 ], "dual": [ 4 ], "glucose\u2010dependent": [ 5 ], "insulinotropic": [ 6 ], "polypeptide": [ 7 ], "(GIP)": [ 8 ], "and": [ 9, 29, 37, 55, 123, 129 ], "glucagon\u2010like": [ 10 ], "peptide\u20101": [ 11 ], "(GLP\u20101)": [ 12 ], "receptor": [ 13 ], "agonist": [ 14 ], "(RA)": [ 15 ], "tirzepatide": [ 16, 41, 82, 127, 146, 162 ], "on": [ 17, 112, 115, 118, 183 ], "gastric": [ 18 ], "emptying": [ 19 ], "(GE)": [ 20 ], "was": [ 21, 33, 75, 171 ], "compared": [ 22 ], "to": [ 23, 85, 89, 187 ], "that": [ 24, 90, 180, 188 ], "GLP\u20101RAs": [ 26 ], "in": [ 27, 42, 149 ], "non\u2010clinical": [ 28 ], "clinical": [ 30 ], "studies.": [ 31 ], "GE": [ 32, 74, 84, 113, 134, 169, 184 ], "assessed": [ 34, 76 ], "following": [ 35 ], "acute": [ 36, 96 ], "chronic": [ 38 ], "treatment": [ 39 ], "with": [ 40, 92, 122, 154, 157 ], "diet\u2010induced": [ 43 ], "obese": [ 44 ], "mice": [ 45 ], "versus": [ 46 ], "semaglutide": [ 47 ], "or": [ 48, 72, 114, 147, 164 ], "long\u2010acting": [ 49 ], "GIP": [ 50, 106 ], "analogue": [ 51, 107 ], "alone.": [ 52 ], "Participants": [ 53 ], "[with": [ 54 ], "without": [ 56, 124 ], "type": [ 57 ], "2": [ 58, 102 ], "diabetes": [ 59 ], "(T2DM)]": [ 60 ], "from": [ 61 ], "a": [ 62, 86, 136, 167 ], "phase": [ 63 ], "1,": [ 64 ], "4\u2010week": [ 65 ], "multiple": [ 66, 143, 175 ], "dose": [ 67 ], "study": [ 68 ], "received": [ 69 ], "tirzepatide,": [ 70 ], "dulaglutide": [ 71, 148 ], "placebo.": [ 73 ], "by": [ 77 ], "acetaminophen": [ 78 ], "absorption.": [ 79 ], "In": [ 80, 120, 152 ], "mice,": [ 81 ], "delayed": [ 83, 133 ], "similar": [ 87 ], "degree": [ 88 ], "achieved": [ 91 ], "semaglutide;": [ 93 ], "however,": [ 94 ], "these": [ 95 ], "inhibitory": [ 97 ], "effects": [ 98 ], "were": [ 99 ], "abolished": [ 100 ], "after": [ 101, 135, 142, 174 ], "weeks": [ 103 ], "treatment.": [ 105 ], "alone": [ 108 ], "had": [ 109 ], "no": [ 110 ], "GLP\u20101's": [ 116 ], "GE.": [ 119 ], "participants": [ 121, 153 ], "T2DM,": [ 125 ], "once\u2010weekly": [ 126 ], "(\u22655": [ 128 ], "\u22654.5": [ 130 ], "mg,": [ 131, 166 ], "respectively)": [ 132 ], "single": [ 137 ], "dose.": [ 138 ], "This": [ 139 ], "diminished": [ 141 ], "doses": [ 144 ], "healthy": [ 150 ], "participants.": [ 151 ], "T2DM": [ 155 ], "treated": [ 156 ], "an": [ 158 ], "escalation": [ 159 ], "schedule": [ 160 ], "5/5/10/10": [ 163 ], "5/5/10/15": [ 165 ], "residual": [ 168 ], "delay": [ 170 ], "still": [ 172 ], "observed": [ 173 ], "doses.": [ 176 ], "These": [ 177 ], "data": [ 178 ], "suggest": [ 179 ], "tirzepatide's": [ 181 ], "activity": [ 182 ], "is": [ 185 ], "comparable": [ 186 ], "selective": [ 190 ], "GLP\u20101RAs.": [ 191 ] }, "publication_date": "2020-06-10", "publication_year": 2020, "type": "article", "cited_by_count": 110, "authors": [ { "id": "https://openalex.org/A5031510744", "display_name": "Shweta Urva" }, { "id": "https://openalex.org/A5054260296", "display_name": "Tamer Co\u015fkun" }, { "id": "https://openalex.org/A5030999700", "display_name": "Corina Loghin" }, { "id": "https://openalex.org/A5058864022", "display_name": "Xuewei Cui" }, { "id": "https://openalex.org/A5043115803", "display_name": "Emily Beebe" }, { "id": "https://openalex.org/A5075599028", "display_name": "Libbey S. O\u2019Farrell" }, { "id": "https://openalex.org/A5046834158", "display_name": "Daniel A. Briere" }, { "id": "https://openalex.org/A5023603655", "display_name": "Charles Benson" }, { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5040811419", "display_name": "Axel Haupt" } ] }, { "id": "https://openalex.org/W2016542902", "doi": "https://doi.org/10.2165/11208110-000000000-00000", "title": "Liraglutide", "abstract": null, "publication_date": "2011-11-16", "publication_year": 2011, "type": "review", "cited_by_count": 41, "authors": [ { "id": "https://openalex.org/A5108415008", "display_name": "Caroline M. Perry" } ] }, { "id": "https://openalex.org/W1972057139", "doi": "https://doi.org/10.1002/dmrr.1080", "title": "Engineering and characterization of the long\u2010acting glucagon\u2010like peptide\u20101 analogue LY2189265, an Fc fusion protein", "abstract": { "Abstract": [ 0 ], "Background": [ 1 ], "Glucagon\u2010like": [ 2 ], "peptide\u20101": [ 3 ], "(GLP\u20101)": [ 4 ], "receptor": [ 5, 55, 118 ], "agonists": [ 6 ], "are": [ 7 ], "novel": [ 8, 64 ], "agents": [ 9 ], "for": [ 10, 186, 197, 212 ], "type": [ 11, 239 ], "2": [ 12, 240 ], "diabetes": [ 13 ], "treatment,": [ 14 ], "offering": [ 15 ], "glucose\u2010dependent": [ 16, 194 ], "insulinotropic": [ 17, 124 ], "effects,": [ 18 ], "reduced": [ 19 ], "glucagonemia": [ 20 ], "and": [ 21, 41, 69, 92, 97, 107, 111, 122, 135, 141, 176, 179, 215, 229 ], "a": [ 22, 29, 63, 74, 80, 200, 235 ], "neutral": [ 23 ], "bodyweight": [ 24 ], "or": [ 25 ], "weight\u2010reducing": [ 26 ], "profile.": [ 27 ], "However,": [ 28 ], "short": [ 30 ], "half\u2010life": [ 31, 228 ], "(minutes),": [ 32 ], "secondary": [ 33 ], "to": [ 34, 129, 199 ], "rapid": [ 35 ], "inactivation": [ 36 ], "by": [ 37 ], "dipeptidyl": [ 38 ], "peptidase\u2010IV": [ 39 ], "(DPP\u2010IV)": [ 40 ], "excretion,": [ 42 ], "limits": [ 43 ], "the": [ 44, 48, 53, 222 ], "therapeutic": [ 45 ], "potential": [ 46 ], "of": [ 47, 101, 224, 238 ], "native": [ 49, 130 ], "GLP\u20101": [ 50, 54, 71, 81, 225 ], "hormone.": [ 51 ], "Recently,": [ 52 ], "agonist": [ 56 ], "exenatide": [ 57 ], "injected": [ 58 ], "subcutaneously": [ 59 ], "twice": [ 60, 184 ], "daily": [ 61 ], "established": [ 62 ], "therapy": [ 65 ], "class.": [ 66 ], "Developing": [ 67 ], "long\u2010acting": [ 68 ], "efficacious": [ 70 ], "analogues": [ 72 ], "represents": [ 73 ], "pivotal": [ 75 ], "research": [ 76 ], "goal.": [ 77 ], "We": [ 78 ], "developed": [ 79 ], "immunoglobulin": [ 82 ], "G": [ 83 ], "(IgG4)": [ 84 ], "Fc": [ 85 ], "fusion": [ 86 ], "protein": [ 87 ], "(LY2189265)": [ 88 ], "with": [ 89, 226 ], "extended": [ 90 ], "pharmacokinetics": [ 91 ], "activity.": [ 93 ], "Methods": [ 94 ], "In": [ 95, 151, 189 ], "vitro": [ 96, 121 ], "in": [ 98, 105, 120, 126, 133, 170 ], "vivo": [ 99 ], "activity": [ 100, 119, 125 ], "LY2189265": [ 102, 115, 153, 166, 191, 220 ], "was": [ 103, 138, 216 ], "characterized": [ 104 ], "rodent": [ 106 ], "primate": [ 108 ], "cell": [ 109 ], "systems": [ 110 ], "animal": [ 112 ], "models.": [ 113 ], "Results": [ 114 ], "retained": [ 116, 205 ], "full": [ 117 ], "elicited": [ 123 ], "islets": [ 127 ], "similar": [ 128 ], "peptide.": [ 131 ], "Half\u2010life": [ 132 ], "rats": [ 134 ], "cynomolgus": [ 136 ], "monkeys": [ 137 ], "1.5\u20132": [ 139 ], "days,": [ 140 ], "serum": [ 142 ], "immunoreactivity": [ 143 ], "representing": [ 144 ], "active": [ 145 ], "compound": [ 146 ], "persisted": [ 147 ], ">": [ 148 ], "6": [ 149 ], "days.": [ 150 ], "rats,": [ 152 ], "enhanced": [ 154 ], "insulin": [ 155, 195 ], "responses": [ 156 ], "during": [ 157 ], "graded": [ 158 ], "glucose": [ 159, 168 ], "infusion": [ 160 ], "24": [ 161 ], "h": [ 162 ], "after": [ 163, 173, 202 ], "one": [ 164, 174, 203 ], "dose.": [ 165 ], "increased": [ 167, 193, 227 ], "tolerance": [ 169 ], "diabetic": [ 171 ], "mice": [ 172 ], "dose": [ 175 ], "lowered": [ 177 ], "weight": [ 178 ], "delayed": [ 180 ], "hyperglycaemia": [ 181 ], "when": [ 182, 207 ], "administered": [ 183, 208 ], "weekly": [ 185, 211 ], "4": [ 187, 213 ], "weeks.": [ 188 ], "monkeys,": [ 190 ], "significantly": [ 192 ], "secretion": [ 196 ], "up": [ 198 ], "week": [ 201 ], "dose,": [ 204 ], "efficacy": [ 206 ], "subchronically": [ 209 ], "(once": [ 210 ], "weeks)": [ 214 ], "well": [ 217 ], "tolerated.": [ 218 ], "Conclusions": [ 219 ], "retains": [ 221 ], "effects": [ 223 ], "efficacy,": [ 230 ], "supporting": [ 231 ], "further": [ 232 ], "evaluation": [ 233 ], "as": [ 234 ], "once\u2010weekly": [ 236 ], "treatment": [ 237 ], "diabetes.": [ 241 ], "Copyright": [ 242 ], "\u00a9": [ 243 ], "2010": [ 244 ], "John": [ 245 ], "Wiley": [ 246 ], "&": [ 247 ], "Sons,": [ 248 ], "Ltd.": [ 249 ] }, "publication_date": "2010-05-01", "publication_year": 2010, "type": "article", "cited_by_count": 285, "authors": [ { "id": "https://openalex.org/A5044906331", "display_name": "Wolfgang Glaesner" }, { "id": "https://openalex.org/A5009594283", "display_name": "Andrew Vick" }, { "id": "https://openalex.org/A5027365523", "display_name": "Rohn Millican" }, { "id": "https://openalex.org/A5047229428", "display_name": "Bernice Ellis" }, { "id": "https://openalex.org/A5055483643", "display_name": "Sheng\u2010Hung Tschang" }, { "id": "https://openalex.org/A5014087113", "display_name": "Yu Tian" }, { "id": "https://openalex.org/A5090291879", "display_name": "Krister Bokvist" }, { "id": "https://openalex.org/A5110618369", "display_name": "Martin Brenner" }, { "id": "https://openalex.org/A5110290841", "display_name": "Anja K\u00f6ester" }, { "id": "https://openalex.org/A5027152767", "display_name": "Niels P\u00f6rksen" }, { "id": "https://openalex.org/A5060824985", "display_name": "Garret J. Etgen" }, { "id": "https://openalex.org/A5002459195", "display_name": "Tom Bumol" } ] }, { "id": "https://openalex.org/W2211963426", "doi": "https://doi.org/10.1016/j.neuroscience.2015.06.054", "title": "Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson\u2019s disease", "abstract": null, "publication_date": "2015-07-04", "publication_year": 2015, "type": "article", "cited_by_count": 222, "authors": [ { "id": "https://openalex.org/A5053959983", "display_name": "Wen-Hong Liu" }, { "id": "https://openalex.org/A5043340675", "display_name": "Jaishree Jalewa" }, { "id": "https://openalex.org/A5012265790", "display_name": "Mohit Sharma" }, { "id": "https://openalex.org/A5028725230", "display_name": "G Li" }, { "id": "https://openalex.org/A5056271380", "display_name": "L Li" }, { "id": "https://openalex.org/A5082707086", "display_name": "Christian H\u00f6lscher" } ] }, { "id": "https://openalex.org/W2105000105", "doi": "https://doi.org/10.1177/1932296813511733", "title": "Comparative Assessment of Lixisenatide, Exenatide, and Liraglutide Pen Devices", "abstract": { "Background:": [ 0 ], "Glucagon-like": [ 1 ], "peptide-1": [ 2 ], "(GLP-1)": [ 3 ], "receptor": [ 4, 39 ], "agonists": [ 5 ], "are": [ 6, 22, 206 ], "a": [ 7, 63, 76, 86, 239 ], "relatively": [ 8 ], "recent": [ 9 ], "addition": [ 10 ], "to": [ 11, 84 ], "the": [ 12, 108, 114, 127, 156, 161, 165, 173, 186, 192, 214, 219 ], "treatment": [ 13 ], "options": [ 14 ], "for": [ 15, 71, 107, 185, 199, 242 ], "type": [ 16 ], "2": [ 17 ], "diabetes": [ 18 ], "mellitus": [ 19 ], "(T2DM)": [ 20 ], "and": [ 21, 33, 54, 96, 101, 110, 124, 132, 146, 188, 203, 224, 248, 252, 257 ], "administered": [ 23 ], "using": [ 24, 75 ], "prefilled": [ 25 ], "pen": [ 26, 41, 158, 167, 175, 194, 221, 235, 249 ], "devices.": [ 27 ], "Method:": [ 28 ], "In": [ 29, 217 ], "this": [ 30 ], "open-label": [ 31 ], "task": [ 32 ], "interview-based": [ 34 ], "pilot": [ 35 ], "study,": [ 36 ], "3": [ 37 ], "GLP-1": [ 38 ], "agonist": [ 40 ], "devices\u2014exenatide": [ 42 ], "(Byetta": [ 43 ], "\u00ae": [ 44, 50, 57 ], ",": [ 45, 51, 58 ], "Bristol-Myers": [ 46 ], "Squibb/AstraZeneca),": [ 47 ], "liraglutide": [ 48, 111, 166, 189, 204 ], "(Victoza": [ 49 ], "Novo": [ 52 ], "Nordisk),": [ 53 ], "lixisenatide": [ 55, 109, 157, 187, 220, 234 ], "(Lyxumia": [ 56 ], "Sanofi-Aventis)\u2014were": [ 59 ], "comparatively": [ 60 ], "assessed": [ 61 ], "in": [ 62, 66, 226 ], "randomized": [ 64 ], "order": [ 65 ], "30": [ 67 ], "participants": [ 68, 128 ], "with": [ 69, 147, 155, 160, 208, 213, 244, 254 ], "T2DM": [ 70 ], "ease": [ 72 ], "of": [ 73, 78, 88, 91, 126 ], "use,": [ 74 ], "series": [ 77, 87 ], "key": [ 79 ], "performance": [ 80, 150 ], "measures": [ 81 ], "(time": [ 82 ], "taken": [ 83 ], "complete": [ 85 ], "tasks,": [ 89 ], "number": [ 90 ], "user": [ 92, 97, 180, 210 ], "errors": [ 93, 228 ], "[successful": [ 94 ], "performance],": [ 95 ], "satisfaction": [ 98, 181, 211 ], "rating).": [ 99 ], "Linear": [ 100 ], "logistic": [ 102 ], "regression": [ 103 ], "analysis": [ 104 ], "was": [ 105, 120, 168, 182 ], "conducted": [ 106 ], "pens": [ 112, 190, 205 ], "versus": [ 113, 172, 191 ], "exenatide": [ 115, 162, 174, 193, 215 ], "pen.": [ 116, 216 ], "Participants\u2019": [ 117 ], "mean": [ 118 ], "age": [ 119 ], "60": [ 121 ], "years;": [ 122 ], "27%": [ 123 ], "20%": [ 125 ], "had": [ 129 ], "visual": [ 130, 255 ], "impairments": [ 131, 256 ], "reduced": [ 133, 258 ], "manual": [ 134, 259 ], "dexterity,": [ 135 ], "respectively.": [ 136 ], "Results:": [ 137 ], "Tasks": [ 138 ], "were": [ 139 ], "completed": [ 140 ], "faster": [ 141, 223 ], "(": [ 142, 151, 195 ], "P": [ 143, 152, 196 ], "<": [ 144, 197 ], ".001)": [ 145, 154 ], "higher": [ 148, 184, 209 ], "successful": [ 149 ], "=": [ 153 ], "than": [ 159, 229 ], "pen,": [ 163 ], "whereas": [ 164 ], "not": [ 169 ], "statistically": [ 170, 183 ], "significant": [ 171 ], "on": [ 176 ], "these": [ 177 ], "parameters.": [ 178 ], "Overall,": [ 179 ], ".001": [ 198 ], "both).": [ 200 ], "Conclusions:": [ 201 ], "Lixisenatide": [ 202 ], "associated": [ 207 ], "compared": [ 212 ], "addition,": [ 218 ], "is": [ 222 ], "results": [ 225 ], "fewer": [ 227 ], "its": [ 230 ], "comparator": [ 231 ], "(exenatide).": [ 232 ], "The": [ 233 ], "may": [ 236 ], "therefore": [ 237 ], "be": [ 238 ], "suitable": [ 240 ], "choice": [ 241 ], "patients": [ 243 ], "T2DM,": [ 245 ], "including": [ 246 ], "older": [ 247 ], "device-na\u00efve": [ 250 ], "patients,": [ 251 ], "those": [ 253 ], "dexterity.": [ 260 ] }, "publication_date": "2014-01-01", "publication_year": 2014, "type": "article", "cited_by_count": 15, "authors": [ { "id": "https://openalex.org/A5024795655", "display_name": "Udo Stauder" }, { "id": "https://openalex.org/A5081930935", "display_name": "Diplom Enginee" }, { "id": "https://openalex.org/A5036723598", "display_name": "Hina Elton" }, { "id": "https://openalex.org/A5006947224", "display_name": "A. Penfornis" }, { "id": "https://openalex.org/A5111780435", "display_name": "Steve Edelman" } ] }, { "id": "https://openalex.org/W4389180607", "doi": "https://doi.org/10.1192/j.eurpsy.2023.2474", "title": "Postmarket safety profile of suicide/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis", "abstract": { "Abstract": [ 0 ], "Background": [ 1 ], "Recent": [ 2 ], "reports": [ 3 ], "of": [ 4, 23, 85, 127, 175, 191, 217 ], "individuals": [ 5 ], "experiencing": [ 6 ], "suicidal": [ 7, 108 ], "and/or": [ 8 ], "self-injurious": [ 9, 110 ], "behaviors": [ 10 ], "while": [ 11, 154 ], "using": [ 12 ], "liraglutide": [ 13 ], "and": [ 14, 40, 69, 109, 134, 221 ], "semaglutide": [ 15 ], "have": [ 16 ], "heightened": [ 17 ], "the": [ 18, 36, 44, 79, 93, 96, 155, 184 ], "concerns": [ 19 ], "regarding": [ 20 ], "neuropsychiatric": [ 21 ], "safety": [ 22, 125, 203, 229 ], "Glucagon-like": [ 24 ], "peptide-1": [ 25 ], "agonists": [ 26 ], "(GLP-1RAs).": [ 27 ], "As": [ 28 ], "real-world": [ 29 ], "evidence": [ 30 ], "is": [ 31 ], "very": [ 32 ], "limited,": [ 33 ], "we": [ 34 ], "explored": [ 35 ], "association": [ 37 ], "between": [ 38 ], "GLP-1RA": [ 39, 99, 130, 141, 180, 207, 224 ], "suicide/self-injury": [ 41, 88, 139, 176 ], "by": [ 42, 233 ], "mining": [ 43 ], "FDA": [ 45 ], "Adverse": [ 46 ], "Event": [ 47 ], "Reporting": [ 48, 65 ], "System": [ 49 ], "(FAERS)": [ 50 ], "database.": [ 51 ], "Methods": [ 52 ], "The": [ 53, 64, 136, 189 ], "FAERS": [ 54, 94, 197 ], "database": [ 55 ], "was": [ 56, 142, 157, 167, 177, 231 ], "queried": [ 57 ], "from": [ 58 ], "2005": [ 59 ], "Q2": [ 60 ], "to": [ 61, 77, 196, 206, 245 ], "2023": [ 62 ], "Q2.": [ 63 ], "Odds": [ 66 ], "Ratio": [ 67 ], "(ROR)": [ 68 ], "Empirical": [ 70 ], "Bayes": [ 71 ], "Geometric": [ 72 ], "Mean": [ 73 ], "(EBGM)": [ 74 ], "were": [ 75, 90 ], "used": [ 76 ], "conduct": [ 78 ], "disproportionality": [ 80 ], "analysis.": [ 81 ], "Results": [ 82 ], "A": [ 83 ], "total": [ 84 ], "534": [ 86 ], "GLP-1RA-associated": [ 87 ], "cases": [ 89, 111, 190 ], "reported": [ 91, 195 ], "in": [ 92, 106, 131, 152, 160, 169, 225, 235 ], "during": [ 95 ], "study": [ 97 ], "period.": [ 98 ], "did": [ 100 ], "not": [ 101, 199 ], "cause": [ 102 ], "a": [ 103, 214 ], "disproportionate": [ 104 ], "increase": [ 105 ], "overall": [ 107, 202 ], "(ROR:": [ 112, 145 ], "0.16,": [ 113 ], "95%CI": [ 114, 147 ], "0.15-0.18,": [ 115 ], "P": [ 116, 149 ], "<": [ 117, 158 ], "0.001;": [ 118 ], "EBGM05:": [ 119 ], "0.15).": [ 120 ], "Stratified": [ 121 ], "analyses": [ 122 ], "found": [ 123 ], "no": [ 124, 228 ], "signal": [ 126, 165, 204, 230 ], "suicide/injury": [ 128 ], "for": [ 129, 138, 179, 219 ], "both": [ 132 ], "females": [ 133 ], "males.": [ 135 ], "ROR": [ 137, 218 ], "with": [ 140, 223 ], "slightly": [ 143 ], "elevated": [ 144 ], "2.50,": [ 146 ], "1.02-6.13,": [ 148 ], "=": [ 150 ], "0.05)": [ 151 ], "children,": [ 153, 226 ], "EBGM05": [ 156, 234 ], "2": [ 159 ], "this": [ 161, 209, 236, 248 ], "population.": [ 162, 237 ], "No": [ 163, 173 ], "significant": [ 164 ], "value": [ 166 ], "observed": [ 168 ], "other": [ 170 ], "age": [ 171 ], "groups.": [ 172 ], "over-reporting": [ 174 ], "identified": [ 178 ], "before": [ 181 ], "or": [ 182, 193 ], "after": [ 183 ], "COVID-19": [ 185 ], "pandemic": [ 186 ], "outbreak.": [ 187 ], "Conclusions": [ 188 ], "suicide": [ 192, 220 ], "self-injury": [ 194, 222 ], "do": [ 198 ], "indicate": [ 200 ], "any": [ 201 ], "attributable": [ 205 ], "at": [ 208 ], "time.": [ 210 ], "Subgroup": [ 211 ], "analysis": [ 212 ], "revealed": [ 213 ], "marginal": [ 215 ], "elevation": [ 216 ], "but": [ 227 ], "detected": [ 232 ], "Further": [ 238 ], "large-scale": [ 239 ], "prospective": [ 240 ], "investigations": [ 241 ], "are": [ 242 ], "still": [ 243 ], "warranted": [ 244 ], "further": [ 246 ], "confirm": [ 247 ], "finding.": [ 249 ] }, "publication_date": "2023-01-01", "publication_year": 2023, "type": "article", "cited_by_count": 52, "authors": [ { "id": "https://openalex.org/A5009770034", "display_name": "Congqin Chen" }, { "id": "https://openalex.org/A5102585762", "display_name": "Rijing Zhou" }, { "id": "https://openalex.org/A5022472130", "display_name": "Fang Fu" }, { "id": "https://openalex.org/A5057618188", "display_name": "Jie Xiao" } ] }, { "id": "https://openalex.org/W2083357334", "doi": "https://doi.org/10.1089/dia.2011.0050", "title": "Encapsulation of Exenatide in Poly-(d,l-Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes", "abstract": { "Exenatide": [ 0 ], "once-weekly": [ 1 ], "(EQW": [ 2 ], "[2": [ 3 ], "mg": [ 4 ], "s.c.])": [ 5 ], "is": [ 6, 182, 238, 244 ], "under": [ 7 ], "development": [ 8 ], "as": [ 9, 11, 19, 132, 147, 180 ], "monotherapy": [ 10 ], "an": [ 12, 24, 77 ], "adjunct": [ 13 ], "to": [ 14, 72, 75, 108, 119, 128, 173, 177, 231 ], "diet": [ 15 ], "and": [ 16, 59, 70, 140, 150, 164, 220 ], "exercise": [ 17 ], "or": [ 18, 217, 233 ], "a": [ 20, 123 ], "combination": [ 21 ], "therapy": [ 22 ], "with": [ 23, 30, 185, 194 ], "oral": [ 25 ], "antidiabetes": [ 26 ], "drug(s)": [ 27 ], "in": [ 28, 49, 68, 92, 100 ], "adults": [ 29 ], "type": [ 31 ], "2": [ 32, 162 ], "diabetes.": [ 33 ], "This": [ 34, 170 ], "long-acting": [ 35 ], "formulation": [ 36, 47 ], "contains": [ 37 ], "the": [ 38, 42, 63, 93, 133, 158, 239 ], "active": [ 39 ], "ingredient": [ 40 ], "of": [ 41, 52, 82 ], "original": [ 43 ], "exenatide": [ 44, 114, 155 ], "twice-daily": [ 45 ], "(EBID)": [ 46 ], "encapsulated": [ 48, 113 ], "0.06-mm-diameter": [ 50 ], "microspheres": [ 51, 66 ], "medical-grade": [ 53 ], "poly-(D,L-lactide-co-glycolide)": [ 54 ], "(PLG).": [ 55 ], "After": [ 56 ], "mechanical": [ 57 ], "suspension": [ 58 ], "subcutaneous": [ 60 ], "injection": [ 61 ], "by": [ 62, 161, 167 ], "patient,": [ 64 ], "EQW": [ 65, 186, 189, 208, 232, 237 ], "hydrate": [ 67 ], "situ": [ 69 ], "adhere": [ 71 ], "one": [ 73 ], "another": [ 74 ], "form": [ 76 ], "amalgam.": [ 78 ], "A": [ 79 ], "small": [ 80 ], "amount": [ 81 ], "loosely": [ 83 ], "bound": [ 84 ], "surface": [ 85 ], "exenatide,": [ 86 ], "typically": [ 87 ], "less": [ 88, 183 ], "than": [ 89, 187, 213, 226 ], "1%,": [ 90 ], "releases": [ 91, 121 ], "first": [ 94, 240 ], "few": [ 95 ], "hours,": [ 96 ], "whereas": [ 97 ], "drug": [ 98, 116 ], "located": [ 99 ], "deeper": [ 101 ], "interstices": [ 102 ], "diffuses": [ 103 ], "out": [ 104 ], "more": [ 105, 212, 225 ], "slowly": [ 106 ], "(time": [ 107, 127 ], "maximum,": [ 109, 129 ], "~2": [ 110 ], "weeks).": [ 111 ], "Fully": [ 112 ], "(i.e.,": [ 115 ], "initially": [ 117 ], "inaccessible": [ 118 ], "diffusion)": [ 120 ], "over": [ 122 ], "still": [ 124 ], "longer": [ 125 ], "period": [ 126 ], "~7": [ 130 ], "weeks)": [ 131 ], "PLG": [ 134 ], "matrix": [ 135 ], "hydrolyzes": [ 136 ], "into": [ 137 ], "lactic": [ 138 ], "acid": [ 139 ], "glycolic": [ 141 ], "acid,": [ 142 ], "which": [ 143 ], "are": [ 144 ], "subsequently": [ 145 ], "eliminated": [ 146 ], "carbon": [ 148 ], "dioxide": [ 149 ], "water.": [ 151 ], "For": [ 152 ], "EQW,": [ 153 ], "plasma": [ 154, 223 ], "concentrations": [ 156 ], "reach": [ 157 ], "therapeutic": [ 159 ], "range": [ 160 ], "weeks": [ 163 ], "steady": [ 165, 174 ], "state": [ 166, 175 ], "6-7": [ 168 ], "weeks.": [ 169 ], "gradual": [ 171 ], "approach": [ 172 ], "seems": [ 176 ], "improve": [ 178 ], "tolerability,": [ 179 ], "nausea": [ 181 ], "frequent": [ 184 ], "EBID.": [ 188, 227 ], "administrations": [ 190 ], "may": [ 191 ], "be": [ 192 ], "associated": [ 193 ], "palpable": [ 195 ], "skin": [ 196 ], "nodules": [ 197 ], "that": [ 198, 243 ], "generally": [ 199 ], "resolve": [ 200 ], "without": [ 201 ], "further": [ 202 ], "medical": [ 203 ], "intervention.": [ 204 ], "In": [ 205 ], "comparative": [ 206 ], "trials,": [ 207 ], "improved": [ 209 ], "hemoglobin": [ 210 ], "A1c": [ 211 ], "EBID,": [ 214 ], "sitagliptin,": [ 215 ], "pioglitazone,": [ 216 ], "insulin": [ 218 ], "glargine": [ 219 ], "reduced": [ 221 ], "fasting": [ 222 ], "glucose": [ 224 ], "Weight": [ 228 ], "loss": [ 229 ], "due": [ 230 ], "EBID": [ 234 ], "was": [ 235 ], "similar.": [ 236 ], "glucose-lowering": [ 241 ], "agent": [ 242 ], "administered": [ 245 ], "once": [ 246 ], "weekly.": [ 247 ] }, "publication_date": "2011-07-13", "publication_year": 2011, "type": "review", "cited_by_count": 232, "authors": [ { "id": "https://openalex.org/A5010846329", "display_name": "Mary Beth DeYoung" }, { "id": "https://openalex.org/A5018272606", "display_name": "Leigh MacConell" }, { "id": "https://openalex.org/A5066900264", "display_name": "Viren Sarin" }, { "id": "https://openalex.org/A5062021087", "display_name": "Michael Trautmann" }, { "id": "https://openalex.org/A5110584149", "display_name": "Paul Herbert" } ] }, { "id": "https://openalex.org/W2153003051", "doi": "https://doi.org/10.1177/1479164112449562", "title": "Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: Results from an observational research", "abstract": { "The": [ 0, 37 ], "GLP-1": [ 1, 16 ], "receptor": [ 2 ], "agonist": [ 3 ], "exenatide": [ 4, 30, 47, 102, 148 ], "has": [ 5, 34 ], "been": [ 6, 35 ], "approved": [ 7 ], "for": [ 8 ], "adjunctive": [ 9 ], "treatment": [ 10, 133 ], "of": [ 11, 29, 39, 91, 123, 147 ], "type": [ 12, 67 ], "2": [ 13, 68 ], "diabetes.": [ 14, 69 ], "Continuous": [ 15 ], "infusion": [ 17 ], "improves": [ 18, 149 ], "endothelial": [ 19 ], "function": [ 20, 33, 52 ], "in": [ 21, 64, 98, 130 ], "vivo;": [ 22 ], "no": [ 23 ], "evidence": [ 24, 142 ], "about": [ 25 ], "a": [ 26 ], "beneficial": [ 27 ], "effect": [ 28 ], "on": [ 31 ], "vascular": [ 32 ], "published.": [ 36 ], "aim": [ 38 ], "our": [ 40 ], "observational": [ 41 ], "study": [ 42, 93, 137 ], "was": [ 43, 73, 95 ], "to": [ 44 ], "evaluate": [ 45 ], "whether": [ 46 ], "would": [ 48 ], "improve": [ 49 ], "brachial": [ 50 ], "artery": [ 51 ], "evaluated": [ 53 ], "by": [ 54, 75, 119 ], "the": [ 55, 89, 92, 120, 131, 139 ], "flow": [ 56 ], "mediated": [ 57 ], "dilation": [ 58 ], "(FMD)": [ 59 ], "technique,": [ 60 ], "compared": [ 61, 103 ], "with": [ 62, 66, 104 ], "glimepiride,": [ 63 ], "subjects": [ 65, 99 ], "FMD": [ 70, 94, 141 ], "time": [ 71 ], "course": [ 72 ], "assessed": [ 74 ], "ultrasound,": [ 76 ], "after": [ 77, 85 ], "5": [ 78 ], "min": [ 79 ], "forearm": [ 80 ], "ischaemia,": [ 81 ], "at": [ 82 ], "baseline": [ 83 ], "and": [ 84 ], "16-week": [ 86 ], "treatment.": [ 87 ], "At": [ 88 ], "end": [ 90 ], "significantly": [ 96 ], "higher": [ 97 ], "who": [ 100, 126 ], "assumed": [ 101 ], "glimepiride": [ 105 ], "(9.1": [ 106 ], "\u00b1": [ 107, 111 ], "3.6": [ 108 ], "vs.": [ 109 ], "5.6": [ 110 ], "1.0,": [ 112 ], "p": [ 113 ], "=": [ 114 ], "0.01).": [ 115 ], "Even": [ 116 ], "if": [ 117 ], "limited": [ 118 ], "small": [ 121 ], "number": [ 122 ], "studied": [ 124 ], "subjects,": [ 125 ], "were": [ 127 ], "not": [ 128 ], "matched": [ 129 ], "two": [ 132 ], "groups,": [ 134 ], "this": [ 135 ], "research": [ 136 ], "represents": [ 138 ], "first": [ 140 ], "suggesting": [ 143 ], "that": [ 144 ], "chronic": [ 145 ], "administration": [ 146 ], "arterial": [ 150 ], "dilation.": [ 151 ] }, "publication_date": "2012-06-25", "publication_year": 2012, "type": "article", "cited_by_count": 67, "authors": [ { "id": "https://openalex.org/A5055244786", "display_name": "Concetta Irace" }, { "id": "https://openalex.org/A5081837065", "display_name": "Simona De Luca" }, { "id": "https://openalex.org/A5071470208", "display_name": "Ermal Shehaj" }, { "id": "https://openalex.org/A5059172817", "display_name": "Claudio Carallo" }, { "id": "https://openalex.org/A5086210278", "display_name": "Antonio Loprete" }, { "id": "https://openalex.org/A5034747646", "display_name": "Faustina Scavelli" }, { "id": "https://openalex.org/A5008383255", "display_name": "Agostino Gnasso" } ] }, { "id": "https://openalex.org/W2963614034", "doi": "https://doi.org/10.1007/s40261-019-00826-0", "title": "Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features", "abstract": null, "publication_date": "2019-07-18", "publication_year": 2019, "type": "review", "cited_by_count": 73, "authors": [ { "id": "https://openalex.org/A5037083528", "display_name": "Katherine A. Lyseng\u2010Williamson" } ] }, { "id": "https://openalex.org/W2518324998", "doi": "https://doi.org/10.2337/diaspect.29.3.152", "title": "Basal Insulin Use With GLP-1 Receptor Agonists", "abstract": { "IN": [ 0 ], "BRIEF": [ 1 ], "The": [ 2 ], "combination": [ 3, 62, 100 ], "of": [ 4, 39, 97, 101, 106 ], "basal": [ 5 ], "insulin": [ 6, 56 ], "and": [ 7, 18, 36, 41, 51, 76, 83, 95 ], "a": [ 8, 49, 69 ], "glucagon-like": [ 9 ], "peptide": [ 10 ], "1": [ 11 ], "receptor": [ 12 ], "agonist": [ 13 ], "is": [ 14 ], "becoming": [ 15 ], "increasingly": [ 16 ], "common": [ 17 ], "offers": [ 19 ], "several": [ 20 ], "potential": [ 21 ], "benefits": [ 22 ], "to": [ 23, 54 ], "patients": [ 24 ], "with": [ 25, 44, 57 ], "type": [ 26, 107 ], "2": [ 27, 108 ], "diabetes.": [ 28, 109 ], "Clinical": [ 29 ], "studies": [ 30 ], "have": [ 31 ], "demonstrated": [ 32 ], "improved": [ 33 ], "glycemic": [ 34 ], "control": [ 35 ], "low": [ 37 ], "risks": [ 38 ], "hypoglycemia": [ 40 ], "weight": [ 42 ], "gain": [ 43 ], "the": [ 45, 74, 89, 104 ], "combination,": [ 46 ], "which": [ 47 ], "provides": [ 48 ], "safe": [ 50 ], "effective": [ 52 ], "alternative": [ 53 ], "basal-bolus": [ 55 ], "less": [ 58 ], "treatment": [ 59, 105 ], "burden.": [ 60 ], "Fixed-ratio": [ 61 ], "products": [ 63 ], "that": [ 64 ], "administer": [ 65 ], "both": [ 66 ], "agents": [ 67 ], "in": [ 68, 73, 103 ], "single": [ 70 ], "injection": [ 71 ], "are": [ 72 ], "pipeline": [ 75 ], "will": [ 77 ], "offer": [ 78 ], "additional": [ 79 ], "options": [ 80 ], "for": [ 81 ], "clinicians": [ 82 ], "patients.": [ 84 ], "This": [ 85 ], "review": [ 86 ], "focuses": [ 87 ], "on": [ 88 ], "rationale": [ 90 ], "for,": [ 91 ], "clinical": [ 92 ], "evidence": [ 93 ], "on,": [ 94 ], "implications": [ 96 ], "using": [ 98 ], "this": [ 99 ], "therapies": [ 102 ] }, "publication_date": "2016-08-01", "publication_year": 2016, "type": "article", "cited_by_count": 47, "authors": [ { "id": "https://openalex.org/A5027067847", "display_name": "Sarah L. Anderson" }, { "id": "https://openalex.org/A5054620018", "display_name": "Jennifer Trujillo" } ] }, { "id": "https://openalex.org/W1559082056", "doi": "https://doi.org/10.1111/j.1742-1241.2011.02656.x", "title": "One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial", "abstract": { "Liraglutide": [ 0 ], "provides": [ 1 ], "greater": [ 2, 17 ], "sustained": [ 3 ], "glycaemic": [ 4 ], "control": [ 5 ], "and": [ 6, 31 ], "body": [ 7 ], "weight": [ 8 ], "reduction": [ 9 ], "over": [ 10 ], "52": [ 11 ], "weeks.": [ 12 ], "Treatment": [ 13 ], "satisfaction": [ 14 ], "was": [ 15 ], "significantly": [ 16 ], "with": [ 18, 35 ], "1.8": [ 19 ], "mg": [ 20 ], "liraglutide,": [ 21 ], "similar": [ 22 ], "to": [ 23 ], "26-week": [ 24 ], "results.": [ 25 ], "The": [ 26 ], "safety": [ 27 ], "profiles": [ 28 ], "of": [ 29 ], "liraglutide": [ 30 ], "sitagliptin": [ 32 ], "are": [ 33 ], "consistent": [ 34 ], "previous": [ 36 ], "reports.": [ 37 ] }, "publication_date": "2011-03-01", "publication_year": 2011, "type": "article", "cited_by_count": 248, "authors": [ { "id": "https://openalex.org/A5059098934", "display_name": "Richard E. Pratley" }, { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5054058644", "display_name": "Timothy S. Bailey" }, { "id": "https://openalex.org/A5031060251", "display_name": "Eduard Montanya" }, { "id": "https://openalex.org/A5101709468", "display_name": "Robert Cuddihy" }, { "id": "https://openalex.org/A5027823950", "display_name": "S\u00e9bastiano Filetti" }, { "id": "https://openalex.org/A5111569181", "display_name": "A. J. Garber" }, { "id": "https://openalex.org/A5112354612", "display_name": "Anne Bloch Thomsen" }, { "id": "https://openalex.org/A5017679173", "display_name": "Helle B\u00f8ggild Hartvig" }, { "id": "https://openalex.org/A5084593004", "display_name": "Melanie J. Davies" } ] }, { "id": "https://openalex.org/W4323356536", "doi": "https://doi.org/10.1136/bmjopen-2022-061807", "title": "Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis", "abstract": { "Objective": [ 0 ], "To": [ 1 ], "compare": [ 2 ], "the": [ 3, 76, 108, 111, 192, 274 ], "efficacy": [ 4, 73 ], "and": [ 5, 8, 15, 38, 59, 83, 93, 132, 148, 217, 242, 284 ], "safety": [ 6, 87 ], "between": [ 7 ], "within": [ 9 ], "glucagon-like": [ 10 ], "peptide-1": [ 11 ], "receptor": [ 12 ], "agonists": [ 13 ], "(GLP-1RAs)": [ 14 ], "sodium-glucose": [ 16 ], "cotransporter": [ 17 ], "2": [ 18 ], "inhibitors": [ 19 ], "(SGLT-2is)": [ 20 ], "in": [ 21, 61, 127, 137, 161, 196 ], "overweight": [ 22, 62 ], "or": [ 23, 27, 63 ], "obese": [ 24, 64 ], "adults": [ 25 ], "with": [ 26, 154, 255, 263, 292 ], "without": [ 28 ], "diabetes": [ 29 ], "mellitus.": [ 30 ], "Methods": [ 31 ], "PubMed,": [ 32 ], "ISI": [ 33 ], "Web": [ 34 ], "of": [ 35, 42, 55, 57, 78, 175, 266, 295 ], "Science,": [ 36 ], "Embase": [ 37 ], "Cochrane": [ 39 ], "Central": [ 40 ], "Register": [ 41 ], "Controlled": [ 43 ], "Trials": [ 44 ], "database": [ 45 ], "were": [ 46, 75, 89, 114, 125, 180 ], "comprehensively": [ 47 ], "searched": [ 48 ], "to": [ 49, 68, 96, 159, 169, 206, 215, 227, 240, 253 ], "identify": [ 50 ], "randomised": [ 51 ], "controlled": [ 52 ], "trials": [ 53 ], "(RCTs)": [ 54 ], "effects": [ 56, 276 ], "GLP-1RAs": [ 58, 131, 156, 171 ], "SGLT-2is": [ 60, 133, 160, 179 ], "participants": [ 65 ], "from": [ 66 ], "inception": [ 67 ], "16": [ 69 ], "January": [ 70 ], "2022.": [ 71 ], "The": [ 72, 86, 99 ], "outcomes": [ 74, 88 ], "changes": [ 77 ], "body": [ 79, 138, 198, 279 ], "weight,": [ 80, 280 ], "glucose": [ 81, 151, 220 ], "level": [ 82, 283 ], "blood": [ 84, 231, 244, 286 ], "pressure.": [ 85 ], "serious": [ 90 ], "adverse": [ 91, 97, 176, 267, 296 ], "events": [ 92 ], "discontinuation": [ 94 ], "due": [ 95 ], "events.": [ 98, 268, 297 ], "mean": [ 100 ], "differences,": [ 101 ], "ORs,": [ 102 ], "95%": [ 103, 166, 203, 212, 224, 237, 250 ], "credible": [ 104 ], "intervals": [ 105 ], "(95%": [ 106 ], "CI),": [ 107 ], "surface": [ 109 ], "under": [ 110 ], "cumulative": [ 112 ], "ranking": [ 113 ], "evaluated": [ 115 ], "for": [ 116 ], "each": [ 117 ], "outcome": [ 118 ], "by": [ 119 ], "network": [ 120 ], "meta-analysis.": [ 121 ], "Results": [ 122 ], "Sixty-one": [ 123 ], "RCTs": [ 124 ], "included": [ 126 ], "our": [ 128 ], "analysis.": [ 129 ], "Both": [ 130 ], "conferred": [ 134 ], "greater": [ 135 ], "extents": [ 136 ], "weight": [ 139, 199 ], "reduction,": [ 140 ], "achieving": [ 141 ], "at": [ 142 ], "least": [ 143 ], "5%": [ 144 ], "wt": [ 145 ], "loss,": [ 146 ], "HbA1c": [ 147, 162, 209 ], "fasting": [ 149, 218 ], "plasma": [ 150, 219 ], "decrease": [ 152 ], "compared": [ 153 ], "placebo.": [ 155 ], "was": [ 157, 190, 261, 290 ], "superior": [ 158 ], "reduction": [ 163 ], "(MD:": [ 164, 200, 210, 221, 233, 246 ], "\u22120.39%,": [ 165 ], "CI": [ 167, 204, 213, 225, 238, 251 ], "\u22120.70": [ 168 ], "\u22120.08).": [ 170 ], "had": [ 172 ], "high": [ 173, 264, 293 ], "risk": [ 174, 265, 294 ], "events,": [ 177 ], "while": [ 178, 259, 288 ], "relatively": [ 181 ], "safe.": [ 182 ], "Based": [ 183 ], "on": [ 184, 277 ], "intraclass": [ 185 ], "comparison,": [ 186 ], "semaglutide": [ 187 ], "2.4": [ 188, 271 ], "mg": [ 189, 272 ], "among": [ 191 ], "most": [ 193 ], "effective": [ 194 ], "interventions": [ 195 ], "losing": [ 197, 278 ], "\u221211.51": [ 201 ], "kg,": [ 202 ], "\u221212.83": [ 205 ], "\u221210.21),": [ 207 ], "decreasing": [ 208 ], "\u22121.49%,": [ 211 ], "\u22122.07": [ 214 ], "\u22120.92)": [ 216 ], "\u22122.15": [ 222 ], "mmol/L,": [ 223 ], "\u22122.83": [ 226 ], "\u22121.59),": [ 228 ], "reducing": [ 229, 285 ], "systolic": [ 230 ], "pressure": [ 232, 245, 287 ], "\u22124.89": [ 234 ], "mm": [ 235, 248 ], "Hg,": [ 236, 249 ], "\u22126.04": [ 239 ], "\u22123.71)": [ 241 ], "diastolic": [ 243 ], "\u22121.59": [ 247 ], "\u22122.37": [ 252 ], "\u22120.86)": [ 254 ], "moderate": [ 256 ], "certainty": [ 257 ], "evidences,": [ 258 ], "it": [ 260, 289 ], "associated": [ 262, 291 ], "Conclusions": [ 269 ], "Semaglutide": [ 270 ], "showed": [ 273 ], "greatest": [ 275 ], "controlling": [ 281 ], "glycaemic": [ 282 ], "PROSPERO": [ 298 ], "registration": [ 299 ], "number": [ 300 ], "CRD42021258103.": [ 301 ] }, "publication_date": "2023-03-01", "publication_year": 2023, "type": "review", "cited_by_count": 80, "authors": [ { "id": "https://openalex.org/A5080468736", "display_name": "Hong Ma" }, { "id": "https://openalex.org/A5061611657", "display_name": "Yuhao Lin" }, { "id": "https://openalex.org/A5018735356", "display_name": "Li-Zhen Dai" }, { "id": "https://openalex.org/A5050595826", "display_name": "Chenshi Lin" }, { "id": "https://openalex.org/A5073182721", "display_name": "Yanling Huang" }, { "id": "https://openalex.org/A5077496597", "display_name": "Shu-Yuan Liu" } ] }, { "id": "https://openalex.org/W3101200379", "doi": "https://doi.org/10.1186/s12933-020-01197-z", "title": "Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis", "abstract": null, "publication_date": "2021-01-07", "publication_year": 2021, "type": "review", "cited_by_count": 135, "authors": [ { "id": "https://openalex.org/A5021425190", "display_name": "Takayuki Yamada" }, { "id": "https://openalex.org/A5080099495", "display_name": "Mako Wakabayashi" }, { "id": "https://openalex.org/A5071191035", "display_name": "Abhinav Bhalla" }, { "id": "https://openalex.org/A5001967667", "display_name": "Nitin Chopra" }, { "id": "https://openalex.org/A5057695365", "display_name": "Hirotaka Miyashita" }, { "id": "https://openalex.org/A5056975966", "display_name": "Takahisa Mikami" }, { "id": "https://openalex.org/A5049228806", "display_name": "Hiroki Ueyama" }, { "id": "https://openalex.org/A5007146853", "display_name": "Tomohiro Fujisaki" }, { "id": "https://openalex.org/A5032761079", "display_name": "Yusuke Saigusa" }, { "id": "https://openalex.org/A5110845516", "display_name": "Takahiro Yamaji" }, { "id": "https://openalex.org/A5044044075", "display_name": "Kengo Azushima" }, { "id": "https://openalex.org/A5075543691", "display_name": "Shingo Urate" }, { "id": "https://openalex.org/A5101664849", "display_name": "Toru Suzuki" }, { "id": "https://openalex.org/A5108627096", "display_name": "Eriko Abe" }, { "id": "https://openalex.org/A5028819689", "display_name": "Hiromichi Wakui" }, { "id": "https://openalex.org/A5063566174", "display_name": "Kouichi Tamura" } ] }, { "id": "https://openalex.org/W2750733474", "doi": "https://doi.org/10.1038/nrneph.2017.123", "title": "GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes", "abstract": null, "publication_date": "2017-09-04", "publication_year": 2017, "type": "review", "cited_by_count": 361, "authors": [ { "id": "https://openalex.org/A5084278641", "display_name": "Marcel H.A. Muskiet" }, { "id": "https://openalex.org/A5067721247", "display_name": "Lennart Tonneijck" }, { "id": "https://openalex.org/A5091895526", "display_name": "Mark M. Smits" }, { "id": "https://openalex.org/A5006323923", "display_name": "Micha\u00ebl J.B. van Baar" }, { "id": "https://openalex.org/A5028760009", "display_name": "Mark H.H. Kramer" }, { "id": "https://openalex.org/A5027968873", "display_name": "Ewout J. Hoorn" }, { "id": "https://openalex.org/A5062438369", "display_name": "Jaap A. Joles" }, { "id": "https://openalex.org/A5067127165", "display_name": "Dani\u00ebl H. van Raalte" } ] }, { "id": "https://openalex.org/W3021856094", "doi": "https://doi.org/10.2337/dc19-2251", "title": "Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial", "abstract": { "OBJECTIVE": [ 0 ], "The": [ 1, 44 ], "Liraglutide": [ 2 ], "Effect": [ 3 ], "and": [ 4, 124, 163, 177, 189, 200, 204, 209 ], "Action": [ 5 ], "in": [ 6, 65, 141, 147 ], "Diabetes:": [ 7 ], "Evaluation": [ 8 ], "of": [ 9, 23, 81, 84, 93, 216, 241, 245, 252 ], "Cardiovascular": [ 10 ], "Outcome": [ 11 ], "Results": [ 12 ], "(LEADER)": [ 13 ], "trial": [ 14 ], "(ClinicalTrials.gov": [ 15 ], "reg.": [ 16 ], "no.": [ 17 ], "NCT01179048)": [ 18 ], "demonstrated": [ 19 ], "a": [ 20, 145, 158, 234, 250, 257, 261 ], "reduced": [ 21 ], "risk": [ 22, 133, 149 ], "cardiovascular": [ 24 ], "(CV)": [ 25 ], "events": [ 26, 90 ], "for": [ 27, 58, 180, 224 ], "patients": [ 28 ], "with": [ 29, 63 ], "type": [ 30 ], "2": [ 31 ], "diabetes": [ 32 ], "who": [ 33 ], "received": [ 34 ], "the": [ 35, 59, 66, 82, 103, 164, 175, 186, 214, 242 ], "glucagon-like": [ 36 ], "peptide": [ 37 ], "1": [ 38 ], "receptor": [ 39 ], "agonist": [ 40 ], "liraglutide": [ 41, 64, 85, 137, 217 ], "versus": [ 42 ], "placebo.": [ 43 ], "mechanisms": [ 45 ], "behind": [ 46 ], "this": [ 47 ], "CV": [ 48, 60, 89, 94, 132, 148, 243 ], "benefit": [ 49, 61 ], "remain": [ 50 ], "unclear.": [ 51 ], "We": [ 52, 73, 152 ], "aimed": [ 53 ], "to": [ 54, 77, 169, 178, 198, 207, 233 ], "identify": [ 55, 78, 230 ], "potential": [ 56, 79, 193, 239 ], "mediators": [ 57, 80, 240 ], "observed": [ 62 ], "LEADER": [ 67, 142 ], "trial.": [ 68 ], "RESEARCH": [ 69 ], "DESIGN": [ 70 ], "AND": [ 71 ], "METHODS": [ 72 ], "performed": [ 74 ], "exploratory": [ 75 ], "analyses": [ 76, 229 ], "effect": [ 83, 140, 215 ], "on": [ 86, 135, 157, 213, 218 ], "major": [ 87 ], "adverse": [ 88 ], "(MACE;": [ 91 ], "composite": [ 92 ], "death,": [ 95 ], "nonfatal": [ 96, 100 ], "myocardial": [ 97 ], "infarction,": [ 98 ], "or": [ 99, 256 ], "stroke)": [ 101 ], "from": [ 102, 174 ], "following": [ 104 ], "candidates:": [ 105 ], "glycated": [ 106 ], "hemoglobin": [ 107 ], "(HbA1c),": [ 108 ], "body": [ 109 ], "weight,": [ 110 ], "urinary": [ 111 ], "albumin-to-creatinine": [ 112 ], "ratio": [ 113 ], "(UACR),": [ 114 ], "confirmed": [ 115 ], "hypoglycemia,": [ 116 ], "sulfonylurea": [ 117 ], "use,": [ 118, 120 ], "insulin": [ 119 ], "systolic": [ 121 ], "blood": [ 122 ], "pressure,": [ 123 ], "LDL": [ 125 ], "cholesterol.": [ 126 ], "These": [ 127, 228 ], "candidates": [ 128 ], "were": [ 129, 222 ], "selected": [ 130 ], "as": [ 131, 238 ], "factors": [ 134 ], "which": [ 136 ], "had": [ 138 ], "an": [ 139, 253 ], "such": [ 143 ], "that": [ 144, 264 ], "reduction": [ 146 ], "might": [ 150 ], "result.": [ 151 ], "used": [ 153 ], "two": [ 154 ], "methods": [ 155, 188 ], "based": [ 156 ], "Cox": [ 159, 187 ], "proportional": [ 160 ], "hazards": [ 161 ], "model": [ 162 ], "new": [ 165 ], "Vansteelandt": [ 166, 190 ], "method": [ 167, 191 ], "designed": [ 168 ], "use": [ 170 ], "all": [ 171 ], "available": [ 172 ], "information": [ 173 ], "mediator": [ 176, 259 ], "control": [ 179 ], "confounding": [ 181 ], "factors.": [ 182 ], "RESULTS": [ 183 ], "Analyses": [ 184 ], "using": [ 185 ], "indicated": [ 192 ], "mediation": [ 194 ], "by": [ 195 ], "HbA1c": [ 196, 231 ], "(up": [ 197, 206 ], "41%": [ 199 ], "83%": [ 201 ], "mediation,": [ 202, 211 ], "respectively)": [ 203, 212 ], "UACR": [ 205, 237 ], "29%": [ 208 ], "33%": [ 210 ], "MACE.": [ 219 ], "Mediation": [ 220 ], "effects": [ 221, 244 ], "small": [ 223 ], "other": [ 225 ], "candidates.": [ 226 ], "CONCLUSIONS": [ 227 ], "and,": [ 232 ], "lesser": [ 235 ], "extent,": [ 236 ], "liraglutide.": [ 246 ], "Whether": [ 247 ], "either": [ 248 ], "is": [ 249 ], "marker": [ 251 ], "unmeasured": [ 254 ], "factor": [ 255 ], "true": [ 258 ], "remains": [ 260 ], "key": [ 262 ], "question": [ 263 ], "invites": [ 265 ], "further": [ 266 ], "investigation.": [ 267 ] }, "publication_date": "2020-05-04", "publication_year": 2020, "type": "article", "cited_by_count": 151, "authors": [ { "id": "https://openalex.org/A5040182038", "display_name": "John B. Buse" }, { "id": "https://openalex.org/A5080463002", "display_name": "Stephen C. Bain" }, { "id": "https://openalex.org/A5043842967", "display_name": "Johannes F.E. Mann" }, { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5040589473", "display_name": "Steven E. Nissen" }, { "id": "https://openalex.org/A5023436129", "display_name": "Stuart Pocock" }, { "id": "https://openalex.org/A5072011562", "display_name": "Neil R Poulter" }, { "id": "https://openalex.org/A5059098934", "display_name": "Richard E. Pratley" }, { "id": "https://openalex.org/A5113321224", "display_name": "Martin Linder" }, { "id": "https://openalex.org/A5067480548", "display_name": "Tea Monk Fries" }, { "id": "https://openalex.org/A5006684229", "display_name": "David D. \u00d8rsted" }, { "id": "https://openalex.org/A5090437675", "display_name": "Bernard Zinman" } ] }, { "id": "https://openalex.org/W3133495047", "doi": "https://doi.org/10.1016/j.diabres.2021.108737", "title": "GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis", "abstract": null, "publication_date": "2021-03-08", "publication_year": 2021, "type": "review", "cited_by_count": 120, "authors": [ { "id": "https://openalex.org/A5084182369", "display_name": "Thomas Karagiannis" }, { "id": "https://openalex.org/A5018882870", "display_name": "\u0391\u03c0\u03cc\u03c3\u03c4\u03bf\u03bb\u03bf\u03c2 \u03a4\u03c3\u03ac\u03c0\u03b1\u03c2" }, { "id": "https://openalex.org/A5061500093", "display_name": "Eleni Athanasiadou" }, { "id": "https://openalex.org/A5026527950", "display_name": "Ioannis Avgerinos" }, { "id": "https://openalex.org/A5010856150", "display_name": "Aris Liakos" }, { "id": "https://openalex.org/A5011127007", "display_name": "David R. Matthews" }, { "id": "https://openalex.org/A5051305906", "display_name": "Eleni Bekiari" } ] }, { "id": "https://openalex.org/W1539916041", "doi": "https://doi.org/10.1002/dmrr.2561", "title": "Benefits of exenatide on obesity and non\u2010alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes", "abstract": { "Abstract": [ 0 ], "Background": [ 1 ], "The": [ 2, 56, 64, 188, 221 ], "purpose": [ 3 ], "of": [ 4, 12, 37, 190, 230, 257 ], "this": [ 5 ], "study": [ 6 ], "was": [ 7, 107, 260 ], "to": [ 8 ], "evaluate": [ 9 ], "the": [ 10, 54, 80, 120, 126, 158, 174, 180, 205, 213, 228, 254, 264, 269 ], "advantages": [ 11 ], "exenatide": [ 13, 65, 75, 175, 206, 265 ], "treatment": [ 14, 66 ], "on": [ 15 ], "obesity": [ 16 ], "and": [ 17, 49, 76, 79, 94, 105, 112, 150, 167, 197, 233, 289, 310 ], "non\u2010alcoholic": [ 18, 302 ], "fatty": [ 19, 258, 303 ], "liver": [ 20, 25, 47, 259, 304, 308 ], "disease": [ 21, 305 ], "(NAFLD)": [ 22 ], "with": [ 23, 29, 42, 45, 74, 91, 227, 300, 306 ], "elevated": [ 24, 46, 307 ], "enzymes": [ 26, 48, 309 ], "in": [ 27, 53, 157, 173, 179, 204, 212, 263 ], "patients": [ 28, 41, 57, 299 ], "type": [ 30 ], "2": [ 31 ], "diabetes": [ 32 ], "(T2D).": [ 33 ], "Methods": [ 34 ], "A": [ 35 ], "total": [ 36, 145, 151 ], "60": [ 38 ], "newly": [ 39 ], "diagnosed": [ 40 ], "obesity,": [ 43, 301 ], "NAFLD": [ 44 ], "T2D": [ 50 ], "were": [ 51, 58, 72, 89, 103, 123, 154, 170, 208 ], "included": [ 52 ], "study.": [ 55 ], "randomly": [ 59 ], "divided": [ 60 ], "into": [ 61 ], "two": [ 62, 127, 159 ], "groups.": [ 63, 128 ], "group": [ 67, 84, 176, 183, 207, 216, 266, 272 ], "(": [ 68, 85, 161, 184, 201, 217, 274 ], "n": [ 69, 86 ], "=": [ 70, 87, 239, 243, 248 ], "30)": [ 71, 88 ], "treated": [ 73, 90 ], "insulin": [ 77, 82, 92, 95, 182, 215, 271, 287 ], "glargine,": [ 78 ], "intensive": [ 81, 181, 214, 270, 286 ], "therapy": [ 83, 288, 297 ], "aspart": [ 93 ], "glargine": [ 96 ], "for": [ 97, 295, 298 ], "12": [ 98, 113, 130 ], "weeks.": [ 99 ], "Selected": [ 100 ], "clinical": [ 101, 121 ], "characteristics": [ 102, 122 ], "determined,": [ 104 ], "ultrasonography": [ 106 ], "performed": [ 108 ], "at": [ 109 ], "both": [ 110 ], "baseline": [ 111 ], "weeks": [ 114 ], "following": [ 115 ], "treatment.": [ 116 ], "Results": [ 117 ], "At": [ 118 ], "baseline,": [ 119 ], "matched": [ 124 ], "between": [ 125 ], "After": [ 129 ], "weeks,": [ 131 ], "fasting": [ 132 ], "blood": [ 133, 137 ], "glucose": [ 134, 138 ], "(FBG),": [ 135 ], "postprandial": [ 136 ], "(PBG),": [ 139 ], "glycosylated": [ 140 ], "haemoglobin": [ 141 ], "(HbA": [ 142 ], "1c": [ 143 ], "),": [ 144 ], "cholesterol": [ 146 ], "(TC),": [ 147 ], "triglyceride": [ 148 ], "(TG)": [ 149 ], "bilirubin": [ 152 ], "levels": [ 153, 189, 229 ], "significantly": [ 155, 171, 209, 261 ], "decreased": [ 156, 172 ], "groups": [ 160 ], "p": [ 162, 185, 218, 250, 275 ], "<": [ 163, 186, 219, 251, 276 ], "0.001).": [ 164, 187, 220, 252 ], "Body": [ 165 ], "weight": [ 166, 224 ], "waist": [ 168 ], "circumference": [ 169 ], "but": [ 177 ], "increased": [ 178 ], "alanine": [ 191 ], "aminotransferase": [ 192, 195 ], "(ALT),": [ 193 ], "aspartate": [ 194 ], "(AST)": [ 196 ], "\u03b3": [ 198, 202, 234, 245 ], "\u2010glutamyl": [ 199 ], "transpeptidase": [ 200 ], "GGT)": [ 203 ], "lower": [ 210 ], "than": [ 211, 268, 285 ], "mean": [ 222 ], "body": [ 223 ], "change": [ 225, 236 ], "correlated": [ 226 ], "ALT,": [ 231 ], "AST": [ 232 ], "GGT": [ 235 ], "(ALT,": [ 237 ], "r": [ 238, 242, 247 ], "0.761;": [ 240 ], "AST,": [ 241 ], "0.733;": [ 244 ], "GGT,": [ 246 ], "0.752;": [ 249 ], "Moreover,": [ 253 ], "reversal": [ 255 ], "rate": [ 256 ], "higher": [ 262 ], "(93.3%)": [ 267 ], "(66.7%)": [ 273 ], "0.01).": [ 277 ], "Conclusions": [ 278 ], "Exenatide": [ 279 ], "has": [ 280 ], "a": [ 281, 292 ], "better": [ 282 ], "hepatic\u2013protective": [ 283 ], "effect": [ 284 ], "perhaps": [ 290 ], "represents": [ 291 ], "unique": [ 293 ], "option": [ 294 ], "adjunctive": [ 296 ], "T2D.": [ 311 ], "Copyright": [ 312 ], "\u00a9": [ 313 ], "2014": [ 314 ], "John": [ 315 ], "Wiley": [ 316 ], "&": [ 317 ], "Sons,": [ 318 ], "Ltd.": [ 319 ] }, "publication_date": "2014-05-14", "publication_year": 2014, "type": "article", "cited_by_count": 180, "authors": [ { "id": "https://openalex.org/A5025073941", "display_name": "Ning Shao" }, { "id": "https://openalex.org/A5007865743", "display_name": "Hong Kuang" }, { "id": "https://openalex.org/A5063268197", "display_name": "Ming Hao" }, { "id": "https://openalex.org/A5100713602", "display_name": "X\u012bn G\u00e0o" }, { "id": "https://openalex.org/A5035784144", "display_name": "Wen Jian Lin" }, { "id": "https://openalex.org/A5101529138", "display_name": "Wei Zou" } ] }, { "id": "https://openalex.org/W1945989183", "doi": "https://doi.org/10.1111/j.1742-1241.2006.01196.x", "title": "Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data", "abstract": { "The": [ 0, 38 ], "therapeutic": [ 1, 156, 228 ], "options": [ 2 ], "for": [ 3, 81, 99, 155 ], "treating": [ 4 ], "type": [ 5, 68, 85, 100, 188, 231 ], "2": [ 6, 69, 86, 101, 189, 232 ], "diabetes": [ 7, 102 ], "have": [ 8, 74, 169 ], "been": [ 9 ], "widened": [ 10 ], "by": [ 11, 158 ], "the": [ 12, 17, 28, 76, 82, 110, 124, 227 ], "introduction": [ 13 ], "of": [ 14, 30, 84, 89, 127, 131, 197, 230 ], "exenatide": [ 15, 168, 209, 238 ], "as": [ 16 ], "first": [ 18 ], "incretin": [ 19, 39, 128 ], "mimetic.": [ 20 ], "Incretins": [ 21 ], "are": [ 22, 240 ], "gut": [ 23 ], "hormones": [ 24 ], "that": [ 25, 151 ], "contribute": [ 26 ], "to": [ 27, 78, 119, 123 ], "stimulation": [ 29 ], "insulin": [ 31, 47 ], "secretion": [ 32, 48 ], "after": [ 33, 208 ], "a": [ 34, 106, 116, 137, 147, 171, 181 ], "carbohydrate": [ 35 ], "rich": [ 36 ], "meal.": [ 37 ], "hormone": [ 40 ], "glucagon-like": [ 41 ], "peptide-1": [ 42 ], "(GLP-1)": [ 43 ], "not": [ 44, 97 ], "only": [ 45 ], "stimulates": [ 46 ], "under": [ 49 ], "hyperglycaemic": [ 50 ], "conditions,": [ 51 ], "but": [ 52 ], "also": [ 53 ], "suppresses": [ 54 ], "glucagon": [ 55 ], "secretion,": [ 56 ], "slows": [ 57 ], "gastric": [ 58 ], "emptying,": [ 59 ], "induces": [ 60 ], "satiety": [ 61 ], "and": [ 62, 114, 145, 164, 177, 180, 201, 221, 224 ], "improves": [ 63 ], "beta": [ 64, 198, 205 ], "cell": [ 65, 199, 206 ], "function": [ 66, 200 ], "in": [ 67, 109, 174, 184, 187, 204, 226 ], "diabetes.": [ 70, 87, 233 ], "These": [ 71 ], "beneficial": [ 72 ], "effects": [ 73 ], "awakened": [ 75 ], "interest": [ 77 ], "use": [ 79 ], "GLP-1": [ 80, 94, 144, 148 ], "treatment": [ 83 ], "Because": [ 88 ], "its": [ 90, 132, 218, 222 ], "short": [ 91 ], "biological": [ 92, 140 ], "half-life,": [ 93 ], "itself": [ 95 ], "is": [ 96, 105, 146 ], "practical": [ 98 ], "therapy.": [ 103 ], "Exenatide": [ 104, 121 ], "peptide": [ 107 ], "found": [ 108 ], "lizard": [ 111 ], "Heloderma": [ 112 ], "suspectum": [ 113 ], "has": [ 115, 136 ], "high": [ 117 ], "similarity": [ 118 ], "GLP-1.": [ 120 ], "belongs": [ 122 ], "novel": [ 125 ], "class": [ 126 ], "mimetics": [ 129 ], "because": [ 130 ], "incretin-like": [ 133 ], "action.": [ 134 ], "It": [ 135 ], "much": [ 138 ], "longer": [ 139 ], "half": [ 141 ], "life": [ 142 ], "than": [ 143 ], "receptor": [ 149 ], "agonist": [ 150 ], "can": [ 152 ], "be": [ 153 ], "used": [ 154 ], "purposes": [ 157 ], "twice": [ 159 ], "daily": [ 160 ], "injection.": [ 161 ], "Clinical": [ 162 ], "studies": [ 163, 193 ], "clinical": [ 165 ], "experience": [ 166 ], "with": [ 167 ], "shown": [ 170 ], "significant": [ 172 ], "reduction": [ 173, 183 ], "HbA1c,": [ 175 ], "fasting-": [ 176 ], "postprandial": [ 178 ], "glucose": [ 179 ], "marked": [ 182 ], "body": [ 185 ], "weight": [ 186 ], "diabetic": [ 190 ], "patients.": [ 191 ], "Animal": [ 192 ], "reveal": [ 194 ], "an": [ 195, 202, 214 ], "improvement": [ 196 ], "increase": [ 203 ], "mass": [ 207 ], "treatment.": [ 210 ], "This": [ 211 ], "review": [ 212 ], "gives": [ 213 ], "overview": [ 215 ], "on": [ 216 ], "exenatide,": [ 217 ], "pharmacological": [ 219 ], "profile": [ 220 ], "role": [ 223 ], "potential": [ 225 ], "setting": [ 229 ], "Furthermore,": [ 234 ], "future": [ 235 ], "developments": [ 236 ], "concerning": [ 237 ], "application": [ 239 ], "highlighted.": [ 241 ] }, "publication_date": "2006-11-10", "publication_year": 2006, "type": "review", "cited_by_count": 63, "authors": [ { "id": "https://openalex.org/A5105783630", "display_name": "Baptist Gallwitz" } ] }, { "id": "https://openalex.org/W2137805490", "doi": "https://doi.org/10.2174/138920006776873490", "title": "Investigation of Exenatide Elimination and Its In Vivo and In Vitro Degradation", "abstract": { "Exenatide": [ 0, 23, 166, 208, 226 ], "is": [ 1, 24 ], "a": [ 2, 25 ], "39": [ 3 ], "amino": [ 4, 117 ], "acid": [ 5 ], "incretin": [ 6 ], "mimetic": [ 7 ], "for": [ 8, 28 ], "the": [ 9, 29, 56, 63, 68, 157, 177, 181, 236, 243, 248 ], "treatment": [ 10 ], "of": [ 11, 32, 59, 71, 107, 138, 180, 186, 251, 255 ], "type": [ 12 ], "2": [ 13 ], "diabetes,": [ 14 ], "with": [ 15, 235 ], "glucoregulatory": [ 16 ], "activity": [ 17, 233 ], "similar": [ 18 ], "to": [ 19, 49, 54, 92, 222, 246 ], "glucagon-like": [ 20 ], "peptide-1": [ 21 ], "(GLP-1).": [ 22 ], "poor": [ 26 ], "substrate": [ 27 ], "major": [ 30, 57 ], "route": [ 31, 58, 250 ], "GLP-1": [ 33 ], "degradation": [ 34, 73, 100, 140, 188, 254 ], "by": [ 35, 130, 141, 176, 189 ], "dipeptidyl": [ 36 ], "peptidase-IV,": [ 37 ], "and": [ 38, 42, 74, 76, 85, 99, 122, 150, 155, 164, 192, 205, 212, 228, 253 ], "displays": [ 39 ], "enhanced": [ 40 ], "pharmacokinetics": [ 41 ], "in": [ 43, 46, 62, 87, 104, 196, 224 ], "vivo": [ 44 ], "potency": [ 45 ], "rats": [ 47 ], "relative": [ 48 ], "GLP-1.": [ 50 ], "The": [ 51, 134, 184 ], "kidney": [ 52, 132, 143, 178, 194, 244 ], "appears": [ 53, 245 ], "be": [ 55, 247 ], "exenatide": [ 60, 72, 81, 97, 127, 139, 187, 223, 239 ], "elimination": [ 61, 98, 252 ], "rat.": [ 64 ], "We": [ 65 ], "further": [ 66 ], "investigated": [ 67 ], "putative": [ 69 ], "sites": [ 70, 115, 137, 160 ], "excretion,": [ 75 ], "identified": [ 77, 125 ], "primary": [ 78, 113, 135, 158, 249 ], "degradants.": [ 79 ], "Plasma": [ 80 ], "concentrations": [ 82 ], "were": [ 83, 124, 145, 161, 198, 214 ], "elevated": [ 84 ], "sustained": [ 86 ], "renal-ligated": [ 88 ], "rats,": [ 89 ], "when": [ 90, 126 ], "compared": [ 91, 234 ], "sham-operated": [ 93 ], "controls.": [ 94 ], "By": [ 95 ], "contrast,": [ 96 ], "was": [ 101, 128, 167 ], "not": [ 102, 215 ], "affected": [ 103 ], "rat": [ 105, 142, 206 ], "models": [ 106 ], "hepatic": [ 108 ], "dysfunction.": [ 109 ], "In": [ 110, 152, 241 ], "vitro,": [ 111 ], "four": [ 112 ], "cleavage": [ 114, 136, 159 ], "after": [ 116, 146, 162 ], "acids": [ 118 ], "(AA)-15,": [ 119 ], "-21,": [ 120, 149 ], "-22": [ 121 ], "-34": [ 123 ], "degraded": [ 129, 170 ], "mouse": [ 131, 204 ], "membranes.": [ 133, 207 ], "membranes": [ 144, 179, 195 ], "AA-14,": [ 147 ], "-15,": [ 148 ], "-22.": [ 151, 165 ], "rabbit,": [ 153, 190 ], "monkey,": [ 154 ], "human,": [ 156 ], "AA-21": [ 163 ], "almost": [ 168 ], "completely": [ 169 ], "into": [ 171 ], "peptide": [ 172 ], "fragments": [ 173 ], "<3": [ 174 ], "AA": [ 175 ], "species": [ 182 ], "tested.": [ 183 ], "rates": [ 185 ], "monkey": [ 191 ], "human": [ 193 ], "vitro": [ 197 ], "at": [ 199 ], "least": [ 200 ], "15-fold": [ 201 ], "slower": [ 202 ], "than": [ 203 ], "(1-14),": [ 209 ], "(1-15),": [ 210 ], "(1-22),": [ 211 ], "(23-39)": [ 213 ], "active": [ 216 ], "as": [ 217 ], "either": [ 218 ], "agonists": [ 219 ], "or": [ 220 ], "antagonists": [ 221 ], "vitro.": [ 225 ], "(15-39)": [ 227 ], "(16-39)": [ 229 ], "had": [ 230 ], "moderate-to-weak": [ 231 ], "antagonist": [ 232 ], "known": [ 237 ], "antagonist,": [ 238 ], "(9-39).": [ 240 ], "conclusion,": [ 242 ], "exenatide.": [ 256 ] }, "publication_date": "2006-04-28", "publication_year": 2006, "type": "article", "cited_by_count": 100, "authors": [ { "id": "https://openalex.org/A5039825706", "display_name": "Kathrin Copley" }, { "id": "https://openalex.org/A5091293213", "display_name": "Kevin McCowen" }, { "id": "https://openalex.org/A5079734406", "display_name": "Richard Hiles" }, { "id": "https://openalex.org/A5075068030", "display_name": "Loretta L. Nielsen" }, { "id": "https://openalex.org/A5024629053", "display_name": "Andrew Young" }, { "id": "https://openalex.org/A5077809872", "display_name": "David G. Parkes" } ] }, { "id": "https://openalex.org/W2103274121", "doi": "https://doi.org/10.2337/dc14-1984", "title": "Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial", "abstract": { "OBJECTIVE": [ 0 ], "This": [ 1, 30 ], "mechanistic": [ 2 ], "trial": [ 3, 37 ], "compared": [ 4, 144 ], "the": [ 5, 76 ], "pharmacodynamics": [ 6 ], "and": [ 7, 11, 42, 45, 111, 115, 118, 132, 168, 188, 201, 239, 251, 254, 314, 333, 349 ], "safety": [ 8, 351 ], "of": [ 9, 140, 290, 347 ], "lixisenatide": [ 10, 39, 248, 285 ], "liraglutide": [ 12, 43, 146, 165, 180, 199, 252, 262, 312, 334 ], "in": [ 13, 21, 53, 72, 95, 213, 338 ], "combination": [ 14, 54 ], "with": [ 15, 55, 145, 198, 284, 295, 302, 311, 344 ], "optimized": [ 16, 59, 339 ], "insulin": [ 17, 56, 340 ], "glargine": [ 18, 57 ], "with/without": [ 19 ], "metformin": [ 20 ], "type": [ 22 ], "2": [ 23 ], "diabetes": [ 24 ], "(T2D).": [ 25 ], "RESEARCH": [ 26 ], "DESIGN": [ 27 ], "AND": [ 28 ], "METHODS": [ 29 ], "was": [ 31, 65, 191, 211, 224, 293 ], "a": [ 32, 85, 194 ], "multicenter,": [ 33 ], "randomized,": [ 34 ], "open-label,": [ 35 ], "three-arm": [ 36 ], "comparing": [ 38 ], "20": [ 40, 135, 249 ], "\u00b5g": [ 41, 136, 250 ], "1.2": [ 44, 166, 200, 253, 313 ], "1.8": [ 46, 181, 202, 255, 315 ], "mg": [ 47, 167, 203, 316 ], "once": [ 48 ], "daily": [ 49 ], "for": [ 50, 81, 186, 207, 247, 326 ], "8": [ 51, 71 ], "weeks": [ 52 ], "after": [ 58, 84 ], "titration.": [ 60 ], "The": [ 61 ], "primary": [ 62 ], "end": [ 63 ], "point": [ 64 ], "change": [ 66 ], "from": [ 67, 93, 272, 309 ], "baseline": [ 68, 94, 273, 310 ], "to": [ 69, 193 ], "week": [ 70, 218, 259 ], "incremental": [ 73 ], "area": [ 74 ], "under": [ 75 ], "postprandial": [ 77 ], "plasma": [ 78, 99, 104 ], "glucose": [ 79, 100, 105 ], "curve": [ 80 ], "4": [ 82, 237, 245 ], "h": [ 83, 143, 156, 161, 171, 176 ], "standardized": [ 86 ], "solid": [ 87 ], "breakfast": [ 88 ], "(AUC": [ 89 ], "PPG0030\u20130430": [ 90 ], "h).": [ 91 ], "Changes": [ 92 ], "gastric": [ 96, 189 ], "emptying,": [ 97 ], "24-h": [ 98, 107, 269 ], "profile,": [ 101 ], "HbA1c,": [ 102 ], "fasting": [ 103 ], "(FPG),": [ 106 ], "ambulatory": [ 108 ], "heart": [ 109, 270 ], "rate": [ 110, 271 ], "blood": [ 112 ], "pressure,": [ 113 ], "amylase": [ 114 ], "lipase": [ 116 ], "levels,": [ 117 ], "adverse": [ 119 ], "events": [ 120 ], "(AEs)": [ 121 ], "were": [ 122, 130, 299, 306 ], "also": [ 123 ], "assessed.": [ 124 ], "RESULTS": [ 125 ], "In": [ 126 ], "total,": [ 127 ], "142": [ 128 ], "patients": [ 129 ], "randomized": [ 131 ], "treated.": [ 133 ], "Lixisenatide": [ 134, 332 ], "achieved": [ 137 ], "greater": [ 138, 195 ], "reductions": [ 139 ], "AUC": [ 141 ], "PPG0030\u22120430": [ 142 ], "(marginal": [ 147, 317 ], "mean": [ 148, 220, 266, 318 ], "[95%": [ 149 ], "one-sided": [ 150 ], "CI]": [ 151 ], "treatment": [ 152, 208, 215 ], "difference,": [ 153 ], "\u22126.0": [ 154 ], "[\u22127.8]": [ 155 ], "\u22c5": [ 157, 162, 172, 177 ], "mmol/L": [ 158, 173 ], "[\u2212108.3": [ 159 ], "(\u2212140.0)": [ 160 ], "mg/dL]": [ 163, 178 ], "vs.": [ 164, 179, 279 ], "\u22124.6": [ 169 ], "[\u22126.3]": [ 170 ], "[\u221283.0": [ 174 ], "(\u2212114.2)": [ 175 ], "mg;": [ 182 ], "P": [ 183, 328 ], "&lt;": [ 184, 205, 287, 329 ], "0.001": [ 185, 206 ], "both),": [ 187 ], "emptying": [ 190 ], "delayed": [ 192 ], "extent": [ 196 ], "than": [ 197 ], "(P": [ 204, 286 ], "comparisons).": [ 209 ], "FPG": [ 210 ], "unchanged": [ 212 ], "all": [ 214 ], "arms.": [ 216 ], "At": [ 217, 258 ], "8,": [ 219, 260 ], "\u00b1": [ 221, 226, 229, 233, 236, 241, 244, 267, 276, 281, 319, 323 ], "SD": [ 222 ], "HbA1c": [ 223 ], "6.2": [ 225 ], "0.4%": [ 227 ], "(44": [ 228, 235, 243 ], "5": [ 230 ], "mmol/mol),": [ 231, 238 ], "6.1": [ 232, 240 ], "0.3%": [ 234, 242 ], "mmol/mol)": [ 246 ], "mg,": [ 256 ], "respectively.": [ 257 ], "both": [ 261 ], "doses": [ 263 ], "increased": [ 264, 308 ], "marginal": [ 265 ], "SE": [ 268, 320 ], "by": [ 274 ], "9": [ 275 ], "1": [ 277, 282 ], "bpm": [ 278, 283 ], "3": [ 280 ], "0.001).": [ 288 ], "Occurrence": [ 289 ], "symptomatic": [ 291 ], "hypoglycemia": [ 292 ], "higher": [ 294 ], "lixisenatide;": [ 296 ], "gastrointestinal": [ 297 ], "AEs": [ 298 ], "more": [ 300 ], "common": [ 301 ], "liraglutide.": [ 303 ], "Lipase": [ 304 ], "levels": [ 305 ], "significantly": [ 307 ], "increase": [ 321 ], "21": [ 322 ], "7": [ 324 ], "IU/L": [ 325 ], "both;": [ 327 ], "0.05).": [ 330 ], "CONCLUSIONS": [ 331 ], "improved": [ 335 ], "glycemic": [ 336 ], "control": [ 337 ], "glargine-treated": [ 341 ], "T2D": [ 342 ], "albeit": [ 343 ], "contrasting": [ 345 ], "mechanisms": [ 346 ], "action": [ 348 ], "differing": [ 350 ], "profiles.": [ 352 ] }, "publication_date": "2015-04-17", "publication_year": 2015, "type": "article", "cited_by_count": 249, "authors": [ { "id": "https://openalex.org/A5002832666", "display_name": "Juris J. Meier" }, { "id": "https://openalex.org/A5045489578", "display_name": "Julio Rosenstock" }, { "id": "https://openalex.org/A5072715151", "display_name": "Agn\u00e8s Hincelin-M\u00e9ry" }, { "id": "https://openalex.org/A5009161997", "display_name": "Christine Roy-Duval" }, { "id": "https://openalex.org/A5012829925", "display_name": "A. Delfolie" }, { "id": "https://openalex.org/A5112095922", "display_name": "Hans\u2010Veit Coester" }, { "id": "https://openalex.org/A5111991123", "display_name": "Bjoern A. Menge" }, { "id": "https://openalex.org/A5044778195", "display_name": "Thomas F\u00f6rst" }, { "id": "https://openalex.org/A5068619321", "display_name": "Christoph Kapitza" } ] }, { "id": "https://openalex.org/W2744885053", "doi": "https://doi.org/10.14341/dm20151s1-112", "title": "Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies", "abstract": { "For": [ 0 ], "the": [ 1, 5, 24, 61, 127, 154, 225 ], "purpose": [ 2 ], "of": [ 3, 20, 27, 30, 37, 55, 67, 144, 160, 180, 190, 231, 285 ], "exploring": [ 4 ], "development,": [ 6 ], "pharmacology": [ 7 ], "and": [ 8, 73, 105, 139, 147, 175, 205, 238, 257, 273 ], "clinical": [ 9 ], "trial": [ 10 ], "program": [ 11, 36 ], "related": [ 12 ], "to": [ 13, 107, 126, 153, 229, 275 ], "dulaglutide,": [ 14, 21, 224 ], "we": [ 15 ], "conducted": [ 16, 85 ], "a": [ 17, 44, 53, 77, 177, 186, 283 ], "nonsystematic": [ 18 ], "review": [ 19 ], "focusing": [ 22 ], "on": [ 23, 60 ], "AWARD": [ 25, 81, 215, 236 ], "(Assessment": [ 26 ], "Weekly": [ 28 ], "Administration": [ 29 ], "LY2189265": [ 31 ], "[dulaglutide]": [ 32 ], "in": [ 33, 86, 122, 199, 213, 234, 246, 279, 282 ], "Diabetes": [ 34 ], "Assessment)": [ 35 ], "randomized,": [ 38 ], "phase": [ 39 ], "3": [ 40 ], "studies.": [ 41, 216 ], "Dulaglutide": [ 42 ], "is": [ 43 ], "glucagon-like": [ 45 ], "peptide": [ 46 ], "1": [ 47 ], "(GLP-1)": [ 48 ], "receptor": [ 49 ], "agonist": [ 50 ], "that": [ 51, 165, 176, 230 ], "causes": [ 52 ], "variety": [ 54 ], "antidiabetogenic": [ 56 ], "actions": [ 57 ], "by": [ 58 ], "acting": [ 59 ], "incretin": [ 62 ], "system.": [ 63 ], "Steady-state": [ 64 ], "plasma": [ 65 ], "concentrations": [ 66 ], "dulaglutide": [ 68, 135, 170, 184, 209, 269 ], "are": [ 69 ], "achieved": [ 70, 116, 185 ], "between": [ 71 ], "2": [ 72, 267 ], "4": [ 74 ], "weeks": [ 75 ], "following": [ 76 ], "once-weekly": [ 78 ], "administration.": [ 79 ], "The": [ 80, 158 ], "16": [ 82 ], "studies": [ 83 ], "were": [ 84, 136, 211, 221, 242, 260 ], "patients": [ 87, 94, 108, 181, 247, 264 ], "with": [ 88, 95, 102, 117, 134, 169, 183, 193, 223, 248, 253, 265 ], "different": [ 89 ], "treatment": [ 90, 210, 286 ], "needs,": [ 91 ], "ranging": [ 92 ], "from": [ 93, 124 ], "mild": [ 96 ], "diabetes": [ 97 ], "who": [ 98 ], "can": [ 99 ], "be": [ 100, 115 ], "treated": [ 101, 182 ], "diet": [ 103 ], "management": [ 104 ], "exercise": [ 106 ], "for": [ 109, 173 ], "whom": [ 110 ], "target": [ 111, 187 ], "glycemic": [ 112, 166, 271 ], "control": [ 113, 167, 272 ], "cannot": [ 114 ], "conventional": [ 118 ], "insulin": [ 119 ], "treatment.": [ 120 ], "Changes": [ 121 ], "HbA1c": [ 123, 188 ], "baseline": [ 125 ], "primary": [ 128 ], "endpoint": [ 129 ], "assessment": [ 130 ], "(primary": [ 131 ], "efficacy": [ 132 ], "outcome)": [ 133 ], "generally": [ 137, 243 ], "dose-dependent": [ 138 ], "significantly": [ 140 ], "greater": [ 141, 178 ], "than": [ 142 ], "those": [ 143 ], "active": [ 145, 196, 232 ], "comparators": [ 146, 155, 233 ], "placebos": [ 148 ], "(AWARD": [ 149, 156 ], "15)": [ 150 ], "or": [ 151, 252 ], "non-inferior": [ 152 ], "6).": [ 157 ], "results": [ 159 ], "secondary": [ 161 ], "outcome": [ 162 ], "measures": [ 163 ], "demonstrated": [ 164 ], "attained": [ 168 ], "was": [ 171, 227 ], "sustained": [ 172 ], "long-term": [ 174 ], "proportion": [ 179 ], "level": [ 189 ], "7.0%": [ 191 ], "compared": [ 192 ], "placebo": [ 194 ], "and/or": [ 195 ], "comparators.": [ 197 ], "Reduction": [ 198 ], "fasting": [ 200 ], "serum": [ 201 ], "glucose,": [ 202 ], "glucagon": [ 203 ], "levels": [ 204 ], "body": [ 206, 280 ], "weight": [ 207, 281 ], "after": [ 208 ], "noted": [ 212 ], "most": [ 214, 235 ], "Although": [ 217 ], "treatment-emergent": [ 218 ], "adverse": [ 219, 240 ], "events": [ 220, 241, 259 ], "common": [ 222 ], "incidence": [ 226 ], "similar": [ 228 ], "studies,": [ 237 ], "serious": [ 239 ], "infrequent,": [ 244 ], "except": [ 245 ], "more": [ 249 ], "severe": [ 250 ], "disease": [ 251 ], "prolonged": [ 254 ], "therapy.": [ 255 ], "Hypoglycemic": [ 256 ], "immunogenic": [ 258 ], "also": [ 261 ], "infrequent.": [ 262 ], "In": [ 263 ], "type": [ 266 ], "diabetes,": [ 268 ], "improves": [ 270 ], "leads": [ 274 ], "clinically": [ 276 ], "useful": [ 277 ], "reduction": [ 278 ], "range": [ 284 ], "settings.": [ 287 ] }, "publication_date": "2015-03-02", "publication_year": 2015, "type": "article", "cited_by_count": 65, "authors": [ { "id": "https://openalex.org/A5060918913", "display_name": "Marina V. Shestakova" }, { "id": "https://openalex.org/A5045908330", "display_name": "Ekaterina A. Yudovich" } ] }, { "id": "https://openalex.org/W2137352234", "doi": "https://doi.org/10.1007/s00125-009-1472-y", "title": "Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial", "abstract": { "The": [ 0 ], "study": [ 1 ], "was": [ 2 ], "funded": [ 3 ], "by": [ 4 ], "Novo": [ 5 ], "Nordisk": [ 6 ], "A/S.": [ 7 ] }, "publication_date": "2009-08-13", "publication_year": 2009, "type": "article", "cited_by_count": 822, "authors": [ { "id": "https://openalex.org/A5082184915", "display_name": "David Russell\u2010Jones" }, { "id": "https://openalex.org/A5069291545", "display_name": "Allan Vaag" }, { "id": "https://openalex.org/A5108600845", "display_name": "O. Schmitz" }, { "id": "https://openalex.org/A5108417645", "display_name": "Bipin Sethi" }, { "id": "https://openalex.org/A5000893155", "display_name": "Neboj\u0161a Lali\u0107" }, { "id": "https://openalex.org/A5045813766", "display_name": "Slobodan Anti\u0107" }, { "id": "https://openalex.org/A5059007137", "display_name": "Marija Zdravkovi\u0107" }, { "id": "https://openalex.org/A5032084622", "display_name": "Gabriela Martinez Ravn" }, { "id": "https://openalex.org/A5091908088", "display_name": "Rafael Sim\u00f3" } ] }, { "id": "https://openalex.org/W4220656413", "doi": "https://doi.org/10.1186/s12933-022-01474-z", "title": "The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs", "abstract": null, "publication_date": "2022-03-16", "publication_year": 2022, "type": "article", "cited_by_count": 131, "authors": [ { "id": "https://openalex.org/A5056173815", "display_name": "Dario Giugliano" }, { "id": "https://openalex.org/A5005827466", "display_name": "Miriam Longo" }, { "id": "https://openalex.org/A5005815956", "display_name": "Simona Signoriello" }, { "id": "https://openalex.org/A5043443418", "display_name": "Maria Ida Maiorino" }, { "id": "https://openalex.org/A5027200822", "display_name": "Bruno Solerte" }, { "id": "https://openalex.org/A5048229494", "display_name": "Paolo Chiodini" }, { "id": "https://openalex.org/A5052044111", "display_name": "Katherine Esposito" } ] }, { "id": "https://openalex.org/W1977102586", "doi": "https://doi.org/10.7326/0003-4819-154-2-201101180-00300", "title": "Use of Twice-Daily Exenatide in Basal Insulin\u2013Treated Patients With Type 2 Diabetes", "abstract": { "Alliance": [ 0 ], "of": [ 1 ], "Eli": [ 2 ], "Lilly": [ 3 ], "and": [ 4, 6 ], "Company": [ 5 ], "Amylin": [ 7 ], "Pharmaceuticals.": [ 8 ] }, "publication_date": "2011-01-18", "publication_year": 2011, "type": "article", "cited_by_count": 503, "authors": [ { "id": "https://openalex.org/A5040182038", "display_name": "John B. Buse" }, { "id": "https://openalex.org/A5034096266", "display_name": "Richard M. Bergenstal" }, { "id": "https://openalex.org/A5111625146", "display_name": "Leonard C. Glass" }, { "id": "https://openalex.org/A5084630296", "display_name": "Cory R. Heilmann" }, { "id": "https://openalex.org/A5103567970", "display_name": "Michelle S. Lewis" }, { "id": "https://openalex.org/A5021162116", "display_name": "Anita Y. M. Kwan" }, { "id": "https://openalex.org/A5058778822", "display_name": "Byron J. Hoogwerf" }, { "id": "https://openalex.org/A5045489578", "display_name": "Julio Rosenstock" } ] }, { "id": "https://openalex.org/W2067314875", "doi": "https://doi.org/10.1016/j.bbrc.2009.10.015", "title": "Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression", "abstract": null, "publication_date": "2009-10-21", "publication_year": 2009, "type": "article", "cited_by_count": 147, "authors": [ { "id": "https://openalex.org/A5109617173", "display_name": "Le Thi Kim Chung" }, { "id": "https://openalex.org/A5078703658", "display_name": "Toshio Hosaka" }, { "id": "https://openalex.org/A5101533889", "display_name": "Masaki Yoshida" }, { "id": "https://openalex.org/A5020382541", "display_name": "Nagakatsu Harada" }, { "id": "https://openalex.org/A5028675062", "display_name": "Hiroshi Sakaue" }, { "id": "https://openalex.org/A5053123312", "display_name": "Tohru Sakai" }, { "id": "https://openalex.org/A5038923350", "display_name": "Yutaka Nakaya" } ] }, { "id": "https://openalex.org/W2887586721", "doi": "https://doi.org/10.1016/j.jnutbio.2018.07.009", "title": "Liraglutide modulates gut microbiota and reduces NAFLD in obese mice", "abstract": null, "publication_date": "2018-08-11", "publication_year": 2018, "type": "article", "cited_by_count": 142, "authors": [ { "id": "https://openalex.org/A5018441478", "display_name": "Gabriela Moreira" }, { "id": "https://openalex.org/A5108202763", "display_name": "F.P. Azevedo" }, { "id": "https://openalex.org/A5001534747", "display_name": "Ribeiro Lm" }, { "id": "https://openalex.org/A5067684898", "display_name": "Andrey Santos" }, { "id": "https://openalex.org/A5061573170", "display_name": "Dioze Guadagnini" }, { "id": "https://openalex.org/A5038670044", "display_name": "Patr\u0131\u0301cia Gama" }, { "id": "https://openalex.org/A5001400601", "display_name": "EA Liberti" }, { "id": "https://openalex.org/A5109914337", "display_name": "Mja Saad" }, { "id": "https://openalex.org/A5003117158", "display_name": "Carla Roberta de Oliveira Carvalho" } ] }, { "id": "https://openalex.org/W560666237", "doi": "https://doi.org/10.1016/j.physbeh.2015.06.013", "title": "The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice", "abstract": null, "publication_date": "2015-06-13", "publication_year": 2015, "type": "article", "cited_by_count": 118, "authors": [ { "id": "https://openalex.org/A5102932645", "display_name": "G. S\u00f8rensen" }, { "id": "https://openalex.org/A5029493476", "display_name": "India A. Reddy" }, { "id": "https://openalex.org/A5013981616", "display_name": "Pia Weikop" }, { "id": "https://openalex.org/A5066856401", "display_name": "Devon L. Graham" }, { "id": "https://openalex.org/A5004009433", "display_name": "Gregg D. Stanwood" }, { "id": "https://openalex.org/A5013639019", "display_name": "Gitta W\u00f6rtwein" }, { "id": "https://openalex.org/A5019043893", "display_name": "Aurelio Galli" }, { "id": "https://openalex.org/A5001609083", "display_name": "Anders Fink\u2010Jensen" } ] }, { "id": "https://openalex.org/W2016253107", "doi": "https://doi.org/10.1111/apt.12149", "title": "Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta\u2010analysis of the LEAD program", "abstract": { "Summary": [ 0 ], "Background": [ 1 ], "Non\u2010alcoholic": [ 2 ], "fatty": [ 3 ], "liver": [ 4, 31, 44, 262 ], "disease": [ 5 ], "has": [ 6 ], "reached": [ 7 ], "epidemic": [ 8 ], "proportions": [ 9 ], "in": [ 10, 20, 30, 46, 78, 118, 123, 130, 166, 237, 264 ], "type": [ 11, 267 ], "2": [ 12, 268 ], "diabetes": [ 13 ], "(T2D).": [ 14 ], "Glucagon\u2010like": [ 15 ], "peptide\u20101": [ 16 ], "analogues": [ 17 ], "are": [ 18 ], "licensed": [ 19 ], "T2D,": [ 21 ], "yet": [ 22 ], "little": [ 23 ], "data": [ 24, 53, 59 ], "exist": [ 25 ], "on": [ 26, 43, 94, 279 ], "efficacy": [ 27, 39 ], "and": [ 28, 38, 76, 143, 179, 198, 243, 260, 282 ], "safety": [ 29, 37 ], "injury.": [ 32 ], "Aim": [ 33 ], "To": [ 34 ], "assess": [ 35, 91 ], "the": [ 36, 73, 92 ], "of": [ 40 ], "26\u2010week": [ 41 ], "liraglutide": [ 42, 152, 192, 208, 253 ], "parameters": [ 45 ], "comparison": [ 47 ], "with": [ 48, 151, 189, 197, 266 ], "active\u2010placebo.": [ 49 ], "Methods": [ 50 ], "Individual": [ 51 ], "patient": [ 52 ], "meta\u2010analysis": [ 54 ], "was": [ 55, 88, 144, 159, 231 ], "performed": [ 56 ], "using": [ 57 ], "patient\u2010level": [ 58 ], "combined": [ 60 ], "from": [ 61 ], "six": [ 62 ], "26\u2010week,": [ 63 ], "phase\u2010": [ 64 ], "III": [ 65 ], ",": [ 66 ], "randomised": [ 67 ], "controlled": [ 68 ], "T2D": [ 69 ], "trials,": [ 70 ], "which": [ 71 ], "comprise": [ 72 ], "\u2018Liraglutide": [ 74 ], "Effect": [ 75 ], "Action": [ 77 ], "Diabetes\u2019": [ 79 ], "(": [ 80 ], "LEAD": [ 81, 85, 205 ], ")": [ 82 ], "program.": [ 83 ], "The": [ 84 ], "\u20102": [ 86, 206 ], "sub\u2010study": [ 87 ], "analysed": [ 89 ], "to": [ 90, 273 ], "effect": [ 93, 158, 271 ], "CT": [ 95 ], "\u2010measured": [ 96 ], "hepatic": [ 97, 216 ], "steatosis.": [ 98 ], "Results": [ 99 ], "Of": [ 100 ], "4442": [ 101 ], "patients": [ 102, 106, 132, 196, 265 ], "analysed,": [ 103 ], "2241": [ 104 ], "(50.8%)": [ 105 ], "had": [ 107 ], "an": [ 108 ], "abnormal": [ 109, 201 ], "ALT": [ 110, 114, 129, 169, 202 ], "at": [ 111 ], "baseline": [ 112, 200 ], "[mean": [ 113 ], "33.8(14.9)": [ 115 ], "IU": [ 116, 121, 138, 174, 182 ], "/L": [ 117, 122 ], "females;": [ 119 ], "47.3(18.3)": [ 120 ], "males].": [ 124 ], "Liraglutide": [ 125 ], "1.8": [ 126, 190, 209, 254 ], "mg": [ 127, 191, 210, 255 ], "reduced": [ 128, 232 ], "these": [ 131 ], "vs.": [ 133, 136, 149, 171, 218, 224 ], "placebo": [ 134, 150, 172, 219 ], "(\u22128.20": [ 135 ], "\u22125.01": [ 137 ], "/L;": [ 139 ], "P": [ 140, 176, 184, 226, 240, 247 ], "=": [ 141, 177, 185, 227, 241, 248 ], "0.003),": [ 142 ], "dose\u2010dependent": [ 145 ], "(no": [ 146 ], "significant": [ 147 ], "differences": [ 148 ], "0.6": [ 153 ], "or": [ 154 ], "1.2": [ 155 ], "mg).": [ 156 ], "This": [ 157, 229, 270 ], "lost": [ 160 ], "after": [ 161 ], "adjusting": [ 162 ], "for": [ 163, 235 ], "liraglutide's": [ 164 ], "reduction": [ 165 ], "weight": [ 167, 238, 280 ], "(mean": [ 168 ], "difference": [ 170, 230 ], "\u22121.41": [ 173 ], "/L,": [ 175, 183 ], "0.21)": [ 178 ], "HbA1c": [ 180 ], "(+0.57": [ 181 ], "0.63).": [ 186 ], "Adverse": [ 187 ], "effects": [ 188 ], "were": [ 193 ], "similar": [ 194 ], "between": [ 195 ], "without": [ 199 ], ".": [ 203 ], "In": [ 204 ], "sub\u2010study,": [ 207 ], "showed": [ 211 ], "a": [ 212 ], "trend": [ 213 ], "towards": [ 214 ], "improving": [ 215 ], "steatosis": [ 217 ], "(liver\u2010to\u2010spleen": [ 220 ], "attenuation": [ 221 ], "ratio": [ 222 ], "+0.10": [ 223 ], "0.00;": [ 225 ], "0.07).": [ 228 ], "when": [ 233 ], "correcting": [ 234 ], "changes": [ 236 ], "(+0.06,": [ 239 ], "0.25)": [ 242 ], "HbA": [ 244 ], "1c": [ 245 ], "(0.00,": [ 246 ], "0.93).": [ 249 ], "Conclusions": [ 250 ], "Twenty\u2010six": [ 251 ], "weeks'": [ 252 ], "is": [ 256 ], "safe,": [ 257 ], "well": [ 258 ], "tolerated": [ 259 ], "improves": [ 261 ], "enzymes": [ 263 ], "diabetes.": [ 269 ], "appears": [ 272 ], "be": [ 274 ], "mediated": [ 275 ], "by": [ 276 ], "its": [ 277 ], "action": [ 278 ], "loss": [ 281 ], "glycaemic": [ 283 ], "control.": [ 284 ] }, "publication_date": "2012-11-19", "publication_year": 2012, "type": "review", "cited_by_count": 242, "authors": [ { "id": "https://openalex.org/A5029173327", "display_name": "Matthew J. Armstrong" }, { "id": "https://openalex.org/A5103016342", "display_name": "Diarmaid D. Houlihan" }, { "id": "https://openalex.org/A5023545015", "display_name": "Ian Rowe" }, { "id": "https://openalex.org/A5110947600", "display_name": "W. H. O. Clausen" }, { "id": "https://openalex.org/A5089315488", "display_name": "B. Elbr\u00f8nd" }, { "id": "https://openalex.org/A5107850059", "display_name": "Stephen Gough" }, { "id": "https://openalex.org/A5083236737", "display_name": "Jeremy Tomlinson" }, { "id": "https://openalex.org/A5044832887", "display_name": "Philip N. Newsome" } ] }, { "id": "https://openalex.org/W2116873449", "doi": "https://doi.org/10.2174/1573399811309020007", "title": "Evolution of Exenatide as a Diabetes Therapeutic", "abstract": { "Type": [ 0 ], "2": [ 1 ], "diabetes": [ 2, 46, 72, 248 ], "(T2DM)": [ 3 ], "is": [ 4, 35, 60 ], "a": [ 5, 61, 70, 85, 184 ], "disease": [ 6 ], "of": [ 7, 23, 45, 79, 82, 167, 201, 231 ], "epidemic": [ 8 ], "proportion": [ 9 ], "associated": [ 10 ], "with": [ 11, 89, 108, 155, 163, 197 ], "significant": [ 12 ], "morbidity": [ 13 ], "and": [ 14, 25, 38, 49, 94, 101, 123, 220 ], "excess": [ 15 ], "mortality.": [ 16 ], "Optimal": [ 17 ], "glucose": [ 18 ], "control": [ 19, 34 ], "reduces": [ 20 ], "the": [ 21, 43, 80, 90, 224 ], "risk": [ 22 ], "microvascular": [ 24 ], "possibly": [ 26 ], "macrovascular": [ 27 ], "complications": [ 28 ], "due": [ 29 ], "to": [ 30, 97, 135, 148, 170, 181, 195, 203 ], "diabetes.": [ 31 ], "However,": [ 32 ], "glycemic": [ 33 ], "rarely": [ 36 ], "optimal": [ 37 ], "several": [ 39 ], "therapeutic": [ 40 ], "interventions": [ 41 ], "for": [ 42 ], "treatment": [ 44 ], "cause": [ 47 ], "hypoglycemia": [ 48, 232 ], "weight": [ 50, 165, 199 ], "gain;": [ 51 ], "some": [ 52 ], "may": [ 53 ], "exacerbate": [ 54 ], "cardiovascular": [ 55 ], "risk.": [ 56 ], "Exenatide": [ 57, 206 ], "(synthetic": [ 58 ], "exendin-4)": [ 59 ], "glucagon-": [ 62 ], "like": [ 63 ], "peptide-1": [ 64 ], "receptor": [ 65 ], "(GLP-1R)": [ 66 ], "agonist": [ 67 ], "developed": [ 68, 244 ], "as": [ 69, 84, 150 ], "first-in-class": [ 71 ], "therapy.": [ 73, 249 ], "This": [ 74 ], "review": [ 75 ], "presents": [ 76 ], "an": [ 77, 246 ], "overview": [ 78 ], "evolution": [ 81 ], "exenatide": [ 83, 110, 139, 187, 241 ], "T2DM": [ 86 ], "treatment,": [ 87 ], "beginning": [ 88 ], "seminal": [ 91 ], "preclinical": [ 92 ], "discoveries": [ 93 ], "continuing": [ 95 ], "through": [ 96 ], "clinical": [ 98, 104, 130 ], "pharmacology": [ 99 ], "investigations": [ 100 ], "phase": [ 102, 128, 175 ], "3": [ 103, 129, 176 ], "trials.": [ 105 ], "In": [ 106, 126, 173 ], "patients": [ 107 ], "T2DM,": [ 109 ], "enhanced": [ 111, 124 ], "glucose-dependent": [ 112 ], "insulin": [ 113 ], "secretion,": [ 114, 119 ], "suppressed": [ 115 ], "inappropriately": [ 116 ], "elevated": [ 117 ], "glucagon": [ 118 ], "slowed": [ 120 ], "gastric": [ 121 ], "emptying,": [ 122 ], "satiety.": [ 125 ], "controlled": [ 127, 174 ], "trials": [ 131, 177 ], "ranging": [ 132, 178 ], "from": [ 133, 179 ], "12": [ 134 ], "52": [ 136 ], "weeks,": [ 137, 183 ], "10-mcg": [ 138 ], "twice": [ 140 ], "daily": [ 141 ], "(ExBID)": [ 142 ], "reduced": [ 143, 190 ], "mean": [ 144, 164, 191, 198 ], "HbA1c": [ 145, 192 ], "by": [ 146, 193 ], "-0.8%": [ 147 ], "-1.7%": [ 149 ], "monotherapy": [ 151 ], "or": [ 152 ], "in": [ 153, 217 ], "combination": [ 154 ], "metformin": [ 156 ], "(MET),": [ 157 ], "sulfonylureas": [ 158 ], "(SFU),": [ 159 ], "and/or": [ 160 ], "thiazolidinediones": [ 161 ], "(TZD);": [ 162 ], "losses": [ 166 ], "-1.2": [ 168 ], "kg": [ 169 ], "-8.0": [ 171 ], "kg.": [ 172, 205 ], "24": [ 180 ], "30": [ 182 ], "2-mg": [ 185 ], "once-weekly": [ 186 ], "formulation": [ 188 ], "(ExQW)": [ 189 ], "-1.3%": [ 194 ], "-1.9%,": [ 196 ], "reductions": [ 200 ], "-2.3": [ 202 ], "-3.7": [ 204 ], "was": [ 207, 223, 233, 242 ], "generally": [ 208, 234 ], "well-tolerated.": [ 209 ], "The": [ 210, 229 ], "most": [ 211, 225 ], "common": [ 212 ], "side": [ 213 ], "effects": [ 214 ], "were": [ 215 ], "gastrointestinal": [ 216 ], "nature,": [ 218 ], "mild,": [ 219 ], "transient.": [ 221 ], "Nausea": [ 222 ], "prevalent": [ 226 ], "adverse": [ 227 ], "event.": [ 228 ], "incidence": [ 230 ], "low.": [ 235 ], "By": [ 236 ], "building": [ 237 ], "upon": [ 238 ], "early": [ 239 ], "observations": [ 240 ], "successfully": [ 243 ], "into": [ 245 ], "effective": [ 247 ] }, "publication_date": "2013-02-01", "publication_year": 2013, "type": "review", "cited_by_count": 74, "authors": [ { "id": "https://openalex.org/A5080280327", "display_name": "Sunil Bhavsar" }, { "id": "https://openalex.org/A5089649262", "display_name": "Sunder Mudaliar" }, { "id": "https://openalex.org/A5048059210", "display_name": "Alan D. Cherrington" } ] }, { "id": "https://openalex.org/W3118952290", "doi": "https://doi.org/10.1186/s12933-020-01183-5", "title": "Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial", "abstract": null, "publication_date": "2021-01-04", "publication_year": 2021, "type": "article", "cited_by_count": 60, "authors": [ { "id": "https://openalex.org/A5029938834", "display_name": "Antonino Tuttolomondo" }, { "id": "https://openalex.org/A5047473846", "display_name": "Anna Cirrincione" }, { "id": "https://openalex.org/A5052731557", "display_name": "Alessandra Casuccio" }, { "id": "https://openalex.org/A5078574342", "display_name": "Alessandro Del Cuore" }, { "id": "https://openalex.org/A5076865519", "display_name": "Mario Daidone" }, { "id": "https://openalex.org/A5017645410", "display_name": "Tiziana Di Chiara" }, { "id": "https://openalex.org/A5076436874", "display_name": "Domenico Di Raimondo" }, { "id": "https://openalex.org/A5062628573", "display_name": "Vittoriano Della Corte" }, { "id": "https://openalex.org/A5052816038", "display_name": "Carlo Maida" }, { "id": "https://openalex.org/A5003402407", "display_name": "Irene Simonetta" }, { "id": "https://openalex.org/A5023136375", "display_name": "Stefania Scaglione" }, { "id": "https://openalex.org/A5030692604", "display_name": "Ant\u00f3nio Pinto" } ] }, { "id": "https://openalex.org/W3205584302", "doi": "https://doi.org/10.1177/11795514211051697", "title": "Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia", "abstract": { "A": [ 0 ], "relatively": [ 1 ], "recent": [ 2 ], "addition": [ 3 ], "to": [ 4, 90 ], "the": [ 5, 12, 22, 32, 42, 59, 118, 127, 131, 139, 147, 158, 162, 172 ], "arsenal": [ 6 ], "of": [ 7, 14, 27, 69, 76, 157, 166, 179 ], "antidiabetic": [ 8 ], "drugs": [ 9, 28, 70 ], "used": [ 10 ], "for": [ 11, 149 ], "treatment": [ 13 ], "type": [ 15 ], "2": [ 16 ], "diabetes": [ 17 ], "mellitus": [ 18 ], "(T2DM)": [ 19 ], "has": [ 20 ], "been": [ 21, 88 ], "\u201cincretin": [ 23 ], "mimetics,\u201d": [ 24 ], "a": [ 25, 46, 73 ], "group": [ 26 ], "that": [ 29, 66, 98, 111, 130, 160 ], "work": [ 30 ], "on": [ 31, 122, 138 ], "glucagon-like": [ 33 ], "peptide-1": [ 34 ], "(GLP-1)": [ 35 ], "receptor": [ 36, 85, 134, 168, 181 ], "and": [ 37, 117, 145 ], "enhance": [ 38 ], "insulin": [ 39, 79 ], "secretion": [ 40, 57 ], "from": [ 41 ], "pancreatic": [ 43 ], "\u03b2-cells": [ 44 ], "in": [ 45, 51, 93 ], "glucose-dependent": [ 47, 104 ], "manner,": [ 48 ], "more": [ 49 ], "potently": [ 50 ], "hyperglycemic": [ 52 ], "conditions,": [ 53 ], "while": [ 54 ], "suppressing": [ 55 ], "glucagon": [ 56 ], "at": [ 58 ], "same": [ 60 ], "time.": [ 61 ], "Therefore,": [ 62 ], "it": [ 63 ], "was": [ 64 ], "assumed": [ 65 ], "this": [ 67 ], "class": [ 68 ], "would": [ 71 ], "have": [ 72, 87 ], "lower": [ 74 ], "risk": [ 75, 119 ], "hypoglycemia": [ 77, 92, 116 ], "than": [ 78 ], "secretagogues": [ 80 ], "like": [ 81 ], "sulphonylureas.": [ 82 ], "However,": [ 83, 126 ], "GLP-1": [ 84, 133, 167, 180 ], "agonists": [ 86, 135 ], "proposed": [ 89 ], "cause": [ 91 ], "healthy": [ 94 ], "normoglycemic": [ 95 ], "subjects": [ 96 ], "implying": [ 97 ], "their": [ 99 ], "action": [ 100 ], "is": [ 101, 120 ], "not": [ 102, 114 ], "as": [ 103, 105 ], "once": [ 106 ], "thought.": [ 107 ], "Other": [ 108 ], "studies": [ 109, 159 ], "concluded": [ 110 ], "they": [ 112 ], "might": [ 113 ], "induce": [ 115 ], "dependent": [ 121 ], "other": [ 123, 176 ], "individual": [ 124 ], "factors.": [ 125 ], "FDA": [ 128 ], "announced": [ 129 ], "12": [ 132 ], "currently": [ 136 ], "available": [ 137 ], "market": [ 140 ], "had": [ 141 ], "potential": [ 142 ], "safety": [ 143 ], "signs": [ 144 ], "evaluated": [ 146 ], "need": [ 148 ], "regulatory": [ 150 ], "action.": [ 151 ], "This": [ 152 ], "review": [ 153, 174 ], "provides": [ 154 ], "an": [ 155 ], "overview": [ 156 ], "investigated": [ 161 ], "possible": [ 163 ], "hypoglycemic": [ 164 ], "effect": [ 165 ], "agonists.": [ 169 ], "In": [ 170 ], "addition,": [ 171 ], "current": [ 173 ], "describes": [ 175 ], "adverse": [ 177 ], "effects": [ 178 ], "agonist": [ 182 ], "treatment.": [ 183 ] }, "publication_date": "2021-01-01", "publication_year": 2021, "type": "review", "cited_by_count": 24, "authors": [ { "id": "https://openalex.org/A5040960792", "display_name": "Daria Ja\u2019arah" }, { "id": "https://openalex.org/A5047869985", "display_name": "Mazhar Salim Al Zoubi" }, { "id": "https://openalex.org/A5089156144", "display_name": "Gamal T. Abdelhady" }, { "id": "https://openalex.org/A5071077276", "display_name": "Firas Rabi" }, { "id": "https://openalex.org/A5079513373", "display_name": "Murtaza M. Tambuwala" } ] }, { "id": "https://openalex.org/W3009247057", "doi": "https://doi.org/10.1016/s2213-8587(20)30043-7", "title": "GLP-1 receptor agonists in type 1 diabetes: a MAG1C bullet?", "abstract": null, "publication_date": "2020-03-02", "publication_year": 2020, "type": "letter", "cited_by_count": 21, "authors": [ { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5002832666", "display_name": "Juris J. Meier" } ] }, { "id": "https://openalex.org/W2083415436", "doi": "https://doi.org/10.1111/j.1463-1326.2011.01493.x", "title": "Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta\u2010analysis of the liraglutide clinical trial programme", "abstract": { "Aim:": [ 0 ], "Effective": [ 1 ], "type": [ 2, 124 ], "2": [ 3, 125 ], "diabetes": [ 4, 62, 88 ], "management": [ 5 ], "requires": [ 6 ], "a": [ 7, 40, 54, 69, 82, 141 ], "multifactorial": [ 8 ], "approach": [ 9 ], "extending": [ 10 ], "beyond": [ 11 ], "glycaemic": [ 12 ], "control.": [ 13 ], "Clinical": [ 14 ], "practice": [ 15 ], "guidelines": [ 16 ], "suggest": [ 17 ], "targets": [ 18 ], "for": [ 19, 38, 123, 135, 140 ], "HbA1c,": [ 20 ], "blood": [ 21 ], "pressure": [ 22 ], "and": [ 23, 25, 29, 51, 138, 150, 172, 216 ], "lipids,": [ 24 ], "emphasize": [ 26 ], "weight": [ 27, 52, 96, 148, 218 ], "reduction": [ 28 ], "avoiding": [ 30 ], "hypoglycaemia.": [ 31, 99 ], "The": [ 32 ], "phase": [ 33 ], "3": [ 34 ], "clinical": [ 35, 233 ], "trial": [ 36 ], "programme": [ 37 ], "liraglutide,": [ 39 ], "human": [ 41 ], "glucagon\u2010like": [ 42 ], "peptide": [ 43 ], "1": [ 44 ], "analogue,": [ 45 ], "showed": [ 46 ], "significant": [ 47 ], "improvements": [ 48 ], "in": [ 49 ], "HbA1c": [ 50, 93, 137, 145, 212 ], "with": [ 53, 119 ], "low": [ 55 ], "risk": [ 56 ], "of": [ 57, 71, 79, 87, 91, 144, 159, 166, 174, 211, 235 ], "hypoglycaemia": [ 58, 215 ], "compared": [ 59 ], "to": [ 60, 200, 224, 239 ], "other": [ 61, 226 ], "therapies.": [ 63, 229 ], "In": [ 64 ], "this": [ 65, 189, 236 ], "context,": [ 66 ], "we": [ 67 ], "performed": [ 68, 105 ], "meta\u2010analysis": [ 70, 103 ], "data": [ 72, 109 ], "from": [ 73, 110 ], "these": [ 74 ], "trials": [ 75, 112 ], "evaluating": [ 76, 117 ], "the": [ 77, 160, 167, 208, 225, 231 ], "proportion": [ 78 ], "patients": [ 80 ], "achieving": [ 81 ], "clinically": [ 83 ], "relevant": [ 84 ], "composite": [ 85, 142, 190, 209 ], "measure": [ 86 ], "control": [ 89 ], "consisting": [ 90 ], "an": [ 92 ], "<7%": [ 94 ], "without": [ 95 ], "gain": [ 97, 149 ], "or": [ 98, 132 ], "Methods:": [ 100 ], "A": [ 101 ], "prespecified": [ 102 ], "was": [ 104, 221 ], "on": [ 106 ], "26\u2010week": [ 107 ], "patient\u2010level": [ 108 ], "seven": [ 111 ], "(": [ 113 ], "N": [ 114 ], "=": [ 115 ], "4625)": [ 116 ], "liraglutide": [ 118, 161, 168, 195, 220 ], "commonly": [ 120, 227 ], "used": [ 121, 228 ], "therapies": [ 122 ], "diabetes:": [ 126 ], "glimepiride,": [ 127, 179 ], "rosiglitazone,": [ 128, 177 ], "glargine,": [ 129, 181 ], "exenatide,": [ 130, 183 ], "sitagliptin": [ 131 ], "placebo,": [ 133 ], "adjusting": [ 134 ], "baseline": [ 136 ], "weight,": [ 139 ], "outcome": [ 143, 210 ], "<7.0%,": [ 146 ], "no": [ 147, 151, 214, 217 ], "hypoglycaemic": [ 152 ], "events.": [ 153 ], "Results:": [ 154 ], "At": [ 155 ], "26": [ 156 ], "weeks,": [ 157 ], "40%": [ 158 ], "1.8": [ 162, 196 ], "mg": [ 163, 170, 197 ], "group,": [ 164 ], "32%": [ 165 ], "1.2": [ 169 ], "group": [ 171 ], "6\u201325%": [ 173 ], "comparators": [ 175 ], "(6%": [ 176 ], "8%": [ 178, 186 ], "15%": [ 180 ], "25%": [ 182 ], "11%": [ 184 ], "sitagliptin,": [ 185 ], "placebo)": [ 187 ], "achieved": [ 188 ], "outcome.": [ 191 ], "Odds": [ 192 ], "ratios": [ 193 ], "favoured": [ 194 ], "by": [ 198, 207 ], "2.0\u2010": [ 199 ], "10.5\u2010fold": [ 201 ], "over": [ 202 ], "comparators.": [ 203 ], "Conclusions:": [ 204 ], "As": [ 205 ], "assessed": [ 206 ], "<7%,": [ 213 ], "gain,": [ 219 ], "clearly": [ 222 ], "superior": [ 223 ], "However,": [ 230 ], "long\u2010term": [ 232 ], "impact": [ 234 ], "observation": [ 237 ], "remains": [ 238 ], "be": [ 240 ], "shown.": [ 241 ] }, "publication_date": "2011-08-27", "publication_year": 2011, "type": "review", "cited_by_count": 120, "authors": [ { "id": "https://openalex.org/A5090437675", "display_name": "Bernard Zinman" }, { "id": "https://openalex.org/A5111040183", "display_name": "Wolfgang E. Schmidt" }, { "id": "https://openalex.org/A5058457879", "display_name": "A C Moses" }, { "id": "https://openalex.org/A5085163831", "display_name": "N. Lund" }, { "id": "https://openalex.org/A5107850059", "display_name": "Stephen Gough" } ] }, { "id": "https://openalex.org/W2170235613", "doi": "https://doi.org/10.1016/j.pharmthera.2009.06.002", "title": "Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors", "abstract": null, "publication_date": "2009-06-22", "publication_year": 2009, "type": "review", "cited_by_count": 193, "authors": [ { "id": "https://openalex.org/A5111673977", "display_name": "Eugen J. Verspohl" } ] }, { "id": "https://openalex.org/W2093545531", "doi": "https://doi.org/10.1016/j.bbrc.2005.03.013", "title": "The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits \u03b2-cell apoptosis in vitro", "abstract": null, "publication_date": "2005-03-15", "publication_year": 2005, "type": "article", "cited_by_count": 168, "authors": [ { "id": "https://openalex.org/A5112158455", "display_name": "S\u00f8ren Bregenholt" }, { "id": "https://openalex.org/A5023731487", "display_name": "Annette M\u00f8ldrup" }, { "id": "https://openalex.org/A5075774899", "display_name": "Niels Blume" }, { "id": "https://openalex.org/A5049273814", "display_name": "Allan E. Karlsen" }, { "id": "https://openalex.org/A5108225988", "display_name": "Birgitte Nissen Friedrichsen" }, { "id": "https://openalex.org/A5020402916", "display_name": "Ditte Tornhave" }, { "id": "https://openalex.org/A5088627727", "display_name": "Lotte Bjerre Knudsen" }, { "id": "https://openalex.org/A5103799522", "display_name": "Jacob S. Petersen" } ] }, { "id": "https://openalex.org/W2139401663", "doi": "https://doi.org/10.1016/j.ejphar.2012.07.024", "title": "Effect of exendin (exenatide)\u2014GLP 1 receptor agonist on the thyroid and parathyroid gland in a rat model", "abstract": null, "publication_date": "2012-07-20", "publication_year": 2012, "type": "article", "cited_by_count": 24, "authors": [ { "id": "https://openalex.org/A5031394206", "display_name": "Deepti Bulchandani" }, { "id": "https://openalex.org/A5004550455", "display_name": "Jagdish Nachnani" }, { "id": "https://openalex.org/A5090393773", "display_name": "Betty Herndon" }, { "id": "https://openalex.org/A5111433592", "display_name": "Agostino Molteni" }, { "id": "https://openalex.org/A5025038039", "display_name": "Muhammad Pathan" }, { "id": "https://openalex.org/A5113726626", "display_name": "Tim Quinn" }, { "id": "https://openalex.org/A5113740182", "display_name": "Hana Hamdan" }, { "id": "https://openalex.org/A5057960929", "display_name": "Laura Alba" }, { "id": "https://openalex.org/A5079976883", "display_name": "Leland Graves" } ] }, { "id": "https://openalex.org/W2929823585", "doi": "https://doi.org/10.3389/fendo.2019.00202", "title": "Exenatide Protects Against Cardiac Dysfunction by Attenuating Oxidative Stress in the Diabetic Mouse Heart", "abstract": { "Cardiovascular": [ 0 ], "disease": [ 1 ], "is": [ 2, 37 ], "the": [ 3, 75, 78, 96, 123, 151, 156, 161, 172 ], "major": [ 4 ], "cause": [ 5 ], "of": [ 6, 81, 99, 150, 158, 174 ], "death": [ 7 ], "in": [ 8, 52, 83, 101, 122, 145 ], "patients": [ 9 ], "with": [ 10 ], "diabetes.": [ 11 ], "Current": [ 12 ], "treatment": [ 13, 167 ], "strategies": [ 14 ], "for": [ 15 ], "diabetes": [ 16, 84 ], "rely": [ 17 ], "on": [ 18 ], "lifestyle": [ 19 ], "changes": [ 20 ], "and": [ 21, 27, 63, 104, 131, 141 ], "glucose": [ 22 ], "control": [ 23 ], "to": [ 24, 43, 54 ], "prevent": [ 25 ], "angiopathy": [ 26 ], "organ": [ 28 ], "failure.": [ 29 ], "Exenatide,": [ 30 ], "a": [ 31 ], "glucagon-like": [ 32 ], "peptide-1": [ 33 ], "(GLP-1)": [ 34 ], "receptor": [ 35 ], "agonist,": [ 36 ], "used": [ 38 ], "as": [ 39, 59 ], "an": [ 40 ], "add-on": [ 41 ], "therapy": [ 42 ], "insulin": [ 44 ], "treatment.": [ 45 ], "Exenatide": [ 46 ], "also": [ 47 ], "has": [ 48 ], "multiple": [ 49 ], "beneficial": [ 50 ], "effects": [ 51, 80, 98, 157 ], "addition": [ 53 ], "its": [ 55 ], "hypoglycemic": [ 56 ], "effects,": [ 57 ], "such": [ 58 ], "preventing": [ 60 ], "hepatic": [ 61 ], "steatosis": [ 62 ], "protecting": [ 64 ], "against": [ 65, 171 ], "cardiac": [ 66 ], "injury": [ 67 ], "from": [ 68 ], "doxorubicin-induced": [ 69 ], "cardiotoxicity": [ 70 ], "or": [ 71 ], "ischemic": [ 72 ], "reperfusion.": [ 73 ], "However,": [ 74 ], "mechanisms": [ 76 ], "underlying": [ 77 ], "cardioprotective": [ 79, 97 ], "exenatide": [ 82, 100, 112, 134, 166 ], "have": [ 85 ], "not": [ 86 ], "been": [ 87 ], "fully": [ 88 ], "clarified.": [ 89 ], "To": [ 90 ], "address": [ 91 ], "this": [ 92 ], "issue,": [ 93 ], "we": [ 94 ], "investigated": [ 95 ], "type": [ 102, 105 ], "1": [ 103 ], "2": [ 106 ], "diabetic": [ 107, 175 ], "mice.": [ 108 ], "We": [ 109 ], "found": [ 110 ], "that": [ 111, 165 ], "simultaneously": [ 113 ], "attenuated": [ 114, 155 ], "reactive": [ 115 ], "oxidative": [ 116 ], "species": [ 117 ], "(ROS)": [ 118 ], "production": [ 119 ], "through": [ 120 ], "increases": [ 121 ], "antioxidant": [ 124 ], "enzymes": [ 125 ], "manganese": [ 126 ], "dependent": [ 127 ], "superoxide": [ 128 ], "dismutase": [ 129 ], "(MnSOD)": [ 130 ], "catalase.": [ 132 ], "Moreover,": [ 133 ], "decreased": [ 135 ], "tumor": [ 136 ], "protein": [ 137 ], "P53": [ 138 ], "(p53)": [ 139 ], "expression": [ 140 ], "prevented": [ 142 ], "cell": [ 143 ], "apoptosis": [ 144 ], "H9c2": [ 146 ], "cells.": [ 147 ], "The": [ 148 ], "presence": [ 149 ], "catalase": [ 152 ], "inhibitor": [ 153 ], "3-AT": [ 154 ], "exenatide.": [ 159 ], "Overall,": [ 160 ], "results": [ 162 ], "strongly": [ 163 ], "indicate": [ 164 ], "may": [ 168 ], "be": [ 169 ], "protective": [ 170 ], "development": [ 173 ], "cardiomyopathy.": [ 176 ] }, "publication_date": "2019-04-05", "publication_year": 2019, "type": "article", "cited_by_count": 47, "authors": [ { "id": "https://openalex.org/A5101605212", "display_name": "Wei Ding" }, { "id": "https://openalex.org/A5077828511", "display_name": "Wenguang Chang" }, { "id": "https://openalex.org/A5090016492", "display_name": "Xiao-ci Guo" }, { "id": "https://openalex.org/A5065788628", "display_name": "Ying Liu" }, { "id": "https://openalex.org/A5108059726", "display_name": "Dandan Xiao" }, { "id": "https://openalex.org/A5104178124", "display_name": "Dan Ding" }, { "id": "https://openalex.org/A5075039484", "display_name": "Jianxun Wang" }, { "id": "https://openalex.org/A5002586556", "display_name": "Xuejuan Zhang" } ] }, { "id": "https://openalex.org/W2167170136", "doi": "https://doi.org/10.1210/jc.2007-2109", "title": "Incretin-Based Therapies in Type 2 Diabetes Mellitus", "abstract": { "Context:": [ 0 ], "Glucagon-like": [ 1 ], "peptide-1": [ 2 ], "(GLP-1)": [ 3 ], "and": [ 4, 39, 58, 78, 111, 116, 131, 139, 153, 175, 198, 201, 204, 211, 221, 241, 257 ], "glucose-dependent": [ 5, 101 ], "insulinotropic": [ 6, 102 ], "polypeptide": [ 7 ], "are": [ 8, 63, 86, 118, 141, 148, 155, 195 ], "incretins": [ 9 ], "secreted": [ 10 ], "from": [ 11, 144 ], "enteroendocrine": [ 12 ], "cells": [ 13 ], "postprandially": [ 14 ], "in": [ 15, 27, 267, 274 ], "part": [ 16 ], "to": [ 17, 65, 180, 264 ], "regulate": [ 18 ], "glucose": [ 19, 269 ], "homeostasis.": [ 20 ], "Dysregulation": [ 21 ], "of": [ 22, 75, 82, 136, 218, 238 ], "these": [ 23, 83 ], "hormones": [ 24 ], "is": [ 25 ], "evident": [ 26 ], "type": [ 28 ], "2": [ 29 ], "diabetes": [ 30 ], "mellitus": [ 31 ], "(T2DM).": [ 32 ], "Two": [ 33 ], "new": [ 34 ], "drugs,": [ 35 ], "exenatide": [ 36, 125 ], "(GLP-1": [ 37, 56 ], "mimetic)": [ 38, 57 ], "sitagliptin": [ 40, 161, 210 ], "[dipeptidyl": [ 41 ], "peptidase": [ 42 ], "(DPP)": [ 43 ], "4": [ 44, 61, 223, 243, 261 ], "inhibitor],": [ 45 ], "have": [ 46 ], "been": [ 47 ], "approved": [ 48 ], "by": [ 49, 164, 186, 250 ], "regulatory": [ 50 ], "agencies": [ 51 ], "for": [ 52, 93, 229 ], "treating": [ 53, 230 ], "T2DM.": [ 54, 231 ], "Liraglutide": [ 55 ], "vildagliptin": [ 59, 154, 212 ], "(DPP": [ 60 ], "inhibitor)": [ 62 ], "expected": [ 64 ], "arrive": [ 66 ], "on": [ 67, 124, 150, 245 ], "the": [ 68, 97, 236, 248 ], "market": [ 69 ], "soon.": [ 70 ], "Evidence": [ 71, 113 ], "Acquisition:": [ 72 ], "The": [ 73, 216 ], "background": [ 74 ], "incretin-based": [ 76 ], "therapy": [ 77, 172, 179 ], "selected": [ 79 ], "clinical": [ 80 ], "trials": [ 81 ], "four": [ 84 ], "drugs": [ 85 ], "reviewed.": [ 87 ], "A": [ 88 ], "MEDLINE": [ 89 ], "search": [ 90 ], "was": [ 91 ], "conducted": [ 92 ], "published": [ 94 ], "articles": [ 95 ], "using": [ 96 ], "key": [ 98 ], "words": [ 99 ], "incretin,": [ 100 ], "polypeptide,": [ 103 ], "GLP-1,": [ 104 ], "exendin-4,": [ 105 ], "exenatide,": [ 106 ], "DPP": [ 107, 222, 242, 260 ], "4,": [ 108 ], "liraglutide,": [ 109 ], "sitagliptin,": [ 110 ], "vildagliptin.": [ 112 ], "Synthesis:": [ 114 ], "Exenatide": [ 115, 203 ], "liraglutide": [ 117, 205 ], "injection": [ 119 ], "based.": [ 120 ], "Three-year": [ 121 ], "follow-up": [ 122 ], "data": [ 123 ], "showed": [ 126 ], "a": [ 127, 265 ], "sustained": [ 128 ], "weight": [ 129, 207 ], "loss": [ 130 ], "glycosylated": [ 132 ], "hemoglobin": [ 133 ], "(HbA1c)": [ 134 ], "reduction": [ 135 ], "1%.": [ 137 ], "Nausea": [ 138 ], "vomiting": [ 140 ], "common.": [ 142 ], "Results": [ 143 ], "phase": [ 145 ], "3": [ 146 ], "studies": [ 147 ], "pending": [ 149 ], "liraglutide.": [ 151 ], "Sitagliptin": [ 152 ], "orally": [ 156 ], "active.": [ 157 ], "In": [ 158 ], "24-wk": [ 159 ], "studies,": [ 160 ], "reduces": [ 162 ], "HbA1c": [ 163, 185 ], "0.6\u20130.8%": [ 165 ], "as": [ 166, 169, 177, 235 ], "monotherapy,": [ 167 ], "1.8%": [ 168 ], "initial": [ 170 ], "combination": [ 171 ], "with": [ 173 ], "metformin,": [ 174 ], "0.7%": [ 176 ], "add-on": [ 178 ], "metformin.": [ 181 ], "Vildagliptin": [ 182 ], "monotherapy": [ 183 ], "lowered": [ 184 ], "1.0\u20131.4%": [ 187 ], "after": [ 188 ], "24": [ 189 ], "wk.": [ 190 ], "Their": [ 191 ], "major": [ 192 ], "side": [ 193 ], "effects": [ 194, 237 ], "urinary": [ 196 ], "tract": [ 197 ], "nasopharyngeal": [ 199 ], "infections": [ 200 ], "headaches.": [ 202 ], "cause": [ 206 ], "loss,": [ 208 ], "whereas": [ 209 ], "do": [ 213 ], "not.": [ 214 ], "Conclusions:": [ 215 ], "availability": [ 217 ], "GLP-1": [ 219, 239, 252 ], "mimetics": [ 220, 240, 253 ], "inhibitors": [ 224, 244, 262 ], "has": [ 225 ], "increased": [ 226 ], "our": [ 227 ], "armamentarium": [ 228 ], "Unresolved": [ 232 ], "issues": [ 233 ], "such": [ 234 ], "\u03b2-cell": [ 246 ], "mass,": [ 247 ], "mechanism": [ 249 ], "which": [ 251 ], "lowers": [ 254 ], "glucagon": [ 255 ], "levels,": [ 256 ], "exactly": [ 258 ], "how": [ 259 ], "lead": [ 263 ], "decline": [ 266 ], "plasma": [ 268 ], "levels": [ 270 ], "without": [ 271 ], "an": [ 272 ], "increase": [ 273 ], "insulin": [ 275 ], "secretion,": [ 276 ], "need": [ 277 ], "further": [ 278 ], "research.": [ 279 ] }, "publication_date": "2008-07-16", "publication_year": 2008, "type": "review", "cited_by_count": 223, "authors": [ { "id": "https://openalex.org/A5058369658", "display_name": "Chee W. Chia" }, { "id": "https://openalex.org/A5000777749", "display_name": "Josephine M. Egan" } ] }, { "id": "https://openalex.org/W2156133857", "doi": "https://doi.org/10.1186/1475-2840-9-76", "title": "Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure", "abstract": { "Abstract": [ 0 ], "Background": [ 1 ], "Accumulating": [ 2 ], "evidence": [ 3 ], "suggests": [ 4 ], "glucagon-like": [ 5 ], "peptide-1": [ 6 ], "(GLP-1)": [ 7 ], "exerts": [ 8 ], "cardioprotective": [ 9, 217, 240 ], "effects": [ 10, 218, 241 ], "in": [ 11, 42, 223, 242 ], "animal": [ 12 ], "models": [ 13 ], "of": [ 14, 187, 200, 246, 260 ], "myocardial": [ 15 ], "infarction": [ 16 ], "(MI).": [ 17 ], "We": [ 18 ], "hypothesized": [ 19 ], "that": [ 20 ], "chronic": [ 21, 46 ], "treatment": [ 22, 232, 259 ], "with": [ 23, 44, 64, 107, 110, 198, 204, 233, 262, 268 ], "GLP-1": [ 24, 65, 112, 158, 168, 205, 213, 235, 249 ], "or": [ 25, 67, 72, 75, 113, 159, 169, 206, 214, 225, 228, 236, 264 ], "the": [ 26, 195, 258 ], "exenatide": [ 27 ], "analog": [ 28 ], "AC3174": [ 29, 70, 114, 160, 170, 215, 237 ], "would": [ 30 ], "improve": [ 31 ], "cardiac": [ 32, 34, 117 ], "function,": [ 33, 118 ], "remodeling,": [ 35 ], "insulin": [ 36, 164 ], "sensitivity,": [ 37 ], "and": [ 38, 85, 96, 125, 140, 143, 154, 165, 176, 179, 183 ], "exercise": [ 39, 181 ], "capacity": [ 40, 182 ], "(EC)": [ 41 ], "rats": [ 43, 61, 109, 150, 192, 202 ], "MI-induced": [ 45 ], "heart": [ 47 ], "failure": [ 48 ], "(CHF)": [ 49 ], "caused": [ 50 ], "by": [ 51, 89, 135, 211 ], "coronary": [ 52 ], "artery": [ 53 ], "ligation.": [ 54 ], "Methods": [ 55 ], "Two": [ 56 ], "weeks": [ 57 ], "post-MI,": [ 58 ], "male": [ 59 ], "Sprague-Dawley": [ 60 ], "were": [ 62, 87, 100 ], "treated": [ 63, 203 ], "(2.5": [ 66 ], "25": [ 68 ], "pmol/kg/min),": [ 69 ], "(1.7": [ 71 ], "5": [ 73 ], "pmol/kg/min)": [ 74 ], "vehicle": [ 76, 189 ], "via": [ 77 ], "subcutaneous": [ 78 ], "infusion": [ 79 ], "for": [ 80, 257 ], "11": [ 81 ], "weeks.": [ 82 ], "Cardiac": [ 83, 129 ], "function": [ 84 ], "morphology": [ 86 ], "assessed": [ 88 ], "echocardiography": [ 90 ], "during": [ 91, 194 ], "treatment.": [ 92 ], "Metabolic,": [ 93 ], "hemodynamic,": [ 94 ], "exercise-capacity,": [ 95 ], "body": [ 97, 174 ], "composition": [ 98 ], "measurements": [ 99 ], "made": [ 101 ], "at": [ 102 ], "study": [ 103, 196 ], "end.": [ 104 ], "Results": [ 105 ], "Compared": [ 106 ], "vehicle-treated": [ 108 ], "CHF,": [ 111 ], "significantly": [ 115, 172 ], "improved": [ 116, 132, 180 ], "including": [ 119 ], "left": [ 120, 145 ], "ventricular": [ 121 ], "(LV)": [ 122 ], "ejection": [ 123 ], "fraction,": [ 124 ], "end": [ 126, 138 ], "diastolic": [ 127, 139 ], "pressure.": [ 128 ], "dimensions": [ 130 ], "also": [ 131, 171 ], "as": [ 133 ], "evidenced": [ 134 ], "reduced": [ 136, 144, 173 ], "LV": [ 137 ], "systolic": [ 141 ], "volumes": [ 142 ], "atrial": [ 146 ], "volume.": [ 147 ], "Vehicle-treated": [ 148 ], "CHF": [ 149, 191, 263 ], "exhibited": [ 151 ], "fasting": [ 152, 162 ], "hyperglycemia": [ 153 ], "hyperinsulinemia.": [ 155 ], "In": [ 156 ], "contrast,": [ 157 ], "normalized": [ 161 ], "plasma": [ 163 ], "glucose": [ 166 ], "levels.": [ 167 ], "fat": [ 175 ], "fluid": [ 177 ], "mass": [ 178 ], "respiratory": [ 184 ], "efficiency.": [ 185 ], "Four": [ 186 ], "16": [ 188 ], "control": [ 190 ], "died": [ 193 ], "compared": [ 197 ], "1": [ 199 ], "44": [ 201 ], "AC3174.": [ 207 ], "The": [ 208 ], "cellular": [ 209 ], "mechanism": [ 210 ], "which": [ 212 ], "exert": [ 216 ], "appears": [ 219 ], "unrelated": [ 220 ], "to": [ 221 ], "changes": [ 222 ], "GLUT1": [ 224 ], "GLUT4": [ 226 ], "translocation": [ 227 ], "expression.": [ 229 ], "Conclusions": [ 230 ], "Chronic": [ 231 ], "either": [ 234 ], "showed": [ 238 ], "promising": [ 239 ], "a": [ 243, 254 ], "rat": [ 244 ], "model": [ 245 ], "CHF.": [ 247 ], "Hence,": [ 248 ], "receptor": [ 250 ], "agonists": [ 251 ], "may": [ 252 ], "represent": [ 253 ], "novel": [ 255 ], "approach": [ 256 ], "patients": [ 261 ], "cardiovascular": [ 265 ], "disease": [ 266 ], "associated": [ 267 ], "type": [ 269 ], "2": [ 270 ], "diabetes.": [ 271 ] }, "publication_date": "2010-11-16", "publication_year": 2010, "type": "article", "cited_by_count": 121, "authors": [ { "id": "https://openalex.org/A5017690868", "display_name": "Que Liu" }, { "id": "https://openalex.org/A5077880056", "display_name": "Christen M. Anderson" }, { "id": "https://openalex.org/A5073585074", "display_name": "Anatoly Broyde" }, { "id": "https://openalex.org/A5022328113", "display_name": "Clara J. Polizzi" }, { "id": "https://openalex.org/A5037739158", "display_name": "Rayne Fernandez" }, { "id": "https://openalex.org/A5110941359", "display_name": "Alain Baron" }, { "id": "https://openalex.org/A5077809872", "display_name": "David G. Parkes" } ] }, { "id": "https://openalex.org/W2811221346", "doi": "https://doi.org/10.1038/s41598-018-28314-z", "title": "Preventive treatment with liraglutide protects against development of glucose intolerance in a rat model of Wolfram syndrome", "abstract": { "Abstract": [ 0 ], "Wolfram": [ 1 ], "syndrome": [ 2, 19 ], "(WS)": [ 3 ], "is": [ 4, 36 ], "a": [ 5, 40, 125, 129 ], "rare": [ 6 ], "autosomal": [ 7 ], "recessive": [ 8 ], "disorder": [ 9 ], "caused": [ 10 ], "by": [ 11, 26 ], "mutations": [ 12 ], "in": [ 13, 69, 71, 74, 110, 113 ], "the": [ 14, 81, 88, 94 ], "WFS1": [ 15 ], "(Wolframin1)": [ 16 ], "gene.": [ 17 ], "The": [ 18, 33 ], "first": [ 20 ], "manifests": [ 21 ], "as": [ 22, 128 ], "diabetes": [ 23 ], "mellitus,": [ 24 ], "followed": [ 25 ], "optic": [ 27 ], "nerve": [ 28 ], "atrophy,": [ 29 ], "deafness,": [ 30 ], "and": [ 31, 73, 101, 108 ], "neurodegeneration.": [ 32 ], "underlying": [ 34 ], "mechanism": [ 35 ], "believed": [ 37 ], "to": [ 38, 51, 64 ], "be": [ 39, 124 ], "dysregulation": [ 41 ], "of": [ 42, 90, 96 ], "endoplasmic": [ 43 ], "reticulum": [ 44 ], "(ER)": [ 45 ], "stress": [ 46, 67, 107 ], "response,": [ 47 ], "which": [ 48 ], "ultimately": [ 49 ], "leads": [ 50 ], "cellular": [ 52 ], "death.": [ 53 ], "Treatment": [ 54 ], "with": [ 55, 80, 119 ], "glucagon-like": [ 56 ], "peptide-1": [ 57 ], "(GLP-1)": [ 58 ], "receptor": [ 59, 83, 121 ], "agonists": [ 60, 122 ], "has": [ 61 ], "been": [ 62 ], "shown": [ 63 ], "normalize": [ 65 ], "ER": [ 66, 106 ], "response": [ 68 ], "several": [ 70 ], "vitro": [ 72 ], "vivo": [ 75 ], "models.": [ 76 ], "Early": [ 77 ], "chronic": [ 78 ], "intervention": [ 79 ], "GLP-1": [ 82, 120 ], "agonist": [ 84 ], "liraglutide": [ 85 ], "starting": [ 86 ], "before": [ 87 ], "onset": [ 89 ], "metabolic": [ 91 ], "symptoms": [ 92 ], "prevented": [ 93 ], "development": [ 95 ], "glucose": [ 97 ], "intolerance,": [ 98 ], "improved": [ 99 ], "insulin": [ 100 ], "glucagon": [ 102 ], "secretion": [ 103 ], "control,": [ 104 ], "reduced": [ 105 ], "inflammation": [ 109 ], "Langerhans": [ 111 ], "islets": [ 112 ], "Wfs1": [ 114 ], "mutant": [ 115 ], "rats.": [ 116 ], "Thus,": [ 117 ], "treatment": [ 118, 131 ], "might": [ 123 ], "promising": [ 126 ], "strategy": [ 127 ], "preventive": [ 130 ], "for": [ 132 ], "human": [ 133 ], "WS": [ 134 ], "patients.": [ 135 ] }, "publication_date": "2018-06-29", "publication_year": 2018, "type": "article", "cited_by_count": 44, "authors": [ { "id": "https://openalex.org/A5004852760", "display_name": "Maarja Toots" }, { "id": "https://openalex.org/A5028452806", "display_name": "Kadri Seppa" }, { "id": "https://openalex.org/A5075013832", "display_name": "Toomas Jagom\u00e4e" }, { "id": "https://openalex.org/A5066483057", "display_name": "Tuuliki Koppel" }, { "id": "https://openalex.org/A5088704266", "display_name": "Maia Pallase" }, { "id": "https://openalex.org/A5045377800", "display_name": "Indrek Heinla" }, { "id": "https://openalex.org/A5089896099", "display_name": "Anton Terasmaa" }, { "id": "https://openalex.org/A5072489475", "display_name": "Mario Plaas" }, { "id": "https://openalex.org/A5048622515", "display_name": "Eero Vasar" } ] }, { "id": "https://openalex.org/W2161051960", "doi": "https://doi.org/10.1016/j.jdiacomp.2013.06.003", "title": "Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying \u2013 preclinical evidence", "abstract": { "In": [ 0 ], "addition": [ 1 ], "to": [ 2, 106, 109, 167, 177, 180 ], "promoting": [ 3 ], "glucose": [ 4, 31, 98 ], "homeostasis,": [ 5 ], "glucagon-like": [ 6 ], "peptide": [ 7 ], "1": [ 8 ], "(GLP-1)": [ 9 ], "has": [ 10 ], "a": [ 11, 43, 88, 113 ], "number": [ 12, 44 ], "of": [ 13, 45, 57, 123, 136, 154, 172 ], "extra-pancreatic": [ 14 ], "effects": [ 15 ], "that": [ 16, 127, 132 ], "regulate": [ 17 ], "appetite": [ 18 ], "and": [ 19, 83, 99, 131, 141, 160 ], "body": [ 20 ], "weight.": [ 21 ], "GLP-1": [ 22, 35, 47 ], "delays": [ 23 ], "gastric": [ 24, 85, 103, 139, 162 ], "emptying,": [ 25 ], "which": [ 26 ], "is": [ 27, 36, 112 ], "vital": [ 28 ], "for": [ 29, 54 ], "postprandial": [ 30 ], "(PPG)": [ 32 ], "control.": [ 33 ], "As": [ 34 ], "rapidly": [ 37 ], "degraded": [ 38 ], "by": [ 39 ], "protease": [ 40 ], "dipeptidyl": [ 41 ], "peptidase-4,": [ 42 ], "degradation-resistant": [ 46 ], "receptor": [ 48 ], "agonists": [ 49, 79 ], "(GLP-1RAs)": [ 50 ], "have": [ 51 ], "been": [ 52 ], "developed": [ 53 ], "the": [ 55, 124, 134, 152, 170 ], "treatment": [ 56 ], "Type": [ 58 ], "2": [ 59 ], "diabetes": [ 60 ], "mellitus.": [ 61 ], "These": [ 62 ], "agents": [ 63, 93 ], "can": [ 64 ], "be": [ 65, 107, 178 ], "broadly": [ 66 ], "categorized": [ 67 ], "as": [ 68 ], "being": [ 69 ], "short-": [ 70 ], "or": [ 71 ], "long-acting,": [ 72 ], "based": [ 73 ], "on": [ 74, 138 ], "their": [ 75, 100 ], "pharmacokinetic": [ 76 ], "profile.": [ 77 ], "Short-acting": [ 78 ], "predominantly": [ 80 ], "affect": [ 81, 95 ], "PPG": [ 82, 142, 158 ], "delay": [ 84, 101 ], "emptying": [ 86, 104, 140 ], "in": [ 87, 102, 148, 156, 165 ], "sustained": [ 89 ], "manner,": [ 90 ], "whereas": [ 91 ], "long-acting": [ 92, 168 ], "largely": [ 94 ], "fasting": [ 96 ], "plasma": [ 97 ], "appears": [ 105 ], "subjected": [ 108, 179 ], "tachyphylaxis.": [ 110, 181 ], "Lixisenatide": [ 111 ], "\"short-acting\"": [ 114 ], "once-daily": [ 115 ], "prandial": [ 116 ], "GLP-1RA.": [ 117 ], "This": [ 118 ], "review": [ 119, 150 ], "provides": [ 120 ], "an": [ 121 ], "overview": [ 122 ], "preclinical": [ 125, 145 ], "studies": [ 126 ], "are": [ 128 ], "currently": [ 129 ], "available": [ 130 ], "evaluate": [ 133 ], "efficacy": [ 135, 153 ], "lixisenatide": [ 137, 155, 173 ], "levels.": [ 143 ], "The": [ 144 ], "evidence": [ 146 ], "outlined": [ 147 ], "this": [ 149 ], "supports": [ 151 ], "reducing": [ 157 ], "excursions": [ 159 ], "delaying": [ 161 ], "emptying.": [ 163 ], "Furthermore,": [ 164 ], "contrast": [ 166 ], "agents,": [ 169 ], "actions": [ 171 ], "do": [ 174 ], "not": [ 175 ], "appear": [ 176 ] }, "publication_date": "2013-08-28", "publication_year": 2013, "type": "review", "cited_by_count": 43, "authors": [ { "id": "https://openalex.org/A5077344547", "display_name": "Werner Ulrich" } ] }, { "id": "https://openalex.org/W2936627199", "doi": "https://doi.org/10.1016/j.neuropharm.2019.04.018", "title": "Topical ocular administration of the GLP-1 receptor agonist liraglutide arrests hyperphosphorylated tau-triggered diabetic retinal neurodegeneration via activation of GLP-1R/Akt/GSK3\u03b2 signaling", "abstract": null, "publication_date": "2019-04-20", "publication_year": 2019, "type": "article", "cited_by_count": 45, "authors": [ { "id": "https://openalex.org/A5034361449", "display_name": "Xing\u2010sheng Shu" }, { "id": "https://openalex.org/A5100758230", "display_name": "Yilin Zhang" }, { "id": "https://openalex.org/A5053868737", "display_name": "Meiqi Li" }, { "id": "https://openalex.org/A5100721857", "display_name": "Xiaoyan Huang" }, { "id": "https://openalex.org/A5102915483", "display_name": "Yangfan Yang" }, { "id": "https://openalex.org/A5059658708", "display_name": "Junhui Zeng" }, { "id": "https://openalex.org/A5067584293", "display_name": "Yingying Zhao" }, { "id": "https://openalex.org/A5100457092", "display_name": "Xiaomei Wang" }, { "id": "https://openalex.org/A5000172750", "display_name": "Weizhen Zhang" }, { "id": "https://openalex.org/A5101755133", "display_name": "Ying Ying" } ] }, { "id": "https://openalex.org/W2946574770", "doi": "https://doi.org/10.1530/joe-19-0007", "title": "Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis", "abstract": { "Exenatide": [ 0, 107, 158, 207 ], "(Exe)": [ 1 ], "is": [ 2, 14 ], "a": [ 3, 54, 63, 146, 234 ], "glucagon-like": [ 4 ], "peptide": [ 5 ], "(GLP)-1": [ 6 ], "receptor": [ 7, 269 ], "agonist": [ 8 ], "that": [ 9 ], "enhances": [ 10 ], "insulin": [ 11, 123, 170, 249 ], "secretion": [ 12 ], "and": [ 13, 26, 102, 116, 140, 163, 172, 191, 219, 224, 246, 252 ], "associated": [ 15, 168 ], "with": [ 16, 20, 79, 169, 273 ], "induction": [ 17 ], "of": [ 18, 31, 91, 210, 238, 265, 267, 282 ], "satiety": [ 19 ], "weight": [ 21 ], "loss.": [ 22 ], "As": [ 23 ], "mitochondrial": [ 24, 40, 242 ], "dysfunction": [ 25 ], "lipotoxicity": [ 27 ], "are": [ 28 ], "central": [ 29 ], "features": [ 30 ], "nonalcoholic": [ 32 ], "steatohepatitis": [ 33 ], "(NASH),": [ 34 ], "we": [ 35 ], "tested": [ 36 ], "whether": [ 37 ], "Exe": [ 38, 80, 126, 240 ], "improved": [ 39, 159 ], "function": [ 41 ], "in": [ 42, 145, 150, 222, 233, 271 ], "this": [ 43 ], "setting.": [ 44 ], "We": [ 45 ], "studied": [ 46 ], "C57BL/6J": [ 47 ], "mice": [ 48, 76 ], "fed": [ 49 ], "for": [ 50 ], "24": [ 51 ], "weeks": [ 52 ], "either": [ 53 ], "control-": [ 55 ], "or": [ 56, 83 ], "high-fructose,": [ 57 ], "high-": [ 58 ], "trans": [ 59 ], "-fat": [ 60 ], "(TFD)-diet": [ 61 ], "(i.e.,": [ 62 ], "NASH": [ 64 ], "model": [ 65, 237 ], "previously": [ 66 ], "validated": [ 67 ], "by": [ 68, 89 ], "our": [ 69 ], "laboratory).": [ 70 ], "For": [ 71 ], "the": [ 72, 160, 262, 279 ], "final": [ 73 ], "8": [ 74 ], "weeks,": [ 75 ], "were": [ 77 ], "treated": [ 78 ], "(30": [ 81 ], "\u00b5g/kg/day)": [ 82 ], "vehicle.": [ 84 ], "Mitochondrial": [ 85 ], "metabolism": [ 86 ], "was": [ 87 ], "assessed": [ 88 ], "infusion": [ 90 ], "[": [ 92 ], "13": [ 93, 98, 104, 180, 185 ], "C": [ 94, 99 ], "3": [ 95 ], "]propionate,": [ 96 ], "[3,4-": [ 97 ], "2": [ 100 ], "]glucose": [ 101 ], "NMR-based": [ 103 ], "C-isotopomer": [ 105 ], "analysis.": [ 106 ], "significantly": [ 108, 247 ], "decreased": [ 109, 164 ], "fasting": [ 110 ], "plasma": [ 111 ], "glucose,": [ 112 ], "free": [ 113 ], "fatty": [ 114 ], "acids": [ 115 ], "triglycerides,": [ 117 ], "as": [ 118, 120, 175 ], "well": [ 119 ], "adipose": [ 121 ], "tissue": [ 122 ], "resistance.": [ 124 ], "Moreover,": [ 125 ], "reduced": [ 127 ], "23%": [ 128 ], "hepatic": [ 129, 165, 211 ], "glucose": [ 130 ], "production,": [ 131 ], "15%": [ 132 ], "tri-carboxylic": [ 133 ], "acid": [ 134 ], "(TCA)": [ 135 ], "cycle": [ 136, 244 ], "flux,": [ 137 ], "20%": [ 138 ], "anaplerosis": [ 139 ], "17%": [ 141 ], "pyruvate": [ 142 ], "cycling": [ 143 ], "resulting": [ 144 ], "significant": [ 147, 258 ], "31%": [ 148 ], "decrease": [ 149 ], "intrahepatic": [ 151 ], "triglyceride": [ 152 ], "content": [ 153 ], "(": [ 154, 214, 226 ], "P": [ 155, 188, 204 ], "=": [ 156, 189, 205 ], "0.02).": [ 157 ], "lipidomic": [ 161 ], "profile": [ 162 ], "lipid": [ 166 ], "byproducts": [ 167 ], "resistance": [ 171 ], "lipotoxicity,": [ 173 ], "such": [ 174 ], "diacylglycerols": [ 176 ], "(TFD:": [ 177, 193 ], "111": [ 178 ], "\u00b1": [ 179, 184, 195, 200 ], "vs": [ 181, 197, 284 ], "Exe:": [ 182, 198 ], "64": [ 183 ], "\u00b5mol/g": [ 186, 202 ], "protein,": [ 187, 203 ], "0.03)": [ 190 ], "ceramides": [ 192 ], "1.6": [ 194 ], "0.1": [ 196, 201 ], "1.3": [ 199 ], "0.03).": [ 206 ], "lowered": [ 208 ], "expression": [ 209 ], "lipogenic": [ 212 ], "genes": [ 213, 220 ], "Srebp1C": [ 215 ], ",": [ 216, 228 ], "Cd36": [ 217 ], ")": [ 218 ], "involved": [ 221 ], "inflammation": [ 223 ], "fibrosis": [ 225 ], "Tnfa": [ 227 ], "Timp1": [ 229 ], ").": [ 230 ], "In": [ 231 ], "conclusion,": [ 232 ], "diet-induced": [ 235 ], "mouse": [ 236 ], "NASH,": [ 239 ], "ameliorates": [ 241 ], "TCA": [ 243 ], "flux": [ 245 ], "decreases": [ 248 ], "resistance,": [ 250 ], "steatosis": [ 251 ], "hepatocyte": [ 253 ], "lipotoxicity.": [ 254 ], "This": [ 255 ], "may": [ 256 ], "have": [ 257 ], "clinical": [ 259 ], "implications": [ 260 ], "to": [ 261 ], "potential": [ 263 ], "mechanism": [ 264 ], "action": [ 266 ], "GLP-1": [ 268 ], "agonists": [ 270 ], "patients": [ 272 ], "NASH.": [ 274 ], "Future": [ 275 ], "studies": [ 276 ], "should": [ 277 ], "elucidate": [ 278 ], "relative": [ 280 ], "contribution": [ 281 ], "direct": [ 283 ], "indirect": [ 285 ], "mechanisms": [ 286 ], "at": [ 287 ], "play.": [ 288 ] }, "publication_date": "2019-05-14", "publication_year": 2019, "type": "article", "cited_by_count": 45, "authors": [ { "id": "https://openalex.org/A5041160943", "display_name": "Srilaxmi Kalavalapalli" }, { "id": "https://openalex.org/A5056877243", "display_name": "Fernando Bril" }, { "id": "https://openalex.org/A5024793919", "display_name": "Joy Guingab" }, { "id": "https://openalex.org/A5000892749", "display_name": "Ariana Vergara" }, { "id": "https://openalex.org/A5010665082", "display_name": "Timothy J. Garrett" }, { "id": "https://openalex.org/A5037761853", "display_name": "Nishanth E. Sunny" }, { "id": "https://openalex.org/A5086957117", "display_name": "Kenneth Cusi" } ] }, { "id": "https://openalex.org/W2264072095", "doi": "https://doi.org/10.2337/dc15-1437", "title": "Effects of GLP-1 Receptor Agonists on Heart Rate and the Autonomic Nervous System Using Holter Electrocardiography and Power Spectrum Analysis of Heart Rate Variability", "abstract": { "Long-": [ 0 ], "and": [ 1, 10, 77, 79, 90, 128 ], "short-acting": [ 2 ], "glucagon-like": [ 3 ], "peptide": [ 4 ], "1": [ 5 ], "receptor": [ 6 ], "agonists": [ 7 ], "(GLP-1RAs)": [ 8 ], "liraglutide": [ 9, 142 ], "lixisenatide,": [ 11 ], "which": [ 12 ], "are": [ 13 ], "available": [ 14 ], "for": [ 15, 125 ], "diabetes": [ 16, 121, 126, 159 ], "therapy,": [ 17 ], "may": [ 18 ], "act": [ 19 ], "on": [ 20, 55, 73 ], "the": [ 21, 50, 56, 66, 70, 81 ], "autonomic": [ 22, 57 ], "nervous": [ 23, 58 ], "system": [ 24 ], "to": [ 25, 48 ], "increase": [ 26 ], "heart": [ 27 ], "rate": [ 28 ], "(1,2).": [ 29 ], "We": [ 30 ], "performed": [ 31 ], "a": [ 32, 39, 44, 141 ], "prospective,": [ 33 ], "single-center,": [ 34 ], "randomized,": [ 35 ], "open-label": [ 36 ], "study": [ 37, 104 ], "with": [ 38, 65, 80, 118 ], "1:1": [ 40 ], "allocation": [ 41 ], "ratio": [ 42 ], "using": [ 43 ], "24-h": [ 45 ], "Holter": [ 46 ], "electrocardiogram": [ 47 ], "compare": [ 49 ], "effects": [ 51 ], "of": [ 52, 69, 84 ], "these": [ 53 ], "GLP-1RAs": [ 54, 136 ], "system.": [ 59 ], "All": [ 60 ], "procedures": [ 61 ], "were": [ 62, 123, 137 ], "in": [ 63, 88, 100 ], "accordance": [ 64 ], "ethical": [ 67 ], "standards": [ 68 ], "responsible": [ 71 ], "committee": [ 72 ], "human": [ 74 ], "experimentation": [ 75 ], "(institutional": [ 76 ], "national)": [ 78 ], "Helsinki": [ 82 ], "Declaration": [ 83 ], "1975,": [ 85 ], "as": [ 86 ], "revised": [ 87 ], "2000": [ 89 ], "2008.": [ 91 ], "Informed": [ 92 ], "consent": [ 93 ], "was": [ 94 ], "obtained": [ 95 ], "from": [ 96 ], "all": [ 97 ], "patients": [ 98, 117 ], "participating": [ 99 ], "this": [ 101 ], "study.": [ 102 ], "The": [ 103 ], "is": [ 105 ], "registered": [ 106 ], "at": [ 107 ], "University": [ 108 ], "Hospital": [ 109 ], "Medical": [ 110 ], "Information": [ 111 ], "Network": [ 112 ], "Clinical": [ 113 ], "Trials": [ 114 ], "Registry": [ 115 ], "(UMI17770).\n\nSixty": [ 116 ], "type": [ 119 ], "2": [ 120 ], "who": [ 122 ], "admitted": [ 124 ], "treatment": [ 127 ], "had": [ 129 ], "not": [ 130 ], "received": [ 131 ], "dipeptidyl": [ 132 ], "peptidase-4": [ 133 ], "inhibitors": [ 134 ], "or": [ 135, 165 ], "randomly": [ 138 ], "divided": [ 139 ], "into": [ 140 ], "(age": [ 143 ], "64.9": [ 144 ], "\u00b1": [ 145, 150, 156, 162 ], "12.7": [ 146 ], "years,": [ 147 ], "HbA1c": [ 148 ], "10.3": [ 149 ], "2.5%": [ 151 ], "[89.1": [ 152 ], "mmol/mol],": [ 153 ], "BMI": [ 154 ], "24.6": [ 155 ], "4.8": [ 157 ], "kg/m2,": [ 158 ], "duration": [ 160 ], "7.8": [ 161, 163 ], "years)": [ 164 ], "\u2026": [ 166 ] }, "publication_date": "2015-12-17", "publication_year": 2015, "type": "letter", "cited_by_count": 80, "authors": [ { "id": "https://openalex.org/A5084456792", "display_name": "Yuki Nakatani" }, { "id": "https://openalex.org/A5072997020", "display_name": "Atsuhiko Kawabe" }, { "id": "https://openalex.org/A5081590770", "display_name": "Mihoko Matsumura" }, { "id": "https://openalex.org/A5002804119", "display_name": "Yoshimasa Aso" }, { "id": "https://openalex.org/A5038398017", "display_name": "Takanori Yasu" }, { "id": "https://openalex.org/A5030509095", "display_name": "Nobuyuki Banba" }, { "id": "https://openalex.org/A5041952333", "display_name": "Takaaki Nakamoto" } ] }, { "id": "https://openalex.org/W1969489686", "doi": "https://doi.org/10.1590/s0004-27302013000900005", "title": "Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease", "abstract": { "OBJECTIVE:": [ 0 ], "To": [ 1 ], "investigate": [ 2 ], "the": [ 3, 89, 119, 127 ], "effects": [ 4 ], "of": [ 5, 66 ], "exenatide": [ 6, 46, 55, 120, 134 ], "on": [ 7 ], "blood": [ 8, 139 ], "glucose,": [ 9, 140 ], "body": [ 10, 68, 70, 142 ], "weight": [ 11, 143 ], "and": [ 12, 23, 35, 40, 48, 56, 83, 88, 92, 108, 113, 116, 144 ], "hepatic": [ 13, 146 ], "enzymes": [ 14 ], "in": [ 15, 97, 118, 126, 150 ], "patients": [ 16, 37, 151 ], "with": [ 17, 38, 54, 132, 152, 155 ], "type": [ 18 ], "2": [ 19 ], "diabetes": [ 20 ], "mellitus": [ 21 ], "(T2DM)": [ 22 ], "concomitant": [ 24, 154 ], "non-alcoholic": [ 25 ], "fatty": [ 26 ], "liver": [ 27 ], "disease": [ 28 ], "(NAFLD).": [ 29 ], "SUBJECTS": [ 30 ], "AND": [ 31 ], "METHODS:": [ 32 ], "One": [ 33 ], "hundred": [ 34 ], "seventeen": [ 36 ], "T2DM": [ 39, 153 ], "NAFLD": [ 41, 149 ], "were": [ 42, 52, 85, 94, 110, 122 ], "randomly": [ 43 ], "divided": [ 44 ], "into": [ 45 ], "group": [ 47, 121 ], "metformin": [ 49, 128 ], "group.": [ 50, 129 ], "Patients": [ 51 ], "treated": [ 53 ], "metformin,": [ 57, 133 ], "respectively,": [ 58 ], "for": [ 59 ], "12": [ 60, 64 ], "weeks.": [ 61 ], "RESULTS:": [ 62 ], "After": [ 63 ], "weeks": [ 65 ], "treatment,": [ 67 ], "weight,": [ 69 ], "mass": [ 71 ], "index": [ 72 ], "(BMI),": [ 73 ], "waist-to-hip": [ 74, 101 ], "ratio,": [ 75, 102 ], "HbA1c,": [ 76 ], "FPG,": [ 77 ], "2-h": [ 78, 103 ], "PPG,": [ 79, 104 ], "ALT,": [ 80, 105 ], "AST,": [ 81, 106 ], "\u03b3-GT,": [ 82, 107 ], "hs-CRP": [ 84, 109 ], "significantly": [ 86 ], "reduced,": [ 87 ], "AST/ALT": [ 90, 114 ], "ratio": [ 91, 115 ], "adiponectin": [ 93, 117 ], "markedly": [ 95, 111 ], "increased": [ 96 ], "both": [ 98 ], "groups.": [ 99 ], "BMI,": [ 100 ], "lower,": [ 112 ], "dramatically": [ 123 ], "higher": [ 124 ], "than": [ 125 ], "CONCLUSION:": [ 130 ], "Compared": [ 131 ], "is": [ 135 ], "better": [ 136 ], "to": [ 137 ], "control": [ 138 ], "reduces": [ 141 ], "improves": [ 145 ], "enzymes,": [ 147 ], "attenuating": [ 148 ], "NAFLD.": [ 156 ] }, "publication_date": "2013-12-01", "publication_year": 2013, "type": "article", "cited_by_count": 112, "authors": [ { "id": "https://openalex.org/A5103004933", "display_name": "Hui Fan" }, { "id": "https://openalex.org/A5101045667", "display_name": "Qingrong Pan" }, { "id": "https://openalex.org/A5035886806", "display_name": "Yuan Xu" }, { "id": "https://openalex.org/A5078718847", "display_name": "Xinchun Yang" } ] }, { "id": "https://openalex.org/W3197938525", "doi": "https://doi.org/10.3390/healthcare9091125", "title": "Weekly Semaglutide vs. Liraglutide Efficacy Profile: A Network Meta-Analysis", "abstract": { "Introduction:": [ 0 ], "Glucagon-like": [ 1 ], "peptide": [ 2 ], "1": [ 3, 137, 185 ], "receptor": [ 4 ], "agonist": [ 5 ], "(GLP-1": [ 6 ], "RA)": [ 7 ], "is": [ 8, 115 ], "a": [ 9, 116, 147, 173, 192, 200 ], "class": [ 10 ], "of": [ 11, 52, 93, 118, 135, 150, 176, 203, 228, 236, 244, 261 ], "hypoglycemic": [ 12 ], "medications.": [ 13 ], "Semaglutide": [ 14, 155, 224 ], "once-weekly": [ 15, 79 ], "(QW)": [ 16 ], "and": [ 17, 38, 54, 59, 99, 107, 143, 152, 184, 205, 220, 231, 240, 264 ], "liraglutide": [ 18, 39, 82, 141, 166, 196, 218 ], "once-daily": [ 19 ], "(OD)": [ 20 ], "significantly": [ 21, 163, 189 ], "improved": [ 22, 225 ], "glycemic": [ 23, 238 ], "control": [ 24, 227, 239, 243 ], "compared": [ 25 ], "to": [ 26, 47, 69, 161, 165, 217, 247, 276 ], "placebo.": [ 27 ], "To": [ 28 ], "date,": [ 29 ], "no": [ 30, 210 ], "long-term": [ 31, 50, 74, 237 ], "phase": [ 32 ], "III": [ 33 ], "trials": [ 34, 77, 272 ], "directly": [ 35 ], "comparing": [ 36, 78 ], "semaglutide": [ 37, 53, 80, 136, 182, 245 ], "are": [ 40, 274 ], "available.": [ 41 ], "This": [ 42, 114 ], "network": [ 43 ], "meta-analysis": [ 44 ], "(NMA)": [ 45 ], "aims": [ 46 ], "compare": [ 48 ], "the": [ 49, 119, 226, 259 ], "efficacy": [ 51 ], "liraglutide.": [ 55, 256 ], "Methods:": [ 56 ], "PubMed,": [ 57 ], "Embase,": [ 58 ], "Cochrane": [ 60 ], "Library": [ 61 ], "were": [ 62, 89, 95, 109, 188 ], "searched": [ 63 ], "from": [ 64 ], "inception": [ 65 ], "until": [ 66 ], "June": [ 67 ], "2019": [ 68 ], "identify": [ 70 ], "relevant": [ 71 ], "articles.": [ 72 ], "Nine": [ 73 ], "randomized": [ 75 ], "controlled": [ 76 ], "or": [ 81, 85 ], "with": [ 83, 146, 172, 191, 199 ], "placebo": [ 84 ], "other": [ 86, 252 ], "active": [ 87 ], "comparisons": [ 88 ], "identified.": [ 90 ], "The": [ 91, 127, 234 ], "outcomes": [ 92 ], "interest": [ 94 ], "changes": [ 96 ], "in": [ 97, 122, 132, 169, 215 ], "HbA1c": [ 98, 133, 170 ], "weight": [ 100, 179, 242 ], "after": [ 101 ], "52": [ 102 ], "weeks.": [ 103 ], "A": [ 104 ], "Bayesian": [ 105 ], "framework": [ 106 ], "NMA": [ 108 ], "used": [ 110 ], "for": [ 111 ], "data": [ 112, 128 ], "synthesis.": [ 113 ], "sub-study": [ 117 ], "protocol": [ 120 ], "registered": [ 121 ], "PROSPERO": [ 123 ], "(number": [ 124 ], "CRD42018091598).": [ 125 ], "Results:": [ 126 ], "showed": [ 129 ], "significant": [ 130, 211 ], "superiority": [ 131 ], "reduction": [ 134, 171, 180, 194, 212 ], "mg": [ 138, 145, 157, 168, 186, 198 ], "QW": [ 139, 158, 187 ], "over": [ 140 ], "1.2": [ 142, 167, 219 ], "1.8": [ 144, 221 ], "treatment": [ 148, 174, 201 ], "difference": [ 149, 175, 202 ], "0.47%": [ 151 ], "0.3%,": [ 153 ], "respectively.": [ 154, 208 ], "0.5": [ 156, 183 ], "was": [ 159, 213 ], "found": [ 160, 214 ], "be": [ 162, 248 ], "superior": [ 164 ], "0.17%.": [ 177 ], "Regarding": [ 178 ], "analysis,": [ 181 ], "associated": [ 190 ], "greater": [ 193 ], "than": [ 195, 251 ], "0.6": [ 197 ], "2.42": [ 204 ], "3.06": [ 206 ], "kg,": [ 207 ], "However,": [ 209, 257 ], "comparison": [ 216 ], "mg.": [ 222 ], "Conclusions:": [ 223 ], "blood": [ 229 ], "glucose": [ 230 ], "body": [ 232, 241 ], "weight.": [ 233 ], "capacity": [ 235 ], "appears": [ 246 ], "more": [ 249, 267 ], "effective": [ 250 ], "GLP-1": [ 253 ], "RAs,": [ 254 ], "including": [ 255 ], "considering": [ 258 ], "number": [ 260 ], "included": [ 262 ], "studies": [ 263 ], "potential": [ 265 ], "limitations,": [ 266 ], "large-scale,": [ 268 ], "head-to-head,": [ 269 ], "well-designed": [ 270 ], "randomized-controlled": [ 271 ], "(RCTs)": [ 273 ], "needed": [ 275 ], "confirm": [ 277 ], "these": [ 278 ], "findings.": [ 279 ] }, "publication_date": "2021-08-30", "publication_year": 2021, "type": "review", "cited_by_count": 22, "authors": [ { "id": "https://openalex.org/A5007366909", "display_name": "Hassan A. Alsugair" }, { "id": "https://openalex.org/A5027717834", "display_name": "Ibrahim F. Alshugair" }, { "id": "https://openalex.org/A5054260049", "display_name": "Turki Alharbi" }, { "id": "https://openalex.org/A5089221317", "display_name": "Abdulaziz M. Bin Rsheed" }, { "id": "https://openalex.org/A5020545567", "display_name": "Ayla M. Tourkmani" }, { "id": "https://openalex.org/A5091643140", "display_name": "Wedad AlMadani" } ] }, { "id": "https://openalex.org/W1753769072", "doi": "https://doi.org/10.1177/0145721715607981", "title": "GLP-1 Receptor Agonists", "abstract": { "Purpose": [ 0 ], "Type": [ 1 ], "2": [ 2 ], "diabetes": [ 3 ], "(T2D)": [ 4 ], "imparts": [ 5 ], "an": [ 6 ], "increased": [ 7, 201 ], "risk": [ 8, 57 ], "of": [ 9, 24, 31, 41, 51, 64, 86, 133, 176, 242 ], "adverse": [ 10, 181 ], "health": [ 11 ], "outcomes": [ 12 ], "in": [ 13, 68, 115, 153, 158, 172, 216, 237 ], "patients": [ 14, 217, 249 ], "unable": [ 15 ], "to": [ 16, 98 ], "achieve": [ 17 ], "glycemic": [ 18, 222 ], "control.": [ 19 ], "Patient": [ 20 ], "education": [ 21 ], "and": [ 22, 54, 79, 83, 112, 128, 143, 161, 169, 189, 220 ], "individualization": [ 23 ], "treatment": [ 25, 188, 246 ], "are": [ 26, 38, 91, 175, 190, 204, 226 ], "important": [ 27 ], "for": [ 28, 76, 113, 247 ], "effective": [ 29 ], "management": [ 30, 78 ], "T2D.": [ 32 ], "Glucagon-like": [ 33 ], "peptide-1": [ 34 ], "receptor": [ 35 ], "agonists": [ 36 ], "(GLP-1RAs)": [ 37 ], "a": [ 39, 94 ], "class": [ 40, 232 ], "injectable": [ 42 ], "glucose-lowering": [ 43, 120 ], "agents": [ 44, 121 ], "that": [ 45, 233 ], "lower": [ 46 ], "A1C": [ 47, 155 ], "with": [ 48, 117, 186, 193, 206, 218 ], "added": [ 49 ], "benefits": [ 50 ], "weight": [ 52, 160 ], "loss": [ 53 ], "improved": [ 55, 131 ], "cardiovascular": [ 56 ], "markers.": [ 58 ], "This": [ 59 ], "review": [ 60 ], "discusses": [ 61 ], "the": [ 62, 69, 81, 243 ], "role": [ 63 ], "GLP-1RAs": [ 65, 90, 126, 203, 211 ], "currently": [ 66 ], "approved": [ 67 ], "United": [ 70 ], "States": [ 71 ], "(exenatide,": [ 72 ], "liraglutide,": [ 73 ], "albiglutide,": [ 74 ], "dulaglutide)": [ 75 ], "T2D": [ 77, 219 ], "characterizes": [ 80 ], "efficacy": [ 82 ], "safety": [ 84 ], "profiles": [ 85 ], "individual": [ 87, 167, 248 ], "GLP-1RAs.": [ 88, 195 ], "Conclusions": [ 89 ], "recommended": [ 92 ], "as": [ 93, 102 ], "preferred": [ 95 ], "add-on": [ 96 ], "agent": [ 97 ], "existing": [ 99 ], "metformin": [ 100, 106 ], "monotherapy,": [ 101 ], "first-line": [ 103 ], "therapy": [ 104 ], "if": [ 105 ], "is": [ 107, 198, 250 ], "contraindicated": [ 108 ], "or": [ 109, 122, 209 ], "poorly": [ 110 ], "tolerated,": [ 111 ], "use": [ 114 ], "combination": [ 116 ], "other": [ 118 ], "oral": [ 119 ], "basal": [ 123 ], "insulin.": [ 124, 210 ], "Shorter-acting": [ 125 ], "(exenatide": [ 127, 140 ], "liraglutide)": [ 129 ], "offer": [ 130 ], "coverage": [ 132 ], "postprandial": [ 134 ], "hyperglycemia,": [ 135 ], "while": [ 136 ], "longer-acting": [ 137, 194 ], "GLP-1RA": [ 138 ], "formulations": [ 139 ], "extended-release,": [ 141 ], "dulaglutide,": [ 142 ], "albiglutide)": [ 144 ], "further": [ 145 ], "improve": [ 146, 221 ], "fasting": [ 147 ], "plasma": [ 148 ], "glucose,": [ 149 ], "which": [ 150 ], "can": [ 151 ], "result": [ 152 ], "additional": [ 154 ], "lowering.": [ 156 ], "Reductions": [ 157 ], "body": [ 159 ], "blood": [ 162 ], "pressure": [ 163 ], "appear": [ 164 ], "similar": [ 165 ], "among": [ 166 ], "agents,": [ 168 ], "small": [ 170 ], "increases": [ 171 ], "heart": [ 173 ], "rate": [ 174 ], "unknown": [ 177 ], "clinical": [ 178, 238 ], "relevance.": [ 179 ], "Gastrointestinal": [ 180 ], "events": [ 182 ], "abate": [ 183 ], "over": [ 184 ], "time": [ 185 ], "continued": [ 187 ], "less": [ 191 ], "frequent": [ 192 ], "Hypoglycemia": [ 196 ], "incidence": [ 197 ], "low": [ 199 ], "but": [ 200 ], "when": [ 202 ], "used": [ 205 ], "insulin": [ 207 ], "secretagogues": [ 208 ], "target": [ 212 ], "multiple": [ 213 ], "pathophysiologic": [ 214 ], "mechanisms": [ 215 ], "control,": [ 223 ], "although": [ 224 ], "there": [ 225 ], "some": [ 227 ], "differences": [ 228 ], "within": [ 229 ], "this": [ 230 ], "drug": [ 231 ], "may": [ 234 ], "be": [ 235 ], "relevant": [ 236 ], "practice.": [ 239 ], "Therefore,": [ 240 ], "selection": [ 241 ], "most": [ 244 ], "appropriate": [ 245 ], "important.": [ 251 ] }, "publication_date": "2015-10-08", "publication_year": 2015, "type": "review", "cited_by_count": 13, "authors": [ { "id": "https://openalex.org/A5083775716", "display_name": "Curtis Triplitt" }, { "id": "https://openalex.org/A5010083131", "display_name": "Carolina Solis\u2010Herrera" } ] }, { "id": "https://openalex.org/W4200183746", "doi": "https://doi.org/10.1016/j.dsx.2021.102382", "title": "Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial", "abstract": null, "publication_date": "2021-12-28", "publication_year": 2021, "type": "review", "cited_by_count": 37, "authors": [ { "id": "https://openalex.org/A5061857615", "display_name": "Matthew M.Y. Lee" }, { "id": "https://openalex.org/A5012666230", "display_name": "S\u00f8ren Lund Kristensen" }, { "id": "https://openalex.org/A5024577116", "display_name": "Hertzel C. Gerstein" }, { "id": "https://openalex.org/A5027213857", "display_name": "John J.V. McMurray" }, { "id": "https://openalex.org/A5078498803", "display_name": "Naveed Sattar" } ] }, { "id": "https://openalex.org/W4387098554", "doi": "https://doi.org/10.7150/thno.86831", "title": "Targeting redox imbalance in neurodegeneration: characterizing the role of GLP-1 receptor agonists", "abstract": { "Reactive": [ 0 ], "oxygen": [ 1 ], "species": [ 2 ], "(ROS)": [ 3 ], "have": [ 4, 168 ], "emerged": [ 5 ], "as": [ 6, 29 ], "essential": [ 7, 95 ], "signaling": [ 8 ], "molecules": [ 9 ], "regulating": [ 10 ], "cell": [ 11, 130 ], "survival,": [ 12 ], "death,": [ 13, 131 ], "inflammation,": [ 14 ], "differentiation,": [ 15 ], "growth,": [ 16 ], "and": [ 17, 54, 60, 66, 79, 83, 85, 101, 105, 124, 150, 175, 185, 225, 251, 259 ], "immune": [ 18 ], "response.": [ 19 ], "Environmental": [ 20 ], "factors,": [ 21, 23 ], "genetic": [ 22 ], "or": [ 24 ], "many": [ 25 ], "pathological": [ 26 ], "condition": [ 27 ], "such": [ 28 ], "diabetes": [ 30, 149 ], "increase": [ 31 ], "the": [ 32, 39, 68, 74, 98, 114, 120, 196, 201, 244, 253 ], "level": [ 33 ], "of": [ 34, 41, 70, 76, 103, 109, 246, 256 ], "ROS": [ 35, 92, 117, 141, 173, 239, 249 ], "generation": [ 36, 174 ], "by": [ 37, 55, 195, 218, 264 ], "elevating": [ 38 ], "production": [ 40, 142 ], "advanced": [ 42 ], "glycation": [ 43 ], "end": [ 44 ], "products,": [ 45 ], "reducing": [ 46 ], "free": [ 47 ], "radical": [ 48 ], "scavengers,": [ 49 ], "increasing": [ 50 ], "mitochondrial": [ 51, 177 ], "oxidative": [ 52 ], "stress,": [ 53, 65 ], "interfering": [ 56 ], "with": [ 57, 87, 119, 209 ], "DAG-PKC-NADPH": [ 58 ], "oxidase": [ 59, 62 ], "xanthine": [ 61 ], "pathways.": [ 63 ], "Oxidative": [ 64 ], "therefore": [ 67 ], "accumulation": [ 69 ], "intracellular": [ 71 ], "ROS,": [ 72 ], "determines": [ 73 ], "deregulation": [ 75 ], "several": [ 77 ], "proteins": [ 78 ], "caspases,": [ 80 ], "damages": [ 81 ], "DNA": [ 82, 121 ], "RNA,": [ 84 ], "interferes": [ 86 ], "normal": [ 88 ], "neuronal": [ 89, 115 ], "function.": [ 90 ], "Furthermore,": [ 91 ], "play": [ 93 ], "an": [ 94 ], "role": [ 96 ], "in": [ 97, 143, 200, 261 ], "polymerization,": [ 99 ], "phosphorylation,": [ 100 ], "aggregation": [ 102 ], "tau": [ 104 ], "amyloid-beta,": [ 106 ], "key": [ 107 ], "mediators": [ 108 ], "cognitive": [ 110 ], "function": [ 111 ], "decline.": [ 112 ], "At": [ 113 ], "level,": [ 116 ], "interfere": [ 118 ], "methylation": [ 122 ], "pattern": [ 123 ], "various": [ 125 ], "apoptotic": [ 126 ], "factors": [ 127 ], "related": [ 128 ], "to": [ 129, 139, 171 ], "promoting": [ 132 ], "neurodegeneration.": [ 133 ], "Only": [ 134 ], "few": [ 135 ], "drugs": [ 136 ], "are": [ 137 ], "able": [ 138 ], "quench": [ 140 ], "neurons.": [ 144 ], "The": [ 145, 187 ], "cross-linking": [ 146 ], "pathways": [ 147 ], "between": [ 148 ], "dementia": [ 151, 263 ], "suggest": [ 152 ], "that": [ 153, 237 ], "antidiabetic": [ 154, 161 ], "medications": [ 155 ], "can": [ 156 ], "potentially": [ 157 ], "treat": [ 158 ], "dementia.": [ 159 ], "Among": [ 160 ], "drugs,": [ 162 ], "glucagon-like": [ 163, 190 ], "peptide-1": [ 164, 191 ], "receptor": [ 165, 211 ], "agonists": [ 166 ], "(GLP-1RAs)": [ 167 ], "been": [ 169 ], "found": [ 170 ], "reduce": [ 172 ], "ameliorate": [ 176 ], "function,": [ 178 ], "protein": [ 179 ], "aggregation,": [ 180 ], "neuroinflammation,": [ 181 ], "synaptic": [ 182 ], "plasticity,": [ 183 ], "learning,": [ 184 ], "memory.": [ 186 ], "incretin": [ 188 ], "hormone": [ 189 ], "(GLP-1)": [ 192 ], "is": [ 193 ], "produced": [ 194 ], "enteroendocrine": [ 197 ], "L": [ 198 ], "cells": [ 199 ], "distal": [ 202 ], "intestine": [ 203 ], "after": [ 204 ], "food": [ 205 ], "ingestion.": [ 206 ], "Upon": [ 207 ], "interacting": [ 208 ], "its": [ 210 ], "(GLP-1R),": [ 212 ], "it": [ 213 ], "regulates": [ 214 ], "blood": [ 215 ], "glucose": [ 216 ], "levels": [ 217 ], "inducing": [ 219 ], "insulin": [ 220 ], "secretion,": [ 221 ], "inhibiting": [ 222 ], "glucagon": [ 223 ], "production,": [ 224 ], "slowing": [ 226 ], "gastric": [ 227 ], "emptying.": [ 228 ], "No": [ 229 ], "study": [ 230 ], "has": [ 231 ], "evidenced": [ 232 ], "a": [ 233 ], "specific": [ 234 ], "GLP-1RA": [ 235 ], "pathway": [ 236 ], "quenches": [ 238 ], "production.": [ 240 ], "Here": [ 241 ], "we": [ 242 ], "summarize": [ 243 ], "effects": [ 245 ], "GLP-1RAs": [ 247 ], "against": [ 248 ], "overproduction": [ 250 ], "discuss": [ 252 ], "putative": [ 254 ], "efficacy": [ 255 ], "Exendin-4,": [ 257 ], "Lixisenatide,": [ 258 ], "Liraglutide": [ 260 ], "treating": [ 262 ], "decreasing": [ 265 ], "ROS.": [ 266 ] }, "publication_date": "2023-01-01", "publication_year": 2023, "type": "review", "cited_by_count": 42, "authors": [ { "id": "https://openalex.org/A5066641356", "display_name": "Puja Ghosh" }, { "id": "https://openalex.org/A5026808010", "display_name": "Rosaria Anna Fontanella" }, { "id": "https://openalex.org/A5084385725", "display_name": "Lucia Scisciola" }, { "id": "https://openalex.org/A5022608336", "display_name": "Ada Pesapane" }, { "id": "https://openalex.org/A5008034484", "display_name": "Fatemeh Taktaz" }, { "id": "https://openalex.org/A5032212340", "display_name": "Martina Franzese" }, { "id": "https://openalex.org/A5017240245", "display_name": "Armando Puocci" }, { "id": "https://openalex.org/A5044764461", "display_name": "Antonio Ceriello" }, { "id": "https://openalex.org/A5018275689", "display_name": "Francesco Prattichizzo" }, { "id": "https://openalex.org/A5004686163", "display_name": "Maria Rosaria Rizzo" }, { "id": "https://openalex.org/A5084616356", "display_name": "Giuseppe Paolisso" }, { "id": "https://openalex.org/A5001101425", "display_name": "Michelangela Barbieri" } ] }, { "id": "https://openalex.org/W2507524244", "doi": "https://doi.org/10.1097/mib.0000000000000847", "title": "GLP-1 Induces Barrier Protective Expression in Brunner\u02bcs Glands and Regulates Colonic Inflammation", "abstract": { "We": [ 0 ], "demonstrate": [ 1 ], "that": [ 2, 13, 45 ], "IL-33,": [ 3, 31 ], "GLP-1R,": [ 4 ], "and": [ 5, 12, 34, 55 ], "CCL20": [ 6, 35 ], "are": [ 7 ], "deregulated": [ 8 ], "in": [ 9, 22, 36, 52 ], "human": [ 10 ], "IBD,": [ 11 ], "prophylactic": [ 14 ], "treatment": [ 15 ], "with": [ 16 ], "0.6": [ 17 ], "mg/kg": [ 18 ], "liraglutide": [ 19 ], "improves": [ 20 ], "disease": [ 21 ], "AdTr": [ 23 ], "colitis.": [ 24 ], "In": [ 25 ], "addition,": [ 26 ], "GLP-1": [ 27, 46 ], "receptor": [ 28, 47 ], "agonists": [ 29, 48 ], "upregulate": [ 30 ], "mucin": [ 32 ], "5b,": [ 33 ], "murine": [ 37 ], "Brunner's": [ 38 ], "glands.": [ 39 ], "Taken": [ 40 ], "together,": [ 41 ], "our": [ 42 ], "data": [ 43 ], "indicate": [ 44 ], "affect": [ 49 ], "gut": [ 50 ], "homeostasis": [ 51 ], "both": [ 53 ], "proximal": [ 54 ], "distal": [ 56 ], "parts": [ 57 ], "of": [ 58 ], "the": [ 59 ], "gut.": [ 60 ] }, "publication_date": "2016-08-19", "publication_year": 2016, "type": "article", "cited_by_count": 94, "authors": [ { "id": "https://openalex.org/A5057488369", "display_name": "Claus Heiner Bang\u2010Berthelsen" }, { "id": "https://openalex.org/A5064604287", "display_name": "Thomas Lindebo Holm" }, { "id": "https://openalex.org/A5084425804", "display_name": "Charles Pyke" }, { "id": "https://openalex.org/A5088597413", "display_name": "Lotte Simonsen" }, { "id": "https://openalex.org/A5061533768", "display_name": "Rolf S\u00f8kilde" }, { "id": "https://openalex.org/A5031070879", "display_name": "Flemming Pociot" }, { "id": "https://openalex.org/A5103504864", "display_name": "R. Scott Heller" }, { "id": "https://openalex.org/A5031969480", "display_name": "Lasse Folkersen" }, { "id": "https://openalex.org/A5064111567", "display_name": "Peter Helding Kvist" }, { "id": "https://openalex.org/A5075022233", "display_name": "Malene Jackerott" }, { "id": "https://openalex.org/A5006360414", "display_name": "Jan Fleckner" }, { "id": "https://openalex.org/A5079264376", "display_name": "M. Vilien" }, { "id": "https://openalex.org/A5088627727", "display_name": "Lotte Bjerre Knudsen" }, { "id": "https://openalex.org/A5052331621", "display_name": "Anders Heding" }, { "id": "https://openalex.org/A5015151949", "display_name": "Klaus Stensgaard Frederiksen" } ] }, { "id": "https://openalex.org/W3008572558", "doi": "https://doi.org/10.1002/oby.22726", "title": "Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial", "abstract": { "Objective": [ 0 ], "Previous": [ 1 ], "studies": [ 2 ], "have": [ 3 ], "shown": [ 4 ], "additive": [ 5 ], "weight": [ 6, 105, 145, 162, 178, 223 ], "loss": [ 7, 106, 146, 163, 179, 224 ], "when": [ 8 ], "intensive": [ 9 ], "behavioral": [ 10 ], "therapy": [ 11 ], "(IBT)": [ 12 ], "was": [ 13, 68, 113, 198 ], "combined": [ 14, 119 ], "with": [ 15, 49, 62, 78, 107, 117, 120, 196, 201 ], "weight\u2010loss": [ 16 ], "medication.": [ 17 ], "The": [ 18, 54 ], "present": [ 19 ], "multisite": [ 20 ], "study": [ 21 ], "provides": [ 22 ], "the": [ 23, 30, 33, 230 ], "first": [ 24 ], "evaluation,": [ 25 ], "in": [ 26, 47, 60, 76, 194 ], "primary": [ 27, 210 ], "care,": [ 28 ], "of": [ 29, 32, 232 ], "effect": [ 31 ], "Centers": [ 34, 213 ], "for": [ 35, 214 ], "Medicare": [ 36, 215 ], "and": [ 37, 56, 63, 115, 175, 216 ], "Medicaid": [ 38, 217 ], "Services\u2013based": [ 39, 218 ], "IBT": [ 40, 67, 112, 121, 197, 219 ], "benefit,": [ 41 ], "delivered": [ 42 ], "alone": [ 43 ], "(with": [ 44 ], "placebo)": [ 45 ], "or": [ 46, 89 ], "combination": [ 48, 195 ], "liraglutide": [ 50, 82, 108, 137, 233 ], "3.0": [ 51, 83, 109, 138, 192, 234 ], "mg.": [ 52, 235 ], "Methods": [ 53 ], "Satiety": [ 55 ], "Clinical": [ 57 ], "Adiposity\u2014Liraglutide": [ 58 ], "Evidence": [ 59 ], "individuals": [ 61, 77, 135 ], "without": [ 64 ], "diabetes": [ 65 ], "(SCALE)": [ 66 ], "a": [ 69, 209 ], "56\u2010week,": [ 70 ], "randomized,": [ 71 ], "double\u2010blind,": [ 72 ], "placebo\u2010controlled,": [ 73 ], "multicenter": [ 74 ], "trial": [ 75 ], "obesity": [ 79 ], "who": [ 80 ], "received": [ 81 ], "mg": [ 84, 110, 139, 193 ], "(": [ 85, 91 ], "n": [ 86, 92 ], "=": [ 87, 93, 131, 158, 173, 189 ], "142)": [ 88 ], "placebo": [ 90, 118, 141 ], "140)": [ 94 ], "as": [ 95 ], "an": [ 96 ], "adjunct": [ 97 ], "to": [ 98, 128, 155, 170, 186 ], "IBT.": [ 99 ], "Results": [ 100 ], "At": [ 101 ], "week": [ 102 ], "56,": [ 103 ], "mean": [ 104 ], "plus": [ 111 ], "7.5%": [ 114 ], "4.0%": [ 116 ], "(estimated": [ 122 ], "treatment": [ 123 ], "difference": [ 124 ], "[95%": [ 125 ], "CI]\u20133.4%": [ 126 ], "[\u20135.3%": [ 127 ], "\u20131.6%],": [ 129 ], "P": [ 130, 157, 172, 188 ], "0.0003).": [ 132 ], "Significantly": [ 133 ], "more": [ 134 ], "on": [ 136 ], "than": [ 140 ], "achieved": [ 142 ], "\u2265": [ 143 ], "5%": [ 144 ], "(61.5%": [ 147 ], "vs.": [ 148, 165, 181 ], "38.8%;": [ 149 ], "odds": [ 150 ], "ratio": [ 151 ], "[OR]": [ 152 ], "2.5%": [ 153 ], "[1.5%": [ 154 ], "4.1%],": [ 156 ], "0.0003),": [ 159 ], ">": [ 160, 176 ], "10%": [ 161 ], "(30.5%": [ 164 ], "19.8%;": [ 166 ], "OR": [ 167, 183 ], "1.8%": [ 168 ], "[1.0%": [ 169 ], "3.1%],": [ 171 ], "0.0469),": [ 174 ], "15%": [ 177 ], "(18.1%": [ 180 ], "8.9%;": [ 182 ], "2.3%": [ 184 ], "[1.1%": [ 185 ], "4.7%],": [ 187 ], "0.0311).": [ 190 ], "Liraglutide": [ 191 ], "well": [ 199 ], "tolerated,": [ 200 ], "no": [ 202 ], "new": [ 203 ], "safety": [ 204 ], "signals": [ 205 ], "identified.": [ 206 ], "Conclusions": [ 207 ], "In": [ 208 ], "care": [ 211 ], "setting,": [ 212 ], "produced": [ 220 ], "clinically": [ 221 ], "meaningful": [ 222 ], "at": [ 225 ], "56": [ 226 ], "weeks,": [ 227 ], "enhanced": [ 228 ], "by": [ 229 ], "addition": [ 231 ] }, "publication_date": "2020-02-24", "publication_year": 2020, "type": "article", "cited_by_count": 170, "authors": [ { "id": "https://openalex.org/A5026596594", "display_name": "Thomas A. Wadden" }, { "id": "https://openalex.org/A5001055593", "display_name": "Jena Shaw Tronieri" }, { "id": "https://openalex.org/A5081546904", "display_name": "Danny Sugimoto" }, { "id": "https://openalex.org/A5114003928", "display_name": "Michael Lund" }, { "id": "https://openalex.org/A5035576643", "display_name": "Pernille Auerbach" }, { "id": "https://openalex.org/A5078072521", "display_name": "Camilla Jensen" }, { "id": "https://openalex.org/A5060266336", "display_name": "Domenica Rubino" } ] }, { "id": "https://openalex.org/W2115357902", "doi": "https://doi.org/10.2337/db11-0936", "title": "The Human GLP-1 Analog Liraglutide and the Pancreas", "abstract": { "Glucagon-like": [ 0 ], "peptide": [ 1 ], "(GLP)-1": [ 2 ], "analogs": [ 3 ], "have": [ 4 ], "been": [ 5 ], "implicated": [ 6 ], "as": [ 7 ], "a": [ 8 ], "risk": [ 9 ], "factor": [ 10 ], "for": [ 11, 152, 185 ], "pancreatitis": [ 12, 25, 88, 142, 177 ], "in": [ 13, 26, 48, 66, 77, 102, 109, 126, 138, 149, 164, 178, 200 ], "humans.": [ 14, 201 ], "We": [ 15 ], "investigated": [ 16 ], "whether": [ 17 ], "liraglutide,": [ 18 ], "the": [ 19, 49, 67, 78, 95, 103, 111, 122, 167 ], "once-daily": [ 20 ], "human": [ 21 ], "GLP-1": [ 22 ], "analog,": [ 23 ], "induces": [ 24 ], "rats,": [ 27, 34, 180 ], "mice,": [ 28, 33, 179 ], "and": [ 29, 35, 41, 70, 74, 106, 190 ], "monkeys.": [ 30 ], "Pancreata": [ 31 ], "from": [ 32, 51 ], "nonhuman": [ 36, 52 ], "primates": [ 37, 53 ], "were": [ 38, 97, 130 ], "examined": [ 39 ], "macro-": [ 40 ], "microscopically.": [ 42 ], "Evaluation": [ 43 ], "of": [ 44, 59, 62, 99, 124, 133 ], "preneoplastic": [ 45, 144 ], "proliferative": [ 46, 145 ], "lesions": [ 47, 146 ], "pancreata": [ 50 ], "was": [ 54, 120, 147 ], "performed.": [ 55 ], "After": [ 56 ], "2": [ 57, 188 ], "years": [ 58, 189 ], "treatment,": [ 60 ], "3": [ 61, 107 ], "79": [ 63, 100 ], "male": [ 64 ], "mice": [ 65, 76, 84, 101, 108, 116 ], "control": [ 68, 104 ], "group": [ 69, 105 ], "2,": [ 71 ], "1,": [ 72, 73 ], "1": [ 75 ], "different": [ 79 ], "liraglutide": [ 80, 112, 157, 173 ], "groups": [ 81, 113 ], "(of": [ 82, 114 ], "67\u201379": [ 83 ], "per": [ 85, 117 ], "group)": [ 86 ], "had": [ 87 ], "based": [ 89 ], "on": [ 90 ], "microscopic": [ 91 ], "criteria.": [ 92 ], "For": [ 93 ], "females,": [ 94 ], "numbers": [ 96 ], "0": [ 98 ], "all": [ 110 ], "66\u201376": [ 115 ], "group).": [ 118 ], "Pancreatitis": [ 119 ], "not": [ 121, 175 ], "cause": [ 123 ], "death": [ 125 ], "any": [ 127 ], "animals.": [ 128 ], "There": [ 129 ], "no": [ 131 ], "cases": [ 132 ], "pancreatitis,": [ 134 ], "macroscopically": [ 135 ], "or": [ 136, 181 ], "microscopically,": [ 137 ], "400": [ 139 ], "rats.": [ 140 ], "Neither": [ 141 ], "nor": [ 143 ], "found": [ 148 ], "monkeys": [ 150, 182 ], "dosed": [ 151, 184 ], "87": [ 153 ], "weeks,": [ 154 ], "with": [ 155 ], "plasma": [ 156 ], "exposure": [ 158, 192 ], "60-fold": [ 159 ], "higher": [ 160, 198 ], "than": [ 161, 199 ], "that": [ 162 ], "observed": [ 163 ], "humans": [ 165 ], "at": [ 166, 191 ], "maximal": [ 168 ], "clinical": [ 169 ], "dose.": [ 170 ], "In": [ 171 ], "conclusion,": [ 172 ], "did": [ 174 ], "induce": [ 176 ], "when": [ 183 ], "up": [ 186, 194 ], "to": [ 187, 195 ], "levels": [ 193 ], "60": [ 196 ], "times": [ 197 ] }, "publication_date": "2012-02-16", "publication_year": 2012, "type": "article", "cited_by_count": 122, "authors": [ { "id": "https://openalex.org/A5090786732", "display_name": "Niels C. Berg Nyborg" }, { "id": "https://openalex.org/A5111572681", "display_name": "Anne\u2010Marie M\u00f8lck" }, { "id": "https://openalex.org/A5073611205", "display_name": "Lars Wichmann Madsen" }, { "id": "https://openalex.org/A5088627727", "display_name": "Lotte Bjerre Knudsen" } ] }, { "id": "https://openalex.org/W4391440666", "doi": "https://doi.org/10.1038/s41366-024-01473-y", "title": "What is the pipeline for future medications for obesity?", "abstract": { "Abstract": [ 0 ], "Obesity": [ 1 ], "is": [ 2 ], "a": [ 3, 58, 142, 242, 277 ], "chronic": [ 4 ], "disease": [ 5 ], "associated": [ 6 ], "with": [ 7, 76, 109, 113, 215, 257, 276 ], "increased": [ 8 ], "risk": [ 9 ], "of": [ 10, 18, 26, 36, 78, 103, 107, 138, 176, 218, 250, 273 ], "obesity-related": [ 11 ], "complications": [ 12 ], "and": [ 13, 23, 38, 87, 126, 135, 183, 200, 232, 267, 283, 289 ], "mortality.": [ 14 ], "Our": [ 15 ], "better": [ 16 ], "understanding": [ 17 ], "the": [ 19, 24, 34, 100, 133, 184, 227, 254, 265, 271, 286, 292 ], "weight": [ 20, 73 ], "regulation": [ 21 ], "mechanisms": [ 22, 217 ], "role": [ 25 ], "gut-brain": [ 27 ], "axis": [ 28 ], "on": [ 29, 279 ], "appetite": [ 30 ], "has": [ 31, 147 ], "led": [ 32 ], "to": [ 33, 94, 99, 131, 166, 193, 207, 220 ], "development": [ 35, 86 ], "safe": [ 37 ], "effective": [ 39 ], "entero-pancreatic": [ 40, 111, 177, 221, 251, 280 ], "hormone-based": [ 41, 281 ], "treatments": [ 42, 199, 282 ], "for": [ 43, 64, 150, 160, 245, 270 ], "obesity": [ 44, 65, 104, 161, 172, 198, 246, 274, 296 ], "such": [ 45 ], "as": [ 46, 120, 157, 159, 197 ], "glucagon-like": [ 47 ], "peptide-1": [ 48 ], "(GLP-1)": [ 49 ], "receptor": [ 50, 145 ], "agonists": [ 51 ], "(RA).": [ 52 ], "Semaglutide": [ 53 ], "2.4": [ 54, 96 ], "mg": [ 55 ], "once": [ 56 ], "weekly,": [ 57 ], "subcutaneously": [ 59 ], "administered": [ 60 ], "GLP-1": [ 61, 81, 108, 139 ], "RA": [ 62, 82 ], "approved": [ 63, 149 ], "treatment": [ 66 ], "in": [ 67, 70, 153, 164, 169, 234, 241, 295 ], "2021,": [ 68 ], "results": [ 69 ], "15\u201317%": [ 71 ], "mean": [ 72 ], "loss": [ 74 ], "(WL)": [ 75 ], "evidence": [ 77 ], "cardioprotection.": [ 79 ], "Oral": [ 80 ], "are": [ 83, 128, 233, 240 ], "also": [ 84, 191 ], "under": [ 85, 129 ], "early": [ 88, 201, 235 ], "data": [ 89, 202, 269 ], "shows": [ 90 ], "similar": [ 91 ], "WL": [ 92, 134, 168, 210, 231, 255 ], "efficacy": [ 93, 266 ], "semaglutide": [ 95 ], "mg.": [ 97 ], "Looking": [ 98 ], "next": [ 101 ], "generation": [ 102 ], "treatments,": [ 105 ], "combinations": [ 106, 175, 249 ], "other": [ 110 ], "hormones": [ 112, 178, 222, 252 ], "complementary": [ 114 ], "actions": [ 115 ], "and/or": [ 116 ], "synergistic": [ 117 ], "potential": [ 118 ], "(such": [ 119 ], "glucose-dependent": [ 121 ], "insulinotropic": [ 122 ], "polypeptide": [ 123 ], "(GIP),": [ 124 ], "glucagon,": [ 125 ], "amylin)": [ 127 ], "investigation": [ 130 ], "enhance": [ 132 ], "cardiometabolic": [ 136 ], "benefits": [ 137 ], "RA.": [ 140 ], "Tirzepatide,": [ 141 ], "dual": [ 143 ], "GLP-1/GIP": [ 144 ], "agonist": [ 146, 186 ], "been": [ 148 ], "glycaemic": [ 151 ], "control": [ 152 ], "type": [ 154 ], "2": [ 155 ], "diabetes": [ 156 ], "well": [ 158 ], "management": [ 162, 297 ], "leading": [ 163 ], "up": [ 165 ], "22.5%": [ 167 ], "phase": [ 170, 194, 236 ], "3": [ 171, 195 ], "trials.": [ 173, 238 ], "Other": [ 174 ], "including": [ 179 ], "cagrisema": [ 180 ], "(GLP-1/amylin": [ 181 ], "RA)": [ 182, 189 ], "triple": [ 185 ], "retatrutide": [ 187 ], "(GLP-1/GIP/glucagon": [ 188 ], "have": [ 190 ], "progressed": [ 192 ], "trials": [ 196 ], "suggests": [ 203 ], "that": [ 204, 291 ], "may": [ 205, 225, 298 ], "lead": [ 206 ], "even": [ 208 ], "greater": [ 209 ], "than": [ 211 ], "tirzepatide.": [ 212 ], "Additionally,": [ 213 ], "agents": [ 214 ], "different": [ 216 ], "action": [ 219 ], "(e.g.": [ 223 ], "bimagrumab)": [ 224 ], "improve": [ 226 ], "body": [ 228 ], "composition": [ 229 ], "during": [ 230 ], "clinical": [ 237, 287 ], "We": [ 239 ], "new": [ 243, 293 ], "era": [ 244, 294 ], "pharmacotherapy": [ 247 ], "where": [ 248 ], "approach": [ 253 ], "achieved": [ 256 ], "bariatric": [ 258 ], "surgery.": [ 259 ], "In": [ 260 ], "this": [ 261 ], "review,": [ 262 ], "we": [ 263, 284 ], "present": [ 264 ], "safety": [ 268 ], "pipeline": [ 272 ], "pharmacotherapies": [ 275 ], "focus": [ 278 ], "consider": [ 285 ], "implications": [ 288 ], "challenges": [ 290 ], "bring.": [ 299 ] }, "publication_date": "2024-02-01", "publication_year": 2024, "type": "review", "cited_by_count": 224, "authors": [ { "id": "https://openalex.org/A5005166583", "display_name": "Eka Melson" }, { "id": "https://openalex.org/A5111122584", "display_name": "Uzma Ashraf" }, { "id": "https://openalex.org/A5017193412", "display_name": "Dimitris Papamargaritis" }, { "id": "https://openalex.org/A5084593004", "display_name": "Melanie J. Davies" } ] }, { "id": "https://openalex.org/W4403479516", "doi": "https://doi.org/10.1210/clinem/dgae719", "title": "Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide", "abstract": { "Abstract": [ 0 ], "Context": [ 1 ], "Glucagon-like": [ 2 ], "peptide-1": [ 3 ], "(GLP-1)": [ 4 ], "receptor": [ 5, 148 ], "agonists": [ 6 ], "(RAs)": [ 7 ], "are": [ 8, 96, 105, 128, 138 ], "established": [ 9 ], "therapeutics": [ 10 ], "for": [ 11, 75, 112, 125, 219, 246 ], "type": [ 12 ], "2": [ 13 ], "diabetes": [ 14, 190 ], "and": [ 15, 24, 37, 41, 80, 124, 165, 205, 223, 234 ], "obesity.": [ 16 ], "Among": [ 17 ], "other": [ 18 ], "mechanisms,": [ 19 ], "they": [ 20 ], "slow": [ 21, 151, 176 ], "gastric": [ 22, 53, 87, 152, 171, 177, 203, 221 ], "emptying": [ 23, 153, 172, 178 ], "motility": [ 25, 45 ], "of": [ 26, 92, 116, 146, 189, 197, 226 ], "the": [ 27, 72, 90, 113, 144, 167, 187, 195, 224 ], "small": [ 28 ], "intestine.": [ 29 ], "This": [ 30 ], "helps": [ 31 ], "to": [ 32, 120, 135, 150, 242 ], "limit": [ 33 ], "postprandial": [ 34 ], "glycemic": [ 35 ], "excursions": [ 36 ], "reduce": [ 38 ], "chylomicron": [ 39 ], "formation": [ 40 ], "triglyceride": [ 42 ], "absorption.": [ 43 ], "Conversely,": [ 44 ], "effects": [ 46 ], "may": [ 47, 231 ], "have": [ 48 ], "detrimental": [ 49 ], "consequences,": [ 50 ], "eg,": [ 51 ], "retained": [ 52, 202, 220 ], "contents": [ 54, 88, 204 ], "at": [ 55, 89, 155 ], "endoscopy": [ 56, 95 ], "or": [ 57, 65 ], "general": [ 58 ], "anesthesia,": [ 59 ], "potentially": [ 60 ], "complicated": [ 61 ], "by": [ 62, 130 ], "pulmonary": [ 63, 108, 206 ], "aspiration": [ 64 ], "bowel": [ 66 ], "obstruction.": [ 67 ], "Data": [ 68, 84 ], "Acquisition": [ 69 ], "We": [ 70 ], "searched": [ 71 ], "PubMed": [ 73 ], "database": [ 74 ], "studies": [ 76 ], "involving": [ 77 ], "GLP-1RA": [ 78 ], "therapy": [ 79 ], "adverse": [ 81 ], "gastrointestinal/biliary": [ 82 ], "events.": [ 83 ], "Synthesis": [ 85 ], "Retained": [ 86 ], "time": [ 91 ], "upper": [ 93 ], "gastrointestinal": [ 94 ], "found": [ 97 ], "more": [ 98 ], "frequently": [ 99 ], "with": [ 100, 107, 162, 175, 249 ], "GLP-1": [ 101, 147, 157, 198, 250 ], "RAs": [ 102 ], "but": [ 103 ], "rarely": [ 104 ], "associated": [ 106 ], "aspiration.": [ 109, 207 ], "Well-justified": [ 110 ], "recommendations": [ 111 ], "periprocedural": [ 114 ], "management": [ 115 ], "GLP-1RAs": [ 117 ], "(eg,": [ 118 ], "whether": [ 119 ], "withhold": [ 121 ], "these": [ 122 ], "medications": [ 123, 228 ], "how": [ 126 ], "long)": [ 127 ], "compromised": [ 129 ], "limited": [ 131, 168 ], "evidence.": [ 132 ], "Important": [ 133 ], "aspects": [ 134 ], "be": [ 136 ], "considered": [ 137 ], "(1)": [ 139 ], "their": [ 140 ], "long": [ 141 ], "half-lives,": [ 142 ], "(2)": [ 143 ], "capacity": [ 145 ], "agonism": [ 149 ], "even": [ 154 ], "physiological": [ 156 ], "concentrations,": [ 158 ], "(c)": [ 159 ], "tachyphylaxis": [ 160 ], "observed": [ 161 ], "prolonged": [ 163 ], "treatment,": [ 164 ], "(d)": [ 166 ], "effect": [ 169 ], "on": [ 170, 186, 201 ], "in": [ 173, 194 ], "individuals": [ 174 ], "before": [ 179 ], "initiating": [ 180 ], "treatment.": [ 181 ], "Little": [ 182 ], "information": [ 183 ], "is": [ 184 ], "available": [ 185 ], "influence": [ 188 ], "mellitus": [ 191 ], "itself": [ 192 ], "(ie,": [ 193 ], "absence": [ 196 ], "RA": [ 199 ], "treatment)": [ 200 ], "Conclusion": [ 208 ], "Prolonged": [ 209 ], "fasting": [ 210 ], "periods": [ 211 ], "regarding": [ 212 ], "solid": [ 213 ], "meal": [ 214 ], "components,": [ 215 ], "point-of-care": [ 216 ], "ultrasound": [ 217 ], "examination": [ 218 ], "content,": [ 222 ], "use": [ 225 ], "prokinetic": [ 227 ], "like": [ 229 ], "erythromycin": [ 230 ], "prove": [ 232 ], "helpful": [ 233 ], "represent": [ 235 ], "an": [ 236 ], "important": [ 237 ], "area": [ 238 ], "needing": [ 239 ], "further": [ 240 ], "study": [ 241 ], "increase": [ 243 ], "patient": [ 244 ], "safety": [ 245 ], "those": [ 247 ], "treated": [ 248 ], "RAs.": [ 251 ] }, "publication_date": "2024-10-10", "publication_year": 2024, "type": "review", "cited_by_count": 42, "authors": [ { "id": "https://openalex.org/A5072607848", "display_name": "Ryan J. Jalleh" }, { "id": "https://openalex.org/A5078516494", "display_name": "Mark P. Plummer" }, { "id": "https://openalex.org/A5005883576", "display_name": "Chinmay S. Marathe" }, { "id": "https://openalex.org/A5016588809", "display_name": "Mahesh M. Umapathysivam" }, { "id": "https://openalex.org/A5091130352", "display_name": "Daniel R. Quast" }, { "id": "https://openalex.org/A5002868708", "display_name": "Christopher Rayner" }, { "id": "https://openalex.org/A5069047882", "display_name": "Karen Jones" }, { "id": "https://openalex.org/A5074396199", "display_name": "Tongzhi Wu" }, { "id": "https://openalex.org/A5012213812", "display_name": "Michael Horowitz" }, { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" } ] }, { "id": "https://openalex.org/W3198173302", "doi": "https://doi.org/10.1038/s41366-021-00955-7", "title": "Obese mice weight loss role on nonalcoholic fatty liver disease and endoplasmic reticulum stress treated by a GLP-1 receptor agonist", "abstract": null, "publication_date": "2021-08-31", "publication_year": 2021, "type": "article", "cited_by_count": 64, "authors": [ { "id": "https://openalex.org/A5032374000", "display_name": "Rayane Miranda Pontes-da-Silva" }, { "id": "https://openalex.org/A5024493537", "display_name": "Thatiany de Souza Marinho" }, { "id": "https://openalex.org/A5001973676", "display_name": "Luiz E.M. Cardoso" }, { "id": "https://openalex.org/A5072346695", "display_name": "Carlos Alberto Mandarim\u2010de\u2010Lacerda" }, { "id": "https://openalex.org/A5084203631", "display_name": "M\u00e1rcia Barbosa \u00c1guila" } ] }, { "id": "https://openalex.org/W4302024172", "doi": "https://doi.org/10.1016/j.jdiacomp.2022.108332", "title": "Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist", "abstract": null, "publication_date": "2022-10-05", "publication_year": 2022, "type": "review", "cited_by_count": 27, "authors": [ { "id": "https://openalex.org/A5023087190", "display_name": "Shasta Tall Bull" }, { "id": "https://openalex.org/A5016624558", "display_name": "Wesley Nuffer" }, { "id": "https://openalex.org/A5054620018", "display_name": "Jennifer Trujillo" } ] }, { "id": "https://openalex.org/W2946264273", "doi": "https://doi.org/10.1186/s12933-019-0857-6", "title": "Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial", "abstract": { "Abstract": [ 0 ], "Background": [ 1 ], "Liraglutide": [ 2, 204, 261 ], "is": [ 3, 15 ], "an": [ 4 ], "antidiabetic": [ 5 ], "agent": [ 6 ], "with": [ 7, 27, 38, 109, 142 ], "cardioprotective": [ 8 ], "effect.": [ 9 ], "The": [ 10 ], "purpose": [ 11 ], "of": [ 12, 19, 54, 113, 298 ], "this": [ 13, 51 ], "study": [ 14 ], "to": [ 16, 21, 43, 134, 138, 153, 162, 175, 184, 194, 202, 213, 223, 237, 247, 258, 289 ], "test": [ 17 ], "efficacy": [ 18 ], "liraglutide": [ 20, 45, 135, 144 ], "improve": [ 22 ], "diabetic": [ 23, 299 ], "cardiomyopathy": [ 24, 300 ], "in": [ 25, 50 ], "patients": [ 26, 131 ], "diabetes": [ 28 ], "mellitus": [ 29 ], "type": [ 30 ], "2": [ 31, 169, 244 ], "(DM2)": [ 32 ], "without": [ 33, 187 ], "cardiovascular": [ 34 ], "disease.": [ 35 ], "Methods": [ 36 ], "Patients": [ 37 ], "DM2": [ 39 ], "were": [ 40, 60, 132 ], "randomly": [ 41 ], "assigned": [ 42 ], "receive": [ 44 ], "1.8": [ 46, 181 ], "mg/day": [ 47 ], "or": [ 48 ], "placebo": [ 49 ], "double-blind": [ 52 ], "trial": [ 53 ], "26": [ 55, 137 ], "weeks.": [ 56 ], "Primary": [ 57 ], "outcome": [ 58 ], "measures": [ 59 ], "LV": [ 61, 89, 264, 268, 276 ], "diastolic": [ 62, 265 ], "function": [ 63, 95, 278 ], "(early": [ 64 ], "(E)": [ 65 ], "and": [ 66, 87, 93, 104, 136, 178, 196, 216, 249, 267, 280 ], "late": [ 67 ], "(A)": [ 68 ], "transmitral": [ 69 ], "peak": [ 70, 77, 80, 105, 250 ], "flow": [ 71 ], "rate,": [ 72 ], "E/A": [ 73, 156 ], "ratio,": [ 74 ], "early": [ 75, 79, 263 ], "deceleration": [ 76 ], "(Edec),": [ 78 ], "mitral": [ 81 ], "annular": [ 82 ], "septal": [ 83 ], "tissue": [ 84 ], "velocity": [ 85 ], "(Ea)": [ 86 ], "estimated": [ 88, 121 ], "filling": [ 90, 266, 269 ], "pressure": [ 91 ], "(E/Ea),": [ 92 ], "systolic": [ 94, 277 ], "(stroke": [ 96 ], "volume,": [ 97 ], "ejection": [ 98, 106, 217, 251 ], "fraction,": [ 99 ], "cardiac": [ 100, 102, 230, 239 ], "output,": [ 101 ], "index": [ 103, 240 ], "rate)": [ 107 ], "assessed": [ 108 ], "CMR.": [ 110 ], "Intention-to-treat": [ 111 ], "analysis": [ 112 ], "between-group": [ 114 ], "differences": [ 115, 123 ], "was": [ 116 ], "performed": [ 117 ], "using": [ 118 ], "ANCOVA.": [ 119 ], "Mean": [ 120 ], "treatment": [ 122 ], "(95%": [ 124 ], "confidence": [ 125 ], "intervals)": [ 126 ], "are": [ 127, 287 ], "reported.": [ 128 ], "Results": [ 129 ], "23": [ 130 ], "randomized": [ 133 ], "placebo.": [ 139 ], "As": [ 140 ], "compared": [ 141 ], "placebo,": [ 143 ], "significantly": [ 145 ], "reduced": [ 146, 205, 262, 279 ], "E": [ 147 ], "(\u2212": [ 148, 151, 158, 160, 166, 173, 180, 182, 192, 200, 208, 211, 219, 221, 232, 235, 241, 245, 253, 256 ], "56": [ 149 ], "mL/s": [ 150, 168, 191, 255 ], "91": [ 152 ], "\u2212": [ 154, 163, 176, 185, 214, 224 ], "21)),": [ 155 ], "ratio": [ 157 ], "0.17": [ 159 ], "0.27": [ 161 ], "0.06)),": [ 164 ], "Edec": [ 165 ], "0.9": [ 167, 201, 236 ], "*": [ 170 ], "10": [ 171 ], "\u22123": [ 172 ], "1.3": [ 174 ], "0.2))": [ 177 ], "E/Ea": [ 179 ], "3.0": [ 183 ], "0.6)),": [ 186 ], "affecting": [ 188 ], "A": [ 189 ], "(3": [ 190 ], "35": [ 193 ], "41))": [ 195 ], "Ea": [ 197 ], "(0.4": [ 198 ], "cm/s": [ 199 ], "1.4)).": [ 203 ], "stroke": [ 206 ], "volume": [ 207 ], "9": [ 209 ], "mL": [ 210 ], "16": [ 212 ], "2))": [ 215 ], "fraction": [ 218 ], "3%": [ 220 ], "6": [ 222 ], "0.1)),": [ 225 ], "but": [ 226 ], "did": [ 227 ], "not": [ 228 ], "change": [ 229 ], "output": [ 231 ], "0.4": [ 233, 246 ], "L/min": [ 234 ], "0.2)),": [ 238 ], "0.1": [ 242 ], "L/min/m": [ 243 ], "0.1))": [ 248 ], "rate": [ 252 ], "46": [ 254 ], "95": [ 257 ], "3)).": [ 259 ], "Conclusions": [ 260 ], "pressure,": [ 270 ], "thereby": [ 271 ], "unloading": [ 272, 295 ], "the": [ 273 ], "left": [ 274, 293 ], "ventricle.": [ 275 ], "remained": [ 281 ], "within": [ 282 ], "normal": [ 283 ], "range.": [ 284 ], "Future": [ 285 ], "studies": [ 286 ], "needed": [ 288 ], "investigate": [ 290 ], "if": [ 291 ], "liraglutide-induced": [ 292 ], "ventricular": [ 294 ], "slows": [ 296 ], "progression": [ 297 ], "into": [ 301 ], "symptomatic": [ 302 ], "stages.": [ 303 ], "Trial": [ 304 ], "registration": [ 305 ], "ClinicalTrials.gov:": [ 306 ], "NCT01761318.": [ 307 ] }, "publication_date": "2019-04-30", "publication_year": 2019, "type": "article", "cited_by_count": 130, "authors": [ { "id": "https://openalex.org/A5067334429", "display_name": "Maurice B. Bizino" }, { "id": "https://openalex.org/A5062964331", "display_name": "Ingrid M. Jazet" }, { "id": "https://openalex.org/A5049452068", "display_name": "Jos J.M. Westenberg" }, { "id": "https://openalex.org/A5091678325", "display_name": "Huub J. van Eyk" }, { "id": "https://openalex.org/A5090316420", "display_name": "Elisabeth H.M. Paiman" }, { "id": "https://openalex.org/A5052838073", "display_name": "Johannes W. A. Smit" }, { "id": "https://openalex.org/A5019397910", "display_name": "Hildebrandus J. Lamb" } ] }, { "id": "https://openalex.org/W2933306415", "doi": "https://doi.org/10.1007/s41669-019-0131-6", "title": "Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada", "abstract": null, "publication_date": "2019-03-29", "publication_year": 2019, "type": "article", "cited_by_count": 28, "authors": [ { "id": "https://openalex.org/A5051180257", "display_name": "Pierre Johansen" }, { "id": "https://openalex.org/A5075867168", "display_name": "Jonas H\u00e5kan\u2010Bloch" }, { "id": "https://openalex.org/A5047305485", "display_name": "Aiden R. Liu" }, { "id": "https://openalex.org/A5052560763", "display_name": "Peter G. Bech" }, { "id": "https://openalex.org/A5021095048", "display_name": "Sofie Persson" }, { "id": "https://openalex.org/A5080414941", "display_name": "Lawrence A. Leiter" } ] }, { "id": "https://openalex.org/W4406979066", "doi": "https://doi.org/10.1016/j.amjmed.2025.01.021", "title": "Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation", "abstract": null, "publication_date": "2025-01-31", "publication_year": 2025, "type": "review", "cited_by_count": 49, "authors": [ { "id": "https://openalex.org/A5092200248", "display_name": "Areesha Moiz" }, { "id": "https://openalex.org/A5042964192", "display_name": "Kristian B. Filion" }, { "id": "https://openalex.org/A5077247868", "display_name": "Michael A. Tsoukas" }, { "id": "https://openalex.org/A5002024158", "display_name": "Oriana Hoi Yun Yu" }, { "id": "https://openalex.org/A5076404799", "display_name": "Tricia M. Peters" }, { "id": "https://openalex.org/A5072116483", "display_name": "Mark J. Eisenberg" } ] }, { "id": "https://openalex.org/W2185206376", "doi": "https://doi.org/10.1111/ijpo.12131", "title": "Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader\u2010Willi syndrome", "abstract": { "Summary": [ 0 ], "Background": [ 1 ], "Prader\u2013Willi": [ 2 ], "syndrome": [ 3 ], "(PWS)": [ 4 ], "is": [ 5, 30, 54, 194 ], "associated": [ 6 ], "with": [ 7, 11, 73, 81, 206, 230, 256 ], "hyperphagia": [ 8 ], "and": [ 9, 38, 40, 68, 78, 118, 135, 151, 162, 181, 238, 242 ], "hyperghrelinemia": [ 10 ], "major": [ 12 ], "morbidity": [ 13 ], "because": [ 14 ], "of": [ 15, 51, 59, 63, 154, 199, 202, 240 ], "obesity": [ 16 ], "without": [ 17, 107, 214 ], "effective": [ 18, 44, 210 ], "medical": [ 19 ], "treatment": [ 20, 45, 155 ], "targeting": [ 21 ], "hyperphagia.": [ 22 ], "Exenatide": [ 23, 100 ], "(Byetta": [ 24 ], "[synthetic": [ 25 ], "Exendin\u20104];": [ 26 ], "AstraZeneca,": [ 27 ], "Wilmington": [ 28 ], "DE)": [ 29 ], "a": [ 31, 60, 88 ], "GLP\u20101": [ 32 ], "receptor": [ 33 ], "agonist": [ 34 ], "which": [ 35 ], "reduces": [ 36 ], "appetite": [ 37, 117 ], "weight": [ 39, 67, 217, 250 ], "may": [ 41 ], "be": [ 42 ], "an": [ 43 ], "in": [ 46, 71, 190, 204, 211, 216, 220, 228, 254 ], "PWS.": [ 47, 74, 207 ], "Objective": [ 48 ], "The": [ 49 ], "objective": [ 50 ], "this": [ 52 ], "study": [ 53, 93 ], "to": [ 55, 234, 243 ], "determine": [ 56 ], "the": [ 57, 195, 200, 221, 236 ], "effect": [ 58 ], "6\u2010month": [ 61, 89 ], "trial": [ 62 ], "exenatide": [ 64, 203, 241 ], "on": [ 65 ], "appetite,": [ 66, 213 ], "gut": [ 69 ], "hormones": [ 70 ], "youth": [ 72 ], "Methods": [ 75 ], "Ten": [ 76 ], "overweight": [ 77 ], "obese": [ 79 ], "subjects": [ 80, 205 ], "PWS": [ 82, 231 ], "(13\u201325": [ 83 ], "years)": [ 84 ], "were": [ 85, 122, 131 ], "recruited": [ 86 ], "for": [ 87 ], "open\u2010label,": [ 90 ], "non\u2010randomized,": [ 91 ], "longitudinal": [ 92, 197 ], "conducted": [ 94 ], "at": [ 95, 133 ], "Children's": [ 96 ], "Hospital": [ 97 ], "Los": [ 98 ], "Angeles.": [ 99 ], "was": [ 101, 186, 209 ], "given": [ 102, 253 ], "using": [ 103 ], "standard": [ 104 ], "diabetes": [ 105 ], "dosing": [ 106 ], "dietary": [ 108 ], "modifications.": [ 109 ], "Weight,": [ 110 ], "body": [ 111 ], "mass": [ 112 ], "index": [ 113 ], "(BMI),": [ 114 ], "truncal": [ 115 ], "fat,": [ 116 ], "plasma": [ 119 ], "acylated": [ 120 ], "ghrelin": [ 121 ], "measured": [ 123 ], "over": [ 124 ], "6": [ 125, 136, 152 ], "months.": [ 126, 137 ], "Mixed": [ 127 ], "meal": [ 128 ], "tolerance": [ 129 ], "tests": [ 130 ], "performed": [ 132 ], "0": [ 134 ], "Results": [ 138 ], "Appetite": [ 139 ], "scores": [ 140 ], "significantly": [ 141, 173 ], "decreased": [ 142, 172 ], "from": [ 143 ], "baseline": [ 144 ], "(32.2": [ 145 ], "\u00b1": [ 146, 157, 160, 164 ], "8.7)": [ 147 ], "after": [ 148, 174 ], "1,": [ 149 ], "3": [ 150 ], "moths": [ 153 ], "(27.5": [ 156 ], "8.8,": [ 158 ], "25.4": [ 159, 163 ], "9.3,": [ 161 ], "7.2": [ 165 ], "respectively;": [ 166 ], "p": [ 167 ], "=": [ 168 ], "0.004).": [ 169 ], "Hemoglobin": [ 170 ], "A1c": [ 171 ], "treatment,": [ 175 ], "but": [ 176 ], "weight,": [ 177 ], "BMI": [ 178, 219 ], "z": [ 179 ], "\u2010score": [ 180 ], "adiposity": [ 182 ], "did": [ 183 ], "not.": [ 184 ], "There": [ 185 ], "no": [ 187 ], "significant": [ 188 ], "change": [ 189, 215 ], "ghrelin.": [ 191 ], "Conclusions": [ 192 ], "This": [ 193 ], "first": [ 196 ], "investigation": [ 198 ], "effects": [ 201 ], "It": [ 208 ], "decreasing": [ 212 ], "or": [ 218 ], "short": [ 222 ], "term.": [ 223 ], "Larger,": [ 224 ], "controlled,": [ 225 ], "longer\u2010term": [ 226 ], "trials": [ 227 ], "patients": [ 229 ], "are": [ 232 ], "needed": [ 233 ], "confirm": [ 235 ], "efficacy": [ 237 ], "safety": [ 239 ], "evaluate": [ 244 ], "whether": [ 245 ], "its": [ 246 ], "use": [ 247 ], "might": [ 248 ], "induce": [ 249 ], "loss": [ 251 ], "when": [ 252 ], "conjunction": [ 255 ], "behavioural": [ 257 ], "modification.": [ 258 ] }, "publication_date": "2016-04-13", "publication_year": 2016, "type": "article", "cited_by_count": 72, "authors": [ { "id": "https://openalex.org/A5101724047", "display_name": "Parisa Salehi" }, { "id": "https://openalex.org/A5029177430", "display_name": "Isabel Hsu" }, { "id": "https://openalex.org/A5113548058", "display_name": "C. Azen" }, { "id": "https://openalex.org/A5018231342", "display_name": "Steven D. Mittelman" }, { "id": "https://openalex.org/A5055821983", "display_name": "Mitchell E. Geffner" }, { "id": "https://openalex.org/A5011939802", "display_name": "Debra Jeandron" } ] }, { "id": "https://openalex.org/W2337473245", "doi": "https://doi.org/10.1111/dom.12680", "title": "Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy", "abstract": { "Aim": [ 0 ], "To": [ 1 ], "conduct": [ 2 ], "a": [ 3, 81, 106, 119, 149, 194 ], "prospective": [ 4 ], "randomized": [ 5 ], "trial": [ 6 ], "to": [ 7, 41, 48, 148, 275, 302 ], "investigate": [ 8 ], "the": [ 9, 172, 188, 209, 244 ], "effect": [ 10 ], "of": [ 11, 25, 99, 114, 124, 262 ], "glucagon\u2010like": [ 12 ], "peptide\u20101": [ 13 ], "(": [ 14, 54, 60, 66, 73, 110, 139, 212 ], "GLP": [ 15 ], "\u20101)": [ 16 ], "analogues": [ 17 ], "on": [ 18, 34 ], "ectopic": [ 19, 236 ], "fat": [ 20, 237, 252, 305, 309 ], "stores.": [ 21 ], "Methods": [ 22 ], "A": [ 23 ], "total": [ 24 ], "44": [ 26 ], "obese": [ 27, 311 ], "subjects": [ 28 ], "with": [ 29, 84, 208, 247, 258, 313 ], "type": [ 30, 314 ], "2": [ 31, 129, 315 ], "diabetes": [ 32 ], "uncontrolled": [ 33 ], "oral": [ 35 ], "antidiabetic": [ 36 ], "drugs": [ 37 ], "were": [ 38, 76, 255, 272 ], "randomly": [ 39 ], "assigned": [ 40 ], "receive": [ 42 ], "exenatide": [ 43, 173, 297 ], "or": [ 44, 240, 268 ], "reference": [ 45, 145, 210 ], "treatment": [ 46, 146, 211, 301 ], "according": [ 47 ], "French": [ 49 ], "guidelines.": [ 50 ], "Epicardial": [ 51 ], "adipose": [ 52 ], "tissue": [ 53 ], "EAT": [ 55, 198, 213, 254 ], "),": [ 56, 62 ], "myocardial": [ 57 ], "triglyceride": [ 58, 64, 71 ], "content": [ 59, 65, 72, 306 ], "MTGC": [ 61, 241 ], "hepatic": [ 63, 135 ], "HTGC": [ 67, 140, 203, 221 ], ")": [ 68, 75, 112 ], "and": [ 69, 89, 95, 118, 144, 202, 253, 284, 307, 317 ], "pancreatic": [ 70 ], "PTGC": [ 74, 239 ], "assessed": [ 77 ], "45": [ 78 ], "min": [ 79 ], "after": [ 80, 96 ], "standardized": [ 82 ], "meal": [ 83 ], "3T": [ 85 ], "magnetic": [ 86, 91 ], "resonance": [ 87, 92 ], "imaging": [ 88 ], "proton": [ 90 ], "spectroscopy": [ 93 ], "before": [ 94 ], "26": [ 97 ], "weeks": [ 98 ], "treatment.": [ 100 ], "Results": [ 101 ], "The": [ 102 ], "study": [ 103 ], "population": [ 104 ], "had": [ 105, 134 ], "mean": [ 107, 120 ], "glycated": [ 108 ], "haemoglobin": [ 109 ], "HbA1c": [ 111, 153, 267 ], "level": [ 113 ], "7.5": [ 115 ], "\u00b1": [ 116, 126, 155, 159, 176, 181, 200, 205, 216, 224 ], "0.2%": [ 117 ], "body": [ 121 ], "mass": [ 122 ], "index": [ 123 ], "36.1": [ 125 ], "1.1": [ 127 ], "kg/m": [ 128 ], ".": [ 130, 242 ], "Ninety": [ 131 ], "five": [ 132 ], "percent": [ 133 ], "steatosis": [ 136 ], "at": [ 137 ], "baseline": [ 138 ], "\u2265": [ 141 ], "5.6%).": [ 142 ], "Exenatide": [ 143, 192 ], "led": [ 147 ], "similar": [ 150 ], "improvement": [ 151 ], "in": [ 152, 171, 197, 234, 250, 310 ], "(\u22120.7": [ 154 ], "0.3%": [ 156 ], "vs.": [ 157, 179 ], "\u22120.7": [ 158 ], "0.4%;": [ 160 ], "p": [ 161, 184, 218, 226, 281, 288 ], "=": [ 162, 185, 219, 227, 279, 282, 286, 289 ], "0.29),": [ 163 ], "whereas": [ 164 ], "significant": [ 165, 195, 230 ], "weight": [ 166, 276, 322 ], "loss": [ 167, 277, 323 ], "was": [ 168, 232 ], "observed": [ 169, 233 ], "only": [ 170 ], "group": [ 174, 245 ], "(\u22125.5": [ 175 ], "1.2": [ 177 ], "kg": [ 178 ], "\u22120.2": [ 180 ], "0.8": [ 182 ], "kg;": [ 183 ], "0.001": [ 186 ], "for": [ 187 ], "difference": [ 189, 231 ], "between": [ 190 ], "groups).": [ 191 ], "induced": [ 193 ], "reduction": [ 196 ], "(\u22128.8": [ 199 ], "2.1%)": [ 201 ], "(\u221223.8": [ 204 ], "9.5%),": [ 206 ], "compared": [ 207 ], ":": [ 214, 222 ], "\u22121.2": [ 215 ], "1.6%,": [ 217 ], "0.003;": [ 220 ], "+12.5": [ 223 ], "9.6%,": [ 225 ], "0.007).": [ 228 ], "No": [ 229 ], "other": [ 235 ], "stores,": [ 238 ], "In": [ 243 ], "treated": [ 246 ], "exenatide,": [ 248 ], "reductions": [ 249 ], "liver": [ 251, 304 ], "not": [ 256 ], "associated": [ 257 ], "homeostatic": [ 259 ], "model": [ 260 ], "assessment": [ 261 ], "insulin": [ 263 ], "resistance": [ 264 ], "index,": [ 265 ], "adiponectin,": [ 266 ], "fructosamin": [ 269 ], "change,": [ 270 ], "but": [ 271 ], "significantly": [ 273 ], "related": [ 274 ], "(r": [ 278 ], "0.47,": [ 280 ], "0.03,": [ 283 ], "r": [ 285 ], "0.50,": [ 287 ], "0.018,": [ 290 ], "respectively).": [ 291 ], "Conclusion": [ 292 ], "Our": [ 293 ], "data": [ 294 ], "indicate": [ 295 ], "that": [ 296 ], "is": [ 298 ], "an": [ 299 ], "effective": [ 300 ], "reduce": [ 303 ], "epicardial": [ 308 ], "patients": [ 312 ], "diabetes,": [ 316 ], "these": [ 318 ], "effects": [ 319 ], "are": [ 320 ], "mainly": [ 321 ], "dependent.": [ 324 ] }, "publication_date": "2016-04-23", "publication_year": 2016, "type": "article", "cited_by_count": 242, "authors": [ { "id": "https://openalex.org/A5014399685", "display_name": "Anne Dutour" }, { "id": "https://openalex.org/A5049123827", "display_name": "In\u00e8s Abdesselam" }, { "id": "https://openalex.org/A5090070297", "display_name": "Patricia Ancel" }, { "id": "https://openalex.org/A5086192226", "display_name": "Frank Kober" }, { "id": "https://openalex.org/A5046276088", "display_name": "G. Mrad" }, { "id": "https://openalex.org/A5078721857", "display_name": "Patrice Darmon" }, { "id": "https://openalex.org/A5061036356", "display_name": "O. Ronsin" }, { "id": "https://openalex.org/A5079002916", "display_name": "Vincent Pradel" }, { "id": "https://openalex.org/A5091449904", "display_name": "Nathalie Lesavre" }, { "id": "https://openalex.org/A5015309348", "display_name": "Jean\u2010Charles Martin" }, { "id": "https://openalex.org/A5084084155", "display_name": "Alexis Jacquier" }, { "id": "https://openalex.org/A5017311414", "display_name": "Yann Lefur" }, { "id": "https://openalex.org/A5085978408", "display_name": "Monique Bernard" }, { "id": "https://openalex.org/A5063777397", "display_name": "B\u00e9n\u00e9dicte Gaborit" } ] }, { "id": "https://openalex.org/W2109728760", "doi": "https://doi.org/10.2337/db09-9028", "title": "From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus", "abstract": { "Insulin": [ 0 ], "resistance": [ 1, 288 ], "in": [ 2, 14, 37, 91, 97, 118, 167, 176, 226, 236, 254, 259 ], "muscle": [ 3 ], "and": [ 4, 6, 29, 50, 65, 83, 110, 141, 148, 189, 203, 207, 213, 238 ], "liver": [ 5 ], "\u03b2-cell": [ 7, 24, 57, 66, 160, 201, 211, 242 ], "failure": [ 8, 25, 161 ], "represent": [ 9 ], "the": [ 10, 23, 38, 62, 68, 92, 107, 125, 146, 158, 286 ], "core": [ 11 ], "pathophysiologic": [ 12 ], "defects": [ 13 ], "type": [ 15, 98, 247, 265 ], "2": [ 16, 99, 129, 248, 266 ], "diabetes.": [ 17 ], "It": [ 18 ], "now": [ 19 ], "is": [ 20, 30, 164, 174, 180, 289 ], "recognized": [ 21 ], "that": [ 22, 162, 276 ], "occurs": [ 26 ], "much": [ 27 ], "earlier": [ 28 ], "more": [ 31 ], "severe": [ 32 ], "than": [ 33 ], "previously": [ 34 ], "thought.": [ 35 ], "Subjects": [ 36 ], "upper": [ 39 ], "tertile": [ 40 ], "of": [ 41, 55, 94, 137, 241, 246, 271 ], "impaired": [ 42 ], "glucose": [ 43, 81, 95 ], "tolerance": [ 44 ], "(IGT)": [ 45 ], "are": [ 46, 218, 230 ], "maximally/near-maximally": [ 47 ], "insulin": [ 48, 187, 198, 282, 287 ], "resistant": [ 49, 280 ], "have": [ 51 ], "lost": [ 52 ], "over": [ 53 ], "80%": [ 54 ], "their": [ 56, 274, 278 ], "function.": [ 58 ], "In": [ 59, 284 ], "addition": [ 60 ], "to": [ 61, 123, 156, 263, 281 ], "muscle,": [ 63 ], "liver,": [ 64, 285 ], "(triumvirate),": [ 67 ], "fat": [ 69 ], "cell": [ 70 ], "(accelerated": [ 71 ], "lipolysis),": [ 72 ], "gastrointestinal": [ 73 ], "tract": [ 74 ], "(incretin": [ 75 ], "deficiency/resistance),": [ 76 ], "\u03b1-cell": [ 77 ], "(hyperglucagonemia),": [ 78 ], "kidney": [ 79 ], "(increased": [ 80 ], "reabsorption),": [ 82 ], "brain": [ 84 ], "(insulin": [ 85 ], "resistance)": [ 86 ], "all": [ 87 ], "play": [ 88 ], "important": [ 89 ], "roles": [ 90 ], "development": [ 93 ], "intolerance": [ 96 ], "diabetic": [ 100 ], "individuals.": [ 101 ], "Collectively,": [ 102 ], "these": [ 103 ], "eight": [ 104 ], "players": [ 105 ], "comprise": [ 106 ], "ominous": [ 108 ], "octet": [ 109 ], "dictate": [ 111 ], "that:": [ 112 ], "1": [ 113 ], ")": [ 114, 130, 150 ], "multiple": [ 115, 126, 255 ], "drugs": [ 116 ], "used": [ 117 ], "combination": [ 119, 178 ], "will": [ 120 ], "be": [ 121, 133, 153 ], "required": [ 122 ], "correct": [ 124 ], "pathophysiological": [ 127 ], "defects,": [ 128 ], "treatment": [ 131, 171 ], "should": [ 132 ], "based": [ 134 ], "upon": [ 135 ], "reversal": [ 136 ], "known": [ 138 ], "pathogenic": [ 139 ], "abnormalities": [ 140 ], "not": [ 142, 219 ], "simply": [ 143 ], "on": [ 144 ], "reducing": [ 145 ], "A1C,": [ 147 ], "3": [ 149 ], "therapy": [ 151, 179 ], "must": [ 152 ], "started": [ 154 ], "early": [ 155 ], "prevent/slow": [ 157 ], "progressive": [ 159, 234, 239 ], "already": [ 163 ], "well": [ 165, 252 ], "established": [ 166 ], "IGT": [ 168 ], "subjects.": [ 169 ], "A": [ 170 ], "paradigm": [ 172 ], "shift": [ 173 ], "recommended": [ 175, 220 ], "which": [ 177 ], "initiated": [ 181 ], "with": [ 182, 232 ], "diet/exercise,": [ 183 ], "metformin": [ 184 ], "(which": [ 185, 196, 209 ], "improves": [ 186, 197 ], "sensitivity": [ 188 ], "has": [ 190, 250 ], "antiatherogenic": [ 191, 205 ], "effects),": [ 192, 206 ], "a": [ 193, 233, 269 ], "thiazolidinedione": [ 194 ], "(TZD)": [ 195 ], "sensitivity,": [ 199 ], "preserves": [ 200, 210 ], "function,": [ 202 ], "exerts": [ 204 ], "exenatide": [ 208 ], "function": [ 212 ], "promotes": [ 214 ], "weight": [ 215 ], "loss).": [ 216 ], "Sulfonylureas": [ 217 ], "because,": [ 221 ], "after": [ 222 ], "an": [ 223 ], "initial": [ 224 ], "improvement": [ 225 ], "glycemic": [ 227 ], "control,": [ 228 ], "they": [ 229 ], "associated": [ 231 ], "rise": [ 235 ], "A1C": [ 237 ], "loss": [ 240 ], "function.\n\nThe": [ 243 ], "natural": [ 244 ], "history": [ 245 ], "diabetes": [ 249, 267 ], "been": [ 251 ], "described": [ 253 ], "populations": [ 256 ], "(1\u201316)": [ 257 ], "(rev.": [ 258 ], "(17,18).": [ 260 ], "Individuals": [ 261 ], "destined": [ 262 ], "develop": [ 264 ], "inherit": [ 268 ], "set": [ 270 ], "genes": [ 272 ], "from": [ 273 ], "parents": [ 275 ], "make": [ 277 ], "tissues": [ 279 ], "(1,16,19\u201324).": [ 283 ], "manifested": [ 290 ], "by": [ 291 ], "\u2026": [ 292 ] }, "publication_date": "2009-03-31", "publication_year": 2009, "type": "article", "cited_by_count": 2893, "authors": [ { "id": "https://openalex.org/A5073917506", "display_name": "Ralph A. DeFronzo" } ] }, { "id": "https://openalex.org/W2979288514", "doi": "https://doi.org/10.1016/j.ejphar.2019.172715", "title": "Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy", "abstract": null, "publication_date": "2019-10-05", "publication_year": 2019, "type": "article", "cited_by_count": 176, "authors": [ { "id": "https://openalex.org/A5091054508", "display_name": "Xinyang Yu" }, { "id": "https://openalex.org/A5063268197", "display_name": "Ming Hao" }, { "id": "https://openalex.org/A5022072267", "display_name": "Yu Liu" }, { "id": "https://openalex.org/A5041927337", "display_name": "Xuefei Ma" }, { "id": "https://openalex.org/A5059844042", "display_name": "Wenjian Lin" }, { "id": "https://openalex.org/A5081687805", "display_name": "Xu Qian" }, { "id": "https://openalex.org/A5024736961", "display_name": "Huanran Zhou" }, { "id": "https://openalex.org/A5025073941", "display_name": "Ning Shao" }, { "id": "https://openalex.org/A5036171984", "display_name": "Hongyu Kuang" } ] }, { "id": "https://openalex.org/W4318754266", "doi": "https://doi.org/10.1111/dom.14998", "title": "Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open\u2010label, parallel\u2010group comparison study ( SWITCH\u2010SEMA 1 study)", "abstract": { "Abstract": [ 0 ], "Aim": [ 1 ], "To": [ 2 ], "investigate": [ 3 ], "the": [ 4, 66, 79, 116, 125 ], "effects": [ 5 ], "of": [ 6, 81 ], "switching": [ 7, 226 ], "from": [ 8, 203, 227 ], "liraglutide": [ 9, 42, 228 ], "or": [ 10, 47, 58, 229 ], "dulaglutide": [ 11, 48, 204 ], "to": [ 12, 56, 136, 145, 158, 167 ], "once\u2010weekly": [ 13 ], "semaglutide": [ 14, 57, 126, 217 ], "on": [ 15 ], "glycaemic": [ 16, 220 ], "control": [ 17, 221 ], "and": [ 18, 28, 89, 99, 109, 211, 222 ], "treatment": [ 19, 223, 236 ], "satisfaction": [ 20, 224 ], "in": [ 21, 69, 106, 112, 124, 128, 183, 208 ], "patients": [ 22, 39, 96, 105, 111, 239 ], "with": [ 23, 41, 240 ], "type": [ 24 ], "2": [ 25 ], "diabetes.": [ 26 ], "Materials": [ 27 ], "Methods": [ 29 ], "In": [ 30, 93 ], "this": [ 31 ], "multicentre,": [ 32 ], "open\u2010labelled,": [ 33 ], "prospective,": [ 34 ], "randomized,": [ 35 ], "parallel\u2010group": [ 36 ], "comparison": [ 37 ], "study,": [ 38 ], "treated": [ 40 ], "0.9\u20101.8": [ 43 ], "mg/day": [ 44 ], "(plan": [ 45, 51, 186 ], "A)": [ 46 ], "0.75": [ 49 ], "mg/week": [ 50 ], "B)": [ 52 ], "were": [ 53, 97, 101, 121 ], "either": [ 54 ], "switched": [ 55 ], "continued": [ 59 ], "current": [ 60 ], "therapy.": [ 61 ], "The": [ 62, 75 ], "primary": [ 63 ], "endpoint": [ 64 ], "was": [ 65 ], "mean": [ 67 ], "change": [ 68 ], "glycated": [ 70 ], "haemoglobin": [ 71, 119 ], "over": [ 72 ], "24": [ 73 ], "weeks.": [ 74 ], "secondary": [ 76 ], "endpoints": [ 77 ], "included": [ 78 ], "changes": [ 80 ], "Diabetes": [ 82, 178 ], "Treatment": [ 83, 179 ], "Satisfaction": [ 84, 180 ], "Questionnaire": [ 85, 181 ], "scores,": [ 86 ], "body": [ 87, 209 ], "weight": [ 88, 210 ], "metabolic": [ 90, 213, 241 ], "indices.": [ 91 ], "Results": [ 92 ], "total,": [ 94 ], "110": [ 95 ], "enrolled,": [ 98 ], "10": [ 100 ], "excluded;": [ 102 ], "therefore,": [ 103 ], "37": [ 104 ], "plan": [ 107, 113, 153, 194 ], "A": [ 108 ], "63": [ 110 ], "B": [ 114 ], "completed": [ 115 ], "study.": [ 117 ], "Glycated": [ 118 ], "levels": [ 120 ], "significantly": [ 122 ], "reduced": [ 123 ], "group": [ 127 ], "both": [ 129, 184 ], "plans": [ 130 ], "[plan": [ 131 ], "A,": [ 132, 187 ], "7.8%": [ 133, 137, 155, 164 ], "\u00b1": [ 134, 138, 143, 147, 156, 160, 165, 169 ], "1.0%": [ 135, 157 ], "0.7%": [ 139, 144, 148 ], "(liraglutide)": [ 140 ], "vs.": [ 141, 163, 189, 197 ], "7.9%": [ 142, 159 ], "7.3%": [ 146 ], "(semaglutide),": [ 149, 171 ], "p": [ 150, 172, 191, 199 ], "<": [ 151, 173, 192, 200 ], ".01;": [ 152, 193 ], "B,": [ 154, 195 ], "1.2%": [ 161 ], "(dulaglutide)": [ 162 ], "0.8%": [ 166 ], "7.1%": [ 168 ], "0.6%": [ 170 ], ".01].": [ 174 ], "Semaglutide": [ 175 ], "also": [ 176 ], "improved": [ 177, 212, 219 ], "scores": [ 182 ], "groups": [ 185 ], "+0.1": [ 188 ], "+8.3,": [ 190 ], "\u22121.2": [ 196 ], "+3.5,": [ 198 ], ".01).": [ 201 ], "Switching": [ 202 ], "yielded": [ 205 ], "greater": [ 206 ], "reductions": [ 207 ], "parameters.": [ 214 ], "Conclusions": [ 215 ], "Once\u2010weekly": [ 216 ], "administration": [ 218 ], "after": [ 225 ], "dulaglutide.": [ 230 ], "These": [ 231 ], "results": [ 232 ], "highlighted": [ 233 ], "a": [ 234 ], "useful": [ 235 ], "option": [ 237 ], "for": [ 238 ], "abnormalities": [ 242 ], "despite": [ 243 ], "glucagon\u2010like": [ 244 ], "receptor\u20101": [ 245 ], "receptor": [ 246 ], "agonist": [ 247 ], "treatment.": [ 248 ] }, "publication_date": "2023-02-01", "publication_year": 2023, "type": "article", "cited_by_count": 24, "authors": [ { "id": "https://openalex.org/A5112039381", "display_name": "Yuka Takahashi" }, { "id": "https://openalex.org/A5060578424", "display_name": "Hiroshi Nomoto" }, { "id": "https://openalex.org/A5005153787", "display_name": "Hiroki Yokoyama" }, { "id": "https://openalex.org/A5047325241", "display_name": "Yoshinari Takano" }, { "id": "https://openalex.org/A5110720724", "display_name": "So Nagai" }, { "id": "https://openalex.org/A5073904332", "display_name": "Atsushi Tsuzuki" }, { "id": "https://openalex.org/A5078843127", "display_name": "Kyu Yong Cho" }, { "id": "https://openalex.org/A5006626284", "display_name": "Aika Miya" }, { "id": "https://openalex.org/A5073112205", "display_name": "Hiraku Kameda" }, { "id": "https://openalex.org/A5110944753", "display_name": "Jun Takeuchi" }, { "id": "https://openalex.org/A5018695765", "display_name": "Shinji Taneda" }, { "id": "https://openalex.org/A5110352459", "display_name": "Yoshio Kurihara" }, { "id": "https://openalex.org/A5079071350", "display_name": "Tatsuya Atsumi" }, { "id": "https://openalex.org/A5055696290", "display_name": "Akinobu Nakamura" }, { "id": "https://openalex.org/A5032820934", "display_name": "Hideaki Miyoshi" } ] }, { "id": "https://openalex.org/W2569635760", "doi": "https://doi.org/10.1016/j.bbr.2017.01.004", "title": "Liraglutide prevents cognitive decline in a rat model of streptozotocin-induced diabetes independently from its peripheral metabolic effects", "abstract": null, "publication_date": "2017-01-05", "publication_year": 2017, "type": "article", "cited_by_count": 93, "authors": [ { "id": "https://openalex.org/A5024765683", "display_name": "Caterina Palleria" }, { "id": "https://openalex.org/A5050245959", "display_name": "Antonio Leo" }, { "id": "https://openalex.org/A5044887229", "display_name": "Francesco Andreozzi" }, { "id": "https://openalex.org/A5078959397", "display_name": "Rita Citraro" }, { "id": "https://openalex.org/A5089443540", "display_name": "Michelangelo Iannone" }, { "id": "https://openalex.org/A5001328630", "display_name": "Rosangela Spiga" }, { "id": "https://openalex.org/A5084623347", "display_name": "Giorgio Sesti" }, { "id": "https://openalex.org/A5085409739", "display_name": "Andrew Constanti" }, { "id": "https://openalex.org/A5080237017", "display_name": "Giovambattista De Sarro" }, { "id": "https://openalex.org/A5056017720", "display_name": "Franco Arturi" }, { "id": "https://openalex.org/A5049665672", "display_name": "Emilio Russo" } ] }, { "id": "https://openalex.org/W2802483308", "doi": "https://doi.org/10.1080/03007995.2018.1465903", "title": "Patient perceptions of injection devices used with dulaglutide and liraglutide for treatment of type 2 diabetes", "abstract": { "High": [ 0 ], "DID-EQ": [ 1 ], "scores": [ 2, 22 ], "indicate": [ 3 ], "positive": [ 4 ], "perceptions": [ 5 ], "of": [ 6, 25 ], "both": [ 7 ], "the": [ 8, 30 ], "liraglutide": [ 9, 31 ], "and": [ 10, 27 ], "dulaglutide": [ 11, 15 ], "injection": [ 12 ], "devices.": [ 13 ], "The": [ 14 ], "device": [ 16 ], "was": [ 17 ], "associated": [ 18 ], "with": [ 19 ], "slightly": [ 20 ], "higher": [ 21 ], "for": [ 23 ], "ease": [ 24 ], "use": [ 26 ], "convenience": [ 28 ], "than": [ 29 ], "device.": [ 32 ] }, "publication_date": "2018-04-17", "publication_year": 2018, "type": "article", "cited_by_count": 26, "authors": [ { "id": "https://openalex.org/A5051703711", "display_name": "Louis S. Matza" }, { "id": "https://openalex.org/A5039006946", "display_name": "Kristina S. Boye" }, { "id": "https://openalex.org/A5060624698", "display_name": "Brooke M. Currie" }, { "id": "https://openalex.org/A5055558946", "display_name": "Rosirene Paczkowski" }, { "id": "https://openalex.org/A5072715491", "display_name": "Laura Fern\u00e1ndez Land\u00f3" }, { "id": "https://openalex.org/A5011388259", "display_name": "Reema Mody" }, { "id": "https://openalex.org/A5111937124", "display_name": "Jessica Jordan" } ] }, { "id": "https://openalex.org/W2005582534", "doi": "https://doi.org/10.1111/j.1463-1326.2008.01018.x", "title": "Exenatide: a review from pharmacology to clinical practice", "abstract": { "Background:": [ 0 ], "Exenatide": [ 1, 218 ], "is": [ 2, 219 ], "an": [ 3 ], "incretin": [ 4 ], "mimetic": [ 5 ], "that": [ 6, 155 ], "activates": [ 7 ], "glucagon\u2010like\u2010peptide\u20101": [ 8 ], "receptors.": [ 9 ], "It": [ 10 ], "blunts": [ 11 ], "the": [ 12, 83, 134, 160, 174, 239 ], "postprandial": [ 13, 99, 248 ], "rise": [ 14 ], "of": [ 15, 87, 242 ], "plasma": [ 16 ], "glucose": [ 17, 249 ], "by": [ 18, 51, 61, 190, 232 ], "increasing": [ 19 ], "glucose\u2010dependent": [ 20 ], "insulin": [ 21, 110, 114, 129, 236 ], "secretion,": [ 22 ], "suppressing": [ 23 ], "inappropriately": [ 24 ], "high": [ 25 ], "glucagon": [ 26 ], "secretion": [ 27 ], "and": [ 28, 67, 89, 98, 101, 106, 112, 137, 172, 205, 216, 246 ], "delaying": [ 29 ], "gastric": [ 30 ], "emptying.": [ 31 ], "Methods:": [ 32 ], "In": [ 33 ], "seven": [ 34 ], "clinical": [ 35 ], "trials": [ 36 ], "performed": [ 37 ], "in": [ 38, 116, 140, 159, 170, 209 ], "2845": [ 39 ], "adult": [ 40 ], "patients": [ 41, 210, 229 ], "with": [ 42, 122, 127, 146, 177, 212 ], "type": [ 43, 226 ], "2": [ 44, 227 ], "diabetes": [ 45 ], "mellitus": [ 46 ], "who": [ 47 ], "were": [ 48, 143, 157, 165 ], "inadequately": [ 49, 230 ], "controlled": [ 50, 231 ], "a": [ 52, 138, 213, 220 ], "sulphonylurea": [ 53 ], "and/or": [ 54 ], "metformin": [ 55 ], "(glycosylated": [ 56 ], "haemoglobin,": [ 57 ], "HbA1c": [ 58 ], "\u226411%),": [ 59 ], "or": [ 60, 64 ], "thiazolidinediones": [ 62 ], "(with": [ 63 ], "without": [ 65 ], "metformin)": [ 66 ], "treated": [ 68, 211 ], "for": [ 69, 82, 225 ], "periods": [ 70 ], "from": [ 71, 194 ], "16": [ 72 ], "weeks": [ 73, 86 ], "to": [ 74, 109, 151, 168, 198 ], "3": [ 75, 152 ], "years,": [ 76 ], "exenatide": [ 77 ], "(5": [ 78 ], "\u03bcg": [ 79, 91, 196, 200 ], "b.i.d.": [ 80, 92, 197 ], "s.c.": [ 81, 93 ], "first": [ 84 ], "4": [ 85 ], "treatment": [ 88 ], "10": [ 90, 199 ], "thereafter)": [ 94 ], "reduced": [ 95, 189 ], "HbA1c,": [ 96 ], "fasting": [ 97 ], "glucose,": [ 100 ], "body": [ 102, 243 ], "weight": [ 103, 120, 244 ], "dose": [ 104, 192 ], "dependently,": [ 105 ], "was": [ 107, 183 ], "similar": [ 108 ], "glargine": [ 111 ], "biphasic": [ 113 ], "aspart": [ 115 ], "reducing": [ 117 ], "HbA1c.": [ 118 ], "Body": [ 119 ], "diminished": [ 121 ], "exenatide,": [ 123 ], "whereas": [ 124 ], "it": [ 125 ], "increased": [ 126 ], "both": [ 128 ], "preparations.": [ 130 ], "Positive": [ 131 ], "effects": [ 132 ], "on": [ 133 ], "lipid": [ 135 ], "profile": [ 136 ], "reduction": [ 139, 245 ], "C\u2010reactive": [ 141 ], "protein": [ 142 ], "also": [ 144 ], "recorded": [ 145 ], "exenatide.": [ 147 ], "Treatment": [ 148 ], "extensions": [ 149 ], "up": [ 150 ], "years": [ 153 ], "showed": [ 154 ], "benefits": [ 156, 241 ], "maintained": [ 158 ], "long": [ 161 ], "term.": [ 162 ], "Adverse": [ 163 ], "events": [ 164 ], "usually": [ 166 ], "mild": [ 167 ], "moderate": [ 169 ], "intensity,": [ 171 ], "generally": [ 173 ], "frequency": [ 175 ], "decreased": [ 176 ], "continued": [ 178 ], "therapy.": [ 179 ], "The": [ 180 ], "most": [ 181 ], "common": [ 182 ], "nausea": [ 184 ], "(whose": [ 185 ], "incidence": [ 186 ], "may": [ 187 ], "be": [ 188 ], "gradual": [ 191 ], "escalation": [ 193 ], "5": [ 195 ], "b.i.d.),": [ 201 ], "vomiting,": [ 202 ], "diarrhoea,": [ 203 ], "headache": [ 204 ], "hypoglycaemia": [ 206 ], "(almost": [ 207 ], "exclusively": [ 208 ], "sulphonylurea).": [ 214 ], "Results": [ 215 ], "conclusions:": [ 217 ], "new,": [ 221 ], "promising": [ 222 ], "therapeutic": [ 223 ], "option": [ 224 ], "diabetic": [ 228 ], "oral": [ 233 ], "agents,": [ 234 ], "before": [ 235 ], "therapy,": [ 237 ], "offering": [ 238 ], "added": [ 240 ], "tight": [ 247 ], "control.": [ 250 ] }, "publication_date": "2009-04-06", "publication_year": 2009, "type": "review", "cited_by_count": 103, "authors": [ { "id": "https://openalex.org/A5060140104", "display_name": "R. Gentilella" }, { "id": "https://openalex.org/A5078869173", "display_name": "Cristina Bianchi" }, { "id": "https://openalex.org/A5038898384", "display_name": "Andrea Rossi" }, { "id": "https://openalex.org/A5068223964", "display_name": "Carlo Maria Rotella" } ] }, { "id": "https://openalex.org/W2572949702", "doi": "https://doi.org/10.1080/14656566.2017.1282463", "title": "Exenatide: pharmacokinetics, clinical use, and future directions", "abstract": { "The": [ 0, 173 ], "first-in-class": [ 1 ], "glucagon-like": [ 2 ], "peptide-1": [ 3 ], "receptor": [ 4 ], "agonist": [ 5 ], "(GLP-1RA)": [ 6 ], "exenatide,": [ 7, 103 ], "which": [ 8 ], "was": [ 9, 51 ], "initially": [ 10 ], "approved": [ 11 ], "in": [ 12, 16, 107, 130, 150, 180, 190 ], "2005,": [ 13 ], "is": [ 14 ], "available": [ 15, 58 ], "twice-daily": [ 17 ], "(BID)": [ 18 ], "and": [ 19, 31, 43, 71, 80, 84, 97, 109, 117, 132, 158 ], "once-weekly": [ 20 ], "(QW)": [ 21 ], "formulations.": [ 22 ], "Clinical": [ 23 ], "trial": [ 24 ], "data": [ 25, 106 ], "suggest": [ 26 ], "both": [ 27, 40, 100 ], "formulations": [ 28, 101, 147 ], "are": [ 29, 74, 170 ], "effective": [ 30 ], "safe": [ 32 ], "for": [ 33, 59 ], "patients": [ 34 ], "with": [ 35, 124 ], "type": [ 36 ], "2": [ 37 ], "diabetes": [ 38 ], "(T2D),": [ 39 ], "as": [ 41, 44 ], "monotherapy": [ 42 ], "part": [ 45 ], "of": [ 46, 94, 99, 102, 138, 144, 153, 164, 177 ], "combination": [ 47, 85 ], "therapy.": [ 48 ], "Since": [ 49 ], "exenatide": [ 50, 69, 72, 165, 178, 186 ], "approved,": [ 52 ], "several": [ 53 ], "other": [ 54, 125, 181, 192 ], "GLP-1RAs": [ 55, 126, 154 ], "have": [ 56, 119 ], "become": [ 57 ], "clinical": [ 60, 66, 121, 175, 188 ], "use.": [ 61 ], "Areas": [ 62 ], "covered:": [ 63 ], "Many": [ 64 ], "ongoing": [ 65, 111 ], "trials": [ 67 ], "involving": [ 68 ], "BID": [ 70, 116, 179 ], "QW": [ 73, 118, 145, 166 ], "investigating": [ 75 ], "new": [ 76, 81 ], "indications": [ 77, 182 ], "(exenatide": [ 78, 87 ], "BID)": [ 79 ], "end": [ 82 ], "points": [ 83 ], "therapies": [ 86 ], "QW).": [ 88 ], "This": [ 89 ], "review": [ 90 ], "provides": [ 91 ], "an": [ 92 ], "overview": [ 93 ], "the": [ 95, 151, 162 ], "delivery": [ 96 ], "pharmacokinetics": [ 98 ], "reviews": [ 104 ], "existing": [ 105 ], "T2D,": [ 108 ], "summarizes": [ 110 ], "investigations.": [ 112 ], "Expert": [ 113 ], "opinion:": [ 114 ], "Exenatide": [ 115 ], "substantial": [ 120 ], "benefits.": [ 122 ], "Comparisons": [ 123 ], "demonstrate": [ 127 ], "some": [ 128 ], "differences": [ 129 ], "efficacy": [ 131, 157 ], "safety": [ 133 ], "profiles": [ 134 ], "that": [ 135 ], "make": [ 136 ], "assessment": [ 137 ], "benefit:risk": [ 139 ], "ratios": [ 140 ], "complex.": [ 141 ], "Head-to-head": [ 142 ], "comparisons": [ 143 ], "GLP-1RA": [ 146 ], "may": [ 148 ], "assist": [ 149 ], "ranking": [ 152 ], "according": [ 155 ], "to": [ 156 ], "safety.": [ 159 ], "Results": [ 160 ], "on": [ 161, 167 ], "impact": [ 163 ], "cardiovascular": [ 168 ], "outcomes": [ 169 ], "eagerly": [ 171 ], "awaited.": [ 172 ], "potential": [ 174 ], "utility": [ 176 ], "will": [ 183 ], "clarify": [ 184 ], "whether": [ 185 ], "holds": [ 187 ], "promise": [ 189 ], "diagnoses": [ 191 ], "than": [ 193 ], "T2D.": [ 194 ] }, "publication_date": "2017-01-13", "publication_year": 2017, "type": "review", "cited_by_count": 90, "authors": [ { "id": "https://openalex.org/A5079352451", "display_name": "Filip K. Knop" }, { "id": "https://openalex.org/A5024869586", "display_name": "Andreas Br\u00f8nden" }, { "id": "https://openalex.org/A5004120950", "display_name": "Tina Vilsb\u00f8ll" } ] }, { "id": "https://openalex.org/W2887432359", "doi": "https://doi.org/10.2337/db17-1212", "title": "Glucagon-Like Peptide 1 and Its Cleavage Products Are Renoprotective in Murine Diabetic Nephropathy", "abstract": { "Incretin-based": [ 0 ], "therapies,": [ 1 ], "including": [ 2 ], "glucagon-like": [ 3 ], "peptide": [ 4, 26, 71 ], "1": [ 5 ], "(GLP-1)": [ 6 ], "receptor": [ 7, 22, 37, 67, 201 ], "agonists": [ 8, 23, 38, 68 ], "and": [ 9, 31, 84, 89, 109, 117, 154, 160 ], "dipeptidyl": [ 10 ], "peptidase": [ 11 ], "4": [ 12 ], "(DPP-4)": [ 13 ], "inhibitors,": [ 14 ], "are": [ 15 ], "potent": [ 16 ], "glucose-lowering": [ 17 ], "drugs.": [ 18 ], "Still,": [ 19, 138 ], "only": [ 20, 63 ], "GLP-1": [ 21, 29, 36, 54, 58, 66, 88, 106, 112, 115, 118, 125, 140, 184, 200 ], "with": [ 24, 69, 166 ], "close": [ 25, 70 ], "homology": [ 27 ], "to": [ 28, 44, 53, 73, 189, 196 ], "(liraglutide": [ 30 ], "semaglutide)": [ 32 ], "but": [ 33, 128 ], "neither": [ 34 ], "exenatide-based": [ 35 ], "nor": [ 39 ], "DPP-4": [ 40 ], "inhibitors": [ 41 ], "were": [ 42 ], "found": [ 43, 174 ], "reduce": [ 45 ], "cardiovascular": [ 46 ], "events.": [ 47 ], "This": [ 48, 163 ], "different": [ 49 ], "response": [ 50 ], "might": [ 51, 194 ], "relate": [ 52 ], "receptor-independent": [ 55 ], "actions": [ 56 ], "of": [ 57, 87, 130, 149, 158 ], "caused": [ 59 ], "by": [ 60, 65 ], "cleavage": [ 61, 91, 113, 132, 185 ], "products": [ 62, 92, 186 ], "liberated": [ 64 ], "structure": [ 72 ], "GLP-1.": [ 74 ], "To": [ 75 ], "test": [ 76 ], "this": [ 77 ], "hypothesis,": [ 78 ], "we": [ 79, 103 ], "directly": [ 80 ], "compared": [ 81 ], "metabolic,": [ 82 ], "renal,": [ 83 ], "cardiac": [ 85 ], "effects": [ 86 ], "its": [ 90 ], "in": [ 93, 120, 175 ], "diabetic": [ 94, 121 ], "db/db": [ 95, 122 ], "mice.": [ 96, 123 ], "Using": [ 97 ], "an": [ 98, 176 ], "adeno-associated": [ 99 ], "viral": [ 100 ], "vector": [ 101 ], "system,": [ 102 ], "overexpressed": [ 104 ], "DPP-4-resistant": [ 105 ], "(7-37": [ 107, 126 ], "Mut8)": [ 108 ], "the": [ 110, 131, 150 ], "two": [ 111 ], "products,": [ 114, 133 ], "(9-37)": [ 116 ], "(28-37),": [ 119 ], "Only": [ 124 ], "Mut8),": [ 127 ], "none": [ 129 ], "significantly": [ 134, 142 ], "improved": [ 135 ], "glucose": [ 136 ], "metabolism.": [ 137 ], "all": [ 139 ], "constructs": [ 141 ], "reduced": [ 143 ], "tubulointerstitial": [ 144 ], "renal": [ 145, 156, 178 ], "damage,": [ 146 ], "lowered": [ 147 ], "expression": [ 148 ], "tubular": [ 151 ], "injury": [ 152, 180 ], "markers,": [ 153 ], "attenuated": [ 155 ], "accumulation": [ 157 ], "macrophages": [ 159 ], "T": [ 161 ], "cells.": [ 162 ], "was": [ 164, 172 ], "associated": [ 165 ], "a": [ 167 ], "systemic": [ 168 ], "immunomodulatory": [ 169 ], "effect,": [ 170 ], "which": [ 171, 193 ], "similarly": [ 173 ], "acute": [ 177 ], "ischemia/reperfusion": [ 179 ], "model.": [ 181 ], "In": [ 182 ], "conclusion,": [ 183 ], "proved": [ 187 ], "sufficient": [ 188 ], "mediate": [ 190 ], "organ-protective": [ 191 ], "effects,": [ 192 ], "help": [ 195 ], "explain": [ 197 ], "differences": [ 198 ], "between": [ 199 ], "agonists.": [ 202 ] }, "publication_date": "2018-08-13", "publication_year": 2018, "type": "article", "cited_by_count": 57, "authors": [ { "id": "https://openalex.org/A5111017697", "display_name": "Julia Moellmann" }, { "id": "https://openalex.org/A5068465621", "display_name": "Barbara M. Klinkhammer" }, { "id": "https://openalex.org/A5059586303", "display_name": "Julia Onstein" }, { "id": "https://openalex.org/A5104581149", "display_name": "Robert St\u00f6hr" }, { "id": "https://openalex.org/A5035333638", "display_name": "Vera Jankowski" }, { "id": "https://openalex.org/A5082473440", "display_name": "Joachim Jankowski" }, { "id": "https://openalex.org/A5008516600", "display_name": "Corinna Lebherz" }, { "id": "https://openalex.org/A5083825910", "display_name": "Frank Tacke" }, { "id": "https://openalex.org/A5019976194", "display_name": "Nikolaus Marx" }, { "id": "https://openalex.org/A5049305761", "display_name": "Peter Boor" }, { "id": "https://openalex.org/A5078666970", "display_name": "Michael Lehrke" } ] }, { "id": "https://openalex.org/W4322761541", "doi": "https://doi.org/10.1016/j.jclinane.2023.111091", "title": "Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy", "abstract": null, "publication_date": "2023-03-02", "publication_year": 2023, "type": "article", "cited_by_count": 200, "authors": [ { "id": "https://openalex.org/A5087081081", "display_name": "Saullo Queiroz Silveira" }, { "id": "https://openalex.org/A5024123345", "display_name": "Leopoldo Muniz da Silva" }, { "id": "https://openalex.org/A5050174672", "display_name": "Arthur de Campos Vieira Abib" }, { "id": "https://openalex.org/A5085673165", "display_name": "Diogo Turiani Hourneaux de Moura" }, { "id": "https://openalex.org/A5009528074", "display_name": "Eduardo Guimar\u00e3es Hourneaux de Moura" }, { "id": "https://openalex.org/A5076680901", "display_name": "Leonardo Barbosa Santos" }, { "id": "https://openalex.org/A5050548542", "display_name": "Anthony M.\u2010H. Ho" }, { "id": "https://openalex.org/A5071222865", "display_name": "Rafael Souza Fava Nersessian" }, { "id": "https://openalex.org/A5022557092", "display_name": "Filipe Lugon Moulin Lima" }, { "id": "https://openalex.org/A5021771935", "display_name": "Marcela Viana Silva" }, { "id": "https://openalex.org/A5079659880", "display_name": "Glenio B. Mizubuti" } ] }, { "id": "https://openalex.org/W4388609820", "doi": "https://doi.org/10.1161/circulationaha.123.067584", "title": "Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria", "abstract": { "BACKGROUND:": [ 0 ], "Sodium": [ 1 ], "glucose": [ 2 ], "cotransporter": [ 3 ], "2": [ 4, 33, 55, 75, 102, 163, 375 ], "inhibitors": [ 5 ], "(SGLT2i),": [ 6 ], "glucagon-like": [ 7 ], "peptide-1": [ 8 ], "receptor": [ 9, 17 ], "agonists": [ 10 ], "(GLP-1": [ 11 ], "RA),": [ 12 ], "and": [ 13, 26, 35, 62, 65, 84, 91, 94, 105, 113, 132, 140, 157, 165, 189, 202, 315, 362, 377, 389, 400, 403 ], "the": [ 14, 38, 106, 120, 196, 392 ], "nonsteroidal": [ 15 ], "mineralocorticoid": [ 16 ], "antagonist": [ 18 ], "(ns-MRA)": [ 19 ], "finerenone": [ 20 ], "all": [ 21 ], "individually": [ 22 ], "reduce": [ 23 ], "cardiovascular,": [ 24, 138 ], "kidney,": [ 25, 139 ], "mortality": [ 27, 141 ], "outcomes": [ 28 ], "in": [ 29, 68, 80, 87, 98, 159, 187, 287, 328, 333, 398 ], "patients": [ 30, 160, 372 ], "with": [ 31, 44, 70, 152, 161, 193, 206, 242, 270, 373 ], "type": [ 32, 162, 374 ], "diabetes": [ 34, 164, 376 ], "albuminuria.": [ 36 ], "However,": [ 37 ], "lifetime": [ 39 ], "benefits": [ 40 ], "of": [ 41, 96, 109, 123, 198, 210, 248, 339, 385 ], "combination": [ 42, 124, 153, 179, 197, 258, 340, 383 ], "therapy": [ 43, 125 ], "these": [ 45 ], "medicines": [ 46 ], "are": [ 47 ], "not": [ 48 ], "known.": [ 49 ], "METHODS:": [ 50 ], "We": [ 51 ], "used": [ 52 ], "data": [ 53 ], "from": [ 54, 290 ], "SGLT2i": [ 56 ], "trials": [ 57, 77, 117 ], "(CANVAS": [ 58 ], "[Canagliflozin": [ 59, 64 ], "Cardiovascular": [ 60 ], "Assessment]": [ 61 ], "CREDENCE": [ 63 ], "Renal": [ 66 ], "Events": [ 67 ], "Diabetes": [ 69, 103 ], "Established": [ 71 ], "Nephropathy": [ 72 ], "Clinical": [ 73, 107 ], "Evaluation]),": [ 74 ], "ns-MRA": [ 76, 158, 203, 390 ], "(FIDELIO-DKD": [ 78 ], "[Finerenone": [ 79 ], "Reducing": [ 81 ], "Kidney": [ 82, 89, 111 ], "Failure": [ 83 ], "Disease": [ 85 ], "Progression": [ 86 ], "Diabetic": [ 88, 110 ], "Disease]": [ 90 ], "FIGARO-DKD": [ 92 ], "[Efficacy": [ 93 ], "Safety": [ 95 ], "Finerenone": [ 97 ], "Subjects": [ 99 ], "With": [ 100 ], "Type": [ 101 ], "Mellitus": [ 104 ], "Diagnosis": [ 108 ], "Disease]),": [ 112 ], "8": [ 114 ], "GLP-1": [ 115, 155, 200, 387 ], "RA": [ 116 ], "to": [ 118, 182, 246, 394 ], "estimate": [ 119 ], "relative": [ 121 ], "effects": [ 122, 181, 338 ], "versus": [ 126 ], "conventional": [ 127, 185, 194, 274 ], "care": [ 128, 186, 275 ], "(renin-angiotensin": [ 129 ], "system": [ 130 ], "blockade": [ 131 ], "traditional": [ 133 ], "risk": [ 134, 150, 232 ], "factor": [ 135 ], "control)": [ 136 ], "on": [ 137 ], "outcomes.": [ 142 ], "Using": [ 143 ], "actuarial": [ 144 ], "methods,": [ 145 ], "we": [ 146 ], "then": [ 147 ], "estimated": [ 148, 178, 230, 260 ], "absolute": [ 149, 231 ], "reductions": [ 151 ], "SGLT2i,": [ 154, 199, 386 ], "RA,": [ 156, 201, 388 ], "at": [ 166, 378 ], "least": [ 167, 379 ], "moderately": [ 168, 380 ], "increased": [ 169, 381 ], "albuminuria": [ 170 ], "(urinary": [ 171 ], "albumin:creatinine": [ 172 ], "ratio": [ 173, 209 ], "\u226530": [ 174 ], "mg/g)": [ 175 ], "by": [ 176 ], "applying": [ 177 ], "treatment": [ 180, 384 ], "participants": [ 183 ], "receiving": [ 184 ], "CANVAS": [ 188 ], "CREDENCE.": [ 190 ], "RESULTS:": [ 191 ], "Compared": [ 192 ], "care,": [ 195 ], "was": [ 204, 237, 266 ], "associated": [ 205 ], "a": [ 207, 243, 254 ], "hazard": [ 208 ], "0.65": [ 211 ], "(95%": [ 212, 239, 250 ], "CI,": [ 213, 240, 251, 280, 297, 306, 313, 321, 351, 360, 368 ], "0.55\u20130.76)": [ 214 ], "for": [ 215, 273, 343 ], "major": [ 216, 261, 344 ], "adverse": [ 217, 262, 345 ], "cardiovascular": [ 218, 226, 263, 308, 346, 399 ], "events": [ 219, 347 ], "(nonfatal": [ 220 ], "myocardial": [ 221 ], "infarction,": [ 222 ], "nonfatal": [ 223 ], "stroke,": [ 224 ], "or": [ 225 ], "death).": [ 227 ], "The": [ 228 ], "corresponding": [ 229 ], "reduction": [ 233 ], "over": [ 234 ], "3": [ 235 ], "years": [ 236, 268, 272, 277, 295, 304, 311, 319, 349, 358, 366 ], "4.4%": [ 238 ], "3.0\u20135.7),": [ 241 ], "number": [ 244 ], "needed": [ 245 ], "treat": [ 247 ], "23": [ 249 ], "18\u201333).": [ 252 ], "For": [ 253 ], "50-year-old": [ 255 ], "patient": [ 256 ], "commencing": [ 257 ], "therapy,": [ 259, 341 ], "event\u2013free": [ 264 ], "survival": [ 265, 288, 330 ], "21.1": [ 267 ], "compared": [ 269 ], "17.9": [ 271 ], "(3.2": [ 276, 294 ], "gained": [ 278 ], "[95%": [ 279, 296, 305, 312, 320, 350, 359, 367 ], "2.1\u20134.3]).": [ 281 ], "There": [ 282 ], "were": [ 283, 331 ], "also": [ 284 ], "projected": [ 285 ], "gains": [ 286, 327, 397 ], "free": [ 289 ], "hospitalized": [ 291 ], "heart": [ 292 ], "failure": [ 293 ], "2.4\u20134.0]),": [ 298 ], "chronic": [ 299, 353 ], "kidney": [ 300, 354, 401 ], "disease": [ 301, 355 ], "progression": [ 302, 356 ], "(5.5": [ 303 ], "4.0\u20136.7]),": [ 307 ], "death": [ 309, 317, 364 ], "(2.2": [ 310 ], "1.2\u20133.0]),": [ 314 ], "all-cause": [ 316, 363 ], "(2.4": [ 318, 348 ], "1.4\u20133.4]).": [ 322 ], "Attenuated": [ 323 ], "but": [ 324 ], "clinically": [ 325 ], "relevant": [ 326, 396 ], "event-free": [ 329, 402 ], "observed": [ 332 ], "analyses": [ 334 ], "assuming": [ 335 ], "50%": [ 336 ], "additive": [ 337 ], "including": [ 342 ], "1.1\u20133.5]),": [ 352 ], "(4.5": [ 357 ], "2.8\u20135.9]),": [ 361 ], "(1.8": [ 365 ], "0.7\u20132.8]).": [ 369 ], "CONCLUSIONS:": [ 370 ], "In": [ 371 ], "albuminuria,": [ 382 ], "has": [ 391 ], "potential": [ 393 ], "afford": [ 395 ], "overall": [ 404 ], "survival.": [ 405 ] }, "publication_date": "2023-11-12", "publication_year": 2023, "type": "article", "cited_by_count": 206, "authors": [ { "id": "https://openalex.org/A5015488634", "display_name": "Brendon L. Neuen" }, { "id": "https://openalex.org/A5031624913", "display_name": "Hiddo J.L. Heerspink" }, { "id": "https://openalex.org/A5064862183", "display_name": "Priya Vart" }, { "id": "https://openalex.org/A5010456790", "display_name": "Brian Claggett" }, { "id": "https://openalex.org/A5017801776", "display_name": "Robert A. Fletcher" }, { "id": "https://openalex.org/A5040550338", "display_name": "Clare Arnott" }, { "id": "https://openalex.org/A5114099174", "display_name": "Julianna de Oliveira Costa" }, { "id": "https://openalex.org/A5056828221", "display_name": "Michael O. Falster" }, { "id": "https://openalex.org/A5019760776", "display_name": "Sallie\u2010Anne Pearson" }, { "id": "https://openalex.org/A5039432822", "display_name": "Kenneth W. Mahaffey" }, { "id": "https://openalex.org/A5075162144", "display_name": "Bruce Neal" }, { "id": "https://openalex.org/A5051708137", "display_name": "Rajiv Agarwal" }, { "id": "https://openalex.org/A5012514694", "display_name": "George L. Bakris" }, { "id": "https://openalex.org/A5027520502", "display_name": "Vlado Perkovic" }, { "id": "https://openalex.org/A5054830306", "display_name": "Scott D. Solomon" }, { "id": "https://openalex.org/A5061881316", "display_name": "Muthiah Vaduganathan" } ] }, { "id": "https://openalex.org/W2127306264", "doi": "https://doi.org/10.2337/dc09-1959", "title": "The Role of Adjunctive Exenatide Therapy in Pediatric Type 1 Diabetes", "abstract": { "OBJECTIVE": [ 0 ], "Exenatide": [ 1, 10, 102 ], "improves": [ 2 ], "postprandial": [ 3, 120 ], "glycemic": [ 4 ], "excursions": [ 5, 95 ], "in": [ 6, 30, 122, 130, 136, 149 ], "type": [ 7, 13, 33, 125, 150 ], "2": [ 8 ], "diabetes.": [ 9, 35, 127, 152 ], "could": [ 11 ], "benefit": [ 12 ], "1": [ 14, 34, 126, 151 ], "diabetes": [ 15 ], "as": [ 16, 146 ], "well.": [ 17 ], "We": [ 18, 139 ], "aimed": [ 19 ], "to": [ 20, 105 ], "determine": [ 21 ], "an": [ 22 ], "effective": [ 23 ], "and": [ 24, 57, 74 ], "safe": [ 25 ], "glucose-lowering": [ 26 ], "adjuvant": [ 27 ], "exenatide": [ 28, 55, 88, 117, 142 ], "dose": [ 29, 67 ], "adolescents": [ 31, 123 ], "with": [ 32, 62, 84, 124 ], "RESEARCH": [ 36 ], "DESIGN": [ 37 ], "AND": [ 38 ], "METHODS": [ 39 ], "Eight": [ 40 ], "subjects": [ 41 ], "completed": [ 42 ], "a": [ 43 ], "three-part": [ 44 ], "double-blinded": [ 45 ], "randomized": [ 46 ], "controlled": [ 47 ], "study": [ 48 ], "of": [ 49, 54, 87 ], "premeal": [ 50 ], "exenatide.": [ 51 ], "Two": [ 52 ], "doses": [ 53, 86 ], "(1.25": [ 56 ], "2.5": [ 58 ], "\u03bcg)": [ 59 ], "were": [ 60, 76 ], "compared": [ 61 ], "insulin": [ 63, 66, 90, 137 ], "monotherapy.": [ 64 ], "Prandial": [ 65 ], "was": [ 68 ], "reduced": [ 69, 93 ], "by": [ 70 ], "20%.": [ 71 ], "Gastric": [ 72 ], "emptying": [ 73, 111 ], "hormones": [ 75 ], "analyzed": [ 77 ], "for": [ 78 ], "300": [ 79, 97 ], "min": [ 80, 98 ], "postmeal.": [ 81 ], "RESULTS": [ 82 ], "Treatment": [ 83 ], "both": [ 85 ], "versus": [ 89 ], "monotherapy": [ 91 ], "significantly": [ 92 ], "glucose": [ 94, 131 ], "over": [ 96 ], "(P": [ 99, 112 ], "&lt;": [ 100, 113 ], "0.0001).": [ 101 ], "administration": [ 103 ], "failed": [ 104 ], "suppress": [ 106 ], "glucagon": [ 107 ], "but": [ 108 ], "delayed": [ 109 ], "gastric": [ 110 ], "0.004).": [ 114 ], "CONCLUSIONS": [ 115 ], "Adjunctive": [ 116 ], "therapy": [ 118, 148 ], "reduces": [ 119 ], "hyperglycemia": [ 121 ], "This": [ 128 ], "reduction": [ 129, 135 ], "excursion": [ 132 ], "occurs": [ 133 ], "despite": [ 134 ], "dose.": [ 138 ], "suggest": [ 140 ], "that": [ 141 ], "has": [ 143 ], "therapeutic": [ 144 ], "potential": [ 145 ], "adjunctive": [ 147 ] }, "publication_date": "2010-03-23", "publication_year": 2010, "type": "article", "cited_by_count": 85, "authors": [ { "id": "https://openalex.org/A5078107829", "display_name": "Vandana Raman" }, { "id": "https://openalex.org/A5109451351", "display_name": "Kimberly Mason" }, { "id": "https://openalex.org/A5084519276", "display_name": "Luisa M. Rodr\u00edguez" }, { "id": "https://openalex.org/A5011531976", "display_name": "Krishnavathana Hassan" }, { "id": "https://openalex.org/A5077205077", "display_name": "Xiaoying Yu" }, { "id": "https://openalex.org/A5004008487", "display_name": "Lisa Bomgaars" }, { "id": "https://openalex.org/A5001152901", "display_name": "Rubina A. Heptulla" } ] }, { "id": "https://openalex.org/W2011499650", "doi": "https://doi.org/10.1016/j.clinthera.2007.01.015", "title": "Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials", "abstract": null, "publication_date": "2007-01-01", "publication_year": 2007, "type": "article", "cited_by_count": 278, "authors": [ { "id": "https://openalex.org/A5040182038", "display_name": "John B. Buse" }, { "id": "https://openalex.org/A5086077960", "display_name": "David C. Klonoff" }, { "id": "https://openalex.org/A5075068030", "display_name": "Loretta L. Nielsen" }, { "id": "https://openalex.org/A5103833180", "display_name": "Xuesong Guan" }, { "id": "https://openalex.org/A5029813521", "display_name": "Christopher L. Bowlus" }, { "id": "https://openalex.org/A5111741705", "display_name": "John H. Holcombe" }, { "id": "https://openalex.org/A5062921481", "display_name": "David Maggs" }, { "id": "https://openalex.org/A5087662137", "display_name": "Matthew Wintle" } ] }, { "id": "https://openalex.org/W2144149396", "doi": "https://doi.org/10.1345/aph.1p714", "title": "Acute Pancreatitis Associated with Liraglutide", "abstract": { "Objective:": [ 0 ], "To": [ 1 ], "report": [ 2 ], "what": [ 3 ], "is,": [ 4 ], "to": [ 5, 54 ], "our": [ 6 ], "knowledge,": [ 7 ], "the": [ 8, 113, 150, 154, 159, 167 ], "first": [ 9 ], "postmarketing": [ 10 ], "case": [ 11, 117 ], "of": [ 12, 32, 126, 145, 156, 161, 169, 186, 195 ], "acute": [ 13 ], "pancreatitis": [ 14, 85, 127, 141, 170 ], "associated": [ 15 ], "with": [ 16, 23, 28, 149, 183 ], "liraglutide": [ 17, 55, 157 ], "Case": [ 18 ], "Summary:": [ 19 ], "A": [ 20 ], "60-year-old": [ 21 ], "female": [ 22 ], "type": [ 24 ], "2": [ 25 ], "diabetes": [ 26 ], "presented": [ 27 ], "a": [ 29, 91, 119, 184, 192 ], "16-hour": [ 30 ], "history": [ 31, 185 ], "mid-epigastric": [ 33 ], "pain": [ 34 ], "3": [ 35 ], "weeks": [ 36 ], "after": [ 37 ], "treatment": [ 38 ], "was": [ 39, 63, 78, 104, 171 ], "changed": [ 40 ], "from": [ 41 ], "exenatide": [ 42 ], "10": [ 43 ], "\u03bcg": [ 44 ], "twice": [ 45 ], "daily,": [ 46 ], "which": [ 47 ], "she": [ 48, 103 ], "had": [ 49 ], "taken": [ 50 ], "for": [ 51, 84, 197 ], "4": [ 52 ], "years,": [ 53 ], "1.8": [ 56 ], "mg": [ 57 ], "daily.": [ 58 ], "Her": [ 59 ], "serum": [ 60, 95 ], "lipase": [ 61, 96 ], "level": [ 62 ], "elevated": [ 64 ], "(478": [ 65 ], "units/L)": [ 66, 98 ], "at": [ 67, 80 ], "admission,": [ 68 ], "and": [ 69, 90, 142, 158, 188 ], "other": [ 70 ], "laboratory": [ 71 ], "values": [ 72 ], "were": [ 73, 128 ], "within": [ 74 ], "normal": [ 75 ], "limits.": [ 76 ], "Liraglutide": [ 77, 176 ], "discontinued": [ 79 ], "admission.": [ 81 ], "Standard": [ 82 ], "therapy": [ 83 ], "resulted": [ 86 ], "in": [ 87, 94, 130, 133, 181 ], "symptom": [ 88 ], "resolution": [ 89 ], "significant": [ 92 ], "decrease": [ 93 ], "(131": [ 97 ], "by": [ 99, 173 ], "hospital": [ 100, 107 ], "day": [ 101, 108 ], "4;": [ 102 ], "discharged": [ 105 ], "on": [ 106, 112 ], "5.": [ 109 ], "Discussion:": [ 110 ], "Based": [ 111 ], "Naranjo": [ 114 ], "scale,": [ 115 ], "this": [ 116, 162, 198 ], "represents": [ 118 ], "probable": [ 120 ], "adverse": [ 121, 203 ], "drug": [ 122 ], "reaction.": [ 123 ], "Eight": [ 124 ], "cases": [ 125 ], "observed": [ 129 ], "liraglutide-treated": [ 131 ], "patients": [ 132, 182 ], "premarketing": [ 134, 143 ], "clinical": [ 135 ], "trials.": [ 136 ], "Extensive": [ 137 ], "literature": [ 138 ], "describing": [ 139 ], "exenatide-related": [ 140 ], "reports": [ 144 ], "liraglutide-related": [ 146 ], "pancreatitis,": [ 147, 187 ], "along": [ 148 ], "temporal": [ 151 ], "relationship": [ 152 ], "between": [ 153 ], "initiation": [ 155 ], "onset": [ 160 ], "patient's": [ 163 ], "symptoms,": [ 164 ], "suggest": [ 165 ], "that": [ 166 ], "episode": [ 168 ], "induced": [ 172 ], "liraglutide.": [ 174 ], "Conclusions:": [ 175 ], "should": [ 177, 190 ], "be": [ 178 ], "used": [ 179 ], "cautiously": [ 180 ], "clinicians": [ 189 ], "have": [ 191 ], "high": [ 193 ], "index": [ 194 ], "suspicion": [ 196 ], "rare,": [ 199 ], "but": [ 200 ], "potentially": [ 201 ], "serious,": [ 202 ], "effect.": [ 204 ] }, "publication_date": "2011-04-01", "publication_year": 2011, "type": "article", "cited_by_count": 56, "authors": [ { "id": "https://openalex.org/A5006612671", "display_name": "Phillip H. Lee" }, { "id": "https://openalex.org/A5068052011", "display_name": "M. David Stockton" }, { "id": "https://openalex.org/A5050752749", "display_name": "Andrea S. Franks" } ] }, { "id": "https://openalex.org/W2430926173", "doi": "https://doi.org/10.1080/13696998.2016.1203329", "title": "Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective", "abstract": { "Results": [ 0 ], "suggest": [ 1 ], "that": [ 2 ], "exenatide": [ 3 ], "2": [ 4 ], "mg": [ 5, 17, 21, 25 ], "once-weekly": [ 6 ], "is": [ 7 ], "cost-effective": [ 8 ], "over": [ 9 ], "a": [ 10 ], "lifetime": [ 11 ], "horizon": [ 12 ], "compared": [ 13 ], "to": [ 14 ], "dulaglutide": [ 15 ], "1.5": [ 16 ], "QW,": [ 18 ], "liraglutide": [ 19, 23 ], "1.2": [ 20 ], "QD,": [ 22, 26 ], "1.8": [ 24 ], "and": [ 27 ], "lixisenatide": [ 28 ], "20": [ 29 ], "\u03bcg": [ 30 ], "QD": [ 31 ], "for": [ 32 ], "the": [ 33 ], "treatment": [ 34 ], "of": [ 35 ], "T2DM": [ 36 ], "in": [ 37 ], "adults": [ 38 ], "not": [ 39 ], "adequately": [ 40 ], "controlled": [ 41 ], "on": [ 42 ], "metformin": [ 43 ], "alone.": [ 44 ] }, "publication_date": "2016-06-17", "publication_year": 2016, "type": "article", "cited_by_count": 18, "authors": [ { "id": "https://openalex.org/A5057802030", "display_name": "Ling\u2010Hsiang Chuang" }, { "id": "https://openalex.org/A5109223880", "display_name": "B.G. Verheggen" }, { "id": "https://openalex.org/A5113828454", "display_name": "M. Charokopou" }, { "id": "https://openalex.org/A5060904655", "display_name": "Danny Gibson" }, { "id": "https://openalex.org/A5035420893", "display_name": "Susan Grandy" }, { "id": "https://openalex.org/A5074693806", "display_name": "Bernt Kartman" } ] }, { "id": "https://openalex.org/W1997332398", "doi": "https://doi.org/10.1007/s00125-010-1831-8", "title": "RETRACTED ARTICLE: A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells", "abstract": null, "publication_date": "2010-06-30", "publication_year": 2010, "type": "article", "cited_by_count": 178, "authors": [ { "id": "https://openalex.org/A5101659028", "display_name": "Yuichi Hattori" }, { "id": "https://openalex.org/A5066098744", "display_name": "Teruo Jojima" }, { "id": "https://openalex.org/A5012117138", "display_name": "Atsuko Tomizawa" }, { "id": "https://openalex.org/A5023483685", "display_name": "Hiroaki Satoh" }, { "id": "https://openalex.org/A5058216244", "display_name": "Sachiko Hattori" }, { "id": "https://openalex.org/A5045166593", "display_name": "Kikuo Kasai" }, { "id": "https://openalex.org/A5101471672", "display_name": "Toshio Hayashi" } ] }, { "id": "https://openalex.org/W4384498104", "doi": "https://doi.org/10.1186/s10194-023-01631-z", "title": "Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension", "abstract": null, "publication_date": "2023-07-17", "publication_year": 2023, "type": "article", "cited_by_count": 52, "authors": [ { "id": "https://openalex.org/A5059613674", "display_name": "Nik Krajnc" }, { "id": "https://openalex.org/A5046407459", "display_name": "Bianca Itariu" }, { "id": "https://openalex.org/A5083474896", "display_name": "Stefan Macher" }, { "id": "https://openalex.org/A5075872750", "display_name": "Wolfgang Marik" }, { "id": "https://openalex.org/A5026711776", "display_name": "J\u00fcrgen Harreiter" }, { "id": "https://openalex.org/A5020508147", "display_name": "Martin Michl" }, { "id": "https://openalex.org/A5083506480", "display_name": "Klaus Novak" }, { "id": "https://openalex.org/A5053194455", "display_name": "Christian W\u00f6ber" }, { "id": "https://openalex.org/A5047042432", "display_name": "Berthold Pemp" }, { "id": "https://openalex.org/A5037651315", "display_name": "Gabriel Bsteh" } ] }, { "id": "https://openalex.org/W4389432356", "doi": "https://doi.org/10.1001/jamaoncol.2023.5573", "title": "GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity", "abstract": { "This": [ 0 ], "cohort": [ 1 ], "study": [ 2 ], "compares": [ 3 ], "glucagon-like": [ 4 ], "peptide": [ 5 ], "1": [ 6 ], "receptor": [ 7 ], "agonists": [ 8 ], "(GLP-1RAs)": [ 9 ], "with": [ 10, 17 ], "7": [ 11 ], "non\u2013GLP-1RA": [ 12 ], "antidiabetics": [ 13 ], "among": [ 14 ], "drug-naive": [ 15 ], "patients": [ 16 ], "type": [ 18 ], "2": [ 19 ], "diabetes.": [ 20 ] }, "publication_date": "2023-12-07", "publication_year": 2023, "type": "article", "cited_by_count": 107, "authors": [ { "id": "https://openalex.org/A5024175424", "display_name": "Lindsey Wang" }, { "id": "https://openalex.org/A5100702485", "display_name": "William Yang Wang" }, { "id": "https://openalex.org/A5075366571", "display_name": "David C. Kaelber" }, { "id": "https://openalex.org/A5050134236", "display_name": "Rong Xu" }, { "id": "https://openalex.org/A5037635525", "display_name": "Nathan A. Berger" } ] }, { "id": "https://openalex.org/W2236659707", "doi": "https://doi.org/10.2337/dc14-2883", "title": "Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial", "abstract": { "OBJECTIVE": [ 0 ], "Renal": [ 1 ], "impairment": [ 2, 63 ], "in": [ 3, 31, 94, 142, 159, 197, 252, 266 ], "type": [ 4, 36, 269 ], "2": [ 5, 37, 270 ], "diabetes": [ 6, 38, 271 ], "limits": [ 7 ], "available": [ 8 ], "glucose-lowering": [ 9, 29 ], "treatment": [ 10, 92, 174, 203 ], "options.": [ 11 ], "This": [ 12 ], "trial": [ 13 ], "was": [ 14, 101, 138, 200, 224 ], "conducted": [ 15 ], "to": [ 16, 27, 76, 98, 108, 111, 167, 220, 260 ], "establish": [ 17 ], "the": [ 18 ], "efficacy": [ 19 ], "and": [ 20, 39, 60, 228, 244, 272 ], "safety": [ 21 ], "of": [ 22, 208 ], "liraglutide": [ 23, 78, 122, 146, 227 ], "as": [ 24 ], "an": [ 25 ], "add-on": [ 26 ], "existing": [ 28 ], "medications": [ 30 ], "patients": [ 32, 53, 267 ], "with": [ 33, 54, 121, 128, 145, 150, 249, 256, 268 ], "inadequately": [ 34 ], "controlled": [ 35 ], "moderate": [ 40, 61, 273 ], "renal": [ 41, 62, 160, 242, 274 ], "impairment.": [ 42, 275 ], "RESEARCH": [ 43 ], "DESIGN": [ 44 ], "AND": [ 45 ], "METHODS": [ 46 ], "In": [ 47 ], "this": [ 48 ], "26-week,": [ 49 ], "double-blind": [ 50 ], "trial,": [ 51 ], "279": [ 52 ], "HbA1c": [ 55, 95 ], "7\u201310%,": [ 56 ], "BMI": [ 57 ], "20\u201345": [ 58 ], "kg/m2,": [ 59 ], "(estimated": [ 64 ], "glomerular": [ 65 ], "filtration": [ 66 ], "rate": [ 67 ], "[eGFR]": [ 68 ], "30\u201359": [ 69 ], "mL/min/1.73": [ 70 ], "m2;": [ 71 ], "MDRD)": [ 72 ], "were": [ 73, 162, 186 ], "randomized": [ 74 ], "(1:1)": [ 75 ], "once-daily": [ 77 ], "1.8": [ 79 ], "mg": [ 80 ], "(n": [ 81, 86 ], "=": [ 82, 87, 135, 155, 179, 215 ], "140)": [ 83 ], "or": [ 84 ], "placebo": [ 85, 129, 151, 231, 265 ], "139).": [ 88 ], "RESULTS": [ 89 ], "The": [ 90, 181, 217 ], "estimated": [ 91, 173, 218 ], "difference": [ 93, 196 ], "from": [ 96 ], "baseline": [ 97, 221 ], "week": [ 99 ], "26": [ 100 ], "\u22120.66%": [ 102 ], "(\u22127.25": [ 103 ], "mmol/mol)": [ 104 ], "(95%": [ 105 ], "CI": [ 106 ], "\u22120.90": [ 107 ], "\u22120.43": [ 109 ], "[\u22129.82": [ 110 ], "\u22124.69]),": [ 112 ], "P": [ 113, 134, 154, 178, 214, 234 ], "&lt;": [ 114, 235 ], "0.0001).": [ 115, 236 ], "Fasting": [ 116 ], "plasma": [ 117 ], "glucose": [ 118 ], "decreased": [ 119 ], "more": [ 120 ], "(\u22121.22": [ 123 ], "mmol/L": [ 124, 131 ], "[\u221222.0": [ 125 ], "mg/dL])": [ 126 ], "than": [ 127, 149, 264 ], "(\u22120.57": [ 130 ], "[\u221210.3": [ 132 ], "mg/dL],": [ 133 ], "0.036).": [ 136 ], "There": [ 137 ], "a": [ 139 ], "greater": [ 140 ], "reduction": [ 141 ], "body": [ 143 ], "weight": [ 144 ], "(\u22122.41": [ 147 ], "kg)": [ 148 ], "(\u22121.09": [ 152 ], "kg,": [ 153 ], "0.0052).": [ 156 ], "No": [ 157, 195 ], "changes": [ 158 ], "function": [ 161, 243 ], "observed": [ 163, 201 ], "(eGFR": [ 164 ], "relative": [ 165 ], "ratio": [ 166, 175, 219 ], "baseline:": [ 168 ], "\u22121%": [ 169 ], "liraglutide,": [ 170, 210 ], "+1%": [ 171 ], "placebo;": [ 172 ], "[ETR]": [ 176 ], "0.98,": [ 177 ], "0.36).": [ 180 ], "most": [ 182 ], "common": [ 183 ], "adverse": [ 184, 189, 262 ], "events": [ 185, 263 ], "gastrointestinal": [ 187 ], "(GI)": [ 188 ], "effects": [ 190 ], "(liraglutide,": [ 191 ], "35.7%;": [ 192 ], "placebo,": [ 193, 212 ], "17.5%).": [ 194 ], "hypoglycemic": [ 198 ], "episodes": [ 199 ], "between": [ 202 ], "groups": [ 204 ], "(event": [ 205 ], "rate/100": [ 206 ], "patient-years": [ 207 ], "exposure:": [ 209 ], "30.47;": [ 211 ], "40.08;": [ 213 ], "0.54).": [ 216 ], "for": [ 222, 226, 230 ], "lipase": [ 223 ], "1.33": [ 225 ], "0.97": [ 229 ], "(ETR": [ 232 ], "1.37,": [ 233 ], "CONCLUSIONS": [ 237 ], "Liraglutide": [ 238 ], "did": [ 239 ], "not": [ 240 ], "affect": [ 241 ], "demonstrated": [ 245 ], "better": [ 246 ], "glycemic": [ 247 ], "control,": [ 248 ], "no": [ 250 ], "increase": [ 251 ], "hypoglycemia": [ 253 ], "risk": [ 254 ], "but": [ 255 ], "higher": [ 257 ], "withdrawals": [ 258 ], "due": [ 259 ], "GI": [ 261 ] }, "publication_date": "2015-12-17", "publication_year": 2015, "type": "article", "cited_by_count": 217, "authors": [ { "id": "https://openalex.org/A5084593004", "display_name": "Melanie J. Davies" }, { "id": "https://openalex.org/A5080463002", "display_name": "Stephen C. Bain" }, { "id": "https://openalex.org/A5064495299", "display_name": "Stephen L. Atkin" }, { "id": "https://openalex.org/A5085592050", "display_name": "Peter Rossing" }, { "id": "https://openalex.org/A5039505685", "display_name": "David A. Scott" }, { "id": "https://openalex.org/A5035859311", "display_name": "\u041c\u0438\u043d\u0430\u0440\u0430 \u0428\u0430\u043c\u0445\u0430\u043b\u043e\u0432\u043d\u0430 \u0428\u0430\u043c\u0445\u0430\u043b\u043e\u0432\u0430" }, { "id": "https://openalex.org/A5070579413", "display_name": "Heidrun Bosch\u2010Traberg" }, { "id": "https://openalex.org/A5089910765", "display_name": "Annika Syr\u00e9n" }, { "id": "https://openalex.org/A5061058170", "display_name": "Guillermo E. Umpierrez" } ] }, { "id": "https://openalex.org/W3203749178", "doi": "https://doi.org/10.1007/s40200-021-00899-9", "title": "Efficacy and safety of semaglutide in glycemic control, body weight management, lipid profiles and other biomarkers among obese type 2 diabetes patients initiated or switched to semaglutide from other GLP-1 receptor agonists", "abstract": { "Abstract": [ 0 ], "Purpose": [ 1 ], "Evidence": [ 2 ], "of": [ 3, 8, 33, 42, 93, 98, 109, 114 ], "the": [ 4, 39, 120 ], "efficacy": [ 5 ], "and": [ 6, 96, 104, 130, 167, 222, 233 ], "safety": [ 7 ], "semaglutide": [ 9, 24, 45, 69, 125 ], "among": [ 10 ], "patients": [ 11, 56, 116, 150, 206, 232 ], "with": [ 12, 57, 75 ], "type": [ 13, 58, 228, 240 ], "2": [ 14, 59, 229, 241 ], "diabetes": [ 15, 60, 73, 230, 242 ], "who": [ 16, 61 ], "were": [ 17, 21, 62, 66, 101, 117, 146 ], "initiated": [ 18, 63 ], "on": [ 19, 64 ], "or": [ 20, 65, 79, 82 ], "switched": [ 22, 67, 207 ], "to": [ 23, 37, 44, 68, 71, 124, 214 ], "from": [ 25, 46, 208 ], "other": [ 26, 47, 76, 80, 209 ], "GLP-1": [ 27, 48, 77, 210, 245 ], "RAs": [ 28, 78 ], "remains": [ 29 ], "limited.": [ 30 ], "The": [ 31, 143 ], "objective": [ 32 ], "this": [ 34 ], "study": [ 35, 54 ], "was": [ 36 ], "investigate": [ 38 ], "short-term": [ 40 ], "effects": [ 41 ], "switching": [ 43, 123 ], "RAs.": [ 49, 211, 246 ], "Methods": [ 50 ], "This": [ 51 ], "retrospective": [ 52 ], "cohort": [ 53 ], "evaluated": [ 55 ], "due": [ 70 ], "poor": [ 72 ], "control": [ 74, 225 ], "medications,": [ 81 ], "obesity.": [ 83 ], "HbA1c,": [ 84 ], "body": [ 85, 131, 223 ], "weight,": [ 86 ], "serum": [ 87, 89, 189 ], "creatinine,": [ 88 ], "uric": [ 90, 162 ], "acid,": [ 91, 163 ], "parameters": [ 92, 97 ], "lipid": [ 94 ], "metabolism,": [ 95 ], "liver": [ 99 ], "function": [ 100 ], "measured": [ 102 ], "before": [ 103 ], "6": [ 105 ], "months": [ 106 ], "after": [ 107 ], "administration": [ 108 ], "semaglutide.": [ 110 ], "Results": [ 111 ], "A": [ 112 ], "total": [ 113, 164 ], "50": [ 115 ], "registered": [ 118 ], "in": [ 119, 148, 205, 226, 238 ], "study.": [ 121 ], "After": [ 122 ], "(n": [ 126, 158 ], "=": [ 127, 153, 159, 177, 180, 183, 186, 197 ], "43),": [ 128 ], "HbA1c": [ 129 ], "weight": [ 132, 224 ], "significantly": [ 133, 172, 194 ], "decreased": [ 134, 171 ], "(": [ 135, 151, 175, 195 ], "p": [ 136, 139, 152, 155, 176, 179, 182, 185, 196 ], "<": [ 137, 140, 156 ], "0.01,": [ 138 ], "0.01),": [ 141 ], "respectively.": [ 142 ], "same": [ 144 ], "findings": [ 145 ], "observed": [ 147 ], "semaglutide-na\u00efve": [ 149 ], "0.04,": [ 154, 178, 181 ], "0.02)": [ 157 ], "7).": [ 160 ], "Serum": [ 161 ], "cholesterol,": [ 165 ], "triglycerides,": [ 166 ], "urinary": [ 168 ], "albumin-creatinine": [ 169 ], "ratio": [ 170 ], "as": [ 173 ], "well": [ 174 ], "0.02,": [ 184 ], "0.04),": [ 187 ], "whereas": [ 188 ], "creatinine": [ 190 ], "did": [ 191 ], "not": [ 192 ], "change": [ 193 ], "0.51).": [ 198 ], "Conclusions": [ 199 ], "Semaglutide": [ 200, 212 ], "showed": [ 201 ], "excellent": [ 202 ], "efficacy,": [ 203 ], "even": [ 204 ], "appears": [ 213 ], "be": [ 215, 235 ], "a": [ 216 ], "promising": [ 217 ], "agent": [ 218 ], "for": [ 219 ], "blood": [ 220 ], "glucose": [ 221 ], "obese": [ 227 ], "mellitus": [ 231 ], "could": [ 234 ], "more": [ 236 ], "potent": [ 237 ], "treating": [ 239 ], "than": [ 243 ], "existing": [ 244 ] }, "publication_date": "2021-09-25", "publication_year": 2021, "type": "article", "cited_by_count": 31, "authors": [ { "id": "https://openalex.org/A5032069625", "display_name": "Aki Okamoto" }, { "id": "https://openalex.org/A5059266983", "display_name": "Hirohide Yokokawa" }, { "id": "https://openalex.org/A5049067981", "display_name": "Tomoko Nagamine" }, { "id": "https://openalex.org/A5051034795", "display_name": "Hiroshi Fukuda" }, { "id": "https://openalex.org/A5020348697", "display_name": "Teruhiko Hisaoka" }, { "id": "https://openalex.org/A5067992113", "display_name": "Toshio Naito" } ] }, { "id": "https://openalex.org/W4391943471", "doi": "https://doi.org/10.1016/j.eclinm.2024.102475", "title": "Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial", "abstract": null, "publication_date": "2024-02-19", "publication_year": 2024, "type": "article", "cited_by_count": 136, "authors": [ { "id": "https://openalex.org/A5078868922", "display_name": "Simon Birk Kj\u00e6r Jensen" }, { "id": "https://openalex.org/A5101591653", "display_name": "Martin B\u00e6k Blond" }, { "id": "https://openalex.org/A5007796517", "display_name": "Rasmus Michael Sandsdal" }, { "id": "https://openalex.org/A5045178005", "display_name": "Lisa Olsen" }, { "id": "https://openalex.org/A5043941957", "display_name": "Christian R. Juhl" }, { "id": "https://openalex.org/A5007991615", "display_name": "J. Lundgren" }, { "id": "https://openalex.org/A5089416119", "display_name": "Charlotte Janus" }, { "id": "https://openalex.org/A5066604050", "display_name": "Bente Stallknecht" }, { "id": "https://openalex.org/A5085434984", "display_name": "Jens J. Holst" }, { "id": "https://openalex.org/A5062239390", "display_name": "Sten Madsbad" }, { "id": "https://openalex.org/A5038081896", "display_name": "Signe S. Torekov" } ] }, { "id": "https://openalex.org/W2990541661", "doi": "https://doi.org/10.1161/atv.0000615456.97862.30", "title": "Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension", "abstract": { "Objective:": [ 0 ], "Cardiovascular": [ 1 ], "outcome": [ 2 ], "trials": [ 3 ], "demonstrated": [ 4 ], "that": [ 5 ], "GLP-1": [ 6, 24, 68 ], "(glucagon-like": [ 7 ], "peptide-1)": [ 8 ], "analogs": [ 9, 25 ], "including": [ 10, 50 ], "liraglutide": [ 11, 70, 145, 173, 201 ], "reduce": [ 12, 26 ], "the": [ 13, 27, 40, 61, 67, 72, 112, 150, 167, 253, 257 ], "risk": [ 14, 28 ], "of": [ 15, 32, 66, 80, 111, 154, 183, 195, 200, 241, 246 ], "cardiovascular": [ 16, 198, 239 ], "events": [ 17 ], "in": [ 18, 75, 140, 203, 217 ], "type": [ 19 ], "2": [ 20 ], "diabetes": [ 21 ], "mellitus.": [ 22 ], "Whether": [ 23 ], "for": [ 29 ], "atherosclerosis": [ 30 ], "independent": [ 31 ], "glycemic": [ 33 ], "control": [ 34 ], "is": [ 35, 44 ], "challenging": [ 36 ], "to": [ 37 ], "elucidate": [ 38 ], "as": [ 39, 90, 92, 180 ], "GLP-1R": [ 41, 113, 232, 236 ], "(GLP-1": [ 42 ], "receptor)": [ 43 ], "expressed": [ 45 ], "on": [ 46, 149 ], "different": [ 47 ], "cell": [ 48, 205, 259 ], "types,": [ 49 ], "endothelial": [ 51, 93, 133, 224, 254 ], "and": [ 52, 56, 63, 100, 116, 137, 152, 160, 189, 223 ], "immune": [ 53 ], "cells.": [ 54 ], "Approach": [ 55 ], "Results:": [ 57 ], "Here,": [ 58 ], "we": [ 59 ], "reveal": [ 60 ], "cardio-": [ 62 ], "vasoprotective": [ 64 ], "mechanism": [ 65 ], "analog": [ 69 ], "at": [ 71 ], "cellular": [ 73 ], "level": [ 74 ], "a": [ 76, 141, 171, 181 ], "murine,": [ 77 ], "nondiabetic": [ 78 ], "model": [ 79 ], "arterial": [ 81, 117, 242 ], "hypertension.": [ 82 ], "Wild-type": [ 83 ], "(C57BL/6J),": [ 84 ], "global": [ 85, 218 ], "(": [ 86, 94, 105, 207, 219, 226 ], "Glp1r": [ 87, 95, 106, 208, 220, 227 ], "\u2212/\u2212": [ 88, 221 ], "),": [ 89 ], "well": [ 91 ], "f": [ 96 ], "lox/floxxCdh5": [ 97 ], "cre": [ 98, 109, 211, 230 ], ")": [ 99, 110, 212, 222, 231 ], "myeloid": [ 101, 155, 204, 258 ], "cell\u2013specific": [ 102, 225 ], "knockout": [ 103, 233 ], "mice": [ 104, 213 ], "flox/flox": [ 107, 209, 228 ], "xLysM": [ 108, 210 ], "were": [ 114, 215 ], "studied,": [ 115 ], "hypertension": [ 118, 243 ], "was": [ 119 ], "induced": [ 120 ], "by": [ 121, 244 ], "angiotensin": [ 122 ], "II.": [ 123 ], "Liraglutide": [ 124 ], "treatment": [ 125 ], "normalized": [ 126 ], "blood": [ 127 ], "pressure,": [ 128 ], "cardiac": [ 129 ], "hypertrophy,": [ 130 ], "vascular": [ 131, 138, 168, 175, 247 ], "fibrosis,": [ 132 ], "dysfunction,": [ 134 ], "oxidative": [ 135, 176 ], "stress,": [ 136, 177 ], "inflammation": [ 139, 248 ], "GLP-1R\u2013dependent": [ 142 ], "manner.": [ 143 ], "Mechanistically,": [ 144 ], "reduced": [ 146, 178 ], "leukocyte": [ 147 ], "rolling": [ 148 ], "endothelium": [ 151 ], "infiltration": [ 153 ], "Ly6G": [ 156, 161 ], "\u2212": [ 157 ], "Ly6C": [ 158, 163 ], "+": [ 159, 162, 164 ], "cells": [ 165 ], "into": [ 166 ], "wall.": [ 169 ], "As": [ 170 ], "consequence,": [ 172 ], "prevented": [ 174 ], "S-glutathionylation": [ 179 ], "marker": [ 182 ], "eNOS": [ 184 ], "(endothelial": [ 185 ], "NO": [ 186, 191 ], "synthase)": [ 187 ], "uncoupling,": [ 188 ], "increased": [ 190 ], "bioavailability.": [ 192 ], "Importantly,": [ 193 ], "all": [ 194 ], "these": [ 196 ], "beneficial": [ 197 ], "effects": [ 199 ], "persisted": [ 202 ], "GLP-1R-deficient": [ 206 ], "but": [ 214, 255 ], "abolished": [ 216 ], "xCdh5": [ 229 ], "mice.": [ 234 ], "Conclusions:": [ 235 ], "activation": [ 237 ], "attenuates": [ 238 ], "complications": [ 240 ], "reduction": [ 245 ], "through": [ 249 ], "selective": [ 250 ], "actions": [ 251 ], "requiring": [ 252 ], "not": [ 256 ], "GLP-1R.": [ 260 ] }, "publication_date": "2019-11-21", "publication_year": 2019, "type": "article", "cited_by_count": 208, "authors": [ { "id": "https://openalex.org/A5068831026", "display_name": "Johanna Helmst\u00e4dter" }, { "id": "https://openalex.org/A5090175367", "display_name": "Katie Frenis" }, { "id": "https://openalex.org/A5075095307", "display_name": "Konstantina Filippou" }, { "id": "https://openalex.org/A5086903606", "display_name": "Alexandra Grill" }, { "id": "https://openalex.org/A5076592380", "display_name": "Mobin Dib" }, { "id": "https://openalex.org/A5110645567", "display_name": "Sanela Kalinovic" }, { "id": "https://openalex.org/A5016687654", "display_name": "Franziska Pawelke" }, { "id": "https://openalex.org/A5031283150", "display_name": "Kamil Ku\u015b" }, { "id": "https://openalex.org/A5015861190", "display_name": "Swenja Kr\u00f6ller\u2010Sch\u00f6n" }, { "id": "https://openalex.org/A5064993444", "display_name": "Matthias Oelze" }, { "id": "https://openalex.org/A5045778168", "display_name": "Stefan Ch\u0142opicki" }, { "id": "https://openalex.org/A5101548659", "display_name": "Detlef Schuppan" }, { "id": "https://openalex.org/A5074883323", "display_name": "Philip Wenzel" }, { "id": "https://openalex.org/A5005286957", "display_name": "Wolfram Ruf" }, { "id": "https://openalex.org/A5057472647", "display_name": "Daniel J. Drucker" }, { "id": "https://openalex.org/A5113521673", "display_name": "Thomas M\u00fcnzel" }, { "id": "https://openalex.org/A5039361810", "display_name": "Andreas Daiber" }, { "id": "https://openalex.org/A5066963864", "display_name": "Sebastian Steven" } ] }, { "id": "https://openalex.org/W2761594440", "doi": "https://doi.org/10.1186/s12933-017-0610-y", "title": "Updates on cardiovascular outcome trials in diabetes", "abstract": { "In": [ 0 ], "2008": [ 1 ], "the": [ 2, 14, 44, 80, 83 ], "Food": [ 3 ], "and": [ 4, 46, 49, 69, 87, 100, 102, 122 ], "Drug": [ 5 ], "Administration": [ 6 ], "introduced": [ 7 ], "a": [ 8 ], "guidance": [ 9 ], "for": [ 10, 41, 59 ], "industry": [ 11 ], "that": [ 12, 90 ], "requires": [ 13 ], "investigation": [ 15 ], "of": [ 16, 19, 27, 43, 82, 94, 119 ], "cardiovascular": [ 17, 28, 39, 57, 74, 92 ], "outcomes": [ 18 ], "glucose-lowering": [ 20, 120 ], "medications.": [ 21 ], "Since": [ 22 ], "then,": [ 23 ], "an": [ 24, 124 ], "increasing": [ 25 ], "number": [ 26 ], "outcome": [ 29 ], "trials": [ 30, 55, 89, 118 ], "have": [ 31 ], "been": [ 32 ], "completed": [ 33 ], "in": [ 34, 65, 105, 130 ], "diabetes": [ 35 ], "patients": [ 36 ], "with": [ 37, 116 ], "high": [ 38 ], "risk": [ 40 ], "members": [ 42 ], "SGLT-2": [ 45 ], "DPP4": [ 47 ], "inhibitors": [ 48 ], "GLP-1": [ 50 ], "receptor": [ 51 ], "agonist": [ 52 ], "classes.": [ 53 ], "The": [ 54, 76 ], "confirmed": [ 56 ], "safety": [ 58, 93 ], "all": [ 60 ], "tested": [ 61, 91 ], "anti-hyperglycaemic": [ 62 ], "drugs": [ 63, 121 ], "and,": [ 64 ], "addition": [ 66 ], "empagliflozin,": [ 67 ], "semaglutide": [ 68 ], "liraglutide": [ 70 ], "could": [ 71 ], "even": [ 72 ], "reduce": [ 73 ], "risk.": [ 75 ], "present": [ 77 ], "review": [ 78 ], "summarizes": [ 79 ], "results": [ 81, 112 ], "DEVOTE,": [ 84 ], "CANVAS,": [ 85 ], "EXSCEL": [ 86 ], "ACE": [ 88 ], "Insulin": [ 95 ], "degludec,": [ 96 ], "canagliflozin,": [ 97 ], "once-weekly": [ 98 ], "exenatide": [ 99 ], "acarbose": [ 101 ], "were": [ 103 ], "published": [ 104 ], "2017.": [ 106 ], "We": [ 107 ], "provide": [ 108 ], "context": [ 109 ], "on": [ 110, 126 ], "these": [ 111 ], "by": [ 113 ], "comparing": [ 114 ], "them": [ 115 ], "earlier": [ 117 ], "give": [ 123 ], "outlook": [ 125 ], "what": [ 127 ], "to": [ 128 ], "expect": [ 129 ], "coming": [ 131 ], "years.": [ 132 ] }, "publication_date": "2017-10-11", "publication_year": 2017, "type": "review", "cited_by_count": 52, "authors": [ { "id": "https://openalex.org/A5011161870", "display_name": "Oliver Schnell" }, { "id": "https://openalex.org/A5041670111", "display_name": "Lars Ryd\u00e9n" }, { "id": "https://openalex.org/A5090174827", "display_name": "Eberhard Standl" }, { "id": "https://openalex.org/A5044764461", "display_name": "Antonio Ceriello" } ] }, { "id": "https://openalex.org/W3107982895", "doi": "https://doi.org/10.1210/clinem/dgaa891", "title": "Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis", "abstract": { "Abstract": [ 0 ], "Context": [ 1 ], "Risk": [ 2 ], "of": [ 3, 12, 17, 26, 46, 62, 72, 94, 107, 120, 129, 133, 146, 178, 200, 209, 253 ], "cancer": [ 4, 48, 151, 174 ], "is": [ 5 ], "a": [ 6, 35, 42, 59, 104 ], "major": [ 7 ], "concern": [ 8 ], "in": [ 9, 96 ], "the": [ 10, 15, 27, 123, 230, 251 ], "development": [ 11 ], "drugs": [ 13 ], "for": [ 14, 92, 244 ], "treatment": [ 16 ], "obesity": [ 18, 245 ], "and": [ 19, 74, 89, 103, 116, 127, 137, 153, 198, 246 ], "diabetes.": [ 20 ], "In": [ 21 ], "randomized": [ 22 ], "controlled": [ 23 ], "trials": [ 24 ], "(RCTs)": [ 25 ], "Liraglutide": [ 28 ], "Clinical": [ 29 ], "Development": [ 30, 136 ], "Program,": [ 31 ], "subjects": [ 32, 167 ], "treated": [ 33, 55, 168 ], "with": [ 34, 56, 98, 122, 131, 169, 176, 242 ], "glucagon-like": [ 36 ], "peptide-1": [ 37 ], "receptor": [ 38 ], "agonist": [ 39 ], "(GLP-1RA)": [ 40 ], "had": [ 41, 58 ], "higher": [ 43, 60 ], "absolute": [ 44 ], "number": [ 45 ], "breast": [ 47, 63, 150, 157, 173, 211, 254 ], "events.": [ 49 ], "Objective": [ 50 ], "To": [ 51 ], "assess": [ 52 ], "whether": [ 53 ], "patients": [ 54 ], "GLP-1RAs": [ 57, 95, 243 ], "risk": [ 61, 119, 183, 208, 252 ], "neoplasms.": [ 64, 158, 255 ], "Data": [ 65, 110, 140 ], "Sources": [ 66 ], "We": [ 67, 142 ], "searched": [ 68 ], "MEDLINE,": [ 69 ], "Embase,": [ 70 ], "Web": [ 71 ], "Science,": [ 73 ], "CENTRAL": [ 75 ], "from": [ 76 ], "July": [ 77 ], "31,": [ 78 ], "2019": [ 79 ], "to": [ 80, 194, 235 ], "February": [ 81 ], "8,": [ 82 ], "2020.": [ 83 ], "Study": [ 84 ], "Selection": [ 85 ], "Reviewers": [ 86 ], "assessed": [ 87, 117 ], "abstracts": [ 88 ], "full-text": [ 90 ], "articles": [ 91 ], "RCTs": [ 93 ], "adults": [ 97 ], "excessive": [ 99 ], "weight": [ 100 ], "and/or": [ 101 ], "diabetes": [ 102, 247 ], "minimum": [ 105 ], "follow-up": [ 106 ], "24": [ 108 ], "weeks.": [ 109 ], "Extraction": [ 111 ], "Researchers": [ 112 ], "extracted": [ 113 ], "study-level": [ 114 ], "data": [ 115 ], "within-study": [ 118 ], "bias": [ 121 ], "RoB": [ 124 ], "2.0": [ 125 ], "tool": [ 126 ], "quality": [ 128, 161 ], "evidence": [ 130, 228 ], "Grading": [ 132 ], "Recommendations": [ 134 ], "Assessment,": [ 135 ], "Evaluation": [ 138 ], "(GRADE).": [ 139 ], "Synthesis": [ 141 ], "included": [ 143 ], "52": [ 144 ], "trials,": [ 145 ], "which": [ 147 ], "50": [ 148 ], "reported": [ 149, 155 ], "events": [ 152 ], "11": [ 154 ], "benign": [ 156, 210 ], "Overall": [ 159 ], "methodological": [ 160 ], "was": [ 162, 233 ], "high.": [ 163 ], "Among": [ 164 ], "48": [ 165 ], "267": [ 166 ], "GLP-1RAs,": [ 170 ], "130": [ 171 ], "developed": [ 172 ], "compared": [ 175 ], "107": [ 177 ], "40": [ 179 ], "755": [ 180 ], "controls": [ 181 ], "(relative": [ 182 ], "[RR],": [ 184 ], "0.98;": [ 185 ], "95%": [ 186, 221 ], "confidence": [ 187 ], "interval": [ 188 ], "[CI],": [ 189 ], "0.76\u20131.26).": [ 190 ], "Subset": [ 191 ], "analyses": [ 192 ], "according": [ 193 ], "follow-up,": [ 195 ], "participant/investigator": [ 196 ], "blinding,": [ 197 ], "type": [ 199 ], "GLP-1RA": [ 201 ], "did": [ 202, 214 ], "not": [ 203, 215, 249 ], "reveal": [ 204 ], "any": [ 205 ], "differences.": [ 206 ], "The": [ 207 ], "neoplasms": [ 212 ], "also": [ 213 ], "differ": [ 216 ], "between": [ 217 ], "groups": [ 218 ], "(RR,": [ 219 ], "0.99;": [ 220 ], "CI,": [ 222 ], "0.48\u20132.01).": [ 223 ], "Trial": [ 224 ], "sequential": [ 225 ], "analysis": [ 226 ], "provided": [ 227 ], "that": [ 229 ], "sample": [ 231 ], "size": [ 232 ], "sufficient": [ 234 ], "avoid": [ 236 ], "missing": [ 237 ], "alternative": [ 238 ], "results.": [ 239 ], "Conclusions": [ 240 ], "Treatment": [ 241 ], "does": [ 248 ], "increase": [ 250 ] }, "publication_date": "2020-11-28", "publication_year": 2020, "type": "review", "cited_by_count": 69, "authors": [ { "id": "https://openalex.org/A5070690645", "display_name": "Giovana Fagundes Piccoli" }, { "id": "https://openalex.org/A5111134658", "display_name": "Leonardo A Mesquita" }, { "id": "https://openalex.org/A5038528759", "display_name": "Cinara Stein" }, { "id": "https://openalex.org/A5006663511", "display_name": "Marina Aziz" }, { "id": "https://openalex.org/A5025248319", "display_name": "Maira Zoldan" }, { "id": "https://openalex.org/A5070802393", "display_name": "Nath\u00e1lia Abi Habib Degobi" }, { "id": "https://openalex.org/A5051718584", "display_name": "Bernardo Frison Spiazzi" }, { "id": "https://openalex.org/A5110575336", "display_name": "Gilberto Lopes" }, { "id": "https://openalex.org/A5069024230", "display_name": "Ver\u00f4nica Colpani" }, { "id": "https://openalex.org/A5048466377", "display_name": "Fernando Gerchman" } ] }, { "id": "https://openalex.org/W3159698927", "doi": "https://doi.org/10.1038/s41598-021-88612-x", "title": "Effects of GLP-1 receptor agonist on changes in the gut bacterium and the underlying mechanisms", "abstract": { "Abstract": [ 0 ], "There": [ 1 ], "is": [ 2, 113 ], "a": [ 3, 36 ], "close": [ 4 ], "relationship": [ 5 ], "between": [ 6 ], "the": [ 7, 19, 29, 56, 64, 78, 86, 94, 114, 119, 124, 131 ], "gut": [ 8, 132 ], "microbiota": [ 9 ], "and": [ 10, 42 ], "metabolic": [ 11 ], "disorders.": [ 12 ], "In": [ 13 ], "this": [ 14 ], "study,": [ 15 ], "acute": [ 16 ], "administration": [ 17 ], "of": [ 18, 32, 38, 43, 63, 72, 77, 107, 126 ], "glucagon-like": [ 20 ], "peptide-1": [ 21 ], "receptor": [ 22 ], "agonist": [ 23 ], "(GLP-1RA)": [ 24 ], "liraglutide": [ 25 ], "to": [ 26, 53, 117 ], "mice": [ 27, 98 ], "increased": [ 28 ], "cecal": [ 30 ], "levels": [ 31 ], "caseinolytic": [ 33 ], "protease": [ 34 ], "B,": [ 35 ], "component": [ 37 ], "Escherichia": [ 39 ], "coli": [ 40, 90 ], ",": [ 41 ], "norepinephrine.": [ 44 ], "Chemical": [ 45 ], "sympathectomy": [ 46 ], "blocked": [ 47 ], "these": [ 48 ], "events.": [ 49 ], "Norepinephrine": [ 50 ], "was": [ 51, 67, 103 ], "found": [ 52 ], "pass": [ 54 ], "into": [ 55 ], "intestinal": [ 57, 79 ], "lumen": [ 58 ], "in": [ 59, 88, 97, 130 ], "vitro.": [ 60 ], "c-Fos": [ 61 ], "staining": [ 62 ], "intermediolateral": [ 65 ], "nucleus": [ 66 ], "identified": [ 68 ], "as": [ 69 ], "indirect": [ 70 ], "evidence": [ 71 ], "sympathetic": [ 73 ], "nervous": [ 74 ], "system": [ 75 ], "activation": [ 76 ], "tract": [ 80 ], "by": [ 81 ], "GLP-1RA.": [ 82 ], "Under": [ 83 ], "normal": [ 84 ], "conditions,": [ 85 ], "increase": [ 87 ], "E.": [ 89 ], "did": [ 91 ], "not": [ 92 ], "affect": [ 93 ], "host.": [ 95 ], "However,": [ 96 ], "with": [ 99, 105 ], "colitis,": [ 100 ], "bacterial": [ 101 ], "translocation": [ 102 ], "observed": [ 104 ], "attenuation": [ 106 ], "tight": [ 108 ], "junction": [ 109 ], "gene": [ 110 ], "expression.": [ 111 ], "This": [ 112 ], "first": [ 115 ], "study": [ 116 ], "investigate": [ 118 ], "unique": [ 120 ], "underlying": [ 121 ], "mechanisms": [ 122 ], "related": [ 123 ], "effects": [ 125 ], "GLP-1RA": [ 127 ], "on": [ 128 ], "changes": [ 129 ], "bacterium.": [ 133 ] }, "publication_date": "2021-04-28", "publication_year": 2021, "type": "article", "cited_by_count": 43, "authors": [ { "id": "https://openalex.org/A5113910111", "display_name": "Shunsuke Kato" }, { "id": "https://openalex.org/A5047099462", "display_name": "Takehiro Sato" }, { "id": "https://openalex.org/A5026408372", "display_name": "Hiroki Fujita" }, { "id": "https://openalex.org/A5003867296", "display_name": "Masahiro Kawatani" }, { "id": "https://openalex.org/A5101701620", "display_name": "Yuichiro Yamada" } ] }, { "id": "https://openalex.org/W140545298", "doi": "https://doi.org/10.1016/b978-0-12-800101-1.00002-8", "title": "Regulation of Glucose Homeostasis by GLP-1", "abstract": null, "publication_date": "2014-01-01", "publication_year": 2014, "type": "review", "cited_by_count": 257, "authors": [ { "id": "https://openalex.org/A5047832409", "display_name": "Prashant Nadkarni" }, { "id": "https://openalex.org/A5020235785", "display_name": "Oleg G. Chepurny" }, { "id": "https://openalex.org/A5058178334", "display_name": "George G. Holz" } ] }, { "id": "https://openalex.org/W4380739173", "doi": "https://doi.org/10.1016/j.arr.2023.101979", "title": "Antidiabetic agents as a novel treatment for Alzheimer\u2019s and Parkinson\u2019s disease", "abstract": { "Therapeutic": [ 0 ], "strategies": [ 1, 188 ], "for": [ 2, 91, 105, 189, 194, 282, 314, 333 ], "neurodegenerative": [ 3, 99, 155 ], "disorders": [ 4, 77 ], "have": [ 5, 139, 205 ], "commonly": [ 6 ], "targeted": [ 7 ], "individual": [ 8 ], "aspects": [ 9 ], "of": [ 10, 42, 59, 98, 143, 151, 184, 197, 285, 328, 336 ], "the": [ 11, 96, 117, 122, 141, 180, 185, 195, 218, 241, 283, 312, 334 ], "disease": [ 12, 21, 25 ], "pathogenesis": [ 13 ], "to": [ 14, 226 ], "little": [ 15 ], "success.": [ 16 ], "Neurodegenerative": [ 17 ], "diseases,": [ 18 ], "including": [ 19, 290 ], "Alzheimer's": [ 20 ], "(AD)": [ 22 ], "and": [ 23, 35, 55, 70, 153, 163, 170, 212, 231, 252, 269, 303, 318, 338 ], "Parkinson's": [ 24 ], "(PD),": [ 26 ], "are": [ 27, 310 ], "characterized": [ 28 ], "by": [ 29 ], "several": [ 30, 113, 329 ], "pathological": [ 31, 80, 119 ], "features.": [ 32 ], "In": [ 33, 216 ], "AD": [ 34, 169, 217, 319, 337 ], "PD,": [ 36, 240 ], "there": [ 37 ], "is": [ 38, 246, 279 ], "an": [ 39 ], "abnormal": [ 40 ], "accumulation": [ 41 ], "toxic": [ 43, 263 ], "proteins,": [ 44 ], "increased": [ 45, 52 ], "inflammation,": [ 46, 259 ], "decreased": [ 47 ], "synaptic": [ 48 ], "function,": [ 49 ], "neuronal": [ 50 ], "loss,": [ 51 ], "astrocyte": [ 53 ], "activation,": [ 54 ], "perhaps": [ 56 ], "a": [ 57, 66, 83, 88, 110, 325 ], "state": [ 58 ], "insulin": [ 60, 126, 174, 276 ], "resistance.": [ 61 ], "Epidemiological": [ 62 ], "evidence": [ 63 ], "has": [ 64, 85, 223 ], "revealed": [ 65 ], "link": [ 67, 84 ], "between": [ 68 ], "AD/PD": [ 69, 106, 134 ], "type": [ 71 ], "2": [ 72 ], "diabetes": [ 73 ], "mellitus,": [ 74 ], "with": [ 75, 157 ], "these": [ 76 ], "sharing": [ 78 ], "some": [ 79 ], "commonalities.": [ 81 ], "Such": [ 82 ], "opened": [ 86 ], "up": [ 87 ], "promising": [ 89, 187, 330 ], "avenue": [ 90 ], "repurposing": [ 92, 190 ], "antidiabetic": [ 93 ], "agents": [ 94, 114, 193, 332 ], "in": [ 95, 121, 132, 147, 168, 179, 210, 234, 239, 248, 311, 316 ], "treatment": [ 97, 196, 335 ], "disorders.": [ 100 ], "A": [ 101 ], "successful": [ 102 ], "therapeutic": [ 103 ], "strategy": [ 104 ], "would": [ 107 ], "likely": [ 108 ], "require": [ 109 ], "single": [ 111 ], "or": [ 112 ], "which": [ 115, 309 ], "target": [ 116 ], "separate": [ 118 ], "processes": [ 120 ], "disease.": [ 123 ], "Targeting": [ 124, 254 ], "cerebral": [ 125, 228 ], "signalling": [ 127 ], "produces": [ 128 ], "numerous": [ 129, 158 ], "neuroprotective": [ 130 ], "effects": [ 131 ], "preclinical": [ 133, 211 ], "brain": [ 135, 181, 255 ], "models.": [ 136 ], "Clinical": [ 137 ], "trials": [ 138, 162, 166 ], "shown": [ 140 ], "promise": [ 142 ], "approved": [ 144, 287 ], "diabetic": [ 145, 288 ], "compounds": [ 146 ], "improving": [ 148 ], "motor": [ 149, 250 ], "symptoms": [ 150 ], "PD": [ 152, 171, 317 ], "preventing": [ 154 ], "decline,": [ 156 ], "further": [ 159 ], "phase": [ 160, 164 ], "II": [ 161 ], "III": [ 165 ], "underway": [ 167 ], "populations.": [ 172 ], "Alongside": [ 173 ], "signalling,": [ 175 ], "targeting": [ 176 ], "incretin": [ 177, 256 ], "receptors": [ 178, 257 ], "represents": [ 182 ], "one": [ 183 ], "most": [ 186 ], "currently": [ 191 ], "available": [ 192 ], "AD/PD.": [ 198 ], "Most": [ 199 ], "notably,": [ 200 ], "glucagon-like-peptide-1": [ 201 ], "(GLP-1)": [ 202 ], "receptor": [ 203, 220, 243, 298 ], "agonists": [ 204 ], "displayed": [ 206 ], "impressive": [ 207 ], "clinical": [ 208, 214 ], "potential": [ 209 ], "early": [ 213 ], "studies.": [ 215 ], "GLP-1": [ 219, 242 ], "agonist,": [ 221 ], "liraglutide,": [ 222 ], "been": [ 224 ], "demonstrated": [ 225 ], "improve": [ 227 ], "glucose": [ 229 ], "metabolism": [ 230 ], "functional": [ 232 ], "connectivity": [ 233 ], "small-scale": [ 235 ], "pilot": [ 236 ], "trials.": [ 237 ], "Whilst": [ 238 ], "agonist": [ 244 ], "exenatide": [ 245 ], "effective": [ 247 ], "restoring": [ 249 ], "function": [ 251 ], "cognition.": [ 253 ], "reduces": [ 258 ], "inhibits": [ 260 ], "apoptosis,": [ 261 ], "prevents": [ 262 ], "protein": [ 264, 304 ], "aggregation,": [ 265 ], "enhances": [ 266 ], "long-term": [ 267 ], "potentiation": [ 268 ], "autophagy": [ 270 ], "as": [ 271, 273 ], "well": [ 272 ], "restores": [ 274 ], "dysfunctional": [ 275 ], "signalling.": [ 277 ], "Support": [ 278 ], "also": [ 280 ], "increasing": [ 281 ], "use": [ 284 ], "additional": [ 286 ], "treatments,": [ 289 ], "intranasal": [ 291 ], "insulin,": [ 292 ], "metformin": [ 293 ], "hydrochloride,": [ 294 ], "peroxisome": [ 295 ], "proliferator-activated": [ 296 ], "nuclear": [ 297 ], "\u03b3": [ 299 ], "agonists,": [ 300 ], "amylin": [ 301 ], "analogs,": [ 302 ], "tyrosine": [ 305 ], "phosphatase": [ 306 ], "1B": [ 307 ], "inhibitors": [ 308 ], "investigation": [ 313 ], "deployment": [ 315 ], "treatment.": [ 320 ], "As": [ 321 ], "such,": [ 322 ], "we": [ 323 ], "provide": [ 324 ], "comprehensive": [ 326 ], "review": [ 327 ], "anti-diabetic": [ 331 ], "PD.": [ 339 ] }, "publication_date": "2023-06-15", "publication_year": 2023, "type": "review", "cited_by_count": 140, "authors": [ { "id": "https://openalex.org/A5114037296", "display_name": "Joseph Nowell" }, { "id": "https://openalex.org/A5003804924", "display_name": "Eleanor G Blunt" }, { "id": "https://openalex.org/A5101456955", "display_name": "Dhruv Gupta" }, { "id": "https://openalex.org/A5036174826", "display_name": "Paul Edison" } ] }, { "id": "https://openalex.org/W4312019552", "doi": "https://doi.org/10.1016/s2213-8587(22)00340-0", "title": "Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials", "abstract": null, "publication_date": "2022-12-15", "publication_year": 2022, "type": "article", "cited_by_count": 80, "authors": [ { "id": "https://openalex.org/A5060778553", "display_name": "Adem Y. Dawed" }, { "id": "https://openalex.org/A5102028274", "display_name": "Andrea Mari" }, { "id": "https://openalex.org/A5049834415", "display_name": "Andrew Brown" }, { "id": "https://openalex.org/A5103163871", "display_name": "Timothy J. McDonald" }, { "id": "https://openalex.org/A5081928745", "display_name": "Lin Li" }, { "id": "https://openalex.org/A5052105805", "display_name": "Shuaicheng Wang" }, { "id": "https://openalex.org/A5110578571", "display_name": "Mun\u2010Gwan Hong" }, { "id": "https://openalex.org/A5101481228", "display_name": "Sapna Sharma" }, { "id": "https://openalex.org/A5103854218", "display_name": "Neil R. Robertson" }, { "id": "https://openalex.org/A5030469052", "display_name": "Anubha Mahajan" }, { "id": "https://openalex.org/A5100329012", "display_name": "Xuan Wang" }, { "id": "https://openalex.org/A5101730056", "display_name": "Mark Walker" }, { "id": "https://openalex.org/A5108267083", "display_name": "Stephen Gough" }, { "id": "https://openalex.org/A5015404078", "display_name": "Leen M. \u2018t Hart" }, { "id": "https://openalex.org/A5017895470", "display_name": "Kaixin Zhou" }, { "id": "https://openalex.org/A5030461339", "display_name": "Ian Forgie" }, { "id": "https://openalex.org/A5106699371", "display_name": "Hartmut Ruetten" }, { "id": "https://openalex.org/A5026505577", "display_name": "Imre P\u00e1v\u00f3" }, { "id": "https://openalex.org/A5008544198", "display_name": "Pallav Bhatnagar" }, { "id": "https://openalex.org/A5036287780", "display_name": "Angus G. Jones" }, { "id": "https://openalex.org/A5087774397", "display_name": "Ewan R. Pearson" }, { "id": "https://openalex.org/A5015404078", "display_name": "Leen M. \u2018t Hart" }, { "id": "https://openalex.org/A5015704292", "display_name": "Mohamed Elhassan Abdalla" }, { "id": "https://openalex.org/A5055691046", "display_name": "Jean\u2010Michel Adam" }, { "id": "https://openalex.org/A5036469090", "display_name": "J. Adamski" }, { "id": "https://openalex.org/A5000372029", "display_name": "Kofi P. Adragni" }, { "id": "https://openalex.org/A5021440854", "display_name": "Kristine H. Allin" }, { "id": "https://openalex.org/A5058914957", "display_name": "Manimozhiyan Arumugam" }, { "id": "https://openalex.org/A5110642066", "display_name": "Naeimeh Atabaki Pasdar" }, { "id": "https://openalex.org/A5082284195", "display_name": "Tania Baltauss" }, { "id": "https://openalex.org/A5046155248", "display_name": "Kamil Banasik" }, { "id": "https://openalex.org/A5006827357", "display_name": "Patrick Baum" }, { "id": "https://openalex.org/A5057380504", "display_name": "Jimmy D. Bell" }, { "id": "https://openalex.org/A5112741124", "display_name": "Mats Bergstr\u00f6m" }, { "id": "https://openalex.org/A5085784987", "display_name": "Joline W. J. Beulens" }, { "id": "https://openalex.org/A5097764787", "display_name": "Susaana Bianzano" }, { "id": "https://openalex.org/A5075784923", "display_name": "Roberto Bizzotto" }, { "id": "https://openalex.org/A5089093375", "display_name": "Amelie Bonneford" }, { "id": "https://openalex.org/A5002513408", "display_name": "Caroline Brorsson" }, { "id": "https://openalex.org/A5062562793", "display_name": "A.A. Brown" }, { "id": "https://openalex.org/A5069176289", "display_name": "S.B. Brunak" }, { "id": "https://openalex.org/A5021230631", "display_name": "Louise Cabrelli" }, { "id": "https://openalex.org/A5031309328", "display_name": "Robert Ca\u00efazzo" }, { "id": "https://openalex.org/A5038262522", "display_name": "Micka\u00ebl Canouil" }, { "id": "https://openalex.org/A5112801880", "display_name": "M.M. Dale" }, { "id": "https://openalex.org/A5112882050", "display_name": "David Davtian" }, { "id": "https://openalex.org/A5060778553", "display_name": "Adem Y. Dawed" }, { "id": "https://openalex.org/A5109593136", "display_name": "F.M. De Masi" }, { "id": "https://openalex.org/A5004499681", "display_name": "Nathalie de Pr\u00e9ville" }, { "id": "https://openalex.org/A5072291643", "display_name": "Koen F. Dekkers" }, { "id": "https://openalex.org/A5039719354", "display_name": "E. T. Dermitzakis" }, { "id": "https://openalex.org/A5088604122", "display_name": "Harshal Deshmukh" }, { "id": "https://openalex.org/A5042636897", "display_name": "Christiane Dings" }, { "id": "https://openalex.org/A5018760410", "display_name": "Louise Donnelly" }, { "id": "https://openalex.org/A5011753237", "display_name": "Avirup Dutta" }, { "id": "https://openalex.org/A5029735541", "display_name": "Beate Ehrhardt" }, { "id": "https://openalex.org/A5036526464", "display_name": "Petra J. M. Elders" }, { "id": "https://openalex.org/A5108825888", "display_name": "Cecilia Engel Thomas" }, { "id": "https://openalex.org/A5081723449", "display_name": "Line Engelbrechtsen" }, { "id": "https://openalex.org/A5106699607", "display_name": "R.G. Eriksen" }, { "id": "https://openalex.org/A5104535058", "display_name": "R.E. Eriksen" }, { "id": "https://openalex.org/A5068801040", "display_name": "Yong Fan" }, { "id": "https://openalex.org/A5029950952", "display_name": "J. Fernandez" }, { "id": "https://openalex.org/A5083179875", "display_name": "Jos\u00e9 Illnait Ferrer" }, { "id": "https://openalex.org/A5042428378", "display_name": "Hugo Fitipaldi" }, { "id": "https://openalex.org/A5030461339", "display_name": "Ian Forgie" }, { "id": "https://openalex.org/A5091682274", "display_name": "Axel Forman" }, { "id": "https://openalex.org/A5024645589", "display_name": "Paul W. Franks" }, { "id": "https://openalex.org/A5057967588", "display_name": "Franco Frau" }, { "id": "https://openalex.org/A5014571442", "display_name": "A. Fritsche" }, { "id": "https://openalex.org/A5028149911", "display_name": "P. Froguel" }, { "id": "https://openalex.org/A5078144383", "display_name": "Gary Frost" }, { "id": "https://openalex.org/A5071015774", "display_name": "Johann Gassenhuber" }, { "id": "https://openalex.org/A5017301900", "display_name": "Guillermo Giordano" }, { "id": "https://openalex.org/A5052899068", "display_name": "Toni Giorgino" }, { "id": "https://openalex.org/A5108267083", "display_name": "Stephen Gough" }, { "id": "https://openalex.org/A5066453545", "display_name": "Ulrike Graefe\u2010Mody" }, { "id": "https://openalex.org/A5011060264", "display_name": "H. Grallert" }, { "id": "https://openalex.org/A5082492698", "display_name": "Rolf Grempler" }, { "id": "https://openalex.org/A5044151936", "display_name": "Lenka Groeneveld" }, { "id": "https://openalex.org/A5074771810", "display_name": "Leif Groop" }, { "id": "https://openalex.org/A5022520658", "display_name": "V Gudmundsdottir" }, { "id": "https://openalex.org/A5053425036", "display_name": "R.G. Gupta" }, { "id": "https://openalex.org/A5072563406", "display_name": "Mark Haid" }, { "id": "https://openalex.org/A5065848008", "display_name": "T. Hansen" }, { "id": "https://openalex.org/A5085970754", "display_name": "Tue H. Hansen" }, { "id": "https://openalex.org/A5060736941", "display_name": "Andrew T. Hattersley" }, { "id": "https://openalex.org/A5060542550", "display_name": "Ragna S. H\u00e4ussler" }, { "id": "https://openalex.org/A5040137496", "display_name": "A.J. Heggie" }, { "id": "https://openalex.org/A5036652363", "display_name": "Anita M. Hennige" }, { "id": "https://openalex.org/A5037138357", "display_name": "Adrian V. S. Hill" }, { "id": "https://openalex.org/A5019444853", "display_name": "Reinhard W. Holl" }, { "id": "https://openalex.org/A5110578571", "display_name": "Mun\u2010Gwan Hong" }, { "id": "https://openalex.org/A5091056160", "display_name": "Michelle Hudson" }, { "id": "https://openalex.org/A5108127468", "display_name": "Bernd Jablonka" }, { "id": "https://openalex.org/A5030704721", "display_name": "Christopher Jennison" }, { "id": "https://openalex.org/A5001029466", "display_name": "Jian Jiao" }, { "id": "https://openalex.org/A5016432937", "display_name": "Jon Johansen" }, { "id": "https://openalex.org/A5088944655", "display_name": "Adam G. Jones" }, { "id": "https://openalex.org/A5087981303", "display_name": "A. Jonsson" } ] }, { "id": "https://openalex.org/W2166714657", "doi": "https://doi.org/10.1111/j.1463-1326.2011.01393.x", "title": "Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit *", "abstract": { "Aim:": [ 0 ], "To": [ 1 ], "assess": [ 2 ], "the": [ 3, 104, 198 ], "extent,": [ 4 ], "safety,": [ 5 ], "efficacy": [ 6 ], "and": [ 7, 42, 56, 63, 70, 78, 83, 95, 127, 144, 186, 214, 232, 273, 286 ], "tolerability": [ 8 ], "of": [ 9, 21, 30, 33, 161, 197, 223, 265 ], "reported": [ 10 ], "off\u2010licence": [ 11 ], "exenatide": [ 12, 34, 59, 110, 119, 162, 224, 252, 289 ], "use": [ 13, 35 ], "through": [ 14 ], "a": [ 15, 26 ], "nationwide": [ 16 ], "audit.": [ 17 ], "Methods:": [ 18 ], "The": [ 19 ], "Association": [ 20 ], "British": [ 22 ], "Clinical": [ 23 ], "Diabetologists": [ 24 ], "hosted": [ 25 ], "password\u2010protected,": [ 27 ], "online": [ 28 ], "collection": [ 29 ], "anonymized": [ 31 ], "data": [ 32, 51 ], "in": [ 36, 256 ], "real": [ 37 ], "clinical": [ 38 ], "practice.": [ 39 ], "Three": [ 40 ], "hundred": [ 41, 77 ], "fifteen": [ 43 ], "contributors": [ 44 ], "from": [ 45, 288 ], "126": [ 46 ], "centres": [ 47 ], "across": [ 48 ], "UK": [ 49 ], "provided": [ 50 ], "on": [ 52 ], "6717": [ 53 ], "patients.": [ 54, 72, 220 ], "HbA1c": [ 55, 91, 126, 204, 258 ], "weight": [ 57, 128, 272 ], "changes,": [ 58 ], "discontinuation,": [ 60, 211 ], "adverse": [ 61 ], "events": [ 62, 235 ], "treatment": [ 64, 85, 187, 246, 290 ], "satisfaction": [ 65 ], "were": [ 66, 133, 236 ], "compared": [ 67 ], "between": [ 68 ], "non\u2010insulin": [ 69 ], "insulin\u2010treated": [ 71, 219, 227, 260, 266, 281 ], "Results:": [ 73 ], "Four": [ 74 ], "thousand": [ 75 ], "eight": [ 76 ], "fifty\u2010seven": [ 79 ], "patients": [ 80, 114, 157, 199, 228, 267, 282 ], "had": [ 81, 158 ], "baseline": [ 82, 90 ], "follow\u2010up": [ 84 ], "status": [ 86 ], "with": [ 87, 111, 118, 120 ], "mean": [ 88, 123 ], "(\u00b1s.d.)": [ 89 ], "9.45": [ 92 ], "\u00b1": [ 93, 98, 135, 139, 146, 150 ], "1.69%": [ 94 ], "BMI": [ 96 ], "40.0": [ 97 ], "8.2": [ 99 ], "kg/m": [ 100 ], "2": [ 101 ], ".": [ 102 ], "Of": [ 103 ], "4857": [ 105 ], "patients,": [ 106, 122, 261 ], "1921": [ 107 ], "(39.6%)": [ 108 ], "used": [ 109 ], "insulin.": [ 112 ], "Comparing": [ 113 ], "who": [ 115, 283 ], "continued": [ 116 ], "insulin": [ 117, 201, 210, 274 ], "non\u2010insulin\u2010treated": [ 121 ], "(\u00b1s.e.)": [ 124 ], "latest": [ 125 ], "reduction": [ 129, 205, 213 ], "(median": [ 130 ], "26": [ 131 ], "weeks)": [ 132 ], "0.51": [ 134 ], "0.06": [ 136 ], "versus": [ 137, 148 ], "0.94": [ 138 ], "0.04%": [ 140 ], "(p": [ 141, 153 ], "<": [ 142, 168, 175, 193 ], "0.001)": [ 143 ], "5.8": [ 145 ], "0.2": [ 147 ], "5.5": [ 149 ], "0.1": [ 151 ], "kg": [ 152 ], "=": [ 154, 184 ], "0.278).": [ 155 ], "Insulin\u2010treated": [ 156 ], "higher": [ 159 ], "rates": [ 160 ], "discontinuation": [ 163, 217 ], "(31.0": [ 164 ], "vs.": [ 165, 172, 181, 190 ], "13.9%,": [ 166 ], "p": [ 167, 174, 183, 192 ], "0.001),": [ 169, 176 ], "hypoglycaemia": [ 170 ], "(8.9": [ 171 ], "6.1%,": [ 173 ], "gastrointestinal": [ 177 ], "side": [ 178 ], "effects": [ 179 ], "(28.4": [ 180 ], "25.0%,": [ 182 ], "0.008)": [ 185 ], "dissatisfaction": [ 188 ], "(20.8": [ 189 ], "5.7%,": [ 191 ], "0.001).": [ 194 ], "However,": [ 195 ], "34.2%": [ 196 ], "continuing": [ 200 ], "still": [ 202, 268 ], "achieved": [ 203, 269 ], "\u22651%.": [ 206 ], "There": [ 207 ], "was": [ 208, 247, 253 ], "significant": [ 209, 263, 270 ], "dose": [ 212 ], "greater": [ 215 ], "sulphonylurea": [ 216 ], "among": [ 218, 259 ], "Conclusions:": [ 221 ], "Addition": [ 222 ], "to": [ 225 ], "obese,": [ 226, 280 ], "can": [ 229 ], "improve": [ 230 ], "glycaemia": [ 231 ], "weight.": [ 233 ], "Adverse": [ 234 ], "statistically": [ 237 ], "but": [ 238, 244 ], "probably": [ 239 ], "not": [ 240 ], "clinically": [ 241 ], "significantly": [ 242 ], "higher,": [ 243 ], "combination": [ 245 ], "less": [ 248, 254 ], "well": [ 249 ], "tolerated.": [ 250 ], "Overall,": [ 251 ], "effective": [ 255 ], "lowering": [ 257 ], "although": [ 262 ], "number": [ 264 ], "HbA1c,": [ 271 ], "reductions.": [ 275 ], "Further": [ 276 ], "research": [ 277 ], "into": [ 278 ], "identifying": [ 279 ], "will": [ 284 ], "tolerate": [ 285 ], "benefit": [ 287 ], "is": [ 291 ], "urgently": [ 292 ], "needed.": [ 293 ] }, "publication_date": "2011-03-16", "publication_year": 2011, "type": "article", "cited_by_count": 96, "authors": [ { "id": "https://openalex.org/A5111421440", "display_name": "K. Y. Thong" }, { "id": "https://openalex.org/A5001782559", "display_name": "Biju Jose" }, { "id": "https://openalex.org/A5080472658", "display_name": "Nithya Sukumar" }, { "id": "https://openalex.org/A5063239208", "display_name": "ML Cull" }, { "id": "https://openalex.org/A5110835652", "display_name": "A. P. Mills" }, { "id": "https://openalex.org/A5062170233", "display_name": "Thozhukat Sathyapalan" }, { "id": "https://openalex.org/A5048758932", "display_name": "Waqas Shafiq" }, { "id": "https://openalex.org/A5002725702", "display_name": "Alan S. Rigby" }, { "id": "https://openalex.org/A5102857211", "display_name": "Chloe Walton" }, { "id": "https://openalex.org/A5071127270", "display_name": "Robert E. J. Ryder" } ] }, { "id": "https://openalex.org/W2070181092", "doi": "https://doi.org/10.1016/j.mce.2014.12.021", "title": "Effect of liraglutide on proliferation and differentiation of human adipose stem cells", "abstract": null, "publication_date": "2015-01-06", "publication_year": 2015, "type": "article", "cited_by_count": 34, "authors": [ { "id": "https://openalex.org/A5052580834", "display_name": "Giulia Cantini" }, { "id": "https://openalex.org/A5030161236", "display_name": "A. Di Franco" }, { "id": "https://openalex.org/A5052502800", "display_name": "Jinous Samavat" }, { "id": "https://openalex.org/A5107925363", "display_name": "Gianni Forti" }, { "id": "https://openalex.org/A5059685674", "display_name": "Edoardo Mannucci" }, { "id": "https://openalex.org/A5016806501", "display_name": "Michaela Luconi" } ] }, { "id": "https://openalex.org/W3005805429", "doi": "https://doi.org/10.1111/ijpo.12624", "title": "A 6\u2010month randomized, double\u2010blind, placebo\u2010controlled trial of weekly exenatide in adolescents with obesity", "abstract": { "Summary": [ 0 ], "Background": [ 1 ], "Pharmacological": [ 2 ], "treatment": [ 3, 19, 272 ], "options": [ 4 ], "for": [ 5, 21, 280 ], "adolescents": [ 6, 62, 240 ], "with": [ 7, 63, 84, 224, 241, 244 ], "obesity": [ 8, 243 ], "are": [ 9 ], "very": [ 10 ], "limited.": [ 11 ], "Glucagon\u2010like\u2010peptide\u20101": [ 12 ], "(GLP\u20101)": [ 13 ], "receptor": [ 14 ], "agonist": [ 15 ], "could": [ 16 ], "be": [ 17 ], "a": [ 18, 254 ], "option": [ 20 ], "adolescent": [ 22 ], "obesity.": [ 23, 64 ], "Objective": [ 24 ], "To": [ 25 ], "investigate": [ 26 ], "the": [ 27, 133, 138, 225, 271, 281 ], "effect": [ 28 ], "of": [ 29, 137, 227, 239 ], "exenatide": [ 30, 107, 246 ], "extended": [ 31, 108 ], "release": [ 32, 109 ], "on": [ 33 ], "body": [ 34 ], "mass": [ 35 ], "index": [ 36 ], "(BMI)\u2010SDS": [ 37 ], "as": [ 38, 53 ], "primary": [ 39 ], "outcome,": [ 40 ], "and": [ 41, 49, 56, 59, 103, 135, 191, 217, 251, 260, 265 ], "glucose": [ 42, 126, 263 ], "metabolism,": [ 43 ], "cardiometabolic": [ 44 ], "risk": [ 45 ], "factors,": [ 46 ], "liver": [ 47, 203 ], "steatosis,": [ 48 ], "other": [ 50 ], "BMI": [ 51, 152, 192, 258, 278 ], "metrics": [ 52, 259 ], "secondary": [ 54 ], "outcomes,": [ 55 ], "its": [ 57 ], "safety": [ 58 ], "tolerability": [ 60, 218 ], "in": [ 61, 73, 202, 212, 234, 257, 262 ], "Methods": [ 65 ], "Six\u2010month,": [ 66 ], "randomized,": [ 67 ], "double\u2010blinded,": [ 68 ], "parallel,": [ 69 ], "placebo\u2010controlled": [ 70 ], "clinical": [ 71 ], "trial": [ 72 ], "patients": [ 74 ], "(n": [ 75, 112, 117 ], "=": [ 76, 82, 113, 118, 210 ], "44,": [ 77 ], "10\u201018": [ 78 ], "years,": [ 79 ], "females": [ 80 ], "n": [ 81 ], "22)": [ 83, 114, 119 ], "BMI\u2010SDS": [ 85, 147 ], ">": [ 86, 90 ], "2.0": [ 87 ], "or": [ 88, 115 ], "age\u2010adapted\u2010BMI": [ 89 ], "30": [ 91 ], "kg/m": [ 92, 194 ], "2": [ 93, 110, 195 ], "according": [ 94 ], "to": [ 95, 106, 214, 222, 253 ], "WHO": [ 96 ], "were": [ 97, 104, 130, 220 ], "included.": [ 98 ], "Patients": [ 99 ], "received": [ 100 ], "lifestyle": [ 101 ], "intervention": [ 102 ], "randomized": [ 105 ], "mg": [ 111 ], "placebo": [ 116, 223 ], "subcutaneous": [ 120, 169 ], "injections": [ 121 ], "given": [ 122 ], "once": [ 123 ], "weekly.": [ 124 ], "Oral": [ 125 ], "tolerance": [ 127, 264 ], "tests": [ 128 ], "(OGTT)": [ 129 ], "conducted": [ 131 ], "at": [ 132 ], "beginning": [ 134 ], "end": [ 136 ], "intervention.": [ 139 ], "Results": [ 140 ], "Exenatide": [ 141 ], "reduced": [ 142 ], "(": [ 143 ], "P": [ 144, 209 ], "<": [ 145 ], ".05)": [ 146 ], "(\u22120.09;": [ 148 ], "\u22120.18,": [ 149 ], "0.00),": [ 150 ], "%": [ 151 ], "95th": [ 153 ], "percentile": [ 154 ], "(\u22122.9%;": [ 155 ], "\u22125.4,": [ 156 ], "\u22120.3),": [ 157 ], "weight": [ 158 ], "(\u22123": [ 159 ], "kg;": [ 160 ], "\u22125.8,": [ 161, 167 ], "\u22120.1),": [ 162 ], "waist": [ 163 ], "circumference": [ 164 ], "(\u22123.2": [ 165 ], "cm;": [ 166 ], "\u22120.7),": [ 168 ], "adipose": [ 170 ], "tissue": [ 171 ], "(\u2212552": [ 172 ], "cm": [ 173 ], "3": [ 174 ], ";": [ 175, 196 ], "\u2212989,": [ 176 ], "\u2212114),": [ 177 ], "2\u2010hour\u2010glucose": [ 178 ], "during": [ 179 ], "OGTT": [ 180 ], "(\u221215.3": [ 181 ], "mg/dL;": [ 182, 188 ], "\u221227.5,": [ 183 ], "\u22123.1),": [ 184 ], "total": [ 185 ], "cholesterol": [ 186 ], "(11.6": [ 187 ], "\u221221.7,": [ 189 ], "\u22121.5),": [ 190 ], "(\u22120.83": [ 193 ], "\u22121.68,": [ 197 ], "0.01)": [ 198 ], "without": [ 199 ], "significant": [ 200 ], "change": [ 201 ], "fat": [ 204 ], "content": [ 205 ], "(\u22121.36;": [ 206 ], "\u22123.12,": [ 207 ], "0.4;": [ 208 ], ".06)": [ 211 ], "comparison": [ 213 ], "placebo.": [ 215 ], "Safety": [ 216 ], "profiles": [ 219 ], "comparable": [ 221 ], "exception": [ 226 ], "mild": [ 228 ], "adverse": [ 229 ], "events": [ 230 ], "being": [ 231 ], "more": [ 232 ], "frequent": [ 233 ], "exenatide\u2010treated": [ 235 ], "patients.": [ 236 ], "Conclusions": [ 237 ], "Treatment": [ 238 ], "severe": [ 242 ], "extended\u2010release": [ 245 ], "is": [ 247 ], "generally": [ 248 ], "well": [ 249 ], "tolerated": [ 250 ], "leads": [ 252 ], "modest": [ 255 ], "reduction": [ 256, 279 ], "improvement": [ 261 ], "cholesterol.": [ 266 ], "The": [ 267 ], "study": [ 268 ], "indicates": [ 269 ], "that": [ 270 ], "provides": [ 273 ], "additional": [ 274 ], "beneficial": [ 275 ], "effects": [ 276 ], "beyond": [ 277 ], "patient": [ 282 ], "group.": [ 283 ] }, "publication_date": "2020-02-16", "publication_year": 2020, "type": "article", "cited_by_count": 65, "authors": [ { "id": "https://openalex.org/A5087302320", "display_name": "Daniel Weghuber" }, { "id": "https://openalex.org/A5076981178", "display_name": "Anders Forslund" }, { "id": "https://openalex.org/A5023269056", "display_name": "H\u00e5kan \u00c5hlstr\u00f6m" }, { "id": "https://openalex.org/A5086378984", "display_name": "Anders Alderborn" }, { "id": "https://openalex.org/A5039555173", "display_name": "Kendra Gail Bergstrom" }, { "id": "https://openalex.org/A5059829670", "display_name": "Susanne M. Brunner" }, { "id": "https://openalex.org/A5085273180", "display_name": "Janne Cadamuro" }, { "id": "https://openalex.org/A5074219298", "display_name": "Iris Ciba" }, { "id": "https://openalex.org/A5070508678", "display_name": "Magnus Dahlbom" }, { "id": "https://openalex.org/A5027984746", "display_name": "Verena Heu" }, { "id": "https://openalex.org/A5104622569", "display_name": "Johanna Hofmann" }, { "id": "https://openalex.org/A5031193479", "display_name": "H\u00f6r\u00f0ur G. Kristinsson" }, { "id": "https://openalex.org/A5075154897", "display_name": "Joel Kullberg" }, { "id": "https://openalex.org/A5070306360", "display_name": "A. Ladinger" }, { "id": "https://openalex.org/A5079918919", "display_name": "Florian B. Lagler" }, { "id": "https://openalex.org/A5031561494", "display_name": "M. Lidstr\u00f6m" }, { "id": "https://openalex.org/A5072853800", "display_name": "Hannes Manell" }, { "id": "https://openalex.org/A5034966170", "display_name": "Malin Meirik" }, { "id": "https://openalex.org/A5090520824", "display_name": "Katharina M\u00f6rwald" }, { "id": "https://openalex.org/A5075842572", "display_name": "Kirsten Roomp" }, { "id": "https://openalex.org/A5079833473", "display_name": "Reinhard Schneider" }, { "id": "https://openalex.org/A5091612254", "display_name": "H. Vil\u00e9n" }, { "id": "https://openalex.org/A5022329438", "display_name": "Kurt Widhalm" }, { "id": "https://openalex.org/A5061400840", "display_name": "Fanni Zsoldos" }, { "id": "https://openalex.org/A5089532594", "display_name": "Peter Bergsten" } ] }, { "id": "https://openalex.org/W4283460245", "doi": "https://doi.org/10.3390/cells11132023", "title": "GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight", "abstract": { "Defects": [ 0 ], "in": [ 1, 10, 113, 132, 143, 181 ], "brain": [ 2 ], "energy": [ 3 ], "metabolism": [ 4 ], "and": [ 5, 19, 54, 103, 108, 117, 136, 145, 170 ], "proteopathic": [ 6 ], "stress": [ 7 ], "are": [ 8 ], "implicated": [ 9 ], "age-related": [ 11 ], "degenerative": [ 12 ], "neuronopathies,": [ 13 ], "exemplified": [ 14 ], "by": [ 15 ], "Alzheimer\u2019s": [ 16 ], "disease": [ 17, 21, 60 ], "(AD)": [ 18 ], "Parkinson\u2019s": [ 20 ], "(PD).": [ 22 ], "As": [ 23 ], "the": [ 24, 58, 77, 127, 133, 137, 159, 166, 186 ], "currently": [ 25 ], "available": [ 26 ], "drug": [ 27 ], "regimens": [ 28 ], "largely": [ 29 ], "aim": [ 30 ], "to": [ 31, 50, 158 ], "mitigate": [ 32 ], "cognitive": [ 33 ], "decline": [ 34 ], "and/or": [ 35 ], "motor": [ 36 ], "symptoms,": [ 37 ], "there": [ 38 ], "is": [ 39 ], "a": [ 40, 65 ], "dire": [ 41 ], "need": [ 42 ], "for": [ 43 ], "mechanism-based": [ 44 ], "therapies": [ 45 ], "that": [ 46, 71, 177 ], "can": [ 47 ], "be": [ 48, 179 ], "used": [ 49 ], "improve": [ 51 ], "neuronal": [ 52 ], "function": [ 53 ], "potentially": [ 55 ], "slow": [ 56 ], "down": [ 57 ], "underlying": [ 59 ], "processes.": [ 61 ], "In": [ 62, 121 ], "this": [ 63, 122, 148 ], "context,": [ 64, 149 ], "new": [ 66 ], "class": [ 67 ], "of": [ 68, 106, 130, 139, 162, 173, 189 ], "pharmacological": [ 69 ], "agents": [ 70 ], "achieve": [ 72 ], "improved": [ 73 ], "glycaemic": [ 74 ], "control": [ 75 ], "via": [ 76 ], "glucagon-like": [ 78 ], "peptide": [ 79 ], "1": [ 80 ], "(GLP-1)": [ 81 ], "receptor": [ 82 ], "has": [ 83, 110 ], "attracted": [ 84 ], "significant": [ 85 ], "attention": [ 86 ], "as": [ 87 ], "putative": [ 88 ], "neuroprotective": [ 89, 187 ], "agents.": [ 90, 194 ], "The": [ 91 ], "experimental": [ 92, 175 ], "evidence": [ 93 ], "supporting": [ 94 ], "their": [ 95 ], "potential": [ 96, 160 ], "therapeutic": [ 97 ], "value,": [ 98 ], "mainly": [ 99 ], "derived": [ 100 ], "from": [ 101 ], "cellular": [ 102 ], "animal": [ 104 ], "models": [ 105 ], "AD": [ 107, 144 ], "PD,": [ 109 ], "been": [ 111 ], "discussed": [ 112 ], "several": [ 114 ], "research": [ 115 ], "reports": [ 116 ], "review": [ 118, 123 ], "opinions": [ 119 ], "recently.": [ 120 ], "article,": [ 124 ], "we": [ 125, 150 ], "discuss": [ 126, 152 ], "pathological": [ 128 ], "relevance": [ 129 ], "derangements": [ 131 ], "neurovascular": [ 134, 167 ], "unit": [ 135, 168 ], "significance": [ 138 ], "neuron\u2013glia": [ 140 ], "metabolic": [ 141 ], "coupling": [ 142 ], "PD.": [ 146 ], "With": [ 147 ], "also": [ 151 ], "some": [ 153 ], "unresolved": [ 154 ], "questions": [ 155 ], "with": [ 156, 192 ], "regard": [ 157 ], "benefits": [ 161 ], "GLP-1": [ 163 ], "agonists": [ 164 ], "on": [ 165 ], "(NVU),": [ 169 ], "provide": [ 171 ], "examples": [ 172 ], "novel": [ 174 ], "paradigms": [ 176 ], "could": [ 178 ], "useful": [ 180 ], "improving": [ 182 ], "our": [ 183 ], "understanding": [ 184 ], "regarding": [ 185 ], "mode": [ 188 ], "action": [ 190 ], "associated": [ 191 ], "these": [ 193 ] }, "publication_date": "2022-06-25", "publication_year": 2022, "type": "review", "cited_by_count": 44, "authors": [ { "id": "https://openalex.org/A5024236709", "display_name": "Giulia Monti" }, { "id": "https://openalex.org/A5076313077", "display_name": "Diana Gomes Moreira" }, { "id": "https://openalex.org/A5045579576", "display_name": "Mette Richner" }, { "id": "https://openalex.org/A5080856061", "display_name": "Henricus A. M. Mutsaers" }, { "id": "https://openalex.org/A5013150457", "display_name": "Nelson Ferreira" }, { "id": "https://openalex.org/A5017717567", "display_name": "Asad Jan" } ] }, { "id": "https://openalex.org/W2133533488", "doi": "https://doi.org/10.1124/dmd.110.034066", "title": "Metabolism and Excretion of the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide in Healthy Male Subjects and Its In Vitro Degradation by Dipeptidyl Peptidase IV and Neutral Endopeptidase", "abstract": null, "publication_date": "2010-08-14", "publication_year": 2010, "type": "article", "cited_by_count": 191, "authors": [ { "id": "https://openalex.org/A5066155159", "display_name": "Monika Malm-Erjef\u00e4lt" }, { "id": "https://openalex.org/A5042403500", "display_name": "Inga Bj\u00f8rnsdottir" }, { "id": "https://openalex.org/A5036664679", "display_name": "Jan Vanggaard" }, { "id": "https://openalex.org/A5012114174", "display_name": "Hans Helleberg" }, { "id": "https://openalex.org/A5083075188", "display_name": "Uffe S. Larsen" }, { "id": "https://openalex.org/A5049436470", "display_name": "B. Oosterhuis" }, { "id": "https://openalex.org/A5055811263", "display_name": "Jan Jaap van Lier" }, { "id": "https://openalex.org/A5103492502", "display_name": "Milan Zdravkovic" }, { "id": "https://openalex.org/A5082276988", "display_name": "Annette Olsen" } ] }, { "id": "https://openalex.org/W3216421984", "doi": "https://doi.org/10.1016/j.eclinm.2021.101213", "title": "Association of glucagon-like peptide 1 analogs and agonists administered for obesity with weight loss and adverse events: a systematic review and network meta-analysis", "abstract": null, "publication_date": "2021-11-27", "publication_year": 2021, "type": "review", "cited_by_count": 89, "authors": [ { "id": "https://openalex.org/A5054128697", "display_name": "Kia Vosoughi" }, { "id": "https://openalex.org/A5077795610", "display_name": "Jessica Atieh" }, { "id": "https://openalex.org/A5064860318", "display_name": "Lehar Khanna" }, { "id": "https://openalex.org/A5001226059", "display_name": "Katayoun Khoshbin" }, { "id": "https://openalex.org/A5073495332", "display_name": "Larry J. Prokop" }, { "id": "https://openalex.org/A5008870343", "display_name": "Perica Davitkov" }, { "id": "https://openalex.org/A5054802858", "display_name": "M. Hassan Murad" }, { "id": "https://openalex.org/A5001729912", "display_name": "Michael Camilleri" } ] }, { "id": "https://openalex.org/W2793876367", "doi": "https://doi.org/10.1111/nmo.13313", "title": "Allelic variant in the glucagon\u2010like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: A pilot pharmacogenetics study", "abstract": { "Abstract": [ 0 ], "Background": [ 1 ], "Weight": [ 2 ], "loss": [ 3, 52, 210, 275 ], "in": [ 4, 21, 39, 53, 69, 132, 167, 208, 248, 252, 276 ], "response": [ 5, 253, 277 ], "to": [ 6, 33, 172, 187, 254, 262, 278 ], "the": [ 7, 60, 72, 116, 267 ], "long\u2010acting": [ 8 ], "GLP": [ 9, 13, 40, 62, 78, 146, 213, 240, 270, 279 ], "\u20101": [ 10, 63 ], "receptor": [ 11 ], "(": [ 12, 23, 138, 152 ], "1R)": [ 14 ], "analog,": [ 15 ], "liraglutide,": [ 16, 105 ], "is": [ 17, 243 ], "correlated": [ 18 ], "with": [ 19, 47, 57, 227, 245 ], "delay": [ 20, 166, 247 ], "gastric\u2010emptying": [ 22 ], "GE": [ 24, 49, 86, 135, 168, 249 ], ").": [ 25 ], "The": [ 26, 235 ], "aim": [ 27 ], "of": [ 28, 74, 77, 220, 239, 266 ], "this": [ 29 ], "pilot": [ 30 ], "study": [ 31 ], "was": [ 32, 126, 204 ], "assess": [ 34 ], "whether": [ 35 ], "specific": [ 36 ], "genetic": [ 37, 75, 118 ], "variants": [ 38 ], "1R": [ 41, 79, 147, 214, 241, 271, 280 ], "or": [ 42, 59, 104, 162 ], "TCF": [ 43, 82, 228 ], "7L2": [ 44, 83, 229 ], "are": [ 45 ], "associated": [ 46, 244 ], "delayed": [ 48 ], "and": [ 50, 81, 89, 120, 134, 181, 194, 256 ], "weight": [ 51, 90, 133, 209, 274 ], "obese": [ 54, 70 ], "patients": [ 55 ], "treated": [ 56 ], "liraglutide": [ 58, 163, 255 ], "short\u2010acting": [ 61 ], "agonist,": [ 64 ], "exenatide.": [ 65, 257 ], "Methods": [ 66 ], "We": [ 67 ], "evaluated": [ 68, 95 ], "individuals": [ 71 ], "associations": [ 73 ], "variations": [ 76 ], "(rs6923761)": [ 80, 242, 272 ], "(rs7903146)": [ 84, 230 ], "on": [ 85, 212 ], "T": [ 87, 136, 169, 250 ], "1/2": [ 88, 137, 170, 251 ], "from": [ 91 ], "two": [ 92 ], "trials": [ 93 ], "that": [ 94, 269 ], "separately": [ 96 ], "exenatide,": [ 97 ], "5": [ 98, 110, 218 ], "\u03bcg": [ 99 ], "BID": [ 100 ], "for": [ 101, 109 ], "30": [ 102 ], "days,": [ 103 ], "3": [ 106 ], "mg": [ 107 ], "daily": [ 108 ], "weeks.": [ 111 ], "Data": [ 112 ], "were": [ 113, 223 ], "analyzed": [ 114 ], "using": [ 115 ], "dominant": [ 117 ], "model": [ 119 ], "intention\u2010to\u2010treat": [ 121 ], "analysis.": [ 122 ], "Key": [ 123 ], "Results": [ 124 ], "There": [ 125, 203, 222 ], "a": [ 127, 205 ], "significant": [ 128, 225 ], "correlation": [ 129 ], "between": [ 130 ], "changes": [ 131 ], "r": [ 139 ], "s": [ 140 ], "=": [ 141, 144, 201 ], "\u2212.382,": [ 142 ], "P": [ 143, 200 ], ".004).": [ 145 ], "rs6923761": [ 148, 215 ], "minor": [ 149, 236 ], "allele": [ 150, 238 ], "A": [ 151, 237 ], "AA": [ 153 ], "_": [ 154 ], "AG": [ 155 ], ")": [ 156 ], "carriers": [ 157 ], "who": [ 158 ], "received": [ 159 ], "either": [ 160 ], "exenatide": [ 161 ], "had": [ 164 ], "greater": [ 165, 246 ], "relative": [ 171 ], "baseline": [ 173 ], "(117.9": [ 174 ], "\u00b1": [ 175, 183, 191, 196 ], "27.5": [ 176 ], "[": [ 177 ], "SEM": [ 178 ], "]": [ 179 ], "minutes": [ 180, 193 ], "128.9": [ 182 ], "38.32": [ 184 ], "minutes)": [ 185 ], "compared": [ 186 ], "GG": [ 188 ], "genotype": [ 189, 216 ], "(95.8": [ 190 ], "30.4": [ 192 ], "61.4": [ 195 ], "21.4": [ 197 ], "minutes,": [ 198 ], "respectively;": [ 199 ], ".11).": [ 202 ], "non\u2010significant": [ 206 ], "difference": [ 207 ], "based": [ 211 ], "after": [ 217 ], "weeks": [ 219 ], "treatment.": [ 221 ], "no": [ 224 ], "correlations": [ 226 ], "genotype.": [ 231 ], "Conclusions": [ 232 ], "&": [ 233 ], "Inferences": [ 234 ], "These": [ 258 ], "studies": [ 259 ], "provide": [ 260 ], "data": [ 261 ], "plan": [ 263 ], "pharmacogenetics": [ 264 ], "testing": [ 265 ], "hypothesis": [ 268 ], "influences": [ 273 ], "agonists.": [ 281 ] }, "publication_date": "2018-02-28", "publication_year": 2018, "type": "article", "cited_by_count": 58, "authors": [ { "id": "https://openalex.org/A5046389819", "display_name": "Victor Chedid" }, { "id": "https://openalex.org/A5040247973", "display_name": "Prakhar Vijayvargiya" }, { "id": "https://openalex.org/A5107828987", "display_name": "Paula Carlson" }, { "id": "https://openalex.org/A5063171591", "display_name": "Kathleen Van Malderen" }, { "id": "https://openalex.org/A5060455870", "display_name": "Andr\u00e9s Acosta" }, { "id": "https://openalex.org/A5055945168", "display_name": "Alan R. Zinsmeister" }, { "id": "https://openalex.org/A5001729912", "display_name": "Michael Camilleri" } ] }, { "id": "https://openalex.org/W4289868569", "doi": "https://doi.org/10.1111/dom.14831", "title": "Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective", "abstract": { "Abstract": [ 0 ], "Tirzepatide": [ 1, 171 ], "is": [ 2 ], "a": [ 3, 98, 176, 190, 211 ], "novel": [ 4 ], "glucose\u2010dependent": [ 5 ], "insulinotropic": [ 6 ], "polypeptide/glucagon\u2010like": [ 7 ], "peptide": [ 8 ], "1": [ 9, 169 ], "(GLP\u20101)": [ 10 ], "receptor": [ 11, 166, 198 ], "agonist": [ 12, 167, 199 ], "approved": [ 13 ], "in": [ 14, 29, 40, 110, 139, 224 ], "the": [ 15, 49, 164, 196, 215 ], "United": [ 16 ], "States": [ 17 ], "as": [ 18, 92, 135, 137, 148 ], "an": [ 19 ], "adjunct": [ 20 ], "to": [ 21, 25, 77, 122, 125, 132, 195 ], "diet": [ 22 ], "and": [ 23, 35, 48, 61, 63, 80, 89, 128, 153, 188, 221 ], "exercise": [ 24 ], "improve": [ 26 ], "glycaemic": [ 27 ], "control": [ 28 ], "adults": [ 30, 225 ], "with": [ 31, 57, 103, 115, 143, 163, 175, 226 ], "type": [ 32, 104, 227 ], "2": [ 33, 105, 228 ], "diabetes": [ 34 ], "under": [ 36 ], "investigation": [ 37 ], "for": [ 38, 214 ], "use": [ 39 ], "chronic": [ 41 ], "weight": [ 42, 130, 223 ], "management,": [ 43 ], "major": [ 44 ], "adverse": [ 45 ], "cardiovascular": [ 46 ], "events": [ 47 ], "management": [ 50 ], "of": [ 51, 82, 101, 108, 118, 179, 218 ], "other": [ 52 ], "conditions,": [ 53 ], "including": [ 54 ], "heart": [ 55 ], "failure": [ 56 ], "preserved": [ 58 ], "ejection": [ 59 ], "fraction": [ 60 ], "obesity": [ 62 ], "non\u2010cirrhotic": [ 64 ], "non\u2010alcoholic": [ 65 ], "steatohepatitis.": [ 66 ], "The": [ 67 ], "Phase": [ 68 ], "3": [ 69 ], "SURPASS": [ 70 ], "1\u20105": [ 71 ], "clinical": [ 72, 111, 205 ], "trial": [ 73 ], "programme": [ 74 ], "was": [ 75, 113, 172 ], "designed": [ 76 ], "assess": [ 78 ], "efficacy": [ 79 ], "safety": [ 81, 193 ], "once\u2010weekly": [ 83 ], "subcutaneously": [ 84 ], "injected": [ 85 ], "tirzepatide": [ 86, 109, 209 ], "(5,": [ 87 ], "10": [ 88 ], "15": [ 90 ], "mg),": [ 91 ], "monotherapy": [ 93 ], "or": [ 94, 185 ], "combination": [ 95 ], "therapy,": [ 96 ], "across": [ 97 ], "broad": [ 99 ], "spectrum": [ 100 ], "people": [ 102 ], "diabetes.": [ 106, 229 ], "Use": [ 107 ], "studies": [ 112 ], "associated": [ 114, 142 ], "marked": [ 116 ], "reductions": [ 117, 138, 159 ], "glycated": [ 119, 219 ], "haemoglobin": [ 120, 220 ], "(\u22121.87": [ 121 ], "\u22122.59%,": [ 123 ], "\u221220": [ 124 ], "\u221228": [ 126 ], "mmol/mol)": [ 127 ], "body": [ 129, 222 ], "(\u22126.2": [ 131 ], "\u221212.9": [ 133 ], "kg),": [ 134 ], "well": [ 136, 173 ], "parameters": [ 140 ], "commonly": [ 141 ], "heightened": [ 144 ], "cardiometabolic": [ 145 ], "risk": [ 146, 178 ], "such": [ 147 ], "blood": [ 149 ], "pressure,": [ 150 ], "visceral": [ 151 ], "adiposity": [ 152 ], "circulating": [ 154 ], "triglycerides.": [ 155 ], "In": [ 156 ], "SUPRASS\u20102,": [ 157 ], "these": [ 158, 204 ], "were": [ 160 ], "greater": [ 161 ], "than": [ 162 ], "GLP\u20101": [ 165, 197 ], "semaglutide": [ 168 ], "mg.": [ 170 ], "tolerated,": [ 174 ], "low": [ 177 ], "hypoglycaemia": [ 180 ], "when": [ 181 ], "used": [ 182 ], "without": [ 183 ], "insulin": [ 184, 186 ], "secretagogues": [ 187 ], "showed": [ 189 ], "generally": [ 191 ], "similar": [ 192 ], "profile": [ 194 ], "class.": [ 200 ], "Accordingly,": [ 201 ], "evidence": [ 202 ], "from": [ 203 ], "trials": [ 206 ], "suggests": [ 207 ], "that": [ 208 ], "offers": [ 210 ], "new": [ 212 ], "opportunity": [ 213 ], "effective": [ 216 ], "lowering": [ 217 ] }, "publication_date": "2022-08-05", "publication_year": 2022, "type": "review", "cited_by_count": 92, "authors": [ { "id": "https://openalex.org/A5032977803", "display_name": "Christophe De Block" }, { "id": "https://openalex.org/A5031933657", "display_name": "Clifford J. Bailey" }, { "id": "https://openalex.org/A5040652845", "display_name": "Carol Wysham" }, { "id": "https://openalex.org/A5085357286", "display_name": "Andrea Hemmingway" }, { "id": "https://openalex.org/A5040437831", "display_name": "Sheryl Allen" }, { "id": "https://openalex.org/A5077787771", "display_name": "Jennifer Peleshok" } ] }, { "id": "https://openalex.org/W3192357907", "doi": "https://doi.org/10.2165/00003495-200565120-00008", "title": "Exenatide", "abstract": null, "publication_date": "2005-01-01", "publication_year": 2005, "type": "article", "cited_by_count": 60, "authors": [ { "id": "https://openalex.org/A5020417840", "display_name": "Gillian M. Keating" } ] }, { "id": "https://openalex.org/W2786178453", "doi": "https://doi.org/10.1007/s40265-018-0871-0", "title": "Semaglutide: First Global Approval", "abstract": null, "publication_date": "2018-01-23", "publication_year": 2018, "type": "review", "cited_by_count": 88, "authors": [ { "id": "https://openalex.org/A5111640949", "display_name": "Sohita Dhillon" } ] }, { "id": "https://openalex.org/W1643809894", "doi": "https://doi.org/10.1371/journal.pone.0126769", "title": "The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis", "abstract": { "This": [ 0 ], "review": [ 1 ], "provides": [ 2 ], "evidence": [ 3 ], "that": [ 4 ], "glucagon-like": [ 5 ], "peptide-1": [ 6 ], "receptor": [ 7, 37 ], "agonist": [ 8 ], "therapies": [ 9 ], "are": [ 10 ], "associated": [ 11 ], "with": [ 12, 20, 24 ], "weight": [ 13, 28 ], "loss": [ 14, 29 ], "in": [ 15, 27 ], "overweight": [ 16 ], "or": [ 17 ], "obese": [ 18 ], "patients": [ 19 ], "type": [ 21 ], "2": [ 22 ], "diabetes": [ 23 ], "no": [ 25 ], "difference": [ 26 ], "seen": [ 30 ], "between": [ 31 ], "the": [ 32 ], "different": [ 33 ], "types": [ 34 ], "of": [ 35 ], "GLP-1": [ 36 ], "agonists": [ 38 ], "assessed.": [ 39 ] }, "publication_date": "2015-06-29", "publication_year": 2015, "type": "review", "cited_by_count": 164, "authors": [ { "id": "https://openalex.org/A5032207160", "display_name": "Jessica Potts" }, { "id": "https://openalex.org/A5015345040", "display_name": "Laura J. Gray" }, { "id": "https://openalex.org/A5045843829", "display_name": "Emer M. Brady" }, { "id": "https://openalex.org/A5083222970", "display_name": "Kamlesh Khunti" }, { "id": "https://openalex.org/A5084593004", "display_name": "Melanie J. Davies" }, { "id": "https://openalex.org/A5069545975", "display_name": "Danielle H. Bodicoat" } ] }, { "id": "https://openalex.org/W4388463113", "doi": "https://doi.org/10.1016/j.cgh.2023.11.002", "title": "AGA Rapid Clinical Practice Update on the Management of Patients Taking GLP-1 Receptor Agonists Prior to Endoscopy: Communication", "abstract": null, "publication_date": "2023-11-07", "publication_year": 2023, "type": "article", "cited_by_count": 107, "authors": [ { "id": "https://openalex.org/A5091185024", "display_name": "Jana G. Hashash" }, { "id": "https://openalex.org/A5051425820", "display_name": "Christopher C. Thompson" }, { "id": "https://openalex.org/A5042165140", "display_name": "Andrew Y. Wang" } ] }, { "id": "https://openalex.org/W2012506661", "doi": "https://doi.org/10.4158/ep.13.5.444", "title": "Exenatide Therapy in Obese Patients With Type 2 Diabetes Mellitus Treated with Insulin", "abstract": null, "publication_date": "2007-01-01", "publication_year": 2007, "type": "article", "cited_by_count": 141, "authors": [ { "id": "https://openalex.org/A5108978199", "display_name": "Prabhakar Viswanathan" }, { "id": "https://openalex.org/A5113664206", "display_name": "Ajay Chaudhuri" }, { "id": "https://openalex.org/A5045128736", "display_name": "Ruchi Bhatia" }, { "id": "https://openalex.org/A5026148401", "display_name": "Fida Al-Atrash" }, { "id": "https://openalex.org/A5110005088", "display_name": "Priya Mohanty" }, { "id": "https://openalex.org/A5032877471", "display_name": "Paresh Dandona" } ] }, { "id": "https://openalex.org/W2104788765", "doi": "https://doi.org/10.1530/eje-11-0330", "title": "Liraglutide as additional treatment for type 1 diabetes", "abstract": { "Objective": [ 0 ], "To": [ 1 ], "determine": [ 2 ], "whether": [ 3 ], "the": [ 4, 57, 69, 126, 144, 211 ], "addition": [ 5 ], "of": [ 6, 113, 128 ], "liraglutide": [ 7, 52, 172 ], "to": [ 8, 10, 18, 86, 95, 119, 133, 149, 160, 204, 238 ], "insulin": [ 9, 47, 146, 157, 188 ], "treat": [ 11 ], "patients": [ 12, 35, 167 ], "with": [ 13, 36, 51, 171 ], "type": [ 14, 38, 232 ], "1": [ 15, 39, 54, 82, 107, 233 ], "diabetes": [ 16, 40 ], "leads": [ 17, 237 ], "an": [ 19, 224 ], "improvement": [ 20 ], "in": [ 21, 143, 231 ], "glycemic": [ 22, 26, 182, 229 ], "control": [ 23, 230 ], "and": [ 24, 29, 45, 74, 92, 125, 155, 184, 186 ], "diminish": [ 25 ], "variability.": [ 27 ], "Subjects": [ 28 ], "methods": [ 30 ], "In": [ 31, 67, 166 ], "this": [ 32 ], "study,": [ 33 ], "14": [ 34, 58, 70 ], "well-controlled": [ 37 ], "on": [ 41 ], "continuous": [ 42 ], "glucose": [ 43, 77, 114, 180 ], "monitoring": [ 44 ], "intensive": [ 46 ], "therapy": [ 48, 62, 170 ], "were": [ 49 ], "treated": [ 50 ], "for": [ 53, 63, 173, 227 ], "week.": [ 55, 108 ], "Of": [ 56 ], "patients,": [ 59, 71 ], "eight": [ 60 ], "continued": [ 61, 169 ], "24": [ 64, 174, 200 ], "weeks.": [ 65 ], "Results": [ 66 ], "all": [ 68 ], "mean": [ 72, 75, 110, 176, 178 ], "fasting": [ 73 ], "weekly": [ 76, 179 ], "concentrations": [ 78, 115 ], "significantly": [ 79, 104, 191, 198 ], "decreased": [ 80, 116, 130, 192, 197 ], "after": [ 81 ], "week": [ 83 ], "from": [ 84, 93, 117, 131, 147, 158, 202 ], "130\u00b110": [ 85 ], "110\u00b18": [ 87 ], "mg/dl": [ 88, 97, 121 ], "(": [ 89, 98, 122, 135, 152, 163, 193, 206, 217 ], "P": [ 90, 99, 123, 136, 153, 164, 194, 207, 218 ], "<0.01)": [ 91, 100, 124, 154 ], "137.5\u00b120": [ 94 ], "115\u00b112": [ 96 ], "respectively.": [ 101 ], "Glycemic": [ 102 ], "excursions": [ 103 ], "improved": [ 105 ], "at": [ 106, 199 ], "The": [ 109 ], "s.d": [ 111 ], ".": [ 112 ], "56\u00b110": [ 118 ], "26\u00b16": [ 120 ], "coefficient": [ 127 ], "variation": [ 129 ], "39.6\u00b110": [ 132 ], "22.6\u00b17": [ 134 ], "<0.01).": [ 137, 165, 195 ], "There": [ 138 ], "was": [ 139 ], "a": [ 140 ], "concomitant": [ 141 ], "fall": [ 142 ], "basal": [ 145, 185 ], "24.5\u00b16": [ 148 ], "16.5\u00b16": [ 150 ], "units": [ 151, 162 ], "bolus": [ 156, 187 ], "22.5\u00b14": [ 159 ], "15.5\u00b14": [ 161 ], "who": [ 168 ], "weeks,": [ 175 ], "fasting,": [ 177 ], "concentrations,": [ 181 ], "excursions,": [ 183 ], "dose": [ 189 ], "also": [ 190, 236 ], "HbA1c": [ 196 ], "weeks": [ 201 ], "6.5": [ 203 ], "6.1%": [ 205 ], "=0.02),": [ 208 ], "as": [ 209 ], "did": [ 210 ], "body": [ 212 ], "weight": [ 213, 239 ], "by": [ 214 ], "4.5\u00b11.5": [ 215 ], "kg": [ 216 ], "=0.02).": [ 219 ], "Conclusion": [ 220 ], "Liraglutide": [ 221 ], "treatment": [ 222 ], "provides": [ 223 ], "additional": [ 225 ], "strategy": [ 226 ], "improving": [ 228 ], "diabetes.": [ 234 ], "It": [ 235 ], "loss.": [ 240 ] }, "publication_date": "2011-06-07", "publication_year": 2011, "type": "article", "cited_by_count": 128, "authors": [ { "id": "https://openalex.org/A5025793502", "display_name": "Ajay Varanasi" }, { "id": "https://openalex.org/A5047580485", "display_name": "Natalie Bellini" }, { "id": "https://openalex.org/A5110198781", "display_name": "Deepti Rawal" }, { "id": "https://openalex.org/A5067479908", "display_name": "Mehul Vora" }, { "id": "https://openalex.org/A5069086977", "display_name": "Antoine Makdissi" }, { "id": "https://openalex.org/A5021182210", "display_name": "Sandeep Dhindsa" }, { "id": "https://openalex.org/A5113664206", "display_name": "Ajay Chaudhuri" }, { "id": "https://openalex.org/A5032877471", "display_name": "Paresh Dandona" } ] }, { "id": "https://openalex.org/W2163293377", "doi": null, "title": "Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus.", "abstract": { "Lixisenatide,": [ 0 ], "under": [ 1 ], "development": [ 2 ], "by": [ 3, 45 ], "sanofi-aventis,": [ 4 ], "is": [ 5, 39 ], "a": [ 6, 57, 139 ], "novel": [ 7 ], "human": [ 8, 54, 62 ], "glucagon-like": [ 9 ], "peptide-1": [ 10 ], "receptor": [ 11 ], "(GLP-1R)": [ 12 ], "agonist": [ 13 ], "for": [ 14, 155, 173, 183 ], "the": [ 15, 158, 180 ], "treatment": [ 16, 181 ], "of": [ 17, 28, 74, 142, 149, 157, 161 ], "type": [ 18 ], "2": [ 19 ], "diabetes": [ 20 ], "mellitus": [ 21 ], "(T2DM;": [ 22 ], "non-insulin": [ 23 ], "dependent": [ 24 ], "diabetes).": [ 25 ], "The": [ 26, 147 ], "structure": [ 27 ], "lixisenatide,": [ 29 ], "based": [ 30 ], "on": [ 31, 163 ], "exendin-4(1-39)": [ 32 ], "modified": [ 33 ], "C-terminally": [ 34 ], "with": [ 35, 56, 88, 124, 133 ], "six": [ 36 ], "Lys": [ 37 ], "residues,": [ 38 ], "able": [ 40 ], "to": [ 41, 53, 118 ], "withstand": [ 42 ], "physiological": [ 43 ], "degradation": [ 44 ], "dipeptidyl": [ 46 ], "peptidase": [ 47 ], "IV.": [ 48 ], "In": [ 49, 66, 86, 96 ], "vitro,": [ 50 ], "lixisenatide": [ 51, 76, 92, 102, 162, 172 ], "bound": [ 52 ], "GLP-1R": [ 55, 177 ], "greater": [ 58 ], "affinity": [ 59 ], "than": [ 60 ], "native": [ 61 ], "GLP-1": [ 63 ], "(7-36": [ 64 ], "amide).": [ 65 ], "various": [ 67 ], "in": [ 68, 71, 107, 179 ], "vitro": [ 69 ], "and": [ 70, 80, 110, 166 ], "vivo": [ 72 ], "models": [ 73 ], "T2DM,": [ 75, 89 ], "improved": [ 77, 103 ], "glycemic": [ 78, 164 ], "measures": [ 79, 165 ], "demonstrated": [ 81 ], "promising": [ 82 ], "pancreatic": [ 83 ], "beta-cell-preserving": [ 84 ], "actions.": [ 85 ], "patients": [ 87, 117 ], "subcutaneously": [ 90 ], "administered": [ 91 ], "displayed": [ 93 ], "linear": [ 94 ], "pharmacokinetics.": [ 95 ], "two": [ 97 ], "phase": [ 98, 150 ], "II": [ 99 ], "clinical": [ 100 ], "trials,": [ 101 ], "glucose": [ 104 ], "tolerance,": [ 105 ], "resulted": [ 106 ], "weight": [ 108 ], "loss": [ 109 ], "lowered": [ 111 ], "HbA1C,": [ 112 ], "thereby": [ 113 ], "causing": [ 114 ], "significantly": [ 115 ], "more": [ 116 ], "achieve": [ 119 ], "target": [ 120 ], "HbA1C": [ 121 ], "levels": [ 122 ], "compared": [ 123 ], "placebo.": [ 125 ], "Lixisenatide": [ 126 ], "exhibited": [ 127 ], "well-established": [ 128 ], "GLP-1-related": [ 129 ], "gastrointestinal": [ 130 ], "side": [ 131 ], "effects,": [ 132 ], "mild": [ 134 ], "nausea": [ 135 ], "occurring": [ 136 ], "most": [ 137 ], "frequently;": [ 138 ], "low": [ 140 ], "frequency": [ 141 ], "hypoglycemia": [ 143 ], "was": [ 144 ], "also": [ 145 ], "reported.": [ 146 ], "results": [ 148, 169 ], "III": [ 151 ], "trials": [ 152 ], "are": [ 153 ], "awaited": [ 154 ], "confirmation": [ 156 ], "anticipated": [ 159 ], "effects": [ 160 ], "weight;": [ 167 ], "favorable": [ 168 ], "would": [ 170 ], "place": [ 171 ], "consideration": [ 174 ], "among": [ 175 ], "other": [ 176 ], "agonists": [ 178 ], "armamentarium": [ 182 ], "T2DM.": [ 184 ] }, "publication_date": "2009-08-01", "publication_year": 2009, "type": "article", "cited_by_count": 75, "authors": [ { "id": "https://openalex.org/A5051382562", "display_name": "Mikkel Christensen" }, { "id": "https://openalex.org/A5079352451", "display_name": "Filip K. Knop" }, { "id": "https://openalex.org/A5085434984", "display_name": "Jens J. Holst" }, { "id": "https://openalex.org/A5004120950", "display_name": "Tina Vilsb\u00f8ll" } ] }, { "id": "https://openalex.org/W2009155872", "doi": "https://doi.org/10.1210/jc.2008-0115", "title": "Comparison of Single and Combined Treatment with Exenatide and Metformin on Menstrual Cyclicity in Overweight Women with Polycystic Ovary Syndrome", "abstract": { "Abstract": [ 0 ], "Context:": [ 1 ], "Insulin": [ 2 ], "resistance": [ 3 ], "and": [ 4, 17, 29, 39, 43, 54, 65, 131, 159, 163, 166, 198, 200, 219, 244 ], "obesity": [ 5 ], "are": [ 6, 237 ], "common": [ 7 ], "features": [ 8 ], "of": [ 9, 19, 32, 84, 234, 246 ], "the": [ 10, 139, 212, 241 ], "polycystic": [ 11 ], "ovary": [ 12 ], "syndrome": [ 13 ], "(PCOS).": [ 14 ], "Weight": [ 15 ], "loss": [ 16, 178 ], "use": [ 18 ], "insulin-lowering": [ 20 ], "drugs": [ 21 ], "have": [ 22 ], "been": [ 23 ], "shown": [ 24 ], "to": [ 25, 82, 145, 239 ], "improve": [ 26 ], "both": [ 27 ], "reproductive": [ 28, 215 ], "metabolic": [ 30, 52, 201 ], "aspects": [ 31 ], "PCOS.": [ 33, 62, 254 ], "Objective:": [ 34 ], "We": [ 35 ], "evaluated": [ 36 ], "exenatide": [ 37 ], "(EX)": [ 38 ], "metformin": [ 40 ], "(MET),": [ 41 ], "alone": [ 42, 193 ], "in": [ 44, 57, 122, 150, 175, 206, 214, 222, 250 ], "combination": [ 45 ], "(COM),": [ 46 ], "on": [ 47, 194 ], "menstrual": [ 48, 115, 152, 195 ], "cyclicity,": [ 49, 153 ], "hormonal": [ 50, 199 ], "parameters,": [ 51, 218 ], "profiles,": [ 53 ], "inflammatory": [ 55, 132 ], "markers": [ 56 ], "overweight,": [ 58 ], "insulin-resistant": [ 59 ], "women": [ 60, 70, 225, 252 ], "with": [ 61, 71, 226, 229, 253 ], "Design,": [ 63 ], "Setting,": [ 64 ], "Participants:": [ 66 ], "Sixty": [ 67 ], "overweight": [ 68, 224, 251 ], "oligoovulatory": [ 69 ], "PCOS": [ 72, 227 ], "(body": [ 73 ], "mass": [ 74 ], "index": [ 75 ], "&gt;": [ 76 ], "27;": [ 77 ], "18\u201340": [ 78 ], "yr)": [ 79 ], "were": [ 80, 172 ], "randomized": [ 81 ], "one": [ 83 ], "three": [ 85 ], "treatment": [ 86 ], "groups:": [ 87 ], "MET": [ 88, 148, 180, 192 ], "[1000": [ 89 ], "mg": [ 90, 102 ], "twice": [ 91 ], "daily": [ 92 ], "(BID)],": [ 93 ], "EX": [ 94, 104, 146, 170, 190 ], "(10": [ 95 ], "\u03bcg": [ 96, 106 ], "BID),": [ 97 ], "or": [ 98, 147, 191 ], "COM": [ 99, 141, 185, 230 ], "(MET": [ 100 ], "1000": [ 101 ], "BID,": [ 103 ], "10": [ 105 ], "BID)": [ 107 ], "for": [ 108 ], "24": [ 109 ], "wk.": [ 110 ], "The": [ 111 ], "primary": [ 112 ], "outcome": [ 113, 118 ], "was": [ 114, 143 ], "frequency;": [ 116 ], "secondary": [ 117 ], "measures": [ 119, 162 ], "included": [ 120 ], "changes": [ 121 ], "ovulation": [ 123, 154 ], "rate,": [ 124, 155 ], "insulin": [ 125, 160 ], "action,": [ 126 ], "anthropometric": [ 127 ], "measures,": [ 128 ], "androgen": [ 129, 157 ], "levels,": [ 130 ], "markers.": [ 133 ], "Results:": [ 134 ], "Forty-two": [ 135 ], "(70%)": [ 136 ], "patients": [ 137 ], "completed": [ 138 ], "study.": [ 140 ], "therapy": [ 142, 249 ], "superior": [ 144 ], "monotherapy": [ 149 ], "improving": [ 151 ], "free": [ 156 ], "index,": [ 158 ], "sensitivity": [ 161 ], "reducing": [ 164 ], "weight": [ 165, 177 ], "abdominal": [ 167 ], "fat.": [ 168 ], "Both": [ 169 ], "arms": [ 171 ], "more": [ 173 ], "effective": [ 174 ], "promoting": [ 176 ], "than": [ 179, 188 ], "(P": [ 181 ], "=": [ 182 ], "0.003).": [ 183 ], "Conclusions:": [ 184 ], "appears": [ 186 ], "better": [ 187 ], "either": [ 189 ], "cycle": [ 196 ], "frequency": [ 197 ], "derangements.": [ 202 ], "A": [ 203 ], "marked": [ 204 ], "decrease": [ 205 ], "central": [ 207 ], "adiposity": [ 208 ], "could": [ 209 ], "partly": [ 210 ], "explain": [ 211 ], "improvements": [ 213 ], "function,": [ 216 ], "insulin-glucose": [ 217 ], "adiponectin": [ 220 ], "observed": [ 221 ], "these": [ 223 ], "treated": [ 228 ], "therapy.": [ 231 ], "Larger": [ 232 ], "trials": [ 233 ], "longer": [ 235 ], "duration": [ 236 ], "warranted": [ 238 ], "assess": [ 240 ], "long-term": [ 242 ], "efficacy": [ 243 ], "safety": [ 245 ], "combined": [ 247 ], "EX-MET": [ 248 ] }, "publication_date": "2008-05-07", "publication_year": 2008, "type": "article", "cited_by_count": 256, "authors": [ { "id": "https://openalex.org/A5051058058", "display_name": "Karen Elkind\u2010Hirsch" }, { "id": "https://openalex.org/A5068311949", "display_name": "Ory Marrioneaux" }, { "id": "https://openalex.org/A5103775441", "display_name": "Madhu Bhushan" }, { "id": "https://openalex.org/A5076900516", "display_name": "Denise Vernor" }, { "id": "https://openalex.org/A5111788980", "display_name": "Rajat Bhushan" } ] }, { "id": "https://openalex.org/W3023598453", "doi": "https://doi.org/10.3892/etm.2020.8714", "title": "Metabolic and cardiovascular benefits of GLP\u20111 agonists, besides the hypoglycemic effect (Review)", "abstract": { "Patients": [ 0 ], "with": [ 1, 36, 71, 80, 92, 109, 122, 214 ], "type": [ 2, 110, 210 ], "2": [ 3, 111, 211 ], "diabetes": [ 4, 212 ], "exhibit": [ 5 ], "higher": [ 6 ], "cardiovascular": [ 7, 57, 76, 98, 120, 126, 132, 216 ], "risk": [ 8, 217 ], "than": [ 9, 62 ], "normal": [ 10 ], "individuals.": [ 11 ], "Optimal": [ 12 ], "blood": [ 13, 147, 167 ], "glucose": [ 14 ], "levels": [ 15 ], "are": [ 16, 196 ], "rarely": [ 17 ], "achieved": [ 18 ], "in": [ 19, 107, 119, 209, 222 ], "diabetic": [ 20 ], "patients.": [ 21 ], "Glucagon-like": [ 22 ], "peptide-1": [ 23 ], "receptor": [ 24 ], "agonists": [ 25 ], "(GLP-1": [ 26 ], "RAs)": [ 27 ], "have": [ 28, 42 ], "emerged": [ 29 ], "as": [ 30, 90, 206, 219 ], "a": [ 31, 72, 81, 117 ], "new": [ 32, 54 ], "antidiabetic": [ 33 ], "drug": [ 34 ], "class": [ 35, 55 ], "multiple": [ 37 ], "metabolic": [ 38, 100 ], "effects.": [ 39 ], "Some": [ 40 ], "trials": [ 41, 129, 195 ], "evaluated": [ 43 ], "their": [ 44 ], "safety,": [ 45 ], "but": [ 46, 192 ], "it": [ 47 ], "has": [ 48, 56 ], "been": [ 49 ], "recently": [ 50 ], "demonstrated": [ 51, 116, 143, 183 ], "that": [ 52 ], "this": [ 53 ], "benefits,": [ 58 ], "through": [ 59 ], "other": [ 60 ], "mechanisms": [ 61 ], "glycemic": [ 63 ], "control.": [ 64 ], "The": [ 65 ], "use": [ 66 ], "of": [ 67, 75, 102, 137, 146, 154, 166 ], "GLP-1RAs": [ 68 ], "was": [ 69 ], "associated": [ 70 ], "significant": [ 73 ], "reduction": [ 74, 118, 151 ], "and": [ 77, 99, 114, 134, 141, 152, 161, 174, 178 ], "all-cause": [ 78 ], "mortality,": [ 79 ], "safe": [ 82 ], "profile": [ 83 ], "related": [ 84 ], "to": [ 85, 225 ], "pancreatitis": [ 86 ], "or": [ 87, 218 ], "thyroid": [ 88 ], "cancer,": [ 89 ], "compared": [ 91 ], "placebo.": [ 93 ], "This": [ 94 ], "review": [ 95 ], "presents": [ 96 ], "the": [ 97, 131, 144, 170, 176, 199 ], "benefits": [ 101, 133 ], "GLP-1": [ 103, 204 ], "RAs": [ 104, 205 ], "versus": [ 105 ], "placebo,": [ 106 ], "patients": [ 108, 213, 223 ], "diabetes.": [ 112 ], "Semaglutide": [ 113 ], "liraglutide": [ 115, 142, 182 ], "events,": [ 121 ], "similar": [ 123 ], "rates": [ 124 ], "on": [ 125, 186 ], "mortality.": [ 127 ], "Ongoing": [ 128 ], "assess": [ 130 ], "side": [ 135 ], "effects": [ 136, 185 ], "dulaglutide": [ 138 ], "treatment.": [ 139 ], "Exenatide": [ 140 ], "decrease": [ 145 ], "pressure": [ 148 ], "values,": [ 149 ], "weight": [ 150 ], "improvement": [ 153, 165 ], "dyslipidemia.": [ 155 ], "Liraglutide": [ 156 ], "induced,": [ 157 ], "both": [ 158 ], "in": [ 159, 162 ], "vivo": [ 160 ], "vitro,": [ 163 ], "an": [ 164 ], "circulation,": [ 168 ], "increasing": [ 169 ], "nitric": [ 171 ], "oxide": [ 172 ], "level": [ 173 ], "inhibiting": [ 175 ], "adhesion": [ 177 ], "procoagulant": [ 179 ], "factors.": [ 180 ], "Also,": [ 181 ], "beneficial": [ 184 ], "cardiac": [ 187 ], "remodeling": [ 188 ], "after": [ 189 ], "myocardial": [ 190 ], "infarction,": [ 191 ], "more": [ 193 ], "large": [ 194 ], "required.": [ 197 ], "However,": [ 198 ], "international": [ 200 ], "guidelines": [ 201 ], "recommend": [ 202 ], "using": [ 203 ], "first-line": [ 207, 220 ], "therapy": [ 208 ], "high": [ 215 ], "agents": [ 221 ], "intolerant": [ 224 ], "metformin.": [ 226 ] }, "publication_date": "2020-05-05", "publication_year": 2020, "type": "review", "cited_by_count": 74, "authors": [ { "id": "https://openalex.org/A5084951190", "display_name": "Roua Iorga" }, { "id": "https://openalex.org/A5052246635", "display_name": "Nicolae Bacalba\u0219a" }, { "id": "https://openalex.org/A5011371139", "display_name": "Mara Car\u015fote" }, { "id": "https://openalex.org/A5008776276", "display_name": "Ovidiu Gabriel Bratu" }, { "id": "https://openalex.org/A5085278189", "display_name": "Ana Maria Alexandra St\u0103nescu" }, { "id": "https://openalex.org/A5069616412", "display_name": "Simona Bung\u0103u" }, { "id": "https://openalex.org/A5058297277", "display_name": "Carmen Panti\u0219" }, { "id": "https://openalex.org/A5035127360", "display_name": "Camelia Cristina Diaconu" } ] }, { "id": "https://openalex.org/W2003956196", "doi": "https://doi.org/10.1155/2011/898913", "title": "From Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy", "abstract": { "Promoting": [ 0 ], "long-term": [ 1 ], "adherence": [ 2 ], "to": [ 3, 178 ], "lifestyle": [ 4 ], "modification": [ 5 ], "and": [ 6, 16, 31, 49, 60, 66, 80, 87, 126, 160, 170 ], "choice": [ 7 ], "of": [ 8, 83, 91, 110, 147, 182, 190 ], "antidiabetic": [ 9 ], "agent": [ 10 ], "with": [ 11, 107, 152, 194 ], "low": [ 12 ], "hypoglycemia": [ 13, 111 ], "risk": [ 14, 109 ], "profile": [ 15, 19, 82 ], "positive": [ 17, 153 ], "weight": [ 18, 159 ], "could": [ 20 ], "be": [ 21 ], "the": [ 22, 78, 176, 180 ], "most": [ 23 ], "effective": [ 24 ], "strategy": [ 25 ], "in": [ 26, 32, 64, 67, 142, 162, 192 ], "achieving": [ 27 ], "sustained": [ 28 ], "glycemic": [ 29 ], "control": [ 30 ], "reducing": [ 33 ], "comorbidities.": [ 34 ], "From": [ 35 ], "this": [ 36, 55 ], "perspective,": [ 37 ], "vast": [ 38 ], "interest": [ 39 ], "has": [ 40 ], "been": [ 41 ], "generated": [ 42 ], "by": [ 43, 63 ], "glucagon-like": [ 44 ], "peptide-1": [ 45 ], "(GLP-1)": [ 46 ], "receptor": [ 47, 85, 124 ], "agonists": [ 48, 86, 125 ], "dipeptidyl": [ 50 ], "peptidase-4": [ 51 ], "inhibitors": [ 52 ], "(DPP-4i).": [ 53 ], "In": [ 54, 119 ], "review": [ 56 ], "our": [ 57 ], "ten-year": [ 58 ], "clinical": [ 59, 120 ], "laboratory": [ 61 ], "experience": [ 62 ], "vitro": [ 65 ], "vivo": [ 68 ], "studies": [ 69 ], "is": [ 70, 150, 186 ], "reported.": [ 71 ], "Herein,": [ 72 ], "we": [ 73 ], "reviewed": [ 74 ], "available": [ 75 ], "data": [ 76 ], "on": [ 77, 139, 157 ], "efficacy": [ 79 ], "safety": [ 81 ], "GLP-1": [ 84, 123 ], "DPP-4i.": [ 88 ], "The": [ 89, 145 ], "introduction": [ 90 ], "incretin": [ 92 ], "hormone-based": [ 93 ], "therapies": [ 94 ], "represents": [ 95 ], "a": [ 96, 187 ], "novel": [ 97 ], "therapeutic": [ 98 ], "strategy,": [ 99 ], "because": [ 100 ], "these": [ 101, 134, 148 ], "drugs": [ 102, 149 ], "not": [ 103 ], "only": [ 104 ], "improve": [ 105, 128 ], "glycemia": [ 106 ], "minimal": [ 108 ], "but": [ 112 ], "also": [ 113 ], "have": [ 114, 175 ], "other": [ 115 ], "extraglycemic": [ 116 ], "beneficial": [ 117 ], "effects.": [ 118 ], "studies,": [ 121 ], "both": [ 122 ], "DPP-4i,": [ 127 ], "\u03b2": [ 129 ], "cell": [ 130 ], "function": [ 131 ], "indexes.": [ 132 ], "All": [ 133 ], "agents": [ 135 ], "showed": [ 136 ], "trophic": [ 137 ], "effects": [ 138, 174 ], "beta-cell": [ 140 ], "mass": [ 141 ], "animal": [ 143 ], "studies.": [ 144 ], "use": [ 146 ], "associated": [ 151 ], "or": [ 154 ], "neucral": [ 155 ], "effect": [ 156 ], "body": [ 158 ], "improvements": [ 161 ], "blood": [ 163 ], "pressure,": [ 164 ], "diabetic": [ 165 ], "dyslipidemia,": [ 166 ], "hepatic": [ 167 ], "steazosis": [ 168 ], "markets,": [ 169 ], "myocardial": [ 171 ], "function.": [ 172 ], "These": [ 173 ], "potential": [ 177 ], "reduce": [ 179 ], "burden": [ 181 ], "cardiovascular": [ 183 ], "disease,": [ 184 ], "which": [ 185 ], "major": [ 188 ], "cause": [ 189 ], "mortality": [ 191 ], "patients": [ 193 ], "diabetes.": [ 195 ] }, "publication_date": "2011-01-01", "publication_year": 2011, "type": "review", "cited_by_count": 24, "authors": [ { "id": "https://openalex.org/A5014780759", "display_name": "Ilaria Dicembrini" }, { "id": "https://openalex.org/A5103211860", "display_name": "Laura Pala" }, { "id": "https://openalex.org/A5068223964", "display_name": "Carlo Maria Rotella" } ] }, { "id": "https://openalex.org/W2744010740", "doi": "https://doi.org/10.1002/ddr.21404", "title": "Recent Advances in GLP\u20101 Receptor Agonists for Use in Diabetes Mellitus", "abstract": { "ABSTRACT": [ 0 ], "Preclinical": [ 1 ], "Research": [ 2 ], "Mimetics": [ 3 ], "of": [ 4, 22, 27, 43, 66, 100, 117, 136, 156 ], "Glucagon\u2010like": [ 5 ], "peptide": [ 6 ], "1": [ 7 ], "(GLP\u20101)": [ 8 ], "represent": [ 9 ], "a": [ 10, 30, 88 ], "useful": [ 11 ], "alternative": [ 12 ], "or": [ 13, 49 ], "complementary": [ 14 ], "treatment": [ 15, 21, 76 ], "choice": [ 16 ], "to": [ 17, 47, 77, 96 ], "insulin": [ 18 ], "in": [ 19, 58, 108 ], "the": [ 20, 41, 98, 115, 134, 153, 164 ], "diabetes": [ 23 ], "mellitus.": [ 24 ], "The": [ 25 ], "lack": [ 26 ], "hypoglycemia": [ 28 ], "as": [ 29, 123, 161, 163 ], "side": [ 31 ], "effect": [ 32 ], "when": [ 33 ], "GLP\u20101": [ 34, 63, 101, 171 ], "receptor": [ 35, 172 ], "agonists": [ 36 ], "are": [ 37, 85, 121 ], "used": [ 38 ], "along": [ 39 ], "with": [ 40, 114, 139 ], "tendency": [ 42 ], "these": [ 44 ], "therapeutic": [ 45, 79 ], "agents": [ 46 ], "prevent": [ 48 ], "even": [ 50 ], "reduce": [ 51 ], "weight": [ 52 ], "gain": [ 53 ], "makes": [ 54 ], "them": [ 55 ], "valuable": [ 56 ], "targets": [ 57 ], "therapy": [ 59 ], "development.": [ 60 ], "However,": [ 61, 129 ], "native": [ 62 ], "and": [ 64, 158 ], "many": [ 65 ], "its": [ 67 ], "early": [ 68 ], "analogues": [ 69, 102, 160 ], "have": [ 70 ], "very": [ 71 ], "short": [ 72 ], "half\u2010lives,": [ 73 ], "requiring": [ 74 ], "repeated": [ 75 ], "maintain": [ 78 ], "levels.": [ 80 ], "As": [ 81 ], "all": [ 82 ], "current": [ 83 ], "treatments": [ 84 ], "injected": [ 86 ], "subcutaneously,": [ 87 ], "large": [ 89 ], "focus": [ 90 ], "has": [ 91, 111 ], "been": [ 92, 112 ], "made": [ 93 ], "on": [ 94, 133 ], "trying": [ 95 ], "extend": [ 97 ], "half\u2010lives": [ 99, 141 ], "while": [ 103 ], "retaining": [ 104 ], "bioactivity.": [ 105 ], "Most": [ 106 ], "success": [ 107 ], "this": [ 109 ], "regard": [ 110 ], "achieved": [ 113 ], "use": [ 116 ], "peptide\u2010protein": [ 118 ], "fusions,": [ 119 ], "which": [ 120 ], "not": [ 122 ], "well": [ 124, 162 ], "suited": [ 125 ], "for": [ 126, 147 ], "oral": [ 127, 148 ], "administration.": [ 128, 149 ], "recent": [ 130, 165 ], "work": [ 131, 166 ], "focused": [ 132 ], "development": [ 135 ], "non\u2010fusion": [ 137 ], "peptides": [ 138 ], "increased": [ 140 ], "that": [ 142 ], "may": [ 143 ], "be": [ 144 ], "more": [ 145 ], "appropriate": [ 146 ], "This": [ 150 ], "minireview": [ 151 ], "discusses": [ 152 ], "structural": [ 154 ], "characteristics": [ 155 ], "past": [ 157 ], "present": [ 159 ], "conducted": [ 167 ], "toward": [ 168 ], "developing": [ 169 ], "novel": [ 170 ], "agonists.": [ 173 ], "Drug": [ 174 ], "Dev": [ 175 ], "Res": [ 176 ], "78": [ 177 ], ":": [ 178 ], "292\u2013299,": [ 179 ], "2017.": [ 180 ], "\u00a9": [ 181 ], "2017": [ 182 ], "Wiley": [ 183 ], "Periodicals,": [ 184 ], "Inc.": [ 185 ] }, "publication_date": "2017-08-08", "publication_year": 2017, "type": "review", "cited_by_count": 26, "authors": [ { "id": "https://openalex.org/A5070080064", "display_name": "Dominic N. McBrayer" }, { "id": "https://openalex.org/A5070074639", "display_name": "Yftah Tal\u2010Gan" } ] }, { "id": "https://openalex.org/W2113064802", "doi": "https://doi.org/10.1100/2012/496453", "title": "The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone", "abstract": { "BACKGROUND.": [ 0 ], "Liraglutide": [ 1 ], "leading": [ 2 ], "to": [ 3, 27, 43, 106, 127 ], "improve": [ 4 ], "not": [ 5, 147 ], "only": [ 6 ], "glycaemic": [ 7 ], "control": [ 8 ], "but": [ 9, 186 ], "also": [ 10, 187 ], "liver": [ 11, 16, 190, 194 ], "inflammation": [ 12 ], "in": [ 13, 33, 111, 122, 142, 149 ], "non-alcoholic": [ 14 ], "fatty": [ 15 ], "disease": [ 17 ], "(NAFLD)": [ 18 ], "patients.": [ 19 ], "AIMS.": [ 20 ], "The": [ 21, 117 ], "aim": [ 22 ], "of": [ 23, 31, 80, 90, 158, 164, 182, 189, 193, 198 ], "this": [ 24 ], "study": [ 25 ], "is": [ 26 ], "elucidate": [ 28 ], "the": [ 29, 76, 88, 102, 134, 137 ], "effectiveness": [ 30 ], "liraglutide": [ 32, 112, 123, 159, 183 ], "NAFLD": [ 34, 53 ], "patients": [ 35, 54 ], "with": [ 36, 55 ], "type": [ 37 ], "2": [ 38 ], "diabetes": [ 39 ], "mellitus": [ 40 ], "(T2DM)": [ 41 ], "compared": [ 42, 75 ], "sitagliptin": [ 44, 150 ], "and": [ 45, 57, 83, 96, 114, 145, 196 ], "pioglitazone.": [ 46 ], "METHODS.": [ 47 ], "We": [ 48, 74 ], "retrospectively": [ 49 ], "enrolled": [ 50 ], "82": [ 51 ], "Japanese": [ 52 ], "T2DM": [ 56, 185 ], "divided": [ 58 ], "into": [ 59 ], "three": [ 60, 103 ], "groups": [ 61 ], "(liraglutide:": [ 62 ], "N": [ 63, 67, 71 ], "=": [ 64, 68, 72, 178 ], "26,": [ 65 ], "sitagliptin;": [ 66 ], "36,": [ 69 ], "pioglitazone;": [ 70 ], "20).": [ 73 ], "baseline": [ 77 ], "characteristics,": [ 78 ], "changes": [ 79 ], "laboratory": [ 81 ], "data": [ 82 ], "body": [ 84, 118, 138, 165, 199 ], "weight.": [ 85, 200 ], "RESULTS.": [ 86 ], "At": [ 87 ], "end": [ 89 ], "follow-up,": [ 91 ], "ALT,": [ 92 ], "fast": [ 93 ], "blood": [ 94 ], "glucose,": [ 95 ], "HbA1c": [ 97 ], "level": [ 98 ], "significantly": [ 99, 109, 120, 140 ], "improved": [ 100, 184 ], "among": [ 101 ], "groups.": [ 104 ], "AST": [ 105 ], "platelet": [ 107 ], "ratio": [ 108 ], "decreased": [ 110, 121 ], "group": [ 113, 124, 144 ], "pioglitazone": [ 115, 143 ], "group.": [ 116, 151 ], "weight": [ 119, 139, 166 ], "(81.8": [ 125 ], "kg": [ 126 ], "78.0": [ 128 ], "kg,": [ 129 ], "P": [ 130, 177 ], "<": [ 131 ], "0.01).": [ 132 ], "On": [ 133 ], "other": [ 135 ], "hands,": [ 136 ], "increased": [ 141 ], "did": [ 146 ], "change": [ 148 ], "Multivariate": [ 152 ], "regression": [ 153 ], "analysis": [ 154 ], "indicated": [ 155 ], "that": [ 156 ], "administration": [ 157 ], "as": [ 160 ], "an": [ 161 ], "independent": [ 162 ], "factor": [ 163 ], "reduction": [ 167, 197 ], "for": [ 168 ], "more": [ 169 ], "than": [ 170 ], "5%": [ 171 ], "(OR": [ 172 ], "9.04;": [ 173 ], "95%": [ 174 ], "CI": [ 175 ], "1.12-73.1,": [ 176 ], "0.04).": [ 179 ], "CONCLUSIONS.": [ 180 ], "Administration": [ 181 ], "improvement": [ 188 ], "inflammation,": [ 191 ], "alteration": [ 192 ], "fibrosis,": [ 195 ] }, "publication_date": "2012-01-01", "publication_year": 2012, "type": "article", "cited_by_count": 133, "authors": [ { "id": "https://openalex.org/A5052001303", "display_name": "Takamasa Ohki" }, { "id": "https://openalex.org/A5003380681", "display_name": "Akihiro Isogawa" }, { "id": "https://openalex.org/A5075887555", "display_name": "Masahiko Iwamoto" }, { "id": "https://openalex.org/A5057074085", "display_name": "Mitsuru Ohsugi" }, { "id": "https://openalex.org/A5103456139", "display_name": "Haruhiko Yoshida" }, { "id": "https://openalex.org/A5031521743", "display_name": "Nobuo Toda" }, { "id": "https://openalex.org/A5047174570", "display_name": "Kazumi Tagawa" }, { "id": "https://openalex.org/A5089860446", "display_name": "Masao Omata" }, { "id": "https://openalex.org/A5046522736", "display_name": "Kazuhiko Koike" } ] }, { "id": "https://openalex.org/W2568501181", "doi": "https://doi.org/10.1007/s13300-016-0219-2", "title": "Evaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom", "abstract": null, "publication_date": "2017-01-04", "publication_year": 2017, "type": "article", "cited_by_count": 18, "authors": [ { "id": "https://openalex.org/A5072605000", "display_name": "Barnaby Hunt" }, { "id": "https://openalex.org/A5100347568", "display_name": "Qing Ye" }, { "id": "https://openalex.org/A5037654589", "display_name": "William J. Valentine" }, { "id": "https://openalex.org/A5061425827", "display_name": "Donna Ashley" } ] }, { "id": "https://openalex.org/W4404574654", "doi": "https://doi.org/10.1093/ckj/sfae296", "title": "GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity", "abstract": { "ABSTRACT": [ 0 ], "Glucagon-like": [ 1 ], "peptide-1": [ 2 ], "receptor": [ 3 ], "agonists": [ 4 ], "(GLP-1": [ 5 ], "RAs)": [ 6 ], "have": [ 7 ], "emerged": [ 8 ], "as": [ 9, 72, 131, 133, 175, 228 ], "game-changers": [ 10 ], "across": [ 11 ], "the": [ 12, 190, 208 ], "cardiovascular\u2013kidney\u2013metabolic": [ 13 ], "(CKM)": [ 14 ], "spectrum:": [ 15 ], "overweight/obesity,": [ 16 ], "type": [ 17 ], "2": [ 18 ], "diabetes": [ 19, 137 ], "mellitus": [ 20 ], "(T2DM)": [ 21 ], "and": [ 22, 28, 34, 47, 76, 80, 92, 106, 111, 119, 126, 141, 169, 183, 215, 223, 225 ], "associated": [ 23, 67 ], "chronic": [ 24 ], "kidney": [ 25, 118, 161, 224 ], "disease": [ 26, 30 ], "(CKD)": [ 27 ], "cardiovascular": [ 29, 120, 226 ], "(CVD).": [ 31 ], "Liraglutide,": [ 32 ], "semaglutide": [ 33, 81 ], "tirzepatide": [ 35 ], "are": [ 36, 82 ], "European": [ 37 ], "Medicines": [ 38 ], "Agency": [ 39 ], "approved": [ 40, 83, 97 ], "to": [ 41, 48, 84, 98, 152, 196, 235 ], "improve": [ 42, 153, 160 ], "metabolic": [ 43, 154, 219 ], "control": [ 44 ], "in": [ 45, 51, 88, 102, 112, 122, 134, 163 ], "T2DM": [ 46, 125 ], "decrease": [ 49 ], "weight": [ 50 ], "persons": [ 52, 135, 198 ], "with": [ 53, 62, 68, 90, 104, 124, 167, 181, 185, 199, 203 ], "obesity": [ 54, 108, 182 ], "[body": [ 55 ], "mass": [ 56 ], "index": [ 57 ], "(BMI)": [ 58 ], "\u226530": [ 59 ], "kg/m2]": [ 60 ], "or": [ 61, 109, 159, 178, 201, 204 ], "overweight": [ 63, 110, 168, 200 ], "(BMI": [ 64 ], "\u226527": [ 65 ], "kg/m2)": [ 66 ], "weight-related": [ 69 ], "comorbidities": [ 70 ], "such": [ 71, 174 ], "hypertension,": [ 73, 176 ], "dyslipidaemia,": [ 74 ], "CVD": [ 75, 86, 91, 100, 105, 140, 157 ], "others.": [ 77 ], "Additionally,": [ 78 ], "liraglutide": [ 79 ], "reduce": [ 85, 99, 156 ], "risk": [ 87, 101, 158 ], "patients": [ 89, 103, 123, 166, 180, 184 ], "T2DM.": [ 93, 186 ], "Semaglutide": [ 94 ], "is": [ 95 ], "also": [ 96 ], "either": [ 107 ], "phase": [ 113 ], "3": [ 114 ], "clinical": [ 115 ], "trials": [ 116 ], "showed": [ 117 ], "protection": [ 121 ], "albuminuric": [ 127 ], "CKD": [ 128 ], "(FLOW": [ 129 ], "trial)": [ 130 ], "well": [ 132 ], "without": [ 136, 205 ], "that": [ 138 ], "had": [ 139 ], "overweight/obesity": [ 142 ], "(SELECT": [ 143 ], "trial).": [ 144 ], "Thus,": [ 145 ], "nephrologists": [ 146 ], "should": [ 147 ], "consider": [ 148 ], "prescribing": [ 149 ], "GLP-1": [ 150, 194 ], "RAs": [ 151, 195 ], "control,": [ 155, 220 ], "outcomes": [ 162 ], "three": [ 164 ], "scenarios:": [ 165 ], "a": [ 170, 231 ], "related": [ 171 ], "comorbid": [ 172 ], "condition": [ 173 ], "dyslipidaemia": [ 177 ], "CVD,": [ 179 ], "This": [ 187 ], "review": [ 188 ], "addresses": [ 189 ], "promising": [ 191 ], "landscape": [ 192 ], "of": [ 193, 210, 230 ], "treat": [ 197 ], "obesity,": [ 202 ], "T2DM,": [ 206 ], "within": [ 207 ], "context": [ 209 ], "CKD,": [ 211 ], "assessing": [ 212 ], "their": [ 213 ], "safety": [ 214 ], "impact": [ 216 ], "on": [ 217 ], "weight,": [ 218 ], "blood": [ 221 ], "pressure": [ 222 ], "outcomes,": [ 227 ], "part": [ 229 ], "holistic": [ 232 ], "patient-centred": [ 233 ], "approach": [ 234 ], "preserve": [ 236 ], "CKM": [ 237 ], "health.": [ 238 ] }, "publication_date": "2024-11-22", "publication_year": 2024, "type": "article", "cited_by_count": 29, "authors": [ { "id": "https://openalex.org/A5084894677", "display_name": "Daria Abasheva" }, { "id": "https://openalex.org/A5063245254", "display_name": "Alberto Ort\u00edz" }, { "id": "https://openalex.org/A5054160581", "display_name": "Beatriz Fern\u00e1ndez\u2010Fern\u00e1ndez" } ] }, { "id": "https://openalex.org/W4361212412", "doi": "https://doi.org/10.1007/s12630-023-02440-3", "title": "Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report", "abstract": null, "publication_date": "2023-03-28", "publication_year": 2023, "type": "article", "cited_by_count": 145, "authors": [ { "id": "https://openalex.org/A5069057149", "display_name": "Sandra R. Klein" }, { "id": "https://openalex.org/A5027687979", "display_name": "Ion A. Hobai" } ] }, { "id": "https://openalex.org/W4226059925", "doi": null, "title": "Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study", "abstract": { "Yu": [ 0 ], "Zhou,1": [ 1 ], "Mingyu": [ 2 ], "Chen,1": [ 3 ], "Libin": [ 4, 41 ], "Liu,2": [ 5 ], "Zhou": [ 6, 39 ], "Chen1": [ 7 ], "1Department": [ 8 ], "of": [ 9, 16, 24, 27, 37, 64, 107, 130, 154, 175, 180, 219, 228, 231, 236, 246, 254 ], "Clinical": [ 10 ], "Pharmacy": [ 11, 13 ], "and": [ 12, 80, 82, 89, 99, 109, 128, 145, 159, 170, 222, 240 ], "Administration,": [ 14 ], "School": [ 15 ], "Pharmacy,": [ 17 ], "Fujian": [ 18, 29 ], "Medical": [ 19, 30 ], "University,": [ 20 ], "Fuzhou,": [ 21, 34 ], "People\u2019s": [ 22, 35 ], "Republic": [ 23, 36 ], "China;": [ 25 ], "2Department": [ 26 ], "Endocrinology,": [ 28 ], "University": [ 31 ], "Union": [ 32 ], "Hospital,": [ 33 ], "ChinaCorrespondence:": [ 38 ], "Chen;": [ 40 ], "Liu": [ 42 ], "Tel": [ 43 ], "+86-591-22862587;": [ 44 ], "+86-591-86218562Email": [ 45 ], "chenzhou@fjmu.edu.cn;": [ 46 ], "libinliu@fjmu.edu.cnBackground:": [ 47 ], "Glucagon-like": [ 48 ], "peptide-1": [ 49 ], "(GLP-1)": [ 50 ], "receptor": [ 51, 258 ], "agonists": [ 52 ], "(GLP-1RAs)": [ 53 ], "are": [ 54, 69 ], "promising": [ 55 ], "weight-loss": [ 56 ], "drugs,": [ 57 ], "but": [ 58 ], "real-world": [ 59 ], "data": [ 60, 101 ], "concerning": [ 61 ], "the": [ 62, 73, 86, 103, 113, 140, 151, 217, 252 ], "liability": [ 63 ], "GLP-1RAs": [ 65, 211, 224 ], "in": [ 66, 75, 216 ], "gastrointestinal": [ 67, 76, 117, 260 ], "safety": [ 68, 77 ], "lacking.": [ 70 ], "We": [ 71, 84 ], "examined": [ 72 ], "differences": [ 74 ], "between": [ 78, 238 ], "semaglutide": [ 79, 108, 155, 164, 239 ], "liraglutide.Materials": [ 81 ], "Methods:": [ 83 ], "used": [ 85 ], "US": [ 87 ], "Food": [ 88 ], "Drug": [ 90 ], "Administration": [ 91 ], "(FDA)": [ 92 ], "Adverse": [ 93 ], "Event": [ 94 ], "Reporting": [ 95 ], "System": [ 96 ], "(FAERS)": [ 97 ], "database": [ 98, 265 ], "retrieved": [ 100 ], "during": [ 102 ], "first": [ 104 ], "three": [ 105 ], "years": [ 106 ], "liraglutide": [ 110, 160, 181, 241 ], "approved": [ 111 ], "by": [ 112, 138 ], "FDA.": [ 114 ], "Thirteen": [ 115 ], "main": [ 116 ], "adverse": [ 118, 261 ], "drug": [ 119, 262 ], "reactions": [ 120 ], "(GADRs)": [ 121 ], "were": [ 122, 132, 136 ], "evaluated.": [ 123 ], "Patient": [ 124 ], "demographics,": [ 125 ], "treatment": [ 126, 245 ], "information,": [ 127 ], "outcome": [ 129 ], "events": [ 131 ], "summarized.": [ 133 ], "Disproportionality": [ 134 ], "analyses": [ 135 ], "conducted": [ 137 ], "estimating": [ 139 ], "reporting": [ 141, 220 ], "odds": [ 142 ], "ratios": [ 143 ], "(RORs)": [ 144 ], "95%": [ 146, 183, 189 ], "confidence": [ 147 ], "intervals": [ 148 ], "(CIs).Results:": [ 149 ], "In": [ 150 ], "reported": [ 152 ], "cases": [ 153 ], "(n": [ 156, 161 ], "=": [ 157, 162 ], "2047)": [ 158 ], "4175),": [ 163 ], "had": [ 165 ], "a": [ 166, 213, 226 ], "higher": [ 167 ], "pooled": [ 168, 172 ], "ROR": [ 169 ], "later": [ 171 ], "time-to-onset": [ 173 ], "median": [ 174 ], "GADRs": [ 176, 206, 237 ], "compared": [ 177 ], "with": [ 178, 208 ], "those": [ 179 ], "(5.53,": [ 182 ], "CI": [ 184, 190 ], "5.23\u2013": [ 185 ], "5.85": [ 186 ], "vs": [ 187, 198 ], "3.95,": [ 188 ], "3.81\u2013": [ 191 ], "4.10;": [ 192 ], "7": [ 193 ], "days,": [ 194, 200 ], "Q1\u2013Q3:": [ 195, 201 ], "0\u2013": [ 196, 202 ], "48": [ 197 ], "4": [ 199 ], "34.5).": [ 203 ], "The": [ 204, 233 ], "thirteen": [ 205 ], "associated": [ 207 ], "these": [ 209 ], "two": [ 210 ], "showed": [ 212 ], "significant": [ 214 ], "difference": [ 215 ], "profile": [ 218 ], "risk": [ 221 ], "time-to-onset.Conclusion:": [ 223 ], "produce": [ 225 ], "spectrum": [ 227 ], "distinct": [ 229 ], "classes": [ 230 ], "GADRs.": [ 232 ], "individual": [ 234 ], "properties": [ 235 ], "might": [ 242 ], "enable": [ 243 ], "incretin-based": [ 244 ], "obesity": [ 247 ], "to": [ 248, 251 ], "be": [ 249 ], "\u201ctailored\u201d": [ 250 ], "needs": [ 253 ], "each": [ 255 ], "patient.Keywords:": [ 256 ], "GLP-1": [ 257 ], "agonists,": [ 259 ], "reactions,": [ 263 ], "pharmacovigilance": [ 264 ] }, "publication_date": "2022-01-01", "publication_year": 2022, "type": "article", "cited_by_count": 15, "authors": [ { "id": "https://openalex.org/A5100452791", "display_name": "Yu Zhou" }, { "id": "https://openalex.org/A5101645578", "display_name": "Mingyu Chen" }, { "id": "https://openalex.org/A5100644187", "display_name": "Libin Liu" }, { "id": "https://openalex.org/A5100382812", "display_name": "Zhou Chen" } ] }, { "id": "https://openalex.org/W2800291410", "doi": "https://doi.org/10.1002/jcph.1131", "title": "Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment", "abstract": { "Abstract": [ 0 ], "Semaglutide": [ 1, 87 ], "is": [ 2, 215 ], "a": [ 3 ], "human": [ 4 ], "glucagon\u2010like": [ 5, 182 ], "peptide\u20101": [ 6, 183 ], "analog": [ 7 ], "that": [ 8, 209 ], "has": [ 9 ], "been": [ 10 ], "co\u2010formulated": [ 11 ], "with": [ 12, 166, 177, 220 ], "the": [ 13, 31, 104, 113, 124, 195 ], "absorption": [ 14 ], "enhancer,": [ 15 ], "sodium": [ 16 ], "N\u2010(8\u2010[2\u2010hydroxybenzoyl]": [ 17 ], "amino)": [ 18 ], "caprylate,": [ 19 ], "for": [ 20, 77, 84, 95, 180 ], "oral": [ 21, 37, 73, 201, 213 ], "administration.": [ 22 ], "This": [ 23 ], "trial": [ 24, 207 ], "(NCT02016911)": [ 25 ], "investigated": [ 26 ], "whether": [ 27 ], "hepatic": [ 28, 45, 64, 130, 140, 167, 192, 221 ], "impairment": [ 29, 65, 141, 168, 193 ], "affects": [ 30 ], "pharmacokinetics,": [ 32, 196 ], "safety,": [ 33, 197 ], "and": [ 34, 50, 70, 94, 119, 198 ], "tolerability": [ 35, 199 ], "of": [ 36, 139, 191, 200, 205, 212 ], "semaglutide.": [ 38, 170, 202 ], "Subjects": [ 39 ], "were": [ 40, 90, 162, 174 ], "classified": [ 41 ], "into": [ 42 ], "groups:": [ 43 ], "normal": [ 44 ], "function": [ 46, 131 ], "(n": [ 47, 52, 56, 61 ], "=": [ 48, 53, 57, 62 ], "24),": [ 49 ], "mild": [ 51 ], "12),": [ 54, 58 ], "moderate": [ 55 ], "or": [ 59, 152 ], "severe": [ 60 ], "8)": [ 63 ], "according": [ 66 ], "to": [ 67, 97, 144 ], "Child\u2010Pugh": [ 68 ], "criteria,": [ 69 ], "received": [ 71 ], "once\u2010daily": [ 72 ], "semaglutide": [ 74, 105, 121, 146, 214 ], "(5": [ 75 ], "mg": [ 76, 83 ], "5": [ 78, 85 ], "days": [ 79, 99 ], "followed": [ 80 ], "by": [ 81 ], "10": [ 82 ], "days).": [ 86 ], "plasma": [ 88, 106 ], "concentrations": [ 89 ], "measured": [ 91 ], "during": [ 92 ], "dosing": [ 93 ], "up": [ 96 ], "21": [ 98 ], "post\u2010last": [ 100 ], "dose.": [ 101 ], "Area": [ 102 ], "under": [ 103 ], "concentration\u2013time": [ 107 ], "curve": [ 108 ], "from": [ 109 ], "0\u201324": [ 110 ], "hours": [ 111 ], "after": [ 112, 123 ], "10th": [ 114, 125 ], "dose": [ 115, 126, 210 ], "(primary": [ 116 ], "end": [ 117 ], "point)": [ 118 ], "maximum": [ 120, 145 ], "concentration": [ 122, 147 ], "appeared": [ 127 ], "similar": [ 128 ], "across": [ 129 ], "groups.": [ 132 ], "Similarly,": [ 133 ], "there": [ 134 ], "was": [ 135, 187 ], "no": [ 136, 188 ], "apparent": [ 137, 189 ], "effect": [ 138, 190 ], "on": [ 142, 194 ], "time": [ 143 ], "(median": [ 148 ], "range": [ 149, 156 ], "1.0\u20131.5": [ 150 ], "hours)": [ 151 ], "half\u2010life": [ 153 ], "(geometric": [ 154 ], "mean": [ 155 ], "142\u2013156": [ 157 ], "hours).": [ 158 ], "No": [ 159 ], "safety": [ 160 ], "concerns": [ 161 ], "identified": [ 163 ], "in": [ 164, 175, 218 ], "subjects": [ 165, 219 ], "receiving": [ 169 ], "Reported": [ 171 ], "adverse": [ 172 ], "events": [ 173 ], "line": [ 176 ], "those": [ 178 ], "observed": [ 179 ], "other": [ 181 ], "receptor": [ 184 ], "agonists.": [ 185 ], "There": [ 186 ], "The": [ 203 ], "results": [ 204 ], "this": [ 206 ], "suggest": [ 208 ], "adjustment": [ 211 ], "not": [ 216 ], "warranted": [ 217 ], "impairment.": [ 222 ] }, "publication_date": "2018-04-25", "publication_year": 2018, "type": "article", "cited_by_count": 83, "authors": [ { "id": "https://openalex.org/A5043297080", "display_name": "Tine A. B\u00e6kdal" }, { "id": "https://openalex.org/A5017671388", "display_name": "Mette S. Thomsen" }, { "id": "https://openalex.org/A5091075659", "display_name": "Viera Kup\u010dov\u00e1" }, { "id": "https://openalex.org/A5102324627", "display_name": "Cilie W. Hansen" }, { "id": "https://openalex.org/A5073012388", "display_name": "Thomas W. Anderson" } ] }, { "id": "https://openalex.org/W2124762650", "doi": "https://doi.org/10.1152/ajpregu.00424.2010", "title": "Brain activation following peripheral administration of the GLP-1 receptor agonist exendin-4", "abstract": { "The": [ 0, 112 ], "aim": [ 1 ], "of": [ 2, 14, 17, 25, 49, 83, 136, 151, 153, 161, 187, 199, 211, 216, 223, 232, 243 ], "our": [ 3 ], "study": [ 4, 201 ], "was": [ 5, 41 ], "to": [ 6, 21 ], "investigate": [ 7, 22 ], "the": [ 8, 23, 26, 65, 77, 92, 103, 134, 145, 148, 154, 158, 162, 171, 183, 205, 221, 229, 241, 244 ], "anorectic": [ 9, 206 ], "and": [ 10, 20, 68, 79, 100, 109, 123, 157, 181, 203, 207, 213, 218 ], "brain": [ 11, 31, 113, 179, 208 ], "stimulatory": [ 12, 209 ], "effects": [ 13, 56, 210 ], "various": [ 15 ], "doses": [ 16, 215 ], "exendin-4": [ 18 ], "(Ex-4)": [ 19 ], "role": [ 24 ], "vagus": [ 27, 245 ], "nerve": [ 28 ], "in": [ 29, 36, 64, 76, 144, 177, 182, 237 ], "Ex-4-induced": [ 30 ], "activation.": [ 32 ], "A": [ 33 ], "dose-related": [ 34 ], "increase": [ 35 ], "c-": [ 37, 61, 114, 137 ], "fos": [ 38, 62, 115, 138 ], "mRNA": [ 39, 139 ], "expression": [ 40, 63, 140 ], "observed": [ 42 ], "following": [ 43 ], "Ex-4": [ 44, 50, 84, 119, 143, 176, 188, 217, 233 ], "administration": [ 45, 231 ], "(0.155\u201315.5": [ 46 ], "\u03bcg/kg).": [ 47 ], "Doses": [ 48, 82 ], "that": [ 51, 85, 126, 220 ], "caused": [ 52, 86 ], "anorexia": [ 53 ], "without": [ 54 ], "aversive": [ 55, 212 ], "(0.155,": [ 57 ], "0.775": [ 58 ], "\u03bcg/kg)": [ 59, 90 ], "induced": [ 60, 117, 127, 141, 227 ], "hypothalamic": [ 66, 105 ], "arcuate": [ 67 ], "paraventricular": [ 69 ], "(PVH;": [ 70 ], "parvocellular)": [ 71 ], "nuclei": [ 72 ], "as": [ 73, 75 ], "well": [ 74 ], "limbic": [ 78 ], "brainstem": [ 80 ], "structures.": [ 81 ], "aversion": [ 87 ], "(1.55,": [ 88 ], "15.5": [ 89 ], "stimulated": [ 91 ], "same": [ 93 ], "regions": [ 94, 180, 226 ], "(in": [ 95 ], "a": [ 96 ], "more": [ 97 ], "intense": [ 98 ], "way)": [ 99 ], "additionally": [ 101 ], "activated": [ 102 ], "magnocellular": [ 104 ], "structures": [ 106 ], "(supraoptic": [ 107 ], "nucleus": [ 108, 152 ], "PVH": [ 110 ], "magnocellular).": [ 111 ], "pattern": [ 116 ], "by": [ 118, 128, 142, 175, 196, 228 ], "showed": [ 120 ], "both": [ 121 ], "similarities": [ 122 ], "differences": [ 124 ], "with": [ 125, 165 ], "refeeding.": [ 129 ], "Subdiaphragmatic": [ 130 ], "vagotomy": [ 131 ], "significantly": [ 132 ], "blunted": [ 133 ], "stimulation": [ 135 ], "nodose": [ 146, 184 ], "ganglion,": [ 147 ], "medial": [ 149 ], "part": [ 150 ], "solitary": [ 155 ], "tract,": [ 156 ], "parvocellular": [ 159 ], "division": [ 160 ], "PVH.": [ 163 ], "Pretreatment": [ 164 ], "Ex-9-39": [ 166 ], "(330": [ 167 ], "\u03bcg/kg": [ 168 ], "ip)": [ 169 ], "impaired": [ 170 ], "neuronal": [ 172 ], "activation": [ 173, 222 ], "evoked": [ 174 ], "all": [ 178 ], "ganglion.": [ 185 ], "Effects": [ 186 ], "on": [ 189, 240 ], "hypothalamic-pituitary-adrenal": [ 190 ], "axis": [ 191 ], "activity": [ 192 ], "were": [ 193 ], "not": [ 194 ], "altered": [ 195 ], "vagotomy.": [ 197 ], "Results": [ 198 ], "this": [ 200 ], "demonstrate": [ 202 ], "relate": [ 204 ], "nonaversive": [ 214 ], "indicate": [ 219 ], "specific": [ 224 ], "central": [ 225 ], "peripheral": [ 230 ], "is,": [ 234 ], "at": [ 235 ], "least": [ 236 ], "part,": [ 238 ], "dependent": [ 239 ], "integrity": [ 242 ], "nerve.": [ 246 ] }, "publication_date": "2011-07-21", "publication_year": 2011, "type": "article", "cited_by_count": 75, "authors": [ { "id": "https://openalex.org/A5011618072", "display_name": "Elena\u2010Dana Baraboi" }, { "id": "https://openalex.org/A5059989833", "display_name": "David H. St\u2010Pierre" }, { "id": "https://openalex.org/A5043754938", "display_name": "Julie Shooner" }, { "id": "https://openalex.org/A5041637732", "display_name": "Elena Timofeeva" }, { "id": "https://openalex.org/A5051764425", "display_name": "Denis Richard" } ] }, { "id": "https://openalex.org/W1758829516", "doi": "https://doi.org/10.1016/j.jhep.2015.08.038", "title": "Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis", "abstract": null, "publication_date": "2015-09-21", "publication_year": 2015, "type": "article", "cited_by_count": 411, "authors": [ { "id": "https://openalex.org/A5029173327", "display_name": "Matthew J. Armstrong" }, { "id": "https://openalex.org/A5064807470", "display_name": "Diana Hull" }, { "id": "https://openalex.org/A5109060739", "display_name": "Kathy Guo" }, { "id": "https://openalex.org/A5066381179", "display_name": "Darren Barton" }, { "id": "https://openalex.org/A5043977432", "display_name": "Jonathan Hazlehurst" }, { "id": "https://openalex.org/A5051963267", "display_name": "Laura Gathercole" }, { "id": "https://openalex.org/A5062219876", "display_name": "Maryam Nasiri" }, { "id": "https://openalex.org/A5082744618", "display_name": "Jinglei Yu" }, { "id": "https://openalex.org/A5107850059", "display_name": "Stephen Gough" }, { "id": "https://openalex.org/A5044832887", "display_name": "Philip N. Newsome" }, { "id": "https://openalex.org/A5083236737", "display_name": "Jeremy Tomlinson" } ] }, { "id": "https://openalex.org/W1983883248", "doi": "https://doi.org/10.1016/j.metabol.2012.03.002", "title": "GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases", "abstract": null, "publication_date": "2012-06-26", "publication_year": 2012, "type": "article", "cited_by_count": 224, "authors": [ { "id": "https://openalex.org/A5110661023", "display_name": "Hari Hendarto" }, { "id": "https://openalex.org/A5031196721", "display_name": "Toyoshi Inoguchi" }, { "id": "https://openalex.org/A5056748713", "display_name": "Yasutaka Maeda" }, { "id": "https://openalex.org/A5025600026", "display_name": "Noriko Ikeda" }, { "id": "https://openalex.org/A5109314109", "display_name": "Jing Zheng" }, { "id": "https://openalex.org/A5040483066", "display_name": "Ryoko Takei" }, { "id": "https://openalex.org/A5088935382", "display_name": "Hisashi Yokomizo" }, { "id": "https://openalex.org/A5020621129", "display_name": "Eiichi Hirata" }, { "id": "https://openalex.org/A5089020683", "display_name": "Noriyuki Sonoda" }, { "id": "https://openalex.org/A5110010291", "display_name": "Ryoichi Takayanagi" } ] }, { "id": "https://openalex.org/W3204118678", "doi": "https://doi.org/10.1186/s12933-021-01386-4", "title": "Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND", "abstract": { "Abstract": [ 0 ], "Background": [ 1 ], "The": [ 2, 159, 212 ], "REWIND": [ 3, 54 ], "trial": [ 4 ], "demonstrated": [ 5 ], "cardiovascular": [ 6, 49, 347 ], "(CV)": [ 7 ], "benefits": [ 8 ], "to": [ 9, 30, 144, 148, 326, 353 ], "patients": [ 10 ], "with": [ 11, 115, 166, 197, 265, 296, 360 ], "type": [ 12 ], "2": [ 13 ], "diabetes": [ 14 ], "and": [ 15, 82, 97, 193, 199, 230, 249, 251, 256, 273, 289, 304, 312, 358 ], "multiple": [ 16 ], "CV": [ 17, 22, 37, 61 ], "risk": [ 18, 38, 62 ], "factors": [ 19, 39, 63 ], "or": [ 20, 322 ], "established": [ 21, 60 ], "disease.": [ 23 ], "This": [ 24 ], "exploratory": [ 25 ], "analysis": [ 26, 76 ], "evaluated": [ 27, 182 ], "the": [ 28, 32, 53, 106, 134, 138, 146, 150, 163, 203, 226, 234, 260, 278, 286, 292, 329, 341 ], "degree": [ 29, 147 ], "which": [ 31, 105, 149 ], "effect": [ 33, 139, 161, 204 ], "of": [ 34, 59, 140, 153, 162, 205, 254, 332, 344 ], "dulaglutide": [ 35, 69, 141, 154, 206, 219, 266, 333, 345 ], "on": [ 36, 46, 142, 207, 334, 346 ], "could": [ 40 ], "statistically": [ 41 ], "account": [ 42 ], "for": [ 43, 104, 216, 218, 243, 263, 285, 291 ], "its": [ 44 ], "effects": [ 45, 331, 343 ], "major": [ 47 ], "adverse": [ 48 ], "events": [ 50 ], "(MACE)": [ 51 ], "in": [ 52, 72, 108, 133, 174, 191, 202, 247, 259, 310, 317, 355 ], "trial.": [ 55 ], "Methods": [ 56 ], "Potential": [ 57 ], "mediators": [ 58 ], "that": [ 64, 340 ], "were": [ 65, 70, 118, 184, 195, 275 ], "significantly": [ 66, 113, 185 ], "reduced": [ 67, 222, 282 ], "by": [ 68, 170, 187, 223, 225, 231, 233, 283 ], "assessed": [ 71, 169 ], "a": [ 73, 131, 200, 252 ], "post": [ 74 ], "hoc": [ 75 ], "using": [ 77, 120 ], "repeated": [ 78 ], "measures": [ 79 ], "mixed": [ 80 ], "models": [ 81 ], "included": [ 83, 129 ], "glycated": [ 84 ], "hemoglobin": [ 85 ], "(HbA1c),": [ 86 ], "body": [ 87 ], "weight,": [ 88, 318 ], "waist-to-hip": [ 89 ], "ratio,": [ 90 ], "systolic": [ 91, 319 ], "blood": [ 92, 320 ], "pressure,": [ 93, 321 ], "low-density": [ 94 ], "lipoprotein": [ 95 ], "(LDL),": [ 96 ], "urine": [ 98 ], "albumin/creatinine": [ 99 ], "ratio": [ 100, 152, 215, 262, 281 ], "(UACR).": [ 101 ], "These": [ 102, 337 ], "factors,": [ 103 ], "change": [ 107, 244, 293 ], "level": [ 109 ], "during": [ 110 ], "follow-up": [ 111 ], "was": [ 112, 127, 157, 168, 210, 241, 269 ], "associated": [ 114, 165, 196 ], "incident": [ 116 ], "MACE,": [ 117 ], "identified": [ 119, 125 ], "Cox": [ 121, 135, 177 ], "regression": [ 122 ], "modeling.": [ 123 ], "Each": [ 124 ], "variable": [ 126 ], "then": [ 128 ], "as": [ 130 ], "covariate": [ 132 ], "model": [ 136 ], "assessing": [ 137 ], "MACE": [ 143, 198, 217, 264, 335 ], "estimate": [ 145 ], "hazard": [ 151, 214, 261, 280 ], "vs": [ 155, 220, 267 ], "placebo": [ 156, 221, 268 ], "attenuated.": [ 158 ], "combined": [ 160 ], "variables": [ 164, 173, 183 ], "attenuation": [ 167 ], "including": [ 171 ], "all": [ 172, 181 ], "an": [ 175 ], "additional": [ 176 ], "model.": [ 178 ], "Results": [ 179 ], "Although": [ 180 ], "improved": [ 186 ], "treatment,": [ 188 ], "only": [ 189 ], "changes": [ 190, 316, 354 ], "HbA1c": [ 192, 248, 272, 311 ], "UACR": [ 194, 250, 274 ], "reduction": [ 201, 253 ], "this": [ 208 ], "outcome": [ 209 ], "observed.": [ 211, 270 ], "observed": [ 213, 242, 279 ], "36.1%": [ 224 ], "updated": [ 227, 235, 287 ], "mean": [ 228, 236, 288 ], "HbA1c,": [ 229 ], "28.5%": [ 232 ], "UACR.": [ 237 ], "A": [ 238 ], "similar": [ 239 ], "pattern": [ 240 ], "from": [ 245, 294 ], "baseline": [ 246, 295 ], "16.7%": [ 255 ], "25.4%,": [ 257 ], "respectively": [ 258 ], "When": [ 271 ], "both": [ 276 ], "included,": [ 277 ], "65.4%": [ 284 ], "41.7%": [ 290 ], "no": [ 297 ], "HbA1c-UACR": [ 298 ], "interaction": [ 299, 301 ], "(P": [ 300 ], "=": [ 302 ], "0.75": [ 303 ], "0.15,": [ 305 ], "respectively).": [ 306 ], "Conclusions": [ 307 ], "Treatment-induced": [ 308 ], "improvement": [ 309 ], "UACR,": [ 313 ], "but": [ 314 ], "not": [ 315 ], "LDL": [ 323 ], "cholesterol,": [ 324 ], "appear": [ 325 ], "partly": [ 327 ], "mediate": [ 328 ], "beneficial": [ 330 ], "outcomes.": [ 336 ], "observations": [ 338 ], "suggest": [ 339 ], "proven": [ 342 ], "disease": [ 348 ], "benefit": [ 349 ], "are": [ 350 ], "partially": [ 351 ], "related": [ 352 ], "glycemic": [ 356 ], "control": [ 357 ], "albuminuria,": [ 359 ], "residual": [ 361 ], "unexplained": [ 362 ], "benefit.": [ 363 ], "Clinicaltrials.gov;": [ 364 ], "Trial": [ 365 ], "registration": [ 366 ], "number:": [ 367 ], "NCT01394952.": [ 368 ], "URL:": [ 369 ], "https://clinicaltrials.gov/ct2/show/NCT01394952": [ 370 ] }, "publication_date": "2021-09-25", "publication_year": 2021, "type": "article", "cited_by_count": 69, "authors": [ { "id": "https://openalex.org/A5077985126", "display_name": "\u041c\u0430\u043d\u0438\u0433\u0435 \u041a\u043e\u043d\u0438\u0433" }, { "id": "https://openalex.org/A5087844534", "display_name": "Matthew C. Riddle" }, { "id": "https://openalex.org/A5005414020", "display_name": "Helen M. Colhoun" }, { "id": "https://openalex.org/A5001064258", "display_name": "Kelley R. Branch" }, { "id": "https://openalex.org/A5057242778", "display_name": "Charles Atisso" }, { "id": "https://openalex.org/A5055443598", "display_name": "Mark Lakshmanan" }, { "id": "https://openalex.org/A5011388259", "display_name": "Reema Mody" }, { "id": "https://openalex.org/A5017710279", "display_name": "Sohini Raha" }, { "id": "https://openalex.org/A5024577116", "display_name": "Hertzel C. Gerstein" } ] }, { "id": "https://openalex.org/W2061627213", "doi": "https://doi.org/10.2337/dc09-0773", "title": "Effects of Exenatide Alone and in Combination With Daclizumab on \u03b2-Cell Function in Long-Standing Type 1 Diabetes", "abstract": { "OBJECTIVE": [ 0 ], "In": [ 1, 99, 199 ], "patients": [ 2, 137 ], "with": [ 3, 22, 55, 84, 103 ], "long-standing": [ 4, 56, 104, 200 ], "type": [ 5, 57, 105, 201 ], "1": [ 6, 58, 106, 202 ], "diabetes,": [ 7, 203 ], "we": [ 8 ], "investigated": [ 9 ], "whether": [ 10 ], "improved": [ 11, 237 ], "\u03b2-cell": [ 12, 28, 32 ], "function": [ 13, 238 ], "can": [ 14 ], "be": [ 15 ], "achieved": [ 16 ], "by": [ 17, 93 ], "combining": [ 18 ], "intensive": [ 19 ], "insulin": [ 20, 89, 146, 218, 229 ], "therapy": [ 21 ], "agents": [ 23 ], "that": [ 24 ], "may": [ 25 ], "1)": [ 26 ], "promote": [ 27 ], "growth": [ 29 ], "and/or": [ 30 ], "limit": [ 31 ], "apoptosis": [ 33 ], "and": [ 34, 130, 145, 232 ], "2)": [ 35 ], "weaken": [ 36 ], "the": [ 37, 178, 225 ], "anti\u2013\u03b2-cell": [ 38 ], "autoimmunity.": [ 39 ], "RESEARCH": [ 40 ], "DESIGN": [ 41 ], "AND": [ 42 ], "METHODS": [ 43 ], "For": [ 44 ], "this": [ 45, 67, 114 ], "study,": [ 46 ], "20": [ 47 ], "individuals": [ 48, 102 ], "(mean": [ 49 ], "age": [ 50 ], "39.5": [ 51 ], "\u00b1": [ 52, 61, 140, 156, 160 ], "11.1": [ 53 ], "years)": [ 54, 63 ], "diabetes": [ 59, 107 ], "(21.3": [ 60 ], "10.7": [ 62 ], "were": [ 64, 80, 109, 122, 182 ], "enrolled": [ 65 ], "in": [ 66, 113, 219 ], "prospective": [ 68 ], "open-label": [ 69 ], "crossover": [ 70 ], "trial.": [ 71 ], "After": [ 72 ], "achieving": [ 73 ], "optimal": [ 74 ], "blood": [ 75 ], "glucose": [ 76 ], "control,": [ 77 ], "16": [ 78 ], "subjects": [ 79 ], "randomized": [ 81 ], "to": [ 82, 127 ], "exenatide": [ 83, 135, 154 ], "or": [ 85 ], "without": [ 86, 167 ], "daclizumab.": [ 87 ], "Endogenous": [ 88 ], "production": [ 90 ], "was": [ 91 ], "determined": [ 92 ], "repeatedly": [ 94 ], "measuring": [ 95 ], "serum": [ 96 ], "C-peptide.": [ 97 ], "RESULTS": [ 98 ], "85%": [ 100 ], "of": [ 101, 174, 177, 227, 239 ], "who": [ 108 ], "screened": [ 110 ], "for": [ 111 ], "participation": [ 112 ], "trial,": [ 115 ], "C-peptide": [ 116, 196 ], "levels": [ 117 ], "\u22650.05": [ 118 ], "ng/ml": [ 119 ], "(0.02": [ 120 ], "nmol/l)": [ 121 ], "found.": [ 123 ], "Residual": [ 124 ], "\u03b2-cells": [ 125, 216 ], "responded": [ 126 ], "physiological": [ 128 ], "(mixed-meal)": [ 129 ], "pharmacological": [ 131 ], "(arginine)": [ 132 ], "stimuli.": [ 133 ], "During": [ 134 ], "treatment,": [ 136 ], "lost": [ 138 ], "4.1": [ 139 ], "2.9": [ 141 ], "kg": [ 142 ], "body": [ 143 ], "wt": [ 144 ], "requirements": [ 147 ], "declined": [ 148 ], "significantly": [ 149 ], "(total": [ 150 ], "daily": [ 151 ], "dose": [ 152 ], "on": [ 153 ], "0.48": [ 155 ], "0.11": [ 157 ], "vs.": [ 158 ], "0.55": [ 159 ], "0.13": [ 161 ], "units": [ 162 ], "\u00b7": [ 163, 165 ], "kg\u22121": [ 164 ], "day\u22121": [ 166 ], "exenatide;": [ 168 ], "P": [ 169 ], "=": [ 170 ], "0.0062).": [ 171 ], "No": [ 172 ], "signs": [ 173 ], "further": [ 175 ], "activation": [ 176 ], "underlying": [ 179 ], "autoimmune": [ 180, 208 ], "disease": [ 181, 209 ], "observed.": [ 183 ], "Exenatide": [ 184 ], "delayed": [ 185 ], "gastric": [ 186 ], "emptying,": [ 187 ], "suppressed": [ 188 ], "endogenous": [ 189 ], "incretin": [ 190 ], "levels,": [ 191 ], "but": [ 192 ], "did": [ 193, 234 ], "not": [ 194, 235 ], "increase": [ 195 ], "secretion.": [ 197 ], "CONCLUSIONS": [ 198 ], "which": [ 204 ], "remains": [ 205 ], "an": [ 206 ], "active": [ 207 ], "even": [ 210 ], "decades": [ 211 ], "after": [ 212 ], "its": [ 213 ], "onset,": [ 214 ], "surviving": [ 215 ], "secrete": [ 217 ], "a": [ 220 ], "physiologically": [ 221 ], "regulated": [ 222 ], "manner.": [ 223 ], "However,": [ 224 ], "combination": [ 226 ], "intensified": [ 228 ], "therapy,": [ 230 ], "exenatide,": [ 231 ], "daclizumab": [ 233 ], "induce": [ 236 ], "these": [ 240 ], "remaining": [ 241 ], "\u03b2-cells.": [ 242 ] }, "publication_date": "2009-10-06", "publication_year": 2009, "type": "article", "cited_by_count": 130, "authors": [ { "id": "https://openalex.org/A5052600685", "display_name": "Kristina I. Rother" }, { "id": "https://openalex.org/A5108378871", "display_name": "Lisa M. Spain" }, { "id": "https://openalex.org/A5033936594", "display_name": "Robert Wesley" }, { "id": "https://openalex.org/A5079625089", "display_name": "Benigno J. Digon" }, { "id": "https://openalex.org/A5110941359", "display_name": "Alain Baron" }, { "id": "https://openalex.org/A5037370379", "display_name": "Kim Chen" }, { "id": "https://openalex.org/A5020475314", "display_name": "Patric Nelson" }, { "id": "https://openalex.org/A5112793380", "display_name": "H. M. Dosch" }, { "id": "https://openalex.org/A5005436471", "display_name": "Jerry P. Palmer" }, { "id": "https://openalex.org/A5084030890", "display_name": "Barbara Brooks\u2010Worrell" }, { "id": "https://openalex.org/A5111464899", "display_name": "Michael Ring" }, { "id": "https://openalex.org/A5055271857", "display_name": "David M. Harlan" } ] }, { "id": "https://openalex.org/W2158742250", "doi": "https://doi.org/10.2337/dc14-1958", "title": "Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes", "abstract": { "OBJECTIVE": [ 0 ], "GLP-1": [ 1 ], "receptor": [ 2 ], "(GLP-1R)": [ 3 ], "agonists": [ 4 ], "induce": [ 5 ], "natriuresis": [ 6 ], "and": [ 7, 22, 37, 40, 88, 92, 104, 121, 124, 132, 177, 196, 200, 209, 213, 247 ], "reduce": [ 8 ], "blood": [ 9 ], "pressure": [ 10 ], "(BP)": [ 11 ], "through": [ 12 ], "incompletely": [ 13 ], "understood": [ 14 ], "mechanisms.": [ 15 ], "We": [ 16 ], "examined": [ 17 ], "the": [ 18, 72 ], "effects": [ 19 ], "of": [ 20, 25, 100, 108, 136, 239 ], "acute": [ 21, 147 ], "21-day": [ 23 ], "administration": [ 24, 230 ], "liraglutide": [ 26, 101, 109, 171, 225, 229 ], "on": [ 27 ], "plasma": [ 28, 83 ], "atrial": [ 29 ], "natriuretic": [ 30 ], "peptide": [ 31 ], "(ANP),": [ 32 ], "urinary": [ 33, 179, 235 ], "sodium": [ 34, 180, 236 ], "excretion,": [ 35 ], "office": [ 36, 86 ], "24-h": [ 38, 118, 125, 176, 183, 195 ], "BP,": [ 39, 87 ], "heart": [ 41 ], "rate": [ 42 ], "(HR).": [ 43 ], "RESEARCH": [ 44 ], "DESIGN": [ 45 ], "AND": [ 46 ], "METHODS": [ 47 ], "Liraglutide": [ 48, 173 ], "or": [ 49, 160, 243 ], "placebo": [ 50, 115 ], "was": [ 51, 186, 216 ], "administered": [ 52 ], "for": [ 53, 231 ], "3": [ 54, 232 ], "weeks": [ 55, 233 ], "to": [ 56, 111, 221 ], "hypertensive": [ 57, 249 ], "subjects": [ 58 ], "with": [ 59, 204, 224, 251 ], "type": [ 60, 252 ], "2": [ 61, 158, 169, 253 ], "diabetes": [ 62 ], "in": [ 63, 71, 82, 194, 241, 245 ], "a": [ 64, 97 ], "double-blinded,": [ 65 ], "randomized,": [ 66 ], "placebo-controlled": [ 67 ], "crossover": [ 68 ], "clinical": [ 69 ], "trial": [ 70 ], "ambulatory": [ 73, 119 ], "setting.": [ 74 ], "End": [ 75 ], "points": [ 76 ], "included": [ 77 ], "within-subject": [ 78 ], "change": [ 79, 144 ], "from": [ 80 ], "baseline": [ 81, 91, 131 ], "ANP,": [ 84 ], "Nt-proBNP,": [ 85 ], "HR": [ 89, 122, 201, 215 ], "at": [ 90, 130, 157, 168 ], "over": [ 93 ], "4": [ 94, 222 ], "h": [ 95 ], "following": [ 96, 133 ], "single": [ 98 ], "dose": [ 99 ], "(0.6": [ 102 ], "mg)": [ 103, 113 ], "after": [ 105, 146 ], "21": [ 106, 134 ], "days": [ 107, 135 ], "(titrated": [ 110 ], "1.8": [ 112 ], "versus": [ 114 ], "administration.": [ 116, 172, 226 ], "Simultaneous": [ 117 ], "BP": [ 120, 185, 199, 244 ], "monitoring": [ 123 ], "urine": [ 126 ], "collections": [ 127 ], "were": [ 128, 202, 211 ], "measured": [ 129 ], "treatment.": [ 137 ], "RESULTS": [ 138 ], "Plasma": [ 139 ], "ANP": [ 140, 242 ], "levels": [ 141 ], "did": [ 142 ], "not": [ 143, 187 ], "significantly": [ 145, 174, 188 ], "(+16.72": [ 148 ], "pg/mL,": [ 149, 163 ], "P": [ 150 ], "=": [ 151 ], "0.24,": [ 152 ], "95%": [ 153, 164 ], "CI": [ 154, 165 ], "[\u221212.1,": [ 155 ], "+45.5]": [ 156 ], "h)": [ 159, 170, 223 ], "chronic": [ 161 ], "(\u221217.42": [ 162 ], "[\u221236.0,": [ 166 ], "+1.21]": [ 167 ], "increased": [ 175, 218 ], "nighttime": [ 178, 197 ], "excretion;": [ 181 ], "however,": [ 182 ], "systolic": [ 184 ], "different.": [ 189 ], "Small": [ 190 ], "but": [ 191 ], "significant": [ 192 ], "increases": [ 193, 234 ], "diastolic": [ 198 ], "observed": [ 203 ], "liraglutide.": [ 205 ], "Body": [ 206 ], "weight,": [ 207 ], "HbA1c,": [ 208 ], "cholesterol": [ 210 ], "lower,": [ 212 ], "office-measured": [ 214 ], "transiently": [ 217 ], "(for": [ 219 ], "up": [ 220 ], "CONCLUSIONS": [ 227 ], "Sustained": [ 228 ], "excretion": [ 237 ], "independent": [ 238 ], "changes": [ 240 ], "overweight": [ 246 ], "obese": [ 248 ], "patients": [ 250 ], "diabetes.": [ 254 ] }, "publication_date": "2014-11-20", "publication_year": 2014, "type": "article", "cited_by_count": 165, "authors": [ { "id": "https://openalex.org/A5082289947", "display_name": "Julie A. Lovshin" }, { "id": "https://openalex.org/A5090209238", "display_name": "Annette Barnie" }, { "id": "https://openalex.org/A5086081381", "display_name": "Ariana DeAlmeida" }, { "id": "https://openalex.org/A5002244032", "display_name": "Alexander G. Logan" }, { "id": "https://openalex.org/A5090437675", "display_name": "Bernard Zinman" }, { "id": "https://openalex.org/A5057472647", "display_name": "Daniel J. Drucker" } ] }, { "id": "https://openalex.org/W2111765225", "doi": "https://doi.org/10.1186/1475-2840-9-6", "title": "Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study", "abstract": null, "publication_date": "2010-01-28", "publication_year": 2010, "type": "article", "cited_by_count": 134, "authors": [ { "id": "https://openalex.org/A5036341294", "display_name": "Anne Gill" }, { "id": "https://openalex.org/A5058778822", "display_name": "Byron J. Hoogwerf" }, { "id": "https://openalex.org/A5000895745", "display_name": "Jude Burger" }, { "id": "https://openalex.org/A5062076953", "display_name": "Simon Bruce" }, { "id": "https://openalex.org/A5018272606", "display_name": "Leigh MacConell" }, { "id": "https://openalex.org/A5101819344", "display_name": "Ping Yan" }, { "id": "https://openalex.org/A5101809616", "display_name": "Daniel Braun" }, { "id": "https://openalex.org/A5091856313", "display_name": "Joseph M. Giaconia" }, { "id": "https://openalex.org/A5112515114", "display_name": "James Malone" } ] }, { "id": "https://openalex.org/W2006573193", "doi": "https://doi.org/10.1007/s12020-014-0361-4", "title": "Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists\u2019 treatment: a meta-analysis of randomized controlled trials", "abstract": null, "publication_date": "2014-07-29", "publication_year": 2014, "type": "review", "cited_by_count": 185, "authors": [ { "id": "https://openalex.org/A5091303181", "display_name": "Bin Su" }, { "id": "https://openalex.org/A5019536188", "display_name": "Hui Sheng" }, { "id": "https://openalex.org/A5076869458", "display_name": "Manna Zhang" }, { "id": "https://openalex.org/A5111745259", "display_name": "Le Bu" }, { "id": "https://openalex.org/A5100733911", "display_name": "Peng Yang" }, { "id": "https://openalex.org/A5100420636", "display_name": "Liang Li" }, { "id": "https://openalex.org/A5100325829", "display_name": "Fei Li" }, { "id": "https://openalex.org/A5111417811", "display_name": "Chunjun Sheng" }, { "id": "https://openalex.org/A5100935996", "display_name": "Yuqi Han" }, { "id": "https://openalex.org/A5027522098", "display_name": "Shen Qu" }, { "id": "https://openalex.org/A5101772319", "display_name": "Jiying Wang" } ] }, { "id": "https://openalex.org/W2905793358", "doi": "https://doi.org/10.1080/13696998.2019.1609482", "title": "Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy", "abstract": { "Aims:": [ 0 ], "Several": [ 1 ], "glucagon": [ 2 ], "like": [ 3 ], "peptide-1": [ 4 ], "(GLP-1)": [ 5 ], "receptor": [ 6, 247 ], "agonists": [ 7 ], "are": [ 8, 212, 217 ], "available": [ 9 ], "as": [ 10, 206, 208 ], "weekly": [ 11, 56, 105, 112, 245 ], "injections": [ 12 ], "for": [ 13, 54, 166, 170, 175, 204, 244, 262, 275, 288 ], "treatment": [ 14, 96, 100 ], "of": [ 15, 37, 86, 94, 118, 221, 251 ], "type": [ 16, 64, 87, 289 ], "2": [ 17, 65, 88, 290 ], "diabetes.": [ 18, 291 ], "These": [ 19 ], "medications": [ 20 ], "vary": [ 21 ], "in": [ 22, 67, 76, 92 ], "their": [ 23 ], "injection": [ 24, 52, 140, 184, 201, 242, 276 ], "devices,": [ 25 ], "and": [ 26, 32, 45, 60, 108, 172, 261 ], "these": [ 27 ], "differences": [ 28 ], "could": [ 29, 278 ], "impact": [ 30, 269 ], "quality-of-life": [ 31 ], "patient": [ 33, 43, 228, 238 ], "preference.": [ 34 ], "The": [ 35, 80, 177, 249 ], "purpose": [ 36 ], "this": [ 38, 265 ], "study": [ 39 ], "was": [ 40, 188 ], "to": [ 41, 198, 283 ], "examine": [ 42 ], "preferences": [ 44, 239, 274 ], "estimate": [ 46 ], "health": [ 47, 73, 81, 136, 141, 152, 186, 194, 223 ], "state": [ 48, 74, 137 ], "utilities": [ 49, 162 ], "associated": [ 50, 240 ], "with": [ 51, 63, 230, 241 ], "devices": [ 53, 243, 277 ], "two": [ 55, 146 ], "GLP-1": [ 57, 246 ], "therapies.": [ 58 ], "Materials": [ 59 ], "methods:": [ 61 ], "Participants": [ 62 ], "diabetes": [ 66 ], "Italy": [ 68 ], "(Milan,": [ 69 ], "Rome)": [ 70 ], "valued": [ 71 ], "three": [ 72 ], "vignettes": [ 75 ], "time": [ 77 ], "trade-off": [ 78 ], "interviews.": [ 79 ], "states": [ 82, 187, 195, 224 ], "had": [ 83, 267 ], "identical": [ 84 ], "descriptions": [ 85 ], "diabetes,": [ 89 ], "but": [ 90 ], "differed": [ 91 ], "description": [ 93 ], "the": [ 95, 134, 145, 150, 157, 183, 193, 200, 222, 231, 254, 258 ], "process:": [ 97 ], "(1)": [ 98 ], "oral": [ 99, 103, 110, 135 ], "regimen,": [ 101 ], "(2)": [ 102 ], "plus": [ 104, 111 ], "dulaglutide": [ 106, 151, 255 ], "injection,": [ 107 ], "(3)": [ 109 ], "semaglutide": [ 113, 158, 259 ], "injection.": [ 114 ], "Results:": [ 115 ], "A": [ 116 ], "total": [ 117 ], "216": [ 119 ], "participants": [ 120 ], "completed": [ 121 ], "interviews": [ 122 ], "(57.9%": [ 123 ], "male;": [ 124 ], "mean": [ 125, 178 ], "age": [ 126 ], "=": [ 127 ], "60.5).": [ 128 ], "Almost": [ 129 ], "all": [ 130 ], "patients": [ 131, 252 ], "(99.5%)": [ 132 ], "preferred": [ 133, 149, 156, 253 ], "over": [ 138, 257 ], "either": [ 139 ], "state.": [ 142, 159 ], "Comparing": [ 143 ], "between": [ 144, 182 ], "injections,": [ 147 ], "88.4%": [ 148 ], "state,": [ 153 ], "while": [ 154 ], "11.6%": [ 155 ], "Mean": [ 160 ], "(SD)": [ 161, 179 ], "were": [ 163, 196 ], "0.907": [ 164 ], "(0.076)": [ 165 ], "oral,": [ 167 ], "0.894": [ 168 ], "(0.085)": [ 169 ], "dulaglutide,": [ 171 ], "0.887": [ 173 ], "(0.087)": [ 174 ], "semaglutide.": [ 176 ], "utility": [ 180, 271 ], "difference": [ 181, 266 ], "device": [ 185, 202, 256 ], "0.007": [ 189 ], "(0.019).": [ 190 ], "Limitations:": [ 191 ], "Although": [ 192 ], "designed": [ 197 ], "match": [ 199 ], "instructions": [ 203 ], "use": [ 205 ], "closely": [ 207 ], "possible,": [ 209 ], "vignette-based": [ 210 ], "methods": [ 211 ], "inherently": [ 213 ], "limited": [ 214 ], "because": [ 215 ], "results": [ 216 ], "based": [ 218 ], "on": [ 219, 270 ], "perceptions": [ 220 ], "rather": [ 225 ], "than": [ 226 ], "actual": [ 227 ], "experience": [ 229 ], "devices.": [ 232 ], "Conclusions:": [ 233 ], "Results": [ 234 ], "provide": [ 235 ], "insight": [ 236 ], "into": [ 237 ], "agonists.": [ 248 ], "majority": [ 250 ], "device,": [ 260 ], "some": [ 263 ], "patients,": [ 264 ], "an": [ 268, 280 ], "valuations.": [ 272 ], "Patient": [ 273 ], "be": [ 279 ], "important": [ 281 ], "factor": [ 282 ], "consider": [ 284 ], "when": [ 285 ], "selecting": [ 286 ], "treatments": [ 287 ] }, "publication_date": "2019-04-23", "publication_year": 2019, "type": "article", "cited_by_count": 20, "authors": [ { "id": "https://openalex.org/A5039006946", "display_name": "Kristina S. Boye" }, { "id": "https://openalex.org/A5051703711", "display_name": "Louis S. Matza" }, { "id": "https://openalex.org/A5000247720", "display_name": "Katie D. Stewart" }, { "id": "https://openalex.org/A5111937124", "display_name": "Jessica Jordan" }, { "id": "https://openalex.org/A5088082257", "display_name": "Giovanni Biricolti" }, { "id": "https://openalex.org/A5036859156", "display_name": "Silvia Del Santo" }, { "id": "https://openalex.org/A5029675803", "display_name": "Magaly Perez\u2010Nieves" }, { "id": "https://openalex.org/A5032085205", "display_name": "Marco Orsini Federici" }, { "id": "https://openalex.org/A5060140104", "display_name": "R. Gentilella" }, { "id": "https://openalex.org/A5069480320", "display_name": "Serena Losi" }, { "id": "https://openalex.org/A5070145722", "display_name": "Kirsi Norrbacka" } ] }, { "id": "https://openalex.org/W2147091345", "doi": "https://doi.org/10.2337/dc13-0354", "title": "Benefits of Liraglutide Treatment in Overweight and Obese Older Individuals With Prediabetes", "abstract": { "OBJECTIVE": [ 0 ], "The": [ 1, 229 ], "aim": [ 2 ], "was": [ 3, 82 ], "to": [ 4, 10, 55, 72, 115, 128, 136, 233 ], "evaluate": [ 5 ], "the": [ 6, 86, 93, 118, 212 ], "ability": [ 7 ], "of": [ 8, 59, 110, 124, 185, 231, 259 ], "liraglutide": [ 9, 60, 116, 138, 219, 232 ], "augment": [ 11 ], "weight": [ 12, 146, 238 ], "loss": [ 13, 239 ], "and": [ 14, 23, 34, 53, 101, 178, 199, 240, 248, 261 ], "improve": [ 15 ], "insulin": [ 16, 80, 94, 242 ], "resistance,": [ 17, 243 ], "cardiovascular": [ 18 ], "disease": [ 19 ], "(CVD)": [ 20 ], "risk": [ 21, 99, 256 ], "factors,": [ 22 ], "inflammation": [ 24 ], "in": [ 25, 168, 251 ], "a": [ 26, 165 ], "high-risk": [ 27 ], "population": [ 28, 253 ], "for": [ 29, 65, 257 ], "type": [ 30 ], "2": [ 31 ], "diabetes": [ 32 ], "(T2DM)": [ 33 ], "CVD.": [ 35, 262 ], "RESEARCH": [ 36 ], "DESIGN": [ 37 ], "AND": [ 38 ], "METHODS": [ 39 ], "We": [ 40 ], "randomized": [ 41 ], "68": [ 42 ], "older": [ 43 ], "individuals": [ 44, 112 ], "(mean": [ 45 ], "age,": [ 46 ], "58": [ 47 ], "\u00b1": [ 48 ], "8": [ 49 ], "years)": [ 50 ], "with": [ 51, 121 ], "overweight/obesity": [ 52 ], "prediabetes": [ 54 ], "this": [ 56, 252 ], "double-blind": [ 57 ], "study": [ 58, 119 ], "1.8": [ 61 ], "mg": [ 62 ], "versus": [ 63 ], "placebo": [ 64, 129, 150 ], "14": [ 66 ], "weeks.": [ 67 ], "All": [ 68 ], "subjects": [ 69, 162 ], "were": [ 70, 105 ], "advised": [ 71 ], "decrease": [ 73 ], "calorie": [ 74, 234 ], "intake": [ 75 ], "by": [ 76, 84 ], "500": [ 77 ], "kcal/day.": [ 78 ], "Peripheral": [ 79 ], "resistance": [ 81 ], "quantified": [ 83 ], "measuring": [ 85 ], "steady-state": [ 87 ], "plasma": [ 88 ], "glucose": [ 89, 194 ], "(SSPG)": [ 90 ], "concentration": [ 91, 170, 250 ], "during": [ 92 ], "suppression": [ 95 ], "test.": [ 96 ], "Traditional": [ 97 ], "CVD": [ 98 ], "factors": [ 100 ], "inflammatory": [ 102 ], "markers": [ 103, 207 ], "also": [ 104, 163 ], "assessed.": [ 106 ], "RESULTS": [ 107 ], "Eleven": [ 108 ], "out": [ 109, 123 ], "35": [ 111 ], "(31%)": [ 113 ], "assigned": [ 114, 127 ], "discontinued": [ 117 ], "compared": [ 120 ], "6": [ 122 ], "33": [ 125 ], "(18%)": [ 126 ], "(P": [ 130, 180 ], "=": [ 131, 140, 152, 226 ], "0.26).": [ 132 ], "Subjects": [ 133 ], "who": [ 134 ], "continued": [ 135 ], "use": [ 137 ], "(n": [ 139, 151 ], "24)": [ 141 ], "lost": [ 142 ], "twice": [ 143 ], "as": [ 144, 147 ], "much": [ 145 ], "those": [ 148 ], "using": [ 149 ], "27;": [ 153 ], "6.8": [ 154 ], "vs.": [ 155, 172, 190, 196, 202, 222 ], "3.3": [ 156 ], "kg;": [ 157 ], "P": [ 158, 175, 225 ], "&lt;": [ 159, 176 ], "0.001).": [ 160, 227 ], "Liraglutide-treated": [ 161 ], "had": [ 164 ], "significant": [ 166 ], "improvement": [ 167 ], "SSPG": [ 169 ], "(\u22123.2": [ 171 ], "0.2": [ 173 ], "mmol/L;": [ 174 ], "0.001)": [ 177 ], "significantly": [ 179, 236 ], "\u2264": [ 181 ], "0.04)": [ 182 ], "greater": [ 183 ], "lowering": [ 184 ], "systolic": [ 186, 244 ], "blood": [ 187, 245 ], "pressure": [ 188 ], "(\u22128.1": [ 189 ], "\u22122.6": [ 191 ], "mmHg),": [ 192 ], "fasting": [ 193 ], "(\u22120.5": [ 195 ], "0": [ 197 ], "mmol/L),": [ 198 ], "triglyceride": [ 200, 249 ], "(\u22120.4": [ 201 ], "\u22120.1": [ 203 ], "mmol/L)": [ 204 ], "concentration.": [ 205 ], "Inflammatory": [ 206 ], "did": [ 208 ], "not": [ 209 ], "differ": [ 210 ], "between": [ 211 ], "two": [ 213 ], "groups,": [ 214 ], "but": [ 215 ], "pulse": [ 216 ], "increased": [ 217 ], "after": [ 218 ], "treatment": [ 220 ], "(6.4": [ 221 ], "\u22120.9": [ 223 ], "bpm;": [ 224 ], "CONCLUSIONS": [ 228 ], "addition": [ 230 ], "restriction": [ 235 ], "augmented": [ 237 ], "improved": [ 241 ], "pressure,": [ 246 ], "glucose,": [ 247 ], "at": [ 254 ], "high": [ 255 ], "development": [ 258 ], "T2DM": [ 260 ] }, "publication_date": "2013-07-09", "publication_year": 2013, "type": "article", "cited_by_count": 120, "authors": [ { "id": "https://openalex.org/A5034657479", "display_name": "Sun H. Kim" }, { "id": "https://openalex.org/A5005299025", "display_name": "Fahim Abbasi" }, { "id": "https://openalex.org/A5112922884", "display_name": "Cindy Lamendola" }, { "id": "https://openalex.org/A5022590189", "display_name": "Alice Liu" }, { "id": "https://openalex.org/A5055779523", "display_name": "Danit Ariel" }, { "id": "https://openalex.org/A5010796361", "display_name": "Patricia Schaaf" }, { "id": "https://openalex.org/A5050608892", "display_name": "Kaylene Grove" }, { "id": "https://openalex.org/A5039506016", "display_name": "Vanessa Tomasso" }, { "id": "https://openalex.org/A5086312335", "display_name": "Hector Ochoa" }, { "id": "https://openalex.org/A5071324848", "display_name": "Yeheng V. Liu" }, { "id": "https://openalex.org/A5088089511", "display_name": "Yii\u2010Der Ida Chen" }, { "id": "https://openalex.org/A5113596148", "display_name": "Gerald M. Reaven" } ] }, { "id": "https://openalex.org/W4401511475", "doi": "https://doi.org/10.1001/jamanetworkopen.2024.27258", "title": "Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes", "abstract": { "Importance": [ 0 ], "Despite": [ 1 ], "its": [ 2 ], "demonstrated": [ 3 ], "benefits": [ 4 ], "in": [ 5, 51, 224, 231, 306, 393 ], "improving": [ 6 ], "cardiovascular": [ 7, 17, 43, 147, 380 ], "risk": [ 8 ], "profiles,": [ 9 ], "the": [ 10, 35, 150, 225, 232, 261, 402 ], "association": [ 11, 36 ], "of": [ 12, 37, 69, 120, 152, 217, 244, 263, 376, 404 ], "tirzepatide": [ 13, 38, 85, 126, 185, 226, 300, 370, 405 ], "with": [ 14, 22, 39, 48, 53, 75, 125, 128, 184, 199, 241, 299, 303, 335, 369, 373, 390, 395 ], "mortality": [ 15, 40, 246, 267 ], "and": [ 16, 18, 41, 44, 59, 93, 108, 133, 141, 154, 162, 195, 228, 265, 288, 321, 360, 363, 385 ], "kidney": [ 19, 45, 101, 104, 157, 160, 165, 273, 281, 291, 383, 387 ], "outcomes": [ 20, 46, 143, 168 ], "compared": [ 21, 47, 127, 334, 389 ], "glucagon-like": [ 23 ], "peptide": [ 24 ], "1": [ 25 ], "receptor": [ 26 ], "agonists": [ 27 ], "(GLP-1": [ 28 ], "RAs)": [ 29 ], "remains": [ 30 ], "unknown.": [ 31 ], "Objective": [ 32 ], "To": [ 33 ], "investigate": [ 34 ], "adverse": [ 42, 146, 164, 290, 379, 386 ], "GLP-1": [ 49, 87, 129, 200, 233, 336, 391 ], "RAs": [ 50 ], "patients": [ 52, 182, 222, 394 ], "type": [ 54, 76, 396 ], "2": [ 55, 77, 397 ], "diabetes.": [ 56, 398 ], "Design,": [ 57 ], "Setting,": [ 58 ], "Participants": [ 60 ], "This": [ 61 ], "retrospective": [ 62 ], "cohort": [ 63 ], "study": [ 64 ], "used": [ 65 ], "US": [ 66 ], "Collaborative": [ 67 ], "Network": [ 68 ], "TriNetX": [ 70 ], "data": [ 71 ], "collected": [ 72 ], "on": [ 73 ], "individuals": [ 74 ], "diabetes": [ 78 ], "aged": [ 79 ], "18": [ 80 ], "years": [ 81 ], "or": [ 82, 86, 103, 112, 114 ], "older": [ 83 ], "initiating": [ 84 ], "RA": [ 88, 201, 234, 392 ], "between": [ 89 ], "June": [ 90, 94 ], "1,": [ 91 ], "2022,": [ 92 ], "30,": [ 95 ], "2023;": [ 96 ], "without": [ 97, 109 ], "stage": [ 98 ], "5": [ 99 ], "chronic": [ 100 ], "disease": [ 102 ], "failure": [ 105 ], "at": [ 106 ], "baseline;": [ 107 ], "myocardial": [ 110 ], "infarction": [ 111 ], "ischemic": [ 113 ], "hemorrhagic": [ 115 ], "stroke": [ 116 ], "within": [ 117 ], "60": [ 118 ], "days": [ 119 ], "drug": [ 121 ], "initiation.": [ 122 ], "Exposures": [ 123 ], "Treatment": [ 124, 298 ], "RA.": [ 130, 337 ], "Main": [ 131 ], "Outcomes": [ 132 ], "Measures": [ 134 ], "The": [ 135 ], "primary": [ 136 ], "outcome": [ 137 ], "was": [ 138, 239, 301, 371 ], "all-cause": [ 139, 155, 245, 266, 377 ], "mortality,": [ 140, 156, 378 ], "secondary": [ 142 ], "included": [ 144 ], "major": [ 145, 163, 289 ], "events": [ 148, 274, 292, 388 ], "(MACEs),": [ 149 ], "composite": [ 151, 262 ], "MACEs": [ 153, 255, 264 ], "events,": [ 158, 381 ], "acute": [ 159, 280, 382 ], "injury,": [ 161, 384 ], "events.": [ 166 ], "All": [ 167 ], "were": [ 169, 179 ], "analyzed": [ 170 ], "using": [ 171 ], "Cox": [ 172 ], "proportional": [ 173 ], "hazards": [ 174, 243, 375 ], "regression": [ 175 ], "models.": [ 176 ], "Results": [ 177 ], "There": [ 178 ], "14": [ 180 ], "834": [ 181 ], "treated": [ 183, 198 ], "(mean": [ 186, 202 ], "[SD]": [ 187, 203 ], "age,": [ 188, 204 ], "55.4": [ 189 ], "[11.8]": [ 190 ], "years;": [ 191, 207 ], "8444": [ 192 ], "[56.9%]": [ 193 ], "female)": [ 194 ], "125": [ 196 ], "474": [ 197, 209 ], "58.1": [ 205 ], "[13.3]": [ 206 ], "67": [ 208 ], "[53.8%]": [ 210 ], "female).": [ 211 ], "After": [ 212 ], "a": [ 213 ], "median": [ 214 ], "(IQR)": [ 215 ], "follow-up": [ 216 ], "10.5": [ 218 ], "(5.2-15.7)": [ 219 ], "months,": [ 220 ], "95": [ 221 ], "(0.6%)": [ 223 ], "group": [ 227, 235 ], "166": [ 229 ], "(1.1%)": [ 230 ], "died.": [ 236 ], "Tirzepatide": [ 237 ], "treatment": [ 238, 368 ], "associated": [ 240, 302, 372 ], "lower": [ 242, 374 ], "(adjusted": [ 247 ], "hazard": [ 248 ], "ratio": [ 249 ], "[AHR],": [ 250 ], "0.58;": [ 251 ], "95%": [ 252, 258, 270, 277, 285, 295, 314, 328 ], "CI,": [ 253, 259, 271, 278, 286, 296, 315, 329 ], "0.45-0.75),": [ 254 ], "(AHR,": [ 256, 268, 275, 283, 293 ], "0.80;": [ 257 ], "0.71-0.91),": [ 260 ], "0.76;": [ 269 ], "0.68-0.84),": [ 272 ], "0.52;": [ 276 ], "0.37-0.73),": [ 279 ], "injury": [ 282 ], "0.78;": [ 284 ], "0.70-0.88),": [ 287 ], "0.54;": [ 294 ], "0.44-0.67).": [ 297 ], "greater": [ 304 ], "decreases": [ 305 ], "glycated": [ 307, 353 ], "hemoglobin": [ 308, 354 ], "(treatment": [ 309, 324 ], "difference,": [ 310, 325 ], "\u22120.34": [ 311 ], "percentage": [ 312, 319 ], "points;": [ 313 ], "\u22120.44": [ 316 ], "to": [ 317, 331 ], "\u22120.24": [ 318 ], "points)": [ 320 ], "body": [ 322, 356 ], "weight": [ 323 ], "\u22122.9": [ 326 ], "kg,": [ 327 ], "\u22124.8": [ 330 ], "\u22121.1": [ 332 ], "kg)": [ 333 ], "An": [ 338 ], "interaction": [ 339 ], "test": [ 340 ], "for": [ 341, 409 ], "subgroup": [ 342 ], "analysis": [ 343 ], "revealed": [ 344 ], "consistent": [ 345 ], "results": [ 346 ], "stratified": [ 347 ], "by": [ 348 ], "estimated": [ 349 ], "glomerular": [ 350 ], "filtration": [ 351 ], "rate,": [ 352 ], "level,": [ 355 ], "mass": [ 357 ], "index,": [ 358 ], "comedications,": [ 359 ], "comorbidities.": [ 361 ], "Conclusions": [ 362 ], "Relevance": [ 364 ], "In": [ 365 ], "this": [ 366, 410 ], "study,": [ 367 ], "These": [ 399 ], "findings": [ 400 ], "support": [ 401 ], "integration": [ 403 ], "into": [ 406 ], "therapeutic": [ 407 ], "strategies": [ 408 ], "population.": [ 411 ] }, "publication_date": "2024-08-12", "publication_year": 2024, "type": "article", "cited_by_count": 73, "authors": [ { "id": "https://openalex.org/A5085551938", "display_name": "Min\u2010Hsiang Chuang" }, { "id": "https://openalex.org/A5074552399", "display_name": "Jui\u2010Yi Chen" }, { "id": "https://openalex.org/A5110175356", "display_name": "Hsien\u2010Yi Wang" }, { "id": "https://openalex.org/A5070308082", "display_name": "Zheng-Hong Jiang" }, { "id": "https://openalex.org/A5026131228", "display_name": "Vin\u2010Cent Wu" } ] }, { "id": "https://openalex.org/W2964932552", "doi": "https://doi.org/10.1111/dom.13847", "title": "GLP\u20101 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta\u2010analysis including the REWIND and PIONEER 6 trials", "abstract": { "Abstract": [ 0 ], "A": [ 1, 45 ], "meta\u2010analysis": [ 2, 46 ], "of": [ 3, 47, 105, 122, 127, 132, 139, 192, 198 ], "cardiovascular": [ 4, 79, 86, 110, 123 ], "outcome": [ 5, 149 ], "trials": [ 6 ], "(CVOTs)": [ 7 ], "comparing": [ 8 ], "glucagon\u2010like": [ 9 ], "peptide\u20101": [ 10 ], "receptor": [ 11 ], "agonists": [ 12 ], "(GLP\u20101RAs)": [ 13 ], "and": [ 14, 63, 108, 144, 176, 183 ], "placebo": [ 15 ], "concerning": [ 16, 174 ], "cardiorenal": [ 17 ], "outcomes": [ 18 ], "in": [ 19, 162 ], "patients": [ 20, 75, 106 ], "with": [ 21, 77, 99, 107 ], "type": [ 22 ], "2": [ 23 ], "diabetes": [ 24 ], "(T2D)": [ 25 ], "is": [ 26 ], "presented.": [ 27 ], "An": [ 28 ], "electronic": [ 29 ], "search": [ 30 ], "without": [ 31, 109, 194 ], "language": [ 32 ], "restrictions": [ 33 ], "up": [ 34 ], "to": [ 35, 41, 57, 155 ], "June": [ 36 ], "15,": [ 37 ], "2019": [ 38 ], "was": [ 39, 51 ], "conducted": [ 40 ], "determine": [ 42 ], "eligible": [ 43 ], "trials.": [ 44 ], "available": [ 48 ], "trial": [ 49 ], "data": [ 50 ], "undertaken,": [ 52 ], "using": [ 53 ], "a": [ 54, 100, 160 ], "random\u2010effects": [ 55 ], "model": [ 56 ], "calculate": [ 58 ], "overall": [ 59 ], "hazard": [ 60 ], "ratios": [ 61 ], "(HRs)": [ 62 ], "95%": [ 64, 93 ], "confidence": [ 65 ], "intervals": [ 66 ], "(CIs).": [ 67 ], "Data": [ 68 ], "from": [ 69 ], "seven": [ 70 ], "CVOTs,": [ 71 ], "comprising": [ 72 ], "56": [ 73 ], "004": [ 74 ], "(68.9%": [ 76 ], "established": [ 78 ], "disease)": [ 80 ], "were": [ 81 ], "included.": [ 82 ], "GLP\u20101RA": [ 83, 117 ], "reduced": [ 84, 119 ], "major": [ 85 ], "events": [ 87 ], "(MACE)": [ 88 ], "by": [ 89, 125, 130, 137, 142, 150, 159 ], "13%": [ 90 ], "(HR,": [ 91, 164 ], "0.87;": [ 92 ], "CI,": [ 94 ], "0.80\u20130.96;": [ 95 ], "P": [ 96, 114, 167 ], "=": [ 97, 115, 168 ], "0.011)": [ 98 ], "non\u2010significant": [ 101 ], "heterogeneity": [ 102 ], "between": [ 103 ], "subgroups": [ 104 ], "disease": [ 111 ], "(CVD)": [ 112 ], "(": [ 113 ], "0.220).": [ 116 ], "also": [ 118, 177, 187 ], "the": [ 120, 145, 152, 190, 196 ], "risk": [ 121 ], "death": [ 124 ], "12%,": [ 126 ], "non\u2010fatal": [ 128 ], "stroke": [ 129 ], "16%,": [ 131 ], "hospitalization": [ 133, 179 ], "for": [ 134, 180 ], "heart": [ 135, 181 ], "failure": [ 136, 182 ], "9%,": [ 138 ], "all\u2010cause": [ 140, 184 ], "mortality": [ 141 ], "11%,": [ 143 ], "broad": [ 146 ], "composite": [ 147 ], "kidney": [ 148 ], "17%;": [ 151 ], "latter": [ 153 ], "appeared": [ 154 ], "be": [ 156 ], "driven": [ 157 ], "only": [ 158 ], "reduction": [ 161 ], "macroalbuminuria": [ 163 ], "0.76": [ 165 ], "[0.68\u20130.86];": [ 166 ], "0.003).": [ 169 ], "GLP\u20101RAs": [ 170 ], "have": [ 171 ], "moderate": [ 172 ], "benefits": [ 173 ], "MACE,": [ 175 ], "reduce": [ 178, 189 ], "mortality;": [ 185 ], "they": [ 186 ], "robustly": [ 188 ], "incidence": [ 191 ], "macroalbuminuria,": [ 193 ], "affecting": [ 195 ], "progression": [ 197 ], "diabetic": [ 199 ], "renal": [ 200 ], "disease.": [ 201 ] }, "publication_date": "2019-08-02", "publication_year": 2019, "type": "review", "cited_by_count": 130, "authors": [ { "id": "https://openalex.org/A5056173815", "display_name": "Dario Giugliano" }, { "id": "https://openalex.org/A5043443418", "display_name": "Maria Ida Maiorino" }, { "id": "https://openalex.org/A5025735798", "display_name": "Giuseppe Bellastella" }, { "id": "https://openalex.org/A5005827466", "display_name": "Miriam Longo" }, { "id": "https://openalex.org/A5048229494", "display_name": "Paolo Chiodini" }, { "id": "https://openalex.org/A5052044111", "display_name": "Katherine Esposito" } ] }, { "id": "https://openalex.org/W3016916224", "doi": "https://doi.org/10.2337/dc19-2088", "title": "Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study", "abstract": { "OBJECTIVE": [ 0 ], "To": [ 1 ], "assess": [ 2 ], "the": [ 3, 81, 114, 118, 147, 259, 263, 266 ], "association": [ 4 ], "between": [ 5 ], "use": [ 6, 287 ], "of": [ 7, 16, 55, 80, 117, 146, 167, 182, 206, 217, 277, 288, 303 ], "glucagon-like": [ 8 ], "peptide": [ 9 ], "1": [ 10 ], "(GLP-1)": [ 11 ], "receptor": [ 12, 57, 169, 208, 290 ], "agonists": [ 13, 58, 170, 209 ], "and": [ 14, 38, 45, 65, 73, 106, 129, 154, 178, 224 ], "risk": [ 15, 216, 302 ], "serious": [ 17, 93, 160, 304 ], "renal": [ 18, 94, 99, 104, 109, 161, 218, 227, 236, 305 ], "events": [ 19, 174, 186, 198, 228 ], "in": [ 20, 164, 179, 248, 280, 284 ], "routine": [ 21, 281 ], "clinical": [ 22, 282 ], "practice.": [ 23 ], "RESEARCH": [ 24 ], "DESIGN": [ 25 ], "AND": [ 26 ], "METHODS": [ 27 ], "This": [ 28 ], "was": [ 29, 92, 138, 150, 210, 269, 297 ], "a": [ 30, 77, 96, 213, 300 ], "cohort": [ 31, 50, 276 ], "study": [ 32, 148, 261 ], "using": [ 33, 126 ], "an": [ 34, 130, 244 ], "active-comparator,": [ 35 ], "new-user": [ 36 ], "design": [ 37 ], "nationwide": [ 39 ], "register": [ 40 ], "data": [ 41 ], "from": [ 42, 103, 235 ], "Sweden,": [ 43 ], "Denmark,": [ 44 ], "Norway": [ 46 ], "during": [ 47 ], "2010\u20132016.": [ 48 ], "The": [ 49, 89 ], "included": [ 51 ], "38,731": [ 52 ], "new": [ 53, 78 ], "users": [ 54, 166, 181 ], "GLP-1": [ 56, 168, 207, 289 ], "(liraglutide": [ 59 ], "92.5%,": [ 60 ], "exenatide": [ 61 ], "6.2%,": [ 62 ], "lixisenatide": [ 63 ], "0.7%,": [ 64 ], "dulaglutide": [ 66 ], "0.6%),": [ 67 ], "matched": [ 68 ], "1:1": [ 69 ], "on": [ 70 ], "age,": [ 71 ], "sex,": [ 72 ], "propensity": [ 74 ], "score": [ 75 ], "to": [ 76, 203, 258 ], "user": [ 79 ], "active": [ 82 ], "comparator,": [ 83 ], "dipeptidyl": [ 84 ], "peptidase": [ 85 ], "4": [ 86 ], "(DPP-4)": [ 87 ], "inhibitors.": [ 88 ], "main": [ 90, 119 ], "outcome": [ 91, 268 ], "events,": [ 95 ], "composite": [ 97 ], "including": [ 98 ], "replacement": [ 100, 219 ], "therapy,": [ 101 ], "death": [ 102, 234 ], "causes,": [ 105 ], "hospitalization": [ 107, 225 ], "for": [ 108, 226, 265 ], "events.": [ 110, 306 ], "Secondary": [ 111 ], "outcomes": [ 112 ], "were": [ 113, 124, 251 ], "individual": [ 115 ], "components": [ 116 ], "outcome.": [ 120 ], "Hazard": [ 121 ], "ratios": [ 122 ], "(HRs)": [ 123 ], "estimated": [ 125 ], "Cox": [ 127 ], "models": [ 128 ], "intention-to-treat": [ 131 ], "exposure": [ 132, 246 ], "definition.": [ 133 ], "Mean": [ 134, 143 ], "(SD)": [ 135, 144 ], "follow-up": [ 136 ], "time": [ 137 ], "3.0": [ 139 ], "(1.7)": [ 140 ], "years.": [ 141 ], "RESULTS": [ 142 ], "age": [ 145 ], "population": [ 149 ], "59": [ 151 ], "(10)": [ 152 ], "years,": [ 153 ], "18%": [ 155 ], "had": [ 156 ], "cardiovascular": [ 157 ], "disease.": [ 158 ], "A": [ 159 ], "event": [ 162 ], "occurred": [ 163 ], "570": [ 165 ], "(incidence": [ 171 ], "rate": [ 172 ], "4.8": [ 173 ], "per": [ 175, 187, 199 ], "1,000": [ 176, 188, 200 ], "person-years)": [ 177 ], "722": [ 180 ], "DPP-4": [ 183, 295 ], "inhibitors": [ 184 ], "(6.3": [ 185 ], "person-years,": [ 189 ], "HR": [ 190, 264 ], "0.76": [ 191 ], "[95%": [ 192 ], "CI": [ 193 ], "0.68\u20130.85],": [ 194 ], "absolute": [ 195 ], "difference": [ 196 ], "\u22121.5": [ 197 ], "person-years": [ 201 ], "[\u22122.1": [ 202 ], "\u22120.9]).": [ 204 ], "Use": [ 205 ], "associated": [ 211, 298 ], "with": [ 212, 294, 299 ], "significantly": [ 214 ], "lower": [ 215 ], "therapy": [ 220 ], "(HR": [ 221, 229, 238 ], "0.73": [ 222, 230 ], "[0.62\u20130.87])": [ 223 ], "[0.65\u20130.83])": [ 231 ], "but": [ 232 ], "not": [ 233 ], "causes": [ 237 ], "0.72": [ 239 ], "[0.48\u20131.10]).": [ 240 ], "When": [ 241 ], "we": [ 242 ], "used": [ 243 ], "as-treated": [ 245 ], "definition": [ 247 ], "which": [ 249 ], "patients": [ 250, 278 ], "censored": [ 252 ], "at": [ 253 ], "treatment": [ 254 ], "cessation": [ 255 ], "or": [ 256 ], "switch": [ 257 ], "other": [ 260 ], "drug,": [ 262 ], "primary": [ 267 ], "0.60": [ 270 ], "(0.49\u20130.74).": [ 271 ], "CONCLUSIONS": [ 272 ], "In": [ 273 ], "this": [ 274 ], "large": [ 275 ], "seen": [ 279 ], "practice": [ 283 ], "three": [ 285 ], "countries,": [ 286 ], "agonists,": [ 291 ], "as": [ 292 ], "compared": [ 293 ], "inhibitors,": [ 296 ], "reduced": [ 301 ] }, "publication_date": "2020-04-15", "publication_year": 2020, "type": "article", "cited_by_count": 71, "authors": [ { "id": "https://openalex.org/A5072660677", "display_name": "Bj\u00f6rn Pasternak" }, { "id": "https://openalex.org/A5026440130", "display_name": "Viktor Wintzell" }, { "id": "https://openalex.org/A5061198575", "display_name": "Bj\u00f6rn Eliasson" }, { "id": "https://openalex.org/A5072886929", "display_name": "Ann\u2010Marie Svensson" }, { "id": "https://openalex.org/A5013441824", "display_name": "Stefan Franz\u00e9n" }, { "id": "https://openalex.org/A5002631805", "display_name": "Soffia Gu\u00f0bj\u00f6rnsd\u00f3ttir" }, { "id": "https://openalex.org/A5033780024", "display_name": "Kristian Hveem" }, { "id": "https://openalex.org/A5043082194", "display_name": "Christian Jonasson" }, { "id": "https://openalex.org/A5001189522", "display_name": "Mads Melbye" }, { "id": "https://openalex.org/A5046772961", "display_name": "Henrik Svanstr\u00f6m" }, { "id": "https://openalex.org/A5052794043", "display_name": "Peter Ueda" } ] }, { "id": "https://openalex.org/W1984430136", "doi": "https://doi.org/10.1111/j.1464-5491.2009.02790.x", "title": "Exenatide efficacy and safety: a systematic review", "abstract": { "Abstract": [ 0 ], "Objective": [ 1 ], "To": [ 2 ], "examine": [ 3 ], "the": [ 4, 39, 183, 270 ], "efficacy,": [ 5 ], "effectiveness": [ 6 ], "and": [ 7, 23, 42, 46, 113, 145, 190, 200, 215, 263 ], "side": [ 8 ], "effects": [ 9, 57 ], "of": [ 10, 31, 38, 69, 124, 179, 194, 275 ], "exenatide": [ 11, 83, 114, 199, 207, 232 ], "when": [ 12, 59, 220 ], "compared": [ 13, 212 ], "with": [ 14, 36, 54, 71, 121, 166, 206, 213, 228, 235, 257 ], "oral": [ 15, 80, 247 ], "glucose\u2010lowering": [ 16, 81 ], "agents": [ 17 ], "or": [ 18, 249 ], "insulin": [ 19, 136, 165, 201 ], "therapy.": [ 20 ], "Research": [ 21 ], "design": [ 22 ], "methods": [ 24 ], "Relevant": [ 25 ], "citations": [ 26 ], "were": [ 27, 196, 204 ], "identified": [ 28, 63 ], "from": [ 29 ], "searches": [ 30, 37 ], "multiple": [ 32 ], "bibliographic": [ 33 ], "databases": [ 34 ], "supplemented": [ 35 ], "US": [ 40 ], "Food": [ 41 ], "Drug": [ 43 ], "Administration": [ 44 ], "website": [ 45 ], "other": [ 47 ], "sources.": [ 48 ], "A": [ 49 ], "qualitative": [ 50 ], "synthesis": [ 51 ], "was": [ 52, 119, 162, 182, 217, 223, 233, 242 ], "performed,": [ 53 ], "a": [ 55, 131, 221, 236 ], "random": [ 56 ], "meta\u2010analysis": [ 58 ], "appropriate.": [ 60 ], "Results": [ 61 ], "We": [ 62 ], "17": [ 64 ], "studies.": [ 65 ], "In": [ 66, 226 ], "placebo\u2010controlled": [ 67 ], "trials": [ 68 ], "subjects": [ 70, 227 ], "poorly": [ 72, 229 ], "controlled": [ 73, 230 ], "diabetes": [ 74 ], "(with": [ 75 ], "both": [ 76 ], "groups": [ 77 ], "receiving": [ 78 ], "various": [ 79, 135 ], "agents),": [ 82 ], "10": [ 84, 208 ], "\u03bcg": [ 85, 209 ], "twice": [ 86, 210 ], "daily": [ 87, 211 ], "improved": [ 88 ], "glycated": [ 89 ], "haemoglobin": [ 90 ], "(HbA": [ 91 ], "1c": [ 92, 151, 240 ], ")": [ 93 ], "by": [ 94 ], "approximately": [ 95 ], "1.0%": [ 96 ], "over": [ 97, 116, 164 ], "30": [ 98 ], "weeks": [ 99, 118, 147, 178 ], "[pooled": [ 100 ], "estimate": [ 101, 149 ], "\u22120.97%,": [ 102 ], "95%": [ 103, 153 ], "confidence": [ 104 ], "interval": [ 105 ], "(CI),": [ 106 ], "\u22121.16": [ 107 ], "to": [ 108, 129, 134, 156, 168, 176, 244, 268 ], "\u22120.79%,": [ 109 ], "P": [ 110, 158 ], "<": [ 111 ], "0.0001]": [ 112 ], "treatment": [ 115 ], "16\u201330": [ 117 ], "associated": [ 120, 234 ], "weight": [ 122, 169 ], "loss": [ 123, 170, 173, 252 ], "1.0\u20132.5": [ 125 ], "kg.": [ 126 ], "Exenatide": [ 127 ], "appeared": [ 128 ], "confer": [ 130 ], "similar": [ 132, 197, 243 ], "benefit": [ 133, 271 ], "regimes": [ 137 ], "for": [ 138 ], "glycaemic": [ 139 ], "control": [ 140 ], "at": [ 141, 174 ], "follow\u2010up": [ 142 ], "between": [ 143 ], "16": [ 144 ], "52": [ 146, 177 ], "(pooled": [ 148 ], "HbA": [ 150, 239 ], "\u22120.04%,": [ 152 ], "CI,": [ 154 ], "\u22120.14": [ 155 ], "0.06%,": [ 157 ], "=": [ 159 ], "0.41),": [ 160 ], "but": [ 161, 203 ], "advantageous": [ 163 ], "respect": [ 167 ], "(3\u20136": [ 171 ], "kg": [ 172 ], "up": [ 175 ], "follow\u2010up).": [ 180 ], "Nausea": [ 181 ], "most": [ 184, 218 ], "common": [ 185 ], "adverse": [ 186 ], "event": [ 187 ], "in": [ 188, 198, 238, 261 ], "placebo\u2010": [ 189 ], "active\u2010controlled": [ 191 ], "trials.": [ 192 ], "Rates": [ 193 ], "hypoglycaemia": [ 195, 216 ], "groups,": [ 202 ], "higher": [ 205 ], "placebo": [ 214 ], "frequent": [ 219 ], "sulphonylurea": [ 222 ], "administered.": [ 224 ], "Conclusions": [ 225 ], "diabetes,": [ 231 ], "reduction": [ 237 ], "that": [ 241 ], "introducing": [ 245 ], "another": [ 246 ], "agent": [ 248 ], "insulin.": [ 250 ], "Weight": [ 251 ], "may": [ 253 ], "be": [ 254 ], "an": [ 255 ], "advantage": [ 256 ], "exenatide.": [ 258 ], "Long\u2010term": [ 259 ], "studies": [ 260 ], "diverse": [ 262 ], "unselected": [ 264 ], "populations": [ 265 ], "are": [ 266 ], "needed": [ 267 ], "clarify": [ 269 ], "vs.": [ 272 ], "harm": [ 273 ], "profile": [ 274 ], "this": [ 276 ], "drug.": [ 277 ] }, "publication_date": "2009-06-27", "publication_year": 2009, "type": "review", "cited_by_count": 86, "authors": [ { "id": "https://openalex.org/A5003894233", "display_name": "Susan L. Norris" }, { "id": "https://openalex.org/A5053724654", "display_name": "N. Lee" }, { "id": "https://openalex.org/A5109060290", "display_name": "Sujata Thakurta" }, { "id": "https://openalex.org/A5010408626", "display_name": "Benjamin Chan" } ] }, { "id": "https://openalex.org/W2100377339", "doi": "https://doi.org/10.1161/atvbaha.112.246207", "title": "Exenatide, a Glucagon-like Peptide-1 Receptor Agonist, Acutely Inhibits Intestinal Lipoprotein Production in Healthy Humans", "abstract": { "Objectives\u2014": [ 0 ], "Incretin-based": [ 1 ], "therapies": [ 2 ], "for": [ 3 ], "the": [ 4, 29, 33, 123, 132, 189 ], "treatment": [ 5 ], "of": [ 6, 22, 32, 89, 138, 144, 156, 164, 178, 188, 191, 203 ], "type": [ 7 ], "2": [ 8, 59 ], "diabetes": [ 9 ], "mellitus": [ 10 ], "improve": [ 11 ], "plasma": [ 12, 133 ], "lipid": [ 13 ], "profiles": [ 14 ], "and": [ 15, 41, 46, 52, 92, 135, 169, 176 ], "postprandial": [ 16 ], "lipemia,": [ 17 ], "but": [ 18, 142 ], "their": [ 19 ], "exact": [ 20 ], "mechanism": [ 21 ], "action": [ 23 ], "remains": [ 24 ], "unclear.": [ 25 ], "Here,": [ 26 ], "we": [ 27 ], "examined": [ 28, 83 ], "acute": [ 30 ], "effect": [ 31, 155 ], "glucagon-like": [ 34 ], "peptide-1": [ 35 ], "receptor": [ 36 ], "agonist,": [ 37 ], "exenatide,": [ 38 ], "on": [ 39, 158 ], "intestinal": [ 40, 159 ], "hepatic": [ 42 ], "triglyceride-rich": [ 43, 78, 139, 145 ], "lipoprotein": [ 44, 79, 160 ], "production": [ 45, 136 ], "clearance": [ 47 ], "in": [ 48, 73, 76, 166, 173, 180, 193, 201 ], "healthy": [ 49 ], "humans.": [ 50 ], "Methods": [ 51 ], "Results\u2014": [ 53 ], "Fifteen": [ 54 ], "normolipidemic,": [ 55 ], "normoglycemic": [ 56 ], "men": [ 57 ], "underwent": [ 58 ], "studies": [ 60, 175 ], "each": [ 61, 107 ], "(SC": [ 62 ], "10": [ 63 ], "\u03bcg": [ 64 ], "exenatide": [ 65, 157, 192 ], "versus": [ 66 ], "placebo),": [ 67 ], "4": [ 68 ], "to": [ 69 ], "6": [ 70 ], "weeks": [ 71 ], "apart,": [ 72 ], "random": [ 74 ], "order,": [ 75 ], "which": [ 77 ], "particle": [ 80, 161 ], "kinetics": [ 81 ], "were": [ 82 ], "with": [ 84 ], "a": [ 85, 111, 118, 126, 152 ], "primed,": [ 86 ], "constant": [ 87, 119 ], "infusion": [ 88 ], "deuterated": [ 90 ], "leucine": [ 91 ], "analyzed": [ 93 ], "by": [ 94, 109 ], "multicompartmental": [ 95 ], "modeling": [ 96 ], "under": [ 97 ], "pancreatic": [ 98 ], "clamp": [ 99 ], "conditions.": [ 100 ], "A": [ 101 ], "fed": [ 102 ], "state": [ 103 ], "was": [ 104 ], "maintained": [ 105 ], "during": [ 106 ], "study": [ 108 ], "infusing": [ 110 ], "high-fat,": [ 112 ], "mixed": [ 113 ], "macronutrient,": [ 114 ], "liquid": [ 115 ], "formula": [ 116 ], "at": [ 117 ], "rate": [ 120, 137 ], "directly": [ 121 ], "into": [ 122 ], "duodenum": [ 124 ], "via": [ 125 ], "nasoduodenal": [ 127 ], "tube.": [ 128 ], "Exenatide": [ 129 ], "significantly": [ 130 ], "suppressed": [ 131 ], "concentration": [ 134 ], "lipoprotein-apolipoprotein": [ 140, 146 ], "B-48,": [ 141 ], "not": [ 143 ], "B-100.": [ 147 ], "Conclusions\u2014": [ 148 ], "These": [ 149 ], "results": [ 150 ], "suggest": [ 151 ], "possible": [ 153 ], "direct": [ 154 ], "production,": [ 162 ], "independent": [ 163, 177 ], "changes": [ 165, 179 ], "weight": [ 167 ], "gain": [ 168 ], "satiety": [ 170 ], "as": [ 171 ], "seen": [ 172 ], "long-term": [ 174 ], "gastric": [ 181 ], "emptying.": [ 182 ], "This": [ 183 ], "finding": [ 184 ], "expands": [ 185 ], "our": [ 186 ], "understanding": [ 187 ], "effects": [ 190 ], "metabolic": [ 194 ], "regulation": [ 195, 202 ], "beyond": [ 196 ], "its": [ 197 ], "primary": [ 198 ], "therapeutic": [ 199 ], "role": [ 200 ], "glucose": [ 204 ], "homeostasis.": [ 205 ], "Clinical": [ 206 ], "Trial": [ 207 ], "Registration\u2014": [ 208 ], "URL:": [ 209 ], "http://www.clinicaltrials.gov": [ 210 ], ",": [ 211 ], "NCT01056549.": [ 212 ] }, "publication_date": "2012-04-06", "publication_year": 2012, "type": "article", "cited_by_count": 154, "authors": [ { "id": "https://openalex.org/A5071484843", "display_name": "Changting Xiao" }, { "id": "https://openalex.org/A5025503136", "display_name": "Robert Bandsma" }, { "id": "https://openalex.org/A5021774415", "display_name": "Satya Dash" }, { "id": "https://openalex.org/A5052593999", "display_name": "Linda Szeto" }, { "id": "https://openalex.org/A5034414826", "display_name": "Gary F. Lewis" } ] }, { "id": "https://openalex.org/W2016726554", "doi": "https://doi.org/10.1016/j.ejim.2011.10.007", "title": "Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: Yes", "abstract": null, "publication_date": "2011-11-16", "publication_year": 2011, "type": "review", "cited_by_count": 28, "authors": [ { "id": "https://openalex.org/A5039563874", "display_name": "Andr\u00e9 Scheen" } ] }, { "id": "https://openalex.org/W4399012115", "doi": "https://doi.org/10.1038/s41591-024-03015-5", "title": "Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial", "abstract": { "Abstract": [ 0 ], "The": [ 1, 56, 125 ], "SELECT": [ 2, 54 ], "trial": [ 3 ], "previously": [ 4 ], "reported": [ 5 ], "a": [ 6, 183 ], "20%": [ 7 ], "reduction": [ 8, 95 ], "in": [ 9, 26, 52, 96, 166, 190 ], "major": [ 10 ], "adverse": [ 11 ], "cardiovascular": [ 12, 32 ], "events": [ 13 ], "with": [ 14, 28, 105, 168, 192 ], "semaglutide": [ 15, 46, 106, 186 ], "(": [ 16, 22 ], "n": [ 17, 23 ], "=": [ 18, 24, 114, 123 ], "8,803)": [ 19 ], "versus": [ 20, 108 ], "placebo": [ 21, 109 ], "8,801)": [ 25 ], "patients": [ 27, 167 ], "overweight/obesity": [ 29 ], "and": [ 30, 150 ], "established": [ 31 ], "disease,": [ 33, 68 ], "without": [ 34, 194 ], "diabetes.": [ 35, 195 ], "In": [ 36 ], "the": [ 37, 42, 53, 59 ], "present": [ 38 ], "study,": [ 39 ], "we": [ 40 ], "examined": [ 41 ], "effect": [ 43 ], "of": [ 44, 58, 70, 76, 100, 185 ], "once-weekly": [ 45 ], "2.4": [ 47 ], "mg": [ 48 ], "on": [ 49, 187 ], "kidney": [ 50, 63, 67, 72, 188 ], "outcomes": [ 51, 189 ], "trial.": [ 55 ], "incidence": [ 57 ], "pre-specified": [ 60 ], "main": [ 61 ], "composite": [ 62 ], "endpoint": [ 64 ], "(death": [ 65 ], "from": [ 66 ], "initiation": [ 69 ], "chronic": [ 71 ], "replacement": [ 73 ], "therapy,": [ 74 ], "onset": [ 75, 99 ], "persistent": [ 77, 93, 101 ], "estimated": [ 78 ], "glomerular": [ 79 ], "filtration": [ 80 ], "rate": [ 81 ], "(eGFR)": [ 82 ], "<": [ 83, 147, 164 ], "15": [ 84 ], "ml": [ 85, 135, 152, 172 ], "min": [ 86, 136, 153, 173 ], "\u22121": [ 87, 137, 154, 174 ], "1.73": [ 88, 138, 155, 175 ], "m": [ 89, 139, 156, 176 ], "\u2212": [ 90, 140, 157, 177 ], "2": [ 91, 141, 158, 178 ], ",": [ 92 ], "\u226550%": [ 94 ], "eGFR": [ 97, 132, 170 ], "or": [ 98 ], "macroalbuminuria)": [ 102 ], "was": [ 103, 133 ], "lower": [ 104 ], "(1.8%)": [ 107 ], "(2.2%):": [ 110 ], "hazard": [ 111 ], "ratio": [ 112 ], "(HR)": [ 113 ], "0.78;": [ 115 ], "95%": [ 116 ], "confidence": [ 117 ], "interval": [ 118 ], "(CI)": [ 119 ], "0.63,": [ 120 ], "0.96;": [ 121 ], "P": [ 122, 146, 163 ], "0.02.": [ 124 ], "treatment": [ 126 ], "benefit": [ 127, 184 ], "at": [ 128 ], "104": [ 129 ], "weeks": [ 130 ], "for": [ 131 ], "0.75": [ 134 ], "(95%": [ 142, 159 ], "CI": [ 143, 160 ], "0.43,": [ 144 ], "1.06;": [ 145 ], "0.001)": [ 148, 165 ], "overall": [ 149 ], "2.19": [ 151 ], "1.00,": [ 161 ], "3.38;": [ 162 ], "baseline": [ 169 ], "<60": [ 171 ], ".": [ 179, 199 ], "These": [ 180 ], "results": [ 181 ], "suggest": [ 182 ], "individuals": [ 191 ], "overweight/obesity,": [ 193 ], "ClinicalTrials.gov": [ 196 ], "identifier:": [ 197 ], "NCT03574597": [ 198 ] }, "publication_date": "2024-05-25", "publication_year": 2024, "type": "article", "cited_by_count": 146, "authors": [ { "id": "https://openalex.org/A5005414020", "display_name": "Helen M. Colhoun" }, { "id": "https://openalex.org/A5001655356", "display_name": "Ildiko Lingvay" }, { "id": "https://openalex.org/A5101556058", "display_name": "Paul Brown" }, { "id": "https://openalex.org/A5039316946", "display_name": "John Deanfield" }, { "id": "https://openalex.org/A5102890913", "display_name": "Kirstine Brown\u2010Frandsen" }, { "id": "https://openalex.org/A5066700951", "display_name": "Steven E. Kahn" }, { "id": "https://openalex.org/A5051351787", "display_name": "Jorge Plutzky" }, { "id": "https://openalex.org/A5052966356", "display_name": "Koichi Node" }, { "id": "https://openalex.org/A5007989674", "display_name": "Alexander Parkhomenko" }, { "id": "https://openalex.org/A5041670111", "display_name": "Lars Ryd\u00e9n" }, { "id": "https://openalex.org/A5047195042", "display_name": "John Wilding" }, { "id": "https://openalex.org/A5043842967", "display_name": "Johannes F.E. Mann" }, { "id": "https://openalex.org/A5046793050", "display_name": "Katherine R. Tuttle" }, { "id": "https://openalex.org/A5113682378", "display_name": "Thomas Idorn" }, { "id": "https://openalex.org/A5039838502", "display_name": "Naveen Rathor" }, { "id": "https://openalex.org/A5001994412", "display_name": "A. Michael Lincoff" } ] }, { "id": "https://openalex.org/W3141710292", "doi": "https://doi.org/10.1007/s40262-021-01012-2", "title": "Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide", "abstract": null, "publication_date": "2021-03-29", "publication_year": 2021, "type": "article", "cited_by_count": 51, "authors": [ { "id": "https://openalex.org/A5031510744", "display_name": "Shweta Urva" }, { "id": "https://openalex.org/A5069687205", "display_name": "Tonya Quinlan" }, { "id": "https://openalex.org/A5112307149", "display_name": "John Landry" }, { "id": "https://openalex.org/A5031753799", "display_name": "Jennifer A. Martin" }, { "id": "https://openalex.org/A5030999700", "display_name": "Corina Loghin" } ] }, { "id": "https://openalex.org/W2954905478", "doi": "https://doi.org/10.1111/apt.15316", "title": "Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity", "abstract": { "Summary": [ 0 ], "Background": [ 1 ], "Obesity": [ 2 ], "and": [ 3, 21, 25, 47, 75, 96, 155, 167, 238, 254 ], "type": [ 4, 22, 67, 264 ], "2": [ 5, 23, 68, 265 ], "diabetes": [ 6, 24, 69 ], "are": [ 7 ], "drivers": [ 8 ], "of": [ 9, 37, 56, 133, 171, 178, 195 ], "non\u2010alcoholic": [ 10 ], "fatty": [ 11 ], "liver": [ 12 ], "disease": [ 13 ], "(NAFLD).": [ 14 ], "Glucagon\u2010like": [ 15 ], "peptide\u20101": [ 16, 40 ], "analogues": [ 17 ], "effectively": [ 18 ], "treat": [ 19 ], "obesity": [ 20, 262 ], "may": [ 26 ], "offer": [ 27 ], "potential": [ 28 ], "for": [ 29, 92, 106, 113, 152, 165, 214, 225, 234, 246 ], "NAFLD": [ 30 ], "treatment.": [ 31 ], "Aim": [ 32 ], "To": [ 33 ], "evaluate": [ 34 ], "the": [ 35, 38 ], "effect": [ 36 ], "glucagon\u2010like": [ 39 ], "analogue,": [ 41 ], "semaglutide,": [ 42 ], "on": [ 43, 185 ], "alanine": [ 44 ], "aminotransferase": [ 45 ], "(ALT)": [ 46 ], "high\u2010sensitivity": [ 48 ], "C\u2010reactive": [ 49 ], "protein": [ 50 ], "(hsCRP)": [ 51 ], "in": [ 52, 66, 115, 130, 176, 192, 236, 256, 259 ], "subjects": [ 53, 260 ], "at": [ 54, 212 ], "risk": [ 55 ], "NAFLD.": [ 57 ], "Methods": [ 58 ], "Data": [ 59 ], "from": [ 60 ], "a": [ 61, 76, 103, 218 ], "104\u2010week": [ 62 ], "cardiovascular": [ 63, 196 ], "outcomes": [ 64, 197 ], "trial": [ 65, 80, 100, 136, 181, 198 ], "(semaglutide": [ 70, 81 ], "0.5": [ 71, 215 ], "or": [ 72, 110 ], "1.0": [ 73, 226 ], "mg/week)": [ 74 ], "52\u2010week": [ 77 ], "weight": [ 78, 134, 179, 247 ], "management": [ 79, 99, 135, 180 ], "0.05\u20100.4": [ 82 ], "mg/day)": [ 83, 154 ], "were": [ 84, 90, 147, 240 ], "analysed.": [ 85 ], "Treatment": [ 86, 232 ], "ratios": [ 87, 233 ], "vs": [ 88, 159, 183, 221 ], "placebo": [ 89, 160, 222 ], "estimated": [ 91 ], "ALT": [ 93, 121, 145, 174, 189, 208, 237, 253 ], "(both": [ 94 ], "trials)": [ 95 ], "hsCRP": [ 97, 156, 239, 255 ], "(weight": [ 98 ], "only)": [ 101 ], "using": [ 102 ], "mixed": [ 104 ], "model": [ 105 ], "repeated": [ 107 ], "measurements,": [ 108 ], "with": [ 109, 141, 203, 261 ], "without": [ 111 ], "adjustment": [ 112, 245 ], "change": [ 114 ], "body": [ 116 ], "weight.": [ 117 ], "Results": [ 118 ], "Elevated": [ 119, 187 ], "baseline": [ 120, 173, 188 ], "(men": [ 122 ], ">30": [ 123 ], "IU/L;": [ 124 ], "women": [ 125 ], ">19": [ 126 ], "IU/L)": [ 127 ], "was": [ 128, 190, 210, 223 ], "present": [ 129, 191 ], "52%": [ 131 ], "(499/957)": [ 132 ], "subjects.": [ 137, 199 ], "In": [ 138, 200 ], "this": [ 139, 201 ], "group": [ 140, 202 ], "elevated": [ 142, 172, 204 ], "ALT,": [ 143, 205 ], "end\u2010of\u2010treatment": [ 144, 213 ], "reductions": [ 146, 157 ], "6%\u201021%": [ 148 ], "(": [ 149, 161, 228 ], "P": [ 150, 162, 229 ], "<0.05": [ 151 ], "doses\u22650.2": [ 153 ], "25%\u201043%": [ 158 ], "<": [ 163 ], "0.05": [ 164 ], "0.2": [ 166 ], "0.4": [ 168 ], "mg/day).": [ 169 ], "Normalisation": [ 170 ], "occurred": [ 175 ], "25%\u201046%": [ 177 ], "subjects,": [ 182 ], "18%": [ 184 ], "placebo.": [ 186 ], "41%": [ 193 ], "(1325/3268)": [ 194 ], "no": [ 206 ], "significant": [ 207, 243 ], "reduction": [ 209, 220 ], "noted": [ 211 ], "mg/week,": [ 216 ], "while": [ 217 ], "9%": [ 219 ], "seen": [ 224 ], "mg/week": [ 227 ], "=": [ 230 ], "0.0024).": [ 231 ], "changes": [ 235 ], "not": [ 241 ], "statistically": [ 242 ], "after": [ 244 ], "change.": [ 248 ], "Conclusions": [ 249 ], "Semaglutide": [ 250 ], "significantly": [ 251 ], "reduced": [ 252 ], "clinical": [ 257 ], "trials": [ 258 ], "and/or": [ 263 ], "diabetes.": [ 266 ] }, "publication_date": "2019-06-10", "publication_year": 2019, "type": "article", "cited_by_count": 169, "authors": [ { "id": "https://openalex.org/A5044832887", "display_name": "Philip N. Newsome" }, { "id": "https://openalex.org/A5070970519", "display_name": "Sven Francque" }, { "id": "https://openalex.org/A5091625375", "display_name": "Stephen A. Harrison" }, { "id": "https://openalex.org/A5072395263", "display_name": "Vlad Ratziu" }, { "id": "https://openalex.org/A5109054975", "display_name": "Luc Van Gaal" }, { "id": "https://openalex.org/A5011187014", "display_name": "Salvatore Calanna" }, { "id": "https://openalex.org/A5001519679", "display_name": "Morten Hansen" }, { "id": "https://openalex.org/A5113321224", "display_name": "Martin Linder" }, { "id": "https://openalex.org/A5070639714", "display_name": "Arun J. Sanyal" } ] }, { "id": "https://openalex.org/W3195383478", "doi": "https://doi.org/10.1111/cen.14583", "title": "The effects of glucagon\u2010like peptide (GLP)\u20101 receptor agonists on weight and glycaemic control in Prader\u2013Willi syndrome: A systematic review", "abstract": { "Abstract": [ 0 ], "Objective": [ 1 ], "The": [ 2 ], "mainstay": [ 3 ], "management": [ 4 ], "of": [ 5, 41, 69, 77, 87, 151, 159, 188, 246, 256 ], "hyperphagia": [ 6 ], "and": [ 7, 19, 29, 55, 66, 105, 109, 194, 222, 230 ], "obesity": [ 8, 54 ], "in": [ 9, 51, 64, 89, 97, 126, 168, 182, 186, 205, 219, 240, 249, 259 ], "Prader\u2013Willi": [ 10 ], "syndrome": [ 11 ], "(PWS)": [ 12 ], "relies": [ 13 ], "on": [ 14, 84, 243 ], "dietary": [ 15 ], "restrictions,": [ 16 ], "strict": [ 17 ], "supervision": [ 18 ], "behavioural": [ 20 ], "modifications,": [ 21 ], "which": [ 22, 252 ], "can": [ 23 ], "be": [ 24, 62 ], "stressful": [ 25 ], "for": [ 26, 227 ], "the": [ 27, 78, 82, 85, 241, 244, 254 ], "patient": [ 28 ], "caregiver.": [ 30 ], "There": [ 31, 208 ], "is": [ 32 ], "no": [ 33, 210 ], "established": [ 34 ], "pharmacological": [ 35 ], "strategy": [ 36 ], "to": [ 37, 80, 154, 175 ], "manage": [ 38 ], "this": [ 39, 250 ], "aspect": [ 40 ], "PWS.": [ 42 ], "Theoretically,": [ 43 ], "glucagon\u2010like": [ 44 ], "peptide\u20101": [ 45 ], "(GLP\u20101)": [ 46 ], "receptor": [ 47, 107 ], "agonists": [ 48 ], "(GLP1\u2010RA)": [ 49 ], "used": [ 50, 135 ], "patients": [ 52, 129, 161, 165, 221, 261 ], "with": [ 53 ], "type": [ 56 ], "2": [ 57, 178 ], "diabetes": [ 58 ], "mellitus": [ 59 ], "(T2DM)": [ 60 ], "may": [ 61, 223 ], "efficacious": [ 63 ], "weight": [ 65 ], "glycaemic": [ 67, 114, 229 ], "control": [ 68, 112, 115 ], "PWS": [ 70, 90, 128, 220, 260 ], "patients.": [ 71, 91 ], "We": [ 72 ], "conducted": [ 73 ], "a": [ 74, 149, 237 ], "systematic": [ 75 ], "review": [ 76 ], "literature": [ 79, 242 ], "summarize": [ 81 ], "evidence": [ 83 ], "use": [ 86, 125, 258 ], "GLP1\u2010RA": [ 88, 124, 216, 257 ], "Design": [ 92 ], "Primary": [ 93 ], "studies": [ 94, 121, 198, 248 ], "were": [ 95, 209 ], "searched": [ 96 ], "major": [ 98 ], "databases": [ 99 ], "using": [ 100 ], "key": [ 101 ], "concepts": [ 102 ], "\u2018Prader\u2013Willi": [ 103 ], "syndrome\u2019": [ 104 ], "\u2018GLP1": [ 106 ], "agonist\u2019": [ 108 ], "outcomes,": [ 110 ], "\u2018weight": [ 111 ], "OR": [ 113, 116 ], "appetite": [ 117, 200, 231 ], "regulation\u2019.": [ 118 ], "Results": [ 119 ], "Ten": [ 120, 164 ], "included,": [ 122 ], "summarizing": [ 123 ], "23": [ 127, 189 ], "(age,": [ 130 ], "13\u201337": [ 131 ], "years),": [ 132 ], "who": [ 133 ], "had": [ 134, 162 ], "either": [ 136 ], "exenatide": [ 137 ], "(": [ 138, 144 ], "n": [ 139, 145 ], "=": [ 140, 146 ], "14)": [ 141 ], "or": [ 142, 201 ], "liraglutide": [ 143 ], "9)": [ 147 ], "over": [ 148 ], "duration": [ 150 ], "14": [ 152 ], "weeks": [ 153 ], "4": [ 155 ], "years.": [ 156 ], "Sixteen": [ 157 ], "(70%)": [ 158 ], "these": [ 160 ], "T2DM.": [ 163 ], "experienced": [ 166 ], "improvement": [ 167, 181, 204 ], "body": [ 169 ], "mass": [ 170 ], "index,": [ 171 ], "ranging": [ 172, 191 ], "from": [ 173 ], "1.5": [ 174 ], "16.0": [ 176 ], "kg/m": [ 177 ], ",": [ 179 ], "while": [ 180 ], "HbA1c": [ 183 ], "was": [ 184 ], "seen": [ 185 ], "19": [ 187 ], "cases,": [ 190 ], "between": [ 192 ], "0.3%": [ 193 ], "7.5%.": [ 195 ], "All": [ 196 ], "five": [ 197 ], "reporting": [ 199 ], "satiety": [ 202, 206 ], "showed": [ 203 ], "levels.": [ 207 ], "reported": [ 211 ], "serious": [ 212 ], "side": [ 213 ], "effects.": [ 214 ], "Conclusions": [ 215 ], "appears": [ 217 ], "safe": [ 218 ], "have": [ 224 ], "potential": [ 225 ], "benefits": [ 226 ], "weight,": [ 228 ], "control.": [ 232 ], "Nonetheless,": [ 233 ], "we": [ 234 ], "also": [ 235 ], "highlight": [ 236 ], "significant": [ 238 ], "gap": [ 239 ], "lack": [ 245 ], "well\u2010designed": [ 247 ], "area,": [ 251 ], "limits": [ 253 ], "recommendation": [ 255 ], "at": [ 262 ], "present.": [ 263 ] }, "publication_date": "2021-08-26", "publication_year": 2021, "type": "review", "cited_by_count": 34, "authors": [ { "id": "https://openalex.org/A5070864532", "display_name": "Nicholas Beng Hui Ng" }, { "id": "https://openalex.org/A5024785952", "display_name": "Yue Wey Low" }, { "id": "https://openalex.org/A5073089477", "display_name": "Dimple Rajgor" }, { "id": "https://openalex.org/A5054218287", "display_name": "Jia Ming Low" }, { "id": "https://openalex.org/A5101887371", "display_name": "Yvonne Yijuan Lim" }, { "id": "https://openalex.org/A5110729170", "display_name": "Kah Yin Loke" }, { "id": "https://openalex.org/A5072736104", "display_name": "Yung Seng Lee" } ] }, { "id": "https://openalex.org/W4389480516", "doi": "https://doi.org/10.3389/fcdhc.2023.1293926", "title": "The benefits of GLP1 receptors in cardiovascular diseases", "abstract": { "Glucagon": [ 0 ], "like": [ 1 ], "peptide-1": [ 2 ], "(GLP-1)": [ 3 ], "receptor": [ 4, 24, 62, 91, 103, 118, 202 ], "agonists": [ 5, 25, 63, 119 ], "are": [ 6, 38, 192 ], "well": [ 7 ], "established": [ 8 ], "drugs": [ 9 ], "for": [ 10 ], "the": [ 11, 42, 72, 156, 227 ], "treatment": [ 12 ], "of": [ 13, 51, 60, 89, 100, 110, 189, 196, 200, 217, 220 ], "type": [ 14 ], "2": [ 15 ], "diabetes": [ 16 ], "(T2D).": [ 17 ], "In": [ 18, 71, 129 ], "addition": [ 19 ], "to": [ 20, 34, 55, 85, 127, 158, 185, 209, 225, 231 ], "glycemic": [ 21 ], "control,": [ 22 ], "GLP-1": [ 23, 35, 61, 90, 102, 117, 201 ], "have": [ 26, 80, 114, 132, 166, 172 ], "beneficial": [ 27 ], "other": [ 28 ], "effects.": [ 29, 170 ], "They": [ 30 ], "act": [ 31 ], "by": [ 32, 143 ], "binding": [ 33 ], "receptors,": [ 36 ], "which": [ 37, 222 ], "widely": [ 39 ], "distributed": [ 40 ], "in": [ 41, 83, 122, 180, 194, 236 ], "body,": [ 43 ], "including": [ 44 ], "cardiomyocytes": [ 45 ], "and": [ 46, 68, 98, 149, 165, 168, 214, 230 ], "blood": [ 47, 147, 150 ], "vessels.": [ 48 ], "The": [ 49, 187 ], "aim": [ 50 ], "this": [ 52 ], "article": [ 53 ], "is": [ 54, 207 ], "provide": [ 56 ], "a": [ 57 ], "comprehensive": [ 58 ], "review": [ 59 ], "impact": [ 64, 134, 176 ], "on": [ 65, 135, 177 ], "cardiovascular": [ 66, 76, 87, 96, 108, 137 ], "outcomes": [ 67, 77, 179 ], "risk": [ 69, 138 ], "reduction.": [ 70 ], "last": [ 73 ], "decade,": [ 74 ], "several": [ 75, 136 ], "trials": [ 78, 191 ], "(CVOT)": [ 79 ], "been": [ 81 ], "conducted": [ 82 ], "order": [ 84 ], "explore": [ 86 ], "benefit": [ 88, 109 ], "agonists.": [ 92, 203 ], "CVOTs": [ 93, 113 ], "primarily": [ 94 ], "proved": [ 95 ], "safety": [ 97 ], "tolerability": [ 99 ], "different": [ 101 ], "agonists,": [ 104 ], "but": [ 105 ], "also": [ 106 ], "showed": [ 107 ], "specific": [ 111 ], "drugs.": [ 112 ], "shown": [ 115, 173 ], "that": [ 116 ], "reduce": [ 120, 162 ], "MACE": [ 121 ], "patients": [ 123, 181 ], "with": [ 124, 182 ], "T2D": [ 125, 183 ], "compared": [ 126, 184 ], "placebo.": [ 128, 186 ], "addition,": [ 130 ], "they": [ 131, 154 ], "positive": [ 133, 175, 198 ], "factors": [ 139 ], "such": [ 140 ], "as": [ 141 ], "obesity": [ 142 ], "promoting": [ 144 ], "weight": [ 145 ], "loss,": [ 146 ], "pressure": [ 148 ], "lipid": [ 151 ], "levels.": [ 152 ], "Also,": [ 153 ], "stimulate": [ 155 ], "endothelium": [ 157 ], "produce": [ 159 ], "nitric": [ 160 ], "oxide,": [ 161 ], "oxidative": [ 163 ], "stress,": [ 164 ], "antiatherogenic": [ 167 ], "antiinflammatory": [ 169 ], "Studies": [ 171 ], "their": [ 174, 211, 218, 233 ], "kidney": [ 178 ], "results": [ 188 ], "previous": [ 190 ], "encouraging": [ 193 ], "terms": [ 195 ], "multiple": [ 197 ], "effects": [ 199 ], "However,": [ 204 ], "further": [ 205 ], "research": [ 206 ], "needed": [ 208 ], "understand": [ 210 ], "full": [ 212 ], "potential": [ 213 ], "all": [ 215 ], "details": [ 216 ], "mechanism": [ 219 ], "action,": [ 221 ], "will": [ 223 ], "enable": [ 224 ], "expand": [ 226 ], "therapeutic": [ 228 ], "indications": [ 229 ], "determine": [ 232 ], "optimal": [ 234 ], "use": [ 235 ], "clinical": [ 237 ], "practice.": [ 238 ] }, "publication_date": "2023-12-08", "publication_year": 2023, "type": "article", "cited_by_count": 87, "authors": [ { "id": "https://openalex.org/A5055349699", "display_name": "Lamija Ferhatbegovi\u0107" }, { "id": "https://openalex.org/A5020236778", "display_name": "Denis Mr\u0161i\u0107" }, { "id": "https://openalex.org/A5029781627", "display_name": "Amra Maci\u0107-D\u017eankovi\u0107" } ] }, { "id": "https://openalex.org/W4223941107", "doi": "https://doi.org/10.1016/j.jhep.2022.04.003", "title": "Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial", "abstract": null, "publication_date": "2022-04-16", "publication_year": 2022, "type": "article", "cited_by_count": 183, "authors": [ { "id": "https://openalex.org/A5053405300", "display_name": "Naim Alkhouri" }, { "id": "https://openalex.org/A5111751242", "display_name": "Robert Herring" }, { "id": "https://openalex.org/A5090385625", "display_name": "Heidi Kabler" }, { "id": "https://openalex.org/A5108081078", "display_name": "Zeid Kayali" }, { "id": "https://openalex.org/A5039696464", "display_name": "Tarek Hassanein" }, { "id": "https://openalex.org/A5031884118", "display_name": "Anita Kohli" }, { "id": "https://openalex.org/A5080404343", "display_name": "Ryan S. Huss" }, { "id": "https://openalex.org/A5108548927", "display_name": "Yanni Zhu" }, { "id": "https://openalex.org/A5035626395", "display_name": "Andrew N. Billin" }, { "id": "https://openalex.org/A5104035218", "display_name": "Lars Holm Damgaard" }, { "id": "https://openalex.org/A5108666776", "display_name": "Kristine Buchholtz" }, { "id": "https://openalex.org/A5101498640", "display_name": "Mette Skalsh\u00f8i Kj\u00e6r" }, { "id": "https://openalex.org/A5048101745", "display_name": "Clare A. Balendran" }, { "id": "https://openalex.org/A5108739802", "display_name": "Robert P. Myers" }, { "id": "https://openalex.org/A5052059601", "display_name": "Rohit Loomba" }, { "id": "https://openalex.org/A5043846829", "display_name": "Mazen Noureddin" } ] }, { "id": "https://openalex.org/W3000000012", "doi": "https://doi.org/10.3233/jpd-191768", "title": "The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson\u2019s Disease", "abstract": { "The": [ 0 ], "results": [ 1 ], "demonstrate": [ 2 ], "that": [ 3 ], "the": [ 4 ], "DA-CH5": [ 5 ], "is": [ 6 ], "superior": [ 7 ], "to": [ 8 ], "liraglutide": [ 9 ], "and": [ 10 ], "could": [ 11 ], "be": [ 12 ], "a": [ 13 ], "therapeutic": [ 14 ], "treatment": [ 15 ], "for": [ 16 ], "PD.": [ 17 ] }, "publication_date": "2020-01-15", "publication_year": 2020, "type": "article", "cited_by_count": 63, "authors": [ { "id": "https://openalex.org/A5100758902", "display_name": "Lingyu Zhang" }, { "id": "https://openalex.org/A5100405781", "display_name": "Ping Zhang" }, { "id": "https://openalex.org/A5115588378", "display_name": "Yanwei Li" }, { "id": "https://openalex.org/A5081928745", "display_name": "Lin Li" }, { "id": "https://openalex.org/A5010661160", "display_name": "Josefine Ulrikke Melchiorsen" }, { "id": "https://openalex.org/A5035872776", "display_name": "Mette M. Rosenkilde" }, { "id": "https://openalex.org/A5082707086", "display_name": "Christian H\u00f6lscher" } ] }, { "id": "https://openalex.org/W4389077969", "doi": "https://doi.org/10.1038/s41598-023-48267-2", "title": "Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity", "abstract": null, "publication_date": "2023-11-28", "publication_year": 2023, "type": "article", "cited_by_count": 106, "authors": [ { "id": "https://openalex.org/A5011694829", "display_name": "Fatima Quddos" }, { "id": "https://openalex.org/A5093358047", "display_name": "Zachary Hubshman" }, { "id": "https://openalex.org/A5058471655", "display_name": "Allison N. Tegge" }, { "id": "https://openalex.org/A5113056308", "display_name": "Daniel Sane" }, { "id": "https://openalex.org/A5109659231", "display_name": "Erin Marti" }, { "id": "https://openalex.org/A5040740648", "display_name": "Anita S. Kablinger" }, { "id": "https://openalex.org/A5009181802", "display_name": "Kirstin M. Gatchalian" }, { "id": "https://openalex.org/A5083929411", "display_name": "Amber L. Kelly" }, { "id": "https://openalex.org/A5003243983", "display_name": "Alexandra G. DiFeliceantonio" }, { "id": "https://openalex.org/A5081714379", "display_name": "Warren K. Bickel" } ] }, { "id": "https://openalex.org/W4400040599", "doi": "https://doi.org/10.1136/bmj-2023-078483", "title": "SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study", "abstract": { "Abstract": [ 0 ], "Objectives": [ 1 ], "To": [ 2 ], "evaluate": [ 3 ], "the": [ 4, 57, 108, 128, 253, 274, 286, 309, 321, 361, 376 ], "comparative": [ 5 ], "effectiveness": [ 6 ], "of": [ 7, 145, 177, 187, 312, 355, 370, 391, 413 ], "sodium-glucose": [ 8 ], "cotransporter-2": [ 9 ], "(SGLT-2)": [ 10 ], "inhibitors,": [ 11, 308 ], "glucagon-like": [ 12 ], "peptide-1": [ 13 ], "(GLP-1)": [ 14 ], "receptor": [ 15, 86, 98, 170, 179, 225, 244, 283, 303, 329, 347, 381, 396 ], "agonists,": [ 16 ], "and": [ 17, 50, 93, 124, 161, 233, 256, 269, 281, 327, 345, 364, 379, 394 ], "dipeptidyl": [ 18 ], "peptidase-4": [ 19 ], "(DPP-4)": [ 20 ], "inhibitors": [ 21, 79, 82, 90, 95, 191, 211, 214, 229, 241, 280, 344, 359, 393 ], "in": [ 22, 25, 31, 56, 107, 127, 165, 320, 360, 375, 402, 409 ], "preventing": [ 23 ], "hyperkalemia": [ 24, 116, 125, 146, 188, 313, 356 ], "people": [ 26, 338, 403 ], "with": [ 27, 40, 72, 141, 168, 183, 293, 306, 339, 351, 404 ], "type": [ 28, 73, 340, 405 ], "2": [ 29, 74, 341, 406 ], "diabetes": [ 30, 75 ], "routine": [ 32 ], "clinical": [ 33 ], "practice.": [ 34 ], "Design": [ 35 ], "Population": [ 36 ], "based": [ 37 ], "cohort": [ 38 ], "study": [ 39 ], "active-comparator,": [ 41 ], "new": [ 42 ], "user": [ 43 ], "design.": [ 44 ], "Setting": [ 45 ], "Claims": [ 46 ], "data": [ 47 ], "from": [ 48, 60 ], "Medicare": [ 49 ], "two": [ 51 ], "large": [ 52 ], "commercial": [ 53 ], "insurance": [ 54 ], "databases": [ 55 ], "United": [ 58 ], "States": [ 59 ], "April": [ 61, 64 ], "2013": [ 62 ], "to": [ 63, 159, 174, 194, 206, 220, 236 ], "2022.": [ 65 ], "Participants": [ 66 ], "1:1": [ 67 ], "propensity": [ 68 ], "score": [ 69 ], "matched": [ 70 ], "adults": [ 71 ], "newly": [ 76 ], "starting": [ 77 ], "SGLT-2": [ 78, 94, 136, 210, 240, 279, 322, 343, 377, 392 ], "versus": [ 80, 88, 96 ], "DPP-4": [ 81, 89, 148, 190, 213, 228, 307, 358 ], "(n=778": [ 83 ], "908),": [ 84 ], "GLP-1": [ 85, 97, 169, 178, 224, 243, 282, 328, 346, 380, 395 ], "agonists": [ 87, 99, 171, 180, 226, 245, 284, 348, 397 ], "(n=729": [ 91 ], "820),": [ 92 ], "(n=873": [ 100 ], "460).": [ 101 ], "Main": [ 102 ], "outcome": [ 103 ], "measures": [ 104 ], "Hyperkalemia": [ 105 ], "diagnosis": [ 106, 126 ], "inpatient": [ 109, 129 ], "or": [ 110, 130, 299 ], "outpatient": [ 111 ], "setting.": [ 112, 133 ], "Secondary": [ 113 ], "outcomes": [ 114, 255 ], "were": [ 115, 250, 289, 349 ], "defined": [ 117, 259 ], "as": [ 118 ], "serum": [ 119 ], "potassium": [ 120 ], "levels": [ 121, 272 ], "\u22655.5": [ 122 ], "mmol/L": [ 123 ], "emergency": [ 131 ], "department": [ 132 ], "Results": [ 134 ], "Starting": [ 135 ], "inhibitor": [ 137, 149, 323, 378 ], "treatment": [ 138, 150 ], "was": [ 139, 181, 201, 314 ], "associated": [ 140, 182, 350 ], "a": [ 142, 162, 184, 352, 385 ], "lower": [ 143, 185, 208, 222, 238, 310, 353 ], "rate": [ 144, 166, 186, 311 ], "than": [ 147, 189, 212, 227, 242, 357 ], "(hazard": [ 151 ], "ratio": [ 152 ], "0.75,": [ 153 ], "95%": [ 154 ], "confidence": [ 155 ], "interval": [ 156 ], "(CI)": [ 157 ], "0.73": [ 158 ], "0.78)": [ 160 ], "slight": [ 163 ], "reduction": [ 164 ], "compared": [ 167 ], "(0.92,": [ 172 ], "0.89": [ 173 ], "0.95).": [ 175 ], "Use": [ 176 ], "(0.79,": [ 192 ], "0.77": [ 193 ], "0.82).": [ 195 ], "The": [ 196, 368 ], "three": [ 197 ], "year": [ 198 ], "absolute": [ 199, 287 ], "risk": [ 200, 354, 412 ], "2.4%": [ 202 ], "(95%": [ 203 ], "CI": [ 204 ], "2.1%": [ 205 ], "2.7%)": [ 207 ], "for": [ 209, 223, 239, 252, 278, 291 ], "(4.6%": [ 215 ], "v": [ 216, 231, 247 ], "7.0%),": [ 217 ], "1.8%": [ 218 ], "(1.4%": [ 219 ], "2.1%)": [ 221 ], "(5.7%": [ 230 ], "7.5%),": [ 232 ], "1.2%": [ 234 ], "(0.9%": [ 235 ], "1.5%)": [ 237 ], "(4.7%": [ 246 ], "6.0%).": [ 248 ], "Findings": [ 249 ], "consistent": [ 251 ], "secondary": [ 254 ], "among": [ 257, 372 ], "subgroups": [ 258 ], "by": [ 260 ], "age,": [ 261 ], "sex,": [ 262 ], "race,": [ 263 ], "medical": [ 264 ], "conditions,": [ 265 ], "other": [ 266 ], "drug": [ 267 ], "use,": [ 268 ], "hemoglobin": [ 270 ], "A1c": [ 271 ], "on": [ 273, 285 ], "relative": [ 275 ], "scale.": [ 276 ], "Benefits": [ 277 ], "scale": [ 288 ], "largest": [ 290 ], "those": [ 292, 300, 410 ], "heart": [ 294 ], "failure,": [ 295 ], "chronic": [ 296 ], "kidney": [ 297 ], "disease,": [ 298 ], "using": [ 301 ], "mineralocorticoid": [ 302 ], "antagonists.": [ 304 ], "Compared": [ 305 ], "consistently": [ 315 ], "observed": [ 316 ], "across": [ 317, 365 ], "individual": [ 318, 373 ], "agents": [ 319, 374 ], "(canagliflozin,": [ 324 ], "dapagliflozin,": [ 325 ], "empagliflozin)": [ 326 ], "agonist": [ 330, 382 ], "(dulaglutide,": [ 331 ], "exenatide,": [ 332 ], "liraglutide,": [ 333 ], "semaglutide)": [ 334 ], "classes.": [ 335 ], "Conclusions": [ 336 ], "In": [ 337 ], "diabetes,": [ 342, 407 ], "overall": [ 362 ], "population": [ 363 ], "relevant": [ 366 ], "subgroups.": [ 367 ], "consistency": [ 369 ], "associations": [ 371 ], "classes": [ 383 ], "suggests": [ 384 ], "class": [ 386 ], "effect.": [ 387 ], "These": [ 388 ], "ancillary": [ 389 ], "benefits": [ 390 ], "further": [ 398 ], "support": [ 399 ], "their": [ 400 ], "use": [ 401 ], "especially": [ 408 ], "at": [ 411 ], "hyperkalemia.": [ 414 ] }, "publication_date": "2024-06-26", "publication_year": 2024, "type": "article", "cited_by_count": 19, "authors": [ { "id": "https://openalex.org/A5029305012", "display_name": "Edouard L. Fu" }, { "id": "https://openalex.org/A5076997901", "display_name": "Deborah J. Wexler" }, { "id": "https://openalex.org/A5084953114", "display_name": "Sara J. Cromer" }, { "id": "https://openalex.org/A5083832003", "display_name": "Katsiaryna Bykov" }, { "id": "https://openalex.org/A5085331349", "display_name": "Julie M. Paik" }, { "id": "https://openalex.org/A5044474781", "display_name": "Elisabetta Patorno" } ] }, { "id": "https://openalex.org/W2163844983", "doi": "https://doi.org/10.1186/1758-5996-6-110", "title": "Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes", "abstract": null, "publication_date": "2014-10-15", "publication_year": 2014, "type": "article", "cited_by_count": 22, "authors": [ { "id": "https://openalex.org/A5043513172", "display_name": "Kenjiro Imai" }, { "id": "https://openalex.org/A5031424961", "display_name": "Tetsuro Tsujimoto" }, { "id": "https://openalex.org/A5065856181", "display_name": "Atsushi Goto" }, { "id": "https://openalex.org/A5088688171", "display_name": "Maki Goto" }, { "id": "https://openalex.org/A5101647203", "display_name": "Miyako Kishimoto" }, { "id": "https://openalex.org/A5076406876", "display_name": "Ritsuko Yamamoto\u2010Honda" }, { "id": "https://openalex.org/A5003757241", "display_name": "Hiroshi Noto" }, { "id": "https://openalex.org/A5062373555", "display_name": "Hiroshi Kajio" }, { "id": "https://openalex.org/A5017888890", "display_name": "Mitsuhiko Noda" } ] }, { "id": "https://openalex.org/W2999774672", "doi": "https://doi.org/10.1038/s41366-019-0513-y", "title": "Short-term GLP-1 receptor agonist exenatide ameliorates intramyocellular lipid deposition without weight loss in ob/ob mice", "abstract": null, "publication_date": "2020-01-07", "publication_year": 2020, "type": "article", "cited_by_count": 31, "authors": [ { "id": "https://openalex.org/A5001571073", "display_name": "Fen Xu" }, { "id": "https://openalex.org/A5108726379", "display_name": "Huanyi Cao" }, { "id": "https://openalex.org/A5061044616", "display_name": "Zonglan Chen" }, { "id": "https://openalex.org/A5084407477", "display_name": "Huimin Gu" }, { "id": "https://openalex.org/A5090709412", "display_name": "Wanrong Guo" }, { "id": "https://openalex.org/A5100914386", "display_name": "Beisi Lin" }, { "id": "https://openalex.org/A5012775407", "display_name": "Jianping Weng" } ] }, { "id": "https://openalex.org/W2808271763", "doi": "https://doi.org/10.1111/dom.13353", "title": "Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials", "abstract": { "Aims": [ 0 ], "To": [ 1 ], "assess": [ 2 ], "the": [ 3, 12, 31, 54, 60, 207 ], "effect": [ 4 ], "of": [ 5, 14, 33, 117, 182, 206, 237, 242 ], "baseline": [ 6, 112, 124, 172, 238 ], "body": [ 7, 126 ], "mass": [ 8 ], "index": [ 9 ], "(BMI)": [ 10 ], "and": [ 11, 43, 70, 114, 133, 178, 191, 212 ], "occurrence": [ 13 ], "nausea": [ 15, 119, 147, 185, 217, 243 ], "and/or": [ 16, 120 ], "vomiting": [ 17, 187, 219, 245 ], "on": [ 18, 81 ], "weight": [ 19, 45, 64, 127, 139, 168, 229, 248 ], "loss": [ 20, 46, 65, 140, 169, 230, 249 ], "induced": [ 21 ], "by": [ 22, 111, 146, 216 ], "semalgutide,": [ 23 ], "a": [ 24, 163 ], "once\u2010weekly": [ 25 ], "glucagon\u2010like": [ 26 ], "peptide": [ 27 ], "1": [ 28, 56, 225 ], "analogue": [ 29 ], "for": [ 30 ], "treatment": [ 32, 208 ], "type": [ 34, 76 ], "2": [ 35, 77 ], "diabetes.": [ 36 ], "Semaglutide": [ 37 ], "demonstrated": [ 38 ], "superior": [ 39, 44 ], "reductions": [ 40 ], "in": [ 41, 125 ], "HbA1c": [ 42 ], "(by": [ 47 ], "2.3\u20106.3": [ 48 ], "kg)": [ 49 ], "versus": [ 50, 195, 234 ], "different": [ 51 ], "comparators": [ 52, 213 ], "across": [ 53, 158 ], "SUSTAIN": [ 55, 92, 224 ], "to": [ 57, 63, 86, 176, 180, 197, 203, 226, 246 ], "5": [ 58 ], "trials;": [ 59 ], "contributing": [ 61 ], "factors": [ 62 ], "are": [ 66 ], "not": [ 67 ], "established.": [ 68 ], "Materials": [ 69 ], "Methods": [ 71 ], "Subjects": [ 72, 108 ], "with": [ 73, 162, 170, 188, 199 ], "inadequately": [ 74 ], "controlled": [ 75 ], "diabetes": [ 78 ], "(drug\u2010na\u00efve": [ 79 ], "or": [ 80, 98, 105, 143, 148, 186, 218, 244 ], "background": [ 82 ], "treatment)": [ 83 ], "were": [ 84, 109, 156 ], "randomized": [ 85 ], "subcutaneous": [ 87 ], "semaglutide": [ 88, 189, 211 ], "0.5": [ 89, 190, 204 ], "mg": [ 90, 95 ], "(excluding": [ 91 ], "3),": [ 93 ], "1.0": [ 94, 192 ], "(all": [ 96 ], "trials),": [ 97 ], "comparator": [ 99 ], "(placebo,": [ 100 ], "sitagliptin,": [ 101 ], "exenatide": [ 102 ], "extended": [ 103 ], "release": [ 104 ], "insulin": [ 106 ], "glargine).": [ 107 ], "subdivided": [ 110 ], "BMI": [ 113, 160 ], "reporting": [ 115 ], "(yes/no)": [ 116 ], "any": [ 118 ], "vomiting.": [ 121 ], "Change": [ 122 ], "from": [ 123 ], "was": [ 128, 214, 231, 250 ], "assessed": [ 129 ], "within": [ 130 ], "each": [ 131 ], "trial": [ 132 ], "subgroup.": [ 134 ], "A": [ 135 ], "mediation": [ 136 ], "analysis": [ 137 ], "separated": [ 138 ], "into": [ 141 ], "direct": [ 142 ], "indirect": [ 144 ], "(mediated": [ 145 ], "vomiting)": [ 149 ], "effects.": [ 150 ], "Results": [ 151 ], "Clinically": [ 152 ], "relevant": [ 153 ], "weight\u2010loss": [ 154 ], "differences": [ 155 ], "observed": [ 157 ], "all": [ 159 ], "subgroups,": [ 161 ], "trend": [ 164 ], "towards": [ 165 ], "higher": [ 166, 171 ], "absolute": [ 167 ], "BMI.": [ 173, 239 ], "Overall,": [ 174 ], "15.2%": [ 175 ], "24.0%": [ 177 ], "21.5%": [ 179 ], "27.2%": [ 181 ], "subjects": [ 183 ], "experienced": [ 184 ], "mg,": [ 193 ], "respectively,": [ 194 ], "6.0%": [ 196 ], "14.1%": [ 198 ], "comparators.": [ 200 ], "Only": [ 201 ], "0.07": [ 202 ], "kg": [ 205 ], "difference": [ 209 ], "between": [ 210 ], "mediated": [ 215 ], "(indirect": [ 220 ], "effects).": [ 221 ], "Conclusions": [ 222 ], "In": [ 223 ], "5,": [ 227 ], "semaglutide\u2010induced": [ 228 ], "consistently": [ 232 ], "greater": [ 233 ], "comparators,": [ 235 ], "regardless": [ 236 ], "The": [ 240 ], "contribution": [ 241 ], "this": [ 247 ], "minor.": [ 251 ] }, "publication_date": "2018-05-15", "publication_year": 2018, "type": "article", "cited_by_count": 127, "authors": [ { "id": "https://openalex.org/A5027109387", "display_name": "Bo \u00c5hr\u00e9n" }, { "id": "https://openalex.org/A5064495299", "display_name": "Stephen L. Atkin" }, { "id": "https://openalex.org/A5022459640", "display_name": "G. Charpentier" }, { "id": "https://openalex.org/A5011320591", "display_name": "Mark Warren" }, { "id": "https://openalex.org/A5047195042", "display_name": "John Wilding" }, { "id": "https://openalex.org/A5076526695", "display_name": "Stephen Birch" }, { "id": "https://openalex.org/A5015716676", "display_name": "Anders G. Holst" }, { "id": "https://openalex.org/A5080414941", "display_name": "Lawrence A. Leiter" } ] }, { "id": "https://openalex.org/W2793719460", "doi": "https://doi.org/10.1111/dom.13223", "title": "Effect of immediate and prolonged GLP\u20101 receptor agonist administration on uric acid and kidney clearance: Post\u2010hoc analyses of four clinical trials", "abstract": { "Aims": [ 0 ], "To": [ 1 ], "determine": [ 2 ], "the": [ 3, 347, 385 ], "effects": [ 4, 45, 68 ], "of": [ 5, 29, 37, 46, 69, 72, 85, 88, 114, 144, 388 ], "glucagon\u2010like": [ 6 ], "peptide": [ 7 ], "(GLP)\u20101": [ 8 ], "receptor": [ 9 ], "agonists": [ 10 ], "(RA)": [ 11 ], "on": [ 12, 40 ], "uric": [ 13 ], "acid": [ 14 ], "(UA)": [ 15 ], "levels": [ 16, 374 ], "and": [ 17, 22, 60, 84, 110, 119, 124, 163, 190, 204, 243, 307, 333, 375 ], "kidney": [ 18, 41 ], "UA": [ 19, 115, 117, 133, 155, 166, 183, 189, 193, 212, 236, 246, 317, 320, 328, 363, 366, 373 ], "clearance.": [ 20 ], "Material": [ 21 ], "methods": [ 23 ], "This": [ 24 ], "study": [ 25 ], "involved": [ 26 ], "post\u2010hoc": [ 27 ], "analyses": [ 28 ], "4": [ 30 ], "controlled": [ 31 ], "clinical": [ 32 ], "trials,": [ 33 ], "which": [ 34 ], "assessed": [ 35 ], "actions": [ 36 ], "GLP\u20101RA": [ 38, 47, 74, 90, 358, 389 ], "administration": [ 39 ], "physiology.": [ 42 ], "The": [ 43, 67 ], "immediate": [ 44 ], "exenatide": [ 48, 150, 225, 324 ], "infusion": [ 49, 151, 226, 325 ], "vs": [ 50, 76, 92 ], "placebo": [ 51, 77 ], "were": [ 52, 103, 127, 146, 265 ], "determined": [ 53 ], "in": [ 54, 61, 78, 97, 197, 269, 273, 277, 329, 334, 346, 367, 395 ], "9": [ 55 ], "healthy": [ 56, 331 ], "overweight": [ 57, 63, 80, 99, 330 ], "men": [ 58, 332 ], "(Study\u2010A)": [ 59 ], "52": [ 62 ], "T2DM": [ 64, 81, 100, 335, 368 ], "patients": [ 65, 82, 101, 369 ], "(Study\u2010B).": [ 66 ], "12": [ 70 ], "weeks": [ 71, 87 ], "long\u2010acting": [ 73, 355 ], "liraglutide": [ 75, 283 ], "36": [ 79 ], "(Study\u2010C)": [ 83 ], "8": [ 86 ], "short\u2010acting": [ 89, 357 ], "lixisenatide": [ 91, 302 ], "once\u2010daily": [ 93 ], "titrated": [ 94 ], "insulin": [ 95 ], "glulisine": [ 96 ], "35": [ 98 ], "(Study\u2010D)": [ 102 ], "also": [ 104 ], "examined.": [ 105 ], "Plasma": [ 106 ], "UA,": [ 107, 231, 289, 291 ], "fractional": [ 108, 181, 216, 234 ], "(inulin\u2010corrected)": [ 109 ], "absolute": [ 111, 191, 244 ], "urinary": [ 112 ], "excretion": [ 113 ], "(UE": [ 116, 121 ], ")": [ 118 ], "sodium": [ 120 ], "Na": [ 122, 218, 279, 293, 306, 340 ], "),": [ 123 ], "urine": [ 125, 198, 270, 295, 308 ], "pH": [ 126, 199, 271, 309 ], "determined.": [ 128 ], "Results": [ 129 ], "Median": [ 130 ], "baseline": [ 131 ], "plasma": [ 132, 154, 230, 288, 316, 362, 372 ], "level": [ 134 ], "was": [ 135 ], "5.39": [ 136 ], "to": [ 137, 185, 258, 298 ], "6.33": [ 138 ], "mg/dL": [ 139 ], "across": [ 140 ], "all": [ 141 ], "studies": [ 142 ], "(17%\u201022%": [ 143 ], "subjects": [ 145 ], "hyperuricaemic).": [ 147 ], "In": [ 148, 223, 260, 281, 300 ], "Study\u2010A,": [ 149 ], "slightly": [ 152 ], "increased": [ 153, 215, 233, 304 ], "(+0.07": [ 156 ], "\u00b1": [ 157, 168, 238, 248 ], "0.02": [ 158 ], "mg/dL,": [ 159 ], "P": [ 160, 174, 201, 206, 220, 240, 254 ], "=": [ 161, 175, 202, 221, 241, 255 ], ".04),": [ 162 ], "raised": [ 164 ], "absolute\u2010UE": [ 165 ], "(+1.58": [ 167 ], "0.65": [ 169 ], "mg/min/1.73": [ 170, 250 ], "m": [ 171, 251 ], "2": [ 172, 252 ], ",": [ 173, 253 ], ".02),": [ 176 ], "but": [ 177, 232, 312 ], "did": [ 178, 227, 285, 313 ], "not": [ 179, 228, 286, 314, 360, 391 ], "affect": [ 180, 229, 287, 315, 361 ], "UE": [ 182, 188, 192, 211, 217, 235, 245, 278, 290, 292, 305, 319, 327, 365 ], "compared": [ 184, 257, 297 ], "placebo.": [ 186, 259, 299 ], "Fractional": [ 187, 210 ], "correlated": [ 194, 213 ], "with": [ 195, 214, 353, 370 ], "increases": [ 196, 326 ], "(r:0.86,": [ 200 ], ".003": [ 203 ], "r:0.92,": [ 205 ], "<": [ 207 ], ".001,": [ 208 ], "respectively).": [ 209 ], "(r:0.76,": [ 219 ], ".02).": [ 222 ], "Study\u2010B,": [ 224 ], "(+0.76": [ 237 ], "0.38%,": [ 239 ], ".049)": [ 242 ], "(+0.75": [ 247 ], "0.27": [ 249 ], ".007),": [ 256 ], "regression": [ 261 ], "analyses,": [ 262 ], "both": [ 263 ], "parameters": [ 264 ], "explained": [ 266 ], "by": [ 267, 275, 338 ], "changes": [ 268, 276, 394 ], "and,": [ 272 ], "part,": [ 274 ], ".": [ 280, 321 ], "Study\u2010C,": [ 282 ], "treatment": [ 284, 303, 352 ], "or": [ 294, 318, 356, 364 ], "pH,": [ 296 ], "Study\u2010D,": [ 301 ], "from": [ 310 ], "baseline,": [ 311 ], "Conclusion": [ 322 ], "Immediate": [ 323 ], "patients,": [ 336 ], "probably": [ 337 ], "inhibiting": [ 339 ], "+": [ 341, 343 ], "/H": [ 342 ], "\u2010exchanger": [ 344 ], "type\u20103": [ 345 ], "renal": [ 348 ], "proximal": [ 349 ], "tubule.": [ 350 ], "Prolonged": [ 351 ], "a": [ 354 ], "does": [ 359 ], "normal": [ 371 ], "at": [ 376 ], "relatively": [ 377 ], "low": [ 378 ], "cardiovascular": [ 379 ], "risk.": [ 380 ], "Our": [ 381 ], "results": [ 382 ], "suggest": [ 383 ], "that": [ 384 ], "cardio\u2010renal": [ 386 ], "benefits": [ 387 ], "are": [ 390 ], "mediated": [ 392 ], "through": [ 393 ], "UA.": [ 396 ] }, "publication_date": "2018-01-17", "publication_year": 2018, "type": "article", "cited_by_count": 38, "authors": [ { "id": "https://openalex.org/A5067721247", "display_name": "Lennart Tonneijck" }, { "id": "https://openalex.org/A5084278641", "display_name": "Marcel H.A. Muskiet" }, { "id": "https://openalex.org/A5091895526", "display_name": "Mark M. Smits" }, { "id": "https://openalex.org/A5036425382", "display_name": "Petter Bjornstad" }, { "id": "https://openalex.org/A5028760009", "display_name": "Mark H.H. Kramer" }, { "id": "https://openalex.org/A5109335776", "display_name": "Micha\u00ebla Diamant" }, { "id": "https://openalex.org/A5027968873", "display_name": "Ewout J. Hoorn" }, { "id": "https://openalex.org/A5113916096", "display_name": "Jaap A. Joles" }, { "id": "https://openalex.org/A5067127165", "display_name": "Dani\u00ebl H. van Raalte" } ] }, { "id": "https://openalex.org/W2148495354", "doi": "https://doi.org/10.1016/j.amjmed.2009.11.019", "title": "Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes", "abstract": null, "publication_date": "2010-04-16", "publication_year": 2010, "type": "article", "cited_by_count": 125, "authors": [ { "id": "https://openalex.org/A5022112585", "display_name": "Caroline M. Apovian" }, { "id": "https://openalex.org/A5034096266", "display_name": "Richard M. Bergenstal" }, { "id": "https://openalex.org/A5101709468", "display_name": "Robert Cuddihy" }, { "id": "https://openalex.org/A5036911910", "display_name": "Yongming Qu" }, { "id": "https://openalex.org/A5067880040", "display_name": "Sheila M. Lenox" }, { "id": "https://openalex.org/A5103567970", "display_name": "Michelle S. Lewis" }, { "id": "https://openalex.org/A5111625146", "display_name": "Leonard C. Glass" } ] }, { "id": "https://openalex.org/W3045958310", "doi": "https://doi.org/10.1097/01.jaa.0000669452.63883.45", "title": "Long-acting GLP-1 receptor agonists", "abstract": { "ABSTRACT": [ 0 ], "Cardiovascular": [ 1 ], "disease": [ 2 ], "(CVD)": [ 3 ], "is": [ 4 ], "a": [ 5, 130, 151, 157, 174 ], "common": [ 6 ], "and": [ 7, 16, 103, 183, 201 ], "serious": [ 8 ], "comorbidity": [ 9 ], "of": [ 10, 26, 87, 108, 129, 133, 142, 153, 164, 195, 232, 235, 246 ], "type": [ 11 ], "2": [ 12 ], "diabetes": [ 13, 239 ], "mellitus": [ 14 ], "(T2DM),": [ 15 ], "cardiovascular": [ 17, 137, 143 ], "(CV)": [ 18 ], "risk": [ 19, 194, 208 ], "assessment": [ 20 ], "has": [ 21, 185 ], "become": [ 22 ], "an": [ 23, 59, 189, 217 ], "important": [ 24 ], "aspect": [ 25 ], "evaluating": [ 27 ], "new": [ 28, 44 ], "therapies": [ 29, 45 ], "for": [ 30, 46, 67, 84, 105, 179, 191 ], "T2DM": [ 31, 47, 200 ], "before": [ 32 ], "approval": [ 33 ], "by": [ 34 ], "the": [ 35, 85, 154, 176, 193, 229 ], "FDA.": [ 36 ], "Since": [ 37 ], "2008,": [ 38 ], "in": [ 39, 58, 62, 161, 197, 249 ], "order": [ 40 ], "to": [ 41, 51, 82, 116, 119, 126, 228 ], "establish": [ 42 ], "safety,": [ 43 ], "have": [ 48, 112, 214 ], "been": [ 49, 186 ], "required": [ 50 ], "demonstrate": [ 52 ], "that": [ 53 ], "they": [ 54 ], "will": [ 55 ], "not": [ 56, 224 ], "result": [ 57 ], "unacceptable": [ 60 ], "increase": [ 61 ], "CV": [ 63, 72, 207, 226, 236 ], "risk.": [ 64 ], "Studies": [ 65 ], "performed": [ 66 ], "this": [ 68 ], "purpose": [ 69 ], "are": [ 70 ], "termed": [ 71 ], "outcome": [ 73, 132, 141 ], "trials,": [ 74 ], "or": [ 75, 205 ], "CVOTs.": [ 76 ], "This": [ 77 ], "article": [ 78 ], "reviews": [ 79 ], "CVOTs": [ 80, 111 ], "completed": [ 81 ], "date": [ 83 ], "class": [ 86 ], "long-acting": [ 88, 114 ], "glucagon-like": [ 89 ], "peptide-1": [ 90 ], "receptor": [ 91 ], "agonists": [ 92 ], "(GLP-1RAs;": [ 93 ], "liraglutide,": [ 94, 180 ], "exenatide": [ 95 ], "extended-release,": [ 96 ], "albiglutide,": [ 97 ], "dulaglutide,": [ 98 ], "semaglutide": [ 99, 101, 181 ], "injectable,": [ 100, 182 ], "oral)": [ 102 ], "implications": [ 104 ], "clinical": [ 106 ], "management": [ 107 ], "T2DM.": [ 109 ], "All": [ 110 ], "confirmed": [ 113 ], "GLP-1RAs": [ 115 ], "be": [ 117 ], "noninferior": [ 118 ], "(not": [ 120 ], "worse": [ 121 ], "than)": [ 122 ], "placebo": [ 123 ], "with": [ 124, 167, 171, 188, 199, 251 ], "regard": [ 125 ], "first": [ 127 ], "occurrence": [ 128 ], "primary": [ 131, 162 ], "three-point": [ 134, 165 ], "major": [ 135 ], "adverse": [ 136 ], "events": [ 138 ], "(MACE;": [ 139 ], "composite": [ 140 ], "death,": [ 144 ], "nonfatal": [ 145, 148 ], "myocardial": [ 146 ], "infarction,": [ 147 ], "stroke).": [ 149 ], "Further,": [ 150 ], "number": [ 152 ], "studies": [ 155 ], "demonstrated": [ 156 ], "statistically": [ 158 ], "significant": [ 159 ], "reduction": [ 160 ], "outcomes": [ 163 ], "MACE": [ 166, 196 ], "GLP-1RA": [ 168, 247 ], "treatment": [ 169 ], "compared": [ 170 ], "placebo.": [ 172 ], "As": [ 173 ], "result,": [ 175 ], "product": [ 177 ], "labeling": [ 178 ], "dulaglutide": [ 184 ], "updated": [ 187 ], "indication": [ 190 ], "reducing": [ 192, 233 ], "adults": [ 198 ], "established": [ 202 ], "CVD": [ 203 ], "(all)": [ 204 ], "multiple": [ 206 ], "factors": [ 209 ], "(dulaglutide": [ 210 ], "only).": [ 211 ], "These": [ 212 ], "findings": [ 213 ], "brought": [ 215 ], "about": [ 216, 223 ], "exciting": [ 218, 230 ], "paradigm": [ 219 ], "shift": [ 220 ], "from": [ 221 ], "concern": [ 222 ], "inflicting": [ 225 ], "harm": [ 227 ], "prospect": [ 231 ], "risks": [ 234 ], "outcomes.": [ 237 ], "Major": [ 238 ], "care": [ 240 ], "guidelines": [ 241 ], "now": [ 242 ], "encourage": [ 243 ], "early": [ 244 ], "consideration": [ 245 ], "use": [ 248 ], "patients": [ 250 ], "atherosclerotic": [ 252 ], "CVD.": [ 253 ] }, "publication_date": "2020-07-29", "publication_year": 2020, "type": "review", "cited_by_count": 10, "authors": [ { "id": "https://openalex.org/A5044466000", "display_name": "Scott Urquhart" }, { "id": "https://openalex.org/A5025628661", "display_name": "Stephen G. Willis" } ] }, { "id": "https://openalex.org/W4282044710", "doi": "https://doi.org/10.1002/osp4.619", "title": "A pilot randomized controlled trial of liraglutide 3.0\u00a0mg for binge eating disorder", "abstract": { "Abstract": [ 0 ], "Objective": [ 1 ], "To": [ 2 ], "assess": [ 3 ], "the": [ 4, 114, 133, 190, 193, 216 ], "efficacy": [ 5 ], "of": [ 6, 42, 53, 175, 233 ], "liraglutide": [ 7, 43, 115, 149, 191, 217, 239 ], "3.0": [ 8, 44, 128 ], "mg,": [ 9 ], "a": [ 10, 24, 35, 230 ], "glucagon\u2010like": [ 11 ], "peptide\u20101": [ 12 ], "(GLP\u20101)": [ 13 ], "receptor": [ 14 ], "agonist,": [ 15 ], "for": [ 16, 46, 73, 82, 132, 244 ], "binge": [ 17, 55 ], "eating": [ 18 ], "disorder": [ 19 ], "(BED).": [ 20 ], "Methods": [ 21 ], "Adults": [ 22 ], "with": [ 23, 127, 215 ], "body": [ 25 ], "mass": [ 26 ], "index": [ 27 ], "(BMI)": [ 28 ], "\u2265": [ 29 ], "27": [ 30 ], "kg/m": [ 31, 101 ], "2": [ 32, 102 ], "enrolled": [ 33 ], "in": [ 34, 148, 156, 189, 208, 213 ], "pilot,": [ 36 ], "17\u2010week": [ 37 ], "double\u2010blind,": [ 38 ], "randomized": [ 39 ], "controlled": [ 40 ], "trial": [ 41 ], "mg/day": [ 45 ], "BED.": [ 47 ], "The": [ 48 ], "primary": [ 49 ], "outcome": [ 50 ], "was": [ 51, 186, 229 ], "number": [ 52 ], "objective": [ 54 ], "episodes": [ 56 ], "(OBEs)/week.": [ 57 ], "Binge": [ 58 ], "remission,": [ 59 ], "weight": [ 60, 184, 222 ], "change,": [ 61 ], "and": [ 62, 76, 106, 109, 151, 177, 240 ], "psychosocial": [ 63 ], "variables": [ 64 ], "were": [ 65, 71, 80, 91 ], "secondary": [ 66 ], "outcomes.": [ 67 ], "Mixed": [ 68 ], "effect": [ 69 ], "models": [ 70 ], "used": [ 72, 81 ], "continuous": [ 74 ], "variables,": [ 75 ], "generalized": [ 77 ], "estimating": [ 78 ], "equations": [ 79 ], "remission": [ 83, 173 ], "rates.": [ 84 ], "Results": [ 85 ], "Participants": [ 86, 207 ], "(": [ 87, 117, 159 ], "n": [ 88, 118 ], "=": [ 89, 97, 119, 137, 161, 165, 204 ], "27)": [ 90 ], "44.2": [ 92 ], "\u00b1": [ 93, 99, 123, 129, 146, 154, 197, 201 ], "10.6": [ 94 ], "years;": [ 95 ], "BMI": [ 96 ], "37.9": [ 98 ], "11.8": [ 100 ], ";": [ 103 ], "63%": [ 104 ], "women;": [ 105 ], "59%": [ 107 ], "White": [ 108 ], "41%": [ 110 ], "Black.": [ 111 ], "At": [ 112, 139 ], "baseline,": [ 113 ], "group": [ 116, 195, 218 ], "13)": [ 120 ], "reported": [ 121, 211 ], "4.7": [ 122 ], "0.7": [ 124, 130 ], "OBEs/week,": [ 125 ], "compared": [ 126 ], "OBEs/week": [ 131, 142 ], "placebo": [ 134, 157, 194 ], "group,": [ 135 ], "p": [ 136, 160, 203 ], "0.07.": [ 138 ], "week": [ 140 ], "17,": [ 141 ], "decreased": [ 143 ], "by": [ 144, 152 ], "4.0": [ 145 ], "0.6": [ 147 ], "participants": [ 150, 158 ], "2.5": [ 153 ], "0.5": [ 155 ], "0.37,": [ 162 ], "mean": [ 163 ], "difference": [ 164 ], "1.2,": [ 166 ], "95%": [ 167 ], "confidence": [ 168 ], "interval": [ 169 ], "1.3,": [ 170 ], "2.0).": [ 171 ], "BED": [ 172, 245 ], "rates": [ 174 ], "44%": [ 176 ], "36%,": [ 178 ], "respectively,": [ 179 ], "did": [ 180 ], "not": [ 181 ], "differ.": [ 182 ], "Percent": [ 183 ], "loss": [ 185 ], "significantly": [ 187 ], "greater": [ 188 ], "versus": [ 192 ], "(5.2": [ 196 ], "1.0%": [ 198 ], "vs.": [ 199 ], "0.9": [ 200 ], "0.7%,": [ 202 ], "0.005).": [ 205 ], "Conclusion": [ 206 ], "both": [ 209 ], "groups": [ 210 ], "reductions": [ 212 ], "OBEs,": [ 214 ], "showing": [ 219 ], "clinically": [ 220 ], "meaningful": [ 221 ], "loss.": [ 223 ], "A": [ 224 ], "pharmacy": [ 225 ], "medication": [ 226 ], "dispensing": [ 227 ], "error": [ 228 ], "significant": [ 231 ], "limitation": [ 232 ], "this": [ 234 ], "study.": [ 235 ], "Further": [ 236 ], "research": [ 237 ], "on": [ 238 ], "other": [ 241 ], "GLP\u20101": [ 242 ], "agonists": [ 243 ], "is": [ 246 ], "warranted.": [ 247 ] }, "publication_date": "2022-06-07", "publication_year": 2022, "type": "article", "cited_by_count": 56, "authors": [ { "id": "https://openalex.org/A5017461155", "display_name": "Kelly C. Allison" }, { "id": "https://openalex.org/A5021408335", "display_name": "Ariana M. Chao" }, { "id": "https://openalex.org/A5064178503", "display_name": "Maija B. Bruzas" }, { "id": "https://openalex.org/A5070686192", "display_name": "Courtney McCuen\u2010Wurst" }, { "id": "https://openalex.org/A5029347481", "display_name": "Elizabeth Jones" }, { "id": "https://openalex.org/A5082392101", "display_name": "Cooper McAllister" }, { "id": "https://openalex.org/A5091448088", "display_name": "Kathryn Gruber" }, { "id": "https://openalex.org/A5082460301", "display_name": "Robert I. Berkowitz" }, { "id": "https://openalex.org/A5026596594", "display_name": "Thomas A. Wadden" }, { "id": "https://openalex.org/A5001055593", "display_name": "Jena Shaw Tronieri" } ] }, { "id": "https://openalex.org/W2071539395", "doi": "https://doi.org/10.1016/j.atherosclerosis.2010.05.028", "title": "Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus", "abstract": null, "publication_date": "2010-05-26", "publication_year": 2010, "type": "article", "cited_by_count": 171, "authors": [ { "id": "https://openalex.org/A5034236019", "display_name": "Eric A. Schwartz" }, { "id": "https://openalex.org/A5109148559", "display_name": "Juraj Ko\u0161ka" }, { "id": "https://openalex.org/A5009910145", "display_name": "Michael P. Mullin" }, { "id": "https://openalex.org/A5018037084", "display_name": "Iyad Syoufi" }, { "id": "https://openalex.org/A5003255105", "display_name": "Dawn C. Schwenke" }, { "id": "https://openalex.org/A5007571294", "display_name": "Peter D. Reaven" } ] }, { "id": "https://openalex.org/W4377094139", "doi": "https://doi.org/10.1002/oby.23752", "title": "Liraglutide versus semaglutide for weight reduction\u2014a cost needed to treat analysis", "abstract": { "Abstract": [ 0 ], "Objective": [ 1 ], "Higher": [ 2 ], "doses": [ 3 ], "of": [ 4, 95, 108, 121, 129, 153 ], "the": [ 5, 60, 66, 78, 82, 134, 146 ], "glucagon\u2010like": [ 6 ], "peptide\u20101": [ 7 ], "agonists": [ 8 ], "liraglutide": [ 9, 50, 132, 158, 183 ], "and,": [ 10 ], "more": [ 11 ], "recently,": [ 12 ], "semaglutide": [ 13, 48 ], "have": [ 14 ], "demonstrated": [ 15 ], "a": [ 16, 41, 105, 118 ], "significant": [ 17 ], "reduction": [ 18, 43, 156 ], "in": [ 19, 44, 100, 104, 114, 117 ], "body": [ 20, 45, 54, 154 ], "weight.": [ 21 ], "However,": [ 22 ], "their": [ 23 ], "comparative": [ 24 ], "value": [ 25, 179 ], "for": [ 26, 28, 180, 184 ], "money": [ 27, 181 ], "this": [ 29 ], "indication": [ 30 ], "is": [ 31, 159 ], "unclear.": [ 32 ], "Methods": [ 33 ], "The": [ 34, 53, 126 ], "cost": [ 35, 128, 147 ], "needed": [ 36, 148 ], "to": [ 37, 39, 76, 149 ], "treat": [ 38, 150 ], "achieve": [ 40 ], "1%": [ 42, 152 ], "weight": [ 46, 55, 106, 119, 155, 185 ], "using": [ 47 ], "or": [ 49 ], "was": [ 51, 74, 136 ], "calculated.": [ 52 ], "reductions": [ 56 ], "were": [ 57, 88 ], "extracted": [ 58 ], "from": [ 59 ], "published": [ 61 ], "STEP": [ 62, 101 ], "1": [ 63, 102 ], "trial": [ 64, 68, 135 ], "and": [ 65 ], "SCALE": [ 67, 115 ], "results,": [ 69 ], "respectively.": [ 70 ], "A": [ 71 ], "scenario": [ 72 ], "analysis": [ 73 ], "performed": [ 75 ], "mitigate": [ 77 ], "primary": [ 79 ], "differences": [ 80 ], "between": [ 81 ], "two": [ 83 ], "studies'": [ 84 ], "populations.": [ 85 ], "Drug": [ 86 ], "costs": [ 87 ], "based": [ 89 ], "on": [ 90 ], "US": [ 91 ], "GoodRx": [ 92 ], "prices": [ 93 ], "as": [ 94 ], "October": [ 96 ], "2022.": [ 97 ], "Results": [ 98 ], "Liraglutide": [ 99 ], "resulted": [ 103, 116 ], "loss": [ 107, 120 ], "5.4%": [ 109 ], "(95%": [ 110, 123, 163, 169 ], "CI:": [ 111, 124, 164, 170 ], "5%\u20105.8%).": [ 112 ], "Semaglutide": [ 113, 175 ], "12.4%": [ 122 ], "11.5%\u201013.4%).": [ 125 ], "total": [ 127 ], "therapy": [ 130 ], "with": [ 131, 141, 143, 157, 167, 172 ], "during": [ 133 ], "estimated": [ 137, 160 ], "at": [ 138, 161 ], "$17,585": [ 139 ], "compared": [ 140, 166 ], "$22,878": [ 142 ], "semaglutide.": [ 144, 173 ], "Accordingly,": [ 145 ], "per": [ 151 ], "$3256": [ 162 ], "$3032\u2010$3517)": [ 165 ], "$1845": [ 168 ], "$1707\u2010$1989)": [ 171 ], "Conclusions": [ 174 ], "provides": [ 176 ], "significantly": [ 177 ], "better": [ 178 ], "than": [ 182 ], "reduction.": [ 186 ] }, "publication_date": "2023-05-19", "publication_year": 2023, "type": "article", "cited_by_count": 22, "authors": [ { "id": "https://openalex.org/A5030931326", "display_name": "Joseph Azuri" }, { "id": "https://openalex.org/A5058266202", "display_name": "Ariel Hammerman" }, { "id": "https://openalex.org/A5035639700", "display_name": "Enis Aboalhasan" }, { "id": "https://openalex.org/A5024606485", "display_name": "Ben Sluckis" }, { "id": "https://openalex.org/A5059868848", "display_name": "Ronen Arbel" } ] }, { "id": "https://openalex.org/W2524571966", "doi": "https://doi.org/10.1080/14712598.2016.1240780", "title": "Albiglutide: a unique GLP-1 receptor agonist", "abstract": { "Albiglutide": [ 0, 54 ], "is": [ 1, 81, 121 ], "a": [ 2, 32, 37, 56, 89, 102, 178 ], "long": [ 3, 161 ], "acting": [ 4 ], "GLP-1": [ 5, 66, 78, 114, 126 ], "receptor": [ 6 ], "agonist": [ 7 ], "(GLP-1": [ 8 ], "RA)": [ 9 ], "administered": [ 10 ], "by": [ 11 ], "weekly": [ 12 ], "injection.": [ 13 ], "Area": [ 14 ], "covered:": [ 15 ], "The": [ 16, 29, 68, 116 ], "pharmacokinetic": [ 17 ], "and": [ 18, 23, 36, 44, 47, 80, 94 ], "pharmacodynamic": [ 19 ], "properties": [ 20 ], "of": [ 21, 34, 40, 63, 104, 106, 134, 151, 157, 174, 183, 188 ], "albiglutide": [ 22 ], "its": [ 24, 171 ], "clinical": [ 25 ], "effects": [ 26, 74 ], "are": [ 27 ], "discussed.": [ 28 ], "review": [ 30 ], "encompassed": [ 31 ], "search": [ 33 ], "PubMed": [ 35 ], "thorough": [ 38 ], "analysis": [ 39 ], "the": [ 41, 138, 181 ], "European": [ 42 ], "Union": [ 43 ], "US": [ 45 ], "Food": [ 46 ], "Drug": [ 48 ], "Administration": [ 49 ], "approval": [ 50, 139 ], "documents.": [ 51 ], "Expert": [ 52 ], "opinion:": [ 53 ], "has": [ 55, 70, 177 ], "chemical": [ 57 ], "structure": [ 58 ], "quite": [ 59 ], "distinct": [ 60 ], "from": [ 61 ], "that": [ 62 ], "other": [ 64, 76, 97, 125 ], "marketed": [ 65 ], "RAs.": [ 67, 115, 127 ], "agent": [ 69 ], "less": [ 71, 110 ], "gastrointestinal": [ 72 ], "side": [ 73 ], "than": [ 75, 111 ], "comparable": [ 77 ], "RAs": [ 79 ], "safe": [ 82 ], "in": [ 83, 137, 153, 180 ], "patients": [ 84, 184 ], "with": [ 85, 96, 170, 185 ], "renal": [ 86 ], "failure.": [ 87 ], "As": [ 88 ], "sole": [ 90 ], "treatment": [ 91, 182 ], "for": [ 92 ], "diabetes": [ 93 ], "used": [ 95 ], "hypoglycemic": [ 98 ], "agents,": [ 99 ], "it": [ 100 ], "achieves": [ 101 ], "lowering": [ 103 ], "HbA1c": [ 105 ], "up": [ 107, 154 ], "to": [ 108, 124, 149, 155 ], "1%,": [ 109 ], "several": [ 112 ], "competitor": [ 113 ], "benefit": [ 117 ], "on": [ 118 ], "weight": [ 119 ], "reduction": [ 120 ], "minimal": [ 122 ], "compared": [ 123 ], "There": [ 128 ], "exists": [ 129 ], "concern": [ 130 ], "about": [ 131 ], "an": [ 132 ], "imbalance": [ 133 ], "pancreatitis": [ 135 ], "cases": [ 136 ], "program": [ 140 ], "as": [ 141, 143 ], "well": [ 142 ], "injection": [ 144 ], "site": [ 145 ], "reactions": [ 146 ], "which": [ 147 ], "led": [ 148 ], "discontinuance": [ 150 ], "therapy": [ 152 ], "2%": [ 156 ], "participants.": [ 158 ], "A": [ 159 ], "large": [ 160 ], "term": [ 162 ], "study": [ 163 ], "now": [ 164 ], "underway": [ 165 ], "will": [ 166 ], "determine": [ 167 ], "if": [ 168 ], "albiglutide,": [ 169 ], "lower": [ 172 ], "level": [ 173 ], "GI": [ 175 ], "intolerance,": [ 176 ], "place": [ 179 ], "increased": [ 186 ], "risk": [ 187 ], "cardiovascular": [ 189 ], "events.": [ 190 ] }, "publication_date": "2016-09-28", "publication_year": 2016, "type": "review", "cited_by_count": 22, "authors": [ { "id": "https://openalex.org/A5079527249", "display_name": "Marc Rendell" } ] }, { "id": "https://openalex.org/W2055187870", "doi": "https://doi.org/10.1038/oby.2011.337", "title": "Exenatide as a Weight\u2010Loss Therapy in Extreme Pediatric Obesity: A Randomized, Controlled Pilot Study", "abstract": { "The": [ 0, 129 ], "objective": [ 1 ], "of": [ 2, 11, 61, 69, 77, 116 ], "this": [ 3 ], "pilot": [ 4 ], "study": [ 5 ], "was": [ 6, 136, 207, 212, 220 ], "to": [ 7, 86, 97, 141, 241 ], "evaluate": [ 8 ], "the": [ 9, 41, 98, 204 ], "effects": [ 10 ], "exenatide": [ 12, 143, 211, 230 ], "on": [ 13 ], "BMI": [ 14, 45, 146, 243 ], "(primary": [ 15 ], "endpoint)": [ 16 ], "and": [ 17, 29, 72, 119, 127, 171, 195, 210, 244 ], "cardiometabolic": [ 18, 246 ], "risk": [ 19, 247 ], "factors": [ 20, 248 ], "in": [ 21, 52, 223, 234, 249 ], "nondiabetic": [ 22 ], "youth": [ 23, 250 ], "with": [ 24, 35, 90, 203, 251 ], "extreme": [ 25, 36, 252 ], "obesity.": [ 26, 253 ], "Twelve": [ 27 ], "children": [ 28 ], "adolescents": [ 30 ], "(age": [ 31 ], "9\u201316": [ 32 ], "years": [ 33 ], "old)": [ 34 ], "obesity": [ 37 ], "(BMI": [ 38 ], "\u22651.2": [ 39 ], "times": [ 40 ], "95th": [ 42 ], "percentile": [ 43 ], "or": [ 44, 92 ], "\u226535": [ 46 ], "kg/m": [ 47, 148 ], "2": [ 48, 149 ], ")": [ 49 ], "were": [ 50, 83, 122, 185 ], "enrolled": [ 51 ], "a": [ 53, 66, 74 ], "6\u2010month,": [ 54 ], "randomized,": [ 55 ], "open\u2010label,": [ 56 ], "crossover,": [ 57 ], "clinical": [ 58 ], "trial": [ 59 ], "consisting": [ 60 ], "two,": [ 62 ], "3\u2010month": [ 63, 134 ], "phases:": [ 64 ], "(i)": [ 65 ], "control": [ 67, 91 ], "phase": [ 68, 76, 135 ], "lifestyle": [ 70, 78 ], "modification": [ 71, 79 ], "(ii)": [ 73 ], "drug": [ 75, 93 ], "plus": [ 80 ], "exenatide.": [ 81 ], "Participants": [ 82 ], "equally": [ 84 ], "randomized": [ 85 ], "phase\u2010order": [ 87 ], "(i.e.,": [ 88 ], "starting": [ 89 ], "therapy)": [ 94 ], "then": [ 95 ], "crossed\u2010over": [ 96 ], "other": [ 99 ], "treatment.": [ 100 ], "BMI,": [ 101 ], "body": [ 102, 160 ], "fat": [ 103 ], "percentage,": [ 104 ], "blood": [ 105 ], "pressure,": [ 106 ], "lipids,": [ 107 ], "oral": [ 108 ], "glucose": [ 109 ], "tolerance": [ 110 ], "tests": [ 111 ], "(OGTT),": [ 112 ], "adipokines,": [ 113 ], "plasma": [ 114 ], "biomarkers": [ 115 ], "endothelial": [ 117, 120 ], "activation,": [ 118 ], "function": [ 121, 197 ], "assessed": [ 123 ], "at": [ 124 ], "baseline,": [ 125 ], "3\u2010,": [ 126 ], "6\u2010months.": [ 128 ], "mean": [ 130 ], "change": [ 131 ], "over": [ 132 ], "each": [ 133 ], "compared": [ 137 ], "between": [ 138 ], "treatments.": [ 139 ], "Compared": [ 140 ], "control,": [ 142 ], "significantly": [ 144 ], "reduced": [ 145 ], "(\u22121.7": [ 147 ], ",": [ 150 ], "95%": [ 151, 164, 176 ], "confidence": [ 152 ], "interval": [ 153 ], "(CI)": [ 154 ], "(\u22123.0,": [ 155 ], "\u22120.4),": [ 156 ], "P": [ 157, 168, 180, 192, 199 ], "=": [ 158, 169, 181, 193, 200 ], "0.01),": [ 159 ], "weight": [ 161 ], "(\u22123.9": [ 162 ], "kg,": [ 163 ], "CI": [ 165, 177 ], "(\u22127.11,": [ 166 ], "\u22120.69),": [ 167 ], "0.02),": [ 170 ], "fasting": [ 172 ], "insulin": [ 173, 189 ], "(\u22127.5": [ 174 ], "mU/l,": [ 175 ], "(\u221213.71,": [ 178 ], "\u22121.37),": [ 179 ], "0.02).": [ 182 ], "Significant": [ 183 ], "improvements": [ 184 ], "observed": [ 186 ], "for": [ 187, 238 ], "OGTT\u2010derived": [ 188 ], "sensitivity": [ 190 ], "(": [ 191, 198 ], "0.02)": [ 194 ], "\u03b2\u2010cell": [ 196 ], "0.03).": [ 201 ], "Compliance": [ 202 ], "injection": [ 205 ], "regimen": [ 206 ], "excellent": [ 208 ], "(\u226594%)": [ 209 ], "generally": [ 213 ], "well\u2010tolerated": [ 214 ], "(the": [ 215 ], "most": [ 216 ], "common": [ 217 ], "adverse": [ 218 ], "event": [ 219 ], "mild": [ 221 ], "nausea": [ 222 ], "36%).": [ 224 ], "These": [ 225 ], "preliminary": [ 226 ], "data": [ 227 ], "suggest": [ 228 ], "that": [ 229 ], "should": [ 231 ], "be": [ 232 ], "evaluated": [ 233 ], "larger,": [ 235 ], "well\u2010controlled": [ 236 ], "trials": [ 237 ], "its": [ 239 ], "ability": [ 240 ], "reduce": [ 242 ], "improve": [ 245 ] }, "publication_date": "2011-11-10", "publication_year": 2011, "type": "article", "cited_by_count": 132, "authors": [ { "id": "https://openalex.org/A5012739284", "display_name": "Aaron S. Kelly" }, { "id": "https://openalex.org/A5010236250", "display_name": "Andrea M. Metzig" }, { "id": "https://openalex.org/A5036273026", "display_name": "Kyle Rudser" }, { "id": "https://openalex.org/A5086401203", "display_name": "Angela Fitch" }, { "id": "https://openalex.org/A5086798332", "display_name": "Claudia K. Fox" }, { "id": "https://openalex.org/A5071275113", "display_name": "Brandon M. Nathan" }, { "id": "https://openalex.org/A5052710334", "display_name": "Mary M. Deering" }, { "id": "https://openalex.org/A5053040902", "display_name": "Betsy L. Schwartz" }, { "id": "https://openalex.org/A5020228435", "display_name": "M. Jennifer Abuzzahab" }, { "id": "https://openalex.org/A5035262482", "display_name": "Laura M. Gandrud" }, { "id": "https://openalex.org/A5010764462", "display_name": "Antoinette Moran" }, { "id": "https://openalex.org/A5090515985", "display_name": "Charles J. Billington" }, { "id": "https://openalex.org/A5002446565", "display_name": "Sarah Jane Schwarzenberg" } ] }, { "id": "https://openalex.org/W2795500323", "doi": "https://doi.org/10.1007/s13300-018-0420-6", "title": "Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk", "abstract": { "The": [ 0 ], "combination": [ 1, 43 ], "of": [ 2, 41, 65 ], "a": [ 3 ], "GLP-1": [ 4 ], "agonist": [ 5 ], "and": [ 6, 15, 21, 24, 33, 61, 63 ], "an": [ 7 ], "SGLT2-inhibitor": [ 8 ], "has": [ 9, 25 ], "additive": [ 10 ], "effects": [ 11 ], "on": [ 12 ], "lowering": [ 13 ], "HbA1c": [ 14 ], "systolic": [ 16 ], "blood": [ 17 ], "pressure,": [ 18 ], "body": [ 19 ], "weight": [ 20 ], "cardiac": [ 22, 56, 59 ], "risk": [ 23, 57 ], "the": [ 26 ], "potential": [ 27 ], "to": [ 28, 46, 55 ], "synergistically": [ 29 ], "reduce": [ 30 ], "cardiovascular": [ 31 ], "events": [ 32, 60 ], "decelerate": [ 34 ], "renal": [ 35, 66 ], "decompensation.": [ 36 ], "A": [ 37 ], "large": [ 38 ], "prospective": [ 39 ], "study": [ 40 ], "this": [ 42, 49 ], "is": [ 44, 68 ], "needed": [ 45 ], "prove": [ 47 ], "that": [ 48 ], "synergism,": [ 50 ], "especially": [ 51 ], "as": [ 52 ], "it": [ 53 ], "applies": [ 54 ], "factors,": [ 58 ], "mortality": [ 62 ], "preservation": [ 64 ], "function,": [ 67 ], "proven.": [ 69 ] }, "publication_date": "2018-04-05", "publication_year": 2018, "type": "review", "cited_by_count": 57, "authors": [ { "id": "https://openalex.org/A5103049660", "display_name": "Edison Gon\u00e7alves" }, { "id": "https://openalex.org/A5028507024", "display_name": "David S.H. Bell" } ] }, { "id": "https://openalex.org/W2340697629", "doi": "https://doi.org/10.1111/dom.12639", "title": "Exposure\u2013response analyses of liraglutide 3.0\u2009mg for weight management", "abstract": { "Aims": [ 0 ], "Liraglutide": [ 1 ], "3.0": [ 2, 69, 88, 122, 228 ], "mg,": [ 3 ], "an": [ 4 ], "acylated": [ 5 ], "GLP\u20101": [ 6 ], "analogue": [ 7 ], "approved": [ 8 ], "for": [ 9, 167, 184, 230 ], "weight": [ 10, 14, 231, 237 ], "management,": [ 11 ], "lowers": [ 12 ], "body": [ 13 ], "through": [ 15 ], "decreased": [ 16 ], "energy": [ 17 ], "intake.": [ 18 ], "We": [ 19, 44 ], "conducted": [ 20 ], "exposure\u2010response": [ 21 ], "analyses": [ 22, 222 ], "to": [ 23, 30, 112 ], "provide": [ 24 ], "important": [ 25 ], "information": [ 26 ], "on": [ 27 ], "individual": [ 28 ], "responses": [ 29, 49 ], "given": [ 31 ], "drug": [ 32, 38, 242 ], "doses,": [ 33 ], "reflecting": [ 34 ], "inter\u2010individual": [ 35 ], "variations": [ 36 ], "in": [ 37, 124, 132, 233, 248 ], "metabolism,": [ 39 ], "absorption": [ 40 ], "and": [ 41, 47, 68, 71, 79, 110, 138 ], "excretion.": [ 42 ], "Methods": [ 43 ], "report": [ 45 ], "efficacy": [ 46 ], "safety": [ 48, 186 ], "across": [ 50 ], "a": [ 51, 99, 145 ], "wide": [ 52 ], "range": [ 53 ], "of": [ 54, 191, 226 ], "exposure": [ 55, 109, 214 ], "levels,": [ 56 ], "using": [ 57 ], "data": [ 58 ], "from": [ 59 ], "one": [ 60 ], "phase": [ 61, 73 ], "II": [ 62 ], "(liraglutide": [ 63 ], "doses": [ 64 ], "1.2,": [ 65 ], "1.8,": [ 66 ], "2.4": [ 67 ], "mg),": [ 70 ], "two": [ 72 ], "IIIa": [ 74 ], "[": [ 75 ], "SCALE": [ 76, 84 ], "O": [ 77 ], "besity": [ 78 ], "P": [ 80 ], "rediabetes": [ 81 ], "(3.0": [ 82 ], "mg);": [ 83 ], "D": [ 85 ], "iabetes": [ 86 ], "(1.8;": [ 87 ], "mg)]": [ 89 ], "randomized,": [ 90 ], "placebo\u2010controlled": [ 91 ], "trials": [ 92 ], "(n": [ 93 ], "=": [ 94 ], "4372).": [ 95 ], "Results": [ 96 ], "There": [ 97 ], "was": [ 98, 144, 182 ], "clear": [ 100, 146 ], "exposure\u2013weight": [ 101 ], "loss": [ 102, 105, 238 ], "response.": [ 103 ], "Weight": [ 104 ], "increased": [ 106, 155, 239 ], "with": [ 107, 120, 136, 156, 169, 188, 199, 216, 240, 244 ], "greater": [ 108 ], "appeared": [ 111 ], "level": [ 113 ], "off": [ 114 ], "at": [ 115, 162 ], "the": [ 116, 189, 217, 224 ], "highest": [ 117 ], "exposures": [ 118 ], "associated": [ 119 ], "liraglutide": [ 121, 159, 213, 227 ], "mg": [ 123, 229 ], "most": [ 125 ], "individuals,": [ 126 ], "but": [ 127 ], "did": [ 128, 175, 209 ], "not": [ 129, 176, 210 ], "fully": [ 130, 177 ], "plateau": [ 131 ], "men.": [ 133 ], "In": [ 134 ], "individuals": [ 135, 168 ], "overweight/obesity": [ 137 ], "comorbid": [ 139 ], "type": [ 140 ], "2": [ 141 ], "diabetes,": [ 142 ], "there": [ 143 ], "exposure\u2013glycated": [ 147 ], "haemoglobin": [ 148 ], "(": [ 149, 195 ], "HbA1c": [ 150, 153, 171, 173 ], ")": [ 151 ], "relationship.": [ 152 ], "reduction": [ 154, 174 ], "higher": [ 157, 212, 241 ], "plasma": [ 158 ], "concentration": [ 160 ], "(plateauing": [ 161 ], "\u223c21": [ 163 ], "nM": [ 164 ], ");": [ 165 ], "however,": [ 166 ], "baseline": [ 170 ], ">8.5%,": [ 172 ], "plateau.": [ 178 ], "No": [ 179 ], "exposure\u2013response": [ 180 ], "relationship": [ 181 ], "identified": [ 183 ], "any": [ 185 ], "outcome,": [ 187 ], "exception": [ 190 ], "gastrointestinal": [ 192, 253 ], "adverse": [ 193 ], "events": [ 194 ], "AEs": [ 196, 201 ], ").": [ 197 ], "Individuals": [ 198 ], "gallbladder": [ 200 ], ",": [ 202 ], "acute": [ 203 ], "pancreatitis": [ 204 ], "or": [ 205 ], "malignant/breast/benign": [ 206 ], "colorectal": [ 207 ], "neoplasms": [ 208 ], "have": [ 211 ], "compared": [ 215 ], "overall": [ 218 ], "population.": [ 219 ], "Conclusions": [ 220 ], "These": [ 221 ], "support": [ 223 ], "use": [ 225 ], "management": [ 232 ], "all": [ 234 ], "subgroups": [ 235 ], "investigated;": [ 236 ], "exposure,": [ 243 ], "no": [ 245 ], "concomitant": [ 246 ], "deterioration": [ 247 ], "safety/tolerability": [ 249 ], "besides": [ 250 ], "previously": [ 251 ], "known": [ 252 ], "side": [ 254 ], "effects.": [ 255 ] }, "publication_date": "2016-02-02", "publication_year": 2016, "type": "article", "cited_by_count": 96, "authors": [ { "id": "https://openalex.org/A5047195042", "display_name": "John Wilding" }, { "id": "https://openalex.org/A5026540782", "display_name": "Rune Viig Overgaard" }, { "id": "https://openalex.org/A5112171221", "display_name": "Lisbeth V. Jacobsen" }, { "id": "https://openalex.org/A5045125689", "display_name": "Camilla Bj\u00f8rn Jensen" }, { "id": "https://openalex.org/A5010753663", "display_name": "Carel W. le Roux" } ] }, { "id": "https://openalex.org/W2200208573", "doi": "https://doi.org/10.1016/j.ahj.2015.12.009", "title": "Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial", "abstract": null, "publication_date": "2015-12-22", "publication_year": 2015, "type": "article", "cited_by_count": 103, "authors": [ { "id": "https://openalex.org/A5049740900", "display_name": "Rury R. Holman" }, { "id": "https://openalex.org/A5107392876", "display_name": "Mary Angelyn Bethel" }, { "id": "https://openalex.org/A5034066967", "display_name": "Jyothis T. George" }, { "id": "https://openalex.org/A5056821482", "display_name": "Harald Sourij" }, { "id": "https://openalex.org/A5018971707", "display_name": "Zo\u00eb Doran" }, { "id": "https://openalex.org/A5024205434", "display_name": "Joanne F. Keenan" }, { "id": "https://openalex.org/A5023004151", "display_name": "Nardev S. Khurmi" }, { "id": "https://openalex.org/A5068642565", "display_name": "Robert J. Mentz" }, { "id": "https://openalex.org/A5051530545", "display_name": "Abderrahim Oulhaj" }, { "id": "https://openalex.org/A5040182038", "display_name": "John B. Buse" }, { "id": "https://openalex.org/A5091832416", "display_name": "Juliana C.N. Chan" }, { "id": "https://openalex.org/A5108458439", "display_name": "Nayyar Iqbal" }, { "id": "https://openalex.org/A5108677282", "display_name": "Sudeep Kundu" }, { "id": "https://openalex.org/A5088186128", "display_name": "Aldo P. Maggioni" }, { "id": "https://openalex.org/A5110355842", "display_name": "Steven P. Marso" }, { "id": "https://openalex.org/A5112827962", "display_name": "Peter \u00d6hman" }, { "id": "https://openalex.org/A5064002558", "display_name": "Michael Pencina" }, { "id": "https://openalex.org/A5072011562", "display_name": "Neil R Poulter" }, { "id": "https://openalex.org/A5103540035", "display_name": "Lisa E. Porter" }, { "id": "https://openalex.org/A5007281961", "display_name": "Ambady Ramachandran" }, { "id": "https://openalex.org/A5090437675", "display_name": "Bernard Zinman" }, { "id": "https://openalex.org/A5012849300", "display_name": "Adrian F. Hernandez" } ] }, { "id": "https://openalex.org/W4391141493", "doi": "https://doi.org/10.3390/ph17020147", "title": "Glucagon-like Peptide-1 Receptor Agonists and Suicidal Ideation: Analysis of Real-Word Data Collected in the European Pharmacovigilance Database", "abstract": { "Background:": [ 0 ], "A": [ 1, 34, 76 ], "potential": [ 2 ], "risk": [ 3 ], "of": [ 4, 23, 38, 69, 78, 81, 120, 149, 212, 234 ], "suicide": [ 5, 110 ], "associated": [ 6, 143, 194 ], "with": [ 7, 144, 187, 195, 215 ], "liraglutide": [ 8, 92, 141, 176 ], "or": [ 9 ], "semaglutide": [ 10, 96, 124, 174, 188 ], "treatments": [ 11 ], "has": [ 12 ], "recently": [ 13 ], "emerged.": [ 14 ], "Therefore,": [ 15 ], "we": [ 16 ], "decided": [ 17 ], "to": [ 18, 52, 64, 201 ], "investigate": [ 19 ], "the": [ 20, 39, 46, 66, 138, 165, 209, 229, 235, 240 ], "reporting": [ 21, 67, 118, 147, 169, 198, 210 ], "probability": [ 22, 68, 119, 148, 170 ], "suicidal": [ 24, 70, 82, 106, 121, 150 ], "events": [ 25, 71, 83, 104, 122, 151, 183, 214 ], "among": [ 26, 72 ], "glucagon-like": [ 27 ], "peptide-1": [ 28 ], "receptor": [ 29 ], "agonists": [ 30 ], "(GLP-1": [ 31 ], "RAs).": [ 32 ], "Methods:": [ 33 ], "retrospective": [ 35 ], "pharmacovigilance": [ 36 ], "study": [ 37, 207 ], "European": [ 40, 236 ], "Pharmacovigilance": [ 41, 230 ], "database": [ 42 ], "was": [ 43, 91, 142, 171 ], "conducted": [ 44 ], "for": [ 45, 123, 173 ], "period": [ 47 ], "from": [ 48 ], "1": [ 49 ], "January": [ 50 ], "2018": [ 51 ], "10": [ 53 ], "July": [ 54 ], "2023.": [ 55 ], "Disproportionality": [ 56, 113 ], "analyses": [ 57 ], "(reporting": [ 58 ], "odds": [ 59 ], "ratio,": [ 60 ], "ROR)": [ 61 ], "were": [ 62, 84, 105, 184, 192 ], "performed": [ 63 ], "assess": [ 65 ], "GLP-1": [ 73, 89, 216 ], "RAs.": [ 74, 204 ], "Results:": [ 75 ], "total": [ 77 ], "230": [ 79 ], "reports": [ 80 ], "identified.": [ 85 ], "The": [ 86, 101 ], "most": [ 87, 102 ], "reported": [ 88, 103, 186 ], "RA": [ 90 ], "(38.3%),": [ 93 ], "followed": [ 94 ], "by": [ 95, 228 ], "(36.5%)": [ 97 ], "and": [ 98, 109, 131, 158, 189 ], "dulaglutide": [ 99, 126, 153 ], "(16.1%).": [ 100 ], "ideation": [ 107 ], "(65.3%)": [ 108 ], "attempt": [ 111 ], "(19.5%).": [ 112 ], "analysis": [ 114 ], "found": [ 115, 172 ], "a": [ 116, 145, 167 ], "higher": [ 117, 146, 197 ], "than": [ 125, 152, 175 ], "(ROR,": [ 127, 133, 154, 160, 177 ], "2.05;": [ 128 ], "95%CI,": [ 129, 135, 156, 162, 179 ], "1.40\u20133.01)": [ 130 ], "exenatide": [ 132, 159 ], "1.81;": [ 134 ], "1.08\u20133.05).": [ 136 ], "In": [ 137 ], "same": [ 139 ], "way,": [ 140 ], "3.98;": [ 155 ], "2.73\u20135.82)": [ 157 ], "3.52;": [ 161 ], "2.10\u20135.92).": [ 163 ], "On": [ 164 ], "contrary,": [ 166 ], "lower": [ 168 ], "0.51;": [ 178 ], "0.38\u20130.69).": [ 180 ], "Conclusions:": [ 181 ], "Suicidal": [ 182 ], "mostly": [ 185 ], "liraglutide,": [ 190 ], "which": [ 191, 223 ], "also": [ 193 ], "significantly": [ 196 ], "probabilities": [ 199 ], "compared": [ 200 ], "other": [ 202 ], "GLP1": [ 203 ], "Although": [ 205 ], "this": [ 206 ], "provides": [ 208 ], "frequencies": [ 211 ], "suicide-related": [ 213 ], "RAs,": [ 217 ], "establishing": [ 218 ], "causality": [ 219 ], "requires": [ 220 ], "further": [ 221 ], "investigation,": [ 222 ], "will": [ 224 ], "probably": [ 225 ], "be": [ 226 ], "addressed": [ 227 ], "Risk": [ 231 ], "Assessment": [ 232 ], "Committee": [ 233 ], "Medicine": [ 237 ], "Agency": [ 238 ], "in": [ 239 ], "future.": [ 241 ] }, "publication_date": "2024-01-23", "publication_year": 2024, "type": "article", "cited_by_count": 35, "authors": [ { "id": "https://openalex.org/A5021562638", "display_name": "Rosanna Ruggiero" }, { "id": "https://openalex.org/A5071695232", "display_name": "Annamaria Mascolo" }, { "id": "https://openalex.org/A5093770680", "display_name": "Angela Spezzaferri" }, { "id": "https://openalex.org/A5114078403", "display_name": "Claudia Carpentieri" }, { "id": "https://openalex.org/A5063747611", "display_name": "Daniele Torella" }, { "id": "https://openalex.org/A5084091332", "display_name": "Liberata Sportiello" }, { "id": "https://openalex.org/A5103640110", "display_name": "Francesco Rossi" }, { "id": "https://openalex.org/A5084616356", "display_name": "Giuseppe Paolisso" }, { "id": "https://openalex.org/A5005557373", "display_name": "Annalisa Capuano" } ] }, { "id": "https://openalex.org/W4388101233", "doi": "https://doi.org/10.15288/jsad.23-00318", "title": "Social media as pharmacovigilance: The potential for patient reports to inform clinical research on glucagon-like peptide 1 (GLP-1) receptor agonists for substance use disorders", "abstract": { "The": [ 0, 74 ], "surge": [ 1 ], "in": [ 2, 25, 61, 71, 147 ], "popularity": [ 3 ], "of": [ 4, 22, 37, 64, 78, 96, 103, 141, 199 ], "semaglutide": [ 5 ], "(Ozempic,": [ 6 ], "Wegovy,": [ 7 ], "Rybelsus)": [ 8 ], "and": [ 9, 76, 100, 190 ], "other": [ 10, 29 ], "glucagon-like-peptide": [ 11 ], "1": [ 12 ], "(GLP-1)": [ 13 ], "receptor": [ 14, 39, 66, 157 ], "agonists": [ 15, 40, 67 ], "has": [ 16 ], "been": [ 17 ], "accompanied": [ 18 ], "by": [ 19, 137 ], "widespread": [ 20 ], "reports": [ 21, 49, 80, 144, 160, 198 ], "unintended": [ 23 ], "reductions": [ 24 ], "alcohol": [ 26, 69, 148 ], "use": [ 27, 43, 70, 149 ], "(and": [ 28 ], "addictive": [ 30, 204 ], "behaviors)": [ 31 ], "during": [ 32, 153 ], "treatment.": [ 33 ], "With": [ 34 ], "clinical": [ 35, 167 ], "trials": [ 36, 168 ], "GLP-1": [ 38, 65, 156 ], "for": [ 41, 59, 108, 129, 166, 187, 195, 220 ], "substance": [ 42 ], "only": [ 44, 162 ], "recently": [ 45 ], "under": [ 46 ], "way,": [ 47 ], "anecdotal": [ 48 ], "(including": [ 50 ], "via": [ 51 ], "social": [ 52, 85, 120 ], "media)": [ 53 ], "are": [ 54 ], "now": [ 55 ], "a": [ 56, 138 ], "primary": [ 57 ], "reason": [ 58 ], "interest": [ 60 ], "potential": [ 62, 173 ], "effects": [ 63, 152, 202 ], "on": [ 68, 203 ], "patient": [ 72, 197 ], "populations.": [ 73 ], "nature": [ 75 ], "volume": [ 77 ], "these": [ 79 ], "raises": [ 81 ], "the": [ 82, 94, 101, 164 ], "prospect": [ 83 ], "that": [ 84, 183 ], "media": [ 86, 121 ], "data": [ 87, 122 ], "can": [ 88 ], "potentially": [ 89, 210 ], "be": [ 90, 126 ], "leveraged": [ 91 ], "to": [ 92, 118, 123, 172, 212, 216 ], "inform": [ 93, 185 ], "study": [ 95 ], "novel": [ 97 ], "addiction": [ 98 ], "treatments": [ 99 ], "prioritization": [ 102 ], "behavioral": [ 104 ], "or": [ 105, 150 ], "neurobiological": [ 106 ], "targets": [ 107 ], "mechanistic": [ 109 ], "research.": [ 110 ], "This": [ 111, 133 ], "approach,": [ 112 ], "which": [ 113 ], "aligns": [ 114 ], "with": [ 115, 155 ], "recent": [ 116 ], "efforts": [ 117 ], "apply": [ 119 ], "pharmacovigilance,": [ 124 ], "may": [ 125 ], "particularly": [ 127 ], "relevant": [ 128 ], "drug": [ 130, 221 ], "repurposing": [ 131, 222 ], "efforts.": [ 132, 223 ], "possibility": [ 134 ], "is": [ 135 ], "illustrated": [ 136 ], "thematic": [ 139 ], "analysis": [ 140 ], "anonymous": [ 142 ], "online": [ 143 ], "concerning": [ 145 ], "changes": [ 146 ], "alcohol-related": [ 151 ], "treatment": [ 154 ], "agonists.": [ 158 ], "These": [ 159 ], "not": [ 161 ], "support": [ 163 ], "rationale": [ 165 ], "but": [ 169 ], "also": [ 170 ], "point": [ 171 ], "neurobehavioral": [ 174 ], "mechanisms": [ 175 ], "(e.g.,": [ 176 ], "satiety,": [ 177 ], "craving/preoccupation,": [ 178 ], "aversion,": [ 179 ], "altered": [ 180 ], "subjective": [ 181 ], "response)": [ 182 ], "might": [ 184 ], "hypotheses": [ 186 ], "human": [ 188 ], "laboratory": [ 189 ], "neuroscience": [ 191 ], "studies.": [ 192 ], "Refined": [ 193 ], "methods": [ 194 ], "capturing": [ 196 ], "incidental": [ 200 ], "medication": [ 201 ], "behaviors": [ 205 ], "at": [ 206 ], "large": [ 207 ], "scale": [ 208 ], "could": [ 209 ], "lead": [ 211 ], "novel,": [ 213 ], "pharmacovigilance-based": [ 214 ], "approaches": [ 215 ], "identify": [ 217 ], "candidate": [ 218 ], "therapies": [ 219 ] }, "publication_date": "2023-10-30", "publication_year": 2023, "type": "article", "cited_by_count": 26, "authors": [ { "id": "https://openalex.org/A5022056962", "display_name": "Michael P. Bremmer" }, { "id": "https://openalex.org/A5012683980", "display_name": "Christian S. Hendershot" } ] }, { "id": "https://openalex.org/W2968366779", "doi": "https://doi.org/10.1016/s2213-8587(19)30267-0", "title": "GLP-1 receptor agonists and cardiovascular outcomes: an updated synthesis", "abstract": null, "publication_date": "2019-08-14", "publication_year": 2019, "type": "letter", "cited_by_count": 11, "authors": [ { "id": "https://openalex.org/A5090174827", "display_name": "Eberhard Standl" } ] }, { "id": "https://openalex.org/W2062265409", "doi": "https://doi.org/10.1016/j.peptides.2013.12.015", "title": "A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis", "abstract": null, "publication_date": "2014-01-11", "publication_year": 2014, "type": "article", "cited_by_count": 139, "authors": [ { "id": "https://openalex.org/A5044425398", "display_name": "Yuko Tashiro" }, { "id": "https://openalex.org/A5101608369", "display_name": "Kengo Sato" }, { "id": "https://openalex.org/A5016475853", "display_name": "Takuya Watanabe" }, { "id": "https://openalex.org/A5066404591", "display_name": "Kyoko Nohtomi" }, { "id": "https://openalex.org/A5027590634", "display_name": "Michishige Terasaki" }, { "id": "https://openalex.org/A5022075735", "display_name": "Masaharu Nagashima" }, { "id": "https://openalex.org/A5073711245", "display_name": "Tsutomu Hirano" } ] }, { "id": "https://openalex.org/W2787870713", "doi": "https://doi.org/10.1155/2018/6482958", "title": "Liraglutide, a GLP-1 Receptor Agonist, Which Decreases Hypothalamic 5-HT2A Receptor Expression, Reduces Appetite and Body Weight Independently of Serotonin Synthesis in Mice", "abstract": { "A": [ 0 ], "recent": [ 1 ], "report": [ 2 ], "suggested": [ 3 ], "that": [ 4, 24, 42, 175 ], "brain-derived": [ 5 ], "serotonin": [ 6 ], "(5-HT)": [ 7 ], "is": [ 8 ], "critical": [ 9 ], "for": [ 10, 78, 117 ], "maintaining": [ 11 ], "weight": [ 12, 32, 50, 111, 181 ], "loss": [ 13, 33, 112 ], "induced": [ 14, 34, 51, 113 ], "by": [ 15, 35, 52, 114 ], "glucagon-like": [ 16 ], "peptide-1": [ 17 ], "(GLP-1)": [ 18 ], "receptor": [ 19, 37, 59, 94, 190 ], "activation": [ 20, 191 ], "in": [ 21, 44, 120, 153, 186 ], "rats": [ 22 ], "and": [ 23, 31, 48, 81, 179 ], "5-HT2A": [ 25, 93, 138, 159, 198 ], "receptors": [ 26, 139 ], "mediate": [ 27 ], "the": [ 28, 71, 97, 104, 109, 133, 145, 157, 193 ], "feeding": [ 29 ], "suppression": [ 30 ], "GLP-1": [ 36, 58, 189 ], "activation.": [ 38 ], "Here,": [ 39 ], "we": [ 40 ], "show": [ 41 ], "changes": [ 43 ], "daily": [ 45 ], "food": [ 46 ], "intake": [ 47 ], "body": [ 49, 110, 180 ], "intraperitoneal": [ 53 ], "administration": [ 54, 128 ], "of": [ 55, 100, 107, 129, 136, 149, 183, 196 ], "liraglutide,": [ 56 ], "a": [ 57 ], "agonist,": [ 60 ], "over": [ 61 ], "4": [ 62, 118 ], "days": [ 63, 80, 119 ], "did": [ 64, 89 ], "not": [ 65, 90 ], "differ": [ 66 ], "between": [ 67 ], "mice": [ 68, 82, 121, 154 ], "treated": [ 69, 122, 155 ], "with": [ 70, 87, 123, 156 ], "tryptophan": [ 72 ], "hydroxylase": [ 73 ], "(Tph)": [ 74 ], "inhibitor": [ 75 ], "p-chlorophenylalanine": [ 76 ], "(PCPA)": [ 77 ], "3": [ 79 ], "without": [ 83, 125 ], "PCPA": [ 84, 88 ], "treatment.": [ 85 ], "Treatment": [ 86 ], "affect": [ 91 ], "hypothalamic": [ 92, 137, 197 ], "expression.": [ 95 ], "Despite": [ 96 ], "anorexic": [ 98, 147 ], "effect": [ 99 ], "liraglutide": [ 101, 115, 130, 150, 170, 176 ], "disappearing": [ 102 ], "after": [ 103, 142 ], "first": [ 105 ], "day": [ 106 ], "treatment,": [ 108 ], "persisted": [ 116 ], "or": [ 124, 166 ], "PCPA.": [ 126 ], "Intraperitoneal": [ 127 ], "significantly": [ 131 ], "decreased": [ 132 ], "gene": [ 134, 194 ], "expression": [ 135, 195 ], "1": [ 140 ], "h": [ 141, 165, 168 ], "injection.": [ 143, 171 ], "Moreover,": [ 144 ], "acute": [ 146 ], "effects": [ 148 ], "were": [ 151 ], "blunted": [ 152 ], "high-affinity": [ 158 ], "agonist": [ 160 ], "(4-bromo-3,6-dimethoxybenzocyclobuten-1-yl)": [ 161 ], "methylamine": [ 162 ], "hydrobromide": [ 163 ], "14": [ 164 ], "24": [ 167 ], "before": [ 169 ], "These": [ 172 ], "findings": [ 173 ], "suggest": [ 174 ], "reduces": [ 177 ], "appetite": [ 178 ], "independently": [ 182 ], "5-HT": [ 184 ], "synthesis": [ 185 ], "mice,": [ 187 ], "whereas": [ 188 ], "downregulates": [ 192 ], "receptors.": [ 199 ] }, "publication_date": "2018-01-01", "publication_year": 2018, "type": "article", "cited_by_count": 18, "authors": [ { "id": "https://openalex.org/A5018040232", "display_name": "Katsunori Nonogaki" }, { "id": "https://openalex.org/A5035722401", "display_name": "Takao Kaji" } ] }, { "id": "https://openalex.org/W3165600686", "doi": "https://doi.org/10.1111/dom.14451", "title": "Comparative efficacy of glucose\u2010lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta\u2010analysis", "abstract": { "Abstract": [ 0 ], "Aim": [ 1 ], "To": [ 2 ], "compare": [ 3 ], "the": [ 4, 26, 48, 96, 102, 130, 145, 160, 186 ], "effects": [ 5, 49 ], "of": [ 6, 41, 50, 82, 86, 197, 237 ], "glucose\u2010lowering": [ 7, 51 ], "drugs": [ 8, 52 ], "on": [ 9, 53 ], "body": [ 10, 54, 135, 174, 210, 225 ], "weight": [ 11, 55, 136, 175, 211, 226 ], "and": [ 12, 29, 56, 70, 75, 144, 153, 176, 192, 205, 212, 218, 227 ], "blood": [ 13, 57, 165, 178, 181, 214, 228 ], "pressure": [ 14, 58, 182, 229 ], "in": [ 15, 59, 98, 133, 163, 172, 224 ], "adults": [ 16, 60 ], "with": [ 17, 61, 185, 199, 248 ], "type": [ 18, 62, 249 ], "2": [ 19, 63, 250 ], "diabetes.": [ 20, 64 ], "Methods": [ 21 ], "We": [ 22, 65, 94 ], "searched": [ 23 ], "Medline,": [ 24 ], "Embase,": [ 25 ], "Cochrane": [ 27 ], "Library,": [ 28 ], "grey": [ 30 ], "literature": [ 31 ], "sources": [ 32 ], "until": [ 33 ], "29": [ 34 ], "September": [ 35 ], "2020": [ 36 ], "for": [ 37, 233, 246 ], "randomized": [ 38 ], "controlled": [ 39 ], "trials": [ 40, 113, 198 ], "at": [ 42 ], "least": [ 43 ], "24": [ 44 ], "weeks'": [ 45, 202 ], "duration": [ 46 ], "assessing": [ 47, 117 ], "performed": [ 66 ], "frequentist": [ 67 ], "network": [ 68 ], "meta\u2010analyses": [ 69 ], "calculated": [ 71 ], "weighted": [ 72 ], "mean": [ 73 ], "differences": [ 74 ], "95%": [ 76 ], "confidence": [ 77, 97 ], "intervals": [ 78 ], "combining": [ 79 ], "trial": [ 80 ], "arms": [ 81 ], "different": [ 83 ], "approved": [ 84 ], "doses": [ 85 ], "a": [ 87, 91, 169 ], "given": [ 88 ], "intervention": [ 89 ], "into": [ 90 ], "single": [ 92 ], "group.": [ 93 ], "evaluated": [ 95 ], "pooled": [ 99 ], "estimates": [ 100 ], "using": [ 101 ], "CINeMA": [ 103 ], "(Confidence": [ 104 ], "In": [ 105, 110, 194 ], "Network": [ 106 ], "Meta\u2010Analysis)": [ 107 ], "framework.": [ 108 ], "Results": [ 109 ], "total,": [ 111 ], "424": [ 112 ], "(276": [ 114 ], "336": [ 115 ], "patients)": [ 116 ], "21": [ 118 ], "antidiabetic": [ 119 ], "medications": [ 120 ], "from": [ 121 ], "nine": [ 122 ], "drug": [ 123 ], "classes": [ 124 ], "were": [ 125, 231 ], "included.": [ 126 ], "Subcutaneous": [ 127 ], "semaglutide": [ 128, 204 ], "was": [ 129, 183 ], "most": [ 131 ], "efficacious": [ 132 ], "reducing": [ 134, 173 ], "followed": [ 137 ], "by": [ 138 ], "oral": [ 139 ], "semaglutide,": [ 140 ], "exenatide": [ 141, 190 ], "twice\u2010daily,": [ 142 ], "liraglutide,": [ 143 ], "sodium\u2010glucose": [ 146 ], "co\u2010transporter\u20102": [ 147 ], "(SGLT\u20102)": [ 148 ], "inhibitors": [ 149, 188, 207, 220 ], "empagliflozin,": [ 150 ], "canagliflozin,": [ 151 ], "dapagliflozin": [ 152 ], "ertugliflozin.": [ 154 ], "The": [ 155 ], "same": [ 156 ], "agents": [ 157, 240 ], "also": [ 158 ], "conferred": [ 159, 221 ], "greatest": [ 161 ], "reductions": [ 162, 222 ], "systolic": [ 164, 177, 213 ], "pressure.": [ 166, 179, 215 ], "Metformin": [ 167 ], "had": [ 168 ], "modest": [ 170 ], "effect": [ 171 ], "Diastolic": [ 180 ], "reduced": [ 184, 208 ], "SGLT\u20102": [ 187, 206, 219 ], "pioglitazone,": [ 189 ], "twice\u2010daily": [ 191 ], "semaglutide.": [ 193 ], "subgroup": [ 195 ], "analyses": [ 196 ], "over": [ 200, 234 ], "52": [ 201 ], "duration,": [ 203 ], "both": [ 209, 223 ], "Conclusions": [ 216 ], "Semaglutide": [ 217 ], "that": [ 230 ], "sustainable": [ 232 ], "1": [ 235 ], "year": [ 236 ], "treatment.": [ 238 ], "These": [ 239 ], "may": [ 241 ], "be": [ 242 ], "preferable": [ 243 ], "treatment": [ 244 ], "options": [ 245 ], "patients": [ 247 ], "diabetes": [ 251 ], "who": [ 252 ], "are": [ 253 ], "overweight/obese": [ 254 ], "and/or": [ 255 ], "hypertensive.": [ 256 ] }, "publication_date": "2021-05-28", "publication_year": 2021, "type": "review", "cited_by_count": 167, "authors": [ { "id": "https://openalex.org/A5018882870", "display_name": "\u0391\u03c0\u03cc\u03c3\u03c4\u03bf\u03bb\u03bf\u03c2 \u03a4\u03c3\u03ac\u03c0\u03b1\u03c2" }, { "id": "https://openalex.org/A5084182369", "display_name": "Thomas Karagiannis" }, { "id": "https://openalex.org/A5083318994", "display_name": "Panagiota Kakotrichi" }, { "id": "https://openalex.org/A5026527950", "display_name": "Ioannis Avgerinos" }, { "id": "https://openalex.org/A5060432869", "display_name": "Chrysanthi Mantsiou" }, { "id": "https://openalex.org/A5023573221", "display_name": "Georgios Tousinas" }, { "id": "https://openalex.org/A5070546163", "display_name": "Apostolos Manolopoulos" }, { "id": "https://openalex.org/A5010856150", "display_name": "Aris Liakos" }, { "id": "https://openalex.org/A5082971097", "display_name": "Konstantinos Malandris" }, { "id": "https://openalex.org/A5011127007", "display_name": "David R. Matthews" }, { "id": "https://openalex.org/A5051305906", "display_name": "Eleni Bekiari" } ] }, { "id": "https://openalex.org/W4306362205", "doi": "https://doi.org/10.3390/biomedicines10102586", "title": "Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists", "abstract": { "Diabetes": [ 0 ], "mellitus": [ 1 ], "is": [ 2 ], "the": [ 3, 27, 37, 63, 118, 171 ], "leading": [ 4 ], "cause": [ 5 ], "of": [ 6, 13, 39, 120, 174 ], "chronic": [ 7 ], "kidney": [ 8, 19, 154 ], "disease,": [ 9 ], "and": [ 10, 56, 80, 87, 97, 110, 132, 144, 177 ], "about": [ 11 ], "30\u201340%": [ 12 ], "patients": [ 14, 101 ], "with": [ 15, 84, 102, 158, 162 ], "diabetes": [ 16, 161 ], "will": [ 17 ], "develop": [ 18 ], "disease.": [ 20 ], "Incretin": [ 21 ], "hormones": [ 22 ], "have": [ 23 ], "received": [ 24 ], "attention": [ 25 ], "during": [ 26 ], "past": [ 28 ], "three": [ 29 ], "decades": [ 30 ], "not": [ 31 ], "only": [ 32 ], "as": [ 33, 181 ], "a": [ 34, 107, 138, 182 ], "pharmacotherapy": [ 35 ], "for": [ 36, 45, 66, 117 ], "treatment": [ 38, 119 ], "type": [ 40, 103, 121, 159, 187 ], "2": [ 41, 104, 122, 160, 188 ], "diabetes,": [ 42 ], "but": [ 43 ], "also": [ 44, 93, 149 ], "their": [ 46 ], "cardiorenometabolic": [ 47 ], "effects.": [ 48 ], "The": [ 49 ], "main": [ 50 ], "incretins": [ 51 ], "are": [ 52, 68 ], "glucagon-like": [ 53 ], "peptide-1": [ 54 ], "(GLP-1)": [ 55 ], "glucose-dependent": [ 57 ], "insulinotropic": [ 58 ], "polypeptide": [ 59 ], "(GIP).": [ 60 ], "Additional": [ 61 ], "to": [ 62, 125, 185 ], "pancreas,": [ 64 ], "receptors": [ 65 ], "GLP-1": [ 67, 90, 111, 126, 133, 178 ], "widely": [ 69 ], "distributed": [ 70 ], "in": [ 71, 100, 141, 156 ], "various": [ 72 ], "organs,": [ 73 ], "causing": [ 74 ], "positive": [ 75 ], "effects": [ 76 ], "on": [ 77 ], "endothelial": [ 78 ], "function": [ 79 ], "vascular": [ 81 ], "atherogenesis.": [ 82 ], "Along": [ 83 ], "glycemic": [ 85 ], "control": [ 86 ], "weight": [ 88 ], "reduction,": [ 89 ], "receptor": [ 91, 112, 127, 134, 179 ], "agonists": [ 92, 180 ], "strongly": [ 94 ], "improve": [ 95 ], "cardiovascular": [ 96, 164 ], "renal": [ 98 ], "outcomes": [ 99, 155 ], "diabetes.": [ 105, 123, 189 ], "Recently,": [ 106 ], "dual": [ 108, 130, 175 ], "GIP": [ 109, 131, 176 ], "agonist": [ 113, 128, 135 ], "has": [ 114 ], "been": [ 115 ], "approved": [ 116 ], "Compared": [ 124 ], "semaglutide,": [ 129 ], "tirzepatide": [ 136, 152 ], "showed": [ 137 ], "superior": [ 139 ], "reduction": [ 140 ], "hemoglobin": [ 142 ], "A1c": [ 143 ], "body": [ 145 ], "weight.": [ 146 ], "Preliminary": [ 147 ], "results": [ 148 ], "suggest": [ 150 ], "that": [ 151 ], "improves": [ 153 ], "adults": [ 157 ], "increased": [ 163 ], "risk.": [ 165 ], "In": [ 166 ], "this": [ 167 ], "review,": [ 168 ], "we": [ 169 ], "present": [ 170 ], "nephroprotective": [ 172 ], "properties": [ 173 ], "new": [ 183 ], "drug": [ 184 ], "treat": [ 186 ] }, "publication_date": "2022-10-15", "publication_year": 2022, "type": "review", "cited_by_count": 15, "authors": [ { "id": "https://openalex.org/A5080243862", "display_name": "Tomislav Bulum" } ] }, { "id": "https://openalex.org/W2580639621", "doi": "https://doi.org/10.1016/j.neulet.2017.01.045", "title": "Delayed administration of the GLP-1 receptor agonist liraglutide improves metabolic and functional recovery after cerebral ischemia in rats", "abstract": null, "publication_date": "2017-01-22", "publication_year": 2017, "type": "article", "cited_by_count": 27, "authors": [ { "id": "https://openalex.org/A5100548355", "display_name": "Wenbin Dong" }, { "id": "https://openalex.org/A5063306279", "display_name": "Yunping Miao" }, { "id": "https://openalex.org/A5071268953", "display_name": "Aiying Chen" }, { "id": "https://openalex.org/A5101720054", "display_name": "Min Cheng" }, { "id": "https://openalex.org/A5073156615", "display_name": "Xiaodi Ye" }, { "id": "https://openalex.org/A5079368655", "display_name": "Fahuan Song" }, { "id": "https://openalex.org/A5102210770", "display_name": "Gaoli Zheng" } ] }, { "id": "https://openalex.org/W2346835864", "doi": "https://doi.org/10.2147/dmso.s75452", "title": "Advances in the treatment of type 2 diabetes: impact of dulaglutide", "abstract": { "The": [ 0, 47, 148 ], "purpose": [ 1 ], "of": [ 2, 10, 13, 26, 71, 168, 178 ], "this": [ 3 ], "review": [ 4, 9 ], "is": [ 5, 74, 171 ], "to": [ 6, 38, 44, 88, 95, 98, 131, 143, 146, 190, 195, 202 ], "provide": [ 7 ], "a": [ 8, 33, 75, 198 ], "current": [ 11 ], "data": [ 12 ], "the": [ 14, 24, 63, 83, 96, 166, 176 ], "most": [ 15, 149 ], "recently": [ 16 ], "approved": [ 17 ], "glucagon-like": [ 18 ], "peptide": [ 19 ], "(GLP)-1-receptor": [ 20 ], "agonist,": [ 21 ], "dulaglutide,": [ 22 ], "in": [ 23, 86, 113, 153 ], "treatment": [ 25, 177 ], "type": [ 27, 179 ], "2": [ 28, 180 ], "diabetes.": [ 29 ], "To": [ 30 ], "complete": [ 31 ], "this,": [ 32 ], "PubMed": [ 34 ], "search": [ 35, 48 ], "was": [ 36, 141, 163 ], "performed": [ 37 ], "identify": [ 39 ], "manuscripts": [ 40 ], "published": [ 41 ], "from": [ 42 ], "1947": [ 43 ], "July": [ 45 ], "2015.": [ 46 ], "terms": [ 49 ], "\"Trulicity\",": [ 50 ], "\"dulaglutide\",": [ 51 ], "and": [ 52, 56, 101, 112, 122, 137, 160, 197 ], "\"LY2189265\"": [ 53 ], "were": [ 54, 58, 156 ], "utilized,": [ 55 ], "publications": [ 57 ], "included": [ 59 ], "if": [ 60 ], "they": [ 61 ], "evaluated": [ 62 ], "pharmacology,": [ 64 ], "pharmacokinetics,": [ 65 ], "efficacy,": [ 66 ], "safety,": [ 67 ], "or": [ 68 ], "patient-reported": [ 69 ], "outcomes": [ 70 ], "dulaglutide.": [ 72, 169 ], "Dulaglutide": [ 73, 106, 125, 170 ], "GLP-1": [ 76, 204 ], "receptor": [ 77, 205 ], "agonist": [ 78 ], "that": [ 79 ], "mimics": [ 80 ], "endogenous": [ 81 ], "GLP-1,": [ 82 ], "hormone": [ 84 ], "produced": [ 85 ], "response": [ 87 ], "food": [ 89 ], "intake.": [ 90 ], "Modifications": [ 91 ], "have": [ 92 ], "been": [ 93, 108 ], "made": [ 94 ], "molecule": [ 97 ], "delay": [ 99 ], "breakdown": [ 100 ], "allow": [ 102 ], "for": [ 103, 175 ], "once-weekly": [ 104, 185 ], "dosing.": [ 105 ], "has": [ 107, 126 ], "studied": [ 109 ], "as": [ 110 ], "monotherapy": [ 111 ], "combination": [ 114 ], "with": [ 115, 165 ], "several": [ 116 ], "agents,": [ 117 ], "including": [ 118 ], "metformin,": [ 119, 133 ], "glimepiride,": [ 120 ], "pioglitazone,": [ 121 ], "insulin": [ 123, 134 ], "lispro.": [ 124 ], "demonstrated": [ 127 ], "superior": [ 128 ], "efficacy": [ 129 ], "compared": [ 130 ], "placebo,": [ 132 ], "glargine,": [ 135 ], "sitagliptin,": [ 136 ], "twice-daily": [ 138 ], "exenatide.": [ 139 ], "It": [ 140 ], "found": [ 142 ], "be": [ 144 ], "noninferior": [ 145 ], "liraglutide.": [ 147 ], "common": [ 150 ], "adverse": [ 151, 158 ], "effects": [ 152 ], "clinical": [ 154 ], "studies": [ 155 ], "gastrointestinal-related": [ 157 ], "events,": [ 159 ], "patient": [ 161 ], "satisfaction": [ 162 ], "high": [ 164 ], "use": [ 167 ], "an": [ 172 ], "appealing": [ 173 ], "option": [ 174 ], "diabetes,": [ 181 ], "based": [ 182 ], "on": [ 183 ], "its": [ 184 ], "dosing,": [ 186 ], "A1c": [ 187 ], "lowering": [ 188 ], "comparable": [ 189, 194 ], "liraglutide,": [ 191 ], "weight": [ 192 ], "reduction": [ 193 ], "exenatide,": [ 196 ], "similar": [ 199 ], "adverse-effect": [ 200 ], "profile": [ 201 ], "other": [ 203 ], "agonists.": [ 206 ] }, "publication_date": "2016-05-01", "publication_year": 2016, "type": "review", "cited_by_count": 10, "authors": [ { "id": "https://openalex.org/A5033402700", "display_name": "Angela Thompson" }, { "id": "https://openalex.org/A5054620018", "display_name": "Jennifer Trujillo" } ] }, { "id": "https://openalex.org/W2000479721", "doi": "https://doi.org/10.1016/j.neuropharm.2014.06.026", "title": "Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampal synaptic plasticity and metabolic control in high-fat fed mice", "abstract": null, "publication_date": "2014-07-03", "publication_year": 2014, "type": "article", "cited_by_count": 74, "authors": [ { "id": "https://openalex.org/A5037057754", "display_name": "Rachael Lennox" }, { "id": "https://openalex.org/A5108363859", "display_name": "David W. Porter" }, { "id": "https://openalex.org/A5064124957", "display_name": "Peter R. Flatt" }, { "id": "https://openalex.org/A5082707086", "display_name": "Christian H\u00f6lscher" }, { "id": "https://openalex.org/A5001545372", "display_name": "Nigel Irwin" }, { "id": "https://openalex.org/A5013136657", "display_name": "Victor A. Gault" } ] }, { "id": "https://openalex.org/W2052870011", "doi": "https://doi.org/10.1111/j.1463-1326.2012.01574.x", "title": "Liraglutide in oral antidiabetic drug combination therapy", "abstract": { "The": [ 0 ], "glucagon\u2010like": [ 1 ], "peptide\u20101": [ 2 ], "(GLP\u20101)": [ 3 ], "receptor": [ 4, 64, 142 ], "agonist": [ 5 ], "liraglutide": [ 6, 36 ], "is": [ 7, 109 ], "indicated": [ 8 ], "as": [ 9, 73 ], "an": [ 10 ], "add\u2010on": [ 11 ], "to": [ 12, 67 ], "oral": [ 13, 46, 81 ], "antidiabetic": [ 14, 47, 82 ], "drug": [ 15 ], "regimens": [ 16 ], "in": [ 17, 39, 89, 95, 120 ], "subjects": [ 18 ], "with": [ 19, 41, 53, 76, 132 ], "type": [ 20 ], "2": [ 21 ], "diabetes.": [ 22 ], "Herein,": [ 23 ], "the": [ 24, 30, 54, 103 ], "results": [ 25 ], "of": [ 26, 35, 56, 118 ], "clinical": [ 27 ], "trials": [ 28, 122 ], "assessing": [ 29 ], "efficacy,": [ 31 ], "safety": [ 32 ], "and": [ 33, 58, 84, 92 ], "tolerability": [ 34 ], "when": [ 37, 71, 130 ], "used": [ 38, 72 ], "combination": [ 40, 74 ], "either": [ 42, 77 ], "one": [ 43, 78 ], "or": [ 44, 79 ], "two": [ 45, 80 ], "therapies": [ 48 ], "are": [ 49, 100, 114 ], "summarised,": [ 50 ], "then": [ 51 ], "contrasted": [ 52 ], "effects": [ 55 ], "exenatide": [ 57 ], "dipeptidyl": [ 59 ], "peptidase": [ 60 ], "(DPP\u20104)": [ 61 ], "inhibitors.": [ 62, 154 ], "GLP\u20101": [ 63, 141 ], "agonists": [ 65, 143 ], "lead": [ 66 ], "effective": [ 68 ], "glycaemic": [ 69 ], "control": [ 70 ], "therapy": [ 75 ], "agents,": [ 83 ], "may": [ 85, 144 ], "confer": [ 86 ], "overall": [ 87 ], "benefits": [ 88 ], "weight": [ 90 ], "loss": [ 91 ], "blood": [ 93 ], "pressure": [ 94 ], "some": [ 96 ], "subjects.": [ 97 ], "These": [ 98 ], "agents": [ 99 ], "well": [ 101 ], "tolerated;": [ 102 ], "most": [ 104 ], "commonly": [ 105 ], "reported": [ 106 ], "adverse": [ 107 ], "effect": [ 108 ], "mild\u2010to\u2010moderate": [ 110 ], "gastrointestinal": [ 111 ], "symptoms,": [ 112 ], "which": [ 113 ], "usually": [ 115 ], "transient.": [ 116 ], "Rates": [ 117 ], "hypoglycaemia": [ 119 ], "these": [ 121 ], "were": [ 123, 128 ], "low,": [ 124 ], "although": [ 125 ], "higher": [ 126 ], "rates": [ 127 ], "noted": [ 129 ], "combined": [ 131 ], "a": [ 133 ], "sulphonylurea.": [ 134 ], "While": [ 135 ], "further": [ 136 ], "study": [ 137 ], "will": [ 138 ], "be": [ 139 ], "required,": [ 140 ], "offer": [ 145 ], "important": [ 146 ], "advantages": [ 147 ], "over": [ 148 ], "other": [ 149 ], "diabetic": [ 150 ], "therapies,": [ 151 ], "including": [ 152 ], "DPP\u20104": [ 153 ] }, "publication_date": "2012-03-08", "publication_year": 2012, "type": "review", "cited_by_count": 19, "authors": [ { "id": "https://openalex.org/A5111569181", "display_name": "A. J. Garber" } ] }, { "id": "https://openalex.org/W4392683020", "doi": "https://doi.org/10.1007/s12020-024-03757-9", "title": "Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future", "abstract": { "Abstract": [ 0 ], "Purpose": [ 1 ], "Chronic": [ 2 ], "kidney": [ 3, 135 ], "disease": [ 4 ], "(CKD)": [ 5 ], "is": [ 6, 38, 179, 205 ], "one": [ 7 ], "of": [ 8, 13, 66, 83, 106, 113, 184, 226 ], "the": [ 9, 26, 40, 60, 63, 75, 79, 103, 157, 185 ], "most": [ 10, 183 ], "common": [ 11 ], "complications": [ 12 ], "type": [ 14 ], "2": [ 15 ], "diabetes": [ 16, 30, 45 ], "(T2D),": [ 17 ], "and": [ 18, 21, 47, 72, 74, 108, 131, 141, 149, 167, 169, 217 ], "CKD-related": [ 19 ], "disability": [ 20 ], "mortality": [ 22 ], "are": [ 23 ], "increasing": [ 24 ], "despite": [ 25 ], "recent": [ 27 ], "advances": [ 28 ], "in": [ 29, 115, 191, 198, 211 ], "management.": [ 31 ], "The": [ 32, 111 ], "dual": [ 33 ], "GIP/GLP-1": [ 34 ], "receptor": [ 35, 69 ], "agonist": [ 36 ], "tirzepatide": [ 37, 73 ], "among": [ 39 ], "furthest": [ 41 ], "developed": [ 42 ], "multi-agonists": [ 43 ], "for": [ 44 ], "care": [ 46 ], "has": [ 48 ], "so": [ 49 ], "far": [ 50 ], "displayed": [ 51, 145 ], "promising": [ 52 ], "nephroprotective": [ 53, 64 ], "effects.": [ 54 ], "This": [ 55 ], "review": [ 56 ], "aims": [ 57 ], "to": [ 58, 94, 98, 159, 181, 189, 207, 222 ], "summarize": [ 59 ], "evidence": [ 61, 204 ], "regarding": [ 62 ], "effects": [ 65, 105 ], "glucagon-like": [ 67 ], "peptide-1": [ 68 ], "agonists": [ 70 ], "(GLP-1RA)": [ 71 ], "putative": [ 76 ], "mechanisms": [ 77 ], "underlying": [ 78 ], "favorable": [ 80 ], "renal": [ 81, 104, 212, 228 ], "profile": [ 82 ], "tirzepatide.": [ 84, 109 ], "Methods": [ 85 ], "A": [ 86 ], "comprehensive": [ 87 ], "literature": [ 88 ], "search": [ 89 ], "was": [ 90 ], "performed": [ 91 ], "from": [ 92 ], "inception": [ 93 ], "July": [ 95 ], "31st": [ 96 ], "2023": [ 97 ], "select": [ 99 ], "research": [ 100 ], "papers": [ 101 ], "addressing": [ 102 ], "GLP-1RA": [ 107 ], "Results": [ 110 ], "pathogenesis": [ 112 ], "CKD": [ 114, 190 ], "patients": [ 116 ], "with": [ 117, 156 ], "T2D": [ 118 ], "likely": [ 119, 180 ], "involves": [ 120 ], "many": [ 121 ], "contributors": [ 122 ], "besides": [ 123 ], "hyperglycemia,": [ 124 ], "such": [ 125 ], "as": [ 126, 219, 221 ], "hypertension,": [ 127 ], "obesity,": [ 128 ], "insulin": [ 129, 161 ], "resistance": [ 130 ], "glomerular": [ 132 ], "atherosclerosis,": [ 133, 218 ], "exerting": [ 134 ], "damage": [ 136, 216 ], "through": [ 137 ], "metabolic,": [ 138 ], "fibrotic,": [ 139 ], "inflammatory,": [ 140 ], "hemodynamic": [ 142 ], "mechanisms.": [ 143 ], "Tirzepatide": [ 144, 178 ], "an": [ 146 ], "unprecedented": [ 147 ], "glucose": [ 148 ], "body": [ 150 ], "weight": [ 151 ], "lowering": [ 152 ], "potential,": [ 153 ], "presenting": [ 154 ], "also": [ 155 ], "ability": [ 158 ], "increase": [ 160 ], "sensitivity,": [ 162 ], "reduce": [ 163 ], "systolic": [ 164 ], "blood": [ 165 ], "pressure": [ 166 ], "inflammation": [ 168 ], "ameliorate": [ 170 ], "dyslipidemia,": [ 171 ], "particularly": [ 172 ], "by": [ 173 ], "reducing": [ 174 ], "triglycerides": [ 175 ], "levels.": [ 176 ], "Conclusion": [ 177 ], "counteract": [ 182 ], "pathogenetic": [ 186 ], "factors": [ 187 ], "contributing": [ 188 ], "T2D,": [ 192 ], "potentially": [ 193 ], "representing": [ 194 ], "a": [ 195 ], "step": [ 196 ], "forward": [ 197 ], "incretin-based": [ 199 ], "therapy": [ 200 ], "towards": [ 201 ], "nephroprotection.": [ 202 ], "Further": [ 203 ], "needed": [ 206 ], "understand": [ 208 ], "its": [ 209 ], "role": [ 210 ], "hemodynamics,": [ 213 ], "fibrosis,": [ 214 ], "cell": [ 215 ], "well": [ 220 ], "conclusively": [ 223 ], "show": [ 224 ], "reduction": [ 225 ], "hard": [ 227 ], "outcomes.": [ 229 ] }, "publication_date": "2024-03-12", "publication_year": 2024, "type": "article", "cited_by_count": 34, "authors": [ { "id": "https://openalex.org/A5103115613", "display_name": "Irene Caruso" }, { "id": "https://openalex.org/A5064872622", "display_name": "Francesco Giorgino" } ] }, { "id": "https://openalex.org/W2056174043", "doi": "https://doi.org/10.1007/s00592-013-0525-3", "title": "GLP-1 receptor agonist-induced polyarthritis: a case report", "abstract": null, "publication_date": "2013-10-24", "publication_year": 2013, "type": "article", "cited_by_count": 15, "authors": [ { "id": "https://openalex.org/A5027904469", "display_name": "Maria Luisa Ambrosio" }, { "id": "https://openalex.org/A5059413618", "display_name": "Matteo Monami" }, { "id": "https://openalex.org/A5037030778", "display_name": "Lavinia Sati" }, { "id": "https://openalex.org/A5068485330", "display_name": "Niccol\u00f2 Marchionni" }, { "id": "https://openalex.org/A5045027966", "display_name": "Mauro Di Bari" }, { "id": "https://openalex.org/A5059685674", "display_name": "Edoardo Mannucci" } ] }, { "id": "https://openalex.org/W2598765141", "doi": "https://doi.org/10.1111/1753-0407.12555", "title": "Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non\u2010alcoholic fatty liver disease", "abstract": { "Abstract": [ 0 ], "Background": [ 1 ], "The": [ 2 ], "aim": [ 3 ], "of": [ 4, 13 ], "the": [ 5, 11, 84, 91 ], "present": [ 6 ], "study": [ 7 ], "was": [ 8 ], "to": [ 9, 40 ], "compare": [ 10 ], "effects": [ 12 ], "gliclazide,": [ 14 ], "liraglutide,": [ 15, 42 ], "and": [ 16, 60, 67, 86, 94, 107, 112, 129, 163, 177, 191, 194 ], "metformin": [ 17, 108 ], "in": [ 18, 74, 83, 90, 96, 117, 125, 140, 145, 152, 158, 181, 184, 188, 198 ], "type": [ 19 ], "2": [ 20 ], "diabetes": [ 21 ], "mellitus": [ 22 ], "(": [ 23, 32, 56 ], "T2DM": [ 24, 169 ], ")": [ 25, 58 ], "patients": [ 26, 170 ], "with": [ 27, 101, 104, 123, 147, 171, 175, 205, 208 ], "non\u2010alcoholic": [ 28 ], "fatty": [ 29 ], "liver": [ 30, 61, 114, 185 ], "disease": [ 31 ], "NAFLD": [ 33, 172 ], ").": [ 34 ], "Methods": [ 35 ], "Eighty\u2010seven": [ 36 ], "subjects": [ 37, 146 ], "were": [ 38, 70, 81, 99, 120, 143, 203 ], "randomized": [ 39 ], "receive": [ 41 ], "metformin,": [ 43, 178 ], "or": [ 44 ], "gliclazide": [ 45, 179 ], "for": [ 46 ], "24": [ 47, 137 ], "weeks.": [ 48 ], "Primary": [ 49 ], "outcomes": [ 50 ], "included": [ 51 ], "HbA1c": [ 52, 65, 79, 160, 164, 192 ], "levels,": [ 53, 131, 193 ], "intrahepatic": [ 54 ], "fat": [ 55 ], "IHF": [ 57, 68, 97, 118, 141, 189 ], "content,": [ 59 ], "function.": [ 62, 115 ], "Results": [ 63 ], "Both": [ 64 ], "levels": [ 66, 80, 165 ], "content": [ 69, 98, 119, 142, 190 ], "reduced": [ 71, 110 ], "after": [ 72 ], "treatment": [ 73 ], "all": [ 75 ], "three": [ 76 ], "groups.": [ 77 ], "However,": [ 78 ], "lower": [ 82 ], "liraglutide\u2010": [ 85 ], "metformin\u2010treated": [ 87 ], "groups": [ 88 ], "than": [ 89, 103, 207 ], "gliclazide\u2010treated": [ 92 ], "group,": [ 93 ], "reductions": [ 95, 124, 139, 161, 187 ], "greater": [ 100, 144 ], "liraglutide": [ 102, 176, 206 ], "gliclazide.": [ 105 ], "Liraglutide": [ 106 ], "treatments": [ 109 ], "weight": [ 111, 148, 196 ], "improved": [ 113 ], "Changes": [ 116 ], "positively": [ 121 ], "correlated": [ 122 ], "serum": [ 126 ], "alanine": [ 127 ], "aminotransferase": [ 128 ], "triglyceride": [ 130 ], "as": [ 132, 134 ], "well": [ 133 ], "weight.": [ 135 ], "At": [ 136 ], "weeks,": [ 138 ], "loss": [ 149 ], "\u22655%,": [ 150 ], "changes": [ 151 ], "waistline": [ 153 ], "\u22640": [ 154 ], "cm": [ 155 ], "(including": [ 156 ], "decreases": [ 157 ], "waistline),": [ 159 ], "\u22652.5%,": [ 162 ], "<6.5%.": [ 166 ], "Conclusions": [ 167 ], "In": [ 168 ], ",": [ 173 ], "compared": [ 174 ], "resulted": [ 180 ], "less": [ 182, 195 ], "improvement": [ 183 ], "function,": [ 186 ], "loss;": [ 197 ], "addition,": [ 199 ], "slightly": [ 200 ], "better": [ 201 ], "improvements": [ 202 ], "achieved": [ 204 ], "metformin.": [ 209 ] }, "publication_date": "2017-03-24", "publication_year": 2017, "type": "article", "cited_by_count": 157, "authors": [ { "id": "https://openalex.org/A5087330486", "display_name": "Wenhuan Feng" }, { "id": "https://openalex.org/A5103196399", "display_name": "Caixia Gao" }, { "id": "https://openalex.org/A5033623201", "display_name": "Yan Bi" }, { "id": "https://openalex.org/A5103054014", "display_name": "Min Wu" }, { "id": "https://openalex.org/A5100782162", "display_name": "Ping Li" }, { "id": "https://openalex.org/A5051094170", "display_name": "Shanmei Shen" }, { "id": "https://openalex.org/A5100655799", "display_name": "Wei Chen" }, { "id": "https://openalex.org/A5051844240", "display_name": "Tingting Yin" }, { "id": "https://openalex.org/A5083822183", "display_name": "Dalong Zhu" } ] }, { "id": "https://openalex.org/W2509835548", "doi": "https://doi.org/10.1016/j.diabres.2016.08.009", "title": "The acute anorexic effect of liraglutide, a GLP-1 receptor agonist, does not require functional leptin receptor, serotonin, and hypothalamic POMC and CART activities in mice", "abstract": null, "publication_date": "2016-08-31", "publication_year": 2016, "type": "article", "cited_by_count": 14, "authors": [ { "id": "https://openalex.org/A5018040232", "display_name": "Katsunori Nonogaki" }, { "id": "https://openalex.org/A5035722401", "display_name": "Takao Kaji" } ] }, { "id": "https://openalex.org/W2119804129", "doi": "https://doi.org/10.2337/db06-0565", "title": "Liraglutide, a Long-Acting Glucagon-Like Peptide-1 Analog, Reduces Body Weight and Food Intake in Obese Candy-Fed Rats, Whereas a Dipeptidyl Peptidase-IV Inhibitor, Vildagliptin, Does Not", "abstract": { "Metabolic": [ 0 ], "effects": [ 1 ], "of": [ 2, 32, 200 ], "the": [ 3, 9, 198 ], "glucagon-like": [ 4 ], "peptide-1": [ 5 ], "analog": [ 6 ], "liraglutide": [ 7, 54 ], "and": [ 8, 76, 93, 107, 120, 130, 163, 175, 188 ], "dipeptidyl": [ 10 ], "peptidase-IV": [ 11 ], "inhibitor": [ 12 ], "vildagliptin": [ 13, 60, 176 ], "were": [ 14, 27, 40, 82 ], "compared": [ 15, 148 ], "in": [ 16, 180 ], "rats": [ 17, 26, 142 ], "made": [ 18 ], "obese": [ 19 ], "by": [ 20, 88, 99 ], "supplementary": [ 21 ], "candy": [ 22, 136 ], "feeding.": [ 23 ], "Female": [ 24 ], "Sprague-Dawley": [ 25 ], "randomized": [ 28, 41 ], "to": [ 29, 46, 67, 69, 114, 202 ], "12-week": [ 30 ], "diets": [ 31 ], "chow": [ 33, 35, 115 ], "or": [ 34, 64, 66, 112 ], "plus": [ 36 ], "candy.": [ 37 ], "The": [ 38 ], "latter": [ 39 ], "for": [ 42 ], "12": [ 43 ], "further": [ 44 ], "weeks": [ 45 ], "continue": [ 47 ], "their": [ 48 ], "diet": [ 49, 116 ], "while": [ 50 ], "receiving": [ 51 ], "0.2": [ 52 ], "mg/kg": [ 53, 59 ], "twice": [ 55, 61 ], "daily": [ 56, 62 ], "subcutaneously,": [ 57 ], "10": [ 58 ], "orally,": [ 63 ], "vehicle": [ 65 ], "revert": [ 68 ], "chow-only": [ 70 ], "diet.": [ 71 ], "Energy": [ 72 ], "expenditure": [ 73, 147 ], "was": [ 74, 86, 97, 124, 184, 205 ], "measured,": [ 75 ], "oral": [ 77 ], "glucose": [ 78 ], "tolerance": [ 79 ], "tests": [ 80 ], "(OGTTs)": [ 81 ], "performed.": [ 83 ], "Body": [ 84 ], "composition": [ 85 ], "determined": [ 87, 98 ], "dual-energy": [ 89 ], "X-ray": [ 90 ], "absorptiometry": [ 91 ], "scanning,": [ 92 ], "pancreatic": [ 94 ], "\u03b2-cell": [ 95, 181, 201 ], "mass": [ 96, 190, 204 ], "histology.": [ 100 ], "Candy": [ 101 ], "feeding": [ 102 ], "increased": [ 103, 171 ], "weight,": [ 104, 155 ], "fat": [ 105, 121, 189 ], "mass,": [ 106 ], "feeding-associated": [ 108 ], "energy": [ 109, 146, 159 ], "expenditure.": [ 110, 160 ], "Liraglutide": [ 111, 123, 174 ], "reversal": [ 113 ], "fully": [ 117 ], "reversed": [ 118 ], "weight": [ 119, 139, 187 ], "gains.": [ 122 ], "associated": [ 125, 185 ], "with": [ 126, 149, 186, 192 ], "decreased": [ 127 ], "calorie": [ 128 ], "intake": [ 129 ], "shifted": [ 131 ], "food": [ 132, 156 ], "preference": [ 133 ], "(increased": [ 134 ], "chow/decreased": [ 135 ], "consumption).": [ 137 ], "Despite": [ 138 ], "loss,": [ 140 ], "liraglutide-treated": [ 141 ], "did": [ 143 ], "not": [ 144, 195 ], "decrease": [ 145 ], "candy-fed": [ 150 ], "controls.": [ 151 ], "Vildagliptin": [ 152 ], "affected": [ 153 ], "neither": [ 154 ], "intake,": [ 157 ], "nor": [ 158 ], "OGTTs,": [ 161 ], "histology,": [ 162 ], "blood": [ 164 ], "analyses": [ 165 ], "indirectly": [ 166 ], "suggested": [ 167 ], "that": [ 168 ], "both": [ 169 ], "drugs": [ 170 ], "insulin": [ 172 ], "sensitivity.": [ 173 ], "inhibited": [ 177 ], "obesity-associated": [ 178 ], "increases": [ 179 ], "mass.": [ 182 ], "This": [ 183 ], "normalization": [ 191 ], "liraglutide,": [ 193 ], "but": [ 194 ], "vildagliptin,": [ 196 ], "where": [ 197 ], "ratio": [ 199 ], "body": [ 203 ], "low.": [ 206 ] }, "publication_date": "2006-12-27", "publication_year": 2006, "type": "article", "cited_by_count": 202, "authors": [ { "id": "https://openalex.org/A5064830959", "display_name": "Kirsten Raun" }, { "id": "https://openalex.org/A5040764230", "display_name": "Pia von Voss" }, { "id": "https://openalex.org/A5103583268", "display_name": "C. F. Gotfredsen" }, { "id": "https://openalex.org/A5040291556", "display_name": "Valeria Golozoubova" }, { "id": "https://openalex.org/A5043387635", "display_name": "Bidda Rolin" }, { "id": "https://openalex.org/A5088627727", "display_name": "Lotte Bjerre Knudsen" } ] }, { "id": "https://openalex.org/W4381893369", "doi": "https://doi.org/10.1016/s0140-6736(23)01201-1", "title": "Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonists", "abstract": null, "publication_date": "2023-06-24", "publication_year": 2023, "type": "letter", "cited_by_count": 9, "authors": [ { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5069463167", "display_name": "Michael Horowitz" } ] }, { "id": "https://openalex.org/W2037791305", "doi": "https://doi.org/10.2165/11201060-000000000-00000", "title": "Liraglutide", "abstract": null, "publication_date": "2009-09-12", "publication_year": 2009, "type": "review", "cited_by_count": 60, "authors": [ { "id": "https://openalex.org/A5063934795", "display_name": "Katherine F Croom" }, { "id": "https://openalex.org/A5001997464", "display_name": "Paul L. McCormack" } ] }, { "id": "https://openalex.org/W2945819271", "doi": "https://doi.org/10.1007/s13300-019-0630-6", "title": "Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting", "abstract": { "Novo": [ 0 ], "Nordisk": [ 1 ], "A/S.": [ 2 ], "Plain": [ 3 ], "language": [ 4 ], "summary": [ 5 ], "available": [ 6 ], "for": [ 7 ], "this": [ 8 ], "article.": [ 9 ] }, "publication_date": "2019-05-16", "publication_year": 2019, "type": "article", "cited_by_count": 30, "authors": [ { "id": "https://openalex.org/A5042890915", "display_name": "Peter G\u00e6de" }, { "id": "https://openalex.org/A5051180257", "display_name": "Pierre Johansen" }, { "id": "https://openalex.org/A5041400677", "display_name": "Christian K. Tikkanen" }, { "id": "https://openalex.org/A5073393924", "display_name": "Richard F. Pollock" }, { "id": "https://openalex.org/A5072605000", "display_name": "Barnaby Hunt" }, { "id": "https://openalex.org/A5029230724", "display_name": "Samuel J. P. Malkin" } ] }, { "id": "https://openalex.org/W2037125132", "doi": "https://doi.org/10.4158/ep13254.or", "title": "Mody-3: Novel HNF1A Mutation and the Utility of Glucagon-Like Peptide (GLP)-1 Receptor Agonist Therapy", "abstract": null, "publication_date": "2013-09-06", "publication_year": 2013, "type": "article", "cited_by_count": 28, "authors": [ { "id": "https://openalex.org/A5063408628", "display_name": "Maricor K. Docena" }, { "id": "https://openalex.org/A5027278078", "display_name": "Charles Faiman" }, { "id": "https://openalex.org/A5112230033", "display_name": "Christine M. Stanley" }, { "id": "https://openalex.org/A5089515974", "display_name": "Kevin M. Pantalone" } ] }, { "id": "https://openalex.org/W2339053935", "doi": "https://doi.org/10.1152/ajpendo.00400.2015", "title": "Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner", "abstract": { "Glucagon-like": [ 0 ], "peptide-1": [ 1 ], "(GLP-1)": [ 2 ], "may": [ 3, 244 ], "have": [ 4 ], "direct": [ 5 ], "favorable": [ 6 ], "effects": [ 7, 20, 187, 218 ], "on": [ 8, 26, 221 ], "cardiovascular": [ 9 ], "system.": [ 10 ], "The": [ 11, 43, 163, 242 ], "aim": [ 12 ], "of": [ 13, 21, 74, 84, 142, 188, 219, 249 ], "this": [ 14 ], "study": [ 15 ], "was": [ 16, 78, 115 ], "to": [ 17, 38 ], "investigate": [ 18, 39 ], "the": [ 19, 22, 40, 101, 107, 110, 186, 216, 222 ], "GLP-1": [ 23, 164 ], "analog": [ 24 ], "exenatide": [ 25, 61, 102, 228 ], "improving": [ 27 ], "coronary": [ 28, 66, 75, 231 ], "endothelial": [ 29, 76, 137, 148, 194, 224, 232 ], "function": [ 30, 233 ], "in": [ 31, 100, 159, 234 ], "patients": [ 32, 235 ], "with": [ 33, 106, 118, 128, 236 ], "type": [ 34, 46, 239 ], "2": [ 35, 47, 240 ], "diabetes": [ 36 ], "and": [ 37, 52, 81, 90, 109, 126, 153, 181, 199, 205, 209 ], "underlying": [ 41 ], "mechanisms.": [ 42 ], "newly": [ 44, 237 ], "diagnosed": [ 45, 238 ], "diabetic": [ 48 ], "subjects": [ 49 ], "were": [ 50, 97 ], "enrolled": [ 51 ], "given": [ 53 ], "either": [ 54 ], "lifestyle": [ 55, 58 ], "intervention": [ 56, 59 ], "or": [ 57, 170 ], "plus": [ 60 ], "treatment.": [ 62 ], "After": [ 63 ], "12-wk": [ 64 ], "treatment,": [ 65 ], "flow": [ 67 ], "velocity": [ 68 ], "reserve": [ 69 ], "(CFVR),": [ 70 ], "an": [ 71 ], "important": [ 72 ], "indicator": [ 73 ], "function,": [ 77 ], "improved": [ 79 ], "significantly,": [ 80 ], "serum": [ 82 ], "levels": [ 83, 204 ], "soluble": [ 85, 91 ], "intercellular": [ 86 ], "adhesion": [ 87, 94 ], "molecule-1": [ 88, 95 ], "(sICAM-1)": [ 89 ], "vascular": [ 92 ], "cell": [ 93 ], "(sVCAM-1)": [ 96 ], "remarkably": [ 98 ], "decreased": [ 99 ], "treatment": [ 103 ], "group": [ 104 ], "compared": [ 105 ], "baseline": [ 108 ], "control": [ 111 ], "group.": [ 112 ], "Notably,": [ 113 ], "CFVR": [ 114 ], "correlated": [ 116 ], "inversely": [ 117 ], "hemoglobin": [ 119 ], "A": [ 120, 123 ], "1c": [ 121, 124 ], "(Hb": [ 122 ], ")": [ 125 ], "positively": [ 127 ], "high-density": [ 129 ], "lipoprotein": [ 130 ], "cholesterol": [ 131 ], "(HDL-C).": [ 132 ], "In": [ 133, 226 ], "human": [ 134 ], "umbilical": [ 135 ], "vein": [ 136 ], "cells,": [ 138 ], "exendin-4": [ 139, 191, 220 ], "(a": [ 140 ], "form": [ 141 ], "exenatide)": [ 143 ], "significantly": [ 144, 229 ], "increased": [ 145 ], "NO": [ 146, 149, 207 ], "production,": [ 147 ], "synthase": [ 150 ], "(eNOS)": [ 151 ], "phosphorylation,": [ 152 ], "GTP": [ 154 ], "cyclohydrolase": [ 155 ], "1": [ 156 ], "(GTPCH1)": [ 157 ], "level": [ 158 ], "a": [ 160, 253 ], "dose-dependent": [ 161 ], "manner.": [ 162 ], "receptor": [ 165 ], "(GLP-1R)": [ 166 ], "antagonist": [ 167 ], "exendin": [ 168, 213 ], "(9\u201339)": [ 169, 214 ], "GLP-1R": [ 171 ], "siRNA,": [ 172 ], "adenylyl": [ 173 ], "cyclase": [ 174 ], "inhibitor": [ 175, 178, 183 ], "SQ-22536,": [ 176 ], "AMPK": [ 177 ], "compound": [ 179 ], "C,": [ 180 ], "PI3K": [ 182 ], "LY-294002": [ 184 ], "abolished": [ 185 ], "exendin-4.": [ 189 ], "Furthermore,": [ 190 ], "reversed": [ 192 ], "homocysteine-induced": [ 193, 223 ], "dysfunction": [ 195 ], "by": [ 196 ], "decreasing": [ 197 ], "sICAM-1": [ 198 ], "reactive": [ 200 ], "oxygen": [ 201 ], "species": [ 202 ], "(ROS)": [ 203 ], "upregulating": [ 206 ], "production": [ 208 ], "eNOS": [ 210 ], "phosphorylation.": [ 211 ], "Likewise,": [ 212 ], "diminished": [ 215 ], "protective": [ 217 ], "dysfunction.": [ 225 ], "conclusion,": [ 227 ], "improves": [ 230 ], "diabetes.": [ 241 ], "effect": [ 243 ], "be": [ 245 ], "mediated": [ 246 ], "through": [ 247 ], "activation": [ 248 ], "AMPK/PI3K-Akt/eNOS": [ 250 ], "pathway": [ 251 ], "via": [ 252 ], "GLP-1R/cAMP-dependent": [ 254 ], "mechanism.": [ 255 ] }, "publication_date": "2016-04-12", "publication_year": 2016, "type": "article", "cited_by_count": 126, "authors": [ { "id": "https://openalex.org/A5050887292", "display_name": "Rui Wei" }, { "id": "https://openalex.org/A5102421613", "display_name": "Shifeng Ma" }, { "id": "https://openalex.org/A5100337613", "display_name": "Chen Wang" }, { "id": "https://openalex.org/A5103221943", "display_name": "Jing Ke" }, { "id": "https://openalex.org/A5019872937", "display_name": "Jin Yang" }, { "id": "https://openalex.org/A5100781286", "display_name": "Weihong Li" }, { "id": "https://openalex.org/A5100346582", "display_name": "Ye Liu" }, { "id": "https://openalex.org/A5023976763", "display_name": "Wenfang Hou" }, { "id": "https://openalex.org/A5100884026", "display_name": "Xinheng Feng" }, { "id": "https://openalex.org/A5100451757", "display_name": "Guang Wang" }, { "id": "https://openalex.org/A5006301048", "display_name": "Tianpei Hong" } ] }, { "id": "https://openalex.org/W3174357295", "doi": "https://doi.org/10.1007/s00125-021-05497-1", "title": "Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors", "abstract": null, "publication_date": "2021-06-30", "publication_year": 2021, "type": "article", "cited_by_count": 72, "authors": [ { "id": "https://openalex.org/A5008828646", "display_name": "Donna Shu\u2010Han Lin" }, { "id": "https://openalex.org/A5026722421", "display_name": "Jen\u2010Kuang Lee" }, { "id": "https://openalex.org/A5022214679", "display_name": "Wen\u2010Jone Chen" } ] }, { "id": "https://openalex.org/W3037339885", "doi": "https://doi.org/10.1136/bmjdrc-2020-001451", "title": "Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life", "abstract": { "Introduction": [ 0 ], "Sodium": [ 1 ], "glucose": [ 2 ], "cotransporter-2": [ 3 ], "inhibitors": [ 4 ], "(SGLT2i)": [ 5 ], "and": [ 6, 41, 76, 96, 123, 139, 161, 209 ], "glucagon-like": [ 7 ], "peptide-1": [ 8 ], "receptor": [ 9 ], "agonists": [ 10 ], "(GLP-1RA)": [ 11 ], "protect": [ 12 ], "type": [ 13 ], "2": [ 14 ], "diabetic": [ 15, 133 ], "(T2D)": [ 16 ], "patients": [ 17, 62, 168 ], "from": [ 18, 56, 71 ], "cardiovascular": [ 19, 28, 101, 121, 165, 212, 253 ], "events,": [ 20 ], "but": [ 21 ], "no": [ 22 ], "trial": [ 23 ], "has": [ 24 ], "directly": [ 25 ], "compared": [ 26 ], "their": [ 27 ], "effects.": [ 29 ], "We": [ 30, 43, 59 ], "aimed": [ 31 ], "to": [ 32, 73, 185, 195, 206, 219 ], "address": [ 33 ], "this": [ 34, 239 ], "gap": [ 35 ], "using": [ 36 ], "real-world": [ 37, 47 ], "data.": [ 38 ], "Research": [ 39 ], "design": [ 40 ], "methods": [ 42 ], "performed": [ 44 ], "a": [ 45, 50, 89, 128, 144, 175 ], "retrospective": [ 46 ], "study": [ 48, 241 ], "on": [ 49, 154 ], "population": [ 51, 129 ], "of": [ 52, 67, 91, 109, 130, 146, 178, 236, 255 ], "~5": [ 53 ], "million": [ 54 ], "inhabitants": [ 55 ], "North-East": [ 57 ], "Italy.": [ 58 ], "identified": [ 60 ], "T2D": [ 61, 167 ], "who": [ 63 ], "received": [ 64 ], "new": [ 65 ], "prescription": [ 66 ], "SGLT2i": [ 68, 75, 138, 171, 244 ], "or": [ 69 ], "GLP-1RA": [ 70, 77, 140, 250 ], "2014": [ 72 ], "2018.": [ 74 ], "initiators": [ 78, 142 ], "were": [ 79, 106, 153, 224 ], "matched": [ 80, 141 ], "1:1": [ 81 ], "by": [ 82 ], "propensity": [ 83 ], "scores.": [ 84 ], "The": [ 85 ], "primary": [ 86, 111 ], "outcome": [ 87 ], "was": [ 88 ], "composite": [ 90 ], "all-cause": [ 92 ], "death,": [ 93 ], "myocardial": [ 94, 188 ], "infarction,": [ 95 ], "stroke": [ 97 ], "(three-point": [ 98 ], "major": [ 99 ], "adverse": [ 100, 124 ], "events": [ 102, 223 ], "(3P-MACE)).": [ 103 ], "Secondary": [ 104 ], "endpoints": [ 105 ], "each": [ 107 ], "component": [ 108 ], "the": [ 110, 229, 234 ], "endpoint,": [ 112 ], "hospitalization": [ 113, 119, 198, 210 ], "for": [ 114, 120, 143, 199, 211 ], "heart": [ 115 ], "failure": [ 116 ], "(HF),": [ 117 ], "revascularization,": [ 118 ], "causes,": [ 122 ], "events.": [ 125 ], "Results": [ 126 ], "From": [ 127 ], "330": [ 131 ], "193": [ 132 ], "patients,": [ 134 ], "we": [ 135 ], "followed": [ 136 ], "8596": [ 137 ], "median": [ 145 ], "13": [ 147 ], "months.": [ 148 ], "Patients": [ 149 ], "in": [ 150, 251 ], "both": [ 151 ], "groups": [ 152 ], "average": [ 155 ], "63": [ 156 ], "years": [ 157 ], "old,": [ 158 ], "63%": [ 159 ], "men,": [ 160 ], "18%": [ 162 ], "had": [ 163 ], "pre-existing": [ 164 ], "disease.": [ 166 ], "treated": [ 169 ], "with": [ 170 ], "versus": [ 172 ], "GLP-1RA,": [ 173 ], "experienced": [ 174 ], "lower": [ 176 ], "rate": [ 177 ], "3P-MACE": [ 179 ], "(HR": [ 180, 190, 201, 214 ], "0.68;": [ 181 ], "95%": [ 182, 192, 203, 216 ], "CI": [ 183, 193, 204, 217 ], "0.61": [ 184 ], "0.99;": [ 186, 207, 220 ], "p=0.043),": [ 187 ], "infarction": [ 189 ], "0.72;": [ 191 ], "0.53": [ 194 ], "0.98;": [ 196 ], "p=0.035),": [ 197 ], "HF": [ 200 ], "0.59;": [ 202 ], "0.35": [ 205 ], "p=0.048),": [ 208 ], "causes": [ 213 ], "0.82;": [ 215 ], "0.69": [ 218 ], "p=0.037).": [ 221 ], "Adverse": [ 222 ], "not": [ 225 ], "significantly": [ 226 ], "different": [ 227 ], "between": [ 228 ], "two": [ 230 ], "groups.": [ 231 ], "Conclusions": [ 232 ], "In": [ 233 ], "absence": [ 235 ], "dedicated": [ 237 ], "trials,": [ 238 ], "observational": [ 240 ], "suggests": [ 242 ], "that": [ 243 ], "may": [ 245 ], "be": [ 246 ], "more": [ 247 ], "effective": [ 248 ], "than": [ 249 ], "improving": [ 252 ], "outcomes": [ 254 ], "T2D.": [ 256 ], "Trial": [ 257 ], "registration": [ 258 ], "number": [ 259 ], "NCT04184947": [ 260 ], ".": [ 261 ] }, "publication_date": "2020-06-01", "publication_year": 2020, "type": "article", "cited_by_count": 76, "authors": [ { "id": "https://openalex.org/A5013911767", "display_name": "Enrico Longato" }, { "id": "https://openalex.org/A5077821068", "display_name": "Barbara Di Camillo" }, { "id": "https://openalex.org/A5071251680", "display_name": "Giovanni Sparacino" }, { "id": "https://openalex.org/A5017207904", "display_name": "Lorenzo Gubian" }, { "id": "https://openalex.org/A5029164653", "display_name": "Angelo Avogaro" }, { "id": "https://openalex.org/A5027393457", "display_name": "Gian Paolo Fadini" } ] }, { "id": "https://openalex.org/W2512809703", "doi": "https://doi.org/10.1016/j.cmet.2016.08.003", "title": "iNKT Cells Induce FGF21 for Thermogenesis and Are Required for Maximal Weight Loss in GLP1 Therapy", "abstract": null, "publication_date": "2016-09-01", "publication_year": 2016, "type": "article", "cited_by_count": 176, "authors": [ { "id": "https://openalex.org/A5082399313", "display_name": "Lydia Lynch" }, { "id": "https://openalex.org/A5067748719", "display_name": "Andrew E. Hogan" }, { "id": "https://openalex.org/A5011672858", "display_name": "Danielle Duquette" }, { "id": "https://openalex.org/A5021865285", "display_name": "Chantel Lester" }, { "id": "https://openalex.org/A5074605415", "display_name": "Alexander S. Banks" }, { "id": "https://openalex.org/A5015867620", "display_name": "Katherine B. LeClair" }, { "id": "https://openalex.org/A5004209066", "display_name": "David E. Cohen" }, { "id": "https://openalex.org/A5029619917", "display_name": "Abhisek Ghosh" }, { "id": "https://openalex.org/A5014627846", "display_name": "Bing L\u00fc" }, { "id": "https://openalex.org/A5112189583", "display_name": "Michelle Corrigan" }, { "id": "https://openalex.org/A5064166989", "display_name": "Darko Stevanovi\u0107" }, { "id": "https://openalex.org/A5051918182", "display_name": "Eleftheria Maratos\u2013Flier" }, { "id": "https://openalex.org/A5057472647", "display_name": "Daniel J. Drucker" }, { "id": "https://openalex.org/A5060039916", "display_name": "Donal O\u2019Shea" }, { "id": "https://openalex.org/A5000815014", "display_name": "Michael B. Brenner" } ] }, { "id": "https://openalex.org/W2046778213", "doi": "https://doi.org/10.1016/j.diabres.2012.02.016", "title": "Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes", "abstract": null, "publication_date": "2012-03-23", "publication_year": 2012, "type": "article", "cited_by_count": 170, "authors": [ { "id": "https://openalex.org/A5069463167", "display_name": "Michael Horowitz" }, { "id": "https://openalex.org/A5019076349", "display_name": "Anne Flint" }, { "id": "https://openalex.org/A5048913465", "display_name": "Karen L. Jones" }, { "id": "https://openalex.org/A5041014919", "display_name": "Charlotte Hindsberger" }, { "id": "https://openalex.org/A5109247811", "display_name": "Mads Frederik Rasmussen" }, { "id": "https://openalex.org/A5068619321", "display_name": "Christoph Kapitza" }, { "id": "https://openalex.org/A5078985799", "display_name": "Selena Doran" }, { "id": "https://openalex.org/A5063998951", "display_name": "Thomas Jax" }, { "id": "https://openalex.org/A5017200089", "display_name": "Milan Zdravkovi\u0107" }, { "id": "https://openalex.org/A5112791832", "display_name": "Ian Chapman" } ] }, { "id": "https://openalex.org/W4388968070", "doi": "https://doi.org/10.1038/s41591-023-02634-8", "title": "GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders", "abstract": null, "publication_date": "2023-11-24", "publication_year": 2023, "type": "article", "cited_by_count": 68, "authors": [ { "id": "https://openalex.org/A5038660835", "display_name": "Lorenzo Leggio" }, { "id": "https://openalex.org/A5012683980", "display_name": "Christian S. Hendershot" }, { "id": "https://openalex.org/A5087628785", "display_name": "Mehdi Farokhnia" }, { "id": "https://openalex.org/A5001609083", "display_name": "Anders Fink\u2010Jensen" }, { "id": "https://openalex.org/A5091141863", "display_name": "Mette Kruse Klausen" }, { "id": "https://openalex.org/A5050495510", "display_name": "Joseph P. Schacht" }, { "id": "https://openalex.org/A5068616976", "display_name": "W. Kyle Simmons" } ] }, { "id": "https://openalex.org/W3095493725", "doi": "https://doi.org/10.1016/j.ejphar.2020.173721", "title": "Effect of combined therapy of mesenchymal stem cells with GLP-1 receptor agonist, exenatide, on early-onset nephropathy induced in diabetic rats", "abstract": null, "publication_date": "2020-11-04", "publication_year": 2020, "type": "article", "cited_by_count": 30, "authors": [ { "id": "https://openalex.org/A5027143408", "display_name": "Heba A. Habib" }, { "id": "https://openalex.org/A5030210239", "display_name": "Gehan H. Heeba" }, { "id": "https://openalex.org/A5101602088", "display_name": "Mohamed Mansour Khalifa" } ] }, { "id": "https://openalex.org/W2109662292", "doi": "https://doi.org/10.1161/hypertensionaha.114.03062", "title": "Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus", "abstract": { "Glucagon-like": [ 0 ], "peptide-1": [ 1, 48 ], "receptor": [ 2, 49 ], "agonists,": [ 3 ], "used": [ 4 ], "to": [ 5, 92, 126, 142, 150, 187, 242 ], "treat": [ 6 ], "type": [ 7, 71 ], "2": [ 8, 72 ], "diabetes": [ 9, 73 ], "mellitus,": [ 10, 74 ], "are": [ 11 ], "associated": [ 12, 220 ], "with": [ 13, 70, 80, 221 ], "small": [ 14 ], "reductions": [ 15 ], "in": [ 16, 23, 129, 154, 224, 230 ], "systolic": [ 17 ], "blood": [ 18, 159 ], "pressure": [ 19 ], "(SBP)": [ 20 ], "and": [ 21, 53, 86, 111, 115, 157, 161, 227 ], "increases": [ 22 ], "heart": [ 24, 54, 197, 232 ], "rate.": [ 25, 233 ], "However,": [ 26 ], "findings": [ 27 ], "based": [ 28 ], "on": [ 29, 51 ], "clinic": [ 30, 82 ], "measurements": [ 31 ], "do": [ 32 ], "not": [ 33, 211 ], "adequately": [ 34 ], "assess": [ 35 ], "a": [ 36, 45, 81, 133, 222 ], "drug\u2019s": [ 37 ], "24-hour": [ 38, 131, 155, 196, 225, 231 ], "pharmacodynamic": [ 39 ], "profile.": [ 40 ], "The": [ 41, 118, 234 ], "effects": [ 42, 139, 240 ], "of": [ 43, 140, 146 ], "dulaglutide,": [ 44 ], "once-weekly": [ 46 ], "glucagon-like": [ 47 ], "agonist,": [ 50 ], "BP": [ 52, 60, 83, 105 ], "rate": [ 55, 198 ], "were": [ 56, 90, 148 ], "investigated": [ 57 ], "using": [ 58 ], "ambulatory": [ 59 ], "monitoring.": [ 61 ], "Patients": [ 62 ], "(n=755;": [ 63 ], "56\u00b110": [ 64 ], "years;": [ 65 ], "81%": [ 66 ], "white;": [ 67 ], "48%": [ 68 ], "women),": [ 69 ], "taking": [ 75 ], "\u22651": [ 76 ], "oral": [ 77 ], "antihyperglycemic": [ 78 ], "medication,": [ 79 ], "between": [ 84 ], "90/60": [ 85 ], "140/90": [ 87 ], "mm": [ 88, 176 ], "Hg": [ 89, 177 ], "randomized": [ 91 ], "dulaglutide": [ 93, 141, 147, 162, 207 ], "(1.5": [ 94 ], "or": [ 95, 98 ], "0.75": [ 96, 183 ], "mg)": [ 97 ], "placebo": [ 99, 151, 188 ], "subcutaneously": [ 100 ], "for": [ 101, 152, 195, 237 ], "26": [ 102, 116 ], "weeks.": [ 103, 117 ], "Ambulatory": [ 104 ], "monitoring": [ 106 ], "was": [ 107, 122, 185, 210, 219 ], "performed": [ 108 ], "at": [ 109, 112 ], "baseline": [ 110, 125 ], "4,": [ 113 ], "16,": [ 114 ], "primary": [ 119 ], "end": [ 120 ], "point": [ 121 ], "change": [ 123 ], "from": [ 124 ], "week": [ 127 ], "16": [ 128 ], "mean": [ 130, 170, 201 ], "SBP,": [ 132 ], "tree": [ 134 ], "gatekeeping": [ 135 ], "strategy": [ 136 ], "compared": [ 137 ], "the": [ 138, 238 ], "placebo.": [ 143 ], "Both": [ 144 ], "doses": [ 145 ], "noninferior": [ 149, 186 ], "changes": [ 153 ], "SBP": [ 156, 167, 226 ], "diastolic": [ 158 ], "pressure,": [ 160 ], "1.5": [ 163, 208, 217 ], "mg": [ 164, 184, 209, 218 ], "significantly": [ 165 ], "reduced": [ 166 ], "(least": [ 168, 199 ], "squares": [ 169, 200 ], "difference": [ 171, 202 ], "[95%": [ 172, 203 ], "confidence": [ 173, 204 ], "interval]),": [ 174, 205 ], "\u22122.8": [ 175 ], "[\u22124.6,": [ 178 ], "\u22121.0];": [ 179 ], "P": [ 180, 193 ], "\u22640.001).": [ 181 ], "Dulaglutide": [ 182, 216 ], "(1.6": [ 189 ], "bpm;": [ 190 ], "[0.3,": [ 191 ], "2.9];": [ 192 ], "\u22640.02)": [ 194 ], "but": [ 206 ], "(2.8": [ 212 ], "bpm": [ 213 ], "[1.5,": [ 214 ], "4.2]).": [ 215 ], "reduction": [ 223 ], "an": [ 228 ], "increase": [ 229 ], "mechanisms": [ 235 ], "responsible": [ 236 ], "observed": [ 239 ], "remain": [ 241 ], "be": [ 243 ], "clarified.": [ 244 ] }, "publication_date": "2014-07-01", "publication_year": 2014, "type": "article", "cited_by_count": 136, "authors": [ { "id": "https://openalex.org/A5071877865", "display_name": "Keith C. Ferdinand" }, { "id": "https://openalex.org/A5056816871", "display_name": "William B. White" }, { "id": "https://openalex.org/A5043389439", "display_name": "David A. Calhoun" }, { "id": "https://openalex.org/A5016752955", "display_name": "Eva Lonn" }, { "id": "https://openalex.org/A5086404218", "display_name": "Philip T. Sager" }, { "id": "https://openalex.org/A5068141665", "display_name": "Rocco L. Brunelle" }, { "id": "https://openalex.org/A5102105301", "display_name": "Honghua Jiang" }, { "id": "https://openalex.org/A5075118496", "display_name": "Rebecca Threlkeld" }, { "id": "https://openalex.org/A5036121357", "display_name": "Kenneth E. Robertson" }, { "id": "https://openalex.org/A5110243358", "display_name": "Mary Jane Geiger" } ] }, { "id": "https://openalex.org/W2038327000", "doi": "https://doi.org/10.1097/01.tp.0000251379.46596.2d", "title": "Effect of Exenatide on ?? Cell Function After Islet Transplantation in Type 1 Diabetes", "abstract": { "Exenatide": [ 0 ], "stimulates": [ 1 ], "insulin": [ 2, 10, 22 ], "secretion": [ 3 ], "in": [ 4, 12, 23 ], "islet": [ 5 ], "transplant": [ 6 ], "recipients.": [ 7 ], "It": [ 8 ], "reduces": [ 9 ], "dose": [ 11 ], "some": [ 13 ], "patients": [ 14 ], "and": [ 15 ], "may": [ 16 ], "delay": [ 17 ], "the": [ 18 ], "need": [ 19 ], "to": [ 20 ], "resume": [ 21 ], "others.": [ 24 ], "We": [ 25 ], "did": [ 26 ], "not": [ 27 ], "find": [ 28 ], "any": [ 29 ], "evidence": [ 30 ], "of": [ 31 ], "a": [ 32 ], "trophic": [ 33 ], "effect": [ 34 ], "on": [ 35 ], "islets.": [ 36 ] }, "publication_date": "2007-01-01", "publication_year": 2007, "type": "article", "cited_by_count": 129, "authors": [ { "id": "https://openalex.org/A5001480223", "display_name": "Khalid Al Ghofaili" }, { "id": "https://openalex.org/A5111593813", "display_name": "Michelle Fung" }, { "id": "https://openalex.org/A5109292771", "display_name": "Ziliang Ao" }, { "id": "https://openalex.org/A5111856943", "display_name": "Mark Meloche" }, { "id": "https://openalex.org/A5000099954", "display_name": "R. Jean Shapiro" }, { "id": "https://openalex.org/A5046141743", "display_name": "Garth L. Warnock" }, { "id": "https://openalex.org/A5007270622", "display_name": "Dariush Elahi" }, { "id": "https://openalex.org/A5046238445", "display_name": "Graydon S. Meneilly" }, { "id": "https://openalex.org/A5006958898", "display_name": "David Thompson" } ] }, { "id": "https://openalex.org/W2997605969", "doi": "https://doi.org/10.1007/s13340-019-00423-8", "title": "The development of oral semaglutide, an oral GLP-1 analog, for the treatment of type 2 diabetes", "abstract": null, "publication_date": "2020-01-04", "publication_year": 2020, "type": "review", "cited_by_count": 45, "authors": [ { "id": "https://openalex.org/A5109247811", "display_name": "Mads Frederik Rasmussen" } ] }, { "id": "https://openalex.org/W3046420687", "doi": "https://doi.org/10.1016/j.ejphar.2020.173443", "title": "Tolerance develops toward GLP-1 receptor agonists\u2019 glucose-lowering effect in mice", "abstract": null, "publication_date": "2020-08-01", "publication_year": 2020, "type": "article", "cited_by_count": 11, "authors": [ { "id": "https://openalex.org/A5015402905", "display_name": "Tuuli Sedman" }, { "id": "https://openalex.org/A5028669651", "display_name": "Maarja Krass" }, { "id": "https://openalex.org/A5089242399", "display_name": "Kertu R\u00fcnkorg" }, { "id": "https://openalex.org/A5048622515", "display_name": "Eero Vasar" }, { "id": "https://openalex.org/A5033444495", "display_name": "Vallo Volke" } ] }, { "id": "https://openalex.org/W4396231664", "doi": "https://doi.org/10.1053/j.gastro.2024.04.029", "title": "Association of GLP-1 Receptor Agonists and Hepatocellular Carcinoma Incidence and Hepatic Decompensation in Patients With Type 2 Diabetes", "abstract": null, "publication_date": "2024-04-29", "publication_year": 2024, "type": "article", "cited_by_count": 88, "authors": [ { "id": "https://openalex.org/A5024175424", "display_name": "Lindsey Wang" }, { "id": "https://openalex.org/A5037635525", "display_name": "Nathan A. Berger" }, { "id": "https://openalex.org/A5075366571", "display_name": "David C. Kaelber" }, { "id": "https://openalex.org/A5050134236", "display_name": "Rong Xu" } ] }, { "id": "https://openalex.org/W2140682563", "doi": "https://doi.org/10.1177/1479164111408937", "title": "Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2\u20143 liraglutide clinical development studies", "abstract": { "We": [ 0 ], "assessed": [ 1 ], "the": [ 2, 27, 53, 109, 159 ], "cardiovascular": [ 3, 40, 43, 154 ], "safety": [ 4, 155 ], "of": [ 5, 37, 78 ], "liraglutide,": [ 6 ], "a": [ 7 ], "glucagon-like": [ 8 ], "peptide-1": [ 9 ], "receptor": [ 10 ], "agonist,": [ 11 ], "using": [ 12, 56, 108 ], "existing": [ 13 ], "clinical": [ 14, 29 ], "data.": [ 15 ], "Patient-level": [ 16 ], "results": [ 17 ], "from": [ 18, 26, 85 ], "all": [ 19, 144 ], "completed": [ 20 ], "phase": [ 21 ], "2": [ 22 ], "and": [ 23, 75, 122 ], "3": [ 24 ], "studies": [ 25, 95 ], "liraglutide": [ 28, 99, 137 ], "development": [ 30 ], "programme": [ 31 ], "were": [ 32, 49, 81, 88, 102, 116, 124 ], "pooled": [ 33 ], "to": [ 34 ], "determine": [ 35 ], "rates": [ 36 ], "major": [ 38 ], "adverse": [ 39, 67, 120 ], "events": [ 41, 68, 84, 121 ], "(MACE):": [ 42 ], "death,": [ 44 ], "myocardial": [ 45 ], "infarction,": [ 46 ], "stroke.": [ 47 ], "MACE": [ 48, 106, 134 ], "identified": [ 50, 107 ], "by": [ 51, 70, 158 ], "querying": [ 52 ], "study": [ 54, 71 ], "database": [ 55 ], "Medical": [ 57 ], "Dictionary": [ 58 ], "for": [ 59, 131, 166 ], "Regulatory": [ 60 ], "Activities": [ 61 ], "(MedDRA)": [ 62 ], "terms": [ 63 ], "combined": [ 64 ], "with": [ 65, 105, 136 ], "serious": [ 66, 119 ], "recorded": [ 69 ], "investigators.": [ 72 ], "Broad,": [ 73 ], "narrow,": [ 74 ], "custom": [ 76 ], "groups": [ 77 ], "MedDRA": [ 79, 111 ], "queries": [ 80 ], "used.": [ 82 ], "Candidate": [ 83 ], "each": [ 86 ], "query": [ 87 ], "independently": [ 89 ], "adjudicated": [ 90, 125, 132 ], "post": [ 91 ], "hoc.": [ 92 ], "In": [ 93 ], "15": [ 94 ], "(6638": [ 96 ], "patients;": [ 97 ], "4257": [ 98 ], "treated),": [ 100 ], "there": [ 101 ], "114": [ 103 ], "patients": [ 104 ], "broad": [ 110 ], "query.": [ 112 ], "Of": [ 113 ], "these,": [ 114 ], "44": [ 115 ], "classified": [ 117 ], "as": [ 118, 126 ], "39": [ 123 ], "MACE.": [ 127 ], "The": [ 128 ], "incidence": [ 129 ], "ratio": [ 130 ], "broad/serious": [ 133 ], "associated": [ 135 ], "was": [ 138 ], "0.73": [ 139 ], "(95%": [ 140 ], "CI": [ 141 ], "0.38\u20141.41)": [ 142 ], "versus": [ 143 ], "comparator": [ 145 ], "drugs": [ 146 ], "(metformin,": [ 147 ], "glimepiride,": [ 148 ], "rosiglitazone,": [ 149 ], "insulin": [ 150 ], "glargine,": [ 151 ], "placebo),": [ 152 ], "within": [ 153 ], "limits": [ 156 ], "defined": [ 157 ], "United": [ 160 ], "States": [ 161 ], "Food": [ 162 ], "&": [ 163 ], "Drug": [ 164 ], "Administration": [ 165 ], "diabetes": [ 167 ], "therapies": [ 168 ], "under": [ 169 ], "current": [ 170 ], "investigation.": [ 171 ] }, "publication_date": "2011-06-08", "publication_year": 2011, "type": "article", "cited_by_count": 103, "authors": [ { "id": "https://openalex.org/A5110355842", "display_name": "Steven P. Marso" }, { "id": "https://openalex.org/A5111302951", "display_name": "Jason B. Lindsey" }, { "id": "https://openalex.org/A5111451520", "display_name": "Joshua M. Stolker" }, { "id": "https://openalex.org/A5034015154", "display_name": "John A. House" }, { "id": "https://openalex.org/A5032084622", "display_name": "Gabriela Martinez Ravn" }, { "id": "https://openalex.org/A5062736539", "display_name": "Kevin F. Kennedy" }, { "id": "https://openalex.org/A5107025145", "display_name": "Troels Mygind Jensen" }, { "id": "https://openalex.org/A5040182038", "display_name": "John B. Buse" } ] }, { "id": "https://openalex.org/W2023462541", "doi": "https://doi.org/10.1111/j.1464-5491.2005.01567.x", "title": "Effects of liraglutide (NN2211), a long\u2010acting GLP\u20101 analogue, on glycaemic control and bodyweight in subjects with Type\u00a02 diabetes", "abstract": { "Abstract": [ 0 ], "Aims": [ 1 ], "Liraglutide": [ 2, 260 ], "(NN2211)": [ 3 ], "is": [ 4 ], "a": [ 5, 10, 75, 135, 255 ], "long\u2010acting": [ 6 ], "GLP\u20101": [ 7 ], "analogue,": [ 8 ], "with": [ 9, 37, 48, 56, 64 ], "pharmacokinetic": [ 11 ], "profile": [ 12 ], "suitable": [ 13 ], "for": [ 14, 102, 109, 119, 128, 144, 155 ], "once\u2010daily": [ 15 ], "administration.": [ 16 ], "This": [ 17 ], "multicentre,": [ 18 ], "double\u2010blind,": [ 19 ], "parallel\u2010group,": [ 20 ], "double\u2010dummy": [ 21 ], "study": [ 22, 274 ], "explored": [ 23 ], "the": [ 24, 110, 145, 188, 214 ], "dose\u2013response": [ 25 ], "relationship": [ 26 ], "of": [ 27, 138, 229, 271 ], "liraglutide": [ 28, 90, 162, 183, 191, 202, 240, 248, 272 ], "effects": [ 29 ], "on": [ 30, 97 ], "bodyweight": [ 31 ], "and": [ 32, 66, 123, 163, 171, 184, 196, 206, 241, 252, 265 ], "glycaemic": [ 33, 250 ], "control": [ 34, 251 ], "in": [ 35, 177, 254, 275 ], "subjects": [ 36, 81 ], "Type": [ 38, 49 ], "2": [ 39, 46, 50 ], "diabetes.": [ 40 ], "Methods": [ 41 ], "Subjects": [ 42 ], "(BMI": [ 43 ], "27\u201342": [ 44 ], "kg/m": [ 45 ], ")": [ 47 ], "diabetes": [ 51 ], "who": [ 52 ], "were": [ 53, 72, 86, 165, 180, 209, 226, 233 ], "previously": [ 54 ], "treated": [ 55 ], "an": [ 57 ], "OAD": [ 58 ], "(oral": [ 59 ], "anti\u2010diabetic": [ 60 ], "drug)": [ 61 ], "monotherapy": [ 62 ], "(69%": [ 63 ], "metformin),": [ 65 ], "had": [ 67 ], "HbA": [ 68, 120, 150, 178 ], "1c": [ 69, 121, 151, 179 ], "\u2264": [ 70 ], "10%": [ 71 ], "enrolled.": [ 73 ], "After": [ 74, 132 ], "4\u2010week": [ 76 ], "metformin": [ 77, 98, 164, 185 ], "run\u2010in": [ 78 ], "period,": [ 79 ], "210": [ 80 ], "(27\u201373": [ 82 ], "years,": [ 83 ], "60%": [ 84 ], "female)": [ 85 ], "randomised": [ 87 ], "to": [ 88, 117, 140, 212, 258, 262 ], "receive": [ 89 ], "(0.045\u20130.75": [ 91 ], "mg)": [ 92, 208 ], "once": [ 93 ], "daily": [ 94 ], "or": [ 95 ], "continued": [ 96 ], "1000": [ 99 ], "mg": [ 100, 161, 205 ], "b.d.": [ 101 ], "12": [ 103 ], "weeks.": [ 104 ], "Results": [ 105 ], "Mean": [ 106, 149 ], "baseline": [ 107, 154 ], "values": [ 108, 218 ], "six": [ 111, 146 ], "treatment": [ 112, 147 ], "groups": [ 113, 186 ], "ranged": [ 114 ], "from": [ 115, 153 ], "6.8": [ 116 ], "7.5%": [ 118 ], ",": [ 122 ], "8.06\u20139.44": [ 124 ], "mmol/l": [ 125 ], "(145\u2013170": [ 126 ], "mg/dl)": [ 127 ], "fasting": [ 129, 215 ], "plasma": [ 130, 216 ], "glucose.": [ 131 ], "12\u2010week": [ 133 ], "treatment,": [ 134 ], "weight": [ 136 ], "change": [ 137 ], "\u22120.05": [ 139 ], "\u22121.9%": [ 141 ], "was": [ 142 ], "observed": [ 143, 181 ], "groups.": [ 148 ], "changes": [ 152 ], "0.045,": [ 156 ], "0.225,": [ 157 ], "0.45,": [ 158 ], "0.6,": [ 159 ], "0.75": [ 160, 197 ], "+1.28%,": [ 166 ], "+0.86%,": [ 167 ], "+0.22%,": [ 168 ], "+0.16%,": [ 169 ], "+0.30%": [ 170 ], "+0.09%,": [ 172 ], "respectively.": [ 173 ], "No": [ 174, 222 ], "significant": [ 175 ], "differences": [ 176 ], "between": [ 182 ], "at": [ 187 ], "three": [ 189, 242 ], "highest": [ 190 ], "dose": [ 192 ], "levels": [ 193 ], "(0.45,": [ 194 ], "0.6": [ 195 ], "mg).": [ 198 ], "The": [ 199 ], "lowest": [ 200 ], "two": [ 201 ], "doses": [ 203, 270 ], "(0.045": [ 204 ], "0.225": [ 207 ], "not": [ 210 ], "sufficient": [ 211 ], "maintain": [ 213 ], "glucose": [ 217 ], "achieved": [ 219 ], "by": [ 220, 235 ], "metformin.": [ 221, 245, 259 ], "major": [ 223 ], "hypoglycaemic": [ 224 ], "episodes": [ 225 ], "reported.": [ 227 ], "Episodes": [ 228 ], "nausea": [ 230 ], "and/or": [ 231 ], "vomiting": [ 232 ], "reported": [ 234 ], "11": [ 236 ], "patients": [ 237 ], "(6.3%)": [ 238 ], "receiving": [ 239, 244 ], "(8.8%)": [ 243 ], "Conclusions": [ 246 ], "Once\u2010daily": [ 247 ], "improved": [ 249 ], "weight,": [ 253 ], "comparable": [ 256 ], "degree": [ 257 ], "appeared": [ 261 ], "be": [ 263 ], "safe": [ 264 ], "generally": [ 266 ], "well": [ 267 ], "tolerated.": [ 268 ], "Higher": [ 269 ], "merit": [ 273 ], "future": [ 276 ], "clinical": [ 277 ], "trials.": [ 278 ] }, "publication_date": "2005-07-13", "publication_year": 2005, "type": "article", "cited_by_count": 148, "authors": [ { "id": "https://openalex.org/A5112804316", "display_name": "Mark N. Feinglos" }, { "id": "https://openalex.org/A5101765750", "display_name": "Mohammed Saad" }, { "id": "https://openalex.org/A5109168061", "display_name": "F X Pi-Sunyer" }, { "id": "https://openalex.org/A5110041283", "display_name": "Bob An" }, { "id": "https://openalex.org/A5111940836", "display_name": "Olga M. Santiago" } ] }, { "id": "https://openalex.org/W4287833463", "doi": "https://doi.org/10.1007/s11695-022-06211-9", "title": "The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery\u2014a Retrospective Analysis", "abstract": null, "publication_date": "2022-07-25", "publication_year": 2022, "type": "article", "cited_by_count": 73, "authors": [ { "id": "https://openalex.org/A5084520603", "display_name": "Anne Lautenbach" }, { "id": "https://openalex.org/A5087877754", "display_name": "Marie Wernecke" }, { "id": "https://openalex.org/A5076632645", "display_name": "Tobias B. Huber" }, { "id": "https://openalex.org/A5079322627", "display_name": "Fabian Stoll" }, { "id": "https://openalex.org/A5036000854", "display_name": "Jonas Wagner" }, { "id": "https://openalex.org/A5031235277", "display_name": "Sebastian M. Meyh\u00f6fer" }, { "id": "https://openalex.org/A5115599142", "display_name": "Svenja Meyh\u00f6fer" }, { "id": "https://openalex.org/A5027433747", "display_name": "Jens Aberle" } ] }, { "id": "https://openalex.org/W3120751109", "doi": "https://doi.org/10.1007/s10157-020-02007-2", "title": "Renoprotective effect of GLP-1 receptor agonist, liraglutide, in early-phase diabetic kidney disease in spontaneously diabetic Torii fatty rats", "abstract": null, "publication_date": "2021-01-06", "publication_year": 2021, "type": "article", "cited_by_count": 30, "authors": [ { "id": "https://openalex.org/A5021681870", "display_name": "Shohei Yamada" }, { "id": "https://openalex.org/A5102926448", "display_name": "Jun Tanabe" }, { "id": "https://openalex.org/A5057128073", "display_name": "Yuji Ogura" }, { "id": "https://openalex.org/A5103203378", "display_name": "Yoshio Nagai" }, { "id": "https://openalex.org/A5006703198", "display_name": "Takeshi Sugaya" }, { "id": "https://openalex.org/A5074170173", "display_name": "Keiichi Ohata" }, { "id": "https://openalex.org/A5017841806", "display_name": "Y. Natsuki" }, { "id": "https://openalex.org/A5002284527", "display_name": "Daisuke Ichikawa" }, { "id": "https://openalex.org/A5112905611", "display_name": "Shiika Watanabe" }, { "id": "https://openalex.org/A5104089110", "display_name": "Kazuho Inoue" }, { "id": "https://openalex.org/A5073594099", "display_name": "Seiko Hoshino" }, { "id": "https://openalex.org/A5103121069", "display_name": "Kenjiro Kimura" }, { "id": "https://openalex.org/A5082673778", "display_name": "Yugo Shibagaki" }, { "id": "https://openalex.org/A5062271654", "display_name": "Atsuko Kamijo\u2010Ikemori" } ] }, { "id": "https://openalex.org/W2041728881", "doi": "https://doi.org/10.1089/dia.2011.0076", "title": "Exenatide Once-Weekly Clinical Development: Safety and Efficacy Across a Range of Background Therapies", "abstract": { "In": [ 0 ], "patients": [ 1, 194, 242 ], "with": [ 2, 49, 196, 243, 246 ], "type": [ 3 ], "2": [ 4 ], "diabetes": [ 5 ], "mellitus": [ 6 ], "(T2DM),": [ 7 ], "the": [ 8, 35, 44, 76, 84, 139, 151, 157, 179 ], "physiologic": [ 9 ], "glucagon-like": [ 10 ], "peptide-1": [ 11 ], "(GLP-1)": [ 12 ], "response,": [ 13 ], "which": [ 14, 137 ], "is": [ 15, 23, 138 ], "involved": [ 16 ], "in": [ 17, 34, 55, 74, 132, 156, 161, 193, 241 ], "glucose": [ 18 ], "regulation": [ 19 ], "through": [ 20 ], "several": [ 21 ], "mechanisms,": [ 22 ], "dysfunctional.": [ 24 ], "GLP-1": [ 25, 61, 95, 98 ], "receptor": [ 26, 62, 96, 99 ], "agonists": [ 27, 63, 100 ], "can": [ 28 ], "fill": [ 29 ], "an": [ 30 ], "unmet": [ 31 ], "therapeutic": [ 32 ], "need": [ 33 ], "treatment": [ 36, 68, 91 ], "of": [ 37, 46, 59, 86, 136, 142, 154, 207 ], "T2DM:": [ 38 ], "improving": [ 39 ], "glycemic": [ 40, 187 ], "control": [ 41 ], "without": [ 42 ], "increasing": [ 43 ], "risk": [ 45 ], "hypoglycemia": [ 47 ], "(except": [ 48 ], "concomitant": [ 50 ], "sulfonylureas)": [ 51 ], "and": [ 52, 80, 189, 213, 236 ], "reducing": [ 53 ], "weight": [ 54, 190 ], "a": [ 56, 108 ], "substantial": [ 57 ], "proportion": [ 58 ], "patients.": [ 60 ], "have": [ 64 ], "impacted": [ 65 ], "established": [ 66 ], "disease": [ 67 ], "algorithms": [ 69 ], "for": [ 70, 83 ], "T2DM.": [ 71 ], "For": [ 72 ], "example,": [ 73 ], "2009": [ 75 ], "American": [ 77 ], "Diabetes": [ 78, 87 ], "Association": [ 79, 82 ], "European": [ 81 ], "Study": [ 85 ], "revised": [ 88 ], "their": [ 89 ], "consensus": [ 90 ], "algorithm": [ 92 ], "to": [ 93, 174, 228, 233 ], "incorporate": [ 94 ], "agonists.": [ 97 ], "were": [ 101, 165, 191, 216, 239 ], "originally": [ 102 ], "represented": [ 103 ], "by": [ 104 ], "exenatide": [ 105, 143 ], "BID": [ 106 ], "(ExBID),": [ 107 ], "short-acting": [ 109 ], "agent": [ 110, 118 ], "requiring": [ 111, 120 ], "twice-daily": [ 112 ], "injections": [ 113 ], "at": [ 114 ], "mealtime.": [ 115 ], "The": [ 116 ], "longer-acting": [ 117 ], "liraglutide,": [ 119 ], "once-daily": [ 121 ], "injections,": [ 122 ], "recently": [ 123 ], "received": [ 124, 182 ], "regulatory": [ 125 ], "approval.": [ 126 ], "Several": [ 127 ], "other": [ 128 ], "long-acting": [ 129 ], "agents": [ 130 ], "are": [ 131 ], "clinical": [ 133, 152, 163, 220, 223 ], "development,": [ 134, 221 ], "one": [ 135 ], "once-weekly": [ 140 ], "formulation": [ 141 ], "(exenatide": [ 144 ], "once": [ 145 ], "weekly": [ 146 ], "[ExQW]).": [ 147 ], "This": [ 148 ], "article": [ 149 ], "reviews": [ 150 ], "development": [ 153 ], "ExQW": [ 155, 197, 219 ], "DURATION": [ 158 ], "program.": [ 159 ], "Patients": [ 160 ], "theses": [ 162 ], "trials": [ 164 ], "receiving": [ 166 ], "various": [ 167 ], "background": [ 168 ], "treatments,": [ 169 ], "ranging": [ 170 ], "from": [ 171 ], "lifestyle": [ 172 ], "therapy": [ 173 ], "combination": [ 175 ], "oral": [ 176 ], "therapy,": [ 177 ], "although": [ 178 ], "majority": [ 180 ], "(68%)": [ 181 ], "metformin": [ 183 ], "monotherapy.": [ 184 ], "Specifically,": [ 185 ], "safety,": [ 186 ], "control,": [ 188 ], "compared": [ 192 ], "treated": [ 195, 245 ], "versus": [ 198 ], "ExBID,": [ 199 ], "sitagliptin,": [ 200 ], "pioglitazone,": [ 201 ], "or": [ 202 ], "insulin": [ 203 ], "glargine.": [ 204 ], "Moreover,": [ 205 ], "measures": [ 206 ], "\u03b2-cell": [ 208 ], "function,": [ 209 ], "cardiovascular": [ 210 ], "risk,": [ 211 ], "inflammation,": [ 212 ], "hepatic": [ 214 ], "health": [ 215 ], "investigated.": [ 217 ], "During": [ 218 ], "consistent": [ 222 ], "efficacy": [ 224 ], "(glycosylated": [ 225 ], "hemoglobin,": [ 226 ], "-1.5%": [ 227 ], "-1.9%;": [ 229 ], "weight,": [ 230 ], "-2": [ 231 ], "kg": [ 232 ], "-4": [ 234 ], "kg)": [ 235 ], "safety": [ 237 ], "data": [ 238 ], "observed": [ 240 ], "T2DM": [ 244 ], "ExQW.": [ 247 ] }, "publication_date": "2011-07-06", "publication_year": 2011, "type": "review", "cited_by_count": 27, "authors": [ { "id": "https://openalex.org/A5049307365", "display_name": "Anthony H. Stonehouse" }, { "id": "https://openalex.org/A5102775095", "display_name": "Brandon Walsh" }, { "id": "https://openalex.org/A5101709468", "display_name": "Robert Cuddihy" } ] }, { "id": "https://openalex.org/W2772871657", "doi": "https://doi.org/10.1016/j.neuropharm.2017.11.048", "title": "GLP-1 receptor agonists downregulate aberrant GnT-III expression in Alzheimer's disease models through the Akt/GSK-3\u03b2/\u03b2-catenin signaling", "abstract": null, "publication_date": "2017-12-07", "publication_year": 2017, "type": "article", "cited_by_count": 55, "authors": [ { "id": "https://openalex.org/A5100347261", "display_name": "Ying Wang" }, { "id": "https://openalex.org/A5100423587", "display_name": "Song Chen" }, { "id": "https://openalex.org/A5101503153", "display_name": "Xu Zheng" }, { "id": "https://openalex.org/A5066309268", "display_name": "Suting Chen" }, { "id": "https://openalex.org/A5004088965", "display_name": "Wenbing Yao" }, { "id": "https://openalex.org/A5024475089", "display_name": "Xiangdong Gao" } ] }, { "id": "https://openalex.org/W2026171909", "doi": "https://doi.org/10.1016/j.clinthera.2006.05.006", "title": "Exenatide: An incretin mimetic for the treatment of type 2 diabetes mellitus", "abstract": null, "publication_date": "2006-05-01", "publication_year": 2006, "type": "review", "cited_by_count": 91, "authors": [ { "id": "https://openalex.org/A5030099154", "display_name": "Jason L. Iltz" }, { "id": "https://openalex.org/A5029438179", "display_name": "Danial E. Baker" }, { "id": "https://openalex.org/A5007314577", "display_name": "Stephen M. Setter" }, { "id": "https://openalex.org/A5087170338", "display_name": "R. Keith Campbell" } ] }, { "id": "https://openalex.org/W7970676", "doi": "https://doi.org/10.1900/rds.2009.6.247", "title": "Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists", "abstract": { "The": [ 0 ], "diverse": [ 1 ], "actions": [ 2, 202 ], "of": [ 3, 88, 132, 156, 192, 196 ], "the": [ 4, 37, 107, 154, 189, 193, 200 ], "incretin": [ 5, 218 ], "hormone": [ 6 ], "glucagon-like": [ 7 ], "peptide": [ 8 ], "(GLP)-1": [ 9 ], "include": [ 10 ], "insulinotropic,": [ 11 ], "beta-cell": [ 12, 118 ], "preservative,": [ 13 ], "cardioprotective": [ 14 ], "and": [ 15, 58, 71, 77, 120, 128, 142, 169, 199, 214, 227 ], "vasodilatory": [ 16 ], "effects.": [ 17, 79 ], "This": [ 18, 186 ], "spectrum": [ 19 ], "makes": [ 20 ], "GLP-1": [ 21, 53, 68, 82, 89, 102, 111 ], "an": [ 22 ], "appealing": [ 23 ], "therapeutic": [ 24 ], "option": [ 25 ], "for": [ 26, 179 ], "patients": [ 27, 180 ], "with": [ 28, 181, 220 ], "type": [ 29, 166 ], "2": [ 30, 167 ], "diabetes.": [ 31 ], "However,": [ 32 ], "its": [ 33, 61, 170 ], "rapid": [ 34 ], "metabolism": [ 35 ], "by": [ 36, 95, 165 ], "enzyme": [ 38 ], "dipeptidyl": [ 39 ], "peptidase": [ 40 ], "(DPP)-4": [ 41 ], "renders": [ 42 ], "it": [ 43, 203, 210 ], "impractical.": [ 44 ], "Incretin-based": [ 45 ], "analogues": [ 46, 90 ], "have": [ 47, 74, 143 ], "been": [ 48 ], "developed": [ 49 ], "to": [ 50, 59, 92, 161, 222 ], "extend": [ 51 ], "endogenous": [ 52, 157, 197 ], "action": [ 54 ], "(GLP-1": [ 55 ], "receptor": [ 56, 69, 83, 112 ], "agonists)": [ 57 ], "hamper": [ 60 ], "degradation": [ 62 ], "(DPP-4": [ 63 ], "inhibitors).": [ 64 ], "Evidence": [ 65 ], "suggests": [ 66 ], "that": [ 67 ], "agonists": [ 70, 84, 113 ], "DPP-4": [ 72, 98, 137, 149, 173 ], "inhibitors": [ 73, 138, 174 ], "different": [ 75 ], "pharmacodynamic": [ 76 ], "pharmacokinetic": [ 78 ], "For": [ 80 ], "example,": [ 81 ], "deliver": [ 85 ], "supraphysiologic": [ 86 ], "levels": [ 87 ], "designed": [ 91 ], "resist": [ 93 ], "inactivation": [ 94 ], "DPP-4,": [ 96 ], "whereas": [ 97 ], "inhibition": [ 99, 150 ], "conserves": [ 100 ], "native": [ 101 ], "resulting": [ 103 ], "in": [ 104, 130 ], "concentrations": [ 105 ], "within": [ 106 ], "physiologic": [ 108 ], "range.": [ 109 ], "Furthermore,": [ 110 ], "induce": [ 114 ], "glucose-dependent": [ 115 ], "insulin": [ 116 ], "secretion,": [ 117 ], "protection,": [ 119 ], "other": [ 121 ], "extraglycemic": [ 122 ], "benefits": [ 123 ], "such": [ 124 ], "as": [ 125 ], "weight": [ 126, 140 ], "loss": [ 127 ], "improvement": [ 129 ], "markers": [ 131 ], "cardiovascular": [ 133 ], "risk.": [ 134 ], "In": [ 135 ], "contrast,": [ 136 ], "are": [ 139 ], "neutral": [ 141 ], "modest": [ 144 ], "effects": [ 145, 195 ], "on": [ 146, 153, 205, 217 ], "glucose": [ 147 ], "control.": [ 148 ], "is": [ 151 ], "dependent": [ 152 ], "availability": [ 155 ], "GLP-1,": [ 158, 198 ], "which": [ 159 ], "appears": [ 160 ], "be": [ 162, 176 ], "adversely": [ 163 ], "affected": [ 164 ], "diabetes": [ 168 ], "progression.": [ 171 ], "Therefore,": [ 172 ], "may": [ 175 ], "better": [ 177 ], "suited": [ 178 ], "mild": [ 182 ], "hyperglycemia": [ 183 ], "without": [ 184 ], "comorbidities.": [ 185 ], "review": [ 187 ], "examines": [ 188 ], "present": [ 190 ], "understanding": [ 191 ], "pancreatic": [ 194 ], "extrapancreatic": [ 201 ], "exerts": [ 204 ], "human": [ 206 ], "bodily": [ 207 ], "systems.": [ 208 ], "Also,": [ 209 ], "analyzes": [ 211 ], "available": [ 212 ], "preclinical": [ 213 ], "clinical": [ 215 ], "data": [ 216 ], "therapies": [ 219 ], "respect": [ 221 ], "glycemia,": [ 223 ], "lipids,": [ 224 ], "blood": [ 225 ], "pressure,": [ 226 ], "weight.": [ 228 ] }, "publication_date": "2009-01-01", "publication_year": 2009, "type": "article", "cited_by_count": 16, "authors": [ { "id": "https://openalex.org/A5105783630", "display_name": "Baptist Gallwitz" } ] }, { "id": "https://openalex.org/W2997634477", "doi": "https://doi.org/10.1007/s00125-019-05065-8", "title": "Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial", "abstract": null, "publication_date": "2020-01-02", "publication_year": 2020, "type": "article", "cited_by_count": 123, "authors": [ { "id": "https://openalex.org/A5049374974", "display_name": "Rory J. McCrimmon" }, { "id": "https://openalex.org/A5009303872", "display_name": "Andrei\u2010Mircea Catarig" }, { "id": "https://openalex.org/A5086072427", "display_name": "Juan P. Fr\u00edas" }, { "id": "https://openalex.org/A5068233206", "display_name": "Nanna L. Lausvig" }, { "id": "https://openalex.org/A5010753663", "display_name": "Carel W. le Roux" }, { "id": "https://openalex.org/A5039484944", "display_name": "Desir\u00e9e Thielke" }, { "id": "https://openalex.org/A5001655356", "display_name": "Ildiko Lingvay" } ] }, { "id": "https://openalex.org/W2085142826", "doi": "https://doi.org/10.1592/phco.31.9.896", "title": "Liraglutide: Clinical Pharmacology and Considerations for Therapy", "abstract": { "Liraglutide": [ 0, 71 ], "is": [ 1, 15, 156, 175 ], "a": [ 2 ], "United": [ 3 ], "States": [ 4 ], "Food": [ 5 ], "and": [ 6, 40, 58, 73, 116, 153, 160, 193 ], "Drug": [ 7 ], "Administration": [ 8 ], "(FDA)\u2010approved": [ 9 ], "glucagon\u2010like": [ 10 ], "peptide\u22121": [ 11 ], "(GLP\u20101)": [ 12 ], "analog": [ 13 ], "that": [ 14 ], "97%": [ 16 ], "homologous": [ 17 ], "to": [ 18, 31, 66, 81, 107, 162, 204, 238 ], "native": [ 19 ], "human": [ 20 ], "GLP\u20101.": [ 21 ], "The": [ 22, 109, 180 ], "additional": [ 23 ], "16\u2010carbon": [ 24 ], "fatty": [ 25 ], "acid": [ 26 ], "chain": [ 27 ], "causes": [ 28 ], "noncovalent": [ 29 ], "binding": [ 30, 57 ], "albumin,": [ 32 ], "which": [ 33 ], "slows": [ 34 ], "absorption": [ 35 ], "from": [ 36, 44, 212 ], "the": [ 37, 42, 47, 240 ], "injection": [ 38 ], "site": [ 39 ], "protects": [ 41 ], "molecule": [ 43 ], "degradation": [ 45 ], "by": [ 46, 187 ], "enzyme": [ 48 ], "dipeptidyl": [ 49 ], "peptidase\u20104,": [ 50 ], "allowing": [ 51 ], "for": [ 52, 68, 79, 132, 197 ], "protraction": [ 53 ], "of": [ 54, 62, 92, 96, 112, 183, 200, 221, 242 ], "action.": [ 55 ], "Albumin": [ 56 ], "an": [ 59, 218 ], "elimination": [ 60 ], "half\u2010life": [ 61 ], "13": [ 63 ], "hours": [ 64 ], "combine": [ 65 ], "allow": [ 67 ], "once\u2010daily": [ 69 ], "dosing.": [ 70 ], "1.2": [ 72 ], "1.8": [ 74 ], "mg/day": [ 75 ], "given": [ 76 ], "as": [ 77, 120, 122 ], "monotherapy": [ 78 ], "up": [ 80, 106 ], "52": [ 82 ], "weeks": [ 83 ], "produced": [ 84 ], "mean": [ 85, 103 ], "reductions": [ 86, 105 ], "in": [ 87, 125, 166, 171, 245 ], "hemoglobin": [ 88 ], "A": [ 89 ], "1c": [ 90 ], "(A1C)": [ 91 ], "0.6\u20131.6%;": [ 93 ], "combination": [ 94, 167, 172 ], "therapy": [ 95 ], "liraglutide": [ 97, 130, 147, 159, 170, 184, 201, 231, 243 ], "with": [ 98, 135, 158, 168, 173, 206, 230 ], "oral": [ 99 ], "antidiabetic": [ 100 ], "agents": [ 101 ], "demonstrated": [ 102 ], "A1C": [ 104 ], "1.5%.": [ 108 ], "satiety": [ 110 ], "effect": [ 111 ], "GLP\u20101": [ 113 ], "receptor": [ 114 ], "agonists": [ 115 ], "documented": [ 117 ], "weight": [ 118 ], "loss": [ 119 ], "great": [ 121 ], "3.38": [ 123 ], "kg": [ 124 ], "clinical": [ 126, 213 ], "trials": [ 127, 214 ], "may": [ 128, 148 ], "make": [ 129 ], "ideal": [ 131 ], "obese": [ 133 ], "patients": [ 134 ], "type": [ 136 ], "2": [ 137 ], "diabetes": [ 138 ], "mellitus.": [ 139 ], "Like": [ 140 ], "other": [ 141 ], "incretin\u2010based": [ 142 ], "agents,": [ 143 ], "preliminary": [ 144 ], "studies": [ 145, 236 ], "suggest": [ 146 ], "also": [ 149 ], "increase": [ 150 ], "\u03b2\u2010cell": [ 151 ], "mass": [ 152 ], "function.": [ 154 ], "Hypoglycemia": [ 155 ], "rare": [ 157 ], "tends": [ 161 ], "occur": [ 163 ], "when": [ 164 ], "used": [ 165 ], "sulfonylureas;": [ 169 ], "insulin": [ 174 ], "not": [ 176, 216 ], "yet": [ 177 ], "FDA": [ 178 ], "approved.": [ 179 ], "pharmacokinetic": [ 181 ], "parameters": [ 182 ], "are": [ 185 ], "unaffected": [ 186 ], "age,": [ 188 ], "sex,": [ 189 ], "race,": [ 190 ], "or": [ 191, 208, 226 ], "ethnicity,": [ 192 ], "no": [ 194 ], "special": [ 195 ], "recommendations": [ 196 ], "altered": [ 198 ], "dosing": [ 199 ], "need": [ 202 ], "apply": [ 203 ], "populations": [ 205 ], "hepatic": [ 207 ], "renal": [ 209 ], "impairment.": [ 210 ], "Results": [ 211 ], "have": [ 215 ], "shown": [ 217 ], "increased": [ 219 ], "risk": [ 220 ], "medullary": [ 222 ], "thyroid": [ 223 ], "cancer,": [ 224 ], "pancreatitis,": [ 225 ], "poor": [ 227 ], "cardiovascular": [ 228 ], "outcomes": [ 229 ], "treatment.": [ 232 ], "Ongoing,": [ 233 ], "long\u2010term": [ 234 ], "monitoring": [ 235 ], "continue": [ 237 ], "evaluate": [ 239 ], "safety": [ 241 ], "treatment": [ 244 ], "these": [ 246 ], "outcomes.": [ 247 ] }, "publication_date": "2011-08-25", "publication_year": 2011, "type": "review", "cited_by_count": 42, "authors": [ { "id": "https://openalex.org/A5028628945", "display_name": "Evan M. Sisson" } ] }, { "id": "https://openalex.org/W3203398030", "doi": "https://doi.org/10.1016/j.mce.2021.111472", "title": "Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats", "abstract": null, "publication_date": "2021-10-01", "publication_year": 2021, "type": "article", "cited_by_count": 20, "authors": [ { "id": "https://openalex.org/A5021681870", "display_name": "Shohei Yamada" }, { "id": "https://openalex.org/A5057128073", "display_name": "Yuji Ogura" }, { "id": "https://openalex.org/A5104089110", "display_name": "Kazuho Inoue" }, { "id": "https://openalex.org/A5102926448", "display_name": "Jun Tanabe" }, { "id": "https://openalex.org/A5006703198", "display_name": "Takeshi Sugaya" }, { "id": "https://openalex.org/A5074170173", "display_name": "Keiichi Ohata" }, { "id": "https://openalex.org/A5103203378", "display_name": "Yoshio Nagai" }, { "id": "https://openalex.org/A5017841806", "display_name": "Y. Natsuki" }, { "id": "https://openalex.org/A5073594099", "display_name": "Seiko Hoshino" }, { "id": "https://openalex.org/A5112905611", "display_name": "Shiika Watanabe" }, { "id": "https://openalex.org/A5002284527", "display_name": "Daisuke Ichikawa" }, { "id": "https://openalex.org/A5103121069", "display_name": "Kenjiro Kimura" }, { "id": "https://openalex.org/A5082673778", "display_name": "Yugo Shibagaki" }, { "id": "https://openalex.org/A5062271654", "display_name": "Atsuko Kamijo\u2010Ikemori" } ] }, { "id": "https://openalex.org/W2885624998", "doi": "https://doi.org/10.1042/cs20171299", "title": "Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review", "abstract": { "Type": [ 0 ], "2": [ 1 ], "diabetes": [ 2 ], "(T2D)": [ 3 ], "carries": [ 4 ], "risks": [ 5 ], "of": [ 6, 80, 109, 131, 168, 193, 230, 238 ], "both": [ 7 ], "cardiovascular": [ 8 ], "(CV)": [ 9 ], "(myocardial": [ 10 ], "infarction,": [ 11 ], "stroke,": [ 12 ], "and": [ 13, 17, 65, 68, 75, 101, 107, 119, 124, 142, 163, 166, 226, 228, 232, 243 ], "peripheral": [ 14 ], "vascular": [ 15 ], "disease)": [ 16 ], "microvascular": [ 18, 28 ], "(retinopathy/nephropathy/neuropathy)": [ 19 ], "complications.": [ 20 ], "Glucose-lowering": [ 21 ], "is": [ 22, 40, 196, 206 ], "an": [ 23 ], "effective": [ 24 ], "strategy": [ 25 ], "for": [ 26 ], "preventing": [ 27 ], "complications,": [ 29 ], "but": [ 30, 51, 140, 185, 234 ], "the": [ 31, 151, 160, 164, 173, 191, 216 ], "extent": [ 32 ], "to": [ 33, 172, 186, 199, 208 ], "which": [ 34, 154 ], "it": [ 35 ], "can": [ 36 ], "reduce": [ 37, 180 ], "CV": [ 38, 83, 134, 161, 181, 194, 204 ], "complications": [ 39 ], "less": [ 41 ], "certain.": [ 42 ], "Glucagon-like": [ 43 ], "peptide-1": [ 44 ], "(GLP-1)": [ 45 ], "agonists": [ 46, 88, 157, 179 ], "are": [ 47, 89, 121 ], "potent": [ 48 ], "glucose-lowering": [ 49 ], "agents": [ 50, 209 ], "also": [ 52, 245 ], "have": [ 53, 93, 126, 144 ], "potentially": [ 54 ], "beneficial": [ 55 ], "effects": [ 56 ], "on": [ 57, 159 ], "other": [ 58 ], "traditional": [ 59 ], "(body": [ 60 ], "weight,": [ 61 ], "blood": [ 62 ], "pressure": [ 63 ], "(BP),": [ 64 ], "LDL": [ 66 ], "cholesterol)": [ 67 ], "non-traditional": [ 69 ], "risk": [ 70 ], "factors": [ 71 ], "(low": [ 72 ], "grade": [ 73, 240 ], "inflammation": [ 74 ], "endothelial": [ 76 ], "dysfunction).": [ 77 ], "The": [ 78, 219 ], "results": [ 79 ], "four": [ 81, 114 ], "large": [ 82 ], "outcome": [ 84 ], "trials": [ 85 ], "with": [ 86, 105, 117, 136 ], "GLP-1": [ 87, 138, 155, 178, 217 ], "now": [ 90 ], "available.": [ 91 ], "These": [ 92 ], "compared": [ 94 ], "lixisenatide": [ 95 ], "(ELIXA),": [ 96 ], "liraglutide": [ 97 ], "(LEADER),": [ 98 ], "semaglutide": [ 99 ], "(SUSTAIN-6),": [ 100 ], "long-acting": [ 102 ], "exenatide": [ 103 ], "(EXSCEL)": [ 104 ], "placebo": [ 106 ], "standard": [ 108 ], "care": [ 110 ], "over": [ 111 ], "2\u20134": [ 112 ], "years;": [ 113 ], "others": [ 115 ], "(including": [ 116 ], "dulaglutide": [ 118 ], "albiglutide)": [ 120 ], "ongoing.": [ 122 ], "LEADER": [ 123 ], "SUSTAIN-6": [ 125 ], "demonstrated": [ 127 ], "reductions": [ 128 ], "in": [ 129, 183, 223 ], "rates": [ 130 ], "major": [ 132 ], "adverse": [ 133 ], "events": [ 135 ], "active": [ 137 ], "treatment": [ 139 ], "ELIXA": [ 141 ], "EXSCEL": [ 143 ], "not.": [ 145 ], "In": [ 146 ], "this": [ 147 ], "review,": [ 148 ], "we": [ 149, 201 ], "discuss": [ 150 ], "mechanisms": [ 152, 220 ], "by": [ 153 ], "receptor": [ 156 ], "act": [ 158 ], "system": [ 162 ], "design": [ 165 ], "conduct": [ 167 ], "these": [ 169 ], "trials.": [ 170 ], "Contrary": [ 171 ], "assertions": [ 174 ], "that": [ 175, 203, 210 ], "(a)": [ 176 ], "all": [ 177 ], "disease": [ 182 ], "T2D": [ 184 ], "different": [ 187 ], "extents": [ 188 ], "or": [ 189 ], "(b)": [ 190 ], "magnitude": [ 192 ], "protection": [ 195 ], "predominantly": [ 197 ], "related": [ 198 ], "glucose-lowering,": [ 200 ], "argue": [ 202 ], "benefit": [ 205 ], "specific": [ 207 ], "provide": [ 211 ], "longer": [ 212 ], "acting": [ 213 ], "agonism": [ 214 ], "at": [ 215 ], "receptor.": [ 218 ], "involve": [ 221 ], "reduction": [ 222 ], "body": [ 224 ], "weight": [ 225 ], "BP,": [ 227 ], "lowering": [ 229 ], "LDL-cholesterol": [ 231 ], "glucose,": [ 233 ], "pleiotropic": [ 235 ], "effects\u2014including": [ 236 ], "suppression": [ 237 ], "low": [ 239 ], "inflammation,": [ 241 ], "vasodilation,": [ 242 ], "natriuresis\u2014are": [ 244 ], "likely": [ 246 ], "relevant.": [ 247 ] }, "publication_date": "2018-08-16", "publication_year": 2018, "type": "review", "cited_by_count": 69, "authors": [ { "id": "https://openalex.org/A5002670424", "display_name": "James G. Boyle" }, { "id": "https://openalex.org/A5026794872", "display_name": "Rachel Livingstone" }, { "id": "https://openalex.org/A5077595764", "display_name": "John R. Petrie" } ] }, { "id": "https://openalex.org/W2263431665", "doi": "https://doi.org/10.1016/j.ejphar.2016.02.003", "title": "Neurobehavioral effects of liraglutide and sitagliptin in experimental models", "abstract": null, "publication_date": "2016-02-02", "publication_year": 2016, "type": "article", "cited_by_count": 47, "authors": [ { "id": "https://openalex.org/A5114046821", "display_name": "Mayur Kamble" }, { "id": "https://openalex.org/A5055058370", "display_name": "Rachna Gupta" }, { "id": "https://openalex.org/A5082659931", "display_name": "Harmeet Singh Rehan" }, { "id": "https://openalex.org/A5087859934", "display_name": "Lalit Gupta" } ] }, { "id": "https://openalex.org/W2728605505", "doi": "https://doi.org/10.1016/j.ejphar.2017.06.029", "title": "A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease", "abstract": null, "publication_date": "2017-06-27", "publication_year": 2017, "type": "article", "cited_by_count": 100, "authors": [ { "id": "https://openalex.org/A5102573424", "display_name": "Ziyue Yuan" }, { "id": "https://openalex.org/A5100365831", "display_name": "Dongfang Li" }, { "id": "https://openalex.org/A5112158837", "display_name": "Peng Feng" }, { "id": "https://openalex.org/A5102764982", "display_name": "Guofang Xue" }, { "id": "https://openalex.org/A5113306247", "display_name": "Chenhui Ji" }, { "id": "https://openalex.org/A5112283343", "display_name": "Guanglai Li" }, { "id": "https://openalex.org/A5082707086", "display_name": "Christian H\u00f6lscher" } ] }, { "id": "https://openalex.org/W2007436871", "doi": "https://doi.org/10.1517/13543784.15.8.887", "title": "Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide", "abstract": { "Although": [ 0 ], "a": [ 1, 15, 102 ], "number": [ 2 ], "of": [ 3, 95, 105 ], "compounds": [ 4, 97 ], "are": [ 5 ], "currently": [ 6 ], "used": [ 7 ], "to": [ 8, 86 ], "treat": [ 9 ], "Type": [ 10, 38 ], "2": [ 11, 39 ], "diabetes": [ 12, 40 ], "mellitus,": [ 13 ], "achieving": [ 14 ], "sustained": [ 16 ], "glycaemic": [ 17 ], "control": [ 18 ], "over": [ 19 ], "time": [ 20 ], "is": [ 21 ], "often": [ 22 ], "not": [ 23 ], "possible": [ 24 ], "using": [ 25 ], "oral": [ 26 ], "antidiabetics.": [ 27 ], "Endogenous": [ 28 ], "incretins": [ 29 ], "exhibit": [ 30 ], "beneficial": [ 31 ], "effects": [ 32, 94 ], "that": [ 33 ], "could": [ 34 ], "be": [ 35 ], "useful": [ 36 ], "for": [ 37, 75 ], "mellitus": [ 41 ], "treatment,": [ 42 ], "such": [ 43, 79 ], "as": [ 44, 80, 101 ], "stimulating": [ 45 ], "insulin": [ 46 ], "secretion": [ 47 ], "during": [ 48 ], "hyperglycaemia,": [ 49 ], "improving": [ 50 ], "\u03b2-cell": [ 51 ], "mass": [ 52 ], "and": [ 53, 64, 82, 98 ], "function,": [ 54 ], "reducing": [ 55, 61 ], "glucagon": [ 56 ], "secretion,": [ 57 ], "delaying": [ 58 ], "gastric": [ 59 ], "emptying,": [ 60 ], "postprandial": [ 62 ], "hyperglycaemia": [ 63 ], "diminishing": [ 65 ], "body": [ 66 ], "weight;": [ 67 ], "however,": [ 68 ], "their": [ 69, 99 ], "short": [ 70 ], "half-life": [ 71 ], "makes": [ 72 ], "them": [ 73 ], "unsuitable": [ 74 ], "treatment.": [ 76 ], "Incretin": [ 77 ], "mimetics": [ 78 ], "liraglutide": [ 81 ], "exenatide": [ 83 ], "were": [ 84 ], "developed": [ 85 ], "overcome": [ 87 ], "this": [ 88 ], "limitation.": [ 89 ], "This": [ 90 ], "review": [ 91 ], "discusses": [ 92 ], "the": [ 93 ], "these": [ 96 ], "potential": [ 100 ], "new": [ 103 ], "class": [ 104 ], "antidiabetic": [ 106 ], "agents.": [ 107 ] }, "publication_date": "2006-07-21", "publication_year": 2006, "type": "review", "cited_by_count": 30, "authors": [ { "id": "https://openalex.org/A5058591494", "display_name": "Claudio Gonz\u00e1lez" }, { "id": "https://openalex.org/A5068321315", "display_name": "Valeria Beruto" }, { "id": "https://openalex.org/A5000467283", "display_name": "Guillermo Alberto Keller" }, { "id": "https://openalex.org/A5040825093", "display_name": "Silvina Santoro" }, { "id": "https://openalex.org/A5080627010", "display_name": "Guillermo Di Girolamo" } ] }, { "id": "https://openalex.org/W4285393010", "doi": "https://doi.org/10.1155/2022/6813017", "title": "Semaglutide Protects against 6\u2010OHDA Toxicity by Enhancing Autophagy and Inhibiting Oxidative Stress", "abstract": { "Parkinson\u2019s": [ 0 ], "disease": [ 1 ], "(PD)": [ 2 ], "is": [ 3, 15, 72 ], "the": [ 4, 62, 79, 88, 93, 110, 125, 133, 166, 178, 198 ], "second": [ 5 ], "most": [ 6, 190 ], "prevalent": [ 7 ], "neurodegenerative": [ 8 ], "disorder": [ 9 ], "for": [ 10, 189, 212 ], "which": [ 11 ], "no": [ 12 ], "effective": [ 13 ], "treatment": [ 14, 77, 211 ], "available.": [ 16 ], "Studies": [ 17 ], "have": [ 18 ], "demonstrated": [ 19, 47, 137 ], "that": [ 20, 138, 183, 196 ], "improving": [ 21 ], "insulin": [ 22 ], "resistance": [ 23 ], "in": [ 24, 48, 105, 160 ], "type": [ 25 ], "2": [ 26 ], "diabetes": [ 27 ], "mellitus": [ 28 ], "(T2DM)": [ 29 ], "can": [ 30 ], "benefit": [ 31 ], "patients": [ 32 ], "with": [ 33, 99, 129 ], "PD.": [ 34, 52, 121, 213 ], "In": [ 35, 53, 87 ], "addition,": [ 36, 54 ], "a": [ 37, 73, 103, 209 ], "neuroprotective": [ 38, 63, 111, 167 ], "effect": [ 39, 64, 126 ], "of": [ 40, 51, 65, 84, 116, 127, 169 ], "glucagon\u2010like": [ 41 ], "peptide\u20101": [ 42 ], "(GLP\u20101)": [ 43 ], "receptor": [ 44 ], "agonists": [ 45 ], "was": [ 46, 185 ], "experimental": [ 49 ], "models": [ 50, 176 ], "there": [ 55 ], "are": [ 56 ], "some": [ 57 ], "clinical": [ 58 ], "trials": [ 59 ], "to": [ 60, 108, 118, 187 ], "study": [ 61 ], "GLP\u20101": [ 66, 85, 204 ], "analog": [ 67 ], "on": [ 68, 173 ], "PD": [ 69, 104, 174 ], "patients.": [ 70 ], "Semaglutide": [ 71 ], "long\u2010acting,": [ 74 ], "once\u2010a\u2010week": [ 75 ], "injection": [ 76 ], "and": [ 78, 113, 141, 151, 171, 201 ], "only": [ 80, 202 ], "available": [ 81 ], "oral": [ 82, 203 ], "form": [ 83 ], "analog.": [ 86 ], "present": [ 89 ], "study,": [ 90 ], "we": [ 91, 123, 181 ], "treated": [ 92 ], "human": [ 94 ], "neuroblastoma": [ 95 ], "SH\u2010SY5Y": [ 96, 161 ], "cell": [ 97, 175 ], "line": [ 98 ], "6\u2010hydroxydopamine": [ 100 ], "(6\u2010OHDA)": [ 101 ], "as": [ 102, 155, 157 ], "vitro": [ 106 ], "model": [ 107 ], "explore": [ 109 ], "effects": [ 112, 168 ], "potential": [ 114 ], "mechanisms": [ 115 ], "semaglutide": [ 117, 128, 140, 170, 184 ], "protect": [ 119, 143 ], "against": [ 120, 144 ], "Moreover,": [ 122, 163 ], "compared": [ 124 ], "liraglutide": [ 130, 142, 172, 188 ], "given": [ 131 ], "at": [ 132, 177 ], "same": [ 134, 179 ], "dose.": [ 135 ], "We": [ 136 ], "both": [ 139 ], "6\u2010OHDA": [ 145 ], "cytotoxicity": [ 146 ], "by": [ 147, 164 ], "increasing": [ 148 ], "autophagy": [ 149 ], "flux": [ 150 ], "decreasing": [ 152 ], "oxidative": [ 153 ], "stress": [ 154 ], "well": [ 156 ], "mitochondrial": [ 158 ], "dysfunction": [ 159 ], "cells.": [ 162 ], "comparing": [ 165 ], "dose,": [ 180 ], "found": [ 182 ], "superior": [ 186 ], "parameters": [ 191 ], "measured.": [ 192 ], "Our": [ 193 ], "results": [ 194 ], "indicate": [ 195 ], "semaglutide,": [ 197 ], "new": [ 199 ], "long\u2010acting": [ 200 ], "analog,": [ 205 ], "may": [ 206 ], "be": [ 207 ], "represent": [ 208 ], "promising": [ 210 ] }, "publication_date": "2022-01-01", "publication_year": 2022, "type": "article", "cited_by_count": 22, "authors": [ { "id": "https://openalex.org/A5053255242", "display_name": "Dong-Xing Liu" }, { "id": "https://openalex.org/A5103159482", "display_name": "Chen-sheng Zhao" }, { "id": "https://openalex.org/A5101909261", "display_name": "Xiaona Wei" }, { "id": "https://openalex.org/A5039608084", "display_name": "Yi-peng Ma" }, { "id": "https://openalex.org/A5032499253", "display_name": "Jian-Kun Wu" } ] }, { "id": "https://openalex.org/W2109895833", "doi": "https://doi.org/10.15277/bjdvd.2014.015", "title": "GLP-1 receptor agonists in type 2 diabetes - NICE guidelines versus clinical practice", "abstract": { "Injectable": [ 0 ], "glucagon-like": [ 1 ], "peptide-1": [ 2 ], "receptor": [ 3 ], "agonists": [ 4 ], "(GLP-1ras)": [ 5 ], "have": [ 6, 93 ], "the": [ 7, 38, 40, 53, 58, 60, 72, 116, 123 ], "distinct": [ 8 ], "advantage": [ 9 ], "of": [ 10, 55, 62, 74, 103, 125 ], "promoting": [ 11 ], "weight": [ 12 ], "loss": [ 13 ], "as": [ 14, 16 ], "well": [ 15 ], "lowering": [ 17 ], "glucose": [ 18 ], "in": [ 19, 37 ], "type": [ 20, 105 ], "2": [ 21, 106 ], "diabetes.": [ 22 ], "Treatment": [ 23 ], "with": [ 24 ], "a": [ 25, 31, 100 ], "GLP-1ra": [ 26 ], "is": [ 27 ], "costly,": [ 28 ], "thereby": [ 29 ], "necessitating": [ 30 ], "restriction": [ 32 ], "on": [ 33, 52, 71 ], "widespread": [ 34 ], "use,": [ 35 ], "thus": [ 36 ], "UK": [ 39, 59 ], "National": [ 41 ], "Institute": [ 42 ], "for": [ 43, 122 ], "Health": [ 44 ], "and": [ 45, 78, 82, 119 ], "Care": [ 46 ], "Excellence": [ 47 ], "(NICE)": [ 48 ], "has": [ 49 ], "published": [ 50 ], "guidance": [ 51 ], "use": [ 54, 73, 124 ], "these": [ 56, 111 ], "drugs.In": [ 57 ], "Association": [ 61 ], "British": [ 63 ], "Clinical": [ 64 ], "Diabetologists": [ 65 ], "(ABCD)": [ 66 ], "conducted": [ 67 ], "two": [ 68 ], "nationwide": [ 69 ], "audits": [ 70, 98 ], "exenatide": [ 75 ], "twice": [ 76 ], "daily": [ 77, 81 ], "liraglutide": [ 79 ], "once": [ 80 ], "noticed": [ 83 ], "that": [ 84 ], "deviations": [ 85 ], "from": [ 86, 96 ], "NICE": [ 87, 117 ], "guidelines": [ 88, 118 ], "were": [ 89 ], "common.": [ 90 ], "Herein": [ 91 ], "data": [ 92 ], "been": [ 94 ], "used": [ 95 ], "both": [ 97 ], "(following": [ 99 ], "combined": [ 101 ], "total": [ 102 ], "12,955": [ 104 ], "diabetes": [ 107 ], "patients)": [ 108 ], "to": [ 109 ], "evaluate": [ 110 ], "treatment": [ 112 ], "decisions,": [ 113 ], "critically": [ 114 ], "appraise": [ 115 ], "formulate": [ 120 ], "recommendations": [ 121 ], "GLP-1ras.": [ 126 ] }, "publication_date": "2014-06-09", "publication_year": 2014, "type": "article", "cited_by_count": 27, "authors": [ { "id": "https://openalex.org/A5058523130", "display_name": "Ken Y Thong" }, { "id": "https://openalex.org/A5013219584", "display_name": "Piya Sen Gupta" }, { "id": "https://openalex.org/A5018412955", "display_name": "Melissa Cull" }, { "id": "https://openalex.org/A5112294148", "display_name": "Karen Adamson" }, { "id": "https://openalex.org/A5005096300", "display_name": "David Dove" }, { "id": "https://openalex.org/A5108732256", "display_name": "Susannah Rowles" }, { "id": "https://openalex.org/A5065428335", "display_name": "Stephanie Tarpey" }, { "id": "https://openalex.org/A5109217418", "display_name": "Catriona Duncan" }, { "id": "https://openalex.org/A5055394217", "display_name": "John Chalmers" }, { "id": "https://openalex.org/A5006940888", "display_name": "Roy Harper" }, { "id": "https://openalex.org/A5109093143", "display_name": "Paula McDonald" }, { "id": "https://openalex.org/A5003479568", "display_name": "Ursula Brennan" }, { "id": "https://openalex.org/A5104105832", "display_name": "Chris Walton" }, { "id": "https://openalex.org/A5071127270", "display_name": "Robert E. J. Ryder" } ] }, { "id": "https://openalex.org/W2111901007", "doi": "https://doi.org/10.1345/aph.1m134", "title": "Liraglutide: A Once-Daily Incretin Mimetic for the Treatment of Type 2 Diabetes Mellitus", "abstract": { "Objective:": [ 0 ], "To": [ 1 ], "review": [ 2 ], "the": [ 3, 18, 38, 51, 59, 84, 116, 133, 188, 233, 285 ], "pharmacology,": [ 4, 85 ], "pharmacokinetics,": [ 5, 86 ], "efficacy,": [ 6, 87 ], "and": [ 7, 46, 55, 68, 78, 88, 132, 158, 168, 179, 185, 200, 230, 260 ], "safety": [ 8, 89 ], "of": [ 9, 20, 61, 90, 118, 122, 148, 190, 273, 287, 294 ], "liraglutide,": [ 10 ], "a": [ 11, 98, 247 ], "glucagon-like": [ 12, 40 ], "peptide": [ 13, 41 ], "1": [ 14 ], "(GLP-1)": [ 15 ], "analog": [ 16, 100 ], "for": [ 17, 34, 58, 73, 105, 137, 187, 250 ], "treatment": [ 19, 189 ], "type": [ 21, 191 ], "2": [ 22, 192 ], "diabetes": [ 23 ], "mellitus.": [ 24 ], "Data": [ 25, 79, 94, 144 ], "Sources:": [ 26 ], "A": [ 27, 124 ], "MEDLINE": [ 28 ], "search": [ 29 ], "(1966\u2013May": [ 30 ], "2009)": [ 31 ], "was": [ 32, 266 ], "conducted": [ 33 ], "English-language": [ 35 ], "articles": [ 36 ], "using": [ 37 ], "terms": [ 39, 121 ], "1,": [ 42 ], "incretin": [ 43 ], "mimetic,": [ 44 ], "NN2211,": [ 45 ], "liraglutide.": [ 47 ], "Abstracts": [ 48 ], "presented": [ 49 ], "at": [ 50 ], "American": [ 52 ], "Diabetes": [ 53, 62 ], "Association": [ 54, 57 ], "European": [ 56 ], "Study": [ 60, 76 ], "annual": [ 63 ], "meetings": [ 64 ], "in": [ 65, 120, 129, 159, 165, 180, 239, 258, 284 ], "2006,": [ 66 ], "2007,": [ 67 ], "2008": [ 69 ], "were": [ 70, 92 ], "also": [ 71, 145 ], "searched": [ 72 ], "relevant": [ 74 ], "data.": [ 75 ], "Selection": [ 77 ], "Extraction:": [ 80 ], "Articles": [ 81 ], "pertinent": [ 82 ], "to": [ 83, 154, 216 ], "liraglutide": [ 91, 119, 149, 171, 222, 251, 265 ], "reviewed.": [ 93 ], "Synthesis:": [ 95 ], "Liraglutide": [ 96, 173 ], "is": [ 97, 223 ], "GLP-1": [ 99, 277 ], "with": [ 101, 156, 170, 182, 197, 226, 255, 268, 276, 291 ], "pharmacokinetic": [ 102 ], "properties": [ 103 ], "suitable": [ 104 ], "once-daily": [ 106 ], "administration.": [ 107 ], "Clinical": [ 108 ], "trial": [ 109 ], "data": [ 110, 161, 196, 213 ], "from": [ 111, 205 ], "large,": [ 112 ], "controlled": [ 113 ], "studies": [ 114 ], "demonstrate": [ 115 ], "effectiveness": [ 117 ], "hemoglobin": [ 123 ], "1c": [ 125 ], "(A1C)": [ 126 ], "reduction,": [ 127 ], "reductions": [ 128 ], "body": [ 130, 261 ], "weight,": [ 131 ], "drug's": [ 134 ], "low": [ 135 ], "risk": [ 136, 293 ], "hypoglycemic": [ 138 ], "events": [ 139, 238 ], "when": [ 140, 264 ], "used": [ 141 ], "as": [ 142, 177 ], "monotherapy.": [ 143 ], "support": [ 146 ], "benefits": [ 147, 164 ], "therapy": [ 150, 202, 279 ], "on": [ 151, 214 ], "\u03b2-cell": [ 152, 166 ], "responsiveness": [ 153 ], "glucose,": [ 155 ], "animal": [ 157 ], "vitro": [ 160 ], "indicating": [ 162 ], "potential": [ 163, 281 ], "mass": [ 167 ], "neogenesis": [ 169 ], "treatment.": [ 172 ], "has": [ 174 ], "been": [ 175 ], "studied": [ 176 ], "monotherapy": [ 178 ], "combination": [ 181 ], "metformin,": [ 183 ], "glimepiride,": [ 184 ], "rosiglitazone": [ 186 ], "diabetes.": [ 193 ], "Additionally,": [ 194 ], "comparative": [ 195 ], "insulin": [ 198, 274 ], "glargine": [ 199 ], "exenatide": [ 201 ], "are": [ 203 ], "available": [ 204 ], "Phase": [ 206 ], "3": [ 207 ], "trials": [ 208 ], "providing": [ 209 ], "practitioners": [ 210 ], "valuable": [ 211 ], "clinical": [ 212, 218, 240, 282 ], "which": [ 215 ], "base": [ 217 ], "decision": [ 219 ], "making.": [ 220 ], "Overall,": [ 221 ], "well": [ 224 ], "tolerated": [ 225 ], "dose-dependent": [ 227 ], "nausea,": [ 228 ], "vomiting,": [ 229 ], "diarrhea": [ 231 ], "being": [ 232 ], "most": [ 234 ], "commonly": [ 235 ], "reported": [ 236 ], "adverse": [ 237 ], "trials.": [ 241 ], "Conclusions:": [ 242 ], "Once-daily": [ 243 ], "administration": [ 244 ], "may": [ 245 ], "provide": [ 246 ], "therapeutic": [ 248 ], "advantage": [ 249 ], "over": [ 252 ], "twice-daily": [ 253 ], "exenatide,": [ 254 ], "similar": [ 256 ], "improvements": [ 257 ], "A1C": [ 259 ], "weight": [ 262 ], "observed": [ 263 ], "compared": [ 267 ], "exenatide.": [ 269 ], "The": [ 270 ], "glucose-dependent": [ 271 ], "mechanism": [ 272 ], "release": [ 275 ], "agonist": [ 278 ], "holds": [ 280 ], "significance": [ 283 ], "management": [ 286 ], "postprandial": [ 288 ], "hyperglycemic": [ 289 ], "excursions,": [ 290 ], "minimal": [ 292 ], "hypoglycemia.": [ 295 ] }, "publication_date": "2009-07-28", "publication_year": 2009, "type": "review", "cited_by_count": 60, "authors": [ { "id": "https://openalex.org/A5082350484", "display_name": "Joshua J. Neumiller" }, { "id": "https://openalex.org/A5087170338", "display_name": "R. Keith Campbell" } ] }, { "id": "https://openalex.org/W2033892901", "doi": "https://doi.org/10.1016/j.atherosclerosis.2010.04.024", "title": "One-year treatment with exenatide vs. Insulin Glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress", "abstract": null, "publication_date": "2010-05-01", "publication_year": 2010, "type": "article", "cited_by_count": 132, "authors": [ { "id": "https://openalex.org/A5110611896", "display_name": "Mathijs C. Bunck" }, { "id": "https://openalex.org/A5059226156", "display_name": "A. H. Corner" }, { "id": "https://openalex.org/A5061198575", "display_name": "Bj\u00f6rn Eliasson" }, { "id": "https://openalex.org/A5113467761", "display_name": "Robert J. Heine" }, { "id": "https://openalex.org/A5112350413", "display_name": "Rimma M. Shaginian" }, { "id": "https://openalex.org/A5101929551", "display_name": "Yan Wu" }, { "id": "https://openalex.org/A5101819344", "display_name": "Ping Yan" }, { "id": "https://openalex.org/A5028599620", "display_name": "Ulf Smith" }, { "id": "https://openalex.org/A5028953583", "display_name": "Hannele Yki\u2010J\u00e4rvinen" }, { "id": "https://openalex.org/A5109335776", "display_name": "Micha\u00ebla Diamant" }, { "id": "https://openalex.org/A5057557099", "display_name": "Marja\u2010Riitta Taskinen" } ] }, { "id": "https://openalex.org/W4386832565", "doi": "https://doi.org/10.1016/j.neuropharm.2023.109716", "title": "Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway", "abstract": null, "publication_date": "2023-09-18", "publication_year": 2023, "type": "article", "cited_by_count": 78, "authors": [ { "id": "https://openalex.org/A5100424192", "display_name": "Zhaojun Wang" }, { "id": "https://openalex.org/A5100671310", "display_name": "Xinru Li" }, { "id": "https://openalex.org/A5103198417", "display_name": "Shi-Fan Chai" }, { "id": "https://openalex.org/A5065878816", "display_name": "Weiran Li" }, { "id": "https://openalex.org/A5102028137", "display_name": "Shuo Li" }, { "id": "https://openalex.org/A5101245825", "display_name": "Meng Hou" }, { "id": "https://openalex.org/A5069254148", "display_name": "Jialei Li" }, { "id": "https://openalex.org/A5113003226", "display_name": "Yu-Cai Ye" }, { "id": "https://openalex.org/A5109518324", "display_name": "Hong-Yan Cai" }, { "id": "https://openalex.org/A5082707086", "display_name": "Christian H\u00f6lscher" }, { "id": "https://openalex.org/A5019910092", "display_name": "Meina Wu" } ] }, { "id": "https://openalex.org/W4309944588", "doi": "https://doi.org/10.15605/jafes.037.02.14", "title": "Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis", "abstract": { "Among": [ 0 ], "individuals": [ 1 ], "with": [ 2, 15 ], "obesity": [ 3 ], "without": [ 4 ], "type": [ 5 ], "2": [ 6 ], "diabetes,": [ 7 ], "subcutaneous": [ 8 ], "semaglutide": [ 9, 29, 52 ], "is": [ 10 ], "effective": [ 11 ], "for": [ 12, 30 ], "weight": [ 13, 31 ], "loss": [ 14 ], "an": [ 16 ], "11.85%": [ 17 ], "reduction": [ 18 ], "from": [ 19 ], "baseline": [ 20 ], "compared": [ 21 ], "to": [ 22 ], "placebo.": [ 23, 55 ], "This": [ 24 ], "supports": [ 25 ], "the": [ 26, 51 ], "use": [ 27 ], "of": [ 28, 37, 42 ], "management": [ 32 ], "in": [ 33, 50 ], "obesity.": [ 34 ], "However,": [ 35 ], "risk": [ 36 ], "gastrointestinal": [ 38 ], "adverse": [ 39, 46 ], "events,": [ 40 ], "discontinuation": [ 41 ], "treatment": [ 43 ], "and": [ 44 ], "serious": [ 45 ], "events": [ 47 ], "were": [ 48 ], "higher": [ 49 ], "group": [ 53 ], "versus": [ 54 ] }, "publication_date": "2022-11-25", "publication_year": 2022, "type": "review", "cited_by_count": 81, "authors": [ { "id": "https://openalex.org/A5083898737", "display_name": "Hanna Clementine Tan" }, { "id": "https://openalex.org/A5072504145", "display_name": "Oliver Allan Dampil" }, { "id": "https://openalex.org/A5072957576", "display_name": "Maricar Mae Marquez" } ] }, { "id": "https://openalex.org/W1966991896", "doi": "https://doi.org/10.4103/2230-8210.111625", "title": "Glucagon-like peptide-1 analogues: An overview", "abstract": { "Abnormalities": [ 0 ], "of": [ 1, 11, 25, 31, 36, 48, 102, 125 ], "the": [ 2, 9, 27 ], "incretin": [ 3, 28 ], "axis": [ 4 ], "have": [ 5, 68 ], "been": [ 6, 69 ], "implicated": [ 7 ], "in": [ 8, 34, 40 ], "pathogenesis": [ 10 ], "type": [ 12 ], "2": [ 13 ], "diabetes": [ 14 ], "mellitus.": [ 15 ], "Glucagon-like": [ 16 ], "peptide-1": [ 17 ], "(GLP-1)": [ 18 ], "and": [ 19, 46, 65, 100, 116 ], "gastroinhibitory": [ 20 ], "intestinal": [ 21 ], "peptide": [ 22 ], "constitutes": [ 23 ], ">90%": [ 24 ], "all": [ 26 ], "function.": [ 29 ], "Augmentation": [ 30 ], "GLP-1": [ 32, 58, 104, 127 ], "results": [ 33 ], "improvement": [ 35 ], "beta": [ 37 ], "cell": [ 38 ], "health": [ 39 ], "a": [ 41, 60 ], "glucose-dependant": [ 42 ], "manner": [ 43 ], "(post-prandial": [ 44 ], "hyperglycemia)": [ 45 ], "suppression": [ 47 ], "glucagon": [ 49 ], "(fasting": [ 50 ], "hyperglycemia),": [ 51 ], "amongst": [ 52 ], "other": [ 53 ], "beneficial": [ 54 ], "pleiotropic": [ 55 ], "effects.": [ 56 ], "Native": [ 57 ], "has": [ 59 ], "very": [ 61 ], "short": [ 62 ], "plasma": [ 63 ], "half-life": [ 64 ], "novel": [ 66 ], "methods": [ 67 ], "developed": [ 70 ], "to": [ 71, 121 ], "augment": [ 72 ], "its": [ 73, 78 ], "half": [ 74 ], "life,": [ 75 ], "such": [ 76 ], "that": [ 77 ], "anti-hyperglycemic": [ 79 ], "effects": [ 80 ], "can": [ 81, 85 ], "be": [ 82, 86 ], "exploited.": [ 83 ], "They": [ 84 ], "broadly": [ 87 ], "classified": [ 88 ], "as": [ 89 ], "exendin-based": [ 90 ], "therapies": [ 91 ], "(exenatide,": [ 92 ], "exenatide": [ 93, 113 ], "once": [ 94, 114 ], "weekly),": [ 95 ], "DPP-4-resistant": [ 96 ], "analogues": [ 97, 101, 110 ], "(lixisenatide,": [ 98 ], "albiglutide),": [ 99 ], "human": [ 103 ], "(liraglutide,": [ 105 ], "taspoglutide).": [ 106 ], "Currently,": [ 107 ], "commercially": [ 108 ], "available": [ 109 ], "are": [ 111 ], "exenatide,": [ 112 ], "weekly,": [ 115 ], "liraglutide.": [ 117 ], "This": [ 118 ], "review": [ 119 ], "aims": [ 120 ], "provide": [ 122 ], "an": [ 123 ], "overview": [ 124 ], "most": [ 126 ], "analogues.": [ 128 ] }, "publication_date": "2013-01-01", "publication_year": 2013, "type": "article", "cited_by_count": 177, "authors": [ { "id": "https://openalex.org/A5013841233", "display_name": "Vishal Gupta" } ] }, { "id": "https://openalex.org/W2487778189", "doi": "https://doi.org/10.1111/ijcp.12847", "title": "Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials", "abstract": { "Once-weekly": [ 0, 36 ], "GLP-1RAs": [ 1 ], "were": [ 2, 19 ], "more": [ 3 ], "effective": [ 4, 10 ], "in": [ 5, 11, 23, 33 ], "controlling": [ 6, 24, 34 ], "glycaemia": [ 7 ], "and": [ 8, 39 ], "equally": [ 9 ], "decreasing": [ 12 ], "body": [ 13 ], "weight": [ 14 ], "than": [ 15 ], "twice-daily": [ 16 ], "exenatide": [ 17, 38 ], "but": [ 18 ], "inferior": [ 20 ], "to": [ 21 ], "liraglutide": [ 22, 32, 40 ], "these": [ 25 ], "two": [ 26 ], "parameters": [ 27 ], "(dulaglutide": [ 28 ], "was": [ 29 ], "similar": [ 30, 43 ], "with": [ 31 ], "glycaemia).": [ 35 ], "GLP-1RAs,": [ 37 ], "had": [ 41 ], "a": [ 42 ], "risk": [ 44 ], "of": [ 45 ], "causing": [ 46 ], "AEs.": [ 47 ] }, "publication_date": "2016-07-25", "publication_year": 2016, "type": "review", "cited_by_count": 22, "authors": [ { "id": "https://openalex.org/A5101698220", "display_name": "Xiaoping Xue" }, { "id": "https://openalex.org/A5108206312", "display_name": "Zhong Ren" }, { "id": "https://openalex.org/A5110432090", "display_name": "A. Zhang" }, { "id": "https://openalex.org/A5043441484", "display_name": "Qing Yang" }, { "id": "https://openalex.org/A5100340232", "display_name": "Wenqing Zhang" }, { "id": "https://openalex.org/A5034448510", "display_name": "Fupeng Liu" } ] }, { "id": "https://openalex.org/W4409485341", "doi": "https://doi.org/10.1038/s41443-025-01061-2", "title": "Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data", "abstract": null, "publication_date": "2025-04-16", "publication_year": 2025, "type": "article", "cited_by_count": 8, "authors": [ { "id": "https://openalex.org/A5026356287", "display_name": "Ashkan Pourabhari Langroudi" }, { "id": "https://openalex.org/A5021668131", "display_name": "Abby L. Chen" }, { "id": "https://openalex.org/A5047841635", "display_name": "Satvir Basran" }, { "id": "https://openalex.org/A5035339784", "display_name": "Elijah Richard Sommer" }, { "id": "https://openalex.org/A5078744038", "display_name": "James Stinson" }, { "id": "https://openalex.org/A5082607633", "display_name": "Yu\u2010Sheng Cheng" }, { "id": "https://openalex.org/A5117069817", "display_name": "Francesco Del Giuduce" }, { "id": "https://openalex.org/A5004898872", "display_name": "Michael A. Scott" }, { "id": "https://openalex.org/A5018901819", "display_name": "Michael L. Eisenberg" } ] }, { "id": "https://openalex.org/W2093534363", "doi": "https://doi.org/10.1016/j.neurobiolaging.2012.04.009", "title": "Liraglutide protects against amyloid-\u03b2 protein-induced impairment of spatial learning and memory in rats", "abstract": null, "publication_date": "2012-05-15", "publication_year": 2012, "type": "article", "cited_by_count": 132, "authors": [ { "id": "https://openalex.org/A5101493506", "display_name": "Wei-Na Han" }, { "id": "https://openalex.org/A5082707086", "display_name": "Christian H\u00f6lscher" }, { "id": "https://openalex.org/A5054725986", "display_name": "Li Yuan" }, { "id": "https://openalex.org/A5101059755", "display_name": "Wei Yang" }, { "id": "https://openalex.org/A5100410734", "display_name": "Xiaohui Wang" }, { "id": "https://openalex.org/A5019910092", "display_name": "Meina Wu" }, { "id": "https://openalex.org/A5041364835", "display_name": "Jin\u2010Shun Qi" } ] }, { "id": "https://openalex.org/W2032364103", "doi": "https://doi.org/10.2217/dmt.13.41", "title": "GLP-1 receptor agonists in the treatment of Type 2 diabetes", "abstract": { "SUMMARY\u00a0Incretin": [ 0 ], "therapy": [ 1, 34 ], "is": [ 2, 35, 48, 97, 140 ], "based": [ 3 ], "on": [ 4, 105 ], "the": [ 5, 9, 49, 90, 94 ], "antidiabetic": [ 6 ], "actions": [ 7 ], "of": [ 8, 27, 45, 93, 101, 117 ], "incretin": [ 10 ], "hormone": [ 11 ], "GLP-1.": [ 12, 55 ], "The": [ 13, 56, 76 ], "treatment": [ 14 ], "both": [ 15, 28 ], "stimulates": [ 16 ], "insulin": [ 17 ], "secretion": [ 18 ], "and": [ 19, 30, 70, 74, 87, 119, 134 ], "inhibits": [ 20 ], "glucagon": [ 21 ], "secretion,": [ 22 ], "which": [ 23, 47 ], "results": [ 24 ], "in": [ 25, 121, 128, 146 ], "lowering": [ 26 ], "fasting": [ 29 ], "postprandial": [ 31 ], "glycemia.": [ 32 ], "Incretin": [ 33 ], "used": [ 36 ], "either": [ 37 ], "with": [ 38, 43, 130, 135 ], "GLP-1": [ 39, 57, 77, 123 ], "receptor": [ 40, 58, 78, 124 ], "agonists": [ 41, 59, 79, 125 ], "or": [ 42, 64, 67 ], "inhibitors": [ 44 ], "DPP-4,": [ 46 ], "enzyme": [ 50 ], "that": [ 51 ], "inactivates": [ 52 ], "endogenously": [ 53 ], "released": [ 54 ], "are": [ 60, 80, 109, 113, 126, 149 ], "injected": [ 61 ], "subcutaneously": [ 62 ], "once": [ 63, 68 ], "twice": [ 65 ], "daily,": [ 66 ], "weekly,": [ 69 ], "they": [ 71 ], "reduce": [ 72 ], "HbA1c": [ 73 ], "bodyweight.": [ 75, 122 ], "highly": [ 81 ], "tolerable": [ 82 ], "and,": [ 83 ], "apart": [ 84 ], "from": [ 85 ], "nausea": [ 86 ], "vomiting": [ 88 ], "during": [ 89 ], "early": [ 91 ], "phases": [ 92 ], "treatment,": [ 95 ], "there": [ 96 ], "a": [ 98 ], "low": [ 99, 115 ], "risk": [ 100 ], "adverse": [ 102 ], "events.": [ 103 ], "Studies": [ 104 ], "long-term": [ 106 ], "cardiovascular": [ 107 ], "safety": [ 108 ], "ongoing.": [ 110 ], "Added": [ 111 ], "advantages": [ 112 ], "very": [ 114 ], "risks": [ 116 ], "hypoglycemia": [ 118 ], "reduction": [ 120 ], "efficacious": [ 127 ], "combination": [ 129 ], "oral": [ 131 ], "antihyperglycemic": [ 132 ], "agents": [ 133 ], "insulin.": [ 136 ], "Their": [ 137 ], "main": [ 138 ], "use": [ 139 ], "as": [ 141 ], "an": [ 142 ], "add-on": [ 143 ], "to": [ 144 ], "metformin": [ 145 ], "patients": [ 147 ], "who": [ 148 ], "insufficiently": [ 150 ], "...": [ 151 ] }, "publication_date": "2013-08-19", "publication_year": 2013, "type": "article", "cited_by_count": 15, "authors": [ { "id": "https://openalex.org/A5027109387", "display_name": "Bo \u00c5hr\u00e9n" } ] }, { "id": "https://openalex.org/W4322629129", "doi": "https://doi.org/10.5114/amsad/161170", "title": "GLP-1 receptor agonists, SGLT-2 inhibitors, and obstructive sleep apnoea: can new allies face an old enemy?", "abstract": { "Obstructive": [ 0 ], "sleep": [ 1, 11 ], "apnoea": [ 2 ], "(OSA)": [ 3 ], "is": [ 4, 15, 33, 45, 60 ], "the": [ 5, 20, 36, 52, 66, 115, 142 ], "most": [ 6 ], "common": [ 7 ], "form": [ 8 ], "of": [ 9, 19, 40, 70, 118, 145 ], "abnormal": [ 10 ], "pattern": [ 12 ], "(ASP).": [ 13 ], "It": [ 14, 132 ], "characterized": [ 16 ], "by": [ 17 ], "narrowing": [ 18 ], "upper": [ 21 ], "airways": [ 22 ], "(complete": [ 23 ], "or": [ 24 ], "partial)": [ 25 ], "during": [ 26 ], "sleep.": [ 27 ], "Although": [ 28 ], "continuous": [ 29 ], "positive": [ 30 ], "airway": [ 31 ], "pressure": [ 32 ], "recognized": [ 34 ], "as": [ 35 ], "gold": [ 37 ], "standard": [ 38 ], "treatment": [ 39, 43 ], "OSA,": [ 41 ], "unfortunately": [ 42 ], "adherence": [ 44 ], "often": [ 46 ], "suboptimal": [ 47 ], "and": [ 48, 68, 75, 79, 89, 110, 122, 129 ], "does": [ 49 ], "not": [ 50 ], "address": [ 51 ], "pathophysiological": [ 53 ], "mechanisms": [ 54 ], "governing": [ 55 ], "its": [ 56 ], "pathogenesis.": [ 57 ], "Weight": [ 58 ], "gain": [ 59 ], "an": [ 61 ], "important": [ 62 ], "risk": [ 63 ], "factor": [ 64 ], "for": [ 65 ], "development": [ 67 ], "worsening": [ 69 ], "OSA": [ 71 ], "both": [ 72, 108 ], "in": [ 73, 76, 125, 138 ], "adults": [ 74 ], "children.": [ 77 ], "Meaningful": [ 78 ], "sustained": [ 80 ], "weight": [ 81 ], "reduction": [ 82 ], "using": [ 83 ], "lifestyle": [ 84 ], "modifications": [ 85 ], "alone": [ 86 ], "remains": [ 87 ], "difficult": [ 88 ], "challenging.": [ 90 ], "Novel": [ 91 ], "therapeutic": [ 92 ], "strategies": [ 93 ], "are": [ 94, 99 ], "vital": [ 95 ], "because": [ 96 ], "currently": [ 97 ], "there": [ 98 ], "no": [ 100 ], "approved": [ 101 ], "pharmacological": [ 102 ], "therapies.": [ 103 ], "This": [ 104 ], "paper": [ 105 ], "explores": [ 106 ], "thoroughly": [ 107 ], "preclinical": [ 109 ], "clinical": [ 111 ], "studies": [ 112 ], "that": [ 113 ], "investigated": [ 114 ], "possible": [ 116 ], "role": [ 117, 137 ], "GLP-1": [ 119 ], "receptor": [ 120 ], "agonists": [ 121 ], "SGLT-2": [ 123 ], "inhibitors": [ 124 ], "individuals": [ 126 ], "with": [ 127 ], "ASP": [ 128 ], "especially": [ 130 ], "OSA.": [ 131, 146 ], "also": [ 133 ], "discusses": [ 134 ], "their": [ 135 ], "future": [ 136 ], "order": [ 139 ], "to": [ 140 ], "ameliorate": [ 141 ], "global": [ 143 ], "burden": [ 144 ] }, "publication_date": "2023-02-28", "publication_year": 2023, "type": "article", "cited_by_count": 30, "authors": [ { "id": "https://openalex.org/A5056019445", "display_name": "Georgios S. Papaetis" } ] }, { "id": "https://openalex.org/W4224443498", "doi": "https://doi.org/10.1186/s12902-022-01026-2", "title": "Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER", "abstract": null, "publication_date": "2022-04-26", "publication_year": 2022, "type": "article", "cited_by_count": 72, "authors": [ { "id": "https://openalex.org/A5036864965", "display_name": "Suzanne V. Arnold" }, { "id": "https://openalex.org/A5102666462", "display_name": "Fengming Tang" }, { "id": "https://openalex.org/A5101689627", "display_name": "Andrew Cooper" }, { "id": "https://openalex.org/A5064716875", "display_name": "Hungta Chen" }, { "id": "https://openalex.org/A5058016055", "display_name": "Mar\u00edlia Brito Gomes" }, { "id": "https://openalex.org/A5021542554", "display_name": "Wolfgang Rathmann" }, { "id": "https://openalex.org/A5037246488", "display_name": "Iichiro Shimomura" }, { "id": "https://openalex.org/A5090192766", "display_name": "Jiten Vora" }, { "id": "https://openalex.org/A5043895658", "display_name": "Hirotaka Watada" }, { "id": "https://openalex.org/A5083222970", "display_name": "Kamlesh Khunti" }, { "id": "https://openalex.org/A5052533254", "display_name": "Mikhail Kosiborod" } ] }, { "id": "https://openalex.org/W2443880063", "doi": "https://doi.org/10.1186/s12868-016-0272-9", "title": "The GLP-1 receptor agonists exendin-4 and liraglutide alleviate oxidative stress and cognitive and micturition deficits induced by middle cerebral artery occlusion in diabetic mice", "abstract": null, "publication_date": "2016-06-13", "publication_year": 2016, "type": "article", "cited_by_count": 63, "authors": [ { "id": "https://openalex.org/A5065757880", "display_name": "Ping\u2010Chia Li" }, { "id": "https://openalex.org/A5035213072", "display_name": "Lifen Liu" }, { "id": "https://openalex.org/A5075081143", "display_name": "Ming\u2010Jia Jou" }, { "id": "https://openalex.org/A5016876268", "display_name": "Hao\u2010Kuang Wang" } ] }, { "id": "https://openalex.org/W1993436544", "doi": "https://doi.org/10.1016/j.ijpharm.2008.01.015", "title": "Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration", "abstract": null, "publication_date": "2008-01-20", "publication_year": 2008, "type": "article", "cited_by_count": 86, "authors": [ { "id": "https://openalex.org/A5113552209", "display_name": "Bronislava Gedulin" }, { "id": "https://openalex.org/A5061694041", "display_name": "Pam Smith" }, { "id": "https://openalex.org/A5068297947", "display_name": "Carolyn M. Jodka" }, { "id": "https://openalex.org/A5078101479", "display_name": "Kim Chen" }, { "id": "https://openalex.org/A5080280327", "display_name": "Sunil Bhavsar" }, { "id": "https://openalex.org/A5075068030", "display_name": "Loretta L. Nielsen" }, { "id": "https://openalex.org/A5077809872", "display_name": "David G. Parkes" }, { "id": "https://openalex.org/A5104285867", "display_name": "Andrew A. Young" } ] }, { "id": "https://openalex.org/W4226038449", "doi": "https://doi.org/10.14336/ad.2021.0928", "title": "Novel Insights into the Roles and Mechanisms of GLP-1 Receptor Agonists against Aging-Related Diseases", "abstract": { "Aging": [ 0 ], "and": [ 1, 10, 20, 28, 69, 101, 113, 129, 164 ], "aging-related": [ 2, 31, 89, 131, 148, 162 ], "diseases": [ 3, 90, 163 ], "have": [ 4, 46, 59 ], "emerged": [ 5 ], "as": [ 6, 76 ], "increasingly": [ 7 ], "severe": [ 8 ], "health": [ 9 ], "social": [ 11 ], "problems.": [ 12 ], "Therefore,": [ 13 ], "it": [ 14 ], "is": [ 15 ], "imperative": [ 16 ], "to": [ 17, 23, 29, 49, 62 ], "discover": [ 18 ], "novel": [ 19, 118 ], "effective": [ 21 ], "therapeutics": [ 22 ], "delay": [ 24 ], "the": [ 25, 41, 77, 98, 121, 136, 159 ], "aging": [ 26, 87, 108 ], "process": [ 27 ], "manage": [ 30, 50 ], "diseases.": [ 32, 132, 149 ], "Glucagon-like": [ 33 ], "peptide-1": [ 34 ], "receptor": [ 35 ], "agonists": [ 36 ], "(GLP-1": [ 37 ], "RAs),": [ 38 ], "one": [ 39 ], "of": [ 40, 43, 81, 104, 124, 144 ], "classes": [ 42 ], "antihyperglycemic": [ 44 ], "drugs,": [ 45 ], "been": [ 47, 60, 93 ], "recommended": [ 48 ], "type": [ 51 ], "2": [ 52 ], "diabetes": [ 53 ], "mellitus": [ 54 ], "(T2DM).": [ 55 ], "Moreover,": [ 56 ], "GLP-1": [ 57, 105, 125, 145, 165 ], "RAs": [ 58, 106, 126, 146 ], "shown": [ 61 ], "protect": [ 63 ], "against": [ 64 ], "oxidative": [ 65 ], "stress,": [ 66 ], "cellular": [ 67, 112 ], "senescence": [ 68 ], "chronic": [ 70 ], "inflammation,": [ 71 ], "which": [ 72 ], "are": [ 73 ], "widely": [ 74 ], "accepted": [ 75 ], "major": [ 78 ], "risk": [ 79 ], "factors": [ 80 ], "aging.": [ 82 ], "However,": [ 83 ], "their": [ 84 ], "significance": [ 85 ], "in": [ 86, 107, 127, 141, 147 ], "or": [ 88 ], "has": [ 91 ], "not": [ 92 ], "elucidated.": [ 94 ], "Herein,": [ 95 ], "we": [ 96, 134 ], "explain": [ 97 ], "underlying": [ 99 ], "mechanisms": [ 100 ], "protective": [ 102 ], "roles": [ 103 ], "from": [ 109 ], "a": [ 110, 153 ], "molecular,": [ 111 ], "phenotypic": [ 114 ], "perspective.": [ 115 ], "We": [ 116 ], "provide": [ 117 ], "insights": [ 119 ], "into": [ 120 ], "broad": [ 122 ], "prospect": [ 123 ], "preventing": [ 128 ], "treating": [ 130 ], "Additionally,": [ 133 ], "highlight": [ 135 ], "gaps": [ 137 ], "for": [ 138, 155 ], "further": [ 139, 156 ], "studies": [ 140, 157 ], "clinical": [ 142 ], "applications": [ 143 ], "This": [ 150 ], "review": [ 151 ], "forms": [ 152 ], "basis": [ 154 ], "on": [ 158 ], "relationship": [ 160 ], "between": [ 161 ], "RAs.": [ 166 ] }, "publication_date": "2022-01-01", "publication_year": 2022, "type": "review", "cited_by_count": 49, "authors": [ { "id": "https://openalex.org/A5115590511", "display_name": "Wei Peng" }, { "id": "https://openalex.org/A5100424815", "display_name": "Rui Zhou" }, { "id": "https://openalex.org/A5100803003", "display_name": "Zefang Sun" }, { "id": "https://openalex.org/A5064655115", "display_name": "Jia-Wei Long" }, { "id": "https://openalex.org/A5109253313", "display_name": "Yong-Qiang Gong" } ] }, { "id": "https://openalex.org/W3093123473", "doi": "https://doi.org/10.1111/dom.14232", "title": "Efficacy and safety of once\u2010weekly semaglutide versus once\u2010daily sitagliptin as add\u2010on to metformin in patients with type 2 diabetes in SUSTAIN China : A 30\u2010week, double\u2010blind, phase 3a, randomized trial", "abstract": { "Abstract": [ 0 ], "Aim": [ 1 ], "To": [ 2 ], "evaluate": [ 3 ], "the": [ 4, 40, 112, 117, 125, 173, 213, 230, 279 ], "efficacy": [ 5, 223 ], "and": [ 6, 37, 87, 101, 116, 141, 172, 224, 244, 258, 267 ], "safety": [ 7, 206, 225, 257 ], "of": [ 8, 111, 127, 131, 147, 151, 156, 164, 176, 217, 265 ], "once\u2010weekly": [ 9, 64, 275 ], "subcutaneous": [ 10 ], "semaglutide,": [ 11 ], "a": [ 12, 32 ], "glucagon\u2010like": [ 13 ], "peptide\u20101": [ 14 ], "(GLP\u20101)": [ 15 ], "analogue,": [ 16 ], "versus": [ 17 ], "once\u2010daily": [ 18, 78 ], "sitagliptin": [ 19, 79, 136, 239 ], "as": [ 20 ], "add\u2010on": [ 21 ], "to": [ 22, 62, 95, 135, 238 ], "metformin": [ 23, 57 ], "in": [ 24, 31, 98, 114, 137, 229, 240, 248 ], "patients": [ 25, 113, 119, 249 ], "with": [ 26, 52, 198, 203, 212, 250, 263 ], "type": [ 27 ], "2": [ 28 ], "diabetes": [ 29 ], "(T2D)": [ 30 ], "multiregional": [ 33 ], "clinical": [ 34 ], "trial.": [ 35 ], "Materials": [ 36 ], "Methods": [ 38 ], "In": [ 39 ], "30\u2010week,": [ 41 ], "randomized,": [ 42 ], "double\u2010blind,": [ 43 ], "double\u2010dummy,": [ 44 ], "active": [ 45 ], "comparator": [ 46 ], "SUSTAIN": [ 47 ], "China": [ 48 ], "trial,": [ 49 ], "868": [ 50 ], "adults": [ 51 ], "T2D": [ 53, 251 ], "inadequately": [ 54, 252 ], "controlled": [ 55, 253 ], "on": [ 56, 254 ], "(HbA1c": [ 58 ], "7.0%\u201010.5%)": [ 59 ], "were": [ 60, 91, 133, 194, 227, 261 ], "randomized": [ 61 ], "receive": [ 63 ], "semaglutide": [ 65, 71, 132, 200, 209, 235, 266 ], "0.5": [ 66 ], "mg": [ 67, 73, 81 ], "(n": [ 68, 74, 82 ], "=": [ 69, 75, 83 ], "288),": [ 70 ], "1.0": [ 72 ], "290)": [ 76 ], "or": [ 77, 166, 168, 170, 186 ], "100": [ 80 ], "290).": [ 84 ], "The": [ 85, 106, 149, 205, 256 ], "primary": [ 86 ], "confirmatory": [ 88 ], "secondary": [ 89 ], "endpoints": [ 90 ], "change": [ 92 ], "from": [ 93, 120 ], "baseline": [ 94 ], "week": [ 96 ], "30": [ 97, 145 ], "HbA": [ 99, 139, 154, 177 ], "1c": [ 100, 140, 155, 178 ], "body": [ 102, 142, 246 ], "weight,": [ 103 ], "respectively.": [ 104 ], "Results": [ 105 ], "trial": [ 107 ], "enrolled": [ 108 ], "~70%": [ 109 ], "(605/868)": [ 110 ], "China,": [ 115 ], "remaining": [ 118 ], "four": [ 121 ], "other": [ 122, 268 ], "countries,": [ 123 ], "including": [ 124 ], "Republic": [ 126 ], "Korea.": [ 128 ], "Both": [ 129 ], "doses": [ 130, 201 ], "superior": [ 134, 237 ], "reducing": [ 138, 245 ], "weight": [ 143, 162, 192, 247 ], "after": [ 144 ], "weeks": [ 146 ], "treatment.": [ 148 ], "odds": [ 150 ], "achieving": [ 152 ], "target": [ 153 ], "less": [ 157, 179 ], "than": [ 158, 180 ], "7.0%": [ 159, 181 ], "(53": [ 160, 182 ], "mmol/mol),": [ 161 ], "loss": [ 163 ], "5%": [ 165 ], "higher,": [ 167, 171 ], "10%": [ 169 ], "composite": [ 174 ], "endpoint": [ 175 ], "mmol/mol)": [ 183 ], "without": [ 184 ], "severe": [ 185 ], "blood": [ 187 ], "glucose\u2010confirmed": [ 188 ], "symptomatic": [ 189 ], "hypoglycaemia": [ 190 ], "no": [ 191 ], "gain,": [ 193 ], "all": [ 195 ], "significantly": [ 196 ], "higher": [ 197 ], "both": [ 199 ], "compared": [ 202 ], "sitagliptin.": [ 204 ], "profile": [ 207 ], "for": [ 208, 278 ], "was": [ 210, 236 ], "consistent": [ 211, 262 ], "known": [ 214 ], "class": [ 215 ], "effects": [ 216 ], "GLP\u20101": [ 218, 269 ], "receptor": [ 219 ], "agonists": [ 220 ], "(RAs).": [ 221 ], "Consistent": [ 222 ], "findings": [ 226 ], "seen": [ 228 ], "Chinese": [ 231, 280 ], "subpopulation.": [ 232 ], "Conclusions": [ 233 ], "Once\u2010weekly": [ 234 ], "improving": [ 241 ], "glycaemic": [ 242 ], "control": [ 243 ], "metformin.": [ 255 ], "tolerability": [ 259 ], "profiles": [ 260 ], "those": [ 264 ], "RAs.": [ 270 ], "Semaglutide": [ 271 ], "is": [ 272 ], "an": [ 273 ], "effective": [ 274 ], "treatment": [ 276 ], "option": [ 277 ], "population.": [ 281 ] }, "publication_date": "2020-10-19", "publication_year": 2020, "type": "article", "cited_by_count": 88, "authors": [ { "id": "https://openalex.org/A5036949656", "display_name": "Linong Ji" }, { "id": "https://openalex.org/A5017610735", "display_name": "Xiaolin Dong" }, { "id": "https://openalex.org/A5100346329", "display_name": "Yiming Li" }, { "id": "https://openalex.org/A5100355146", "display_name": "Yufeng Li" }, { "id": "https://openalex.org/A5009982632", "display_name": "Soo Lim" }, { "id": "https://openalex.org/A5100347830", "display_name": "Ming Liu" }, { "id": "https://openalex.org/A5037805723", "display_name": "Ning Zu" }, { "id": "https://openalex.org/A5110231477", "display_name": "S\u00f8ren Rasmussen" }, { "id": "https://openalex.org/A5041637994", "display_name": "Trine Vang Skj\u00f8th" }, { "id": "https://openalex.org/A5066470511", "display_name": "Guoyue Yuan" }, { "id": "https://openalex.org/A5046305526", "display_name": "Freddy G. Eliaschewitz" } ] }, { "id": "https://openalex.org/W3206235521", "doi": "https://doi.org/10.3389/fendo.2021.735824", "title": "Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis", "abstract": { "Purpose": [ 0 ], "Available": [ 1 ], "data": [ 2, 22, 52, 76 ], "on": [ 3, 9, 23, 29, 160, 226, 263, 360 ], "the": [ 4, 24, 78, 132, 147, 177, 185, 195, 205, 227, 230, 241, 280, 318, 330, 361 ], "effects": [ 5, 25, 80, 159, 262 ], "of": [ 6, 26, 81, 134, 149, 157, 171, 194, 208, 232, 243, 260, 282, 309, 313, 320, 333, 349 ], "anti-diabetic": [ 7, 27, 82, 233, 323, 334 ], "drugs": [ 8, 28, 234, 255, 267, 335 ], "fracture": [ 10, 30, 79, 161, 236, 264, 310 ], "risk": [ 11, 31, 133, 148, 242, 281, 308 ], "are": [ 12 ], "contradictory.": [ 13 ], "Therefore,": [ 14 ], "our": [ 15 ], "study": [ 16 ], "aimed": [ 17 ], "to": [ 18, 322 ], "analyze": [ 19 ], "all": [ 20 ], "available": [ 21 ], "in": [ 32, 121, 155, 204, 258 ], "type": [ 33 ], "2": [ 34, 87 ], "diabetes": [ 35 ], "mellitus": [ 36 ], "(T2DM)": [ 37 ], "patients.": [ 38, 350 ], "Methods": [ 39 ], "Embase,": [ 40 ], "Medline,": [ 41 ], "ClinicalTrials.gov,": [ 42 ], "and": [ 43, 59, 105, 141, 163, 180, 216, 235, 247, 276, 302, 317, 342 ], "Cochrane": [ 44 ], "CENTRAL": [ 45 ], "were": [ 46, 54, 119, 153, 190, 202, 256 ], "searched": [ 47 ], "for": [ 48, 77 ], "relevant": [ 49 ], "trials.": [ 50 ], "All": [ 51 ], "analyses": [ 53 ], "performed": [ 55 ], "with": [ 56, 66, 116, 125, 192, 251 ], "STATA": [ 57 ], "(12.0)": [ 58 ], "R": [ 60 ], "language": [ 61 ], "(3.6.0).": [ 62 ], "Risk": [ 63 ], "ratio": [ 64 ], "(RR)": [ 65 ], "its": [ 67 ], "95%": [ 68 ], "confidence": [ 69 ], "interval": [ 70 ], "(CI)": [ 71 ], "was": [ 72, 167, 311, 357 ], "calculated": [ 73 ], "by": [ 74, 346 ], "combining": [ 75 ], "drugs,": [ 83 ], "including": [ 84 ], "sodium\u2013glucose": [ 85 ], "co-transporter": [ 86 ], "(SGLT2)": [ 88 ], "inhibitors,": [ 89, 93, 101 ], "dipeptidyl": [ 90 ], "peptidase-4": [ 91 ], "(DPP-4)": [ 92 ], "glucagon-like": [ 94 ], "peptide-1": [ 95 ], "(GLP-1)": [ 96 ], "receptor": [ 97 ], "agonists,": [ 98 ], "meglitinides,": [ 99 ], "\u03b1-glucosidase": [ 100 ], "thiazolidinediones,": [ 102 ], "biguanides,": [ 103 ], "insulin,": [ 104 ], "sulfonylureas.": [ 106 ], "Results": [ 107 ], "One": [ 108 ], "hundred": [ 109 ], "seventeen": [ 110 ], "eligible": [ 111 ], "randomized": [ 112 ], "controlled": [ 113 ], "trials": [ 114 ], "(RCTs)": [ 115 ], "221,364": [ 117 ], "participants": [ 118 ], "included": [ 120 ], "this": [ 122 ], "study.": [ 123 ], "Compared": [ 124 ], "placebo,": [ 126 ], "trelagliptin": [ 127, 181, 239 ], "(RR": [ 128, 138, 143 ], "3.51;": [ 129 ], "1.58\u201313.70)": [ 130 ], "increased": [ 131 ], "fracture,": [ 135, 244, 283 ], "whereas": [ 136, 245 ], "albiglutide": [ 137, 248 ], "0.29;": [ 139 ], "0.04\u20130.93)": [ 140 ], "voglibose": [ 142, 173, 246 ], "0.03;": [ 144 ], "0\u20130.11)": [ 145 ], "decreased": [ 146 ], "fracture.": [ 150 ], "Other": [ 151, 254 ], "medications": [ 152 ], "comparable": [ 154, 257 ], "terms": [ 156, 170, 259 ], "their": [ 158, 261, 340 ], "risk,": [ 162 ], "no": [ 164 ], "statistical": [ 165, 252 ], "significance": [ 166 ], "observed.": [ 168 ], "In": [ 169 ], "fractures,": [ 172 ], "(0.01%)": [ 174 ], "may": [ 175, 183, 278, 304 ], "be": [ 176, 184, 337 ], "safest": [ 178 ], "option,": [ 179 ], "(13.64%)": [ 182 ], "worst.": [ 186 ], "Sensitivity": [ 187 ], "analysis": [ 188 ], "results": [ 189, 225 ], "consistent": [ 191 ], "those": [ 193 ], "main": [ 196 ], "analysis.": [ 197 ], "No": [ 198 ], "statistically": [ 199 ], "significant": [ 200 ], "differences": [ 201, 348 ], "observed": [ 203 ], "regression": [ 206 ], "coefficients": [ 207 ], "age": [ 209 ], "(1.03;": [ 210 ], "0.32\u20132.1),": [ 211 ], "follow-up": [ 212 ], "duration": [ 213, 319 ], "(0.79;": [ 214 ], "0.27\u20131.64),": [ 215 ], "sex": [ 217, 315 ], "distribution": [ 218 ], "(0.63;": [ 219 ], "0.15\u20131.56).": [ 220 ], "Conclusions": [ 221 ], "We": [ 222 ], "found": [ 223 ], "varied": [ 224 ], "association": [ 228 ], "between": [ 229 ], "use": [ 231 ], "risk.": [ 237, 265 ], "Specifically,": [ 238 ], "raised": [ 240 ], "showed": [ 249 ], "benefit": [ 250 ], "difference.": [ 253 ], "Some": [ 266 ], "(omarigliptin,": [ 268 ], "sitagliptin,": [ 269 ], "vildagliptin,": [ 270 ], "saxagliptin,": [ 271 ], "empagliflozin,": [ 272 ], "ertugliflozin,": [ 273 ], "rosiglitazone,": [ 274 ], "pioglitazone,": [ 275 ], "nateglinide)": [ 277 ], "increase": [ 279 ], "while": [ 284 ], "others": [ 285 ], "(such": [ 286 ], "as": [ 287 ], "dulaglutide,": [ 288 ], "exenatide,": [ 289 ], "liraglutide,": [ 290 ], "semaglutide,": [ 291 ], "lixisenatide,": [ 292 ], "linagliptin,": [ 293 ], "alogliptin,": [ 294 ], "canagliflozin,": [ 295 ], "dapagliflozin,": [ 296 ], "glipizide,": [ 297 ], "gliclazide,": [ 298 ], "glibenclamide,": [ 299 ], "glimepiride,": [ 300 ], "metformin,": [ 301 ], "insulin)": [ 303 ], "show": [ 305 ], "benefits.": [ 306 ], "The": [ 307 ], "independent": [ 312 ], "age,": [ 314 ], "distribution,": [ 316 ], "exposure": [ 321 ], "drugs.": [ 324 ], "When": [ 325 ], "developing": [ 326 ], "individualized": [ 327 ], "treatment": [ 328 ], "strategies,": [ 329 ], "clinical": [ 331 ], "efficacy": [ 332 ], "must": [ 336 ], "weighed": [ 338 ], "against": [ 339 ], "benefits": [ 341 ], "risks": [ 343 ], "brought": [ 344 ], "about": [ 345 ], "individual": [ 347 ], "Systematic": [ 351, 355 ], "Review": [ 352, 356 ], "Registration": [ 353 ], "This": [ 354 ], "prospectively": [ 358 ], "registered": [ 359 ], "PROSPERO": [ 362 ], "(": [ 363 ], "https://www.crd.york.ac.uk/PROSPERO/": [ 364 ], ",": [ 365 ], "registration": [ 366 ], "number": [ 367 ], "CRD42020189464).": [ 368 ] }, "publication_date": "2021-10-14", "publication_year": 2021, "type": "review", "cited_by_count": 98, "authors": [ { "id": "https://openalex.org/A5100703885", "display_name": "Yusheng Zhang" }, { "id": "https://openalex.org/A5079083995", "display_name": "Yan-Dan Zheng" }, { "id": "https://openalex.org/A5107899161", "display_name": "Yan Yuan" }, { "id": "https://openalex.org/A5049491402", "display_name": "Shichun Chen" }, { "id": "https://openalex.org/A5046520037", "display_name": "Baocheng Xie" } ] }, { "id": "https://openalex.org/W3021290569", "doi": "https://doi.org/10.1111/dom.14079", "title": "The effect of glucagon\u2010like peptide\u20101 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials", "abstract": { "Abstract": [ 0 ], "It": [ 1 ], "is": [ 2 ], "unknown": [ 3 ], "if": [ 4 ], "the": [ 5, 38, 52, 89, 96, 102, 128, 132 ], "cardioprotective": [ 6 ], "and": [ 7, 28, 42, 57, 65, 78, 98, 110, 113, 119, 166 ], "renal": [ 8 ], "effects": [ 9, 133 ], "of": [ 10, 32, 55, 104, 114, 134, 178 ], "glucagon\u2010like": [ 11 ], "peptide\u20101": [ 12 ], "receptor": [ 13 ], "agonists": [ 14 ], "are": [ 15 ], "consistent": [ 16 ], "across": [ 17, 127 ], "blood": [ 18 ], "pressure": [ 19 ], "(BP)": [ 20 ], "categories": [ 21, 70, 130 ], "in": [ 22 ], "patients": [ 23, 172 ], "with": [ 24, 173 ], "type": [ 25, 174 ], "2": [ 26, 116, 175 ], "diabetes": [ 27 ], "at": [ 29 ], "high": [ 30 ], "risk": [ 31, 85 ], "cardiovascular": [ 33, 62 ], "events.": [ 34 ], "Using": [ 35 ], "data": [ 36 ], "from": [ 37, 88 ], "LEADER": [ 39, 97 ], "(9340": [ 40 ], "patients)": [ 41, 46 ], "SUSTAIN": [ 43, 99 ], "6": [ 44, 100 ], "(3297": [ 45 ], "trials,": [ 47, 101 ], "we": [ 48 ], "evaluated": [ 49 ], "post": [ 50 ], "hoc": [ 51 ], "cardiorenal": [ 53, 84 ], "effect": [ 54 ], "liraglutide": [ 56, 135, 165 ], "semaglutide": [ 58, 148, 167 ], "on": [ 59 ], "major": [ 60 ], "adverse": [ 61 ], "events": [ 63 ], "(MACE)": [ 64 ], "nephropathy": [ 66 ], "by": [ 67 ], "baseline": [ 68, 180 ], "BP": [ 69, 129 ], "using": [ 71 ], "a": [ 72 ], "Cox": [ 73 ], "proportional": [ 74 ], "hazards": [ 75 ], "model": [ 76 ], "(treatment": [ 77 ], "subgroup": [ 79 ], "as": [ 80 ], "factors;": [ 81 ], "adjusted": [ 82 ], "for": [ 83, 131, 140, 145, 153, 158, 171 ], "factors).": [ 86 ], "Data": [ 87 ], "two": [ 90 ], "trials": [ 91 ], "were": [ 92 ], "analysed": [ 93 ], "separately.": [ 94 ], "In": [ 95 ], "prevalence": [ 103 ], "stage": [ 105, 115 ], "1": [ 106 ], "hypertension": [ 107, 117 ], "was": [ 108, 123 ], "30%": [ 109 ], "31%,": [ 111 ], "respectively,": [ 112 ], "41%": [ 118 ], "43%,": [ 120 ], "respectively.": [ 121 ], "There": [ 122 ], "no": [ 124 ], "statistical": [ 125 ], "heterogeneity": [ 126 ], "(": [ 136, 149 ], "P": [ 137, 142, 150, 155 ], "=": [ 138, 143, 151, 156 ], ".06": [ 139 ], "MACE;": [ 141, 154 ], ".14": [ 144 ], "nephropathy)": [ 146, 159 ], "or": [ 147 ], ".40": [ 152 ], ".27": [ 157 ], "versus": [ 160 ], "placebo.": [ 161 ], "This": [ 162 ], "implies": [ 163 ], "that": [ 164 ], "may": [ 168 ], "be": [ 169 ], "beneficial": [ 170 ], "diabetes,": [ 176 ], "irrespective": [ 177 ], "their": [ 179 ], "BP.": [ 181 ] }, "publication_date": "2020-05-06", "publication_year": 2020, "type": "article", "cited_by_count": 42, "authors": [ { "id": "https://openalex.org/A5080414941", "display_name": "Lawrence A. Leiter" }, { "id": "https://openalex.org/A5080463002", "display_name": "Stephen C. Bain" }, { "id": "https://openalex.org/A5010571732", "display_name": "Deepak L. Bhatt" }, { "id": "https://openalex.org/A5040182038", "display_name": "John B. Buse" }, { "id": "https://openalex.org/A5041840962", "display_name": "C. David Mazer" }, { "id": "https://openalex.org/A5059098934", "display_name": "Richard E. Pratley" }, { "id": "https://openalex.org/A5110231477", "display_name": "S\u00f8ren Rasmussen" }, { "id": "https://openalex.org/A5078101576", "display_name": "Maria Sejersten Ripa" }, { "id": "https://openalex.org/A5054552742", "display_name": "Hrvoje Vra\u017ei\u0107" }, { "id": "https://openalex.org/A5080334509", "display_name": "Subodh Verma" } ] }, { "id": "https://openalex.org/W2132105666", "doi": "https://doi.org/10.1016/j.mce.2008.11.018", "title": "Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue", "abstract": null, "publication_date": "2008-12-03", "publication_year": 2008, "type": "review", "cited_by_count": 134, "authors": [ { "id": "https://openalex.org/A5082184915", "display_name": "David Russell\u2010Jones" } ] }, { "id": "https://openalex.org/W2753022573", "doi": "https://doi.org/10.1530/joe-17-0278", "title": "Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists", "abstract": { "Type": [ 0 ], "2": [ 1 ], "diabetes": [ 2 ], "mellitus": [ 3 ], "(T2DM)": [ 4 ], "leads": [ 5 ], "to": [ 6, 11, 144, 166 ], "bone": [ 7, 17, 103, 107, 132, 152 ], "fragility": [ 8 ], "and": [ 9, 19, 97, 109, 117, 134, 147, 178, 195 ], "predisposes": [ 10 ], "increased": [ 12 ], "risk": [ 13 ], "of": [ 14, 75, 94, 100, 112, 129, 139, 175, 189 ], "fracture,": [ 15 ], "poor": [ 16 ], "healing": [ 18 ], "other": [ 20 ], "skeletal": [ 21, 34, 57, 79, 127, 172 ], "complications.": [ 22, 58 ], "In": [ 23 ], "addition,": [ 24 ], "some": [ 25 ], "anti-diabetic": [ 26, 182 ], "therapies": [ 27 ], "for": [ 28, 41, 72, 171 ], "T2DM": [ 29, 42, 191 ], "can": [ 30 ], "have": [ 31, 77 ], "notable": [ 32 ], "detrimental": [ 33 ], "effects.": [ 35 ], "Thus,": [ 36 ], "an": [ 37, 92 ], "appropriate": [ 38 ], "therapeutic": [ 39 ], "strategy": [ 40 ], "should": [ 43 ], "not": [ 44, 86 ], "only": [ 45 ], "be": [ 46 ], "effective": [ 47 ], "in": [ 48, 55 ], "re-establishing": [ 49 ], "good": [ 50 ], "glycaemic": [ 51 ], "control": [ 52 ], "but": [ 53 ], "also": [ 54 ], "minimising": [ 56 ], "There": [ 59 ], "is": [ 60, 169, 174 ], "increasing": [ 61 ], "evidence": [ 62 ], "that": [ 63, 160, 180 ], "glucagon-like": [ 64 ], "peptide-1": [ 65 ], "receptor": [ 66 ], "agonists": [ 67 ], "(GLP-1RAs),": [ 68 ], "now": [ 69 ], "greatly": [ 70 ], "prescribed": [ 71 ], "the": [ 73, 82, 95, 115, 186 ], "treatment": [ 74 ], "T2DM,": [ 76 ], "beneficial": [ 78 ], "effects": [ 80, 99, 128, 154 ], "although": [ 81, 136 ], "underlying": [ 83 ], "mechanisms": [ 84, 111, 138 ], "are": [ 85, 155 ], "completely": [ 87 ], "understood.": [ 88 ], "This": [ 89 ], "review": [ 90 ], "provides": [ 91 ], "overview": [ 93 ], "direct": [ 96 ], "indirect": [ 98 ], "GLP-1RAs": [ 101, 130, 146, 161 ], "on": [ 102, 106, 114, 131 ], "physiology,": [ 104 ], "focusing": [ 105 ], "quality": [ 108, 133 ], "novel": [ 110 ], "action": [ 113 ], "vasculature": [ 116 ], "hormonal": [ 118 ], "regulation.": [ 119 ], "The": [ 120, 158 ], "overall": [ 121 ], "experimental": [ 122 ], "studies": [ 123, 149 ], "indicate": [ 124 ], "significant": [ 125 ], "positive": [ 126 ], "strength": [ 135 ], "their": [ 137, 151 ], "actions": [ 140 ], "may": [ 141 ], "differ": [ 142 ], "according": [ 143 ], "various": [ 145 ], "clinical": [ 148 ], "supporting": [ 150 ], "protective": [ 153 ], "still": [ 156 ], "lacking.": [ 157 ], "possibility": [ 159 ], "could": [ 162, 184 ], "improve": [ 163 ], "blood": [ 164 ], "supply": [ 165 ], "bone,": [ 167 ], "which": [ 168 ], "essential": [ 170 ], "health,": [ 173 ], "major": [ 176 ], "interest": [ 177 ], "suggests": [ 179 ], "GLP-1": [ 181 ], "therapy": [ 183 ], "benefit": [ 185 ], "rising": [ 187 ], "number": [ 188 ], "elderly": [ 190 ], "patients": [ 192 ], "with": [ 193 ], "osteoporosis": [ 194 ], "high": [ 196 ], "fracture": [ 197 ], "risk.": [ 198 ] }, "publication_date": "2017-08-31", "publication_year": 2017, "type": "review", "cited_by_count": 52, "authors": [ { "id": "https://openalex.org/A5049469702", "display_name": "Guillaume Mabilleau" }, { "id": "https://openalex.org/A5025799283", "display_name": "Marie Pereira" }, { "id": "https://openalex.org/A5060717412", "display_name": "Chantal Chenu" } ] }, { "id": "https://openalex.org/W2625383462", "doi": "https://doi.org/10.1530/joe-17-0263", "title": "Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice", "abstract": { "This": [ 0 ], "study": [ 1 ], "assessed": [ 2 ], "the": [ 3, 9, 18 ], "metabolic": [ 4, 105, 190 ], "and": [ 5, 51, 64, 75, 94, 117, 122, 127, 137, 168, 175, 186, 191, 224 ], "neuroprotective": [ 6, 192 ], "actions": [ 7 ], "of": [ 8, 82, 162, 184, 212, 222 ], "sodium": [ 10 ], "glucose": [ 11, 50, 93, 110 ], "cotransporter-2": [ 12 ], "inhibitor": [ 13 ], "dapagliflozin": [ 14, 143, 185 ], "in": [ 15, 22, 85, 88, 100, 150, 165, 172, 194, 204, 207, 220 ], "combination": [ 16, 182, 208 ], "with": [ 17, 209 ], "GLP-1": [ 19, 121 ], "agonist": [ 20 ], "liraglutide": [ 21, 187, 206 ], "dietary-induced": [ 23 ], "diabetic": [ 24, 196 ], "mice.": [ 25, 197 ], "Mice": [ 26 ], "administered": [ 27 ], "low-dose": [ 28 ], "streptozotocin": [ 29 ], "(STZ)": [ 30 ], "on": [ 31 ], "a": [ 32 ], "high-fat": [ 33 ], "diet": [ 34 ], "received": [ 35 ], "dapagliflozin,": [ 36, 210 ], "liraglutide,": [ 37 ], "dapagliflozin-plus-liraglutide": [ 38 ], "(DAPA-Lira)": [ 39 ], "or": [ 40 ], "vehicle": [ 41 ], "once-daily": [ 42 ], "over": [ 43 ], "28": [ 44 ], "days.": [ 45 ], "Energy": [ 46 ], "intake,": [ 47 ], "body": [ 48, 89 ], "weight,": [ 49, 90 ], "insulin": [ 52, 61, 95, 112, 139 ], "concentrations": [ 53, 129 ], "were": [ 54, 78, 107, 125 ], "measured": [ 55 ], "at": [ 56 ], "regular": [ 57 ], "intervals.": [ 58 ], "Glucose": [ 59 ], "tolerance,": [ 60, 111 ], "sensitivity,": [ 62, 113 ], "hormone": [ 63 ], "biochemical": [ 65 ], "analysis,": [ 66 ], "dual-energy": [ 67 ], "X-ray": [ 68 ], "absorptiometry": [ 69 ], "densitometry,": [ 70 ], "novel": [ 71 ], "object": [ 72 ], "recognition,": [ 73 ], "islet": [ 74 ], "brain": [ 76 ], "histology": [ 77, 155 ], "examined.": [ 79 ], "Once-daily": [ 80 ], "administration": [ 81 ], "DAPA-Lira": [ 83, 131 ], "resulted": [ 84 ], "significant": [ 86 ], "decreases": [ 87 ], "fat": [ 91 ], "mass,": [ 92 ], "concentrations,": [ 96 ], "despite": [ 97 ], "no": [ 98 ], "change": [ 99 ], "energy": [ 101 ], "intake.": [ 102 ], "Similar": [ 103 ], "beneficial": [ 104, 189 ], "improvements": [ 106 ], "observed": [ 108 ], "regarding": [ 109 ], "HOMA-IR,": [ 114 ], "HOMA-\u03b2,": [ 115 ], "HbA1c": [ 116 ], "triglycerides.": [ 118 ], "Plasma": [ 119 ], "glucagon,": [ 120 ], "IL-6": [ 123 ], "levels": [ 124 ], "increased": [ 126, 138, 157 ], "corticosterone": [ 128 ], "decreased.": [ 130 ], "treatment": [ 132, 152, 221 ], "decreased": [ 133 ], "alpha": [ 134 ], "cell": [ 135 ], "area": [ 136 ], "content": [ 140 ], "compared": [ 141 ], "to": [ 142 ], "monotherapy.": [ 144 ], "Recognition": [ 145 ], "memory": [ 146 ], "was": [ 147 ], "significantly": [ 148 ], "improved": [ 149 ], "all": [ 151 ], "groups.": [ 153 ], "Brain": [ 154 ], "demonstrated": [ 156 ], "staining": [ 158 ], "for": [ 159, 216 ], "doublecortin": [ 160 ], "(number": [ 161 ], "immature": [ 163 ], "neurons)": [ 164 ], "dentate": [ 166 ], "gyrus": [ 167 ], "synaptophysin": [ 169 ], "(synaptic": [ 170 ], "density)": [ 171 ], "stratum": [ 173, 176 ], "oriens": [ 174 ], "pyramidale.": [ 177 ], "These": [ 178 ], "data": [ 179 ], "demonstrate": [ 180 ], "that": [ 181 ], "therapy": [ 183 ], "exerts": [ 188 ], "effects": [ 193 ], "diet-induced": [ 195 ], "Our": [ 198 ], "results": [ 199 ], "highlight": [ 200 ], "important": [ 201 ], "personalised": [ 202 ], "approach": [ 203 ], "utilising": [ 205 ], "instead": [ 211 ], "either": [ 213 ], "agent": [ 214 ], "alone,": [ 215 ], "further": [ 217 ], "clinical": [ 218 ], "evaluation": [ 219 ], "diabetes": [ 223 ], "associated": [ 225 ], "neurodegenerative": [ 226 ], "disorders.": [ 227 ] }, "publication_date": "2017-06-14", "publication_year": 2017, "type": "article", "cited_by_count": 90, "authors": [ { "id": "https://openalex.org/A5051146512", "display_name": "Paul Millar" }, { "id": "https://openalex.org/A5020507104", "display_name": "Nupur Pathak" }, { "id": "https://openalex.org/A5066857047", "display_name": "Vadivel Parthsarathy" }, { "id": "https://openalex.org/A5026962542", "display_name": "Anthony J. Bjourson" }, { "id": "https://openalex.org/A5037592859", "display_name": "Maurice O\u2019Kane" }, { "id": "https://openalex.org/A5007814231", "display_name": "Varun Pathak" }, { "id": "https://openalex.org/A5061926350", "display_name": "R. Charlotte Moffett" }, { "id": "https://openalex.org/A5064124957", "display_name": "Peter R. Flatt" }, { "id": "https://openalex.org/A5013136657", "display_name": "Victor A. Gault" } ] }, { "id": "https://openalex.org/W4404799612", "doi": "https://doi.org/10.3748/wjg.v30.i48.5205", "title": "GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis", "abstract": { "The": [ 0, 51, 128, 162 ], "global": [ 1 ], "prevalence": [ 2 ], "of": [ 3, 42, 100, 122, 130, 165 ], "metabolic": [ 4, 24 ], "dysfunction-associated": [ 5, 25 ], "steatotic": [ 6 ], "liver": [ 7 ], "disease": [ 8 ], "(MASLD)": [ 9 ], "is": [ 10, 44 ], "estimated": [ 11 ], "at": [ 12 ], "32.4%,": [ 13 ], "reflecting": [ 14 ], "its": [ 15 ], "growing": [ 16 ], "clinical": [ 17 ], "significance.": [ 18 ], "MASLD,": [ 19 ], "which": [ 20 ], "includes": [ 21 ], "MASLD": [ 22, 43 ], "and": [ 23, 35, 87, 109, 125, 157 ], "steatohepatitis": [ 26 ], "(MASH)": [ 27 ], "has": [ 28 ], "been": [ 29 ], "linked": [ 30 ], "to": [ 31, 134, 155, 178 ], "increased": [ 32 ], "metabolic,": [ 33 ], "cardiovascular,": [ 34 ], "malignant": [ 36 ], "morbidity.": [ 37 ], "Progression": [ 38 ], "into": [ 39, 105 ], "fibrotic": [ 40 ], "stages": [ 41 ], "also": [ 45, 73 ], "strongly": [ 46 ], "associated": [ 47 ], "with": [ 48, 96, 119, 160, 172 ], "liver-related": [ 49 ], "mortality.": [ 50 ], "past": [ 52 ], "few": [ 53 ], "years": [ 54 ], "have": [ 55, 72, 89, 113 ], "seen": [ 56 ], "a": [ 57, 76, 140, 169 ], "heightened": [ 58 ], "focus": [ 59, 146 ], "on": [ 60, 81, 147 ], "creating": [ 61 ], "innovative": [ 62 ], "therapeutic": [ 63 ], "strategies": [ 64 ], "for": [ 65, 175 ], "MASH": [ 66, 93, 123, 166 ], "management.": [ 67 ], "GLP-1": [ 68, 82 ], "receptor": [ 69 ], "agonists": [ 70 ], "(RA)": [ 71 ], "emerged": [ 74 ], "as": [ 75, 85 ], "potential": [ 77, 174 ], "treatment": [ 78 ], "option.": [ 79 ], "Studies": [ 80 ], "agonists,": [ 83 ], "such": [ 84 ], "liraglutide": [ 86 ], "semaglutide,": [ 88 ], "demonstrated": [ 90 ], "efficacy": [ 91, 159 ], "in": [ 92 ], "management,": [ 94 ], "albeit": [ 95 ], "limited": [ 97 ], "histological": [ 98 ], "improvement": [ 99 ], "fibrosis.": [ 101 ], "However,": [ 102 ], "recent": [ 103 ], "investigations": [ 104 ], "GLP-1/GIP": [ 106 ], "RA": [ 107, 111 ], "(tirzepatide)": [ 108 ], "Glucagon/GLP-1": [ 110 ], "(survodutide)": [ 112 ], "shown": [ 114 ], "even": [ 115 ], "more": [ 116 ], "encouraging": [ 117 ], "results,": [ 118 ], "higher": [ 120 ], "rates": [ 121 ], "resolution": [ 124 ], "fibrosis": [ 126 ], "improvement.": [ 127 ], "tolerability": [ 129 ], "these": [ 131 ], "medications": [ 132 ], "due": [ 133 ], "their": [ 135 ], "gastrointestinal": [ 136 ], "side": [ 137 ], "effects": [ 138 ], "remains": [ 139 ], "major": [ 141 ], "concern.": [ 142 ], "Future": [ 143 ], "research": [ 144 ], "should": [ 145 ], "optimizing": [ 148 ], "drug": [ 149 ], "regimens,": [ 150 ], "identifying": [ 151 ], "patients": [ 152 ], "most": [ 153 ], "likely": [ 154 ], "benefit,": [ 156 ], "balancing": [ 158 ], "tolerability.": [ 161 ], "evolving": [ 163 ], "landscape": [ 164 ], "therapeutics": [ 167 ], "suggests": [ 168 ], "bright": [ 170 ], "future,": [ 171 ], "the": [ 173 ], "combination": [ 176 ], "therapies": [ 177 ], "further": [ 179 ], "enhance": [ 180 ], "patient": [ 181 ], "outcomes.": [ 182 ] }, "publication_date": "2024-11-29", "publication_year": 2024, "type": "review", "cited_by_count": 24, "authors": [ { "id": "https://openalex.org/A5103136552", "display_name": "Anmol Singh" }, { "id": "https://openalex.org/A5054933261", "display_name": "Aalam Sohal" }, { "id": "https://openalex.org/A5070143582", "display_name": "Akash Batta" } ] }, { "id": "https://openalex.org/W1813189286", "doi": "https://doi.org/10.1586/14779072.2015.1054810", "title": "Liraglutide for Type 2 diabetes and obesity: a 2015 update", "abstract": { "Subcutaneous": [ 0 ], "liraglutide": [ 1, 29, 104, 141 ], "(Victoza(\u00ae),": [ 2 ], "Novo": [ 3, 63 ], "Nordisk)": [ 4 ], "was": [ 5, 32 ], "approved": [ 6, 33 ], "for": [ 7, 51 ], "the": [ 8, 22, 35, 46, 52, 59, 93, 133, 138, 152 ], "treatment": [ 9, 53 ], "of": [ 10, 54, 89, 140, 155 ], "Type": [ 11 ], "2": [ 12 ], "diabetes": [ 13 ], "mellitus": [ 14 ], "(T2DM)": [ 15 ], "in": [ 16, 18, 21, 24, 42, 70, 92, 126, 142 ], "Europe": [ 17 ], "2009": [ 19 ], "and": [ 20, 37, 41, 76, 96, 112, 144 ], "USA": [ 23 ], "2010.": [ 25 ], "In": [ 26 ], "December": [ 27 ], "2014,": [ 28 ], "3.0": [ 30 ], "mg": [ 31 ], "by": [ 34, 45, 80, 98, 118 ], "Food": [ 36 ], "Drug": [ 38 ], "Administration": [ 39 ], "(FDA)": [ 40 ], "March": [ 43 ], "2015": [ 44 ], "European": [ 47 ], "Medicines": [ 48 ], "Agency": [ 49 ], "(EMA)": [ 50 ], "chronic": [ 55 ], "weight": [ 56, 78, 124 ], "management": [ 57 ], "under": [ 58 ], "brand": [ 60 ], "name": [ 61 ], "Saxenda(\u00ae)": [ 62 ], "Nordisk.": [ 64 ], "Liraglutide": [ 65, 83 ], "causes": [ 66 ], "a": [ 67 ], "glucose-dependent": [ 68 ], "increase": [ 69 ], "insulin": [ 71 ], "secretion,": [ 72 ], "decreases": [ 73 ], "glucagon": [ 74 ], "secretion": [ 75 ], "promotes": [ 77 ], "loss": [ 79, 117, 125 ], "inhibiting": [ 81 ], "appetite.": [ 82 ], "probably": [ 84 ], "induces": [ 85 ], "satiety": [ 86 ], "through": [ 87 ], "activation": [ 88 ], "different": [ 90 ], "areas": [ 91 ], "hind": [ 94 ], "brain": [ 95 ], "possibly": [ 97 ], "preserving": [ 99 ], "free": [ 100 ], "leptin": [ 101 ], "levels.": [ 102 ], "Recently,": [ 103 ], "has": [ 105 ], "been": [ 106 ], "suggested": [ 107 ], "to": [ 108, 114 ], "protect": [ 109 ], "against": [ 110 ], "prediabetes": [ 111 ], "seems": [ 113 ], "prevent": [ 115 ], "bone": [ 116, 120 ], "increasing": [ 119 ], "formation": [ 121 ], "following": [ 122 ], "diet-induced": [ 123 ], "obesity.": [ 127 ], "This": [ 128 ], "article": [ 129 ], "not": [ 130 ], "only": [ 131 ], "covers": [ 132 ], "major": [ 134 ], "clinical": [ 135 ], "trials": [ 136 ], "evaluating": [ 137 ], "effects": [ 139 ], "obesity": [ 143 ], "T2DM": [ 145 ], "but": [ 146 ], "also": [ 147 ], "provides": [ 148 ], "novel": [ 149 ], "insights": [ 150 ], "into": [ 151 ], "pharmacological": [ 153 ], "mechanisms": [ 154 ], "liraglutide.": [ 156 ] }, "publication_date": "2015-06-24", "publication_year": 2015, "type": "review", "cited_by_count": 93, "authors": [ { "id": "https://openalex.org/A5109903929", "display_name": "Eva W. Iepsen" }, { "id": "https://openalex.org/A5038081896", "display_name": "Signe S. Torekov" }, { "id": "https://openalex.org/A5085434984", "display_name": "Jens J. Holst" } ] }, { "id": "https://openalex.org/W2061738696", "doi": "https://doi.org/10.1111/dom.12230", "title": "A prospective, claims\u2010based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs", "abstract": { "Aim": [ 0 ], "We": [ 1, 62, 152 ], "evaluated": [ 2 ], "the": [ 3 ], "relationship": [ 4 ], "between": [ 5 ], "liraglutide": [ 6, 108, 135, 163 ], "and": [ 7, 54, 76 ], "acute": [ 8, 92, 105 ], "pancreatitis": [ 9, 93, 106 ], "or": [ 10, 27, 35, 94, 167 ], "pancreatic": [ 11, 95, 130 ], "cancer": [ 12, 96, 131 ], "in": [ 13, 39 ], "an": [ 14 ], "ongoing": [ 15 ], "post\u2010marketing": [ 16 ], "safety": [ 17 ], "assessment": [ 18 ], "programme.": [ 19 ], "Methods": [ 20 ], "Initiators": [ 21 ], "of": [ 22, 31, 59, 83, 89, 158 ], "liraglutide,": [ 23 ], "exenatide,": [ 24 ], "metformin,": [ 25 ], "pioglitazone": [ 26 ], "groups": [ 28 ], "containing": [ 29 ], "initiators": [ 30 ], "dipeptidyl": [ 32 ], "peptidase\u20104": [ 33 ], "inhibitors": [ 34 ], "sulfonylureas": [ 36 ], "were": [ 37 ], "identified": [ 38 ], "a": [ 40, 57 ], "US": [ 41 ], "commercial": [ 42 ], "health": [ 43 ], "insurance": [ 44, 85 ], "claims": [ 45, 86 ], "database": [ 46 ], "(1": [ 47 ], "February": [ 48 ], "2010": [ 49 ], "to": [ 50, 165 ], "31": [ 51 ], "March": [ 52 ], "2013)": [ 53 ], "followed": [ 55 ], "for": [ 56, 104, 107, 114, 129, 134, 139 ], "median": [ 58 ], "15": [ 60 ], "months.": [ 61 ], "estimated": [ 63 ], "incidence": [ 64 ], "rates": [ 65 ], "(": [ 66, 73, 80, 118 ], "IR": [ 67, 103, 128 ], "/100": [ 68 ], "000": [ 69 ], "person\u2010years),": [ 70 ], "rate": [ 71 ], "ratio": [ 72 ], "RR": [ 74, 123, 146 ], ")": [ 75, 82 ], "95%": [ 77, 148 ], "confidence": [ 78 ], "intervals": [ 79 ], "CI": [ 81, 125, 149 ], "new": [ 84 ], "with": [ 87, 112, 137, 162 ], "diagnoses": [ 88 ], "primary": [ 90 ], "inpatient": [ 91 ], "from": [ 97 ], "Poisson": [ 98 ], "regression": [ 99 ], "models.": [ 100 ], "Results": [ 101 ], "The": [ 102, 127 ], "was": [ 109, 132 ], "187.5": [ 110 ], "compared": [ 111, 136 ], "154.4": [ 113 ], "all": [ 115, 140 ], "non\u2010glucagon\u2010like": [ 116 ], "peptide\u20101": [ 117 ], "GLP": [ 119, 142 ], "\u20101)\u2010based": [ 120 ], "therapies": [ 121, 144 ], "(adjusted": [ 122, 145 ], "1.10;": [ 124 ], "0.81\u20131.49).": [ 126 ], "19.9": [ 133 ], "33.0": [ 138 ], "non\u2010": [ 141 ], "\u20101\u2010based": [ 143 ], "0.65;": [ 147 ], "0.26\u20131.60).": [ 150 ], "Conclusion": [ 151 ], "did": [ 153 ], "not": [ 154 ], "observe": [ 155 ], "excess": [ 156 ], "risk": [ 157 ], "either": [ 159 ], "outcome": [ 160 ], "associated": [ 161 ], "relative": [ 164 ], "individual": [ 166 ], "pooled": [ 168 ], "comparator": [ 169 ], "drugs.": [ 170 ] }, "publication_date": "2013-11-06", "publication_year": 2013, "type": "article", "cited_by_count": 79, "authors": [ { "id": "https://openalex.org/A5040851165", "display_name": "Donnie Funch" }, { "id": "https://openalex.org/A5008150093", "display_name": "Helge Gydesen" }, { "id": "https://openalex.org/A5017628699", "display_name": "Karen Torn\u00f8e" }, { "id": "https://openalex.org/A5086346174", "display_name": "Atheline Major\u2010Pedersen" }, { "id": "https://openalex.org/A5045255444", "display_name": "K. Arnold Chan" } ] }, { "id": "https://openalex.org/W4394997591", "doi": "https://doi.org/10.1001/jama.2024.5003", "title": "Preoperative GLP-1 Receptor Agonist Use and Risk of Postoperative Respiratory Complications", "abstract": { "This": [ 0 ], "cohort": [ 1 ], "study": [ 2 ], "evaluates": [ 3 ], "the": [ 4 ], "risk": [ 5 ], "of": [ 6 ], "postoperative": [ 7 ], "respiratory": [ 8 ], "complications": [ 9 ], "among": [ 10 ], "patients": [ 11 ], "with": [ 12 ], "diabetes": [ 13 ], "undergoing": [ 14 ], "surgery": [ 15 ], "who": [ 16, 20 ], "had": [ 17, 21 ], "vs": [ 18 ], "those": [ 19 ], "not": [ 22 ], "a": [ 23 ], "prescription": [ 24 ], "fill": [ 25 ], "for": [ 26 ], "glucagon-like": [ 27 ], "peptide": [ 28 ], "1": [ 29 ], "receptor": [ 30 ], "agonists.": [ 31 ] }, "publication_date": "2024-04-22", "publication_year": 2024, "type": "article", "cited_by_count": 58, "authors": [ { "id": "https://openalex.org/A5010571604", "display_name": "Anjali A. Dixit" }, { "id": "https://openalex.org/A5034554999", "display_name": "Brian T. Bateman" }, { "id": "https://openalex.org/A5077415209", "display_name": "Mary T. Hawn" }, { "id": "https://openalex.org/A5073967906", "display_name": "Michelle C. Odden" }, { "id": "https://openalex.org/A5111512217", "display_name": "Eric Sun" } ] }, { "id": "https://openalex.org/W4226333445", "doi": "https://doi.org/10.1136/bmj.o1080", "title": "SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline", "abstract": { "CLINICAL": [ 0 ], "QUESTIONWhat": [ 1 ], "are": [ 2, 67 ], "the": [ 3, 106, 272, 284, 292 ], "benefits": [ 4, 93 ], "and": [ 5, 13, 42, 63, 88, 160, 177, 183, 191, 209, 233, 243, 276, 283 ], "harms": [ 6 ], "of": [ 7, 50, 95, 108, 251 ], "sodium-glucose": [ 8 ], "cotransporter": [ 9 ], "2": [ 10, 35, 52, 119 ], "(SGLT-2)": [ 11 ], "inhibitors": [ 12, 62, 110, 138, 159, 176, 190, 217 ], "glucagon-like": [ 14 ], "peptide": [ 15 ], "1": [ 16 ], "(GLP-1)": [ 17 ], "receptor": [ 18, 65, 113, 141, 165, 179, 197, 221 ], "agonists": [ 19, 66, 114 ], "when": [ 20 ], "added": [ 21 ], "to": [ 22, 202 ], "usual": [ 23 ], "care": [ 24 ], "(lifestyle": [ 25 ], "interventions": [ 26 ], "and/or": [ 27 ], "other": [ 28 ], "diabetes": [ 29, 36, 53, 120 ], "drugs)": [ 30 ], "in": [ 31, 70, 115 ], "adults": [ 32, 116 ], "with": [ 33, 72, 117, 257 ], "type": [ 34, 51, 118 ], "at": [ 37 ], "different": [ 38 ], "risk": [ 39, 126, 147, 206 ], "for": [ 40, 60, 156, 173, 187, 194, 207, 214, 240, 260 ], "cardiovascular": [ 41, 85, 125, 146 ], "kidney": [ 43, 90 ], "outcomes?CURRENT": [ 44 ], "PRACTICE": [ 45 ], "Clinical": [ 46 ], "decisions": [ 47 ], "about": [ 48 ], "treatment": [ 49 ], "have": [ 54 ], "been": [ 55 ], "led": [ 56 ], "by": [ 57 ], "glycaemic": [ 58 ], "control": [ 59 ], "decades.SGLT-2": [ 61 ], "GLP-1": [ 64, 112, 140, 164, 178, 196, 220 ], "traditionally": [ 68 ], "used": [ 69 ], "people": [ 71 ], "elevated": [ 73 ], "glucose": [ 74 ], "level": [ 75 ], "after": [ 76 ], "metformin": [ 77 ], "treatment.This": [ 78 ], "has": [ 79 ], "changed": [ 80 ], "through": [ 81 ], "trials": [ 82 ], "demonstrating": [ 83 ], "atherosclerotic": [ 84 ], "disease": [ 86, 91 ], "(CVD)": [ 87 ], "chronic": [ 89 ], "(CKD)": [ 92 ], "independent": [ 94 ], "medications'": [ 96 ], "glucose-lowering": [ 97 ], "potential.": [ 98 ], "RECOMMENDATIONSThe": [ 99 ], "guideline": [ 100 ], "panel": [ 101, 229 ], "issued": [ 102 ], "risk-stratified": [ 103 ], "recommendations": [ 104, 237, 259 ], "concerning": [ 105 ], "use": [ 107 ], "SGLT-2": [ 109, 137, 158, 175, 189, 216 ], "or": [ 111, 123, 131, 139, 152, 169 ], "\u2022": [ 121 ], "Three": [ 122 ], "fewer": [ 124 ], "factors": [ 127, 148 ], "without": [ 128, 149 ], "established": [ 129, 150 ], "CVD": [ 130, 151, 168, 182, 208 ], "CKD:": [ 132, 153, 170, 184 ], "Weak": [ 133, 154, 171, 212 ], "recommendation": [ 134, 155, 172, 186, 193, 213 ], "against": [ 135, 162 ], "starting": [ 136, 157, 163, 174, 188, 195, 215 ], "agonists.\u2022": [ 142, 166, 180, 198 ], "More": [ 143 ], "than": [ 144, 219 ], "three": [ 145 ], "weak": [ 161, 192 ], "Established": [ 167, 181 ], "Strong": [ 185 ], "For": [ 199 ], "those": [ 200 ], "committed": [ 201 ], "further": [ 203 ], "reducing": [ 204 ], "their": [ 205 ], "CKD": [ 210 ], "outcomes:": [ 211 ], "rather": [ 218 ], "agonists.HOW": [ 222 ], "THIS": [ 223 ], "GUIDELINE": [ 224 ], "WAS": [ 225 ], "CREATED": [ 226 ], "An": [ 227 ], "international": [ 228 ], "including": [ 230, 287 ], "patients,": [ 231 ], "clinicians,": [ 232 ], "methodologists": [ 234 ], "created": [ 235 ], "these": [ 236 ], "following": [ 238 ], "standards": [ 239 ], "trustworthy": [ 241, 258 ], "guidelines": [ 242 ], "This": [ 244 ], "BMJ": [ 245 ], "Rapid": [ 246, 265 ], "Recommendation": [ 247 ], "article": [ 248 ], "is": [ 249, 280, 290 ], "one": [ 250 ], "a": [ 252, 268 ], "series": [ 253 ], "that": [ 254 ], "provides": [ 255 ], "clinicians": [ 256 ], "potentially": [ 261 ], "practice": [ 262 ], "changing": [ 263 ], "evidence.BMJ": [ 264 ], "Recommendations": [ 266 ], "represent": [ 267 ], "collaborative": [ 269 ], "effort": [ 270 ], "between": [ 271 ], "MAGIC": [ 273 ], "group": [ 274 ], "(https://magicevidence.org/)": [ 275 ], "The": [ 277 ], "BMJ.A": [ 278 ], "summary": [ 279 ], "offered": [ 281 ], "here": [ 282 ], "full": [ 285 ], "version": [ 286 ], "decision": [ 288 ], "aids": [ 289 ], "on": [ 291 ], "MAGICapp": [ 293 ], "(https://app.magicapp.org/),for": [ 294 ] }, "publication_date": "2022-04-28", "publication_year": 2022, "type": "erratum", "cited_by_count": 22, "authors": [ { "id": "https://openalex.org/A5091607881", "display_name": "Sheyu Li" }, { "id": "https://openalex.org/A5109707958", "display_name": "O. V. Per" }, { "id": "https://openalex.org/A5108797836", "display_name": "Lyubov Lytvyn" }, { "id": "https://openalex.org/A5030612570", "display_name": "Pierre Guy" }, { "id": "https://openalex.org/A5018429053", "display_name": "Suetonia C. Palmer" }, { "id": "https://openalex.org/A5035283542", "display_name": "Ren\u00e9 Rodr\u00edguez\u2010Guti\u00e9rrez" }, { "id": "https://openalex.org/A5064459641", "display_name": "Farid Foroutan" }, { "id": "https://openalex.org/A5010837310", "display_name": "Thomas Agoritsas" }, { "id": "https://openalex.org/A5072226388", "display_name": "Reed Siemieniuk" }, { "id": "https://openalex.org/A5076452885", "display_name": "Michael Walsh" }, { "id": "https://openalex.org/A5003739848", "display_name": "Lawrie Frere" }, { "id": "https://openalex.org/A5021328880", "display_name": "David J. Tunnicliffe" }, { "id": "https://openalex.org/A5028969645", "display_name": "Evi Nagler" }, { "id": "https://openalex.org/A5028887083", "display_name": "Veena Manja" }, { "id": "https://openalex.org/A5069421607", "display_name": "Bj\u00f8rn Olav \u00c5svold" }, { "id": "https://openalex.org/A5036931186", "display_name": "Vivekanand Jha" }, { "id": "https://openalex.org/A5025403646", "display_name": "Mieke Vermandere" }, { "id": "https://openalex.org/A5028737784", "display_name": "Karim Gariani" }, { "id": "https://openalex.org/A5017047667", "display_name": "Qian Zhao" }, { "id": "https://openalex.org/A5100644439", "display_name": "Yan Ren" }, { "id": "https://openalex.org/A5081581107", "display_name": "Emma Jane Cartwright" }, { "id": "https://openalex.org/A5018643885", "display_name": "Patrick O. Gee" }, { "id": "https://openalex.org/A5080699844", "display_name": "Alan Wickes" }, { "id": "https://openalex.org/A5052341063", "display_name": "Linda Ferns" }, { "id": "https://openalex.org/A5073412298", "display_name": "Robin Wright" }, { "id": "https://openalex.org/A5100435324", "display_name": "Ling Li" }, { "id": "https://openalex.org/A5100602713", "display_name": "Qiukui Hao" }, { "id": "https://openalex.org/A5067205817", "display_name": "Reem A. Mustafa" } ] }, { "id": "https://openalex.org/W2609988692", "doi": "https://doi.org/10.1016/j.rbmo.2017.03.023", "title": "Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial", "abstract": null, "publication_date": "2017-04-24", "publication_year": 2017, "type": "article", "cited_by_count": 111, "authors": [ { "id": "https://openalex.org/A5067223273", "display_name": "Malin Nylander" }, { "id": "https://openalex.org/A5072982204", "display_name": "Signe Fr\u00f8ssing" }, { "id": "https://openalex.org/A5103547084", "display_name": "Helle V. Clausen" }, { "id": "https://openalex.org/A5053899216", "display_name": "Caroline Kistorp" }, { "id": "https://openalex.org/A5072362865", "display_name": "Jens Faber" }, { "id": "https://openalex.org/A5076226111", "display_name": "Sven O. Skouby" } ] }, { "id": "https://openalex.org/W2767450049", "doi": "https://doi.org/10.1155/2017/7839101", "title": "Macrovascular Complications in Patients with Diabetes and Prediabetes", "abstract": { "Diabetes": [ 0 ], "is": [ 1 ], "a": [ 2, 65, 92 ], "significant": [ 3, 79 ], "health": [ 4 ], "problem": [ 5 ], "worldwide,": [ 6 ], "and": [ 7, 20, 26, 45, 53, 73, 98, 114, 124, 136, 143 ], "its": [ 8 ], "association": [ 9 ], "with": [ 10, 60, 87 ], "cardiovascular": [ 11, 82, 122, 139 ], "disease": [ 12, 140 ], "(CVD)": [ 13 ], "was": [ 14, 107 ], "reported": [ 15 ], "in": [ 16, 24, 32, 47, 81, 94, 154 ], "several": [ 17 ], "studies.": [ 18 ], "Hyperglycemia": [ 19 ], "insulin": [ 21 ], "resistance": [ 22 ], "seen": [ 23 ], "diabetes": [ 25, 61, 155 ], "prediabetes": [ 27, 63 ], "lead": [ 28 ], "to": [ 29, 120 ], "an": [ 30, 131 ], "increase": [ 31, 46 ], "reactive": [ 33 ], "oxygen": [ 34 ], "species,": [ 35 ], "which": [ 36 ], "triggers": [ 37 ], "intracellular": [ 38 ], "molecular": [ 39 ], "signaling.": [ 40 ], "The": [ 41 ], "resulting": [ 42 ], "prothrombotic": [ 43 ], "state": [ 44 ], "inflammatory": [ 48 ], "mediators": [ 49 ], "expedite": [ 50 ], "atherosclerotic": [ 51 ], "changes": [ 52, 153 ], "the": [ 54, 99, 134, 149 ], "development": [ 55 ], "of": [ 56, 68, 101, 133, 138, 151 ], "macrovascular": [ 57 ], "complications.": [ 58 ], "Individuals": [ 59 ], "or": [ 62 ], "have": [ 64, 117 ], "higher": [ 66 ], "risk": [ 67, 100, 135 ], "developing": [ 69 ], "myocardial": [ 70 ], "infarction,": [ 71 ], "stroke,": [ 72 ], "peripheral": [ 74 ], "artery": [ 75 ], "disease.": [ 76 ], "However,": [ 77 ], "no": [ 78 ], "difference": [ 80 ], "morbidity": [ 83 ], "has": [ 84 ], "been": [ 85, 118 ], "observed": [ 86 ], "tight": [ 88 ], "glycemic": [ 89 ], "control": [ 90 ], "despite": [ 91 ], "reduction": [ 93 ], "some": [ 95, 110 ], "CVD": [ 96 ], "outcomes,": [ 97 ], "adverse": [ 102 ], "outcomes": [ 103 ], "such": [ 104 ], "as": [ 105, 146, 148 ], "hypoglycemia": [ 106 ], "increased.": [ 108 ], "Recently,": [ 109 ], "GLP-1": [ 111 ], "receptor": [ 112 ], "agonists": [ 113 ], "SGLT-2": [ 115 ], "inhibitors": [ 116 ], "shown": [ 119 ], "reduce": [ 121 ], "events": [ 123 ], "mortality.": [ 125 ], "In": [ 126 ], "this": [ 127 ], "review": [ 128 ], "we": [ 129 ], "give": [ 130 ], "overview": [ 132 ], "pathogenesis": [ 137 ], "among": [ 141 ], "diabetic": [ 142 ], "prediabetic": [ 144 ], "patients,": [ 145 ], "well": [ 147 ], "implication": [ 150 ], "recent": [ 152 ], "management.": [ 156 ] }, "publication_date": "2017-01-01", "publication_year": 2017, "type": "review", "cited_by_count": 270, "authors": [ { "id": "https://openalex.org/A5082365892", "display_name": "Dou Huang" }, { "id": "https://openalex.org/A5059520489", "display_name": "Marwan M. Refaat" }, { "id": "https://openalex.org/A5038737554", "display_name": "Kamel Mohammedi" }, { "id": "https://openalex.org/A5011988774", "display_name": "Amin Jayyousi" }, { "id": "https://openalex.org/A5036739397", "display_name": "Jassim Al Suwaidi" }, { "id": "https://openalex.org/A5081632431", "display_name": "Charbel Abi Khalil" } ] }, { "id": "https://openalex.org/W2048811039", "doi": "https://doi.org/10.2147/vhrm.s4039", "title": "Potential of liraglutide in the treatment of patients with type 2 diabetes", "abstract": { "Liraglutide": [ 0, 84, 122 ], "is": [ 1, 85, 116, 123 ], "a": [ 2, 33, 117 ], "long-acting": [ 3 ], "analog": [ 4 ], "of": [ 5, 20, 43, 109, 112, 120, 166 ], "GLP-1,": [ 6 ], "being": [ 7 ], "developed": [ 8 ], "by": [ 9, 100 ], "Novo": [ 10 ], "Nordisk": [ 11 ], "and": [ 12, 69, 75, 89, 97, 129, 154, 168, 183 ], "currently": [ 13 ], "undergoing": [ 14 ], "regulatory": [ 15 ], "review": [ 16 ], "for": [ 17, 37 ], "the": [ 18, 110, 139, 163 ], "treatment": [ 19 ], "type": [ 21 ], "2": [ 22 ], "diabetes.": [ 23 ], "Upon": [ 24 ], "injection,": [ 25 ], "liraglutide": [ 26, 49, 149, 176 ], "binds": [ 27 ], "non-covalently": [ 28 ], "to": [ 29, 45, 53, 62, 102, 158 ], "albumin,": [ 30 ], "giving": [ 31 ], "it": [ 32 ], "pharmacokinetic": [ 34 ], "profile": [ 35 ], "suitable": [ 36 ], "once-daily": [ 38 ], "administration.": [ 39 ], "In": [ 40 ], "clinical": [ 41, 140, 173 ], "trials": [ 42 ], "up": [ 44, 101 ], "1": [ 46 ], "year": [ 47 ], "duration,": [ 48 ], "has": [ 50 ], "been": [ 51, 136 ], "demonstrated": [ 52 ], "have": [ 54, 135 ], "beneficial": [ 55 ], "effects": [ 56 ], "on": [ 57 ], "islet": [ 58 ], "cell": [ 59 ], "function,": [ 60 ], "leading": [ 61 ], "improvements": [ 63 ], "in": [ 64, 81, 90, 131 ], "glycemic": [ 65 ], "control.": [ 66 ], "Both": [ 67 ], "fasting": [ 68 ], "postprandial": [ 70 ], "glucose": [ 71 ], "concentrations": [ 72 ], "are": [ 73, 76, 150 ], "lowered,": [ 74 ], "associated": [ 77, 124 ], "with": [ 78, 93, 125, 148, 170, 175 ], "lasting": [ 79 ], "reductions": [ 80, 130 ], "HbA1c": [ 82, 99 ], "levels.": [ 83 ], "effective": [ 86 ], "as": [ 87 ], "monotherapy": [ 88 ], "combination": [ 91 ], "therapy": [ 92, 167 ], "oral": [ 94 ], "antidiabetic": [ 95 ], "drugs,": [ 96 ], "reduces": [ 98 ], "approximately": [ 103 ], "1.5%": [ 104 ], "from": [ 105 ], "baseline": [ 106 ], "(8.2%-8.4%).": [ 107 ], "Because": [ 108 ], "glucose-dependency": [ 111 ], "its": [ 113, 179 ], "action,": [ 114 ], "there": [ 115 ], "low": [ 118 ], "incidence": [ 119 ], "hypoglycemia.": [ 121 ], "body": [ 126 ], "weight": [ 127 ], "loss,": [ 128 ], "systolic": [ 132 ], "blood": [ 133 ], "pressure": [ 134 ], "observed": [ 137 ], "throughout": [ 138 ], "trials.": [ 141 ], "The": [ 142 ], "most": [ 143, 160 ], "common": [ 144 ], "adverse": [ 145 ], "events": [ 146 ], "reported": [ 147 ], "gastrointestinal": [ 151 ], "(nausea,": [ 152 ], "vomiting": [ 153 ], "diarrhea).": [ 155 ], "These": [ 156 ], "tend": [ 157 ], "be": [ 159 ], "pronounced": [ 161 ], "during": [ 162 ], "initial": [ 164 ], "period": [ 165 ], "decline": [ 169 ], "time.": [ 171 ], "Further": [ 172 ], "experience": [ 174 ], "will": [ 177 ], "reveal": [ 178 ], "long-term": [ 180 ], "durability,": [ 181 ], "safety": [ 182 ], "efficacy.": [ 184 ] }, "publication_date": "2009-02-01", "publication_year": 2009, "type": "review", "cited_by_count": 73, "authors": [ { "id": "https://openalex.org/A5054335526", "display_name": "Carolyn F. Deacon" } ] }, { "id": "https://openalex.org/W4320032741", "doi": "https://doi.org/10.1007/s11695-023-06484-8", "title": "Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study", "abstract": null, "publication_date": "2023-02-11", "publication_year": 2023, "type": "article", "cited_by_count": 125, "authors": [ { "id": "https://openalex.org/A5038445298", "display_name": "Anders Boisen Jensen" }, { "id": "https://openalex.org/A5085564114", "display_name": "Frida Renstr\u00f6m" }, { "id": "https://openalex.org/A5041474000", "display_name": "Stefan Acz\u00e9l" }, { "id": "https://openalex.org/A5031124574", "display_name": "Patrick Folie" }, { "id": "https://openalex.org/A5044768944", "display_name": "Magdalena Biraima-Steinemann" }, { "id": "https://openalex.org/A5014771501", "display_name": "Felix Beuschlein" }, { "id": "https://openalex.org/A5067406711", "display_name": "Stefan Bilz" } ] }, { "id": "https://openalex.org/W4213427170", "doi": "https://doi.org/10.1038/s41591-022-01707-4", "title": "Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis", "abstract": null, "publication_date": "2022-02-24", "publication_year": 2022, "type": "review", "cited_by_count": 299, "authors": [ { "id": "https://openalex.org/A5078498803", "display_name": "Naveed Sattar" }, { "id": "https://openalex.org/A5071945904", "display_name": "Darren K. McGuire" }, { "id": "https://openalex.org/A5026505577", "display_name": "Imre P\u00e1v\u00f3" }, { "id": "https://openalex.org/A5079645471", "display_name": "Govinda J. Weerakkody" }, { "id": "https://openalex.org/A5065805983", "display_name": "Hiroshi Nishiyama" }, { "id": "https://openalex.org/A5021136102", "display_name": "Russell J. Wiese" }, { "id": "https://openalex.org/A5033053622", "display_name": "Sophia Zoungas" } ] }, { "id": "https://openalex.org/W3006785779", "doi": "https://doi.org/10.1007/s12020-020-02223-6", "title": "GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials", "abstract": null, "publication_date": "2020-02-26", "publication_year": 2020, "type": "review", "cited_by_count": 97, "authors": [ { "id": "https://openalex.org/A5069481778", "display_name": "Chuqing Cao" }, { "id": "https://openalex.org/A5101705986", "display_name": "Shuting Yang" }, { "id": "https://openalex.org/A5100397159", "display_name": "Zhiguang Zhou" } ] }, { "id": "https://openalex.org/W3120876049", "doi": "https://doi.org/10.1016/j.diabres.2021.108656", "title": "Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis", "abstract": null, "publication_date": "2021-01-11", "publication_year": 2021, "type": "review", "cited_by_count": 36, "authors": [ { "id": "https://openalex.org/A5049507373", "display_name": "Jingxin Li" }, { "id": "https://openalex.org/A5101676939", "display_name": "Ke He" }, { "id": "https://openalex.org/A5114473393", "display_name": "Jun Ge" }, { "id": "https://openalex.org/A5100412342", "display_name": "Caixia Li" }, { "id": "https://openalex.org/A5101977719", "display_name": "Jing Zeng" } ] }, { "id": "https://openalex.org/W3014137082", "doi": "https://doi.org/10.1016/j.dsx.2020.03.009", "title": "Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: A pilot study", "abstract": null, "publication_date": "2020-03-31", "publication_year": 2020, "type": "article", "cited_by_count": 52, "authors": [ { "id": "https://openalex.org/A5088308799", "display_name": "Andrea Da Porto" }, { "id": "https://openalex.org/A5053461490", "display_name": "Viviana Casarsa" }, { "id": "https://openalex.org/A5077168871", "display_name": "GianLuca Colussi" }, { "id": "https://openalex.org/A5014180438", "display_name": "Cristiana Catena" }, { "id": "https://openalex.org/A5072360699", "display_name": "Alessandro Cavarape" }, { "id": "https://openalex.org/A5031006924", "display_name": "Leonardo A. Sechi" } ] }, { "id": "https://openalex.org/W4392296984", "doi": "https://doi.org/10.1038/s41598-024-55724-z", "title": "The impact of GLP-1 receptor agonist liraglutide on blood pressure profile, hydration, natriuresis in diabetic patients with severely impaired kidney function", "abstract": null, "publication_date": "2024-02-29", "publication_year": 2024, "type": "article", "cited_by_count": 22, "authors": [ { "id": "https://openalex.org/A5069711022", "display_name": "Ma\u0142gorzata Wajdlich" }, { "id": "https://openalex.org/A5045007278", "display_name": "Micha\u0142 Nowicki" } ] }, { "id": "https://openalex.org/W4289639427", "doi": "https://doi.org/10.1016/j.ekir.2022.07.167", "title": "Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs", "abstract": null, "publication_date": "2022-08-03", "publication_year": 2022, "type": "article", "cited_by_count": 28, "authors": [ { "id": "https://openalex.org/A5029467844", "display_name": "David Z.I. Cherney" }, { "id": "https://openalex.org/A5039339457", "display_name": "Samy Hadjadj" }, { "id": "https://openalex.org/A5108350451", "display_name": "Jack Lawson" }, { "id": "https://openalex.org/A5080475619", "display_name": "Ofri Mosenzon" }, { "id": "https://openalex.org/A5046793050", "display_name": "Katherine R. Tuttle" }, { "id": "https://openalex.org/A5036486713", "display_name": "Blaz Vrhnjak" }, { "id": "https://openalex.org/A5110231477", "display_name": "S\u00f8ren Rasmussen" }, { "id": "https://openalex.org/A5080463002", "display_name": "Stephen C. Bain" } ] }, { "id": "https://openalex.org/W2069942402", "doi": "https://doi.org/10.2337/dc14-0893", "title": "Liraglutide and the Preservation of Pancreatic \u03b2-Cell Function in Early Type 2 Diabetes: The LIBRA Trial", "abstract": { "OBJECTIVE": [ 0 ], "Clinical": [ 1 ], "studies": [ 2 ], "evaluating": [ 3 ], "the": [ 4, 23, 32, 152, 157, 178, 218, 232, 237, 251 ], "effects": [ 5 ], "of": [ 6, 27, 31, 70, 88, 97, 108, 122, 143, 204, 224, 234, 256, 278, 294 ], "medications": [ 7 ], "on": [ 8, 130, 206, 254 ], "\u03b2-cell": [ 9, 28, 59, 123, 279 ], "function": [ 10, 60, 124, 280 ], "in": [ 11, 64, 151, 156, 177, 217, 231, 287 ], "type": [ 12 ], "2": [ 13 ], "diabetes": [ 14 ], "(T2DM)": [ 15 ], "are": [ 16 ], "compromised": [ 17 ], "by": [ 18, 36, 125 ], "an": [ 19, 95, 209 ], "inability": [ 20 ], "to": [ 21, 112 ], "determine": [ 22 ], "actual": [ 24 ], "baseline": [ 25 ], "degree": [ 26 ], "dysfunction": [ 29, 34 ], "independent": [ 30 ], "reversible": [ 33 ], "induced": [ 35 ], "hyperglycemia": [ 37 ], "(glucotoxicity).": [ 38 ], "Short-term": [ 39 ], "intensive": [ 40 ], "insulin": [ 41 ], "therapy": [ 42 ], "(IIT)": [ 43 ], "is": [ 44, 282 ], "a": [ 45 ], "strategy": [ 46 ], "for": [ 47 ], "eliminating": [ 48 ], "glucotoxicity": [ 49, 71 ], "before": [ 50, 110 ], "randomization.": [ 51 ], "This": [ 52 ], "study": [ 53 ], "determined": [ 54 ], "whether": [ 55 ], "liraglutide": [ 56, 115, 153, 179, 207, 238, 257 ], "can": [ 57 ], "preserve": [ 58 ], "over": [ 61, 284 ], "48": [ 62, 147, 173, 285 ], "weeks": [ 63, 107, 148, 174, 246, 286 ], "early": [ 65, 288 ], "T2DM": [ 66, 87, 289 ], "following": [ 67 ], "initial": [ 68 ], "elimination": [ 69 ], "with": [ 72, 86, 119 ], "IIT.": [ 73 ], "RESEARCH": [ 74 ], "DESIGN": [ 75 ], "AND": [ 76 ], "METHODS": [ 77 ], "In": [ 78 ], "this": [ 79, 222 ], "double-blind,": [ 80 ], "randomized,": [ 81 ], "placebo-controlled": [ 82 ], "trial,": [ 83 ], "51": [ 84 ], "patients": [ 85 ], "2.6": [ 89 ], "\u00b1": [ 90, 99, 102, 161, 165, 182, 186, 192, 196, 264, 268 ], "1.9": [ 91 ], "years'": [ 92 ], "duration": [ 93 ], "and": [ 94, 214, 239 ], "A1C": [ 96 ], "6.8": [ 98 ], "0.8%": [ 100 ], "(51": [ 101 ], "8.7": [ 103 ], "mmol/mol)": [ 104, 213 ], "completed": [ 105 ], "4": [ 106 ], "IIT": [ 109 ], "randomization": [ 111 ], "daily": [ 113 ], "subcutaneous": [ 114 ], "or": [ 116 ], "placebo": [ 117, 158, 240, 259 ], "injection,": [ 118 ], "serial": [ 120 ], "assessment": [ 121 ], "Insulin": [ 126 ], "Secretion-Sensitivity": [ 127 ], "Index-2": [ 128 ], "(ISSI-2)": [ 129 ], "oral": [ 131 ], "glucose": [ 132, 215 ], "tolerance": [ 133, 216 ], "test": [ 134 ], "performed": [ 135 ], "every": [ 136 ], "12": [ 137 ], "weeks.": [ 138 ], "RESULTS": [ 139 ], "The": [ 140 ], "primary": [ 141 ], "outcome": [ 142 ], "baseline-adjusted": [ 144 ], "ISSI-2": [ 145, 255 ], "at": [ 146, 172 ], "was": [ 149, 175, 229, 260 ], "higher": [ 150 ], "group": [ 154, 159, 180 ], "than": [ 155 ], "(339.8": [ 160 ], "27.8": [ 162 ], "vs.": [ 163, 184, 194, 266 ], "229.3": [ 164 ], "28.4,": [ 166 ], "P": [ 167, 188, 270 ], "=": [ 168, 189, 243, 271 ], "0.008).": [ 169 ], "Baseline-adjusted": [ 170 ], "HbA1c": [ 171, 210 ], "lower": [ 176 ], "(6.2": [ 181 ], "0.1%": [ 183 ], "6.6": [ 185 ], "0.1%,": [ 187 ], "0.055)": [ 190 ], "(44": [ 191 ], "1.1": [ 193, 197 ], "49": [ 195 ], "mmol/mol).": [ 198 ], "At": [ 199 ], "each": [ 200 ], "quarterly": [ 201 ], "assessment,": [ 202 ], "&gt;50%": [ 203 ], "participants": [ 205 ], "had": [ 208 ], "\u22646.0%": [ 211 ], "(42": [ 212 ], "nondiabetic": [ 219 ], "range.": [ 220 ], "Despite": [ 221 ], "level": [ 223 ], "glycemic": [ 225 ], "control,": [ 226 ], "no": [ 227 ], "difference": [ 228 ], "found": [ 230 ], "incidence": [ 233 ], "hypoglycemia": [ 235 ], "between": [ 236 ], "groups": [ 241 ], "(P": [ 242 ], "0.61).": [ 244 ], "Two": [ 245 ], "after": [ 247 ], "stopping": [ 248 ], "treatment,": [ 249 ], "however,": [ 250 ], "beneficial": [ 252 ], "effect": [ 253 ], "versus": [ 258 ], "entirely": [ 261 ], "lost": [ 262, 291 ], "(191.9": [ 263 ], "24.7": [ 265 ], "238.1": [ 267 ], "25.2,": [ 269 ], "0.20).": [ 272 ], "CONCLUSIONS": [ 273 ], "Liraglutide": [ 274 ], "provides": [ 275 ], "robust": [ 276 ], "enhancement": [ 277 ], "that": [ 281 ], "sustained": [ 283 ], "but": [ 290 ], "upon": [ 292 ], "cessation": [ 293 ], "therapy.": [ 295 ] }, "publication_date": "2014-09-24", "publication_year": 2014, "type": "article", "cited_by_count": 130, "authors": [ { "id": "https://openalex.org/A5070607809", "display_name": "Ravi Retnakaran" }, { "id": "https://openalex.org/A5026062713", "display_name": "Caroline K. Kramer" }, { "id": "https://openalex.org/A5061469784", "display_name": "Haysook Choi" }, { "id": "https://openalex.org/A5113808176", "display_name": "Balakumar Swaminathan" }, { "id": "https://openalex.org/A5090437675", "display_name": "Bernard Zinman" } ] }, { "id": "https://openalex.org/W2511827836", "doi": "https://doi.org/10.2146/ajhp150990", "title": "Role of glucagon-like peptide 1 receptor agonists in management of obesity", "abstract": { "Originally": [ 0 ], "marketed": [ 1 ], "for": [ 2, 16, 38 ], "glycemic": [ 3 ], "control": [ 4 ], "in": [ 5, 19 ], "type": [ 6, 24 ], "2": [ 7, 25 ], "diabetes,": [ 8 ], "GLP-1": [ 9, 32 ], "receptor": [ 10, 33 ], "agonists": [ 11 ], "have": [ 12 ], "been": [ 13 ], "found": [ 14 ], "effective": [ 15 ], "weight": [ 17 ], "reduction": [ 18 ], "patients": [ 20 ], "with": [ 21 ], "and": [ 22 ], "without": [ 23 ], "diabetes.": [ 26 ], "Liraglutide": [ 27 ], "is": [ 28 ], "currently": [ 29 ], "the": [ 30 ], "only": [ 31 ], "agonist": [ 34 ], "approved": [ 35 ], "by": [ 36 ], "FDA": [ 37 ], "obesity": [ 39 ], "treatment.": [ 40 ] }, "publication_date": "2016-09-19", "publication_year": 2016, "type": "review", "cited_by_count": 64, "authors": [ { "id": "https://openalex.org/A5022179243", "display_name": "Diana Isaacs" }, { "id": "https://openalex.org/A5031092578", "display_name": "Lalita Prasad-Reddy" }, { "id": "https://openalex.org/A5103905512", "display_name": "Sneha Baxi Srivastava" } ] }, { "id": "https://openalex.org/W1968697688", "doi": "https://doi.org/10.1016/j.diabres.2012.10.017", "title": "Attempted suicide with liraglutide overdose did not induce hypoglycemia", "abstract": null, "publication_date": "2012-11-11", "publication_year": 2012, "type": "article", "cited_by_count": 28, "authors": [ { "id": "https://openalex.org/A5018532002", "display_name": "Rie Nakanishi" }, { "id": "https://openalex.org/A5109233870", "display_name": "T. Hirose" }, { "id": "https://openalex.org/A5061830609", "display_name": "Yoshifumi Tamura" }, { "id": "https://openalex.org/A5027831207", "display_name": "Yoshio Fujitani" }, { "id": "https://openalex.org/A5043895658", "display_name": "Hirotaka Watada" } ] }, { "id": "https://openalex.org/W2059140614", "doi": "https://doi.org/10.1371/journal.pone.0058784", "title": "Chronic Treatment with the GLP1 Analogue Liraglutide Increases Cell Proliferation and Differentiation into Neurons in an AD Mouse Model", "abstract": { "Neurogenesis": [ 0 ], "is": [ 1, 42, 207 ], "a": [ 2, 43, 213 ], "life": [ 3 ], "long": [ 4 ], "process,": [ 5 ], "but": [ 6, 140 ], "the": [ 7, 23, 28, 59, 210 ], "rate": [ 8 ], "of": [ 9, 25, 84, 159 ], "cell": [ 10, 36, 39, 68, 88, 135, 148 ], "proliferation": [ 11, 37, 69, 136, 149 ], "and": [ 12, 38, 58, 81, 92, 101, 108, 154, 168, 198 ], "differentiation": [ 13, 91, 95 ], "decreases": [ 14 ], "with": [ 15, 21, 123, 129, 190 ], "age.": [ 16 ], "In": [ 17 ], "Alzheimer's": [ 18, 72 ], "patients,": [ 19 ], "along": [ 20 ], "age,": [ 22 ], "presence": [ 24 ], "A\u03b2": [ 26 ], "in": [ 27, 70, 98, 134, 137, 142, 165, 227 ], "brain": [ 29 ], "inhibits": [ 30 ], "this": [ 31 ], "process": [ 32 ], "by": [ 33 ], "reducing": [ 34 ], "stem": [ 35 ], "differentiation.": [ 40 ], "GLP-1": [ 41, 60 ], "growth": [ 44 ], "factor": [ 45 ], "that": [ 46, 204 ], "has": [ 47, 63 ], "neuroprotective": [ 48 ], "properties.": [ 49 ], "GLP1": [ 50 ], "receptors": [ 51 ], "are": [ 52 ], "present": [ 53 ], "on": [ 54, 86, 209 ], "neuronal": [ 55 ], "progenitor": [ 56, 87 ], "cells,": [ 57 ], "analogue": [ 61 ], "liraglutide": [ 62, 85, 130 ], "been": [ 64 ], "shown": [ 65 ], "to": [ 66 ], "increase": [ 67, 133, 187 ], "an": [ 71, 132 ], "disease": [ 73 ], "(AD)": [ 74 ], "mouse": [ 75 ], "model.": [ 76 ], "Here": [ 77 ], "we": [ 78 ], "investigated": [ 79 ], "acute": [ 80, 167 ], "chronic": [ 82, 145, 169 ], "effects": [ 83, 226 ], "proliferation,": [ 89 ], "neuroblast": [ 90 ], "their": [ 93, 109 ], "subsequent": [ 94 ], "into": [ 96, 180 ], "neurons": [ 97, 161, 182 ], "wild": [ 99 ], "type": [ 100, 216 ], "APP/PS-1": [ 102 ], "mice": [ 103 ], "at": [ 104, 150, 172 ], "different": [ 105 ], "ages.": [ 106, 174 ], "APP/PS1": [ 107, 138, 197 ], "littermate": [ 110 ], "controls,": [ 111 ], "aged": [ 112 ], "3,": [ 113 ], "6,": [ 114, 193 ], "12,": [ 115, 194 ], "15": [ 116, 195 ], "months": [ 117 ], "were": [ 118, 163 ], "injected": [ 119 ], "acutely": [ 120 ], "or": [ 121 ], "chronically": [ 122, 191 ], "25": [ 124 ], "nmol/kg": [ 125 ], "liraglutide.": [ 126 ], "Acute": [ 127 ], "treatment": [ 128, 146, 214 ], "showed": [ 131 ], "mice,": [ 139 ], "not": [ 141 ], "controls": [ 143 ], "whereas": [ 144 ], "increased": [ 147, 164 ], "all": [ 151, 173 ], "ages": [ 152 ], "(BrdU": [ 153 ], "Ki67": [ 155 ], "markers).": [ 156 ], "Moreover,": [ 157 ], "numbers": [ 158 ], "immature": [ 160 ], "(DCX)": [ 162 ], "both": [ 166 ], "treated": [ 170, 192 ], "animals": [ 171 ], "Most": [ 175 ], "newly": [ 176 ], "generated": [ 177 ], "cells": [ 178 ], "differentiated": [ 179 ], "mature": [ 181 ], "(NeuN": [ 183 ], "marker).": [ 184 ], "A": [ 185 ], "significant": [ 186 ], "was": [ 188 ], "observed": [ 189 ], "month": [ 196 ], "WT": [ 199 ], "groups.": [ 200 ], "These": [ 201 ], "results": [ 202 ], "demonstrate": [ 203 ], "liraglutide,": [ 205 ], "which": [ 206, 222 ], "currently": [ 208 ], "market": [ 211 ], "as": [ 212 ], "for": [ 215 ], "2": [ 217 ], "diabetes": [ 218 ], "(Victoza(TM)),": [ 219 ], "increases": [ 220 ], "neurogenesis,": [ 221 ], "may": [ 223 ], "have": [ 224 ], "beneficial": [ 225 ], "neurodegenerative": [ 228 ], "disorders": [ 229 ], "like": [ 230 ], "AD.": [ 231 ] }, "publication_date": "2013-03-11", "publication_year": 2013, "type": "article", "cited_by_count": 131, "authors": [ { "id": "https://openalex.org/A5066857047", "display_name": "Vadivel Parthsarathy" }, { "id": "https://openalex.org/A5082707086", "display_name": "Christian H\u00f6lscher" } ] }, { "id": "https://openalex.org/W4396793537", "doi": "https://doi.org/10.3233/adr-230181", "title": "Clinical Evidence for GLP-1 Receptor Agonists in Alzheimer\u2019s Disease: A\u00a0Systematic Review", "abstract": { "Background:": [ 0 ], "Alzheimer\u2019s": [ 1 ], "disease": [ 2 ], "(AD)": [ 3 ], "is": [ 4, 215 ], "the": [ 5, 145, 195 ], "most": [ 6 ], "common": [ 7 ], "cause": [ 8 ], "of": [ 9, 17, 97, 107, 141, 160 ], "dementia.": [ 10 ], "While": [ 11 ], "preclinical": [ 12 ], "studies": [ 13, 31, 109 ], "have": [ 14 ], "shown": [ 15 ], "benefits": [ 16 ], "glucagon-like": [ 18 ], "peptide": [ 19, 79 ], "1": [ 20, 80 ], "receptor": [ 21, 81 ], "agonists": [ 22 ], "(GLP-1": [ 23 ], "RA)": [ 24 ], "in": [ 25, 44, 188, 197, 231 ], "targeting": [ 26 ], "core": [ 27, 51 ], "AD": [ 28, 45, 52 ], "pathology,": [ 29 ], "clinical": [ 30 ], "are": [ 32 ], "limited.": [ 33 ], "Objective:": [ 34 ], "A": [ 35, 105 ], "systematic": [ 36 ], "review": [ 37 ], "was": [ 38, 157 ], "performed": [ 39 ], "to": [ 40, 49 ], "evaluate": [ 41 ], "GLP-1": [ 42, 98, 168, 191, 218 ], "RAs": [ 43 ], "for": [ 46 ], "their": [ 47 ], "potential": [ 48, 235 ], "target": [ 50 ], "pathology": [ 53 ], "and": [ 54, 67, 83, 94, 102, 124, 132, 147, 165, 179, 201, 225, 237 ], "improve": [ 55 ], "cognition.": [ 56 ], "Methods:": [ 57 ], "Searches": [ 58 ], "were": [ 59, 110, 117 ], "conducted": [ 60 ], "via": [ 61 ], "three": [ 62, 95, 151 ], "different": [ 63 ], "databases": [ 64 ], "(PubMed,": [ 65 ], "Embase,": [ 66 ], "Cochrane": [ 68 ], "Library).": [ 69 ], "Search": [ 70 ], "terms": [ 71, 90 ], "included": [ 72, 118 ], "Medical": [ 73 ], "Subject": [ 74 ], "Headings": [ 75 ], "(MeSH)": [ 76 ], "terms:": [ 77 ], "\u2018glucagon-like": [ 78 ], "agonist\u2019": [ 82 ], "\u2018Alzheimer\u2019s": [ 84 ], "disease\u2019,": [ 85 ], "as": [ 86, 88, 174 ], "well": [ 87 ], "entry": [ 89 ], "\u2018GLP-1": [ 91 ], "RA\u2019,": [ 92 ], "\u2018AD\u2019,": [ 93 ], "types": [ 96 ], "RA:": [ 99 ], "\u2018liraglutide\u2019,": [ 100 ], "\u2018exenatide\u2019,": [ 101 ], "\u2018lixisenatide\u2019.": [ 103 ], "Results:": [ 104 ], "total": [ 106 ], "1,444": [ 108 ], "screened.": [ 111 ], "Six": [ 112 ], "articles": [ 113 ], "that": [ 114 ], "met": [ 115 ], "criteria": [ 116 ], "(four": [ 119 ], "randomized": [ 120 ], "control": [ 121 ], "trials": [ 122 ], "[RCTs]": [ 123 ], "two": [ 125 ], "protocol": [ 126 ], "studies).": [ 127 ], "Two": [ 128 ], "RCTs": [ 129, 152 ], "with": [ 130, 153 ], "amyloid-\u03b2": [ 131, 224 ], "tau": [ 133, 226 ], "biomarker": [ 134 ], "endpoints": [ 135 ], "did": [ 136, 221 ], "not": [ 137, 222 ], "observe": [ 138 ], "an": [ 139 ], "end": [ 140, 159 ], "treatment": [ 142, 161 ], "difference": [ 143, 162 ], "between": [ 144, 163 ], "placebo": [ 146, 164 ], "treated": [ 148, 166, 189 ], "groups.": [ 149, 167, 190 ], "In": [ 150 ], "cognitive": [ 154 ], "endpoints,": [ 155 ], "there": [ 156 ], "no": [ 158 ], "RA": [ 169, 192, 219 ], "showed": [ 170, 234 ], "metabolic": [ 171, 236 ], "benefits,": [ 172 ], "such": [ 173 ], "lower": [ 175 ], "body": [ 176 ], "mass": [ 177 ], "index": [ 178 ], "improved": [ 180 ], "glucose": [ 181, 185, 199, 205 ], "levels": [ 182 ], "on": [ 183 ], "oral": [ 184 ], "tolerance": [ 186 ], "tests": [ 187 ], "may": [ 193 ], "mitigate": [ 194 ], "decline": [ 196 ], "cerebral": [ 198 ], "metabolism": [ 200 ], "show": [ 202, 229 ], "enhanced": [ 203 ], "blood-brain": [ 204 ], "transport": [ 206 ], "capacity": [ 207 ], "using": [ 208 ], "18": [ 209 ], "F-FDG": [ 210 ], "PET,": [ 211 ], "however,": [ 212 ], "more": [ 213 ], "data": [ 214 ], "needed.": [ 216 ], "Conclusions:": [ 217 ], "therapy": [ 220 ], "alter": [ 223 ], "biomarkers": [ 227 ], "nor": [ 228 ], "improvements": [ 230 ], "cognition": [ 232 ], "but": [ 233 ], "neuroprotective": [ 238 ], "benefits.": [ 239 ] }, "publication_date": "2024-01-09", "publication_year": 2024, "type": "review", "cited_by_count": 33, "authors": [ { "id": "https://openalex.org/A5102161839", "display_name": "Yulin Liang" }, { "id": "https://openalex.org/A5000636220", "display_name": "Vincent Dor\u00e9" }, { "id": "https://openalex.org/A5022818431", "display_name": "Christopher C. Rowe" }, { "id": "https://openalex.org/A5066212403", "display_name": "Natasha Krishnadas" } ] }, { "id": "https://openalex.org/W4206839459", "doi": "https://doi.org/10.1016/j.mce.2022.111560", "title": "Liraglutide prevents high glucose induced HUVECs dysfunction via inhibition of PINK1/Parkin-dependent mitophagy", "abstract": { "Functional": [ 0 ], "loss": [ 1 ], "of": [ 2, 11, 18, 36, 59, 71, 111, 126, 139, 187, 201, 223, 237 ], "endothelial": [ 3, 19, 48, 76 ], "cells": [ 4, 20, 77 ], "will": [ 5 ], "lead": [ 6 ], "to": [ 7, 25, 31, 80, 164, 191, 219, 229, 244 ], "development": [ 8 ], "and": [ 9, 50, 62, 65, 68, 108, 128, 150, 153, 157 ], "progression": [ 10 ], "atherosclerosis": [ 12 ], "in": [ 13, 21, 147, 168 ], "diabetic": [ 14 ], "patients.": [ 15 ], "However,": [ 16 ], "dysfunction": [ 17, 49, 198 ], "diabetes": [ 22, 215 ], "has": [ 23 ], "yet": [ 24 ], "be": [ 26 ], "fully": [ 27 ], "understood.": [ 28 ], "We": [ 29, 83 ], "aimed": [ 30 ], "characterize": [ 32 ], "the": [ 33, 72, 188, 202, 221, 231, 238, 246 ], "potential": [ 34 ], "effects": [ 35, 92 ], "liraglutide,": [ 37 ], "a": [ 38 ], "glucagon-like": [ 39 ], "peptide-1": [ 40 ], "(GLP-1)": [ 41 ], "receptor": [ 42 ], "agonist,": [ 43 ], "on": [ 44 ], "preventing": [ 45 ], "high": [ 46, 81, 101, 123, 169, 194 ], "glucose-induced": [ 47, 102, 124 ], "excessive": [ 51 ], "mitophagic": [ 52 ], "response.": [ 53 ], "Pretreatment": [ 54 ], "with": [ 55 ], "liraglutide": [ 56, 87, 121, 184, 242 ], "prevented": [ 57 ], "downregulation": [ 58 ], "eNOS": [ 60 ], "phosphorylation": [ 61 ], "NO": [ 63 ], "secretion,": [ 64 ], "reduced": [ 66, 154 ], "apoptosis": [ 67 ], "oxidative": [ 69 ], "stress": [ 70 ], "human": [ 73 ], "umbilical": [ 74 ], "vein": [ 75 ], "(HUVECs)": [ 78 ], "exposed": [ 79 ], "glucose.": [ 82 ], "further": [ 84 ], "demonstrated": [ 85 ], "that": [ 86, 120, 183, 241 ], "likely": [ 88 ], "mediated": [ 89, 96 ], "such": [ 90 ], "protective": [ 91 ], "by": [ 93, 141, 177, 199 ], "reducing": [ 94 ], "PINK1/Parkin": [ 95, 189 ], "mitophagy.": [ 97, 204 ], "Liraglutide": [ 98 ], "markedly": [ 99 ], "decreased": [ 100 ], "mitochondrial": [ 103, 109, 149, 155, 158, 247 ], "ROS,": [ 104 ], "lessened": [ 105 ], "PINK1": [ 106 ], "expression": [ 107 ], "accumulation": [ 110 ], "Parkin,": [ 112 ], "but": [ 113, 161 ], "recovered": [ 114 ], "SIRT1": [ 115 ], "expression.": [ 116 ], "Seahorse": [ 117 ], "analysis": [ 118 ], "revealed": [ 119 ], "mitigated": [ 122 ], "reduction": [ 125 ], "basal": [ 127 ], "maximum": [ 129 ], "respiration": [ 130, 136 ], "rates": [ 131 ], "as": [ 132, 134, 208 ], "well": [ 133 ], "spare": [ 135 ], "capacity.": [ 137 ], "Inhibition": [ 138 ], "Parkin": [ 140 ], "RNA": [ 142 ], "silencing": [ 143 ], "not": [ 144, 175 ], "only": [ 145 ], "resulted": [ 146 ], "increased": [ 148, 165 ], "cytosolic": [ 151 ], "ROS": [ 152 ], "mass": [ 156 ], "membrane": [ 159 ], "potential,": [ 160 ], "also": [ 162 ], "led": [ 163 ], "apoptotic": [ 166 ], "responses": [ 167 ], "glucose": [ 170, 195 ], "treated": [ 171 ], "HUVECs": [ 172 ], "which": [ 173 ], "were": [ 174 ], "preventable": [ 176 ], "liraglutide.": [ 178 ], "Together,": [ 179 ], "our": [ 180 ], "study": [ 181 ], "reveals": [ 182 ], "acts": [ 185 ], "upstream": [ 186, 236 ], "pathway": [ 190, 240 ], "effectively": [ 192 ], "counteract": [ 193 ], "induced": [ 196 ], "cell": [ 197 ], "suppression": [ 200 ], "PINK1/Parkin-dependent": [ 203 ], "Therefore,": [ 205 ], "its": [ 206 ], "use": [ 207 ], "an": [ 209 ], "adjunct": [ 210 ], "therapy": [ 211 ], "for": [ 212 ], "type": [ 213 ], "2": [ 214 ], "mellitus": [ 216 ], "is": [ 217, 227 ], "warranted": [ 218 ], "reduce": [ 220 ], "risk": [ 222 ], "atherosclerosis.": [ 224 ], "Further": [ 225 ], "research": [ 226 ], "required": [ 228 ], "examine": [ 230 ], "exact": [ 232 ], "molecules,": [ 233 ], "including": [ 234 ], "SIRT1,": [ 235 ], "PINK1/parkin": [ 239 ], "targets": [ 243 ], "maintain": [ 245 ], "homeostasis.": [ 248 ] }, "publication_date": "2022-01-13", "publication_year": 2022, "type": "article", "cited_by_count": 55, "authors": [ { "id": "https://openalex.org/A5054636731", "display_name": "Yikai Zhang" }, { "id": "https://openalex.org/A5101785486", "display_name": "Sheng\u2010Yao Wang" }, { "id": "https://openalex.org/A5100729135", "display_name": "Xia Chen" }, { "id": "https://openalex.org/A5100665936", "display_name": "Zhe Wang" }, { "id": "https://openalex.org/A5100382937", "display_name": "Xinyi Wang" }, { "id": "https://openalex.org/A5006502427", "display_name": "Qiao Zhou" }, { "id": "https://openalex.org/A5021770801", "display_name": "Weihuan Fang" }, { "id": "https://openalex.org/A5100698713", "display_name": "Chao Zheng" } ] }, { "id": "https://openalex.org/W4386781026", "doi": "https://doi.org/10.1016/j.cgh.2023.08.034", "title": "Use of DPP4 Inhibitors and GLP-1 Receptor Agonists and Risk of Intestinal Obstruction: Scandinavian Cohort Study", "abstract": { "In": [ 0 ], "this": [ 1 ], "analysis": [ 2 ], "of": [ 3, 16, 21 ], "nationwide": [ 4 ], "data": [ 5 ], "from": [ 6 ], "3": [ 7 ], "countries,": [ 8 ], "previous": [ 9 ], "safety": [ 10 ], "signals": [ 11 ], "indicating": [ 12 ], "an": [ 13 ], "increased": [ 14 ], "risk": [ 15 ], "intestinal": [ 17 ], "obstruction": [ 18 ], "with": [ 19 ], "use": [ 20 ], "DPP4": [ 22 ], "inhibitors": [ 23 ], "and": [ 24 ], "GLP-1": [ 25 ], "receptor": [ 26 ], "agonists": [ 27 ], "were": [ 28 ], "not": [ 29 ], "confirmed.": [ 30 ] }, "publication_date": "2023-09-15", "publication_year": 2023, "type": "article", "cited_by_count": 19, "authors": [ { "id": "https://openalex.org/A5052794043", "display_name": "Peter Ueda" }, { "id": "https://openalex.org/A5026440130", "display_name": "Viktor Wintzell" }, { "id": "https://openalex.org/A5001189522", "display_name": "Mads Melbye" }, { "id": "https://openalex.org/A5061198575", "display_name": "Bj\u00f6rn Eliasson" }, { "id": "https://openalex.org/A5107701736", "display_name": "Jonas S\u00f6derling" }, { "id": "https://openalex.org/A5002631805", "display_name": "Soffia Gu\u00f0bj\u00f6rnsd\u00f3ttir" }, { "id": "https://openalex.org/A5033780024", "display_name": "Kristian Hveem" }, { "id": "https://openalex.org/A5043082194", "display_name": "Christian Jonasson" }, { "id": "https://openalex.org/A5046772961", "display_name": "Henrik Svanstr\u00f6m" }, { "id": "https://openalex.org/A5022804650", "display_name": "Anders Hviid" }, { "id": "https://openalex.org/A5072660677", "display_name": "Bj\u00f6rn Pasternak" } ] }, { "id": "https://openalex.org/W4293030286", "doi": "https://doi.org/10.1186/s12933-022-01572-y", "title": "Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study", "abstract": { "Abstract": [ 0 ], "Background": [ 1 ], "GLP-1": [ 2, 51, 89 ], "receptor": [ 3 ], "agonists": [ 4 ], "(GLP-1": [ 5 ], "RA)": [ 6 ], "and": [ 7, 24, 41, 47, 53, 58, 86, 107, 112, 134, 158, 199, 223, 270, 282, 301 ], "SGLT-2": [ 8 ], "inhibitors": [ 9 ], "(SGLT-2i)": [ 10 ], "have": [ 11 ], "shown": [ 12 ], "to": [ 13, 29, 72, 266, 287, 306, 309 ], "reduce": [ 14 ], "the": [ 15, 45, 218, 226, 234, 247, 277, 288, 295, 310 ], "risk": [ 16, 183, 278 ], "of": [ 17, 31, 50, 61, 220, 236, 252, 279, 291, 299 ], "major": [ 18 ], "adverse": [ 19, 164, 254 ], "cardiovascular": [ 20, 137 ], "events": [ 21, 94, 165, 255 ], "(MACE),": [ 22 ], "death": [ 23 ], "worsening": [ 25 ], "nephropathy": [ 26 ], "when": [ 27 ], "added": [ 28 ], "standard": [ 30 ], "care.": [ 32 ], "However,": [ 33 ], "these": [ 34 ], "two": [ 35, 227 ], "dug": [ 36 ], "classes": [ 37 ], "differ": [ 38 ], "in": [ 39, 55, 68, 131, 154, 206, 217, 233, 258, 275, 303 ], "efficacy": [ 40 ], "safety.": [ 42 ], "We": [ 43 ], "compared": [ 44, 142, 208 ], "effectiveness": [ 46 ], "safety": [ 48 ], "profile": [ 49 ], "RA": [ 52, 90 ], "SGLT-2i": [ 54, 210, 274, 302 ], "a": [ 56, 181 ], "large": [ 57 ], "unselected": [ 59 ], "cohort": [ 60 ], "patients": [ 62, 82, 174, 237 ], "with": [ 63, 133, 209 ], "type": [ 64 ], "2": [ 65 ], "diabetes": [ 66 ], "resident": [ 67 ], "Lombardy": [ 69 ], "from": [ 70 ], "2015": [ 71 ], "2020.": [ 73 ], "Methods": [ 74 ], "Using": [ 75 ], "linkable": [ 76 ], "administrative": [ 77 ], "health": [ 78 ], "databases,": [ 79 ], "we": [ 80 ], "included": [ 81 ], "aged": [ 83 ], "50": [ 84 ], "years": [ 85 ], "older": [ 87 ], "initiating": [ 88 ], "or": [ 91 ], "SGLT-2i.": [ 92 ], "Clinical": [ 93 ], "were:": [ 95 ], "death,": [ 96 ], "hospital": [ 97 ], "admission": [ 98 ], "for": [ 99, 185 ], "myocardial": [ 100 ], "infarction": [ 101 ], "(MI),": [ 102 ], "stroke,": [ 103 ], "heart": [ 104 ], "failure": [ 105 ], "(HF),": [ 106 ], "renal": [ 108 ], "disease": [ 109 ], "as": [ 110 ], "individual": [ 111, 311 ], "composite": [ 113 ], "outcomes": [ 114 ], "(MACE-3:": [ 115 ], "all": [ 116 ], "cause-death,": [ 117 ], "non-fatal": [ 118, 120, 186 ], "MI,": [ 119 ], "stroke;": [ 121 ], "MACE-4:": [ 122 ], "MACE-3": [ 123, 193 ], "plus": [ 124 ], "unstable": [ 125 ], "angina).": [ 126 ], "Outcomes": [ 127 ], "were": [ 128, 141, 166, 231 ], "evaluated": [ 129 ], "separately": [ 130 ], "subjects": [ 132 ], "without": [ 135, 238 ], "previous": [ 136, 239 ], "(CV)": [ 138 ], "diseases.": [ 139 ], "Treatments": [ 140 ], "using": [ 143 ], "Cox": [ 144 ], "proportional": [ 145 ], "hazards": [ 146 ], "regression": [ 147 ], "model": [ 148 ], "after": [ 149 ], "Propensity": [ 150 ], "Score": [ 151 ], "Matching": [ 152 ], "(PSM)": [ 153 ], "both": [ 155, 259 ], "intention-to-treat": [ 156 ], "(ITT)": [ 157 ], "per": [ 159, 175 ], "protocol": [ 160 ], "(PP)": [ 161 ], "analyses.": [ 162 ], "Serious": [ 163 ], "also": [ 167 ], "evaluated.": [ 168 ], "Results": [ 169 ], "The": [ 170, 177, 250 ], "analysis": [ 171, 179, 244 ], "comprised": [ 172 ], "20,762": [ 173 ], "cohort.": [ 176 ], "ITT": [ 178 ], "showed": [ 180, 265 ], "significant": [ 182 ], "reduction": [ 184 ], "MI": [ 187 ], "(HR": [ 188, 194, 201 ], "0.77;": [ 189 ], "CI": [ 190, 196, 203 ], "95%": [ 191, 197, 204 ], "0.66\u20130.90),": [ 192 ], "0.91;": [ 195 ], "0.84\u20130.98),": [ 198 ], "MACE-4": [ 200, 281 ], "0.92;": [ 202 ], "0.86\u20130.99)": [ 205 ], "GLP-1RA": [ 207, 264, 300 ], "users,": [ 211 ], "while": [ 212 ], "no": [ 213 ], "difference": [ 214 ], "was": [ 215, 256 ], "reported": [ 216 ], "incidence": [ 219, 251 ], "HF": [ 221 ], "hospitalization": [ 222 ], "stroke": [ 224 ], "between": [ 225 ], "cohorts.": [ 228 ], "Similar": [ 229 ], "benefits": [ 230 ], "found": [ 232 ], "subgroup": [ 235 ], "CV": [ 240 ], "diseases": [ 241 ], "only.": [ 242 ], "PP": [ 243 ], "largely": [ 245 ], "confirmed": [ 246 ], "main": [ 248 ], "results.": [ 249 ], "serious": [ 253 ], "low": [ 257 ], "cohorts": [ 260 ], "(<": [ 261 ], "1%).": [ 262 ], "Conclusions": [ 263 ], "be": [ 267 ], "equally": [ 268 ], "safe": [ 269 ], "more": [ 271 ], "effective": [ 272 ], "than": [ 273 ], "reducing": [ 276 ], "MACE-3,": [ 280 ], "MI.": [ 283 ], "This": [ 284 ], "study": [ 285 ], "adds": [ 286 ], "growing": [ 289 ], "body": [ 290 ], "real-world": [ 292 ], "evidence": [ 293 ], "addressing": [ 294 ], "specific": [ 296 ], "clinical": [ 297 ], "properties": [ 298 ], "everyday": [ 304 ], "practice": [ 305 ], "tailor": [ 307 ], "treatment": [ 308 ], "patient.": [ 312 ] }, "publication_date": "2022-08-24", "publication_year": 2022, "type": "article", "cited_by_count": 41, "authors": [ { "id": "https://openalex.org/A5018220482", "display_name": "Marta Baviera" }, { "id": "https://openalex.org/A5001900667", "display_name": "Andreana Foresta" }, { "id": "https://openalex.org/A5080794224", "display_name": "Pierluca Colacioppo" }, { "id": "https://openalex.org/A5051105526", "display_name": "Giulia Macaluso" }, { "id": "https://openalex.org/A5048427107", "display_name": "Maria Carla Roncaglioni" }, { "id": "https://openalex.org/A5081493233", "display_name": "Mauro Tettamanti" }, { "id": "https://openalex.org/A5085817977", "display_name": "Ida Fortino" }, { "id": "https://openalex.org/A5049715149", "display_name": "Stefano Genovese" }, { "id": "https://openalex.org/A5103115613", "display_name": "Irene Caruso" }, { "id": "https://openalex.org/A5064872622", "display_name": "Francesco Giorgino" } ] }, { "id": "https://openalex.org/W3088988988", "doi": "https://doi.org/10.1111/ijcp.13731", "title": "Switching between GLP\u20101 receptor agonists in clinical practice: Expert consensus and practical guidance", "abstract": { "Switching": [ 0 ], "from": [ 1 ], "one": [ 2 ], "GLP-1RA": [ 3 ], "to": [ 4 ], "another,": [ 5 ], "such": [ 6 ], "as": [ 7 ], "OW": [ 8 ], "semaglutide,": [ 9 ], "can": [ 10 ], "provide": [ 11 ], "clinical": [ 12 ], "benefits": [ 13 ], "and": [ 14 ], "may": [ 15 ], "delay": [ 16 ], "the": [ 17 ], "need": [ 18 ], "for": [ 19 ], "treatment": [ 20 ], "intensification.": [ 21 ] }, "publication_date": "2020-09-25", "publication_year": 2020, "type": "article", "cited_by_count": 36, "authors": [ { "id": "https://openalex.org/A5087185790", "display_name": "Akshay Jain" }, { "id": "https://openalex.org/A5104046729", "display_name": "Amar Ali" }, { "id": "https://openalex.org/A5076277987", "display_name": "Juan Jos\u00e9 Gorgojo Mart\u00ednez" }, { "id": "https://openalex.org/A5088887856", "display_name": "Irene Hramiak" }, { "id": "https://openalex.org/A5057376491", "display_name": "Ketan Kavia" }, { "id": "https://openalex.org/A5062239390", "display_name": "Sten Madsbad" }, { "id": "https://openalex.org/A5063045773", "display_name": "Louis Potier" }, { "id": "https://openalex.org/A5053007427", "display_name": "Ben D. Prohaska" }, { "id": "https://openalex.org/A5058980845", "display_name": "Jodi Strong" }, { "id": "https://openalex.org/A5004120950", "display_name": "Tina Vilsb\u00f8ll" } ] }, { "id": "https://openalex.org/W1975591028", "doi": "https://doi.org/10.1007/s00125-010-1896-4", "title": "Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?", "abstract": null, "publication_date": "2010-09-24", "publication_year": 2010, "type": "review", "cited_by_count": 453, "authors": [ { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5064920377", "display_name": "Irfan Vardarli" }, { "id": "https://openalex.org/A5054335526", "display_name": "Carolyn F. Deacon" }, { "id": "https://openalex.org/A5085434984", "display_name": "Jens J. Holst" }, { "id": "https://openalex.org/A5002832666", "display_name": "Juris J. Meier" } ] }, { "id": "https://openalex.org/W2019002829", "doi": "https://doi.org/10.1055/s-2006-924230", "title": "Five Weeks of Treatment with the GLP-1 Analogue Liraglutide Improves Glycaemic Control and Lowers Body weight in Subjects with Type 2 Diabetes", "abstract": { "Using": [ 0 ], "a": [ 1, 60 ], "weekly": [ 2 ], "dose-titration": [ 3 ], "liraglutide": [ 4, 14, 38 ], "is": [ 5, 59 ], "well": [ 6 ], "tolerated": [ 7 ], "up": [ 8 ], "to": [ 9, 42, 54 ], "2": [ 10, 68 ], "mg": [ 11 ], "daily.": [ 12 ], "While": [ 13 ], "caused": [ 15 ], "transient": [ 16 ], "gastrointestinal": [ 17 ], "side": [ 18 ], "effects,": [ 19 ], "this": [ 20 ], "rarely": [ 21 ], "interfered": [ 22 ], "with": [ 23 ], "continuing": [ 24 ], "treatment.": [ 25 ], "An": [ 26 ], "improvement": [ 27 ], "in": [ 28, 32, 52 ], "FSG": [ 29 ], "over": [ 30 ], "that": [ 31 ], "control": [ 33 ], "groups": [ 34 ], "was": [ 35, 50 ], "seen": [ 36 ], "for": [ 37, 63 ], "as": [ 39 ], "an": [ 40 ], "add-on": [ 41 ], "metformin.": [ 43 ], "In": [ 44 ], "the": [ 45, 64 ], "latter": [ 46 ], "case,": [ 47 ], "body": [ 48 ], "weight": [ 49 ], "reduced": [ 51 ], "comparison": [ 53 ], "metformin": [ 55 ], "plus": [ 56 ], "glimepiride.": [ 57 ], "Liraglutide": [ 58 ], "promising": [ 61 ], "drug": [ 62 ], "treatment": [ 65 ], "of": [ 66 ], "type": [ 67 ], "diabetes.": [ 69 ] }, "publication_date": "2006-10-13", "publication_year": 2006, "type": "article", "cited_by_count": 140, "authors": [ { "id": "https://openalex.org/A5079071370", "display_name": "M. Nauck" }, { "id": "https://openalex.org/A5044166679", "display_name": "Marcus Hompesch" }, { "id": "https://openalex.org/A5055762193", "display_name": "R. Filipczak" }, { "id": "https://openalex.org/A5101966548", "display_name": "Thanh Van Le" }, { "id": "https://openalex.org/A5059007137", "display_name": "Marija Zdravkovi\u0107" }, { "id": "https://openalex.org/A5011207294", "display_name": "Jakub Gumprecht" } ] }, { "id": "https://openalex.org/W1557569792", "doi": "https://doi.org/10.1111/j.2040-1124.2011.00168.x", "title": "Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin\u2010secreting capacity", "abstract": { "Abstract": [ 0 ], "Aims/Introduction:": [ 1 ], "Recently,": [ 2 ], "glucagon\u2010like": [ 3 ], "peptide\u20101": [ 4 ], "(GLP\u20101)": [ 5 ], "receptor": [ 6 ], "agonists": [ 7 ], "of": [ 8, 52, 96, 117, 127, 151, 175, 197, 213, 224 ], "liraglutide": [ 9, 97, 176, 225 ], "have": [ 10 ], "become": [ 11 ], "available": [ 12 ], "in": [ 13, 115, 124, 156, 160, 226 ], "Japan.": [ 14 ], "It": [ 15 ], "has": [ 16 ], "not": [ 17 ], "yet": [ 18 ], "been": [ 19 ], "clarified": [ 20 ], "what": [ 21 ], "clinical": [ 22 ], "parameters": [ 23, 126, 219 ], "could": [ 24 ], "discriminate": [ 25 ], "liraglutide\u2010effective": [ 26, 145, 157 ], "patients": [ 27, 38, 54, 158, 227 ], "from": [ 28 ], "liraglutide\u2010ineffective": [ 29, 161 ], "patients.": [ 30, 119, 148, 162 ], "Materials": [ 31 ], "and": [ 32, 72, 77, 84, 140, 146, 192, 210 ], "Methods:": [ 33 ], "We": [ 34 ], "reviewed": [ 35 ], "23": [ 36, 118 ], "consecutive": [ 37 ], "with": [ 39, 57, 228 ], "type": [ 40, 198, 214, 229 ], "2": [ 41, 199, 215, 230 ], "diabetes": [ 42, 152, 216 ], "admitted": [ 43 ], "to": [ 44, 66, 101 ], "Osaka": [ 45 ], "University": [ 46 ], "Hospital": [ 47 ], "for": [ 48, 171, 179, 182, 186, 190, 195, 220 ], "glycemic": [ 49, 103 ], "control.": [ 50 ], "All": [ 51 ], "the": [ 53, 108, 125, 168, 173, 211, 222 ], "were": [ 55, 87, 121, 217 ], "treated": [ 56 ], "diet": [ 58 ], "plus": [ 59, 62 ], "insulin": [ 60, 82, 85, 89, 128 ], "(or": [ 61 ], "oral": [ 63 ], "antidiabetic": [ 64 ], "drugs)": [ 65 ], "improve": [ 67 ], "fasting": [ 68, 131 ], "plasma": [ 69 ], "glucose": [ 70, 74 ], "(FPG)": [ 71 ], "postprandial": [ 73 ], "below": [ 75 ], "150": [ 76 ], "200": [ 78 ], "mg/dL,": [ 79 ], "respectively.": [ 80 ], "After": [ 81 ], "secretion": [ 83, 203 ], "resistance": [ 86 ], "evaluated,": [ 88 ], "was": [ 90, 98, 105, 113, 153, 177 ], "replaced": [ 91 ], "by": [ 92, 205 ], "liraglutide.": [ 93 ], "The": [ 94, 149 ], "efficacy": [ 95, 174, 223 ], "determined": [ 99 ], "according": [ 100 ], "whether": [ 102 ], "control": [ 104 ], "maintained": [ 106 ], "at": [ 107 ], "target": [ 109 ], "levels.": [ 110 ], "Results:": [ 111 ], "Liraglutide": [ 112 ], "effective": [ 114 ], "13": [ 116 ], "There": [ 120 ], "significant": [ 122 ], "differences": [ 123 ], "secretion,": [ 129 ], "including": [ 130 ], "C\u2010peptide": [ 132, 134, 142 ], "(F\u2010CPR),": [ 133 ], "index": [ 135, 138 ], "(CPI),": [ 136 ], "insulinogenic": [ 137 ], "(I.I.)": [ 139 ], "urine": [ 141 ], "(U\u2010CPR),": [ 143 ], "between": [ 144 ], "\u2010ineffective": [ 147 ], "duration": [ 150, 196, 212 ], "significantly": [ 154 ], "shorter": [ 155 ], "than": [ 159 ], "In": [ 163 ], "receiver": [ 164 ], "operating": [ 165 ], "characteristic": [ 166 ], "analyses,": [ 167 ], "cut\u2010off": [ 169 ], "value": [ 170 ], "predicting": [ 172, 221 ], "0.14": [ 178 ], "I.I.,": [ 180, 208 ], "1.1": [ 181 ], "CPI,": [ 183, 207 ], "1.5": [ 184 ], "ng/mL": [ 185 ], "F\u2010CPR,": [ 187, 206 ], "33.3": [ 188 ], "\u03bcg/day": [ 189 ], "U\u2010CPR": [ 191, 209 ], "19.5": [ 193 ], "years": [ 194 ], "diabetes.": [ 200, 231 ], "Conclusions:": [ 201 ], "Insulin": [ 202 ], "evaluated": [ 204 ], "useful": [ 218 ], "(J": [ 232 ], "Diabetes": [ 233 ], "Invest,": [ 234 ], "doi:": [ 235 ], "10.1111/j.2040\u20101124.2011.00168.x,": [ 236 ], "2011)": [ 237 ] }, "publication_date": "2011-10-11", "publication_year": 2011, "type": "article", "cited_by_count": 44, "authors": [ { "id": "https://openalex.org/A5067533233", "display_name": "Junji Kozawa" }, { "id": "https://openalex.org/A5113602063", "display_name": "Kana Inoue" }, { "id": "https://openalex.org/A5002490822", "display_name": "Ryuya Iwamoto" }, { "id": "https://openalex.org/A5050226686", "display_name": "Yukiko Kurashiki" }, { "id": "https://openalex.org/A5090877060", "display_name": "Yukiyoshi Okauchi" }, { "id": "https://openalex.org/A5088194019", "display_name": "Susumu Kashine" }, { "id": "https://openalex.org/A5103217195", "display_name": "Tetsuhiro Kitamura" }, { "id": "https://openalex.org/A5045989814", "display_name": "Norikazu Maeda" }, { "id": "https://openalex.org/A5113826717", "display_name": "Kohei Okita" }, { "id": "https://openalex.org/A5083356005", "display_name": "Hiromi Iwahashi" }, { "id": "https://openalex.org/A5110046673", "display_name": "Tohru Funahashi" }, { "id": "https://openalex.org/A5013468065", "display_name": "Akihisa Imagawa" }, { "id": "https://openalex.org/A5037246488", "display_name": "Iichiro Shimomura" } ] }, { "id": "https://openalex.org/W2067204442", "doi": "https://doi.org/10.1016/j.nut.2009.07.008", "title": "Exenatide and weight loss", "abstract": null, "publication_date": "2010-02-12", "publication_year": 2010, "type": "review", "cited_by_count": 57, "authors": [ { "id": "https://openalex.org/A5038494048", "display_name": "David Bradley" }, { "id": "https://openalex.org/A5063494081", "display_name": "Roger Kulstad" }, { "id": "https://openalex.org/A5085602557", "display_name": "Dale A. Schoeller" } ] }, { "id": "https://openalex.org/W2905966229", "doi": "https://doi.org/10.1001/jamanetworkopen.2018.6125", "title": "Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes", "abstract": { "Among": [ 0 ], "insured": [ 1 ], "adult": [ 2 ], "patients": [ 3 ], "with": [ 4, 32, 40 ], "type": [ 5 ], "2": [ 6 ], "diabetes": [ 7 ], "initiating": [ 8 ], "second-line": [ 9 ], "ADM": [ 10, 42 ], "therapy,": [ 11 ], "the": [ 12 ], "short-term": [ 13 ], "cardiovascular": [ 14, 28 ], "outcomes": [ 15 ], "of": [ 16, 34 ], "GLP-1": [ 17, 48 ], "receptor": [ 18, 49 ], "agonists,": [ 19, 50 ], "SGLT-2": [ 20, 51 ], "inhibitors,": [ 21, 52 ], "and": [ 22 ], "DPP-4": [ 23, 54 ], "inhibitors": [ 24, 55 ], "were": [ 25 ], "similar.": [ 26 ], "Higher": [ 27 ], "risk": [ 29 ], "was": [ 30 ], "associated": [ 31 ], "use": [ 33 ], "sulfonylureas": [ 35, 62 ], "or": [ 36, 53, 63 ], "basal": [ 37, 64 ], "insulin": [ 38 ], "compared": [ 39 ], "newer": [ 41 ], "classes.": [ 43 ], "Clinicians": [ 44 ], "may": [ 45 ], "consider": [ 46 ], "prescribing": [ 47 ], "more": [ 56 ], "routinely": [ 57 ], "after": [ 58 ], "metformin": [ 59 ], "rather": [ 60 ], "than": [ 61 ], "insulin.": [ 65 ] }, "publication_date": "2018-12-21", "publication_year": 2018, "type": "article", "cited_by_count": 119, "authors": [ { "id": "https://openalex.org/A5004619468", "display_name": "Matthew J. O\u2019Brien" }, { "id": "https://openalex.org/A5044397430", "display_name": "Susan Karam" }, { "id": "https://openalex.org/A5071437513", "display_name": "Amisha Wallia" }, { "id": "https://openalex.org/A5014548361", "display_name": "Raymond Kang" }, { "id": "https://openalex.org/A5101689627", "display_name": "Andrew Cooper" }, { "id": "https://openalex.org/A5003480484", "display_name": "Nicola Lancki" }, { "id": "https://openalex.org/A5023073575", "display_name": "Margaret Moran" }, { "id": "https://openalex.org/A5025331388", "display_name": "David T. Liss" }, { "id": "https://openalex.org/A5065732172", "display_name": "Theodore A. Prospect" }, { "id": "https://openalex.org/A5026841591", "display_name": "Ronald T. Ackermann" } ] }, { "id": "https://openalex.org/W4384821648", "doi": "https://doi.org/10.7759/cureus.42153", "title": "Anesthesia Considerations for a Patient on Semaglutide and Delayed Gastric Emptying", "abstract": { "Semaglutide": [ 0 ], "is": [ 1, 142 ], "a": [ 2, 25, 30, 123 ], "class": [ 3, 46 ], "of": [ 4, 15, 34, 44, 77, 81, 94, 101, 108, 135, 151 ], "long-acting": [ 5 ], "glucagon-like": [ 6 ], "peptide-1": [ 7 ], "receptor": [ 8 ], "agonists": [ 9 ], "(GLP1-RA)": [ 10 ], "used": [ 11 ], "for": [ 12, 64, 112 ], "the": [ 13, 73, 78, 89, 95, 99, 106, 145, 149 ], "treatment": [ 14 ], "type": [ 16 ], "2": [ 17 ], "diabetes": [ 18 ], "mellitus": [ 19 ], "(T2DM)": [ 20 ], "and": [ 21, 38, 55, 118 ], "obesity.": [ 22 ], "We": [ 23 ], "present": [ 24, 143 ], "31-year-old": [ 26 ], "female": [ 27 ], "patient": [ 28 ], "with": [ 29 ], "past": [ 31 ], "medical": [ 32 ], "history": [ 33 ], "T2DM": [ 35 ], "without": [ 36 ], "complication": [ 37 ], "no": [ 39, 140 ], "long-term": [ 40 ], "or": [ 41 ], "current": [ 42 ], "use": [ 43 ], "insulin,": [ 45 ], "3": [ 47 ], "obesity,": [ 48 ], "hypertension,": [ 49 ], "hyperlipidemia,": [ 50 ], "polycystic": [ 51 ], "ovary": [ 52 ], "syndrome": [ 53 ], "(PCOS),": [ 54 ], "anxiety,": [ 56 ], "who": [ 57 ], "underwent": [ 58 ], "an": [ 59 ], "esophagogastroduodenoscopy": [ 60 ], "(EGD)": [ 61 ], "in": [ 62, 88, 144 ], "preparation": [ 63 ], "bariatric": [ 65 ], "surgery": [ 66 ], "while": [ 67 ], "taking": [ 68, 129 ], "semaglutide.": [ 69 ], "Despite": [ 70 ], "appropriately": [ 71 ], "following": [ 72 ], "preoperative": [ 74, 109 ], "fasting": [ 75, 110 ], "guidelines": [ 76, 111 ], "American": [ 79 ], "Society": [ 80 ], "Anesthesiologists": [ 82 ], "(ASA),": [ 83 ], "endoscopy": [ 84 ], "revealed": [ 85 ], "food": [ 86, 141 ], "residue": [ 87 ], "gastric": [ 90, 120 ], "body,": [ 91 ], "necessitating": [ 92 ], "abortion": [ 93 ], "procedure": [ 96 ], "to": [ 97, 116, 138, 147 ], "reduce": [ 98 ], "risk": [ 100, 150 ], "intraoperative": [ 102 ], "pulmonary": [ 103, 152 ], "aspiration.": [ 104 ], "Given": [ 105 ], "lack": [ 107 ], "patients": [ 113, 128 ], "on": [ 114 ], "semaglutide": [ 115 ], "date,": [ 117 ], "delayed": [ 119 ], "emptying": [ 121 ], "being": [ 122 ], "known": [ 124 ], "side": [ 125 ], "effect": [ 126 ], "among": [ 127 ], "semaglutide,": [ 130 ], "anesthesiologists": [ 131 ], "should": [ 132 ], "be": [ 133 ], "aware": [ 134 ], "alternative": [ 136 ], "methods": [ 137 ], "ensure": [ 139 ], "stomach": [ 146 ], "mitigate": [ 148 ], "aspiration": [ 153 ], "during": [ 154 ], "general": [ 155 ], "anesthesia.": [ 156 ] }, "publication_date": "2023-07-19", "publication_year": 2023, "type": "article", "cited_by_count": 66, "authors": [ { "id": "https://openalex.org/A5092500441", "display_name": "Erina Fujino" }, { "id": "https://openalex.org/A5071487048", "display_name": "Kathryn W Cobb" }, { "id": "https://openalex.org/A5087506715", "display_name": "Jay Schoenherr" }, { "id": "https://openalex.org/A5066681297", "display_name": "Lindsey N. Gouker" }, { "id": "https://openalex.org/A5078274721", "display_name": "Elisa Lund" } ] }, { "id": "https://openalex.org/W2898592605", "doi": "https://doi.org/10.1152/ajprenal.00432.2018", "title": "Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus", "abstract": { "Glucagon-like": [ 0 ], "peptide-1": [ 1 ], "(GLP-1)": [ 2 ], "receptor": [ 3 ], "agonists": [ 4 ], "(RAs)": [ 5 ], "are": [ 6, 37 ], "well-established": [ 7 ], "glucose-lowering": [ 8 ], "drugs": [ 9 ], "for": [ 10 ], "type": [ 11 ], "2": [ 12 ], "diabetes": [ 13 ], "mellitus": [ 14 ], "(T2DM)": [ 15 ], "management.": [ 16 ], "Acute": [ 17 ], "GLP-1RA": [ 18, 35 ], "administration": [ 19 ], "increases": [ 20, 207 ], "urinary": [ 21, 118, 150, 182, 194, 201, 208 ], "excretion": [ 22, 183, 202 ], "of": [ 23, 33, 44, 54, 111, 128, 184, 203, 220 ], "sodium": [ 24 ], "and": [ 25, 108, 114, 116, 125, 131, 188, 190, 206 ], "other": [ 26 ], "electrolytes.": [ 27 ], "However,": [ 28 ], "the": [ 29, 50, 165, 178, 181, 191, 241 ], "renal": [ 30, 51 ], "tubular": [ 31, 52 ], "effects": [ 32, 53, 237 ], "prolonged": [ 34 ], "treatment": [ 36, 56 ], "largely": [ 38 ], "unknown.": [ 39 ], "In": [ 40, 120, 196 ], "this": [ 41 ], "secondary": [ 42 ], "analysis": [ 43 ], "a": [ 45, 61, 102, 228 ], "randomized": [ 46 ], "trial,": [ 47 ], "we": [ 48 ], "determined": [ 49 ], "8-wk": [ 55 ], "with": [ 57, 138, 174, 211 ], "20": [ 58 ], "\u03bcg": [ 59 ], "lixisenatide,": [ 60 ], "short-acting": [ 62 ], "(prandial)": [ 63 ], "GLP-1RA,": [ 64 ], "versus": [ 65 ], "titrated": [ 66 ], "once-daily": [ 67 ], "insulin": [ 68, 76, 156, 212 ], "glulisine": [ 69, 157, 213 ], "in": [ 70, 149, 164, 170, 180, 193, 214, 231, 240 ], "35": [ 71 ], "overweight": [ 72 ], "T2DM-patients": [ 73 ], "on": [ 74, 155, 238 ], "stable": [ 75 ], "glargine": [ 77 ], "background": [ 78 ], "therapy": [ 79 ], "(age:": [ 80 ], "62": [ 81 ], "\u00b1": [ 82, 88 ], "7": [ 83 ], "yr,": [ 84 ], "glycated": [ 85 ], "hemoglobin:": [ 86 ], "8.0": [ 87 ], "0.9%,": [ 89 ], "estimated": [ 90 ], "glomerular": [ 91 ], "filtration": [ 92 ], "rate:": [ 93 ], ">60": [ 94 ], "ml\u00b7min": [ 95 ], "\u22121": [ 96 ], "\u00b71.73": [ 97 ], "m": [ 98 ], "\u22122": [ 99 ], ").": [ 100 ], "After": [ 101 ], "standardized": [ 103 ], "breakfast,": [ 104 ], "lixisenatide": [ 105, 122, 139, 175, 198 ], "increased": [ 106, 117 ], "absolute": [ 107, 124 ], "fractional": [ 109, 126 ], "excretions": [ 110, 127 ], "sodium,": [ 112, 185 ], "chloride,": [ 113 ], "potassium": [ 115 ], "pH.": [ 119, 195 ], "contrast,": [ 121 ], "reduced": [ 123 ], "magnesium,": [ 129, 187 ], "calcium,": [ 130 ], "phosphate.": [ 132 ], "At": [ 133 ], "week": [ 134 ], "8,": [ 135 ], "patients": [ 136, 216 ], "treated": [ 137 ], "had": [ 140 ], "significantly": [ 141 ], "more": [ 142 ], "phosphorylated": [ 143 ], "sodium-hydrogen": [ 144 ], "exchanger": [ 145 ], "isoform": [ 146 ], "3": [ 147 ], "(NHE3)": [ 148 ], "extracellular": [ 151 ], "vesicles": [ 152 ], "than": [ 153 ], "those": [ 154 ], "treatment,": [ 158 ], "which": [ 159 ], "suggested": [ 160 ], "decreased": [ 161 ], "NHE3": [ 162, 239 ], "activity": [ 163 ], "proximal": [ 166, 242 ], "tubule.": [ 167, 243 ], "A": [ 168 ], "rise": [ 169, 230 ], "postprandial": [ 171, 200 ], "blood": [ 172, 232 ], "pressure": [ 173, 233 ], "partly": [ 176 ], "explained": [ 177, 226 ], "changes": [ 179, 192 ], "potassium,": [ 186 ], "phosphate": [ 189 ], "conclusion,": [ 197 ], "affects": [ 199 ], "several": [ 204 ], "electrolytes": [ 205 ], "pH": [ 209 ], "compared": [ 210 ], "T2DM": [ 215 ], "after": [ 217 ], "8": [ 218 ], "wk": [ 219 ], "treatment.": [ 221 ], "This": [ 222 ], "is": [ 223 ], "most": [ 224 ], "likely": [ 225 ], "by": [ 227 ], "drug-induced": [ 229 ], "or": [ 234 ], "direct": [ 235 ], "inhibitory": [ 236 ] }, "publication_date": "2018-10-24", "publication_year": 2018, "type": "article", "cited_by_count": 44, "authors": [ { "id": "https://openalex.org/A5067721247", "display_name": "Lennart Tonneijck" }, { "id": "https://openalex.org/A5084278641", "display_name": "Marcel H.A. Muskiet" }, { "id": "https://openalex.org/A5028444678", "display_name": "Charles J. Blijdorp" }, { "id": "https://openalex.org/A5091895526", "display_name": "Mark M. Smits" }, { "id": "https://openalex.org/A5048711005", "display_name": "Jos W. R. Twisk" }, { "id": "https://openalex.org/A5028760009", "display_name": "Mark H.H. Kramer" }, { "id": "https://openalex.org/A5046295598", "display_name": "A.H. Jan Danser" }, { "id": "https://openalex.org/A5109335776", "display_name": "Micha\u00ebla Diamant" }, { "id": "https://openalex.org/A5062438369", "display_name": "Jaap A. Joles" }, { "id": "https://openalex.org/A5027968873", "display_name": "Ewout J. Hoorn" }, { "id": "https://openalex.org/A5067127165", "display_name": "Dani\u00ebl H. van Raalte" } ] }, { "id": "https://openalex.org/W2887818584", "doi": "https://doi.org/10.1016/j.bbr.2018.08.006", "title": "Neural correlates of liraglutide effects in persons at risk for Alzheimer\u2019s disease", "abstract": null, "publication_date": "2018-08-09", "publication_year": 2018, "type": "article", "cited_by_count": 116, "authors": [ { "id": "https://openalex.org/A5065708220", "display_name": "Kathleen Watson" }, { "id": "https://openalex.org/A5113848408", "display_name": "Tonita Wroolie" }, { "id": "https://openalex.org/A5039089089", "display_name": "Gabby Tong" }, { "id": "https://openalex.org/A5030767579", "display_name": "Lara C. Foland\u2010Ross" }, { "id": "https://openalex.org/A5015454510", "display_name": "Sophia Frangou" }, { "id": "https://openalex.org/A5062405101", "display_name": "Manpreet K. Singh" }, { "id": "https://openalex.org/A5068850044", "display_name": "Roger S. McIntyre" }, { "id": "https://openalex.org/A5011862507", "display_name": "Siena Roat-Shumway" }, { "id": "https://openalex.org/A5055256583", "display_name": "Alison Myoraku" }, { "id": "https://openalex.org/A5046688401", "display_name": "Allan L. Reiss" }, { "id": "https://openalex.org/A5061342108", "display_name": "Natalie Rasgon" } ] }, { "id": "https://openalex.org/W2931543462", "doi": "https://doi.org/10.3390/ijms20071584", "title": "Dulaglutide Modulates the Development of Tissue-Infiltrating Th1/Th17 Cells and the Pathogenicity of Encephalitogenic Th1 Cells in the Central Nervous System", "abstract": { "GLP-1": [ 0, 49, 66, 84 ], "(glucagon-like": [ 1 ], "peptide-1)": [ 2 ], "has": [ 3 ], "been": [ 4 ], "reported": [ 5 ], "to": [ 6, 24, 89, 140 ], "play": [ 7 ], "a": [ 8, 18, 29, 82 ], "vital": [ 9 ], "role": [ 10 ], "in": [ 11, 33, 76, 133, 163, 198 ], "neuroprotection.": [ 12 ], "Experimental": [ 13 ], "autoimmune": [ 14 ], "encephalomyelitis": [ 15 ], "(EAE)": [ 16 ], "is": [ 17, 63 ], "well-established": [ 19, 83 ], "animal": [ 20 ], "model": [ 21 ], "widely": [ 22 ], "used": [ 23 ], "study": [ 25 ], "human": [ 26 ], "multiple": [ 27 ], "sclerosis,": [ 28 ], "chronic": [ 30 ], "demyelination": [ 31 ], "disease": [ 32 ], "the": [ 34, 45, 54, 70, 77, 99, 103, 112, 134, 142, 156, 164, 174, 180 ], "central": [ 35 ], "nervous": [ 36 ], "system": [ 37 ], "(CNS).": [ 38 ], "Recently,": [ 39 ], "important": [ 40 ], "studies": [ 41 ], "have": [ 42 ], "designated": [ 43 ], "that": [ 44, 171 ], "signaling": [ 46, 68 ], "axis": [ 47 ], "of": [ 48, 59, 72, 102, 118, 123, 137, 145, 158, 176, 182 ], "and": [ 50, 57, 96, 115, 127, 148, 161, 179 ], "its": [ 51 ], "receptor": [ 52, 67, 85 ], "controls": [ 53 ], "clinical": [ 55, 113 ], "manifestations": [ 56, 114 ], "pathogenesis": [ 58 ], "EAE.": [ 60, 119 ], "However,": [ 61 ], "it": [ 62 ], "elusive": [ 64 ], "whether": [ 65 ], "regulates": [ 69 ], "phenotype": [ 71 ], "autoreactive": [ 73 ], "T": [ 74, 195 ], "cells": [ 75, 101, 126, 160, 184, 189, 196 ], "CNS.": [ 78, 104, 135 ], "We": [ 79 ], "administered": [ 80 ], "dulaglutide,": [ 81 ], "agonist": [ 86 ], "(GLP-1": [ 87 ], "RA),": [ 88 ], "treat": [ 90 ], "EAE": [ 91, 200 ], "mice": [ 92 ], "prophylactically": [ 93 ], "or": [ 94 ], "semi-therapeutically": [ 95 ], "subsequently": [ 97 ], "analyzed": [ 98 ], "mononuclear": [ 100 ], "In": [ 105 ], "this": [ 106 ], "study,": [ 107 ], "dulaglutide": [ 108, 138, 172 ], "treatment": [ 109, 153 ], "significantly": [ 110 ], "alleviates": [ 111 ], "histopathological": [ 116 ], "outcomes": [ 117 ], "Dulaglutide": [ 120 ], "decreases": [ 121 ], "incidences": [ 122 ], "encephalitogenic": [ 124, 146, 177 ], "Th1/Th17": [ 125, 178 ], "Th1": [ 128, 147, 183 ], "granulocyte-macrophage-colony-stimulating": [ 129 ], "factor": [ 130 ], "(GM-CSF)": [ 131 ], "expression": [ 132 ], "Administration": [ 136 ], "failed": [ 139 ], "control": [ 141 ], "chemotactic": [ 143 ], "abilities": [ 144 ], "Th17": [ 149 ], "cells;": [ 150 ], "however,": [ 151 ], "prophylactic": [ 152 ], "considerably": [ 154 ], "decreased": [ 155 ], "populations": [ 157 ], "dendritic": [ 159 ], "macrophages": [ 162 ], "CNS": [ 165 ], "parenchyma.": [ 166 ], "These": [ 167 ], "results": [ 168 ], "obtained": [ 169 ], "indicate": [ 170 ], "modulates": [ 173 ], "differentiation": [ 175 ], "pathogenicity": [ 181 ], "by": [ 185, 201 ], "influencing": [ 186 ], "antigen": [ 187 ], "presenting": [ 188 ], "quantities,": [ 190 ], "providing": [ 191 ], "mechanism": [ 192 ], "insight": [ 193 ], "on": [ 194 ], "regulation": [ 197 ], "ameliorating": [ 199 ], "GLP-1.": [ 202 ] }, "publication_date": "2019-03-29", "publication_year": 2019, "type": "article", "cited_by_count": 39, "authors": [ { "id": "https://openalex.org/A5034081035", "display_name": "Hung\u2010Yi Chiou" }, { "id": "https://openalex.org/A5064631411", "display_name": "Ming\u2010Wei Lin" }, { "id": "https://openalex.org/A5084240133", "display_name": "Pi\u2010Jung Hsiao" }, { "id": "https://openalex.org/A5100697165", "display_name": "Chun\u2010Lin Chen" }, { "id": "https://openalex.org/A5088441166", "display_name": "Shiang Chiao" }, { "id": "https://openalex.org/A5080479396", "display_name": "Ting\u2010Yi Lin" }, { "id": "https://openalex.org/A5100450914", "display_name": "Yi\u2010Chen Chen" }, { "id": "https://openalex.org/A5057988975", "display_name": "Deng\u2010Chyang Wu" }, { "id": "https://openalex.org/A5082917185", "display_name": "Ming\u2010Hong Lin" } ] }, { "id": "https://openalex.org/W2590664415", "doi": "https://doi.org/10.1016/s0140-6736(17)30069-7", "title": "3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial", "abstract": null, "publication_date": "2017-02-23", "publication_year": 2017, "type": "article", "cited_by_count": 788, "authors": [ { "id": "https://openalex.org/A5010753663", "display_name": "Carel W. le Roux" }, { "id": "https://openalex.org/A5048067129", "display_name": "Arne Astrup" }, { "id": "https://openalex.org/A5077479009", "display_name": "Ken Fujioka" }, { "id": "https://openalex.org/A5080400693", "display_name": "Frank L. Greenway" }, { "id": "https://openalex.org/A5103533013", "display_name": "David Lau" }, { "id": "https://openalex.org/A5110682944", "display_name": "Luc Van Gaal" }, { "id": "https://openalex.org/A5114256392", "display_name": "Rafael Violante Ort\u00edz" }, { "id": "https://openalex.org/A5047195042", "display_name": "John Wilding" }, { "id": "https://openalex.org/A5041637994", "display_name": "Trine Vang Skj\u00f8th" }, { "id": "https://openalex.org/A5031134402", "display_name": "Linda Shapiro Manning" }, { "id": "https://openalex.org/A5025844791", "display_name": "F. Xavier Pi\u2010Sunyer" }, { "id": "https://openalex.org/A5108566994", "display_name": "A. Hamann" }, { "id": "https://openalex.org/A5053982862", "display_name": "Alain Barakat" }, { "id": "https://openalex.org/A5073471236", "display_name": "Matthias Bl\u00fcher" }, { "id": "https://openalex.org/A5064447648", "display_name": "Thomas Linn" }, { "id": "https://openalex.org/A5111635480", "display_name": "Andrea M\u00f6lle" }, { "id": "https://openalex.org/A5004281786", "display_name": "Alexander Segner" }, { "id": "https://openalex.org/A5037211699", "display_name": "Petra St\u00fcbler" }, { "id": "https://openalex.org/A5106661197", "display_name": "Regina Tosch-Sisting" }, { "id": "https://openalex.org/A5083770629", "display_name": "Furio Pacini" }, { "id": "https://openalex.org/A5041749393", "display_name": "Ferruccio Santini" }, { "id": "https://openalex.org/A5039273685", "display_name": "Giulio Marchesini" }, { "id": "https://openalex.org/A5068223964", "display_name": "Carlo Maria Rotella" }, { "id": "https://openalex.org/A5065105188", "display_name": "Cecilia Invitti" }, { "id": "https://openalex.org/A5025875546", "display_name": "Roberto Vettor" }, { "id": "https://openalex.org/A5052679600", "display_name": "Silvio Buscemi" }, { "id": "https://openalex.org/A5039297952", "display_name": "Pedro Mezquita Raya" }, { "id": "https://openalex.org/A5106661198", "display_name": "Felipe Casanueva Freijoo" }, { "id": "https://openalex.org/A5110475753", "display_name": "Ram\u00f3n Gomis de Barbar\u00e1" }, { "id": "https://openalex.org/A5082931469", "display_name": "Raffaele Carraro" }, { "id": "https://openalex.org/A5064701285", "display_name": "Enrique Romero Bobillo" }, { "id": "https://openalex.org/A5104004428", "display_name": "Carmen de la Cuesta" }, { "id": "https://openalex.org/A5108139218", "display_name": "Csaba Farsang" }, { "id": "https://openalex.org/A5030727395", "display_name": "Albert Cs\u00e1sz\u00e1r" }, { "id": "https://openalex.org/A5027647722", "display_name": "Barbara Zahorska\u2010Markiewicz" }, { "id": "https://openalex.org/A5062294790", "display_name": "Danuta Pupek-Musialik" }, { "id": "https://openalex.org/A5030909625", "display_name": "Edward Franek" }, { "id": "https://openalex.org/A5007563342", "display_name": "Lucyna Ostrowska" }, { "id": "https://openalex.org/A5058104418", "display_name": "Magdalena Olszanecka\u2010Glinianowicz" }, { "id": "https://openalex.org/A5000893155", "display_name": "Neboj\u0161a Lali\u0107" }, { "id": "https://openalex.org/A5056608368", "display_name": "Dragan Mici\u0107" }, { "id": "https://openalex.org/A5071354955", "display_name": "Bernhard Ludvik" }, { "id": "https://openalex.org/A5025058942", "display_name": "Bernhard Paulweber" }, { "id": "https://openalex.org/A5034967151", "display_name": "Rudolf Prager" }, { "id": "https://openalex.org/A5110475754", "display_name": "Andr\u00e9 Scheen" }, { "id": "https://openalex.org/A5110682944", "display_name": "Luc Van Gaal" }, { "id": "https://openalex.org/A5048067129", "display_name": "Arne Astrup" }, { "id": "https://openalex.org/A5088641715", "display_name": "Kjeld Hermansen" }, { "id": "https://openalex.org/A5062239390", "display_name": "Sten Madsbad" }, { "id": "https://openalex.org/A5104085781", "display_name": "Aila Rissanen" }, { "id": "https://openalex.org/A5107007886", "display_name": "Sakari Nieminen" }, { "id": "https://openalex.org/A5025549582", "display_name": "Markku J. Savolainen" }, { "id": "https://openalex.org/A5043484813", "display_name": "Michel Krempf" }, { "id": "https://openalex.org/A5105703944", "display_name": "Monique Romon" }, { "id": "https://openalex.org/A5108404606", "display_name": "M. Laville" }, { "id": "https://openalex.org/A5088350286", "display_name": "Michel Marre" }, { "id": "https://openalex.org/A5111646913", "display_name": "R Mira" }, { "id": "https://openalex.org/A5040975014", "display_name": "Francis Finucane" }, { "id": "https://openalex.org/A5106661199", "display_name": "Aletha Veenendaal" }, { "id": "https://openalex.org/A5014018904", "display_name": "Frank van Berkum" }, { "id": "https://openalex.org/A5106661200", "display_name": "Solrun Johannsson-Vidarsd\u00f3ttir" }, { "id": "https://openalex.org/A5106661201", "display_name": "V. Van de Walle" }, { "id": "https://openalex.org/A5034348972", "display_name": "Eelco W. Meesters" }, { "id": "https://openalex.org/A5079047032", "display_name": "J\u00f8ran Hjelmes\u00e6th" }, { "id": "https://openalex.org/A5079090451", "display_name": "Tor Ole Klemsdal" }, { "id": "https://openalex.org/A5110254682", "display_name": "B\u00e5rd Kulseng" }, { "id": "https://openalex.org/A5003897050", "display_name": "Birgit Bach-Kliegel" }, { "id": "https://openalex.org/A5012178025", "display_name": "Kurt Laederach" }, { "id": "https://openalex.org/A5003090187", "display_name": "Lukas Villiger" }, { "id": "https://openalex.org/A5107771860", "display_name": "Alain Golay" }, { "id": "https://openalex.org/A5067406711", "display_name": "Stefan Bilz" }, { "id": "https://openalex.org/A5062170233", "display_name": "Thozhukat Sathyapalan" }, { "id": "https://openalex.org/A5080463002", "display_name": "Stephen C. Bain" }, { "id": "https://openalex.org/A5086295953", "display_name": "Sudhesh Kumar" }, { "id": "https://openalex.org/A5108108550", "display_name": "Carel Wynard Le Roux" }, { "id": "https://openalex.org/A5012241596", "display_name": "Michael E. J. Lean" }, { "id": "https://openalex.org/A5021130189", "display_name": "Barbara McGowan" }, { "id": "https://openalex.org/A5111546680", "display_name": "Tariq Rehman" }, { "id": "https://openalex.org/A5047195042", "display_name": "John Wilding" }, { "id": "https://openalex.org/A5066189921", "display_name": "Gary Wittert" }, { "id": "https://openalex.org/A5017577899", "display_name": "Ian Caterson" }, { "id": "https://openalex.org/A5075507596", "display_name": "Joeseph Proietto" }, { "id": "https://openalex.org/A5017815672", "display_name": "John Prins" }, { "id": "https://openalex.org/A5014712431", "display_name": "Bruno Geloneze Neto" }, { "id": "https://openalex.org/A5102728954", "display_name": "Jorge Luiz Gross" }, { "id": "https://openalex.org/A5047323233", "display_name": "Ant\u00f4nio Roberto Chacra" }, { "id": "https://openalex.org/A5014511991", "display_name": "Alfredo Halpern" }, { "id": "https://openalex.org/A5113573796", "display_name": "Henrique Suplicy" }, { "id": "https://openalex.org/A5022902793", "display_name": "Francis Chun Chung Chow" }, { "id": "https://openalex.org/A5073134238", "display_name": "Hemant Thacker" }, { "id": "https://openalex.org/A5105530506", "display_name": "Manoj Chadha" }, { "id": "https://openalex.org/A5110475755", "display_name": "Hemaraj Chandalia" }, { "id": "https://openalex.org/A5033473100", "display_name": "AG Unnikrishnan" }, { "id": "https://openalex.org/A5112255433", "display_name": "Sanjay Kalra" }, { "id": "https://openalex.org/A5040058009", "display_name": "Neeta Deshpande" }, { "id": "https://openalex.org/A5113800006", "display_name": "Minakshi Shunmugavelu" }, { "id": "https://openalex.org/A5089805721", "display_name": "Vaishali Deshmukh" }, { "id": "https://openalex.org/A5025013377", "display_name": "Maximo Maislos" }, { "id": "https://openalex.org/A5112255434", "display_name": "G. Lieberman" }, { "id": "https://openalex.org/A5067846755", "display_name": "Ilan Shimon" } ] }, { "id": "https://openalex.org/W2141624924", "doi": "https://doi.org/10.2337/dc12-1925", "title": "Exenatide-Induced Reduction in Energy Intake Is Associated With Increase in Hypothalamic Connectivity", "abstract": { "OBJECTIVE": [ 0 ], "Glucagon-like": [ 1 ], "peptide-1": [ 2 ], "receptor": [ 3 ], "agonists": [ 4 ], "such": [ 5 ], "as": [ 6 ], "exenatide": [ 7, 74, 95, 105, 163, 190, 220 ], "are": [ 8 ], "known": [ 9 ], "to": [ 10, 20, 211 ], "influence": [ 11 ], "neural": [ 12 ], "activity": [ 13 ], "in": [ 14, 33, 64, 70, 96, 161, 176, 194 ], "the": [ 15, 142, 151, 157, 162, 195, 207, 213, 217 ], "hypothalamus": [ 16 ], "of": [ 17, 37, 94, 139, 150, 187, 219 ], "animals": [ 18 ], "and": [ 19, 47, 76, 112 ], "reduce": [ 21 ], "energy": [ 22, 71, 119, 222 ], "intake.": [ 23, 223 ], "In": [ 24, 53 ], "humans,": [ 25 ], "however,": [ 26 ], "significant": [ 27, 173 ], "weight": [ 28, 45 ], "loss": [ 29, 46 ], "has": [ 30 ], "been": [ 31 ], "observed": [ 32 ], "only": [ 34, 40, 193 ], "a": [ 35, 84, 137, 183 ], "subgroup": [ 36 ], "patients.": [ 38 ], "Why": [ 39 ], "some": [ 41 ], "individuals": [ 42 ], "respond": [ 43 ], "with": [ 44, 91, 103, 166 ], "others": [ 48 ], "do": [ 49 ], "not": [ 50, 170 ], "remains": [ 51 ], "unclear.": [ 52 ], "this": [ 54 ], "functional": [ 55 ], "magnetic": [ 56 ], "resonance": [ 57 ], "imaging": [ 58 ], "(fMRI)": [ 59 ], "study,": [ 60 ], "we": [ 61 ], "investigated": [ 62 ], "differences": [ 63 ], "hypothalamic": [ 65, 129, 177, 185, 208 ], "connectivity": [ 66, 130 ], "between": [ 67 ], "\u201cresponders\u201d": [ 68 ], "(reduction": [ 69 ], "intake": [ 72, 120 ], "after": [ 73 ], "infusion)": [ 75 ], "\u201cnonresponders.\u201d": [ 77 ], "RESEARCH": [ 78 ], "DESIGN": [ 79 ], "AND": [ 80 ], "METHODS": [ 81 ], "We": [ 82 ], "performed": [ 83 ], "randomized,": [ 85 ], "double-blinded,": [ 86 ], "placebo-controlled,": [ 87 ], "cross-over": [ 88 ], "fMRI": [ 89 ], "study": [ 90 ], "intravenous": [ 92 ], "administration": [ 93 ], "obese": [ 97 ], "male": [ 98 ], "volunteers.": [ 99 ], "During": [ 100 ], "brain": [ 101 ], "scanning": [ 102, 117 ], "continuous": [ 104 ], "or": [ 106 ], "placebo": [ 107 ], "administration,": [ 108 ], "participants": [ 109 ], "rated": [ 110 ], "food": [ 111, 158 ], "nonfood": [ 113 ], "images.": [ 114 ], "After": [ 115 ], "each": [ 116 ], "session,": [ 118 ], "was": [ 121, 131, 154 ], "measured": [ 122 ], "using": [ 123 ], "an": [ 124, 199 ], "ad": [ 125 ], "libitum": [ 126 ], "buffet.": [ 127 ], "Functional": [ 128 ], "assessed": [ 132 ], "by": [ 133 ], "eigenvector": [ 134 ], "centrality": [ 135 ], "mapping,": [ 136 ], "measure": [ 138 ], "connectedness": [ 140, 149 ], "throughout": [ 141 ], "brain.": [ 143 ], "RESULTS": [ 144 ], "Responders": [ 145 ], "showed": [ 146, 198 ], "significantly": [ 147 ], "higher": [ 148 ], "hypothalamus,": [ 152 ], "which": [ 153 ], "specific": [ 155 ], "for": [ 156, 216 ], "pictures": [ 159 ], "condition,": [ 160 ], "condition": [ 164 ], "compared": [ 165 ], "placebo.": [ 167 ], "Nonresponders": [ 168 ], "did": [ 169 ], "show": [ 171 ], "any": [ 172 ], "exenatide-induced": [ 174 ], "changes": [ 175 ], "connectedness.": [ 178 ], "CONCLUSIONS": [ 179 ], "Our": [ 180 ], "results": [ 181 ], "demonstrate": [ 182 ], "central": [ 184 ], "effect": [ 186, 218 ], "peripherally": [ 188 ], "administered": [ 189 ], "that": [ 191, 197, 206 ], "occurred": [ 192 ], "group": [ 196 ], "exenatide-dependent": [ 200 ], "anorexigenic": [ 201 ], "effect.": [ 202 ], "These": [ 203 ], "findings": [ 204 ], "indicate": [ 205 ], "response": [ 209 ], "seems": [ 210 ], "be": [ 212 ], "crucial": [ 214 ], "factor": [ 215 ], "on": [ 221 ] }, "publication_date": "2013-03-06", "publication_year": 2013, "type": "article", "cited_by_count": 86, "authors": [ { "id": "https://openalex.org/A5037057856", "display_name": "Haiko Schl\u00f6gl" }, { "id": "https://openalex.org/A5057177496", "display_name": "Stefan Kabisch" }, { "id": "https://openalex.org/A5023403405", "display_name": "Annette Horstmann" }, { "id": "https://openalex.org/A5057758584", "display_name": "Gabriele Lohmann" }, { "id": "https://openalex.org/A5108156548", "display_name": "Karsten M\u00fcller" }, { "id": "https://openalex.org/A5110454115", "display_name": "J\u00f6ran Lepsien" }, { "id": "https://openalex.org/A5082456774", "display_name": "F.P. Busse-Voigt" }, { "id": "https://openalex.org/A5113181929", "display_name": "J\u00fcrgen Kratzsch" }, { "id": "https://openalex.org/A5063936949", "display_name": "Burkhard Pleger" }, { "id": "https://openalex.org/A5020270555", "display_name": "Arno Villringer" }, { "id": "https://openalex.org/A5053898553", "display_name": "Michael St\u00fcmvoll" } ] }, { "id": "https://openalex.org/W91242618", "doi": "https://doi.org/10.1331/japha.2009.09079", "title": "Efficacy and safety of incretin-based therapies: Clinical trial data", "abstract": null, "publication_date": "2009-09-01", "publication_year": 2009, "type": "review", "cited_by_count": 74, "authors": [ { "id": "https://openalex.org/A5057977258", "display_name": "John R. White" } ] }, { "id": "https://openalex.org/W2145924144", "doi": "https://doi.org/10.1111/j.1464-5491.2007.02333.x", "title": "Liraglutide, a once\u2010daily human GLP\u20101 analogue, improves pancreatic B\u2010cell function and arginine\u2010stimulated insulin secretion during hyperglycaemia in patients with Type\u00a02 diabetes mellitus", "abstract": { "Abstract": [ 0 ], "Aims": [ 1 ], "To": [ 2 ], "assess": [ 3 ], "the": [ 4, 54, 83, 124, 136 ], "effect": [ 5, 157 ], "of": [ 6, 53, 82, 96, 167 ], "liraglutide,": [ 7 ], "a": [ 8, 68 ], "once\u2010daily": [ 9 ], "human": [ 10 ], "glucagon\u2010like": [ 11 ], "peptide\u20101": [ 12 ], "analogue": [ 13 ], "on": [ 14, 158 ], "pancreatic": [ 15 ], "B\u2010cell": [ 16 ], "function.": [ 17 ], "Methods": [ 18 ], "Patients": [ 19 ], "with": [ 20, 32, 169, 180 ], "Type": [ 21 ], "2": [ 22 ], "diabetes": [ 23 ], "(": [ 24, 112, 148 ], "n": [ 25 ], "=": [ 26 ], "39)": [ 27 ], "were": [ 28, 49, 78 ], "randomized": [ 29 ], "to": [ 30 ], "treatment": [ 31, 156, 168 ], "0.65,": [ 33 ], "1.25": [ 34, 125 ], "or": [ 35, 39, 161 ], "1.9": [ 36, 100 ], "mg/day": [ 37, 126 ], "liraglutide": [ 38, 97, 170 ], "placebo": [ 40, 142 ], "for": [ 41 ], "14": [ 42 ], "weeks.": [ 43 ], "First\u2010": [ 44 ], "and": [ 45, 75, 99, 109, 145, 175 ], "second\u2010phase": [ 46, 176 ], "insulin": [ 47, 63, 76, 105, 117, 131, 162, 177, 184 ], "release": [ 48 ], "measured": [ 50, 66 ], "by": [ 51, 80, 107, 143 ], "means": [ 52, 81 ], "insulin\u2010modified": [ 55, 84 ], "frequently": [ 56, 85 ], "sampled": [ 57, 86 ], "intravenous": [ 58, 87 ], "glucose": [ 59, 88, 159 ], "tolerance": [ 60, 89 ], "test.": [ 61, 90 ], "Arginine\u2010stimulated": [ 62, 130 ], "secretion": [ 64, 106, 118, 132, 185 ], "was": [ 65, 119, 153 ], "during": [ 67, 186 ], "hyperglycaemic": [ 69 ], "clamp": [ 70 ], "(20": [ 71 ], "mmol/l).": [ 72 ], "Glucose": [ 73 ], "effectiveness": [ 74, 160 ], "sensitivity": [ 77 ], "estimated": [ 79 ], "Results": [ 91 ], "The": [ 92 ], "two": [ 93, 137 ], "highest": [ 94, 138 ], "doses": [ 95 ], "(1.25": [ 98 ], "mg/day)": [ 101 ], "significantly": [ 102, 120, 134 ], "increased": [ 103, 121, 133 ], "first\u2010phase": [ 104 ], "118": [ 108 ], "103%,": [ 110 ], "respectively": [ 111, 147 ], "P": [ 113, 149 ], "<": [ 114, 150 ], "0.05).": [ 115, 151 ], "Second\u2010phase": [ 116 ], "only": [ 122 ], "in": [ 123, 173, 182 ], "group": [ 127 ], "vs.": [ 128, 141 ], "placebo.": [ 129 ], "at": [ 135 ], "dose": [ 139 ], "levels": [ 140 ], "114": [ 144 ], "94%,": [ 146 ], "There": [ 152 ], "no": [ 154 ], "significant": [ 155 ], "sensitivity.": [ 163 ], "Conclusions": [ 164 ], "Fourteen": [ 165 ], "weeks": [ 166 ], "showed": [ 171 ], "improvements": [ 172, 181 ], "first\u2010": [ 174 ], "secretion,": [ 178 ], "together": [ 179 ], "arginine\u2010stimulated": [ 183 ], "hyperglycaemia.": [ 187 ] }, "publication_date": "2008-01-21", "publication_year": 2008, "type": "article", "cited_by_count": 210, "authors": [ { "id": "https://openalex.org/A5060033937", "display_name": "T. Vilsb\u00f8ll" }, { "id": "https://openalex.org/A5066663009", "display_name": "Birgitte Brock" }, { "id": "https://openalex.org/A5022699151", "display_name": "Hans Perrild" }, { "id": "https://openalex.org/A5036986704", "display_name": "Klaus Levin" }, { "id": "https://openalex.org/A5109515298", "display_name": "Hans-Henrik Lervang" }, { "id": "https://openalex.org/A5023352813", "display_name": "Klaus K\u00f8lendorf" }, { "id": "https://openalex.org/A5018061859", "display_name": "Thure Krarup" }, { "id": "https://openalex.org/A5108600845", "display_name": "O. Schmitz" }, { "id": "https://openalex.org/A5017200089", "display_name": "Milan Zdravkovi\u0107" }, { "id": "https://openalex.org/A5087556486", "display_name": "T Le-Thi" }, { "id": "https://openalex.org/A5062239390", "display_name": "Sten Madsbad" } ] }, { "id": "https://openalex.org/W2176260350", "doi": "https://doi.org/10.2337/diaspect.28.4.283", "title": "Injection-Site Nodules Associated With the Use of Exenatide Extended-Release Reported to the U.S. Food and Drug Administration Adverse Event Reporting System", "abstract": { "Glucagon-like": [ 0 ], "peptide-1": [ 1 ], "(GLP-1)": [ 2 ], "receptor": [ 3, 34, 94, 124, 213 ], "agonists": [ 4, 95, 125 ], "are": [ 5, 52, 58, 96, 192 ], "safe": [ 6 ], "and": [ 7, 11, 46, 56, 62, 71, 161, 188, 198, 264 ], "effective": [ 8 ], "U.S.": [ 9, 209, 276 ], "Food": [ 10 ], "Drug": [ 12 ], "Administration": [ 13 ], "(FDA)-approved": [ 14 ], "drug": [ 15, 120, 150, 180 ], "products": [ 16, 181 ], "for": [ 17, 80 ], "use": [ 18 ], "in": [ 19, 121, 138, 176, 274, 286, 292 ], "the": [ 20, 28, 76, 105, 148, 202, 208, 216, 223, 227, 246, 275 ], "treatment": [ 21 ], "of": [ 22, 49, 69, 104, 108, 113, 179, 204, 218, 225, 231 ], "type": [ 23 ], "2": [ 24 ], "diabetes.": [ 25 ], "To": [ 26 ], "date,": [ 27 ], "FDA": [ 29, 228 ], "has": [ 30 ], "approved": [ 31, 79, 277 ], "five": [ 32 ], "GLP-1": [ 33, 93, 123, 212 ], "agonist": [ 35, 214 ], "parenteral": [ 36 ], "formulations:": [ 37 ], "exenatide,": [ 38 ], "liraglutide,": [ 39 ], "exenatide": [ 40, 73, 137, 205, 241, 255, 287, 295 ], "extended-release,": [ 41 ], "and,": [ 42 ], "most": [ 43 ], "recently,": [ 44 ], "albiglutide": [ 45, 70 ], "dulaglutide.": [ 47 ], "All": [ 48 ], "these": [ 50, 259 ], "formulations": [ 51 ], "administered": [ 53, 59 ], "subcutaneously.": [ 54 ], "Exenatide": [ 55 ], "liraglutide": [ 57 ], "twice": [ 60 ], "daily": [ 61 ], "once": [ 63 ], "daily,": [ 64 ], "respectively.": [ 65 ], "Until": [ 66 ], "recent": [ 67, 102 ], "approvals": [ 68 ], "dulaglutide,": [ 72 ], "extended-release": [ 74, 132, 206, 242, 256, 288 ], "was": [ 75, 229 ], "only": [ 77 ], "formulation": [ 78 ], "once-weekly": [ 81 ], "use.": [ 82, 243 ], "Relative": [ 83 ], "to": [ 84, 128, 135, 266 ], "other": [ 85 ], "antidiabetic": [ 86, 109, 119 ], "pharmacotherapies,": [ 87 ], "such": [ 88 ], "as": [ 89, 142, 171, 195 ], "metformin": [ 90 ], "or": [ 91 ], "sulfonylureas,": [ 92 ], "not": [ 97 ], "widely": [ 98 ], "used": [ 99, 170 ], "drugs.": [ 100 ], "A": [ 101 ], "study": [ 103 ], "usage": [ 106 ], "patterns": [ 107 ], "drugs": [ 110 ], "estimate": [ 111 ], "that,": [ 112 ], "16,316,580": [ 114 ], "patients": [ 115 ], "prescribed": [ 116 ], "a": [ 117, 152, 159, 172, 177 ], "noninsulin": [ 118 ], "2012,": [ 122, 201 ], "were": [ 126, 238, 261, 282 ], "dispensed": [ 127 ], "673,367": [ 129 ], "(4.1%)": [ 130 ], "(1).\n\nExenatide": [ 131 ], "is": [ 133, 158 ], "formulated": [ 134 ], "encapsulate": [ 136 ], "poly-(D,L-lactide-co-glycolide)": [ 139 ], "(also": [ 140 ], "known": [ 141 ], "PLG": [ 143, 157, 183 ], "matrix)": [ 144 ], "microspheres,": [ 145 ], "which": [ 146, 191 ], "release": [ 147, 174 ], "active": [ 149 ], "over": [ 151 ], "sustained": [ 153 ], "time": [ 154, 224 ], "interval": [ 155 ], "(2).": [ 156 ], "biodegradable": [ 160 ], "biocompatible": [ 162 ], "medical": [ 163 ], "polymer": [ 164 ], "with": [ 165, 240, 254 ], "an": [ 166 ], "established": [ 167 ], "safety": [ 168 ], "profile": [ 169 ], "controlled": [ 173, 271 ], "excipient": [ 175 ], "variety": [ 178 ], "(3).": [ 182 ], "undergoes": [ 184 ], "hydrolysis": [ 185 ], "into": [ 186, 207 ], "lactic": [ 187 ], "glycolic": [ 189 ], "acids,": [ 190 ], "eventually": [ 193 ], "eliminated": [ 194 ], "carbon": [ 196 ], "dioxide": [ 197 ], "water.": [ 199 ], "In": [ 200 ], "introduction": [ 203 ], "market": [ 210 ], "offered": [ 211 ], "users": [ 215, 289 ], "advantage": [ 217 ], "fewer": [ 219 ], "injections": [ 220 ], "per": [ 221 ], "week.\n\nAt": [ 222 ], "approval,": [ 226 ], "aware": [ 230 ], "small,": [ 232 ], "largely": [ 233 ], "asymptomatic": [ 234 ], "injection-site": [ 235, 249, 280 ], "nodules": [ 236, 250 ], "that": [ 237 ], "associated": [ 239 ], "Based": [ 244, 269 ], "on": [ 245, 270 ], "microsphere": [ 247 ], "excipient,": [ 248 ], "could": [ 251 ], "be": [ 252 ], "expected": [ 253 ], "administration.": [ 257 ], "However,": [ 258 ], "reactions": [ 260, 281 ], "considered": [ 262 ], "nonserious": [ 263 ], "believed": [ 265 ], "resolve": [ 267 ], "quickly.": [ 268 ], "data": [ 272 ], "provided": [ 273 ], "prescribing": [ 278 ], "information,": [ 279 ], "observed": [ 283 ], "more": [ 284 ], "frequently": [ 285 ], "(17.1%)": [ 290 ], "than": [ 291 ], "those": [ 293 ], "using": [ 294 ], "(12.7%)": [ 296 ], "\u2026": [ 297 ] }, "publication_date": "2015-11-01", "publication_year": 2015, "type": "article", "cited_by_count": 15, "authors": [ { "id": "https://openalex.org/A5023557273", "display_name": "S. Christopher Jones" }, { "id": "https://openalex.org/A5020444607", "display_name": "Debra L. Ryan" }, { "id": "https://openalex.org/A5039614057", "display_name": "Valerie Pratt" }, { "id": "https://openalex.org/A5004956121", "display_name": "Ali Niak" }, { "id": "https://openalex.org/A5031689341", "display_name": "Allen Brinker" } ] }, { "id": "https://openalex.org/W3133746780", "doi": "https://doi.org/10.1016/s0140-6736(21)00213-0", "title": "Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial", "abstract": null, "publication_date": "2021-03-01", "publication_year": 2021, "type": "article", "cited_by_count": 1080, "authors": [ { "id": "https://openalex.org/A5084593004", "display_name": "Melanie J. Davies" }, { "id": "https://openalex.org/A5021206081", "display_name": "Louise F\u00e6rch" }, { "id": "https://openalex.org/A5055974284", "display_name": "Ole Kleist Jeppesen" }, { "id": "https://openalex.org/A5054404609", "display_name": "Arash Pakseresht" }, { "id": "https://openalex.org/A5040913971", "display_name": "Sue D. Pedersen" }, { "id": "https://openalex.org/A5018346963", "display_name": "Leigh Perreault" }, { "id": "https://openalex.org/A5045489578", "display_name": "Julio Rosenstock" }, { "id": "https://openalex.org/A5037246488", "display_name": "Iichiro Shimomura" }, { "id": "https://openalex.org/A5070756199", "display_name": "Adie Viljoen" }, { "id": "https://openalex.org/A5026596594", "display_name": "Thomas A. Wadden" }, { "id": "https://openalex.org/A5001655356", "display_name": "Ildiko Lingvay" } ] }, { "id": "https://openalex.org/W2055213286", "doi": "https://doi.org/10.3892/ijmm.2013.1475", "title": "Cardioprotective effects of exenatide against oxidative stress-induced injury", "abstract": { "Myocardial": [ 0 ], "ischemia/reperfusion": [ 1 ], "(MI/R)": [ 2 ], "leads": [ 3 ], "to": [ 4, 12, 49, 59, 69, 257 ], "oxidative": [ 5, 31, 243, 261 ], "stress,": [ 6 ], "which": [ 7 ], "may": [ 8, 254 ], "in": [ 9, 34, 37, 40, 96, 107, 119, 124, 157, 169, 177, 193, 216, 219, 246, 249, 269, 290 ], "turn": [ 10 ], "lead": [ 11 ], "myocardial": [ 13 ], "injury.": [ 14, 182, 198 ], "In": [ 15, 39, 123 ], "the": [ 16, 21, 51, 86, 97, 108, 113, 120, 143, 151, 160, 170, 174, 178, 186, 194, 227, 258, 267, 270, 277, 294, 297 ], "present": [ 17 ], "study,": [ 18 ], "we": [ 19 ], "investigated": [ 20 ], "effects": [ 22, 54, 223, 241, 284 ], "of": [ 23, 55, 88, 104, 130, 153, 162, 260, 272, 279, 285, 296 ], "exenatide,": [ 24 ], "a": [ 25 ], "glucagon-like": [ 26 ], "peptide-1": [ 27 ], "(GLP-1)": [ 28 ], "analogue,": [ 29 ], "on": [ 30 ], "stress-induced": [ 32, 244 ], "injury": [ 33, 148, 245 ], "vitro": [ 35, 41, 217, 247 ], "and": [ 36, 75, 92, 111, 155, 165, 172, 189, 208, 211, 218, 248, 276 ], "vivo.": [ 38, 250 ], "experiments,": [ 42, 126 ], "H9c2": [ 43, 109, 121 ], "cells": [ 44, 110 ], "were": [ 45, 224 ], "incubated": [ 46 ], "with": [ 47, 64, 138, 180, 196, 201, 293 ], "exenatide": [ 48, 56, 65, 139, 202, 237, 286 ], "determine": [ 50 ], "direct": [ 52 ], "cytoprotective": [ 53 ], "following": [ 57 ], "exposure": [ 58 ], "hydrogen": [ 60 ], "peroxide": [ 61 ], "(H2O2).": [ 62 ], "Pre-treatment": [ 63, 137 ], "(1": [ 66 ], "nM),": [ 67 ], "prior": [ 68 ], "H2O2": [ 70 ], "exposure,": [ 71 ], "increased": [ 72, 112, 206 ], "cell": [ 73 ], "viability": [ 74 ], "inhibited": [ 76, 203 ], "H2O2-induced": [ 77 ], "reactive": [ 78 ], "oxygen": [ 79 ], "species": [ 80 ], "(ROS)": [ 81 ], "production.": [ 82 ], "Exenatide": [ 83, 183 ], "also": [ 84, 184 ], "decreased": [ 85, 212 ], "levels": [ 87, 118, 152, 161, 176 ], "lactate": [ 89 ], "dehydrogenase": [ 90 ], "(LDH)": [ 91 ], "creatine": [ 93 ], "kinase-MB": [ 94 ], "(CK-MB)": [ 95 ], "cultured": [ 98 ], "supernatants,": [ 99 ], "as": [ 100, 102, 265 ], "well": [ 101 ], "those": [ 103 ], "malondialdehyde": [ 105 ], "(MDA)": [ 106 ], "total": [ 114 ], "superoxide": [ 115 ], "dismutase": [ 116 ], "(T-SOD)": [ 117 ], "cells.": [ 122 ], "vivo": [ 125 ], "an": [ 127 ], "animal": [ 128 ], "model": [ 129 ], "MI/R": [ 131 ], "was": [ 132 ], "induced": [ 133 ], "by": [ 134, 149, 226 ], "coronary": [ 135 ], "occlusion.": [ 136 ], "(10": [ 140 ], "\u00b5g/kg/day)": [ 141 ], "protected": [ 142 ], "rat": [ 144 ], "hearts": [ 145 ], "from": [ 146 ], "MI/R-induced": [ 147, 181, 197 ], "decreasing": [ 150, 173 ], "LDH": [ 154 ], "CK-MB": [ 156 ], "plasma,": [ 158 ], "increasing": [ 159 ], "catalase,": [ 163 ], "T-SOD": [ 164 ], "glutathione": [ 166 ], "peroxidase": [ 167 ], "(GSH-Px)": [ 168 ], "heart": [ 171 ], "MDA": [ 175 ], "rats": [ 179, 195 ], "reduced": [ 185 ], "infarct": [ 187 ], "size": [ 188 ], "enhanced": [ 190 ], "cardiac": [ 191 ], "function": [ 192 ], "Moreover,": [ 199 ], "pre-treatment": [ 200 ], "cardiomyocyte": [ 204, 280 ], "apoptosis,": [ 205 ], "Aktserine473": [ 207 ], "Badserine136": [ 209 ], "phosphorylation": [ 210 ], "cleaved": [ 213 ], "caspase-3": [ 214 ], "expression": [ 215 ], "vivo;": [ 220 ], "however,": [ 221 ], "these": [ 222 ], "attenuated": [ 225 ], "phosphoinositide": [ 228 ], "3-kinase": [ 229 ], "(PI3K)": [ 230 ], "inhibitor,": [ 231 ], "LY294002.": [ 232 ], "Our": [ 233 ], "results": [ 234 ], "suggest": [ 235 ], "that": [ 236 ], "exerts": [ 238 ], "significant": [ 239 ], "cardioprotective": [ 240 ], "against": [ 242 ], "The": [ 251, 282 ], "mechanisms": [ 252 ], "involved": [ 253 ], "be": [ 255 ], "attributed": [ 256 ], "scavenging": [ 259 ], "stress": [ 262 ], "products,": [ 263 ], "such": [ 264 ], "ROS,": [ 266 ], "increase": [ 268 ], "concentrations": [ 271 ], "antioxidant": [ 273 ], "defense": [ 274 ], "enzymes": [ 275 ], "inhibition": [ 278 ], "apoptosis.": [ 281 ], "anti-apoptotic": [ 283 ], "were,": [ 287 ], "at": [ 288 ], "least": [ 289 ], "part,": [ 291 ], "associated": [ 292 ], "activation": [ 295 ], "PI3K/Akt": [ 298 ], "signaling": [ 299 ], "pathway.": [ 300 ] }, "publication_date": "2013-08-27", "publication_year": 2013, "type": "article", "cited_by_count": 81, "authors": [ { "id": "https://openalex.org/A5086729488", "display_name": "Guanglei Chang" }, { "id": "https://openalex.org/A5100719467", "display_name": "Dongying Zhang" }, { "id": "https://openalex.org/A5100695383", "display_name": "Hui Yu" }, { "id": "https://openalex.org/A5108055628", "display_name": "Peng Zhang" }, { "id": "https://openalex.org/A5030371908", "display_name": "Ying Wang" }, { "id": "https://openalex.org/A5102209237", "display_name": "Aihua Zheng" }, { "id": "https://openalex.org/A5101924827", "display_name": "Shu Qin" } ] }, { "id": "https://openalex.org/W2773698516", "doi": "https://doi.org/10.1111/dom.13186", "title": "Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment", "abstract": { "Aims": [ 0 ], "To": [ 1 ], "investigate": [ 2 ], "whether": [ 3 ], "the": [ 4, 96, 117, 123, 131 ], "pharmacokinetic": [ 5 ], "characteristics": [ 6 ], "of": [ 7, 41, 75, 111, 153, 199 ], "semaglutide": [ 8, 97, 179, 227 ], "were": [ 9, 82, 252, 285 ], "altered": [ 10 ], "in": [ 11, 274 ], "people": [ 12 ], "with": [ 13, 22, 43, 144, 193, 276 ], "hepatic": [ 14, 24, 45, 68, 112, 191, 264, 277 ], "impairment,": [ 15, 265 ], "assessed": [ 16, 83 ], "using": [ 17 ], "Child\u2013Pugh": [ 18 ], "criteria,": [ 19 ], "vs": [ 20 ], "those": [ 21 ], "normal": [ 23, 44 ], "function.": [ 25 ], "Methods": [ 26 ], "In": [ 27, 234 ], "this": [ 28 ], "multicentre,": [ 29 ], "open\u2010label,": [ 30 ], "parallel\u2010group": [ 31 ], "trial": [ 32 ], "(sponsor": [ 33 ], "Novo": [ 34 ], "Nordisk,": [ 35 ], "ClinicalTrials.gov": [ 36 ], "ID": [ 37 ], "NCT02210871),": [ 38 ], "four": [ 39 ], "groups": [ 40 ], "participants": [ 42, 237 ], "function": [ 46, 152, 161, 170, 196, 207, 216 ], "(": [ 47, 53, 58, 64 ], "n": [ 48, 54, 59, 65 ], "=": [ 49, 55, 60, 66 ], "19)": [ 50 ], "or": [ 51, 62, 241, 249 ], "mild": [ 52, 150, 194, 240 ], "8),": [ 56 ], "moderate": [ 57, 159, 205, 242 ], "10)": [ 61 ], "severe": [ 63, 168, 214 ], "7)": [ 67 ], "impairment": [ 69, 113 ], "received": [ 70 ], "a": [ 71 ], "single,": [ 72 ], "subcutaneous": [ 73 ], "dose": [ 74, 268 ], "0.5": [ 76 ], "mg": [ 77 ], "semaglutide.": [ 78 ], "Semaglutide": [ 79, 137, 255, 279 ], "plasma": [ 80, 98, 178 ], "concentrations": [ 81 ], "frequently": [ 84 ], "for": [ 85, 122, 149 ], "35": [ 86 ], "days": [ 87 ], "after": [ 88 ], "dosing.": [ 89 ], "The": [ 90, 176 ], "primary": [ 91 ], "endpoint": [ 92 ], "was": [ 93, 114, 129, 139, 280 ], "area": [ 94 ], "under": [ 95 ], "concentration\u2013time": [ 99 ], "curve": [ 100 ], "from": [ 101 ], "time": [ 102 ], "zero": [ 103 ], "to": [ 104, 134, 187, 260 ], "infinity": [ 105 ], "(AUC": [ 106 ], "0\u2010\u221e": [ 107, 146 ], ").": [ 108 ], "No": [ 109, 246 ], "effect": [ 110 ], "declared": [ 115 ], "if": [ 116 ], "90%": [ 118 ], "confidence": [ 119 ], "interval": [ 120, 132 ], "(CI)": [ 121 ], "between\u2010group": [ 124 ], "ratio": [ 125 ], "(hepatic": [ 126 ], "impairment/normal": [ 127, 151, 160, 169, 195, 206, 215 ], "function)": [ 128 ], "within": [ 130 ], "0.70": [ 133 ], "1.43.": [ 135 ], "Results": [ 136 ], "exposure": [ 138, 256 ], "similar": [ 140 ], "across": [ 141 ], "all": [ 142 ], "groups,": [ 143 ], "AUC": [ 145 ], "treatment": [ 147, 197 ], "ratios": [ 148, 198 ], "0.95": [ 154 ], "(90%": [ 155, 163, 172, 201, 209, 218 ], "CI": [ 156, 164, 173, 202, 210, 219, 231 ], "0.77,": [ 157 ], "1.16),": [ 158 ], "1.02": [ 162, 208 ], "0.93,": [ 165 ], "1.12),": [ 166 ], "and": [ 167, 213, 283 ], "0.97": [ 171 ], "0.84,": [ 174 ], "1.12).": [ 175 ], "maximum": [ 177 ], "concentration": [ 180 ], "(C": [ 181 ], "max": [ 182 ], ")": [ 183 ], "did": [ 184, 257 ], "not": [ 185, 258, 271 ], "appear": [ 186, 259 ], "be": [ 188, 261, 272 ], "influenced": [ 189 ], "by": [ 190, 263 ], "function,": [ 192 ], "0.99": [ 200 ], "0.80,": [ 203 ], "1.23),": [ 204 ], "0.88,": [ 211, 232 ], "1.18)": [ 212 ], "1.15": [ 217 ], "0.89,": [ 220 ], "1.48;": [ 221 ], "sensitivity": [ 222 ], "analysis": [ 223 ], "excluding": [ 224 ], "one": [ 225 ], "extreme": [ 226 ], "concentration:": [ 228 ], "1.05": [ 229 ], "[90%": [ 230 ], "1.25]).": [ 233 ], "all,": [ 235 ], "10": [ 236 ], "reported": [ 238 ], "12": [ 239 ], "non\u2010serious": [ 243 ], "adverse": [ 244 ], "events.": [ 245 ], "unexpected": [ 247, 287 ], "safety": [ 248, 288 ], "tolerability": [ 250 ], "issues": [ 251 ], "observed.": [ 253 ], "Conclusions": [ 254 ], "affected": [ 262 ], "suggesting": [ 266 ], "that": [ 267 ], "adjustment": [ 269 ], "may": [ 270 ], "necessary": [ 273 ], "patients": [ 275 ], "impairment.": [ 278 ], "well": [ 281 ], "tolerated": [ 282 ], "there": [ 284 ], "no": [ 286 ], "issues.": [ 289 ] }, "publication_date": "2017-12-05", "publication_year": 2017, "type": "article", "cited_by_count": 61, "authors": [ { "id": "https://openalex.org/A5019447119", "display_name": "Lene Jensen" }, { "id": "https://openalex.org/A5091075659", "display_name": "Viera Kup\u010dov\u00e1" }, { "id": "https://openalex.org/A5006711474", "display_name": "Gerhard Arold" }, { "id": "https://openalex.org/A5027935267", "display_name": "Jonas Pettersson" }, { "id": "https://openalex.org/A5085348099", "display_name": "Julie Hjerpsted" } ] }, { "id": "https://openalex.org/W2443999297", "doi": "https://doi.org/10.2337/dc15-2479", "title": "Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial", "abstract": { "OBJECTIVE": [ 0 ], "To": [ 1 ], "compare": [ 2 ], "the": [ 3, 66, 78, 179, 245, 250 ], "efficacy": [ 4 ], "and": [ 5, 115, 122, 128, 232, 242, 283 ], "safety": [ 6 ], "of": [ 7, 65, 281 ], "liraglutide": [ 8, 46, 87, 125, 186, 254 ], "versus": [ 9, 119 ], "lixisenatide": [ 10, 50, 95, 120, 144, 177, 259 ], "as": [ 11, 53, 260 ], "add-on": [ 12, 54, 261 ], "to": [ 13, 45, 55, 77, 262 ], "metformin": [ 14, 27, 263 ], "in": [ 15, 161, 221, 229, 264 ], "patients": [ 16, 41, 109 ], "with": [ 17, 107, 176, 185, 190, 236, 278 ], "type": [ 18 ], "2": [ 19 ], "diabetes": [ 20 ], "not": [ 21 ], "achieving": [ 22 ], "adequate": [ 23 ], "glycemic": [ 24, 266 ], "control": [ 25 ], "on": [ 26 ], "alone.": [ 28 ], "RESEARCH": [ 29 ], "DESIGN": [ 30 ], "AND": [ 31 ], "METHODS": [ 32 ], "In": [ 33 ], "this": [ 34 ], "26-week,": [ 35 ], "randomized,": [ 36 ], "parallel-group,": [ 37 ], "open-label": [ 38 ], "trial,": [ 39 ], "404": [ 40 ], "were": [ 42, 174, 224, 234, 240, 271, 275 ], "randomized": [ 43 ], "1:1": [ 44 ], "1.8": [ 47 ], "mg": [ 48 ], "or": [ 49, 80 ], "20": [ 51 ], "\u00b5g": [ 52 ], "metformin.": [ 56 ], "Liraglutide": [ 57, 137, 157 ], "was": [ 58, 69, 255 ], "administered": [ 59, 70 ], "once": [ 60, 71 ], "daily": [ 61, 72 ], "at": [ 62 ], "any": [ 63 ], "time": [ 64 ], "day.": [ 67 ], "Lixisenatide": [ 68 ], "within": [ 73 ], "1": [ 74 ], "h": [ 75 ], "prior": [ 76 ], "morning": [ 79 ], "evening": [ 81 ], "meal.": [ 82 ], "RESULTS": [ 83 ], "At": [ 84, 249 ], "week": [ 85 ], "26,": [ 86 ], "reduced": [ 88, 138 ], "HbA1c": [ 89, 111 ], "(primary": [ 90 ], "end": [ 91 ], "point)": [ 92 ], "more": [ 93, 108, 142, 256 ], "than": [ 94, 143, 258 ], "(estimated": [ 96, 145 ], "treatment": [ 97, 146 ], "difference": [ 98, 147 ], "\u22120.62%": [ 99 ], "[95%": [ 100, 150 ], "CI": [ 101, 151 ], "\u22120.8;": [ 102 ], "\u22120.4];": [ 103 ], "P": [ 104, 132, 154, 213 ], "&lt;": [ 105, 133, 155, 168, 188 ], "0.0001),": [ 106 ], "reaching": [ 110 ], "&lt;7%": [ 112 ], "(53": [ 113 ], "mmol/mol)": [ 114, 118 ], "\u22646.5%": [ 116 ], "(48": [ 117 ], "(74.2%": [ 121 ], "54.6%": [ 123 ], "for": [ 124, 130, 135, 178, 207, 211 ], "vs.": [ 126 ], "45.5%": [ 127 ], "26.2%": [ 129 ], "lixisenatide;": [ 131, 212 ], "0.0001": [ 134 ], "both).": [ 136 ], "fasting": [ 139 ], "plasma": [ 140, 165 ], "glucose": [ 141, 166, 172 ], "\u22121.15": [ 148 ], "mmol/L": [ 149 ], "\u22121.5;": [ 152 ], "\u22120.8];": [ 153 ], "0.0001).": [ 156, 169 ], "provided": [ 158 ], "greater": [ 159 ], "reduction": [ 160 ], "mean": [ 162 ], "9-point": [ 163 ], "self-measured": [ 164 ], "(P": [ 167, 187 ], "However,": [ 170 ], "postprandial": [ 171 ], "increments": [ 173 ], "smaller": [ 175 ], "meal": [ 180 ], "directly": [ 181 ], "after": [ 182 ], "injection": [ 183 ], "compared": [ 184 ], "0.05),": [ 189 ], "no": [ 191 ], "differences": [ 192 ], "between": [ 193, 244 ], "treatments": [ 194, 274 ], "across": [ 195 ], "all": [ 196 ], "meals.": [ 197 ], "Both": [ 198, 273 ], "drugs": [ 199 ], "promoted": [ 200 ], "similar": [ 201, 243, 284 ], "body": [ 202 ], "weight": [ 203, 269 ], "decrease": [ 204 ], "(\u22124.3": [ 205 ], "kg": [ 206, 210 ], "liraglutide,": [ 208 ], "\u22123.7": [ 209 ], "=": [ 214 ], "0.23).": [ 215 ], "The": [ 216 ], "most": [ 217 ], "common": [ 218 ], "adverse": [ 219, 286 ], "events": [ 220 ], "both": [ 222 ], "groups": [ 223 ], "gastrointestinal": [ 225, 285 ], "disorders.": [ 226 ], "Greater": [ 227 ], "increases": [ 228 ], "pulse,": [ 230 ], "lipase,": [ 231 ], "amylase": [ 233 ], "observed": [ 235 ], "liraglutide.": [ 237 ], "Hypoglycemic": [ 238 ], "episodes": [ 239 ], "rare": [ 241 ], "two": [ 246 ], "treatments.": [ 247 ], "CONCLUSIONS": [ 248 ], "dose": [ 251 ], "levels": [ 252 ], "studied,": [ 253 ], "effective": [ 257 ], "improving": [ 265 ], "control.": [ 267 ], "Body": [ 268 ], "reductions": [ 270 ], "similar.": [ 272 ], "well": [ 276 ], "tolerated,": [ 277 ], "low": [ 279 ], "risk": [ 280 ], "hypoglycemia": [ 282 ], "event": [ 287 ], "profiles.": [ 288 ] }, "publication_date": "2016-06-16", "publication_year": 2016, "type": "article", "cited_by_count": 139, "authors": [ { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5049796469", "display_name": "Manfredi Rizzo" }, { "id": "https://openalex.org/A5087911869", "display_name": "A.B. Johnson" }, { "id": "https://openalex.org/A5070579413", "display_name": "Heidrun Bosch\u2010Traberg" }, { "id": "https://openalex.org/A5028471911", "display_name": "Jesper Madsen" }, { "id": "https://openalex.org/A5004521406", "display_name": "Bertrand Cariou" } ] }, { "id": "https://openalex.org/W3010125829", "doi": "https://doi.org/10.2337/dc19-1745", "title": "Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial", "abstract": { "OBJECTIVE": [ 0 ], "Most": [ 1 ], "individuals": [ 2, 34, 88, 161, 229 ], "with": [ 3, 12, 35, 89, 98, 123, 142, 168, 185, 213, 230 ], "type": [ 4, 41, 94, 236 ], "2": [ 5, 42, 95, 237 ], "diabetes": [ 6, 14, 96 ], "also": [ 7 ], "have": [ 8, 29 ], "obesity,": [ 9 ], "and": [ 10, 39, 72, 93, 101, 192, 197, 234, 254, 264 ], "treatment": [ 11, 145 ], "some": [ 13 ], "medications,": [ 15 ], "including": [ 16 ], "insulin,": [ 17 ], "can": [ 18 ], "cause": [ 19 ], "further": [ 20 ], "weight": [ 21, 26, 62, 132, 164, 252 ], "gain.": [ 22 ], "No": [ 23, 219 ], "approved": [ 24 ], "chronic": [ 25 ], "management": [ 27 ], "medications": [ 28 ], "been": [ 30 ], "prospectively": [ 31 ], "investigated": [ 32 ], "in": [ 33, 64, 87, 189, 267 ], "overweight": [ 36, 90, 231 ], "or": [ 37, 91, 117, 222, 232 ], "obesity": [ 38, 92, 233 ], "insulin-treated": [ 40, 235 ], "diabetes.": [ 43 ], "The": [ 44 ], "primary": [ 45 ], "objective": [ 46 ], "of": [ 47, 55, 160, 261 ], "this": [ 48, 65 ], "study": [ 49 ], "was": [ 50, 78, 134, 183, 247 ], "to": [ 51, 110, 245, 249 ], "assess": [ 52 ], "the": [ 53 ], "effect": [ 54 ], "liraglutide": [ 56, 111, 137, 156, 216, 239 ], "3.0": [ 57, 112, 138, 157, 181, 217, 240 ], "mg": [ 58, 113, 139, 182, 241 ], "versus": [ 59, 140, 166, 202 ], "placebo": [ 60, 118, 143, 169, 214, 250 ], "on": [ 61 ], "loss": [ 63, 165, 253 ], "population.": [ 66 ], "RESEARCH": [ 67 ], "DESIGN": [ 68 ], "AND": [ 69 ], "METHODS": [ 70 ], "Satiety": [ 71 ], "Clinical": [ 73 ], "Adiposity\u2014Liraglutide": [ 74 ], "Evidence": [ 75 ], "(SCALE)": [ 76 ], "Insulin": [ 77 ], "a": [ 79, 205 ], "56-week,": [ 80 ], "randomized,": [ 81 ], "double-blind,": [ 82 ], "placebo-controlled,": [ 83 ], "multinational,": [ 84 ], "multicenter": [ 85 ], "trial": [ 86 ], "treated": [ 97 ], "basal": [ 99, 262 ], "insulin": [ 100, 201, 263 ], "\u22642": [ 102 ], "oral": [ 103 ], "antidiabetic": [ 104 ], "drugs.": [ 105 ], "RESULTS": [ 106 ], "Individuals": [ 107 ], "were": [ 108, 211, 225 ], "randomized": [ 109 ], "(n": [ 114, 119 ], "=": [ 115, 120 ], "198)": [ 116 ], "198),": [ 121 ], "combined": [ 122 ], "intensive": [ 124 ], "behavioral": [ 125 ], "therapy": [ 126 ], "(IBT).": [ 127 ], "At": [ 128 ], "56": [ 129 ], "weeks,": [ 130 ], "mean": [ 131, 190, 193 ], "change": [ 133 ], "\u22125.8%": [ 135 ], "for": [ 136, 200 ], "\u22121.5%": [ 141 ], "(estimated": [ 144 ], "difference": [ 146 ], "\u22124.3%": [ 147 ], "[95%": [ 148, 173 ], "CI": [ 149, 174 ], "\u22125.5;": [ 150 ], "\u22123.2];": [ 151 ], "P": [ 152, 177 ], "&lt;": [ 153, 178 ], "0.0001).": [ 154, 179 ], "With": [ 155 ], "mg,": [ 158 ], "51.8%": [ 159 ], "achieved": [ 162 ], "\u22655%": [ 163 ], "24.0%": [ 167 ], "(odds": [ 170 ], "ratio": [ 171 ], "3.41": [ 172 ], "2.19;": [ 175 ], "5.31];": [ 176 ], "Liraglutide": [ 180 ], "associated": [ 184 ], "significantly": [ 186 ], "greater": [ 187 ], "reductions": [ 188 ], "HbA1c": [ 191 ], "daytime": [ 194 ], "glucose": [ 195 ], "values": [ 196 ], "less": [ 198 ], "need": [ 199 ], "placebo,": [ 203 ], "despite": [ 204, 258 ], "treat-to-glycemic-target": [ 206 ], "protocol.": [ 207 ], "More": [ 208 ], "hypoglycemic": [ 209, 268 ], "events": [ 210 ], "observed": [ 212 ], "than": [ 215 ], "mg.": [ 218 ], "new": [ 220 ], "safety": [ 221 ], "tolerability": [ 223 ], "issues": [ 224 ], "observed.": [ 226 ], "CONCLUSIONS": [ 227 ], "In": [ 228 ], "diabetes,": [ 238 ], "as": [ 242 ], "an": [ 243 ], "adjunct": [ 244 ], "IBT": [ 246 ], "superior": [ 248 ], "regarding": [ 251 ], "improved": [ 255 ], "glycemic": [ 256 ], "control": [ 257 ], "lower": [ 259 ], "doses": [ 260 ], "without": [ 265 ], "increases": [ 266 ], "events.": [ 269 ] }, "publication_date": "2020-03-04", "publication_year": 2020, "type": "article", "cited_by_count": 162, "authors": [ { "id": "https://openalex.org/A5038221659", "display_name": "W. Timothy Garvey" }, { "id": "https://openalex.org/A5013839934", "display_name": "Andreas L. Birkenfeld" }, { "id": "https://openalex.org/A5009921349", "display_name": "Dror Dicker" }, { "id": "https://openalex.org/A5053488036", "display_name": "Geltrude Mingrone" }, { "id": "https://openalex.org/A5040913971", "display_name": "Sue D. Pedersen" }, { "id": "https://openalex.org/A5082115026", "display_name": "Altynai Satylganova" }, { "id": "https://openalex.org/A5029901911", "display_name": "Dorthe Skovgaard" }, { "id": "https://openalex.org/A5081546904", "display_name": "Danny Sugimoto" }, { "id": "https://openalex.org/A5078072521", "display_name": "Camilla Jensen" }, { "id": "https://openalex.org/A5080475619", "display_name": "Ofri Mosenzon" } ] }, { "id": "https://openalex.org/W2060979843", "doi": "https://doi.org/10.3389/fendo.2014.00140", "title": "The Effect of Liraglutide on Weight Loss in Women with Polycystic Ovary Syndrome: An Observational Study", "abstract": { "Treatment": [ 0 ], "with": [ 1, 5, 21 ], "liraglutide": [ 2, 25 ], "in": [ 3, 11, 16, 34 ], "combination": [ 4 ], "metformin": [ 6 ], "and": [ 7, 18 ], "lifestyle": [ 8 ], "intervention": [ 9 ], "resulted": [ 10 ], "a": [ 12 ], "significant": [ 13 ], "weight": [ 14, 32 ], "loss": [ 15, 33 ], "overweight": [ 17 ], "obese": [ 19 ], "women": [ 20 ], "PCOS,": [ 22 ], "indicating": [ 23 ], "that": [ 24 ], "may": [ 26 ], "be": [ 27 ], "an": [ 28 ], "effective": [ 29 ], "alternative": [ 30 ], "for": [ 31 ], "this": [ 35 ], "group": [ 36 ], "of": [ 37 ], "patients.": [ 38 ], "However,": [ 39 ], "larger": [ 40 ], "placebo-controlled": [ 41 ], "studies": [ 42 ], "are": [ 43 ], "needed": [ 44 ], "to": [ 45 ], "confirm": [ 46 ], "this.": [ 47 ] }, "publication_date": "2014-08-27", "publication_year": 2014, "type": "article", "cited_by_count": 85, "authors": [ { "id": "https://openalex.org/A5027324711", "display_name": "Christina B. Rasmussen" }, { "id": "https://openalex.org/A5108481851", "display_name": "Svend Lindenberg" } ] }, { "id": "https://openalex.org/W2103969845", "doi": "https://doi.org/10.4239/wjd.v5.i1.40", "title": "Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes", "abstract": { "There": [ 0 ], "are": [ 1 ], "many": [ 2 ], "advantages": [ 3 ], "of": [ 4, 36, 40, 52, 70, 112, 123 ], "combining": [ 5 ], "incretin": [ 6, 41, 59, 124 ], "therapy": [ 7, 20, 60, 91, 97, 125 ], "[glucagon-like": [ 8 ], "peptide-1": [ 9 ], "(GLP-1)": [ 10 ], "receptor": [ 11, 72, 101 ], "agonists": [ 12, 73 ], "and": [ 13, 42, 54, 117, 133 ], "dipeptidyl": [ 14 ], "peptidase-4": [ 15 ], "(DPP-4)": [ 16 ], "inhibitors]": [ 17 ], "with": [ 18, 98, 120, 126 ], "insulin": [ 19, 43, 90, 94 ], "as": [ 21 ], "a": [ 22, 99 ], "glucose-lowering": [ 23 ], "strategy": [ 24 ], "in": [ 25, 50, 109 ], "type": [ 26 ], "2": [ 27 ], "diabetes.": [ 28 ], "One": [ 29 ], "important": [ 30 ], "advantage": [ 31, 46 ], "is": [ 32, 47 ], "the": [ 33, 37, 48, 68, 110, 121, 131 ], "complementary": [ 34 ], "mode": [ 35 ], "mechanistic": [ 38 ], "action": [ 39 ], "therapy.": [ 44 ], "Another": [ 45 ], "reduction": [ 49 ], "risk": [ 51, 114 ], "hypoglycemia": [ 53, 116 ], "weight": [ 55, 118 ], "gain": [ 56, 119 ], "when": [ 57 ], "adding": [ 58, 93 ], "to": [ 61, 88, 95 ], "insulin.": [ 62, 127 ], "Several": [ 63 ], "clinical": [ 64, 134 ], "trials": [ 65 ], "have": [ 66 ], "studied": [ 67 ], "addition": [ 69 ], "GLP-1": [ 71, 100 ], "[exenatide": [ 74 ], "BID": [ 75 ], "(twice": [ 76 ], "daily),": [ 77 ], "lixisenatide,": [ 78 ], "albiglutide]": [ 79 ], "or": [ 80, 92 ], "DPP-4": [ 81 ], "inhibitors": [ 82 ], "(vildagliptin,": [ 83 ], "sitagliptin,": [ 84 ], "saxagliptin,": [ 85 ], "alogliptin,": [ 86 ], "linagliptin)": [ 87 ], "ongoing": [ 89, 96 ], "agonist": [ 102 ], "(liraglutide).": [ 103 ], "These": [ 104 ], "studies": [ 105, 135 ], "show": [ 106 ], "improved": [ 107 ], "glycemia": [ 108 ], "presence": [ 111 ], "limited": [ 113 ], "for": [ 115 ], "combination": [ 122 ], "This": [ 128 ], "article": [ 129 ], "reviews": [ 130 ], "background": [ 132 ], "on": [ 136 ], "this": [ 137 ], "combination.": [ 138 ] }, "publication_date": "2014-01-01", "publication_year": 2014, "type": "review", "cited_by_count": 52, "authors": [ { "id": "https://openalex.org/A5027109387", "display_name": "Bo \u00c5hr\u00e9n" } ] }, { "id": "https://openalex.org/W2887502192", "doi": "https://doi.org/10.1111/jdi.12906", "title": "Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial", "abstract": { "Abstract": [ 0 ], "Aims/Introduction": [ 1 ], "We": [ 2 ], "compared": [ 3 ], "treatment": [ 4, 237 ], "satisfaction": [ 5, 238 ], "in": [ 6, 83, 95, 104, 126, 137, 144, 153, 160, 168, 177, 184, 193, 214, 217, 239, 245 ], "type": [ 7, 40, 242 ], "2": [ 8, 41, 243 ], "diabetes": [ 9, 42 ], "patients": [ 10, 38, 240 ], "taking": [ 11, 63 ], "daily": [ 12, 52, 66 ], "and": [ 13, 20, 114, 129 ], "weekly": [ 14, 74 ], "glucagon\u2010like": [ 15, 47 ], "peptide\u20101": [ 16, 48 ], "receptor": [ 17, 49 ], "agonists.": [ 18 ], "Materials": [ 19 ], "Methods": [ 21 ], "The": [ 22, 34, 77, 99, 135, 175 ], "study": [ 23 ], "was": [ 24, 80, 148, 188, 230 ], "a": [ 25 ], "12\u2010week,": [ 26 ], "multicenter,": [ 27 ], "open\u2010label,": [ 28 ], "prospective,": [ 29 ], "randomized,": [ 30 ], "parallel\u2010group": [ 31 ], "comparison": [ 32 ], "trial.": [ 33 ], "participants": [ 35, 122, 131 ], "were": [ 36, 57, 123, 208 ], "Japanese": [ 37 ], "with": [ 39, 45, 234, 241 ], "being": [ 43 ], "administered": [ 44 ], "the": [ 46, 81, 84, 96, 105, 127, 133, 138, 145, 154, 161, 169, 185, 194, 215, 246 ], "agonist,": [ 50 ], "liraglutide,": [ 51 ], "for": [ 53 ], ">3": [ 54 ], "months.": [ 55 ], "Patients": [ 56 ], "randomly": [ 58 ], "assigned": [ 59 ], "to": [ 60, 71, 92, 232, 236 ], "either": [ 61 ], "continue": [ 62 ], "liraglutide": [ 64, 233 ], "once": [ 65, 73 ], "(Lira": [ 67 ], "group)": [ 68 ], "or": [ 69, 222 ], "switch": [ 70 ], "dulaglutide": [ 72, 229 ], "(Dula": [ 75 ], "group).": [ 76 ], "primary": [ 78 ], "outcome": [ 79 ], "change": [ 82, 136, 176 ], "Diabetes": [ 85, 106, 139, 178 ], "Treatment": [ 86, 140 ], "Satisfaction": [ 87, 141 ], "Questionnaire": [ 88, 142 ], "score": [ 89, 143, 183 ], "from": [ 90 ], "baseline": [ 91 ], "week": [ 93 ], "12": [ 94 ], "two": [ 97 ], "groups.": [ 98 ], "secondary": [ 100 ], "outcomes": [ 101 ], "comprised": [ 102 ], "changes": [ 103, 216 ], "Therapy\u2010Related": [ 107, 179 ], "Quality": [ 108, 180 ], "of": [ 109, 120, 181, 228, 248 ], "Life": [ 110, 182 ], "score,": [ 111 ], "body": [ 112, 218 ], "mass": [ 113 ], "glycemic": [ 115, 253 ], "control.": [ 116, 254 ], "Results": [ 117 ], "A": [ 118 ], "total": [ 119 ], "33": [ 121 ], "initially": [ 124 ], "enrolled": [ 125 ], "trial,": [ 128 ], "31": [ 130 ], "completed": [ 132 ], "protocol.": [ 134 ], "Dula": [ 146, 170, 186 ], "group": [ 147, 156, 163, 187, 196 ], "significantly": [ 149, 189 ], "greater": [ 150, 190 ], "than": [ 151, 191 ], "that": [ 152, 192 ], "Lira": [ 155, 162, 195 ], "(+0.1": [ 157 ], "\u00b1": [ 158, 166, 198, 202 ], "4.7": [ 159 ], "vs": [ 164, 200 ], "+4.9": [ 165 ], "5.2": [ 167 ], "group;": [ 171 ], "P": [ 172, 204 ], "=": [ 173, 205 ], "0.013).": [ 174 ], "(\u22123.7": [ 197 ], "6.9": [ 199 ], "+8.9": [ 201 ], "15.1;": [ 203 ], "0.007).": [ 206 ], "There": [ 207 ], "no": [ 209 ], "significant": [ 210 ], "differences": [ 211 ], "between": [ 212 ], "groups": [ 213 ], "mass,": [ 219 ], "plasma": [ 220 ], "glucose": [ 221 ], "glycated": [ 223 ], "hemoglobin.": [ 224 ], "Conclusions": [ 225 ], "Weekly": [ 226 ], "administration": [ 227 ], "superior": [ 231 ], "regard": [ 235 ], "diabetes,": [ 244 ], "absence": [ 247 ], "any": [ 249 ], "negative": [ 250 ], "effect": [ 251 ], "on": [ 252 ] }, "publication_date": "2018-08-07", "publication_year": 2018, "type": "article", "cited_by_count": 37, "authors": [ { "id": "https://openalex.org/A5081575573", "display_name": "Takahiro Takase" }, { "id": "https://openalex.org/A5055696290", "display_name": "Akinobu Nakamura" }, { "id": "https://openalex.org/A5050023508", "display_name": "Kohei Yamamoto" }, { "id": "https://openalex.org/A5060578424", "display_name": "Hiroshi Nomoto" }, { "id": "https://openalex.org/A5006626284", "display_name": "Aika Miya" }, { "id": "https://openalex.org/A5028944796", "display_name": "Midori Dannoura" }, { "id": "https://openalex.org/A5078843127", "display_name": "Kyu Yong Cho" }, { "id": "https://openalex.org/A5110352459", "display_name": "Yoshio Kurihara" }, { "id": "https://openalex.org/A5021502376", "display_name": "Naoki Manda" }, { "id": "https://openalex.org/A5102416199", "display_name": "Shin Aoki" }, { "id": "https://openalex.org/A5079071350", "display_name": "Tatsuya Atsumi" }, { "id": "https://openalex.org/A5032820934", "display_name": "Hideaki Miyoshi" } ] }, { "id": "https://openalex.org/W4385955544", "doi": "https://doi.org/10.1038/s42255-023-00859-y", "title": "Liraglutide restores impaired associative learning in individuals with obesity", "abstract": null, "publication_date": "2023-08-17", "publication_year": 2023, "type": "article", "cited_by_count": 39, "authors": [ { "id": "https://openalex.org/A5072712178", "display_name": "Ruth Han\u00dfen" }, { "id": "https://openalex.org/A5007865690", "display_name": "Lionel Rigoux" }, { "id": "https://openalex.org/A5061249056", "display_name": "Bojana Kuzmanovic" }, { "id": "https://openalex.org/A5041891092", "display_name": "Sandra Iglesias" }, { "id": "https://openalex.org/A5088276998", "display_name": "Alina Chlo\u00e9 Kretschmer" }, { "id": "https://openalex.org/A5022948027", "display_name": "Marc Schlamann" }, { "id": "https://openalex.org/A5031380809", "display_name": "Kerstin Albus" }, { "id": "https://openalex.org/A5032138727", "display_name": "Sharmili Edwin Thanarajah" }, { "id": "https://openalex.org/A5043414323", "display_name": "Tamara Sitnikow" }, { "id": "https://openalex.org/A5065976799", "display_name": "Corina Melzer" }, { "id": "https://openalex.org/A5070655188", "display_name": "Oliver A. Cornely" }, { "id": "https://openalex.org/A5112420225", "display_name": "Jens C. Br\u00fcning" }, { "id": "https://openalex.org/A5030256799", "display_name": "Marc Tittgemeyer" } ] }, { "id": "https://openalex.org/W4383740618", "doi": "https://doi.org/10.1007/s00125-023-05956-x", "title": "Incretin hormones and type 2 diabetes", "abstract": null, "publication_date": "2023-07-11", "publication_year": 2023, "type": "review", "cited_by_count": 129, "authors": [ { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5055064257", "display_name": "Timo D. M\u00fcller" } ] }, { "id": "https://openalex.org/W2990539453", "doi": "https://doi.org/10.1111/dom.13924", "title": "Incretin\u2010based glucose\u2010lowering medications and the risk of acute pancreatitis and malignancies: a meta\u2010analysis based on cardiovascular outcomes trials", "abstract": { "Abstract": [ 0 ], "Some": [ 1 ], "epidemiological": [ 2 ], "data": [ 3, 126 ], "have": [ 4, 31 ], "suggested": [ 5 ], "an": [ 6, 158, 241 ], "elevated": [ 7, 144, 187 ], "risk": [ 8, 145, 160, 190, 235 ], "of": [ 9, 39, 50, 52, 79, 91, 98, 118, 130, 146, 161, 191, 198, 207, 240, 249 ], "acute": [ 10, 53, 147, 162, 242 ], "pancreatitis": [ 11, 54, 243 ], "and": [ 12, 23, 34, 55, 74, 102, 122, 218 ], "pancreatic": [ 13, 56, 192, 224 ], "cancer": [ 14, 57, 193, 225 ], "after": [ 15 ], "exposure": [ 16 ], "to": [ 17, 96 ], "glucagon\u2010like": [ 18 ], "peptide": [ 19 ], "(GLP)\u20101": [ 20 ], "receptor": [ 21, 72, 120, 132, 177, 216 ], "agonists": [ 22, 73, 121, 133, 178, 217 ], "dipeptidyl": [ 24 ], "peptidase": [ 25 ], "(DPP)\u20104": [ 26 ], "inhibitors.": [ 27, 76, 124 ], "Recently,": [ 28 ], "such": [ 29 ], "outcomes": [ 30, 44, 67, 212 ], "been": [ 32 ], "assessed": [ 33 ], "adjudicated": [ 35 ], "as": [ 36, 58, 60, 112, 114 ], "adverse": [ 37 ], "events": [ 38 ], "special": [ 40 ], "interest": [ 41 ], "in": [ 42, 65, 167, 246 ], "cardiovascular": [ 43, 66, 211 ], "studies.": [ 45 ], "We": [ 46 ], "performed": [ 47 ], "a": [ 48, 89, 142, 154, 185, 204, 233 ], "meta\u2010analysis": [ 49, 136, 169, 248 ], "cases": [ 51, 80 ], "well": [ 59, 113 ], "any": [ 61, 227 ], "malignant": [ 62, 200, 228 ], "neoplasm": [ 63 ], "reported": [ 64 ], "trials": [ 68 ], "(CVOTs)": [ 69 ], "with": [ 70, 82, 184, 214 ], "GLP\u20101": [ 71, 119, 131, 176, 215 ], "DPP\u20104": [ 75, 123, 151, 180, 219, 250 ], "The": [ 77 ], "numbers": [ 78 ], "observed": [ 81 ], "active": [ 83 ], "drug": [ 84 ], "or": [ 85, 188, 194, 226 ], "placebo": [ 86 ], "(both": [ 87 ], "on": [ 88, 127, 203 ], "background": [ 90 ], "standard": [ 92 ], "care)": [ 93 ], "were": [ 94, 106, 182, 230 ], "related": [ 95 ], "patient\u2010years": [ 97 ], "observation.": [ 99 ], "Rate": [ 100 ], "ratios": [ 101 ], "their": [ 103, 135 ], "confidence": [ 104 ], "intervals": [ 105 ], "calculated": [ 107 ], "for": [ 108, 115, 195, 223, 237 ], "the": [ 109, 116, 168, 196, 238, 247 ], "individual": [ 110, 128, 150 ], "agents": [ 111 ], "classes": [ 117 ], "Neither": [ 125, 175 ], "CVOTs": [ 129 ], "nor": [ 134, 179 ], "[rate": [ 137 ], "ratio:": [ 138 ], "1.05": [ 139 ], "(0.78\u20131.41)]": [ 140 ], "indicated": [ 141 ], "significantly": [ 143, 186 ], "pancreatitis.": [ 148 ], "All": [ 149 ], "inhibitors": [ 152, 181 ], "displayed": [ 153 ], "non\u2010significant": [ 155 ], "trend": [ 156 ], "towards": [ 157 ], "increased": [ 159 ], "pancreatitis,": [ 163 ], "which": [ 164 ], "was": [ 165, 244 ], "significant": [ 166 ], "[1.75": [ 170 ], "(1.14\u20132.70);": [ 171 ], "P": [ 172 ], "=": [ 173 ], "0.01].": [ 174 ], "associated": [ 183 ], "reduced": [ 189 ], "totality": [ 197 ], "all": [ 199 ], "neoplasms.": [ 201 ], "Based": [ 202 ], "large": [ 205 ], "database": [ 206 ], "randomized,": [ 208 ], "placebo\u2010controlled,": [ 209 ], "prospective": [ 210 ], "studies": [ 213 ], "inhibitors,": [ 220 ], "no": [ 221 ], "signal": [ 222 ], "neoplasms": [ 229 ], "detected.": [ 231 ], "However,": [ 232 ], "75%": [ 234 ], "increase": [ 236 ], "development": [ 239 ], "seen": [ 245 ], "inhibitor": [ 251 ], "CVOTs.": [ 252 ] }, "publication_date": "2019-11-21", "publication_year": 2019, "type": "review", "cited_by_count": 138, "authors": [ { "id": "https://openalex.org/A5070441611", "display_name": "Mirna Abd El Aziz" }, { "id": "https://openalex.org/A5062501335", "display_name": "Oscar Cahyadi" }, { "id": "https://openalex.org/A5002832666", "display_name": "Juris J. Meier" }, { "id": "https://openalex.org/A5111040183", "display_name": "Wolfgang E. Schmidt" }, { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" } ] }, { "id": "https://openalex.org/W2893451510", "doi": "https://doi.org/10.1016/s2213-8587(18)30241-9", "title": "GLP-1 receptor agonists, CKD, and eGFR trajectory", "abstract": null, "publication_date": "2018-09-25", "publication_year": 2018, "type": "letter", "cited_by_count": 12, "authors": [ { "id": "https://openalex.org/A5006323923", "display_name": "Micha\u00ebl J.B. van Baar" }, { "id": "https://openalex.org/A5067127165", "display_name": "Dani\u00ebl H. van Raalte" }, { "id": "https://openalex.org/A5084278641", "display_name": "Marcel H.A. Muskiet" } ] }, { "id": "https://openalex.org/W3203076793", "doi": "https://doi.org/10.1186/s12933-021-01385-5", "title": "Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence", "abstract": null, "publication_date": "2021-09-28", "publication_year": 2021, "type": "review", "cited_by_count": 58, "authors": [ { "id": "https://openalex.org/A5055458112", "display_name": "Andrea Natali" }, { "id": "https://openalex.org/A5005504738", "display_name": "Lorenzo Nesti" }, { "id": "https://openalex.org/A5024359799", "display_name": "Domenico Tric\u00f2" }, { "id": "https://openalex.org/A5089847244", "display_name": "Ele Ferrannini" } ] }, { "id": "https://openalex.org/W2803591279", "doi": "https://doi.org/10.2337/db17-1385", "title": "Liraglutide Modulates Appetite and Body Weight Through Glucagon-Like Peptide 1 Receptor\u2013Expressing Glutamatergic Neurons", "abstract": { "Glucagon-like": [ 0 ], "peptide": [ 1 ], "1": [ 2 ], "receptor": [ 3 ], "(GLP-1R)": [ 4 ], "agonists": [ 5, 26 ], "are": [ 6, 33, 48 ], "U.S.": [ 7 ], "Food": [ 8 ], "and": [ 9, 30, 53, 67, 101, 104, 144 ], "Drug": [ 10 ], "Administration\u2013approved": [ 11 ], "weight": [ 12, 32, 99 ], "loss": [ 13, 100 ], "drugs.": [ 14 ], "Despite": [ 15 ], "their": [ 16 ], "widespread": [ 17 ], "use,": [ 18 ], "the": [ 19, 51, 57, 120 ], "sites": [ 20 ], "of": [ 21, 56, 91, 113 ], "action": [ 22 ], "through": [ 23 ], "which": [ 24 ], "GLP-1R": [ 25, 149 ], "(GLP1RAs)": [ 27 ], "affect": [ 28 ], "appetite": [ 29 ], "body": [ 31, 65 ], "still": [ 34 ], "not": [ 35, 154 ], "fully": [ 36 ], "understood.": [ 37 ], "We": [ 38, 71, 128 ], "determined": [ 39 ], "whether": [ 40 ], "GLP-1Rs": [ 41, 76, 92, 114 ], "in": [ 42, 77, 85, 93 ], "either": [ 43 ], "GABAergic": [ 44, 79, 155 ], "or": [ 45 ], "glutamatergic": [ 46, 95, 116, 152 ], "neurons": [ 47, 80, 96, 117 ], "necessary": [ 49 ], "for": [ 50 ], "short-": [ 52 ], "long-term": [ 54 ], "effects": [ 55, 108, 143, 147 ], "GLP1RA": [ 58 ], "liraglutide": [ 59, 126, 131 ], "on": [ 60, 109, 151 ], "food": [ 61 ], "intake,": [ 62 ], "visceral": [ 63, 102 ], "illness,": [ 64 ], "weight,": [ 66 ], "neural": [ 68, 121, 137 ], "network": [ 69, 122, 138 ], "activation.": [ 70 ], "found": [ 72 ], "that": [ 73, 130, 145 ], "mice": [ 74 ], "lacking": [ 75 ], "vGAT-expressing": [ 78 ], "responded": [ 81 ], "identically": [ 82 ], "to": [ 83, 139 ], "controls": [ 84 ], "all": [ 86 ], "parameters": [ 87 ], "measured,": [ 88 ], "whereas": [ 89 ], "deletion": [ 90, 112 ], "vGlut2-expressing": [ 94 ], "eliminated": [ 97 ], "liraglutide-induced": [ 98 ], "illness": [ 103 ], "severely": [ 105 ], "attenuated": [ 106 ], "its": [ 107, 141 ], "feeding.": [ 110 ], "Concomitantly,": [ 111 ], "from": [ 115 ], "completely": [ 118 ], "abolished": [ 119 ], "activation": [ 123 ], "observed": [ 124 ], "after": [ 125 ], "administration.": [ 127 ], "conclude": [ 129 ], "activates": [ 132 ], "a": [ 133 ], "dispersed": [ 134 ], "but": [ 135, 153 ], "discrete": [ 136 ], "mediate": [ 140 ], "physiological": [ 142 ], "these": [ 146 ], "require": [ 148 ], "expression": [ 150 ], "neurons.": [ 156 ] }, "publication_date": "2018-05-18", "publication_year": 2018, "type": "article", "cited_by_count": 142, "authors": [ { "id": "https://openalex.org/A5042216961", "display_name": "Jessica M. Adams" }, { "id": "https://openalex.org/A5077602516", "display_name": "Hongjuan Pei" }, { "id": "https://openalex.org/A5045342696", "display_name": "Darleen A. Sandoval" }, { "id": "https://openalex.org/A5065488328", "display_name": "Randy J. Seeley" }, { "id": "https://openalex.org/A5017619994", "display_name": "Rui B. Chang" }, { "id": "https://openalex.org/A5061951793", "display_name": "Stephen D. Liberles" }, { "id": "https://openalex.org/A5044286863", "display_name": "David P. Olson" } ] }, { "id": "https://openalex.org/W4394997309", "doi": "https://doi.org/10.1016/j.isci.2024.109784", "title": "Correlation between intestinal flora and GLP-1 receptor agonist dulaglutide in type 2 diabetes mellitus treatment\u2014A preliminary longitudinal study", "abstract": { "GLP-1": [ 0 ], "receptor": [ 1 ], "agonists": [ 2 ], "(GLP-1": [ 3 ], "RA)": [ 4 ], "are": [ 5, 127 ], "presently": [ 6 ], "used": [ 7, 36 ], "as": [ 8 ], "the": [ 9, 13, 46, 49, 71, 75, 95, 98, 108, 143 ], "first-line": [ 10 ], "drugs": [ 11 ], "for": [ 12, 79 ], "clinical": [ 14 ], "treatment": [ 15 ], "of": [ 16, 48, 52, 61, 77, 92, 97, 110, 142 ], "type": [ 17 ], "2": [ 18 ], "diabetes": [ 19 ], "mellitus": [ 20 ], "(T2DM).": [ 21 ], "It": [ 22 ], "can": [ 23 ], "regulate": [ 24 ], "blood": [ 25 ], "glucose": [ 26, 118 ], "by": [ 27, 145 ], "stimulating": [ 28 ], "insulin": [ 29 ], "secretion": [ 30 ], "and": [ 31, 58, 125 ], "lowering": [ 32 ], "glucagon": [ 33 ], "levels.": [ 34 ], "We": [ 35 ], "16S": [ 37 ], "rRNA": [ 38 ], "amplicon": [ 39 ], "sequencing": [ 40 ], "to": [ 41, 82 ], "detect": [ 42 ], "structural": [ 43 ], "changes": [ 44, 69 ], "in": [ 45, 70, 107 ], "composition": [ 47, 96 ], "intestinal": [ 50, 72, 99, 111, 132, 137 ], "flora": [ 51, 73, 100, 138 ], "newly": [ 53, 85 ], "diagnosed": [ 54, 86 ], "T2DM": [ 55 ], "after": [ 56, 74, 89 ], "1": [ 57, 80 ], "48": [ 59, 90 ], "weeks": [ 60, 91 ], "dulaglutide": [ 62, 78, 93, 147 ], "administration.": [ 63 ], "Our": [ 64 ], "research": [ 65 ], "found": [ 66, 115 ], "no": [ 67 ], "significant": [ 68, 105 ], "administration": [ 76 ], "week": [ 81 ], "subjects": [ 83 ], "with": [ 84, 103, 131 ], "T2DM.": [ 87, 149 ], "Nevertheless,": [ 88 ], "administration,": [ 94 ], "changed": [ 101 ], "significantly,": [ 102 ], "a": [ 104 ], "reduction": [ 106 ], "abundance": [ 109 ], "flora.": [ 112, 133 ], "Furthermore,": [ 113 ], "we": [ 114 ], "that": [ 116, 136 ], "fasting": [ 117, 120 ], "levels,": [ 119, 122, 124 ], "c-peptide": [ 121 ], "HbA1c": [ 123 ], "BMI": [ 126 ], "also": [ 128 ], "closely": [ 129 ], "associated": [ 130 ], "This": [ 134 ], "reveals": [ 135 ], "may": [ 139 ], "be": [ 140 ], "one": [ 141 ], "mechanisms": [ 144 ], "which": [ 146 ], "treats": [ 148 ] }, "publication_date": "2024-04-22", "publication_year": 2024, "type": "article", "cited_by_count": 12, "authors": [ { "id": "https://openalex.org/A5110767476", "display_name": "Lei Liang" }, { "id": "https://openalex.org/A5101009053", "display_name": "Xiaoyun Su" }, { "id": "https://openalex.org/A5102652156", "display_name": "Yaxin Guan" }, { "id": "https://openalex.org/A5051982289", "display_name": "Bing Wu" }, { "id": "https://openalex.org/A5011132555", "display_name": "Xuxiang Zhang" }, { "id": "https://openalex.org/A5100751153", "display_name": "Xin Nian" } ] }, { "id": "https://openalex.org/W2608246442", "doi": "https://doi.org/10.1002/hep.29238", "title": "SIRT1/HSF1/HSP pathway is essential for exenatide\u2010alleviated, lipid\u2010induced hepatic endoplasmic reticulum stress", "abstract": { "Recent": [ 0 ], "studies": [ 1, 155 ], "have": [ 2 ], "indicated": [ 3, 91 ], "that": [ 4, 83, 157 ], "lipid\u2010induced": [ 5, 45, 248 ], "endoplasmic": [ 6 ], "reticulum": [ 7 ], "(ER)": [ 8 ], "stress": [ 9, 48, 89, 146, 229, 250 ], "is": [ 10, 27, 244 ], "a": [ 11, 22, 64, 258 ], "major": [ 12 ], "contributor": [ 13 ], "to": [ 14, 29, 167, 190, 261 ], "the": [ 15, 56, 121, 144, 160, 168, 182, 213 ], "progression": [ 16 ], "of": [ 17, 95, 162, 170, 184, 197, 215 ], "hepatic": [ 18, 31, 46, 87, 125, 192, 231, 252, 272 ], "steatosis.": [ 19, 273 ], "Exenatide": [ 20, 118 ], "(exendin\u20104),": [ 21 ], "glucagon\u2010like": [ 23 ], "peptide\u20101": [ 24 ], "receptor": [ 25 ], "agonist,": [ 26 ], "known": [ 28 ], "improve": [ 30 ], "steatosis,": [ 32, 253 ], "with": [ 33, 63, 70 ], "accumulating": [ 34 ], "evidence.": [ 35 ], "In": [ 36 ], "this": [ 37 ], "study,": [ 38 ], "we": [ 39 ], "investigated": [ 40 ], "whether": [ 41 ], "exenatide": [ 42, 71, 216, 263 ], "could": [ 43 ], "alleviate": [ 44, 191 ], "ER": [ 47, 88, 102, 145, 193, 228, 249 ], "through": [ 49, 176 ], "mammal": [ 50 ], "sirtuin": [ 51 ], "1": [ 52, 166 ], "(SIRT1)": [ 53 ], "and": [ 54, 104, 124, 136, 147, 188, 226, 230, 251, 264 ], "illustrated": [ 55 ], "detailed": [ 57 ], "mechanisms.": [ 58 ], "Male": [ 59 ], "C57BL/6J": [ 60 ], "mice": [ 61 ], "challenged": [ 62 ], "high\u2010fat": [ 65 ], "diet": [ 66 ], "(HFD)": [ 67 ], "were": [ 68, 113 ], "treated": [ 69 ], "or": [ 72, 204 ], "normal": [ 73 ], "saline": [ 74 ], "by": [ 75, 92, 116, 128, 151, 199, 205 ], "intraperitoneal": [ 76 ], "injection": [ 77 ], "for": [ 78, 246, 257, 270 ], "4": [ 79 ], "weeks.": [ 80 ], "We": [ 81 ], "observed": [ 82 ], "HFD": [ 84, 129 ], "feeding": [ 85 ], "induced": [ 86, 127, 150 ], "as": [ 90, 267 ], "increased": [ 93, 181 ], "expression": [ 94, 183, 225 ], "glucose\u2010regulated": [ 96 ], "protein": [ 97, 100, 173 ], "78,": [ 98 ], "phosphorylated": [ 99, 105 ], "kinase\u2010like": [ 101 ], "kinase,": [ 103 ], "eukaryotic": [ 106 ], "initiation": [ 107 ], "factor": [ 108, 165, 221, 241 ], "2\u03b1,": [ 109 ], "while": [ 110 ], "these": [ 111 ], "increases": [ 112 ], "significantly": [ 114, 142 ], "inhibited": [ 115 ], "exenatide.": [ 117 ], "notably": [ 119 ], "decreased": [ 120 ], "liver": [ 122 ], "weight": [ 123 ], "steatosis": [ 126, 232 ], "challenge.": [ 130 ], "Consistently,": [ 131 ], "in": [ 132, 233 ], "human": [ 133 ], "HepG2": [ 134 ], "cells": [ 135 ], "primary": [ 137 ], "murine": [ 138 ], "hepatocytes,": [ 139 ], "exendin\u20104": [ 140, 158 ], "also": [ 141 ], "alleviated": [ 143 ], "lipid": [ 148 ], "accumulation": [ 149 ], "palmitate.": [ 152 ], "Importantly,": [ 153 ], "further": [ 154 ], "showed": [ 156 ], "enhanced": [ 159 ], "binding": [ 161 ], "heat": [ 163, 171, 219 ], "shock": [ 164, 172, 220, 240 ], "promoter": [ 169 ], "(HSP)": [ 174 ], "genes": [ 175 ], "SIRT1\u2010mediated": [ 177 ], "deacetylation,": [ 178 ], "which": [ 179, 254 ], "then": [ 180 ], "molecular": [ 185, 259 ], "chaperones": [ 186 ], "HSP70": [ 187 ], "HSP40": [ 189 ], "stress.": [ 194 ], "Finally,": [ 195 ], "inhibition": [ 196 ], "SIRT1": [ 198 ], "genetic": [ 200 ], "whole\u2010body": [ 201 ], "heterozygous": [ 202 ], "knockout": [ 203 ], "lentiviral": [ 206 ], "short": [ 207 ], "hairpin": [ 208 ], "RNA": [ 209 ], "knockdown": [ 210 ], "greatly": [ 211 ], "diminished": [ 212 ], "effect": [ 214 ], "on": [ 217 ], "deacetylating": [ 218 ], "1,": [ 222 ], "increasing": [ 223 ], "HSP": [ 224 ], "alleviating": [ 227 ], "HFD\u2010fed": [ 234 ], "mice.": [ 235 ], "Conclusion": [ 236 ], ":": [ 237 ], "The": [ 238 ], "SIRT1/heat": [ 239 ], "1/HSP": [ 242 ], "pathway": [ 243 ], "essential": [ 245 ], "exenatide\u2010alleviated,": [ 247 ], "provides": [ 255 ], "evidence": [ 256 ], "mechanism": [ 260 ], "support": [ 262 ], "incretin": [ 265 ], "mimetics": [ 266 ], "promising": [ 268 ], "therapeutics": [ 269 ], "obesity\u2010induced": [ 271 ], "(H": [ 274 ], "epatology": [ 275 ], "2017;66:809\u2013824)": [ 276 ] }, "publication_date": "2017-04-25", "publication_year": 2017, "type": "article", "cited_by_count": 84, "authors": [ { "id": "https://openalex.org/A5071498928", "display_name": "Xiaobin Zheng" }, { "id": "https://openalex.org/A5001571073", "display_name": "Fen Xu" }, { "id": "https://openalex.org/A5023641721", "display_name": "Hua Liang" }, { "id": "https://openalex.org/A5108726379", "display_name": "Huanyi Cao" }, { "id": "https://openalex.org/A5070322018", "display_name": "Mengyin Cai" }, { "id": "https://openalex.org/A5061894086", "display_name": "Wen Xu" }, { "id": "https://openalex.org/A5012775407", "display_name": "Jianping Weng" } ] }, { "id": "https://openalex.org/W4408960945", "doi": "https://doi.org/10.1056/nejmoa2501006", "title": "Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes", "abstract": { "Among": [ 0 ], "persons": [ 1 ], "with": [ 2, 22 ], "type": [ 3 ], "2": [ 4 ], "diabetes": [ 5 ], "and": [ 6 ], "atherosclerotic": [ 7 ], "cardiovascular": [ 8, 30 ], "disease,": [ 9, 12 ], "chronic": [ 10 ], "kidney": [ 11 ], "or": [ 13 ], "both,": [ 14 ], "the": [ 15, 38 ], "use": [ 16 ], "of": [ 17, 27, 40 ], "oral": [ 18 ], "semaglutide": [ 19 ], "was": [ 20 ], "associated": [ 21 ], "a": [ 23 ], "significantly": [ 24 ], "lower": [ 25 ], "risk": [ 26 ], "major": [ 28 ], "adverse": [ 29, 42 ], "events": [ 31 ], "than": [ 32 ], "placebo,": [ 33 ], "without": [ 34 ], "an": [ 35 ], "increase": [ 36 ], "in": [ 37 ], "incidence": [ 39 ], "serious": [ 41 ], "events.": [ 43 ], "(Funded": [ 44 ], "by": [ 45 ], "Novo": [ 46 ], "Nordisk;": [ 47 ], "SOUL": [ 48 ], "ClinicalTrials.gov": [ 49 ], "number,": [ 50 ], "NCT03914326.).": [ 51 ] }, "publication_date": "2025-03-29", "publication_year": 2025, "type": "article", "cited_by_count": 127, "authors": [ { "id": "https://openalex.org/A5071945904", "display_name": "Darren K. McGuire" }, { "id": "https://openalex.org/A5019976194", "display_name": "Nikolaus Marx" }, { "id": "https://openalex.org/A5025608840", "display_name": "Sharon L. Mulvagh" }, { "id": "https://openalex.org/A5039316946", "display_name": "John Deanfield" }, { "id": "https://openalex.org/A5005006476", "display_name": "Silvio E. Inzucchi" }, { "id": "https://openalex.org/A5018561083", "display_name": "Rodica Pop\u2010Busui" }, { "id": "https://openalex.org/A5043842967", "display_name": "Johannes F.E. Mann" }, { "id": "https://openalex.org/A5090993994", "display_name": "Scott S. Emerson" }, { "id": "https://openalex.org/A5072011562", "display_name": "Neil R Poulter" }, { "id": "https://openalex.org/A5114035153", "display_name": "Mads D.M. Engelmann" }, { "id": "https://openalex.org/A5078101576", "display_name": "Maria Sejersten Ripa" }, { "id": "https://openalex.org/A5004099465", "display_name": "G. Kees Hovingh" }, { "id": "https://openalex.org/A5102890913", "display_name": "Kirstine Brown\u2010Frandsen" }, { "id": "https://openalex.org/A5080463002", "display_name": "Stephen C. Bain" }, { "id": "https://openalex.org/A5083542202", "display_name": "Matthew A. Cavender" }, { "id": "https://openalex.org/A5054860387", "display_name": "Mette Gislum" }, { "id": "https://openalex.org/A5034206406", "display_name": "Jens\u2010Peter David" }, { "id": "https://openalex.org/A5040182038", "display_name": "John B. Buse" } ] }, { "id": "https://openalex.org/W2922550132", "doi": "https://doi.org/10.1001/jama.2019.2942", "title": "Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea", "abstract": { "ClinicalTrials.gov": [ 0 ], "Identifier:": [ 1 ], "NCT02607865.": [ 2 ] }, "publication_date": "2019-03-23", "publication_year": 2019, "type": "article", "cited_by_count": 359, "authors": [ { "id": "https://openalex.org/A5045489578", "display_name": "Julio Rosenstock" }, { "id": "https://openalex.org/A5023839322", "display_name": "Nils Holger Petersen" }, { "id": "https://openalex.org/A5013839934", "display_name": "Andreas L. Birkenfeld" }, { "id": "https://openalex.org/A5027926667", "display_name": "Thalia Marie Blicher" }, { "id": "https://openalex.org/A5112650825", "display_name": "Srikanth Deenadayalan" }, { "id": "https://openalex.org/A5110457964", "display_name": "Jacob Jacobsen" }, { "id": "https://openalex.org/A5061673342", "display_name": "Pierre S\u00e9rusclat" }, { "id": "https://openalex.org/A5078442479", "display_name": "Rafael Violante" }, { "id": "https://openalex.org/A5043895658", "display_name": "Hirotaka Watada" }, { "id": "https://openalex.org/A5084593004", "display_name": "Melanie J. Davies" } ] }, { "id": "https://openalex.org/W4390064123", "doi": "https://doi.org/10.23736/s2724-6507.23.04101-5", "title": "Exploring the potential impact of GLP-1 receptor agonists in cancer therapy", "abstract": { "Glucagon-like": [ 0 ], "peptide-1": [ 1 ], "(GLP-1)": [ 2 ], "receptor": [ 3, 60, 72, 143, 192 ], "agonists": [ 4, 61, 73, 144, 193 ], "are": [ 5, 174 ], "used": [ 6 ], "in": [ 7, 16, 22, 36, 62, 78, 95, 139, 149, 206 ], "diabetes": [ 8 ], "management": [ 9 ], "and": [ 10, 52, 65, 85, 88, 101, 126, 158, 168, 186 ], "can": [ 11 ], "have": [ 12, 34, 74, 89, 106, 146 ], "a": [ 13 ], "potential": [ 14, 110, 148 ], "application": [ 15 ], "cancer": [ 17, 23, 37, 80 ], "therapy.": [ 18, 38 ], "While": [ 19 ], "their": [ 20, 153 ], "involvement": [ 21 ], "treatment": [ 24 ], "is": [ 25 ], "still": [ 26 ], "being": [ 27 ], "studied,": [ 28 ], "recent": [ 29 ], "research": [ 30, 173 ], "suggests": [ 31 ], "they": [ 32 ], "may": [ 33, 136, 145 ], "benefits": [ 35 ], "A": [ 39 ], "comprehensive": [ 40 ], "literature": [ 41 ], "search": [ 42, 46 ], "was": [ 43 ], "conducted": [ 44 ], "using": [ 45 ], "engines": [ 47 ], "like": [ 48 ], "Google": [ 49 ], "Scholar,": [ 50 ], "Scopus,": [ 51 ], "PubMed": [ 53 ], "to": [ 54, 92, 117, 152, 189 ], "explore": [ 55 ], "the": [ 56, 169 ], "effects": [ 57, 77 ], "of": [ 58, 123, 132, 156, 166 ], "GLP-1": [ 59, 71, 142, 191 ], "tumor": [ 63 ], "suppression": [ 64 ], "regression.": [ 66 ], "Mostly": [ 67 ], "in-vitro": [ 68 ], "studies": [ 69, 178 ], "on": [ 70, 181 ], "shown": [ 75 ], "promising": [ 76 ], "inhibiting": [ 79 ], "cell": [ 81 ], "growth,": [ 82 ], "inducing": [ 83 ], "apoptosis,": [ 84 ], "modulating": [ 86 ], "angiogenesis": [ 87 ], "been": [ 90, 107, 115 ], "reported": [ 91, 116 ], "be": [ 93, 118, 137 ], "beneficial": [ 94, 138 ], "colon,": [ 96 ], "prostate,": [ 97 ], "gall": [ 98 ], "bladder,": [ 99 ], "ovarian,": [ 100 ], "endometrial": [ 102 ], "carcinomas.": [ 103, 128 ], "However,": [ 104 ], "concerns": [ 105 ], "raised": [ 108 ], "about": [ 109 ], "tumorigeneses,": [ 111 ], "as": [ 112 ], "liraglutide": [ 113 ], "has": [ 114 ], "associated": [ 119 ], "with": [ 120, 134 ], "increased": [ 121 ], "incidence": [ 122 ], "breast,": [ 124 ], "thyroid,": [ 125 ], "pancreatic": [ 127, 140 ], "Whereas": [ 129 ], "combination": [ 130 ], "therapy": [ 131 ], "exendin-4": [ 133 ], "gemcitabine": [ 135 ], "cancer.": [ 141 ], "significant": [ 147 ], "oncology,": [ 150 ], "due": [ 151 ], "various": [ 154 ], "mechanisms": [ 155 ], "action": [ 157 ], "favorable": [ 159 ], "safety": [ 160 ], "profiles.": [ 161 ], "Limited": [ 162 ], "clinical": [ 163, 204 ], "application,": [ 164 ], "lack": [ 165 ], "awareness,": [ 167 ], "need": [ 170 ], "for": [ 171, 198 ], "further": [ 172 ], "current": [ 175 ], "barriers.": [ 176 ], "Future": [ 177 ], "should": [ 179 ], "focus": [ 180 ], "optimal": [ 182 ], "dosage,": [ 183 ], "patient": [ 184 ], "selection,": [ 185 ], "interdisciplinary": [ 187 ], "collaboration": [ 188 ], "integrate": [ 190 ], "into": [ 194 ], "routine": [ 195 ], "oncological": [ 196 ], "practice": [ 197 ], "improved": [ 199 ], "outcomes,": [ 200 ], "warranting": [ 201 ], "large": [ 202 ], "randomized": [ 203 ], "trials": [ 205 ], "this": [ 207 ], "field.": [ 208 ] }, "publication_date": "2023-12-21", "publication_year": 2023, "type": "article", "cited_by_count": 12, "authors": [ { "id": "https://openalex.org/A5108888027", "display_name": "Baseer Aslam" }, { "id": "https://openalex.org/A5054544824", "display_name": "Muhammad Daim Bin Zafar" }, { "id": "https://openalex.org/A5093552951", "display_name": "Mah I Khan CHANGEZ" }, { "id": "https://openalex.org/A5054415116", "display_name": "Muhammad ABDULLAH" }, { "id": "https://openalex.org/A5088343657", "display_name": "Muhammad Safwan" }, { "id": "https://openalex.org/A5093552952", "display_name": "Bisma QAMAR" }, { "id": "https://openalex.org/A5093552953", "display_name": "Abdullah SHINWARI" }, { "id": "https://openalex.org/A5105036679", "display_name": "Sanjana RAI" } ] }, { "id": "https://openalex.org/W2959708126", "doi": "https://doi.org/10.1155/2019/1534365", "title": "Risk of Malignant Neoplasia with Glucagon-Like Peptide-1 Receptor Agonist Treatment in Patients with Type 2 Diabetes: A Meta-Analysis", "abstract": { "Background": [ 0 ], ".": [ 1, 40, 118, 245 ], "Glucagon-like": [ 2 ], "peptide-1": [ 3 ], "(GLP-1)": [ 4 ], "receptor": [ 5, 32, 68, 157, 225, 247 ], "agonists": [ 6, 33, 69, 158, 248 ], "are": [ 7 ], "effective": [ 8 ], "glucose-lowering": [ 9 ], "drugs,": [ 10 ], "but": [ 11 ], "there": [ 12 ], "is": [ 13 ], "concern": [ 14 ], "that": [ 15, 55 ], "they": [ 16 ], "may": [ 17 ], "increase": [ 18, 145, 218 ], "the": [ 19, 28, 57, 79, 101, 130, 134, 153, 220 ], "risk": [ 20, 222 ], "of": [ 21, 30, 52, 59, 89, 100, 136, 155, 208 ], "malignant": [ 22, 37, 137, 147, 257 ], "neoplasia.": [ 23, 38, 116 ], "The": [ 24 ], "present": [ 25 ], "meta-analysis": [ 26, 99 ], "examined": [ 27 ], "safety": [ 29, 253 ], "GLP-1": [ 31, 67, 156, 224, 246 ], "with": [ 34, 48, 71, 85, 133, 139, 152, 223, 261 ], "regard": [ 35 ], "to": [ 36, 110, 256 ], "Methods": [ 39 ], "We": [ 41, 77 ], "analyzed": [ 42 ], "data": [ 43, 104, 123 ], "from": [ 44 ], "randomized": [ 45 ], "controlled": [ 46 ], "trials": [ 47, 209 ], "a": [ 49, 86, 98, 106 ], "minimum": [ 50 ], "duration": [ 51 ], "24": [ 53 ], "weeks": [ 54 ], "assessed": [ 56 ], "incidence": [ 58, 135 ], "neoplasms": [ 60 ], "in": [ 61, 129, 146, 219, 259 ], "type": [ 62, 262 ], "2": [ 63, 263 ], "diabetes": [ 64 ], "patients": [ 65, 260 ], "receiving": [ 66 ], "compared": [ 70 ], "placebo": [ 72, 140 ], "or": [ 73, 141, 196 ], "other": [ 74, 142 ], "hypoglycemic": [ 75 ], "drugs.": [ 76 ], "searched": [ 78 ], "MEDLINE,": [ 80 ], "Embase,": [ 81 ], "and": [ 82, 95 ], "Cochrane": [ 83 ], "databases": [ 84 ], "language": [ 87 ], "restriction": [ 88 ], "English": [ 90 ], "through": [ 91 ], "October": [ 92 ], "1,": [ 93 ], "2018,": [ 94 ], "carried": [ 96 ], "out": [ 97 ], "available": [ 102 ], "trial": [ 103 ], "using": [ 105 ], "fixed": [ 107 ], "effects": [ 108 ], "model": [ 109 ], "calculate": [ 111 ], "odds": [ 112 ], "ratios": [ 113 ], "(ORs)": [ 114 ], "for": [ 115, 124, 241 ], "Results": [ 117 ], "Thirty-four": [ 119 ], "relevant": [ 120 ], "articles,": [ 121 ], "providing": [ 122 ], "50452": [ 125 ], "patients,": [ 126 ], "were": [ 127 ], "included": [ 128 ], "meta-analysis.": [ 131 ], "Compared": [ 132 ], "neoplasia": [ 138, 221, 258 ], "interventions,": [ 143 ], "no": [ 144, 217 ], "neoplasm": [ 148 ], "formation": [ 149 ], "was": [ 150, 239 ], "observed": [ 151 ], "use": [ 154, 227 ], "(OR": [ 159, 170, 179, 188, 198, 228 ], "1.04,": [ 160 ], "95%": [ 161, 172, 181, 190, 200, 230 ], "confidence": [ 162 ], "interval": [ 163 ], "(CI)": [ 164 ], "0.94\u20131.15;": [ 165 ], "p=0.46),": [ 168 ], "liraglutide": [ 169 ], "1.08,": [ 171 ], "CI": [ 173, 182, 191, 201, 231 ], "0.91\u20131.27;": [ 174 ], "id=\"M2\">p=0.38),": [ 177 ], "exenatide": [ 178 ], "1.00,": [ 180 ], "0.86\u20131.16;": [ 183 ], "id=\"M3\">p=1.00),": [ 186 ], "semaglutide": [ 187 ], "0.89,": [ 189 ], "0.35\u20132.22;": [ 192 ], "id=\"M4\">p=0.80),": [ 195 ], "albiglutide": [ 197 ], "1.07,": [ 199 ], "0.23\u20134.88;": [ 202 ], "id=\"M5\">p=0.93).": [ 205 ], "A": [ 206 ], "subanalysis": [ 207 ], "lasting": [ 210 ], "longer": [ 211 ], "than": [ 212 ], "3": [ 213 ], "years": [ 214 ], "also": [ 215 ], "showed": [ 216 ], "agonist": [ 226 ], "1.03,": [ 229 ], "0.92\u20131.15;": [ 232 ], "id=\"M6\">p=0.60).": [ 235 ], "Between-trial": [ 236 ], "statistical": [ 237 ], "heterogeneity": [ 238 ], "low": [ 240 ], "all": [ 242 ], "comparisons.": [ 243 ], "Conclusion": [ 244 ], "can": [ 249 ], "be": [ 250 ], "used": [ 251 ], "without": [ 252 ], "concerns": [ 254 ], "related": [ 255 ], "diabetes.": [ 264 ] }, "publication_date": "2019-07-16", "publication_year": 2019, "type": "review", "cited_by_count": 43, "authors": [ { "id": "https://openalex.org/A5100761344", "display_name": "Yufang Liu" }, { "id": "https://openalex.org/A5100352992", "display_name": "Xiaomei Zhang" }, { "id": "https://openalex.org/A5080038308", "display_name": "Sanbao Chai" }, { "id": "https://openalex.org/A5101851200", "display_name": "Xin Zhao" }, { "id": "https://openalex.org/A5015002294", "display_name": "Linong Ji" } ] }, { "id": "https://openalex.org/W4280540962", "doi": "https://doi.org/10.1177/87551225221092681", "title": "Once-Weekly Semaglutide for Weight Management: A Clinical Review", "abstract": { "Objective:": [ 0 ], "To": [ 1 ], "review": [ 2 ], "the": [ 3, 9, 33, 58, 166, 191, 239 ], "efficacy,": [ 4 ], "safety,": [ 5 ], "and": [ 6, 27, 39, 51, 60, 89, 149, 152, 176 ], "role": [ 7 ], "of": [ 8, 25, 43, 62, 215 ], "glucagon-like": [ 10 ], "peptide-1": [ 11 ], "(GLP-1)": [ 12 ], "receptor": [ 13, 193, 218 ], "agonist": [ 14, 194 ], "semaglutide": [ 15, 36, 44, 63, 77, 181 ], "for": [ 16, 66, 92, 157, 180, 190, 205, 225, 231 ], "chronic": [ 17, 93, 226 ], "weight": [ 18, 67, 94, 134, 206, 227, 242 ], "management.": [ 19 ], "Data": [ 20, 52, 73 ], "Sources:": [ 21 ], "A": [ 22 ], "literature": [ 23 ], "search": [ 24, 34 ], "PubMed/MEDLINE": [ 26 ], "Google": [ 28 ], "Scholar": [ 29 ], "was": [ 30 ], "performed": [ 31 ], "using": [ 32 ], "terms:": [ 35 ], "2.4,": [ 37 ], "weight,": [ 38 ], "obesity.": [ 40 ], "Ongoing": [ 41 ], "studies": [ 42 ], "were": [ 45, 71, 165, 184 ], "identified": [ 46 ], "utilizing": [ 47 ], "clinicaltrials.gov.": [ 48 ], "Study": [ 49 ], "Selection": [ 50 ], "Extraction:": [ 53 ], "All": [ 54 ], "English-language": [ 55 ], "articles": [ 56 ], "evaluating": [ 57 ], "efficacy": [ 59, 151 ], "safety": [ 61, 153, 210 ], "2.4": [ 64, 78, 127, 182, 198 ], "mg": [ 65, 79, 128, 183, 199 ], "management": [ 68, 95 ], "in": [ 69, 96, 144 ], "humans": [ 70 ], "included.": [ 72 ], "Synthesis:": [ 74 ], "Once-weekly": [ 75 ], "injectable": [ 76 ], "is": [ 80, 200, 221, 237 ], "indicated": [ 81 ], "as": [ 82, 118 ], "an": [ 83 ], "adjunct": [ 84 ], "to": [ 85, 159, 213, 233 ], "a": [ 86, 99, 201, 209, 222 ], "reduced-calorie": [ 87 ], "diet": [ 88 ], "increased": [ 90 ], "exercise": [ 91 ], "adults": [ 97 ], "with": [ 98, 111, 146, 186, 208, 229 ], "body": [ 100 ], "mass": [ 101 ], "index": [ 102 ], "(BMI)": [ 103 ], "\u226530": [ 104 ], "kg/m": [ 105, 109 ], "2": [ 106, 110, 121, 160, 234 ], "or": [ 107, 124 ], "\u226527": [ 108 ], "at": [ 112 ], "least": [ 113 ], "one": [ 114 ], "weight-related": [ 115 ], "comorbidity,": [ 116 ], "such": [ 117 ], "hypertension,": [ 119 ], "type": [ 120 ], "diabetes": [ 122 ], "mellitus,": [ 123 ], "dyslipidemia.": [ 125 ], "Semaglutide": [ 126, 197 ], "has": [ 129 ], "consistently": [ 130 ], "demonstrated": [ 131 ], "clinically": [ 132 ], "significant": [ 133 ], "loss": [ 135, 243 ], "across": [ 136 ], "all": [ 137 ], "phase": [ 138 ], "3": [ 139 ], "STEP": [ 140 ], "(semaglutide": [ 141 ], "treatment": [ 142 ], "effect": [ 143 ], "people": [ 145 ], "obesity)": [ 147 ], "trials,": [ 148 ], "long-term": [ 150 ], "have": [ 154 ], "been": [ 155 ], "confirmed": [ 156 ], "up": [ 158, 232 ], "years.": [ 161, 235 ], "Gastrointestinal": [ 162 ], "side": [ 163, 170 ], "effects": [ 164 ], "most": [ 167 ], "frequently": [ 168 ], "reported": [ 169, 188 ], "effects,": [ 171 ], "including": [ 172 ], "nausea,": [ 173 ], "vomiting,": [ 174 ], "constipation,": [ 175 ], "diarrhea.": [ 177 ], "Safety": [ 178 ], "data": [ 179, 230 ], "consistent": [ 185 ], "that": [ 187, 214 ], "previously": [ 189 ], "GLP-1": [ 192, 217 ], "class.": [ 195 ], "Conclusions:": [ 196 ], "highly": [ 202 ], "efficacious": [ 203 ], "agent": [ 204 ], "management,": [ 207, 228 ], "profile": [ 211 ], "similar": [ 212 ], "other": [ 216 ], "agonists.": [ 219 ], "It": [ 220, 236 ], "feasible": [ 223 ], "option": [ 224 ], "currently": [ 238 ], "only": [ 240 ], "once-weekly": [ 241 ], "medication,": [ 244 ], "although": [ 245 ], "cost": [ 246 ], "may": [ 247 ], "limit": [ 248 ], "its": [ 249 ], "utilization.": [ 250 ] }, "publication_date": "2022-05-13", "publication_year": 2022, "type": "review", "cited_by_count": 27, "authors": [ { "id": "https://openalex.org/A5009379860", "display_name": "Abby Fornes" }, { "id": "https://openalex.org/A5110916087", "display_name": "Jamie Huff" }, { "id": "https://openalex.org/A5108811393", "display_name": "Roger Iain Pritchard" }, { "id": "https://openalex.org/A5021652822", "display_name": "Miranda Godfrey" } ] }, { "id": "https://openalex.org/W2558288750", "doi": "https://doi.org/10.1186/s12933-016-0480-8", "title": "Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study", "abstract": null, "publication_date": "2016-12-01", "publication_year": 2016, "type": "article", "cited_by_count": 129, "authors": [ { "id": "https://openalex.org/A5049796469", "display_name": "Manfredi Rizzo" }, { "id": "https://openalex.org/A5008776901", "display_name": "Ali A. Rizvi" }, { "id": "https://openalex.org/A5049777035", "display_name": "Angelo Maria Patti" }, { "id": "https://openalex.org/A5002357548", "display_name": "Dragana Nikoli\u0107" }, { "id": "https://openalex.org/A5054572477", "display_name": "Rosaria Vincenza Giglio" }, { "id": "https://openalex.org/A5088586382", "display_name": "Giuseppa Castellino" }, { "id": "https://openalex.org/A5026039152", "display_name": "Giovanni Li Volti" }, { "id": "https://openalex.org/A5034828130", "display_name": "Massimiliano Caprio" }, { "id": "https://openalex.org/A5082733849", "display_name": "Giuseppe Montalto" }, { "id": "https://openalex.org/A5015438056", "display_name": "Vincenzo Provenzano" }, { "id": "https://openalex.org/A5049715149", "display_name": "Stefano Genovese" }, { "id": "https://openalex.org/A5044764461", "display_name": "Antonio Ceriello" } ] }, { "id": "https://openalex.org/W2072691447", "doi": "https://doi.org/10.2337/dc11-1107", "title": "Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)", "abstract": { "OBJECTIVE": [ 0 ], "To": [ 1 ], "test": [ 2 ], "the": [ 3, 256, 270 ], "safety": [ 4 ], "and": [ 5, 18, 28, 87, 136, 154, 167, 187, 202, 208, 214, 217, 221, 243, 260, 275 ], "efficacy": [ 6 ], "of": [ 7, 272, 279 ], "exenatide": [ 8 ], "once": [ 9 ], "weekly": [ 10 ], "(EQW)": [ 11 ], "compared": [ 12 ], "with": [ 13, 32, 96, 149, 247, 269 ], "metformin": [ 14 ], "(MET),": [ 15 ], "pioglitazone": [ 16 ], "(PIO),": [ 17 ], "sitagliptin": [ 19 ], "(SITA)": [ 20 ], "over": [ 21 ], "26": [ 22, 84, 145, 253 ], "weeks,": [ 23 ], "in": [ 24, 265 ], "suboptimally": [ 25 ], "treated": [ 26 ], "(diet": [ 27 ], "exercise)": [ 29 ], "drug-naive": [ 30 ], "patients": [ 31 ], "type": [ 33 ], "2": [ 34 ], "diabetes.": [ 35 ], "RESEARCH": [ 36 ], "DESIGN": [ 37 ], "AND": [ 38 ], "METHODS": [ 39 ], "Patients": [ 40 ], "were": [ 41, 90, 100, 114, 156, 176, 196 ], "randomized": [ 42 ], "to": [ 43, 92, 238, 245, 249 ], "subcutaneous": [ 44 ], "(SC)": [ 45 ], "EQW": [ 46, 97, 150, 235, 259 ], "2.0": [ 47 ], "mg": [ 48 ], "+": [ 49, 58, 67, 77 ], "oral": [ 50, 104 ], "placebo": [ 51, 60, 69, 79, 99, 107 ], "(n": [ 52, 61, 70, 80 ], "=": [ 53, 62, 71, 81, 161, 165, 181 ], "248),": [ 54 ], "MET": [ 55, 86, 239, 261 ], "2,000": [ 56 ], "mg/day": [ 57, 66, 76 ], "SC": [ 59, 68, 78 ], "246),": [ 63 ], "PIO": [ 64, 88, 242 ], "45": [ 65 ], "163),": [ 72 ], "or": [ 73, 98, 106 ], "SITA": [ 74, 155, 246 ], "100": [ 75 ], "163)": [ 82 ], "for": [ 83 ], "weeks.": [ 85, 254 ], "therapies": [ 89 ], "increased": [ 91, 277 ], "maximum-tolerated": [ 93 ], "dosages.": [ 94 ], "Injections": [ 95 ], "administered": [ 101, 109 ], "weekly,": [ 102 ], "while": [ 103 ], "medication": [ 105 ], "was": [ 108, 227, 236 ], "daily.": [ 110 ], "RESULTS": [ 111 ], "Baseline": [ 112 ], "characteristics": [ 113 ], "as": [ 115, 197 ], "follows:": [ 116, 198 ], "59%": [ 117 ], "men,": [ 118 ], "67%": [ 119 ], "Caucasian,": [ 120 ], "mean": [ 121 ], "age": [ 122 ], "54": [ 123 ], "years,": [ 124 ], "HbA1c": [ 125, 141, 250 ], "8.5%,": [ 126 ], "fasting": [ 127 ], "serum": [ 128 ], "glucose": [ 129 ], "9.9": [ 130 ], "mmol/L,": [ 131 ], "body": [ 132 ], "weight": [ 133, 273 ], "87.0": [ 134 ], "kg,": [ 135 ], "diabetes": [ 137 ], "duration": [ 138 ], "2.7": [ 139 ], "years.": [ 140 ], "reductions": [ 142 ], "(%)": [ 143 ], "at": [ 144, 252 ], "weeks": [ 146 ], "(least-squares": [ 147 ], "means)": [ 148 ], "versus": [ 151 ], "MET,": [ 152, 205 ], "PIO,": [ 153, 211 ], "\u22121.53": [ 157 ], "vs.": [ 158, 178 ], "\u22121.48": [ 159 ], "(P": [ 160, 164, 169, 180, 184, 189 ], "0.620),": [ 162 ], "\u22121.63": [ 163 ], "0.328),": [ 166 ], "\u22121.15": [ 168 ], "&lt;": [ 170, 185, 190 ], "0.001),": [ 171, 186, 191 ], "respectively.": [ 172, 192 ], "Weight": [ 173 ], "changes": [ 174 ], "(kg)": [ 175 ], "\u22122.0": [ 177, 179 ], "0.892),": [ 182 ], "+1.5": [ 183 ], "\u22120.8": [ 188 ], "Common": [ 193 ], "adverse": [ 194 ], "events": [ 195 ], "EQW,": [ 199 ], "nausea": [ 200 ], "(11.3%)": [ 201 ], "diarrhea": [ 203, 206 ], "(10.9%);": [ 204 ], "(12.6%)": [ 207 ], "headache": [ 209, 215, 222 ], "(12.2%);": [ 210 ], "nasopharyngitis": [ 212, 219 ], "(8.6%)": [ 213 ], "(8.0%);": [ 216 ], "SIT,": [ 218 ], "(9.8%)": [ 220 ], "(9.2%).": [ 223 ], "Minor": [ 224 ], "(confirmed)": [ 225 ], "hypoglycemia": [ 226, 232 ], "rarely": [ 228 ], "reported.": [ 229 ], "No": [ 230 ], "major": [ 231 ], "occurred.": [ 233 ], "CONCLUSIONS": [ 234 ], "noninferior": [ 237 ], "but": [ 240 ], "not": [ 241 ], "superior": [ 244 ], "regard": [ 248 ], "reduction": [ 251, 274 ], "Of": [ 255 ], "agents": [ 257 ], "studied,": [ 258 ], "provided": [ 262 ], "similar": [ 263 ], "improvements": [ 264 ], "glycemic": [ 266 ], "control": [ 267 ], "along": [ 268 ], "benefit": [ 271 ], "no": [ 276 ], "risk": [ 278 ], "hypoglycemia.": [ 280 ] }, "publication_date": "2011-12-31", "publication_year": 2011, "type": "article", "cited_by_count": 332, "authors": [ { "id": "https://openalex.org/A5082184915", "display_name": "David Russell\u2010Jones" }, { "id": "https://openalex.org/A5101709468", "display_name": "Robert Cuddihy" }, { "id": "https://openalex.org/A5052329017", "display_name": "M Hanefeld" }, { "id": "https://openalex.org/A5027011735", "display_name": "Ajay Kumar" }, { "id": "https://openalex.org/A5031965655", "display_name": "Jos\u00e9 Gerardo Gonz\u00e1lez\u2010Gonz\u00e1lez" }, { "id": "https://openalex.org/A5087381976", "display_name": "Melanie Chan" }, { "id": "https://openalex.org/A5063856648", "display_name": "Anne M. Wolka" }, { "id": "https://openalex.org/A5012995950", "display_name": "Marilyn K. Boardman" } ] }, { "id": "https://openalex.org/W2981776558", "doi": "https://doi.org/10.1111/dom.13899", "title": "Oral semaglutide for type 2 diabetes: A systematic review and meta\u2010analysis", "abstract": { "Abstract": [ 0 ], "Aim": [ 1 ], "To": [ 2 ], "assess": [ 3 ], "the": [ 4, 28, 118, 241 ], "efficacy": [ 5 ], "and": [ 6, 31, 72, 82, 96, 128, 138, 160, 174, 187, 211, 221, 232, 246, 260, 267, 291 ], "safety": [ 7, 290 ], "of": [ 8, 164, 176, 243, 250, 278 ], "oral": [ 9, 46, 124, 199, 238 ], "semaglutide,": [ 10 ], "a": [ 11, 189, 223 ], "novel": [ 12 ], "glucagon\u2010like": [ 13 ], "peptide\u20101": [ 14 ], "receptor": [ 15 ], "agonist,": [ 16 ], "for": [ 17, 40, 93, 100 ], "patients": [ 18, 116 ], "with": [ 19, 48, 104, 114, 122, 197, 237, 275 ], "type": [ 20 ], "2": [ 21 ], "diabetes.": [ 22 ], "Methods": [ 23 ], "We": [ 24, 85, 110 ], "searched": [ 25 ], "Medline,": [ 26 ], "Embase,": [ 27 ], "Cochrane": [ 29 ], "Library": [ 30 ], "grey": [ 32 ], "literature": [ 33 ], "sources": [ 34 ], "up": [ 35 ], "to": [ 36, 136, 145, 153, 172, 185, 209, 219, 286 ], "July": [ 37 ], "1,": [ 38 ], "2019": [ 39 ], "randomized": [ 41 ], "controlled": [ 42 ], "trials": [ 43 ], "(RCTs)": [ 44 ], "comparing": [ 45 ], "semaglutide": [ 47, 125, 149, 200, 239, 257 ], "placebo": [ 49 ], "or": [ 50 ], "other": [ 51, 154, 295 ], "antidiabetic": [ 52, 296 ], "agents.": [ 53, 297 ], "The": [ 54 ], "primary": [ 55 ], "outcome": [ 56 ], "was": [ 57, 150 ], "change": [ 58, 66 ], "from": [ 59, 67 ], "baseline": [ 60, 68 ], "in": [ 61, 69, 117, 162 ], "HbA1c.": [ 62 ], "Secondary": [ 63 ], "outcomes": [ 64, 95 ], "included": [ 65, 111 ], "body": [ 70, 129, 177, 265 ], "weight": [ 71, 130, 178, 266 ], "blood": [ 73, 194, 263, 269 ], "pressure,": [ 74 ], "cardiovascular": [ 75, 212 ], "endpoints,": [ 76 ], "severe": [ 77, 230 ], "hypoglycaemia,": [ 78 ], "gastrointestinal": [ 79, 279 ], "adverse": [ 80, 280 ], "events": [ 81, 249 ], "diabetic": [ 83, 233 ], "retinopathy.": [ 84, 234 ], "synthesized": [ 86 ], "results": [ 87 ], "using": [ 88 ], "weighted": [ 89 ], "mean": [ 90 ], "differences": [ 91 ], "(WMDs)": [ 92 ], "continuous": [ 94 ], "odds": [ 97 ], "ratios": [ 98 ], "(ORs)": [ 99 ], "dichotomous": [ 101 ], "outcomes,": [ 102 ], "along": [ 103 ], "95%": [ 105, 133, 142, 169, 182, 206, 216 ], "confidence": [ 106 ], "intervals": [ 107 ], "(CIs).": [ 108 ], "Results": [ 109 ], "11": [ 112 ], "RCTs": [ 113 ], "9890": [ 115 ], "systematic": [ 119 ], "review.": [ 120 ], "Compared": [ 121, 196 ], "placebo,": [ 123, 198 ], "reduced": [ 126, 201 ], "HbA1c": [ 127, 166 ], "(WMD": [ 131, 167, 179 ], "\u20130.89%,": [ 132 ], "CI": [ 134, 143, 170, 183, 207, 217 ], "\u22121.07": [ 135 ], "\u22120.71": [ 137 ], "\u2212": [ 139 ], "2.99": [ 140 ], "kg,": [ 141, 181 ], "\u22123.69": [ 144 ], "\u22122.30,": [ 146 ], "respectively).": [ 147 ], "Oral": [ 148, 256 ], "also": [ 151 ], "superior": [ 152 ], "active": [ 155 ], "comparators": [ 156 ], "(including": [ 157 ], "liraglutide,": [ 158 ], "empagliflozin": [ 159 ], "sitaglipitin)": [ 161 ], "terms": [ 163 ], "lowering": [ 165 ], "\u20130.35%,": [ 168 ], "\u22120.43": [ 171 ], "\u22120.26)": [ 173 ], "reduction": [ 175 ], "\u22121.48": [ 180 ], "\u22122.28": [ 184 ], "\u22120.67),": [ 186 ], "had": [ 188, 222 ], "favourable": [ 190 ], "effect": [ 191, 225 ], "on": [ 192, 226 ], "systolic": [ 193, 268 ], "pressure.": [ 195, 270 ], "all\u2010cause": [ 202 ], "mortality": [ 203, 213 ], "(OR": [ 204, 214 ], "0.58,": [ 205 ], "0.37": [ 208 ], "0.92)": [ 210 ], "0.55,": [ 215 ], "0.31": [ 218 ], "0.98),": [ 220 ], "neutral": [ 224 ], "myocardial": [ 227 ], "infarction,": [ 228 ], "stroke,": [ 229 ], "hypoglycaemia": [ 231 ], "However,": [ 235 ], "treatment": [ 236 ], "increased": [ 240, 276 ], "incidence": [ 242, 277 ], "nausea,": [ 244 ], "vomiting": [ 245 ], "diarrhea,": [ 247 ], "while": [ 248 ], "acute": [ 251 ], "pancreatitis": [ 252 ], "were": [ 253 ], "rare.": [ 254 ], "Conclusions": [ 255 ], "can": [ 258 ], "effectively": [ 259 ], "safely": [ 261 ], "reduce": [ 262 ], "glucose,": [ 264 ], "Nevertheless,": [ 271 ], "it": [ 272 ], "is": [ 273, 284 ], "associated": [ 274 ], "events.": [ 281 ], "Further": [ 282 ], "research": [ 283 ], "needed": [ 285 ], "clarify": [ 287 ], "its": [ 288 ], "long\u2010term": [ 289 ], "comparative": [ 292 ], "effectiveness": [ 293 ], "against": [ 294 ] }, "publication_date": "2019-10-21", "publication_year": 2019, "type": "review", "cited_by_count": 76, "authors": [ { "id": "https://openalex.org/A5026527950", "display_name": "Ioannis Avgerinos" }, { "id": "https://openalex.org/A5064268470", "display_name": "Theodoros Michailidis" }, { "id": "https://openalex.org/A5010856150", "display_name": "Aris Liakos" }, { "id": "https://openalex.org/A5084182369", "display_name": "Thomas Karagiannis" }, { "id": "https://openalex.org/A5011127007", "display_name": "David R. Matthews" }, { "id": "https://openalex.org/A5018882870", "display_name": "\u0391\u03c0\u03cc\u03c3\u03c4\u03bf\u03bb\u03bf\u03c2 \u03a4\u03c3\u03ac\u03c0\u03b1\u03c2" }, { "id": "https://openalex.org/A5051305906", "display_name": "Eleni Bekiari" } ] }, { "id": "https://openalex.org/W2516298414", "doi": "https://doi.org/10.1111/bph.13549", "title": "Glucagon\u2010like peptide\u20101 receptor signalling reduces microvascular thrombosis, nitro\u2010oxidative stress and platelet activation in endotoxaemic mice", "abstract": { "Abstract": [ 0 ], "Background": [ 1 ], "and": [ 2, 11, 17, 32, 67, 122, 129, 142, 179, 185, 192, 208, 219, 223, 232, 239, 250, 267, 272 ], "Purpose": [ 3 ], "Excessive": [ 4 ], "inflammation": [ 5, 126 ], "in": [ 6, 52, 111, 127, 228, 270, 279 ], "sepsis": [ 7 ], "causes": [ 8 ], "microvascular": [ 9, 42, 109, 237 ], "thrombosis": [ 10, 43, 110, 238 ], "thrombocytopenia": [ 12 ], "associated": [ 13 ], "with": [ 14, 34, 103, 148, 199, 211 ], "organ": [ 15, 252 ], "dysfunction": [ 16, 121, 249 ], "high": [ 18 ], "mortality.": [ 19 ], "The": [ 20 ], "present": [ 21 ], "studies": [ 22 ], "aimed": [ 23 ], "to": [ 24 ], "investigate": [ 25 ], "whether": [ 26 ], "inhibition": [ 27 ], "of": [ 28, 59, 125, 139, 144, 164, 187, 190, 216, 260 ], "dipeptidyl": [ 29 ], "peptidase\u20104": [ 30 ], "(DPP\u20104)": [ 31 ], "supplementation": [ 33 ], "glucagon\u2010like": [ 35 ], "peptide\u20101": [ 36 ], "(GLP\u20101)": [ 37 ], "receptor": [ 38, 156, 197, 201, 226 ], "agonists": [ 39, 202 ], "improved": [ 40, 169 ], "endotoxaemia\u2010associated": [ 41 ], "via": [ 44 ], "immunomodulatory": [ 45 ], "effects.": [ 46 ], "Experimental": [ 47 ], "Approach": [ 48 ], "Endotoxaemia": [ 49 ], "was": [ 50, 80 ], "induced": [ 51 ], "C57BL/6J": [ 53 ], "mice": [ 54 ], "by": [ 55, 230, 241 ], "a": [ 56, 137, 212, 242, 261 ], "single": [ 57 ], "injection": [ 58 ], "LPS": [ 60, 85, 97, 104 ], "(17.5": [ 61 ], "mg": [ 62, 69 ], "kg": [ 63, 70 ], "\u20101": [ 64, 71 ], "for": [ 65, 72 ], "survival": [ 66, 77 ], "10": [ 68 ], "all": [ 73, 88, 170 ], "other": [ 74, 89, 277 ], "studies).": [ 75 ], "For": [ 76, 87 ], "studies,": [ 78, 90 ], "treatment": [ 79 ], "started": [ 81 ], "6": [ 82 ], "h": [ 83, 95 ], "after": [ 84 ], "injection.": [ 86 ], "drugs": [ 91 ], "were": [ 92 ], "injected": [ 93 ], "48": [ 94 ], "before": [ 96 ], "treatment.": [ 98 ], "Key": [ 99 ], "Results": [ 100 ], "Mice": [ 101 ], "treated": [ 102 ], "alone": [ 105 ], "showed": [ 106 ], "severe": [ 107 ], "thrombocytopenia,": [ 108 ], "the": [ 112, 149, 154, 204, 276 ], "pulmonary": [ 113 ], "circulation": [ 114 ], "(fluorescence": [ 115 ], "imaging),": [ 116 ], "increased": [ 117, 123 ], "LDH": [ 118 ], "activity,": [ 119 ], "endothelial": [ 120 ], "markers": [ 124 ], "aorta": [ 128 ], "whole": [ 130 ], "blood": [ 131 ], "(leukocyte\u2010dependent": [ 132 ], "oxidative": [ 133, 206 ], "burst,": [ 134 ], "nitrosyl\u2010iron": [ 135 ], "haemoglobin,": [ 136 ], "marker": [ 138 ], "nitrosative": [ 140 ], "stress,": [ 141 ], "expression": [ 143 ], "inducible": [ 145 ], "NOS).": [ 146 ], "Treatment": [ 147 ], "DPP\u20104": [ 150, 165 ], "inhibitor": [ 151 ], "linagliptin": [ 152, 178, 231 ], "or": [ 153 ], "GLP\u20101": [ 155, 174, 196, 200, 213, 225 ], "agonist": [ 157 ], "liraglutide,": [ 158 ], "as": [ 159, 161 ], "well": [ 160 ], "genetic": [ 162 ], "deletion": [ 163 ], "(DPP4": [ 166 ], "\u2212/\u2212": [ 167 ], "mice)": [ 168 ], "these": [ 171 ], "parameters.": [ 172 ], "In": [ 173 ], "receptor\u2010deficient": [ 175 ], "mice,": [ 176 ], "both": [ 177 ], "liraglutide": [ 180, 233 ], "lost": [ 181 ], "their": [ 182 ], "beneficial": [ 183 ], "effects": [ 184 ], "improvement": [ 186 ], "prognosis.": [ 188 ], "Incubation": [ 189 ], "platelets": [ 191, 229 ], "cultured": [ 193 ], "monocytes": [ 194 ], "(containing": [ 195 ], "protein)": [ 198 ], "inhibited": [ 203 ], "monocytic": [ 205 ], "burst": [ 207 ], "platelet": [ 209 ], "activation,": [ 210 ], "receptor\u2010dependent": [ 214 ], "elevation": [ 215 ], "cAMP": [ 217 ], "levels": [ 218 ], "PKA": [ 220 ], "activation.": [ 221 ], "Conclusions": [ 222 ], "Implications": [ 224 ], "activation": [ 227 ], "strongly": [ 234 ], "attenuated": [ 235 ], "endotoxaemia\u2010induced": [ 236 ], "mortality": [ 240 ], "cAMP/PKA\u2010dependent": [ 243 ], "mechanism,": [ 244 ], "preventing": [ 245 ], "systemic": [ 246 ], "inflammation,": [ 247 ], "vascular": [ 248 ], "end": [ 251 ], "damage.": [ 253 ], "Linked": [ 254 ], "Articles": [ 255 ], "This": [ 256 ], "article": [ 257 ], "is": [ 258 ], "part": [ 259 ], "themed": [ 262 ], "section": [ 263, 281 ], "on": [ 264 ], "Redox": [ 265 ], "Biology": [ 266 ], "Oxidative": [ 268 ], "Stress": [ 269 ], "Health": [ 271 ], "Disease.": [ 273 ], "To": [ 274 ], "view": [ 275 ], "articles": [ 278 ], "this": [ 280 ], "visit": [ 282 ], "http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.12/issuetoc": [ 283 ] }, "publication_date": "2016-07-20", "publication_year": 2016, "type": "article", "cited_by_count": 90, "authors": [ { "id": "https://openalex.org/A5066963864", "display_name": "Sebastian Steven" }, { "id": "https://openalex.org/A5086436604", "display_name": "Kerstin Jurk" }, { "id": "https://openalex.org/A5113138421", "display_name": "Maximilian Kopp" }, { "id": "https://openalex.org/A5015861190", "display_name": "Swenja Kr\u00f6ller\u2010Sch\u00f6n" }, { "id": "https://openalex.org/A5112330130", "display_name": "Yuliya Mikhed" }, { "id": "https://openalex.org/A5006746542", "display_name": "Kathrin Schwierczek" }, { "id": "https://openalex.org/A5052961878", "display_name": "Siyer Roohani" }, { "id": "https://openalex.org/A5025797296", "display_name": "F. Ravandi Kashani" }, { "id": "https://openalex.org/A5064993444", "display_name": "Matthias Oelze" }, { "id": "https://openalex.org/A5032965517", "display_name": "Thomas Klein" }, { "id": "https://openalex.org/A5001841161", "display_name": "Sergey V. Tokalov" }, { "id": "https://openalex.org/A5033188383", "display_name": "Sven Danckwardt" }, { "id": "https://openalex.org/A5073672091", "display_name": "Susanne Strand" }, { "id": "https://openalex.org/A5074883323", "display_name": "Philip Wenzel" }, { "id": "https://openalex.org/A5113521673", "display_name": "Thomas M\u00fcnzel" }, { "id": "https://openalex.org/A5039361810", "display_name": "Andreas Daiber" } ] }, { "id": "https://openalex.org/W2884008074", "doi": "https://doi.org/10.1007/s40265-018-0946-y", "title": "Centrally Acting Agents for Obesity: Past, Present, and Future", "abstract": null, "publication_date": "2018-07-01", "publication_year": 2018, "type": "review", "cited_by_count": 143, "authors": [ { "id": "https://openalex.org/A5072070675", "display_name": "Ann A. Coulter" }, { "id": "https://openalex.org/A5065704242", "display_name": "Candida J. Rebello" }, { "id": "https://openalex.org/A5080400693", "display_name": "Frank L. Greenway" } ] }, { "id": "https://openalex.org/W2113991576", "doi": "https://doi.org/10.1177/0192623315588999", "title": "Effects of the GLP-1 Receptor Agonist Dulaglutide on the Structure of the Exocrine Pancreas of Cynomolgus Monkeys", "abstract": { "Clinical": [ 0 ], "and": [ 1, 72, 77, 131, 187 ], "nonclinical": [ 2 ], "studies": [ 3 ], "have": [ 4 ], "implicated": [ 5 ], "glucagon-like": [ 6 ], "peptide-1": [ 7 ], "(GLP-1)": [ 8 ], "receptor": [ 9, 38 ], "agonist": [ 10 ], "therapy": [ 11 ], "as": [ 12 ], "a": [ 13 ], "risk": [ 14 ], "factor": [ 15 ], "for": [ 16, 64 ], "acute": [ 17 ], "pancreatitis": [ 18 ], "in": [ 19, 125, 143, 147, 171, 179, 182, 208 ], "patients": [ 20 ], "with": [ 21, 164, 199 ], "type": [ 22 ], "2": [ 23 ], "diabetes.": [ 24 ], "Therefore,": [ 25 ], "it": [ 26 ], "is": [ 27 ], "critical": [ 28 ], "to": [ 29, 67, 112 ], "understand": [ 30 ], "the": [ 31, 42, 51, 107, 120, 126, 150, 172 ], "effect": [ 32, 157 ], "that": [ 33, 193 ], "dulaglutide,": [ 34 ], "an": [ 35, 156 ], "approved": [ 36 ], "GLP-1": [ 37 ], "agonist,": [ 39 ], "has": [ 40 ], "on": [ 41, 57 ], "exocrine": [ 43, 209 ], "pancreas.": [ 44, 210 ], "Dulaglutide": [ 45, 95 ], "8.15": [ 46 ], "mg/kg": [ 47 ], "(approximately": [ 48 ], "500": [ 49 ], "times": [ 50 ], "maximum": [ 52 ], "recommended": [ 53 ], "human": [ 54 ], "dose": [ 55 ], "based": [ 56 ], "plasma": [ 58 ], "exposure)": [ 59 ], "was": [ 60, 90, 154, 161, 176 ], "administered": [ 61 ], "twice": [ 62 ], "weekly": [ 63 ], "12": [ 65 ], "months": [ 66 ], "cynomolgus": [ 68 ], "monkeys.": [ 69, 189 ], "Serum": [ 70 ], "amylase": [ 71, 101 ], "lipase": [ 73, 103 ], "activities": [ 74, 104 ], "were": [ 75, 83 ], "measured": [ 76, 105 ], "6": [ 78 ], "sections": [ 79 ], "of": [ 80, 109, 119, 134, 149, 158, 169, 196 ], "each": [ 81 ], "pancreas": [ 82, 121 ], "examined": [ 84 ], "microscopically.": [ 85 ], "Ductal": [ 86 ], "epithelial": [ 87 ], "cell": [ 88, 180 ], "proliferation": [ 89, 181 ], "estimated": [ 91 ], "using": [ 92 ], "Ki67": [ 93 ], "labeling.": [ 94 ], "administration": [ 96 ], "did": [ 97 ], "not": [ 98, 162, 202 ], "alter": [ 99 ], "serum": [ 100 ], "or": [ 102, 128, 137, 167, 205 ], "at": [ 106 ], "end": [ 108 ], "treatment": [ 110 ], "compared": [ 111 ], "control": [ 113, 186 ], "values.": [ 114 ], "An": [ 115, 141 ], "extensive": [ 116 ], "histologic": [ 117 ], "evaluation": [ 118 ], "revealed": [ 122 ], "no": [ 123, 132, 177 ], "changes": [ 124, 207 ], "acinar": [ 127 ], "endocrine": [ 129 ], "portions": [ 130 ], "evidence": [ 133 ], "pancreatitis,": [ 135 ], "necrosis,": [ 136 ], "pancreatic": [ 138, 173 ], "intraepithelial": [ 139 ], "neoplasia.": [ 140 ], "increase": [ 142 ], "goblet": [ 144 ], "cells": [ 145 ], "noted": [ 146 ], "4": [ 148 ], "19": [ 151 ], "treated": [ 152 ], "monkeys": [ 153 ], "considered": [ 155 ], "dulaglutide": [ 159, 200 ], "but": [ 160 ], "associated": [ 163 ], "dilation,": [ 165 ], "blockage,": [ 166 ], "accumulation": [ 168 ], "mucin": [ 170 ], "duct.": [ 174 ], "There": [ 175 ], "difference": [ 178 ], "ductal": [ 183 ], "epithelium": [ 184 ], "between": [ 185 ], "dulaglutide-treated": [ 188 ], "These": [ 190 ], "data": [ 191 ], "reveal": [ 192 ], "chronic": [ 194 ], "dosing": [ 195 ], "nondiabetic": [ 197 ], "primates": [ 198 ], "does": [ 201 ], "induce": [ 203 ], "inflammatory": [ 204 ], "preneoplastic": [ 206 ] }, "publication_date": "2015-06-09", "publication_year": 2015, "type": "article", "cited_by_count": 7, "authors": [ { "id": "https://openalex.org/A5042601716", "display_name": "John L. Vahle" }, { "id": "https://openalex.org/A5047433195", "display_name": "Richard A. Byrd" }, { "id": "https://openalex.org/A5002096833", "display_name": "Jamie L. Blackbourne" }, { "id": "https://openalex.org/A5105937279", "display_name": "Jennifer A. Martin" }, { "id": "https://openalex.org/A5001483460", "display_name": "Steven D. Sorden" }, { "id": "https://openalex.org/A5085333979", "display_name": "Thomas E. Ryan" }, { "id": "https://openalex.org/A5108537539", "display_name": "Thomas P. Pienkowski" }, { "id": "https://openalex.org/A5035821309", "display_name": "Thomas J. Rosol" }, { "id": "https://openalex.org/A5009558693", "display_name": "Paul W. Snyder" }, { "id": "https://openalex.org/A5089124733", "display_name": "G\u00fcnter Kl\u00f6ppel" } ] }, { "id": "https://openalex.org/W2112694389", "doi": "https://doi.org/10.1111/j.1463-1326.2010.01259.x", "title": "Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary\u2010induced obesity and insulin resistance", "abstract": { "Aim:": [ 0 ], "Liraglutide": [ 1, 50, 84, 142, 163, 190, 213 ], "is": [ 2, 10 ], "a": [ 3, 11 ], "long\u2010acting": [ 4 ], "glucagon\u2010like": [ 5 ], "peptide\u20101": [ 6 ], "(GLP\u20101)": [ 7 ], "mimetic": [ 8 ], "which": [ 9 ], "treatment": [ 12, 143 ], "option": [ 13 ], "for": [ 14, 77 ], "type": [ 15, 244 ], "2": [ 16, 245 ], "diabetes.": [ 17 ], "GLP\u20101": [ 18, 236 ], "peptides,": [ 19 ], "including": [ 20 ], "Liraglutide,": [ 21 ], "cross": [ 22 ], "the": [ 23, 38, 139, 192 ], "blood\u2010brain": [ 24 ], "barrier": [ 25 ], "and": [ 26, 64, 113, 129, 151, 158, 186, 207, 229 ], "may": [ 27 ], "additionally": [ 28 ], "act": [ 29 ], "to": [ 30, 43, 248 ], "improve": [ 31 ], "brain": [ 32 ], "function.": [ 33 ], "The": [ 34 ], "present": [ 35 ], "study": [ 36 ], "tested": [ 37 ], "hypothesis": [ 39 ], "that,": [ 40 ], "in": [ 41, 57, 145, 149, 174, 241 ], "addition": [ 42 ], "its": [ 44 ], "antihyperglycaemic": [ 45 ], "actions,": [ 46 ], "peripheral": [ 47 ], "administration": [ 48 ], "of": [ 49, 83, 98, 138, 183, 195, 202 ], "exerts": [ 51, 222 ], "positive": [ 52 ], "actions": [ 53 ], "on": [ 54, 73, 100, 199, 226 ], "cognitive": [ 55, 227 ], "function": [ 56, 228 ], "mice": [ 58, 71, 99, 170 ], "with": [ 59, 235, 243 ], "high": [ 60, 74, 196 ], "fat": [ 61, 75, 197 ], "dietary\u2010induced": [ 62 ], "obesity": [ 63 ], "insulin": [ 65, 114 ], "resistance.": [ 66 ], "Methods:": [ 67 ], "Young": [ 68 ], "Swiss": [ 69 ], "TO": [ 70 ], "maintained": [ 72 ], "diet": [ 76, 102, 198 ], "20": [ 78 ], "weeks": [ 79 ], "received": [ 80, 103 ], "twice\u2010daily": [ 81, 104 ], "injections": [ 82 ], "(200": [ 85 ], "\u00b5g/kg": [ 86 ], "bw;": [ 87 ], "sc)": [ 88 ], "or": [ 89 ], "saline": [ 90, 105 ], "vehicle": [ 91 ], "over": [ 92 ], "28": [ 93 ], "days.": [ 94 ], "An": [ 95 ], "additional": [ 96, 223 ], "group": [ 97 ], "standard": [ 101 ], "injections.": [ 106 ], "Energy": [ 107 ], "intake,": [ 108, 153 ], "bodyweight,": [ 109 ], "non\u2010fasting": [ 110, 156 ], "plasma": [ 111 ], "glucose": [ 112, 157, 160 ], "concentrations": [ 115 ], "were": [ 116, 134 ], "monitored": [ 117 ], "at": [ 118, 136 ], "regular": [ 119 ], "intervals.": [ 120 ], "Glucose": [ 121 ], "tolerance,": [ 122 ], "open": [ 123 ], "field": [ 124 ], "assessment,": [ 125 ], "object": [ 126, 179 ], "recognition": [ 127, 175, 180 ], "testing": [ 128 ], "electrophysiological": [ 130 ], "long\u2010term": [ 131 ], "potentiation": [ 132 ], "(LTP)": [ 133 ], "performed": [ 135 ], "termination": [ 137 ], "study.": [ 140 ], "Results:": [ 141 ], "resulted": [ 144 ], "significant": [ 146 ], "time\u2010dependent": [ 147 ], "reduction": [ 148 ], "bodyweight": [ 150 ], "energy": [ 152 ], "whilst": [ 154 ], "improving": [ 155 ], "normalizing": [ 159 ], "tolerance.": [ 161 ], "Although": [ 162 ], "did": [ 164 ], "not": [ 165, 216 ], "alter": [ 166 ], "general": [ 167 ], "behaviour,": [ 168 ], "treated": [ 169 ], "exhibited": [ 171 ], "marked": [ 172 ], "increase": [ 173 ], "index": [ 176 ], "(RI)": [ 177 ], "during": [ 178 ], "testing,": [ 181 ], "indicative": [ 182 ], "enhanced": [ 184 ], "learning": [ 185 ], "memory": [ 187 ], "ability.": [ 188 ], "Furthermore,": [ 189 ], "rescued": [ 191 ], "deleterious": [ 193 ], "effects": [ 194, 225, 240 ], "hippocampal": [ 200, 230 ], "LTP": [ 201 ], "neurotransmission": [ 203 ], "following": [ 204 ], "both": [ 205 ], "chronic": [ 206 ], "direct": [ 208 ], "intracerebroventricular": [ 209 ], "(icv)": [ 210 ], "administration.": [ 211 ], "Conclusion:": [ 212 ], "administered": [ 214 ], "peripherally": [ 215 ], "only": [ 217 ], "improves": [ 218 ], "metabolic": [ 219 ], "parameters": [ 220 ], "but": [ 221 ], "beneficial": [ 224 ], "synaptic": [ 231 ], "plasticity.": [ 232 ], "Whether": [ 233 ], "therapy": [ 234 ], "mimetics": [ 237 ], "has": [ 238 ], "similar": [ 239 ], "humans": [ 242 ], "diabetes": [ 246 ], "needs": [ 247 ], "be": [ 249 ], "established.": [ 250 ] }, "publication_date": "2010-06-24", "publication_year": 2010, "type": "article", "cited_by_count": 148, "authors": [ { "id": "https://openalex.org/A5108363859", "display_name": "David W. Porter" }, { "id": "https://openalex.org/A5110567947", "display_name": "Barry D. Kerr" }, { "id": "https://openalex.org/A5064124957", "display_name": "Peter R. Flatt" }, { "id": "https://openalex.org/A5082707086", "display_name": "Christian H\u00f6lscher" }, { "id": "https://openalex.org/A5013136657", "display_name": "Victor A. Gault" } ] }, { "id": "https://openalex.org/W2992083029", "doi": "https://doi.org/10.1080/14656566.2019.1695779", "title": "An evaluation of liraglutide including its efficacy and safety for the treatment of obesity", "abstract": { "Introduction:": [ 0 ], "The": [ 1 ], "prevalence": [ 2 ], "of": [ 3, 28, 59, 76, 88, 102, 107, 128, 134 ], "obesity": [ 4, 31, 77, 191 ], "is": [ 5, 35, 41, 66 ], "increasing": [ 6, 19 ], "worldwide": [ 7 ], "and": [ 8, 38, 64, 81, 100, 115, 123, 168 ], "associated": [ 9 ], "conditions,": [ 10 ], "particularly": [ 11 ], "type": [ 12 ], "2": [ 13 ], "diabetes": [ 14 ], "mellitus": [ 15 ], "(T2DM),": [ 16 ], "also": [ 17 ], "show": [ 18 ], "prevalence.": [ 20 ], "Lifestyle": [ 21 ], "intervention": [ 22 ], "should": [ 23 ], "be": [ 24, 71 ], "the": [ 25, 57, 67, 74, 92, 95, 105, 135, 166, 169 ], "first": [ 26, 68 ], "line": [ 27 ], "management": [ 29, 58 ], "for": [ 30, 56, 73, 104, 140, 171, 190 ], "but": [ 32, 165 ], "additional": [ 33, 155 ], "pharmacotherapy": [ 34 ], "often": [ 36 ], "required": [ 37 ], "bariatric": [ 39 ], "surgery": [ 40 ], "appropriate": [ 42 ], "in": [ 43, 78, 157, 161, 178, 188 ], "more": [ 44 ], "severe": [ 45 ], "cases.": [ 46 ], "Drugs": [ 47 ], "acting": [ 48 ], "as": [ 49, 183 ], "glucagon-like": [ 50 ], "peptide-1": [ 51 ], "receptor": [ 52 ], "agonists": [ 53 ], "(GLP-1RAs)": [ 54 ], "developed": [ 55 ], "T2DM": [ 60, 164 ], "reduce": [ 61 ], "body": [ 62, 113, 116 ], "weight": [ 63, 114 ], "liraglutide": [ 65, 103, 142 ], "GLP-1RA": [ 69 ], "to": [ 70 ], "approved": [ 72 ], "treatment": [ 75, 106 ], "patients": [ 79, 162 ], "with": [ 80, 163 ], "without": [ 82 ], "T2DM.Areas": [ 83 ], "covered:": [ 84 ], "In": [ 85 ], "this": [ 86 ], "review": [ 87 ], "relevant": [ 89 ], "published": [ 90 ], "material,": [ 91 ], "authors": [ 93 ], "summarize": [ 94 ], "pharmacokinetics,": [ 96 ], "pharmacodynamics,": [ 97 ], "clinical": [ 98 ], "efficacy": [ 99 ], "safety": [ 101 ], "obesity.Expert": [ 108 ], "opinion:": [ 109 ], "Liraglutide": [ 110, 153 ], "effectively": [ 111 ], "reduces": [ 112 ], "fat": [ 117 ], "through": [ 118 ], "mechanisms": [ 119 ], "involving": [ 120 ], "reduced": [ 121 ], "appetite": [ 122 ], "lowered": [ 124 ], "energy": [ 125 ], "intake,": [ 126 ], "independent": [ 127 ], "its": [ 129, 176 ], "glucose-lowering": [ 130 ], "effects.": [ 131 ], "Like": [ 132 ], "most": [ 133 ], "other": [ 136, 186 ], "medications": [ 137 ], "currently": [ 138 ], "available": [ 139 ], "obesity,": [ 141 ], "has": [ 143, 154 ], "some": [ 144 ], "common": [ 145 ], "adverse": [ 146 ], "effects,": [ 147 ], "although": [ 148 ], "generally": [ 149 ], "not": [ 150 ], "serious": [ 151 ], "ones.": [ 152 ], "benefits": [ 156 ], "reducing": [ 158 ], "cardiovascular": [ 159 ], "events": [ 160 ], "cost": [ 167 ], "need": [ 170 ], "daily": [ 172 ], "injections": [ 173 ], "may": [ 174, 192 ], "limit": [ 175 ], "use": [ 177 ], "obesity.": [ 179 ], "Newer": [ 180 ], "GLP-1RAs,": [ 181 ], "such": [ 182 ], "semaglutide,": [ 184 ], "or": [ 185 ], "drugs": [ 187 ], "development": [ 189 ], "have": [ 193 ], "advantages": [ 194 ], "over": [ 195 ], "liraglutide.": [ 196 ] }, "publication_date": "2019-12-02", "publication_year": 2019, "type": "review", "cited_by_count": 62, "authors": [ { "id": "https://openalex.org/A5101066305", "display_name": "Chen-Hsiu Lin" }, { "id": "https://openalex.org/A5076576399", "display_name": "Shao Li" }, { "id": "https://openalex.org/A5110171177", "display_name": "Yu-Mei Zhang" }, { "id": "https://openalex.org/A5055205328", "display_name": "Yu-Ju Tu" }, { "id": "https://openalex.org/A5100721872", "display_name": "Yuzhen Zhang" }, { "id": "https://openalex.org/A5068775883", "display_name": "Brian Tomlinson" }, { "id": "https://openalex.org/A5043935811", "display_name": "Paul Chan" }, { "id": "https://openalex.org/A5100660728", "display_name": "Zhongmin Liu" } ] }, { "id": "https://openalex.org/W3137471921", "doi": "https://doi.org/10.1007/s40268-021-00341-8", "title": "A Review on the Efficacy and Safety of Oral Semaglutide", "abstract": null, "publication_date": "2021-03-26", "publication_year": 2021, "type": "review", "cited_by_count": 29, "authors": [ { "id": "https://openalex.org/A5040508646", "display_name": "Stephanie Niman" }, { "id": "https://openalex.org/A5102810725", "display_name": "Jennifer Hardy" }, { "id": "https://openalex.org/A5017815687", "display_name": "Rebecca F. Goldfaden" }, { "id": "https://openalex.org/A5087854375", "display_name": "Jessica Reid" }, { "id": "https://openalex.org/A5006862514", "display_name": "Mae Sheikh\u2010Ali" }, { "id": "https://openalex.org/A5044119169", "display_name": "David Sutton" }, { "id": "https://openalex.org/A5028917116", "display_name": "Rushab Choksi" } ] }, { "id": "https://openalex.org/W4212930879", "doi": "https://doi.org/10.1186/s13098-022-00801-4", "title": "The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal", "abstract": null, "publication_date": "2022-02-14", "publication_year": 2022, "type": "article", "cited_by_count": 11, "authors": [ { "id": "https://openalex.org/A5029230724", "display_name": "Samuel J. P. Malkin" }, { "id": "https://openalex.org/A5025832509", "display_name": "Davide Carvalho" }, { "id": "https://openalex.org/A5101878830", "display_name": "Catarina Costa" }, { "id": "https://openalex.org/A5076410380", "display_name": "Vasco Conde" }, { "id": "https://openalex.org/A5072605000", "display_name": "Barnaby Hunt" } ] }, { "id": "https://openalex.org/W4205761485", "doi": "https://doi.org/10.2337/dc21-1815", "title": "Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs", "abstract": { "OBJECTIVE": [ 0 ], "There": [ 1, 36, 209 ], "is": [ 2, 37 ], "mounting": [ 3 ], "evidence": [ 4 ], "regarding": [ 5 ], "the": [ 6, 71, 102, 110, 269 ], "cardiovascular": [ 7, 27, 287 ], "benefits": [ 8 ], "of": [ 9, 39, 55, 104, 127, 136, 160, 167, 189, 235, 252, 271 ], "sodium\u2013glucose": [ 10 ], "cotransporter": [ 11 ], "2": [ 12, 32 ], "inhibitors": [ 13 ], "(SGLT2i)": [ 14 ], "and": [ 15, 30, 59, 89, 95, 106, 109, 138, 145, 153, 184, 203, 221, 242, 254 ], "glucagon-like": [ 16 ], "peptide": [ 17 ], "1": [ 18, 82 ], "receptor": [ 19 ], "agonists": [ 20 ], "(GLP-1": [ 21 ], "RA)": [ 22 ], "among": [ 23, 214, 257, 289 ], "patients": [ 24, 91, 142, 150, 161, 168, 259 ], "with": [ 25, 92, 143, 151, 262 ], "atherosclerotic": [ 26 ], "disease": [ 28 ], "(ASCVD)": [ 29 ], "type": [ 31 ], "diabetes": [ 33 ], "mellitus": [ 34 ], "(T2DM).": [ 35 ], "paucity": [ 38 ], "data": [ 40, 79 ], "assessing": [ 41 ], "real-world": [ 42 ], "practice": [ 43 ], "patterns": [ 44 ], "for": [ 45, 201, 206, 233 ], "these": [ 46, 56, 98, 175, 272, 290 ], "drug": [ 47, 57, 178, 273 ], "classes.": [ 48, 274 ], "We": [ 49, 69 ], "aimed": [ 50 ], "to": [ 51, 85, 279, 283 ], "assess": [ 52 ], "utilization": [ 53, 250 ], "rates": [ 54, 197, 251 ], "classes": [ 58, 179 ], "facility-level": [ 60, 111, 196, 212, 229, 266 ], "variation": [ 61, 112, 117, 213, 230, 267 ], "in": [ 62, 113, 134, 141, 268 ], "their": [ 63, 114, 281 ], "use.": [ 64, 115 ], "RESEARCH": [ 65 ], "DESIGN": [ 66 ], "AND": [ 67 ], "METHODS": [ 68 ], "used": [ 70 ], "nationwide": [ 72 ], "Veterans": [ 73 ], "Affairs": [ 74 ], "(VA)": [ 75 ], "health": [ 76 ], "care": [ 77 ], "system": [ 78 ], "set": [ 80 ], "from": [ 81 ], "January": [ 83 ], "2020": [ 84, 88 ], "31": [ 86 ], "December": [ 87 ], "included": [ 90 ], "established": [ 93 ], "ASCVD": [ 94, 144, 152 ], "T2DM.": [ 96, 146 ], "Among": [ 97, 148 ], "patients,": [ 99 ], "we": [ 100 ], "assessed": [ 101 ], "use": [ 103, 135, 234, 270, 282 ], "SGLT2i": [ 105, 137, 164, 202, 215, 253 ], "GLP-1": [ 107, 139, 171, 207, 236, 255 ], "RA": [ 108, 140, 256 ], "Facility-level": [ 116 ], "was": [ 118, 210, 231 ], "computed": [ 119 ], "using": [ 120 ], "median": [ 121, 193 ], "rate": [ 122 ], "ratios": [ 123 ], "(MRR),": [ 124 ], "a": [ 125, 170, 186 ], "measure": [ 126 ], "likelihood": [ 128 ], "that": [ 129 ], "two": [ 130 ], "random": [ 131 ], "facilities": [ 132 ], "differ": [ 133 ], "RESULTS": [ 147 ], "537,980": [ 149 ], "T2DM": [ 154 ], "across": [ 155 ], "130": [ 156 ], "VA": [ 157 ], "facilities,": [ 158 ], "11.2%": [ 159 ], "received": [ 162, 169 ], "an": [ 163 ], "while": [ 165 ], "8.0%": [ 166 ], "RA.": [ 172, 208 ], "Patients": [ 173 ], "receiving": [ 174 ], "cardioprotective": [ 176 ], "glucose-lowering": [ 177 ], "were": [ 180, 198 ], "on": [ 181 ], "average": [ 182 ], "younger": [ 183 ], "had": [ 185 ], "higher": [ 187, 264 ], "proportion": [ 188 ], "non-Hispanic": [ 190 ], "Whites.": [ 191 ], "Overall,": [ 192 ], "(10th\u201390th": [ 194 ], "percentile)": [ 195 ], "14.92%": [ 199 ], "(9.31\u201322.50)": [ 200 ], "10.88%": [ 204 ], "(4.44\u201317.07)": [ 205 ], "significant": [ 211 ], "use\u2014MRRunadjusted:": [ 216 ], "1.41": [ 217 ], "(95%": [ 218, 224, 239, 245 ], "CI": [ 219, 225, 240, 246 ], "1.35\u20131.47)": [ 220 ], "MRRadjusted:": [ 222, 243 ], "1.55": [ 223 ], "1.46": [ 226 ], "\u20131.63).": [ 227 ], "Similar": [ 228 ], "observed": [ 232 ], "RA\u2014MRRunadjusted:": [ 237 ], "1.34": [ 238 ], "1.29\u20131.38)": [ 241 ], "1.78": [ 244 ], "1.65\u20131.90).": [ 247 ], "CONCLUSIONS": [ 248 ], "Overall": [ 249 ], "eligible": [ 258 ], "are": [ 260 ], "low,": [ 261 ], "significantly": [ 263 ], "residual": [ 265 ], "Our": [ 275 ], "results": [ 276 ], "suggest": [ 277 ], "opportunities": [ 278 ], "optimize": [ 280 ], "prevent": [ 284 ], "future": [ 285 ], "adverse": [ 286 ], "events": [ 288 ], "patients.": [ 291 ] }, "publication_date": "2022-01-11", "publication_year": 2022, "type": "article", "cited_by_count": 112, "authors": [ { "id": "https://openalex.org/A5050686676", "display_name": "Dhruv Mahtta" }, { "id": "https://openalex.org/A5000701800", "display_name": "David J. Ramsey" }, { "id": "https://openalex.org/A5100728425", "display_name": "Michelle Lee" }, { "id": "https://openalex.org/A5100334546", "display_name": "Liang Chen" }, { "id": "https://openalex.org/A5069046885", "display_name": "Mahmoud Al Rifai" }, { "id": "https://openalex.org/A5034240621", "display_name": "Julia M. Akeroyd" }, { "id": "https://openalex.org/A5075661344", "display_name": "Elizabeth M. Vaughan" }, { "id": "https://openalex.org/A5011689338", "display_name": "Michael E. Matheny" }, { "id": "https://openalex.org/A5110834100", "display_name": "Karla Rodrigues do Espirito Santo" }, { "id": "https://openalex.org/A5088788555", "display_name": "Sankar D. Navaneethan" }, { "id": "https://openalex.org/A5059582018", "display_name": "Carl J. Lavie" }, { "id": "https://openalex.org/A5062213046", "display_name": "Yochai Birnbaum" }, { "id": "https://openalex.org/A5052604218", "display_name": "Christie M. Ballantyne" }, { "id": "https://openalex.org/A5059250797", "display_name": "Laura A. Petersen" }, { "id": "https://openalex.org/A5010041931", "display_name": "Salim S. Virani" } ] }, { "id": "https://openalex.org/W2999377366", "doi": "https://doi.org/10.1002/dmrr.3292", "title": "Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes", "abstract": { "Abstract": [ 0 ], "Background": [ 1 ], "The": [ 2, 56, 183, 213 ], "aim": [ 3 ], "of": [ 4, 12, 215 ], "this": [ 5 ], "study": [ 6 ], "was": [ 7, 151 ], "to": [ 8, 49 ], "investigate": [ 9 ], "the": [ 10, 197, 205, 221 ], "efficacy": [ 11 ], "exenatide": [ 13, 51, 101, 158, 198, 226, 240 ], "and": [ 14, 27, 69, 87, 95, 140, 171, 191, 227, 237, 256 ], "insulin": [ 15, 53, 154, 177, 206, 228 ], "glargine": [ 16, 54, 155, 178, 207, 229 ], "in": [ 17, 60, 161, 164, 196, 232, 244 ], "patients": [ 18, 44, 233 ], "with": [ 19, 234 ], "newly": [ 20 ], "diagnosed": [ 21 ], "type": [ 22 ], "2": [ 23, 112, 119 ], "diabetes": [ 24 ], "mellitus": [ 25 ], "(T2DM)": [ 26 ], "nonalcoholic": [ 28 ], "fatty": [ 29 ], "liver": [ 30, 61, 81, 250 ], "disease": [ 31 ], "(NAFLD).": [ 32 ], "Methods": [ 33 ], "We": [ 34 ], "performed": [ 35 ], "a": [ 36 ], "24\u2010week": [ 37 ], "randomized": [ 38 ], "controlled": [ 39 ], "multicentre": [ 40 ], "clinical": [ 41 ], "trial.": [ 42 ], "Seventy\u2010six": [ 43 ], "were": [ 45, 97, 218 ], "randomly": [ 46 ], "assigned": [ 47 ], "1:1": [ 48 ], "receive": [ 50 ], "or": [ 52, 144 ], "treatment.": [ 55, 156 ], "endpoints": [ 57 ], "included": [ 58 ], "changes": [ 59 ], "fat": [ 62, 248 ], "content": [ 63 ], "(LFC),": [ 64 ], "visceral": [ 65, 247 ], "adipose": [ 66, 71 ], "tissue": [ 67, 72 ], "(VAT),": [ 68 ], "subcutaneous": [ 70 ], "(SAT)": [ 73 ], "measured": [ 74 ], "by": [ 75 ], "magnetic": [ 76 ], "resonance": [ 77 ], "spectroscopy,": [ 78 ], "blood": [ 79 ], "glucose,": [ 80, 190, 255 ], "enzymes,": [ 82, 251 ], "lipid": [ 83 ], "profile,": [ 84 ], "body": [ 85, 184, 245 ], "weight,": [ 86, 185, 246 ], "Fibrosis\u20104": [ 88 ], "index": [ 89, 146 ], "(FIB\u20104).": [ 90 ], "Results": [ 91 ], "LFC,": [ 92 ], "VAT,": [ 93, 142 ], "SAT,": [ 94, 143 ], "FIB\u20104": [ 96, 145 ], "significantly": [ 98 ], "reduced": [ 99, 152, 230 ], "after": [ 100, 153 ], "treatment": [ 102, 159 ], "(\u0394LFC,": [ 103, 133 ], "\u221217.55": [ 104 ], "\u00b1": [ 105, 109, 116, 123, 135 ], "12.93%;": [ 106 ], "\u0394VAT,": [ 107 ], "\u221243.57": [ 108 ], "68.20": [ 110 ], "cm": [ 111, 118 ], ";": [ 113, 120 ], "\u0394SAT,": [ 114 ], "\u221228.44": [ 115 ], "51.48": [ 117 ], "\u0394FIB\u20104,": [ 121 ], "\u22120.10": [ 122 ], "0.26;": [ 124 ], "all": [ 125 ], "P": [ 126, 137, 148, 180, 210 ], "<": [ 127, 138, 181, 211 ], ".05).": [ 128, 212 ], "In": [ 129 ], "comparison,": [ 130 ], "only": [ 131 ], "LFC": [ 132, 231 ], "\u221210.49": [ 134 ], "11.38%;": [ 136 ], ".05),": [ 139, 150 ], "not": [ 141 ], "(all": [ 147 ], ">": [ 149 ], "Moreover,": [ 157 ], "resulted": [ 160 ], "greater": [ 162, 202, 242 ], "reductions": [ 163, 203, 243 ], "alanine": [ 165 ], "transaminase": [ 166, 169 ], "(ALT),": [ 167 ], "aspartate": [ 168 ], "(AST),": [ 170 ], "gamma": [ 172 ], "glutamyl": [ 173 ], "transpeptidase": [ 174 ], "(GGT)": [ 175 ], "than": [ 176, 204 ], "(": [ 179, 209 ], "0.05).": [ 182 ], "waist": [ 186 ], "circumference,": [ 187 ], "postprandial": [ 188, 253 ], "plasma": [ 189, 254 ], "low\u2010density": [ 192 ], "lipoprotein": [ 193 ], "cholesterol": [ 194 ], "(LDL\u2010C)": [ 195 ], "group": [ 199, 208 ], "also": [ 200 ], "presented": [ 201 ], "proportion": [ 214 ], "adverse": [ 216 ], "events": [ 217 ], "comparable": [ 219 ], "between": [ 220 ], "two": [ 222 ], "groups.": [ 223 ], "Conclusion": [ 224 ], "Both": [ 225 ], "drug\u2010naive": [ 235 ], "T2DM": [ 236 ], "NAFLD;": [ 238 ], "however,": [ 239 ], "showed": [ 241 ], "area,": [ 249 ], "FIB\u20104,": [ 252 ], "LDL\u2010C.": [ 257 ] }, "publication_date": "2020-01-19", "publication_year": 2020, "type": "article", "cited_by_count": 107, "authors": [ { "id": "https://openalex.org/A5101506901", "display_name": "Lin Liu" }, { "id": "https://openalex.org/A5019171727", "display_name": "Hongmei Yan" }, { "id": "https://openalex.org/A5025931317", "display_name": "Mingfeng Xia" }, { "id": "https://openalex.org/A5101406167", "display_name": "Lin Zhao" }, { "id": "https://openalex.org/A5078193310", "display_name": "Minzhi Lv" }, { "id": "https://openalex.org/A5101068848", "display_name": "Zhao Nai-qin" }, { "id": "https://openalex.org/A5003420702", "display_name": "Shengxiang Rao" }, { "id": "https://openalex.org/A5112115797", "display_name": "Xiuzhong Yao" }, { "id": "https://openalex.org/A5101966552", "display_name": "Weiyun Wu" }, { "id": "https://openalex.org/A5110817206", "display_name": "Baishen Pan" }, { "id": "https://openalex.org/A5071078640", "display_name": "Hua Bian" }, { "id": "https://openalex.org/A5101763714", "display_name": "Xin Gao" } ] }, { "id": "https://openalex.org/W2625478053", "doi": "https://doi.org/10.1021/acschembio.7b00218", "title": "A Hydrogel-Microsphere Drug Delivery System That Supports Once-Monthly Administration of a GLP-1 Receptor Agonist", "abstract": { "We": [ 0, 63 ], "have": [ 1 ], "developed": [ 2 ], "a": [ 3, 15, 32, 181 ], "chemically": [ 4 ], "controlled": [ 5 ], "very": [ 6 ], "long-acting": [ 7 ], "delivery": [ 8, 175 ], "system": [ 9, 176 ], "to": [ 10, 28 ], "support": [ 11 ], "once-monthly": [ 12, 182 ], "administration": [ 13 ], "of": [ 14, 79, 150, 166, 187 ], "peptidic": [ 16 ], "GLP-1R": [ 17, 22, 90, 183 ], "agonist.": [ 18 ], "Initially,": [ 19 ], "the": [ 20, 41, 47, 51, 60, 129, 133, 137, 151, 154, 174 ], "prototypical": [ 21 ], "agonist": [ 23, 91, 184 ], "exenatide": [ 24, 54, 66, 87 ], "was": [ 25, 43 ], "covalently": [ 26 ], "attached": [ 27 ], "hydrogel": [ 29 ], "microspheres": [ 30 ], "by": [ 31 ], "self-cleaving": [ 33 ], "\u03b2-eliminative": [ 34, 118 ], "linker;": [ 35 ], "after": [ 36 ], "subcutaneous": [ 37, 61, 125 ], "injection": [ 38, 126 ], "in": [ 39, 59, 73, 76, 100, 127, 153, 191 ], "rats,": [ 40 ], "peptide": [ 42 ], "slowly": [ 44 ], "released": [ 45, 134 ], "into": [ 46 ], "systemic": [ 48 ], "circulation.": [ 49 ], "However,": [ 50 ], "short": [ 52 ], "serum": [ 53, 130 ], "half-life": [ 55, 78 ], "suggested": [ 56 ], "its": [ 57 ], "degradation": [ 58 ], "depot.": [ 62 ], "found": [ 64 ], "that": [ 65, 173 ], "undergoes": [ 67 ], "deamidation": [ 68 ], "at": [ 69 ], "Asn28": [ 70 ], "with": [ 71, 120 ], "an": [ 72 ], "vitro": [ 74 ], "and": [ 75, 86, 97, 144 ], "vivo": [ 77 ], "approximately": [ 80 ], "2": [ 81, 142, 189 ], "weeks.": [ 82 ], "The": [ 83 ], "[Gln28]exenatide": [ 84, 105, 135 ], "variant": [ 85 ], "showed": [ 88, 159 ], "indistinguishable": [ 89, 162 ], "activities": [ 92 ], "as": [ 93, 95, 180 ], "well": [ 94, 179 ], "pharmacokinetic": [ 96 ], "pharmacodynamic": [ 98, 160 ], "effects": [ 99, 161 ], "rodents;": [ 101 ], "however,": [ 102 ], "unlike": [ 103 ], "exenatide,": [ 104 ], "is": [ 106 ], "stable": [ 107 ], "for": [ 108, 132, 185 ], "long": [ 109 ], "periods.": [ 110 ], "Two": [ 111, 147 ], "different": [ 112, 121 ], "hydrogel-[Gln28]exenatide": [ 113 ], "conjugates": [ 114, 139 ], "were": [ 115, 140 ], "prepared": [ 116 ], "using": [ 117 ], "linkers": [ 119 ], "cleavage": [ 122 ], "rates.": [ 123 ], "After": [ 124 ], "rodents,": [ 128 ], "half-lives": [ 131 ], "from": [ 136, 163 ], "two": [ 138, 164 ], "about": [ 141 ], "weeks": [ 143 ], "one": [ 145 ], "month.": [ 146 ], "monthly": [ 148 ], "injections": [ 149 ], "latter": [ 152 ], "Zucker": [ 155 ], "diabetic": [ 156 ], "fatty": [ 157 ], "rat": [ 158 ], "months": [ 165 ], "continuously": [ 167 ], "infused": [ 168 ], "exenatide.": [ 169 ], "Pharmacokinetic": [ 170 ], "simulations": [ 171 ], "indicate": [ 172 ], "should": [ 177 ], "serve": [ 178 ], "treatment": [ 186 ], "type": [ 188 ], "diabetes": [ 190 ], "humans.": [ 192 ] }, "publication_date": "2017-06-12", "publication_year": 2017, "type": "article", "cited_by_count": 31, "authors": [ { "id": "https://openalex.org/A5074694916", "display_name": "Eric L. Schneider" }, { "id": "https://openalex.org/A5009899105", "display_name": "Brian R. Hearn" }, { "id": "https://openalex.org/A5110698184", "display_name": "Samuel J. Pfaff" }, { "id": "https://openalex.org/A5041099893", "display_name": "Ralph R. Reid" }, { "id": "https://openalex.org/A5077809872", "display_name": "David G. Parkes" }, { "id": "https://openalex.org/A5088582143", "display_name": "Niels Vrang" }, { "id": "https://openalex.org/A5082839466", "display_name": "Gary W. Ashley" }, { "id": "https://openalex.org/A5058934270", "display_name": "Daniel V. Santi" } ] }, { "id": "https://openalex.org/W4283030781", "doi": "https://doi.org/10.1016/j.cmet.2022.06.002", "title": "Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions", "abstract": null, "publication_date": "2022-06-17", "publication_year": 2022, "type": "article", "cited_by_count": 98, "authors": [ { "id": "https://openalex.org/A5053054124", "display_name": "M\u00f3nica Imbern\u00f3n" }, { "id": "https://openalex.org/A5018948109", "display_name": "Chiara Saponaro" }, { "id": "https://openalex.org/A5010563977", "display_name": "Hans Christian Cederberg Helms" }, { "id": "https://openalex.org/A5044662557", "display_name": "Manon Duquenne" }, { "id": "https://openalex.org/A5029933241", "display_name": "Daniela Fernandois" }, { "id": "https://openalex.org/A5060699065", "display_name": "Eleonora Deligia" }, { "id": "https://openalex.org/A5034986738", "display_name": "R Denis" }, { "id": "https://openalex.org/A5010846794", "display_name": "Daniela Herrera Moro Chao" }, { "id": "https://openalex.org/A5029842746", "display_name": "Sowmyalakshm\u00ed Rasika" }, { "id": "https://openalex.org/A5001127450", "display_name": "Bart Staels" }, { "id": "https://openalex.org/A5006759849", "display_name": "Fran\u00e7ois Pattou" }, { "id": "https://openalex.org/A5052144876", "display_name": "Frank W. Pfrieger" }, { "id": "https://openalex.org/A5044156865", "display_name": "Birger Brodin" }, { "id": "https://openalex.org/A5007928374", "display_name": "Serge Luquet" }, { "id": "https://openalex.org/A5087179037", "display_name": "Caroline Bonner" }, { "id": "https://openalex.org/A5083058332", "display_name": "Vincent Pr\u00e9vot" } ] }, { "id": "https://openalex.org/W2950088643", "doi": "https://doi.org/10.1111/cob.12323", "title": "Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post\u2010bariatric surgery", "abstract": { "Summary": [ 0 ], "To": [ 1 ], "assess": [ 2 ], "the": [ 3, 22, 34, 110, 139, 183 ], "effectiveness": [ 4 ], "of": [ 5, 24, 57, 99, 109, 112, 128, 161, 174, 182, 185 ], "liraglutide": [ 6, 45, 90, 130, 178, 198 ], "3.0": [ 7, 46, 91, 131, 179, 199 ], "mg": [ 8, 47, 132, 180, 200 ], "in": [ 9, 41, 122, 154 ], "post\u2010bariatric": [ 10, 30, 155, 166, 194 ], "surgery": [ 11, 31, 113, 156, 167, 186, 195 ], "patients,": [ 12, 52 ], "and": [ 13, 53, 64, 209 ], "to": [ 14, 191, 212, 216 ], "determine": [ 15 ], "whether": [ 16 ], "this": [ 17, 162 ], "would": [ 18 ], "differ": [ 19 ], "based": [ 20 ], "on": [ 21 ], "type": [ 23, 111, 184 ], "bariatric": [ 25, 58 ], "surgery.": [ 26 ], "One": [ 27 ], "hundred": [ 28 ], "seventeen": [ 29 ], "patients": [ 32, 93, 157, 168, 196 ], "from": [ 33 ], "Wharton": [ 35 ], "Medical": [ 36 ], "Clinic": [ 37 ], "were": [ 38, 48 ], "analysed.": [ 39 ], "Changes": [ 40 ], "weight": [ 42, 100, 123, 152, 175, 214 ], "while": [ 43, 176 ], "taking": [ 44, 89, 129, 177, 197 ], "examined": [ 49 ], "for": [ 50, 150 ], "all": [ 51 ], "by": [ 54, 145 ], "three": [ 55 ], "types": [ 56 ], "surgery\u2014Roux\u2010en\u2010Y": [ 59 ], "gastric": [ 60, 62, 65, 71, 78 ], "bypass,": [ 61 ], "banding": [ 63, 79 ], "sleeve.": [ 66 ], "Patients": [ 67 ], "primarily": [ 68 ], "underwent": [ 69 ], "Roux\u2010en\u2010Y": [ 70 ], "bypass": [ 72 ], "(n": [ 73, 80 ], "=": [ 74, 81 ], "53,": [ 75 ], "45.3%)": [ 76 ], "or": [ 77 ], "50,": [ 82 ], "42.7%).": [ 83 ], "Over": [ 84 ], "7.6": [ 85 ], "\u00b1": [ 86, 102 ], "7.1": [ 87 ], "months": [ 88 ], "mg,": [ 92 ], "lost": [ 94 ], "a": [ 95, 171 ], "statistically": [ 96 ], "significant": [ 97, 125, 172 ], "amount": [ 98, 173 ], "(\u22126.3": [ 101 ], "7.7": [ 103 ], "kg,": [ 104 ], "P": [ 105, 117, 134 ], "<": [ 106, 135 ], ".05)": [ 107 ], "regardless": [ 108, 181 ], "they": [ 114, 187 ], "had": [ 115 ], "(": [ 116, 133 ], ">": [ 118 ], ".05).": [ 119, 136 ], "This": [ 120 ], "decrease": [ 121 ], "remained": [ 124 ], "after": [ 126 ], "1\u2010year": [ 127 ], "Nausea": [ 137 ], "was": [ 138 ], "most": [ 140 ], "prevalent": [ 141 ], "side": [ 142, 204 ], "effect,": [ 143 ], "reported": [ 144 ], "29.1%": [ 146 ], "patients.": [ 147 ], "While": [ 148 ], "options": [ 149 ], "excess": [ 151 ], "management": [ 153 ], "are": [ 158 ], "limited,": [ 159 ], "results": [ 160 ], "study": [ 163 ], "suggest": [ 164 ], "that": [ 165 ], "can": [ 169, 210 ], "lose": [ 170, 213 ], "had.": [ 188 ], "Further,": [ 189 ], "similar": [ 190 ], "non\u2010surgical": [ 192 ], "populations,": [ 193 ], "may": [ 201 ], "experience": [ 202 ], "gastrointestinal": [ 203 ], "effects": [ 205 ], "such": [ 206 ], "as": [ 207 ], "nausea": [ 208 ], "continue": [ 211 ], "up": [ 215 ], "1": [ 217 ], "year.": [ 218 ] }, "publication_date": "2019-06-10", "publication_year": 2019, "type": "article", "cited_by_count": 130, "authors": [ { "id": "https://openalex.org/A5027441223", "display_name": "Sean Wharton" }, { "id": "https://openalex.org/A5041058650", "display_name": "Jennifer L. Kuk" }, { "id": "https://openalex.org/A5035466360", "display_name": "Magdalena Luszczynski" }, { "id": "https://openalex.org/A5074329825", "display_name": "Elham Kamran" }, { "id": "https://openalex.org/A5018089296", "display_name": "Rebecca Christensen" } ] }, { "id": "https://openalex.org/W2157365347", "doi": "https://doi.org/10.2147/dddt.s46970", "title": "Long-acting preparations of exenatide", "abstract": { "Exenatide": [ 0 ], "has": [ 1, 21 ], "been": [ 2 ], "widely": [ 3 ], "used": [ 4 ], "for": [ 5 ], "the": [ 6, 30, 54 ], "treatment": [ 7 ], "of": [ 8, 18, 57 ], "type": [ 9 ], "2": [ 10 ], "diabetes": [ 11 ], "mellitus.": [ 12 ], "However,": [ 13 ], "its": [ 14, 23, 65 ], "short": [ 15 ], "plasma": [ 16 ], "half-life": [ 17 ], "2.4": [ 19 ], "hours": [ 20 ], "limited": [ 22 ], "clinical": [ 24 ], "application.": [ 25 ], "The": [ 26 ], "exenatide": [ 27, 58, 79 ], "products": [ 28 ], "on": [ 29 ], "market,": [ 31 ], "twice-daily": [ 32 ], "Byetta\u2122": [ 33 ], "and": [ 34, 69 ], "once-weekly": [ 35 ], "Bydureon\u2122": [ 36 ], "(both": [ 37 ], "Amylin": [ 38 ], "Pharmaceuticals,": [ 39 ], "San": [ 40 ], "Diego,": [ 41 ], "CA,": [ 42 ], "USA),": [ 43 ], "are": [ 44 ], "still": [ 45 ], "not": [ 46 ], "perfect.": [ 47 ], "Many": [ 48 ], "researchers": [ 49 ], "have": [ 50 ], "attempted": [ 51 ], "to": [ 52 ], "prolong": [ 53 ], "acting": [ 55 ], "time": [ 56 ], "by": [ 59 ], "preparing": [ 60 ], "sustained-release": [ 61 ], "dosage": [ 62 ], "forms,": [ 63 ], "modifying": [ 64 ], "structure,": [ 66 ], "gene": [ 67 ], "therapies,": [ 68 ], "other": [ 70 ], "means.": [ 71 ], "This": [ 72 ], "review": [ 73 ], "summarizes": [ 74 ], "recent": [ 75 ], "advances": [ 76 ], "in": [ 77 ], "long-acting": [ 78 ], "preparations.": [ 80 ] }, "publication_date": "2013-09-01", "publication_year": 2013, "type": "review", "cited_by_count": 54, "authors": [ { "id": "https://openalex.org/A5100519642", "display_name": "Weien Yuan" }, { "id": "https://openalex.org/A5090194899", "display_name": "Yunpeng Cai" }, { "id": "https://openalex.org/A5111641193", "display_name": "Liangming Liangming Wei" }, { "id": "https://openalex.org/A5069917349", "display_name": "Liuqing Ma" }, { "id": "https://openalex.org/A5040710079", "display_name": "Xiwen Huang" }, { "id": "https://openalex.org/A5011467364", "display_name": "Anqi Tao" }, { "id": "https://openalex.org/A5100448067", "display_name": "Zhenguo Liu" } ] }, { "id": "https://openalex.org/W2969024986", "doi": "https://doi.org/10.1007/s12020-019-02055-z", "title": "GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials", "abstract": null, "publication_date": "2019-08-16", "publication_year": 2019, "type": "review", "cited_by_count": 83, "authors": [ { "id": "https://openalex.org/A5069481778", "display_name": "Chuqing Cao" }, { "id": "https://openalex.org/A5101705986", "display_name": "Shuting Yang" }, { "id": "https://openalex.org/A5100397159", "display_name": "Zhiguang Zhou" } ] }, { "id": "https://openalex.org/W3197758912", "doi": "https://doi.org/10.3390/jcm10173955", "title": "GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Physiology to Clinical Outcomes", "abstract": { "Diabetic": [ 0 ], "kidney": [ 1, 82 ], "disease": [ 2 ], "(DKD)": [ 3 ], "is": [ 4, 40, 44, 84 ], "one": [ 5 ], "of": [ 6, 21, 31, 34, 38, 51, 74, 135 ], "the": [ 7, 28, 36, 48, 121, 133, 138 ], "most": [ 8 ], "common": [ 9 ], "complications": [ 10 ], "in": [ 11, 25, 89, 117, 142 ], "type": [ 12 ], "2": [ 13 ], "diabetes": [ 14 ], "mellitus": [ 15 ], "(T2D)": [ 16 ], "and": [ 17, 23, 42, 70, 91, 96, 114, 120, 140, 144 ], "a": [ 18, 115 ], "major": [ 19 ], "cause": [ 20, 50 ], "morbidity": [ 22 ], "mortality": [ 24 ], "diabetes.": [ 26 ], "Despite": [ 27 ], "widespread": [ 29 ], "use": [ 30 ], "nephroprotective": [ 32 ], "treatment": [ 33 ], "T2D,": [ 35 ], "incidence": [ 37 ], "DKD": [ 39, 143 ], "increasing,": [ 41 ], "it": [ 43 ], "expected": [ 45 ], "to": [ 46 ], "become": [ 47 ], "fifth": [ 49 ], "death": [ 52 ], "worldwide": [ 53 ], "within": [ 54 ], "20": [ 55 ], "years.": [ 56 ], "Previous": [ 57 ], "studies": [ 58 ], "have": [ 59, 67 ], "demonstrated": [ 60 ], "that": [ 61 ], "GLP-1": [ 62 ], "receptor": [ 63 ], "agonists": [ 64 ], "(GLP-1": [ 65 ], "RA)": [ 66 ], "improved": [ 68, 103 ], "macrovascular": [ 69 ], "microvascular": [ 71 ], "outcomes": [ 72, 105 ], "independent": [ 73 ], "glycemic": [ 75 ], "differences,": [ 76 ], "including": [ 77 ], "DKD.": [ 78 ], "GLP-1Ras\u2019": [ 79 ], "improvement": [ 80 ], "on": [ 81, 137 ], "physiology": [ 83 ], "mediated": [ 85 ], "by": [ 86 ], "natriuresis,": [ 87 ], "reduction": [ 88, 116 ], "hyperfiltration": [ 90 ], "renin-angiotensin-aldosterone": [ 92 ], "system": [ 93 ], "(RAAS)": [ 94 ], "activity": [ 95 ], "anti-inflammatory": [ 97 ], "properties.": [ 98 ], "These": [ 99 ], "findings": [ 100 ], "translate": [ 101 ], "into": [ 102 ], "clinical": [ 104, 146 ], "such": [ 106 ], "as": [ 107 ], "an": [ 108 ], "enhanced": [ 109 ], "urine": [ 110 ], "albumin-to-creatinine": [ 111 ], "ratio": [ 112 ], "(UACR)": [ 113 ], "renal": [ 118, 124 ], "impairment": [ 119 ], "need": [ 122 ], "for": [ 123 ], "replacement": [ 125 ], "therapies": [ 126 ], "(RRT).": [ 127 ], "In": [ 128 ], "this": [ 129 ], "article,": [ 130 ], "we": [ 131 ], "review": [ 132 ], "role": [ 134 ], "GLP-1RAs": [ 136 ], "mechanisms": [ 139 ], "effect": [ 141 ], "their": [ 145 ], "efficacy.": [ 147 ] }, "publication_date": "2021-08-31", "publication_year": 2021, "type": "review", "cited_by_count": 26, "authors": [ { "id": "https://openalex.org/A5074617800", "display_name": "Alba Rojano\u2010Toimil" }, { "id": "https://openalex.org/A5087812090", "display_name": "Andreea Ciudin" } ] }, { "id": "https://openalex.org/W3184801395", "doi": "https://doi.org/10.1111/dom.14497", "title": "An indirect treatment comparison of the efficacy of semaglutide 1.0\u00a0mg versus dulaglutide 3.0 and 4.5\u00a0mg", "abstract": { "Abstract": [ 0 ], "Aim": [ 1 ], "To": [ 2 ], "compare": [ 3, 37 ], "the": [ 4, 54, 78, 165 ], "effects": [ 5 ], "of": [ 6, 40, 80, 105, 125, 147 ], "semaglutide": [ 7, 41, 180 ], "1.0": [ 8, 42, 90, 132, 181, 196 ], "mg": [ 9, 15, 43, 49, 91, 121, 133, 143, 182, 186, 197 ], "versus": [ 10, 44, 95, 118, 138, 183, 191, 202 ], "dulaglutide": [ 11, 45, 96, 119, 139, 184, 192, 204 ], "3.0": [ 12, 46, 97, 140, 185, 205 ], "and": [ 13, 18, 28, 47, 57, 69, 141, 154, 187, 206 ], "4.5": [ 14, 48, 120, 142, 193, 207 ], "on": [ 16 ], "HbA1c": [ 17, 94, 117, 178, 189 ], "body": [ 19, 136, 200 ], "weight": [ 20, 137, 201 ], "in": [ 21, 85, 116, 177 ], "patients": [ 22 ], "with": [ 23, 99, 113, 122, 144, 179 ], "type": [ 24 ], "2": [ 25 ], "diabetes.": [ 26 ], "Materials": [ 27 ], "Methods": [ 29 ], "A": [ 30 ], "Bucher": [ 31 ], "indirect": [ 32, 171 ], "comparison": [ 33, 172 ], "was": [ 34 ], "conducted": [ 35, 75 ], "to": [ 36, 76, 224 ], "efficacy": [ 38, 220 ], "outcomes": [ 39 ], "using": [ 50, 62 ], "published": [ 51 ], "results": [ 52 ], "from": [ 53, 66, 72 ], "SUSTAIN": [ 55, 67 ], "7": [ 56, 68 ], "AWARD\u201011": [ 58, 73 ], "trials.": [ 59 ], "Sensitivity": [ 60, 162 ], "analyses": [ 61, 163 ], "individual": [ 63 ], "patient": [ 64 ], "data": [ 65, 71 ], "aggregate": [ 70 ], "were": [ 74 ], "explore": [ 77 ], "impact": [ 79 ], "adjustment": [ 81 ], "for": [ 82 ], "cross\u2010trial": [ 83 ], "imbalances": [ 84 ], "baseline": [ 86 ], "characteristics.": [ 87 ], "Results": [ 88 ], "Semaglutide": [ 89, 131, 195 ], "significantly": [ 92, 134, 174, 198 ], "reduced": [ 93, 135, 199 ], "mg,": [ 98 ], "an": [ 100, 123, 145 ], "estimated": [ 101 ], "treatment": [ 102 ], "difference": [ 103 ], "(ETD)": [ 104 ], "\u22120.24%\u2010points": [ 106 ], "(95%": [ 107, 127, 150, 157 ], "confidence": [ 108 ], "interval": [ 109 ], "[CI]": [ 110 ], "\u22120.43,": [ 111 ], "\u22120.05),": [ 112 ], "comparable": [ 114, 188 ], "reductions": [ 115, 176, 190 ], "ETD": [ 124, 146 ], "\u22120.07%\u2010points": [ 126 ], "CI": [ 128, 151, 158 ], "\u22120.26,": [ 129 ], "0.12).": [ 130 ], "\u22122.65": [ 148 ], "kg": [ 149, 156 ], "\u22123.57,": [ 152 ], "\u22121.73)": [ 153 ], "\u22121.95": [ 155 ], "\u22122.87,": [ 159 ], "\u22121.03),": [ 160 ], "respectively.": [ 161 ], "supported": [ 164 ], "primary": [ 166 ], "analysis": [ 167 ], "findings.": [ 168 ], "Conclusions": [ 169 ], "This": [ 170 ], "showed": [ 173 ], "greater": [ 175 ], "mg.": [ 194, 208 ], "both": [ 203 ], "With": [ 209 ], "several": [ 210 ], "glucagon\u2010like": [ 211 ], "peptide\u20101": [ 212 ], "receptor": [ 213 ], "agonists": [ 214 ], "available,": [ 215 ], "information": [ 216 ], "regarding": [ 217 ], "their": [ 218 ], "comparative": [ 219 ], "can": [ 221 ], "be": [ 222 ], "valuable": [ 223 ], "clinicians.": [ 225 ] }, "publication_date": "2021-07-19", "publication_year": 2021, "type": "article", "cited_by_count": 20, "authors": [ { "id": "https://openalex.org/A5059098934", "display_name": "Richard E. Pratley" }, { "id": "https://openalex.org/A5009303872", "display_name": "Andrei\u2010Mircea Catarig" }, { "id": "https://openalex.org/A5001655356", "display_name": "Ildiko Lingvay" }, { "id": "https://openalex.org/A5070756199", "display_name": "Adie Viljoen" }, { "id": "https://openalex.org/A5068478387", "display_name": "Abby Paine" }, { "id": "https://openalex.org/A5108350451", "display_name": "Jack Lawson" }, { "id": "https://openalex.org/A5064518045", "display_name": "Barrie Chubb" }, { "id": "https://openalex.org/A5053640365", "display_name": "Anders Gorst\u2010Rasmussen" }, { "id": "https://openalex.org/A5029061663", "display_name": "Nino Miresashvili" } ] }, { "id": "https://openalex.org/W3018053472", "doi": "https://doi.org/10.1016/s2213-8587(20)30074-7", "title": "Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial", "abstract": null, "publication_date": "2020-04-22", "publication_year": 2020, "type": "article", "cited_by_count": 177, "authors": [ { "id": "https://openalex.org/A5081800565", "display_name": "Daisuke Yabe" }, { "id": "https://openalex.org/A5106027150", "display_name": "Jiro Nakamura" }, { "id": "https://openalex.org/A5024295858", "display_name": "Hideaki Kaneto" }, { "id": "https://openalex.org/A5112650825", "display_name": "Srikanth Deenadayalan" }, { "id": "https://openalex.org/A5020470965", "display_name": "Andrea Navarria" }, { "id": "https://openalex.org/A5054860387", "display_name": "Mette Gislum" }, { "id": "https://openalex.org/A5077189198", "display_name": "Nobuya Inagaki" }, { "id": "https://openalex.org/A5052136909", "display_name": "T Arisaka" }, { "id": "https://openalex.org/A5038033168", "display_name": "Toshihisa Asakura" }, { "id": "https://openalex.org/A5002298392", "display_name": "Naoto Azuma" }, { "id": "https://openalex.org/A5110360596", "display_name": "Sumiaki Fukuda" }, { "id": "https://openalex.org/A5007583907", "display_name": "Yasushi Fukushima" }, { "id": "https://openalex.org/A5049754800", "display_name": "Norio Harada" }, { "id": "https://openalex.org/A5102951798", "display_name": "Shin\u2010ichiro Inoue" }, { "id": "https://openalex.org/A5100781225", "display_name": "Hitoshi Ishida" }, { "id": "https://openalex.org/A5056948964", "display_name": "Hiroshi Ishii" }, { "id": "https://openalex.org/A5052534465", "display_name": "San\u2010e Ishikawa" }, { "id": "https://openalex.org/A5103007377", "display_name": "Hideaki Jinnouchi" }, { "id": "https://openalex.org/A5101474154", "display_name": "Shizuka Kaneko" }, { "id": "https://openalex.org/A5109757322", "display_name": "K. Kanno" }, { "id": "https://openalex.org/A5110879266", "display_name": "Mai Kato" }, { "id": "https://openalex.org/A5008378873", "display_name": "Yoichiro Kato" }, { "id": "https://openalex.org/A5022306960", "display_name": "Tatsushi Kawada" }, { "id": "https://openalex.org/A5100724831", "display_name": "Hyun-Mi Kim" }, { "id": "https://openalex.org/A5048971859", "display_name": "Arihiro Kiyosue" }, { "id": "https://openalex.org/A5020583276", "display_name": "Osamu Matsuoka" }, { "id": "https://openalex.org/A5110588955", "display_name": "Otoya Miho" }, { "id": "https://openalex.org/A5112785110", "display_name": "S. Nakamoto" }, { "id": "https://openalex.org/A5072654104", "display_name": "Susumu Nakamura" }, { "id": "https://openalex.org/A5057147980", "display_name": "Shuhei Nakanishi" }, { "id": "https://openalex.org/A5059859682", "display_name": "Hideki Nishimura" }, { "id": "https://openalex.org/A5065092809", "display_name": "Akira Numata" }, { "id": "https://openalex.org/A5113612104", "display_name": "T. Ohama" }, { "id": "https://openalex.org/A5081074322", "display_name": "Tomoko Okabe" }, { "id": "https://openalex.org/A5044191091", "display_name": "FUMINOBU OKUGUCHI" }, { "id": "https://openalex.org/A5070116155", "display_name": "Takeshi Osonoi" }, { "id": "https://openalex.org/A5112141640", "display_name": "T Sasaki" }, { "id": "https://openalex.org/A5006188126", "display_name": "Hiroaki Seino" }, { "id": "https://openalex.org/A5112641484", "display_name": "Koki Shin" }, { "id": "https://openalex.org/A5079463427", "display_name": "Toshihiko Shiraiwa" }, { "id": "https://openalex.org/A5112161905", "display_name": "Toshiyuki Sugiura" }, { "id": "https://openalex.org/A5109316164", "display_name": "Seiki Wada" }, { "id": "https://openalex.org/A5068870878", "display_name": "Akira Yamauchi" } ] }, { "id": "https://openalex.org/W2143996444", "doi": "https://doi.org/10.2337/dc11-0096", "title": "Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual \u03b2-Cell Function", "abstract": { "OBJECTIVE": [ 0 ], "To": [ 1 ], "investigate": [ 2 ], "the": [ 3 ], "effect": [ 4 ], "of": [ 5, 8, 210, 212 ], "4": [ 6 ], "weeks": [ 7 ], "treatment": [ 9, 221 ], "with": [ 10, 23, 38, 56, 76, 100, 153, 159, 178, 194, 216, 244, 248, 258 ], "liraglutide": [ 11, 57, 67, 154, 217, 249 ], "on": [ 12 ], "insulin": [ 13, 69, 71, 95, 160, 173, 187, 256 ], "dose": [ 14, 115, 174, 257 ], "and": [ 15, 24, 44, 80, 88, 105, 108, 134, 183 ], "glycemic": [ 16, 262 ], "control": [ 17 ], "in": [ 18, 94, 131, 149, 164, 171, 239, 250 ], "type": [ 19, 34, 251 ], "1": [ 20, 35, 252 ], "diabetic": [ 21, 36, 253 ], "patients": [ 22, 37, 53, 62, 133, 151, 185, 214, 242, 254 ], "without": [ 25, 46 ], "residual": [ 26, 39 ], "\u03b2-cell": [ 27, 40, 179 ], "function.": [ 28 ], "RESEARCH": [ 29 ], "DESIGN": [ 30 ], "AND": [ 31 ], "METHODS": [ 32 ], "Ten": [ 33 ], "function": [ 41, 180 ], "(C-peptide": [ 42, 47 ], "positive)": [ 43 ], "19": [ 45, 213 ], "negative)": [ 48 ], "were": [ 49, 54, 63, 111 ], "studied.": [ 50 ], "All": [ 51 ], "C-peptide\u2013positive": [ 52, 132, 190 ], "treated": [ 55, 152, 215, 243 ], "plus": [ 58, 68 ], "insulin,": [ 59 ], "whereas": [ 60 ], "C-peptide\u2013negative": [ 61, 150 ], "randomly": [ 64 ], "assigned": [ 65 ], "to": [ 66, 121, 139, 202, 229 ], "or": [ 70, 260 ], "monotherapy.": [ 72, 161 ], "Continuous": [ 73 ], "glucose": [ 74, 102, 196 ], "monitoring": [ 75 ], "identical": [ 77 ], "food": [ 78 ], "intake": [ 79 ], "physical": [ 81 ], "activity": [ 82 ], "was": [ 83, 175 ], "performed": [ 84 ], "before": [ 85 ], "(week": [ 86, 90 ], "0)": [ 87 ], "during": [ 89, 220 ], "4)": [ 91 ], "treatment.": [ 92, 188 ], "Differences": [ 93 ], "dose;": [ 96 ], "HbA1c;": [ 97 ], "time": [ 98, 192 ], "spent": [ 99, 193 ], "blood": [ 101, 195 ], "&lt;3.9,": [ 103 ], "&gt;10,": [ 104 ], "3.9\u20139.9": [ 106 ], "mmol/L;": [ 107 ], "body": [ 109 ], "weight": [ 110, 219 ], "evaluated.": [ 112 ], "RESULTS": [ 113 ], "Insulin": [ 114 ], "decreased": [ 116, 163, 199 ], "from": [ 117, 135, 200 ], "0.50": [ 118 ], "\u00b1": [ 119, 123, 137, 141, 225 ], "0.06": [ 120, 142 ], "0.31": [ 122 ], "0.08": [ 124, 138 ], "units/kg": [ 125, 143 ], "per": [ 126, 144 ], "day": [ 127, 145 ], "(P": [ 128, 146, 205 ], "&lt;": [ 129, 147, 232 ], "0.001)": [ 130 ], "0.72": [ 136 ], "0.59": [ 140 ], "0.01)": [ 148 ], "but": [ 155 ], "did": [ 156 ], "not": [ 157 ], "change": [ 158 ], "HbA1c": [ 162 ], "both": [ 165 ], "liraglutide-treated": [ 166 ], "groups.": [ 167 ], "The": [ 168 ], "percent": [ 169 ], "reduction": [ 170 ], "daily": [ 172 ], "positively": [ 176 ], "correlated": [ 177 ], "at": [ 181 ], "baseline,": [ 182 ], "two": [ 184 ], "discontinued": [ 186 ], "In": [ 189 ], "patients,": [ 191 ], "&lt;3.9": [ 197 ], "mmol/L": [ 198 ], "3.0": [ 201 ], "1.0": [ 203 ], "h": [ 204 ], "=": [ 206 ], "0.03).": [ 207 ], "A": [ 208 ], "total": [ 209 ], "18": [ 211 ], "lost": [ 218 ], "(mean": [ 222 ], "[range]": [ 223 ], "\u22122.3": [ 224 ], "0.3": [ 226 ], "kg": [ 227 ], "[\u22120.5": [ 228 ], "\u22125.1];": [ 230 ], "P": [ 231 ], "0.001).": [ 233 ], "Transient": [ 234 ], "gastrointestinal": [ 235 ], "adverse": [ 236 ], "effects": [ 237 ], "occurred": [ 238 ], "almost": [ 240 ], "all": [ 241 ], "liraglutide.": [ 245 ], "CONCLUSIONS": [ 246 ], "Treatment": [ 247 ], "reduces": [ 255 ], "improved": [ 259 ], "unaltered": [ 261 ], "control.": [ 263 ] }, "publication_date": "2011-05-19", "publication_year": 2011, "type": "article", "cited_by_count": 159, "authors": [ { "id": "https://openalex.org/A5051507182", "display_name": "Urd Kielgast" }, { "id": "https://openalex.org/A5018061859", "display_name": "Thure Krarup" }, { "id": "https://openalex.org/A5085434984", "display_name": "Jens J. Holst" }, { "id": "https://openalex.org/A5062239390", "display_name": "Sten Madsbad" } ] }, { "id": "https://openalex.org/W1993070711", "doi": "https://doi.org/10.1111/j.1463-1326.2009.01175.x", "title": "Diabetes and obesity: therapeutic targeting and risk reduction \u2013 a complex interplay", "abstract": { "Obesity": [ 0 ], "is": [ 1, 241 ], "a": [ 2, 48, 129, 242 ], "major": [ 3, 29 ], "risk": [ 4, 23, 73, 174 ], "factor": [ 5 ], "for": [ 6, 24, 123, 133, 279 ], "the": [ 7, 22, 28, 137, 167, 197, 238, 276 ], "development": [ 8 ], "of": [ 9, 31, 125, 141, 234, 256 ], "diabetes": [ 10, 38, 164 ], "and": [ 11, 16, 33, 45, 59, 68, 104, 107, 139, 144, 194, 196, 203, 209, 213, 216, 221, 250, 262 ], "predisposes": [ 12 ], "individuals": [ 13 ], "to": [ 14, 53, 99, 118, 135, 150, 229, 245, 274 ], "hypertension": [ 15, 261 ], "dyslipidaemia.": [ 17, 263 ], "Together": [ 18 ], "these": [ 19 ], "pathologies": [ 20 ], "increase": [ 21 ], "cardiovascular": [ 25, 72, 173 ], "disease": [ 26 ], "(CVD),": [ 27 ], "cause": [ 30, 65 ], "morbidity": [ 32 ], "mortality": [ 34 ], "in": [ 35, 43, 111, 148, 248, 253, 282 ], "type": [ 36 ], "2": [ 37 ], "mellitus": [ 39 ], "(T2DM).": [ 40 ], "Worsening": [ 41 ], "trends": [ 42 ], "obesity": [ 44 ], "T2DM": [ 46 ], "raise": [ 47 ], "serious": [ 49 ], "conundrum,": [ 50 ], "namely,": [ 51 ], "how": [ 52 ], "control": [ 54 ], "blood": [ 55, 57, 101, 214 ], "glucose,": [ 56 ], "pressure,": [ 58, 102 ], "lipids": [ 60 ], "when": [ 61 ], "many": [ 62 ], "antidiabetic": [ 63 ], "agents": [ 64, 85 ], "weight": [ 66, 212, 224 ], "gain": [ 67 ], "thereby": [ 69 ], "exacerbate": [ 70 ], "other": [ 71, 177 ], "factors": [ 74 ], "associated": [ 75 ], "with": [ 76 ], "T2DM.": [ 77 ], "Further,": [ 78 ], "evidence": [ 79 ], "suggests": [ 80 ], "that": [ 81 ], "some": [ 82 ], "established": [ 83 ], "antihypertensive": [ 84 ], "may": [ 86, 110, 170 ], "worsen": [ 87 ], "glucose": [ 88 ], "intolerance.": [ 89 ], "Many": [ 90 ], "patients": [ 91 ], "who": [ 92 ], "are": [ 93, 185, 223 ], "obese,": [ 94 ], "hypertensive,": [ 95 ], "and/or": [ 96 ], "hyperlipidaemic": [ 97 ], "fail": [ 98 ], "achieve": [ 100 ], "lipid": [ 103, 218, 231 ], "glycaemic": [ 105 ], "goals,": [ 106 ], "this": [ 108 ], "failure": [ 109 ], "part": [ 112 ], "be": [ 113, 272 ], "explained": [ 114 ], "by": [ 115 ], "physician": [ 116 ], "reluctance": [ 117 ], "utilize": [ 119 ], "complex": [ 120 ], "combination": [ 121 ], "regimens": [ 122 ], "fear": [ 124 ], "off\u2010target": [ 126 ], "effects.": [ 127 ], "Thus,": [ 128 ], "clear": [ 130 ], "need": [ 131 ], "exists": [ 132 ], "clinicians": [ 134 ], "understand": [ 136 ], "risks": [ 138 ], "benefits": [ 140 ], "different": [ 142 ], "pharmacologic,": [ 143 ], "indeed": [ 145 ], "non\u2010pharmacologic,": [ 146 ], "options": [ 147 ], "order": [ 149 ], "maximize": [ 151 ], "treatment": [ 152, 283 ], "outcomes.": [ 153 ], "While": [ 154 ], "intensive": [ 155 ], "lifestyle": [ 156 ], "modification": [ 157 ], "remains": [ 158 ], "an": [ 159 ], "elusive": [ 160 ], "gold": [ 161 ], "standard,": [ 162 ], "newer": [ 163 ], "targets,": [ 165 ], "including": [ 166, 267 ], "incretin": [ 168, 235 ], "axis,": [ 169 ], "offer": [ 171 ], "greater": [ 172 ], "reduction": [ 175 ], "than": [ 176 ], "antidiabetes": [ 178 ], "therapies,": [ 179 ], "although": [ 180 ], "definitive": [ 181 ], "clinical": [ 182 ], "trial": [ 183 ], "data": [ 184 ], "needed.": [ 186 ], "The": [ 187 ], "glucagon\u2010like": [ 188 ], "peptide\u20101": [ 189 ], "(GLP\u20101)": [ 190 ], "receptor": [ 191 ], "agonists": [ 192 ], "exenatide": [ 193, 208 ], "liraglutide": [ 195, 210 ], "dipeptidyl": [ 198 ], "peptidase\u20104": [ 199 ], "(DPP\u20104)": [ 200 ], "inhibitors": [ 201 ], "sitagliptin": [ 202 ], "vildagliptin": [ 204, 222 ], "effectively": [ 205 ], "lower": [ 206 ], "HbA1c;": [ 207 ], "reduce": [ 211 ], "pressure": [ 215 ], "improve": [ 217, 230 ], "profiles.": [ 219, 232 ], "Sitagliptin": [ 220 ], "neutral": [ 225 ], "but": [ 226 ], "also": [ 227 ], "appear": [ 228 ], "Integration": [ 233 ], "therapies": [ 236, 281 ], "into": [ 237 ], "therapeutic": [ 239 ], "armamentarium": [ 240 ], "promising": [ 243 ], "approach": [ 244 ], "improving": [ 246 ], "outcomes": [ 247 ], "T2DM,": [ 249, 257 ], "perhaps": [ 251 ], "even": [ 252 ], "reducing": [ 254 ], "complications": [ 255 ], "such": [ 258 ], "as": [ 259 ], "co\u2010morbid": [ 260 ], "Additional": [ 264 ], "long\u2010term": [ 265 ], "studies,": [ 266, 270 ], "CVD": [ 268 ], "end\u2010point": [ 269 ], "will": [ 271 ], "necessary": [ 273 ], "determine": [ 275 ], "appropriate": [ 277 ], "places": [ 278 ], "incretin\u2010based": [ 280 ], "algorithms.": [ 284 ] }, "publication_date": "2009-11-06", "publication_year": 2009, "type": "review", "cited_by_count": 85, "authors": [ { "id": "https://openalex.org/A5068362253", "display_name": "Kevin D. Niswender" } ] }, { "id": "https://openalex.org/W2079123198", "doi": "https://doi.org/10.1002/jps.23648", "title": "In Vitro Protein Binding of Liraglutide in Human Plasma Determined by Reiterated Stepwise Equilibrium Dialysis", "abstract": { "Liraglutide": [ 0 ], "is": [ 1, 17 ], "a": [ 2, 26, 81, 102, 149 ], "human": [ 3, 20, 135, 168 ], "glucagon-like": [ 4 ], "peptide-1": [ 5 ], "(GLP-1)": [ 6 ], "analogue": [ 7 ], "approved": [ 8 ], "for": [ 9 ], "the": [ 10, 23, 38, 63, 69, 73, 86, 99, 189 ], "treatment": [ 11 ], "of": [ 12, 25, 60, 75, 88, 101, 124, 159, 191, 195 ], "type": [ 13 ], "2": [ 14 ], "diabetes.": [ 15 ], "It": [ 16, 45 ], "based": [ 18 ], "on": [ 19 ], "GLP-1": [ 21 ], "with": [ 22 ], "addition": [ 24 ], "16-carbon": [ 27 ], "fatty": [ 28 ], "acid,": [ 29 ], "which": [ 30 ], "facilitates": [ 31 ], "binding": [ 32, 54, 90, 126, 166, 194 ], "to": [ 33, 50, 79, 91, 114, 127, 163, 167 ], "plasma": [ 34, 92, 117, 131, 136, 142, 192 ], "proteins,": [ 35 ], "thus": [ 36 ], "prolonging": [ 37 ], "elimination": [ 39 ], "half-life": [ 40 ], "and": [ 41, 134, 138, 171, 176 ], "allowing": [ 42 ], "once-daily": [ 43 ], "administration.": [ 44 ], "has": [ 46, 110 ], "not": [ 47 ], "been": [ 48, 112 ], "possible": [ 49 ], "quantify": [ 51, 115 ], "liraglutide": [ 52, 89, 116, 125, 152, 160 ], "protein": [ 53, 118, 132, 193 ], "by": [ 55 ], "ultrafiltration": [ 56 ], "(the": [ 57 ], "usual": [ 58 ], "method": [ 59 ], "choice),": [ 61 ], "as": [ 62, 144, 146 ], "lipophilic": [ 64, 198 ], "molecule": [ 65 ], "becomes": [ 66 ], "trapped": [ 67 ], "in": [ 68, 94, 129, 188 ], "filter": [ 70 ], "membrane.": [ 71 ], "Therefore,": [ 72 ], "aim": [ 74 ], "this": [ 76 ], "study": [ 77 ], "was": [ 78, 139, 161, 174 ], "develop": [ 80 ], "methodology": [ 82, 181 ], "that": [ 83, 109 ], "could": [ 84, 184 ], "determine": [ 85 ], "extent": [ 87 ], "proteins": [ 93, 128 ], "vitro.": [ 95 ], "We": [ 96 ], "report": [ 97 ], "here": [ 98 ], "details": [ 100 ], "novel": [ 103, 180 ], "reiterated": [ 104 ], "stepwise": [ 105 ], "equilibrium": [ 106 ], "dialysis": [ 107 ], "assay": [ 108, 121 ], "successfully": [ 111 ], "used": [ 113 ], "binding.": [ 119 ], "The": [ 120, 179 ], "allowed": [ 122 ], "quantification": [ 123, 190 ], "purified": [ 130 ], "solutions": [ 133 ], "samples": [ 137 ], "effective": [ 140 ], "at": [ 141 ], "dilutions": [ 143 ], "low": [ 145 ], "5%.": [ 147 ], "At": [ 148 ], "clinically": [ 150 ], "relevant": [ 151 ], "concentration": [ 153 ], "(10(4)": [ 154 ], "pM),": [ 155 ], "greater": [ 156 ], "than": [ 157 ], "98.9%": [ 158 ], "bound": [ 162 ], "protein.": [ 164 ], "Specific": [ 165 ], "serum": [ 169 ], "albumin": [ 170 ], "\u03b11-acid": [ 172 ], "glycoprotein": [ 173 ], "99.4%": [ 175 ], "99.3%,": [ 177 ], "respectively.": [ 178 ], "described": [ 182 ], "herein": [ 183 ], "have": [ 185 ], "an": [ 186 ], "application": [ 187 ], "other": [ 196 ], "highly": [ 197 ], "drug": [ 199 ], "molecules.": [ 200 ] }, "publication_date": "2013-07-12", "publication_year": 2013, "type": "article", "cited_by_count": 84, "authors": [ { "id": "https://openalex.org/A5111970078", "display_name": "Anne Plum" }, { "id": "https://openalex.org/A5111523695", "display_name": "Lisbeth Bjerring Jensen" }, { "id": "https://openalex.org/A5089425665", "display_name": "Jesper B. Kristensen" } ] }, { "id": "https://openalex.org/W2102052385", "doi": "https://doi.org/10.1152/ajpendo.00479.2010", "title": "Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents", "abstract": { "The": [ 0 ], "risk": [ 1 ], "of": [ 2, 14, 44, 153, 199, 229 ], "developing": [ 3 ], "pancreatitis": [ 4, 15, 93, 246, 251 ], "is": [ 5 ], "elevated": [ 6 ], "in": [ 7, 19, 48, 105, 145, 157, 213, 243, 252 ], "type": [ 8, 20 ], "2": [ 9, 21 ], "diabetes": [ 10, 22 ], "and": [ 11, 54, 64, 79, 103, 108, 122, 124, 132, 155, 160, 174, 208, 215, 224, 240, 247, 254 ], "obesity.": [ 12 ], "Cases": [ 13 ], "have": [ 16 ], "been": [ 17 ], "reported": [ 18 ], "patients": [ 23 ], "treated": [ 24 ], "with": [ 25, 76, 96 ], "GLP-1": [ 26 ], "(GLP-1R)": [ 27 ], "receptor": [ 28 ], "agonists.": [ 29 ], "To": [ 30 ], "examine": [ 31 ], "whether": [ 32 ], "the": [ 33, 42, 167, 196 ], "GLP-1R": [ 34 ], "agonist": [ 35 ], "exenatide": [ 36, 45, 60, 77, 200, 234 ], "potentially": [ 37 ], "induces": [ 38 ], "or": [ 39, 50, 67, 71, 86, 99, 143, 189, 203 ], "modulates": [ 40 ], "pancreatitis,": [ 41 ], "effect": [ 43 ], "was": [ 46, 94 ], "evaluated": [ 47 ], "normal": [ 49, 158, 253 ], "diabetic": [ 51, 55, 255 ], "rodents.": [ 52, 256 ], "Normal": [ 53 ], "rats": [ 56, 159 ], "received": [ 57 ], "a": [ 58 ], "single": [ 59, 210 ], "dose": [ 61 ], "(0.072,": [ 62 ], "0.24,": [ 63 ], "0.72": [ 65 ], "nmol/kg)": [ 66 ], "vehicle.": [ 68 ], "Diabetic": [ 69 ], "ob/ob": [ 70, 113, 161, 230 ], "HF-STZ": [ 72 ], "mice": [ 73, 162, 214 ], "were": [ 74, 110, 127, 130, 177, 222 ], "infused": [ 75 ], "(1.2": [ 78 ], "7.2": [ 80 ], "nmol\u00b7kg": [ 81 ], "\u22121": [ 82, 84 ], "\u00b7day": [ 83 ], ")": [ 85 ], "vehicle": [ 87 ], "for": [ 88 ], "4": [ 89 ], "wk.": [ 90 ], "Post-exenatide": [ 91 ], "treatment,": [ 92 ], "induced": [ 95, 250 ], "caerulein": [ 97 ], "(CRN)": [ 98 ], "sodium": [ 100 ], "taurocholate": [ 101 ], "(ST),": [ 102 ], "changes": [ 104 ], "plasma": [ 106, 115, 141, 238 ], "amylase": [ 107, 142, 154, 239 ], "lipase": [ 109, 144, 156, 241 ], "measured.": [ 111 ], "In": [ 112, 232 ], "mice,": [ 114 ], "cytokines": [ 116, 173 ], "(IL-1\u03b2,": [ 117 ], "IL-2,": [ 118 ], "IL-6,": [ 119 ], "MCP-1,": [ 120 ], "IFN\u03b3,": [ 121 ], "TNF\u03b1)": [ 123 ], "pancreatitis-associated": [ 125 ], "genes": [ 126 ], "assessed.": [ 128 ], "Pancreata": [ 129 ], "weighed": [ 131 ], "examined": [ 133 ], "histologically.": [ 134 ], "Exenatide": [ 135, 149, 181 ], "treatment": [ 136 ], "alone": [ 137 ], "did": [ 138, 164, 235 ], "not": [ 139, 165, 185, 236 ], "modify": [ 140, 166, 237 ], "any": [ 146 ], "models": [ 147 ], "tested.": [ 148 ], "attenuated": [ 150 ], "CRN-induced": [ 151 ], "release": [ 152 ], "but": [ 163, 184 ], "response": [ 168 ], "to": [ 169 ], "ST": [ 170 ], "infusion.": [ 171 ], "Plasma": [ 172 ], "pancreatic": [ 175 ], "weight": [ 176 ], "unaffected": [ 178 ], "by": [ 179 ], "exenatide.": [ 180 ], "upregulated": [ 182 ], "Reg3b": [ 183 ], "Il6,": [ 186 ], "Ccl2,": [ 187 ], "Nfkb1,": [ 188 ], "Vamp8": [ 190 ], "expression.": [ 191 ], "Histological": [ 192 ], "analysis": [ 193 ], "revealed": [ 194 ], "that": [ 195 ], "highest": [ 197 ], "doses": [ 198 ], "decreased": [ 201 ], "CRN-": [ 202 ], "ST-induced": [ 204 ], "acute": [ 205 ], "inflammation,": [ 206 ], "vacuolation,": [ 207 ], "acinar": [ 209 ], "cell": [ 211, 219 ], "necrosis": [ 212 ], "rats,": [ 216 ], "respectively.": [ 217 ], "Ductal": [ 218 ], "proliferation": [ 220 ], "rates": [ 221 ], "low": [ 223 ], "similar": [ 225 ], "across": [ 226 ], "all": [ 227 ], "groups": [ 228 ], "mice.": [ 231 ], "conclusion,": [ 233 ], "concentrations": [ 242 ], "rodents": [ 244 ], "without": [ 245 ], "improved": [ 248 ], "chemically": [ 249 ] }, "publication_date": "2010-10-06", "publication_year": 2010, "type": "article", "cited_by_count": 89, "authors": [ { "id": "https://openalex.org/A5071153791", "display_name": "Krystyna Tatarkiewicz" }, { "id": "https://openalex.org/A5061694041", "display_name": "Pam Smith" }, { "id": "https://openalex.org/A5036070779", "display_name": "Emmanuel J. Sablan" }, { "id": "https://openalex.org/A5022328113", "display_name": "Clara J. Polizzi" }, { "id": "https://openalex.org/A5052474981", "display_name": "Donald E. Aumann" }, { "id": "https://openalex.org/A5052916432", "display_name": "Christiane Villescaz" }, { "id": "https://openalex.org/A5111925367", "display_name": "Diane M. Hargrove" }, { "id": "https://openalex.org/A5113552209", "display_name": "Bronislava Gedulin" }, { "id": "https://openalex.org/A5021025830", "display_name": "Melissa G. W. Lu" }, { "id": "https://openalex.org/A5005164520", "display_name": "Lisa C. Adams" }, { "id": "https://openalex.org/A5069559571", "display_name": "Tina Whisenant" }, { "id": "https://openalex.org/A5031603815", "display_name": "Denis Roy" }, { "id": "https://openalex.org/A5077809872", "display_name": "David G. Parkes" } ] }, { "id": "https://openalex.org/W1498870695", "doi": "https://doi.org/10.1111/j.1464-5491.2011.03276.x", "title": "Patient\u2010reported outcomes are superior in patients with Type\u20032 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open\u2010label study", "abstract": { "Diabet.": [ 0 ], "Med.": [ 1 ], "28,": [ 2 ], "715\u2013723": [ 3 ], "(2011)": [ 4 ], "Abstract": [ 5 ], "Aims": [ 6 ], "The": [ 7, 91 ], "Liraglutide": [ 8 ], "Effect": [ 9 ], "and": [ 10, 87, 108, 190, 222 ], "Action": [ 11 ], "in": [ 12, 62, 77, 93, 171, 182, 194, 216, 229, 240 ], "Diabetes": [ 13, 81 ], "6": [ 14 ], "trial": [ 15, 19 ], "was": [ 16, 55, 106, 111 ], "an": [ 17, 25 ], "open\u2010label": [ 18 ], "comparing": [ 20 ], "liraglutide": [ 21, 40, 67, 105, 135, 177, 221, 245 ], "with": [ 22, 33, 104, 109, 134, 137, 176, 179, 244, 247 ], "exenatide": [ 23, 46, 138, 180 ], "as": [ 24 ], "\u2018add\u2010on\u2019": [ 26 ], "to": [ 27, 39 ], "metformin": [ 28 ], "and/or": [ 29 ], "sulphonylurea.": [ 30 ], "Methods": [ 31 ], "Patients": [ 32, 166 ], "Type": [ 34 ], "2": [ 35 ], "diabetes": [ 36 ], "were": [ 37, 75 ], "randomized": [ 38 ], "1.8": [ 41, 68 ], "mg": [ 42, 69 ], "once": [ 43, 70 ], "daily": [ 44, 50 ], "or": [ 45 ], "10": [ 47 ], "\u03bcg": [ 48 ], "twice": [ 49 ], "for": [ 51 ], "26": [ 52, 103, 175 ], "weeks.": [ 53 ], "This": [ 54 ], "followed": [ 56 ], "by": [ 57 ], "a": [ 58, 168, 191 ], "14\u2010week": [ 59 ], "extension": [ 60, 205 ], "phase,": [ 61, 206 ], "which": [ 63 ], "all": [ 64, 208 ], "patients": [ 65, 79, 209, 217 ], "received": [ 66, 210 ], "daily.": [ 71 ], "Results": [ 72 ], "Patient\u2010reported": [ 73 ], "outcomes": [ 74 ], "measured": [ 76 ], "379": [ 78 ], "using": [ 80 ], "Treatment": [ 82 ], "Satisfaction": [ 83 ], "Questionnaire": [ 84 ], "status": [ 85 ], "(DTSQs)": [ 86 ], "DTSQ": [ 88 ], "change": [ 89, 92 ], "(DTSQc).": [ 90 ], "overall": [ 94 ], "treatment": [ 95, 141, 242 ], "satisfaction": [ 96, 243 ], "(DTSQs": [ 97 ], "score)": [ 98 ], "from": [ 99, 232 ], "baseline": [ 100 ], "at": [ 101, 173 ], "week": [ 102, 174 ], "4.71": [ 107 ], "exentaide": [ 110 ], "1.66": [ 112 ], "[difference": [ 113, 181, 197 ], "between": [ 114 ], "groups": [ 115 ], "3.04": [ 116 ], "(95%": [ 117 ], "CI": [ 118 ], "1.73\u20134.35),": [ 119 ], "P": [ 120, 143, 148, 153, 158, 163, 187, 200, 226 ], "<": [ 121, 149 ], "0.0001].": [ 122 ], "Five": [ 123 ], "of": [ 124 ], "the": [ 125, 129, 204 ], "six": [ 126 ], "items": [ 127 ], "on": [ 128, 220 ], "DTSQs": [ 130, 212 ], "improved": [ 131 ], "significantly": [ 132, 224 ], "more": [ 133 ], "than": [ 136, 178 ], "(differences:": [ 139 ], "current": [ 140 ], "0.37,": [ 142 ], "=": [ 144, 154, 159, 164, 188, 201, 227 ], "0.0093;": [ 145 ], "convenience": [ 146 ], "0.68,": [ 147 ], "0.0001;": [ 150 ], "flexibility": [ 151 ], "0.57,": [ 152 ], "0.0002;": [ 155 ], "recommend": [ 156 ], "0.49,": [ 157 ], "0.0003;": [ 160 ], "continue": [ 161 ], "0.66,": [ 162 ], "0.0001).": [ 165 ], "perceived": [ 167, 195 ], "greater": [ 169, 192 ], "reduction": [ 170, 193 ], "hypoglycaemia": [ 172 ], "DTSQc": [ 183 ], "score": [ 184 ], "0.48": [ 185 ], "(0.08\u20130.89),": [ 186 ], "0.0193]": [ 189 ], "hyperglycaemia": [ 196 ], "0.74": [ 198 ], "(0.31\u20131.17),": [ 199 ], "0.0007].": [ 202 ], "During": [ 203 ], "when": [ 207 ], "liraglutide,": [ 211 ], "scores": [ 213 ], "remained": [ 214 ], "stable": [ 215 ], "who": [ 218 ], "continued": [ 219 ], "increased": [ 223 ], "(": [ 225 ], "0.0026)": [ 228 ], "those": [ 230 ], "switching": [ 231 ], "exenatide.": [ 233, 248 ], "Conclusions": [ 234 ], "These": [ 235 ], "results": [ 236 ], "demonstrate": [ 237 ], "significant": [ 238 ], "improvements": [ 239 ], "patients\u2019": [ 241 ], "compared": [ 246 ] }, "publication_date": "2011-03-09", "publication_year": 2011, "type": "article", "cited_by_count": 31, "authors": [ { "id": "https://openalex.org/A5111040183", "display_name": "Wolfgang E. Schmidt" }, { "id": "https://openalex.org/A5066686056", "display_name": "Jens Sandahl Christiansen" }, { "id": "https://openalex.org/A5109998971", "display_name": "Mette Hammer" }, { "id": "https://openalex.org/A5113524401", "display_name": "Marcin Zychma" }, { "id": "https://openalex.org/A5040182038", "display_name": "John B. Buse" } ] }, { "id": "https://openalex.org/W3087450863", "doi": "https://doi.org/10.2337/dc20-1890", "title": "Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases", "abstract": { "OBJECTIVE": [ 0 ], "To": [ 1 ], "examine": [ 2 ], "the": [ 3, 70, 73, 138, 168, 185, 206, 211, 221, 245 ], "comparative": [ 4 ], "effectiveness": [ 5 ], "of": [ 6, 27, 72, 76, 114, 137, 184, 220, 244, 281 ], "sodium\u2013glucose": [ 7 ], "cotransporter": [ 8 ], "2": [ 9, 34, 263 ], "inhibitors": [ 10, 21 ], "(SGLT2i),": [ 11 ], "glucagon-like": [ 12 ], "peptide": [ 13 ], "1": [ 14 ], "receptor": [ 15 ], "agonists": [ 16 ], "(GLP-1),": [ 17 ], "dipeptidyl": [ 18 ], "peptidase": [ 19 ], "4": [ 20 ], "(DPP-4),": [ 22 ], "and": [ 23, 129, 151, 170, 178, 193, 213, 238, 256 ], "sulfonylureas": [ 24, 57, 274 ], "on": [ 25, 43 ], "risk": [ 26, 71, 136, 166, 183, 219, 243, 280 ], "kidney": [ 28, 85, 283 ], "outcomes": [ 29 ], "among": [ 30 ], "people": [ 31 ], "with": [ 32, 120, 123, 126, 133, 205, 234, 266, 271, 277 ], "type": [ 33, 262 ], "diabetes.": [ 35 ], "RESEARCH": [ 36 ], "DESIGN": [ 37 ], "AND": [ 38 ], "METHODS": [ 39 ], "U.S.": [ 40 ], "veterans": [ 41 ], "initiated": [ 42 ], "SGLT2i": [ 44, 169, 177, 212, 237, 267 ], "(n": [ 45, 49, 53, 58 ], "=": [ 46, 50, 54, 59 ], "18,544),": [ 47 ], "GLP-1": [ 48, 171, 179, 214, 239, 269 ], "23,711),": [ 51 ], "DPP-4": [ 52, 130, 189, 272 ], "39,399),": [ 55 ], "or": [ 56, 88, 268, 273 ], "134,904)": [ 60 ], "were": [ 61, 92 ], "followed": [ 62 ], "for": [ 63, 98 ], "up": [ 64 ], "to": [ 65, 68, 251, 254 ], "3": [ 66 ], "years": [ 67 ], "evaluate": [ 69 ], "composite": [ 74, 139, 186, 222, 246 ], "outcome": [ 75, 140, 187, 223, 247 ], "estimated": [ 77, 93 ], "glomerular": [ 78 ], "filtration": [ 79 ], "rate": [ 80 ], "(eGFR)": [ 81 ], "decline": [ 82 ], "&gt;50%,": [ 83 ], "end-stage": [ 84 ], "disease": [ 86 ], "(ESKD),": [ 87 ], "all-cause": [ 89 ], "mortality.": [ 90 ], "Risks": [ 91 ], "using": [ 94 ], "survival": [ 95 ], "models": [ 96 ], "adjusted": [ 97 ], "predefined": [ 99 ], "covariates": [ 100, 104 ], "as": [ 101, 103 ], "well": [ 102 ], "identified": [ 105 ], "by": [ 106, 199 ], "a": [ 107, 134, 161, 181, 217, 241, 278 ], "high-dimensional": [ 108 ], "variable": [ 109 ], "selection": [ 110 ], "algorithm": [ 111 ], "through": [ 112 ], "application": [ 113 ], "generalized": [ 115 ], "propensity": [ 116 ], "scores.": [ 117 ], "RESULTS": [ 118 ], "Compared": [ 119, 233 ], "those": [ 121, 209 ], "treated": [ 122 ], "sulfonylureas,": [ 124 ], "treatment": [ 125, 265 ], "SGLT2i,": [ 127 ], "GLP-1,": [ 128 ], "was": [ 131, 275 ], "associated": [ 132, 276 ], "lower": [ 135, 182, 218, 279 ], "(hazard": [ 141 ], "ratio": [ 142 ], "0.68": [ 143 ], "[95%": [ 144 ], "CI": [ 145 ], "0.63,": [ 146 ], "0.74],": [ 147 ], "0.72": [ 148 ], "[0.67,": [ 149 ], "0.77],": [ 150 ], "0.90": [ 152 ], "[0.86,": [ 153 ], "0.95],": [ 154 ], "respectively).": [ 155, 197 ], "While": [ 156 ], "we": [ 157 ], "did": [ 158 ], "not": [ 159 ], "observe": [ 160 ], "statistically": [ 162 ], "significant": [ 163 ], "difference": [ 164 ], "in": [ 165, 210, 224, 248 ], "between": [ 167 ], "arms": [ 172, 215 ], "(0.95": [ 173 ], "[0.87,": [ 174 ], "1.04]),": [ 175 ], "both": [ 176, 236 ], "had": [ 180 ], "than": [ 188 ], "(0.76": [ 190 ], "[0.70,": [ 191 ], "0.82]": [ 192 ], "0.79": [ 194 ], "[0.74,": [ 195 ], "0.85],": [ 196 ], "Analyses": [ 198 ], "eGFR": [ 200, 226, 229, 249 ], "category": [ 201 ], "suggested": [ 202 ], "that": [ 203 ], "compared": [ 204, 270 ], "sulfonylurea": [ 207 ], "arm,": [ 208 ], "exhibited": [ 216, 240 ], "all": [ 225 ], "categories,": [ 227 ], "including": [ 228 ], "&lt;45": [ 230, 257 ], "mL/min/1.73": [ 231, 258 ], "m2.": [ 232, 259 ], "DPP-4,": [ 235 ], "reduced": [ 242 ], "&lt;90": [ 250 ], "\u226560,": [ 252 ], "&lt;60": [ 253 ], "\u226545,": [ 255 ], "CONCLUSIONS": [ 260 ], "In": [ 261 ], "diabetes,": [ 264 ], "adverse": [ 282 ], "outcomes.": [ 284 ] }, "publication_date": "2020-09-16", "publication_year": 2020, "type": "article", "cited_by_count": 134, "authors": [ { "id": "https://openalex.org/A5044152940", "display_name": "Yan Xie" }, { "id": "https://openalex.org/A5088449459", "display_name": "Benjamin Bowe" }, { "id": "https://openalex.org/A5042854456", "display_name": "Andrew K. Gibson" }, { "id": "https://openalex.org/A5050076657", "display_name": "Janet B. McGill" }, { "id": "https://openalex.org/A5040827897", "display_name": "Geetha Maddukuri" }, { "id": "https://openalex.org/A5100395068", "display_name": "Yan Yan" }, { "id": "https://openalex.org/A5047490642", "display_name": "Ziyad Al\u2010Aly" } ] }, { "id": "https://openalex.org/W3124422045", "doi": "https://doi.org/10.1186/s12933-020-01211-4", "title": "Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review", "abstract": null, "publication_date": "2021-01-19", "publication_year": 2021, "type": "review", "cited_by_count": 36, "authors": [ { "id": "https://openalex.org/A5112687114", "display_name": "Chen-Yi Yang" }, { "id": "https://openalex.org/A5112604201", "display_name": "Ying-Ren Chen" }, { "id": "https://openalex.org/A5064013873", "display_name": "Huang\u2010Tz Ou" }, { "id": "https://openalex.org/A5000139592", "display_name": "Shihchen Kuo" } ] }, { "id": "https://openalex.org/W4206503891", "doi": "https://doi.org/10.1016/j.peptides.2022.170749", "title": "GLP-1 and GIP receptor signaling in beta cells \u2013 A review of receptor interactions and co-stimulation", "abstract": { "Glucagon-like": [ 0 ], "peptide": [ 1 ], "1": [ 2 ], "receptor": [ 3, 9 ], "(GLP-1R)": [ 4 ], "and": [ 5, 26, 45, 57, 108, 148, 173, 192 ], "glucose-dependent": [ 6, 46 ], "insulinotropic": [ 7 ], "polypeptide": [ 8 ], "(GIPR)": [ 10 ], "are": [ 11, 19, 139, 158 ], "two": [ 12, 190 ], "class": [ 13, 63 ], "B1": [ 14 ], "G": [ 15 ], "protein-coupled": [ 16 ], "receptors,": [ 17 ], "which": [ 18 ], "stimulated": [ 20 ], "by": [ 21, 104 ], "the": [ 22, 30, 82, 88, 121, 130, 145, 153, 167, 176, 184, 189, 194, 200 ], "gastrointestinal": [ 23 ], "hormones": [ 24 ], "GLP-1": [ 25 ], "GIP,": [ 27 ], "respectively.": [ 28 ], "In": [ 29, 76, 162 ], "pancreatic": [ 31, 177 ], "beta": [ 32, 178 ], "cells,": [ 33 ], "activation": [ 34 ], "of": [ 35, 100, 113, 120, 132, 152, 188, 196, 202 ], "both": [ 36 ], "receptors": [ 37, 137, 191 ], "lead": [ 38 ], "to": [ 39, 141 ], "increased": [ 40 ], "cyclic": [ 41 ], "adenosine": [ 42 ], "monophosphate": [ 43 ], "(cAMP)": [ 44 ], "insulin": [ 47 ], "secretion.": [ 48 ], "Marketed": [ 49 ], "GLP-1R": [ 50, 122, 172 ], "agonists": [ 51 ], "such": [ 52 ], "as": [ 53, 123, 125 ], "dulaglutide,": [ 54 ], "liraglutide,": [ 55 ], "exenatide": [ 56 ], "semaglutide": [ 58 ], "constitute": [ 59 ], "an": [ 60 ], "expanding": [ 61 ], "drug": [ 62, 80 ], "with": [ 64, 180 ], "beneficial": [ 65 ], "effects": [ 66 ], "for": [ 67, 96, 115, 171 ], "persons": [ 68 ], "suffering": [ 69 ], "from": [ 70 ], "type": [ 71, 101 ], "2": [ 72, 102 ], "diabetes": [ 73, 103 ], "and/or": [ 74 ], "obesity.": [ 75 ], "recent": [ 77, 203 ], "years": [ 78 ], "another": [ 79 ], "class,": [ 81 ], "GLP-1R-GIPR": [ 83, 154, 197 ], "co-agonists,": [ 84 ], "has": [ 85 ], "emerged.": [ 86 ], "Especially": [ 87 ], "peptide-based,": [ 89 ], "co-agonist": [ 90 ], "tirzepatide": [ 91, 116 ], "is": [ 92 ], "a": [ 93, 97, 181 ], "promising": [ 94 ], "candidate": [ 95 ], "better": [ 98 ], "treatment": [ 99 ], "improving": [ 105 ], "glycemic": [ 106 ], "control": [ 107 ], "weight": [ 109 ], "reduction.": [ 110 ], "The": [ 111 ], "mechanism": [ 112 ], "action": [ 114 ], "include": [ 117 ], "biased": [ 118 ], "signaling": [ 119, 150, 169, 186 ], "well": [ 124 ], "potent": [ 126 ], "GIPR": [ 127, 174 ], "signaling.": [ 128 ], "Since": [ 129 ], "implications": [ 131, 195 ], "co-targeting": [ 133 ], "these": [ 134 ], "closely": [ 135 ], "related": [ 136 ], "concomitantly": [ 138 ], "challenging": [ 140 ], "study": [ 142 ], "in": [ 143, 156, 175, 199 ], "vivo,": [ 144 ], "pharmacodynamic": [ 146 ], "mechanisms": [ 147 ], "downstream": [ 149 ], "pathways": [ 151, 170, 187 ], "co-agonists": [ 155 ], "general,": [ 157 ], "not": [ 159 ], "fully": [ 160 ], "elucidated.": [ 161 ], "this": [ 163 ], "review,": [ 164 ], "we": [ 165 ], "present": [ 166 ], "individual": [ 168 ], "cell": [ 179 ], "focus": [ 182 ], "on": [ 183 ], "shared": [ 185 ], "interpret": [ 193 ], "co-activation": [ 198 ], "light": [ 201 ], "co-activating": [ 204 ], "therapeutic": [ 205 ], "compounds.": [ 206 ] }, "publication_date": "2022-01-19", "publication_year": 2022, "type": "review", "cited_by_count": 118, "authors": [ { "id": "https://openalex.org/A5021515413", "display_name": "Ashok Mayendraraj" }, { "id": "https://openalex.org/A5035872776", "display_name": "Mette M. Rosenkilde" }, { "id": "https://openalex.org/A5045349000", "display_name": "L\u00e6rke S. Gasbjerg" } ] }, { "id": "https://openalex.org/W4210711301", "doi": "https://doi.org/10.1038/s41598-022-05323-7", "title": "Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts\u00a0analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis", "abstract": null, "publication_date": "2022-01-28", "publication_year": 2022, "type": "article", "cited_by_count": 106, "authors": [ { "id": "https://openalex.org/A5054712951", "display_name": "C. Meurot" }, { "id": "https://openalex.org/A5062425427", "display_name": "C. Martin" }, { "id": "https://openalex.org/A5059395176", "display_name": "L. Sudre" }, { "id": "https://openalex.org/A5111879643", "display_name": "John Breton" }, { "id": "https://openalex.org/A5088717445", "display_name": "Carole Bougault" }, { "id": "https://openalex.org/A5056948280", "display_name": "R\u00e9vital Rattenbach" }, { "id": "https://openalex.org/A5016437591", "display_name": "Keren Bismuth" }, { "id": "https://openalex.org/A5015458036", "display_name": "C. Jacques" }, { "id": "https://openalex.org/A5085771274", "display_name": "Francis B\u00e9renbaum" } ] }, { "id": "https://openalex.org/W4403628095", "doi": "https://doi.org/10.1093/ibd/izae250", "title": "GLP-1 Receptor Agonists Confer No Increased Rates of IBD Exacerbation Among Patients With IBD", "abstract": { "Abstract": [ 0 ], "Background": [ 1 ], "In": [ 2, 241 ], "patients": [ 3, 31, 38, 64, 141, 242 ], "with": [ 4, 10, 32, 39, 231, 243, 255 ], "inflammatory": [ 5 ], "bowel": [ 6 ], "disease": [ 7, 259 ], "(IBD),": [ 8 ], "multimorbidity": [ 9 ], "obesity": [ 11 ], "and": [ 12, 18, 77, 82, 89, 94, 162, 253 ], "type": [ 13 ], "2": [ 14 ], "diabetes": [ 15 ], "is": [ 16, 41 ], "common": [ 17 ], "increasing.": [ 19 ], "Glucagon-like": [ 20 ], "peptide": [ 21 ], "1": [ 22 ], "(GLP-1)": [ 23 ], "receptor": [ 24, 52, 67, 91, 111, 147, 176, 184, 219, 246 ], "agonists": [ 25, 53, 68, 247 ], "are": [ 26, 248 ], "increasingly": [ 27 ], "being": [ 28 ], "prescribed": [ 29, 65 ], "for": [ 30, 250 ], "IBD,": [ 33, 244 ], "yet": [ 34 ], "their": [ 35 ], "impact": [ 36, 49 ], "on": [ 37, 54 ], "IBD": [ 40, 63, 83, 104, 194 ], "largely": [ 42 ], "unknown.": [ 43 ], "We": [ 44, 60, 79 ], "aimed": [ 45 ], "to": [ 46, 97, 169, 174, 236 ], "assess": [ 47 ], "the": [ 48, 55, 86, 107, 150, 170, 180, 215 ], "of": [ 50, 57, 118, 193, 233, 258 ], "GLP-1": [ 51, 66, 110, 146, 175, 218, 245 ], "course": [ 56 ], "IBD.": [ 58 ], "Methods": [ 59 ], "identified": [ 61 ], "all": [ 62 ], "at": [ 69 ], "a": [ 70, 116, 209 ], "large": [ 71 ], "academic": [ 72 ], "healthcare": [ 73 ], "network": [ 74 ], "between": [ 75 ], "2009": [ 76 ], "2023.": [ 78 ], "analyzed": [ 80 ], "demographics": [ 81 ], "characteristics": [ 84 ], "in": [ 85, 106, 134, 179, 191, 212, 214 ], "year": [ 87, 108, 216 ], "pre-": [ 88 ], "post\u2013GLP-1": [ 90, 183 ], "agonist": [ 92, 112, 148, 177, 185, 220 ], "prescription": [ 93 ], "matched": [ 95, 238 ], "them": [ 96 ], "non-IBD": [ 98, 237 ], "controls.": [ 99, 239 ], "Our": [ 100 ], "primary": [ 101 ], "outcome": [ 102 ], "was": [ 103, 153, 165, 188, 208 ], "exacerbation": [ 105 ], "following": [ 109, 217 ], "initiation,": [ 113, 149, 178, 186 ], "measured": [ 114 ], "as": [ 115 ], "composite": [ 117 ], "IBD-related": [ 119, 128, 196, 205 ], "hospitalization,": [ 120, 197 ], "corticosteroid": [ 121 ], "prescription,": [ 122, 199 ], "medication": [ 123, 200 ], "escalation": [ 124, 201 ], "or": [ 125, 127, 202, 204 ], "changes,": [ 126, 203 ], "surgery.": [ 129, 206 ], "Secondary": [ 130 ], "outcomes": [ 131 ], "included": [ 132 ], "change": [ 133, 190 ], "metabolic": [ 135 ], "risk": [ 136 ], "factors.": [ 137 ], "Results": [ 138 ], "Overall,": [ 139 ], "224": [ 140 ], "met": [ 142 ], "inclusion": [ 143 ], "criteria.": [ 144 ], "At": [ 145 ], "median": [ 151, 163 ], "age": [ 152 ], "54": [ 154 ], "years,": [ 155 ], "63%": [ 156 ], "were": [ 157, 160 ], "female,": [ 158 ], "77%": [ 159 ], "White,": [ 161 ], "BMI": [ 164, 213, 223 ], "33.2": [ 166 ], "kg/m2.": [ 167 ], "Compared": [ 168 ], "12-month": [ 171 ], "period": [ 172 ], "prior": [ 173 ], "12": [ 181 ], "months": [ 182 ], "there": [ 187 ], "no": [ 189 ], "rates": [ 192, 232 ], "exacerbation,": [ 195 ], "steroids": [ 198 ], "There": [ 207 ], "significant": [ 210 ], "decrease": [ 211, 234 ], "initiation": [ 221 ], "(median": [ 222 ], "33.5": [ 224 ], "vs": [ 225 ], "31.6": [ 226 ], "kg/m2,": [ 227 ], "P": [ 228 ], "&lt;": [ 229 ], ".01),": [ 230 ], "comparable": [ 235 ], "Conclusions": [ 240 ], "effective": [ 249 ], "weight": [ 251 ], "loss": [ 252 ], "associated": [ 254 ], "few": [ 256 ], "episodes": [ 257 ], "exacerbation.": [ 260 ] }, "publication_date": "2024-10-22", "publication_year": 2024, "type": "article", "cited_by_count": 16, "authors": [ { "id": "https://openalex.org/A5028932823", "display_name": "Irving Levine" }, { "id": "https://openalex.org/A5033336413", "display_name": "Shaina Sekhri" }, { "id": "https://openalex.org/A5014647529", "display_name": "William Schreiber-Stainthorp" }, { "id": "https://openalex.org/A5113197862", "display_name": "Brandon Locke" }, { "id": "https://openalex.org/A5064434233", "display_name": "Olivia Delau" }, { "id": "https://openalex.org/A5110129654", "display_name": "M. F. S. El-Hawary" }, { "id": "https://openalex.org/A5110268507", "display_name": "Krutika Pandit" }, { "id": "https://openalex.org/A5102659705", "display_name": "Xucong Meng" }, { "id": "https://openalex.org/A5081605770", "display_name": "Jordan E. Axelrad" } ] }, { "id": "https://openalex.org/W3045885164", "doi": "https://doi.org/10.1097/01.jaa.0000669456.13763.bd", "title": "Long-acting GLP-1RAs", "abstract": { "ABSTRACT": [ 0 ], "Over": [ 1 ], "recent": [ 2 ], "decades,": [ 3 ], "an": [ 4, 234 ], "improved": [ 5 ], "understanding": [ 6 ], "of": [ 7, 10, 30, 49, 77, 89, 99, 123, 196 ], "the": [ 8, 31, 44, 47, 97, 140, 148, 194 ], "pathophysiology": [ 9 ], "type": [ 11 ], "2": [ 12 ], "diabetes": [ 13 ], "mellitus": [ 14 ], "(T2DM)": [ 15 ], "and": [ 16, 24, 37, 65, 170, 176, 223, 245 ], "glucose": [ 17, 41 ], "regulation": [ 18, 42 ], "has": [ 19, 203 ], "led": [ 20 ], "to": [ 21, 101, 106, 136, 152, 167, 191 ], "innovative": [ 22 ], "research": [ 23 ], "new": [ 25 ], "treatment": [ 26, 226 ], "paradigms.": [ 27 ], "The": [ 28, 56, 201, 216 ], "discovery": [ 29 ], "gut": [ 32 ], "peptide": [ 33 ], "glucagon-like": [ 34 ], "peptide-1": [ 35 ], "(GLP-1)": [ 36 ], "its": [ 38 ], "role": [ 39 ], "in": [ 40, 96, 108, 139, 147, 156, 186 ], "paved": [ 43 ], "way": [ 45 ], "for": [ 46, 242 ], "class": [ 48, 202 ], "GLP-1": [ 50 ], "receptor": [ 51 ], "agonist": [ 52 ], "compounds,": [ 53 ], "or": [ 54, 117 ], "GLP-1RAs.": [ 55 ], "long-acting": [ 57, 90, 160, 229 ], "GLP-1RAs": [ 58, 111, 144, 161 ], "(dulaglutide,": [ 59 ], "exenatide": [ 60 ], "extended-release,": [ 61 ], "liraglutide,": [ 62 ], "semaglutide": [ 63, 179 ], "[injectable": [ 64 ], "oral])": [ 66 ], "are": [ 67, 132 ], "classified": [ 68 ], "as": [ 69, 233 ], "such": [ 70 ], "based": [ 71 ], "on": [ 72 ], "a": [ 73, 120 ], "minimum": [ 74 ], "24-hour": [ 75 ], "duration": [ 76 ], "clinically": [ 78 ], "relevant": [ 79 ], "effects": [ 80, 131 ], "after": [ 81 ], "administration.": [ 82 ], "In": [ 83, 134 ], "phase": [ 84 ], "3": [ 85 ], "clinical": [ 86 ], "trial": [ 87 ], "programs": [ 88 ], "GLP-1RAs,": [ 91 ], "A1C": [ 92 ], "typically": [ 93 ], "was": [ 94 ], "reduced": [ 95 ], "range": [ 98 ], "1%": [ 100 ], "1.5%,": [ 102 ], "with": [ 103, 207 ], "reductions": [ 104 ], "close": [ 105 ], "2%": [ 107 ], "some": [ 109, 243 ], "studies.": [ 110 ], "when": [ 112 ], "used": [ 113 ], "alone": [ 114 ], "(without": [ 115 ], "sulfonylureas": [ 116 ], "insulin)": [ 118 ], "have": [ 119, 183 ], "low": [ 121 ], "risk": [ 122, 175, 195 ], "hypoglycemia": [ 124 ], "because,": [ 125 ], "like": [ 126 ], "endogenous": [ 127 ], "GLP-1,": [ 128 ], "their": [ 129 ], "insulinotropic": [ 130 ], "glucose-dependent.": [ 133 ], "addition": [ 135 ], "local": [ 137 ], "actions": [ 138 ], "gastrointestinal": [ 141 ], "(GI)": [ 142 ], "tract,": [ 143 ], "stimulate": [ 145 ], "receptors": [ 146 ], "central": [ 149 ], "nervous": [ 150 ], "system": [ 151 ], "increase": [ 153, 172 ], "satiety,": [ 154 ], "resulting": [ 155 ], "weight": [ 157 ], "loss.": [ 158 ], "All": [ 159 ], "have,": [ 162 ], "at": [ 163 ], "minimum,": [ 164 ], "been": [ 165, 184 ], "shown": [ 166, 185 ], "be": [ 168, 240 ], "safe": [ 169 ], "not": [ 171 ], "cardiovascular": [ 173 ], "(CV)": [ 174 ], "most": [ 177, 214 ], "(liraglutide,": [ 178 ], "injectable,": [ 180 ], "dulaglutide,": [ 181 ], "albiglutide)": [ 182 ], "CV": [ 187 ], "outcomes": [ 188 ], "trials": [ 189 ], "(CVOTs)": [ 190 ], "significantly": [ 192 ], "reduce": [ 193 ], "major": [ 197 ], "cardiac": [ 198 ], "adverse": [ 199, 211 ], "events.": [ 200 ], "good": [ 204 ], "tolerability": [ 205 ], "overall,": [ 206 ], "generally": [ 208 ], "transient": [ 209 ], "GI": [ 210 ], "events": [ 212 ], "being": [ 213 ], "common.": [ 215 ], "weekly": [ 217 ], "injectable": [ 218 ], "agents": [ 219 ], "offer": [ 220 ], "scheduling": [ 221 ], "convenience": [ 222 ], "may": [ 224, 239 ], "promote": [ 225 ], "adherence.": [ 227 ], "One": [ 228 ], "GLP-1RA": [ 230 ], "is": [ 231 ], "available": [ 232 ], "oral": [ 235 ], "daily": [ 236 ], "tablet,": [ 237 ], "which": [ 238 ], "preferable": [ 241 ], "patients": [ 244 ], "providers.": [ 246 ] }, "publication_date": "2020-07-29", "publication_year": 2020, "type": "review", "cited_by_count": 39, "authors": [ { "id": "https://openalex.org/A5064679613", "display_name": "Ji Hyun Chun" }, { "id": "https://openalex.org/A5048332082", "display_name": "Amy Butts" } ] }, { "id": "https://openalex.org/W2730596924", "doi": "https://doi.org/10.1111/dom.13053", "title": "Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial", "abstract": { "Women": [ 0 ], "with": [ 1, 10, 51, 54, 66, 104 ], "polycystic": [ 2 ], "ovary": [ 3 ], "syndrome": [ 4 ], "(": [ 5, 28, 39, 135, 142, 152 ], "PCOS": [ 6, 52, 189 ], ")": [ 7, 30, 137 ], "were": [ 8, 64, 164 ], "treated": [ 9, 65 ], "the": [ 11, 19, 32, 124, 200 ], "GLP": [ 12 ], "\u20101": [ 13 ], "receptor": [ 14 ], "agonist": [ 15 ], "liraglutide": [ 16, 67, 106, 186 ], "to": [ 17 ], "investigate": [ 18 ], "effect": [ 20 ], "on": [ 21 ], "liver": [ 22, 37, 115, 195 ], "fat": [ 23, 78, 116, 196 ], "content,": [ 24, 197 ], "visceral": [ 25 ], "adipose": [ 26 ], "tissue": [ 27 ], "VAT": [ 29, 86, 120, 198 ], "and": [ 31, 95, 123, 146, 162, 176, 199 ], "prevalence": [ 33, 125, 201 ], "of": [ 34, 126, 172, 185, 202 ], "nonalcoholic": [ 35 ], "fatty": [ 36 ], "disease": [ 38 ], "NAFLD": [ 40, 127, 203 ], ").": [ 41 ], "In": [ 42, 181 ], "a": [ 43, 55 ], "double\u2010blind,": [ 44 ], "placebo\u2010controlled,": [ 45 ], "randomized": [ 46 ], "clinical": [ 47 ], "trial": [ 48 ], "72": [ 49 ], "women": [ 50 ], ",": [ 53, 89, 94 ], "BMI": [ 56 ], ">": [ 57 ], "25": [ 58 ], "kg/m": [ 59 ], "2": [ 60 ], "and/or": [ 61 ], "insulin": [ 62, 173 ], "resistance,": [ 63, 174 ], "or": [ 68 ], "received": [ 69 ], "placebo": [ 70 ], "1.8": [ 71 ], "mg/d": [ 72 ], "(2:1)": [ 73 ], "for": [ 74 ], "26": [ 75, 183 ], "weeks.": [ 76 ], "Liver": [ 77 ], "content": [ 79, 117 ], "was": [ 80 ], "assessed": [ 81 ], "by": [ 82, 87, 92, 98, 111, 118, 121, 128, 140, 150 ], "1": [ 83 ], "HMR": [ 84 ], "spectroscopy,": [ 85 ], "MRI": [ 88 ], "body": [ 90, 109 ], "composition": [ 91 ], "DXA": [ 93 ], "glucose": [ 96, 100, 161 ], "metabolism": [ 97 ], "oral": [ 99 ], "tolerance": [ 101 ], "test.": [ 102 ], "Compared": [ 103 ], "placebo,": [ 105 ], "treatment": [ 107, 187 ], "reduced": [ 108, 165 ], "weight": [ 110 ], "5.2": [ 112 ], "kg": [ 113 ], "(5.6%),": [ 114 ], "44%,": [ 119 ], "18%,": [ 122 ], "two\u2010thirds": [ 129 ], "(all": [ 130 ], "P": [ 131, 143, 153, 167 ], "<": [ 132, 168 ], ".01).": [ 133 ], "Sex\u2010hormone\u2010binding\u2010globulin": [ 134 ], "SHBG": [ 136 ], "levels": [ 138 ], "increased": [ 139 ], "19%": [ 141, 151 ], "=": [ 144, 154 ], ".03),": [ 145 ], "free": [ 147 ], "testosterone": [ 148 ], "decreased": [ 149 ], ".054).": [ 155 ], "H": [ 156 ], "b": [ 157 ], "A": [ 158 ], "1c,": [ 159 ], "fasting": [ 160 ], "leptin": [ 163 ], "(all:": [ 166 ], ".05),": [ 169 ], "whereas": [ 170 ], "measures": [ 171 ], "adiponectin": [ 175 ], "glucagon": [ 177 ], "did": [ 178 ], "not": [ 179 ], "change.": [ 180 ], "conclusion,": [ 182 ], "weeks": [ 184 ], "in": [ 188, 191, 194 ], "resulted": [ 190 ], "significant": [ 192 ], "reductions": [ 193 ], ".": [ 204 ] }, "publication_date": "2017-07-06", "publication_year": 2017, "type": "article", "cited_by_count": 150, "authors": [ { "id": "https://openalex.org/A5072982204", "display_name": "Signe Fr\u00f8ssing" }, { "id": "https://openalex.org/A5067223273", "display_name": "Malin Nylander" }, { "id": "https://openalex.org/A5085353486", "display_name": "Elizaveta Chabanova" }, { "id": "https://openalex.org/A5040378891", "display_name": "Jan Frystyk" }, { "id": "https://openalex.org/A5085434984", "display_name": "Jens J. Holst" }, { "id": "https://openalex.org/A5053899216", "display_name": "Caroline Kistorp" }, { "id": "https://openalex.org/A5076226111", "display_name": "Sven O. Skouby" }, { "id": "https://openalex.org/A5072362865", "display_name": "Jens Faber" } ] }, { "id": "https://openalex.org/W2026462831", "doi": "https://doi.org/10.1016/j.ejphar.2012.12.012", "title": "The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain", "abstract": null, "publication_date": "2012-12-28", "publication_year": 2012, "type": "article", "cited_by_count": 115, "authors": [ { "id": "https://openalex.org/A5066857047", "display_name": "Vadivel Parthsarathy" }, { "id": "https://openalex.org/A5082707086", "display_name": "Christian H\u00f6lscher" } ] }, { "id": "https://openalex.org/W2055194261", "doi": "https://doi.org/10.1016/j.clinthera.2013.03.021", "title": "Retrospective Real-World Adherence in Patients With Type 2 Diabetes Initiating Once-Daily Liraglutide 1.8 mg or Twice-Daily Exenatide 10 \u03bcg", "abstract": null, "publication_date": "2013-05-01", "publication_year": 2013, "type": "article", "cited_by_count": 42, "authors": [ { "id": "https://openalex.org/A5040185696", "display_name": "Maria Malmen\u00e4s" }, { "id": "https://openalex.org/A5016779179", "display_name": "Jonathan Bouchard" }, { "id": "https://openalex.org/A5020446741", "display_name": "J Langer" } ] }, { "id": "https://openalex.org/W2923719040", "doi": "https://doi.org/10.1001/jama.2019.2941", "title": "The Future of the GLP-1 Receptor Agonists", "abstract": { "Our": [ 0 ], "website": [ 1 ], "uses": [ 2 ], "cookies": [ 3 ], "to": [ 4, 10, 20, 171 ], "enhance": [ 5 ], "your": [ 6, 158 ], "experience.": [ 7 ], "By": [ 8 ], "continuing": [ 9 ], "use": [ 11 ], "our": [ 12, 21 ], "site,": [ 13 ], "or": [ 14 ], "clicking": [ 15 ], "\"Continue,\"": [ 16 ], "you": [ 17 ], "are": [ 18 ], "agreeing": [ 19 ], "Cookie": [ 22 ], "Policy": [ 23, 92 ], "|": [ 24, 90, 93 ], "Continue": [ 25 ], "JAMA": [ 26, 42, 43, 46, 48, 50, 53, 56, 58, 60, 62, 67, 69, 71, 105, 106, 109, 111, 113, 116, 119, 122, 124, 126, 128, 133, 135, 137, 173 ], "HomeNew": [ 27 ], "OnlineCurrent": [ 28 ], "IssueFor": [ 29 ], "Authors": [ 30 ], "Podcasts": [ 31 ], "Clinical": [ 32 ], "Reviews": [ 33 ], "Editors'": [ 34 ], "Summary": [ 35 ], "Medical": [ 36, 98 ], "News": [ 37 ], "Author": [ 38 ], "Interviews": [ 39 ], "More": [ 40 ], "Publications": [ 41 ], "Network": [ 44, 107 ], "Open": [ 45, 108 ], "Cardiology": [ 47, 110 ], "Dermatology": [ 49, 112 ], "Health": [ 51, 117 ], "Forum": [ 52, 114, 118 ], "Internal": [ 54, 120 ], "Medicine": [ 55, 121 ], "Neurology": [ 57, 75, 123, 141 ], "Oncology": [ 59, 125 ], "Ophthalmology": [ 61, 127 ], "Otolaryngology\u2013Head": [ 63, 129 ], "&": [ 64, 76, 85, 130, 142 ], "Neck": [ 65, 131 ], "Surgery": [ 66, 72, 132, 138 ], "Pediatrics": [ 68, 134 ], "Psychiatry": [ 70, 77, 136, 143 ], "Archives": [ 73, 139 ], "of": [ 74, 88, 140 ], "(1919-1959)": [ 78 ], "JN": [ 79 ], "Learning": [ 80 ], "/": [ 81, 83 ], "CMESubscribeJobsInstitutions": [ 82 ], "LibrariansReprints": [ 84 ], "Permissions": [ 86 ], "Terms": [ 87 ], "Use": [ 89 ], "Privacy": [ 91 ], "Accessibility": [ 94 ], "Statement": [ 95 ], "2023": [ 96 ], "American": [ 97 ], "Association.": [ 99 ], "All": [ 100, 104 ], "Rights": [ 101 ], "Reserved": [ 102 ], "Search": [ 103, 145 ], "Archive": [ 115 ], "Input": [ 144 ], "Term": [ 146 ], "Sign": [ 147, 150, 152, 160 ], "In": [ 148, 151, 161 ], "Individual": [ 149 ], "inCreate": [ 153 ], "an": [ 154 ], "Account": [ 155 ], "Access": [ 156 ], "through": [ 157 ], "institution": [ 159 ], "Purchase": [ 162 ], "Options:": [ 163 ], "Buy": [ 164 ], "this": [ 165, 168 ], "article": [ 166, 169 ], "Rent": [ 167 ], "Subscribe": [ 170 ], "the": [ 172 ], "journal": [ 174 ] }, "publication_date": "2019-03-23", "publication_year": 2019, "type": "letter", "cited_by_count": 29, "authors": [ { "id": "https://openalex.org/A5029280234", "display_name": "Irl B. Hirsch" } ] }, { "id": "https://openalex.org/W2107080737", "doi": "https://doi.org/10.1530/eje-13-0797", "title": "Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin", "abstract": { "Objective": [ 0 ], "The": [ 1, 121, 202 ], "effect": [ 2, 24 ], "of": [ 3, 25, 56, 85, 204, 211, 213, 224, 305 ], "metformin": [ 4, 67, 89, 324, 351 ], "on": [ 5, 34, 145, 148, 152, 176, 350 ], "weight": [ 6, 35, 48, 205, 315, 329, 348 ], "reduction": [ 7, 349 ], "in": [ 8, 37, 74, 126, 164, 186, 195, 226, 235, 246, 253, 257, 271, 279, 284, 333, 336 ], "polycystic": [ 9 ], "ovary": [ 10 ], "syndrome": [ 11 ], "(PCOS)": [ 12 ], "is": [ 13 ], "often": [ 14 ], "unsatisfactory.": [ 15 ], "In": [ 16 ], "this": [ 17 ], "study,": [ 18 ], "we": [ 19 ], "investigated": [ 20 ], "the": [ 21, 28, 142, 187, 196, 227, 236, 247, 258, 272, 285 ], "potential": [ 22 ], "add-on": [ 23 ], "treatment": [ 26, 87, 320 ], "with": [ 27, 41, 51, 60, 66, 173, 181, 231, 251, 276, 293, 301, 314, 321, 327, 339 ], "glucagon-like": [ 29 ], "peptide-1": [ 30 ], "receptor": [ 31 ], "agonist": [ 32 ], "liraglutide": [ 33, 95, 294, 322 ], "loss": [ 36, 185, 194, 206, 330 ], "obese": [ 38, 58, 337 ], "nondiabetic": [ 39 ], "women": [ 40, 59, 338 ], "PCOS": [ 42, 340 ], "who": [ 43, 62, 218, 341 ], "had": [ 44, 63, 342 ], "lost": [ 45, 175, 219 ], "<5%": [ 46 ], "body": [ 47, 127, 221 ], "during": [ 49 ], "pretreatment": [ 50 ], "metformin.": [ 52 ], "Methods": [ 53 ], "A": [ 54 ], "total": [ 55, 210 ], "40": [ 57 ], "PCOS,": [ 61 ], "been": [ 64, 344 ], "pretreated": [ 65 ], "for": [ 68 ], "at": [ 69 ], "least": [ 70 ], "6": [ 71 ], "months,": [ 72 ], "participated": [ 73 ], "a": [ 75, 182, 191, 209 ], "12-week": [ 76 ], "open-label,": [ 77 ], "prospective": [ 78 ], "study.": [ 79 ], "They": [ 80 ], "were": [ 81, 215 ], "randomized": [ 82 ], "to": [ 83, 159 ], "one": [ 84 ], "three": [ 86 ], "arms:": [ 88 ], "(MET)": [ 90 ], "arm": [ 91, 97, 229, 240, 249, 260, 274, 287 ], "1000": [ 92, 105 ], "mg": [ 93, 99, 106, 112 ], "BID,": [ 94 ], "(LIRA)": [ 96 ], "1.2": [ 98, 111 ], "QD": [ 100, 113 ], "s.c.,": [ 101 ], "or": [ 102 ], "combined": [ 103, 153, 319 ], "MET": [ 104, 162, 197, 239, 259, 286 ], "BID": [ 107 ], "and": [ 108, 150, 161, 168, 190, 233, 238, 255, 281, 310, 323, 331 ], "LIRA": [ 109, 160, 188, 237, 254, 280 ], "(COMBI)": [ 110 ], "s.c.": [ 114 ], "Lifestyle": [ 115 ], "intervention": [ 116 ], "was": [ 117, 124, 157, 207, 325 ], "not": [ 118, 312 ], "actively": [ 119 ], "promoted.": [ 120 ], "primary": [ 122 ], "outcome": [ 123 ], "change": [ 125 ], "weight.": [ 128 ], "Results": [ 129 ], "Thirty": [ 130 ], "six": [ 131 ], "patients": [ 132 ], "(aged": [ 133 ], "31.3\u00b17.1": [ 134 ], "years,": [ 135 ], "BMI": [ 136, 242 ], "37.1\u00b14.6": [ 137 ], "kg/m": [ 138 ], "2": [ 139 ], ")": [ 140 ], "completed": [ 141 ], "study:": [ 143 ], "14": [ 144 ], "MET,": [ 146 ], "11": [ 147, 151 ], "LIRA,": [ 149 ], "treatment.": [ 154 ], "COMBI": [ 155, 174, 228, 248, 273 ], "therapy": [ 156 ], "superior": [ 158 ], "monotherapy": [ 163 ], "reducing": [ 165 ], "weight,": [ 166, 222 ], "BMI,": [ 167 ], "waist": [ 169, 334 ], "circumference.": [ 170 ], "Subjects": [ 171, 291 ], "treated": [ 172, 292, 300 ], "average": [ 177 ], "6.5\u00b12.8": [ 178 ], "kg": [ 179, 184, 193 ], "compared": [ 180, 230, 250, 275 ], "3.8\u00b13.7": [ 183 ], "group": [ 189, 198 ], "1.2\u00b11.4": [ 192 ], "(": [ 199, 261, 288 ], "P": [ 200, 262, 289 ], "<0.001).": [ 201, 263 ], "extent": [ 203 ], "stratified:": [ 208 ], "38%": [ 212 ], "subjects": [ 214 ], "high": [ 216 ], "responders": [ 217, 346 ], "\u22655%": [ 220 ], "22%": [ 223 ], "them": [ 225 ], "16": [ 232 ], "0%": [ 234 ], "respectively.": [ 241 ], "decreased": [ 243, 267, 307 ], "by": [ 244, 268 ], "2.4\u00b11.0": [ 245 ], "1.3\u00b11.3": [ 252 ], "0.5\u00b10.5": [ 256 ], "Waist": [ 264 ], "circumference": [ 265, 335 ], "also": [ 266 ], "5.5\u00b13.8": [ 269 ], "cm": [ 270, 278, 283 ], "3.2\u00b12.9": [ 277 ], "1.6\u00b12.9": [ 282 ], "=0.029).": [ 290 ], "experienced": [ 295 ], "more": [ 296 ], "nausea": [ 297, 306 ], "than": [ 298 ], "those": [ 299 ], "metformin,": [ 302 ], "but": [ 303 ], "severity": [ 304 ], "over": [ 308 ], "time": [ 309 ], "did": [ 311 ], "correlate": [ 313 ], "loss.": [ 316 ], "Conclusions": [ 317 ], "Short-term": [ 318 ], "associated": [ 326 ], "significant": [ 328 ], "decrease": [ 332 ], "previously": [ 343 ], "poor": [ 345 ], "regarding": [ 347 ], "monotherapy.": [ 352 ] }, "publication_date": "2013-12-21", "publication_year": 2013, "type": "article", "cited_by_count": 160, "authors": [ { "id": "https://openalex.org/A5091436678", "display_name": "Mojca Jensterle" }, { "id": "https://openalex.org/A5053086437", "display_name": "Toma\u017e Kocjan" }, { "id": "https://openalex.org/A5113802632", "display_name": "Marija Pfeifer" }, { "id": "https://openalex.org/A5002717358", "display_name": "Nika Aleksandra Kravos" }, { "id": "https://openalex.org/A5002770606", "display_name": "Andrej Jane\u017e" } ] }, { "id": "https://openalex.org/W2652429844", "doi": null, "title": "Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes.", "abstract": { "Currently,": [ 0 ], "5": [ 1 ], "GLP-1": [ 2, 29, 37 ], "receptor": [ 3, 30, 38 ], "agonists": [ 4 ], "are": [ 5, 15 ], "available": [ 6 ], "for": [ 7 ], "use": [ 8 ], "in": [ 9, 17 ], "the": [ 10, 18, 27, 43 ], "United": [ 11 ], "States.": [ 12 ], "Although": [ 13 ], "they": [ 14 ], "all": [ 16 ], "same": [ 19 ], "drug": [ 20 ], "class,": [ 21 ], "some": [ 22 ], "significant": [ 23 ], "differences": [ 24 ], "exist": [ 25 ], "among": [ 26 ], "various": [ 28 ], "agonists.": [ 31 ], "The": [ 32 ], "choice": [ 33 ], "of": [ 34 ], "a": [ 35 ], "specific": [ 36 ], "agonist": [ 39 ], "will": [ 40 ], "depend": [ 41 ], "on": [ 42 ], "patient": [ 44 ], "preferences,": [ 45 ], "potential": [ 46 ], "adverse": [ 47 ], "effects,": [ 48 ], "and": [ 49 ], "cost.": [ 50 ] }, "publication_date": "2017-06-01", "publication_year": 2017, "type": "article", "cited_by_count": 105, "authors": [ { "id": "https://openalex.org/A5103270875", "display_name": "Kelvin Tran" }, { "id": "https://openalex.org/A5027524889", "display_name": "Young In Park" }, { "id": "https://openalex.org/A5091569302", "display_name": "Shalin Pandya" }, { "id": "https://openalex.org/A5104782095", "display_name": "Navin John Muliyil" }, { "id": "https://openalex.org/A5113812738", "display_name": "Brandon David Jensen" }, { "id": "https://openalex.org/A5109366933", "display_name": "Kovin Huynh" }, { "id": "https://openalex.org/A5026941681", "display_name": "Quang T. Nguyen" } ] }, { "id": "https://openalex.org/W2781517806", "doi": "https://doi.org/10.3892/mmr.2018.8371", "title": "Liraglutide repairs the infarcted heart: The role of the SIRT1/Parkin/mitophagy pathway", "abstract": { "Liraglutide": [ 0 ], "is": [ 1 ], "glucagon\u2011like": [ 2, 127 ], "peptide\u20111": [ 3 ], "receptor": [ 4, 130 ], "agonist": [ 5 ], "used": [ 6 ], "for": [ 7, 49 ], "treating": [ 8 ], "patients": [ 9 ], "with": [ 10 ], "type": [ 11 ], "2": [ 12 ], "diabetes": [ 13 ], "mellitus.": [ 14 ], "The": [ 15, 35 ], "present": [ 16, 39, 149 ], "study": [ 17, 40, 150 ], "aimed": [ 18 ], "to": [ 19, 54, 101 ], "investigate": [ 20 ], "the": [ 21, 29, 38, 45, 64, 74, 79, 86, 96, 117, 135, 145, 148, 152, 159, 165 ], "role": [ 22, 154 ], "and": [ 23, 60, 115 ], "mechanism": [ 24 ], "of": [ 25, 37, 44, 47, 88, 98, 126, 133, 138, 147, 155, 164 ], "liraglutide": [ 26, 48, 69, 84, 139, 156 ], "in": [ 27, 63, 157 ], "repairing": [ 28, 158 ], "infarcted": [ 30, 160 ], "heart": [ 31, 161 ], "following": [ 32, 124 ], "myocardial": [ 33, 61 ], "infarction.": [ 34 ], "results": [ 36, 146 ], "demonstrated": [ 41 ], "that": [ 42 ], "amplification": [ 43 ], "dose": [ 46 ], "~28": [ 50 ], "days": [ 51 ], "was": [ 52 ], "able": [ 53 ], "reduce": [ 55 ], "cardiac": [ 56 ], "fibrosis,": [ 57 ], "inflammatory": [ 58 ], "responses": [ 59 ], "death": [ 62 ], "post\u2011infarcted": [ 65 ], "heart.": [ 66 ], "In": [ 67, 143 ], "vitro,": [ 68 ], "protected": [ 70 ], "cardiomyocyte": [ 71 ], "mitochondria": [ 72, 141 ], "against": [ 73 ], "chronic": [ 75 ], "hypoxic": [ 76 ], "damage,": [ 77 ], "inhibiting": [ 78 ], "mitochondrial": [ 80, 121 ], "apoptosis": [ 81 ], "pathways.": [ 82 ], "Mechanistically,": [ 83 ], "elevated": [ 85 ], "expression": [ 87, 97 ], "NAD\u2011dependent": [ 89 ], "protein": [ 90 ], "deacetylase": [ 91 ], "sirtuin\u20111": [ 92 ], "(SIRT1),": [ 93 ], "which": [ 94 ], "increased": [ 95 ], "Parkin,": [ 99, 134 ], "leading": [ 100 ], "mitophagy": [ 102, 105 ], "activation.": [ 103 ], "Protective": [ 104 ], "reversed": [ 106 ], "cellular": [ 107, 112 ], "adenosine": [ 108 ], "5'\u2011triphosphate": [ 109 ], "production,": [ 110 ], "reduced": [ 111 ], "oxidative": [ 113 ], "stress": [ 114 ], "balanced": [ 116 ], "redox": [ 118 ], "response,": [ 119 ], "sustaining": [ 120 ], "homeostasis.": [ 122 ], "Notably,": [ 123 ], "blockade": [ 125 ], "peptide": [ 128 ], "1": [ 129 ], "or": [ 131 ], "knockdown": [ 132 ], "beneficial": [ 136 ], "effects": [ 137 ], "on": [ 140 ], "disappeared.": [ 142 ], "conclusion,": [ 144 ], "illustrated": [ 151 ], "protective": [ 153 ], "via": [ 162 ], "regulation": [ 163 ], "SIRT1/Parkin/mitophagy": [ 166 ], "pathway.": [ 167 ] }, "publication_date": "2018-01-02", "publication_year": 2018, "type": "article", "cited_by_count": 80, "authors": [ { "id": "https://openalex.org/A5037242038", "display_name": "Huiying Qiao" }, { "id": "https://openalex.org/A5085451146", "display_name": "Haiyan Ren" }, { "id": "https://openalex.org/A5101439587", "display_name": "He Du" }, { "id": "https://openalex.org/A5082548949", "display_name": "Minfang Zhang" }, { "id": "https://openalex.org/A5103033938", "display_name": "Xiaofang Xiong" }, { "id": "https://openalex.org/A5111502286", "display_name": "Rong Lv" } ] }, { "id": "https://openalex.org/W2149821062", "doi": "https://doi.org/10.1136/bmjopen-2013-004158", "title": "Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist\u2014protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol", "abstract": { "Introduction": [ 0 ], "Antipsychotic": [ 1 ], "medication": [ 2 ], "is": [ 3, 20, 73 ], "widely": [ 4 ], "associated": [ 5 ], "with": [ 6, 65, 81, 91, 94, 121, 127 ], "dysmetabolism": [ 7 ], "including": [ 8, 213 ], "obesity": [ 9, 36 ], "and": [ 10, 16, 31, 39, 101, 106, 109, 111, 116, 153, 164, 174, 184, 216, 224, 228 ], "type": [ 11, 52 ], "2": [ 12, 53 ], "diabetes,": [ 13, 54 ], "cardiovascular-related": [ 14 ], "diseases": [ 15 ], "early": [ 17 ], "death.": [ 18 ], "Obesity": [ 19 ], "considered": [ 21 ], "the": [ 22, 49, 161, 167, 175, 204, 208 ], "single": [ 23 ], "most": [ 24 ], "important": [ 25 ], "risk": [ 26 ], "factor": [ 27 ], "for": [ 28, 48, 144 ], "cardiovascular": [ 29 ], "morbidity": [ 30 ], "mortality.": [ 32 ], "Interventions": [ 33 ], "against": [ 34 ], "antipsychotic-associated": [ 35, 95 ], "are": [ 37, 46 ], "limited": [ 38 ], "insufficient.": [ 40 ], "Glucagon-like": [ 41 ], "peptide-1": [ 42 ], "(GLP-1)": [ 43 ], "receptor": [ 44, 84 ], "agonists": [ 45 ], "approved": [ 47, 159 ], "treatment": [ 50, 80 ], "of": [ 51, 70, 79, 136 ], "but": [ 55 ], "their": [ 56, 149 ], "bodyweight-lowering": [ 57 ], "effects": [ 58 ], "have": [ 59 ], "also": [ 60 ], "been": [ 61, 158 ], "recognised": [ 62 ], "in": [ 63, 89 ], "patients": [ 64, 90, 120 ], "non-diabetes.": [ 66 ], "The": [ 67, 155, 255 ], "primary": [ 68 ], "endpoint": [ 69 ], "this": [ 71 ], "trial": [ 72, 156 ], "weight": [ 74 ], "loss": [ 75 ], "after": [ 76 ], "3": [ 77, 145 ], "months": [ 78 ], "a": [ 82 ], "GLP-1": [ 83 ], "agonist": [ 85 ], "(exenatide": [ 86 ], "once": [ 87, 138 ], "weekly)": [ 88 ], "non-diabetic": [ 92 ], "schizophrenia": [ 93, 122 ], "obesity.": [ 96 ], "Secondary": [ 97 ], "endpoints": [ 98 ], "include": [ 99 ], "physiological": [ 100 ], "metabolic": [ 102 ], "measurements,": [ 103 ], "various": [ 104 ], "psychopathological": [ 105 ], "cognitive": [ 107 ], "measures,": [ 108 ], "structural": [ 110 ], "functional": [ 112 ], "brain": [ 113 ], "MRI.": [ 114 ], "Methods": [ 115 ], "analysis": [ 117 ], "40": [ 118 ], "obese": [ 119 ], "or": [ 123, 142 ], "schizoaffective": [ 124 ], "disorder": [ 125 ], "treated": [ 126 ], "antipsychotic": [ 128, 150 ], "drugs": [ 129 ], "will": [ 130, 202, 219, 231 ], "be": [ 131, 220, 232 ], "randomised": [ 132 ], "to": [ 133, 148, 207, 234 ], "subcutaneous": [ 134 ], "injection": [ 135 ], "exenatide": [ 137 ], "weekly": [ 139 ], "(2": [ 140 ], "mg)": [ 141 ], "placebo": [ 143 ], "months,": [ 146 ], "adjunctive": [ 147 ], "treatment.": [ 151 ], "Ethics": [ 152, 173, 248 ], "dissemination": [ 154 ], "has": [ 157 ], "by": [ 160 ], "Danish": [ 162, 176, 256 ], "Health": [ 163, 171, 246 ], "Medicines": [ 165 ], "Authority,": [ 166 ], "National": [ 168, 243 ], "Committee": [ 169, 244 ], "on": [ 170, 245 ], "Research": [ 172, 247 ], "Data": [ 177, 257 ], "Protection": [ 178, 258 ], "Agency.": [ 179 ], "Trial": [ 180, 211, 237 ], "participation": [ 181 ], "presupposes": [ 182 ], "theoral": [ 183 ], "written": [ 185 ], "patient": [ 186 ], "informed": [ 187 ], "consent.": [ 188 ], "An": [ 189 ], "external,": [ 190 ], "independent": [ 191 ], "monitoring": [ 192 ], "committee": [ 193 ], "(Good": [ 194 ], "Clinical": [ 195 ], "Practice": [ 196 ], "Unit": [ 197 ], "at": [ 198, 222 ], "Copenhagen": [ 199 ], "University": [ 200 ], "Hospital)": [ 201 ], "monitor": [ 203 ], "study": [ 205 ], "according": [ 206 ], "GCP": [ 209 ], "Guidelines.": [ 210 ], "data,": [ 212 ], "positive,": [ 214 ], "negative": [ 215 ], "inconclusive": [ 217 ], "results,": [ 218 ], "presented": [ 221 ], "national": [ 223 ], "international": [ 225 ], "scientific": [ 226 ], "meetings": [ 227 ], "conferences.": [ 229 ], "Papers": [ 230 ], "submitted": [ 233 ], "peer-reviewed": [ 235 ], "journals.": [ 236 ], "registration": [ 238 ], "ClinicalTrials.gov": [ 239 ], "identifier:": [ 240 ], "NCT01794429": [ 241 ], ";": [ 242 ], "project": [ 249, 260 ], "number:": [ 250, 261 ], "36378;": [ 251 ], "EudraCT": [ 252 ], "nr:": [ 253 ], "2012-005404-17;": [ 254 ], "Agency": [ 259 ], "RHP-2012-027.": [ 262 ] }, "publication_date": "2014-01-01", "publication_year": 2014, "type": "article", "cited_by_count": 24, "authors": [ { "id": "https://openalex.org/A5030460701", "display_name": "Pelle L. Ish\u00f8y" }, { "id": "https://openalex.org/A5079352451", "display_name": "Filip K. Knop" }, { "id": "https://openalex.org/A5027992573", "display_name": "Brian V. Broberg" }, { "id": "https://openalex.org/A5043345480", "display_name": "Lone Baandrup" }, { "id": "https://openalex.org/A5088557617", "display_name": "Birgitte Fagerlund" }, { "id": "https://openalex.org/A5069431123", "display_name": "Niklas Rye J\u00f8rgensen" }, { "id": "https://openalex.org/A5047316473", "display_name": "Ulrik B. Andersen" }, { "id": "https://openalex.org/A5064325537", "display_name": "Egill Rostrup" }, { "id": "https://openalex.org/A5055136911", "display_name": "Birte Glenth\u00f8j" }, { "id": "https://openalex.org/A5074014109", "display_name": "Bj\u00f8rn H. Ebdrup" } ] }, { "id": "https://openalex.org/W3210695289", "doi": "https://doi.org/10.1016/j.clinthera.2021.08.015", "title": "Lifetime Cost-effectiveness of Oral Semaglutide Versus Dulaglutide and Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Oral Antidiabetics", "abstract": null, "publication_date": "2021-10-31", "publication_year": 2021, "type": "review", "cited_by_count": 10, "authors": [ { "id": "https://openalex.org/A5058947386", "display_name": "Nancy Risebrough" }, { "id": "https://openalex.org/A5031372755", "display_name": "Timothy Baker" }, { "id": "https://openalex.org/A5101822746", "display_name": "Lirong Zhang" }, { "id": "https://openalex.org/A5021916965", "display_name": "Sarah Ali" }, { "id": "https://openalex.org/A5010140102", "display_name": "Michael Radin" }, { "id": "https://openalex.org/A5034860372", "display_name": "Tam Dang\u2010Tan" } ] }, { "id": "https://openalex.org/W2168899316", "doi": "https://doi.org/10.1172/jci72434", "title": "Neuronal GLP1R mediates liraglutide\u2019s anorectic but not glucose-lowering effect", "abstract": { "Glucose": [ 0 ], "control": [ 1 ], "and": [ 2, 25, 30, 62, 99, 149, 190 ], "weight": [ 3, 23, 32, 127, 189 ], "loss": [ 4, 24 ], "are": [ 5, 18, 33, 70, 196 ], "cornerstones": [ 6 ], "of": [ 7, 53, 66, 80, 83, 97, 112, 193 ], "type": [ 8 ], "2": [ 9 ], "diabetes": [ 10 ], "treatment.": [ 11 ], "Currently,": [ 12 ], "only": [ 13 ], "glucagon-like": [ 14 ], "peptide-1": [ 15 ], "(GLP1)": [ 16 ], "analogs": [ 17 ], "able": [ 19 ], "to": [ 20, 49 ], "achieve": [ 21 ], "both": [ 22, 147 ], "glucose": [ 26, 29 ], "tolerance.": [ 27 ], "Both": [ 28 ], "body": [ 31, 63, 126, 168, 188 ], "regulated": [ 34 ], "by": [ 35 ], "the": [ 36, 45, 51, 60, 78, 115, 119, 155 ], "brain,": [ 37 ], "which": [ 38 ], "contains": [ 39 ], "GLP1": [ 40, 54 ], "receptors": [ 41 ], "(GLP1R).": [ 42 ], "Even": [ 43 ], "though": [ 44 ], "brain": [ 46 ], "is": [ 47 ], "poised": [ 48 ], "mediate": [ 50, 187 ], "effects": [ 52, 65, 145, 192 ], "analogs,": [ 55 ], "it": [ 56 ], "remains": [ 57 ], "unclear": [ 58 ], "whether": [ 59 ], "glucose-": [ 61 ], "weight-lowering": [ 64 ], "long-acting": [ 67, 104 ], "GLP1R": [ 68, 76, 105, 113, 153 ], "agonists": [ 69 ], "via": [ 71 ], "direct": [ 72 ], "action": [ 73 ], "on": [ 74 ], "CNS": [ 75, 116, 156 ], "or": [ 77, 93, 128, 136, 157, 170 ], "result": [ 79 ], "downstream": [ 81 ], "activation": [ 82 ], "afferent": [ 84 ], "neuronal": [ 85, 92, 179, 185 ], "GLP1R.": [ 86, 180 ], "We": [ 87, 107 ], "generated": [ 88 ], "mice": [ 89, 151, 177 ], "with": [ 90 ], "either": [ 91 ], "visceral": [ 94, 120, 158 ], "nerve-specific": [ 95 ], "deletion": [ 96 ], "Glp1r": [ 98 ], "then": [ 100 ], "administered": [ 101 ], "liraglutide,": [ 102, 194 ], "a": [ 103, 137, 172 ], "agonist.": [ 106 ], "found": [ 108 ], "that": [ 109, 184 ], "neither": [ 110 ], "reduction": [ 111 ], "in": [ 114, 118, 123, 125, 131, 146, 154, 176 ], "nor": [ 117 ], "nerves": [ 121 ], "resulted": [ 122 ], "alterations": [ 124 ], "food": [ 129, 166 ], "intake": [ 130 ], "animals": [ 132 ], "fed": [ 133 ], "normal": [ 134 ], "chow": [ 135 ], "high-fat": [ 138 ], "diet.": [ 139 ], "Liraglutide": [ 140 ], "treatment": [ 141 ], "provided": [ 142 ], "beneficial": [ 143 ], "glucose-lowering": [ 144, 200 ], "chow-": [ 148 ], "high-fat-fed": [ 150 ], "lacking": [ 152, 178 ], "nerves;": [ 159 ], "however,": [ 160 ], "liraglutide": [ 161 ], "was": [ 162 ], "ineffective": [ 163 ], "at": [ 164 ], "altering": [ 165 ], "intake,": [ 167 ], "weight,": [ 169 ], "causing": [ 171 ], "conditioned": [ 173 ], "taste": [ 174 ], "aversion": [ 175 ], "These": [ 181 ], "data": [ 182 ], "indicate": [ 183 ], "GLP1Rs": [ 186 ], "anorectic": [ 191 ], "but": [ 195 ], "not": [ 197 ], "required": [ 198 ], "for": [ 199 ], "effects.": [ 201 ] }, "publication_date": "2014-04-24", "publication_year": 2014, "type": "article", "cited_by_count": 384, "authors": [ { "id": "https://openalex.org/A5058209072", "display_name": "Stephanie Sisley" }, { "id": "https://openalex.org/A5076901458", "display_name": "Ruth Guti\u00e9rrez\u2010Aguilar" }, { "id": "https://openalex.org/A5030904270", "display_name": "Michael M. Scott" }, { "id": "https://openalex.org/A5071074041", "display_name": "David A. D\u2019Alessio" }, { "id": "https://openalex.org/A5045342696", "display_name": "Darleen A. Sandoval" }, { "id": "https://openalex.org/A5065488328", "display_name": "Randy J. Seeley" } ] }, { "id": "https://openalex.org/W2080373006", "doi": "https://doi.org/10.1016/j.neuropharm.2013.01.013", "title": "Separation of emetic and anorexic responses of exendin-4, a GLP-1 receptor agonist in Suncus murinus (house musk shrew)", "abstract": null, "publication_date": "2013-01-25", "publication_year": 2013, "type": "article", "cited_by_count": 29, "authors": [ { "id": "https://openalex.org/A5048206087", "display_name": "Sze Wa Chan" }, { "id": "https://openalex.org/A5047540439", "display_name": "Ge Lin" }, { "id": "https://openalex.org/A5063609958", "display_name": "David T. Yew" }, { "id": "https://openalex.org/A5072022608", "display_name": "Chi Kong Yeung" }, { "id": "https://openalex.org/A5048546365", "display_name": "John A. Rudd" } ] }, { "id": "https://openalex.org/W2905657342", "doi": "https://doi.org/10.1007/s41669-019-0171-y", "title": "Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus", "abstract": { "Exenatide": [ 0 ], "2": [ 1 ], "mg/week": [ 2 ], "would": [ 3 ], "be": [ 4 ], "a": [ 5 ], "dominant": [ 6 ], "strategy": [ 7 ], "(more": [ 8 ], "effective": [ 9 ], "and": [ 10 ], "less": [ 11 ], "costly)": [ 12 ], "versus": [ 13 ], "the": [ 14, 21 ], "other": [ 15 ], "GLP-1": [ 16 ], "receptor": [ 17 ], "agonists": [ 18 ], "assessed": [ 19 ], "for": [ 20 ], "treatment": [ 22 ], "of": [ 23 ], "T2DM": [ 24 ], "patients": [ 25 ], "who": [ 26 ], "are": [ 27 ], "not": [ 28 ], "adequately": [ 29 ], "controlled": [ 30 ], "on": [ 31 ], "metformin": [ 32 ], "alone.": [ 33 ] }, "publication_date": "2019-07-23", "publication_year": 2019, "type": "article", "cited_by_count": 7, "authors": [ { "id": "https://openalex.org/A5091664176", "display_name": "Margarita Capel" }, { "id": "https://openalex.org/A5087812090", "display_name": "Andreea Ciudin" }, { "id": "https://openalex.org/A5028204670", "display_name": "Mar\u00eda Mareque" }, { "id": "https://openalex.org/A5086114848", "display_name": "Raquel Mar\u00eda Rodr\u00edguez-Rinc\u00f3n" }, { "id": "https://openalex.org/A5038643382", "display_name": "Susana Sim\u00f3n" }, { "id": "https://openalex.org/A5069146288", "display_name": "Itziar Oyag\u00fcez" } ] }, { "id": "https://openalex.org/W2068059840", "doi": "https://doi.org/10.4065/mcp.2010.0469", "title": "Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors", "abstract": null, "publication_date": "2010-11-25", "publication_year": 2010, "type": "review", "cited_by_count": 45, "authors": [ { "id": "https://openalex.org/A5081667069", "display_name": "Jaime A. Davidson" } ] }, { "id": "https://openalex.org/W1650430460", "doi": "https://doi.org/10.1080/08998280.2006.11928181", "title": "Exenatide (Byetta) as a Novel Treatment Option for Type 2 Diabetes Mellitus", "abstract": { "Exenatide": [ 0, 96 ], "is": [ 1, 11, 60, 97 ], "the": [ 2, 6, 24, 87 ], "first": [ 3 ], "drug": [ 4 ], "in": [ 5, 46 ], "incretin": [ 7 ], "mimetic": [ 8 ], "class": [ 9 ], "and": [ 10, 67, 84 ], "indicated": [ 12 ], "for": [ 13 ], "treatment": [ 14 ], "of": [ 15, 36 ], "type": [ 16 ], "2": [ 17 ], "diabetes": [ 18, 80 ], "mellitus.": [ 19 ], "Although": [ 20 ], "structurally": [ 21 ], "similar": [ 22 ], "to": [ 23, 43, 71, 77, 109 ], "native": [ 25 ], "glucagon-like": [ 26 ], "peptide,": [ 27 ], "this": [ 28 ], "synthetic": [ 29 ], "form": [ 30 ], "has": [ 31 ], "a": [ 32, 56, 110 ], "much": [ 33 ], "longer": [ 34 ], "duration": [ 35 ], "action.": [ 37 ], "Randomized": [ 38 ], "trials": [ 39 ], "have": [ 40 ], "shown": [ 41 ], "exenatide": [ 42, 94 ], "be": [ 44, 69 ], "efficacious": [ 45 ], "improving": [ 47 ], "glycemic": [ 48 ], "control": [ 49 ], "when": [ 50 ], "combined": [ 51 ], "with": [ 52, 93, 100 ], "either": [ 53 ], "metformin": [ 54 ], "or": [ 55, 112 ], "sulfonylurea.": [ 57 ], "The": [ 58 ], "dose": [ 59 ], "initially": [ 61 ], "5": [ 62 ], "mcg": [ 63, 73 ], "subcutaneously": [ 64, 74 ], "twice": [ 65, 75 ], "daily": [ 66, 76 ], "may": [ 68, 103 ], "titrated": [ 70 ], "10": [ 72 ], "achieve": [ 78 ], "better": [ 79 ], "management.": [ 81 ], "Nausea,": [ 82 ], "vomiting,": [ 83 ], "diarrhea": [ 85 ], "were": [ 86 ], "most": [ 88 ], "common": [ 89 ], "adverse": [ 90 ], "events": [ 91 ], "reported": [ 92 ], "therapy.": [ 95 ], "not": [ 98 ], "associated": [ 99 ], "hypoglycemia,": [ 101 ], "which": [ 102 ], "provide": [ 104 ], "advantages": [ 105 ], "over": [ 106 ], "adding": [ 107 ], "insulin": [ 108 ], "sulfonylurea": [ 111 ], "metformin.": [ 113 ] }, "publication_date": "2006-07-01", "publication_year": 2006, "type": "article", "cited_by_count": 84, "authors": [ { "id": "https://openalex.org/A5003920367", "display_name": "A.E. Bond" } ] }, { "id": "https://openalex.org/W4402581625", "doi": "https://doi.org/10.1001/jamainternmed.2024.4661", "title": "GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease", "abstract": { "Importance": [ 0 ], "Metabolic": [ 1 ], "dysfunction-associated": [ 2 ], "steatotic": [ 3 ], "liver": [ 4, 24, 215, 235 ], "disease": [ 5, 465 ], "(MASLD)": [ 6 ], "is": [ 7, 38 ], "an": [ 8, 68, 308 ], "increasing": [ 9 ], "cause": [ 10 ], "of": [ 11, 35, 43, 137, 144, 214, 251, 311, 334, 371, 375, 434, 460 ], "cirrhosis.": [ 12, 417 ], "Glucagon-like": [ 13 ], "peptide": [ 14 ], "1": [ 15 ], "receptor": [ 16 ], "agonists": [ 17 ], "(GLP-1": [ 18 ], "RAs)": [ 19 ], "are": [ 20 ], "effective": [ 21 ], "in": [ 22, 26, 164, 414, 452, 463 ], "improving": [ 23 ], "inflammation": [ 25 ], "patients": [ 27, 56, 183, 195, 241, 267, 304, 312, 318, 415, 441, 453 ], "with": [ 28, 40, 57, 67, 89, 186, 242, 325, 330, 362, 367, 416, 430, 442, 454 ], "MASLD.": [ 29, 58 ], "Objective": [ 30 ], "To": [ 31 ], "determine": [ 32 ], "whether": [ 33 ], "use": [ 34, 411, 427 ], "GLP-1": [ 36, 111, 156, 270, 321, 358, 409, 425 ], "RAs": [ 37 ], "associated": [ 39, 103, 329, 366, 429 ], "lower": [ 41, 332, 369, 432 ], "risk": [ 42, 333, 370, 433 ], "developing": [ 44 ], "cirrhosis": [ 45, 187, 204, 221, 252, 277, 291, 335, 376, 437 ], "and": [ 46, 51, 61, 84, 91, 102, 106, 123, 185, 192, 217, 228, 237, 254, 260, 288, 390, 412, 419, 438, 444 ], "its": [ 47 ], "complications,": [ 48, 230, 253 ], "including": [ 49, 231 ], "decompensation": [ 50 ], "hepatocellular": [ 52 ], "cancer": [ 53 ], "(HCC),": [ 54 ], "among": [ 55, 182, 440 ], "Design,": [ 59 ], "Setting,": [ 60 ], "Participants": [ 62 ], "This": [ 63 ], "retrospective": [ 64 ], "cohort": [ 65, 423 ], "study": [ 66, 139, 146 ], "active": [ 69 ], "comparator,": [ 70 ], "new-user": [ 71 ], "design": [ 72 ], "used": [ 73 ], "data": [ 74 ], "from": [ 75, 133 ], "the": [ 76, 138, 142, 145, 175, 198, 244, 355, 372, 458, 464 ], "national": [ 77 ], "Veterans": [ 78, 98 ], "Health": [ 79, 99 ], "Administration": [ 80, 100 ], "Corporate": [ 81 ], "Data": [ 82 ], "Warehouse": [ 83 ], "Central": [ 85 ], "Cancer": [ 86 ], "Registry.": [ 87 ], "Patients": [ 88, 129 ], "MASLD": [ 90, 443 ], "diabetes": [ 92 ], "who": [ 93, 107, 170, 268, 313 ], "were": [ 94, 127, 130, 180, 220, 257, 305, 352, 405 ], "seen": [ 95, 353, 451 ], "at": [ 96, 188, 301 ], "130": [ 97 ], "hospitals": [ 101 ], "ambulatory": [ 104 ], "clinics": [ 105 ], "initiated": [ 108, 171, 269, 314 ], "either": [ 109 ], "a": [ 110, 168, 172, 211, 226, 248, 315, 331, 368, 431 ], "RA": [ 112, 157, 322, 359, 410, 426 ], "or": [ 113, 141, 210, 234 ], "dipeptidyl": [ 114 ], "peptidase": [ 115 ], "4": [ 116 ], "inhibitor": [ 117 ], "(DPP-4i)": [ 118 ], "between": [ 119, 408 ], "January": [ 120 ], "1,": [ 121 ], "2006,": [ 122 ], "June": [ 124 ], "30,": [ 125 ], "2022,": [ 126 ], "included.": [ 128 ], "followed": [ 131 ], "up": [ 132 ], "baseline": [ 134 ], "until": [ 135 ], "one": [ 136 ], "outcomes": [ 140, 219, 256, 413 ], "end": [ 143 ], "period": [ 147 ], "(December": [ 148 ], "31,": [ 149 ], "2022),": [ 150 ], "whichever": [ 151 ], "came": [ 152 ], "first.": [ 153 ], "Exposures": [ 154 ], "Each": [ 155 ], "new": [ 158 ], "user": [ 159 ], "was": [ 160, 201, 247, 328, 365, 428, 449 ], "propensity": [ 161 ], "score": [ 162 ], "matched": [ 163, 306 ], "1:1": [ 165 ], "ratio": [ 166, 344 ], "to": [ 167, 203, 307, 436 ], "patient": [ 169 ], "DPP-4i": [ 173, 326, 363 ], "during": [ 174 ], "same": [ 176 ], "month.": [ 177 ], "Separate": [ 178 ], "analyses": [ 179 ], "conducted": [ 181 ], "without": [ 184, 196, 319 ], "baseline.": [ 189, 302 ], "Main": [ 190 ], "Outcomes": [ 191 ], "Measures": [ 193 ], "For": [ 194, 240 ], "cirrhosis,": [ 197, 243, 320, 456 ], "primary": [ 199, 245 ], "outcome": [ 200, 246, 250, 374 ], "progression": [ 202, 435 ], "defined": [ 205, 223 ], "by": [ 206 ], "validated": [ 207 ], "diagnoses": [ 208 ], "codes": [ 209 ], "noninvasive": [ 212 ], "marker": [ 213 ], "fibrosis,": [ 216 ], "secondary": [ 218, 255, 356 ], "complications": [ 222, 377 ], "both": [ 224 ], "as": [ 225 ], "composite": [ 227, 249, 373 ], "individual": [ 229 ], "decompensation,": [ 232, 258 ], "HCC,": [ 233, 259 ], "transplant,": [ 236 ], "all-cause": [ 238, 261 ], "mortality.": [ 239, 262 ], "Results": [ 263 ], "Of": [ 264 ], "16": [ 265 ], "058": [ 266 ], "RAs,": [ 271 ], "14": [ 272 ], "606": [ 273 ], "did": [ 274 ], "not": [ 275, 450 ], "have": [ 276 ], "(mean": [ 278, 292 ], "[SD]": [ 279, 293 ], "age,": [ 280, 294 ], "60.56": [ 281 ], "[10.31]": [ 282 ], "years;": [ 283, 297 ], "13": [ 284 ], "015": [ 285 ], "[89.1%]": [ 286 ], "male),": [ 287 ], "1452": [ 289 ], "had": [ 290 ], "66.99": [ 295 ], "[7.09]": [ 296 ], "1360": [ 298 ], "[93.7%]": [ 299 ], "male)": [ 300 ], "These": [ 303 ], "equal": [ 309 ], "number": [ 310 ], "DPP-4i.": [ 316 ], "In": [ 317, 421 ], "use,": [ 323, 327, 360, 364 ], "compared": [ 324, 361 ], "(9.98": [ 336 ], "vs": [ 337, 379, 393 ], "11.10": [ 338 ], "events": [ 339, 381, 395 ], "per": [ 340, 382, 396 ], "1000": [ 341, 383, 397 ], "person-years;": [ 342, 384, 398 ], "hazard": [ 343 ], "[HR],": [ 345 ], "0.86;": [ 346 ], "95%": [ 347, 387, 401 ], "CI,": [ 348, 388, 402 ], "0.75-0.98).": [ 349 ], "Similar": [ 350 ], "results": [ 351 ], "for": [ 354 ], "outcomes.": [ 357 ], "(1.89": [ 378 ], "2.55": [ 380 ], "HR,": [ 385, 399 ], "0.78;": [ 386 ], "0.59-1.04)": [ 389 ], "mortality": [ 391, 439 ], "(21.77": [ 392 ], "24.43": [ 394 ], "0.89;": [ 400 ], "0.81-0.98).": [ 403 ], "There": [ 404 ], "no": [ 406 ], "associations": [ 407 ], "Conclusions": [ 418 ], "Relevance": [ 420 ], "this": [ 422 ], "study,": [ 424 ], "diabetes.": [ 445 ], "The": [ 446 ], "protective": [ 447 ], "association": [ 448 ], "existing": [ 455 ], "underscoring": [ 457 ], "importance": [ 459 ], "treatment": [ 461 ], "earlier": [ 462 ], "course.": [ 466 ] }, "publication_date": "2024-09-16", "publication_year": 2024, "type": "article", "cited_by_count": 80, "authors": [ { "id": "https://openalex.org/A5086965411", "display_name": "Fasiha Kanwal" }, { "id": "https://openalex.org/A5075525513", "display_name": "Jennifer R. Kramer" }, { "id": "https://openalex.org/A5100420615", "display_name": "Liang Li" }, { "id": "https://openalex.org/A5042304706", "display_name": "Yu\u2010Xiao Yang" }, { "id": "https://openalex.org/A5101184915", "display_name": "Yumei Cao" }, { "id": "https://openalex.org/A5102829424", "display_name": "Xian Yu" }, { "id": "https://openalex.org/A5112963988", "display_name": "Ronald Samuel" }, { "id": "https://openalex.org/A5086608905", "display_name": "Basim Ali" }, { "id": "https://openalex.org/A5056132513", "display_name": "Roxanne Desiderio" }, { "id": "https://openalex.org/A5068997870", "display_name": "George Cholankeril" }, { "id": "https://openalex.org/A5104043969", "display_name": "Mandeep Bajaj" }, { "id": "https://openalex.org/A5027343826", "display_name": "Hashem B. El\u2010Serag" }, { "id": "https://openalex.org/A5064421397", "display_name": "Steven M. Asch" } ] }, { "id": "https://openalex.org/W1980053049", "doi": "https://doi.org/10.1016/j.toxicon.2010.12.016", "title": "The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent", "abstract": null, "publication_date": "2010-12-30", "publication_year": 2010, "type": "article", "cited_by_count": 147, "authors": [ { "id": "https://openalex.org/A5111685843", "display_name": "Brian L. Furman" } ] }, { "id": "https://openalex.org/W4388871128", "doi": "https://doi.org/10.1016/j.xcrm.2023.101292", "title": "Use of a biomimetic hydrogel depot technology for sustained delivery of GLP-1 receptor agonists reduces burden of diabetes management", "abstract": null, "publication_date": "2023-11-01", "publication_year": 2023, "type": "article", "cited_by_count": 34, "authors": [ { "id": "https://openalex.org/A5024165886", "display_name": "Andrea I. d\u2019Aquino" }, { "id": "https://openalex.org/A5062824120", "display_name": "Caitlin L. Maikawa" }, { "id": "https://openalex.org/A5059554430", "display_name": "Leslee T. Nguyen" }, { "id": "https://openalex.org/A5033898039", "display_name": "Katie Lu" }, { "id": "https://openalex.org/A5047212915", "display_name": "Ian A. Hall" }, { "id": "https://openalex.org/A5080640866", "display_name": "Carolyn K. Jons" }, { "id": "https://openalex.org/A5012074457", "display_name": "Catherine M. Kasse" }, { "id": "https://openalex.org/A5101828742", "display_name": "Jerry Yan" }, { "id": "https://openalex.org/A5002677777", "display_name": "Alexander N. Prossnitz" }, { "id": "https://openalex.org/A5028924430", "display_name": "Enmian Chang" }, { "id": "https://openalex.org/A5112637282", "display_name": "Sam W. Baker" }, { "id": "https://openalex.org/A5024434752", "display_name": "Lars Hovgaard" }, { "id": "https://openalex.org/A5047967902", "display_name": "Dorte B. Steensgaard" }, { "id": "https://openalex.org/A5077601648", "display_name": "Hanne B. Andersen" }, { "id": "https://openalex.org/A5088597413", "display_name": "Lotte Simonsen" }, { "id": "https://openalex.org/A5045990567", "display_name": "Eric A. Appel" } ] }, { "id": "https://openalex.org/W2332664660", "doi": "https://doi.org/10.1016/j.freeradbiomed.2016.03.035", "title": "Liraglutide protects cardiac microvascular endothelial cells against hypoxia/reoxygenation injury through the suppression of the SR-Ca2+\u2013XO\u2013ROS axis via activation of the GLP-1R/PI3K/Akt/survivin pathways", "abstract": null, "publication_date": "2016-04-01", "publication_year": 2016, "type": "article", "cited_by_count": 180, "authors": [ { "id": "https://openalex.org/A5100386204", "display_name": "Ying Zhang" }, { "id": "https://openalex.org/A5035051058", "display_name": "Hao Zhou" }, { "id": "https://openalex.org/A5087062727", "display_name": "Wenbo Wu" }, { "id": "https://openalex.org/A5100362211", "display_name": "Shi Chen" }, { "id": "https://openalex.org/A5045213014", "display_name": "Shunying Hu" }, { "id": "https://openalex.org/A5010098260", "display_name": "Tong Yin" }, { "id": "https://openalex.org/A5101595736", "display_name": "Qiang Ma" }, { "id": "https://openalex.org/A5108252183", "display_name": "Tianwen Han" }, { "id": "https://openalex.org/A5030348312", "display_name": "Yingqian Zhang" }, { "id": "https://openalex.org/A5034654931", "display_name": "Feng Tian" }, { "id": "https://openalex.org/A5100770707", "display_name": "Yundai Chen" } ] }, { "id": "https://openalex.org/W2985631573", "doi": "https://doi.org/10.1007/s00125-019-05021-6", "title": "Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation", "abstract": null, "publication_date": "2019-11-05", "publication_year": 2019, "type": "article", "cited_by_count": 111, "authors": [ { "id": "https://openalex.org/A5067334429", "display_name": "Maurice B. Bizino" }, { "id": "https://openalex.org/A5062964331", "display_name": "Ingrid M. Jazet" }, { "id": "https://openalex.org/A5015365247", "display_name": "Paul de Heer" }, { "id": "https://openalex.org/A5091678325", "display_name": "Huub J. van Eyk" }, { "id": "https://openalex.org/A5028587946", "display_name": "Ilona A. Dekkers" }, { "id": "https://openalex.org/A5035385427", "display_name": "Patrick C.N. Rensen" }, { "id": "https://openalex.org/A5090316420", "display_name": "Elisabeth H.M. Paiman" }, { "id": "https://openalex.org/A5019397910", "display_name": "Hildebrandus J. Lamb" }, { "id": "https://openalex.org/A5052838073", "display_name": "Johannes W. A. Smit" } ] }, { "id": "https://openalex.org/W3106528346", "doi": "https://doi.org/10.1111/dom.14255", "title": "Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes", "abstract": { "Abstract": [ 0 ], "Aim": [ 1 ], "To": [ 2 ], "evaluate": [ 3 ], "the": [ 4, 101 ], "effect": [ 5 ], "of": [ 6, 39, 103, 159, 166, 223 ], "oral": [ 7, 43, 129, 160, 192, 205, 232 ], "semaglutide": [ 8, 44, 130, 161, 193, 206, 233 ], "on": [ 9 ], "energy": [ 10, 122, 227 ], "intake": [ 11, 62, 123, 228 ], "and": [ 12, 22, 72, 90, 97, 106, 111, 169, 185, 207, 242, 248, 254 ], "appetite": [ 13, 172 ], "in": [ 14, 108, 133, 157, 237 ], "subjects": [ 15, 33, 136 ], "with": [ 16, 34, 41, 128, 174, 191, 204, 210, 231, 245 ], "type": [ 17 ], "2": [ 18 ], "diabetes": [ 19 ], "(T2D).": [ 20 ], "Materials": [ 21 ], "Methods": [ 23 ], "In": [ 24 ], "this": [ 25 ], "randomized,": [ 26 ], "double\u2010blind,": [ 27 ], "placebo\u2010controlled,": [ 28 ], "two\u2010period": [ 29 ], "cross\u2010over": [ 30 ], "trial,": [ 31 ], "15": [ 32 ], "T2D": [ 35 ], "received": [ 36 ], "12": [ 37, 221 ], "weeks": [ 38, 222 ], "treatment": [ 40, 138 ], "once\u2010daily": [ 42 ], "(4\u2010week": [ 45 ], "dose": [ 46 ], "escalation": [ 47 ], "from": [ 48 ], "3": [ 49 ], "to": [ 50, 52, 214 ], "7": [ 51 ], "14": [ 53 ], "mg)": [ 54 ], "followed": [ 55 ], "by": [ 56, 201 ], "placebo,": [ 57, 211, 235 ], "or": [ 58 ], "vice": [ 59 ], "versa.": [ 60 ], "Energy": [ 61 ], "was": [ 63, 124, 229, 243 ], "measured": [ 64, 82 ], "during": [ 65 ], "an": [ 66 ], "ad": [ 67, 120, 225 ], "libitum": [ 68, 121, 226 ], "lunch,": [ 69 ], "evening": [ 70 ], "meal": [ 71 ], "snack": [ 73 ], "box": [ 74 ], "after": [ 75, 88, 250 ], "a": [ 76, 84, 115, 150, 179, 251 ], "standard": [ 77, 89, 116, 180 ], "breakfast.": [ 78, 181 ], "Appetite": [ 79 ], "ratings": [ 80 ], "were": [ 81, 154, 189 ], "using": [ 83 ], "visual": [ 85 ], "analogue": [ 86 ], "scale": [ 87 ], "fat\u2010rich": [ 91, 151, 252 ], "breakfasts.": [ 92 ], "Other": [ 93 ], "assessments": [ 94 ], "included": [ 95 ], "eating": [ 96, 187, 256 ], "craving": [ 98 ], "control": [ 99, 188 ], "(using": [ 100 ], "Control": [ 102 ], "Eating": [ 104 ], "Questionnaire),": [ 105 ], "changes": [ 107 ], "body": [ 109, 198, 215, 239 ], "weight": [ 110, 199 ], "composition.": [ 112 ], "Results": [ 113 ], "Following": [ 114 ], "breakfast,": [ 117, 152, 253 ], "total": [ 118 ], "daily": [ 119 ], "significantly": [ 125 ], "lower": [ 126, 230 ], "(38.9%)": [ 127 ], "versus": [ 131, 162, 194, 234 ], "placebo": [ 132, 163 ], "13": [ 134 ], "evaluable": [ 135 ], "(estimated": [ 137 ], "difference,": [ 139 ], "\u22125096.0": [ 140 ], "kJ;": [ 141 ], "95%": [ 142 ], "CI": [ 143 ], "\u20137000.0,": [ 144 ], "\u22123192.1;": [ 145 ], "P": [ 146 ], "=": [ 147 ], ".0001).": [ 148 ], "After": [ 149, 220 ], "there": [ 153 ], "significant": [ 155, 176 ], "differences": [ 156, 177 ], "favour": [ 158 ], "for": [ 164, 170 ], "measures": [ 165 ], "satiety,": [ 167 ], "hunger": [ 168 ], "overall": [ 171 ], "score,": [ 173 ], "no": [ 175 ], "following": [ 178 ], "Fewer": [ 182 ], "food": [ 183 ], "cravings": [ 184 ], "better": [ 186 ], "seen": [ 190 ], "placebo.": [ 195 ], "Overall,": [ 196 ], "mean": [ 197 ], "decreased": [ 200 ], "2.7": [ 202 ], "kg": [ 203, 209 ], "0.1": [ 208 ], "mostly": [ 212 ], "attributable": [ 213 ], "fat": [ 216, 240 ], "mass": [ 217 ], "loss.": [ 218 ], "Conclusion": [ 219 ], "treatment,": [ 224 ], "resulting": [ 236 ], "reduced": [ 238 ], "mass,": [ 241 ], "associated": [ 244 ], "increased": [ 246 ], "satiety": [ 247 ], "fullness": [ 249 ], "improved": [ 255 ], "control.": [ 257 ], "Trial": [ 258 ], "registration": [ 259 ], "number": [ 260 ], "NCT02773381": [ 261 ] }, "publication_date": "2020-11-13", "publication_year": 2020, "type": "article", "cited_by_count": 99, "authors": [ { "id": "https://openalex.org/A5008159825", "display_name": "Catherine Gibbons" }, { "id": "https://openalex.org/A5039586613", "display_name": "John E. Blundell" }, { "id": "https://openalex.org/A5078003599", "display_name": "S\u00f8ren T. Hoff" }, { "id": "https://openalex.org/A5020283181", "display_name": "Kirsten Dahl" }, { "id": "https://openalex.org/A5104042654", "display_name": "Robert Bauer" }, { "id": "https://openalex.org/A5043297080", "display_name": "Tine A. B\u00e6kdal" } ] }, { "id": "https://openalex.org/W2784085811", "doi": "https://doi.org/10.1038/s41598-018-19170-y", "title": "Fc-modified exenatide-loaded nanoparticles for oral delivery to improve hypoglycemic effects in mice", "abstract": { "Abstract": [ 0 ], "To": [ 1 ], "improve": [ 2 ], "the": [ 3, 27, 30, 39, 49, 68, 75, 120, 128, 137, 143, 147, 151, 161, 167, 175 ], "oral": [ 4, 21, 108, 194 ], "efficiency": [ 5, 71 ], "of": [ 6, 38, 48, 72, 110, 127, 139, 174 ], "exenatide,": [ 7 ], "we": [ 8 ], "prepared": [ 9 ], "polyethylene": [ 10 ], "glycol-poly(lactic-co-glycolic": [ 11 ], "acid)": [ 12 ], "(PEG-PLGA)": [ 13 ], "NPs": [ 14, 28, 51, 76, 82, 113, 132 ], "modified": [ 15, 114 ], "with": [ 16, 52, 124, 160 ], "Fc": [ 17, 117, 140 ], "(NPs-Fc)": [ 18 ], "for": [ 19, 154, 193 ], "exenatide": [ 20, 73, 129 ], "delivery.": [ 22, 197 ], "Exenatide": [ 23 ], "was": [ 24, 41, 77 ], "encapsulated": [ 25 ], "into": [ 26 ], "by": [ 29, 65, 98, 115, 166, 179 ], "w/o/w": [ 31 ], "emulsion-solvent": [ 32 ], "evaporation": [ 33 ], "method.": [ 34 ], "The": [ 35 ], "particle": [ 36 ], "size": [ 37 ], "NPs-Fc": [ 40, 148 ], "approximately": [ 42 ], "30": [ 43 ], "nm": [ 44 ], "larger": [ 45 ], "than": [ 46, 79 ], "that": [ 47, 107, 146 ], "unmodified": [ 50, 94, 162 ], "polydispersity": [ 53 ], "indices": [ 54 ], "in": [ 55, 74, 150, 158, 180, 183 ], "a": [ 56, 89, 155 ], "narrow": [ 57 ], "range": [ 58 ], "(PDIs;": [ 59 ], "PDI": [ 60 ], "<": [ 61 ], "0.3)": [ 62 ], "as": [ 63, 96, 164 ], "detected": [ 64, 178 ], "DLS,": [ 66 ], "and": [ 67, 87, 100, 142, 171 ], "highest": [ 69 ], "encapsulation": [ 70 ], "greater": [ 78, 90 ], "80%.": [ 80 ], "Fc-conjugated": [ 81 ], "permeated": [ 83 ], "Caco-2": [ 84 ], "cells": [ 85 ], "faster": [ 86 ], "to": [ 88, 93, 135 ], "extent": [ 91 ], "compared": [ 92, 123 ], "NPs,": [ 95, 163 ], "verified": [ 97 ], "CLSM": [ 99 ], "flow": [ 101 ], "cytometry.": [ 102 ], "Hypoglycemic": [ 103 ], "effect": [ 104 ], "studies": [ 105 ], "demonstrated": [ 106, 145 ], "administration": [ 109 ], "exenatide-loaded": [ 111 ], "PEG-PLGA": [ 112 ], "an": [ 116 ], "group": [ 118 ], "extended": [ 119 ], "hypoglycemic": [ 121 ], "effects": [ 122, 138 ], "s.c.": [ 125 ], "injection": [ 126 ], "solution.": [ 130 ], "Fluorescence-labeled": [ 131 ], "were": [ 133 ], "used": [ 134 ], "investigate": [ 136 ], "targeting,": [ 141 ], "results": [ 144 ], "stayed": [ 149 ], "gastrointestinal": [ 152 ], "tract": [ 153 ], "longer": [ 156 ], "time": [ 157 ], "comparison": [ 159 ], "shown": [ 165 ], "whole-body": [ 168 ], "fluorescence": [ 169, 172 ], "images": [ 170, 173 ], "dissected": [ 176 ], "organs": [ 177 ], "vivo": [ 181 ], "imaging": [ 182 ], "live": [ 184 ], "mice.": [ 185 ], "Therefore,": [ 186 ], "Fc-targeted": [ 187 ], "nano-delivery": [ 188 ], "systems": [ 189 ], "show": [ 190 ], "great": [ 191 ], "promise": [ 192 ], "peptide/protein": [ 195 ], "drug": [ 196 ] }, "publication_date": "2018-01-09", "publication_year": 2018, "type": "article", "cited_by_count": 80, "authors": [ { "id": "https://openalex.org/A5069865611", "display_name": "Yanan Shi" }, { "id": "https://openalex.org/A5001945622", "display_name": "Xinfeng Sun" }, { "id": "https://openalex.org/A5100426751", "display_name": "Liping Zhang" }, { "id": "https://openalex.org/A5015603864", "display_name": "Kaoxiang Sun" }, { "id": "https://openalex.org/A5100764803", "display_name": "Keke Li" }, { "id": "https://openalex.org/A5051996274", "display_name": "Youxin Li" }, { "id": "https://openalex.org/A5100381953", "display_name": "Qiang Zhang" } ] }, { "id": "https://openalex.org/W2330429556", "doi": "https://doi.org/10.3810/pgm.2014.11.2836", "title": "Clinical Pharmacology of Albiglutide, a GLP-1 Receptor Agonist", "abstract": { "NCT00938158,": [ 0 ], "NCT01406262,": [ 1 ], "NCT00537719,": [ 2 ], "NCT01077505,": [ 3 ], "NCT01147731,": [ 4 ], "NCT01147718,": [ 5 ], "NCT01147692,": [ 6 ], "NCT00354536,": [ 7 ], "NCT00394030,": [ 8 ], "NCT00530309,": [ 9 ], "NCT01357889,": [ 10 ], "NCT00518115,": [ 11 ], "NCT01098461,": [ 12 ], "NCT01475734,": [ 13 ], "NCT00849017,": [ 14 ], "NCT00838916,": [ 15 ], "NCT00839527,": [ 16 ], "NCT01098539.": [ 17 ] }, "publication_date": "2014-11-01", "publication_year": 2014, "type": "review", "cited_by_count": 37, "authors": [ { "id": "https://openalex.org/A5113534859", "display_name": "Malcolm A. Young" }, { "id": "https://openalex.org/A5111526314", "display_name": "Jeffrey A. Wald" }, { "id": "https://openalex.org/A5102196780", "display_name": "Jessica Matthews" }, { "id": "https://openalex.org/A5112132748", "display_name": "Rhona Scott" }, { "id": "https://openalex.org/A5108437272", "display_name": "Rebecca J. Hodge" }, { "id": "https://openalex.org/A5101824287", "display_name": "Hui Zhi" }, { "id": "https://openalex.org/A5103533877", "display_name": "Rickey R. Reinhardt" } ] }, { "id": "https://openalex.org/W3009912045", "doi": "https://doi.org/10.1016/j.jacc.2019.12.063", "title": "Effects of Liraglutide on Cardiovascular\u00a0Outcomes in Patients With Diabetes With or Without Heart\u00a0Failure", "abstract": null, "publication_date": "2020-03-01", "publication_year": 2020, "type": "article", "cited_by_count": 95, "authors": [ { "id": "https://openalex.org/A5110355842", "display_name": "Steven P. Marso" }, { "id": "https://openalex.org/A5112384687", "display_name": "Florian M.M. Baeres" }, { "id": "https://openalex.org/A5080463002", "display_name": "Stephen C. Bain" }, { "id": "https://openalex.org/A5075289235", "display_name": "Bryan Goldman" }, { "id": "https://openalex.org/A5044527590", "display_name": "Mansoor Husain" }, { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5072011562", "display_name": "Neil R Poulter" }, { "id": "https://openalex.org/A5059098934", "display_name": "Richard E. Pratley" }, { "id": "https://openalex.org/A5112354612", "display_name": "Anne Bloch Thomsen" }, { "id": "https://openalex.org/A5040182038", "display_name": "John B. Buse" } ] }, { "id": "https://openalex.org/W2021929263", "doi": "https://doi.org/10.1016/j.ejim.2009.05.009", "title": "Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical Use", "abstract": null, "publication_date": "2009-06-25", "publication_year": 2009, "type": "review", "cited_by_count": 58, "authors": [ { "id": "https://openalex.org/A5013350892", "display_name": "David M. Kendall" }, { "id": "https://openalex.org/A5101709468", "display_name": "Robert Cuddihy" }, { "id": "https://openalex.org/A5113817930", "display_name": "Richard M. Bergenstal" } ] }, { "id": "https://openalex.org/W4308963355", "doi": "https://doi.org/10.1155/2022/1428817", "title": "DA5\u2010CH and Semaglutide Protect against Neurodegeneration and Reduce \u03b1\u2010Synuclein Levels in the 6\u2010OHDA Parkinson\u2019s Disease Rat Model", "abstract": { "Insulin": [ 0 ], "desensitization": [ 1 ], "has": [ 2 ], "been": [ 3 ], "observed": [ 4 ], "in": [ 5, 48, 54, 63, 105, 140, 146, 170, 193, 215 ], "the": [ 6, 37, 70, 90, 106, 128, 137, 141, 171, 175, 186, 244 ], "brains": [ 7 ], "of": [ 8, 110, 177 ], "patients": [ 9, 55, 65 ], "with": [ 10, 56, 69, 154, 204 ], "Parkinson\u2019s": [ 11 ], "disease": [ 12 ], "(PD),": [ 13 ], "which": [ 14, 21 ], "is": [ 15, 23, 27, 35, 47 ], "a": [ 16, 28, 40, 49, 81, 95, 225 ], "progressive": [ 17 ], "neurodegenerative": [ 18, 230 ], "disorder": [ 19 ], "for": [ 20, 42, 121, 229 ], "there": [ 22 ], "no": [ 24 ], "cure.": [ 25 ], "Semaglutide": [ 26 ], "novel": [ 29 ], "long\u2010actingglucagon\u2010likepeptide\u20101": [ 30 ], "(GLP\u20101)": [ 31 ], "receptor": [ 32, 73, 84, 237 ], "agonist": [ 33, 85 ], "that": [ 34, 87, 239 ], "on": [ 36 ], "market": [ 38 ], "as": [ 39, 144, 191, 233 ], "treatment": [ 41 ], "type": [ 43 ], "2": [ 44 ], "diabetes.": [ 45 ], "It": [ 46 ], "phase": [ 50, 60 ], "II": [ 51, 61 ], "clinical": [ 52 ], "trial": [ 53 ], "PD.": [ 57, 111 ], "Two": [ 58 ], "previous": [ 59 ], "trials": [ 62 ], "PD": [ 64, 217, 234 ], "showed": [ 66, 212 ], "good": [ 67, 213 ], "effects": [ 68, 214 ], "older": [ 71 ], "GLP\u20101": [ 72, 236 ], "agonists,": [ 74 ], "exendin\u20104": [ 75 ], "and": [ 76, 103, 132, 136, 150, 166, 179, 188, 222 ], "liraglutide.": [ 77 ], "We": [ 78, 100 ], "have": [ 79 ], "developed": [ 80 ], "dual": [ 82 ], "GLP\u20101/GIP": [ 83 ], "(DA5\u2010CH)": [ 86 ], "can": [ 88 ], "cross": [ 89, 243 ], "blood\u2010brain": [ 91 ], "barrier": [ 92 ], "(BBB)": [ 93 ], "at": [ 94 ], "higher": [ 96 ], "rate": [ 97 ], "than": [ 98, 235 ], "semaglutide.": [ 99 ], "tested": [ 101 ], "semaglutide": [ 102, 114, 211 ], "DA5\u2010CH": [ 104, 116, 155, 205, 219 ], "6\u2010OHDA\u2010lesion": [ 107 ], "rat": [ 108 ], "model": [ 109 ], "Treatment": [ 112 ], "was": [ 113, 183, 198, 220 ], "or": [ 115 ], "(25": [ 117 ], "nmol/kg,": [ 118 ], "i.p.)": [ 119 ], "daily": [ 120 ], "30": [ 122 ], "days": [ 123 ], "postlesion.": [ 124 ], "Both": [ 125 ], "drugs": [ 126, 162 ], "reduced": [ 127, 147, 184, 194 ], "apomorphine\u2010induced": [ 129 ], "rotational": [ 130 ], "behavior": [ 131 ], "alleviated": [ 133 ], "dopamine": [ 134 ], "depletion": [ 135 ], "inflammation": [ 138 ], "response": [ 139 ], "lesioned": [ 142 ], "striatum": [ 143 ], "shown": [ 145, 192 ], "IL\u20101": [ 148 ], "\u03b2": [ 149 ], "TNF\u2010": [ 151 ], "\u03b1": [ 152, 181 ], "levels,": [ 153 ], "being": [ 156, 206 ], "more": [ 157, 207 ], "effective.": [ 158, 208 ], "In": [ 159 ], "addition,": [ 160 ], "both": [ 161 ], "protected": [ 163 ], "dopaminergic": [ 164 ], "neurons": [ 165 ], "increased": [ 167 ], "TH": [ 168 ], "expression": [ 169 ], "substantia": [ 172 ], "nigra.": [ 173 ], "Furthermore,": [ 174 ], "level": [ 176 ], "monomer": [ 178 ], "aggregated": [ 180 ], "\u2010synuclein": [ 182 ], "by": [ 185 ], "drugs,": [ 187 ], "insulin": [ 189 ], "resistance": [ 190 ], "pIRS\u20101": [ 195 ], "ser312": [ 196 ], "phosphorylation": [ 197 ], "also": [ 199 ], "attenuated": [ 200 ], "after": [ 201 ], "drug": [ 202, 228 ], "treatment,": [ 203 ], "Therefore,": [ 209 ], "while": [ 210 ], "this": [ 216 ], "model,": [ 218 ], "superior": [ 221 ], "may": [ 223 ], "be": [ 224 ], "better": [ 226 ], "therapeutic": [ 227 ], "disorders": [ 231 ], "such": [ 232 ], "agonists": [ 238 ], "do": [ 240 ], "not": [ 241 ], "easily": [ 242 ], "BBB.": [ 245 ] }, "publication_date": "2022-01-01", "publication_year": 2022, "type": "article", "cited_by_count": 22, "authors": [ { "id": "https://openalex.org/A5100758902", "display_name": "Lingyu Zhang" }, { "id": "https://openalex.org/A5100373933", "display_name": "Chun Li" }, { "id": "https://openalex.org/A5007760639", "display_name": "Zijuan Zhang" }, { "id": "https://openalex.org/A5018229662", "display_name": "Zhenqiang Zhang" }, { "id": "https://openalex.org/A5107918479", "display_name": "Qianqian Jin" }, { "id": "https://openalex.org/A5100412926", "display_name": "Lin Li" }, { "id": "https://openalex.org/A5082707086", "display_name": "Christian H\u00f6lscher" } ] }, { "id": "https://openalex.org/W1963917033", "doi": "https://doi.org/10.1111/dom.12133", "title": "Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat\u2010rich meal in patients with type 2 diabetes: a randomized, double\u2010blind, placebo\u2010controlled, cross\u2010over trial", "abstract": { "Aims": [ 0 ], "Postprandial": [ 1, 193 ], "triglyceridaemia": [ 2 ], "is": [ 3 ], "a": [ 4, 43, 79, 245 ], "risk": [ 5, 259 ], "factor": [ 6 ], "for": [ 7, 172 ], "cardiovascular": [ 8 ], "disease": [ 9 ], "(CVD).": [ 10 ], "This": [ 11 ], "study": [ 12 ], "investigated": [ 13 ], "the": [ 14, 86, 204 ], "effects": [ 15, 87 ], "of": [ 16, 31, 88, 239, 249, 262 ], "steady\u2010state": [ 17 ], "liraglutide": [ 18, 64, 89, 151, 190, 225 ], "1.8": [ 19, 71, 152 ], "mg": [ 20, 153 ], "versus": [ 21, 154, 191, 226 ], "placebo": [ 22 ], "on": [ 23, 90 ], "postprandial": [ 24, 124, 177, 237, 263 ], "plasma": [ 25 ], "lipid": [ 26 ], "concentrations": [ 27 ], "after": [ 28, 244 ], "3": [ 29, 121 ], "weeks": [ 30 ], "treatment": [ 32, 168, 214, 230 ], "in": [ 33, 231 ], "patients": [ 34, 46, 232 ], "with": [ 35, 47, 150, 189, 224, 233 ], "type": [ 36 ], "2": [ 37, 57 ], "diabetes": [ 38 ], "mellitus": [ 39 ], "(T2DM).": [ 40 ], "Methods": [ 41 ], "In": [ 42 ], "cross\u2010over": [ 44 ], "trial,": [ 45 ], "T2DM": [ 48, 234 ], "(n": [ 49 ], "=": [ 50, 135 ], "20,": [ 51 ], "18\u201375": [ 52 ], "years,": [ 53 ], "BMI": [ 54 ], "18.5\u201340": [ 55 ], "kg/m": [ 56 ], ")": [ 58 ], "were": [ 59, 108, 170, 186 ], "randomized": [ 60 ], "to": [ 61, 70, 256 ], "once\u2010daily": [ 62 ], "subcutaneous": [ 63 ], "(weekly": [ 65 ], "dose": [ 66 ], "escalation": [ 67 ], "from": [ 68 ], "0.6": [ 69 ], "mg)": [ 72 ], "and": [ 73, 85, 105, 137, 160, 179, 183, 203, 219, 241 ], "placebo.": [ 74, 192, 227 ], "After": [ 75, 120 ], "each": [ 76 ], "3\u2010week": [ 77 ], "period,": [ 78 ], "standardized": [ 80 ], "fat\u2010rich": [ 81, 246 ], "meal": [ 82 ], "was": [ 83 ], "provided,": [ 84 ], "triglyceride": [ 91, 125, 240 ], "(primary": [ 92 ], "endpoint": [ 93 ], "AUC": [ 94, 181 ], "0\u20138h": [ 95, 127, 141, 159, 182 ], "),": [ 96 ], "apolipoprotein": [ 97, 138, 242 ], "B48": [ 98, 139, 243 ], ",": [ 99 ], "non\u2010esterified": [ 100, 173 ], "fatty": [ 101, 174 ], "acids,": [ 102 ], "glycaemic": [ 103 ], "responses": [ 104 ], "gastric": [ 106, 194, 250 ], "emptying": [ 107, 195 ], "assessed.": [ 109 ], "ClinicalTrials.gov": [ 110 ], "ID": [ 111 ], ":": [ 112 ], "NCT00993304": [ 113 ], ".": [ 114 ], "Funding:": [ 115 ], "Novo": [ 116 ], "Nordisk": [ 117 ], "A/S.": [ 118 ], "Results": [ 119, 252 ], "weeks,": [ 122 ], "mean": [ 123 ], "(AUC": [ 126, 140 ], "liraglutide/placebo": [ 128 ], "treatment\u2010ratio": [ 129 ], "0.72,": [ 130 ], "95%": [ 131 ], "CI": [ 132 ], "[0.62\u20130.83],": [ 133 ], "p": [ 134, 145 ], "0.0004)": [ 136 ], "ratio": [ 142 ], "0.65": [ 143 ], "[0.58\u20130.73],": [ 144 ], "<": [ 146, 164 ], "0.0001)": [ 147 ], "significantly": [ 148, 187, 223, 235 ], "decreased": [ 149, 222 ], "placebo,": [ 155 ], "as": [ 156 ], "did": [ 157 ], "iAUC": [ 158 ], "C": [ 161, 184, 206 ], "max": [ 162, 185 ], "(p": [ 163 ], "0.001).": [ 165 ], "No": [ 166 ], "significant": [ 167 ], "differences": [ 169 ], "observed": [ 171 ], "acids.": [ 175 ], "Mean": [ 176, 216 ], "glucose": [ 178 ], "glucagon": [ 180 ], "reduced": [ 188, 236 ], "rate": [ 196 ], "[assessed": [ 197 ], "by": [ 198 ], "paracetamol": [ 199 ], "absorption": [ 200 ], "(liquid": [ 201 ], "phase)": [ 202 ], "13": [ 205 ], "\u2010octanoate": [ 207 ], "breath": [ 208 ], "test": [ 209 ], "(solid": [ 210 ], "phase)]": [ 211 ], "displayed": [ 212 ], "no": [ 213 ], "differences.": [ 215 ], "low\u2010density": [ 217 ], "lipoprotein": [ 218 ], "total": [ 220 ], "cholesterol": [ 221 ], "Conclusions": [ 228 ], "Liraglutide": [ 229 ], "excursions": [ 238 ], "meal,": [ 247 ], "independently": [ 248 ], "emptying.": [ 251 ], "indicate": [ 253 ], "liraglutide's": [ 254 ], "potential": [ 255 ], "reduce": [ 257 ], "CVD": [ 258 ], "via": [ 260 ], "improvement": [ 261 ], "lipaemia.": [ 264 ] }, "publication_date": "2013-05-17", "publication_year": 2013, "type": "article", "cited_by_count": 134, "authors": [ { "id": "https://openalex.org/A5088641715", "display_name": "Kjeld Hermansen" }, { "id": "https://openalex.org/A5043297080", "display_name": "Tine A. B\u00e6kdal" }, { "id": "https://openalex.org/A5078549507", "display_name": "Maria D\u00fcring" }, { "id": "https://openalex.org/A5003013879", "display_name": "Anna Pietraszek" }, { "id": "https://openalex.org/A5109956426", "display_name": "Lene Mortensen" }, { "id": "https://openalex.org/A5026952185", "display_name": "Hanne Skou J\u00f8rgensen" }, { "id": "https://openalex.org/A5019076349", "display_name": "Anne Flint" } ] }, { "id": "https://openalex.org/W3134058430", "doi": "https://doi.org/10.2147/cpaa.s276085", "title": "Clinical Impact of Liraglutide as a Treatment of Obesity", "abstract": { "Obesity": [ 0, 14 ], "is": [ 1, 65, 123 ], "defined": [ 2 ], "as": [ 3, 23, 156, 158 ], "a": [ 4, 66, 72 ], "chronic,": [ 5 ], "complex,": [ 6 ], "relapsing": [ 7 ], "disease": [ 8, 39, 173 ], "characterized": [ 9 ], "by": [ 10, 19, 146, 177 ], "excessive": [ 11 ], "adipose": [ 12 ], "tissue.": [ 13 ], "impacts": [ 15 ], "an": [ 16 ], "individual's": [ 17 ], "health": [ 18 ], "increasing": [ 20 ], "complications": [ 21 ], "such": [ 22 ], "prediabetes,": [ 24 ], "type": [ 25 ], "2": [ 26 ], "diabetes": [ 27 ], "mellitus": [ 28 ], "(T2DM),": [ 29 ], "hypertension,": [ 30 ], "dyslipidemia,": [ 31 ], "metabolic": [ 32, 108 ], "syndrome,": [ 33 ], "cardiovascular": [ 34, 172 ], "disease,": [ 35 ], "nonalcoholic": [ 36 ], "fatty": [ 37 ], "liver": [ 38 ], "(NAFLD),": [ 40 ], "cancers": [ 41 ], "(eg": [ 42 ], "endometrial),": [ 43 ], "and": [ 44, 55, 106, 120, 132, 135, 139, 150, 170, 182, 206, 209 ], "obstructive": [ 45 ], "sleep": [ 46 ], "apnea": [ 47 ], "(OSA).": [ 48 ], "With": [ 49 ], "the": [ 50, 90, 151, 159, 192 ], "increase": [ 51 ], "of": [ 52, 62, 79, 92, 113, 137, 194, 196 ], "obesity": [ 53, 93, 205 ], "prevalence": [ 54 ], "its": [ 56, 127, 198, 201, 207 ], "negative": [ 57 ], "influences": [ 58 ], "on": [ 59, 116, 129, 161, 166, 204 ], "individuals'": [ 60 ], "quality": [ 61 ], "life,": [ 63 ], "there": [ 64 ], "great": [ 67 ], "need": [ 68 ], "for": [ 69 ], "therapy": [ 70 ], "with": [ 71 ], "purpose": [ 73 ], "to": [ 74, 85, 126, 190 ], "produce": [ 75 ], "sustainable": [ 76 ], "weight": [ 77, 104, 121, 143, 152, 167 ], "loss": [ 78, 153, 168 ], "more": [ 80 ], "than": [ 81 ], "10%": [ 82 ], "in": [ 83 ], "order": [ 84 ], "improve": [ 86, 107 ], "or": [ 87 ], "even": [ 88 ], "reverse": [ 89 ], "progress": [ 91 ], "related": [ 94 ], "complications.": [ 95 ], "The": [ 96, 110, 141 ], "GLP-1": [ 97, 114 ], "analogue,": [ 98 ], "liraglutide": [ 99, 147 ], "reduce": [ 100 ], "food": [ 101, 117 ], "consumption,": [ 102 ], "promote": [ 103 ], "reduction": [ 105, 122, 144 ], "functions.": [ 109 ], "primary": [ 111 ], "mechanism": [ 112, 193 ], "effect": [ 115 ], "intake,": [ 118 ], "metabolism,": [ 119 ], "mainly": [ 124 ], "due": [ 125 ], "actions": [ 128 ], "peripheral": [ 130 ], "(vagal)": [ 131 ], "central": [ 133 ], "pathways": [ 134 ], "activation": [ 136 ], "hindbrain": [ 138 ], "hypothalamus.": [ 140 ], "average": [ 142 ], "induced": [ 145 ], "was": [ 148, 154 ], "significant": [ 149 ], "maintained": [ 155 ], "long": [ 157 ], "patients": [ 160 ], "therapy.": [ 162 ], "Liraglutide": [ 163 ], "has": [ 164 ], "advantages": [ 165 ], "maintenance": [ 169 ], "promoting": [ 171 ], "(CVD)": [ 174 ], "risk": [ 175 ], "reduction,": [ 176 ], "decreasing": [ 178 ], "systolic": [ 179 ], "blood": [ 180 ], "pressure": [ 181 ], "glycemic": [ 183 ], "index.": [ 184 ], "In": [ 185 ], "this": [ 186 ], "review,": [ 187 ], "we": [ 188 ], "aim": [ 189 ], "explain": [ 191 ], "action": [ 195 ], "Liraglutide,": [ 197 ], "pharmacokinetic": [ 199 ], "properties,": [ 200 ], "clinical": [ 202 ], "impact": [ 203 ], "safety": [ 208 ], "tolerability.": [ 210 ] }, "publication_date": "2021-03-01", "publication_year": 2021, "type": "review", "cited_by_count": 63, "authors": [ { "id": "https://openalex.org/A5059698414", "display_name": "Heshma Alruwaili" }, { "id": "https://openalex.org/A5088183734", "display_name": "Babak Dehestani" }, { "id": "https://openalex.org/A5010753663", "display_name": "Carel W. le Roux" } ] }, { "id": "https://openalex.org/W4288423816", "doi": "https://doi.org/10.3389/fcvm.2022.936651", "title": "Online searches for SGLT-2 inhibitors and GLP-1 receptor agonists correlate with prescription rates in the United States: An infodemiological study", "abstract": { "Several": [ 0 ], "clinical": [ 1 ], "trials": [ 2 ], "have": [ 3 ], "demonstrated": [ 4 ], "that": [ 5 ], "many": [ 6 ], "SGLT-2": [ 7 ], "inhibitors": [ 8 ], "(SGLT2i)": [ 9 ], "and": [ 10, 29, 44, 71, 95, 101, 110, 119, 122, 142, 159, 166, 170, 180, 187, 211, 248 ], "GLP-1": [ 11, 45, 111, 120 ], "receptor": [ 12 ], "agonists": [ 13 ], "(GLP-1": [ 14 ], "RA)": [ 15, 121 ], "can": [ 16 ], "reduce": [ 17 ], "the": [ 18, 51, 75, 128, 222 ], "risk": [ 19 ], "of": [ 20, 38, 53, 67, 81, 84, 130, 203, 225, 252 ], "cardiovascular": [ 21, 31 ], "events": [ 22 ], "in": [ 23, 239 ], "patients": [ 24 ], "with": [ 25, 200, 233 ], "Type": [ 26 ], "2": [ 27 ], "diabetes": [ 28 ], "atherosclerotic": [ 30 ], "disease.": [ 32 ], "Recent": [ 33 ], "reports": [ 34 ], "indicate": [ 35 ], "an": [ 36, 217 ], "underutilization": [ 37 ], "new": [ 39 ], "cardiometabolic": [ 40, 226, 253 ], "drugs,": [ 41 ], "including": [ 42 ], "SGLT2i": [ 43, 109, 165, 186 ], "RA.": [ 46, 112 ], "We": [ 47 ], "aimed": [ 48 ], "to": [ 49, 57, 220, 246 ], "evaluate": [ 50 ], "use": [ 52 ], "online": [ 54, 93, 151, 240 ], "search": [ 55, 69 ], "volumes": [ 56, 70 ], "reflect": [ 58, 247 ], "United": [ 59 ], "States": [ 60 ], "prescription": [ 61, 96, 250 ], "rates.": [ 62 ], "A": [ 63 ], "repeated": [ 64 ], "cross-sectional": [ 65 ], "analysis": [ 66 ], "Google": [ 68 ], "corresponding": [ 72 ], "data": [ 73, 91, 114, 132, 245 ], "from": [ 74 ], "IQVIA": [ 76 ], "National": [ 77 ], "Prescription": [ 78, 113, 172 ], "Audit": [ 79 ], "(NPA)": [ 80 ], "pharmacy": [ 82 ], "dispensing": [ 83 ], "newly": [ 85 ], "prescribed": [ 86 ], "drugs": [ 87, 116, 124, 199, 232 ], "was": [ 88 ], "performed.": [ 89 ], "Monthly": [ 90 ], "for": [ 92, 107, 115, 133, 140, 164, 185, 189, 198, 205, 231 ], "searches": [ 94, 152, 214, 241 ], "between": [ 97, 168 ], "January": [ 98 ], "1,": [ 99 ], "2016": [ 100, 169 ], "December": [ 102 ], "31,": [ 103 ], "2021": [ 104 ], "were": [ 105, 125, 138, 196, 229 ], "collected": [ 106 ], "selected": [ 108 ], "classes": [ 117 ], "(SGLT2i": [ 118 ], "individual": [ 123 ], "calculated": [ 126 ], "as": [ 127, 145, 147 ], "total": [ 129 ], "queried": [ 131 ], "branded": [ 134 ], "drug": [ 135 ], "names.": [ 136 ], "Trends": [ 137 ], "analyzed": [ 139 ], "visual": [ 141 ], "quantitative": [ 143 ], "correlation": [ 144 ], "well": [ 146 ], "predictive": [ 148 ], "patterns.": [ 149 ], "Overall,": [ 150 ], "increased": [ 153 ], "by": [ 154, 175 ], "157.6%": [ 155 ], "(95%": [ 156, 161, 177, 182 ], "CI:": [ 157, 162, 178, 183 ], "142.2\u2013173.1%)": [ 158 ], "295.2%": [ 160 ], "257.7\u2013332.6%)": [ 163 ], "GLP-1RA": [ 167, 188 ], "2021.": [ 171 ], "rates": [ 173 ], "raised": [ 174 ], "114.6%": [ 176 ], "110.8\u2013118.4%)": [ 179 ], "221.0%": [ 181 ], "212.1\u2013229.9%)": [ 184 ], "this": [ 190 ], "period.": [ 191 ], "Correlation": [ 192 ], "coefficients": [ 193 ], "(range": [ 194 ], "0.86\u20130.99)": [ 195 ], "strongest": [ 197, 230 ], "growing": [ 201 ], "number": [ 202 ], "prescriptions,": [ 204 ], "example": [ 206 ], "dapagliflozin,": [ 207 ], "empagliflozin,": [ 208 ], "ertugliflozin,": [ 209 ], "dulaglutide,": [ 210 ], "semaglutide.": [ 212 ], "Online": [ 213 ], "might": [ 215 ], "represent": [ 216 ], "additional": [ 218 ], "tool": [ 219 ], "monitor": [ 221 ], "utilization": [ 223 ], "trends": [ 224, 238, 251 ], "drugs.": [ 227, 254 ], "Associations": [ 228 ], "reported": [ 234 ], "cardioprotective": [ 235 ], "effect.": [ 236 ], "Thus,": [ 237 ], "complement": [ 242 ], "conventionally": [ 243 ], "acquired": [ 244 ], "forecast": [ 249 ] }, "publication_date": "2022-07-29", "publication_year": 2022, "type": "article", "cited_by_count": 23, "authors": [ { "id": "https://openalex.org/A5069052759", "display_name": "Omar Dzaye" }, { "id": "https://openalex.org/A5040781762", "display_name": "Philipp Berning" }, { "id": "https://openalex.org/A5001671716", "display_name": "Alexander C. Razavi" }, { "id": "https://openalex.org/A5043616933", "display_name": "Rishav Adhikari" }, { "id": "https://openalex.org/A5064873712", "display_name": "Kunal Jha" }, { "id": "https://openalex.org/A5101423613", "display_name": "Khurram Nasir" }, { "id": "https://openalex.org/A5057589919", "display_name": "John W. Ayers" }, { "id": "https://openalex.org/A5065926842", "display_name": "Martin B\u00f8dtker Mortensen" }, { "id": "https://openalex.org/A5008531984", "display_name": "Michael J. Blaha" } ] }, { "id": "https://openalex.org/W4214696772", "doi": "https://doi.org/10.3389/fmed.2022.793203", "title": "Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials", "abstract": { "Objective": [ 0 ], "To": [ 1, 465 ], "evaluate": [ 2 ], "the": [ 3, 59, 179, 207, 220, 236, 248, 292, 302, 319, 329, 341, 353, 366, 374, 386, 393, 406, 417, 423, 429, 435, 448, 467 ], "effects": [ 4, 60 ], "of": [ 5, 39, 61, 86, 97, 115, 164, 274, 368, 388, 437, 450 ], "vitamin": [ 6, 89, 184, 265, 362, 451 ], "E,": [ 7, 185, 452 ], "pioglitazone,": [ 8, 94, 186, 227, 263, 453 ], "sodium-glucose": [ 9 ], "cotransporter-2": [ 10 ], "(SGLT2)": [ 11 ], "inhibitors,": [ 12, 455 ], "and": [ 13, 37, 76, 80, 92, 103, 111, 113, 119, 154, 157, 162, 190, 212, 228, 240, 264, 284, 315, 345, 381, 384, 400, 439, 456, 485 ], "glucagon-like": [ 14 ], "peptide-1": [ 15 ], "(GLP-1)": [ 16 ], "receptor": [ 17, 99, 188, 458 ], "agonists": [ 18, 100, 459 ], "in": [ 19, 65, 129, 178, 205, 219, 234, 247, 259, 272, 290, 301, 317, 328, 339, 352, 364, 378, 397, 410, 421, 433, 460 ], "patients": [ 20, 66, 173, 462, 484 ], "with": [ 21, 67, 463, 478 ], "non-alcoholic": [ 22, 165 ], "fatty": [ 23 ], "liver": [ 24, 146, 150 ], "disease": [ 25 ], "(NAFLD).": [ 26 ], "Design": [ 27 ], "A": [ 28 ], "network": [ 29, 443 ], "meta-analysis.": [ 30 ], "Data": [ 31 ], "Sources": [ 32 ], "PubMed,": [ 33 ], "Embase,": [ 34 ], "Cochrane": [ 35 ], "Library,": [ 36 ], "Web": [ 38 ], "Science": [ 40 ], "databases": [ 41 ], "from": [ 42 ], "their": [ 43 ], "inception": [ 44 ], "until": [ 45 ], "September": [ 46 ], "1,": [ 47 ], "2021.": [ 48 ], "Eligibility": [ 49 ], "Criteria": [ 50 ], "for": [ 51, 176, 280, 447 ], "Selecting": [ 52 ], "Studies": [ 53 ], "Randomized": [ 54 ], "controlled": [ 55, 141 ], "trials": [ 56, 82, 170 ], "(RCTs)": [ 57 ], "comparing": [ 58 ], "four": [ 62, 105 ], "different": [ 63, 117 ], "drugs": [ 64 ], "NAFLD": [ 68 ], "were": [ 69, 83, 174, 195, 230, 286 ], "included.": [ 70, 84 ], "All": [ 71 ], "superiority,": [ 72 ], "non-inferiority,": [ 73 ], "phase": [ 74 ], "II": [ 75 ], "III,": [ 77 ], "non-blinded,": [ 78 ], "single-blinded,": [ 79 ], "double-blinded": [ 81 ], "Interventions": [ 85 ], "interest": [ 87 ], "included": [ 88, 127 ], "E": [ 90, 266, 363 ], "(\u03b1-tocopherol": [ 91 ], "\u03b4-tocotrienol),": [ 93 ], "three": [ 95 ], "kinds": [ 96 ], "GLP-1": [ 98, 187, 457 ], "(liraglutide,": [ 101 ], "semaglutide,": [ 102 ], "dulaglutide),": [ 104 ], "SGLT2": [ 106, 191, 454 ], "inhibitors": [ 107 ], "(dapagliflozin,": [ 108 ], "empagliflozin,": [ 109, 312 ], "ipragliflozin,": [ 110, 211 ], "tofogliflozin),": [ 112 ], "comparisons": [ 114 ], "these": [ 116, 479 ], "drugs,": [ 118, 470, 481 ], "placebos.": [ 120 ], "Main": [ 121 ], "Outcome": [ 122 ], "Measures": [ 123 ], "The": [ 124, 442 ], "outcome": [ 125 ], "measures": [ 126 ], "changes": [ 128 ], "non-invasive": [ 130 ], "tests": [ 131, 159 ], "[alanine": [ 132 ], "aminotransferase": [ 133, 136 ], "(ALT),": [ 134 ], "aspartate": [ 135 ], "(AST),": [ 137 ], "gamma-glutamyl": [ 138 ], "transferase": [ 139 ], "(GGT),": [ 140 ], "attenuation": [ 142 ], "parameter": [ 143 ], "(CAP),": [ 144 ], "enhanced": [ 145 ], "fibrosis": [ 147, 401 ], "(ELF)": [ 148 ], "score,": [ 149 ], "fat": [ 151 ], "content": [ 152 ], "(LFC),": [ 153 ], "keratin-18": [ 155 ], "(K-18)]": [ 156 ], "invasive": [ 158 ], "[fibrosis": [ 160 ], "score": [ 161 ], "resolution": [ 163, 273, 367, 387 ], "steatohepatitis": [ 166 ], "(NASH)].": [ 167 ], "Results": [ 168, 181 ], "Twenty-seven": [ 169 ], "including": [ 171 ], "3,416": [ 172 ], "eligible": [ 175 ], "inclusion": [ 177 ], "study.": [ 180 ], "refer": [ 182 ], "to": [ 183, 203, 232, 257, 288, 311, 337, 361, 474 ], "agonists,": [ 189 ], "inhibitors.": [ 192 ], "First,": [ 193 ], "placebos": [ 194 ], "used": [ 196 ], "as": [ 197 ], "a": [ 198, 215, 224, 243, 252, 268, 277, 297, 324, 348 ], "reference.": [ 199 ], "\u03b4-Tocotrienol": [ 200, 334 ], "was": [ 201, 255, 308, 335, 359 ], "superior": [ 202, 231, 256, 287, 310, 336, 360 ], "placebo": [ 204, 233, 258 ], "decreasing": [ 206, 235, 260, 291, 318, 340, 379, 398, 411, 422, 434 ], "GGT": [ 208, 330, 342, 424 ], "level.": [ 209, 238, 294, 321, 343, 425 ], "Semaglutide,": [ 210, 226 ], "pioglitazone": [ 213, 241, 285, 346 ], "induced": [ 214, 242, 267, 296, 323, 347 ], "significantly": [ 216, 244, 269, 298, 325, 349 ], "higher": [ 217, 245, 270, 299, 326, 350 ], "decrease": [ 218, 246, 300, 327, 351 ], "ALT": [ 221, 293, 303, 438 ], "level": [ 222, 250, 304, 331, 355 ], "than": [ 223, 251, 276, 305, 332, 356 ], "placebo.": [ 225, 253, 278 ], "dapagliflozin": [ 229, 414 ], "AST": [ 237, 320 ], "Tofogliflozin": [ 239, 344, 403 ], "K-18": [ 249, 354 ], "Liraglutide": [ 254 ], "CAP.": [ 261 ], "Liraglutide,": [ 262 ], "increase": [ 271 ], "NASH": [ 275 ], "As": [ 279 ], "pairwise": [ 281 ], "comparisons,": [ 282 ], "semaglutide": [ 283 ], "liraglutide": [ 289, 338, 371 ], "Semaglutide": [ 295, 307, 426 ], "dulaglutide.": [ 306, 357 ], "obviously": [ 309 ], "liraglutide,": [ 313 ], "dulaglutide,": [ 314 ], "tofogliflozin": [ 316 ], "Pioglitazone": [ 322, 358, 390 ], "ipragliflozin.": [ 333 ], "increasing": [ 365, 385 ], "NASH.": [ 369, 389 ], "Furthermore,": [ 370 ], "treatment": [ 372, 391, 404, 415, 427 ], "had": [ 373, 392, 405, 416, 428 ], "highest": [ 375, 394, 407, 418, 430 ], "SUCRA": [ 376, 395, 408, 419, 431 ], "ranking": [ 377, 396, 409, 420, 432 ], "CAP": [ 380 ], "ELF": [ 382 ], "scores": [ 383 ], "LFC": [ 399 ], "scores.": [ 402 ], "K-18,": [ 412 ], "while": [ 413 ], "levels": [ 436 ], "AST.": [ 440 ], "Conclusion": [ 441 ], "meta-analysis": [ 444 ], "provided": [ 445 ], "evidence": [ 446 ], "efficacy": [ 449 ], "treating": [ 461 ], "NAFLD.": [ 464 ], "find": [ 466 ], "best": [ 468 ], "guide-level": [ 469 ], "it": [ 471 ], "is": [ 472 ], "necessary": [ 473 ], "include": [ 475 ], "more": [ 476 ], "RCTs": [ 477 ], "off-label": [ 480 ], "so": [ 482 ], "that": [ 483 ], "clinicians": [ 486 ], "can": [ 487 ], "make": [ 488 ], "optimal": [ 489 ], "decisions": [ 490 ], "together.": [ 491 ], "Systematic": [ 492 ], "Review": [ 493 ], "Registration": [ 494 ], "https://www.crd.york.ac.uk/prospero": [ 495 ], ",": [ 496 ], "identifier:": [ 497 ], "CRD42021283129.": [ 498 ] }, "publication_date": "2022-02-25", "publication_year": 2022, "type": "review", "cited_by_count": 24, "authors": [ { "id": "https://openalex.org/A5102952000", "display_name": "Qian Luo" }, { "id": "https://openalex.org/A5032959348", "display_name": "Ruojun Wei" }, { "id": "https://openalex.org/A5080837668", "display_name": "Yuzi Cai" }, { "id": "https://openalex.org/A5010116678", "display_name": "Qihan Zhao" }, { "id": "https://openalex.org/A5087846423", "display_name": "Yuning Liu" }, { "id": "https://openalex.org/A5083412151", "display_name": "Wei Jing Liu" } ] }, { "id": "https://openalex.org/W2107949845", "doi": "https://doi.org/10.1016/s0140-6736(10)60590-9", "title": "Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial", "abstract": null, "publication_date": "2010-06-29", "publication_year": 2010, "type": "article", "cited_by_count": 602, "authors": [ { "id": "https://openalex.org/A5034096266", "display_name": "Richard M. Bergenstal" }, { "id": "https://openalex.org/A5040652845", "display_name": "Carol Wysham" }, { "id": "https://openalex.org/A5018272606", "display_name": "Leigh MacConell" }, { "id": "https://openalex.org/A5004842224", "display_name": "Jaret Malloy" }, { "id": "https://openalex.org/A5102775095", "display_name": "Brandon Walsh" }, { "id": "https://openalex.org/A5101819344", "display_name": "Ping Yan" }, { "id": "https://openalex.org/A5112080455", "display_name": "Ken Wilhelm" }, { "id": "https://openalex.org/A5069752010", "display_name": "Jim Malone" }, { "id": "https://openalex.org/A5103540035", "display_name": "Lisa E. Porter" } ] }, { "id": "https://openalex.org/W1992061662", "doi": "https://doi.org/10.4158/ep14290.or", "title": "Adding Rapid-Acting Insulin or Glp-1 Receptor Agonist to Basal Insulin: Outcomes in A Community Setting", "abstract": null, "publication_date": "2014-08-22", "publication_year": 2014, "type": "article", "cited_by_count": 19, "authors": [ { "id": "https://openalex.org/A5045292117", "display_name": "Mehul Dalal" }, { "id": "https://openalex.org/A5101549412", "display_name": "Lin Xie" }, { "id": "https://openalex.org/A5101839342", "display_name": "Onur Ba\u015fer" }, { "id": "https://openalex.org/A5080844321", "display_name": "Andr\u00e9s Digenio" } ] }, { "id": "https://openalex.org/W2789407137", "doi": "https://doi.org/10.1016/j.eplepsyres.2018.03.009", "title": "Post-treatment with the GLP-1 analogue liraglutide alleviate chronic inflammation and mitochondrial stress induced by Status epilepticus", "abstract": null, "publication_date": "2018-03-09", "publication_year": 2018, "type": "article", "cited_by_count": 46, "authors": [ { "id": "https://openalex.org/A5100769141", "display_name": "Ruifang Wang" }, { "id": "https://openalex.org/A5102764982", "display_name": "Guofang Xue" }, { "id": "https://openalex.org/A5082707086", "display_name": "Christian H\u00f6lscher" }, { "id": "https://openalex.org/A5074780172", "display_name": "Miao-Jing Tian" }, { "id": "https://openalex.org/A5112158837", "display_name": "Peng Feng" }, { "id": "https://openalex.org/A5001911438", "display_name": "Ji-Ying Zheng" }, { "id": "https://openalex.org/A5100365831", "display_name": "Dongfang Li" } ] }, { "id": "https://openalex.org/W2791143589", "doi": "https://doi.org/10.1111/dom.13237", "title": "Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post\u2010hoc analysis of the AWARD\u20102, \u20104 and \u20105 Trials", "abstract": { "Aims": [ 0 ], "Patients": [ 1 ], "with": [ 2, 83, 114 ], "a": [ 3 ], "type\u20102\u2010diabetes": [ 4 ], "(T2D)": [ 5 ], "phenotype": [ 6 ], "positive": [ 7 ], "for": [ 8, 34, 130 ], "glutamic": [ 9 ], "acid": [ 10 ], "decarboxylase": [ 11 ], "antibodies": [ 12 ], "(GADA)": [ 13 ], "represent": [ 14 ], "the": [ 15, 24, 52, 90, 170, 232 ], "majority": [ 16 ], "of": [ 17, 19, 23, 36, 54, 89, 112 ], "cases": [ 18 ], "latent": [ 20 ], "autoimmune": [ 21 ], "diabetes": [ 22 ], "adult": [ 25 ], "(LADA).": [ 26 ], "The": [ 27 ], "GLP\u20101": [ 28 ], "receptor": [ 29 ], "agonist": [ 30 ], "dulaglutide,": [ 31 ], "recently": [ 32 ], "introduced": [ 33 ], "treatment": [ 35, 113 ], "T2D,": [ 37 ], "has": [ 38 ], "yet": [ 39 ], "to": [ 40, 50, 234 ], "be": [ 41 ], "evaluated": [ 42 ], "in": [ 43, 60, 95, 107, 174, 178, 205, 240, 243 ], "LADA": [ 44, 62, 97, 244 ], "patients.": [ 45, 66, 245 ], "Our": [ 46 ], "primary": [ 47 ], "objective": [ 48 ], "was": [ 49, 71, 238 ], "evaluate": [ 51 ], "effect": [ 53 ], "dulaglutide": [ 55, 91, 115, 237 ], "on": [ 56 ], "glycaemic": [ 57 ], "control": [ 58 ], "(HbA1c)": [ 59 ], "GADA\u2010positive": [ 61, 188 ], "vs": [ 63, 211 ], "GADA\u2010negative": [ 64, 143, 179 ], "T2D": [ 65 ], "Methods": [ 67 ], "A": [ 68 ], "post\u2010hoc": [ 69 ], "analysis": [ 70 ], "performed": [ 72 ], "using": [ 73, 120 ], "data": [ 74, 230 ], "from": [ 75 ], "3": [ 76, 79, 224 ], "randomized": [ 77 ], "phase": [ 78 ], "trials": [ 80 ], "(AWARD\u20102,\u20104,\u20105;": [ 81 ], "patients": [ 82, 98, 152, 159, 189, 207, 213 ], "GADA": [ 84, 102, 131 ], "assessment)": [ 85 ], "which": [ 86 ], "were": [ 87, 99, 118, 142, 147, 167, 198, 221 ], "part": [ 88 ], "clinical": [ 92 ], "development": [ 93 ], "programme": [ 94 ], "T2D.": [ 96 ], "identified": [ 100 ], "by": [ 101 ], "\u22655": [ 103, 162 ], "IU/mL": [ 104 ], "(ELISA).": [ 105 ], "Changes": [ 106 ], "HbA1c": [ 108, 176, 196, 242 ], "during": [ 109 ], "12": [ 110, 194, 217 ], "months": [ 111 ], "or": [ 116 ], "comparator": [ 117 ], "analysed": [ 119 ], "mixed\u2010effect": [ 121 ], "model": [ 122 ], "repeated": [ 123 ], "measures.": [ 124 ], "Results": [ 125 ], "Of": [ 126 ], "2466": [ 127 ], "adults": [ 128 ], "tested": [ 129 ], "(dulaglutide,": [ 132 ], "1710;": [ 133 ], "glargine,": [ 134 ], "298;": [ 135 ], "sitagliptin,": [ 136 ], "294;": [ 137 ], "placebo,": [ 138 ], "164),": [ 139 ], "2278": [ 140 ], "(92.4%)": [ 141 ], "and": [ 144, 156, 161, 187, 225 ], "188": [ 145 ], "(7.6%)": [ 146 ], "GADA\u2010positive,": [ 148 ], "including": [ 149 ], "58": [ 150 ], "GADA\u2010high": [ 151, 212 ], "(>": [ 153 ], "200": [ 154 ], "IU/mL)": [ 155 ], "130": [ 157 ], "GADA\u2010low": [ 158, 206 ], "(\u2264200": [ 160 ], "IU/mL).": [ 163 ], "Overall,": [ 164 ], "baseline": [ 165 ], "parameters": [ 166 ], "comparable": [ 168, 175 ], "between": [ 169 ], "groups.": [ 171 ], "Dulaglutide": [ 172 ], "resulted": [ 173 ], "reductions": [ 177, 197 ], "(LS": [ 180 ], "mean": [ 181 ], "change": [ 182 ], "[95%CI],": [ 183 ], "\u22121.09%": [ 184 ], "[\u22121.15,": [ 185, 191 ], "\u22121.03])": [ 186 ], "(\u22120.94%": [ 190 ], "\u22120.72])": [ 192 ], "at": [ 193, 216, 223 ], "months.": [ 195, 218, 227 ], "numerically,": [ 199 ], "but": [ 200 ], "not": [ 201 ], "statistically,": [ 202 ], "significantly": [ 203 ], "larger": [ 204 ], "(\u22121.02%": [ 208 ], "[\u22121.26,": [ 209 ], "\u22120.78])": [ 210 ], "(\u22120.72%": [ 214 ], "[\u22121.21,\u22120.24])": [ 215 ], "Similar": [ 219 ], "outcomes": [ 220 ], "observed": [ 222 ], "6": [ 226 ], "Conclusions": [ 228 ], "These": [ 229 ], "are": [ 231 ], "first": [ 233 ], "indicate": [ 235 ], "that": [ 236 ], "effective": [ 239 ], "reducing": [ 241 ] }, "publication_date": "2018-01-29", "publication_year": 2018, "type": "article", "cited_by_count": 57, "authors": [ { "id": "https://openalex.org/A5087265840", "display_name": "Paolo Pozzilli" }, { "id": "https://openalex.org/A5039395009", "display_name": "Richard Leslie" }, { "id": "https://openalex.org/A5001347850", "display_name": "Anne L. Peters" }, { "id": "https://openalex.org/A5016239812", "display_name": "Raffaella Buzzetti" }, { "id": "https://openalex.org/A5102026047", "display_name": "Sudha S. Shankar" }, { "id": "https://openalex.org/A5024563374", "display_name": "Zvonko Mili\u010devi\u0107" }, { "id": "https://openalex.org/A5026505577", "display_name": "Imre P\u00e1v\u00f3" }, { "id": "https://openalex.org/A5078047344", "display_name": "J\u00e9r\u00e9mie Lebrec" }, { "id": "https://openalex.org/A5111702291", "display_name": "Sherry Martin" }, { "id": "https://openalex.org/A5074953985", "display_name": "Nanette C. Schloot" } ] }, { "id": "https://openalex.org/W2799426717", "doi": "https://doi.org/10.2147/dmso.s134960", "title": "Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data", "abstract": { "Dulaglutide": [ 0, 19, 76, 101 ], "is": [ 1, 150 ], "a": [ 2, 82, 95, 207 ], "once-weekly": [ 3 ], "glucagon-like": [ 4 ], "peptide-1": [ 5 ], "receptor": [ 6 ], "agonist,": [ 7 ], "which": [ 8 ], "has": [ 9, 20 ], "been": [ 10 ], "on": [ 11, 210 ], "the": [ 12, 15, 141, 189, 194, 200, 211, 215 ], "market": [ 13 ], "in": [ 14, 23, 128, 160, 214 ], "USA": [ 16 ], "since": [ 17 ], "2014.": [ 18 ], "performed": [ 21 ], "well": [ 22, 89 ], "head-to-head": [ 24 ], "studies": [ 25, 116 ], "against": [ 26 ], "metformin,": [ 27 ], "glargine,": [ 28 ], "and": [ 29, 43, 72, 153, 155 ], "sitagliptin,": [ 30 ], "where": [ 31 ], "its": [ 32 ], "A1c": [ 33, 58, 134 ], "lowering": [ 34, 59 ], "ranged": [ 35 ], "from": [ 36 ], "-0.78%": [ 37 ], "to": [ 38, 62, 81, 94, 104, 107, 111, 121 ], "-1.64%": [ 39 ], "over": [ 40, 64 ], "52-104": [ 41 ], "weeks,": [ 42, 74 ], "it": [ 44 ], "consistently": [ 45 ], "outperformed": [ 46, 77 ], "each": [ 47 ], "of": [ 48, 60, 84, 97, 143, 179, 191, 217 ], "these": [ 49 ], "agents.": [ 50 ], "As": [ 51 ], "an": [ 52 ], "add-on": [ 53 ], "therapy,": [ 54 ], "dulaglutide": [ 55, 123 ], "provided": [ 56 ], "additional": [ 57 ], "-1.4%": [ 61 ], "-1.44%": [ 63 ], "monotherapy": [ 65 ], "with": [ 66, 86, 99, 188 ], "glimepiride": [ 67 ], "or": [ 68, 186 ], "glargine": [ 69, 91 ], "at": [ 70, 124 ], "24": [ 71 ], "28": [ 73 ], "respectively.": [ 75 ], "exenatide": [ 78 ], "when": [ 79, 92, 109, 119 ], "added": [ 80, 93, 110 ], "regimen": [ 83, 96 ], "metformin": [ 85, 98 ], "pioglitazone": [ 87 ], "as": [ 88, 90, 164, 184 ], "glimepiride.": [ 100 ], "was": [ 102 ], "shown": [ 103, 175 ], "be": [ 105, 169 ], "non-inferior": [ 106 ], "liraglutide": [ 108 ], "metformin.": [ 112 ], "In": [ 113 ], "all": [ 114 ], "AWARD": [ 115 ], "other": [ 117 ], "than": [ 118 ], "compared": [ 120 ], "liraglutide,": [ 122 ], "full": [ 125 ], "strength": [ 126 ], "resulted": [ 127 ], "significantly": [ 129 ], "more": [ 130, 170 ], "patients": [ 131 ], "achieving": [ 132 ], "their": [ 133 ], "goal.": [ 135 ], "Recent": [ 136 ], "class-wide": [ 137 ], "meta-analyses": [ 138 ], "indicate": [ 139 ], "that": [ 140 ], "incidence": [ 142 ], "commonly": [ 144 ], "experienced": [ 145 ], "gastrointestinal": [ 146 ], "(GI)": [ 147 ], "side": [ 148, 181 ], "effects": [ 149, 182 ], "dose": [ 151 ], "dependent,": [ 152 ], "nausea": [ 154 ], "vomiting": [ 156 ], "are": [ 157 ], "less": [ 158 ], "common": [ 159 ], "longer-acting": [ 161 ], "agents": [ 162 ], "such": [ 163, 183 ], "dulaglutide,": [ 165 ], "but": [ 166 ], "diarrhea": [ 167 ], "may": [ 168 ], "common.": [ 171 ], "Pooled": [ 172 ], "data": [ 173 ], "have": [ 174, 206 ], "no": [ 176 ], "increased": [ 177 ], "risk": [ 178 ], "serious": [ 180 ], "pancreatitis": [ 185 ], "neoplasm": [ 187 ], "use": [ 190 ], "dulaglutide.": [ 192, 218 ], "Given": [ 193 ], "evidence": [ 195 ], "supporting": [ 196 ], "liraglutide's": [ 197 ], "cardiovascular": [ 198 ], "benefits,": [ 199 ], "highly": [ 201 ], "anticipated": [ 202 ], "REWIND": [ 203 ], "trial": [ 204 ], "will": [ 205 ], "significant": [ 208 ], "impact": [ 209 ], "future": [ 212 ], "place": [ 213 ], "therapy": [ 216 ] }, "publication_date": "2018-05-01", "publication_year": 2018, "type": "review", "cited_by_count": 23, "authors": [ { "id": "https://openalex.org/A5065691273", "display_name": "Anne Kugler" }, { "id": "https://openalex.org/A5053389266", "display_name": "Michael Thiman" } ] }, { "id": "https://openalex.org/W2509428713", "doi": "https://doi.org/10.1038/srep32714", "title": "The efficacy and safety of liraglutide added to metformin in patients with diabetes: a meta-analysis of randomized controlled trials", "abstract": { "Abstract": [ 0 ], "Liraglutide,": [ 1 ], "a": [ 2, 90, 152 ], "glucagon-like": [ 3 ], "peptide": [ 4 ], "(GLP-1)": [ 5 ], "receptor": [ 6 ], "agonist,": [ 7 ], "has": [ 8 ], "showed": [ 9 ], "favorable": [ 10 ], "effects": [ 11 ], "in": [ 12, 19, 44, 117, 122, 125, 134, 186 ], "the": [ 13, 32, 59, 78, 102, 146, 163, 183 ], "glycaemic": [ 14 ], "control": [ 15, 107 ], "and": [ 16, 34, 58, 83, 114, 129, 131, 136, 175 ], "weight": [ 17 ], "reduction": [ 18 ], "patients": [ 20, 45, 73, 178 ], "with": [ 21, 41, 46, 74, 106, 119, 141, 179 ], "type": [ 22 ], "2": [ 23 ], "diabetes": [ 24 ], "mellitus": [ 25 ], "(T2DM).": [ 26 ], "The": [ 27 ], "meta-analysis": [ 28, 161 ], "was": [ 29 ], "to": [ 30, 39, 169, 172, 195 ], "compare": [ 31 ], "efficacy": [ 33 ], "safety": [ 35 ], "of": [ 36, 56, 72, 81, 98, 148, 155, 165 ], "liraglutide": [ 37, 82, 116, 139, 166 ], "added": [ 38 ], "metformin": [ 40, 120, 142, 170 ], "other": [ 42 ], "treatments": [ 43 ], "T2DM.": [ 47, 180 ], "A": [ 48, 96 ], "systematic": [ 49 ], "literature": [ 50 ], "search": [ 51 ], "on": [ 52 ], "PubMed,": [ 53 ], "Embase,": [ 54 ], "Web": [ 55 ], "Science": [ 57 ], "Cochrane": [ 60 ], "library": [ 61 ], "databases": [ 62 ], "were": [ 63, 67, 87 ], "performed.": [ 64 ], "Eligible": [ 65 ], "studies": [ 66 ], "randomized": [ 68 ], "controlled": [ 69 ], "trials": [ 70 ], "(RCTs)": [ 71 ], "T2DM": [ 75 ], "who": [ 76 ], "received": [ 77 ], "combination": [ 79, 118 ], "treatment": [ 80 ], "metformin.": [ 84 ], "Pooled": [ 85 ], "estimates": [ 86 ], "performed": [ 88 ], "using": [ 89 ], "fixed-effects": [ 91 ], "model": [ 92 ], "or": [ 93 ], "random-effects": [ 94 ], "model.": [ 95 ], "total": [ 97 ], "nine": [ 99 ], "RCTs": [ 100, 192 ], "met": [ 101 ], "inclusion": [ 103 ], "criteria.": [ 104 ], "Compared": [ 105 ], "(placebo,": [ 108 ], "sitagliptin,": [ 109 ], "glimepiride,": [ 110 ], "dulaglutide,": [ 111 ], "insulin": [ 112 ], "glargine,": [ 113 ], "NPH),": [ 115 ], "resulted": [ 121 ], "significant": [ 123 ], "reductions": [ 124, 133 ], "HbA1c,": [ 126 ], "bodyweight,": [ 127 ], "FPG,": [ 128 ], "PPG,": [ 130 ], "similar": [ 132 ], "SBP,": [ 135 ], "DBP.": [ 137 ], "Moreover,": [ 138 ], "combined": [ 140 ], "did": [ 143 ], "not": [ 144 ], "increase": [ 145 ], "risk": [ 147 ], "hypoglycemia,": [ 149 ], "but": [ 150 ], "induced": [ 151 ], "higher": [ 153 ], "incidence": [ 154 ], "gastrointestinal": [ 156 ], "disorders.": [ 157 ], "In": [ 158 ], "conclusion,": [ 159 ], "this": [ 160, 187 ], "confirmed": [ 162 ], "use": [ 164 ], "as": [ 167 ], "add-on": [ 168 ], "appeared": [ 171 ], "be": [ 173 ], "effective": [ 174 ], "safe": [ 176 ], "for": [ 177 ], "However,": [ 181 ], "considering": [ 182 ], "potential": [ 184 ], "limitations": [ 185 ], "study,": [ 188 ], "more": [ 189 ], "large-scale,": [ 190 ], "well-conducted": [ 191 ], "are": [ 193 ], "needed": [ 194 ], "identify": [ 196 ], "our": [ 197 ], "findings.": [ 198 ] }, "publication_date": "2016-09-07", "publication_year": 2016, "type": "review", "cited_by_count": 24, "authors": [ { "id": "https://openalex.org/A5067044590", "display_name": "Jianqiu Gu" }, { "id": "https://openalex.org/A5101917367", "display_name": "Meng Xin" }, { "id": "https://openalex.org/A5056796466", "display_name": "Yan Guo" }, { "id": "https://openalex.org/A5091432366", "display_name": "Lei Wang" }, { "id": "https://openalex.org/A5101810368", "display_name": "Hongzhi Zheng" }, { "id": "https://openalex.org/A5100746006", "display_name": "Yixuan Liu" }, { "id": "https://openalex.org/A5103135302", "display_name": "Bingshu Wu" }, { "id": "https://openalex.org/A5018955027", "display_name": "Difei Wang" } ] }, { "id": "https://openalex.org/W2911729520", "doi": "https://doi.org/10.2337/dc18-1760", "title": "A Randomized Controlled Trial on the Safety and Efficacy of Exenatide Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes", "abstract": { "OBJECTIVE": [ 0 ], "This": [ 1 ], "multicenter,": [ 2 ], "open-label,": [ 3 ], "randomized": [ 4, 64 ], "trial": [ 5 ], "examined": [ 6 ], "the": [ 7, 178, 191, 271 ], "safety": [ 8 ], "and": [ 9, 44, 107, 122, 158, 164, 180, 246, 268, 277 ], "efficacy": [ 10 ], "of": [ 11, 35, 150, 230, 252, 273 ], "exenatide": [ 12, 66, 72, 104, 123, 133, 163, 179, 181, 207, 258 ], "alone": [ 13, 67, 134, 259 ], "or": [ 14, 54, 76, 187, 228, 260 ], "in": [ 15, 20, 87, 127, 146, 153, 177, 190, 216, 261 ], "combination": [ 16, 262 ], "with": [ 17, 24, 38, 50, 103, 162, 202, 263, 280 ], "basal": [ 18, 74, 106, 125, 144, 183, 242, 264 ], "insulin": [ 19, 55, 79, 265 ], "non\u2013critically": [ 21 ], "ill": [ 22 ], "patients": [ 23, 37, 101, 176, 204, 279 ], "type": [ 25 ], "2": [ 26 ], "diabetes": [ 27 ], "(T2D).": [ 28 ], "RESEARCH": [ 29 ], "DESIGN": [ 30 ], "AND": [ 31 ], "METHODS": [ 32 ], "A": [ 33 ], "total": [ 34, 58 ], "150": [ 36 ], "blood": [ 39 ], "glucose": [ 40 ], "(BG)": [ 41 ], "between": [ 42, 100, 156 ], "140": [ 43 ], "400": [ 45 ], "mg/dL,": [ 46, 118, 138 ], "treated": [ 47, 102 ], "at": [ 48, 56 ], "home": [ 49 ], "diet,": [ 51 ], "oral": [ 52 ], "agents,": [ 53 ], "a": [ 57, 77, 108, 147 ], "daily": [ 59, 89, 96, 129 ], "dose": [ 60 ], "&lt;0.5": [ 61 ], "units/kg,": [ 62 ], "were": [ 63, 213 ], "to": [ 65, 209 ], "(5": [ 68, 232 ], "\u03bcg": [ 69 ], "twice": [ 70 ], "daily),": [ 71 ], "plus": [ 73, 105, 124, 143, 182, 243 ], "insulin,": [ 75 ], "basal-bolus": [ 78, 109, 165, 192, 247 ], "regimen.": [ 80 ], "The": [ 81, 250 ], "primary": [ 82 ], "end": [ 83 ], "point": [ 84 ], "was": [ 85, 98 ], "difference": [ 86 ], "mean": [ 88 ], "BG": [ 90, 97, 130, 151 ], "concentration": [ 91 ], "among": [ 92, 241 ], "groups.": [ 93, 248 ], "RESULTS": [ 94 ], "Mean": [ 95 ], "similar": [ 99 ], "regimen": [ 110 ], "(154": [ 111 ], "\u00b1": [ 112, 116, 136 ], "39": [ 113 ], "vs.": [ 114, 167, 169, 195, 197, 221, 223, 233, 235 ], "166": [ 115 ], "40": [ 117 ], "P": [ 119, 139, 172, 199, 225, 238 ], "=": [ 120, 140, 173, 200, 226, 239 ], "0.31),": [ 121 ], "resulted": [ 126, 145 ], "lower": [ 128 ], "than": [ 131, 189 ], "did": [ 132 ], "(177": [ 135 ], "41": [ 137 ], "0.02).": [ 141 ], "Exenatide": [ 142 ], "higher": [ 148 ], "proportion": [ 149 ], "levels": [ 152 ], "target": [ 154 ], "range": [ 155 ], "70": [ 157 ], "180": [ 159 ], "mg/dL": [ 160, 219 ], "compared": [ 161 ], "(78%": [ 166 ], "62%": [ 168 ], "63%,": [ 170 ], "respectively,": [ 171 ], "0.023).": [ 174 ], "More": [ 175 ], "groups": [ 184 ], "experienced": [ 185 ], "nausea": [ 186 ], "vomiting": [ 188 ], "group": [ 193 ], "(10%": [ 194 ], "11%": [ 196 ], "2%,": [ 198 ], "0.17),": [ 201 ], "three": [ 203 ], "(6%)": [ 205 ], "discontinued": [ 206 ], "owing": [ 208 ], "adverse": [ 210 ], "events.": [ 211 ], "There": [ 212 ], "no": [ 214 ], "differences": [ 215 ], "hypoglycemia": [ 217 ], "&lt;54": [ 218 ], "(2%": [ 220 ], "0%": [ 222 ], "4%,": [ 224 ], "0.77)": [ 227 ], "length": [ 229 ], "stay": [ 231 ], "4": [ 234, 236 ], "days,": [ 237 ], "0.23)": [ 240 ], "exenatide,": [ 244, 245 ], "CONCLUSIONS": [ 249 ], "results": [ 251 ], "this": [ 253 ], "pilot": [ 254 ], "study": [ 255 ], "indicate": [ 256 ], "that": [ 257 ], "is": [ 266 ], "safe": [ 267 ], "effective": [ 269 ], "for": [ 270 ], "management": [ 272 ], "hospitalized": [ 274 ], "general": [ 275 ], "medical": [ 276 ], "surgical": [ 278 ], "T2D.": [ 281 ] }, "publication_date": "2019-01-24", "publication_year": 2019, "type": "article", "cited_by_count": 79, "authors": [ { "id": "https://openalex.org/A5051377580", "display_name": "Maya Fayfman" }, { "id": "https://openalex.org/A5023482091", "display_name": "Rodolfo J. Galindo" }, { "id": "https://openalex.org/A5081419421", "display_name": "Daniel J. Rubin" }, { "id": "https://openalex.org/A5019058743", "display_name": "Dara Mize" }, { "id": "https://openalex.org/A5082098754", "display_name": "Isabel Anzola" }, { "id": "https://openalex.org/A5022418786", "display_name": "Maria A. Urrutia" }, { "id": "https://openalex.org/A5104003748", "display_name": "Clementina Ramos" }, { "id": "https://openalex.org/A5063337323", "display_name": "Francisco J. Pasquel" }, { "id": "https://openalex.org/A5000051963", "display_name": "J. Sonya Haw" }, { "id": "https://openalex.org/A5060127002", "display_name": "Priyathama Vellanki" }, { "id": "https://openalex.org/A5025856837", "display_name": "Heqiong Wang" }, { "id": "https://openalex.org/A5057894062", "display_name": "Bonnie Albury" }, { "id": "https://openalex.org/A5006572120", "display_name": "Rita Weaver" }, { "id": "https://openalex.org/A5003966394", "display_name": "Saumeth Cardona" }, { "id": "https://openalex.org/A5061058170", "display_name": "Guillermo E. Umpierrez" } ] }, { "id": "https://openalex.org/W2154474547", "doi": "https://doi.org/10.1016/j.amjmed.2009.12.007", "title": "Incretin-Based Therapies: Review of Current Clinical Trial Data", "abstract": null, "publication_date": "2010-03-01", "publication_year": 2010, "type": "review", "cited_by_count": 112, "authors": [ { "id": "https://openalex.org/A5001347850", "display_name": "Anne L. Peters" } ] }, { "id": "https://openalex.org/W2917210623", "doi": "https://doi.org/10.3390/ijms20051050", "title": "Liraglutide and its Neuroprotective Properties\u2014Focus on Possible Biochemical Mechanisms in Alzheimer\u2019s Disease and Cerebral Ischemic Events", "abstract": { "Liraglutide": [ 0, 69, 139, 167, 185, 244 ], "is": [ 1, 251 ], "a": [ 2, 224 ], "GLP-1": [ 3 ], "analog": [ 4 ], "(glucagon": [ 5, 206 ], "like": [ 6, 207 ], "peptide-1)": [ 7 ], "used": [ 8 ], "primarily": [ 9 ], "in": [ 10, 55, 241, 281 ], "the": [ 11, 30, 43, 56, 64, 67, 71, 96, 134, 144, 151, 158, 170, 236 ], "treatment": [ 12 ], "of": [ 13, 32, 46, 73, 98, 105, 117, 136, 146, 153, 213, 238, 278 ], "diabetes": [ 14 ], "mellitus": [ 15 ], "type": [ 16 ], "2": [ 17 ], "(DM2)": [ 18 ], "and": [ 19, 61, 66, 90, 100, 103, 107, 132, 156, 165, 197, 210, 232, 293 ], "obesity.": [ 20 ], "The": [ 21, 49, 111, 262 ], "literature": [ 22 ], "starts": [ 23 ], "to": [ 24, 114, 142, 178, 204, 246 ], "suggest": [ 25 ], "that": [ 26, 253 ], "liraglutide": [ 27, 254, 279 ], "may": [ 28, 168, 186, 222, 255, 264 ], "reduce": [ 29, 143 ], "effects": [ 31, 45, 93, 263 ], "ischemic": [ 33 ], "stroke": [ 34 ], "by": [ 35, 76, 88, 94, 149, 234 ], "activating": [ 36 ], "anti-apoptotic": [ 37, 92 ], "pathways,": [ 38, 221 ], "as": [ 39, 41, 121, 190, 192 ], "well": [ 40, 191 ], "limiting": [ 42 ], "harmful": [ 44 ], "free": [ 47, 147 ], "radicals.": [ 48 ], "GLP-1R": [ 50, 205 ], "expression": [ 51, 97 ], "has": [ 52 ], "been": [ 53 ], "reported": [ 54 ], "cerebral": [ 57, 79, 294 ], "cortex,": [ 58 ], "especially": [ 59 ], "occipital": [ 60 ], "frontal": [ 62 ], "lobes,": [ 63 ], "hypothalamus,": [ 65 ], "thalamus.": [ 68 ], "reduced": [ 70, 133 ], "area": [ 72 ], "ischemia": [ 74 ], "caused": [ 75, 87 ], "MCAO": [ 77 ], "(middle": [ 78 ], "artery": [ 80 ], "occlusion),": [ 81 ], "limited": [ 82 ], "neurological": [ 83 ], "deficits,": [ 84 ], "decreased": [ 85 ], "hyperglycemia": [ 86 ], "stress,": [ 89 ], "presented": [ 91 ], "increasing": [ 95, 157, 235 ], "Bcl-2": [ 99 ], "Bcl-xl": [ 101 ], "proteins": [ 102 ], "reduction": [ 104 ], "Bax": [ 106 ], "Bad": [ 108 ], "protein": [ 109, 218 ], "expression.": [ 110 ], "pharmaceutical": [ 112 ], "managed": [ 113 ], "decrease": [ 115 ], "concentrations": [ 116 ], "proapoptotic": [ 118 ], "factors,": [ 119 ], "such": [ 120 ], "NF-\u03baB": [ 122 ], "(Nuclear": [ 123 ], "Factor-kappa": [ 124 ], "\u03b2),": [ 125 ], "ICAM-1": [ 126 ], "(Intercellular": [ 127 ], "Adhesion": [ 128 ], "Molecule": [ 129 ], "1),": [ 130 ], "caspase-3,": [ 131 ], "level": [ 135, 145, 152, 161 ], "TUNEL-positive": [ 137 ], "cells.": [ 138 ], "was": [ 140 ], "able": [ 141 ], "radicals": [ 148 ], "decreasing": [ 150 ], "malondialdehyde": [ 154 ], "(MDA),": [ 155 ], "superoxide": [ 159 ], "dismutase": [ 160 ], "(SOD),": [ 162 ], "glutathione": [ 163 ], "(GSH),": [ 164 ], "catalase.": [ 166 ], "affect": [ 169, 247 ], "neurovascular": [ 171 ], "unit": [ 172 ], "causing": [ 173 ], "its": [ 174, 194, 202 ], "remodeling,": [ 175 ], "which": [ 176 ], "seems": [ 177, 245 ], "be": [ 179, 265 ], "crucial": [ 180 ], "for": [ 181 ], "recovery": [ 182 ], "after": [ 183 ], "stroke.": [ 184 ], "stabilize": [ 187 ], "atherosclerotic": [ 188 ], "plaque,": [ 189 ], "counteract": [ 193 ], "early": [ 195 ], "formation": [ 196 ], "further": [ 198 ], "development.": [ 199 ], "Liraglutide,": [ 200 ], "through": [ 201 ], "binding": [ 203 ], "peptide-1": [ 208 ], "receptor)": [ 209 ], "consequent": [ 211 ], "activation": [ 212 ], "PI3K/MAPK": [ 214 ], "(Phosphoinositide": [ 215 ], "3-kinase/mitogen": [ 216 ], "associated": [ 217 ], "kinase)": [ 219 ], "dependent": [ 220 ], "have": [ 223, 256 ], "positive": [ 225 ], "impact": [ 226 ], "on": [ 227, 290 ], "A\u03b2": [ 228, 239 ], "(amyloid": [ 229 ], "beta)": [ 230 ], "trafficking": [ 231 ], "clearance": [ 233 ], "presence": [ 237 ], "transporters": [ 240 ], "cerebrospinal": [ 242 ], "fluid.": [ 243 ], "tau": [ 248 ], "pathology.": [ 249 ], "It": [ 250 ], "possible": [ 252 ], "some": [ 257 ], "stem": [ 258 ], "cell": [ 259 ], "stimulating": [ 260 ], "properties.": [ 261 ], "connected": [ 266, 283 ], "with": [ 267, 284, 287 ], "PKA": [ 268 ], "(phosphorylase": [ 269 ], "kinase": [ 270 ], "A)": [ 271 ], "activation.": [ 272 ], "This": [ 273 ], "paper": [ 274 ], "presents": [ 275 ], "potential": [ 276 ], "mechanisms": [ 277 ], "activity": [ 280 ], "conditions": [ 282 ], "neuronal": [ 285 ], "damage,": [ 286 ], "special": [ 288 ], "emphasis": [ 289 ], "Alzheimer\u2019s": [ 291 ], "disease": [ 292 ], "ischemia.": [ 295 ] }, "publication_date": "2019-02-28", "publication_year": 2019, "type": "review", "cited_by_count": 86, "authors": [ { "id": "https://openalex.org/A5015212397", "display_name": "Micha\u0142 Wici\u0144ski" }, { "id": "https://openalex.org/A5053854999", "display_name": "Maciej W. Socha" }, { "id": "https://openalex.org/A5060104907", "display_name": "Bartosz Malinowski" }, { "id": "https://openalex.org/A5013079288", "display_name": "Eryk W\u00f3dkiewicz" }, { "id": "https://openalex.org/A5049904806", "display_name": "Maciej Walczak" }, { "id": "https://openalex.org/A5088258209", "display_name": "Karol G\u00f3rski" }, { "id": "https://openalex.org/A5022804627", "display_name": "Maciej S\u0142upski" }, { "id": "https://openalex.org/A5001608182", "display_name": "Katarzyna Pawlak-Osi\u0144ska" } ] }, { "id": "https://openalex.org/W2047187313", "doi": "https://doi.org/10.1007/s12325-015-0199-z", "title": "Impact of Medication Adherence and Persistence on Clinical and Economic Outcomes in Patients with Type 2 Diabetes Treated with Liraglutide: A Retrospective Cohort Study", "abstract": { "Adherence": [ 0 ], "and": [ 1, 29 ], "persistence": [ 2 ], "to": [ 3 ], "liraglutide": [ 4 ], "are": [ 5 ], "associated": [ 6 ], "with": [ 7 ], "improved": [ 8 ], "A1C": [ 9 ], "outcomes.": [ 10 ], "Persistent": [ 11 ], "patients": [ 12 ], "showed": [ 13 ], "significantly": [ 14 ], "lower": [ 15 ], "medical": [ 16 ], "costs": [ 17, 24 ], "versus": [ 18 ], "those": [ 19 ], "discontinuing": [ 20 ], "liraglutide.": [ 21 ], "Total": [ 22 ], "healthcare": [ 23 ], "were": [ 25 ], "higher": [ 26, 34 ], "for": [ 27 ], "adherent": [ 28 ], "persistent": [ 30 ], "cohorts": [ 31 ], "driven": [ 32 ], "by": [ 33 ], "pharmacy": [ 35 ], "costs.": [ 36 ] }, "publication_date": "2015-04-01", "publication_year": 2015, "type": "article", "cited_by_count": 99, "authors": [ { "id": "https://openalex.org/A5078012819", "display_name": "Erin Buysman" }, { "id": "https://openalex.org/A5100453123", "display_name": "Fang Liu" }, { "id": "https://openalex.org/A5109998971", "display_name": "Mette Hammer" }, { "id": "https://openalex.org/A5020446741", "display_name": "J Langer" } ] }, { "id": "https://openalex.org/W4406586156", "doi": "https://doi.org/10.1001/jamahealthforum.2024.5015", "title": "Marketing and Safety Concerns for Compounded GLP-1 Receptor Agonists", "abstract": { "This": [ 0 ], "Viewpoint": [ 1 ], "discusses": [ 2 ], "supply": [ 3 ], "and": [ 4, 13 ], "demand": [ 5 ], "for": [ 6 ], "glucagon-like": [ 7 ], "peptide": [ 8 ], "1": [ 9 ], "(GLP-1)": [ 10 ], "receptor": [ 11 ], "agonists": [ 12 ], "concerns": [ 14 ], "with": [ 15 ], "using": [ 16 ], "compounded": [ 17 ], "drugs": [ 18 ], "to": [ 19 ], "fill": [ 20 ], "this": [ 21 ], "demand.": [ 22 ] }, "publication_date": "2025-01-17", "publication_year": 2025, "type": "article", "cited_by_count": 12, "authors": [ { "id": "https://openalex.org/A5077239022", "display_name": "T. Joseph Mattingly" }, { "id": "https://openalex.org/A5031911776", "display_name": "Rena M. Conti" } ] }, { "id": "https://openalex.org/W2030562170", "doi": "https://doi.org/10.2337/dc09-1961", "title": "Improvement of Postprandial Endothelial Function After a Single Dose of Exenatide in Individuals With Impaired Glucose Tolerance and Recent-Onset Type 2 Diabetes", "abstract": { "OBJECTIVE": [ 0 ], "Endothelial": [ 1, 83 ], "dysfunction": [ 2, 151 ], "is": [ 3 ], "frequently": [ 4 ], "present": [ 5 ], "in": [ 6, 57, 114, 133 ], "individuals": [ 7, 59 ], "with": [ 8, 60, 87, 103, 120 ], "insulin": [ 9 ], "resistance": [ 10 ], "or": [ 11, 21, 64, 75 ], "type": [ 12, 66 ], "2": [ 13, 67 ], "diabetes": [ 14, 68 ], "and": [ 15, 29, 92 ], "can": [ 16 ], "be": [ 17 ], "induced": [ 18 ], "by": [ 19 ], "high-fat": [ 20, 81, 154 ], "high-carbohydrate": [ 22 ], "meals.": [ 23 ], "Because": [ 24 ], "exenatide": [ 25, 74, 101 ], "reduces": [ 26 ], "postprandial": [ 27, 39, 52, 112, 122, 134, 143, 149 ], "glucose": [ 28, 62 ], "lipid": [ 30 ], "excursions,": [ 31 ], "we": [ 32 ], "hypothesized": [ 33 ], "that": [ 34 ], "it": [ 35 ], "may": [ 36 ], "also": [ 37 ], "improve": [ 38 ], "endothelial": [ 40, 53, 96, 115, 144, 150 ], "function.": [ 41, 145 ], "RESEARCH": [ 42 ], "DESIGN": [ 43 ], "AND": [ 44 ], "METHODS": [ 45 ], "In": [ 46, 108 ], "a": [ 47, 70, 80, 153 ], "double-blinded": [ 48 ], "randomized": [ 49 ], "crossover": [ 50 ], "design,": [ 51 ], "function": [ 54, 84, 97, 116 ], "was": [ 55, 85, 98, 117 ], "examined": [ 56 ], "28": [ 58 ], "impaired": [ 61 ], "tolerance": [ 63 ], "recent-onset": [ 65 ], "after": [ 69, 100, 152 ], "single": [ 71 ], "injection": [ 72 ], "of": [ 73, 124, 139 ], "placebo": [ 76, 104, 110 ], "given": [ 77 ], "just": [ 78 ], "before": [ 79 ], "meal.": [ 82, 155 ], "determined": [ 86 ], "peripheral": [ 88 ], "arterial": [ 89 ], "tonometry": [ 90 ], "pre-": [ 91 ], "postprandially.": [ 93 ], "RESULTS": [ 94 ], "Postprandial": [ 95 ], "higher": [ 99 ], "compared": [ 102 ], "(P": [ 105 ], "=": [ 106, 127, 130 ], "0.0002).": [ 107 ], "the": [ 109 ], "phase,": [ 111 ], "change": [ 113 ], "inversely": [ 118 ], "associated": [ 119 ], "mean": [ 121 ], "concentrations": [ 123, 136 ], "triglycerides": [ 125 ], "(r": [ 126 ], "\u22120.62,": [ 128 ], "P": [ 129 ], "0.0004).": [ 131 ], "Changes": [ 132 ], "triglyceride": [ 135 ], "explained": [ 137 ], "64%": [ 138 ], "exenatide's": [ 140 ], "effect": [ 141 ], "on": [ 142 ], "CONCLUSIONS": [ 146 ], "Exenatide": [ 147 ], "ameliorates": [ 148 ] }, "publication_date": "2010-03-03", "publication_year": 2010, "type": "article", "cited_by_count": 125, "authors": [ { "id": "https://openalex.org/A5109148559", "display_name": "Juraj Ko\u0161ka" }, { "id": "https://openalex.org/A5034236019", "display_name": "Eric A. Schwartz" }, { "id": "https://openalex.org/A5009910145", "display_name": "Michael P. Mullin" }, { "id": "https://openalex.org/A5003255105", "display_name": "Dawn C. Schwenke" }, { "id": "https://openalex.org/A5007571294", "display_name": "Peter D. Reaven" } ] }, { "id": "https://openalex.org/W154275555", "doi": null, "title": "Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.", "abstract": { "Dulaglutide": [ 0, 25 ], "(LY-2189265)": [ 1 ], "is": [ 2 ], "a": [ 3, 66, 107 ], "novel,": [ 4 ], "long-acting": [ 5 ], "glucagon-like": [ 6 ], "peptide": [ 7 ], "1": [ 8 ], "(GLP-1)": [ 9 ], "analog": [ 10 ], "being": [ 11 ], "developed": [ 12 ], "by": [ 13, 45, 197 ], "Eli": [ 14 ], "Lilly": [ 15 ], "for": [ 16, 80, 169 ], "the": [ 17, 40, 138, 172, 189 ], "treatment": [ 18, 191 ], "of": [ 19, 27, 35, 70, 114, 140, 161, 171 ], "type": [ 20 ], "2": [ 21 ], "diabetes": [ 22 ], "mellitus": [ 23 ], "(T2DM).": [ 24 ], "consists": [ 26 ], "GLP-1(7-37)": [ 28 ], "covalently": [ 29 ], "linked": [ 30 ], "to": [ 31, 72, 116, 151, 185 ], "an": [ 32, 77, 93 ], "Fc": [ 33 ], "fragment": [ 34 ], "human": [ 36 ], "IgG4,": [ 37 ], "thereby": [ 38 ], "protecting": [ 39 ], "GLP-1": [ 41, 187 ], "moiety": [ 42 ], "from": [ 43 ], "inactivation": [ 44 ], "dipeptidyl": [ 46 ], "peptidase": [ 47 ], "4.": [ 48 ], "In": [ 49 ], "vitro": [ 50 ], "and": [ 51, 91, 98, 154, 177 ], "in": [ 52, 68, 110 ], "vivo": [ 53 ], "studies": [ 54, 64 ], "on": [ 55, 137, 175 ], "T2DM": [ 56 ], "models": [ 57 ], "demonstrated": [ 58, 65, 106 ], "glucose-dependent": [ 59 ], "insulin": [ 60, 97 ], "secretion": [ 61 ], "stimulation.": [ 62 ], "Pharmacokinetic": [ 63 ], "t1/2": [ 67 ], "humans": [ 69 ], "up": [ 71, 115 ], "90": [ 73 ], "h,": [ 74 ], "making": [ 75 ], "dulaglutide": [ 76, 87, 125, 181 ], "ideal": [ 78 ], "candidate": [ 79 ], "once-weekly": [ 81, 190 ], "dosing.": [ 82 ], "Clinical": [ 83 ], "trials": [ 84, 105, 166 ], "suggest": [ 85 ], "that": [ 86 ], "reduces": [ 88 ], "plasma": [ 89 ], "glucose,": [ 90 ], "has": [ 92 ], "insulinotropic": [ 94 ], "effect": [ 95 ], "increasing": [ 96 ], "C-peptide": [ 99 ], "levels.": [ 100 ], "Two": [ 101 ], "phase": [ 102, 163 ], "II": [ 103 ], "clinical": [ 104, 165 ], "dose-dependent": [ 108 ], "reduction": [ 109 ], "glycated": [ 111 ], "hemoglobin": [ 112 ], "(HbA1c)": [ 113 ], "1.52%": [ 117 ], "compared": [ 118 ], "with": [ 119, 124, 199 ], "placebo.": [ 120 ], "Side": [ 121 ], "effects": [ 122, 174 ], "associated": [ 123 ], "administration": [ 126 ], "were": [ 127 ], "mainly": [ 128 ], "gastrointestinal.": [ 129 ], "To": [ 130 ], "date,": [ 131 ], "there": [ 132 ], "have": [ 133 ], "been": [ 134 ], "no": [ 135 ], "reports": [ 136 ], "formation": [ 139 ], "antibodies": [ 141 ], "against": [ 142 ], "dulaglutide,": [ 143 ], "but,": [ 144 ], "clearly,": [ 145 ], "long-term": [ 146 ], "data": [ 147 ], "will": [ 148, 192 ], "be": [ 149, 195 ], "needed": [ 150 ], "asses": [ 152 ], "this": [ 153 ], "other": [ 155, 186 ], "possible": [ 156 ], "side": [ 157 ], "effects.": [ 158 ], "The": [ 159 ], "results": [ 160 ], "several": [ 162 ], "III": [ 164 ], "are": [ 167 ], "awaited": [ 168 ], "clarification": [ 170 ], "expected": [ 173 ], "HbA1c": [ 176 ], "body": [ 178 ], "weight.": [ 179 ], "If": [ 180 ], "possesses": [ 182 ], "similar": [ 183 ], "efficacy": [ 184 ], "analogs,": [ 188 ], "most": [ 193 ], "likely": [ 194 ], "welcomed": [ 196 ], "patients": [ 198 ], "T2DM.": [ 200 ] }, "publication_date": "2010-12-01", "publication_year": 2010, "type": "article", "cited_by_count": 90, "authors": [ { "id": "https://openalex.org/A5011746115", "display_name": "Espen Jimenez\u2010Solem" }, { "id": "https://openalex.org/A5056077844", "display_name": "Mette H Rasmussen" }, { "id": "https://openalex.org/A5051382562", "display_name": "Mikkel Christensen" }, { "id": "https://openalex.org/A5079352451", "display_name": "Filip K. Knop" } ] }, { "id": "https://openalex.org/W2432078508", "doi": "https://doi.org/10.1016/j.ijcard.2016.06.028", "title": "Exenatide in obese or overweight patients without diabetes: A systematic review and meta-analyses of randomized controlled trials", "abstract": null, "publication_date": "2016-06-16", "publication_year": 2016, "type": "review", "cited_by_count": 28, "authors": [ { "id": "https://openalex.org/A5112524083", "display_name": "Na Su" }, { "id": "https://openalex.org/A5100658595", "display_name": "Yun Li" }, { "id": "https://openalex.org/A5089420346", "display_name": "Ting Xu" }, { "id": "https://openalex.org/A5100435314", "display_name": "Ling Li" }, { "id": "https://openalex.org/A5110810200", "display_name": "Joey Sum-Wing Kwong" }, { "id": "https://openalex.org/A5101819613", "display_name": "Heyue Du" }, { "id": "https://openalex.org/A5056287734", "display_name": "Kaiun Ren" }, { "id": "https://openalex.org/A5101812767", "display_name": "Qianrui Li" }, { "id": "https://openalex.org/A5011866398", "display_name": "Jianshu Li" }, { "id": "https://openalex.org/A5067326635", "display_name": "Xin Sun" }, { "id": "https://openalex.org/A5091607881", "display_name": "Sheyu Li" }, { "id": "https://openalex.org/A5085639572", "display_name": "Haoming Tian" } ] }, { "id": "https://openalex.org/W2506233247", "doi": "https://doi.org/10.1080/17446651.2016.1220295", "title": "Liraglutide, GLP-1 receptor agonist, for chronic weight loss", "abstract": { "Since": [ 0 ], "1990,": [ 1 ], "the": [ 2, 11, 15, 31, 46, 89, 116 ], "prevalence": [ 3 ], "of": [ 4, 33, 52 ], "obesity": [ 5, 125 ], "has": [ 6, 139, 158 ], "been": [ 7, 140 ], "steadily": [ 8 ], "increasing": [ 9 ], "in": [ 10, 30, 88, 103, 150, 160, 162, 172 ], "United": [ 12 ], "States.": [ 13 ], "Over": [ 14 ], "past": [ 16 ], "four": [ 17 ], "years,": [ 18 ], "new": [ 19 ], "medications": [ 20 ], "have": [ 21 ], "become": [ 22 ], "approved": [ 23 ], "and": [ 24, 49, 83, 91, 101, 132, 166, 170, 177, 181 ], "available,": [ 25 ], "allowing": [ 26 ], "for": [ 27, 124 ], "more": [ 28 ], "options": [ 29 ], "management": [ 32 ], "chronic": [ 34 ], "weight": [ 35, 97, 144 ], "loss": [ 36, 145 ], "among": [ 37, 54, 175 ], "overweight": [ 38, 55, 176 ], "or": [ 39, 56, 60, 148 ], "obese": [ 40, 57, 178 ], "patients.": [ 41 ], "This": [ 42 ], "review": [ 43 ], "article": [ 44 ], "summarizes": [ 45 ], "efficacy,": [ 47 ], "safety,": [ 48 ], "clinical": [ 50, 86 ], "attributes": [ 51 ], "liraglutide": [ 53, 114, 157 ], "patients": [ 58, 151, 179 ], "with": [ 59, 92, 130, 142, 180 ], "without": [ 61, 152, 182 ], "comorbidities.": [ 62 ], "Areas": [ 63 ], "covered:": [ 64 ], "A": [ 65 ], "MEDLINE": [ 66 ], "search,": [ 67 ], "from": [ 68 ], "1970": [ 69 ], "to": [ 70, 96 ], "June": [ 71 ], "2016,": [ 72 ], "was": [ 73 ], "conducted": [ 74 ], "using": [ 75 ], "key": [ 76 ], "terms-glucagon-like": [ 77 ], "peptide-1": [ 78, 119 ], "receptor": [ 79, 121 ], "agonist,": [ 80 ], "liraglutide,": [ 81 ], "overweight,": [ 82 ], "obesity.": [ 84 ], "Published": [ 85 ], "trials,": [ 87 ], "English-language": [ 90 ], "primary": [ 93 ], "endpoints": [ 94 ], "related": [ 95 ], "loss,": [ 98 ], "were": [ 99 ], "reviewed": [ 100 ], "critiqued": [ 102 ], "this": [ 104 ], "article.": [ 105 ], "Expert": [ 106 ], "commentary:": [ 107 ], "Available": [ 108 ], "as": [ 109, 127 ], "a": [ 110 ], "subcutaneous": [ 111 ], "daily": [ 112, 138 ], "injection,": [ 113 ], "is": [ 115 ], "first": [ 117 ], "glucagon-like": [ 118 ], "(GLP-1)": [ 120 ], "agonist": [ 122 ], "indicated": [ 123 ], "management,": [ 126 ], "adjunct": [ 128 ], "therapy": [ 129 ], "lifestyle": [ 131 ], "behavioral": [ 133 ], "modifications.": [ 134 ], "Liraglutide": [ 135 ], "3": [ 136 ], "mg": [ 137 ], "associated": [ 141 ], "greater": [ 143 ], "than": [ 146 ], "placebo": [ 147 ], "orlistat": [ 149 ], "type": [ 153, 183 ], "2": [ 154, 184 ], "diabetes.": [ 155, 185 ], "Additionally,": [ 156 ], "resulted": [ 159 ], "reductions": [ 161 ], "waist": [ 163 ], "circumference,": [ 164 ], "systolic": [ 165 ], "diastolic": [ 167 ], "blood": [ 168 ], "pressure,": [ 169 ], "improvements": [ 171 ], "lipid": [ 173 ], "panel": [ 174 ] }, "publication_date": "2016-08-04", "publication_year": 2016, "type": "article", "cited_by_count": 7, "authors": [ { "id": "https://openalex.org/A5064625522", "display_name": "Katherine Moore" }, { "id": "https://openalex.org/A5084697005", "display_name": "Kayce M. Shealy" }, { "id": "https://openalex.org/A5029137344", "display_name": "Jennifer N. Clements" } ] }, { "id": "https://openalex.org/W3175962993", "doi": "https://doi.org/10.3389/fendo.2021.645507", "title": "Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide", "abstract": { "Early": [ 0 ], "and": [ 1, 29, 39, 53, 75, 101, 117, 144, 158, 163, 246, 257 ], "effective": [ 2, 48 ], "glycemic": [ 3, 49 ], "control": [ 4 ], "can": [ 5 ], "prevent": [ 6 ], "or": [ 7, 130 ], "delay": [ 8 ], "the": [ 9, 42, 88, 169, 185, 228, 248, 267 ], "complications": [ 10 ], "associated": [ 11 ], "with": [ 12, 105, 127, 147, 152, 190, 216, 237 ], "type": [ 13 ], "2": [ 14 ], "diabetes": [ 15 ], "(T2D).": [ 16 ], "The": [ 17, 66, 133, 224 ], "benefits": [ 18, 110, 268 ], "of": [ 19, 57, 90, 166, 187, 196, 231, 252, 269 ], "glucagon-like": [ 20 ], "peptide-1": [ 21 ], "receptor": [ 22 ], "agonists": [ 23 ], "(GLP-1RAs)": [ 24 ], "are": [ 25, 60, 209 ], "becoming": [ 26 ], "increasingly": [ 27 ], "recognized": [ 28 ], "they": [ 30 ], "now": [ 31 ], "feature": [ 32 ], "prominently": [ 33 ], "in": [ 34, 63, 76, 97, 111, 122, 168 ], "international": [ 35 ], "T2D": [ 36, 91, 170, 250 ], "treatment": [ 37, 89, 171 ], "recommendations": [ 38 ], "guidelines": [ 40 ], "across": [ 41 ], "disease": [ 43 ], "continuum.": [ 44 ], "However,": [ 45 ], "despite": [ 46 ], "providing": [ 47 ], "control,": [ 50 ], "weight": [ 51, 103 ], "loss,": [ 52 ], "a": [ 54, 77, 119, 137, 153 ], "low": [ 55 ], "risk": [ 56 ], "hypoglycemia,": [ 58 ], "GLP-1RAs": [ 59, 167 ], "currently": [ 61 ], "underutilized": [ 62 ], "clinical": [ 64, 229 ], "practice.": [ 65 ], "long-acting": [ 67 ], "GLP-1RA,": [ 68 ], "semaglutide,": [ 69 ], "is": [ 70, 83, 198, 233 ], "available": [ 71 ], "for": [ 72, 87, 150, 155, 200 ], "once-weekly": [ 73 ], "injection": [ 74 ], "new": [ 78 ], "once-daily": [ 79 ], "oral": [ 80, 134, 156, 217 ], "formulation.": [ 81, 188 ], "Semaglutide": [ 82 ], "an": [ 84, 179 ], "advantageous": [ 85 ], "choice": [ 86, 186 ], "since": [ 92 ], "it": [ 93 ], "has": [ 94, 108, 118 ], "greater": [ 95 ], "efficacy": [ 96 ], "reducing": [ 98, 112 ], "glycated": [ 99 ], "hemoglobin": [ 100 ], "body": [ 102 ], "compared": [ 104, 146 ], "other": [ 106, 274 ], "GLP-1RAs,": [ 107, 192 ], "demonstrated": [ 109 ], "major": [ 113 ], "adverse": [ 114, 206 ], "cardiovascular": [ 115, 244 ], "events,": [ 116 ], "favorable": [ 120 ], "profile": [ 121 ], "special": [ 123 ], "populations": [ 124 ], "(e.g.,": [ 125 ], "patients": [ 126, 151 ], "hepatic": [ 128 ], "impairment": [ 129 ], "renal": [ 131 ], "impairment).": [ 132 ], "formulation": [ 135 ], "represents": [ 136 ], "useful": [ 138 ], "option": [ 139 ], "to": [ 140, 161, 203, 214, 219, 272 ], "help": [ 141 ], "improve": [ 142 ], "acceptance": [ 143 ], "adherence": [ 145 ], "injectable": [ 148 ], "formulations": [ 149, 202 ], "preference": [ 154 ], "therapy,": [ 157 ], "may": [ 159, 183 ], "lead": [ 160 ], "earlier": [ 162 ], "broader": [ 164 ], "use": [ 165, 230 ], "trajectory.": [ 172 ], "Oral": [ 173 ], "semaglutide": [ 174, 197, 218, 232, 270 ], "should": [ 175 ], "be": [ 176 ], "taken": [ 177 ], "on": [ 178, 241, 247 ], "empty": [ 180 ], "stomach,": [ 181 ], "which": [ 182 ], "influence": [ 184 ], "As": [ 189 ], "most": [ 191 ], "initial": [ 193 ], "dose": [ 194, 212 ], "escalation": [ 195 ], "required": [ 199 ], "both": [ 201 ], "mitigate": [ 204 ], "gastrointestinal": [ 205 ], "events.": [ 207 ], "There": [ 208 ], "also": [ 210 ], "specific": [ 211 ], "instructions": [ 213 ], "follow": [ 215 ], "ensure": [ 220 ], "sufficient": [ 221 ], "gastric": [ 222 ], "absorption.": [ 223 ], "evidence": [ 225 ], "base": [ 226 ], "surrounding": [ 227 ], "being": [ 234 ], "further": [ 235, 263 ], "expanded": [ 236 ], "trials": [ 238 ], "investigating": [ 239 ], "effects": [ 240 ], "diabetic": [ 242 ], "retinopathy,": [ 243 ], "outcomes,": [ 245 ], "common": [ 249 ], "comorbidities": [ 251 ], "obesity,": [ 253 ], "chronic": [ 254 ], "kidney": [ 255 ], "disease,": [ 256 ], "non-alcoholic": [ 258 ], "steatohepatitis.": [ 259 ], "These": [ 260 ], "will": [ 261 ], "provide": [ 262 ], "information": [ 264 ], "about": [ 265 ], "whether": [ 266 ], "extend": [ 271 ], "these": [ 273 ], "indications.": [ 275 ] }, "publication_date": "2021-06-29", "publication_year": 2021, "type": "review", "cited_by_count": 55, "authors": [ { "id": "https://openalex.org/A5031742996", "display_name": "Baptist Gallwitz" }, { "id": "https://openalex.org/A5064872622", "display_name": "Francesco Giorgino" } ] }, { "id": "https://openalex.org/W3082464276", "doi": "https://doi.org/10.1093/cvr/cvaa256", "title": "The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction", "abstract": { "Abstract": [ 0 ], "Aims": [ 1 ], "Heart": [ 2 ], "failure": [ 3 ], "with": [ 4, 23, 178, 194, 199, 212, 222 ], "preserved": [ 5, 195 ], "ejection": [ 6 ], "fraction": [ 7 ], "(HFpEF)": [ 8 ], "is": [ 9, 41 ], "a": [ 10, 19, 98, 134, 166, 256, 266, 290 ], "multifactorial": [ 11, 99 ], "disease": [ 12, 271 ], "that": [ 13, 51, 103, 259, 283 ], "constitutes": [ 14 ], "several": [ 15 ], "distinct": [ 16 ], "phenotypes,": [ 17 ], "including": [ 18, 170, 189 ], "common": [ 20 ], "cardiometabolic": [ 21, 91, 107, 167, 216, 286 ], "phenotype": [ 22 ], "obesity": [ 24 ], "and": [ 25, 36, 67, 82, 110, 117, 123, 175, 192, 207, 218, 229, 237, 273 ], "type": [ 26 ], "2": [ 27, 70 ], "diabetes": [ 28 ], "mellitus.": [ 29 ], "Treatment": [ 30, 211 ], "options": [ 31 ], "for": [ 32, 142, 154, 294 ], "HFpEF": [ 33, 49, 92, 100, 108, 168, 187, 251, 263 ], "are": [ 34 ], "limited,": [ 35 ], "development": [ 37, 275 ], "of": [ 38, 46, 55, 89, 231, 276, 285, 297 ], "novel": [ 39, 267, 291 ], "therapeutics": [ 40 ], "hindered": [ 42 ], "by": [ 43 ], "the": [ 44, 53, 87, 90, 106, 112, 118, 215, 250, 261, 274, 295 ], "paucity": [ 45 ], "suitable": [ 47 ], "preclinical": [ 48 ], "models": [ 50 ], "recapitulate": [ 52 ], "complexity": [ 54 ], "human": [ 56, 262 ], "HFpEF.": [ 57, 298 ], "Metabolic": [ 58 ], "drugs,": [ 59 ], "like": [ 60 ], "glucagon-like": [ 61 ], "peptide": [ 62, 235 ], "receptor": [ 63 ], "agonist": [ 64 ], "(GLP-1": [ 65 ], "RA)": [ 66 ], "sodium-glucose": [ 68 ], "co-transporter": [ 69 ], "inhibitors": [ 71 ], "(SGLT2i),": [ 72 ], "have": [ 73, 84 ], "emerged": [ 74 ], "as": [ 75 ], "promising": [ 76 ], "drugs": [ 77 ], "to": [ 78, 96, 269 ], "restore": [ 79 ], "metabolic": [ 80, 176 ], "perturbations": [ 81 ], "may": [ 83, 288 ], "value": [ 85 ], "in": [ 86, 165, 184 ], "treatment": [ 88, 241, 296 ], "phenotype.": [ 93, 252 ], "We": [ 94, 254, 280 ], "aimed": [ 95 ], "develop": [ 97 ], "mouse": [ 101, 257 ], "model": [ 102, 258 ], "closely": [ 104 ], "resembles": [ 105 ], "phenotype,": [ 109, 169 ], "evaluated": [ 111 ], "GLP-1": [ 113 ], "RA": [ 114 ], "liraglutide": [ 115 ], "(Lira)": [ 116 ], "SGLT2i": [ 119 ], "dapagliflozin": [ 120 ], "(Dapa).": [ 121 ], "Methods": [ 122 ], "results": [ 124 ], "Aged": [ 125 ], "(18\u201322": [ 126 ], "months": [ 127 ], "old)": [ 128 ], "female": [ 129 ], "C57BL/6J": [ 130 ], "mice": [ 131 ], "were": [ 132 ], "fed": [ 133 ], "standardized": [ 135 ], "chow": [ 136 ], "(CTRL)": [ 137 ], "or": [ 138 ], "high-fat": [ 139 ], "diet": [ 140 ], "(HFD)": [ 141 ], "12": [ 143 ], "weeks.": [ 144 ], "After": [ 145 ], "8": [ 146 ], "weeks": [ 147, 156 ], "HFD,": [ 148 ], "angiotensin": [ 149 ], "II": [ 150 ], "(ANGII),": [ 151 ], "was": [ 152 ], "administered": [ 153 ], "4": [ 155 ], "via": [ 157 ], "osmotic": [ 158 ], "mini": [ 159 ], "pumps.": [ 160 ], "HFD": [ 161 ], "+": [ 162 ], "ANGII": [ 163 ], "resulted": [ 164, 183 ], "obesity,": [ 171 ], "impaired": [ 172, 200 ], "glucose": [ 173, 243 ], "handling,": [ 174, 244 ], "dysregulation": [ 177, 217, 287 ], "inflammation.": [ 179 ], "The": [ 180 ], "multiple": [ 181 ], "hit": [ 182 ], "typical": [ 185 ], "clinical": [ 186 ], "features,": [ 188 ], "cardiac": [ 190, 220, 224 ], "hypertrophy": [ 191 ], "fibrosis": [ 193 ], "fractional": [ 196 ], "shortening": [ 197 ], "but": [ 198, 245 ], "myocardial": [ 201, 227 ], "deformation,": [ 202 ], "atrial": [ 203, 232 ], "enlargement,": [ 204 ], "lung": [ 205, 238 ], "congestion,": [ 206 ], "elevated": [ 208 ], "blood": [ 209 ], "pressures.": [ 210 ], "Lira": [ 213 ], "attenuated": [ 214 ], "improved": [ 219, 242 ], "function,": [ 221 ], "reduced": [ 223 ], "hypertrophy,": [ 225 ], "less": [ 226 ], "fibrosis,": [ 228 ], "attenuation": [ 230, 284 ], "weight,": [ 233 ], "natriuretic": [ 234 ], "levels,": [ 236 ], "congestion.": [ 239 ], "Dapa": [ 240 ], "had": [ 246 ], "mild": [ 247 ], "effects": [ 248 ], "on": [ 249 ], "Conclusions": [ 253 ], "developed": [ 255 ], "recapitulates": [ 260 ], "disease,": [ 264 ], "providing": [ 265 ], "opportunity": [ 268 ], "study": [ 270 ], "pathogenesis": [ 272 ], "enhanced": [ 277 ], "therapeutic": [ 278, 292 ], "approaches.": [ 279 ], "furthermore": [ 281 ], "show": [ 282 ], "represent": [ 289 ], "target": [ 293 ] }, "publication_date": "2020-08-25", "publication_year": 2020, "type": "article", "cited_by_count": 196, "authors": [ { "id": "https://openalex.org/A5001646889", "display_name": "Coenraad Withaar" }, { "id": "https://openalex.org/A5033838879", "display_name": "Laura M G Meems" }, { "id": "https://openalex.org/A5049192621", "display_name": "George Markousis\u2010Mavrogenis" }, { "id": "https://openalex.org/A5029996537", "display_name": "Cornelis J. Boogerd" }, { "id": "https://openalex.org/A5065012134", "display_name": "Herman H.W. Sillj\u00e9" }, { "id": "https://openalex.org/A5082476351", "display_name": "Elisabeth M. Schouten" }, { "id": "https://openalex.org/A5033408880", "display_name": "Martin M. Dokter" }, { "id": "https://openalex.org/A5074566771", "display_name": "Adriaan A. Voors" }, { "id": "https://openalex.org/A5059047444", "display_name": "B. Daan Westenbrink" }, { "id": "https://openalex.org/A5067422552", "display_name": "Carolyn S.P. Lam" }, { "id": "https://openalex.org/A5031658795", "display_name": "Rudolf A. de Boer" } ] }, { "id": "https://openalex.org/W4399623216", "doi": "https://doi.org/10.3390/biomedicines12061320", "title": "New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes\u2014Beyond and within GLP-1 Receptor Agonists", "abstract": { "Guidelines": [ 0 ], "for": [ 1, 26, 67, 101, 148 ], "the": [ 2, 12, 37, 65, 90, 102, 132, 157, 182, 194 ], "management": [ 3 ], "of": [ 4, 14, 83, 92, 104, 131, 138, 185, 196 ], "obesity": [ 5 ], "and": [ 6, 21, 71, 76, 86, 96, 129, 163, 166, 189, 198 ], "type": [ 7 ], "2": [ 8 ], "diabetes": [ 9 ], "(T2DM)": [ 10 ], "emphasize": [ 11 ], "importance": [ 13 ], "lifestyle": [ 15 ], "changes,": [ 16 ], "including": [ 17, 152 ], "a": [ 18 ], "reduced-calorie": [ 19 ], "diet": [ 20 ], "increased": [ 22 ], "physical": [ 23 ], "activity.": [ 24 ], "However,": [ 25 ], "many": [ 27 ], "people,": [ 28 ], "these": [ 29 ], "changes": [ 30 ], "can": [ 31, 49 ], "be": [ 32, 125 ], "difficult": [ 33 ], "to": [ 34, 45 ], "maintain": [ 35 ], "over": [ 36 ], "long": [ 38 ], "term.": [ 39 ], "Medication": [ 40 ], "options": [ 41 ], "are": [ 42, 80, 145 ], "already": [ 43 ], "available": [ 44, 147 ], "treat": [ 46 ], "obesity,": [ 47 ], "which": [ 48, 171 ], "help": [ 50 ], "reduce": [ 51, 54 ], "appetite": [ 52 ], "and/or": [ 53 ], "caloric": [ 55 ], "intake.": [ 56 ], "Incretin-based": [ 57 ], "peptides": [ 58 ], "exert": [ 59 ], "their": [ 60, 122 ], "effect": [ 61 ], "through": [ 62 ], "G-protein-coupled": [ 63 ], "receptors,": [ 64 ], "receptors": [ 66 ], "glucagon-like": [ 68 ], "peptide-1": [ 69 ], "(GLP-1)": [ 70 ], "glucose-dependent": [ 72 ], "insulinotropic": [ 73 ], "polypeptide": [ 74 ], "(GIP),": [ 75 ], "glucagon": [ 77 ], "peptide": [ 78 ], "hormones": [ 79, 144, 188 ], "important": [ 81 ], "regulators": [ 82 ], "insulin": [ 84 ], "secretion": [ 85 ], "energy": [ 87 ], "metabolism.": [ 88 ], "Understanding": [ 89 ], "role": [ 91 ], "intercellular": [ 93 ], "signaling": [ 94 ], "pathways": [ 95 ], "inflammatory": [ 97 ], "processes": [ 98 ], "is": [ 99, 119 ], "essential": [ 100 ], "development": [ 103 ], "effective": [ 105 ], "pharmacological": [ 106 ], "agents": [ 107, 140 ], "in": [ 108, 193 ], "obesity.": [ 109, 199 ], "GLP-1": [ 110, 154 ], "receptor": [ 111, 155, 160, 169 ], "agonists": [ 112 ], "have": [ 113 ], "been": [ 114 ], "successfully": [ 115 ], "used,": [ 116 ], "but": [ 117 ], "it": [ 118 ], "assumed": [ 120 ], "that": [ 121 ], "effectiveness": [ 123 ], "may": [ 124, 172 ], "limited": [ 126 ], "by": [ 127 ], "desensitization": [ 128 ], "downregulation": [ 130 ], "target": [ 133 ], "receptor.": [ 134 ], "A": [ 135 ], "growing": [ 136 ], "number": [ 137 ], "new": [ 139 ], "acting": [ 141 ], "on": [ 142 ], "incretin": [ 143, 187 ], "becoming": [ 146 ], "everyday": [ 149 ], "clinical": [ 150 ], "practice,": [ 151 ], "oral": [ 153 ], "agonists,": [ 156, 170 ], "dual": [ 158, 165 ], "GLP-1/GIP": [ 159 ], "agonist": [ 161 ], "tirzepatide,": [ 162 ], "other": [ 164 ], "triple": [ 167 ], "GLP-1/GIP/glucagon": [ 168 ], "show": [ 173 ], "further": [ 174 ], "significant": [ 175 ], "therapeutic": [ 176, 183 ], "potential.": [ 177 ], "This": [ 178 ], "narrative": [ 179 ], "review": [ 180 ], "summarizes": [ 181 ], "effects": [ 184 ], "different": [ 186 ], "presents": [ 190 ], "future": [ 191 ], "prospects": [ 192 ], "treatment": [ 195 ], "T2DM": [ 197 ] }, "publication_date": "2024-06-13", "publication_year": 2024, "type": "article", "cited_by_count": 25, "authors": [ { "id": "https://openalex.org/A5020171818", "display_name": "Ferenc Sztanek" }, { "id": "https://openalex.org/A5104326788", "display_name": "L\u00e1szl\u00f3 Imre T\u00f3th" }, { "id": "https://openalex.org/A5066113306", "display_name": "Attila Pet\u0151" }, { "id": "https://openalex.org/A5095112648", "display_name": "Marcell Herny\u00e1k" }, { "id": "https://openalex.org/A5039663814", "display_name": "\u00c1gnes Di\u00f3szegi" }, { "id": "https://openalex.org/A5002306496", "display_name": "Mariann Harangi" } ] }, { "id": "https://openalex.org/W1980614842", "doi": "https://doi.org/10.1002/phar.1014", "title": "Liraglutide\u2010Induced Acute Kidney Injury", "abstract": { "Published": [ 0 ], "case": [ 1, 217 ], "reports": [ 2, 177 ], "have": [ 3, 40 ], "documented": [ 4, 216 ], "the": [ 5, 33, 101, 107, 122, 137, 176, 179, 214, 239, 248 ], "relationship": [ 6, 132 ], "between": [ 7, 136 ], "exenatide": [ 8 ], "use": [ 9 ], "and": [ 10, 57, 68, 87, 144, 148, 162, 173, 207, 231 ], "acute": [ 11, 71, 141, 193, 220 ], "kidney": [ 12, 72, 142 ], "injury.": [ 13, 73 ], "However,": [ 14 ], "to": [ 15, 51, 66, 84, 91, 167, 187, 250 ], "our": [ 16, 210 ], "knowledge,": [ 17, 211 ], "no": [ 18 ], "cases": [ 19 ], "of": [ 20, 35, 70, 121, 134, 140, 159, 178, 192, 203, 218, 227 ], "this": [ 21, 212, 228 ], "adverse": [ 22, 124, 163 ], "effect": [ 23 ], "with": [ 24, 55, 201 ], "liraglutide,": [ 25, 204 ], "another": [ 26 ], "glucagon\u2010like": [ 27 ], "peptide\u20101": [ 28 ], "receptor": [ 29 ], "agonist": [ 30 ], "approved": [ 31 ], "for": [ 32, 62, 115 ], "treatment": [ 34 ], "type": [ 36, 117 ], "2": [ 37, 118 ], "diabetes": [ 38 ], "mellitus,": [ 39 ], "been": [ 41 ], "reported.": [ 42 ], "We": [ 43 ], "describe": [ 44 ], "a": [ 45, 52, 130, 189 ], "53\u2010year\u2010old": [ 46 ], "Caucasian": [ 47 ], "woman": [ 48 ], "who": [ 49 ], "came": [ 50 ], "community": [ 53 ], "hospital": [ 54 ], "severe": [ 56 ], "progressively": [ 58 ], "worsening": [ 59 ], "gastrointestinal": [ 60, 255 ], "symptoms": [ 61 ], "several": [ 63 ], "weeks,": [ 64 ], "leading": [ 65 ], "dehydration": [ 67 ], "development": [ 69, 139 ], "Laboratory": [ 74 ], "results": [ 75 ], "showed": [ 76 ], "an": [ 77 ], "increase": [ 78 ], "in": [ 79, 100, 153, 238 ], "her": [ 80 ], "serum": [ 81 ], "creatinine": [ 82 ], "concentration": [ 83 ], "22.8": [ 85 ], "mg/dl": [ 86 ], "blood": [ 88 ], "urea": [ 89 ], "nitrogen": [ 90 ], "150": [ 92 ], "mg/dl;": [ 93 ], "she": [ 94 ], "also": [ 95, 244 ], "had": [ 96, 109 ], "lost": [ 97 ], "8.9": [ 98 ], "kg": [ 99 ], "previous": [ 102 ], "month.": [ 103 ], "One": [ 104 ], "month": [ 105 ], "earlier,": [ 106 ], "patient": [ 108, 197 ], "begun": [ 110 ], "liraglutide": [ 111, 184 ], "1.8": [ 112 ], "mg/day": [ 113 ], "subcutaneously": [ 114 ], "uncontrolled": [ 116 ], "diabetes.": [ 119 ], "Use": [ 120 ], "Naranjo": [ 123 ], "drug": [ 125, 164 ], "reaction": [ 126 ], "probability": [ 127 ], "scale": [ 128 ], "indicated": [ 129 ], "possible": [ 131, 229 ], "(score": [ 133 ], "3)": [ 135 ], "patient's": [ 138 ], "injury": [ 143 ], "liraglutide.": [ 145 ], "Renal": [ 146 ], "biopsy": [ 147, 181 ], "laboratory": [ 149 ], "testing": [ 150 ], "were": [ 151, 182 ], "helpful": [ 152 ], "ruling": [ 154 ], "out": [ 155 ], "other": [ 156, 168 ], "potential": [ 157 ], "causes": [ 158 ], "renal": [ 160, 180 ], "failure": [ 161 ], "reactions": [ 165 ], "due": [ 166 ], "drugs": [ 169 ], "such": [ 170 ], "as": [ 171 ], "ciprofloxacin": [ 172 ], "quinapril.": [ 174 ], "After": [ 175 ], "obtained,": [ 183 ], "was": [ 185, 198 ], "determined": [ 186 ], "be": [ 188, 225, 245 ], "likely": [ 190 ], "cause": [ 191 ], "tubular": [ 194, 221 ], "necrosis.": [ 195, 222 ], "The": [ 196 ], "successfully": [ 199 ], "treated": [ 200 ], "discontinuation": [ 202 ], "volume": [ 205 ], "repletion,": [ 206 ], "hemodialysis.": [ 208 ], "To": [ 209 ], "is": [ 213 ], "first": [ 215 ], "liraglutide\u2010induced": [ 219 ], "Clinicians": [ 223 ], "should": [ 224, 243 ], "aware": [ 226 ], "complication": [ 230 ], "closely": [ 232 ], "follow": [ 233 ], "liraglutide's": [ 234 ], "dosage": [ 235 ], "titration": [ 236 ], "recommendations": [ 237 ], "package": [ 240 ], "insert.": [ 241 ], "Patients": [ 242 ], "educated": [ 246 ], "about": [ 247 ], "need": [ 249 ], "report": [ 251 ], "unusual": [ 252 ], "or": [ 253 ], "prolonged": [ 254 ], "symptoms.": [ 256 ] }, "publication_date": "2012-01-01", "publication_year": 2012, "type": "article", "cited_by_count": 51, "authors": [ { "id": "https://openalex.org/A5062189786", "display_name": "Yaman Kaakeh" }, { "id": "https://openalex.org/A5084424457", "display_name": "Sanna Kanjee" }, { "id": "https://openalex.org/A5036055094", "display_name": "Kevin Boone" }, { "id": "https://openalex.org/A5103152466", "display_name": "James Sutton" } ] }, { "id": "https://openalex.org/W2098730220", "doi": "https://doi.org/10.1007/s13300-011-0002-3", "title": "Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus", "abstract": { "Type": [ 0 ], "2": [ 1 ], "diabetes": [ 2 ], "mellitus": [ 3 ], "(T2DM)": [ 4 ], "is": [ 5, 18 ], "a": [ 6, 80, 123 ], "progressive": [ 7 ], "multisystemic": [ 8, 105 ], "disease": [ 9 ], "that": [ 10, 107 ], "increases": [ 11 ], "significantly": [ 12, 191 ], "cardiovascular": [ 13, 132, 243 ], "morbidity": [ 14, 244 ], "and": [ 15, 26, 39, 75, 87, 104, 118, 139, 146, 154, 165, 186, 190, 195, 245 ], "mortality.": [ 16 ], "It": [ 17 ], "associated": [ 19 ], "with": [ 20, 251 ], "obesity,": [ 21 ], "insulin": [ 22, 73 ], "resistance,": [ 23 ], "beta-cell": [ 24, 85, 89 ], "dysfunction,": [ 25 ], "hyperglucagonemia,": [ 27 ], "the": [ 28, 55, 131, 217 ], "combination": [ 29 ], "of": [ 30, 54, 59, 64, 116, 127, 144, 176, 208, 215, 222, 237 ], "which": [ 31 ], "typically": [ 32 ], "leads": [ 33 ], "to": [ 34, 50, 183, 248 ], "hyperglycemia.": [ 35 ], "Incretin-based": [ 36 ], "treatment": [ 37 ], "modalities,": [ 38 ], "in": [ 40, 79, 130, 235 ], "particular": [ 41 ], "glucagon-like": [ 42 ], "peptide": [ 43 ], "1": [ 44 ], "(GLP-1)": [ 45 ], "receptor": [ 46, 66, 178 ], "agonists,": [ 47 ], "are": [ 48, 93 ], "able": [ 49 ], "successfully": [ 51 ], "counteract": [ 52 ], "several": [ 53 ], "underlying": [ 56 ], "pathophysiological": [ 57 ], "abnormalities": [ 58 ], "T2DM.": [ 60 ], "The": [ 61, 173, 212 ], "pancreatic": [ 62, 111 ], "effects": [ 63, 70, 106, 221 ], "GLP-1": [ 65, 91, 128, 177, 203, 223 ], "agonists": [ 67, 179 ], "include": [ 68 ], "glucose-lowering": [ 69 ], "by": [ 71, 202 ], "stimulating": [ 72 ], "secretion": [ 74 ], "inhibiting": [ 76 ], "glucagon": [ 77 ], "release": [ 78 ], "strictly": [ 81 ], "glucose-dependent": [ 82 ], "manner,": [ 83 ], "increased": [ 84 ], "proliferation,": [ 86 ], "decreased": [ 88 ], "apoptosis.": [ 90 ], "receptors": [ 92 ], "widely": [ 94 ], "expressed": [ 95 ], "throughout": [ 96 ], "human": [ 97 ], "body;": [ 98 ], "thus,": [ 99 ], "GLP-1-based": [ 100 ], "therapies": [ 101 ], "exert": [ 102 ], "pleiotropic": [ 103 ], "extend": [ 108 ], "far": [ 109 ], "beyond": [ 110 ], "islets.": [ 112 ], "A": [ 113 ], "large": [ 114 ], "body": [ 115 ], "experimental": [ 117 ], "clinical": [ 119, 230, 254 ], "data": [ 120 ], "have": [ 121 ], "suggested": [ 122 ], "considerable": [ 124 ], "protective": [ 125 ], "role": [ 126 ], "analogs": [ 129, 204, 224 ], "system": [ 133, 168 ], "(decreased": [ 134 ], "blood": [ 135, 188 ], "pressure,": [ 136, 189 ], "improved": [ 137 ], "endothelial": [ 138 ], "myocardial": [ 140 ], "function,": [ 141 ], "functional": [ 142 ], "recovery": [ 143 ], "failing": [ 145 ], "ischemic": [ 147 ], "heart,": [ 148 ], "arterial": [ 149 ], "vasodilatation),": [ 150 ], "kidneys": [ 151 ], "(increased": [ 152 ], "diuresis": [ 153 ], "natriuresis),": [ 155 ], "gastrointestinal": [ 156 ], "tract": [ 157 ], "(delayed": [ 158 ], "gastric": [ 159, 162 ], "emptying,": [ 160 ], "reduced": [ 161 ], "acid": [ 163 ], "secretion),": [ 164 ], "central": [ 166 ], "nervous": [ 167 ], "(appetite": [ 169 ], "suppression,": [ 170 ], "neuroprotective": [ 171 ], "properties).": [ 172 ], "pharmacologic": [ 174 ], "use": [ 175 ], "has": [ 180 ], "been": [ 181 ], "shown": [ 182 ], "reduce": [ 184 ], "bodyweight": [ 185 ], "systolic": [ 187 ], "improve": [ 192 ], "glycemic": [ 193 ], "control": [ 194 ], "lipid": [ 196 ], "profile.": [ 197 ], "Interestingly,": [ 198 ], "weight": [ 199 ], "reduction": [ 200 ], "induced": [ 201 ], "reflects": [ 205 ], "mainly": [ 206 ], "loss": [ 207 ], "abdominal": [ 209 ], "visceral": [ 210 ], "fat.": [ 211 ], "critical": [ 213 ], "issue": [ 214 ], "whether": [ 216 ], "emerging": [ 218 ], "positive": [ 219 ], "cardiometabolic": [ 220 ], "can": [ 225 ], "be": [ 226, 249 ], "translated": [ 227 ], "into": [ 228 ], "better": [ 229 ], "outcomes": [ 231 ], "for": [ 232 ], "diabetic": [ 233 ], "patients": [ 234 ], "terms": [ 236 ], "long-term": [ 238 ], "hard": [ 239 ], "endpoints,": [ 240 ], "such": [ 241 ], "as": [ 242 ], "mortality,": [ 246 ], "remains": [ 247 ], "elucidated": [ 250 ], "prospective,": [ 252 ], "large-scale": [ 253 ], "trials.": [ 255 ] }, "publication_date": "2011-02-28", "publication_year": 2011, "type": "article", "cited_by_count": 139, "authors": [ { "id": "https://openalex.org/A5072295652", "display_name": "Chrysi Koliaki" }, { "id": "https://openalex.org/A5090372980", "display_name": "John Doupis" } ] }, { "id": "https://openalex.org/W3046216547", "doi": "https://doi.org/10.1186/s12933-020-01106-4", "title": "Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials", "abstract": null, "publication_date": "2020-09-30", "publication_year": 2020, "type": "article", "cited_by_count": 55, "authors": [ { "id": "https://openalex.org/A5044527590", "display_name": "Mansoor Husain" }, { "id": "https://openalex.org/A5080463002", "display_name": "Stephen C. Bain" }, { "id": "https://openalex.org/A5015716676", "display_name": "Anders G. Holst" }, { "id": "https://openalex.org/A5111052927", "display_name": "Thomas Mark" }, { "id": "https://openalex.org/A5110231477", "display_name": "S\u00f8ren Rasmussen" }, { "id": "https://openalex.org/A5001655356", "display_name": "Ildiko Lingvay" } ] }, { "id": "https://openalex.org/W1971310798", "doi": "https://doi.org/10.1111/jnc.12469", "title": "Neuroprotective and anti\u2010apoptotic effects of liraglutide on SH\u2010SY5Y cells exposed to methylglyoxal stress", "abstract": { "Abstract": [ 0 ], "Glucagon\u2010like": [ 1 ], "peptide": [ 2 ], "1": [ 3 ], "(": [ 4, 29, 94, 103 ], "GLP": [ 5, 64, 161 ], "\u20101)": [ 6 ], "is": [ 7, 185, 199 ], "a": [ 8, 17, 45, 98, 174, 191, 276 ], "growth": [ 9, 177, 279 ], "factor": [ 10, 132, 252, 280 ], "that": [ 11, 87 ], "has": [ 12 ], "demonstrated": [ 13 ], "neuroprotective": [ 14, 60, 214 ], "properties": [ 15, 61, 215 ], "in": [ 16, 53, 68, 97, 202, 205, 221 ], "range": [ 18, 175, 277 ], "of": [ 19, 26, 47, 62, 111, 122, 152, 176, 216, 239, 246, 266, 278 ], "studies.": [ 20 ], "In": [ 21, 144 ], "an": [ 22 ], "APPswe/PS1\u0394E9": [ 23 ], "mouse": [ 24 ], "model": [ 25 ], "Alzheimer's": [ 27 ], "disease": [ 28 ], "AD": [ 30 ], "),": [ 31 ], "we": [ 32, 57 ], "previously": [ 33 ], "found": [ 34 ], "protective": [ 35 ], "effects": [ 36 ], "on": [ 37, 187 ], "memory": [ 38 ], "formation,": [ 39 ], "synaptic": [ 40 ], "plasticity,": [ 41 ], "synapse": [ 42 ], "survival": [ 43, 124, 229 ], "and": [ 44, 50, 106, 129, 141, 149, 234, 249, 258, 263 ], "reduction": [ 46 ], "amyloid": [ 48 ], "synthesis": [ 49 ], "plaque": [ 51 ], "load": [ 52 ], "the": [ 54, 59, 63, 84, 112, 130, 146, 150, 155, 169, 188, 213, 217, 240, 250, 264, 269, 286 ], "brain.": [ 55 ], "Here,": [ 56 ], "analyse": [ 58 ], "\u20101": [ 65, 162 ], "analogue": [ 66, 219 ], "liraglutide": [ 67, 93, 220 ], "human": [ 69 ], "neuroblastoma": [ 70 ], "cell": [ 71, 88, 123, 156, 270 ], "line": [ 72 ], "SH": [ 73 ], "\u2010": [ 74 ], "SY": [ 75 ], "5Y": [ 76 ], "during": [ 77, 224 ], "methyl": [ 78, 225 ], "glyoxal": [ 79, 226 ], "stress.": [ 80, 227 ], "We": [ 81, 211 ], "show": [ 82 ], "for": [ 83, 193 ], "first": [ 85 ], "time": [ 86 ], "viability": [ 89 ], "was": [ 90, 117, 120, 165, 230, 236, 254, 261, 271 ], "enhanced": [ 91, 158 ], "by": [ 92, 159, 168, 182, 285 ], "XTT": [ 95 ], "assay)": [ 96, 105 ], "dose\u2010dependent": [ 99 ], "way,": [ 100 ], "while": [ 101, 232 ], "cytotoxicity": [ 102, 233 ], "LDH": [ 104 ], "apoptosis": [ 107, 235 ], "were": [ 108, 157 ], "reduced.": [ 109, 237 ], "Expression": [ 110, 238 ], "pro\u2010survival": [ 113, 241 ], "Mcl1": [ 114, 242 ], "signaling": [ 115, 243 ], "protein": [ 116 ], "increased,": [ 118 ], "as": [ 119, 190 ], "activation": [ 121, 245 ], "kinases": [ 125 ], "Akt,": [ 126, 247 ], "MEK": [ 127 ], "1/2": [ 128 ], "transcription": [ 131, 251 ], "p90": [ 133 ], "RSK": [ 134 ], ".": [ 135 ], "Liraglutide": [ 136 ], "also": [ 137, 166, 200 ], "decreased": [ 138 ], "pro\u2010apoptotic": [ 139 ], "Bax": [ 140, 257 ], "Bik": [ 142, 259 ], "expression.": [ 143 ], "addition,": [ 145 ], "membrane": [ 147 ], "potential": [ 148 ], "influx": [ 151, 265 ], "calcium": [ 153, 267 ], "into": [ 154, 268 ], "liraglutide.": [ 160, 288 ], "receptor": [ 163 ], "expression": [ 164, 260 ], "increased": [ 167 ], "drug.": [ 170 ], "The": [ 171, 273 ], "results": [ 172, 274 ], "demonstrate": [ 173, 275 ], "factor\u2010related": [ 178 ], "cytoprotective": [ 179, 282 ], "processes": [ 180, 283 ], "induced": [ 181, 284 ], "liraglutide,": [ 183 ], "which": [ 184 ], "currently": [ 186 ], "market": [ 189 ], "treatment": [ 192 ], "type": [ 194 ], "2": [ 195 ], "diabetes": [ 196 ], "(Victoza\u00ae).": [ 197 ], "It": [ 198 ], "tested": [ 201 ], "clinical": [ 203 ], "trials": [ 204 ], "patients": [ 206 ], "with": [ 207 ], "Alzheimer": [ 208 ], "disease.": [ 209 ], "image": [ 210 ], "investigated": [ 212 ], "GLP\u20101": [ 218 ], "SH\u2010SY5Y": [ 222 ], "cells": [ 223 ], "Cell": [ 228 ], "enhanced,": [ 231 ], "protein,": [ 244 ], "MEK1/2": [ 248 ], "p90RSK": [ 253 ], "increased.": [ 255 ], "Pro\u2010apoptotic": [ 256 ], "reduced,": [ 262 ], "normalised.": [ 272 ], "related": [ 281 ], "drug": [ 287 ] }, "publication_date": "2013-10-12", "publication_year": 2013, "type": "article", "cited_by_count": 147, "authors": [ { "id": "https://openalex.org/A5012265790", "display_name": "Mohit Sharma" }, { "id": "https://openalex.org/A5043340675", "display_name": "Jaishree Jalewa" }, { "id": "https://openalex.org/A5082707086", "display_name": "Christian H\u00f6lscher" } ] }, { "id": "https://openalex.org/W4285820616", "doi": "https://doi.org/10.1177/20420188221112490", "title": "The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice", "abstract": { "Chronic": [ 0 ], "kidney": [ 1, 22, 32, 99, 180 ], "disease": [ 2, 84 ], "(CKD)": [ 3 ], "affects": [ 4 ], "around": [ 5 ], "10%": [ 6 ], "of": [ 7, 56, 185 ], "the": [ 8, 39, 57 ], "global": [ 9 ], "population": [ 10 ], "and": [ 11, 34, 42, 64, 78, 116, 118, 155, 178, 194 ], "is": [ 12, 25, 48 ], "most": [ 13 ], "often": [ 14 ], "caused": [ 15 ], "by": [ 16 ], "diabetes.": [ 17 ], "Diabetes": [ 18 ], "with": [ 19, 50, 114, 133, 144, 171 ], "CKD": [ 20 ], "(diabetic": [ 21 ], "disease,": [ 23 ], "DKD)": [ 24 ], "a": [ 26, 109, 183 ], "progressive": [ 27 ], "condition": [ 28 ], "that": [ 29 ], "may": [ 30 ], "cause": [ 31 ], "failure": [ 33 ], "which": [ 35, 80 ], "contributes": [ 36 ], "significantly": [ 37 ], "to": [ 38, 97, 139, 156 ], "excess": [ 40 ], "morbidity": [ 41 ], "mortality": [ 43 ], "in": [ 44, 112, 124, 142, 160 ], "these": [ 45 ], "patients.": [ 46 ], "DKD": [ 47 ], "treated": [ 49 ], "direct": [ 51 ], "disease-targeting": [ 52 ], "therapies": [ 53, 73 ], "like": [ 54 ], "blockers": [ 55 ], "renin\u2013angiotensin": [ 58 ], "system,": [ 59 ], "sodium\u2013glucose": [ 60 ], "cotransporter-2": [ 61 ], "(SGLT-2)": [ 62 ], "inhibitors": [ 63 ], "non-steroidal": [ 65 ], "mineralocorticoid": [ 66 ], "receptor": [ 67, 91 ], "antagonists": [ 68 ], "as": [ 69, 71, 189, 191 ], "well": [ 70, 190 ], "indirect": [ 72 ], "impacting": [ 74 ], "hyperglycaemia,": [ 75 ], "dyslipidaemia,": [ 76 ], "obesity": [ 77 ], "hypertension,": [ 79 ], "all": [ 81 ], "together": [ 82 ], "reduce": [ 83, 157 ], "progression.": [ 85 ], "While": [ 86 ], "no": [ 87 ], "glucagon-like": [ 88 ], "peptide-1": [ 89 ], "(GLP-1)": [ 90 ], "agonists": [ 92 ], "(RAs)": [ 93 ], "are": [ 94, 121, 137, 149, 165 ], "currently": [ 95 ], "indicated": [ 96, 138 ], "improve": [ 98, 140 ], "outcomes,": [ 100 ], "accumulating": [ 101 ], "evidence": [ 102, 193 ], "from": [ 103, 182 ], "cardiovascular": [ 104, 158 ], "outcomes": [ 105, 181 ], "trials": [ 106, 164, 188 ], "(CVOTs)": [ 107 ], "corroborates": [ 108 ], "kidney-protective": [ 110 ], "effect": [ 111 ], "people": [ 113, 143 ], "T2D": [ 115, 170 ], "CKD,": [ 117 ], "GLP-1": [ 119, 135, 147 ], "RAs": [ 120, 136, 148 ], "now": [ 122 ], "mentioned": [ 123 ], "international": [ 125 ], "treatment": [ 126 ], "guidelines": [ 127 ], "for": [ 128, 152 ], "type": [ 129 ], "2": [ 130 ], "diabetes": [ 131 ], "(T2D)": [ 132 ], "CKD.": [ 134, 172 ], "glycaemia": [ 141 ], "T2D;": [ 145 ], "certain": [ 146 ], "also": [ 150 ], "approved": [ 151 ], "weight": [ 153 ], "management": [ 154 ], "risk": [ 159 ], "T2D.": [ 161 ], "Ongoing": [ 162 ], "pivotal": [ 163 ], "assessing": [ 166 ], "additional": [ 167 ], "indications,": [ 168 ], "including": [ 169 ], "In": [ 173 ], "this": [ 174 ], "article,": [ 175 ], "we": [ 176 ], "review": [ 177 ], "discuss": [ 179 ], "multitude": [ 184 ], "completed": [ 186 ], "clinical": [ 187, 196 ], "real-world": [ 192 ], "ongoing": [ 195 ], "trials.": [ 197 ] }, "publication_date": "2022-01-01", "publication_year": 2022, "type": "review", "cited_by_count": 37, "authors": [ { "id": "https://openalex.org/A5038074967", "display_name": "Bernt Johan von Scholten" }, { "id": "https://openalex.org/A5090783212", "display_name": "Frederik Flindt Kreiner" }, { "id": "https://openalex.org/A5110231477", "display_name": "S\u00f8ren Rasmussen" }, { "id": "https://openalex.org/A5085592050", "display_name": "Peter Rossing" }, { "id": "https://openalex.org/A5113682378", "display_name": "Thomas Idorn" } ] }, { "id": "https://openalex.org/W4388914883", "doi": "https://doi.org/10.1016/j.nsa.2023.103925", "title": "GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling", "abstract": null, "publication_date": "2023-11-22", "publication_year": 2023, "type": "article", "cited_by_count": 15, "authors": [ { "id": "https://openalex.org/A5031732652", "display_name": "Karlijn L. Kooij" }, { "id": "https://openalex.org/A5081888375", "display_name": "Derek IJsbrand Koster" }, { "id": "https://openalex.org/A5004915841", "display_name": "E. Eeltink" }, { "id": "https://openalex.org/A5111825381", "display_name": "Mieneke C. M. Luijendijk" }, { "id": "https://openalex.org/A5056335677", "display_name": "Lisa Drost" }, { "id": "https://openalex.org/A5022075524", "display_name": "Fabien Ducrocq" }, { "id": "https://openalex.org/A5035433879", "display_name": "Roger A.H. Adan" } ] }, { "id": "https://openalex.org/W2792638657", "doi": "https://doi.org/10.1080/14712598.2018.1439014", "title": "Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes", "abstract": { "It": [ 0 ], "is": [ 1 ], "critical": [ 2 ], "for": [ 3 ], "individuals": [ 4 ], "with": [ 5, 118 ], "type": [ 6 ], "2": [ 7 ], "diabetes": [ 8 ], "mellitus": [ 9 ], "(T2DM)": [ 10 ], "to": [ 11, 146, 156 ], "maintain": [ 12 ], "optimal": [ 13 ], "glycemia": [ 14 ], "while": [ 15 ], "avoiding": [ 16 ], "hypoglycemia,": [ 17 ], "control": [ 18 ], "body": [ 19, 114 ], "weight,": [ 20 ], "and": [ 21, 43, 98, 113, 120, 139, 165 ], "reduce": [ 22 ], "cardiovascular": [ 23, 71, 142 ], "risk.": [ 24, 72 ], "The": [ 25, 48, 88 ], "GLP-1": [ 26, 85, 158 ], "receptor": [ 27, 86, 159 ], "agonists": [ 28, 160 ], "stimulate": [ 29 ], "glucose-dependent": [ 30 ], "insulin": [ 31 ], "release": [ 32 ], "(low": [ 33, 161 ], "risk": [ 34, 143, 162 ], "of": [ 35, 51, 65, 136, 163, 168 ], "hypoglycemia),": [ 36 ], "inhibit": [ 37 ], "glucagon": [ 38 ], "secretion,": [ 39 ], "slow": [ 40 ], "gastric": [ 41 ], "emptying": [ 42 ], "suppress": [ 44 ], "appetite": [ 45 ], "(weight": [ 46 ], "loss).": [ 47 ], "new": [ 49, 81 ], "members": [ 50, 64 ], "the": [ 52, 66, 92 ], "class": [ 53, 67 ], "are": [ 54, 96 ], "available": [ 55 ], "as": [ 56, 125 ], "once": [ 57, 147 ], "daily": [ 58, 148 ], "or": [ 59, 127 ], "weekly": [ 60 ], "injections.": [ 61 ], "Additionally,": [ 62 ], "some": [ 63 ], "have": [ 68, 140 ], "demonstrated": [ 69 ], "reduced": [ 70 ], "Areas": [ 73 ], "covered:": [ 74 ], "This": [ 75 ], "manuscript": [ 76 ], "describes": [ 77 ], "semaglutide": [ 78, 105, 133, 152 ], "-": [ 79 ], "a": [ 80 ], "investigational": [ 82 ], "long": [ 83 ], "acting": [ 84 ], "agonist.": [ 87 ], "key": [ 89 ], "trials": [ 90 ], "from": [ 91 ], "clinical": [ 93 ], "development": [ 94 ], "process": [ 95 ], "reviewed": [ 97 ], "important": [ 99 ], "end-points": [ 100 ], "highlighted.": [ 101 ], "Expert": [ 102 ], "opinion:": [ 103 ], "Once-weekly": [ 104 ], "has": [ 106 ], "shown": [ 107, 141 ], "superiority": [ 108 ], "in": [ 109, 116, 128, 173 ], "reducing": [ 110 ], "glycosylated": [ 111 ], "hemoglobin": [ 112 ], "weight": [ 115 ], "comparison": [ 117 ], "placebo": [ 119 ], "active": [ 121 ], "comparators": [ 122 ], "when": [ 123 ], "used": [ 124 ], "monotherapy": [ 126 ], "combination": [ 129 ], "treatment.": [ 130 ], "In": [ 131 ], "addition,": [ 132 ], "improved": [ 134 ], "markers": [ 135 ], "\u03b2-cell": [ 137 ], "function": [ 138 ], "reduction": [ 144 ], "similar": [ 145 ], "liraglutide.": [ 149 ], "Although,": [ 150 ], "overall": [ 151 ], "safety": [ 153 ], "was": [ 154 ], "comparable": [ 155 ], "other": [ 157 ], "hypoglycemia": [ 164 ], "high": [ 166 ], "frequency": [ 167 ], "gastrointestinal": [ 169 ], "side": [ 170 ], "effects),": [ 171 ], "increase": [ 172 ], "retinopathy": [ 174 ], "complications": [ 175 ], "requires": [ 176 ], "further": [ 177 ], "investigation.": [ 178 ] }, "publication_date": "2018-02-12", "publication_year": 2018, "type": "review", "cited_by_count": 18, "authors": [ { "id": "https://openalex.org/A5030521441", "display_name": "Maka S. Hedrington" }, { "id": "https://openalex.org/A5040590069", "display_name": "Ana Tsiskarishvili" }, { "id": "https://openalex.org/A5080379883", "display_name": "Stephen N. Davis" } ] }, { "id": "https://openalex.org/W4407768173", "doi": "https://doi.org/10.1001/jamaophthalmol.2024.6555", "title": "Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy", "abstract": { "Importance": [ 0 ], "Semaglutide,": [ 1 ], "a": [ 2, 58, 134, 187, 379 ], "glucagonlike": [ 3 ], "peptide-1": [ 4 ], "receptor": [ 5 ], "agonist": [ 6 ], "(GLP-1RA),": [ 7 ], "has": [ 8 ], "recently": [ 9 ], "been": [ 10 ], "implicated": [ 11 ], "in": [ 12, 24, 42, 242, 382 ], "cases": [ 13 ], "of": [ 14, 27, 102, 123, 240, 268, 286, 294, 353, 360, 375, 385, 408 ], "nonarteritic": [ 15 ], "anterior": [ 16 ], "ischemic": [ 17 ], "optic": [ 18 ], "neuropathy": [ 19 ], "(NAION),": [ 20 ], "raising": [ 21 ], "safety": [ 22 ], "concerns": [ 23 ], "the": [ 25, 35, 43, 213, 235, 243, 295, 298, 348, 383, 405 ], "treatment": [ 26 ], "type": [ 28 ], "2": [ 29, 114, 201 ], "diabetes": [ 30 ], "(T2D).": [ 31 ], "Objective": [ 32 ], "To": [ 33 ], "investigate": [ 34 ], "potential": [ 36 ], "association": [ 37 ], "between": [ 38, 107 ], "semaglutide": [ 39, 108, 124, 232, 241, 277, 287, 354, 393 ], "and": [ 40, 48, 54, 67, 100, 109, 130, 133, 145, 181, 193, 197, 211, 217, 259, 319, 372, 400 ], "NAION": [ 41, 103, 110, 199, 269, 282, 300, 361, 386 ], "Observational": [ 44 ], "Health": [ 45 ], "Data": [ 46, 247 ], "Sciences": [ 47 ], "Informatics": [ 49 ], "(OHDSI)": [ 50 ], "network.": [ 51 ], "Design,": [ 52 ], "Setting,": [ 53 ], "Participants": [ 55 ], "This": [ 56 ], "was": [ 57, 111, 270, 288, 331 ], "retrospective": [ 59 ], "study": [ 60, 221, 377 ], "across": [ 61 ], "14": [ 62 ], "databases": [ 63 ], "(6": [ 64 ], "administrative": [ 65 ], "claims": [ 66 ], "8": [ 68 ], "electronic": [ 69 ], "health": [ 70 ], "records).": [ 71 ], "Included": [ 72 ], "were": [ 73, 104, 184, 253, 263 ], "adults": [ 74 ], "with": [ 75, 125, 226, 292, 335, 389, 392 ], "T2D": [ 76, 390 ], "taking": [ 77, 127, 337 ], "semaglutide,": [ 78 ], "other": [ 79, 128, 214 ], "GLP-1RA": [ 80, 192 ], "(dulaglutide,": [ 81 ], "exenatide),": [ 82 ], "or": [ 83 ], "non\u2013GLP-1RA": [ 84, 131 ], "medications": [ 85 ], "(empagliflozin,": [ 86 ], "sitagliptin,": [ 87 ], "glipizide)": [ 88 ], "from": [ 89 ], "December": [ 90, 94 ], "1,": [ 91 ], "2017,": [ 92 ], "to": [ 93, 139, 161, 173, 256 ], "31,": [ 95 ], "2023.": [ 96 ], "The": [ 97, 151, 166, 220, 265, 279, 329 ], "incidence": [ 98, 175, 266 ], "proportion": [ 99 ], "rate": [ 101, 176, 267 ], "calculated.": [ 105 ], "Association": [ 106 ], "assessed": [ 112 ], "using": [ 113, 186, 297, 347 ], "approaches:": [ 115 ], "an": [ 116, 357 ], "active-comparator": [ 117 ], "cohort": [ 118, 152 ], "design": [ 119, 153 ], "comparing": [ 120 ], "new": [ 121, 231, 238, 284 ], "users": [ 122, 239, 285 ], "those": [ 126 ], "GLP-1RAs": [ 129 ], "drugs,": [ 132 ], "self-controlled": [ 135 ], "case-series": [ 136 ], "(SCCS)": [ 137 ], "analysis": [ 138, 352 ], "compare": [ 140 ], "individuals\u2019": [ 141 ], "risks": [ 142 ], "during": [ 143 ], "exposure": [ 144, 355 ], "nonexposure": [ 146 ], "periods": [ 147 ], "for": [ 148, 281 ], "each": [ 149 ], "drug.": [ 150 ], "used": [ 154, 168 ], "propensity": [ 155 ], "score\u2013adjusted": [ 156 ], "Cox": [ 157 ], "proportional": [ 158 ], "hazards": [ 159 ], "models": [ 160, 172 ], "estimate": [ 162, 174 ], "hazard": [ 163 ], "ratios": [ 164, 177 ], "(HRs).": [ 165 ], "SCCS": [ 167, 351 ], "conditional": [ 169 ], "Poisson": [ 170 ], "regression": [ 171 ], "(IRRs).": [ 178 ], "Network-wide": [ 179 ], "HR": [ 180, 280 ], "IRR": [ 182 ], "estimates": [ 183 ], "generated": [ 185 ], "random-effects": [ 188 ], "meta-analysis": [ 189 ], "model.": [ 190 ], "Exposures": [ 191 ], "non\u2013GLP-1RAs.": [ 194 ], "Main": [ 195 ], "Outcomes": [ 196 ], "Measures": [ 198 ], "under": [ 200 ], "alternative": [ 202 ], "definitions": [ 203 ], "based": [ 204 ], "on": [ 205 ], "diagnosis": [ 206 ], "codes:": [ 207 ], "one": [ 208 ], "more": [ 209, 215 ], "inclusive": [ 210 ], "sensitive,": [ 212 ], "restrictive": [ 216 ], "specific.": [ 218 ], "Results": [ 219, 374 ], "included": [ 222 ], "37.1": [ 223 ], "million": [ 224 ], "individuals": [ 225, 388 ], "T2D,": [ 227 ], "including": [ 228 ], "810": [ 229 ], "390": [ 230 ], "users.": [ 233, 278 ], "Of": [ 234 ], "43": [ 236 ], "620": [ 237 ], "Optum\u2019s": [ 244 ], "deidentified": [ 245 ], "Clinformatics": [ 246 ], "Mart": [ 248 ], "Database,": [ 249 ], "24": [ 250 ], "473": [ 251 ], "(56%)": [ 252 ], "aged": [ 254 ], "50": [ 255 ], "69": [ 257 ], "years,": [ 258 ], "26": [ 260 ], "699": [ 261 ], "(61%)": [ 262 ], "female.": [ 264 ], "14.5": [ 271 ], "per": [ 272 ], "100": [ 273 ], "000": [ 274 ], "person-years": [ 275 ], "among": [ 276, 283, 387 ], "not": [ 289 ], "different": [ 290 ], "compared": [ 291, 334 ], "that": [ 293, 397 ], "non\u2013GLP-1RAs": [ 296 ], "sensitive": [ 299 ], "definition\u2014empagliflozin": [ 301 ], "(HR,": [ 302, 311, 321, 339 ], "1.44;": [ 303 ], "95%": [ 304, 313, 323, 341, 365 ], "CI,": [ 305, 314, 324, 342, 366 ], "0.78-2.68;": [ 306 ], "P": [ 307, 316, 326, 344, 368 ], "=": [ 308, 317, 327, 345 ], ".12),": [ 309 ], "sitagliptin": [ 310 ], "1.30;": [ 312 ], "0.56-3.01;": [ 315 ], ".27),": [ 318 ], "glipizide": [ 320 ], "1.23;": [ 322 ], "0.66-2.28;": [ 325 ], ".25).": [ 328 ], "risk": [ 330, 359, 384 ], "higher": [ 332 ], "only": [ 333 ], "patients": [ 336 ], "empagliflozin": [ 338 ], "2.27;": [ 340 ], "1.16-4.46;": [ 343 ], ".02)": [ 346 ], "specific": [ 349 ], "definition.": [ 350 ], "showed": [ 356 ], "increased": [ 358 ], "(meta-analysis": [ 362 ], "IRR,": [ 363 ], "1.32;": [ 364 ], "1.14-1.54;": [ 367 ], "&amp;lt;": [ 369 ], ".001).": [ 370 ], "Conclusions": [ 371 ], "Relevance": [ 373 ], "this": [ 376, 409 ], "suggest": [ 378 ], "modest": [ 380 ], "increase": [ 381 ], "associated": [ 391 ], "use,": [ 394 ], "smaller": [ 395 ], "than": [ 396 ], "previously": [ 398 ], "reported,": [ 399 ], "warranting": [ 401 ], "further": [ 402 ], "investigation": [ 403 ], "into": [ 404 ], "clinical": [ 406 ], "implications": [ 407 ], "association.": [ 410 ] }, "publication_date": "2025-02-20", "publication_year": 2025, "type": "letter", "cited_by_count": 48, "authors": [ { "id": "https://openalex.org/A5058002567", "display_name": "Cindy X. Cai" }, { "id": "https://openalex.org/A5043005198", "display_name": "Michelle R. Hribar" }, { "id": "https://openalex.org/A5069439888", "display_name": "Sally L. Baxter" }, { "id": "https://openalex.org/A5037787846", "display_name": "Kerry Goetz" }, { "id": "https://openalex.org/A5103125603", "display_name": "Swarup S. Swaminathan" }, { "id": "https://openalex.org/A5052284260", "display_name": "Alexis Flowers" }, { "id": "https://openalex.org/A5039078544", "display_name": "Eric N. Brown" }, { "id": "https://openalex.org/A5066443014", "display_name": "Brian C. Toy" }, { "id": "https://openalex.org/A5071539089", "display_name": "Benjamin Y. Xu" }, { "id": "https://openalex.org/A5074343390", "display_name": "John J. Chen" }, { "id": "https://openalex.org/A5070461327", "display_name": "Aiyin Chen" }, { "id": "https://openalex.org/A5000683013", "display_name": "Sophia Y. Wang" }, { "id": "https://openalex.org/A5067663922", "display_name": "Cecilia S. Lee" }, { "id": "https://openalex.org/A5035477663", "display_name": "Theodore Leng" }, { "id": "https://openalex.org/A5008939020", "display_name": "Joshua R. Ehrlich" }, { "id": "https://openalex.org/A5016643297", "display_name": "Andrew J. Barkmeier" }, { "id": "https://openalex.org/A5036431053", "display_name": "Karen R. Armbrust" }, { "id": "https://openalex.org/A5032325357", "display_name": "Michael V. Boland" }, { "id": "https://openalex.org/A5009855380", "display_name": "David A Dorr" }, { "id": "https://openalex.org/A5077202824", "display_name": "Danielle Boyce" }, { "id": "https://openalex.org/A5109646442", "display_name": "Thamir Alshammari" }, { "id": "https://openalex.org/A5068014330", "display_name": "Joel N. Swerdel" }, { "id": "https://openalex.org/A5039905606", "display_name": "Marc A. Suchard" }, { "id": "https://openalex.org/A5077586396", "display_name": "Martijn J. Schuemie" }, { "id": "https://openalex.org/A5100713584", "display_name": "Fan Bu" }, { "id": "https://openalex.org/A5012791909", "display_name": "Anthony G. Sena" }, { "id": "https://openalex.org/A5053670656", "display_name": "George Hripcsak" }, { "id": "https://openalex.org/A5063240078", "display_name": "Akihiko Nishimura" }, { "id": "https://openalex.org/A5016301901", "display_name": "Paul Nagy" }, { "id": "https://openalex.org/A5024868620", "display_name": "Thomas Falconer" }, { "id": "https://openalex.org/A5037435182", "display_name": "Scott L. DuVall" }, { "id": "https://openalex.org/A5011689338", "display_name": "Michael E. Matheny" }, { "id": "https://openalex.org/A5025119361", "display_name": "Benjamin Viernes" }, { "id": "https://openalex.org/A5061417458", "display_name": "William J. O\u2019Brien" }, { "id": "https://openalex.org/A5085167653", "display_name": "Linying Zhang" }, { "id": "https://openalex.org/A5053197687", "display_name": "Benjamin Martin" }, { "id": "https://openalex.org/A5095111618", "display_name": "Erik Westlund" }, { "id": "https://openalex.org/A5051572835", "display_name": "Nestoras Mathioudakis" }, { "id": "https://openalex.org/A5038601803", "display_name": "Rong Fan" }, { "id": "https://openalex.org/A5064822514", "display_name": "Adam Wilcox" }, { "id": "https://openalex.org/A5052315320", "display_name": "Albert M. Lai" }, { "id": "https://openalex.org/A5060644045", "display_name": "Jacqueline C. Stocking" }, { "id": "https://openalex.org/A5075372257", "display_name": "Sahar Takkouche" }, { "id": "https://openalex.org/A5079771748", "display_name": "Lok Hin Lee" }, { "id": "https://openalex.org/A5007746572", "display_name": "Yangyiran Xie" }, { "id": "https://openalex.org/A5116340303", "display_name": "Izabelle Humes" }, { "id": "https://openalex.org/A5103205149", "display_name": "David McCoy" }, { "id": "https://openalex.org/A5059342685", "display_name": "Mohammad Adibuzzaman" }, { "id": "https://openalex.org/A5077621447", "display_name": "Raymond G. Areaux" }, { "id": "https://openalex.org/A5001426590", "display_name": "William Rojas\u2010Carabali" }, { "id": "https://openalex.org/A5024524820", "display_name": "James T. Brash" }, { "id": "https://openalex.org/A5014358729", "display_name": "David A. Lee" }, { "id": "https://openalex.org/A5077590934", "display_name": "Nicole G. Weiskopf" }, { "id": "https://openalex.org/A5079871623", "display_name": "Louise A. Mawn" }, { "id": "https://openalex.org/A5114212238", "display_name": "Rupesh Agrawal" }, { "id": "https://openalex.org/A5114335194", "display_name": "Hannah Morgan\u2010Cooper" }, { "id": "https://openalex.org/A5029957243", "display_name": "Priya Desai" }, { "id": "https://openalex.org/A5065153070", "display_name": "Patrick Ryan" } ] }, { "id": "https://openalex.org/W2894644761", "doi": "https://doi.org/10.1111/dom.13553", "title": "Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial", "abstract": { "Aims": [ 0 ], "To": [ 1 ], "assess": [ 2 ], "the": [ 3, 10, 132, 140, 144, 149, 195, 226 ], "cardiovascular": [ 4 ], "(CV)": [ 5 ], "safety": [ 6, 228 ], "of": [ 7, 14, 41, 91, 102, 137, 143, 148, 161, 198, 213, 229 ], "oral": [ 8, 80, 124, 230 ], "semaglutide,": [ 9 ], "first": [ 11, 100 ], "tablet": [ 12 ], "formulation": [ 13 ], "a": [ 15, 26 ], "glucagon\u2010like": [ 16 ], "peptide\u20101": [ 17 ], "receptor": [ 18 ], "agonist.": [ 19 ], "Materials": [ 20 ], "and": [ 21, 50, 211, 238 ], "methods": [ 22 ], "PIONEER": [ 23, 152, 220 ], "6": [ 24, 153, 221 ], "is": [ 25, 97, 154, 169 ], "multinational,": [ 27 ], "randomized,": [ 28 ], "placebo\u2010controlled,": [ 29 ], "double\u2010blind": [ 30 ], "trial": [ 31 ], "in": [ 32, 120, 187, 232 ], "patients": [ 33, 177, 214, 233 ], "with": [ 34, 69, 123, 156, 234 ], "type": [ 35, 235 ], "2": [ 36, 236 ], "diabetes": [ 37, 199, 237 ], "at": [ 38, 162 ], "high": [ 39, 239 ], "risk": [ 40, 73, 122 ], "CV": [ 42, 53, 72, 103, 121, 227, 240 ], "events": [ 43 ], "(defined": [ 44 ], "as": [ 45 ], "being": [ 46, 65 ], "aged": [ 47, 66 ], "\u226550": [ 48 ], "years": [ 49, 68 ], "having": [ 51 ], "established": [ 52, 216 ], "disease": [ 54, 62 ], "[CVD]": [ 55 ], "or": [ 56, 64, 86, 105, 109 ], "moderate": [ 57 ], "[stage": [ 58 ], "3]": [ 59 ], "chronic": [ 60 ], "kidney": [ 61 ], "[CKD],": [ 63 ], "\u226560": [ 67 ], "\u22651": [ 70 ], "other": [ 71 ], "factor).": [ 74 ], "Patients": [ 75 ], "were": [ 76 ], "randomized": [ 77 ], "to": [ 78, 83, 89, 99, 116 ], "once\u2010daily": [ 79 ], "semaglutide": [ 81, 125, 231 ], "(up": [ 82 ], "14": [ 84 ], "mg)": [ 85 ], "placebo": [ 87, 130 ], "added": [ 88 ], "standard": [ 90 ], "care.": [ 92 ], "The": [ 93, 112 ], "primary": [ 94, 113, 133, 165 ], "composite": [ 95 ], "endpoint": [ 96, 134 ], "time": [ 98 ], "occurrence": [ 101 ], "death": [ 104 ], "non\u2010fatal": [ 106, 110 ], "myocardial": [ 107 ], "infarction": [ 108 ], "stroke.": [ 111 ], "hypothesis": [ 114 ], "was": [ 115, 200, 207 ], "exclude": [ 117 ], "an": [ 118 ], "excess": [ 119 ], "by": [ 126 ], "assessing": [ 127 ], "non\u2010inferiority": [ 128 ], "versus": [ 129 ], "for": [ 131, 139 ], "(non\u2010inferiority": [ 135 ], "margin": [ 136 ], "1.8": [ 138 ], "upper": [ 141 ], "boundary": [ 142 ], "95%": [ 145 ], "confidence": [ 146 ], "interval": [ 147 ], "hazard": [ 150 ], "ratio).": [ 151 ], "event\u2010driven,": [ 155 ], "follow\u2010up": [ 157 ], "continuing": [ 158 ], "until": [ 159 ], "accrual": [ 160 ], "least": [ 163 ], "122": [ 164 ], "outcome": [ 166 ], "events.": [ 167 ], "There": [ 168 ], "no": [ 170 ], "pre\u2010defined": [ 171 ], "minimal": [ 172 ], "duration.": [ 173 ], "Results": [ 174 ], "Overall,": [ 175 ], "3183": [ 176 ], "have": [ 178 ], "been": [ 179 ], "enrolled": [ 180 ], "(mean": [ 181 ], "age": [ 182 ], "66.1": [ 183 ], "years,": [ 184, 202 ], "31.6%": [ 185 ], "females)": [ 186 ], "214": [ 188 ], "sites": [ 189 ], "across": [ 190 ], "21": [ 191 ], "countries.": [ 192 ], "At": [ 193 ], "baseline,": [ 194 ], "mean": [ 196, 203 ], "duration": [ 197 ], "14.9": [ 201 ], "glycated": [ 204 ], "haemoglobin": [ 205 ], "concentration": [ 206 ], "66": [ 208 ], "mmol/mol": [ 209 ], "(8.2%),": [ 210 ], "84.6%": [ 212 ], "had": [ 215 ], "CVD/moderate": [ 217 ], "CKD.": [ 218 ], "Conclusions": [ 219 ], "will": [ 222 ], "provide": [ 223 ], "evidence": [ 224 ], "regarding": [ 225 ], "risk.": [ 241 ] }, "publication_date": "2018-10-05", "publication_year": 2018, "type": "article", "cited_by_count": 93, "authors": [ { "id": "https://openalex.org/A5080463002", "display_name": "Stephen C. Bain" }, { "id": "https://openalex.org/A5080475619", "display_name": "Ofri Mosenzon" }, { "id": "https://openalex.org/A5022712557", "display_name": "Rosario Arechavaleta" }, { "id": "https://openalex.org/A5074308535", "display_name": "Pawe\u0142 Bogda\u0144ski" }, { "id": "https://openalex.org/A5022933840", "display_name": "Abdurrahman \u00c7\u00f6mlek\u00e7i" }, { "id": "https://openalex.org/A5003186286", "display_name": "Agostino Consoli" }, { "id": "https://openalex.org/A5058016758", "display_name": "Chaicharn Deerochanawong" }, { "id": "https://openalex.org/A5007315645", "display_name": "Kathleen Dungan" }, { "id": "https://openalex.org/A5054692440", "display_name": "Mar\u00eda Cristina Faingold" }, { "id": "https://openalex.org/A5043621364", "display_name": "Michael E. Farkouh" }, { "id": "https://openalex.org/A5047248546", "display_name": "Denise Reis Franco" }, { "id": "https://openalex.org/A5015594299", "display_name": "Jeppe Gram" }, { "id": "https://openalex.org/A5002278673", "display_name": "Cristian Guja" }, { "id": "https://openalex.org/A5057336874", "display_name": "P Joshi" }, { "id": "https://openalex.org/A5087830425", "display_name": "Rachid Malek" }, { "id": "https://openalex.org/A5081762662", "display_name": "Juan Francisco Merino-Torres" }, { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5040913971", "display_name": "Sue D. Pedersen" }, { "id": "https://openalex.org/A5110577958", "display_name": "Wayne Huey-Heng Sheu" }, { "id": "https://openalex.org/A5051736421", "display_name": "Robert Silver" }, { "id": "https://openalex.org/A5011314920", "display_name": "Cees J. Tack" }, { "id": "https://openalex.org/A5018621533", "display_name": "Nikhil Tandon" }, { "id": "https://openalex.org/A5055974284", "display_name": "Ole Kleist Jeppesen" }, { "id": "https://openalex.org/A5084133742", "display_name": "Mette Strange" }, { "id": "https://openalex.org/A5017671388", "display_name": "Mette S. Thomsen" }, { "id": "https://openalex.org/A5044527590", "display_name": "Mansoor Husain" } ] }, { "id": "https://openalex.org/W2948579396", "doi": "https://doi.org/10.1186/s12933-019-0871-8", "title": "Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial", "abstract": null, "publication_date": "2019-06-05", "publication_year": 2019, "type": "article", "cited_by_count": 130, "authors": [ { "id": "https://openalex.org/A5080414941", "display_name": "Lawrence A. Leiter" }, { "id": "https://openalex.org/A5080463002", "display_name": "Stephen C. Bain" }, { "id": "https://openalex.org/A5088887856", "display_name": "Irene Hramiak" }, { "id": "https://openalex.org/A5088506788", "display_name": "Esteban J\u00f3dar" }, { "id": "https://openalex.org/A5062239390", "display_name": "Sten Madsbad" }, { "id": "https://openalex.org/A5040173991", "display_name": "Theis Gondolf" }, { "id": "https://openalex.org/A5109185807", "display_name": "Thomas K. Hansen" }, { "id": "https://openalex.org/A5057128293", "display_name": "Ingrid Holst" }, { "id": "https://openalex.org/A5001655356", "display_name": "Ildiko Lingvay" } ] }, { "id": "https://openalex.org/W2161407981", "doi": "https://doi.org/10.1111/j.1463-1326.2007.00832.x", "title": "Exenatide prevents fat\u2010induced insulin resistance and raises adiponectin expression and plasma levels", "abstract": { "Background:": [ 0 ], "Exenatide": [ 1, 92 ], "(exendin\u20104)": [ 2 ], "can": [ 3 ], "reduce": [ 4 ], "blood": [ 5 ], "glucose": [ 6, 35, 38, 105 ], "levels,": [ 7 ], "increase": [ 8 ], "insulin": [ 9, 13, 41, 45, 101, 103, 112, 146, 153 ], "secretion": [ 10 ], "and": [ 11, 53, 57, 89, 99, 107, 118, 131, 148 ], "improve": [ 12 ], "sensitivity": [ 14, 42, 147 ], "through": [ 15 ], "mechanisms": [ 16 ], "that": [ 17, 141 ], "are": [ 18 ], "not": [ 19 ], "completely": [ 20 ], "understood.": [ 21 ], "Methods:": [ 22 ], "In": [ 23 ], "the": [ 24, 29 ], "present": [ 25 ], "study,": [ 26 ], "we": [ 27 ], "examined": [ 28 ], "effects": [ 30 ], "of": [ 31, 65, 111, 134 ], "exenatide": [ 32, 66, 143 ], "treatment": [ 33, 144 ], "on": [ 34 ], "tolerance": [ 36, 39, 106 ], "(intravenous": [ 37 ], "test),": [ 40 ], "(euglycaemic\u2013hyperinsulinaemic": [ 43 ], "clamps),": [ 44 ], "signalling": [ 46 ], "(insulin": [ 47 ], "receptor": [ 48, 113 ], "substrate": [ 49 ], "1": [ 50 ], "tyrosine": [ 51, 109 ], "phosphorylation)": [ 52 ], "adipocytokine": [ 54 ], "levels": [ 55, 124, 133 ], "(visfatin": [ 56 ], "adiponectin)": [ 58 ], "in": [ 59, 81, 97, 116, 126 ], "high": [ 60, 151 ], "fat\u2013fed": [ 61 ], "rats.": [ 62 ], "Results:": [ 63 ], "Administration": [ 64 ], "(0.5": [ 67 ], "or": [ 68 ], "2.0": [ 69 ], "\u03bcg/kg": [ 70 ], "twice": [ 71 ], "daily": [ 72 ], "\u00d7": [ 73 ], "6": [ 74 ], "weeks)": [ 75 ], "prevented": [ 76, 94 ], "high\u2010fat": [ 77 ], "diet": [ 78 ], "(HFD)\u2013induced": [ 79 ], "increases": [ 80 ], "body": [ 82 ], "weight,": [ 83 ], "plasma": [ 84, 122, 132 ], "free": [ 85 ], "fatty": [ 86 ], "acids,": [ 87 ], "triglycerides": [ 88 ], "total": [ 90 ], "cholesterol.": [ 91 ], "also": [ 93 ], "HFD\u2010induced": [ 95 ], "deterioration": [ 96 ], "peripheral": [ 98 ], "hepatic": [ 100 ], "sensitivity,": [ 102 ], "clearance,": [ 104 ], "decreased": [ 108, 125 ], "phosphorylation": [ 110 ], "substrate\u20101": [ 114 ], "(IRS\u20101)": [ 115 ], "fat": [ 117 ], "skeletal": [ 119 ], "muscles.": [ 120 ], "Interestingly,": [ 121 ], "visfatin": [ 123 ], "exenatide\u2010treated": [ 127 ], "rats,": [ 128 ], "whereas": [ 129 ], "expression": [ 130 ], "adiponectin": [ 135 ], "increased.": [ 136 ], "Conclusions:": [ 137 ], "These": [ 138 ], "results": [ 139 ], "indicate": [ 140 ], "chronic": [ 142 ], "enhances": [ 145 ], "protects": [ 149 ], "against": [ 150 ], "fat\u2013induced": [ 152 ], "resistance.": [ 154 ] }, "publication_date": "2008-09-15", "publication_year": 2008, "type": "article", "cited_by_count": 89, "authors": [ { "id": "https://openalex.org/A5057516773", "display_name": "L. Li" }, { "id": "https://openalex.org/A5100411617", "display_name": "Gangyi Yang" }, { "id": "https://openalex.org/A5010253740", "display_name": "Q. Li" }, { "id": "https://openalex.org/A5005320095", "display_name": "Xu Tan" }, { "id": "https://openalex.org/A5082045422", "display_name": "H. Liu" }, { "id": "https://openalex.org/A5101795460", "display_name": "Yi Tang" }, { "id": "https://openalex.org/A5109280622", "display_name": "G. Boden" } ] }, { "id": "https://openalex.org/W2588900219", "doi": "https://doi.org/10.1080/14712598.2017.1296131", "title": "Dulaglutide for the treatment of type 2 diabetes", "abstract": { "Glucagon-like": [ 0 ], "peptide-1": [ 1 ], "receptor": [ 2 ], "agonists": [ 3 ], "(GLP-1": [ 4 ], "RAs)": [ 5 ], "are": [ 6 ], "injectable": [ 7 ], "agents": [ 8, 82 ], "used": [ 9 ], "for": [ 10, 21 ], "the": [ 11, 28, 35, 49, 65, 124, 146, 165, 192 ], "treatment": [ 12 ], "of": [ 13, 30, 37, 53, 117, 126, 155 ], "hyperglycemia": [ 14 ], "in": [ 15, 41, 64, 83, 191 ], "type": [ 16 ], "2": [ 17 ], "diabetes.": [ 18 ], "The": [ 19, 46, 161 ], "interest": [ 20 ], "this": [ 22 ], "pharmacological": [ 23 ], "class": [ 24 ], "is": [ 25, 151 ], "rising": [ 26 ], "with": [ 27, 86, 111, 113 ], "development": [ 29 ], "once": [ 31 ], "weekly": [ 32 ], "compounds": [ 33 ], "and": [ 34, 73, 96, 102, 119, 145, 148, 164, 173, 188 ], "demonstration": [ 36 ], "a": [ 38, 55, 114 ], "potential": [ 39 ], "reduction": [ 40 ], "cardiorenal": [ 42 ], "outcomes.": [ 43 ], "Areas": [ 44 ], "covered:": [ 45 ], "paper": [ 47 ], "describes": [ 48 ], "main": [ 50 ], "pharmacokinetic/pharmacodynamic": [ 51 ], "characteristics": [ 52 ], "dulaglutide,": [ 54, 112 ], "new": [ 56 ], "once-weekly": [ 57, 162 ], "GLP-1": [ 58, 157 ], "RA.": [ 59 ], "Dulaglutide": [ 60, 139, 180 ], "was": [ 61 ], "extensively": [ 62 ], "investigated": [ 63 ], "phase-3": [ 66 ], "AWARD": [ 67 ], "program,": [ 68 ], "which": [ 69 ], "demonstrated": [ 70 ], "its": [ 71, 141, 183 ], "safety": [ 72, 147 ], "efficacy": [ 74 ], "when": [ 75 ], "compared": [ 76 ], "to": [ 77, 132, 153, 185 ], "placebo": [ 78 ], "or": [ 79, 90 ], "active": [ 80 ], "glucose-lowering": [ 81 ], "patients": [ 84 ], "treated": [ 85 ], "diet": [ 87 ], "alone,": [ 88 ], "metformin": [ 89 ], "sulfonylurea": [ 91 ], "monotherapy,": [ 92 ], "oral": [ 93 ], "dual": [ 94 ], "therapies": [ 95 ], "basal": [ 97 ], "insulin.": [ 98 ], "In": [ 99 ], "both": [ 100, 170 ], "Caucasian": [ 101 ], "Japanese": [ 103 ], "patients,": [ 104 ], "comparative": [ 105 ], "trials": [ 106 ], "showed": [ 107 ], "better": [ 108 ], "glucose": [ 109, 171 ], "control": [ 110, 172 ], "minimal": [ 115 ], "risk": [ 116 ], "hypoglycemia": [ 118 ], "weight": [ 120, 174 ], "loss,": [ 121 ], "but": [ 122 ], "at": [ 123 ], "expense": [ 125 ], "an": [ 127 ], "increased": [ 128 ], "dropout": [ 129 ], "rate": [ 130 ], "due": [ 131 ], "side": [ 133 ], "effects,": [ 134 ], "mostly": [ 135 ], "transient": [ 136 ], "gastrointestinal": [ 137 ], "disturbances.": [ 138 ], "proved": [ 140 ], "non-inferiority": [ 142 ], "versus": [ 143 ], "liraglutide": [ 144 ], "tolerance": [ 149 ], "profile": [ 150 ], "similar": [ 152 ], "that": [ 154 ], "other": [ 156 ], "RAs.": [ 158 ], "Expert": [ 159 ], "opinion:": [ 160 ], "formulation": [ 163 ], "combined": [ 166 ], "positive": [ 167 ], "effects": [ 168 ], "on": [ 169 ], "improves": [ 175 ], "patient": [ 176 ], "satisfaction": [ 177 ], "despite": [ 178 ], "nausea.": [ 179 ], "must": [ 181 ], "prove": [ 182 ], "capacity": [ 184 ], "reduce": [ 186 ], "cardiovascular": [ 187 ], "diabetic": [ 189 ], "complications": [ 190 ], "ongoing": [ 193 ], "prospective": [ 194 ], "REWIND": [ 195 ], "trial.": [ 196 ] }, "publication_date": "2017-02-15", "publication_year": 2017, "type": "review", "cited_by_count": 39, "authors": [ { "id": "https://openalex.org/A5039563874", "display_name": "Andr\u00e9 Scheen" } ] }, { "id": "https://openalex.org/W2081311004", "doi": "https://doi.org/10.1007/s00125-011-2069-9", "title": "The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes", "abstract": { "Liraglutide": [ 0 ], "increases": [ 1 ], "beta": [ 2 ], "cell": [ 3, 10 ], "mass": [ 4 ], "not": [ 5 ], "only": [ 6 ], "by": [ 7, 14 ], "directly": [ 8 ], "regulating": [ 9 ], "kinetics,": [ 11 ], "but": [ 12 ], "also": [ 13 ], "suppressing": [ 15 ], "oxidative": [ 16 ], "and": [ 17 ], "ER": [ 18 ], "stress,": [ 19 ], "secondary": [ 20 ], "to": [ 21 ], "amelioration": [ 22 ], "of": [ 23 ], "glucolipotoxicity.": [ 24 ] }, "publication_date": "2011-02-21", "publication_year": 2011, "type": "article", "cited_by_count": 156, "authors": [ { "id": "https://openalex.org/A5084036501", "display_name": "Masashi Shimoda" }, { "id": "https://openalex.org/A5049157332", "display_name": "Yukiko Kanda" }, { "id": "https://openalex.org/A5004181639", "display_name": "Sumiko Hamamoto" }, { "id": "https://openalex.org/A5076688248", "display_name": "Kazuhito Tawaramoto" }, { "id": "https://openalex.org/A5080564390", "display_name": "Mitsuru Hashiramoto" }, { "id": "https://openalex.org/A5075985193", "display_name": "Michihiro Matsuki" }, { "id": "https://openalex.org/A5036190568", "display_name": "Kohei Kaku" } ] }, { "id": "https://openalex.org/W2489853663", "doi": "https://doi.org/10.1152/ajpendo.00205.2016", "title": "Liraglutide prevents microvascular insulin resistance and preserves muscle capillary density in high-fat diet-fed rats", "abstract": { "Muscle": [ 0, 132 ], "microvasculature": [ 1 ], "critically": [ 2 ], "regulates": [ 3 ], "endothelial": [ 4, 52, 81, 145, 160 ], "exchange": [ 5 ], "surface": [ 6 ], "area": [ 7 ], "to": [ 8, 17, 32, 46, 60, 106 ], "facilitate": [ 9 ], "transendothelial": [ 10 ], "delivery": [ 11 ], "of": [ 12, 64, 67, 102, 144, 169, 176, 196, 225, 231, 246 ], "insulin,": [ 13 ], "nutrients,": [ 14 ], "and": [ 15, 25, 41, 50, 75, 83, 104, 122, 128, 137, 147, 156, 162, 179, 193, 198, 218, 228 ], "oxygen": [ 16 ], "myocytes.": [ 18 ], "Insulin": [ 19 ], "resistance": [ 20, 155, 239 ], "blunts": [ 21 ], "insulin-mediated": [ 22, 72, 148 ], "microvascular": [ 23, 34, 120, 153, 215 ], "recruitment": [ 24, 74, 121 ], "decreases": [ 26 ], "muscle": [ 27, 84, 119, 123, 152, 164, 219 ], "capillary": [ 28, 73, 85, 133, 165, 220 ], "density;": [ 29 ], "both": [ 30 ], "contribute": [ 31 ], "lower": [ 33 ], "blood": [ 35, 48 ], "volume.": [ 36 ], "Glucagon-like": [ 37 ], "peptide": [ 38 ], "1": [ 39 ], "(GLP-1)": [ 40 ], "its": [ 42, 199 ], "analogs": [ 43 ], "are": [ 44 ], "able": [ 45 ], "dilate": [ 47 ], "vessels": [ 49 ], "stimulate": [ 51 ], "cell": [ 53 ], "proliferation.": [ 54 ], "In": [ 55 ], "this": [ 56 ], "study,": [ 57 ], "we": [ 58 ], "aim": [ 59 ], "determine": [ 61 ], "the": [ 62, 68, 194, 223 ], "effects": [ 63 ], "sustained": [ 65 ], "stimulation": [ 66 ], "GLP-1": [ 69, 204, 232 ], "receptors": [ 70 ], "on": [ 71 ], "metabolic": [ 76, 237 ], "insulin": [ 77, 130, 154, 216, 226, 238 ], "responses,": [ 78 ], "small": [ 79, 157 ], "arterial": [ 80, 158 ], "function,": [ 82 ], "density.": [ 86, 166 ], "Rats": [ 87 ], "were": [ 88, 125, 185 ], "fed": [ 89 ], "a": [ 90, 107, 188 ], "high-fat": [ 91 ], "diet": [ 92 ], "(HFD)": [ 93 ], "for": [ 94, 111, 142 ], "4": [ 95 ], "wk": [ 96 ], "with": [ 97, 172, 187 ], "or": [ 98 ], "without": [ 99 ], "simultaneous": [ 100 ], "administration": [ 101 ], "liraglutide": [ 103, 173 ], "subjected": [ 105 ], "euglycemic": [ 108 ], "hyperinsulinemic": [ 109 ], "clamp": [ 110 ], "120": [ 112 ], "min": [ 113 ], "after": [ 114 ], "an": [ 115 ], "overnight": [ 116 ], "fast.": [ 117 ], "Insulin-mediated": [ 118 ], "oxygenation": [ 124 ], "determined": [ 126, 136 ], "before": [ 127 ], "during": [ 129, 222 ], "infusion.": [ 131 ], "density": [ 134, 221 ], "was": [ 135 ], "distal": [ 138 ], "saphenous": [ 139 ], "artery": [ 140 ], "used": [ 141 ], "determination": [ 143 ], "function": [ 146 ], "vasodilation.": [ 149 ], "HFD": [ 150 ], "induced": [ 151 ], "vessel": [ 159 ], "dysfunction": [ 161 ], "decreased": [ 163 ], "Simultaneous": [ 167 ], "treatment": [ 168 ], "HFD-fed": [ 170 ], "rats": [ 171 ], "prevented": [ 174 ], "all": [ 175 ], "these": [ 177 ], "changes": [ 178 ], "improved": [ 180 ], "insulin-stimulated": [ 181 ], "glucose": [ 182 ], "disposal.": [ 183 ], "These": [ 184 ], "associated": [ 186 ], "significantly": [ 189 ], "increased": [ 190 ], "AMPK": [ 191 ], "phosphorylation": [ 192 ], "expressions": [ 195 ], "VEGF": [ 197 ], "receptors.": [ 200 ], "We": [ 201 ], "conclude": [ 202 ], "that": [ 203 ], "receptor": [ 205, 233 ], "agonists": [ 206, 234 ], "may": [ 207, 235 ], "exert": [ 208 ], "their": [ 209 ], "salutary": [ 210 ], "glycemic": [ 211 ], "effect": [ 212 ], "via": [ 213 ], "improving": [ 214 ], "sensitivity": [ 217 ], "development": [ 224 ], "resistance,": [ 227 ], "early": [ 229 ], "use": [ 230 ], "attenuate": [ 236 ], "as": [ 240, 242 ], "well": [ 241 ], "prevent": [ 243 ], "cardiovascular": [ 244 ], "complications": [ 245 ], "diabetes.": [ 247 ] }, "publication_date": "2016-07-19", "publication_year": 2016, "type": "article", "cited_by_count": 49, "authors": [ { "id": "https://openalex.org/A5101015319", "display_name": "Weidong Chai" }, { "id": "https://openalex.org/A5031036081", "display_name": "Zhuo Fu" }, { "id": "https://openalex.org/A5109438621", "display_name": "Kevin W. Aylor" }, { "id": "https://openalex.org/A5046840650", "display_name": "Eugene J. Barrett" }, { "id": "https://openalex.org/A5051839885", "display_name": "Zhenqi Liu" } ] }, { "id": "https://openalex.org/W3044102982", "doi": "https://doi.org/10.1016/j.biopha.2020.110523", "title": "Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses osteoclastogenesis through the inhibition of NF-\u03baB and MAPK pathways via GLP-1R", "abstract": null, "publication_date": "2020-07-20", "publication_year": 2020, "type": "article", "cited_by_count": 53, "authors": [ { "id": "https://openalex.org/A5100389142", "display_name": "Ziyi Li" }, { "id": "https://openalex.org/A5045567474", "display_name": "Shilun Li" }, { "id": "https://openalex.org/A5103489204", "display_name": "Na Wang" }, { "id": "https://openalex.org/A5100784178", "display_name": "Peng Xue" }, { "id": "https://openalex.org/A5100416175", "display_name": "Yukun Li" } ] }, { "id": "https://openalex.org/W3080877256", "doi": "https://doi.org/10.1016/j.jdiacomp.2020.107723", "title": "Anti-inflammatory properties of antidiabetic drugs: A \u201cpromised land\u201d in the COVID-19 era?", "abstract": null, "publication_date": "2020-08-26", "publication_year": 2020, "type": "review", "cited_by_count": 84, "authors": [ { "id": "https://openalex.org/A5058321397", "display_name": "Niki Katsiki" }, { "id": "https://openalex.org/A5089847244", "display_name": "Ele Ferrannini" } ] }, { "id": "https://openalex.org/W3199001556", "doi": "https://doi.org/10.1111/dom.14551", "title": "Gastrointestinal tolerability of once\u2010weekly semaglutide 2.4\u00a0mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss", "abstract": { "Abstract": [ 0 ], "Aim": [ 1 ], "We": [ 2 ], "evaluated": [ 3, 97 ], "gastrointestinal": [ 4 ], "(GI)": [ 5 ], "adverse": [ 6 ], "events": [ 7 ], "(AEs)": [ 8 ], "with": [ 9, 16, 86, 117, 123, 148, 181, 192, 197, 216, 244 ], "once\u2010weekly": [ 10 ], "semaglutide": [ 11, 53, 87, 109, 118, 149, 182, 217, 231, 245 ], "2.4": [ 12, 54, 88, 119, 183, 232, 246 ], "mg": [ 13, 55, 89, 120, 184, 233, 247 ], "in": [ 14, 39, 187 ], "adults": [ 15 ], "overweight": [ 17 ], "or": [ 18, 59 ], "obesity": [ 19 ], "and": [ 20, 28, 79, 91, 140, 158, 253 ], "their": [ 21 ], "contribution": [ 22 ], "to": [ 23, 49, 81, 208 ], "weight": [ 24 ], "loss": [ 25 ], "(WL).": [ 26 ], "Materials": [ 27 ], "methods": [ 29 ], "AE": [ 30 ], "analyses": [ 31 ], "pooled": [ 32 ], "data": [ 33, 101 ], "from": [ 34 ], "the": [ 35, 212 ], "Semaglutide": [ 36 ], "Treatment": [ 37 ], "Effect": [ 38 ], "People": [ 40 ], "With": [ 41 ], "Obesity": [ 42 ], "(STEP)": [ 43 ], "1\u20103": [ 44 ], "trials": [ 45 ], "for": [ 46, 173 ], "participants": [ 47, 104, 168, 188 ], "randomized": [ 48 ], "68": [ 50 ], "weeks": [ 51, 107 ], "of": [ 52, 69, 108, 130, 153, 211, 260 ], "(n": [ 56, 61 ], "=": [ 57, 62 ], "2117)": [ 58 ], "placebo": [ 60 ], "1262).": [ 63 ], "WL": [ 64, 75, 180, 215, 256 ], "was": [ 65, 96, 185, 223, 235, 257 ], "analysed": [ 66 ], "by": [ 67, 78, 225 ], "presence/absence": [ 68 ], "GI": [ 70, 82, 84, 112, 146, 174, 193, 204, 226, 239, 261 ], "AEs.": [ 71, 83, 175, 227, 262 ], "Mediation": [ 72 ], "analysis": [ 73, 201 ], "estimated": [ 74 ], "effects": [ 76 ], "mediated": [ 77, 224 ], "unrelated": [ 80 ], "tolerability": [ 85 ], "maintenance": [ 90, 234 ], "cessation": [ 92 ], "after": [ 93, 163 ], "dose": [ 94, 164 ], "escalation": [ 95 ], "using": [ 98 ], "STEP": [ 99, 177, 229 ], "4": [ 100 ], "among": [ 102 ], "803": [ 103 ], "tolerating": [ 105 ], "20": [ 106 ], "run\u2010in.": [ 110 ], "Results": [ 111 ], "AEs": [ 113, 147, 194, 205, 240 ], "were": [ 114, 150, 241 ], "more": [ 115, 242 ], "common": [ 116, 243 ], "than": [ 121, 248 ], "placebo,": [ 122, 219, 249 ], "most": [ 124, 160 ], "frequently": [ 125, 161 ], "nausea": [ 126 ], "(43.9%": [ 127 ], "vs.": [ 128, 134, 138, 143 ], "16.1%": [ 129 ], "participants),": [ 131 ], "diarrhoea": [ 132 ], "(29.7%": [ 133 ], "15.9%),": [ 135 ], "vomiting": [ 136 ], "(24.5%": [ 137 ], "6.3%)": [ 139 ], "constipation": [ 141 ], "(24.2%": [ 142 ], "11.1%).": [ 144 ], "Most": [ 145 ], "non\u2010serious": [ 151 ], "(99.5%": [ 152 ], "AEs),": [ 154 ], "mild\u2010to\u2010moderate": [ 155, 252 ], "(98.1%),": [ 156 ], "transient": [ 157 ], "occurred": [ 159 ], "during/shortly": [ 162 ], "escalation.": [ 165 ], "Few": [ 166 ], "semaglutide\u2010treated": [ 167 ], "(4.3%)": [ 169 ], "permanently": [ 170 ], "discontinued": [ 171 ], "treatment": [ 172 ], "In": [ 176, 228 ], "1\u20103,": [ 178 ], "mean": [ 179 ], "similar": [ 186 ], "without": [ 189 ], "(9.6%\u201017.1%)": [ 190 ], "versus": [ 191, 218 ], "(11.4%\u201017.7%).": [ 195 ], "Consistent": [ 196 ], "this": [ 198 ], "observation,": [ 199 ], "mediation": [ 200 ], "found": [ 202 ], "that": [ 203 ], "contributed": [ 206 ], "little": [ 207 ], "semaglutide\u2010induced": [ 209 ], "WL:": [ 210 ], "additional": [ 213 ], "7.6%\u201014.4%": [ 214 ], "<1": [ 220 ], "percentage": [ 221 ], "point": [ 222 ], "4,": [ 230 ], "well": [ 236 ], "tolerated.": [ 237 ], "Conclusions": [ 238 ], "but": [ 250 ], "typically": [ 251 ], "transient.": [ 254 ], "Semaglutide\u2010induced": [ 255 ], "largely": [ 258 ], "independent": [ 259 ] }, "publication_date": "2021-09-13", "publication_year": 2021, "type": "article", "cited_by_count": 120, "authors": [ { "id": "https://openalex.org/A5027441223", "display_name": "Sean Wharton" }, { "id": "https://openalex.org/A5011187014", "display_name": "Salvatore Calanna" }, { "id": "https://openalex.org/A5084593004", "display_name": "Melanie J. Davies" }, { "id": "https://openalex.org/A5009921349", "display_name": "Dror Dicker" }, { "id": "https://openalex.org/A5075289235", "display_name": "Bryan Goldman" }, { "id": "https://openalex.org/A5001655356", "display_name": "Ildiko Lingvay" }, { "id": "https://openalex.org/A5080475619", "display_name": "Ofri Mosenzon" }, { "id": "https://openalex.org/A5060266336", "display_name": "Domenica Rubino" }, { "id": "https://openalex.org/A5017671388", "display_name": "Mette S. Thomsen" }, { "id": "https://openalex.org/A5026596594", "display_name": "Thomas A. Wadden" }, { "id": "https://openalex.org/A5040913971", "display_name": "Sue D. Pedersen" } ] }, { "id": "https://openalex.org/W2755440592", "doi": "https://doi.org/10.1016/j.yexcr.2017.09.018", "title": "Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), extracellular signal-related kinase (ERK)1/2, and cAMP/protein kinase A (PKA) signaling pathways involving \u03b2-catenin", "abstract": null, "publication_date": "2017-09-15", "publication_year": 2017, "type": "article", "cited_by_count": 74, "authors": [ { "id": "https://openalex.org/A5081050879", "display_name": "Xuelun Wu" }, { "id": "https://openalex.org/A5045567474", "display_name": "Shilun Li" }, { "id": "https://openalex.org/A5100784178", "display_name": "Peng Xue" }, { "id": "https://openalex.org/A5100416176", "display_name": "Yukun Li" } ] }, { "id": "https://openalex.org/W2772734366", "doi": "https://doi.org/10.1016/j.jneuroim.2017.12.005", "title": "Both classic Gs-cAMP/PKA/CREB and alternative Gs-cAMP/PKA/p38\u03b2/CREB signal pathways mediate exenatide-stimulated expression of M2 microglial markers", "abstract": null, "publication_date": "2017-12-12", "publication_year": 2017, "type": "article", "cited_by_count": 51, "authors": [ { "id": "https://openalex.org/A5080638735", "display_name": "Haiyun Wu" }, { "id": "https://openalex.org/A5084219550", "display_name": "Xue-Qi Tang" }, { "id": "https://openalex.org/A5100458764", "display_name": "Hao Liu" }, { "id": "https://openalex.org/A5053665163", "display_name": "Xiao-Fang Mao" }, { "id": "https://openalex.org/A5100641858", "display_name": "Yong\u2010Xiang Wang" } ] }, { "id": "https://openalex.org/W2417601845", "doi": "https://doi.org/10.1155/2016/5908656", "title": "Increasing GLP-1 Circulating Levels by Bariatric Surgery or by GLP-1 Receptor Agonists Therapy: Why Are the Clinical Consequences so Different?", "abstract": { "The": [ 0 ], "\u201cincretin": [ 1 ], "effect\u201d": [ 2 ], "is": [ 3, 12, 40, 106, 163 ], "used": [ 4 ], "to": [ 5, 21, 42, 137, 154 ], "describe": [ 6 ], "the": [ 7, 15, 24, 28, 34, 38, 62, 83, 96, 110, 133, 138, 145, 152, 189 ], "observation": [ 8 ], "that": [ 9, 22, 51, 126, 166 ], "more": [ 10 ], "insulin": [ 11, 44 ], "secreted": [ 13 ], "after": [ 14, 23, 132 ], "oral": [ 16 ], "administration": [ 17, 26 ], "of": [ 18, 27, 31, 36, 64, 113, 128, 141, 147, 192 ], "glucose": [ 19, 186 ], "compared": [ 20 ], "intravenous": [ 25 ], "same": [ 29 ], "amount": [ 30 ], "glucose.": [ 32 ], "During": [ 33, 78 ], "absorption": [ 35 ], "meals,": [ 37, 79 ], "gut": [ 39, 84 ], "thought": [ 41 ], "regulate": [ 43 ], "secretion": [ 45, 131 ], "by": [ 46 ], "secreting": [ 47 ], "a": [ 48, 195, 200 ], "specific": [ 49, 80 ], "factor": [ 50 ], "targets": [ 52 ], "pancreatic": [ 53 ], "beta": [ 54 ], "cells.": [ 55 ], "Additional": [ 56 ], "research": [ 57 ], "confirmed": [ 58 ], "this": [ 59, 156 ], "hypothesis": [ 60 ], "with": [ 61 ], "discovery": [ 63 ], "two": [ 65 ], "hormones": [ 66 ], "called": [ 67 ], "incretins:": [ 68 ], "gastric": [ 69 ], "inhibitory": [ 70 ], "peptide": [ 71, 75, 196 ], "(GIP)": [ 72 ], "and": [ 73, 86, 102, 170, 182, 198 ], "glucagon-like": [ 74 ], "1": [ 76 ], "(GLP-1).": [ 77 ], "cells": [ 81 ], "in": [ 82, 95, 117 ], "(L": [ 85 ], "K": [ 87 ], "enteroendocrine": [ 88 ], "cells)": [ 89 ], "secrete": [ 90 ], "incretins,": [ 91 ], "causing": [ 92 ], "an": [ 93 ], "increase": [ 94 ], "blood": [ 97 ], "concentrations": [ 98 ], "of,": [ 99 ], "respectively,": [ 100 ], "GLP-1": [ 101, 130, 148, 167, 184, 193 ], "GIP.": [ 103 ], "Bariatric": [ 104 ], "surgery": [ 105, 134, 172 ], "now": [ 107, 164 ], "proposed": [ 108 ], "during": [ 109 ], "therapeutic": [ 111 ], "management": [ 112 ], "type": [ 114, 175 ], "2": [ 115, 176 ], "diabetes": [ 116 ], "obese": [ 118 ], "or": [ 119 ], "overweight": [ 120 ], "populations.": [ 121 ], "It": [ 122 ], "has": [ 123 ], "been": [ 124 ], "hypothesized": [ 125 ], "restoration": [ 127 ], "endogenous": [ 129, 181 ], "may": [ 135 ], "contribute": [ 136 ], "postsurgical": [ 139 ], "resolution": [ 140 ], "diabetes.": [ 142, 177 ], "In": [ 143 ], "2005,": [ 144 ], "commercialization": [ 146 ], "receptor": [ 149, 168 ], "agonists": [ 150, 169 ], "gave": [ 151 ], "possibility": [ 153 ], "test": [ 155 ], "hypothesis.": [ 157 ], "A": [ 158 ], "few": [ 159 ], "years": [ 160 ], "later,": [ 161 ], "it": [ 162 ], "accepted": [ 165 ], "bariatric": [ 171 ], "differently": [ 173 ], "improve": [ 174 ], "These": [ 178 ], "differences": [ 179 ], "between": [ 180 ], "exogenous": [ 183 ], "on": [ 185 ], "homeostasis": [ 187 ], "emphasized": [ 188 ], "dual": [ 190 ], "properties": [ 191 ], "as": [ 194, 199 ], "hormone": [ 197 ], "neurotransmitter.": [ 201 ] }, "publication_date": "2016-01-01", "publication_year": 2016, "type": "review", "cited_by_count": 25, "authors": [ { "id": "https://openalex.org/A5027712968", "display_name": "Chlo\u00e9 Amouyal" }, { "id": "https://openalex.org/A5081180378", "display_name": "Fabrizio Andr\u00e9elli" } ] }, { "id": "https://openalex.org/W2085673400", "doi": "https://doi.org/10.1097/mjt.0b013e3182204c16", "title": "Liraglutide for the Treatment of Type 2 Diabetes", "abstract": { "This": [ 0 ], "review": [ 1 ], "updates": [ 2 ], "the": [ 3, 19, 41, 131, 138, 149, 174, 188 ], "pharmacology,": [ 4 ], "efficacy,": [ 5 ], "safety,": [ 6 ], "and": [ 7, 50, 60, 66, 109, 128, 141, 171, 203, 210, 223, 237 ], "tolerability": [ 8 ], "of": [ 9, 21, 133, 151, 156, 190, 192, 200 ], "liraglutide,": [ 10, 43 ], "a": [ 11, 246 ], "glucagon-like": [ 12, 47 ], "peptide": [ 13, 48 ], "1": [ 14 ], "(GLP-1)": [ 15 ], "analog": [ 16, 77 ], "approved": [ 17 ], "for": [ 18, 36, 72, 115, 130, 249 ], "treatment": [ 20, 132 ], "type": [ 22 ], "2": [ 23, 154 ], "diabetes": [ 24 ], "(T2DM)": [ 25 ], "in": [ 26, 38, 97, 104, 123, 143, 180, 218, 232 ], "January": [ 27 ], "2010.": [ 28 ], "MEDLINE": [ 29 ], "was": [ 30 ], "searched": [ 31, 71 ], "(May": [ 32 ], "2009-January": [ 33 ], "1,": [ 34 ], "2011)": [ 35 ], "articles": [ 37 ], "English,": [ 39 ], "using": [ 40 ], "terms": [ 42 ], "NN2211,": [ 44 ], "incretin": [ 45 ], "mimetic,": [ 46 ], "(GLP)-1,": [ 49 ], "GLP-1": [ 51, 76 ], "receptor": [ 52 ], "agonist.": [ 53 ], "Abstracts": [ 54 ], "from": [ 55 ], "key": [ 56 ], "meetings": [ 57 ], "(ADA": [ 58 ], "2009": [ 59 ], "2010,": [ 61, 63 ], "AACE": [ 62 ], "EASD": [ 64, 67 ], "2009,": [ 65 ], "2010)": [ 68 ], "were": [ 69 ], "also": [ 70, 120 ], "relevant": [ 73 ], "data.": [ 74 ], "A": [ 75 ], "with": [ 78, 112, 125, 167, 194, 208, 230, 251 ], "pharmacokinetic": [ 79 ], "properties": [ 80 ], "allowing": [ 81 ], "once-daily": [ 82 ], "administration": [ 83 ], "via": [ 84 ], "subcutaneous": [ 85 ], "injection,": [ 86 ], "liraglutide": [ 87, 152, 159, 193, 212, 231, 243 ], "has": [ 88, 101, 119, 160 ], "shown": [ 89, 162 ], "clinical": [ 90, 145, 181, 233 ], "benefits": [ 91 ], "when": [ 92 ], "used": [ 93 ], "as": [ 94 ], "monotherapy": [ 95, 100 ], "or": [ 96 ], "combination.": [ 98 ], "Liraglutide": [ 99, 118, 139 ], "demonstrated": [ 102, 148, 187 ], "efficacy": [ 103, 150 ], "reducing": [ 105 ], "hemoglobin": [ 106 ], "A1c": [ 107 ], "(A1C)": [ 108 ], "body": [ 110, 224 ], "weight,": [ 111 ], "low": [ 113 ], "risk": [ 114 ], "hypoglycemic": [ 116 ], "events.": [ 117 ], "been": [ 121, 161 ], "studied": [ 122 ], "combination": [ 124 ], "metformin,": [ 126 ], "glimepiride,": [ 127 ], "rosiglitazone": [ 129 ], "T2DM.": [ 134, 252 ], "Extension": [ 135 ], "studies": [ 136 ], "within": [ 137 ], "Effects": [ 140 ], "Action": [ 142 ], "Diabetes": [ 144 ], "program": [ 146 ], "have": [ 147, 186 ], "over": [ 153 ], "years": [ 155 ], "treatment.": [ 157 ], "Overall,": [ 158 ], "to": [ 163, 196, 214 ], "be": [ 164, 245 ], "well": [ 165 ], "tolerated,": [ 166 ], "dose-dependent": [ 168 ], "nausea,": [ 169 ], "vomiting,": [ 170 ], "diarrhea": [ 172 ], "being": [ 173 ], "most": [ 175 ], "commonly": [ 176, 228 ], "reported": [ 177 ], "adverse": [ 178 ], "events": [ 179, 227 ], "trials.": [ 182 ], "Extended": [ 183 ], "dosing": [ 184 ], "periods": [ 185 ], "durability": [ 189 ], "response": [ 191 ], "respect": [ 195 ], "glycemic": [ 197 ], "control,": [ 198 ], "lack": [ 199 ], "weight": [ 201 ], "gain,": [ 202 ], "blood": [ 204 ], "pressure": [ 205 ], "benefits.": [ 206 ], "Compared": [ 207 ], "exenatide": [ 209 ], "sitagliptin,": [ 211 ], "seems": [ 213 ], "offer": [ 215 ], "greater": [ 216 ], "improvements": [ 217 ], "A1C,": [ 219 ], "fasting": [ 220 ], "plasma": [ 221 ], "glucose,": [ 222 ], "weight.": [ 225 ], "Adverse": [ 226 ], "associated": [ 229 ], "trials": [ 234 ], "included": [ 235 ], "nausea": [ 236 ], "hypoglycemia.": [ 238 ], "Emerging": [ 239 ], "data": [ 240 ], "suggest": [ 241 ], "that": [ 242 ], "may": [ 244 ], "useful": [ 247 ], "option": [ 248 ], "patients": [ 250 ] }, "publication_date": "2011-07-06", "publication_year": 2011, "type": "review", "cited_by_count": 24, "authors": [ { "id": "https://openalex.org/A5110471765", "display_name": "Kyle R. Peters" } ] }, { "id": "https://openalex.org/W4318716359", "doi": "https://doi.org/10.1136/bmjopen-2022-068652", "title": "Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry)", "abstract": { "Introduction": [ 0 ], "Clozapine": [ 1 ], "and": [ 2, 18, 24, 52, 86, 111, 171, 174, 181, 204, 212, 229, 238, 249, 264, 280, 292 ], "olanzapine": [ 3, 103 ], "are": [ 4, 13 ], "some": [ 5 ], "of": [ 6, 48, 60, 142, 177, 221, 227, 231, 255, 259 ], "the": [ 7, 46, 57, 74, 106, 218, 245, 250, 256, 281 ], "most": [ 8 ], "effective": [ 9 ], "antipsychotics,": [ 10 ], "but": [ 11 ], "both": [ 12 ], "associated": [ 14 ], "with": [ 15, 63, 94, 125, 133, 209, 271 ], "weight": [ 16 ], "gain": [ 17 ], "relevant": [ 19 ], "metabolic": [ 20, 75 ], "disturbances,": [ 21 ], "including": [ 22 ], "pre-diabetes": [ 23, 134 ], "diabetes.": [ 25 ], "Non-pharmacological/behavioural": [ 26 ], "interventions": [ 27 ], "have": [ 28 ], "had": [ 29 ], "limited": [ 30 ], "effects": [ 31, 59, 216 ], "counteracting": [ 32 ], "these": [ 33 ], "adverse": [ 34 ], "effects.": [ 35 ], "Semaglutide,": [ 36 ], "a": [ 37, 66, 71, 95, 115, 126, 147, 222 ], "glucagon-like": [ 38 ], "peptide": [ 39 ], "1": [ 40 ], "receptor": [ 41 ], "agonist,": [ 42 ], "is": [ 43, 114, 157, 242 ], "approved": [ 44, 243 ], "for": [ 45, 151, 274 ], "treatment": [ 47, 62, 104 ], "type": [ 49 ], "2": [ 50 ], "diabetes": [ 51, 136 ], "obesity.": [ 53 ], "We": [ 54 ], "will": [ 55, 137, 233, 265, 286 ], "investigate": [ 56 ], "long-term": [ 58 ], "add-on": [ 61 ], "semaglutide": [ 64, 145 ], "once": [ 65, 70, 146 ], "week": [ 67, 72, 148 ], "versus": [ 68 ], "placebo": [ 69, 150 ], "on": [ 73, 217 ], "status": [ 76 ], "in": [ 77, 161, 167, 269 ], "pre-diabetic": [ 78 ], "(glycated": [ 79 ], "haemoglobin": [ 80 ], "A1c": [ 81 ], "(HbA1c)": [ 82 ], "35\u201347": [ 83 ], "mmol/mol": [ 84, 90 ], "(5.4%\u20136.4%)": [ 85 ], "diabetic": [ 87 ], "(HbA1c": [ 88 ], "48\u201357": [ 89 ], "(6.5%\u20137.4%))": [ 91 ], "patients": [ 92, 123 ], "diagnosed": [ 93, 124 ], "schizophrenia": [ 96, 127 ], "spectrum": [ 97, 128 ], "disorder": [ 98 ], "who": [ 99 ], "initiated": [ 100 ], "clozapine": [ 101 ], "or": [ 102, 135, 149 ], "within": [ 105 ], "last": [ 107 ], "60": [ 108 ], "months.": [ 109 ], "Methods": [ 110 ], "analysis": [ 112 ], "This": [ 113, 240 ], "26-week,": [ 116 ], "double-blinded,": [ 117 ], "randomised,": [ 118 ], "placebo-controlled": [ 119 ], "trial.": [ 120 ], "Altogether,": [ 121 ], "104": [ 122 ], "disorder,": [ 129 ], "aged": [ 130 ], "18\u201365": [ 131 ], "years,": [ 132 ], "be": [ 138, 235, 266, 287 ], "randomised": [ 139 ], "to": [ 140 ], "injections": [ 141 ], "1.0": [ 143 ], "mg": [ 144 ], "26": [ 152 ], "weeks.": [ 153 ], "The": [ 154, 284 ], "primary": [ 155 ], "endpoint": [ 156 ], "change": [ 158 ], "from": [ 159 ], "baseline": [ 160 ], "HbA1c.": [ 162 ], "Secondary": [ 163 ], "endpoints": [ 164 ], "include": [ 165 ], "changes": [ 166 ], "body": [ 168, 198 ], "weight,": [ 169 ], "hip": [ 170 ], "waist": [ 172 ], "circumference": [ 173 ], "plasma": [ 175 ], "levels": [ 176 ], "insulin,": [ 178 ], "glucagon,": [ 179 ], "glucose,": [ 180 ], "C-peptide,": [ 182 ], "insulin": [ 183 ], "sensitivity,": [ 184 ], "beta": [ 185 ], "cell": [ 186 ], "function,": [ 187, 189 ], "hepatic": [ 188 ], "fibrosis-4": [ 190 ], "score,": [ 191 ], "lipid": [ 192 ], "profile,": [ 193 ], "incretin": [ 194 ], "hormones,": [ 195 ], "bone": [ 196, 200 ], "markers,": [ 197 ], "composition,": [ 199 ], "density,": [ 201 ], "proteomic": [ 202 ], "analyses": [ 203 ], "oxidative": [ 205 ], "stress": [ 206 ], "markers.": [ 207 ], "Together": [ 208 ], "alcohol,": [ 210 ], "tobacco": [ 211 ], "drug": [ 213 ], "use,": [ 214 ], "potential": [ 215 ], "reward": [ 219 ], "value": [ 220 ], "sweet\u2013fat": [ 223 ], "stimulus,": [ 224 ], "psychopathology,": [ 225 ], "level": [ 226 ], "activity": [ 228 ], "quality": [ 230 ], "life": [ 232 ], "also": [ 234 ], "assessed.": [ 236 ], "Ethics": [ 237 ], "dissemination": [ 239 ], "study": [ 241 ], "by": [ 244 ], "Danish": [ 246 ], "Medicines": [ 247 ], "Agency": [ 248 ], "regional": [ 251 ], "scientific": [ 252 ], "ethics": [ 253 ], "committee": [ 254 ], "Capital": [ 257 ], "Region": [ 258 ], "Denmark": [ 260 ], "(committee": [ 261 ], "C,": [ 262 ], "#H-20019008)": [ 263 ], "carried": [ 267 ], "out": [ 268 ], "accordance": [ 270 ], "International": [ 272 ], "Council": [ 273 ], "Harmonisation": [ 275 ], "Good": [ 276 ], "Clinical": [ 277 ], "Practice": [ 278 ], "guidelines": [ 279 ], "Helsinki": [ 282 ], "Declaration.": [ 283 ], "results": [ 285 ], "disseminated": [ 288 ], "through": [ 289 ], "peer-review": [ 290 ], "publications": [ 291 ], "conference": [ 293 ], "presentations.": [ 294 ], "Trial": [ 295 ], "registration": [ 296 ], "number": [ 297 ], "NCT04892199": [ 298 ], ".": [ 299 ] }, "publication_date": "2023-01-01", "publication_year": 2023, "type": "article", "cited_by_count": 32, "authors": [ { "id": "https://openalex.org/A5015849186", "display_name": "Marie Reeberg Sass" }, { "id": "https://openalex.org/A5043115961", "display_name": "Andreas Aalkj\u00e6r Danielsen" }, { "id": "https://openalex.org/A5001564110", "display_name": "Ole K\u00f6hler\u2010Forsberg" }, { "id": "https://openalex.org/A5055959400", "display_name": "Heidi Storgaard" }, { "id": "https://openalex.org/A5079352451", "display_name": "Filip K. Knop" }, { "id": "https://openalex.org/A5062126653", "display_name": "Mette \u00d8degaard Nielsen" }, { "id": "https://openalex.org/A5050303522", "display_name": "Anders Sj\u00f6din" }, { "id": "https://openalex.org/A5015327943", "display_name": "Ole Mors" }, { "id": "https://openalex.org/A5056944189", "display_name": "Christoph U. Correll" }, { "id": "https://openalex.org/A5065962810", "display_name": "Claus Thorn Ekstr\u00f8m" }, { "id": "https://openalex.org/A5087770071", "display_name": "Maj Vinberg" }, { "id": "https://openalex.org/A5001762767", "display_name": "Jimmi Nielsen" }, { "id": "https://openalex.org/A5004120950", "display_name": "Tina Vilsb\u00f8ll" }, { "id": "https://openalex.org/A5001609083", "display_name": "Anders Fink\u2010Jensen" } ] }, { "id": "https://openalex.org/W2010000105", "doi": "https://doi.org/10.1007/s00125-011-2440-x", "title": "Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety", "abstract": null, "publication_date": "2012-01-13", "publication_year": 2012, "type": "article", "cited_by_count": 95, "authors": [ { "id": "https://openalex.org/A5009485093", "display_name": "David Nathanson" }, { "id": "https://openalex.org/A5058729901", "display_name": "Bengt Ullman" }, { "id": "https://openalex.org/A5015304728", "display_name": "Ulrika L\u00f6fstr\u00f6m" }, { "id": "https://openalex.org/A5051635215", "display_name": "Anders Hedman" }, { "id": "https://openalex.org/A5058455382", "display_name": "Mats Frick" }, { "id": "https://openalex.org/A5071915626", "display_name": "\u00c5ke Sj\u00f6holm" }, { "id": "https://openalex.org/A5041540706", "display_name": "Thomas Nystr\u00f6m" } ] }, { "id": "https://openalex.org/W3014553064", "doi": "https://doi.org/10.1007/s00415-020-09813-4", "title": "GLP-1 receptor agonists in diabetes for stroke prevention: a systematic review and meta-analysis", "abstract": null, "publication_date": "2020-04-04", "publication_year": 2020, "type": "review", "cited_by_count": 54, "authors": [ { "id": "https://openalex.org/A5054317612", "display_name": "Konark Malhotra" }, { "id": "https://openalex.org/A5049558076", "display_name": "Aristeidis H. Katsanos" }, { "id": "https://openalex.org/A5009013499", "display_name": "Vaia Lambadiari" }, { "id": "https://openalex.org/A5057166846", "display_name": "Nitin Goyal" }, { "id": "https://openalex.org/A5037648017", "display_name": "Lina Palaiodimou" }, { "id": "https://openalex.org/A5063924715", "display_name": "Maria Kosmidou" }, { "id": "https://openalex.org/A5038111489", "display_name": "Christos Krogias" }, { "id": "https://openalex.org/A5060351508", "display_name": "Andrei V. Alexandrov" }, { "id": "https://openalex.org/A5019953858", "display_name": "Georgios Tsivgoulis" } ] }, { "id": "https://openalex.org/W4233375494", "doi": "https://doi.org/10.2146/ajhp050459", "title": "Exenatide", "abstract": { "Exenatide": [ 0 ], "offers": [ 1 ], "a": [ 2 ], "novel": [ 3 ], "treatment": [ 4 ], "option": [ 5 ], "for": [ 6 ], "patients": [ 7 ], "with": [ 8 ], "type": [ 9 ], "2": [ 10 ], "diabetes": [ 11 ], "mellitus": [ 12 ], "who": [ 13 ], "are": [ 14 ], "refractory": [ 15 ], "to": [ 16 ], "metformin": [ 17 ], "or": [ 18, 21 ], "sulfonylurea": [ 19 ], "therapy": [ 20 ], "both.": [ 22 ] }, "publication_date": "2006-02-16", "publication_year": 2006, "type": "review", "cited_by_count": 47, "authors": [ { "id": "https://openalex.org/A5001681602", "display_name": "Grant M. Bray" } ] }, { "id": "https://openalex.org/W2996954386", "doi": "https://doi.org/10.1172/jci.insight.134221", "title": "Exenatide induces frataxin expression and improves mitochondrial function in Friedreich ataxia", "abstract": { "Friedreich": [ 0, 24, 82, 140, 164, 202 ], "ataxia": [ 1, 25, 141, 165 ], "is": [ 2, 16, 26 ], "an": [ 3 ], "autosomal": [ 4 ], "recessive": [ 5 ], "neurodegenerative": [ 6 ], "disease": [ 7, 22 ], "associated": [ 8 ], "with": [ 9, 81 ], "a": [ 10, 160, 174, 198 ], "high": [ 11 ], "diabetes": [ 12 ], "prevalence.": [ 13 ], "No": [ 14 ], "treatment": [ 15, 176 ], "available": [ 17 ], "to": [ 18, 119 ], "prevent": [ 19 ], "or": [ 20 ], "delay": [ 21 ], "progression.": [ 23 ], "caused": [ 27 ], "by": [ 28 ], "intronic": [ 29 ], "GAA": [ 30 ], "trinucleotide": [ 31 ], "repeat": [ 32 ], "expansions": [ 33 ], "in": [ 34, 52, 71, 72, 75, 79, 100, 111, 122, 139, 159, 163, 171, 185, 201 ], "the": [ 35, 60 ], "frataxin-encoding": [ 36 ], "FXN": [ 37 ], "gene": [ 38 ], "that": [ 39 ], "reduce": [ 40 ], "frataxin": [ 41, 106, 130, 169, 190 ], "expression,": [ 42, 131 ], "impair": [ 43 ], "iron-sulfur": [ 44, 108 ], "cluster": [ 45 ], "biogenesis,": [ 46 ], "cause": [ 47 ], "oxidative": [ 48, 133 ], "stress,": [ 49, 134 ], "and": [ 50, 55, 63, 74, 78, 98, 107, 114, 116, 135, 149, 188 ], "result": [ 51 ], "mitochondrial": [ 53, 137, 183 ], "dysfunction": [ 54 ], "apoptosis.": [ 56 ], "Here": [ 57 ], "we": [ 58 ], "examined": [ 59 ], "metabolic,": [ 61 ], "neuroprotective,": [ 62 ], "frataxin-inducing": [ 64, 153 ], "effects": [ 65 ], "of": [ 66, 91, 155 ], "glucagon-like": [ 67 ], "peptide-1": [ 68 ], "(GLP-1)": [ 69 ], "analogs": [ 70, 127, 181 ], "vivo": [ 73 ], "vitro": [ 76 ], "models": [ 77 ], "patients": [ 80 ], "ataxia.": [ 83, 203 ], "The": [ 84, 152 ], "GLP-1": [ 85, 126, 180 ], "analog": [ 86 ], "exenatide": [ 87, 156 ], "improved": [ 88, 136 ], "glucose": [ 89 ], "homeostasis": [ 90 ], "frataxin-deficient": [ 92, 186 ], "mice": [ 93 ], "through": [ 94 ], "enhanced": [ 95 ], "insulin": [ 96 ], "content": [ 97 ], "secretion": [ 99 ], "pancreatic": [ 101 ], "\u03b2": [ 102, 112, 147 ], "cells.": [ 103 ], "Exenatide": [ 104 ], "induced": [ 105, 129, 143 ], "cluster-containing": [ 109 ], "proteins": [ 110 ], "cells": [ 113, 148, 187 ], "brain": [ 115 ], "was": [ 117, 157 ], "protective": [ 118 ], "sensory": [ 120, 150 ], "neurons": [ 121 ], "dorsal": [ 123 ], "root": [ 124 ], "ganglia.": [ 125 ], "also": [ 128 ], "reduced": [ 132 ], "function": [ 138, 184 ], "patients'": [ 142 ], "pluripotent": [ 144 ], "stem": [ 145 ], "cell-derived": [ 146 ], "neurons.": [ 151 ], "effect": [ 154 ], "confirmed": [ 158 ], "pilot": [ 161 ], "trial": [ 162 ], "patients,": [ 166 ], "showing": [ 167 ], "modest": [ 168 ], "induction": [ 170 ], "platelets": [ 172 ], "over": [ 173 ], "5-week": [ 175 ], "course.": [ 177 ], "Taken": [ 178 ], "together,": [ 179 ], "improve": [ 182 ], "induce": [ 189 ], "expression.": [ 191 ], "Our": [ 192 ], "findings": [ 193 ], "identify": [ 194 ], "incretin": [ 195 ], "receptors": [ 196 ], "as": [ 197 ], "therapeutic": [ 199 ], "target": [ 200 ] }, "publication_date": "2019-12-26", "publication_year": 2019, "type": "article", "cited_by_count": 71, "authors": [ { "id": "https://openalex.org/A5080380194", "display_name": "Mariana Igoillo\u2010Esteve" }, { "id": "https://openalex.org/A5050297472", "display_name": "Ana F. Oliveira" }, { "id": "https://openalex.org/A5016441509", "display_name": "Cristina Cosentino" }, { "id": "https://openalex.org/A5057698631", "display_name": "Federica Fantuzzi" }, { "id": "https://openalex.org/A5077185495", "display_name": "C\u00e9line Demarez" }, { "id": "https://openalex.org/A5110298193", "display_name": "Sanna Toivonen" }, { "id": "https://openalex.org/A5009097976", "display_name": "Am\u00e9lie Hu" }, { "id": "https://openalex.org/A5011384937", "display_name": "Satyan Chintawar" }, { "id": "https://openalex.org/A5101931631", "display_name": "Miguel Lopes" }, { "id": "https://openalex.org/A5071354164", "display_name": "Nathalie Pachera" }, { "id": "https://openalex.org/A5102020919", "display_name": "Ying Cai" }, { "id": "https://openalex.org/A5076815074", "display_name": "Baroj Abdulkarim" }, { "id": "https://openalex.org/A5000608187", "display_name": "Myriam Rai" }, { "id": "https://openalex.org/A5054574491", "display_name": "Lorella Marselli" }, { "id": "https://openalex.org/A5000550995", "display_name": "Piero Marchetti" }, { "id": "https://openalex.org/A5112902741", "display_name": "Tariq Mohammad" }, { "id": "https://openalex.org/A5048048176", "display_name": "Jean\u2010Christophe Jonas" }, { "id": "https://openalex.org/A5033948203", "display_name": "Marina Boscolo" }, { "id": "https://openalex.org/A5080418392", "display_name": "Massimo Pandolfo" }, { "id": "https://openalex.org/A5064248322", "display_name": "D\u00e9cio L. Eizirik" }, { "id": "https://openalex.org/A5056936819", "display_name": "Miriam Cnop" } ] }, { "id": "https://openalex.org/W3033951558", "doi": "https://doi.org/10.2215/cjn.02690320", "title": "Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease", "abstract": { "Diabetic": [ 0 ], "kidney": [ 1, 24, 57, 65, 97, 121, 148, 161, 185 ], "disease": [ 2 ], "and": [ 3, 14, 26, 29, 40, 56, 64, 69, 93, 96, 101, 110, 117, 120, 142, 147, 169, 184, 189, 200, 211, 214 ], "its": [ 4 ], "comorbid": [ 5 ], "conditions,": [ 6 ], "including": [ 7 ], "atherosclerotic": [ 8 ], "cardiovascular": [ 9, 27, 54, 63, 119, 183 ], "disease,": [ 10 ], "heart": [ 11, 95, 146 ], "failure,": [ 12 ], "diabetes,": [ 13 ], "obesity,": [ 15 ], "are": [ 16, 48 ], "interconnected": [ 17 ], "conditions": [ 18 ], "that": [ 19, 52 ], "compound": [ 20 ], "the": [ 21, 62, 75, 105, 165, 190, 196, 206 ], "risk": [ 22, 122, 155, 174, 187 ], "of": [ 23, 67, 78, 99, 107, 167, 192, 198, 209 ], "failure": [ 25, 186 ], "mortality,": [ 28 ], "exponentiate": [ 30 ], "health": [ 31 ], "care": [ 32 ], "costs.": [ 33 ], "Sodium": [ 34 ], "glucose": [ 35 ], "cotransporter": [ 36 ], "2": [ 37 ], "inhibitor": [ 38 ], "(SGLT2i)": [ 39 ], "glucagon-like": [ 41 ], "peptide": [ 42 ], "1": [ 43 ], "receptor": [ 44 ], "agonist": [ 45 ], "(GLP-1": [ 46 ], "RA)": [ 47 ], "novel": [ 49 ], "diabetes": [ 50, 83, 116 ], "medications": [ 51 ], "prevent": [ 53 ], "events": [ 55 ], "failure.": [ 58 ], "Clinical": [ 59, 80 ], "trials": [ 60 ], "exploring": [ 61 ], "outcomes": [ 66 ], "SGLT2i": [ 68, 100, 109, 141, 168, 199, 210 ], "GLP-1": [ 70, 102, 111, 143, 170, 201, 212 ], "RA": [ 71, 112, 144, 171, 213 ], "have": [ 72 ], "fundamentally": [ 73 ], "shifted": [ 74 ], "treatment": [ 76 ], "paradigm": [ 77 ], "diabetes.": [ 79 ], "guidelines": [ 81 ], "for": [ 82, 113, 145, 157, 172, 195 ], "management": [ 84 ], "recommend": [ 85 ], "a": [ 86, 131, 153, 179 ], "more": [ 87 ], "holistic": [ 88 ], "approach": [ 89 ], "beyond": [ 90 ], "glycemic": [ 91 ], "control": [ 92 ], "emphasize": [ 94 ], "protection": [ 98 ], "RA.": [ 103, 202 ], "However,": [ 104 ], "adoption": [ 106 ], "prescribing": [ 108 ], "patients": [ 114, 158 ], "with": [ 115, 159 ], "high": [ 118 ], "has": [ 123 ], "been": [ 124 ], "slow.": [ 125 ], "In": [ 126 ], "this": [ 127 ], "review,": [ 128 ], "we": [ 129, 151, 177, 204 ], "provide": [ 130 ], "decision-making": [ 132 ], "tool": [ 133 ], "to": [ 134, 139 ], "help": [ 135 ], "clinicians": [ 136 ], "determine": [ 137 ], "when": [ 138 ], "consider": [ 140 ], "protection.": [ 149 ], "First,": [ 150 ], "discuss": [ 152 ], "comprehensive": [ 154 ], "assessment": [ 156 ], "diabetic": [ 160 ], "disease.": [ 162 ], "We": [ 163 ], "compare": [ 164 ], "effectiveness": [ 166 ], "different": [ 173 ], "categories.": [ 175 ], "Then,": [ 176 ], "present": [ 178 ], "decision": [ 180 ], "algorithm": [ 181 ], "using": [ 182 ], "stratification": [ 188 ], "strength": [ 191 ], "current": [ 193 ], "evidence": [ 194 ], "use": [ 197 ], "Lastly,": [ 203 ], "review": [ 205 ], "adverse": [ 207 ], "effects": [ 208 ], "propose": [ 215 ], "mitigation": [ 216 ], "strategies.": [ 217 ] }, "publication_date": "2020-06-09", "publication_year": 2020, "type": "review", "cited_by_count": 59, "authors": [ { "id": "https://openalex.org/A5100724273", "display_name": "Jiahua Li" }, { "id": "https://openalex.org/A5030853156", "display_name": "Oltjon Albajrami" }, { "id": "https://openalex.org/A5010084638", "display_name": "Min Zhuo" }, { "id": "https://openalex.org/A5047375622", "display_name": "Chelsea E. Hawley" }, { "id": "https://openalex.org/A5085331349", "display_name": "Julie M. Paik" } ] }, { "id": "https://openalex.org/W2884974106", "doi": "https://doi.org/10.1515/hmbci-2018-0031", "title": "Liraglutide for psychiatric disorders: clinical evidence and challenges", "abstract": { "Abstract": [ 0 ], "Obesity": [ 1 ], "and": [ 2, 8, 31, 52, 67, 94, 97 ], "diabetes": [ 3, 30 ], "are": [ 4, 23, 34 ], "both": [ 5 ], "risk": [ 6 ], "factors": [ 7 ], "consequences": [ 9 ], "of": [ 10, 29, 37, 43, 47, 83, 101 ], "psychiatric": [ 11, 84, 95 ], "disorders.": [ 12, 85 ], "Glucagon": [ 13 ], "like": [ 14 ], "peptide": [ 15 ], "1": [ 16 ], "(GLP-1)": [ 17 ], "receptor": [ 18 ], "agonists": [ 19 ], "such": [ 20 ], "as": [ 21, 76 ], "liraglutide": [ 22, 44, 60, 72, 102 ], "widely": [ 24 ], "used": [ 25 ], "in": [ 26, 103 ], "the": [ 27, 41, 81, 90, 98 ], "treatment": [ 28 ], "obesity.": [ 32 ], "There": [ 33 ], "considerable": [ 35 ], "amounts": [ 36 ], "preclinical": [ 38 ], "studies": [ 39 ], "showing": [ 40 ], "effects": [ 42 ], "on": [ 45 ], "promotion": [ 46 ], "neurogenesis,": [ 48 ], "while": [ 49 ], "preventing": [ 50 ], "apoptosis": [ 51 ], "oxidation.": [ 53 ], "Preliminary": [ 54 ], "clinical": [ 55 ], "evidence": [ 56 ], "has": [ 57, 73 ], "suggested": [ 58 ], "that": [ 59 ], "could": [ 61 ], "decrease": [ 62 ], "weight": [ 63 ], "gain,": [ 64 ], "improve": [ 65 ], "cognition": [ 66 ], "prevent": [ 68 ], "cognitive": [ 69 ], "decline.": [ 70 ], "Accordingly,": [ 71 ], "been": [ 74 ], "regarded": [ 75 ], "a": [ 77 ], "potential": [ 78 ], "candidate": [ 79 ], "for": [ 80 ], "management": [ 82 ], "Herein,": [ 86 ], "we": [ 87 ], "will": [ 88 ], "discuss": [ 89 ], "association": [ 91 ], "between": [ 92 ], "obesity/diabetes": [ 93 ], "disorders,": [ 96 ], "emerging": [ 99 ], "use": [ 100 ], "psychiatry.": [ 104 ] }, "publication_date": "2018-07-18", "publication_year": 2018, "type": "review", "cited_by_count": 26, "authors": [ { "id": "https://openalex.org/A5027184454", "display_name": "Mehmet Akif Camkurt" }, { "id": "https://openalex.org/A5046905888", "display_name": "Luca Lavagnino" }, { "id": "https://openalex.org/A5015615473", "display_name": "Xiang Y. Zhang" }, { "id": "https://openalex.org/A5040845311", "display_name": "Ant\u00f4nio L\u00facio Teixeira" } ] }, { "id": "https://openalex.org/W4360952476", "doi": "https://doi.org/10.1186/s12933-023-01800-z", "title": "Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study", "abstract": null, "publication_date": "2023-03-25", "publication_year": 2023, "type": "article", "cited_by_count": 40, "authors": [ { "id": "https://openalex.org/A5088133732", "display_name": "Sara Piccini" }, { "id": "https://openalex.org/A5052870822", "display_name": "Giuseppe Favacchio" }, { "id": "https://openalex.org/A5030483396", "display_name": "Cristina Panico" }, { "id": "https://openalex.org/A5047976239", "display_name": "Emanuela Morenghi" }, { "id": "https://openalex.org/A5053802958", "display_name": "Franco Folli" }, { "id": "https://openalex.org/A5021896784", "display_name": "Gherardo Mazziotti" }, { "id": "https://openalex.org/A5011245991", "display_name": "Andrea Lania" }, { "id": "https://openalex.org/A5046822593", "display_name": "Marco Mirani" } ] }, { "id": "https://openalex.org/W2130249104", "doi": "https://doi.org/10.1152/ajpregu.00326.2009", "title": "Lesions of area postrema and subfornical organ alter exendin-4-induced brain activation without preventing the hypophagic effect of the GLP-1 receptor agonist", "abstract": { "The": [ 0, 33, 124 ], "mechanism": [ 1 ], "and": [ 2, 14, 55, 64, 99, 102, 121, 157, 167, 170, 174, 184 ], "route": [ 3 ], "whereby": [ 4 ], "glucagon-like": [ 5 ], "peptide": [ 6 ], "1": [ 7 ], "(GLP-1)": [ 8 ], "receptor": [ 9 ], "agonists,": [ 10 ], "such": [ 11 ], "as": [ 12 ], "GLP-1": [ 13 ], "exendin-4": [ 15 ], "(Ex-4),": [ 16 ], "access": [ 17 ], "the": [ 18, 37, 43, 51, 56, 62, 75, 86, 105, 110, 118, 127, 154, 181, 190, 199, 202, 215, 222, 227 ], "central": [ 19, 158 ], "nervous": [ 20 ], "system": [ 21 ], "(CNS)": [ 22 ], "to": [ 23, 30, 41 ], "exert": [ 24 ], "their": [ 25 ], "metabolic": [ 26, 63 ], "effects": [ 27, 66, 88 ], "have": [ 28 ], "yet": [ 29 ], "be": [ 31 ], "clarified.": [ 32 ], "primary": [ 34 ], "objective": [ 35 ], "of": [ 36, 46, 67, 74, 89, 107, 113, 126, 137, 153, 180, 210, 224, 229 ], "present": [ 38, 191 ], "study": [ 39, 128 ], "was": [ 40 ], "investigate": [ 42 ], "potential": [ 44 ], "role": [ 45, 197 ], "two": [ 47 ], "circumventricular": [ 48 ], "organs": [ 49 ], "(CVOs),": [ 50 ], "area": [ 52 ], "postrema": [ 53 ], "(AP)": [ 54 ], "subfornical": [ 57 ], "organ": [ 58 ], "(SFO),": [ 59 ], "in": [ 60, 117, 147, 201, 220, 226, 233 ], "mediating": [ 61, 221 ], "CNS-stimulating": [ 65 ], "Ex-4.": [ 68, 90 ], "We": [ 69 ], "demonstrated": [ 70 ], "that": [ 71, 131, 214 ], "electrolytic": [ 72 ], "ablation": [ 73 ], "AP,": [ 76 ], "SFO,": [ 77 ], "or": [ 78 ], "AP": [ 79, 91 ], "+": [ 80, 92 ], "SFO": [ 81, 93 ], "does": [ 82 ], "not": [ 83, 194 ], "acutely": [ 84 ], "prevent": [ 85 ], "anorectic": [ 87, 203 ], "lesion": [ 94 ], "chronically": [ 95 ], "decreased": [ 96 ], "food": [ 97 ], "intake": [ 98 ], "body": [ 100 ], "weight": [ 101 ], "also": [ 103, 129 ], "modulated": [ 104 ], "effect": [ 106, 204 ], "Ex-4": [ 108, 225 ], "on": [ 109 ], "neuronal": [ 111, 144 ], "activation": [ 112, 228 ], "brain": [ 114 ], "structures": [ 115, 150, 231 ], "involved": [ 116, 232 ], "hypothalamic-pituitary-adrenal": [ 119 ], "axis": [ 120 ], "glucose": [ 122 ], "metabolism.": [ 123 ], "results": [ 125, 192 ], "showed": [ 130 ], "CVO": [ 132 ], "lesions": [ 133 ], "blunted": [ 134 ], "Ex-4-induced": [ 135 ], "expression": [ 136 ], "c-": [ 138 ], "fos": [ 139 ], "mRNA": [ 140 ], "(a": [ 141 ], "widely": [ 142 ], "used": [ 143 ], "activity": [ 145 ], "marker)": [ 146 ], "1)": [ 148 ], "limbic": [ 149 ], "(bed": [ 151 ], "nucleus": [ 152, 179 ], "stria": [ 155 ], "terminalis": [ 156 ], "amygdala),": [ 159 ], "2)": [ 160 ], "hypothalamus": [ 161 ], "(paraventricular": [ 162 ], "hypothalamic": [ 163 ], "nucleus,": [ 164, 166, 177 ], "supraoptic": [ 165 ], "arcuate": [ 168 ], "nucleus),": [ 169 ], "3)": [ 171 ], "hindbrain": [ 172 ], "(lateral": [ 173 ], "lateral-external": [ 175 ], "parabrachial": [ 176 ], "medial": [ 178 ], "solitary": [ 182 ], "tract,": [ 183 ], "ventrolateral": [ 185 ], "medulla).": [ 186 ], "In": [ 187 ], "conclusion,": [ 188 ], "although": [ 189 ], "do": [ 193 ], "support": [ 195 ], "a": [ 196, 207 ], "for": [ 198 ], "CVOs": [ 200, 216 ], "induced": [ 205 ], "by": [ 206 ], "single": [ 208 ], "injection": [ 209 ], "Ex-4,": [ 211 ], "they": [ 212 ], "suggest": [ 213 ], "play": [ 217 ], "important": [ 218 ], "roles": [ 219 ], "actions": [ 223 ], "CNS": [ 230 ], "homeostatic": [ 234 ], "control.": [ 235 ] }, "publication_date": "2010-01-28", "publication_year": 2010, "type": "article", "cited_by_count": 44, "authors": [ { "id": "https://openalex.org/A5011618072", "display_name": "Elena\u2010Dana Baraboi" }, { "id": "https://openalex.org/A5037629850", "display_name": "Pauline Smith" }, { "id": "https://openalex.org/A5045866756", "display_name": "Alastair V. Ferguson" }, { "id": "https://openalex.org/A5051764425", "display_name": "Denis Richard" } ] }, { "id": "https://openalex.org/W1976367840", "doi": "https://doi.org/10.1177/0091270005278806", "title": "Effect of Exenatide on the Steady\u2010State Pharmacokinetics of Digoxin", "abstract": { "This": [ 0 ], "open\u2010label": [ 1 ], "study": [ 2 ], "investigated": [ 3 ], "the": [ 4, 10, 62, 101, 114, 130 ], "effect": [ 5 ], "of": [ 6, 14, 18, 135 ], "exenatide": [ 7, 38 ], "coadministration": [ 8, 58 ], "on": [ 9, 52, 167 ], "steady\u2010state": [ 11, 65, 149 ], "plasma": [ 12, 46, 81 ], "pharmacokinetics": [ 13, 150 ], "digoxin.": [ 15 ], "A": [ 16 ], "total": [ 17 ], "21": [ 19 ], "healthy": [ 20 ], "male": [ 21 ], "subjects": [ 22 ], "received": [ 23 ], "digoxin": [ 24, 66, 82, 93, 104, 148 ], "(day": [ 25 ], "1,": [ 26 ], "0.5": [ 27 ], "mg": [ 28, 34 ], "twice": [ 29, 43 ], "daily;": [ 30 ], "days": [ 31, 53 ], "2\u201312,": [ 32 ], "0.25": [ 33 ], "once": [ 35 ], "daily)": [ 36 ], "and": [ 37, 47, 55, 71, 89 ], "(days": [ 39 ], "8\u201312,": [ 40 ], "10": [ 41 ], "\u03bcg": [ 42 ], "daily).": [ 44 ], "Digoxin": [ 45, 121 ], "urine": [ 48 ], "concentrations": [ 49, 111 ], "were": [ 50, 112, 125 ], "measured": [ 51 ], "7": [ 54 ], "12.": [ 56 ], "Exenatide": [ 57, 140 ], "did": [ 59 ], "not": [ 60, 126, 143, 163 ], "change": [ 61 ], "overall": [ 63 ], "24\u2010hour": [ 64 ], "exposure": [ 67 ], "(AUC": [ 68 ], "\u03c4,ss": [ 69 ], ")": [ 70 ], "C": [ 72, 83, 105 ], "min,ss": [ 73 ], "but": [ 74 ], "caused": [ 75 ], "a": [ 76 ], "17%": [ 77 ], "decrease": [ 78, 102 ], "in": [ 79, 92, 103, 118, 147 ], "mean": [ 80 ], "max,ss": [ 84, 95, 106 ], "(1.40": [ 85 ], "to": [ 86, 155 ], "1.16": [ 87 ], "ng/mL)": [ 88 ], "an": [ 90 ], "increase": [ 91 ], "t": [ 94 ], "(median": [ 96 ], "increase,": [ 97 ], "2.5": [ 98 ], "hours).": [ 99 ], "Although": [ 100 ], "was": [ 107 ], "statistically": [ 108 ], "significant,": [ 109 ], "peak": [ 110 ], "within": [ 113 ], "therapeutic": [ 115 ], "concentration": [ 116 ], "range": [ 117 ], "all": [ 119 ], "subjects.": [ 120 ], "urinary": [ 122 ], "pharmacokinetic": [ 123, 168 ], "parameters": [ 124 ], "altered.": [ 127 ], "Gastrointestinal": [ 128 ], "symptoms,": [ 129 ], "most": [ 131 ], "common": [ 132 ], "adverse": [ 133 ], "effects": [ 134 ], "exenatide,": [ 136 ], "decreased": [ 137 ], "over": [ 138 ], "time.": [ 139 ], "administration": [ 141 ], "does": [ 142, 162 ], "cause": [ 144 ], "any": [ 145 ], "changes": [ 146 ], "that": [ 151 ], "would": [ 152 ], "be": [ 153 ], "expected": [ 154 ], "have": [ 156 ], "clinical": [ 157 ], "sequelae;": [ 158 ], "thus,": [ 159 ], "dosage": [ 160 ], "adjustment": [ 161 ], "appear": [ 164 ], "warranted,": [ 165 ], "based": [ 166 ], "considerations.": [ 169 ] }, "publication_date": "2005-08-12", "publication_year": 2005, "type": "article", "cited_by_count": 68, "authors": [ { "id": "https://openalex.org/A5079794570", "display_name": "Prajakti A. Kothare" }, { "id": "https://openalex.org/A5112090783", "display_name": "Danny Soon" }, { "id": "https://openalex.org/A5064098013", "display_name": "Helle Linnebjerg" }, { "id": "https://openalex.org/A5100716431", "display_name": "Soomin Park" }, { "id": "https://openalex.org/A5100861990", "display_name": "Clark Chan" }, { "id": "https://openalex.org/A5031595875", "display_name": "Adeline Yeo" }, { "id": "https://openalex.org/A5103398375", "display_name": "Maggie Lim" }, { "id": "https://openalex.org/A5058443646", "display_name": "Kenneth Mace" }, { "id": "https://openalex.org/A5113704708", "display_name": "Stephen D. Wise" } ] }, { "id": "https://openalex.org/W2611973976", "doi": "https://doi.org/10.1111/dom.12963", "title": "Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials", "abstract": { "Aims": [ 0 ], "Liraglutide,": [ 1 ], "a": [ 2, 63, 93, 272 ], "GLP": [ 3 ], "\u20101": [ 4 ], "receptor": [ 5 ], "agonist,": [ 6 ], "regulates": [ 7 ], "appetite": [ 8 ], "via": [ 9 ], "receptors": [ 10 ], "in": [ 11, 108, 112, 158, 259, 265, 276, 288 ], "the": [ 12, 18, 53, 113, 127, 232, 250, 266 ], "brain.": [ 13 ], "Because": [ 14 ], "of": [ 15, 20, 130, 137, 176, 191, 239, 253 ], "concerns": [ 16 ], "regarding": [ 17, 249 ], "potential": [ 19 ], "centrally\u2010acting": [ 21 ], "anti\u2010obesity": [ 22 ], "medications": [ 23 ], "to": [ 24, 77, 103, 204, 262 ], "affect": [ 25 ], "mental": [ 26 ], "health,": [ 27 ], "pooled": [ 28, 128, 242 ], "neuropsychiatric": [ 29, 104, 251 ], "safety": [ 30, 105, 252 ], "data": [ 31 ], "from": [ 32, 52 ], "all": [ 33, 109 ], "phase": [ 34, 114, 182 ], "2": [ 35, 71, 169 ], "and": [ 36, 122, 133, 144, 160, 168 ], "3a": [ 37, 115, 183 ], "randomized,": [ 38 ], "double\u2010blind": [ 39 ], "trials": [ 40 ], "with": [ 41, 62, 72, 92, 255, 279 ], "liraglutide": [ 42, 54, 80, 159, 167, 200, 220, 256, 280 ], "3.0": [ 43, 81, 194, 221, 257 ], "mg": [ 44, 82, 222, 258 ], "were": [ 45, 57, 75, 106, 120, 155, 293 ], "evaluated": [ 46 ], "post": [ 47 ], "hoc": [ 48 ], ".": [ 49 ], "Methods": [ 50 ], "Data": [ 51 ], "weight\u2010management": [ 55 ], "programme": [ 56 ], "pooled.": [ 58 ], "Across": [ 59 ], "trials,": [ 60, 116, 184 ], "individuals": [ 61, 165, 217 ], "body": [ 64 ], "mass": [ 65 ], "index": [ 66 ], "\u226530": [ 67 ], "or": [ 68, 86, 179, 291 ], "\u226527": [ 69 ], "kg/m": [ 70 ], "weight\u2010related": [ 73 ], "comorbidities": [ 74 ], "randomized": [ 76, 132 ], "once\u2010daily": [ 78 ], "subcutaneous": [ 79 ], "(n": [ 83, 88 ], "=": [ 84, 89 ], "3384)": [ 85 ], "placebo": [ 87, 161, 172, 202, 227 ], "1941),": [ 90 ], "both": [ 91 ], "500": [ 94 ], "kcal/d": [ 95 ], "deficit": [ 96 ], "diet,": [ 97 ], "plus": [ 98 ], "exercise.": [ 99 ], "Adverse": [ 100 ], "events": [ 101, 175 ], "related": [ 102 ], "collected": [ 107 ], "trials.": [ 110, 268 ], "Additionally,": [ 111 ], "validated": [ 117 ], "mental\u2010health": [ 118 ], "questionnaires": [ 119 ], "prospectively": [ 121 ], "systematically": [ 123 ], "administered.": [ 124 ], "Results": [ 125, 238 ], "In": [ 126, 181 ], "analysis": [ 129, 243 ], "5325": [ 131 ], "exposed": [ 134 ], "individuals,": [ 135 ], "rates": [ 136 ], "depression": [ 138, 292 ], "(2.1": [ 139 ], "vs": [ 140, 147, 195, 201, 208, 223 ], "2.1": [ 141 ], "events/100": [ 142, 149 ], "person\u2010years)": [ 143, 150 ], "anxiety": [ 145 ], "(1.9": [ 146 ], "1.7": [ 148 ], "through": [ 151, 281, 295 ], "adverse": [ 152, 174, 282 ], "event": [ 153, 283 ], "reporting": [ 154 ], "similarly": [ 156 ], "low": [ 157 ], "groups.": [ 162 ], "Nine": [ 163 ], "(0.3%)": [ 164 ], "receiving": [ 166, 171, 219, 226 ], "(0.1%)": [ 170 ], "reported": [ 173, 228 ], "suicidal": [ 177, 229, 277, 289 ], "ideation": [ 178, 230, 278 ], "behaviour.": [ 180 ], "mean": [ 185 ], "baseline": [ 186 ], "Patient": [ 187 ], "Health": [ 188 ], "Questionnaire\u20109": [ 189 ], "scores": [ 190 ], "2.8": [ 192 ], "\u00b1": [ 193, 197, 206, 210 ], "2.9": [ 196 ], "3.1": [ 198 ], "for": [ 199, 247 ], "improved": [ 203 ], "1.8": [ 205 ], "2.7": [ 207 ], "1.9": [ 209 ], "2.7,": [ 211 ], "respectively,": [ 212 ], "at": [ 213 ], "treatment": [ 214, 254 ], "end;": [ 215 ], "34/3291": [ 216 ], "(1.0%)": [ 218, 225 ], "19/1843": [ 224 ], "on": [ 231 ], "Columbia\u2010Suicide": [ 233 ], "Severity": [ 234 ], "Rating": [ 235 ], "Scale.": [ 236 ], "Conclusions": [ 237 ], "this": [ 240 ], "exploratory": [ 241 ], "provide": [ 244 ], "no": [ 245, 285 ], "cause": [ 246 ], "concern": [ 248 ], "patients": [ 260 ], "similar": [ 261 ], "those": [ 263 ], "included": [ 264 ], "examined": [ 267 ], "Although": [ 269 ], "there": [ 270 ], "was": [ 271 ], "small": [ 273 ], "numerical": [ 274 ], "imbalance": [ 275 ], "reporting,": [ 284 ], "between\u2010treatment": [ 286 ], "imbalances": [ 287 ], "ideation/behaviour": [ 290 ], "noted": [ 294 ], "prospective": [ 296 ], "questionnaire": [ 297 ], "assessments.": [ 298 ] }, "publication_date": "2017-04-06", "publication_year": 2017, "type": "article", "cited_by_count": 102, "authors": [ { "id": "https://openalex.org/A5085642856", "display_name": "Patrick M. O\u2019Neil" }, { "id": "https://openalex.org/A5005405894", "display_name": "Vanita R. Aroda" }, { "id": "https://openalex.org/A5048067129", "display_name": "Arne Astrup" }, { "id": "https://openalex.org/A5062192624", "display_name": "Robert F. Kushner" }, { "id": "https://openalex.org/A5044479380", "display_name": "David C.W. Lau" }, { "id": "https://openalex.org/A5026596594", "display_name": "Thomas A. Wadden" }, { "id": "https://openalex.org/A5111550916", "display_name": "Jason Brett" }, { "id": "https://openalex.org/A5017538508", "display_name": "Ana\u2010Paula Cancino" }, { "id": "https://openalex.org/A5047195042", "display_name": "John Wilding" } ] }, { "id": "https://openalex.org/W2257678016", "doi": "https://doi.org/10.1517/13543784.2016.1123249", "title": "An overview of new GLP-1 receptor agonists for type 2 diabetes", "abstract": { "The": [ 0 ], "new": [ 1 ], "GLP-1RAs": [ 2 ], "may": [ 3, 66 ], "have": [ 4, 23 ], "the": [ 5, 34, 45, 48, 68 ], "benefit": [ 6 ], "of": [ 7, 70 ], "requiring": [ 8 ], "less": [ 9 ], "frequent": [ 10 ], "subcutaneous": [ 11 ], "dosing": [ 12 ], "or": [ 13 ], "being": [ 14 ], "active": [ 15 ], "by": [ 16 ], "oral": [ 17 ], "administration.": [ 18 ], "However,": [ 19 ], "cardiovascular": [ 20, 31, 36, 56, 64 ], "outcome": [ 21, 37 ], "trials": [ 22 ], "shown": [ 24 ], "that": [ 25 ], "DPP4": [ 26 ], "inhibitors": [ 27, 72 ], "are": [ 28 ], "neutral": [ 29 ], "for": [ 30, 88 ], "events": [ 32 ], "and": [ 33 ], "first": [ 35 ], "trial": [ 38, 46 ], "with": [ 39, 47, 62 ], "lixisenatide": [ 40 ], "reported": [ 41 ], "similar": [ 42 ], "results,": [ 43 ], "whereas": [ 44 ], "SGLT2": [ 49, 71 ], "inhibitor": [ 50 ], "empagliflozin": [ 51 ], "showed": [ 52 ], "a": [ 53, 74 ], "reduction": [ 54, 94 ], "in": [ 55, 60 ], "events.": [ 57 ], "These": [ 58 ], "findings": [ 59 ], "patients": [ 61 ], "high": [ 63 ], "risk": [ 65 ], "favor": [ 67 ], "use": [ 69 ], "as": [ 73 ], "second": [ 75 ], "line": [ 76 ], "treatment": [ 77 ], "after": [ 78 ], "metformin": [ 79 ], "but": [ 80 ], "there": [ 81 ], "should": [ 82 ], "still": [ 83 ], "be": [ 84 ], "an": [ 85 ], "important": [ 86 ], "role": [ 87 ], "novel": [ 89 ], "GLP-1RAs,": [ 90 ], "especially": [ 91 ], "when": [ 92 ], "weight": [ 93 ], "is": [ 95 ], "required.": [ 96 ] }, "publication_date": "2015-11-20", "publication_year": 2015, "type": "review", "cited_by_count": 43, "authors": [ { "id": "https://openalex.org/A5068775883", "display_name": "Brian Tomlinson" }, { "id": "https://openalex.org/A5102729971", "display_name": "Miao Hu" }, { "id": "https://openalex.org/A5100721872", "display_name": "Yuzhen Zhang" }, { "id": "https://openalex.org/A5043935811", "display_name": "Paul Chan" }, { "id": "https://openalex.org/A5112031007", "display_name": "Zhong-Min Liu" } ] }, { "id": "https://openalex.org/W2029228033", "doi": "https://doi.org/10.2337/dc11-0291", "title": "Effects of Exenatide on Measures of \u03b2-Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes", "abstract": { "OBJECTIVE": [ 0 ], "We": [ 1 ], "previously": [ 2 ], "showed": [ 3 ], "that": [ 4 ], "exenatide": [ 5 ], "(EXE)": [ 6 ], "enhanced": [ 7 ], "insulin": [ 8, 17 ], "secretion": [ 9, 132 ], "after": [ 10, 30, 40, 118, 267 ], "1": [ 11 ], "year": [ 12 ], "of": [ 13, 44, 120, 156 ], "treatment,": [ 14 ], "relative": [ 15 ], "to": [ 16, 59 ], "glargine": [ 18 ], "(GLAR),": [ 19 ], "with": [ 20, 53, 108, 172, 216, 219, 223, 261 ], "a": [ 21, 31, 268, 275 ], "similar": [ 22, 154 ], "glucose-lowering": [ 23 ], "action.": [ 24 ], "These": [ 25, 272 ], "effects": [ 26 ], "were": [ 27, 57, 98 ], "not": [ 28 ], "sustained": [ 29, 240, 266 ], "4-week": [ 32, 187, 210, 269 ], "off-drug": [ 33, 188, 211, 270 ], "period.": [ 34, 90, 271 ], "This": [ 35 ], "article": [ 36 ], "reports": [ 37 ], "the": [ 38, 66, 87, 141, 186, 192, 209, 213, 243, 258, 263 ], "results": [ 39 ], "additional": [ 41 ], "2": [ 42, 55 ], "years": [ 43 ], "exposure.": [ 45 ], "RESEARCH": [ 46 ], "DESIGN": [ 47 ], "AND": [ 48 ], "METHODS": [ 49 ], "Sixty-nine": [ 50 ], "metformin-treated": [ 51 ], "patients": [ 52, 64 ], "type": [ 54 ], "diabetes": [ 56 ], "randomized": [ 58 ], "EXE": [ 60, 149, 170, 190, 237, 248 ], "or": [ 61 ], "GLAR.": [ 62 ], "Forty-six": [ 63 ], "entered": [ 65 ], "2-year": [ 67 ], "extension": [ 68 ], "study": [ 69, 121 ], "in": [ 70, 153 ], "which": [ 71 ], "they": [ 72 ], "continued": [ 73 ], "their": [ 74 ], "allocated": [ 75 ], "therapy.": [ 76 ], "Thirty-six": [ 77 ], "completed": [ 78 ], "(EXE:": [ 79 ], "n": [ 80, 84 ], "=": [ 81, 85, 168, 198, 206, 234 ], "16;": [ 82 ], "GLAR:": [ 83 ], "20)": [ 86 ], "3-year": [ 88, 244, 259 ], "exposure": [ 89 ], "Insulin": [ 91 ], "sensitivity": [ 92 ], "(M": [ 93 ], "value)": [ 94 ], "and": [ 95, 115, 125, 138, 150, 162, 228, 238, 252 ], "\u03b2-cell": [ 96, 279 ], "function": [ 97 ], "measured": [ 99 ], "by": [ 100, 105, 195 ], "euglycemic": [ 101 ], "hyperinsulinemic": [ 102 ], "clamp": [ 103, 107 ], "followed": [ 104 ], "hyperglycemic": [ 106 ], "arginine": [ 109 ], "stimulation": [ 110 ], "at": [ 111 ], "pretreatment": [ 112 ], "(week": [ 113, 123 ], "52)": [ 114 ], "4": [ 116 ], "weeks": [ 117 ], "discontinuation": [ 119 ], "medication": [ 122 ], "56": [ 124 ], "week": [ 126 ], "172).": [ 127 ], "First-phase": [ 128 ], "glucose": [ 129 ], "stimulated": [ 130 ], "C-peptide": [ 131 ], "was": [ 133, 265 ], "adjusted": [ 134 ], "for": [ 135 ], "M": [ 136, 193 ], "value": [ 137, 194 ], "calculated": [ 139 ], "as": [ 140 ], "disposition": [ 142 ], "index": [ 143 ], "(DI).": [ 144 ], "RESULTS": [ 145 ], "At": [ 146 ], "3": [ 147 ], "years,": [ 148 ], "GLAR": [ 151, 173, 201, 224, 239, 253 ], "resulted": [ 152 ], "levels": [ 155 ], "glycemic": [ 157 ], "control:": [ 158 ], "6.6": [ 159 ], "\u00b1": [ 160, 164, 179, 226, 230 ], "0.2%": [ 161 ], "6.9": [ 163 ], "0.2%,": [ 165 ], "respectively": [ 166 ], "(P": [ 167, 197, 205 ], "0.186).": [ 169 ], "compared": [ 171, 215 ], "significantly": [ 174 ], "reduced": [ 175, 249 ], "body": [ 176, 250, 255 ], "weight": [ 177, 251 ], "(\u22127.9": [ 178 ], "1.8": [ 180 ], "kg;": [ 181 ], "P": [ 182, 233 ], "&lt;": [ 183 ], "0.001).": [ 184 ], "After": [ 185 ], "period,": [ 189, 212, 246 ], "increased": [ 191, 218, 254 ], "39%": [ 196 ], "0.006)": [ 199 ], "while": [ 200, 247 ], "had": [ 202 ], "no": [ 203 ], "effect": [ 204, 277 ], "0.647).": [ 207 ], "Following": [ 208, 257 ], "DI,": [ 214 ], "pretreatment,": [ 217 ], "EXE,": [ 220, 262 ], "but": [ 221 ], "decreased": [ 222 ], "(1.43": [ 225 ], "0.78": [ 227 ], "\u22120.99": [ 229 ], "0.65,": [ 231 ], "respectively;": [ 232 ], "0.028).": [ 235 ], "CONCLUSIONS": [ 236 ], "HbA1c": [ 241 ], "over": [ 242 ], "treatment": [ 245, 260 ], "weight.": [ 256 ], "DI": [ 264 ], "findings": [ 273 ], "suggest": [ 274 ], "beneficial": [ 276 ], "on": [ 278 ], "health.": [ 280 ] }, "publication_date": "2011-08-19", "publication_year": 2011, "type": "article", "cited_by_count": 236, "authors": [ { "id": "https://openalex.org/A5110611896", "display_name": "Mathijs C. Bunck" }, { "id": "https://openalex.org/A5059226156", "display_name": "A. H. Corner" }, { "id": "https://openalex.org/A5061198575", "display_name": "Bj\u00f6rn Eliasson" }, { "id": "https://openalex.org/A5113467761", "display_name": "Robert J. Heine" }, { "id": "https://openalex.org/A5112350413", "display_name": "Rimma M. Shaginian" }, { "id": "https://openalex.org/A5057557099", "display_name": "Marja\u2010Riitta Taskinen" }, { "id": "https://openalex.org/A5028599620", "display_name": "Ulf Smith" }, { "id": "https://openalex.org/A5028953583", "display_name": "Hannele Yki\u2010J\u00e4rvinen" }, { "id": "https://openalex.org/A5109335776", "display_name": "Micha\u00ebla Diamant" } ] }, { "id": "https://openalex.org/W2085912144", "doi": "https://doi.org/10.2337/dc06-2532", "title": "Exploring the Substitution of Exenatide for Insulin in Patients With Type 2 Diabetes Treated With Insulin in Combination With Oral Antidiabetes Agents", "abstract": { "OBJECTIVE\u2014": [ 0 ], "This": [ 1, 184 ], "16-week": [ 2 ], "study": [ 3, 93, 186 ], "explored": [ 4 ], "the": [ 5, 117, 130, 134, 176, 213, 219, 221 ], "safety": [ 6, 156 ], "of": [ 7, 32, 41, 45, 65, 92, 97, 99, 111, 114, 116, 127, 129, 149, 151, 210, 218, 235 ], "substituting": [ 8, 197 ], "exenatide": [ 9, 76, 163, 177, 198, 250 ], "for": [ 10, 77, 175, 199, 253 ], "insulin": [ 11, 19, 78, 84, 179, 236, 254 ], "in": [ 12, 20, 104, 246 ], "patients": [ 13, 47, 119, 137, 225 ], "with": [ 14, 22, 53, 124, 161, 226 ], "type": [ 15 ], "2": [ 16 ], "diabetes": [ 17, 66 ], "using": [ 18 ], "combination": [ 21 ], "oral": [ 23 ], "antidiabetes": [ 24 ], "agents.": [ 25 ], "RESEARCH": [ 26 ], "DESIGN": [ 27 ], "AND": [ 28 ], "METHODS\u2014": [ 29 ], "Successful": [ 30 ], "maintenance": [ 31 ], "glycemic": [ 33, 100, 121, 194 ], "control": [ 34, 101, 122, 195, 248 ], "was": [ 35, 158 ], "predefined": [ 36 ], "as": [ 37 ], "an": [ 38 ], "A1C": [ 39, 59 ], "increase": [ 40 ], "&lt;0.5%.": [ 42 ], "A": [ 43, 109 ], "total": [ 44, 110 ], "49": [ 46 ], "(aged": [ 48 ], "53": [ 49 ], "\u00b1": [ 50, 56, 61, 68 ], "8": [ 51 ], "years,": [ 52 ], "BMI": [ 54 ], "34": [ 55 ], "4": [ 57 ], "kg/m2,": [ 58 ], "8.1": [ 60 ], "1.1%,": [ 62 ], "and": [ 63, 172, 178, 215, 237 ], "duration": [ 64 ], "11": [ 67, 135 ], "7": [ 69 ], "years)": [ 70 ], "were": [ 71, 102, 170 ], "randomized": [ 72 ], "to": [ 73, 192, 206 ], "either": [ 74, 88 ], "substitute": [ 75 ], "or": [ 79, 94 ], "remain": [ 80 ], "on": [ 81 ], "their": [ 82 ], "current": [ 83 ], "regimen.": [ 85 ], "Patients": [ 86 ], "who": [ 87, 138, 230 ], "completed": [ 89 ], "\u22658": [ 90 ], "weeks": [ 91 ], "discontinued": [ 95, 144 ], "because": [ 96, 148 ], "loss": [ 98, 150 ], "included": [ 103 ], "primary": [ 105 ], "efficacy": [ 106 ], "analysis.": [ 107 ], "RESULTS\u2014": [ 108 ], "62%": [ 112 ], "(18": [ 113 ], "29)": [ 115 ], "exenatide-treated": [ 118, 136 ], "maintained": [ 120 ], "compared": [ 123 ], "81%": [ 125 ], "(13": [ 126 ], "16)": [ 128 ], "insulin-treated": [ 131 ], "patients.": [ 132 ], "Of": [ 133 ], "did": [ 139 ], "not": [ 140, 204 ], "maintain": [ 141 ], "control,": [ 142 ], "5": [ 143 ], "before": [ 145 ], "week": [ 146 ], "16": [ 147 ], "glucose": [ 152, 247 ], "control.": [ 153 ], "The": [ 154, 165 ], "overall": [ 155, 167 ], "profile": [ 157 ], "generally": [ 159 ], "consistent": [ 160 ], "previous": [ 162 ], "trials.": [ 164 ], "mean": [ 166 ], "hypoglycemia": [ 168 ], "rates": [ 169 ], "1.72": [ 171 ], "0.97": [ 173 ], "events/patient-year": [ 174 ], "reference": [ 180 ], "groups,": [ 181 ], "respectively.": [ 182 ], "CONCLUSIONS\u2014": [ 183 ], "pilot": [ 185 ], "suggests": [ 187 ], "that": [ 188, 224 ], "it": [ 189, 202 ], "is": [ 190, 203, 251 ], "feasible": [ 191 ], "sustain": [ 193 ], "when": [ 196 ], "insulin.": [ 200 ], "Although": [ 201 ], "possible": [ 205 ], "characterize": [ 207 ], "clear": [ 208 ], "predictors": [ 209 ], "outcome": [ 211 ], "given": [ 212 ], "size": [ 214 ], "exploratory": [ 216 ], "nature": [ 217 ], "study,": [ 220 ], "data": [ 222 ], "suggest": [ 223 ], "longer": [ 227 ], "disease": [ 228 ], "duration,": [ 229 ], "are": [ 231 ], "taking": [ 232 ], "higher": [ 233 ], "doses": [ 234 ], "have": [ 238 ], "less": [ 239 ], "endogenous": [ 240 ], "\u03b2-cell": [ 241 ], "function,": [ 242 ], "may": [ 243 ], "experience": [ 244 ], "deterioration": [ 245 ], "if": [ 249 ], "substituted": [ 252 ], "therapy.": [ 255 ] }, "publication_date": "2007-10-26", "publication_year": 2007, "type": "article", "cited_by_count": 96, "authors": [ { "id": "https://openalex.org/A5080379883", "display_name": "Stephen N. Davis" }, { "id": "https://openalex.org/A5071736666", "display_name": "Don Johns" }, { "id": "https://openalex.org/A5062921481", "display_name": "David Maggs" }, { "id": "https://openalex.org/A5074998128", "display_name": "Hangtao Xu" }, { "id": "https://openalex.org/A5024896088", "display_name": "Justin Northrup" }, { "id": "https://openalex.org/A5109961740", "display_name": "Robert G. Brodows" } ] }, { "id": "https://openalex.org/W2808008353", "doi": "https://doi.org/10.1016/s2213-8587(18)30104-9", "title": "Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial", "abstract": null, "publication_date": "2018-06-14", "publication_year": 2018, "type": "article", "cited_by_count": 586, "authors": [ { "id": "https://openalex.org/A5046793050", "display_name": "Katherine R. Tuttle" }, { "id": "https://openalex.org/A5055443598", "display_name": "Mark Lakshmanan" }, { "id": "https://openalex.org/A5009408665", "display_name": "Brian Rayner" }, { "id": "https://openalex.org/A5103165011", "display_name": "Robert S. Busch" }, { "id": "https://openalex.org/A5113170261", "display_name": "Alan G. Zimmermann" }, { "id": "https://openalex.org/A5026159613", "display_name": "D. Bradley Woodward" }, { "id": "https://openalex.org/A5051731762", "display_name": "Fady T. Botros" } ] }, { "id": "https://openalex.org/W2113983413", "doi": "https://doi.org/10.1111/hepr.12351", "title": "Pilot study of liraglutide effects in non\u2010alcoholic steatohepatitis and non\u2010alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN\u2010J)", "abstract": { "Aim": [ 0 ], "Non\u2010alcoholic": [ 1 ], "fatty": [ 2 ], "liver": [ 3, 49, 159, 219 ], "disease": [ 4, 29 ], "(": [ 5, 68 ], "NAFLD": [ 6 ], "),": [ 7 ], "a": [ 8, 53, 212 ], "hepatic": [ 9, 44 ], "manifestation": [ 10 ], "of": [ 11, 20, 42, 81 ], "metabolic": [ 12 ], "syndrome,": [ 13 ], "is": [ 14, 52 ], "associated": [ 15 ], "with": [ 16, 65, 200, 209, 227 ], "an": [ 17 ], "increased": [ 18 ], "risk": [ 19 ], "developing": [ 21 ], "lifestyle\u2010related": [ 22 ], "diseases": [ 23 ], "including": [ 24 ], "type": [ 25 ], "2": [ 26 ], "diabetes,": [ 27 ], "cardiovascular": [ 28 ], "and": [ 30, 79, 153, 185, 216, 221 ], "cerebral": [ 31 ], "vessel": [ 32 ], "disease.": [ 33 ], "No": [ 34 ], "current": [ 35 ], "drug": [ 36 ], "therapy": [ 37, 142, 169, 199 ], "provides": [ 38 ], "the": [ 39, 60, 77, 134 ], "ideal": [ 40 ], "effects": [ 41 ], "decreasing": [ 43 ], "inflammation": [ 45, 178 ], "while": [ 46 ], "simultaneously": [ 47 ], "improving": [ 48 ], "fibrosis.": [ 50 ], "Liraglutide": [ 51 ], "glucagon\u2010like": [ 54 ], "peptide\u20101": [ 55 ], "receptor": [ 56 ], "agonist": [ 57 ], "that": [ 58, 207 ], "affects": [ 59 ], "histological": [ 61, 177, 222 ], "findings": [ 62 ], "in": [ 63, 163, 224 ], "patients": [ 64, 226 ], "non\u2010alcoholic": [ 66 ], "steatohepatitis": [ 67 ], "NASH": [ 69, 85, 182, 225 ], ").": [ 70 ], "This": [ 71 ], "study": [ 72, 205 ], "was": [ 73, 161 ], "conducted": [ 74 ], "to": [ 75, 102, 104 ], "evaluate": [ 76 ], "effect": [ 78 ], "action": [ 80 ], "liraglutide": [ 82, 119, 141, 168, 210 ], "for": [ 83, 92, 125, 143, 170 ], "biopsy\u2010proven": [ 84 ], ".": [ 86 ], "Methods": [ 87 ], "After": [ 88 ], "lifestyle": [ 89, 135 ], "modification": [ 90, 136 ], "intervention": [ 91 ], "24": [ 93, 126, 144 ], "weeks,": [ 94 ], "subjects": [ 95, 139, 165, 174 ], "whose": [ 96, 109 ], "hemoglobin": [ 97 ], "A": [ 98 ], "1c": [ 99 ], "levels": [ 100, 112 ], "failed": [ 101 ], "improve": [ 103 ], "less": [ 105 ], "than": [ 106, 116 ], "6.0%": [ 107 ], "and/or": [ 108 ], "alanine": [ 110 ], "aminotransferase": [ 111 ], "were": [ 113 ], "not": [ 114 ], "lower": [ 115 ], "baseline,": [ 117 ], "received": [ 118, 140 ], "at": [ 120 ], "0.9": [ 121 ], "mg/body": [ 122 ], "per": [ 123 ], "day": [ 124 ], "weeks.": [ 127, 145, 172 ], "Results": [ 128 ], "Of": [ 129 ], "27": [ 130 ], "subjects,": [ 131 ], "26": [ 132 ], "completed": [ 133 ], "intervention.": [ 137 ], "Nineteen": [ 138 ], "Body": [ 146 ], "mass": [ 147 ], "index,": [ 148 ], "visceral": [ 149 ], "fat": [ 150 ], "accumulation,": [ 151 ], "aminotransferases": [ 152 ], "glucose": [ 154, 228 ], "abnormalities": [ 155 ], "improved": [ 156, 218 ], "significantly.": [ 157 ], "Repeated": [ 158 ], "biopsy": [ 160 ], "performed": [ 162 ], "10": [ 164 ], "who": [ 166 ], "continued": [ 167 ], "96": [ 171 ], "Six": [ 173 ], "showed": [ 175 ], "decreased": [ 176 ], "as": [ 179 ], "determined": [ 180, 187 ], "by": [ 181, 188 ], "activity": [ 183 ], "score": [ 184 ], "stage": [ 186 ], "B": [ 189 ], "runt": [ 190 ], "classification.": [ 191 ], "We": [ 192 ], "saw": [ 193 ], "no": [ 194 ], "significant": [ 195 ], "adverse": [ 196 ], "events": [ 197 ], "during": [ 198 ], "liraglutide.": [ 201 ], "Conclusion": [ 202 ], "Our": [ 203 ], "pilot": [ 204 ], "demonstrated": [ 206 ], "treatment": [ 208 ], "had": [ 211 ], "good": [ 213 ], "safety": [ 214 ], "profile": [ 215 ], "significantly": [ 217 ], "function": [ 220 ], "features": [ 223 ], "intolerance.": [ 229 ] }, "publication_date": "2014-05-05", "publication_year": 2014, "type": "article", "cited_by_count": 176, "authors": [ { "id": "https://openalex.org/A5060035569", "display_name": "Yuichiro Eguchi" }, { "id": "https://openalex.org/A5109407606", "display_name": "Yoichiro Kitajima" }, { "id": "https://openalex.org/A5016110387", "display_name": "Hideyuki Hyogo" }, { "id": "https://openalex.org/A5071111958", "display_name": "Kazuhiro Takahashi" }, { "id": "https://openalex.org/A5042052779", "display_name": "Motoyasu Kojima" }, { "id": "https://openalex.org/A5085574358", "display_name": "Masafumi Ono" }, { "id": "https://openalex.org/A5025920308", "display_name": "Norimasa Araki" }, { "id": "https://openalex.org/A5101508358", "display_name": "Kenichi Tanaka" }, { "id": "https://openalex.org/A5010245495", "display_name": "Miyuki Yamaguchi" }, { "id": "https://openalex.org/A5112415318", "display_name": "Yayoi Matsuda" }, { "id": "https://openalex.org/A5063119641", "display_name": "Yasushi Ide" }, { "id": "https://openalex.org/A5109483265", "display_name": "Taiga Otsuka" }, { "id": "https://openalex.org/A5026097438", "display_name": "Iwata Ozaki" }, { "id": "https://openalex.org/A5110388236", "display_name": "Naofumi Ono" }, { "id": "https://openalex.org/A5084250379", "display_name": "Takahisa Eguchi" }, { "id": "https://openalex.org/A5054851148", "display_name": "Keizo Anzai" } ] }, { "id": "https://openalex.org/W2092361523", "doi": "https://doi.org/10.1007/s00125-009-1515-4", "title": "Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas", "abstract": null, "publication_date": "2009-09-12", "publication_year": 2009, "type": "article", "cited_by_count": 188, "authors": [ { "id": "https://openalex.org/A5004550455", "display_name": "Jagdish Nachnani" }, { "id": "https://openalex.org/A5031394206", "display_name": "Deepti Bulchandani" }, { "id": "https://openalex.org/A5032195413", "display_name": "Anantha Ram Nookala" }, { "id": "https://openalex.org/A5090393773", "display_name": "Betty Herndon" }, { "id": "https://openalex.org/A5111433592", "display_name": "Agostino Molteni" }, { "id": "https://openalex.org/A5111088694", "display_name": "P. Pandya" }, { "id": "https://openalex.org/A5033122933", "display_name": "Richard Taylor" }, { "id": "https://openalex.org/A5113888872", "display_name": "Timothy P. Quinn" }, { "id": "https://openalex.org/A5113755490", "display_name": "Lamont G. Weide" }, { "id": "https://openalex.org/A5057960929", "display_name": "Laura Alba" } ] }, { "id": "https://openalex.org/W2527740737", "doi": "https://doi.org/10.1016/j.jad.2016.09.056", "title": "Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study", "abstract": null, "publication_date": "2016-10-07", "publication_year": 2016, "type": "article", "cited_by_count": 143, "authors": [ { "id": "https://openalex.org/A5032613018", "display_name": "Rodrigo B. Mansur" }, { "id": "https://openalex.org/A5041928272", "display_name": "Juhie Ahmed" }, { "id": "https://openalex.org/A5064858366", "display_name": "S. Danielle" }, { "id": "https://openalex.org/A5026591760", "display_name": "Hanna O. Woldeyohannes" }, { "id": "https://openalex.org/A5019579801", "display_name": "Mehala Subramaniapillai" }, { "id": "https://openalex.org/A5082289947", "display_name": "Julie A. Lovshin" }, { "id": "https://openalex.org/A5032384847", "display_name": "Jung Goo Lee" }, { "id": "https://openalex.org/A5083198014", "display_name": "Yena Lee" }, { "id": "https://openalex.org/A5076331964", "display_name": "Elisa Brietzke" }, { "id": "https://openalex.org/A5078192657", "display_name": "Eva Z. Reininghaus" }, { "id": "https://openalex.org/A5072555008", "display_name": "Kang Sim" }, { "id": "https://openalex.org/A5087770071", "display_name": "Maj Vinberg" }, { "id": "https://openalex.org/A5061342108", "display_name": "Natalie Rasgon" }, { "id": "https://openalex.org/A5011746730", "display_name": "Tom\u00e1\u0161 H\u00e1jek" }, { "id": "https://openalex.org/A5068850044", "display_name": "Roger S. McIntyre" } ] }, { "id": "https://openalex.org/W1539187429", "doi": "https://doi.org/10.3233/jpd-140364", "title": "Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson\u2019s Disease", "abstract": { "While": [ 0 ], "these": [ 1 ], "data": [ 2 ], "must": [ 3 ], "still": [ 4 ], "not": [ 5 ], "be": [ 6 ], "interpreted": [ 7 ], "as": [ 8, 24 ], "evidence": [ 9 ], "of": [ 10, 21 ], "neuroprotection,": [ 11 ], "they": [ 12 ], "nevertheless": [ 13 ], "provide": [ 14 ], "strong": [ 15 ], "encouragement": [ 16 ], "for": [ 17 ], "the": [ 18 ], "further": [ 19 ], "study": [ 20 ], "this": [ 22 ], "drug": [ 23 ], "a": [ 25 ], "potential": [ 26 ], "disease": [ 27 ], "modifying": [ 28 ], "agent": [ 29 ], "in": [ 30 ], "Parkinson's": [ 31 ], "disease.": [ 32 ] }, "publication_date": "2014-07-28", "publication_year": 2014, "type": "article", "cited_by_count": 282, "authors": [ { "id": "https://openalex.org/A5030193280", "display_name": "Ic\u00edar Avil\u00e9s-Olmos" }, { "id": "https://openalex.org/A5067401921", "display_name": "John Dickson" }, { "id": "https://openalex.org/A5000414294", "display_name": "Zinovia Kefalopoulou" }, { "id": "https://openalex.org/A5003960100", "display_name": "Atbin Djamshidian" }, { "id": "https://openalex.org/A5006880808", "display_name": "Joshua Kahan" }, { "id": "https://openalex.org/A5110225490", "display_name": "Peter J. Ell" }, { "id": "https://openalex.org/A5017380295", "display_name": "Peter S. Whitton" }, { "id": "https://openalex.org/A5021732872", "display_name": "Richard Wyse" }, { "id": "https://openalex.org/A5108758328", "display_name": "Tom Isaacs" }, { "id": "https://openalex.org/A5063335320", "display_name": "Andrew J. Lees" }, { "id": "https://openalex.org/A5040249146", "display_name": "Patricia Limousin" }, { "id": "https://openalex.org/A5031389008", "display_name": "Thomas Foltynie" } ] }, { "id": "https://openalex.org/W2887342240", "doi": "https://doi.org/10.2337/dc18-0680", "title": "Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial", "abstract": { "OBJECTIVE": [ 0 ], "Among": [ 1, 261 ], "patients": [ 2, 112, 244, 262 ], "with": [ 3, 8, 66, 138, 188, 214, 238, 246, 263, 268, 285 ], "type": [ 4, 67, 264 ], "2": [ 5, 68, 265 ], "diabetes": [ 6, 69, 266 ], "uncontrolled": [ 7, 267 ], "metformin,": [ 9, 269 ], "exenatide": [ 10, 32, 83, 94, 139, 151, 189, 199, 230, 247, 270 ], "once": [ 11 ], "weekly": [ 12 ], "(QW)": [ 13 ], "plus": [ 14, 88, 96, 101, 141, 191, 232, 272 ], "dapagliflozin": [ 15, 35, 90, 100, 142, 160, 192, 215, 233, 273 ], "combination": [ 16 ], "produced": [ 17 ], "greater": [ 18, 137, 187 ], "reductions": [ 19, 135, 185 ], "in": [ 20, 277 ], "glycemia,": [ 21, 278 ], "weight,": [ 22, 279 ], "and": [ 23, 43, 77, 127, 177, 183, 195, 203, 218, 224, 251, 280 ], "systolic": [ 24 ], "blood": [ 25 ], "pressure": [ 26 ], "(SBP)": [ 27 ], "at": [ 28, 47 ], "28": [ 29 ], "weeks": [ 30 ], "than": [ 31 ], "QW": [ 33, 84, 95, 140, 152, 190, 200, 231, 248, 271 ], "or": [ 34, 99, 159 ], "alone": [ 36 ], "(DURATION-8).": [ 37 ], "Here,": [ 38 ], "we": [ 39 ], "investigated": [ 40 ], "the": [ 41, 125 ], "safety": [ 42, 241, 288 ], "maintenance": [ 44 ], "of": [ 45 ], "efficacy": [ 46 ], "52": [ 48, 132, 283 ], "weeks,": [ 49, 133, 284 ], "after": [ 50 ], "a": [ 51 ], "24-week": [ 52 ], "extension.": [ 53 ], "RESEARCH": [ 54 ], "DESIGN": [ 55 ], "AND": [ 56 ], "METHODS": [ 57 ], "This": [ 58 ], "phase": [ 59 ], "3,": [ 60 ], "multicenter,": [ 61 ], "double-blind": [ 62 ], "study": [ 63 ], "randomized": [ 64, 116 ], "adults": [ 65 ], "(with": [ 70 ], "glycated": [ 71 ], "hemoglobin": [ 72 ], "[HbA1c]": [ 73 ], "8.0\u201312.0%": [ 74 ], "[64\u2013108": [ 75 ], "mmol/mol]": [ 76 ], "on": [ 78 ], "metformin": [ 79 ], "\u22651,500": [ 80 ], "mg/day)": [ 81 ], "to": [ 82, 212 ], "(2-mg": [ 85 ], "subcutaneous": [ 86 ], "injection)": [ 87 ], "once-daily": [ 89 ], "(10-mg": [ 91 ], "oral": [ 92, 97 ], "tablet),": [ 93 ], "placebo,": [ 98 ], "injected": [ 102 ], "placebo.": [ 103 ], "Extension-period": [ 104 ], "P": [ 105, 156, 164, 207, 221, 225 ], "values": [ 106, 169 ], "were": [ 107, 115, 136, 170, 186 ], "nominal.": [ 108 ], "RESULTS": [ 109 ], "Of": [ 110 ], "1,375": [ 111 ], "screened,": [ 113 ], "695": [ 114 ], "(mean": [ 117 ], "baseline": [ 118 ], "HbA1c": [ 119, 134, 168 ], "9.3%": [ 120 ], "[78": [ 121 ], "mmol/mol]);": [ 122 ], "81.2%": [ 123 ], "completed": [ 124, 129 ], "study,": [ 126 ], "75.3%": [ 128 ], "treatment.": [ 130 ], "At": [ 131 ], "(least": [ 143 ], "squares": [ 144 ], "mean": [ 145, 167 ], "change": [ 146 ], "\u22121.75%": [ 147 ], "[\u221219.1": [ 148 ], "mmol/mol])": [ 149 ], "versus": [ 150, 198 ], "(\u22121.38%": [ 153 ], "[\u221215.1": [ 154 ], "mmol/mol];": [ 155, 163 ], "=": [ 157, 222, 226 ], "0.006)": [ 158 ], "(\u22121.23%": [ 161 ], "[\u221213.4": [ 162 ], "&lt;": [ 165, 208 ], "0.001);": [ 166 ], "6.9%": [ 171 ], "(52": [ 172 ], "mmol/mol),": [ 173, 176, 180 ], "7.2%": [ 174 ], "(55": [ 175 ], "7.4%": [ 178 ], "(57": [ 179 ], "respectively.": [ 181 ], "Weight": [ 182 ], "SBP": [ 184, 281 ], "(\u22123.31": [ 193 ], "kg": [ 194, 202, 217 ], "\u22124.5": [ 196 ], "mmHg)": [ 197 ], "(\u22121.51": [ 201 ], "\u22120.7": [ 204 ], "mmHg;": [ 205, 220 ], "both": [ 206 ], "0.001)": [ 209 ], "but": [ 210 ], "similar": [ 211 ], "those": [ 213 ], "(\u22122.28": [ 216 ], "\u22122.7": [ 219 ], "0.057": [ 223 ], "0.100,": [ 227 ], "respectively).": [ 228 ], "The": [ 229 ], "regimen": [ 234 ], "was": [ 235 ], "well": [ 236 ], "tolerated": [ 237 ], "no": [ 239, 286 ], "unexpected": [ 240, 287 ], "findings;": [ 242 ], "more": [ 243 ], "treated": [ 245 ], "experienced": [ 249 ], "gastrointestinal": [ 250 ], "injection": [ 252 ], "site\u2013related": [ 253 ], "adverse": [ 254 ], "events.": [ 255 ], "No": [ 256 ], "major": [ 257 ], "hypoglycemia": [ 258 ], "occurred.": [ 259 ], "CONCLUSIONS": [ 260 ], "provided": [ 274 ], "sustained": [ 275 ], "improvements": [ 276 ], "over": [ 282 ], "findings.": [ 289 ] }, "publication_date": "2018-08-06", "publication_year": 2018, "type": "article", "cited_by_count": 94, "authors": [ { "id": "https://openalex.org/A5076877188", "display_name": "Serge Jabbour" }, { "id": "https://openalex.org/A5086072427", "display_name": "Juan P. Fr\u00edas" }, { "id": "https://openalex.org/A5050249929", "display_name": "Elise Hardy" }, { "id": "https://openalex.org/A5011258913", "display_name": "Azazuddin Ahmed" }, { "id": "https://openalex.org/A5100460656", "display_name": "Hui Wang" }, { "id": "https://openalex.org/A5112827962", "display_name": "Peter \u00d6hman" }, { "id": "https://openalex.org/A5002278673", "display_name": "Cristian Guja" } ] }, { "id": "https://openalex.org/W3036339650", "doi": "https://doi.org/10.1111/dom.14121", "title": "Exenatide extended release in patients with type 1 diabetes with and without residual insulin production", "abstract": { "Abstract": [ 0 ], "Aims": [ 1 ], "To": [ 2 ], "test": [ 3 ], "whether": [ 4, 24, 42 ], "a": [ 5, 53 ], "long\u2010acting": [ 6 ], "GLP\u20101": [ 7 ], "receptor": [ 8 ], "agonist": [ 9 ], "would": [ 10, 32, 45 ], "improve": [ 11 ], "glucose": [ 12 ], "control": [ 13 ], "in": [ 14, 62, 101, 144, 155, 177, 188, 279 ], "patients": [ 15 ], "with": [ 16, 64, 66, 206, 213, 227, 262, 272, 282 ], "type": [ 17 ], "1": [ 18 ], "diabetes": [ 19 ], "(T1D)": [ 20 ], "and": [ 21, 67, 220, 232, 249 ], "to": [ 22, 40, 77, 224 ], "determine": [ 23, 41 ], "the": [ 25, 34, 43, 87, 99, 123, 126, 129, 145, 156, 166, 178, 189 ], "presence": [ 26, 88 ], "of": [ 27, 57, 71, 91, 125, 209, 292 ], "residual": [ 28, 254 ], "beta": [ 29, 47 ], "cell": [ 30, 48 ], "function": [ 31 ], "affect": [ 33, 46 ], "response.": [ 35 ], "In": [ 36 ], "addition,": [ 37 ], "we": [ 38 ], "sought": [ 39 ], "drug": [ 44 ], "function.": [ 49 ], "Methods": [ 50 ], "We": [ 51 ], "performed": [ 52 ], "randomized": [ 54, 76 ], "placebo\u2010controlled": [ 55 ], "trial": [ 56 ], "exenatide": [ 58, 78, 146, 179, 214, 263, 273 ], "extended": [ 59 ], "release": [ 60 ], "(ER)": [ 61 ], "participants": [ 63, 74 ], "T1D": [ 65, 283 ], "without": [ 68 ], "detectable": [ 69, 92, 207, 290 ], "levels": [ 70, 105, 170, 208, 291 ], "C\u2010peptide.": [ 72, 210 ], "Seventy\u2010nine": [ 73 ], "were": [ 75, 110, 171, 259, 297 ], "ER": [ 79, 147, 180, 215, 274 ], "2": [ 80 ], "mcg": [ 81 ], "weekly,": [ 82 ], "or": [ 83, 89, 287 ], "placebo,": [ 84 ], "stratified": [ 85 ], "by": [ 86, 204, 253 ], "absence": [ 90 ], "C\u2010peptide": [ 93 ], "levels.": [ 94 ], "The": [ 95, 196, 236 ], "primary": [ 96, 127 ], "outcome": [ 97 ], "was": [ 98, 136, 201, 240, 250, 267 ], "difference": [ 100 ], "glycated": [ 102 ], "haemoglobin": [ 103 ], "(HbA1c)": [ 104 ], "at": [ 106, 198, 218 ], "24": [ 107, 221 ], "weeks.": [ 108 ], "Participants": [ 109 ], "followed": [ 111 ], "for": [ 112, 246 ], "another": [ 113 ], "6": [ 114 ], "months": [ 115 ], "off": [ 116 ], "study": [ 117 ], "drug.": [ 118 ], "Results": [ 119 ], "At": [ 120, 163 ], "week": [ 121, 164, 199 ], "24,": [ 122 ], "time": [ 124 ], "outcome,": [ 128 ], "least": [ 130 ], "squares": [ 131 ], "(LS)": [ 132 ], "mean": [ 133, 168 ], "HbA1c": [ 134, 169 ], "level": [ 135 ], "7.76%": [ 137 ], "(95%": [ 138, 151, 173, 184 ], "confidence": [ 139 ], "interval": [ 140 ], "[CI]": [ 141 ], "7.42,": [ 142 ], "8.10)": [ 143 ], "group": [ 148, 158, 181, 191 ], "versus": [ 149, 182 ], "8.0%": [ 150 ], "CI": [ 152, 174, 185 ], "7.64,": [ 153 ], "8.35)": [ 154 ], "placebo": [ 157, 190, 228 ], "(": [ 159, 192, 229 ], "P": [ 160, 193, 230, 233 ], "=": [ 161, 194, 234 ], "0.08).": [ 162 ], "12": [ 165, 200, 219 ], "LS": [ 167 ], "7.71%": [ 172 ], "7.37,": [ 175 ], "8.05)": [ 176 ], "8.05%": [ 183 ], "7.7,": [ 186 ], "8.4)": [ 187 ], "0.01).": [ 195 ], "improvement": [ 197 ], "driven": [ 202 ], "mainly": [ 203 ], "those": [ 205, 225 ], "Those": [ 211 ], "treated": [ 212, 226 ], "lost": [ 216 ], "weight": [ 217 ], "weeks": [ 222 ], "compared": [ 223 ], "<0.001": [ 231 ], "0.007).": [ 235 ], "total": [ 237 ], "insulin": [ 238, 255 ], "dose": [ 239 ], "lower,": [ 241 ], "but": [ 242, 265, 294 ], "not": [ 243, 251, 268, 298 ], "when": [ 244 ], "corrected": [ 245 ], "body": [ 247 ], "weight,": [ 248 ], "affected": [ 252 ], "production.": [ 256 ], "Adverse": [ 257 ], "events": [ 258 ], "more": [ 260 ], "frequent": [ 261 ], "ER,": [ 264 ], "hypoglycaemia": [ 266 ], "increased.": [ 269 ], "Conclusion": [ 270 ], "Treatment": [ 271 ], "may": [ 275 ], "have": [ 276, 289 ], "short\u2010term": [ 277, 295 ], "benefits": [ 278 ], "some": [ 280 ], "individuals": [ 281 ], "who": [ 284, 288 ], "are": [ 285 ], "overweight": [ 286 ], "C\u2010peptide,": [ 293 ], "improvements": [ 296 ], "sustained.": [ 299 ] }, "publication_date": "2020-06-23", "publication_year": 2020, "type": "article", "cited_by_count": 37, "authors": [ { "id": "https://openalex.org/A5025956771", "display_name": "Kevan C. Herold" }, { "id": "https://openalex.org/A5083194155", "display_name": "Jesse Reynolds" }, { "id": "https://openalex.org/A5053895234", "display_name": "James Dziura" }, { "id": "https://openalex.org/A5060191140", "display_name": "David A. Baidal" }, { "id": "https://openalex.org/A5001253005", "display_name": "Jason L. Gaglia" }, { "id": "https://openalex.org/A5091635904", "display_name": "Stephen E. Gitelman" }, { "id": "https://openalex.org/A5083458282", "display_name": "Peter A. Gottlieb" }, { "id": "https://openalex.org/A5046982623", "display_name": "Jennifer A. Marks" }, { "id": "https://openalex.org/A5073002116", "display_name": "Louis H. Philipson" }, { "id": "https://openalex.org/A5018561083", "display_name": "Rodica Pop\u2010Busui" }, { "id": "https://openalex.org/A5080916339", "display_name": "Ruth S. Weinstock" } ] }, { "id": "https://openalex.org/W2160274347", "doi": "https://doi.org/10.2337/dc11-1928", "title": "Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets", "abstract": { "OBJECTIVE": [ 0 ], "We": [ 1 ], "evaluated": [ 2 ], "the": [ 3, 109, 231, 271 ], "addition": [ 4, 66 ], "of": [ 5, 67, 140, 145, 198, 259, 273 ], "liraglutide": [ 6, 46, 73, 262 ], "to": [ 7, 62, 70, 148, 179, 191 ], "metformin": [ 8, 39, 71, 260 ], "in": [ 9, 270 ], "type": [ 10 ], "2": [ 11 ], "diabetes": [ 12 ], "followed": [ 13 ], "by": [ 14, 158, 212, 218 ], "intensification": [ 15 ], "with": [ 16, 56, 164, 200, 221, 249, 261, 275 ], "basal": [ 17 ], "insulin": [ 18, 68, 80, 165, 174, 201, 222, 228, 252, 265 ], "(detemir)": [ 19 ], "if": [ 20 ], "glycated": [ 21 ], "hemoglobin": [ 22 ], "(A1C)": [ 23 ], "\u22657%.": [ 24 ], "RESEARCH": [ 25 ], "DESIGN": [ 26 ], "AND": [ 27 ], "METHODS": [ 28 ], "In": [ 29, 230 ], "988": [ 30, 141 ], "participants": [ 31, 107, 199 ], "from": [ 32, 121, 133 ], "North": [ 33 ], "America": [ 34 ], "and": [ 35, 45, 181, 238, 244, 250, 263, 282 ], "Europe": [ 36 ], "uncontrolled": [ 37 ], "on": [ 38 ], "\u00b1": [ 40 ], "sulfonylurea,": [ 41 ], "sulfonylurea": [ 42 ], "was": [ 43, 98, 267 ], "discontinued": [ 44 ], "1.8": [ 47 ], "mg/day": [ 48 ], "added": [ 49 ], "for": [ 50 ], "12": [ 51 ], "weeks": [ 52 ], "(run-in).": [ 53 ], "Subsequently,": [ 54 ], "those": [ 55 ], "A1C": [ 57, 87, 99, 116, 155, 207 ], "\u22657%": [ 58 ], "were": [ 59, 242 ], "randomized": [ 60, 102, 232 ], "1:1": [ 61 ], "26": [ 63 ], "weeks\u2019": [ 64 ], "open-label": [ 65 ], "detemir": [ 69, 81, 166, 175, 202, 223, 253, 266 ], "+": [ 72 ], "(n": [ 74, 82, 112, 127, 167, 176 ], "=": [ 75, 83, 113, 128, 168, 177 ], "162)": [ 76, 169 ], "or": [ 77, 224 ], "continuation": [ 78 ], "without": [ 79, 173, 205, 227, 251 ], "161).": [ 84 ], "Patients": [ 85 ], "achieving": [ 86 ], "&lt;7%": [ 88, 117 ], "continued": [ 89 ], "unchanged": [ 90 ], "treatment": [ 91, 185 ], "(observational": [ 92 ], "arm).": [ 93 ], "The": [ 94 ], "primary": [ 95 ], "end": [ 96 ], "point": [ 97 ], "change": [ 100, 119 ], "between": [ 101 ], "groups.": [ 103 ], "RESULTS": [ 104 ], "Of": [ 105 ], "821": [ 106 ], "completing": [ 108 ], "run-in,": [ 110, 138, 216 ], "61%": [ 111 ], "498)": [ 114 ], "achieved": [ 115 ], "(mean": [ 118 ], "\u22121.3%": [ 120 ], "7.7%": [ 122 ], "at": [ 123, 135, 162 ], "start),": [ 124 ], "whereas": [ 125 ], "39%": [ 126 ], "323)": [ 129 ], "did": [ 130 ], "not": [ 131 ], "(\u22120.6%": [ 132 ], "8.3%": [ 134 ], "start).": [ 136 ], "During": [ 137 ], "167": [ 139 ], "(17%)": [ 142 ], "withdrew;": [ 143 ], "46%": [ 144 ], "these": [ 146 ], "due": [ 147 ], "gastrointestinal": [ 149 ], "adverse": [ 150 ], "events.": [ 151 ], "At": [ 152 ], "week": [ 153 ], "26,": [ 154 ], "decreased": [ 156, 211 ], "further,": [ 157 ], "0.5%": [ 159 ], "(from": [ 160 ], "7.6%": [ 161 ], "randomization)": [ 163 ], "versus": [ 170, 203 ], "0.02%": [ 171 ], "increase": [ 172 ], "157)": [ 178 ], "7.1": [ 180 ], "7.5%,": [ 182 ], "respectively": [ 183 ], "(estimated": [ 184 ], "difference": [ 186 ], "\u22120.52": [ 187 ], "[95%": [ 188 ], "CI": [ 189 ], "\u22120.68": [ 190 ], "\u22120.36];": [ 192 ], "P": [ 193 ], "&lt;": [ 194 ], "0.0001).": [ 195 ], "Forty-three": [ 196 ], "percent": [ 197 ], "17%": [ 204 ], "reached": [ 206 ], "&lt;7%.": [ 208 ], "Mean": [ 209 ], "weight": [ 210, 280 ], "3.5": [ 213 ], "kg": [ 214, 220, 226 ], "during": [ 215 ], "then": [ 217, 264 ], "0.16": [ 219 ], "0.95": [ 225 ], "detemir.": [ 229 ], "phase,": [ 233 ], "no": [ 234 ], "major": [ 235 ], "hypoglycemia": [ 236, 240, 285 ], "occurred": [ 237 ], "minor": [ 239 ], "rates": [ 241 ], "0.286": [ 243 ], "0.029": [ 245 ], "events": [ 246 ], "per": [ 247 ], "participant-year": [ 248 ], "(9.2": [ 254 ], "vs.": [ 255 ], "1.3%).": [ 256 ], "CONCLUSIONS": [ 257 ], "Supplementation": [ 258 ], "well": [ 268 ], "tolerated": [ 269 ], "majority": [ 272 ], "patients,": [ 274 ], "good": [ 276 ], "glycemic": [ 277 ], "control,": [ 278 ], "sustained": [ 279 ], "loss,": [ 281 ], "very": [ 283 ], "low": [ 284 ], "rates.": [ 286 ] }, "publication_date": "2012-05-15", "publication_year": 2012, "type": "article", "cited_by_count": 158, "authors": [ { "id": "https://openalex.org/A5027649851", "display_name": "J. Hans DeVries" }, { "id": "https://openalex.org/A5080463002", "display_name": "Stephen C. Bain" }, { "id": "https://openalex.org/A5020174004", "display_name": "Helena W. Rodbard" }, { "id": "https://openalex.org/A5056074989", "display_name": "Jochen Seufert" }, { "id": "https://openalex.org/A5071074041", "display_name": "David A. D\u2019Alessio" }, { "id": "https://openalex.org/A5112354612", "display_name": "Anne Bloch Thomsen" }, { "id": "https://openalex.org/A5113524401", "display_name": "Marcin Zychma" }, { "id": "https://openalex.org/A5045489578", "display_name": "Julio Rosenstock" } ] }, { "id": "https://openalex.org/W1826263849", "doi": "https://doi.org/10.1111/dom.12539", "title": "Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo\u2010controlled trial", "abstract": { "Aim": [ 0 ], "To": [ 1 ], "confirm": [ 2 ], "the": [ 3, 96 ], "superiority,": [ 4 ], "compared": [ 5, 222, 251 ], "with": [ 6, 20, 115, 121, 213, 223, 252, 263 ], "placebo,": [ 7, 216 ], "of": [ 8 ], "adding": [ 9 ], "liraglutide": [ 10, 55, 116, 132, 214, 233 ], "to": [ 11, 53, 79, 234 ], "pre\u2010existing": [ 12, 81 ], "basal": [ 13, 82, 236 ], "insulin": [ 14, 83, 93, 154, 237 ], "analogue": [ 15, 84, 238 ], "\u00b1": [ 16, 87, 239 ], "metformin": [ 17, 88, 240 ], "in": [ 18, 42, 174 ], "adults": [ 19 ], "inadequately": [ 21 ], "controlled": [ 22 ], "type": [ 23 ], "2": [ 24 ], "diabetes": [ 25 ], "[glycated": [ 26 ], "haemoglobin": [ 27 ], "(": [ 28 ], "HbA1c": [ 29, 106, 112, 134 ], ")": [ 30 ], "7.0\u201310.0%": [ 31 ], "(53\u201386": [ 32 ], "mmol/mol)].": [ 33 ], "Methods": [ 34 ], "In": [ 35 ], "this": [ 36 ], "26\u2010week,": [ 37 ], "double\u2010blind,": [ 38 ], "parallel\u2010group": [ 39 ], "study,": [ 40 ], "conducted": [ 41 ], "clinics": [ 43 ], "or": [ 44, 73, 228 ], "hospitals,": [ 45 ], "451": [ 46 ], "subjects": [ 47, 130 ], "were": [ 48, 99, 210, 260 ], "randomized": [ 49 ], "1": [ 50, 52, 67 ], ":": [ 51 ], "once\u2010daily": [ 54 ], "1.8": [ 56 ], "mg": [ 57 ], "(dose": [ 58 ], "escalated": [ 59 ], "from": [ 60, 163 ], "0.6": [ 61 ], "and": [ 62, 143, 189, 204, 217, 247, 257 ], "1.2": [ 63 ], "mg/day,": [ 64 ], "respectively,": [ 65 ], "for": [ 66 ], "week": [ 68 ], "each;": [ 69 ], "n": [ 70 ], "=": [ 71, 76 ], "226)": [ 72 ], "placebo": [ 74, 122 ], "(n": [ 75 ], "225)": [ 77 ], "added": [ 78 ], "their": [ 80 ], "(\u226520": [ 85 ], "U/day)": [ 86 ], "(\u22651500": [ 89 ], "mg/day).": [ 90 ], "After": [ 91, 109 ], "randomization,": [ 92 ], "adjustments": [ 94 ], "above": [ 95 ], "pre\u2010study": [ 97 ], "dose": [ 98 ], "not": [ 100 ], "allowed.": [ 101 ], "The": [ 102 ], "primary": [ 103 ], "endpoint": [ 104 ], "was": [ 105 ], "change.": [ 107 ], "Results": [ 108 ], "26": [ 110 ], "weeks,": [ 111 ], "decreased": [ 113 ], "more": [ 114, 211, 261 ], "[\u22121.3%": [ 117 ], "(\u221214.2": [ 118 ], "mmol/mol)]": [ 119 ], "than": [ 120, 215 ], "[\u22120.1%": [ 123 ], "(\u22121.2": [ 124 ], "mmol/mol);": [ 125 ], "p": [ 126, 140, 148, 170 ], "<": [ 127, 141, 149, 171 ], "0.0001].": [ 128 ], "More": [ 129 ], "on": [ 131 ], "reached": [ 133 ], "targets:": [ 135 ], "<7.0%": [ 136 ], "(59%": [ 137 ], "vs": [ 138, 146, 157, 168, 202, 208 ], "14%;": [ 139 ], "0.0001)": [ 142, 150, 172 ], "\u22646.5%": [ 144 ], "(43%": [ 145 ], "4%;": [ 147 ], "using": [ 151 ], "slightly": [ 152 ], "less": [ 153 ], "(35.8": [ 155 ], "IU": [ 156, 159 ], "40.1": [ 158 ], ").": [ 160, 195 ], "Greater": [ 161 ], "decreases": [ 162 ], "baseline": [ 164 ], "(estimated": [ 165 ], "treatment": [ 166 ], "differences": [ 167 ], "placebo;": [ 169 ], "occurred": [ 173 ], "fasting": [ 175 ], "plasma": [ 176 ], "glucose": [ 177, 181 ], "(\u22121.3": [ 178 ], "mmol/l),": [ 179, 184 ], "seven\u2010point": [ 180 ], "profiles": [ 182 ], "(\u22121.6": [ 183 ], "body": [ 185, 245 ], "weight": [ 186, 246 ], "(\u22123.1": [ 187 ], "kg)": [ 188 ], "systolic": [ 190, 248 ], "blood": [ 191, 249 ], "pressure": [ 192, 250 ], "(\u22125.0": [ 193 ], "mmHg": [ 194 ], "Transient": [ 196 ], "gastrointestinal": [ 197, 255 ], "adverse": [ 198 ], "events": [ 199 ], "(nausea:": [ 200 ], "22.2%": [ 201 ], "3.1%)": [ 203 ], "minor": [ 205, 258 ], "hypoglycaemia": [ 206, 227, 259 ], "(18.2%": [ 207 ], "12.4%)": [ 209 ], "frequent": [ 212, 262 ], "pulse": [ 218 ], "increased": [ 219 ], "(4.5": [ 220 ], "beats/min)": [ 221 ], "placebo.": [ 224, 253 ], "No": [ 225 ], "severe": [ 226 ], "pancreatitis": [ 229 ], "occurred.": [ 230 ], "Conclusions": [ 231 ], "Adding": [ 232 ], "a": [ 235 ], "significantly": [ 241 ], "improved": [ 242 ], "glycaemic": [ 243 ], "control,": [ 244 ], "Typical": [ 254 ], "symptoms": [ 256 ], "liraglutide.": [ 264 ] }, "publication_date": "2015-07-14", "publication_year": 2015, "type": "article", "cited_by_count": 97, "authors": [ { "id": "https://openalex.org/A5082525611", "display_name": "Andrew Ahmann" }, { "id": "https://openalex.org/A5020174004", "display_name": "Helena W. Rodbard" }, { "id": "https://openalex.org/A5045489578", "display_name": "Julio Rosenstock" }, { "id": "https://openalex.org/A5032391694", "display_name": "Jorma Lahtela" }, { "id": "https://openalex.org/A5022890768", "display_name": "Luis De Loredo" }, { "id": "https://openalex.org/A5017628699", "display_name": "Karen Torn\u00f8e" }, { "id": "https://openalex.org/A5041765163", "display_name": "A. Boopalan" }, { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" } ] }, { "id": "https://openalex.org/W3047956076", "doi": "https://doi.org/10.3390/ijms21165722", "title": "Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis", "abstract": { "Glucagon-like": [ 0 ], "peptide-1": [ 1 ], "(GLP-1)": [ 2 ], "receptor": [ 3, 175 ], "agonists": [ 4, 176 ], "are": [ 5 ], "used": [ 6, 179 ], "to": [ 7, 180 ], "treat": [ 8 ], "diabetes,": [ 9 ], "but": [ 10, 158 ], "their": [ 11 ], "effects": [ 12 ], "on": [ 13 ], "nonalcoholic": [ 14 ], "steatohepatitis": [ 15 ], "(NASH)": [ 16 ], "and": [ 17, 32, 36, 52, 85, 133, 147, 168 ], "the": [ 18, 58, 68, 73, 140, 144, 153, 182 ], "development": [ 19 ], "of": [ 20, 136, 185 ], "hepatocellular": [ 21 ], "carcinoma": [ 22 ], "(HCC)": [ 23 ], "remain": [ 24 ], "unclear.": [ 25 ], "In": [ 26, 163 ], "this": [ 27 ], "study,": [ 28 ], "mice": [ 29, 114, 157 ], "with": [ 30, 41, 143 ], "streptozotocin-": [ 31 ], "high-fat": [ 33 ], "diet-induced": [ 34 ], "diabetes": [ 35 ], "NASH": [ 37, 167 ], "were": [ 38, 55, 64, 89, 150 ], "subcutaneously": [ 39 ], "treated": [ 40 ], "liraglutide": [ 42, 69, 93, 165 ], "or": [ 43 ], "saline": [ 44 ], "(control)": [ 45 ], "for": [ 46 ], "14": [ 47 ], "weeks.": [ 48 ], "Glycemic": [ 49 ], "control,": [ 50 ], "hepatocarcinogenesis,": [ 51, 106 ], "liver": [ 53, 141 ], "histology": [ 54 ], "compared": [ 56, 142 ], "between": [ 57 ], "groups.": [ 59 ], "Fasting": [ 60 ], "blood": [ 61 ], "glucose": [ 62 ], "levels": [ 63, 88 ], "significantly": [ 65, 90, 129 ], "lower": [ 66 ], "in": [ 67, 72, 111, 139, 152, 155, 160, 171 ], "group": [ 70, 75 ], "than": [ 71 ], "control": [ 74, 113, 145, 161 ], "(210.0": [ 76 ], "\u00b1": [ 77, 82, 95, 100, 119, 125 ], "17.3": [ 78 ], "mg/dL": [ 79 ], "vs.": [ 80, 98 ], "601.8": [ 81 ], "123.6": [ 83 ], "mg/dL),": [ 84 ], "fasting": [ 86 ], "insulin": [ 87 ], "increased": [ 91 ], "by": [ 92 ], "(0.18": [ 94 ], "0.06": [ 96 ], "ng/mL": [ 97 ], "0.09": [ 99 ], "0.03": [ 101 ], "ng/mL).": [ 102 ], "Liraglutide": [ 103, 128 ], "completely": [ 104 ], "suppressed": [ 105, 169 ], "whereas": [ 107 ], "HCC": [ 108 ], "was": [ 109 ], "observed": [ 110, 151 ], "all": [ 112 ], "(average": [ 115 ], "tumor": [ 116, 122 ], "count,": [ 117 ], "5.5": [ 118 ], "3.87;": [ 120 ], "average": [ 121 ], "size,": [ 123 ], "8.1": [ 124 ], "5.0": [ 126 ], "mm).": [ 127 ], "ameliorated": [ 130, 166 ], "steatosis,": [ 131 ], "inflammation,": [ 132 ], "hepatocyte": [ 134 ], "ballooning": [ 135 ], "non-tumorous": [ 137 ], "lesions": [ 138 ], "findings,": [ 146 ], "insulin-positive": [ 148 ], "\u03b2-cells": [ 149 ], "pancreas": [ 154 ], "liraglutide-treated": [ 156 ], "not": [ 159 ], "mice.": [ 162, 173 ], "conclusion,": [ 164 ], "hepatocarcinogenesis": [ 170 ], "diabetic": [ 172 ], "GLP-1": [ 174 ], "can": [ 177 ], "be": [ 178 ], "improve": [ 181 ], "hepatic": [ 183 ], "outcome": [ 184 ], "diabetes.": [ 186 ] }, "publication_date": "2020-08-10", "publication_year": 2020, "type": "article", "cited_by_count": 54, "authors": [ { "id": "https://openalex.org/A5042052779", "display_name": "Motoyasu Kojima" }, { "id": "https://openalex.org/A5100761016", "display_name": "Hirokazu Takahashi" }, { "id": "https://openalex.org/A5034304409", "display_name": "Takuya Kuwashiro" }, { "id": "https://openalex.org/A5101508358", "display_name": "Kenichi Tanaka" }, { "id": "https://openalex.org/A5108815830", "display_name": "Hitoe Mori" }, { "id": "https://openalex.org/A5026097438", "display_name": "Iwata Ozaki" }, { "id": "https://openalex.org/A5109407606", "display_name": "Yoichiro Kitajima" }, { "id": "https://openalex.org/A5112415318", "display_name": "Yayoi Matsuda" }, { "id": "https://openalex.org/A5088174367", "display_name": "Kenji Ashida" }, { "id": "https://openalex.org/A5060035569", "display_name": "Yuichiro Eguchi" }, { "id": "https://openalex.org/A5054851148", "display_name": "Keizo Anzai" } ] }, { "id": "https://openalex.org/W2774952509", "doi": "https://doi.org/10.1016/s2213-8587(17)30413-8", "title": "GLP-1 receptor agonists: differentiation within the class", "abstract": null, "publication_date": "2017-12-05", "publication_year": 2017, "type": "letter", "cited_by_count": 34, "authors": [ { "id": "https://openalex.org/A5064924632", "display_name": "Simeon I. Taylor" } ] }, { "id": "https://openalex.org/W2911630547", "doi": "https://doi.org/10.1530/ec-18-0514", "title": "Effects of liraglutide on obesity-associated functional hypogonadism in men", "abstract": { "Lifestyle": [ 0 ], "measures": [ 1, 133 ], "(LSMs)": [ 2 ], "should": [ 3 ], "be": [ 4 ], "the": [ 5, 17, 57 ], "first-line": [ 6 ], "approach": [ 7 ], "offered": [ 8 ], "for": [ 9, 140, 205 ], "obesity-related": [ 10 ], "functional": [ 11 ], "hypogonadism": [ 12 ], "(FH).": [ 13 ], "When": [ 14 ], "LSMs": [ 15 ], "fail,": [ 16 ], "role": [ 18 ], "of": [ 19, 42, 59, 77, 79, 123, 142, 193 ], "testosterone": [ 20, 158, 163 ], "replacement": [ 21 ], "treatment": [ 22 ], "(TRT)": [ 23 ], "is": [ 24, 30 ], "unclear.": [ 25 ], "GLP1": [ 26, 43 ], "receptor": [ 27 ], "agonist": [ 28 ], "liraglutide": [ 29, 60, 115 ], "linked": [ 31 ], "to": [ 32, 55, 73, 114, 183, 251 ], "progressive": [ 33 ], "and": [ 34, 61, 81, 131, 144, 155, 181, 197, 242 ], "sustained": [ 35 ], "weight": [ 36, 82 ], "loss.": [ 37 ], "A": [ 38 ], "potential": [ 39 ], "direct": [ 40 ], "impact": [ 41 ], "on": [ 44, 63, 213 ], "hypothalamus-pituitary-testicular": [ 45 ], "(HPT)": [ 46 ], "axis": [ 47 ], "was": [ 48, 138, 235, 249 ], "reported": [ 49 ], "in": [ 50, 65, 166, 172, 179, 189, 227, 237, 240, 243, 246, 253, 259 ], "animal": [ 51 ], "models.": [ 52 ], "We": [ 53, 84 ], "aimed": [ 54 ], "compare": [ 56 ], "effects": [ 58 ], "TRT": [ 62, 173, 228, 252 ], "FH": [ 64, 80, 263 ], "obese": [ 66 ], "men": [ 67, 94, 260 ], "that": [ 68, 111 ], "had": [ 69 ], "been": [ 70 ], "poor": [ 71 ], "responders": [ 72 ], "LSM,": [ 74 ], "by": [ 75, 148 ], "means": [ 76 ], "reversal": [ 78 ], "reduction.": [ 83 ], "designed": [ 85 ], "a": [ 86, 190, 221 ], "16-week": [ 87 ], "prospective": [ 88 ], "randomized": [ 89, 113 ], "open-label": [ 90 ], "study": [ 91 ], "with": [ 92, 210, 220, 261 ], "30": [ 93 ], "(aged": [ 95 ], "46.5": [ 96 ], "\u00b1": [ 97, 102, 108, 170, 176, 216, 223 ], "10.9": [ 98 ], "years,": [ 99 ], "BMI": [ 100 ], "41.2": [ 101 ], "8.4": [ 103 ], "kg/m": [ 104 ], "2": [ 105 ], ",": [ 106 ], "mean": [ 107 ], "s.d.": [ 109 ], ")": [ 110 ], "were": [ 112, 134, 160 ], "3.0": [ 116 ], "mg": [ 117, 122 ], "QD": [ 118, 127 ], "(LIRA)": [ 119 ], "or": [ 120 ], "50": [ 121 ], "1%": [ 124 ], "transdermal": [ 125 ], "gel": [ 126 ], "(TRT).": [ 128 ], "Sexual": [ 129 ], "function": [ 130 ], "anthropometric": [ 132 ], "assessed.": [ 135 ], "Fasting": [ 136 ], "blood": [ 137 ], "drawn": [ 139 ], "determination": [ 141 ], "endocrine": [ 143 ], "metabolic": [ 145 ], "parameters": [ 146, 151 ], "followed": [ 147 ], "OGTT.": [ 149 ], "Model-derived": [ 150 ], "including": [ 152 ], "HOMA": [ 153 ], "IR": [ 154 ], "calculated": [ 156 ], "free": [ 157 ], "(cFT)": [ 159 ], "calculated.": [ 161 ], "Total": [ 162 ], "significantly": [ 164 ], "increased": [ 165 ], "both": [ 167 ], "arms": [ 168 ], "(+5.9": [ 169 ], "7.2": [ 171 ], "vs": [ 174 ], "+2.6": [ 175 ], "3.5": [ 177 ], "nmol/L": [ 178 ], "LIRA)": [ 180 ], "led": [ 182 ], "improved": [ 184 ], "sexual": [ 185 ], "function.": [ 186 ], "LIRA": [ 187, 211, 241 ], "resulted": [ 188 ], "significant": [ 191 ], "increase": [ 192 ], "luteinizing": [ 194 ], "hormone": [ 195, 199 ], "(LH)": [ 196 ], "follicle-stimulating": [ 198 ], "(FSH)": [ 200 ], "(": [ 201, 229 ], "P": [ 202, 230 ], "<": [ 203, 231 ], "0.001": [ 204 ], "between-treatment": [ 206 ], "effect).": [ 207 ], "Subjects": [ 208 ], "treated": [ 209 ], "lost": [ 212 ], "average": [ 214 ], "7.9": [ 215 ], "3.8": [ 217 ], "kg": [ 218, 225 ], "compared": [ 219 ], "0.9": [ 222 ], "4.5": [ 224 ], "loss": [ 226 ], "0.001).": [ 232 ], "Metabolic": [ 233 ], "syndrome": [ 234 ], "resolved": [ 236 ], "two": [ 238 ], "patients": [ 239 ], "no": [ 244 ], "subjects": [ 245 ], "TRT.": [ 247 ], "Liraglutide": [ 248 ], "superior": [ 250 ], "improving": [ 254 ], "an": [ 255 ], "overall": [ 256 ], "health": [ 257 ], "benefit": [ 258 ], "obesity-associated": [ 262 ], "after": [ 264 ], "LSM": [ 265 ], "failed.": [ 266 ] }, "publication_date": "2019-02-04", "publication_year": 2019, "type": "article", "cited_by_count": 82, "authors": [ { "id": "https://openalex.org/A5091436678", "display_name": "Mojca Jensterle" }, { "id": "https://openalex.org/A5041669776", "display_name": "Ana Podbregar" }, { "id": "https://openalex.org/A5042310619", "display_name": "Katja Gori\u010dar" }, { "id": "https://openalex.org/A5013864211", "display_name": "Nadan Gregori\u010d" }, { "id": "https://openalex.org/A5002770606", "display_name": "Andrej Jane\u017e" } ] }, { "id": "https://openalex.org/W2140952918", "doi": "https://doi.org/10.2337/dc09-2191", "title": "Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin", "abstract": { "OBJECTIVE": [ 0 ], "To": [ 1 ], "assess": [ 2 ], "the": [ 3, 83, 156, 219 ], "effect": [ 4 ], "of": [ 5, 10, 105, 124, 159, 201, 210, 223 ], "a": [ 6, 26, 53, 61, 322 ], "4-week": [ 7, 74 ], "adjunctive": [ 8 ], "therapy": [ 9 ], "exenatide": [ 11 ], "(EXE)": [ 12 ], "(5\u201310": [ 13 ], "\u03bcg": [ 14 ], "b.i.d.)": [ 15 ], "or": [ 16, 34, 235, 305 ], "sitagliptin": [ 17 ], "(SITA)": [ 18 ], "(100": [ 19 ], "mg": [ 20 ], "once": [ 21 ], "daily)": [ 22 ], "in": [ 23, 31, 148, 321 ], "response": [ 24 ], "to": [ 25, 70, 89, 308, 327 ], "standardized": [ 27 ], "breakfast": [ 28 ], "meal": [ 29 ], "challenge": [ 30 ], "48": [ 32 ], "men": [ 33 ], "women": [ 35 ], "with": [ 36, 60, 155, 229, 266, 282 ], "type": [ 37 ], "2": [ 38 ], "diabetes": [ 39 ], "receiving": [ 40 ], "insulin": [ 41 ], "glargine": [ 42 ], "(GLAR)": [ 43 ], "+": [ 44, 108, 110, 114, 116, 126, 165, 167, 170, 172, 178, 184, 186, 190, 214, 216, 233, 237, 239, 268, 270, 284, 292, 294, 298, 310 ], "metformin": [ 45 ], "(MET).": [ 46 ], "RESEARCH": [ 47 ], "DESIGN": [ 48 ], "AND": [ 49 ], "METHODS": [ 50 ], "This": [ 51 ], "was": [ 52, 86, 118, 203 ], "single-center,": [ 54 ], "randomized,": [ 55 ], "open-label,": [ 56 ], "active": [ 57 ], "comparator\u2013controlled": [ 58 ], "study": [ 59 ], "three-arm": [ 62 ], "parallel": [ 63 ], "group": [ 64 ], "design,": [ 65 ], "consisting": [ 66 ], "of:": [ 67 ], "screening,": [ 68 ], "4-": [ 69 ], "8-week": [ 71 ], "run-in": [ 72 ], "period,": [ 73, 76 ], "treatment": [ 75 ], "and": [ 77, 112, 143, 208, 244, 249, 260, 279 ], "follow-up.": [ 78 ], "In": [ 79 ], "all": [ 80, 149 ], "three": [ 81, 150 ], "groups,": [ 82 ], "GLAR": [ 84, 107, 113, 125, 164, 177, 183, 189, 213, 232, 236, 267, 283, 291, 297, 309 ], "dose": [ 85 ], "titrated": [ 87 ], "according": [ 88 ], "an": [ 90 ], "algorithm": [ 91 ], "(fasting": [ 92 ], "blood": [ 93, 102, 316 ], "glucose": [ 94, 103, 254, 317 ], "\u2264100": [ 95 ], "mg/dl).": [ 96 ], "RESULTS": [ 97 ], "The": [ 98, 195 ], "unadjusted": [ 99 ], "6-h": [ 100 ], "postprandial": [ 101, 315 ], "excursion": [ 104 ], "both": [ 106 ], "MET": [ 109, 115, 127, 166, 171, 179, 185, 191, 215, 234, 238, 269, 285, 293, 299, 311 ], "EXE": [ 111, 168, 187, 217, 271, 295, 304 ], "SITA": [ 117, 173, 240, 306 ], "statistically": [ 119 ], "significantly": [ 120, 146 ], "smaller": [ 121 ], "than": [ 122 ], "that": [ 123 ], "(606": [ 128 ], "\u00b1": [ 129, 133, 137, 161, 175, 181, 273, 287 ], "104": [ 130 ], "vs.": [ 131, 135, 188, 296 ], "612": [ 132 ], "133": [ 134 ], "728": [ 136 ], "132": [ 138 ], "mg/dl/h;": [ 139 ], "P": [ 140, 192, 276, 300 ], "=": [ 141, 193, 277, 301 ], "0.0036": [ 142 ], "0.0008).": [ 144 ], "A1C": [ 145, 199 ], "decreased": [ 147, 265 ], "groups": [ 151 ], "(P": [ 152 ], "&lt;": [ 153 ], "0.0001),": [ 154 ], "greatest": [ 157 ], "reduction": [ 158 ], "\u22121.9": [ 160 ], "0.7": [ 162 ], "under": [ 163 ], "(GLAR": [ 169 ], "\u22121.5": [ 174 ], "0.7;": [ 176 ], "\u22121.2": [ 180 ], "0.5%-points;": [ 182 ], "0.0154).": [ 194 ], "American": [ 196 ], "Diabetes": [ 197 ], "Association": [ 198 ], "target": [ 200 ], "&lt;7.0%": [ 202 ], "reached": [ 204 ], "by": [ 205 ], "80.0,": [ 206 ], "87.5,": [ 207 ], "62.5%": [ 209 ], "subjects,": [ 211 ], "respectively.": [ 212 ], "had": [ 218, 242 ], "highest": [ 220 ], "number": [ 221 ], "(47)": [ 222 ], "adverse": [ 224, 246 ], "events,": [ 225, 247 ], "mostly": [ 226 ], "gastrointestinal": [ 227 ], "(56%)": [ 228 ], "one": [ 230 ], "dropout.": [ 231 ], "only": [ 241 ], "10": [ 243 ], "12": [ 245 ], "respectively,": [ 248 ], "no": [ 250 ], "dropouts.": [ 251 ], "Hypoglycemia": [ 252 ], "(blood": [ 253 ], "&lt;50": [ 255 ], "mg/dl)": [ 256 ], "rates": [ 257 ], "were": [ 258 ], "low": [ 259 ], "comparable": [ 261 ], "among": [ 262 ], "groups.": [ 263 ], "Weight": [ 264 ], "(\u22120.9": [ 272 ], "1.7": [ 274 ], "kg;": [ 275, 289 ], "0.0396)": [ 278 ], "increased": [ 280 ], "slightly": [ 281 ], "(0.4": [ 286 ], "1.5": [ 288 ], "NS;": [ 290 ], "0.0377).": [ 302 ], "CONCLUSIONS": [ 303 ], "added": [ 307 ], "further": [ 312 ], "substantially": [ 313 ], "reduced": [ 314 ], "excursions.": [ 318 ], "Longer-term": [ 319 ], "studies": [ 320 ], "larger": [ 323 ], "population": [ 324 ], "are": [ 325 ], "warranted": [ 326 ], "confirm": [ 328 ], "these": [ 329 ], "findings.": [ 330 ] }, "publication_date": "2010-03-31", "publication_year": 2010, "type": "article", "cited_by_count": 167, "authors": [ { "id": "https://openalex.org/A5034644535", "display_name": "Sabine Arnolds" }, { "id": "https://openalex.org/A5031228180", "display_name": "Sibylle Dellweg" }, { "id": "https://openalex.org/A5049367576", "display_name": "Janina Clair" }, { "id": "https://openalex.org/A5110438636", "display_name": "Marie\u2010Paule Dain" }, { "id": "https://openalex.org/A5067359287", "display_name": "Michael A. Nauck" }, { "id": "https://openalex.org/A5014825286", "display_name": "Klaus Rave" }, { "id": "https://openalex.org/A5068619321", "display_name": "Christoph Kapitza" } ] }, { "id": "https://openalex.org/W2125482086", "doi": "https://doi.org/10.1002/bip.22474", "title": "A GLP\u20101 receptor agonist conjugated to an albumin\u2010binding domain for extended half\u2010life", "abstract": { "ABSTRACT": [ 0 ], "Glucagon\u2010like": [ 1 ], "peptide": [ 2, 7 ], "1": [ 3 ], "(GLP\u20101)": [ 4 ], "and": [ 5, 20, 48, 56, 71, 87, 104, 127, 134, 146, 173 ], "related": [ 6 ], "agonists": [ 8, 196 ], "have": [ 9, 23, 59, 83 ], "been": [ 10, 60, 84 ], "extensively": [ 11 ], "investigated": [ 12 ], "for": [ 13, 26, 53 ], "glycaemic": [ 14 ], "control": [ 15 ], "in": [ 16, 102, 110, 136, 180, 201 ], "Type": [ 17 ], "2": [ 18, 38 ], "diabetes,": [ 19 ], "may": [ 21 ], "also": [ 22 ], "therapeutic": [ 24 ], "applications": [ 25 ], "other": [ 27 ], "diseases.": [ 28 ], "Due": [ 29 ], "to": [ 30, 94, 160, 187, 198 ], "the": [ 31, 41, 63, 111, 118, 168, 183, 190 ], "short": [ 32 ], "half\u2010life": [ 33, 54 ], "(": [ 34 ], "t": [ 35 ], "1/2": [ 36 ], "<": [ 37 ], "min)": [ 39 ], "of": [ 40, 124 ], "endogenous": [ 42 ], "peptide,": [ 43 ], "caused": [ 44 ], "by": [ 45, 122 ], "proteolytic": [ 46 ], "degradation": [ 47 ], "renal": [ 49 ], "clearance,": [ 50 ], "different": [ 51, 114, 170 ], "strategies": [ 52 ], "extension": [ 55 ], "sustained": [ 57 ], "release": [ 58, 155 ], "explored.": [ 61 ], "In": [ 62 ], "present": [ 64 ], "study,": [ 65 ], "conjugates": [ 66, 172, 192 ], "between": [ 67, 167 ], "a": [ 68, 72, 107 ], "GLP\u20101": [ 69, 175, 194 ], "analogue": [ 70 ], "5": [ 73 ], "kDa": [ 74 ], "albumin\u2010binding": [ 75 ], "domain": [ 76 ], "(ABD)": [ 77 ], "derived": [ 78 ], "from": [ 79 ], "streptococcal": [ 80 ], "protein": [ 81 ], "G": [ 82 ], "chemically": [ 85 ], "synthesized": [ 86, 133 ], "evaluated.": [ 88 ], "ABD": [ 89 ], "binds": [ 90 ], "with": [ 91, 117, 182 ], "high": [ 92, 141, 184 ], "affinity": [ 93, 185 ], "human": [ 95 ], "serum": [ 96 ], "albumin,": [ 97, 188 ], "which": [ 98 ], "is": [ 99 ], "highly": [ 100 ], "abundant": [ 101 ], "plasma": [ 103 ], "functions": [ 105 ], "as": [ 106 ], "drug": [ 108 ], "carrier": [ 109 ], "circulation.": [ 112 ], "Three": [ 113 ], "GLP\u20101\u2010ABD": [ 115, 171, 191 ], "conjugates,": [ 116 ], "two": [ 119 ], "peptides": [ 120 ], "connected": [ 121 ], "linkers": [ 123 ], "two,": [ 125 ], "four,": [ 126 ], "six": [ 128 ], "PEG": [ 129 ], "units,": [ 130 ], "respectively,": [ 131 ], "were": [ 132 ], "tested": [ 135 ], "mouse": [ 137 ], "pancreatic": [ 138 ], "islets": [ 139 ], "at": [ 140 ], "(11": [ 142 ], "m": [ 143, 149 ], "M": [ 144, 150 ], ")": [ 145, 151 ], "low": [ 147 ], "(3": [ 148 ], "glucose": [ 152 ], "concentration.": [ 153 ], "Insulin": [ 154 ], "upon": [ 156 ], "stimulation": [ 157 ], "was": [ 158 ], "shown": [ 159 ], "be": [ 161 ], "glucose\u2010dependent,": [ 162 ], "showing": [ 163 ], "no": [ 164 ], "significant": [ 165 ], "difference": [ 166 ], "three": [ 169 ], "unconjugated": [ 174 ], "analogue.": [ 176 ], "The": [ 177 ], "biological": [ 178 ], "activity,": [ 179 ], "combination": [ 181 ], "binding": [ 186 ], "make": [ 189 ], "promising": [ 193 ], "receptor": [ 195 ], "expected": [ 197 ], "show": [ 199 ], "extended": [ 200 ], "vivo": [ 202 ], "half\u2010life.": [ 203 ], "\u00a9": [ 204 ], "2014": [ 205 ], "Wiley": [ 206 ], "Periodicals,": [ 207 ], "Inc.": [ 208 ], "Biopolymers": [ 209 ], "(Pept": [ 210 ], "Sci)": [ 211 ], "102:": [ 212 ], "252\u2013259,": [ 213 ], "2014.": [ 214 ] }, "publication_date": "2014-02-18", "publication_year": 2014, "type": "article", "cited_by_count": 27, "authors": [ { "id": "https://openalex.org/A5065940584", "display_name": "Joel Lindgren" }, { "id": "https://openalex.org/A5057832347", "display_name": "Essam Refai" }, { "id": "https://openalex.org/A5101946472", "display_name": "\u0421. \u0412. \u0417\u0430\u0439\u0446\u0435\u0432" }, { "id": "https://openalex.org/A5005212856", "display_name": "Lars Abrahms\u00e9n" }, { "id": "https://openalex.org/A5074543896", "display_name": "Per\u2010Olof Berggren" }, { "id": "https://openalex.org/A5046621958", "display_name": "Amelie Eriksson Karlstr\u00f6m" } ] }, { "id": "https://openalex.org/W2999528472", "doi": "https://doi.org/10.1016/j.jdiacomp.2019.107520", "title": "Oral semaglutide in type 2 diabetes", "abstract": null, "publication_date": "2020-01-08", "publication_year": 2020, "type": "review", "cited_by_count": 73, "authors": [ { "id": "https://openalex.org/A5027067847", "display_name": "Sarah L. Anderson" }, { "id": "https://openalex.org/A5082923226", "display_name": "Trevor R. Beutel" }, { "id": "https://openalex.org/A5054620018", "display_name": "Jennifer Trujillo" } ] } ] }